Gossai	O
and	O
Lau-Cam	O
compared	O
taurine,	B
aminomethanesulfonic	B
acid,	I
homotaurine,	B
and	O
HTAU	O
for	O
the	O
ability	O
to	O
modify	O
indices	O
of	O
oxidative	O
stress	O
and	O
membrane	O
damage	O
associated	O
with	O
T2DM.	O

Freeze-thaw	O
(FT)	O
stability.	O
_a	O
Signal	O
change	O
compared	O
to	O
FT	B
cycle	O
1.	O

In	O
this	O
study,	O
the	O
HTG	O
group	O
also	O
exhibited	O
a	O
higher	O
HOMA-IR	O
index;	O
however,	O
the	O
HOMA-IR	O
index	O
was	O
not	O
an	O
independent	O
predictor	O
of	O
the	O
fasting	O
TG	B
levels.	O

Insets:	O
expansions	O
of	O
the	O
aliphatic	B
region	O
(0.5-4.5	O
ppm)	O
and	O
assignment	O
of	O
the	O
most	O
abundant	O
metabolites.	O

Six	O
metabolites	O
were	O
directly	O
assigned	O
to	O
AD	O
classification	O
in	O
HMDB	O
based	O
on	O
literature	O
record,	O
including	O
glutamate,	B
tryptophan,	B
glucose,	B
tyrosine,	B
glycerophosphocholine,	B
and	O
homocitric	O
acids.	O

(B)	O
Increased	O
levels	O
of	O
4-methylcatechol	B
sulfate	I
in	O
post-BRB	O
urine	O
(dash	O
line)	O
and	O
post-BRB	O
plasma	O
(solid	O
line)	O
were	O
significantly	O
correlated	O
with	O
TUNEL	O
staining	O
in	O
post-BRB	O
tumors.	O

In	O
addition,	O
Yuan	O
et	O
al.	O
revealed	O
that	O
low	O
level	O
of	O
serum	O
retinol	B
is	O
associated	O
with	O
the	O
increase	O
of	O
lung	O
cancer	O
risk	O
in	O
China	O
population.	O

(b,	O
right	O
panel)	O
and	O
the	O
glycolysis-derived	O
amino	O
acids	O
alanine,	O
serine	B
and	O
glycine	B
with	O
maximal	O
enrichments	O
of	O
0.51%	O
(25.5%	O
when	O
100%	O
labeling	O
is	O
assumed),	O
0.14%	O
(7%	O
when	O
100%	O
labeling	O
is	O
assumed)	O
and	O
0.18%	O
(9%	O
when	O
100%	O
labeling	O
is	O
assumed)	O
(b,	O
middle	O
panel),	O
respectively.	O

The	O
extraction	O
recovery	O
for	O
the	O
internal	O
standard	O
was	O
88.12	O
±	O
7.84%	O
from	O
plasma	O
with	O
high	O
triglyceride	B
levels.	O

The	O
above	O
results	O
are	O
clear	O
evidence	O
of	O
de	O
novo	O
synthesis	O
of	O
Glu	O
from	O
labeled	O
glucose	B
(10	O
mM),	O
even	O
though	O
unlabeled	O
Gln	O
(2	O
mM)	O
and	O
Glu	O
(0.13	O
mM)	O
were	O
both	O
present	O
in	O
the	O
medium.	O

A	O
series	O
of	O
[_13	O
C_1	O
]cholic	O
acid	O
dilutions	O
in	O
ethyl	B
acetate	I
from	O
Randox	O
serum	O
extracts	O
was	O
used	O
to	O
generate	O
a	O
standard	O
curve	O
ranging	O
between	O
0.00022	O
μg/mL	O
and	O
0.222	O
μg/mL.	O
100	O
μL	O
of	O
sample	O
were	O
injected	O
by	O
flow-injection	O
analysis	O
into	O
the	O
4000QTRAP™	O
equipped	O
with	O
a	O
TurboV™	O
source	O
with	O
an	O
APCI	O
probe.	O

The	O
assay	O
developed	O
allowed	O
us	O
to	O
determine	O
the	O
concentrations	O
of	O
DHEA,	O
AED,	O
AET	O
and	O
7-oxo-DHEA	B
in	O
human	O
plasma	O
samples.	O

Following	O
a	O
20	O
h	O
incubation	O
at	O
37°C,	O
each	O
sample	O
was	O
extracted	O
two	O
times	O
with	O
an	O
equal	O
volume	O
of	O
t	B
-butyl	I
methyl	I
ether.	I

Serum	O
concentrations	O
of	O
glutamic	B
acid	I
were	O
significantly	O
lower	O
in	O
HCC-C	O
than	O
in	O
HCC-B,	O
whereas	O
those	O
of	O
methionine	B
and	O
γ-Glu-Gly-Gly	B
were	O
significantly	O
higher	O
in	O
HCC-C	O
than	O
in	O
HCC-B	O
(glutamic	O
acid:	I
475.4	O
±	O
206.7	O
vs	O
182.6	O
±	O
71.7,	O
P	O
<	O
0.0001;	O
methionine:	B
37.1	O
±	O
36.1	O
vs	O
52.6	O
±	O
29.2,	O
P	O
=	O
0.016;	O
γ-Glu-Gly-Gly:	B
0.035	O
±	O
0.052	O
vs	O
0.109	O
±	O
0.106,	O
P	O
=	O
0.001,	O
HCC-B	O
vs	O
HCC-C,	O
mean	O
±	O
SD)	O
(Figure	O
-C).	O

The	O
absence	O
of	O
metabolites	O
such	O
as	O
formic	B
acid	I
in	O
the	O
lyophilized	O
samples	O
may	O
be	O
due	O
to	O
chemical	O
conversion	O
during	O
speed-vacuum	O
drying	O
at	O
a	O
higher	O
temperature.	O

Finally,	O
metabolic	O
pathways	O
can	O
directly	O
affect	O
cell	O
signaling	O
by	O
controlling	O
ATP	B
levels	O
and	O
the	O
ATP/ADP	B
ratio.	O

The	O
tryptophan	B
breakdown	O
index	O
(kynurenine	O
/	O
tryptophan)	O
correlated	O
with	O
neopterin	B
(Pearson	O
R	O
 = 0.51	O
P	O
 = 0.006)	O
but	O
not	O
with	O
cortisol.	B

The	O
phosphocreatine-creatine	B
couple	O
is	O
also	O
thought	O
to	O
act	O
as	O
an	O
energy	O
shuttle	O
[,	O
]	O
in	O
which	O
the	O
high	O
energy	O
phosphates	B
of	O
the	O
ATP	B
molecules,	O
created	O
at	O
the	O
inner	O
mitochondrial	O
membrane	O
by	O
oxidative	O
phosphorylation,	O
are	O
transferred	O
(via	O
creatine	B
kinase)	O
to	O
creatine	B
molecules	O
in	O
order	O
to	O
form	O
phosphocreatine.	B

Sedentary	O
time	O
(per	O
SD	O
[50	O
min/d]	O
higher	O
based	O
on	O
3	O
measures)	O
appeared	O
more	O
strongly	O
associated	O
with	O
most	O
metabolic	O
traits	O
versus	O
sedentary	O
time	O
based	O
on	O
a	O
single	O
measure,	O
with	O
several	O
effect	O
sizes	O
having	O
increased,	O
particularly	O
for	O
small	O
HDL-related	O
traits,	O
pyruvate	B
(from	O
0.08	O
to	O
0.15	O
SD	O
units),	O
and	O
alanine.	B

Here,	O
we	O
demonstrate	O
that	O
liquid–liquid	O
or	O
solid-phase	O
extraction	O
of	O
vitamin	B
D	I
metabolites	O
in	O
combination	O
with	O
Diels–Alder	O
derivatization	O
with	O
the	O
commercially	O
available	O
reagent	O
4-phenyl-1,2,4-triazoline-3,5-dione	B
(PTAD)	O
followed	O
by	O
ultra-performance	O
liquid	O
chromatography	O
(UPLC)–electrospray/tandem	O
mass	O
spectrometry	O
analysis	O
provides	O
rapid	O
and	O
simultaneous	O
quantification	O
of	O
1α,25-dihydroxyvitamin	B
D_3	I
,	I
1α,25-dihydroxyvitamin	I
D_2	I
,	I
24R	I
,25-dihydroxyvitamin	I
D_3	I
,	I
25-hydroxyvitamin	I
D_3	O
and	O
25-hydroxyvitamin	B
D_2	O
in	O
0.5	O
mL	O
human	O
serum	O
at	O
a	O
lower	O
limit	O
of	O
quantification	O
of	O
25	O
pg/mL.	O
Precision	O
ranged	O
from	O
1.6–4.8	O
%	O
and	O
5–16	O
%	O
for	O
25-hydroxyvitamin	B
D_3	O
and	O
1α,25-dihydroxyvitamin	B
D_3	O
,	O
respectively,	O
using	O
solid-phase	O
extraction.	O

For	O
Alzheimer's	O
disease	O
versus	O
controls,	O
P = 1.6×10_−9	O
for	O
sphingomyelins	B
and	O
P = 0.00034	O
for	O
ceramides	B
(Wilcoxon	O
signed	O
rank	O
test	O
two	O
sided	O
on	O
means	O
over	O
the	O
standardized	O
data).	O

The	O
dried	O
material	O
was	O
reconstituted	O
in	O
0.1%	O
formic	B
acid	I
in	O
water	O
for	O
LC-MS	O
analysis	O
in	O
positive	O
and	O
negative	O
ionization	O
modes.	O

For	O
statistical	O
analysis	O
of	O
Con	O
A-induced	O
intraocular	O
inflammation,	O
the	O
comparisons	O
of	O
the	O
negative	O
control	O
eyes	O
(sham	O
group)	O
and	O
Con	O
A-treated	O
and	O
followed	O
by	O
saline	B
administration	O
eyes	O
(saline	O
group)	O
was	O
performed	O
by	O
the	O
Student's	O
t	O
test	O
(1-sided).	O

However,	O
recent	O
findings	O
from	O
a	O
study	O
of	O
patients	O
with	O
colectomies	O
showed	O
that	O
in	O
humans,	O
hippurate	B
is	O
derived	O
from	O
precursors	O
absorbed	O
in	O
the	O
small	O
intestine	O
and	O
its	O
production	O
may	O
not	O
be	O
specific	O
to	O
the	O
gut.	O

Serum	O
metabolite	O
recoveries	O
were	O
typically	O
>85%,	O
with	O
quinolinic	O
acid-D_3	O
(79%)	O
and	O
nicotinamide	B
riboside-D_3	I
(52%)	O
being	O
the	O
exceptions	O
(Tables	O
S8	O
and	O
S9).	O

This	O
dysfunction	O
is	O
correlated	O
with	O
an	O
increased	O
observation	O
of	O
trimethylamine-N-oxide.	B

The	O
Spd,	O
spermine,	B
and	O
Put	O
are	O
essential	O
ubiquitary	O
cellular	O
polyamines	B
essentially	O
constituted	O
of	O
organic	O
polycations	O
having	O
variable	O
hydrocarbon	B
chains	O
and	O
two	O
or	O
more	O
primary	O
amino	B
groups.	O

Figure	O
1	O
data	O
depict	O
comparisons	O
of	O
the	O
mean	O
BRB	O
anthocyanin	B
levels	O
±	O
s.e.m.	O

According	O
to	O
a	O
well-established	O
protocol[],	O
aliquots	O
of	O
200	O
μL	O
of	O
serum	O
were	O
transferred	O
into	O
a	O
polypropylene	B
Eppendorf	O
tube	O
and	O
400	O
μL	O
of	O
0.9%	O
saline	B
solution	O
in	O
15%	O
D_2	O
O,	O
containing	O
3	O
mmol/L	O
3-(trimethylsilyl)-2,2’,3,3’-tetradeuteropropionate	B
sodium	I
salt	O
TSP-d4	O
(TSP)	O
were	O
added.	O

Associated	O
network	O
functions	O
include	O
lipid	O
metabolism,	O
nitric	B
oxide	I
synthesis,	O
carboxylic	B
acid	I
transport,	O
and	O
purine	B
nucleotide	O
metabolism.	O

In	O
particular,	O
data	O
have	O
suggested	O
that	O
a	O
reduction	O
in	O
intracellular	O
concentrations	O
of	O
competitive	O
and	O
non-competitive	O
inhibitors	O
by	O
extracellular	O
arginine	B
displacement	O
may	O
augment	O
NO	O
synthase	O
activity,	O
thereby	O
increasing	O
NO	O
production().	O

The	O
quadratic	O
model	O
reasonably	O
described	O
the	O
negative	O
association	O
between	O
TCDD	O
body	O
burden	O
and	O
4-OH-E_2	B
level.	O

A	O
metabolite	O
panel	O
containing	O
dodecanamide	B
and	O
leukotriene	B
B4	I
dimethylamide	I
(LTB4-DMA)	O
had	O
the	O
power	O
capacity	O
to	O
differentiate	O
the	O
two	O
groups	O
of	O
patients,	O
yielding	O
an	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
of	O
0.945	O
(85.2%	O
sensitivity	O
and	O
88.9%	O
specificity)	O
in	O
the	O
training	O
set	O
and	O
0.944(84.6%	O
sensitivity	O
and	O
80.0%	O
specificity)	O
in	O
the	O
test	O
set.	O

Most	O
of	O
the	O
metabolites	O
detected	O
in	O
male	O
plasma	O
could	O
be	O
identified	O
and	O
include	O
phosphate,	B
glycoursodeoxycholic	B
acid	I
(GUDCA),	O
lysophosphatidylcholine	B
(lysoPC)	O
a	O
C18:2,	B
and	O
l-methionine,	B
which	O
show	O
negative	O
weights,	O
i.e.	O
generally	O
higher	O
concentrations	O
in	O
younger	O
men.	O

They	O
observed	O
that	O
plasma	O
alanine	B
levels	O
were	O
lowered	O
in	O
EBC	O
patients	O
compared	O
to	O
healthy	O
controls	O
and	O
especially	O
in	O
patients	O
bearing	O
the	O
aggressive	O
TRN	O
tumors.	O

Levels	O
of	O
the	O
lysine	B
metabolites	O
6	O
(measured	O
as	O
[_2	O
H_3	O
]1)	O
and	O
1	O
were	O
also	O
elevated	O
in	O
smokers	O
relative	O
to	O
non-smokers	O
in	O
the	O
Singapore	O
and	O
Shanghai	O
cohort	O
samples	O
(	O
and	O
).	O

The	O
ratio	O
of	O
arginine	B
to	O
ornithine	B
+	O
citrulline,	B
which	O
reflects	O
global	O
arginine	B
bioavailability	O
and	O
has	O
emerged	O
as	O
a	O
potential	O
PH	O
biomarker	O
in	O
select	O
PH	O
populations	O
with	O
sickle	O
cell	O
disease	O
and	O
heart	O
failure,	O
was	O
inversely	O
related	O
to	O
PAP,	O
PVR,	O
and	O
ΔPQ	O
(all	O
p	O
<	O
0.005).	O

These	O
findings	O
might	O
explain	O
why	O
betaine	B
levels	O
were	O
increased	O
in	O
subjects	O
who	O
had	O
undergone	O
dietary	O
intervention	O
with	O
BSP.	O

[10.6%	O
(P = 0.02)	O
and	O
9.1%	O
(P < 0.05),	O
respectively]	O
but	O
was	O
not	O
consistently	O
better	O
than	O
eGFR	O
using	O
both	O
creatinine	B
and	O
cystatin	B
C	O
[3.7%	O
(P > 0.05)	O
and	O
9.1%	O
(P < 0.05),	O
respectively].	O

The	O
first	O
step	O
consists	O
of	O
the	O
immersion	O
of	O
the	O
tissue	O
in	O
the	O
formalin	B
solution.	O

Furthermore,	O
L-3-hydroxykynurenine	B
is	O
a	O
metabolite	O
in	O
the	O
kynurenine	B
pathway,	O
the	O
major	O
route	O
of	O
tryptophan	B
metabolism.	O

Higher	O
uracil	B
level	O
in	O
CRC	O
tumors	O
than	O
in	O
ANIT	O
observed	O
in	O
our	O
study	O
has	O
also	O
been	O
reported	O
previously	O
in	O
CRC	O
and	O
hepatocellular	O
carcinoma	O
due	O
to	O
reduced	O
dihydropyrimidine	O
dehydrogenase	O
(DPD)	O
activity_,	O
.	O

There	O
were	O
significant	O
correlations	O
between	O
proteinuria	O
and	O
urinary	O
excretion	O
of	O
12	O
AAs	O
(ρ=0.74–0.29	O
for	O
proline,	B
citrulline,	B
asparagine,	B
valine,	B
alanine,	B
threonine,	B
lysine,	B
phenylalanine,	B
methionine,	B
serine,	B
tyrosine,	B
and	O
tryptophan;	B
P	O
<0.05).	O

Top	O
pane,	O
overlaid	O
D-mannose	B
(blue	O
line)	O
and	O
glucose	B
spectrum	O
(red	O
line);	O
bottom	O
pane,	O
representative	O
chromatogram	O
of	O
human	O
serum	O
(blue	O
line)	O
sample	O
spiked	O
with	O
internal	O
standard	O
(D-mannose-_13	O
C_6	O
,	O
red	O
line),	O
with	O
calculated	O
D-mannose	B
concentration	O
of	O
12.98	O
μg/mL.	O
(For	O
interpretation	O
of	O
the	O
references	O
to	O
colour	O
in	O
this	O
figure	O
legend,	O
the	O
reader	O
is	O
referred	O
to	O
the	O
web	O
version	O
of	O
this	O
article.)	O

HCMV	O
virions	O
and	O
synaptic	O
vesicles	O
contain	O
similar	O
ratios	O
of	O
phospholipid	B
head	O
group	O
classes	O
(i.e.,	O
both	O
have	O
higher	O
PE	O
content	O
and	O
lower	O
PS).	O

Average	O
total	O
metabolite	O
recovery	O
(TMR	O
±	O
95%	O
confidence	O
interval)	O
was	O
9.5%	O
higher	O
in	O
MeOH:	B

Formic	B
acid	I
(98%),	O
acetic	B
acid	I
(for	O
LC–MS),	O
ammonium	B
formate	I
(≥99.0%),	O
ammonium	B
acetate	I
(≥99.0%),	O
ammonium	B
hydroxide	I
solution	O
(∼10%	O
in	O
water,	O
for	O
HPLC),	O
isopropylamine	B
(99%),	O
isobutylamine	B
(99%)	O
and	O
isopentylamine	B
(99%)	O
were	O
also	O
purchased	O
from	O
Sigma.	O

In	O
this	O
study,	O
commercially	O
available	O
spirometry	B
filters	O
(MicroGard™,	O
Vyaire	O
Medical,	O
USA;	O
3	O
cm	O
ID;	O
filters	O
99.98%	O
of	O
bacteria	O
and	O
99.92%	O
of	O
viruses)	O
were	O
used	O
as	O
a	O
mouthpiece.	O

Furthermore,	O
although	O
acetyl-CoA	B
is	O
the	O
final	O
product	O
of	O
beta-oxidation	O
of	O
fatty	O
acids	O
in	O
healthy	O
men,	O
in	O
IR	O
hypogonadism,	O
the	O
beta-oxidation	O
of	O
fatty	O
acids	O
does	O
not	O
occur	O
properly	O
as	O
shown	O
by	O
the	O
acyl-carnitine	B
levels	O
(Fig. ).	O

Fifty	O
microliters	O
of	O
serum	O
were	O
aliquoted	O
to	O
a	O
1.5	O
mL	O
Eppendorf	O
LoBind	O
tube	O
and	O
mixed	O
with	O
5	O
μL	O
of	O
internal	O
standard	O
and	O
167	O
μL	O
of	O
methanol.	B

It	O
is	O
important	O
to	O
note	O
that	O
we	O
also	O
observed	O
significant	O
changes	O
of	O
ceramides	B
and	O
other	O
more	O
complex	O
sphingolipids,	B
such	O
as	O
glucosylceramides,	B
and	O
lactosylceramide	B
in	O
the	O
plasma	O
but	O
they	O
did	O
not	O
display	O
a	O
consistent	O
pattern	O
of	O
expression	O
(File	O
).	O

Bilirubin	B
was	O
also	O
upregulated	O
in	O
HCC	O
relative	O
to	O
AML	O
plasma	O
and	O
this	O
is	O
confirmed	O
by	O
clinical	O
chemistry	O
data	O
in	O
(t	O
=	O
3.24;	O
P	O
=	O
0.0024).	O

Matrix	O
[1,8-bis(dimethylamino)naphthalene;	O
DMAN]	O
dissolved	O
in	O
chloroform/methanol	O
(2/1)	O
mixture	O
was	O
applied	O
either	O
on	O
extracts	O
or	O
directly	O
on	O
tissues.	O

Thus,	O
Myc	O
-mediated	O
elevated	O
glutamate	B
levels	O
may	O
in	O
turn	O
drive	O
the	O
increase	O
in	O
ALDH	O
levels	O
that	O
promote	O
HNSCC	O
stemness.	O

The	O
most	O
abundant	O
lipid	O
species	O
observed	O
in	O
the	O
representative	O
spectra	O
of	O
samples	O
G41	O
(oligodendroglioma	O
grade	O
II)	O
and	O
G23	O
(oligodendroglioma	O
grade	O
III)	O
are	O
plasmenyl-PE,	B
PS,	O
and	O
PI.	O

The	O
ions	O
at	O
m/z	O
343.2	O
and	O
348.2	O
(y*)	O
for	O
desamino-PhIP-	B
and	O
desamino-[_2	B
H_5	I
]-PhIP	I
adducts	O
are	O
assigned	O
to	O
the	O
desamino-PhIP-Y	B
immonium	O
ions.	O

For	O
all	O
55	O
patients'	O
plasma	O
samples,	O
8-OH-WAR	B
was	O
observed	O
in	O
15%	O
of	O
these	O
patients,	O
but	O
was	O
below	O
the	O
LOQ.	O

Subsequently,	O
a	O
300 μL	O
volume	O
of	O
methanol	B
(containing	O
12.5 μg/ml	O
L-2-chlorophenylalanine	B
as	O
the	O
internal	O
standard)	O
was	O
added	O
to	O
100 μL	O
of	O
serum.	O

Although	O
the	O
glutaminolytic	B
pathway	O
may	O
have	O
contributed	O
to	O
the	O
generation	O
of	O
lactate,	B
the	O
amount	O
of	O
produced	O
lactate	B
corresponds	O
to	O
90	O
to	O
96%	O
of	O
the	O
consumed	O
glucose	B
suggesting	O
that	O
most	O
of	O
the	O
glucose	B
is	O
metabolized	O
to	O
lactate	B
via	O
aerobic	O
glycolysis	O
and	O
mainly	O
serves	O
as	O
energy	O
rather	O
than	O
as	O
carbon	O
source.	O

In	O
the	O
current	O
study,	O
altered	O
patterns	O
of	O
acylcarnitines	B
as	O
well	O
as	O
TMAO,	B
choline,	B
phenylalanine,	B
BCAAs,	O
alanine,	B
and	O
proline	B
were	O
observed.	O

The	O
global	O
arginine	B
bioavailability	O
ratio	O
(GABR)	O
is	O
a	O
more	O
sensitive	O
diagnostic	O
measurement	O
compared	O
to	O
single	O
concentration.	O

This	O
suggests	O
that	O
there	O
are	O
genetic	O
factors	O
that	O
regulate	O
basal	O
SP	B
metabolism	O
and	O
that	O
resulting	O
differences	O
may	O
explain	O
ethnic	O
variability	O
in	O
disease	O
susceptibility	O
and	O
other	O
similar	O
lipidomic	O
studies.	O

No	O
significant	O
differences	O
in	O
the	O
phosphorylation	O
levels	O
of	O
insulin	O
receptor	O
β	O
and	O
its	O
downstream	O
target	O
Akt,	O
were	O
found,	O
nor	O
was	O
there	O
any	O
significant	O
difference	O
in	O
the	O
level	O
of	O
phosphorylated	O
AS160,	O
which	O
promotes	O
translocation	O
of	O
glucose	B
transporters	O
to	O
the	O
cell	O
membrane.	O

(b)	O
Heatmaps	O
comparing	O
the	O
plasma	O
samples	O
of	O
the	O
non-AF	O
group	O
(S-2)	O
to	O
those	O
of	O
the	O
AF	B
group	O
(AF-2).	O

The	O
intake	O
of	O
histidine	B
in	O
a	O
mouse	O
model	O
of	O
hepatic	O
injury	O
has	O
been	O
reported	O
to	O
reduce	O
the	O
levels	O
of	O
inflammatory	O
cytokines	O
in	O
the	O
liver.	O

In	O
WB,	O
high	O
quality,	O
quantifiable	O
spectra	O
were	O
obtained	O
with	O
the	O
use	O
of	O
a	O
methanol:	B
chloroform	B
precipitation.	O

Fifth,	O
one	O
patient	O
with	O
AN	O
showed	O
somewhat	O
low	O
sum	O
of	O
cortisol	B
metabolites	O
in	O
the	O
daytime,	O
which	O
may	O
be	O
interpreted	O
as	O
“cortisol	O
hyposecretion”.	O

Exclusion	O
criteria	O
were	O
stroke	O
within	O
the	O
last	O
6	O
months,	O
acute	O
liver	O
failure	O
within	O
the	O
last	O
6	O
months	O
or	O
known	O
chronic	O
hepatic	O
failure	O
(alanine	O
aminotransferase	O
or	O
aspartate	B
amino	I
transférase	O
>	O
5	O
times	O
the	O
upper	O
regular	O
limits),	O
history	O
for	O
alcohol	O
abuse	O
or	O
drug	O
addiction,	O
cancer	O
or	O
a	O
diagnosis	O
of	O
cancer	O
within	O
5	O
years,	O
history	O
of	O
recent	O
or	O
current	O
drug	O
or	O
alcohol	O
abuse,	O
participation	O
in	O
any	O
clinical	O
trial	O
within	O
30	O
days	O
prior	O
to	O
admission,	O
hematological	O
pathology	O
(myelodegenerative	O
syndrome,	O
severe	O
anemia	O
(Hb	O
<	O
8	O
g	O
/	O
100	O
ml)	O
or	O
severe	O
neutropenia	O
(neutrophile	O
count	O
<	O
1000	O
cells	O
/µl),	O
thrombocypenia	O
(platelet	O
count	O
<	O
7500	O
plts/µl).	O

(a)	O
7-oxo-DHEA	B
plasma	O
levels	O
positively	O
correlated	O
with	O
absolute	O
CD4+	O
T	O
cell	O
count	O
(number	O
of	O
pairs	O
XY = 11)	O
and	O
the	O
CD4+	O
T	O
cell	O
nadir	O
values	O
(number	O
of	O
pairs	O
XY = 9)	O
in	O
HIV-TB	O
patients.	O

The	O
classic	O
form	O
of	O
21OHD	O
is	O
divided	O
into	O
the	O
salt-wasting	O
(SW)	O
and	O
simple	O
virilizing	O
(SV)	O
forms,	O
depending	O
on	O
the	O
degree	O
of	O
aldosterone	B
deficiency.	O

While	O
of	O
interest	O
as	O
a	O
cancer	O
chemopreventive,	O
the	O
biological	O
activity	O
of	O
limonene	B
in	O
humans	O
is	O
poorly	O
understood.	O

 0.21	O
and	O
P	O
 = 0.25,	O
respectively)	O
and	O
both	O
the	O
aliphatic	B
and	O
aromatic	O
resonances	O
of	O
hippurate	B
(3.97 ppm,	O
P	O
 = 0.52	O
and	O
7.56 ppm,	O
P	O
 = 0.69),	O
neither	O
of	O
these	O
results	O
reaching	O
significance.	O

In	O
addition,	O
a	O
combination	O
of	O
alanine,	B
histidine,	B
leucine,	B
pyruvate,	B
tyrosine,	B
and	O
valine	B
in	O
CSF	O
showed	O
a	O
superior	O
correlation	O
with	O
the	O
presence	O
of	O
T2DM	O
(AUC:0.951),	O
diabetic	O
retinopathy	O
(AUC:0.858),	O
nephropathy	O
(AUC:0.811),	O
and	O
neuropathy	O
(AUC:0.691).	O

This	O
confers	O
upon	O
cells	O
the	O
ability	O
to	O
produce	O
ATP	B
by	O
harnessing	O
fumarate	B
to	O
succinate	B
conversion,	O
rather	O
than	O
oxygen	O
to	O
water,	O
as	O
the	O
final	O
electron	O
transport	O
step	O
via	O
the	O
reverse	O
reaction	O
of	O
succinate	O
dehydrogenase	O
(Kita	O
and	O
Takamiya	O
).	O

Purine	B
metabolism	O
and	O
expression	O
of	O
ATIC	O
and	O
ADSL.	O

This	O
suggested	O
that	O
the	O
source	O
of	O
glucocorticoid	B
and	O
adrenal	O
androgen	O
excess	O
in	O
these	O
patients	O
was	O
indeed	O
the	O
surgically	O
removed	O
adrenocortical	O
adenoma.	O

In	O
addition,	O
we	O
found	O
decreased	O
glycerophosphocholines	B
to	O
be	O
associated	O
with	O
DED,	O
although	O
not	O
at	O
metabolome-wide	O
significance.	O

In	O
particular,	O
FA	B
(20:4),	I
or	O
arachidonic	B
acid,	I
is	O
a	O
precursor	O
of	O
prostaglandins	B
that	O
were	O
shown	O
to	O
be	O
elevated	O
in	O
BCC	O
compared	O
with	O
normal	O
skin,	O
and	O
are	O
predictive	O
of	O
tumor	O
aggressiveness	O
(,	O
).	O

Conjointly,	O
this	O
could	O
improve	O
the	O
prediction	O
of	O
active	O
tamoxifen	B
metabolite	O
levels	O
(Z‐endoxifen)	O
and	O
possibly	O
clinical	O
efficacy,_17	O
,	O
_20	O
,	O
_38	O
a	O
high	O
priority	O
goal	O
in	O
personalized	O
endocrine	O
treatment.	O

Similar	O
to	O
the	O
other	O
sphingolipids,	B
most	O
of	O
the	O
species	O
of	O
ceramide	B
levels	O
were	O
significantly	O
higher	O
in	O
the	O
cancer	O
tissue	O
than	O
in	O
the	O
normal	O
breast	O
tissue,	O
except	O
the	O
C14:0,	B
C18:1,	B
and	O
C26:0	B
ceramides..	I

Calibration	O
curves	O
for	O
quantifying	O
each	O
androgen	O
metabolite	O
using	O
calibrators	O
in	O
the	O
range	O
from	O
2	O
to	O
1000	O
pg	B
using	O
CDS-FBS	O
as	O
a	O
matrix.	O

Equal	O
volume	O
(1–2 μl)	O
of	O
lipid	O
extract	O
and	O
MALDI	O
matrix	O
solution	O
(0.5 M	O
2,5-dihydroxybenzoic	B
acid,	I
DHB,	O
in	O
methanol	B
containing	O
0.1%	O
trifluoroacetic	B
acid)	O
was	O
mixed	O
in	O
a	O
0.6-ml	O
microcentrifuge	O
tube.	O

Leucine	B
enkephalin	I
was	O
used	O
as	O
the	O
lock	O
mass	O
(m/z	O
556.2771	O
in	O
ES+	O
and	O
554.2615	O
in	O
ES-)	O
at	O
a	O
concentration	O
of	O
100	O
ng/ml	O
and	O
flow	O
rate	O
of	O
0.2	O
ml/min	O
for	O
all	O
analyses.	O

Blood	O
was	O
collected	O
in	O
an	O
Heparin	B
Vacutainer	O
and	O
was	O
immediately	O
centrifuged	O
at	O
3,000	O
×	O
g	O
for	O
10	O
min.	O

_13	O
C_6	B
-Phenylalanine	I
was	O
used	O
as	O
an	O
internal	O
standard.	O

Analytes	O
were	O
eluted	O
from	O
the	O
column	O
with	O
a	O
gradient	O
elution	O
(A	O
(10	O
mM	O
ammonium	B
formate	I
and	O
0.1%	O
formic	B
acid,	I
v/v	O
)	O
and	O
B	O
(acetonitrile	O
with	O
0.1%	O
formic	B
acid,	I
v/v	O
)).	O

Table 	O
summarizes	O
11	O
identified	O
metabolic	O
pathways,	O
from	O
which	O
the	O
first	O
5	O
were	O
found	O
to	O
be	O
significantly	O
altered	O
in	O
terms	O
of	O
pathway	O
enrichment	O
(p < 0.05)	O
and/or	O
topology	O
(Impact > 0.1):	O
glyoxylate	B
and	O
dicarboxylate	B
metabolism,	O
glycine	B
serine	I
and	O
threonine	B
metabolism,	O
cyanoamino	O
acid	O
metabolism,	O
citrate	B
cycle	O
(TCA	O
cycle)	O
as	O
well	O
as	O
glutathione	B
metabolism.	O

To	O
address	O
this	O
hypothesis,	O
we	O
developed	O
a	O
sensitive	O
assay	O
for	O
both	O
11-dehydro-TXB2	B
and	O
TXB2,	O
using	O
capillary	O
gas	O
chromatography/negative-ion	O
chemical	O
ionization	O
mass	O
spectrometry.	O

Analyses	O
showed	O
that	O
lower	O
levels	O
of	O
tryptophan	B
[OR:	O
0.58	O
(95 %	O
CI	O
0.35–0.93,	O
p	O
value	O
0.03)]	O
and	O
XA	O
[0.56	O
(0.22–0.91,	O
0.02)],	O
and	O
higher	O
KTR	O
[1.65	O
(1.02–2.71,	O
0.04)],	O
were	O
associated	O
with	O
the	O
age	O
34–40	O
subgroup.	O

By	O
the	O
use	O
of	O
triangulation	O
among	O
diet	O
intake,	O
visceral	O
fat	O
mass	O
and	O
gut	O
microbial	O
profiling	O
in	O
the	O
Twins-UK	O
study	O
the	O
authors	O
suggested	O
plasma	O
levels	O
of	O
hippurate	B
as	O
a	O
putative	O
link	O
between	O
dietary	O
habits	O
and	O
adipocyte	O
function	O
with	O
neuroglobin	O
expression	O
as	O
putative	O
candidate	O
regulator.	O

The	O
vitamin	O
D_2	O
metabolites	O
25(OH)D_2	O
and	O
1,25(OH)_2	B
D_2	O
were	O
not	O
found	O
in	O
the	O
investigated	O
CLD	O
patient	O
samples.	O

Panel	O
(d)	O
shows	O
relative	O
amounts	O
of	O
urinary	O
glycolic	B
acid	I
contributing	O
to	O
differentiation	O
in	O
the	O
OPLS-DA	O
model	O
(VIP	O
>	O
1.0	O
and	O
p	O
<	O
0.05).	O

Aromatic	O
region	O
(5.0–9.5	O
ppm)	O
magnified	O
×4	O
compared	O
with	O
the	O
aliphatic	B
region	O
(0.7–4.3	O
p.p.m).	O

Abbreviations:	O
DAPI:	O
4′,	O
6-diamidino-2-phenylindole;	B
CTR:	O
controls;	O
BPA:	O
bisphenol	B
A;	O
Sil:	O
silybin.	O

Cell	O
viability	O
was	O
measured	O
by	O
A	O
Cell-Titer-Glo_®	O
luminescent	O
cell	O
viability	O
assay	O
kit	O
(Promega,	O
Madison,	O
WI,	O
USA)	O
which	O
based	O
on	O
the	O
production	O
of	O
ATP	B
in	O
viable	O
cells.	O

Creatinine	B
was	O
quantified	O
in-house	O
in	O
24	O
h	O
urine	O
specimens	O
using	O
a	O
photometric	O
assay	O
based	O
on	O
the	O
Jaffé	O
reaction	O
(DetectX®	O
Urinary	O
Creatinine	B
Detection	O
Kit;	O
Arbor	O
Assays,	O
Ann	O
Arbor,	O
Michigan,	O
USA).	O

The	O
glucose	B
regions	O
of	O
the	O
NMR	O
spectra	O
had	O
to	O
be	O
removed	O
due	O
to	O
very	O
high	O
urine	O
glucose	B
levels	O
in	O
several	O
of	O
the	O
HNF1A-MODY	O
subjects.	O

A	O
principal	O
component	O
analysis	O
(PCA)	O
model	O
was	O
constructed	O
for	O
a	O
subset	O
of	O
INTERMAP	O
participants	O
from	O
the	O
United	O
States	O
in	O
order	O
to	O
identify	O
a	O
subset	O
of	O
urine	O
specimens	O
from	O
participants	O
who	O
had	O
ingested	O
acetaminophen	B
and	O
those	O
who	O
had	O
not.	O

Liu	O
et	O
al.	O
used	O
[2,3,3-_2	B
H]serine	I
to	O
evaluate	O
the	O
total	O
contribution	O
of	O
folate	B
metabolism	O
to	O
cellular	O
NADPH	B
levels.	O

Dried	O
samples	O
were	O
reconstituted	O
in	O
0.1%	O
(v	O
/v	O
)	O
formic	B
acid	I
and	O
subjected	O
to	O
liquid	O
chromatography-tandem	O
mass	O
spectrometry	O
(LC-MS/MS)	O
using	O
a	O
Nexera	O
X2	O
system	O
(Shimadzu,	O
Tokyo,	O
Japan)	O
coupled	O
to	O
a	O
triple	O
time-of-flight	O
(TOF)	O
5600+	O
system	O
(Sciex,	O
Tokyo,	O
Japan)	O
equipped	O
at	O
the	O
front	O
end	O
with	O
a	O
DuoSpray	O
ion	O
source	O
(Sciex).	O

Fractions	O
of	O
different	O
isotopomers	O
of	O
_13	O
C	O
citrate	B
(A)	O
and	O
_13	O
C	O
malate	B
(B)	O
in	O
the	O
PC	O
knockdown	O
cell	O
lines	O
and	O
scramble	O
control	O
cell	O
line	O
are	O
shown	O
within	O
the	O
same	O
bars.	O

The	O
ordinate	O
of	O
this	O
bar	O
graph	O
corresponds	O
to	O
the	O
ratio	O
of	O
depurinating	O
DNA	O
adducts	O
divided	O
by	O
their	O
respective	O
estrogen	B
metabolites	O
and	O
conjugates:	O
	O
(4−OHE1(E2)−1−N3Ade+4−OHE1(E2)−1−N7Gua4−catecholestrogens+4−catecholestrogenconjugates+2−OHE1(E2)−6−N3Ade2−catecholestrogens+2−catecholestrogenconjugates)×1000	O
(4−OHE1(E2)−1−N3Ade+4−OHE1(E2)−1−N7Gua4−catecholestrogens+4−catecholestrogenconjugates+2−OHE1(E2)−6−N3Ade2−catecholestrogens+2−catecholestrogenconjugates)×1000	O
(4−OHE1(E2)−1−N3Ade+4−OHE1(E2)−1−N7Gua4−catecholestrogens+4−catecholestrogenconjugates+2−OHE1(E2)−6−N3Ade2−catecholestrogens+2−catecholestrogenconjugates)×1000	O
(4−OHE1(E2)−1−N3Ade+4−OHE1(E2)−1−N7Gua4−catecholestrogens+4−catecholestrogenconjugates+2−OHE1(E2)−6−N3Ade2−catecholestrogens+2−catecholestrogenconjugates)×1000	O
(4−OHE1(E2)−1−N3Ade+4−OHE1(E2)−1−N7Gua4−catecholestrogens+4−catecholestrogenconjugates+2−OHE1(E2)−6−N3Ade2−catecholestrogens+2−catecholestrogenconjugates)×1000	O
(4−OHE1(E2)−1−N3Ade+4−OHE1(E2)−1−N7Gua4−catecholestrogens+4−catecholestrogenconjugates+2−OHE1(E2)−6−N3Ade2−catecholestrogens+2−catecholestrogenconjugates)×1000	O
(4−OHE1(E2)−1−N3Ade+4−OHE1(E2)−1−N7Gua4−catecholestrogens+4−catecholestrogenconjugates	O
(	O
(	O
4−OHE1(E2)−1−N3Ade+4−OHE1(E2)−1−N7Gua4−catecholestrogens+4−catecholestrogenconjugates	O
4−OHE1(E2)−1−N3Ade+4−OHE1(E2)−1−N7Gua4−catecholestrogens+4−catecholestrogenconjugates	O
4−OHE1(E2)−1−N3Ade+4−OHE1(E2)−1−N7Gua4−catecholestrogens+4−catecholestrogenconjugates	O
4−OHE1(E2)−1−N3Ade+4−OHE1(E2)−1−N7Gua	O
4−OHE1(E2)−1−N3Ade+4−OHE1(E2)−1−N7Gua	O
4	O
−	O
OHE1	O
OHE1	O
OHE	O
OHE	O
1	O
1	O
(	O
E2	O
E2	O
E	O
E	O
2	O
2	O
)	O
−	O
1	O
−	O
N	O
3	O
Ade	O
+	O
4	O
−	O
OHE1	O
OHE1	O
OHE	O
OHE	O
1	O
1	O
(	O
E	O
2	O
)	O
−	O
1	O
−	O
N	O
7	O
Gua	O
4−catecholestrogens+4−catecholestrogenconjugates	O
4−catecholestrogens+4−catecholestrogenconjugates	O
4	O
−	O
catechol	O
estrogens	O
+	O
4	O
−	O
catechol	O
estrogen	O
conjugates	O
	O
	O
+2−OHE1(E2)−6−N3Ade2−catecholestrogens+2−catecholestrogenconjugates)×1000	O
+2−OHE1(E2)−6−N3Ade2−catecholestrogens+2−catecholestrogenconjugates	O
+	O
2−OHE1(E2)−6−N3Ade2−catecholestrogens+2−catecholestrogenconjugates	O
2−OHE1(E2)−6−N3Ade2−catecholestrogens+2−catecholestrogenconjugates	O

Based	O
on	O
these	O
data,	O
oxoTBA02	O
was	O
tentatively	O
identified	O
as	O
7β,	O
12α-dihydroxy-3-oxo-5β-cholan-24-oic	B
acid	I
(3-dehydroUCA)	O
and	O
diketoTBA01	O
was	O
tentatively	O
identified	O
as	O
12α-hydroxy-3,7-dioxo-5β-cholan-24-oic	B
acid	I
(3,	O
7-dioxoLCA).	I

Tryptophan	B
can	O
be	O
degraded	O
by	O
tryptophan	O
2,3-dioxygenase	O
(TDO)	O
or	O
indoleamine	O
2,3-dioxygenase	O
(IDO),	O
which	O
is	O
triggered	O
by	O
interferon-γ	O
(IFN-γ)	O
and	O
tumor	O
necrosis	O
factor-α	O
(TNF-α).	O

Although	O
three	O
of	O
the	O
four	O
patients	O
taking	O
a	O
strong	O
CYP2D6	O
inhibitor	O
(fluoxetine)	O
showed	O
low	O
levels	O
of	O
(Z)‐endoxifen	B
(6–15 nM),	O
CYP2D6	O
inhibitor	O
use	O
was	O
not	O
significantly	O
associated	O
with	O
tamoxifen	B
metabolite	O
concentrations.	O

The	O
tripartite	O
motif-containing	O
29	O
(TRIM29)	O
is	O
also	O
increased	O
in	O
cervical	O
cancer	O
lesions,	O
and	O
its	O
downregulation	O
results	O
in	O
enhanced	O
GSK3β	O
expression	O
and	O
inhibition	O
of	O
the	O
epithelial-mesenchymal	O
transition	O
(EMT)	O
in	O
cancer	O
cells,	O
which	O
could	O
explain	O
how	O
GSK3β	B
is	O
inactivated	O
by	O
Wnt/β-catenin	O
signaling	O
to	O
promote	O
tumor	O
progression	O
[,].	O

Previous	O
reports	O
show	O
female	O
free	O
Carn	O
and	O
acyl-Carn	B
levels	O
decrease	O
significantly	O
upon	O
reaching	O
fertile	O
age.	O

The	O
potential	O
importance	O
of	O
this	O
finding	O
lies	O
in	O
the	O
reported	O
overexpression	O
of	O
ALDH	O
in	O
stem	O
cells	O
of	O
many	O
tumor	O
types,	O
making	O
these	O
stem	O
cells	O
potential	O
targets	O
for	O
BEN	O
therapy,	O
existing	O
polymorphisms	O
in	O
ALDH	O
and	O
potential	O
drug–drug	O
interactions	O
with	O
inhibitors	O
of	O
ALDH	O
such	O
as	O
disulfiram	B
and	O
metronidazole	B
[–].	O

Multivariate	O
PLS-DA	O
analysis	O
of	O
the	O
targeted	O
metabolomic	O
data	O
revealed	O
a	O
significant	O
separation	O
by	O
cystathionine	B
groups,	O
which	O
reflects	O
overall	O
differences	O
in	O
the	O
metabolite	O
profiles	O
between	O
the	O
groups.	O

N-acetyl-5-methoxy-tryptamine-α,α,β,β-d_4	B
(d_4	O
-MEL)	O
was	O
obtained	O
from	O
C/D/N	O
Isotopes,	O
Inc.	O

For	O
carbohydrate	O
metabolites,	O
2,3,4-trihydroxybutyrate	B
was	O
also	O
found	O
to	O
be	O
decreased	O
in	O
the	O
TBI	O
patients	O
with	O
cognitive	O
impairment.	O

1,4-dihydropyrimidines;	B
synthesis	O
and	O
characterization;	O

While	O
the	O
association	O
between	O
DES	B
and	O
estrogen	B
metabolism	O
is	O
in	O
the	O
direction	O
of	O
higher	O
breast	O
cancer	O
risk	O
for	O
the	O
prenatally	O
DES	B
exposed	O
and	O
could	O
therefore	O
possibly	O
explain	O
some	O
of	O
their	O
modestly	O
increased	O
risk	O
compared	O
with	O
the	O
unexposed,	O
it	O
will	O
take	O
a	O
larger	O
study	O
to	O
quantify	O
the	O
magnitude	O
of	O
the	O
effect.	O

eGFR = 133 × min(serum	O
cystatin	B
C/0.8,	O
1)-0.499	O
 × max(serum	O
cystatin	B
C/0.8,	O
1)-1.328	O
 × 0.996_age	O
[×0.932	O
if	O
female].	O

a	O
,	O
major	O
MS_2	O
fragmentation	O
routes	O
for	O
GP-tagged	O
sterols	O
and	O
bile	O
acids	O
exemplified	O
by	O
27-hydroxycholesterol.	B

Crude	O
extracts	O
of	O
plasma	O
from	O
normal	O
and	O
diabetic	O
monkeys	O
under	O
fasting	O
and	O
fed	O
conditions	O
were	O
examined	O
by	O
LCMS	O
to	O
quantitatively	O
assess	O
the	O
differences	O
in	O
the	O
levels	O
of	O
phospholipids	B
and	O
sphingolipids	B
(,	O
,	O
,	O
).	O

The	O
disjoint	O
rules	O
indicate	O
that	O
aAIP	O
patients	O
were	O
specifically	O
characterized	O
by	O
higher	O
concentrations	O
of	O
acetate,	B
citrate	B
and	O
pyruvate,	B
the	O
inverse	O
being	O
observed	O
for	O
PCT	O
patients.	O

With	O
internal	O
standard	O
calibration,	O
MALDI-TOF-MS	O
is	O
widely	O
used	O
to	O
obtain	O
the	O
relatively	O
accurate	O
average	O
MW	O
of	O
glycoconjugates.	B

d	O
d	O
d	O
d	O
d	O
For	O
the	O
calibrators	O
and	O
QC	O
samples,	O
spiked	O
directly	O
with	O
diosmetin,	B
a	O
deconjugation	O
is	O
not	O
needed;	O
therefore,	O
these	O
samples	O
were	O
not	O
incubated	O
with	O
enzymes	O
but	O
just	O
diluted	O
with	O
0.3 mL	O
sodium	B
acetate	I
0.2 M,	O
pH	O
4.5	O
and	O
further	O
processed	O
as	O
described	O
in	O
“Extraction	O
procedure	O
for	O
the	O
determination	O
of	O
diosmetin	B
in	O
plasma.”	O

Furthermore,	O
the	O
increase	O
of	O
pyruvate	B
could	O
be	O
mediated	O
through	O
the	O
methylcitrate	B
cycle	O
(MCC),	O
which	O
oxidizes	O
propionyl-CoA	B
generated	O
by	O
β-oxidation	O
of	O
odd-chain	O
fatty	O
acids	O
to	O
pyruvate	B
,	O
which	O
then	O
feed	O
into	O
the	O
TCA	O
cycle	O
_,	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
above	O
model	O
and	O
also	O
with	O
our	O
previous	O
study	O
showing	O
additive	O
improvement	O
in	O
metabolic	O
flexibility	O
and	O
insulin	O
sensitivity	O
by	O
combined	O
interventions	O
using	O
EPA + DHA	O
and	O
thiazolidinediones	B
in	O
dietary	O
obese	O
mice.	O

Acetate	B
was	O
the	O
dominant	O
SCFA	O
produced	O
in	O
all	O
fermentations	O
in	O
both	O
IBS	O
and	O
healthy	O
donors.	O

Interestingly,	O
the	O
edges	O
connecting	O
isoleucine	B
to	O
other	O
amino	O
acids	O
(threonine,	O
serine,	B
proline)	B
all	O
consist	O
of	O
positive	O
correlations,	O
while	O
the	O
connections	O
to	O
the	O
two	O
monounsaturated	O
fatty	O
acids	O
(MUFAs),	O
oleic	B
acid	I
and	O
palmitoleic	B
acid,	I
represent	O
negative	O
correlations.	O

Less	O
strongly	O
retained	O
creatinine	B
(mean	O
t	O
_R	O
=6.8	O
min,	O
k	O
=3.9)	O
gave	O
an	O
RSD	O
of	O
0.2	O
%.	O

It	O
should	O
be	O
noted	O
that	O
even	O
substances	O
with	O
low	O
solubility	O
in	O
organic	O
solvents,	O
like	O
for	O
example	O
alanine,	B
are	O
still	O
readily	O
dissolved	O
as	O
the	O
concentration	O
present	O
in	O
urine	O
is	O
sufficiently	O
low.	O

Chloroform	B
(HPLC	O
grade)	O
and	O
ammonia	B
solution	I
were	O
purchased	O
from	O
Merck	O
(Germany).	O

While	O
the	O
C18	O
BEH	O
phase	O
does	O
not	O
separate	O
isomers	O
of	O
1α,25(OH)_2	B
D_3	O
-PTAD,	O
it	O
does	O
separate	O
the	O
isomers	O
of	O
1α,25(OH)_2	B
D_2	O
-PTAD	O
(see	O
the	O
“”).	O

Increased	O
levels	O
of	O
hypoxanthine,	B
a	O
substrate	O
for	O
xanthine	B
oxidase,	O
may	O
result	O
in	O
generating	O
reactive	O
oxygen	O
species	O
(ROS).	O

SPE	O
and	O
LLE	O
methods	O
demonstrated	O
lower	O
repeatability	O
then	O
methanol	B
blends	O
with	O
the	O
poorest	O
performance	O
by	O
MTBE	B
and	O
C18	O
SPE.	O

The	O
retina	O
presented	O
a	O
large	O
diversity	O
of	O
GGs	O
since	O
7	O
different	O
classes	O
could	O
be	O
detected	O
and	O
quantified:	O
GM3,	B
GM1,	O
GD3,	O
GD1a,	O
GD1b,	O
GT1b	O
and	O
GQ1b.	O

Maltose	B
is	O
a	O
disaccharide	B
derived	O
from	O
two	O
units	O
of	O
glucose	B
and	O
is	O
found	O
largely	O
in	O
vegetables,	O
fruits	O
and	O
grains.	O

Analysis	O
by	O
the	O
paired	O
Wilcoxon	O
test	O
showed	O
non-significant	O
results	O
for	O
both	O
oxysterols	B
as	O
well	O
as	O
for	O
others.	O

Relative	O
risk	O
(RR)	O
and	O
95%	O
CIs	O
were	O
calculated	O
at	O
the	O
12‐month	O
time	O
point	O
to	O
evaluate	O
the	O
risk	O
of	O
patients	O
not	O
achieving	O
a	O
previously	O
proposed	O
clinical	O
threshold	O
of	O
5.9 ng/mL	O
(15.8 nM)	O
(Z)‐endoxifen._20	B
All	O
P	O
values	O
were	O
two‐sided,	O
and	O
values	O
< 0.05	O
were	O
considered	O
statistically	O
significant	O
(details	O
provided	O
in	O
Supplemental	O
Material).	O

We	O
did	O
not	O
detect	O
kynurenine	B
in	O
our	O
urinary	O
samples	O
but	O
noted	O
a	O
catabolite,	O
xanthurenate,	B
to	O
be	O
lowered	O
in	O
CRC	O
patients	O
prior	O
to	O
surgery	O
compared	O
to	O
post-surgery	O
patients.	O

The	O
hepatic	O
growth	O
factor	O
receptor	O
,	O
also	O
known	O
as	O
MET,	O
is	O
part	O
of	O
a	O
tyrosine	B
kinase	O
signaling	O
complex	O
that	O
functions	O
in	O
cell	O
growth	O
and	O
survival,	O
angiogenesis	O
and	O
tissue	O
regeneration	O
[–].	O

Abbreviations:	O
15-LO,	O
15-lipoxygenase	O
inhibitor;	O
DHPM,	O
dihydropyrimidine.	B

These	O
results	O
suggest	O
that	O
metabolic	O
reprogramming	O
occurs	O
in	O
aAIP	O
individuals,	O
even	O
in	O
the	O
absence	O
of	O
overt	O
symptoms,	O
and	O
supports	O
the	O
relationship	O
that	O
occur	O
between	O
heme	B
synthesis	O
and	O
mitochondrial	O
energetic	O
metabolism.	O

Upon	O
analysis	O
the	O
dried	O
samples	O
were	O
reconstituted	O
in	O
100 µL	O
5%	O
MeOH,	B
0.1%	O
formic	B
acid	I
and	O
94.9%	O
deionized	O
MilliQ	O
water.	O

(rs116855232)	O
were	O
significantly	O
different	O
within	O
8,	O
12	O
weeks	O
and	O
6	O
months	O
of	O
thiopurine	B
initiation	O
(overall	O
p	O
<	O
0.05).	O

It	O
is	O
believed	O
that	O
erythronic	B
acid	I
is	O
increased	O
when	O
there	O
is	O
diminished	O
flux	O
through	O
the	O
PPP,	O
as	O
in	O
the	O
case	O
of	O
transaldolase	O
deficiency.	O

However,	O
thiamine	B
was	O
significantly	O
decreased	O
in	O
BCa,	O
and	O
its	O
level	O
was	O
significantly	O
decreased	O
in	O
normal	O
tissues	O
after	O
submucosal	O
injection	O
of	O
gemcitabine.	O

With	O
an	O
exception	O
of	O
pyruvate,	B
kIBS	O
samples	O
contained	O
higher	O
levels	O
of	O
these	O
metabolites.	O

Additionally,	O
from	O
the	O
three	O
group	O
analysis,	O
we	O
have	O
observed	O
tryptophan,	B
tyrosine,	B
and	O
creatine	B
as	O
common	O
metabolites	O
present	O
in	O
both	O
tissue	O
and	O
serum.	O

Other	O
gut-derived	O
metabolites	O
from	O
PSPC	O
polyphenolics	O
that	O
were	O
elevated	O
post-exercise	O
compared	O
to	O
placebo	O
included	O
2-hydroxyhippurate	B
(interaction	O
effect,	O
P = 0.0221),	O
3-hydroxyhippurate	B
(P = 0.0352),	O
catechol	B
sulfate	I
(P = 0.0687),	O
and	O
O-methylcatecholsulfate	B
(P = 0.085).	O

Diets	O
high	O
in	O
refined	O
carbohydrates	O
(sugar)	O
are	O
known	O
to	O
increase	O
TG	B
levels.	O

Sleep	O
restriction	O
also	O
induced	O
elevations	O
in	O
several	O
fatty	O
acid,	O
bile	O
acid,	O
steroid	O
hormone,	O
and	O
tricarboxylic	B
acid	I
cycle	O
intermediates.	O

Samples	O
were	O
methoximated	O
by	O
incubating	O
lyophilized	O
serum	O
residues	O
in	O
50	O
µl	O
of	O
methoxyamine	B
in	O
pyridine	B
(0.3	O
µg/µL)	O
for	O
16	O
hours	O
at	O
room	O
temperature.	O

Reagent	O
grade	O
pyridine	B
and	O
methoxyamine	B
hydrochloride	I
(Sigma	O
Aldrich,	O
St	O
Louis,	O
MO,	O
USA)	O
were	O
used	O
in	O
the	O
preparation	O
of	O
a	O
methoximation	O
reagent.	O

1 mM	O
3-trimethylsilyl-1-[2,	B
2,	I
3,	I
3-_2	I
H4]	I
propionate	I
(TSP),	O
and	O
3 mM	O
sodium	O
azide;	O
pH	O
7.4).	O

The	O
SEM	O
microscopic	O
technique	O
confirmed	O
that	O
the	O
application	O
of	O
acetonitrile	B
gave	O
rise	O
to	O
a	O
higher	O
number	O
of	O
specific	O
interactions	O
between	O
CDHB	O
template	O
and	O
monomers	O
(1-ALPP),	O
resulting	O
in	O
compact	O
and	O
more	O
porous	O
morphology	O
of	O
the	O
imprinted	O
polymers.	O

Finally,	O
pre-cooled	O
methanol	B
was	O
added	O
for	O
fixation.	O

For	O
this	O
reason,	O
acetonitrile/water	O
extracts	O
(84:16%	O
v/v	O
)	O
from	O
acetonitrile/water	O
extract	O
tissue	O
(84:16%	O
v/v	O
)	O
were	O
diluted	O
with	O
water	O
at	O
the	O
1:5	O
ratio	O
without	O
hexane	B
degreasing,	O
and	O
they	O
were	O
applied	O
to	O
the	O
conditioned	O
MIP-CDHB	O
polymer	O
bed.	O

Subclasses	O
that	O
were	O
increased	O
in	O
fatalities	O
vs.	O
healthy	O
controls	O
include	O
PS,	O
diacylglycerophosphoethanolamine	B
(PE),	O
Cer,	B
PG,	B
and	O
diacylglycerol	B
(DG).	O

The	O
correlations	O
were	O
significant	O
for	O
C14:2-OH,	B
C16:2,	B
C18:1-OH,	B
C2,	O
C3,	O
C5,	O
C5-DC,	O
C5-OH,	O
C5:1-DC,	B
C6	O
and	O
C6:1.	B

 ),	O
and	O
there	O
was	O
a	O
moderate	O
correlation	O
between	O
tryptophan	B
and	O
kynurenine	B
(R	O
 = 0.56,	O
P	O
 < 0.01).	O

It	O
was	O
found	O
that	O
a	O
reagent	O
concentration	O
of	O
0.5 mg/mL	O
PTAD	O
in	O
acetonitrile	B
exhibited	O
the	O
highest	O
signal-to-noise	O
ratios	O
in	O
the	O
mass	O
spectra.	O

In	O
the	O
present	O
study,	O
we	O
identified	O
LMI	O
with	O
147.0764 m/z	O
as	O
D,L-glutamine,	B
and	O
the	O
mass	O
peak	O
area	O
of	O
D,L-glutamine	B
was	O
lower	O
in	O
OVC	O
(Fig. ).	O

Only	O
betaine	B
and	O
fibrinogen	O
maintained	O
a	O
significant	O
association	O
(β	O
=	O
-0.153,	O
p	O
=	O
0.015,	O
r_2	O
=	O
0.54),	O
whereas	O
TMAO	B
and	O
choline	B
had	O
no	O
significant	O
effect	O
on	O
the	O
estimate	O
for	O
IL-6,	O
fibrinogen	O
or	O
hsCRP	O
when	O
GFR	O
was	O
taken	O
into	O
account.	O

FT	B
full	O
MS	O
scan	O
was	O
acquired	O
at	O
30,000	O
resolution	O
with	O
m/z	O
range	O
of	O
50–400	O
Th;	O
whereas	O
linear	O
ion	O
trap	O
(LIT)	O
MS/MS	O
scan	O
was	O
obtained	O
via	O
collision	O
induced	O
dissociation	O
(CID)	O
with	O
a	O
normal	O
m/z	O
range	O
of	O
50–400	O
Th;	O
isolation	O
width	O
of	O
1	O
Th;	O
and	O
normalized	O
collision	O
energy	O
of	O
35.	O

Although	O
CYP3A5	O
is	O
polymorphically	O
expressed	O
among	O
different	O
ethnic	O
groups,	O
with	O
CYP3A5*3	O
(inactive	O
gene	O
form)	O
allele	O
frequencies	O
of	O
30%,	O
50%	O
and	O
90%	O
in	O
African,	O
Asian	O
and	O
Caucasian,	O
respectively	O
[,	O
],	O
the	O
role	O
of	O
CYP3A5	O
and	O
any	O
SNPs	O
in	O
the	O
gene	O
that	O
codes	O
for	O
this	O
enzyme	O
in	O
anastrozole	B
metabolism	O
in	O
vivo	O
is	O
likely	O
to	O
be	O
small	O
because	O
the	O
in	O
vitro	O
kinetic	O
data	O
presented	O
here	O
suggest	O
CYP3A4	O
(not	O
CYP3A5)	O
is	O
the	O
dominant	O
enzyme	O
responsible	O
for	O
anastrazole	B
metabolism	O
at	O
therapeutically	O
relevant	O
concentrations.	O

Mean	O
estimated	O
total	O
clearance	O
of	O
fentanyl	O
and	O
mean	O
metabolic	O
clearance	O
of	O
midazolam	B
(as	O
a	O
marker	O
of	O
CYP3A	O
activity)	O
were	O
75.5	O
and	O
36.3 L/h.	O

Therefore,	O
while	O
performing	O
serum	O
metabolite	O
profiling,	O
it	O
is	O
important	O
to	O
consider	O
the	O
sum	O
of	O
the	O
apparent	O
glutamine	B
and	O
pyroglutamic	B
acid	I
levels	O
as	O
the	O
actual	O
blood	O
glutamine	B
level	O
for	O
biomarker	O
discovery	O
and	O
biological	O
interpretations.	O

Only	O
one	O
metabolite	O
(formate)	O
in	O
univariate	O
statistical	O
analysis	O
was	O
significantly	O
lower	O
in	O
patients	O
with	O
active	O
CD,	O
and	O
two	O
metabolites	O
(alanine	O
and	O
N	O
-acetylated	O
compounds)	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
CD	O
when	O
comparing	O
jointly	O
patients	O
in	O
the	O
remission	O
and	O
active	O
phase	O
of	O
the	O
diseases.	O

Of	O
these	O
columns,	O
an	O
Ascentis	O
Express	O
F5	O
(PFPP)	O
column	O
was	O
selected	O
and	O
was	O
evaluated	O
for	O
its	O
ability	O
to	O
resolve	O
a	O
standard	O
mixture	O
of	O
25(OH)D_3	B
,	I
3-epi-25(OH)D_3	I
,	O
and	O
25(OH)D_2	O
.	O

After	O
methanol	B
incubation,	O
the	O
needle	O
biopsies	O
were	O
placed	O
in	O
biopsy	O
bags	O
and	O
cassettes,	O
which	O
were	O
then	O
transferred	O
to	O
Molecular	O
Fixative	O
(UMFix,	O
Sakura,	O
Torrance,	O
CA,	O
USA)	O
until	O
processed	O
for	O
histology.	O

These	O
data	O
implied	O
that	O
the	O
new	O
diagnostic	O
model	O
combining	O
1-methyladenosine	B
with	O
AFP	O
possesses	O
improved	O
sensitivity	O
and	O
could	O
identify	O
those	O
patients	O
who	O
missed	O
the	O
diagnosis	O
of	O
HCC	O
by	O
determining	O
serum	O
AFP	O
alone.	O

An	O
amount	O
of	O
40	O
µL	O
as	O
injected	O
and	O
separated	O
using	O
the	O
following	O
mobile	O
phases:	O
water	O
(solvent	O
A)	O
and	O
acetonitrile	B
(solvent	O
B),	O
both	O
with	O
0.1%	O
formic	B
acid.	I

We	O
demonstrated	O
that	O
Sil	O
alone	O
or	O
in	O
combination	O
with	O
BPA	O
in	O
our	O
experimental	O
model	O
(H-HepG2)	O
counteracts	O
the	O
BPA	O
proliferation	O
effect	O
both	O
decreasing	O
the	O
glucose	B
uptake	O
and	O
phosphorylation	O
of	O
ERK1/2.	O

The	O
greatest	O
statistical	O
and	O
biological	O
finding	O
was	O
the	O
appearance	O
of	O
two	O
fatty	O
acid	O
amides	O
(FAAs),	O
oleamide	B
and	O
palmitoleoyl	B
ethanolamide	I
(POEA),	O
in	O
AML	O
plasma,	O
both	O
of	O
which	O
can	O
be	O
considered	O
to	O
be	O
endocannabinoids	B
that	O
act	O
on	O
CB1	O
and	O
CB2	O
receptors	O
,	O
,	O
with	O
elevated	O
plasma	O
POEA	B
reported	O
to	O
be	O
associated	O
with	O
certain	O
anxiety	O
states	O
and	O
oleamide	B
being	O
an	O
important	O
regulator	O
of	O
sleep	O
via	O
the	O
CB1	O
receptor	O
.	O

It	O
can	O
be	O
observed	O
that	O
in	O
this	O
plasma	O
sample,	O
all	O
studied	O
metabolites	O
were	O
detected	O
with	O
the	O
exception	O
of	O
fumarate.	B

Serine	B
and	O
glycine	B
have	O
also	O
been	O
reported	O
to	O
positively	O
correlate	O
with	O
insulin	O
action,	O
as	O
assessed	O
by	O
repeated	O
glucose	B
tolerance	O
tests	O
in	O
overweight	O
and	O
obese	O
sedentary	O
men	O
and	O
women.	O

We	O
did	O
not	O
adjust	O
for	O
AF	B
since	O
this	O
was	O
one	O
of	O
our	O
major	O
outcomes	O
of	O
interest	O
and	O
AF	B
is	O
known	O
to	O
have	O
a	O
strong	O
association	O
with	O
CE	O
stroke.	O

(D	O
)	O
Bright-field	O
images	O
of	O
HCT15	O
cells	O
grown	O
in	O
soft	O
agar	O
and	O
incubated	O
with	O
DMSO	B
or	O
25	O
µM	O
680C91,	O
epacadostat,	O
or	O
CH223191	O
for	O
4	O
wk	O
in	O
DMEM	O
containing	O
1%	O
serum.	O

Many	O
of	O
the	O
metabolites	O
that	O
contributed	O
to	O
significant	O
differences	O
in	O
the	O
NMR	O
model	O
were	O
amino	O
acids	O
and	O
the	O
cluster	O
of	O
signals	O
from	O
glucose.	B

MPO	O
associated	O
baseline	O
metabolites	O
supported	O
by	O
all	O
three	O
levels	O
of	O
evidence	O
were:	O
serum	O
glycerol,	B
muscle	O
alanine,	B
proline,	B
threonine,	B
creatinine,	B
AMP	B
and	O
pyruvate	B
for	O
ET,	O
and	O
serum	O
lysine,	B
phenylalanine,	B
creatine,	B
and	O
muscle	O
glycolate	B
for	O
HIIT.	O

The	O
subjects	O
were	O
screened	O
by	O
age	O
(18	O
lower	O
limit),	O
body	O
mass	O
index	O
(18–31)	O
and	O
applying	O
the	O
following	O
clinical	O
criteria:	O
no	O
hormone	O
contraceptives,	O
no	O
topical	O
estrogen	B
agents,	O
no	O
statins/lipid	O
lowering	O
agents,	O
no	O
allergy	O
medications	O
at	O
least	O
2	O
weeks	O
prior	O
to	O
blood	O
drawing,	O
no	O
diabetic	O
medications,	O
no	O
anti-inflammatory	O
medications	O
at	O
least	O
2	O
weeks	O
prior	O
to	O
blood	O
drawing,	O
no	O
heart	O
failure	O
medications,	O
no	O
anti-hypertensive	O
medications	O
and	O
no	O
anticoagulants.	O

By	O
MS	O
analysis	O
we	O
showed	O
that	O
several	O
of	O
the	O
acylcarnitines	B
are	O
increased	O
in	O
plasma	O
from	O
PCa	O
patients,	O
while	O
several	O
glycerophospholipids	B
are	O
decreased.	O

Other	O
amino	O
acids	O
such	O
as	O
proline,	B
isoleucine	B
and	O
leucine	B
also	O
varied,	O
although	O
no	O
statistically	O
significance	O
could	O
be	O
demonstrated.	O

Interestingly,	O
the	O
lactose	B
levels	O
are	O
almost	O
back	O
to	O
their	O
baseline	O
level	O
at	O
6	O
h	O
in	O
our	O
study	O
in	O
which	O
the	O
subjects	O
have	O
ingested	O
600	O
mL	O
of	O
milk,	O
whereas	O
significant	O
amounts	O
of	O
lactose	B
remained	O
in	O
serum	O
6	O
h	O
after	O
the	O
ingestion	O
of	O
800	O
mL.	O
This	O
difference,	O
which	O
may	O
be	O
due	O
to	O
limitation	O
in	O
the	O
passive	O
absorption	O
properties	O
of	O
the	O
intestinal	O
barrier,	O
highlights	O
the	O
importance	O
of	O
dose-response	B
studies	O
in	O
the	O
field	O
of	O
food	O
intake	O
markers.	O

In	O
each	O
sample,	O
the	O
cortisol	B
metabolites	O
were	O
measured	O
(5β-tetrahydrocortisol,	O
5α-tetrahydrocortisol,	B
5β-tetrahydrocortisone,	B
and	O
5α-tetrahydrocortisone)	B
according	O
to	O
methods	O
previously	O
reported	O
(,	O
).	O

c	O
In	O
malignant	O
gliomas	O
(grade	O
III + IV)	O
alone,	O
higher	O
CSF	O
levels	O
of	O
lactic	B
acid	I
were	O
significantly	O
associated	O
with	O
having	O
a	O
shorter	O
OS	O
(log-rank:	O
p	O
 = 0.032)	O

“/”	O
indicates	O
co-eluting	O
lipid	O
classes	O
Using	O
standards	O
and	O
yeast	O
samples,	O
it	O
could	O
be	O
shown	O
that	O
lipid	O
class-specific	O
fractionation	O
was	O
successfully	O
accomplished	O
for	O
14	O
different	O
lipid	O
classes	O
or	O
subclasses	O
(FA,	O
DG,	O
ST,	O
MG,	O
SPH,	B
HexCer,	O
PG,	B
Hex2Cer,	O
PC,	O
SM,	O
LPC,	O
Cer	B
d,	O
Cer	B
t,	O
Cer	B
e)	O
paving	O
the	O
way	O
to	O
further	O
purification,	O
in-depth	O
profiling,	O
or	O
facilitating	O
a	O
detailed	O
fatty	O
acyl	O
chain	O
composition	O
determination	O
via	O
gas	O
chromatography-mass	O
spectrometry	O
(GC-MS)	O
as	O
previously	O
addressed	O
by	O
TLC	O
or	O
SPE	O

Recent	O
study	O
has	O
proposed	O
that	O
lactate	B
is	O
also	O
a	O
tricarboxylic	B
acid	I
(TCA)	O
cycle	O
carbon	O
source	O
for	O
NSCLC	O
and	O
sustain	O
tumor	O
metabolism	O
in	O
vivo.	O

Prior	O
to	O
the	O
analysis,	O
a	O
volume	O
of	O
400 μL	O
of	O
methanol	B
was	O
added	O
to	O
100 μL	O
of	O
plasma.	O

The	O
increased	O
concentrations	O
of	O
proline,	B
serine,	B
and	O
threonine	B
that	O
were	O
observed	O
in	O
CRC	O
samples	O
could	O
also	O
be	O
the	O
result	O
from	O
degradation	O
of	O
intestinal	O
mucins,	B
which	O
are	O
primarily	O
comprised	O
of	O
glycoproteins	B
rich	O
in	O
these	O
amino	O
acids	O
.	O

_,	O
Our	O
earlier	O
metabolomic	O
analyses	O
of	O
HNSCC	O
cells	O
showed	O
that	O
several	O
metabolites,	O
including	O
glutamate	B
and	O
those	O
involved	O
with	O
glycolysis,	O
are	O
important	O
in	O
distinguishing	O
HNSCC	O
cells	O
from	O
normal	O
oral	O
keratinocytes.	O

(A)	O
Tryptophan	B
based	O
on	O
median	O
split	O
of	O
daily	O
abdominal	O
pain	O
after	O
eating,	O
(B)	O
serotonin	B
based	O
on	O
median	O
split	O
of	O
percent	O
of	O
days	O
with	O
loose	O
stools,	O
(C)	O
melatonin	B
based	O
on	O
median	O
split	O
of	O
reported	O
sleep	O
quality	O
across	O
the	O
month,	O
(D)	O
tryptamine	B
based	O
on	O
median	O
split	O
of	O
wake	O
time	O
reported	O
in	O
the	O
daily	O
diary,	O
(E)	O
indole-3-lactic	B
acid	I
based	O
on	O
median	O
split	O
of	O
time	O
in	O
bed	O
reported	O
in	O
the	O
daily	O
diary,	O
and	O
(F)	O
indole-pyruvate	O
based	O
on	O
median	O
split	O
of	O
percent	O
time	O
in	O
rapid	O
eye	O
movement	O
(REM)	O
sleep	O
recorded	O
by	O
polysomnography.	O

Chemical	O
shifts	O
were	O
referenced	O
internally	O
to	O
the	O
CH_3	O
resonance	O
of	O
alanine	B
at	O
1.47	O
ppm.	O

The	O
mass	O
spectra	O
in	O
panels	O
(a)–(d)	O
are	O
from	O
FA	B
solutions	O
having	O
sequentially	O
decreasing	O
concentrations	O
and	O
all	O
are	O
presented	O
by	O
the	O
same	O
y-axis	O
scale	O
as	O
demonstrated	O
in	O
panels	O
(a).	O

The	O
expression	O
of	O
sphingomyelin	O
phosphodiesterase	O
2	O
(SMPD2),	O
sphingomyelin	O
phosphodiesterase	O
4	O
(SMPD4),	O
sphingomyelin	O
phosphodiesterase	O
5	O
(SMPD5)	O
and	O
sphingomyelin	B
synthase	O
2	O
(SGMS2)	O
in	O
The	O
Cancer	O
Genome	O
Atlas	O
(TCGA)	O
cohort	O
(n=112)	O
were	O
analyzed.	O

	O
LC-MS	O
analyses	O
on	O
the	O
fecal	O
lipids	O
were	O
performed	O
on	O
a	O
1260	O
Infinity	O
High	O
Performance	O
Liquid	O
Chromatography	O
system	O
coupled	O
with	O
a	O
6540	O
UHD	O
Accurate-Mass	B
Q-TOF	O
mass	O
spectrometer	O
from	O
Agilent	O
Technologies	O
(Santa	O
Clara,	O
CA)	O
with	O
a	O
Dual	O
Agilent	O
Jet	O
Stream	O
Electrospray	O
Ionization	O
(Dual	O
AJS	O
ESI)	O
source.	O

In	O
addition,	O
few	O
other	O
metabolites	O
like	O
citrulline	B
(a	O
participant	O
in	O
urea	B
cycle),	O
mevalonic	B
acid,	I
3-octanone	B
and	O
pregnenolone	B
sulfate	I
also	O
exhibited	O
the	O
same	O
co-variation	O
(initially	O
increases	O
with	O
subsequent	O
decline)	O
as	O
the	O
above	O
metabolites.	O

In	O
addition,	O
two	O
signals	O
of	O
some	O
metabolites	O
were	O
statistically	O
not	O
relevant,	O
such	O
as	O
isoleucine	B
and	O
Hypoxanthine	B
(Table ),	O
glutathione	B
(Table ),	O
which	O
should	O
be	O
verified	O
in	O
better	O
metabolomics	O
platform.	O

Twenty	O
healthy	O
male	O
volunteers	O
were	O
recruited	O
(aged	O
41–63	O
years);	O
ten	O
were	O
asymptomatic	O
with	O
high	O
plasma	O
cholesterol	B
> 6.5 mM	O
and	O
ten	O
were	O
healthy	O
with	O
normal	O
plasma	O
cholesterol	B
(< 6.5 mM).	O

In	O
males,	O
1,3-dimethylurate,	B
malonate,	B
and	O
2-hydroxybutyrate	B
contributed	O
most	O
to	O
the	O
separation	O
when	O
subjective	O
distress	O
was	O
included	O
(Fig. ),	O
with	O
VIP	O
scores	O
of	O
1.47,	O
1.35,	O
and	O
1.15	O
(Table ).	O

The	O
following	O
demographic,	O
clinical	O
and	O
laboratory	O
variables	O
were	O
considered:	O
(i)	O
information	O
about	O
the	O
patient	O
collected	O
at	O
ICU	O
admission:	O
age	O
(years),	O
sex,	O
body	O
mass	O
index,	O
pathological	O
conditions	O
before	O
hospitalization	O
(presence	O
of	O
hepatic	O
insufficiency,	O
renal	O
insufficiency,	O
respiratory	O
pathologies,	O
immunocompromised	O
state,	O
cardiovascular	O
pathologies),	O
Simplified	O
Acute	O
Physiology	O
Score	O
(SAPS),	O
duration	B
of	O
primary	O
infection;	O
(ii)	O
hemodynamic	O
parameters:	O
heart	O
rate	O
(bpm),	O
mean	O
arterial	O
pressure	O
(mmHg),	O
venous	O
central	O
pressure	O
(mmHg),	O
daily	O
urinary	O
output	O
(ml/die);	O
(iii)	O
ventilation	O
parameters:	O
the	O
need	O
for	O
ventilatory	O
support,	O
positive	O
end-expiratory	O
pressure	O
(cmH_2	O
0),	O
FiO_2	O
(%);	O
(iv)	O
blood	O
gas	O
analysis:	O
central	O
venous	O
O_2	O
saturation,	O
venous	O
partial	O
pressure	O
of	O
CO_2	O
,	O
arterial	O
partial	O
pressure	O
of	O
CO_2	O
,	O
arterial	O
partial	O
pressure	O
of	O
O_2	O
,	O
central	O
venous	O
partial	O
pressure	O
of	O
O_2	O
,	O
arterial	O
and	O
venous	O
pH;	O
(v)	O
laboratory	O
and	O
clinical	O
parameters:	O
serum	O
concentrations	O
of	O
creatinine	B
(mg/dL),	O
biliuribin	O
(mg/dL),	O
and	O
lactate	B
(mmol/L),	O
platelet	O
count	O
(x10_3	O
cells/mm_3	O
);	O
(vi)	O
Sequential	O
Organ	O
Failure	O
Assessment	O
Score	O
(SOFA),	O
total	O
SOFA	O
score	O
and	O
the	O
sub-scores	O
relating	O
to	O
the	O
respiratory,	O
coagulation,	O
hepatic,	O
cardiovascular,	O
and	O
renal	O
systems;	O
(vii)	O
outcome:	O
mortality	O
at	O
28	O
and	O
90.	O

The	O
lower	O
phase	O
was	O
collected	O
and	O
transferred	O
into	O
the	O
same	O
glass	O
tube	O
and	O
dried	O
under	O
nitrogen	B
gas.	I

D	O
,	O
Example	O
metabolites	O
cholesteryl-sulfate	B
and	O
myo-inositol	B
that	O
positively	O
and	O
negatively	O
correlate	O
(R_2	O
)	O
with	O
tumor	O
size	O
as	O
measured	O
with	O
MRI	O
using	O
Tgad	O
and	O
FLAIR	O
(x	O
axis)	O
and	O
correlated	O
with	O
the	O
integrated	O
total	O
ion	O
current	O
(TIC)	O
peak	O
areas	O
(y	O
axis)	O
obtained	O
from	O
targeted	O
LC-MS/MS	O
measurements.	O

Ceramides	B
are	O
typically	O
recognized	O
as	O
[M+H]_+	O
and	O
[M+H−H_2	O
O]_+	O
in	O
positive	O
ion	O
mode.	O

The	O
fact	O
that	O
DEHP	O
metabolites	O
are	O
associated	O
with	O
obesity	O
in	O
males	O
may	O
be	O
the	O
consequence	O
of	O
their	O
anti-androgenic	O
effect	O
that	O
reduce	O
levels	O
of	O
free	O
testosterone	B
(;	O
;	O
)	O
and	O
an	O
alteration	O
in	O
adipose	O
tissue.	O

For	O
most	O
compounds	O
investigated,	O
expected	O
concentrations	O
in	O
meconium	O
were	O
unavailable;	O
therefore,	O
a	O
1,000	O
ng/g	O
concentration	O
was	O
chosen	O
for	O
Δ_9	B
-tetrahydrocannabinol,	I
11-hydroxy-Δ_9	B
tetrahydrocannabinol,	I
11-nor-9-carboxy-Δ_9	B
-tetrahydrocannabinol,	I
diazepam,	B
lorazepam,	B
oxazepam,	B
alprazolam,	B
nitrazepam,	B
flunitrazepam,	B
temazepam,	B
nordiazepam,	B
bromazepam,	B
clonazepam,	B
flurazepam,	B
7-aminoclonazepam,	B
7-aminoflunitrazepam,	B
imipramine,	B
diphenydramine,	B
chlorpheniramine,	B
brompheniramine,	B
clomipramine,	B
paraxetine,	B
fluoxetine,	B
norfluoxetine,	B
clonidine,	B
pentazocine,	B
ibuprofen,	B
caffeine,	B
acetylsalicylic	B
acid,	I
acetaminophen,	B
phencyclidine,	B
normorphine,	B
norcodeine,	O
noroxycodone,	B
oxymorphone,	B
noroxymorphone,	B
propoxyphene,	B
3,4-(methylenedioxyphenyl)-2-butanamine,	B
N	B
-methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine,	I
cathinone,	B
ethylamphetamine,	B
4-bromo-2,5-dimethoxyphenethylamine,	B
3,4-methylenedioxymethamphetamine,	B
3,4-methylenedioxyamphetamine,	B
3,4-methylenedioxyethylamphetamine,	B
4-hydroxy-3-methoxymethamphetamine,	B
4-hydroxy-3-methoxyamphetamine,	B
phentermine,	O
ketamine,	B
and	O
dextromethorphan.	B

Interestingly,	O
the	O
prognostic	O
evaluation	O
suggested	O
that	O
the	O
ceramide-related	O
enzymes	O
related	O
to	O
increased	O
ceramide	B
expression	O
were	O
associated	O
with	O
worse	O
survival	O
in	O
breast	O
cancer	O
patients.	O

These	O
cholesterol	B
metabolites	O
represent	O
early	O
members	O
of	O
the	O
“acidic	O
pathway”	O
of	O
bile	O
acid	O
biosynthesis	O
which	O
is	O
known	O
to	O
be	O
operative	O
in	O
the	O
CNS	O
[,	O
].	O

For	O
the	O
LC-MS/MS	O
analysis	O
experiment,	O
the	O
cell	O
lines	O
were	O
maintained	O
for	O
1	O
h	O
in	O
DMEM	O
medium	O
modified	O
to	O
contain	O
either	O
10	O
mM	O
U-_13	O
C_6	O
glucose	B
plus	O
2	O
mM	O
unlabeled	O
glutamine	B
or	O
2	O
mM	O
U-_13	O
C_5	O
glutamine	B
plus	O
10	O
mM	O
unlabeled	O
glucose.	B

More	O
recently,	O
it	O
has	O
been	O
shown	O
that	O
there	O
was	O
no	O
significant	O
difference	O
in	O
plasma	O
2-hydroxybutyrate	B
levels	O
between	O
HF	O
patients	O
without	O
diabetes	O
and	O
controls.	O

The	O
direction	O
of	O
effect	O
size	O
appeared	O
to	O
flip	O
for	O
cholesterol	B
and	O
triglycerides	B
in	O
VLDL	O
and	O
LDL	O
particles,	O
while	O
the	O
direction	O
of	O
effect	O
remained	O
consistently	O
inverse	O
with	O
cholesterol	B
and	O
triglycerides	B
in	O
HDL	O
particles,	O
particularly	O
medium	O
and	O
small	O
HDL.	O

The	O
inverse	O
correlation	O
of	O
the	O
putrescine	B
concentration	O
in	O
sperm	O
with	O
abstention	O
time	O
is	O
consistent	O
with	O
the	O
observation	O
of	O
a	O
similar	O
negative	O
correlation	O
in	O
seminal	O
plasma.	O

Decreased	O
urinary	O
concentration	O
of	O
20-HETE,	B
associated	O
with	O
RVD,	O
may	O
reflect	O
diminished	O
20-HETE	B
production	O
by	O
nephron	B
segments,	O
the	O
TAL	O
and	O
proximal	O
tubules.	O

Levels	O
of	O
the	O
different	O
vitamin	B
D	I
metabolites	O
according	O
to	O
the	O
patients’	O
disease	O
type	O
(Crohn’s	O
disease	O
(CD)	O
versus	O
ulcerative	O
colitis	O
(UC))	O
are	O
shown	O
in	O
.	O

For	O
both	O
studies,	O
each	O
aliquot	O
of	O
methanolic	B
extract	O
ballasted	O
with	O
MeOH/H_2	O
O	O
was	O
dried	O
with	O
a	O
SpeedVac	O
SPD111V	O
sample	O
concentrator	O
(Thermo	O
Fisher	O
Scientific,	O
Asheville,	O
NC,	O
USA)	O
for	O
5	O
h,	O
followed	O
by	O
the	O
addition	O
of	O
100	O
µL	O
ethyl	B
acetate	I
as	O
an	O
azeotropic	O
drying	O
agent,	O
and	O
another	O
45	O
min	O
of	O
SpeedVac	O
drying.	O

The	O
covalent	O
binding	O
of	O
drugs	O
to	O
proteins	O
as	O
a	O
mechanism	O
of	O
toxicity	O
emerged	O
in	O
the	O
early	O
1970s	O
with	O
a	O
series	O
of	O
studies	O
conducted	O
with	O
acetaminophen,	B
using	O
covalent	O
binding	O
of	O
the	O
_14	O
C-radiolabeled	O
molecule	O
to	O
liver	O
proteins._−	O

In	O
this	O
study,	O
significantly	O
changed	O
metabolites	O
L-tyrosine,	B
LysoPC,	O
protorifamycin	B
I,	O
pimelic	B
acid,	I
epothilone	B
A,	O
PE,	O
7-dehydro-desmosterol,	B
L-lysine,	B
and	O
teasterone	B
were	O
involved	O
in	O
the	O
significant	O
pathways.	O

Comparison	O
of	O
vitamin	B
D	I
markers	O
in	O
patients	O
with	O
Crohn’s	O
disease	O
(CD)	O
versus	O
ulcerative	O
colitis	O
(UC).	O

[PubMed]	O
[Google	O
Scholar]	O
Prostaglandins.	B
1978	O

154	O
distinct	O
metabolites	O
representing	O
ten	O
classes	O
and	O
subclasses	O
were	O
measured	O
in	O
the	O
FHS:	O
four	O
ceramides	B
(Cers),	O
11	O
cholesteryl	B
esters	I
(CEs),	O
eight	O
diacylglycerols	B
(DAGs),	O
21	O
lysophosphatidylcholines	B
(LPCs),	O
four	O
lysophosphatidylethanolamines	B
(LPEs),	O
28	O
phosphatidylcholines	B
(PCs),	O
11	O
phosphatidylethanolamines	B
(PEs),	O
one	O
phosphatidylserine	B
(PS),	O
26	O
sphingomyelins	B
(SMs),	O
and	O
40	O
triacylglycerols	B
(TAGs).	O

Glutamate	B
showed	O
a	O
significant	O
decrease	O
in	O
venous	O
vs.	O
arterial	O
plasma	O
(p = 3.8E-06,	O
median	O
fold	O
change = 2.9,	O
)	O
across	O
all	O
20	O
subjects.	O

Previous	O
human	O
and	O
macaque	O
studies	O
suggest	O
that	O
cannabis	B
may	O
have	O
an	O
impact	O
on	O
plasma	O
viral	O
load;	O
however,	O
the	O
relationship	O
between	O
cannabis	B
use	O
and	O
HIV-associated	O
systemic	O
inflammation	O
and	O
immune	O
activation	O
has	O
not	O
been	O
well	O
defined.	O

In	O
the	O
medication	O
model,	O
the	O
disease	O
models	O
were	O
additionally	O
adjusted	O
for	O
intake	O
of	O
oral	O
contraceptives,	O
estrogens,	O
diuretics,	O
statins,	B
antiepileptic	O
and	O
oral	O
antidiabetic	O
medication,	O
corticoids	O
and	O
calcium	O
channel	O
blockers	O
as	O
well	O
as	O
for	O
angiotensin-converting	O
enzyme	O
inhibitors	O
or	O
angiotensin	B
antagonists.	O

We	O
observed	O
a	O
novel	O
positive	O
association	O
between	O
VAT	O
and	O
plasma	O
levels	O
of	O
the	O
potential	O
pharmacological	O
agent	O
piperine.	B

A	O
clinical	O
study	O
assessing	O
the	O
efficacy	O
of	O
sofosbuvir	B
and	O
ribavirin	B
administered	O
prior	O
to	O
liver	O
transplantation	O
to	O
prevent	O
HCV	O
recurrence	O
provided	O
a	O
unique	O
opportunity	O
to	O
quantify	O
nucleotide	O
concentrations	O
in	O
human	O
liver.	O

L-arginine,	B
L-citrulline,	B
ADMA,	B
SDMA,	O
hydrochloride	B
salts	O
of	O
unlabeled	O
DMA,	B
hexadeutero-dimethylamine	B
(D6-DMA,	O
99%),	O
benzoyl	B
chloride	I
(BCl),	O
sodium	O
tetraborate,	O
and	O
formic	B
acid	I
(FA;	O
HPLC	O
grade)	O
were	O
purchased	O
from	O
Sigma	O
Aldrich	O
(Poznan,	O
Poland).	O

Despite	O
being	O
at	O
least	O
as	O
potent	O
as	O
ADMA	B
(Supplementary	O
Fig.	O

The	O
resulting	O
solution	O
was	O
again	O
applied	O
to	O
the	O
column	O
followed	O
by	O
a	O
wash	O
of	O
1	O
ml	O
of	O
17%	O
methanol.	B

Carboxylic	B
acids	I
and	O
amines	O
represent	O
a	O
majority	O
of	O
the	O
metabolites	O
in	O
body	O
fluids	O
and	O
their	O
analysis	O
by	O
isotope	O
tagging	O
enables	O
a	O
significant	O
enhancement	O
of	O
the	O
metabolic	O
pool	O
for	O
biomarker	O
discovery	O
applications.	O

Perchloric	B
acid	I
(70%)	O
and	O
dithiothreitol	B
used	O
in	O
the	O
hydrolysis	O
process	O
were	O
purchased	O
from	O
Sigma	O
Aldrich.	O

Due	O
to	O
their	O
potential	O
to	O
transfer	O
amino	B
groups,	O
they	O
occur	O
in	O
numerous	O
pathways.	O

A	O
similar	O
pattern	O
of	O
nutrient	O
consumption	O
and	O
by	O
product	O
release	O
was	O
also	O
observed	O
with	O
glutamine	B
consumption,	O
closely	O
mirrored	O
by	O
glutamate	B
release,	O
making	O
it	O
available	O
for	O
gluconeogenesis	O
or	O
for	O
subsequent	O
conversion	O
to	O
other	O
amino	O
acids.	O

Simultaneous	O
extraction	O
of	O
lipophilic	O
and	O
polar	O
metabolites	O
was	O
performed	O
with	O
ice-cold	O
methanol,	B
chloroform	B
and	O
water	O
(2∶2∶1.3,	O
v/v/v)	O
.	O

In	O
absolute	O
concentration	O
analysis	O
of	O
four	O
metabolites,	O
glutamate	B
concentration	O
in	O
the	O
patients	O
using	O
benzodiazepines	B
(n	O
=17)	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
the	O
patients	O
using	O
no	O
benzodiazepine	B
(n	O
=13,	O
U	O
=51.0,	O
P	O
=0.012).	O

The	O
Eppendorf	O
concentrator	O
was	O
vented	O
with	O
argon	O
to	O
prevent	O
degradation	O
of	O
eicosanoids	B
and	O
docosanoids.	B

Seven	O
differential	O
metabolites	O
were	O
identified	O
as	O
candidate	O
diagnostic	O
biomarkers,	O
including	O
PC(20:4),	B
2-hexenoylcarnitine,	B
beta-D-glucopyranuronicacid,	B
DG(38:9),	B
MG(20:3),	B
LysoPC(18:2)	B
and	O
LysoPC(16:0).	B

Conversion	O
was	O
considered	O
to	O
be	O
close	O
to	O
100%	O
as	O
judged	O
by	O
the	O
absence	O
of	O
un-derivatized	O
2	O
in	O
the	O
urine	O
samples	O
treated	O
with	O
acetic	B
anhydride.	I

For	O
the	O
statistical	O
analysis,	O
the	O
0.8–4.5	O
and	O
6.5–9.0	O
ppm	O
regions	O
were	O
considered,	O
thus	O
excluding	O
the	O
spectral	O
regions	O
where	O
water	O
and	O
urea	B
resonances	O
appeared.	O

All	O
patients	O
admitted	O
to	O
the	O
hospital	O
were	O
kept	O
for	O
2	O
days,	O
except	O
for	O
one	O
subject	O
with	O
AP	B
who	O
was	O
kept	O
in	O
the	O
hospital	O
for	O
5	O
days.	O

 m_2	O
(deduced	O
from	O
increased	O
serum	O
creatinine	B
by	O
the	O
Modification	O
of	O
Diet	O
in	O
Renal	O
Disease	O
Study	O
equation),	O
and	O
clinical	O
chemistry	O
tests	O
within	O
the	O
normal	O
range	O
±	O
10%.	O

This	O
is	O
further	O
supported	O
by	O
the	O
distribution	O
of	O
diacylglycerol	B
and	O
triacylglycerol	B
species	O
among	O
clusters	O
11	O
and	O
12;	O
the	O
species	O
in	O
cluster	O
12	O
contain	O
primarily	O
saturated	O
and	O
monounsaturated	O
fatty	O
acids	O
while	O
cluster	O
11	O
contains	O
a	O
high	O
proportion	O
of	O
polyunsaturated	O
species	O
particularly	O
reflecting	O
the	O
omega-6	B
fatty	O
acid,	O
linoleic	B
acid	I
(C18:2)	O
in	O
the	O
triacylglycerols.	B

By	O
contrast,	O
breast	O
cancer	O
rate	O
estimates	O
changed	O
by	O
greater	O
than	O
50	O
cancers	O
per	O
10_5	O
person-years	O
for	O
36%,	O
30%,	O
and	O
23%	O
of	O
women	O
when	O
the	O
ratio	O
of	O
the	O
2-hydroxylation	O
pathway	O
to	O
parent	O
estrogens,	O
the	O
ratio	O
of	O
the	O
2-hydroxylation	O
pathway	O
to	O
the	O
16-hydroxylation	O
pathway,	O
and	O
the	O
ratio	O
of	O
4-hydroxylation	O
pathway	O
catechols	B
to	O
4-hydroxylation	O
pathway	O
methylated	B
catechols,	I
respectively,	O
were	O
added	O
to	O
a	O
model	O
with	O
unconjugated	O
estradiol.	B

In	O
addition,	O
our	O
results	O
indicate	O
that	O
allantoin	B
is	O
a	O
promising	O
biomarker.	O

Findings	O
confirmed	O
our	O
hypothesis	O
that	O
the	O
neurotrophic	O
branch	O
of	O
the	O
KP	B
would	O
be	O
associated	O
with	O
an	O
increase	O
in	O
network	O
connectivity,	O
while	O
the	O
neurotoxic	O
branch	O
would	O
be	O
associated	O
with	O
a	O
decrease.	O

Baseline	O
characteristics	O
of	O
80	O
adults	O
from	O
the	O
Western	O
Norway	O
Coronary	O
Angiography	O
Cohort	O
classified	O
according	O
to	O
plasma	O
cystathionine	B
concentration_1	O
One-carbon	O
metabolism	O
requires	O
folate,	B
vitamin	O
B-6,	O
vitamin	O
B-12,	O
and	O
riboflavin	B
as	O
cofactors	O
to	O
different	O
enzymes	O
throughout	O
the	O
pathway.	O

 U/L,	O
p	O
 < 0.001),	O
as	O
well	O
as	O
elevated	O
levels	O
of	O
arginase-mediated	O
l-arginine	B
catalytic	O
product	O
l-ornithine	B
(108.64 ± 30.26	O
vs.	O
69.3 ± 20.71 μmol/L,	O
p	O
 < 0.001),	O
whereas	O
a	O
nitric	B
oxide	I
synthase	O
(NOS)	O
catalytic	O
product,	O
the	O
l-citrulline	B
level,	O
was	O
diminished	O
in	O
RA	O
(30.32 ± 9.93	O
vs.	O
36.17 ± 11.64 μmol/L,	O
p	O
 < 0.001).	O

To	O
assess	O
levels	O
and	O
structures	O
of	O
metabolites,	O
samples	O
were	O
obtained	O
from	O
a	O
multicenter	O
safety	O
and	O
tolerability	O
study	O
in	O
which	O
15	O
g	O
of	O
phenylbutyrate	B
was	O
given	O
daily	O
to	O
60	O
early	O
symptomatic	O
subjects	O
with	O
HD,	O
in	O
collaboration	O
with	O
the	O
HSG.	O

TG	B
are	O
central	O
to	O
energy	O
storage	O
and	O
as	O
a	O
source	O
of	O
building	O
blocks	O
for	O
complex	O
lipids;	O
therefore,	O
high	O
TG	B
levels	O
have	O
been	O
associated	O
with	O
breast	O
cancer	O
progression	O
and	O
aggressiveness	O
[–].	O

This	O
result	O
may	O
suggest	O
the	O
existence	O
of	O
an	O
association	O
between	O
BRAF	O
mutation	O
background	O
and	O
altered	O
mRNA	O
expression	O
of	O
KP	B
members.	O

The	O
precision	O
(coefficient	O
of	O
variation)	O
were	O
≤10.7%,	O
7.7%	O
and	O
9.5%	O
and	O
the	O
accuracies	O
ranged	O
from	O
88.8	O
to	O
103.1%	O
for	O
exemestane,	O
98.5	O
to	O
106.1%	O
for	O
17β-dihydroexemestane	B
and	O
92.0	O
to	O
103.2%	O
for	O
17β-dihydroexemestane-17-O-β-D-glucuronide.	B

The	O
IP	B
values	O
reflect,	O
in	O
fact,	O
the	O
importance	O
of	O
terms	O
in	O
the	O
model	O
both	O
with	O
respect	O
to	O
Y,	O
i.e.	O
its	O
correlation	O
with	O
all	O
the	O
responses,	O
and	O
with	O
respect	O
to	O
X.	O

In	O
the	O
presence	O
of	O
mTOR	O
inhibitor,	O
free	O
fatty	O
acids	O
are	O
not	O
stored	O
and	O
remain	O
in	O
the	O
bloodstream	O
[,	O
,	O
–],	O
which	O
is	O
consistent	O
with	O
an	O
observed	O
higher	O
concentration	O
of	O
free	O
fatty	O
acids	O
and	O
glycerol	B
backbone	O
of	O
PGLYs	O
&	O
TAGs	O
in	O
sera	O
of	O
patients	O
treated	O
with	O
T+E.	O
On	O
the	O
other	O
hand,	O
high	O
levels	O
of	O
LDL	O
and	O
VLDL	O
lipoproteins	O
during	O
treatment	O
reflect	O
the	O
role	O
of	O
mTOR	O
in	O
the	O
control	O
of	O
lipid	O
mobilization	O
and	O
transport	O
[,	O
].	O

[,])	O
and	O
formate	B
(formed	O
in	O
the	O
colonic	O
lumen	O
by	O
intestinal	O
bacteria	O
such	O
as	O
Enterobacteriaceae	O
,	O
in	O
the	O
process	O
of	O
unabsorbed	O
carbohydrates	O
fermentation[,,])	O
may	O
be	O
associated	O
with	O
changes	O
in	O
gut	O
microbiome	O
that	O
occur	O
in	O
IBD	O
patients[].	O

At	O
baseline,	O
univariate	O
analyses	O
showed	O
that	O
3	O
acylcarnitines,	B
20	O
phosphatidylcholines	B
and	O
SM	B
C24:1	I
had	O
significantly	O
lower	O
levels	O
in	O
patients	O
who	O
later	O
gained	O
weight	O
before	O
but	O
not	O
after	O
correcting	O
for	O
multiple	O
tests	O
(Supplementary	O
Table 2).	O

Lipid	O
metabolism	O
in	O
the	O
meal	O
test	O
and	O
metabolic	O
flexibility	O
were	O
additively	O
improved	O
by	O
Pio&	O
Omega-3.	B

The	O
treated	O
lipid	O
samples	O
were	O
used	O
for	O
the	O
analysis	O
of	O
the	O
sphingolipidome	B
of	O
each	O
individual	O
plasma	O
sample.	O

Lipoprotein	O
particle	O
sizes	O
(I)	O
and	O
lipoprotein	O
composition;	O
lipids	O
within	O
lipoproteins	O
(J),	O
cholesterol	B
within	O
lipoproteins	O
(K)	O
and	O
triglycerides	B
within	O
lipoproteins	O
(L)	O
before	O
exercise	O
intervention	O
during	O
cold	O
(blue	O
bars)	O
and	O
after	O
exercise	O
intervention	O
during	O
cold	O
(patterned	O
black	O
bars).	O

Through	O
these	O
mechanisms,	O
long‐chain	O
acylcarnitines	B
may	O
contribute	O
to	O
the	O
heart	O
failure	O
phenotype.	O

All	O
the	O
samples	O
were	O
introduced	O
into	O
the	O
source	O
by	O
flow	O
injection	O
(10μl	O
loop)	O
using	O
methanol	B
as	O
the	O
mobile	O
phase	O
at	O
a	O
flow	O
rate	O
of	O
0.03	O
ml/min.	O

Regarding	O
the	O
first,	O
this	O
concurrence	O
can	O
be	O
explained	O
due	O
to	O
the	O
known	O
common	O
ethiopathogenic	B
mechanisms	O
involved	O
in	O
preeclampsia	O
and	O
severe	O
IUGR;	O
however,	O
this	O
clinical	O
feature	O
was	O
not	O
associated	O
to	O
any	O
sample	O
clustering	O
or	O
group	O
differentiation	O
based	O
on	O
the	O
PCA	O
that	O
was	O
performed	O
to	O
examine	O
the	O
influence	O
of	O
this	O
variable.	O

A	O
permanent	O
positive	O
charge	O
is	O
then	O
appended	O
by	O
subsequent	O
quaternarization	O
of	O
the	O
piperazine	B
amino	I
group	O
using	O
methyl	B
iodide.	I

Mobile	O
phase	O
A	O
and	O
B	O
were	O
0.1%	O
formic	B
acid	I
in	O
water	O
and	O
acetonitrile	B
respectively.	O

In	O
addition	O
to	O
increased	O
glycolysis,	O
a	O
higher	O
level	O
of	O
serine	B
in	O
rectal	O
cancer	O
tissues	O
was	O
also	O
observed.	O

TC,	O
TG,	B
LDL-C,	O
and	O
HDL-C	O
levels	O
were	O
measured	O
in	O
the	O
blood	O
samples	O
with	O
a	O
biochemical	O
auto-analyser	O
(Hitachi	O
7060,	O
Tokyo,	O
Japan).	O

While	O
CKM	O
decreases	O
in	O
DMD	O
cases	O
with	O
age,	O
thus	O
leading	O
to	O
levels	O
more	O
similar	O
to	O
those	O
in	O
healthy	O
controls,	O
which	O
makes	O
it	O
not	O
an	O
ideal	O
marker	O
of	O
disease	O
progression,	O
the	O
creatine	B
to	O
creatinine	B
ratio	O
appears	O
to	O
increase	O
in	O
cases	O
and	O
decrease	O
in	O
controls.	O

The	O
mobile	O
phase	O
consisted	O
of	O
0.1%	O
formic	B
acid	I
(A)	O
and	O
ACN	O
modified	O
with	O
0.1%	O
formic	B
acid	I
(B),	O
using	O
a	O
gradient	O
elution	O
of	O
5%B	O
at	O
0–2 min,	O
5%–95%	O
B	O
at	O
2–13 min,	O
95%	O
B	O
at	O
13–15 min.	O

Also,	O
mice	O
exposed	O
prenatally	O
to	O
MIA	O
triggered	O
by	O
poly(I:C)	O
injected	O
at	O
E12.5	O
and	O
E17.5	O
show	O
an	O
excess	O
of	O
urinary	O
inosine.	B

Since	O
new	O
synthetic	O
cannabinoids	B
appear	O
on	O
the	O
market	O
regularly,	O
adding	O
new	O
substances	O
will	O
be	O
a	O
constant	O
issue.	O

The	O
UPLC	O
mobile	O
phases	O
consisted	O
of	O
(A)	O
a	O
1-mM	O
ammonium	B
acetate	I
solution	O
and	O
(B)	O
ACN.	O

For	O
chromatography	O
using	O
the	O
Shimadzu	O
LC	O
system,	O
the	O
mobile	O
phase	O
was	O
composed	O
of	O
solvent	O
A,	O
10	O
mM	O
ammonium	B
acetate	I
in	O
95%	O
H_2	O
O/3%	O
acetonitrile/2%	O
methanol/0.2%	O
acetic	O
acid,	O
and	O
solvent	O
B,	O
10	O
mM	O
ammonium	B
acetate	I
in	O
93%	O
acetonitrile/2%	O
methanol/5%	O
H_2	O
O/0.2%	O
acetic	B
acid.	I

In	O
the	O
present	O
study,	O
4-heptanone,	B
2-methylbutanal	B
and	O
decanoic	B
acid	I
were	O
identified	O
as	O
novel	O
volatile	O
biomarkers	O
with	O
satisfactory	O
accuracy	O
to	O
differentiate	O
aggressive	O
B-NHL	O
from	O
indolent	O
B-NHL.	O

The	O
RI	B
(retention	O
time	O
index)	O
method	O
was	O
used	O
in	O
the	O
peak	O
identification,	O
and	O
the	O
RI	B
tolerance	O
was	O
5000.	O

A	O
low	O
level	O
of	O
citrate	B
in	O
the	O
CSF	O
of	O
MS	O
patients	O
may	O
also	O
provide	O
unfavorable	O
surroundings	O
for	O
the	O
biosynthesis	O
of	O
fatty	O
acids	O
that	O
result	O
in	O
the	O
formation	O
of	O
myelin	B
because	O
acetyl-CoA	B
used	O
for	O
fatty	O
acid	O
synthesis	O
must	O
be	O
shuttled	O
out	O
of	O
the	O
mitochondria	O
into	O
the	O
cytosol	O
in	O
its	O
citrate	B
form	O
(so	O
called	O
citrate	B
shuttle).	O

The	O
abnormalities	O
of	O
KYN,	O
5-MIAA,	B
and	O
the	O
KYN/TRP	O
ratio	O
found	O
in	O
this	O
study	O
implicate	O
disruption	O
of	O
the	O
TRP	O
pathway	O
in	O
the	O
pathogenesis	O
of	O
MDD.	O

The	O
Ostro	O
plate	O
provided	O
a	O
high-throughput	O
reproducible	O
method	O
of	O
removing	O
proteins	O
and	O
phospholipids	B
with	O
minimal	O
sample	O
preparation.	O

PC	B
aa	I
C36:2;	I
71.	O

With	O
regard	O
to	O
this	O
and	O
the	O
fact	O
that	O
we	O
could	O
observe	O
a	O
slight,	O
but	O
not	O
significant	O
increase	O
of	O
urinary	O
betaine	B
levels	O
in	O
the	O
CG	O
(see	O
a),	O
it	O
can	O
be	O
speculated	O
that	O
the	O
CG,	O
which	O
had	O
to	O
refrain	O
from	O
their	O
usual	O
daily	O
training	O
during	O
the	O
study	O
period,	O
demonstrated	O
a	O
minor	O
use	O
of	O
betaine	B
for	O
exercise-related	O
physiological	O
processes,	O
thus	O
leading	O
to	O
a	O
higher	O
urinary	O
betaine	B
excretion	O
in	O
the	O
inactive	O
state.	O

The	O
data	O
showed	O
that	O
this	O
simple	O
method	O
successfully	O
separated	O
D-mannose	B
from	O
glucose	B
with	O
no	O
interferential	O
peaks.	O

This	O
spectrum	O
matched	O
well	O
with	O
the	O
MS/MS	O
spectrum	O
of	O
the	O
standard	O
FA	B
(20:4)	I
available	O
in	O
the	O
Metline	O
database.	O

The	O
amino	O
acid	O
adduct	O
N	O
_2	B
-cysteinesulfinyl-PhIP	I
was	O
not	O
detected	O
in	O
the	O
3-enzyme	O
digest;	O
however,	O
data-dependent	O
scanning	O
identified	O
two	O
pairs	O
of	O
HONH-PhIP-tripeptide	O
adducts	O
(t	O
_R	O
=17.8	O
and	O
19.3	O
min)	O
(,	O
).	O

The	O
CPT1A-Rab14	O
interaction	O
facilitates	O
fatty	O
acid	O
transfer	O
from	O
lipid	O
droplets	O
to	O
mitochondria,	O
which	O
promotes	O
fatty	O
acid	O
utilization	O
and	O
maximizes	O
ATP	B
production.	O

Treatment	O
of	O
these	O
products	O
with	O
formic	B
acid	I
yielded	O
the	O
dehydrated	O
compounds	O
7,	O
10,	O
14,	O
and	O
17.	O

Similar	O
to	O
xylitol,	B
also	O
urinary	O
PAA	O
in	O
obese	O
children	O
was	O
lower	O
than	O
in	O
NW	O
subjects.	O

Serum	O
samples	O
were	O
separated	O
on	O
an	O
Eclipse	O
Plus	O
C18	O
column	O
(2.1×150mm,	O
3.5μm,	O
Agilent	O
Technologies,	O
USA),	O
with	O
the	O
condition	O
of	O
180	O
μl	O
injection	O
volume,	O
0.8	O
ml/min	O
flow	O
rate	O
and	O
45°C	O
column	O
temperature,	O
by	O
using	O
a	O
gradient	O
program	O
of	O
the	O
mobile	O
phase	O
A	O
0.1%	O
formic	B
acid	I
solution	O
(ESI_+	O
)/water	O

The	O
HMDB	O
indicates	O
that	O
glycerophosphocholine	B
is	O
involved	O
in	O
signal	O
transduction,	O
glycerophospholipid	B
metabolism,	O
prostaglandin	B
and	O
leukotriene	O
metabolism,	O
and	O
energy	O
storage	O
and	O
consumption.	O

Still,	O
we	O
found	O
no	O
strong	O
correlation	O
between	O
cotinine	B
and	O
tryptophan,	B
KTR,	O
kynurenines	O
or	O
vitamins	O
in	O
our	O
material	O
when	O
using	O
Spearman’s	O
correlation	O
analyses	O
(Table ).	O

In	O
2017,	O
Ijare	O
et	O
al.	O
used	O
ex	O
vivo	O
NMR	O
spectrometry	O
to	O
assess	O
the	O
metabolomic	O
profile	O
of	O
postoperative	O
pituitary	O
tissue	O
sampled	O
from	O
patients	O
with	O
gonadotropin-	O
and	O
PRL-secreting	O
PA,	O
respectively,	O
with	O
the	O
main	O
finding	O
that	O
both	O
types	O
of	O
PA	O
contain	O
central	O
nervous	O
system	O
metabolites	O
such	O
as	O
phosphoethanolamine,	B
glutamate,	B
glutamine,	B
N-acetyl	B
aspartate,	I
aspartate,	B
and	O
myo-inositol.	B

In	O
our	O
study,	O
variations	O
of	O
ketone	B
bodies	O
and	O
related	O
compounds	O
including	O
acetone,	B
acetate,	B
and	O
acetamide	B
were	O
observed	O
that	O
are	O
related	O
to	O
lipid	O
metabolism.	O

Finally,	O
acylcarnitines	B
are	O
converted	O
back	O
to	O
Acyls-CoA	O
by	O
carnitine	O
palmitoyltransferase	O
2	O
localized	O
on	O
the	O
inner	O
mitochondrial	O
membrane.	O

Women	O
had	O
higher	O
total	O
cholesterol	B
levels	O
than	O
men;	O
however	O
when	O
lipoprotein	O
subclasses	O
were	O
analyzed	O
individually,	O
differences	O
did	O
not	O
reach	O
statistical	O
significance.	O

–	O
We	O
recently	O
described	O
the	O
potential	O
role	O
of	O
a	O
complex	O
phosphatidylcholine–choline	B
metabolic	O
pathway	O
involving	O
gut	O
microbiota	O
in	O
contributing	O
to	O
the	O
pathogenesis	O
of	O
atherosclerotic	O
coronary	O
artery	O
disease	O
in	O
animal	O
models.	O

Another	O
metabolite	O
that	O
shows	O
different	O
patterns	O
of	O
change,	O
PC	B
aa	I
C34:2,	I
significantly	O
decreased	O
during	O
the	O
first	O
stage	O
of	O
treatment	O
in	O
both	O
CCRT	O
and	O
RT;	O
yet,	O
at	O
the	O
end	O
of	O
treatment,	O
it	O
increased	O
to	O
the	O
initial	O
pretreatment	O
level	O
only	O
in	O
case	O
of	O
the	O
CCRT	O
group.	O

Bilirubin	B
is	O
a	O
lipophilic	O
linear	O
tetrapyrrole	O
found	O
abundantly	O
in	O
blood	O
plasma	O
of	O
mammals.	O

In	O
the	O
present	O
study,	O
the	O
higher	O
CSF	O
level	O
of	O
citric	B
acid	I
tended	O
to	O
be	O
associated	O
with	O
a	O
shorter	O
OS	O
in	O
all	O
glioma	O
patients.	O

The	O
change	O
of	O
metabolites	O
(glutamine,	O
glutamate,	B
alanine,	B
and	O
aspartate)	O
involved	O
with	O
these	O
two	O
pathways	O
was	O
similar	O
to	O
that	O
between	O
colorectal	O
polyp	O
and	O
CRC	O
patients.	O

For	O
this	O
purpose,	O
the	O
aminopropyl	O
column	O
from	O
Phenomenex	O
was	O
chosen	O
due	O
to	O
its	O
good	O
selectivity,	O
high	O
reproducibility,	O
and	O
broad	O
coverage	O
of	O
hydrophilic	B
metabolites.	O

Additionally,	O
a	O
targeted	O
LC-MS/MS	O
approach	O
[,,],	O
covering	O
~300	O
metabolites	O
from	O
>35	O
metabolic	O
pathways	O
of	O
strong	O
biological	O
significance,	O
such	O
as	O
central	O
carbon	O
metabolism	O
and	O
purine	B
metabolism,	O
was	O
used	O
herein	O
to	O
analyze	O
changes	O
to	O
metabolites	O
with	O
enhanced	O
detection	O
sensitivity	O
and	O
specificity.	O

We	O
found	O
marked	O
reduction	O
in	O
the	O
number	O
of	O
phospholipids	B
and	O
lysolipids	O
during	O
infection	O
and	O
enrichment	O
in	O
fatty	O
acids.	O

In	O
serum,	O
glutamine	B
(P	O
 < 0.001),	O
pyrophosphate	B
(P	O
 < 0.001)	O
and	O
octulose‐1,8‐bisphosphate	B
(P 	O
< 0.001)	O
significantly	O
differed	O
between	O
the	O
p‐GDM	O
and	O
control	O
groups.	O

Changes	O
in	O
levels	O
of	O
these	O
three	O
metabolites	O
were	O
significantly	O
correlated	O
with	O
each	O
other	O
in	O
samples	O
from	O
individuals	O
across	O
the	O
full	O
range	O
of	O
simvastatin	B
response.	O

2013	O
demonstrated	O
that	O
valine,	B
leucine,	B
and	O
isoleucine	B
are	O
reduced	O
in	O
acute	O
ischemic	O
stroke,	O
and	O
here,	O
we	O
observed	O
that	O
leucine	B
is	O
increased	O
in	O
chronic	O
ischemic	O
stroke.	O

Some	O
significant	O
differences	O
in	O
companies	O
were	O
found,	O
showing	O
the	O
variability	O
across	O
the	O
different	O
plants:	O
indeed,	O
if	O
compared	O
to	O
the	O
plant	O
producing	O
low-phosphor	B
coke	O
and	O
broken	O
coke	O
(J),	O
significant	O
higher	O
levels	O
of	O
SPMA,	O
metabolite	O
of	O
benzene,	B
were	O
found	O
in	O
the	O
plant	O
producing	O
domestic	O
coke	O
(D),	O
and	O
significant	O
higher	O
levels	O
of	O
AAMA,	O
metabolite	O
of	O
acrylamide,	B
were	O
found	O
in	O
the	O
plant	O
producing	O
foundry	O
and	O
blast	O
furnace	O
coke	O

Briefly,	O
the	O
resonances	O
putatively	O
assigned	O
to	O
urocanate	B
molecule	O
exhibited	O
high	O
correlation	O
coefficient	O
values	O
in	O
analyzed	O
set	O
of	O
spectra	O
(Fig	O
A	O
in	O
).	O

Contrariwise,	O
the	O
urinary	O
excretion	O
rate	O
of	O
acetone,	B
one	O
of	O
the	O
ketone	B
bodies,	O
is	O
found	O
to	O
be	O
higher	O
during	O
fasting	O
or	O
low-sugar	O
diet.	O

Previous	O
studies	O
have	O
reported	O
that	O
UPLC/MS-MS	O
method	O
is	O
suitable	O
for	O
the	O
determination	O
of	O
urinary	O
3-methylhistidine	B
to	O
monitor	O
muscle	O
protein	O
catabolism	O
.	O

Finally,	O
low	O
levels	O
of	O
N,N-dimethylglycine	B
were	O
also	O
found	O
to	O
be	O
associated	O
with	O
high	O
disease	O
activity	O
in	O
CD	O
(P	O
 = 9.0 × 10_–4	O
).	O

Thus,	O
our	O
study	O
is	O
unique	O
regarding	O
the	O
use	O
of	O
a	O
complex	O
methodological	O
approach	O
including	O
the	O
indirect	O
calorimetry,	O
clamp	O
as	O
well	O
as	O
a	O
meal	O
test,	O
which	O
allowed	O
us	O
to	O
demonstrate	O
the	O
additive	O
improvements	O
in	O
metabolic	O
flexibility	O
to	O
glucose,	B
and	O
namely	O
in	O
the	O
postprandial	O
lipid	O
metabolism,	O
by	O
pioglitazone	B
in	O
combination	O
with	O
highly	O
purified	O
EPA + DHA.	O

Biosynthesis	O
of	O
PGE-M.	O
Arachidonic	B
acid,	I
released	O
from	O
membrane	O
phospholipids	B
by	O
phospholipase	O
A_2	O
(PLA	O
_2	O
)	O
is	O
metabolized	O
by	O
COX-1and	O
COX-2	O
to	O
PGH_2	O
.	O

On	O
the	O
other	O
hand,	O
WAX	O
column	O
G	O
did	O
not	O
produce	O
acceptable	O
peaks	O
for	O
any	O
phosphate	B
and	O
many	O
phosphates	B
could	O
not	O
even	O
be	O
detected	O
with	O
this	O
method.	O

Our	O
data	O
support	O
the	O
superiority	O
of	O
this	O
approach,	O
where	O
the	O
LPIR	O
SD	O
HR,	O
1.41	O
(95%CI:	O
1.31,	O
1.53),	O
outranked	O
HDL-c,	O
triglycerides	B
and	O
each	O
individual	O
LPIR	O
sub–particle.	O

Thereafter,	O
aliquots	O
of	O
50	O
μL	O
of	O
the	O
diluted	O
samples	O
were	O
transferred	O
to	O
the	O
well	O
plates,	O
adding	O
25	O
μL	O
of	O
the	O
multianalyte	O
mixture	O
of	O
labeled	O
internal	O
standards	O
prepared	O
in	O
methanol	B
to	O
each	O
well.	O

Those	O
lysoPCs	O
include	O
very	O
long	O
chain	O
fatty	O
acids,	O
such	O
as	O
lysoPC	O
a	O
C24:0,	B
lysoPC	O
a	O
C26:0	B
and	O
lysoPC	O
a	O
C28:0,	B
which	O
were	O
also	O
significantly	O
lower	O
in	O
breast	O
cancer	O
patients.	O

The	O
deuterated	O
internal	O
standards	O
(IS)	O
26,26,26,27,27,27-hexadeuterium-1α,25-dihydroxyvitamin	B
D_3	O
(Medical	O
Isotopes)	O
and	O
26,26,26,	B
27,27,27-hexadeuterium-25-hydroxyvitamin	I
D_3	O
(Synthetica)	O
were	O
dissolved	O
in	O
acetonitrile	B
to	O
prepare	O
stock	O
solutions.	O

This	O
is	O
in	O
line	O
with	O
results	O
of	O
previous	O
studies	O
showing	O
that	O
a	O
decreased	O
liver	O
function	O
and/or	O
damage	O
to	O
the	O
liver	O
result	O
in	O
increased	O
serum	O
levels	O
of	O
tyrosine	B
and	O
other	O
aromatic	O
amino	O
acids.	O

Methanol	B
and	O
methanol/ethanol	O
are	O
the	O
solvents	O
of	O
choice	O
due	O
to	O
high	O
metabolite	O
coverage	O
as	O
shown	O
by	O
several	O
studies_,	O
_,	O
.	O

Solvent	O
A	O
was	O
0.1%	O
(v/v)	O
formic	B
acid	I
in	O
5%	O
(v/v)	O
acetonitrile,	B
and	O
solvent	O
B	O
was	O
0.1%	O
(v/v)	O
formic	B
acid	I
in	O
acetonitrile.	B

PON1	O
generates	O
an	O
endo-thiol	B
from	O
clopidogrel	B
thiolactone	I
that	O
is	O
not	O
a	O
pharmacologically	O
active	O
metabolite.	O

In	O
addition	O
to	O
the	O
identification	O
of	O
an	O
inverse	O
association	O
between	O
plasma	O
hexosylceramides	B
and	O
T2DM,	O
this	O
study	O
identified	O
unexpected	O
correlations	O
between	O
increased	O
BMI	O
and	O
SPs	O
that	O
contain	O
d16:1	B
and	O
d18:2	B
sphingoid	I
backbone	O
structures.	O

We	O
had	O
access	O
to	O
synthetic	O
triazole	B
standard	O
from	O
commercial	O
sources,	O
but	O
repeated	O
attempts	O
to	O
develop	O
an	O
assay	O
for	O
this	O
metabolite	O
did	O
not	O
materialize,	O
which	O
could	O
be	O
due	O
to	O
its	O
low	O
molecular	O
weight	O
and	O
high	O
polarity.	O

Recent	O
investigations	O
reveal	O
that	O
the	O
NSAID	O
indomethacin	B
and	O
diclofenac	O
can	O
cause	O
endoplasmic	O
reticulum	O
stress,	O
which	O
could	O
alter	O
the	O
lipid	O
machinery.	O

Finally,	O
high	O
levels	O
of	O
inter-donor	O
differences	O
in	O
β-glucosidase	O
activities	O
were	O
observed	O
in	O
both	O
whole	O
saliva	O
samples	O
(including	O
oral	O
microflora,	O
80	O
fold)	O
as	O
well	O
as	O
after	O
rinsing	O
with	O
chlorhexidine	B
gluconate	I
(38-fold).	O

Intra-tumoural	O
genetic	O
alterations	O
in	O
KP	B
enzymes	O
have	O
been	O
reported	O
in	O
various	O
cancer	O
types.	O

The	O
same	O
dietary	O
intervention	O
protocol	O
was	O
used	O
in	O
both	O
studies;	O
the	O
high	O
soy	O
diet	O
consisted	O
of	O
2	O
servings	O
of	O
soy	O
foods	O
providing	O
approximately	O
50	O
mg	O
of	O
isoflavones	B
per	O
day.	O

Phenylalanine	B
and	O
valine	B
were	O
superior	O
to	O
the	O
other	O
3	O
in	O
the	O
studies	O
with	O
American	O
populations[],	O
whereas	O
tyrosine	B
showed	O
better	O
performance	O
among	O
participants	O
in	O
South	O
Asian[].	O

Glycerophospholipids	B
are	O
major	O
components	O
of	O
cellular	O
membranes.	O

Desmethyldiazepam	B
(20	O
µl	O
of	O
250	O
ng	O
ml_−1	O
)	O
was	O
added	O
as	O
an	O
internal	O
standard	O
to	O
the	O
incubation	O
sample	O
which	O
was	O
then	O
vortex	O
mixed	O
for	O
30	O
s,	O
and	O
centrifuged	O
at	O
14	O
000	O
rev	O
min_−1	O
for	O
5	O
min	O
in	O
an	O
Eppendorf	O
model	O
5415D	O
centrifuge	O
(Brinkmann	O
Instruments,	O
Westbury,	O
NY).	O

In	O
the	O
current	O
study,	O
we	O
present	O
the	O
novel	O
finding	O
that	O
adipocytes	O
sequester	O
and	O
metabolize	O
the	O
anthracycline,	B
DNR.	O

The	O
observed	O
significant	O
arteriovenous	O
metabolite	O
changes	O
that	O
fit	O
into	O
the	O
context	O
are	O
pointed	O
out	O
in	O
red	O
(glucose,	O
glutamate,	B
aspartate,	B
serine)	B
and	O
blue	O
(lactate,	O
alanine,	B
glutamine	B
and	O
succinate).	B

Other	O
targeted	O
metabolites	O
that	O
were	O
increased	O
in	O
the	O
RYGB	O
cohort	O
include	O
NEFA,	O
valine,	B
branched-chain	O
amino	O
acids	O
(BCAA,	O
combined	O
leucine/isoleucine	O
and	O
valine),	B
and	O
glutamate/glutamine,	O
whereas	O
glycine	B
was	O
decreased,	O
as	O
have	O
previously	O
been	O
associated	O
with	O
dysglycemia.	O

These	O
results,	O
along	O
with	O
the	O
higher	O
levels	O
detected	O
of	O
proline,	B
Pro‐hydroxy‐Pro	B
or	O
dimethylarginine	B
in	O
the	O
tumor	O
samples,	O
suggest	O
an	O
increase	O
in	O
extracellular	O
matrix	O
remodeling,	O
cellular	O
proliferation	O
and	O
lung	O
function	O
(Rafikova	O
et al	O
.,	O
2016;	O
Wells	O
et al	O
.,	O
2009).	O

Geometric	O
Mean	O
Concentration_*	O
,	O
Percent	O
of	O
Total	O
EM,	O
and	O
Rank	O
Order	O
of	O
Fifteen	O
Urinary	O
Estrogens	O
and	O
Estrogen	B
Metabolites	O
(EM)	O

Specimen	O
preparation	O
included	O
methanol	B
homogenization	O
and	O
solid	O
phase	O
extraction.	O

These	O
findings	O
validate	O
biologically	O
the	O
changes	O
in	O
arginine	B
and	O
methylarginines	B
in	O
plasma	O
after	O
bypass	O
measured	O
on	O
our	O
platform.	O

LysoPCs	O
are	O
emerging	O
as	O
a	O
novel	O
class	O
of	O
inflammatory	O
lipids,	O
joining	O
thromboxanes,	B
leukotrienes	O
and	O
prostaglandins,	B
with	O
which	O
they	O
share	O
common	O
metabolic	O
pathways	O
and	O
regulatory	O
mechanisms.	O

Methyl	B
non-adecanoate	I
(74208,	O
Honeywell	O
Fluka™;	O
Honeywell,	O
Seelze,	O
Germany)	O
was	O
used	O
as	O
an	O
internal	O
standard.	O

Considering	O
model	O
experiments,	O
extracellular	O
succinic	B
acid	I
increased	O
as	O
a	O
consequence	O
of	O
ischemia	O
or	O
hypoxia	O
[,,,],	O
reaching	O
millimolar	O
concentrations	O
in	O
the	O
hypoxic	O
area.	O

The	O
T2D	O
subjects	O
used	O
in	O
the	O
extended	O
study	O
were	O
independent	O
of	O
those	O
used	O
in	O
the	O
Discovery	O
study,	O
and	O
represented	O
a	O
more	O
typical	O
mixture	O
of	O
T2D	O
cases	O
(longer	O
duration,	B
treated	O
with	O
diet,	O
oral	O
agents	O
or	O
insulin).	O

Combination	O
of	O
L-citrulline	B
and	O
D-aspartic	B
acid	I
for	O
BDTT	O
diagnosis	O
has	O
high	O
sensitivity	O
and	O
specificity.	O

(,	O
)	O
Depletion	O
of	O
the	O
circulating	O
pools	O
of	O
branched	O
chain	O
amino	O
acids	O
and	O
tryptophan	B
are	O
known	O
phenomena	O
accompanying	O
advanced	O
chronic	O
kidney	O
disease.	O

Total	O
choline	B
in	O
plasma	O
increased	O
over	O
10-times	O
from	O
early	O
to	O
late	O
lactation,	O
with	O
the	O
majority	O
of	O
the	O
increase	O
coming	O
from	O
elevated	O
PC	O
levels.	O

Possibly,	O
the	O
benzoate-BMI	B
association	O
is	O
driven	O
by	O
behavioral	O
patterns	O
related	O
to	O
personal	O
care	O
product	O
use.	O

Combined	O
with	O
a	O
LDA	O
method	O
and	O
after	O
selection	O
of	O
the	O
wished	O
number	O
of	O
discriminant	O
vectors:	O
H	O
≤	O
min	O
(p,	O
K−1),	O
where	O
p	O
is	O
the	O
total	O
number	O
of	O
variables	O
and	O
K	O
is	O
the	O
number	O
of	O
classes,	O
a	O
p-dimensional	O
data	O
are	O
projected	O
onto	O
a	O
H-dimensional	O
space	O
spanned	O
by	O
the	O
first	O
H	O
discriminant	O
vectors,	O
also	O
known	O
as	O
dimensions	O
in	O
the	O
case	O
of	O
sPLS,	O
and	O
the	O
following	O
function	O
minimized:	O
	O
minah, bh∥Mh−ahb′h∥2+Pλ(ah),	O
minah, bh∥Mh−ahb′h∥2+Pλ(ah),	O
minah, bh∥Mh−ahb′h∥2+Pλ(ah),	O
minah, bh∥Mh−ahb′h∥2+Pλ(ah),	O
minah, bh∥Mh−ahb′h∥2+Pλ(ah),	O
minah, bh∥Mh−ahb′h∥2+Pλ(ah),	O
minah, bh	O
minah, bh	O
min	O
min	O
min	O
ah, bh	B
ah, bh	B
ah	B
ah	I
a	O
a	O
h	O
h	O
, bh	O
, bh	O
, b	O
, b	O
,	O
 	O
b	O
h	O
h	O
	O
∥	O

Oxone,	B
2-iodobenzoic	B
acid	I
(IBA),	O
dimethyl	B
formamide	I
(DMF),	O
chloroform	B
(CHCl_3	O
),	O
methanol	B
(MeOH,	O
Omnisolv	O
grade),	O
acetonitrile	B
(ACN,	O
Omnisolv	O
grade),	O
formic	B
acid	I
(FA,	O
LC/MS	O
grade)	O
double-distilled	O
acetic	B
acid	I
(AcOH,	O
Teflon	O
grade,	O
99.5%)	O
and	O
NH_3	O
·H_2	O
O,	O
LC/MS	O
grade,	O
25%	O
in	O
H_2	O
O)	O
were	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
MO).	O

Trytophan,	O
phenylalanine,	B
p-tyrosine,	B
kynurenine	B
and	O
serotonin	B
concentrations	O
provided	O
by	O
both	O
methods	O
were,	O
as	O
expected,	O
highly	O
correlated	O
and	O
only	O
those	O
obtained	O
using	O
the	O
Biocrates	O
approach	O
were	O
retained	O
for	O
further	O
analysis.	O

In	O
particular,	O
a	O
recent	O
metabolomics	O
study	O
reported	O
a	O
prognostic	O
model	O
that	O
included	O
butyrylcarnitine	B
as	O
an	O
essential	O
component,	O
which	O
achieved	O
better	O
results	O
in	O
predicting	O
the	O
outcome	O
of	O
patients	O
with	O
HF	O
compared	O
to	O
conventional	O
biomarkers.	O

As	O
expected,	O
TG	B
was	O
significantly	O
increased	O
in	O
FTD	O
serum	O
compared	O
to	O
controls	O
(Fig.	O

Compounds	O
were	O
eluted	O
via	O
a	O
19	O
minute	O
linear	O
gradient	O
starting	O
from	O
90:10	O
acetonitrile:20	O
mM	O
ammonium	B
bicarbonate	O
to	O
45:55	O
acetonitrile:20	O
mM	O
ammonium	B
bicarbonate.	O

In	O
Group	O
P,	O
we	O
found	O
SM	B
C22:3	I
(i.e	O
sphingomyeline	B
with	O
22	O
carbons	O
and	O
3	O
unsaturations	O
on	O
fatty	O
acids)	O
as	O
discriminating	O
with	O
respect	O
to	O
the	O
prediction	O
of	O
several	O
clinical	O
indicators	O
by	O
overlapping	O
statistical	O
analyses,	O
as	O
was	O
SM	B
C34:1	I
in	O
group	O
O.	O
Previous	O
studies	O
have	O
implicated	O
the	O
role	O
for	O
sphingolipids	B
in	O
the	O
pathogenesis	O
in	O
ALS;	O
suggesting	O
modulation	O
of	O
receptor-mediated	O
signalling	O
pathways,	O
activity	O
as	O
lipid	O
second	O
messengers,	O
perturbation	O
of	O
muscle	O
function,	O
and	O
ceramide	B
accumulation	O
[–].	O

In	O
addition,	O
the	O
utility	O
of	O
PIS	O
of	O
m/z	O
183	O
of	O
AMPP-derivatized	O
FAs	O
for	O
FA	B
profiling	O
has	O
multiple	O
advantages	O
over	O
direct	O
profiling	O
of	O
FAs	O
in	O
the	O
negative-ion	O
mode.	O

For	O
the	O
lipid	O
fraction,	O
tandem-MS	O
experiments	O
made	O
the	O
observation	O
of	O
specific	O
transitions	O
possible	O
that	O
are	O
typical	O
for	O
certain	O
lipid	O
classes,	O
especially	O
phospholipids.	B

Increased	O
activation	O
of	O
cytochrome	O
P450	O
pathway	O
in	O
centenarians	O
is	O
further	O
supported	O
by	O
increased	O
circulating	O
levels	O
of	O
8,9-epoxyeicosatrienoic	B
(8,9-EpETrE)	I
and	O
decreased	O
concentration	O
of	O
11,12-dihydroxy-eicosatrienoic	B
acid	I
(11,12-DiHETrE).	O

An	O
in	O
vitro	O
experiment	O
showed	O
that	O
citrate	B
induced	O
apoptosis	O
in	O
two	O
GC	O
cell	O
lines	O
in	O
a	O
dose-dependent	O
manner.	O

We	O
found	O
significant	O
changes	O
in	O
three	O
salivary	O
metabolites	B
-	I
Butyric	I
acid,	I
Lactic	B
acid	I
and	O
Ethanol,	B
which	O
may	O
be	O
associated	O
with	O
opportunistic	O
pathogens	O
prevalent	O
in	O
HIV/AIDS	O
patients.	O

Decreased	O
serine	B
palmitoyl-CoA	I
transferase	O
(SPT)	O
activity	O
is	O
associated	O
with	O
methacholine-induced	O
airway	O
hyperreactivity.	O

Increased	O
ADMA	B
and	O
SDMA	O
concentrations	O
in	O
the	O
circulation	O
of	O
IBD	O
patients	O
have	O
been	O
reported	O
in	O
an	O
isolated	O
and	O
unchallenged	O
study	O
of	O
Owczarek	O
et	O
al.,	O
in	O
which	O
both	O
metabolites	O
positively	O
correlated	O
with	O
clinical	O
activity	O
of	O
CD	O
and	O
systemic	O
arginine	B
show	O
no	O
significant	O
differences	O
between	O
IBD	O
patients	O
and	O
controls.	O

To	O
validate	O
the	O
increase	O
of	O
Gln	O
in	O
HCC-NAFLD,	O
we	O
analyzed	O
Glutamine	B
Synthetase	O
(GS)	O
expression	O
by	O
immunohistochemical	O
staining	O
on	O
tumor	O
tissues.	O

Therefore,	O
HIF-1α	B
remains	I
in	O
a	O
dynamic	O
status;	O
the	O
HIF-1	O
signaling	O
pathway	O
could	O
be	O
increased,	O
decreased,	O
or	O
unchanged	O
in	O
patients	O
with	O
sepsis.	O

These	O
are	O
major	O
components	O
of	O
ceramides	B
that	O
have	O
been	O
shown	O
to	O
have	O
a	O
protective	O
role	O
against	O
insulin	O
resistance	O
and	O
diabetes	O
(Lemaitre	O
et	O
al.,	O
).	O

As	O
an	O
antioxidative,	O
it	O
is	O
known	O
to	O
attenuate	O
hypoxia,	O
inflammation,	O
vascular	O
leak,	O
and	O
edema	O
and	O
to	O
decrease	O
HIF-1α	B
protein	I
levels.	O

These	O
higher	O
concentrations	O
of	O
glucose	B
and	O
non-carbohydrate	O
glucose	O
precursors	O
such	O
as	O
amino	O
acids	O
and	O
glycerol	B
suggests	O
involvement	O
of	O
the	O
gluconeogenesis	O
pathway.	O

H_5	O
]-PhIP)	O
sulfonamide	B
adduct	O
([M+H]_+	O
at	O
m/z	O
625.2)	O
recovered	O
from	O
HONH-[_2	O
H_5	O
]-PhIP	O
modified	O
SA	O
digested	O
with	O
Pronase	O
E,	O
leucine	O
aminopeptidase,	O
and	O
prolidase.	O

As	O
an	O
example,	O
compared	O
to	O
exposure	O
group	O
0	O
(cereal	O
≤17%),	O
a	O
unit	O
increase	O
in	O
lactate	B
level	O
multiplies	O
the	O
odds	O
of	O
belonging	O
to	O
exposure	O
group	O
1	O
(cereal	O
>17%–25%)	O
and	O
group	O
2	O
(cereal	O
>25%)	O
by	O
1.36	O
and	O
1.47	O
respectively.	O

Furthermore,	O
the	O
endoscopic	O
activity	O
model	O
[comparing	O
low	O
vs	O
high	O
UCEIS]	O
revealed	O
significant	O
differences	O
in	O
isoleucine,	B
valine	B
and	O
glucose	B
plasma	O
concentrations,	O
but	O
there	O
were	O
no	O
significant	O
differences	O
in	O
these	O
metabolites	O
in	O
the	O
prognostic	O
model	O
[comparing	O
improved	O
vs	O
worsened].	O

SPC	O
was	O
found	O
also	O
in	O
humans	O
occupationally	O
exposed	O
to	O
0–23	O
ppm	O
benzene.	B

The	O
confirmed	O
changes	O
in	O
metabolites	O
(Table	O
2)	O
are	O
highlighted	O
in	O
these	O
networks	O
(thick	O
borders)	O
and	O
can	O
be	O
classified	O
into	O
three	O
major	O
correlated	O
clusters	O
(Figure	O
A):	O
(1)	O
cytidine,	B
cystathionine,	B
acetylglucosamine,	B
hydroxyproline,	B
and	O
taurine;	B
(2)	O
ornithine,	B
arginine,	B
threonine,	B
methionine,	B
glutamine,	B
glycine,	B
citrulline,	B
and	O
proline;	B
and	O
(3)	O
phenylanine,	B
cystine,	B
GlcCer(C16:0),	B
aspartate,	B
and	O
glutamate.	B

SBP	O
=	O
systolic	O
blood	O
pressure;	O
DBP	B
=	O
diastolic	O
blood	O
pressure;	O
FPG	O
=	O
fasting	O
plasma	O
glucose;	B
TC	O
=	O
total	O
cholesterol;	B
TG	B
=	O
triglycerides;	B
Hs-CRP	O
=	O
high-sensitivity	O
C-reactive	O
protein.	O

Regardless,	O
speed,	O
efficiency,	O
and	O
the	O
low	O
induced	O
variance	O
due	O
to	O
sample	O
handling	O
make	O
MeOH:	B

The	O
cholesterol	B
to	O
coprostanol	B
ratio	O
has	O
been	O
used	O
as	O
a	O
measure	O
of	O
ability	O
to	O
remove	O
cholesterol	B
from	O
circulation,	O
and	O
has	O
been	O
shown	O
to	O
be	O
controlled	O
by	O
the	O
amount	O
of	O
coprostanoligenic	B
bacteria	O
in	O
the	O
gut	O
.	O

We	O
believe	O
that	O
the	O
higher	O
concentration	O
of	O
PS	B
(22:0/0:0)	I
observed	O
in	O
the	O
study	O
is	O
correlated	O
with	O
higher	O
metastasis	O
and	O
death	O
rate	O
of	O
TNBC	O
patients.	O

Discriminatory	O
metabolic	O
features	O
were	O
identified	O
through	O
partial	O
least	O
squares	O
discriminant	O
analysis,	O
and	O
linear	O
regression	O
was	O
used	O
to	O
adjust	O
for	O
age,	O
sex,	O
diabetes	O
duration,	B
and	O
hemoglobin	O
A1c.	O

However,	O
clearly	O
shows	O
that	O
a	O
number	O
of	O
participants	O
did	O
in	O
fact	O
have	O
lower	O
urinary	O
lactose	B
concentrations	O
post	O
partum	O
(visit	O
V3)	O
than	O
during	O
pregnancy	O
(visit	O
V1	O
and	O
particularly	O
visity	O
V2).	O

Case	O
subjects	O
had	O
higher	O
median	O
serum	O
concentrations	O
of	O
nearly	O
all	O
estrogens,	O
estrogen	B
metabolites,	O
and	O
metabolic	O
pathway	O
groups	O
compared	O
with	O
control	O
subjects.	O

The	O
present	O
study	O
clearly	O
showed	O
alterations	O
in	O
TG	B
levels	O
and	O
several	O
other	O
aqueous	O
metabolites	O
in	O
tumor	O
as	O
compared	O
to	O
NAT,	O
also	O
LN-Met	O
tissues	O
showed	O
similar	O
changes	O
as	O
observed	O
in	O
tumor.	O

Histamine	B
has	O
been	O
implicated	O
in	O
murine	B
models	O
of	O
CM,	O
with	O
histamine	B
receptor	O
inhibition	O
providing	O
a	O
protective	O
effect.	O

Total	O
metabolite	O
recovery	O
(TMR,	O
calculated	O
as	O
the	O
sum	O
of	O
the	O
concentrations	O
of	O
all	O
commonly	O
detected	O
metabolites	O
averaged	O
across	O
all	O
samples	O
in	O
each	O
condition)	O
was	O
17.9%	O
higher	O
in	O
MeOH	B
ppt	O
+UF	O
samples	O
than	O
MeOH:	B

A	O
high	O
ethanolamine	B
level	O
was	O
associated	O
with	O
worse	O
survival.	O

The	O
pineal	O
hormone	O
melatonin	B
was	O
also	O
measured	O
in	O
the	O
present	O
and	O
previous	O
study,	O
with	O
significantly	O
increased	O
plasma	O
concentrations	O
being	O
observed	O
during	O
sleep	O
deprivation.	O

There	O
were	O
also	O
previous	O
studies	O
showed	O
tyrosine	B
and	O
phenylalanine	B
levels	O
in	O
cerebrospinal	O
fluid	O
of	O
patients	O
with	O
PD	O
were	O
unchanged.	O

Finally,	O
the	O
acyl	O
chains	O
were	O
identified	O
by	O
their	O
representative	O
fragment	O
ion:	O
(i)	O
in	O
positive	O
ionization:	O
sphingolipids:	B
RCN_+	O
(e.g.	O
264.269	O
for	O
d18:1)	B
and	O
for	O
glycerolipids:	B
from	O
the	O
loss	O
of	O
RCOO;	O
and	O
(ii)	O
in	O
negative	O
ionization:	O
glycerophospholipids:	B
RCOO_−	O
(e.g.	O
281.247	O
for	O
18:1	O
acyl	O
chain).	O

Only	O
β-sitosterol	B
-	I
a	O
plant-derived	O
sterol	O
that	O
reduces	O
cholesterol	B
absorption	O
in	O
the	O
intestine	O
and	O
lowers	O
plasma	O
cholesterol	B
levels	O
-	O
was	O
significantly	O
decreased	O
following	O
sleep	O
restriction.	O

The	O
supernatant	O
was	O
desiccated	O
and	O
then	O
dissolved	O
with	O
100	O
μL	O
of	O
50%	O
isopropanol	B
/Milli-Q	O
water	O
for	O
LC-TOFMS	O
analysis	O
at	O
Human	O
Metabolome	O
Technologies,	O
Inc.	O

Alteration	O
in	O
glutamine	B
and	O
glutamate	B
level	O
was	O
observed	O
in	O
Stage	O
II	O
and	O
Stage	O
III	O
of	O
endometriosis	O
patients.	O

Based	O
on	O
questionnaires,	O
daily	O
smoking	O
(yes/no),	O
hormonal	O
birth	O
control	O
of	O
women	O
(yes/no),	O
cholesterol	B
lowering	O
medication	O
(yes/no)	O
and	O
socio-economic	O
status	O
based	O
on	O
occupation	O
(manual/lower	O
non-manual/upper	O
non-manual)	O
were	O
all	O
tested	O
as	O
covariates	O
to	O
associate	O
with	O
several	O
different	O
metabolic	O
levels,	O
but	O
to	O
have	O
negligible	O
or	O
zero	O
effect	O
on	O
the	O
apoE	O
β-values.	O

Application	O
of	O
these	O
methods	O
to	O
urine	O
required	O
more	O
extensive	O
sample	O
clean	O
up	O
prior	O
to	O
the	O
mass	O
spectral	O
analysis	O
so	O
we	O
adapted	O
a	O
published	O
method	O
for	O
the	O
detection	O
of	O
urinary	O
mercapturic	B
acid	I
metabolites	O
of	O
tobacco	O
smoke	O
constituents	O
for	O
our	O
purposes.	O

MM2	O
energy	O
minimizations	O
of	O
possible	O
conformations	O
of	O
emericellenes	B
were	O
performed	O
using	O
CambridgeSoft	O
Chembio3D	O
Ultra.	O

Multiple	O
amino	O
acids,	O
particularly	O
leucine,	B
are	O
important	O
regulators	O
of	O
mTORC1	O
signaling.	O

In	O
fact,	O
among	O
female	O
patients	O
alone	O
the	O
creatinine	B
change	O
from	O
HCV	O
to	O
HCC	O
is	O
quite	O
significant	O
(p	O
=0.003,	O
).	O

Briefly,	O
samples	O
were	O
prepared	O
in	O
the	O
following	O
manner:	O
5 μg	O
DNA	O
in	O
a	O
total	O
volume	O
of	O
100 μL	O
double-deionised	O
water,	O
containing	O
124.38 ng/mL	O
(0.735 μM)	O
Methymercaptopurine-D3	B
(MeMP-d3)	O
as	O
an	O
internal	O
standard	O
to	O
control	O
for	O
extraction	O
efficiency,	O
was	O
denatured	O
by	O
heating	O
to	O
100	O
°C	O
for	O
5 min.	O

Acylcarnitines	B
are	O
involved	O
in	O
fatty	O
acid	O
β	O
-oxidation,	O
and	O
are	O
formed	O
for	O
transport	O
of	O
fatty	O
acids	O
into	O
the	O
inner	O
mitochondrial	O
membrane	O
by	O
conjugation	O
of	O
long-chain	O
fatty	O
acids	O
to	O
carnitine.	B

Two	O
hundred	O
and	O
fifty	O
microlitres	O
of	O
methanol	B
was	O
added	O
into	O
100 μ	O
L	O
of	O
plasma	O
for	O
protein	O
precipitation	O
(kept	O
on	O
ice	O
for	O
15 min)	O
and	O
immediately	O
centrifuged	O
at	O
11,200 g	O
for	O
10 min.	O

For	O
ADMA	B
and	O
SDMA	O
isomers	O
separation,	O
the	O
following	O
gradient	O
was	O
applied:	O
11%	O
B	O
for	O
0–1	O
min,	O
11%–13%	O
B	O
for	O
1–2	O
min,	O
13%–60%	O
B	O
for	O
2–5	O
min,	O
60%–90%	O
B	O
for	O
5–5.5	O
min,	O
90%	O
B	O
for	O
5.5–6	O
min	O
and	O
90%–11%	O
B	O
for	O
6–6.05	O
min.	O

The	O
11	O
metabolites	O
were	O
as	O
follows:	O
guanidoacetic	B
acid,	I
histidine,	B
homoarginine	B
or	O
N6,N6,N6-trimethyllysine,	B
N,N-dimethylglycine,	B
and	O
urea	B
in	O
plasma,	O
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine,	B
2-quinolinecarboxylic	B
acid,	I
gibberellic	O
acid,	O
hypotaurine,	B
N-acetylglucosamine	B
1-phosphate,	I
and	O
riboflavin	B
in	O
urine.	O

All	O
patients	O
had	O
beta-blockers	O
and	O
nitrates	B
held	O
for	O
at	O
least	O
24	O
hrs	O
prior	O
to	O
catheterization,	O
and	O
participants	O
were	O
brought	O
to	O
the	O
cardiac	O
catheterization	O
suite	O
in	O
an	O
overnight-fasted	O
state.	O

This	O
suggests	O
that	O
the	O
prior	O
findings	O
were	O
due	O
to	O
the	O
free	O
and	O
esterified	O
fatty	O
acid	O
compartment	O
and	O
not	O
the	O
phospholipid	B
fraction.	O

In	O
spite	O
of	O
the	O
fact	O
that	O
pioglitazone	B
is	O
a	O
well-established	O
pharmaceutical	O
with	O
lasting	O
insulin-sensitizing	O
effects,	O
and	O
despite	O
its	O
other	O
beneficial	O
effects	O
in	O
patients	O
with	O
T2D,	O
its	O
clinical	O
use	O
has	O
declined	O
recently	O
due	O
to	O
the	O
risk	O
of	O
the	O
side-effects	O
(see	O
Background).	O

Participants	O
with	O
fasting	O
or	O
postprandial	O
blood	O
glucose	B
levels	O
above	O
the	O
diagnostic	O
cut-off	O
point	O
were	O
asked	O
to	O
repeat	O
the	O
test	O
on	O
the	O
next	O
day.	O

Moreover,	O
creatine	B
is	O
a	O
biomarker	O
of	O
cachexia	O
and	O
sarcopenia	O
related	O
to	O
the	O
malignancy	O
condition.	O

Na_2	O
HPO_4	O
pH	O
7.4,	O
in	O
D_2	O
O)	O
containing	O
0.1	O
mM	O
deuterated	O
trimethylsilylpropanoic	B
acid	I
(internal	O
standard)	O
were	O
added	O
and	O
samples	O
were	O
transferred	O
to	O
a	O
5	O
mm	O
NMR	O
tube.	O

Similar	O
to	O
most	O
studies	O
on	O
urinary	O
metabolites	O
using	O
LC/MS	O
[,	O
],	O
we	O
did	O
not	O
detected	O
phosphatidylethanolamine,	B
phosphatidylserine,	B
and	O
neutral	O
lipids.	O

Strongest	O
negative	O
relationships	O
(P < 0.0001)	O
were	O
observed	O
for	O
pregnenolone	B
(r_s	O
 =	O

Cystathionine	B
and	O
cysteine	B
are	O
products	O
of	O
homocysteine	B
catabolism	O
important	O
in	O
production	O
of	O
glutathione.	B

We	O
found	O
that	O
_13	O
C	O
enrichment	O
in	O
acylcarnitines	B
was	O
higher	O
in	O
CNE2-IR	O
and	O
HK1-IR	O
cells	O
in	O
response	O
to	O
a	O
dose	O
of	O
4	O
Gy	O
radiation,	O
indicating	O
that	O
radiation-resistant	O
cells	O
utilize	O
palmitate	B
and	O
may	O
have	O
an	O
active	O
FAO.	O

The	O
corresponding	O
sulfoxide	B
metabolites	O
were	O
also	O
prepared.	O

High	O
levels	O
of	O
circulating	O
sphingomyelin	B
are	O
associated	O
with	O
coronary	O
artery	O
disease	O
as	O
they	O
increase	O
the	O
atherogenic	O
potential	O
of	O
lipoproteins	O
and	O
also	O
function	O
as	O
a	O
physiological	O
inhibitor	O
of	O
HTGL	O
activity.	O

shows	O
10	O
peptide	O
matches	O
for	O
Fraction	O
2	O
using	O
the	O
Spectrum	O
Mill	O
database	O
searching	O
tool	O
with	O
the	O
five	O
phosphorylated	O
peptides	O
shown	O
and	O
including	O
phosphorylations	B
at	O
all	O
three	O
possible	O
sites;	O
serine	B
(S),	O
threonine	B
(T),	O
and	O
tyrosine	B
(Y).	O

Participants	O
also	O
received	O
a	O
continuous	O
infusion	O
of	O
AA	O
(5.4%	O
NephrAmine,	B
B.	O
Braun	O
Medical	O
Inc.)	O
to	O
prevent	O
insulin-induced	O
hypoaminoacidemia.	O

Unexpectedly,	O
we	O
found	O
here	O
that	O
glucose	B
levels	O
in	O
AD	O
were	O
markedly	O
elevated	O
rather	O
than	O
decreased	O
in	O
all	O
seven	O
brain	O
regions	O
of	O
these	O
patients	O
with	O
late-onset	O
AD:	O
therefore,	O
diminished	O
cerebral	O
GLUT	O
activity	O
is	O
unlikely	O
to	O
play	O
an	O
initiating	O
role	O
in	O
decreased	O
glucose	B
uptake	O
in	O
AD.	O

Finally,	O
a	O
gas	O
chromatography	O
(GC)-MS-based	O
study	O
of	O
the	O
amino	O
acid	O
metabolome	O
in	O
the	O
serum,	O
including	O
pyruvic	O
acids	O
and	O
L-aspartic	B
acid,	I
was	O
able	O
to	O
differentiate	O
DM	O
patients	O
into	O
pre-clinical,	O
non-proliferative	O
and	O
PDR	O
groups.	O

Among	O
the	O
lipids	O
investigated,	O
fewer	O
than	O
ten	O
correlations	O
were	O
found	O
for	O
LPC	B
14:0	I
(8),	I
PC	B
26:0	I
(7),	O
PC	B
36:0	I
(5),	O
PC	B
40:1	I
(9),	O
GPCe	O
42:0	O
(5),	O
GPCe	O
42:5	O
(7),	O
GPCe	O
44:5	O
and	O
SM	B
22:3	I
(2).	O

The	O
reduction	O
of	O
citrate,	B
glucose,	B
and	O
lactate	B
concentrations	O
in	O
NR	O
patients	O
compared	O
with	O
R	O
and	O
C	O
patients	O
suggest	O
a	O
switch	O
from	O
glucose	B
metabolism,	O
the	O
suitable	O
energetic	O
substrate	O
of	O
the	O
brain,	O
to	O
ketogenic	O
metabolites.	O

The	O
needle-rinse	O
solvent	O
was	O
methanol.	B

Clinical	O
application	O
of	O
the	O
developed	O
algorithm	O
proposed	O
to	O
identify	O
high	O
risk	O
FDR	O
(Y	O
=	O
−4.97	O
+	O
0.0898	O
age	O
+	O
0.0843	O
PG-II	O
+	O
0.283	O
SM(OH)22:1	B
+	O
0.604	O
C16)	O
compared	O
with	O
the	O
PG-I/PG-II	O
basal	O
model	O
currently	O
in	O
use.	O

Two	O
thousand	O
units	O
of	O
E.	O
coli	O
β-glucuronidase	O
in	O
0.1	O
mL	O
of	O
phosphate	B
buffered	O
saline	B
(0.26%,	O
w/v)	O
and	O
10	O
pmol	O
[_2	O
H_2	O
]DIM	O
internal	O
standard	O
were	O
added	O
to	O
1	O
mL	O
of	O
urine.	O

These	O
weaker	O
correlation	O
values	O
were	O
influenced	O
by	O
partial	O
overlap	O
of	O
signals	O
of	O
glucose	B
at	O
δ	O
~3.89.	O

_–	O
The	O
biological	O
function,	O
if	O
any,	O
of	O
3-epi-25(OH)D_3	B
remains	O
unclear;	O
however,	O
failure	O
to	O
account	O
for	O
the	O
potential	O
presence	O
of	O
3-epi-25(OH)D_3	B
can	O
result	O
in	O
overestimation	O
of	O
the	O
concentration	O
of	O
25(OH)D_3	O
,	O
and	O
the	O
extent	O
of	O
this	O
measurement	O
bias	O
is	O
difficult	O
to	O
predict	O
in	O
advance.	O

The	O
transitions	O
monitored	O
were	O
m/z	O
220	O
→	O
m/z	O
91	O
for	O
3-HPMA,	O
m/z	O
223	O
→	O
m/z	O
91	O
for	O
[N	O
-acetyl-D_3	I
]3-HPMA,	O
m/z	O
234	O
→	O
m/z	O
105	O
for	O
HMPMA,	O
and	O
m/z	O
237	O
→	O
m/z	O
105	O
for	O
[N	O
-acetyl-D_3	I
]HMPMA.	O

Indolepropionate,	B
a	O
tryptophan	B
derivative	O
that	O
acts	O
as	O
a	O
neuroprotective	O
free-radical	O
scavenger,	O
demonstrated	O
a	O
large	O
reduction	O
during	O
CM.	O

Previous	O
metabolomics	O
studies	O
already	O
linked	O
urinary	O
excretion	O
of	O
glycine,	B
alanine	B
and	O
lactic	B
acid	I
with	O
thyroid	O
function	O
by	O
reporting	O
inverse	O
associations	O
with	O
FT4	O
in	O
cross-sectional	O
analyses.	O

Serum	O
creatinine	B
testing	O
is	O
a	O
common	O
used	O
test	O
for	O
the	O
indication	O
of	O
renal	O
function.	O

Metabolites	O
involved	O
in	O
such	O
patterns	O
included	O
reduced	O
levels	O
of	O
fatty	O
acids,	O
phosphatidyl-choline,	B
N-acetyl	O
species,	O
lactate,	B
and	O
glucose	B
and	O
increased	O
levels	O
of	O
other	O
fatty	O
acids	O
and	O
β-hydroxybutyrate	B
in	O
patients	O
with	O
progressive	O
disease.	O

Specifically,	O
we	O
show	O
that	O
patients	O
with	O
advanced	O
atherosclerosis	O
(patients	O
undergoing	O
either	O
carotid	O
endarterectomy;	O
leg	O
revascularization;	O
or	O
major	O
amputation	O
for	O
critical	O
limb	O
ischemia)	O
have	O
significantly	O
lower	O
baseline	O
plasma	O
concentrations	O
of	O
trp,	O
indole,	B
and	O
indole	B
derivatives	O
I3A	O
and	O
I3P,	O
and	O
higher	O
plasma	O
concentrations	O
of	O
the	O
kyn/trp	O
ratio	O
compared	O
to	O
an	O
age-	O
and	O
sex-matched	O
cohort	O
without	O
clinically	O
apparent	O
atherosclerosis	O
after	O
adjustment	O
for	O
traditional	O
risk	O
factors	O
for	O
atherosclerosis.	O

Therefore,	O
tryptophan	B
metabolism	O
might	O
be	O
upregulated	O
in	O
colorectal	O
cancer	O
patients.	O

As	O
depicted	O
in	O
b,	O
we	O
were	O
able	O
to	O
detect	O
and	O
quantify	O
the	O
_13	O
C-enrichment	O
profiles	O
of	O
12	O
central	O
carbon	O
metabolites,	O
specifically	O
for	O
glucose,	B
serine,	B
glycine,	B
lactate,	B
alanine,	B
citrate,	B
glutamate,	B
glutamine,	B
threonine,	B
tyrosine,	B
lysine	B
and	O
isoleucine.	B

The	O
introduction	O
of	O
an	O
imide	O
could	O
theoretically	O
be	O
conducted	O
by	O
the	O
inversion	O
of	O
a	O
deamination	O
reaction	O
but	O
such	O
a	O
metabolism	O
step	O
has	O
never	O
been	O
reported	O
before	O
and	O
was	O
therefore	O
classified	O
as	O
an	O
artifact	O
of	O
the	O
dehydro	B
impurity.	O

Focusing	O
on	O
the	O
optimization	O
of	O
separation	O
conditions,	O
we	O
achieved	O
such	O
separation	O
by	O
constructing	O
chiral	O
tandem	O
LC	O
systems	O
using	O
two	O
kinds	O
of	O
ion-exchange	O
type	O
chiral	O
columns	O
(cinchona	O
alkaloid-based	O
chiral	O
stationary	O
phases)	O
in	O
a	O
methanol	B
solvent.	O

For	O
example,	O
individuals	O
who	O
reported	O
a	O
greater	O
amount	O
of	O
nocturnal	O
waking	O
had	O
significantly	O
higher	O
indole-3-acetic	B
acid	I
throughout	O
the	O
night.	O

Our	O
previous	O
urinary	O
metabolomics-based	O
analysis	O
showed	O
that	O
patients	O
with	O
BCA	O
had	O
the	O
elevated	O
levels	O
of	O
urinary	O
carnitine	B
and	O
several	O
acylcarnitines,	B
such	O
as	O
isovalerylcarnitine	B
and	O
octenoylcarnitine,	B
and	O
the	O
decreased	O
levels	O
of	O
urinary	O
melatonin,	B
glutarylcarnitine,	B
and	O
decanolycarnitine,	B
compared	O
to	O
the	O
control	O
group.	O

Our	O
results	O
suggest	O
that	O
changes	O
in	O
premenopausal	O
estrogen	B
metabolism	O
may	O
be	O
a	O
mechanism	O
by	O
which	O
increased	O
physical	O
activity	O
lowers	O
breast	O
cancer	O
risk.	O

A	O
total	O
of	O
5	O
ml	O
peripheral	O
venous	O
blood	O
was	O
obtained	O
from	O
the	O
participants	O
and	O
collected	O
in	O
anticoagulation	O
tubes	O
containing	O
heparin	B
sodium.	I

In	O
older	O
adults	O
free	O
of	O
cardiovascular	O
or	O
kidney	O
disease	O
increased	O
levels	O
of	O
NT-proBNP	O
related	O
to	O
lower	O
LDL-cholesterol	B
and	O
higher	O
HDL-cholesterol.	B

Our	O
findings	O
of	O
a	O
lack	O
of	O
association	O
of	O
dietary	O
marine-derived	O
n−3	O
PUFAs	O
on	O
hyperplastic,	O
as	O
opposed	O
to	O
adenomatous,	O
polyp	O
risk	O
would	O
be	O
expected	O
if	O
the	O
beneficial	O
effects	O
of	O
n−3	O
PUFAs	O
are	O
mediated	O
through	O
a	O
reduction	O
in	O
prostaglandin	B
E_2	O
.	O

Most	O
of	O
the	O
FA	B
that	O
exhibited	O
increased	O
levels	O
in	O
the	O
CRC	O
tissue	O
samples	O
were	O
unsaturated	O
FA.	B

The	O
chemical	O
shifts	O
of	O
the	O
tissue	O
specimens	O
were	O
referenced	O
to	O
the	O
anomeric	O
proton	O
of	O
a-glucose	B
at	O
d5.233	O
ppm	O
prior	O
to	O
data	O
reduction	O
into	O
2,834	O
integrated	O
regions	O
of	O
0.003	O
ppm	O
corresponding	O
to	O
δH	O
=	O
9.0–0.5	O
ppm.	O

On	O
the	O
other	O
hand,	O
tryptophan	B
was	O
decreased	O
in	O
the	O
PAH	O
group,	O
which	O
can	O
be	O
of	O
relevance	O
for	O
PAH	O
pathogenesis.	O

The	O
tested	O
drugs	O
were	O
typical	O
and	O
widely	O
used	O
representatives	O
of	O
four	O
major	O
classes	O
of	O
blood	O
pressure-lowering	O
agents:	O
hydrochlorothiazide	B
(diuretic);	O
amlodipine	B
(Ca_+2	O
channel	O
blocker);	O
bisoprolol	O
(beta	O
blocker)	O
and	O
losartan	O
(angiotensin	O
II	O
receptor	O
antagonist).	O

Dried	O
extracts	O
were	O
treated	O
with	O
sulfonyl	B
chloride	I
and	O
sodium	O
bicarbonate	O
in	O
a	O
simple	O
one-step	O
reaction,	O
and	O
the	O
resulting	O
reaction	O
mixture	O
was	O
directly	O
subjected	O
to	O
LC/MS	O
analysis	O
without	O
further	O
purification.	O

The	O
scan	O
type	O
in	O
full	O
scan	O
mode	O
was	O
TOF	O
with	O
an	O
accumulation	O
time	O
of	O
1.0000	O
s,	O
mass	O
range	O
between	O
50	O
and	O
1500	O
Da	O
and	O
duration	B
time	O
of	O
55	O
min.	O

Win-	O
55–212-2	O
(CB1	O
and	O
CB2	O
agonist)	O
and	O
CP55940	O
(CB1	O
and	O
CB2	O
agonist);	O
the	O
selective	O
and	O
nonselective	O
inhibitors	O
for	O
cyclooxygenase-1	O
and	O
-2	O
(COX-1,	O
COX-2),	O
SC-560	O
(selective	O
for	O
COX-1),	O
CAY10404	O
(selective	O
for	O
COX-	O
2),	O
Ibuprofen	B
(nonselective	O
for	O
COX-1	O
and	O
COX-2);	O
and	O
the	O
selective	O
inhibitors	O
for	O
hydrolases	O
of	O
2-AG,	O
JZL	O
184	O
(selective	O
for	O
enzyme	O
monoacylglycerol	B
lipase,	O
MAGL.	O

Diglucotol	B
(82)	O
and	O
ergosterol	B
peroxide	I
(83)	O
showed	O
weak	O
potency	O
(IC_50	O
52.4–99.39	O
μM)	O
and	O
cerevisterol	B
(84)	O
was	O
moderately	O
active	O
(IC_50	O
32.4–41.5	O
μM)	O
against	O
MCF-7,	O
MDA-MB-231	O
and	O
Caco-2	O
cancer	O
cells	O
(Wang	O
et	O
al.	O
2014).	O

Cysteine	B
(Cys),	O
homocysteine	B
(HCys),	O
N	B
-acetyl-cysteine	I
(Nac),	O
γ-glutamylcysteine	B
(γ-GluCys),	I
glutathione	B
(GSH),	O
pantetheine,	O
and	O
glycine	B
were	O
purchased	O
from	O
Sigma	O
(St.	O
Louis,	O
MO,	O
USA).	O

13:0,	O
ceramide	B
(Cer)	O
d18:1/17:0,	B
sphingomyelin	B

Following	O
magnetic	O
resonance	O
spectroscopy	O
investigations,	O
it	O
has	O
been	O
demonstrated	O
that	O
increased	O
levels	O
of	O
GABA	B
neurotransmission	O
are	O
detected	O
in	O
cerebrospinal	O
fluid	O
of	O
patients	O
with	O
KD	O
(,	O
)	O
underlining	O
a	O
possible	O
action	O
of	O
ketone	B
bodies	O
upon	O
the	O
modulation	O
of	O
GABA-A	O
receptors	O
by	O
increasing	O
the	O
synaptic	O
inhibition	O
(,	O
).	O

Early	O
stage	O
samples	O
have	O
significantly	O
higher	O
concentrations	O
of	O
3-hydroxybutyrate,	B
acetoacetate	B
and	O
acetone.	B

For	O
each	O
cell	O
line,	O
8×10_6	O
cells	O
were	O
frozen	O
in	O
1	O
ml	O
methanol	B
(at	O
-20°C)	O
in	O
glass	O
tubes	O
for	O
lipid	O
analyses.	O

The	O
identification	O
of	O
8,	O
9,	O
12,	O
13,	O
14,	O
15	O
and	O
18	O
as	O
urinary	O
metabolites	O
of	O
furan	B
in	O
addition	O
to	O
the	O
previously	O
identified	O
metabolites,	O
4	O
and	O
5,	O
indicates	O
that	O
the	O
cysteine-BDA-lysine	B
crosslink	O
6	O
is	O
an	O
important	O
intermediate	O
in	O
the	O
biotransformation	O
of	O
furan.	B

The	O
synthesis	O
of	O
methoxyestrone	B
3-sulfate	I
in	O
human	O
liver	O
may	O
occur	O
through	O
two	O
subsequently	O
steps:	O
(1)	O
hydroxylation	O
of	O
E_1	O
-sulphate	O
(2-OHE_1	O
)	O
catalyzed	O
by	O
cytochrome	O
P	O
(CYP)1A1	O
or	O
CYP1B1;	O
(2)	O
methylation	O
of	O
2-OHE_1	O
-sulphate	O
to	O
methoxy	B
estrogens	O
by	O
catechol-O	O
-methyltransferase	O
enzyme.	O

Recent	O
metabolic	O
profiles	O
of	O
ovarian	O
cyst	O
fluid	O
samples	O
from	O
benign,	O
borderline,	O
and	O
malignant	O
ovarian	O
tumors	O
showed	O
that	O
hypoxanthine	B
was	O
present	O
only	O
in	O
a	O
sub-cohort	O
of	O
malignant	O
tumors.	O

(b)	O
Total	O
phospholipids	B
in	O
each	O
group	O
of	O
patients.	O

In	O
total,	O
1,851	O
molecular	O
features	O
were	O
extracted	O
and	O
detected	O
in	O
negative	O
and	O
positive	O
mode	O
when	O
the	O
methanol	B
precipitation	O
method	O
was	O
used	O
versus	O
2,073	O
features	O
when	O
methanol-ethanol	B
(1:1)	I
precipitation	O
was	O
used.	O

eicosanoids,	B
20-HETE,	B
EETs,	O
DHETs,	O
renal	O
artery	O
stenosis,	O
hypertension,	O
angiotensin	B
II	I

To	O
our	O
knowledge,	O
this	O
was	O
the	O
first	O
study	O
to	O
provide	O
evidence	O
supporting	O
CYP	O
enzyme	O
induction	O
as	O
a	O
result	O
of	O
β-carotene	B
supplementation	O
in	O
humans.	O

According	O
to	O
our	O
multiple	O
regression	O
analysis,	O
we	O
conclude	O
that	O
the	O
plasma	O
inosine	B
levels	O
are	O
negatively	O
correlated	O
with	O
depression	O
symptoms	O
severity,	O
and	O
that	O
boys	O
have	O
lower	O
inosine	B
level	O
than	O
girls,	O
which	O
may	O
result	O
from	O
the	O
antioxidant	O
effect	O
of	O
female	O
hormones	O
reducing	O
the	O
demand	O
of	O
uric	B
acid	I
in	O
girls.	O

Effect	O
of	O
nebulizer	O
pressure	O
on	O
the	O
simultaneous	O
enantioseparation	O
of	O
1,1’	B
=	I
O	I
-DVX	I
and	O
2,2’	B
=	I
VX.	I

The	O
ions	O
m/z	O
of	O
319	O
and	O
327	O
were	O
monitored	O
for	O
endogenous	O
and	O
deuterium	O
(d8)-labeled	O
EETs,	O
the	O
ions	O
m/z	O
of	O
391	O
and	O
397	O
were	O
monitored	O
for	O
20-HETE,	B
and	O
the	O
ions	O
m/z	O
of	O
481	O
and	O
489	O
were	O
monitored	O
for	O
DHETs.	O

Urinary	O
creatinine	B
was	O
measured	O
using	O
the	O
Jaffè	O
colorimetric	O
method.	O

L-Proline-_13	B
C_5	O
,	O
_15	O
N_1	O
(97-99	O
atom	O
%	O
_13	O
C,	O
97-99	O
atom	O
%	O
_15	O
N)	O
was	O
purchased	O
from	O
Cambridge	O
Isotope	O
Laboratories	O
(Andover,	O
MA).	O

Abbreviations:	O
11KDHT,	O
11-ketodihydrotestosterone;	B
17OH-PREG,	O
17α	B
-hydroxypregnenolone;	I
CYB5A,	O
cytochrome	O
b_5	O
;	O
CYP11B1,	O
cytochrome	O
P450	O
11β	O
-hydroxylase;	O
CYP17A1,	O
cytochrome	O
P450	O
17α	O
-hydroxylase/17,-20-lyase;	O
DHT,	O
5α	B
-dihydrotestosterone;	I
HSD11B2,	O
11β	O
-hydroxysteroid	O
dehydrogenase	O
type	O
2;	O
HSD3B,	O
3β	O
-hydroxysteroid	O
dehydrogenase;	O
PREG,	O
pregnenolone;	B
SRD5A,	O
steroid	O
5α	O
-reductase;	O
SULT2A1,	O
sulfotransferase	O
family	O
2A	O
member	O
1.	O

After	O
adjusting	O
the	O
pH	O
to	O
7.0 ± 0.1,	O
540 μL	O
of	O
sample	O
was	O
mixed	O
with	O
60 μL	O
of	O
5 mM	O
3-(trimethylsilyl)	B
propionic	O
2,2,3,3-acid	B
(TSP)	O
in	O
D_2	O
O;	O
see	O
Supplementary	O
Methods.	O

Increased	O
BCAA	O
availability,	O
irrespective	O
of	O
the	O
source	O
(e.g.	O
protein	O
breakdown	O
or	O
nutrition)	O
might	O
fuel	O
other	O
metabolic	O
pathways	O
including	O
gluconeogenesis	O
upsetting	O
glucose	B
homeostasis.	O

Hydrochloric	B
acid	I
(HCl),	O
sodium	B
chloride	I
(NaCl),	O
all	O
the	O
standards	O
used	O
for	O
VOMs	O
confirmation	O
(purity	O
higher	O
than	O
98.5%)	O
and	O
the	O
n	O
-alkanes	O
mixture	O
containing	O
C_8	O
–C_20	O
straight-chain	O
alkanes	O
in	O
hexane	B
were	O
obtained	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
MO,	O
USA).	O

We	O
fit	O
logistic	O
regression	O
models	O
to	O
assess	O
the	O
risk	O
of	O
angina	O
and	O
MI	O
after	O
adjustment	O
for	O
age,	O
sex,	O
BMI,	O
LDL	B
cholesterol,	I
and	O
fasting	O
glucose	B
(	O
and	O
).	O

It	O
should	O
also	O
be	O
pointed	O
out	O
that	O
the	O
elution	O
range	O
of	O
∼16−20	O
min	O
for	O
the	O
four	O
metabolites	O
in	O
is	O
earlier	O
than	O
that	O
of	O
the	O
parent	O
drug,	O
which	O
was	O
observed	O
at	O
20.74	O
min	O
when	O
translated	O
to	O
the	O
formate	B
buffer	O
system	O
(data	O
not	O
shown).	O

The	O
concentrations	O
of	O
nine	O
γ-glutamyl	O
dipeptides	O
(γ-Glu-Trp,	O
γ-Glu-Tyr,	B
γ-Glu-Phe,	B
γ-Glu-Val,	B
γ-Glu-Leu,	B
γ-Glu-Ile,	B
γ-Glu-His,	B
γ-Glu-Thr	B
and	O
γ-Glu-Glu),	B
as	O
well	O
as	O
those	O
of	O
their	O
binding	O
amino	O
acids	O
(Asp,	O
Glu,	O
Ile,	O
Val,	O
Leu,	O
Thr,	O
Ser,	O
Gly	O
and	O
Ala),	O
were	O
greater	O
in	O
cluster	O
X	O
than	O
in	O
cluster	O
Y,	O
and	O
are	O
shown	O
as	O
cluster	O
A	O
on	O
the	O
vertical	O
axis	O
of	O
Figure	O
.	O

The	O
methyl	O
signal	O
of	O
the	O
small	O
metabolite	O
3-hydroxybutyric	B
acid,	I
however,	O
normally	O
occurs	O
in	O
the	O
same	O
region	O
of	O
the	O
CSF	O
spectrum	O
as	O
the	O
ethanol	O
methyl	O
triplet	O
(1.18 ppm).	O

This	O
further	O
confirms	O
that	O
fatty	O
acid	O
oxidation,	O
as	O
evidenced	O
by	O
elevated	O
levels	O
of	O
acylcarnitines,	B
is	O
dysfunctional	O
in	O
the	O
ischemic	O
myocardial	O
cell.	O

The	O
transitions	O
308	O
to	O
84	O
and	O
311	O
to	O
87	O
at	O
a	O
collision	O
energy	O
of	O
20	O
eV	O
were	O
used	O
for	O
the	O
hexanoate	B
derivatives	O
of	O
NNAL	O
and	O
the	O
internal	O
standard,	O
NNAL-d_3	O
,	O
respectively.	O

(A)	O
Discriminators	O
without	O
glycerolipid	B
metabolism	O
and	O
fatty	O
acids.	O

The	O
polar	O
and	O
nonpolar	O
fractions	O
were	O
further	O
derivatized	O
with	O
O-methyl-hydroxylamine	B
hydrochloride	I
to	O
convert	O
oxo-groups	O
to	O
O-methyl-oximes,	B
and	O
subsequently	O
with	O
a	O
N-methyl-N-(trimethylsilyl)trifluoroacetamide	B
prior	O
to	O
analysis.	O

(A)	O
ADMA,	B
(B)	O
L-NMMA,	B
(C)	O
SDMA,	O
(D)	O
L-arginine,	B
(E)	O
ADMA:	B
L-arginine	B
ratio,	O
(F)	O
L-NMMA:	B
L-arginine	B
ratio,	O
(G)	O
SDMA:	O
L-arginine	B
ratio	O
in	O
plasma	O
and	O
(H)	O
iNOS	O
supporting	O
activity	O
of	O
plasma	O
applied	O
to	O
LPS	O
activated	O
J774	O
macrophages.	O

(20–4	O
arachidonic	B
acid)	I

Arginine	B
as	O
an	O
acidifying	O
agent	O
might	O
alter	O
the	O
acid-base	O
equilibrium	O
in	O
CKD,	O
and	O
increased	O
arginine	B
may	O
promote	O
kidney	O
injury.	O

(c)	O
Markers	O
of	O
lipid	O
beta-oxidation	O
(acetyl-carnitines,	O
ketone	B
bodies)	O
and	O
omega-oxidation	O
were	O
lower	O
at	O
three	O
months.	O

Only	O
3-hydroxybutyrate	B
was	O
increased	O
(P	O
 < .05)	O
in	O
the	O
normal	O
tissue	O
of	O
the	O
EAC	O
patients	O
compared	O
with	O
the	O
normal	O
tissue	O
of	O
the	O
Barrett's	O
patients.	O

Cachexia	O
has	O
been	O
linked	O
with	O
psoriasis,	O
and	O
cytokine	O
inhibitors	O
(e.g.,	O
anti-TNFα)	B
have	O
been	O
suggested	O
in	O
the	O
treatment	O
of	O
cachexia.	O

Moreover,	O
the	O
2-h	O
insulin	O
was	O
negatively	O
correlated	O
with	O
histidine	B
(r	O
:	O
−0.355,	O
p	O
<	O
0.05).	O

Considering	O
that	O
S1P	O
and	O
other	O
sphingolipids	B
act	O
as	O
mediators	O
inside	O
and	O
outside	O
of	O
cancer	O
cells	O
to	O
promote	O
their	O
progression,	O
it	O
appears	O
that	O
sphingolipids	B
play	O
a	O
pivotal	O
role	O
in	O
the	O
tumor	O
microenvironment.	O

Baseline	O
taurine	B
and	O
asymmetric	B
dimethylarginine	I
(ADMA)/symmetric	O
dimethylarginine	B
(SDMA)	O
concentrations	O
were	O
inversely	O
associated	O
with	O
changes	O
in	O
WC	O
and	O
2-hour	O
glucose,	B
respectively,	O
while	O
glutamate	B
was	O
positively	O
associated	O
with	O
change	O
in	O
DBP	B
(p	O
<	O
3	O
×	O
10-4	O
).	O

As	O
oxysterol	B
levels	O
are	O
impacted	O
by	O
circadian	O
and	O
feeding	O
rhythm,	O
patients	O
were	O
asked	O
to	O
refrain	O
from	O
eating	O
after	O
8	O
p.m.	O
before	O
the	O
day	O
of	O
sampling,	O
which	O
was	O
performed	O
between	O
8–9	O
AM	O
on	O
the	O
next	O
day.	O

The	O
urine	O
samples	O
were	O
analysed	O
for	O
the	O
nicotine	B
metabolites	O
cotinine	B
(Cot)	O
and	O
trans	B
-3′-hydroxycotinine	I
(T3HCot)	O
and	O
the	O
PAH	O
metabolites	O
2-naphthol	B
(2-Nap),	O
1-hydroxyfluorene	B
(1-HFl),	O
2-hydroxyfluorene	B
(2-HFl),	O
3-hydroxyfluorene	B
(3-HFl),	O
1-hydroxyphenanthrene	B
(1-HPhe),	O
2-hydroxyphenanthrene	B
(2-HPhe),	O
3+4-hydroxyphenanthrene	B
(3+4-HPhe)	I
and	O
1-hydroxypyrene	B
(1-HPyr).	O

As	O
indicated	O
in	O
,	O
the	O
assay	O
is	O
more	O
sensitive	O
for	O
the	O
neurotransmitter	O
DA,	O
detecting	O
reproducibly	O
down	O
to	O
25	O
ng/mL,	O
which	O
translates	O
to	O
0.625	O
ng	O
of	O
material	O
on	O
column	O
of	O
which	O
0.13	O
and	O
500	O
pg	B
are	O
delivered	O
to	O
the	O
MS	O
and	O
EC-array,	O
respectively.	O

Although	O
the	O
associations	O
between	O
metabolites	O
and	O
DBP	B
were	O
not	O
significant,	O
the	O
effect	O
sizes	O
of	O
the	O
associations	O
before	O
and	O
after	O
the	O
intervention	O
were	O
highly	O
similar,	O
indicated	O
by	O
the	O
high	O
correlation	O
between	O
the	O
effect	O
sizes	O
(r	O
 = 0.959).	O

The	O
concentrations	O
of	O
inflammation	O
and	O
all-cause	O
mortality	O
reflecting	O
GlycA,	B
as	O
well	O
as	O
diabetogenic	O
branched	O
chain	O
amino	O
acid	O
isoleucine	O
were	O
elevated	O
in	O
apoE	O
ε4+	O
group.	O

Our	O
addition	O
of	O
acetonitrile	B
is	O
suggestive	O
of	O
hydrophobic	O
interactions	O
between	O
MEL	O
and	O
plasma	O
proteins.	O

Although	O
the	O
TMAO	B
level	O
has	O
been	O
suggested	O
to	O
be	O
involved	O
in	O
atherosclerosis,4,	O
5	O
and	O
many	O
cohort	O
studies	O
have	O
suggested	O
that	O
an	O
increased	O
number	O
of	O
adverse	O
outcomes	O
are	O
associated	O
with	O
high	O
TMAO	B
levels,4,	O
5,	O
6,	O
7	O
no	O
reports	O
have	O
examined	O
the	O
increase	O
in	O
TMAO	B
levels	O
in	O
asymptomatic	O
atherosclerosis	O
patients.	O

The	O
mobile	O
phase	O
was	O
composed	O
of	O
solvent	O
A	O
(0.1%	O
FA	B
in	O
H_2	O
O)	O
and	O
solvent	O
B	O
(0.1%	O
FA	B
in	O
ACN).	O

The	O
application	O
of	O
HPLM	O
resulted	O
in	O
significant	O
metabolic	O
alterations	O
relative	O
to	O
the	O
traditional	O
media	O
including	O
an	O
inhibition	O
of	O
de	O
novo	O
pyrimidine	B
synthesis.	O

The	O
MTBE-extracted	O
lipid	O
fraction	O
was	O
dried	O
by	O
N_2	O
,	O
and	O
dried	O
lipids	O
were	O
dissolved	O
into	O
500	O
µL	O
chloroform.	B

Addition	O
of	O
all	O
EM,	O
the	O
sum	O
of	O
all	O
15	O
parent	O
estrogens	O
and	O
estrogen	B
metabolites,	O
to	O
a	O
model	O
containing	O
unconjugated	O
estradiol	B
changed	O
the	O
absolute	O
risk	O
estimate	O
by	O
at	O
least	O
14%	O
for	O
only	O
14%	O
of	O
the	O
women.	O

Cysteamine	B
is	O
also	O
a	O
degradation	O
product	O
of	O
the	O
amino	O
acid	O
cysteine.	O

Medical	O
treatment	O
for	O
the	O
HF	O
patients	O
consisted	O
of	O
diuretics	O
(71.7%),	O
β-blockers	O
(73.9%),	O
angiotensin	B
converting	O
enzyme	O
inhibitors	O
or	O
angiotensin	B
II	I
receptor	O
blocker	O
(69.6%),	O
and	O
statins	B
(28.3%).	O

Serum	O
metabolite	O
extraction	O
was	O
performed	O
by	O
adding	O
400	O
μl	O
of	O
ice-cold	O
methanol	B
to	O
50	O
μl	O
of	O
serum.	O

Measured	O
glycosphingolipids	B
included	O
glucosyl-	B
(GC),	I
dihexosyl-	B
(DHC),	I
and	O
trihexosyl-	B
(THC)	I
ceramides.	I

Plasma	O
triglycerides	B
were	O
measured	O
using	O
the	O
WAKO	O
TrigA	O
kit	O
(WAKO,	O
Japan)	O
per	O
the	O
manufacturer's	O
instructions.	O

Similarly,	O
betaine	B
acts	O
also	O
as	O
osmolyte	O
and	O
accumulates	O
together	O
with	O
GPC,	B
sorbitol,	B
and	O
inositol	B
to	O
sufficiently	O
counterbalance	O
osmolality.	O

Ion	O
number	O
4	O
with	O
[M−H]_−	O
 = 135.0303	O
m/z	O
,	O
retention	O
time	O
of	O
0.3158	O
min	O
was	O
verified	O
to	O
be	O
hypoxanthine,	B
also	O
involved	O
in	O
the	O
metabolism	O
of	O
purines	B
(,	O
p = 0.008).	O

SPE-LC-MS/MS	O
(solid	O
phase	O
extraction-LC-MS/MS)	O
was	O
applied	O
for	O
the	O
determination	O
of	O
catecholamine	B
and	O
steroid	O
levels.	O

Choline	B
kinase	O
(CHK),	O
the	O
enzyme	O
that	O
catalyzes	O
the	O
phosphorylation	O
of	O
choline	B
to	O
pCho	O
is	O
also	O
upregulated	O
in	O
cancer.	O

In	O
brief,	O
to	O
the	O
dried	O
sample,	O
we	O
added	O
100	O
μL	O
of	O
freshly	O
prepared	O
condensation	O
mixture	O
(containing	O
100	O
mg	O
2-methyl-6-nitrobenzoic	B
anhydride,	O
30	O
mg	O
4-dimethylaminopyridine,	B
and	O
80	O
mg	O
picolinic	B
acid	I
in	O
1.5	O
mL	O
anhydrous	B
pyridine)	I
and	O
20	O
μL	O
of	O
triethylamine.	B

The	O
higher	O
concentration	O
in	O
dopamine,	B
closely	O
related	O
to	O
higher	O
levels	O
of	O
homogentisic	B
acid	I
(another	O
product	O
of	O
tyrosine	B
metabolism)	O
may	O
reflect	O
this	O
disbalance,	O
yet	O
serotonin	B
metabolism	O
could	O
not	O
be	O
captured	O
with	O
our	O
analytical	O
approach	O
in	O
urine.	O

Similarly,	O
the	O
t-choline	B
and	O
(PC + GPC)	O
contents	O
observed	O
the	O
prostate	O
cancer	O
samples	O
were	O
significantly	O
higher	O
than	O
in	O
benign	O
prostate.	O

The	O
increased	O
pyruvate	B
and	O
decreased	O
intermediates	O
in	O
TCA	O
cycle	O
suggest	O
an	O
impaired	O
mitochondrial	O
respiration	O
in	O
CRC,	O
which	O
is	O
in	O
line	O
with	O
previous	O
metabonomics	O
studies._,	O
Interestingly,	O
a	O
decreased	O
entry	O
of	O
pyruvate	B
into	O
the	O
TCA	O
cycle	O
in	O
cancer	O
cells	O
was	O
also	O
observed	O
in	O
leukemia	O
cells	O
by	O
Ismael	O
et	O
al.	O

A	O
pooled	O
sample	O
was	O
generated	O
by	O
taking	O
an	O
aliquot	O
from	O
each	O
individual	O
sample	O
and	O
labeled	O
with	O
_13	O
C-dansyl	B
chloride.	I

Separation	O
by	O
LC	O
requires	O
a	O
column	O
that	O
can	O
adequately	O
retain	O
glucuronide	B
conjugates	O
and	O
provide	O
sufficient	O
resolution	O
of	O
analytes	O
of	O
interest.	O

The	O
vertical	O
line	O
at	O
X=~0	O
in	O
all	O
plots	O
of	O
,	O
Panel	O
I	O
shows	O
that,	O
regardless	O
of	O
PCT	O
or	O
dilution,	O
some	O
highly	O
abundant	O
lipids/artifacts	O
are	O
poorly	O
extracted	O
by	O
MTBE.	B

TCA:	O
tricarboxylic	B
acid.	I

We	O
previously	O
reported	O
that	O
TDO	O
activity	O
increased	O
in	O
TNBC	O
cell	O
lines	O
under	O
anchorage-independent	O
conditions,	O
resulting	O
in	O
increased	O
intracellular	O
and	O
secreted	O
kynurenine.	B

Thiamethoxam	B
was	O
from	O
Dr.	O
Ehrenstorfer	O
(Augsburg,	O
Germany).	O

Panel	O
(f)	O
shows	O
difference	O
in	O
serum	O
lactate	B
contents	O
between	O
Tae-Eum	O
and	O
So-Yang	O
types	O
with	O
normal	O
weight	O
and	O
overweight,	O
demonstrating	O
metabolic	O
dependence	O
of	O
serum	O
lactate	B
level	O
on	O
SC	O
types.	O

We	O
demonstrate	O
the	O
results	O
of	O
the	O
simultaneous	O
determination	O
of	O
the	O
microbial	O
and	O
mitochondrial	O
metabolites	O
and	O
lactate	B
in	O
the	O
same	O
serum	O
samples	O
of	O
patients	O
with	O
late	O
sepsis	O
(n	O
=	O
22)	O
of	O
Group	O
II	O
in	O
comparison	O
with	O
healthy	O
controls	O
(Group	O
III,	O
n	O
=	O
20).	O

Race,	O
diabetes,	O
urine	O
albumin	O
excretion,	O
and	O
the	O
circulating	O
concentrations	O
of	O
parathyroid	O
hormone	O
and	O
fibroblast	O
growth	O
factor	O
23	O
more	O
modestly	O
modified	O
the	O
association	O
of	O
24,25(OH)_2	B
D_3	O
with	O
25(OH)D_3	O
.	O

Parameters	O
of	O
liquid	O
chromatography-tandem	O
mass	O
spectrometry	O
method	O
for	O
measuring	O
glutamate,	B
aspartate,	B
glutamine	B
and	O
asparagine.	B

Aliquots	O
of	O
200	O
μl	O
human	O
plasma	O
were	O
mixed	O
with	O
5	O
μl	O
Master	O
ISDT	O
before	O
loading	O
onto	O
96-well	O
SPE	O
cartridges	O
(30	O
mg,	O
HLB,	O
Waters,	O
Milford,	O
MA),	O
which	O
had	O
been	O
pre-conditioned	O
with	O
1	O
ml	O
MeOH	B
and	O
followed	O
by	O
1	O
ml	O
water.	O

Abbreviations:	O
TCDCA,	O
taurochenodeoxycholic	B
acid;	I
GCDCA,	B
glycochenodeoxycholic	B
acid;	I
GCA,	O
glycocholic	B
acid,	I
Orn:	O
ornithine,	B
Cit:	O
citrulline,	B
β-OH-B:	B
β-hydroxybutyrate.	B

In	O
multivariate	O
analyses,	O
adherence	O
was	O
confirmed	O
as	O
the	O
sole	O
determinant	O
that	O
explained	O
47%	O
of	O
tamoxifen	B
plasma	O
concentration	O
variability	O
(P	O
 < 0.001;	O
Table	O
).	O

Of	O
the	O
serum	O
metabolites	O
quantified	O
in	O
this	O
study,	O
high	O
levels	O
of	O
kynurenic	B
acid	I
were	O
associated	O
with	O
low	O
cognitive	O
functioning	O
(R	O
 = −0.39,	O
P	O
 < 0.05).	O

However,	O
the	O
present	O
examination	O
of	O
the	O
blood	O
metabolome	O
at	O
70,	O
220	O
and	O
330	O
min	O
after	O
exercise	O
and	O
protein	O
intake	O
showed	O
a	O
similar	O
change	O
in	O
the	O
blood	O
metabolome	O
for	O
the	O
whey	B
and	O
calcium	B
caseinate	I
protein	O
treatment	O
groups.	O

Hydrochlorothiazide	B
administration	O
was	O
associated	O
with	O
an	O
increase	O
of	O
plasma	O
uric	B
acid	I
level	O
(P	O
=	O
5	O
x	O
10-4	O
)	O
and	O
urea	B
cycle	O
metabolites.	O

To	O
test	O
the	O
hypothetic	O
scenario	O
that	O
the	O
detected	O
cyanidin-3-sambubioside	B
glucuronides	O
were	O
generated	O
intracellularly	O
from	O
within	O
oral	O
surface	O
epithelial	O
cells	O
and	O
then	O
transported	O
to	O
saliva,	O
an	O
ex-vivo	O
15	O
minute	O
incubation	O
of	O
10%	O
FBR	O
(37	O
°C,	O
5%	O
CO2)	O
with	O
saliva	O
collected	O
from	O
6	O
volunteers	O
was	O
conducted.	O

To	O
confirm	O
further	O
the	O
assignment	O
for	O
G6P	O
(as	O
opposed	O
to	O
glucose),	B
2-D	O
high-resolution	O
_1	O
H-_13	O
C	O
HSQC-TOCSY	O
spectra	O
were	O
analyzed	O
and	O
that	O
for	O
the	O
myocytes	O
is	O
illustrated	O
in	O
Figure	O
.	O

However,	O
a	O
case-control	O
study	O
from	O
New	O
Hampshire	O
investigated	O
the	O
effect	O
of	O
minerals	O
and	O
vitamins	O
on	O
the	O
risk	O
of	O
BCa,	O
and	O
found	O
that	O
a	O
higher	O
total	O
intake	O
of	O
thiamine	B
was	O
inversely	O
correlated	O
with	O
BCa	O
risk	O
in	O
older	O
participants.	O

Further,	O
kitchen	O
workers	O
who	O
were	O
smokers,	O
consuming	O
alcohol,	O
caffeine,	B
vitamin	O
supplements	O
or	O
medicines	O
like	O
psychotropic	O
drugs,	O
antihypertensive	O
drugs	O
and	O
antihistamines	B
were	O
excluded	O
from	O
the	O
study,	O
as	O
these	O
chemicals	O
can	O
inhibit	O
thermoregulation	O
and	O
interfere	O
with	O
the	O
study.	O

Interestingly,	O
the	O
combination	O
of	O
cysteine	B
elevation	O
and	O
uridine	B
decrease	O
is	O
best	O
suited	O
for	O
distinguishing	O
these	O
AD	O
patients	O
from	O
healthy	O
controls.	O

No	O
carryover	O
was	O
observed	O
for	O
cannabinoids	B
after	O
injecting	O
negative	O
specimens	O
after	O
samples	O
containing	O
twice	O
the	O
ULOQ.	O

Internal	O
standards	O
C8–C30	O
fatty	O
acid	O
methyl	O
esters	O
(FAMEs)	O
were	O
added	O
and	O
the	O
sample	O
was	O
derivatized	O
by	O
methoxyamine	B
hydrochloride	I
in	O
pyridine	B
and	O
subsequently	O
by	O
N-methyl-trimethylsilyltrifluoroacetamide	B
(MSTFA)	O
(1	O
ml	O
bottles,	O
Sigma-Aldrich)	O
for	O
trimethylsilylation	O
of	O
acidic	O
protons.	O

In	O
newborns	O
with	O
HIE,	O
both	O
metabolites	O
showed	O
a	O
decrease	O
with	O
time	O
(although	O
not	O
statistically	O
significant	O
for	O
acetoacetate),	B
which	O
might	O
probably	O
be	O
attributed	O
to	O
their	O
consumption	O
as	O
energy	O
fuels.	O

HT-116	O
cells	O
(left)	O
or	O
HT-29	O
cells	O
(right)	O
were	O
incubated	O
with	O
the	O
indicated	O
concentrations	O
of	O
9-HSA	O
(black	O
circles)	O
or	O
oleic	B
acid	I
(open	O
circles),	O
as	O
a	O
negative	O
control	O
for	O
24	O
h.	O
Cell	O
viability	O
was	O
measured	O
with	O
the	O
CellTiter	O
96_®	O
AQ_ueous	O
One	O
Solution	O
Cell	O
Proliferation	O
Assay	O
kit.	O

The	O
authors	O
identified	O
a	O
1.9-fold	O
increase	O
in	O
acetate	B
in	O
the	O
patients	O
with	O
MS	O
vs	O
the	O
HC,	O
but	O
it	O
was	O
mainly	O
increased	O
in	O
patients	O
with	O
NMO	O
(1.8-fold	O
and	O
3.4-fold	O
higher	O
than	O
patients	O
with	O
MS	O
and	O
HC).	O

Surrogate	O
transitions	O
for	O
oxylipins	B
were	O
optimized	O
by	O
using	O
TSQ	O
Quantiva	O
Tune	O
2.1	O
(Thermo	O
Fisher	O
Scientific,	O
Haverhill,	O
MA)	O
via	O
direct	O
infusion	O
of	O
individual	O
standard	O
solution	O
with	O
a	O
syringe	O
pump	O
at	O
flow	O
rate	O
of	O
10	O
μl/min.	O

Ethanolamine	B
was	O
the	O
only	O
metabolite	O
to	O
strongly	O
correlate	O
at	O
baseline	O
to	O
both	O
post-treatment	O
and	O
to	O
change	O
in	O
clinical	O
measures	O
of	O
diabetes,	O
indicating	O
that	O
this	O
phospholipid	B
head	O
group	O
may	O
be	O
a	O
potential	O
biomarker	O
of	O
simvastatin-induced	O
insulin	O
resistance	O
and	O
hyperglycemia	O
and	O
may	O
indicate	O
statin-induced	O
alterations	O
in	O
lipid	O
metabolism	O
leading	O
towards	O
a	O
diabetic	O
state.	O

SM	O
species	O
are	O
metabolized	O
into	O
ceramides,	B
an	O
important	O
second	O
messenger	O
involving	O
in	O
regulation	O
of	O
cellular	O
differentiation,	O
proliferation,	O
and	O
apoptosis	O
.	O

There	O
are	O
two	O
main	O
processes	O
that	O
orchestrate	O
DNA	O
methylation	O
of	O
key	O
epigenetic	O
regulators;	O
these	O
involve	O
5-methylcytosine	B
(5mC)	O
and	O
5-hydroxymethylcytosine	B
(5hmC),	O
which	O
are	O
located	O
on	O
the	O
CpG	O
islands	O
of	O
gene	O
promoters	O
and	O
enhancers.	O

6-,	O
7-OH-WARs,	B
).	O

To	O
explore	O
this	O
concept,	O
we	O
investigated	O
ion	O
pairs	O
of	O
4	O
aromatic	O
bases	O
with	O
aliphatic	B
acids	I
monitoring	O
the	O
formation	O
of	O
anions	O
using	O
TOF	O
mass	O
spectrometry.	O

PC	B
ae	I
C38:1;	I
23.	O

In	O
our	O
study,	O
eicosanoids	B
were	O
significantly	O
overexpressed	O
in	O
HCC	O
patients	O
vs.	O
DCs	O
and	O
downregulated	O
in	O
DCs	O
vs.	O
NHC.	O

In	O
this	O
experiment,	O
glycine	B
content	O
in	O
papillary	O
thyroid	O
carcinoma	O
was	O
increased,	O
which	O
is	O
related	O
to	O
high	O
methylation	O
of	O
the	O
promoter	O
region.	O

Two	O
PPP-involved	O
metabolites,	O
arabitol	B
and	O
ribitol,	B
were	O
found	O
significantly	O
increased	O
in	O
the	O
comparison	O
of	O
R_BT	O
to	O
NR_BT	O
.	O

Upon	O
initial	O
evaluation,	O
spectra	O
revealed	O
a	O
high	O
heterogeneity	O
(Fig. )	O
and	O
numerous	O
peaks	O
could	O
be	O
assigned	O
to	O
[M+NH_4	O
]_+	O
ions	O
of	O
DG	O
and	O
TG	B
species.	O

Samples	O
with	O
a	O
low	O
glutamine/glutamate	B
ratio	O
were	O
excluded	O
from	O
analyses	O
of	O
glutamine	B
associations.	O

L-Aspartate.	B

The	O
next	O
step	O
in	O
the	O
procedure	O
involved	O
washing	O
the	O
eluted	O
SPE	O
columns	O
with	O
1mL	O
of	O
a	O
2%	O
formic	B
acid	I
solution,	O
followed	O
by	O
a	O
wash	O
with	O
1mL	O
of	O
methanol.	B

Glutamine	B
plays	O
a	O
role	O
in	O
the	O
fatty	O
acid	O
and	O
protein	O
synthesis,	O
and	O
it	O
is	O
a	O
primary	O
energy	O
source	O
for	O
many	O
cells	O
such	O
as	O
the	O
intestinal	O
epithelial,	O
immune	O
system	O
and	O
cardiac	O
cells.	O

The	O
patients	O
were	O
a	O
82-year	O
old	O
male	O
with	O
a	O
cerebellar	O
infarct	O
(patient	O
3),	O
a	O
46-year	O
old	O
female	O
with	O
subarachnoid	B
hemorrhage	O
(patient	O
4),	O
a	O
35-year	O
old	O
male	O
with	O
a	O
cerebellar	O
infarct	O
(patient	O
5),	O
and	O
a	O
55-year	O
old	O
female	O
with	O
a	O
tumor	O
(patient	O
6).	O

By	O
analyzing	O
samples	O
in	O
parallel	O
by	O
routes	O
A	O
(without	O
cholesterol	B
oxidase)	O
and	O
B	O
(with	O
cholesterol	B
oxidase),	O
analytes	O
possessing	O
a	O
3-oxo	O
group	O
are	O
differentiated	O
from	O
those	O
oxidized	O
to	O
contain	O
one	O
(i.e.	O
3β-hydroxy-5-ene	B
or	O
3β-hydroxy-5α-hydrogen	B
sterols/bile	O
acids).	O

L-Cysteinesulfonic	B
acid	I
Creatinine	I
Unknown	O
1	O
Unknown	O
2	O
Unknown	O
5	O
Unknown	O
6	O
Unknown	O
7	O
Unknown	O
8	O
Unknown	O
9	O
Fumarate	B
3-hydroxyvalerate	I
Unknown	O
10	O
Unknown	O
11	O
Unknown	O
12	O
Unknown	O
13	O
Unknown	O
14	O
Unknown	O
15	O
Unknown	O
16	B
2-Methylhippuric	I
acid	I
5-Acetylamino-6-amino-3-methyluracil	I
_1	O
Underlined	O
metabolites	O
were	O
used	O
for	O
generating	O
prediction	O
model.	O

Using	O
a	O
logistic	O
regression	O
algorithm,	O
a	O
metabolite	O
panel	O
consisting	O
of	O
N-acetyl-4-O-acetylneuraminic	B
acid,	I
4-(2-aminophenyl)-2,4-dioxobutanoic	B
acid,	I
6-keto-decanoylcarnitine,	B
3-hydroxydecanoyl	B
carnitine,	I
and	O
2-hydroxylauroylcarnitine	B
was	O
established.	O

As	O
previously	O
discussed	O
by	O
our	O
group,	O
glycerophospholipids	B
participate	O
in	O
signal	O
transduction	O
[,],	O
and	O
are	O
involved	O
in	O
oxidative	O
stress	O
processes	O
in	O
neurologic	O
disorders,	O
namely,	O
in	O
Alzheimer’s	O
disease,	O
which	O
may	O
share	O
important	O
pathogenic	O
mechanisms	O
with	O
AMD.	O

In	O
a	O
sensitivity	O
analysis	O
including	O
HOMA-IR	O
and	O
2	O
h	O
glucose	B
as	O
additional	O
type	O
2	O
diabetes	O
risk	O
factors,	O
metabolites	O
still	O
significantly	O
improved	O
type	O
2	O
diabetes	O
prediction	O
(AUC	O
was	O
0.828	O

Regarding	O
the	O
hydrophobic	O
ceramide	O
moiety,	O
the	O
amide	B
group	O
forming	O
a	O
network	O
of	O
hydrogen	O
bonds	O
at	O
the	O
water-lipid	O
interface	O
of	O
the	O
plasma	O
membrane	O
and	O
the	O
double	O
bond	O
of	O
the	O
LCB	O
near	O
this	O
interface	O
are	O
considered	O
to	O
make	O
ceramide	B
a	O
rigid	O
structure	O
and	O
contribute	O
to	O
the	O
decrease	O
in	O
membrane	O
fluidity	O
induced	O
by	O
GGs.	O

None	O
of	O
the	O
compounds	O
tested	O
for	O
LXR	O
activity	O
here	O
activated	B
either	O
NURR1	O
or	O
FXR.	O

The	O
gathered	O
information	O
of	O
all	O
the	O
potential	O
binding	O
sites	O
of	O
the	O
Atlantic	B
cod	O
albumin-like	O
protein	O
are	O
visualized	O
in	O
a	O
3D	O
model.	O

Defects	O
in	O
mitochondrial	O
energetic	O
metabolism	O
occur	O
during	O
active	O
AIP	O
(Homedan	O
et	O
al.	O
),	O
and	O
TCA	O
seems	O
to	O
be	O
profoundly	O
affected	O
at	O
the	O
level	O
of	O
enzymes	O
that	O
orients	O
the	O
first	O
step	O
of	O
the	O
TCA	O
flux	O
and	O
the	O
synthesis	O
or	O
utilization	O
of	O
succinyl-CoA.	B

_–	O
Next,	O
1 mL	O
of	O
water	O
and	O
2 mL	O
of	O
methyl-tert-butyl	B
ether	I
were	O
added	O
and	O
the	O
tubes	O
vigorously	O
shaken	O
at	O
room	O
temperature	O
for	O
30 min	O
prior	O
to	O
centrifugation	O
at	O
4000 xg	O
for	O
10 min	O
at	O
room	O
temp.	O

Lower	O
fecal	O
levels	O
(p	O
<	O
0.05)	O
of	O
SCFAs	O
(acetate,	O
propionate	B
and	O
butyrate),	B
glucose	B
and	O
glutamine	B
and	O
higher	O
metabolite	O
levels	O
(p	O
<	O
0.05)	O
of	O
proline,	B
succinate,	B
isoleucine,	B
leucine,	B
valine,	B
alanine,	B
glutamate,	B
dimethylglycine	B
and	O
lactate	B
were	O
present	O
in	O
the	O
feces	O
of	O
stage	O
I/II	O
CRC	O
patients,	O
as	O
compared	O
to	O
the	O
healthy	O
controls	O
(Table	O
).	O

In	O
our	O
cohort	O
of	O
established	O
RA,	O
miR-146a	O
was	O
instead	O
associated	O
with	O
multiple	O
measures	O
of	O
adiposity	O
as	O
well	O
as	O
plasma	O
short-chain	O
dicarboxyl/hydroxyl	O
acylcarnitines,	B
strong	O
markers	O
of	O
myocardial	O
infarction	O
and	O
coronary	O
artery	O
disease	O
risk.	O

Serotonin	B
is	O
involved	O
in	O
neurotransmission	O
and	O
influences	O
visceral	O
pain	O
sensitivity,	O
motility	O
and	O
secretion.	O

Tryptophan	O
hydroxylase	O
(TPH)	O
is	O
involved	O
in	O
the	O
synthesis	O
of	O
the	O
neurotransmitters	O
serotonin	B
and	O
melatonin	B
in	O
tryptophan	B
metabolism.	O

Some	O
support	O
for	O
this	O
supposition	O
comes	O
from	O
the	O
studies	O
of	O
the	O
of	O
breast	O
cancer	O
cells	O
(Bartmann	O
et	O
al.	O
):	O
the	O
authors	O
failed	O
to	O
find	O
any	O
influence	O
of	O
3-hydroxybutyrate	B
on	O
the	O
sensitivity	O
to	O
chemotherapy	O
or	O
ionizing	O
radiation	O
in	O
the	O
cell	O
lines	O
tested.	O

However,	O
in	O
the	O
untargeted	O
analysis,	O
only	O
valine’s	B
adjusted	O
p-value	O
was	O
significant	O
(q-value	O
<	O
0.1).	O

After	O
exposure,	O
cells	O
were	O
washed	O
with	O
phosphate	B
buffered	O
saline,	B
trypsinized	O
with	O
Trypsin-EDTA	O
(0.05	O
%)	O
(Thermo	O
Fisher	O
Scientific)	O
and	O
suspended	O
in	O
growth	O
medium.	O

Overall,	O
the	O
results	O
presented	O
here	O
are	O
supported	O
by	O
prior	O
references	O
and	O
in	O
concordance	O
with	O
our	O
previous	O
results	O
obtained	O
by	O
ultra	O
performance	O
liquid	O
chromatography	O
mass	O
spectrometry	O
(UPLC-MS)	O
showing	O
the	O
perturbation	O
of	O
phenylalanine,	B
arginine,	B
proline,	B
and	O
tyrosine	B
metabolic	O
pathways,	O
among	O
others,	O
in	O
NMIBC.	O

The	O
sample	O
size	O
in	O
the	O
quetiapine	B
and	O
olanzapine	B
groups	O
had	O
been	O
increased	O
based	O
on	O
the	O
results	O
of	O
an	O
interim	O
analysis	O
showing	O
higher	O
variability	O
than	O
anticipated	O
for	O
these	O
2	O
medications.	O

HPLC-grade	O
formic	B
acid	I
(0.1	O
%)	O
in	O
water	O
was	O
purchased	O
from	O
Honeywell	O
Burdick	O
and	O
Jackson	O
(Muskegon,	O
MI).	O

Thus,	O
in	O
addition	O
to	O
pyruvate	B
derived	O
from	O
glycolysis,	O
fatty	O
acids	O
and	O
particularly	O
amino	O
acids	O
can	O
supply	O
substrates	O
to	O
the	O
tricarboxylic	B
acid	I
(TCA)	O
cycle	O
to	O
maintain	O
mitochondrial	O
production	O
in	O
cancer	O
cells	O
(Chen	O
and	O
Russo	O
).	O

Cluster	O
A	O
reflects	O
alterations	O
in	O
alcohols	B
(2‐methylpropan‐2‐ol,	I
2‐methylpropan‐1‐ol	I
and	O
2‐methylbutan‐2‐ol),	B
carbonyl	O
compounds	O
(2‐oxopropanal	O
and	O
4‐methylheptan2‐one)	B
and	O
ethers	B
(2‐ethoxy‐2‐methylpropane	I
and	O
2,2,5,5‐tetramethyltetrahydrofuran).	B

The	O
mean	O
PK	O
plasma	O
curves	O
of	O
O	O
-Gluc,	O
7-O	O
-Gluc,	O
and	O
3,7-O	B
-Digluc	I
measured	O
in	O
the	O
same	O
samples	O
analyzed	O
first	O
after	O
enzymatic	O
conjugates	O
degradation	O
are	O
reported	O
in	O
Fig.	O

Standards	O
of	O
25(OH)D_2/3	B
,	I
3-epi-25(OH)D_3	I
,	I
1,25(OH)_2	I
D_3/2	O
and	O
24,25(OH)_2	B
D_3	O
and	O
methanol	B
(HPLC	O
grade)	O
were	O
purchased	O
from	O
Sigma-Aldrich	O
(Steinheim,	O
Germany).	O

Diabetic	O
patients	O
have	O
previously	O
been	O
shown	O
to	O
have	O
higher	O
concentrations	O
of	O
both	O
free	O
and	O
total	O
p-cresol	B
concentrations	O
in	O
their	O
blood	O
.	O

In	O
contrast,	O
insulin	O
sensitizer	O
therapy	O
increased	O
the	O
plasma	O
serine	B
and	O
glycine	B
concentrations.	O

The	O
methanolic	B
supernatant	O
was	O
diluted	O
with	O
acidified	O
water	O
up	O
to	O
12.5	O
%	O
of	O
methanol	B
for	O
loading	O
onto	O
an	O
SPE	O
cartridge.	O

On	O
the	O
other	O
hand,	O
the	O
higher	O
CV	O
metabolites	O
belonged	O
to	O
the	O
unknowns	O
(six	O
of	O
them),	O
Asp,	O
sedoheptulose,	B
valeric	B
acid,	I
and	O
ribose.	B

However,	O
ID	O
6054	O
had	O
fragments	O
characteristic	O
of	O
[C_16	O
H_29	O
O_2	O
]_−	O
and	O
losses	O
of	O
two	O
H_2	O
O	O
molecules,	O
consistent	O
with	O
the	O
loss	O
of	O
two	O
hydroxyl	O
groups	O
and	O
a	O
hexadecenoic	O
acetate	B
fragment.	O

Alanine	B
and	O
3-hydroxybutanoic	B
acid	I
also	O
correlated	O
to	O
these	O
three	O
clinical	O
measures,	O
but	O
the	O
relation	O
to	O
glucose	B
had	O
a	O
high	O
q-value.	O

The	O
potential	O
roles	O
of	O
SL	B
metabolites	O
in	O
respiratory	O
diseases	O
have	O
been	O
discussed,	O
although	O
there	O
is	O
some	O
debate_,	O
.	O

The	O
differential	O
metabolites	O
were	O
found	O
to	O
belong	O
to	O
an	O
amino	O
acid,	O
nucleotide,	O
carbohydrate,	O
lipid,	O
and	O
carnitine	B
metabolism.	O

Consistent	O
with	O
the	O
sharp	O
decreases	O
of	O
9-HSA	O
already	O
observed	O
with	O
GC/MS,	O
tumor	O
samples	O
showed	O
a	O
general	O
decrease	O
in	O
all	O
phospholipid	B
classes	O
examined.	O

Second,	O
we	O
identified	O
metabolites	O
that	O
might	O
be	O
lost	O
in	O
FPPE	O
due	O
to	O
their	O
reaction	O
with	O
formaldehyde	B
when	O
tissues	O
are	O
immersed	O
in	O
a	O
formalin	B
solution.	O

t	O
test),	O
but	O
no	O
effect	O
on	O
CSF	O
glucose	B
levels	O
was	O
observed	O
(p	O
=	O
0.20,	O
t	O
test;	O
see	O
).	O

Twenty	O
patients	O
in	O
the	O
advanced	O
atherosclerosis	O
cohort	O
experienced	O
a	O
major	O
adverse	O
cardiac	O
event	O
during	O
the	O
follow-up	O
period,	O
which	O
was	O
associated	O
with	O
hippuric	B
acid	I
(P=.002)	O
and	O
the	O
kynurenine/tryptophan	O
ratio	O
(P<.001).	O

Measured	O
metabolites	O
of	O
the	O
different	O
pathways	O
including	O
glycolysis,	O
TCA-Cycle	O
and	O
Urea	B
Cycle	O
are	O
shown	O
in	O
circles.	O

We	O
also	O
observed	O
2.5	O
and	O
1.49	O
times	O
higher	O
levels	O
of	O
ascorbic	B
acid	I
and	O
pantothenate,	B
respectively,	O
in	O
the	O
CRC	O
tissue	O
samples.	O

,	O
It	O
also	O
acts	O
to	O
maintain	O
ATP	B
levels	O
and	O
serves	O
in	O
an	O
energy	O
shuttle	O
between	O
the	O
sites	O
of	O
ATP	B
synthesis	O
and	O
utilization.	O

Cholesteryl	B
ester,	I
triacylglycerol	B
and	O
diacylglycerol	B
levels	O
at	O
1 month	O
were	O
significant	O
predictors	O
of	O
a	O
decrease	O
in	O
C-peptide	O
over	O
6 months	O
and	O
after	O
12 months	O
however	O
at	O
12 months	O
the	O
associations	O
did	O
not	O
maintain	O
significance	O
after	O
correction	O
for	O
multiple	O
testing.	O

Additional	O
studies	O
of	O
patients	O
with	O
other	O
neuropsychiatric	O
disorders	O
and	O
demyelinating	O
diseases,	O
such	O
as	O
adrenoleukodystrophy,	O
are	O
necessary	O
to	O
determine	O
if	O
increased	O
levels	O
of	O
plasma	O
nervonic	B
acid	I
level	O
are	O
specific	O
to	O
patients	O
with	O
MDD.	O

β-Cyclocitral	B
and	O
β-ionone	B
(both	O
from	O
Sigma-Aldrich)	O
were	O
purified	O
by	O
preparative	O
TLC	O
prior	O
to	O
use.	O

The	O
free	O
fatty	O
acids	O
palmitate,	O
stearate	B
and	O
octadecenoate,	B
as	O
well	O
as	O
the	O
ketone	B
body	O
3-hydroxybutyrate	B
were	O
increased	O
in	O
response	O
to	O
the	O
supplementation	O
(Supp.	O

In	O
some	O
studies,	O
particularly	O
in	O
prostate	O
cancer,	O
increased	O
levels	O
in	O
choline	B
have	O
been	O
described,	O
leading	O
to	O
the	O
development	O
of	O
_18	O
F-fluorocholine	B
positron	O
emission	O
tomography	O
(PET)	O
imaging	O
in	O
order	O
to	O
detect	O
the	O
increased	O
uptake	O
and	O
the	O
phosphorylation	O
of	O
the	O
tracer.	O

For	O
viability	O
experiments,	O
cells	O
were	O
allowed	O
to	O
attach	O
for	O
6	O
h	O
after	O
trypsinization	O
and	O
were	O
incubated	O
with	O
DMSO,	B
25	O
µM	O
680091,	O
or	O
10	O
µM	O
CH-223191.	O

Finally,	O
α-hydroxy-isobutyrate	B
(α-HIBA)	I
also	O
formed	O
a	O
complex	O
with	O
borate,	O
again	O
2:1	O
α-HIBA:	O
borate.	O

Estrogen	B
standard	O
and	O
internal	O
standard	O
stock	O
solutions	O
were	O
individually	O
prepared	O
in	O
methanol	B
containing	O
0.1%	O
(w/v)	O
L-ascorbic	B
acid	I
at	O
a	O
concentration	O
of	O
1	O
mg/mL	O
then	O
stored	O
at	O
−20	O
°C	O
.	O

The	O
basic	O
extracts	O
were	O
gradient	O
eluted	O
from	O
the	O
column	O
using	O
methanol	B
and	O
water,	O
however	O
with	O
6.5mM	O
ammonium	B
bicarbonate	O
at	O
pH	O
8.	O

Cells	O
were	O
grown	O
in	O
the	O
presence	O
0.2%	O
[U-_13	B
C]-glucose	I
for	O
24	O
h	O
(Rh30)	O
or	O
48	O
h	O
(myocytes).	O

Acetate,	B
a	O
source	O
for	O
lipid	O
and	O
myelin	B
synthesis[],	O
is	O
derived	O
from	O
acetyl-CoA	B
via	O
the	O
deacetylation	O
of	O
N-acetylaspartate.	B

Cys_34	O
is	O
the	O
only	O
unpaired	O
cysteine	B
residue	O
in	O
SA	O
that	O
is	O
available	O
for	O
reaction	O
with	O
carcinogenic	O
metabolites	O
and	O
toxic	O
electrophiles._,	O
However,	O
human	O
SA	O
contains	O
59	O
lysine	B
and	O
18	O
tyrosine	B
residues	O
that	O
can	O
potentially	O
react	O
with	O
NO_2	O
-PhIP	O
to	O
form	O
adducts.	O

Compared	O
to	O
previous	O
_1	O
H	O
NMR-based	O
study,	O
UHPLC-Q-TOFMS-based	O
metabolomic	O
approach	O
provided	O
larger	O
coverage	O
of	O
HAPE-related	O
metabonome	O
including	O
sphingolipid,	B
phospholipids,	B
fatty	O
acid	O
amides	O
and	O
several	O
amino	O
acids.	O

This	O
panel	O
of	O
metabolites	O
included	O
nicotinamide,	B
N-acetyl-L-leucine,	B
hypoxanthine,	B
1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline,	B
1-oleoyl-rac-glycerol,	B
arginine,	B
xanthine,	B
and	O
rac-glycerol	B
1-myristate,	I
the	O
latter	O
three	O
belonging	O
to	O
the	O
metabolite	O
panel	O
highlighted	O
by	O
univariate	O
analysis,	O
but	O
with	O
a	O
fold	O
change	O
of	O
1.3,	O
hence,	O
lower	O
than	O
1.5.	O

At	O
the	O
end	O
of	O
treatment,	O
cells	O
were	O
washed	O
twice	O
with	O
phosphate	B
buffer	O
solution	O
(pH	O
7.4)	O
and	O
stained	O
by	O
incubating	O
with	O
5	O
μ	O
M	O
of	O
dihydroethidium	B
in	O
Hank’s	O
buffer	O
saline	B
solution	O
(HBSS)	O
at	O
37°C	O
for	O
30	O
minutes.	O

Additionally,	O
we	O
examined	O
the	O
effect	O
of	O
myo-inositol	B
treatment	O
in	O
the	O
in	O
vitro	O
FSGS	O
model.	O

Specifically,	O
300	O
µl	O
of	O
1	O
M	O
ammonium	B
acetate	I
containing	O
30	O
U	O
of	O
β-glucuronidase	O
(pH	O
=	O
5.5)	O
was	O
added	O
to	O
500	O
µl	O
of	O
urine	O
sample,	O
followed	O
by	O
incubation	O
at	O
37°C	O
for	O
12	O
h.	O
Target	O
analytes	O
were	O
extracted	O
thrice	O
with	O
ethyl	B
acetate	I
and	O
were	O
quantified	O
by	O
ultra-high	O
performance	O
liquid	O
chromatography	O
(Acquity	O
I	O
Class;	O
Waters,	O
Milford,	O
MA,	O
USA)	O
coupled	O
with	O
an	O
electrospray	O
triple	O
quadrupole	O
mass	O
spectrometry	O
(API	O
5500;	O
AB	O
SCIEX,	O
Framingham,	O
MA,	O
USA)	O
(UPLC-ESI-MS/MS).	O

Each	O
calibration	O
standard	O
contained	O
lysate	O
from	O
approximately	O
50,000	O
MCF-10A	O
cells	O
and	O
was	O
prepared	O
by	O
adding	O
2	O
μl	O
of	O
the	O
SI-EM	O
working	O
internal	O
standard	O
solution	O
(16	O
pg	B
of	O
each	O
SI-EM)	O
to	O
various	O
volumes	O
of	O
the	O
EM	O
working	O
standard	O
solution.	O

_1	O
H	O
NMR	O
(500	O
MHz,	O
DMSO-d_6	O
):	O
δ	O
8.19	O
(d,	O
1H,	O
J	O
=8	O
Hz,	O
NH),	O
6.85	O
(s,	O
1H,	O
H2′),	O
6.76	O
(t,	O
1H,	O
J	O
=2.5	O
Hz,	O
H5′),	O
6.05	O
(dd,	O
1H,	O
J	O
=1.5,	O
2.5	O
Hz,	O
H4′),	O
4.24	O
(ddd,	O
1H,	O
J	O
=5.0,	O
9.5,	O
13.5	O
Hz,	O
Cys	O
α-CH),	B
3.84	O
(t,	O
2H,	O
J	O
=6.5	O

It	O
is	O
known	O
that	O
uremic	O
toxin	B
levels	O
rise	O
in	O
concordance	O
with	O
CKD	O
severity	O
.	O

A	O
previous	O
study	O
on	O
19	O
patients	O
with	O
stage	O
2/3,	O
lymph	O
node-positive	O
breast	O
cancer	O
showed	O
that	O
ADMA	B
levels	O
decreased	O
in	O
breast	O
cancer	O
patients	O
after	O
chemotherapy	O
with	O
taxotere,	O
epirubicin	B
and	O
cyclophosphamide.	O

(P	O
<	O
0.01),	O
but	O
not	O
with	O
tetrahydroaldosterone.	B

Glucose	B
and	O
insulin	O
were	O
measured	O
using	O
methods	O
described	O
previously.	O

NAAG	B
is	O
one	O
of	O
the	O
three	O
most	O
prevalent	O
dipeptide	O
neurotransmitters	O
in	O
the	O
mammalian	O
nervous	O
system.	O

We	O
undertook	O
diagnostic	O
analyses	O
to	O
assess	O
whether	O
the	O
apparent	O
differences	O
in	O
breast	O
gene	O
expression	O
in	O
response	O
to	O
IER	O
could	O
be	O
an	O
artefact	O
linked	O
to	O
different	O
composition	O
of	O
the	O
breast	O
biopsies,	O
i.e.	O
the	O
proportion	O
of	O
fat,	O
stroma	O
and	O
epithelium	O
or	O
differences	O
in	O
the	O
day	O
of	O
cycle	O
or	O
serum	O
oestradiol	B
and	O
progesterone	B
levels	O
between	O
the	O
pre	O
and	O
post	O
intervention	O
biopsies.	O

As	O
presented	O
in	O
and	O
,	O
three	O
metabolites	O
(valine,	O
methionine	B
and	O
citrulline)	O
were	O
decreased	O
in	O
the	O
patients	O
with	O
lung	O
cancer	O
compared	O
with	O
the	O
healthy	O
controls	O
in	O
the	O
two	O
data	O
sets.	O

The	O
number	O
of	O
white	O
blood	O
cells	O
(WBC)	O
and	O
levels	O
of	O
protein,	O
glucose,	B
albumin,	O
and	O
IgG	O
were	O
also	O
assessed	O
in	O
the	O
CSF	O
of	O
patients.	O

Furthermore,	O
it	O
has	O
been	O
also	O
reported	O
that	O
hypoxanthine	B
aggravated	O
myocardial	O
and	O
renal	O
graft	O
ischemia/reperfusion	O
injury	O
by	O
ROS.	O

Phe,	O
Phenylalanine;	B
Tyr,	O
Tyrosine;	B
Ala,	O
Alanine.	B

Ceramide	B
1-phosphate	I
(C1P)	O
is	O
generated	O
through	O
direct	O
phosphorylation	O
of	O
ceramide	B
by	O
ceramide	B
kinase	O
(CERK).	O

Then	O
50	O
μL	O
of	O
MSTFA	O
(N	O
-Methyl-N	I
-trimethyl-silyltrifluoroacetamide)	I
were	O
added	O
and	O
left	O
to	O
react	O
for	O
1	O
h	O
at	O
room	O
temperature.	O

Interestingly,	O
a	O
recent	O
study	O
showed	O
that	O
3,4-dihydroxyphenylacetic	B
acid	I
is	O
also	O
one	O
of	O
the	O
metabolites	O
of	O
dopamine	B
(DA);	O
furthermore,	O
it	O
can	O
cross	O
the	O
BBB	O
and	O
the	O
levels	O
of	O
3,4-dihydroxyphenylacetic	B
acid	I
could	O
change	O
in	O
the	O
brain	O
in	O
a	O
regional-	O
and	O
dose-related	O
manner.	O

Separation	O
was	O
achieved	O
on	O
a	O
Kinetex	O
C18	O
column	O
using	O
gradient	O
elution	O
with	O
flow	O
rate	O
0.5	O
mL/min,	O
mobile	O
phase	O
A	O
(10	O
mM	O
ammonium	B
acetate	I
in	O
water)	O
and	O
mobile	O
phase	O
B	O
(15%	O
methanol	B
in	O
acetonitrile).	O

In	O
apolipoprotein	O
E-deficient	O
mice	O
and	O
cells,	O
hypoxanthine	B
also	O
induces	O
cholesterol	B
accumulation	O
and	O
stimulates	O
atherosclerosis	O
through	O
alterations	O
in	O
lipid	O
transport	O
enzymes,	O
independent	O
of	O
conversion	O
to	O
xanthine	B
and	O
uric	B
acid,	I
a	O
known	O
risk	O
for	O
cardiovascular	O
disease.	O

LASSO	O
regularized	O
logistic	O
regression	O
(LASSO-LR)	O
identified	O
three	O
discriminatory	O
metabolites:	O
2-hydroxyisobutyrate,	B
3-indoxylsulfate,	B
and	O
alanine,	B
which	O
clearly	O
separated	O
gastric	O
cancer	O
from	O
healthy	O
controls	O
(AUC:	O
0.95).	O

FAD	O
is	O
synthesized	O
from	O
riboflavin	B
(vitamin	O
B2)	O
and	O
ATP.	B

Three	O
MS/MS	O
transitions	O
monitored	O
for	O
β-apo-13-carotenone	B
were	O
m	O
/z	O
259	O
>	O
175,	O
119,	O
and	O
69	O
at	O
collision	O
energies	O
of	O
21,	O
31,	O
and	O
27	O
eV,	O
respectively,	O
with	O
150-ms	O
dwell	O
times	O
and	O
using	O
nitrogen	O
as	O
the	O
collision-activated	O
dissociation	O
gas.	O

Nevertheless,	O
LR	O
analysis	O
of	O
the	O
metabolites	O
combined	O
with	O
the	O
standard	O
cardiac	O
peptides	O
revealed	O
that	O
measuring	O
only	O
one	O
metabolite	O
(acetoacetate)	O
along	O
with	O
the	O
NT-proBNP	O
increased	O
the	O
AUC	O
of	O
the	O
ROC	O
curve	O
from	O
0.991	O
for	O
NT-proBNP	O
alone	O
to	O
0.997	O
for	O
the	O
acetoacetate	B
plus	O
the	O
NT-proBNP.	O

Also,	O
in	O
urine,	O
homoserine	B
and	O
gamma-glutamyl-2-aminobutyrate	B
positively	O
correlated	O
with	O
DAS28-ESR,	O
and	O
ophthalmic	O
acid	O
was	O
elevated	O
in	O
active	O
RA	O
patients.	O

Supernatants	O
from	O
methanol	B
and	O
the	O
MTBE	B
aqueous	O
fraction	O
were	O
compared	O
using	O
HILIC	O
chromatography	O
in	O
both	O
positive	O
and	O
negative	O
ionization	O
mode.	O

KP	B
mRNA	O
expression	O
levels	O
were	O
measured	O
by	O
RT-PCR	O
and	O
expressed	O
as	O
fold	O
change	O
compared	O
to	O
normal	O
control.	O

observed	O
decreased	O
vitamin	B
D	I
catabolism	O
and	O
1,25(OH)_2	B
D_3	O
production	O
in	O
chronic	O
kidney	O
disease	O
(CKD).	O

Phosphatidylocholines	B
are	O
the	O
main	O
building	O
blocks	O
of	O
membrane	O
bilayers	O
and	O
in	O
plasma	O
they	O
are	O
mostly	O
located	O
in	O
high	O
density	O
lipoproteins	O
(HDL).	O

AFP,	O
alpha-foetoprotein;	B
MELD,	O
Model	O
for	O
End-Stage	O
Liver	O
Disease.	O

Known	O
barriers	O
to	O
prevent	O
tamoxifen	B
adherence	O
are	O
manifold	O
and	O
include	O
low	O
recurrence	O
risk	O
perception,	O
side	O
effects,	O
age	O
extremes,	O
medication	O
cost,	O
ethnicity,	O
educational	O
level,	O
lack	O
of	O
social	O
support,	O
and	O
suboptimal	O
patient	O
physician	O
communication._3	O
,	O
_4	O
,	O
_13	O

Plasma	O
total	O
methionine	B
and	O
homocysteine	B
concentrations	O
were	O
both	O
significantly	O
higher	O
in	O
the	O
high–cystathionine	B
concentration	O
group.	O

Addition	O
of	O
human	O
liver	O
microsomes	O
to	O
the	O
ex	O
vivo	O
saliva	O
samples	O
from	O
these	O
same	O
donors	O
+	O
10%	O
BRB	O
incubates	O
did	O
result	O
in	O
peaks	O
corresponding	O
to	O
a	O
sambubioside	B
glucuronidated	O
conjugate	O
in	O
2	O
of	O
the	O
6	O
samples.	O

Intracellular	O
DNR	O
was	O
measured	O
using	O
the	O
phycoerythrin	B
(PE)	O
channel,	O
taking	O
advantage	O
of	O
the	O
natural	O
fluorescence	O
of	O
DNR.	O

UC	O
ulcerative	O
colitis;	O
ala	O
alanine;	B
buty	B
butyrate;	I
ileu	O
isoleucine;	B
lac	O
lactate;	B
leu	O
leucine;	B
lys	O
lysine;	B
prop	O
proprionate;	O
tau	O
taurine;	B
val	O
valine	B
(Color	O
figure	O
online)	O

A	O
Mean	O
PK	O
curves	O
of	O
diosmetin	B
measured	O
in	O
plasma	O
after	O
enzymatic	O
degradation	O
and	O
PK	O
parameters	O
obtained	O
on	O
12	O
patients	O
orally	O
treated	O
with	O
diosmin	O
450 mg	O
in	O
a	O
PK	O
study.	O

Since	O
oxygen	O
is	O
not	O
consumed	O
for	O
the	O
TCA	O
cycle,	O
the	O
cell	O
would	O
have	O
an	O
increased	O
in	O
demand	O
on	O
their	O
anti-oxidative	O
machinery,	O
e.g.	O
glutathione,	B
for	O
relieving	O
the	O
oxidative	O
stress.	O

Indeed,	O
4/20	O
HCC	O
patients	O
had	O
inordinately	O
high	O
LPA(16:0)	B
plasma	O
levels	O
and	O
that	O
LPA(16:0)	B
strongly	O
correlated	O
with	O
plasma	O
AFP	O
concentrations.	O

The	O
LOQs	O
for	O
the	O
reference	O
standards	O
were	O
~20 pg/mL	O
for	O
1,25-(OH)_2	B
D_3	O
and	O
~10 pg/mL	O
for	O
1,25-(OH)_2	B
D_2	O
,	O
25-OH	O
D_3	O
,	O
and	O
25-OH	O
D_2	O
.	O

After	O
addition	O
of	O
d4	O
internal	O
standard	O
(d4-11-dTxB_2	O
)	O
to	O
each	O
sample,	O
the	O
samples	O
were	O
positive	O
pressure-filtered,	O
and	O
the	O
11-dTxB_2	O
was	O
separated	O
from	O
the	O
urine	O
matrix	O
via	O
turboflow	O
online	O
extraction.	O

The	O
lowest	O
concentrations	O
that	O
could	O
be	O
reliably	O
detected	O
using	O
NMR	O
were	O
0.4	O
±	O
0.1	O
µM/mM	O
creatinine	B
(for	O
maleic	B
acid),	O
0.5	O
±	O
0.2	O
µM/mM	O
creatinine	B
(for	O
alpha-ketoisovaleric	B
acid	I
and	O
N-acetylputrescine)	B
and	O
0.7	O
±	O
0.4	O
µM/mM	O
creatinine	B
(for	O
fumaric	O
acid).	O

Upon	O
confluency	O
they	O
were	O
treated	O
with	O
respective	O
C75	O
and	O
celecoxib	B
drug	O
concentrations	O
for	O
24h.	O

Faecal	O
metabolomics	O
studies	O
have	O
shown	O
that	O
CHD	O
patients	O
are	O
unable	O
to	O
excrete	O
adequate	O
amounts	O
of	O
bile	O
acids	O
to	O
remove	O
excess	O
serum	O
cholesterol.	B

Two	O
species,	O
1-methylguanine	B
and	O
17-beta-estradiol	B
17-(beta-D-glucuronide),	O
have	O
not	O
been	O
observed	O
with	O
sufficient	O
appearance	O
frequency	O
in	O
LC-QTOF	O
acquisitions	O
across	O
clinical	O
sample	O
sets	O
to	O
confidently	O
choose	O
them	O
as	O
initial	O
contributors	O
to	O
a	O
supervised	O
model	O
as	O
other	O
more	O
ubiquitously	O
observed	O
metabolites	O
in	O
ESI	O
would	O
be	O
more	O
appropriate.	O

Among	O
them,	O
phosphatidycholine	B
(PtdCho)	O
and	O
leucine/isoleucine	O
(Leu/Ile)	O
were	O
positively	O
and	O
negatively	O
correlated	O
with	O
the	O
NDI	O
Symptom	O
Index	O
(NDSI)	O
respectively.	O

This	O
higher	O
plasma	O
glucose	B
in	O
lung	O
cancer	O
patients	O
has	O
been	O
previously	O
described	O
by	O
Louis	O
et	O
al	O
.	O

Whereas	O
alanine	B
(pre-HFD	O
vs.	O
control	O
FC = 0.97,	O
FDR = 0.541;	O
pre-HD	O
vs.	O
control	O
FC = 0.97,	O
FDR = 0.298)	O
and	O
creatine	B
(1.29,	O
0.651;	O
1.21,	O
0.730)	O
showed	O
no	O
difference	O
in	O
pre-dialysis	O
vs.	O
control.	O

For	O
QC,	O
Bland–Altman	O
prediction	O
errors	O
and	O
correlation	O
coefficients	O
were	O
calculated	O
between	O
the	O
NMR	O
measurements	O
and	O
standard	O
clinical	O
chemistry	O
values	O
for	O
total-cholesterol,	B
high	O
density	O
lipoprotein	O
(HDL)-cholesterol,	B
low	O
density	O
lipoprotein	O
(LDL)-cholesterol,	B
and	O
total	O
triglycerides.	B

and,	O
metabolically,	O
with	O
the	O
decreased	O
glutamine	B
and	O
elevated	O
pyroglutamine	B
noted	O
by	O
Weiner	O
et	O
al.	O
.	O

The	O
2-ml	O
aliquots	O
of	O
activated	B
charcoal-treated	O
human	O
urine	O
samples	O
were	O
spiked	O
with	O
the	O
total	O
(a	O
)	O
250,	O
(b	O
)	O
500	O
and	O
(c	O
)	O
1,000	O
pg	O
of	O
40	O
estrogen-related	O
compounds	O
before	O
and	O
after	O
(control)	O
passing	O
over	O
phenyl	O
SPE	O
cartridges.	O

Following	O
simvastatin	B
treatment,	O
a	O
significant	O
decrease	O
was	O
found	O
in	O
plasma	O
levels	O
of	O
cholesterol	B
(p<0.0027,	O
q<0.055),	O
alpha-tocopherol	B
(p<0.0003,	O
q<0.017),	O
and	O
gamma-tocopherol	B
(p<0.037,	O
q<0.13),	O
(vitamin	O
E),	O
and	O
lauric	B
acid	I
(p<0.0055,	O
q<0.055).	O

RV	B
RV	I
RV	I
HU+NAFD	O
HU+NAFD	O

In	O
addition,	O
urinary	O
excretion	O
mainly	O
represents	O
recent	O
mycotoxin	B
intake,	O
whereas	O
measurements	O
in	O
plasma/serum	O
are	O
more	O
likely	O
to	O
represent	O
long-term	O
exposure.	O

Furthermore,	O
the	O
blinded	O
study	O
found	O
the	O
ketoconazole	B
arm	O
to	O
be	O
the	O
only	O
treatment	O
group	O
to	O
confer	O
a	O
statistically	O
significant	O
(p	O
<	O
0.05)	O
reduction	O
in	O
serum	O
DHEA-S.	B

Firstly,	O
we	O
analyzed	O
the	O
abundance	O
of	O
saturated	O
and	O
unsaturated	O
fatty	O
acids	O
(i.e.	O
in	O
TG)	O
present	O
in	O
the	O
serum;	O
fatty	O
acids	O
are	O
usually	O
derived	O
from	O
TG.	B

600	O
μl	O
of	O
methanol	B
was	O
added	O
into	O
each	O
sample.	O

Fifty	O
μl	O
aliquots	O
of	O
samples	O
were	O
treated	O
with	O
acetonitrile	B
(1:4,	O
v/v),	O
and	O
centrifuged	O
at	O
14,000	O
x	O
g	O
for	O
5 min	O
at	O
4 °C	O
for	O
protein	O
separating.	O

In	O
the	O
present	O
work,	O
fatty	O
acids	O
were	O
methylated	O
by	O
diazomethane	B
and	O
the	O
FAMEs	O
were	O
subjected	O
to	O
GC-MS	O
analyses	O
under	O
electron	O
ionization	O
(EI)	O
conditions.	O

	O
Enzalutamide	B
and	O
N-desmethylenzalutamide	B
and	O
the	O
internal	O
standard	O
(D_6	O
-enzalutamide)	I
were	O
stable	O
for	O
at	O
least	O
11	O
months	O
in	O
stock	O
solution	O
at	O
−40	O
°C.	O

Some	O
of	O
our	O
tested	O
normalization	O
factors	O
such	O
as	O
CD9	O
optical	O
density	O
_,	O
	O
and	O
choline	B
concentration	O
have	O
been	O
shown	O
to	O
increase	O
in	O
Pca.	O

Since	O
25OH-vitamin	O
D	O
(25OHD)	O
has	O
been	O
suggested	O
to	O
be	O
an	O
acute-phase	O
protein,	O
its	O
utility	O
as	O
a	O
vitamin	B
D	I
status	O
marker	O
is	O
therefore	O
questionable.	O

Linoleoyl	B
carnitine	I
is	O
a	O
long-chain	O
acyl	O
fatty	O
acid	O
derivative	O
ester	O
of	O
carnitine.	B

Two	O
major	O
non-protein	O
metabolic	O
routes	O
use	O
Trp	O
as	O
a	O
precursor:	O
(a	O
)	O
the	O
methoxyindoles	B
pathway,	O
involved	O
in	O
the	O
synthesis	O
of	O
Set	O
and	O
Melatonin;	B
and	O
(b	O
),	O
the	O
Kyn	O
pathway,	O
responsible	O
for	O
the	O
production	O
of	O
Kyn	O
through	O
Niacin	B
synthesis.	O

The	O
statistical	O
analyses	O
were	O
performed	O
using	O
Stata	O
12.0	O
(StataCorp	O
LP,	B
College	O
Station,	O
TX,	O
USA),	O
R	O
software	O
3.3.3	O
(R	O
Foundation	O
for	O
Statistical	O
Computing,	O
Vienna,	O
Austria)	O
and	O
SIMCA‐P	O
13.0	O
(Umetrics	O
AB,	O
Umea,	O
Vasterbotten,	O
Sweden).	O

For	O
example,	O
using	O
[U–_13	B
C]-glucose	I
as	O
tracer,	O
_13	O
C3,_13	O
C4-Asp	O
plus	O
_13	O
C1,_13	O
C2-Asp	O
are	O
products	O
of	O
the	O
Krebs	O
cycle	O
after	O
one	O
turn	O
while	O
_13	O
C1,_13	O
C2,_13	O
C3-Asp	O
is	O
derived	O
from	O
pyruvate	O
carboxylation,	O
an	O
important	O
anaplerotic	O
reaction	O
for	O
the	O
Krebs	O
cycle.	O

The	O
resulting	O
quantitative	O
metabolomic	O
data	O
showed	O
differences	O
in	O
the	O
levels	O
of	O
total	O
glutathione,	B
adenosine,	B
phosphatidylserine	B
(PtdSer),	O
and	O
sphingomyelin	B
compared	O
with	O
healthy	O
volunteers.	O

This	O
means	O
that	O
increase	O
in	O
HDL	B
triglycerides	I
is	O
another	O
sign	O
of	O
VLDL	O
triglyceride	B
overproduction.	O

Among	O
those	O
compounds	O
were	O
carbohydrate-related	O
metabolites	O
(glucose,	O
fructose,	B
gluconic	B
acid)	O
and	O
amino	O
acids	O
(such	O
as	O
phenylalanine,	B
threonine,	B
serine,	B
tyrosine,	B
glutamine,	B
isoleucine,	B
valine,	B
glutamate,	B
lysine,	B
proline	B
and	O
glycine)	B
resulting	O
from	O
the	O
hydrolysis	O
of	O
starch	O
and	O
proteins	O
present	O
in	O
the	O
flatbread.	O

The	O
results	O
suggest	O
that	O
the	O
observed	O
response	O
of	O
these	O
incretin	B
hormones	O
with	O
both	O
the	O
aspartame	B
and	O
control	O
bar	O
is	O
due	O
to	O
the	O
nutrients	O
in	O
the	O
bar	O
rather	O
than	O
aspartame.	B

T.	O
cruzi	O
has	O
at	O
least	O
two	O
different	O
myo-inositol	B
transporters	O
based	O
on	O
a	O
biochemical	O
analysis	O
of	O
import	O
activities	O
.	O

Ceramides	B
34:1,	I
36:1,	O
38:1,	O
40:1,	O
42:2	O
and	O
42:1	O
were	O
present	O
in	O
almost	O
every	O
GG	O
class	O
of	O
every	O
tissue.	O

Several	O
statistically	O
significant	O
correlations	O
were	O
observed	O
between	O
particular	O
taxa	O
and	O
estrogen	B
measures	O
(Supplemental	O
Table	O
2).	O

The	O
aqueous	O
methanol	B
extract	O
was	O
retained	O
and	O
stored	O
at	O
−80 °C	O
for	O
metabolite	O
analysis,	O
and	O
the	O
tissue	O
was	O
transferred	O
to	O
10%	O
formalin	B
and	O
processed	O
by	O
standard	O
histopathology	O
methods.	O

The	O
pyridoxic	B
acid:pyridoxal plus	O
pyridoxal	B
phosphate	I
ratio	O
(PAr)	O
was	O
greater	O
in	O
the	O
high–cystathionine	B
concentration	O
group,	O
which	O
indicated	O
a	O
greater	O
extent	O
of	O
vitamin	O
B-6	O
catabolism	O
(P	O
=	O
0.001).	O

A	O
simplification	O
of	O
the	O
previous	O
27-metabolite	O
model	O
(Pro	O
and	O
C34:1	B
PC)	O
plus	O
Matsuda	O
Index	O
showed	O
an	O
AUC	O
of	O
0.75	O
(0.67–0.83).	O

Among	O
docosanoids	B
starting	O
at	O
formula	O
C_22	O
H_34	O
O_2	O
,	O
database	O
entries	O
were	O
present	O
for	O
every	O
addition	O
of	O
oxygen	O
up	O
to	O
C_22	O
H_34	O
O_6	O
with	O
the	O
lone	O
exception	O
of	O
C_22	O
H_34	O
O_3	O
.	O

In	O
current	O
study,	O
we	O
proposed	O
an	O
IL-LC-MRM-MS	O
method	O
to	O
investigate	O
the	O
content	O
changes	O
of	O
thiol	B
between	O
cancers	O
and	O
healthy	O
controls.	O

Another	O
metabolite,	O
L-acetylcarnitine,	B
was	O
not	O
validated	O
in	O
the	O
overall	O
sample	O
(p	O
=	O
0.11),	O
but	O
appeared	O
significant	O
in	O
the	O
male-only	O
validation	O
sample	O
(p	O
=	O
0.026;	O
Appendix	O
1,	O
Table	O
S2	O
and	O
S3).	O

On	O
the	O
other	O
hand,	O
valine	B
was	O
found	O
to	O
be	O
higher	O
in	O
healthy	O
older	O
men	O
than	O
women.	O

Lysophospholipids	B
can	O
be	O
produced	O
by	O
PLA_2	O
activity	O
over	O
PC	O
and	O
others	O
glycerophospholipids.	B

Pearson	O
correlation	O
coefficients	O
between	O
serum	O
hormones	O
and	O
maternal	O
serum	O
phthalate	B
metabolites	O
for	O
188	O
male	O
participants,	O
adjusting	O
for	O
BMI	O
at	O
20 years	O
of	O
age	O
(n	O
 = 172).	O

Even	O
if	O
ceramide	B
is	O
involved	O
in	O
cell-cycle	O
arrest,	O
apoptosis,	O
and	O
senescence	O
in	O
CRC	O
cells,,	O
its	O
degradation	O
product,	O
sphingosine1P,	O
induces	O
cell	O
proliferation	O
and	O
angiogenesis	O
and	O
triggers	O
cell	O
motility.	O

PS,	O
phosphatidylglycerol	B
15:0–18:1(d7)	I

lists	O
the	O
oxysterols	B
identified	O
in	O
this	O
study.	O

The	O
serum	O
steroids	O
were	O
separated	O
using	O
a	O
UPLC	O
high-strength	O
silica	B
T3	O
column	O
(2.1	O
mm	O
×	O
50	O
mm,	O
1.8	O
μm)	O
(Waters)	O
and	O
1%	O
formic	B
acid	I
(A)	O
and	O
100%	O
methanol	B
(B)	O
as	O
mobile	O
phases.	O

_•	O
OH	O
causes	O
DNA	O
base	O
damage,	O
particularly	O
to	O
guanine	B
which	O
is	O
the	O
DNA	O
base	O
most	O
prone	O
to	O
oxidative	O
damage	O
[,].	O

An	O
internal	O
standard	O
(DL-alanine-2,3,3,3-d4:	O
DL-d4-Ala)	O
was	O
purchased	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(Dallas,	O
TX,	O
USA).	O

Thr,	O
C3DC/C10	O
and	O
C18:1	B
seemed	O
to	O
be	O
the	O
risk	O
factors	O
for	O
cirrhosis.	O

AUC,	O
area	O
under	O
the	O
ROC	O
curve;	O
ROC,	O
receiver	O
operating	O
characteristic;	O
Sa,	O
sphinganine;	B
So1P,	O
sphingosine-1-phosphate.	B

Figure	O
shows	O
there	O
is	O
no	O
signal	O
for	O
PGF_2α	B
in	O
the	O
procedure	O
blank	O
sample	O
while	O
a	O
high	O
level	O
of	O
PGF_2α	B
were	O
found	O
especially	O
in	O
the	O
H.	O
pomatia	O
GUS	O
blank	O
sample.	O

Specialized	O
sample	O
prep	O
with	O
immediate	O
deproteinization	O
for	O
redox	O
reactive	O
metabolites	O
such	O
as	O
malondialdehyde	B
and	O
cystine/cysteine	O
ratios	O
was	O
not	O
performed.	O

The	O
1.3ppm	O
lipid	O
signals	O
(hereafter	O
referred	O
to	O
as	O
lipids)	O
showed	O
uniformly	O
negative	O
correlations	O
with	O
the	O
small-molecule	O
metabolites	O
involved	O
in	O
glycolysis,	O
membrane	O
metabolism	O
energy	O
metabolism,	O
and	O
glutamine	B
and	O
glutamate	B
metabolism	O
(except	O
in	O
oligodendrogliomas)	O
(	O
and	O
).	O

Levels	O
of	O
the	O
key	O
arachidonic	O
(ω-6)	O
and	O
docosahexaenoic	O
acid	O
(ω-6)-derived	O
mediators	O
prostaglandins	B
(PG),	O
leukotrienes,	O
hydroxyeicosatetraenoic	B
acids	I
(HETE)	O
and	O
resolution	O
agonists	O
lipoxin	B
A_4	O

High	O
total	O
blood	O
cholesterol	B
levels	O
were	O
associated	O
with	O
higher	O
plasma	O
sphingomyelins	B
and	O
phosphatidylcholines	B
concentrations.	O

Score	O
and	O
loading	O
plots	O
showed	O
that	O
patients	O
who	O
had	O
gained	O
weight	O
had	O
higher	O
levels	O
of	O
acylcarnitines,	B
isoleucine	B
and	O
lipid2	O
(Supplementary	O
Figure 5).	O

A	O
small	O
peak	O
at	O
the	O
same	O
retention	O
time	O
as	O
trans,	O
anti	O
-BaPT	O
was	O
also	O
observed	O
in	O
the	O
incubations	O
of	O
BaP-4,5-diol	B
with	O
human	O
hepatocytes,	O
but	O
the	O
yield	O
of	O
this	O
product	O
was	O
at	O
least	O
10,000	O
times	O
lower	O
than	O
those	O
from	O
the	O
two	O
other	O
diols.	O

The	O
current	O
dataset	O
shows	O
that	O
1,5-anhydrosorbitol	B
levels	O
are	O
significantly	O
lower	O
in	O
OB/D	O
versus	O
OB	O
subjects.	O

Indeed,	O
its	O
reduction	O
may	O
also	O
indicate	O
S-adenosylmethionine	B
depletion	O
due	O
to	O
its	O
redirection	O
to	O
help	O
replenish	O
reduced	B
glutathione	I
(GSH)	O
levels,	O
an	O
important	O
cellular	O
antioxidant	O
molecule,	O
believed	O
to	O
be	O
associated	O
with	O
increased	O
production	O
of	O
reactive	O
oxygen	O
species	O
(ROS)	O
in	O
cancer	O
cells.	O

All	O
lipid	O
classes	O
were	O
significantly	O
and	O
negatively	O
affected	O
by	O
age	O
from	O
56–100	O
years	O
(p<0.05),	O
with	O
the	O
exception	O
of	O
DG(18:0/X)	B
(p<0.10),	O
while	O
DG(18:1/X)	B
did	O
not	O
yield	O
a	O
significant	O
model	O
(p>0.05).	O

Association	O
of	O
(a)	O
SM(OH)22:1	B
and	O
(b)	O
C16	O
metabolites,	O
and	O
(c)	O
serum	O
PG-II	O
level	O
on	O
GC	O
diagnosis	O
was	O
retained	O
in	O
the	O
multivariate	O
model.	O

Majority	O
of	O
the	O
species	O
observed	O
belong	O
to	O
TG,	B
SM,	O
PC,	O
and	O
PE	O
classes.	O

After	O
these	O
analyses,	O
it	O
was	O
discovered	O
that	O
the	O
liquid	O
chromatography	O
method	O
did	O
not	O
separate	O
24,25(OH)_2	B
D_3	O
from	O
another	O
analyte	O
or	O
analytes,	O
present	O
at	O
low	O
concentrations,	O
which	O
we	O
presumed	O
based	O
on	O
elution	O
time	O
and	O
fragmentation	O
pattern	O
to	O
be	O
23S,25-dihydroxyvitamin	B
D_3	O
and/or	O
25,26-dihydroxyvitamin	B
D_3	O
.	O

We	O
also	O
identified	O
five	O
lipid	O
molecules—TG	O
(16:0/16:0/16:0),	O
diglyceride	B
(18:1/22:0),	I
phosphatidylcholine	B
(32:0),	I
phosphatidylserine	B
(41:5),	I
and	O
sphingomyelin	B
(36:4)—that	I
could	O
potentially	O
be	O
used	O
for	O
developing	O
biomarkers	O
for	O
bvFTD.	O

The	O
data	O
reported	O
here,	O
support	O
increased	O
flux	O
through	O
GNMT	O
resulting	O
in	O
the	O
increased	O
formation	O
of	O
homocysteine	B
and	O
sarcosine	B
through	O
increased	O
utilization	O
of	O
SAM.	O

Cells	O
were	O
passaged	O
routinely	O
twice	O
a	O
week	O
using	O
0.05%	O
EDTA	O
in	O
phosphate	B
buffered	O
saline	B
(PBS;	O
Sigma-Aldrich)	O
and	O
0.05%	O
trypsin/0.02%	O
EDTA	O
in	O
PBS	O
(Biochrom	O
AG).	O

ORs	O
and	O
95%	O
CIs	O
of	O
PLC	O
in	O
four	O
groups:	O
low	O
TMAO/high	O
choline,	B
low	O
TMAO/low	O
choline,	B
high	O
TMAO/high	O
choline,	B
and	O
high	O
TMAO/low	O
choline.	B

However,	O
the	O
expression	O
of	O
one	O
member,	O
SLC25A5,	O
has	O
been	O
implicated	O
in	O
cancer	O
cell	O
metabolism,	O
with	O
expression	O
shown	O
to	O
correlate	O
with	O
glycolytic	B
metabolism	O
in	O
osteosarcoma	O
and	O
hepatocellular	O
carcinoma	O
cells.	O

Conversely,	O
the	O
PC	O
derivatives:	O
PC	B
ae	I
40:1,	I
PC	B
ae	I
42:2	I
and	O
PC	B
ae	I
42:3	I
as	O
well	O
as	O
the	O
SM	O
derivatives	O
SM(OH)22:1	B
and	O
SM(OH)22:2	B
were	O
found	O
to	O
be	O
lower	O
only	O
in	O
the	O
GC	O
patients	O
(Figure	O
S2,	O
Supplemental	O
Data).	O

The	O
amino	O
acid	O
metabolite	O
sarcosine,	B
an	O
N-methyl	O
derivative	O
of	O
glycine,	B
fit	O
these	O
criteria.	O

Furthermore,	O
most	O
of	O
the	O
other	O
subjects	O
(87%)	O
had	O
levels	O
of	O
cotinine	B
greater	O
than	O
the	O
limit	O
of	O
quantitation	O
(LOQ)	O
(0.1	O
μg/L),	O
with	O
a	O
median	O
value	O
equal	O
to	O
2.2	O
µg/L	O
(<LOQ	O
and	O
12.5	O
µg/L,	O
5th	O
and	O
95th	O
percentile	O
respectively),	O
showing	O
that	O
most	O
subjects	O
were	O
exposed	O
to	O
passive	O
smoking.	O

Phenylalanine	B
can	O
be	O
converted	O
into	O
fumarate.	B

Intracellular	O
reactive	O
oxygen	O
species	O
(ROS)	O
was	O
detected	O
by	O
dihydroethidium	B
assay.	O

GDM	O
was	O
diagnosed	O
with	O
a	O
standard	O
2	O
h	O
75	O
g	O
oral	O
glucose	B
tolerance	O
test	O
(oGTT),	O
according	O
to	O
the	O
International	O
Association	O
of	O
Diabetes	O
and	O
Pregnancy	O
Study	O
Groups	O
(IADPSG)	O
criteria	O
(International	O
Association	O
of	O
Pregnancy	O
Study	O
Groups	O
Consensus	O
Panel	O
et	O
al.,	O
;	O
Colagiuri	O
et	O
al.,	O
).	O

Based	O
on	O
these	O
results,	O
we	O
performed	O
a	O
multiple	O
regression	O
to	O
identify	O
independent	O
predictors	O
of	O
the	O
fasting	O
TG	B
level.	O

It	O
is	O
likely	O
that	O
urea,	B
a	O
well	O
known	O
chaotrope,	O
facilitates	O
the	O
dissolution	O
of	O
small	O
amounts	O
of	O
fatty	O
acids	O
and	O
other	O
lipid	O
species	O
in	O
urine.	O

This	O
is	O
in	O
line	O
with	O
a	O
previous	O
prospective	O
cohort	O
study	O
based	O
on	O
866	O
participants	O
with	O
seven	O
years’	O
follow-up	O
that	O
a	O
series	O
of	O
PC	O
such	O
as	O
C32:1,	B
C36:1,	B
C38:3,	B
and	O
C40:5	B
were	O
independently	O
associated	O
with	O
increased	O
risk	O
of	O
T2D	O
and	O
C34:3,	B
C40:6,	B
C42:5,	B
C44:4,	B
and	O
C44:5	B
with	O
decreased	O
risk.	O

In	O
contrast	O
to	O
reduction	O
of	O
BCAAs,	O
a	O
significant	O
increase	O
of	O
serum	O
glycine	B
and	O
alanine	B
following	O
RYGB	O
at	O
6 months	O
is	O
reported	O
in	O
the	O
present	O
study.	O

This	O
analysis	O
yielded	O
a	O
clear	O
separation	O
of	O
low–	O
and	O
high–cystathionine	B
concentration	O
groups	O
that	O
was	O
not	O
subject	O
to	O
any	O
potential	O
effects	O
of	O
feeding	O
state	O
(Supplemental	O
Figure	O
3).	O

Thus,	O
the	O
results	O
indicate	O
that	O
the	O
OPLS-DA	O
models	O
generated	O
from	O
the	O
LC-(±)ESI-MS	B
data	O
were	O
reliable.	O

shows	O
the	O
relative	O
concentrations	O
of	O
tryptophan,	B
kynureinine	O
and	O
3-hydroxykynurenine	B
in	O
different	O
groups.	O

For	O
that	O
reason,	O
FA	B
are	O
crucial	O
to	O
maintaining	O
cancer	O
cell	O
proliferation,	O
migration,	O
survival	O
and	O
tissue	O
invasion.	O

The	O
phosphatidylcholines	B
reference	O
values	O
of	O
the	O
present	O
study	O
were	O
slightly	O
lower	O
than	O
those	O
reported	O
in	O
100	O
HVs	O
from	O
the	O
EPIC-Potsdam	O
cohort,	O
probably	O
because	O
the	O
100	O
HVs	O
recruited	O
by	O
Floegel	O
et	O
al.	O
were	O
aged	O
between	O
35	O
and	O
65,	O
compared	O
to	O
the	O
present	O
18–86	O
year-old	O
800	O
HVs,	O
391	O
of	O
whom	O
were	O
aged	O
between	O
18	O
and	O
29.	O

The	O
signals	O
from	O
ethanol	B
represent	O
a	O
contamination	O
accidently	O
introduced	O
by	O
the	O
incomplete	O
drying	O
of	O
reused	O
NMR	O
tubes	O
following	O
a	O
cleaning	O
with	O
water	O
and	O
ethanol.	B

HNSCC	O
stemness	O
properties	O
are	O
defined	O
by	O
elevated	O
glutamate	B
and	O
glutaminase	O
expression	O
in	O
vitro	O
and	O
in	O
vivo	O
and	O
regulated	O
by	O
glutaminolysis.	O

We	O
analyzed	O
the	O
correlation	O
between	O
the	O
ceramide	B
level	O
of	O
breast	O
cancer	O
tissue	O
and	O
that	O
of	O
normal	O
breast	O
tissue	O
(Figure	O
),	O
or	O
peri-tumor	O
in	O
individual	O
patients	O
(Figure	O
),	O
and	O
found	O
no	O
correlation	O
between	O
them	O
(R_2	O
=0.00,	O
p=0.38,	O
and	O
R_2	O
=0.00,	O
p=0.35,	O
respectively).	O

The	O
ether-linked	O
phospholipids,	B
including	O
those	O
identified	O
in	O
our	O
analysis	O
with	O
arachidonic	B
acid	I
at	O
the	O
sn-2	O
position	O
and	O
choline	B
head	O
groups,	O
may	O
serve	O
as	O
substrate	O
for	O
PAF	O
formation	O
and	O
thus	O
be	O
characterized	O
as	O
pro-inflammatory.	O

Briefly,	O
10	O
ug/ml	O
[_13	O
C_1	O
]	O
cholic	B
acid	I
was	O
added	O
to	O
the	O
serum	O
prior	O
to	O
extraction	O
and	O
the	O
samples	O
sequentially	O
extracting	O
using	O
equal	O
volumes	O
of	O
serum	O
with	O
1%	O
ammonium	B
hydroxide	I
and	O
ethyl	B
acetate	I
(EtOAc)	O
four	O
times.	O

All	O
metabolites	O
that	O
were	O
detected	O
in	O
serum	O
were	O
detected	O
in	O
WB	O
with	O
the	O
exception	O
of	O
acetoacetate,	B
which	O
was	O
only	O
detectable	O
in	O
45%	O
of	O
the	O
WB	O
samples,	O
and	O
propylene	B
glycol,	I
which	O
may	O
be	O
a	O
contaminant	O
from	O
the	O
SST	O
blood	O
collection	O
tube	O
but	O
has	O
been	O
reported	O
as	O
a	O
human	O
serum	O
metabolite,	O
resulting	O
in	O
a	O
total	O
of	O
32	O
common	O
metabolites	O
between	O
the	O
two	O
biofluids.	O

Major	O
metabolites	O
recognized	O
include	O
1	O
Valine;	B
2	B
3-Hydroxybutyrate;	I
3	O
Lactate;	B
4	O
Alanine;	B
5	O
Homocysteine;	B
6	O
Acetoacetate;	B
7	O
Pyruvate;	B
8	O
Citrate;	B
9	O
Choline;	B
10	O
Carnitine;	B
11	O
Trimethylamine-N	B
-oxide;	I
12	O
Cystine;	B
13	O
Glucose	B
Relative	O
levels	O
of	O
metabolites	O
found	O
to	O
be	O
altered	O
in	O
sarcoidosis	O
patients	O
as	O
compared	O
with	O
healthy	O
controls,	O
represented	O
by	O
box	O
plots.	O

Only	O
valine	B
and	O
tryptophane	B
stability	O
is	O
in	O
accordance	O
with	O
our	O
results	O
in	O
human	O
plasma	O
samples.	O

Hence,	O
we	O
speculate	O
that	O
enhanced	O
expression	O
level	O
of	O
carnosine	B
may	O
be	O
beneficial	O
for	O
COPD	O
patients	O
to	O
scavenge	O
ROS	O
and	O
α,	O
β-unsaturated	B
aldehydes	I
generated	O
by	O
lipid	O
peroxidation	O
during	O
oxidative	O
stress.	O

300	O
µl	O
of	O
serum	O
samples	O
from	O
remaining	O
available	O
biological	O
material	O
from	O
the	O
three	O
age	O
groups	O
were	O
homogenized	O
with	O
10	O
µl	O
of	O
BHT-buffer	O
(butylated	O
hydroxytoluene;	I
79.2	O
mg/ml	O
PBS)	O
using	O
the	O
FastPrep®	O
24	O
system.	O

Freshly	O
isolated	O
T	O
cells	O
(200	O
×	O
10_3	O
cells/50 μL	O
HBSS	O
(with	O
calcium	O
and	O
magnesium,	O
no	O
phenol	B
red)	O
medium;	O
Thermo	O
Fisher	O
Scientific,	O
Waltham,	O
MA	O
02451)	O
were	O
stained	O
with	O
Fluo-3	O
AM	O
(diluted	O
1:	O
200;	O
Sigma-Aldrich,	O
St.	O
Louis,	O
MO	O
63178)	O
for	O
20 min.	O

It	O
has	O
been	O
shown	O
that	O
patients,	O
who	O
were	O
supplemented	O
with	O
vitamin	B
D,	I
exhibited	O
increased	O
clearance	O
of	O
atorvastatin	B
(substrate	O
of	O
CYP3A4).	O

Inositol,	B
a	O
water-soluble	O
vitamin,	O
can	O
play	O
insulin-like	O
roles	O
on	O
a	O
metabolic	O
enzyme.	O

Some	O
metabolites	O
of	O
valine	B
(3-hydroxyisobutyrate	I
and	O
γ-glutamyl-valine)	B
were	O
present	O
in	O
higher	O
concentrations	O
pre-surgery.	O

The	O
amount	O
and	O
degree	O
of	O
_13	O
C	O
enrichment	O
in	O
lactate	B
secreted	O
was	O
very	O
much	O
higher	O
for	O
the	O
Rh30	O
cells	O
than	O
the	O
primary	O
myocytes	O
(Table	O
and	O
Figure	O
).	O

Five	O
hundred	O
microliters	O
of	O
methanol	B
was	O
added	O
to	O
each	O
tube	O
and	O
vortexed	O
for	O
30	O
s	O
to	O
ensure	O
all	O
components	O
were	O
thoroughly	O
mixed.	O

Glucometer	B
and	O
strips	O
will	O
be	O
given	O
to	O
the	O
patients	O
to	O
record	O
three	O
values	O
daily	O
(after	O
fasting,	O
before	O
a	O
meal	O
and	O
two	O
hours	O
after	O
a	O
meal).	O

Alanine	B
correlated	O
to	O
glucose	B
and	O
c-peptide	O
changes;	O
ketoleucine	B
correlated	O
to	O
insulin	O
and	O
HOMA	O
changes.	O

Abbreviations:	O
AF,	B
atrial	O
fibrillation;	O
VIP,	O
variable	O
importance	O
in	O
the	O
projection;	O
SFA,	O
saturated	O
fatty	O
acid;	O

Shimming	O
quality,	O
expressed	O
as	O
%	O
v	O
/p	O
of	O
anomeric	O
proton	O
of	O
sucrose.	B

Thus,	O
the	O
increased	O
GABA	B
in	O
the	O
HLP	O
subjects	O
might	O
have	O
been	O
a	O
stress	O
response	O
to	O
ameliorate	O
or	O
prevent	O
high	O
postprandial	O
oxidative	O
stress	O
in	O
HLP	O
individuals.	O

Finally,	O
the	O
impact	O
of	O
cannabis	B
and	O
the	O
resulting	O
decreased	O
inflammation	O
on	O
the	O
viral	O
reservoir	O
will	O
be	O
an	O
important	O
avenue	O
of	O
future	O
research.	O

Conclusions:	O
In	O
healthy	O
human	O
serum	O
methanol	B
precipitation	O
of	O
serum	O
with	O
ultrafiltration	O
was	O
superior,	O
but	O
was	O
similar	O
in	O
recovery	O
and	O
variance	O
to	O
methanol:chloroform:water	B
extraction	O
with	O
ultrafiltration	O
in	O
pooled	O
serum	O
from	O
patients	O
with	O
sepsis.	O

Extracellular	O
regulated	O
protein	O
kinase;	O
EtOAc:	O
Ethyl	B
acetate;	I
FDA:	O

Briefly,	O
the	O
aqueous	O
humor	O
(25	O
µL)	O
was	O
mixed	O
with	O
an	O
internal	O
reference	O
standard	O
(20	O
µL),	O
diclofenac-d4,	O
dissolved	O
in	O
methanol,	B
and	O
diluted	O
in	O
255	O
µL	O
of	O
ultra-pure	O
water.	O

(Figure _S2	O
)	O
while	O
DBP	B
vs.	I
alanine	B
(R	O
_2	O
 = 0.38),	O
DBP	B
vs.	I
arginine	B
(R	O
_2	O
 = 0.50),	O
DBP	B
vs.	I
methionine	B
(R	O
_2	O
 = 0.59),	O
DBP	B
vs.	I
pyruvate	B
(R	O
_2	O
 = 0.69),	O
DBP	B
vs.	I
adenine	B
(R	O
_2	O
 = 0.73),	O
and	O
DBP	B
vs.	I
uracil	B
(R	O
_2	O
 = 0.69)	O

d	O
d	O
d	O
Glycocholic	B
acid	I
was	O
not	O
selected	O
in	O
the	O
panel	O
of	O
markers	O
(glutamate,	O
choline,	B
1,5-anhydro-d-glucitol,	B
betaine,	B
and	O
methylguanidine)	B
for	O
the	O
prediction	O
of	O
PC	O
using	O
the	O
forward	O
stepwise	O
regression	O
method.	O

TMAO	B
levels	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
diabetes	O
mellitus	O
(9.4	O
[4.9,	O
13.2]	O
vs	O
4.8	O
[3.4,	O
9.8]	O
μM,	O
p=0.005)	O
and	O
in	O
subjects	O
with	O
New	O
York	O
Heart	O
Association	O
(NYHA)	O
class	O
III	O
or	O
greater	O
(7.0	O
[4.7,	O
14.8]	O
vs	O
4.7	O
[3.4,	O
11.3]	O
μM,	O
p=0.02).	O

Histamine	B
is	O
derived	O
from	O
the	O
decarboxylation	O
of	O
histidine	B
by	O
histidine	O
decarboxylase	O
(HDC).	O

Muscle	O
palmitoleate	B
CoA	O
(16:1;	O
from	O
0.73	O
±	O
0.12	O
to	O
0.44	O
±	O
0.13	O
nmol/g;	O
P	O
<	O
0.05),	O
stearate	B
CoA	O
(18:0;	O
1.44	O
±	O
0.08	O
to	O
0.88	O
±	O
0.11	O
nmol/g;	O
P	O
<	O
0.01),	O
oleate	B
CoA	O
(18:1;	O
from	O
5.06	O
±	O
0.50	O
to	O
3.33	O
±	O
0.65	O
nmol/g;	O
P	O
<	O
0.05),	O
and	O
linoleate	B
CoA	O
(18:2;	O
from	O
3.74	O
±	O
0.53	O
to	O
2.28	O
±	O
0.59	O
nmol/g;	O
P	O
<	O
0.05)	O
decreased	O
after	O
pioglitazone	B
treatment.	O

Phosphatidylcholines	B
are	O
a	O
large	O
class	O
of	O
lipid	O
molecules	O
commonly	O
known	O
as	O
the	O
glycerophospholipids.	B

In	O
fifteen	O
cases	O
with	O
detection	O
of	O
DMAP	O
or	O
thiamethoxam,	B
four	O
cases	O
did	O
not	O
visit	O
the	O
clinic	O
again.	O

2-PY	O
2-Pyridone-3-carboxamide,	B
4-CG	O
4-Cresol	B
glucuronide,	I
Ace	O
Acetate,	B
Ala	O
Alanine,	B
Crea	O
Creatinine,	B
GL	O
Glycerol	B
of	O
lipids,	O
Gln	O
Glutamine,	B
Glu	O
Glutamate,	B
Gly	O
Glycine,	B
GPC	B
Glycerophosphocholine,	I
His	O
Histidine,	B
Ile	O
Isoleucine,	B
L1	O
CH	O
_3	O
(CH_2	O
)n.,	O
L2	O
CH	O
_3	O
CH_2	O

This	O
is	O
consistent	O
with	O
PC	O
suppression	O
inhibiting	O
the	O
mitochondrial	O
synthesis	O
of	O
citrate	B
and	O
consequently	O
the	O
export	O
of	O
citrate	B
to	O
the	O
cytosol	O
thus	O
lowering	O
the	O
supply	O
of	O
cytosolic	O
acetyl-CoA	B
and	O
malonyl-CoA	B
needed	O
for	O
fatty	O
acid	O
synthesis	O
as	O
depicted	O
in	O
.	O

It	O
is	O
interesting	O
to	O
note	O
from	O
this	O
study	O
that	O
while	O
there	O
was	O
a	O
reduction	O
in	O
the	O
level	O
of	O
3-hydroxybutyrate	B
that	O
there	O
also	O
was	O
an	O
increase	O
in	O
the	O
levels	O
of	O
several	O
DCAs.	O

The	O
samples	O
were	O
diluted	O
to	O
a	O
final	O
volume	O
of	O
100	O
μL	O
by	O
adding	O
50	O
μL	O
n-hexane.	B

Understanding	O
whether	O
or	O
not	O
vitamins	O
D_2	O
is	O
really	O
biosimilar	O
to	O
vitamin	O
D_3	O
is	O
important	O
to	O
ensure	O
proper	O
public	O
health	O
advice	O
in	O
preventing	O
or	O
correcting	O
vitamin	B
D	I
as	O
vitamin	O
D_2	O
is	O
the	O
major	O
compound	O
used	O
in	O
some	O
countries	O
whereas	O
vitamin	O
D_3	O
is	O
used	O
more	O
in	O
others.	O

Other	O
organic	O
acid	O
levels	O
such	O
as	O
citrate	B
and	O
malate	B
also	O
discriminated	O
the	O
samples.	O

In	O
contrast,	O
increased	O
CSF	O
levels	O
of	O
PGE_2	B
,	I
15-HETE	I
and	O
RvD1	O
correlated	O
with	O
active	O
MS.	O

The	O
up-regulation	O
of	O
and	O
phosphocholine	B
found	O
in	O
our	O
NP	O
group,	O
when	O
compared	O
to	O
NC,	O
corroborates	O
the	O
previous	O
finding	O
of	O
a	O
damage	O
of	O
nervous	O
system	O
linked	O
to	O
neuropathic	O
pain.	O

Sterol	O
homeostasis	O
in	O
Naegleria	O
may	O
be	O
orchestrated	O
over	O
the	O
course	O
of	O
its	O
life-cycle	O
by	O
a	O
“switch”	O
between	O
ergosterol	B
and	O
cholesterol	B
biosynthesis.	O

The	O
m/z	O
for	O
the	O
administered	O
anti-TB	O
drugs	O
isoniazid	O
(m/z	O
120.0548)	O
and	O
pyrazinamide	B
(m/z	O
124.0498)	O
were	O
detected	O
at	O
low	O
intensity	O
in	O
some	O
individuals	O
with	O
TB	O
disease.	O

Arachidonic	B
acid	I
(100	O
µM,	O
Cayman	O
Chemical	O
Co.,	O
Ann	O
Arbor,	O
MI)	O
was	O
added	O
to	O
initiate	O
the	O
reaction,	O
and	O
samples	O
were	O
incubated	O
for	O
an	O
additional	O
15	O
minutes	O
at	O
37°C.	O

These	O
less	O
polar	O
GGs	O
likely	O
have	O
an	O
oligosaccharide	B
chain	O
shorter	O
than	O
GM3,	B
the	O
simplest	O
GG	O
of	O
the	O
ganglio-series,	B
and	O
thus	O
belong	O
to	O
another	O
series	O
of	O
GGs.	O

The	O
ions	O
at	O
m/z	O
343.2	O
and	O
348.2	O
(y*)	O
for	O
desamino-PhIP-	B
and	O
desamino-[_2	B
H_5	I
]-PhIP	I
adducts	O
are	O
assigned	O
to	O
the	O
desamino-PhIP-Y	B
immonium	O
ions.	O

Neither	O
baseline	O
HIV	O
characteristics	O
(CD4+	O
T-cell	O
count,	O
nadir	O
CD4+T	O
cell	O
count,	O
HIV	O
VL,	B
duration	B
of	O
HIV	O
infection)	O
nor	O
baseline	O
metabolic	O
results	O
(total	O
cholesterol,	B
LDL,	O
HDL,	O
triglycerides,	B
glucose)	B
predicted	O
the	O
observed	O
change	O
in	O
lipid	O
species	O
at	O
12	O
or	O
48	O
weeks	O
(data	O
not	O
shown).	O

(95%CI:	O
0.53-0.81,	O
P	O
=	O
0.016)	O
for	O
methionine,	B
and	O
0.73	O
(95%CI:	O
0.61-0.85,	O
P	O
=	O
0.001)	O
for	O
γ-Glu-Gly-Gly	B
(Figure	O
-C).	O

exp{β0+∑mj=1βjXij}1+exp{β0+∑mj=1βjXij}	B
exp{β0+∑mj=1βjXij}1+exp{β0+∑mj=1βjXij}	I
exp{β0+∑mj=1βjXij}	I
exp{β0+∑mj=1βjXij}	I
exp	O
{β0+∑mj=1βjXij}	O
{	O
{	O
β0+∑mj=1βjXij	B
β0	O
β0	O
β	O
β	O
β	O
	O
0	O
0	O
+	O
∑mj=1	O
∑mj=1	O
∑	O
∑	O
m	O
m	O
j=1	O
j=1	O
j	O
=	O
1	O
βjXij	O
βj	O
βj	O
β	O
β	O
β	O

Moreover,	O
it	O
has	O
been	O
demonstrated	O
that	O
the	O
bioenergetic	O
metabolism	O
of	O
neutrophils	O
(main	O
fraction	O
of	O
PMNs)	O
is	O
mainly	O
glycolytic.	B

Patients	O
who	O
had	O
received	O
insulin,	O
metformin,	B
a	O
thiazolidinedione,	B
or	O
lipid-lowing	O
agents	O
within	O
the	O
previous	O
12	O
months	O
were	O
excluded.	O

Aqueous	O
phase	O
A	O
consisted	O
of	O
10	O
%	O
v/v	O
acetonitrile	B
in	O
water	O
containing	O
0.1%	O
formic	B
acid	I
as	O
a	O
modifier.	O

Applying	O
the	O
oxylipin	B
profiling	O
platform	O
to	O
human	O
EDTA-plasma,	O
we	O
were	O
able	O
to	O
detect	O
36	O
oxylipins	B
derived	O
from	O
6	O
different	O
PUFAs	O
(Table ).	O

Circulating	O
PC	O
species,	O
containing	O
linoleic	B
acids	I
(PC	O
34:2,	O
PC	B
36:2,	I
PC	B
38:2)	I
and	O
α-linolenic	B
acids	I
(PC	O
34:3,	O
PC	B
36:3,	I
PC	B
38:3),	I
were	O
markedly	O
increased	O
in	O
these	O
patients,	O
whereas	O
those	O
containing	O
arachidonic	B
acid	I
remained	O
unaffected	O
(D–G).	O

The	O
optic	O
nerve,	O
despite	O
being	O
a	O
nervous	O
tissue,	O
often	O
presented	O
similar	O
proportions	O
of	O
polyunsaturated	O
ceramides	B
than	O
the	O
RPE/choroid,	O
ciliary	O
body	O
or	O
plasma.	O

Subjects	O
on	O
lipid-lowering	O
medication	O
had	O
lower	O
total	O
cholesterol,	B
LDL-C,	O
and	O
triglycerides	B
(p<0.05,	O
Mann-Whitney	O
U-test).	O

Like	O
FAAs,	O
sphingolipids	B
have	O
been	O
suggested	O
to	O
be	O
agonists	O
of	O
PPARs,	O
and	O
therefore,	O
alterations	O
in	O
the	O
levels	O
of	O
sphingolipids	B
might	O
have	O
an	O
impact	O
on	O
lipid	O
metabolism,	O
fatty	O
acid	O
oxidation	O
and	O
glucose	B
homeostasis.	O

Out	O
of	O
408	O
targeted	O
metabolites,	O
196	O
(48%)	O
were	O
detected	O
above	O
the limit	O
of	O
detection	O
(LOD;	O
defined	O
for	O
each	O
metabolite	O
as	O
three	O
times	O
the	O
background	O
noise	O
level),	O
corresponding	O
to	O
82	O
glycerophospholipids,	B
38	O
glycerides,	B
22	O
acylcarnitines,	B
19	O
amino	O
acids,	O
18	O
sphingolipids,	B
9	O
biogenic	O
amines,	O
7	O
cholesterol	B
esters	I
and	O
the	O
sum	O
of	O
hexoses	O
(Fig.	O

From	O
this	O
viewpoint,	O
we	O
have	O
focused	O
on	O
the	O
metabolites	O
associated	O
with	O
glutathione	B
metabolism	O
as	O
indicators	O
for	O
monitoring	O
of	O
liver	O
disease,	O
because	O
glutathione	B
metabolism	O
in	O
liver	O
cells	O
plays	O
a	O
significant	O
role	O
in	O
protecting	O
them	O
against	O
ROS[-].	O

The	O
metabolite	O
samples	O
were	O
first	O
derivatized	O
by	O
methoxyamination	O
by	O
adding	O
50	O
μL	O
of	O
20	O
mg/mL	O
solution	O
of	O
methoxyamine	B
hydrochloride	I
(Sigma-Aldrich)	O
in	O
pyridine	B
(Sigma-Aldrich)	O
and	O
incubated	O
at	O
37°C	O
for	O
two	O
hours.	O

Interestingly,	O
all	O
five	O
sphingomyelins	B
containing	O
hydroxyl	O
fatty	O
acids	O
were	O
significantly	O
higher	O
in	O
breast	O
cancer	O
patients	O
(four	O
were	O
selected	O
as	O
differentiating	O
metabolites,	O
the	O
other	O
one	O
was	O
SM	O
(OH)	O
C24:1	B
with	O
a	O
p	O
-value	O
of	O
0.014	O
and	O
an	O
adjusted	O
q	O
-value	O
of	O
0.050).	O

The	O
comparison	O
of	O
metabolic	O
levels	O
rendered	O
small	O
positive	O
variations	O
for	O
lipids/VLDL	O
(,	O
up	O
to	O
17%)	O
and	O
minor	O
reductions	O
of	O
the	O
metabolites	O
choline,	B
glutamine,	B
valine,	B
leucine	B
and	O
alanine	B
(	O
and	O
).	O

The	O
subjects	O
who	O
answered	O
affirmatively	O
had	O
about	O
15-fold	O
higher	O
levels	O
of	O
3-HPMA	O
(metabolite	O
of	O
acrolein),	O
1.5-fold	O
higher	O
levels	O
of	O
DHBMA	O
(metabolite	O
of	O
1,3-butadiene),	B
1.8-fold	O
higher	O
levels	O
of	O
GAMA	O
(metabolite	O
of	O
acrylamide),	B
6.7-fold	O
higher	O
levels	O
of	O
HMPMA	O
(metabolite	O
of	O
crotonaldehyde),	B
and	O
4-fold	O
higher	O
values	O
of	O
SBMA	O
(metabolite	O
of	O
toluene).	O

Beside	O
ADMA	B
the	O
consumption	O
of	O
fish	O
and	O
seafood	O
represent	O
one	O
source	O
of	O
DMA	B
and	O
therefore	O
DMA	B
might	O
be	O
marker	O
of	O
the	O
dietary	O
intake	O
of	O
iodine.	O

The	O
column	O
was	O
reconditioned	O
with	O
25	O
mL	O
methanol/water	O
(2:8,	O
v/v)	O
and	O
45	O
mL	O
ammonium	B
acetate	I
solution	O
(0.25	O
mM,	O
pH	O
8.8)	O
for	O
the	O
next	O
sample.	O

Box-and-whisker	O
plots	O
show	O
the	O
distribution	O
of	O
abundance	O
values	O
of	O
5-Oxoprolinate,	B
Erythronic	B
acid	I
and	O
N-Acetylaspartic	B
acid	I
in	O
HPV-	B
vs	I
HPV+H	O
samples	O
with	O
the	O
optimal	O
cut-off	O
as	O
a	O
horizontal	O
dotted	O
red	O
line.	O

PC-C36	O
and	O
PC-C38,	O
which	O
contain	O
long-chain	O
FA	B
(side	O
chain	O
of	O
16	O
to	O
20	O
carbons),	O
represented	O
more	O
than	O
50%	O
of	O
total	O
PCs	O
quantified	O
and	O
were	O
also	O
the	O
individual	O
PC	O
species	O
with	O
the	O
most	O
pronounced	O
decrease	O
15	O
days	O
after	O
the	O
surgery,	O
with	O
effects	O
lasting	O
up	O
to	O
90	O
days.	O

In	O
comparison	O
to	O
the	O
controls,	O
only	O
11	O
VLCFA	O
species	O
were	O
significantly	O
elevated	O
in	O
RRMS	O
patients	O
with	O
a	O
lesser	O
disease	O
duration	B
(<13	O
y)	O
(Table ).	O

The	O
final	O
incubation	O
volume	O
was	O
50 µL	O
and	O
consisted	O
of	O
90 mM	O
phosphate	B
buffer,	O
5 mM	O
isocitrate,	B
5 mM	O
Mg_2+	O
,	O
1.2 mM	O
NADP_+	O
,	O
200 U/mL	O
superoxide	B
dismutase,	O
and	O
0.5 U/mL	O
isocitrate	O
dehydrogenase.	O

Receiver	O
operating	O
characteristic	O
curve	O
analysis	O
of	O
the	O
four	O
biomarkers	O
(phosphorylcholine,	O
L-acetylcarnitine,	B
arachidonic	B
acid	I
and	O
glycocholic	B
acid)	O
and	O
the	O
combined	O
model.	O

TMAO	B
and	O
d9‐TMAO	O
were	O
monitored	O
in	O
the	O
positive	O
multiple	O
reaction	O
monitoring	O
mass	O
spectrometry	O
mode	O
using	O
characteristic	O
precursor–production	O
transitions	O
including	O
m/z	O
76/58	O
and	O
m/z	O
85/66,	O
respectively.	O

A,	O
OTα	O
ochratoxin	B
α,	O
QqQ	O
triple	O
quadrupole,	O
SAX	O
strong	O
anion	O
exchange,	O
SIDA	O
stable-isotope	O
standard-dilution	O
assay,	O
SPE	O
solid-phase	O
extraction,	O
ZEN	O
zearalenone,	B
ZEL	O
zearalenol	O
_a	O
Values	O
in	O
parentheses	O
represent	O
the	O
amount	O
of	O
urine	O
injected	O
taking	O
the	O
sample	O
enrichment/dilution	O
into	O
account.	O

In	O
contrast	O
to	O
the	O
metabolite	O
levels	O
presented	O
in	O
the	O
previous	O
section,	O
_13	O
C	O
enrichment	O
profiles	O
of	O
lactate	B
and	O
alanine	B
were	O
indeed	O
significantly	O
altered	O
as	O
a	O
result	O
of	O
the	O
fiber	O
mix	O
addition.	O

The	O
polar	O
and	O
non-polar	O
fractions	O
were	O
further	O
derivatized	O
with	O
O	B
-methyl-hydroxylamine	I
hydrochloride	I
to	O
convert	O
oxo-groups	O
to	O
O	B
-methyloximes,	I
and	O
subsequently	O
with	O
a	O
silylating	O
agent	O
(N	O
-methyl-N	I
-(trimethylsilyl)	I
trifluoroacetamide)	I
before	O
analysis.	O

Tentative	O
identification	O
of	O
compounds	O
showed	O
that	O
species	O
such	O
as	O
homoserine,	B
histidine,	B
uric	B
acid,	I
and	O
glycophosphocholine	B
could	O
be	O
recovered	O
in	O
MTBE	B
aqueous	O
fraction	O
but	O
were	O
not	O
detected	O
in	O
methanol	B
supernatants	O
(Shown	O
in	O
).	O

For	O
PMNs,	O
a	O
tendency	O
for	O
glucose	B
and	O
GSH	B
to	O
increase,	O
and	O
lactate	B
to	O
decrease	O
seem	O
to	O
be	O
present	O
when	O
they	O
are	O
treated	O
with	O
chitosan	O
and	O
CeO_2	O
,	O
but	O
these	O
changes	O
are	O
only	O
significant	O
when	O
Au	O
is	O
introduced.	O

Concentrations	O
of	O
quinolinate	B
in	O
human	O
rabies	O
CSF	O
exceeded	O
those	O
measured	O
in	O
most	O
cases	O
of	O
meningitis,	O
cerebral	O
malaria_,	O
or	O
pediatric	O
HIV	O
encephalopathy.	O

Valine	B
and	O
xleucine	B
are	O
both	O
from	O
the	O
same	O
metabolic	O
sub-pathway	O
valine,	B
leucine	B
and	O
isoleucine	B
metabolism	O
which	O
according	O
to	O
the	O
study	O
by	O
Menni	O
et	O
al.	O

In	O
other	O
studies,	O
urinary	O
Norepinephrine	B
levels	O
correlated	O
positively	O
with	O
HIV	O
viral	O
load	O
,	O
and	O
with	O
depression	O
and	O
anxiety	O
,	O
which	O
is	O
frequently	O
observed	O
in	O
HIV/AIDS	O
patients.	O

(,	O
),	O
and	O
there	O
is	O
evidence	O
for	O
the	O
presence	O
of	O
the	O
necessary	O
enzymes	O
in	O
brain,	O
i.e.	O
CYP46A1,	O
CYP39A1,	O
CYP27A1	O
(,	O
,	O
),	O
HSD3B7,	O
very	O
long	O
chain	O
acyl-CoA	B
synthetase,	O
and	O
l-bifunctional	O
protein	O
to	O
account	O
for	O
their	O
formation	O
(Scheme	O
4).	O

In	O
A,	O
the	O
score	O
plot	O
of	O
phosphatidylcholine/SM	O
phospholipids	B
is	O
shown,	O
whereas	O
B	O
shows	O
the	O
score	O
plot	O
of	O
the	O
phosphatidylethanolamine	B
class;	O
C	O
shows	O
the	O
phosphatidylglycerol	B
lipids;	O
and	O
the	O
phosphatidylserine	B
class	O
is	O
reported	O
in	O
.	O

Obese	O
patients	O
of	O
the	O
L0	O
group	O
presented	O
higher	O
midnight	O
plasma	O
cortisol	B
concentration	O
(P	O
 < 0.001)	O
than	O
the	O
L1	O
group.	O

AMst1	O
endophyte	O
of	O
Annona	O
muricata	O
against	O
P.	O
falciparum	O
Pf	B
3D7,	O
Pf	B
Dd2,	O
and	O
Pf	B
Indo	O
(IC_50	O
1.16–1.43	O
μg/mL).	O

The	O
median	O
level	O
for	O
5-hydroxymethyl-2′-deoxyuridine	B
increased	O
in	O
HCC	O
by	O
factor	O
of	O
1.5,	O
while	O
the	O
levels	O
for	O
the	O
other	O
three	O
metabolites	O
decreased.	O

Although	O
the	O
association	O
with	O
uPCr	O
was	O
not	O
statistically	O
significant,	O
there	O
was	O
a	O
trend	O
for	O
a	O
positive	O
relationship	O
between	O
uPCr	O
and	O
log-transformed	O
urinary	O
myo-inositol	B
(R = 0.251,	O
P = 0.105).	O

CO_2	O
partially	O
reacts	O
with	O
water	O
to	O
form	O
carbonic	B
acid	I
or	O
hydrogen	B
carbonate,	I
its	O
respective	O
anion.	O

Area	O
under	O
the	O
ROC	O
curves	O
were	O
similar	O
(AUC = 0.86)	O
for	O
the	O
cysteine,	B
cystathionine,	B
and	O
homocysteine	B
when	O
combined	O
with	O
the	O
clinical	O
variables	O
and	O
significantly	O
superior	O
to	O
the	O
clinical	O
variables	O
alone	O
(AUC = 0.81).	O

In	O
subjects	O
with	O
high	O
levels	O
of	O
LDL	B
cholesterol	I
(LDL-C)	O
(≥100	O
mg/dL)	O
(n	O
=	O
37),	O
urine	O
nicotinuric	B
acid	I
values	O
were	O
higher	O
than	O
in	O
those	O
with	O
normal	O
levels	O
of	O
LDL-C	O
(<100	O
mg/dL)	O
(n	O
=	O
18)	O
(239	O
±	O
26	O
vs.	O
158	O
±	O
20	O
×	O
10_3	O
mAU,	O
P	O
=	O
0.0426),	O
and	O
it	O
was	O
higher	O
in	O
subjects	O
with	O
high	O
TC	O
levels	O
(≥200	O
mg/dL)	O
than	O
in	O
those	O
with	O
normal	O
levels	O
(data	O
not	O
shown).	O

Regarding	O
nuclear	O
grade,	O
patients	O
with	O
high	O
nuclear	O
grade	O
were	O
significantly	O
associated	O
with	O
low	O
ceramide	B
levels	O
in	O
cancer	O
tissue	O
(p	O
=0.04)	O
as	O
shown	O
in	O
Figure	O
.	O

(c)	O
Discrimination	O
of	O
T2DM	O
in	O
the	O
test	O
set	O
using	O
Linolenic	B
Acid	I
(1),	O
deoxycholic	B
acid	I
(2),	O
and	O
the	O
combination	O
of	O
them	O
(3);	O
(d)	O
Scatter	O
plot	O
of	O
Linolenic	B
Acid;	I
(e)	O
Scatter	O
plot	O
of	O
deoxycholic	B
acid.	I

Cold	O
atmospheric	O
plasma	O
treatment	O
could	O
significantly	O
alter	O
the	O
metabolite	O
profiling	O
of	O
myeloma	O
tumor	O
cells,	O
among	O
which,	O
the	O
beta-alanine	B
metabolism	O
pathway	O
is	O
the	O
most	O
susceptible	O
to	O
He	O
gas	O
plasma	O
treatment.	O

Tissues	O
were	O
sliced	O
at	O
a	O
thickness	O
of	O
5	O
to	O
6 μm	O
using	O
a	O
microtome	O
followed	O
by	O
staining	O
with	O
hematoxylin	B
and	O
eosin	B
for	O
pathological	O
assessment	O
by	O
the	O
department	O
of	O
pathology,	O
Fourth	O
Military	O
Medical	O
University.	O

At	O
the	O
time	O
metabolites	O
were	O
measured,	O
mean	O
age	O
was	O
32.4	O
years	O
and	O
mean	O
duration	B
of	O
diabetes	O
was	O
7.5	O
years.	O

The	O
distribution	O
pattern	O
was	O
similar	O
between	O
the	O
three	O
fatty	O
acids	O
but	O
did	O
not	O
fully	O
overlap	O
with	O
triglyceride	B
distribution.	O

Beyond	O
the	O
above	O
mentioned	O
arteriovenous	O
differences	O
related	O
to	O
muscle	O
metabolism,	O
distinct	O
metabolites,	O
including	O
oxidized	O
fatty	O
acids	O
(HPODE	O
family)	O
and	O
sialic	B
acid	I
may	O
reflect	O
the	O
oxidation	O
state	O
difference	O
between	O
the	O
arterial	O
and	O
venous	O
plasma_,	O
_,	O
_,	O
_,	O
_,	O
.	O

The	O
fact	O
that	O
both	O
systolic	O
and	O
diastolic	O
blood	O
pressure	O
responses	O
to	O
amlodipine	B
treatment	O
were	O
correlated	O
to	O
decreases	O
in	O
plasma	O
hexadecanedioate	B
concentration	O
is	O
intriguing	O
due	O
to	O
recent	O
data	O
by	O
Menni	O
et	O
al.,	O
linking	O
this	O
metabolite	O
to	O
blood	O
pressure	O
regulation.	O

The	O
mean	O
intra-assay	O
and	O
inter-assay	O
CVs	O
were	O
5.1%	O
and	O
13.4%	O
for	O
E_1	O
;	O
5.2%	O
and	O
16.0%	O
for	O
E_2	O
;	O
5.6%	O
and	O
11.4%	O
for	O
E_3	O
;	O
4.2%	O
and	O
12.3%	O
for	O
2-OHE_1	O
;	O
7.7%	O
and	O
10.8%	O
for	O
2-OHE_2	O
;	O
6.2%	O
and	O
18.7%	O
for	O
16α-OHE_1	B
;	O
4.3%	O
and	O
12.2%	O
for	O
4-OHE_1	O
;	O
14.0%	O
and	O
51.2%	O
for	O
4-OHE_2	O
;	O
7.0%	O
and	O
11.3%	O
for	O
2-MeOE_1	O
;	O
5.8%	O
and	O
10.0%	O
for	O
2-MeOE_2	O
;	O
7.4%	O
and	O
10.3%	O
for	O
4-MeOE_1	O
;	O
and	O
6.9%	O
and	O
7.9%	O
for	O
4-MeOE_2	O
.	O

Proline	B
was	O
reduced	O
(P	O
<	O
0.05	O
after	O
the	O
FDR	O
procedure),	O
whereas	O
some	O
lyso-phospholipids	B
increased	O
(6:0,	O
24:0,	O
26:0,	O
28:0,	O
28:1)	O
and	O
others	O
decreased	O
(14:0,	O
16:0,	O
18:0,	O
18:1,	O
18:2)	O
(P	O
<	O
0.05	O
after	O
the	O
FDR	O
procedure).	O

In	O
an	O
initial	O
assessment	O
of	O
the	O
metabolites,	O
we	O
investigated	O
trigonelline	B
as	O
a	O
potential	O
biomarker	O
for	O
kidney	O
rejection.	O

Then,	O
0.1%	O
formic	B
acid	I
in	O
water	O
(v	O
/v	O
)	O
served	O
as	O
mobile	O
phase	O
A,	O
and	O
acetonitrile	B
served	O
as	O
mobile	O
phase	O
B.	O

Also,	O
it	O
has	O
been	O
reported	O
that	O
the	O
solubilities	O
in	O
methanol	B
are	O
3.04	O
g/L	O
at	O
−70	O
°C	O
for	O
LA,	O
13.8	O
g/L	O
at	O
−	O
62	O
°C	O
for	O
ALA,	O
and	O
50	O
mg/ml	O
for	O
AA	O
and	O
EPA	O
(Product	O
Information	O
Sheet	O
from	O
Sigma-Aldrich).	O

Monohexosylceramides	B
major	O
species	O
in	O
healthy	O
corneas	O
and	O
diabetics	O
(n>=3	O
per	O
group).	O

Monohydroxy	B
metabolites	O
of	O
naphthalene,	B
fluorene,	B
phenanthrene,	B
and	O
pyrene	O
were	O
determined	O
by	O
the	O
method	O
of	O
.	O

Recent	O
advances	O
in	O
technology	O
has	O
facilitated	O
investigating	O
the	O
role	O
of	O
ceramides	B
in	O
beta-cell	O
dysfunction,	O
and	O
the	O
current	O
debate	O
on	O
the	O
role	O
of	O
ceramides	B
in	O
type	O
1	O
diabetes	O
focuses	O
on	O
whether	O
ceramides	B
can	O
mimic	O
the	O
effects	O
of	O
IL-1β	B
in	O
promoting	O
beta-cell	O
death	O
and	O
in	O
repressing	O
insulin	O
production	O
(Boslem	O
et	O
al.	O
).	O

15-HETE	B
is	O
a	O
pathway	O
marker	O
of	O
anti-inflammatory	O
and	O
pro-resolving	O
lipoxins	B
(–).	O

Briefly,	O
200 μL	O
serum	O
was	O
added	O
into	O
800 μL	O
methanol-acetonitrile	B
mixture	O
(4:1,	O
v/v),	O
vortex-mixing	O
undertaken	O
for	O
1 minute.	O

We	O
performed	O
Cox	O
proportional-hazards	O
regression	O
analysis	O
with	O
adjustment	O
for	O
traditional	O
cardiovascular	O
risk	O
factors	O
(age,	O
sex,	O
systolic	O
blood	O
pressure,	O
presence	O
or	O
absence	O
of	O
diabetes	O
mellitus,	O
low-density	O
and	O
high-density	O
lipoprotein	O
cholesterol	B
levels,	O
triglyceride	B
levels,	O
and	O
smoking	O
status)	O
and	O
for	O
log-transformed	O
high-sensitivity	O
C-reactive	O
protein	O
levels	O
(both	O
alone	O
and	O
with	O
myeloperoxidase),	O
the	O
log-transformed	O
estimated	O
glomerular	O
filtration	O
rate,	O
total	O
leukocyte	O
count,	O
body-mass	O
index,	O
medication	O
history,	O
and	O
angiographic	O
extent	O
of	O
coronary	O
artery	O
disease.	O

Positive	O
correlations	O
in	O
the	O
meningiomas	O
followed	O
the	O
same	O
general	O
pattern:	O
lactate	B
correlated	O
positively	O
with	O
alanine,	B
tCr,	O
tCho	O
and	O
tGlut,	O
and	O
tCho	O
correlated	O
positively	O
with	O
tCr	O
and	O
tGlut.	O

In	O
the	O
grade	O
II	O
oligodendrioglioma	O
sample	O
G49,	O
we	O
not	O
only	O
detected	O
the	O
phospholipid	B
profile	O
(m/z	O
700	O
–	O
900)	O
characteristic	O
of	O
oligodendrogliomas	O
(transitional	O
between	O
grade	O
II	O
and	O
grade	O
III),	O
but	O
we	O
also	O
noted	O
a	O
very	O
abundant	O
signal	O
of	O
free	O
fatty	O
acid,	O
specifically	O
palmitic	B
acid,	I
m/z	O
255,	O
oleic	B
acid,	I
m/z	O
281	O
and	O
arachidonic	B
acid,	I
m/z	O
303,	O
and	O
fatty	O
acid	O
dimers	O
in	O
the	O
region	O
of	O
m/	O

However,	O
the	O
expression	O
and	O
roles	O
of	O
gangliosides	B
in	O
the	O
retina,	O
although	O
often	O
considered	O
as	O
a	O
window	O
on	O
the	O
brain,	O
has	O
been	O
far	O
less	O
studied.	O

After	O
completion	O
of	O
the	O
aims	O
of	O
the	O
original	O
trial	O
cited	O
above,	O
thirty-nine	O
pairs	O
of	O
plasma	O
samples	O
collected	O
before	O
and	O
after	O
limonene	B
intervention	O
were	O
available	O
for	O
metabolomic	O
profiling.	O

This	O
was	O
associated	O
with	O
an	O
increase	O
in	O
palmitate	B
oxidation	O
rate	O
of	O
50	O
±	O
9%	O
(P	O
<	O
0.001	O
from	O
baseline;	O
).	O

Additional	O
biological	O
testing	O
applied	O
the	O
assay	O
to	O
samples	O
collected	O
from	O
healthy	O
control	O
participants	O
and	O
two	O
groups	O
diagnosed	O
with	O
inflammatory	O
bowel	O
disease	O
(IBD)	O
(one	O
group	O
treated	O
with	O
the	O
anti-inflammatory	O
5-aminosalicylic	B
acid	I
(5-ASA)	O
and	O
one	O
group	O
untreated),	O
with	O
results	O
showing	O
significant	O
differences	O
in	O
the	O
concentrations	O
of	O
picolinic	B
acid,	I
kynurenine,	B
and	O
xanthurenic	B
acid.	I

There	O
were	O
no	O
significant	O
effects	O
of	O
medication	O
status,	O
history	O
of	O
psychosis,	O
or	O
past	O
history	O
of	O
suicide	O
attempts	O
on	O
the	O
concentrations	O
of	O
CRP	O
or	O
the	O
kynurenine	B
metabolic	O
pathway	O
metabolites	O
(all	O
p-values>0.1).	O

The	O
inset	O
is	O
the	O
data-dependent	O
MS/MS	O
scan	O
of	O
the	O
same	O
peak,	O
giving	O
fragment	O
ions	O
of	O
193,	O
175,	O
and	O
163	O
m	O
/z	O
corresponding	O
to	O
the	O
indicated	O
portions	O
of	O
the	O
proposed	O
phenylbutyryl-β	B
-glucuronate	I
metabolite	O
shown.	O

A.	O
12-HETE,	B
B.	O
Taurine,	B
C.	O
Ceramide(d18:1/20:0),	B
D.	O
Sphingomyelin	B
SM(d18:1/26:1	I
OH),	I
E.	O
Xanthosine,	B
F.	O
Plasmalogen	O

Acetate	B
was	O
the	O
dominant	O
SCFA	O
produced	O
after	O
24	O
h	O
fermentation	O
with	O
all	O
breads	O
and	O
in	O
both	O
IBS	O
and	O
healthy	O
donors.	O

The	O
level	O
of	O
urinary	O
tryptophan	B
catabolites	O
involving	O
kynurenine,	B
hydroxytryptophan	B
and	O
xanthurenic	B
acid	I
were	O
significantly	O
elevated	O
in	O
patients	O
with	O
early-stage	O
PD	O
(	O
and	O
).	O

Creatinine	B
tends	O
to	O
increase	O
with	O
age	O
in	O
the	O
controls	O
and	O
decrease	O
in	O
the	O
DMD	O
patients,	O
while	O
creatine	B
tends	O
to	O
decrease	O
in	O
the	O
controls	O
but	O
stay	O
relatively	O
stable	O
in	O
the	O
DMD	O
patients.	O

The	O
two	O
analytical	O
approaches	O
(enzymatic	O
digestion	O
vs.	O
sum	O
of	O
the	O
glucuronide	B
concentrations)	O
employed	O
in	O
plasma	O
samples	O
have	O
been	O
statistically	O
compared	O
by	O
NCSS	O
as	O
shown	O
in	O
Fig.	O

The	O
patients	O
with	O
pre-DM	O
and	O
DM	O
had	O
higher	O
HbA1c,	O
FPG	O
and	O
TG	B
levels	O
compared	O
with	O
those	O
of	O
the	O
healthy	O
controls.	O

Carbon	B
dioxide	I
was	O
purchased	O
from	O
Helget	O
Gas	O
(Kansas	O
City,	O
MO).	O

Choline-containing	O
nutrients	O
that	O
reach	O
the	O
cecum	O
and	O
large	O
bowel	O
may	O
serve	O
as	O
fuel	O
for	O
intestinal	O
microbiota	O
(gut	O
flora),	O
producing	O
trimethylamine	B
(TMA).	O

As	O
seen	O
in	O
,	O
nicotinamide	B
levels	O
are	O
higher	O
in	O
IBS	O
and	O
significantly	O
different	O
between	O
the	O
2	O
groups	O
at	O
Time	O
4	O
(,	O
P	O
<	O
0.01).	O

Several	O
studies	O
have	O
reported	O
that	O
ceramide	B
is	O
intimately	O
involved	O
in	O
cancer	O
pathogenesis.	O

Other	O
studies	O
showed	O
the	O
relationship	O
between	O
lower	O
levels	O
of	O
creatine,	B
lactate,	B
and	O
choline	B
and	O
overall	O
survival.	O

To	O
date,	O
decanoic	B
acid	I
has	O
not	O
been	O
reported	O
to	O
be	O
a	O
biomarker	O
of	O
cancer.	O

This	O
is	O
because	O
carnitine	B
is	O
synthesized	O
endogenously	O
from	O
the	O
essential	O
amino	O
acids	O
.	O

Lower	O
levels	O
of	O
urinary	O
urea	B
in	O
late-stage	O
cancers	O
might	O
indicate	O
less	O
nitrogen	O
flux	O
into	O
catabolic	O
reactions,	O
and	O
a	O
likely	O
higher	O
amino	O
acid	O
flux	O
into	O
protein	O
biosynthesis.	O

In	O
addition	O
to	O
the	O
corresponding	O
(systolic	O
or	O
diastolic)	O
baseline	O
ABP	O
level,	O
the	O
selected	O
covariates	O
were:	O
for	O
amlodipine	B
systolic	O
ABP	O
response,	O
age,	O
daily	O
urinary	O
sodium	O
excretion	O
and	O
serum	O
cholesterol;	B
for	O
amlodipine	B
diastolic	O
ABP	O
response,	O
age,	O
body	O
mass	O
index,	O
daily	O
urinary	O
sodium	O
excretion	O
and	O
serum	O
cholesterol;	B
for	O
bisoprolol	O
systolic	O
ABP	O
response,	O
current	O
smoking	O
and	O
serum	O
cholesterol;	B
for	O
bisoprolol	O
diastolic	O
ABP	O
response,	O
no	O
other	O
covariates;	O
for	O
hydrochlorothiazide	B
systolic	O
ABP	O
response,	O
age,	O
daily	O
urinary	O
sodium	O
excretion	O
and	O
serum	O
triglycerides;	B
for	O
hydrochlorothiazide	B
diastolic	O
ABP	O
response,	O
age	O
and	O
daily	O
urinary	O
sodium	O
excretion;	O
for	O
losartan	O
systolic	O
and	O
diastolic	O
ABP	O
responses,	O
serum	O
creatinine.	B

However,	O
quantitative	O
comparison	O
of	O
steroid	O
excretion	O
between	O
primary	O
aldosteronism	O
patients	O
and	O
healthy	O
controls	O
also	O
revealed	O
24-hour	O
total	O
glucocorticoid	B
output	O
as	O
significantly	O
increased	O
in	O
primary	O
aldosteronism	O
(11,306	O
[interquartile	O
range	O
7,999–14,907]	O

Numerical	O
characteristics	O
are	O
shown	O
of	O
the	O
threshold-average	O
ROC	O
curves	O
for	O
all	O
32	O
steroids	O
and	O
the	O
subsets	O
of	O
three	O
steroids	O
(THS,	O
5-PT,	O
and	O
5-PD)	O
and	O
nine	O
steroids	O
[THS,	O
5-PT,	O
5-PD,	O
PT,	O
THDOC,	O
5αTHA	B
Etio,	O
5αTHF,	B
and	O
PD;	O
for	O
explanation	O
of	O
steriod	O
metabolite	O
abbreviations	O
see	O
Supplemental	O
Table	O
1]	O
identified	O
as	O
most	O
discriminative	O
after	O
GMLVQ	O
analysis.	O

Moreover,	O
in	O
order	O
to	O
gain	O
further	O
insights	O
in	O
the	O
neuroprotection	O
mechanisms	O
during	O
pregnancy	O
and	O
in	O
the	O
metabolic	O
alterations	O
characterizing	O
the	O
precipitous	O
relapse	O
in	O
the	O
post-partum	O
period	O
of	O
MuS	O
patients,	O
we	O
also	O
monitored	O
differences	O
in	O
other	O
metabolic	O
classes,	O
such	O
as	O
sphingolipids,	B
ceramides,	B
AAs,	O
ACCs,	O
SA,	O
nucleosides,	O
and	O
LPCs.	O

One	O
might	O
expect	O
a	O
greater	O
impact	O
from	O
baseline	O
fatty	O
acid	O
levels	O
on	O
TxB_2	O
,	O
in	O
a	O
study	O
targeting	O
only	O
individuals	O
who	O
have	O
an	O
abnormal	O
response	O
to	O
aspirin	B
TxB_2	O
(<500	O
pg/mg	O
creatinine).	O

It	O
is	O
likely	O
that	O
differences	O
in	O
study	O
design	O
and	O
clinical	O
phenotyping,	O
as	O
well	O
as	O
small	O
sample	O
sizes	O
in	O
some	O
studies,	O
contribute	O
to	O
the	O
inconsistencies	O
thus	O
far	O
in	O
the	O
literature	O
regarding	O
carnitine	B
metabolites	O
and	O
DR.	O

Protein	O
precipitation	O
prior	O
to	O
extraction	O
was	O
evaluated	O
using	O
acetone	B
or	O
ACN,	O
followed	O
by	O
centrifugation	O
and	O
evaporation	O
of	O
the	O
solvent	O
from	O
the	O
supernatant,	O
but	O
this	O
treatment	O
did	O
not	O
improve	O
analyte	O
recovery.	O

Using	O
the	O
described	O
method,	O
mean	O
recoveries	O
for	O
the	O
five	O
lipid	O
families	O
were	O
all	O
above	O
80 %	O
(see	O
Table	O
S3	O
provided	O
as	O
supplementary	O
material):	O
i.e.,	O
88.2 %	O
for	O
fatty	O
acyls,	O
90.6 %	O
for	O
sphingolipids,	B
80.6 %	O
for	O
glycerophospholipids	B
and	O
88.7 %	O
for	O
glycerolipids.	B

Moreover,	O
a	O
decreased	O
amount	O
of	O
succinate	B
was	O
shown	O
by	O
the	O
network	O
analysis	O
in	O
long-term	O
survivors	O
compared	O
to	O
short-term	O
survivors,	O
suggesting	O
a	O
decreased	O
activity	O
of	O
the	O
TCA	O
cycle.	O

Increased	O
levels	O
of	O
trigonelline	B
and	O
reduced	O
3-hydroxybutyrate	B
in	O
patient	O
urine	O
may	O
be	O
associated	O
with	O
smoking	O
in	O
these	O
individuals.	O

Their	O
etiology	O
of	O
kidney	O
disease	O
was	O
other	O
than	O
diabetic	O
kidney	O
disease	O
which	O
was	O
excluded	O
to	O
meet	O
the	O
inclusion	O
criterion	O
of	O
glycemic	B
control	O
in	O
this	O
study	O
group.	O

Generally,	O
glycolysis	O
increased	O
in	O
cancer	O
but	O
in	O
this	O
study	O
high	O
level	O
of	O
glucose	B
was	O
found	O
in	O
lung	O
cancer	O
samples	O
as	O
compare	O
to	O
controls.	O

The	O
5	O
mM	O
stock	O
solutions	O
of	O
unconjugated	O
BAs	O
in	O
methanol	B
were	O
pooled	O
and	O
diluted	O
to	O
final	O
concentrations	O
of	O
100	O
μM	O
each	O
with	O
methanol.	B

Serum	O
TNFα	O
was	O
negatively	O
associated	O
with	O
tryptophan	B
(P	O
<	O
0.001),	O
but	O
was	O
not	O
significantly	O
associated	O
with	O
any	O
of	O
its	O
kynurenine	B
metabolites.	O

Changes	O
in	O
L-octanoylcarnitine	B
positively	O
correlated	O
with	O
△	O
WHR,	O
△	O
total	O
cholesterol,	B
△	O
FFA,	O
△	O
L-leucine,	B
△	O
L-phenylalanine,	B
and	O
△	O
decanoylcarnitine	B
(r	O
=	O
0.815,	O
P	O
<0.001).	O

Thus	O
one	O
can	O
speculate	O
that	O
a	O
higher	O
DMA	B
levels	O
are	O
related	O
to	O
higher	O
fish	O
consumption	O
and	O
consequently	O
to	O
higher	O
iodine	O
intake	O
and	O
a	O
better	O
thyroid	O
function.	O

We	O
hypothesized	O
that	O
lower	O
concentrations	O
of	O
each	O
vitamin	B
D	I
metabolite	O
would	O
be	O
associated	O
with	O
increased	O
risk	O
of	O
CAC	O
and	O
greater	O
carotid	O
IMT.	O

Phosphoethanolamine,	B
which	O
appeared	O
to	O
be	O
the	O
key	O
metabolite	O
found	O
in	O
pituitary	O
tumor	O
tissue	O
vs.	O
non-tumoral	O
pituitaries,	O
is	O
a	O
precursor	O
of	O
phosphatidylcholine	B
and	O
phosphatidylethanolamine,	B
both	O
of	O
which	O
are	O
components	O
of	O
cell	O
membranes.	O

The	O
exclusion	O
criteria	O
were	O
prior	O
vitreous	O
surgery,	O
the	O
intravitreal	O
injection	O
of	O
triamcinolone	B
acetonide	O
(IVTA)	O
or	O
anti-vascular	O
endothelial	O
growth	O
factor	O
(VEGF),	O
and	O
the	O
presence	O
of	O
ocular	O
inflammation	O
or	O
vitreoretinal	O
and	O
optic	O
nerve	O
diseases.	O

On	O
the	O
contrary,	O
high	O
LysoPC(16:0)	B
levels	O
were	O
reported	O
to	O
be	O
an	O
ovarian	O
cancer	O
biomarker.	O

The	O
other	O
study	O
from	O
our	O
research	O
group	O
demonstrated	O
that	O
lower	O
L-tryptophan	B
and	O
higher	O
kynurenine	B
were	O
associated	O
with	O
recurrence	O
of	O
EOC.	O

Of	O
the	O
sixty-five	O
promising	O
biomarkers,	O
we	O
chose	O
top	O
three	O
metabolites,	O
xanthine,	B
hypoxanthine	B
and	O
D-mannose	B
for	O
further	O
validation,	O
according	O
to	O
their	O
statistical	O
significance	O
as	O
well	O
as	O
scientific	O
impact	O
from	O
previous	O
literature,	O
by	O
performing	O
standard	O
LC/MS-MS	O
assays.	O

It	O
is	O
apparent	O
that	O
changes	O
in	O
albumin,	O
total	O
cholesterol,	B
LDL,	O
grip	O
strength,	O
lysoPCs	O
(16:0,	O
17:0,	O
18:0,	O
18:1	O
(11Z),	O
18:3(9Z,	O
12Z,	O
15Z),	O
P-18:1	B
(9Z),	I
20:1	O
(11Z),	O
(20:3	O
(8Z,	O
11Z,	I
14Z)),	I
glycerophosphocholine,	B
ornithine,	B
glucuronic	B
acid,	I
glycerophosphoserine	B
and	O
taurocholic	B
acid	I
were	O
correlated	O
with	O
Child-Pugh	O
score,	O
suggesting	O
that	O
these	O
indexes	O
could	O
be	O
used	O
as	O
an	O
indicator	O
of	O
the	O
hepatic	O
compensatory	O
capacity.	O

In	O
the	O
30	O
smokers,	O
the	O
GM	O
concentrations	O
of	O
the	O
metabolites	O
from	O
naphthalene	B
and	O
MeNs	O
were	O
comparable,	O
at	O
33.7	O
and	O
33.4	O
ng/mL,	O
respectively.	O

These	O
findings	O
are	O
consistent	O
with	O
previous	O
observations	O
investigating	O
the	O
relationship	O
between	O
taurine	B
and	O
obesity.	O

However,	O
the	O
observation	O
that	O
the	O
decrease	O
in	O
NAAG	B
in	O
the	O
urine	O
of	O
cancer	O
patients	O
is	O
substantial,	O
suggests	O
that	O
the	O
concentration	O
of	O
NAAG	B
is	O
urine	O
may	O
be	O
used	O
as	O
an	O
indicator	O
of	O
RCC	O
size	O
or	O
activity.	O

As	O
DUP	O
was	O
one	O
of	O
the	O
most	O
promising	O
outcome	O
indicators	O
for	O
schizophrenia,	O
the	O
plasma	O
creatine	B
concentration	O
and	O
its	O
changes	O
in	O
schizophrenia	O
may	O
be	O
a	O
potential	O
biomarker	O
used	O
to	O
detect	O
clinical	O
stage	O
and	O
to	O
predict	O
symptomatic	O
outcome.	O

After	O
washed	O
with	O
TBST,	O
the	O
sections	O
were	O
incubated	O
with	O
liquid	O
DAB-chromogen	O
solution	O
for	O
10	O
min,	O
and	O
counterstained	O
in	O
hematoxylin	B
for	O
2	O
min.	O

Looking	O
at	O
urinary	O
androgen	O
metabolism,	O
excretion	O
of	O
the	O
11-oxygenated	O
androgen	O
metabolite	O
11β	B
-OH-An	I
was	O
significantly	O
higher	O
in	O
the	O
nonobese	O
PCOS	O
cohort	O
[595	O
(IQR,	O
438	O
to	O
841)	O
vs	O
353	O
(IQR,	O
171	O
to	O
487)	O
in	O
controls;	O
P	O
=	O
0.002],	O
whereas	O
there	O
was	O
only	O
a	O
trend	O
toward	O
significantly	O
higher	O
urinary	O
excretion	O
of	O
An	O
(P	O
=	O
0.07).	O

While	O
plasma	O
LDL-	O
and	O
HDL-cholesterol	B
and	O
triglyceride	B
levels	O
were	O
similar	O
in	O
all	O
probands,	O
significant	O
genotype	O
effects	O
were	O
detected	O
in	O
long-chain	O
lysoPCs	O
(C16:0,	O
C16:1,	B
C17:0)	B
and	O
long-chain	O
PC	O
species	O
(PCs	O
containing	O
C28-C44).	O

Tyrosine	B
is	O
also	O
linked	O
to	O
catecholamine	B
synthesis,	O
which,	O
also	O
speculatively,	O
might	O
be	O
relevant	O
to	O
our	O
findings.	O

In	O
contrast,	O
the	O
positive	O
association	O
of	O
TG	B
with	O
IS	O
was	O
limited	O
to	O
TG	B
in	O
VLDL.	O

Using	O
the	O
described	O
method,	O
mean	O
recoveries	O
for	O
the	O
five	O
lipid	O
families	O
were	O
all	O
above	O
80 %	O
(see	O
Table	O
S3	O
provided	O
as	O
supplementary	O
material):	O
i.e.,	O
88.2 %	O
for	O
fatty	O
acyls,	O
90.6 %	O
for	O
sphingolipids,	B
80.6 %	O
for	O
glycerophospholipids	B
and	O
88.7 %	O
for	O
glycerolipids.	B

All	O
of	O
these	O
outcomes	O
are	O
consistent	O
with	O
a	O
phenotype	O
of	O
overweight/obesity	O
and	O
T2D	O
or	O
high	O
risk	O
for	O
T2D.	O
Spearman	O
rank	O
correlations	O
(ρ)	O
revealed	O
inverse	O
correlations	O
between	O
the	O
glucose	B
infusion	O
rate	O
and	O
several	O
AA/AA	O
metabolites	O
at	O
baseline.	O

We	O
found	O
that	O
the	O
levels	O
of	O
glucose,	B
glycine,	B
3-hydroxybutyrate,	B
creatinine	B
and	O
glycoprotein	O
acetyls	O
(mostly	O
alpha-1-acid	B
glycoprotein,	I
AGP)	O
were	O
significantly	O
increased	O
in	O
sepsis	O
compared	O
to	O
healthy	O
sera,	O
whereas	O
citrate	B
and	O
histidine	B
were	O
significantly	O
decreased	O
in	O
sepsis	O
patients	O
compared	O
to	O
healthy	O
controls.	O

6-,	O
7-,	O
8-	O
and	O
10-OH-WAR,	B
non-racemic	O
diclofenac	O
sodium	O
(used	O
as	O
internal	O
standard	O
(I.S.)),	O
HPLC-grade	O
acetonitrile	B
(ACN),	O
methanol	B
(MeOH),	O
ethanol	B
(EtOH)	O
and	O
isopropanol	B
(IPA),	O
analytical-grade	O
ammonium	B
acetate	I
(as	O
7.5	O
M	O
NH_4	O
OAc	O
solution)	O
and	O
dipeptide	O
(L-leucylvalinate,	O
L,L-SULV)	O
were	O
all	O
purchased	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
MO,	O
USA).	O

Fu	O
et	O
al	O
.	O
have	O
reported	O
that	O
dietary	O
L-arginine	B
supplementation	O
markedly	O
reduced	O
white-fat	O
mass	O
in	O
Zucker	O
diabetic	O
fatty	O
rats.	O

A	O
recent	O
study	O
with	O
human	O
plasma	O
has	O
found	O
that	O
serum	O
SM	O
and	O
ceramides	B
varied	O
by	O
time	O
to	O
onset	O
of	O
memory	O
impairment,	O
i.e.,	O
the	O
levels	O
were	O
higher	O
pre-symptomatically	O
but	O
lower	O
at	O
the	O
time	O
of	O
impairment	O
but	O
also	O
that	O
higher	O
ceramide	B
levels	O
in	O
prodromal	O
AD	O
was	O
associated	O
with	O
greater	O
hippocampal	O
atrophy	O
.	O

Example	O
plots	O
of	O
lactate	B
(A)	O
and	O
isoleucine	B
(B),	O
with	O
corresponding	O
_1	O
H-NMR	O
regions,	O
phosphocholine	B
(PC)	O
46	O
carbons:	O
2	O
double	O
bonds	O
(46:2)	O
(C)	O
identified	O
in	O
negative	O
ion	O
mode	O
and	O
sphingomyelin	B
(SM)	O
34:1	O
(D)	O
identified	O
in	O
positive	O
mode.	O

Slightly	O
less	O
lysine-d_4	B
was	O
recovered	O
from	O
the	O
MTBE	B
aqueous	O
fraction,	O
and	O
trace	O
amounts	O
of	O
15:0	O
PC	O
was	O
detected	O
in	O
the	O
MTBE	B
aqueous	O
fraction,	O
while	O
most	O
of	O
it	O
was	O
extracted	O
into	O
the	O
lipid	O
fraction.	O

NMR	O
spectra	O
were	O
referencing	O
to	O
TSP	O
(trimethylsilylpropanoic	O
acid)	O
to	O
ensure	O
comparability	O
on	O
the	O
ppm-axis.	O

L-alanine	B
is	O
formed	O
and	O
then	O
transferred	O
from	O
muscle	O
to	O
the	O
liver	O
through	O
the	O
blood.	O

In	O
HD	O
patients,	O
we	O
observed	O
significant	O
alterations	O
in	O
plasma	O
levels	O
of	O
many	O
compounds,	O
including	O
serine,	B
aspartic	B
acid,	I
valine,	B
leucine,	B
lysine,	B
threonine,	B
tyrosine,	B
and	O
SDMA,	O
which	O
had	O
been	O
shown	O
to	O
differ	O
from	O
healthy	O
controls	O
(,,,,),	O
but	O
we	O
did	O
not	O
find	O
them	O
to	O
be	O
correlated	O
with	O
eGFR	O
in	O
the	O
nondialyzed	O
patients.	O

[,]	O
for	O
pooled	O
thiopurine	B
samples,	O
the	O
temperature	O
of	O
−20	O
°C	O
is	O
more	O
economical	O
and,	O
by	O
that,	O
eligible	O
for	O
routine	O
clinical	O
practice.	O

To	O
analyse	O
the	O
metabolic	O
alterations	O
mainly	O
related	O
to	O
decreased	O
testosterone,	B
we	O
performed	O
metabolomics	O
investigations	O
on	O
the	O
plasma	O
of	O
males	O
with	O
hypogonadism	O
who	O
showed	O
normal	O
insulin	O
levels.	O

Following	O
MALDI	O
MSI	O
analysis	O
the	O
matrix	O
was	O
removed	O
from	O
the	O
samples	O
and	O
the	O
tissue	O
sections	O
were	O
stained	O
with	O
H&E	O
(haematoxylin	O
&	O
eosin).	B

Two-way	O
ANOVA	O
uncorrected	O
Fisher’s	O
Least	O
Significant	O
Difference	O
(LSD)	O
test	O
in	O
mRNAs	O
for	O
pro-inflammatory	O
cytokines	O
(IL-1β,	O
IL-6,	O
TNF	B
-α),	I
and	O
for	O
anti-inflammatory	O
cytokines	O
(IL-4,	O
IL-10	O
and	O
TGF-β).	B

The	O
sample	O
residues	O
were	O
then	O
treated	O
with	O
50	O
µL	O
methoxylamine	B
for	O
a	O
2	O
h	O
incubation	O
at	O
60	O
°C,	O
followed	O
by	O
rapid	O
addition	O
of	O
100	O
µL	O
N-methyl-N-(trimethylsilyl)	B
trifluoroacetamide	I
(MSTFA)	O
with	O
1%	O
trichloromethylsiloxane	O
(TCMS),	O
for	O
a	O
1	O
h	O
incubation	O
at	O
60	O
°C.	O

A	O
total	O
of	O
13	O
fatty	O
acids	O
were	O
determined	O
in	O
plasma	O
by	O
GCMS	O
as	O
μmol/l	O
concentrations	O
derived	O
from	O
calibration	O
curves	O
using	O
heptadecanoic	B
acid	I
(FA(17:0))	O
as	O
an	O
internal	O
standard.	O

The	O
high	O
levels	O
of	O
ceramide	B
in	O
breast	O
cancer	O
tissue	O
were	O
significantly	O
associated	O
with	O
low	O
cell	O
proliferation	O
potency.	O

Samples	O
were	O
then	O
injected	O
in	O
a	O
splitless	O
mode	O
by	O
a	O
CTC	O
Combi	O
Pal	O
autosampler	O
(CTC	O
Analytics	O
AG,	O
Zwingen,	O
Switzerland)	O
into	O
an	O
Agilent	O
6890	O
gas	O
chromatograph	O
equipped	O
with	O
a	O
10	O
m	O
×	O
0.18	O
mm	O
(internal	O
diameter)	O
fused	O
silica	B
capillary	O
column	O
with	O
a	O
chemically	O
bonded	O
0.18-μm	O
DB	O
5-MS	O
stationary	O
phase	O
(J&W	O
Scientific,	O
Folsom,	O
Calif.,	O
USA).	O

[G]	O
Graph	O
showing	O
changes	O
in	O
breast	O
milk	O
succinate	B
and	O
[H]	O
lactate	B
of	O
HC	O
versus	O
IBD	O
mothers	O
are	O
PP3	O
and	O
PP6.	O

Additionally,	O
some	O
peaks	O
not	O
easily	O
observed	O
by	O
visual	O
inspection	O
of	O
the	O
mass	O
spectra,	O
such	O
as	O
PS(40:5),	B
m/z	O
836.2,	O
were	O
recognized	O
by	O
the	O
classifier.	O

The	O
three	O
alkylamine	B
additives	O
were	O
tested	O
using	O
UV–vis	O
(PDA)	O
detection	O
only,	O
due	O
to	O
concerns	O
regarding	O
ion	O
suppression	O
and	O
MS	O
source	O
contamination.	O

an	O
siRNA	O
specific	O
for	O
IE-2	O
(5′AAACGCAUCUCCGAGUUGGACTT3′),	O
or	O
the	O
Mission	O
siRNA	O
Universal	O
Negative	O
Control	O
#1	O
(Sigma-Aldrich)	O
by	O
using	O
Oligofectamine	B
(Invitrogen)	O
in	O
Optimem	O
(Gibco).	O

To	O
assess	O
the	O
reproducibility	O
of	O
the	O
method,	O
low,	O
normal,	O
and	O
high	O
amounts	O
of	O
the	O
conjugates	O
of	O
α-CEHC	B
and	O
α-TL	B
(0.1,	O
0.5,	O
and	O
2.5 nmol)	O
were	O
added	O
to	O
a	O
laboratory	O
control	O
urine.	O

Abbreviations	O
used	O
for	O
steroid	O
compounds:	O
17HP:	O
17-OH-pregnanolone,	B
PT:	O
Pregnanetriol,	B
5PT:	O
Pregnenetriol,	O
PTO:	O
Pregnanetriolone,	B
PD:	O
Pregnanediol,	B
DHEA:	O
Dehydroepiandrosterone,	B
16OHDHEA:	O
16α-OH-dehydroepiandrosterone,	B
Δ5-diol:	O
Androstenediol,	B
5α3αdiol:	B
Androstanediol,	B
AT:	O
Androsterone,	B
11βOHAT:	B
11β-OH-androsterone,	B
ET:	O

Further	O
studies	O
should	O
directly	O
investigate	O
the	O
effect	O
of	O
dual	O
ASA	O
and	O
statin	B
treatment	O
on	O
colon	O
tumorigenesis	O
in	O
humans.	O

shows	O
the	O
total	O
SM	O
levels,	O
which	O
unlike	O
Cer,	B
were	O
significantly	O
down	O
regulated	O
in	O
both	O
T1DM	O
(;	O
p<0.05)	O
and	O
T2DM	O
(;	O
p<0.05).	O

Multiple	O
groups	O
of	O
the	O
mobile	O
phase,	O
including	O
MeOH–water	O
and	O
can–water,	O
which	O
contain	O
different	O
pH	O
modifiers	O
(ammonium	O
acetate,	B
formic	B
acid,	I
and	O
ammonia),	O
were	O
tried	O
to	O
choose	O
the	O
optimal	O
mobile	O
phase	O
system.	O

Exclusion	O
criteria	O
were	O
type	O
1	O
diabetes,	O
uncorrected	O
thyroid	O
dysfunction,	O
significant	O
weight	O
gain	O
or	O
loss	O
(>5 %	O
of	O
total	O
body	O
weight	O
within	O
the	O
past	O
3 months),	O
therapy	O
with	O
insulin,	O
or	O
warfarin	O
or	O
fibrates	O
within	O
past	O
3 months	O
(statins	O
and	O
salicylic	B
acid	I
were	O
allowed;	O
51 %	O
of	O
patients	O
were	O
treated	O
with	O
either	O
simvastatin	B
or	O
atorvastatin),	O
tachycardia	O
(>100	O
beats/min;	O
or	O
use	O
of	O
stable	O
doses	O
of	O
antihypertensives	O
shorter	O
than	O
3 months	O
prior	O
the	O
screening	O
and	O
during	O
the	O
trial),	O
history	O
of	O
cardiovascular	O
disease	O
(myocardial	O
infarction	O
in	O
the	O
last	O
year,	O
coronary	O
revascularization	O
including	O
percutaneous	O
transluminal	O
coronary	O
angioplasty,	O
coronary	O
artery	O
bypass	O
graft	O
surgery	O
in	O
the	O
previous	O
year	O
and	O
no	O
subsequent	O
angina,	O
unstable	O
angina,	O
congestive	O
heart	O
failure),	O
pregnancy	O
or	O
lactation,	O
significant	O
renal	O
impairment	O
(serum	O
creatinine	B
>150 μmol/l),	O
chronic	O
or	O
advanced	O
hepato-biliary	O
diseases,	O
history	O
of	O
alcohol	O
or	O
substance	O
abuse	O
within	O
the	O
past	O
year,	O
allergy	O
to	O
any	O
of	O
the	O
capsule	O
excipients,	O
participation	O
in	O
any	O
other	O
clinical	O
trial	O
during	O
the	O
previous	O
3 months,	O
and	O
clinically	O
significant	O
anemia	O
(hemoglobin < 120 g/l	O
for	O
males	O
and < 110 g/l	O
for	O
females)	O
or	O
any	O
other	O
abnormal	O
hemoglobin	O
profile.	O

In	O
addition,	O
only	O
in	O
male	O
participants,	O
a	O
decreased	O
level	O
of	O
omega-3	B
fatty	O
acids	O
(β	O
−0.24;	O
95%	O
CI	O
−0.36,	O
−0.12;	O
adjusted	O
p	O
=	O
0.033)	O
was	O
associated	O
with	O
migraine.	O

In	O
BAL,	O
subject	O
level	O
clustering	O
based	O
on	O
K-means	O
of	O
Euclidian	O
distance	O
between	O
profiles	O
of	O
all	O
compounds	O
demonstrated	O
two	O
subject	O
groups,	O
one	O
with	O
relatively	O
decreased	O
lung	O
function	O
and	O
one	O
with	O
relatively	O
preserved	O
lung	O
function,	O
using	O
spirometry	B
as	O
a	O
surrogate	O
for	O
lung	O
function	O
(Figure	O
S4A).	O

Phosphatidylcholine	B
can	O
be	O
broken	O
down	O
via	O
phospholipase	O
A2,	O
and	O
lysophospholipase	O
to	O
glycerophosphocholine	B
and	O
then	O
via	O
glycerophosphocholine	O
phosphodiesterase	O
to	O
choline,	B
thus	O
restarting	O
the	O
cycle.	O

All	O
other	O
sulfide	B
species	O
in	O
the	O
analysis	O
had	O
statistically	O
similar	O
levels	O
in	O
the	O
aqueous	O
and	O
vitreous	O
humors	O
of	O
the	O
DM	O
and	O
control	O
eyes.	O

Silybin	O
ameliorates	O
the	O
harmful	O
BPA-induced	O
effect	O
decreasing	O
glucose	B
uptake	O
and	O
lipid	O
peroxidation.	O

Changes	O
in	O
serum	O
metabolites	O
and	O
FA	B
at	O
6 months	O
post‐RYGB	O
surgery	O
in	O
this	O
pilot	O
study	O
with	O
limited	O
number	O
of	O
participants	O
are	O
suggestive	O
of	O
metabolic	O
improvement;	O
larger	O
studies	O
are	O
warranted	O
for	O
confirmation.	O

Nonetheless,	O
risk	O
was	O
increased	O
at	O
high	O
catechol	B
concentrations	O
and	O
reduced	O
at	O
high	O
methylated	B
catechol	I
concentrations.	O

Finally,	O
the	O
slides	O
were	O
removed	O
from	O
the	O
autostainer,	O
counterstained	O
with	O
hematoxylin,	B
dehydrated,	O
cleared,	O
and	O
coverslipped.	O

In	O
the	O
case	O
of	O
AX,	O
covalent	O
modification	O
occurs	O
through	O
nucleophilic	O
attack	O
of	O
the	O
β-lactam	B
ring	O
and	O
adduction	O
by	O
the	O
ε-amino	B
group	O
of	O
Lys	O
in	O
proteins.	O

Concentrations	O
of	O
amino	O
acid	O
among	O
children	O
in	O
Group	O
A	O
Ala:	O
alanine;	B
Asp:	O
aspartic	B
acid;	I
Glu:	O
glutamic	B
acid;	I
Met:	O
methionine;	B
Phe:	O
phenylalanine;	B
Tyr:	O
tyrosine;	B
Leu:	O
leucine;	B
Trp:	O
tryptophane;	B
Val:	O
valine;	B
Arg:	O
argnine;	O
Cit:	O
citrulline;	B
Gly:	O
glycine;	B
Orn:	O
ornithine;	B
Gln:	O
glutamine;	B
His:	O
histidine;	B
Ser:	O
serine;	B
Thr:	O
threonine	B

For	O
example,	O
the	O
sulfonamide	B
adduct	O
formed	O
by	O
reaction	O
of	O
Cys34	O
of	O
Alb	O
with	O
the	O
N-oxidized	O
metabolite	O
of	O
2-amino-1-methyl-6-phenylimidazo[4,5-b	B
]pyridine	I
(PhIP),	O
a	O
carcinogen	O
formed	O
in	O
cooked	O
meat,	O
was	O
quantitatively	O
recovered	O
from	O
Alb	O
by	O
digestion	O
with	O
a	O
mixture	O
of	O
trypsin	O
and	O
chymotrypsin	O
without	O
prior	O
reduction	O
of	O
the	O
disulfide	B
bonds.	O

For	O
methoxyestrogens,	B
product	O
ions	O
of	O
m/z	O
280	O
and	O
250	O
were	O
observed,	O
again	O
without	O
mass	O
increments	O
in	O
the	O
labelled	O
species	O
and	O
thus	O
less	O
specific	O
for	O
analytes.	O

A	O
positive,	O
although	O
non-significant,	O
correlation	O
between	O
age	O
and	O
tryptophan	B
was	O
also	O
found	O
in	O
the	O
control	O
group	O
(r:	O
0.10).	O

(8000–15000	O
nmol/g	O
of	O
tissue)	O
as	O
compared	O
to	O
other	O
tissues	O
where	O
the	O
citrate	B
content	O
is	O
only	O
150–450	O
nmol/g.	O

The	O
relative	O
mRNA	O
level	O
of	O
major	O
genes	O
in	O
phosphatidylcholine	B
synthesis	O
and	O
metabolism	O
in	O
HepG2	O
and	O
HepG2.2.15	O
cells,	O
n = 3,	O
detailed	O
data	O
are	O
shown	O
in	O
Table _S4	O
.	O

Importantly,	O
urinary	O
PGE-M	O
levels	O
were	O
nearly	O
double	O
in	O
ever	O
(n	O
=	O
13)	O
versus	O
never	O
(n	O
=	O
16)	O
smokers	O
among	O
healthy	O
tumor-free	O
controls	O
(15.2	O
versus	O
7.8	O
ng/mg	O
creatinine,	B
P	O
=0.001;	O
).	O

For	O
the	O
triphosphate	B
nucleotides	O
(See	O
C–E	O
and	O
Table	O
S-1),	O
such	O
as	O
ATP,	B
UTP,	O
and	O
GTP,	O
no	O
detectable	O
concentration	O
was	O
left	O
after	O
heating	O
for	O
60	O
s,	O
which	O
was	O
followed	O
by	O
similar	O
degradation	O
of	O
their	O
diphosphate	B
metabolites.	O

The	O
PAH	O
group	O
had	O
higher	O
levels	O
of	O
several	O
pyridine	B
and	O
purine	B
nucleotides,	O
including	O
adenine,	B
xanthosine,	B
urate,	B
and	O
pseudouridine.	B

The	O
present	O
study	O
showed	O
that	O
the	O
cancer	O
group	O
has	O
elevated	O
levels	O
of	O
urinary	O
acetyl-CoA	B
and	O
carnitine,	B
and	O
several	O
acylcarnitines	B
were	O
found	O
to	O
contribute	O
to	O
the	O
differentiation	O
between	O
the	O
cancer	O
and	O
control	O
groups.	O

After	O
diluted	O
with	O
80	O
μL	O
of	O
water,	O
the	O
sample	O
was	O
extracted	O
with	O
500	O
μL	O
of	O
a	O
mixture	O
of	O
methanol	B
and	O
acetonitrile	B
(1:9,	O
v/v).	O

Among	O
lysophospholipids,	B
LPC	O
16:0	O
has	O
been	O
reported	O
as	O
a	O
potential	O
biomarker	O
not	O
only	O
for	O
OVC	O
but	O
also	O
for	O
other	O
types	O
of	O
cancer,	O
and	O
our	O
previous	O
and	O
present	O
studies	O
confirmed	O
its	O
potential	O
screening	O
power	O
for	O
OVC	O
(Figs.	O

TMAO	B
has	O
been	O
recently	O
proposed	O
as	O
a	O
novel	O
prognostic	O
marker	O
of	O
cardiovascular	O
events,	O
given	O
the	O
association	O
of	O
its	O
plasma	O
levels	O
with	O
indexes	O
of	O
atherosclerotic	O
plaque	O
vulnerability,	O
major	O
cardiac	O
events,	O
and	O
death.	O

This	O
panel	O
included	O
creatine,	B
creatinine,	B
carnitine	B
and	O
acetone,	B
that	O
mirror	O
an	O
alteration	O
of	O
energy	O
metabolism	O
and	O
cellular	O
growth	O
in	O
such	O
group	O
of	O
patients.	O

The	O
suppression	O
of	O
polar	O
analytes	O
in	O
RP	B
analysis	O
in	O
both	O
positive	O
and	O
negative	O
ESI	O
is	O
not	O
surprising	O
and	O
could	O
be	O
explained	O
by	O
the	O
co-elution	O
of	O
large	O
number	O
of	O
un-retained	O
metabolites.	O

Altered	O
levels	O
of	O
the	O
four	O
metabolites	O
identified	O
in	O
this	O
study,	O
threonine,	B
glutamine,	B
isoleucine	B
and	O
linolenic	B
acid	I
that	O
predict	O
response	O
to	O
neoadjuvant	O
chemotherapy	O
represent	O
changes	O
in	O
the	O
metabolic	O
activity	O
of	O
several	O
pathways.	O

Moreover,	O
we	O
cannot	O
rule	O
out	O
that	O
the	O
retinal	B
specificities	O
we	O
observed	O
in	O
the	O
GG	O
profile	O
are	O
not	O
age-related	O
since	O
our	O
samples	O
originated	O
from	O
elderly	O
deceased	O
donors	O
(mean	O
age	O
87.3	O
years	O
old).	O

Fucose	B
and	O
mannose	B
metabolism	O
are	O
affected	O
by	O
L-fucose	B
which	O
is	O
an	O
important	O
posttranslational	O
modification	O
in	O
cancer	O
and	O
inflammation.	O

Creatinine	B
normalization	O
leads	O
to	O
the	O
lowest	O
FPR	O
curve	O
among	O
all	O
normalization	O
methods,	O
indicating	O
its	O
superior	O
performance.	O

Although	O
3-oxo-5β-cholan-24-oic	B
acid	I
could	O
not	O
activate	O
LXRα,	O
7α,12α-dihydroxy-3-oxo-5β-cholan-24-oic	B
acid	I
was	O
found	O
to	O
be	O
an	O
LXR	O
ligand.	O

The	O
medication-free	O
MDD	O
patients	O
and	O
control	O
subjects	O
showed	O
significant	O
differences	O
in	O
their	O
mean	O
levels	O
of	O
33	O
metabolites,	O
including	O
kynurenine	B
(KYN),	O
glutamate	B
(Glu),	O
glutamine	B
(Gln),	O
methionine	B
sulfoxide,	I
and	O
methionine	B
(Met).	O

For	O
display	O
purposes,	O
the	O
amplitudes	O
of	O
the	O
choline	B
peak	O
at	O
3.23 ppm,	O
the	O
fatty	O
acids	O
peak	O
at	O
1.30 ppm,	O
and	O
the	O
lactate	B
peak	O
at	O
1.33 ppm	O
were	O
graphically	O
shortened.	O

Samples	O
were	O
dissolved	O
in	O
chloroform.	B

Our	O
data,	O
using	O
measurement	O
of	O
each	O
sphingolipid	B
substrate	O
and	O
enzyme	O
gene	O
expression	O
analysis,	O
demonstrated	O
that	O
all	O
three	O
ceramide-biosynthesis	B
pathways	O
are	O
activated	B
to	O
increase	O
ceramides	B
in	O
human	O
cancer.	O

In	O
the	O
absence	O
of	O
medium	O
chain	O
acyl-CoA	O
dehydroxygenase	O
(MCAD)	O
phenylpropionacid	B
is	O
converted	O
to	O
phenylpropionglycine	B
instead	O
of	O
benzoic	B
acid.	I

Body	O
mass	O
index,	O
serum	O
lipid	O
levels,	O
and	O
hematocrit	O
were	O
strong	O
phenotypic	O
correlates	O
of	O
interindividual	O
variation	O
in	O
multiple	O
sterols	O
and	O
vitamin	B
D	I
metabolites.	O

In	O
order	O
to	O
evaluate	O
the	O
combined	O
effect	O
of	O
these	O
NEFA,	O
PBMC	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
stearic	B
acid	I
(50	O
μM)	O
alone	O
or	O
in	O
combination	O
with	O
increasing	O
amounts	O
of	O
both	O
DHA	O
and	O
EPA	O
(25	O
or	O
50	O
μM	O
each).	O

A	O
competitive	O
enzyme-linked	O
immunoassay	O
was	O
used	O
to	O
measure	O
urinary	O
total	O
15-F2t	O
isoprostane	B
with	O
pretreatment	O
with	O
β-glucuronidase	O
as	O
per	O
the	O
manufacturer’s	O
protocol	O
(Cat#:	O
EA84,	O
Oxford	O
Biomedical	O
Research).	O

Leucine;	B
3.	O

Subsequently,	O
500 μl	O
of	O
chloroform	B
and	O
200 μl	O
of	O
Milli-Q	O
water	O
were	O
added	O
to	O
500 μl	O
of	O
the	O
homogenized	O
solution,	O
and	O
the	O
mixed	O
solution	O
was	O
centrifuged	O
at	O
4,600×g	O
for	O
15 min	O
at	O
4 °C.	O

104	O
cases	O
(77%)	O
had	O
raised	O
serum	O
testosterone,	B
including	O
all	O
those	O
women	O
who	O
did	O
not	O
report	O
being	O
affected	O
by	O
hirsutism.	O

Quantitative	O
estimation	O
of	O
glucose	B
uptake,	O
using	O
a	O
cell	O
based	O
assay	O
kit,	O
was	O
performed	O
as	O
per	O
instructions	O
provided	O
by	O
the	O
manufacturer	O
(Cayman,	O
USA).	O

They	O
included	O
19	O
phosphatidylcholines	B
(PCs),	O
8	O
sphingomyelins	B
(SMs),	O
4	O
lysophosphatidic	B
acids	I
(LPAs),	O
3	O
platelet-activating	O
factors	O
(PAFs),	O
3	O
lyso-PCs	O
(LPCs),	O
2	O
sphingosines	B
(Sos),	O
1	O
phytosphingosine	B
(phSM)	O
and	O
1	O
phosphatidylethanolamine	B
(PE).	O

Before	O
the	O
NMR	O
experiments,	O
serum	O
samples	O
were	O
defrosted	O
at	O
room	O
temperature	O
for	O
less	O
than	O
20	O
minutes	O
and	O
200	O
μL	O
aliquots	O
combined	O
with	O
300	O
μL	O
of	O
saline	B
(0.9%	O
NaCl	O
in	O
20%	O
D_2	O
O/80%	O
H_2	O
O)	O
were	O
centrifuged	O
at	O
12,000	O
×g	O
for	O
5	O
minutes.	O

Choline	B
in	O
the	O
brain	O
is	O
an	O
essential	O
component	O
in	O
cholesterol	B
and	O
other	O
lipids	O
metabolism.	O

Note	O
the	O
fragment	O
corresponding	O
to	O
9-HSA	O
as	O
a	O
carboxylate	B
ion	O
(m/z	O
299.3)	O
and	O
the	O
ion	O
resulting	O
from	O
the	O
neutral	O
loss	O
as	O
a	O
ketene	O
of	O
the	O
9-HSA	O
moiety	O
(m/z	O
466.3).	O

Mechanistically,	O
sphingosine	B
and	O
S1P	O
are	O
typically	O
considered	O
pro-inflammatory,	O
pro-mitogenic,	O
and/or	O
chemotaxic	O
lipids	O
that	O
may	O
facilitate	O
the	O
progression	O
of	O
pancreatic	O
cancer,	O
and	O
it	O
has	O
been	O
recognized	O
and	O
accepted	O
by	O
most	O
researchers	O
that	O
sphingosine	B
kinase	O
acts	O
like	O
an	O
oncogene	O
and	O
is	O
upregulated	O
in	O
many	O
human	O
cancers.	O

Keys:	O
1-MH:	O
1-methylhistidene;	B
3-HB:	O
3-hydroxybutyrate;	B
3-MH:	O
3-methylhistidene;	B
AA:	O
acetoacetate;	B
Ace:	O
acetate;	B
Ace:	O
acetone;	B
Ala:	O
alanine;	B
Asc:	O
ascorbate;	B
Cho:	O
choline;	B
Ci:	O
citrate;	B

Lower	O
plasma	O
1,25(OH)_2	B
D	O
was	O
associated	O
with	O
longer	O
duration	B
of	O
diabetes	O
and	O
white	O
race	O
(Supplementary	O
Table	O
2).	O

For	O
example,	O
estimated	O
VLDL4	O
contents	O
of	O
phospholipids	B
was	O
named	O
V4PL,	O
and	O
estimated	O
total	O
plasma	O
triglycerides	B
was	O
named	O
TPTG.	O

Key	O
inflammatory	O
markers	O
as	O
well	O
as	O
kynurenic	B
acid	I
(KYNA)	O
and	O
quinolinic	B
acid	I
(QUIN),	O
both	O
tryptophan	B
metabolites,	O
have	O
been	O
associated	O
with	O
depressive	O
symptoms	O
and	O
suicidality.	O

Urinary	O
glucocorticoid	B
excretion	O
appeared	O
to	O
gradually	O
increase	O
with	O
the	O
degree	O
of	O
androgen	O
excess,	O
with	O
significantly	O
higher	O
levels	O
in	O
the	O
HA/HT	O
group	O
than	O
in	O
controls.	O

Synthetic	O
opioids	O
analgesics,	O
such	O
as	O
methadone,	B
naloxone	B
or	O
fentanyl,	O
are	O
not	O
detected	O
at	O
all	O
by	O
the	O
regular	O
urine	O
opiate	O
immunoassays.	O

Dehydroepiandrosterone	B
(DHEA)	O
and	O
dehydroepiandrosterone	B
sulfate	I
(DHEA-S)	O
are	O
released	O
into	O
the	O
circulation	O
as	O
inactive	O
hormone	O
precursors	O
and	O
taken	O
up	O
by	O
specific	O
tissues,	O
such	O
as	O
breast,	O
for	O
the	O
local	O
conversion	O
into	O
androgen	O
and	O
estrogen	B
sex	O
steroids	O
where	O
they	O
have	O
a	O
proliferative	O
effect;	O
DHEA-S	B
was	O
non-significantly	O
reduced	O
in	O
our	O
study.	O

Similar	O
results	O
were	O
observed	O
for	O
GP,	B
the	O
m/z	O
1031.54773	O
were	O
overrepresented	O
in	O
the	O
control	O
and	O
the	O
m/z	O
882.39725	O
and	O
881.39308	O
in	O
the	O
CRC	O
group.	O

A	O
synthetic	O
standard	O
for	O
this	O
metabolite	O
was	O
generated	O
by	O
oxidizing	O
N	B
-acetyl-S	I
-[1-(5-hydroxy-5-carboxypentyl)-1H	I
-pyrrol-3-yl]-L-cysteine	I
sulfoxide	I
(10)	O
with	O
pyridinium	B
dichromate.	O

Furthermore,	O
DM	O
patients	O
had	O
increased	O
amounts	O
of	O
branched-chain	O
amino	O
acids	O
(valine	O
(p	O
 = 0.011),	O
leucine	B
(p	O
 = 0.093),	O
isoleucine	B
(p	O
 = 1.29E_−4	O
)	O
(h)),	O
a	O
subclass	O
of	O
amino	O
acids	O
associated	O
with	O
insulin	O
resistance,	O
while	O
glutamine	B
levels	O
were	O
lower	O
(p	O
 = 5.50E_−4	O
)	O

Precursor	O
ion	O
scanning	O
(ESI	O
conditions)	O
identified	O
that	O
this	O
metabolite	O
exhibited	O
309	O
amu	O
(with	O
[M-H]	O
_+	O
at	O
m/z	O
310)	O
in	O
the	O
anastrozole	B
microsomal	O
incubate	O
that	O
consisted	O
of	O
HLMs	O
and	O
cofactors	O
(but	O
not	O
in	O
negative	O
control	O
experiments)	O
in	O
addition	O
to	O
the	O
293	O
amu	O
(with	O
[M-H]	O
_+	O
at	O
m/z	O
294)	O
of	O
anastrozole	B
(data	O
not	O
shown).	O

Separation	O
of	O
mixed	O
standard	O
containing	O
25(OH)D_2	O
,	O
25(OH)D_3	O
,	O
and	O
3-epi-25(OH)D_3	B
with	O
the	O
PFPP	O
column	O
method	O
using	O
an	O
isocratic	O
mobile	O
phase	O
of	O
74%	O
methanol,	B
26%	O
water	O
(volume	O
fractions)	O
and	O
a	O
column	O
temperature	O
of	O
15	O
°C.	O

There	O
was	O
a	O
significant	O
reduction	O
in	O
endotoxin	B
levels	O
after	O
rifaximin	O
therapy	O
compared	O
to	O
baseline	O
(0.55±0.21	O
vs.	O
0.48±0.24	O

The	O
exception	O
was	O
picolinic	B
acid,	I
where	O
stability	O
was	O
90.74%	O
after	O
1	O
week	O
and	O
83.33%	O
after	O
2	O
weeks.	O

This	O
new	O
tandem	O
mass	O
spectrometry	O
(MS/MS)	O
method	O
can	O
be	O
simply	O
incorporated	O
into	O
liquid	O
chromatography	O
by	O
employing	O
ammonium	B
bicarbonate	O
in	O
the	O
mobile	O
phase	O
without	O
any	O
instrument	O
modification	O
needed.	O

32%	O
(74/229)	O
of	O
metabolites	O
mapped	O
to	O
biologically	O
relevant	O
pathways,	O
including	O
phenylalanine	B
and	O
tyrosine	B
metabolites	O
(metabolism	O
of	O
dopamine	B
and	O
other	O
monoamines),	O
tryptophan	B
metabolites	O
(serotonin	O
synthesis),	O
and	O
markers	O
of	O
mitochondrial	O
function	O
(acylcarnitines,	O
TCA	O
components,	O
branched	O
chain	O
amino	O
acid	O
metabolites	O
(BCAA))	O
and	O
oxidative	O
stress	O
(glutathione	O
and	O
purine	B
metabolites).	O

Additionally,	O
oxidized	O
LDL	O
was	O
positively	O
correlated	O
with	O
lysoPC	O
(16:0)	O
and	O
fatty	O
acid	O
amides,	O
including	O
palmitoleamide	B
and	O
palmitic	B
amide.	I

(B)	O
SM-OH	O
C24:1	B
plasma	O
levels	O
displayed	O
the	O
strongest	O
difference	O
between	O
the	O
genotype	O
groups	O
in	O
delta	O
t35	O
(p	O
=	O
8.3E-04)	O
and	O
delta	O
t240	O
(p	O
=	O
5.4E-04).	O

A	O
variety	O
of	O
factors	O
including	O
oxidative	O
stress,	O
endothelial	O
dysfunction,	O
vascular	O
tone,	O
salt	O
sensitivity,	O
the	O
sympathetic	O
nervous	O
system	O
(SNS)	O
involvement,	O
and	O
the	O
renin	O
angiotensin	B
aldosterone	I
system	O
(RAAS)	O
influence	O
systemic	O
arterial	O
blood	O
pressure.	O

Previous	O
studies	O
have	O
shown	O
that	O
a	O
combination	O
of	O
weight	O
loss	O
and	O
fish	O
oil	O
supplementation	O
reduce	O
cardiovascular	O
disease	O
and	O
diabetes	O
risks	O
by	O
increasing	O
adiponectin	O
and	O
reducing	O
triacylglyceride	B
concentrations,	O
while	O
weight	O
loss	O
alone	O
significantly	O
improves	O
insulin	O
sensitivity	O
and	O
reduces	O
inflammation.	O

The	O
levels	O
of	O
10-hydroxyldocosahexaenoic	B
acid	I
(HDoHE),	O
12-	B
hydroxyeicosapentaenoic	I
acid	I
(HEPE),	O
and	O
14-HDoHE	B
were	O
significantly	O
higher	O
in	O
female	O
urine.	O

It	O
is	O
important	O
to	O
note	O
that	O
taurine	B
is	O
an	O
intermediate	O
in	O
the	O
methylamine/homocysteine	O
pathway.	O

Metabolites	O
were	O
isolated	O
from	O
SRM	O
1950	O
(50	O
μL)	O
using	O
ice-cold	O
80%	O
MeOH	B
(200	O
μL,	O
500	O
μL,	O
1000	O
μL,	O
and	O
5000	O
μL),	O
while	O
accounting	O
for	O
the	O
water	O
fraction	O
in	O
plasma,	O
to	O
represent	O
the	O
total	O
volume	O
in	O
a	O
1:4,	O
1:10,	O
1:20,	O
and	O
1:100	O
(v/v)	O
respective	O
sample-to-total	O
solvent	O
ratio.	O

Spectral	O
regions	O
within	O
the	O
range	O
of	O
0.94	O
to	O
10	O
ppm	O
were	O
analyzed	O
after	O
excluding	O
the	O
sub-region	O
δ	O
4.55–6.05	O
ppm	O
to	O
remove	O
variability	O
arising	O
from	O
water	O
suppression	O
and	O
possible	O
cross-relaxation	O
effect	O
on	O
the	O
urea	B
signal	O
via	O
solvent	O
exchanging	O
protons.	O

Phthalic	B
acid	I
is	O
a	O
toxin	B
or	O
pollutant	O
found	O
in	O
blood	O
and	O
when	O
found	O
in	O
tissues	O
or	O
biofluids,	O
it	O
arises	O
from	O
exposure	O
to	O
phthalate	B
products.	O

Since	O
protein	O
and	O
peptide	O
standards	O
for	O
every	O
phosphate	B
containing	O
protein	O
and	O
peptide	O
in	O
CSF	O
are	O
not	O
available,	O
retention	O
time	O
matching	O
cannot	O
be	O
done	O
for	O
all	O
the	O
phosphorus	O
peaks	O
seen	O
in	O
the	O
chromatogram.	O

Despite	O
accumulating	O
evidence	O
supporting	O
the	O
importance	O
of	O
tryptophan	B
and	O
its	O
urinary	O
metabolites	O
in	O
bladder	O
carcinogenesis,	O
the	O
role	O
of	O
THP1,	O
a	O
key	O
enzyme	O
in	O
tryptophan	B
metabolism	O
that	O
catalyzes	O
the	O
conversion	O
of	O
tryptophan	B
to	O
serotonin	B
and	O
the	O
depletion	O
of	O
tryptophan,	B
in	O
BCA	O
has	O
not	O
been	O
investigated	O
to	O
date.	O

A	O
model	O
for	O
predicting	O
BAV	O
in	O
the	O
estimation	O
group	O
was	O
constructed	O
using	O
the	O
concentration	O
levels	O
of	O
monoglyceride	B
(MG)	O
(18:2)	O
and	O
glycerophospho-N-oleoyl	B
ethanolamine	I
(GNOE).	O

α-CEHC,	B
α-carboxyethylhydroxychroman,	B
α-TL,	B
α-tocopheronolactone,	B
α-TTP,	B
α-tocopherol	B
transport	O
protein,	O
ACN,	O
acetonitrile,	B
BMI,	O
body	O
mass	O
index,	O
GC–MS,	O
gas	O
chromatography–mass	O
spectrometry,	O
HbA1c,	O
glycosylated	O
hemoglobin,	O
LC–MS,	O
liquid	O
chromatography–mass	O
spectrometry,	O
MeOH,	B
methanol,	B
ODFR,	O
oxygen-derived	O
free	O
radical,	O
VLDL,	O
very	O
low	O
density	O
lipoprotein	O

On	O
the	O
one	O
hand,	O
the	O
same	O
attenuating	O
influences	O
of	O
both	O
types	O
of	O
thyroidectomy	O
were	O
found	O
on	O
lipid	O
and	O
glucose	B
levels;	O
however,	O
glucose	B
levels	O
were	O
always	O
significantly	O
higher	O
after	O
total	O
thyroidectomy	O
than	O
after	O
unilateral	O
thyroidectomy.	O

We	O
were	O
successful	O
in	O
changing	O
daily	O
sleep	O
duration	B
from	O
∼7h	O
to	O
∼5h	O
(which	O
approximates	O
the	O
epidemiologic	O
sleep	O
categories	O
with	O
low	O
vs.	O
high	O
metabolic	O
risk)	O
while	O
participants	O
maintained	O
comparable	O
levels	O
of	O
food	O
intake,	O
total	O
daily	O
activity,	O
and	O
body	O
weight	O
during	O
each	O
study	O
session.	O

The	O
relationships	O
between	O
(1)	O
overnight	O
urinary	O
aMT6s/Cr	O
and	O
(2)	O
total	O
urinary	O
overnight	O
8-oxodG	B
and	O
8-oxoGua	O
were	O
derived	O
using	O
regression	O
analyses,	O
with	O
age	O
and	O
BMI	O
(or	O
weight)	O
as	O
the	O
covariates.	O

For	O
example,	O
lipids,	O
which	O
serve	O
as	O
major	O
components	O
of	O
cellular	O
membranes	O
and	O
function	O
as	O
signaling	O
molecules,	O
have	O
chemical	O
properties	O
that	O
require	O
specialized	O
analysis	O
relative	O
to	O
other	O
hydrophilic	B
metabolites.	O

Go	O
to:	O
Estrogen	B
metabolites	O
are	O
important	O
biomarkers	O
to	O
evaluate	O
cancer	O
risks	O
and	O
metabolic	O
diseases.	O

Stearic	B
acid	I
was	O
associated	O
with	O
fasting	O
glucose	B
but	O
not	O
associated	O
with	O
fasting	O
insulin	O
or	O
HOMA-IR.	O

For	O
metabolites	O
not	O
associated	O
with	O
BMI,	O
only	O
a	O
few	O
could	O
potentially	O
have	O
reached	O
statistical	O
significance	O
in	O
fasting	O
only	O
samples	O
based	O
on	O
the	O
interactions	O
observed	O
(kynurenate,	O
gamma	O
glutamylvaline,	B
gamma	O
glutmylleucine,	B
urate,	B
1’arachidonoylglycerophosinositol,	B
dihomo-linoleate,	B
and	O
serine).	B

z	O
-score	O
(r	O
=	O
0.26;	O
P	O
<	O
0.050),	O
and	O
2-hour	O
glucose	B
(r	O
=	O
0.46;	O
P	O
=	O
0.0004),	O
and	O
was	O
significantly	O
different	O
between	O
groups	O
(P	O
=	O
0.04),	O
being	O
higher	O
in	O
the	O
first	O
than	O
in	O
the	O
third	O
WBISI	O
tertile	O

This	O
suggests	O
that	O
abnormalities	O
in	O
long-chain	O
acylcarnitines	B
reflect	O
a	O
common	O
signature	O
associated	O
with	O
myocardial	O
mitochondrial	O
dysfunction.	O

Thirty-nine	O
metabolites	O
including	O
glycolytic	B
and	O
TCA	O
cycle	O
intermediates,	O
amino	O
acids,	O
and	O
purine	O
nucleoside	O
phosphates,	O
were	O
absolutely	O
quantified	O
(Supplementary	O
Table	O
S2).	O

The	O
study	O
outcome	O
showed	O
that	O
RCE	O
did	O
not	O
modulate	O
estrogen	B
metabolism	O
in	O
“normal”	O
ER-	O
MCF-10A	O
cells	O
(A).	O

In	O
contrast,	O
the	O
other	O
18	O
carbon-containing	O
unsaturated	O
FAs	O
were	O
comprised	O
of	O
a	O
single	O
isomer	O
(i.e.	O
,	O
Δ_9	O
18:1	O
FA	O
and	O
Δ_9,12	B
18:2	I
FA)	I
in	O
both	O
non-esterified	O
FAs	O
and	O
those	O
esterified	O
in	O
TGs	O
in	O
human	O
serum.	O

In	O
line	O
with	O
the	O
NDMM	O
group,	O
all	O
three	O
BCAAs	O
as	O
well	O
as	O
ADMA	B
were	O
increased	O
in	O
the	O
control	O
samples,	O
whereas	O
a	O
higher	O
kynurenine/tryptophan	B
ratio	O
was	O
present	O
in	O
RRMM	O
patients,	O
pointing	O
towards	O
an	O
elevated	O
kynurenine	B
pathway	O
activation.	O

The	O
enhanced	O
rate	O
of	O
pyrimidine	B
synthesis	O
in	O
Rh30	O
cells	O
may	O
well	O
reflect	O
an	O
increased	O
Asp/malate	O
shuttle	O
activity.	O

Subsequent	O
studies	O
have	O
confirmed	O
that	O
anthocyanins	B
are	O
key	O
contributors	O
to	O
BRB's	O
chemopreventive	O
effects.	O

Plasma	O
tryptophan	B
concentrations	O
were	O
significantly	O
lower	O
in	O
CKD4–5	O
compared	O
with	O
CKD2–3	O
(P	O
<0.001).	O

For	O
a	O
given	O
data	O
point,	O
the	O
linear	O
model	O
can	O
be	O
formulated	O
as	O
where	O
X	O
_i	O
	O
represents	O
the	O
normalized	O
NMR	O
intensity,	O
Y	O
_i	O
	O
is	O
the	O
outcome	O
variable;	O
here	O
the	O
log_10	O
transformed	O
blood	O
glucose	B
concentration	O
and	O
ε_i	O
	O
is	O
the	O
error	O
term	O
for	O
an	O
observation	O
i	O
.	O

We	O
found	O
a	O
significant	O
interaction	O
between	O
obesity,	O
testosterone	B
and	O
dyslipidemia	O
in	O
women	O
with	O
PCOS,	O
which	O
indicates	O
that	O
the	O
syndrome	O
itself	O
is	O
an	O
important	O
player	O
in	O
the	O
lipoprotein	O
abnormalities	O
beyond	O
the	O
effects	O
of	O
obesity	O
per	O
se	O
.	O

Consequently,	O
the	O
purpose	O
of	O
the	O
BRB	O
rinse	O
studies	O
was	O
two-fold	O
i.e.	O
assess	O
human	O
oral	O
mucosal	O
anthocyanin	B
metabolism	O
and	O
determine	O
if	O
rinses	O
can	O
provide	O
sustainable	O
chemopreventive	O
levels	O
in	O
the	O
mouth.	O

The	O
majority	O
of	O
analytes	O
which	O
were	O
not	O
detected	O
under	O
these	O
conditions	O
were	O
organic	O
acids,	O
such	O
as	O
lactic	B
acid,	I
and	O
amino	O
acids	O
such,	O
as	O
histidine:	B
in	O
order	O
to	O
detect	O
these,	O
additional	O
optimisation	O
of	O
MS	O
source	O
or	O
solvent	O
conditions,	O
or	O
the	O
use	O
of	O
MRM	O
analyses,	O
may	O
be	O
required.	O

The	O
serum	O
levels	O
of	O
tamoxifen	B
and	O
its	O
metabolites,	O
estrogens,	O
FSH,	O
and	O
SHBG	O
are	O
given	O
as	O
median	O
values	O
and	O
inter-quartiles	O
ranges.	O

In	O
addition	O
to	O
24-hour	O
urine	O
steroid	O
profiling,	O
they	O
underwent	O
preoperative	O
assessment	O
for	O
glucocorticoid	B
excess	O
including	O
dexamethasone	B
(1	O
mg)	O
overnight	O
suppression	O
test,	O
late-night	O
salivary	O
cortisol,	B
and	O
morning	O
plasma	O
ACTH;	O
all	O
patients	O
underwent	O
a	O
postoperative	O
cosyntropin	O
test	O
(serum	O
cortisol	B
at	O
baseline	O
and	O
30	O
minutes	O
after	O
intravenous	O
injection	O
of	O
250	O
μg	O
ACTH_1–24	O
,	O
Synacthen)	O
10–14	O
days	O
after	O
unilateral	O
adrenalectomy.	O

Methionine	B
is	O
a	O
target	O
of	O
ROS	O
leading	O
to	O
the	O
production	O
of	O
methionine	B
sulfoxide.	I

HTAU	O
is	O
a	O
product	O
of	O
enzyme	O
cysteamine	O
dioxygenase	O
in	O
taurine	B
and	O
hypotaurine	B
metabolic	O
pathway.	O

A	O
likely	O
contributing	O
factor	O
to	O
the	O
performance	O
difference	O
found	O
between	O
healthy	O
and	O
sepsis	O
serum	O
was	O
the	O
duration	B
of	O
storage.	O

Ours	O
is	O
the	O
first	O
study	O
to	O
relate	O
circulating	O
levels	O
of	O
succinate	B
and	O
other	O
TCA	O
cycle	O
intermediates	O
to	O
PH,	O
which	O
raises	O
the	O
possibility	O
that	O
succinate	B
or	O
potentially	O
other	O
TCA-related	O
metabolites	O
could	O
modulate	O
vascular	O
tone	O
in	O
humans.	O

The	O
body	O
produces	O
lactate	B
in	O
throughout	O
the	O
day.	O

In	O
patients	O
from	O
Arm	O
2	O
of	O
the	O
trial,	O
goserelin	O
acetate	B
and	O
dutasteride	O
significantly	O
reduced	O
the	O
mean	O
amount	O
of	O
serum	O
T,	O
DHT	O
and	O
A,	O
but	O
again,	O
a	O
modest	O
increase	O
in	O
was	O
observed	O
in	O
DHEA	O
and	O
Δ_4	O
-AD	O
(	O
and	O
).	O

The	O
total	O
amount	O
of	O
work	O
in	O
Joules	O
performed	O
was	O
quite	O
similar	O
between	O
the	O
two	O
exercise	O
sessions	O
(HIIT:	O
250.2	O
±	O
31.3	O
J;	O
ET:	O
250.9	O
±	O
48.5	O
J)	O
as	O
was	O
the	O
total	O
exercise	O
volume	O
per	O
program	O
calculated	O
as	O
[intensity	O
(%	O
heart	O
rate	O
reserve)	O
x	O
duration	B
(minutes	O
per	O
session)	O
x	O
frequency	O
(sessions	O
per	O
week)	O

In	O
this	O
study,	O
we	O
included	O
the	O
712	O
participants	O
for	O
whom	O
both	O
24,25(OH)_2	B
D_3	O
and	O
its	O
interfering	O
analyte(s)	O
were	O
measured	O
at	O
baseline,	O
as	O
described	O
below.	O

Vitamin	O
B-12	O
and	O
folate	B
status	O
and	O
peripheral	O
nerve	O
conduction	O
were	O
assessed	O
and	O
included	O
in	O
complementary	O
analyses	O
in	O
a	O
correlation	O
analysis.	O

Excluding	O
criteria	O
included	O
unexplained	O
weight	O
change	O
during	O
the	O
past	O
3	O
months,	O
the	O
existence	O
of	O
a	O
previous	O
diagnose	O
of	O
chronic	O
respiratory	O
disease	O
and	O
severe	O
systemic	O
disease	O
such	O
as	O
lung	O
cancer,	O
bronchiectasis,	O
heart	O
disease,	O
hypertension,	O
diabetes	O
or	O
psychiatric	O
disorders;	O
medication	O
use	O
that	O
may	O
alter	O
systemic	O
inflammation	O
and	O
metabolism	O
(e.g.,	O
hormonal	O
contraceptives	O
or	O
statins);	O
pregnant	O
women;	O
contraindication	O
to	O
spirometry	B
or	O
inability	O
to	O
complete	O
study	O
procedures.	O

Retinoid	B
are	O
physiological	O
regulators	O
of	O
embryonic	O
development,	O
vision,	O
reproduction,	O
bone	O
formation,	O
hematopoiesis,	O
differentiation,	O
proliferation	O
and	O
apoptosis.	O

The	O
peaks	O
observed	O
at	O
m/z	O
225.1	O
and	O
230.1,	O
respectively,	O
in	O
the	O
spectra	O
of	O
desamino-PhIP-K	B
and	O
desamino-[_2	B
H_5	I
]-PhIP-K	I
are	O
attributed	O
to	O
protonated	O
PhIP	O
and	O
[_2	O
H_5	O
]-PhIP,	O
which	O
were	O
produced	O
by	O
cleavage	O
of	O
the	O
bond	O
between	O
the	O
ε-carbon	B
and	O
the	O
side	O
chain	O
amine	O
group	O
of	O
Lys.	O

Protein	O
precipitation	O
was	O
conducted	O
by	O
adding	O
500	O
μl	O
aliquots	O
of	O
ice	O
cold	O
methanol	B
to	O
100	O
μl	O
aliquots	O
of	O
plasma	O
samples.	O

Patients	O
with	O
lung	O
metastases	O
who	O
had	O
not	O
taken	O
NSAIDs,	O
prototypic	O
inhibitors	O
of	O
COX	O
activity,	O
in	O
the	O
seven	O
days	O
before	O
urine	O
collection	O
had	O
the	O
highest	O
PGE-M	O
levels	O
(median	O
7.4	O
ng/mg	O
creatinine;	B
range	O
1.8–43.4).	O

LPCa	O
C18:1,	B
LPCa	O
C20:4,	B
LPCa	O
C22:6	B
and	O
SMa	O
C41:0	B
shared	O
different	O
associations	O
depending	O
on	O
the	O
sex	O
category	O
for	O
HDL	O
and	O
WC.	O

Standards	O
of	O
vitamin	B
D	I
metabolites	O
were	O
purchased	O
from	O
Fluka,	O
Sigma–Aldrich	O
(St.	O
Louis,	O
MO,	O
USA)	O
and	O
BIOMOL	O
(Plymouth	O
Meeting,	O
PA,	O
USA)	O
as	O
indicated	O
below.	O

Method-specific	O
results	O
(ng/g)	O
for	O
measurement	O
of	O
25-hydroxyvitamin	B
D3	I
in	O
SRM	O
972.	O

Indeed,	O
the	O
overexpression	O
of	O
the	O
Hsa21	O
gene	O
NRIP1	O
(21q11.2–21q21.1)	O
is	O
known	O
to	O
impair	O
the	O
activity	O
of	O
the	O
transcriptional	O
coactivator	O
PPARGC1A	O
causing	O
mitochondrial	O
dysfunction	O
reverted	O
by	O
the	O
PPARGC1A	O
expression	O
inducer	O
drug	O
metformin.	B

There	O
was	O
also	O
evidence	O
for	O
a	O
trihydroxy-3-oxocholest-4-en-26-oic	B
acid	I
with	O
the	O
appropriate	O
mass	O
and	O
appearing	O
very	O
early	O
in	O
the	O
chromatogram,	O
but	O
its	O
level	O
was	O
too	O
low	O
(<0.01	O
ng/ml)	O
to	O
allow	O
the	O
recording	O
of	O
a	O
structurally	O
informative	O
MS_3	O
spectrum.	O

In	O
the	O
actinomycete	O
Frankia	O
,	O
the	O
hopanoids	B
in	O
diazovesicle	B
membranes	O
probably	O
restrict	O
the	O
entry	O
of	O
oxygen	O
by	O
building	O
the	O
lipid	O
bilayer	O
tighter	O
and	O
more	O
compact	O
(Berry	O
et	O
al.,	O
).	O

These	O
associations	O
remained	O
significant	O
for	O
all	O
tested	O
metabolites	O
except	O
lactate,	B
upon	O
adjusting	O
for	O
the	O
established	O
prognostic	O
parameters	O
in	O
HF,	O
namely	O
age,	O
sex,	O
BMI,	O
T2DM,	O
NT-proBNP,	O
GFR,	O
MAP,	O
and	O
LDL	B
cholesterol.	I

Rank	O
correlations	O
between	O
metabolites	O
and	O
progesterone	B
levels	O
were	O
performed	O
by	O
a	O
Spearman	O
non-parametric	O
correlation	O
test,	O
using	O
MedCalc	O
7.6	O
(MedCalc	O
software,	O
Demo	O
Version,	O

Those	O
observations	O
suggest	O
a	O
race-dependent	O
disparity	O
in	O
tocopherol	B
isomers.	I

Intra-	O
and	O
inter-day	O
accuracy	O
and	O
precision	O
for	O
abiraterone	B
and	O
its	O
metabolites	O
in	O
LLOQ	O
and	O
QC	O
samples.	O

Characteristic	O
MS/MS	O
spectra	O
of	O
m/z	O
302.3042	O
in	O
a	O
biological	O
sample	O
(C)	O
and	O
sphinganine	B
standard	O
at	O
10.13 min,	O
and	O
fragment	O
interpretation	O
(D).	O

Assies	O
et	O
al	O
recently	O
proposed	O
that	O
the	O
complex	O
relationship	O
between	O
FA	B
and	O
the	O
folate	B
cycle	O
in	O
CVD	O
and	O
psychiatric	O
disease	O
could	O
be	O
described	O
as	O
oxidative	O
stress	O
leading	O
to	O
the	O
one-carbon	O
cycle	O
spending	O
proportionally	O
more	O
time	O
on	O
transsulfation	O
compared	O
to	O
methylation.	O

Modified	O
porcine	B
trypsin	O
(sequencing	O
grade)	O
was	O
from	O
Promega	O
(Madison,	O
WI).	O

Since	O
the	O
imidazole	B
is	O
smaller	O
than	O
the	O
dansyl	O
moiety	O
and	O
less	O
lipophilic,	O
all	O
compounds	O
eluted	O
between	O
5	O
and	O
14	O
min	O
and	O
the	O
total	O
run	O
time	O
was	O
shorter	O
(20	O
min)	O
than	O
that	O
of	O
the	O
DS	O
derivatives	O
(35	O
min)	O
and	O
requires	O
less	O
organic	O
solvent	O
(underivatized	O
Prog	O
RT	O
=	O
9	O
min,	O
2nd	O
peak	O
in	O
DS;	O
and	O
RT	O
=	O
13	O
min,	O
last	O
peak	O
in	O
IS).	O

Leucine	B
is	O
negatively	O
correlated	O
with	O
valine	B
but	O
positively	O
correlated	O
with	O
threonine.	B

Acetonitrile	B
was	O
purchased	O
from	O
Honeywell	O
Burdick	O
&	O
Jackson	O
(Morristown,	O
NJ)	O
and	O
formic	B
acid	I
was	O
obtained	O
from	O
Fluka	O
(St.	O
Louis,	O
MO).	O

Sarcosine	B
is	O
converted	O
to	O
Glycine	B
with	O
the	O
help	O
of	O
folate,	B
which	O
is	O
deficient	O
in	O
HIV/AIDS	O
patients	O
.	O

As	O
D	O
illustrates,	O
these	O
general	O
findings	O
are	O
also	O
valid	O
in	O
the	O
case	O
of	O
individual	O
columns,	O
with	O
some	O
exceptions:	O
the	O
use	O
of	O
isopentylamine	B
as	O
an	O
additive	O
resulted	O
in	O
the	O
narrowest	O
peaks	O
for	O
the	O
BEH	O
2-EP	O
column,	O
while	O
it	O
was	O
water	O
rather	O
than	O
the	O
alkylamines	B
that	O
provided	O
the	O
greatest	O
decrease	O
in	O
peak	O
widths	O
for	O
the	O
BEH	O
Amide	B
column	O
(7.1 s	O
for	O
water	O
vs.	O
20.7	O
for	O
isopentylamine).	O

In	O
this	O
study,	O
we	O
now	O
validate	O
our	O
findings	O
in	O
an	O
independent	O
cohort	O
of	O
ambulatory	O
patients	O
with	O
chronic	O
systolic	O
HF,	O
with	O
the	O
added	O
insights	O
into	O
the	O
relationship	O
between	O
all	O
three	O
phosphatidylcholine	B
metabolites,	O
TMAO,	B
choline	B
and	O
betaine,	B
with	O
both	O
echocardiographic	O
determinants,	O
as	O
well	O
as	O
renal	O
and	O
inflammatory	O
biomarker	O
associations.	O

An	O
ultra-pure	O
primary	O
quantitative	O
standard,	O
tris(hydroxymethyl)aminomethane,	B
(99.9%)	O
was	O
obtained	O
from	O
Mallinckrodt	O
Baker	O
Inc.	O
Phillipsburg,	O
NJ.	O

Stock	O
solutions	O
(4.0	O
mg	O
mL_−1	O
)	O
of	O
the	O
analytes	O
and	O
internal	O
standards	O
(	O
and	O
)	O
were	O
prepared	O
by	O
dissolving	O
in	O
0.1	O
M	O
HCl,	O
H_2	O
O,	O
H_2	O
O:MeOH	O
(90:10,	I
v	I
/v	I
)	I
or	O
in	O
MeOH	B
and	O
further	O
diluting	O
them	O
with	O
0.6	O
M	O
carbonate	B
buffer	O
(pH	O
8.9)	O
and	O
1	O
M	O
NaOH	O
(3:1,	O
v	O
/v	O
)	O
(in	O
order	O
to	O
subsequently	O
neutralize	O
and	O
adjust	O
the	O
pH)	O
to	O
the	O
following	O
concentration	O
levels:	O
2.5,	O
5.0,	O
7.5,	O
10.0,	O
25,	O
50,	O
75,	O
100,	O
250,	O
500,	O
750,	O
1000,	O
2500,	O
5000,	O
7500,	O
10,000,	O
25,000,	O
50,000,	O
and	O
75,000	O
ng	O
mL_−1	O
.	O

Levels	O
of	O
mannose	B
in	O
controls,	O
early-stage	O
and	O
late-stage	O
EAC	O
cases.	O

CYP3A4	O
and	O
CYP3A5	O
catalyzed	O
anastrozole	B
(20	O
µm)	O
hydroxylation	O
at	O
the	O
highest	O
rate	O
(0.0023	O
pmol	O
min_−1	O
pmol_−1	O
P450	O
and	O
0.0026	O
pmol	O
min_−1	O
pmol_−1	O
P450,	O
respectively).	O

However,	O
there	O
was	O
lower	O
variance	O
with	O
MeOH	B
ppt	O
+UF	O
(CoV:	O
6.3	O
±	O
1.6%)	O
compared	O
to	O
MeOH:CHCl_3	B
:water	O
ext	O
+UF	O
(CoV:	O
9.5	O
±	O
1.7%,	O
p	O
=	O
0.02).	O

Here,	O
we	O
developed	O
a	O
strategy	O
by	O
combining	O
stable	O
isotope	O
labeling	O
(IL)	O
with	O
liquid	O
chromatography-mass	O
spectrometry	O
(LC-MS)	O
under	O
double	O
precursor	O
ion	O
scan	O
(DPI)	O
and	O
MRM	O
for	O
analysis	O
of	O
thiols	B
in	O
5	O
types	O
of	O
human	O
cancer	O
urine.	O

Physicochemical	O
characteristics	O
of	O
the	O
compounds	O
DHPM1–DHPM8	O
Notes:	O
Abbreviation:	O
DHPM,	O
dihydropyrimidine.	B

This	O
is	O
consistent	O
with	O
the	O
condensation	O
of	O
glucose-derived	O
_13	O
C_2	O
–acetyl	O
CoA	O
with	O
unlabeled	O
OAA,	O
which	O
subsequently	O
leads	O
to	O
the	O
production	O
of	O
_13	O
C-4,5-Glu	B
in	O
the	O
first	O
turn	O
of	O
the	O
Krebs	O
cycle.	O

Serum	O
samples	O
were	O
spiked	O
with	O
a	O
standard	O
solution	O
of	O
glutamine	B
or	O
pyroglutamic	B
acid	I
and	O
used	O
for	O
NMR	O
analysis	O
either	O
with	O
proteins	O
intact,	O
or	O
after	O
protein	O
removal	O
by	O
precipitation	O
or	O
ultrafiltration.	O

Previous	O
studies	O
have	O
provided	O
evidence	O
that	O
glycerophospholipid	B
metabolism	O
is	O
altered	O
in	O
patients	O
with	O
kidney	O
disease.	O

Furthermore,	O
sarcosine	B
levels	O
in	O
the	O
urine	O
also	O
followed	O
the	O
same	O
trend	O
as	O
that	O
observed	O
in	O
tissue	O
biopsies.	O

The	O
amino	O
acids	O
glutamate	O
and	O
glutamine	B
showed	O
good	O
or	O
excellent	O
positive	O
correlations	O
in	O
glioblastomas,	O
meningiomas	O
and	O
metastases	O
(	O
and	O
).	O

The	O
relative	O
content	O
of	O
N-formylkynurenine	B
showed	O
a	O
1.67-fold	O
increase	O
compared	O
to	O
the	O
healthy	O
control	O
group	O
and	O
showed	O
a	O
2.07-fold	O
increase	O
compared	O
to	O
the	O
benign	O
control	O
group.	O

Most	O
cancer	O
cells	O
produce	O
energy	O
by	O
glycolysis	O
rather	O
than	O
oxidative	O
phosphorylation	O
via	O
the	O
tricarboxylic	B
acid	I
(TCA)	O
cycle,	O
termed	O
as	O
Warburg	O
effect.	O

Tyrosine	B
is	O
a	O
precursor	O
of	O
the	O
catecholamine	B
of	O
the	O
brain.	O

Acetonitrile	B
and	O
acetone	B
with	O
at	O
least	O
three	O
of	O
the	O
five	O
evaluated	O
metabolites	O
present,	O
show	O
both	O
strong	O
variations	O
with	O
relative	O
standard	O
deviations	O
of	O
up	O
to	O
44%	O
for	O
MeCN	O
and	O
27%	O
for	O
acetone.	B

In	O
men,	O
there	O
was	O
a	O
significant	O
trend	O
of	O
increased	O
risk	O
of	O
hyperplastic	O
polyps	O
with	O
increasing	O
dietary	O
intake	O
of	O
α-linolenic	B
acid	I
(P	O
-trend	O
=	O
0.03).	O

Some	O
of	O
the	O
ones	O
that	O
could	O
be	O
annotated	O
or	O
were	O
derived	O
from	O
targeted	O
analyses	O
have	O
been	O
described	O
before	O
to	O
differ	O
between	O
men	O
and	O
women,	O
such	O
as	O
creatinine	B
[,	O
,	O
,	O
,	O
],	O
which	O
is	O
higher	O
in	O
men	O
and	O
known	O
to	O
be	O
determined	O
by	O
muscle	O
mass,	O
or	O
citrate	B
[,	O
,	O
,	O
,	O
,	O
],	O
which	O
is	O
higher	O
in	O
women.	O

For	O
individual	O
patients,	O
the	O
ratio	O
of	O
S1P	O
to	O
ceramide	B
showed	O
a	O
trend	O
toward	O
a	O
positive	O
association	O
(R_2	O
=0.07)	O
with	O
levels	O
of	O
nuclear	O
grade	O
(p=0.18)	O
(Figure	O
).	O

LC-MS	O
measurement	O
of	O
18	O
amino	O
acids	O
in	O
porcine	B
cerebrospinal	O
fluid,	O
stored	O
at	O
RT	O
for	O
up	O
to	O
2	O
h,	O
showed	O
increased	O
concentrations	O
in	O
ten	O
amino	O
acids	O
(alanine,	O
asparagine,	B
glycine,	B
glutamate,	B
histidine,	B
isoleucine,	B
phenylalanine,	B
serine,	B
threonine,	B
tyrosine),	B
which	O
is	O
in	O
line	O
with	O
our	O
observations,	O
except	O
that	O
glycine	B
concentration	O
is	O
stable	O
in	O
our	O
experiments	O
.	O

BCAAs	O
contribute	O
to	O
glucose	O
recycling	O
via	O
the	O
glucose-alanine	B
cycle	O
.	O

Formic	B
acid	I
was	O
obtained	O
from	O
Sigma-Aldrich	O
(Zwijndrecht,	O
The	O
Netherlands).	O

These	O
results	O
suggested	O
us	O
to	O
consider	O
the	O
possibility	O
of	O
giving	O
creatine	B
as	O
supplement	O
in	O
the	O
management	O
of	O
APS	O
women.	O

A	O
higher	O
11β-hydroxysteroid	B
dehydrogenase	I
(11β-HSD)	I
type	O
2	O
and	O
a	O
lower	O
11β-HSD	B
type	O
1	O
activity	O
was	O
found	O
for	O
PCOS	O
for	O
some	O
calculated	O
ratios,	O
whereas	O
other	O
ratios	O
indicated	O
no	O
difference.	O

Glycated	O
albumin	O
is	O
a	O
non-traditional	O
glycemic	B
marker	O
shown	O
to	O
be	O
more	O
useful	O
than	O
hemoglobin	O
A1C	O
for	O
monitoring	O
blood	O
glucose	B
control	O
in	O
patients	O
with	O
poorly-controlled	O
type	O
2	O
diabetes;	O
being	O
similar	O
to	O
hemoglobin	O
A1C	O
but	O
integrates	O
over	O
a	O
shorter	O
period	O
of	O
time	O
(14	O
days	O
vs.	O
90	O
days).	O

Finally,	O
∑ps=1∑qj=1ρsj(yj)xs	B
gives	O
the	O
conditional	O
dependencies	O
between	O
a	O
continuous	O
variable	O
x	O
_s	O
	O
and	O
a	O
discrete	O
variable	O
y	O
_j	O
,	O
represented	O
by	O
a	O
vector	O
of	O
size	O
L	O
_j	O
.	O

We	O
also	O
repeated	O
the	O
multiple	O
regression	O
calculation	O
with	O
inclusion	O
of	O
NNAL,	O
as	O
this	O
nitrosamine,	B
although	O
not	O
statistically	O
significant,	O
was	O
approximately	O
two	O
times	O
higher	O
in	O
smokers	O
with	O
HNSCC.	O

Although	O
2HG	O
shares	O
the	O
same	O
AMNPQ	O
spin	O
system	O
as	O
glutamate	B
(Glu),	O
its	O
2-hydroxyl	O
(2-OH)	O
is	O
more	O
electron-withdrawing	O
than	O
Glu’s	O
2-amino	B
(2-NH_2	O
)	O
substituent,	O
causing	O
the	O
α-proton	O
to	O
resonate	O
further	O
downfield	O
at	O
4.05	O
ppm	O
(parts	O
per	O
million)	O
as	O
a	O
doublet	O
of	O
doublets.	O

It	O
has	O
been	O
reported	O
that	O
simvastatin	B
treatment	O
increases	O
the	O
capacity	O
of	O
LDL	O
particles	O
to	O
transport	O
lipid	O
soluble	O
antioxidants	O
and	O
oxygenated	O
and	O
hydrocarbon	B
carotenoids	I
,	O
suggesting	O
that	O
the	O
statin-induced	O
reductions	O
in	O
total	O
plasma	O
levels	O
of	O
tocopherol	B
which	O
we	O
observed	O
are	O
accompanied	O
by	O
increased	O
tocopherol	B
content	O
of	O
LDL	O
particles,	O
and	O
hence	O
the	O
net	O
result	O
may	O
contribute	O
to	O
greater	O
resistance	O
of	O
these	O
particles	O
to	O
oxidative	O
stress,	O
and	O
hence	O
to	O
reduced	O
atherogenic	O
potential.	O

Using	O
_1	O
H	O
NMR,	O
several	O
metabolites	O
were	O
identified	O
allowing	O
a	O
clear	O
discrimination	O
between	O
IUGR	O
and	O
AGA	O
samples,	O
consisting	O
in	O
important	O
increases	O
in	O
lipids,	O
acetoacetate	B
and	O
decreased	O
glucose	B
levels.	O

We	O
studied	O
the	O
Women’s	O
Health	O
Study	O
(WHS),	O
a	O
completed	O
double	O
blinded,	O
placebo-controlled	O
trial	O
of	O
low	O
dose	O
aspirin	B
and	O
vitamin	B
E	I
on	O
the	O
prevention	O
of	O
primary	O
cardiovascular	O
events	O
and	O
cancer	O
in	O
apparently	O
healthy	O
female	O
healthcare	O
professionals	O
45	O
years	O
and	O
older.	O

In	O
addition,	O
we	O
used	O
Spearman’s	O
correlation	O
analysis	O
to	O
investigate	O
the	O
correlation	O
between	O
serum	O
levels	O
of	O
tryptophan	B
and	O
kynurenines	O
and	O
ADHD	O
symptom	O
scores.	O

(b)	O
Typical	O
_1	O
H	O
NMR	O
LED	O
spectra	O
of	O
plasma	O
samples	O
from	O
FD	B
patients	O
and	O
controls.	O

Mannose	B
is	O
a	O
C-2	O
epimer	O
of	O
glucose	B
and	O
blood	O
mannose	B
levels	O
correlate	O
highly	O
with	O
those	O
of	O
glucose	B
(;),	O
but	O
are	O
less	O
sensitive	O
to	O
food	O
intake	O
and	O
are	O
more	O
tightly	O
linked	O
with	O
diabetes.	O

Finally,	O
considering	O
the	O
use	O
of	O
disease-modifying	O
drugs,	O
among	O
all	O
metabolites	O
identified	O
in	O
both	O
cohorts,	O
LysoPC	O
(20:0/0:0)	O
and	O
LysoPC	O
(22:5/0:0)	O
were	O
associated	O
with	O
relapse-free	O
status	O
and	O
glutamic	B
acid	I
was	O
associated	O
with	O
increase	O
in	O
EDSS	O
in	O
patients	O
treated	O
with	O
interferon-β	O
(table	O
e-3).	O

Serum	O
glucose	B
was	O
analysed	O
using	O
glucosehexokinase	O
3	O
kit	O
(Siemens	O
Health	O
Care	O
Diagnostics,	O
Germany)	O
and	O
insulin	O
was	O
determined	O
with	O
immunoradiometric	O
assays	O
(Immunotech,	O
France).	O

The	O
developed	O
CE-MS/MS	O
method,	O
due	O
to	O
its	O
reliability,	O
short	O
analysis	O
time,	O
production	O
of	O
complex	O
clinical	O
profiles,	O
and	O
favorable	O
performance	O
parameters,	O
evaluated	O
according	O
to	O
FDA	O
guidelines	O
for	O
bioanalytical	O
method	O
validation,	O
is	O
proposed	O
for	O
routine	O
clinical	O
laboratories	O
to	O
optimize	O
thiopurine	B
therapy,	O
estimate	O
enzymatic	O
activity,	O
and	O
control	O
patient	O
compliance	O
with	O
medication	O
and	O
co-medication.	O

Liver	O
biopsy	O
specimens	O
were	O
fixed	O
in	O
neutral	O
buffered	O
formalin	B
and	O
embedded	O
in	O
paraffin.	B

Chen	O
et	O
al.	O
found	O
that	O
valine	B
content	O
in	O
colorectal	O
cancer	O
patients	O
was	O
higher	O
than	O
in	O
normal	O
people	O
and	O
they	O
pointed	O
out	O
that	O
the	O
increased	O
valine	B
content	O
was	O
probably	O
induced	O
by	O
the	O
increased	O
glycolysis.	O

b,	O
Assessment	O
of	O
sarcosine	B
levels	O
and	O
cell	O
invasiveness	O
after	O
knockdown	O
of	O
GNMT	O
in	O
DU145	O
cells	O
by	O
RNA	O
interference.	O

The	O
only	O
metabolite	O
present	O
in	O
all	O
solvents	O
was	O
hippurate,	B
while	O
creatinine	B
and	O
lactate	B
were	O
found	O
in	O
all	O
solvents	O
but	O
chloroform	B
and	O
dichloromethane.	B

Citrate	B
is	O
a	O
key	O
intermediate	O
of	O
the	O
TCA	O
cycle	O
and	O
has	O
been	O
closely	O
related	O
to	O
an	O
increase	O
in	O
fatty	O
acid	O
β-oxidation	O
to	O
support	O
cancer	O
cell	O
proliferation.	O

Etiocholanolone,	B
THA:	O
11-dehydro-TH-corticosterone,	B
THB:	B

Hierarchical	O
clustering	O
analysis	O
of	O
C18:2	B
CE	O
and	O
SM	O
22:0	O
in	O
all	O
samples	O
in	O
the	O
training	O
and	O
validation	O
cohorts.	O

The	O
multivariable-adjusted	O
OR	O
for	O
GDM	O
per	O
SD	O
increment	O
of	O
ln-transformed	O
plasma	O
TMAO	B
was	O
1.22	O
(95%	O
CI:	O
1.05,	O
1.41).	O

1-_13	O
C-glycolate	B
was	O
infused	O
for	O
6	O
h	O
and	O
_13	O
C_2	B
-oxalate	I
for	O
10	O
h.	O

5-Hydroxy-imidacloprid	B
(IM-1)	O
was	O
found	O
in	O
Cases	O
#2	O
and	O
#3,	O
4,5-dihydroxy-imidacloprid	O
(IM-3)	O
in	O
the	O
all	O
three	O
cases,	O
and	O
4,5-dehydro-imidacloprid	B
(IM-7)	O
in	O
Case	O
#1.	O

All	O
the	O
samples	O
involved	O
in	O
the	O
experiment,	O
including	O
human	O
PCa	O
and	O
BPH	O
specimens,	O
nude	O
mice	O
xenograft	O
tissues	O
were	O
cut	O
into	O
paraffin	B
sections.	O

We	O
also	O
evaluated	O
the	O
possible	O
relationship	O
between	O
24S-OH-Chol	B
and	O
other	O
available	O
variables.	O

Adenosine	B
monophosphate	I
(AMP)	O
can	O
be	O
produced	O
from	O
adenosine,	B
adenosine	B
diphosphate	I
(ADP)	O
or	O
adenosine	B
triphosphate	I
(ATP).	O

In	O
addition,	O
Cala	O
et	O
al.	O
established	O
that	O
the	O
urinary	O
and	O
lipid	O
profiles	O
of	O
Hispanic	O
women	O
also	O
identified	O
some	O
of	O
the	O
same	O
metabolites	O
of	O
this	O
study,	O
namely	O
amino	O
acids	O
(valine,	O
alanine,	B
glycine,	B
threonine),	B
their	O
levels	O
being	O
decreased	O
in	O
BC	O
patients	O
when	O
compared	O
to	O
controls.	O

Therefore	O
a	O
50	O
μL	O
aliquot	O
was	O
taken	O
from	O
the	O
solution	O
after	O
precipitation	O
and	O
100	O
μL	O
of	O
lithium	B
citrate	I
buffer	O
were	O
added.	O

There	O
was	O
a	O
rapid	O
rise	O
in	O
the	O
level	O
of	O
all	O
signals	O
associated	O
with	O
proline	B
betaine	I
and	O
hydroxy-proline	B
betaine	I
as	O
early	O
as	O
2 h	O
after	O
consumption	O
of	O
the	O
standardized	O
breakfast	O
(Fig. ).	O

The	O
urine	O
networks	O
only	O
share	O
two	O
nodes,	O
glucose	B
and	O
threonic	B
acid.	I

2.32 mg	O
Fdb	O
and	O
1.84 mg	O
5-ClU	O
were	O
individually	O
dissolved	O
in	O
2 mL	O
methanol,	B
and	O
finally	O
combined	O
IS	O
solution	O
was	O
freshly	O
prepared	O
in	O
the	O
extraction	O
solvent	O
at	O
a	O
concentration	O
of	O
30 ng/mL	O
for	O
both	O
Fdb	O
and	O
5-ClU	O
before	O
use.	O

A	O
permanent	O
positive	O
charge	O
is	O
then	O
appended	O
by	O
subsequent	O
quaternarization	O
of	O
the	O
piperazine	B
amino	I
group	O
using	O
methyl	B
iodide.	I

Furthermore,	O
the	O
two	O
metabolites	O
[LysoPC(16:0),	O
LysoPC(20:4)]	B
shown	O
to	O
discriminate	O
these	O
diseases	O
are	O
potentially	O
useful	O
when	O
combined	O
with	O
other,	O
previously	O
identified	O
protein	O
or	O
metabolic	O
biomarkers	O
for	O
predictive,	O
preventive	O
and	O
personalized	O
medical	O
approach.	O

The	O
regions	O
corresponding	O
to	O
the	O
spectrum	O
signal	O
of	O
residual	O
water,	O
complexes	O
and	O
ethanol	B
(3.69–3.58,	O
3.30–3.05,	O
2.73–2.50	O
and	O
1.22–1.16	O
ppm)	O
were	O
excluded.	O

A	O
linear	O
range	O
covering	O
most	O
of	O
the	O
tested	O
samples	O
was	O
demonstrated	O
up	O
to	O
120 mg	O
dw/mL	O
and	O
90 mg	O
dw/mL	O
for	O
DG	O
and	O
TG,	B
respectively.	O

The	O
predictive	O
capacities	O
of	O
GNOE,	O
MG	B
(18:2),	I
PE	B
(18:2)	I
and	O
ZS	O
model	O
were	O
assessed	O
by	O
ROC	O
curve	O
analysis	O
and	O
compared	O
to	O
each	O
other.	O

Our	O
results	O
with	O
regard	O
to	O
other	O
(urinary)	O
metabolites	O
partly	O
corroborate	O
previous	O
findings	O
by	O
Messana	O
et	O
al.	O
,	O
who	O
also	O
reported	O
citrate	B
and	O
hippurate	B
to	O
be	O
elevated	O
in	O
urine	O
of	O
T2DM	O
patients	O
vs.	O
healthy	O
controls	O
using	O
NMR	O
spectroscopy.	O

Summary	O
of	O
arsenic	O
species	O
in	O
saliva	O
samples	O
collected	O
from	O
APL	O
patients	O
ND	O
not	O
detectable,	O
DMA	B
_V	O
	O
dimethylarsinic	B
acid,	I
MMA	O
_V	O
	O
monomethylarsonic	B
acid,	I
MMA	O
_III	O
	O
monomethylarsonous	B
acid,	I
MMMTA	O
_V	O
	O
monomethylmonothioarsonic	B
acid	I
Summary	O
of	O
arsenic	O
species	O
in	O
saliva	O
samples	O
from	O
individual	O
APL	O
patients	O
ND	O
not	O
detectable,	O
SD	O
standard	O
deviation,	O
n	O
number	O
of	O
samples	O
in	O
which	O
MMA_III	O
and	O
MMMTA_V	O

Previous	O
studies	O
postulated	O
that	O
urine	O
phenyl	B
acetate	I
may	O
be	O
a	O
biomarker	O
for	O
depression.38	O
The	O
demand	O
for	O
nutrients	O
leads	O
to	O
the	O
depletion	O
of	O
phenyl	B
acetate	I
in	O
cancer,	O
and	O
cancer	O
cachexia	O
results	O
in	O
the	O
accumulation	O
of	O
urine	O
phenyl	B
acetate.	I

In	O
addition,	O
a	O
subset	O
of	O
patients	O
were	O
also	O
subjected	O
to	O
chemotherapy	O
with	O
the	O
following	O
distribution:	O
AC	O
(Adriamycin+	O
Cyclophosphamide	I
(AC)	O
(Sigma,	O
St	O
Louis,	O
MO,	O
USA))	O

Our	O
current	O
study	O
detected	O
several	O
considerably	O
increased	O
polyphenol-derived	O
benzoate	O
metabolites	O
in	O
post-BRB	O
urine	O
specimens,	O
such	O
as	O
3-hydroxyhippurate	B
(36.59	O
fold),	O
2,4,6-trihydroxybenzoate	B
(21.27	O
fold)	O
and	O
catechol	B
sulfate	I
(5.97	O
fold).	O

Then,	O
trimethylsilylation	O
was	O
performed	O
for	O
another	O
1	O
h	O
at	O
70°C	O
through	O
adding	O
80	O
μL	O
of	O
N,O-bis(trimethylsilyl)	B
trifluoroacetamide	I
plus	O
1%	O
trimethylchlorosilane	B
to	O
the	O
samples.	O

Conditions:	O
buffer	O
25	O
mM	O
NH_4	O
OAc/25	O
mM	O
poly-L,L-SULV	O
containing	O
15%	O
(v/v)	O
MeOH	B
at	O
pH	O
5.0.	O

Of	O
interest	O
they	O
identified	O
increases	O
in	O
a	O
number	O
of	O
lysophosphatidylcholine	B
lipid	O
species	O
(specifically	O
LPC	O
10:0	O
and	O
LPC	B
20:0)	I
with	O
ART	O
initiation	O
which	O
was	O
also	O
seen	O
in	O
all	O
arms	O
of	O
our	O
study,	O
with	O
no	O
difference	O
across	O
arms,	O
suggesting	O
that	O
these	O
changes	O
are	O
not	O
specific	O
to	O
an	O
ARV	O
class	O
and	O
thus	O
may	O
be	O
secondary	O
to	O
changes	O
in	O
HIV	O
driven	O
inflammation	O
and	O
innate	O
immune	O
function.	O

24	O
individuals	O
(16	O
normoglycemic	B
and	O
8	O
diabetic)	O
chose	O
AGB	O
and	O
67	O
individuals	O
(28	O
normoglycemic	B
and	O
39	O
diabetic)	O
chose	O
RYGB.	O

Total	O
cholesterol	B
(TC),	O
HDL	B
cholesterol	I
(HDL),	O
LDL	B
cholesterol	I
(LDL),	O
apolipoprotein	O
A1	O
(Apo	O
A1)	O
and	O
B	O
(Apo	O
B)	O
triglycerides	B
(TG),	O
CRP,	O
glucose	B
(GLU)	O
and	O
insulin	O
(Ins)	O
were	O
measured	O
at	O
Clinic	O
Casa	O
di	O
Cura	O
Eremo	O
Laboratory	O
(Arco,	O
TN,	O
Italy),	O
using	O
ILab	O
650	O
chemistry	O
analyser	O
(Instrumentation	O
Laboratories	O
UK	O
Ltd,	O
Warrington,	O
United	O
Kingdom)	O
for	O
all	O
measures	O
except	O
insulin	O
which	O
was	O
measured	O
using	O
a	O
Roche	O
COBAS	O
6000.	O

Briefly,	O
plasma	O
samples	O
were	O
spiked	O
with	O
a	O
cocktail	O
of	O
heavy-isotope	O
internal	O
standards	O
(Cambridge	O
Isotope	O
Laboratories,	O
MA,	O
USA;	O
C-D-N,	O
Isotopes,	O
Canada)	O
and	O
deproteinated	O
with	O
methanol.	B

We	O
further	O
identified	O
several	O
metabolites	O
that	O
changed	O
from	O
baseline	O
levels	O
within	O
exercise	O
groups	O
at	O
the	O
Bonferroni-adjusted	O
level	O
of	O
significance	O
Products	O
of	O
adenine	B
nucleotide	O
metabolism	O
(cyclic	O
AMP,	I
inosine,	B
xanthine,	B
and	O
xanthosine);	B
lipolysis	O
(glycerol);	O
the	O
nucleotide	O
sugar,	O
UDP-GlcNac;	B
and	O
non-polar	O
amino	O
acids	O
and	O
intermediates	O
(alanine	O
and	O
homogentisic	O
acid)	O
decreased,	O
whereas	O
serine	B
and	O
acetoacetic	B
acid,	I
a	O
fatty-acid	O
intermediate,	O
both	O
increased	O
in	O
HALI.	O

Interestingly,	O
in	O
the	O
first	O
set,	O
reduced	O
betaine	B
was	O
associated	O
with	O
severe	O
positive	O
symptoms.	O

In	O
the	O
current	O
study,	O
the	O
higher	O
levels	O
of	O
cystathionine,	B
cysteine,	B
hypotaurine,	B
and	O
taurine	B
detected	O
in	O
the	O
CRC	O
tissue	O
samples	O
might	O
indicate	O
that	O
a	O
beneficial	O
microenvironment	O
(for	O
CRC),	O
involving	O
vasodilation	O
and	O
angiogenesis,	O
was	O
induced	O
in	O
the	O
CRC	O
via	O
H_2	O
S	O
and	O
that	O
antioxidant	O
activity	O
was	O
induced	O
via	O
SAA[].	O

Increased	O
peroxisomal	O
activity	O
along	O
with	O
increased	O
availability	O
of	O
substrate	O
(acetyl-CoA	O
produced	O
during	O
peroxisomal	O
β-oxidation)	O
will	O
drive	O
PlsEtn	O
synthesis,	O
elevating	O
their	O
levels.	O

A	O
previous	O
study	O
by	O
our	O
group	O
demonstrated	O
decreased	O
plasma	O
TMAO	B
was	O
associated	O
with	O
UC.	O

The	O
ability	O
of	O
different	O
expressed	O
human	O
CYP	O
enzymes	O
(CYP1A2,	O
2A6,	O
2B6,	O
2C8,	O
2C9,	O
2C19,	O
2D6,	O
2E1,	O
3A4,	O
or	O
3A5)	O
to	O
catalyze	O
anastrozole	O
hydroxylation	O
was	O
tested	O
by	O
incubating	O
anastrozole	B
(20	O
µm)	O
with	O
13	O
pmol	O
P450	O
and	O
a	O
NADPH-generating	O
system	O
(same	O
composition	O
as	O
above)	O
at	O
37°C	O
for	O
30	O
min.	O

The	O
molecule	O
observed	O
at	O
m/z	O
241.0118	O
was	O
assigned	O
as	O
inositol	B
cyclic	I
phosphate	I
using	O
the	O
Human	O
Metabolome	O
Database	O
with	O
an	O
error	O
of	O
0.32 ppm	O
and	O
matching	O
the	O
isotope	O
pattern	O
(Supplementary	O
Figure 3).	O

The	O
amount	O
of	O
glutamate	B
and	O
glutamine	B
were	O
calculated	O
by	O
measuring	O
the	O
peak	O
area	O
of	O
the	O
native	O
glutamate	B
(m	O
/z	O
=	O
432)	O
and	O
glutamine	B
(m	O
/z	O
=	O
431)	O
to	O
that	O
corresponding	O
to	O
spiked	O
isotope-labeled	O
glutamate	B
(m	O
/z	O
=	O
437)	O
and	O
glutamine	B
(m	O
/z	O
=	O
436),	O
respectively.	O

Briefly,	O
after	O
enzymatic	O
(β	O
-glucuronidase)	O
hydrolysis	O
of	O
urine	O
samples,	O
phthalate	B
metabolites	O
were	O
extracted	O
with	O
a	O
solvent	O
mixture	O
(hexane,	O
acetone)	O
by	O
sonication.	O

Autotaxin	B
(a	O
secreted	O
lysophospholipase	O
D)	O
was	O
reported	O
to	O
enhance	O
tumor	O
cell	O
motility,	O
survival	O
and	O
proliferation.	O

However,	O
patients	O
who	O
went	O
on	O
to	O
develop	O
AP	B
had	O
a	O
higher	O
incidence	O
of	O
multiple	O
diagnoses	O
indicated	O
than	O
those	O
who	O
did	O
not	O
develop	O
AP.	B

We	O
observed	O
no	O
significant	O
change	O
in	O
HOMA-IR	O
(P	O
0.93),	O
neither	O
in	O
levels	O
of	O
insulin	O
(P	O
0.87),	O
nor	O
in	O
those	O
of	O
glucose	B
(P	O
0.73).	O

Additionally,	O
plasma	O
levels	O
of	O
tricarboxylic	B
acid	I
(TCA)	O
cycle	O
metabolites	O
(TCA-Ms)	O
were	O
closely	O
associated	O
with	O
hemodynamic	O
indexes	O
of	O
RV-PV	O
dysfunction.	O

Furthermore,	O
we	O
also	O
measured	O
the	O
levels	O
of	O
the	O
substrates	O
produced	O
during	O
PC	O
synthesis	O
(choline,	O
phosphocholine,	B
CDP-choline	B
and	O
GPC)	O
in	O
both	O
HepG2	O
and	O
HepG2.2.15	O
cells.	O

Pinpointing	O
the	O
identity	O
of	O
PC	B
37:5	I
and	O
PC	B
O-38:5	I
in	O
human	O
plasma.	O

Copper,	O
then,	O
may	O
have	O
duo	O
impact	O
on	O
the	O
TCA	O
cycle	O
through	O
oxidative	O
stress	O
affecting	O
both	O
α-ketoglutarate	O
dehydrogenase	O
and	O
glutamic	B
acid.	I

Other	O
metabolites	O
such	O
as	O
succinate	B
and	O
fumarate,	B
which	O
accumulate	O
in	O
specific	O
tumor	O
types,	O
may	O
similarly	O
prove	O
to	O
be	O
valuable	O
metabolite	O
markers	O
for	O
guiding	O
surgery	O
with	O
MS	O
approaches.	O

All	O
sequences	O
identified	O
as	O
chloroplast	B
were	O
removed;	O
(vi)	O
sequences	O
were	O
screened	O
(optimize = minlength-end,	O
criteria = 95)	O
and	O
filtered	O
(vertical = T,	O
trump = .)	O

As	O
shown	O
in	O
Table 	O
and	O
Fig.	O
,	O
sphinganine	B
(AUC	O
0.821,	O
p	O
 < 0.001)	O
exhibited	O
a	O
better	O
performance	O
than	O
CURB-65	O
score	O
(AUC	O
0.764)	O
to	O
predict	O
the	O
severity	O
of	O
CAP,	O
with	O
a	O
sensitivity	O
of	O
73.7%	O
and	O
specificity	O
of	O
84.4%.	O

Follow-up	O
and	O
mean	O
change	O
from	O
baseline	O
comparisons	O
in	O
2-OHE_1	O
and	O
2-OHE_1	O
/16α-OHE_1	B
were	O
additionally	O
adjusted	O
for	O
baseline	O
values.	O

These	O
findings	O
agreed	O
with	O
the	O
statistical	O
differences	O
in	O
concentrations	O
between	O
the	O
cystathionine	B
groups	O
observed	O
in	O
the	O
targeted	O
metabolite	O
profile	O
analysis.	O

Hopanoids	B
are	O
bacterial	O
pentacyclic	B
triterpenoids	I
that	O
are	O
analogous	O
to	O
eukaryotic	O
steroids	O
structurally	O
and	O
biosynthetically	O
(Ourisson	O
et	O
al.,	O
;	O

Receiver-operating	O
characteristic	O
analysis	O
confirmed	O
these	O
associations	O
(Table	O
IV	O
in	O
the	O
online-only	B
Data	O
Supplement)	O
and	O
identified	O
prognostic	O
cut-offs	O
(Figure	O
).	O

Carry-over	O
was	O
reduced	O
to	O
acceptable	O
limits	O
(all	O
below	O
20%	O
of	O
the	O
area	O
of	O
the	O
LLOQ)	O
by	O
incorporating	O
a	O
third	O
mobile	O
phase	O
C	O
into	O
the	O
gradient	O
consisting	O
of	O
1%	O
formic	B
acid	I
in	O
ACN.	O

In	O
this	O
way,	O
hippurate	B
may	O
be	O
seen	O
as	O
a	O
surrogate	O
marker	O
of	O
hepatic	O
function.	O

Among	O
the	O
most	O
important	O
metabolites	O
discriminating	O
A	O
and	O
C1	O
(but	O
not	O
A	O
and	O
C2)	O
were	O
acetate,	B
glutamate,	B
succinate,	B
creatinine	B
and	O
betaine	B
(higher	O
in	O
A),	O
and	O
glutamine,	B
lactate	B
and	O
hypoxanthine	B
(higher	O
in	O
C1).	O

As	O
a	O
result,	O
E_2	O
was	O
predominately	O
metabolized	O
by	O
P450	O
1B1	O
to	O
potentially	O
genotoxic	O
catechols	B
in	O
MCF-7	O
cells	O
under	O
these	O
conditions.	O

Components	O
were:	O
1,	O
L1;	O
2,	O
L2;	O
3,	O
isoleucine;	B
4,	O
leucine,	B
isoleucine;	B
5,	O
leucine;	B
6,	O
valine;	B
7,	O
L3;	O
8,	O
lactate;	B
9,	O
alanine;	B
10,	O
L4;	O
11,	O
arginine;	B
12,	O
lysine;	B
13,	O
acetate;	B
14,	O
L5;	O
15,	O
acetylglycoproteins;	B
16,	O
methionine;	B
17,	O
glutamate;	B
18,	O
glutamine;	B
19,	O
L6;	B
20,	I
3-hydroxybutyrate;	I
21,	O
pyruvate;	B
22,	O
pyroglutamate;	B
23,	O
citrate;	B
24,	O
L7;	O
25,	O
aspartate;	B
26,	O
albumin;	O
27,	O
creatine;	B
28,	O
creatinine;	B
29,	O
ornithine,	B
tyrosine;	B
30,	O
ornithine;	B
31,	O
phenylalanine;	B
32,	O
tyrosine;	B
33,	O
choline;	B
34,	O
beta-glucose;	B
35,	O
proline;	B
36,	O
alpha-glucose,	B
beta-glucose;	B
37,	O
alpha-glucose;	B
38,	O
glycine;	B
39,	O
glycerol;	B
40,	O
mannose;	B
41,	O
glyceryl	O
groups	O
of	O
lipids;	O
42,	O
APAP	O
glucuronide;	B
43,	O
L8;	O
44,	O
uridine;	B
45,	B
1-methylhistidine;	I
46,	O
histidine;	B
47,	B
3-methylhistidine;	I
48,	O
formate.	B

Patients	O
with	O
free	O
sialic	B
acid	I
storage	O
disease	O
(Salla	O
disease),	O
another	O
recognized	O
lysosomal	O
storage	O
defect,	O
also	O
exhibit	O
increased	O
CSF	O
levels	O
of	O
NAAG	B
and	O
N-acetylneuraminic	B
acid.	I

 	O
together	O
with	O
main	O
PK	O
parameters;	O
the	O
data	O
were	O
obtained	O
analyzing	O
nondigested	O
samples	O
(evaluation	O
of	O
free	O
diosmetin),	O
following	O
glucuronidase	O
digestion	O
(diosmetin	O
glucuronides	O
levels),	O
sulfatase	O
digestion	O
(diosmetin	O
sulfate	I
levels),	O
and	O
combined	O
sulfatase	O
with	O
glucuronidase	O
digestion	O
(total	O
conjugated	O
diosmetin).	O

Within	O
aldehydes,	O
tridecanal	B
showed	O
the	O
highest	O
level	O
in	O
the	O
fecal	O
samples	O
of	O
HC.	O

The	O
strongest	O
associations	O
with	O
respect	O
to	O
amino	O
acids	O
were	O
demonstrated	O
for	O
plasma	O
levels	O
of	O
glutamine	B
(negatively)	O
and	O
pipecolate	B
(positively)	O
(Fig.	O

Takeda	O
et	O
al.	O
measured	O
the	O
gender-specific	O
differences	O
in	O
salivary	O
metabolites	O
and	O
found	O
that	O
formate,	B
lactate,	B
propionate	B
and	O
taurine	B
were	O
significantly	O
higher	O
in	O
males.	O

The	O
PMC	O
matrix	O
was	O
freshly	O
prepared	O
by	O
mixing	O
200	O
μL	O
of	O
PBS	O
(100	O
mM)	O
and	O
500	O
μL	O
of	O
cold	O
methanol	B
containing	O
20	O
mg/mL	O
BHT/EDTA	O
in	O
an	O
ice	O
bath.	O

We	O
hypothesized	O
that	O
low	O
concentrations	O
of	O
each	O
of	O
these	O
metabolites,	O
reflecting	O
decreased	O
vitamin	B
D	I
intake,	O
activity,	O
and	O
turnover,	O
respectively,	O
would	O
be	O
associated	O
with	O
increased	O
risk	O
of	O
subclinical	O
cardiovascular	O
disease,	O
manifest	O
as	O
a	O
greater	O
prevalence	O
and	O
severity	O
of	O
CAC	O
and	O
greater	O
carotid	O
intima-media	O
thickness	O
(IMT).	O

Considering	O
the	O
interconnected	O
biosynthetic	O
and	O
catabolic	O
pathways	O
of	O
the	O
polyamine	B
metabolome	O
described	O
in	O
,	O
putrescine	B
was	O
derived	O
from	O
l-ornithine	B
by	O
ornithine	O
decarboxylase	O
(ODC)	O
catalysis.	O

Some	O
amino	O
acids	O
(tyrosine,	O
isoleucine,	B
and	O
methionine)	B
were	O
easily	O
affected,	O
which	O
was	O
consistent	O
with	O
the	O
results	O
by	O
Rotter	O
et	O
al..	O

However,	O
in	O
cancer	O
tissue,	O
3-hydroxybutyrate	B
levels	O
may	O
also	O
be	O
elevated	O
because	O
of	O
the	O
“reverse	O
Warburg	O
effect”	O
whereby	O
energy-rich	O
molecules	O
are	O
taken	O
up	O
by	O
cancer	O
cells	O
perhaps	O
from	O
neighboring	O
cells,	O
are	O
converted	O
to	O
acetyl	O
CoA,	O
and	O
enter	O
the	O
TCA	O
cycle,	O
ultimately	O
generating	O
ATP	B
via	O
oxidative	O
phosphorylation.	O

the	O
putative	O
allantoin,	B
citric	B
acid	I
and	O
an	O
unknown)	O
showed	O
high	O
importance	O
but	O
no	O
significant	O
correlation	O
with	O
Δglucose	B
.	O

Hsa-miR-885-5p	O
(n = 835)	O
predicted	O
significantly	O
very	O
large	O
HDL	O
subclass	O
free	O
cholesterol,	B
cholesterol	B
esters,	I
total	O
cholesterol,	B
phospholipid	B
and	O
total	O
lipid	O
concentrations	O
(.	O
and	O
).	O

The	O
international	O
vitamin	B
D	I
Quality	O
Assessment	O
Scheme	O
(DEQAS)	O
monitors	O
the	O
performance	O
of	O
laboratories	O
measuring	O
25-OH	O
D	O
using	O
different	O
analytical	O
methods	O
and	O
allows	O
the	O
comparison	O
between	O
methods	O
and	O
between	O
laboratories	O
using	O
the	O
same	O
or	O
similar	O
methods.	O

The	O
second	O
metabolite	O
is	O
ascorbic	B
acid,	I
whose	O
abundance	O
in	O
serum	O
decreased	O
post	O
surgery.	O

Additionally,	O
ceramide	B
has	O
also	O
been	O
evaluated	O
as	O
a	O
diagnostic	O
biomarker.	O

Inter-individual	O
differences	O
in	O
genetic	O
and	O
epigenetic	O
characteristics	O
can	O
be	O
considerable	O
like	O
slow	O
metabolizers	O
of	O
nicotine	B
with	O
a	O
CYP2A6	O
genotype.	O

We	O
found	O
changes	O
in	O
small	O
molecules	O
levels	O
during	O
CM	O
that	O
have	O
been	O
implicated	O
in	O
seizure	O
and/or	O
encephalopathies,	O
including	O
increases	O
in	O
kynurenate	B
and	O
the	O
branch	O
chain	O
amino	O
acids	O
leucine	O
and	O
valine.	B

However,	O
it	O
should	O
be	O
noted	O
that	O
decreased	O
phenylalanine	B
was	O
observed	O
in	O
the	O
present	O
study	O
which	O
differs	O
from	O
earlier	O
reports	O
,	O
.	O

In	O
the	O
large	O
phospholipid	B
cluster	O
LC2,	O
while	O
no	O
changes	O
were	O
observed	O
for	O
the	O
cluster	O
overall,	O
the	O
major	O
lipid-class-specific	O
changes	O
were	O
observed	O
for	O
sphingomyelins,	B
which	O
were	O
elevated	O
in	O
patients	O
compared	O
to	O
their	O
healthy	O
co-twins	O
(Figure	O
shows	O
one	O
representative	O
abundant	O
sphingomyelin).	B

The	O
left	O
and	O
right	O
ventricles	O
and	O
epicardium	O
were	O
semi-automatically	O
segmented	O
by	O
a	O
technician	O
together	O
with	O
a	O
radiologist	O
from	O
each	O
time	O
frame	O
of	O
the	O
cine	B
MRI	O
series	O
with	O
a	O
software	O
tool	O
developed	O
for	O
this	O
purpose	O
.	O

In	O
meningiomas,	O
alanine,	B
another	O
product	O
of	O
glycolysis,	O
was	O
also	O
positively	O
correlated	O
with	O
tCr	O
(Figs	O
and	O
).	O

The	O
buffer	O
strength	O
of	O
the	O
mobile	O
phases	O
was	O
investigated	O
with	O
ammonium	B
formate	I
and	O
ammonium	B
acetate.	I

An	O
increased	O
concentration	O
of	O
urea	B
in	O
blood,	O
milk	O
and	O
urine	O
is	O
commonly	O
observed	O
in	O
HS	O
dairy	O
cows	O
[,	O
,	O
,	O
]	O
as	O
a	O
result	O
of	O
the	O
strongly	O
up-regulated	O
pathway	O
of	O
nucleotides	O
metabolism	O
during	O
HS.	O

Total	O
plasma	O
concentrations	O
of	O
six	O
inflammatory	O
cytokines	O
[tumor	O
necrosis	O
factor	O
alpha	O
(TNFα),	O
granulocyte	O
colony	O
stimulating	O
factor	O
(GCSF),	O
monocyte	O
chemoattractant	O
protein	O
1	O
(MCP),	O
IL-6,	O
IL-8,	O
and	O
IL-10]	O
were	O
determined	O
using	O
an	O
electrochemiluminescence	O
based	O
solid-phase	O
sandwich	O
immunoassay	O
(Meso	O
Scale	O
Discovery,	O
Gaithersburg,	O
MD,	O
USA).	O

Tryptophan	B
levels	O
showed	O
a	O
moderate	O
correlation	O
with	O
KA,	O
XA	O
and	O
HAA,	O
(r:	O
0.34–0.41),	O
and	O
a	O
weak	O
correlation	O
with	O
HK	O
and	O
QA	O
(r:	O
0.14,	O
0.18).	O

Recently,	O
studies	O
have	O
revealed	O
that	O
there	O
is	O
a	O
change	O
in	O
the	O
amino	O
acid	O
metabolism	O
in	O
addition	O
to	O
the	O
changes	O
in	O
glucose	B
and	O
fatty	O
acid	O
metabolism	O
in	O
patients with	O
type	O
2	O
diabetes	O
.	O

2013),	O
podophyllotoxin	B
(Kour	O
et	O
al.	O
2008;	O
Nadeem	O
et	O
al.	O

Particularly	O
C16-ceramide	B
and	O
S1P	O
may	O
serve	O
as	O
novel	O
diagnostic	O
markers	O
for	O
the	O
identification	O
of	O
HCC	O
in	O
patients	O
with	O
liver	O
diseases.	O

Matrix	O
effects	O
for	O
GLY,	O
M1	O
and	O
GP	B
in	O
three	O
different	O
batches	O
of	O
human	O
plasma	O
and	O
M1,	O
M2	O
and	O
GP	B
in	O
three	O
different	O
batches	O
of	O
human	O
urine	O
%	O
difference	O
=	O
{[Mean	O
peak	O
area	O
or	O
area	O
ratio	O
(post	O
extraction)/mean	O
peak	O
area	O
or	O
area	O
ratio	O
(mobile	O
phase)]	O

Lower	O
total	O
cholesterol	B
levels	O
have	O
been	O
associated	O
with	O
increased	O
in-hospital	O
mortality	O
of	O
patients	O
with	O
various	O
diseases,	O
including	O
miscellaneous	O
heart	O
diseases,	O
and	O
was	O
proposed	O
as	O
one	O
of	O
the	O
first	O
signs	O
of	O
forthcoming	O
deterioration	O
of	O
a	O
preexisting	O
disease	O
.	O

The	O
half-lives	O
of	O
NPO-Alb	O
and	O
1,2-NPQ-Alb	B
were	O
approximately	O
2	O
days	O
and	O
1	O
day,	O
respectively.	O

Gas	O
chromatography	O
time-of-flight	O
mass	O
spectrometry	O
(GC-TOF	O
MS)	O
and	O
Ultraperformance	O
liquid	O
chromatography-quadrupole	O
time-of-flight	O
mass	O
spectrometry	O
(UPLC-QTOF	O
MS)],	O
Ma	O
et	O
al.	O
valine,	B
threonine	B
and	O
glycine	B
significantly	O
decreased	O
in	O
CRC	O
patients	O
using	O
GC-MS.	O

Karkela	O
and	O
coworkers	O
have	O
analyzed	O
the	O
alanine	B
concentration	O
in	O
cerebrospinal	O
fluid	O
of	O
patients	O
after	O
acute	O
ischemic	O
stroke	O
and	O
found	O
that	O
alanine	B
levels	O
gradually	O
increased	O
within	O
the	O
first	O
four	O
hours,	O
and	O
then,	O
there	O
was	O
a	O
rapid	O
decline.	O

Long‐chain	O
acylcarnitines	B
accumulate	O
in	O
tissues	O
and	O
plasma	O
in	O
states	O
of	O
inefficient	O
ß‐oxidation.59	O
Such	O
accumulation	O
causes	O
electrophysiological	O
disturbances,	O
cell	O
stress,	O
and	O
release	O
of	O
circulating	O
inflammatory	O
mediators.63,	O
64,	O
65,	O
66,	O
67,	O
68	O

There	O
was	O
not,	O
however,	O
a	O
significant	O
difference	O
between	O
the	O
levels	O
of	O
haeme	O
catabolites	O
in	O
HCC	O
patients	O
vs.	O
DC.	O
2-pyrrolidinone,	B
a	O
γ	B
-aminobutyric	I
acid	I
(GABA)	O
metabolite	O
with	O
an	O
unknown	O
role	O
in	O
cirrhosis	O
or	O
cancer,	O
exhibited	O
a	O
strongly	O
significant,	O
progressive	O
elevation	O
from	O
NHC	O
to	O
cirrhosis	O
and	O
cirrhosis	O
to	O
HCC.	O

The	O
relationship	O
between	O
levels	O
of	O
urinary	O
3-HPMA	O
and	O
those	O
of	O
acrolein-derived	O
1,-propanodeoxyguanosine	B
(PdG)	O
adducts	O
in	O
lung	O
was	O
investigated	O
in	O
14	O
smokers.	O

An	O
increase	O
of	O
betaine	B
was	O
also	O
observed	O
in	O
altered	O
metabolism	O
and	O
contributes	O
to	O
counteract	O
hepatic,	O
vascular,	O
coronary,	O
and	O
cerebral	O
diseases.	O

No	O
changes	O
in	O
other	O
TCAIs	O
were	O
identified	O
(isocitrate,	O
succinil-coA	B
and	O
oxalacetate),	B
nor	O
was	O
any	O
interaction	O
observed	O
between	O
the	O
groups	O
of	O
T1D	O
and	O
controls	O
in	O
the	O
metabolites	O
that	O
increased	O
following	O
exercise.	O

The	O
bench-top	O
stability	O
test	O
suggested	O
that	O
FAU	O
and	O
FMAU	O
was	O
stable	O
in	O
both	O
methanol	B
(at	O
1	O
and	O
100	O
μg/ml)	O
and	O
in	O
human	O
plasma	O
(at	O
low	O
and	O
high	O
QC	O
concentrations)	O
at	O
ambient	O
temperature	O
(~25°C)	O
for	O
at	O
least	O
6	O
hours.	O

Glycine	B
deficiencies	O
would	O
increase	O
the	O
demands	O
on	O
the	O
urea	B
cycle	O
and	O
the	O
glutamate/AKG	O
pathways.	O

Moreover,	O
patients	O
with	O
chronic	O
kidney	O
disease	O
are	O
permanently	O
exposed	O
to	O
uremic	O
toxins	B
from	O
the	O
kynurenine	B
pathway,	O
which	O
could	O
be	O
mediated	O
by	O
activation	O
of	O
transcription	O
factor	O
aryl	B
hydrocarbon	I
receptor	O
(AhR).	O

([M+H-HCO_2	O
H]_+	O
)	O
contained	O
the	O
prominent	O
fragment	O
ion	O
at	O
m/z	O
226.1,	O
attributed	O
to	O
2-HO-PhIP	B
(m/z	O
231.1	O
for	O
2-HO-[_2	B
H_5	I
]-PhIP),	I
as	O
was	O
observed	O
in	O
the	O
spectra	O
of	O
desamino-PhIP-Y.	B
Accurate	O
mass	O
measurement	O
of	O
the	O
monoisotopic	O
elemental	O
mass	O
of	O
synthetic	O
Y*TK	O
and	O
its	O
product	O
ion	O
spectra	O
confirmed	O
the	O
assignment.	O

Therefore,	O
the	O
accumulation	O
of	O
hippuric	B
acid	I
may	O
account	O
for	O
the	O
progression	O
of	O
muscular	O
weakness	O
in	O
uremic	O
patients.	O

Diosmetin	B
(100 %)	O
and	O
paracetamol-3-β-d-glucuronide	B
(100 %)	O
were	O
purchased	O
from	O
Sigma	O
(Deisenhofen,	O
Germany),	O
while	O
3-O	O
-Gluc	O
(99.1 %),	O

Together,	O
3-HK	O
and	O
KYNA	O
interactions	O
in	O
the	O
PRE-network	O
identify	O
the	O
groups	O
of	O
proteins	O
involved	O
in	O
the	O
angiopoietin	B
receptor	O
Tie2	O
and	O
the	O
tyrosine	O
phosphatase	O
SHP2	O
signaling.	O

The	O
multi-element	O
calibration	O
standard	O
was	O
provided	O
as	O
10	O
mg/l	O
in	O
5%	O
nitric	B
acid	I
and	O
was	O
not	O
in	O
the	O
plasma	O
matrix.	O

The	O
daily	O
dose	O
of	O
the	O
patients’	O
drugs	O
were	O
not	O
to	O
be	O
changed	O
from	O
at	O
least	O
2	O
weeks	O
(aripiprazole)	O
or	O
1	O
week	O
(risperidone,	O
paliperidone,	B
quetiapine,	B
and	O
olanzapine)	B
before	O
day	O
‐1	O
up	O
to	O
the	O
end	O
of	O
the	O
study.	O

Analytical	O
standards	O
were	O
prepared	O
using	O
a	O
dimethyl	B
sulfoxide	I
calibration	O
stock	O
solution	O
containing	O
compounds	O
1–14	O
(100	O
µg/mL).	O

Our	O
sample	O
work	O
up	O
required	O
a	O
combination	O
of	O
sample	O
cleanup	O
and	O
two	O
consecutive	O
derivatization	O
reactions	O
with	O
ethylhydroxylamine	B
and	O
MTBSTFA	O
for	O
sufficient	O
sensitivity	O
and	O
accuracy.	O

Unlike	O
that	O
study,	O
we	O
were	O
not	O
able	O
to	O
demonstrate	O
in	O
LOAD	O
patients	O
a	O
significant	O
correlation	O
between	O
24S-OH-Chol	B
levels	O
and	O
the	O
global	O
cognitive	O
function	O
(MMSE)	O
or	O
functional	O
impairment	O
(Barthel	O
index),	O
perhaps	O
because	O
our	O
subjects	O
were	O
not	O
in	O
the	O
very-early	O
stage	O
of	O
the	O
disease	O
(Global	O
Deterioration	O
Scale:	O
stage	O
3	O
to	O
5).	O

For	O
both,	O
H.	O
pomatia	O
and	O
bovine	O
liver	O
GUS,	O
a	O
200-mM	O
acetate	B
buffer	O
(pH	O
4.5)	O
was	O
used	O
for	O
hydrolysis,	O
and	O
for	O
E.	O
coli	O
GUS,	O
a	O
hydrolysis	O
buffer	O
of	O
75 mM	O
phosphate	B
buffer	O
(pH	O
6.8)	O
was	O
used.	O

Increased	O
levels	O
of	O
homovanillic	B
acid	I
and	O
DOPAC,	O
thought	O
to	O
be	O
involved	O
in	O
reducing	O
oxidative	O
LDL	B
cholesterol,	I
were	O
observed	O
upon	O
OEP	O
ingestion.	O

Both	O
the	O
activation	O
of	O
KMO	O
and,	O
consequently,	O
the	O
potential	O
synthesis	O
of	O
xanthurenic	B
acid	I
may	O
be	O
deleterious	O
to	O
glucose	B
homeostasis.	O

Interestingly,	O
butyrate	B
has	O
been	O
shown	O
to	O
be	O
important	O
in	O
the	O
modulation	O
of	O
T	O
cell	O
immunity	O
and	O
it	O
affects	O
histone	O
acetylation	O
(,	O
).	O

indicates	O
that	O
peaks	O
corresponding	O
to	O
lines	O
3,	O
6,	O
and	O
7	O
in	O
the	O
table	O
below	O
were	O
phosphorylated	O
on	O
serine	B
and	O
threonine.	B

BCAA	O
have	O
been	O
shown	O
to	O
be	O
important	O
in	O
muscle	O
metabolism,	O
which	O
could	O
explain	O
the	O
significantly	O
positive	O
association	O
of	O
leucine	B
with	O
male	O
sex	O
rather	O
than	O
HC	O
or	O
non-HC	O
females,	O
since	O
males	O
have	O
a	O
higher	O
percentage	O
of	O
lean	O
body	O
mass	O
including	O
muscle	O
mass	O
than	O
females.	O

Box	O
plots	O
of	O
potential	O
markers	O
(a)	O
sarcosine,	B
(b)	O
kynurenic	B
acid,	I
and	O
(c)	O
uracil,	B
in	O
urine	O
samples	O
of	O
patients	O
in	O
group	O
B	O
(UGBP)	O
before	O
prostatic	O
massage	O
and	O
(d)	O
sarcosine,	B
(e)	O
kynurenic	B
acid,	I
and	O
(f)	O
uracil.	B

A	O
previous	O
study	O
reported	O
that	O
increased	O
levels	O
of	O
proline	B
and	O
trans	B
-4-hydroxyproline	I
in	O
tumor	O
tissues,	O
in	O
part,	O
are	O
due	O
to	O
an	O
alteration	O
of	O
intracellular	O
redox	O
status	O
and	O
ultimately	O
affect	O
the	O
biosynthesis	O
of	O
nucleic	O
acid	O
and	O
fatty	O
acids.	O

Relative	O
ethanol	B
production	O
derived	O
from	O
the	O
integrated	O
area	O
under	O
the	O
curve	O
of	O
original	O
NMR	O
spectra	O
for	O
the	O
methyl	O
protons	O
at	O
1.18	O
ppm.	O

Briefly,	O
40 μL	O
of	O
serum	O
sample	O
mixed	O
with	O
1.6 mL	O
of	O
10 mM	O
Tris-KCl	O
(0.15 M	O
KCl	O
and	O
pH	O
7.4)	O
buffer,	O
0.5 mL	O
of	O
30%	O
trichloro	O
acetic	O
acid	O
(TCA)	O
and	O
0.5 mL	O
thiobarbuturic	B
acid	I
(TBA)	O
in	O
falcon	O
tubes	O
and	O
covered	O
with	O
aluminium	O
foil.	O

Interestingly,	O
the	O
nodes	O
unique	O
to	O
the	O
HCV	O
network	O
are	O
related	O
to	O
the	O
lipid	O
metabolism,	O
apart	O
from	O
mannose	B
and	O
glycine.	B

Indeed,	O
half	O
of	O
the	O
phospholipids	B
from	O
the	O
signature	O
were	O
significantly	O
down	O
in	O
NASH	O
patients	O

Retention	O
time	O
and	O
specific	O
MRM	O
transitions	O
are	O
shown	O
for	O
each	O
oxylipin	B
Taken	O
together,	O
by	O
employing	O
dMRM	O
and	O
the	O
detection	O
of	O
specified	O
transitions	O
in	O
our	O
HPLC-MS/MS	O
approach,	O
we	O
were	O
able	O
to	O
detect	O
more	O
than	O
100	O
different	O
oxylipins.	B

Metabolites	O
distinguishing	O
early-,	O
intermediate-	B
and	O
late-stage	O
CRC	O
patients	O
pre-surgery	O
We	O
observed	O
that	O
Hyp-Hyp	O
was	O
increased	O
in	O
intermediate-	B
and	O
late-stage	O
pre-surgery	O
patients	O
when	O
compared	O
to	O
early-stage	O
patients.	O

sPAP,	O
systolic	O
pulmonary	O
artery	O
pressure;	O
PCWP,	O
pulmonary	O
capillary	O
wedge	O
pressure;	O
CVP,	O
central	O
venous	O
pressure;	O
CI,	O
cardiac	O
index;	O
eGFR,	O
estimated	O
glomerular	O
filtration	O
rate;	O
BNP,	O
B-type	O
natriuretic	O
peptide;	O
ADMA,	B
asymmetric	B
dimethylarginine;	I
SDMA,	O
symmetric	B
dimethylarginine;	I
MMA,	O
N	B
-mono-methylarginine;	I
GABR,	O
global	O
arginine	B
bioavailability	O
ratio.	O

Specifically,	O
early	O
metabolite	O
changes	O
(at	O
1	O
hour)	O
included	O
the	O
accumulation	O
of	O
amino	O
acid	O
metabolites	O
(eg,	O
N-α	B
-acetyllysine)	I
and	O
acylcarnitines	B
(including	O
linoleylcarnitine,	B
hexanoylcarnitine,	B
and	O
acetylcarnitine)	B
and	O
the	O
decrease	O
of	O
amino	O
acids.	O

Of	O
our	O
identified	O
candidates,	O
hexanoylcarnitine	B
and	O
2-HG	O
hold	O
the	O
most	O
promise.	O

Dietary	O
supplementation	O
of	O
arginine	B
in	O
HD	O
mice	O
hastens	O
disease	O
progression	O
(demonstrated	O
by	O
increased	O
weight	O
loss	O
and	O
abnormal	O
motor	O
function;	O
ref.	O
).	O

The	O
liquid	O
chromatography	O
was	O
performed	O
with	O
a	O
gradient	O
mobile	O
phase	O
consisting	O
of	O
A:	O
acetonitrile/0.1	O
%	O
formic	B
acid	I
(v/v	O
)	O
and	O
B:	O
water/0.1	O
%	O
formic	B
acid	I
(v/v	O
).	O

Water,	O
urea	B
(signal	O
damaged	O
by	O
water-saturation	O
transfer),	O
and	O
fumaric-acid	O
regions	O
were	O
excluded	O
(1810	O
variables	O
excluded).	O

GSH,	B
reduced	B
glutathione;	I
GSSG,	O
oxidized	B
glutathione:	I
GPx,	O
glutathione	B
peroxidase;	O
Hb,	O
hemoglobin;	O
SOD,	O
superoxide	B
dismutase;	O
MDA,	O
malondialdehyde;	B
IL-6,	O
interleukin-6,	O
TNF-α:	O
tumor	O
necrosis	O
factor-alpha;	O
KBR,	O
Korean	O
black	O
raspberry.	O
_1	O

The	O
lysine	B
portion	O
of	O
the	O
crosslink	O
is	O
either	O
N	O
-acetylated	O
or	O
undergoes	O
an	O
oxidative	O
transamination	O
reaction	O
to	O
generate	O
an	O
α-ketoacid	B
metabolite	O
that	O
undergoes	O
oxidative	O
decarboxylation.	O

Several	O
steroid	O
metabolites	O
in	O
the	O
pregnenolone	B
pathway	O
were	O
increased	O
after	O
leptin	O
replacement.	O

Moreover,	O
elevated	O
production	O
of	O
triglycerides	B
in	O
non-adipose	O
tissues,	O
such	O
as	O
liver,	O
induces	O
the	O
overexpression	O
of	O
lipoprotein	O
lipase	O
and	O
contributes	O
to	O
insulin	O
resistance.	O

Different	O
oxidation	O
methods	O
were	O
utilized,	O
namely	O
incubating	O
aqueous	O
dispersions	O
of	O
oleic	B
acid	I
(up	O
to	O
100	O
µM)	O
with	O
the	O
free	O
radical	O
generators	O
2,2′-azobis(2-methylpropionamidine)	B
dihydrochloride,	I
Fenton’s	O
reagent	O
(ferrous	O
sulfate	B
plus	O
hydrogen	B
peroxide),	I
or	O
just	O
by	O
exposing	O
the	O
oleic	B
acid	I
in	O
air	O
for	O
at	O
least	O
1	O
day.	O

Chromatography	O
was	O
carried	O
out	O
on	O
a	O
Kinetex	O
1.7	O
µm	O
F5	O
100	O
Å	O
100	O
×	O
2.1	O
mm	O
column	O
(Phenomenex,	O
Torrance,	O
CA,	O
USA)	O
using	O
a	O
mobile	O
phase	O
consisting	O
of	O
0.1%	O
formic	B
acid	I
(solvent	O
A)	O
and	O
methanol	B
(solvent	O
B).	O

All	O
metabolite	O
measurements	O
are	O
expressed	O
as	O
the	O
ratio	O
between	O
the	O
metabolite	O
area	O
and	O
phosphate	B
area	O
in	O
order	O
to	O
normalize	O
size	O
variation.	O

(B	O
)	O
Negative	O
ion	O
mode	O
DESI	O
mass	O
spectra	O
obtained	O
using	O
an	O
amaZon	B
Speed	O
ion	O
trap	O
from	O
m/z	O
130–165	O
(Bruker	O
Daltonics)	O
from	O
a	O
swab	O
(Left	O
),	O
a	O
smear	O
(Center	O
),	O
and	O
a	O
section	O
(Right	O
)	O
for	O
sample	O
S72.	O

The	O
methoxy	B
estrogen	I
metabolites	O
(2-MeOE_1	O
,	O
4-MeOE_1	O
)	O
were	O
measured	O
by	O
LC-MS/MS,	O
and	O
CYP1A1	O
and	O
CYP1B1	O
gene	O
expression	O
was	O
analyzed	O
by	O
qPCR.	O

This	O
new,	O
combined	O
method	O
fractionates	O
the	O
MTBE	B
lipid	O
fraction	O
into	O
three	O
fractions	O
which	O
are	O
enriched	O
for	O
neutral,	O
fatty	O
acid,	O
and	O
phospholipid	B
compounds	O
respectively.	O

The	O
changes	O
observed	O
based	O
on	O
weight	O
loss	O
alone	O
include	O
the	O
increase	O
in	O
concentration	O
of	O
SM(30:1)	B
containing	O
very	O
short	O
chained	O
fatty	O
acids.	O

Kaplan-Meier	O
survival	O
analysis	O
for	O
patients	O
with	O
3-year	O
incidence	O
of	O
major	O
adverse	O
cardiac	O
events	O
according	O
to	O
global	O
arginine	B
bioavailability	O
ratio	O
(GABR)	O
quartiles	O
Kaplan-Meier	O
survival	O
analysis	O
for	O
patients	O
with	O
3-year	O
incidence	O
of	O
major	O
adverse	O
cardiac	O
events	O
according	O
to	O
citrulline	B
quartiles	O
Additional	O
analyses	O
were	O
performed	O
looking	O
at	O
the	O
relationship	O
between	O
GABR	O
and	O
ADMA	B
in	O
predicting	O
prevalence	O
of	O
CAD	O
and	O
incidence	O
of	O
MACE	O
(3	O
year)	O
within	O
the	O
cohort.	O

Different	O
from	O
the	O
metabolic	O
signature	O
in	O
HepatoCells	O
medium,	O
SN-38	O
exposure	O
induced	O
significant	O
accumulation	O
of	O
pyrimidine/purine	O
nucleosides	O
and	O
nucleobases	O
(ANOVA,	O
FDR-adjusted	O
P	O
<	O
.05)	O
in	O
cancer	O
cell	O
medium,	O
while	O
having	O
no	O
apparent	O
impact	O
on	O
the	O
levels	O
of	O
acylcarnitines	B
or	O
amino	O
acid	O
metabolites.	O

The	O
intersection	O
of	O
significantly	O
changed	O
analytes	O
(p<0.05;	O
AD_all	O
vs.	O
controls)	O
for	O
females	O
(29)	O
and	O
males	O
(27)	O
comprises	O
8	O
metabolites	O
of	O
which	O
7	O
are	O
knowns,	O
namely	O
cysteine,	B
uridine	B
and	O
five	O
hormones/neurotransmitters:	O
cortisol,	B
3-methoxy-4-hydroxy	B
phenylglycol	I
(MHPG),	O
dopamine,	B
noradrenaline	B
and	O
normetanephrine.	B

FGF-23	O
correlated	O
negatively	O
with	O
25(OH)D	O
and	O
24,25(OH)_2	B
D	O
and	O
positively	O
with	O
1,25(OH)_2	B
D.	O

In	O
the	O
brain,	O
taurine	B
regulates	O
cell	O
volume	O
and	O
protects	O
neurons	O
and	O
mitochondria	O
against	O
excitotoxicity.	O

L-DOPA	B
correlated	O
with	O
all	O
cognitive	O
measurements	O
as	O
well	O
as	O
TFC	O
and	O
TMS,	O
whereas	O
xanthine	B
correlated	O
with	O
all	O
measures	O
of	O
disease	O
severity	O
except	O
for	O
SI	O
and	O
the	O
five	O
year	O
risk	O
of	O
onset.	O

Additionally,	O
choline	B
is	O
indirectly	O
involved	O
in	O
the	O
synthesis	O
of	O
the	O
platelet-activating	O
factor,	O
which	O
is	O
a	O
major	O
inflammatory	O
mediator[,].	O

As	O
a	O
typical	O
accumulated	O
uremic	O
toxin,	B
hippuric	B
acid	I
has	O
been	O
characterized	O
as	O
a	O
difficulty	O
that	O
could	O
be	O
cleared	O
by	O
a	O
dialysis	O
regimen.	O

(B)	O
Extracted	O
ion	O
chromatograms	O
for	O
all	O
225	O
oxylipin	B
chemical	O
standards.	O

Meanwhile,	O
L-proline,	B
a	O
non-essential	O
amino	O
acid,	O
was	O
found	O
to	O
be	O
lowered	O
in	O
LCPs,	O
confirming	O
a	O
previously	O
reported	O
study.	O

P	O
-trend	O
from	O
Wald	O
test	O
for	O
nonlinearity.	O
_a	O
Models	O
were	O
adjusted	O
for	O
age,	O
BMI,	O
creatinine,	B
smoking	O
status	O
(cotinine	O
dichotomized	O
at	O
a	O
threshold	O
of	O
10	O
ng/ml),	O
race/ethnicity	O
(dichotomized,	O
non-White	O
versus	O
White)	O
and	O
income	O
(dichotomized	O
at	O
$70	O
000).	O

108	O
participants	O
with	O
pre-DM	O
were	O
followed	O
up	O
for	O
ten	O
years	O
and	O
divided	O
into	O
3	O
groups	O
according	O
to	O
different	O
glycemic	B
outcomes.	O

Extraction	O
recovery	O
and	O
matrix	O
effect	O
(mean	O
±	O
SD	O
and	O
RSD)	O
of	O
D-mannose	B
from	O
human	O
serum.	O

Further,	O
higher	O
levels	O
of	O
ceramide	B
in	O
breast	O
cancer	O
were	O
associated	O
with	O
less	O
aggressive	O
cancer	O
biology	O
presented	O
by	O
Ki-67	O
index	O
and	O
nuclear	O
grade	O
of	O
the	O
cancer.	O

The	O
following	O
exclusion	O
criteria	O
were	O
applied:	O
not	O
fasted	O
for	O
at	O
least	O
6	O
hours,	O
a	O
fasting	O
blood	O
glucose	B
concentration	O
≥200	O
mg/dl,	O
medication	O
intake	O
on	O
the	O
morning	O
of	O
blood	O
sampling,	O
and	O
treatment	O
or	O
history	O
of	O
cancer	O
in	O
the	O
past	O
5	O
years.	O

Estimated	O
glomerular	O
filtration	O
rate	O
(eGFR)	O
used	O
in	O
follow-up	O
after	O
Rtx	O
was	O
calculated	O
by	O
a	O
cystatin	B
C-based	O
equation	O
for	O
estimation	O
of	O
GFR;	O
130	O
x	O
cystatin	O
C	O
-1,069	O
x	O
age	O
-0,117–7,	O
as	O
described	O
previously.	O

Matrix	O
effect	O
on	O
the	O
IS	O
was	O
assessed	O
using	O
the	O
plasma	O
with	O
high	O
triglyceride	B
levels.	O

An	O
additional	O
note	O
on	O
the	O
above	O
mentioned	O
reduction	O
in	O
excreted	O
trigonelline	B
relates	O
to	O
this	O
compound	O
being	O
a	O
byproduct	O
of	O
the	O
conversion	O
of	O
S-adenosylmethionine	B
to	O
S-adenosylhomocysteine	B
in	O
the	O
methionine	B
cycle.	O

The	O
mobile	O
phase	O
consisted	O
of	O
0.1%	O
formic	B
acid	I
in	O
water	O
(A)	O
and	O
ACN	O
modified	O
with	O
0.1%	O
formic	B
acid	I
(B),	O
using	O
a	O
gradient	O
elution	O
of	O
5%B	O
at	O
0–2	O
min,	O
5%–95%	O
B	O
at	O
2–13	O
min,	O
95%	O
B	O
at	O
13–15	O
min.	O

Lysophosphatidylethanolamine	B
(LPE)	O
is	O
a	O
group	O
of	O
signalling	O
lipids,	O
and	O
it	O
has	O
been	O
recently	O
shown	O
to	O
be	O
related	O
to	O
breast	O
cancer.	O

A	O
20	O
mM	O
sucrose	B
solution,	O
0.5	O
mM	O
TSP,	O
2	O
mM	O
NaN_3	O
in	O
90%	O
H_2	O
O/10%	O
D_2	O
O	O
(v/v)	O
was	O
used	O
for	O
line-shape	O
assessment,	O
system	O
equilibration,	O
and	O
quality	O
control.	O

PCA,	O
MeOH,	B
and	O
ACN	O
have	O
been	O
applied	O
in	O
previous	O
studies	O
to	O
extract	O
polyamine	B
and	O
related	O
compounds.	O

Therefore,	O
it	O
is	O
not	O
surprising	O
that	O
increased	O
glucose	B
detected	O
in	O
plasma	O
and	O
liver	O
of	O
hypogonadic	O
men	O
deriving	O
from	O
gluconeogenesis	O
is	O
the	O
last	O
resource	O
for	O
obtaining	O
glucose.	B

Collectively,	O
the	O
work	O
of	O
others	O
as	O
well	O
as	O
the	O
current	O
investigation	O
support	O
further	O
examination	O
of	O
why	O
ether-linked	O
phospholipids	B
vary	O
between	O
lean	O
control	O
and	O
obese	O
subjects	O
and	O
what	O
the	O
role	O
of	O
ether-linked	O
lipids	O
in	O
metabolic	O
disease	O
may	O
be.	O

Accordingly,	O
this	O
study	O
investigated	O
the	O
effects	O
of	O
these	O
oral	O
components	O
on	O
parameters	O
likely	O
to	O
modulate	O
BRB	O
anthocyanins'	B
chemopreventive	O
efficacy.	O

In	O
the	O
present	O
study,	O
we	O
observed	O
that	O
the	O
increase	O
in	O
plasma	O
citrulline	B
concentrations	O
occurred	O
when	O
eGFR	O
reached	O
values	O
below	O
45	O
ml/min	O
per	O
1.73	O
m_2	O
.	O

Gln	O
is	O
a	O
nitrogen	O
donor	O
for	O
the	O
de	O
novo	O
synthesis	O
of	O
both	O
purines	B
and	O
pyrimidines,	B
and	O
is	O
essential	O
for	O
production	O
of	O
nucleotides	O
during	O
cell	O
proliferation.	O

Extracts	O
were	O
derivatised	O
by	O
methylation	O
using	O
methanolic	B
boron	O
trifluoride	B
(BF3,	O
14%	O
in	O
methanol).	B

To	O
avoid	O
miss-interpretation	O
during	O
exposure	O
assessment,	O
we	O
discontinued	O
the	O
measurement	O
of	O
monohydroxyl	O
derivatives	O
of	O
the	O
larger	O
PAHs,	O
including	O
3-BaP,	O
and	O
reported	O
10	O
detectable	O
and	O
stable	O
urinary	O
OH-PAHs,	O
i.e.	O
metabolites	O
of	O
naphthalene,	B
fluorene,	B
phenanthrene	B
and	O
pyrene,	O
in	O
this	O
method	O
and	O
in	O
all	O
recent	O
research	O
projects	O
[,	O
].	O

Comparative	O
electrospray	O
mass	O
spectra	O
of	O
PE	B
18:1(n	I
-9,	I
cis	I
)/18:1(n	I

Derivatized	O
samples	O
were	O
analyzed	O
by	O
positive	O
ion	O
electrospray	O
tandem	O
mass	O
spectrometry	O
using	O
an	O
Agilent	O
1200	O
series	O
nano	O
flow	O
LC	O
system	O
(Agilent	O
Technologies,	O
Santa	O
Clara,	O
CA)	O
coupled	O
to	O
an	O
AB	O
SCIEX	O
QTRAP	O
5500	O
system	O
(AB	O
SCIEX,	O
Framingham,	O
MA)	O
as	O
described	O
previously._,	O
Quantitation	O
was	O
performed	O
using	O
Analyst	O
software	O
(Applied	O
Biosystems,	O
Forster	O
City,	O
CA),	O
and	O
data	O
were	O
normalized	O
to	O
the	O
DMSO	B
treatment.	O

A	O
panel	O
of	O
4	O
metabolites	O
(2-hydroxybutyrate,	O
octadecenoylcarnitine	B
(C18:1),	I
hydroxyprionylcarnitine	B
(C3-OH),	O
and	O
SM(C24:1))	B
was	O
identified	O
that	O
discriminated	O
between	O
HFpEF	O
and	O
HFrEF.	O

The	O
metabolites	O
making	O
significant	O
contribution	O
for	O
group	O
separation	O
were	O
glucose,	B
lactate,	B
lysine,	B
alanine,	B
glutamate,	B
NAG,	O
pyruvate	B
and	O
lipid	O
content.	O

Our	O
preliminary	O
findings	O
suggest	O
that	O
prenatal	O
exposure	O
to	O
endocrine	O
disruptors	O
may	O
influence	O
estrogen	B
metabolism	O
many	O
years	O
later.	O

Thus,	O
although	O
there	O
seems	O
to	O
be	O
an	O
association	O
between	O
higher	O
age,	O
lower	O
tryptophan	B
and	O
increased	O
KTR,	O
low	O
level	O
of	O
tryptophan	B
in	O
the	O
ADHD	O
group	O
cannot	O
be	O
fully	O
explained	O
by	O
higher	O
IDO	O
or	O
TDO	O
activity.	O

WG	O
products	O
have	O
high	O
content	O
of	O
dietary	O
fiber,	O
which	O
can	O
potentially	O
reduce	O
the	O
reabsorption	O
of	O
bile	O
acids	O
from	O
the	O
intestine	O
and	O
therefore	O
increase	O
bile	O
acid	O
biosynthesis	O
from	O
cholesterol,	B
which	O
may	O
eventually	O
reduce	O
circulating	O
cholesterol	B
levels.	O

Polar	O
lipids	O
(PL),	O
acyl-carnitines	B
(acyl-Carn)	I
and	O
amino	O
acids	O
(AA)	O
were	O
analyzed	O
using	O
LC-MS/MS.	O

This	O
may	O
indicate	O
that	O
glutamate	B
is	O
further	O
metabolized	O
to	O
2-oxoglutarate	B
which	O
can	O
be	O
achieved	O
by	O
a	O
coupled	O
transamination	O
reaction	O
in	O
which	O
oxaloacetate	B
is	O
converted	O
to	O
aspartate.	B

Summary	O
of	O
demographics	O
of	O
both	O
study	O
populations	O
as	O
well	O
as	O
the	O
baseline	O
characteristics	O
for	O
the	O
glycaemic	B
control	O
parameters	O
as	O
measured	O
after	O
the	O
2-week	O
placebo	O
run-in	O
period	O
The	O
data	O
in	O
parentheses	O
represent	O
the	O
SD.	O

Analysis	O
of	O
hypoxanthine	B
to	O
xanthine	B
levels	O
as	O
ratio	O
indicated	O
association	O
with	O
CRC	O
progression.	O

These	O
data	O
show	O
that	O
folates	O
are	O
important	O
not	O
only	O
in	O
methylation	O
reactions	O
but	O
also	O
in	O
regulating	O
intracellular	O
redox	O
and	O
NADPH	B
levels.	O

Quetiapine:	B
scatterplot	O
of	O
log‐transformed	O
capillary	O
versus	O
venous	O
plasma	O
concentrations	O
with	O
regression	O
line.	O

This	O
was	O
evident	O
from	O
the	O
TOCSY	O
_13	O
C	O
satellite	O
patterns	O
of	O
the	O
5'-UXP	O
cross-peaks	O
(e.g.	O
Fig.	O
for	O
H1'	O
→	O
H2'	O
of	O
5'-UXP)	O
and	O
_13	O
C	O
spin	O
coupling	O
patterns	O
of	O
C1'	O
to	O
C4'	O
of	O
ribose	B
in	O
5'-UXP	O
(Fig.	O
).	O

Pregnenolone	B
has	O
also	O
been	O
established	O
to	O
display	O
an	O
age-associated	O
negative	O
relationship	O
,	O
with	O
distributions	O
for	O
men	O
and	O
women	O
in	O
line	O
with	O
those	O
described	O
here.	O

The	O
only	O
exception	O
to	O
this	O
observation	O
was	O
acetone	B
(Supplementary	O
Fig.	O

Glycochenodeoxycholic	B
acid;	I
GDCA:	O
Glycodeoxycholic	B
acid;	I
GHCA:	B
Glycohyocholate;	B
GHDCA:	O
Glycohyodeoxycholate;	B
GLCA:	O
Glycolithocholate;	B
GUDCA:	O

Loss	O
of	O
the	O
PE → PC	O
pathway	O
has	O
also	O
been	O
associated	O
with	O
increased	O
activity	O
of	O
the	O
CDP-choline	B
pathway	O
and	O
increased	O
hepatocyte	O
cell	O
proliferation	O
whereas	O
PEMT	O
expression	O
has	O
been	O
shown	O
to	O
inhibit	O
the	O
CDP-choline	B
pathway	O
and	O
acts	O
as	O
a	O
negative	O
regulator	O
of	O
hepatocyte	O
cell	O
proliferation,	O
a	O
potential	O
tumor	O
suppressive	O
action.	O

Our	O
analysis	O
also	O
replicated	O
associations	O
already	O
established	O
between	O
amino	O
acids	O
and	O
BMI,	O
including	O
associations	O
for	O
valine,	B
isoleucine,	B
leucine,	B
tyrosine,	B
phenylalanine,	B
glutamate,	B
kynurenine,	B
and	O
glycine	B
(;;;).	O

Attention	O
was	O
given	O
to	O
chromatographic	O
separation	O
of	O
oxysterol	B
isomers;	I
24-OHC,	O
25-OHC	O
and	O
27-OHC.	O

Creatine	B
may	O
be	O
degraded	O
by	O
intestinal	O
bacteria;	O
therefore,	O
it	O
is	O
conceivable	O
that	O
the	O
elevated	O
creatine	B
levels	O
may	O
even	O
result	O
from	O
reduced	O
bacterial	O
degradation	O
associated	O
with	O
microbial	O
dysbiosis.	O

The	O
primary	O
outcome	O
of	O
this	O
trial	O
is	O
the	O
changes	O
in	O
HbA1C.	O
Secondary	O
outcomes	O
in	O
this	O
study	O
include	O
changes	O
in	O
other	O
glycemic	B
parameters	O
such	O
as	O
fasting	O
glucose,	B
insulin,	O
fructosamine,	B
changes	O
in	O
lipid	O
profile	O
(triglyceride,	O
total	O
cholesterol,	B
HDL-cholesterol,	B
LDL-cholesterol),	B
changes	O
in	O
inflammation	O
(high-sensitivity	O
C-reactive	O
protein)	O
and	O
oxidative	O
stress	O
marker	O
(plasma	O
malondialdehyde),	B
changes	O
in	O
anthropometry	O
parameters	O
(BMI,	O
waist	O
circumference),	O
changes	O
in	O
metabolite	O
profile	O
(urine,	O
serum),	O
changes	O
in	O
safety	O
parameters	O
(liver	O
profile	O
and	O
renal	O
profile),	O
changes	O
in	O
blood	O
pressure,	O
dietary	O
pattern	O
and	O
physical	O
activity.	O

Other	O
compounds	O
potentially	O
derived	O
from	O
pharmaceuticals	O
included	O
the	O
aspirin	B
metabolite	O
salicyluric	B
acid	I
and	O
its	O
glucuronide	B
and	O
the	O
acetaminophen	B
metabolite	O
2-hydroxyacetaminophen	B
sulfate.	I

TRP,	O
tryptophan;	B
KYN,	O
L-kynurenine;	B
KYNA,	O
kynurenic	B
acid;	I
AA,	O
anthranilic	B
acid;	I
3-HK,	O
3-hydroxykynurenine;	B
3HAA,	O
3-hydroxyanthranylic	B
acid;	I
XA,	O
xanthurenic	B
acid;	I
CMM,	O
cutaneous;	O
UM,	O
Unknown	O
Melanoma.	O

Alanine	B
(p ≤ 0.011),	O
tyrosine	B
(p ≤ 0.014)	O
and	O
formate	B
(p ≤ 0.011)	O
were	O
also	O
elevated	O
in	O
NF	O
tumors	O
but	O
none	O
showed	O
statistically	O
significance	O
when	O
compared	O
with	O
prolactinomas.	O

The	O
four	O
cell	O
lines	O
were	O
pre-treated	O
with	O
the	O
MAGL	O
selective	O
inhibitor,	O
JZL184	O
(1	O
μM),	O
the	O
COX-1	O
selective	O
inhibitor,	O
SC-560	O
(1	O
μM);	O
and	O
the	O
COX-1	O
and	O
-2	O
nonselective	O
inhibitor,	O
Ibuprofen	B
(40	O
μM),	O
for	O
6	O
hours	O
and	O
then	O
co-treated	O
with	O
2-AG	O
for	O
3	O
days.	O

PGE_2	B
,	I
15-HETE	I
and	O
the	O
proresolution	O
agonist	O
RvD1	O
were	O
significantly	O
increased	O
in	O
patients	O
with	O
highly	O
active	O
MS,	O
and	O
NPD1	O
was	O
only	O
detectable	O
in	O
this	O
group.	O

_1	O
H	O
NMR	O
([_2	O
H_6	O
]DMSO)	O
showed	O
absence	O
of	O
methylene	B
protons,	O
δ	O
10.7	O
(2H,	O
1,	O
1′NH),	O
7.5	O
(d,	O
J	O
=	O
15.6	O

When	O
maternal	O
plasma	O
cholesterol	B
is	O
low,	O
birthweight	O
is	O
lower	O
than	O
normal.	O

Likewise,	O
patients	O
in	O
diabetic	O
control	O
(C)	O
group	O
will	O
be	O
advised	O
to	O
perform	O
self-monitoring	O
blood	O
glucose.	B

This	O
means	O
that	O
the	O
β-glucuronide	B
and	O
sulfate	B
conjugates	O
(7.9	O
pg/mL,	O
)	O
were	O
lower	O
than	O
the	O
corresponding	O
unconjugated	O
serum	O
E2	O
concentration	O
in	O
the	O
male	O
subjects.	O

Urine	O
samples	O
were	O
processed	O
with	O
an	O
equal	O
volume	O
of	O
50%	O
aqueous	O
acetonitrile	B
containing	O
chloropropamide	B
and	O
aminopimelic	B
acid	I
as	O
internal	O
standards	O
and	O
chromatographed	O
on	O
a	O
50	O
×	O
2.1	O
mm	O
Acquity	O
BEH	O
1.7	O
μm	O
C18	O
column	O
(reverse	O
phase	O
(RP)	O
chromatography	O
for	O
the	O
quantitation	O
of	O
CS	O
and	O
metabolite	O
561+).	O

Compared	O
to	O
control	O
conditions,	O
the	O
final	O
amount	O
of	O
lactate	B
was	O
therefore	O
detected	O
at	O
an	O
almost	O
1.6-fold	O
higher	O
level	O
after	O
rHla-treatment.	O

TCEP	O
has	O
frequently	O
been	O
used	O
as	O
reducing	O
agent	O
and	O
is	O
considered	O
as	O
a	O
suitable	O
choice	O
for	O
low	O
molecular	O
weight	O
disulfides.	B

Estrogen	B
NMPS	O
derivatives	O
factiitate	O
high	O
sensitivity	O
LC-ESI/MS	O
analysis.	O

Thus	O
the	O
Torus	O
columns,	O
and	O
in	O
particular	O
the	O
Diol	B
column,	O
offer	O
improved	O
resolution	O
due	O
to	O
narrower	O
peak	O
base	O
widths	O
for	O
all	O
classes	O
of	O
polar	O
analyte,	O
and	O
a	O
relatively	O
even	O
distribution	O
of	O
peaks	O
across	O
the	O
retention	O
time	O
range.	O

As	O
a	O
result,	O
the	O
biomarker	O
was	O
initially	O
identified	O
as	O
l-carnitine	B
and	O
was	O
finally	O
confirmed	O
by	O
comparison	O
with	O
RRLC-MS/MS	O
analysis	O
of	O
l-carnitine	B
standard	O
(C	O
and	O
D	O
).	O

The	O
low	O
concentration	O
of	O
free	O
glucose	B
is	O
a	O
feature	O
of	O
cancer	O
cells	O
which	O
together	O
with	O
the	O
low	O
level	O
of	O
G6P	O
reflects	O
the	O
high	O
glycolytic	B
flux,	O
making	O
glucose	B
transport	O
rate	O
limiting,	O
despite	O
derepression	O
of	O
GLUT4	O
expression	O
by	O
mutated	O
p53[].	O

Such	O
high	O
percentages	O
have	O
been	O
associated	O
with	O
a	O
rising	O
plasma	O
nonesterified	O
FA	B
concentrations,	O
hypoalbuminemia,	O
and	O
reduction	O
in	O
energy	O
supply	O
to	O
the	O
organs.	O

Patient	O
characteristics	O
BMI	O
body	O
mass	O
index,	O
GPV	O
genetic	O
predicted	O
value,	O
Phe	O
plasma	O
phenylalanine	B
at	O
time	O
of	O
investigation.	O

When	O
we	O
subdivided	O
the	O
patients	O
with	O
CAD	O
into	O
two	O
groups	O
according	O
to	O
treatment	O
with	O
lipid-lowering	O
drugs	O
(LLD),	O
those	O
not	O
treated	O
with	O
LLD	O
showed	O
significantly	O
higher	O
serum	O
concentrations	O
of	O
LDL	B
cholesterol	I
than	O
did	O
those	O
treated	O
with	O
LLD	O
in	O
both	O
the	O
angina	O
and	O
MI	O
groups.	O

Standard	O
laboratory	O
measurements	O
showed	O
a	O
significant	O
increase	O
in	O
triglycerides	B
(p	O
 = 0.002),	O
a	O
significant	O
decrease	O
in	O
HDL	O
(p	O
 = 0.003)	O
and	O
no	O
significant	O
change	O
in	O
LDL	O
(p	O
 = 0.327).	O

rHDL	O
infusion	O
inhibited	O
fasting-induced	O
lipolysis	O
(P	O
=	O
0.03),	O
fatty	O
acid	O
oxidation	O
(P	O
<	O
0.01),	O
and	O
circulating	O
glycerol	B
(P	O
=	O
0.04).	O

Indirect	O
calorimetry	O
was	O
performed	O
using	O
a	O
metabolic	O
cart	O
(VMax	O
Encore,	B
Viasys	O
Healthcare)	O
in	O
the	O
hooded	O
mode	O
and	O
data	O
were	O
obtained	O
for	O
30	O
min	O
while	O
subjects	O
were	O
fasting	O
(day	O
2,	O
0800–0830)	O
and	O
again	O
2.5h	O
(1430)	O
after	O
the	O
initiation	O
of	O
the	O
meal	O
(1200).	O

Our	O
results	O
are	O
in	O
agreement	O
with	O
this	O
report,	O
and	O
CPT-I	O
as	O
the	O
key	O
enzyme	O
of	O
FFA	O
oxidation	O
was	O
significantly	O
decreased	O
and	O
10	O
long-chain	O
acylcarnitines	B
were	O
significantly	O
increased	O
in	O
the	O
post-exposure	O
group.	O

In	O
contrast,	O
tagatose,	B
hydroxylamine,	B
glucopyranose	B
and	O
threonine	B
are	O
glycogenic	B
substrates	O
were	O
found	O
to	O
be	O
indicative	O
of	O
disease	O
progression	O
and	O
do	O
not	O
impact	O
deuterium	O
loading	O
for	O
DNA	O
stabilization	O
to	O
slow	O
tumor	O
growth.	O

To	O
evaluate	O
the	O
presence	O
of	O
possible	O
diagnostic	O
biomarkers,	O
the	O
predictive	O
capability	O
of	O
the	O
discriminant	O
metabolites	O
common	O
in	O
both	O
_1	O
H-NMR	O
and	O
MS	O
techniques	O
(aspartate,	O
alanine	B
and	O
citrate)	O
was	O
tested	O
through	O
the	O
ROC	O
curve	O
analysis.	O

Glucosamine	B
is	O
a	O
naturally	O
occurring	O
amino	B
monosaccharide	I
and	O
well	O
known	O
as	O
a	O
precursor	O
for	O
glycosaminoglycans	B
and	O
mucopolysaccharides,	B
major	O
components	O
of	O
joint	O
cartilage,	O
connective	O
tissue,	O
skin,	O
and	O
tendons.	O

Since	O
BPHL	O
metabolized	O
the	O
thiolactone	B
HCTL,	O
we	O
tested	O
it	O
with	O
several	O
other	O
PON1	O
substrates.	O

Samples	O
were	O
precipitated	O
with	O
methanol	B
under	O
vigorous	O
shaking,	O
centrifuged,	O
and	O
separated	O
into	O
5	O
fractions	O
for	O
analysis.	O

Citrulline,	B
an	O
intermediate	O
of	O
urea	B
biosynthesis,	O
and	O
urea	B
were	O
elevated	O
upon	O
hydrochlorothiazide	B
administration	O
(,	O
).	O

We	O
also	O
attempted	O
to	O
rescue	O
cell	O
death	O
caused	O
by	O
680C91,	O
epacadostat,	O
and	O
the	O
AHR	O
inhibitor	O
CH223191	O
with	O
the	O
NAD	B
precursor	O
nicotinamide	B
mononucleotide	I
(NMN).	O

Moreover,	O
the	O
internal	O
standard	O
that	O
was	O
used	O
(_13	O
CD_3	B
-enzalutamide)	I
was	O
labeled	O
in	O
the	O
N-methyl	O
function	O
group.	O

a,	O
b	O
1-D	O
proton	O
spectrum	O
and	O
TOCSY	O
of	O
the	O
aliphatic	B
region	O
of	O
the	O
spectrum.	O

In	O
addition	O
to	O
lactate,	B
β-hydroxypyruvate,	B
which	O
has	O
not	O
been	O
previously	O
linked	O
to	O
tumor	O
metabolism,	O
was	O
significantly	O
elevated	O
in	O
urine	O
of	O
primary	O
bladder	O
cancer	O
subjects.	O

For	O
the	O
determination	O
of	O
5-HT,	O
L-DOPA	B
and	O
various	O
Trp	O
metabolites	O
by	O
liquid	O
chromatography-electrospray	O
ionization-tandem	O
mass	O
spectrometry	O
(LC-ESI-MS/MS),	O
the	O
frozen	O
serum	O
samples	O
were	O
sent	O
on	O
dry	O
ice	O
to	O
the	O
Institute	O
of	O
Functional	O
Genomics	O
in	O
Regensburg,	O
Germany.	O

Serum	O
levels	O
of	O
phosphatidylcholine	B
(PtdC)	O
36:4	O
in	O
experimentally	O
infected	O
(N = 7)	O
and	O
control	O
cows	O
(N = 6)	O
from	O
time	O
zero	O
and	O
1	O
to	O
16 months	O
post-infection.	O

Effect	O
of	O
the	O
concentration	O
of	O
formic	B
acid	I
in	O
BGE	O
on	O
the	O
signal	O
to	O
noise	O
ratio	O
(S/N)	O
of	O
20	O
proteinogenic	O
amino	O
acids	O
in	O
water	O
solution.	O

Fructose	B
is	O
a	O
normal	O
component	O
of	O
the	O
human	O
diet	O
and	O
is	O
naturally	O
concentrated	O
in	O
sweet	O
fruits,	O
although	O
fructose	B
is	O
also	O
extracted	O
from	O
beets,	O
cane,	O
and	O
sucrose,	B
and	O
is	O
concentrated	O
as	O
high-fructose	O
corn	O
syrup	O
for	O
use	O
as	O
a	O
sweetener.	O

To	O
determine	O
whether	O
pre-activation	O
of	O
the	O
recipient	O
cells	O
influences	O
exosome	O
uptake,	O
we	O
co-incubated	O
resting	O
or	O
activated	B
T	O
cells	O
with	O
PKH26-labeled	O
TEX	O
or	O
DEX.	O

Conversely,	O
we	O
found	O
a	O
decreased	O
concentration	O
of	O
dimethylsulfone	B
in	O
the	O
urine	O
of	O
individuals	O
having	O
an	O
altered	O
renal	O
function.	O

The	O
following	O
bioinformatics	O
analysis	O
showed	O
that	O
these	O
metabolites	O
were	O
enriched	O
in	O
the	O
carnitine-acylcarnitine	B
or	O
tryptophan	B
metabolic	O
pathways.	O

-9,	O
trans	O
)),	O
obtained	O
from	O
Avanti	O
Polar	O
Lipids	O
(Alabaster,	O
AL),	O
and	O
the	O
PC	B
18:0_18:2(n	I
-7	I
trans,	I
n	I
-9	I
cis	I
)	I
and	O
PC	B
18:0_18:2(n	I
-6	I
trans,	I
n	I
-8	I
cis	I
)	I
standards,	O
purchased	O
from	O
Matreya	O
LLC	O
(State	O
College,	O
PA),	O
were	O
diluted	O
to	O
5	O
µM	O
in	O
2:1	O
methanol:chloroform	O
and	O
infused	O
directly	O
into	O
the	O
mass	O
spectrometer	O
at	O
a	O
flow	O
rate	O
of	O
50	O
µL	O
min_−1	O
.	O

Hence,	O
we	O
hypothesize	O
that	O
these	O
types	O
of	O
toxins	B
influence	O
the	O
same	O
network	O
of	O
genes	O
that	O
orchestrates	O
specific	O
cellular	O
pathways.	O

An	O
increase	O
in	O
linolenic	B
acid	I
(18∶3n3),	O
gamma-linolenic	B
acid,	I
linoleic	B
(18∶2n6)	I
and	O
arachidonic	B
acid	I
(20∶3n6)	O
formed	O
by	O
the	O
action	O
of	O
delta	O
6-desaturase	O
and	O
fatty	O
acid	O
elongase	O
was	O
also	O
seen.	O

GSH,	B
GSSH,	O
Cys,	O
CysSSH,	O
GSSG,	O
GSSSG	O
and	O
cystine	B
were	O
all	O
detected	O
in	O
the	O
aqueous	O
humor	O
of	O
both	O
DM	O
patients	O
(n	O
 = 12)	O
and	O
controls	O
(n	O
 = 20).	O

Interindividual	O
variation	O
in	O
estrogen	B
metabolism	O
may	O
also	O
influence	O
the	O
risk	O
of	O
breast	O
cancer	O
and	O
could	O
provide	O
clues	O
to	O
mechanisms	O
of	O
breast	O
carcinogenesis.	O

This	O
pathway	O
is	O
composed	O
of	O
39	O
species,	O
three	O
of	O
which	O
(glycine,	O
taurine	B
and	O
phenylalanine)	B
were	O
prioritised	O
by	O
LASSO	O
in	O
the	O
training	O
set	O
ten	O
or	O
more	O
times.	O

The	O
formalin	B
solution	O
was	O
kept	O
in	O
the	O
culture	O
dish	O
for	O
20-minute	O
cross-links	O
at	O
room	O
temperature.	O

Dihydrothymine	B
is	O
an	O
intermediate	O
decomposition	O
product	O
of	O
thymine.	B

Serum	O
metabolites	O
were	O
gradient-eluted	O
at	O
0.6	O
mL/min	O
using	O
mobile	O
phase	O
A:	O
0.2%	O
acetic	B
acid	I
in	O
water	O
and	O
mobile	O
phase	O
B:	O
0.2%	O
acetic	B
acid	I
in	O
methanol	B
(2%	O
to	O
98%	O
B	O
in	O
13	O
min,	O
98%	O
B	O
for	O
6	O
min).	O

Abbreviations:	O
TICL	O
ticlopidine	B
(CYP2B6	O
and	O
CYP2C19),	O
QUERC	O
quercetin	B
(CYP2C8),	O
TMP	O
trimethoprim	O
(CYP2C8),	O
TAO	O
troleandomycin	B
(CYP3A),	O
Keto	O
ketoconazole	B
(CYP3A),	O
PILO	O
pilocarpine	B
(CYP2A6),	O
DEDCA	O
diethyldiothicarbamate	B
(CYP2E1),	O
SULPH	O
sulfaphenazole	B
(CYP2C9),	O
FURA	O
furafylline	B
(CYP1A2),	O
QUIN	O
quinidine	B
m	O
Because	O
there	O
was	O
a	O
strong	O
correlation	O
between	O
formation	O
rate	O
of	O
hydroxyanastrozole	B
from	O
1	O
µm	O
anastrozole	B
and	O
from	O
20	O
µm	O
anastrozole	B
(Spearman	O
r	O
=	O
0.96,	O
P	O
=	O
0.0005),	O
anastrozole	B
(20	O
µm)	O
was	O
used	O
in	O
the	O
experiments	O
involving	O
expressed	O
CYPs.	O

Neopterin	B
also	O
was	O
negatively	O
associated	O
with	O
tryptophan	B
(P	O
=	O
0.01)	O
and	O
PLP	O
(P	O
<	O
0.0001).	O

Asparagine,	B
uric	B
acid,	I
and	O
tyrosine	B
were	O
associated	O
with	O
pancreatic	O
cancer	O
in	O
subjects	O
who	O
were	O
diagnosed	O
in	O
the	O
first	O
0‐6	O
years	O
(Table	O
).	O

It	O
is	O
possible	O
that	O
inaccuracies	O
such	O
as	O
this	O
could	O
contribute	O
to	O
the	O
conflicting	O
results	O
observed	O
in	O
previous	O
studies	O
conducted	O
to	O
assess	O
the	O
impact	O
of	O
cannabis	B
use	O
on	O
clinical	O
care	O
in	O
HIV-infected	O
individuals.	O

Total	O
cholesterol	B
was	O
lower	O
in	O
T2DM	O
which	O
was	O
in	O
part	O
attributable	O
to	O
lower	O
HDL	B
cholesterol.	I

Cho:	O
choline;	B
Cre:	O
creatinine;	B
Pyr:	O
pyruvate;	B
Ala:	O
alanine;	B
2HiB:	O
2-hydroxyisobutyrate;	B
Lac:	O
lactate;	B
2HB:	O
2-hydroxybutyrate.	B

In	O
the	O
co-infection	O
group,	O
six	O
compounds	O
namely,	O
3-Hydroxyphenylacetic	B
acid,	I
Pyridine,	B
Gentisic	B
acid,	I
Epinephrine,	B
Atrolactic	B
acid	I
and	O
4-Hydroxyphenylpyruvic	B
acid	I
showed	O
substantial	O
regulation	O
and	O
all	O
of	O
them	O
were	O
showing	O
increase	O
in	O
their	O
levels	O
(log2(FC) > 2	O
and	O
p-value < 0.05).	O

Specifically,	O
the	O
recorded	O
data	O
included:	O
a)	O
for	O
the	O
parents:	O
maternal	O
and	O
paternal	O
age	O
at	O
the	O
time	O
of	O
conception,	O
years	O
and	O
number	O
of	O
trials	O
of	O
IVF-ICSI	O
in	O
order	O
to	O
achieve	O
a	O
pregnancy,	O
course	O
of	O
gestation,	O
problems	O
during	O
the	O
perinatal	O
period,	O
type	O
of	O
childbirth	O
(vaginal	O
delivery	O
or	O
cesarean	O
section),	O
chronic	O
disease	O
of	O
the	O
parents,	O
b)	O
for	O
the	O
children:	O
gender,	O
gestational	O
age,	O
twins	O
or	O
singletons,	O
birth	O
weight,	O
birth	O
length,	O
head	O
circumference	O
at	O
birth,	O
duration	B
of	O
breastfeeding,	O
as	O
well	O
as	O
the	O
child's	O
personal	O
and	O
family	O
medical	O
history.	O

Controls	O
were	O
more	O
likely	O
to	O
smoke	O
cigarettes,	O
breastfeed	O
longer,	O
and	O
have	O
a	O
higher	O
intake	O
of	O
red	O
meat	O
and	O
soy	O
isoflavones	B
compared	O
with	O
cases.	O

Typical	O
spectral	O
data	O
from	O
serum,	O
PRP,	O
PPP,	O
and	O
PFP	O
samples	O
analyzed	O
using	O
standard	O
1D	O
_1	O
H	O
NMR	O
are	O
shown	O
in	O
and	O
reveal	O
the	O
presence	O
of	O
a	O
range	O
of	O
amino	O
acids,	O
organic	O
acids,	O
lipids,	O
and	O
glucose.	B
,	O
show	O
the	O
PCA	O
scores	O
plots	O
of	O
standard	O
1D	O
NMR	O
and	O
RP	B
UPLC-MS	O
(ESI+)	O
data	O
summarizing	O
the	O
main	O
sources	O
of	O
variation	O
among	O
the	O
different	O
sample	O
types.	O

Therefore,	O
the	O
increase	O
of	O
1-methyladenosine	B
in	O
HCC	O
samples	O
may	O
be	O
due	O
to	O
the	O
hyperactivation	O
of	O
methyltransferases,	O
which	O
was	O
followed	O
by	O
the	O
nucleotides	O
modification	O
in	O
response	O
to	O
inflammatory	O
stress	O
or	O
oxidative	O
DNA	O
damage.	O

All	O
DCM	O
patients,	O
with	O
or	O
without	O
LMNA	O
mutation,	O
differed	O
from	O
controls	O
in	O
regard	O
to	O
distinct	O
serum	O
lipidomic	O
profile	O
dominated	O
by	O
diminished	O
odd-chain	O
triglycerides	B
and	O
lipid	O
ratios	O
related	O
to	O
desaturation.	O

Results:	O
Betaine	B
assay	O
results	O
were	O
linear	O
(y	O
=	O
1.02X	O
−	O
3.75)	O
over	O
a	O
wide	O
range	O
of	O
concentrations	O
(26.0–1135	O
µM).	O

Bizzarro	O
et	O
al	O
showed	O
that	O
3	O
patients	O
with	O
DED	O
and	O
Sjögren	O
syndrome	O
had significantly	O
increased	O
Schirmer	O
tests	O
and	O
decreased	O
Bijsterveld	O
scores	O
after	O
60	O
days	O
of	O
oral	O
testosterone	B
undecanoate	I
treatment,	O
while	O
no	O
differences	O
were	O
found	O
with	O
respect	O
to	O
basal	O
values	O
after	O
60	O
days	O
of	O
placebo	O
treatment.	O

Although	O
acetate	B
is	O
an	O
important	O
SCFA	O
for	O
maintaining	O
colonic	O
health	O
and	O
as	O
a	O
precurser	O
molecule	O
for	O
endogenous	O
cholesterol	B
production,	O
elevated	O
levels	O
of	O
this	O
metabolite	O
have	O
previously	O
been	O
associated	O
with	O
CRC	O
in	O
humans	O
.	O

a,	O
‘Glycerophospholipid	B
metabolism’;	O
b,	O
‘linoleic	O
acid	O
metabolism’;	O
c,	O
‘primary	O
bile	O
acid	O
biosynthesis’;	O
d,	O
‘fatty	O
acid	O
biosynthesis’;	O
e,	O
‘arachidonic	O
acid	O
metabolism’;	O
f,	O
‘aminoacyl-tRNA	B
biosynthesis’;	O
g,	O
‘seleno	O
amino	O
acid	O
metabolism’.	O

Moreover,	O
in	O
this	O
study	O
we	O
showed	O
that	O
succinate,	B
a	O
tricarboxylic	B
acid	I

In	O
a	O
second	O
experiment	O
to	O
account	O
for	O
the	O
differences	O
in	O
cell	O
doubling	O
rates,	O
the	O
Rh30	O
cells	O
were	O
cultured	O
for	O
24	O
h,	O
and	O
the	O
myocytes	O
for	O
48	O
h	O
in	O
the	O
labeled	O
glucose.	B

The	O
lower	O
panel	O
shows	O
intensities	O
of	O
the	O
metabolite	O
matching	O
phosphatidylinositol	B
(PI),	O
a	O
key	O
phospholipid	B
present	O
the	O
cell	O
wall	O
of	O
mycobacteria	O
,	O
that	O
was	O
increased	O
in	O
TB	O
subjects.	O

We	O
observed	O
therefore	O
an	O
upregulation	O
in	O
PC	O
and	O
a	O
downregulation	O
in	O
lyso-PC	B
species	O
in	O
lipid	O
extracts	O
of	O
both	O
plasma	O
and	O
erythrocytes.	O

L,	O
the	O
blood	O
glucose	B
after	O
1 h ≥ 10.0 mmol/L,	O
the	O
blood	O
glucose	B
after	O
2 h	O

Glucose	B
metabolic	O
disorder	O
is	O
a	O
typical	O
symptom	O
of	O
patients	O
with	O
OSA	O
and	O
usually	O
occurs	O
with	O
an	O
increase	O
in	O
glucose	B
and	O
insulin	O
resistance.	O

Other	O
metabolic	O
differences	O
have	O
been	O
reported	O
in	O
previous	O
IUGR	O
studies	O
[,,],	O
involving	O
molecules	O
such	O
as	O
arginine,	B
proline,	B
glycine,	B
serine,	B
threonine,	B
myo	O
-inositol,	O
sarcosine	B
and	O
creatinine.	B

The	O
ammonium	B
acetate	I
was	O
then	O
replaced	O
by	O
water	O
(80%),	O
which,	O
together	O
with	O
MeOH:ACN	O
(20%),	O
was	O
run	O
for	O
1	O
min.	O

The	O
above	O
findings	O
led	O
us	O
to	O
explore	O
the	O
potential	O
of	O
sarcosine	B
as	O
a	O
candidate	O
for	O
future	O
development	O
in	O
biomarker	O
panels	O
for	O
early	O
disease	O
detection	O
and	O
aggressivity	O
prediction.	O

Kynurenine	B
pathway	O
metabolites	O
in	O
Chronic	O
and	O
Episodic	O
Cluster	O
Headache	O
groups	O
No	O
significant	O
correlations	O
were	O
found	O
between	O
any	O
kynurenine	B
metabolite	O
and	O
daily	O
frequency	O
of	O
headache	O
attacks	O
(not	O
shown).	O

The	O
level	O
of	O
formate	B
and	O
dimethylamine	B
in	O
methane	B
metabolism	O
was	O
found	O
to	O
be	O
significantly	O
changed	O
in	O
BD	O
subjects	O
.	O

Mannitol	B
5%	O
(w/w)	O
in	O
Milli-Q	O
water	O
was	O
prepared	O
and	O
autoclaved	O
as	O
washing	O
buffer.	O

These	O
isotopologues	O
cannot	O
be	O
derived	O
from	O
glucose,	B
and	O
must	O
therefore	O
originate	O
from	O
wheat	O
protein	O
(gluten).	O

These	O
include	O
2-aminoadipate	B
(0.93-fold)	O
representing	O
the	O
lysine	B
metabolic	O
pathway,	O
stearoyl	B
sphingomyelin	I
(0.9-fold)	O
representing	O
the	O
sphingolipid	B
metabolic	O
pathway,	O
4-hydroxyphenylpyruvate	B
(0.88-fold)	O
representing	O
phenylalanine	B
and	O
tyrosine	B
metabolic	O
pathways,	O
sorbitol	B
(0.87-fold)	O
representing	O
fructose,	B
mannose,	B
and	O
galactose	B
metabolic	O
pathways,	O
alpha-hydroxyisovalerate	B
(0.86-fold)	O
representing	O
leucine,	B
isoleucine,	B
and	O
valine	B
metabolic	O
pathways,	O
cys-gly,	B
oxidized	O
(0.84-fold)	O
representing	O
the	O
glutathione	B
metabolic	O
pathway,	O
trytophylglycine	B
(0.84-fold),	O
aspartylvaline	B
(0.81-fold),	O
and	O
aspartyltryptophan	B
(0.76-fold)	O
representing	O
the	O
dipeptide	O
metabolic	O
pathway,	O
deoxycholate	B
(0.84-fold)	O
and	O
7-ketodeoxycholate	B
(0.81-fold)	O
representing	O
secondary	O
bile	O
acid	O
metabolism,	O
asparagine	B
(0.81-fold)	O
representing	O
alanine	B
and	O
aspartate	B
metabolic	O
pathways,	O
and	O
glucose-6-phosphate	B
(0.64-fold)	O
and	O
fructose-6-phosphate	B
(0.75-fold)	O
representing	O
glycolytic,	B
gluconeogenic,	B
and	O
pyruvate	B
metabolic	O
pathways.	O

Triglycerides	O
hydrolysis	O
results	O
in	O
a	O
high	O
concentration	O
of	O
free	O
fatty	O
acids	O
that	O
undergo	O
beta	O
oxidation	O
which	O
is	O
supplementing	O
TCA	O
cycle	O
and	O
ketone	B
bodies	O
synthesis	O
by	O
providing	O
acetyl-CoA	B
moieties.	O

Furthermore,	O
we	O
found	O
that	O
α	B
-hydroxybutyrate	I
concentrations	O
in	O
response	O
to	O
a	O
glucose	B
challenge	O
were	O
associated	O
with	O
deterioration	O
of	O
the	O
DI	O
over	O
time.	O

In	O
a	O
subset	O
of	O
these	O
patients	O
and	O
for	O
subjects	O
in	O
the	O
risperidone	B
and	O
paliperidone	B
cohorts,	O
finger‐stick‐based	O
capillary	O
blood	O
samples	O
were	O
collected	O
at	O
6	O
of	O
the	O
8	O
scheduled	O
times	O
within	O
10	O
minutes	O
after	O
the	O
venous	O
sample	O
(ie,	O
at	O
predose	O
and	O
1,	O
2,	O
4,	O
6,	O
and	O
12	O
hours	O
postdose	O
for	O
oral	O
formulations	O
and	O
at	O
predefined	O
clock	O
times	O
for	O
LAI	O
formulations).	O

Alone,	O
fatty	O
acyl-CoAs	B
(fatty	O
acids)	O
cannot	O
enter	O
the	O
mitochondria	O
for	O
β-oxidation	O
and	O
must	O
first	O
be	O
converted	O
to	O
acylcarnitines	B
by	O
enzymes	O
of	O
the	O
carbamoyl	B
phosphate	I
transport	O
shuttle	O
system.	O

For	O
preparation	O
of	O
the	O
mobile	O
phase	O
and	O
sample	O
pre-treatment,	O
methanol	B
plus	O
(MeOH)	O
for	O
LC/MS	O
and	O
distilled	O
water	O
plus	O
(H_2	O
O)	O
for	O
LC/MS	O
were	O
purchased	O
from	O
Kanto	O
Chemical	O
Co.,	O
Inc.	O

Similarly	O
in	O
DEN,	O
fourteen	O
compounds	O
showed	O
substantial	O
regulation,	O
out	O
of	O
these,	O
twelve	O
metabolites	O
were	O
showing	O
increase	O
in	O
their	O
levels	O
(log2(FC) > 2;	O
p-value < 0.05)	O
and	O
two,	O
namely,	O
N-Methyl-a-aminoisobutyric	B
acid	I
and	O
Sarcosine	B
were	O
found	O
to	O
be	O
present	O
in	O
reduced	O
levels	O
when	O
compared	O
to	O
healthy	O
set.	O

When	O
estrogen	B
metabolism	O
is	O
balanced,	O
the	O
level	O
of	O
estrogen-DNA	O
adducts	O
in	O
tissue	O
and	O
urine	O
is	O
low	O
and/or	O
the	O
levels	O
of	O
estrogen	B
metabolites	O
and	O
conjugates	O
are	O
high.	O

These	O
matrix	O
peaks	O
could	O
possibly	O
represent	O
other	O
unidentified	O
vitamin	B
D	I
metabolites,	O
but	O
identification	O
of	O
these	O
compounds	O
was	O
beyond	O
the	O
scope	O
of	O
the	O
present	O
investigation.	O

The	O
solution	O
of	O
ethoxyamine	B
hydrochloride	I
was	O
prepared	O
by	O
dissolving	O
50	O
mg	O
ethoxyamine	B
hydrochloride	I
from	O
Sigma-Aldrich	O
in	O
1	O
mL	O
pyridine.	B

In	O
the	O
control	O
cells,	O
lactate	B
showed	O
positive	O
correlations	O
with	O
alanine	B
and	O
tCr,	O
and	O
alanine	B
also	O
correlated	O
positively	O
with	O
tCr.	O

We	O
were	O
able	O
to	O
corroborate	O
the	O
elevated	O
PGE_2	O
and	O
15-HETE	B
CSF	O
levels	O
that	O
were	O
recently	O
reported	O
in	O
MS	O
patients	O
as	O
a	O
quantitative	O
CSF	O
marker	O
of	O
neuroinflammation	O
and	O
oxidative	O
stress.	O

The	O
correlation	O
analyses	O
of	O
the	O
amino	O
acids,	O
biogenic	O
amines,	O
acylcarnitines,	B
lysophosphatidylcholines,	B
phosphatidylcholines,	B
sphingomyelins	B
and	O
sugars	O
from	O
sperm	O
and	O
seminal	O
plasma	O
with	O
standard	O
spermiogram	O
parameters	O
revealed	O
that	O
metabolites	O
in	O
sperm	O
are	O
closely	O
related	O
to	O
sperm	O
motility,	O
whereas	O
those	O
in	O
seminal	O
plasma	O
are	O
closely	O
related	O
to	O
sperm	O
concentration	O
and	O
morphology.	O

In	O
details,	O
a	O
negative	O
correlation	O
was	O
found	O
for	O
SMs,	O
AAs,	O
C0,	O
ACCs,	O
and	O
LPCs,	O
while	O
a	O
positive	O
correlation	O
was	O
observed	O
for	O
Sa	O
and	O
ceramides.	B

In	O
conclusion,	O
fasting	O
concentrations	O
of	O
α	B
-hydroxybutyrate	I
and	O
the	O
time	O
courses	O
of	O
α	B
-hydroxybutyrate	I
and	O
BCAAs	O
in	O
response	O
to	O
a	O
glucose	B
challenge	O
characterize	O
IR	O
in	O
youth.	O

The	O
experiments	O
to	O
check	O
for	O
analyte	O
loss	O
during	O
container	O
transfer	O
were	O
performed	O
in	O
the	O
PMC	O
matrix	O
at	O
concentration	O
levels	O
of	O
0.1	O
and	O
0.2	O
ng/mL	O
and	O
1	O
ng/mL	O
for	O
all	O
analytes	O
and	O
0.5	O
ng/mL	O
for	O
RvD2,	B
11-H-9-E	I
LAs,	O
and	O
11-H-12-E	B
LAs	O
(n	O
=	O
4	O
for	O
each).	O

Urine	O
samples	O
from	O
ten	O
synthetic	O
cannabinoid-abstinent	B
individuals	O
contained	O
no	O
peaks	O
fulfilling	O
LOD	O
criteria.	O

The	O
extraction	O
process	O
was	O
repeated	O
for	O
the	O
remaining	O
water	O
layer	O
by	O
adding	O
200 μL	O
of	O
ethyl	B
acetate,	I
and	O
the	O
two	O
resulting	O
ethyl	B
acetate	I
fractions	O
were	O
combined.	O

Given	O
established	O
disparity	O
between	O
biopsy	O
and	O
RP	B
histopathology,	O
risk	O
classification	O
accuracy	O
was	O
optimized	O
using	O
whichever	O
histopathology	O
best	O
described	O
tumor	O
characteristics.	O

Isotope	O
labeled	O
endogenous	O
metabolite	O
standards	O
(at	O
a	O
minimal	O
purity	O
of	O
98%),	O
namely	O
17α-Hydroxyprogesterone-d8	B
(2,2,	I
4,6,6,21,21,21-d8),	I
L-Thyroxine-13C6,	O
Succinic	B
acid-2,2,3,3-d4,	I
Pyruvic	O
acid-1-13C,	O
and	O
DL-Alanine-15N	B
were	O
purchased	O
from	O
Sigma	O
Aldrich	O
(St.	O
Quentin	O
Fallavier,	O
France).	O

Hydrophilic	B
residues	O
were	O
incorporated	O
into	O
derivative	O
compounds	O
in	O
an	O
attempt	O
to	O
increase	O
solubility	O
(as	O
reflected	O
in	O
lower	O
clogP	O
values)	O
to	O
obtain	O
lower	O
MIC_50	O
values.	O

A	O
total	O
of	O
16	O
potential	O
biomarker	O
metabolites	O
were	O
identified	O
in	O
stage	O
I/II	O
CRC,	O
indicating	O
amino	O
acid	O
metabolism,	O
glycolysis,	O
tricarboxylic	B
acid	I
(TCA)	O
cycle,	O
urea	B
cycle,	O
choline	B
metabolism,	O
and	O
gut	O
microflora	O
metabolism	O
pathway	O
disruptions.	O

Three	O
more	O
fractions	O
containing	O
peptides	O
modified	O
with	O
NO_2	O
-PhIP	O
at	O
tyrosine	B
residues	O
were	O
observed	O
in	O
Fraction	O
8	O
(t	O
_R	O
=14.9	O
min),	O
Fraction	O
9	O
(t	O
_R	O
=16.8	O
min),	O
and	O
Fraction	O
10	O
(t	O
_R	O
=21.6	O
min).	O

Exemplars	O
of	O
the	O
relationship	O
of	O
selected	O
tryptophan	B
metabolites	O
with	O
daily	O
diary	O
symptoms	O
in	O
irritable	O
bowel	O
syndrome	O
(IBS)	O
patients.	O

One	O
possible	O
common	O
role	O
for	O
mood	O
stabilizers,	O
including	O
valproic	B
acid,	I
is	O
a	O
reduction	O
in	O
the	O
inositol	B
phosphate	I
level	O
through	O
inhibition	O
of	O
PI3K	O
(phosphatidylinositol	O
3-kinase).	O

Moreover,	O
this	O
work	O
has	O
illuminated	O
the	O
substantial	O
shunting	O
of	O
glycolytic	B
intermediates	O
into	O
anabolic	O
subsidiary	O
pathways	O
and	O
the	O
engagement	O
of	O
reductive	O
glutamine	B
metabolism	O
to	O
sustain	O
mitochondrial	O
function	O
present	O
in	O
many	O
cancers_,	O
.	O

Fatty	O
acid	O
(18:1)	O
is	O
a	O
long	O
chain	O
fatty	O
acid,	O
and	O
decanoic	B
acid	I
is	O
a	O
medium	O
chain	O
fatty	O
acid.	O

Thus,	O
uptake	O
by	O
cancer	O
cells	O
of	O
hypoxanthine	B
and	O
guanine,	B
produced	O
in	O
other	O
tissues	O
or	O
ingested,	O
should	O
facilitate	O
purine	B
biosynthesis.	O

The	O
univariate	O
tests	O
demonstrated	O
that	O
ten	O
of	O
these	O
were	O
independently	O
altered,	O
of	O
which	O
lumichrome,	O
xanthine,	B
N-acetylproline,	B
isoleucine	B
and	O
L-DOPA	B
remained	O
significant	O
after	O
correcting	O
for	O
multiple	O
comparisons.	O

While	O
treatment	O
with	O
FPP	O
augmented	O
NK	O
cell	O
cytotoxicity	O
in	O
elderly	O
patients,	O
it	O
is	O
possible	O
that	O
it	O
has	O
no	O
effect	O
on	O
NK	O
cell	O
cytotoxicity	O
in	O
healthy	O
young	O
people,	O
as	O
observed	O
for	O
hesperidin.	B

One	O
of	O
the	O
most	O
interesting	O
findings	O
of	O
this	O
study	O
is	O
Lipid	O
A-disaccharide-1-P	B
was	O
significantly	O
elevated	O
12	O
and	O
18	O
months	O
post-H.	O
pylori	O
eradication.	O

The	O
model	O
comparing	O
oncocytomas	O
to	O
chromophobes	O
(a)	O
showed	O
distinct	O
group	O
separation	O
which	O
was	O
attributed	O
to	O
reduced	O
citrate	B
and	O
increased	O
carnitine,	B
trans-aconitate,	B
succinate	B
and	O
π-methylhistidine	B
in	O
chromophobe	O
RCC,	O
while	O
lower	O
levels	O
of	O
citrate,	B
1-methylnicotinamide,	B
glycine,	B
2-hydroxyisobutyrate	B
and	O
higher	O
carnitine,	B
tartrate,	B
trans-aconitate	B
and	O
histamine	B
in	O
ccRCC	O
relative	O
to	O
oncocytoma	O
were	O
observed.	O

10	O
metabolites,	O
namely	O
coumaric	B
acid,	I
tryptophan,	B
tyrosine,	B
succinic	B
acid,	I
pimelic	B
acid,	I
lysine,	B
hypoxanthine,	B
pyridoxic	B
acid,	I
glutaric	B
acid	I
and	O
hexanoylglycine,	B
were	O
significantly	O
altered	O
in	O
mid-	O
and	O
advanced-	O
stages	O
PD.	O

The	O
first	O
mechanism	O
likely	O
contributes	O
to	O
increased	O
α–HB	O
formation	O
by	O
supplying	O
more	O
α–KB	O
substrate	O
from	O
increased	O
cysteine	B
anabolism.	O

The	O
derivatized	O
thiols	B
were	O
injected	O
immediately	O
into	O
a	O
hypersil-ODS	O
HPLC	O
Column	O
connected	O
to	O
Agilent	O
fluorometer	B
operating	O
at	O
an	O
excitation	O
wavelength	O
of	O
485	O
nm	O
and	O
emission	O
wavelength	O
of	O
510	O
nm	O
(see	O
for	O
additional	O
information).	O

shows	O
an	O
example	O
TOCSY	O
spectrum	O
of	O
a	O
polar	O
extract	O
of	O
A549	O
cells	O
grown	O
in	O
the	O
presence	O
of	O
[U–_13	B
C]-glucose.	I

Serotonin	B
levels	O
were	O
either	O
reduced	O
or	O
enhanced	O
by	O
MYC,	O
depending	O
on	O
the	O
cell	O
line	O
(Supplemental	O
Fig.	O

Serum	O
was	O
aliquoted	O
in	O
1.5-ml	O
tubes	O
and	O
stored	O
at	O
−80°C	O
until	O
sphingolipid	B
assays	O
were	O
performed.	O

Two	O
sample	O
injections	O
(2	O
μL	O
and	O
10	O
μL)	O
were	O
used	O
for	O
LC-MS/MS	O
analysis	O
in	O
positive	O
and	O
negative	O
modes,	O
respectively.	O
_13	O
C-lactate	B
and	O
_13	O
C-tyrosine	B
were	O
added	O
to	O
each	O
serum	O
sample,	O
after	O
deproteinization,	O
to	O
monitor	O
the	O
system	O
performance.	O

For	O
testosterone,	B
relationships	O
with	O
body	O
mass	O
index	O
and	O
age	O
were	O
gender	O
specific.	O

Nonlinear	O
correlations	O
of	O
ESR,	O
albumin,	O
transferrin,	O
hsCRP	O
and	O
fecal	O
calprotectin	O
with	O
selected	O
vitamin	B
D	I
parameters	O
are	O
presented	O
in	O
.	O

Surprisingly,	O
purchased	O
EDTA	O
whole	O
blood	O
and	O
plasma	O
spiked	O
with	O
abiraterone	B
and	O
stored	O
at	O
2–8°C	O
and	O
at	O
ambient	O
temperature	O
was	O
stable	O
for	O
at	O
least	O
8	O
days	O
in	O
both	O
conditions.	O

Anastrozole	B
(1–200	O
µM)	O
was	O
incubated	O
in	O
duplicate	O
for	O
30	O
min	O
at	O
37°C	O
with	O
HLMs	O
(0.5	O
mg	O
protein	O
ml_−1	O
)	O
and	O
a	O
NADPH-generating	O
system.	O

The	O
nucleoside	O
subgroup	O
contained	O
31	O
nucleobases	O
and	O
derivatives,	O
including	O
the	O
purines	B
adenine	I
(A)	O
and	O
guanine	B
(G)	O
and	O
the	O
pyrimidines	B
cytosine	I
(C),	O
thymine	B
(T)	O
and	O
uracil	B
(U),	O
as	O
well	O
as	O
their	O
ribo-	O
and	O
deoxyribonucleosides.	O

NMR-based	O
metabolomics	O
coupled	O
with	O
sophisticated	O
bioinformatics	O
is	O
indeed	O
capable	O
of	O
identifying	O
rapid	O
changes	O
in	O
global	O
metabolite	O
profiles	O
in	O
urine	O
and	O
plasma	O
(treatment	O
‘fingerprints’),	O
which	O
may	O
be	O
linked	O
to	O
the	O
well-documented	O
early	O
changes	O
in	O
hepatic	O
insulin	O
senstitivity	O
following	O
thiazolidinedione	B
intervention	O
in	O
T2DM	O
patients.	O

The	O
median	O
Σ	O
R_s	O
parameter	O
decreased	O
in	O
the	O
same	O
direction,	O
from	O
4.0 s	O
for	O
isopropylamine	B
to	O
3.1 s	O
for	O
isopentylamine.	B

Our	O
results	O
from	O
the	O
metabonomic	O
analysis	O
were	O
similar:	O
the	O
SOM	O
regions	O
with	O
patients	O
that	O
have	O
a	O
detectable	O
loss	O
in	O
kidney	O
function	O
(i.e.,	O
elevated	O
creatinine	B
and	O
urea,	B
decreased	O
serum	O
albumin)	O
overlapped	O
with	O
insulin	O
resistance	O
and	O
related	O
problems	O
in	O
glucose	B
metabolism	O
(dyslipidemia,	O
high	O
insulin	O
dose,	O
high	O
HbA_1c	O
,	O
elevated	O
lactate	B
and	O
acetate	B
and	O
high	O
fasting	O
glucose)	B
(;	O
;	O
;	O
).	O

Differences	O
in	O
variables	O
such	O
as	O
disease	O
severity,	O
left	O
ventricular	O
ejection	O
fraction,	O
etiologies,	O
duration	B
of	O
disease,	O
co-morbidities,	O
and	O
concomitant	O
medications	O
could	O
have	O
affected	O
pulmonary	O
artery	O
pressure,	O
myocardial	O
DDAH-1,	O
or	O
both.	O

Depending	O
on	O
the	O
mobile	O
phase	O
composition,	O
the	O
ESI	O
response	O
was	O
1.5	O
to	O
2.3	O
times	O
greater	O
for	O
the	O
hexanoate	B
derivative	O
than	O
for	O
underivatized	O
NNAL,	O
with	O
the	O
response	O
for	O
the	O
acetate	B
derivative	O
between	O
the	O
two.	O

We	O
previously	O
reported	O
an	O
association	O
between	O
lysophosphatidylinositol	B
(LPI)	O
(16:1)	O
and	O
risk	O
for	O
type	O
2	O
diabetes	O
in	O
a	O
Chinese	O
population	O
using	O
an	O
untargeted	O
analysis.	O

Tissue	O
distribution	O
and	O
biliary	O
excretion	O
of	O
prostacyclin	B
metabolites	O
in	O
the	O
rat.	O

They	O
also	O
had	O
higher	O
citrulline	B
than	O
controls	O
but	O
it	O
was	O
lower	O
than	O
in	O
patients	O
with	O
IBS	O
or	O
inactive	O
UC.	O

The	O
CH_2	O
lipids	O
also	O
show	O
moderate	O
correlation	O
(r	O
=	O
0.512)	O
with	O
blood	O
triglycerides,	B
which	O
can	O
be	O
explained	O
by	O
the	O
fact	O
that	O
CH_2	O
is	O
also	O
included	O
in	O
the	O
lipid	O
signal	O
arising	O
from	O
triglycerides	B
in	O
the	O
blood.	O

However,	O
our	O
analyses	O
revealed	O
small	O
proportions	O
of	O
original	O
LCB	O
with	O
odd	O
(d17:0	O
and	O
d17:1)	B
and	O
polyunsaturated	O
(d18:2)	O
chain	O
length.	O

The	O
optimum	O
number	O
of	O
metabolites	O
to	O
include	O
is	O
traditionally	O
the	O
minimum	O
required	O
to	O
create	O
a	O
model	O
with	O
the	O
highest	O
sensitivity,	O
selectivity,	O
and	O
AUROC	O
which	O
in	O
this	O
case	O
would	O
be	O
uric	B
acid,	I
xanthine,	B
and	O
cholylglycine.	B

This	O
metabolite	O
is	O
produced	O
from	O
histidine	B
metabolism,	O
and	O
has	O
been	O
defined	O
as	O
a	O
marker	O
of	O
skeletal	O
muscle	O
metabolism.	O

This	O
analysis	O
revealed	O
significant	O
perturbation	O
of	O
14	O
metabolic	O
networks,	O
including	O
but	O
not	O
limited	O
to	O
short-chain	O
fatty	O
acid	O
(23.32),	O
fructose,	B
mannose,	B
and	O
galactose	B
(5.83),	O
and	O
glycolytic,	B
gluconeogenic,	B
and	O
pyruvate	B
(5.18)	O
metabolic	O
pathways	O
(Fig. ).	O

This	O
panel,	O
consisting	O
of	O
one	O
metabolite	O
detected	O
by	O
NMR	O
(α-hydroxybutyrate)	O
and	O
four	O
metabolites	O
detected	O
by	O
GC-MS	O
(2,	O
4-dihydroxypyrimidine,	I
azelaic	B
acid,	I
β-alanine,	B
and	O
pseudouridine),	B
could	O
differentiate	O
BD	O
subjects	O
from	O
healthy	O
controls	O
with	O
a	O
higher	O
accuracy	O
than	O
our	O
previous	O
single	O
platform-derived	O
metabolite	O
biomarker	O
panels.	O

Three	O
methods	O
were	O
employed	O
for	O
analysing	O
1,3-butadiene,	B
the	O
rest	O
of	O
the	O
VOC	O
and	O
all	O
the	O
PAHs	O
as	O
described	O
in	O
detail	O
in	O
.	O

Plasma	O
samples	O
were	O
thawed	O
on	O
ice	O
and	O
extracted	O
using	O
a	O
dual	O
methanol-chloroform	B
extraction	O
(for	O
protein	O
precipitation	O
and	O
separation	O
of	O
hydrophilic	B
and	O
lipophilic	O
fractions)	O
as	O
previously	O
described.	O

Moreover,	O
while	O
the	O
first	O
steps	O
of	O
the	O
Krebs	O
cycle	O
were	O
downregulated,	O
2-oxoglutarate	B
was	O
replenished	O
via	O
glutaminolysis.	O

[the	O
sum	O
of	O
25(OH)D_2	O
and	O
25(OH)D_3	O
)],	O
total	O
1,25(OH)_2	B
D	O
[the	O
sum	O
of	O
1,25(OH)_2	B
D_2	O
and	O
1,25(OH)_2	B
D_3	O
],	O
and	O
24,25(OH)_2	B
D	O
[specifically	O
24,25(OH)_2	B
D_3	O
]	O
(–).	O

For	O
biochemical	O
assessments,	O
fasting	O
serum	O
glucose,	B
total	O
cholesterol,	B
triglyceride,	B
low-density	O
lipoprotein	O
(LDL)-cholesterol,	B
high-density	O
lipoprotein	O
(HDL)-cholesterol,	B
AST,	O
ALT,	O
and	O
high-sensitivity	O
C-reactive	O
protein	O
(hs-CRP)	O
levels	O
were	O
assessed	O
via	O
automatic	O
analyzers.	O

F344	O
rats	O
and	O
B6C3F1	O
mice	O
were	O
selected	O
for	O
these	O
studies	O
because	O
they	O
have	O
been	O
used	O
to	O
assess	O
furan	B
toxicity	O
in	O
numerous	O
short	O
and	O
long	O
term	O
studies.	O

The	O
instrument	O
was	O
operated	O
in	O
a	O
negative-ion	O
mode	O
with	O
an	O
ESI	O
needle	O
voltage	O
of	O
5.00	O
kV	B
and	O
capillary	O
temperature	O
of	O
325	O
°C.	O

N-Methyl-4-pyridone-3-carboxamide	B
is	O
one	O
of	O
the	O
end	O
products	O
of	O
nicotinamide-adenine	B
dinucleotide	I
(NAD)	O
degradation.	O

As	O
HBSS	O
contains	O
1 g/L	O
D-glucose	B
and	O
ejaculate	O
volumes	O
were	O
varied,	O
the	O
exogenous	O
glucose	B
concentration	O
and	O
its	O
influence	O
on	O
subsequent	O
multivariate	O
statistical	O
analysis	O
(MVSA)	O
was	O
unpredictable.	O

The	O
transformation	O
of	O
[U-_13	O
C]-Glc	O
into	O
[U-_13	B
C]-lactate	I
and	O
[U-_13	O
C]-Ala	O
can	O
only	O
occur	O
via	O
glycolysis	O
and	O
to	O
a	O
much	O
lesser	O
extent,	O
the	O
pentose	B
phosphate	I
pathways	O
(PPP),	O
whereas	O
_13	O
C-ribose	O
of	O
nucleotides	O
can	O
only	O
be	O
derived	O
from	O
PPP.	O

Due	O
to	O
the	O
lack	O
of	O
maltase	O
activity	O
in	O
the	O
blood,	O
maltose	B
is	O
mainly	O
transported	O
to	O
the	O
kidney	O
by	O
the	O
maltose-binding	O
protein	O
(MBP),	O
where	O
it	O
is	O
hydrolyzed	O
to	O
glucose	B
by	O
maltase	O
to	O
be	O
reabsorbed	O
into	O
the	O
body.	O

Primary	O
aldosteronism	O
patients	O
had	O
significantly	O
increased	O
cortisol	B
and	O
total	O
glucocorticoid	B
metabolite	O
excretion	O
(all	O
P	O
<	O
0.001),	O
only	O
exceeded	O
by	O
glucocorticoid	B
output	O
in	O
patients	O
with	O
clinically	O
overt	O
adrenal	O
Cushing	O
syndrome.	O

Plasma	O
samples	O
were	O
centrifuged	O
at	O
21,000×g	O
,	O
for	O
5 min	O
after	O
deproteination	O
with	O
an	O
equal	O
volume	O
of	O
perchloric	B
acid	I
(0.4 M,	O
containing	O
0.1 %	O
sodium	B
metabisulfite	I
and	O
0.05 %	O
EDTA).	O

These	O
findings	O
strongly	O
support	O
the	O
concept	O
that	O
NMR/PLS-DA	O
analysis	O
of	O
serum	O
samples	O
can	O
reliably	O
differentiate	O
between	O
the	O
RR	O
and	O
SP	B
stages	O
of	O
MS	O
disease	O
progression.	O

Cyclo(leucyl-prolyl)	B
was	O
obtained	O
from	O
Bachem	O
(USA)	O
and	O
3-hydroxyhippuric	B
acid	I
was	O
kindly	O
provided	O
by	O
P.C.H.	O
Hollman	O
(Rikilt,	O
Wageningen	O
Univ.	O

In	O
Table	O
are	O
reported	O
the	O
correlations	O
between	O
the	O
24S-OH-Chol	B
and	O
other	O
variables	O
observed	O
in	O
the	O
whole	O
sample	O
(n.	O
160	O
subjects).	O

In	O
the	O
_1	O
H	O
NMR	O
spectral	O
of	O
plasma	O
samples,	O
the	O
dominated	O
change	O
of	O
the	O
signals	O
among	O
low	O
molecular	O
weight	O
metabolites	O
like	O
leucine,	B
isoleucine,	B
valine,	B
alanine,	B
glutamine,	B
creatine,	B
proline,	B
glucose	B
etc.	O
were	O
detected.	O

Cholesterol	B
oxidase	O
converts	O
sterols	O
with	O
a	O
3β-hydroxy-5-ene	B
function	O
to	O
3-oxo-4-ene	B
analogues	O
(Scheme	O
2)	O
and	O
a	O
3β-hydroxy-5α-hydrogen	B
function	O
to	O
a	O
3-oxo	O
function.	O

Zinc-alpha-2-glycoprotein	B
(ZA2G),	O
a	O
secreted	O
protein	O
that	O
stimulates	O
lipid	O
degradation	O
in	O
adipocytes	O
and	O
is	O
associated	O
with	O
excessive	O
weight	O
loss	O
and	O
cancer	O
cachexia,	O
was	O
elevated	O
in	O
survivors	O
compared	O
with	O
both	O
fatalities	O
and	O
healthy	O
controls.	O

The	O
effects	O
of	O
hemolyzed	O
blood	O
and	O
commonly	O
used	O
additives	O
in	O
blood	O
tubes	O
such	O
as	O
lithium	B
heparin,	I
ethylenediaminetetraacetic	B
acid	I
(EDTA)	O
and	O
citric	B
acid	I
were	O
investigated.	O

The	O
serum	O
level	O
of	O
L-Aspartyl-4-phosphate	B
in	O
patients	O
with	O
HCC	O
was	O
significantly	O
decreased	O
with	O
the	O
progression	O
of	O
disease.	O

Moreover,	O
because	O
PC	B
16:0_17:0	I
is	O
a	O
saturated	O
lipid,	O
it	O
cannot	O
be	O
analyzed	O
for	O
CC	O
location	O
isomers.	O

N-acetyl-aspartate	B
is	O
exclusively	O
synthesized	O
at	O
high	O
concentrations	O
in	O
the	O
cytoplasm	O
of	O
neurons	O
and	O
was	O
detected	O
in	O
a	O
few	O
other	O
tissues,	O
as	O
well	O
as	O
in	O
peritoneal	B
mast	O
cells,	O
retina,	O
and	O
lens	O
of	O
the	O
eye.	O

LC-MS/MS,	O
abiraterone,	B
abiraterone	B
acetate,	I
stability,	O
validation	O

In	O
the	O
RRMS	O
samples,	O
the	O
concentration	O
of	O
25-hydroxycholesterol	B
(25-HC)	O
is	O
reduced	O
significantly	O
compared	O
to	O
CP	O
(1.19 ± 0.26 ng/mL	O
cf.	O

Creatine’s	B
function	O
is	O
adenosine	B
triphosphate	I
(ATP)	O
recycling.	O

In	O
this	O
study,	O
we	O
used	O
LC-MS/MS	O
to	O
measure	O
the	O
abundance	O
of	O
plasma	O
amino	O
acids	O
and	O
amino	O
acid	O
metabolites,	O
which	O
reflect	O
the	O
balance	O
between	O
AA	O
uptake	O
and	O
release	O
by	O
various	O
tissues	O
that	O
are	O
influenced	O
by	O
changes	O
in	O
protein	O
metabolism	O
in	O
response	O
to	O
the	O
presence	O
or	O
absence	O
of	O
insulin	O
and	O
ketone	B
levels.	O

Fused	O
silica	B
tubes,	O
125	O
µm	O
ID,	O
and	O
stainless	O
steel	O
fittings	O
were	O
used	O
as	O
the	O
transfer	O
lines	O
and	O
connectors,	O
respectively	O
(Upchurch	O
Scientific,	O
WA,	O
USA).	O

Its	O
decarboxylated	O
form,	O
S-adenosylmethionine,	B
is	O
increasingly	O
recognized	O
for	O
its	O
role	O
in	O
hepatocyte	O
growth,	O
death,	O
and	O
malignant	O
degeneration.	O

Marked	O
differences	O
in	O
the	O
regulation	O
of	O
plasma	O
phospholipids	B
were	O
observed	O
in	O
ivGTT	O
and	O
EH	O
clamp.	O

Our	O
results	O
indicate	O
that	O
major	O
neonicotinoid	B
metabolites	O
in	O
the	O
urine	O
of	O
experimental	O
animals,	O
such	O
as	O
AM-2,	O
IM-1	O
and	O
CM-1,	O
can	O
be	O
used	O
as	O
urinary	O
biomarkers	O
for	O
humans.	O

This	O
metabolite	O
is	O
further	O
oxidized	O
into	O
trimethylamine‐N‐oxide	B
(TMAO)	O
in	O
liver	O
and	O
promotes	O
atherogenesis.	O

Two	O
3-oxo-Δ_4	B
-bile	I
acids,	I
that	O
are	O
intermediates	O
in	O
the	O
synthesis	O
of	O
chenodeoxycholic	B
acid	I
from	O
cholesterol	B
and	O
generally	O
considered	O
to	O
be	O
fetal	O
bile	O
acids	O
(–),	O
7α-hydroxy-3-oxochol-4-en-24-oic	B
acid	I
and	O
3-oxochola-4,6-dien-24-oic	B
acid,	I
were	O
upregulated	O
in	O
HCC	O
relative	O
to	O
AML.	O

One	O
possible	O
explanation	O
for	O
the	O
low	O
levels	O
of	O
these	O
phenanthrene	B
metabolites	O
in	O
human	O
urine	O
is	O
that	O
they	O
are	O
excreted	O
mainly	O
in	O
feces,	O
which	O
were	O
not	O
collected	O
or	O
analyzed	O
in	O
this	O
study.	O

CE,	O
cholesterol	B
esters;	I
SM,	O
sphingomyelin;	B
PPV,	O
positive	O
predictive	O
value;	O
NPV,	O
negative	O
predictive	O
value;	O
OR,	O
odds	O
ratio;	O
AUC,	O
area	O
under	O
the	O
curve.	O

Wilcoxon	O
signed	O
rank	O
test	O
and	O
Chi-square	O
tests	O
were	O
used	O
for	O
continuous	O
and	O
categorical	O
variables,	O
respectively	O
Abbreviations:	O
BMI	O
body	O
mass	O
index,	O
SBP	O
systolic	O
blood	O
pressure,	O
DBP	B
diastolic	O
blood	O
pressure	O

In	O
each	O
of	O
these	O
studies,	O
investigators	O
observed	O
that	O
breast	O
cancer	O
risk	O
was	O
increased	O
with	O
circulating	O
concentrations	O
of	O
the	O
parent	O
estrogens	O
and	O
was	O
reduced	O
with	O
increasing	O
ratios	O
of	O
2-	O
and	O
4-pathway	O
estrogen	B
metabolites	O
to	O
parent	O
estrogens.	O

The	O
mass	O
spectrometer	O
was	O
tuned	O
and	O
optimized	O
in	O
negative	O
ion	O
mode	O
using	O
a	O
solution	O
of	O
2-hydroxyphenylacetic	B
acid.	I

Specifically,	O
four	O
lysophosphatidylcholines	B
were	O
up-regulated	O
in	O
tumours	O
with	O
high	O
F_b	O
.	O

Spearman	O
correlation	O
analysis	O
revealed	O
a	O
significant	O
positive	O
correlation	O
between	O
HbA1c	O
and	O
serum	O
putrescine	B
levels.	O

For	O
aqueous	O
mobile	O
phase,	O
a	O
number	O
of	O
buffers	O
were	O
evaluated,	O
particularly	O
such	O
volatile	O
buffers	O
as	O
trifluoroacetate	B
(TFA,	O
pK_a	O
=	O
0.5),	O
formate	B
(pK_a	O
=	O
3.8),	O
and	O
acetate	B
(pK_a	O
=	O
4.8).	O

Comparison	O
of	O
matrix	O
effects	O
(%)	O
in	O
serum	O
samples	O
with	O
the	O
four	O
approaches	O
assessed	O
to	O
extract	O
polyamines	B
and	O
related	O
compounds	O
(n	O
=	O
3).	O

Reactions	O
of	O
oxaprozin-1-O-acyl	B
glucuronide	I
in	O
solutions	O
of	O
human	O
plasma	O
and	O
albumin.	O

Higher	O
levels	O
of	O
GSH	B
have	O
been	O
related	O
to	O
apoptosis	O
resistance.	O

A	O
unique	O
origin	O
for	O
these	O
two	O
sterols	O
was	O
also	O
suggested	O
by	O
the	O
negative	O
or	O
weak	O
positive	O
correlations	O
between	O
14-desmethyl	B
lanosterol	I
and	O
other	O
intermediates	O
in	O
the	O
cholesterol	B
biosynthetic	O
pathways	O
such	O
as	O
lathosterol	B
and	O
lanosterol,	B
and	O
by	O
weaker	O
correlations	O
between	O
4β-hydroxycholesterol	B
and	O
other	O
ring-structure	O
oxysterols	B
such	O
as	O
7α-hydroxycholesterol.	B

Intramyocellular	O
fat	O
content	O
decreased	O
from	O
1.5	O
±	O
0.3	O
to	O
0.9	O
±	O
0.2%	O
(P	O
<	O
0.05)	O
despite	O
increased	O
body	O
weight	O
(70.5	O
±	O
3.5	O
to	O
72.0	O
±	O
3.5	O
kg;	O
P	O
<	O
0.05)	O
after	O
4	O
months	O
of	O
pioglitazone	B
treatment	O
(Fig.	O
1).	O

summarizes	O
PL	O
species	O
with	O
the	O
most	O
significant	O
differences	O
between	O
tumor	O
and	O
non-tumor	O
cells	O
(average	O
values	O
of	O
8	O
patients),	O
including	O
the	O
information	O
on	O
their	O
hypothetical	O
FA	B
composition.	O

HPLC	O
grade	O
toluene,	B
1-butanol,	B
pentane	B
and	O
ethyl	B
acetate	I
from	O
Fisher	O
were	O
used	O
for	O
extractions.	O

Well	O
described	O
prostatic	O
metabolite	O
changes	O
due	O
to	O
CaP,	O
specifically	O
reduced	O
citrate	B
and	O
polyamines	B
(e.g.,	O
myo-inositol,	B
spermine)	O
and	O
increased	O
intracellular	O
lactate,	B
choline,	B
and	O
creatine,	B
were	O
not	O
predictive	O
in	O
this	O
study	O
due	O
to	O
the	O
following	O
underlying	O
clinical	O
and	O
biological	O
factors.	O

Each	O
dried	O
sample	O
was	O
derivatized	O
in	O
60	O
μl	O
1‐butanol	B
and	O
acetyl	B
chloride	I
mixture	O
(90:10,	O
v/v)	O
at	O
65°C	O
for	O
20	O
min.	O

Importantly,	O
CCBL1	O
alteration	O
is	O
correlated	O
to	O
poor	O
prognosis	O
in	O
CMM	O
patients	O
(p	O
<	O
0.001),	O
while	O
KYNU	O
is	O
associated	O
with	O
a	O
better	O
outcome	O
(p	O
<	O
0.05),	O
which	O
can	O
suggest	O
that	O
the	O
KP	B
enzymes	O
possess	O
a	O
different	O
intrinsic	O
mechanism	O
of	O
action.	O

Mortality	O
was	O
increased	O
in	O
patients	O
with	O
high	O
lactate	B
and	O
low	O
total	O
cholesterol	B
concentrations	O
at	O
admission.	O

A	O
subset	O
of	O
patients	O
in	O
the	O
risperidone	B
and	O
paliperidone	B
groups	O
were	O
treated	O
with	O
an	O
LAI	O
formulation.	O

Chromatogram	O
of	O
the	O
second	O
dimension	O
separation	O
of	O
a	O
fraction	O
of	O
interest	O
from	O
the	O
_15	O
N-ethanolamine	B
derivatized	O
urine	O
sample.	O

The	O
autosampler	O
stability	O
(2–8°	O
C)	O
for	O
abiraterone	B
was	O
demonstrated	O
to	O
deviate	O
no	O
more	O
than	O
±2.2%	O
after	O
192	O
hours,	O
and	O
was	O
therefore	O
considered	O
stable	O
for	O
at	O
least	O
8	O
days.	O

The	O
TK	O
pathway	O
has	O
been	O
established	O
as	O
a	O
de	O
novo	O
pathway	O
for	O
NAD+	B
synthesis	O
in	O
the	O
liver	O
and	O
kidneys.	O

It	O
would	O
be	O
interesting	O
to	O
examine	O
the	O
effects	O
of	O
such	O
approaches	O
on	O
patients	O
in	O
various	O
stages	O
of	O
CKD	O
(including	O
transplant	O
and	O
haemodialysis	O
patients),	O
and	O
measure	O
uraemic	O
indole	B
derivatives,	O
tryptophan	B
metabolites,	O
inflammation	O
markers	O
and	O
psychological	O
variables.	O

By	O
hazard	O
ratio	O
(HR)	O
analysis,	O
the	O
HR	O
of	O
p-cresol,	B
proline	B
and	O
4-hydroxybenzoic	B
acid	I
was	O
2.688	O
(95%	O
CI:	O
1.403-5.150),	O
2.473(95%CI:	O
1.293-4.728)	O
and	O

[5-ASA]	O
suppositories	O
or	O
enemas),	O
oral	O
5-ASA,	O
oral	O
prednisolone,	B
immunosupressants	O
[azathioprine,	O
mercaptopurine,	B
methotrexate]	O
and	O
biologics	O
[adalimumab,	O
infliximab,	O
vedolizumab].	O

	O
One	O
mL	O
of	O
thawed	O
urine	O
was	O
mixed	O
with	O
0.5	O
mL	O
of	O
0.2	O
M	O
sodium	B
phosphate	I
buffer.	O

We	O
previously	O
discussed	O
in	O
the	O
context	O
of	O
IBD[],	O
that	O
carbamyl	B
phosphate	I
synthetase	O
(CAD)	O
-	O
rate-limiting	O
enzyme	O
for	O
the	O
urea	B
cycle	O
-	O
was	O
identified	O
as	O
negative	O
regulator	O
of	O
NOD2	O
and	O
might	O
be	O
a	O
pharmacologic	O
target	O
for	O
CD	O
therapies[].	O

_a	O
N	B
-desmethyl-acetamiprid	I
The	O
detection	O
of	O
DMAP,	O
thiamethoxam	B
and	O
nitenpyram	O
were	O
the	O
most	O
frequent	O
in	O
TSG,	O
followed	O
by	O
ASG,	O
and	O
NSG.	O

This	O
platform	O
detects	O
163	O
moieties	O
comprising	O
14	O
amino	O
acids,	O
41	O
acylcarnitines	B
(including	O
hydroxyl	O
and	O
dicarboxyl	B
acylcarnitines),	I
hexoses,	O
15	O
sphingomyelins	B
and	O
sphingomyelin	B
derivatives,	O
15	O
lyso-phosphatidylcholines,	B
and	O
77	O
phosphatidylcholines	B
(including	O
phospholipids	B
and	O
plasmalogens).	O

Formic	B
acid	I
(for	O
mass	O
spectrometry)	O
and	O
ammonium	B
carbonate	I
were	O
acquired	O
from	O
Fluka	O
Analytical	O
(Sigma	O
Aldrich),	O
Steinheim,	O
Germany.	O

Moreover,	O
whereas	O
the	O
glucose	B
uptake	O
rate	O
was	O
lower	O
in	O
rHla-treated	O
16HBE14o_−	O
cells	O
by	O
20%	O
compared	O
to	O
control	O
conditions,	O
it	O
was	O
increased	O
by	O
up	O
to	O
45%	O
(compared	O
with	O
cells	O
under	O
control	O
conditions)	O
in	O
rHla-treated	O
S9	O
cells	O
and	O
accompanied	O
by	O
up	O
to	O
70%	O
higher	O
lactate	B
production	O
rates.	O

The	O
most	O
important	O
finding	O
is	O
that	O
these	O
differences	O
were	O
only	O
observed	O
after	O
challenge	O
tests	O
and	O
were	O
present	O
in	O
a	O
state	O
when	O
all	O
conventional	O
markers	O
of	O
glucose	B
metabolism	O
such	O
as	O
fasting	O
and	O
2-h	O
glucose	B
in	O
oGTT,	O
fasting	O
insulin,	O
proinsulin	O
and	O
insulin	O
sensitivity	O
were	O
still	O
in	O
the	O
normal	O
range.	O

This	O
was	O
determined	O
if	O
the	O
Student	O
t-test	O
results	O
comparing	O
the	O
same	O
normalized	O
metabolite	O
concentrations	O
between	O
the	O
BMI	O
control	O
groups	O
was	O
not	O
significant,	O
or	O
the	O
metabolite	O
concentrations	O
trended	O
in	O
opposite	O
directions	O
with	O
weight	O
in	O
the	O
BMI	O
controls	O
and	O
schizophrenia	O
groups	O
(e.g.,	O
glycine).	B

The	O
choice	O
of	O
the	O
TSKgel	O
Amide-80	B
HILIC	O
column	O
for	O
this	O
study	O
was	O
based	O
on	O
the	O
inherent	O
chemical	O
stability	O
it	O
offers	O
for	O
the	O
separation	O
of	O
derivatized	O
components	O
in	O
a	O
complex	O
biological	O
matrix	O
such	O
as	O
urine.	O

Citrate	B
was	O
lower	O
in	O
MS	O
patients,	O
whereas	O
lactate	B
was	O
higher	O
in	O
only	O
NMOSD	O
specifically.	O

Furthermore,	O
in	O
the	O
partial	O
correlation	O
analysis,	O
tryptophan	B
and	O
kynurenine	B
were	O
both	O
inversely	O
correlated	O
to	O
ADHD	O
symptom	O
scores,	O
even	O
when	O
adjusting	O
for	O
the	O
effect	O
of	O
smoking	O
and	O
age	O
(Table ).	O

However,	O
α-ketoglutarate	B
levels	O
significantly	O
increased	O
only	O
in	O
the	O
case	O
of	O
control	O
exercisers.	O

Based	O
on	O
the	O
constructed	O
ROC	O
curves,	O
the	O
AUC	O
values	O
of	O
MG	B
(18:2),	I
GNOE,	O
PE	B
(18:2)	I
and	O
ZS	O
were	O
calculated	O
to	O
be	O
0.828,	O
0.772,	O
0.798	O
and	O
0.900,	O
respectively,	O
for	O
BAV	O
prediction.	O

Dithiothreitol,	B
Iodoacetamide,	B
and	O
β-casein-90%+	B
were	O
all	O
purchased	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
MO).	O

*	O
Unadjusted	O
p	O
-value;	O
values	O
are	O
means	O
and	O
SD;	O
multivariate	O
GLM	O
was	O
used	O
to	O
compare	O
FA	B
PBMC	O
levels	O
between	O
the	O
vitamin	B
D	I
supplemented	O
and	O
placebo	O
groups.	O

The	O
disc	O
was	O
placed	O
in	O
a	O
well	O
of	O
a	O
Millipore	O
MultiScreen	O
HV	B
96-well	O
plate	O
(Merck	O
KGaA,	O
Darmstadt,	O
Germany)	O
containing	O
100	O
μL	O
of	O
freshly	O
prepared	O
working	O
solution.	O

Although	O
there	O
was	O
no	O
difference	O
in	O
the	O
incidence	O
of	O
AP	B
in	O
their	O
medical	O
history	O
(6/9	O
AP	B
vs.	I
8/18	O
no	O
AP,	B
P	O
=0.49),	O
patients	O
who	O
went	O
on	O
to	O
develop	O
AP	B
did	O
have	O
higher	O
instances	O
of	O
multiple	O
diagnoses	O
coming	O
in	O
to	O
the	O
ERCP	O
procedure.	O

The	O
(C_6	O
-C_1	O
)	O
low-molecular-weight	O
polyphenol	O
catabolites	O
(e.g.,	O
protocatechuic	O
acid)	O
reduce	O
serum	O
levels	O
of	O
total	O
cholesterol,	B
LDL,	O
and	O
HDL	O
in	O
overloaded	O
rats	O
[,].	O

Alternatively,	O
caffeine	B
and	O
theophylline	B
may	O
more	O
closely	O
approximate	O
exposure	O
to	O
bioactive	O
compounds	O
in	O
coffee	O
that	O
are	O
involved	O
in	O
the	O
cause	O
of	O
colorectal	O
cancer.	O

In	O
human	O
studies,	O
HCC	O
has	O
been	O
associated	O
with	O
a	O
down	O
regulation	O
in	O
choline	B
metabolism.	O

Among	O
the	O
identified	O
potential	O
metabolic	O
biomarkers	O
for	O
CAP,	O
the	O
levels	O
of	O
sphinganine	B
in	O
the	O
serum	O
of	O
CAP	O
patients	O
is	O
lower	O
than	O
for	O
controls,	O
and	O
it	O
was	O
observed	O
positively	O
correlated	O
with	O
NE%,	O
ESR	O
and	O
CRP,	O
so	O
it	O
might	O
reflect	O
the	O
presence	O
of	O
an	O
infection	O
and	O
inflammatory	O
response.	O

The	O
phenol	B
must	O
be	O
of	O
high	O
quality	O
as	O
outdated,	O
oxidized	O
phenol	B
can	O
cause	O
ring-opening	O
at	O
the	O
imidazole	B
moiety	O
of	O
arylamine	B
and	O
heteroarylamine	B
substituted	O
dG-C8	O
adducts	O
(;	O
).	O

The	O
total	O
amount	O
of	O
glucose	B
was	O
analyzed	O
by	O
means	O
of	O
gas	O
chromatography–mass	O
spectrometry.	O

We	O
found	O
low	O
concentrations	O
of	O
the	O
omega-3	B
unsaturated	O
fatty	O
acid	O
docosahexaenoic	O
acid	O
(DHA)	O
in	O
PTSD	O
subjects,	O
raising	O
the	O
possibility	O
that	O
its	O
reduced	O
plasma	O
concentration	O
may	O
contribute	O
to	O
inflammation	O
in	O
these	O
PTSD	O
subjects	O
[,	O
].	O

Lipids	O
and	O
apolipoproteins	O
in	O
HDL	O
2–4	O
decreased	O
significantly,	O
except	O
for	O
their	O
triglyceride	B
content,	O
which	O
was	O
increased.	O

Methionine	B
and	O
homocysteine	B
are	O
common	O
amino	O
acid	O
obtained	O
from	O
food.	O

In	O
the	O
setting	O
of	O
0.1%	O
formic	B
acid,	I
the	O
signal	O
was	O
enhanced	O
to	O
2.29E4,	O
with	O
an	O
additional	O
108	O
peaks	O
detected.	O

The	O
p-values	O
corresponding	O
to	O
hippurate	B
and	O
alanine	B
spectral	O
variables	O
are	O
large,	O
reflecting	O
the	O
low	O
power	O
of	O
all	O
methods	O
for	O
correspondingly	O
low	O
association	O
strengths.	O

It	O
is	O
important	O
to	O
mention	O
here	O
that	O
the	O
SLE	O
and	O
LN	O
patients	O
involved	O
in	O
this	O
study	O
were	O
all	O
on	O
immunosuppressive	O
medications	O
including	O
hydroxychloroquine	B
(HCQ),	O
Azathioprine	B
(AZA),	O
Cyclophosphamide,	O
Mycophenolate	O
and	O
prednisolone	B
(see	O
).	O

The	O
concentrations	O
of	O
the	O
glucuronidated	O
and	O
sulfated	B
α-CEHC	I
were	O
similar	O
within	O
each	O
cohort.	O

Interestingly,	O
higher	O
PAL_DLW	O
levels	O
in	O
MetS_any	O
women	O
were	O
associated	O
with	O
serine	B
levels	O
comparable	O
to	O
the	O
less	O
active	O
MetS_zero	O
women.	O

Alternative	O
biomarkers	O
for	O
increased	O
CIMT	O
as	O
an	O
indicator	O
of	O
impaired	O
vascular	O
health	O
are	O
red	O
cell	O
distribution	O
width	O
and	O
serum	O
podocalyxin	B
with	O
DOR	O
values	O
of	O
3.9	O
and	O
3.2,	O
respectively	O
[,	O
].	O

Alongside	O
the	O
ceramides,	B
plasmalogens	O
were	O
identified	O
in	O
the	O
necrosis	O
areas.	O

Only	O
metabolites	O
with	O
a	O
KEGG	O
ID	O
can	O
be	O
included	O
in	O
MetaboAnalyst	O
pathway	O
analysis,	O
thus	O
several	O
of	O
the	O
acylcarnitines	B
were	O
not	O
included,	O
and	O
several	O
of	O
the	O
different	O
phospholipids	B
and	O
sphingolipids	B
have	O
the	O
same	O
KEGG	O
IDs.	O

We	O
developed	O
a	O
liquid	O
chromatography/tandem	O
mass	O
spectrometry	O
(LC-MS/MS)	O
method	O
for	O
the	O
assay	O
of	O
serum	O
levels	O
of	O
all	O
kynurenine	B
metabolites.	O

Incubations	O
(200	O
µl)	O
contained	O
anastrozole	B
(500	O
µm),	O
50	O
mm	O
Tris-HCl	O
buffer	O
(pH	O
7.4),	O
5	O
mm	O
MgCl_2	O
,	O
0.5	O
mg	O
ml_−1	O
microsomes/recombinant	O
UGTs	O
and	O
5	O
mm	O
UDP-glucuronic	O
acid	O
(UDPGA),	O
and	O
were	O
carried	O
out	O
at	O
37°C	O
for	O
90	O
min.	O

acetyl-CoA.	B

We	O
could	O
easily	O
characterize	O
high	O
abundant	O
fatty	O
acids	O
from	O
their	O
EI	B
mass	O
spectra	O
(full	O
scan	O
mode	O
analysis).	O

The	O
LLOQ	O
of	O
most	O
of	O
these	O
methods	O
for	O
the	O
determination	O
of	O
either	O
SMV	O
(ranged	O
0.05–2.5	O
ng/ml)	O
and	O
its	O
metabolite	O
(ranged	O
0.05–5	O
ng/ml)	O
or	O
ATV	O
(ranged	O
0.05–0.2	O
ng/ml)	O
and	O
its	O
two	O
metabolites	O
(ranged	O
0.05–0.5	O
and	O
0.05–0.2	O
ng/ml	O
for	O
2-OH-ATV	B
and	O
4-OH-ATV,	B
respectively)	O
was	O
lower	O
than	O
the	O
LLOQ	O
of	O
our	O
developed	O
method	O
(0.25	O
ng/ml).	O

Methanol	B
(1.7	O
mL)	O
was	O
added,	O
mixed,	O
and	O
centrifuged	O
(10	O
min	O
at	O
1047	O
rad/sec	O
(10,000	O
rpm)	O
at	O
4	O
°C)	O
to	O
precipitate	O
any	O
residual	O
urease.	O

So,	O
sphingosine;	B
So1P,	O
sphingosine-1-phosphate;	B
SBP,	O
systolic	O
blood	O
pressure;	O
DBP,	B
diastolic	O
blood	O
pressure;	O
T2DM,	O
type	O
2	O
diabetes	O
mellitus;	O
BF,	O
body	O
fat;	O
BMI,	O
body	O
mass	O
index;	O
LMI,	O
lean	O
mass	O
index;	O
WC,	O
waist	O
circumference;	O
HC,	O
hip	O
circumference.	O

The	O
C_5	O
branched	O
dibasic	O
acid	O
metabolic	O
pathway	O
is	O
also	O
utilized	O
by	O
Mtb	O
to	O
provide	O
alternative	O
carbon	O
and	O
nitrogen	O
sources	O
for	O
energy,	O
including	O
glutamate	B
,	O
.	O

Our	O
data	O
are	O
consistent	O
with	O
increased	O
flux	O
through	O
the	O
desmosterol	B
pathway	O
to	O
maintain	O
normal	O
cellular	O
levels	O
of	O
cholesterol.	B

The	O
NMR	O
peaks	O
for	O
citrate	B
comprise	O
a	O
standard	O
AB	O
pattern	O
at	O
all	O
frequencies	O
(as	O
seen	O
in	O
)	O
where	O
the	O
CH_2	O
protons	O
are	O
non-equivalent.	O

The	O
influence	O
of	O
the	O
KP	B
in	O
MS	O
has	O
recently	O
been	O
demonstrated	O
in	O
a	O
metabolomics	O
study	O
of	O
blood	O
samples	O
from	O
the	O
experimental	O
autoimmune	O
encephalomyelitis	O
(EAE)	O
model.	O

Serum	O
samples	O
were	O
prepared	O
for	O
FTICR-MS	O
analysis	O
by	O
first	O
sequentially	O
extracting	O
equal	O
volumes	O
of	O
serum	O
with	O
1%	O
ammonium	B
hydroxide	I
and	O
ethyl	B
acetate	I
(EtOAc)	O
three	O
times.	O

We	O
found	O
that	O
LPE	B
(22:5/0:0),	I
SM	B
(d18:2/18:1),	I
LPC	B
(16:0/0:0),	I
LPC	B
(15:1(9z)/0:0),	I
and	O
PC	B
(40:2)	I
are	O
significantly	O
lower	O
in	O
NRP	O
at	O
t0,	O
whereas	O
the	O
LPE	O
level	O
significantly	O
increases	O
in	O
NRP	O
during	O
CRT.	O

The	O
derivatization	O
agent	O
was	O
prepared	O
in	O
the	O
following	O
way:	O
1	O
mL	O
of	O
acetonitrile	B
was	O
added	O
to	O
the	O
vial	O
with	O
AccQTag	O
Ultra	O
reagent	O
powder,	O
vortexed	O
and	O
dissolved	O
by	O
heating	O
at	O
55	O
°C	O
for	O
15	O
min.	O

However	O
citrate	B
levels	O
were	O
lower	O
in	O
stromal	O
BPH	O
tissue	O
and	O
could	O
not	O
be	O
used	O
to	O
discriminate	O
between	O
normal	O
tissue	O
and	O
adenocarcinoma	O
with	O
certainty.	O

We	O
used	O
a	O
gas	O
chromatography-time-of-flight	O
mass-spectrometry-based	O
metabolomics	O
platform	O
to	O
evaluate	O
global	O
effects	O
of	O
simvastatin	B
on	O
intermediary	O
metabolism.	O

Acetoacetate	B
increased	O
significantly	O
at	O
post-event	O
(6.1	O
±	O
1.5	O
mg/ml).	O

Glucuronide	B
conjugates	O
have	O
been	O
synthesized	O
either	O
using	O
chemical	O
synthesis	O
as	O
in	O
the	O
case	O
of	O
DON-3-GlcA	O
and	O
ZEN-14-GlcA	O
or	O
by	O
in	O
vitro	O
assays	O
using	O
liver	O
microsomes.	O

Since	O
PGA	O
is	O
linked	O
to	O
glutathione	B
turnover,	O
the	O
urinary	O
pattern	O
may	O
reflect	O
the	O
higher	O
requirement	O
of	O
the	O
metabolism	O
in	O
glutathione	B
to	O
cope	O
with	O
oxidative	O
stress	O
and	O
immune	O
status[,].	O

Trimethylamine-N-Oxide	B
(TMAO),	O
a	O
gut	O
derived	O
metabolite,	O
has	O
been	O
associated	O
with	O
atherosclerotic	O
burden.	O

The	O
associations	O
between	O
allantoin	B
and	O
allantoin-to-uric	O
acid	O
ratio	O
with	O
T2D	O
risk	O
remained	O
significant.	O

In	O
this	O
context	O
malondialdehyde,	B
4-hydroxynonenal,	B
propanal	B
and	O
hexanal	B
have	O
been	O
described	O
as	O
suitable	O
markers	O
[,	O
].	O

The	O
two	O
pools	O
were	O
mixed	O
overnight	O
at	O
5	O
°C,	O
dispensed	O
in	O
2-mL	O
portions	O
in	O
polypropylene	B
vials,	O
and	O
stored	O
long	O
term	O
at	O
−	O
70	O
°C	O
and	O
up	O
to	O
12	O
weeks	O
at	O
−	O
20	O
°C.	O

In	O
total,	O
18	O
lipid	O
classes	O
and	O
subclasses	O
were	O
detected	O
and	O
eluted	O
in	O
the	O
order	O
of	O
increasing	O
polarity,	O
namely,	O
cholesterol	B
ester	I
(CE),	O
triacylglycerol	B
(TG),	O
cholesterol	B
(Chol),	O
phosphatidylglycerol	B
(PG),	O
phosphatidylethanolamine	B
(PE),	O
phosphatidylethanolamine	B
plasmalogen	O
(p-PE),	O
lysophosphatidylglycerol	B
(LPG),	O
phosphatidylinositol	B
(PI),	O
phosphatidylserine	B
(PS),	O
lysophosphatidylethanolamine	B
(LPE),	O
phosphatidylcholine	B
(PC),	O
phosphatidylcholine	B
plasmalogen	O
(p-PC),	O
sphingomyelin	B
(SM),	O
sn2	B
-lysophosphatidylcholine	I
(sn2	O
-LPC),	O
and	O
sn1	B
--lysophosphatidylcholine	I
(sn1	O
-LPC);	O
ceramide	B
(Cer),	O
1,3	B
-diacylglycerol	I
(1,3	I
-DG),	I
and	O
1,2	B
-diacylglycerol	I
(1,2	I
-DG)	I
existed	O
only	O
in	O
low	O
level	O
in	O
serum;	O
therefore,	O
they	O
were	O
not	O
labeled	O
on	O
the	O
chromatogram.	O

Therefore,	O
our	O
results	O
suggest	O
the	O
effect	O
of	O
the	O
blueberries	O
on	O
gut	O
microflora	O
population	O
and,	O
consequently,	O
on	O
the	O
regulation	O
of	O
methylamine	B
metabolism.	O

Moreover,	O
a	O
population-based	O
cohort	O
even	O
found	O
no	O
association	O
between	O
FT4	O
levels	O
and	O
serum	O
levels	O
of	O
glucogenic	B
AAs	O
including	O
glycine,	B
valine,	B
serine	B
or	O
proline	B
in	O
euthyroid	O
subjects.	O

Photosynthesis	O
of	O
vitamin	B
D	I
is	O
a	O
route	O
parallel	O
to	O
dietary	O
supplementation	O
in	O
humans.	O

IFN-γ, interferon	O
gamma;	O
IL,	O
interleukin;	O
IP-10,	O
interferon	O
gamma-induced protein	O
10;	O
MIP-1β,	B
macrophage	O
inflammatory	O
proteins	O
1	O
beta;	O
TNF-α,	O
tumour	O
necrosis	O
factor	O
alpha.	O

Microsomes	O
were	O
pre-incubated	O
with	O
alamethicin	B
(25	O
µg	O
ml_−1	O
in	O
final	O
incubation)	O
on	O
ice	O
for	O
15	O
min.	O

In	O
the	O
study	O
of	O
trauma	O
patients,	O
citrate	B
concentrations	O
correlated	O
with	O
later	O
development	O
of	O
sepsis.	O

There	O
was	O
a	O
significant	O
improvement	O
in	O
serum	O
bilirubin	B

Interactions	O
between	O
simvastatin	B
and	O
selected	O
bile	O
acids	O
competing	O
for	O
membrane	O
transport	O
may	O
be	O
responsible	O
for	O
some	O
of	O
the	O
off	O
target	O
effects	O
of	O
the	O
drug	O
.	O

For	O
example,	O
a	O
reduced	O
urinary	O
concentration	O
of	O
citrate,	B
which	O
is	O
a	O
tricarboxylic	B
acid	I
intermediate,	O
might	O
be	O
in	O
agreement	O
with	O
Warburg’s	O
hypothesis	O
of	O
altered	O
mitochondrial	O
aerobic	O
respiration	O
and	O
heightened	O
physiological	O
stress	O
of	O
cancer	O
cells[].	O

In	O
single-center	O
analysis,	O
citrate,	B
formate,	B
methionine,	B
and	O
phenylalanine	B
were	O
significantly	O
higher	O
in	O
MBC	O
patients.	O

While	O
the	O
depletion	O
of	O
cysteine	B
and	O
the	O
accumulation	O
of	O
cystine	B
and	O
Met-SO	O
clearly	O
indicate	O
increased	O
oxidative	O
stress	O
in	O
SLE,	O
none	O
of	O
these	O
compounds	O
or	O
the	O
unique	O
PPP	O
substrates	O
R5P	O
or	O
S7P	O
correlated	O
with	O
disease	O
activity	O
of	O
untreated	O
patients.	O

Already	O
after	O
15	O
min,	O
we	O
started	O
to	O
observe	O
M6	O
glucose	B
isotopologues,	O
reaching	O
a	O
maximum	O
of	O
1.5%	O
of	O
total	O
glucose	B
after	O
150–200	O
min.	O

The	O
epoxide	B
metabolites	O
of	O
BD	O
can	O
alkylate	B
DNA	O
to	O
form	O
adducts	O
such	O
as	O
N	O
7-(2,3,4-trihydroxybut-1-yl)	B
guanine	I
(N	O
7-THBG)	O
and	O
N	O
7-(1-hydroxy-3-buten-2-yl)	B
guanine	I
(EB-GII).	O

The	O
level	O
of	O
non-esterified	O
cholesterol	B
in	O
control	O
CSF	O
is	O
1.24 ± 0.33	O

Both	O
reproducibility	O
and	O
the	O
reaction	O
efficiency	O
were	O
assessed	O
based	O
on	O
the	O
integrals	O
of	O
the	O
carbonyl	O
carbon	O
of	O
the	O
derivatized	O
amino	O
acids	O
with	O
reference	O
to	O
an	O
internal	O
standard	O
[sodium	O
3-trimethylsilyl	I
(2,2,3,3-_2	I
H_4	I
)-1-propionate].	I

The	O
present	O
method	O
allows	O
simultaneous	O
determination	O
of	O
taurine	B
and	O
sulfate.	B

Its	O
sulfoxide	B
3	O
was	O
next	O
most	O
abundant	O
followed	O
by	O
the	O
BDA-N	B
-acetyllysine	I
metabolite	O
1.	O

Perturbations	O
of	O
phospholipases,	O
purine	B
nucleotide	O
degradation	O
and	O
LXR/RXR	O
activation	O
are	O
found	O
to	O
be	O
partially	O
responsible	O
for	O
this	O
development.	O

The	O
mean	O
extraction	O
recovery	O
for	O
D-mannose	B
was	O
104.13,	O
105.53,	O
and	O
104.84,	O
for	O
the	O
low,	O
medium,	O
and	O
high	O
QC	O
concentrations,	O
respectively.	O

To	O
exclude	O
uncertainty	O
among	O
the	O
control	O
group,	O
a	O
subanalysis	O
of	O
the	O
presence	O
or	O
absence	O
of	O
Gleason	O
Pattern	O
4	O
on	O
RP	B
histology	O
showed	O
overlap	O
of	O
groups	O
(M10,	O
Figs.	O

Therefore,	O
alteration	O
of	O
their	O
levels	O
indicates	O
that	O
urea	B
cycle	O
has	O
also	O
been	O
impaired.	O

For	O
comparison	O
our	O
previous	O
study	O
of	O
CER	B
involved	O
a	O
60 %	O
daily	O
energy	O
restriction	O
over	O
a	O
one-month	O
period.	O

Sphingolipids	B
are	O
a	O
family	O
of	O
lipid	O
second	O
messengers	O
that	O
regulate	O
various	O
vascular	O
cell	O
functions.	O

These	O
include	O
i)	O
patients	O
with	O
lower	O
circulating	O
ethanolamine	B
plasmalogen	O
levels;	O
ii)	O
patients	O
with	O
augmented	O
plasma	O
diacylglycerol	B
levels;	O
and	O
iii)	O
patients	O
with	O
neither	O
of	O
these	O
lipid	O
alterations.	O

The	O
sealed	O
capillary	O
was	O
reacted	O
at	O
60	O
°C	O
for	O
24	O
h	O
and	O
then	O
flushed	O
with	O
MeOH	B
to	O
remove	O
the	O
unreacted	O
materials.	O

The	O
imbalance	O
of	O
lysoPC/PCs	O
cycling	O
suggests	O
that	O
hepatic	O
homeostasis	O
and	O
function	O
is	O
compromised	O
even	O
before	O
any	O
clinical	O
manifestation,	O
and	O
bilirubin	B
alone	O
cannot	O
give	O
a	O
clear	O
picture	O
of	O
the	O
liver’s	O
condition.	O

Note	O
that	O
the	O
metabolites	O
metabolites	O
that	O
are	O
quantified	O
uniquely	O
on	O
the	O
Biocrates	O
platform	O
carry	O
specific	O
information	O
on	O
the	O
lipid	O
side-chain	O
composition	O
of	O
the	O
different	O
phospholipid	B
classes	O
(sometimes	O
also	O
referred	O
to	O
as	O
lipidomics).	O

We	O
found	O
that	O
hyperlipidemia	O
and	O
glucose	B
metabolic	O
disorders	O
were	O
common	O
in	O
PBC	O
patients.	O

One	O
might	O
speculate	O
that	O
the	O
frequently	O
described	O
beneficial	O
effects	O
of	O
piperine	B
might	O
have	O
contributed	O
to	O
the	O
metabolically	O
healthy	O
state	O
of	O
our	O
study	O
population	O
with	O
respect	O
to	O
major	O
disease	O
traits	O
despite	O
a	O
high	O
amount	O
of	O
VAT/SAT.	O

Regarding	O
the	O
common	O
discriminatory	O
metabolites	O
found	O
in	O
both	O
models,	O
consistent	O
increases	O
in	O
energy-related	O
metabolites,	O
creatinine,	B
1-MH,	O
and	O
several	O
amino	O
acids,	O
as	O
well	O
as	O
decreases	O
in	O
glycoproteins	B
are	O
observed	O
as	O
important	O
signals	O
in	O
the	O
non-survivors.	O

Aliquots	O
were	O
sent	O
to	O
SAIC	O
(Frederick,	O
MD)	O
where	O
15	O
urinary	O
EM	O
were	O
measured,	O
including	O
estrone	B
(E_1	O
),	O
estradiol	B
(E_2	O
),	O
estriol	B
(E_3	O
),	O
2-hydroxyestrone	B
(2-OHE_1	O
),	O
2-methoxyestrone	B
(2-MeOE_1	O
),	O
2-hydroxyestradiol	B
(2-OHE_2	O
),	O
2-methoxyestradiol(2-MeOE_2	B
),	I
2-hydroxyestrone-3-methyl	B
ether	I
(3-MeOE_1	O
),	O
4-hydroxyestrone	B
(4-OHE_1	O
),	O
4-methoxyestrone	B
(4-MeOE_1	O
),	O
4-methoxyestradiol	B
(4-MeOE_2	O
),	O
16α-hydroxyestrone	B
(16α-OHE_1	I
),	I
17-epiestriol	O
(17-epiE_3	O
),	O
16-ketoestradiol	O
(16-ketoE_2	O
),	O
and	O
16-epiestriol	B
(16-epiE_3	O
).	O

A	O
third	O
aliquot	O
in	O
basic	O
conditions	O
was	O
analyzed	O
using	O
a	O
hydrophilic	B
interaction	O
chromatography	O
column	O
(Waters	O
UPLC	O
BEH	O
Amide	B
2.1	O
×	O
150	O
mm,	O
1.7	O
µM)	O
using	O
a	O
gradient	O
of	O
water,	O
acetonitrile,	B
and	O
10	O
mM	O
ammonium	B
formate.	I

Therefore,	O
serum	O
concentrations	O
of	O
glycine,	B
valine,	B
methionine,	B
citrulline,	B
arginine	B
and	O
C16-carnitine	B
may	O
be	O
integrated	O
into	O
the	O
current	O
method	O
for	O
screening	O
for	O
lung	O
cancer.	O

Furthermore,	O
olanzapine	B
is	O
metabolized	O
by	O
direct	O
glucuronidationby	O
CYP1A2	O
and	O
by	O
CYP2D6	O
and	O
CYP3A4,	O
although	O
the	O
later	O
two	O
enzymes	O
play	O
a	O
smaller	O
role	O
in	O
this	O
conversion.	O

This	O
leaves	O
unanswered	O
an	O
important	O
question	O
regarding	O
how	O
essential	O
the	O
timing	O
and	O
duration	B
of	O
AAP	O
exposure	O
is	O
to	O
encouraging	O
the	O
disruption	O
of	O
glucose-insulin	B
homeostasis.	O

Supplementation	O
with	O
galactose	B
leads	O
to	O
biochemical	O
improvement	O
in	O
indexes	O
of	O
glycosylation.	O

DDAH2	O
knockout	O
in	O
macrophages	O
was	O
associated	O
with	O
a	O
significantly	O
higher	O
bacterial	O
load	O
in	O
plasma	O
and	O
the	O
peritoneum.	B

Then,	O
250	O
μL	O
eluent	O
was	O
added	O
to	O
500	O
μL	O
water	O
and	O
3%	O
(v	O
/v	O
)	O
formic	B
acid.	I

ARG,	O
arginase;	O
DDAH,	O
dimethylarginine	O
dimethylaminohydrolase,	O
NOS,	O
nitric	B
oxide	I
synthase;	O
ODC,	O
ornithine	O
decarboxylase;	O
PRMT,	O
arginine	O
N-methyltransferase;	O
BAX,	O
Bcl-2-associated	O
X	O
protein;	O
CCL2–4,	O
chemokine	O
(C-C	O
motif)	O
ligand	O
2–4;	O
FGF2,	O
basic	O
fibroblast	O
growth	O
factor	O
2;	O
HIF1A,	O
hypoxia-inducible	O
factor	O
1α,	O
IL,	O
interleukin;	O
CDKN1A,	O
cyclin-dependent	O
kinase	O
inhibitor	O
1;	O
TP53,	O
tumor	O
protein	O
p53;	O
PCNA,	O
proliferating	O
cell	O
nuclear	O
antigen;	O
TNFA,	O
tumor	O
necrosis	O
factor	O
α;	O
VEGFA,	O
vascular	O
endothelial	O
growth	O
factor	O
A.	O
ARG2	O
expression	O
was	O
positively	O
correlated	O
with	O
CDKN1A	O
as	O
well,	O
both	O
in	O
inflamed	O
and	O
non-inflamed	O
tissue,	O
and	O
with	O
TP53	O
in	O
inflamed	O
tissue.	O

It	O
has	O
been	O
suggested	O
that	O
PC	O
accumulation	O
in	O
BC	O
is	O
caused	O
by	O
an	O
unbalance	O
between	O
a	O
high	O
activity	O
of	O
the	O
enzyme	O
choline	B
kinase	O
in	O
the	O
anabolic	O
pathway	O
[,	O
,	O
]	O
and	O
the	O
activity	O
of	O
the	O
enzymes	O
phospholipases	O
A_2	O
(PLA_2	O
),	O
phospholipase	O
C	O
(PLC)	O
and	O
phospholipase	O
D	O
(PLD)	O
in	O
the	O
catabolic	O
pathway	O
[,	O
–].	O

Beyond	O
the	O
elevated	O
glycolysis,	O
cancer	O
cells	O
depended	O
more	O
on	O
glutamine	B
(Pan	O
et	O
al.	O
),	O
which	O
can	O
be	O
converted	O
into	O
TCA	O
cycle	O
to	O
generate	O
ATP	B
and	O
intermediates	O
for	O
macromolecule	O
synthesis	O
such	O
as	O
proteins,	O
lipids	O
and	O
nucleotides	O
(DeBerardinis	O
and	O
Cheng	O
).	O

()	O
It	O
is	O
interesting	O
also	O
that	O
in	O
our	O
study	O
amino	B
acid-	O
deriving	O
(but	O
not	O
lipid-deriving)	O
acylcarnitines	B
were	O
increased	O
in	O
the	O
subjects	O
at	O
risk.	O

Prothrombin	O
is	O
processed	O
to	O
thrombin,	O
a	O
serine	B
protease	O
that	O
cleaves	O
fibrinogen	O
to	O
fibrin,	O
leading	O
to	O
clotting.	O

This	O
supports	O
the	O
observed	O
physiological	O
roles	O
of	O
mitochondria	O
in	O
coordinating	O
lipid	O
metabolism	O
and	O
in	O
controlling	O
reactive	O
oxygen	O
species	O
(ROS),	O
ATP	B
and	O
calcium	O
levels,	O
several	O
factors	O
that	O
influence	O
the	O
aggressiveness	O
of	O
the	O
disease.	O

Collision	O
Induced	O
Dissociation-Tandem	O
Mass	O
Spectrometry	O
(CID-MS/MS)	O
and	O
MSn	O
analyses	O
were	O
performed	O
using	O
helium	O
with	O
collision	O
energy	O
of	O
25–35	O
eV.	O
The	O
HPLC	O
used	O
a	O
LiChroCART	O
C18	O
column	O
(125	O
mm×4	O
mm;	O
5	O
µm	O
particle	O
diameter,	O
end-capped)	O
with	O
the	O
temperature	O
maintained	O
at	O
25	O
°C;	O
the	O
mobile	O
phase	O
was	O
composed	O
of	O
1%	O
(v/v)	O
acetic	B
acid	I
in	O
water	O
(A)	O
and	O
acetonitrile,	B
which	O
had	O
been	O
degassed	O
and	O
filtered	O
(B).	O

Labeling	O
scheme	O
for	O
the	O
Krebs	O
cycle	O
with	O
pyruvate	O
carboxylation	O
using	O
[U–_13	B
C]-glucose	I
as	O
tracer.	O

The	O
wells	O
were	O
mixed,	O
a	O
200	O
μL	O
aliquot	O
of	O
each	O
was	O
transferred	O
to	O
a	O
protein	O
precipitation	O
plate	O
where	O
each	O
well	O
contained	O
300	O
μL	O
acetonitrile,	B
and	O
the	O
wells	O
were	O
mixed	O
again.	O

In	O
conclusion,	O
in	O
normoglycemic	B
women	O
insulin	O
resistance	O
was	O
associated	O
with	O
increased	O
serum	O
BCAA	O
concentrations,	O
down-regulation	O
of	O
mitochondrial	O
energy	O
metabolism	O
and	O
increased	O
expression	O
of	O
inflammation-related	O
genes	O
in	O
the	O
adipose	O
tissue.	O

In	O
the	O
end,	O
taking	O
into	O
account	O
the	O
necessity	O
to	O
use	O
paracetamol	B
as	O
an	O
indicator	O
of	O
deglucuronidation	O
process,	O
the	O
amide	B
column	O
gave	O
the	O
best	O
results	O
and	O
it	O
was	O
preferred	O
for	O
method	O
validation.	O

Programs	O
such	O
as	O
Skyline,	B
DIA	O
Umpire,	O
and	O
others	O
under	O
development	O
will	O
be	O
required	O
to	O
deconvolute	O
spectral	O
data	O
to	O
identify	O
precursor	O
and	O
product	O
ions	O
of	O
peptide	O
adducts.	O

Future	O
work	O
following	O
on	O
from	O
this	O
study	O
should	O
make	O
use	O
of	O
samples	O
dedicated	O
for	O
_1	O
H	O
NMR	O
analysis,	O
collected	O
into	O
lithium-heparin	B
tubes	O
(in	O
order	O
to	O
avoid	O
the	O
relatively	O
large,	O
interfering	O
EDTA	O
resonances)	O
and	O
omitting	O
the	O
histopaque	O
separation	O
step.	O

Besides	O
the	O
most	O
commonly	O
observed	O
Δ9/Δ11	O
isomer	O
pair	O
in	O
C18:1	B
and	O
ω-3/ω-6	B
isomer	I
pair	O
in	O
C18:3,	B
other	O
less	O
common	O
isomer	O
pairs	O
were	O
also	O
detected,	O
including	O
Δ7/Δ9	O
isomer	O
pair	O
in	O
C16:1,	B
and	O
ω-3/ω-6	B
isomer	I
pair	O
in	O
C18:2	B
(Supplementary	O
Fig.	O

When	O
kept	O
at	O
2–8°C,	O
abiraterone	B
in	O
plasma	O
was	O
stable	O
for	O
24h	O
and	O
in	O
whole	O
blood	O
for	O
8h.	O

Lower	O
protein	O
intake	O
in	O
Pakistan	O
may	O
account	O
for	O
the	O
lower	O
threonine	B
concentration,	O
based	O
on	O
data	O
that	O
threonine	B
decreased	O
in	O
pregnant	O
rats	O
fed	O
a	O
protein-restricted	O
diet.	O

We	O
discovered	O
that	O
CSF	O
concentrations	O
of	O
pyruvate + oxaloacetic	B
acid	I
were	O
significantly	O
lower	O
in	O
the	O
gliomas	O
with	O
IDH	O
mutations	O
compared	O
with	O
those	O
with	O
a	O
wild-type	O
IDH	O
.	O

Furthermore,	O
c-MYC	O
overexpression	O
rescued	O
glucose	B
uptake	O
and	O
lactate	B
secretion	O
in	O
MUC16	O
knockdown	O
cells.	O

Results:	O
Median	O
serum	O
CRP	O
and	O
neopterin	B
concentrations	O
were	O
well	O
below	O
established	O
clinical	O
cutoffs	O
for	O
inflammation.	O

The	O
test	O
articles	O
included	O
vehicle	O
controls	O
of	O
0.1%	O
DMSO,	B
0.1%	O
saline,	B
4-aminopyridine	B
at	O
concentrations	O
of	O
0.025,	O
0.25,	O
2.5,	O
and	O
25 μM,	O
and	O
prototypical	O
inducers	O
of	O
human	O
CYP450	O
including	O
omeprazole	B
(100 μM;	O
CYP1A2),	O
phenobarbital	O
(750 μM;	O
CYP2B6),	O
isoniazid	O
(100 μM;	O
CYP2E1),	O
and	O
rifampin	O
(10 μM;	O
CYP2C9,	O
CYP2C19,	O
and	O
CYP3A4/5);	O
DMSO	B
was	O
the	O
vehicle	O
for	O
4-aminopyridine,	B
omeprazole,	B
phenobarbital,	O
and	O
rifampin,	O
and	O
saline	B
was	O
the	O
vehicle	O
for	O
isoniazid.	O

A	O
stepwise	O
procedure	O
was	O
used	O
where	O
indium	O
powder	O
and	O
ethyl	B
bromoacetate	I
were	O
first	O
taken	O
in	O
dry	O
THF	O
and	O
stirred	O
for	O
5	O
h	O
at	O
room	O
temperature	O
while	O
the	O
required	O
organometallic	O
intermediate	O
was	O
generated.	O

Cells	O
generate	O
PAs	O
from	O
several	O
sources,	O
including	O
diacylglycerols,	B
another	O
family	O
of	O
signaling	O
molecules.	O

In	O
Figure	O
,	O
the	O
levels	O
(AUC)	O
of	O
nine	O
of	O
these	O
discriminant	O
metabolites	O
(lactate,	O
pyruvate,	B
alanine,	B
glucose,	B
glutamine,	B
acetate,	B
phenylalanine,	B
lysine	B
and	O
tyrosine)	B
showed	O
significant	O
differences	O
across	O
the	O
whole	O
study	O
population	O
(Kruskal-Wallis	O
p	O
<	O
0.05).	O

Increased	O
levels	O
of	O
decenedioic	B
acid	I
were	O
detected	O
in	O
the	O
present	O
study,	O
and	O
may	O
represent	O
evidence	O
that	O
this	O
oxidative	O
attack	O
can	O
occur	O
in	O
a	O
prediabetic	O
state.	O

Therefore,	O
it	O
can	O
be	O
deducted	O
that	O
the	O
detected	O
signals	O
of	O
SM	O
and	O
PC	O
mainly	O
arise	O
from	O
those	O
phospholipids	B
appearing	O
in	O
HDL.	O

Here	O
we	O
demonstrate	O
that	O
in	O
human	O
serum,	O
methanol	B
precipitations	O
with	O
ultrafiltration	O
(MeOH	O
ppt	O
+UF)	O
offers	O
effective	O
metabolite	O
recovery,	O
low	O
variance,	O
and	O
efficiency	O
in	O
removing	O
macromolecules.	O

(20:4),	O
PC	B
(20:1p/19:1),	I
SM	B
(d16:0/22:2),	I
PAF	B
(35:4),	I
PC	B
(16:0/22:5)	I
and	O
PC	B
(18:1/20:4)	I
are	O
the	O
metabolites	O
with	O
area	O
under	O
the	O
ROC	O
curve	O
(AUC)	O

Matrix	O
and	O
cross-talk	O
interferences	O
Selectivity	O
was	O
additionally	O
evaluated	O
by	O
analyzing	O
the	O
highest	O
calibration	O
standard	O
sample	O
(2000	O
ng/mL)	O
processed	O
with	O
pure	O
MeOH	B
and	O
a	O
blank	O
human	O
plasma	O
processed	O
with	O
only	O
internal	O
standards	O
solution	O
at	O
40	O
ng/mL,	O
to	O
identify	O
potential	O
(i)	O
interferences	O
affecting	O
co-eluting	O
analytes	O
and	O
internal	O
standards	O
due	O
to	O
the	O
MS-based	O
cross-talk	O
phenomenon	O
or	O
(ii)	O
presence	O
of	O
isobaric	O
impurities.	O

,	O
Nevertheless,	O
elevation	O
in	O
bile	O
acid	O
species,	O
such	O
as	O
tauroursodeoxycholic	B
acid,	I
taurocholic	B
acid,	I
deoxycholylglycine	B
and	O
cholylglycine,	B
has	O
been	O
observed	O
in	O
the	O
plasma	O
MS	O
metabolic	O
proﬁles	O
from	O
nonjaundiced	O
patients	O
with	O
early-stage	O
pancreatic	O
ductal	O
adenocarcinoma.	O

Interestingly,	O
both	O
3β-HCA	B
and	O
3β,7β-diHCA	B
have	O
been	O
shown	O
to	O
be	O
neurotoxic.	O

In	O
this	O
procedure,	O
organic	O
solvent(s)	O
are	O
added	O
to	O
the	O
serum,	O
which	O
denature	O
and	O
precipitate	O
proteins	O
so	O
that	O
they	O
can	O
be	O
subsequently	O
removed	O
by	O
centrifugation,	O
while	O
the	O
organic	O
solvent(s)	O
are	O
removed	O
via	O
a	O
rotary	O
evaporator	O
or	O
lyophilization._,	O
In	O
&	O
,	O
_1	O
H	O
1D	O
NMR	O
spectra	O
of	O
human	O
serum	O
samples	O
are	O
depicted	O
after	O
they	O
have	O
been	O
treated	O
by	O
the	O
addition	O
of	O
methanol	B
or	O
methanol/chloroform.	B

The	O
separation	O
was	O
carried	O
out	O
using	O
mobile	O
phase	O
A-−0.1%	O
formic	B
acid	I
(in	O
HPLC	O
grade	O
H_2	O
O)	O
and	O
mobile	O
phase	O
B-−0.1%	O
formic	B
acid	I
(in	O
methanol).	B

This	O
finding	O
could	O
indicate	O
an	O
upregulation	O
of	O
the	O
polyamine	B
biosynthetic	O
pathway,	O
more	O
specifically,	O
the	O
production	O
of	O
putrescine	B
from	O
ornithine	B
by	O
the	O
biosynthetic	O
enzyme	O
ODC.	O

In	O
spite	O
of	O
the	O
LC-MS	O
based	O
detection	O
of	O
BPDE--dG	O
in	O
BaP-treated	O
rodents,	O
and	O
indirectly	O
through	O
HPLC-fluorescence	O
detection	O
of	O
BaP-7,8,9,10-tetraols	B
released	O
from	O
human	O
DNA	O
upon	O
acid	O
hydrolysis,	O
BPDE--dG	O
adducts	O
have	O
rarely	O
if	O
ever	O
been	O
observed	O
directly	O
in	O
human	O
samples	O
using	O
LC-MS	O
techniques,	O
even	O
though	O
sophisticated	O
methodologies	O
have	O
been	O
employed	O
which	O
should	O
have	O
had	O
sufficient	O
sensitivity.	O

The	O
decreased	O
levels	O
of	O
GPC	B
may	O
be	O
a	O
consequence	O
of	O
the	O
compromised	O
integrity	O
of	O
the	O
intestinal	O
mucosal	O
membrane	O
with	O
an	O
inflammation-driven	O
increased	O
rate	O
of	O
apoptosis	O
and	O
cellular	O
turnover.	O

In	O
comparison	O
of	O
self-reported	O
acetaminophen	B
and/or	O
ibuprofen	B
data	O
with	O
_1	O
H	O
NMR-detected	O
urinary	O
acetaminophen	B
and/or	O
ibuprofen	B
metabolites,	O
overall	O
rates	O
of	O
concordance	O
were	O
high	O
for	O
both	O
populations:	O
83.8%	O
(95%	O
confidence	O
interval	O
(CI):	O
78.9,	O
88.7)	O
in	O
Belfast	O
and	O
81.1%	O
(95%	O
CI:	O
76.5,	O
85.7)	O
in	O
Chicago.	O

As	O
illustrated	O
in	O
Table ,	O
extraction	O
of	O
plasma	O
samples	O
by	O
either	O
100%	O
of	O
methanol	B
or	O
100%	O
of	O
ethanol	B
generated	O
comparable	O
panel	O
of	O
metabolites.	O

Metabolites	O
such	O
as	O
hydroxylamine,	B
tridecan-1-ol,	B
octadecan-1-ol,	B
were	O
indicative	O
of	O
survival	O
(GC–MS	O
p < 0.05)	O
and	O
metabolites	O
such	O
as	O
tagatose,	B
hydroxylamine,	B
glucopyranose,	B
and	O
threonine	B
that	O
were	O
reflective	O
of	O
progression	O
(GC–MS	O
p < 0.05).	O

However,	O
in	O
agreement	O
with	O
previous	O
nutrient	O
limitation	O
studies,	O
niacin	B
deprivation	O
did	O
not	O
lead	O
to	O
a	O
growth	O
defect	O
in	O
vitro	O
suggesting	O
that	O
the	O
niacin	B
provided	O
by	O
the	O
host	O
cell	O
is	O
sufficient	O
to	O
provide	O
the	O
required	O
amount	O
of	O
NAD_+	O
synthesis	O
necessary	O
for	O
growth	O
in	O
vitro	O
.	O

It	O
is	O
worth	O
to	O
underline	O
that	O
PC	B
ae	I
C38:0	I
and	O
alanine	B
have	O
coefficients	O
with	O
the	O
same	O
sign	O
as	O
the	O
coefficients	O
of	O
the	O
models	O
built	O
on	O
targeted	O
metabolomics	O
data	O
only.	O

Aminomalonic	B
acid,	I
a	O
metabolite	O
found	O
in	O
atherosclerotic	O
plaques,	O
had	O
significant	O
negative	O
correlation	O
to	O
insulin	O
and	O
HOMA	O
pre-statin	B
treatment.	O

Co-incubation	O
with	O
TEX	O
induced	O
significant	O
(p	O
<	O
0.0074)	O
upregulation	O
of	O
inosine	B
production	O
in	O
Treg	O
but	O
not	O
in	O
CD4_+	O
T	O
cells,	O
probably	O
because	O
of	O
large	O
differences	O
among	O
the	O
three	O
cell	O
donors.	O

The	O
results	O
showed	O
that,	O
in	O
the	O
experimental	O
group,	O
five	O
metabolites	O
were	O
significantly	O
greater	O
in	O
the	O
group	O
of	O
MsPGN	O
patients	O
than	O
in	O
the	O
normal	O
control	O
group	O
(P < 0.05):	O
Carbamic	B
acid,	I
monoammonium	O
salt;	O
Carbon	B
disulfide;	I
Silanediol,	O
dimethyl-;	B
2H-1,4-Benzodiazepin-2-one,	B
7-chloro-1,3-dihydro-5-phenyl-1-(trimethylsilyl)-;	B
Butylated	B
Hydroxytoluene.	I

l	O
vs	O
0.05	O
mmol/l,	O
p	O
<	O
0.001),	O
and	O
glycoprotein	O
acetyls	O
(mainly	O
alpha−1-acid	O
glycoprotein,	B
AGP)	O
(1.81	O
mmol/l	O
vs	O
1.34	O
mmol/l,	O
p	O
<	O
0.001).	O

Go	O
to:	O
Although	O
statins	B
are	O
widely	O
prescribed	O
medications,	O
there	O
remains	O
considerable	O
variability	O
in	O
therapeutic	O
response.	O

Among	O
these,	O
abundance	O
with	O
age	O
was	O
higher	O
for	O
4	O
Cer,	B
5	O
SM,	O
8	O
FFA,	O
6	O
CE	O
and	O
free	O
cholesterol,	B
but	O
lower	O
for	O
14	O
PCO-,	O
3	O
PE,	O
2	O
PI	O
and	O
6	O
LPE.	O

All	O
available	O
samples	O
(n	O
_FC	O
=	O
27,	O
n	O
_CCT	O
=	O
906,	O
for	O
missing	O
CCT	O
data	O
see	O
Supporting	O
Information)	O
were	O
prepared	O
for	O
_1	O
H	O
NMR	O
spectroscopy	O
following	O
the	O
protocol	O
described	O
in	O
ref	O
mixing	O
540	O
μL	O
of	O
supernatant	O
with	O
60	O
μL	O
of	O
pH	O
7.4	O
phosphate	B
buffer	O
containing	O
trimethylsilyl-[2,2,3,3,-_2	B
H	I
_4	I
]-propionate	I
as	O
an	O
internal	O
reference	O
standard	O
(“NMR	O
buffer”).	O

The	O
next	O
effective	O
cycle	O
is	O
the	O
synthesis	O
and	O
degradation	O
of	O
ketone	B
bodies	O
with	O
3-hydroxybutyric	B
acid	I
as	O
the	O
metabolite	O
involved.	O

Spearman	O
correlation	O
(ρ)	O
of	O
methylation	O
degrees	O
(log-cpm)	O
and	O
(a)	O
genistein,	B
(b)	O
daidzein	B
and	O
(c)	O
total	O
isoflavone	B
concentrations.	O

On	O
the	O
other	O
hand,	O
the	O
negative	O
signals	O
indicated	O
the	O
down-regulated	O
metabolites	O
in	O
gastric	O
cancer	O
tissue,	O
including	O
β-hydroxybutyrate,	B
citrulline,	B
acetate,	B
methylamine,	B
phosphocreatine,	B
creatine,	B
ceatinine,	O
acetic	B
acid,	I
choline,	B
phosphochline,	B
myo-Inositol,	B
glucose,	B
dimethylglycine.	B

Ethanolamine,	B
the	O
metabolite	O
we	O
identified	O
as	O
most	O
likely	O
to	O
predict	O
simvastatin-induced	O
diabetic	O
risk,	O
is	O
biosynthesized	O
via	O
decarboxylation	O
of	O
serine.	B

In	O
spite	O
of	O
these	O
limitations,	O
our	O
data	O
indicate	O
that	O
CM	O
is	O
associated	O
with	O
substantial	O
changes	O
in	O
the	O
levels	O
of	O
kynurenine	B
metabolites	O
that	O
are	O
not	O
easy	O
to	O
explain	O
on	O
the	O
basis	O
of	O
our	O
classical	O
knowledge	O
of	O
the	O
KP.	B

Trypsin	O
is	O
a	O
serine	B
protease	O
and	O
cleaves	O
peptides	O
on	O
the	O
C	O
-terminal	O
side	O
of	O
Lys	O
and	O
Arg	O
residues	O
except	O
for	O
when	O
a	O
proline	B
residue	O
is	O
on	O
the	O
carboxyl	O
side	O
of	O
the	O
cleavage	O
site	O
in	O
which	O
case	O
the	O
cleavage	O
will	O
not	O
occur.	O

Cox	O
proportional	O
hazards	O
regression	O
models	O
revealed	O
that	O
the	O
highest	O
tertile	O
of	O
betaine	B
was	O
associated	O
with	O
a	O
lower	O
incidence	O
of	O
T2DM.	O

In	O
current	O
study,	O
the	O
concentration	O
of	O
uridine	B
also	O
changed	O
significantly	O
in	O
the	O
PDR	O
group.	O

Small	O
metabolites	O
involved	O
in	O
key	O
regulatory	O
steps	O
of	O
glucose	B
transport,	O
glutaminolysis,	O
aerobic	O
glycolysis	O
(Warburg	O
effect),	O
and	O
the	O
Krebs	O
cycle,	O
and	O
larger	O
metabolites	O
such	O
as	O
fatty	O
acids	O
and	O
complex	O
lipids	O
are	O
of	O
great	O
interest	O
as	O
their	O
abnormal	O
expression	O
has	O
been	O
reported	O
in	O
various	O
types	O
of	O
adenocarcinomas	O
(,	O
).	O

AA	O
=	O
amino	O
acids;	O
AC	O
=	O
acylcarnitines;	B
BA	O
=	O
bile	O
acids;	O
Cer	B
=	O
ceramides;	B
ChoE	O
=	O
cholesteryl	B
esters;	I
CMH	O
=	O
monohexosylceramides;	B
DG	O
=	O
diglycerols;	B
LPC	O
=	O
lysophosphatidylcholines;	B
LPE	O
=	O
lysophosphatidylethanolamines;	B
LPI	O
=	O
lysophosphatidylinositols;	B
MUFA	O
=	O
monounsaturated	O
fatty	O
acids;	O
PC	O
=	O
phosphatidylcholines;	B
PE	O
=	O
phosphatidylethanolamines;	B
PI	O
=	O
phosphatidylinositols;	B
PUFA	O
=	O
polyunsaturated	O
fatty	O
acids;	O
SFA	O
=	O
saturated	O
fatty	O
acids;	O
SM	O
=	O
sphingomyelins;	B
ST	O
=	O
steroids;	O
TG	B
=	O
triglycerides.	B

In	O
urine,	O
Glutamic	B
acid	I
and	O
Formic	B
acid	I
levels	O
were	O
higher	O
in	O
HIV/AIDS	O
patients	O
compared	O
to	O
healthy	O
controls,	O
and	O
were	O
even	O
higher	O
following	O
ART	O
administration.	O

Workers	O
were	O
from	O
three	O
different	O
plants:	O
17	O
worked	O
in	O
a	O
plant	O
producing	O
low-phosphor	B
coke	O
and	O
broken	O
coke	O
(plant	O
J),	O
24	O
in	O
a	O
plant	O
producing	O
domestic	O
coke	O
(plant	O
D),	O
and	O
8	O
in	O
a	O
plant	O
producing	O
foundry	O
and	O
blast	O
furnace	O
coke	O
(plant	O
R).	O

The	O
glutamic	B
acid	I
concentration	O
is	O
also	O
one	O
of	O
the	O
most	O
important	O
indicators	O
of	O
diabetic	O
retinas.	O

The	O
filtrate	O
was	O
dried	O
by	O
pure	O
nitrogen	B
gas	I
(50°C).	O

Our	O
data	O
show	O
that	O
NSCLC	O
patients,	O
compared	O
with	O
healthy	O
individuals,	O
exhibit	O
higher	O
serum	O
levels	O
of	O
leucine/isoleucine	O
(15.75%),	O
N-acetyl-cysteine	B
(14.94%)	O
and	O
glutamate	B
(37.65%),	O
and	O
lower	O
levels	O
of	O
glutamine	B
(−14.37%),	O
threonine	B
(−15.34%)	O
and	O
histidine	B
(−20.76%).	O

The	O
results	O
of	O
this	O
study	O
clearly	O
demonstrate	O
that	O
acrolein	B
uptake	O
in	O
smokers	O
is	O
significantly	O
higher	O
than	O
in	O
non-smokers,	O
and	O
underline	O
the	O
need	O
for	O
further	O
investigation	O
of	O
the	O
possible	O
relationship	O
of	O
acrolein	B
uptake	O
to	O
lung	O
cancer.	O

As	O
discussed	O
above,	O
amino	O
acids	O
(tryptophan	O
and	O
tyrosine)	B
increase	O
in	O
IDC	O
patients,	O
is	O
suggestive	O
of	O
their	O
preferred	O
demand	O
in	O
tissue.	O

For	O
the	O
present	O
study,	O
a	O
subset	O
of	O
the	O
available	O
analytical	O
methods	O
was	O
selected:	O
201	O
metabolites	O
covering	O
the	O
compound	O
classes	O
amino	O
acids,	O
biogenic	O
amines	O
and	O
polyamines,	B
reducing	O
mono-	O
and	O
oliogosaccharides,	B
glycerophospho-	B
and	O
sphingolipids,	B
eicosanoids	B
and	O
other	O
oxidized	O
polyunsaturated	O
fatty	O
acids	O
were	O
detected	O
and	O
quantified.	O

Gallstone	O
disease	O
is	O
a	O
common	O
disorder	O
of	O
the	O
hepatobiliary	O
system,	O
characterized	O
by	O
the	O
formation	O
of	O
gallstones	O
(or	O
cholelithiasis)	B
in	O
the	O
gallbladder,	O
common	O
bile	O
duct	O
or	O
hepatic	O
bile	O
duct.	O

Galactose	B
is	O
an	O
important	O
metabolites	O
involved	O
in	O
the	O
formation	O
of	O
glycans	B
featuring	O
galactose	B
and	O
its	O
derivatives	O
which	O
were	O
essentially	O
bound	O
by	O
galectins	O
,	O
.	O

Reduced	O
arginine	B
up-take	O
by	O
inflamed	O
colon	O
may	O
cause	O
amino	O
acid	O
increase	O
in	O
circulation,	O
which	O
would	O
explain	O
a	O
direct	O
correlation	O
between	O
systemic	O
arginine	B
and	O
the	O
severity	O
of	O
endoscopic	O
inflammation	O
observed	O
in	O
this	O
study.	O

In	O
brief,	O
200	O
μl	O
urine	O
was	O
mixed	O
with	O
200	O
μl	O
acetonitrile	B
and	O
vortexed	O
for	O
30	O
s.	O

However,	O
if	O
muscular	O
HGPRT	O
activity	O
actually	O
increased	O
after	O
ten	O
days	O
of	O
HIIT,	O
it	O
is	O
still	O
questionable	O
to	O
what	O
extent	O
a	O
more	O
efficient	O
salvage	O
in	O
muscle	O
is	O
likely	O
to	O
explain	O
the	O
decrease	O
in	O
urinary	O
hypoxanthine	B
excretion	O
at	O
rest.	O

In	O
mouse	O
models,	O
Yea,	O
K	O
et	O
al	O
.	O
have	O
reported	O
that	O
the	O
blood	O
glucose	B
lowering	O
effect	O
of	O
LPC	O
were	O
found	O
to	O
be	O
sensitive	O
to	O
variations	O
in	O
LPC	O
acyl	O
chain	O
length,	O
which	O
may	O
elucidate	O
the	O
divisive	O
findings	O
mentioned	O
above.	O

Next,	O
the	O
OMIX	O
tip	O
was	O
flushed	O
ten	O
times	O
with	O
the	O
acidified	O
sample	O
and	O
subsequently	O
washed	O
one	O
time	O
with	O
100	O
µl	O
water	O
acidified	O
with	O
formic	B
acid.	I

Then,	O
820	O
μL	O
of	O
supernatant	O
was	O
dried	O
with	O
N_2	O
(l),	O
dissolved	O
in	O
100	O
μL	O
of	O
cold	O
10%	O
methanol	B
(J.T.Baker,	O
HPLC	O
grade),	O
mixed	O
by	O
vortexing	O
for	O
1	O
min,	O
and	O
centrifuged	O
at	O
10,000	O
rpm	O
for	O
5	O
min	O
at	O
4°C.	O

The	O
extensive	O
chemical	O
investigation	O
of	O
extract	O
from	O
F.	O
solani	O
JK10,	O
an	O
endophyte	O
of	O
Chlorophora	B
regia	O
,	O
resulted	O
in	O
the	O
isolation	O
of	O
seven	O
new	O
compounds	O
among	O
which	O
compounds	O
7,	O
8,	O
9,	O
10	O
and	O
11	O
demonstrated	O
antibacterial	O
activity	O
against	O
gram-negative	O
and	O
positive	O
bacteria	O
with	O
MIC	O
5–10μg/mL	O

The	O
reduction	O
in	O
cysteine	B
and	O
cystine	B
may	O
therefore	O
reflect	O
a	O
compensatory	O
mechanism	O
of	O
increased	O
glutathione	B
synthesis	O
to	O
counteract	O
toxic	O
ROS	O
buildup.	O

Glycerophospholipids	B
were	O
measured	O
by	O
liquid	O
chromatography-mass	O
spectrometry	O
(LC-MS)	O
profiling	O
of	O
mock	O
vs.	O
infected	O
cells	O
at	O
0	O
(red),	O
6	O
(purple),	O
24	O
(yellow),	O
48	O
(green),	O
72	O
(blue),	O
and	O
96	O
(white)	O
hpi.	O

It	O
is	O
evident	O
that	O
fatty	O
acyls	O
at	O
the	O
sn	O
-1	O
position	O
show	O
lower	O
diversity	O
than	O
those	O
at	O
the	O
sn	O
-2	O
position,	O
with	O
C16:0	B
and	O
C18:0	B
as	O
two	O
high	O
frequency	O
groups.	O

At	O
shorter	O
time	O
points	O
after	O
exposure	O
to	O
IR	O
(e.g	O
.,	O
24	O
h)	O
the	O
deaminated	O
form	O
of	O
uridine	B
(2’-deoxyuridine)	I
is	O
found	O
in	O
higher	O
concentrations	O
compared	O
to	O
controls	O
in	O
urine.	O

PC	B
ae	I
C42:3;	I
117	O
Kynurenine;	B
118.	O

Mobile	O
phases	O
consisted	O
of	O
0.1%	O
formic	B
acid	I
in	O
water	O
(mobile	O
phase	O
A)	O
and	O
0.1%	O
formic	B
acid	I
in	O
acetonitrile	B
(mobile	O
phase	O
B).	O

In	O
agreement	O
with	O
these	O
findings,	O
our	O
metabolomics	O
results	O
revealed	O
substantially	O
higher	O
levels	O
of	O
adenosine,	B
inosine	B
and	O
purine,	B
as	O
well	O
as	O
a	O
moderately	O
lower	O
concentration	O
of	O
hypoxanthine	B
in	O
the	O
BAV	O
patients	O
of	O
this	O
study,	O
which	O
were	O
signs	O
of	O
ATP	B
degradation	O
that	O
possibly	O
arose	O
from	O
a	O
lack	O
of	O
oxygen	O
supply.	O

Identification	O
of	O
Michael	O
adducts	O
and	O
Schiff	O
base	O
adducts	O
of	O
acrolein	B
and	O
4HNE	O
formed	O
with	O
Alb.	O

Tocopherols	B
are	O
a	O
class	O
of	O
biochemicals	O
that	O
have	O
different	O
antioxidant	O
properties	O
dependent	O
on	O
the	O
tocopherol	B
isoform.	O

Further	O
study	O
is	O
required	O
to	O
know	O
if	O
the	O
circadian	O
variation	O
of	O
cortisol	B
secretion	O
is	O
conserved	O
in	O
patients	O
with	O
untreated	O
AN	O
in	O
childhood	O
and	O
adolescence.	O

All	O
patients	O
were	O
screened	O
for	O
DNA-mutations	O
in	O
the	O
following	O
genes:	O
SOD1,	O
vesicle	O
associated	O
membrane	O
protein	O
B,	O
TDP-43,	O
fused	O
in	O
sarcoma	O
(FUS),	O
progranulin,	O
chromatin	B
modifying	O
protein	O
2B,	O
optineurin,	O
ataxin	B
2	O
and	O
angiogenin	O
using	O
standard	O
procedures	O
as	O
described	O
,	O
,	O
,	O
,	O
,	O
,	O
,	O
,	O
.	O

Slides	O
were	O
then	O
placed	O
in	O
eosin	B
for	O
30	O
s	O
followed	O
by	O
3	O
×	O
5	O
minute	O
incubations	O
in	O
95%	O
ethanol,	B
3	O
×	O
5	O
minute	O
incubations	O
in	O
100%	O
ethanol,	B
and	O
3	O
×	O
15	O
minute	O
incubations	O
in	O
xylene.	B

(A,	O
B)	O
Levels	O
of	O
total	O
monohexocylceramide	B
(HexCer)	O
(A)	O
and	O
each	O
monohexocylceramide	B
specie	O
(C14:0,	O
C16:0,	B
C18:1,	B
C18:0,	B
C20:0,	B
C22:0,	B
C24:1,	B
C24:0,	B
C26:1	B
and	O
C26:0)	B
(B)	O
in	O
cancer	O
tissue	O
(Cancer	O
or	O
C),	O
peri-tumor	O
tissue	O
(Peri	O
or	O
P)	O
and	O
normal	O
tissue	O
(Normal	O
or	O
N)	O
were	O
determined	O
by	O
mass	O
spectrometry.	O

Most	O
(12	O
of	O
13)	O
patients	O
were	O
subjected	O
to	O
a	O
standard	O
TB	O
treatment	O
regimen,	O
consisting	O
of	O
2-month	O
induction	O
phase	O
with	O
isoniazid	O
(INH),	O
rifampin	O
(RMP),	O
ethambutol	O
(EMB)	O
and	O
pyrazinamide	B
(PZA),	O
followed	O
by	O
a	O
4-month	O
consolidation	O
phase	O
with	O
at	O
least	O
INH	O
and	O
RMP.	O

Alternate	O
conditions	O
for	O
16αOHE1	B
and	O
16αOHE2	B
applying	O
a	O
40%	O
MeOH	B
wash	O
and	O
95%	O
MeOH	B
elution	O
reduced	O
ion	O
suppression	O
further	O
(18 ± 18%	O
and	O
22 ± 10%,	O
respectively).	O

The	O
amounts	O
of	O
C15:0	B
and	O
C17:0,	B
the	O
two	O
dairy-specific	O
odd-chain	O
fatty	O
acids,	O
were	O
low	O
(0.3	O
g	O
of	O
C15:0	B
in	O
600	O
mL	O
milk,	O
0.3	O
g	O
of	O
C15:0	B
in	O
100	O
g	O
cheese;	O
0.1	O
g	O
of	O
C17:0	B
in	O
600	O
mL	O
milk,	O
0.2	O
g	O
of	O
C17:0	B
in	O
100	O
g	O
cheese).	O

Hydrochloric	B
acid	I
(37%,	O
Merck,	O
Germany),	O
o	B
-ethylhydroxylamine	I
hydrochloride	I
(Aldrich,	O
Germany),	O
double	O
distilled	O
water	O
(Elga,	O
U.K.),	O
sodium	B
chloride	I
(Merck,	O
Germany),	O
ethyl	B
acetate	I
for	O
GC–MS	O
Suprasolv	O
(Millipore,	O
Germany),	O
N	O
-tert	O

Examples	O
for	O
“Ʌ-pattern”	O
are	O
hydroxyisobutyric	B
acid	I
and	O
acetylglycine.	B

Regarding	O
the	O
13	O
reported	O
metabolites	O
linked	O
to	O
stability	O
issues	O
(i.e.,	O
acetic	B
acid,	I
benzoic	B
acid,	I
creatine,	B
creatinine,	B
lactic	B
acid,	I
citric	B
acid,	I
hippuric	B
acid,	I
succinic	B
acid,	I
malonic	B
acid,	I
formic	B
acid,	I
trimethylamine,	B
urea,	B
alanine	B
and	O
glycine),	B
5	O
(i.e.,	O
creatine,	B
creatinine,	B
lactic	B
acid,	I
citric	B
acid,	I
hippuric	B
acid,	I
and	O
malonic	O
acid)	O
were	O
detected	O
by	O
our	O
LC/MS	O
method,	O
and	O
all	O
of	O
them	O
except	O
for	O
benzoic	B
acid	I
were	O
detected	O
by	O
NMR.	O

Mann–Whitney	O
U	O
test	O
showed	O
significantly	O
lower	O
serum	O
concentrations	O
in	O
the	O
ADHD	O
group	O
for	O
tryptophan,	B
KA,	O
XA,	O
HAA,	O
vitamin	B
B2	I
(riboflavin)	O
and	O
total	O
vitamin	B
B6	I
(PL + PLP),	O
as	O
well	O
as	O
a	O
significantly	O
higher	O
level	O
of	O
cotinine,	B
compared	O
with	O
the	O
control	O
group	O
(Table ).	O

Glycine	B
is	O
converted	O
to	O
sarcosine,	B
an	O
N	O
-methyl	O
derivative	O
of	O
glycine	B
that	O
has	O
been	O
previously	O
linked	O
to	O
PCa	O
(Sreekumar	O
et	O
al.	O
),	O
by	O
the	O
enzyme	O
glycine-N	O
-methyltransferase	O
(GNMT).	O

Chromatographic	O
analysis	O
were	O
carried	O
out	O
at	O
60°C	O
using	O
a	O
gradient	O
elution	O
applying	O
10	O
mM	O
ammonium	B
formate	I
in	O
Milli-Q	O
water	O
(A)	O
and	O
10	O
mM	O
ammonium	B
formate	I
in	O
methanol	B
(B)	O
at	O
a	O
constant	O
flow	O
of	O
0.5	O
mL/min.	O

In	O
addition	O
we	O
found	O
a	O
significant	O
decrease	O
in	O
alanine	B
after	O
one	O
year	O
in	O
the	O
group	O
of	O
patients	O
with	O
diabetes	O
remission	O
relative	O
to	O
non-remission.	O

In	O
healthy	O
control	O
newborns	O
(N = 19)	O
significantly	O
lower	O
levels	O
of	O
pyruvate	B
and	O
lactate	B
were	O
found	O
in	O
comparison	O
to	O
age-matched	O
newborns	O
with	O
HIE	O
undergoing	O
TH,	O
whereas	O
acetoacetate	B
and	O
β-hydroxybutyrate	B
levels	O
were	O
clearly	O
increased.	O

Compared	O
to	O
previous	O
studies,	O
our	O
study	O
systematically	O
investigated	O
the	O
influence	O
of	O
storage	O
temperature	O
(4,	O
22,	O
and	O
40	O
°C),	O
storage	O
duration	B
(24	O
and	O
48	O
h),	O
and	O
the	O
use	O
of	O
different	O
preservatives	O
(BA,	O
thymol,	B
NP)	O
on	O
metabolite	O
fingerprints	O
in	O
urine	O
using	O
targeted	O
metabolomics	O
(158	O
reliably	O
detected	O
metabolites).	O

who	O
found	O
elevations	O
of	O
the	O
following	O
metabolites	O
in	O
faecal	O
samples	O
from	O
CD	O
patients:	O
aspartate,	B
glycine,	B
tryptophan,	B
carnosine,	B
allantoin,	B
citrulline,	B
serine,	B
threonine,	B
ornithine,	B
creatine,	B
asparagine,	B
choline,	B
kynurenine,	B
histidine,	B
taurine,	B
phenylalanine,	B
alanine,	B
and	O
metanephrine.	B

For	O
each	O
of	O
the	O
listed	O
pathways,	O
the	O
respective	O
metabolites	O
identified	O
are	O
listed	O
below:	O
Glycerol	B
phosphate	I
shuttle:	O
Hydroquinone	B
(1/11);	O
alanine	B
metabolism:	O
Glycine	B
(1/17);	O
riboflavin	B
metabolism:	O
Hydroquinone	B
(1/20);	O
glutathione	B
metabolism:	O
Glycine	B
(1/21);	O
carnitine	B
synthesis:	O
Glycine	B
(1/22);	O
glycerolipid	B
metabolism:	O
Hydroquinone	B
(1/25);	O
ammonia	O
recycling:	O
Glycine	B
(1/32);	O
porphyrin	O
metabolism:	O
Glycine	B
(1/40);	O
methionine	B
metabolism:	O
Glycine	B
(1/43);	O
glutamate	B
metabolism:	O
Glycine	B
(1/49);	O
arginine	B
and	O
proline	B
metabolism:	O
Glycine	B
(1/53);	O
glycine	B
and	O
serine	B
metabolism:	O
Glycine	B
(1/59);	O
bile	O
acid	O
biosynthesis:	O
Glycine	B
(1/65);	O
tyrosine	B
metabolism:	O
Aminomalonate	B
(1/72);	O
purine	B
metabolism:	O
Glycine	B
(1/74).	O

However,	O
it	O
is	O
reassuring	O
to	O
note	O
that	O
associations	O
between	O
estrogen	B
and	O
estrogen	B
metabolism	O
measures	O
and	O
the	O
risk	O
of	O
breast	O
cancer	O
did	O
not	O
differ	O
between	O
subgroups	O
of	O
women	O
who	O
had	O
and	O
had	O
not	O
used	O
menopausal	O
hormone	O
therapy	O
before	O
PLCO	O
study	O
entry.	O

b	O
,	O
induction	O
of	O
expression	O
of	O
mRNAs	O
for	O
RARβ	O
(left	O
lower	O
panel	O
)	O
or	O
cytochrome	O
P450,	O
26A1	O
(CYP26A1)	O
(right	O
lower	O
panel	O
)	O
by	O
10	O
nm	O
ATRA	O
treatment	O
alone	O
or	O
by	O
co-treatment	O
with	O
ATRA	O
and	O
the	O
test	O
compounds	O
at	O
10	O
nm,	O
including	O
β-carotene	B
(BC	O
),	O
β-ionylideneacetic	B
acid	I
(BIAA	O
),	O
β-apo-14′-carotenal	B
(14′-AL),	O
β-apo-14′-carotenoic	B
acid	I
(14′-CA),	O
and	O
β-apo-13-carotenone	B
(C13	O
ketone).	B

In	O
abdominally	O
obese	O
participants,	O
eight	O
metabolites	O
were	O
associated	O
with	O
25(OH)D	O
at	O
P	O
 < 6.02 x 10_−05	O
in	O
KORA	O
F4,	O
six	O
of	O
which	O
were	O
replicated	O
in	O
FINRISK	O
1997:	O
the	O
average	O
number	O
of	O
methylene	B
groups	O
per	O
double	O
bond	O
(CH_2	O
_DB_ratio)	O
(N)	O
was	O
inversely	O
associated,	O
DB_in_FA	O
(N),	O
the	O
ratio	O
of	O
bisallylic	O
groups	O
to	O
double	O
bonds	O
(Bis_DB_ratio)	O
(N),	O
the	O
ratio	O
of	O
bisallylic	O
groups	O
to	O
total	O
fatty	O
acids	O
(Bis_FA_ratio)	O
(N),	O
creatinine	B
(N)	O
and	O
CMPF	O
(M)	O
were	O
positively	O
associated.	O

Mass	O
chromatograms	O
of	O
methylpiperazine	B
(MPPZ)	O
derivatives	O
of	O
estrone	B
(E1),	O
estradiol	B
(17α	I
&	I
17βE2),	I
16-hydroxyestrogens	B
(16OHE1	O
&	O
16OHE2)	O
and	O
methoxyestrogens	B
(2MeOE1,	O
4MeOE1,	O
2MeOE2	O
&	O
4MeOE2)	O
extracted	O
from	O
plasma.	O

The	O
colorectal	O
cancer	O
patients	O
exhibited	O
lower	O
blood	O
levels	O
of	O
total	O
cholesterol	B
than	O
the	O
healthy	O
volunteers,	O
but	O
their	O
blood	O
levels	O
of	O
triglycerides	B
were	O
higher	O
than	O
those	O
of	O
the	O
colorectal	O
cancer	O
patients,	O
suggesting	O
that	O
there	O
is	O
no	O
relationship	O
between	O
stage	O
0/I/II	O
colorectal	O
cancer	O
and	O
lipid	O
metabolism	O
abnormalities.	O

Most	O
of	O
the	O
neutral	O
lipids	O
and	O
ceramide	B
were	O
elevated	O
in	O
the	O
NAFLD	O
group	O
but	O
were	O
decreased	O
in	O
the	O
CHB	O
without	O
NAFLD	O
group.	O

Metformin	B
and	O
long-acting	O
insulin	O
were	O
discontinued	O
48	O
h	O
before	O
metabolic	O
studies	O
as	O
detailed	O
before.	O

We	O
could	O
not	O
identify	O
significant	O
treatment-related	O
changes	O
in	O
metabolite	O
profiles	O
of	O
the	O
urine	O
samples	O
in	O
the	O
HV	B
group.	O

Glycine	B
is	O
synthesized	O
from	O
threonine	B
through	O
inter-organ	O
metabolism	O
of	O
amino	O
acids,	O
and	O
it	O
is	O
also	O
the	O
precursor	O
of	O
many	O
important	O
metabolites	O
(e.g.,	O
creatine,	B
purines,	B
heme	B
and	O
glutathione).	B

Typical	O
chromatogram	O
for	O
separation	O
and	O
analysis	O
of	O
As	O
compounds	O
(25	O
μg	O
L-1	O
)	O
containing	O
no	O
glutathione	B
using	O
HPLC-ICP-MS.	O

Doubly	O
charged	O
ions	O
and	O
corresponding	O
product	O
ions	O
(precursor	O
minus	O
phosphate	B
group)	O
were	O
chosen	O
as	O
a	O
transition	O
pair	O
for	O
multiple	O
reactions	O
monitoring	O
for	O
quantitation.	O

Decreased	O
levels	O
of	O
lysoPC	O
a	O
C16:0	B
and	O
lysoPC	O
a	O
C18:0	B
were	O
reported	O
to	O
be	O
associated	O
with	O
a	O
decrease	O
PC	O
level	O
in	O
hepatocellular	O
carcinoma	O
tissues.	O

Isotopic	O
labeling	O
was	O
initiated	O
by	O
resuspending	O
cultures	O
in	O
RPMI	O
containing	O
_13	O
C-U-glucose.	B

Identification	O
of	O
monohydroxycholesterols	B
and	O
hydroxynorcholestenedione	B
in	O
CSF.	O

Finally,	O
due	O
to	O
its	O
role	O
as	O
neurotransmitter,	O
glutamate	B
is	O
involved	O
in	O
numerous	O
signaling	O
processes	O
[,]	O
but	O
is	O
also	O
potentially	O
neurotoxic.	O

This	O
signature	O
arose	O
mainly	O
from	O
3-hydroxybutyrate,	B
succinate,	B
and	O
formate,	B
which	O
increased	O
(P	O
 < .0005)	O
along	O
with	O
acetate,	B
glycerophosphocholine,	B
ADP,	B
and	O
lactate	B
(P	O
 < .05).	O

The	O
MPPZ	O
derivatives	O
of	O
E1	O
and	O
17βE2	B
fragmented	O
to	O
give	O
two	O
specific	O
product	O
ions	O
m/z	O
549 → 502	O
and	O
551 → 504	O
by	O
loss	O
of	O
NO_2	O
.	O

In	O
addition,	O
reserpine	B
was	O
also	O
spiked	O
in	O
samples	O
as	O
internal	O
standard	O
for	O
QC	O
purpose.	O

Acquired	O
spectra	O
were	O
processed	O
using	O
Bruker	O
software	O
packages	O
(TopSpin	O
v.2.2	O
and	O
Amix	O
v.3.9.9),	O
and	O
the	O
methyl	O
signal	O
of	O
alanine	B
was	O
used	O
for	O
spectral	O
calibration	O
(1.47	O
ppm).	O

The	O
data	O
were	O
aligned	O
with	O
reference	O
to	O
the	O
TSP	O
signal	O
and	O
the	O
regions	O
containing	O
TSP,	O
urea	B
and	O
residual	O
water	O
(4.6∼5.3	O
ppm)	O
signals	O
were	O
removed.	O

Thus	O
tryptophan	B
can	O
be	O
considered	O
a	O
GFR	O
marker	O
even	O
though	O
it	O
is	O
not	O
a	O
retained	O
solute.	O

 M	O
NaH_2	O
PO_4	O
,	O
pH 7.4),	O
and	O
60 μL	O
of	O
3-trimethylsilyl-(2,2,3,3-_2	B
H_4	I
)-1-propionate	I
(TSP)/D_2	O
O	O
solution	O
was	O
added.	O

According	O
to	O
Muñoz	O
and	O
Costa,	O
the	O
increase	O
in	O
glucose	B
and	O
free	O
fatty	O
acids	O
from	O
energy	O
imbalance	O
causes	O
an	O
increase	O
in	O
the	O
production	O
of	O
Acetyl-Coenzyme	B
A	O
(Acetyl-CoA)	O
in	O
the	O
Tricarboxylic	B
Acid	I
(TCA)	O
cycle,	O
which	O
stimulates	O
the	O
excessive	O
production	O
of	O
superoxide	B
and,	O
consequently,	O
the	O
activation	O
of	O
inflammatory	O
stimuli	O
(Muñoz	O
and	O
Costa,	O
).	O

Other	O
compounds	O
tentatively	O
identified	O
include	O
pyridine	B
and	O
pyrrole.	B

It	O
seems	O
likely	O
that	O
the	O
difference	O
in	O
tryptophan	B
levels	O
could	O
be	O
partially	O
due	O
to	O
a	O
relative	O
tryptophan	B
deficiency	O
in	O
the	O
ADHD	O
group	O
compared	O
to	O
the	O
control	O
group.	O

The	O
remaining	O
metabolites	O
could	O
be	O
assigned	O
to	O
2	O
different	O
metabolic	O
pathways:	O
TRP	O
metabolism	O
(5-OH-TRP	O
and	O
TRP)	O
and	O
energy	O
metabolism	O
(glucose,	O
alanine,	B
OH-butyrate,	B
acetoacetate,	B
and	O
acetone).	O

Metabolic	O
alterations	O
associated	O
with	O
lung	O
cancer	O
risk	O
suggest	O
systemic	O
changes	O
to	O
key	O
biological	O
processes,	O
including	O
1-carbon	O
metabolism	O
(vitamin	O
B_9	O
[folate]	O
metabolism;	O
glycine,	B
serine,	B
alanine,	B
and	O
threonine	B
metabolism),	O
oxidative	O
stress	O
pathways	O
(ascorbate	O
[vitamin	O
C]	O
and	O
aldarate	O
metabolism,	O
methionine	B
and	O
cysteine	B
metabolism,	O
glutamate	B
metabolism),	O
nucleotide	O
metabolism	O
(purine	O
metabolism),	O
and	O
inflammation	O
(leukotriene	O
metabolism).	O

Carnitine	B
can	O
be	O
absorbed	O
from	O
the	O
diet	O
or	O
synthesised	O
in	O
the	O
liver,	O
testis,	O
and	O
kidney	O
and	O
reabsorbed	O
via	O
the	O
renal	O
system[].	O

The	O
letters	O
a,	O
b,	O
c	O
and	O
d	O
represent	O
ethyl	B
2-methylacetoacetate,	I
levulinic	B
acid,	I
p-cresol	B
and	O
benzylmalonic	B
acid,	I
respectively.	O

A	O
number	O
of	O
biochemicals	O
were	O
significantly	O
different	O
between	O
groups,	O
with	O
depressed	O
subjects	O
showing	O
higher	O
concentrations	O
of	O
several	O
amino	O
acids	O
and	O
dicarboxylic	B
fatty	O
acids.	O

Boston	O
subjects	O
differed	O
slightly	O
in	O
terms	O
of	O
the	O
low-M_w	O
domain	O
(,	O
),	O
exhibiting	O
higher	O
levels	O
of	O
glutamine	B
in	O
early	O
AMD	O
and	O
lower	O
levels	O
for	O
intermediate	O
AMD;	O
low	O
histidine	B
levels	O
in	O
intermediate	O
and	O
late	O
AMD	O
(similarly	O
to	O
the	O
Coimbra	O
cohort);	O
and	O
low	O
alanine	B
levels	O
in	O
late	O
AMD.	O

Urine	O
creatinine	B
was	O
measured	O
at	O
the	O
University	O
of	O
Minnesota	O
Medical	O
Center	O
using	O
Vitros	O
Crea	O
slides	O
(Ortho-Clinical	O
Diagnostics,	O
Rochester,	O
NY)	O

Key:	O
_*	O
,	O
3-hydroxyphenylpropionate;	B
_**	O
p-cresol.	B

z	O
840.4)	O
and	O
f	O
PC	B
16:0_20:4	I
(RT:	O
14.3 min,	O
m/z	O
840.4).	O

The	O
association	O
between	O
tyrosine	B
and	O
renal	O
impairment	O
was	O
further	O
investigated	O
by	O
assessing	O
the	O
HRs	O
across	O
tertiles	O
of	O
eGFR	O
and	O
ACR.	O

After	O
5 min,	O
one	O
saline	B
cryotube	O
was	O
removed	O
and	O
capped	O
firmly	O
until	O
_1	O
H-NMR	O
analysis.	O

The	O
activity	O
of	O
xanthine	B
oxidase	O
was	O
observed	O
to	O
decrease	O
in	O
individual	O
cancer.	O

It	O
was	O
reported	O
that	O
glioma	O
cells	O
that	O
expressed	O
high	O
levels	O
of	O
QPRT	O
resisted	O
chemotherapy-induced	O
apoptosis	O
by	O
inducing	O
NAD	B
synthesis.	O

In	O
the	O
glycerolipid	B
metabolism	O
pathway,	O
glycerol	B
was	O
significantly	O
up-regulated	O
and	O
glycerol	B
3-phosphate	I
was	O
significantly	O
down-regulated	O
(Fig.	O

In	O
these	O
identified	O
thiol	B
compounds,	O
pantetheine	O
has	O
been	O
firstly	O
discovered	O
in	O
human	O
urine,	O
which	O
extends	O
the	O
diversity	O
of	O
the	O
thiol	B
metabolites	O
present	O
in	O
human	O
urine.	O

Spironolactone,	B
Ammonium	B
fluoride,	I
Signal	O
enhancement,	O
Liquid	O
chromatography-mass	O
spectrometry,	O
Ionization	O
efficiency,	O
Hexafluoroisopropanol	B

Steroids	O
showing	O
smaller	O
gender	O
differences	O
included	O
21-deoxycortisol,	B
cortisol,	B
cortisone,	B
DHEA	O
and	O
androstenedione,	B
which	O
were	O
6%	O
to	O
24%	O
higher	O
(P < 0.05)	O
in	O
men	O
than	O
women.	O

First,	O
to	O
our	O
knowledge,	O
this	O
is	O
the	O
first	O
population-based	O
study	O
systematically	O
exploring	O
the	O
relation	O
between	O
plasma	O
TMAO	B
and	O
GDM.	O

Additionally,	O
accumulating	O
evidence	O
that	O
25OHD,	O
the	O
traditional	O
marker	O
of	O
vitamin	B
D	I
status,	O
is	O
an	O
acute-phase	O
reactant	O
[,,,]	O
poses	O
the	O
additional	O
question	O
of	O
whether	O
this	O
is	O
also	O
the	O
case	O
in	O
the	O
setting	O
of	O
chronic	O
inflammation:	O
Can	O
25OHD	O
be	O
regarded	O
as	O
a	O
reliable	O
biomarker	O
of	O
vitamin	B
D	I
status	O
in	O
patients	O
with	O
chronic	O
inflammatory	O
conditions?	O

Additionally,	O
a	O
careful	O
literature	O
analysis	O
also	O
indicated	O
the	O
scyllitol	B
is	O
a	O
normal	O
constituent	O
of	O
human	O
urine	O
and	O
has	O
previously	O
been	O
detected	O
in	O
human	O
urine	O
via	O
other	O
methods.	O

Spectra	O
of	O
C18:2	B
CE	O
(A)	O
and	O
SM	B
22:0	I
(B)	I
in	O
a	O
representative	O
healthy	O
individual	O
and	O
a	O
representative	O
cancer	O
patient.	O

Stock	O
solutions	O
were	O
prepared	O
in	O
DMSO	B
at	O
a	O
nominal	O
concentration	O
of	O
1	O
mg/mL	O
abiraterone	B
and	O
D_4	B
-abiraterone.	I

Other	O
major	O
differences	O
between	O
cell	O
culture	O
media	O
were	O
found	O
in	O
the	O
methionine	B
content,	O
appearing	O
to	O
be	O
present	O
in	O
larger	O
amounts	O
in	O
the	O
Com.	O

(I	O
)	O
RT-qPCR	O
for	O
CYP1A1	O
in	O
DLD1	O
cells	O
incubated	O
with	O
DMSO,	B
20	O
µM	O
Kyn,	O
or	O
10	O
µM	O
CH223191.	O

The	O
metabolite	O
2-methoxyestradiol	B
has	O
anti-proliferative	O
and	O
anti-angiogenic	O
effects	O
and	O
therefore	O
may	O
play	O
a	O
role	O
as	O
an	O
endogenous	O
anti-cancer	O
agent.	O

Based	O
on	O
the	O
absorption	O
intensities	O
and	O
extinction	O
coefficients,	O
the	O
mole	O
ratio	O
of	O
biotin	B
and	O
BChE	O
antibody	O
was	O
calculated	O
as	O
6.	O

PG	B
was	O
also	O
significantly	O
decreased	O
in	O
bvFTD	O
compared	O
to	O
control	O
only	O
(Figure	O
).	O

PC	O
847	O
2C,	O
PC	O
2096	O
4B	O
and	O
PC179	O
1A	O
cell	O
lines	O
and	O
the	O
scramble	O
shRNA	O
control	O
cell	O
line	O
were	O
maintained	O
in	O
RPMI	O
1640	O
medium	O
containing	O
5	O
mM	O
glucose	B
for	O
22	O
h	O
and	O
then	O
in	O
Krebs	O
Ringer	O
bicarbonate	O
solution	O
containing	O
10	O
mM	O
glucose	B
for	O
35	O
min	O
before	O
the	O
concentrations	O
of	O
metabolites	O
were	O
measured	O
as	O
described	O
under	O
Experimental	O
Procedures.	O

On	O
the	O
other	O
hand,	O
glucose/sugar,	O
lactate,	B
lipids,	O
and	O
amino	O
acids	O
are	O
all	O
the	O
energy	O
source,	O
and	O
these	O
reduced	O
metabolites	O
might	O
imply	O
high	O
consume	O
of	O
energy	O
in	O
Yang	O
deficiency	O
syndrome	O
patients	O
with	O
HCC.	O

Paracetamol	B
(resulted	O
from	O
paracetamol-β-d-glucuronide	B
degradation)	O
and	O
d_4	B
-paracetamol	I
were	O
monitored	O
in	O
the	O
LC-MS/MS	O
method,	O
and	O
the	O
ratio	O
between	O
them	O
was	O
used	O
to	O
evaluate	O
the	O
efficiency	O
of	O
the	O
deglucuronidation	O
process,	O
keeping	O
in	O
mind	O
that	O
equimolar	O
amount	O
of	O
paracetamol	B
and	O
deuterated-paracetamol	B
were	O
added	O
in	O
the	O
reaction	O
and	O
the	O
ionization	O
efficiency	O
of	O
the	O
two	O
analytes.	O

Creatinine	B
normalization,	O
on	O
the	O
other	O
hand,	O
originates	O
from	O
clinical	O
chemistry	O
and	O
uses	O
the	O
fact	O
that	O
creatinine	B
clearance	O
in	O
an	O
organism	O
is	O
fairly	O
constant.	O

Total	O
content	O
of	O
phosphatidylcholine	B
within	O
each	O
sample,	O
the	O
most	O
abundant	O
phospholipid	B
species	O
in	O
blood,	O
was	O
used	O
as	O
an	O
internal	O
reference	O
and	O
lipids	O
were	O
normalized	O
to	O
this	O
(concentration	O
of	O
individual	O
lipid	O
species/concentration	O
of	O
phosphatidylcholine.	B

The	O
amount	O
of	O
creatinine	B
in	O
urine	O
is	O
related	O
to	O
muscle	O
mass.	O

Characterization	O
of	O
urinary	O
metabolites	O
of	O
furan	B
will	O
lead	O
to	O
the	O
development	O
of	O
biomarkers	O
to	O
assess	O
human	O
health	O
risks	O
associated	O
with	O
furan	B
exposure.	O

The	O
individual	O
and	O
mean	O
±	O
S.D.	O
plasma	O
levels	O
of	O
oxysterols	B
in	O
these	O
patients	O
are	O
presented	O
in	O
.	O

These	O
mutant	O
enzymes	O
have	O
the	O
novel	O
property	O
of	O
converting	O
isocitrate	B
to	O
2-hydroxyglutarate	B
(2-HG).	O

The	O
absence	O
of	O
serotonin	B
at	O
tumor	O
sites	O
compared	O
to	O
corresponding	O
adjacent	O
non-involved	O
sites	O
may	O
suggest	O
increased	O
catabolism	O
of	O
serotonin	B
by	O
cancerous	O
cells.	O

Attenuation	O
of	O
DDAH	O
activity	O
is	O
influenced	O
by	O
factors	O
like	O
oxidized	O
low-density	O
lipoprotein	O
cholesterol,	B
inflammatory	O
cytokines,	O
hyperhomocysteinemia	O
and	O
hyperglycemia,	O
thereby	O
causing	O
accumulation	O
of	O
ADMA	B
and	O
subsequent	O
reduced	O
NO	O
synthesis.	O

The	O
linoleate	B
metabolites	O
13-HODE	B
+	O
9-HODE	B
were	O
also	O
significantly	O
higher	O
in	O
C-3N	O
subjects.	O

In	O
this	O
figure,	O
the	O
differences	O
in	O
the	O
levels	O
of	O
some	O
metabolites	O
related	O
to	O
glycolysis,	O
the	O
pentose	B
phosphate	I
pathway,	O
the	O
TCA	O
cycle,	O
glutathione	B
biosynthesis,	O
or	O
amino	O
acid	O
pathways	O
between	O
the	O
CRC	O
and	O
normal	O
tissue	O
samples	O
are	O
shown.	O

This	O
result	O
indicated	O
that	O
the	O
gaps	O
in	O
chemical	O
series	O
within	O
oxylipin	B
database	O
entries	O
may	O
be	O
utilized	O
to	O
identify	O
putative	O
novel	O
oxylipins.	B

BCAAs	O
such	O
as	O
valine,	B
isoleucine,	B
and	O
leucine	B
are	O
essential	O
amino	O
acids	O
whose	O
carbon	O
structures	O
are	O
marked	O
by	O
a	O
branch	O
point.	O

The	O
ability	O
to	O
separate	O
25(OH)D_2	O
and	O
25(OH)D_3	O
forms	O
of	O
vitamin	B
D	I
is	O
a	O
specific	O
feature	O
of	O
our	O
method	O
compared	O
to	O
typically	O
used	O
immunoassays.	O

Association	O
of	O
prenatal	O
maternal	O
serum	O
phthalates	O
(nanograms/milliliter)	O
with	O
total	O
serum	O
testosterone	B
(nanograms/milliliter)	O
in	O
their	O
adult	O
sons.	O

The	O
metabolomic	O
data	O
set	O
contained	O
acylcarnitines,	B
amino	O
acids,	O
carbohydrates,	O
glycerophospholipids,	B
lipids,	O
nucleotides,	O
peptides,	O
sphingomyelins,	B
steroids,	O
vitamins,	O
and	O
xenobiotics.	O

The	O
ions	O
observed	O
at	O
m/z	O
291.1	O
and	O
m/z	O
296.1,	O
respectively,	O
in	O
the	O
spectrum	O
of	O
NO_2	O
-PhIP-	O
and	O
NO_2	O
-[_2	O
H_5	O
]-PhIP-modified	O
ASSAKQR	O
are	O
at	O
the	O
same	O
m/z	O
observed	O
in	O
the	O
spectra	O
of	O
desamino-PhIP-K	B
([K*-NH_3	O
-HCO_2	O
H]_+	O
,	O
suggesting	O
that	O
NO_2	O
-PhIP	O
had	O
bound	O
to	O
lysine.	B

Brain-glucose	B
levels	O
were	O
lower	O
in	O
cerebellum	O
than	O
other	O
regions	O
whereas	O
elevations	O
in	O
sorbitol	B
and	O
fructose	B
were	O
similar	O
in	O
all	O
regions	O
studied.	O

_,	O
Data	O
were	O
taken	O
for	O
casein	B
spiked	O
into	O
both	O
water	O
and	O
into	O
CSF.	O

They	O
could	O
separate	O
PCa	O
from	O
BPH	O
patients	O
with	O
good	O
sensitivity	O
(81.5%)	O
and	O
specificity	O
(75.2%),	O
demonstrating	O
that	O
fatty	O
acids	O
(acyl	O
carnitines),	I
choline	B
(glycerophospholipids),	I
and	O
amino	O
acids	O
(arginine)	O
can	O
be	O
used	O
as	O
metabolic	O
markers	O
for	O
the	O
diagnostic	O
differentiation	O
between	O
PCa	O
and	O
BPH.	O

SR-A	O
levels	O
were	O
inversely	O
related	O
to	O
levels	O
of	O
the	O
PUFA,	O
docosapentaenoic	B
acid	I
(DPA)	O
(22:5).	O

Two	O
peaks	O
were	O
observed	O
for	O
the	O
α-TL	B
glucuronide,	I
a	O
major	O
peak	O
eluting	O
at	O
8.37	O
min	O
and	O
a	O
minor	O
one	O
at	O
10.56	O
min.	O

To	O
overcome	O
the	O
obstacle	O
of	O
the	O
presence	O
of	O
mutated	O
form	O
of	O
Ras	O
in	O
cancer	O
cells,	O
we	O
have	O
selected	O
a	O
normal	O
human	O
cell	O
line,	O
HRPTEC	O
to	O
study	O
20-HETE	B
signaling	O
by	O
small-GTPase	O
Ras.	O

The	O
significant	O
difference	O
of	O
phospholipids	B
between	O
HepG2	O
and	O
HepG2.2.15	O
cells.	O

Bagdade	O
and	O
Subbaiah	O
propose	O
that	O
such	O
abnormalities	O
may	O
compromise	O
reverse	O
cholesterol	B
transport	O
in	O
diabetic	O
patients	O
and	O
promote	O
atherosclerosis.	O

The	O
relative	O
ion	O
abundance	O
levels	O
of	O
415	O
lipids	O
(81	O
glycerolipids,	B
9	O
cholesterol	B
esters,	I
42	O
sphingolipids,	B
231	O
glycerophospholipids,	B
27	O
NEFA,	O
13	O
bile	O
acids,	O
8	O
oxidized	O
fatty	O
acids,	O
4	O
acyl	B
carnitines	I
–	O
see	O
for	O
individual	O
metabolite	O
identification	O
details),	O
18	O
amino	O
acids,	O
and	O
78	O
unidentified	O
species	O
were	O
included	O
for	O
statistical	O
analysis	O
in	O
the	O
estimation	O
group	O
(80%	O
of	O
all	O
subjects).	O

This	O
research	O
was	O
a	O
part	O
of	O
a	O
double	O
blind	O
placebo-controlled	O
study	O
registered	O
as	O
a	O
clinical	O
trial	O
(LS-10-152-Brennan-Gibney,	O
ISRCTN16158244).	O

The	O
decrease	O
in	O
plasma	O
purines	B
in	O
CFS	O
is	O
consistent	O
with	O
decreased	O
synthesis	O
and/or	O
turnover	O
(flux)	O
of	O
ATP	B
and	O
GTP	O
and	O
decreased	O
reserve	O
capacity	O
caused	O
in	O
part	O
by	O
a	O
generalized	O
decrease	O
in	O
the	O
ability	O
to	O
restore	O
high-energy	O
phosphate	B
stores	O
after	O
exertion.	O

Among	O
several	O
metabolites,	O
uric	B
acid	I
levels	O
were	O
increased	O
in	O
the	O
blood	O
of	O
study	O
participants,	O
while	O
those	O
of	O
hypoxanthine	B
were	O
significantly	O
decreased.	O

Glutamate;	B
103.	O

This	O
state	O
of	O
oxidative	O
stress	O
leads	O
to	O
the	O
induction	O
and	O
increase	O
of	O
inflammatory	O
mediators,	O
such	O
as	O
arachidonic	B
acid	I
metabolites.	O

In	O
the	O
literature,	O
there	O
are	O
reports	O
that	O
associate	O
dimethylamine	B
(DMA)	O
and	O
urea	B
with	O
kidney	O
graft	O
rejection	O
in	O
NMR	O
based	O
studies	O
(Bell	O
et	O
al.	O
;	O

The	O
cartridges	O
were	O
washed	O
with	O
the	O
loading	O
buffer,	O
and	O
then	O
the	O
compounds	O
of	O
interest	O
were	O
eluted	O
from	O
the	O
cartridge	O
by	O
using	O
an	O
elution	O
buffer,	O
methanol/10	O
mM	O
ammonium	B
formate,	I
pH	O
7	O
(90:10)	O
with	O
1%	O
acetic	B
acid.	I

Patients	O
included	O
in	O
this	O
trial	O
were	O
randomized	O
into	O
either	O
Group	O
O	O
receiving	O
olesoxime	B
(n	O
=	O
38)	O
or	O
Group	O
P	O
receiving	O
placebo	O
(n	O
=	O
36).	O

Therefore,	O
the	O
authors	O
looked	O
at	O
a	O
possible	O
correlation	O
in	O
the	O
metabolic	O
profiles	O
of	O
hydrophilic	B
and	O
hydrophobic	O
compounds	O
with	O
clinical	O
parameters	O
to	O
study	O
their	O
relationship	O
with	O
pathology.	O

However,	O
the	O
CV%	O
values	O
of	O
17:0	O
Cer	O
and	O
17:0	O
PE	O
are	O
significantly	O
lower	O
when	O
the	O
methanol	B
method	O
is	O
used	O
(25%	O
and	O
30%	O
versus	O
47%	O
and	O
49%).	O

Validation	O
of	O
LC-MRM-MS	O
based	O
oxylipin	B
assay.	O

The	O
spectral	O
basis	O
set	O
consisted	O
of	O
28	O
previously	O
identified	O
metabolites	O
and	O
included	O
2-hydroxy-butyrate	B
(CHEBI:64552),	O
3-hydroxy-butyrate	B
(CHEBI:37054),	O
acetate	B
(CHEBI:30089),	O
acetoacetate	B
(CHEBI:13705),	O
acetone	B
(CHEBI:15347),	O
alanine	B
(CHEBI:16449),	O
arginine	B
(CHEBI:29016),	O
betaine	B
(CHEBI:22860),	O
carnitine	B
(CHEBI:17126),	O
choline	B
(CHEBI:15354),	O
citrate	B
(CHEBI:53258),	O
creatine	B
(CHEBI:16919),	O
creatinine	B
(CHEBI:16737),	O
ethanol	B
(CHEBI:16236),	O
glucose	B
(CHEBI:17234),	O
glutamate	B
(CHEBI:64243),	O
glutamine	B
(CHEBI:28300),	O
isoleucine	B
(CHEBI:17191),	O
lactate	B
(CHEBI:75228),	O
leucine	B
(CHEBI:25017),	O
lysine	B
(CHEBI:18019),	O
methionine	B
(CHEBI:16811),	O
ornithine	B
(CHEBI:18257),	O
proline	B
(CHEBI:26271),	O
pyruvate	B
(CHEBI:15361),	O
succinate	B
(CHEBI:63675),	O
threonine	B
(CHEBI:16857)	O
and	O
valine	B
(CHEBI:27266).	O

For	O
the	O
analysis	O
of	O
fat	O
mass,	O
bone	O
mass,	O
and	O
LBM	O
enCORE	B
Software	O
v16	O
was	O
used.	O

Furthermore,	O
a	O
ketogenic	O
diet	O
(high	O
fat,	O
low	O
carbohydrate	O
content)	O
has	O
shown	O
to	O
have	O
a	O
protective/therapeutic	O
effect	O
on	O
cancer	O
probably	O
because	O
it	O
diminishes	O
the	O
glycolytic	B
flux	O
in	O
cancer	O
cells_,	O
.	O

Liquid	O
chromatography–tandem	O
mass	O
spectrometry,	O
Mycotoxin,	B
Biomarker,	O
Exposure	O
assessment,	O
Human	O
urine,	O
Glucuronide	B
conjugate	O

Besides	O
preventing	O
a	O
modest	O
negative	O
effect	O
of	O
n	O
-3	O
fatty	O
acids	O
on	O
glycemic	B
control,	O
the	O
combination	O
of	O
pioglitazone	B
and	O
EPA + DHA	O
can	O
be	O
used	O
to	O
improve	O
lipid	O
metabolism	O
in	O
T2D	O
patients	O
on	O
stable	O
metformin	B
therapy.	O

For	O
metabolites	O
that	O
showed	O
multiple	O
peaks	O
during	O
derivatization,	O
i.e.	O
from	O
isomers	O
or	O
partial	O
silylation	O
of	O
amino	B
groups,	O
only	O
the	O
most	O
abundant	O
peak	O
was	O
used	O
for	O
analysis.	O

The	O
absence	O
of	O
metabolites	O
such	O
as	O
ethanol	B
in	O
SpeedVac-dried	O
samples	O
was	O
potentially	O
due	O
to	O
more	O
rapid	O
evaporation	O
at	O
room	O
temperature	O
due	O
to	O
higher	O
vapor	O
pressure	O
at	O
this	O
temperature.	O

We	O
assessed	O
the	O
selectivity	O
of	O
DI–nESI–MS	O
by	O
measuring	O
the	O
response	O
factor	O
for	O
labeled	O
and	O
nonlabeled	O
compounds	O
in	O
neat	O
methanol.	B

Genomic	O
DNA	O
was	O
isolated	O
from	O
paraffin	B
blocks	O
of	O
glioma	O
tissue	O
using	O
the	O
DNeasy	O
FFPE	O
kit	O
(Qiagen,	O
Valencia,	O
CA,	O
USA),	O
according	O
to	O
the	O
manufacturer’s	O
instructions.	O

Samples	O
were	O
reconstituted	O
with	O
acetonitrile/water	O
(20:80),	O
with	O
and	O
without	O
either	O
5	O
%	O
2	O
M	O
H_2	O
SO_4	O
or	O
0.1	O
%	O
formic	B
acid.	I

Further	O
studies	O
are	O
now	O
necessary	O
to	O
directly	O
investigate	O
how	O
dual	O
ASA	O
and	O
statin	B
treatment	O
affects	O
colon	O
tumorigenesis	O
in	O
humans.	O

Vitamin	O
D_3	O
catabolism	O
is	O
accomplished	O
predominantly	O
by	O
CYP24A1,	O
which	O
metabolizes	O
25(OH)D_3	O
to	O
24,25-dihydroxyvitamin	B
D_3	O
(24,25(OH)_2	O
D_3	O
)	O
and	O
1,25(OH)_2	B
D_3	O
to	O
1,24,25-trihydroxyvitamin	B
D_3	O
(1,24,25(OH)_3	O
D_3	O
).	O

Additionally	O
the	O
decreased	O
level	O
of	O
amino	O
acids	O
especially	O
relative	O
integral	O
of	O
serum	O
tyrosine,	B
could	O
not	O
only	O
be	O
related	O
to	O
protein	O
biosynthesis	O
but	O
also	O
for	O
the	O
synthesis	O
catecholamines.	B

Supernatant	O
organic	O
solution	O
was	O
transferred,	O
speed-vacuum	O
dried	O
at	O
room	O
temperature	O
and	O
reconstituted	O
in	O
50	O
μL	O
of	O
mobile	O
phase	O
(50%	O
methanol	B
solution	O
containing	O
0.1%	O
NH_4	O
OH	O
and	O
10	O
mM	O
NH_4	O
OAC)	O
ready	O
for	O
injection.	O

Isoleucine,	B
leucine,	B
valine,	B
phenylalanine,	B
glutamate,	B
pyruvate,	B
and	O
signals	O
from	O
N-acetylglycoproteins	B
were	O
consistently	O
higher	O
among	O
plasma	O
samples	O
with	O
increased	O
platelet	O
content	O
whereas	O
the	O
resonances	O
of	O
the	O
fatty	O
acyl	O
moieties	O
in	O
VLDL/LDL,	O
citrate,	B
and	O
glutamine	B
were	O
consistently	O
lower	O
(	O
and	O
).	O

Consequently,	O
a	O
panel	O
consisting	O
of	O
pyruvate,	B
isobutyrate,	B
N-methylnicotinamide,	B
α-hydroxybutyrate,	B
acetoacetate	B
and	O
malonate	B
was	O
identified	O
as	O
an	O
effective	O
classifier.	O

Our	O
group	O
has	O
observed	O
decreased	O
methylation	O
capacity	O
and	O
worsening	O
endothelial	O
function	O
in	O
schizophrenia	O
patients	O
with	O
genetic	O
polymorphisms	O
in	O
folate	B
cycle	O
enzymes	O
associated	O
with	O
hyperhomocysteinemia.	O

Of	O
the	O
39	O
subclasses	O
of	O
lipids	O
tested,	O
including	O
520	O
specific	O
lipid	O
species,	O
we	O
identified	O
two	O
lipid	O
subclasses,	O
triglycerides	B
and	O
GM3,	B
and	O
33	O
lipid	O
species	O
that	O
were	O
significantly	O
different	O
between	O
PD	O
patients	O
and	O
healthy	O
controls.	O

Benzo[a	B
]pyrene	I
(BaP),	O
an	O
archetypical	O
polycyclic	B
aromatic	O
hydrocarbon,	B
is	O
classified	O
as	O
“carcinogenic	O
to	O
humans”	O
and	O
is	O
ubiquitous	O
in	O
the	O
environment,	O
as	O
evident	O
by	O
the	O
measurable	O
levels	O
of	O
BaP	O
metabolites	O
in	O
virtually	O
all	O
human	O
urine	O
samples	O
examined.	O

Myo-inositol	B
is	O
the	O
parent	O
compound	O
of	O
phytic	B
acid,	I
or	O
inositol	B
hexaphosphate	I
(IP6).	O

However,	O
the	O
extraction	O
recoveries	O
of	O
O	O
-DVX	O
and	O
VX	O
by	O
LLE	O
using	O
ethyl	B
acetate,	I
diethylether	B
and	O
dichloromethane	B
were	O
much	O
lower	O
compared	O
to	O
SPE	O
[,	O
].	O

Additionally,	O
△	O
L-valine	B
(r	O
=	O
0.411,	O
P	O
<0.001)	O
and	O
△	O
L-leucine	B
(r	O
=	O
0.479,	O
P	O
<0.001)	O
positively	O
correlated	O
with	O
△	O
HOMA-IR.	O

p < 0.0001,	O
and	O
)	O
while	O
lactate	B
(1.31 ± 0.06	O
fold	O
higher	O
in	O
venous	O
plasma,	O
p < 0.0001,	O
and	O
)	O
and	O
succinate	B
(1.56 ± 0.09	O
fold	O
higher	O
in	O
venous	O
plasma,	O
p < 0.0001,	O
)	O
displayed	O
the	O
most	O
significant	O
release	O
pattern	O
across	O
human	O
forearm	O
tissue.	O

Most	O
RA	O
patients	O
had	O
been	O
treated	O
with	O
methotrexates	O
and/or	O
glucocorticoids,	B
and	O
none	O
had	O
been	O
treated	O
with	O
biologics.	O

We	O
chose	O
IR	O
hypogonadal	O
patients	O
using	O
very	O
strict	O
conditions	O
as	O
follows:	O
low	O
testosterone	B
concentrations	O
(<8	O
nmol/L),	O
high	O
insulin	O
(>18),	O

(B)	O
Expansion	O
for	O
the	O
aromatic	O
region	O
showing	O
signals	O
for	O
acetaminophen	B
and	O
its	O
related	O
metabolites.	O

Infusion	O
of	O
reconstituted	O
HDL	O
(rHDL)	O
resulted	O
in	O
significant	O
(P	O
<	O
0.001)	O
elevations	O
in	O
both	O
HDL-cholesterol	B
and	O
apoAI	O
protein	O
levels	O
(1.33-fold	O
±	O
0.43	O
and	O
2.41-fold	O
±	O
0.15,	O
respectively;	O
)	O
compared	O
with	O
placebo	O
infusion,	O
as	O
previously	O
described.	O

Lysophosphatidic	B
acid	I
produced	O
from	O
LPC	O
by	O
lysophospholipase	O
D	O
also	O
plays	O
an	O
important	O
role	O
in	O
promoting	O
cell	O
proliferation.	O

Regarding	O
metabolite	O
reductions,	O
the	O
levels	O
of	O
glucose	B
are	O
decreased	O
(NMR	O
signals	O
at	O
5.22	O
and	O
3.90-3.40	O
ppm)	O
for	O
early	O
IUGR	O
cases	O
compared	O
to	O
controls,	O
with	O
an	O
average	O
negative	O
variation	O
of	O
25%.	O

However,	O
Warburg	O
found	O
that	O
tumor	O
cells	O
are	O
still	O
prevalent	O
with	O
high	O
rates	O
of	O
glucose	B
uptake	O
even	O
under	O
oxygenated	O
conditions.	O

For	O
semi-quantification,	O
we	O
calculated	O
the	O
peak	O
height	O
of	O
each	O
ion	O
and	O
normalized	O
to	O
that	O
of	O
2-isopropylmalic	B
acid	I
as	O
an	O
internal	O
standard.	O

Since	O
D-mannose	B
is	O
an	O
endogenous	O
compound,	O
both	O
the	O
LLOQ	O
and	O
ULOQ	O
were	O
determined	O
based	O
on	O
the	O
level	O
of	O
D-mannose	B
found	O
in	O
normal	O
human	O
serum.	O

HA,	B
taurine,	B
serine,	B
cystine,	B
glycine,	B
homocystine	B
(HCy2),	O
riboflavin,	B
methionine,	B
pyridoxine,	B
cystathionine,	B
SAH,	O
pyridoxamine,	B
SAM,	O
DMG,	B
choline,	B
betaine,	B
5-MTHF,	O
taurine-_13	B
C_2	O
,	O
glycine-d_2	B
,	O
riboflavin-dioxopyrimidine-_13	B
C_4	O
_15	O
N_2	O
,	O
and	O
methionine-d_3	B
standards	O
were	O
purchased	O
from	O
Sigma-Aldrich	O
Chemie	O
GmbH.	O
HA-d_4	O
,	O
serine-d_3	B
,	O
pyridoxine-d_2	B
,	O
cystathionine-d_4	B
,	O
SAM-d_4	O
,	O
DMG-d_6	O
,	O
choline-d_9	B
,	O
and	O
betaine-d_11	B
were	O
purchased	O
from	O
CDN	O
Isotopes	O
(Pointe-Claire,	O
Quebec,	O
Canada).	O

The	O
data	O
reported	O
in	O
this	O
study	O
clearly	O
suggest	O
the	O
existence	O
of	O
altered	O
patterns	O
of	O
plasma	O
metabolites	O
strongly	O
indicative	O
of	O
functional	O
alterations	O
associated	O
with	O
elevated	O
cystathionine	B
concentrations.	O

Both	O
can	O
be	O
conjugated,	O
leading	O
to	O
a	O
putative	O
cytotoxic	O
GCDCA	B
(which	O
is	O
increased	O
in	O
AD	O
in	O
our	O
present	O
study).	O

HbA1c,	O
glycated	O
haemoglobin;	O
CO,	O
cardiac	O
output;	O
EF,	O
ejection	O
fraction;	O
2hPG,	O
2-h	O
plasma	O
glucose;	B
FPG,	O
fasting	O
plasma	O
glucose;	B
Cer,	B
ceramide;	B
GluCer,	O
glucosyl	B
ceramide;	I
LacCer,	B
lactosyl	B
ceramide;	I
SM,	O
sphingomyelin;	B
Sa,	O
sphinganine;	B
Sa1P,	O
sphinganine-1-phosphate;	B

Dietary	O
lipids	O
have	O
been	O
shown	O
to	O
be	O
incorporated	O
into	O
liver	O
lipids	O
and	O
are	O
subsequently	O
expected	O
to	O
more	O
widely	O
affect	O
blood	O
phospholipids.	B

All	O
adolescents	O
with	O
MDD	O
met	O
the	O
DSM-IV-TR	O
criteria	O
for	O
MDD,	O
with	O
a	O
current	O
episode	O
duration	B
≥	O
6	O
weeks,	O
a	O
raw	O
depression	O
severity	O
score	O
≥	O
40	O
(T	O
score	O
>	O
63)	O
on	O
the	O
Children’s	O
Depression	O
Rating	O
Scale–Revised	O
(CDRS-R),	O
and	O
were	O
psychotropic	O
medication–free	O
for	O
at	O
least	O
3	O
months.	O

Age-adjusted	O
geometric	O
mean	O
serum	O
concentrations	O
of	O
the	O
parent	O
estrogens	O
and	O
estrogen	B
metabolites	O
by	O
prenatal	O
DES	B
exposure	O
are	O
presented	O
in	O
.	O

Previous	O
research	O
suggests	O
that	O
duration	B
of	O
exposure	O
to	O
AAP	O
influences	O
the	O
metabolome	O
early	O
in	O
schizophrenia	O
treatment,	O
but	O
it	O
is	O
still	O
unclear	O
how	O
drug	O
use	O
influences	O
the	O
metabolome	O
and	O
metabolic	O
risk	O
after	O
several	O
antipsychotic	O
trials.	O

By	O
comparing	O
changes	O
in	O
the	O
SL	B
metabolites	O
following	O
the	O
ASA-BPT,	O
we	O
found	O
a	O
distorted	O
pattern	O
of	O
ceramides	B
and	O
SMs	O
after	O
the	O
ASA-BPT,	O
with	O
a	O
decreased	O
pattern	O
in	O
the	O
AERD	O
group	O
(Fig.	O
E1).	O

During	O
their	O
evaluation	O
of	O
optimum	O
method	O
for	O
lipidomics,	O
Sarafian	O
et	O
al	O
.	O
also	O
showed	O
poor	O
repeatability	O
of	O
MTBE	B
in	O
comparison	O
to	O
methanol	B
with	O
a	O
similar	O
2-fold	O
deterioration	O
of	O
mean	O
RSD	O
and	O
the	O
numbers	O
of	O
highly	O
reproducible	O
lipids	O
consistent	O
with	O
what	O
was	O
observed	O
in	O
current	O
study.	O

Therefore,	O
related	O
enzymes	O
and	O
metabolic	O
abnormalities	O
of	O
raw	O
material	O
products	O
to	O
aerobic	O
respiration,	O
including	O
the	O
reduction	O
of	O
the	O
succinate	O
dehydrogenase,	O
and	O
the	O
increasing	O
content	O
of	O
pyruvate.	B

PIs	O
were	O
metabolized	O
by	O
1-phosphatidylinositol-3-phosphate	B
5-kinase	O
(PIKfyve)	O
to	O
generate	O
phosphatidylinositol	B
5-phosphate,	I
which	O
was	O
further	O
metabolized	O
by	O
1-phosphatidylinositol-5-phosphate	B
4-kinase	O
(PIP4K2)	O
to	O
generate	O
phosphatidylinositol-4,5-bisphosphate	B
(PI(4,5)P2)	I
05:30.	I

Hundreds	O
of	O
mutations	O
in	O
the	O
β-globin	B
gene	O
and/or	O
regulatory	O
elements	O
associated	O
with	O
the	O
β-globin	B
gene	O
are	O
known	O
to	O
be	O
the	O
cause	O
of	O
this	O
genetic	O
haemoglobinopathy.	O

In	O
addition,	O
trp	O
is	O
converted	O
to	O
indole,	B
I3A,	O
and	O
I3P	O
by	O
bacterial	O
enzymatic	O
pathways.	O

The	O
~2.5	O
fold	O
higher	O
concentration	O
of	O
Cer(24:0)	B
compared	O
to	O
the	O
Cer(22:0)	B
in	O
plasma	O
was	O
noted	O
and	O
also	O
reported	O
by	O
another	O
group.	O

Also,	O
among	O
women	O
who	O
did	O
not	O
report	O
diabetes,	O
Spearman	O
correlation	O
coefficients	O
were	O
estimated	O
between	O
the	O
phthalate	B
metabolites	O
and	O
BMI,	O
waist	O
circumference	O
(WC),	O
waist/hip	O
(WH)	O
ratio,	O
age	O
and	O
education.	O

fowleri	O
trophozoites	O
treated	O
for	O
48	O
hours	O
with	O
(A)	O
0.08	O
μM	O
of	O
isavuconazole	B
and	O
0.7	O
μM	O
of	O
epiminolanosterol,	B
(B)	O
1.9	O
μM	O
equimolar	O
concentrations	O
of	O
isavuconazole	B
and	O
tamoxifen,	B
(C)	O
2	O
μM	O
equimolar	O
concentrations	O
of	O
epiminolanosterol	B
and	O
tamoxifen,	B
and	O
(D)	O
0.5%	O
DMSO,	B
which	O
served	O
as	O
a	O
negative	O
control.	O

The	O
products	O
of	O
an	O
enhanced	O
lipolytic	O
activity	O
reach	O
the	O
liver	O
to	O
be	O
used	O
for	O
triglycerides	B
synthesis	O
and	O
to	O
increase	O
circulating	O
availability	O
of	O
triglycerides	B
by	O
208%	O
(transported	O
mainly	O
by	O
VLDL),	O
and	O
total,	O
HDL-	O
and	O
LDL-cholesterol	B
in	O
65,	O
26	O
and	O
64%,	O
respectively.	O

With	O
a	O
database-based	O
verification	O
protocol,	O
11	O
molecules	O
were	O
identified,	O
and	O
six	O
upregulated	O
molecules	O
of	O
interest	O
in	O
ESCC	O
were	O
found	O
to	O
belong	O
to	O
phospholipids	B
as	O
follows:	O
phosphatidylserine,	B
phosphatidic	B
acid,	I
phosphatidyl	B
choline,	I
phosphatidylinositol,	B
phosphatidyl	B
ethanolamine,	I
and	O
sphinganine	B
1-phosphate.	I

Elution	O
was	O
carried	O
out	O
by	O
1.2	O
ml	O
of	O
MeOH.	B

Triglycerides	B
decreased	O
within	O
chylomicrons,	O
medium	O
and	O
small	O
VLDL:	O
small	O
LDL	O
and	O
all	O
classes	O
of	O
HDL,	O
except	O
very	O
large	O
and	O
large	O
HDL	O
(Figure D).	O

The	O
present	O
study	O
identified	O
27	O
biomarkers	O
and	O
established	O
a	O
combined	O
diagnostic	O
model	O
comprising	O
phosphorylcholine,	B
glycocholic	B
acid,	I
arachidonic	B
acid	I
and	O
L-acetylcarnitine	B
for	O
the	O
early	O
diagnosis	O
of	O
GCA.	O

Besides	O
the	O
expected	O
higher	O
concentration	O
of	O
glucose,	B
the	O
relative	O
concentrations	O
of	O
lipids	O
(triglycerides,	O
phospholipids	B
and	O
cholinated	O
phospholipids)	B
are	O
clearly	O
lower	O
in	O
the	O
plasma	O
of	O
T1DM	O
patients	O
as	O
compared	O
to	O
controls.	O

Uric	B
acid	I
is	O
a	O
product	O
of	O
purine	B
metabolism	O
that	O
circulates	O
in	O
the	O
blood,	O
and	O
plays	O
a	O
role	O
in	O
initiating	O
the	O
development	O
of	O
hypertension.	O

Our	O
results	O
revealed	O
that	O
the	O
serum	O
levels	O
of	O
five	O
amino	O
acids	O
(leucine-isoleucine,	O
proline,	B
threonine,	B
glutamic	B
acid,	I
and	O
arginine)	B
differed	O
significantly	O
between	O
GR	O
and	O
PR	O
groups.	O

We	O
then	O
assessed	O
the	O
predictive	O
capability	O
of	O
type	O
2	O
diabetes	O
risk	O
factors	O
alone	O
(including	O
age,	O
sex,	O
parental	O
history	O
of	O
diabetes,	O
fasting	O
glucose,	B
BMI,	O
HDLc,	O
TAG	O
and	O
blood	O
pressure)	O
and	O
the	O
predictive	O
capability	O
of	O
type	O
2	O
diabetes	O
risk	O
factors	O
plus	O
selected	O
metabolites	O
in	O
the	O
testing	O
set	O
(40%	O
of	O
the	O
sample)	O
by	O
generating	O
the	O
area	O
under	O
the	O
receiver	O
operator	O
characteristic	O
(ROC)	O
curve.	O

Norepinephrine	B
sulfate	I
is	O
related	O
to	O
epinephrine,	B
which	O
is	O
an	O
important	O
hormone	O
and	O
neurotransmitter	O
that	O
is	O
involved	O
in	O
a	O
multitude	O
of	O
metabolic	O
pathways.	O

In	O
addition	O
to	O
the	O
determination	O
of	O
midazolam	B
plasma	O
concentration	O
to	O
reveal	O
CYP3A	O
activity,	O
plasma	O
concentrations	O
of	O
fentanyl	O
and	O
its	O
metabolite,	O
norfentanyl,	O
were	O
measured	O
in	O
identical	O
blood	O
samples	O
of	O
20	O
patients	O
who	O
participated	O
in	O
an	O
ongoing	O
trial	O
and	O
had	O
been	O
on	O
transdermal	O
fentanyl.	O

Key	O
nodes	O
linked	O
to	O
hypoxanthine	B
(nucleotide	O
biosynthesis),	O
choline	B
(lipid	O
processing),	O
amino	O
acids,	O
taurine	B
(thiol	I
metabolism),	I
and	O
more	O
indirectly	O
to	O
pyruvate,	B
lactate	B
and	O
cholesterol.	B

MCF-7	O
WS8	O
cells,	O
provided	O
by	O
Dr.	O
C.	O
Jordan,	O
are	O
an	O
estrogen	B
sensitive	O
cell	O
line	O
(ER+)	O
and	O
were	O
cloned	O
from	O
MCF-7	O
cells,	O
as	O
previously	O
described.	O

Sucrose	B
is	O
consumed	O
by	O
humans	O
to	O
provide	O
sufficient	O
energy	O
and	O
is	O
broken	O
down	O
into	O
the	O
constituent	O
monosaccharides	B
of	O
glucose	B
and	O
fructose	B
by	O
sucrase	O
or	O
isomaltase	O
glycoside	O
hydrolases	O
in	O
the	O
membrane	O
of	O
the	O
microvilli	O
lining	O
in	O
the	O
duodenum.	O

While	O
Roseburia	O
spp	O
and	O
butyrate	B
production	O
were	O
decreased,	O
we	O
concluded	O
that	O
decreased	O
butyrate	B
stimulated	O
sphingosine	B
kinase	O
2	O
and	O
then	O
increased	O
sphingosine	B
and	O
S1P.	O
The	O
abundance	O
of	O
Escherichia-Shigella	O
(Enterobacteriaceae)	O
was	O
higher	O
in	O
the	O
feces	O
of	O
UC	O
patients	O
and	O
in	O
rectal	O
biopsies	O
from	O
CD	O
patients,	O
indicating	O
a	O
possible	O
association	O
with	O
the	O
pathogenesis	O
of	O
IBD	O
[,].	O

Hit	O
metabolites	O
were	O
involved	O
in	O
lipid	O
metabolism	O
(glycerophospholipid,	O
glycerolipid,	B
fatty	O
acid	O
metabolism,	O
etc.).	O

These	O
metabolites	O
could	O
potentially	O
serve	O
as	O
biomarkers	O
for	O
progressive	O
disease,	O
one	O
of	O
the	O
factors	O
that	O
motivated	O
us	O
to	O
examine	O
sarcosine	B
in	O
greater	O
detail.	O

A	O
control	O
sample	O
contained	O
cells	O
treated	O
with	O
DMSO	B
(final	O
concentration	O
0.5%)	O
was	O
added	O
to	O
untreated	O
cells.	O

In	O
addition,	O
we	O
show	O
a	O
previously	O
unreported	O
association	O
(inverse)	O
of	O
BMI	O
with	O
urinary	O
3-hydroxymandelate	B
(P	O
=	O
2.81	O
×	O
10_−8	O
,	O
),	O
a	O
metabolite	O
of	O
the	O
a-adrenergic	O
agonist	O
p	B
-synephrine	I
(found	O
in	O
bitter	O
orange	O
extract),	O
and	O
closely	O
related	O
to	O
tyrosine	B
metabolism.	O

Steroidal	O
signatures	O
of	O
liver	O
disease	O
in	O
childhood	O
obesity:	O
differences	O
between	O
z-transformed	O
concentrations	O
of	O
steroid	O
metabolites	O
(androgens,	O
glucocorticoids	B
and	O
mineralocorticoids)	O
in	O
non-liver	O
disease	O
features	O
(L0)	O
patients	O
and	O
(A)	O
patients	O
with	O
ALT+	O
(L1_A	O
),	O
(B)	O
patients	O
with	O
sonographic	O
liver	O
steatosis	O
(L1_L	O
)	O
and	O
(C)	O
patients	O
with	O
ALT+	O
and	O
sonographic	O
liver	O
steatosis	O
(L1_AL	O
).	O

In	O
all	O
plots,	O
individuals	O
are	O
classified	O
as	O
noncannabis	O
users	O
or	O
cannabis	B
users	O
stratified	O
by	O
moderate	O
or	O
heavy	O
cannabis	B
use	O
as	O
determined	O
by	O
plasma	O
quantities	O
of	O
11-nor-carboxy-tetrahydrocannabinol.	B

D-aspartic	B
acid	I
is	O
an	O
amino	O
acid	O
that	O
is	O
found	O
to	O
be	O
decreased	O
in	O
BDTT	O
patient.	O

Instead	O
of	O
plasma	O
lactic	O
acidosis,	O
this	O
may	O
be	O
due	O
to	O
lactic	B
acid	I
producing	O
bacteria	O
in	O
the	O
oral	O
cavity	O
of	O
HIV/AIDS	O
patients	O
.	O

Choline	B
has	O
also	O
been	O
associated	O
with	O
the	O
demyelinating	O
process	O
in	O
the	O
CNS.	O

PC	O
and	O
LPC	O
species	O
were	O
identified	O
and	O
quantified	O
directly	O
from	O
lipid	O
solution	O
after	O
washing	O
with	O
hexane	B
as	O
described	O
.	O

Oxylipins,	B
including	O
eicosanoids,	B
affect	O
a	O
broad	O
range	O
of	O
biological	O
processes,	O
such	O
as	O
the	O
initiation	O
and	O
resolution	O
of	O
inflammation.	O

The	O
upper	O
aqueous	O
phase	O
was	O
transferred	O
into	O
a	O
fresh	O
polypropylene	B
tube	O
and	O
re-extracted	O
by	O
addition	O
of	O
250	O
μl	O
ice-cold	O
chloroform/methanol	O
as	O
described	O
above.	O

There	O
was	O
evidence	O
for	O
differences	O
in	O
glucose	B
elevations	O
between	O
different	O
brain	O
regions	O
in	O
AD	O
where	O
levels	O
tended	O
to	O
be	O
higher	O
in	O
more	O
severely	O
affected	O
regions	O
such	O
as	O
the	O
middle	O
temporal	O
gyrus	O
(;	O
and	O
a).	O

Metabolites	O
in	O
the	O
tryptophan	B
degradation	O
pathway	O
increased	O
following	O
leptin	O
therapy.	O

Triterpene	B
1	O
and	O
Doxorubicin	B
were	O
also	O
cytotoxic	O
against	O
AA8	O
with	O
IC_50	O
values	O
of	O
37.5	O
μg/ml	O
and	O
2.3	O
μg/ml,	O
respectively.	O

ACC	O
is	O
a	O
key	O
regulatory	O
enzyme	O
in	O
lipogenesis,	O
and	O
its	O
activity	O
is	O
under	O
hormonal	O
regulation	O
by	O
insulin,	O
glucagon,	O
and	O
epinephrine.	B

Our	O
results	O
indicate	O
the	O
disturbance	O
of	O
choline	B
metabolism	O
in	O
esophageal	O
cancer	O
tissue,	O
which	O
is	O
supported	O
by	O
previous	O
findings	O
that	O
choline	B
and	O
its	O
metabolites	O
allow	O
a	O
distinct	O
differentiation	O
in	O
human	O
oral	O
cancer.	O

The	O
gradient	O
program	O
was	O
as	O
follows:	O
0–0.3	O
minutes,	O
0%	O
B;	O
0.3–25	O
minutes,	O
0%−95%	O
B;	O
25–25.1	O
minutes,	O
95%−0%;	O
25.1–30	O
minutes,	O
0%	O
B.	O
Separation	O
of	O
highly	O
polar	O
metabolites	O
such	O
as	O
amino	O
acids	O
was	O
achieved	O
based	O
on	O
hydrophilic-interaction	O
liquid	O
chromatography	O
(HILIC)	O
on	O
an	O
Atlantis	O
HILIC	O
Silica	B
column	O
(2.1	O
×	O
150	O
mm,	O
3	O
μ	O
m).	O

Interestingly,	O
succinate	B
levels	O
in	O
breast	O
milk	O
of	O
CD	O
mothers	O
only	O
increased	O
at	O
PP6.	O

 )	O
in	O
which	O
no	O
ethanol	B
was	O
used.	O

Similarly,	O
while	O
human	O
studies	O
across	O
1500	O
individuals	O
focused	O
upon	O
those	O
metabolites	O
that	O
were	O
initially	O
observed	O
in	O
pooled	O
human	O
plasma,	O
a	O
number	O
of	O
additional	O
potential	O
oxylipins	B
were	O
also	O
observed	O
in	O
specific	O
individuals	O
and	O
are	O
currently	O
being	O
investigated.	O

The	O
present	O
work	O
demonstrates	O
that	O
specific	O
β-apocarotenoids	B
exert	O
an	O
anti-vitamin	O
A	O
activity	O
by	O
directly	O
interacting	O
with	O
RARs	O
as	O
high	O
affinity	O
antagonists.	O

In	O
that	O
experimental	O
model,	O
increased	O
levels	O
of	O
tetradecanedionate,	O
stearate	B
and	O
eicosenoate	B
and	O
other	O
fatty	O
acids	O
were	O
observed	O
with	O
transcriptomic	O
changes	O
pointing	O
at	O
a	O
shift	O
in	O
energy	O
production	O
towards	O
glycolysis	O
and	O
depletion	O
of	O
a	O
number	O
of	O
amino	O
acids;	O
findings	O
which	O
are	O
parallel	O
to	O
the	O
metabolite	O
patterns	O
observed	O
in	O
the	O
current	O
study.	O

These	O
pathways	O
included	O
glycolysis	O
(“Warburg	O
effect”)	O
as	O
well	O
as	O
lipid,	O
choline	B
phospholipid	I
(Kennedy	O
pathway),	O
one-carbon,	O
and	O
amino	O
acid	O
metabolism.	O

Table 	O
reveals	O
no	O
statistically	O
significant	O
differences	O
in	O
the	O
glucose	B
levels	O
between	O
the	O
studied	O
groups.	O

Four	O
out	O
of	O
the	O
top	O
five	O
combinations	O
ranked	O
by	O
values	O
of	O
mean	O
AUC	O
in	O
the	O
test	O
set	O
contained	O
both	O
glutamate	B
and	O
arginine.	B

Therefore,	O
based	O
on	O
the	O
following	O
considerations,	O
we	O
reasoned	O
that	O
the	O
peak	O
#3	O
and	O
4	O
contains	O
a	O
20:4	O
fatty	O
acyl	O
side	O
chain	O
of	O
the	O
n-3	O
and	O
n-6	O
series,	O
respectively:	O
(i)	O
total	O
plasma	O
levels	O
of	O
C20:4n-3	B
(eicosatetraenoic	I
acid)	I
are	O
~120-fold	O
less	O
abundant	O
than	O
C20:4n-6	B
(arachidonic	O
acid)	O
in	O
healthy	O
human	O
plasma	O
and	O
(ii)	O
under	O
our	O
chromatographic	O
conditions	O
(RP),	O
lipids	O
containing	O
fatty	O
acyl	O
side	O
chain	O
of	O
n-3	O
series	O
elute	O
prior	O
to	O
their	O
n-6	O
isomer	O
counterparts.	O

Increased	O
serum	O
and	O
urine	O
levels	O
of	O
N2,N2-dimethylguanosine,	B
as	O
well	O
as	O
pseudouridine	B
and	O
1-methylinosine,	B
have	O
been	O
observed	O
in	O
multiple	O
solid	O
tumor	O
malignancies	O
and	O
may	O
reflect	O
the	O
general	O
upregulation	O
of	O
the	O
translational	O
apparatus,	O
including	O
tRNA	O
turnover,	O
in	O
hyperproliferative	O
cancerous	O
cells.	O

These	O
results	O
suggested	O
that	O
aberrant	O
choline	B
and	O
one-carbon	O
metabolism	O
may	O
contribute	O
to	O
carcinogenesis.	O

PC	B
aa	I
C38:6;	I
114.	O

Clinically,	O
cancers	O
that	O
develop	O
in	O
different	O
organs	O
demonstrate	O
elevated	O
total	O
choline	B
levels.	O

However,	O
the	O
exploratory	O
nature	O
of	O
this	O
study	O
does	O
not	O
allow	O
us	O
to	O
establish	O
whether	O
the	O
observed	O
circulatory	O
phospholipid	B
alterations	O
derived	O
from	O
an	O
aggressive	O
tumor	O
growth	O
or	O
from	O
the	O
host	O
response	O
to	O
the	O
tumor.	O

The	O
results	O
of	O
the	O
new	O
method	O
were	O
compared	O
to	O
those	O
obtained	O
upon	O
analysis	O
of	O
the	O
same	O
samples	O
by	O
traditional	O
separate	O
methods,	O
as	O
described	O
previously	O
for	O
total	O
NNAL	O
and	O
total	O
cotinine.	B

15	O
metabolites	O
were	O
identified	O
such	O
as	O
pyridoxine,	B
orotidine,	B
and	O
taurocholic	B
acid.	I

m	O
m	O
m	O
m	O
m	O
Pilot	O
experiments	O
that	O
were	O
performed	O
using	O
HPLC	O
methods	O
with	O
UV	O
and	O
fluorescent	O
detection	O
to	O
identify	O
any	O
potential	O
anastrozole	B
oxidative	O
metabolites	O
or	O
to	O
determine	O
the	O
disappearance	O
of	O
the	O
parent	O
drug	O
from	O
the	O
microsomal	O
incubates	O
consisting	O
of	O
HLMs	O
and	O
cofactors	O
were	O
noninformative.	O

Of	O
interest,	O
tryptophan	B
was	O
positively	O
correlated	O
with	O
mGFR	O
(lower	O
levels	O
at	O
lower	O
levels	O
of	O
mGFR),	O
which	O
is	O
likely	O
due	O
to	O
increased	O
catabolism,	O
but	O
contributed	O
to	O
the	O
accuracy	O
of	O
panels	O
for	O
GFR	O
estimation.	O

These	O
metabolites	O
include	O
constituents	O
of	O
(very)	O
large	O
VLDL	O
and	O
small	O
LDL	O
subclasses	O
and	O
related	O
measures	O
like	O
serum	O
triglycerides	B
and	O
ApoB,	O
various	O
summary	O
measures	O
of	O
fatty	O
acids	O
and	O
fatty	O
acid	O
polyunsaturation	O
as	O
well	O
as	O
CMPF.	O

N1-methylinosine	B
is	O
found	O
3′	O
adjacent	O
to	O
the	O
anticodon	O
at	O
position	O
37	O
of	O
eukaryotic	O
tRNAs	O
and	O
is	O
formed	O
from	O
inosine	B
by	O
a	O
specific	O
S-adenosylmethionine–dependent	O
methylase.	O

Of	O
these,	O
nine	O
were	O
lower	O
(hydroquinone,	O
aminomalate,	B
sugar	O
acid	O
15.429	O
min,	O
4-hydroxy-3-methoxy-mandelate,	B
glucuronide	B
29.801	O
min,	O
sugar	O
acid	O
15.750	O
min,	O
sugar	O
14.575	O
min,	O
disaccharide	B
29.943	O
min,	O
and	O
glycine)	B
and	O
three	O
were	O
higher	O
(one	O
unknown	O
at	O
13.271	O
min,	O
isobutyrate	B
and	O
ethleneglycol)	B
in	O
cachetic	O
compared	O
to	O
pre-cachectic	O
patients.	O

Abnormal	O
glycogen	B
accumulation	O
was	O
noted	O
in	O
the	O
muscles,	O
the	O
level	O
of	O
phosphoglucomutase	O
1	O
activity	O
was	O
only	O
1%	O
of	O
the	O
normal	O
level,	O
and	O
mutations	O
in	O
PGM1	O
were	O
identified.	O

Though	O
there	O
was	O
a	O
general	O
tendency	O
towards	O
lower	O
levels	O
of	O
alanine,	B
choline,	B
glutamate,	B
taurine	B
and	O
myo-inositol	B
in	O
prostate	O
samples	O
from	O
Degarelix-treated	O
patients,	O
the	O
differences	O
were	O
not	O
statistically	O
significant	O
(Table ).	O

Metabolomic	O
analysis	O
revealed	O
changes	O
in	O
pathways	O
involving	O
branched-chain	O
amino	O
acid	O
metabolism,	O
fatty	O
acid	O
oxidation,	O
protein	O
degradation,	O
urea	B
cycle,	O
tryptophan	B
metabolism,	O
nucleotide	O
catabolism,	O
vitamin	B
E,	I
and	O
steroid	O
metabolism.	O

These	O
data	O
suggests	O
that	O
perturbed	O
purine	B
metabolism	O
is	O
implicated	O
in	O
HAPE.	O

Moreover,	O
a	O
decrease	O
of	O
these	O
glycerophospholipids	B
was	O
associated	O
to	O
the	O
event	O
at	O
28-days	O
and	O
90-days	O
in	O
combination	O
with	O
clinical	O
variables	O
such	O
as	O
cardiovascular	O
SOFA	O
score	O
(28-day	O
mortality	O
model)	O
or	O
renal	O
replacement	O
therapy	O
(90-day	O
mortality	O
model).	O

Exclusion	O
criteria	O
were	O
adults	O
who	O
have	O
been	O
taking	O
vitamin	B
D	I
supplement	O
over	O
400 IU/day	O
and/or	O
receiving	O
medication	O
that	O
alter	O
vitamin	B
D	I
metabolites.	O

This	O
deregulation	O
of	O
glycerol	B
involved	O
pathways	O
was	O
also	O
in	O
accordance	O
with	O
what	O
was	O
reported	O
by	O
Cao	O
et	O
al..	O

In	O
principle,	O
either	O
mechanism	O
could	O
result	O
in	O
a	O
positive	O
correlation	O
between	O
lactate	B
and	O
tCr.	O

Xanthine	B
is	O
produced	O
from	O
hypoxanthine	B
by	O
xanthine	B
oxidase,	O
and	O
the	O
production	O
of	O
xanthine	B
is	O
accompanied	O
by	O
generation	O
of	O
H_2	O
O_2	O
.	O

PSAT1,	O
Forward:	O
TGCCGCACTCAGTGTTGTTAG,	O
Reverse:	O
GCAATTCCCGCACAAGATTCT;	O
PSPH,	O
Forward:	O
GAGGACGCGGTGTCAGAAAT,	O
Reverse:	O
GGTTGCTCTGCTATGAGTCTCT;	O
SHMT2,	O
Forward:	O
CCCTTCTGCAACCTCACGAC,	O
Reverse:	O
TGAGCTTATAGGGCATAGACTCG;	O
CyclinD1,	O
Forward:	O
GCTGGAGCCCGTGAAAAAGA,	O
Reverse:	O
CTCCGCCTCTGGCATTTTG;	O
PCNA,	O
Forward:	O
TCAAGAAGGTGTTGGAGGCA,	O
Reverse:	O
CAGCGGTAGGTGTCGAAGC;	O
β-actin,	B
Forward:	O
GGGACCTGACTGACTACCTC,	O
Reverse:	O
ACGAGACCACCTTCAACTCCAC.	O

To	O
the	O
lower	O
liquid	O
200	O
μ	O
L	O
of	O
MTBE	B
was	O
added	O
and	O
it	O
was	O
vortexed	O
vigorously	O
for	O
60	O
s.	O

Bioinformatics	O
analysis	O
suggested	O
that	O
the	O
levels	O
of	O
these	O
metabolites	O
may	O
be	O
altered	O
mainly	O
in	O
two	O
metabolic	O
pathways,	O
the	O
carnitine-acylcarnitine	B
metabolic	O
pathway	O
and	O
the	O
tryptophan	B
metabolism.	O

Thus,	O
modulation	O
of	O
cardiovascular	O
responses	O
and	O
circulating	O
catecholamines	B
seems	O
responsible	O
for	O
alanine’s	B
role	O
in	O
blood	O
pressure	O
elevation.	O

Methanol,	B
acetonitrile	B
and	O
formic	B
acid	I
(100%,	O
v/v)	O
were	O
purchased	O
from	O
Merck	O
(Darmstadt,	O
Germany).	O

On	O
the	O
other	O
hand,	O
increased	O
acylcarnitines	B
in	O
GC	O
patients	O
may	O
be	O
the	O
consequence	O
of	O
the	O
oxidative	O
stress	O
associated	O
to	O
GC	O
itself	O
or	O
to	O
the	O
higher	O
age	O
of	O
patients	O
since	O
oxidative	O
stress	O
has	O
been	O
reported	O
to	O
increase	O
with	O
aging.	O

Interestingly,	O
the	O
PI,	O
PG,	B
and	O
PS	O
species	O
identified	O
in	O
our	O
present	O
study	O
had	O
not	O
been	O
previously	O
identified	O
in	O
human	O
urine	O
by	O
mass	O
spectrometry.	O

It	O
should	O
also	O
be	O
noted	O
that	O
the	O
_1	O
H	O
NMR	O
resonances	O
of	O
5'-AXP	O
and	O
5'-UXP	O
in	O
Fig.	O
were	O
in	O
fact	O
mixtures	O
of	O
3	O
resonances,	O
which	O
correspond	O
to	O
the	O
tri,	O
di	O
and	O
mono	O
phosphates	B
species,	O
with	O
intensities	O
in	O
the	O
order	O
5'-ATP	B
>	O
5'-ADP	O
>	O
5'-AMP	B
and	O
similarly	O
for	O
5'-UTP,	B
5'-UDP	B
and	O
5'-UMP	B
(data	O
not	O
shown).	O

Citrate,	B
myo-inositol	B
and	O
the	O
polyamine	B
spermine	I
have	O
previously	O
been	O
suggested	O
as	O
metabolic	O
markers	O
of	O
PCa	O
in	O
prostatic	O
secretions.	O

Conditions:	O
60	O
cm	O
long	O
(375	O
µm	O
O.D.,	O
50	O
µm	O
I.D.)	O
fused	O
silica	B
capillary.	O

The	O
MS_2	O
and	O
MS_3	O
spectra	O
of	O
these	O
[M]_+	O
ions	O
indicate	O
a	O
7α-hydroxy-26-norcholest-4-en-3-one	B
sterol	I
structure	O
(0.204	O
±	O
0.083	O

Meanwhile	O
in	O
lung	O
cancerous	O
plasma,	O
the	O
most	O
abundant	O
polyamine	B
was	O
putrescine,	B
followed	O
in	O
decreasing	O
order	O
by	O
spermine,	B
spermidine,	B
N	B
-acetylspermidine	I
and	O
N	B
-acetylspermine,	I
while	O
in	O
liver	O
cancerous	O
urine,	O
the	O
most	O
abundant	O
polyamine	B
was	O
spermine,	B
followed	O
by	O
N	B
-acetylspermidine,	I
putrescine,	B
cadaverine,	B
spermidine,	B
N	B
-acetylspermine	I
and	O
N	B
-acetylputrescine	I
in	O
decreasing	O
order.	O

Damage	O
and	O
stress	O
to	O
the	O
vascular	O
system	O
through	O
the	O
production	O
of	O
inflammatory	O
molecules	O
and	O
nitric	B
oxide,	I
as	O
well	O
as	O
endothelial	O
cells	O
being	O
sites	O
of	O
EBOV	O
replication,	O
may	O
also	O
result	O
in	O
the	O
production	O
of	O
EVs.	O

By	O
quantifying	O
the	O
absolute	O
concentration	O
of	O
major	O
metabolites,	O
the	O
changes	O
in	O
the	O
concentrations	O
of	O
three	O
metabolites	O
(creatine,	O
gluconic	B
acid	I
and	O
betaine)	O
were	O
validated	O
in	O
patients	O
with	O
FESZ.	O

The	O
flow	O
rate	O
was	O
150 μL/min	O
of	O
mobile	O
phase	O
consisting	O
of	O
isopropanol/water	O
(60:40,	O
v/v)	O
buffered	O
with	O
5 mM	O
ammonium	B
at	O
pH	O
9	O
for	O
negative	O
mode	O
and	O
methanol/water	O
(60:40,	O
v/v)	O
with	O
0.1%	O
formic	B
acid	I
at	O
pH	O
3	O
for	O
positive	O
mode.	O

Analine	B
;5.	O

T	O
lymphocytes	O
(T-cells)	O
are	O
extremely	O
sensitive	O
to	O
tryptophan	B
shortages.	O

The	O
main	O
features	O
of	O
participants	O
included	O
in	O
the	O
longitudinal	O
analyses	O
were	O
similar	O
to	O
those	O
of	O
the	O
whole	O
study	O
population,	O
including	O
age	O
(15.4	O
±	O
3.1	O
years;	O
P	O
=	O
0.52),	O
sex	O
(nine	O
males	O
and	O
seven	O
females;	O
P	O
=	O
0.33),	O
ethnicity	O
(nine	O
whites,	O
two	O
blacks,	O
three	O
Hispanics,	O
two	O
Asians;	O
P	O
=	O
0.83),	O
BMI	O
(30.5	O
±	O
7.1	O
kg/m_2	O
;	O
P	O
=	O
0.50),	O
BMI	O
z-score	O
(1.76	O
±	O
1.03;	O
P	O
=	O
0.67),	O
WBISI	O
(2.23	O
±	O
1.86;	O
P	O
=	O
0.28),	O
IGI	O
(3.15	O
±	O
1.6;	O
P	O
=	O
0.75);	O
DI	O
(4.4	O
±	O
1.5;	O
P	O
=	O
0.07),	O
HbA1c	O
(5.4%	O
±	O
0.3%;	O
P	O
=	O
0.91),	O
and	O
levels	O
of	O
fasting	O
glucose	B
(92.3	O
±	O
6.9	O
mg/dL;	O
P	O
=	O
0.08)	O
and	O
2-hour	O
glucose	B
(122.3	O
±	O
27.5	O
mg/dL;	O
P	O
=	O
0.21).	O

The	O
EDCs	O
could	O
influence	O
the	O
ER	O
signaling	O
through	O
stimulation	O
of	O
aryl	B
hydrocarbon	I
receptor	O
(Ahr).	O

Local	O
adsorption	O
enables	O
retention	O
of	O
approximately	O
30%	O
of	O
chlorhexidine	B
gluconate,	I
which	O
is	O
then	O
slowly	O
released	O
over	O
time.	O

The	O
absence	O
of	O
metabolites	O
such	O
as	O
ethanol	B
in	O
SpeedVac-dried	O
samples	O
was	O
potentially	O
due	O
to	O
more	O
rapid	O
evaporation	O
at	O
room	O
temperature	O
due	O
to	O
higher	O
vapor	O
pressure	O
at	O
this	O
temperature.	O

Of	O
the	O
degradation	O
enzymes,	O
the	O
activity	O
of	O
11β-HSD	B
type	O
1	O
was	O
reduced	O
in	O
women	O
with	O
PCOS	O
only	O
when	O
calculated	O
from	O
cortoles	O
and	O
cortolones	B
ratios.	O

Interestingly,	O
succinate,	B
another	O
metabolite	O
exhibiting	O
decreased	O
levels	O
in	O
the	O
urine	O
of	O
PCA	O
patients,	O
also	O
tends	O
to	O
accumulate	O
in	O
cancer	O
cells.	O

Increased	O
plasma	O
levels	O
of	O
nicotinate	B
and	O
decreased	O
levels	O
of	O
1-methylhistidine	B
in	O
patients	O
with	O
CAP	O
suggest	O
impairment	O
of	O
the	O
nicotinamide	B
metabolism	O
pathway,	O
indicating	O
alterations	O
in	O
mitochondrial	O
function	O
in	O
these	O
patients.	O

intermediate-NUDT15	B
variants;	O
most	O
likely	O
due	O
to	O
the	O
low	O
frequency	O
of	O
TPMT	O
polymorphic	O
variants	O
in	O
our	O
Asian	O
cohort.	O

Additional	O
selection	O
criterion	O
for	O
FOS-IGT	O
was	O
impaired	O
glucose	B
tolerance	O
(2-h	O
glucose	B
concentration	O
between	O
140	O
and	O
199	O
mg/100	O
ml).	O

Leucine	B
has	O
been	O
shown	O
to	O
rescue	O
insulin	O
signaling	O
via	O
activation	O
of	O
the	O
mTOR	O
pathway,	O
and	O
increasing	O
dietary	O
leucine	B
intake	O
can	O
improve	O
insulin	O
sensitivity	O
and	O
restore	O
many	O
metabolic	O
abnormalities	O
[,].	O

For	O
instance	O
for	O
the	O
bin	O
at	O
3.20	O
ppm	O
(corresponding	O
to	O
choline)	B
yields	O
a	O
sensitivity	O
(i.e.	O
percentage	O
of	O
G4	O
samples	O
correctly	O
classified	O
as	O
positives)	O
and	O
specificity	O
(i.e.	O
percentage	O
of	O
control	O
samples	O
correctly	O
classified	O
as	O
negatives)	O
of	O
80%	O
and	O
70%,	O
respectively,	O
with	O
a	O
classification	O
rate	O
of	O
87%	O
(i.e.	O
total	O
number	O
of	O
correctly	O
classified	O
samples,	O
data	O
not	O
shown).	O

Urinary	O
creatinine	B
was	O
measured	O
with	O
the	O
Beckman	O
LX20	O
analyzer	O
(Brea	O
CA),	O
using	O
a	O
technique	O
based	O
on	O
the	O
Jaffe	O
reaction.	O

The	O
spectra	O
were	O
first	O
normalized	O
to	O
the	O
NMR	O
signal	O
intensity	O
of	O
the	O
CH_3	O
-group	O
of	O
creatinine	B
to	O
compensate	O
for	O
the	O
large	O
variations	O
in	O
urine	O
metabolite	O
concentrations	O
and	O
then	O
segmented	O
into	O
N	O
consecutively	O
integrated	O
spectral	O
regions	O
(buckets)	O
of	O
fixed	O
width.	O

Our	O
HR-MAS	O
results	O
show	O
increased	O
levels	O
of	O
lactate,	B
alanine	B
and	O
glycine	B
in	O
tumor	O
and	O
LN-Met	O
as	O
compared	O
to	O
NAT.	O

We	O
also	O
found	O
that	O
TG	B
levels	O
were	O
about	O
25%	O
lower	O
in	O
PD	O
patients	O
compared	O
to	O
controls	O
(p-value	O
=	O
0.0041;	O
q-value	O
=	O
0.0497;	O
when	O
normalized	O
to	O
total	O
lipid:	O
p-value	O
5.837E-03;	O
q-value	O
=	O
2.382E-02;	O
);	O
however,	O
because	O
of	O
a	O
greater	O
variance	O
(likely	O
reflecting	O
the	O
fact	O
that	O
participants	O
were	O
not	O
fasting	O
for	O
this	O
study),	O
statistical	O
significance	O
of	O
the	O
differences	O
in	O
TG	B
plasma	O
levels	O
was	O
not	O
as	O
strong	O
as	O
differences	O
in	O
GM3	B
levels.	O

Significant	O
inverse	O
associations	O
were	O
limited	O
to	O
glycerophosphocholine,	B
cotinine	B
and	O
catechol	B
sulfate	I
(Fig.	O

Patients	O
under	O
dual	O
treatment,	O
however,	O
presented	O
with	O
a	O
pronounced	O
decrease	O
of	O
many	O
PG	B
and	O
Tx	O
levels,	O
even	O
in	O
comparison	O
to	O
individuals	O
under	O
ASA	O
monotherapy,	O
possibly	O
indicating	O
a	O
synergistic	O
effect	O
of	O
both	O
drugs.	O

Edmands	O
et	O
al.	O
have	O
shown	O
that	O
the	O
methyl-sulfoxide	B
signal	O
correlates	O
mostly	O
with	O
the	O
intake	O
of	O
its	O
substrate,	O
and	O
component	O
of	O
cruciferous	O
vegetables,	O
SMCSO,	O
and	O
two	O
other	O
metabolic	O
products,	O
but	O
intramolecular	O
correlations	O
driven	O
from	O
the	O
δ	O
2.78	O
peak	O
of	O
NAcSMCSO	O
were	O
weaker	O
than	O
those	O
observed	O
between	O
the	O
methyl-sulfoxide	B
signals	O
of	O
other	O
related	O
molecules.	O

In	O
pancreatic	O
cancer	O
cell	O
lines,	O
the	O
UDP-glucose	B
and	O
UDP-galactose	B
decline	O
is	O
reported	O
at	O
the	O
time	O
of	O
glucose	B
starvation,	O
suggesting	O
a	O
correlation	O
between	O
the	O
glucose	B
and	O
galactose	B
reduction	O
in	O
the	O
plasma	O
of	O
OSCC	O
in	O
our	O
study.	O

Acetone	B
is	O
metabolized	O
to	O
isopropanol	B
by	O
alcohol	O
dehydrogenase.	O

In	O
particular,	O
SM(d18:1/23:1)	B
and	O
SM(d18:1/24:2)	B
were	O
elevated	O
in	O
females,	O
which	O
has	O
previously	O
been	O
reported	O
[,	O
]	O
and	O
could	O
potentially	O
be	O
accounted	O
for	O
by	O
differences	O
in	O
LDL-C	O
cholesterol	B
levels.	O

These	O
results	O
suggest	O
that	O
glutamine	B
in	O
serum,	O
and	O
ethanolamine	B
and	O
1,3‐diphosphoglycerate	B
in	O
urine	O
are	O
candidate	O
predictive	O
markers	O
for	O
GDM	O
(Figure ).	O

The	O
data	O
were	O
analyzed	O
by	O
comparing	O
the	O
lipidome	O
between	O
the	O
meloxicam	O
and	O
saline	B
groups.	O

The	O
authors	O
further	O
identified	O
significantly	O
decreased	O
intermediate	O
metabolites	O
of	O
glycolysis,	O
markedly	O
decreased	O
triacylglyceride	B
levels	O
and	O
decreased	O
ATP	B
levels.	O

There	O
were	O
significantly	O
lower	O
levels	O
of	O
total	O
and	O
LDL-cholesterol	B
in	O
PKU	O
patients	O
versus	O
controls:	O
179.4	O
versus	O
200.9 mg/dL	O

Both	O
chromatograms	O
show	O
separation	O
of	O
the	O
nucleobase	O
test	O
mixture	O
(1:uracil,	O
2:adenosine,	O
3:cytidine,	O
4:cytosine)	O
on	O
an	O
HSS	O
Cyano	B
column	O
(3.00	O
i.d.	O

Since	O
histidine	B
has	O
a	O
side	O
chain	O
pK_a	O
of	O
6.0	O
with	O
a	O
pI	O
value	O
of	O
7.59,	O
at	O
pH	O
7.0	O
it	O
is	O
only	O
partially	O
charged	O
and	O
hence	O
it	O
interacts	O
with	O
the	O
SNPs	O
not	O
as	O
strongly	O
as	O
arginine	B
or	O
lysine,	B
which	O
is	O
consistent	O
with	O
the	O
results	O
in	O
.	O

Blood	O
samples	O
were	O
collected	O
in	O
the	O
prescribed	O
anticoagulant	O
tube	O
(EDTA	O
or	O
Li-Heparin)	B
and	O
immediately	O
placed	O
into	O
the	O
fridge	O
at	O
4	O
°C	O
where	O
they	O
were	O
stored	O
until	O
further	O
processing.	O

However,	O
in	O
the	O
presence	O
of	O
testosterone	B
or	O
dihydrotestosterone,	B
the	O
cell	O
grows	O
larger	O
and	O
its	O
metabolic	O
rate	O
increases.	O

To	O
accommodate	O
the	O
expected	O
large	O
number	O
of	O
associations	O
with	O
glucose	B
levels,	O
efficient	O
signal	O
prioritization	O
strategies	O
are	O
key.	O

This	O
was	O
based	O
on	O
8	O
metabolites	O
such	O
as	O
2-hydroxybutyrate,	B
2-oxoisocaproate,	B
acetate,	B
carnitine,	B
3-hydroxyisovalerate,	B
2-hydroxyisovalerate,	B
glycerol	B
and	O
glycine.	B

The	O
urine	O
level	O
of	O
glycine,	B
a	O
non-essential	O
amino	O
acid,	O
was	O
significantly	O
increased	O
in	O
CHB	O
patients	O
compare	O
with	O
the	O
control	O
group,	O
which	O
suggested	O
the	O
abnormality	O
of	O
amino	O
acid	O
metabolism	O
(Zhao	O
et	O
al.,	O
2013).	O

As	O
an	O
example,	O
the	O
analysis	O
of	O
hesperetin	B
sulfate	I
[m/z	O
318	O
[M – H]_1−	O
)	O
in	O
urines	O
from	O
a	O
pool	O
of	O
four	O
randomly	O
selected	O
volunteers	O
is	O
shown	O
in	O
Fig.	O

CRP	O
showed	O
a	O
positive	O
correlation	O
with	O
16-HDoHE	B
(P	O
 = 0.027)	O
and	O
a	O
negative	O
correlation	O
with	O
PGD_3	O
(P	O
 = 0.026);	O
DAS	O
28	O
showed	O
a	O
positive	O
association	O
with	O
14,15-DiHETE	B
(P	O
 = 0.036)	O
and	O
5S,	O
6R-LipoxinA4	O
(P	O
 = 0.005);	O
DAS28	O
improvement	O
(DAS28_month	O
0	O
 − DAS28_month	O
3	O
)	O
showed	O
significantly	O
positive	O
association	O
with	O
PGF_3α	O
(P	O
 = 0.017),	O
PGF_2α	O
(P	O
 = 0.018),	O

After	O
precipitation	O
with	O
acetonitrile	B
samples	O
were	O
spiked	O
with	O
the	O
compounds	O
at	O
two	O
concentrations	O
(QCL	O
and	O
QCH)	O
and	O
the	O
IS.	O

Immediately	O
before	O
measurement,	O
samples	O
were	O
rehydrated	O
in	O
200 μl	O
of	O
50 mM	O
phosphate	B
buffer	O
(pH 7.4)	O
in	O
D_2	O
O,	O
and	O
180 μl	O
was	O
transferred	O
to	O
a	O
3 mm	O
NMR	O
tube.	O

Untreated	O
T2DM	O
is	O
characterized	O
by	O
high	O
blood	O
glucose.	B

In	O
contrast,	O
the	O
GABR	O
showed	O
improved	O
prognostic	O
value	O
among	O
primary	O
prevention	O
subjects	O
compared	O
to	O
secondary	O
prevention,	O
suggesting	O
that	O
processes	O
linked	O
to	O
plaque	O
initiation	O
may	O
have	O
greater	O
sensitivity	O
to	O
substrate	O
(arginine)	O
bioavailability	O
for	O
nitric	B
oxide	I
production.	O

Glucose	B
and	O
xylitol	B
feed	O
the	O
PPP	O
through	O
glucose-6-phosphate	B
and	O
xylulose/xylulose-5-phosphate,	O
respectively.	O

Key	O
among	O
these	O
signaling	O
molecules	O
are	O
eicosanoids	B
and	O
related	O
oxylipin	B
metabolites	O
that	O
derive	O
from	O
polyunsaturated	O
fatty	O
acids	O
and	O
mediate	O
a	O
number	O
of	O
diverse	O
homeostatic	O
functions	O
in	O
humans	O
including	O
systemic	O
inflammation,	O
cellular	O
development,	O
ion	O
transport,	O
muscle	O
contraction,	O
vascular	O
tone,	O
and	O
thrombosis,	O
among	O
many	O
others.	O

Sera	O
were	O
recovered,	O
collected	O
in	O
polypropylene	B
tubes,	O
and	O
snap-frozen	O
at	O
−80	O
°C.	O

In	O
the	O
reverse	O
reaction,	O
glucose-6-phosphate	B
is	O
converted	O
to	O
glucose-1-phosphate	B
by	O
means	O
of	O
PGM1	O
and	O
is	O
used	O
as	O
a	O
substrate	O
in	O
the	O
production	O
of	O
uridine	B
diphosphate	I
(UDP)–glucose,	I
which	O
can	O
be	O
used	O
for	O
the	O
synthesis	O
of	O
glycogen	B
or	O
for	O
protein	O
glycosylation.	O

Glutamate	B
can	O
be	O
converted	O
to	O
glutamine	B
by	O
the	O
action	O
of	O
the	O
GS	O
enzyme.	O

Diketogulonic	O
acid,	O
a	O
metabolite	O
of	O
ascorbic	B
acid	I
(vitamin	O
C)	O
degradation,	O
was	O
also	O
decreased	O
in	O
adenoma	O
cases.	O

One	O
possible	O
explanation	O
for	O
the	O
decline	O
in	O
plasma	O
isoleucine,	B
a	O
BCAA,	O
is	O
that	O
it	O
is	O
used	O
as	O
an	O
energy	O
source,	O
as	O
has	O
been	O
reported	O
for	O
fatigued	O
human	O
subjects.	O

The	O
levels	O
of	O
SCC	O
antigen	O
(SCC-Ag)	O
of	O
the	O
patients	O
in	O
the	O
BT,	O
PP,	O
and	O
GP	B
groups	O
were	O
significantly	O
different	O
(P	O
 <.001)	O
corresponding	O
to	O
the	O
median	O
±	O
standard	O
deviation	O
of	O
12.83 ± 15.31,	O
5.81 ± 10.94,	O
and	O
0.89 ± 0.83,	O
respectively.	O

Median	O
plasma	O
concentrations	O
and	O
reference	O
intervals	O
for	O
men	O
and	O
pre-	O
and	O
post-menopausal	O
women	O
of	O
that	O
study	O
also	O
showed	O
generally	O
good	O
agreement	O
for	O
plasma	O
testosterone,	B
progesterone	B
and	O
17-hydroxyprogesterone	B
to	O
the	O
results	O
of	O
the	O
present	O
study.	O

However,	O
when	O
the	O
reaction	O
of	O
NO_2	O
-PhIP	O
with	O
SA	O
was	O
performed	O
with	O
10-fold	O
less	O
carcinogen	O
(0.3	O
mol	O
NO_2	O
-PhIP:	O
1	O
mol	O
SA),	O
targeted	O
UPLC-ESI/MS_2	O
analysis	O
revealed	O
that	O
the	O
desamino-PhIP	B
adducts	O
were	O
hardly	O
formed	O
at	O
Lys_195	O
,	O
Lys_199	O
,	O
Lys_541	O
,	O
Cys_34	O
,	O
Tyr_138	O
,	O
and	O
Tyr_401	O
,	O
and	O
desamino-PhIP	B
adduct	O
formation	O
at	O
Tyr_411	O
accounted	O
for	O
about	O
99%	O
of	O
the	O
total	O
ion	O
counts	O
of	O
SA	O
adducts.	O

Uric	B
acid,	I
a	O
potent	O
antioxidant	O
in	O
plasma,	O
is	O
a	O
breakdown	O
product	O
of	O
purine	B
nucleotides.	O

Only	O
six	O
lipid	O
species	O
(PC	O
32:1,	O
PC	B
34:2,	I
PC	B
34:1,	I
PE	B
36:1,	I
PE	B
38:4,	I
and	O
PE	B
40:7)	I
out	O
of	O
109	O
identified	O
PCs	O
and	O
PEs	O
were	O
found	O
to	O
have	O
statistically	O
significant	O
changes	O
(P	O
 < 0.001,	O
determined	O
by	O
two-tailed	O
student’s	O
t	O
test,	O
average	O
RSD:	O
27 ± 12%,	O
mean ± s.d.	O

Relatively	O
strong	O
correlations	O
were	O
seen	O
between	O
amino	O
acids	O
(ie,	O
histidine,	B
threonine,	B
methionine,	B
asparagine,	B
glutamine,	B
lysine	B
and	O
tyrosine).	B

The	O
upper	O
organic	O
layer	O
was	O
isolated	O
and	O
dried	O
by	O
centrifugal	O
vacuum	O
evaporation	O
and	O
dissolved	O
in	O
isopropanol:	B
methanol:	B
chloroform	B
(4:2:1)	I
containing	O
7 mM	O
ammonium	B
acetate.	I

In	O
the	O
ozone	O
study,	O
allantoin	B
levels	O
in	O
nasal	O
lavage	O
had	O
returned	O
to	O
pre-exposure	O
levels	O
at	O
6	O
hours	O
after	O
exposure.	O

Finally,	O
LINE-1	O
repeat	O
methylation	O
was	O
considered,	O
often	O
used	O
as	O
a	O
proxy	O
for	O
“global	O
methylation”	B
levels.	O

Higher	O
consumption	O
of	O
these	O
fatty	O
acids	O
was	O
also	O
negatively	O
correlated	O
with	O
prostaglandin	B
E_2	O
production.	O

Cholesterol	B
was	O
measured	O
by	O
the	O
CHOD-PAP	O
method	O
with	O
kit	O
A11A01634	O
and	O
lactate	B
was	O
measured	O
by	O
the	O
enzymatic	O
colorimetric	O
Trinder	O
method	O
with	O
kit	O

To	O
ensure	O
the	O
analytes	O
did	O
not	O
degrade	O
under	O
the	O
basic	O
conditions	O
necessary	O
for	O
their	O
elution	O
from	O
the	O
SPE	O
cartridge,	O
a	O
4-hrs	O
stability	O
experiment	O
at	O
room	O
temperature	O
of	O
BDCPP	O
and	O
DPP	O
in	O
the	O
elution	O
solution	O
(ACN	O
with	O
5%	O
pyrrolidine)	B
was	O
executed.	O

Currently,	O
fucose	B
gaining	O
considerable	O
importance	O
in	O
the	O
post-genomics	O
and	O
post-proteomic	O
period	O
of	O
diagnosis	O
and	O
prognosis	O
of	O
cancer.	O

Since	O
different	O
NEFA	O
profiles	O
were	O
observed,	O
it	O
is	O
conceivable	O
that	O
differences	O
in	O
supplementation	O
requirements	O
exist	O
in	O
RA,	O
thereby	O
stressing	O
the	O
need	O
for	O
(i)	O
an	O
accurate	O
stratification	O
of	O
patients	O
according	O
to	O
their	O
NEFA	O
levels	O
and	O
(ii)	O
a	O
detailed	O
design	O
of	O
FA	B
formulas	O
for	O
supplementation.	O

We	O
conclude	O
the	O
altered	O
metabolism	O
in	O
dyslipidemic	O
subjects	O
produces	O
TGRL	O
with	O
a	O
unique	O
oxylipin	B
signature	O
that	O
promotes	O
a	O
pro-atherogenic	O
endothelial	O
phenotype.	O

D_35	O
_LysoPC18:0	B
was	O
purchased	O
from	O
Avanti	O
Polar	O
Lipids	O
(Alabaster,	O
AL).	O

To	O
investigate	O
erythritol	B
metabolism	O
in	O
humans,	O
an	O
ex	O
vivo	O
stable	O
isotope-assisted	O
blood	O
incubation	O
experiment	O
was	O
performed	O
on	O
five	O
healthy	O
male	O
volunteers.	O

Quantified	O
amino	O
acids	O
and	O
acylcarnitine	B
in	O
serum	O
samples	O
in	O
2015	O
data	O
set.	O

While	O
our	O
findings	O
corroborate	O
a	O
link	O
between	O
energy	O
metabolism	O
and	O
AF,	B
our	O
analysis	O
cannot	O
distinguish	O
whether	O
AF	B
or	O
CE	O
stroke	O
causes	O
TCA	O
cycle	O
alterations,	O
whether	O
TCA	O
cycle	O
changes	O
contribute	O
to	O
atrial	O
remodeling,	O
or	O
whether	O
accumulation	O
of	O
TCA	O
cycle	O
intermediates	O
is	O
associated	O
with	O
other	O
factors	O
that	O
cause	O
AF.	B

Subsequently,	O
oxidative	O
stress	O
reduces	O
glutamine	B
synthesis	O
and	O
impairs	O
glutamate-glutamine	B
cycle	O
between	O
astrocytes	O
and	O
neurons	O
in	O
T2DM,	O
leading	O
to	O
diabetes-induced	O
neurodegeneration	O
and	O
cognitive	O
dysfunction	O
[,].	O

The	O
enzymatic	O
hydrolysis	O
was	O
validated	O
using	O
DHEA-S	B
and	O
DHEA-G	O
standards	O
as	O
substrates	O
followed	O
by	O
quantification	O
of	O
liberated	O
DHEA	O
by	O
mass	O
spectrometry.	O

[−6%	O
(−11%,	O
−3%)	O
vs.	O
6%	O
(3%,	O
9%)],	O
β-aminoisobutyric	B
acid	I
[−49%	O
(−52%,	O
−46%)	O
vs.	O
21%	O
(7%,	O
60%)],	O
asparagine	B
[−36%	O
(−43%,	O
−35%)	O
vs.	O
−11%	O
(−15%,	O
−7%)],	O
and	O
α-amino-n-butyric	B
acid	I

Osmium	O
tetroxide	B
0.2%	O
incubation	O
for	O
30	O
s	O
and	O
methyl	O
green	O
counter	O
stain	O
were	O
used	O
as	O
a	O
signal	O
enhancer.	O

Thus,	O
it	O
is	O
clear	O
that	O
Rh30	O
cells	O
exhibited	O
a	O
higher	O
capacity	O
for	O
the	O
de	O
novo	O
synthesis	O
of	O
pyrimidine	B
nucleotides	O
than	O
myocytes.	O

Similarly,	O
limitations	O
of	O
biopsy-based	O
risk	O
stratification	O
given	O
known	O
upstaging	O
at	O
RP	B
in	O
up	O
to	O
40%	O
of	O
patients	O
may	O
confound	O
the	O
accuracy	O
of	O
risk	O
subgroup	O
analyses.	O

(A)	O
–	O
NN	O
vs	O
HC;	O
(B)	O
–	O
FA	B
vs	I
HC;	O
(C)	O
–	O
TC	O
vs	O
HC;	O
(D)	O
–	O
TC	O
vs	O
NN;	O
(E)	O
–	O
FA	B
vs	I
NN;	O
(F)	O
–	O
FA	B
vs	I
TC;	O
(G)	O
–	O
P	O
vs	O
HC.	O

In	O
addition,	O
succinate	B
exhibited	O
a	O
prominent	O
_13	O
C_0	O
isotopomer	O
that	O
was	O
not	O
present	O
in	O
other	O
TCA	O
cycle	O
metabolites,	O
suggesting	O
a	O
substantial,	O
separate	O
succinate	B
pool	O
derived	O
from	O
an	O
unlabeled	O
substrate.	O

The	O
levels	O
of	O
valine	B
are	O
slightly	O
different	O
(with	O
an	O
uncorrected	O
p	O
-value	O
of	O
0.010),	O
and	O
none	O
of	O
the	O
other	O
individual	O
metabolites	O
show	O
significantly	O
different	O
levels	O
between	O
the	O
patients	O
with	O
polyps	O
and	O
healthy	O
controls	O
as	O
a	O
result	O
of	O
the	O
SUR	O
modeling.	O

Electrospray	O
ionization	O
(ESI)	O
was	O
used	O
in	O
positive	O
mode	O
at	O
3.5	O
kV	B
with	O
a	O
concurrent	O
35	O
psig	O
emitter	O
nebulization	O
pressure.	O

Therefore,	O
one	O
reasonable	O
mechanism	O
underlying	O
the	O
involvement	O
of	O
4-hydroxyphenylacetic	B
acid	I
in	O
UMI	O
is	O
the	O
lack	O
of	O
this	O
anti-oxidant	O
chemical	O
for	O
radical	O
clearage.	O

Box	O
plots	O
showing	O
the	O
levels	O
of	O
salivary	O
glutamate	B
in	O
HNSCC	O
patients	O
(cancer;	O
n	O
=	O
10)	O
and	O
normal	O
healthy	O
controls	O
(control;	O
n	O
=	O
8),	O
and	O
(D)	O
plasma	O
glutamate	B
levels	O
in	O
HNSCC	O
patients	O
(cancer;	O
n	O
=	O
7)	O
and	O
normal	O
healthy	O
controls	O
(control;	O
n	O
=	O
7)	O
based	O
on	O
isotope	O
dilution	O
GC-MS.	O

Quality	O
controls	O
(QC’s)	O
were	O
derived	O
from	O
pooling	O
all	O
samples	O
and	O
serially	O
diluting	O
with	O
chloroform.	B

Characteristics	O
of	O
control	O
subjects	O
and	O
breast	O
cancer	O
case	O
subjects	O
The	O
median	O
serum	O
concentrations	O
of	O
estrogens,	O
estrogen	B
metabolites,	O
and	O
metabolic	O
pathway	O
groups,	O
with	O
interdeciles	O
ranges,	O
for	O
case	O
subjects	O
and	O
control	O
subjects	O
are	O
presented	O
in	O
.	O

Adjusted	O
Means_a	O
	O
(95%	O
Confidence	O
Limits)	O
for	O
Urinary	O
Concentrations	O
of	O
Estrogens	O
and	O
Estrogen	B
Metabolites	O
(Jointly	O
Referred	O
to	O
as	O
EM,	O
in	O
Picomoles	O
per	O
Milligram	O
of	O
Creatinine)	O
by	O
Quintiles	O
of	O
Measures	O
of	O
Diversity	O
and	O
Composition	O
of	O
the	O
Fecal	O
Microbiome	O
in	O
60	O
Postmenopausal	O
Women	O
H' = −ΣRi=1pi⋅lnpi	O
H' = −ΣRi=1pi⋅lnpi	O
H' = −ΣRi=1pi⋅lnpi	O
H' = −ΣRi=1pi⋅lnpi	O
H' = −ΣRi=1pi⋅lnpi	O
H' = −ΣRi=1pi⋅lnpi	O
H	O
'	O
 	O
=	O
 	O
−	O
ΣRi=1pi	O
ΣRi=1pi	O
Σ	O
Σ	O

Increased	O
serum	O
uric	B
acid	I
may	O
increase	O
the	O
risk	O
of	O
thrombosis	O
by	O
promoting	O
lipid	O
peroxidation,	O
the	O
oxidation	O
of	O
low-density	O
lipoprotein,	O
an	O
increase	O
of	O
oxygen	O
free	O
radicals	O
and	O
platelet	O
adhesion,	O
and	O
promote	O
platelet	O
thrombus	O
formation	O
in	O
early	O
thrombosis.	O

Here	O
we	O
combined	O
methanol	B
precipitation	O
with	O
MTBE	B
extraction	O
in	O
order	O
to	O
achieve	O
a	O
higher	O
degree	O
of	O
extraction	O
for	O
lipids.	O

Both	O
metabolites	O
in	O
1-methylnicotinamide/acetone	O
ratio	O
are	O
precursors	O
to	O
NADP	B
+	O
production.	O

Pooled	O
plasma	O
from	O
healthy	O
volunteers	O
(male	O
and	O
female)	O
were	O
used	O
for	O
the	O
estimation	O
of	O
oxysterol	B
recovery	O
and	O
stability.	O

The	O
risk	O
ratio	O
of	O
ascites	O
on	O
recurrence	O
DE,	O
without	O
considering	O
LysoPC(P-15:0),	B
was	O
1.54.	O

The	O
differentiating	O
FA	B
included	O
palmitic	B
(16:0),	I
oleic	O
(18:1),	O
linoleic	B
(18:2)	I
and	O
arachidonic	O
acids	O
(20:4),	O
as	O
well	O
as	O
12-HETE,	B
which	O
have	O
been	O
proposed	O
as	O
potential	O
biomarkers	O
in	O
breast	O
cancer	O
[,	O
].	O

Kendall’s	O
τ	O
values	O
ranged	O
between	O
−0.516	O
(aspartic	O
acid	I
with	O
glutamine)	B
and	O
0.709	O
(threonine	O
with	O
glutamine),	B
the	O
P	O
values	O
between	O
0.001	O
and	O
0.97	O
(Fig. ).	O

(2:1,	O
v/v)	O
and	O
3	O
mL	O
CHCl_3	O
/CH_3	O
OH/H_2	O
O	B
(48:35:10,	O
v/v/v).	O

Thus,	O
we	O
drew	O
ROC	O
curves	O
based	O
on	O
D-glutamic	B
acid.	I

The	O
endocannabinoid	B
system	O
is	O
a	O
vital	O
endogenous	O
signaling	O
system	O
that	O
comprises	O
of	O
the	O
cannabinoid	B
receptors,	O
their	O
endogenous	O
ligands	O
(the	O
endocannabinoids),	B
and	O
the	O
enzymes	O
catalyzing	O
anabolism	O
and	O
catabolism	O
of	O
endocannabinoid	B
(Di	O
Marzo	O
et	O
al.,	O
).	O

Over	O
3	O
times	O
more	O
17:0	O
Cer	O
and	O
17:0	O
PE	O
were	O
extracted	O
using	O
the	O
methanol-ethanol	B
method	O
compared	O
to	O
the	O
methanol	B
method.	O

Biologically,	O
gene	O
expression	O
and	O
metabolite	O
alterations	O
occur	O
early	O
in	O
tumorigenesis	O
and	O
are	O
more	O
pronounced	O
in	O
lower	O
grade	O
(Gleason	O
≤	O
7)	O
compared	O
with	O
higher	O
grade	O
(Gleason	O
≥	O
8)	O
tumors,	O
supported	O
by	O
our	O
analysis	O
of	O
low-	O
and	O
intermediate-risk	B
patients	O
(,	O
Figs.	O

Together,	O
these	O
findings	O
suggest	O
alterations	O
in	O
glucose	B
uptake	O
and	O
utilization,	O
which	O
may	O
support	O
an	O
increase	O
in	O
pentose	B
phosphate	I
pathway	O
activity	O
and	O
the	O
generation	O
of	O
glycation	O
products	O
that	O
may	O
potentially	O
contribute	O
to	O
the	O
pathogenesis	O
and	O
growth	O
of	O
these	O
tumors.	O

A	O
study	O
by	O
Guasch-Ferré	O
et	O
al	O
.	O
also	O
indicated	O
that	O
the	O
elevated	O
concentrations	O
of	O
acylcarnitines	B
are	O
independently	O
associated	O
with	O
risk	O
of	O
stroke.	O

All	O
solutions	O
were	O
properly	O
identified	O
and	O
stored	O
at	O
8ºC	O
in	O
polypropylene	B
tubes.	O

(B)	O
Representation	O
of	O
the	O
molecular	O
structure	O
(C_24	O
H_48	O
NO_6	O
P)	O
m/z	O
478	O
identified	O
as	O
lisophosphatidylcholine	B
[LPC	O
(P-16:1)].	O

Of	O
all	O
the	O
metabolites,	O
we	O
found	O
that	O
20-HETE	B
had	O
the	O
highest	O
fold-change.	O

Acetate	B
had	O
a	O
lower	O
level	O
in	O
female	O
BD	O
subjects	O
but	O
a	O
higher	O
level	O
in	O
male	O
BD	O
subjects.	O

Samples	O
were	O
then	O
loaded	O
onto	O
5	O
mL	O
ChemElut	O
cartridges	O
(Agilent	O
Tech.),	O
and	O
the	O
[D_4	O
]4	O
methyl	B
ester	I
was	O
eluted	O
with	O
25	O
mL	O
of	O
CH_2	O
Cl_2	O
.	O

The	O
enzymatic	O
digestion	O
of	O
HONH-PhIP-	O
and	O
HONH-[_2	O
H_5	O
]-PhIP-modified	O
SA	O
with	O
Pronase	O
E,	O
leucine	O
aminopeptidase,	O
and	O
prolidase	O
resulted	O
in	O
extensive	O
hydrolysis	O
of	O
the	O
sulfinamide	B
linkage,	O
and	O
targeted	O
MS/MS	O
analyses	O
of	O
the	O
protein	O
digest	O
showed	O
that	O
PhIP	O
was	O
recovered	O
in	O
high	O
yields.	O

Another	O
example,	O
2-methylerythritol,	B
was	O
previously	O
detected	O
in	O
human	O
urine	O
but	O
no	O
concentration	O
was	O
reported	O
.	O

To	O
determine	O
_13	O
C	O
enrichment	O
in	O
lactate	B
and	O
glutamine,	B
the	O
measured	O
distribution	O
of	O
mass	O
isotopomers	O
was	O
corrected	O
for	O
natural	O
abundance.	O

These	O
results	O
are	O
consistent	O
with	O
Baratta	O
et	O
al	O
who	O
found	O
no	O
differences	O
in	O
plasma	O
kynurenine	B
and	O
kynurenic	B
acid	I
in	O
female	O
rats	O
exposed	O
to	O
sleep	O
deprivation	O
and	O
stress.	O

This	O
is	O
done	O
by	O
the	O
enzyme	O
alanine	O
transaminase,	O
which	O
converts	O
L-glutamate	B
and	O
pyruvate	B
into	O
α-ketoglutarate	B
and	O
L-alanine.	B

The	O
mean	O
melatonin	B
was	O
significantly	O
higher	O
in	O
participants	O
who	O
slept	O
longer	O
than	O
455	O
minutes.	O

It	O
is	O
important	O
to	O
note	O
that	O
cigarette	O
smoke	O
is	O
also	O
a	O
known	O
inducer	O
of	O
CYP1A2	O
and	O
CYP2E1,	O
and	O
alcohol	O
intake	O
is	O
a	O
known	O
inducer	O
of	O
CYP2E1;	O
experimental	O
data	O
show	O
ferret	O
lung	O
CYP1A2	O
induction	O
in	O
response	O
to	O
both	O
β-carotene	B
and	O
cigarette	O
smoke,	O
with	O
the	O
strongest	O
change	O
resulting	O
from	O
exposure	O
to	O
both,	O
and	O
the	O
original	O
trial	O
finding	O
in	O
ATBC	O
of	O
an	O
increased	O
risk	O
of	O
lung	O
cancer	O
for	O
those	O
supplemented	O
with	O
β-carotene	B
was	O
stronger	O
among	O
men	O
who	O
drank	O
more.	O

The	O
formic	B
acid	I
and	O
acetonitrile	B
were	O
purchased	O
as	O
MS-grade	O
from	O
Sigma-Aldrich.	O

There	O
were	O
changes	O
in	O
parallel	O
with	O
weight	O
loss,	O
especially	O
improvements	O
in	O
glucose	B
and	O
lipid	O
metabolism,	O
and	O
in	O
the	O
circulating	O
levels	O
of	O
leptin	O
and	O
adiponectin	O
and	O
the	O
paraoxonase	O
activity.	O

Nucleobases	O
were	O
mostly	O
_13	O
C_4	O
,	O
indicating	O
active	O
turnover	O
of	O
nucleotide	O
and	O
deoxynucleotide	B
pools,	O
but	O
little	O
salvage	O
of	O
medium	O
(_13	O
C_0	O
)	O
nucleotides.	O

Intensive	O
glucose	B
control	O
can	O
prevent	O
kidney	O
disease,	O
and	O
inhibitors	O
of	O
the	O
renin-angiotensin	O
system	O
(RAS)	O
can	O
slow	O
its	O
progression	O
(–).	O

Notably,	O
alanine,	B
C38:5	B
and	O
C36:1	B
PCs	O
and	O
fructose	B
were	O
selected	O
95	O
times	O
out	O
of	O
100	O
in	O
case	O
of	O
the	O
binary	O
approach	O
and	O
C36:5e	B
PE	I
was	O
selected	O
97	O
times	O
out	O
of	O
100	O
in	O
case	O
of	O
continuous	O
regression	O
approach.	O

[,]	O
To	O
each	O
sample,	O
methanol	B
and	O
MTBE	B
was	O
added	O
according	O
to	O
the	O
amounts	O
outlined	O
in	O
.	O

Resequencing,	O
expression	O
analysis,	O
and	O
biochemical	O
experiments	O
focused	O
on	O
one	O
such	O
locus	O
(CYP39A1	O
),	O
revealed	O
multiple	O
loss-of-function	O
alleles	O
with	O
additive	O
effects	O
on	O
serum	O
levels	O
of	O
the	O
oxysterol,	B
24S	B
-hydroxycholesterol,	I
a	O
substrate	O
of	O
the	O
encoded	O
enzyme.	O

CSF	O
metabolomic	O
profiles	O
in	O
T2DM	O
patients	O
vs.	O
controls	O
revealed	O
significantly	O
increased	O
levels	O
of	O
alanine,	B
leucine,	B
valine,	B
tyrosine,	B
lactate,	B
pyruvate,	B
and	O
decreased	O
levels	O
of	O
histidine.	B

Netrin-1	O
is	O
the	O
most	O
studied	O
member	O
of	O
the	O
family	O
and	O
has	O
been	O
shown	O
as	O
a	O
potent	O
endothelial	O
mitogen	O
stimulating	O
the	O
production	O
of	O
nitric	B
oxide	I
via	O
a	O
DCC-ERK1/2	O
dependent	O
mechanism.	O

This	O
fragmentation	O
pattern	O
may	O
be	O
explained	O
by	O
the	O
presence	O
of	O
a	O
glucuronide	B
metabolite,	O
as	O
shown.	O

In	O
the	O
subset	O
where	O
MMR	O
was	O
not	O
observed	O
(non-MMR,	O
n	O
=	O
85),	O
imatinib	B
serum	O
concentrations	O
were	O
between	O
0.138	O
mg/mL	O
and	O
3.011	O
mg/mL	O
and	O
the	O
median	O
and	O
mean	O
were	O
1.274	O
mg/mL	O
and	O
1.401	O
mg/mL,	O
respectively.	O

Meanwhile	O
there	O
was	O
strong	O
positive	O
correlation	O
between	O
methylated	B
arginine	I
metabolites	O
with	O
choline	B
and	O
to	O
a	O
lesser	O
extent	O
betaine,	B
while	O
an	O
inverse	O
correlation	O
between	O
both	O
choline	B
and	O
betaine	B
was	O
observed	O
with	O
GABR.	O

Changes	O
in	O
lipid	O
metabolism	O
could	O
also	O
explain	O
the	O
variations	O
in	O
the	O
concentration	O
of	O
adipic	B
acid,	I
a	O
metabolite	O
that	O
is	O
associated	O
with	O
abnormalities	O
in	O
the	O
metabolism	O
of	O
fatty	O
acids,	O
in	O
patients	O
at	O
different	O
stages	O
of	O
the	O
disease.	O

Importantly,	O
it	O
is	O
only	O
specific	O
isomers	O
that	O
are	O
biologically	O
active,	O
e.g.	O
24(S	O
)-	O
and	O
25-hydroxycholesterol	B
are	O
both	O
suppressors	O
of	O
cholesterol	B
synthesis	O
and	O
enhancers	O
of	O
cholesterol	B
export,	O
whereas	O
7α-hydroxycholesterol	B
and	O
7-oxocholesterol	B
only	O
weakly	O
suppress	O
cholesterol	B
synthesis	O
and	O
are	O
not	O
ligands	O
to	O
the	O
LXRs	O
(,	O
,	O
).	O

PC	O
was	O
the	O
only	O
phospholipid	B
that	O
correlated	O
with	O
ChE	O
(r	O
 = 0.441,	O
p	O
 = 0.001).	O

Increased	O
arginine	B
levels	O
have	O
been	O
assumed	O
to	O
be	O
the	O
cause	O
of	O
increased	O
NO.	O

In	O
terms	O
of	O
area,	O
the	O
highest	O
results	O
were	O
achieved	O
by	O
CHCl_3	O
:MeOH	O
and	O
PCA,	O
and	O
MeOH	B
and	O
ACN	O
showed	O
the	O
lowest	O
areas	O
with	O
the	O
exception	O
of	O
MeOH	B
in	O
LYS,	O
ORN,	O
1,3-DAP,	B
and	O
PUT,	O
which	O
showed	O
areas	O
similar	O
to	O
that	O
of	O
CHCl_3	O
:MeOH	O
(data	O
shown	O
in	O
Figure	O
S1	O
in	O
the	O
Supplementary	O
Material).	O

Three	O
quality	O
control	O
(QC)	O
working	O
solutions	O
of	O
Exe	O
were	O
prepared	O
by	O
serial	O
dilution	O
with	O
methanol	B
to	O
achieve	O
concentrations	O
of	O
30,	O
75,	O
and	O
250	O
ng/mL.	O
Similarly,	O
three	O
QC	O
working	O
solutions	O
of	O
17DhExe	O
and	O
Exe17Oglu	O
were	O
prepared	O
separately	O
by	O
serial	O
dilution	O
with	O
methanol	B
to	O
achieve	O
concentrations	O
of	O
15,	O
40,	O
and	O
100	O
ng/mL.	O
All	O
stock	O
and	O
working	O
solutions	O
were	O
stored	O
at	O
4°C.	O

However,	O
the	O
derivatization	O
efficiency	O
was	O
less	O
than	O
50%	O
for	O
some	O
molecules	O
in	O
the	O
pathways	O
of	O
purine	B
metabolism	O
(e.g.,	O
adenosine	B
and	O
uric	O
acid)	O
and	O
amino	O
acid	O
synthesis	O
(e.g.,	O
tyrosine	B
and	O
cysteine	B
sulfate).	I

The	O
concentration	O
of	O
individual	O
families	O
of	O
lipid	O
species	O
before	O
(pre)	O
and	O
after	O
(post)	O
both	O
infusions	O
for	O
each	O
group,	O
including	O
DAG,	O
ceramide	B
(Cer),	O
free	O
cholesterol,	B
CE,	O
PC,	O
LPC,	O
and	O
NEFA,	O
are	O
shown	O
in	O
.	O

Furthermore,	O
several	O
tricarboxylic	B
acid	I
(TCA)	O
cycle	O
intermediates,	O
including	O
valine	B
and	O
isoleucine,	B
were	O
found	O
at	O
a	O
lower	O
concentration	O
in	O
patients	O
with	O
CIN	O
and	O
CSCC,	O
suggesting	O
a	O
suppressed	O
TCA	O
cycle.	O

In	O
addition,	O
HBx	O
has	O
been	O
shown	O
to	O
activate	O
fatty	O
acid	O
oxidation,	O
fueling	O
the	O
TCA	O
cycle	O
with	O
increased	O
acetyl-CoA	B
and	O
thus	O
will	O
decrease	O
the	O
demand	O
on	O
amino	O
acid	O
anaplerosis.	O

The	O
five	O
peaks	O
were	O
identified	O
as	O
octanoic	B
acid	I
(caprylic	I
acid),	I
decanoic	O
(capric	O
acid),	O
oleic	B
acid,	I
oxalic	B
acid	I
and	O
glycine,	B
which	O
were	O
all	O
significantly	O
higher	O
in	O
the	O
HCC	O
patients	O
compared	O
to	O
the	O
HCV-cirrhotic	O
group.	O

Triterpene	B
1,	O
DCM,	O
and	O
aqueous	O
leaf	O
extracts	O
were	O
tested	O
for	O
hypoglycemic	B
potential	O
using	O
the	O
oral	O
glucose	B
tolerance	O
test;	O
analgesic	O
potential	O
using	O
the	O
tail-flick	O
assay,	O
and	O
antimicrobial	O
potential	O
using	O
the	O
disc	O
diffusion	O
method.	O

The	O
first	O
major	O
step	O
of	O
heme	B
catabolic	O
pathway	O
involves	O
the	O
formation	O
of	O
water-soluble	O
biliverdin	B
from	O
heme	B
by	O
heme	O
oxygenase	O
(HO)	O
which	O
is	O
subsequently	O
reduced	O
by	O
biliverdin	B
reductase	O
(BVR)	O
to	O
bilirubin	B
(Baranano	O
et	O
al.,	O
).	O

	O
shows	O
a	O
comparison	O
of	O
the	O
mean	O
net	O
percent	O
variation	O
following	O
exercise	O
in	O
the	O
individual	O
T1D	O
and	O
control	O
groups	O
for	O
glucose	B
and	O
insulin.	O

It	O
seems	O
that	O
the	O
reduction	O
in	O
ATP	B
production	O
due	O
to	O
the	O
inhibition	O
of	O
the	O
TCA	O
cycle	O
induced	O
by	O
hypobaric	O
hypoxia	O
as	O
discussed	O
above	O
could	O
lead	O
to	O
the	O
utilization	O
of	O
BCAAs	O
as	O
alternative	O
sources	O
of	O
energy.	O

In	O
response	O
to	O
diseases	O
and	O
malnutrition	O
such	O
as	O
diabetes	O
and	O
starvation,	O
plasma	O
glycine	B
significantly	O
decreased_,	O
.	O

It	O
is	O
noteworthy	O
that	O
the	O
exposure	O
time	O
amplifies	O
the	O
toxicity	O
of	O
NN	O
in	O
bees,	O
i.e.	O
micro-colonies	O
of	O
bumblebees	O
fed	O
with	O
imidacloprid	O
showed	O
a	O
phenomenon:	O
at	O
one	O
tenth	O
of	O
the	O
concentration	O
of	O
the	O
toxin	B
in	O
feed,	O
it	O
took	O
twice	O
as	O
long	O
to	O
produce	O
100%	O
mortality	O
in	O
a	O
bumblebee	O
micro	O
colony,	O
and	O
at	O
a	O
100	O
times	O
lower	O
dose,	O
it	O
took	O
about	O
four	O
times	O
longer	O
to	O
produce	O
100%	O
mortality.	O

The	O
reaction	O
was	O
detected	O
with	O
DAB	O
(Millipore)	O
and	O
counterstained	O
with	O
Harris	O
hematoxylin	B
(Sigma).	O

This	O
result	O
was	O
in	O
accordance	O
with	O
a	O
previous	O
study,	O
in	O
which	O
total	O
cholesterol	B
(measured	O
by	O
an	O
enzymatic	O
colorimetric	O
assay),	O
was	O
unaltered	O
in	O
bvFTD.	O

Thus,	O
the	O
structure	O
of	O
the	O
modified	O
peptide	O
in	O
Fraction	O
5	O
is	O
assigned	O
Y*TK	O
with	O
the	O
site	O
of	O
adduction	O
occurring	O
between	O
the	O
4-HO-tyrosine	B
group	O
and	O
the	O
C-2	O
imidazole	B
atom	O
of	O
NO_2	O
-PhIP.	O

trimethylamine-N	B
-oxide,	I
gestational	O
diabetes	O
mellitus,	O
nested	O
case-control	O
study,	O
nutrition,	O
metabolite	O

Fourth,	O
although	O
we	O
controlled	O
for	O
multiple	O
GDM	O
risk	O
factors,	O
such	O
as	O
age,	O
prepregnancy	O
BMI,	O
gestational	O
age,	O
and	O
parity,	O
we	O
could	O
not	O
rule	O
out	O
the	O
possibility	O
of	O
residual	O
confounding	O
by	O
other	O
unmeasured	O
factors	O
such	O
as	O
data	O
on	O
plasma	O
choline	B
and	O
carnitine	B
and	O
changes	O
during	O
pregnancy	O
that	O
may	O
affect	O
diet,	O
such	O
as	O
morning	O
sickness.	O

Green	O
and	O
red	O
circles	O
represent	O
experimental	O
and	O
database	O
peaks	O
of	O
glyceric	B
acid,	I
respectively,	O
whereas	O
magenta	O
circles	O
represent	O
the	O
expected	O
glyceric	B
acid	I
peaks	O
from	O
the	O
TOCCATA	O
database.	O

Patients	O
with	O
concordance	O
of	O
rapid	O
urease	O
test,	O
urea	B
breath	O
test	O
and	O
histopathology	O
(Giemsa	O
staining)	O
were	O
considered	O
H.	O
pylori	O
positive.	O

Prothrombin	O
is	O
processed	O
to	O
thrombin,	O
a	O
serine	B
protease	O
that	O
cleaves	O
fibrinogen	O
to	O
fibrin,	O
leading	O
to	O
clotting.	O

Using	O
the	O
1	O
mM	O
ammonium	B
fluoride	I
increased	O
retention;	O
therefore,	O
to	O
minimize	O
runtime,	O
the	O
isocratic	O
mobile	O
phase	O
composition	O
was	O
adjusted	O
to	O
8%	O
1	O
mM	O
ammonium	B
fluoride	I
and	O
92%	O
acetonitrile	B
to	O
achieve	O
retention	O
factors	O
of	O
4.6–6.1.	O

Previously	O
it	O
has	O
been	O
shown	O
that	O
the	O
wild-type	O
HTT	O
protein	O
binds	O
to	O
thyroid	O
hormone	O
receptor-ɑ1	O
(TRɑ1),	O
a	O
nuclear	O
receptor	O
for	O
the	O
deiodinated	O
product	O
of	O
thyroxine	B
(T_4	O
),	O
triiodothyronine	B
(T_3	O
),	O
which	O
may	O
be	O
a	O
reason	O
for	O
the	O
altered	O
tyrosine	B
metabolism.	O

Moreover,	O
succinate	B
was	O
positively	O
correlated	O
with	O
decreased	O
levels	O
of	O
isoleucine	B
(R	O
=	O
0.4),	O
an	O
amino	O
acid	O
that	O
after	O
deamination	O
and	O
decarboxylation	O
yields	O
succinyl-CoA	B
to	O
feed	O
into	O
the	O
TCA	O
cycle.	O

	O
Increased	O
levels	O
of	O
cyclooxygenase-2	O
and	O
prostaglandin	B
E_2	O
(PGE_2	O
)	O
have	O
been	O
observed	O
in	O
tobacco-related	O
malignancies	O
of	O
the	O
upper	O
aerodigestive	O
tract.	O

Congenital	O
disorders	O
of	O
glycosylation	O
are	O
genetic	O
syndromes	O
that	O
result	O
in	O
impaired	O
glycoprotein	B
production.	O

As	O
depicted	O
in	O
,	O
creatinine-d_3	B
(p=0.079)	O
had	O
26%	O
increase	O
in	O
abundance	O
using	O
the	O
MTBE-SPE	O
method	O
compared	O
to	O
methanol	B
precipitation,	O
however	O
lysine-d_4	B
(p=0.037)	O
was	O
20%	O
lower.	O

Lipid,	O
-CH=CH-;	O
Lac:	O
Lactate;	B
Leu:	O
Leucine;	B
Lys:	O
Lysine;	B
MA:	O
Methylamine;	B
NAG:	O
N-acetyl	B
glycoprotein	I
signals;	O
PC:	O
Phosphocholine:	B
Phe:	O
Phenylalanine;	B
Py:	O

Explanation	O
of	O
terminology	O
is	O
presented	O
in	O
Table	O
S1	O
Correlation	O
of	O
plasma	O
phenylalanine	B
with	O
(a)	O
VLDL5-free	O
cholesterol	B
(R = -0.5.1,	O

We	O
also	O
attempted	O
to	O
choose	O
women	O
with	O
vaginal	O
epithelial	O
changes	O
(VEC),	O
which	O
are	O
correlated	O
with	O
a	O
higher	O
dose	O
of,	O
and	O
earlier	O
exposure	O
to,	O
DES	B
in	O
utero.	O

As	O
shown	O
in	O
A	O
,	O
a	O
density	O
plot	O
of	O
the	O
inorganic	O
phosphate	B
(79	O
m/z)	O
molecules	O
can	O
be	O
created	O
similarly	O
to	O
doing	O
so	O
for	O
any	O
conventional	O
histological	O
study.	O

Plasma	O
glucose	B
was	O
maximally	O
enriched	O
(up	O
to	O
49%)	O
in	O
_13	O
C	O
immediately	O
(0.5	O
hr)	O
following	O
the	O
tracer	O
infusion.	O

A	O
volume	O
of	O
400	O
µL	O
ice-cold	O
methanol	B
was	O
added	O
to	O
plasma	O
sample	O
aliquots	O
containing	O
internal	O
standards,	O
then	O
the	O
mixture	O
was	O
vortexed	O
vigorously	O
for	O
30	O
sec	O
and	O
centrifuged	O
at	O
18000	O
×	O
g	O
0°C	O
for	O
15	O
min.	O

Few	O
previous	O
studies	O
have	O
reported	O
concentrations	O
of	O
phthalate	B
metabolites	O
in	O
serum.	O

Indeed,	O
both	O
cytokines	O
contribute	O
to	O
the	O
modulation	O
of	O
the	O
patients’	O
immune	O
system,	O
involved	O
in	O
the	O
response	O
to	O
trastuzumab,	O
taxanes	B
as	O
well	O
as	O
hormonal	O
therapy.	O

To	O
assess	O
differences	O
in	O
FA	B
and	O
oxylipin	B
composition	O
in	O
TGRL	O
as	O
a	O
function	O
of	O
the	O
meal,	O
TGRL-induced	O
inflammatory	O
phenotype,	O
and	O
interaction	O
between	O
the	O
two	O
factors,	O
a	O
two-factor	O
analysis	O
of	O
variance	O
(ANOVA)	O
was	O
performed.	O

Subjects	O
who	O
had	O
increased	O
plasma	O
glucose	B
in	O
response	O
to	O
statin	B
treatment	O
apparently	O
had	O
decreased	O
insulin	O
secretion	O
post	O
treatment,	O
and	O
vice	O
versa.	O

In	O
agreement	O
with	O
previous	O
reports	O
analyzing	O
OSCC	O
tumor	O
samples,	O
serum	O
samples	O
showed	O
creatine	B
to	O
be	O
low,	O
creatinine	B
to	O
be	O
high,	O
and	O
choline-creatine	B
ratios	O
to	O
be	O
high.	O

fasting	O
plasma	O
glucose,	B
insulin,	O
and	O
plasma	O
TMAO.	B

We	O
estimated	O
the	O
mediating	O
effect	O
of	O
unconjugated	O
estradiol	B
(E2)	O
on	O
the	O
association	O
between	O
BMI	O
and	O
ER+	O
breast	O
cancer	O
in	O
the	O
following	O
manner.	O

We	O
found	O
that	O
different	O
content	O
changes	O
of	O
thiols	B
are	O
associated	O
with	O
different	O
types	O
of	O
cancers.	O

Peptide	O
adducts	O
observed	O
at	O
11.4	O
min	O
displayed	O
triply	O
charged	O
ions	O
[M+3H]_3+	O
at	O
m/z	O
517.8	O
and	O
519.7,	O
which	O
are	O
an	O
addition	O
mass	O
of	O
207	O
and	O
212	O
Da	O
to	O
the	O
protonated	O
peptide	O
LQQCPFEDHVK	O
(m/z	O
1343.6,	O
residues	O
31–41	O
of	O
SA)	O
with	O
a	O
missed	O
cleavage	O
at	O
C-terminal	O
of	O
phenylalanine.	B

Eight	O
metabolites	O
(ADMA,	O
octadecanoylcarnitine	B
and	O
6	O
PCs)	O
were	O
significantly	O
altered	O
between	O
RRMM-	O
and	O
MGUS	O
patients	O
(	O
and	O
Part	O
E	O
in	O
).	O

Related	O
to	O
the	O
glutathione	B
levels	O
and	O
additional	O
markers	O
of	O
oxidative	O
stress,	O
the	O
increase	O
observed	O
in	O
MetO,	O
reduced	B
glutathione,	I
cysteine	B
and	O
glycine	B
levels	O
in	O
both	O
tumor	O
subtypes	O
provides	O
further	O
support	O
for	O
changes	O
associated	O
with	O
an	O
increase	O
in	O
oxidative	O
stress	O
(Fig.	O

Then	O
proteins	O
were	O
precipitated	O
by	O
the	O
addition	O
of	O
MeOH.	B

The	O
most	O
prominent	O
findings	O
unique	O
to	O
WBC	O
were	O
the	O
positive	O
associations	O
with	O
lactate,	B
pyruvate,	B
sphingosine,	B
and	O
hexadecanedioate.	B

Several	O
studies	O
have	O
demonstrated	O
that	O
the	O
pathophysiology	O
of	O
postprandial	O
deregulated	O
metabolism,	O
especially	O
hyperglycaemia,	O
is	O
characterized	O
by	O
hyperglycaemic	B
spikes	O
that	O
induce	O
oxidative	O
stress	O
[,].	O

The	O
positions	O
of	O
the	O
HSQC	O
cross	O
peak	O
of	O
both	O
spermine	B
and	O
spermidine	B
showed	O
excellent	O
agreement	O
with	O
previously	O
published	O
data	O
after	O
adjusting	O
chemical	O
shift	O
reference.	O

Total	O
RNA	O
extracted	O
(2.5	O
µg)	O
was	O
retrotranscribed	O
to	O
cDNA	O
using	O
random	O
examers	O
and	O
the	O
Tetro	O
cDNA	O
synthesis	O
kit	O
from	O
Bioline	B
(Bioline,	I
Freiburg,	I
Germany),	I
according	O
to	O
the	O
manufacturer's	O
instructions	O
.	O

In	O
addition,	O
2,2,5,5‐tetramethyltetrahydrofuran	B
is	O
positively	O
correlated	O
with	O
an	O
ester	O
compound	O
(2,2‐dimethylpropionic	O
acid	O
butyl	O
ester).	O

(A)	O
QStar	O
Q-o-TOF	O
MS	O
total	O
ion	O
chromatogram	O
of	O
the	O
40%	O
ACN	O
plasma	O
fraction	O
containing	O
phenylbutyrate	B
(PB)	O
and	O
an	O
unknown	O
SPB	O
metabolite.	O

In	O
10	O
other	O
samples	O
containing	O
the	O
lowest	O
amounts	O
of	O
metformin,	B
no	O
IMZ	O
was	O
observed.	O

The	O
analysis	O
described	O
that	O
combined	O
urinary	O
urea	B
and	O
phenylacetylglutamine—two	O
readouts	O
of	O
nitrogen	O
metabolism—may	O
be	O
relevant	O
to	O
monitor	O
metabolic	O
status	O
in	O
the	O
course	O
of	O
disease.	O

Lower	O
levels	O
of	O
succinate	B
in	O
urinary	O
samples	O
after	O
the	O
meals	O
with	O
blueberries	O
(Variable	O
57,	O
)	O
with	O
respect	O
to	O
meals	O
without	O
blueberries	O
were	O
observed.	O

Thunalbene	B
was	O
not	O
observed	O
as	O
a	O
parent	O
compound	O
in	O
the	O
samples,	O
possibly	O
because	O
of	O
binding	O
to	O
the	O
matrix	O
or	O
polymerization.	O

The	O
mixture	O
was	O
loaded	O
onto	O
AFFINIMIP	O
cartridge,	O
previously	O
conditioned	O
with	O
3 mL	O
of	O
acetonitrile	B
and	O
3 mL	O
of	O
ultrapure	O
water.	O

Besides,	O
two	O
separate	O
pooled	O
lipemic	O
plasma	O
samples	O
with	O
triglycerides	B
levels	O
at	O
4.13	O
mmol/L	O
and	O
at	O
14.92	O
mmol/L	O
(Cobas	O
8000	O
Hitachi,	O
Roche	O
Diagnostic,	O
USA)	O
were	O
also	O
used	O
for	O
method	O
validation.	O

Prostaglandins	B
are	O
produced	O
through	O
the	O
COX	O
pathway,	O
and	O
leukotrienes	O
through	O
the	O
LOX	O
pathway.	O

Deaths	O
with	O
following	O
primary	O
or	O
contributory	O
causes	O
(ICD-10	O
codes)	O
were	O
defined	O
as	O
cardiovascular	O
deaths:	O
Rheumatic	O
fever	O
with	O
heart	O
involvement	O
(I01),	O
essential	O
hypertension	O
(I10),	O
rheumatic	O
mitral	O
valve	O
disease	O
(I05.9),	O
hypertensive	O
heart	O
disease	O
(I11.9),	O
hypertensive	O
chronic	O
kidney	O
disease	O
(I12.9),	O
ST	O
elevation	O
myocardial	O
infarction	O
(I21.3	O
and	O
I21.9),	O
atherosclerotic	O
heart	O
disease	O
of	O
native	O
coronary	O
artery	O
(I25.0	O
and	O
I25.1),	O
ischemic	O
cardiomyopathy	O
(I25.5),	O
chronic	O
ischemic	O
heart	O
disease	O
(I25.9),	O
diseases	O
of	O
pericardium	O
(I31.9),	O
hypertrophic	O
cardiomyopathy	O
(I42.2),	O
cardiomyopathy	O
(I42.9),	O
cardiac	O
arrest	O
(I46.9),	O
paroxysmal	B
tachycardia	O
(I47.2),	O
cardiac	O
arrythmia	O
(I49.9),	O
heart	O
failure	O
(I50.0),	O
heart	O
failure	O
(I50.9),	O
nontraumatic	O
intracerebral	O
hemorrhage	O
(I61.9	O
and	O
I62.0),	O
sequelae	O
of	O
nontraumatic	O
intracranial	O
hemorrhage	O
(I69.2	O
and	O
I69.4),	O
atherosclerosis	O
(I70.9),	O
peripheral	O
vascular	O
disease	O
(I73.9),	O
other	O
disorders	O
of	O
arteries	O
and	O
arterioles	O
(I77.6)	O
and	O
hypertension	O
(I95.9).	O

Accurate	O
mass	O
was	O
maintained	O
by	O
introduction	O
of	O
LockSpray	O
interface	O
of	O
Leucine-enkephalin	B
(556.2771	O
[M	O
+	O
H]	O
_+	O
or	O
554.2615	O
[M	O
−	O
H]	O
_−	O
)	O
at	O
a	O
concentration	O
of	O
2	O
pg	B
mL_−1	O
in	O
50%	O
aqueous	O
acetonitrile	B
and	O
a	O
rate	O
of	O
2	O
ml	O
min_−1	O
.	O

Four	O
purine	B
metabolites	O
were	O
decreased	O
in	O
veterans	O
with	O
GWI	O
and	O
contributed	O
to	O
12%	O
of	O
the	O
metabolic	O
impact.	O

The	O
body	O
mass	O
index	O
(BMI)	O
of	O
each	O
patient	O
and	O
serum	O
level	O
of	O
total	O
cholesterol	B
and	O
alkaline	O
phosphatase	O
were	O
determined.	O

We	O
found	O
significantly	O
decreased	O
levels	O
of	O
KYN	O
and	O
5-MIAA,	B
as	O
well	O
as	O
significantly	O
altered	O
KYN/TRP	O
ratio	O
in	O
the	O
plasma	O
samples	O
from	O
medication-free	O
MDD	O
patients.	O

Therefore,	O
small	O
decrease	O
in	O
plasma	O
glucose	B
levels	O
in	O
T3	O
might	O
be	O
attributed	O
with	O
depleting	O
glycogen	B
stores,	O
though	O
influence	O
of	O
diet	O
cannot	O
be	O
excluded.	O

A	O
third	O
possibility	O
is	O
that	O
serum	O
caffeine	B
and	O
theophylline	B
levels	O
are	O
associated	O
with	O
an	O
extraneous	O
factor	O
that	O
is	O
also	O
associated	O
with	O
decreased	O
risk	O
of	O
colorectal	O
cancer.	O

Up-regulation	O
of	O
homocysteine	B
in	O
PA	O
may	O
be	O
responsible	O
for	O
citotoxicity	O
and	O
oxidative	O
stress.	O

Tryptophan	B
depletion	O
by	O
TDO	O
in	O
IDO-negative	O
tumors	O
also	O
induces	O
signaling	O
events	O
in	O
T	O
cells,	O
leading	O
to	O
anergy	O
and	O
apoptosis.	O

Multiple	O
molecular	O
mechanisms,	O
both	O
intrinsic	O
and	O
extrinsic,	O
converge	O
to	O
alter	O
core	O
cellular	O
metabolism	O
and	O
provide	O
support	O
for	O
the	O
3	O
basic	O
needs	O
of	O
tumor	O
cells:	O
rapid	O
adenosine	B
triphosphate	I
(ATP)	O
generation	O
to	O
maintain	O
energy	O
status;	O
increased	O
biosynthesis	O
of	O
macromolecules;	O
and	O
tightened	O
maintenance	O
of	O
appropriate	O
cellular	O
redox	O
status.	O

There	O
are	O
several	O
reports	O
supporting	O
the	O
relationship	O
between	O
SL	B
and	O
airway	O
hyperreactivity.	O

Despite	O
this	O
supplementation,	O
tyrosine	B
was	O
significantly	O
lower	O
in	O
PKU	O
patients	O
which	O
may	O
contribute	O
to	O
neurotransmitter	O
depletion	O
and	O
impaired	O
brain	O
protein	O
synthesis	O
[,	O
,	O
,	O
].	O

Moreover,	O
a	O
significantly	O
enhanced	O
IDH1	O
expression	O
was	O
detected	O
in	O
AML	O
cells	O
with	O
DNMT3A	O
mutation,	O
which	O
could	O
lead	O
to	O
an	O
increased	O
production	O
of	O
α-KG	B
as	O
the	O
precursor	O
of	O
2-HG.	O

Receiver	O
operating	O
characteristic	O
(ROC)	O
curves	O
were	O
plotted	O
to	O
assess	O
disease	O
severity	O
(IC	O
vs.	O
CLI)	O
for	O
TMAO	B
[AUC:	O

These	O
results	O
indicate	O
that	O
lactate	B
plays	O
an	O
important	O
role	O
in	O
MUC16-	O
mediated	O
motility	O
and	O
invasiveness	O
of	O
pancreatic	O
cancer	O
cells.	O

Peak-pair	O
data	O
were	O
extracted	O
from	O
the	O
two	O
ion	O
chromatograms	O
according	O
to	O
a	O
characteristic	O
mass	O
difference	O
and	O
only	O
peak	O
pairs	O
with	O
the	O
same	O
retention	O
time	O
and	O
intensity	O
were	O
assigned	O
as	O
thiol	B
candidates.	O

For	O
instance,	O
search	O
of	O
the	O
LIPID	O
MAPS	O
database	O
for	O
m/z	O
313.2384	O
revealed	O
a	O
possible	O
29	O
theoretical	O
oxylipin	B
species	O
that	O
potentially	O
correspond	O
to	O
the	O
20	O
observed	O
features	O
at	O
that	O
mass.	O

In	O
UC,	O
high	O
disease	O
activity	O
was	O
associated	O
with	O
low	O
levels	O
of	O
urine	O
hippurate	B
and	O
3-hydroxyisovaleric	B
acid	I
(P	O
 = 8.0 × 10_–5	O
and	O
P	O
 = 1.4	O

As	O
expected,	O
the	O
TG,	B
TC	O
and	O
LDL-c	O
levels	O
in	O
the	O
HLP	O
subjects	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
the	O
healthy	O
control	O
group	O
(p	O
<	O
0.001),	O
whereas	O
the	O
HDL-c	O
level	O
of	O
the	O
HLP	O
subjects	O
was	O
lower	O
than	O
that	O
of	O
the	O
healthy	O
control	O
group	O
(p	O
<	O
0.001).	O

ALDH7A1-depletion	O
led	O
to	O
increased	O
levels	O
of	O
several	O
amino	O
acids,	O
fatty	O
acids	O
and	O
glucose,	B
while	O
NAD,	B
ATP	B
and	O
lactate	B
levels	O
were	O
lower	O
(Fig.	O

In	O
subsequent	O
analysis	O
by	O
BMI	O
groups	O
(low	O
vs	O
.	O
high),	O
valine	B
(2.1	O
±	O
0.5	O
vs	O
.	O

This	O
observation,	O
as	O
well	O
as	O
those	O
described	O
for	O
shikimic	B
acid	I
above,	O
suggests	O
that	O
variation	O
in	O
gut	O
microbiome	O
activity	O
can	O
contribute	O
to	O
mechanism	O
of	O
variation	O
in	O
response	O
to	O
simvastatin.	B

The	O
postprandial	O
changes	O
in	O
isoleucine	B
and	O
γ-aminobutyric	B
acid	I
(GABA)	O
during	O
the	O
OGTT	O
were	O
positively	O
associated	O
with	O
the	O
homeostasis	O
model	O
assessment	O
of	O
insulin	O
resistance	O
(HOMA-IR;	O
all	O
p	O
<	O
0.05)	O
in	O
the	O
HLP	O
group.	O

Indeed,	O
during	O
the	O
multistep	O
procedure	O
of	O
fixation	O
and	O
embedding	O
in	O
paraffin,	B
there	O
are	O
factors,	O
such	O
as	O
solvents	O
used	O
in	O
the	O
procedure	O
or	O
reactive	O
groups	O
of	O
certain	O
molecules,	O
which	O
can	O
affect	O
the	O
preservation	O
of	O
metabolites	O
that	O
survive	O
tissue	O
processing.	O

The	O
concentrations	O
of	O
2	O
metabolites,	O
ADMA	B
and	O
symmetric	B
dimethylarginine	I
(SDMA),	O
were	O
decreased	O
at	O
34	O
wk	O
in	O
the	O
+LNS	O
group	O
(Supplemental	O
Figure	O
1).	O

Further,	O
PR	O
−	O
patients	O
showed	O
higher	O
cytosolic	O
β-catenin	B
expression	O
than	O
PR+	O
patients.	O

Our	O
results	O
reflect	O
a	O
significant	O
uptake	O
pattern	O
of	O
glutamate	B
suggesting	O
that	O
glutamate	B
is	O
the	O
major	O
amino	O
acid	O
precursor,	O
primarily	O
as	O
a	O
nitrogen	O
donor,	O
in	O
the	O
synthesis	O
of	O
alanine	B
and	O
glutamine.	B

The	O
concentration	O
of	O
codeine	B
decreases	O
in	O
time	O
as	O
it	O
is	O
metabolized	O
to	O
morphine	B
and	O
the	O
concentration	O
of	O
morphine	B
increases,	O
leading	O
to	O
constantly	O
changing	O
ratio	O
of	O
the	O
two	O
opioids.	O

CHCl_3	O
:TEA	O
(45:45:10,	O
v/v/v)	O
and	O
transferred	O
to	O
a	O
96-well	O
vacuum	O
manifold	O
where	O
vacuum	O
suction	O
was	O
applied	O
for	O
the	O
elution	O
of	O
the	O
phospholipids	B
retained	O
in	O
the	O
first	O
step.	O

The	O
data	O
indicate	O
that	O
in	O
all	O
major	O
classes	O
(Cer,	O
MHC,	O
and	O
SM)	O
of	O
sphingolipids,	B
the	O
first/highest	O
subspecies	O
were	O
identical	O
between	O
healthy,	O
T1DM,	O
and	O
T2DM	O
samples.	O

Our	O
observations	O
reveals	O
an	O
inherent	O
uniqueness	O
since	O
alanine	B
and	O
pyruvate	B
levels	O
have	O
been	O
described	O
as	O
playing	O
important	O
role	O
in	O
manifestation	O
of	O
EH,	O
unlike	O
its	O
sub	O
types	O
or	O
variants.	O

PC	B
ae	I
C40:6;	I
115.	O

Although	O
the	O
functional	O
significance	O
of	O
these	O
changes	O
in	O
inflammatory	O
bowel	O
disease	O
(IBD)	O
is	O
not	O
known,	O
prior	O
studies	O
of	O
IDO	O
and	O
KYNA	O
suggest	O
that	O
these	O
components	O
of	O
the	O
KP	B
exert	O
significant	O
inflammatory	O
and	O
neurologic	O
effects.	O

Metabolites	O
have	O
a	O
wide	O
range	O
of	O
functional	O
groups	O
are	O
present	O
from	O
volatile	O
alcohols,	O
ketones,	B
amines,	O
organic	O
acids	O
to	O
complex	O
lipids,	O
carbohydrates	O
and	O
other	O
secondary	O
metabolites.	O

However,	O
the	O
Q-Q	O
test	O
indicated	O
that	O
taurine	B
was	O
not	O
normally	O
distributed	O
and	O
appears	O
to	O
be	O
normally	O
distributed	O
in	O
two	O
groups	O
(Figure	O
S3);	O
thus,	O
its	O
p	O
values	O
could	O
not	O
be	O
reported.	O

At	O
the	O
basal	O
status	O
before	O
the	O
ASA-BPT	O
test,	O
the	O
serum	O
S1P	O
level	O
was	O
positively	O
correlated	O
with	O
urine	O
sphingosine	B
level	O
(r	O
 = 0.408,	O
P	O
 < 0.001,	O
,	O
a1).	O

The	O
stock	O
solution	O
of	O
internal	O
standard	O
was	O
prepared	O
in	O
methanol	B
at	O
the	O
zileuton	O
concentration	O
of	O
0.1	O
μg/ml.	O

Phenyl	B
acetate	I
can	O
be	O
converted	O
to	O
phenylpyruvate	B
by	O
transamination	O
or	O
may	O
be	O
further	O
conjugated	O
with	O
glutamine	B
to	O
form	O
phenylacetyl	B
glutamine.	I

The	O
inhibition	O
of	O
butyrylcholinesterase	O
(BChE)	O
activity	O
by	O
paraoxon	O
is	O
due	O
to	O
the	O
formation	O
of	O
phosphorylated	O
BChE	O
adduct,	O
and	O
the	O
detection	O
of	O
the	O
phosphorylated	O
BChE	O
adduct	O
in	O
human	O
plasma	O
can	O
serve	O
as	O
an	O
exposure	O
biomarker	O
of	O
organophosphate	B
pesticides	O
and	O
nerve	O
agents.	O

Methionine	B
was	O
among	O
the	O
most	O
released	O
amino	O
acids	O
during	O
the	O
ripening	O
of	O
Appenzeller	O
cheese.	O

Here,	O
we	O
identified	O
AT-rich	O
interactive	O
domain	O
1 A	O
(ARID1A),	O
a	O
key	O
chromatin	B
remodeler,	O
as	O
being	O
hypomethylated	O
and	O
upregulated	O
by	O
α-OG	B
treatment.	O

Despite	O
a	O
plethora	O
of	O
risk	O
factors,	O
CLL	O
therapy	O
initiation	O
is	O
still	O
based	O
on	O
clinical	O
features	O
and	O
currently	O
the	O
diagnosis	O
of	O
CLL	O
does	O
not	O
always	O
lead	O
to	O
prompt	B
treatment	O
due	O
to	O
potentially	O
harmful	O
consequences	O
for	O
the	O
patient.	O

TB-DM	O
patients	O
were	O
further	O
characterized	O
by	O
lower	O
levels	O
of	O
glycine,	B
serine,	B
threonine	B
and	O
homoserine	B
compared	O
to	O
TB	O
patients,	O
which	O
were	O
similarly	O
unaffected	O
by	O
TB	O
treatment.	O

Urine	O
samples	O
were	O
collected	O
at	O
each	O
visit	O
and	O
analyzed	O
by	O
liquid	O
chromatography-tandem	O
mass	O
spectrometry	O
for	O
PGE-M,	O
8-iso	B
-PGF_2α	I
,	O
and	O
cotinine.	B

As	O
reported,	O
an	O
increase	O
in	O
valine	B
has	O
been	O
detected	O
in	O
cancer	O
tissue	O
due	O
to	O
increased	O
glycolysis.	O

Recently,	O
1-methylguanine	B
has	O
been	O
described	O
as	O
one	O
of	O
the	O
N-methyl	O
adducts	O
occurring	O
at	O
the	O
DNA,	O
which	O
are	O
repaired	O
by	O
the	O
adaptive	O
response	O
of	O
AlkB	O
enzyme	O
in	O
order	O
to	O
avoid	O
adverse	O
effect	O
of	O
these	O
DNA	O
lessions.	O

Hypoxia	O
and	O
acidic	O
pH	O
has	O
been	O
shown	O
to	O
regulate	O
choline	B
metabolism	O
in	O
a	O
human	O
prostate	O
cancer	O
xenograft	O
model	O
by	O
regulating	O
choline	B
kinase-α	O
expression	O
by	O
HIF1.	O

Our	O
comprehensive	O
platform	O
allows	O
the	O
quantitative	O
evaluation	O
of	O
approximately	O
100	O
oxylipins	B
down	O
to	O
low	O
nanomolar	O
levels.	O

The	O
low	O
level	O
of	O
glutamine,	B
a	O
key	O
metabolite	O
in	O
the	O
pathway	O
of	O
alanine,	B
aspartate	B
and	O
glutamate	B
metabolism	O
and	O
D-Glutamine	B
and	O
D-glutamate	B
metabolism,	O
was	O
observed	O
in	O
HAPE	O
subjects.	O

Muscle	O
biopsies	O
were	O
obtained	O
from	O
the	O
vastus	O
lateralis	O
of	O
the	O
dominant	O
leg	O
under	O
local	O
anaesthetic	O
[2–3	O
ml	O
of	O
2%	O
lidocaine	B
(Xylestesin)]	O
using	O
the	O
percutaneous	O
biopsy	O
technique	O
combined	O
with	O
suction.	O

,	O
women	O
WC ≥ 80 cm;	O
(2)	O
elevated	O
triglycerides:	B
≥2.3 mmol/	O

Cell	O
pellets	O
(≥2.5	O
×	O
10_6	O
cells)	O
were	O
washed	O
with	O
phosphate-buffered	B
saline,	I
flash	O
frozen	O
in	O
a	O
dry-ice	O
ethanol	B
bath	O
and	O
stored	O
at	O
−80°C.	O

Increased	O
taurine	B
levels	O
during	O
the	O
in-laboratory	O
session	O
might	O
result	O
from	O
inactivity	O
during	O
the	O
protocol.	O

Together	O
with	O
the	O
decreasing	O
tendency	O
of	O
trigonellinamide	B
(or	O
1-methylnicotinamide),	B
this	O
change	O
suggests	O
some	O
impairment	O
of	O
nicotinate	B
and	O
nicotinamide	B
metabolism.	O

However,	O
this	O
trend	O
was	O
not	O
significant	O
in	O
terms	O
of	O
BMI	O
and	O
LMI,	O
which	O
may	O
be	O
due	O
to	O
the	O
different	O
methods	O
used	O
to	O
reflect	O
the	O
body	O
composition,	O
while	O
the	O
association	O
between	O
Cer	B
and	O
obesity	O
is	O
consolidated.	O

Alpha-ketobutyrate	B
and	O
2-hydroxybutyrate,	B
degradation	O
products	O
of	O
threonine	B
and	O
methionine	B
metabolism,	O
were	O
highly	O
enriched	O
during	O
CM.	O

They	O
showed	O
that	O
urinary	O
taurine	B
immediately	O
increased	O
post-exercise,	O
whereas	O
after	O
24	O
h,	O
the	O
urinary	O
taurine	B
excretion	O
declined	O
to	O
slightly	O
lower	O
levels	O
than	O
baseline.	O

This	O
includes	O
a	O
number	O
of	O
molecules	O
that	O
are	O
normal	O
constituents	O
of	O
urine	O
such	O
as	O
thiols	B
and	O
isoflavones.	B

Overnight	O
bacterial	O
cultures	O
were	O
diluted	O
100-fold	O
in	O
appropriate	O
media	O
and	O
40	O
μL	O
were	O
dispensed	O
per	O
well	O
in	O
384-well	O
plates	O
(low	O
evaporation	O
lid,	O
Costar	O
3680)	O
containing	O
metabolites	O
or	O
DMSO	B
control.	O

By	O
implementation	O
of	O
these	O
key	O
excretion	O
metabolites	O
in	O
a	O
method	O
using	O
authentic	O
reference	O
standards,	O
it	O
is	O
possible	O
to	O
investigate	O
the	O
metabolism	O
of	O
a	O
certain	O
mycotoxin	B
as	O
successfully	O
exemplified	O
for	O
DON	O
in	O
vitro	O
and	O
in	O
vivo	O
[,	O
].	O

From	O
this	O
result	O
we	O
can	O
confirm	O
the	O
lack	O
of	O
de	O
novo	O
NAD_+	O
synthesis,	O
as	O
it	O
demonstrates	O
that	O
the	O
production	O
of	O
NAD_+	O
is	O
dependent	O
on	O
the	O
availability	O
of	O
exogenous	O
niacin.	B

Our	O
objective	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
exercise	O
on	O
premenopausal	O
estrogen	B
metabolism	O
pertinent	O
to	O
breast	O
cancer	O
risk.	O

The	O
FC	O
(fold	O
change)	O
of	O
citrulline,	B
valine,	B
and	O
acetoacetate	B
were	O
increasingly	O
changed	O
from	O
stage	O
I	O
to	O
stage	O
IV,	O
suggesting	O
the	O
expression	O
of	O
these	O
metabolites	O
were	O
growing	O
along	O
with	O
the	O
progression	O
of	O
gastric	O
cancer.	O

A	O
smaller	O
proportion	O
of	O
the	O
NP	O
tribal	O
population	O
were	O
CYP2A6	O
genotype	O
reduced	O
nicotine	B
metabolizers	O
compared	O
to	O
the	O
SW	O
tribal	O
population	O
(NP	O
27.5%	O
vs.	O
SW	O
41.8%,	O
P	O
=0.0006).	O

Of	O
the	O
BCAAs	O
and	O
3-HIB,	O
only	O
leucine	B
correlated	O
with	O
body	O
fat	O
percentage	O
(P	O
<	O
0.01,	O
R	O
=	O
0.3,	O
n	O
=	O
89).	O

Myristic	B
acid,	I
an	O
exogenous	O
saturated	O
fatty	O
acid	O
that	O
originates	O
from	O
dietary	O
uptake	O
and	O
is	O
involved	O
in	O
the	O
biological	O
process	O
of	O
energy	O
production	O
(,	O
),	O
was	O
increased	O
in	O
the	O
urine	O
of	O
the	O
low-grade	O
NMIBC	O
patients,	O
further	O
illustrating	O
the	O
lowered	O
level	O
of	O
fatty	O
acid	O
oxidation	O
in	O
the	O
low-grade	O
NMIBC	O
samples	O
vs.	O
the	O
controls.	O

Hydroxyanastrozole	B
glucuronide	I
and	O
hydroxyanastrozole	B
were	O
quantified	O
as	O
the	O
major	O
metabolites	O
of	O
anastrozole	B
in	O
plasma	O
of	O
breast	O
cancer	O
patients.	O

The	O
objective	O
of	O
the	O
study	O
was	O
to	O
investigate	O
whether	O
urinary	O
estrogens	O
and	O
estrogen	B
metabolites	O
are	O
associated	O
with	O
the	O
diversity	O
and	O
composition	O
of	O
the	O
fecal	O
microbiome.	O

CYPFAindex=ΣFA(epoxides)/parentfattyacid	B
CYPFAindex=ΣFA(epoxides)/parentfattyacid	I
CYPFAindex=ΣFA(epoxides)/parentfattyacid	I
CYPFAindex=ΣFA(epoxides)/parentfattyacid	I
CYPFAindex=ΣFA(epoxides)/parentfattyacid	I
CYPFA	O
CYPFA	O
CYP	O
CYP	O
CYP	O
FA	B
FA	I
FA	I
index	O
=	O

Concentrations	O
in	O
21	O
AAs	O
and	O
3	O
biogenic	O
amines	O
(asymmetric	O
dimethyl	B
arginine	I
[ADMA],	O
symmetric	O
dimethyl	B
arginine	I
[SDMA],	O
and	O
hydroxykynurenine	B
[OH-Kyn])	O
were	O
determined	O
by	O
liquid	O
chromatography	O
coupled	O
with	O
tandem	O
mass	O
spectrometry	O
with	O
electrospray	O
ionization	O
using	O
the	O
Absolute	O
IDQ	O
p180	O
Kit	O
(BIOCRATES	O
Life	O
Sciences	O
AG,	O
Innsbruck,	O
Austria).	O

All	O
samples	O
passed	O
these	O
criteria	O
except	O
1α,25(OH)_2	B
D_3	O
measurement	O
in	O
native	O
serum	O
after	O
SPE,	O
which	O
was	O
below	O
the	O
LLOQ	O
and	O
above	O
the	O
20%	O
precision	O
criterion.	O

c	O
a	O
d	O
Copy	O
number	O
and	O
single	O
nucleotide	O
variants	O
in	O
pyrimidine	B
metabolism	O
pathway	O
genes.	O

Other	O
gut-derived	O
phenolics	O
that	O
were	O
expected	O
from	O
consumption	O
of	O
the	O
blueberry	O
and	O
green	O
tea	O
supplement	O
such	O
as	O
gallic	B
acid,	I
coumaric	B
acid,	I
protocatechuic	B
acid,	I
and	O
quinic	B
acid	I
did	O
not	O
reach	O
detectable	O
levels	O
.	O

Superoxide	B
dismutase	O
(SOD)	O
activity	O
was	O
determined	O
following	O
standard	O
method.	O

Our	O
results	O
are	O
consistent	O
with	O
previous	O
analyses	O
of	O
a	O
cross-sectional	O
dataset	O
in	O
the	O
United	O
States	O
that	O
found	O
that	O
the	O
urinary	O
concentrations	O
of	O
several	O
phthalate	B
metabolites	O
were	O
associated	O
with	O
metabolic	O
effects	O
(;	O
).	O

The	O
choline	B
metabolites	O
are	O
interconverted	O
by	O
a	O
complex	O
network	O
of	O
reactions	O
termed	O
the	O
Kennedy	O
Pathway.	O

Identification	O
of	O
a	O
metformin–MG	O
scavenged	O
product	O
reveals	O
that	O
metformin	B
possesses	O
a	O
potential	O
secondary	O
mechanism	O
of	O
lowering	O
the	O
AGEs	O
and	O
MG	O
burden.	O

CFS	O
patients	O
did	O
not	O
have	O
an	O
increase	O
in	O
plasma	O
ADMA.	B

N-acetylaspartate	B
was	O
associated	O
with	O
autophagy	O
and	O
histone	O
acetylation	O
in	O
non-small	O
cell	O
lung	O
cancer	O
and	O
impacted	O
cell	O
survival	O
(,).	O

β-actin	B
was	O
used	O
as	O
a	O
loading	O
control.	O

We	O
found	O
increased	O
levels	O
of	O
a	O
breakdown	O
product	O
of	O
N1-acetylspermidine,	B
acisoga.	B

In	O
T2DM,	O
C24:1	B
was	O
highest,	O
C16:0	B
was	O
second	O
highest,	O
followed	O
by	O
C24:0,	B
and	O
C22:0.	B

The	O
pathways	O
were	O
identified	O
based	O
on	O
significantly	O
altered	O
metabolites	O
listed	O
in	O
Table 	O
and	O
6	O
(with	O
exception	O
to	O
the	O
lipid	O
metabolites	O
and	O
glycoproteins	B
(NAG)).	O

The	O
pattern	O
of	O
declining	O
fasting	O
plasma	O
glucose	B
and	O
pentose	B
phosphate	I
pathway	O
intermediates	O
(gluconate,	O
xylonate)	O
in	O
the	O
present	O
study	O
suggests	O
that	O
postabsorptive	O
carbohydrate	O
availability	O
may	O
be	O
reduced	O
even	O
when	O
short	O
sleep	O
occurs	O
in	O
combination	O
with	O
a	O
weight-maintenance	O
diet.	O

The	O
concentration	O
of	O
4,4-dimethyl-4-silapentane-1-sulfonic	B
acid	I
was	O
used	O
as	O
a	O
reference	O
to	O
determine	O
metabolite	O
concentrations	O
during	O
targeted	O
profiling	O
(Chenomx	O
NMR	O
Suite	O
7.1;	O
Chenomx	O
Inc.,	O
Edmonton,	O
AB,	O
Canada).	O

Go	O
to:	O
Statins,	B
HMG-CoA	O
reductase	O
inhibitors,	O
are	O
considered	O
the	O
first	O
line	O
treatment	O
of	O
hyperlipidemia	O
to	O
reduce	O
the	O
risk	O
of	O
atherosclerotic	O
cardiovascular	O
diseases.	O

Urea	B
was	O
removed	O
from	O
the	O
urine	O
and	O
serum	O
data	O
sets	O
because	O
its	O
signal	O
was	O
compromised	O
by	O
the	O
water	O
suppression	O
used	O
in	O
the	O
CMPG	O
and	O
NOESY	O
pulse	O
sequences.	O

Thus,	O
glutamate	B
accumulation	O
in	O
the	O
liver	O
stimulates	O
gluconeogenesis	O
and	O
contributes	O
to	O
the	O
development	O
of	O
glucose	B
intolerance,	O
as	O
described	O
by	O
Newgard	O
et	O
al.	O
for	O
obese	O
subjects.	O

The	O
affinities	O
of	O
β-apo-14′-carotenal	B
and	O
β-apo-14′-carotenoic	B
acid	I
for	O
RXRα	O
were	O
>250	O
nm	O
in	O
keeping	O
with	O
their	O
lack	O
of	O
effect	O
on	O
inhibiting	O
RXR	O
transactivation.	O

Although	O
(25R)26-HC	B
and	O
7αH,3O-CA	B
were,	O
like	O
25-HC,	O
also	O
found	O
to	O
be	O
reduced	O
(P	O
 < 0.05)	O
in	O
RRMS	O
plasma	O
(Fig.	O
),	O
the	O
latter	O
is	O
not	O
known	O
to	O
bind	O
to	O
INSIG,	O
while	O
neither	O
sterol	O
is	O
formed	O
by	O
IFN-activated	O
macrophages	O
to	O
any	O
significant	O
extent.	O

Post-hoc	O
Mann	O
Whitney	O
U	O
tests	O
were	O
conducted	O
to	O
compare	O
aspartame	B
and	O
no	O
aspartame	B
bars	O
in	O
each	O
session.	O

However,	O
lactate,	B
Leu/Ile,	O
unsaturated	O
fatty	O
acid,	O
glutamine	B
and	O
β-glucose	B
levels	O
were	O
significantly	O
lower	O
in	O
FD	B
patients.	O

Plasma	O
lipid	O
extracts	O
were	O
reconstituted	O
in	O
200	O
μL	O
of	O
isopropanol.	B

Cannabinoids	B
concentrations	O
in	O
urine	O
collected	O
from	O
a	O
participant	O
after	O
vaporizing	O
a	O
single	O
54	O
mg	O
THC	O
dose	O
ad	O
libitum	O
over	O
10	O
minutes.	O

For	O
the	O
400	O
MHz	O
spectrum,	O
the	O
four	O
integration	O
regions	O
from	O
left	O
to	O
right	O
aim	O
to	O
capture	O
the	O
signal	O
corresponding	O
to	O
(1)	O
cysteine,	B
lysine,	B
and	O
tyrosine;	B
(2)	O
cysteine,	B
lysine,	B
tyrosine,	B
and	O
creatinine;	B
(3)	O
cysteine,	B
lysine,	B
tyrosine,	B
creatinine,	B
and	O
creatine;	B
and	O
(4)	O
cysteine,	B
lysine,	B
tyrosine,	B
and	O
α	B
-ketoglutarate.	I

Analytes	O
were	O
eluted	O
with	O
3	O
mL	O
dichloromethane/2-propanol/ammonium	O
hydroxide	B
(78:20:2,	I
v	I
/v	I
).	I

These	O
pathways	O
are	O
associated	O
with	O
amino	O
acid	O
metabolism	O
and	O
the	O
pentose	B
phosphate	I
pathway.	O

To	O
our	O
knowledge,	O
this	O
study	O
is	O
the	O
first	O
to	O
confirm	O
that	O
glutamic	B
acid	I
and	O
glutamine	B
are	O
closely	O
related	O
to	O
DR	O
outcome	O
in	O
humans.	O

This	O
is	O
in	O
contrast	O
to	O
a	O
recent	O
report	O
on	O
glioblastoma	O
cells,	O
in	O
which	O
more	O
than	O
95%	O
of	O
the	O
glucose	B
consumed	O
was	O
converted	O
to	O
lactate	B
and	O
Ala.	O

Finally,	O
the	O
acyl	O
chains	O
were	O
identified	O
by	O
their	O
representative	O
fragment	O
ion:	O
(i)	O
in	O
positive	O
ionization:	O
sphingolipids:	B
RCN_+	O
(e.g.	O
264.269	O
for	O
d18:1)	B
and	O
for	O
glycerolipids:	B
from	O
the	O
loss	O
of	O
RCOO;	O
and	O
(ii)	O
in	O
negative	O
ionization:	O
glycerophospholipids:	B
RCOO_−	O
(e.g.	O
281.247	O
for	O
18:1	O
acyl	O
chain).	O

Only	O
2	O
metabolites	O
were	O
depleted,	O
cysteine	B
and	O
inosine.	B

Prominently,	O
three	O
branched-chain	O
amino	O
acids	O
(leucine,	O
isoleucine,	B
and	O
valine)	B
displayed	O
low	O
concentrations	O
in	O
NDMM	O
patients,	O
indicating	O
a	O
possible	O
higher	O
consumption	O
of	O
these	O
metabolites	O
(uptake	O
by	O
the	O
MM	O
cells	O
in	O
the	O
bone	O
marrow).	O

Sorbitol	B
has	O
also	O
been	O
shown	O
to	O
have	O
a	O
strong	O
copper-chelating	O
action,	O
thus	O
high	O
sorbitol	B
levels	O
in	O
WD	O
patients	O
could	O
help	O
maintain	O
cellular	O
homeostasis	O
by	O
attempting	O
chelation	O
of	O
excess	O
copper.	O

Dice	O
coefficient	O
pairwise	O
comparisons	O
of	O
total	O
bacteria	O
(using	O
universal	O
bacterial	O
primers)	O
and	O
Bacteroidetes	O
,	O
Bifidobacterium	O
,	O
Clostridium	O
coccoides	O
and	O
Lactobacillus	B
groups	O
in	O
the	O
IBS	O
versus	O
nIBS	O
faecal	O
community.	O

Consistently,	O
metabolic	O
validation	O
studies	O
confirmed	O
decreased	O
levels	O
of	O
glutamate	B
levels	O
in	O
these	O
tumors.	O

Routine	O
targeted	O
metabolic	O
diagnostics	O
revealed	O
a	O
severely	O
decreased	O
plasma	O
l-carnitine	B
(1.5	O
µmol/L,	O
reference	O
range	O
21.6–57.4	O
µmol/L).	O

Caffeine,	B
which	O
is	O
metabolized	O
in	O
the	O
liver	O
by	O
the	O
cytochrome	O
P450	O
oxidase	O
enzyme	O
system	O
into	O
theophylline	B
and	O
paraxanthine	B
(,	O
),	O
may	O
directly	O
reduce	O
colorectal	O
cancer	O
risk.	O

We	O
observed	O
significantly	O
lower	O
macrophage	O
inflammatory	O
protein-1α	B
in	O
moderate	O
cannabis	B
users	O
compared	O
to	O
levels	O
in	O
noncannabis	O
users	O
(P	O
=	O
.022;	O
),	O
but	O
no	O
evidence	O
of	O
a	O
dose-response	B
effect.	O

The	O
observed	O
similarities	O
in	O
the	O
variations	O
of	O
histidine,	B
unsaturated	O
fatty	O
acids	O
and	O
protein	O
levels	O
suggest	O
that	O
such	O
variations	O
may	O
be	O
a	O
global	O
reflection	O
of	O
the	O
disease,	O
possibly	O
transversal	O
to	O
different	O
cohorts	O
and,	O
therefore,	O
with	O
potential	O
value	O
in	O
contributing	O
to	O
the	O
current	O
knowledge	O
of	O
the	O
biology	O
of	O
AMD.	O

In	O
the	O
current	O
study,	O
cytidine,	B
the	O
most	O
strongly	O
retained	O
of	O
the	O
nucleobases	O
tested,	O
only	O
eluted	O
from	O
the	O
amide	B
column	O
when	O
5%	O
water	O
was	O
used	O
as	O
an	O
additive:	O
this	O
supports	O
the	O
findings	O
of	O
Taylor	O
and	O
other	O
groups,	O
and	O
suggests	O
that	O
water	O
could	O
be	O
used	O
in	O
combination	O
with	O
other	O
additives	O
to	O
improve	O
separation	O
of	O
the	O
most	O
polar	O
analytes	O
,	O
.	O

1,25(OH)_2	B
D	O
correlated	O
weakly	O
with	O
25(OH)D	O
(Kendall's	O
τ	O
=	O
0.16),	O
whereas	O
24,25(OH)_2	B
D	O
correlated	O
strongly	O
with	O
both	O
total	O
25(OH)D	O
and	O
25(OH)D_3	O
(τ	O
=	O
0.70	O
and	O
τ	O
=	O
0.73,	O
respectively).	O

Ultimately	O
we	O
elected	O
to	O
use	O
the	O
concentrations	O
of	O
3-epi-25(OH)D_3	B
determined	O
by	O
the	O
NIST	O
LC-MS/MS	O
method	O
to	O
adjust	O
the	O
25(OH)D_3	O
concentrations	O
determined	O
by	O
the	O
NIST	O
LC-MS	O
method	O
employing	O
a	O
C_18	O
column	O
and	O
those	O
determined	O
by	O
the	O
CDC	O
LC-MS/MS	O
method.	O

Pancreatic	O
cancer	O
tissue	O
had	O
a	O
unique	O
profile	O
showing	O
decreased	O
levels	O
of	O
phosphocholine	B
and	O
glycerophosphocholine,	B
but	O
not	O
choline	B
(Fang	O
et	O
al.	O
).	O

The	O
creatinine	B
is	O
a	O
standard	O
manner	O
to	O
normalize	O
the	O
concentrations	O
of	O
urine	O
sample	O
since	O
the	O
excretion	O
of	O
creatinine	B
is	O
rather	O
constant	O
over	O
a	O
longer	O
time	O
interval.	O

Triglycerides,	B
HDL	B
cholesterol,	I
total	O
cholesterol	B
and	O
fasting	O
glucose	B
were	O
determined	O
at	O
the	O
Calgary	O
Laboratory	O
Services	O
using	O
established	O
protocols	O
and	O
fasting	O
whole	O
blood.	O

However,	O
recent	O
studies	O
indicate	O
that	O
high	O
concentrations	O
of	O
arginine	B
can	O
increase	O
oxidative	O
stress	O
in	O
the	O
general	O
population.	O

Plasma	O
samples	O
were	O
prepared	O
by	O
deproteinization	O
with	O
methanol	B
as	O
well	O
as	O
defatting	O
with	O
tert-butyl	B
methyl	I
ether	I
in	O
order	O
to	O
reduce	O
instrument	O
contamination	O
during	O
the	O
prolonged	O
measurements.	O

Synthetic	O
phosphopeptides	B
Pp60	O
c-src	O
and	O
P60	O
c-src	O
were	O
purchased	O
from	O
American	O
Peptide	O
Company	O
(Sunnyvale,	O
CA).	O

These	O
results	O
taken	O
together	O
merit	O
continued	O
metabolomics	O
investigation	O
of	O
short-chain	O
fatty	O
acids	O
in	O
the	O
context	O
of	O
CRC	O
pathogenesis	O
and	O
prevention,	O
specifically	O
valerate	B
[–].	O

Lipidomic	O
profiling	O
was	O
applied	O
to	O
identify	O
altered	O
lipids	O
in	O
plasma	O
from	O
patients	O
with	O
AF	B
using	O
ultra-performance	O
liquid	O
chromatography/quadrupole	O
time-of-flight	O
mass	O
spectrometry	O
coupled	O
with	O
multivariate	O
statistical	O
analysis.	O

Interestingly,	O
higher	O
cysteine	B
values	O
are	O
associated	O
with	O
obesity	O
–.	O

Nonpolar	O
lipid	O
metabolites	O
were	O
extracted	O
from	O
20	O
μL	O
of	O
serum	O
in	O
3	O
ml	O
of	O
2:1	O
chloroform:methanol	O
and	O
1	O
ml	O
of	O
PBS	O
with	O
inclusion	O
of	O
internal	O
standards	O
dodecylglycerol	B
(10	O
nmol)	O
and	O
pentadecanoic	B
acid	I
(10	O
nmol).	O

Sphingolipids	B
are	O
a	O
class	O
of	O
lipids	O
with	O
important	O
functions	O
in	O
cell	O
structure	O
and	O
signalling,	O
and	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
metabolic	O
syndrome.	O

Reported	O
are	O
the	O
results	O
of	O
three	O
multivariable	O
regression	O
models	O
(one	O
for	O
each	O
cohort),	O
with	O
circulating	O
24,25(OH)_2	B
D_3	O
concentration	O
as	O
dependent	O
variable.	O

For	O
example,	O
it	O
is	O
unclear	O
whether	O
the	O
doublet	O
of	O
C2,5	O
of	O
citrate	B
represents	O
_13	O
C1,_13	O
C2/_13	O
C5,_13	O
C6,_13	O
C2,_13	O
C3/_13	O
C3,_13	O
C5	O
or	O
both	O
(cf.	O
for	O
numbering	O
of	O
citrate).	O

Both	O
TIC	O
chromatograms	O
show	O
separation	O
of	O
the	O
nucleobase	O
test	O
mixture	O
(1:caffeine,	O
2:uracil,	O
3:adenosine,	O
4:cytosine	O
and	O
5:cytidine)	O
using	O
20 mM	O
ammonium	B
formate	I
in	O
methanol	B
as	O
a	O
modifier	O
at	O
the	O
relevant	O
temperature,	O
using	O
the	O
7.35 min	O
gradient	O
described	O
in	O
Section	O
2.3.4.	O

Patient	O
characteristics	O
(shown	O
as	O
the	O
median	O
and	O
range)	O
were:	O
age	O
(53	O
years;	O
31–72	O
years),	O
weight	O
(71	O
kg;	O
51–107	O
kg),	O
height	O
(168	O
cm;	O
154–184	O
cm),	O
body	O
surface	O
area	O
(1.79	O
m_2	O
;	O
1.51–2.30	O
m_2	O
),	O
total	O
bilirubin	B
(0.2	O
mg/dL;	O
0.1–0.8	O
mg/dL),	O
aspartate	O
aminotransferase	O
(22	O
IU/L,	O
12–76	O
IU/L),	O
and	O
alanine	O
aminotransferase	O
(30	O
IU/L,	O
7–49	O
IU/L),	O
and	O
serum	O
creatine	B
(0.8	O
mg/dL;	O
0.4–1.2	O
mg/dL).	O

Acetone,	B
acetate,	B
ethanol,	B
and	O
methanol	B
were	O
also	O
detected	O
but	O
were	O
excluded	O
from	O
analysis	O
as	O
they	O
are	O
volatile	O
and	O
samples	O
were	O
dried	O
by	O
lyophilization.	O

For	O
instance,	O
one	O
of	O
the	O
76	O
metabolites	O
reported	O
by	O
Jiye	O
et	O
al.	O
was	O
butylamine.	B

Taurine	B
was	O
decreased	O
13%	O

Notable	O
upregulation	O
of	O
glycerol	B
(p	O
<	O
0.01),	O
which	O
is	O
another	O
precursor	O
of	O
triglyceride	B
(TG)	O
synthesis	O
other	O
than	O
FFAs,	O
was	O
observed	O
in	O
R_AT	O
patients	O
compared	O
with	O
NR_AT	O
patients.	O

Notably,	O
the	O
rate	O
of	O
nicotine	B
metabolism	O
was	O
higher	O
in	O
NP	O
compared	O
to	O
SW	O
smokers	O
(P	O
=0.03),	O
and	O
in	O
comparison	O
to	O
other	O
ethnic	O
groups	O
in	O
the	O
United	O
States.	O

When	O
considered	O
together,	O
pyroglutamic	B
acid,	I
serine,	B
phenylalanine,	B
galactose,	B
palmitic	B
acid,	I
2,3,4-trihydroxybutyrate,	B
linoleic	B
acid,	I
citric	B
acid	I
and	O
arachidonic	B
acid	I
could	O
serve	O
as	O
a	O
potential	O
biomarker	O
panel	O
diagnosing	O
of	O
TBI	O
patients	O
with	O
cognitive	O
impairment.	O

Glutamine	B
uptake	O
is	O
also	O
linked	O
with	O
the	O
immune	O
system,	O
since	O
several	O
T	O
cell	O
metabolic	O
processes	O
require	O
it.	O

This	O
effect	O
is	O
compounded	O
by	O
the	O
conversion	O
of	O
citrate	B
to	O
acetyl	O
CoA	O
by	O
the	O
enzyme	O
ATP	B
citrate	I
lyase	O
;	O
an	O
effect	O
that	O
is	O
likely	O
to	O
contribute	O
to	O
the	O
NMR-observable	O
increases	O
in	O
plasma	O
acetate.	B

Of	O
the	O
known	O
metabolites,	O
4-hydroxymandelic	B
acid,	I
glutaric	B
acid,	I
creatinine,	B
N-acetylaspartic	B
acid,	I
and	O
sedoheptulose	B
show	O
higher	O
concentrations	O
in	O
younger	O
men,	O
whereas	O
2,5-furandicarboxylic	B
acid,	I
hippuric	B
acid,	I
citric	B
acid,	I
3-aminoisobutyric	B
acid,	I
and	O
quinolinic	B
acid	I
show	O
a	O
higher	O
concentration	O
in	O
older	O
men.	O

As	O
shown	O
in	O
Figure ,	O
the	O
disturbed	O
metabolic	O
pathway	O
included	O
glycolysis	O
(glucose,	O
lactate),	O
tricarboxylic	B
acid	I
cycle	O
(succinate),	O
choline	B
metabolism	O
(TMAO,	O
DMA,	B
methylamine,	B
betaine,	B
dimethylgcine,	B
sarcosine,	B
creatine	B
and	O
phosphocreatine),	B
ketone	B
body	O
(acetoacetate,	O
β-hydroxybutyrate	B
and	O
acetone)	O
and	O
amino	O
acid	O
metabolism	O
(serine	O
and	O
glycine).	B

The	O
combined	O
effluent	O
(5	O
ml)	O
was	O
diluted	O
with	O
water	O
(4	O
ml)	O
to	O
give	O
9	O
ml	O
of	O
∼35%	O
methanol.	B

Finally,	O
Cox	O
proportional	O
hazard	O
models	O
were	O
used	O
to	O
investigate	O
the	O
association	O
between	O
prioritised	O
metabolites	O
and	O
type	O
2	O
diabetes	O
risk	O
after	O
adjusting	O
for	O
age,	O
sex,	O
BMI,	O
fasting	O
glucose	B
and	O
fasting	O
TAG	O
at	O
baseline.	O

Levels	O
of	O
arginine-NO	B
metabolites	O
(Arg-Ms:	O
arginine,	B
ornithine,	B
citrulline,	B
asymmetric	B
dimethylarginine,	I
and	O
symmetric	O
dimethylarginine)	B
were	O
related	O
to	O
indexes	O
of	O
RV-PV	O
dysfunction	O
(,	O
).	O

Since	O
atractyligenin	O
glucuronide	B
is	O
not	O
commercially	O
available,	O
we	O
tested	O
the	O
performance	O
of	O
a	O
combination	O
of	O
cyclo(isoleucyl-prolyl),	O
1-methylxanthine	B
and	O
trigonelline,	B
the	O
three	O
best	O
candidate	O
biomarkers	O
commercially	O
available.	O

Blood	O
was	O
centrifuged	O
immediately	O
(10	O
minutes,	O
2000	O
g	O
at	O
4°C)	O
and	O
plasma	O
was	O
aliquoted	O
into	O
separate	O
polypropylene	B
tubes	O
that	O
were	O
immediately	O
stored	O
at	O
-80°C.	O

In	O
addition	O
to	O
glutamate;	B
aspartate	B
and	O
serine	B
displayed	O
consistent	O
uptake	O
patterns	O
as	O
well,	O
with	O
significantly	O
decreased	O
levels	O
in	O
venous	O
vs.	O
arterial	O
plasma	O
while	O
alanine,	B
glutamine	B
and	O
phenylalanine	B
together	O
with	O
lactate,	B
succinate,	B
malate	B
and	O
sialic	B
acid	I
exhibited	O
a	O
consistent	O
release	O
pattern	O
with	O
significantly	O
increased	O
levels	O
in	O
venous	O
vs.	O
arterial	O
plasma	O
(	O
and	O
).	O

Dipeptides	O
of	O
hydroxyproline	B
might	O
be	O
derived	O
from	O
the	O
process	O
of	O
disseminating	O
tumor	O
cells,	O
degrading	O
collagen	O
during	O
the	O
process	O
of	O
early	O
metastasis,	O
although	O
the	O
definitive	O
origin	O
of	O
the	O
metabolite	O
remains	O
to	O
be	O
determined.	O

For	O
example,	O
creatinine	B
was	O
seen	O
to	O
decrease	O
in	O
the	O
urine	O
of	O
liver	O
cancer	O
patients	O
compared	O
with	O
healthy	O
controls	O
as	O
detected	O
by	O
MS.	O

Each	O
plate	O
was	O
conditioned	O
sequentially	O
with	O
1	O
mL	O
of	O
MeOH,	B
1	O
mL	O
of	O
CH_3	O
CN	O
and	O
3	O
mL	O
of	O
50	O
mM	O
potassium	B
phosphate	I
buffer,	O
pH	O
3.	O

Particular	O
attention	O
should	O
be	O
paid	O
to	O
the	O
strong	O
decrease	O
of	O
branched-chain	O
amino	O
acids	O
(BCAAs):	O
leucine/isoleucine	O
and	O
valine	B
(Fig. ).	O

As	O
creatine	B
and	O
creatinine	B
are	O
well-studied	O
metabolites,	O
the	O
use	O
of	O
more	O
targeted	O
methods	O
to	O
measure	O
them	O
as	O
well	O
as	O
their	O
ratio	O
in	O
future	O
studies	O
may	O
also	O
provide	O
additional	O
validation	O
for	O
our	O
results.	O

Compared	O
with	O
CIN	O
and	O
NC,	O
CSCC	O
group	O
showed	O
significant	O
increases	O
in	O
low-density	O
lipoprotein	O
(LDL),	O
lactate,	B
and	O
alanine	B
and	O
decreases	O
in	O
α-	O
and	O
β-glucose,	B
tyrosine,	B
and	O
phenylalanine.	B

We	O
obtained	O
evidence	O
that	O
the	O
leading	O
GWAS	O
SNP	O
for	O
carnitine	B
(rs1171614)	O
influenced	O
the	O
expression	O
of	O
SLC16A9	O
in	O
lymphoblasts	O
(P-value	O
 = 8.91×10_−6	O
)	O
and	O
rs8056893	O
(associated	O
with	O
lysine)	B
influenced	O
the	O
expression	O
of	O
ZPF90	O
in	O
lymphoblasts	O
(P-value	O
 = 4.01×10_−6	O
)	O
and	O
SLC7A9	O
in	O
thyroid	O
cells	O
(P-value	O
 = 0.00008).	O

Preoperatively,	O
the	O
patient	O
was	O
examined	O
using	O
in	O
vivo	O
single	O
vortex	O
_1	O
H-MRS,	O
and	O
a	O
high	O
peak	O
of	O
choline	B
was	O
noticed	O
(Table	O
).	O

Chemiluminescence	O
using	O
the	O
automated	O
Immulite	O
Analyzer	O
(Diagnostic	O
Products	O
Co,	O
Los	O
Angeles,	O
CA,	O
USA)	O
was	O
used	O
to	O
measure	O
serum	O
cortisol	B
levels.	O

Thus,	O
it	O
can	O
be	O
assumed	O
that	O
a	O
method	O
allowing	O
a	O
good	O
recovery	O
rate	O
of	O
both	O
polar	O
oxylipins	B
such	O
as	O
prostanoids	B
(e.g.,	O
PGE_2	O
)	O
and	O
less	O
polar	O
hydroxy-PUFA	B
(e.g.,	O
5-HETE)	O
is	O
also	O
appropriate	O
for	O
the	O
extraction	O
of	O
SPMs.	O

Distribution	O
of	O
numbers	O
of	O
errors	O
(based	O
on	O
1,000	O
re-sampling	O
iterations)	O
for	O
the	O
24	O
acetaminophen	B
OPLS-DA	O
prediction	O
models	O
for	O
spectra	O
with	O
acetaminophen	B
metabolites	O
is	O
shown	O
in	O
;	O
for	O
spectra	O
without	O
acetaminophen	B
metabolites	O
in	O
.	O

Peptide	O
adducts	O
observed	O
at	O
11.4	O
min	O
displayed	O
triply	O
charged	O
ions	O
[M+3H]_3+	O
at	O
m/z	O
517.8	O
and	O
519.7,	O
which	O
are	O
an	O
addition	O
mass	O
of	O
207	O
and	O
212	O
Da	O
to	O
the	O
protonated	O
peptide	O
LQQCPFEDHVK	O
(m/z	O
1343.6,	O
residues	O
31–41	O
of	O
SA)	O
with	O
a	O
missed	O
cleavage	O
at	O
C-terminal	O
of	O
phenylalanine.	B

The	O
relatively	O
low	O
level	O
of	O
lactate	B
is	O
markedly	O
different	O
from	O
observations	O
in	O
other	O
types	O
of	O
cancer	O
where,	O
commonly,	O
lactate	B
levels	O
are	O
high	O
(,,).	O

Choline	B
and	O
betaine,	B
as	O
major	O
methyl	O
donors	O
in	O
one-carbon	O
metabolism	O
(Zeisel	O
and	O
Blusztajn	O
),	O
may	O
be	O
involved	O
in	O
carcinogenesis,	O
such	O
as	O
colorectal,	O
breast,	O
lung	O
and	O
liver	O
cancer	O
(Lu	O
et	O
al.	O
;	O

An	O
in	O
vivo	O
study	O
evaluated	O
uridine	B
homeostasis	O
in	O
liver	O
tissue	O
and	O
its	O
impact	O
on	O
hepatic	O
cellular	O
function.	O

Finally,	O
both	O
N-methyl	B
nicotinate	I
and	O
hydroquinone	B
(HQ)	O
urinary	O
levels	O
tended	O
to	O
be	O
associated	O
with	O
a	O
possible	O
beneficial	O
effect	O
against	O
liver	O
steatosis,	O
already	O
signaled	O
in	O
adult	O
NAFLD,	O
in	O
keeping	O
with	O
a	O
cytoprotective	O
role.	O

Further	O
studies	O
are	O
necessary	O
to	O
confirm	O
these	O
results	O
and	O
to	O
light	O
up	O
the	O
impact	O
of	O
menstrual	O
cycle	O
also	O
on	O
the	O
urinary	O
excretion	O
of	O
progesterones,	B
estrogens,	O
corticosterones,	B
and	O
mineralocorticoids.	O

(18:2),	O
PC	B
(36:2),	I
PC	B
(32:0),	I
SM	B
(16:0),	I
PC	B
(36:3),	I
PC	B
(38:4),	I
PC	B
(34:1)	I
in	O
MF	O
patients	O
compared	O
to	O
control	O
subjects	O
(Figure	O
).	O

Our	O
previous	O
study	O
also	O
revealed	O
a	O
relationship	O
between	O
fumarate	B
excess	O
and	O
salt-induced	O
hypertension	O
[,].	O

For	O
the	O
whole	O
population,	O
3-HIB	O
correlated	O
with	O
acetoacetate	B
(P	O
<	O
0.001,	O
R	O
=	O
0.386,	O
n	O
=	O
232).	O

Thus,	O
we	O
cannot	O
exclude	O
that	O
changes	O
of	O
at	O
least	O
some	O
kynurenine	B
metabolites	O
we	O
have	O
found	O
in	O
CM	O
patients	O
originate	O
in	O
the	O
liver	O
and	O
other	O
organs	O
rather	O
than	O
in	O
the	O
CNS.	O

Observed	O
variations	O
in	O
estrogen	B
metabolism	O
may	O
modify	O
breast	O
cancer	O
risk.	O

Here	O
we	O
determined	O
the	O
relationships	O
of	O
PLTP	O
and	O
LCAT	O
activity	O
with	O
betaine	B
in	O
subjects	O
with	O
and	O
without	O
T2DM.	O

The	O
activity	O
of	O
antioxidant	O
enzymes	O
such	O
as	O
GSH	B
reductase	O
and	O
glutathione	B
peroxidase	O
in	O
MS	O
patients	O
was	O
shown	O
to	O
be	O
modified.	O

Arg	O
Arg	O
Met;	O
COM261:	O
Creatine;	B
COM330:	O
Formylmethionyl-leucyl-phenylalanine	B
methyl	I
ester;	I
COM465:	O
m-Coumaric	B
acid;	I
COM507:	O

The	O
two	O
analytical	O
approaches	O
(enzymatic	O
digestion	O
vs.	O
sum	O
of	O
the	O
glucuronide	B
concentrations)	O
employed	O
in	O
plasma	O
samples	O
have	O
been	O
statistically	O
compared	O
by	O
NCSS	O
as	O
shown	O
in	O
Fig.	O

3α,5β-Tetrahydroaldosterone	B
(THAldo)	O
represents	O
the	O
major	O
mineralocorticoid	O
metabolite.	O

However,	O
the	O
addition	O
of	O
arachidonyl	O
lysolecithin	O
and	O
dioleoylphosphatidylcholine	B
improves	O
the	O
model	O
significantly	O
with	O
a	O
new	O
calculated	O
sensitivity	O
and	O
specificity	O
of	O
92%	O
and	O
95%,	O
respectively,	O
and	O
an	O
AUROC	O
of	O
0.93.	O

NADPH,	B
NADH,	B
glucose-6-phosphate,	B
uridine-5′-diphosphoglucuronic	B
acid	I
(UDPGA),	O
glucose-6-phosphate	O
dehydrogenase,	O
alamethicin,	B
and	O
NH_4	O
OH	O
solution	O
(25%)	O
were	O
from	O
Sigma	O
(St.	O
Louis,	O
MO).	O

Individuals	O
with	O
faster	O
metabolism	O
of	O
nicotine	B
tend	O
to	O
smoke	O
more	O
cigarettes	O
for	O
longer	O
periods	O
of	O
time.	O

Diketopiperazines	B
have	O
not	O
previously	O
been	O
proposed	O
as	O
biomarkers	O
of	O
consumption,	O
although	O
urinary	O
cyclo(pro-pro)	O
and	O
cyclo(ser-tyr)	O
have	O
been	O
found	O
to	O
correlate	O
with	O
high	O
cocoa	O
consumption	O
.	O

-9,	O
cis	O
)	O
and	O
PE	B
18:1(n	I

In	O
summary,	O
our	O
work	O
demonstrates	O
that	O
heavy	O
cannabis	B
use	O
is	O
associated	O
with	O
lower	O
markers	O
of	O
inflammation	O
and	O
immune	O
activation	O
in	O
HIV-infected,	O
ART-treated	O
individuals.	O

Sample	O
derivatization	O
involved	O
addition	O
of	O
50 µL	O
methoxylamine	B
hydrochloride	I
in	O
15 µg/µL	O
pyridine	B
followed	O
by	O
mixing	O
at	O
600 rpm	O
(Eppendorf™	O
Thermomixer)	O
for	O
2 hours	O
at	O
35 °C.	O

Two	O
of	O
the	O
concentrations	O
values	O
were	O
not	O
provided	O
(PEA	O
and	O
sarcosine	B
for	O
‘low’	O
–	O
QC1),	O
and	O
therefore	O
data	O
for	O
these	O
are	O
not	O
presented.	O

Finally,	O
both	O
the	O
spectra	O
and	O
the	O
concentration	O
variables	O
were	O
individually	O
normalized	O
to	O
the	O
absolute	O
creatinine	B
concentration	O
of	O
the	O
respective	O
urine	O
sample.	O

It	O
was	O
reported	O
that	O
pimelic	B
acid	I
originating	O
from	O
the	O
fatty	O
acid	O
synthesis	O
pathway	O
is	O
a	O
bona	O
fide	O
precursor	O
of	O
biotin	B
in	O
Bacillus	O
subtilis	O
.	O

Additionally,	O
glutamate,	B
aspartate	B
and	O
serine	B
play	O
an	O
important	O
role	O
with	O
N-methyl	B
D-aspartate	I
(NMDA)	O
receptors.	O

In	O
this	O
context,	O
our	O
current	O
findings	O
of	O
severely-elevated	O
glucose	B
coupled	O
with	O
markedly-deficient	O
copper	O
levels	O
in	O
AD	O
brain	O
are	O
significant,	O
particularly	O
given	O
that	O
elevated	O
CML	B
levels	O
are	O
also	O
widespread	O
in	O
AD	O
brain.	O

Our	O
data	O
points	O
to	O
the	O
enrichment	O
of	O
non-esterified	O
PUFA	O
and	O
oxylipins	B
in	O
pro-atherogenic	O
TGRL,	O
consistent	O
with	O
our	O
previous	O
analysis.	O

It	O
is	O
possible	O
that	O
different	O
genetic	O
variants	O
of	O
the	O
enzymes	O
in	O
pyrimidine/orotate	O
synthesis,	O
such	O
as	O
the	O
variants	O
we	O
have	O
observed,	O
will	O
be	O
more	O
or	O
less	O
sensitive	O
to	O
these	O
treatments,	O
and,	O
therefore,	O
ctDNA	O
sequencing	O
of	O
these	O
genes	O
and	O
orotate	B
detection	O
by	O
metabolomics	O
could	O
help	O
in	O
selecting	O
better	O
personalised	O
treatment	O
for	O
these	O
patients.	O

We	O
found	O
higher	O
total	O
activity	O
to	O
associate	O
widely	O
across	O
metabolic	O
traits	O
including	O
higher	O
cholesterol	B
in	O
high-density	O
lipoprotein	O
(HDL)	O
particles,	O
lower	O
cholesterol	B
and	O
triglycerides	B
in	O
very	O
low-density	O
lipoprotein	O
(VLDL)	O
particles,	O
and	O
lower	O
inflammatory	O
glycoprotein	O
acetyls,	O
among	O
others.	O

The	O
crude	O
methanol	B
extract	O
of	O
T.	O
harzianum	O
strain	O
ES39	O
was	O
diluted	O
to	O
90%	O
(vol/vol)	O
methanol	B
by	O
adding	O
aqueous	O
0.1%	O
HCOOH	O
before	O
fractionation	O
by	O
reversed-phase	O
high-performance	O
liquid	O
chromatography	O
(HPLC)	O
(Smart	O
System,	O
Amersham	O
Biosciences,	O
Uppsala,	O
Sweden).	O

The	O
most	O
generalized	O
metabolite	O
response	O
to	O
anti-hypertensive	O
treatment	O
was	O
a	O
decline	O
in	O
the	O
levels	O
of	O
acylcarnitines,	B
in	O
particular	O
by	O
a	O
calcium	O
channel	O
and	O
a	O
beta	O
blocker,	O
indicative	O
of	O
a	O
change	O
in	O
fatty	O
acid	O
metabolism.	O

Under	O
control	O
conditions,	O
16HBE14o_−	O
cells	O
reduced	O
the	O
extracellular	O
glutamine	B
concentration	O
by	O
568	O
µmol/l	O
glutamine	B
within	O
2	O
h.	O
After	O
2	O
h	O
exposure	O
to	O
rHla,	O
however,	O
the	O
cells	O
had	O
reduced	O
the	O
extracellular	O
glutamine	B
concentration	O
by	O
1.1	O
mmol/	O

They	O
are	O
also	O
anti-oxidants	O
preventing	O
lipoprotein	O
peroxidation;	O
the	O
hydrogen	O
atoms	O
adjacent	O
to	O
the	O
vinyl-ether	B
bond	O
have	O
relatively	O
low	O
disassociation	O
energies	O
and	O
are	O
preferentially	O
oxidized	O
over	O
diacyl	B
GP	I
when	O
exposed	O
to	O
various	O
free	O
radicals	O
and	O
singlet	B
oxygen.	I

Glycolysis	O
and	O
the	O
synthesis	O
and	O
degradation	O
of	O
ketone	B
bodies	O
were	O
identified	O
as	O
two	O
potentially	O
high-impact	O
pathways	O
from	O
our	O
NMR	O
metabolomics	O
analysis	O
of	O
urine	O
samples	O
from	O
MS	O
patients.	O

In	O
metabolomics	O
analysis	O
of	O
the	O
Acon	O
-knockdown	O
fly	O
study,	O
authors	O
found	O
increased	O
levels	O
of	O
cis-aconitate,	B
citrate/isocitrate	O
ratio	O
and	O
acetyl-CoA,	B
metabolites	O
proximal	O
to	O
the	O
metabolic	O
block,	O
while	O
downstream	O
TCA	O
cycle	O
metabolites	O
including	O
alpha-ketoglutarate	B
(AKG),	O
succinate,	B
fumarate	B
and	O
malate	B
were	O
decreased,	O
albeit	O
a	O
mild	O
perturbation.	O

Oscillibacter	O
was	O
also	O
significantly	O
associated	O
with	O
pantothenate	B
and	O
CoA	O
biosynthesis	O
(p	O
-value	O
<	O
0.01,	O
normal	O
group;	O
p	O
-value	O
<	O
0.001,	O
tumor	O
group).	O

Consistent	O
with	O
its	O
implicated	O
role	O
in	O
advanced	O
liver	O
disease,	O
we	O
observed	O
significantly	O
elevated	O
levels	O
of	O
haeme	O
catabolites	O
bilirubin	B
and	O
elevations	O
in	O
biliverdin	B
and	O
urobilinogen	B
in	O
DC	O
vs.	O
NHC	O
and	O
HCC	O
vs.	O
NHC.	O

The	O
spectra	O
are	O
dominated	O
by	O
the	O
resonances	O
of	O
carbohydrates,	O
in	O
particular,	O
both	O
anomeric	O
forms	O
of	O
glucose	B
(∼3–5.5	O
ppm,	O
Gluc)	O
and	O
some	O
of	O
the	O
intermediate	O
metabolites	O
of	O
the	O
glycolytic	B
pathway,	O
such	O
as	O
lactate	B
(δ	O
1.33	O
and	O
4.11	O
ppm,	O
Lac).	O

On	O
the	O
other	O
hand,	O
metabolites	O
with	O
lower	O
levels	O
included	O
steroid	O
glucuronidation	O
metabolites	O
such	O
as	O
tetrahydroaldosterone-3-glucuronide	B
and	O
cortolone-3-glucuronide,	B
indicating	O
a	O
potential	O
roles	O
for	O
glucuronidation	O
in	O
RCC	O
development.	O

Alternatively,	O
SAM	O
may	O
transfer	O
the	O
methyl	B
group	I
to	O
glycine	B
to	O
form	O
sarcosine	B
via	O
the	O
enzyme	O
glycine	O
N-methyltransferase	O
(GNMT.	O

Some	O
solutes,	O
such	O
as	O
vanillic	B
acid	I
and	O
indole-3-methyl	B
acetate,	I
are	O
themselves	O
found	O
in	O
plants	O
and	O
can	O
presumably	O
be	O
absorbed	O
intact	O
from	O
plant	O
foods[,	O
].	O

Glutamate	B
is	O
a	O
non-essential	O
amino	O
acid	O
that	O
accounts	O
for	O
15%	O
of	O
the	O
total	O
amino	O
acids	O
in	O
dietary	O
proteins.	O

The	O
catechol	B
estrogen	I
2-OHE_2	O
was	O
the	O
only	O
catechol	B
estrogen	I
detected	O
in	O
the	O
tumor	O
cell	O
lines,	O
except	O
for	O
the	O
NSCL	O
cancer	O
cell	O
line	O
NCI-H460,	O
which	O
also	O
contains	O
a	O
relatively	O
high	O
level	O
of	O
2-OHE_1	O
(Table	O
).	O

Another	O
metabolite	O
identified	O
in	O
the	O
present	O
study	O
based	O
on	O
its	O
high	O
AUC	O
value	O
was	O
p-cresol	B
sulfate,	I
which	O
is	O
a	O
microbial	O
metabolite	O
that	O
likely	O
derives	O
from	O
secondary	O
metabolism	O
of	O
p-cresol.	B

Our	O
findings	O
indicate	O
that	O
the	O
analytical	O
platform	O
developed	O
here	O
allows	O
the	O
detection	O
of	O
consistent	O
alterations	O
in	O
oxylipin	B
profiles,	O
even	O
within	O
a	O
small	O
patient	O
population	O
(n	O
 = 5).	O

Serum	O
samples	O
were	O
prepared	O
by	O
mixing	O
400	O
μl	O
of	O
serum	O
and	O
200	O
μl	O
of	O
D_2	O
O,	O
using	O
the	O
signal	O
attribute	O
to	O
lactate	B
(δ	O
1.33	O
ppm)	O
as	O
a	O
chemical	O
shift	O
reference.	O

ECHA	O
also	O
suggested	O
a	O
biological	O
guidance	O
value	O
(BGV)	O
equal	O
to	O
0.5	O
µg/g	O
creatinine;	B
all	O
subjects	O
in	O
the	O
control	O
group	O
had	O
SPMA	O
levels	O
below	O
than	O
this	O
value,	O
while	O
15	O
workers	O
had	O
higher	O
levels.	O

Overall,	O
it	O
appeared	O
that	O
retinal	B
GT3	O
and	O
AcGT3	O
exhibited	O
specificities	O
in	O
their	O
ceramide	B
composition.	O

LLE,	O
200 μL	O
of	O
plasma,	O
dried	O
and	O
extracted	O
with	O
200 μL	O
ethyl	B
acetate	I
and	O
100 μLH_2	O
O	O
after	O
protein	O
precipitation.	O

To	O
validate	O
the	O
proposed	O
dicarboxylic	B
structure	O
of	O
VLCDCA	B
28:4,	I
we	O
used	O
picolylamine,	B
which	O
derivatizes	O
carboxylic	B
functions.	O

Decline	O
in	O
the	O
production	O
of	O
the	O
neurotransmitter	O
GABA	B
occurs	O
in	O
stable	O
MCI	O
(a.)	O
and	O
is	O
not	O
further	O
affected	O
by	O
conversion	O
to	O
AD.	O

The	O
very	O
long	O
fatty	O
acyl	O
chain	O
ceramides	B
N-(docosanoyl)-sphing-4-enine	I
(Cer(22:0))	I
and	O
N-(tetracosanoyl)-sphing-4-enine	B
(Cer(24:0))	I
are	O
associated	O
with	O
multiple	O
biological	O
functions.	O

Similarly,	O
we	O
found	O
a	O
significant	O
decrease	O
of	O
sphingosine	B
in	O
the	O
plasma	O
of	O
PAH	O
patients.	O

Within	O
the	O
ER(+)	B
group	O
an	O
immune-metabolomics	O
model,	O
based	O
on	O
TNF-α	O
and	O
valine,	B
predicted	O
pathological	O
complete	O
response	O
to	O
NATC	O
with	O
90.9%	O
accuracy	O
(AUROC	O
=	O
0.92,	O
p	O
=	O
0.004).	O

So	O
the	O
alternative	O
modes	O
of	O
metabolism	O
of	O
glucose	B
and	O
glutamine	B
enable	O
cancer	O
cells	O
to	O
resist	O
metabolic	O
stress	O
and	O
contribute	O
to	O
cancer	O
cells	O
survive	O
and	O
growth.	O

Taken	O
together,	O
these	O
results	O
suggest	O
that	O
purine	B
degradation	O
may	O
be	O
accelerated	O
during	O
depression.	O

According	O
to	O
previous	O
studies,	O
the	O
mean/median	O
concentrations	O
of	O
plasma	O
TMAO	B
in	O
humans	O
were	O
in	O
the	O
range	O
of	O
1.43–3.70	O
μmol/L	O
(108.68–281.20	O
μg/L)	O
in	O
healthy	O
individuals	O
(,	O
,	O
),	O
2.39–7.50	O
μmol/L	O
(181.64–570.00	O
μg/L)	O
in	O
diabetic	O
patients	O
(,	O
,	O
),	O
and	O
1.80–5.00	O
μmol/L	O
(136.80–380.00	O
μg/L)	O
in	O
patients	O
with	O
cardiovascular	O
disease	O
(,	O
,	O
),	O
which	O
were	O
higher	O
than	O
our	O
measurements	O
in	O
pregnant	O
women	O
in	O
China.	O

Finally,	O
PLS-DA	O
models	O
of	O
age	O
of	O
intermediate	O
AMD	O
groups	O
revealed	O
increases	O
in	O
acetoacetate	B
(p-	O
value	O
=	O
3.8x10-2	O
),	O
citrate	B
(p-	O
value	O
=	O
1.9x10-4	O
),	O
dimethyl	B
sulfone	I
(p-	O
value	O
=	O
1.4x10-2	O
)	O
and	O
β-hydroxybutyrate	B
(p-	O
value	O
=	O
8.6x10-3	O
)	O
in	O
older	O
Coimbra	O
subjects,	O
whereas	O
older	O
Boston	O
subjects	O
exhibited	O
a	O
weak	O
tendency	O
for	O
higher	O
circulating	O
urea	B
levels	O
(p-	O
value	O
=	O
3.9x10-2	O
).	O

Additionally,	O
phenylalanine	B
and	O
tyrosine,	B
precursors	O
for	O
catecholamine	B
biosynthesis,	O
were	O
significantly	O
altered	O
in	O
post-surgery	O
patients.	O

The	O
elevated	O
plasma	O
concentrations	O
of	O
20-HETE	B
in	O
RVD	O
occurred	O
with	O
decreased	O
urinary	O
excretion	O
of	O
20-HETE	B
and	O
probably	O
reflects	O
the	O
multiple	O
pathways	O
for	O
disposition	O
of	O
20-HETE,	B
namely,	O
incorporation	O
of	O
20-HETE	B
into	O
phospholipids,	B
ω	O
-	O
and	O
β	O
-oxidation,	O
and	O
transformation	O
of	O
20-HETE	B
via	O
cyclooxygenase	O
into	O
prostaglandin	B
analogs._,	O

To	O
conclude,	O
low	O
serum	O
levels	O
of	O
2,4-hexadienoic	B
acid,	I
4-methylphenyl	B
dodecanoate	I
and	O
glycerol	B
tributanoate	I
may	O
be	O
important	O
independent	O
prognostic	O
factors	O
of	O
GC.	O

l	O
vs	O
0.10	O
mmol/l,	O
p	O
<	O
0.01),	O
glycine	B
(0.43	O
mmol/l	O
vs	O
0.31	O
mmol/l,	O
p	O
<	O
0.001),	O
histidine	B
(0.07	O
mmol/	O

In	O
this	O
last	O
case,	O
serine	B
is	O
decarboxylated	O
to	O
ethanolamine,	B
leading	O
in	O
two	O
further	O
steps	O
to	O
glycolic	B
acid,	I
whereas	O
glycine	B
is	O
transaminated	O
to	O
glyoxylic	B
acid,	I
which	O
is	O
reduced	O
to	O
glycolic	B
acid.	I

We	O
hypothesized	O
that	O
urinary	O
CR	O
and	O
NANA	B
may	O
derive	O
from	O
tumor	O
tissue,	O
as	O
has	O
been	O
previously	O
observed	O
in	O
lung	O
cancer.	O

All	O
standards	O
were	O
from	O
Sigma	O
(Taufkirchen,	O
Germany)	O
except	O
m_2	O
_2	O
G,	O
m_2,2,7	O
G	O
and	O
t_6	O
A,	O
obtained	O
from	O
Biolog	O
(Bremen,	O
Germany),	O
1-methyl-L-histidine,	B
purchased	O
from	O
Calbiochem/Merck	O
(Nottingham,	O
UK)	O
and	O
pyridine	B
from	O
Gruessing	O
(Filsum,	O
Germany).	O

Nevertheless,	O
recent	O
advances	O
in	O
glycomics	O
and	O
glycol	B
biomarker	O
profiling	O
show	O
direct	O
or	O
indirect	O
associations	O
between	O
glycosylation	O
modifications	O
and	O
autoimmune	O
disturbances	O
in	O
RA:	O
peptide	O
epitope/glycol	O
epitope	O
cross-reactivity,	O
neo-expression	O
of	O
normally-restricted	O
glycans,	B
sugar	O
induction	O
of	O
inappropriate	O
processing	O
and	O
presentation	O
of	O
self-antigens	O
to	O
T-lymphocytes	O
and	O
conformational	O
glycomodification	O
leading	O
to	O
unmasking	O
of	O
antigenic	O
epitopes.	O

We	O
believe	O
that	O
the	O
explanatory	O
power	O
of	O
HOMA-IR	O
for	O
the	O
fasting	O
TG	B
levels	O
in	O
the	O
regression	O
model	O
was	O
weaker	O
than	O
that	O
of	O
other	O
variables	O
that	O
were	O
indicated	O
as	O
independent	O
predictors	O
of	O
the	O
fasting	O
TG	B
levels,	O
such	O
as	O
lysoPC	O
(16:0),	O
cis	O
-4-octenedioic	O
acid,	O
glucose,	B
the	O
FFA	O
response	O
area,	O
and	O
HDL,	O
suggesting	O
that	O
the	O
fasting	O
TG	B
levels	O
are	O
explained	O
more	O
by	O
these	O
variables	O
than	O
by	O
HOMA-IR.	O

A	O
study	O
in	O
people	O
with	O
dyslipidaemia	O
however	O
showed	O
a	O
reduction	O
in	O
COH	O
levels	O
after	O
treatment	O
with	O
simvastatin,	B
as	O
compared	O
to	O
placebo.	O

The	O
lipids	O
were	O
separated	O
using	O
an	O
Acquity	O
UPLC	O
charged	O
surface	O
hybrid	O
C18	O
column	O
(2.1	O
×	O
100	O
mm,	O
1.7	O
μm,	O
Waters)	O
with	O
a	O
gradient	O
mobile	O
phase	O
comprised	O
of	O
10	O
mM	O
ammonium	B
formate	I
with	O
0.1%	O
formic	B
acid	I
in	O
acetonitrile/water	O
(A,	O
60:40,	O
v/v	O
)	O
and	O
10	O
mM	O
ammonium	B
formate	I
with	O
0.1%	O
formic	B
acid	I
in	O
isopropanol/acetonitrile	O
(B,	O
90:10,	O
v/v	O
).	O

Before	O
blood	O
collection,	O
basal	O
glucose	B
levels	O
were	O
determined	O
with	O
a	O
commercially	O
available	O
glucometer	B
(Diamond	O
Mini;	O
ForaCare).	O

,	O
sum	O
of	O
daidzein,	B
dihydrodaidzein,	B
O-	B
desmethylangolensin,	I
and	O
equol)	O
serum	O
concentrations	O
ranged	O
from	O
246.4	O
to	O
2,831	O
nmol/L	O
and	O
from	O
105.1	O
to	O
1,314	O
nmol/L	O
upon	O
treatment,	O
respectively.	O

The	O
ETS	O
status	O
self-reported	O
in	O
the	O
initial	O
screening	O
questionnaire	O
was	O
confirmed	O
with	O
information	O
reported	O
in	O
the	O
questionnaires	O
daily	O
and	O
with	O
the	O
personal	O
exposures	O
to	O
3-ethenylpyridine,	B
an	O
ETS	O
tracer.	O

Thyroxine	B
demonstrated	O
reduced	O
levels	O
in	O
manifest	O
compared	O
with	O
premanifest	O
HD	O
subjects,	O
moderate	O
to	O
strong	O
associations	O
to	O
all	O
measures	O
of	O
disease	O
severity	O
and	O
lower	O
thyroxine	B
levels	O
were	O
associated	O
to	O
an	O
increased	O
five	O
year	O
risk	O
of	O
onset	O
in	O
premanifest	O
HD	O
subject.	O

Cholesterol	B
production	O
slightly	O
increased	O
in	O
IS	O
hypogonadism,	O
as	O
did	O
its	O
precursor	O
mevalonic	B
acid	I
(but	O
not	O
significantly),	O
in	O
agreement	O
with	O
the	O
hypothesis	O
that	O
low	O
testosterone	B
promotes	O
cholesterol	B
mobilisation	O
from	O
the	O
liver.	O

Baseline	O
chromatographic	O
separation	O
of	O
estrogen	B
derivatives	O
was	O
achieved	O
in	O
aqueous	O
standards.	O

d	O
Model	O
based	O
on	O
the	O
cross-validated	O
(CV)	O
case/control	O
status	O
of	O
the	O
O-PLS	O
analysis	O
_e	O
Combination	O
between	O
the	O
CV	O
status	O
of	O
the	O
O-PLS	O
and	O
the	O
AFP	O
variable	O
_f	O
Combination	O
between	O
the	O
CV	O
status	O
of	O
the	O
O-PLS	O
and	O
the	O
liver	O
function	O
score	O
Odds	O
ratios	O
[OR	O
(95 %	O
confidence	O
intervals)]	O
of	O
HCC	O
risk	O
by	O
serum	O
metabolites	O
*P	O
value	O
<0.05;	O
**P	O
value	O
<0.01;	O
***P	O
value	O
<0.001	O
_a	O
Model	O
1,	O
Crude	O
OR	O
based	O
on	O
logistic	O
regression	O
conditioned	O
on	O
matching	O
factors	O
(sex,	O
age,	O
date	O
and	O
time	O
of	O
blood	O
collection,	O
fasting	O
status,	O
and	O
menopausal	O
status	O
and	O
use	O
of	O
hormones)	O
_b	O
Model	O
2,	O
OR	O
based	O
on	O
multivariable	O
CLR	O
adjusted	O
for	O
smoking	O
status,	O
ethanol	B
at	O
recruitment,	O
lifetime	O
alcohol,	O
educational	O
status,	O
physical	O
activity,	O
body	O
mass	O
index,	O
serum-clot	O
contact	O
time,	O
and	O
waist	O
circumference	O
_c	O
Model	O
3,	O
as	O
in	O
model	O
2	O
and	O
additionally	O
adjusted	O
for	O
liver	O
function	O
score	O
_d	O
Model	O
4,	O
as	O
model	O
2	O
but	O
obtained	O
on	O
HCC	O
cases	O
free	O
of	O
HBV/HCV	O
infection	O
and	O
their	O
matched	O
controls	O
(n = 224)	O
_e	O
Model	O
5,	O
Crude	O
OR	O
obtained	O
on	O
HCC	O
cases	O
diagnosed	O
<2 years	O
after	O
blood	O
collection	O
and	O
their	O
matched	O
controls	O
_f	O
Model	O
6,	O
Crude	O
OR	O
obtained	O
on	O
HCC	O
cases	O
diagnosed	O
≥2 years	O
after	O
blood	O
collection	O
and	O
their	O
matched	O
controls	O
_g	O
Model	O
7,	O
as	O
in	O
model	O
2	O
but	O
obtained	O
on	O
HCC	O
cases	O
diagnosed	O
≥2 years	O
after	O
blood	O
collection	O
and	O
their	O
matched	O
controls	O
_h	O
OR	O
of	O
ethanol	B
from	O
multivariable	O
CLR	O
model	O
are	O
obtained	O
after	O
adjustment	O
for	O
variables	O
as	O
mentioned	O
for	O
model	O
2	O
expect	O
for	O
lifetime	O
alcohol	O
The	O
O-PLS	O
analyses	O
stratified	O
by	O
hepatitis	O
infection	O
status	O
of	O
the	O
cases	O
(Fig.	O

To	O
examine	O
the	O
overall	O
associations	O
of	O
LPIs	O
and	O
their	O
related	O
metabolites,	O
such	O
as	O
nonesterified	O
fatty	O
acids	O
(NEFAs)	O
and	O
acylcarnitines,	B
with	O
incident	O
and	O
prevalent	O
type	O
2	O
diabetes	O
using	O
a	O
targeted	O
approach.	O

We	O
have	O
demonstrated	O
previously	O
that	O
various	O
lipid	O
species	O
belonging	O
to	O
the	O
diacylgylcerol,	B
triacylglycerol,	B
dihydroceramide	B
and	O
phosphatidylcholine	B
classes	O
can	O
provide	O
clinically	O
meaningful	O
information	O
relating	O
to	O
complex	O
diseases	O
like	O
obesity,	O
hypertension,	O
type	O
2	O
diabetes	O
and	O
metabolic	O
syndrome	O
in	O
this	O
population.	O

The	O
small	O
sample	O
size	O
of	O
the	O
individual	O
lymphoma	O
subtypes	O
prevented	O
obtaining	O
PLS-DA	O
validated	O
models,	O
although	O
specific	O
peculiar	O
features	O
of	O
each	O
subtype	O
were	O
observed;	O
for	O
instance,	O
fatty	O
acids	O
were	O
most	O
represented	O
in	O
MM	O
and	O
HL	B
patients,	O
while	O
2-aminoadipic	B
acid,	I
2-aminoheptanedioic	B
acid,	I
erythritol,	B
and	O
threitol	B
characterized	O
DLBCL	O
and	O
CLL.	O

To	O
assess	O
the	O
production	O
of	O
cytokines,	O
cells	O
were	O
treated	O
with	O
20	O
ng/ml	O
phorbol-12-myristate-13-acetate	B
(PMA),	O
500	O
ng/ml	O
ionomycin	B
and	O
2	O
μM	O
monensin	O
(all	O
from	O
Sigma)	O
for	O
5	O
hours.	O

(254.1	O
or	O
259.1	O
Da),	O
where	O
the	O
amine	O
group	O
of	O
the	O
side	O
chain	O
of	O
lysine	B
displaced	O
the	O
nitro	O
moiety	O
of	O
PhIP.	O

The	O
_1	O
H	O
NMR	O
and	O
_13	O
C	O
NMR	O
spectra	O
supported	O
the	O
proposed	O
structure	O
with	O
the	O
coumarin	B
unit	O
attached	O
to	O
the	O
3	O
position	O
of	O
5-oxo-3-pyrroline	B
(AFB-Lys).	O

Taken	O
together,	O
HNSCC	O
may	O
be	O
associated	O
with	O
the	O
alteration	O
of	O
lipid	O
metabolism	O
facilitated	O
by	O
lipolysis	O
of	O
triglycerides	B
and	O
concomitant	O
fatty	O
acid	O
oxidation.	O

The	O
RT	O
and	O
fragmentation	O
pattern	O
were	O
virtually	O
identical	O
between	O
marker	O
and	O
standard	O
in	O
the	O
cases	O
of	O
sphinganine	B
(Fig. )	O
and	O
PC	B
(18:1)	I
(Fig.	O

LPCs	O
enriched	O
for	O
the	O
SaFA	O
margaric	B
acid	I
(17:0)	O
were	O
positively	O
associated	O
with	O
the	O
proportion	O
of	O
patrolling	O
monocytes,	O
and	O
LPC(20:0)	B
was	O
positively	O
associated	O
with	O
surface	O
expression	O
of	O
SR-A	O
on	O
patrolling	O
monocytes	O
and	O
CD36	O
on	O
inflammatory	O
monocytes.	O

Tamoxifen	B
adherence	O
was	O
assessed	O
using	O
the	O
Morisky,	O
Green,	O
and	O
Levine	O
Medication	O
Adherence	O
Scale	O
questionnaire,	O
a	O
structured	O
four‐item	O
self‐reported	O
adherence	O
measure	O
validated	O
for	O
a	O
wide	O
range	O
of	O
diseases,	O
including	O
cancer._34	O

Analysis	O
of	O
the	O
metabolites	O
present	O
in	O
all	O
11	O
urine	O
extracts	O
containing	O
spectra	O
of	O
this	O
cluster	O
(the	O
nodes	O
with	O
m/z	O
313.086	O
and	O
271.079	O
([M+H]_+	O
))	O
resulted	O
in	O
the	O
top-ranked	O
candidate	O
structure	O
of	O
paracetamol-mercapturate	B
(conjugate	O
of	O
paracetamol	B
and	O
N	B
-acetylcysteine)	I

Likewise,	O
correlation	O
coefficients	O
for	O
apolipoproteins	O
A1	O
and	O
B,	O
creatinine,	B
and	O
albumin	O
were	O
high	O
(0.87,	O
0.90,	O
0.98,	O
and	O
0.80,	O
respectively).	O

We	O
included	O
adults	O
(>18	O
years	O
old)	O
with	O
an	O
admission	O
SOFA	O
score	O
≥6	O
and	O
arterial	O
lactate	B
≥2 mmol/	O

Acetonitrile	B
was	O
from	O
SDS	O
(Peypin,	O
France)	O
and	O
formic	B
acid	I
from	O
Merck	O
(Briare-le-Canal,	O
France).	O

Fifty	O
HPHPA-positive	O
autistic	O
children	O
(9/50	O
patients	O
3HPA-positive	O
and	O
17/50	O
patients	O
3HHA-positive)	O
were	O
selected	O
for	O
oral	O
vancomycin	B
treatment	O
at	O
standard	O
age-appropriate	O
dosages	O
(50 mg/kg/d,	O
30	O
days	O
as	O
one	O
therapeutic	O
course)	O
followed	O
by	O
supplement	O
therapy	O
with	O
Bifidobacterium	O
agent	O
(Bifidobacterium	O
BB-12,	O
2	O
pills	O
a	O
day).	O

Both	O
derivatized	O
and	O
nonderivatized	O
vitamin	B
D	I
metabolites	O
containing	O
a	O
hydroxyl	O
group	O
at	O
position	O
25	O
easily	O
lose	O
water	O
in	O
the	O
Z-spray	O
source	O
probably	O
due	O
to	O
the	O
formation	O
of	O
a	O
stable	O
tertiary	O
carbocation.	O

For	O
injection,	O
samples	O
were	O
reconstituted	O
in	O
50	O
μL	O
of	O
5%	O
aqueous	O
CH_3	O
CN	O
with	O
0.1%	O
formic	B
acid.	I

The	O
TOCSY	O
satellite	O
cross-peak	O
pattern	O
of	O
the	O
uracil	B
ring	O
(cf.	O
)	O
revealed	O
the	O
presence	O
of	O
all	O
three	O
uracil	B
_13	O
C	O
isotopomers,	O
thereby	O
confirming	O
the	O
biosynthetic	O
route	O
from	O
the	O
tracer	O
[U–_13	B
C]-glucose	I
through	O
glycolysis,	O
the	O
Krebs	O
cycle	O
with	O
and	O
without	O
PC	O
to	O
pyrimidine	B
ring	O
biosynthesis.	O

Increased	O
levels	O
of	O
3-hydroxybutyrate	B
involved	O
in	O
butanoate	B
metabolism,	O
indicate	O
upregulation	O
of	O
the	O
synthesis	O
of	O
ketone	B
bodies.	O

A,	O
36-carbon	O
long-chain	O
FA	B
system;	O
B,	O
PlsEtn	O
system;	O
C,	O
lysoPC	O
system;	O
D,	O
SM	O
system;	O
E,	O
PtdCho	O
system;	O
F,	O
PtdEtn	O
system.	O

This	O
result	O
indicates	O
that	O
ribose	B
or	O
ribose-5-phosphate	B
(R5P)	O
may	O
undergo	O
in	O
vivo	O
Maillard	O
reaction	O
as	O
well	O
or	O
that	O
in	O
vivo	O
glucosone	B
decomposition	O
results	O
in	O
3-DPs.	O

NAc,	O
N-acetyl	O
methyl	O
groups	O
of	O
glycoproteins;	B
Gln,	O
glutamine;	B
Glu,	O
glutamate.	B

The	O
only	O
significant	O
uni-variate	O
change	O
in	O
urine	O
metabolites	O
was	O
a	O
minor	O
increase	O
in	O
urine	O
succinic	B
acid.	I

Total	O
flow	O
through	O
the	O
column	O
was	O
400	O
µL/min,	O
with	O
93:7	O
MeOH:H_2	O
O	O
with	O
5	O
mM	O
ammonium	B
acetate	I
and	O
0.01%	O
ammonium	B
hydroxide	I
as	O
solvent.	O

The	O
intensity	O
of	O
peaks	O
in	O
the	O
chemical	O
shift	O
region	O
6.7	O
–	O
8.5	O
ppm	O
was	O
increased	O
equally	O
in	O
all	O
spectra	O
to	O
show	O
the	O
low-abundant	O
taurine	B
and	O
phenylalanine.	B

Careful	O
clinical	O
diagnosis	O
was	O
done	O
using	O
clinical	O
criteria	O
in	O
the	O
AUA	O
guidelines;	O
“An	O
unpleasant	O
sensation	O
(pain,	O
pressure,	O
discomfort)	O
perceived	O
to	O
be	O
related	O
to	O
the	O
urinary	O
bladder,	O
associated	O
with	O
lower	O
urinary	O
tract	O
symptom(s)	O
of	O
more	O
than	O
6	O
weeks	O
duration,	B
in	O
the	O
absence	O
of	O
infection	O
or	O
other	O
identifiable	O
causes”	O
(http://www.auanet.org/education/guidelines/ic-bladder-pain-syndrome.cfm).	O

Tissue	O
factor	O
(TF)	O
is	O
a	O
pro-coagulant	O
molecule	O
previously	O
shown	O
to	O
be	O
related	O
to	O
immune	O
activation	O
in	O
HIV	O
infection,	O
and	O
TF	O
surface	O
expression	O
on	O
inflammatory	O
monocytes	O
was	O
inversely	O
related	O
to	O
the	O
proportions	O
of	O
PUFAs	O
α-linolenic	B
acid	I
(18:3)	O
and	O
EPA	B
(20:5).	I

Interleukin	O
(IL)-1β,	B
IL-4,	O
IL-5,	O
IL-6,	O
IL-8,	O
IL-13	O
and	O
tumor	O
necrosis	O
factor	O
(TNF)-α	O
in	O
sputum	O
supernatant	O
as	O
local	O
inflammation	O
were	O
detected	O
by	O
a	O
Luminex-based	O
MILLIPLEX_®	O
MAP	O
Human	O
Cytokine/Chemokine	O
Magnetic	O
bead	O
Panel	O
Kit	O
(EMD	O
Millipore	O
Corporation,	O
Billerica,	O
MA,	O
USA),	O
and	O
were	O
analyzed	O
using	O
the	O
software	O
of	O
Milliplex	O
Analyst	O
5.1	O
as	O
it	O
has	O
been	O
demonstrated	O
that	O
the	O
Luminex-based	O
xMAP_®	O
panel	O
can	O
be	O
used	O
for	O
multi-analyte	O
profiling	O
of	O
sputum	O
using	O
the	O
routinely	O
applied	O
method	O
of	O
sputum	O
processing	O
with	O
dithiothreitol._,	B

Lower	O
baseline	O
levels	O
of	O
xanthine	B
(p<0.0001,	O
q<0.00068),	O
2-hydroxyvaleric	B
acid	I
(p<0.0001,	O
q<0.0013),	O
succinic	B
acid	I
(p<0.0009,	O
q<0.017)	O
and	O
stearic	B
acid	I
(p<0.0039,	O
q<0.037)	O
were	O
all	O
significantly	O
correlated	O
with	O
greater	O
LDL-C	O
response.	O

A	O
was	O
a	O
linear	O
gradient	O
from	O
10%	O
methanol	B
to	O
70%	O
methanol	B
over	O
15	O
minutes;	O
B	O
was	O
a	O
linear	O
gradient	O
from	O
33%	O
methanol	B
to	O
100%	O
methanol	B
over	O
11	O
minutes.	O

This	O
leads	O
to	O
d18:1	B
(sphingosine)	I
being	O
by	O
far	O
the	O
most	O
abundant	O
LCB	O
in	O
sphingolipids,	B
among	O
which	O
GGs,	O
as	O
we	O
report	O
here	O
in	O
our	O
tissues	O
of	O
interest.	O

The	O
false	O
discovery	O
rate	O
(FDR)	O
was	O
calculated	O
by	O
the	O
Multiple	O
Experiment	O
Viewer	O
Toll	O
(version	O
4.9.0,	O
OriginLab,	O
Northampton,	B
USA);	O
the	O
correction	O
of	O
P	O
value	O
is	O
performed	O
with	O
“adjusted	O
Bonferroni	O
correction”.	O

Glutamate,	B
however,	O
was	O
selected	O
in	O
all	O
the	O
LASSO	O
models	O
and	O
was	O
the	O
most	O
significant	O
variable	O
in	O
the	O
univariate	O
analyses.	O

A	O
1.0	O
mM	O
solution	O
of	O
the	O
LPO	O
product	O
of	O
interest	O
was	O
made	O
up	O
in	O
ethanol	B
and	O
100	O
μl	O
was	O
added	O
to	O
the	O
MAd_3	O
solution	O
(10-fold	O
molar	O
excess).	O

a	O
,	O
competitive	O
displacement	O
of	O
10	O
nm	O
tritiated	O
9-cis	O
-RA	O
from	O
purified	O
RXRα	O
protein	O
by	O
unlabeled	O
9-cis	O
-RA(♦)as	O
a	O
positive	O
control,	O
C13	O
ketone	B
(▴),	O
14′-AL	O
(■),	O
14′-CA	O
(+),	O
and	O
retinyl	B
acetate	I
(×)	O
as	O
a	O
negative	O
control.	O

The	O
product	O
ion	O
spectra	O
of	O
desamino-PhIP-K	B
([M+H]_+	O
at	O
m/z	O
354.2)	O
and	O
[_2	B
H_5	I
]-desamino-PhIP-K	I
([M+H]_+	O
at	O
m/z	O
359.2)	O
exhibited	O
a	O
‘twin’	O
pattern	O
of	O
ions	O
that	O
differ	O
by	O
5	O
Da.	O

3β,7α-diHCA	B
correlates	O
most	O
strongly	O
with	O
7α,(25R)26-diHC	B
and	O
3β,7β-diHCA.	B

Intriguingly,	O
the	O
most	O
significant	O
metabolites,	O
as	O
listed	O
in	O
,	O
are	O
sphingolipids	B
and	O
ceramides.	B

Furthermore,	O
AGP	O
and	O
citrate	B
have	O
been	O
identified	O
in	O
an	O
NMR	O
study	O
as	O
two	O
of	O
four	O
predictive	O
biomarkers	O
in	O
blood	O
to	O
estimate	O
the	O
short-term	O
risk	O
of	O
death	O
from	O
any	O
cause	O
in	O
two	O
general	O
population	O
cohorts,	O
AGP	O
being	O
the	O
strongest	O
biomarker.	O

The	O
FFA	O
composition	O
(%	O
of	O
total	O
FFAs)	O
indicated	O
a	O
higher	O
percentage	O
of	O
SFAs	O
(43.7%	O
±	O
6.2%	O
vs.	O
32.9%	O
±	O
3.1%,	O
p	O
<	O
0.001)	O
and	O
a	O
lower	O
percentage	O
of	O
MUFAs	O
(33.7%	O
±	O
4.4%	O
vs.	O
36.7%	O
±	O
2.6%,	O
p	O
=	O
0.003)	O
and	O
PUFAs	O
(22.6%	O
±	O
3.9%	O
vs.	O
30.5%	O
±	O
3.3%,	O
p	O
<	O
0.001)	O
in	O
AF	B
patients	O
than	O
in	O
controls.	O

The	O
product	O
ion	O
spectra	O
were	O
acquired	O
simultaneously	O
using	O
collision	O
energy	O
of	O
30	O
eV	O
with	O
a	O
cone	O
voltage	O
of	O
40	O
V.	O
Due	O
to	O
the	O
absence	O
of	O
authentic	O
standards	O
for	O
anastrozole	B
glucuronide,	I
quantification	O
of	O
the	O
glucuronide	B
was	O
accomplished	O
using	O
a	O
standard	O
curve	O
for	O
anastrozole.	B

HPLC	O
grade	O
ammonium	B
formate,	I
chloroform,	B
2-propanol	B
(IPA)	O
and	O
formic	B
acid	I
were	O
from	O
Sigma-Aldrich	O
(Sigma	O
Chemical	O
Co.,	O
St	O
Louis,	O
MO,	O
USA).	O

These	O
results	O
are	O
consistent	O
with	O
the	O
proposal	O
of	O
a	O
purine-driven	B
cell	O
danger	O
response,	O
accompanied	O
by	O
overproduction	O
of	O
epileptogenic	O
and	O
excitotoxic	O
quinolinic	B
acid,	I
large	O
reductions	O
in	O
melatonin	B
synthesis,	O
and	O
gut	O
dysbiosis.	O

Further	O
increased	O
inosine	B
after	O
antidepressants	O
treatment	O
may	O
indicate	O
that	O
inosine	B
could	O
also	O
be	O
a	O
potential	O
predictor	O
of	O
antidepressant	O
effects.	O

We	O
used	O
the	O
Spearman	O
correlation	O
as	O
a	O
filter	O
and	O
included	O
all	O
metabolites	O
significantly	O
correlated	O
with	O
Δglucose	B
to	O
build	O
a	O
linear	O
regression	O
model.	O

Changes	O
in	O
plasma	O
and/or	O
urinary	O
acylcarnitine	B
profiles	O
are	O
used	O
to	O
detect	O
disorders	O
in	O
fatty	O
acid	O
and	O
amino	O
acid	O
oxidation	O
[,	O
].	O

Twelve	O
of	O
the	O
lipid	O
species	O
and	O
two	O
lipid	O
classes	O
(cholesterol	O
esters	I
and	O
ceramides)	B
that	O
were	O
significantly	O
increased	O
in	O
the	O
efavirenz	O
arm	O
compared	O
with	O
the	O
atazanavir/r	O
or	O
zidovudine/abacavir	O
arms	O
have	O
previously	O
been	O
associated	O
with	O
future	O
cardiovascular	O
events	O
in	O
HIV	O
positive	O
patients.	O

Comparing	O
the	O
two	O
CRC	O
metabonomics	O
studies,	O
among	O
the	O
32	O
differential	O
metabolites	O
identified	O
in	O
the	O
previous	O
study,	O
only	O
nervonic	B
acid	I
was	O
not	O
detected	O
in	O
the	O
present	O
study.	O

The	O
three	O
major	O
classes	O
of	O
eicosanoids	B
are	O
prostanoids,	B
products	O
of	O
cyclooxygenases,	O
5,	O
12,	O
15-HETEs	O
and	O
leukotrienes	O
products	O
of	O
lipoxygenases,	O
and	O
EETs	O
and	O
HETEs	O
products	O
of	O
CYP	O
mono-oxygenases.	O

The	O
mobile	O
phases	O
consisted	O
of	O
0.1%	O
formic	B
acid	I
in	O
water	O
(solvent	O
A)	O
and	O
0.1%	O
formic	B
acid	I
in	O
acetonitrile	B
(solvent	O
B).	O

Only	O
one	O
metabolite	O
α-Ketoglutaric	B
acid	I
followed	O
the	O
pattern	O
of	O
increased	O
concentration	O
in	O
IDC	O
compared	O
with	O
benign	O
and	O
control.	O

The	O
lower	O
limit	O
of	O
quantification	O
(LLOQ)	O
and	O
higher	O
limit	O
of	O
quantification	O
(HLOQ)	O
were	O
selected	O
at	O
the	O
outer	O
range	O
of	O
the	O
concentration	O
levels	O
measured	O
in	O
patients	O
treated	O
with	O
enzalutamide	B
160	O
mg	O
once	O
daily.	O

Human	O
prostate	O
biopsy	O
samples	O
were	O
processed	O
using	O
the	O
intact	O
biopsy	O
method	O
in	O
80%	O
methanol	B
followed	O
by	O
paraffin	B
embedding	O
and	O
sectioning.	O

Multivariable	O
linear	O
regression	O
analyses	O
were	O
carried	O
out	O
to	O
disclose	O
the	O
independent	O
relationships	O
of	O
PLTP	O
and	O
LCAT	O
activity	O
with	O
betaine.	B

Nonetheless,	O
the	O
fourth	O
quartile	O
of	O
male	O
partners'	O
urinary	O
paracetamol	B
was	O
associated	O
with	O
delayed	O
TTP	O
in	O
the	O
adjusted	O
couple-based	O
models	O
[a	O
FOR	O
=	O
0.65;	O
95%	O
CI	O
=	O
(0.47,	O
0.98);	O
P	O
-trend	O
=	O
0.02].	O

The	O
very	O
long	O
acyl	O
chain	O
ceramide	B
assay	O
was	O
used	O
to	O
quantify	O
Cer(22:0)	B
and	O
Cer	B
(24:0)	I
in	O
human	O
plasma	O
samples	O
from	O
five	O
control,	O
five	O
obese	O
and	O
four	O
type	O
2	O
diabetic	O
women.	O

The	O
eight	O
metabolites	O
selected	O
were	O
phosphatidyl	B
choline	I
PC(16:0/16:0),	I
glucosylceramide	B
GC(18:1/16:0),	I
1-P5C,	O
FAD,	O
pyroglutamic	B
acid	I
(also	O
known	O
as	O
5-oxoproline),	B
2-hydroxyisocaproic	B
acid	I
(HICA),	O
l-serine,	B
and	O
lathosterol.	B

l‐Asparaginase	O
catalyzes	O
the	O
extracellular	O
conversion	O
of	O
asparagine	B
into	O
aspartic	B
acid	I
and	O
ammonia._29	O
It	O
is	O
important	O
for	O
solid	O
tumor	O
progression	O
to	O
maintain	O
asparagine	B
production,	O
because	O
solid	O
tumor	O
is	O
nutritionally	O
dependent	O
on	O
an	O
external	O
supply	O
of	O
asparagine._30	B

In	O
this	O
work,	O
it	O
was	O
found	O
that	O
the	O
addition	O
of	O
least	O
10%	O
(v/v	O
)	O
acetonitrile	B
during	O
the	O
centrifugal	O
filtration	O
step	O
significantly	O
improved	O
extraction	O
efficiency.	O

The	O
capillary	O
voltage	O
was	O
4.0	O
kV	B
at	O
ESI+	O
mode	O
and	O
3.5	O
kV	B
at	O
ESI-	O
mode.	O

A	O
second	O
Citrate	B
peak	O
(d)	O
is	O
shown	O
with	O
a	O
nonlinear	O
fit	O
to	O
the	O
three	O
protonation	O
site	O
form	O
of	O
Eq.	O

Citrulline	B
and	O
dimethylamine	B
increased	O
(p	O
<	O
0.05)	O
in	O
active-CD	O
(68.7	O
and	O
70.9	O
µM)	O
and	O
active-UC	O
(65.9	O
and	O
73.9	O
µM)	O
compared	O
to	O
controls	O
(42.7	O
and	O
50.4	O
µM).	O

In	O
this	O
direction,	O
to	O
understand	O
the	O
molecular	O
mechanisms	O
behind	O
the	O
elevated	O
tCho	O
level	O
in	O
breast	O
cancer	O
and	O
its	O
association	O
with	O
β-catenin	B
and	O
cyclin	O
D,	O
a	O
study	O
using	O
in	O
vivo	O
MRS	O
and	O
enzyme-linked	O
immunosorbent	O
assay	O
(ELISA)	O
techniques	O
was	O
carried	O
out	O
in	O
our	O
laboratory.	O

We	O
identified	O
elevated	O
NAG	O
as	O
well	O
as	O
decreased	O
alanine	B
as	O
some	O
of	O
the	O
characteristic	O
features	O
of	O
high	O
ARS	O
in	O
HNSCC	O
patients,	O
but	O
alanine	B
is	O
also	O
strongly	O
connected	O
with	O
energy	O
metabolism	O
(Boguszewicz	O
et	O
al.	O
).	O

Five	O
amino	O
acids	O
increased	O
significantly,	O
and	O
two	O
(methylcysteine	O
and	O
serine)	B
decreased.	O

Pentose	B
phosphate	I
pathway	O
and	O
Galactose	B
metabolism	O
were	O
found	O
to	O
be	O
significant,	O
each	O
with	O
p-value	O
0.008741	O
and	O
0.01413	O
respectively.	O

There	O
is	O
also	O
the	O
possibility	O
that	O
amino	O
acids	O
themselves	O
(particularly	O
BCAAs)	O
may	O
affect	O
metabolism	O
by	O
suppressing	O
postprandial	O
glucose	B
levels.	O

All	O
the	O
metabolites	O
measured	O
in	O
this	O
study	O
were	O
detected	O
in	O
all	O
608	O
serum	O
samples	O
except	O
LPI	B
(22:6),	I
which	O
was	O
detected	O
in	O
92.4%	O
of	O
all	O
samples.	O

In	O
fact,	O
glutamine	B
participates	O
in	O
virtually	O
all	O
core	O
metabolic	O
functions	O
including	O
bioenergetics,	O
the	O
support	O
of	O
cell	O
defenses	O
against	O
oxidative	O
stress	O
and	O
as	O
a	O
complement	O
to	O
glucose	B
metabolism	O
in	O
the	O
production	O
of	O
energy	O
and	O
macro-molecules.	O

The	O
column	O
was	O
eluted	O
at	O
a	O
flow	O
rate	O
of	O
450	O
μL/min	O
isocratically	O
for	O
1	O
minute	O
at	O
80%	O
mobile	O
phase	O
A	O
(95:5:0.1	O
vol/vol/vol	O
10	O
mM	O
ammonium	B
acetate/methanol/acetic	O
acid),	O
followed	O
by	O
a	O
linear	O
gradient	O
to	O
80%	O
mobile­phase	O
B	O
(99.9:0.1	O
vol/vol	O
methanol/acetic	O
acid)	O
over	O
2	O
minutes,	O
a	O
linear	O
gradient	O
to	O
100%	O
mobile	O
phase	O
B	O
over	O
7	O
minutes,	O
and	O
then	O
3	O
minutes	O
at	O
100%	O
mobile­phase	O
B.	O
MS	O
analyses	O
were	O
carried	O
out	O
using	O
electrospray	O
ionization	O
in	O
the	O
positive	O
ion	O
mode	O
using	O
full	O
scan	O
analysis	O
over	O
m/z	O
200­1100	O
at	O
70,000	O
resolution	O
and	O
3	O
Hz	O
data	O
acquisition	O
rate.	O

Adenosine	B
and	O
guanosine	B
phosphates,	I
total	O
adenylates	O
and	O
guanylates,	O
and	O
adenylate	B
and	O
guanylate	B
energy	O
charges	O
of	O
normal	O
(left	O
,	O
open	O
dots	O
)	O
and	O
tumor	O
(right	O
,	O
filled	O
dots	O
)	O
tissues	O
obtained	O
from	O
lung	O
(a)	O
and	O
prostate	O
(b)	O
cancer	O
patients.	O

metabolomics,	O
multiple	O
sclerosis,	O
mass	O
spectrometry,	O
pregnancy,	O
ceramides,	B
amino	O
acids,	O
acylcarnitines,	B
steroids,	O
estrogens,	O
biomarkers	O

The	O
exceptions	O
to	O
this	O
general	O
pattern	O
were	O
the	O
oligodendrogliomas:	O
in	O
those	O
tumours,	O
the	O
only	O
significant	O
positive	O
correlations	O
were	O
between	O
lactate	B
and	O
tGlut	O
and	O
between	O
tCr	O
and	O
lactate.	B

Lastly,	O
tryptophan	B
metabolism	O
is	O
important	O
for	O
the	O
activation	O
and	O
suppression	O
of	O
inflammation	O
(,	O
,	O
,	O
).	O

Calibration	O
standards	O
were	O
prepared	O
by	O
dilution	O
of	O
standard	O
stock	O
solutions	O
in	O
ACN/H_2	O
O	O
(5/95;	O
v	O
/v	O
)	O
to	O
obtain	O
seven	O
calibration	O
solutions	O
(calibrants	O
1	O
to	O
7)	O
in	O
micromolar	O
range	O
for	O
HA,	B
taurine,	B
serine,	B
cystine,	B
glycine,	B
methionine,	B
HCy2,	O
DMG,	B
betaine,	B
and	O
choline	B
and	O
in	O
nanomolar	O
range	O
for	O
riboflavin,	B
pyridoxine,	B
cystathionine,	B
pyridoxamine,	B
SAH,	O
SAM,	O
and	O
5-MTHF	O
as	O
described	O
in	O
Table	O
S2	O
(see	O
ESM).	O

Then,	O
50	O
μL	O
of	O
plasma	O
was	O
spiked	O
with	O
10	O
μL	O
of	O
an	O
internal	O
standard	O
(2-chlorophenylalanine,	O
0.3	O
mg/mL)	O
and	O
vortexed	O
for	O
10	O
seconds.	O

mTOR	O
activation	O
is	O
also	O
known	O
to	O
enhance	O
lactate	B
production.	O

The	O
level	O
of	O
urea,	B
a	O
side	O
product	O
of	O
arginine-to-ornithine	O
conversion,	O
was	O
slightly	O
higher	O
in	O
patients	O
with	O
pancreatic	O
cancer.	O

Citrate	B
acid	I
was	O
found	O
at	O
lower	O
concentrations	O
before	O
TURBT.	O

The	O
calibration	O
ranges	O
were	O
0.4–12.5	O
μg/ml	O
for	O
EPA	O
and	O
γ-linolenic;	B
1.2–37.5	O
μg/ml	O
for	O
DHA	O
and	O
linolenic;	O
2.3–75	O
μg/ml	O
for	O
AA	O
and	O
palmitoleic;	B
7.8–250	O
μg/ml	O
for	O
oleic	O
and	O
linoleic	B
and	O
15.6–500	O
μg/ml	O
for	O
palmitic	B
and	O
stearic.	O

Taken	O
together,	O
5-Oxoprolinate,	B
Erythronic	B
acid	I
and	O
N-acetylaspartic	B
acid	I
could	O
serve	O
as	O
prognostic	O
biomarkers	O
to	O
discriminate	O
high-risk	O
HPV	O
infections	O
from	O
non-infected	O
controls.	O

Protein	O
removal	O
via	O
ultrafiltration	O
and	O
acetonitrile	B
precipitation	O
are	O
complementary	O
techniques	O
and	O
both	O
are	O
required	O
to	O
obtain	O
a	O
clear	O
metabolome	O
profile.	O

420	O
µl	O
of	O
filtered	O
serum	O
(volume	O
adjusted	O
with	O
water,	O
when	O
needed)	O
were	O
mixed	O
with	O
120	O
µl	O
of	O
phosphate	B
buffer	O
0.5	O
M	O
(pH	O
7.0±0.1)	O
containing	O
0.75%	O
w/v	O
sodium	O
azide	O
and	O
60	O
µl	O
of	O
5	O
mM	O
TMSP	O
in	O
D_2	O
O	O
(99.9%	O
pure;	O
GOSS	O
Scientific	O
Instruments	O
Ltd,	O
Essex	O
UK)	O
and	O
transferred	O
to	O
an	O
NMR	O
tube.	O

These	O
include	O
an	O
increase	O
in	O
the	O
levels	O
of	O
azelate,	B
suberate,	B
sebacate	B
and	O
3-hydroxysebacate.	B

The	O
AUC	O
values	O
in	O
SqCC	O
prediction	O
for	O
C18:2	B
CE	O
(top),	O
SM	B
22:0	I
(middle)	I
and	O
the	O
2	O
combined	O
lipid	O
markers	O
(bottom)	O
in	O
the	O
(A)	O
training	O
and	O
(B)	O
validation	O
samples.	O

Blood	O
samples	O
(5 mL	O
each)	O
were	O
collected,	O
using	O
heparin	B
as	O
anticoagulant	O
(sampling	O
tubes	O
S-Monovette	O
Hematology	O
7.5 mL	O
from	O
Sartstedt,	O
Nümbrecht,	O
Germany),	O
before	O
dosing	O
(0.0)	O
then	O
0.25,	O
0.5,	O
0.75,	O
1.0,	O
1.25,	O
1.5,	O
2.0,	O
2.5,	O
3.0,	O
4.0,	O
6.0,	O
8.0,	O
12.0,	O
16.0,	O
24.0,	O
and	O
36.0 h	O
post-dose.	O

Cohort	O
description	O
DCIS	O
ductal	O
carcinoma	O
in	O
situ,	O
ER	O
oestrogen	O
receptor,	O
BCS	O
breast	O
conserving	O
surgery,	O
PRE	O
primary	O
reconstruction	O
with	O
expansion,	O
AI	B
aromatase	O
inhibitor,	O
FEC	O
fluorouraicil,	B
epirubicine,	B
cyclophosphamide	O

This	O
is	O
because	O
both	O
ACN	O
and	O
MeOH	B
compete	O
for	O
hydrogen	O
bonding	O
sites	O
on	O
vancomycin	B
CSP	O
with	O
the	O
analytes.	O

However,	O
less	O
frequent	O
RAS	O
inhibitor	O
use	O
cannot	O
explain	O
the	O
observed	O
associations	O
of	O
low	O
25(OH)D	O
and	O
24,25(OH)_2	B
D	O
concentrations	O
with	O
greater	O
microalbuminuria	O
risk	O
because	O
it	O
was	O
slightly	O
more	O
frequent	O
among	O
participants	O
with	O
lower	O
baseline	O
vitamin	B
D	I
metabolite	O
concentrations.	O

The	O
differential	O
signals	O
were	O
identified	O
using	O
Lipidmaps	O
and	O
Human	O
Metabolome	O
Databases	O
(HMDB),	O
obtaining	O
32	O
phospholipids	B
(divided	O
into	O
15	O
PCs,	O
6	O
lysoPCs	O
LPCs	O
and	O
11	O
SMs).	O

Using	O
a	O
VIP	O
threshold	O
of	O
1.5,	O
ketoglutaric	B
acid,	I
sucrose,	B
cellobiose,	B
and	O
hypoxanthine	B
were	O
selected	O
as	O
important	O
features	O
in	O
differentiating	O
the	O
follow-up	O
plasma	O
of	O
the	O
ATG	O
from	O
the	O
ITG.	O

Decreases	O
in	O
N	B
-acetyl	I
glycoproteins	I
may	O
correspond	O
to	O
a	O
breakdown	O
of	O
proteins.	O

Based	O
on	O
the	O
atom	O
transitions	O
of	O
the	O
oxidative	O
and	O
reductive	O
PPP,	O
no	O
significant	O
isotopic	O
enrichment	O
in	O
erythritol	B
was	O
expected.	O

LPL	O
is	O
considered	O
the	O
rate-limiting	O
enzyme	O
for	O
hydrolysis	O
of	O
lipoprotein	O
triglycerides,	B
and	O
it	O
is	O
likely	O
to	O
be	O
secreted	O
by	O
macrophages	O
within	O
atherosclerotic	O
lesions	O
(,).	O

As	O
compared	O
with	O
non-cases,	O
those	O
participants	O
who	O
developed	O
T2D	O
were	O
also	O
more	O
likely	O
to	O
have	O
a	O
higher	O
prevalence	O
of	O
hypertension	O
and	O
dyslipidaemia	O
in	O
addition	O
to	O
higher	O
BMI,	O
fasting	O
glucose	B
and	O
triacylglycerol	B
levels	O
while	O
lower	O
HDL	B
cholesterol	I
levels	O
(Table ).	O

We	O
found	O
that	O
fasting	O
levels	O
of	O
α	B
-hydroxybutyrate	I
and	O
the	O
time	O
courses	O
of	O
α	B
-hydroxybutyrate	I
and	O
BCAAs	O
in	O
response	O
to	O
a	O
glucose	B
challenge	O
characterize	O
IR	O
in	O
youth.	O

γ-GCT:	B
γ-glutamyl	O
cyclotransferase;	O
LDH:	O
lactate	O
dehydrogenase;	O
CoA:	O

The	O
change	O
from	O
baseline	O
in	O
2-OHE_1	O
/16α-OHE_1	B
was	O
significantly	O
different	O
between	O
groups	O
(P	O
=	O
0.045),	O
even	O
after	O
adjustment	O
for	O
baseline	O
values.	O

Surprisingly,	O
the	O
most	O
abundant	O
cholesterol	B
metabolites	O
were	O
found	O
to	O
be	O
C_27	O
and	O
C_24	O
intermediates	O
of	O
the	O
bile	O
acid	O
biosynthetic	O
pathways	O
with	O
structures	O
corresponding	O
to	O
7α-hydroxy-3-oxocholest-4-en-26-oic	B
acid	I
(7.170	O
±	O
2.826	O
ng/ml,	O
mean	O
±	O
S.D.,	O
six	O
subjects),	O
3β-hydroxycholest-5-en-26-oic	B
acid	I
(0.416	O
±	O
0.193	O
ng/ml),	O
7α,x	B
-dihydroxy-3-oxocholest-4-en-26-oic	I
acid	I
(1.330	O
±	O
0.543	O
ng/ml),	O
and	O
7α-hydroxy-3-oxochol-4-en-24-oic	B
acid	I
(0.172	O
±	O
0.085	O
ng/ml),	O
and	O
the	O
C_26	O
sterol	B
7α-hydroxy-26-norcholest-4-ene-3,x	I
-dione	I
(0.204	O
±	O
0.083	O
ng/ml),	O
where	O
x	O
is	O
an	O
oxygen	O
atom	O
either	O
on	O
the	O
CD	O
rings	O
or	O
more	O
likely	O
on	O
the	O
C-17	O
side	O
chain.	O

Phenotypic	O
measurements	O
of	O
CYP2A6	O
activity	O
also	O
confirmed	O
that	O
the	O
NP	O
tribal	O
population	O
has	O
an	O
elevated	O
rate	O
of	O
nicotine	B
metabolism	O
relative	O
to	O
the	O
SW	O
tribal	O
population,	O
and	O
compared	O
to	O
Alaska	O
Native,	O
Caucasian,	O
and	O
African	O
American	O
populations.	O

A	O
metabolite	O
panel	O
consisting	O
of	O
dopamine	B
4-sulfate,	I
MG00/1846Z,9Z,12Z,15Z/00,	O
aspartyl-histidine,	B
and	O
tyrosyl-methionine	B
was	O
found	O
to	O
have	O
the	O
best	O
prediction	O
accuracy	O
for	O
NMIBC.	O

Magnoflorine,	B
one	O
of	O
the	O
aporphine	B
alkaloids,	O
performed	O
better	O
in	O
the	O
Chinese	O
volunteers	O
than	O
in	O
the	O
Africans.	O

Univariate	O
analyses	O
were	O
performed	O
to	O
assess	O
the	O
distributions	O
of	O
paracetamol,	B
its	O
metabolite	O
p	B
-aminophenol	I
and	O
relevant	O
covariates.	O

To	O
each	O
sample	O
316	O
µl	O
MeOH	B
was	O
added	O
and	O
vortexed	O
for	O
30	O
seconds	O
before	O
the	O
addition	O
of	O
633	O
µl	O
DCM.	O

Moreover,	O
we	O
observed	O
for	O
this	O
sample	O
a	O
decrease	O
in	O
the	O
concentrations	O
of	O
most	O
of	O
the	O
TG	B
species	O
from	O
day	O
to	O
day.	O

The	O
compound	O
class	O
of	O
sphingolipids	B
was	O
the	O
most	O
stable	O
one,	O
as	O
all	O
analyzed	O
sphingolipid	B
concentrations	O
were	O
stable	O
on	O
CP	O
and	O
at	O
RT	O
for	O
at	O
least	O
24	O
h.	O

A	O
novel,	O
rapid	O
and	O
sensitive	O
liquid	O
chromatography-tandem	O
mass	O
spectrometric	O
(LC-MS/MS)	O
method	O
was	O
developed	O
and	O
validated	O
for	O
the	O
evaluation	O
of	O
exemestane	O
pharmacokinetics	O
and	O
its	O
metabolites,	O
17β-dihydroexemestane	B
(active	O
metabolite)	O
and	O
17β-dihydroexemestane-17-O-β-D-glucuronide	B
(inactive	O
metabolite)	O
in	O
human	O
plasma.	O

We	O
found	O
that	O
ceramides	B
correlated	O
positively	O
but	O
hexosylceramides	B
correlated	O
negatively	O
with	O
BMI	O
and	O
homeostatic	O
model	O
assessment	O
of	O
insulin	O
resistance	O
(HOMA-IR).	O

Some	O
high	O
molecular	O
weight	O
metabolites	O
such	O
as	O
lipoproteins,	O
fatty	O
acids	O
and	O
phospholipids	B
were	O
also	O
observed.	O

-hydroxylation	O
of	O
cholesterol	B
by	O
neuron-specific	O
CYP46A1,	O
followed	O
by	O
7α-hydroxylation	O
by	O
the	O
presumed	O
liver-specific	O
enzyme	O
CYP39A1.	O

Citrulline,	B
ornithine,	B
arginine	B
and	O
aspartic	B
acid	I
are	O
important	O
intermediates	O
of	O
the	O
urea	B
cycle,	O
which	O
is	O
responsible	O
for	O
the	O
majority	O
of	O
nitrogen	O
excretion	O
through	O
conversion	O
of	O
toxic	O
ammonia	O
to	O
urea	B
in	O
the	O
liver.	O

inflammatory	O
bowel	O
diseases,	O
therapeutic	O
drug	O
monitoring,	O
profiling	O
of	O
thiopurines,	B
comprehensive	O
stability	O
study,	O
sample	O
treatment,	O
clinical	O
analysis,	O
high	O
performance	O
liquid	O
chromatography,	O
mass	O
spectrometry	O

In	O
addition,	O
-(CH_2	O
-)_n	O
VLDL	O
loads	O
strongly	O
in	O
the	O
positive	O
direction	O
of	O
component	O
2	O
while	O
lactate,	B
Mg_2+	O
-EDTA,	O
and	O
Ca_2+	O
-EDTA	O
load	O
strongly	O
in	O
the	O
negative	O
direction	O
suggesting	O
an	O
inverse	O
correlation	O
of	O
these	O
metabolite	O
resonances.	O

Plasma	O
adenosine	B
was	O
decreased	O
in	O
females	O
(,	O
Females).	O

After	O
injection	O
(300	O
μL),	O
the	O
sample	O
was	O
loaded	O
onto	O
an	O
Oasis	O
WAX	O
on-line	O
SPE	O
cartridge	O
with	O
0.1%	O
formic	B
acid	I
in	O
water	O
(1.5	O
mL),	O
and	O
the	O
cartridge	O
was	O
washed	O
with	O
acetonitrile/methanol/water	O
(~0.4	O
mL,	O
1/1/2,	O
v/v/v).	O

The	O
decrease	O
in	O
GluCer	O
and	O
ganglioside	B
GM3	I
species	O
in	O
diabetic	O
monkeys	O
might	O
be	O
attributed	O
to	O
a	O
down-regulation	O
of	O
glycosyltransferases	O
activity,	O
which	O
transfers	O
a	O
specific	O
sugar	O
(e.g.	O
glucose)	B
from	O
an	O
appropriate	O
sugar-nucleotide	O
(e.g.	O
UDP-Glc)	O
to	O
ceramide.	B

Therefore,	O
we	O
aimed	O
to	O
investigate	O
the	O
systemic	O
metabolite	O
and	O
gene	O
expression	O
profiles	O
of	O
subcutaneous	O
adipose	O
tissue	O
and	O
skeletal	O
muscle	O
in	O
(fasting)	O
normoglycemic	B
women	O
but	O
differing	O
in	O
insulin	O
resistance.	O

There	O
was	O
a	O
nearly	O
four-fold	O
increase	O
in	O
guanosine	B
and	O
41	O
and	O
19	O
fold	O
increases	O
in	O
hypoxantine	B
and	O
xanthine,	B
respectively.	O

For	O
both	O
clinical	O
features	O
and	O
CRP	O
measures,	O
dozens	O
of	O
both	O
known	O
and	O
putative	O
oxylipins	B
were	O
found	O
to	O
be	O
highly	O
related,	O
at	O
‘metabolome-wide’	O
significance	O
thresholds.	O

To	O
investigate	O
the	O
alteration	O
of	O
amine-	B
and	O
phenol-containing	O
submetabolome	O
among	O
patients	O
who	O
had	O
undergone	O
cardiac	O
surgery,	O
we	O
used	O
a	O
total	O
of	O
14,642	O
concentration	O
ratios	O
of	O
metabolite	O
peak	O
pairs	O
from	O
all	O
100	O
urine	O
samples	O
in	O
principal	O
component	O
analysis	O
(PCA).	O

On	O
the	O
other	O
hand,	O
although	O
levels	O
of	O
some	O
oxysterols	B
varied	O
according	O
to	O
estrogen	B
receptor	O
expression	O
or	O
tamoxifen-based	O
therapy	O
in	O
the	O
first	O
sampling,	O
they	O
did	O
not	O
differ	O
in	O
the	O
second	O
sampling	O
again,	O
suggesting	O
that	O
the	O
tumor	O
presence	O
plays	O
a	O
key	O
role.	O

Representative	O
chromatograms	O
of	O
the	O
urine	O
extract	O
in	O
a	O
patient	O
with	O
simultaneous	O
detection	O
of	O
DMAP	O
and	O
thiamethoxam	B
are	O
shown	O
in	O
.	O

We	O
generated	O
Sequential	O
Organ	O
Failure	O
Assessment	O
(SOFA)	O
scores	O
for	O
each	O
patient	O
and	O
defined	O
three	O
groups:	O
patients	O
admitted	O
to	O
the	O
ICU	O
post-surgery	O
were	O
categorized	O
as	O
“surgical	O
trauma”,	O
patients	O
admitted	O
to	O
the	O
ICU	O
with	O
suspected	O
or	O
diagnosed	O
infections	O
were	O
categorized	O
as	O
“sepsis”,	O
and	O
patients	O
with	O
hypotension	O
requiring	O
vasopressor	O
therapy	O
to	O
maintain	O
mean	O
BP	O
65 mmHg	O
or	O
greater	O
and	O
with	O
a	O
plasma	O
lactate	B
concentration	O
>2 mmol/	O

The	O
total	O
volume	O
of	O
the	O
sample	O
cell	O
was	O
40	O
μl,	O
and	O
tissue	O
samples	O
weighing	O
an	O
average	O
of	O
25	O
mg	O
were	O
placed	O
in	O
the	O
cell	O
with	O
the	O
remaining	O
volume	O
filled	O
with	O
D_2	O
O	O
containing	O
0.01%	O
trimethylsilyl	B
propionic	I
acid	I
(TSP).	O

For	O
a	O
random	O
classifier,	O
the	O
VUS	O
could	O
be	O
geometrically	O
determined	O
(Landgrebe	O
and	O
Duin	O
)	O
with	O
a	O
value	O
of	O
To	O
illustrate	O
the	O
selectivity	O
of	O
CA 19-9	O
and	O
the	O
predictors,	O
we	O
generated	O
true	O
class	O
rate-plots	B
depicting	O
the	O
ROC	O
surface	O
(Fig. ).	O

A	O
direct	O
correlation	O
(P	O
<	O
0.05)	O
was	O
also	O
observed	O
between	O
the	O
nerve	O
score	O
and	O
serum	O
arginine,	B
as	O
was	O
an	O
inverse	O
correlation	O
(P	O
<	O
0.05)	O
between	O
tHcy	O
and	O
tryptophan	B
and	O
tyrosine.	B

*	O
indicates	O
a	O
solute	O
for	O
which	O
a	O
reagent	O
standard	O
was	O
not	O
run	O
but	O
for	O
which	O
identity	O
was	O
considered	O
well	O
established	O
by	O
MS/MS.	O
_§	O
indicates	O
that	O
the	O
analysis	O
does	O
not	O
distinguish	O
between	O
the	O
D-	O
and	O
L-	O
forms	O
of	O
arabitol.	B

This	O
metabolite	O
is	O
involved	O
in	O
nicotinamide	B
adenine	I
dinucleotide	I
redox	O
reactions,	O
which	O
are	O
essential	O
to	O
the	O
tricarboxylic	B
acid	I
cycle	O
and	O
oxidative	O
phosphorylation.	O

Vitamin	O
B-12	O
treatment	O
increased	O
metabolic	O
markers	O
of	O
myelin	B
integrity	O
and	O
modulators	O
of	O
membrane	O
dynamics,	O
such	O
as	O
plasmalogens	O
(a	O
specific	O
type	O
of	O
ether	B
phospholipids)	I
and	O
other	O
long-chain	O
phospholipids	B
(C38–40).	O

HR-MS	O
and	O
MS_2	O
of	O
the	O
synthetic	O
standard	O
of	O
VLCDCA	B
28:4	I
and	O
VLCDCA	B
28:4	I
extracted	O
from	O
3	O
mL	O
of	O
human	O
plasma	O
and	O
semipurified	O
by	O
anion	O
exchange	O
chromatography.	O

The	O
method	O
is	O
characterized	O
by	O
the	O
following	O
intra-	O
and	O
inter-assay	O
CVs:	O
1.6%	O
and	O
3.3%	O
(L-arginine),	O
3.2%	O
and	O
3.1%	O
(L-citrulline),	O
1.8%	O
and	O
5.9%	O
(DMA),	O
7.5%	O
and	O
9.4%	O
(ADMA),	O
and	O
6.4%	O
and	O
7.1%	O
(SDMA)	O
and	O
was	O
successfully	O
used	O
in	O
patients	O
with	O
hematological	O
malignancies,	O
neurodegenerative	O
disorders,	O
and	O
cardiometabolic	O
diseases.	O

Lipid	O
metabolites	O
with	O
a	O
variable	O
importance	O
in	O
the	O
projection	O
(VIP)	O
score	O
>	O
1	O
were	O
considered	O
to	O
be	O
the	O
metabolites	O
responsible	O
for	O
the	O
differences	O
between	O
healthy	O
controls	O
and	O
AF	B
patients.	O

The	O
concentrations	O
of	O
four	O
metabolites,	O
three	O
(threonine,	O
isoleucine,	B
glutamine)	B
from	O
NMR	O
and	O
one	O
(linolenic	O
acid)	O
from	O
LC–MS	O
were	O
significantly	O
different	O
when	O
comparing	O
response	O
to	O
chemotherapy.	O

Cells	O
were	O
then	O
maintained	O
for	O
18	O
h	O
in	O
DMEM	O
modified	O
to	O
contain	O
10	O
mM	O
[U-_13	B
C_6	I
]glucose	I
and	O
_13	O
C	O
incorporation	O
into	O
palmitate	B
was	O
measured	O
by	O
LC-MS/MS.	O

It	O
has	O
also	O
been	O
reported	O
that	O
other	O
environmental	O
contaminants,	O
including	O
polycyclic	B
aromatic	O
hydrocarbons,	B
are	O
highly	O
detrimental	O
to	O
human	O
health.	O

Then,	O
the	O
reaction	O
was	O
terminated	O
by	O
placing	O
tubes	O
on	O
ice	O
and	O
immediately	O
adding	O
500	O
µl	O
of	O
acetonitrile.	B

The	O
levels	O
of	O
S1P,	O
ceramides,	B
and	O
other	O
sphingolipids	B
in	O
the	O
tumor	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
normal	O
breast	O
tissue.	O

Whole	O
body	O
insulin-mediated	O
glucose	B
disposal	O
(Rd)	O
increased	O
significantly	O
(4.6	O
±	O
0.7	O
to	O
7.2	O
±	O

Albumin-lipid	O
interactions:	O
prostaglandin	B
stability	O
as	O
a	O
probe	O
for	O
characterizing	O
binding	O
sites	O
on	O
vertebrate	O
albumins.	O

Therefore,	O
the	O
temperature	O
was	O
set	O
to	O
26°C	O
after	O
calibration	O
with	O
methanol.	B

The	O
analyses	O
revealed	O
that	O
four	O
canonical	O
pathways	O
(purine	O
nucleotide	O
degradation	O
II,	O
phospholipases,	O
serotonin	B
receptor	O
signaling	O
and	O
LXR/RXR	O
activation)	O
and	O
two	O
network	O
functions	O
(purine	O
nucleotide	O
metabolism	O
and	O
lipid	O
metabolism)	O
were	O
closely	O
related	O
to	O
the	O
identified	O
differential	O
metabolites	O
in	O
both	O
HU	O
and	O
HU+NAFLD.	O

Top	O
metabolites	O
that	O
correlate	O
with	O
separation	O
of	O
the	O
groups	O
include	O
xanthine	B
(VIP:	O
3.5,	O
cvSE:	O
0.69),	O
2-hydroxyvaleric	B
acid	I
(VIP:	O
3.0,	O
cvSE:	O
0.44),	O
succinic	B
acid	I
(VIP:	O
2.5,	O
cvSE:	O
0.78),	O
stearic	B
acid	I
(VIP:	O
2.3,	O
cvSE:	O
0.55)	O
and	O
fructose	B
(VIP:	O
2.0,	O
cvSE:	O
0.87).	O

Elution	O
with	O
methanol	B
improved	O
recovery	O
compared	O
with	O
acetonitrile	B
(data	O
not	O
shown).	O

Through	O
the	O
comparison	O
of	O
different	O
substances	O
between	O
groups,	O
we	O
found	O
that	O
Dodecanoylcarnitine,	B
(3R)-3-isopropenyl-6-oxoheptanoic	B
acid	I
and	O
Tomatidine	B
could	O
be	O
used	O
as	O
potential	O
biomarkers	O
for	O
distinguishing	O
LSIL	O
patients;	O
L-Carnitine,	B
2-Amino-3-methyl-1-	B
Butanol	I
and	O
Choline	B
could	O
be	O
used	O
as	O
potential	O
biomarkers	O
for	O
distinguishing	O
patients	O
with	O
HSIL;	O
Penaresidin	O
A/B,	O
Asn	O
Asn	O
Gln	O
Arg,	O
3-OL-rhamnosyl-3-hydroxydecanoyl-3-hydroxydecanoic	B
acid,	I
Phe	O
Ile	O
Met	O
Val,	O
Ala	O
Ile	O
Gln	O
Arg,	O
Prosopinine,	O
2-amino-14,16-dimethyloctadecan-3-ol	B
and	O
3ʹ-O-Aminopropyl-25-hydroxyvitamin	B
could	O
be	O
used	O
as	O
potential	O
biomarkers	O
for	O
distinguishing	O
patients	O
with	O
CC.	O

Our	O
LC-MS/MS	O
analyses	O
revealed	O
that	O
circulating	O
PC,	O
containing	O
linoleic	B
(LA)	O
and	O
α-linolenic	B
acids	I
(ALA),	O
was	O
increased	O
in	O
NAFLD	O
patients	O
with	O
hypertension.	O

NGT,	O
normal	O
glucose	B
tolerant;	O
IGT,	O
impaired	O
glucose	B
tolerant;	O
NGT-IS,	O
normal	O
glucose	B
tolerant	O
and	O
insulin	O
sensitive	O
(M_FFM	O
>45	O
µmol·min_−1	O
·kg_FFM	O
_−1	O
);	O
NGT-IR,	O
normal	O
glucose	B
tolerant	O
and	O
insulin	O
resistant	O
(M_FFM	O
≤45	O
µmol·min_−1	O
·kg_FFM	O
_−1	O
);	O
IFG,	O
normal	O
glucose	B
tolerant	O
and	O
impaired	O
fasting	O
glucose.	B

The	O
question,	O
therefore,	O
is	O
whether	O
or	O
not	O
glucose	B
transporters	O
operate	O
differently	O
in	O
HBV+	O
and	O
HCV+	O
livers.	O

Moreover,	O
there	O
are	O
evidences	O
confirming	O
that	O
elevated	O
insulin	O
levels	O
induced	O
by	O
infusion	O
in	O
healthy	O
men	O
promote	O
muscle	O
protein	O
anabolism	O
by	O
inhibiting	O
protein	O
breakdown	O
and	O
elicit	O
the	O
ability	O
to	O
stimulate	O
glucose	B
uptake	O
and	O
alanine	B
transport,	O
thus	O
suppressing	O
protein	O
degradation	O
in	O
skeletal	O
muscle	O
.	O

Adenylosuccinate,	B
isovalerate,	B
valerate,	B
N1-methyl-2-pyridone-5-carboxamide,	B
stearoyl	B
sphingomyelin,	I
4-hydroxyphenylpyruvate,	B
aspartylvaline,	B
aspartyltryptophan,	B
tryptophyglycine,	B
glucose-6-phosphate,	B
and	O
fructose-6-phosphate	B
merit	O
further	O
investigation	O
as	O
key	O
small	O
molecules	O
in	O
CRC	O
pathogenesis.	O

The	O
multi-element	O
calibration	O
standard	O
was	O
provided	O
as	O
10	O
mg/l	O
in	O
5%	O
nitric	B
acid	I
and	O
was	O
not	O
in	O
the	O
plasma	O
matrix.	O

As	O
expected,	O
variables	O
that	O
were	O
excluded	O
from	O
further	O
analysis	O
at	O
this	O
stage	O
(29/540)	O
were	O
the	O
most	O
abundant	O
species	O
detected	O
by	O
their	O
respective	O
platforms,	O
e.g.	O
ChoE(18:2)	B

Free	O
palmitic	B
acid	I
(16:0)	O
was	O
positively	O
associated	O
with	O
serum	O
levels	O
of	O
sCD163,	O
and	O
free	O
erucic	B
acid	I
(22:1)	O
was	O
inversely	O
related	O
to	O
serum	O
levels	O
of	O
oxidized	O
LDL.	O

A	O
portion	O
of	O
the	O
_1	O
H-_15	O
N	O
HSQC	O
spectrum	O
of	O
human	O
serum	O
tagged	O
with	O
_15	O
N-cholamine.	B

Most	O
lipid	O
mediator-related	O
studies	O
employ	O
C18-based	O
columns	O
to	O
perform	O
the	O
separation;	O
however,	O
C30	O
column	O
also	O
showed	O
great	O
potential	O
in	O
separation	O
of	O
lipid	O
molecular	O
species	O
[,]	O
and	O
could	O
be	O
used	O
as	O
an	O
alternative	O
for	O
analyzing	O
oxylipins.	B

HETE,	O
hydroxyeicosatetranoic	B
acid.	I

1-(N	B
-acetylcysteinyl)phenanthrene	I

Potential	O
target	O
metabolic	O
pathway	O
analysis	O
revealed	O
that	O
the	O
metabolites,	O
identified	O
by	O
multivariate	O
statistical	O
analysis,	O
are	O
responsible	O
for	O
the	O
metabolism	O
of	O
glycerophospholipid,	B
sphingolipid,	B
ether	O
lipid,	O
and	O
glycerolipid	B
(impact-value ≥ 0.00,	O
).	O

(DNOP	O
-	I
1,2	I
Benzenedicarboxylic	I
acid,	I
bis	O
(2-ethylhexyl)	O
ester).	O

A	O
previous	O
report	O
used	O
an	O
MS-based	O
method	O
to	O
identify	O
biologically	O
relevant	O
synthetic	O
polysulfide	B
compounds,	O
and	O
examined	O
the	O
endogenous	O
formation	O
of	O
polysulfide-related	O
products	O
and	O
metabolites.	O

We	O
assessed	O
whether	O
the	O
risk	O
associations	O
for	O
all	O
estrogen	B
and	O
estrogen	B
metabolism	O
measures	O
listed	O
in	O
were	O
modified	O
by	O
time	O
from	O
blood	O
draw	O
to	O
diagnosis,	O
by	O
period	O
of	O
blood	O
draw	O
(and	O
therefore	O
by	O
the	O
length	O
of	O
time	O
blood	O
was	O
stored	O
before	O
assay),	O
by	O
age	O
at	O
study	O
entry,	O
or	O
by	O
history	O
of	O
menopausal	O
hormone	O
therapy;	O
no	O
statistically	O
significant	O
interactions	O
were	O
noted	O
(data	O
not	O
shown).	O

(B)	O
In	O
FSGS	O
patients,	O
as	O
myo-inositol	B
increased,	O
myo-inositol	O
oxygenase	O
expression	O
significantly	O
decreased.	O

Androstenedione	B
(A)	O
is	O
the	O
immediate	O
precursor	O
of	O
T.	O

However,	O
the	O
hexapeptide	O
N	O
_2	B
-cysteinesulfinyl-PhIP	I
LQQC*PF	O
(C-[S=O]-PhIP,	O
t	O
_R	O
=	O
16.8	O
min,	O
[M+2H]_2+	O
m/z	O
487.4	O
and	O
489.7	O
for	O
PhIP	O
and	O
[_2	O
H_5	O
]-PhIP-modified	O
peptides)	O
was	O
recovered	O
from	O
HONH-PhIP-modified	O
SA,	O
following	O
digestion	O
with	O
trypsin/chymotrypsin	O
without	O
heat	O
denaturation	O
and	O
DTT	O
treatment.	O

Our	O
research	O
is	O
consistent	O
with	O
the	O
report	O
that	O
2-ketobutyric	B
acid	I
is	O
associated	O
with	O
both	O
prevalent	O
diabetes	O
(OR:	O
1.43,	O
95% CI	O
(1.06,1.92))	O
and	O
incident	O
diabetes	O
(OR:	O
1.81,	O
95% CI	O
(1.35,	O
2.42)	O
while	O
glycine	B
is	O
found	O
inversely	O
associated	O
with	O
diabetes	O
risk.	O

Lipoprotein	O
particle	O
sizes	O
(E)	O
and	O
lipoprotein	O
composition;	O
lipids	O
within	O
lipoproteins	O
(F),	O
cholesterol	B
within	O
lipoproteins	O
(G)	O
and	O
triglycerides	B
within	O
lipoproteins	O
(H)	O
at	O
room	O
temperature	O
before	O
(red	O
bars)	O
and	O
during	O
cold	O
exposure	O
(blue).	O

The	O
difference	O
in	O
one	O
metabolite,	O
meso-erythritol	B
(nominal	O
P	O
value	O
=	O
0.0004,	O
FDR	O
=	O
0.0435),	O
reached	O
the	O
FDR	O
threshold	O
for	O
statistical	O
significance,	O
and	O
the	O
concentration	O
of	O
meso-erythritol	B
was	O
13.4-fold	O
greater	O
in	O
the	O
baseline	O
pooled	O
blood	O
aliquots	O
from	O
participants	O
with	O
incident	O
central	O
adiposity	O
gain	O
compared	O
with	O
pooled	O
blood	O
aliquots	O
from	O
participants	O
who	O
maintained	O
a	O
stable	O
adiposity	O
phenotype.	O

This	O
supports	O
the	O
glycolytic	B
shift	O
induced	O
by	O
ACM	O
from	O
obese	O
patients	O
in	O
vitro	O
and	O
suggests	O
that	O
in	O
vivo	O
,	O
a	O
shift	O
to	O
glycolysis	O
is	O
associated	O
with	O
obesity	O
and	O
may	O
provide	O
a	O
mechanism	O
by	O
which	O
obesity	O
promotes	O
tumorigenesis	O
in	O
EAC.	O

After	O
normalization	O
for	O
gene	O
copies	O
and	O
number	O
of	O
samples,	O
PICRUSt	O
showed	O
great	O
contributions	O
of	O
the	O
Pseudomonas	O
,	O
Sphingomonas	B
,	O
Acinetobacter	O
and	O
Delftia	O
genera	O
in	O
the	O
peripheral	O
and	O
portal	O
blood	O
to	O
iron-related	O
KOrths	O
(K02014,	O
K07165,	O
K03832)	O
(Fig.	O

Concordance	O
correlation	O
coefficients	O
were	O
close	O
to	O
1	O
for	O
all	O
parent	O
drugs,	O
the	O
measured	O
metabolites,	O
and	O
the	O
sums	O
of	O
parent	O
drug	O
and	O
metabolite	O
(range	O
between	O
0.95	O
and	O
0.99;	O
olanzapine,	B
0.92).	O

SRM	O
1950	O
has	O
been	O
employed	O
in	O
an	O
inter	O
laboratory	O
comparison	O
study	O
for	O
lipid	O
profiling,	O
we	O
compared	O
our	O
results	O
to	O
the	O
concentrations	O
of	O
oxylipins	B
reported	O
by	O
Bowden	O
et	O
al	O
.,	O
using	O
LipidQC	O
software.	O

Although	O
CTM-1−10	O
can	O
be	O
developed	O
from	O
thiamethoxam	B
directly,	O
CM-1−13	O
is	O
always	O
developed	O
from	O
clothianidin,	B
which	O
can	O
be	O
developed	O
from	O
thiamethoxam.	B

The	O
first	O
contained	O
a	O
high	O
concentration	O
of	O
JWH-018	O
N	B
-(5-hydroxypentyl)	I
glucuronide	I
that	O
is	O
available	O
as	O
a	O
reference	O
standard.	O

No	O
studies	O
have	O
investigated	O
F_2	B
-isoprostanes	I
(F_2	O
-IsoPs),	O
valid	O
biomarkers	O
of	O
systemic	O
oxidative	O
stress,	O
in	O
association	O
with	O
breast	O
cancer	O
prognosis.	O

The	O
instrumental	O
detection	O
limit	O
(IDL),	O
defined	O
as	O
3	O
times	O
the	O
average	O
baseline	O
noise,	O
was	O
lower	O
for	O
BDCPP	O
(0.3	O
pg	B
per	O
5	O
μL	O
injection)	O
than	O
for	O
DPP	O
(1.7	O
pg	B
per	O
5	O
μL	O
injection).	O

The	O
three	O
together	O
catalyze	O
the	O
conversion	O
of	O
uridine/cytidine	O
containing	O
nucleotide	O
triphosphates	B
to	O
their	O
deoxygenated	O
counterparts,	O
a	O
key	O
step	O
in	O
DNA	O
synthesis.	O

Formate	B
is	O
an	O
essential	O
intermediary	O
metabolite	O
in	O
virtually	O
all	O
living	O
organisms,	O
but	O
in	O
this	O
study,	O
formate	B
was	O
found	O
in	O
low	O
levels	O
in	O
IBD	O
patients	O
(Table ).	O

In	O
the	O
case	O
of	O
compound	O
classes	O
(i.e.	O
level	O
3	O
annotations),	O
we	O
mapped	O
metabolites	O
to	O
their	O
closest	O
annotated	O
chemical	O
entity	O
(i.e.	O
gluconic	B
acid	I
for	O
sugar	O
acids,	O
sucrose	B
for	O
disaccharides).	B

These	O
results	O
begin	O
clinically	O
validating	O
the	O
LC-MS/MS	O
assay	O
for	O
detecting	O
and	O
quantifying	O
aminoalkylindole	B
metabolites.	O

The	O
stock	O
solutions	O
were	O
prepared	O
as	O
follows:	O
6TG	O
2	O
mg/mL	O
in	O
1M	O
sodium	B
hydroxide,	I
6MMP	O
2	O
mg/mL	O
in	O
1M	O
sodium	B
hydroxide,	I
6TG	O
IS	O
1	O
mg/mL	O
in	O
DMSO,	B
and	O
6MMP	O
IS	O
2.5	O
mg/mL	O
in	O
methanol.	B

In	O
contrast,	O
nonanoic	B
acid	I
was	O
high	O
in	O
the	O
OSCC	O
group	O
compared	O
to	O
patients	O
with	O
OD,	O
and	O
also	O
pre-	O
and	O
postoperative	O
comparisons	O
of	O
OSCC	O
revealed	O
a	O
high	O
value	O
in	O
nonanoic	B
acid.	I

Long	O
chain,	O
polyunsaturated,	O
branched	O
chain,	O
and	O
monohydroxy	B
fatty	O
acids	O
were	O
consistently	O
decreased	O
in	O
all	O
IBD	O
and	O
CD	O
compared	O
with	O
controls,	O
as	O
well	O
as	O
in	O
CD	O
compared	O
with	O
UC.	O

We	O
identified	O
L-methionine,	B
the	O
ratio	O
of	O
L-asparagine	B
to	O
L-aspartic	B
acid,	I
glutaric	B
acid,	I
L-sorbose	B
and	O
vanillylmandelic	B
acid	I
as	O
predictors	O
of	O
violence	O
in	O
schizophrenia	O
patients.	O

When	O
assessing	O
changes	O
in	O
metabolite	O
levels	O
across	O
timepoints	O
while	O
controlling	O
for	O
age,	O
gender	O
and	O
BMI,	O
5	O
metabolites	O
had	O
FDR	O
<	O
0.2:	O
alanine,	B
C14:1-OH,	B
C16:1,	B
C18:2,	B
C20:4.	B

Accordingly,	O
anti-inflammatory	O
and	O
vasodilatory	O
oxylipins	B
had	O
significantly	O
higher	O
concentrations	O
in	O
female	O
urine	O
than	O
in	O
male	O
urine.	O

The	O
hydroxykynurenine:XA	O
ratio,	O
a	O
biomarker	O
of	O
vitamin	O
B-6	O
insufficiency,	O
was	O
not	O
a	O
significant	O
discriminatory	O
variable	O
between	O
the	O
cystathionine	B
groups	O
in	O
PLS-DA.	O

The	O
contribution	O
of	O
selected	O
serum	O
inflammation	O
biomarker	O
and	O
cytokine	O
concentrations	O
as	O
independent	O
predictors	O
of	O
tryptophan,	B
its	O
metabolites,	O
and	O
pyridoxal	B
5′-phosphate	I
in	O
a	O
subset	O
of	O
healthy	O
young	O
adults	O
from	O
the	O
TSS_1	O

However,	O
except	O
for	O
the	O
association	O
between	O
alanine	B
and	O
1styear	O
recurrent	O
wheezing	O
using	O
combined	O
sample	O
(n	O
=	O
140)	O
analysis,	O
none	O
of	O
the	O
results	O
were	O
significant	O
after	O
adjusting	O
for	O
multiple	O
testing.	O

CES-D	O
correlated	O
negatively	O
with	O
isovalerylcarnitine,	B
isobutyrylcarnitine,	B
and	O
propionylcarnitine	B
in	O
the	O
HIV-positive	O
validation	O
cohort	O
and	O
negatively	O
with	O
phenylacetate	B
and	O
isobutyrylcarnitine	B
in	O
the	O
HIV-negative	O
cohort	O
(p<0.05,	O
Spearman	O
correlation).	O

Additionally,	O
excess	O
circulation	O
of	O
glutamic	B
acid	I
during	O
the	O
disease	O
state	O
requires	O
special	O
attention	O
in	O
this	O
particular	O
human	O
population	O
as	O
it	O
can	O
be	O
associated	O
with	O
central	O
nervous	O
system	O
damage,	O
which	O
is	O
sometimes	O
associated	O
with	O
severe	O
pneumonia	O
.	O

Lower	O
2	O
pathway	O
metabolism	O
has	O
been	O
associated	O
with	O
increased	O
postmenopausal	O
breast	O
cancer	O
risk	O
and	O
could	O
potentially	O
offer	O
a	O
partial	O
explanation	O
for	O
the	O
modest	O
increased	O
risk	O
observed	O
for	O
prenatally	O
DES	B
exposed	O
women.	O

The	O
pathway	O
analysis	O
suggested	O
a	O
number	O
of	O
significantly	O
altered	O
pathways,	O
with	O
the	O
pathways	O
phenylalanine	B
metabolism,	O
aminoacyl-tRNA	B
biosynthesis,	O
nitrogen	O
metabolism,	O
lysine	B
degradation,	O
pantothenate	B
and	O
CoA	O
biosynthesis	O
and	O
arginine	B
and	O
proline	B
metabolism	O
among	O
the	O
top-listed	O
pathways	O
with	O
three	O
or	O
more	O
metabolite	O
hits.	O

Fourteen	O
of	O
the	O
MS	O
measured	O
metabolites,	O
including	O
acylcarnitines,	B
amino	O
acids,	O
biogenic	O
amines	O
and	O
glycerophospholipids,	B
had	O
significantly	O
different	O
levels	O
between	O
patients	O
and	O
controls	O
(P	O
⩽0.05).	O

Temperature	O
calibration	O
was	O
performed	O
using	O
a	O
100%	O
d_4	B
-methanol	I
sample.	O

This	O
reduction	O
is	O
particularly	O
pronounced	O
for	O
nucleobases	O
and	O
amines,	O
in	O
keeping	O
with	O
the	O
basic	O
nature	O
of	O
the	O
ammonium	B
salt	O
additives.	O

Consistent	O
with	O
the	O
hypothesis	O
that	O
inflammation	O
activates	O
the	O
kynurenine	B
metabolic	O
pathway,	O
IL-1RA	O
was	O
significantly	O
correlated	O
with	O
a	O
proxy	O
measure	O
of	O
IDO	O
,	O
Kyn/TRP	O

The	O
major	O
findings	O
of	O
this	O
study	O
are	O
that	O
rectal	O
absorption	O
of	O
methadone	B
is	O
rapid	O
and	O
the	O
bioavailability	O
of	O
the	O
drug	O
given	O
by	O
this	O
route	O
is	O
76%,	O
only	O
slightly	O
lower	O
than	O
reported	O
by	O
us	O
for	O
oral	O
and	O
nasal	O
administration.	O

Remarkably,	O
citrate	B
was	O
positively	O
correlated	O
with	O
phenylalanine,	B
glutamine,	B
tyrosine	B
and	O
TMAO	B
between	O
patients	O
of	O
psychological	O
suboptimal	O
health	O
and	O
healthy	O
controls.	O

i	O
,	O
5	O
n	O
KOH/EtOH	O
(±	O
benzene);	B
room	O
temperature,	O
12	O
h	O
(99%,	O
β-ionone;	B
96%,	O
β-apo-12′-carotenoic	B
acid;	I
92%,	O
β-apo-10′-carotenoic	B
acid;	I
94%,	O
β-apo-14′-carotenoic	B
acid).	O

Then,	O
the	O
mixture	O
was	O
sonicated	O
in	O
an	O
ultrasonic	O
bath	O
(ambient	O
temperature	O
×	O
1	O
min),	O
extracted	O
in	O
dark	O
on	O
an	O
orbital	O
shaker	O
(Torrey	O
Pines	B
Scientific	O
Inc.;	O
San	O
Marcos,	O
CA,	O
USA)	O
(750	O
rpm	O
at	O
4	O
°C	O
×	O
2	O
h),	O
centrifuged	O
at	O
4	O
°C	O
(13,000	O
rpm	O
×	O
5	O
min).	O

[,	O
]	O
Although	O
choline	B
was	O
accurately	O
identified	O
using	O
a	O
commercial	O
standard	O
and	O
has	O
a	O
low	O
p	O
-value	O
of	O
6.0E-04,	O
including	O
it	O
in	O
the	O
model	O
would	O
likely	O
bias	O
the	O
clinical	O
results	O
to	O
a	O
significant	O
degree	O
based	O
on	O
the	O
dietary	O
intake	O
of	O
patients	O
in	O
addition	O
to	O
any	O
effect	O
caused	O
by	O
disease;	O
therefore	O
we	O
chose	O
to	O
exclude	O
this	O
species.	O

For	O
minors,	O
the	O
median	O
levels	O
of	O
most	O
phthalate	B
metabolites	O
in	O
boys	O
(n	O
=	O
54)	O
was	O
higher	O
than	O
those	O
in	O
girls	O
(n	O
=	O
43),	O
but	O
no	O
statistical	O
significance	O
was	O
observed.	O

Remarkably,	O
the	O
PROVIDE	O
Study,	O
a	O
recent	O
randomized,	O
double-blind,	O
placebo	O
controlled	O
trial	O
has	O
stressed	O
the	O
benefit	O
of	O
leucine	B
plus	O
vitamin	B
D3	I
supplementation	O
on	O
measures	O
of	O
sarcopenia	O
in	O
older	O
adults.	O

In	O
our	O
study,	O
intramuscular	O
triglycerides	B
were	O
not	O
increased	O
in	O
subjects	O
with	O
high	O
HOMA-IR.	O

The	O
analytical	O
measurement	O
range	O
of	O
the	O
creatinine	B
in	O
urine	O
was	O
250–35,400	O
μM.	O

When	O
the	O
analyses	O
were	O
restricted	O
to	O
males	O
without	O
missing	O
chemical	O
data,	O
the	O
observed	O
association	O
with	O
the	O
fourth	O
quartile	O
of	O
urinary	O
paracetamol	B
remained	O
although	O
it	O
was	O
slightly	O
attenuated	O
(Supplementary	O
data,	O
Table	O
SII).	O

Heating	O
meat	O
creates	O
various	O
imidazoquinoline,	B
imidazoquinoxaline	B
and	O
imidazopyridine	B
compounds	O
which	O
are	O
potent	O
and	O
highly	O
mutagenic	O
towards	O
some	O
strains	O
of	O
Salmonella	O
typhimurium.	O

PC	O
aa	O
C28:1;	B
11.	O

Citrate	B
also	O
connects	O
the	O
TCA	O
cycle	O
with	O
hepatic	O
fatty	O
acid	O
and	O
cholesterol	B
synthesis	O
by	O
being	O
exported	O
via	O
transport	O
proteins	O
from	O
mitochondrion	O
to	O
cytosol	O
where	O
it	O
is	O
cleaved	O
to	O
acetyl-CoA	B
by	O
ATP-citrate	O
lyase.	O

Other	O
baseline	O
variables	O
included	O
age,	O
sex,	O
diabetes	O
defined	O
according	O
to	O
the	O
International	O
Classification	O
of	O
Diseases,	O
Tenth	O
Revision	O
(ICD-10)	O
codes	O
E10-E14,	O
systolic	O
blood	O
pressure,	O
diastolic	O
blood	O
pressure,	O
hemoglobin,	O
albumin,	O
calcium,	O
phosphate,	B
and	O
use	O
of	O
renin-angiotensin	O
system	O
inhibitor,	O
beta-blocker,	O
and	O
calcium	O
blocker.	O

On	O
the	O
other	O
hand,	O
enhanced	O
expression	O
levels	O
of	O
carnosine,	B
phenylacetyglycine,	B
pyruvate,	B
m-hydroxyphenylacetate,	B
α-ketoglutarate,	B
acetate,	B
acetoacetate	B
and	O
acetone	B
were	O
found	O
in	O
the	O
urine	O
of	O
COPD	O
patients	O
relative	O
to	O
healthy	O
controls.	O

We	O
do	O
not	O
find	O
differences	O
in	O
ceramides	B
between	O
the	O
darunavir/cobicistat-based	O
and	O
the	O
integrase	O
inhibitor-based	O
groups.	O

Methods	O
for	O
profiling	O
bioactive	O
lipids	O
such	O
as	O
eicosanoids	B
in	O
CLL	O
cells	O
to	O
better	O
understand	O
the	O
signalling	O
cascade	O
has	O
been	O
previously	O
performed.	O

To	O
fully	O
validate	O
the	O
use	O
of	O
urinary	O
conjugates	O
of	O
α-TL	B
as	O
a	O
potential	O
biomarker	O
of	O
oxidative	O
stress,	O
it	O
will	O
be	O
necessary	O
to	O
synthesize	O
the	O
deuterated	O
conjugates	O
of	O
α-TL	B
and	O
α-CEHC	B
to	O
use	O
them	O
as	O
internal	O
standards	O
for	O
the	O
assay	O
in	O
place	O
of	O
the	O
current	O
type	O
II	O
internal	O
standards	O
(androsterone	O
glucuronide	I
and	O
lithocholic	B
acid	I
sulfate)	I
and	O
to	O
carry	O
out	O
the	O
following	O
additional	O
studies.	O

The	O
highest	O
impact	O
value	O
was	O
obtained	O
for	O
the	O
alanine,	B
aspartate,	B
and	O
glutamate	B
metabolic	O
pathways;	O
these	O
results	O
were	O
consistent	O
with	O
the	O
global	O
pathway	O
analysis	O
(Figures	O
S4	O
and	O
S5;	O
impact	O
value	O
>	O
0.4,	O
FDR	O
p	O
-value	O
<	O
0.05).	O

-9,	O
cis	O
)),	O
and	O
1,2-dielaidoyl-sn	B
-glycero-3-phosphoethanolamine	I
(PE	O
18:1(n	O
-9,	O
trans	O
)/18:1(n	O

As	O
for	O
the	O
inflammatory	O
mediators	O
in	O
induced	O
sputum	O
supernatant,	O
we	O
found	O
that	O
IL-1β	B
was	O
significantly	O
elevated	O
in	O
obese	O
asthmatic	O
subjects	O
compared	O
with	O
lean	O
asthmatic	O
subjects	O
(P	O
=	O
0.047).	O

The	O
dehydrated	O
compounds	O
7,	O
10,	O
14,	O
and	O
17	O
and	O
the	O
sulfoxide	B
derivatives	O
8,	O
11,	O
15,	O
and	O
18,	O
were	O
analyzed	O
in	O
positive	O
mode	O
monitoring	O
for	O
the	O
transitions	O
m/z	O
340	O
→	O
m/z	O
209.0419	O
and	O
m/z	O
356	O
→	O
m/z	O
209.0419	O
respectively.	O

Indeed,	O
it	O
has	O
been	O
shown	O
that	O
there	O
was	O
a	O
significant	O
increase	O
in	O
interstitial	O
glycerol	B
level	O
immediately	O
following	O
trauma	O
on	O
the	O
rat	O
brain,	O
and	O
it	O
was	O
concluded	O
that	O
interstitial	O
glycerol	B
could	O
serve	O
as	O
a	O
marker	O
for	O
phospholipid	B
degradation	O
in	O
acute	O
brain	O
injury.	O

The	O
KEGG	O
analysis	O
offered	O
us	O
a	O
foundation	O
on	O
which	O
to	O
determine	O
that	O
the	O
metabolite	O
D-glutamic	B
was	O
indispensable	O
to	O
AF.	B

Of	O
the	O
lipid	O
metabolites,	O
2-hydroxypalmitate	B
(2HP),	O
with	O
a	O
sensitivity	O
of	O
80	O
and	O
a	O
specificity	O
of	O
63,	O
was	O
the	O
most	O
accurate	O
distinguishing	O
lipid	O
marker	O
between	O
HCC	O
patients	O
and	O
cirrhosis	O
controls	O
(AUC	O
=	O
0.736,	O
P	O
<	O
0.0004).	O

Significant	O
differences	O
in	O
relative	O
abundance	O
of	O
Lactobacillus,	B
Ruminococcus,	O
Gemellaceae	O
and	O
Anaerofustis	O
were	O
observed	O
between	O
treatments	O
using	O
community	O
level	O
16S	O
rRNA	O
profiling.	O

Several	O
mobile	O
phases	O
had	O
been	O
tested:	O
0.05%	O
formic	B
acid,	I
0.1%	O
formic	B
acid,	I
0.05%	O
acetic	B
acid,	I
0.1%	O
acetic	B
acid,	I
5 mmol/	O

Glutathione	B
has	O
also	O
been	O
implicated	O
in	O
growth-factor-mediated	O
chemoresistance	O
of	O
colon	O
cancer	O
cells.	O

Additionally,	O
as	O
a	O
routine	O
constituent	O
of	O
most	O
protein-based	O
foods	O
or	O
dietary	O
proteins,	O
serum	O
tryptophan	B
level	O
could	O
be	O
regulated	O
conveniently	O
by	O
diet,	O
as	O
long	O
as	O
the	O
metabolic	O
and	O
physiological	O
mechanism	O
and	O
safety	O
is	O
clarified.	O

Interestingly,	O
while	O
the	O
level	O
of	O
24R	O
,25(OH)_2	O
D_3	O
correlates	O
well	O
with	O
the	O
level	O
of	O
25(OH)D_3	O
in	O
two	O
groups	O
of	O
51	O
(17	O
subjects	O
×	O
3	O
time	O
points)	O
measurements	O
(R	O
_2	O
=0.8065	O
in	O
fall	O
and	O
R	O
_2	O
=0.7452	O
in	O
winter),	O
the	O
level	O
of	O
1α,25(OH)_2	B
D_3	O
correlates	O
with	O
the	O
level	O
of	O
25(OH)D_3	O
poorly	O

3-hydroxyisovalerate,	B
also	O
named	O
β-hydroxyisovalerate	B
or	O
3-hydroxy-3-methylbutyric	B
acid,	I
is	O
a	O
final	O
product	O
of	O
leucine	B
catabolism,	O
which	O
is	O
not	O
further	O
degraded	O
and,	O
therefore,	O
can	O
be	O
contemplated	O
as	O
a	O
useful	O
biomarker.	O

Subsequently,	O
200 μL	O
citric	O
acid/phosphate	O
buffer	O
(pH	O
3)	O
was	O
added	O
to	O
the	O
total	O
and	O
free	O
urine	O
samples,	O
and	O
oxidised	O
lipids	O
were	O
extracted	O
by	O
adding	O
1 mL	O
ethyl	B
acetate	I
followed	O
by	O
shaking	O
for	O
1 min.	O

Ascorbic	B
acid	I
had	O
been	O
added	O
to	O
the	O
samples	O
to	O
prevent	O
oxidation	O
of	O
individual	O
EM.	O

Eight	O
other	O
metabolites,	O
acetate,	B
acetone,	B
citrate,	B
creatine,	B
creatinine,	B
lactate,	B
methylmalonate,	B
and	O
succinate	B
were	O
identified	O
as	O
being	O
uniquely	O
altered	O
in	O
urine	O
samples	O
from	O
NMO-SD	O
patients	O
relative	O
to	O
MS	O
patients.	O

LC-MRM-MS	O
Chromatograms	O
for	O
19-HETE	O
and	O
20-HETE	B
at	O
three	O
different	O
ratios	O
in	O
neat	O
solution.	O

Thus,	O
the	O
structure	O
of	O
the	O
modified	O
peptide	O
in	O
Fraction	O
5	O
is	O
assigned	O
Y*TK	O
with	O
the	O
site	O
of	O
adduction	O
occurring	O
between	O
the	O
4-HO-tyrosine	B
group	O
and	O
the	O
C-2	O
imidazole	B
atom	O
of	O
NO_2	O
-PhIP.	O

To	O
determine	O
whether	O
sarcosine	B
elevation	O
in	O
prostate	O
cancer	O
has	O
biological	O
relevance,	O
we	O
measured	O
its	O
levels	O
in	O
prostate	O
cancer	O
cell	O
lines	O
VCaP,	O
DU145,	O
22RV1	O
and	O
LNCaP	O
(n=3	O
each)	O
and	O
their	O
benign	O
epithelial	O
counterparts,	O
primary	O
benign	O
prostate	O
epithelial	O
cells	O
(PrEC,	O
n=2)	O
and	O
immortalized	O
benign	O
RWPE	O
prostate	O
cells	O
(n=3).	O

The	O
hydrodynamic	B
size	O
and	O
the	O
zeta	O
potential	O
were	O
determined	O
by	O
dynamic	O
light	O
scattering	O
(DLS)	O
(Zetasizer	O
Nano	O
ZS	O
(Malvern	O
Instrument,	O
UK)).	O

(D)	O
Caffeine	B
metabolism.	O

For	O
instance	O
some	O
of	O
the	O
most	O
relevant	O
metabolic	O
changes	O
in	O
blood	O
serum	O
of	O
patients	O
at	O
diagnosis	O
and	O
after	O
the	O
end	O
of	O
chemotherapy	O
included	O
the	O
accumulation	O
of	O
blood	O
serum	O
creatinine	B
and	O
glucose	B
in	O
patients	O
with	O
active	O
disease	O
which	O
are	O
likely	O
associated	O
with	O
the	O
mild	O
renal	O
dysfunction	O
suffered	O
by	O
MM	O
patients.	O

The	O
cartridge	O
was	O
then	O
washed	O
with	O
100	O
µL	O
of	O
30%	O
CH_3	O
OH	O
in	O
H_2	O
O,	O
placed	O
under	O
vacuum	O
overnight	O
to	O
remove	O
residual	O
H_2	O
O,	O
and	O
then	O
washed	O
twice	O
with	O
1	O
mL	O
acetone	B
which	O
had	O
been	O
dried	O
with	O
Na_2	O
SO_4	O
.	O

The	O
metabolites	O
will	O
be	O
also	O
conjugated	O
to	O
glucuronide	B
and	O
eliminated	O
via	O
the	O
urine.	O

Xanthine,	B
O-succinyl-homoserine,	B
N-acylproline,	B
glutarylcarnitine,	B
tyrosine,	B
5-methylcytosine	B
had	O
been	O
corrected	O
for	O
a	O
significant	O
age	O
dependence.	O

In	O
meningiomas,	O
alanine,	B
another	O
product	O
of	O
glycolysis,	O
was	O
also	O
positively	O
correlated	O
with	O
tCr	O
(Figs	O
and	O
).	O

However,	O
glycogen	B
reserves	O
being	O
limited,	O
other	O
substrates	O
such	O
as	O
gluconeogenic	O
amino	O
acids	O
are	O
progressively	O
recruited	O
to	O
synthesize	O
glucose	B
through	O
gluconeogenesis.	O

The	O
ions	O
observed	O
at	O
m/z	O
242.1	O
in	O
the	O
mass	O
spectrum	O
of	O
NO_2	O
-PhIP-modified	O
peptide	O
and	O
at	O
m/z	O
247.1	O
in	O
the	O
spectrum	O
of	O
NO_2	O
-[_2	O
H_5	O
]-PhIP-modified	O
peptide	O
were	O
identified	O
as	O
the	O
protonated	O
2-thioimdazole	B
derivatives	O
of	O
PhIP	O
and	O
[_2	O
H_5	O
]-PhIP,	O
by	O
their	O
spectra	O
at	O
the	O
MS_3	O
scan	O
stage	O
as	O
reported	O
previously.	O

As	O
shown	O
in	O
,	O
metabolic	O
disorders	O
of	O
glucose	B
may	O
be	O
the	O
shared	O
pathway	O
of	O
YDYHS	O
and	O
YYDS.	O

The	O
mixture	O
was	O
then	O
analyzed	O
under	O
the	O
conditions	O
as	O
described	O
in	O
the	O
Section	O
LC-MS/MS	O
Detection	O
of	O
Anthocyanin	B
Conjugates.	O

Lactate	B
is	O
an	O
end	O
product	O
of	O
glycolysis	O
which	O
shows	O
elevation	O
during	O
tissue	O
hypoxia	O
and	O
ischemia.	O

For	O
analysis	O
of	O
tissue	O
metabolite	O
levels,	O
fresh	O
frozen	O
liver	O
tumor	O
specimens	O
were	O
pulverized	O
by	O
cryogenic	O
grinding	O
using	O
a	O
5mm	O
stainless	O
steel	O
ball	O
bearing	O
(Cryomill,	O
Retsch)	O
before	O
being	O
extracted	O
in	O
a	O
monophasic	O
mixture	O
of	O
2:5:2	O
water:methanol:chloroform	O
with	O
aminopimelic	B
acid	I
internal	O
standard.	O

Indeed,	O
kynurenine	B
can	O
be	O
effectively	O
transported	O
over	O
the	O
blood-brain	O
barrier	O
(BBB)	O
through	O
the	O
neutral	O
amino	O
acid	O
transporter.	O

Galactose	B
enters	O
glycolysis	O
through	O
the	O
Leloir	O
pathway,	O
which	O
occurs	O
at	O
a	O
significantly	O
lower	O
rate	O
than	O
glucose	B
entry	O
into	O
glycolysis.	O

At	O
becomes	O
apparent	O
that	O
the	O
increase	O
in	O
the	O
proportion	O
of	O
furans	O
and	O
terpenes	B
in	O
the	O
urine	O
of	O
the	O
healthies	O
against	O
the	O
patients,	O
while	O
the	O
spectrum	O
in	O
patients	O
is	O
shifted	O
to	O
the	O
phenols	O
and	O
sulfur-containing	O
compounds	O
(Fig.	O

This	O
co-compartmentalization	O
of	O
the	O
metabolic	O
processes	O
rather	O
than	O
simple	O
enzymatic	O
activity	O
explains	O
why	O
the	O
close	O
relationship	O
between	O
hippurate	B
and	O
TCA	O
cycle	O
intermediate	O
excretion	O
is	O
not	O
directly	O
apparent	O
from	O
,	O
which	O
maps	O
shortest	O
path	O
connectivities	O
between	O
metabolites	O
based	O
on	O
the	O
KEGG	O
pathways.	O

Underlying	O
diagnosis	O
was	O
ascertained	O
by	O
histology	O
and	O
metastasis	O
in	O
ACC	O
and	O
by	O
clinical	O
follow-up	O
[median	O
duration	B
52	O
(range	O
26–201)	O
months]	O
without	O
evidence	O
of	O
metastasis	O
in	O
ACA.	O

It	O
is	O
involved	O
in	O
purine	B
metabolism	O
and	O
is	O
a	O
precursor	O
of	O
uric	B
acid.	I

Reserpine	B
stock	O
solution	O
was	O
0.2	O
mg/mL	O
in	O
methanol.	B

Interestingly,	O
glycine	B
levels	O
were	O
not	O
different	O
between	O
benign	O
thyroid	O
lesions	O
and	O
healthy	O
controls.	O

This	O
line	O
of	O
thought	O
is	O
supported	O
by	O
a	O
PK	O
study	O
showing	O
that	O
doxorubicinol	B
plasma	O
clearance	O
was	O
decreased	O
in	O
children	O
with	O
>30%	O
body	O
fat.	O

It	O
has	O
been	O
shown	O
by	O
Liang	O
and	O
coworkers	O
in	O
primary	O
human	O
adrenocortical	O
cells,	O
that	O
BNP	O
inhibited	O
gene	O
expression	O
related	O
to	O
the	O
angiotensin	B
II	I
induced	O
steroidogenesis,	O
including	O
the	O
de	O
novo	O
synthesis	O
of	O
cholesterol	B
and	O
other	O
steps	O
from	O
cholesterol	B
supply	O
till	O
steroid	O
formation,	O
namely	O
cortisol,	B
in	O
mitochondria.	O

This	O
gave	O
rise	O
to	O
ions	O
at	O
m/z	O
103.06	O
(free	O
α-HIBA)	B
and	O
the	O
complex	O
with	O
peaks	O
at	O
m/z	O
214.14	O
(α-HIBA-[_10	O
B]-	I
α-HIBA)	I
and	O
m/	O

Mobile	O
phase	O
B	O
was	O
0.1%	O
formic	B
acid	I
acetonitrile	I
solution.	O

The	O
AUC	O
values	O
in	O
SqCC	O
prediction	O
for	O
C18:2	B
CE	O
(top),	O
SM	B
22:0	I
(middle)	I
and	O
the	O
2	O
combined	O
lipid	O
markers	O
(bottom)	O
in	O
the	O
(A)	O
training	O
and	O
(B)	O
validation	O
samples.	O

Significant	O
increases	O
in	O
the	O
abundances	O
of	O
Bifidobacterium	O
sp.	B

Butyric	B
acid	I
is	O
a	O
product	O
of	O
P.	O
gingivalis	O
and	O
F.	O
nucleatum	O
,	O
which	O
cause	O
peridontal	O
disease	O
observed	O
in	O
these	O
patients,	O
including	O
those	O
on	O
ART	O
.	O

The	O
oligosaccharide	B
compounds,	O
which	O
elute	O
immediately	O
after	O
the	O
void	O
volume	O
and	O
overwhelmingly	O
prefer	O
MTBE	B
extraction,	O
also	O
exemplify	O
this	O
trend.	O

After	O
the	O
sample	O
mixture,	O
comprised	O
of	O
100	O
μL	O
of	O
serum,	O
25	O
μL	O
of	O
internal	O
standard	O
solution	O
and	O
1000	O
μL	O
of	O
acetonitrile)	O
was	O
loaded,	O
the	O
sorbent	O
was	O
rinsed	O
with	O
1000	O
μL	O
of	O
acetonitrile,	B
followed	O
by	O
1000	O
μL	O
of	O
10%	O
water	O
in	O
acetonitrile.	B

A	O
targeted	O
quantification	O
UPLC-MS/MS	O
method	O
for	O
seven	O
amino	B
compounds	O
in	O
plasma,	O
including	O
l-carnitine,	B
choline,	B
and	O
trimethylamine-N-oxide	B
(TMAO),	O
was	O
established	O
using	O
an	O
Acquity	O
UPLC	O
H-Class	O
system	O
coupled	O
to	O
a	O
Xevo	O
TQD	O
triple	O
quadrupole	O
MS	O
(both	O
from	O
Waters,	O
Eschborn,	O
Germany).	O

And	O
bacterial	O
catabolism	O
of	O
dietary	O
polyphenols	O
may	O
be	O
the	O
predominant	O
origin	O
of	O
benzoate,	B
which	O
is	O
normally	O
conjugated	O
with	O
glycine	B
in	O
the	O
liver	O
to	O
form	O
hippurate.	B

Consequently	O
mass	O
bins	O
expected	O
to	O
contain	O
glucuronidated	O
and	O
sulfonated	B
hesperetin	I
and	O
naringenin	B
signals	O
were	O
analyzed	O
using	O
FT-ICR-MS	O
to	O
determine	O
whether	O
the	O
effects	O
of	O
colonic	O
fermentation	O
could	O
be	O
identified.	O

(EAR:	O
2.0	O
μg;	O
RDA:	O
2.4	O
μg),	O
and	O
folate	B
(EAR:	O
320	O
μg;	O
RDA:	O
400	O
μg)	O
intake,	O
expressed	O
as	O
dietary	O
folate	B
equivalents.	O

Relative	O
to	O
the	O
control,	O
the	O
major	O
sn	O
-isomer	O
PC	B
16:0/18:1	I
and	O
the	O
CC	O
location	O
isomer	B
C18:1(Δ9)	I
were	O
found	O
to	O
increase	O
significantly	O
in	O
the	O
cancerous	O
tissue	O
samples	O
(P	O
=	O
3.5	O
×	O
10_–7	O
and	O
P	O
=	O
2	O
×	O
10_–4	O
,	O
respectively,	O
).	O

Such	O
an	O
early	O
assessment	O
might	O
spare	O
potential	O
toxicity	O
in	O
patients	O
with	O
no	O
signal	O
of	O
efficacy	O
and	O
allow	O
a	O
prompt	B
switch	O
to	O
other	O
potentially	O
efficacious	O
treatment.	O

Cysteine	B
was	O
reduced	O
more	O
than	O
2-fold	O
in	O
patients	O
with	O
WD.	O

Representative	O
images	O
of	O
lung	O
tumor	O
and	O
adjacent	O
normal	O
tissue	O
stained	O
with	O
ADSL	O
or	O
ATIC	O
antibody	O
(×20)	O
and	O
hematoxylin–eosin	B
(HE;	O
×20).	O

i-l	O
Relative	O
expression	O
or	O
AR	O
responsive	O
genes	O
upon	O
dihydrotestosterone	B
(DHT)	O
or	O
control	O
(EtOH)	O
stimulation,	O
and	O
palmitate	B
(PA)	O
or	O
vehicle	O
(BSA	O
fatty	O
acid	O
free-FFA)	O
or	O
combination	O
(PA + DHT)	O
in	O
AR	O
positive	O
C4–2	O

Cholesteryl	B
ester	I
(22:1)	I
was	O
purchased	O
from	O
Nu-Chek	O
(cat.	O

Neither	O
an	O
increase	O
in	O
organic	O
phase	O
nor	O
in	O
ammonium	B
salt	O
improved	O
these	O
parameters.	O

Mitochondrial	O
function	O
in	O
EAC	O
cell	O
lines	O
was	O
assessed	O
using	O
fluorescent	O
probes,	O
mitochondrial	O
gene	O
expression	O
was	O
assessed	O
using	O
qPCR-based	O
gene	O
arrays	O
and	O
intracellular	O
ATP	B
levels	O
were	O
determined	O
using	O
a	O
luminescence-based	O
kit.	O

Fourth,	O
changes	O
in	O
some	O
biochemicals	O
have	O
been	O
shown	O
to	O
emerge	O
far	O
sooner	O
than	O
3	O
months	O
after	O
a	O
drop	O
in	O
testosterone	B
levels	O
(e.g.	O
insulin_,	O
).	O

After	O
combining	O
the	O
different	O
adducts	O
of	O
the	O
same	O
feature	O
and	O
eliminating	O
the	O
classes	O
consisting	O
of	O
2	O
or	O
fewer	O
lipid	O
molecules	O
(PA,	O
PG,	B
PS,	O
pPC,	O
ceramide	B
phosphate,	I
and	O
MAG),	O
236	O
unique	O
lipids,	O
including	O
16	O
FFAs	O
(6.8%),	O
76	O
glycerolipids	B
(32.2%),	O
83	O
phospholipids	B
(35.1%),	O
12	O
CEs	O
(5.1%),	O
20	O
SMs	O
(8.5%),	O
and	O
29	O
ACs	O
(12.3%),	O
were	O
included	O
in	O
the	O
analysis.	O

Likewise,	O
the	O
observed	O
increase	O
in	O
glycerate	B
may	O
derive	O
from	O
oxidation	O
of	O
glyceraldehyde,	B
an	O
intermediate	O
of	O
sugar	O
metabolism.	O

Such	O
alterations	O
suggest	O
a	O
role	O
of	O
the	O
following	O
metabolic	O
pathways	O
in	O
the	O
pathophysiology	O
of	O
cancer	O
cachexia:	O
arginine	B
and	O
proline	B
metabolism;	O
alanine,	B
aspartate,	B
and	O
glutamate	B
metabolism;	O
phenylalanine	B
metabolism;	O
lysine	B
degradation;	O
aminoacyl‐tRNA	B
biosynthesis;	O
fatty	O
acid	O
elongation	O
in	O
mitochondria;	O
tricarboxylic	B
acids	I
cycle;	O
among	O
others.	O

This	O
region	O
contains	O
resonances	O
from	O
creatine	B
(singlet),	O
creatinine	B
(singlet),	O
lysine	B
(triplet),	O
and	O
tyrosine	B
(double	O
doublet),	O
as	O
well	O
as	O
a	O
part	O
of	O
the	O
lipid	O
=	O
CH–CH_2	O
–CH	O
=	O
resonance.	O

In	O
conclusion,	O
using	O
a	O
novel	O
integrative	O
approach	O
by	O
combining	O
serum	O
lipidomics	O
and	O
MR	O
imaging	O
in	O
LMNA	O
mutation	O
carriers	O
at	O
risk	O
of	O
DCM,	O
we	O
have	O
shown	O
that	O
specific	O
lipid	O
abnormalities	O
such	O
as	O
diminished	O
odd-chain	O
triglycerides	B
precede	O
DCM.	O

Moreover,	O
after	O
oral	O
assumption	O
of	O
L-phenylalanine,	B
patients	O
with	O
liver	O
cirrhosis	O
or	O
acute	O
hepatitis	O
show	O
significant	O
higher	O
serum	O
concentrations	O
of	O
phenylalanine,	B
and	O
significantly	O
lower	O
concentrations	O
of	O
tyrosine	B
than	O
normal	O
persons.	O

The	O
strongest	O
associated	O
SNP	O
rs715	O
was	O
also	O
identified	O
in	O
previous	O
mGWAS	O
with	O
higher	O
glycine	B
concentrations	O
in	O
blood	O
[,	O
,	O
].	O

The	O
independent	O
variables	O
were:	O
study	O
group	O
(controls	O
or	O
workers),	O
age	O
(years),	O
log_10	O
creatinine	B
(g/L),	O
log_10	O
cotinine	B
(µg/L),	O
presence	O
of	O
hobbies	O
at	O
home	O
involving	O
exposure	O
during	O
the	O
last	O
3	O
days	O
(no	O
or	O
yes).	O

We	O
sought	O
to	O
evaluate	O
whether	O
baseline	O
omega-3	B
fatty	O
acid	O
levels	O
influence	O
arachidonic	B
acid	I
proven	O
platelet-cyclooxygenase-1	B
(COX-1)	O
independent	O
TxA_2	O
generation	O
(TxA_2	O
generation	O
despite	O
adequate	O
aspirin	B
use).	O

Finally,	O
we	O
identified	O
LysoPC(22:6)	B
as	O
a	O
potential	O
LAA	O
biomarker.	O

Phytosphingosine	B
can	O
correctly	O
predict	O
100%	O
patients	O
with	O
the	O
corresponding	O
AUC	O
equal	O
to	O
1.00	O
in	O
the	O
training	O
set	O
and	O
can	O
correctly	O
predict	O
92%	O
patients	O
with	O
the	O
corresponding	O
AUC	O
equal	O
to	O
0.98	O
in	O
the	O
test	O
set.	O

Are	O
the	O
high	O
levels	O
of	O
tamoxifen	B
and	O
its	O
metabolites	O
in	O
postmenopausal	O
women	O
of	O
any	O
clinical	O
relevance	O
after	O
the	O
advent	O
of	O
aromatase	O
inhibitors?	O

Higher	O
elimination	O
of	O
phenylalanine	B
in	O
urine	O
of	O
ARD	O
may	O
also	O
reduce	O
catecholamine	B
production	O
and	O
that	O
may	O
interfere	O
with	O
the	O
antioxidant	O
repair	O
mechanism.	O

The	O
genetic	O
variance	O
attributed	O
to	O
CPS1	O
was	O
10%	O
and	O
the	O
allele	O
associated	O
with	O
higher	O
glycine	B
concentrations	O
is	O
also	O
associated	O
with	O
lower	O
risk	O
of	O
type	O
2	O
diabetes.	O

Heatmap	O
clustering	O
lipids	O
in	O
plasma	O
from	O
meloxicam-treated	O
(n = 6)	O
and	O
saline-treated	O
(n = 6)	O
cats	O
before	O
(time	O
1)	O
and	O
after	O
the	O
administration	O
of	O
saline	B
or	O
meloxicam	O
at	O
0.3 mg/kg	O

The	O
column	O
was	O
then	O
evaluated	O
with	O
samples	O
of	O
SRM	O
909c,	O
and	O
the	O
conditions	O
that	O
provided	O
the	O
best	O
separation	O
of	O
the	O
SRM	O
909c	O
matrix	O
peaks	O
without	O
sacrificing	O
sensitivity	O
included	O
a	O
mobile	O
phase	O
composition	O
of	O
74	O
%	O
methanol,	B
26	O
%	O
water	O
and	O
a	O
column	O
temperature	O
of	O
15	O
°C.	O

Limits	O
of	O
quantification	O
were	O
0.1 μmol/L	O
for	O
hArg,	O
0.25 μmol/L	O
for	O
lArg,	O
and	O
0.005 μmol/L	O
for	O
ADMA.	B

Currently,	O
changes	O
in	O
metabolic	O
fluxes	O
following	O
consumption	O
of	O
stable	O
isotope-enriched	O
foods	O
are	O
usually	O
limited	O
to	O
the	O
analysis	O
of	O
postprandial	O
kinetics	O
of	O
glucose.	B

Due	O
to	O
the	O
observed	O
higher	O
serum	O
glucose	B
level	O
in	O
ADV	O
with	O
respect	O
to	O
EAR	O
HCC	O
patients,	O
we	O
speculated	O
that	O
an	O
altered	O
histidine	B
metabolism,	O
revealed	O
by	O
a	O
modified	O
serum	O
level	O
of	O
1-methylistine,	B
might	O
be	O
associated	O
with	O
the	O
hyperglycemia	O
of	O
these	O
patients.	O

Because	O
factor	O
analysis	O
confirmed	O
that	O
EM	O
cluster	O
according	O
to	O
metabolic	O
pathways	O
described	O
in	O
the	O
literature,	O
EM	O
groups	O
were	O
defined	O
to	O
include	O
EM	O
deriving	O
from	O
specific	O
metabolic	O
events:	O
hydroxylation	O
(at	O
carbon	O
2,	O
4,	O
or	O
16	O
of	O
the	O
estrogen	B
ring)	O
and	O
methylation.	O

Muscle	O
Branched	O
chain	O
amino	O
acids,	O
3-hydroxybutyrate,	B
succinate,	B
and	O
imidazole	B
levels	O
are	O
higher	O
in	O
FS	O
animals	O
when	O
compared	O
to	O
CPF	O
animals.	O

In	O
fact,	O
a	O
positive	O
correlation	O
with	O
PROG	O
levels	O
was	O
observed	O
for	O
Sa	O
and	O
ceramides.	B

In	O
order	O
to	O
achieve	O
this,	O
we	O
assessed	O
three	O
different	O
columns:	O
a	O
Phenomenex	O
Luna	O
C18(2)	O
150	O
×	O
2	O
mm,	O
Phenomenex	O
Synergi	O
4µ	B
Polar-RP	I
100	O
×	O
2	O
mm	O
and	O
a	O
Phenomenex	O
Synergi	O
4µ	O
Hydro-RP	O
100	O
×	O
2	O
mm.	O

Studies	O
to	O
elucidate	O
the	O
intraoral	O
glucuronidation	O
kinetics	O
of	O
intraoral	O
anthocyanin	B
and	O
related	O
compounds	O
are	O
ongoing.	O

Ion	O
suppression	O
was	O
minimized	O
by	O
washing	O
with	O
30%	O
MeOH	B
prior	O
to	O
elution	O
with	O
100%	O
MeOH.	B

Total	O
parent	O
estrogens	O
were	O
the	O
sum	O
of	O
estrone	B
and	O
estradiol;	B
total	O
metabolites	O
were	O
the	O
sum	O
of	O
Path2,	O
Path4	O
and	O
Path16;	O
and	O
total	O
estrogens	O
was	O
defined	O
as	O
the	O
sum	O
of	O
the	O
parent	O
estrogens	O
and	O
metabolites.	O

Conversely,	O
no	O
significant	O
relationship	O
between	O
the	O
SM(OH)22:1	B
metabolite	O
and	O
age	O
(b)	O
was	O
reported.	O

DG(16:0/18:1)	B
is	O
likely	O
the	O
most	O
abundant	O
product	O
of	O
glucose	B
stimulated	O
triacylglycerol	O
hydrolysis	O
(Pearson	O
et	O
al.	O
),	O
in	O
our	O
study	O
this	O
specie	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
C-peptide	O
after	O
6 months,	O
indicating	O
a	O
potential	O
link	O
between	O
glucose	B
levels	O
at	O
1 month	O
and	O
a	O
significant	O
higher	O
decrease	O
in	O
c-peptide	O
over	O
time.	O

From	O
an	O
analysis	O
of	O
the	O
pathways	O
involved	O
in	O
each	O
principal	O
component,	O
it	O
is	O
apparent	O
that	O
metabolites	O
from	O
pyrimidine	B
metabolism	O
contribute	O
to	O
both	O
components	O
(C	O
).	O

Therefore,	O
SPE	O
was	O
used	O
for	O
the	O
pre-concentration	O
of	O
OHCs	O
and	O
clean-up	O
of	O
interferences	O
such	O
as	O
cholesterol	B
from	O
the	O
matrix.	O

In	O
our	O
study,	O
the	O
results	O
of	O
the	O
association	O
of	O
PBMC	O
FA	B
content	O
with	O
plasma	O
inflammatory	O
markers	O
showed	O
the	O
opposite,	O
but	O
this	O
was	O
observed	O
based	O
on	O
non-stimulated	O
PBMC	O
metabolome	O
and	O
plasma	O
biomarkers	O
levels	O
in	O
healthy	O
subjects.	O

The	O
spray	O
voltage	O
was	O
set	O
to	O
4	O
kV.	B
The	O
heated	O
capillary	O
and	O
HESI	O
probe	O
were	O
held	O
at	O
300°	O
and	O
400°	O
C,	O
respectively.	O

Clozapine,	B
Norclozapine,	B
LCMS	O

Serine	B
was	O
significantly	O
higher	O
in	O
females.	O

Although	O
phosphatidylcholines	B
had	O
been	O
described	O
as	O
major	O
phospholipids	B
in	O
lipoproteins	O
and	O
cellular	O
membranes	O
for	O
a	O
long	O
time,	O
several	O
recent	O
advances	O
have	O
expanded	O
on	O
the	O
notion	O
that	O
PCs	O
are	O
not	O
just	O
a	O
kind	O
of	O
cellular	O
bricks.	O

For	O
each	O
LC-MS	O
run,	O
masses	O
were	O
calibrated	O
to	O
the	O
spectrum	O
that	O
contained	O
the	O
dansyl-amine	B
peaks	O
at	O
m/z	O
242.57160	O
(two	O
tags	O
two	O
charges),	O
m/z	O
484.13592	O
(two	O
tags	O
one	O
charge)	O
and	O
m/z	O
971.27799	O
(dimer)	O
using	O
the	O
Data	O
Analysis	O
software	O
and	O
the	O
calibration	O
result	O
was	O
applied	O
to	O
all	O
the	O
other	O
spectra	O
in	O
the	O
same	O
LC-MS	O
run.	O

Bis(trimethylsilyl)trifluoroacetamide	B
(BSTFA)	O
containing	O
1	O
%	O
trimethylchlorosilane	B
was	O
purchased	O
from	O
Supelco	O
(Bellefonte,	O
USA).	O

presents	O
the	O
group-wise	O
median	O
urinary	O
concentrations	O
(with	O
IQR)	O
of	O
selected	O
compounds	O
and	O
unidentified	O
substances	O
relative	O
to	O
the	O
creatinine	B
concentration	O
at	O
the	O
three	O
visits,	O
along	O
with	O
the	O
mean	O
fold	O
change	O
between	O
the	O
visits	O
calculated	O
at	O
the	O
individual	O
level.	O

Lactate	B
is	O
also	O
an	O
important	O
precursor	O
of	O
gluconeogenesis.	O

The	O
other	O
differences	O
in	O
metabolites	O
were	O
3-hydroxybutyrate,	B
lipid,	O
PUFA,	O
glycerol,	B
and	O
glucose.	B

Cytosolic	O
and	O
nuclear	O
expressions	O
of	O
β-catenin	B
and	O
cyclin	O
D1	O
were	O
estimated	O
using	O
ELISA	O
from	O
100	O
fractions	O
isolated	O
from	O
malignant	O
(n	O
=	O
20),	O
benign	O
(n	O
=	O
10)	O
and	O
non-involved	O
breast	O
tissues	O
(n	O
=	O
10)	O
obtained	O
after	O
surgery.	O

[1,2-_13	O
C]	I
and	O
[2,3-_13	O
C]	I
isotopomers	O
of	O
glucose	B
in	O
the	O
plasma	O
would	O
generate	O
[2,3-_13	B
C]pyruvate	I
and	O
[1,2-_13	B
C]pyruvate,	I
respectively,	O
in	O
the	O
tumor	O
which	O
would	O
yield	O
the	O
same	O
_13	O
C	O
labeled	O
isotopomers	O
of	O
lactate.	B

Acetonitrile,	B
formic	B
acid,	I
and	O
HPLC-grade	O
water	O
were	O
purchased	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
MO).	O

(Gln	O
glutamine	B
Glu	O

Previously,	O
lower	O
betaine	B
levels	O
were	O
reported	O
to	O
be	O
associated	O
with	O
incident	O
T2DM	O
development	O
in	O
subjects	O
across	O
a	O
spectrum	O
of	O
risks	O
for	O
CVD,	O
such	O
as	O
in	O
Norwegian	O
subjects	O
with	O
suspected	O
angina	O
pectoris,	O
as	O
well	O
as	O
in	O
primary	O
prevention	O
individuals	O
enrolled	O
in	O
the	O
PREDIMED	O
dietary	O
intervention	O
trial	O
[,].	O

Low	O
plasma	O
24,25(OH)_2	B
D	O
concentration	O
was	O
also	O
associated	O
with	O
increased	O
microalbuminuria	O
risk,	O
although	O
this	O
association	O
was	O
not	O
as	O
consistent	O
as	O
the	O
association	O
of	O
low	O
plasma	O

We	O
repeated	O
the	O
models	O
without	O
adjusting	O
for	O
cotinine,	B
with	O
no	O
meaningful	O
change	O
in	O
results	O
(data	O
not	O
shown).	O

These	O
four	O
metabolites	O
may	O
also	O
be	O
considered	O
to	O
be	O
candidate	O
biomarkers,	O
but	O
confirmation	O
would	O
require	O
an	O
independent	O
cohort	O
that	O
had	O
also	O
been	O
profiled	O
on	O
the	O
accurate-mass	B
instrument.	O

Aqueous	O
fecal	O
extracts,	O
after	O
the	O
above	O
two-step	O
extraction	O
with	O
sodium	B
hydroxide	I
solution	O
followed	O
by	O
methanol	B
(or	O
ethanol)	O
were	O
then	O
derivatized	O
following	O
the	O
aforementioned	O
procedure,	O
omitting	O
the	O
initial	O
addition	O
of	O
200	O
µL	O
of	O
sodium	B
hydroxide	I
solution	O
(1	O
M)	O
and	O
167	O
µL	O
of	O
methanol	B
or	O
ethanol.	B

Wang	O
argued	O
that	O
the	O
metabolism	O
of	O
tryptophan	B
was	O
affected	O
when	O
GDM	O
occurred,	O
which	O
was	O
very	O
similar	O
to	O
the	O
results	O
of	O
Law,	O
Bentley-Lewis	O
and	O
Daniel	O
studied	O
the	O
early	O
serum	O
of	O
GDM	O
patients	O
and	O
normal	O
pregnant	O
women,	O
respectively,	O
they	O
both	O
found	O
that	O
the	O
amino	O
acid	O
metabolites	O
of	O
GDM	O
patients	O
in	O
serum	O
were	O
different	O
from	O
those	O
of	O
normal	O
pregnant	O
women,	O
but	O
the	O
differential	O
metabolites	O
in	O
these	O
two	O
studies	O
were	O
not	O
completely	O
the	O
same,	O
which	O
may	O
be	O
due	O
to	O
different	O
sample	O
collection	O
periods	O
or	O
different	O
gestational	O
weeks	O
in	O
the	O
two	O
groups.	O

CYP3A4	O
and	O
CYP3A5	O
catalyzed	O
anastrozole	B
(20	O
µm)	O
hydroxylation	O
at	O
the	O
highest	O
rate	O
(0.0023	O
pmol	O
min_−1	O
pmol_−1	O
P450	O
and	O
0.0026	O
pmol	O
min_−1	O
pmol_−1	O
P450,	O
respectively).	O

IR89	O
represents	O
glutamate	B
and	O
methionine,	B
IR15	O
represent	O
tyrosine	B
and	O
IR96	O
contains	O
signals	O
from	O
alanine,	B
isoleucine	B
and	O
lysine.	B

In	O
addition,	O
the	O
brain-specific	O
metabolite	O
homocarnosine	B
could	O
not	O
be	O
detected	O
in	O
serum.	O

Additionally,	O
the	O
utilities	O
of	O
kynurenine	B
(Kyn),	O
tryptophan	B
(Trp),	O
and	O
their	O
ratio,	O
Kyn/Trp,	O
were	O
evaluated	O
because	O
the	O
activation	O
of	O
indoleamine	O
2,3-dioxygenase	O
(IDO-1),	O
which	O
converts	O
Trp	O
to	O
Kyn,	O
has	O
been	O
widely	O
reported	O
in	O
macrophages	O
exposed	O
to	O
Mtb.	O

Finally,	O
high	O
levels	O
of	O
TMAO	B
predicted	O
reduced	O
5-year	O
survival	O
that	O
remained	O
significant	O
after	O
multivariate	O
adjustment.	O

Activation	O
of	O
alveolar	O
macrophages	O
leads	O
to	O
release	O
of	O
cytokines	O
and	O
in	O
our	O
study	O
we	O
observed	O
significantly	O
higher	O
concentrations	O
of	O
serum	O
IL-1α,	B
IL-6	O
and	O
TNF-	O
α	O
in	O
ARD	O
with	O
respect	O
to	O
OW.	O

oral	O
glucose	B
tolerance	O
test,	O
profiles,	O
amino	O
acids,	O
insulin	O
resistance,	O
HLP	O

Allantoin	B
calibrants	O
covered	O
concentrations	O
from	O
1	O
to	O
500	O
μmol/L;	O
LLOQ	O
(accuracy	O
>	O
80%)	O
was	O
0.06	O
pmol.	O

The	O
reducing	O
solution	O
was	O
prepared	O
just	O
before	O
the	O
experiment	O
from	O
125	O
mg	O
cysteine	B
hydrochloride,	I
0.8	O
mL	O
1M	O
NaOH,	O
125	O
mg	O
Na_2	O
S,	O
and	O
distilled	O
water	O

A	O
receiver	O
operator	O
curve	O
analysis	O
revealed	O
that	O
the	O
combination	O
of	O
4-hydroxypentenoic	B
acid,	I
arabinose,	B
glycochenodeoxycholate-3-sulfate,	B
isoleucine,	B
serine,	B
and	O
xanthine	B
produced	O
a	O
moderate	O
diagnostic	O
score	O
with	O
a	O
sensitivity	O
(specificity)	O
of	O
75%	O
(78%)	O
for	O
distinguishing	O
OSA	O
from	O
those	O
without	O
OSA.	O

Of	O
the	O
seven	O
LMIs,	O
fourwith	O
a	O
137.0455	O
m/z	O
ion	O
atretention	O
times	O
of	O
2.04-3.14	O
minuteswere	O
upregulated	O
in	O
sera	O
from	O
OVC	O
patients;	O
the	O
ion	O
was	O
identified	O
as	O
that	O
derived	O
from	O
hypoxanthine.	B

Ethanol	B
(1	O
ml)	O
was	O
added	O
to	O
each	O
tube,	O
and	O
the	O
samples	O
were	O
sonicated	O
using	O
an	O
Ultrasonic	O
Dismembrator	O
(model	O
150E,	O
Fisher	O
Scientific).	O

The	O
cells	O
were	O
maintained	O
in	O
DMEM	O
cell	O
culture	O
medium	O
(contains	O
25	O
mM	O
glucose	B
and	O
4	O
mM	O
glutamine)	B
10%	O
(v/v)	O
FBS	O
100	O
units/ml	O
penicillin	B
and	O
100	O
µg/ml	O
streptomycin	B
with	O
0.5	O
µg/ml	O
puromycin	B
on	O
150	O
mm.	O

The	O
mass	O
spectrometer	O
was	O
operated	O
under	O
electron	O
impact	O
(EI)	O
in	O
a	O
full-scan	O
mode	O
over	O
the	O
range	O
from	O
m/z	O
50	O
to	O
800	O
with	O
a	O
0.5	O
second	O
scan	O
velocity,	O
and	O
the	O
detector	O
voltage	O
was	O
0.96	O
kV.	B

Glutamate	B
may	O
have	O
a	O
key	O
role	O
in	O
the	O
differentiation	O
between	O
lung	O
inflammation	O
and	O
lung	O
cancer.	O

The	O
smaller	O
distribution	O
at	O
140.7	O
Å_2	O
(light	O
red,	O
A)	O
closely	O
aligns	O
with	O
3	O
isomers	O
of	O
C6H12O6	O
in	O
the	O
standards	O
(fructose,	O
galactose	B
and	O
mannose	B
at	O
ca.	O

Of	O
the	O
SRM	O
transitions	O
evaluated,	O
m/z	O
308	O
to	O
m/z	O
84	O
of	O
the	O
hexanoate	B
derivative	O
provided	O
the	O
best	O
selectivity	O
in	O
terms	O
of	O
minimizing	O
interference	O
by	O
urinary	O
constituents.	O

The	O
lower	O
level	O
of	O
taurine	B
in	O
the	O
L2	O
group	O
probably	O
represents	O
less	O
liver	O
and	O
kidney	O
damage	O
in	O
these	O
patients	O
than	O
in	O
those	O
in	O
the	O
L2	O
group,	O
which	O
is	O
induced	O
by	O
high	O
taurine	B
levels	O
to	O
some	O
extent.	O

The	O
significant	O
metabolic	O
pathway	O
associated	O
with	O
them	O
was	O
that	O
of	O
glycerophospholipid	B
metabolism	O
(false	O
discovery	O
rate	O
(FDR)	O
=	O
0.002,	O
pathway	O
impact	O
=	O
0.231)	O
(h).	O

More	O
recently,	O
therapeutic	O
manipulation	O
of	O
bile	O
acids	O
with	O
sequestrants	O
has	O
been	O
shown	O
to	O
improve	O
whole	O
body	O
insulin	O
sensitivity	O
and	O
to	O
improve	O
markers	O
of	O
glycemic	B
control	O
among	O
diabetic	O
men	O
in	O
the	O
general	O
population._,	O
	O
With	O
further	O
investigation	O
of	O
the	O
present	O
observations,	O
these	O
agents	O
may	O
find	O
a	O
rational	O
role	O
in	O
the	O
medical	O
management	O
of	O
men	O
who	O
suffer	O
from	O
treatment-induced	O
metabolic	O
effects	O
such	O
as	O
insulin	O
resistance	O
or	O
hypertriglyceridemia.	O

We	O
identified	O
several	O
potential	O
biomarkers	O
with	O
high	O
AUC	O
values	O
for	O
TB	O
and/or	O
TB-DM	O
diagnosis,	O
which	O
included	O
ratios	O
of	O
citrulline,	B
arginine,	B
phenylalanine	B
and	O
histidine	B
among	O
others.	O

Dulbecco’s	O
Modified	O
Eagle’s	O
Medium	O
(DMEM),	O
GlutaMAX-1,	B
insulin,	O
MEM-non-essential	O
amino	O
acids,	O
modified	O
Eagle’s	O
Medium	O
Dr.	O
Chee’s	O
modification	O
(MCM),	O
and	O
penicillin-streptomycin	B
were	O
purchased	O
from	O
Invitrogen	O
(Grand	O
Island,	O
NY).	O

Aspartic	B
acid	I
was	O
lower	O
in	O
the	O
PBMC	O
from	O
males	O
(p	O
=	O
0.02).	O

We	O
have	O
no	O
ready	O
explanation	O
as	O
to	O
why	O
the	O
children	O
with	O
type	O
1	O
diabetes	O
excreted	O
increased	O
urinary	O
concentrations	O
of	O
the	O
conjugated	O
vitamin	B
E	I
metabolites	O
compared	O
to	O
the	O
controls.	O

(D)	O
Caffeine	B
metabolism.	O

This	O
is	O
illustrated	O
in	O
the	O
ternary	O
diagrams	O
shown	O
in	O
representing	O
ceramide	B
profile	O
as	O
average	O
proportions	O
and	O
confidence	O
ellipses	O
of	O
different	O
variables:	O
(36:1	O
+	O
38:1),	O
(40:1	B
+	I
42:2	I
+	I
42:1)	I
ceramides	I
and	O
other	O
molecular	O
species;	O
ceramides	B
with	O
34	O
carbons	O
or	O
less,	O
42	O
carbons	O
or	O
more	O
and	O
other	O
molecular	O
species;	O
ceramides	B
with	O
1,	O
2	O
and	O
3	O
unsaturations.	O

Much	O
of	O
the	O
experimental	O
research	O
on	O
estrogen-mediated	O
carcinogenesis	O
over	O
the	O
last	O
30	O
years	O
has	O
focused	O
on	O
whether	O
the	O
underlying	O
mechanism	O
is	O
related	O
to	O
the	O
role	O
of	O
estrogen	B
as	O
a	O
mitogen	O
that	O
stimulates	O
breast	O
cell	O
proliferation	O
through	O
activation	O
of	O
the	O
estrogen	B
receptor,	O
or	O
its	O
role	O
as	O
a	O
precursor	O
to	O
a	O
potent	O
mutagen.	O

Finally,	O
18	O
most	O
significantly	O
altered	O
plasma	O
metabolites	O
in	O
ESCC	O
patients,	O
relative	O
to	O
healthy	O
controls,	O
were	O
tentatively	O
identified	O
as	O
lysophosphatidylcholines	B
(lysoPCs),	O
fatty	O
acids,	O
l-carnitine,	B
acylcarnitines,	B
organic	O
acids,	O
and	O
a	O
sterol	O
metabolite.	O

However,	O
this	O
conflicts	O
with	O
a	O
previous	O
Mendelian	O
randomisation	O
analysis	O
that	O
showed	O
no	O
association	O
between	O
a	O
single	O
genetic	O
variant	O
for	O
glycine	B
or	O
glycine-to-serine	O
ratio	O
and	O
diabetes-related	O
traits.	O

Glucose,	B
sorbitol	B
and	O
fructose	B
were	O
markedly	O
elevated	O
in	O
all	O
AD	O
brain	O
regions,	O
whereas	O
copper	O
was	O
correspondingly	O
deficient	O
throughout	O
(all	O
P	O
 < 0.0001).	O

Finally,	O
the	O
application	O
of	O
both	O
mass	O
spectrometry	O
and	O
lipidomics	O
platforms	O
in	O
the	O
CAP	O
study	O
has	O
demonstrated	O
the	O
value	O
of	O
this	O
approach	O
in	O
mapping	O
global	O
metabolic	O
effects	O
of	O
simvastatin	B
and	O
in	O
highlighting	O
the	O
pathways	O
that	O
may	O
modulate	O
variation	O
in	O
its	O
clinical	O
efficacy	O
and	O
in	O
its	O
multiple	O
biological	O
effects.	O

Metabolomic	O
profiles	O
at	O
V1	O
and	O
V12	O
and	O
changes	O
in	O
metabolomic	O
profiles	O
between	O
V1	O
and	O
V12	O
accurately	O
discriminated	O
between	O
Groups	O
O	O
and	O
P	O
(p<5×10–6),	O
and	O
identified	O
glycine,	B
kynurenine	B
and	O
citrulline/arginine	O
as	O
the	O
best	O
predictors	O
of	O
group	O
membership.	O

Alterations	O
of	O
the	O
amino	O
acids	O
metabolism	O
in	O
PA,	O
especially	O
involving	O
alanine,	B
glutamate	B
and	O
aspartate	B
represents	O
another	O
feature	O
that	O
deserves	O
to	O
be	O
taken	O
into	O
account.	O

Because	O
formate	B
is	O
utilized	O
in	O
the	O
gut	O
by	O
methanogenic	B
microbes,	O
increased	O
fecal	O
formate	B
is	O
consistent	O
with	O
a	O
lower	O
methanogenic	B
activity	O
in	O
the	O
IBS-D	O
lumen.	O

High	O
levels	O
of	O
BCAA	O
(including	O
leucine,	B
isoleucine,	B
and	O
valine)	B
are	O
associated	O
with	O
insulin	O
resistance,	O
diabetes,	O
and	O
coronary	O
artery	O
disease	O
and	O
predict	O
development	O
of	O
diabetes.38	O
Khoo	O
et	O
al	O
observed	O
that	O
RYGB	O
improves	O
metabolic	O
flexibility	O
with	O
removal	O
of	O
glucose	B
and	O
amino	O
acids	O
including	O
BCAA	O
as	O
early	O
as	O
2 weeks	O
post‐surgery.15	O

Decision	O
rules	O
(detailed	O
in	O
the	O
appendix	O
)	O
were	O
designed	O
to	O
identify	O
women	O
who	O
were	O
clearly	O
premenopausal	O
(having	O
regular	O
menstrual	O
cycles	O
or	O
evidence	O
of	O
continuing	O
ovulation)	O
and	O
women	O
who	O
were	O
clearly	O
post-menopausal	O
(questionnaire	O
data	O
indicating	O
cessation	O
of	O
menstrual	O
cycles	O
due	O
to	O
natural	O
menopause	O
at	O
least	O
1	O
year	O
prior	O
to	O
urine	O
collection	O
or	O
circulating	O
hormone	O
levels	O
indicating	O
cessation	O
of	O
ovarian	O
estrogen	B
production).	O

Adjustments	O
were	O
made	O
for	O
Framingham	O
Global	O
Risk	O
Score,	O
creatinine	B
clearance,	O
and	O
plasma	O
hsCRP	O
levels.	O

Some	O
specific	O
sphingomyelins	B
rose	O
very	O
significantly	O
along	O
with	O
liver	O
fibrosis	O
severity	O
in	O
the	O
studied	O
patients	O
after	O
liver	O
transplantation.	O

Our	O
data	O
demonstrated	O
that	O
increased	O
cysteine	B
and	O
taurine	B
occur	O
during	O
OGTTs	O
in	O
HLP	O
subjects.	O

On	O
the	O
contrary,	O
C5:1,	B
Phe/Tyr,	O
(C0	B
+	I
C2	I
+	I
C3	I
+	I
C16	I
+	I
C18:1)/Cit,	I
and	O
Met/Leu	O
were	O
of	O
lower	O
levels	O
in	O
the	O
CI	O
group.	O

PlsEtn	O
levels	O
did	O
not	O
differ	O
in	O
RRMS	O
relative	O
to	O
controls,	O
irrespective	O
of	O
the	O
disease	O
duration.	B

Thus,	O
the	O
elevated	O
level	O
of	O
formate	B
might	O
also	O
reflect	O
the	O
dysfunction	O
of	O
brain	O
mitochondria	O
as	O
described	O
above.	O

It	O
is	O
well	O
known	O
that	O
lactose	B
is	O
first	O
hydrolysed	O
into	O
its	O
glucose	B
and	O
galactose	B
moieties	O
by	O
lactase,	O
located	O
in	O
the	O
mucosa	O
of	O
the	O
small	O
intestine,	O
which	O
can	O
modulate	O
gut	O
microbiota	O
and	O
immune	O
responses	O
during	O
the	O
suckling	O
period	O
by	O
inducing	O
the	O
expression	O
of	O
IL-37	O
in	O
colonic	O
epithelial	O
cells,	O
monocytes,	O
and	O
macrophages.	O

Interestingly,	O
the	O
edges	O
connecting	O
isoleucine	B
to	O
other	O
amino	O
acids	O
(threonine,	O
serine,	B
proline)	B
all	O
consist	O
of	O
positive	O
correlations,	O
while	O
the	O
connections	O
to	O
the	O
two	O
monounsaturated	O
fatty	O
acids	O
(MUFAs),	O
oleic	B
acid	I
and	O
palmitoleic	B
acid,	I
represent	O
negative	O
correlations.	O

Leptin	O
treatment	O
restores	O
mitochondrial	O
function	O
through	O
increased	O
β-oxidation	O
in	O
vitro	O
cell	O
culture	O
and	O
in	O
animal	O
models,	O
primarily	O
mediated	O
through	O
activation	O
of	O
adenosine	B
5′-monophosphate	I
(AMP)—activated	O
protein	O
kinase	O
(AMPK).	O

The	O
peak	O
intensities	O
of	O
the	O
fragment	O
ions	O
corresponding	O
to	O
d17:1	B
sphingosine	I
and	O
d18:1	B
spingosine,	O
respectively,	O
were	O
obtained	O
from	O
the	O
MS/MS_ALL	O
acquisitions.	O

Identification	O
and	O
quantification	O
are	O
limited	O
by	O
the	O
commercial	O
availability	O
of	O
reference	O
standards	O
for	O
parent	O
synthetic	O
cannabinoids	B
and,	O
even	O
more	O
relevant	O
for	O
identification	O
and	O
monitoring,	O
their	O
human	O
urinary	O
metabolites.	O

The	O
4–5	O
doublets	O
in	O
glutamate	B
and	O
glutamine	B
confirmed	O
that	O
PDH	O
was	O
active	O
in	O
all	O
tumors.	O

Univariate	O
and	O
multivariate	O
statistical	O
analysis	O
of	O
untargeted	O
metabolomics	O
data	O
comparing	O
ICC	O
vs.	O
control	O
samples	O
identified	O
significant	O
differences	O
in	O
specific	O
metabolite	O
abundances	O
between	O
the	O
two	O
groups:	O
(a)	O
Box	O
plots	O
show	O
differences	O
between	O
normalised	O
compound	O
abundances	O
illustrating	O
2-HG	O
and	O
lactate	B
both	O
correlate	O
directly	O
with	O
IDH1	O
mutation	O
status.	O

Glucose	B
and	O
1,5-AG	B
compete	O
for	O
reabsorption	O
in	O
the	O
kidney	O
and	O
are	O
their	O
plasma	O
levels	O
are	O
inversely	O
proportional	O
to	O
each	O
other,	O
with	O
serum	O
1,5-AG	B
levels	O
reducing	O
in	O
hyperglycemia.	O

As	O
for	O
the	O
blood	O
test	O
results,	O
the	O
blood	O
levels	O
of	O
total	O
cholesterol,	B
triglycerides,	B
glucose,	B
total	O
bilirubin,	B
aspartate	O
transaminase	O
(AST),	O
C-reactive	O
protein	O
(CRP),	O
CEA,	O
and	O
CA19-9	O
differed	O
significantly	O
between	O
the	O
colorectal	O
cancer	O
patients	O
and	O
healthy	O
volunteers.	O

580.3745	O
with	O
a	O
retention	O
time	O
compatible	O
with	O
a	O
GP-tagged	O
dihydroxy-3-oxocholest-4-en-26-oic	B
acid.	I

A	O
further,	O
mechanistically-related	O
finding	O
is	O
that	O
pan-cerebral	O
brain-copper	O
deficiency	O
accompanies	O
these	O
glucose	B
and	O
polyol-pathway	B
defects:	O
elevated	O
tissue-CML	O
levels	O
provide	O
a	O
molecular	O
linkage	O
between	O
elevated	O
brain	O
glucose	B
and	O
copper	O
deficiency.	O

(A)	O
The	O
comparison	O
of	O
ceramide	B
levels	O
in	O
breast	O
cancer	O
tissue	O
between	O
patients	O
with	O
Ki-67	O
index.	O

The	O
three	O
other	O
metabolites	O
were	O
identified	O
as	O
l-threonic	B
acid,	I
l-cysteine,	B
and	O
creatine	B
from	O
both	O
the	O
GC-MS	O
and	O
GC×GC-MS	O
data.	O

Studies	O
in	O
mouse	O
models	O
of	O
DR	O
and	O
in	O
bovine	O
retinal	B
endothelial	O
cells	O
cultured	O
in	O
high	O
glucose	B
found	O
elevated	O
arginase	O
activity,	O
also	O
implicating	O
derangements	O
in	O
arginine	B
metabolism	O
as	O
a	O
mediator	O
of	O
DR.	O

Previous	O
studies	O
have	O
shown	O
that	O
even	O
when	O
individuals	O
have	O
the	O
same	O
physical	O
condition,	O
gender,	O
and	O
health,	O
their	O
basal	O
oxylipin	B
concentrations	O
can	O
differ	O
remarkably.	O

Both	O
E_1	O
(E_2	B
)-3,4-Q	I
and	O
E_1	O
(E_2	B
)-2,3-Q	I
form	O
much	O
lower	O
levels	O
of	O
stable	O
DNA	O
adducts	O
than	O
depurinating	O
adducts.	O

Briefly,	O
plasma	O
samples	O
(40 μl)	O
were	O
put	O
into	O
360 μl	O
of	O
methanol	B
which	O
contained	O
internal	O
standards	O
[20 μmol/	O

Various	O
studies	O
have	O
found	O
that	O
choline	B
is	O
associated	O
with	O
obesity.	O

AMP	B
is	O
derived	O
from	O
ATP	B
and	O
ADP	O
hydrolysis.	O

Ten	O
mg	O
of	O
methadone-HCl	B
corresponds	O
to	O
8.94	O
mg	O
free	O
base.	O

This	O
might	O
be	O
expected	O
to	O
increase	O
betaine	B
excretion	O
in	O
subjects	O
such	O
as	O
the	O
HNF1A-MODY	O
cases	O
who	O
have	O
a	O
low	O
renal	O
threshold	O
for	O
glucose.	B

Furthermore,	O
the	O
proportional	O
amounts	O
of	O
the	O
individual	O
free	O
SaFAs	O
lauric	B
acid	I
(12:0),	O
myristic	B
acid	I
(14:0),	O
pentadecylic	B
acid	I
(15:0),	O
and	O
margaric	B
acid	I
(17:0)	O
were	O
positively	O
associated	O
with	O
serum	O
levels	O
of	O
CRP	O
(p	O
<	O
0.05	O
for	O
all).	O

They	O
also	O
had	O
higher	O
citrulline	B
than	O
controls	O
but	O
it	O
was	O
lower	O
than	O
in	O
patients	O
with	O
IBS	O
or	O
inactive	O
UC.	O

For	O
cabozantinib	B
QCXL	O
was	O
also	O
included	O
in	O
this	O
analysis.	O

A	O
consisted	O
of	O
0.1%	O
formic	B
acid	I
in	O
water,	O
and	O
phase	O
B	O
consisted	O
of	O
0.1%	O
formic	B
acid	I
in	O
methanol.	B

However,	O
metabolites	O
such	O
as	O
pyruvate,	B
lactate,	B
valine,	B
proline,	B
isoleucine,	B
histidine,	B
2-aminobutyrate,	B
leucine	B
and	O
alloisoleucine	B
were	O
relatively	O
lower	O
in	O
the	O
patients	O
with	O
adenocarcinoma.	O

In	O
addition	O
to	O
LPI	B
(16:1),	I
we	O
found	O
that	O
all	O
seven	O
measured	O
LPIs	O
in	O
prevalent	O
type	O
2	O
diabetes	O
cases	O
were	O
relatively	O
higher	O
than	O
those	O
in	O
incident	O
type	O
2	O
diabetes	O
cases	O
and	O
controls,	O
and	O
they	O
were	O
relatively	O
higher	O
in	O
incident	O
type	O
2	O
diabetes	O
cases	O
than	O
in	O
controls	O
(Supplemental	O
Fig.	O

The	O
separation	O
was	O
achieved	O
under	O
the	O
column	O
temperature	O
of	O
40 °C	O
using	O
a	O
controlled	O
gradient	O
of	O
mobile	O
phase	O
A	O
consisting	O
of	O
0.1%	O
(v/v)	O
formic	B
acid	I
in	O
water	O
and	O
mobile	O
phase	O
B,	O
consisting	O
of	O
0.1%	O
formic	B
acid	I
in	O
acetonitrile	B
at	O
a	O
flow	O
rate	O
of	O
0.4 mL/min.	O

Serum	O
glucose	B
concentrations	O
were	O
determined	O
by	O
the	O
enzymatic	O
hexokinase	O
method	O
(Beckman	O
Coulter	O
Biomedical).	O

Diets	O
high	O
in	O
protein	O
and	O
polyphenols	O
(e.g.	O
fruits,	O
vegetables,	O
coffee,	O
tea,	O
and	O
chocolate)	O
are	O
degraded	O
by	O
gut	O
microbes	O
to	O
quinic	O
and	O
benzoic	B
acid,	I
which	O
is	O
then	O
oxidized	O
in	O
the	O
host	O
liver	O
to	O
hippuric	B
acid.	I

[m/z	O
263.0890],	O
a	O
dibasic	O
urofuran	O
acid	O
catabolized	O
from	O
furan	B
fatty	O
acids	O
incorporated	O
into	O
phospholipids	B
and	O
cholesterol	B
esters,	I
already	O
described	O
in	O
the	O
literature	O
as	O
related	O
to	O
uremia.	O

This	O
was	O
confirmed	O
by	O
the	O
lower	O
mean	O
CV	O
observed	O
in	O
males	O
than	O
females	O
for	O
both	O
8-iso	B
-PGF_2α	I

Lipid	O
extracts	O
from	O
metacyclogenic	O
intestinal	O
preparations	O
were	O
shown	O
to	O
induce	O
significant	O
differentiation	O
of	O
epimastigotes	O
into	O
infective	O
metacyclic	B
trypomastigotes	O
.	O

MRM	O
chromatograms	O
of	O
vitamin	B
D	I
metabolites	O
in	O
plasma	O
after	O
SPE	O
and	O
PTAD	O
derivatization	O
using	O
sequential	O
MRM	O
time	O
windows	O
(the	O
concentration	O
levels	O
are	O
given	O
in	O
parentheses	O
).	O

These	O
metabolites	O
(citrulline,	O
valine,	B
PC	B
aa	I
C40:4,	I
PC	B
aa	I
C36:5,	I
lysoPC	O
a	O
C17:0,	B
SM	O
(OH)	O
C24:1,	B
threonine,	B
C14:1)	B
come	O
from	O
4	O
of	O
the	O
5	O
metabolite	O
classes	O
quantified.	O

Considering	O
the	O
pK_a	O
values	O
of	O
arsenicals,	O
a	O
number	O
of	O
buffers,	O
including	O
trifluoroacetate	B
(TFA,	O
pK_a	O
=	O
0.5),	O
formate	B
(pK_a	O
=	O
3.8),	O
and	O
acetate	B
(pK_a	O
=	O
4.8),	O
were	O
tested.	O

Bradman	O
et	O
al.	O
studied	O
the	O
determinants	O
of	O
organophosphorous	O
exposure	O
in	O
400	O
Californian	O
children	O
and	O
showed	O
that	O
among	O
the	O
12-month-old	O
infants,	O
the	O
concentrations	O
of	O
dialkylphosphate	B
metabolites	O
(coming	O
from	O
organophosphorus)	B
in	O
urine	O
were	O
higher	O
when	O
children	O
lived	O
within	O
60	O
m	O
of	O
an	O
agricultural	O
field	O
.	O

The	O
measured	O
values	O
by	O
our	O
CE-MS	O
method	O
for	O
creatinine	B
and	O
uric	B
acid	I
were	O
similar	O
to	O
established	O
clinical	O
laboratory	O
assays	O
for	O
these	O
compounds	O
widely	O
used	O
in	O
epidemiologic	O
studies.	O

Forty-eight	O
individual	O
who	O
has	O
self	O
reported	O
sensitivity	O
to	O
aspartame	B
were	O
compared	O
to	O
48	O
age	O
and	O
gender	O
matched	O
aspartame	B
non-sensitive	O
individuals.	O

A	O
total	O
of	O
250	O
plasma	O
samples	O
of	O
infants	O
aged	O
4	O
months	O
(IF:	O
80,	O
CF:	O
79,	O
BF:	O
91)	O
were	O
analyzed	O
to	O
investigate	O
59	O
different	O
carnitine	B
esters	I
and	O
425	O
phospholipids.	B

Tumor	O
citrate,	B
cis	O
-aconitate,	O
and	O
isocitrate	B
levels	O
in	O
P1,	O
P3	O
and	O
P7	O
were	O
consistently	O
lower	O
than	O
their	O
respective	O
normal	O
levels,	O
leaving	O
the	O
possibility	O
that	O
zinc	O
and	O
m-aconitase	O
activity	O
levels	O
may	O
vary	O
depending	O
on	O
a	O
factor	O
other	O
than	O
differentiation	O
status.	O

To	O
investigate	O
whether	O
specific	O
lipid	O
metabolites	O
were	O
associated	O
with	O
MI,	O
the	O
following	O
metabolite	O
selection	O
criteria	O
were	O
used:	O
(a)	O
a	O
VIP	O
score	O
of	O
>1	O
in	O
the	O
PLS-DA	O
and	O
(b)	O
a	O
general	O
linear	O
model	O
after	O
adjustment	O
for	O
age,	O
sex,	O
BMI,	O
LDL	B
cholesterol,	I
and	O
fasting	O
glucose	B
between	O
patients	O
with	O
MI	O
and	O
controls	O
and	O
between	O
patients	O
with	O
MI	O
and	O
those	O
with	O
angina	O
(q	O
<	O
0.05).	O

The	O
observed	O
elevation	O
in	O
serine	B
levels	O
in	O
our	O
HCC	O
patient	O
group	O
may	O
reflect	O
not	O
only	O
the	O
tumour’s	O
heightened	O
biosynthetic	O
needs	O
and	O
serine’s	B
enhancement	O
of	O
HCC	O
proliferation	O
through	O
PKM2,	O
but	O
also	O
the	O
heightened	O
activity	O
of	O
pathways	O
such	O
as	O
AC.	O

As	O
shown	O
by	O
the	O
fatty	O
acid	O
profiles	O
of	O
total	O
lipids	O
of	O
the	O
test	O
foods,	O
C12:0	B
was	O
the	O
dominant	O
fatty	O
acid	O
in	O
the	O
soy	O
drink	O
containing	O
vegetable	O
fat	O
composed	O
of	O
palm	O
and	O
palm	O
kernel	O
oil.	O

This	O
study	O
demonstrated	O
that	O
FFAs,	O
including	O
SFAs,	O
MUFAs,	O
and	O
PUFAs,	O
are	O
elevated	O
or	O
reduced	O
in	O
plasma	O
samples	O
of	O
AF	B
patients,	O
supporting	O
an	O
important	O
role	O
for	O
inflammation	O
in	O
the	O
pathogenesis	O
of	O
AF.	B

Complementary	O
biochemical	O
analyses	O
of	O
cholesterol	B
and	O
triglycerides	B
in	O
serum	O
were	O
performed	O
to	O
further	O
investigate	O
the	O
metabolic	O
effects	O
of	O
RB.	O

To	O
the	O
best	O
of	O
our	O
knowledge,	O
only	O
two	O
assays	O
included	O
more	O
than	O
two	O
compounds:	O
Hutter	O
et	O
al.	O
performed	O
a	O
study	O
of	O
seven	O
compounds	O
and	O
de	O
Jager	O
et	O
al.	O
quantified	O
eleven	O
urinary	O
metabolites	O
from	O
eight	O
synthetic	O
cannabinoids.	B

A	O
second	O
aliquot	O
of	O
milk	O
was	O
stored	O
at	O
−40°C	O
for	O
choline	B
metabolite	O
analysis.	O

Carnosine	B
is	O
an	O
amino	O
acid	O
found	O
in	O
red	O
meat	O
that	O
has	O
a	O
known	O
protective	O
effect	O
against	O
oxidative	O
stress	O
in	O
intestinal	O
epithelial	O
cells.	O

The	O
significant	O
fold	O
change	O
was	O
C	B
19:0	I
CE	I
(fold-change	O
=	O
3.73).	O

For	O
the	O
external	O
validation,	O
duplicate	O
sets	O
of	O
blinded	O
QCs	O
at	O
the	O
three	O
concentration	O
levels	O
were	O
exchanged	O
with	O
the	O
University	O
of	O
Pittsburgh	O
Cancer	O
Institute	O
where	O
a	O
validated	O
enzalutamide	B
assay	O
is	O
in	O
use.	O

There	O
is	O
much	O
evidence	O
suggesting	O
that	O
arginine	B
may	O
play	O
a	O
prominent	O
role	O
in	O
the	O
pathogenesis	O
of	O
diverse	O
age-related	O
diseases,	O
and	O
could	O
be	O
required	O
for	O
memory	O
consolidation	O
(Rayatnia	O
et	O
al.,	O
).	O

Index	O
variables	O
with	O
connection	O
to	O
depression	O
and	O
fatigue	O
were	O
investigated	O
(SLAM	O
headache,	O
SLAM	O
fatigue,	O
SLAM	O
cortical	O
dysfunction,	O
SLICC	O
neuropsychiatric,	O
HADS	O
anxiety	O
and	O
HADS	O
depression),	O
but	O
no	O
correlation	O
was	O
found	O
in	O
relation	O
to	O
the	O
metabolites	O
in	O
the	O
kynurenine	B
pathway	O
except	O
weak	O
correlations	O
between	O
kynurenine	B
and	O
SLICC	O
neuropsychiatric	O
damage	O
(=0.18,	O
p=0.03)	O
and	O
between	O
tryptophan	B
and	O
SLAM	O
cortical	O
dysfunction	O
(=	O

In	O
particular,	O
myo-inositol	B
concentrations	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
FSGS	O
than	O
in	O
both	O
healthy	O
controls	O
(2.34-fold;	O
P < 0.001)	O
and	O
MCD	O
patients	O
(2.48-fold;	O
P = 0.002)	O

The	O
biomarker	O
panel,	O
including	O
the	O
ratio	O
of	O
L-asparagine	B
to	O
L-aspartic	B
acid,	I
vanillylmandelic	B
acid	I
and	O
glutaric	B
acid,	I
yielded	O
an	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
of	O
0.808.	O

	O
Three	O
sets	O
of	O
QC	O
samples	O
in	O
pooled	O
human	O
serum	O
displayed	O
97.3%,	O
98.5%,	O
and	O
96.8%	O
average	O
proline	B
amount	O
remaining	O
after	O
4,	O
8,	O
or	O
24	O
h,	O
respectively.	O

Each	O
sample	O
was	O
injected	O
in	O
a	O
split	O
ratio	O
of	O
1:10,	O
and	O
then	O
separation	O
was	O
carried	O
out	O
on	O
a	O
fused	O
silica	B
capillary	O
column	O
(BPX5;	O
inner	O
diameter:	O
30	O
m	O
×	O
0.25	O
mm,	O
film	O
thickness:	O
0.25	O
μm;	O
SGE	O
Analytical	O
Science).	O

Due	O
to	O
consistent,	O
significant	O
associations	O
with	O
HAM-D	O
score	O
in	O
both	O
covariate-adjusted	O
models,	O
PAFs	O
PC(O	B
-12:0/2:0),	I
PC(O	B
-14:1/2:0),	I
PC(O	B
-17:3/2:0),	I
and	O
PC(O	B
-18:3/2:0)	I
were	O
identified	O
as	O
key	O
species	O
of	O
potential	O
relevance	O
to	O
depressive	O
symptoms	O
in	O
CAD	O
patients.	O

The	O
solutions	O
were	O
vortexed,	O
spun	O
down	O
and	O
mixed	O
with	O
25 μL	O
freshly	O
prepared	O
_12	O
C-dansyl	B
chloride	I
solution	O
(18 mg/mL)	O
(for	O
light	O
labeling)	O
or	O
_13	O
C-dansyl	B
chloride	I
solution	O
(18 mg/mL)	O
(for	O
heavy	O
labeling).	O

Beside	O
the	O
xenobiotic	O
hydroxycotinine,	B
the	O
urinary	O
concentration	O
of	O
1-MU	O
was	O
positively	O
related	O
with	O
OCN.	O

Furthermore,	O
the	O
lipid	O
profile	O
of	O
GWI	O
can	O
be	O
replicated	O
in	O
rat	O
and	O
mouse	O
models	O
exposed	O
to	O
a	O
nerve	O
gas	O
antidote,	O
pyridostigmine	B
bromide.	I

A	O
recent	O
study	O
also	O
demonstrated	O
that	O
systemic	O
administration	O
of	O
AICAR	B
in	O
humans	O
reduced	O
whole	O
body	O
lipolysis	O
in	O
a	O
manner	O
similar	O
to	O
that	O
observed	O
in	O
the	O
current	O
clinical	O
trial.	O

Indeed,	O
we	O
found	O
serum	O
glucose	B
levels	O
increased	O
in	O
patients	O
treated	O
with	O
atypical	O
antipsychotic	O
medication.	O

Therefore,	O
we	O
first	O
tested	O
whether	O
centrifugation	O
affects	O
DG	O
and	O
TG	B
concentrations.	O

It	O
is	O
now	O
understood	O
that	O
even	O
modest	O
increases	O
in	O
circulating	O
ammonia	O
occur	O
in	O
patients	O
with	O
OHE	O
and	O
increased	O
levels	O
of	O
glutamate	B
secondary	O
to	O
this	O
have	O
been	O
demonstrated	O
by	O
NMR	O
spectroscopy	O
in	O
plasma	O
of	O
patients	O
with	O
acute	O
liver	O
failure.	O

Leukotriene	B
B4	I
in	O
breath	O
has	O
been	O
associated	O
with	O
the	O
inflammatory	O
response	O
to	O
traffic	O
exposures,	O
where	O
long-term	O
traffic	O
exposures,	O
assessed	O
by	O
land	O
use	O
regression	O
models	O
estimating	O
exposure	O
to	O
PM_2.5	O
,	O
were	O
shown	O
to	O
be	O
associated	O
with	O
increased	O
LTB4	B
measured	O
in	O
induced	O
sputum	O
(2μg/m_3	O
PM_2.5	O
:	O
~23%	O
CI_95%	O
(4%-42%)	O
LTB4).	O

The	O
tCho	O
pool	O
correlated	O
positively	O
with	O
tCr	O
and	O
tGlut,	O
as	O
well	O
as	O
with	O
lactate.	B

Physiological	O
functions	O
of	O
arginine	B
(–),	O
glycine	B
(–),	O
methionine	B
(–),	O
valine	B
(–),	O
citrulline	B
(,)	O
and	O
C16-carnitine	B
(–)	O
were	O
summarized	O
in	O
.	O

Next,	O
the	O
samples	O
were	O
mixed	O
with	O
60	O
μL	O
of	O
2.5	O
mol/L	O
phosphate	B
buffer	O
solution	O
with	O
a	O
pH	O
of	O
7.00	O
in	O
99.8%	O
D_2	O
O	O
containing	O
TSP	O
as	O
an	O
internal	O
standard.	O

Subsequently,	O
200 μL	O
of	O
a	O
methoxyamine	B
pyridine	I
solution	O
(15 g/L)	O
was	O
added	O
into	O
the	O
ampoule	O
bottle.	O

Filtrate	O
from	O
four	O
samples	O
were	O
dried,	O
two	O
of	O
these	O
used	O
for	O
_1	O
H	O
1D	O
NMR	O
and	O
the	O
other	O
two	O
for	O
detecting	O
carboxyl	O
containing	O
metabolites	O
after	O
smart	O
isotope	O
tagging	O
with	O
_15	O
N-cholamine,	B
as	O
described	O
below	O
and	O
in	O
ref.	O

Indoleamine	O
2,3-dioxygenase	O
(IDO),	O
a	O
rate-limiting	O
enzymes	O
for	O
tryptophan	B
catabolism	O
by	O
the	O
kynurenine	B
pathway,	O
is	O
induced	O
by	O
inflammatory	O
cytokines	O
and	O
its	O
activity	O
is	O
enhanced	O
in	O
chronic	O
inflammatory	O
conditions	O
such	O
as	O
atherosclerosis	O
and	O
obesity	O
[,	O
].	O

This	O
sulfate	B
metabolite	O
exists	O
as	O
a	O
zwitterion	O
under	O
our	O
LC	O
solvent	O
conditions,	O
and	O
may	O
have	O
escaped	O
detection.	O

In	O
vitro	O
effects	O
of	O
4-aminopyridine	B
on	O
inhibition	O
of	O
human	O
CYP	O
enzymes.	O

B	O
y	O
-axis	O
represents	O
the	O
peak	O
area	O
without	O
normalisation	O
since	O
8-iso-13,14-dihydro-PGF_2α	B
and	O
13,14-dihydro-PGF_2α	B
were	O
exclusively	O
detected	O
in	O
GUS-hydrolysed	O
urine.	O

Neonicotinoid	B
pesticides	O
have	O
been	O
widely	O
applied	O
for	O
the	O
production	O
of	O
fruits	O
and	O
vegetables,	O
and	O
occasionally	O
detected	O
in	O
conventionally	O
grown	O
produce.	O

The	O
highest	O
recoveries	O
for	O
the	O
Alshehry	O
method	O
were	O
achieved	O
with	O
the	O
phospholipids	B
(>95%)	O
and	O
lowest	O
for	O
the	O
less	O
polar	O
TG,	B
DG	O
lipids	O
(<80%).	O

Lactate	B
to	O
pyruvate	B
ratio	O
was	O
decreased	O
in	O
AF	B
and	O
conversely	O
increased	O
in	O
PL.	O

Ether-linked	O
lipids	O
are	O
characterized	O
by	O
an	O
ether	O
linkage	O
as	O
opposed	O
to	O
an	O
ester	O
linkage	O
at	O
one	O
or	O
both	O
fatty	O
acid	O
side	O
chains,	O
with	O
the	O
subclass	O
plasmalogens	O
having	O
a	O
vinyl	B
ether	I
linkage.	O

Typical	O
800	O
MHz	O
(cryo-probe)	O
1D	O
CPMG	O
_1	O
H	O
NMR	O
spectrum	O
of	O
human	O
serum	O
obtained	O
after	O
protein	O
precipitation	O
using	O
methanol	B
(1:2,	I
v/v,	I
serum/methanol)	I
with	O
expanded	O
regions	O
and	O
peak	O
annotations	O
for	O
the	O
30	O
metabolites,	O
which	O
were	O
quantitated	O
using	O
NMR	O
to	O
guide	O
their	O
absolute	O
quantitation	O
using	O
MS.	O

[Google	O
Scholar]	O
Polet	O
H,	O
Levine	O
L.	O
Metabolism	O
of	O
prostaglandins	B
E,	O
A,	O
and	O
C	O
in	O
serum.	O

The	O
ALDEFLUOR	B
assay	O
kit	O
(01700,	O
StemCell,	O
Vancouver,	O
British	O
Columbia,	O
Canada)	O
was	O
used	O
to	O
isolate	O
the	O
ALDH_hi	O
CD44_hi	O
and	O
ALDH_lo	O
CD44_lo	O
HNSCC	O
cells	O
according	O
to	O
the	O
manufacturer’s	O
instructions.	O

ARG,	O
arginase;	O
DDAH,	O
dimethylarginine	O
dimethylaminohydrolase,	O
NOS,	O
nitric	B
oxide	I
synthase;	O
ODC,	O
ornithine	O
decarboxylase;	O
PRMT,	O
arginine	O
N-methyltransferase;	O
BAX,	O
Bcl-2-associated	O
X	O
protein;	O
CCL2–4,	O
chemokine	O
(C-C	O
motif)	O
ligand	O
2–4;	O
FGF2,	O
basic	O
fibroblast	O
growth	O
factor	O
2;	O
HIF1A,	O
hypoxia-inducible	O
factor	O
1α,	O
IL,	O
interleukin;	O
CDKN1A,	O
cyclin-dependent	O
kinase	O
inhibitor	O
1;	O
TP53,	O
tumor	O
protein	O
p53;	O
PCNA,	O
proliferating	O
cell	O
nuclear	O
antigen;	O
TNFA,	O
tumor	O
necrosis	O
factor	O
α;	O
VEGFA,	O
vascular	O
endothelial	O
growth	O
factor	O
A.	O
ARG2	O
expression	O
was	O
positively	O
correlated	O
with	O
CDKN1A	O
as	O
well,	O
both	O
in	O
inflamed	O
and	O
non-inflamed	O
tissue,	O
and	O
with	O
TP53	O
in	O
inflamed	O
tissue.	O

Omega-3	B
supplement	O
can	O
reduce	O
violent	O
behaviours	O
in	O
children,	O
young	O
men,	O
schizophrenia	O
patients	O
and	O
adult	O
prisoners.	O

Rico	O
et	O
al	O
.	O
also	O
observed	O
similar	O
repeatability	O
between	O
methanol	B
and	O
C18	O
SPE	O
with	O
approximately	O
80%	O
of	O
features	O
which	O
met	O
30%	O
RSD	O
criteria	O
for	O
both	O
methods.	O

Then,	O
250	O
μl	O
of	O
chloroform	B
at	O
4°C	O
per	O
20	O
million	O
cells	O
were	O
added	O
to	O
the	O
corresponding	O
pellets	O
and	O
let	O
stand	O
for	O
30	O
min.	O

From	O
,	O
SM16:0	B
and	O
SM22:0	B
were	O
identified	O
only	O
in	O
the	O
extracts	O
of	O
protocols	O
(i)–(iv),	O
but	O
could	O
not	O
be	O
identified	O
from	O
protocols	O
(v)	O
and	O
(vi).	O

Consequently,	O
GABA	B
plays	O
an	O
important	O
protective	O
role	O
both	O
in	O
obesity	O
and	O
asthma	O
which	O
may	O
lead	O
to	O
new	O
therapeutic	O
strategies	O
for	O
the	O
management	O
of	O
obese	O
asthma.	O

Human	O
plasma	O
total	O
lipid	O
extracts	O
spiked	O
with	O
the	O
isobaric	O
ceramide	B
standards	O
(shown	O
in	O
)	O
were	O
utilized	O
for	O
evaluating	O
the	O
linear	O
instrument	O
response.	O

Quantification	O
of	O
purine	B
metabolites.	O

Existing	O
evidence	O
suggests	O
that	O
impaired	O
vitamin	B
D	I
metabolism	O
may	O
promote	O
atherosclerosis.	O

The	O
absence	O
of	O
metabolites	O
such	O
as	O
trimethylamine	B
in	O
the	O
lyophilized	O
samples	O
was	O
potentially	O
due	O
to	O
chemical	O
degradation.	O

Negative	O
correlations	O
with	O
the	O
absence	O
of	O
ADs	O
were	O
found	O
in	O
lack	O
of	O
exercise,	O
cis-10	B
pentadecanoic	I
acid	I
(C15:1)	O
and	O
gamma-linolenic	B
acid	I
(C18:3n6).	O

Out	O
of	O
the	O
134	O
patients	O
recruited,	O
three	O
patients	O
had	O
received	O
thiopurine	B
treatment	O
for	O
less	O
than	O
6	O
months	O
and	O
were	O
excluded	O
from	O
analysis.	O

We	O
did	O
not	O
include	O
glucocorticoid	B
metabolites	O
as	O
these	O
are	O
uninterpretable	O
in	O
mitotane-treated	O
ACC	O
patients,	O
who	O
all	O
receive	O
high-dose	O
glucocorticoid	B
replacement	O
while	O
also	O
being	O
subject	O
to	O
the	O
strong	O
induction	O
of	O
the	O
cortisol-metabolizing	O
enzyme	O
CYP3A4	O
by	O
mitotane.	O

6.4	O
×	O
10_−1	O
,	O
C17:0	B
p	O
=	O
8.3	O
×	O
10_−1	O
,	O
unknown	O
C17	O
p	O
=	O

In	O
addition	O
to	O
its	O
role	O
as	O
a	O
PPAR	O
ligand,	O
12,13-DiHOME	B
exerts	O
toxic	O
and	O
oxidative	O
effects,	O
inhibits	O
mitochondrial	O
function,	O
stimulates	O
neutrophil	O
chemotactic	O
activity	O
and	O
suppresses	O
neutrophil	O
respiratory	O
burst	O
activity_,	O
_,	O
_,	O
.	O

Our	O
method	O
allows	O
for	O
identification	O
and	O
quantification	O
of	O
32	O
different	O
steroid	O
metabolites	O
derived	O
from	O
mineralocorticoids,	O
glucocorticoids,	B
androgens,	O
and	O
their	O
precursors;	O
details	O
are	O
summarized	O
in	O
.	O

Concomitantly,	O
a	O
high	O
degree	O
of	O
correlation	O
exists	O
between	O
the	O
levels	O
of	O
isobutyrate	B
and	O
isovalerate	B
regardless	O
of	O
the	O
host	O
species	O
[,	O
]	O
which	O
suggests	O
the	O
presence	O
of	O
a	O
universal	O
substrate.	O

The	O
present	O
study	O
shows	O
that	O
the	O
serum	O
levels	O
of	O
NAG,	O
creatine,	B
lipids	O
(at	O
1.3	O
and	O
0.9	O
ppm),	O
glycine	B
and	O
lactate	B
are	O
increased	O
in	O
children	O
with	O
drug-resistant	O
epilepsy,	O
thus	O
these	O
metabolites	O
might	O
be	O
considered	O
as	O
the	O
systemic	O
biomarkers	O
of	O
a	O
diagnostic	O
utility.	O

An	O
improved	O
understanding	O
of	O
vitamin	B
D	I
catabolism	O
may	O
help	O
identify	O
new	O
diagnostic	O
and	O
therapeutic	O
strategies	O
to	O
improve	O
health	O
in	O
chronic	O
kidney	O
disease	O
(CKD)	O
because	O
impaired	O
vitamin	B
D	I
metabolism	O
leads	O
to	O
secondary	O
hyperparathyroidism	O
and	O
bone	O
disease	O
and	O
may	O
contribute	O
to	O
cardiovascular	O
disease,	O
progression	O
to	O
end	O
stage	O
renal	O
disease,	O
and	O
premature	O
death._–	O
To	O
better	O
assess	O
vitamin	B
D	I
catabolism	O
in	O
humans,	O
we	O
developed	O
a	O
novel	O
high-throughput	O
assay	O
for	O
circulating	O
24,25-dihydroxyvitamin	B
D	I
(24,25(OH)_2	I
D_3	I
).	I

Accumulations	O
of	O
circulating	O
acylcarnitines	B
and	O
specific	O
amino	O
acid	O
metabolites	O
may	O
reflect,	O
at	O
least	O
in	O
part,irinotecan-induced	O
mitochondrial	O
dysfunction	O
and	O
oxidative	O
stress	O
in	O
the	O
liver.	O

Hydrogen	B
peroxide	I
was	O
added	O
to	O
the	O
cultures	O
at	O
a	O
final	O
concentration	O
of	O
100 μM	O
to	O
trigger	O
oxidative	O
stress	O
and	O
cell	O
death	O
in	O
the	O
RGC-5	O
cells.	O

In	O
total,	O
eight	O
metabolites	O
were	O
significantly	O
altered	O
between	O
the	O
NDMM	O
and	O
the	O
MGUS	O
group,	O
including	O
free	O
carnitine,	B
acetylcarnitine,	B
glutamate,	B
ADMA,	B
and	O
four	O
PCs	O
species	O
(	O
and	O
Part	O
D	O
in	O
).	O

For	O
example,	O
the	O
first	O
box	O
in	O
,	O
the	O
normalized	O
(filtered)	O
plot	O
of	O
glioblastoma	O
(GBM)	O
data,	O
highlights	O
the	O
metabolite	O
correlations	O
of	O
lactate	B
and	O
alanine,	B
whose	O
details	O
are	O
shown	O
in	O
the	O
first	O
plot	O
in	O
the	O
bottom	O
left.	O

Concentrations	O
were	O
expressed	O
both	O
as	O
nanomol	O
per	O
day	O
(nmol/day)	O
and	O
nanograms	O
per	O
milligram	O
of	O
creatinine	B
(ng/mg	O
Cr).	O

Considering	O
IBD	O
children	O
have	O
overall	O
higher	O
urinary	O
UDCA	O
and	O
TUDCA,	O
lower	O
urinary	O
hippurate	B
and	O
3-hydroxyphenylacetate,	B
and	O
lower	O
BMI	O
z	O
-scores,	O
the	O
signature	O
may	O
be	O
reflecting	O
a	O
higher	O
degree	O
of	O
gastrointestinal	O
deregulations	O
with	O
IBD.	O

An	O
example	O
of	O
the	O
ratio	O
of	O
2	O
statistically	O
different	O
metabolites	O
between	O
normal	O
and	O
tumor	O
tissue	O
and	O
cytidine	B
5′-diphosphocholine	I
is	O
reported	O
in	O
and	O
.	O

As	O
BA	O
and	O
FN	O
significantly	O
increased	O
both	O
P450	O
1A1	O
and	O
P450	O
1B1	O
pathways,	O
they	O
are	O
most	O
likely	O
the	O
reason	O
that	O
RCE	O
increased	O
estrogen	B
metabolism	O
in	O
MCF-7	O
cells.	O

The	O
largest	O
increase	O
in	O
median	O
steroid	O
metabolite	O
excretion	O
was	O
found	O
in	O
the	O
PCOS	O
group	O
for	O
dehydroepiandrosterone	B
(4.9-fold,	O
p	O
<0.001),	O
androstenediol	B
(3.0-fold,	O
p	O
<0.001),	O
pregnenetriol	O
(2.8-fold,	O
p	O
<0.001),	O
16α-OH-dehydroepiandrosterone	B
(2.3-fold,	O
p	O
<0.001)	O
and	O
androstanediol	B
(2.3-fold,	O
p	O
<0.001).	O

In	O
detail,	O
the	O
aspartate	B
(Asp),	O
citrulline	B
(Cit),	O
glycine	B
(Gly),	O
histidine	B
(His),	O
lysine	B
(Lys),	O
methionine	B
(Met),	O
ornithine	B
(Orn),	O
tryptophan	B
(Trp),	O
valine	B
(Val)	O
and	O
etherphosphorylcholine	B
(GPCe)	O
42:4	O
levels	O
in	O
sperm	O
cells	O
and	O
the	O
acetylornithine	B
(Ac-Orn),	O
phenethylamine	B
(PEA),	O
phosphatidylcholine	B
(PC)	O
30:2	O
and	O
PC	B
38:1	I
levels	O
in	O
seminal	O
plasma	O
were	O
not	O
included	O
in	O
the	O
correlation	O
analyses.	O

Decensi	O
et	O
al.	O
observed	O
in	O
a	O
preoperative	O
study,	O
using	O
1,	O
5,	O
or	O
20 mg	O
tamoxifen	B
daily	O
for	O
4 weeks,	O
that	O
the	O
expression	O
of	O
the	O
tumor	O
proliferation	O
marker	O
Ki-67	O
decreased	O
to	O
the	O
same	O
extent	O
irrespective	O
of	O
dose.	O

(A)	O
Gas	O
chromatography	O
(GC)	O
separation	O
of	O
9-HSA	O
and	O
12-HSA	O
methyl	B
esters	I
as	O
trimethylsilyl	O
(TMS)	O
derivatives.	O

Xanthurenic	B
acid	I
levels	O
were	O
measured	O
using	O
a	O
fluorometric	B
method.	O

Therefore,	O
it	O
can	O
be	O
stated	O
that	O
increase	O
phosphoric	B
acid	I
levels	O
are	O
indicator	O
that	O
various	O
metabolic	O
pathways	O
are	O
up-regulated	O
in	O
this	O
disease.	O

Deproteinized	O
supernatants	O
were	O
then	O
transferred	O
to	O
clean	O
plastic	O
Eppendorf	O
tubes,	O
and	O
fifty	O
volumes	O
of	O
methanol	B
containing	O
0.1%	O
formic	B
acid	I
(Fluka)	O
was	O
added	O
to	O
each	O
tube.	O

Our	O
results	O
demonstrate	O
that	O
MUC16	O
knockdown	O
reduces	O
expression	O
of	O
key	O
glycolytic	B
genes	O
and	O
glycolytic	B
activity	O
of	O
the	O
pancreatic	O
cancer	O
cells.	O

The	O
supernatant	O
was	O
dried	O
with	O
N_2	O
,	O
dissolved	O
in	O
10%	O
methanol,	B
mixed	O
by	O
vortexing,	O
and	O
centrifuged	O
at	O
10,000	O
rpm	O
for	O
5	O
minutes	O
at	O
4°C.	O

y	O
y	O
y	O
	O
r	O
r	O
r	O
)	O
	O
φjr	O
φjr	O
φjr	O
φjr	O
φjr	O
φjr	O
φjr	O
φjr	O
φ	O
φ	O
φ	O
jr	O
jr	O
j	O
r	O
	O
∑ps=1∑qj=1ρsj(yj)xs	B
∑ps=1∑qj=1ρsj(yj)xs	I
∑ps=1∑qj=1ρsj(yj)xs	I
∑ps=1∑qj=1ρsj(yj)xs	I
∑ps=1∑qj=1ρsj(yj)xs	I
∑ps=1∑qj=1ρsj(yj)xs	I

The	O
aqueous	O
layer	O
was	O
aspirated	O
off,	O
whereas	O
the	O
remaining	O
chloroform	B
layer	O
containing	O
derivatives	O
were	O
isolated	O
and	O
dried	O
with	O
anhydrous	B
sodium	I
sulfate	I
and	O
subsequently	O
subjected	O
to	O
GC-TOFMS	O
analysis.	O

The	O
smart	O
isotope	O
tag,	O
_15	O
N-cholamine,	B
designed,	O
developed	O
and	O
used	O
in	O
this	O
stu`dy	O
retains	O
all	O
the	O
characteristics	O
of	O
the	O
_15	O
N-ethanolamine	B
tag	O
including	O
the	O
solubility	O
of	O
the	O
tagged	O
metabolites	O
in	O
aqueous	O
media,	O
large	O
one-bond	O
J-coupling	O
between	O
_1	O
H	O
and	O
_15	O
N	O
of	O
∼90	O
Hz	O
for	O
efficient	O
polarization	O
transfer	O
between	O
_1	O
H	O
and	O
_15	O
N	O
nuclei,	O
and	O
wide	O
chemical	O
shift	O
dispersion	O
for	O
different	O
metabolites	O
in	O
the	O
resulting	O
2D	O
NMR	O
spectra.	O

Parameters	O
of	O
liquid	O
chromatography-tandem	O
mass	O
spectrometry	O
method	O
for	O
measuring	O
glutamate,	B
aspartate,	B
glutamine	B
and	O
asparagine.	B

Reported	O
are	O
the	O
results	O
of	O
a	O
single	O
multivariable	O
regression	O
model,	O
with	O
circulating	O
24,25(OH)_2	B
D_3	O
concentration	O
as	O
dependent	O
variable.	O

Total	O
sum,	O
creatinine	B
and	O
VSN	O
normalizations	O
all	O
account	O
for	O
the	O
dilutions	O
by	O
setting	O
the	O
medians	O
of	O
peak	O
intensities	O
to	O
a	O
comparable	O
level.	O

Secondly,	O
in	O
the	O
present	O
study,	O
we	O
only	O
suggested	O
that	O
the	O
subjects	O
who	O
have	O
a	O
statistically	O
higher	O
mean	O
value	O
of	O
background	O
urinary	O
glycine	B
and	O
PAG	B
levels	O
may	O
have	O
a	O
good	O
prognosis	O
following	O
a	O
nutritional	O
intervention	O
against	O
oxidative	O
stress.	O

However,	O
the	O
concentration	O
of	O
the	O
putative	O
3-epi-25(OH)D_3	B
could	O
not	O
be	O
quantified	O
in	O
the	O
first	O
three	O
levels	O
of	O
SRM	O
972	O
with	O
the	O
desired	O
level	O
of	O
precision	O
by	O
LC-MS,	O
and	O
we	O
elected	O
to	O
pursue	O
LC-MS/MS	O
methodology	O
to	O
further	O
investigate	O
this	O
species.	O

On	O
the	O
basis	O
of	O
its	O
structure,	O
we	O
assume	O
that	O
it	O
is	O
a	O
direct	O
metabolite	O
of	O
S	B
-propenyl-cysteine-sulfoxide	I
(SPCSO).	O

A	O
simple	O
protein	O
precipitation	O
method	O
was	O
performed	O
with	O
acetonitrile.	B

Additional	O
CSF	O
parameters	O
including	O
cell	O
count,	O
lactate,	B
glucose,	B
protein,	O
and	O
albumin	O
were	O
recorded.	O

The	O
estrogen	B
and	O
estrogen	B
metabolite	O
profiles	O
resulting	O
from	O
the	O
LC/MS/MS	O
assay	O
included	O
five	O
estrogens	O
and	O
estrogen	B
metabolites	O
found	O
in	O
circulation	O
in	O
both	O
conjugated	O
and	O
unconjugated	O
forms	O
and	O
10	O
found	O
in	O
conjugated	O
form	O
only,	O
and	O
therefore	O
provide	O
a	O
novel	O
phenotypic	O
characterization	O
of	O
individual	O
patterns	O
of	O
estrogen	B
metabolism.	O

A	O
precipitation	O
of	O
low-density	O
lipoprotein	O
cholesterol	B
(LDL-C)	O
fraction	O
in	O
the	O
infranatant	O
with	O
heparin-manganese	B
chloride	I
was	O
used	O
to	O
obtain	O
the	O
HDL-C	O
fraction.	O

In	O
β-cell,	O
glutamine	B
is	O
carried	O
by	O
blood	O
and	O
accumulated	O
on	O
plasma	O
membrane,	O
then	O
further	O
converted	O
to	O
glutamic	B
acid	I
(Jenstad	O
and	O
Chaudhry	O
).	O

In	O
short,	O
ubiquinone	B
accepts	O
electrons	O
transferred	O
from	O
succinate	B
by	O
succinate	O
dehydrogenase	O
(complex	O
II).	O

The	O
glutaminase	O
reaction	O
generates	O
ammonium	B
ions	O
and	O
glutamate,	B
which	O
can	O
be	O
used	O
in	O
a	O
wide	O
variety	O
of	O
metabolic	O
reactions,	O
including	O
anaplerotic	O
incorporation	O
of	O
the	O
carbon	O
skeleton	O
into	O
the	O
Krebs	O
cycle	O
(;	O
;	O
).	O

gives	O
a	O
schematic	O
representation	O
of	O
the	O
glycolate/glyoxalate/oxalate	O
metabolism,	O
shown	O
with	O
the	O
different	O
isotopic	O
labels	O
used	O
during	O
this	O
study,	O
in	O
which	O
both	O
healthy	O
volunteers	O
and	O
PH1	O
patients	O
received	O
a	O
primed,	O
continuous	O
infusion	O
of	O
_13	O
C_2	B
-oxalate	I
and	O
1-_13	O
C-glycolate.	B

Published	O
methods	O
for	O
the	O
quantification	O
of	O
statins	B
and	O
their	O
active	O
metabolites	O
did	O
not	O
test	O
for	O
matrix	O
effect	O
of	O
or	O
validate	O
the	O
method	O
in	O
hyperlipidemic	O
plasma.	O

(90:10,	O
v/v)	O
containing	O
10	O
mM	O
ammonium	B
acetate	I
and	O
(B)	O
CH_3	O

Since	O
SL	B
parameters	O
showed	O
a	O
significant	O
accumulation	O
in	O
the	O
serum	O
of	O
HCC	O
patients	O
we	O
further	O
used	O
Spearman	O
rank	O
correlations	O
to	O
identify	O
potential	O
relationships	O
to	O
demographic	O
characteristics	O
and	O
biochemical	O
parameters	O
in	O
these	O
patients.	O

Even	O
if	O
most	O
studies	O
point	O
towards	O
TMAO	B
as	O
marker	O
of	O
worse	O
outcome	O
in	O
CV	O
pathologies,	O
controversy	O
remains	O
when	O
specific	O
patient	O
cohorts	O
are	O
evaluated.	O

Cancer	O
cachexia,	O
Metabolomics,	O
Logistic	O
regression,	O
Biomarker,	O
Leucine	B

b	O
,	O
induction	O
of	O
expression	O
of	O
mRNAs	O
for	O
RARβ	O
(left	O
lower	O
panel	O
)	O
or	O
cytochrome	O
P450,	O
26A1	O
(CYP26A1)	O
(right	O
lower	O
panel	O
)	O
by	O
10	O
nm	O
ATRA	O
treatment	O
alone	O
or	O
by	O
co-treatment	O
with	O
ATRA	O
and	O
the	O
test	O
compounds	O
at	O
10	O
nm,	O
including	O
β-carotene	B
(BC	O
),	O
β-ionylideneacetic	B
acid	I
(BIAA	O
),	O
β-apo-14′-carotenal	B
(14′-AL),	O
β-apo-14′-carotenoic	B
acid	I
(14′-CA),	O
and	O
β-apo-13-carotenone	B
(C13	O
ketone).	B

In	O
separate	O
regression	O
models,	O
we	O
selected	O
each	O
of	O
the	O
tryptophan	B
metabolites	O
and	O
PLP	O
as	O
dependent	O
variables.	O

In	O
particular,	O
triglycerides	B
and	O
LDL	B
cholesterol	I
have	O
been	O
found	O
to	O
be	O
higher	O
in	O
women	O
with	O
PCOS,	O
while	O
HDL-C	O
was	O
lower.	O

There	O
is	O
also	O
increasing	O
evidence	O
that	O
accumulation	O
of	O
long-chain	O
acylcarnitines	B
may	O
contribute	O
to	O
insulin	O
resistance,	O
which	O
is	O
itself	O
common	O
and	O
associated	O
with	O
prognosis	O
in	O
PAH.	O

Prior	O
to	O
the	O
structural	O
elucidation	O
of	O
VLCDCA	B
28:4,	I
by	O
monitoring	O
the	O
anion	O
of	O
this	O
lipid,	O
it	O
was	O
found	O
to	O
be	O
decreased	O
in	O
the	O
plasma	O
of	O
colorectal	O
and	O
pancreatic	O
cancer	O
patients,	O
but	O
not	O
to	O
be	O
altered	O
in	O
patients	O
with	O
breast,	O
prostate,	O
or	O
liver	O
cancers	O
[,,,,,].	O

The	O
system	O
was	O
calibrated	O
routinely	O
with	O
LTQ	O
FT	B
calibration	O
solution	O
prepared	O
according	O
to	O
the	O
instrument	O
instructions.	O

Yij=βoj+Xi1β1j+Xi2β2j+…+Xipβpj+εij	B

We	O
additionally	O
used	O
the	O
leave-one	O
out	O
(LOO)	O
CV	O
approach	O
to	O
obtain	O
the	O
unbiased	O
estimates	O
of	O
these	O
model	O
scores	O
and	O
avoid	O
overfitting	O
when	O
the	O
model	O
was	O
internally	O
validated	O
in	O
the	O
SATIN	B
population.	O

50	O
0.5	B
4,4-dimethyl-4-silapentane-1-sulfonic	I
acid	I
(	O
)	O

Accordingly,	O
patients	O
with	O
a	O
low	O
uptake	O
of	O
_18	O
F-FDG	O
may	O
not	O
only	O
exhibit	O
lower	O
concentrations	O
of	O
glucogenic	B
precursors	O
in	O
their	O
plasma	O
but	O
also	O
use	O
other	O
pathways	O
to	O
sustain	O
their	O
growth	O
and	O
proliferation.	O

To	O
circumvent	O
this	O
ion-suppression	O
problem,	O
two	O
commonly	O
used,	O
volatile,	O
and	O
LC-MS	O
friendly	O
additives	O
were	O
tested	O
as	O
alternatives	O
to	O
the	O
non-volatile	O
PSA	O
used	O
in	O
the	O
LC-EC	O
profiling	O
experiments:	O
(1)	O
perfluoropentanoic	B
acid	I
(PFA),	O
a	O
negatively	O
charged	O
reagent,	O
commonly	O
used	O
to	O
enhance	O
the	O
retention	O
of	O
cationic	O
metabolites	O
in	O
LC-MS	O
analysis	O
and	O
(2)	O
triethylamine	B
(TEA),	O
a	O
volatile	O
cationic	O
compound	O
that	O
ion-pairs	O
with	O
negatively-charged	O
analytes,	O
commonly	O
used	O
to	O
improve	O
both	O
retention	O
and	O
separation	O
in	O
LC-MS.	O

While	O
an	O
adiponectin‐FGF‐21‐ceramide	B
axis	O
has	O
been	O
proposed	O
in	O
animal	O
models,	O
correlations	O
between	O
these	O
adipokines/hepatokines	O
and	O
muscle	O
Cer	B
were	O
not	O
impressive.	O

Cells	O
were	O
grown	O
in	O
Dulbecco’s	O
modified	O
Eagle’s	O
medium	O
(DMEM)	O
(Corning)	O
supplemented	O
with	O
10%	O
(v/v)	O
fetal	O
bovine	O
serum	O
(FBS),	O
100	O
units/ml	O
penicillin	B
and	O
100	O
µg/ml	O
streptomycin,	B
and	O
maintained	O
at	O
37	O
°C	O
with	O
5%	O
CO_2	O
.	O

The	O
extracts	O
were	O
combined,	O
dried	O
under	O
nitrogen	O
at	O
45	O
°C,	O
and	O
reconstituted	O
with	O
120	O
μL	O
methanol	B
prior	O
to	O
analysis.	O

It	O
remains	O
elusive	O
whether	O
So1P	O
is	O
associated	O
with	O
the	O
duration	B
of	O
diabetes	O
and	O
severity	O
of	O
atherosclerosis	O
in	O
diabetic	O
patients.	O

TOCSY	O
spectrum	O
of	O
TCA	O
extract	O
of	O
Rh30	O
cells	O
grown	O
for	O
24	O
h	O
in	O
the	O
presence	O
of	O
0.2%	O
[U-_13	B
C]-glucose	I
and	O
10%	O
FCS,	O
using	O
a	O
mixing	O
time	O
of	O
50	O
ms	O
and	O
a	O
spin	O
lock	O
strength	O
of	O
8	O
kHz.	O

However,	O
there	O
was	O
lower	O
variance	O
with	O
MeOH	B
ppt	O
+UF	O
(CoV:	O
6.3	O
±	O
1.6%)	O
compared	O
to	O
MeOH:CHCl_3	B
:water	O
ext	O
+UF	O
(CoV:	O
9.5	O
±	O
1.7%,	O
p	O
=	O
0.02).	O

Plasmas	O
were	O
mixed	O
with	O
430 µl	O
methanol,	B
vortexed	O
and	O
incubated	O
on	O
ice	O
for	O
10 min	O
in	O
the	O
presence	O
of	O
4 mg/ml	O
BHT	O
before	O
centrifugation	O
at	O
14,000 × g	O
for	O
10 min.	O

For	O
some	O
steroids,	O
in	O
particular	O
21-deoxycortisol,	B
11-deoxycorticosterone	B
and	O
18-oxocortisol,	B
plasma	O
concentrations	O
were	O
below	O
detectable	O
limits	O
in	O
15%,	O
11%	O
and	O
2%	O
of	O
patients	O
respectively	O
so	O
that	O
only	O
upper	O
cut-offs	O
of	O
reference	O
intervals	O
could	O
be	O
established.	O

The	O
_1	O
H	O
and	O
_15	O
N	O
chemical	O
shift	O
data	O
derived	O
from	O
the	O
2D	O
NMR	O
experiments,	O
after	O
tagging	O
with	O
_15	O
N	O
cholamine,	B
are	O
shown	O
in	O
.	O

For	O
ensuring	O
accuracy	O
and	O
reproducibility,	O
leucine	B
enkephalin	I
in	O
200	O
pg/mL	O
was	O
used	O
as	O
the	O
lock-mass	O
for	O
positive	O
ESI	O
mode	O
([M+H]+	O
=	O
556.2771)	O
via	O
a	O
lock	O
spray	O
interface.	O

In	O
female	O
plasma	O
samples	O
many	O
metabolites	O
important	O
for	O
the	O
correct	O
prediction	O
of	O
age	O
could	O
be	O
identified	O
and	O
include	O
ornithine,	B
choline,	B
pseudouridine,	B
hippuric	B
acid,	I
meso-erythritol,	B
potassium,	O
phenylalanine,	B
SM(OH)C14:1,	B
SM(OH)C16:1,	B
cholesterol,	B
d-glucuronic	B
acid,	I
glucose,	B
and	O
phosphatidylcholine	B
(PC).aa.	O

Cheng	O
et	O
al.	O
reported	O
that	O
when	O
radiolabeled	O
choline	B
forms	O
were	O
added	O
to	O
infant	O
formula	O
fed	O
to	O
suckling	O
rat	O
pups,	O
Cho	O
and	O
PCho	O
rapidly	O
appeared	O
in	O
blood	O
and	O
the	O
liver,	O
whereas	O
PC	O
took	O
longer	O
to	O
appear	O
in	O
blood	O
and	O
was	O
metabolized	O
differently	O
by	O
the	O
liver.	O

The	O
identities	O
of	O
novel	O
incorporated	O
compounds,	O
H-E-LAs,	O
K-E-LAs,	O
and	O
9,10,11-TriHOME,	B
in	O
plasma	O
were	O
confirmed	O
by	O
comparing	O
retention	O
times	O
and	O
product	O
ion	O
spectra	O
with	O
authentic	O
standard.	O

However,	O
the	O
high	O
ULOQ	O
concentration	O
required	O
for	O
the	O
analysis	O
of	O
tryptophan	B
initially	O
resulted	O
in	O
a	O
nonlinear	O
response,	O
caused	O
by	O
in-source	O
ionization	O
saturation.	O

The	O
increased	O
levels	O
of	O
lipid	O
and	O
PUFA	O
and	O
the	O
decreased	O
level	O
of	O
glycerol	B
could	O
also	O
prove	O
that	O
the	O
glycerolipid	B
metabolism	O
was	O
abnormal	O
in	O
the	O
colorectal	O
polyp.	O

Based	O
on	O
our	O
earlier	O
findings	O
that	O
EZH2	O
over-expression	O
in	O
benign	O
cells	O
could	O
mediate	O
cell	O
invasion	O
and	O
neoplastic	O
progression_,	O
_,	O
,	O
sarcosine	B
levels	O
were	O
assessed	O
upon	O
modulation	O
of	O
EZH2	O
expression.	O

GlyOH3P	O
glycerol-3-phosphate,	B
all	O
other	O
abbreviations	O
and	O
numbering	O
were	O
the	O
same	O
as	O
in	O
The	O
HCCH-TOCSY	O
experiment	O
also	O
reduces	O
spectral	O
crowding	O
by	O
selecting	O
only	O
those	O
isotopomers	O
that	O
contains	O
at	O
least	O
two	O
contiguous	O
_13	O
C	O
in	O
the	O
same	O
molecule.	O

First,	O
a	O
targeted	O
metabolomics	O
approach	O
was	O
used,	O
which	O
focuses	O
on	O
water-soluble	O
small	O
molecules	O
such	O
as	O
amino	O
acid	O
metabolites,	O
acylcarnitines,	B
and	O
nucleotide	O
metabolites.	O

Stability	O
of	O
5,6-EET	B
and	O
deuterated	O
5,6-EET-d_11	B
decreased	O
to	O
61	O
and	O
57%,	O
respectively,	O
at	O
this	O
storage	O
condition	O
for	O
plasma	O
extract	O
at	O
24	O
h	O
relative	O
to	O
0	O
h.	O

[],	O
while	O
in	O
the	O
other	O
one	O
based	O
on	O
the	O
chromatography	O
data	O
system	O
and	O
generation	O
of	O
a	O
multivariate	O
index	O
using	O
the	O
‘‘AminoIndex™	B
technology’’	O
(MIAI)	O
a	O
very	O
good	O
separation	O
was	O
achieved	O
with	O
a	O
decrease	O
in	O
the	O
concentration	O
of	O
tryptophan	B
and	O
histidine	B
(only	O
serum	O
analysis)	O

Altered	O
levels	O
of	O
phenylacetylglutamine	B
might	O
indicate	O
a	O
deregulation	O
of	O
the	O
phenylalanine	B
or	O
glutamine	B
metabolism	O
as	O
well,	O
as	O
observed	O
in	O
a	O
previous	O
urinary	O
metabolomic	O
study	O
involving	O
BC	O
patients	O
and	O
healthy	O
controls	O
that	O
attributed	O
this	O
deregulation	O
to	O
the	O
increased	O
energy	O
demands	O
of	O
cancer	O
cells	O
for	O
growing	O
and	O
proliferation.	O

Attenuation	O
of	O
hypoxia-induced	O
loss	O
in	O
body	O
mass	O
has	O
been	O
reported	O
with	O
BCAA	O
supplementation,	O
whereas	O
supplementation	O
solely	O
with	O
leucine	B
was	O
not	O
effective.	O

The	O
mean	O
concentrations	O
of	O
the	O
α-TL	B
conjugates	O
are	O
all	O
highly	O
significantly	O
increased	O
in	O
the	O
patients	O
with	O
diabetes	O
(p	O
<0.001).	O

Elevated	O
glycine	B
levels	O
in	O
serum	O
were	O
confirmed	O
(along	O
with	O
alanine	B
and	O
serine,	B
however)	O
in	O
epileptic	O
patients	O
treated	O
with	O
VPA	O
alone	O
and	O
in	O
patients	O
receiving	O
VPA	O
in	O
combination	O
with	O
other	O
AEDs.	O

Tryptophan	B
metabolism	O
was	O
significantly	O
altered,	O
with	O
perturbed	O
levels	O
of	O
kynurenate,	B
5-hydroxytryptophan,	B
5-hydroxyindoleacetate,	B
and	O
N	B
-acetylserotonin	I
in	O
SPMS	O
patients	O
compared	O
with	O
RRMS	O
and	O
controls.	O

The	O
observed	O
increased	O
levels	O
of	O
taurine	B
and	O
hypotaurine	B
in	O
the	O
plasma	O
of	O
subjects	O
with	O
AMD	O
may	O
represent	O
a	O
compensatory	O
response	O
to	O
increased	O
levels	O
of	O
lipid	O
peroxidation	O
and	O
oxidative	O
stress.	O

Plasma	O
samples	O
(20	O
μL)	O
were	O
precipitated	O
by	O
adding	O
750	O
μL	O
of	O
acetonitrile	B
(ACN)	O
and	O
10	O
μL	O
internal	O
standards	O
(TMAO-d9,	O
choline-d9,	B
betaine-d9,	B
creatinine-d3,	B
and	O
L-carnitine-d3).	B

The	O
scaled	O
down	O
method	O
was	O
optimized	O
using	O
25-hydroxycholesterol	B
and	O
cholesterol,	B
and	O
25-hydroxycholesterol	B
was	O
found	O
to	O
elute	O
in	O
fraction	O
1	O
from	O
the	O
first	O
SPE	O
column	O
(SPE1-Fr-1)	O
and,	O
in	O
its	O
GP-tagged	O
form,	O
in	O
fractions	O
1	O
and	O
2	O
from	O
the	O
second	O
SPE	O
column	O
(SPE2-Fr-1	O
and	O
SPE2-Fr-2).	B

Hydroimizalones	B
were	O
determined	O
as	O
molar	O
amount	O
of	O
affected	O
amino	O
acid	O
[nmol/mol].	O

Collectively,	O
these	O
results	O
by	O
multiple	O
independent	O
approaches	O
validated	O
the	O
quantitative	O
analysis	O
of	O
FA	B
isomeric	O
mixtures	O
using	O
the	O
developed	O
strategy.	O

On	O
the	O
contrary,	O
after	O
the	O
tumor	O
was	O
removed,	O
significant	O
declines,	O
not	O
only	O
in	O
the	O
above	O
two	O
metabolites	O
but	O
also	O
in	O
ribonic	B
acid	I
and	O
xylonic	B
acid,	I
were	O
observed	O
in	O
R_AT	O
compared	O
to	O
NR_AT	O
.	O

CE,	O
cholesterol	B
esters;	I
SM,	O
sphingomyelin;	B
SqCC,	O
squamous	O
cell	O
lung	O
cancer.	O

However,	O
the	O
abundances	O
of	O
PC	B
(35:4)B,	I
PC	B
(36:5)B	I
and	O
PC	B
(36:6)	I
were	O
lower	O
in	O
the	O
meloxicam	O
group	O
than	O
those	O
in	O
the	O
control	O
group.	O

Significant	O
decreases	O
in	O
levels	O
of	O
HPHPA	O
(mean	O
value	O
from	O
302.78	O
to	O
37.06 mmol/mol	O
creatinine,	B
p	O
<	O
0.001)	O

GABR	O
may	O
serve	O
as	O
a	O
more	O
comprehensive	O
concept	O
of	O
reduced	O
NO	O
synthetic	O
capacity	O
compared	O
to	O
systemic	O
arginine	B
levels.	O

Endogenous	O
amino	O
acids	O
include	O
all	O
amino	O
acids	O
except	O
for	O
ornithine;	B
gluconeogenic	O
amino	O
acids	O
include	O
alanine,	B
valine,	B
isoleucine,	B
proline,	B
glycine,	B
serine,	B
threonine,	B
aspartate,	B
phenylalanine,	B
lysine	B
and	O
tyrosine;	B
branched-chain	O
amino	O
acids	O

The	O
ideal	O
assay	O
would	O
determine	O
all	O
relevant	O
high	O
and	O
low-abundant	O
vitamin	B
D	I
species	O
simultaneously.	O

Palmitic	B
acid	I
trended	O
upward	O
in	O
Q3-4,	O
whereas	O
linoleic	B
and	O
lignoceric	O
acids	O
trended	O
lower.	O

Our	O
technique	O
did	O
not	O
detect	O
methane.	B

Adenylate	B
and	O
guanylate	B
energy	O
charges	O
(([RTP] + 0.5 × [RDP])/([RTP] +	O

Previous	O
studies	O
have	O
indicated	O
that	O
the	O
levels	O
of	O
urinary	O
cotinine	B
in	O
non-smokers	O
were	O
usually	O
less	O
than	O
20	O
μg/L	O
and	O
the	O
discrimination	O
threshold	O
between	O
active	O
and	O
passive	O
smokers	O
was	O
from	O
50	O
to	O
100	O
μg/L.	O

Querying	O
the	O
identity	O
of	O
the	O
accurate	O
mass	O
signals	O
against	O
MZedDB	O
(Draper	O
et	O
al.	O
)	O
suggested	O
that	O
three	O
of	O
the	O
top	O
four	O
explanatory	O
signals	O
distinguishing	O
‘PRE’	O
urine	O
from	O
fasting	O
urine	O
were	O
ionization	O
products	O
of	O
the	O
dipeptide,	O
anserine,	B
a	O
metabolite	O
present	O
at	O
high	O
concentration	O
in	O
chicken	O
breast	O
meat	O
(Aristoy	O
and	O
Toldra	O
;	O
Yeum	O
et	O
al.	O
)	O
and	O
known	O
to	O
be	O
excreted,	O
largely	O
without	O
biotransformation,	O
in	O
humans	O
(Yeum	O
et	O
al.	O
).	O

About	O
10	O
amino	O
acids	O
detected	O
in	O
our	O
study	O
such	O
as	O
intermediates	O
in	O
urea	B
cycle	O
(aspartate	O
and	O
ornithine)	O
and	O
metabolites	O
related	O
to	O
glutamine	B
and	O
proline	B
metabolism	O
were	O
found	O
decreased	O
significantly	O
in	O
CRC	O
serum	O
compared	O
to	O
healthy	O
controls.	O

Due	O
to	O
a	O
high	O
background	O
response	O
resulting	O
from	O
the	O
ammonium	B
fluoride	I
buffer,	O
the	O
initial	O
transition	O
selected	O
for	O
CMPA	O
(177>79	O
m/z)	O
did	O
not	O
result	O
in	O
a	O
discernible	O
peak	O
within	O
the	O
reportable	O
range.	O

These	O
included	O
metabolites	O
such	O
as	O
hydroxylamine	B
(down-regulated),	O
glucopyranose,	B
tagatose,	B
glutamine,	B
tyramine,	B
and	O
proline	B
(up-regulated).	O

For	O
example,	O
salivary	O
metabolites	O
in	O
choline	B
and	O
polyamine	B
pathways	O
had	O
also	O
been	O
suggested	O
as	O
potential	O
biomarkers	O
for	O
oral	O
and	O
breast	O
cancers,	O
respectively_,	O
_,	O
.	O

Methionine	B
pathway,	O
One-carbon	O
metabolism,	O
LC–MS/MS,	O
High	O
throughput,	O
Plasma,	O
Cerebrospinal	O
fluid	O

Briefly,	O
100 µl	O
of	O
serum	O
was	O
mixed	O
with	O
fentanyl-d5	B
(Cerilliant,	O
Round	O
Rock,	O
Texas,	O
USA)	O
as	O
the	O
internal	O
standard,	O
and	O
1000 µl	O
cold	O
acetonitrile	B
was	O
added.	O

Nucleosides:	O
The	O
research	O
for	O
a	O
urinary	O
biomarker	O
of	O
HCC	O
dates	O
back	O
to	O
the	O
1970s	O
when	O
high	O
levels	O
of	O
methylated	B
purines	I
(7-methylguanine,	I
1-methylhypoxanthine,	I
N-dimethylguanine,	I
1-methylguanine	I
and	O
adenine)	B
were	O
detected	O
in	O
the	O
urine	O
of	O
patients	O
with	O
HCC	O
compared	O
to	O
both	O
cirrhotic	O
patients	O
and	O
healthy	O
controls[]	O
(Table	O
).	O

Since	O
24S-OH-Chol	B
and	O
TC	O
plasma	O
levels	O
are	O
known	O
to	O
be	O
correlated	O
(in	O
our	O
sample	O
r:	O
0.28,	O
p:	O
0.005)	O
as	O
they	O
are	O
both	O
transported	O
by	O
the	O
low-density	O
lipoproteins,	O
24S-OH-Chol	B
values	O
were	O
adjusted	O
for	O
TC	O
levels	O
by	O
calculating	O
the	O
24S-OH-Chol/TC	B
ratio	O
(ng/mg).	O

Each	O
cartridge	O
was	O
eluted	O
with	O
2	O
mL	O
ACN	O
containing	O
5%	O
pyrrolidine,	B
concentrated	O
to	O
dryness	O
under	O
N_2	O
at	O
45°	O
C,	O
reconstituted	O
in	O
500	O
μL	O
of	O
4:1	O
HPLC-grade	O
water:MeOH,	O
and	O
filtered	O
through	O
a	O
0.2	O
μm	O
nylon	O
membrane.	O

Given	O
that	O
taurine	B
may	O
prevent	O
the	O
neurotoxicity	O
of	O
β-amyloid	B
and	O
the	O
excitotoxicity	O
of	O
glutamate,	B
it	O
may	O
be	O
neuroprotective	O
for	O
some	O
neurodegenerative	O
diseases.	O

Our	O
goal	O
was	O
to	O
determine	O
the	O
concentrations	O
of	O
all	O
kynurenine	B
metabolites	O
after	O
bariatric	O
surgery	O
and	O
whether	O
they	O
were	O
correlated	O
with	O
glucose	B
control	O
improvement.	O

In	O
our	O
study,	O
butylamine	B
was	O
also	O
detected.	O

Similar	O
to	O
the	O
sphingolipids	B
described	O
above,	O
most	O
of	O
the	O
species	O
of	O
ceramide	B
had	O
levels	O
that	O
were	O
significantly	O
higher	O
in	O
cancer	O
than	O
in	O
the	O
normal	O
breast	O
tissue.	O

The	O
nine	O
metabolites	O
differentiating	O
BE	O
from	O
GERD	O
(P<0.05)	O
included	O
seven	O
amino	O
acids	O
or	O
amino	O
acid	O
derivatives	O
(creatine,	O
homocysteine,	B
3-nitrotyrosine,	B
hydroxyproline/aminolevulinate,	O
arginine,	B
tyrosine,	B
ornithine),	O
one	O
fatty	O
acid	O
(linoleic	O
acid),	O
and	O
one	O
sugar	O
alcohol	O
(sorbitol).	O

HPLC	O
grade	O
methanol,	B
acetonitrile,	B
and	O
formic	B
acid	I
were	O
purchased	O
from	O
Merck	O
Chemicals	O
(Darmstadt,	O
Germany).	O

Several	O
distinct	O
clusters	O
that	O
correspond	O
to	O
biochemical	O
pathways	O
were	O
observed,	O
including	O
phosphatidylcholine	B
(PC,	O
light	O
blue),	O
lyso-PC	B
(LPC,	O
black),	O
lysophosphatidylethanolamine	B
(LPE,	O
yellow),	O
acylcarnitine	B
(green),	O
bile	O
acid	O
(purple),	O
and	O
amino	O
acid	O
(orange)	O
clusters.	O

Nunc	O
International,	O
Naperville,	O
IL.)	O
fixed	O
with	O
4%	O
paraformaldehyde,	B
permeabilized	O
with	O
0.4%	O
Triton	O
X-100,	O
and	O
stained	O
with	O
primary	O
antibody	O
overnight	O
at	O
4°C.	O

Normal	O
glucose	B
tolerance	O
was	O
a	O
2-hour	O
glucose	B
OGTT	O
7.7	O
mmol/	O

2D	O
spectra	O
of	O
NIST	O
plasma	O
obtained	O
with	O
and	O
without	O
isotope	O
tagging:	O
(a)	O
_1	O
H-_15	O
N	O
HSQC	O
spectrum	O
obtained	O
after	O
_15	O
N	O
tagging	O
of	O
carboxylic	B
acids	I
(b)	O
_1	O
H-_13	O
C	O
HSQC	O
spectrum	O
obtained	O
after	O
_13	O
C	O
tagging	O
of	O
amines	O
and	O
amino	O
acids;	O
and	O
(c)	O
_1	O
H-_1	O
H	O
TOCSY	O
spectrum	O
of	O
the	O
neat	O
mixture.	O

Working	O
at	O
high	O
pH	O
values	O
would	O
also	O
have	O
the	O
advantage	O
that	O
the	O
signal	O
from	O
the	O
urea	B
peak	O
would	O
be	O
removed	O
or	O
have	O
reduced	O
intensity.	O

(b)	O
Three	O
distinct	O
peaks	O
identified	O
by	O
ChromaTOF	O
software	O
as	O
L-Methionine	B
(two	O
of	O
these	O
are	O
false	O
positives).	O

Upon	O
elucidation	O
of	O
weight	O
gain-associated	O
biomarkers,	O
it	O
was	O
possible	O
to	O
demonstrate	O
the	O
presence	O
of	O
Argininosuccinate	B
[m/z	O
308.1565],	O
a	O
basic	O
amino	O
acid	O
and	O
immediate	O
precursor	O
of	O
arginine	B
in	O
the	O
urea	B
cycle.	O

Lipids	O
and	O
apolipoproteins	O
associated	O
with	O
HDL	O
subfractions	O
were	O
decreased,	O
with	O
the	O
exception	O
of	O
triglycerides,	B
which	O
were	O
increased.	O

The	O
association	O
between	O
urinary	O
concentrations	O
of	O
phthalates	O
metabolites	O
(continuous)	O
and	O
diabetes	O
was	O
assessed	O
by	O
multivariate	O
logistic	O
regression	O
models	O
that	O
were	O
adjusted	O
by	O
creatinine,	B
as	O
recommended	O
by	O
,	O
as	O
well	O
as	O
the	O
variables	O
that	O
were	O
significantly	O
correlated	O
to	O
the	O
specific	O
phthalate	B
metabolite	O
among	O
healthy	O
women.	O

The	O
inset	O
is	O
its	O
data-dependent	O
MS/MS	O
scan	O
giving	O
fragments	O
of	O
135,	O
119,	O
and	O
59	O
m	O
/z	O
indicating	O
fragments	O
of	O
the	O
proposed	O
hydroxyphenylbutyric	B
acid	I
metabolite	O
shown.	O

The	O
homogenates	O
were	O
mixed	O
with	O
0.5 ml	O
chloroform	B
and	O
0.2 ml	O
ice-cold	O
Milli-Q	O
water.	O

Postmenopausal	O
status	O
was	O
defined	O
as	O
FSH	O
levels	O
>20 IU/L	O
and	O
estradiol	B
(E2)	O
levels	O
<70 pmol/L,	O
using	O
the	O
automated	O
analyzer	O
Immulite	O
2000	O
(Diagnostic	O
Products	O
Corporation,	O
Los	O
Angeles,	O
CA).	O

Although	O
metabolites	O
such	O
as	O
lysophosphatidic	B
acid	I
and	O
lipid	O
associated	O
sialic	B
acid,	I
that	O
have	O
been	O
investigated	O
as	O
metabolic	O
biomarkers	O
for	O
ovarian	O
cancer	O
in	O
literature	O
[-],	O
were	O
not	O
pinpointed	O
in	O
the	O
study,	O
the	O
presence	O
of	O
several	O
endogenous	O
lipids	O
as	O
well	O
as	O
other	O
endogenous	O
metabolites	O
in	O
the	O
set	O
of	O
selected	O
features	O
suggests	O
that	O
this	O
approach	O
has	O
merit	O
and	O
should	O
be	O
further	O
explored.	O

As	O
with	O
most	O
other	O
studies	O
on	O
tryptophan	B
metabolism,	O
this	O
is	O
an	O
association	O
study,	O
which	O
does	O
not	O
provide	O
causal	O
evidence.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
three	O
of	O
the	O
top	O
biochemicals	O
(azelate,	O
3-hydroxysebacate	B
and	O
sebacate)	O
that	O
contributed	O
to	O
the	O
discrimination	O
of	O
depressed	O
from	O
non-depressed	O
subjects,	O
are	O
DCAs	O
associated	O
with	O
ω-oxidation	O
of	O
fatty	O
acids.	O

Of	O
these,	O
the	O
following	O
four	O
metabolites	O
were	O
finally	O
selected	O
as	O
biomarker	O
candidates	O
by	O
cross-validation:	O
nonanoic	B
acid,	I
glucose,	B
galactose,	B
and	O
cysteine	B
+	O
cystine.	B

(A)	O
Water	O
with	O
0.1%	O
formic	B
acid	I
and	O
(B)	O
acetonitrile	B
with	O
0.1%	O
formic	B
acid	I
were	O
used	O
for	O
positive	O
ion	O
mode	O
(ESI+),	O
while	O
(A)	O
water	O
and	O
(B)	O
acetonitrile	B
for	O
negative	O
ion	O
mode	O
(ESI−).	O

(b)	O
Negative	O
correlation	O
of	O
serum	O
sphingosine	B
level	O
at	O
the	O
basal	O
status	O
with	O
(b1)	O
serum	O
SM	B
(d18:0/16:0),	I
(b2)	O
with	O
serum	O
SM	B
(d18:0/18),	I
(b3)	O
with	O
serum	O
SM	B
(d18:0/18:1),	I
(b4)	O
with	O
serum	O
LysoSM	O
before	O
the	O
ASA-BPT.	O

The	O
euglycemic-hyperinsulinemic	B
clamp	O
method	O
is	O
based	O
on	O
the	O
glucose	B
infusion	O
rate,	O
where	O
glucose	B
is	O
kept	O
steady	O
at	O
5	O
mmol/L	O
and	O
insulin	O
is	O
infused	O
at	O
a	O
constant	O
rate,	O
most	O
commonly	O
40	O
mU/m_2	O
body	O
surface	O
area/minute.	O

These	O
presumably	O
dietary	O
related	O
changes	O
did	O
not,	O
however,	O
result	O
in	O
the	O
corresponding	O
increases	O
in	O
TMAO	B
levels	O
that	O
have	O
been	O
shown	O
in	O
previous	O
studies	O
[,	O
].	O

In	O
addition,	O
when	O
looking	O
at	O
the	O
follow-up	O
blood	O
pressures,	O
active	O
acupoints	O
treatment	O
can	O
be	O
seen	O
to	O
significantly	O
lower	O
systolic	O
blood	O
pressure	O
and	O
DBP	B
variation,	O
but	O
not	O
diastolic	O
blood	O
pressure,	O
as	O
compared	O
with	O
inactive	O
acupoint	O
acupuncture	O
(P	O
 < 0.05).	O

Abbreviations:	O
LDL=low-density	O
lipoprotein;	O
NAC=N	B
-acetylglycoprotein;	I
PGLYs=Phosphoglycerides;	B
TAGs=Triacylglycerides;	B
VLDL=very	O
low-density	O
lipoprotein.	O
Variation:+corresponds	O
to	O
higher	O
concentration	O
in	O
W5–6	O
serum	O
metabolic	O
profiles	O
than	O
at	O
baseline;–to	O
lower	O
concentration	O
in	O
W5–6	O
serum	O
metabolic	O
profiles	O
than	O
at	O
baseline.	O

The	O
changed	O
metabolites	O
identified	O
in	O
the	O
present	O
study,	O
such	O
as	O
glycine,	B
may	O
be	O
used	O
as	O
potential	O
biomarkers	O
for	O
BCa.	O

Many	O
of	O
these	O
were	O
easily	O
identified	O
as	O
caffeine	B
metabolites,	O
based	O
on	O
the	O
comparison	O
of	O
accurate	O
mass,	O
RT	O
and	O
fragmentation	O
spectra	O
of	O
unknown	O
features	O
and	O
commercial	O
standards.	O

A	O
decreased	O
level	O
of	O
methionine	B
with	O
a	O
corresponding	O
increase	O
in	O
homocysteine	B
levels	O
in	O
EH	O
patients	O
as	O
compared	O
to	O
HC	O
may	O
reflect	O
a	O
trend	O
towards	O
increased	O
conversion	O
of	O
methionine	B
to	O
homocysteine	B
which	O
agrees	O
with	O
earlier	O
findings	O
establishing	O
the	O
role	O
of	O
homocysteine	B
in	O
aggravating	O
hypertension	O
mediated	O
by	O
diminished	O
NO	O
bioavailability.	O

The	O
column	O
was	O
eluted	O
at	O
a	O
flow	O
rate	O
of	O
400	O
μL/min	O
with	O
initial	O
conditions	O
of	O
10%	O
mobile	O
phase	O
A	O
(20	O
mM	O
ammonium	B
acetate	I
and	O
20	O
mM	O
ammonium	B
hydroxide	I
in	O
water)	O
and	O
90%	O
mobile	O
phase	O
B	O
(10	O
mM	O
ammonium	B
hydroxide	I
in	O
75:25	O
v/v	O
acetonitrile/methanol)	O
followed	O
by	O
a	O
10	O
min	O
linear	O
gradient	O
to	O
100%	O
mobile	O
phase	O
A.	O
MS	O
analyses	O
were	O
carried	O
out	O
using	O
electrospray	O
ionization	O
in	O
the	O
negative	O
ion	O
mode	O
using	O
full	O
scan	O
analysis	O
over	O
m/z	O
60­750	O
at	O
70,000	O
resolution	O
and	O
3	O
Hz	O
data	O
acquisition	O
rate.	O

Additionally,	O
seven	O
lysophosphocholines,	B
LPC(14:0),	B
LPC(16:0),	B
LPC(18:1),	B
LPC(20:2),	B
LPC(20:3),	B
LPC(20:4)	B
and	O
LPC(20:5),	B
were	O
downregulated	O
in	O
HCC	O
plasma	O
relative	O
to	O
HV	B
plasma.	O

These	O
include	O
amino	O
acids,	O
nucleotides,	O
fatty	O
acids,	O
amino	B
sugar	O
derivatives,	O
organic	O
acids	O
etc.	O

P5C	O
can	O
be	O
produced	O
by	O
the	O
stress-induced	O
oxidation	O
of	O
proline	B
and	O
hydroxyproline	B
from	O
collagen	O
turnover	O
via	O
the	O
enzyme	O
proline	B
oxidase	O
or	O
from	O
glutamate	B
oxidation	O
via	O
P5C	O
synthase	O
(P5CS).	O

Costello	O
and	O
Franklin	O
(–)	O
and	O
Costello	O
et	O
al.	O
proposed	O
that	O
high	O
uptake	O
of	O
zinc	O
by	O
normal	O
prostate	O
mitochondria	O
inhibits	O
the	O
activity	O
of	O
m-aconitase,	O
thereby	O
slowing	O
the	O
citrate	B
oxidation	O
in	O
the	O
Krebs	O
cycle	O
that	O
results	O
in	O
a	O
high	O
level	O
of	O
citrate	B
in	O
normal	O
prostate	O
tissue	O
(	O
and	O
).	O

As	O
such,	O
the	O
increased	O
levels	O
of	O
4-hydroxyproline	B
seen	O
in	O
patient	O
samples	O
is	O
consistent	O
with	O
the	O
nature	O
of	O
inflammatory	O
events	O
occurring	O
in	O
this	O
type	O
of	O
major	O
surgery,	O
whilst	O
cystathionine	B
is	O
a	O
substrate	O
for	O
the	O
gaseous	O
mediator	O
hydrogen	B
sulphide	I
and	O
also	O
a	O
precursor	O
for	O
glutathione	B
production.	O

pathway	O
and	O
tyrosine	B
metabolism.	O

In	O
the	O
urine	O
sample	O
obtained	O
immediately	O
postpartum,	O
hippurate,	B
4-cresylsulfate,	B
and	O
PAG	B
are	O
found	O
in	O
the	O
infant	O
urine	O
in	O
approximately	O
equivalent	O
concentrations	O
to	O
the	O
maternal	O
urine.	O

The	O
size	O
of	O
the	O
LA	O
measured	O
by	O
echocardiography	O
was	O
significantly	O
larger	O
in	O
the	O
AF	B
group	O
(AF	O
vs.	O
control:	O
47.6	O
±	O
7.0	O
vs.	O
36.7	O
±	O
5.9,	O
p	O
<	O
0.001).	O

For	O
example,	O
it	O
has	O
been	O
shown	O
that	O
the	O
relative	O
solubility	O
of	O
amino	O
acids	O
such	O
as	O
glycine,	B
alanine,	B
isoleucine,	B
phenylalanine	B
and	O
asparagine	B
decreases	O
as	O
much	O
as	O
3	O
orders	O
of	O
magnitude	O
from	O
water	O
to	O
pure	O
methanol.	B

Synthetic	O
phospholipids	B
including	O
1,2-dimyristoleoyl-sn	B
-glycero-3-phosphocholine	I
(14:1-14:1	I
PC),	I
1,2-dipalmitoleoyl-sn	B
-glycero-3-phosphoethanolamine	I
(16:1-16:1	I
PE),	I
1,2-dipentadecanoyl-sn	B
-glycero-3-phosphoglycerol	I
(15:0-15:0	I
PG),	I
1-myristoyl-2-hydroxyl-sn	B
-glycero-3-phosphocholine	I
(14:0	I
LPC),	I
N-lauroyl	B
sphingomyelin	I
(N12:0	I
SM),	I
and	O
N-heptadecanoyl	B
ceramide	I
(N17:0	I
ceramide)	I
were	O
purchased	O
from	O
Avanti	O
Polar	O
Lipids,	O
Inc.	O
(Alabaster,	O
AL,	O
USA).	O

There	O
were	O
nine	O
specimens	O
in	O
the	O
training	O
set,	O
and	O
two	O
specimens	O
in	O
the	O
validation	O
set	O
with	O
a	O
ratio	O
between	O
0.5	O
and	O
1;	O
the	O
significance	O
of	O
this	O
ratio	O
is	O
unknown,	O
although	O
some	O
of	O
those	O
were	O
classified	O
as	O
normal	O
and	O
some	O
as	O
cancer	O
by	O
H&E.	O
Negative	O
ion	O
mode	O
DESI-MS	O
ion	O
signal	O
intensity	O
ratios	O
for	O
glucose/citrate	B
are	O
plotted	O
for	O
(A	O
)	O
the	O
training	O
set	O
(18	O
benign	O
and	O
18	O
cancer	O
specimens),	O
and	O
(B	O
)	O
the	O
validation	O
set	O
(10	O
benign	O
and	O
8	O
cancer	O
specimens)	O
by	O
averaging	O
the	O
ion	O
signals	O
of	O
glucose	B
and	O
citrate	B
from	O
all	O
pixels	O
acquired	O
from	O
the	O
individual	O
tissue	O
sample.	O

In	O
addition	O
several	O
intermediates	O
in	O
TCA	O
cycle	O
such	O
as	O
fumarate	B
and	O
cis	O
-aconitate	O
were	O
found	O
depleted	O
in	O
CRC	O
subjects.	O

In	O
this	O
study,	O
the	O
level	O
of	O
PC	B
(15:0/16:0)	I
was	O
highest	O
in	O
the	O
GP	B
group,	O
followed	O
by	O
BT	O
and	O
PP.	O

We	O
found	O
that	O
breast	O
milk	O
from	O
IBD	O
mothers	O
showed	O
significantly	O
lower	O
levels	O
of	O
IgA,	O
sugar	O
metabolite	O
[lactose],	O
and	O
2-aminobutyrate.	B

Chromosomal	O
nadD	O
was	O
replaced	O
by	O
a	O
kanamycin	B
resistance	O
cassette	O
amplified	O
using	O
the	O
primers	O
CamKanNadD	O
F	O
and	O
R	O
primers	O
(Table	O
S1	O
in	O
)	O
in	O
the	O
E.	O
coli	O
strain	O
DY378	O
(Yu	O
et	O
al.,	O
2000)	O
containing	O
pNadD	O
by	O
lambda	O
Red	O
recombineering	O
.	O

As	O
it	O
was	O
expected,	O
Spearman	O
correlation	O
coefficients	O
indicated	O
moderate	O
to	O
strong	O
associations	O
between	O
the	O
urinary	O
concentrations	O
of	O
the	O
DEHP	O
metabolites	O
(0.66–0.97),	O
and	O
between	O
the	O
major	O
(MBP)	O
and	O
minor	O
(MCPP)	O
metabolites	O
of	O
di-n	B
-butyl	I
phthalate	I
(ρ:	O
0.62)	O
(data	O
not	O
shown).	O

We	O
found	O
the	O
lower	O
levels	O
of	O
citric	B
acid,	I
malic	B
acid,	I
and	O
succinate	B
in	O
the	O
CRC	O
urine	O
specimens,	O
which	O
are	O
most	O
likely	O
related	O
to	O
the	O
deregulation	O
of	O
the	O
tricarboxylic	B
acid	I
cycle	O
and	O
the	O
increased	O
demand	O
for	O
energy	O
in	O
tumors	O
[,	O
].	O

Our	O
studies	O
showed	O
that	O
sera	O
of	O
subjects	O
after	O
12	O
weeks	O
of	O
diet	O
intervention	O
exhibited	O
slight	O
reductions	O
in	O
the	O
levels	O
of	O
both	O
total	O
triglycerides	B
and	O
percent	O
body	O
fat	O
though	O
those	O
of	O
lysoPCs	O
did	O
not	O
show	O
a	O
definite	O
trend	O
and	O
were	O
shown	O
to	O
be	O
dependent	O
on	O
the	O
types	O
of	O
fatty	O
acid	O
chains	O
esterified	O
to	O
the	O
glycerol	B
moiety.	O

However,	O
what	O
we	O
should	O
point	O
out	O
is	O
that	O
non-identical	O
analogs	O
(levofloxacin,	O
hesperidin	B
and	O
rhein),	O
instead	O
of	O
heavy	O
isotope	O
labeled	O
internal	O
standards,	O
were	O
used	O
in	O
our	O
targeted	O
approach	O
to	O
monitor	O
the	O
stability	O
of	O
analysis,	O
which	O
might	O
lead	O
to	O
some	O
deviation	O
of	O
the	O
results.	O

As	O
shown	O
in	O
this	O
study,	O
the	O
serum	O
levels	O
of	O
serine,	B
and	O
phenylalanine	B
were	O
significantly	O
higher	O
whereas	O
the	O
pyroglutamic	B
acid	I
level	O
was	O
significantly	O
lower	O
in	O
TBI	O
patients	O
with	O
cognitive	O
impairment	O
than	O
in	O
those	O
without	O
cognitive	O
impairment.	O

We	O
found	O
that	O
Bacteroidaceae	O
changed	O
their	O
linkages	O
from	O
being	O
positively	O
correlated	O
with	O
NCT-B	O
(indicates	O
poor	O
cognition)	O
and	O
glycocholic	B
acid	I
before	O
to	O
a	O
negative	O
correlation	O
after;	O
also	O
there	O
was	O
a	O
reduction	O
in	O
intensity	O
of	O
the	O
positive	O
correlation	O
with	O
glutamic	B
acid	I
and	O
asparagine,	B
both	O
ammonia	O
sources	O
after	O
rifaximin.	O

Cystathionine	B
dominated,	O
although	O
methionine	B
was	O
also	O
detected.	O

In	O
addition,	O
decreases	O
in	O
the	O
amounts	O
of	O
the	O
amino	O
acids	O
choline,	O
phenylalanine,	B
tyrosine	B
and	O
valine	B
were	O
observed	O
for	O
the	O
vasodilated	O
late-onset	O
IUGR	O
cases	O
relative	O
to	O
the	O
control	O
samples	O
(	O
and	O
).	O

The	O
injected	O
samples	O
were	O
equilibrated	O
with	O
water	O
containing	O
0.1%	O
formic	B
acid.	I

Hypertension	O
was	O
defined	O
as	O
systolic	O
blood	O
pressure	O
≥	O
140	O
mmHg	O
and/or	O
diastolic	O
blood	O
pressure	O
≥	O
90	O
mmHg	O
and/or	O
currently	O
on	O
antihypertensive	O
therapy;	O
impaired	O
glucose	B
tolerance	O
as	O
fasting	O
plasma	O
glucose	B
≥	O
110mg	O
mg/dL	O
and/or	O
hemoglobin	O
A1c	O
(NGSP)	O
≥	O
6.5%	O
and/or	O
current	O
use	O
of	O
antidiabetic	O
medication;	O
and	O
dyslipidemia	O
as	O
serum	O
triglyceride	B
≥	O
150	O
mg/dL	O
and/or	O
low-density	O
lipoprotein	O
cholesterol	B
≥	O
140	O
mg/dL	O
and/or	O
high-density	O
lipoprotein	O
cholesterol	B
≤	O
40	O
mg/dL	O
and/or	O
current	O
use	O
of	O
antidyslipidemic	O
medication.	O

Accumulating	O
evidences	O
suggest	O
that	O
intestinal	O
microbiota	O
composition	O
and	O
perturbation	O
represent	O
a	O
very	O
important	O
environmental	O
factor	O
to	O
the	O
development	O
and	O
treatment	O
of	O
type	O
2	O
diabetes,	O
by	O
influencing	O
bile	O
acid	O
metabolism,	O
glucose	B
and	O
lipid	O
metabolism,	O
proinflammatory	O
activity,	O
and	O
insulin	O
resistance[,	O
].	O

Third,	O
unlike	O
the	O
studies	O
of	O
Campbell	O
et	O
al.	O
and	O
Robles-Gil	O
et	O
al.,	O
in	O
which	O
first	O
morning	O
urine	O
samples	O
were	O
used,	O
WISER	O
participants	O
collected	O
three	O
24-hour	O
urine	O
collections	O
allowing	O
for	O
a	O
more	O
robust	O
and	O
representative	O
analysis	O
of	O
the	O
chronic	O
effect	O
of	O
aerobic	O
exercise	O
on	O
estrogen	B
metabolism.	O

Atmospheric	O
pressure	O
chemical	O
ionization	O
(APCI)	O
was	O
employed	O
in	O
the	O
positive	O
ion	O
mode	O
using	O
a	O
published	O
method	O
with	O
minor	O
modifications	O
to	O
accommodate	O
a	O
more	O
specific	O
internal	O
standard,	O
namely,	O
3-epi-25(OH)D_3	B
-d	I
_3.	O

Acetyl	B
chloride	I
and	O
1‐butanol	B
were	O
purchased	O
from	O
Sigma‐Aldrich	O
(St.	O
Louis,	O
MO).	O

Glucogenic	O
amino	O
acids	O
can	O
be	O
broken	O
down	O
into	O
one	O
of	O
the	O
following	O
metabolites:	O
pyruvate	B
(Ala,	O
Ser,	O
Thr,	O
Try,	O
Gly,	O
Cys),	O
α-ketoglutarate	B
(KGA)	O
(Pro,	O
Arg,	O
His,	O
Glu,	O
Orn,	O
Cit),	O
succinyl	O
CoA	O

Multiple	O
linear	O
regression	O
analysis	O
was	O
performed	O
to	O
determine	O
the	O
associations	O
between	O
HbA1c	O
and	O
HOMA-IR	O
with	O
clinical	O
variables	O
and	O
serum	O
polyamines.	B

Therefore,	O
the	O
best	O
results	O
were	O
achieved	O
with	O
ammonium	B
acetate	I
at	O
pH = 8.5–9.5.	O

We	O
prepared	O
working	O
solutions	O
for	O
calibrators	O
and	O
QCs	O
from	O
serial	O
dilutions	O
of	O
primary	O
stock	O
solutions	O
with	O
methanol	B
and	O
water	O
(v/v	O
60:40)	O
and	O
stored	O
them	O
in	O
Teflon-capped	O
amber	O
glass	O
vials	O
at	O
−24	O
°C.	O

Cells	O
were	O
fixed	O
with	O
1%	O
gluteraldehyde	B
(Sigma-Aldrich)	O
for	O
20 min	O
at	O
room	O
temperature.	O

Briefly,	O
fresh	O
human	O
whole	O
blood	O
samples	O
were	O
diluted	O
(1:100)	O
with	O
Triton	O
X-100	O
(0.03%	O
in	O
phosphate	B
buffer	O
0.1 M,	O
pH	O
7.4).	O

Dividing	O
subjects	O
into	O
obese	O
(n = 9)	O
and	O
obese/diabetic	O
(n = 5)	O
groups	O
identified	O
8	O
metabolites	O
that	O
differed	O
consistently	O
at	O
all	O
time	O
points	O
and	O
whose	O
serum	O
levels	O
changed	O
following	O
RYGB:	O
asparagine,	B
lysophosphatidylcholine	B
(C18:2),	I
nervonic	B
(C24:1)	I
acid,	I
p-Cresol	B
sulfate,	I
lactate,	B
lycopene,	B
glucose,	B
and	O
mannose.	B

From	O
the	O
100	O
selected	O
samples,	O
eight	O
samples	O
from	O
five	O
subjects	O
were	O
not	O
considered	O
in	O
the	O
data	O
analysis,	O
as	O
from	O
the	O
high	O
cotinine	B
values	O
(>50	O
ng/mL),	O
it	O
is	O
highly	O
likely	O
that	O
these	O
subjects	O
smoked	O
at	O
some	O
point	O
prior	O
to	O
the	O
urine	O
collection	O
as	O
confirmed	O
later.	O

Following	O
RYGB,	O
the	O
levels	O
of	O
1,5-anhydrosorbitol	B
increased	O
from	O
T0→T3→T6,	O
while	O
glucose	B
levels	O
decreased.	O

Of	O
the	O
lipids	O
that	O
underwent	O
the	O
greatest	O
change	O
[>4.5	O
log2	O
fold	O
change	O
(FC);	O
typically	O
P	O
<	O
0.01]	O
from	O
s1	O
to	O
s3	O
in	O
survivors	O
vs.	O
fatalities	O
or	O
healthy	O
controls,	O
all	O
ceramides	B
(Cer)	O
containing	O
16:0	O
or	O
18:0	O
fatty	O
acids	O
decreased	O
in	O
survivors,	O
whereas	O
all	O
but	O
one	O
diacylglycerophosphoinositol	B
(PI)	O
containing	O
18:3	O
or	O
20:3	O
fatty	O
acids	O
increased	O
(	O
and	O
SI	O
Appendix	O
,	O
Table	O
S3).	O

Serum	O
samples	O
(25	O
μL)	O
were	O
mixed	O
with	O
100	O
μL	O
of	O
methanol	B
and	O
chloroform	B
(2:1,	O
v/v),	O
mixed	O
by	O
vortexing,	O
and	O
then	O
incubated	O
for	O
10	O
minutes	O
at	O
room	O
temperature.	O

Group	O
1	O
showed	O
a	O
distinctive	O
urine	O
profile,	O
marked	O
by	O
a	O
higher	O
urine	O
concentration	O
of	O
acylcarnitine	B
compared	O
to	O
other	O
IBD	O
groups	O
and	O
healthy	O
subjects.	O

Conditions:	O
118	O
cm	O
long	O
(375	O
μm	O
O.D.,	O
50	O
μm	O
I.D.)	O
fused	O
silica	B
capillary.	O

It	O
goes	O
without	O
saying	O
that	O
the	O
role	O
of	O
glutamate	B
as	O
a	O
potential	O
marker	O
of	O
lung	O
inflammation	O
needs	O
further	O
evaluation	O
in	O
a	O
prospective	O
study	O
with	O
external	O
validation	O
and	O
attention	O
for	O
possible	O
confounders.	O

Mass	O
spectra	O
were	O
recorded	O
in	O
a	O
range	O
of	O
35–650 m/z	O
in	O
EI	B
+	O
mode	O
under	O
standard	O
70 eV	O
ionization	O
conditions.	O

Lactosylceramide,	B
one	O
of	O
the	O
ubiquitous	O
glycosphingolipids,	B
is	O
generated	O
in	O
endothelial	O
cells	O
after	O
treatment	O
with	O
vascular	O
endothelial	O
growth	O
factor,	O
which	O
has	O
been	O
implicated	O
in	O
vascular	O
pathologies.	O

In	O
plasma	O
samples	O
from	O
patients	O
with	O
septic	O
shock	O
[n	O
=	O
18,	O
APACHE	O
II	O
score	O
41.5	O
(22–52)],	O
severe	O
clinical	O
and	O
humoral	O
signs	O
of	O
inflammation	O
[CRP	O
236	O
mg/L	O
(68–422	O
mg/L)]	O
and	O
multi-organ	O
failure,	O
SPMs	O
and	O
other	O
oxylipins	B
were	O
quantified	O
and	O
compared	O
to	O
plasma	O
samples	O
of	O
healthy	O
individuals	O
serving	O
as	O
control	O
(n	O
=	O
10).	O

5-Oxoprolinate	B
(the	O
conjugate	O
base	O
of	O
5-Oxoproline)	B
is	O
an	O
intermediate	O
in	O
the	O
isomerization	O
of	O
glutathione	B
to	O
5-Oxoproline	B
via	O
the	O
action	O
of	O
γ-glutamyl	O
cyclotransferase	O
in	O
the	O
γ-glutamyl	O
cycle.	O

The	O
acceleration	O
voltage	O
was	O
turned	O
on	O
after	O
a	O
solvent	O
delay	O
of	O
290	O
s	O
and	O
the	O
detector	O
voltage	O
was	O
1520	O
V.	O
Samples	O
with	O
methyl	B
stearate	I
in	O
heptane	B
(5ng/ml)	O
were	O
analyzed	O
in	O
addition	O
to	O
the	O
study	O
samples	O
allowing	O
continuous	O
check	O
of	O
instrumental	O
sensitivity.	O

Chromatograms	O
recorded	O
on	O
the	O
MRM	O
transitions	O
of	O
3-O	O
-Gluc	O
and	O
3,7-O	B
-Digluc	I
after	O
the	O
injection	O
of	O
blank	O
(A,	O
E),	O
calibrators	O
1	O
(B,	O
F)	O
and	O
8	O
(C,	O
G)	O
in	O
urine,	O
together	O
with	O
a	O
sample	O
from	O
a	O
treated	O
volunteer	O
(D,	O
H).	O

The	O
solution	O
was	O
decanted	O
into	O
the	O
preconditioned	O
cartridge	O
with	O
6	O
mL	O
of	O
methanol	B
and	O
6	O
mL	O
of	O
water.	O

Distributions	O
of	O
plasma	O
concentrations	O
of	O
DHEA	O
(A,	O
B),	O
DHEA-SO_4	O
(C,	O
D),	O
androstenedione	B
(E,	O
F),	O
and	O
pregnenolone	B
(G,	O
H)	O
according	O
to	O
age	O
for	O
males	O
(•	O
A,	O
C,	O
E	O
&	O
G)	O
and	O
females	O
(▴	O
B,	O
D,	O
F	O
&	O
H).	O

Based	O
on	O
the	O
chemical	O
logic,	O
studies	O
were	O
undertaken	O
to	O
investigate	O
if	O
estrogens	O
could	O
generate	O
quinone	B
methides	O
in	O
an	O
oxidative	O
environment	O
which	O
then	O
could	O
cause	O
DNA	O
damage	O
in	O
humans.	O

In	O
addition,	O
COH	O
was	O
positively	O
correlated	O
with	O
total	O
and	O
LDL-cholesterols	B
in	O
overweight	O
and	O
obese	O
children.	O

The	O
action	O
of	O
lyso-PC	B
on	O
immunoregulatory	O
cells	O
is	O
very	O
diverse	O
and	O
they	O
participate	O
in	O
many	O
induced	O
inflammation	O
signaling	O
pathway.	O

PLTP	O
and	O
LCAT	O
activity	O
were	O
correlated	O
positively	O
with	O
BMI,	O
glycemia,	O
total	O
cholesterol	B
and	O
non-HDL	O
cholesterol,	B
triglycerides	B
and	O
apoB,	O
and	O
inversely	O
with	O
HDL	B
cholesterol.	I

As	O
described	O
earlier,	O
activation	O
of	O
the	O
NOS	O
family	O
following	O
SCI	O
would	O
promote	O
generation	O
of	O
NO	O
as	O
well	O
as	O
the	O
by-product	O
citrulline.	B

A	O
mixed	O
stock	O
solution	O
of	O
six	O
estrogens	O
or	O
the	O
corresponding	O
internal	O
standards	O
at	O
1	O
µg/mL	O
was	O
prepared	O
by	O
adding	O
10	O
µL	O
of	O
each	O
estrogen	B
standard	O
stock	O
solution	O
to	O
a	O
10	O
mL	O
volumetric	O
flask	O
with	O
methanol	B
containing	O
0.1%	O
L-ascorbic	B
acid.	I

This	O
provided	O
a	O
distinct	O
pool	O
of	O
acetyl-CoA	B
for	O
histone	O
acetylation	O
that	O
preserved	O
exogenous	O
acetate	B
for	O
mitochondrial	O
oxidation	O
or	O
cytosolic	O
fatty	O
acid	O
biosynthesis	O
during	O
nutrient	O
limitation.	O

Concomitant	O
statin	B
use	O
is	O
common	O
in	O
the	O
elderly	O
and	O
may	O
confound	O
the	O
identification	O
of	O
the	O
altered	O
plasma	O
SM	O
and	O
ceramide	B
profiles	O
in	O
AD.	O

Others	O
have	O
reported	O
reduced	O
concentrations	O
of	O
antioxidants	O
including	O
vitamin	B
E	I
in	O
diabetes	O
(see	O
),	O
and	O
the	O
role	O
of	O
vitamin	B
E	I
and	O
oxidative	O
stress	O
in	O
diabetes	O
has	O
recently	O
been	O
reviewed	O
.	O

Specifically	O
12.5 μl	O
of	O
2×	O
KAPA	B
HiFi	O
HotStart	O
ReadyMix,	O
5 μl	O
forward	O
primer,	O
5 μl	O
reverse	O
primer	O
were	O
used	O
in	O
combination	O
with	O
2.5 μl	O
of	O
template	O
DNA	O
(5 ng/μl).	O

In	O
investigating	O
the	O
association	O
between	O
ceramide	B
levels	O
and	O
Ki-67	O
index	O
within	O
each	O
individual	O
patient,	O
ceramide	B
in	O
cancer	O
tissue	O
showed	O
a	O
trend	O
toward	O
a	O
negative	O
association	O
(R_2	O
=0.05)	O
with	O
levels	O
of	O
Ki-67	O
index	O
(p	O
=0.09)	O

Perturbations	O
in	O
CSF	O
acetate	B
concentrations	O
have	O
also	O
been	O
observed	O
in	O
patients	O
with	O
Creutzfeldt-Jakob	O
disease,	O
although	O
in	O
contrast	O
to	O
the	O
current	O
study,	O
Creutzfeldt-Jakob	O
disease	O
was	O
associated	O
with	O
an	O
increase	O
in	O
acetate	B
concentrations.	O

In	O
addition	O
to	O
NMR	O
analysis,	O
a	O
targeted	O
ultra-performance	O
liquid	O
chromatography-tandem	O
mass	O
spectrometry	O
(UPLC-MS/MS)	O
analysis	O
of	O
methylated	B
amino	I
compounds	O
was	O
conducted	O
using	O
an	O
Acquity	O
H-Class	O
UPLC	O
coupled	O
to	O
a	O
Xevo	O
TQD	O
triple	O
quadrupole	O
MS	O
(both	O
from	O
Waters,	O
Eschborn,	O
Germany).	O

In	O
contrast,	O
some	O
studies	O
have	O
found	O
that	O
elevated	O
levels	O
of	O
glutathione	B
in	O
tumors	O
may	O
increase	O
resistance	O
to	O
chemotherapy	O
and	O
radiotherapy	O
(,	O
).	O

However,	O
SM(36:3)	B
was	O
not	O
detected	O
in	O
the	O
negative	O
mode	O
which	O
could	O
be	O
a	O
potential	O
reason	O
for	O
the	O
lower	O
classification	O
performance.	O

Briefly,	O
the	O
sample	O
preparation	O
procedure	O
consisted	O
of	O
four	O
simple	O
steps	O
(i)	O
urine	O
samples	O
were	O
withdrawn	O
from	O
−80	O
°C	O
and	O
left	O
at	O
room	O
temperature	O
to	O
thaw,	O
(ii)	O
the	O
samples	O
were	O
then	O
treated	O
with	O
methanol	B
(1:1,	I
v	I
/v	I
)	I
and	O
centrifuged,	O
(iii)	O
the	O
supernatant	O
was	O
collected	O
and	O
subjected	O
to	O
evaporation	O
in	O
a	O
nitrogen	O
current	O
to	O
remove	O
methanol,	B
and	O
(iv)	O
reconstituted	O
with	O
200	O
µL	O
of	O
1%	O
acetonitrile	B
and	O
0.1%	O
formic	B
acid	I
previously	O
spiked	O
with	O
a	O
labeled	O
compound.	O

For	O
two	O
groups	O
of	O
metabolites–the	O
creatine	B
and	O
choline	B
compounds–the	O
NMR	O
peaks	O
could	O
not	O
always	O
be	O
resolved.	O

However,	O
the	O
accuracy	O
of	O
the	O
assay	O
in	O
measuring	O
total	O
estradiol	B
or	O
any	O
of	O
the	O
other	O
EM	O
is	O
not	O
provided.	O

In	O
addition	O
to	O
altered	O
purine	B
metabolism,	O
our	O
data	O
revealed	O
that	O
de	O
novo	O
pyrimidine	B
and	O
nucleic	O
acid	O
synthesis	O
pathways	O
were	O
increased,	O
as	O
were	O
products	O
of	O
pyrimidine	B
degradation.	O

Positive	O
associations	O
with	O
serum	O
NT-proBNP	O
comprised	O
neopterin,	B
N	B
-acetylneuraminate,	I
pseudouridine,	B
adenosine,	B
phosphate,	B
and	O
acetone	B
as	O
well	O
as	O
several	O
unknown	O
compounds.	O

2mm_2	O
segments	O
that	O
were	O
surface-sterilized	O
by	O
agitating	O
sequentially	O
in	O
95%	O
EtOH	B
for	O
30	O
sec,	O
0.5	O
%	O
NaOCl	O
for	O
2	O
min,	O
and	O
70%	O
EtOH	B
for	O
2	O
min.	O

The	O
mobile	O
phase	O
consisted	O
of	O
water	O
(A),	O
methanol	B
(B),	O
and	O
ACN	O
(C)	O
with	O
initial	O
solvent	O
conditions	O
of	O
60%	O
A,	O
34%	O
B,	O
and	O
6%	O
C	O
at	O
a	O
rate	O
of	O
1 mL/min	O
at	O
room	O
temperature.	O

Urinary	O
estrone	B
and	O
estradiol	B
levels	O
were	O
each	O
strongly,	O
statistically	O
significantly,	O
and	O
inversely	O
associated	O
with	O
risk	O
in	O
multivariate	O
models	O
[top	O
vs.	O
bottom	O
quartile	O
RR:	O
estrone=0.52;	O
95%	O
CI=0.30	O
to	O
0.88;	O
p-curvature	O
for	O
non-linear	O
trend=.01;	O
estradiol=0.51;	O
95%	O
CI=0.30	O
to	O
0.86;	O
p-trend=.005].	O

Transcriptional	O
changes	O
similar	O
to	O
those	O
seen	O
with	O
CER	B
are	O
limited	O
to	O
the	O
IER	O
responders	O
(R	O
,	O
blue	O
,	O
diamonds),	O
rather	O
than	O
non-responders	O
(NR	O
,	O
grey	O
,	O
diamonds	O
)	O
identified	O
in	O
Fig.	O

The	O
BATMAN	O
model	O
was	O
applied	O
to	O
estimate	O
the	O
relative	O
concentrations	O
of	O
the	O
following	O
metabolites	O
in	O
the	O
400	O
MHz	O
spectra:	O
alanine,	B
arginine,	B
asparagine,	B
aspartate,	B
cysteine,	B
glutamine,	B
glutamate,	B
glycine,	B
histidine,	B
isoleucine,	B
leucine,	B
lysine,	B
methionine,	B
phenylalanine,	B
proline,	B
serine,	B
threonine,	B
tryptophan,	B
tyrosine,	B
valine,	B
α	B
-D-glucopyranose,	I
β	B
-D-glucopyranose,	I
myo-inositol,	B
acetate,	B
acetoacetate,	B
α	B
-ketoglutarate,	I
β	B
-hydroxybutyrate,	I
citrate,	B
lactate,	B
pyruvate,	B
succinate,	B
creatine,	B
and	O
creatinine.	B

Alterations	O
in	O
organic	O
acid	O
profiles	O
in	O
blood	O
of	O
lung	O
cancer	O
subjects	O
were	O
also	O
found	O
in	O
some	O
previous	O
metabolomic	O
studies;	O
however,	O
they	O
were	O
usually	O
related	O
to	O
elevated	O
lactic	B
acid	I
(Hori	O
et	O
al.	O

During	O
further	O
investigation	O
of	O
MTBE	B
extraction	O
repeatability,	O
the	O
repeatability	O
of	O
solvent	O
pipetting	O
was	O
investigated	O
and	O
found	O
not	O
to	O
be	O
significant	O
contributing	O
factor	O
to	O
overall	O
method	O
performance.	O

In	O
the	O
present	O
study,	O
the	O
significantly	O
decreased	O
LysoPE	O
and	O
PS	O
in	O
the	O
serum	O
of	O
patients	O
with	O
IS	O
suggest	O
an	O
abnormity	O
of	O
phospholipid	B
metabolism	O
in	O
patients	O
with	O
IS,	O
and	O
also	O
maybe	O
one	O
of	O
the	O
potential	O
reasons	O
for	O
IS.	O

The	O
second	O
step	O
is	O
to	O
identify	O
the	O
structure	O
of	O
phospholipids	B
through	O
MS/MS	O
spectra	O
performed	O
on	O
only	O
the	O
selected	O
ions	O
that	O
presented	O
in	O
samples	O
by	O
step	O
1.	O

Additional	O
selection	O
criteria	O
for	O
FOS-NGT	O
were	O
normal	O
fasting	O
glucose	B
concentrations	O
and	O
normal	O
glucose	B
tolerance.	O

In	O
females,	O
the	O
purine	B
derivative	O
and	O
adenosine	B
reaction	O
intermediate	O
hypoxanthine,	B
as	O
well	O
as	O
the	O
purine	O
base	O
adenine,	O
were	O
found	O
to	O
significantly	O
contribute	O
to	O
group	O
separation.	O

Together	O
with	O
the	O
expected	O
higher	O
level	O
of	O
sugars,	O
several	O
metabolites,	O
such	O
as	O
alanine,	B
carnitine,	B
citrate,	B
creatine,	B
glutamate,	B
glutamine,	B
isoleucine,	B
leucine,	B
lactate,	B
lysine,	B
methionine,	B
N-acetyl-glycoproteins,	B
phenylalanine,	B
tyrosine	B
and	O
valine	B
were	O
also	O
quantified	O
and	O
statistically	O
validated	O
as	O
significantly	O
reduced	O
in	O
T2DM-C	O
patients	O
compared	O
to	O
the	O
CG	O
(C	O
and	O
).	O

These	O
miRNAs	O
may	O
be	O
associated	O
with	O
FL	O
formation	O
through	O
the	O
regulation	O
of	O
lipoprotein	O
metabolism	O
as	O
hsa-miR-122-5p	O
levels	O
associated	O
with	O
small	O
VLDL,	O
IDL,	O
and	O
large	O
LDL	O
lipoprotein	O
subclass	O
components,	O
while	O
hsa-miR-885-5p	O
levels	O
associated	O
inversely	O
with	O
XL	O
HDL	B
cholesterol	I
levels.	O

Also,	O
in	O
all	O
12	O
patients	O
with	O
drug-susceptible	O
TB	O
with	O
detectable	O
plasma	O
D-series	O
resolvin(s)	O
metabolite,	O
both	O
the	O
trehalose-6-mycolate	B
and	O
the	O
PI	O
metabolites	O
were	O
detected.	O

In	O
contrast,	O
hydrochlorothiazide	B
therapy	O
did	O
not	O
result	O
in	O
marked	O
alterations	O
of	O
plasma	O
long-chain	O
acylcarnitine	B
levels,	O
but	O
slightly	O
increased	O
plasma	O
carnitine	B

As	O
known,	O
glutamine	B
is	O
converted	O
to	O
glutamate,	B
and	O
further	O
metabolized	O
to	O
α-ketoglutarate	B
for	O
ATP	B
synthesis	O
through	O
the	O
tricarboxylic	B
acid	I
cycle.	O

To	O
evaluate	O
the	O
effects	O
of	O
the	O
confounding	O
factors	O
on	O
the	O
plasma	O
levels	O
of	O
nervonic	B
acid,	I
we	O
applied	O
an	O
ANCOVA	O
with	O
a	O
dependent	O
variable	O
of	O
the	O
metabolite	O
levels,	O
an	O
independent	O
variable	O
of	O
diagnosis,	O
and	O
the	O
covariates	O
of	O
age	O
and	O
sex.	O

Insulin	O
sensitivity	O
was	O
increased	O
by	O
Pio&Omega-3,	B
and	O
tended	O
to	O
be	O
improved	O
by	O
Pio	O
compared	O
with	O
Omega-3	B
(Table ),	O
which	O
is	O
also	O
in	O
agreement	O
with	O
the	O
induction	O
of	O
adiponectin	O
by	O
both	O
Pio&	O
Omega-3	B
and	O
Pio	O
(Table ).	O

After	O
correcting	O
for	O
creatinine	B
and	O
diuretic	O
use,	O
no	O
other	O
potentially	O
confounding	O
factor	O
was	O
associated	O
with	O
survival.	O

To	O
our	O
knowledge,	O
this	O
is	O
the	O
first	O
study	O
to	O
quantify	O
the	O
levels	O
of	O
sphingolipids	B
both	O
in	O
breast	O
cancer	O
and	O
in	O
normal	O
breast	O
tissue	O
and	O
to	O
reveal	O
the	O
correlation	O
of	O
the	O
levels	O
of	O
sphingolipids	B
in	O
the	O
two	O
tissues.	O

In	O
a	O
second	O
example	O
from	O
human	O
plasma	O
extract,	O
the	O
elution	O
profile	O
of	O
a	O
phosphatidylcholine	B
of	O
sum	O
composition	O
PC	B
32:2	I
is	O
shown	O
in	O
.	O

All	O
participants	O
were	O
asked	O
not	O
to	O
use	O
any	O
pain	O
medications	O
except	O
for	O
paracetamol	B
preparations	O
for	O
three	O
days	O
before	O
the	O
day	O
of	O
the	O
experiment.	O

The	O
residue	O
was	O
dissolved	O
in	O
80	O
μl	O
of	O
methoxyamine	B
with	O
pyridine	B
(15	O
mg/ml)	O
and	O
kept	O
for	O
90	O
min	O
at	O
30	O
°C.	O

Interestingly,	O
the	O
brain	O
also	O
uses	O
ketone	B
bodies	O
as	O
an	O
alternative	O
energy	O
source.	O

The	O
loading	O
plot	O
shows	O
an	O
increase	O
in	O
the	O
levels	O
of	O
H_2	O
S,	O
urea,	B
uric	B
acid	I
and	O
glucose	B
in	O
the	O
serum	O
of	O
STEMI	O
patients.	O

The	O
NoID	B
samples	O
(no	O
weight	O
record	O
for	O
a	O
particular	O
monitoring	O
time-point	O
during	O
the	O
RT/CHRT	O
course)	O
are	O
projected	O
onto	O
the	O
OPLS-DA	O
plane.	O

The	O
measurement	O
conditions	O
were	O
as	O
follows:	O
ESI:	O
source	O
voltage	O
5.5	O
kV	B
or	O
−4.5	O
kV,	B
vaporizer	O
temperature:	O
375	O
°C,	O
turbo	O
gas:	O
75	O
psi,	O
nebulizer	O
gas:	O
65	O
psi,	O
curtain	O
gas:	O
40	O
psi,	O
and	O
declustering	O
potential:	O

Metabolites	O
contributing	O
to	O
this	O
separation	O
included	O
formate	B
which	O
increased	O
and	O
3-hydroxybutyrate	B
which	O
decreased	O
in	O
Barrett's	O
patients.	O

Quinolinate	B
concentrations	O
in	O
one	O
survivor	O
decreased	O
as	O
their	O
metabolomic	O
profile	O
approached	O
the	O
controls.	O

Methylene/methyl	O
ratio	O
in	O
aliphatic	B
lipid	O
chains	O
from	O
plasma	O
lipids	O
of	O
control,	O
hypertensive	O
patients	O
with	O
normal	O
LV	O
size	O
(HTN	O
normal	O
LV	O
size)	O
and	O
hypertensive	O
patients	O
with	O
LV	O
hypertrophy	O
(HTN	O
LVH).	O

One	O
group	O
was	O
used	O
to	O
label	O
metabolites	O
containing	O
carboxylic	B
acid	I
groups	O
with	O
_15	O
N-ethanolamine,	B
and	O
the	O
second	O
group	O
was	O
used	O
to	O
label	O
metabolites	O
containing	O
amine	O
groups	O
with	O
_13	O
C-formic	O
acid,	O
after	O
the	O
addition	O
of	O
internal	O
standards,	O
either	O
maleic	B
acid	I
or	O
ethanolamine,	B
appropriately.	O

The	O
dried	O
extract	O
was	O
then	O
reconstituted	O
in	O
50 μL	O
of	O
methanol.	B

Each	O
acquired	O
spectrum	O
was	O
then	O
phased,	O
baseline	O
corrected	O
and	O
aligned	O
with	O
reference	O
to	O
alanine	B
(δ=1.479	O
ppm)	O
using	O
Bruker	O
Topspin	O
3.0	O
software.	O

To	O
our	O
knowledge,	O
this	O
is	O
the	O
first	O
study	O
to	O
explore	O
the	O
relation	O
between	O
tryptophan	B
metabolites	O
and	O
multiple	O
immune	O
system	O
biomarkers	O
in	O
a	O
large	O
cohort	O
of	O
healthy	O
adults	O
with	O
no	O
apparent	O
inflammatory	O
conditions.	O

Similarly	O
to	O
the	O
mass	O
spectrometry	O
measurements	O
of	O
malate	B
and	O
citrate	B
in	O
the	O
cell	O
lines	O
maintained	O
in	O
DMEM	O
cell	O
culture	O
medium	O
the	O
cell	O
lines	O
with	O
knocked	O
down	O
PC	O
maintained	O
in	O
the	O
modified	O
RPMI	O
1640	O
medium	O
followed	O
by	O
the	O
Krebs	O
Ringer	O
solution,	O
the	O
PC	O
knockdown	O
cell	O
lines	O
PC	O
847	O
2C,	O
PC	O
2096	O
4B	O
and	O
PC	O
179	O
1A,	O
showed	O
decreased	O
levels	O
of	O
malate	B
and	O
citrate	B
compared	O
to	O
the	O
control	O
cell	O
line	O
containing	O
a	O
scrambled	O
shRNA.	O

Moreover,	O
osteoporosis	O
and	O
bone	O
fractures	O
were	O
increased	O
with	O
letrozole	B
compared	O
to	O
tamoxifen	B
mono-therapy.	O

Because	O
no	O
such	O
categories	O
exist	O
for	O
24,25	B
(OH)_2	I
D	O
and	O
1,25(OH)_2	B
D,	O
these	O
metabolites	O
were	O
examined	O
in	O
quartiles.	O

Most	O
previous	O
research	O
on	O
phosphocreatine,	B
either	O
in	O
muscle	O
or	O
in	O
the	O
brain,	O
and	O
whether	O
as	O
an	O
energy	O
buffer	O
or	O
as	O
an	O
energy	O
shuttle,	O
has	O
been	O
concerned	O
with	O
its	O
breakdown	O
and	O
resynthesis,	O
and	O
it	O
has	O
been	O
tacitly	O
assumed	O
that	O
the	O
tCr	O
pool	O
stays	O
constant.	O

To	O
our	O
knowledge,	O
the	O
current	O
literature	O
only	O
describes	O
elevated	O
levels	O
of	O
NAAG	B
in	O
Canavan	O
disease,	O
arising	O
from	O
a	O
deficiency	O
in	O
aminoacylase	O
2,	O
the	O
enzyme	O
principally	O
responsible	O
for	O
the	O
breakdown	O
of	O
N-acetylaspartate.	B

Whether	O
associations	O
with	O
LDL	B
cholesterol	I
were	O
underestimated	O
here	O
due	O
to	O
smaller	O
sample	O
size	O
or	O
were	O
more	O
realistically	O
estimated	O
due	O
to	O
enhanced	O
activity	O
measurement	O
with	O
accelerometry	O
is	O
unclear.	O

A	O
potential	O
metabolic	O
hallmark	O
discovered	O
in	O
this	O
study	O
apart	O
from	O
creatinine,	B
is	O
the	O
elevated	O
serum	O
levels	O
of	O
LDL/VLDL	O
lipoproteins	O
(triglyceride	O
and	O
fatty	O
acid)	O
and	O
decreased	O
serum	O
levels	O
of	O
acetate	B
in	O
LN	O
compared	O
to	O
SLE	O
patients.	O

The	O
original	O
Breast,	O
Estrogen,	B
and	O
Nutrition	O
(BEAN	O
1)	O
study,	O
conducted	O
in	O
2000–2003,	O
randomized	O
220	O
women	O
to	O
intervention	O
and	O
control	O
groups;	O
190	O
women	O
contributed	O
at	O
least	O
4	O
samples	O
to	O
the	O
present	O
analysis.	O

SPME	O
manual	O
holder	O
and	O
the	O
carboxen-polydimethylsiloxane	B
(CAR-PDMS)	O
fiber	O
were	O
produced	O
from	O
Sigma-Aldrich,	O
(Merck	O
KGaA,	O
Darmstadt,	O
Germany).	O

However,	O
it	O
could	O
reflect	O
the	O
activation	O
of	O
the	O
mevalonate	B
pathway	O
leading	O
to	O
cholesterol	B
biosynthesis,	O
and	O
increases	O
in	O
α-tocopherol	B
accumulation	O
(Vitamin	O
E),	O
which	O
will	O
preserve	O
membrane	O
integrity	O
under	O
oxidative	O
stress	O
conditions	O
(Supplementary	O
Figure	O
S4).	O

To	O
measure	O
the	O
combined	O
parent	O
estrogen	B
or	O
estrogen	B
metabolite	O
level,	O
an	O
enzymatic	O
hydrolysis	O
with	O
sulfatase	O
and	O
glucuronidase	O
activity	O
was	O
added	O
to	O
the	O
sample	O
preparation	O
to	O
cleave	O
any	O
sulfate	B
and	O
glucuronide	B
groups.	O

Following	O
application	O
of	O
the	O
samples,	O
the	O
plate	O
was	O
washed	O
with	O
additional	O
volumes	O
of	O
phosphate	B
buffer	O
and	O
hexanes,	B
3	O
mL	O
each,	O
before	O
elution	O
with	O
1.25	O
mL	O
ethyl	B
acetate	I
into	O
a	O
Tru-Taper	O
96-well	O
collection	O
plate	O
(Analytical	O
Sales	O
and	O
Services,	O
Cat.	O

These	O
21	O
significantly	O
altered	O
metabolites	O
span	O
pathways	O
previously	O
studied	O
in	O
the	O
context	O
of	O
glucose	B
homeostasis,	O
as	O
well	O
as	O
some	O
never	O
linked	O
to	O
this	O
program.	O

(LC–MS-MS)	O
using	O
validated	O
methods	O
for	O
GS-331007	O
and	O
ribavirin	B
in	O
adherence	O
to	O
good	O
laboratory	O
practice.	O

Comparison	O
of	O
25-hydroxyvitamin	B
D_3	O
concentrations	O
(ng/g)	O
in	O
SRM	O
972	O
Level	O
1	O
(control)	O
and	O
SRM	O
909c	O
obtained	O
using	O
the	O
three	O
developed	O
methods.	O

Notably,	O
comparison	O
of	O
previously	O
collected	O
and	O
frozen	O
plasma	O
samples	O
with	O
fresh	O
plasma	O
preparations	O
revealed	O
that	O
76%	O
of	O
observed	O
putative	O
oxylipins	B
in	O
frozen	O
samples	O
were	O
also	O
observed	O
in	O
fresh	O
samples,	O
suggesting	O
that	O
assayed	O
oxylipin	B
metabolites	O
were	O
not	O
due	O
non-enzymatic	O
oxidation	O
during	O
years	O
of	O
storage	O
(data	O
not	O
shown).	O

Representative	O
chromatogram	O
of	O
selectivity	O
studies	O
comparing	O
blank	O
samples	O
(left	O
chromatograms)	O
matched	O
to	O
LLOQ	O
(right	O
chromatograms)	O
for	O
A,	O
Abi;	O
B,	O
D4A;	O
C,	O
3-keto-5α-Abi;	B
D,	O
3-keto-5β-Abi;	B
E,	O
3α-OH-5α-Abi;	B
F,	O
3α-OH-5β-Abi;	B
G,	O
3β-OH-5α-Abi;	B
and	O
H,	O
3β-OH-5β-Abi.	B

In	O
the	O
carnitine-acylcarnitine	B
metabolic	O
pathway,	O
the	O
mRNA	O
expression	O
levels	O
of	O
CPT1B	O
and	O
CPT1C,	O
SLC25A20	O
,	O
and	O
CRAT	O
,	O
but	O
not	O
CPT1A	O
or	O
CPT2	O
,	O
were	O
significantly	O
lower	O
in	O
NIMBC	O
patients	O
than	O
in	O
controls	O
(p	O
<0.05	O
each)	O
(,	O
).	O

Portions	O
of	O
typical	O
800	O
MHz	O
_1	O
H	O
NMR	O
spectra	O
of	O
human	O
whole	O
blood	O
and	O
blood	O
plasma	O
from	O
the	O
same	O
individual	O
obtained	O
after	O
extraction	O
using	O
methanol	B
and	O
chloroform	B
in	O
a	O
1:2:2	O
ratio	O
(v/v/v).	O

In	O
seminal	O
plasma,	O
SM	O
16:0,	O
PC	B
34:1	I
and	O
SM	O
24:0	O
were	O
present	O
at	O
the	O
highest	O
concentrations	O
of	O
all	O
lipids	O
investigated.	O

Its	O
highest	O
scoring	O
homolog	O
from	O
the	O
NCBI	O
Blast	O
search	O
was	O
the	O
serum	O
albumin	O
1	O
precursor	O
of	O
Atlantic	B
salmon	O
(Salmo	O
salar	O
)	O
(results	O
not	O
shown).	O

Also,	O
we	O
used	O
the	O
ISs	O
and	O
the	O
FAMEs	O
RI	B
standards	O
to	O
evaluate	O
the	O
RT	O
shift.	O

fasting	O
plasma	O
glucose,	B
insulin,	O
and	O
plasma	O
TMAO.	B

Another	O
study,	O
comprising	O
of	O
30,252	O
breast	O
cancer	O
patients,	O
revealed	O
that	O
eicosapentaenoic	B
acid	I
and	O
docosahexaenoic	B
acid	I
were	O
significantly	O
inversely	O
associated	O
with	O
risk	O
for	O
breast	O
cancer	O
(HR:	O
0.70,	O
95%	O
CI:	O
0.54–0.90;	O
HR:	O
0.67,	O
95%	O
CI:	O
0.52–0.87).	O

Vitamin	O
D_3	O
synthesized	O
in	O
the	O
skin	O
or	O
consumed	O
by	O
mouth	O
is	O
metabolized	O
to	O
25-hydroxyvitamin	B
D_3	O
(25(OH)D_3	O
),	O
which	O
can	O
then	O
be	O
metabolized	O
to	O
1,25-dihydroxyvitamin	B
D_3	O
(1,25(OH)_2	O
D_3	O
,	O
the	O
active	O
vitamin	B
D	I
hormone)	O
by	O
CYP27B1.	O

Cer	B
has	O
been	O
confirmed	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
DM,	O
and	O
is	O
elevated	O
in	O
adipocyte	O
tissues	O
and	O
skeletal	O
muscle	O
of	O
obese	O
humans	O
and	O
C57BL/6J	O
mice	O
on	O
a	O
high-fat	O
diet.	O

Optical	O
rotations	O
were	O
measured	O
with	O
a	O
Jasco	O
Dip-370	O
polarimeter	O
using	O
MeOH	B
as	O
the	O
solvent.	O

This	O
difference	O
could	O
reflect	O
the	O
time	O
lag	O
necessary	O
to	O
shift	O
the	O
metabolic	O
machinery	O
dedicated	O
to	O
glucose	B
use	O
in	O
CPF	O
animals	O
at	O
baseline	O
to	O
that	O
necessary	O
to	O
process	O
the	O
greater	O
load	O
of	O
amino	O
acids	O
at	O
shock.	O

It	O
did	O
however	O
produce	O
bladder	O
tumors	O
in	O
rats	O
when	O
given	O
as	O
a	O
tumor	O
initiator,	O
followed	O
by	O
promotion	O
with	O
dietary	O
uracil.	B

The	O
ratio	O
of	O
24(S	O
)-	O
to	O
27-	O
to	O
7α-hydroxycholesterol	B
(cholest-5-ene-3β,7α-diol,	I
C_5	I
-3β,7α-diol)	I
in	O
CSF	O
was	O
found	O
to	O
be	O
1:1.6:1.1	O
(six	O
subjects).	O

We	O
found	O
a	O
sharp	O
increase	O
in	O
S	B
-(3-methylbutanoyl)-dihydrolipoamide-E	I
and	O
N	B
-nonanoyl-glycine	I
and	O
significant	O
decreases	O
in	O
lactitol	O
dehydrate	O
and	O
S	B
-phenyl-d-cysteine.	I

Allantoin	B
(Sigma-Aldrich,	O
St.	O
Louis,	O
MO)	O
and	O
DL-allantoin-5-_13	O
C;1-_15	O
N	O
(C/D/N	O
Isotopes,	O
Quebec,	O
Canada)	O
were	O
used	O
as	O
the	O
standard	O
and	O
internal	O
standard,	O
respectively.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
(ω)-	B
and	O
(ω-1)-hydroxyl	O
derivatives	O
(analytes	O
4	O
and	O
6)	O
were	O
only	O
detected	O
in	O
the	O
specimen	O
known	O
to	O
have	O
administered	O
JWH-073	O
(Specimen	O
4)	O
and	O
that	O
analyte	O
5	O
was	O
present	O
in	O
specimens	O
that	O
presumably	O
administered	O
only	O
JWH-018.	O

The	O
observed	O
increase	O
in	O
urinary	O
lactate	B
supports	O
the	O
hypothesis	O
of	O
an	O
alteration	O
of	O
the	O
energy	O
metabolism	O
.	O

The	O
blue	O
symbols	O
are	O
from	O
two	O
of	O
the	O
glioblastoma	O
patients	O
analyzed	O
using	O
the	O
4	O
gram	O
per	O
hour	O
infusion	O
with	O
[U-_13	B
C]-glucose	I
(Fc3	O
could	O
not	O
be	O
calculated	O
from	O
the	O
spectrum	O
of	O
the	O
third	O
patient	O
infused	O
on	O
this	O
protocol).	O

 mL	O
internal	O
standard	O
mixture	O
containing	O
_13	O
C,d_3	B
-diosmetin	I
at	O
200 ng/mL	O
and	O
d_4	B
-paracetamol	I
at	O
2.5 μg/mL	O
was	O
added,	O
followed	O
by	O
0.6 mL	O
acetonitrile.	B

The	O
SM	O
and	O
Cer	B
species	O
are	O
dihydrosphingolipids	B
(dhSLs),	O
which	O
have	O
backbones	O
comprised	O
of	O
sphinganine	B
(d18:0)	I
rather	O
than	O
sphingosine	B
(d18:1)	I
as	O
is	O
the	O
case	O
for	O
sphingolipids	B
(SLs).	O

Higher	O
lactate	B
levels	O
in	O
cancer	O
tissue	O
could	O
be	O
caused	O
by	O
activation	O
of	O
glycolysis.	O

The	O
chromatographic	O
separation	O
was	O
performed	O
in	O
gradient	O
elution	O
with	O
ultrapure	O
water	O
with	O
formic	B
acid	I
(0,025%)	O
and	O
with	O
acetonitrile	B
(B)	O
as	O
the	O
mobile	O
phases,	O
at	O
a	O
flow	O
rate	O
of	O
0.4	O
mL/min.	O

It	O
is	O
believed	O
that	O
sex	O
differences	O
largely	O
are	O
the	O
result	O
of	O
the	O
immune-enhancing	O
effects	O
of	O
estrogens	O
and	O
immunosuppressive	O
effects	O
of	O
androgens	O
and	O
progesterone,	B
giving	O
women	O
a	O
stronger	O
humoral	O
immune	O
response,	O
but	O
also	O
a	O
higher	O
susceptibility	O
to	O
autoimmunity.	O

This	O
complexity	O
reflects	O
the	O
diabetes	O
research	O
results	O
made	O
on	O
the	O
genome	O
level	O
during	O
the	O
past	O
years:	O
no	O
single	O
gene,	O
but	O
rather	O
a	O
high	O
number	O
of	O
genes	O
are	O
associated	O
with	O
type	O
2	O
diabetes	O
[-]	O
and	O
fasting	O
glucose	B
development.	O

For	O
AAAs,	O
Tyr	O
correlated	O
with	O
fasting	O
insulin	O
(P	O
<	O
0.001,	O
R	O
=	O
0.31)	O
and	O
the	O
leptin : adiponectin	O
ratio	O
(P	O
<	O
0.001,	O
R	O
=	O
0.28),	O
whereas	O
Phe	O
did	O
not	O
correlate	O
with	O
any	O
glucose	B
metabolism	O
or	O
lipid	O
parameters	O
after	O
BMI	O
adjustment.	O

GGs	O
were	O
first	O
separated	O
by	O
liquid	O
chromatography	O
under	O
Hydrophilic	B
Interaction	O
Liquid	O
Chromatography	O
(HILIC)	O
conditions	O
and	O
then	O
analyzed	O
by	O
both	O
a	O
Triple	O
Quadrupole	O
mass	O
spectrometer	O
and	O
a	O
LTQ	O
Orbitrap	O
mass	O
spectrometer	O
thanks	O
to	O
analytical	O
methods	O
previously	O
developed.	O

After	O
addition	O
of	O
water	O
(1 ml)	O
to	O
the	O
crude,	O
FAMEs	O
were	O
extracted	O
with	O
hexane	B
(3 ml),	O
evaporated	O
to	O
dryness	O
and	O
dissolved	O
in	O
ethyl	B
acetate	I
(20 μl).	O

Finally,	O
the	O
most	O
abundant	O
amino	O
acid	O
in	O
plasma,	O
glutamine,	B
can	O
be	O
transported	O
across	O
the	O
blood-brain-barrier	O
and	O
undergo	O
conversion	O
into	O
glutamate	B
-	I
a	O
neurotransmitter	O
which	O
is	O
increased	O
in	O
the	O
posterior	O
hypothalamic	O
region	O
of	O
sleep-deprived	O
rodents.	O

Our	O
results	O
in	O
cystathionine	B
strata	O
were	O
comparable	O
to	O
the	O
abovementioned	O
studies,	O
which	O
did	O
not	O
measure	O
plasma	O
cystathionine	B
concentrations.	O

Most	O
of	O
the	O
differential	O
enriched	O
metabolites	O
were	O
involved	O
in	O
metabolic	O
processes,	O
including	O
carbohydrate	O
metabolism,	O
starch	O
and	O
sucrose	B
metabolism,	O
phenylpropanoid	B
biosynthesis,	O
and	O
biosynthesis	O
of	O
amino	O
acids.	O

In	O
our	O
investigations,	O
we	O
observed	O
that	O
alpha-linolenic	B
acid	I
induced	O
growth	O
of	O
LNCaP	O
cells	O
significantly	O
at	O
lower	O
concentrations	O
even	O
at	O
1	O
μM	O
where	O
as	O
its	O
effect	O
on	O
PC-3	O
cells	O
growth	O
was	O
significant	O
at	O
higher	O
concentrations.	O

The	O
weak	O
wash	O
solvent	O
was	O
acetonitrile-isopropanol	O
(3:1,	O
v/v)	O
and	O
the	O
strong	O
wash	O
solvent	O
is	O
H_2	O
O-methanol	B
(1:1,	O
v/v).	O

Portion	O
of	O
the	O
_1	O
H–_15	O
N	O
HSQC	O
800	O
MHz	O
cryo-probe	O
spectrum	O
of	O
a	O
pooled	O
human	O
serum	O
metabolites	O
extracted	O
by	O
protein	O
precipitation	O
using	O
methanol	B
and	O
carboxyl	O
group	O
containing	O
metabolites	O
tagged	O
with	O
_15	O
N-cholamine.	B

(A)	O
histidine;	B
(B)	O
hippurate;	B
(C)	O
creatinine;	B
(D)	O
alanine;	B
(E)	O
lactate.	B

[Google	O
Scholar]	O
Evanochko	O
WT,	O
Sakai	O
TT,	O
Ng	O
TC,	O
Krishna	O
NR,	O
Kim	O
HD,	O
Zeidler	O
RB,	O
Ghanta	O
VK,	B
Brockman	O
RW,	O
Schiffer	O
LM,	O
Braunschweiger	O
PG,	B
et	O
al.	O

Positive	O
differences	O
indicate	O
that	O
aspartame	B
was	O
rated	O
higher	O
than	O
control.	O

Et_2	O
O:	O
CH_2	O
Cl_2	O
(0.5:0.5:9,	O
v/v),	O
followed	O
by	O
rechromatography	O
(×2)	O
in	O
CH_3	O
CN:	O

Association	O
between	O
plasma	O
TMAO	B
concentration	O
and	O
GDM:	O
initial	O
case-control	O
study_1	O
	O
_1	O
Values	O
are	O
ORs	O
(95%	O
CIs).	O

Furthermore,	O
a	O
perturbation	O
of	O
the	O
metabolism	O
of	O
other	O
amino	O
acids,	O
namely,	O
alanine,	B
aspartate,	B
glutamate	B
and	O
D-	B
glutamine	I
metabolism,	O
has	O
also	O
been	O
revealed	O
between	O
the	O
group	O
of	O
cancer	O
patients	O
(BC	O
vs	O
RCC	O
with	O
haematuria),	O
which	O
suggested	O
a	O
distinguished	O
protein	O
metabolism	O
between	O
BC	O
and	O
RCC	O
patients.	O

In	O
the	O
atazanavir/r	O
arm	O
seven	O
lipid	O
species	O
(from	O
the	O
ceramide,	B
monohexosylceramide,	B
trihexosylceramide	B
and	O
G_M3	O
ganglioside	B
classes)	O
decreased	O
in	O
concentration,	O
while	O
a	O
further	O
34	O
species	O
increased.	O

As	O
a	O
sensitivity	O
analysis,	O
we	O
included	O
HOMA-IR	O
and	O
2	O
h	O
glucose	B
in	O
the	O
model	O
for	O
type	O
2	O
diabetes	O
risk	O
factors	O
and	O
repeated	O
the	O
same	O
methodological	O
approach.	O

The	O
method	O
used	O
0.1%	O
formic	B
acid	I
in	O
water	O
and	O
acetonitrile	B
as	O
eluents	O
A	O
and	O
B,	O
respectively.	O

Hyperthyroidism	O
increases	O
the	O
flux	O
of	O
gluconeogenesis,	O
the	O
Cori	O
cycle	O
and	O
adipose	O
tissue	O
lipolysis	O
,	O
leading	O
to	O
glucose	B
intolerance	O
and	O
insulin	O
resistance	O
.	O

As	O
regards	O
the	O
remodeling	O
markers	O
of	O
the	O
extracellular	O
matrix,	O
we	O
found	O
a	O
significant	O
increase	O
in	O
proline,	B
trans‐4‐hydroxyproline	B
and	O
pro‐hydroxy‐pro,	B
as	O
well	O
as	O
in	O
asymmetric	B
dimethylarginine.	I

Even-chain	O
length	O
lysophosphatidylcholines	B
(Fig. ),	O
were	O
significantly	O
(p < 0.05)	O
positively	O
correlated	O
with	O
diarrhea	O
and	O
depth	O
of	O
breathing	O
and	O
negatively	O
correlated	O
with	O
height,	O
pulse	O
rate,	O
breathing	O
rate	O
and	O
temperature	O
of	O
the	O
patients.	O

Choline,	B
serine	B
and	O
putrescine	B
showed	O
the	O
highest	O
potential	O
for	O
discriminating	O
TB-DM	O
from	O
TB	O
patients.	O

It	O
is	O
well	O
established	O
that	O
exercise	O
increases	O
energy	O
expenditure,	O
resulting	O
in	O
the	O
promotion	O
of	O
amino	O
acid	O
catabolism	O
in	O
general	O
and,	O
in	O
particular,	O
in	O
the	O
oxidation	O
of	O
branched	O
chain	O
amino	O
acids,	O
mainly	O
leucine	B
,	O
.	O

Gangliosides	B
make	O
a	O
wide	O
family	O
of	O
glycosphingolipids,	B
highly	O
heterogeneous	O
in	O
both	O
the	O
ceramide	B
moiety	O
and	O
the	O
oligosaccharide	B
chain.	O

The	O
most	O
significant	O
metabolic	O
effects	O
are	O
related	O
to	O
sex	O
(blue)	O
and	O
age	O
(green):	O
increased	O
levels	O
of	O
testosterone	B
and,	O
to	O
a	O
lesser	O
extent,	O
elevated	O
levels	O
of	O
1,5-anhydrosorbitol,	B
phenylalanine,	B
valine,	B
choline,	B
carnitine	B
and	O
uric	O
acids	O
in	O
males,	O
and	O
increased	O
levels	O
of	O
uric	B
acid	I
and	O
several	O
unknowns	O
with	O
respect	O
to	O
age.	O

In	O
our	O
study,	O
we	O
used	O
surrogate	O
standards	O
to	O
reference	O
GM3	B
levels	O
because	O
no	O
suitable	O
synthetic	O
GM3	B
standards	O
exist.	O

The	O
body's	O
uric	B
acid	I
is	O
constantly	O
being	O
produced	O
and	O
excreted,	O
so	O
it	O
maintains	O
a	O
certain	O
concentration	O
in	O
the	O
blood.	O

Dry	O
residues	O
were	O
suspended	O
in	O
20 µL	O
of	O
a	O
freshly	O
prepared	O
4%	O
(w/w)	O
methoxyamine	B
solution	O
in	O
pyridine.	B

This	O
meant	O
that	O
the	O
caffeine	B
peak	O
was	O
also	O
more	O
susceptible	O
to	O
spray-pulsing	O
or	O
spray	O
stability	O
phenomena	O
seen	O
at	O
the	O
MS	O
inlet	O
in	O
high	O
percentages	O
of	O
CO_2,	O
and	O
thus	O
functioned	O
as	O
a	O
sensitive	O
indicator	O
of	O
such	O
problems.	O

We	O
also	O
identified	O
phenyl	B
alanine,	I
tyrosine,	B
linoleic	B
acid	I
and	O
glycerophospholipid	B
metabolism	O
as	O
the	O
most	O
significant	O
pathways	O
representing	O
late	O
response	O
to	O
I/R	O
injury.	O

LC-MS	O
analysis	O
was	O
performed	O
using	O
an	O
Agilent	O
LC-QTOF	O
system	O
(Agilent	O
Technologies,	O
Santa	O
Clara,	O
CA)	O
consisting	O
of	O
an	O
Agilent	O
1200	O
SL	B
liquid	O
chromatography	O
system	O
coupled	O
online	O
with	O
an	O
Agilent	O
6520	O
time-of-flight	O
mass	O
spectrometer.	O

This	O
is	O
in	O
contrast	O
with	O
findings	O
of	O
a	O
recent	O
study	O
that	O
showed	O
a	O
significant	O
association	O
of	O
lactate	B
with	O
1-year	O
mortality	O
in	O
AHF	O
patients.	O

In	O
addition,	O
a	O
previous	O
study	O
in	O
Sprague-Dawley	O
rats,	O
by	O
Bollard	O
and	O
colleagues,	O
observed	O
reduced	O
urinary	O
citrate	B
after	O
partial	O
hepatectomy,	O
which	O
they	O
proposed	O
to	O
be	O
a	O
marker	O
of	O
heightened	O
energy	O
demand	O
and	O
cellular	O
stress,	O
as	O
would	O
be	O
the	O
case	O
in	O
patients	O
with	O
HCC.	O

Changes	O
in	O
31	O
FA	B
in	O
serum	O
following	O
RYGB	O
until	O
6 months	O
(n	O
 = 8)	O
were	O
measured.	O

The	O
cytokines,	O
vitamin	O
B-6	O
vitamers,	O
and	O
tryptophan	B
metabolites	O
had	O
non-normal	O
distributions,	O
so	O
data	O
are	O
expressed	O
as	O
median	O
(range:	O
5th,	O
95th	O
percentile).	O

To	O
identify	O
the	O
diagnostic	O
potential	O
of	O
the	O
four	O
most	O
significant	O
metabolites	O
5-Oxoprolinate,	B
Erythronic	B
acid,	I
N-Acetylaspartic	B
acid	I
and	O
4-Hydroxybuturic	B
acid	I
as	O
prognostic	O
biomarkers	O
for	O
high-risk	O
HPV	O
infection,	O
we	O
conducted	O
an	O
additional	O
ROC	O
analysis.	O

Because	O
Xu	O
et	O
al.	O
found	O
that	O
estrogen	B
metabolism	O
changes	O
over	O
the	O
course	O
of	O
the	O
menstrual	O
cycle	O
premenopausal	O
women	O
thought	O
to	O
be	O
in	O
other	O
phases	O
of	O
the	O
menstrual	O
cycle	O
at	O
the	O
time	O
of	O
urine	O
collection	O
have	O
been	O
excluded	O
from	O
most	O
analyses.	O

Finally,	O
these	O
findings	O
are	O
limited	O
to	O
PAFs	O
derived	O
from	O
alkylacyl-glycerophosphocholines;	B
however,	O
as	O
mentioned,	O
these	O
are	O
highly	O
abundant	O
PAFs	O
and	O
are	O
therefore	O
appropriate	O
for	O
this	O
first-step	O
exploration.	O

By	O
and	O
large,	O
it	O
appears	O
that	O
the	O
physiological	O
state	O
of	O
HNSCC	O
involves	O
a	O
large	O
influx	O
of	O
amino	O
acids	O
into	O
the	O
tricarboxylic	B
acid	I
cycle.	O

However,	O
more	O
severe	O
vitamin	O
B-6	O
status	O
likely	O
needed	O
to	O
cause	O
an	O
elevated	O
cystathionine	B
concentration	O
(,	O
).	O

The	O
difference	O
between	O
total	O
AUC	O
for	O
each	O
analyte	O
measured	O
at	O
week	O
24	O
and	O
baseline	O
(∆AUC)	O
is	O
shown	O
for	O
glucose	B
(a)	O
C-peptide	O
(b)	O
NEFA	O
(c)	O
and	O
triacylglycerol	B
TG;	I
(d).	O

Instrument	O
control	O
and	O
data	O
processing	O
were	O
carried	O
out	O
by	O
means	O
of	O
Xcalibur	O
Software	O
2.2	O
SP	B
1.48	O
(Thermo	O
Electron,	O
San	O
José,	O
USA).	O

The	O
levels	O
of	O
7α-hydroxy-3-oxocholest-4-en-26-oic	B
and	O
3β-hydroxycholest-5-en-26-oic	B
acid	I
in	O
CSF	O
were	O
found	O
to	O
be	O
7.170	O
±	O
2.826	O
and	O
0.416	O
±	O

Mann–Whitney	O
U	O
test	O
showed	O
significantly	O
lower	O
serum	O
concentrations	O
in	O
the	O
ADHD	O
group	O
for	O
tryptophan,	B
KA,	O
XA,	O
HAA,	O
vitamin	B
B2	I
(riboflavin)	O
and	O
total	O
vitamin	B
B6	I
(PL + PLP),	O
as	O
well	O
as	O
a	O
significantly	O
higher	O
level	O
of	O
cotinine,	B
compared	O
with	O
the	O
control	O
group	O
(Table ).	O

The	O
distributions	O
of	O
SG-corrected	O
urinary	O
phthalate	B
metabolite	O
and	O
isoprostane	B
concentrations	O
(ng/mL)	O
as	O
well	O
as	O
sperm	O
mtDNAcn	O
(ratio	O
of	O
mtDNA	O
copies	O
per	O
nuclear	O
DNA	O
copies)	O
and	O
mtDNAdel	O
(percent	O
of	O
mtDNA	O
deletions	O
per	O
total	O
mtDNA	O
copies)	O
for	O
male	O
partners	O
are	O
shown	O
in	O
.	O

Van	O
Beek	O
et	O
al.	O
suggested	O
a	O
dual	O
interaction	O
between	O
hydroxyl	B
oxygen	I
and	O
the	O
double	O
bonds,	O
with	O
silver	O
ions.	O

In	O
liver	O
succinyl-CoA	B
can	O
be	O
used	O
for	O
synthesis	O
of	O
glucose.	B

The	O
C18:2	B
CE	O
and	O
SM	O
22:0	O
levels	O
ranged	O
from	O
the	O
lowest	O
at	O
−2.37	O
(deep	O
blue)	O
to	O
the	O
highest	O
at	O
2.37	O
(deep	O
red).	O

(B)	O
Formal	O
Concept	O
Analysis	O
to	O
visualize	O
sorting	O
of	O
samples	O
based	O
on	O
the	O
relative	O
abundance	O
of	O
PC	B
(39:6)	I
and	O
FC	B
(22:3)	I
in	O
PCa	O
(red	O
squares)	O
compared	O
to	O
control	O
(black	O
squares).	O

These	O
steroid	O
precursors	O
are	O
required	O
to	O
produce	O
estrogens,	O
estradiol	B
and	O
testosterone.	B

Five	O
to	O
seven	O
percent	O
of	O
skeletal	O
muscle	O
is	O
composed	O
of	O
alanine,	B
an	O
endogenous	O
amino	O
acid.	O

Leucine	B
enkaphalin	O
was	O
used	O
as	O
the	O
reference	O
compound	O
(positive	O
ion	O
mode	O
([M+H]_+	O
 = 556.2771)	O
and	O
[M−H]_−	O
 = 554.2615)	O
at	O
a	O
concentration	O
of	O
0.2	O
ng/mL	O
under	O
a	O
flow	O
rate	O
of	O
100	O
µl·min_−1	O
,	O
to	O
ensure	O
accuracy	O
and	O
reproducibility	O
during	O
the	O
MS	O
analysis.	O

Using	O
the	O
same	O
LC-MS/MS	O
platform,	O
we	O
also	O
measured	O
the	O
levels	O
of	O
other	O
stable	O
Trp	O
metabolites	O
downstream	O
from	O
Kyn	O
(kynurenic	O
acid,	O
cinnabarinic	O
acid,	O
xanthurenic	B
acid,	I
and	O
3-hydroxyantharanilic	B
acid)	O
in	O
addition	O
to	O
serotonin	B
and	O
melatonin.	B

Neither	O
ketone	B
body	O
marker	O
however	O
meets	O
the	O
criteria	O
for	O
correlation	O
with	O
HOMA-IR	O
at	O
baseline	O
(and	O
acetoacetic	B
acid	I
also	O
fails	O
for	O
the	O
changes).	O

Indeed,	O
with	O
the	O
exception	O
of	O
lactate	B
the	O
levels	O
of	O
2-HB,	O
3-HB,	O
citrate,	B
and	O
tyrosine	B
were	O
significantly	O
positively	O
correlated	O
with	O
NT-proBNP,	O
reflecting	O
a	O
positive	O
relationship	O
with	O
the	O
severity	O
of	O
HF.	O

In	O
particular,	O
the	O
mRNAs	O
expression	O
of	O
interleukin-6	O
(IL-6)	O
and	O
Transforming	O
Growth	O
Factor-β	O
(TGF-β),	O
pro	O
and	O
anti-inflammation	O
cytokines,	O
respectively,	O
significantly	O
decreased	O
and	O
increased	O
after	O
blueberry	O
supplementation,	O
indicating	O
a	O
positive	O
impact	O
of	O
blueberry	O
ingestion	O
in	O
the	O
reduction	O
of	O
risk	O
of	O
inflammation.	O

The	O
defined	O
integration	O
regions	O
aim	O
to	O
capture	O
the	O
following	O
broad	O
lipid	O
resonances:	O
CH_3	O
–(CH_2	O
)_n	O
–in	O
the	O
fatty	O
acid	O
chain	O
(FAC),	O
–CH_3	O
–(CH_2	O
)_n	O
–in	O
the	O
FAC	O
(captured	O
using	O
two	O
integration	O
regions	O
in	O
the	O
900	O
MHz	O
analysis),	O
–CH_2	O
–CH_2	O
–C	O
=	O
O	O
or	O
–CH_2	O
–CH_2	O
–CH	O
=	O
CH–in	O
the	O
FAC,	O
–CH_2	O
–CH	O
=	O
CH–in	O
the	O
FAC	O
and	O
CH_3	O
in	O
N-acetylated	B
glycoproteins	I
(NAG),	O
–CH_2	O
–C	O
=	O
O	O
or	O
–CH_2	O
–CH	O
=	O
CH–in	O
FAC,	O
=	O
CH–CH_2	O
–CH	O
=	O
in	O
FAC,	O
lysyl,	O
and	O
–CH	O
=	O
CH–in	O
FAC.	O

These	O
included	O
metabolites	O
in	O
the	O
2-hydroxylation	O
pathway	O
(Path2,	O
i.e.,	O
2-hydroxyestrone,	B
2-methoxyestrone,	B
2-hydroxyestradiol,	B
2-methoxyestradiol,	B
and	O
2-hydroxyestrone-3-methyl	O
ether);	O
metabolites	O
in	O
the	O
4-hydroxylation	O
pathway	O
(Path4,	O
i.e.,	O
4-hydroxyestrone,	B
4-methoxyestrone,	B
and	O
4-methoxyestradiol);	B
and	O
metabolites	O
in	O
the	O
16-hydroxylation	O
pathway	O
(Path16,	O
i.e.,	O
16α-hydroxyestrone,	B
estriol,	B
17-epiestriol,	O
16-ketoestradiol,	O
and	O
16-epiestriol).	O

Hamman	O
et	O
al.	O
have	O
demonstrated	O
that	O
0.1%	O
ammonium	B
hydroxide	I
in	O
methanol	B
as	O
a	O
modifier	O
improves	O
peak	O
shape	O
and	O
decreases	O
retention	O
of	O
basic	O
drugs	O
on	O
both	O
ethylpyridine	B
and	O
diol	B
columns	O
,	O
and	O
have	O
also	O
tested	O
the	O
stability	O
of	O
silica-supported	O
chiral	O
stationary	O
phases	O
in	O
the	O
presence	O
of	O
this	O
modifier	O
under	O
SFC	O
conditions.	O

In	O
the	O
HCT116	O
cells,	O
we	O
found	O
that	O
the	O
fatty	O
acid	O
carrier	O
carnitine	B
was	O
_13	O
C_0	O
and	O
hence	O
not	O
synthesized,	O
although	O
the	O
initial	O
steps	O
of	O
this	O
pathway	O
leading	O
to	O
_13	O
C_7	O
trimethylammoniobutanoate	B
were	O
found	O
to	O
be	O
active,	O
suggesting	O
that	O
the	O
carnitine-synthesizing	O
BBOX1	O
enzyme	O
was	O
absent.	O

An	O
additional	O
LC–MS	O
analysis	O
was	O
able	O
to	O
confirm	O
the	O
NMR-based	O
data	O
and	O
showed	O
that	O
levels	O
of	O
tyramine	B
and	O
2-oxoglutarate	B
were	O
significantly	O
increased	O
in	O
urine	O
specimens	O
from	O
IC	O
patients	O
compared	O
to	O
that	O
in	O
controls	O
(approximately	O
2-fold,	O
p	O
<	O
0.05)	O
(Figure	O
D,E).	O

× 10_–15	O
),	O
free	O
acetate	B
(P	O
_CD	O
 = 2.8	O

A	O
very	O
consistent	O
finding	O
in	O
the	O
MMCA	O
plots	O
was	O
the	O
negative	O
correlations	O
of	O
the	O
1.3ppm	O
fatty	O
acid	O
signals	O
with	O
lactate,	B
tGlut,	O
tCr	O
and	O
tCho	O
(see	O
and	O
);	O
this	O
was	O
observed	O
in	O
four	O
of	O
the	O
five	O
tumour	O
types,	O
while	O
oligodendrogliomas	O
had	O
significant	O
negative	O
correlations	O
of	O
the	O
fatty	O
acids	O
with	O
lactate	B
and	O
tCr	O
but	O
not	O
with	O
tGlut	O
or	O
tCho.	O

β-glucuronidase	O
and	O
100	O
unit	O
sulfatase	O
activity/mL	O
buffer)	O
and	O
ascorbic	B
acid	I
solution	O
(10	O
μL,	O
250	O
mg/mL)	O

After	O
each	O
challenge,	O
choline	B
metabolites	O
were	O
measured	O
in	O
plasma	O
and	O
urine,	O
as	O
described	O
below.	O

We	O
observed	O
significant	O
correlations	O
of	O
both	O
log	O
8-iso	B
-PGF_2α	I
and	O
log	O
PGE-M	O
with	O
log	O
TNE.	O

For	O
each	O
OPLS-DA	O
model,	O
100	O
spectra	O
were	O
randomly	O
selected,	O
50	O
from	O
class	O
‘P’	O
(acetaminophen	O
group)	O
and	O
50	O
from	O
class	O
‘Cp’	O
(group	O
without	O
acetaminophen	B
metabolites).	O

Analyses	O
showed	O
that	O
lower	O
levels	O
of	O
tryptophan	B
[OR:	O
0.58	O
(95 %	O
CI	O
0.35–0.93,	O
p	O
value	O
0.03)]	O
and	O
XA	O
[0.56	O
(0.22–0.91,	O
0.02)],	O
and	O
higher	O
KTR	O
[1.65	O
(1.02–2.71,	O
0.04)],	O
were	O
associated	O
with	O
the	O
age	O
34–40	O
subgroup.	O

Choline	B
has	O
a	O
key	O
role	O
in	O
neurodevelopment,	O
being	O
the	O
precursor	O
of	O
phosphatidylcholine	B
for	O
myelinization.	O

The	O
chloroform	B
layer	O
was	O
then	O
dried	O
over	O
Na_2	O
SO_4	O
and	O
concentrated	O
under	O
diminished	O
pressure	O
to	O
obtain	O
the	O
crude	O
diethyl	B
α-nicotinyl	I
succinate	I
as	O
a	O
brown	O
oil.	O

In	O
contrast,	O
cancer	O
cells	O
have	O
increased	O
uptake	O
of	O
glucose	B
and	O
glutamine	B
to	O
feed	O
cell	O
growth	O
and	O
proliferation.	O

In	O
CRPC,	O
the	O
tumor	O
either	O
acquires	O
the	O
ability	O
to	O
conduct	O
de	O
novo	O
androgen	O
biosynthesis	O
from	O
cholesterol	B
or	O
utilizes	O
the	O
circulating	O
depot	O
of	O
adrenal	O
androgens	O
as	O
precursors	O
for	O
T	O
and	O
DHT	O
to	O
drive	O
tumor	O
proliferation	O
and	O
metastasis	O
[,,–].	O

Effects	O
of	O
WOL	O
on	O
milk	O
composition	O
and	O
milk	O
and	O
plasma	O
choline	B
metabolites	O
were	O
analyzed	O
using	O
the	O
GLIMMIX	O
procedure	O
of	O
SAS	O
(SAS	O
version	O
9.3	O
Institute	O
Inc.,	O
Cary,	O
NC,	O
USA).	O

A	O
similar	O
graded	O
increase	O
in	O
risk	O
was	O
observed	O
when	O
levels	O
of	O
TMAO	B
were	O
analyzed	O
as	O
a	O
continuous	O
variable	O
in	O
increments	O
of	O
1	O
SD	O
(unadjusted	O
hazard	O
ratio,	O
1.40	O
[95%	O
CI,	O
1.29	O
to	O
1.51;	O
P<0.001];	O
adjusted	O
hazard	O
ratio,	O
1.30	O
[95%	O
CI,	O
1.20	O
to	O
1.41;	O
P<0.001]).	O

For	O
all	O
55	O
patients'	O
plasma	O
samples,	O
8-OH-WAR	B
was	O
observed	O
in	O
15%	O
of	O
these	O
patients,	O
but	O
was	O
below	O
the	O
LOQ.	O

The	O
sodium	B
phosphate	I
buffer	O
for	O
preparation	O
of	O
the	O
faecal	O
slurries	O
was	O
made	O
of	O
1.77	O
g	O
KH_2	O
PO_4	O
in	O
195	O
mL	O
distilled	O
water	O
and	O
3.62	O
g	O
of	O
Na_2	O
HPO_4	O
in	O
305	O
mL	O
distilled	O
water	O
(both	O
1/15	O
M).	O

In	O
contrast,	O
tumor	O
tissues	O
showed	O
significant	O
high	O
levels	O
of	O
polyamines	B
such	O
as	O
putrescine,	B
spermine	B
and	O
spermidine,	B
as	O
well	O
as	O
numerous	O
molecules	O
related	O
to	O
polyamines,	B
such	O
as	O
N	O
‐acetylputrescine	B
and	O
5‐methylthioadenosine	B
(MTA).	O

Because	O
menopausal	O
status	O
is	O
an	O
important	O
determinant	O
of	O
circulating	O
and	O
urinary	O
endogenous	O
estrogen	B
levels	O
and	O
so	O
many	O
of	O
the	O
participants	O
in	O
this	O
study	O
were	O
aged	O
45–55	O
years	O
and	O
potentially	O
perimenopausal,	O
we	O
assessed	O
menopausal	O
status	O
carefully	O
using	O
data	O
from	O
multiple	O
sources,	O
including	O
self-reported	O
histories	O
of	O
menopause	O
and	O
surgical	O
procedures	O
from	O
the	O
baseline	O
interview,	O
surgical	O
procedures	O
reported	O
in	O
interviews	O
at	O
the	O
time	O
of	O
urine	O
collection,	O
a	O
postcard	O
mailed	O
by	O
participants	O
to	O
study	O
investigators	O
recording	O
the	O
day	O
of	O
the	O
first	O
menstrual	O
period	O
following	O
urine	O
collection,	O
and	O
levels	O
of	O
follicle	O
stimulating	O
hormone	O
(FSH),	O
progesterone,	B
and	O
estradiol	B
in	O
serum	O
collected	O
on	O
the	O
same	O
day	O
as	O
urine.	O

The	O
gut	O
is	O
an	O
environment	O
with	O
reduced	O
oxygen	O
availability,	O
which	O
implies	O
anaerobic	O
fermentation	O
of	O
glucose	B
and	O
amino	O
acid	O
carbon	O
sources.	O

Briefly,	O
RBCs	O
and	O
plasma	O
(0.2	O
g	O
each)	O
were	O
taken	O
into	O
a	O
15	O
mL	O
polypropylene	B
centrifuge	O
tube.	O

Samples	O
were	O
separated	O
on	O
7.5%	O
polyacrylamide	B
gels	O
at	O
125 V,	O
and	O
transferred	O
to	O
nitrocellulose	O
membranes	O
(BioRad,	O
Hercules,	O
CA)	O
for	O
1 hr	O
at	O
50 V.	O
Membranes	O
were	O
blocked	O
for	O
1 hr	O
in	O
Superblock	O
(Thermo	O
Scientific,	O
Rockford,	O
IL)	O
and	O
then	O
incubated	O
with	O
primary	O
antibodies	O
against	O
VCAM	O
(1:200)	O
and	O
ICAM	O
(1:200)	O
followed	O
by	O
the	O
appropriate	O
HRP-conjugated	O
secondary	O
antibodies.	O

Further,	O
studies	O
showed	O
that	O
serotonin	B
via	O
autocrine	O
signaling	O
increases	O
beta-	O
cell	O
function	O
and	O
ß-cell	O
mass	O
during	O
insulin	O
resistant	O
states	O
(e.g.,	O
pregnancy).	O

Glucose	B
M6	O
starts	O
appearing	O
and	O
reaching	O
a	O
maximum	O
after	O
150	O
min	O
for	O
subject	O
1	O
and	O
3,	O
and	O
after	O
250	O
min	O
for	O
subject	O
2.	O

Finally,	O
ADMA	B
and	O
hydroxykynurenine	B
concentrations	O
were	O
increased	O
in	O
HD	O
patients	O
(P	O
<0.001),	O
whereas	O
SDMA	O
concentrations	O
were	O
reduced	O
(P	O
=0.03).	O

Ablation	O
disrupted	O
the	O
mitochondrial	O
membrane	O
potential,	O
resulting	O
in	O
the	O
change	O
in	O
the	O
redox	O
status	O
of	O
cells,	O
inducing	O
cancer	O
cell	O
killing,	O
thus	O
leading	O
to	O
the	O
reduced	O
consumption	O
of	O
taurine.	B

(11.1	O
mmmol/L)	O
or	O
higher;	O
(2)	O
in	O
the	O
absence	O
of	O
symptoms,	O
2	O
or	O
more	O
elevated	O
plasma	O
glucose	B
concentrations	O
(	O

Clandestine	B
laboratories	O
constantly	O
produce	O
new	O
synthetic	O
cannabinoids	B
to	O
circumvent	O
legislative	O
efforts,	O
complicating	O
toxicological	O
analysis.	O

Higher	O
concentrations	O
(>	O
20	O
μM)	O
of	O
SM	B
34:1,	I
36:1,	O
38:1,	O
40:1,	O
40:2,	O
42:2,	O
and	O
42:3	O
were	O
found	O
in	O
the	O
plasma.	O

Since	O
glutamine	B
and	O
glutamate	B
can	O
be	O
interconverted	O
by	O
the	O
enzymes	O
glutamine	B
synthetase	O
	O
and	O
glutaminase,	O
	O
it	O
is	O
not	O
surprising	O
that	O
their	O
concentrations	O
seem	O
to	O
rise	O
and	O
fall	O
in	O
unison	O
in	O
some	O
tumour	O
types.	O

Multivariate	O
ROC	O
plots	O
based	O
on	O
the	O
troponin	O
and	O
creatine	B
kinase	O
(CK)	O
concentration.	O

Mobile	O
phase	O
A	O
was	O
95:5	O
(v:v)	O
water:	O
acetonitrile	B
with	O
20	O
mM	O
ammonium	B
acetate	I
and	O
20	O
mM	O
ammonium	B
hydroxide	I
(pH	O
9.5).	O

The	O
MS	O
resolution	O
was	O
set	O
at	O
100,000	O
full	O
width	O
half	O
maximum	O
and	O
the	O
calibration	O
standards	O
were	O
provided	O
by	O
Thermo	O
Fisher	O
Scientific,	O
Inc.	O
(caffeine,	O
Ultramark	O
1621	O
and	O
MRFA).	O

Model	O
consisting	O
of	O
body	O
mass	O
index	O
(BMI),	O
retinol	B
binding	O
protein	O
4	O
(RBP4),	O
n-acetylaspartic	B
acid	I
and	O
C16:1	B
(cis-7)	I
manifested	O
the	O
best	O
discrimination	O
[AUC	O
0.751	O
(95%	O
CI:	O
0.693–0.809),	O
p	O
<	O
0.001],	O
followed	O
by	O
model	O
consisting	O
of	O
BMI,	O
Cystatin	B
C,	O
acetylaspartic	B
acid	I
and	O
6,7-diketoLCA	B
[AUC	O
0.749	O
(95%	O
CI:	O
0.691–0.808),	O
p	O
<	O
0.001].	O

Instead	O
of	O
developing	O
a	O
quantitative	O
MRM	O
method,	O
we	O
chose	O
an	O
IDA	O
full-scan	O
approach	O
because	O
reliable	O
identification	O
of	O
structurally	O
related	O
synthetic	O
cannabinoids	B
is	O
critical,	O
while	O
also	O
having	O
the	O
ability	O
to	O
quickly	O
incorporate	O
new	O
analytes	O
as	O
reference	O
standards	O
become	O
available.	O

Compensation	O
mechanisms	O
can	O
increase	O
the	O
activity	O
of	O
the	O
remaining	O
neurons	O
to	O
an	O
extent	O
that	O
the	O
levels	O
of	O
dopamine	B
or	O
HVA	O
in	O
CSF	O
appear	O
unchanged	O
until	O
late	O
into	O
the	O
course	O
of	O
the	O
disease	O
.	O

While	O
both	O
parameters	O
could	O
be	O
used	O
to	O
gain	O
a	O
better	O
insight	O
into	O
individual	O
vitamin	B
D	I
status,	O
neither	O
1,25OH2D	O
nor	O
24,25OH2D	O
seems	O
to	O
be	O
a	O
better	O
sole	O
marker	O
of	O
vitamin	B
D	I
status	O
than	O
25OHD.	O

For	O
example,	O
choline	B
and	O
pipecolate	B
detected	O
OSCC	O
even	O
in	O
early	O
stages	O
(I	O
and	O
II).	O

The	O
endogenous	O
pyrroles	O
can	O
come	O
from	O
the	O
metabolism	O
of	O
amino	B
sugars	O
and	O
N-acetylneurominic	B
acid	I
in	O
the	O
central	O
nervous	O
system.	O

FA,	B
fatty	O
acid;	O
AC,	O
acylcarnitine;	B
LPC,	O
lysophosphatidylcholine;	B
PC,	O
phosphatidylcholine;	B
LPE,	O
lysophosphatidylethanolamine;	B
PE,	O
phosphatidylethanolamine.	B

We	O
observed	O
a	O
direct	O
correlation	O
between	O
the	O
nerve	O
score	O
and	O
arginine;	B
this	O
is	O
consistent	O
with	O
the	O
role	O
of	O
arginine	B
in	O
nerve	O
regeneration	O
(,	O
).	O

In	O
95%	O
and	O
4%	O
of	O
these	O
patients,	O
the	O
major	O
observed	O
metabolites	O
were	O
S	B
-7-OH-WAR	I
and	O
R	B
-10-OH-WAR	I
confirming	O
that	O
the	O
formation	O
of	O
these	O
two	O
major	O
isomers	O
are	O
catalyzed	O
by	O
human	O
CYP2C9	O
and	O
CYP3A4,	O
respectively.	O

In	O
earlier	O
reports	O
where	O
SP	B
metabolites	O
significantly	O
improved	O
CaP	O
detection,	O
CaP-positive	O
samples	O
were	O
compared	O
with	O
healthy	O
controls	O
or	O
men	O
unlikely	O
to	O
have	O
CaP,	O
suggested	O
by	O
marked	O
discrepancies	O
in	O
serum	O
PSA	O
between	O
groups.	O

When	O
we	O
saw	O
the	O
pronounced	O
increase	O
in	O
Cit	O
and	O
Arg	O
concentrations,	O
we	O
added	O
urea	B
measurement	O
to	O
our	O
testing	O
protocol.	O

Monodimensional	O
1H	O
NMR	O
spectra	O
for	O
all	O
samples	O
were	O
acquired	O
using	O
a	O
Bruker	O
600	O
MHz	O
spectrometer	O
(Bruker	O
BioSpin)	O
operating	O
at	O
600.13	O
MHz	O
proton	O
Larmor	O
frequency	O
and	O
equipped	O
with	O
a	O
5-mm	O
CPTCI	O
1H-13C-31P	B
and	O
2H-decoupling	O
cryoprobe,	O
including	O
a	O
z	O
-axis	O
gradient	O
coil,	O
an	O
automatic	O
tuning-matching,	O
and	O
an	O
automatic	O
sample	O
changer.	O

Ceramide	B
also	O
plays	O
a	O
role	O
in	O
apoptosis	O
in	O
cancer	O
tissue.	O

AM-2	O
or	O
acetamiprid	B
was	O
also	O
not	O
detected	O
in	O
the	O
urine	O
of	O
Case	O
#3	O
at	O
more	O
than	O
LOQ	O
who	O
had	O
already	O
recovered	O
after	O
stopping	O
the	O
high	O
dose	O
intake	O
of	O
tea	O
or	O
fruits.	O

Cells	O
were	O
treated	O
with	O
Ciprofibrate,	O
GW501516,	O
or	O
Rosiglitazone	B
at	O
the	O
concentration	O
indicated	O
in	O
the	O
figures	O
at	O
t	O
 = 0	O
of	O
the	O
scratch	O
assay,	O
and	O
at	O
seeding	O
time	O
in	O
the	O
invasion	O
assays	O
(both	O
chambers).	O

For	O
plasma	O
collection,	O
0.5 mL	O
of	O
blood	O
was	O
drawn	O
by	O
venipuncture	O
employing	O
a	O
heparinized	O
syringe	O
(1%	O
sodium	B
heparin).	I

Estrone	B
(E1);	O
estradiol	B
(17	O
α/β	O
E2);	O
2,	O
4	O
or	O
16-hydroxyestrone	B
(16OHE1);	O
16-hydroxyestradiol	B
(16OHE2);	O
2	O
or	O
4-methoxyestrone	B
(2	O
or	O
4-MeOE1);	O
2	O
or	O
4-methoxyestradiol	B
(2	O
or	O
4-MeOE2);	O
IS =	O

The	O
difference	O
of	O
unit	O
mass	O
between	O
the	O
fragment	O
ions	O
of	O
m/z	O
250/251	O
and	O
m/z	O
280/281	O
between	O
methoxy	B
and	O
hydroxy	B
metabolites	O
respectively	O
suggests	O
a	O
block	O
to	O
proton	O
migration	O
from	O
the	O
2′	O
or	O
4’	O
position	O
of	O
estrogen	B
due	O
to	O
the	O
methylated	O
group.	O

Our	O
platform	O
does	O
not	O
include	O
this	O
metabolite,	O
but	O
X-10510	O
may	O
be	O
also	O
related	O
to	O
this	O
sphingolipid	B
pathway.	O

This	O
cluster,	O
as	O
can	O
be	O
seen	O
from	O
,	O
is	O
mainly	O
comprised	O
of	O
lysophosphatidylcholine	B
species.	O

Metabolites	O
of	O
the	O
sphinganine/sphingosine	B
pathway	O
including	O
sphinganine,	B
sphinganine	B
1-phosphate,	I
sphingosine,	B
and	O
sphingosine	B
1-phosphate	I
were	O
all	O
significantly	O
increased	O
in	O
Rett	O
syndrome	O
subjects	O
compared	O
to	O
controls	O
(p	O
<	O
0.01).	O

In	O
addition	O
to	O
its	O
role	O
in	O
producing	O
energy,	O
glucose	B
also	O
contributed	O
to	O
biosynthesis.	O

Phe	O
Phenylalanine,	B
His	O
Histidine,	B
Glu	O
Glutamate,	B
Ace	O
Acetate,	B
Lys	O
Lysine,	B
Ala	O
Alanine,	B
Val	O
Valine,	B
Leu	O
Leucine,	B
Ile	O
Isoleucine,	B
Tyr	O
Tyrosine,	B
Met	O
Methionine,	B
Gln	O
Glutamine,	B
PC	B
Phosphorylcholine,	I
GPC	B
Glycerophosphocholine,	I
OAG	O
O-acetyl	B
glycoprotein,	I
Lac	O
Lactate,	B
Pyr	O
Pyruvate,	B
Citr	O
Citrate,	B
Gly	O
Glycine,	B
4-CG	O
4-Cresol	B
glucuronide,	I
GL	O
Glyceryl	O
of	O
lipids,	O
3-HB	O
3-Hydroxybutyrate,	B
NAG	O
N-acetyl	B
glycoprotein,	I
NMR	O
Nuclear	O
magnetic	O
resonance,	O
TG	B
triglycerides,	I
PAG	B
phenylacetylglycine,	I
2-PY	O
2-Pyridone-3-carboxamide,	B
L1	O
:CH	O
_3	O

VOC	O
were	O
identified	O
from	O
fecal	O
(74	O
compounds)	O
and	O
urine	O
(73	O
compounds)	O
samples,	O
and	O
grouped	O
according	O
to	O
chemical	O
classes:	O
alcohols	O
(10	O
and	O
15	O
compounds	O
were	O
identified	O
from	O
feces	O
and	O
urine,	O
respectively),	O
aldehydes	O
(7	O
and	O
10),	O
esters	O
(22	O
and	O
4),	O
aromatic	O
heterocyclic	B
(5	O
and	O
4),	O
hydrocarbons	B
(14	O
and	O
16),	O
ketones	B
(8	O
and	O
16),	O
short	O
and	O
medium	O
chain	O
fatty	O
acids	O
(SCFA)	O
(5	O
and	O
4),	O
sulfur	O
compounds	O
(2	O
and	O
2)	O
and	O
terpens	O
(1	O
and	O
2).	O

A	O
total	O
of	O
six	O
metabolites	O
were	O
able	O
to	O
differentiate	O
liver	O
cirrhosis	O
from	O
each	O
HCC	O
stage	O
group,	O
namely	O
LysoPC	O
[18:2	O
(9Z,12Z)],	O
LysoPC	O
(P-16:0),	O
asparaginyl-proline,	B
vaccenic	B
acid,	I
L-aspartyl-4-phosphate	B
and	O
LysoPC	O

Urinary	O
urea,	B
as	O
the	O
prime	O
end	O
product	O
of	O
amino	O
acid	O
catabolism,	O
is	O
an	O
indicator	O
of	O
nitrogen	O
excretion.	O

In	O
this	O
regard,	O
recent	O
observations	O
in	O
an	O
established	O
murine	B
CRC	O
model	O
impressively	O
revealed	O
the	O
significance	O
of	O
the	O
tumor	O
status	O
on	O
the	O
time	O
of	O
treatment	O
initiation	O
for	O
the	O
efficacy	O
of	O
chemopreventive	O
agents	O
against	O
adenoma	O
formation.	O

Serine	B
is	O
required	O
for	O
cellular	O
and	O
tissue	O
growth	O
in	O
general	O
and	O
for	O
the	O
nervous	O
system	O
in	O
particular.	O

The	O
total	O
urinary	O
concentrations	O
of	O
all	O
the	O
metabolites	O
(sulfate	O
and	O
glucuronide)	O
were	O
found	O
to	O
be	O
greater,	O
by	O
a	O
factor	O
of	O
approximately	O
8,	O
in	O
the	O
children	O
with	O
diabetes	O
compared	O
to	O
their	O
age-matched	O
controls,	O
with	O
the	O
total	O
concentration	O
of	O
α-TL	B
(glucuronide	O
and	O
sulfate)	B
being	O
approximately	O
15	O
times	O
greater	O
and	O
the	O
total	O
α-CEHC	B
(glucuronide	O
and	O
sulfate)	B
being	O
2	O
times	O
greater	O
than	O
in	O
the	O
control	O
subjects.	O

ko02010,	O
phosphotransferase	O
system	O
PTS	O
ko02060),	O
Metabolism	O
of	O
Cofactors	O
and	O
Vitamins	O
(nicotinate	O
and	O
nicotinamide	B
metabolism	O
ko00760,	O
one	O
carbon	O
pool	O
by	O
folate	B
ko00670,	O
pantothenate	B
and	O
CoA	O
biosynthesis	O
ko00770,	O
porphyrin	O
and	O
chlorophyll	B
metabolism	O
ko00860,	O
riboflavin	B
metabolism	O
ko00740,	O
thiamine	B
metabolism	O
ko00730),	O
Metabolism	O
of	O
Terpenoids	B
and	O
Polyketides	O
(terpenoid	O
backbone	O
biosynthesis	O
ko00900),	O
Nucleotide	O
Metabolism	O
(purine	O
metabolism	O
ko00230,	O
pyrimidine	B
metabolism	O
ko00240),	O
Replication	O
and	O
Repair	O
(homologous	O
recombination	O
ko03440,	O
mismatch	O
repair	O
ko03430),	O
and	O
Translation	O
(ribosome	O
ko03010,	O
RNA	O
transport	O
ko03013).	O

Also,	O
C_26	O
bile	O
alcohols	O
have	O
been	O
described	O
previously	O
in	O
the	O
glucuronide	B
fraction	O
from	O
human	O
urine	O
(,	O
).	O

An	O
intervention	O
study	O
among	O
women	O
of	O
advanced	O
age	O
showed	O
that	O
a	O
6-month	O
administration	O
of	O
amino	O
acids,	O
including	O
glutamine,	B
significantly	O
reduced	O
hsCRP	O
and	O
thus	O
has	O
potential	O
beneficial	O
effects.	O

Of	O
the	O
21	O
metabolites	O
displaying	O
significant	O
change	O
in	O
MACS	O
at	O
any	O
time	O
point	O
during	O
OGTT,	O
the	O
levels	O
of	O
20	O
(glucose	O
excluded)	O
remained	O
significantly	O
(P	O
<0.05)	O
altered	O
at	O
the	O
2-h	O
time	O
point.	O

We	O
could	O
not	O
observe	O
additional	O
species	O
upon	O
isopropanol	B
addition	O
and	O
no	O
common	O
pattern	O
in	O
the	O
increased	O
DG	O
species	O
for	O
the	O
individual	O
samples.	O

15:0–18:1(d7)	O
PE,	O
phosphatidylserine	B
15:0–18:1(d7)	I

Interestingly,	O
we	O
saw	O
a	O
significant	O
decrease	O
in	O
levels	O
of	O
phytosphingosine,	B
sphinganine	B
and	O
sphingosine-1-phosphate	B
in	O
T2DM	O
patients,	O
however,	O
levels	O
of	O
phytosphingosine	B
and	O
sphinganine	B
were	O
elevated	O
in	O
DACD	O
patients,	O
which	O
is	O
consistent	O
with	O
the	O
reported	O
changing	O
tendency	O
of	O
sphingolipids	B
metabolism	O
in	O
the	O
plasma	O
of	O
T2DM	O
patients,	O
and	O
there	O
was	O
no	O
report	O
about	O
that	O
in	O
the	O
plasma	O
or	O
other	O
body	O
fluid	O
of	O
DACD	O
patients.	O

The	O
third	O
obstacle	O
resides	O
in	O
the	O
ability	O
of	O
the	O
phosphate	B
groups	O
of	O
the	O
nucleotides	O
to	O
interact	O
with	O
stainless	O
steel,	O
causing	O
a	O
peak	O
tailing	O
on	O
chromatograms.	O

In	O
COSY,	O
the	O
_2	O
CH-_3	O
CH_2	O
cross	O
peaks	O
from	O
lysine	B
and	O
arginine	B
showed	O
significant	O
overlap	O
with	O
each	O
other,	O
although	O
they	O
were	O
still	O
distinguishable.	O

The	O
decreased	O
activity	O
of	O
the	O
desaturase	O
FADS1	O
appeared	O
as	O
a	O
bottleneck,	O
leading	O
upstream	O
to	O
an	O
accumulation	O
of	O
fatty	O
acids	O
and	O
downstream	O
to	O
a	O
deficiency	O
of	O
long-chain	O
fatty	O
acids	O
resulting	O
to	O
impaired	O
phospholipid	B
synthesis.	O

In	O
summary,	O
structural	O
characterization	O
of	O
furan	B
urinary	O
metabolites	O
supports	O
the	O
hypothesis	O
that	O
furan	B
is	O
oxidized	O
to	O
reactive	O
BDA,	O
which	O
triggers	O
the	O
formation	O
of	O
cysteine-BDA-lysine	B
crosslinks.	O

Conclusion:	O
Higher	O
intakes	O
of	O
marine-derived	O
n−3	O
PUFAs	O
are	O
associated	O
with	O
lower	O
risk	O
of	O
adenomatous	O
polyps	O
in	O
women,	O
and	O
the	O
association	O
may	O
be	O
mediated	O
in	O
part	O
through	O
a	O
reduction	O
in	O
the	O
production	O
of	O
prostaglandin	B
E_2	O
.	O

These	O
phenomena	O
suggested	O
that	O
the	O
ATP	B
generation	O
from	O
carbon	O
flux	O
was	O
different	O
between	O
colorectal	O
polyp	O
and	O
CRC.	O

Steroids,	O
catecholamines	B
and	O
their	O
metabolites	O
were	O
measured	O
by	O
online	O
SPE-LC-MS/MS	O
.	O

Data	O
for	O
9	O
of	O
the	O
top	O
15	O
known	O
metabolites	O
from	O
Study	O
1	O
with	O
mean	O
values,	O
fold	O
changes	O
and	O
p-values	O
are	O
shown	O
in	O
A.	O
These	O
metabolites	O
are	O
maltose,	B
ethanolamine,	B
glycerol,	B
palmitic	B
acid,	I
lactic	B
acid,	I
tryptophan,	B
lysine,	B
histidine	B
and	O
glutamic	B
acid.	I

These	O
metabolites	O
are	O
associated	O
with	O
oxidant	O
stress	O
(total	O
glutathione),	B
loss	O
of	O
ATP	B
homeostasis	O
(adenosine),	O
apoptosis	O
(PtdSer),	O
and	O
disruption	O
of	O
endothelial	O
barrier	O
function	O
(sphingomyelin).	O

Summary:	O
Pre-processing	O
parameters	O
for	O
each	O
acetaminophen	B
prediction	O
model.	O

Moreover,	O
Svensson	O
et	O
al.,	O
used	O
a	O
GC–MS-based	O
fatty	O
acid	O
profiling	O
approach	O
to	O
measure	O
palmitate	B
and	O
stearate	B
and	O
demonstrated	O
a	O
necessity	O
for	O
de	O
novo	O
fatty	O
acid	O
synthesis	O
in	O
sustaining	O
lung	O
tumor	O
growth,	O
and	O
an	O
associated	O
sensitivity	O
of	O
multiple	O
NSCLC	O
models	O
to	O
acetyl-CoA	O
carboxylase	O
(ACC)	O
inhibition.	O

As	O
PG	B
and	O
PI	O
are	O
the	O
low	O
abundant	O
lipid	O
species	O
as	O
compared	O
to	O
other	O
species,	O
this	O
data	O
suggested	O
that	O
our	O
extraction	O
protocol	O
is	O
quite	O
successful	O
to	O
enrich	O
and	O
recover	O
these	O
two	O
lipid	O
species	O
from	O
the	O
human	O
urine	O
and	O
will	O
be	O
useful	O
in	O
clinical	O
applications.	O

In	O
this	O
regard,	O
the	O
present	O
findings	O
regarding	O
inositol	B
and	O
lysolipid	O
metabolites	O
are	O
of	O
interest	O
in	O
that	O
they	O
(e.g.,	O
I1P)	O
were	O
associated	O
with	O
aggressive	O
prostate	O
cancer	O
in	O
our	O
recent	O
serum	O
metabolomic	O
analysis.	O

The	O
rise	O
of	O
VLDL	O
and	O
decrease	O
of	O
HDL	O
associated	O
with	O
high	O
testosterone	B
levels	O
potentially	O
increase	O
cardiovascular	O
disease	O
risk.	O

Although	O
intriguing,	O
there	O
was	O
no	O
apparent	O
correlation	O
between	O
significantly	O
high	O
tumor	O
levels	O
of	O
S481	O
phosphorylation	O
in	O
ATP	B
citrate	I
lyase	O
in	O
SCC	O
samples,	O
L1,	O
L3	O
and	O
L7,	O
and	O
their	O
citrate	B
concentrations.	O

This	O
study	O
describes	O
for	O
the	O
first	O
time	O
anastrozole	B
metabolic	O
pathways	O
and	O
the	O
enzymes	O
involved,	O
which	O
may	O
serve	O
as	O
the	O
scientific	O
basis	O
for	O
pharmacogenetic	O
and	O
drug-interaction	O
assessments.	O

Increased	O
palmitate	B
promotes	O
elongation	O
and	O
desaturation,	O
as	O
evidenced	O
by	O
upregulation	O
of	O
stearoyl-CoA	B
desaturase	O
(SCD	O
)	O
1	O
and	O
2	O
(	O
and	O
ref.	O
).	O

The	O
levels	O
of	O
total	O
serum	O
2-MeO-E2	B
in	O
older	O
men	O
were	O
below	O
the	O
limit	O
of	O
detection	O
of	O
0.5	O
pg/mL.	O
There	O
are	O
no	O
reports	O
of	O
total	O
serum	O
4-OH-E2	B
levels	O
in	O
postmenopausal	O
women	O
or	O
older	O
men.	O

Atractyloside	B
is	O
well	O
known	O
as	O
an	O
exceptionally	O
specific	O
and	O
effective	O
inhibitor	O
of	O
the	O
ADP/ATP	O
transport	O
in	O
mitochondria,	O
able	O
to	O
block	O
oxidative	O
phosphorylation	O
(34).	O

For	O
MetS_zero	O
women,	O
serine	B
and	O
arginine	B
were	O
found	O
to	O
be	O
higher	O
with	O
high	O
levels	O
of	O
AEE/kg_DLW	O
(R_2	O
 = 0.32,	O
Q_2	O
 = 0.21)	O
and	O
PAL_DLW	O
(R_2	O
 = 0.40,	O
Q_2	O
 = 0.33)	O
compared	O
with	O
low	O
levels	O
in	O
MetS_zero	O
women	O
(Fig. ).	O

Subjects	O
were	O
infused	O
with	O
[1,2-_13	B
C]acetate	I
at	O
6	O
mg/kg/min	O
for	O
5	O
minutes,	O
followed	O
by	O
3	O
mg/kg/min	O
for	O
2	O
hours.	O

Positron	O
emission	O
tomography	O
(PET)	O
in	O
combination	O
with	O
_18	O
F-fluorine-labeled	B
deoxyglucose	I
([_18	O
F]FDG)	O
and	O
euglycemic-hyperinsulinemic	B
clamp	O
allows	O
direct	O
measurement	O
of	O
skeletal	O
muscle	O
insulin	O
sensitivity	O
independently	O
of	O
endogenous	O
glucose	B
production.	O

Furthermore,	O
urinary	O
myo-inositol	B
exhibited	O
an	O
increase	O
in	O
the	O
power	O
to	O
discriminate	O
FSGS	O
patients,	O
and	O
its	O
addition	O
could	O
better	O
predict	O
the	O
response	O
to	O
initial	O
treatment.	O

On	O
the	O
other	O
hand,	O
3-hydroxybutyric	B
acid,	I
creatine	B
and	O
hypoxanthine	B
may	O
be	O
associated	O
with	O
CAD	O
independent	O
of	O
the	O
presence	O
of	O
type	O
2	O
diabetes.	O

Metabolomic	O
profiling	O
using	O
high	O
resolution	O
mass	O
spectrometry	O
with	O
hydrophilic	B
interaction	O
chromatography	O
was	O
applied	O
to	O
11	O
faecal	O
extracts	O
from	O
eleven	O
healthy	O
children	O
and	O
to	O
43	O
faecal	O
extracts	O
from	O
eleven	O
children	O
undergoing	O
exclusive	O
enteral	O
nutrition	O
for	O
the	O
treatment	O
of	O
active	O
Crohn’s	O
disease	O
(CD)	O
at	O
timepoints	O
before,	O
during	O
(15,	O
30,	O
and	O
60	O
days),	O
and	O
after	O
treatment.	O

	O
Urinary	O
creatinine	B
was	O
assayed	O
in	O
all	O
subjects	O
by	O
Fairview-University	O
Medical	O
Center	O
Diagnostic	O
Laboratories	O
with	O
a	O
Kodak	O
Ektachem	O
500	O
chemistry	O
analyzer.	O

Mass	O
calibration	O
was	O
done	O
with	O
perfluorotributylamine	B
(PFTBA).	O

Vanillic	B
acid	I
is	O
a	O
food	O
metabolite,	O
which	O
is	O
often	O
found	O
in	O
the	O
urine	O
of	O
humans	O
who	O
have	O
consumed	O
coffee,	O
tea	O
and	O
vanilla-flavored	O
food.	O

Lactate	B
and	O
pyruvate	B
could	O
result	O
from	O
CT-induced	O
immunopathology,	O
as	O
a	O
product	O
of	O
the	O
inflammatory	O
microenvironment.	O

In	O
this	O
study,	O
patients	O
with	O
FESZ	O
demonstrated	O
a	O
significantly	O
decreased	O
betaine	B
concentration	O
in	O
both	O
data	O
sets	O
(first	O
set	O
and	O
second	O
set).	O

In	O
summary,	O
we	O
observed	O
that	O
the	O
serum	O
concentrations	O
of	O
4OHNDtam	O
(endoxifen)	O
in	O
breast	O
cancer	O
patients	O
increase	O
with	O
age	O
during	O
steady-state	O
tamoxifen	B
treatment.	O

As	O
regards	O
the	O
PAH	O
urinary	O
metabolites,	O
reported	O
that	O
the	O
hydroxyfluorenes,	B
hydroxyphenanthrenes,	B
1-hydroxypyrene	B
and	O
2-naphthol	B
were	O
all	O
significantly	O
higher	O
in	O
smokers	O
compared	O
to	O
non-smokers	O
(;	O
).	O

No	O
glucuronidated	O
conjugates	O
of	O
the	O
other	O
BRB	O
anthocyanins	B
were	O
detected	O
within	O
any	O
of	O
the	O
post	O
rinse	O
saliva	O
samples	O
and	O
no	O
cyanidin	B
3-sambubioside	I
glucuronides	O
were	O
observed	O
after	O
the	O
30	O
minute	O
post	O
rinse	O
samples.	O

Prostaglandins.	B
1972	O
Oct;2(4):251–263.	O

ACN	O
was	O
eventually	O
selected,	O
as	O
it	O
has	O
higher	O
eluotropic	O
strength	O
when	O
used	O
at	O
the	O
same	O
volume	O
percentage	O
compared	O
to	O
methanol	B
achieving	O
adequate	O
separation	O
within	O
reasonable	O
time.	O

These	O
facts	O
indicate	O
that	O
tyrosine	B
metabolism	O
may	O
be	O
related	O
to	O
pancreatic	O
cancer.	O

A	O
large	O
amount	O
of	O
endogenous	O
substance	O
such	O
as	O
cholesterol,	B
can	O
give	O
rise	O
to	O
poor	O
chromatographic	O
separation	O
and	O
ion	O
suppression.	O

Besides	O
increased	O
uptake	O
of	O
glycine	B
for	O
gluconeogenesis	O
even	O
a	O
decreased	O
production	O
could	O
account	O
for	O
this	O
finding.	O

Applying	O
these	O
diagnostic	O
tools	O
to	O
some	O
preliminary	O
data	O
sets	O
of	O
suspected	O
PCOS	O
women	O
available	O
from	O
our	O
lab,	O
we	O
found	O
that	O
PCOS	O
diagnosis	O
could	O
be	O
supported	O
in	O
9/10	O
subjects	O
using	O
androstanediol	B
as	O
single	O
classifier	O
and	O
in	O
6/10	O
subjects	O
using	O
the	O
best	O
ratio	O
comprising	O
of	O
4	O
steroid	O
metabolites.	O

While	O
structurally	O
similar	O
deuterated	O
internal	O
standards	O
compensated	O
for	O
the	O
matrix	O
effect	O
(BUP	O
and	O
NBUP),	O
deuterated	O
glucuronide	B
internal	O
standards	O
were	O
not	O
available.	O

Enterolactone,	B
as	O
well	O
as	O
other	O
polyphenols,	O
are	O
readily	O
conjugated	O
in	O
the	O
intestinal	O
wall	O
and	O
in	O
the	O
liver.	O

Briefly	O
whole	O
blood	O
was	O
mixed	O
with	O
3	O
vols	O
of	O
ice-cold	O
buffer	O
A	O
(10 mM	O
Tris,	O
320 mM	O
sucrose,	B

Interestingly,	O
the	O
expression	O
level	O
of	O
GULT	O
1,	O
a	O
major	O
glucose	B
transporter	O
in	O
the	O
BBB,	O
is	O
down-regulated	O
in	O
the	O
brain	O
lesion	O
of	O
MS	O
patients.	O

Non-targeted	O
metabolomic	O
profiling	O
was	O
performed	O
using	O
ultra-high	O
performance	O
liquid	O
chromatography/mass	O
spectrometry	O
(UPLC-MS/MS)	O
optimized	O
for	O
basic	O
or	O
acidic	O
species	O
and	O
hydrophilic	B
interaction	O
liquid	O
chromatography	O
(HILIC/UPLC-MS/MS).	O

However,	O
the	O
metabolic	O
aberration	O
of	O
renal	O
tubular	O
cells	O
in	O
an	O
hyperglycemic	B
milieu	O
has	O
not	O
been	O
fully	O
elucidated.	O

There	O
are	O
more	O
than	O
10	O
human	O
cytochrome	O
P450	O
isoforms	O
capable	O
of	O
hydroxylating	B
estrone	I
and	O
estradiol	B
to	O
produce	O
a	O
wide	O
range	O
of	O
potential	O
metabolites.	O

The	O
correlation	O
coefficients	O
could	O
be	O
affected	O
by	O
factors	O
other	O
than	O
cigarette	O
smoking	O
that	O
induce	O
oxidative	O
damage	O
and	O
inflammation,	O
as	O
noted	O
above,	O
or	O
by	O
the	O
different	O
pharmacokinetic	O
profiles	O
of	O
TNE,	O
8-iso	B
-PGF_2α	I
and	O
PGE-M.	O

Threonine	B
(a	O
key	O
metabolite	O
within	O
cirrhotic	O
FMN,	O
Fig.	O

Patients	O
undergoing	O
bariatric	O
surgery	O
were	O
sporadically	O
supplemented	O
in	O
vitamins	O
after	O
the	O
intervention	O
to	O
avoid	O
any	O
deficiency;	O
unfortunately	O
we	O
had	O
no	O
information	O
on	O
vitamin	B
B6	I
concentrations	O
in	O
patients’	O
sera.	O

The	O
verified	O
metabolites	O
are	O
involved	O
in	O
primary	O
bile	O
acid	O
biosynthesis	O
and	O
glycerophospholipid	B
metabolism.	O

While	O
that	O
sounds	O
like	O
a	O
plausible	O
explanation	O
for	O
the	O
negative	O
correlations	O
between	O
fatty	O
acids	O
and	O
tGlut,	O
tCr	O
and	O
tCho,	O
the	O
negative	O
correlation	O
with	O
lactate	B
is	O
harder	O
to	O
understand	O
since	O
there	O
are	O
many	O
reports	O
in	O
the	O
literature	O
that	O
lactate	B
is	O
found	O
along	O
with	O
lipids	O
in	O
necrotic	O
and	O
pre-necrotic	O
regions	O
of	O
brain	O
tumours	O
(most	O
of	O
these	O
studies	O
have	O
been	O
on	O
gliomas)	O
both	O
in	O
vivo	O
(e.g.	O
by	O
MRS)	O
and	O
ex	O
vivo	O
.	O

Glycine	B
was	O
observed	O
to	O
be	O
significantly	O
decreased	O
in	O
the	O
patients	O
with	O
lung	O
cancer	O
in	O
the	O
two	O
data	O
sets.	O

However,	O
C1D12	O
tumor	O
lactate	B
value	O
(0.30±0.07)	O
is	O
slightly	O
higher	O
than	O
C2D23	O
of	O
plasma	O
glucose	B
value	O
of	O
(0.23±0.05).	O

In	O
a,b	O
(Pearson	O
correlation	O
heatmap)	O
it	O
can	O
be	O
observed	O
that	O
sarcosine	B
correlates	O
positively	O
with	O
biopsy	O
results	O
in	O
both	O
pre-	O
and	O
post-PM	O
cases.	O

In	O
set	O
2,	O
1	O
ml	O
of	O
plasma	O
from	O
6	O
different	O
donors	O
was	O
spiked	O
with	O
200	O
μl	O
of	O
methanol	B
(to	O
simulate	O
the	O
addition	O
of	O
100	O
μl	O
of	O
working	O
standard	O
and	O
100	O
μl	O
of	O
internal	O
standard	O
stock	O
solution	O
into	O
plasma	O
in	O
set	O
3).	O

This	O
species	O
was	O
tentatively	O
identified	O
as	O
total	O
PE	B
40:5,	I
based	O
on	O
the	O
characteristic	O
NL	O
and	O
the	O
molecular	O
ion.	O

In	O
this	O
study,	O
the	O
plasma	O
levels	O
of	O
alanine	B
and	O
glycine	B
were	O
decreased	O
in	O
the	O
ELS/MDD	O
when	O
they	O
were	O
compared	O
to	O
non-ELS/MDD.	O

The	O
multivariate	O
analysis	O
performed	O
using	O
all	O
the	O
metabolites	O
significantly	O
different	O
revealed	O
glycolysis,	O
gluconeogenesis,	O
energetic	O
pathways,	O
glutamate	B
metabolism,	O
degradation	O
of	O
ketone	B
bodies	O
and	O
pyruvate	B
metabolism	O
as	O
the	O
most	O
important	O
networks.	O

Moreover,	O
to	O
a	O
lesser	O
extent,	O
2-hydroxybutyrate,	B
3-hydroxybutyrate,	B
alanine,	B
formate,	B
glucose,	B
glutamate	B
and	O
lactate	B
were	O
higher	O
in	O
B	O
and	O
glutamine	B
and	O
hypoxanthine	B
were	O
higher	O
in	O
C1.	O

This	O
procedure	O
provides	O
measurements	O
of	O
up	O
to	O
186	O
endogenous	O
metabolites	O
in	O
quantitative	O
mode	O
(amino	O
acids	O
and	O
biogenic	O
amines)	O
and	O
semi-quantitative	O
mode	O
(acylcarnitines,	O
sphingomyelins,	B
phosphatidylcholines	B
and	O
lysophosphatidylcholines	B
across	O
multiple	O
classes).	O

Another	O
interesting	O
metabolite	O
that,	O
although	O
not	O
significant	O
in	O
terms	O
of	O
p_FDR	O
but	O
classified	O
as	O
medium	O
in	O
terms	O
of	O
Cliff’s	O
delta,	O
increases	O
in	O
urine	O
is	O
TMAO.	B

For	O
most	O
analyses	O
of	O
outcomes,	O
we	O
divided	O
plasma	O
TMAO	B
levels	O
into	O
quartiles.	O

d_6	B
-25-Hydroxycholesterol	I
was	O
added	O
to	O
500	O
μL	O
of	O
serum	O
and	O
CSF	O
as	O
an	O
internal	O
standard,	O
and	O
alkaline	O
hydrolysis	O
was	O
performed	O
in	O
2	O
mL	O
of	O
1	O
N	O
ethanolic	O
KOH	O
at	O
50°C	O
for	O
2	O
h.	O

The	O
samples	O
(20 µl)	O
were	O
injected	O
at	O
2-min	O
intervals	O
into	O
a	O
flowing	O
stream	O
of	O
80%	O
acetonitrile.	B

The	O
aromatase	O
enzyme,	O
encoded	O
by	O
the	O
CYP19	O
gene,	O
converts	O
the	O
androgens	O
testosterone	B
and	O
androstenedione	B
to	O
estradiol	B
and	O
oestrone,	B
respectively.	O

Plasma	O
ADMA	B
levels	O
were	O
increased	O
in	O
patients	O
with	O
sepsis;	O
and	O
both	O
hArg	O
and	O
ADMA	B
were	O
associated	O
with	O
sepsis	O
severity.	O

In	O
a	O
pairwise	O
comparison	O
before	O
and	O
after	O
the	O
ASA-BPT	O
in	O
the	O
AERD	O
patients,	O
the	O
levels	O
of	O
serum	O
SM	B
(d18:0/18:0,	I
d18:0/18:1,	I
d18:0/24:0,	I
d18:0/24:1)	I
were	O
significantly	O
decreased	O
following	O
the	O
ASA-BPT	O
(,	O
).	O

The	O
results	O
reveal	O
a	O
surprisingly	O
poor	O
performance	O
for	O
protein	O
precipitation	O
using	O
acetonitrile:	B
nearly	O
1/3	O
of	O
the	O
metabolites	O
were	O
attenuated	O
by	O
10	O
to	O
67%	O
compared	O
with	O
methanol	B
precipitation	O
at	O
the	O
same	O
solvent-to-serum	O
ratio	O
of	O
2:1.	O

This	O
was	O
confirmed	O
with	O
the	O
demonstration	O
that	O
HDL	O
both	O
increased	O
the	O
phosphorylation	O
of	O
the	O
AMPK	O
target	O
ACC	O
and	O
reduced	O
NEFA	O
and	O
glycerol	B
release	O
from	O
adipocytes.	O

The	O
efavirenz	O
arm	O
demonstrated	O
the	O
weakest	O
association	O
with	O
only	O
five	O
lipid	O
species	O
and	O
two	O
classes	O
significantly	O
associated	O
with	O
total	O
cholesterol	B
at	O
week	O
48	O
(see	O
).	O

These	O
three	O
validated	O
differential	O
diagnostic	O
metabolites	O
were	O
all	O
found	O
when	O
comparing	O
the	O
profiles	O
of	O
the	O
two	O
inflammatory	O
bowel	O
diseases	O
UC	O
and	O
CD:	O
hippurate	B
(P	O
 = 9.2 × 10_–8	O
),	O
citrate	B
(P	O
 = 1.6 × 10_–8	O
),	O
and	O
Unknown	O
7	O
(P	O
 = 6.7	O

HPLC-grade	O
acetonitrile	B
and	O
formic	B
acid	I
were	O
supplied	O
by	O
Sigma-Aldrich	O
(France)	O
and	O
water	O
used	O
for	O
liquid	O
chromatography-mass	O
spectrometry	O
(LC-MS)	O
was	O
generated	O
from	O
a	O
Milli-Q	O
integral	O
water	O
purification	O
system.	O

Azelaic	B
acid	I
was	O
inversely	O
correlated	O
with	O
insulin	O
and	O
HOMA	O
measurements	O
at	O
baseline.	O

Also,	O
we	O
observe	O
abnormal	O
regulation	O
of	O
small	O
peptides	O
in	O
sera	O
of	O
HCC	O
compared	O
with	O
cirrhosis	O
(shown	O
in	O
),	O
e.g.	O
down	O
regulation	O
of	O
L-alanine	B
(Beta-leucine/T-butyl	O
glycine)	B
and	O
L-N2-(2-arboxyethyl)	B
arginine,	I
and	O
up	O
regulation	O
of	O
Phe-Phe.	B

The	O
concentration	O
of	O
leucine	B
enkephalin	I
was	O
200 ρ	O
M	O
and	O
the	O
flow	O
rate	O
was	O
set	O
at	O
5 μ	O
L/min.	O

The	O
amount	O
and	O
volume	O
of	O
sample	O
injected	O
into	O
LC-MS	O
can	O
affect	O
the	O
detectability	O
of	O
the	O
metabolites,	O
which	O
can	O
be	O
gauged	O
by	O
examining	O
the	O
number	O
of	O
peak	O
pairs	O
detected	O
from	O
a	O
mixture	O
of	O
the	O
same	O
sample	O
labeled	O
differentially	O
with	O
_12	O
C-	O
and	O
_13	O
C-dansyl	B
chloride.	I

Consistent	O
with	O
palmitate	B
tracer	O
data,	O
the	O
increases	O
in	O
plasma	O
glycerol	B
concentration	O
observed	O
during	O
the	O
placebo	O
trial	O
were	O
abolished	O
during	O
the	O
rHDL	O
infusion.	O

Finally,	O
428	O
different	O
lipids	O
were	O
identified,	O
namely	O
9	O
fatty	O
acyls,	O
227	O
glycerophospholipids,	B
54	O
sphingolipids,	B
15	O
sterols,	O
122	O
glycerolipids	B
and	O
1	O
prenol	B
lipid.	O

Mercapturic	O
acids	O
are	O
detoxication	O
products	O
resulting	O
from	O
glutathione	B
conjugation	O
of	O
the	O
parent	O
aldehydes,	O
or	O
in	O
the	O
case	O
of	O
benzene,	B
a	O
primary	O
metabolite,	O
benzene	B
oxide,	I
is	O
conjugated	O
with	O
glutathione	B
followed	O
by	O
dehydration	O
giving	O
SPMA.	O

They	O
found	O
the	O
decreased	O
level	O
of	O
metabolites	O
related	O
to	O
pathways	O
including	O
NO	O
synthesis,	O
energy	O
metabolism,	O
polyamine	B
synthesis,	O
and	O
levels	O
of	O
endogenous	O
antioxidants.	O

15-lipoxygenation	O
products	O
were	O
quantified	O
only	O
in	O
low	O
concentrations	O
(≤1	O
nM)	O
and	O
SPM	O
precursor	O
18-HEPE	B
was	O
<LLOQ	O
in	O
>50%	O
of	O
the	O
samples.	O

Univariate	O
analyses	O
further	O
identified	O
significant	O
changes	O
in	O
individual	O
metabolite	O
concentrations	O
between	O
baseline	O
and	O
on-treatment	O
samples	O
for	O
group	O
T+E.	O
As	O
illustrated	O
in	O
Figure	O
,	O
administration	O
of	O
the	O
everolimus	O
and	O
trastuzumab	O
combination	O
is	O
correlated	O
at	O
W1	O
with	O
an	O
increase	O
in	O
fatty	O
acids	O
and	O
acetone	B
concentrations	O
and	O
a	O
relative	O
decrease	O
in	O
acetate,	B
amino	O
acids	O
(alanine,	O
histidine,	B
lysine,	B
phenylalanine,	B
tyrosine	B
and	O
valine),	B
albumin	O
lysyl,	O
betaine,	B
creatine	B
and	O
creatinine	B
(p	O
<	O
0.05).	O

Asymmetric	B
dimethylarginine;	I
116.	O

Serum	O
metabolite	O
clusters	O
increased	O
in	O
patients	O
who	O
were	O
hospitalized	O
were	O
pyridines	B
and	O
pyrimidines,	B
sugar	O
acids,	O
sugar	O
alcohols,	O
amino	O
acids	O
and	O
sulfur	O
amino	O
acids,	O
phenylacetates,	B
disaccharides,	B
monosaccharides,	B
hexoses,	O
uronic	O
acid	O
and	O
glutarates.	B

They	O
likewise	O
discovered	O
that	O
palmitic	B
acid,	I
linoleic	B
acid,	I
stearic	B
acid	I
and	O
oleic	B
acid,	I
(all	O
16	O
or	O
18-carbon	O
chain	O
fatty	O
acids)	O
were	O
relatively	O
elevated	O
in	O
the	O
serum	O
of	O
STEMI	O
patients.	O

High	O
levels	O
of	O
tryptophan,	B
KA,	O
XA,	O
HAA	O
and	O
riboflavin	B
were	O
associated	O
with	O
lower	O
odds	O
ratio	O
for	O
ADHD.	O

Unsaturated	O
FAs	O
including	O
C18:1,	B
C18:2,	B
and	O
C20:4	B
have	O
been	O
shown	O
to	O
activate	O
protein	O
kinase	O
C	O
(PKC)	O
dependently	O
on	O
or	O
independently	O
of	O
Ca_2+	O
and	O
phospholipids	B
(Murakami	O
et	O
al.	O
),	O
and	O
might	O
be	O
involved	O
in	O
sustaining	O
parasite	O
growth.	O

In	O
addition,	O
when	O
these	O
triglyceride‐rich	O
VLDL	O
particles	O
undergo	O
further	O
lipolysis,	O
they	O
give	O
rise	O
to	O
LDL	B
cholesterol.	I

Therefore,	O
arginine	B
deprivation	O
may	O
offer	O
a	O
potential	O
treatment	O
method	O
for	O
lung	O
cancer.	O

The	O
chromatographic	O
separation	O
of	O
metabolites	O
associated	O
with	O
the	O
metabolomic	O
profiling	O
used	O
a	O
multistep	O
gradient	O
containing	O
ultra-pure	O
water	O
(mobile	O
phase	O
A)	O
and	O
acetonitrile	B
(ACN;	O
mobile	O
phase	O
B),	O
both	O
acidified	O
with	O
0.1%	O
formic	B
acid.	I

Ribavirin	B
metabolite	O
levels	O
suggest	O
that	O
its	O
monophosphate	B
is	O
in	O
great	O
excess	O
of	O
its	O
inhibition	O
constant	O
for	O
IMP	O
dehydrogenase	O
and	O
that	O
its	O
triphosphate	B
is	O
approaching	O
the	O
binding	O
constant	O
for	O
incorporation	O
by	O
the	O
HCV	O
NS5B	O
RNA-dependent	O
RNA	O
polymerase.	O

The	O
proposed	O
glucuronide	B
metabolite	O
structure	O
also	O
explains	O
the	O
absence	O
of	O
any	O
EC-array	O
signal	O
at	O
18.4	O
min	O
since	O
its	O
functional	O
groups	O
are	O
not	O
expected	O
to	O
undergo	O
redox	O
reaction	O
at	O
the	O
voltages	O
employed.	O

Association	O
between	O
genotypes	O
and	O
clinical	O
characteristics	O
ER,	O
estrogen	B
receptor;	O
PR,	O
progesterone;	B
HER2,	O
human	O
epidermal	O
growth	O
factor	O
receptor-2.	O

More	O
astonishing	O
is	O
the	O
discrepancy	O
with	O
the	O
above-mentioned	O
protective,	O
immune-modulating	O
effects	O
of	O
3'-sialyllactose	B
in	O
neonates	O
[,	O
].	O

_,	O
The	O
decrease	O
in	O
LysoPCs	O
was	O
reported	O
to	O
be	O
associated	O
with	O
body	O
weight	O
loss	O
and	O
activated	B
inflammatory	O
status	O
in	O
cancer	O
patients.	O

Nonetheless,	O
we	O
have	O
previously	O
shown	O
that	O
supplementation	O
with	O
carnosine	B
increased	O
the	O
level	O
of	O
carnosine	B
in	O
urine	O
and	O
prevented	O
worsening	O
of	O
insulin	O
sensitivity	O
in	O
non-diabetic	O
overweight	O
and	O
obese	O
adults.	O

An	O
example	O
of	O
catabolic/anabolic	O
switch	O
is	O
the	O
decrease	O
in	O
the	O
level	O
of	O
glucose	B
in	O
amniotic	O
fluid,	O
which	O
overlaps	O
with	O
increasing	O
energy	O
demand	O
during	O
the	O
pregnancy	O
progression.	O

Fragments	O
derived	O
from	O
ion	O
fragmentation	O
at	O
30	O
EV	O
match	O
the	O
amino	O
acid	O
sequence	O
of	O
fibrinogen	O
peptide	O
B	O
with	O
truncated	O
C-terminal	O
arginine	B
and	O
N-terminal	O
amino	O
acid	O
modified	O
as	O
pyroglutamate.	B

Creatinine	B
values	O
in	O
the	O
matched	O
urine	O
and	O
plasma	O
samples	O
were	O
measured	O
in	O
Helsinki-Uusimaa	O
Central	O
Hospital	O
to	O
ascertain	O
that	O
the	O
donors	O
did	O
not	O
have	O
a	O
kidney	O
defect	O
affecting	O
the	O
composition	O
of	O
urine	O
and	O
hence,	O
the	O
urinary	O
EV	O
pool.	O

The	O
negative	O
correlation	O
between	O
glycine	B
and	O
ethanolamine	B
would	O
be	O
explained	O
by	O
fluxes	O
in	O
these	O
pathways,	O
especially	O
as	O
glycine	B
and	O
serine	B
are	O
metabolically	O
interchangeable.	O

Test	O
samples	O
(0.3	O
to	O
1000	O
nM)	O
and	O
vehicle	O
(1%	O
dimethyl	B
sulfoxide	I
in	O
the	O
final	O
assay)	O
were	O
pre-incubated	O
with	O
washed	O
human	O
platelets	O
(5×10_7	O
/mL)	O
in	O
modified	O
buffer	O
(Hanks'	O
balanced	O
salt	O
solution	O
with	O
15	O
mM	O
HEPES,	O
pH	O
7.4)	O
for	O
15	O
minutes	O
at	O
37°C.	O

BaP	O
metabolites	O
are	O
mainly	O
excreted	O
in	O
feces	O
while	O
phenanthrene	B
metabolites	O
are	O
excreted	O
mainly	O
in	O
urine,	O
based	O
on	O
studies	O
in	O
laboratory	O
animals	O
(–).	O

Eluants	O
were	O
evaporated	O
to	O
dryness	O
under	O
nitrogen,	O
reconstituted	O
in	O
50	O
µl	O
of	O
30%	O
methanol	B
and	O
12	O
µl	O
was	O
injected	O
onto	O
the	O
HPLC.	O

Since	O
anastrozole	B
has	O
a	O
mean	O
terminal	O
elimination	O
half-life	O
of	O
∼50	O
h	O
in	O
postmenopausal	O
women,	O
it	O
is	O
unlikely	O
that	O
time	O
of	O
sampling	O
post	O
dose	O
will	O
have	O
a	O
significant	O
effect	O
on	O
concentrations.	O

When	O
sensitivity	O
is	O
an	O
issue,	O
some	O
reports	O
propose	O
the	O
use	O
of	O
liquid-liquid	O
extraction	O
to	O
enrich	O
the	O
sample	O
with	O
respect	O
to	O
the	O
analyte	O
and	O
eliminate	O
proteins	O
and	O
other	O
hydrophilic	B
metabolites.	O

Ammonium	B
hydrogen	I
carbonate	I
caused	O
an	O
increase	O
in	O
peak	O
tailing,	O
a	O
decrease	O
in	O
effective	O
plate	O
numbers	O
for	O
all	O
analytes	O
except	O
for	O
ZDV-TP	O
at	O
both	O
10	O
and	O
20	O
mM,	O
and	O
worsened	O
the	O
peak	O
symmetry	O
of	O
all	O
analytes	O
at	O
20	O
mM.	O
Ammonium	B
phosphate	I
at	O
2	O
mM,	O
but	O
not	O
1	O
mM,	O
increased	O
the	O
effective	O
plate	O
number	O
of	O
all	O
the	O
analytes	O
tested,	O
except	O
for	O
DXG-TP	O
and	O
appeared	O
to	O
be	O
a	O
superior	O
buffer	O
for	O
running	O
samples	O
over	O
several	O
days,	O
without	O
the	O
peak	O
shift	O
observed	O
with	O
the	O
ammonium	B
hydrogen	I
carbonate	I
buffers.	O

Ex	O
vivo	O
HR-MAS	O
spectra	O
are	O
presented	O
to	O
demonstrate	O
the	O
improved	O
spectral	O
resolution	O
over	O
conventional	O
MR	O
spectroscopy	O
through	O
the	O
separation	O
of	O
individual	O
choline-containing	O
species	O
that	O
contribute	O
to	O
the	O
in	O
vivo	O
total	O
choline	B
(tCHO)	O
peak.	O

Fraction	O
6	O
contained	O
triply	O
charged	O
desamino-PhIP-	B
and	O
desamino-[_2	B
H_5	I
]-PhIP-labeled	I
peptide	O
adducts	O
[M+3H]_3+	O
at	O
m/z	O
572.4	O
and	O
574.0.	O

Four	O
metabolites	O
including	O
lysoPC	O
a	O
C18:2,	B
lysoPC	O
a	O
C20:3,	B
lysoPC	O
a	O
C20:4	B
and	O
AC	B
C18:2	I
were	O
found	O
to	O
associate	O
with	O
all	O
three	O
groups.	O

In	O
particular,	O
medium	O
and	O
long	O
chain	O
acylcarnitines	B
have	O
been	O
associated	O
with	O
increased	O
risk.	O

When	O
dividing	O
the	O
group	O
according	O
to	O
infant	O
sex,	O
more	O
correlations	O
with	O
estrogen	B
metabolites	O
appeared	O
for	O
women	O
carrying	O
male	O
than	O
female	O
fetuses.	O

The	O
cooked	O
meat	O
carcinogen	O
PhIP	O
and	O
the	O
non-nucleoside	O
reverse	O
transcriptase	O
inhibitor	O
Nevaripine	B
also	O
form	O
adducts	O
at	O
the	O
Trp214	O
of	O
human	O
Alb	O
in	O
vitro._−	O
Since	O
rat	O
and	O
human	O
Alb	O
contain	O
only	O
a	O
single	O
tryptophan	B
residue	O
at	O
Trp214	O
situated	O
in	O
a	O
hydrophobic	O
drug-binding	O
site,	O
its	O
high	O
selectivity	O
for	O
carcinogen	O
binding	O
suggests	O
a	O
unique	O
role	O
for	O
Alb	O
in	O
the	O
detoxification	O
and/or	O
transport	O
of	O
ultimate	O
carcinogenic/toxic	O
metabolites.	O

Recently,	O
more	O
and	O
more	O
studies	O
have	O
found	O
that	O
vitamin	B
K2	I
can	O
result	O
in	O
growth	O
inhibition	O
of	O
a	O
variety	O
of	O
malignant	O
tumor	O
cell	O
growth	O
inhibition,	O
including	O
colon	O
cancer,	O
lung	O
cancer,	O
breast	O
cancer	O
cells	O
(,),	O
and	O
induce	O
the	O
apoptosis	O
of	O
liver	O
cell	O
cancer,	O
ovarian	O
cancer,	O
and	O
another	O
solid	O
tumor,	O
leukemia,	O
myelodysplastic	O
syndrome.	O

 S3	O
and	O
Table S2)	O
and	O
glycerophosphocholine	B
(Table )	O
were	O
increased	O
in	O
the	O
saliva	O
samples	O
from	O
oral	O
cancer	O
patients	O
and	O
were	O
decreased	O
in	O
the	O
other	O
groups.	O

In	O
the	O
laboratory,	O
10	O
ml	O
urine	O
samples	O
were	O
transported	O
into	O
GC	O
vials	O
that	O
were	O
previously	O
added	O
with	O
3	O
g	O
sodium	B
chloride.	I

Differentially	O
expressed	O
metabolites	O
in	O
HCC	O
subjects,	O
such	O
as	O
bile	O
acids,	O
histidine,	B
and	O
inosine	B
are	O
of	O
great	O
statistical	O
significance	O
and	O
high	O
fold	O
changes,	O
which	O
warrant	O
further	O
validation	O
as	O
potential	O
biomarkers	O
for	O
HCC.	O

The	O
increased	O
CSF	O
concentrations	O
of	O
metabolites	O
of	O
the	O
“acidic	O
pathway”	O
of	O
bile	O
acid	O
biosynthesis	O
indicate	O
that	O
this	O
pathway	O
represents	O
a	O
salvage	O
route	O
for	O
removal	O
of	O
excess	O
cholesterol	B
in	O
CNS	O
disease	O
which	O
may	O
be	O
defective	O
or	O
overstretched	O
in	O
ALS	O
and	O
PBI.	O

This	O
was	O
due	O
to	O
the	O
glutaminolysis	O
process,	O
where	O
glutamine	B
is	O
converted	O
into	O
glutamate	B
and	O
finally	O
into	O
2-oxoglutarate,	B
which	O
is	O
activated	B
in	O
IS	O
male	O
hypogonadism,	O
and	O
not	O
in	O
IR	O
hypogonadism.	O

Cobalamin	B
and	O
folate	B
deficiencies	O
also	O
yield	O
elevated	O
plasma	O
homocysteine	B
concentrations.	O

These	O
are	O
also	O
involved	O
in	O
the	O
cysteine	B
and	O
methionine	B
metabolism	O
pathway.	O

Second,	O
we	O
highlighted	O
a	O
significant	O
difference	O
in	O
the	O
concentration	O
of	O
2-furoylglycine	B
and	O
acetone	B
between	O
the	O
study	O
groups.	O

Given	O
the	O
low	O
variability	O
in	O
retention	O
time	O
values	O
across	O
columns,	O
the	O
large	O
variations	O
in	O
caffeine	B
peak	O
area	O
were	O
investigated	O
further,	O
and	O
found	O
to	O
be	O
indicative	O
of	O
spray	O
pulsing	O
into	O
the	O
ESI	O
source.	O

Reactive	O
oxygen	O
species	O
(ROS),	O
mitochondrial	O
mass	O
and	O
mitochondrial	O
membrane	O
potential	O
(ΔΨ_m	O
)	O
were	O
measured	O
using	O
2,7-dichlorofluorescein	B
diacetate	I
(5 μM,	O
Invitrogen),	O
MitoTracker	O
Green	O
FM	O
(0.3 μM,	O
Invitrogen)	O
and	O
Rhodamine	B
123	O
(5 μM,	O
Sigma)	O
fluorescent	O
probes,	O
respectively.	O

Multivariable	O
linear	O
regression	O
models	O
were	O
adjusted	O
for	O
age,	O
sex,	O
body-mass-index,	O
HbA1c,	O
low-density	O
lipoprotein	O
cholesterol	B
and	O
systolic	O
blood	O
pressure.	O

The	O
best	O
metabolite	O
pair	O
(cysteine+uridine)	O
allows	O
AD	O
prediction	O
with	O
e.g.	O
∼75%	O
sensitivity	O
and	O
∼75%	O
specificity.	O

Ammonium	B
phosphate	I
buffer	O
(1	O
and	O
2	O
mM)	O
and	O
ammonium	B
hydrogen	I
carbonate	I
(10	O
and	O
20	O
mM)	O
were	O
assayed	O
by	O
preparation	O
of	O
four	O
separate	O
buffers	O
containing	O
3	O
mM	O
HMA.	O

Only	O
ions	O
(3.65	O
min:	O
165.007	O
m/z)	O
and	O
(3.65	O
min:	O
183.018	O
m/z)	O
were	O
identified	O
as	O
imidazoleacetic	B
acid,	I
and	O
others	O
were	O
unknown	O
metabolites.	O

GPR81	O
is	O
also	O
found	O
in	O
neurons	O
of	O
the	O
cerebral	O
cortex,	O
hippocampus	O
(pyramidal	O
and	O
granule	O
cells)	O
and	O
cerebellum	O
(granule	O
cells),	O
where	O
it	O
can	O
be	O
activated	B
by	O
physiological	O
concentrations	O
(low	O
mM)	O
of	O
lactate	B
[,	O
].	O

Conditions	O
for	O
multiple	O
reaction	O
monitoring	O
(MRM)	O
were	O
optimized	O
by	O
auto-tuning	O
during	O
infusion	O
of	O
the	O
estrogen	B
metabolites	O
and	O
IS	O
(1 μg mL_−1	O
).	O

This	O
study	O
suggested	O
that	O
sarcosine	B
could	O
be	O
a	O
potential	O
prognostic	O
biomarker	O
that	O
could	O
be	O
detected	O
non-invasively	O
in	O
the	O
urine	O
and	O
may	O
be	O
a	O
useful	O
approach	O
to	O
follow	O
PCa	O
disease	O
progression.	O

For	O
GC-MS	O
analysis,	O
the	O
non-polar	O
fraction	O
was	O
treated	O
with	O
methanol	B
under	O
acidic	O
conditions	O
to	O
yield	O
the	O
fatty	O
acid	O
methyl	O
esters	O
derived	O
from	O
both	O
free	O
fatty	O
acids	O
and	O
hydrolyzed	O
complex	O
lipids.	O

Plasma	O
20-HETE	B
significantly	O
correlated	O
with	O
plasma	O
renin	O
activity	O
in	O
renovascular	O
disease	O
(r	O
_s	O
=0.67;	O
n=10;	O
P	O
<0.05).	O

In	O
this	O
context,	O
the	O
hydrolysis	O
of	O
glutamine	B
for	O
the	O
production	O
of	O
ammonia	O
and	O
glutamate	B
to	O
balance	O
the	O
pH	O
in	O
tumor	O
cells	O
could	O
explain	O
the	O
high	O
serum	O
levels	O
of	O
glutamate	B
observed	O
in	O
the	O
group	O
of	O
NSCLC	O
patients.	O

Several	O
associated	O
metabolites,	O
e.g.	O
uridine	B
in	O
plasma	O
as	O
well	O
as	O
adenosine	B
or	O
1-methylimidazole	B
in	O
urine	O
point	O
towards	O
the	O
vasodilatory	O
role	O
of	O
BNP.	O

Moreover,	O
the	O
glycolysis	O
and	O
glycine,	B
serine,	B
and	O
threonine	B
metabolism	O
were	O
activated	B
in	O
CRC.	O

Likewise,	O
methionine,	B
proline,	B
and	O
leucine	B
levels	O
were	O
significantly	O
higher	O
at	O
these	O
time-points	O
after	O
cheese	O
intake	O
although	O
an	O
increasing	O
postprandial	O
response	O
was	O
also	O
observed	O
after	O
milk	O
and	O
soy	O
drink	O
intake.	O

Plasma	O
samples	O
(300	O
μL)	O
were	O
mixed	O
with	O
cold	O
methanol	B
(1:2,	I
vol:vol)	I
in	O
1.5-mL	O
microcentrifuge	O
tubes	O
on	O
ice,	O
vortexed	O
and	O
incubated	O
at	O
–20°C	O
for	O
20	O
min,	O
and	O
centrifuged	O
at	O
14,000	O
×	O
g	O
for	O
30	O
min	O
at	O
4°C.	O

Typically	O
employed	O
reversed-phase	O
(RP)	O
methods	O
fail	O
to	O
target	O
polar	O
metabolites	O
but	O
the	O
introduction	O
of	O
hydrophilic	B
interaction	O
liquid	O
chromatography	O
(HILIC)	O
is	O
slow	O
due	O
to	O
perceived	O
issues	O
of	O
reproducibility	O
and	O
ruggedness	O
and	O
a	O
limited	O
understanding	O
of	O
the	O
complex	O
retention	O
mechanisms.	O

Further,	O
we	O
found	O
that	O
gene	O
expression	O
of	O
the	O
enzymes	O
that	O
generate	O
ceramide	B
(GBA	O
in	O
the	O
salvage	O
pathway,	O
SMPD	O
in	O
the	O
sphingomyelin	B
pathway,	O
DES1	O
in	O
the	O
de	O
novo	O
pathway,	O
and	O
ceramide	B
synthases	O
in	O
the	O
catabolic	O
pathway)	O
were	O
significantly	O
increased	O
in	O
breast	O
cancer.	O

In	O
our	O
study,	O
few	O
patients	O
were	O
taking	O
statins	B
(14.5%),	O
despite	O
the	O
higher	O
prevalence	O
of	O
dyslipidaemia	O
(41%).	O

The	O
most	O
abundant	O
hydroxy	B
PUFA	O
in	O
human	O
colorectal	O
tissue	O
samples	O
was	O
the	O
linoleic	B
acid	I
(LA)-derived	O
metabolite,	O
9-HODE.	B

Uridine	B
in	O
both	O
positive	O
and	O
negative	O
ion	O
modes,	O
phenethylamine,	B
and	O
pyridine-2,3-dicarboxylate	B
concentrations	O
were	O
significantly	O
higher	O
in	O
the	O
low–cystathionine	B
concentration	O
group	O
(P	O
<	O
0.0002).	O

The	O
instrument	O
was	O
operated	O
with	O
leucine	B
enkephalin	I
employed	O
as	O
the	O
lock-spray	O
(Waters	O
Corporation,	O
Milford,	O
USA)	O
solution	O
at	O
a	O
concentration	O
of	O
200	O
pg/µL,	O
infused	O
into	O
the	O
instrument	O
at	O
20	O
µL/min,	O
with	O
scans	O
to	O
average	O
set	O
to	O
3.	O

Serum	O
serotonin	B
levels	O
(nmol/L)	O
in	O
relation	O
to	O
circulating	O
TPH-1	O
and	O
AADC	O
Aabs.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
study	O
two	O
sulfate	B
metabolites	O
of	O
morphine	B
in	O
humans.	O

OEP	O
ingestion	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
excretion	O
of	O
homovanillic	B
acid,	I
3,4-dihydroxyphenyl	B
acetic	I
acid,	I
scopoletin,	B
protocatechuic	B
acid,	I
sinapic	B
acid,	I
3-hydroxyphenyl	B
acetic	I
acid,	I
isoferulic	B
acid,	I
caffeic	B
acid,	I
hippuric	B
acid,	I
3,3-hydroxyphenyl	B
acetic	I
acid,	I
2,5-dihydroxybenzoic	B
acid	I
and	O
2,4-dihydroxybenzoic	B
acid.	I

Total	O
cholesterol	B
and	O
LDL	B
cholesterol	I
did	O
not	O
change	O
significantly	O
after	O
pioglitazone	B
monotherapy	O
(Table	O
1).	O

Furthermore,	O
our	O
results	O
from	O
the	O
LC-MS/MS	O
metabolomics	O
analysis	O
regarding	O
hypoxanthine,	B
D-glutamic	B
acid,	I
and	O
niacinamide	B
suggest	O
that	O
these	O
metabolites	O
might	O
be	O
novel	O
biomarkers	O
associated	O
with	O
AF,	B
but	O
this	O
conclusion	O
should	O
be	O
closely	O
inspected.	O

Previously,	O
a	O
European	O
study	O
analyzing	O
genomic	O
alterations	O
in	O
promoter	O
variants	O
involved	O
in	O
bilirubin	B
homeostasis,	O
and	O
another	O
study	O
investigating	O
serum	O
bilirubin	B
levels	O
in	O
a	O
large	O
U.S.	O
population	O
have	O
proposed	O
a	O
protective	O
effect	O
of	O
bilirubin	B
against	O
colorectal	O
carcinogenesis;	O
43,	O
44	O
our	O
metabolomics	O
findings	O
carefully	O
support	O
this	O
hypothesis.	O

In	O
constrast,	O
the	O
method	O
of	O
Solfrizzo	O
et	O
al.	O
used	O
β-glucuronidase-assisted	O
hydrolysis,	O
resulting	O
in	O
increased	O
levels	O
of	O
the	O
parent	O
toxins.	B

Sample	O
pairs	O
with	O
oxysterol	B
levels	O
below	O
the	O
limit	O
of	O
quantitation	O
in	O
one	O
or	O
both	O
samplings	O
were	O
also	O
removed	O
from	O
subsequent	O
paired	O
analyses.	O

The	O
mobile	O
phase	O
consisted	O
of	O
Solvent	O
A,	O
0.1	O
%	O
(v/v)	O
formic	B
acid	I
in	O
water,	O
and	O
Solvent	O
B,	O
acetonitrile	B
containing	O
0.1	O
%	O
(v/v)	O
formic	B
acid.	I

Glutamic	B
acid	I
as	O
well	O
as	O
citric	B
acid	I
were	O
significantly	O
higher	O
in	O
PKU	O
patients	O
versus	O
controls:	O
87.6	O
versus	O
50.5 μmol/L	O
(p	O
 < 0.015)	O
and	O
186.9	O
versus	O
157.2 μmol/L	O
(	O

The	O
latter	O
might	O
be	O
likely	O
due	O
to	O
limited	O
statistical	O
power	O
since	O
more	O
recent	O
genome-wide	O
association	O
analysis	O
using	O
data	O
from	O
UK	O
Biobank	O
(N > 300k)	O
showed	O
significant	O
associations	O
(p < 5e-8,	O
retrieved	O
via	O
www.phenoscanner.medscl.cam.ac.uk	O
on	O
15/09/2019)	O
with	O
several	O
refined	O
anthropometric	O
traits,	O
in	O
particular	O
measures	O
of	O
fat-free	O
mass,	O
with	O
the	O
exact	O
same	O
missense	O
SNV	O
(rs4680)	O
as	O
has	O
been	O
used	O
to	O
annotate	O
X-11593	O
as	O
O-methylascorbate.	B

This	O
suggests	O
that	O
DKD	O
with	O
lower	O
triglycerides	B
is	O
not	O
a	O
product	O
of	O
lipid-lowering	O
treatment	O
alone.	O

The	O
human	O
colonic	O
flora	O
is	O
able	O
to	O
degrade	O
pectins,_,	O
and	O
methanol	B
is	O
released	O
into	O
the	O
blood	O
upon	O
this	O
degradation.	O

In	O
the	O
TCA	O
cycle,	O
AKG	O
is	O
produced	O
by	O
the	O
oxidative	O
decarboxylation	O
of	O
isocitrate	B
catalyzed	O
by	O
isocitrate	O
dehydrogenase	O
(IDH;	O
).	O

Phospholipids,	B
one	O
of	O
the	O
major	O
components	O
of	O
cell	O
membranes,	O
participate	O
in	O
various	O
biological	O
functions,	O
and	O
their	O
levels	O
are	O
altered	O
in	O
various	O
human	O
cancers	O
[,	O
].	O

The	O
column	O
was	O
eluted	O
isocratically	O
at	O
a	O
flow	O
rate	O
of	O
250	O
μL/min	O
with	O
5%	O
mobile	O
phase	O
A	O
(10	O
mM	O
ammonium	B
formate	I
and	O
0.1%	O
formic	B
acid	I
in	O
water)	O
for	O
1	O
minute	O
followed	O
by	O
a	O
linear	O
gradient	O
to	O
40%	O
mobile	O
phase	O
B	O
(acetonitrile	O
with	O
0.1%	O
formic	O
acid)	O
over	O
10	O
minutes.	O

Legends:	O
a:	O
-CH_3	O
of	O
fatty	O
acid;	O
b;	O
-CH_2	O
of	O
fatty	O
acid;	O
c:	O
glucose	B
(C)	O
and	O
hydroxy-ethyl	O
starch	O
(B);	O
d:	O
fumaric	B
acid;	I
1:	O
cholesterol;	B
2:	O
hydroxybutyrate;	B
3:	O
lactate;	B
4:	O
acetoacetate;	B
5:	O
pyruvate;	B
6:	O
glutamine;	B
7:	O
creatinine;	B
8	O
&	O
9:	O
aromatic	O
amino	O
acids	O
(phenylalanine	O
and	O
tyrosine).	B

A	O
deficiency	O
of	O
PC	O
in	O
the	O
secretory	O
pathway	O
or	O
in	O
the	O
nascent	O
particle	O
may	O
limit	O
the	O
secretion	O
of	O
very-low-density	O
lipoproteins	O
and	O
leads	O
to	O
the	O
accumulation	O
of	O
hepatic	O
triglycerides.	B

The	O
abundance	O
of	O
oxylipins	B
was	O
reported	O
as	O
pmol/mg	O
ApoB	O
and	O
fatty	O
acids	O
as	O
nmol/mg	O
ApoB.	O
Lipids	O
were	O
isolated	O
using	O
a	O
liquid-liquid	O
extraction	O
with	O
cyclohexane/isopropanol/ammonium	O
acetate	B
after	O
enrichment	O
with	O
a	O
suite	O
of	O
deuterated	O
and	O
rare	O
compounds	O
used	O
as	O
analytical	O
surrogates.	O

Arabinose	B
is	O
a	O
monosaccharide	B
containing	O
five	O
carbon	O
atoms	O
and	O
is	O
decomposed	O
into	O
glucose	B
and	O
fructose	B
by	O
intestinal	O
sucrose.	B

Another	O
fragment	O
ion	O
observed	O
in	O
the	O
CTS	O
total	O
product	O
ion	O
spectrum	O
occurred	O
at	O
m/z	O
241,	O
which	O
is	O
the	O
cyclic	O
phosphodiester	O
of	O
inositol.	B

Proposed	O
fragmentation	O
patterns	O
following	O
accurate	O
mass	O
analysis	O
at	O
1 μg mL_−1	O
of	O
estrogen	B
methylpiperazine	I
derivatives	O
displaying	O
common	O
mass	O
fragments;	O
(A)	O

Blood	O
glucose,	B
lactate,	B
and	O
blood	O
urea	B
nitrogen	I
were	O
measured	O
using	O
a	O
Gem	O
Premier	O
3000	O
blood	O
gas	O
analyzer	O
(Instrumentation	O
Laboratories,	O
Chicago,	O
IL).	O

Of	O
BAL	O
cell	O
counts,	O
BAL	O
eosinophils	B
correlated	O
most	O
highly	O
with	O
a	O
BAL	O
compound	O
module	O
(Figure	O
S6).	O

Fasting	O
venous	O
blood	O
samples	O
were	O
collected	O
in	O
10	O
ml	O
lithium-heparin	B
tubes	O
and	O
stored	O
at	O
4°C	O
within	O
5	O
to	O
10	O
minutes.	O

It	O
has	O
also	O
been	O
suggested	O
that	O
anesthesia	O
used	O
during	O
ECT	O
could	O
affect	O
the	O
plasma	O
levels	O
of	O
tryptophan.	B

Values	O
recorded	O
for	O
DMSO	B
controls	O
and	O
metabolite-treated	O
triplicates	O
were	O
averaged.	O

RP.	B

Methionine	B
is	O
an	O
essential	O
amino	O
acid	O
that	O
has	O
a	O
critical	O
role	O
in	O
cellular	O
metabolism.	O

For	O
more	O
details	O
and	O
potential	O
FA	B
composition	O
of	O
individual	O
MW	O
species,	O
see	O
.	O

C	O
,	O
The	O
levels	O
of	O
acetyl-CoA	B
in	O
cells	O
before	O
labeled	O
glucose	B
or	O
glutamine	B
was	O
added	O
to	O
the	O
culture	O
media.	O

In	O
our	O
study,	O
the	O
most	O
significant	O
lipids	O
altered	O
in	O
stool	O
were	O
cholesteryl	B
esters,	I
particularly	O
ChoE(18:2)	B
and	O
ChoE(20:4)	B
that	O
were	O
increased	O
in	O
CRC	O
samples.	O

In	O
light	O
of	O
low	O
correlation	O
between	O
both	O
partners'	O
biomarker	O
levels	O
(r	O
=	O
0.11	O
for	O
paracetamol	B
and	O
r	O
=	O
0.10	O
for	O
p	B
-aminophenol),	I
we	O
re-ran	O
models	O
with	O
the	O
same	O
covariates	O
including	O
the	O
urinary	O
concentrations	O
of	O
the	O
other	O
partner	O
to	O
assess	O
TTP	O
as	O
a	O
couple-dependent	O
outcome.	O

After	O
24	O
h	O
at	O
room	O
temperature,	O
a	O
significant	O
reduction	O
in	O
the	O
levels	O
of	O
NADH	B
and	O
NADPH	B
was	O
detected	O
with	O
a	O
proportional	O
increase	O
of	O
corresponding	O
oxidized	O
coenzymes.	O

POOL	O
fractions	O
were	O
dissolved	O
in	O
10	O
μL	O
of	O
DMSO-d6	O
and	O
8μl	O
was	O
loaded	O
into	O
the	O
capillary	O
probe	O
using	O
One-Minute-NMR	O
(Version	O
2.18.43)	O
automation	O
(Protasis,	O
Savoy,	O
IL)	O
controlling	O
a	O
CTC-PAL	O
autosampler	O
(LEAP	O
Technologies,	O
Carrboro,	O
NC)	O
with	O
dimethyl	B
sulfoxide-d6	I
(DMSO-d6)	O
as	O
the	O
push	O
solvent.	O

The	O
serotonin	B
pathway	O
shows	O
a	O
significant	O
decrease	O
in	O
melatonin	B
and	O
its	O
catabolite	O
N-acetyl-5-methoxytryptamine,	B
which	O
have	O
the	O
same	O
molecular	O
weight	O
and	O
thus	O
fall	O
under	O
the	O
same	O
MS	O
peak	O
(Fig.	O

AUC,	O
area	O
under	O
the	O
receiver	O
operating	O
curve;	O
HCC,	O
hepatocellular	O
carcinoma;	O
LC,	O
liver	O
cirrhosis;	O
AFP,	O
α-fetoprotein.	B

Then	O
each	O
dried	O
sample	O
was	O
reconstituted	O
in	O
200	O
μL	O
of	O
H_2	O
O/ACN	O
(75/25),	O
containing	O
0.2%	O
formic	B
acid.	I

To	O
generate	O
OP-BChE	O
in	O
human	O
plasma,	O
500	O
µl	O
of	O
human	O
plasma	O
sample	O
with	O
1%	O
protease	O
inhibitor	O
cocktail	O
(Roche	O
Applied	O
Science,	O
Germany)	O
was	O
pre-treated	O
with	O
10	O
µl	O
(10	O
µg)	O
of	O
streptavidin	O
magnetic	O
beads	O
for	O
2	O
hours	O
to	O
deplete	O
biotin	B
in	O
plasma.	O

The	O
linear	O
model	O
combination	O
of	O
the	O
two	O
significant	O
and	O
uncorrelated	O
(R	O
=	O
−0.37,	O
p	O
-value	O
=	O
0.1)	O
variables	O
valine	B
and	O
TNF-α	O
(78.4%	O
TNF-α	O
and	O
21.6%	O
valine)	B
was	O
found	O
to	O
enhance	O
significantly	O
the	O
GR	O
and	O
PR	O
discrimination,	O
yielding	O
an	O
AUROC	O
=	O
0.92,	O
a	O
Cliff’s	O
delta	O
effect	O
size	O
of	O
−0.83	O
(large	O
effect)	O
and	O
a	O
p	O
-value	O
of	O
0.004	O
(C).	O

However,	O
urine	O
levels	O
of	O
closely	O
related	O
catabolites	O
of	O
BCAAs,	O
such	O
as	O
propionylglycine	B
and	O
more	O
in	O
general	O
glycine-conjugated	O
metabolites	O
were	O
inversely	O
associated	O
with	O
VAT.	O

As	O
a	O
membrane	O
constituent,	O
sphingomyelins	B
are	O
implicated	O
in	O
transmembrane	O
signaling	O
and	O
are	O
generated	O
from	O
phosphatidylcholine	B
and	O
ceramide	B
by	O
sphingomyelin	B
synthase,	O
the	O
knockout	O
of	O
which	O
leads	O
to	O
mitochondrial	O
dysfunction	O
and	O
reduced	O
insulin	O
release.	O

After	O
centrifugation	O
at	O
4000	O
g	O
for	O
20	O
minutes,	O
the	O
supernatants	O
were	O
transferred	O
into	O
new	O
96-well	O
plates	O
and	O
diluted	O
to	O
1:10	O
with	O
IPA/acetonitrile	O
(ACN)/H_2	O
O	B
(2:1:1,	I
v:v:v).	I

The	O
mass	O
spectra	O
of	O
tryptophan	B
obtained	O
via	O
DIA	O
alone	O
or	O
with	O
IMS	O
shown	O
with	O
the	O
mass	O
chromatograms	O
in	O
also	O
demonstrate	O
the	O
improved	O
data	O
that	O
can	O
be	O
obtained	O
using	O
this	O
combination.	O

Nitrogen	B
gas	I
was	O
used	O
for	O
both	O
nebulizing	O
and	O
drying.	O

In	O
addition,	O
short	O
sleep	O
was	O
accompanied	O
by	O
elevations	O
in	O
bile	O
acids	O
and	O
the	O
major	O
bile	O
acid	O
precursor	O
7-Hoca,	O
whereas	O
the	O
diet-derived	O
cholesterol-lowering	O
phytochemical	O
β-sitosterol	B
was	O
reduced.	O

Aberrant	O
amino	O
acid	O
biosynthesis,	O
cell	O
turnover	O
regulation,	O
reactive	O
oxygen	O
species	O
neutralization	O
and	O
eicosanoid	B
pathways	O
may	O
be	O
hallmarks	O
of	O
HCC.	O

LDA	O
and	O
OPLS-DA	O
indicated	O
the	O
important	O
spectral	O
regions	O
for	O
discrimination,	O
making	O
possible	O
to	O
assign	O
the	O
metabolites	O
involved	O
in	O
the	O
skeletal	O
system	O
homeostasis,	O
as	O
follows:	O
VLDL,	O
LDL,	O
leucine,	B
isoleucine,	B
allantoin,	B
taurine	B
and	O
unsaturated	O
lipids.	O

The	O
samples	O
were	O
purified	O
by	O
solid-phase	O
extraction	O
using	O
polymeric	O
reversed	O
phase	O
cartridges,	O
and	O
then	O
phenylboronic	B
acid	I
cartridges	O
which	O
retain	O
cis	B
-hydroxy	I
groups	O
with	O
high	O
specificity.	O

We	O
further	O
found	O
a	O
role	O
for	O
the	O
intestinal	O
microbiota	O
in	O
the	O
production	O
of	O
TMAO	B
through	O
its	O
suppression	O
by	O
means	O
of	O
oral	O
broad-spectrum	O
antibiotics	O
and	O
then	O
reacquisition	O
of	O
trimethylamine	B
and	O
the	O
production	O
of	O
TMAO	B
from	O
dietary	O
phosphatidylcholine	B
after	O
the	O
withdrawal	O
of	O
antibiotics	O
and	O
subsequent	O
intestinal	O
recolonization.	O

Metyrapone	B
is	O
a	O
drug	O
used	O
for	O
the	O
diagnosis	O
of	O
adrenal	O
insufficiency	O
and	O
occasionally	O
for	O
treatment	O
of	O
Cushing's	O
syndrome.	O

We	O
therefore	O
speculate	O
that	O
higher	O
concentrations	O
of	O
ADMA	B
lead	O
to	O
increased	O
blockade	O
of	O
NOS3,	O
resulting	O
in	O
a	O
decrease	O
in	O
NO	O
availability	O
and	O
diminished	O
albuminuria	O
response.	O

Recent	O
studies	O
have	O
shown	O
that	O
high	O
rates	O
of	O
pyruvate	B
oxidation	O
augment	O
oncogene-induced	O
senescence	O
(OIS),	O
which	O
prevents	O
tumor	O
progression.	O

Previous	O
studies	O
have	O
confirmed	O
that	O
saliva	O
is	O
the	O
intraoral	O
compartment	O
that	O
retains	O
the	O
highest	O
BRB	O
anthocyanin	B
levels	O
following	O
topical	O
intraoral	O
gel	O
application.	O

Thus	O
both	O
nicotine	B
metabolites	O
correlated	O
extremely	O
well,	O
but	O
cotinine	B
correlates	O
most	O
highly	O
with	O
our	O
chemical	O
marker	O
of	O
vapour	O
phase	O
ETS	O
(3-EP),	O
supporting	O
the	O
hypothesis	O
that	O
3-EP	O
can	O
be	O
used	O
as	O
a	O
chemical	O
tracer	O
of	O
ETS.	O

Another	O
study	O
reported	O
the	O
alteration	O
in	O
the	O
OSCC	O
patients’	O
serum	O
or	O
plasma	O
levels	O
of	O
metabolites	O
associated	O
with	O
the	O
glycolytic	B
pathway,	O
especially	O
about	O
glucose	B
(,).	O

In	O
this	O
study	O
we	O
determine	O
the	O
full	O
metabolomic	O
profile	O
of	O
HK-2	O
cells	O
in	O
response	O
to	O
hyperglycemia	O
and	O
compare	O
the	O
metabolite	O
levels	O
between	O
HK-2	O
cells	O
stimulated	O
with	O
high	O
glucose,	B
osmotic	O
control,	O
and	O
serum-free	O
medium.	O

Therefore,	O
we	O
hypothesized	O
that	O
sperm	O
mtDNAcn	O
and	O
mtDNAdel	O
would	O
be	O
positively	O
associated	O
with	O
urinary	O
phthalate	B
metabolite	O
and	O
isoprostane	B
concentrations.	O

We	O
were	O
also	O
able	O
to	O
identify	O
glutamine	B
and	O
xanthurenic	B
acid	I
in	O
the	O
urine	O
samples	O
that	O
were	O
used	O
for	O
NMR	O
analysis	O
using	O
ion-exchange	O
chromatography	O
and	O
a	O
fluorometric	B
method,	O
respectively.	O

This,	O
unfortunately,	O
prevents	O
a	O
comparison	O
with	O
the	O
intriguing	O
report	O
of	O
lower	O
serum	O
indoxyl	B
sulfate	I
in	O
depressed	O
haemodialysis	O
patients	O
(compared	O
to	O
non-depressed	O
patients).	O

The	O
long	O
chain	O
fatty	O
acids	O
eicosenoate	O
(20:1n9	O
or	O
11)	O
(Discovery	O
group:	O
p	O
=	O
0.019,	O
q	O
=	O
0.28;	O
Test	O
group:	O
p	O
=	O
0.014,	O
q	O
=	O
0.12)	O
and	O
10-nonadecenoate	B
(19:1n9)	I
(Discovery	O
group:	O
p	O
=	O
0.047,	O
q	O
=	O
0.38;	O
Test	O
group:	O
p	O
=	O
0.091,	O
q	O
=	O
0.27)	O
were	O
less	O
abundant	O
in	O
PTSD	O
than	O
in	O
the	O
controls.	O

After	O
adding	O
100	O
μl	O
of	O
1-2-chlorophenylalanine	B
(0.1	O
mg/ml),	O
400	O
μl	O
of	O
anhydrous	B
ethanol,	I
and	O
100	O
μl	O
of	O
pyridine	B
to	O
the	O
urine	O
sample,	O
50	O
μl	O
of	O
ECF	O
was	O
added	O
for	O
first	O
derivatization	O
at	O
20.0	O
±	O
0.1°C.	O

bacteria	O
colon	O
model,	O
fecal	O
fermentation,	O
metabolites,	O
phenolics,	O
polyphenols,	O
stilbenoids,	B
liquid	O
chromatography	O
high	O
resolution	O
mass	O
spectrometry	O

Increased	O
levels	O
of	O
these	O
metabolites	O
as	O
well	O
as	O
lactate	B
in	O
AHF	O
patients	O
who	O
did	O
not	O
survive	O
the	O
first	O
three	O
months	O
after	O
onset	O
of	O
AHF	O
strongly	O
indicate	O
a	O
more	O
severe	O
state	O
of	O
the	O
disease	O
and	O
more	O
severe	O
systemic	O
metabolic	O
perturbations	O
in	O
this	O
group	O
of	O
AHF	O
patients,	O
compared	O
to	O
AHF	O
patients	O
who	O
survived	O
3	O
months	O
after	O
onset	O
of	O
AHF.	O

We	O
are	O
aware	O
that	O
the	O
Morisky,	O
Green,	O
and	O
Levine	O
Medication	O
Adherence	O
Scale	O
scoring	O
system	O
does	O
not	O
quantitatively	O
capture	O
adherence,	O
yet	O
we	O
consider	O
this	O
approach	O
appropriate	O
as	O
it	O
allowed	O
us	O
to	O
assess	O
tamoxifen	B
adherence	O
in	O
this	O
patient	O
group	O
with	O
a	O
high	O
proportion	O
of	O
illiteracy.	O

Here,	O
in	O
order	O
to	O
reveal	O
more	O
details	O
of	O
the	O
pathomechanism	O
of	O
DR,	O
we	O
examined	O
clinically	O
harvested	O
intraocular	O
samples	O
from	O
patients	O
with	O
DR,	O
identified	O
potentially	O
important	O
metabolites,	O
and	O
determined	O
the	O
significance	O
of	O
these	O
metabolites	O
in	O
retinal	B
cells	O
in	O
vitro	O
.	O

Decreased	O
choline	B
bioavailability	O
due	O
to	O
reduced	O
intake	O
or	O
gut	O
microbiome	O
dysbiosis	O
have	O
been	O
linked	O
to	O
NAFLD	O
and	O
therefore	O
align	O
with	O
the	O
detected	O
low	O
levels	O
of	O
glycine,	B
serine,	B
threonine	B
and	O
homoserine,	B
all	O
of	O
which	O
similarly	O
did	O
not	O
normalize	O
to	O
HC	O
levels	O
during	O
treatment.	O

500 µL	O
of	O
a	O
working	O
solution	O
containing	O
1000	O
µmol	O
L_−1	O
of	O
lactate,	B
100	O
µmol	O
L_−1	O
of	O
pyruvate,	B
acetoacetate	B
and	O
β-hydroxybutyrate	B
and	O
25	O
µmol	O
L_−1	O
of	O
succinate,	B
fumarate,	B
malate	B
and	O
α-ketoglutarate	B
was	O
prepared	O
in	O
H_2	O
O:CH_3	O
CN	O
(1:4 v/v).	O

Levels	O
of	O
distinct	O
sphingolipids	B
have	O
been	O
shown	O
to	O
have	O
predictive	O
potential	O
for	O
symptomatic	O
CAD	O
that	O
is	O
superior	O
to	O
the	O
currently	O
used	O
LDL	O
measurement,	O
underscoring	O
the	O
value	O
that	O
molecular	O
lipidomic	O
analyses	O
can	O
add	O
to	O
CAD	O
risk	O
stratification.	O

These	O
can	O
be	O
supplemented	O
with	O
additional	O
standards	O
spiked	O
post	O
extraction	O
to	O
monitor	O
for	O
matrix	O
effects	O
such	O
as	O
SIL	O
analogues	O
of	O
adenine	B
and	O
thyroxine	B
for	O
±ESI	O
RP;	B
neurotensin,	O
melatonin,	B
thyroxine	B
and	O
cortisol	B
for	O
+ESI	O
Scherzo	O
and	O
homovanillic	B
acid,	I
melatonin	B
and	O
thyroxine	B
-ESI	I
Scherzo.	O

This	O
modification	O
would	O
allow	O
for	O
tissues	O
to	O
be	O
processed	O
using	O
formalin	B
fixation,	O
minimizing	O
the	O
deviation	O
from	O
standard	O
pathology	O
practice.	O

They	O
are	O
activated	B
to	O
acyl-CoA	B
in	O
a	O
2-step	O
reaction,	O
forming	O
diacylglycerides	B
with	O
glycerol	B
3-phosphate.	I

Warburg	O
reported	O
the	O
conversion	O
of	O
glucose	B
to	O
lactic	B
acid	I
in	O
the	O
presence	O
of	O
oxygen	O
as	O
a	O
specific	O
metabolic	O
abnormality	O
of	O
cancer	O
cells(Mishra	O
and	O
Verma,	O
2010).	O

To	O
overcome	O
this	O
obstacle,	O
Mashego	O
et	O
al.,	O
have	O
generated	O
a	O
wide	O
range	O
of	O
stable	O
isotope-labeled	O
metabolites	O
from	O
Saccharomyces	O
cerevisiae	O
by	O
growing	O
them	O
in	O
medium	O
containing	O
only	O
_13	O
C	O
glucose	B
as	O
a	O
nutrient.	O

From	O
the	O
pathway	O
analysis,	O
it	O
was	O
concluding	O
that	O
glycolysis	O
results	O
in	O
the	O
breakdown	O
of	O
glucose,	B
but	O
several	O
reactions	O
may	O
be	O
responsible	O
for	O
the	O
increased	O
levels	O
of	O
glucose	B
in	O
lung	O
cancer	O
like	O
gluconeogenesis,	O
carbohydrate	O
metabolism	O
and	O
lipogenesis	O
to	O
provide	O
the	O
energy	O
in	O
the	O
form	O
of	O
glucose.	B

Isocitrate	B
levels	O
were	O
reduced	O
in	O
CRC	O
patient	O
urine	O
compared	O
to	O
that	O
of	O
HCs,	O
suggesting	O
TCA	O
cycle	O
deregulation	O
and	O
increased	O
energy	O
metabolism	O
due	O
to	O
tumor	O
cell	O
activation	O
[,	O
].	O

Current	O
monitoring	O
of	O
drug	O
metabolite	O
levels	O
for	O
guiding	O
treatment	O
are	O
limited	O
to	O
analysis	O
of	O
thioguanine	B
nucleotides	O
(TGNs)	O
in	O
erythrocytes	O
after	O
chemical	O
derivatisation.	O

Conversely,	O
significant	O
increases	O
were	O
recorded	O
for	O
D-glutamate	B
(70%).	O

The	O
final	O
volume	O
of	O
filtrate	O
ranged	O
from	O
100	O
to	O
400	O
μL.	O
Samples	O
were	O
brought	O
to	O
650	O
μL	O
by	O
addition	O
of	O
D_2	O
O,	O
130	O
μL	O
of	O
sodium	B
phosphate	I
buffer	O
(final	O
concentration	O
0.1	O
M)	O
containing	O
dimethyl-silapentane-sulfonate	B
(final	O
concentration	O
0.5	O
mM)	O
for	O
NMR	O
chemical	O
shift	O
reference	O
and	O
concentration	O
calibration,	O
and	O
10	O
μL	O
of	O
1	O
M	O
sodium	O
azide	O
to	O
prevent	O
growth	O
of	O
bacteria.	O

Citrate	B
is	O
far	O
more	O
soluble	O
in	O
water	O
than	O
in	O
MeOH,	B
suggesting	O
that	O
these	O
differences	O
in	O
recovery	O
could	O
be	O
due	O
to	O
differential	O
solubilities	O
in	O
the	O
two	O
solvents.	O

Methanol	B
was	O
used	O
as	O
the	O
organic	O
modifier	O
throughout	O
the	O
method	O
development	O
phase,	O
and	O
contained	O
one	O
of	O
nine	O
different	O
additives	O
at	O
a	O
concentration	O
of	O
0.5%	O
v/v	O
(for	O
formic	B
acid,	I
acetic	B
acid,	I
isopropylamine,	B
isobutylamine	B
and	O
isopentylamine),	O
20 mM	O
(for	O
ammonium	B
formate,	I
acetate	B
and	O
hydroxide),	B
or	O
5%	O
v/v	O
(for	O
water).	O

Given	O
that	O
a	O
number	O
of	O
nuclear	O
receptors	O
form	O
heterodimers	O
with	O
RXR	O
and	O
that	O
ligand	O
binding	O
(either	O
agonist	O
or	O
antagonist)	O
to	O
the	O
RXR	O
leads	O
to	O
modulation	O
of	O
the	O
transcriptional	O
activity	O
of	O
the	O
heterodiomers,	O
these	O
eccentric	O
cleavage	O
products	O
of	O
β-carotene	B
could	O
have	O
complex	O
global	O
effects	O
on	O
gene	O
expression.	O

Ultrafiltration	O
also	O
has	O
other	O
advantages:	O
it	O
is	O
relatively	O
quick,	O
very	O
reproducible,	O
does	O
not	O
introduce	O
unwanted	O
solvent	O
peaks	O
and	O
is	O
“safe”	O
in	O
terms	O
of	O
avoiding	O
unwanted	O
side-reactions	B
with	O
biofluid	O
metabolites.	O

Moreover,	O
a	O
study	O
investigating	O
the	O
metabolic	O
profile	O
of	O
bortezomib	O
resistance	O
in	O
cell	O
culture	O
and	O
primary	O
cells	O
showed	O
that	O
the	O
serine	B
synthesis	O
pathway	O
(SSP)	O
has	O
significantly	O
increased	O
activity	O
in	O
bortezomib	O
resistant	O
MM	O
and	O
plasmacytoid	O
lymphoma	O
cell	O
lines.	O

Data	O
acquisition	O
was	O
performed	O
through	O
a	O
parent	O
ion	O
scan	O
of	O
m/z	O
=	O
184	O
Da,	O
which	O
corresponds	O
to	O
the	O
choline	B
fragment,	O
allowing	O
the	O
MS/MS	O
detection	O
of	O
PCs,	O
SMs	O
and	O
the	O
respective	O
Lyso-forms	O
(LPCs	O
and	O
LSMs).	O

For	O
example,	O
the	O
lysophospholipid	B
1-linoleoylglycerophosphocholine	I
and	O
long-chain	O
acylcarnitines	B
such	O
as	O
decanoylcarnitine	B
decrease	O
in	O
concentration	O
with	O
increasing	O
insulin	O
resistance	O
and	O
dysglycemia.	O

Internal	O
standards	O
solution	O
for	O
plasma	O
processing	O
(plasma	O
protein	O
precipitation)	O
was	O
prepared	O
in	O
PP	O
tube	O
by	O
diluting	O
50-fold	O
in	O
MeOH	B
the	O
internal	O
standards	O
WS	O
to	O
obtain	O
a	O
final	O
concentration	O
for	O
all	O
internal	O
standards	O
of	O
40	O
ng/mL.	O

Forming	O
a	O
panel	O
of	O
selected	O
acylcarnitines	B
and	O
fatty	O
acid	O
amides,	O
it	O
was	O
possible	O
to	O
reach	O
a	O
highly	O
specific	O
and	O
sensitive	O
diagnostic	O
approach.	O

Pyruvate	B
can	O
then	O
re-enter	O
mitochondria	O
and	O
be	O
reconverted	O
to	O
oxaloacetate	B
by	O
PC	O
(the	O
pyruvate-malate	B
shuttle)	O

LC-MS/MS	O
was	O
performed	O
as	O
described	O
above	O
by	O
employing	O
HILIC	O
chromatography	O
and	O
electrospray	O
ionization	O
in	O
positive	O
mode	O
(Waters,	O
Xevo	O
TQ-Smicro	O
triple	O
quad)	O
on	O
a	O
C18	O
BEH	O
Amide	B
1.7um	O
50mmx2.1mm	O
column	O
(Waters).	O

The	O
cores	O
were	O
then	O
placed	O
directly	O
into	O
methanol.	B

ESI-MS	O
parameters	O
were	O
as	O
follows:	O
potential	O
of	O
ESI	O
source,	O
4	O
kV;	B
capillary	O
temperature,	O
315°C;	O
sheath	O
gas,	O
45	O
arbitrary	O
units;	O
auxiliary	O
gas,	O
10	O
arbitrary	O
units.	O

Moreover,	O
receiver–operator	O
curves	O
were	O
calculated	O
with	O
1-methyladenosine	B
and/or	O
alpha	O
fetal	O
protein	O
(AFP).	O

Nonetheless,	O
while	O
statistical	O
power	O
has	O
become	O
less	O
of	O
a	O
problem,	O
achieving	O
adequate	O
accuracy	O
and	O
specificity	O
for	O
the	O
estradiol	B
assays	O
remains	O
a	O
challenge.	O

The	O
levels	O
of	O
73	O
out	O
of	O
129	O
metabolites	O
were	O
significantly	O
correlated	O
with	O
eGFR	O
(Figs	O
S1–3):	O
the	O
increased	O
levels	O
of	O
urea	B
and	O
creatinine,	B
which	O
represent	O
kidney	O
function,	O
showed	O
the	O
strongest	O
correlation	O
with	O
the	O
decreased	O
level	O
of	O
eGFR,	O
whereas	O
the	O
levels	O
of	O
the	O
rest	O
of	O
metabolites	O
variably,	O
but	O
less	O
strongly,	O
correlated.	O

A	O
novel,	O
rapid,	O
and	O
a	O
reproducible	O
ion-pair	O
chromatography–tandem	O
mass	O
spectrometry	O
(MS/MS)	O
method	O
was	O
developed	O
to	O
simultaneously	O
quantify	O
the	O
intracellular	O
phosphorylated	O
metabolites	O
of	O
abacavir,	O
emtricitabine,	O
tenofovir	O
disoproxil	O
fumarate,	B
amdoxovir,	B
and	O
zidovudine,	B
as	O
well	O
as	O
four	O
natural	O
endogenous	O
dNTP.	O

We	O
used	O
Cox	O
proportional	O
hazard	O
models,	O
with	O
Barlow	O
weights	O
(to	O
account	O
for	O
the	O
over-representation	O
of	O
cases),	O
to	O
estimate	O
hazard	O
ratios	O
(HRs)	O
and	O
their	O
95%	O
confidence	O
intervals	O
(CIs)	O
for	O
risk	O
of	O
T2D.	O
A	O
crude	O
model	O
and	O
two	O
multivariable-adjusted	O
Cox	O
regression	O
models	O
were	O
fitted	O
as	O
follows:	O
a)	O
multivariable	O
model	O
1	O
(MV1),	O
adjusted	O
for	O
age	O
(years),	O
sex	O
(male,	O
female),	O
body	O
mass	O
index	O
(kg/m_2	O
),	O
intervention	O
group	O
and	O
baseline	O
fasting	O
glucose	B
(mg/dl)	O
(adding	O
a	O
quadratic	O
term	O
to	O
account	O
for	O
the	O
departure	O
from	O
linearity;	O
b)	O
MV2,	O
additionally	O
adjusted	O
for	O
the	O
TCF7L2	O
-rs7903146	O
polymorphism	O
(assuming	O
an	O
additive	O
genetic	O
model),	O
smoking	O
(never,	O
current,	O
former),	O
leisure-time	O
physical	O
activity	O
(metabolic	O
equivalent	O
tasks	O
in	O
minutes/day),	O
baseline	O
dyslipidaemia	O
(yes/no),	O
and	O
hypertension	O
(yes/no).	O

Finally,	O
cells	O
were	O
harvested	O
and	O
subjected	O
to	O
an	O
extraction	O
process	O
with	O
methanol,	B
chloroform	B
and	O
water,	O
a	O
method	O
that	O
had	O
been	O
successfully	O
applied	O
in	O
previous	O
metabolomics	O
studies.	O

Many	O
risk	O
factors	O
of	O
PD	O
such	O
as	O
aging	O
and	O
environmental	O
toxins	B
are	O
likely	O
to	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
PD	O
by	O
initiating	O
chronic	O
changes	O
throughout	O
the	O
body.	O

C	O
illustrates	O
the	O
improvement	O
in	O
separation	O
observed	O
when	O
using	O
a	O
Torus	O
Diol	B
column	O
rather	O
than	O
a	O
BEH	O
2-EP	O
column.	O

The	O
lower	O
4-OH-E_2	B
level,	O
which	O
correlated	O
with	O
TCDD	O
exposure,	O
suggests	O
that	O
TCDD	O
has	O
already	O
modified	O
4-hydroxylation.	O

In	O
conclusion,	O
a	O
potential	O
peroxidase	O
mediated	O
oxidation	O
of	O
estrogens	O
to	O
very	O
reactive	O
carcinogenic	O
quinone	B
methides	O
has	O
been	O
demonstrated	O
in	O
humans.	O

For	O
oximation,	O
40	O
µl	O
of	O
20	O
mg/ml	O
methoxyamine	B
hydrochloride	I
(Sigma-Aldrich,	O
Tokyo,	O
Japan)	O
dissolved	O
in	O
pyridine	B
were	O
mixed	O
with	O
a	O
lyophilized	O
sample,	O
before	O
being	O
shaken	O
at	O
1,200	O
rpm	O
for	O
90	O
min	O
at	O
30°C.	O

The	O
effect	O
of	O
THF	O
in	O
our	O
case	O
was	O
the	O
acceleration	O
of	O
the	O
retention	O
of	O
spironolactone	B
and	O
7-alpha-methylthiospironolactone,	B
resulting	O
in	O
a	O
cleaner	O
separation	O
from	O
canrenone	B
(Fig. ).	O

Another	O
group	O
measured	O
sarcosine	B
levels	O
in	O
the	O
supernatant	O
of	O
post-DRE	O
urine	O
of	O
17	O
PCa	O
patients	O
and	O
compared	O
them	O
with	O
the	O
values	O
in	O
biopsy-negative	O
patients.	O

Creatinine	B
was	O
used	O
as	O
an	O
internal	O
reference,	O
and	O
the	O
obtained	O
quantitative	O
values	O
were	O
expressed	O
as	O
millimoles	O
of	O
metabolite	O
per	O
mole	O
of	O
creatinine.	B

Six	O
metabolites	O
(taurine,	O
hypoxanthine,	B
valine,	B
leucine,	B
bilirubin,	B
and	O
1‐methylnicotinamide)	B
were	O
identified	O
using	O
authentic	O
standards	O
resulting	O
in	O
a	O
level	O
1	O
identification	O
according	O
to	O
the	O
Metabolomics	O
Standards	O
Initiative	O
(MSI),	O
nine	O
compounds	O
(seven	O
lysophosphatidylcholines	B
(LysoPCs)	O
and	O
two	O
lysophosphatidylethanolamines	B
(LysoPEs))	O
reached	O
MSI	O
level	O
2	O
identification,	O
and	O
14	O
compounds	O
could	O
not	O
be	O
identified	O
(unknown	O
metabolites,	O
MSI	O
level	O
4).	O

Of	O
these,	O
the	O
ratio	O
of	O
Classical	O
Oestrogens	O
to	O
Unusual	O
Metabolites	O
(CE/UM)	O
proved	O
a	O
fair	O
discriminant,	O
but	O
the	O
product	O
of	O
this	O
ratio	O
and	O
the	O
oestriol	B
ratio	O
(CE/UM	O
x	O
E3R)	O
was	O
much	O
the	O
best	O
discriminant.	O

The	O
final	O
logistic	O
model	O
included	O
five	O
plasma	O
biomarkers:	O
glutamate,	B
choline,	B
1,5-anhydro-d-glucitol,	B
betaine,	B
and	O
methylguanidine.	B

WC,	O
waist	O
circumference;	O
DBP,	B
diastolic	O
blood	O
pressure;	O
ADMA/SDMA,	O
asymmetric	O
dimethylarginine/symmetricdimethylarginine.	O

In	O
multivariable	O
linear	O
regression	O
models,	O
263	O
metabolites	O
were	O
associated	O
with	O
retinol	B
concentrations	O
at	O
p	O
 < 0.05	O
(Supplemental	O
Table _1	O
),	O
of	O
which	O
63	O
(Table )	O
were	O
significant	O
after	O
Bonferroni	O
correction	O
(p	O
 < 5.3 × 10_−5	O
).	O

Just	O
before	O
analysis,	O
100 µL	O
samples	O
were	O
thawed	O
at	O
room	O
temperature	O
following	O
by	O
mixture	O
with	O
400 µL	O
methanol,	B
intense	O
vibration	O
for	O
30 s,	O
and	O
incubation	O
at	O
4 °C	O
for	O
5 min	O
to	O
precipitate	O
the	O
protein.	O

Univariate	O
analysis	O
utilizing	O
medians	O
as	O
cut-off	O
points	O
showed	O
that	O
serum	O
enterolactone	B
levels	O
had	O
no	O
statistically	O
significant	O
association	O
with	O
CSS	O
(glucuronide:	O
hazard	O
ratio	O
(HR):	O
1.83,	O

We	O
thus	O
focused	O
on	O
cell-cell	O
adhesion	O
and	O
chromatin	B
remodeling.	O

1 μl	O
of	O
the	O
lipid	O
extract	O
was	O
analyzed	O
by	O
gas-liquid	O
chromatography	O
on	O
a	O
FOCUS	O
Thermo	O
Electron	O
system	O
using	O
a	O
Zebron-1	O
Phenomenex	O
fused	O
silica	B
capillary	O
columns	O
coupled	O
to	O
mass	O
spectrometry	O
according	O
to	O
previous	O
publication.	O

All	O
subjects	O
had	O
a	O
waist	O
circumference	O
higher	O
than	O
the	O
cut-offs	O
provided	O
by	O
ATP-III,	O
four	O
subjects	O
had	O
low	O
HDL-cholesterol	B
level,	O
two	O
subjects	O
suffered	O
from	O
hypertension,	O
three	O
subjects	O
had	O
hypertriglyceridemia,	O
and	O
two	O
subjects	O
suffered	O
from	O
impaired	O
fasting	O
glycemia	O
(IFG).	O

Ellipse	O
represents	O
Hotelling	O
T2	O
with	O
95%	O
confidence	O
in	O
score	O
plots	O
Score	O
contribution	O
for	O
hydrophilic	B
compounds	O
for	O
MS	O
group	O
versus	O
control	O
group.	O

Gram-negative-derived	O
LPS	B
interacts	O
with	O
macrophages,	O
releasing	O
proinflammatory	O
cytokines	O
such	O
as	O
TNF-alpha,	O
IL-6,	O
and	O
IL-1b.	O

A	O
Mean	O
PK	O
curves	O
of	O
diosmetin	B
measured	O
in	O
plasma	O
after	O
enzymatic	O
degradation	O
and	O
PK	O
parameters	O
obtained	O
on	O
12	O
patients	O
orally	O
treated	O
with	O
diosmin	O
450 mg	O
in	O
a	O
PK	O
study.	O

Similarly,	O
serum	O
choline	B
concentration	O
is	O
increased	O
in	O
oral	O
cancer.	O

In	O
plasma,	O
these	O
differences	O
were	O
related	O
mainly	O
to	O
increased	O
concentrations	O
of	O
several	O
lipid	O
fractions	O
and	O
lactate,	B
whereas	O
there	O
were	O
decreased	O
levels	O
of	O
several	O
amino	O
acids	O
in	O
the	O
T2DMvs.	O

With	O
the	O
availability	O
and	O
advancement	O
of	O
methods	O
such	O
as	O
NMR	O
and	O
mass	O
spectrometry,	O
several	O
other	O
nonglucose	O
metabolites	O
associated	O
with	O
insulin	O
resistance	O
have	O
been	O
identified,	O
such	O
as	O
2-hydroxybutyrate	B
(interestingly	O
also	O
linked	O
to	O
amino	O
acid	O
metabolism	O
and	O
the	O
TCA	O
cycle	O
in	O
similarity	O
with	O
3-HIB),	O
lipid	O
signalling	O
molecules,	O
and	O
fatty	O
acids	O
[,	O
].	O

The	O
dried	O
mixture	O
was	O
resolved	O
and	O
vortexed	O
with	O
50	O
μL	O
hydroxyl	O
amine	O
(10	O
mg/mL	O
pyridine)	B
agent	O
and	O
again	O
evaporated	O
to	O
dryness	O
under	O
the	O
same	O
conditions	O
as	O
before.	O

The	O
low	O
amount	O
of	O
phospholipids	B
may	O
impact	O
cellular	O
membranes	O
in	O
which	O
phospholipids	B
are	O
important	O
components.	O

Due	O
to	O
the	O
long	O
half-life	O
of	O
tamoxifen	B
and	O
to	O
ensure	O
that	O
these	O
patients	O
had	O
reached	O
steady-state	O
drug	O
levels,	O
only	O
patients	O
treated	O
for	O
at	O
least	O
80	O
days	O
were	O
included	O
in	O
the	O
study.	O

Low	O
circulating	O
24,25(OH)_2	B
D_3	O
concentration	O
could	O
reflect	O
reduced	O
non-renal	O
CYP24A1-mediated	O
25(OH)D	O
clearance,	O
instead	O
of	O
or	O
in	O
addition	O
to	O
reduced	O
renal	O
CYP24A1-mediated	O
25(OH)D_3	O
clearance.	O

Hydroxytetradecenoylcarnitine;	B
58.	O

These	O
data	O
provide	O
evidence	O
that	O
changes	O
in	O
individual	O
oxylipins	B
transported	O
in	O
TGRL	O
could	O
skew	O
the	O
nature	O
of	O
an	O
inflammatory	O
response	O
defining	O
an	O
atherogenic	O
phenotype.	O

The	O
possible	O
stoichiometry	O
of	O
the	O
citrate-	B
and	O
mannitol-borate	B
complexes	O
was	O
investigated	O
further	O
using	O
mass	O
spectrometry.	O

Furthermore,	O
Cer	B
was	O
associated	O
with	O
central	O
obesity	O
(P<0.01;	O
)	O
and	O
LMI	O
was	O
positively	O
associated	O
with	O
So1P	O
(tertile	O
1,	O
1.67±1.44×10_−2	O
ng/ml;	O
tertile	O
2,	O
4.27±3.94×10_−2	O
ng/ml;	O
tertile	O
3,	O
4.82±3.26×10_−2	O
ng/ml;	O
P<0.01,	O
tertile	O
1	O
vs.	O
3;	O
).	O

Atractyligenin	O
glucuronide	B
has	O
been	O
identified	O
in	O
the	O
urine	O
of	O
habitual	O
coffee	O
consumers	O
at	O
3	O
µg/mL	O
,	O
but	O
is	O
proposed	O
for	O
the	O
first	O
time	O
here	O
as	O
a	O
biomarker	O
of	O
coffee	O
intake.	O

The	O
same	O
trend	O
was	O
observed	O
for	O
fasting	O
concentrations	O
of	O
the	O
BCAAs	O
valine	B
(P	O
=	O
0.096),	O
leucine	B
(P	O
=	O
0.092),	O
and	O
isoleucine	B
(P	O
=	O
0.115),	O
but	O
not	O
for	O
lactate	B
and	O
β	B
-hydroxybutyrate	I
after	O
adjustment	O
for	O
confounding	O
factors.	O

As	O
expected,	O
glucose,	B
insulin,	O
and	O
HOMA-IR	O
were	O
higher	O
in	O
the	O
IGT	O
and	O
T2DM	O
groups	O
even	O
after	O
BMI	O
adjustment.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
24-oxo-26-norcholestanes	B
are	O
known	O
decarboxylation	O
products	O
of	O
24-oxocholestan-26-oic	B
acids	I
(,	O
),	O
which	O
can	O
themselves	O
be	O
formed	O
from	O
24(S	O
)	O

Then,	O
TPS	O
(3-trimethylsilylpropanesulfonate	O
sodium;	I
0.048%	O
final	O
concentration)	O
was	O
added	O
as	O
an	O
internal	O
standard.	O

Hypoxanthine	B
slightly	O
increased	O
at	O
2	O
Gy	O
but	O
decreased	O
at	O
higher	O
IR	O
exposures,	O
which	O
has	O
been	O
observed	O
in	O
the	O
urine	O
of	O
male	O
human	O
patients.	O

Moreover,	O
we	O
found	O
evidence	O
to	O
support	O
the	O
notion	O
that	O
the	O
pathophysiology	O
of	O
children	O
and	O
adolescents	O
with	O
MDD	O
was	O
different	O
from	O
that	O
of	O
adults,	O
especially	O
in	O
the	O
metabolism	O
of	O
tryptophan.	B

**	O
p	O
<	O
0.01,	O
compared	O
to	O
lung	O
cancer	O
patient;	O
_a	O
DAP	O
for	O
1,3-diaminopropane,	B
PUT	O
for	O
putrescine,	B
CAD	O
for	O
cadaverine,	B
SPD	O
for	O
spermidine,	B
SPM	O
for	O
spermine,	B
AGM	O
for	O
agmatine,	B
N	O
-PUT	O
for	O
N	B
-acetylputrescine,	I
N	O
-SPM	O
for	O
N	B
-acetylspermine,	I
N	O
-SPD	O
for	O
N	B
-acetylspermidine,	I
l-ORN	O
for	O
l-ornithine,	B
LYS	O
for	O
lysine,	B
l-ARG	O
for	O
l-arginine,	B
SAM	O
for	O
S	B
-adenosyl-l-methionine	I
and	O
GABA	B
for	O
γ-aminobutyric	B
acid.	I

Factor	O
2	O
was	O
composed	O
of	O
short	O
and	O
long	O
chain	O
ACs	O
and	O
several	O
AA	O
(C0,	O
C16,	O
C18,	O
C3,	O
C4,	O
glutamic	B
acid,	I
isoleucine,	B
leucine,	B
methionine,	B
phenylalanine,	B
tyrosine	B
and	O
valine),	B
whereas	O
factor	O
3	O
was	O
composed	O
of	O
few	O
medium	O
chain	O
ACs	O
(C12,	O
C14:1-OH,	B
C14:2,	B
C18:2).	B

Dietary	O
intake	O
of	O
phytosterols,	B
like	O
campesterol	B
and	O
β–sitosterol,	B
competitively	O
reduces	O
the	O
cholesterol	B
intestinal	O
absorption	O
efficiency	O
and	O
could	O
potentially	O
account	O
for	O
the	O
observed	O
difference	O
in	O
cholesterol.	B

In	O
plasma,	O
the	O
mean	O
recovery	O
of	O
enzalutamide	B
was	O
100%	O
with	O
a	O
CV	O
of	O
2%;	O
for	O
N-desmethylenzalutamide,	B
it	O
was	O
141%	O
with	O
a	O
CV	O
of	O
2%;	O
and	O
for	O
the	O
internal	O
standard,	O
the	O
mean	O
recovery	O
was	O
102%	O
with	O
a	O
CV	O
of	O
2%.	O

Mirroring	O
these	O
observations	O
in	O
adolescent	O
girls	O
with	O
PCOS,	O
metabolic	O
syndrome	O
risk	O
increased	O
4-fold	O
for	O
every	O
quartile	O
increase	O
in	O
testosterone	B
after	O
adjusting	O
for	O
SHBG.	O

It	O
was	O
found	O
out	O
in	O
our	O
previous	O
work	O
that	O
the	O
presence	O
of	O
a	O
20%	O
methanol	B
in	O
the	O
samples	O
improved	O
the	O
peak	O
shape	O
(avoiding	O
a	O
peak	O
tailing)	O
and,	O
by	O
that,	O
improved	O
the	O
separation	O
efficiency.	O

HCV+	O
patients	O
tend	O
to	O
be	O
hyperglycemic,	B
as	O
shown	O
in	O
and	O
as	O
has	O
been	O
discussed	O
elsewhere.	O

Other	O
modified	O
amino	O
acids	O
are	O
derived	O
from	O
the	O
muscle	O
dipeptide	O
carnosine.	B

The	O
activated	B
indium	O
powder	O
was	O
then	O
used	O
for	O
the	O
reaction.	O

On	O
the	O
other	O
hand	O
such	O
accumulation	O
may	O
inhibit	O
the	O
formation	O
of	O
long-chain	O
acyl-CoA,	B
which	O
causes	O
a	O
relatively	O
smaller	O
accumulation	O
of	O
long-chain	O
acylcarnitines	B
in	O
HCC	O
compared	O
with	O
cirrhosis.	O

Similarly,	O
a	O
change	O
in	O
lactosylceramide	B
was	O
one	O
of	O
the	O
independent	O
predictors	O
of	O
ba-PWV	O
change	O
in	O
this	O
study.	O

Cystine,	B
ornithine,	B
and	O
lysine,	B
the	O
three	O
most	O
significantly	O
correlated	O
metabolites,	O
are	O
all	O
substrates	O
for	O
the	O
cystinuria-related	O
transporter	O
rBAT/B	O
(0,	O
+)	O
AT	O
(SLC3A1/SLC7A9),	O
which	O
mediates	O
uptake	O
of	O
dibasic	O
amino	O
acids	O
at	O
the	O
intestinal	O
and	O
renal	O
membranes.	O

Our	O
data	O
show	O
sex	O
differences	O
in	O
concentrations	O
for	O
most	O
metabolites	O
even	O
after	O
adjusting	O
for	O
potential	O
confounders	O
including	O
unique	O
metabolites	O
in	O
our	O
CE-MS	O
platform	O
such	O
as	O
guanidinoacetate,	B
gamma-butyrobetaine,	B
and	O
mucate	B
that	O
may	O
contribute	O
to	O
explaining	O
the	O
biological	O
sex	O
differences.	O

Consequently,	O
functional	O
assays,	O
immunoblotting	O
and	O
immunohistochemical	O
analyses	O
to	O
evaluate	O
levels	O
and	O
distribution	O
of	O
BRB	O
anthocyanin-relevant	B
metabolic	O
enzymes	O
in	O
human	O
oral	O
tissues	O
were	O
performed.	O

In	O
chronic	O
heart	O
failure,	O
serum	O
lactate	B
was	O
not	O
predictive	O
of	O
the	O
severity	O
of	O
heart	O
failure	O
in	O
a	O
population	O
of	O
cardiac	O
transplant	O
candidates	O
.	O

For	O
instance,	O
the	O
level	O
of	O
3-hydroxybutyric	B
acid	I
in	O
urine	O
increases	O
during	O
fasting	O
and	O
can	O
range	O
from	O
0	O
to	O
200	O
µM/mM	O
creatinine,	B
with	O
the	O
maximum	O
level	O
reported	O
in	O
the	O
literature	O
(200	O
µM/mM	O
creatinine)	O
corresponding	O
to	O
healthy	O
male	O
after	O
35	O
h	O
of	O
fasting	O
.	O

Lactate	B
levels	O
were	O
significantly	O
increased	O
in	O
the	O
urine	O
samples	O
from	O
bladder	O
cancer	O
patients	O
in	O
cohorts	O
1	O
and	O
2	O
and	O
may	O
be	O
an	O
indication	O
of	O
increased	O
glycolysis	O
in	O
BCa	O
cells.	O

Although	O
an	O
initial	O
report	O
suggested	O
that	O
3-epi-25(OH)D_3	B
was	O
only	O
present	O
in	O
serum	O
from	O
infants	O
and	O
neonates,	O
subsequent	O
studies	O
have	O
now	O
confirmed	O
that	O
3-epi-25(OH)D_3	B
is	O
nearly	O
always	O
present	O
in	O
adult	O
serum.	O

The	O
following	O
were	O
purchased	O
from	O
Cayman	O
(Ann	O
Arbor,	O
MI):	O
2-AG;	O
the	O
endocannabinoid	B
receptor	O
inhibitors,	O
SR141716A	O
(Rimonabant,	O
CB1	O
inverse	O
agonist),	O
AM251	O
(CB1	O
antagonist)	O
and	O
SR144528	O
(CB2	O
inverse	O
agonist);	O
the	O
endocannabinoid	B
receptor	O
activators,	O
CP47497	O
(CB1	O
agonist),	O
AM1241	O
(CB2	O
agonist),	O

Borate-1,2	B
diol	I
complex	O
Borate-1,3	B
diol	I
complex	O

ADMA	B
also	O
acts	O
on	O
vascular	O
function	O
by	O
inhibiting	O
NO	O
synthase.	O

 0.998,	O
Q	O
_2	O
 = 0.678),	O
(B	O
)	O
capillary	O
electrophoresis–mass	O
spectrometry	O
ESI(+)	B
(R	O
_2	O
 = 0.929,	O
Q	O
_2	O
 = 0.816),	O
(C	O
)	O
liquid	O
chromatography–mass	O
spectrometry	O
ESI(+)	B
(R	O
_2	O
 =	O

As	O
anticipated,	O
the	O
presence	O
of	O
double	O
bond(s)	O
disrupts	O
the	O
continuity	O
of	O
ions	O
corresponding	O
to	O
the	O
successive	O
cleavages	O
of	O
methylene	B
groups.	O

The	O
list	O
of	O
detected	O
but	O
not	O
previously	O
quantified	O
by	O
NMR	O
compounds	O
includes:	O
2-hydroxy-3-methylpentanoic	B
acid,	I
2-methyl-3-ketovaleric	B
acid,	I
2-methylerythritol,	B
glucuronic	B
acid,	I
monomethyl	B
glutaric	I
acid,	I
N-methylhydantoin,	B
phosphorylcholine	B
and	O
scyllitol.	B

Coefficient	O
of	O
variation	O
(CV)	O
of	O
intra-	O
and	O
inter-day	O
precision	O
of	O
DG	O
species	O
determined	O
in	O
five	O
different	O
human	O
fecal	O
samples	O
by	O
FIA-FTMS/MS	O
analyzed	O
in	O
fivefold	O
Coefficient	O
of	O
variation	O
(CV)	O
of	O
intra-	O
and	O
inter-day	O
precision	O
of	O
TG	B
species	O
determined	O
in	O
five	O
different	O
human	O
fecal	O
samples	O
by	O
FIA-FTMS/MS	O
analyzed	O
in	O
fivefold	O

According	O
to	O
the	O
KEGG	O
database	O
and	O
other	O
references,	O
several	O
enzymes,	O
including	O
glutathion	B
S-transferases	O
(GSTs),	O
leucine	O
aminopeptidase	O
(LAP),	O
cyclooxygenase	O
(COX),	O
hormone-sensitive	O
lipase	O
(HSL),	O
and	O
fatty	O
acid	O
synthase	O
(FAS)	O
are	O
involved	O
in	O
the	O
biosynthesis	O
and	O
degradation	O
of	O
valine,	B
leucine	B
and	O
isoleucine.	B

Long-chain	O
FAs	O
are	O
unable	O
to	O
cross	O
the	O
inner	O
mitochondrial	O
membrane	O
without	O
esterification	O
in	O
the	O
cytosole	O
in	O
an	O
ATP-consuming	O
step	O
to	O
Acyl-S-CoA	B
followed	O
by	O
biotransformation	O
to	O
ACs	O
by	O
means	O
of	O
carnitine	O
palmitoyltransferase	O
1	O
(CPT1).	O

AAMU	O
is	O
also	O
a	O
major	O
caffeine	B
metabolite,	O
synthesized	O
by	O
N-acetyltransferase	O
2.	O

To	O
evaluate	O
linearity	O
of	O
standard	O
curves,	O
calibration	O
standards	O
were	O
prepared	O
at	O
concentrations	O
of	O
0.5,	O
1,	O
2,	O
5,	O
10,	O
20,	O
50,	O
100	O
and	O
200	O
pg/mL	O
of	O
each	O
estrogen	B
in	O
charcoal	O
stripped	O
human	O
serum,	O
except	O
for	O
4-OH-E2	B
and	O
2-OH-E2,	B
which	O
were	O
prepared	O
at	O
10	O
times	O
higher	O
concentration.	O

Hydroxyanastrozole	B
and	O
anastrozole	B
glucuronide	I
were	O
identified	O
as	O
the	O
main	O
oxidative	O
and	O
conjugated	O
metabolites	O
of	O
anastrozole	B
in	O
vitro	O
,	O
respectively.	O

As	O
our	O
findings	O
indicated	O
that	O
9-HSA	O
is	O
present	O
only	O
in	O
phospholipids,	B
in	O
the	O
next	O
series	O
of	O
experiments	O
we	O
investigated	O
the	O
phospholipid	B
fatty	O
acid	O
composition	O
of	O
normal	O
tissue	O
and	O
tumor	O
samples	O
by	O
GC/MS.	O

The	O
formation	O
of	O
E_1	O
(E_2	B
)-9-N-Ade	I
could	O
be	O
possible	O
only	O
through	O
metabolism	O
of	O
estrogens	O
to	O
quinone	B
methide	O
followed	O
by	O
its	O
interaction	O
with	O
adenine	B
from	O
DNA.	O

Additionally,	O
Kool	O
et	O
al.	O
have	O
identified	O
that	O
uric	B
acid	I
is	O
released	O
in	O
airways	O
of	O
allergen-chanllenged	O
asthmatic	O
patients	O
and	O
mice,	O
which	O
play	O
an	O
unexpected	O
role	O
in	O
initiating	O
and	O
amplifying	O
T_H	O
2	O
cell	O
immunity	O
and	O
allergic	O
inflammation	O
in	O
mice.	O

shows	O
the	O
leaning	O
effect	O
of	O
two	O
doublets	O
of	O
citrate.	B

Thirty	O
microliters	O
of	O
plasma	O
was	O
mixed	O
with	O
70	O
μL	O
of	O
ice	O
cold	O
acetonitrile:	B
methanol	B
(75:25;	O
v:v)	O
containing	O
deuterated	O
internal	O
standards	O
(	O

Furthermore,	O
as	O
women	O
are	O
turning	O
to	O
BDSs	O
for	O
relief	O
of	O
menopausal	O
symptoms	O
during	O
breast	O
cancer	O
treatments	O
(i.e.,	O
tamoxifen,	B
aromatase	O
inhibitors),	O
it	O
could	O
be	O
necessary	O
to	O
advise	O
women	O
with	O
cancer	O
against	O
the	O
consumption	O
of	O
certain	O
BDSs	O
containing	O
isoflavones	B
that	O
induce	O
the	O
undesirable	O
estrogen	O
4-hydroxylation	O
pathway.	O

Thanks	O
to	O
the	O
high	O
mass	O
accuracy	O
of	O
the	O
Orbitrap	O
analyses,	O
we	O
identified	O
the	O
peak	O
detected	O
before	O
GM3	B
in	O
the	O
optic	O
nerve	O
and	O
brain,	O
previously	O
revealed	O
in	O
HPTLC,	O
as	O
GM4,	O
a	O
gala-series	O
GG.	O

The	O
use	O
of	O
metformin,	B
sulfonylurea	B
and	O
antihypertensive	O
medication	O
was	O
allowed,	O
but	O
insulin	O
use	O
was	O
an	O
exclusion	O
criterion.	O

The	O
following	O
ISs	O
were	O
utilized:	O
16:0/16:0	O
PC-d6	O
(33.3	O
μM),	O
tripalmitin-1,1,1-_13	B
C_3	O
(3.3	O
μM),	O
deuterated	O
PGE_2	O

However,	O
when	O
compared	O
to	O
a	O
T_2	O
filter	O
with	O
the	O
same	O
total	O
duration	B
with	O
shorter	O
spin	O
echoes,	O
the	O
CPMG	O
presat	O
with	O
longer	O
spin	O
echoes	O
leads	O
to	O
sensitivity	O
losses	O
for	O
most	O
of	O
the	O
peaks	O
(from	O
10%	O
to	O
more	O
than	O
50%	O
in	O
our	O
data	O
set),	O
along	O
with	O
line	O
shape	O
distortion	O
for	O
some	O
peaks	O
that	O
is	O
caused	O
by	O
J-modulation	O
that	O
is	O
not	O
completely	O
suppressed	O
by	O
CPMG	O
presat	O
(e).	O

Plasma	O
α	B
-hydroxybutyrate	I
and	O
BCAAs	O
were	O
increased	O
throughout	O
the	O
course	O
of	O
the	O
OGTT	O
in	O
this	O
group	O
(P	O
<	O
0.03).	O

The	O
amino	O
acids	O
associated	O
with	O
BMI	O
include	O
two	O
neurotransmitters	O
(glutamate,	O
and	O
glycine),	B
three	O
neurotransmitter	O
precursors	O
(histidine,	O
tyrosine,	B
and	O
phenylalanine),	B
and	O
kynurenine,	B
which	O
has	O
neuroactive	O
properties.	O

Apart	O
from	O
that,	O
lysine	B
is	O
an	O
activator	O
of	O
GPRC6A,	O
the	O
OCN	O
receptor.	O

Subsequently,	O
the	O
alanine	O
aminotransferase	O
transfers	O
the	O
amino	B
group	O
from	O
glutamate	B
to	O
pyruvate,	B
which	O
arises	O
from	O
glycolysis.	O

Although	O
knowledge	O
of	O
triatomine	O
physiology	O
is	O
fragmented	O
among	O
insect	O
vector	O
species,	O
R.	O
prolixus	O
digestion	O
has	O
been	O
studied	O
for	O
many	O
years,	O
and	O
the	O
activities	O
of	O
several	O
cysteine	B
and/or	O
aspartic	B
proteinases	O
have	O
been	O
identified	O
in	O
the	O
posterior	O
midgut	O
,	O
,	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
reveal	O
the	O
underlying	O
mechanisms	O
of	O
how	O
ceramide	B
and	O
sphingolipid	B
homeostasis	O
affect	O
oncologic	O
processes	O
in	O
breast	O
cancer	O
patients.	O

The	O
effect	O
on	O
Glyc-ER-GFP	B
was	O
further	O
enhanced	O
by	O
the	O
addition	O
of	O
uridine	B
to	O
the	O
culture	O
medium,	O
which	O
resulted	O
in	O
essentially	O
normal	O
glycosylation	O
of	O
this	O
test	O
protein.	O

Tamoxifen	B
efficacy	O
in	O
breast	O
cancer	O
is	O
suspected	O
to	O
depend	O
on	O
adherence	O
and	O
intact	O
drug	O
metabolism.	O

(A)	O
Positive	O
ion	O
mode	O
TOF	O
MS	O
reveals	O
two	O
distinct	O
peaks	O
at	O
m/z	O
794.5695	O
and	O
at	O
m/z	O
794.6058	O
suggesting	O
the	O
presence	O
of	O
both	O
PC	B
37:5	I
and	O
PC	B
O-38:5,	I
based	O
on	O
their	O
masses;	O
(B)	O
Positive	O
ion	O
mode	O
MS/MS	O
of	O
the	O
precursor	O
ion	O
(m/z	O
794.6)	O
confirms	O
the	O
presence	O
of	O
PC,	O
based	O
on	O
the	O
detection	O
of	O
the	O
phosphoryl	B
choline	I
head	O
group	O
(m/z	O
at	O
184.0731),	O
but	O
simultaneously	O
reveals	O
the	O
presence	O
of	O
PE	O
species	O
based	O
on	O
the	O
detection	O
of	O
the	O
mass	O
at	O
m/z	O
653.5548,	O
corresponding	O
to	O
the	O
NL	O
of	O
the	O
PE	O
head	O
group;	O
(C)	O
Negative	O
ion	O
mode	O
MS/MS	O
of	O
the	O
precursor	O
ion	O
monitored	O
as	O
an	O
acetate	B
adduct	O
(m/	O
z	O
852.7),	O
detects	O
the	O
underlying	O
acyl	O
anions.	O

Two	O
amino	O
acids	O
detected	O
in	O
aMCI	O
patients,	O
arginine	B
and	O
cysteine,	B
were	O
significantly	O
different	O
from	O
normal	O
controls	O
(q	O
<	O
0.2	O
and	O
p	O
<	O
0.05),	O
whereas	O
other	O
amino	O
acid	O
levels	O
did	O
not	O
significantly	O
differ	O
between	O
patients	O
with	O
aMCI	O
and	O
normal	O
controls.	O

Urea	B
was	O
removed	O
from	O
the	O
urine	O
data	O
set	O
because	O
its	O
signal	O
is	O
compromised	O
by	O
the	O
NOESY	O
pulse	O
sequence.	O

In	O
the	O
present	O
report,	O
we	O
show	O
the	O
success	O
of	O
HPLC-ICPQQQMS	O
for	O
the	O
simultaneous	O
determination	O
of	O
two	O
major	O
sulfur	O
metabolites,	O
taurine	B
and	O
sulfate,	B
in	O
human	O
urine	O
and	O
serum,	O
by	O
direct	O
injection	O
without	O
the	O
need	O
for	O
sample	O
clean-up.	O

It	O
plays,	O
in	O
addition	O
to	O
general	O
protein	O
synthesis,	O
critical	O
roles	O
in	O
important	O
human	O
metabolic	O
processes,	O
including	O
transmethylation	O
reactions,	O
the	O
tetrahydrofolate	B
associated	O
1-carbon	O
metabolism,	O
and	O
as	O
a	O
precursor	O
for	O
other	O
sulfur	O
compounds.	O

Of	O
105	O
primary	O
metabolites,	O
6	O
(5.7%)	O
compounds	O
were	O
present	O
at	O
significantly	O
different	O
levels	O
in	O
the	O
SLE	O
groups	O
as	O
compared	O
to	O
healthy	O
pregnant	O
controls,	O
namely	O
2-deoxytetronic	B
acid,	I
erythritol,	B
pyruvic	B
acid,	I
uric	B
acid,	I
valine,	B
xylose	B
(Mann-Whitney	O
U	O
test,	O
p	O
value < 0.05).	O

Moreover,	O
Marchesi	O
et	O
al	O
has	O
observed	O
reduced	O
butyrate,	B
acetate,	B
methylamine	B
and	O
trimethylamine,	B
accompanied	O
by	O
elevated	O
quantities	O
of	O
amino	O
acids	O
in	O
the	O
feces	O
of	O
inflammatory	O
bowel	O
disease	O
(IBD)	O
patients.	O

_,	O
There	O
was	O
no	O
statistically	O
significant	O
correlation	O
coefficients	O
with	O
the	O
mercapturic	B
acid	I
metabolites	O
of	O
1,3-butadiene	B
(MHBMA	O
and	O
DHBMA,	O
ρ	O
=	O
0.349	O
and	O
0.392,	O
respectively)	O
or	O
benzene	B
(SPMA,	O
ρ	O
=	O
0.158).	O

The	O
results	O
were	O
within	O
7.5%	O
of	O
nominal	O
abiraterone	B
concentrations	O
of	O
5,	O
300	O
and	O
400	O
ng/mL.	O
Vice	O
versa	O
Pittsburgh	O
exchanged	O
one	O
blinded	O
set	O
of	O
QCs	O
with	O
our	O
laboratory	O
at	O
three	O
concentration	O
levels	O
which	O
we	O
analyzed.	O

Detection	O
of	O
intracellular	O
reactive	O
oxygen	O
species	O
(ROS)	O
by	O
dihydroethidium	B
(DHE)	O
assay	O
in	O
human	O
primary	O
hepatocytes	O
(HepatoCells)	O
and	O
cancer	O
cells	O
(MDA-MB-231	O
and	O
T47D)	O
on	O
exposure	O
to	O
SN-38	O
(500	O
nM)	O
or	O
drug-free	O
medium	O
(control)	O
for	O
2	O
hours.	O

A	O
mixture	O
of	O
internal	O
RI	B
markers	O
was	O
prepared	O
by	O
combining	O
equal	O
volumes	O
of	O
5	O
mg	O
mL_−1	O
chloroform	B
stock	O
solutions	O
of	O
thirteen	O
normal	O
alkanes	O
with	O
carbon	O
chain	O
lengths,	O
C8,	O
C9,	O
C10,	O
C12,	O
C14,	O
C16,	O
C18,	O
C20,	O
C22,	O
C24,	O
C26,	O
C28,	O
and	O
C30.	O

lists	O
the	O
oxysterols	B
identified	O
in	O
this	O
study.	O

In	O
the	O
condition	O
of	O
a	O
1:3	O
ratio,	O
300 μL	O
of	O
either	O
methanol	B
or	O
ethanol	B
was	O
added	O
to	O
100 μL	O
of	O
plasma;	O
whereas	O
in	O
the	O
setting	O
of	O
a	O
1:9	O
ratio,	O
900 μL	O
of	O
methanol	B
or	O
ethanol	B
was	O
added	O
to	O
100 μL	O
of	O
plasma.	O

Both	O
extraction	O
methods	O
tend	O
to	O
overestimate	O
1α,25(OH)_2	B
D_3	O
levels	O
while	O
precision	O
is	O
slightly	O
better	O
with	O
SPE,	O
which	O
corresponds	O
to	O
the	O
data	O
obtained	O
by	O
direct	O
comparison	O
of	O
both	O
techniques.	O

The	O
cartridge	O
was	O
conditioned	O
with	O
1ml	O
of	O
methanol	B
followed	O
by	O
equilibration	O
with	O
1ml	O
of	O
distilled	O
water.	O

In	O
another	O
study	O
of	O
Phe	O
metabolism	O
in	O
346	O
smokers	O
who	O
were	O
genotyped	O
for	O
11	O
polymorphisms	O
in	O
genes	O
involved	O
in	O
PAH	O
metabolism,	O
including	O
GSTM1	O
,	O
we	O
found	O
that	O
the	O
combination	O
of	O
CYP1A1I462V	O
and	O
GSTM1	O
null	O
resulted	O
in	O
significantly	O
higher	O
levels	O
of	O
the	O
ratio	O
of	O
Phe-tetraols	O
to	O
3-hydroxy-Phe,	B
an	O
indicator	O
of	O
metabolic	O
activation	O
capacity.	O

()	O
For	O
example,	O
altered	O
glycerophospholipids,	B
such	O
as	O
increased	O
phosphoethanolamine	B
levels,	O
were	O
reported	O
to	O
be	O
predictive	O
biomarkers	O
of	O
NAFLD	O
progression.	O

Of	O
interest	O
are	O
the	O
elevated	O
levels	O
of	O
2-(2-phenylacetoxy)propionylglycine	B
in	O
the	O
progressive	O
patients.	O

The	O
following	O
urinary	O
phthalate	B
and	O
DINCH	O
metabolites	O
and	O
were	O
analyzed:	O
Mono(2-ethylhexyl)	B
phthalate	I
(MEHP);	O
Mono(2-ethyl-5-hydroxyhexyl)	B
phthalate	I
(MEHHP);	O
Mono(2-ethyl-5-oxohexyl)	B
phthalate	I
(MEOHP);	O
Mono(2-ethyl-5-carboxypentyl)	B
phthalate	I
(MECPP);	O
Monocarbxyisooctyl	B
phthalate	I
(MCOP);	O
Mono-isononyl	B
phthalate	I
(MNP);	O
Monobenzyl	B
phthalate	I
(MBzP);	O
Mono	O
(3-carboxypropyl)	O

Although	O
only	O
a	O
few	O
reports	O
have	O
reported	O
a	O
decrease	O
in	O
guanidoacetic	B
acid	I
level	O
in	O
disease,	O
low	O
homoarginine	B
concentration	O
is	O
reported	O
to	O
be	O
associated	O
with	O
myocardial	O
dysfunction	O
[,	O
]	O
and	O
renal	O
failure	O
[,	O
],	O
and	O
also	O
affects	O
the	O
production	O
of	O
vasodilator	O
nitric	B
oxide	I
(NO)	O
and	O
mineral	O
metabolism.	O

This	O
may	O
also	O
have	O
relevance	O
to	O
energy	O
metabolism	O
as	O
phosphorylated	B
creatine	I
synthesized	O
primarily	O
by	O
the	O
liver	O
and	O
kidneys	O
is	O
taken	O
up	O
by	O
peripheral	O
tissues	O
and	O
serves	O
as	O
a	O
reservoir	O
for	O
rapid	O
generation	O
of	O
adenosine-triphosphate	B
(ATP)	O
to	O
satisfy	O
acute	O
elevations	O
in	O
local	O
energy	O
needs.	O

The	O
latter	O
compound	O
and	O
indolyl	O
3-acetic	O
acid	O
are	O
direct	O
precursors	O
of	O
indolylacrylol	O
glycine,	B
found	O
elevated	O
in	O
ASD	O
by	O
some	O
but	O
not	O
all	O
studies	O
[,	O
].	O

The	O
predictive	O
values	O
of	O
C18:2	B
CE	O
and	O
SM	O
22:0	O
were	O
analyzed	O
in	O
the	O
validation	O
samples.	O

In	O
support	O
of	O
this	O
notion,	O
others	O
have	O
found	O
that	O
hyperglycemia	O
increases	O
superoxide	B
production	O
in	O
endothelial	O
cells	O
by	O
oversupply	O
of	O
respiratory	O
chain	O
reducing	O
equivalents	O
and	O
elevated	O
Δψ	O
.	O

We	O
employed	O
ultra-performance	O
liquid	O
chromatography	O
tandem	O
mass-spectrometry	O
(UPLC-MS/MS)	O
for	O
the	O
quantitation	O
of	O
metabolites	O
creatine	B
riboside	I
(CR),	O
N	B
-acetylneuraminic	I
acid	I
(NANA),	O
cortisol	B
sulfate,	I
and	O
a	O
lipid	O
molecule	O
designated	O
as	O
561+	O
in	O
urine	O
samples	O
from	O
the	O
NCI-MD	O
cohort	O
comprising	O
98	O
hepatocellular	O
carcinoma	O
(HCC)	O
cases,	O
101	O
high-risk	O
subjects	O
and	O
95	O
controls.	O

Cotinine	B
is	O
a	O
known	O
marker	O
for	O
exposure	O
to	O
cigarette	O
smoke,	O
and	O
other	O
metabolites	O
are	O
known	O
food	O
markers	O
such	O
as	O
caffeine	B
and	O
theobromine	B
for	O
coffee	O
consumption.	O

Eleven	O
metabolites	O
i.e.	O
lactic	B
acid	I
(CAS	O
#	O
79-33-4),	O
phosphoric	B
acid	I
(CAS	O
#	O
7664-38-2),	O
benzoic	B
acid	I
(CAS	O
#	O
2078-12-8),	O
naphthalene	B
(CAS	O
#	O
29422-13-7),	O
d-glucose	B
(CAS	O
#	O
128705-73-7),	O
altrose	O
(CAS	O
#	O
1990-29-0),	O
palmitic	B
acid	I
(CAS	O
#	O
64519-82-0),	O
octadecanoic	B
acid	I
(CAS	O
#	O
1188-75-6),	O
stearic	B
acid	I
(CAS	O
#	O
57-11-4),	O
1-propene	O
(CAS	O
#	O
1000154-23-3)	O
and	O
cholesterol	B
(CAS	O
#	O
1856-05-9),	O
out	O
of	O
32	O
low	O
molecular	O
weight	O
metabolites	O
were	O
putatively	O
identified	O
(level	O
2	O
of	O
Metabolomics	O
Standard	O
Initiative	O
for	O
the	O
identification)	O
by	O
comparing	O
the	O
mass	O
spectra	O
of	O
the	O
peaks	O
with	O
those	O
available	O
in	O
the	O
NIST	O
mass	O
spectral	O
(Wiley	O
registry	O
NIST	O
11)	O
and	O
Fiehn	O
RTL	O
libraries	O
at	O
70%	O
similarity	O
index,	O
while	O
the	O
remaining	O
were	O
not	O
identified	O
at	O
this	O
similarity	O
index.	O

Demographic	O
Details	O
and	O
CSF	O
and	O
Serum	O
Glucose	B
Levels	O
of	O
Patients	O
Due	O
to	O
an	O
overrepresentation	O
of	O
females	O
in	O
the	O
healthy	O
volunteer	O
group	O
we	O
examined	O
the	O
effect	O
of	O
gender	O
on	O
the	O
metabolite	O
profile,	O
but	O
did	O
not	O
find	O
a	O
gender-specific	O
effect	O
(see	O
).	O

In	O
fact,	O
despite	O
the	O
different	O
expression	O
of	O
NHL	O
seen	O
in	O
the	O
subject	O
population,	O
the	O
first	O
step,	O
reaction	O
of	O
estrogen	B
quinone	I
with	O
DNA,	O
in	O
the	O
initiation	O
of	O
NHL	O
is	O
hypothesized	O
to	O
be	O
the	O
same.	O

PtdCho;	O
9.Glycerol;	B
10.Glucose;	B
11.Proline;	B
12.Leu/Ile;	O
13.	O

The	O
leukotrienes,	O
hydroxyl-fatty	O
acids,	O
epoxy-fatty	O
acids	O
and	O
lipoxins	B
were	O
analysed	O
by	O
high-performance	O
liquid	O
chromatography	O
(Agilent	O
1260,	O
San	O
Jose,	O
CA,	O
USA)	O
coupled	O
to	O
a	O
triple-quadrupole	O
mass	O
spectrometer	O
(Agilent	O
6460,	O
San	O
Jose,	O
CA,	O
USA),	O
using	O
an	O
Ascentis®	O
Express	O
column	O
(2.7 μm,	O
2.1 × 150 mm)	O
as	O
detailed	O
in	O
Strassburg	O
et	O
al..	O

(a)	O
Evaluation	O
of	O
ELOVL5	O
activity	O
using	O
C20:2n-6	B
to	O
C18:2n-6	B
ratio,	O
(b)	O
ELOVL6	O
activity	O
using	O
C18:0	B
to	O
C16:0	B
ratio,	O
(c)	O
FADS2	O
activity	O
using	O
C18:3n-3	B
to	O
C18:2n-6	B
ratio,	O
(d)	O
SCD1	O
activity	O
using	O
C16:1	B
to	O
C16:0	B
ratio	O
and	O
(e)	O
FADS1	O
activity	O
using	O
C20:4n-6	B
to	O
C20:3n-6	B
ratio.	O

(R2X = 0.66,	O
R2Y = 0.47,	O
Q2Y = 0.31,	O
sensitivity-60 %,	O
specificity-100 %)	O
as	O
the	O
cirrhosis	O
group	O
had	O
higher	O
1-methylnicotinamide	B
with	O
lower	O
hippurate,	B
acetate,	B
phenylacetylglycine	B
and	O
N-methyl	B
nicotinic	I
acid	I
levels.	O

In	O
total,	O
140	O
of	O
159	O
serum	O
metabolites	O
had	O
stable	O
concentrations	O
on	O
CP	O
for	O
at	O
least	O
24	O
h.	O
19	O
metabolites	O
showed	O
significant	O
changes	O
in	O
serum	O
concentration	O
during	O
storage	O
on	O
CP	O
within	O
the	O
first	O
24	O
h.	O
14	O
metabolite	O
concentrations	O
increased	O
significantly	O
with	O
time	O
(,	O
,	O
,	O
,	O
and	O
17),	O
whereas	O
five	O
metabolite	O
concentrations	O
decreased	O
significantly	O
(arginine,	O
putrescine*,	O
serotonin*,	O
spermidine*	O
and	O
hexose).	O

A	O
different	O
clustering	O
of	O
metabolites	O
was	O
associated	O
with	O
a	O
different	O
disease	O
outcome,	O
with	O
significantly	O
lower	O
levels	O
of	O
isovalerylsarcosine	O
observed	O
in	O
patients	O
with	O
chronic	O
articular	O
pattern	O
(median,	O
77.0AU/ml)	O
compared	O
with	O
monocyclic	B
(341.5AU/ml,	O
p<0.01)	O
or	O
polycyclic	B
systemic	O
pattern	O
(168.0AU/ml,	O
p<0.05).	O

In	O
our	O
study,	O
baseline	O
xanthine	B
levels	O
and	O
xanthine-to-hypoxanthine	O
ratio	O
were	O
correlated	O
with	O
higher	O
HOMA-IR	O
levels.	O

We	O
used	O
a	O
VIP	O
value ≥ 1.5,	O
a	O
P	O
value < 0.01,	O
and	O
an	O
FDR < 0.05	O
to	O
screen	O
the	O
metabolites,	O
and	O
5	O
identical	O
metabolites	O
(creatinine,	O
D-glutamic	B
acid,	I
choline,	B
hypoxanthine,	B
and	O
niacinamide)	B
in	O
the	O
samples	O
from	O
the	O
two	O
groups	O
were	O
filtered	O
(Supplementary	O
Table _S1	O
and	O
_S2	O
).	O

The	O
plasma	O
metabolic	O
biomarkers	O
(the	O
binary	O
logistic	O
regression	O
function	O
of	O
tryptophan	B
and	O
lysoPC	O
22:5)	O
and	O
sFlt-1/PlGF	O
according	O
to	O
pregnancy	O
outcomes	O
in	O
women	O
with	O
SLE.	O

Along	O
with	O
the	O
traditional	O
method	O
of	O
normalising	O
biomarker	O
data	O
with	O
creatinine	B
(i.e.	O
ratio	O
of	O
biomarker	O
to	O
creatinine	B
concentration),	O
we	O
tested	O
also	O
the	O
method	O
proposed	O
by	O
.	O

A	O
further	O
3.0	O
%	O
(n	O
=	O
266)	O
of	O
the	O
spectra	O
were	O
selected	O
from	O
the	O
remainder	O
of	O
the	O
9,000	O
spectra	O
and	O
all	O
266	O
spectra	O
were	O
confirmed	O
not	O
to	O
have	O
ibuprofen	B
metabolites.	O

Therefore,	O
1,5‐AG	B
has	O
been	O
used	O
as	O
a	O
short‐term	O
biomarker	O
of	O
DM,_19	O
,	O
_20	O
,	O
_21	O
which	O
is	O
a	O
well‐known	O
risk	O
factor	O
for	O
pancreatic	O
cancer._22	O
,	O
_23	O
,	O
_24	B
1,5‐AG,	I
which	O
is	O
a	O
biomarker	O
of	O
DM,	O
showed	O
a	O
statistically	O
significant	O
difference	O
between	O
cases	O
and	O
controls	O
in	O
the	O
present	O
study	O
(Table	O
),	O
but	O
did	O
not	O
show	O
an	O
apparent	O
association	O
with	O
the	O
risk	O
of	O
pancreatic	O
cancer	O
(Table	O
).	O

The	O
possible	O
metabolic	O
pathways	O
of	O
P	O
and	O
IP	B
by	O
human	O
intestinal	O
bacteria.	O
P-1:	O
C_11	O
H_10	O
O_4	O
,	O
white	O
powder.	O

The	O
base	O
line	O
and	O
phase	O
were	O
manually	O
corrected	O
and	O
referenced	O
to	O
internal	O
lactate	B
peaks	O
at	O
4.12	O
ppm.	O

Fasting	O
plasma	O
glucose	B
was	O
similar	O
in	O
both	O
groups,	O
but	O
serum	O
insulin	O
was	O
higher	O
in	O
PCOS	O
subjects	O
with	O
a	O
median	O
of	O
16.6	O
versus	O
3.2	O
mU/l	O
(range	O
5.2–26.7	O
versus	O
1–19	O
mmHg,	O
p	O
<0.001).	O

The	O
results	O
of	O
the	O
PLS-DA	O
model	O
using	O
six	O
metabolites	O
(glycine,	O
valine,	B
methionine,	B
citrulline,	B
arginine	B
and	O
C16-carnitine)	B
identified	O
from	O
the	O
2017	O
data	O
set	O
are	O
presented	O
in	O
.	O

In	O
the	O
present	O
study,	O
we	O
clearly	O
demonstrated	O
that	O
ceramide	B
levels	O
were	O
increased	O
to	O
the	O
highest	O
levels	O
within	O
cancer	O
and	O
IF	O
and	O
to	O
lower	O
levels	O
within	O
the	O
surrounding	O
normal	O
breast	O
tissue,	O
serum,	O
or	O
plasma.	O

We	O
also	O
acknowledge	O
that	O
linking	O
metabolic	O
data	O
such	O
as	O
these	O
to	O
taxanomic	B
data	O
is	O
statistically	O
challenging	O
using	O
clinical	O
sample	O
sets.	O

NBUP-Gluc	O
was	O
diluted	O
1:4	O
with	O
blank	O
urine	O
and	O
reanalyzed	O
to	O
achieve	O
a	O
final	O
concentration	O
of	O
1,356.4	O
ng/mL	O
Liquid	O
chromatography–tandem	O
mass	O
spectrometry	O
(LCMSMS)	O
calibration	O
data	O
for	O
buprenorphine,	B
norbuprenorphine,	B
and	O
conjugated	O
metabolites	O
in	O
urine	O
(N	O
=7	O
curves)	O

Two	O
transitions	O
per	O
vitamin	B
D	I
metabolite	O
along	O
with	O
one	O
transition	O
per	O
internal	O
standard	O
were	O
monitored:	O
25(OH)D_3	O
:	O
m/z	O
383	O
→	O
m/z	O
365	O
and	O
m/z	O
383	O
→	O
m/z	O
105;	O
25(OH)D_3-	O
d	O
_6	O
:	O
m/	O
z	O
389	O
→	O
m/z	O
371;	B
3-epi-25(OH)D_3	I
:	O
m/z	O
383	O
→	O
m/z	O
365	O
and	O
m/z	O
383	O
→	O
m/z	O
105;	B
3-epi-25(OH)D_3-	I
d	I
_3	O
:	O
m/	O
z	O
386	O
→	O
m/z	O
368;	O
25(OH)D_2	O
:	O
m/	O
z	O
395	O
→	O
m/z	O
377	O
and	O
m/	O
z	O
395	O
→	O
m/z	O
209;	O
25(OH)D_2-	O
d	O
_3:	O
m/z	O
398	O
→	O
m/z	O
380.	O

Transthyretin	B
are	O
well	O
known	O
that	O
it	O
plays	O
an	O
important	O
role	O
in	O
the	O
transport	O
of	O
thyroxine	B
and	O
retinol	B
from	O
maternal	O
to	O
fetal	O
circulation.	O

Consistent	O
with	O
previous	O
studies,	O
our	O
data	O
demonstrated	O
lower	O
levels	O
of	O
choline-containing	O
metabolites	O
including	O
choline,	B
phosphocholine,	B
and	O
glycerophosphocholine	B
in	O
the	O
serum	O
of	O
lung	O
cancer	O
patients	O
compared	O
to	O
healthy	O
controls.	O

	O
Stability	O
of	O
the	O
stock	O
solutions	O
in	O
DMSO	B
was	O
tested	O
at	O
−40°C.	O

Seventy-six	O
different	O
phosphatidylcholines	B
(PC),	O
18	O
lyso-phosphatidylcholines	B
(L-PC)	O
and	O
15	O
sphingomyelins	B
(SM)	O
were	O
quantified	O
(,	O
Appendix).	O

All	O
participants	O
were	O
instructed	O
to	O
smoke	O
these	O
cigarettes	O
for	O
the	O
duration	B
of	O
the	O
study.	O

This	O
is	O
illustrated	O
in	O
which	O
shows	O
that	O
those	O
who	O
report	O
feeling	O
more	O
rested	O
when	O
they	O
awake	O
in	O
the	O
morning	O
have	O
higher	O
melatonin	B
at	O
Time	O
T1,	O
followed	O
by	O
a	O
steeper	O
decline	O
over	O
the	O
night.	O

Tamoxifen	B
(parent	O
drug).	O

Lower	O
serum	O
vitamin	B
D	I
levels	O
were	O
associated	O
with	O
AMD	O
in	O
an	O
evaluation	O
of	O
patients	O
in	O
the	O
third	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
(NHANES)	O
,	O
as	O
well	O
as	O
in	O
post-menopausal	O
women	O
in	O
the	O
Carotenoids	B
in	O
Age-Related	O
Eye	O
Disease	O
Study	O
(CAREDS)	O
.	O

Leucine	B
and	O
isoleucine	B
(leu/ile)	O
were	O
reported	O
as	O
a	O
single	O
metabolite,	O
as	O
these	O
amino	O
acids	O
were	O
not	O
resolved	O
with	O
our	O
method.	O

We	O
believe	O
that	O
the	O
metabolite	O
identified	O
in	O
this	O
study	O
represents	O
methyl-hydroxylation	O
of	O
anastrozole.	B

The	O
present	O
study	O
indicated	O
that	O
4-heptanone,	B
2-methylpyrazine,	B
2-methylbutanal,	B
2,6-dimethyl-7-octen-2-ol	B
and	O
decanoic	B
acid	I
may	O
serve	O
as	O
potential	O
biomarkers	O
for	O
B-NHL.	O

We	O
adopt	O
the	O
view	O
that	O
the	O
observed	O
spectra	O
have	O
an	O
additive	O
noise	O
background	O
and	O
a	O
multiplicative	O
signal._,	O
-	O
The	O
model	O
for	O
a	O
single	O
spectrum	O
can	O
be	O
described	O
mathematically	O
as	O
where	O
ω	O
denotes	O
values	O
of	O
chemical	O
shifts	O
on	O
the	O
ppm	O
scale,	O
f(ω)	B
is	O
the	O
signal	O
intensity	O
at	O
the	O
chemical	O
shift	O
ω	O
,	O
B	O
(ω	O
)	O
is	O
a	O
random	O
quantity	O
due	O
to	O
baseline	O
distortion	O
and	O
background	O
noise,	O
N	O
is	O
the	O
fixed	O
normalization	O
factor,	O
μ(ω)	B
is	O
the	O
fixed	O
signal	O
of	O
our	O
primary	O
interest,	O
and	O
η(ω)	B
is	O
the	O
random	O
deviation	O
from	O
the	O
signal	O
due	O
to	O
the	O
biological	O
and	O
instrumental	O
variation.	O

Several	O
studies	O
suggest	O
that	O
mTORC1	O
signaling	O
is	O
respectively	O
activated	B
and	O
inhibited	O
by	O
feeding	O
and	O
fasting	O
[,	O
].	O

In	O
addition	O
to	O
these	O
candidate	O
markers,	O
we	O
also	O
quantified	O
creatinine	B
which	O
is	O
required	O
for	O
normalization	O
in	O
urine.	O

The	O
2-OHE1/16α-OHE1	B
ratio	O
has	O
been	O
used	O
as	O
an	O
index	O
of	O
the	O
relative	O
strengths	O
of	O
the	O
two	O
competing	O
oxidative	O
pathways	O
in	O
breast	O
cancer	O
with	O
higher	O
ratios	O
having	O
been	O
associated	O
with	O
a	O
reduced	O
risk	O
for	O
the	O
disease.	O

In	O
both	O
cell	O
types,	O
the	O
decline	O
observed	O
over	O
time	O
under	O
control	O
conditions,	O
e.g.	O
for	O
threonine	B
and	O
serine,	B
is	O
attenuated	O
during	O
the	O
presence	O
of	O
rHla	O
in	O
the	O
culture	O
medium.	O

Some	O
limitations	O
should	O
also	O
be	O
acknowledged,	O
including	O
that	O
our	O
study	O
was	O
cross-sectional,	O
which	O
limits	O
our	O
ability	O
to	O
make	O
causal	O
inferences	O
about	O
the	O
association	O
between	O
metabolites	O
and	O
retinol	B
levels.	O

As	O
shown	O
in	O
,	O
bilirubin	B
was	O
significantly	O
elevated	O
in	O
the	O
post-exposure	O
group.	O

Structural	O
variations	O
in	O
the	O
surface	O
morphology	O
and	O
internal	O
structure	O
of	O
the	O
both	O
MIP	B
and	O
NIP	O
polymer	O
particles	O
resulting	O
were	O
studied	O
by	O
the	O
SEM	O
microscope	O
(Fig. ).	O

Phosphocholine	B
metabolites,	O
including	O
PC	O
and	O
LysoPC,	O
are	O
key	O
components	O
of	O
the	O
biomembranes	O
of	O
cells,	O
as	O
well	O
as	O
participating	O
in	O
various	O
biological	O
pathways,	O
especially	O
in	O
cellular	O
signaling	O
and	O
metabolism.	O

As	O
shown	O
in	O
and	O
,	O
ceramides	B
36:1	I
and	O
38:1	O
were	O
the	O
most	O
abundant	O
species,	O
especially	O
in	O
the	O
retina	O
and	O
brain	O
where	O
they	O
totalized	O
85	O
to	O
100%	O
of	O
all	O
molecular	O
species	O
for	O
most	O
of	O
the	O
GG	O
classes.	O

Tyramine	B
is	O
a	O
product	O
of	O
tyrosine	B
metabolism	O
and,	O
like	O
other	O
trace	O
amines,	O
is	O
a	O
neuro-transmodulator.	O

To	O
analyze	O
15-HETE,	B
20	O
HETE,	O
11(12)-DiHET	O
and	O
14(15)-DiHET	O
a	O
modified	O
version	O
of	O
the	O
method	O
described	O
by	O
Mangal	O
et	O
al.	O
was	O
used.	O

oppositifolone	B

	O
Forty	O
microlitres	O
of	O
each	O
sample	O
was	O
added	O
to	O
160 μL	O
of	O
water	O
and	O
480 μL	O
of	O
extraction	O
liquid	O
(V_MTBE	O
:V_MeOH	O
 = 5:1,	B
containing	O
10 μL	O
of	O
160 μg/mL	O
PC(15:0/18:0)(d7))	B
and	O
vigorously	O
vortexed	O
for	O
60 s.	O

Two	O
peaks	O
were	O
annotated	O
as	O
2-oxoglutarate.	B

Geometric	O
means	O
for	O
creatinine	B
adjusted	O
urinary	O
phthalates	O
metabolites_a	O
by	O
diabetes	O
status.	O

The	O
betaine	B
peak	O
is	O
not	O
affected	O
by	O
the	O
change	O
in	O
pH,	O
however,	O
the	O
TMAO	B
peak	O
is	O
shifted	O
downfield	O
in	O
the	O
NMR	O
spectrum	O
which	O
allows	O
for	O
accurate	O
quantification	O
of	O
both	O
betaine	B
and	O
TMAO	B
separately.	O

This	O
platform	O
provides	O
simultaneous	O
quantification	O
of	O
147	O
individual	O
metabolites	O
and	O
79	O
metabolite	O
ratios,	O
for	O
example,	O
routine	O
lipids,	O
lipoprotein	O
subclass	O
profiling	O
with	O
lipid	O
concentrations	O
within	O
14	O
subclasses,	O
esterified	O
fatty	O
acid	O
composition,	O
and	O
various	O
low‐molecular-weight	O
metabolites,	O
including	O
amino	O
acids,	O
ketone	B
bodies,	O
and	O
gluconeogenesis‐related	O
metabolites	O
in	O
molar	O
concentration	O
units.	O

In	O
fact,	O
T.	O
cruzi	O
epimastigotes	O
are	O
induced	O
to	O
differentiate	O
into	O
metacyclic	B
trypomastigotes	O
by	O
increased	O
cAMP	O
levels	O
that	O
result	O
from	O
the	O
addition	O
of	O
catecholamines	B
(epinephrine),	O
which	O
are	O
tyrosine	B
derivatives	O
that	O
bind	O
to	O
a	O
subclass	O
of	O
G-protein-coupled	O
receptors	O
.	O

Serum	O
periostin	O
levels	O
were	O
measured	O
with	O
a	O
proprietary	O
sandwich	O
ELISA	O
(Shino-test,	O
Kanagawa,	O
Japan),	O
as	O
previously	O
described.	O

It	O
is	O
evident	O
that	O
selectivity	O
varies	O
significantly	O
between	O
RP	B
and	O
HILIC	O
but,	O
more	O
importantly,	O
also	O
between	O
the	O
HILIC	O
methods.	O

Excess	O
copper	O
accumulation	O
has	O
long	O
been	O
reported	O
to	O
inhibit	O
glycolysis	O
and	O
some	O
of	O
its	O
enzymes,	O
theoretically	O
resulting	O
in	O
cytoplasmic	O
accumulation	O
of	O
excess	O
glucose.	B

Cluster	O
1	O
is	O
a	O
highly	O
correlated	O
serotonin	B
cluster	O
and	O
cluster	O
2	O
a	O
highly	O
correlated	O
melatonin	B
cluster	O
in	O
normal	O
metabolic	O
conditions.	O

Clinical	O
and	O
hemodynamic	O
indices	O
stratified	O
by	O
median	O
asymmetric	B
dimethylarginine	I
(ADMA,	O
1.29	O
μM)	O
and	O
median	O
global	O
arginine	B
bioavailability	O
ratio	O
(GABR,	O
0.9)	O
in	O
patients	O
with	O
advanced	O
decompensated	O
heart	O
failure.	O

Well-established	O
associated	O
effects	O
on	O
nucleotide,	O
amino	O
acid	O
and	O
thiol	B
metabolism	O
were	O
also	O
seen.	O

Dzf18	O
isolated	O
from	O
Garcinia	O
parvifolia	O
(Sim	O
et	O
al.	O
2010),	O
endophytic	O
F.	O
oxysporum	B
(Musavi	O
and	O
Balakrishnan	O
2013),	O
F.	O
oxysporum	B
isolated	O
from	O
C.odorata	O
(Toghueo	O
et	O
al.	O

Previous	O
work	O
by	O
also	O
demonstrated	O
rapid	O
alterations	O
in	O
myostatin	B
mRNA	O
in	O
response	O
to	O
exercise	O
performed	O
even	O
under	O
moderately	O
cold	O
conditions.	O

Fractions	O
of	O
different	O
isotopomers	O
of	O
_13	O
C-pyruvate	O
(A	O
),	O
_13	O
C–lactate	B
(B	O
)	O
or	O
_13	O
C-acetyl-CoA	B
(D	O
)	O
in	O
the	O
PC	O
knockdown	O
cell	O
lines	O
and	O
the	O
scramble	O
control	O
cell	O
line	O
are	O
shown	O
within	O
the	O
same	O
bars.	O

Of	O
70	O
urinary	O
metabolites,	O
myo-inositol	B
was	O
significantly	O
higher	O
in	O
FSGS	O
patients	O
than	O
in	O
control	O
patients	O
(discovery	O
set,	O
2.34-fold,	O
P < 0.001;	O
validation	O
set,	O
2.35-fold,	O
P = 0.008)	O
and	O
MCD	O
patients	O
(discovery	O
set,	O
2.48-fold,	O
P = 0.002;	O
validation	O
set,	O
1.69-fold,	O
P = 0.042).	O

Except	O
methionine	B
sulfoxide,	I
all	O
159	O
investigated	O
metabolites	O
of	O
this	O
panel	O
maintained	O
stable	O
concentrations	O
after	O
one	O
freeze-thaw	O
cycle.	O

This	O
result	O
further	O
demonstrated	O
that	O
the	O
concentrations	O
of	O
C18:2	B
CE	O
and	O
SM	B
22:0	I
lipid	I
species	O
in	O
plasma	O
samples	O
were	O
associated	O
with	O
the	O
disease	O
status	O
of	O
SqCC,	O
with	O
a	O
decreasing	O
tendency	O
in	O
patients	O
with	O
SqCC.	O

The	O
gradient	O
elution	O
involved	O
a	O
mobile	O
phase	O
consisting	O
of	O
(A)	O
0.1%	O
formic	B
acid	I
in	O
water	O
and	O
(B)	O
0.1%	O
formic	B
acid	I
in	O
methanol.	B

The	O
systolic	O
blood	O
pressure,	O
serum	O
fasting	O
and	O
post-load	O
glucose	B
levels,	O
and	O
glycated	O
hemoglobin	O
were	O
significantly	O
higher	O
in	O
subjects	O
with	O
DM	O
compared	O
with	O
those	O
without	O
DM	O
(P	O
<	O
0.001).	O

Interrogation	O
of	O
the	O
discriminatory	O
metabolites	O
selected	O
by	O
the	O
models	O
revealed	O
that	O
the	O
concentration	O
of	O
formate	B
and	O
leucine	B
was	O
increased	O
in	O
MOG-Ab	O
plasma	O
relative	O
to	O
both	O
AQP4-Ab	O
NMOSD	O
and	O
RRMS	O
whilst	O
the	O
concentration	O
of	O
myo-inositol	B
was	O
decreased.	O

A	O
guar	O
gum	O
intervention	O
not	O
only	O
delayed	O
glucose	B
kinetics,	O
but	O
also	O
attenuated	O
the	O
formation	O
of	O
lactate	B
and	O
alanine	B
from	O
exogenous	O
sources.	O

Eight	O
microliters	O
per	O
milligram	O
of	O
methanol	B
and	O
2.5	O
μl/mg	O
of	O
water	O
were	O
added	O
to	O
each	O
Precellys	O
tube,	O
and	O
tubes	O
were	O
placed	O
in	O
the	O
Precellys	O
24	O
homogenizer	O
for	O
two	O
10-second	O
bursts	O
at	O
6400	O
rpm.	O

To	O
overcome	O
this	O
challenge,	O
it	O
is	O
suggested	O
that	O
the	O
unstable	O
thiol	B
group	O
of	O
GSH	B
be	O
blocked	O
by	O
derivatization	O
using	O
agents	O
such	O
as	O
N	B
-ethylmaleimide	I
before	O
extraction/protein	O
precipitation.	O

These	O
results,	O
together	O
with	O
other	O
recently	O
published	O
data,	O
indicate	O
that	O
carnosine	B
contributes	O
to	O
body‐weight	O
regulation.22	O
Leucine	B
is	O
a	O
branched‐chain	O
amino	O
acid	O
(BCAA).	O

Among	O
other	O
covariates,	O
age	O
at	O
diagnosis	O
was	O
positively	O
associated	O
with	O
increased	O
tamoxifen	B
and	O
DM‐TAM	O
concentrations,	O
whereas	O
DMEs	O
other	O
than	O
CYP2D6	O
had	O
little	O
influence	O
(Table	O
).	O

We	O
investigated	O
the	O
effect	O
of	O
BPA	O
and	O
silybin,	O
alone	O
or	O
in	O
combination,	O
on	O
proliferation,	O
oxidative	O
stress	O
and	O
steroid	O
metabolism	O
in	O
HepG2	O
grown	O
in	O
high	O
glucose	B
concentration	O
medium	O
(H-HepG2).	O

b),	O
from	O
which	O
we	O
could	O
easily	O
draw	O
the	O
conclusion:	O
compared	O
with	O
the	O
healthy	O
controls,	O
the	O
lipid	O
metabolism	O
pathway	O
was	O
upregulated	O
while	O
the	O
purine	B
metabolism	O
and	O
acetaminophen	B
metabolism	O
pathways	O
were	O
downregulated	O
in	O
the	O
cancer	O
group.	O

All	O
discussed	O
pathways:	O
beta-oxidation,	O
ketone	B
bodies	O
production,	O
glycolysis	O
and	O
TCA	O
cycle	O
are	O
linked	O
via	O
oxidative	O
phosphorylation	O
to	O
cellular	O
redox	O
state.	O

In	O
conclusion,	O
we	O
have	O
identified	O
a	O
characteristic	O
oxylipin	B
signature	O
in	O
postprandial	O
TGRL	O
that	O
distinguishes	O
an	O
acute	O
pro-	O
versus	O
anti-inflammatory	O
endothelial	O
response	O
in	O
subjects	O
consuming	O
an	O
identical	O
high	O
fat	O
meal.	O

Interestingly,	O
the	O
concentration	O
of	O
kynurenine	B
in	O
the	O
conditioned	O
media	O
was	O
lower	O
than	O
the	O
concentration	O
of	O
purified	O
kynurenine	B
that	O
reduced	O
CD8	O
T	O
cell	O
viability,	O
a	O
phenomenon	O
which	O
could	O
be	O
explained	O
by	O
the	O
milieu	O
of	O
other	O
factors	O
that	O
are	O
secreted	O
by	O
suspended	O
TNBC	O
cells	O
which	O
might	O
have	O
immune-modulatory	O
effects.	O

The	O
intracellular	O
pharmacokinetic	O
profile	O
of	O
ribavirin	B
in	O
PBMC	O
and	O
RBC	O
of	O
HCV-infected	O
patients	O
has	O
also	O
been	O
reported	O
previously.	O

Our	O
current	O
retrospective	O
clinical	O
association	O
study	O
cannot	O
prove	O
a	O
causal	O
relationship	O
between	O
SL	B
metabolism	O
and	O
HCC.	O

In	O
fact,	O
elevation	O
of	O
circulating	O
asymmetric	B
dimethylarginine	I
has	O
been	O
observed	O
in	O
various	O
pathological	O
conditions	O
associated	O
with	O
liver	O
dysfunction.	O

Increased	O
dietary	O
intake	O
of	O
lignans	B
or	O
fortification	O
of	O
food	O
with	O
the	O
plant	O
lignans	B
have	O
resulted	O
in	O
increased	O
serum	O
enterolactone	B
levels.	O

Receiver	O
operating	O
characteristic	O
analysis	O
revealed	O
high	O
diagnostic	O
accuracies,	O
as	O
measured	O
by	O
the	O
area	O
under	O
the	O
curve	O
(AUC)	O
of	O
myoinositol	B
(AUC	O
0.914,	O
95%	O
CI	O
0.862–0.967)	O
and	O
formate	B
(AUC	O
0.907,	O
95%	O
CI	O
0.849–0.965).	O

 ,	O
Supplementary	O
Table _S4	O
)	O
with	O
the	O
top	O
three	O
significantly	O
altered	O
metabolic	O
pathways	O
being	O
glycerophospholipid	B
metabolism,	O
aminoacyl-tRNA	B
biosynthesis,	O
and	O
valine,	B
leucine	B
and	O
isoleucine	B
biosynthesis.	O

Again,	O
we	O
were	O
underpowered	O
to	O
detect	O
a	O
difference	O
between	O
the	O
two	O
groups	O
in	O
the	O
concentrations	O
of	O
indoxyl	B
sulfate,	I
hippuric	B
acid,	I
and	O
PCS.	O

The	O
number	O
of	O
metabolites	O
that	O
significantly	O
correlated	O
to	O
clinical	O
measures	O
of	O
diabetes	O
decreased	O
after	O
simvastatin	B
treatment,	O
indicating	O
that	O
the	O
general	O
trends	O
that	O
were	O
associated	O
with	O
a	O
fasting	O
state	O
at	O
baseline	O
were	O
obstructed	O
by	O
individuals’	O
development	O
of	O
pre-diabetes.	O

Endoxifen	B
and	O
ND-tamoxifen,	B
were	O
obtained	O
from	O
Toronto	O
Research	O
Chemicals,	O
Ontario,	O
Canada.	O

Androstenedione	B
(1),,	O
testosterone	B
(2),	O
estrone	B
(E_1	O
)	O
sulfate	B
(3),	O
E_2	O
(4),	O
E_1	O
(5),	O
2-OHE_2	O
(6),	O
2-OHE_1	O
(7),	O
16α-OHE_2	B
(10),	O
16α-OHE_1	B
(11),	O
2-OCH_3	O
E_2	O
(12),	O
2-OCH_3	O
E_1	O
(13),	O
4-OCH_3	O
E_2	O
(14),	O
4-OCH_3	O
E_1	O
(15),	O
2-OH-3-OCH_3	B
E_2	O
(16)	O
and	O
2-OH-3-OCH_3	B
E_1	O
(17)	O
were	O
purchased	O
from	O
Steraloids	O
(Newport,	O
RI).	O

The	O
b_2	O
*-CO_2	O
ion	O
(C_25	O
H_26	O
N_5	O
O_2	O
)	O
at	O
m/z	O
428.3	O
and	O
433.3	O
for	O
unlabeled	O
and	O
desamino-[_2	B
H_5	I
]-PhIP	I
adducts	O
is	O
proposed	O
to	O
occur	O
by	O
a	O
rearrangement	O
involving	O
the	O
HO-group	O
of	O
the	O
threonine	B
side	O
chain	O
to	O
the	O
electrophilic	O
carbonyl	O
moiety,	O
followed	O
by	O
loss	O
of	O
CO_2	O
.	O

Blood	O
samples	O
were	O
drawn	O
fasting	O
and	O
120	O
min	O
after	O
glucose	B
ingestion.	O

The	O
test	O
was	O
performed	O
by	O
7-fold	O
cross	O
validation;	O
then,	O
the	O
validity	O
of	O
the	O
model	O
was	O
judged	O
by	O
RY	B
(the	O
interpretability	O
of	O
the	O
model	O
for	O
categorical	O
variable	O
Y	O
)	O
and	O
Q	O
(predictability	O
of	O
the	O
model)	O
obtained	O
by	O
cross-validation;	O
finally,	O
through	O
the	O
permutation	O
test,	O
the	O
order	O
of	O
the	O
categorical	O
variables	O
Y	O
is	O
randomly	O
changed	O
several	O
times	O
to	O
obtain	O
different	O
random	O
Q	O
values,	O
and	O
the	O
validity	O
of	O
the	O
model	O
is	O
further	O
tested.	O

Both	O
phosphopeptides	B
were	O
studied	O
over	O
a	O
range	O
of	O
concentrations	O
to	O
test	O
the	O
sensitivity	O
and	O
linearity.	O

Olanzapine	B
capillary	O
plasma	O
concentrations,	O
however,	O
were	O
on	O
average	O
approximately	O
20%	O
higher	O
than	O
venous	O
concentrations,	O
with	O
a	O
trend	O
for	O
a	O
relatively	O
greater	O
difference	O
occurring	O
shortly	O
after	O
dosing.	O

It	O
is	O
noteworthy	O
that	O
in	O
the	O
ketoconazole	B
arm,	O
patients	O
received	O
ketoconazole	B
and	O
prednisone.	B

MDD,	O
major	O
depressive	O
disorder;	O
TRP,	O
Tryptophan;	B
KYN,	O
Kynurenine;	B
KYNA,	O
Kynurenic	B
acid;	I
QUIN,	O
Quinolinic	B
acid.	I

PC	B
aa	I
C36:5;	I
128.	O

These	O
cycles	O
provide	O
cytosolic	O
NADPH,	B
a	O
coupling	O
factor,	O
required	O
for	O
glucose-induced	O
insulin	O
secretion	O
in	O
pancreatic	O
beta	O
cells	O
[,]	O
and	O
lipid	O
synthesis	O
in	O
many	O
different	O
tissues.	O

To	O
assess	O
the	O
robustness	O
of	O
our	O
findings	O
for	O
specific	O
estrogen	B
and	O
estrogen	B
metabolism	O
measures,	O
we	O
used	O
log-transformed	O
continuous	O
and	O
categorical	O
measures,	O
both	O
without	O
and	O
with	O
adjustment	O
for	O
unconjugated	O
estradiol,	B
in	O
our	O
models	O
and	O
emphasized	O
the	O
findings	O
that	O
were	O
consistent	O
across	O
the	O
models.	O

Groups	O
of	O
discovered	O
metabolites	O
are	O
often	O
placed	O
schematically	O
into	O
boxes	O
labeled,	O
for	O
example,	O
phospholipid	B
metabolism,	O
long-chain	O
fatty	O
acids,	O
or	O
steroid	O
biosynthesis.	O

HOMA-IR	O
was	O
calculated	O
according	O
to	O
the	O
following	O
equation:	O
fasting	O
insulin	O
(mU/L)	O
×	O
fasting	O
glucose	B
(mmol/L)/22.5.	O

We	O
sought	O
to	O
further	O
define	O
the	O
importance	O
of	O
the	O
role	O
of	O
sphingolipids	B
in	O
cancer	O
biology	O
in	O
this	O
way.	O

The	O
urinary	O
urea	B
concentration	O
positively	O
associated	O
with	O
kidney	O
transplant	O
rejection	O
in	O
our	O
study	O
might	O
be	O
reflective	O
of	O
increases	O
in	O
the	O
respective	O
serum	O
levels.	O

The	O
levels	O
of	O
creatine,	B
lactate	B
and	O
methoxyacetic	B
acid	I
gradually	O
increased	O
with	O
CAP	O
severity,	O
while	O
those	O
of	O
DHEA-S	B
and	O
4-hydroxybenzenesulfonic	B
acid	I
showed	O
the	O
opposite	O
pattern.	O

The	O
stability	O
of	O
the	O
IsoP,	O
PG	B
and	O
NO_2	O
-FA	O
ISTDs	O
during	O
the	O
2-h	O
hydrolyses.	O

For	O
instance,	O
lactic	B
acid	I
is	O
produced	O
through	O
anaerobic	O
glycolysis.	O

Dry	O
eye	O
disease	O
has	O
been	O
associated	O
with	O
a	O
wide	O
range	O
of	O
traits,	O
including	O
systemic	O
and	O
metabolic	O
conditions	O
and	O
dysfunctions,	O
such	O
as	O
vitamin	O
A	O
deficiency,	O
lower	O
intake	O
of	O
omega-3	B
and	O
omega-6	B
fatty	O
acids,	O
ovarian	O
dysfunction,	O
menopause,	O
acne,	O
diabetes	O
mellitus,	O
sarcoidosis,	O
and	O
use	O
of	O
systemic	O
medications	O
such	O
as	O
antihistamines,	B
β-blockers,	O
antidiuretics,	O
and	O
antidepressants.	O

Data	O
from	O
15	O
subjects	O
were	O
analyzed	O
after	O
exclusion	O
of	O
non-smokers,	O
very	O
light	O
smokers,	O
or	O
subjects	O
who	O
did	O
not	O
stop	O
smoking	O
based	O
on	O
inspection	O
of	O
the	O
decrease	O
in	O
urinary	O
cotinine	B
over	O
the	O
course	O
of	O
the	O
study,	O
typically	O
to	O
less	O
than	O
15	O
ng/ml.	O

We	O
also	O
identified	O
perturbations	O
in	O
other	O
glycerophosphatidylcholine	B
lipids,	O
including	O
LPC,	O
PC,	O
and	O
ether	B
PC.	I

The	O
first	O
dimension	O
chromatographic	O
column	O
was	O
a	O
10	O
m	O
DB-5	O
capillary	O
column	O
((5%-phenyl)-methylpolysiloxane)	O
with	O
an	O
internal	O
diameter	O
of	O
180	O
µm	O
and	O
a	O
film	O
thickness	O
of	O
0.18	O
µm.	O

Metabolites	O
were	O
measured	O
using	O
a	O
targeted	O
mass	O
spectrometry-based	O
quantitative	O
metabolomic	O
approach	O
that	O
included	O
acylcarnitines,	B
aminoacids,	B
biogenic	O
amines,	O
glycerophospholipids,	B
sphingolipids,	B
and	O
sugars.	O

The	O
authors	O
followed	O
through	O
with	O
a	O
targeted	O
MS	O
approach	O
that	O
quantified	O
sarcosine	B
levels	O
in	O
89	O
tissue	O
samples	O
(36	O
PCa,	O
25	O
benign,	O
and	O
28	O
metastatic).	O

(Sigma,USA)	O
and	O
1%	O
penicillin,	B
streptomycin	B
antibiotic	O
mixture	O
(Life	O
Technologies,	O
USA).	O

Only	O
three	O
metabolites	O
showed	O
pattern	O
differentiating	O
UC	O
from	O
CD	O
patients	O
consistently	O
over	O
time,	O
including	O
higher	O
urinary	O
concentrations	O
of	O
deoxycholic	B
acid	I
(DCA),	O
7-ketolithocholic	B
acid	I
and	O
beta-ursocholic	O
acid	O
(βUCA)	O
in	O
urine	O
from	O
UC	O
patients	O
(Table	O
).	O

While	O
we	O
are	O
able	O
to	O
detect	O
particular	O
orally	O
ingested	O
antioxidants	O
such	O
as	O
carotenoids	B
in	O
the	O
skin,	O
quantitative	O
measures	O
of	O
other	O
antioxidants	O
(such	O
as	O
catechins)	B
in	O
the	O
skin	O
can	O
be	O
difficult.	O

Further,	O
pharmacological	O
inhibition	O
of	O
LOX,	O
COX,	O
CYP,	O
and	O
sEH	O
enzymes	O
have	O
consistently	O
demonstrated	O
that	O
perturbing	O
oxylipin	B
metabolism	O
can	O
alter	O
systemic	O
inflammation.	O

Each	O
white	O
circle	O
represents	O
a	O
known	O
locus	O
for	O
glycine	B
(a)	O
or	O
phenylalanine	B
(b).	O

Organophosphates	B
(OPs)	O
are	O
a	O
class	O
of	O
chemicals	O
that	O
are	O
widely	O
used	O
as	O
pesticides	O
in	O
agriculture.	O

Lipids	O
and	O
triglycerides	B
were	O
statistically	O
important	O
metabolic	O
descriptors	O
(Fig.	O

In	O
summary,	O
we	O
observed	O
metabolic	O
changes	O
associated	O
with	O
several	O
metabolic	O
pathways,	O
including	O
fatty	O
acid	O
metabolism–particularly	O
the	O
PUFAs	O
metabolism,	O
and	O
purine	B
metabolism	O
in	O
child	O
and	O
adolescent	O
MDD.	O

We	O
used	O
10	O
μL	O
of	O
0.5	O
mg/mL	O
2-isopropylmalic	B
acid	I
dissolved	O
in	O
distilled	O
water	O
as	O
an	O
internal	O
standard.	O

One	O
to	O
two	O
passages	O
after	O
thawing,	O
BJ-4F3,	O
HUH7,	O
CAKI2	O
cells	O
were	O
transduced	O
with	O
control	O
shRNAs	O
(Sigma:	O
SHC001	O
as	O
empty	O
vector,	O
SHC002	O
as	O
non-targeting	O
shRNA	O
control)	O
or	O
ALDH7A1-specific	O
shRNAs	O
(Sigma:	O
TRCN0000028424	O
(sh1)	O
and	O
TRCN0000028447	O
(sh2))	O
for	O
24 h,	O
allowed	O
to	O
recover	O
for	O
24 h,	O
and	O
placed	O
under	O
puromycin	B
selection	O
(2 μg/ml)	O
for	O
6 days.	O

The	O
other	O
peaks	O
present	O
in	O
the	O
DIA	O
results	O
were	O
also	O
detected	O
in	O
the	O
IMS	O
analysis	O
but	O
were	O
clearly	O
resolved	O
from	O
the	O
tryptophan	B
peak.	O

The	O
feedback	O
regulation	O
of	O
diacylglycerol	B
biosynthesis	O
occurred	O
through	O
the	O
correlated	O
synthesis	O
of	O
phosphatidylcholine.	B

Detailed	O
analysis	O
of	O
the	O
differentially	O
regulated	O
metabolites	O
revealed	O
a	O
significant	O
change	O
in	O
glycerophospholipid	B
metabolism.	O

Very	O
recently,	O
Rao	O
et	O
al	O
.	O
postulated	O
that	O
circulating	O
oxalate	B
precipitate	O
might	O
be	O
a	O
potential	O
mechanism	O
for	O
stroke.	O

Low	O
(1	O
µm)	O
and	O
high	O
(20	O
µm)	O
concentrations	O
of	O
anastrozole	B
were	O
incubated	O
with	O
microsomes	O
from	O
different	O
characterized	O
human	O
livers.	O

Concentrations	O
of	O
creatine,	B
glycine,	B
histidine	B
and	O
threonine	B
were	O
notably	O
lower	O
in	O
COPD	O
compared	O
to	O
NCS.	O

Trypsin	O
digestion	O
yields	O
an	O
optimal	O
average	O
peptide	O
length	O
of	O
∼14	O
amino	O
acids,	O
with	O
a	O
well-defined	O
positive	O
charge	O
at	O
the	O
N	O
-terminus,	O
and	O
the	O
peptides	O
often	O
exist	O
as	O
doubly	O
[M+2H]_2+	O
or	O
triply	O
charged	O
species	O
[M+3H]_3+	O
which	O
favors	O
the	O
formation	O
of	O
y	O
-ions	O
by	O
ESI/MS._,	O
Other	O
serine	B
proteases	O
including	O
Lys-C,	O
which	O
retains	O
activity	O
in	O
strong	O
denaturants,	O
(cleaves	O
Lys	O
following	O
Pro	O
to	O
decrease	O
missed	O
cleavages);	O
chymotrypsin	O
(cleaves	O
C	O
-terminal	O
of	O
Phe,	O
Tyr,	O
Leu,	O
Trp,	O
and	O
Met);	O
Glu-C	O
(cleaves	O
C	O
-terminal	O
of	O
Glu	O
and	O
Asp);	O
and	O
pepsin,	O
an	O
aspartate	B
protease	O
(cleaves	O
C-terminal	O
of	O
Tyr,	O
Phe,	O
and	O
Trp)	O
have	O
also	O
been	O
employed.	O

It	O
is	O
not	O
clear	O
whether	O
low	O
levels	O
of	O
glucose	B
are	O
caused	O
by	O
their	O
impaired	O
delivery	O
through	O
the	O
blood-brain	O
barrier	O
(BBB)	O
and/or	O
by	O
rapid	O
consumption	O
due	O
to	O
increased	O
energy	O
demand	O
in	O
active	O
MS	O
and	O
NMOSD	O
lesions.	O

In	O
subsequent	O
work	O
by	O
Ferrannini	O
and	O
coworkers,	O
improvement	O
in	O
insulin	O
resistance	O
by	O
pharmaceutical	O
means	O
to	O
increase	O
levels	O
of	O
the	O
incretin,	B
glucagon	O
like	O
peptide	O
(GLP)-1,	O
also	O
showed	O
2-HBA	O
to	O
decrease.	O

Difference	O
of	O
sphingolipid	B
(SP)	O
profile	O
in	O
urine	O
of	O
patient	O
with	O
Fabry	O
disease	O
can	O
be	O
used	O
for	O
discriminating	O
type	O
of	O
Fabry	O
disease.	O

recently	O
discovered	O
that	O
G	O
protein-coupled	O
estrogen	B
receptor	O
(GPER)	O
can	O
activate	O
YAP	O
through	O
PLCβ	O
signaling	O
pathway	O
and	O
is	O
related	O
to	O
cell	O
invasion	O
and	O
metastasis	O
in	O
breast	O
cancer.	O

HPLC-grade	O
methanol	B
for	O
LC–MS	O
was	O
supplied	O
by	O
J.T.	O
Baker	O
(Griesheim,	O
Germany).	O

This	O
combination	O
could	O
lead	O
to	O
reduced	O
serine	B
production	O
and	O
a	O
state	O
of	O
reduced	O
substrate	O
for	O
the	O
tetrahydrofolate	B
cycle.	O

Ethanol	B
diffusion	O
through	O
air	O
during	O
sampling	O
and	O
preparation	O
stages	O
appeared	O
the	O
only	O
logical	O
explanation.	O

Histidine	B
was	O
higher	O
in	O
MBC	O
compared	O
with	O
EBC,	O
but	O
in	O
this	O
case,	O
it	O
is	O
at	O
odds	O
with	O
three	O
other	O
studies	O
(–)	O
in	O
which	O
it	O
was	O
lower.	O

H-HepG2	O
cells	O
were	O
seeded	O
in	O
96-well	O
plates	O
at	O
the	O
density	O
of	O
5 × 10_3	O
cells/well	O
in	O
complete	O
media	O
in	O
presence	O
of	O
high	O
glucose	B
concentration.	O

β-Actin	B
was	O
used	O
as	O
a	O
load	O
control.	O

Second,	O
limited	O
by	O
the	O
case-control	O
design,	O
this	O
study	O
could	O
not	O
definitively	O
conclude	O
whether	O
elevated	O
serum	O
TMAO	B
was	O
involved	O
in	O
the	O
liver	O
carcinogenesis,	O
or	O
if	O
liver	O
cancer	O
caused	O
the	O
serum	O
TMAO	B
elevations.	O

These	O
results	O
indicate	O
that	O
bilirubin	B
and	O
retinal	B
changes	O
were	O
correlated	O
with	O
cancer	O
stage,	O
and	O
gemcitabine	O
may	O
exert	O
its	O
effect	O
through	O
metabolic	O
pathways	O
associated	O
with	O
cancer	O
stage.	O

Neither	O
clopidogrel	B
or	O
prasugrel	O
thiolactones	B
nor	O
the	O
PON1	O
lactone	B
substrates	O
dihydrocoumarin	B
and	O
2-coumaranone	B
were	O
substrates	O
for	O
rBPHL.	O

Effect	O
sizes	O
indicate	O
the	O
association	O
magnitudes	O
in	O
units	O
of	O
1-SD	O
metabolite	O
concentration	O
per	O
1-kg/m_2	O
increment;	O
(B)	O
DBP:	B
1-SD	O
metabolite	O
concentration	O
per	O
1-mm	O
Hg	O
increment;	O
(C)	O

Previous	O
studies	O
show	O
that	O
GC	O
cells	O
preferentially	O
convert	O
glucose	B
into	O
lactate	B
even	O
in	O
the	O
presence	O
of	O
sufficient	O
oxygen	O
(Warburg	O
effect)	O
(;	O
;	O
;	O
).	O

For	O
GC-TOF/MS,	O
700 μL	O
of	O
MeOH	B
and	O
40 μL	O
of	O
L-2-chlorophenylalanine	B
(1 mg/mL	O
stock	O
in	O
dH_2	O
O)	O
were	O
added	O
to	O
200 μL	O
of	O
each	O
serum	O
sample,	O
and	O
the	O
samples	O
were	O
vigorously	O
vortexed	O
for	O
10 s.	O

Resveratrol	B
(3,5,4′-hydroxystilbene),	I
present	O
in	O
grapes	O
and	O
other	O
plants,	O
has	O
several	O
anti-carcinogenic	O
properties.	O

Gel	O
to	O
BRB	O
rinse	O
comparisons	O
of	O
salivary	O
levels	O
of	O
cyanidin	B
3-rutinoside	I
(most	O
prevalent	O
BRB	O
anthocyanin)	B
and	O
total	O
anthocyanins	B
(collective	O
chemopreventive	O
compounds)	O
were	O
therefore	O
performed	O
at	O
all	O
shared	O
saliva	O
collection	O
time	O
points	O
(5,	O
60,	O
120	O
and	O
240	O
minutes).	O

Based	O
on	O
receiver	O
operating	O
characteristic	O
(ROC)	O
curve	O
analysis	O
and	O
a	O
biomarker	O
panel	O
with	O
an	O
area	O
under	O
the	O
curve	O
(AUC)	O
of	O
0.969,	O
six	O
serum	O
metabolites	O
(α-glucose,	O
choline,	B
glutamine,	B
glutamate,	B
valine,	B
and	O
dihydrothymine)	B
were	O
selected	O
as	O
potential	O
diagnostic	O
biomarkers	O
for	O
early	O
stage	O
ESCC.	O

After	O
removal	O
of	O
non-reactive	O
reagents	O
through	O
a	O
micro-desalting	O
spin	O
column,	O
absorption	O
maxima	O
at	O
354	O
nm	O
were	O
recorded	O
for	O
biotin	B
and	O
at	O
280	O
nm	O
for	O
the	O
presence	O
of	O
antibody.	O

Oral	O
high	O
fat	O
supplementation-induced	O
upregulation	O
of	O
LysoPC	O
metabolites,	O
including	O
LysoPC(16:0),	B
might	O
have	O
yielded	O
beneficial	O
health	O
effects	O
in	O
postoperative	O
pancreatic	O
cancer	O
patients.	O

Increased	O
circulating	O
levels	O
of	O
fatty	O
acids	O
(notably	O
palmitic,	B
oleic	O
and	O
linoleic	B
acids)	O
are	O
associated	O
with	O
insulin	O
resistance,	O
including	O
in	O
models	O
of	O
obesity	O
through	O
a	O
mechanism	O
reliant	O
upon	O
c-Jun	O
amino	B
terminal	O
kinases	O
(JNKs).	O

The	O
SA	O
reduced	O
with	O
β-mercaptoethanol	B
contained	O
a	O
sulfhydryl	O
content	O
of	O
0.95	O
mol	O
-SH/mol	O
SA,	O
whereas	O
the	O
sulfhydryl	O
content	O
of	O
4-CMB	O
or	O
NEM	O
modified	O
SA	O
was	O
0.02	O
mol	O
-SH/mol	O
SA.	O

Automated	O
chloroformate	B
derivatization	O
and	O
GC/MS	O
analysis:	O

Serum	O
metabolomics	O
has	O
unveiled	O
changed	O
levels	O
of	O
glucose,	B
glutamine,	B
pyruvate	B
and	O
lactate_,	B
consistent	O
with	O
enhanced	O
glycolytic	B
and	O
glutaminolytic	B
activities,	O
showed	O
potential	O
in	O
nephrectomy	O
follow-up	O
and	O
patient	O
staging,	O
and	O
more	O
recently	O
produced	O
a	O
possible	O
biomarker	O
cluster	O
of	O
7	O
metabolites	O
(alanine,	O
creatine,	B
choline,	B
isoleucine,	B
lactate,	B
leucine,	B
valine)	B
for	O
early	O
RCC.	O

High-resolution	O
spectra	O
of	O
a	O
potential	O
predictor,	O
m/z	O
407.1527	O
at	O
positive	O
mode	O
[M+Na]_+	O
and	O
m/z	O
383.1545	O
at	O
negative	O
mode	O
[M-H]_−	O
,	O
illustrating	O
isotopic	O
pattern	O
at	O
1,000,000	O
resolution	O
using	O
NanoMate	O
nano	O
ESI-LTQ	O
FT	B
Ultra	O
MS.	O

Sphingomyelinase	O
(SMase)	O
is	O
an	O
enzyme	O
responsible	O
for	O
SMs	O
degradation	O
to	O
ceramides	B
and	O
oxidative	O
stress	O
can	O
accelerate	O
SMs	O
degradation	O
[,	O
].	O

For	O
our	O
study	O
group	O
fifty	O
individuals	O
having	O
fasting	O
blood	O
glucose	B
levels	O
between	O
4.5	O
and	O
6.5	O
mmol/l	O
(mean:	O
5.3±0.53	O
mmol/l)	O
which	O
are	O
all	O
below	O
the	O
current	O
diagnostic	O
criteria	O
of	O
the	O
WHO	O
for	O
type	O
2	O
diabetes	O
,	O
were	O
recruited.	O

Relative	O
intensities	O
(mean	O
±	O
SEM)	O
of	O
triglycerides	B
and	O
metabolites	O
obtained	O
from	O
normalized	O
CPMG	O
NMR	O
spectra	O
along	O
with	O
univariate	O
statistical	O
analysis	O
(Mann-Whitney).	O

The	O
combined	O
concentrations	O
of	O
glutamine	B
and	O
glutamate	B
(tGlut)	O
showed	O
a	O
good	O
positive	O
correlation	O
with	O
lactate	B
in	O
all	O
the	O
five	O
tumour	O
types	O
(	O
and	O
).	O

A	O
second	O
source	O
of	O
analytical	O
standards	O
was	O
not	O
available	O
for	O
this	O
study,	O
but	O
quality	O
control	O
(QC)	O
samples	O
were	O
prepared	O
independent	O
of	O
standards	O
by	O
spiking	O
blank	O
human	O
urine	O
with	O
varying	O
levels	O
of	O
analytes	O
1–6	O
(0.1,	O
2.0	O
and	O
50	O
ng/mL	O
final	O
concentrations)	O
and	O
DMSO	B
(50%	O
final	O
concentration).	O

This	O
platform	O
detects	O
163	O
moieties	O
comprising	O
14	O
amino	O
acids,	O
41	O
acylcarnitines	B
(including	O
hydroxyl	O
and	O
dicarboxyl	B
acylcarnitines),	I
hexoses,	O
15	O
sphingomyelins	B
and	O
sphingomyelin	B
derivatives,	O
15	O
lyso-phosphatidylcholines,	B
and	O
77	O
phosphatidylcholines	B
(including	O
phospholipids	B
and	O
plasmalogens).	O

Here,	O
we	O
utilize	O
an	O
LXR-response	O
element/LXRα	O
luciferase	O
assay	O
to	O
examine	O
the	O
activational	O
capacity	O
of	O
intermediates	O
in	O
the	O
acidic	O
pathway	O
of	O
bile	O
acid	O
biosynthesis	O
downstream	O
of	O
27-hydroxycholesterol.	B

In	O
Boston,	O
ex-smokers	O
showed	O
a	O
slight	O
increase	O
in	O
isoleucine	B
(p-	O
value	O
=	O
4.35x10-2	O
),	O
compared	O
to	O
non-smokers.	O

The	O
synthetic	O
product	O
was	O
obtained	O
by	O
the	O
acylase	O
catalyzed	O
deacetylation	O
of	O
the	O
reaction	O
product	O
of	O
N	O
_α	B
-acetyl-l-lysine	I
with	O
AFB-dibromo	B
and	O
characterized	O
by	O
UV,	O
fluorescence,	O
_1	O
H	O
NMR,	O
_13	O
C	O
NMR,	O
and	O
fast	O
atom	O
bombardment	O
mass	O
spectrometry.	O

Our	O
study,	O
which	O
included	O
an	O
initial	O
phase	O
and	O
a	O
validation	O
phase	O
in	O
2	O
independent	O
populations,	O
provides	O
consistent	O
evidence	O
of	O
a	O
positive	O
relation	O
between	O
plasma	O
TMAO	B
concentration	O
and	O
GDM.	O

On	O
the	O
other	O
hand,	O
compared	O
to	O
the	O
control	O
group,	O
the	O
LC	O
group	O
showed	O
11	O
metabolites	O
having	O
significantly	O
higher	O
peak	O
intensities;	O
succinylacetone	B
(q	O
=	O
3.242	O
×	O
10_–10	O
),	O
phenylalanine	B
(q	O
=	O
0.023),	O
tyrosine	B
(q	O
=	O
0.004),	O
indoleacrylic	B
acid	I
(q	O
=	O
2.931	O
×	O
10_–6	O
),	O
tryptophan	B
(q	O
=	O
5.017	O
×	O
10_–6	O
),	O
palmitic	B
acid	I
(q	O
=	O
0.043),	O
palmitoylcarnitine	B
(q	O
=	O
8.624	O
×	O
10_–4	O
),	O
oleoylcarnitine	B
(q	O
=	O
7.053	O
×	O
10_–4	O
),	O
lysoPC	O
(16:0)	O
(q	O
=	O
0.006),	O
lysoPC	O
(18:2)	O
(q	O
=	O
0.017),	O
and	O
lysoPC	O
(22:6)	O
(q	O
=	O
0.026).	O

Once	O
GP-tagged,	O
sterols	O
and	O
bile	O
acids	O
(with	O
a	O
3-oxo-4-ene	B
or	O
3β-hydroxy-5-ene	B
structure)	O
give	O
a	O
similar	O
mass	O
spectrometric	O
response,	O
and	O
thus	O
24(SR	O
)-[_2	O
H_6	I
]hydroxycholesterol	I
was	O
used	O
as	O
the	O
internal	O
standard	O
for	O
all	O
detected	O
analytes.	O

Subjects	O
were	O
then	O
randomized	O
to	O
three	O
study	O
protocols	O
of	O
similar	O
design:	O
1)	O
subjects	O
received	O
a	O
3-h	O
80	O
mU/min	O
·	O
m_2	O
euglycemic	B
insulin	O
clamp	O
in	O
combination	O
with	O
3-[_3	O
H]glucose	I
[prime	O
(25	O
μCi	O
×	O
FPG/5.55)	O

To	O
further	O
validate	O
novel	O
circulating	O
metabolites	O
in	O
an	O
independent	O
cohort,	O
we	O
compared	O
levels	O
of	O
IDO	O
tryptophan	B
metabolites	O
(IDO-TMs)	O
in	O
patients	O
with	O
known	O
PAH	O
and	O
control	O
subjects.	O

A	O
unique	O
feature	O
of	O
prostatic	O
fluid	O
from	O
normal	O
and	O
BPH	O
prostates	O
is	O
that	O
it	O
contains	O
very	O
high	O
levels	O
of	O
citrate	B
(Cit)	O

The	O
most	O
significantly	O
enriched	O
pathways	O
involved	O
in	O
the	O
pathogenesis	O
of	O
papillary	O
thyroid	O
carcinoma,	O
including	O
aspartate	B
metabolism,	O
urea	B
cycle,	O
and	O
metabolism	O
of	O
methionine	B
and	O
betaine.	B

If	O
corroborated	O
with	O
more	O
robust	O
studies,	O
findings	O
from	O
our	O
exploratory	O
analysis	O
may	O
have	O
both	O
clinical	O
and	O
public	O
health	O
relevance	O
among	O
reproductive	O
aged	O
individuals,	O
including	O
those	O
trying	O
for	O
pregnancy,	O
given	O
the	O
prevalent	O
use	O
of	O
paracetamol/acetaminophen	B
medications	O
and	O
the	O
ubiquitous	O
nature	O
of	O
paracetamol	B
in	O
the	O
environment.	O

4-Aminopyridine,	B
Dalfampridine,	B
Metabolism,	O
Cytochrome	O
P450,	O
Drug-drug	O
interactions	O

Linear	O
mixed	O
model	O
analysis	O
showed	O
that	O
tryptophan	B
concentrations	O
were	O
negatively	O
correlated	O
with	O
C	O
Reactive	O
Protein	O
concentrations	O
(usCRP,	O
β	O
=	O
-0.018;	O
p	O
=	O
0.0072)	O
and	O
that	O
kynurenine	B
and	O
kynurenic	B
acid	I
concentrations	O
were	O
positively	O
correlated	O
with	O
usCRP	O
concentrations	O
(β	O
=	O
0.019;	O
p	O
=	O
0.028	O
and	O
β	O
=	O
0.038;	O
p	O
=	O
4.21x10-2	O
,	O
respectively).	O

However	O
from	O
it	O
can	O
be	O
seen	O
that	O
Pearson	O
correlations	O
of	O
0.75	O
and	O
0.64	O
respectively	O
are	O
obtained	O
when	O
correlating	O
cotinine	B
and	O
trans	B
-3′-hydroxycotinine	I
with	O
3-EP	O
respectively.	O

For	O
example,	O
Shoemaker	O
et	O
al	O
,	O
reported	O
the	O
presence	O
of	O
bisethane	B
in	O
human	O
urine.	O

Aberrant	O
DNA	O
replication	O
and	O
damage	O
occur	O
early	O
during	O
cellular	O
carcinogenesis,	O
in	O
which	O
imbalance	O
of	O
nucleotide	O
metabolism,	O
particularly	O
deoxyribonucleotide	B
triphosphates	I
(dNTP),	O
drives	O
tumorigenesis	O
and	O
leads	O
to	O
nucleotide	O
pool	O
imbalance	O
in	O
tissue	O
and	O
biological	O
ﬂuids.	O

In	O
contrast,	O
the	O
signal	O
intensity	O
in	O
m/z	O
496.3,	O
16:	O
0	O
LPC	O
lysophosphatidylcholine,	B
was	O
lower	O
in	O
cancer	O
lesions.	O

The	O
whole	O
analytical	O
sample	O
preparation	O
procedure	O
is	O
based	O
on	O
an	O
established	O
method	O
used	O
for	O
retinoid	B
quantification.	O

Early-life	O
exposure	O
to	O
soy	O
may	O
alter	O
estrogen	B
mediated	O
processes	O
and	O
therefore,	O
alter	O
the	O
effect	O
of	O
genistein,	B
daidzein	B
and	O
other	O
isoflavones,	B
which	O
are	O
estrogen	B
antagonists.	O

Betaine	B
and	O
a	O
number	O
of	O
close	O
metabolites	O
in	O
the	O
one-carbon	O
pathway	O
were	O
selected	O
for	O
analysis:	O
total	O
homocysteine,	B
methylmalonic	B
acid,	I
cysteine,	B
methionine,	B
serine,	B
glycine,	B
cystathionine,	B
kynurenine	B
(analysed	O
by	O
gas	O
chromatography/mass	O
spectrometry);	O
sarcosine	B
and	O
tryptophan	B
(gas	O
chromatography/tandem	O
mass	O
spectrometry)	O
and	O
choline,	B
betaine,	B
dimethylglycine,	B
arginine	B
and	O
asymmetric/symmetric	O
dimethylarginine	B
(by	O
liquid	O
chromatography/tandem	O
mass	O
spectrometry).	O

For	O
instance,	O
acetate,	B
an	O
important	O
short-chain	O
fatty	O
acid	O
(SCFA)	O
for	O
keeping	O
gut	O
health	O
and	O
a	O
precursor	O
for	O
endogenous	O
cholesterol	B
production,	O
was	O
also	O
increased	O
in	O
the	O
H	O
group.	O

In	O
T1DM,	O
C16:0	B
species	O
were	O
also	O
the	O
highest	O
followed	O
by	O
C18:0,	B
C24:1,	B
and	O
C24:0.	B

(C)	O
Hexadecanedioate	B
levels	O
among	O
SLCO1B1	O
(c.481+1G>T)	O
LoF	O
mutation	O
carriers.	O

Compared	O
with	O
the	O
data	O
reported	O
in	O
the	O
published	O
paper,	O
this	O
compound	O
was	O
identified	O
as	O
6,7-furano-hydrocoumaric	B
acid	I
methyl	I
ester.	I

Lyophilized	O
samples	O
were	O
reconstituted	O
in	O
500	O
μl	O
D_2	O
O	O
(D_2	O
O,	O
Aldrich,	O
99.9%);	O
50	O
μl	O
of	O
3	O
mM	O
2,2-dimethyl-2-	B
silapentane-5-sulfonate	I
(DSS,	O
Cambridge	O
Labs)	O
were	O
added	O
to	O
serve	O
as	O
a	O
lock	O
signal	O
and	O
chemical	O
shift	O
references	O
(δ	O
=	O
0.0).	O

Arginine	B
association	O
with	O
Mayo	O
endoscopic	O
score.	O

Serum	O
cystatin	B
C	O
concentrations	O
were	O
measured	O
using	O
a	O
nephelometric	O
assay	O
(Dimension	O
VISTA,	O
Siemens	O
Healthcare	O
Diagnostics)	O
with	O
a	O
functional	O
sensitivity	O
of	O
0.05 mg/L.	O
Cystatin	B
C-based	O
estimated	O
glomerular	O
filtration	O
rate	O
(eGFR)	O
was	O
calculated	O
using	O
the	O
CKD-EPI	O
cystatin	B
C	O
equation:	O

Compared	O
to	O
IBS	O
subjects	O
who	O
typically	O
go	O
to	O
bed	O
early	O
and	O
get	O
up	O
early,	O
those	O
who	O
stay	O
up	O
late	O
and	O
sleep	O
later	O
in	O
the	O
morning	O
have	O
lower	O
mean	O
levels	O
of	O
most	O
of	O
the	O
metabolites,	O
with	O
this	O
trend	O
being	O
statistically	O
significant	O
for	O
melatonin,	B
tryptamine,	B
and	O
indole-3-acetic	B
acid.	I

Mean	O
8-oxoGua	O
urinary	O
excretion	O
levels	O
were	O
6-8	O
times	O
that	O
of	O
mean	O
urinary	O
8-oxodG	B
levels.	O

Scatterplot	O
showing	O
the	O
correlation	O
between	O
total	O
hippocampal	O
GM	O
volume	O
(X	O
axis)	O
and	O
the	O
serum	O
concentration	O
of	O
the	O
ratio	O
of	O
kynurenic	B
acid	I
(KA)	O
to	O
quinolinic	B
acid	I
(QA)	O
(Y	O
axis)	O
in	O
subjects	O
with	O
MDD	O
(β	O
-weight=0.42,	O
t	O
=2.5,	O
p	O
=0.022).	O

BMI:	O
body	O
mass	O
index;	O
SBP:	O
systolic	O
blood	O
pressure;	O
DBP:	B
diastolic	O
blood	O
pressure;	O
LDL:	O
low	O
density	O
lipoproteins;	O
HDL:	O
high	O
density	O
lipoproteins;	O
BUN:	O
blood	O
urea	B
nitrogen;	I
SCr:	O
serum	O
creatinine;	B
HbA1c:	O
glycated	O
hemoglobin;	O
FPG:	O
fasting	O
plasma	O
glucose;	B
2hPG:	O
2h	O
plasma	O
glucose;	B
FINS:	O
fasting	O
insulin.	O

RV	B
is	O
the	O
power	O
of	O
the	O
metabolite	O
to	O
reflect	O
the	O
abnormal	O
state	O
in	O
the	O
disease.	O

Glucose	B
consumption	O
was	O
hence	O
24%	O
higher	O
after	O
120	O
min	O
in	O
the	O
presence	O
of	O
rHla	O
when	O
compared	O
to	O
S9	O
cells	O
under	O
control	O
conditions.	O

Methylarginines	B
are	O
produced	O
after	O
arginine	B
residues	O
in	O
proteins	O
are	O
methylated	O
by	O
PRMT1	O
and	O
following	O
subsequent	O
protein	O
breakdown.	O

When	O
grown	O
in	O
the	O
presence	O
of	O
the	O
inducer	O
arabinose,	B
PfNMNAT	O
is	O
able	O
to	O
rescue	O
growth	O
more	O
efficiently	O
than	O
in	O
the	O
no-inducer	O
control	O
(Figure	O
S6	O
in	O
).	O

PC	B
aa	I
C36:6;	I
108.	O

To	O
evaluate	O
the	O
gut	O
microbial	O
profile	O
of	O
subjects	O
with	O
UC	O
and	O
healthy	O
controls	O
to	O
determine	O
if	O
it	O
is	O
predictive	O
of	O
plasma	O
TMAO	B
concentrations.	O

Tertiary	O
butyl	B
methyl	I
ether	I
(TBME),	O
HPLC	O
grade	O
methanol	B
and	O
acetonitrile	B
were	O
purchased	O
from	O
J.T.	O
Baker,	O
USA.	O

One	O
milliliter	O
will	O
be	O
taken	O
in	O
potassium	O
oxalate/sodium	O
fluoride	B
tubes	O
for	O
fasting	O
glucose.	B

In	O
agreement	O
with	O
previous	O
reports,	O
the	O
levels	O
of	O
the	O
urinary	O
ω-6	O
fatty	O
acid	O
derivatives	O
8-HETE	B
and	O
12-HETE	B
were	O
also	O
significantly	O
different	O
between	O
men	O
and	O
women.	O

Arginine	B
can	O
then	O
be	O
hydrolyzed	O
by	O
arginase	O
to	O
form	O
urea	B
and	O
ornithine,	B
or	O
be	O
used	O
by	O
NOS	O
leading	O
to	O
the	O
production	O
of	O
NO	O
and	O
citrulline,	B
a	O
balance	O
which	O
has	O
shifted	O
in	O
TB	O
patients	O
as	O
reflected	O
by	O
their	O
relatively	O
decreased	O
Cit/Arg	O
ratio.	O

Polyamines	B
are	O
known	O
to	O
be	O
involved	O
in	O
important	O
cell	O
growth	O
and	O
development	O
processes,	O
which	O
thereby	O
also	O
have	O
great	O
impact	O
in	O
tumor	O
genesis.	O

We	O
observed	O
metabolite	O
concentration	O
changes	O
that	O
may	O
agree	O
with	O
this	O
hypothesis:	O
saturated	O
FA	B
were	O
elevated	O
in	O
schizophrenia	O
patients	O
with	O
higher	O
fasting	O
insulin	O
concentrations	O
(e.g.,	O
Q3-4),	O
whereas	O
patients	O
with	O
lower	O
fasting	O
insulin	O
concentrations	O
(e.g.,	O
Q1-2)	O
had	O
higher	O
concentrations	O
of	O
methyl-donating	O
amino	O
acids.	O

The	O
significant	O
decrease	O
in	O
glucose	B
found	O
in	O
our	O
study	O
demonstrated	O
that	O
the	O
metabolic	O
feature	O
of	O
ESCC	O
with	O
strong	O
aerobic	O
glycolysis	O
is	O
consistent	O
with	O
the	O
results	O
observed	O
in	O
many	O
other	O
rapidly	O
proliferating	O
cancers	O
(;	O
).	O

Therefore,	O
the	O
most	O
obvious	O
explanation	O
for	O
increased	O
glycolysis	O
in	O
cancer	O
metabolism	O
is	O
a	O
rapid	O
requirement	O
for	O
ATP.	B

However,	O
other	O
than	O
TNF-	O
α	O
levels,	O
significant	O
variation	O
in	O
IL-1α	B
and	O
IL-6	O
concentrations	O
between	O
ARD	O
and	O
TC	O
groups	O
were	O
observed.	O

Aromatic	O
amino	O
acids,	O
such	O
tyrosine	B
and	O
phenylalanine,	B
were	O
significantly	O
higher	O
in	O
the	O
ACLF	O
group	O
compared	O
to	O
the	O
CLF	O
group.	O

Each	O
200	O
µL	O
of	O
supernatant	O
was	O
transferred	O
into	O
an	O
auto-sampler	O
vial,	O
and	O
the	O
residue	O
was	O
further	O
exacted	O
with	O
200	O
µL	O
of	O
cold	O
methanol.	B

Within	O
the	O
kynurenine	B
and	O
serotonin-melatonin	O
pathways	O
there	O
were	O
many	O
significant	O
positive	O
associations	O
among	O
metabolites.	O

Anandamide	B
0-phosphate	I
is	O
one	O
of	O
the	O
intermediates	O
in	O
the	O
biosynthesis	O
of	O
anandamine	B
(KEGG:	O
map04723).	O

The	O
metabolic	O
systems	O
included	O
36-carbon	O
ultra	O
long-chain	O
fatty	O
acids,	O
multiple	O
choline-related	O
systems	O
including	O
phosphatidylcholines,	B
lysophosphatidylcholines	B
and	O
sphingomyelins,	B
as	O
well	O
as	O
vinyl	O
ether-containing	O
plasmalogen	O
ethanolamines.	B

Each	O
compound	O
was	O
independently	O
weighed	O
and	O
the	O
corresponding	O
powder	O
dissolved	O
in	O
the	O
required	O
volume	O
of	O
DMSO	B
to	O
give	O
a	O
1	O
mg/mL	O
stock	O
solution	O
of	O
the	O
compound	O
that	O
was	O
sonicated	O
for	O
5	O
minutes.	O

We	O
observed	O
elevated	O
heme	B
degradation	O
products	O
including	O
bilirubin,	B
biliverdin	B
and	O
urobilinogen	B
during	O
CM.	O

In	O
contrast,	O
the	O
MS/MS	O
patterns	O
of	O
other	O
candidate	O
metabolites,	O
such	O
as	O
N-methylnicotinamide	B
(Table	O
),	O
differed	O
from	O
that	O
of	O
the	O
137.1-m/z	O
ion	O
in	O
urine	O
(data	O
not	O
shown),	O
and	O
were	O
thus	O
ruled	O
out.	O

Prior	O
investigations	O
have	O
identified	O
the	O
presence	O
of	O
the	O
sphingomyelin	B
isomers	I
SM	I
d18:2/22:0,	I
SM	B
d18:1/22:1	I
and	O
SM	B
d16:1/24:1	I
that	O
as	O
[M+H]_+	O
precursor	O
ions	O
could	O
all	O
potentially	O
contribute	O
to	O
the	O
m/z	O
785.6	O
ion	O
population	O
in	O
.	O

This	O
finding	O
may	O
have	O
implications	O
for	O
sperm	O
count	O
and	O
couple	O
fecundity,	O
but	O
there	O
remains	O
a	O
need	O
for	O
more	O
research	O
to	O
further	O
elucidate	O
the	O
mechanisms	O
by	O
which	O
paracetamol	B
affects	O
fecundity.	O

These	O
data	O
are	O
also	O
in	O
accordance	O
with	O
the	O
literature,	O
which	O
describes	O
low	O
levels	O
of	O
SMs,	O
accumulation	O
of	O
neurotoxic	O
ceramides	B
in	O
CSF	O
and	O
of	O
reactive	O
astrocytes	O
in	O
active	O
lesions	O
of	O
MuS	O
patients.	O

Moreover	O
Cheng	O
et	O
al.	O
reported	O
diminished	O
levels	O
of	O
another	O
catabolites	O
of	O
kynurenine	B
(kynurenate)	O
in	O
the	O
urine	O
of	O
CRC	O
patients	O
compared	O
to	O
urine	O
of	O
healthy	O
controls.	O

We	O
obtained	O
similar	O
results	O
when	O
using	O
70%	O
methanol	B
(Additional	O
file	O
).	O

Robinson	O
and	O
Robinson	O
(40),	O
reported	O
higher	O
urinary	O
levels	O
of	O
several	O
ketones	B
(namely	O
carvone)	O
and	O
furans	O
(such	O
as	O
2‐methyltetrahydrofuran,	B
2‐methylfuran	B
and	O
3‐methylfuran)	B
in	O
the	O
urine	O
of	O
younger	O
males	O
compared	O
to	O
older	O
(mean	O
age	O
not	O
referred)	O
40.	O

Zidovudine/abacavir:	O
ceramide	B
(p	O
=	O
0.004),	O
monohexosylceramide	B
(p	O
=	O
0.035),	O
dihexosylceramide	B
(p	O
=	O
0.015),	O
GM3	B
ganglioside	I
(p	O
=	O
0.015),	O
sphingomyelin	B
(p	O
=	O
0.035),	O
phosphatidylcholine	B
(p	O
=	O
0.024),	O
alkylphosphatidylcholine	B
(p	O
=	O
0.046),	O
alkenylphosphatidylcholine	B
(p	O
=	O
0.031),	O
lysoalkylphosphatidylcholine	B
(p	O
=	O
0.046),	O
phosphatidylethanolamine	B
(p	O
=	O
0.015),	O
alkylphosphatidylethanolamine	B
(p	O
=	O
0.029),	O
alkenylphosphatidylethanolamine	B
(p	O
=	O
0.005),	O
lysophosphatidylethanolamine	B
(p	O
=	O
0.043),	O
phosphatidylinositol	B
(p	O
=	O
0.011),	O
phosphatidylserine	B
(p	O
=	O
0.015),	O
free	O
cholesterol	B
(p	O
=	O
0.001),	O
cholesteryl	B
ester	I
(p	O
=	O
0.015).	O

The	O
serum	O
levels	O
of	O
nearly	O
all	O
estrogens,	O
estrogen	B
metabolites,	O
and	O
metabolic	O
pathway	O
groups	O
were	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
breast	O
cancer,	O
but	O
none	O
of	O
the	O
associations	O
remained	O
statistically	O
significant	O
after	O
adjusting	O
for	O
serum	O
level	O
of	O
unconjugated	O
estradiol.	B

Go	O
to:	O
Background:	O
An	O
elevated	O
circulating	O
cystathionine	B
concentration,	O
which	O
arises	O
in	O
part	O
from	O
insufficiencies	O
of	O
vitamin	O
B-6,	O
B-12,	O
or	O
folate,	B
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
cardiovascular	O
disease	O
(CVD)	O
risk.	O

Falchook	O
et	O
al.	O
reported	O
similar	O
metabolite	O
concentrations	O
as	O
seen	O
in	O
Table	O
with	O
the	O
exception	O
of	O
carboxy-dabrafenib	B
where	O
they	O
reported	O
an	O
8-fold	O
higher	O
concentration	O
than	O
found	O
in	O
this	O
study.	O

In	O
multiple	O
myeloma	O
patients,	O
fumarate	B
is	O
an	O
intermediate	O
in	O
the	O
citric	B
acid	I
cycle	O
used	O
by	O
cells	O
to	O
produce	O
energy	O
in	O
the	O
form	O
of	O
ATP.	B

These	O
results	O
can	O
also	O
be	O
verified	O
physiologically	O
as	O
amino	O
acids	O
enter	O
pathways	O
to	O
sustain	O
blood	O
glucose	B
homeostasis	O
as	O
a	O
substrate	O
to	O
gluconeogenesis	O
in	O
the	O
liver	O
and	O
kidneys,	O
as	O
well	O
as	O
oxidation	O
in	O
skeletal	O
muscle.	O

Chen	O
JL	O
found	O
that	O
glycine	B
content	O
is	O
increased	O
in	O
the	O
body	O
of	O
stomach	O
cancer	O
patients	O
with	O
lymph	O
node	O
metastasis.	O

Stata	O
v.12	O
(StataCorp	O
LP,	B
College	O
Station,	O
TX	O
USA)	O
was	O
used	O
for	O
the	O
statistical	O
analysis,	O
and	O
statistical	O
significance	O
was	O
defined	O
as	O
p	O
<	O
0.05	O
for	O
a	O
two-tailed	O
test.	O

Moreover,	O
almost	O
identical	O
variation	O
in	O
glucose	B
concentrations	O
was	O
reported	O
in	O
both	O
studies	O
highlighting	O
the	O
analytical	O
reproducibility	O
of	O
NMR	O
measurements.	O

Through	O
the	O
pathway	O
analysis,	O
we	O
found	O
sphingolipid	B
metabolism	O
was	O
one	O
of	O
the	O
most	O
significantly	O
increased	O
pathways.	O

The	O
changes	O
of	O
lactate,	B
acetate,	B
glucose,	B
3-hydroxybutyrate,	B
phenylalanine,	B
oxaloacetate,	B
and	O
creatinine	B
were	O
very	O
heterogeneous.	O

double	O
quantum	O
filtered	O
correlation	O
spectroscopy	O
(DQF-COSY)	O
and	O
_1	O
H–_1	O
H	O
total	O
correlation	O
spectroscopy	O
(TOCSY)	O
experiments,	O
were	O
performed	O
on	O
serum	O
samples	O
after	O
protein	O
precipitation	O
using	O
methanol	B
(2:1	O
v/v).	O

[,]	O
To	O
each	O
sample,	O
methanol	B
and	O
MTBE	B
was	O
added	O
according	O
to	O
the	O
amounts	O
outlined	O
in	O
.	O

Generally,	O
choline	B
is	O
an	O
essential	O
metabolite	O
in	O
the	O
synthesis	O
of	O
phospholipids	B
for	O
cancer	O
cell	O
membranes.	O

Significant	O
alterations	O
in	O
levels	O
of	O
tricarboxylic	B
acid	I
cycle	O
intermediates,	O
carnitines	B
and	O
its	O
derivatives	O
were	O
detected	O
in	O
RCC	O
relative	O
to	O
benign	O
masses	O
and	O
in	O
oncocytomas	O
vs.	O
chromophobe	O
RCC.	O

Across	O
>8,000	O
measured	O
metabolite	O
features,	O
we	O
identified	O
chemicals	O
and	O
chemical	O
classes	O
that	O
were	O
differentially	O
abundant	O
(DA)	O
in	O
IBD,	O
including	O
enrichments	O
for	O
sphingolipids	B
and	O
bile	O
acids,	O
and	O
depletions	O
for	O
triacylglycerols	B
and	O
tetrapyrroles.	O

The	O
extraction	O
supernatants	O
of	O
each	O
serum	O
sample	O
were	O
pooled	O
together	O
and	O
diluted	O
with	O
10-volume	O
water	O
containing	O
0.005%	O
BHT	O
and	O
0.01	O
mM	O
acetic	B
acid.	I

Evaluation	O
of	O
serum	O
levels	O
of	O
both	O
pioglitazone	B
and	O
EPA + DHA	O
increased	O
the	O
power	O
of	O
the	O
study	O
by	O
controlling	O
the	O
adherence	O
to	O
the	O
therapy,	O
and	O
enabled	O
a	O
more	O
detailed	O
analysis	O
of	O
the	O
measured	O
parameters	O
relative	O
to	O
the	O
changes	O
in	O
Omega-3	B
PhL	O
Index.	O

RA	O
patients	O
were	O
required	O
to	O
fulfill	O
the	O
1987	O
revised	O
classification	O
criteria	O
of	O
the	O
American	O
College	O
of	O
Rheumatology,	O
to	O
be	O
positive	O
for	O
rheumatoid	O
factor	O
(RF)	O
and/or	O
anti–cyclic	B
citrullinated	O
peptide	O
(anti-CCP)	O
antibodies,	O
and	O
to	O
have	O
a	O
disease	O
duration	B
of	O
≥6	O
months	O
and	O
a	O
Disease	O
Activity	O
Score	O
in	O
28	O
joints	O
(DAS28)	O
of	O
≥4.0.	O

This	O
large-scale	O
agnostic	O
investigation	O
of	O
nearly	O
1,300	O
men	O
identified	O
63	O
metabolites	O
in	O
several	O
chemical	O
classes	O
associated	O
with	O
serum	O
retinol	B
concentrations	O
after	O
stringent	O
correction	O
for	O
947	O
retinol-metabolite	B
comparisons.	O

[_13	O
CD_3	O
]cotinine	O
(110	O
pmol)	O
and	O
[_13	O
C_6	O
]NNAL	O
(0.93	O
pmol)	O
were	O
dissolved	O
in	O
50	O
μL	O
of	O
pH	O
7.4	O
phosphate	B
buffered	O
saline	B
(4.24	O
mM	O
KH_2	O
PO_4	O
,	O
620.7	O
mM	O
NaCl,	O
11.86	O
mM	O
Na_2	O
HPO_4	O
)	O
and	O
added	O
to	O
each	O
well	O
along	O
with	O
3000	O
units	O
of	O
β-glucuronidase	O
in	O
50	O
μL	O
of	O
pH	O
7.4	O
phosphate	B
buffered	O
saline	B
(1.06	O
mM	O
KH_2	O
PO_4	O
,	O
155.2	O
mM	O
NaCl,	O
2.97	O

Also,	O
the	O
region	O
at	O
1.00–1.04	O
ppm,	O
containing	O
signals	O
from	O
the	O
amino	O
acids	O
valine	O
and	O
isoleucine,	B
had	O
increased	O
signals	O
after	O
cheese	O
consumption,	O
compared	O
to	O
milk	O
and	O
soy	O
drink	O
intake.	O

The	O
glycolytic	B
ratio	O
was	O
significantly	O
higher	O
in	O
veterans	O
with	O
PTSD	O
than	O
in	O
veterans	O
without	O
PTSD	O
in	O
both	O
the	O
Discovery	O
(p<1x10-4	O
q	O
=	O
0.00)	O
and	O
Test	O
(p	O
=	O
0.005;	O
q	O
=	O
0.07)	O
groups,	O
suggesting	O
increased	O
anaerobic	O
and	O
decreased	O
aerobic	O
respiration	O
in	O
these	O
subjects,	O
which	O
may	O
indicate	O
mitochondrial	O
(TCA	O
cycle)	O
alterations	O
or	O
dysfunction.	O

2-Naphthalenesulfonic	B
acid	I
was	O
successfully	O
applied	O
for	O
MAILD	O
analysis	O
of	O
simple	O
amines.	O

This	O
study	O
for	O
the	O
first	O
time	O
reports	O
ranges	O
and	O
evolution	O
of	O
lactate	B
values	O
in	O
newborns	O
with	O
HIE	O
during	O
TH.	O

The	O
levels	O
of	O
7α-hydroxy-3-oxocholest-4-en-26-oic	B
and	O
3β-hydroxycholest-5-en-26-oic	B
acid	I
in	O
CSF	O
were	O
found	O
to	O
be	O
7.170	O
±	O
2.826	O
and	O
0.416	O
±	O

We	O
employed	O
mass	O
spectrometry	O
(MS)	O
to	O
measure	O
metabolites	O
and	O
metals	O
in	O
seven	O
post-mortem	O
brain	O
regions	O
of	O
nine	O
AD	O
patients	O
and	O
nine	O
controls,	O
and	O
plasma-glucose	B
and	O
plasma-copper	O
levels	O
in	O
an	O
ante-mortem	O
case-control	O
study.	O

(C)	O
Leucine	B
present	O
only	O
in	O
the	O
lyophilized	O
Panc-1	O
samples.	O

Diabetes	O
was	O
confirmed	O
by	O
oral	O
glucose	B
tolerance	O
testing	O
and	O
diabetics	O
were	O
treated	O
with	O
oral	O
medications	O
only.	O

2-hydroxybutyrate	B
(2-HB,	O
or	O
AHB)	O
and	O
branch	O
chain	O
keto-acid	O
dehydrogenase	O
(BCKDH)	O
complex	O
products	O
have	O
previously	O
been	O
associated	O
with	O
IR.	O

Plasma	O
total	O
glutathione	B
concentrations	O
were	O
significantly	O
lower	O
in	O
the	O
high–cystathionine	B
concentration	O
group	O
(P	O
<	O
0.001;	O
)	O
even	O
though	O
concentrations	O
of	O
its	O
limiting	O
precursor,	O
cysteine,	B
were	O
modestly	O
higher	O
(P	O
=	O
0.024).	O

Since	O
CYP4F2	O
is	O
the	O
major	O
enzyme	O
involved	O
in	O
the	O
production	O
of	O
20-HETE	B
in	O
man	O
and	O
antibodies	O
are	O
available	O
for	O
this	O
specific	O
isoform,	O
we	O
further	O
investigated	O
whether	O
the	O
expression	O
of	O
CYP4F2	O
is	O
also	O
elevated	O
at	O
the	O
protein	O
level	O
in	O
ovarian	O
cancer.	O

The	O
occurrence	O
of	O
PAH	O
adduct	O
formation	O
in	O
the	O
Atlantic	B
cod	O
albumin-like	O
protein	O
can	O
therefore	O
be	O
considered	O
as	O
a	O
possible	O
event.	O

NMR	O
spectroscopy	O
was	O
able	O
to	O
identify	O
and	O
quantify	O
209	O
compounds;	O
GC-MS	O
was	O
able	O
to	O
identify	O
179	O
and	O
quantify	O
85	O
compounds;	O
DFI/LC-MS/MS	O
identified	O
and	O
quantified	O
127	O
compounds;	O
ICP-MS	O
identified	O
and	O
quantified	O
40	O
compounds;	O
while	O
customized	O
HPLC	O
assays	O
(with	O
UV	O
or	O
FD	B
detection)	O
identified	O
and	O
quantified	O
10	O
compounds.	O

Recent	O
work	O
has	O
demonstrated	O
that	O
TxA_2	O
production	O
may	O
persist	O
despite	O
appropriate	O
aspirin	B
action	O
in	O
acute	O
cardiac	O
patients.	O

In	O
order	O
to	O
eliminate	O
the	O
effect	O
of	O
residual	O
water	O
peaks,	O
for	O
each	O
peak	O
period	O
remove	O
4.315-6.65	O
ppm	O
including	O
residual	O
water	O
peak	O
and	O
containing	O
urea	B
peak	O
signal.	O

Thus,	O
excess	O
ammonia	O
in	O
these	O
tissues	O
must	O
combine	O
with	O
glutamate	B
to	O
yield	O
glutamine	B
first	O
before	O
transport	O
to	O
the	O
liver.	O

Accordingly,	O
the	O
complex	O
interplay	O
of	O
endogenous	O
primary	O
and	O
bacterial	O
metabolized	O
secondary	O
bile	O
acids	O
can	O
affect	O
the	O
retention	O
and	O
metabolism	O
of	O
plasma	O
cholesterol.	B

Sarcosine	B
levels	O
are	O
also	O
regulated	O
by	O
sarcosine	O
dehydrogenase	O
(SARDH),	O
the	O
enzyme	O
that	O
converts	O
sarcosine	B
back	O
to	O
glycine,	B
and	O
dimethylglycine	O
dehydrogenase	O
(DMGDH)	O
which	O
generates	O
sarcosine	B
from	O
dimethylglycine	B
(Sreekumar	O
et	O
al.	O
).	O

The	O
increase	O
in	O
creatine	B
levels	O
deserves	O
special	O
attention	O
as	O
a	O
chemically	O
related	O
metabolite,	O
creatine	B
riboside,	I
was	O
recently	O
associated	O
with	O
NSCLC	O
in	O
a	O
urinary	O
metabolomics	O
study.	O

(D)	O
Tilted	O
J	O
-resolved	O
NMR	O
experiment	O
confirms	O
that	O
the	O
putative	O
signal	O
is	O
a	O
doublet	O
which	O
overlaps	O
with	O
3-hydroxyisovalerate.	B

7-Ketocholesterol	B
(ChemSpider	O
ID:	O
82599),	O
7α	B
-hydroxycholesterol	I
(96891),	O
25-hydroxycholesterol	B
(58604),	O
and	O
27-hydroxycholesterol	B
(110495)	O
and	O
their	O
deuterated	O
standards	O
(7-ketocholesterol-d	O
_7	I
,	I
7α	I
-hydroxycholesterol-d	I
_7	I
,	I
25-hydroxycholesterol-d	I
_6	O
,	O
and	O
27-hydroxycholesterol-d	B
_6	O
)	O
were	O
purchased	O
from	O
Steraloids	O
(Newport,	O
RI).	O

In	O
this	O
species,	O
the	O
cysteine-BDA-lysine	B
derived	O
sulfide	B
2	O
is	O
more	O
abundant	O
than	O
the	O
BDA-lysine	B
reaction	O
product	O
1,	O
suggesting	O
that	O
cysteine-BDA-lysine	B
cross-link	O
formation	O
is	O
more	O
abundant	O
than	O
direct	O
BDA-lysine	B
adduct	O
formation.	O

The	O
dynamic	O
properties	O
of	O
sialylated	O
oligosaccharide	B
chain	O
would	O
also	O
contribute	O
to	O
determine	O
a	O
large	O
interfacial	O
area	O
for	O
this	O
specific	O
GG	O
class.	O

IMZ	O
was	O
never	O
detected	O
when	O
metformin	B
was	O
not	O
found	O
to	O
be	O
present.	O

Inter-regional	O
differences	O
were	O
not	O
significant	O
and	O
variation	O
in	O
PMD	O
did	O
not	O
affect	O
fructose	B
levels.	O

Trimethylsilyl	O
derivatives	O
of	O
succinic,	B
fumaric,	O
α-ketoglutaric	B
and	O
itaconic	O
acids	O
were	O
identified	O
using	O
retention	O
times	O
and	O
characteristic	O
m/z	O
values,	O
described	O
in	O
.	O

In	O
the	O
present	O
study,	O
we	O
have	O
established	O
a	O
method	O
to	O
isolate	O
EVs	O
from	O
human	O
plasma	O
and	O
serum	O
that	O
enables	O
a	O
comprehensive	O
lipidomics-based	O
analysis	O
of	O
their	O
glycerophospholipid	B
and	O
sphingolipid	B
profiles.	O

IBD,	O
inflammatory	O
bowel	O
disease;	O
IBS,	O
irritable	O
bowel	O
syndrome;	O
n	O
,	O
number	O
of	O
observations;	O
ADMA,	B
asymmetric	B
dimethylarginine;	I
SDMA,	O
symmetric	B
dimethylarginine;	I
DMA,	B
dimethylamine;	B
_a	O
significantly	O
different	O
from	O
IBS;	O
_b	O
significantly	O
different	O
from	O
IBD;	O
_c	O
significantly	O
different	O
from	O
controls.	O

Representative	O
SRM	O
positive	O
product	O
ion	O
mass	O
spectra	O
for	O
(a)	O
SMV,	O
(b)	O
SMVA,	O
(c)	O
ATV,	O
(d)	O
2-OH-ATV	B
and	O
4-OH-ATV,	B
(e)	O
RSV,	O
and	O
(f)	O
IS.	O

The	O
two-day	O
restriction	O
was	O
also	O
associated	O
with	O
increased	O
urine	O
levels	O
of	O
beta-aminoisobutyric	B
acid	I
and	O
increased	O
TCA	O
metabolites,	O
which	O
have	O
both	O
been	O
linked	O
to	O
improved	O
mitochondrial	O
function	O
and	O
insulin	O
sensitivity	O
and	O
reduced	O
risk	O
of	O
diabetes,	O
obesity	O
and	O
cardiovascular	O
disease	O
[–].	O

Cannabinoids	B
were	O
separated	O
using	O
a	O
Supelco	O
Ascentis	O
Express	O
RP	B
amide	I
column	O
(2.1	O
×	O
150	O
mm,	O
2.7	O
μM)	O
at	O
50°C.	O

C=,	O
L3	O
-(CH	O
_2	O
)n-,	O
L4	O
CH	O
_2	O
CH_2	O
CO,	O
L5	O
-CH	O
_2	O
C = C-,	O
L6	O
CH	O
_2	O
CO,	O
L7	O
C = CCH	O
_2	O
C = C,	O
L8	O
-CH	O
 = CH	O
-,	O
Lac	O
Lactate,	B
Leu	O
Leucine,	B
Lys	O
Lysine,	B
Met	O
Methionine,	B
NAG	O
N-acetyl	B
glycoprotein,	I
PAG	B
Phenylacetylglycine,	I
Phe	O
Phenylalanine,	B
Pyr	O
Pyruvate,	B
Tyr	O
Tyrosine,	B
Val	O
Valine	B

This	O
hypothesis	O
was	O
supported	O
by	O
the	O
observed	O
decreased	O
levels	O
of	O
two	O
ketogenic	O
amino	O
acids:	O
leucine	B
and	O
isoleucine.	B

All	O
standard	O
[L-phenylalanine,	O
glycocholic	B
acid	I
and	O
lysophosphatidylcholine	B
(LysoPC),	O
14:0]	O
preparations	O
were	O
purchased	O
from	O
Sigma-Aldrich;	O
Merck	O
KGaA.	O
Ultra	O
HPLC	O
was	O
performed	O
using	O
a	O
Thermo	O
Fisher	O
Accela	O
system	O
(Thermo	O
Fisher	O
Scientific,	O
Inc.,	O
Waltham,	O
MA,	O
USA).	O

For	O
olanzapine,	B
the	O
intercept	O
(0.267;	O
95%CI,	O
0.171–0.363)	O
and	O
slope	O
(0.971;	O
95%CI,	O
0.945–0.996)	O
estimates	O
of	O
the	O
regression	O
line	O
were	O
slightly	O
though	O
statistically	O
significantly	O
different	O
from	O
0	O
and	O
1,	O
respectively.	O

The	O
serum	O
concentration	O
of	O
low-density	O
lipoprotein	O
(LDL)	O
and	O
very	O
low-density	O
lipoprotein	O
cholesterol	B
(VLDL-C)	O
was	O
calculated	O
as	O
described.	O

Chloroform	B
was	O
HPLC-grade	O
from	O
RCI	O
Labscan	O
(Bangkok,	O
Thailand).	O

Interestingly,	O
the	O
bioavailability	O
of	O
the	O
GR	O
contribution	O
to	O
systemic	O
SF	B
appeared	O
to	O
increase	O
over	O
the	O
84-day	O
period,	O
perhaps	O
due	O
to	O
changes	O
in	O
the	O
composition	O
of	O
the	O
microflora.	O

Meperidine	B
is	O
a	O
phenylpiperidine	B
derivative	O
that	O
is	O
primarily	O
a	O
mu-receptor	O
agonist.	O

≥90	O
mm	O
Hg	O
or	O
receipt	O
of	O
antihypertensive	O
drugs],	O
type	O
2	O
diabetes	O
[American	O
Diabetes	O
Association	O
criteria_,	O
]	O
and	O
metabolic	O
syndrome	O
defined	O
as:	O
presence	O
of	O
central	O
obesity	O
combined	O
with	O
any	O
two	O
of	O
the	O
following:	O
raised	O
triglycerides,	B
low	O
HDL-C,	O
high	O
blood	O
pressure	O
and	O
raised	O
fasting	O
plasma	O
glucose	B
(≥5.6	O
mmol/l),	O
previously	O
diagnosed	O
type	O
2	O
diabetes	O
or	O
receiving	O
anti-diabetic	O
medication	O
[International	O
Diabetes	O
Federation	O
definition].	O

Regarding	O
polyunsaturated	O
fatty	O
acids	O
(PUFAs)	O
hydroxy-eicosatetraenoic,	B
Eicosapentaenoic,	B
and	O
Eicosatetraenoic	B
were	O
significantly	O
lower	O
in	O
CLL	O
relative	O
to	O
controls	O
and	O
moreover	O
lower	O
in	O
aggressive	O
relative	O
to	O
indolent	O
patient	O
samples.	O

We	O
therefore	O
employed	O
a	O
dual	O
digest	O
strategy	O
to	O
quantify	O
the	O
high	O
levels	O
of	O
DHEA-S	B
(μg/dL)	O
and	O
the	O
lower	O
levels	O
of	O
circulating	O
glucuronide	B
conjugates	O
(ng/dL)	O
in	O
human	O
serum.	O

In	O
addition,	O
the	O
meals	O
were	O
classified	O
according	O
to	O
if	O
the	O
subject	O
reported	O
eating	O
nuts,	O
whole	O
grain,	O
fresh	O
vegetables	O
or	O
any	O
other	O
phytosterol	B
rich	O
food	O
or	O
not.	O

There	O
are	O
two	O
routes	O
of	O
label	O
incorporation	O
from	O
[_13	B
C-U]-glucose	I
into	O
2-oxoglutarate	B
via	O
pyruvate	B
(Figures	O
,	O
).	O

Hexane	B
(2	O
mL)	O
was	O
added	O
to	O
the	O
tube,	O
and	O
the	O
tube	O
was	O
vortex-mixed	O
for	O
30	O
s.	O

EH	O
clamp	O
was	O
accompanied	O
by	O
a	O
significant	O
increase	O
in	O
carnitine	B
(C0)	O
levels	O
in	O
control	O
subjects	O
but	O
not	O
in	O
TCF7L2	O
risk	O
allele	O
carriers	O
and	O
a	O
marked	O
decrease	O
of	O
short-chain	O
acylcarnitines	B
(C2,	O
C3)	O
and	O
NEFAs	O
levels	O
in	O
both	O
groups.	O

Note	O
phospholipids	B
presented	O
were	O
taken	O
from	O
subjects	O
aged	O
over	O
75	O
years	O
by	O
sex;	O
p-values	O
derived	O
based	O
on	O
Mann-Whitney	O
U	O
test.	O

Finally,	O
we	O
supposed	O
that	O
the	O
presence	O
of	O
higher	O
levels	O
of	O
pyruvate	B
and	O
lactate	B
in	O
urines	O
of	O
infected	O
women	O
could	O
be	O
ascribed	O
to	O
CT-induced	O
immunopathology.	O

Fifty-five	O
(55)	O
nuclear	O
biologic	O
families	O
were	O
recruited	O
in	O
an	O
earlier	O
cross-sectional	O
study	O
designed	O
to	O
model	O
the	O
relationship	O
between	O
mother	O
and	O
daughter	O
levels	O
of	O
melatonin	B
production,	O
after	O
adjusting	O
the	O
daughter's	O
melatonin	B
level	O
for	O
the	O
father's	O
melatonin	B
level.	O

Medium	O
)	O
might	O
be	O
explained	O
by	O
the	O
use	O
of	O
supplements	O
such	O
as	O
Glutamax	B
in	O
this	O
commercial	O
medium.	O

This	O
result	O
is	O
in	O
good	O
agreement	O
with	O
previous	O
studies	O
conducted	O
by	O
Biocrates	O
(Application	O
Note	O
1001-1),	O
which	O
indicated	O
a	O
typical	O
pool	O
of	O
human	O
plasma	O
from	O
healthy	O
people	O
yields	O
an	O
average	O
of	O
23	O
acylcarntines	O
below	O
the	O
limit	O
of	O
detection._1	O
That	O
note	O
also	O
reported	O
that	O
the	O
concentrations	O
of	O
5	O
lysophosphatidylcholines	B
in	O
pooled	O
normal	O
human	O
plasma	O
are	O
typically	O
below	O
the	O
normal	O
LOD,	O
whereas	O
in	O
the	O
present	O
study	O
only	O
3	O
lysophosphatidylcholines	B
were	O
below	O
the	O
LOD.	O

Two	O
NMR	O
peaks,	O
at	O
4.4422	O
and	O
4.444	O
ppm,	O
were	O
annotated	O
as	O
trigonelline.	B

The	O
RT	O
index	O
(RI)	O
method	O
was	O
used	O
for	O
peak	O
identification,	O
and	O
the	O
RI	B
tolerance	O
was	O
5,000.	O

Extracellular	O
glutamate,	B
on	O
the	O
other	O
hand,	O
was	O
found	O
to	O
significantly	O
increase	O
upon	O
rHla-exposure	O
in	O
both	O
cell	O
types	O
in	O
amounts	O
corresponding	O
to	O
approximately	O
87%	O
of	O
the	O
consumed	O
glutamine.	B

Anti-inflammatory	O
properties	O
of	O
1-methylnicotinamide	B
have	O
also	O
been	O
recently	O
described,	O
including	O
as	O
a	O
potential	O
scavenger	O
of	O
reactive	O
forms	O
of	O
oxygen,	O
in	O
particular	O
superoxide	B
radical	O
anions	O
and	O
hydroxyl	O
radicals,	O
as	O
well	O
as	O
reducers	O
of	O
adherence	O
of	O
pro-inflammatory	O
cells	O
and	O
molecules	O
to	O
the	O
surface	O
of	O
vascular	O
endothelium.	O

The	O
creatine/phosphocreatine/creatine	O
kinase	O
system	O
is	O
critical	O
for	O
maintaining	O
energy	O
levels	O
in	O
the	O
brain	O
and	O
as	O
a	O
high-energy	O
phosphate	B
shuttle	O
from	O
the	O
mitochondria	O
to	O
the	O
cytoplasm.	O

The	O
activity	O
of	O
rate-limiting	O
enzyme	O
of	O
tryptophan-kynurenine,	O
indoleamine-2,3-dioxygenase	O
(IDO),	O
was	O
enhanced	O
significantly	O
in	O
T2D	O
patients[],	O
thus	O
downstream	O
metabolites	O
such	O
as	O
kynurenine,	B
kynurenic	B
acid,	I
xanthurenic	B
acid	I
and	O
hydroxykynurenine,	B
were	O
higher	O
in	O
T2D	O
than	O
in	O
non-diabetic	O
subjects[,	O
],	O
although	O
inconsistent	O
observations	O
of	O
tryptophan	B
levels	O
were	O
reported[,	O
].	O

We	O
found	O
significant	O
but	O
modest	O
decreases	O
in	O
both	O
PGE-M	O
(44%	O
in	O
84	O
days)	O
and	O
8-iso	B
-PGF_2α	I
(27%).	I

CYP24A1	O
also	O
converts	O
1,25(OH)_2	B
D_3	O
to	O
1,24,25-trihydroxyvitamin	B
D_3	O
.	O

Therefore,	O
a	O
sensitive	O
LC/MS/MS	O
analytical	O
method	O
was	O
developed	O
to	O
identify	O
and	O
quantify	O
human	O
metabolism	O
of	O
anastrozole.	B

As	O
shown	O
in	O
the	O
supplementary	O
data,	O
from	O
0	O
to	O
2h	O
postprandially	O
LCAC	O
(C16,	O
C18:1,	B
C18:2)	B
were	O
constant	O
against	O
a	O
background	O
of	O
significant	O
plasma	O
FFA	O
reduction.	O

Our	O
group	O
and	O
others	O
have	O
shown	O
that	O
fatty	O
acyl	B
C18:1	I
typically	O
contains	O
C=C	O
location	O
isomers	O
at	O
Δ9	O
(major)	O
and	O
Δ11	O
(minor)	O
for	O
lipids	O
analyzed	O
from	O
mammalian	O
cells,	O
animal	O
tissue,	O
and	O
human	O
plasma.	O

Acetate	B
as	O
well	O
as	O
the	O
ketone	B
bodies	O
result	O
from	O
the	O
beta-oxidation	O
of	O
adipose	O
tissue	O
fatty	O
acids	O
under	O
the	O
starved	O
condition	O
(Yamashita	O
et	O
al.	O
).	O

The	O
authors	O
suggested	O
that	O
a	O
theophylline	B
mediated	O
increase	O
in	O
intracellular	O
cAMP	O
led	O
to	O
the	O
observed	O
increase	O
in	O
T4	O
production.	O

A	O
significant	O
association	O
between	O
Sphingosine	B
−1	O
phosphate	B
and	O
sex	O
was	O
identified.	O

eGFR,	O
estimated	O
glomerular	O
filtration	O
ratio;	O
ACEi,	O
angiotensin	B
converting	O
enzyme	O
inhibitor;	O
ARB,	O
angiotensin	B
receptor	O
blocker.	O

In	O
general,	O
high	O
concentrations	O
of	O
polyamines	B
are	O
found	O
in	O
rapidly	O
growing	O
cells,	O
while	O
low	O
concentrations	O
are	O
present	O
in	O
quiescent	O
cells	O
[,	O
].	O

This	O
was	O
consistent	O
with	O
our	O
observations	O
with	O
20	O
mM	O
ammonium	B
hydrogen	I
carbonate	I
wherein	O
a	O
loss	O
in	O
chromatography	O
quality	O
was	O
seen	O
possibly	O
due	O
to	O
clogging	O
of	O
the	O
column.	O

Under	O
conditions	O
of	O
increased	O
oxidative	O
stress,	O
a	O
higher	O
flux	O
of	O
cysteine	B
into	O
production	O
of	O
glutathione,	B
the	O
primary	O
antioxidant	O
in	O
cells,	O
occurs	O
from	O
a	O
shift	O
in	O
homocysteine	B
production	O
from	O
transmethylation	O
of	O
methionine	B
to	O
transsulfuration	O
of	O
homocysteine	B
to	O
produce	O
cystathionine	B
.	O

One	O
of	O
the	O
aforementioned	O
studies	O
determined	O
circulating	O
levels	O
of	O
CEL,	O
CML	B
and	O
the	O
cross-linked	O
pentosidine.	B

For	O
example,	O
the	O
decrease	O
in	O
the	O
fatty	O
acids	O
18:3	O
and	O
20:3	O
with	O
fish	O
oil	O
supplementation	O
as	O
determined	O
by	O
GC-MS	O
is	O
consistent	O
with	O
the	O
decrease	O
of	O
PC(36:3)	B
and	O
PC(38:3)	B
if	O
one	O
assumes	O
that	O
one	O
of	O
the	O
fatty	O
acids	O
in	O
these	O
species	O
is	O
the	O
highly	O
abundant	O
palmitate	B
(16:0—Fig.	I

Calibration	O
range	O
included	O
0.500	O
to	O
20.0	O
µg/mL	O
α-HB.	B

Pathway	O
topology	O
enrichment	O
analysis	O
revealed	O
that	O
cyanoamino	O
acid	O
metabolism,	O
caffeine	B
metabolism,	O
alanine,	B
aspartate	B
and	O
glutamate	B
metabolism,	O
phenylalanine,	B
tyrosine	B
and	O
tryptophan	B
biosynthesis,	O
pentose	B
phosphate	I
pathway	O
in	O
sputum,	O
and	O
glyoxylate	B
and	O
dicarboxylate	B
metabolism,	O
glycerolipid	B
metabolism	O
and	O
pentose	B
phosphate	I
pathway	O
in	O
serum	O
are	O
suggested	O
to	O
be	O
significant	O
pathways	O
related	O
to	O
obese	O
asthma.	O

The	O
beneficial	O
effect	O
of	O
carnosine	B
on	O
PC	O
levels	O
may	O
therefore	O
contribute	O
to	O
the	O
prevention	O
of	O
T2DM	O
and	O
CVD	O
via	O
regulation	O
of	O
SREBP-1	O
activity.	O

BMI:	O
body	O
mass	O
index;	O
SBP:	O
systolic	O
blood	O
pressure;	O
Cr:	O
creatine.	B

Positive	O
correlation	O
was	O
found	O
between	O
the	O
increase	O
of	O
urinary	O
1-hydroxypyrene	B
and	O
the	O
airborne	O
PAH	O
exposure	O
in	O
the	O
occupationally	O
exposed	O
workers	O
[,	O
].	O

[]	O
Declining	O
levels	O
of	O
AADC	O
may	O
contribute	O
to	O
decreasing	O
effectiveness	O
of	O
L-dopa	B
medication	O
over	O
time.	O

A	O
common	O
origin	O
related	O
to	O
formation	O
by	O
spontaneous	O
oxidation	O
may	O
explain	O
the	O
positive	O
associations	O
between	O
cholestenone,	B
7-oxocholesterol,	B
5α-hydroxycholesterol,	B
and	O
the	O
5,6-epoxycholesterols,	B
as	O
enzymatic	O
pathways	O
for	O
the	O
formation	O
of	O
these	O
sterols	O
have	O
not	O
been	O
defined.	O

Of	O
note,	O
2-hydroxybutyrate	B
was	O
elevated	O
in	O
the	O
urine	O
of	O
young	O
patients	O
with	O
lactic	O
acidosis.	O

Values	O
on	O
the	O
original	O
scale	O
were	O
1.05	O
pmol/mg	O
creatinine	B
at	O
baseline	O
and	O
0.73	O
pmol/mg	O
creatinine	B
at	O
day	O
84.	O

(a)	O
Percent	O
blood	O
glucose	B
reduction	O
of	O
dichloromethane	B
extract	O
at	O
25,	O
50,	O
100,	O
and	O
200	O
mg/kg	O
body	O
weight	O
taken	O
at	O
0.5	O
h	O
(b)	O
Percent	O
blood	O
glucose	B
reduction	O
of	O
dichloromethane	B
extract	O
at	O
25,	O
50,	O
100,	O
and	O
200	O
mg/kg	O
body	O
weight	O
taken	O
at	O
1	O
h	O
(c)	O
Percent	O
blood	O
glucose	B
reduction	O
of	O
dichloromethane	B
extract	O
at	O
25,	O
50,	O
100,	O
and	O
200	O
mg/kg	O
body	O
weight	O
taken	O
at	O
1.5	O
h	O
(d)	O
Percent	O
blood	O
glucose	B
reduction	O
of	O
dichloromethane	B
extract	O
at	O
25,	O
50,	O
100,	O
and	O
200	O
mg/kg	O
body	O
weight	O
taken	O
at	O
2	O
h	O
(e)	O
Percent	O
blood	O
glucose	B
reduction	O
of	O
dichloromethane	B
extract	O
at	O
25,	O
50,	O
100,	O
and	O
200	O
mg/kg	O
body	O
weight	O
taken	O
at	O
2.5	O
h	O

Pathway	O
analysis	O
shows	O
the	O
alteration	O
of	O
phosphoric	B
acid	I
and	O
cholesterol	B
involved	O
in	O
ABC	O
family	O
protein	O
mediated	O
transport,	O
as	O
shown	O
in	O
.	O

Of	O
the	O
40	O
patients	O
in	O
the	O
study,	O
23	O
[58%]	O
were	O
female,	O
median	O
age	O
was	O
40	O
years	O
[range	O
17–62	O
years],	O
median	O
disease	O
duration	B
was	O
6	O
years	O
[range	O
1.2	O
months	O
to	O
46	O
years],	O
and	O
extent	O
of	O
disease	O
was	O
8/40	O
proctitis,	O
15/40	O
left-sided	O
colitis,	O
15/40	O
extensive	O
disease	O
and	O
2/40	O
unsure.	O

Panagiotidis	O
et	O
al.	O
demonstrated	O
that	O
hydroxylamine	B
inhibited	O
both	O
glucose-induced	O
and	O
L-arginine-induced	O
insulin	O
secretion	O
in	O
freshly	O
prepared	O
mouse	O
islets.	O

This	O
NMR-based	O
metabolomic	O
analysis	O
focused	O
on	O
postoperative	O
AF.	B

Changes	O
in	O
lipids,	O
glucose,	B
pyruvate,	B
lactate,	B
alanine	B
and	O
glutamine	B
suggest	O
shifts	O
in	O
energy	O
metabolism.	O

The	O
cells	O
were	O
grown	O
in	O
the	O
presence	O
of	O
10.75	O
mM	O
[U–_13	B
C]-glucose	I
for	O
24	O
h,	O
and	O
the	O
metabolites	O
were	O
extracted	O
as	O
described	O
in	O
the	O
“Methods”.	O

Decreased	O
metabolite	O
levels	O
of	O
glucose,	B
glycine,	B
creatinine	B
and	O
taurine,	B
as	O
well	O
as	O
increased	O
citrate	B
and	O
glutamate	B
in	O
EC	O
tissues,	O
were	O
also	O
detectable	O
in	O
the	O
urine	O
of	O
EC	O
patients.	O

Stool	O
homogenates	O
(30	O
μL)	O
were	O
extracted	O
using	O
90	O
μL	O
of	O
methanol	B
containing	O
PGE2­d4	O
as	O
an	O
internal	O
standard	O
(Cayman	O
Chemical	O
Co.;	O
Ann	O
Arbor,	O
MI)	O
and	O
centrifuged	O
(10	O
min,	O
9,000	O
x	O
g,	O
4°C).	O

In	O
contrast,	O
higher	O
level	O
of	O
D-Mannose	B
was	O
associated	O
with	O
increased	O
risks	O
of	O
PLP	O
and	O
CRC	O
(OR	O
ranges	O
from	O
8	O
to	O
16).	O

Dalfampridine-ER	B
is	O
incorporated	O
into	O
MS	O
management	O
strategies	O
that	O
may	O
include	O
disease-modifying	O
and	O
symptomatic	O
therapies.	O

The	O
content	O
of	O
linoleic	B
acid	I
(LA;	O
18:2	O
n	O
-6)	O
in	O
serum	O
phospholipids	B
was	O
also	O
determined.	O

The	O
samples	O
were	O
washed	O
with	O
5 mL	O
of	O
water	O
to	O
remove	O
the	O
chloroform	B
layer.	O

Panels	O
A1	O
to	O
D1	O
show	O
the	O
expression	O
of	O
pyruvate	B
kinase	O
muscle	O
isozyme	O
2	O
(PKM2),	O
carnitine	O
palmitoyltransferase	O
1	O
(CPT1),	O
glycogen	B
synthase	O
kinase	O
3	O
beta	O
(GSK3β),	O
and	O
glutamate	O
decarboxylase	O
1	O
(GAD1),	O
respectively	O
in	O
the	O
normal	O
cervical	O
epithelium.	O

(B)	O
Decanoylcarnitine	B
levels	O
among	O
CD36	O
(c.975T>G)	O
LoF	O
mutation	O
carriers.	O

1-MN,	O
a	O
methylation	O
product	O
of	O
nicotinamide,	B
has	O
been	O
shown	O
to	O
exert	O
anti-inflammatory	O
properties	O
and	O
scavenge	O
oxygen	O
radicals	O
,	O
.	O

Tryptophan	B
also	O
plays	O
fundamental	O
roles	O
in	O
the	O
synthesis	O
of	O
neurotransmitters	O
like	O
serotonin,	B
melatonin,	B
and	O
tryptamine.	B

Furthermore,	O
grade	O
II	O
oligoastrocytoma	O
presented	O
higher	O
relative	O
intensities	O
of	O
plasmenyl-PEs	B
and	O
glycerophosphoglycerols	B
PG,	I
when	O
compared	O
to	O
grade	O
III	O
oligoastrocytoma,	O
a	O
trend	O
not	O
as	O
clearly	O
observed	O
for	O
any	O
of	O
the	O
other	O
subtypes	O
of	O
gliomas.	O

Whilst	O
the	O
increases	O
in	O
phenylalanine	B
were	O
relatively	O
modest,	O
our	O
results	O
are	O
consistent	O
with	O
findings	O
showing	O
increased	O
plasma	O
levels	O
of	O
phenylalanine	B
in	O
patients	O
with	O
trauma	O
and	O
sepsis.	O

Alternatives	O
to	O
the	O
oxo	O
group	O
x	O
are	O
an	O
enol	O
or	O
epoxy	B
group;	O
all	O
add	O
14	O
Da	O
to	O
the	O
sterol	O
structure.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
age	O
at	O
study	O
entry	O
(mean	O
age	O
±	O
standard	O
deviation,	O
39.7±15.3	O
years	O
versus	O
35.0±9.46	O
years),	O
the	O
proportion	O
of	O
females	O
(33/44,	O
75.0%	O
versus	O
33/42,	O
78.6%),	O
serum	O
creatinine	B
levels,	O
body	O
mass	O
index	O
(BMI),	O
or	O
the	O
proportion	O
of	O
past	O
or	O
present	O
smoker	O
between	O
AOSD	O
patients	O
and	O
healthy	O
subjects.	O

However,	O
the	O
average	O
plasma	O
concentration	O
of	O
hydroxyanastrozole	B
was	O
significantly	O
higher	O
(>11-fold)	O
in	O
the	O
β-glucuronidase	O
samples	O
compared	O
with	O
those	O
samples	O
untreated	O
with	O
β-glucuronidase	O
(;	O

Concomitantly,	O
as	O
most	O
prominently	O
increased	O
metabolites	O
in	O
urine	O
were	O
characterized:	O
mannitol,	B
allantoin,	B
xylose,	B
carnitine,	B
lactate,	B
threonine[]	B
and	O
formate[],	O
whereas	O
decreased	O
hippurate[,,],	O
succinate,	B
citrate,	B
1-methylhistidine,	B
methanol,	B
formate,	B
trigonelline,	B
urea,	B
taurine[,],	B
asparagine,	B
lysine,	B
histidine,	B
acetate,	B
methylamine,	B
creatine,	B
trans-aconitate[],	B
betaine[]	O
and	O
4-cresol	B
sulfate[].	I

The	O
robust	O
production	O
and	O
export	O
of	O
lactate	B
by	O
many	O
tumors	O
is	O
associated	O
with	O
the	O
acidification	O
of	O
the	O
microenvironment,	O
which	O
disrupts	O
the	O
function	O
of	O
tumor	O
associated	O
stromal	O
cells	O
while	O
enhancing	O
the	O
aggressiveness	O
of	O
neoplastic	O
cells.	O

For	O
instance,	O
there	O
is	O
conflicting	O
information	O
regarding	O
the	O
concentration	O
changes	O
of	O
cysteine	B
(,	O
,	O
),	O
phenylalanine	B
(,	O
),	O
and	O
taurine	B
(,	O
,	O
)	O
toward	O
the	O
end	O
of	O
pregnancy.	O

–	O
However,	O
in	O
both	O
groups	O
melatonin	B
levels	O
were	O
higher	O
at	O
T1	O
and	O
T2.	O

A	O
subset	O
of	O
the	O
samples	O
was	O
processed	O
prior	O
to	O
the	O
optimization	O
of	O
the	O
glucuronidase	O
reaction	O
and	O
this	O
is	O
the	O
reason	O
for	O
the	O
smaller	O
‘n’	O
for	O
DHEA-G	O
measurements	O
compared	O
to	O
DHEA-S	B
measurements	O
in	O
TAPS	O
Arm	O
1.	O

As	O
shown	O
in	O
,	O
42	O
metabolites,	O
which	O
were	O
involved	O
in	O
the	O
metabolic	O
processes	O
related	O
to	O
amino	O
acids,	O
carbohydrates,	O
energy,	O
lipids,	O
organic	O
acids	O
and	O
urea,	B
were	O
identified	O
and	O
then	O
qualitatively	O
and	O
quantitatively	O
analyzed	O
in	O
detail.	O

Low	O
levels	O
of	O
glucose	B
and	O
propylene	B
glycol	I
probably	O
result	O
from	O
the	O
rapid	O
oxidation	O
of	O
these	O
metabolites	O
into	O
pyruvate	B
and	O
reflect	O
increasing	O
energy	O
demands	O
during	O
septic	O
shock.	O

Early	O
tracing	O
experiments	O
using	O
rat	O
muscle	O
in	O
vitro	O
indicate	O
that	O
glutamate,	B
aspartate	B
and	O
specific	O
branched	O
amino	O
acids	O
(isoleucine	O
and	O
valine)	B
should	O
enter	O
the	O
TCA	O
cycle	O
and	O
serve	O
as	O
carbon	O
skeleton	O
and	O
nitrogen	O
supply	O
for	O
glutamine	B
synthesis_,	O
,	O
however	O
only	O
the	O
uptake	O
pattern	O
of	O
glutamate	B
has	O
been	O
previously	O
reported,	O
The	O
uptake	O
pattern	O
of	O
serine,	B
reflected	O
as	O
lower	O
concentration	O
in	O
venous	O
blood,	O
is	O
a	O
new	O
finding	O
as	O
well,	O
which	O
may	O
imply	O
its	O
usage	O
for	O
pyruvate	B
anaplerosis,	O
as	O
a	O
non-carbohydrate	O
precursor,	O
by	O
serine	B
dehydratase	O
mediated	O
direct	O
conversion	O
to	O
pyruvate.	B

Likewise,	O
in	O
the	O
literature,	O
finger‐stick‐based	O
capillary	O
and	O
venous	O
concentrations	O
were	O
reported	O
to	O
be	O
similar	O
after	O
repeated	O
dosing	O
for	O
a	O
number	O
of	O
antipsychotics16	O
and	O
for,	O
for	O
example,	O
theophylline,17	B
cyclosporin,18	O
and	O
tobramycin.19	B
Finally,	O
variability	O
(in	O
%difference)	O
was	O
evaluated.	O

This	O
finding	O
suggests	O
a	O
connection	O
between	O
HACE1	O
and	O
the	O
equol-producing	O
phenotype,	O
based	O
on	O
the	O
structural	O
similarity	O
of	O
equol	O
to	O
the	O
potent	O
estrogen	B
estradiol	I
(Setchell	O
and	O
Clerici	O
as	O
a	O
review).	O

Subjects	O
were	O
asked	O
to	O
abstain	O
from	O
food	O
and	O
liquids	O
after	O
midnight	O
prior	O
to	O
the	O
day	O
of	O
methadone	B
administration.	O

Among	O
the	O
LASSO-selected	O
11	O
metabolites,	O
four	O
(valine,	O
isoleucine,	B
glutamic	B
acid,	I
and	O
the	O
furanose	O
sugar)	O
were	O
also	O
found	O
statistically	O
significant	O
in	O
a	O
GC-MS–based	O
metabolomic	O
analysis	O
we	O
conducted	O
previously	O
using	O
plasma	O
samples	O
from	O
HCC	O
cases	O
and	O
patients	O
with	O
liver	O
cirrhosis	O
recruited	O
in	O
Tanta,	O
Egypt.	O

The	O
present	O
chiral	O
tandem	O
LC-MS/MS	O
system	O
was	O
a	O
promising	O
tool	O
for	O
the	O
simultaneous	O
analysis	O
of	O
chiral	O
amino	O
acids	O
(L-amino	O
acids	O
and	O
trace	O
D-amino	B
acids)	O
within	O
short	O
time,	O
although	O
some	O
peaks	O
could	O
be	O
only	O
partially	O
separated.	O

The	O
hypothesis	O
that	O
we	O
have	O
proposed	O
to	O
explain	O
the	O
consistently	O
negative	O
correlations	O
between	O
metabolite	O
groups	O
and	O
lipids	O
that	O
we	O
have	O
observed	O
in	O
the	O
five	O
types	O
of	O
brain	O
tumours—that	O
cells	O
with	O
strong	O
metabolic	O
pathway	O
flux	O
(and	O
thus	O
high	O
concentrations	O
of	O
lactate,	B
tCr,	O
tGlut	O
and	O
tCho)	O
tend	O
not	O
to	O
contain	O
NMR-visible	O
lipid	O
droplets,	O
and	O
vice	O
versa	O
—suggests	O
a	O
possible	O
mechanism	O
for	O
explaining	O
the	O
phenomena	O
observed	O
in	O
earlier	O
studies.	O

Other	O
than	O
the	O
pathways	O
discussed	O
previously,	O
it	O
is	O
worth	O
note	O
that	O
the	O
glyoxylate	B
and	O
dicarboxylate	B
metabolism	O
has	O
also	O
been	O
reported	O
in	O
the	O
previous	O
study	O
as	O
one	O
of	O
the	O
most	O
probable	O
pathways	O
involved	O
in	O
class	O
separation	O
between	O
lean	O
and	O
obese	O
asthmatic	O
patients.	O

Alanine	O
aminotransferase	O
(ALT),	O
aspartate	O
aminotransferase	O
(AST),	O
γ-GT,	B
cholinesterase	O
(ChE),	O
blood	O
urea	B
nitrogen	I
(BUN),	O
creatinine	B
(Cr),	O
and	O
uric	B
acid	I
(UA)	O
were	O
assessed	O
on	O
an	O
automatic	O
analyzer	O
(7600–020	O
biochemistry	O
automatic	O
analyzer,	O
Hitachi,	O
Tokyo,	O
Japan).	O

For	O
ceramides	B
quantification	O
by	O
LC-MS/MS	O
analysis,	O
the	O
reconstituted	O
sample	O
was	O
diluted	O
1:4	O
before	O
injection.	O

Moreover,	O
Lv	O
et	O
al.	O
demonstrated	O
circulating	O
levels	O
of	O
PC	B
40:1	I
and	O
PC	B
40:4	I
as	O
upregulated	O
lipid	O
molecular	O
species	O
that	O
are	O
specific	O
for	O
small	O
cell	O
lung	O
cancer	O
(SCLC).	O

Additionally,	O
four	O
potential	O
PO	O
biomarkers	O
(α-glucose,	O
pyruvate,	B
glutamate,	B
and	O
valine)	B
with	O
an	O
AUC	O
of	O
0.985	O
were	O
selected	O
to	O
distinguish	O
ESCC	O
and	O
PO.	O

Ultimately,	O
approximately	O
47	O
metabolites	O
were	O
tagged	O
in	O
the	O
spectra	O
between	O
the	O
two	O
groups,	O
including	O
amino	O
acids,	O
organic	O
acids,	O
energy	O
metabolism,	O
methylguanidine,	B
myo-inositol,	B
trimethylamine	B
N-oxide,	I
glucose	B
components,	O
lipids,	O
carbohydrates,	O
nucleotides	O
and	O
so	O
on.	O

(Epirubicin,	O
1).	O

In	O
brief,	O
duplicate	O
incubations	O
were	O
conducted	O
at	O
37 ± 1°C	O
in	O
400 μL	O
incubation	O
mixtures	O
containing	O
potassium	B
phosphate	I
buffer	O
(50 mM,	O
pH	O
7.4),	O
MgCl_2	O
(3 mM),	O
EDTA	O

More	O
carnitine	B
relative	O
to	O
isobutyryl-L-carnitine	B
suggests	O
that	O
fatty	O
acids	O
are	O
preferentially	O
transported	O
to	O
mitochondria	O
or	O
used	O
as	O
building	O
blocks	O
for	O
membrane	O
biogenesis.	O

In	O
this	O
context,	O
the	O
enrichment	O
in	O
M3	O
glucose,	B
a	O
marker	O
for	O
gluconeogenesis,	O
is	O
of	O
high	O
interest,	O
but	O
did	O
not	O
exceed	O
the	O
limit	O
of	O
detection.	O

Erucic	B
acid	I
intake	O
(through	O
canola,	O
Wallflower,	O
or	O
Lorenzo's	O
oil)	O
has	O
been	O
suggested	O
to	O
be	O
beneficial	O
for	O
peroxisomal	O
disorders	O
like	O
X-linked	O
adrenoleukodystrophy	O
by	O
reducing	O
the	O
saturated	O
VLCFA	O
by	O
negative	O
feedback	O
(Risé	O
et	O
al.,	O
).	O

Even	O
though	O
thunalbene	B
was	O
not	O
observed	O
in	O
the	O
samples,	O
its	O
demethylated	O
metabolite,	O
isoresveratrol	O
(3,3’,5-trihydroxystilbene),	O
was	O
detected.	O

SN-38	O
exposure	O
induced	O
concentration-	O
and	O
time-dependent	O
accumulation	O
of	O
amino	O
acid	O
metabolites,	O
acylcarnitines,	B
and	O
pyrimidine/purine	O
nucleosides	O
and	O
nucleobases	O
in	O
HepatoCells,	O
whereas,	O
in	O
the	O
culture	O
medium	O
of	O
2	O
cancer	O
cell	O
lines,	O
SN-38	O
exposure	O
only	O
led	O
to	O
significant	O
accumulations	O
of	O
pyrimidine/purine	O
nucleosides	O
and	O
nucleobases,	O
while	O
having	O
no	O
apparent	O
impact	O
on	O
amino	O
acid	O
metabolites	O
and	O
acylcarnitines.	B

2-(N	B
-acetylcysteinyl)phenanthrene	I

Carnitine	B
was	O
a	O
major	O
contributor	O
to	O
the	O
pathway	O
differences.	O

Acyl	O
group	O
arising	O
from	O
the	O
metabolism	O
of	O
BCAAs	O
has	O
been	O
suggested	O
to	O
be	O
contributing	O
proportionately	O
to	O
the	O
acyl-carnitine	B
fraction	O
in	O
cirrhosis.	O

Patients	O
in	O
the	O
darunavir-based	O
group	O
had	O
a	O
higher	O
prevalence	O
of	O
dyslipidaemia	O
and	O
higher	O
cholesterol	B
and	O
triglyceride	B
concentrations	O
than	O
patients	O
taking	O
integrase	O
inhibitor-based	O
ART,	O
but	O
these	O
differences	O
were	O
not	O
significant.	O

In	O
addition,	O
there	O
were	O
some	O
disparities	O
in	O
the	O
removal	O
efficiencies	O
of	O
HFD	O
and	O
HD	O
in	O
some	O
amino	O
acids	O
and	O
alkaline	B
compounds.	O

Resolvin	B
D1	I
(RvD1,	O
82	O
±	O
11	O
pM	O
vs.	O
152	O
±	O
17	O
pM,	O
p	O
=	O
0.001)	O
and	O
docosahexaenoic	B
acid	I
(DHA)	O
(0.052	O
±	O
0.007	O
μM	O
versus	O
0.076	O
±	O
0.008	O
μM,	O
p	O
=	O
0.025)	O
levels	O
are	O
decreased	O
in	O
the	O
sera	O
of	O
patients	O
presenting	O
with	O
an	O
acutely	O
symptomatic	O
carotid	O
plaque	O
rupture	O
event	O
(n=21)	O
compared	O
to	O
patients	O
with	O
asymptomatic	O
(n=24)	O
high-grade	O
carotid	O
stenosis.	O

Metabolic	O
profiling	O
of	O
plasma	O
after	O
stress	O
testing	O
and	O
marathon-running	O
have	O
previously	O
demonstrated	O
significant	O
changes	O
accompanying	O
exercise	O
in	O
purine	B
metabolites	O
and	O
Krebs'	O
cycle	O
intermediates.	O

Branched-chain	O
amino	O
acids	O
(BCAAs)	O
show	O
higher	O
connectivity	O
in	O
deceased	O
patients,	O
in	O
particular	O
isoleucine	B
in	O
low-risk	O
networks	O
and	O
valine	B
in	O
high-risk	O
networks,	O
thus	O
implying	O
a	O
central	O
role	O
of	O
their	O
metabolism	O
in	O
AMI.	O

Dehydroepiandrosterone	B
(DHEA)	O
is	O
the	O
most	O
abundant	O
adrenal	O
steroid	O
hormone	O
in	O
humans,	O
and	O
DHEA-S,	B
the	O
sulphated	O
ester	O
of	O
DHEA,	O
is	O
the	O
hydrophilic	B
storage	O
form	O
bound	O
to	O
albumin	O
in	O
the	O
bloodstream.	O

Urinary	O
concentrations	O
of	O
3.2485,	O
2.924,	O
and	O
3.243	O
ppm	O
(annotated	O
as	O
tyramine)	O
and	O
3.0157	O
and	O
3.0212	O
ppm	O
(annotated	O
as	O
2-oxoglutarate)	B
were	O
increased	O
in	O
the	O
IC	O
patient	O
group	O
compared	O
to	O
that	O
in	O
controls	O
(Figure	O
C).	O

High	O
levels	O
of	O
glutamate	B
in	O
the	O
present	O
study	O
can	O
be	O
associated	O
with	O
an	O
activation	O
of	O
glutaminolysis	O
through	O
an	O
increased	O
activity	O
of	O
the	O
mitochondrial	O
enzyme	O
glutaminase.	O

Identified	O
metabolites	O
with	O
VIP	O
values	O
>1	O
were:	O
glucose,	B
lactate,	B
alanine,	B
leucine,	B
isoleucine,	B
glutamate,	B
glutamine,	B
valine,	B
lysine,	B
tyrosine,	B
phenylalanine,	B
threonine,	B
β-hydroxy-butyrate,	B
acetate,	B
acetoacetate,	B
urea,	B
creatine	B
and	O
creatinine.	B

Recurrence	O
was	O
defined	O
as	O
the	O
duration	B
of	O
the	O
period	O
from	O
the	O
first	O
day	O
of	O
treatment	O
to	O
the	O
detection	O
of	O
tumor	O
progression	O
including	O
distant	O
recurrence	O
or	O
pelvic	O
recurrence	O
within	O
3	O
years.	O

Rac-methadone-HCl	B
(d_0	O
)	O
was	O
obtained	O
from	O
Roxane	B
Laboratories,	O
INC	O
(Columbus,	O
Ohio).	O

We	O
also	O
uncovered	O
a	O
set	O
of	O
compounds	O
remarkably	O
similar	O
in	O
circulating	O
levels	O
among	O
young	O
subjects	O
and	O
centenarians,	O
while	O
varying	O
in	O
the	O
elderly	O
only,	O
characterized	O
by	O
an	O
increased	O
concentration	O
of	O
specific	O
glycerophospholipids	B
mostly	O
polyunsaturated	O
diacyl	B
phospholipids	I
(PC)	O
(,	O
).	O

Signals	O
related	O
to	O
medications	O
(5-aminosalicylate,	O
azathioprine	B
and	O
acetaminophen)	B
were	O
eliminated	O
from	O
the	O
statistical	O
and	O
chemometric	O
evaluation.	O

This	O
lipidomic	O
study,	O
by	O
highlighting	O
retina	O
specific	O
ganglioside	B
species,	O
opens	O
up	O
novel	O
research	O
directions	O
for	O
a	O
better	O
understanding	O
of	O
the	O
biological	O
role	O
of	O
gangliosides	B
in	O
the	O
retina.	O

We	O
also	O
observe	O
that	O
weight	O
gain	O
during	O
breast	O
cancer	O
treatment	O
may	O
be	O
associated	O
with	O
decreased	O
acylcarnitines,	B
lyso-phosphatidylcholines,	B
phosphatidylcholines	B
and	O
sphingolipids	B
at	O
baseline,	O
suggesting	O
alterations	O
in	O
lipid	O
metabolism	O
in	O
these	O
patients.	O

Concentrations	O
of	O
13	O
plasma	O
metabolites	O
showed	O
linear	O
trends	O
with	O
relation	O
to	O
TPA	O
level	O
in	O
the	O
original	O
dataset	O
even	O
after	O
adjustment	O
for	O
multiplicity	O
(FDR	O
p	O
<0.05),	O
of	O
which	O
concentrations	O
of	O
five	O
(isoleucine,	O
4-methyl-2-oxopentanoate,	B
alanine,	B
proline,	B
and	O
pipecolate)	B
were	O
replicated.	O

In	O
particular	O
it	O
was	O
found	O
that	O
when	O
mice	O
deficient	O
for	O
the	O
α-tocopherol	B
transport	O
protein	O
(α-TTP)	O
were	O
supplemented	O
with	O
α-tocopherol	B
there	O
was	O
an	O
increase	O
in	O
their	O
glucose	B
tolerance.	O

Four	O
metabolites	O
(5-hydroxymethyl-2′-deoxyuridine,	O
1-methyladenosine,	B
2-deoxyguanosine,	B
and	O
4-hydroxybenzoic	B
acid)	O
were	O
found	O
to	O
have	O
the	O
highest	O
VIP	O
scores.	O

Spectral	O
regions	O
of	O
0.3	O
to	O
10.0	O
ppm	O
were	O
used	O
for	O
the	O
analysis	O
after	O
deleting	O
the	O
water	O
and	O
urea	B
signals	O
(4.5	O
to	O
6.0	O
ppm).	O

Glycerophospholipids,	B
1-palmitoyl-2-oleyl-sn	B
-glycero-3-phosphocholine	I
(POPC)	O
and	O
1-palmitoyl-2-oleyl-sn	B
-glycero-3-phosphoglycerol	I
(POPG),	O
were	O
purchased	O
from	O
Avanti	O
Polar	O
Lipids	O
(Alabaster,	O
AL)	O
with	O
a	O
purity	O
grade	O
of	O
>99%.	O

The	O
concentration	O
of	O
fructose	B
was	O
2.2-fold	O
greater	O
in	O
the	O
baseline	O
pooled	O
blood	O
aliquots	O
from	O
participants	O
with	O
incident	O
central	O
adiposity	O
gain	O
compared	O
with	O
the	O
stable	O
adiposity	O
group	O
[46.2	O
(SE	O
=	O
0.9)	O
vs.	O
27.8	O
(SE	O
=	O
1.6);	O
P	O
=	O
0.022].	O

Glutamine	B
is	O
reported	O
to	O
increase	O
insulin	O
secretion	O
and	O
suppress	O
β‐cell	O
apoptosis	O
in	O
diabetic	O
rats_44	O
.	O

The	O
HCCH-TOCSY	O
spectrum	O
of	O
the	O
myocyte	O
extract	O
(Figure	O
)	O
displayed	O
covalent	O
connectivities	O
of	O
protons	O
attached	O
to	O
consecutively	O
_13	O
C-labeled	O
carbons	O
of	O
various	O
metabolites	O
such	O
as	O
lactate,	B
Ala,	O
Glu,	O
β-glucose-6-phosphate	B
(βG6P),	O
glycogen,	B
and	O
AXP.	O

The	O
increment	O
in	O
serum	O
creatinine	B
and	O
BUN	O
concentrations	O
are	O
consistent	O
with	O
acute	O
kidney	O
injury	O
in	O
cats,	O
according	O
to	O
the	O
International	O
Renal	O
Interest	O
Society,	O
suggesting	O
that	O
the	O
repeated	O
administration	O
of	O
meloxicam	O
altered	O
kidneys’	O
filtration.	O

(A)	O
Glycerophospholipid	B
metabolism.	O

Go	O
to:	O
Exposure	O
to	O
tobacco-specific	O
nitrosamines	B
(TSNA)	O
and	O
polycyclic	B
aromatic	O
hydrocarbons	B
(PAH)	O
is	O
recognized	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
oral/head	O
and	O
neck	O
squamous	O
cell	O
cancer	O
(HNSCC).	O

Acon	O
-knockdown	O
flies	O
showed	O
significantly	O
decreased	O
intermediate	O
metabolites	O
of	O
glycolysis,	O
namely	O
glucose-1-phosphate,	B
glucose-6-phosphate,	B
fructose-6-phosphate,	B
glyceraldehyde-3-phosphate,	B
2-phosphoglycerate,	B
3-phosphoglycerate,	B
phosphoenolpyruvate	B
(PEP)	O
and	O
pyruvate.	B

The	O
cluster	O
containing	O
glutamine,	B
N	B
-acetyltryptophan,	I
O	B
-succinyl-homoserine,	I
thymine,	B
uridine,	B
glutarylcarnitine,	B
3-methoxytyrosine,	B
methionine,	B
4-acetamidobutanoate,	B
pipecolate,	B
ketoleucine,	B
indole-3-acetate	B
and	O
1-methyladenosine	B
depicted	O
multiple	O
significant	O
positive	O
associations	O
to	O
clinical	O
measures	O
as	O
well	O
as	O
a	O
negative	O
association	O
to	O
the	O
size	O
of	O
the	O
spinal	O
cord	O
(see	O
,	O
,	O
and	O
Table	O
S4).	O

Therefore,	O
it	O
only	O
can	O
be	O
speculated	O
that	O
the	O
decreased	O
resting	O
urinary	O
hypoxanthine	B
levels	O
are	O
evidence	O
of	O
an	O
increased	O
ability	O
of	O
the	O
body	O
to	O
conserve	O
or	O
restore	O
the	O
purine	B
nucleotide	O
pool.	O

Incubation	O
of	O
primary	O
human	O
hepatocytes	O
with	O
BaP-7,8-diol	B
produced	O
four	O
isomers	O
of	O
BaPT,	O
as	O
summarized	O
in	O
.	O

Information	O
on	O
concomitant	O
medication	O
and	O
self‐reported	O
adverse	O
events	O
during	O
tamoxifen	B
treatment	O
were	O
recorded	O
during	O
all	O
visits.	O

Finally,	O
in	O
IR	O
hypogonadism,	O
only	O
a	O
small	O
percentage	O
of	O
acetyl-CoA	B
enters	O
the	O
Krebs	O
cycle,	O
being	O
transformed	O
into	O
citrate.	B

Calibration	O
standards	O
(caffeine,	O
Ultramark	O
1621	O
and	O
MRFA)	O
were	O
provided	O
by	O
Thermo	O
Fisher	O
Scientific.	O

In	O
the	O
control	O
cultures	O
of	O
16HBE14o_−	O
cells,	O
a	O
drop	O
of	O
160	O
µmol/l	O
in	O
the	O
extracellular	O
concentration	O
of	O
aspartate	B
was	O
detected	O
during	O
the	O
culture	O
period	O
of	O
2	O
h.	O
During	O
rHla-treatment	O
of	O
cells	O
for	O
2	O
h,	O
however,	O
the	O
extracellular	O
aspartate	B
concentration	O
increased	O
by	O
145	O
µmol/l.	O

Transcriptomic	O
and	O
metabolomics	O
studies	O
have	O
revealed	O
that	O
expression	O
of	O
PPM1K	O
(the	O
gene	O
encoding	O
PP2Cm)	O
is	O
suppressed	O
in	O
cardiomyopathy	O
and	O
that	O
proteins	O
involved	O
in	O
the	O
rate-limiting	O
step	O
of	O
BCAA	O
degradation,	O
including	O
BCKDH	O
E1	O
α/β	O
and	O
E2	O
subunits,	O
are	O
downregulated	O
during	O
pathological	O
stress,	O
leading	O
to	O
marked	O
accumulation	O
of	O
branched-chain	O
alpha-keto	B
acids	I
(BCKAs)	O
in	O
stressed	O
heart	O
tissue.	O

HPLC-grade	O
chloroform	B
was	O
purchased	O
from	O
Scharlau	O
(Spain).	O

A	O
Conover-Inman	O
test	O
for	O
multiple	O
comparison	O
between	O
milk	O
and	O
soy	O
drink	O
intake	O
further	O
revealed	O
significant	O
differences	O
for	O
C15:0,	B
which	O
were	O
suggestive	O
of	O
a	O
discriminating	O
potential	O
of	O
this	O
molecule.	O

The	O
SLE	O
patients	O
with	O
severe	O
APO	O
were	O
best	O
characterized	O
by	O
reduced	O
amino	O
acids	O
(e.g.	O
methionine,	B
tryptophan,	B
and	O
valine).	B

The	O
residues	O
were	O
dissolved	O
in	O
a	O
mixture	O
of	O
anhydrous	B
methanol	I
and	O
toluene	B
2:1	I
(2.0	O
ml)	O
containing	O
BHT	O
(0.01	O
%)	O
and	O
the	O
samples	O
placed	O
on	O
ice.	O

(2018),	O
bostrycoidin	O
(12),	O
anhydrofusarubin	B
(13),	O
4-hydroxybenzaldehyde	B
(78)	O
and	O
fusarubin	O
(7)	O
exhibited	O
significant	O
antioxidant	O
activity	O
with	O
IC_50	O
values	O
of	O
1.6,	O
12.4,	O
28.9	O
and	O
34.8	O
μg/mL,	O
respectively.	O

Promotion	O
of	O
glycolysis	O
and	O
disruption	O
of	O
the	O
TCA	O
cycle	O
occur	O
in	O
gastric	O
cancer	O
cells	O
and	O
the	O
intermediate	O
products	O
such	O
as	O
fumaric	B
acid	I
and	O
α-ketoglutaric	B
acid	I
prominently	O
increase	O
in	O
the	O
metabolic	O
profile	O
of	O
gastric	O
cancer	O
tissue.	O

Fifty	O
microliters	O
of	O
well-mixed	O
serum	O
was	O
added	O
to	O
the	O
internal	O
standard,	O
followed	O
by	O
1000	O
μl	O
of	O
acetonitrile.	B

Mobile	O
phase	O
A	O
is	O
0.1%	O
formic	B
acid	I
in	O
water,	O
mobile	O
phase	O
B	O
is	O
0.1%	O
formic	B
acid	I
in	O
acetonitrile.	B

α-KG	B
is	O
a	O
component	O
of	O
the	O
tricarboxylic	B
acid	I
(TCA)	O
cycle,	O
is	O
linked	O
to	O
glutamate	B
via	O
anaplerotic	O
reactions,	O
but	O
it	O
is	O
also	O
a	O
substrate	O
for	O
more	O
than	O
50	O
mammalian	O
dioxygenases,	O
such	O
as	O
TET2	O
that	O
hydroxylates	B
5-methyl	I
cytosine,	I
the	O
histone	O
demethylases	O
KDM,	O
the	O
prolyl	O
hydroxylases	O
EGLN	O
1/2/3,	O
and	O
the	O
histone	O
methyltransferases	O
KMT_,	O
.	O

Because	O
of	O
the	O
non-polar	O
nature	O
of	O
vitamin	B
D	I
derivatives,	O
a	O
derivatization	O
reaction	O
was	O
required	O
in	O
this	O
study	O
to	O
enhance	O
the	O
ionization	O
efficiencies,	O
thus	O
allowing	O
detection	O
of	O
the	O
very	O
low	O
abundant	O
vitamin	B
D	I
metabolites.	O

It	O
is	O
likely	O
that	O
the	O
scale	O
of	O
underreporting	O
of	O
total	O
analgesic	O
use	O
is	O
greater,	O
since	O
only	O
acetaminophen	B
and	O
ibuprofen	B
metabolites	O
were	O
detected	O
by	O
the	O
present	O
method.	O

The	O
participants	O
were	O
requested	O
not	O
to	O
consume	O
alcohol	O
or	O
caffeine,	B
use	O
non-steroidal	O
anti-inflammatory	O
drugs,	O
perform	O
heavy	O
exercise,	O
or	O
be	O
exposed	O
to	O
bright	O
light	O
in	O
the	O
evenings	O
and	O
nights	O
for	O
72 hours	O
before	O
the	O
in-laboratory	O
session	O
to	O
ensure	O
a	O
stable	O
circadian	O
phase	O
and	O
minimize	O
sleep	O
deprivation	O
prior	O
to	O
entry	O
into	O
the	O
laboratory	O
study.	O

Prevalence	O
of	O
Analgesic	O
Use	O
According	O
to	O
Detection	O
of	O
Urinary	O
Acetaminophen	B
and	O
Ibuprofen	B
Metabolites	O
and	O
According	O
to	O
Self-Reports	O
Among	O
Male	O
Participants,	O
by	O
Country	O
and	O
Age	O
Group,	O
International	O
Study	O
of	O
Macro-/Micro-Nutrients	O
and	O
Blood	O
Pressure,	O
1996–1999	O
Abbreviation:	O
_1	O
H	O
NMR,	O
hydrogen-1	B
nuclear	O
magnetic	O
resonance.	O

Creatinine	B
was	O
assayed	O
by	O
a	O
fast	O
ESI-MS/MS	O
method	O
as	O
described	O
previously.	O

Mobile	O
phase	O
A	O
(0.1	O
M	O
ammonium	B
acetate)	I
was	O
delivered	O
at	O
0.3	O
mL/min	O
and	O
mobile	O
phase	O
B	O
(60%	O
ACN/0.1	O
M	O
ammonium	B
acetate)	I
was	O
delivered	O
at	O
0.2	O
mL/min.	O

The	O
level	O
of	O
citrulline	B
decreased	O
along	O
with	O
the	O
processes	O
of	O
gastric	O
cancer,	O
which	O
may	O
suggest	O
the	O
deterioration	O
of	O
the	O
redox	O
state	O
of	O
tumor.	O

(desamino-[_2	O
H_5	I
]-PhIP-Y)	I
adduct	O
([M+2H]_2+	O
at	O
m/z	O
312.4);	O
E)	O
Fraction	O
8,	O
Y*LYEIAR	O
(desamino-PhIP-Y)	O
adduct	O
([M+2H]_2+	O
at	O
m/z	O
568.1)	O
recovered	O
from	O
NO_2	O
-PhIP-modified	O
SA;	O
and	O
F)	O
Y*LYEIAR	O
(desamino-[_2	O
H_5	I
]-PhIP-Y)	I
adduct	O
([M+2H]_2+	O
at	O
m/z	O
570.6)	O
recovered	O
from	O
NO_2	O
-[_2	O
H_5	O
]-PhIP	O
modified	O
SA	O
by	O
trypsin	O
digestion.	O

eGFR	O
was	O
calculated	O
using	O
the	O
CKD-EPI	O
formula	O
from	O
serum	O
creatinine	B
quantified	O
by	O
enzymatic	O
assay	O
and	O
IDMS-aligned.	O

Once	O
corrected	O
for	O
surgery	O
(and	O
TNF-α	O
inhibitor	O
treatment)	O
the	O
higher	O
abundance	O
of	O
BCAA,	O
lysine,	B
alanine,	B
and	O
taurine	B
remained	O
evident	O
only	O
for	O
active	O
UC	O
compare	O
to	O
inactive	O
UC	O
and	O
control	O
subjects,	O
respectively	O
(Table B).	O

The	O
flow	O
rate	O
was	O
350	O
μL/min	O
and	O
the	O
injection	O
volume	O
was	O
4	O
μL.	O
The	O
Q-TOF	O
mass	O
spectrometer	O
was	O
operated	O
in	O
electrospray	O
ionization	O
source	O
(ESI)	O
positive	O
ion	O
mode	O
with	O
a	O
capillary	O
voltage	O
of	O
3.5	O
kV,	B
drying	O
gas	O
flow	O
of	O
11	O
L/min,	O
and	O
a	O
gas	O
temperature	O
of	O
350	O
°C.	O

In	O
a	O
study	O
conducted	O
on	O
serum	O
from	O
64	O
PCa	O
cases	O
and	O
50	O
healthy	O
controls,	O
Zang	O
et	O
al.	O
shown	O
that	O
tryptophan	B
is	O
a	O
specific	O
discriminatory	O
metabolite	O
of	O
PCa.	O

LC-MS	O
identifies	O
this	O
trend,	O
making	O
PC	O
1	O
essentially	O
a	O
nicotine-exposure	B
axis.	O

Extracts	O
are	O
loaded	O
onto	O
columns	O
(Waters	O
UPLC	O
BEH	O
C18-2.1	O
×	O
100	O
mm,	O
1.7	O
μm)	O
and	O
gradient-eluted	O
with	O
water	O
and	O
95%	O
methanol	B
containing	O
0.1%	O
formic	B
acid	I
(acidic	O
extracts)	O
or	O
6.5	O
mM	O
ammonium	B
bicarbonate	O
(basic	O
extracts).	O

PCs	O
are	O
synthesized	O
in	O
the	O
liver	O
and	O
are	O
the	O
only	O
phospholipid	B
necessary	O
for	O
lipoprotein	O
assembly	O
and	O
excretion.	O

It	O
is	O
worth	O
noting	O
that	O
thymol	B
was	O
the	O
only	O
preservative	O
to	O
show	O
minor	O
variation	O
at	O
40	O
°C,	O
indicating	O
that	O
thymol	B
was	O
effective	O
at	O
preserving	O
urine	O
samples	O
even	O
at	O
high	O
temperature.	O

They	O
can	O
be	O
formed	O
non-enzymatically	O
or	O
by	O
glutathione	B
S	O
-transferase	O
(GST)-catalyzed	O
reactions	O
(-).	O

The	O
concentration	O
measured	O
in	O
this	O
plasma	O
sample	O
is	O
464	O
ng/mL,	O
147	O
ng/mL,	O
13	O
ng/mL,	O
12	O
ng/mL	O
and	O
2	O
ng/mL	O
for	O
PBTZ169,	O
Met	O
3-OH,	O
Met	O
3-oxo,	O
Met	O
amino	B
and	O
Met	O
1-OH,	O
respectively.	O

A	O
illustrates	O
the	O
effect	O
of	O
column	O
and	O
modifier	O
selection	O
on	O
chromatographic	O
separation	O
for	O
polar	O
analyte	O
standards	O
spiked	O
into	O
human	O
urine	O
(1:caffeine,	O
2:cytosine	O
and	O
3:uridine);	O
in	O
B,	O
the	O
cytosine	B
peak	O
from	O
each	O
separation	O
shown	O
in	O
A	O
is	O
magnified,	O
to	O
show	O
the	O
improvement	O
in	O
peak	O
symmetry	O
upon	O
replacement	O
of	O
the	O
BEH	O
2-EP	O
column	O
with	O
the	O
Torus	O
Diol	B
column.	O

Triacylglycerides	B
detected	O
with	O
LCMS	O
method	O
showed	O
negative	O
correlation	O
with	O
ApoA1	O
levels	O
and	O
positive	O
with	O
both	O
ApoB	O
and	O
ApoB:ApoA1	O
ratio,	O
although	O
significant	O
for	O
majority	O
of	O
triglycerides	B
only	O
in	O
pre-symptomatic	O
individuals.	O

Urate	B
is	O
another	O
compound	O
known	O
to	O
accumulate	O
in	O
the	O
uremic	O
state.	O

The	O
findings	O
were	O
not	O
altered	O
by	O
adjustment	O
for	O
serum	O
creatinine.	B

The	O
negative	O
correlation	O
between	O
urinary	O
mucic	B
acid	I
and	O
threonic	B
acid	I
in	O
HCV	O
is	O
also	O
of	O
interest	O
(d).	O

The	O
mobile	O
phases	O
consisted	O
of	O
0.01%	O
formic	B
acid	I
in	O
water	O
(mobile	O
phase	O
A)	O
and	O
acetonitrile	B
(mobile	O
phase	O
B).	O

It	O
is	O
hard	O
to	O
predict	O
what	O
consequences	O
modest	O
differences	O
in	O
the	O
number	O
of	O
unsaturations	O
or	O
chain	O
length	O
of	O
the	O
FA	B
and	O
LCB	O
would	O
have	O
for	O
the	O
cell.	O

The	O
challenge	O
of	O
matrix	O
effect	O
is	O
even	O
greater	O
if	O
the	O
sample	O
source	O
has	O
higher	O
levels	O
of	O
triglycerides,	B
cholesterol,	B
and	O
other	O
lipids	O
than	O
normal	O
values,	O
and	O
the	O
levels	O
of	O
lipids	O
may	O
change	O
during	O
the	O
course	O
of	O
treatment,	O
such	O
as	O
GBS.	O

Through	O
the	O
action	O
of	O
the	O
sphingomyelinase	O
(SMse),	O
the	O
sphingomyelins	B
play	O
a	O
relevant	O
role	O
also	O
in	O
determining	O
the	O
cell	O
fate	O
by	O
hydrolyzing	O
back	O
to	O
ceramide	B
which	O
is	O
an	O
important	O
metabolic	O
intermediate	O
able	O
to	O
induce	O
cellular	O
apoptosis.	O

The	O
reverse	O
fusion	O
primer	O
was	O
constructed	O
with	O
(5′–3′)	O
a	O
biotin	B
molecule,	O
the	O
Roche	O
B	O
linker	O
(CCTATCCCCTGTGTGCCTTGGCAGTCTCAG	O
),	O
and	O
reverse	O
519R	O
GTNTTACNGCGGCKGCTG.	O

HPLC	O
grade	O
methanol	B
was	O
purchased	O
from	O
Thermo	O
Fisher	O
Scientific	O
(Sydney,	O
Australia).	O

Hexane,	B
methyl	B
tert	I
-butyl	I
ether,	I
dichloromethane,	B
acetonitrile,	B
ethyl	B
acetate,	I
methanol,	B
formic	B
acid,	I
and	O
K_2	O
HPO_4	O
were	O
purchased	O
from	O
Fisher	O
Scientific	O
(Pittsburgh,	O
PA,	O
USA).	O

The	O
standards	O
of	O
metabolites	O
(L-arginine,	O
L-histidine,	B
L-aspartic	B
acid,	I
lactic	B
acid,	I
and	O
citric	O
acid)	O
were	O
added	O
into	O
the	O
blank	O
urine	O
in	O
accordance	O
with	O
low	O
(20 μ	O
M),	O
middle	O
(50 μ	O
M),	O
and	O
high	O
(80 μ	O
M)	O
concentration;	O
each	O
QC	O
sample	O
was	O
repeatedly	O
measured	O
three	O
times	O
continuously.	O

Putatively	O
identified	O
20-OH-LTB4	B
was	O
associated	O
with	O
both	O
Al	O
exposures	O
and	O
ΔIL-6	O
in	O
our	O
metabolomics	O
population.	O

Three	O
different	O
ways	O
to	O
use	O
silica	B
nanoparticles	O
(SNPs)	O
for	O
serum	O
sample	O
preparation	O
for	O
NMR-based	O
metabolomics.	O

(A)	O
Source	O
temperature	O
(TEM)	O
between	O
300	O
and	O
550°C,	O
(B)	O
declustering	O
potential	O
(DP)	O
between	O
−20	O
and	O
−100	O
V	O
(C)	O
collision	O
energy	O
(CE)	O
in	O
steps	O
of	O
2	O
V	O
from	O
−13	O
to	O
−31	O
V	O
for	O
RvE1	O
(m/z	O
349	O
→	O
195)	O
and	O
RvD5	O
(m/z	O
359	O
→	O
199),	O
CE	O
from	O
−21	O
to	O
−39	O
V	O
for	O
RvD2	O
(m/z	O
375	O
→	O
175)	O
with	O
collision	O
activated	B
dissociation	O
(CAD)	O
gas	O
set	O
to	O
high	O
(15	O
psi),	O
(D)	O
collision	O
cell	O
exit	O
potential	O
(CXP)	O
in	O
steps	O
of	O
2	O
V	O
from	O
−4	O
to	O
−18	O
V,	O
(E)	O
collision	O
energy	O
(CE)	O
in	O
steps	O
of	O
2	O
V	O
from	O
−13	O
to	O
−31	O
V	O
for	O
RvE1	O
(m/z	O
349	O
→	O
195)	O
and	O
RvD5	O
(m/z	O
359	O
→	O
199),	O
CE	O
from	O
−21	O
to	O
−39	O
for	O
RvD2	O
(m/z	O
375	O
→	O
175)	O
with	O
collision	O
activated	B
dissociation	O
(CAD)	O
gas	O
set	O
to	O
high	O
(15	O
psi),	O
medium	O
(9	O
psi)	O
and	O
low	O
(6	O
psi).	O

A	O
recent	O
study	O
demonstrated	O
that	O
2-HG	O
could	O
block	O
cell	O
differentiation	O
through	O
inhibiting	O
the	O
H3K9	O
demethylase	O
KDM4C	O
in	O
the	O
absence	O
of	O
major	O
changes	O
of	O
DNA	O
methylation,	O
whereas	O
the	O
prolylhydroxylases,	O
which	O
regulates	O
the	O
stability	O
of	O
the	O
transcription	O
factor	O
HIF1α,	B
could	O
be	O
directly	O
modified	O
by	O
2-HG.	O

Urinary	O
choline	B
was	O
reported	O
to	O
be	O
one	O
of	O
the	O
predictor	O
candidates	O
for	O
GDM_48	O
,	O
_49	O
,	O
_50	O
.	O

Serum	O
bile	O
acids,	O
such	O
as	O
glycocholate	B
(GCA),	O
glycochenodeoxycholate	B
(GCDCA),	O
taurocholate	B
(TCA)	O
and	O
taurochenodeoxycholate	B
(TCDCA),	O
increased	O
significantly	O
in	O
liver	O
cirrhosis	O
patients.	O

Consistent	O
with	O
all	O
of	O
this,	O
KM	O
plots	O
also	O
showed	O
higher	O
expression	O
of	O
pyrimidine	B
metabolism	O
pathway	O
genes	O
as	O
being	O
associated	O
with	O
shorter	O
metastasis-free	O
survival,	O
across	O
all	O
BCa	O
(E	O
,	O
N	O
=	O
1340,	O
log-rank	O
P	O
value	O
=	O
.0004)	O
as	O
well	O
as	O
within	O
the	O
subset	O
of	O
ER +	O
tumors	O
(F	O
,	O
N	O
=	O
686,	O
log-rank	O
P	O
value	O
=	O
.003).	O

Methanol,	B
acetonitrile,	B
formic	B
acid,	I
and	O
acetic	B
acid	I
were	O
all	O
HPLC-grade.	O

Serine	B
is	O
crucial	O
for	O
the	O
growth	O
and	O
survival	O
of	O
many	O
cancer	O
cells	O
and	O
is	O
closely	O
related	O
to	O
the	O
folate	B
cycle	O
as	O
a	O
donor	O
of	O
one-carbon	O
units.	O

A	O
total	O
of	O
100	O
µl	O
plasma	O
was	O
added	O
to	O
300	O
µl	O
methanol	B
and	O
acetonitrile	B
mixture	O
(1:1)	O
containing	O
5	O
µg/ml	O
L-2	O
chlorophenylalanine	B
internal	O
standard,	O
which	O
was	O
used	O
to	O
check	O
the	O
integrity	O
of	O
the	O
automated	O
integration	O
and	O
to	O
assess	O
instrument	O
performance	O
throughout	O
the	O
batch	O
analysis.	O

Ice-cold	O
perchloric	B
acid	I
(6%,	O
5	O
mL/g	O
wet	O
weight)	O
was	O
added	O
to	O
the	O
pulverized	O
tissue	O
(100–150	O
mg	O
wet	O
wt),	O
and	O
the	O
sample	O
vortexed	O
for	O
30	O
seconds.	O

In	O
this	O
regard,	O
PLD	O
which	O
is	O
activated	B
by	O
divalent	O
metal	O
ions	O
hydrolyzes	O
PtdC	O
and	O
lysophosphatidylcholines	B
to	O
generate	O
phosphatidic	B
acids	I
(PA)	O
and	O
LPA,	O
respectively.	O

Therefore,	O
stereoisomers	O
of	O
10-OH-WAR	B
are	O
able	O
to	O
bond	O
more	O
strongly	O
to	O
the	O
CSP	O
resulting	O
in	O
improved	O
separation.	O

–	O
Scyllo-inositol,	B
also	O
detected	O
in	O
our	O
study,	O
is	O
a	O
myo-Inositol	B
isomer	I
that	O
(interestingly)	O
is	O
under	O
investigation	O
for	O
its	O
potential	O
use	O
following	O
derivatization	O
as	O
a	O
novel	O
Positron	O
Emission	O
Tomography	O
(PET)	O
radiotracer,	O
[18F]-1-deoxy-1-fluoro-scylloinositol,	B
for	O
both	O
breast	O
cancer	O
and	O
Alzheimer’s	O
disease	O
(AD)._,	O
Both	O
scyllo-inositol	B
and	O
myo-inositol	B
are	O
components	O
of	O
the	O
prostate	O
metabolite	O
profile	O
generated	O
by	O
HRMAS	O
NMR	O
and	O
profiles	O
of	O
both	O
lung	O
tumors	O
and	O
colon	O
cancer.	O

Significance:	O
<0.05	O
‘*’	O
Trp	O
tryptophan,	B
Kyn	O
kynurenine,	B
KTR	O
kynurenine/tryptophan	B
ratio,	O
HK	O
3-hydroxykynurenine,	B
KA	O
kynurenic	B
acid,	I
XA	O
xanthurenic	B
acid,	I
AA	O
anthranilic	B
acid,	I
HAA	O
3-hydroxyanthranilic	B
acid,	I
QA	O
quinolinic	B
acid,	I

Depression,	O
other	O
cognitive	O
issues	O
or	O
indexes	O
for	O
disease	O
activity	O
did	O
not	O
show	O
any	O
correlation	O
to	O
quinolinic	B
acid,	I
kynurenine,	B
tryptophan	B
or	O
kynurenine/tryptophan	B
ratio;	O
however,	O
a	O
weak	O
correlation	O
to	O
fatigue	O
was	O
observed.	O

Changes	O
were	O
also	O
observed	O
in	O
lyso-phospholipids,	B
which	O
are	O
considered	O
to	O
be	O
potent	O
biologically	O
active	O
lipid	O
mediators	O
that	O
exert	O
cellular	O
effects	O
through	O
the	O
specific	O
G	O
protein–coupled	O
receptors.	O

An	O
estimate	O
of	O
creatinine	B
clearance	O
(CrCl)	O
was	O
calculated	O
using	O
the	O
Cockcroft-Gault	O
equation.	O

There	O
was	O
no	O
difference	O
in	O
the	O
concentration	O
of	O
meso-erythritol	B
between	O
the	O
stable	O
adiposity	O
phenotype	O
subgroups.	O

HPLC	O
grade	O
2-propanol,	B
acetonitrile	B
and	O
water	O
were	O
used	O
for	O
metabolites	O
extraction.	O

Choline	B
levels	O
were	O
decreased	O
in	O
all	O
clinical	O
subforms	O
of	O
IUGR.	O

Clinically,	O
it	O
is	O
known	O
that	O
the	O
levels	O
of	O
several	O
metabolites,	O
such	O
as	O
choline	B
and	O
lactic	B
acid,	I
are	O
elevated	O
in	O
malignant	O
glioma	O
tissue	O
compared	O
with	O
contralateral	O
normal	O
brain	O
tissue.	O

As	O
with	O
acetaminophen,	B
the	O
metabolism	O
of	O
ibuprofen	B
is	O
well	O
documented_,	O
and	O
produces	O
distinctive	O
resonances	O
in	O
the	O
_1	O
H	O
NMR	O
urine	O
spectrum().	O

In	O
order	O
for	O
long-chain	O
FAs	O
to	O
cross	O
the	O
mitochondrial	O
matrix	O
for	O
FA	O
β-oxidation,	O
they	O
must	O
be	O
conjugated	O
to	O
carnitine	B
forming	O
long-chain	O
acylcarnitines	B
(e.g.,	O
laurylcarnitine	B
and	O
oleoylcarnitine).	B

In	O
one	O
study,	O
GC-TOF/MS	O
was	O
used	O
to	O
measure	O
altered	O
metabolites	O
in	O
paired	O
malignant	O
and	O
non-malignant	O
lung	O
tissues	O
from	O
early-stage	O
adenocarcinoma,	O
and	O
cancer-associated	O
biochemical	O
alterations	O
were	O
characterized	O
by	O
decreased	O
levels	O
of	O
glucose	B
and	O
elevated	O
levels	O
of	O
cysteine,	B
antioxidants,	O
alpha-	B
and	O
gamma-tocopherol,	B
and	O
the	O
nucleotide	O
metabolite	O
5,6-dihydrouracil.	B

Absorbance	O
was	O
assayed	O
at	O
550 nm	O
and	O
compared	O
with	O
a	O
standard	O
curve	O
obtained	O
using	O
sodium	B
nitrite.	I

The	O
individual	O
AUCs	O
of	O
all	O
15	O
metabolites	O
showed	O
good	O
predictive	O
accuracy	O
(AUC	O
>	O
0.7)	O
and	O
combination	O
of	O
2	O
or	O
3	O
MSA-specific	O
metabolites	O
with	O
higher	O
significance,	O
Preg-S,	O
guanidinosuccinic	B
acid,	I
and	O
methionine,	B
efficiently	O
discriminated	O
MSA	O
from	O
controls.	O

Angiotensin	B
Converting	O
Enzyme	O
Inhibitor,	O
ARB	O
=	O
Angiotensin	B
Receptor	O
Blocker,	O
CCB	O
=	O
Calcium	O
Channel	O
Blocker.	O

Briefly,	O
urine	O
samples	O
were	O
thawed	O
and	O
a	O
5-ml	O
aliquot	O
was	O
spiked	O
with	O
mass-labeled	O
internal	O
standards	O
(d_10	O
-BDCIPP	O
and	O
d_10	O
-DPHP)	O
and	O
acidified	O
to	O
pH	O
< 6.5	O
with	O
formic	B
acid.	I

One	O
milliliter	O
of	O
ethyl	B
acetate	I
was	O
added,	O
and	O
samples	O
were	O
then	O
vortexed	O
and	O
centrifuged	O
for	O
5	O
min	O
at	O
3000g	O
.	O

From	O
the	O
21‐panel,	O
only	O
five	O
VOCs	O
appeared	O
statistically	O
significant	O
(P	O
 < 0.05)	O
when	O
comparing	O
these	O
RCC‐DMT2	O
samples	O
with	O
controls:	O
2‐oxopropanal,	O
2,2,5,5‐tetramethyltetrahydrofuran,	B
α‐methylstyrene,	B
2,5,8‐trimethyl‐1,2,3,4‐tetrahydronaphthalen‐1‐ol,	B
and	O
DHEA‐S.	O
Interestingly	O
and	O
confirming	O
the	O
potential	O
of	O
these	O
compounds	O
to	O
detect	O
RCC,	O
the	O
variation	O
for	O
all	O
of	O
them	O
between	O
RCC	O
and	O
controls	O
was	O
the	O
same	O
found	O
during	O
the	O
untargeted	O
study	O
(Table ).	O

This	O
investigation,	O
when	O
compared	O
with	O
data	O
recorded	O
from	O
IR	O
patents,	O
will	O
help	O
improve	O
diagnosis,	O
therapy	O
and	O
monitoring	O
of	O
hypogonadism	O
and	O
offer	O
a	O
variety	O
of	O
scientific	O
opportunities	O
to	O
improve	O
the	O
clinical	O
management	O
of	O
testosterone	B
deficiency	O
in	O
men.	O

Furthermore,	O
sarcosine	B
levels	O
in	O
the	O
urine	O
also	O
followed	O
the	O
same	O
trend	O
as	O
that	O
observed	O
in	O
tissue	O
biopsies.	O

Boxplots	O
of	O
asymmetric	B
dimethylarginine,	I
glycine,	B
hexoses	O
and	O
PC-O	O
(34:0)	O
which	O
were	O
significantly	O
(p < 0.05)	O
elevated	O
in	O
SPMS	O
patients	O
compared	O
with	O
the	O
controls.	O

To	O
aid	O
in	O
metabolite	O
identification,	O
homonuclear	O
two-dimensional	O
(2D)	O
experiments,	O
such	O
as	O
_1	O
H−_1	O
H	O
double	O
quantum	O
filtered	O
correlation	O
spectroscopy	O
(DQF-COSY)	O
and	O
_1	O
H−_1	O
H	O
total	O
correlation	O
spectroscopy	O
(TOCSY)	O
experiments,	O
were	O
performed	O
on	O
whole	O
blood	O
extracts	O
using	O
methanol/chloroform	O
in	O
a	O
(1	O
(sample):2:2	B
v/v/v)	O
ratio	O
for	O
extraction.	O

Phospholipids	B
accounted	O
for	O
17%	O
of	O
the	O
metabolic	O
impact.	O

Columns	O
represent	O
KEGG	O
pathway,	O
the	O
number	O
of	O
genes	O
in	O
a	O
pathway,	O
the	O
number	O
of	O
“differentially	O
methylated”	B
genes	O
(loose	O
P	O
 < 0.0005	O
cut-off),	O
the	O
P	O
-value,	O
and	O
False	O
Discovery	O
Rate	O
(FDR).	O

(A)	O
ROC	O
curve	O
analysis	O
showed	O
that	O
the	O
decrease	O
of	O
L-citrulline	B
and	O
D-aspartic	B
acid	I
concentration	O
in	O
serum	O
could	O
be	O
good	O
biomarker	O
for	O
distinguishing	O
BDTT	O
and	O
other	O
bile	O
duct	O
diseases.	O

The	O
sterol	O
fractions	O
from	O
above	O
were	O
reconstituted	O
in	O
100	O
μl	O
of	O
propan-2-ol,	B
and	O
a	O
solution	O
of	O
1	O
ml	O
of	O
50	O
mm	O
phosphate	B
buffer	O
(KH_2	O
PO_4	O
,	O
pH	O
7)	O
containing	O
3.0	O
μl	O
of	O
cholesterol	B
oxidase	O
(2	O
mg/ml	O
in	O
H_2	O
O,	O
44	O
units/mg	O
of	O
protein)	O
was	O
added	O
to	O
each.	O

Correspondingly,	O
significant	O
changes	O
in	O
phosphatidylcholine	B
metabolism	O
were	O
observed	O
in	O
our	O
study.	O

On	O
the	O
other	O
hand,	O
in	O
hypoxic	O
states	O
choline	B
is	O
released	O
from	O
hypoxic	O
tissue	O
into	O
the	O
plasma,	O
thus	O
increasing	O
the	O
basal	O
circulating	O
levels	O
(Storm	O
et	O
al.	O
).	O

In	O
our	O
study,	O
we	O
report	O
higher	O
urinary	O
excretion	O
of	O
taurohyocholic	B
acid	I
(THCA,	O
a	O
product	O
of	O
TCDCA	O
metabolism	O
by	O
CYP3A4),	O
ursodeoxycholic	B
acid	I
(UDCA,	O
a	O
product	O
of	O
CDCA	O
by	O
the	O
gut	O
microbiota	O
and	O
the	O
liver),	O
tauroursodeoxycholic	B
acid	I
(TUDCA,	O
a	O
taurine	B
conjugate	O
of	O
UCDA),	O
and	O
βUCA.	O

c	O
Adjusted	O
for	O
baseline	O
fasting	O
glucose	B
(mg/dl)	O
(centered	O
on	O
the	O
sample	O
mean	O
and	O
adding	O
quadratic	O
term),	O
age	O
(years),	O
sex	O
(male,	O
female),	O
intervention	O
group	O
(MedDiet + EVOO,	O
MedDiet + nuts),	O
body	O
mass	O
index	O
(kg/m_2	O
),	O
smoking	O
(never,	O
current,	O
former),	O
leisure-time	O
physical	O
activity	O
(metabolic	O
equivalent	O
tasks	O
in	O
minutes/day),	O
dyslipidemia	O
and	O
hypertension.	O

Urea	B
is	O
eliminated	O
from	O
body	O
by	O
urination,	O
and	O
glutamine	B
is	O
not	O
toxic.	O

24TDI	O
and	O
26TDI	O
formed	O
adducts	O
with	O
lysine:	B
3A4MP-Lys,	O
5A2MP-Lys,	O
and	O
3A2MP-Lys._,	O

Chromatography	O
parameters	O
of	O
NRTI-TP	O
represented	O
by	O
the	O
symbols:	O
+,	O
3TC-TP;	O
×,	O
DXG-TP;	O
◆,	O
TFV-DP;	O
□,	O
CBV-TP;	O
△,	O
(−)-FTC-TP;	O
and	O
○,	O
ZDV-TP:	O
(a)	O
tailing	O
factor	O
(Tf)	O
at	O
five	O
different	O
HMA	O
concentrations;	O
0,	O
3,	O
6,	O
9,	O
and	O
12	O
mM.	O
(b)	O
Effective	O
plate	O
number	O
(Ne)	O
at	O
four	O
different	O
buffer	O
compositions;	O
1	O
and	O
2	O
mM	O
ammonium	B
phosphate;	I
10	O
and	O
20	O
mM	O
ammonium	B
hydrogen	I
carbonate.	I

is	O
the	O
higher	O
rate	O
of	O
synthesis	O
for	O
purine	B
nucleotides	O
(i.e.	O
5'-AXP	O
and	O
5'-GXP),	O
as	O
shown	O
by	O
the	O
higher	O
abundance	O
of	O
[U-_13	O
C-ribose]-5'-AXP	O
and	O
5'-GXP.	O

The	O
differences	O
of	O
FA	B
composition	O
between	O
groups	O
were	O
analyzed	O
by	O
1-way	O
analysis	O
of	O
variance,	O
followed	O
by	O
the	O
Tukey	O
test	O
and	O
P	O
 < .05	O
was	O
considered	O
to	O
be	O
statistically	O
significant.	O

(CA_4,6	O
-3-one,	I
1.799	O
±	O
0.666	O
ng/ml),	O
respectively,	O
on	O
the	O
basis	O
of	O
their	O
retention	O
time	O
and	O
MS_3	O
spectra	O
(	O
and	O
supplemental	O
Fig.	O

In	O
the	O
combined	O
multicenter	O
populations,	O
compared	O
with	O
EBC	O
patients,	O
patients	O
with	O
MBC	O
are	O
characterized	O
by	O
higher	O
serum	O
levels	O
(adjusted	O
P	O
<	O
0.05)	O
of	O
citrate,	B
choline,	B
acetate,	B
formate,	B
lactate,	B
glutamate,	B
3-hydroxybutyrate,	B
phenylalanine,	B
glycine,	B
leucine,	B
alanine,	B
proline,	B
tyrosine,	B
isoleucine,	B
creatine,	B
creatinine,	B
and	O
methionine	B
and	O
lower	O
serum	O
levels	O
(adjusted	O
P	O
<	O
0.05)	O
of	O
glucose	B
and	O
glutamine.	B

High	O
pyroglutamate	B
alone	O
discriminated	O
WNV,	O
Lyme	O
and	O
histoplasmosis	O
from	O
controls.	O

In	O
addition,	O
depurination	O
of	O
methide	O
adducts	O
as	O
well	O
as	O
quinone	B
adducts	O
leads	O
to	O
formation	O
of	O
same	O
abasic	O
sites,	O
hence	O
it	O
is	O
reasonable	O
to	O
expect	O
that	O
methide	O
adducts	O
could	O
initiate	O
similar	O
molecular	O
cascade	O
leading	O
to	O
mutation	O
and	O
cancer	O
as	O
that	O
of	O
quinone	B
adducts	O
–,	O
.	O

Nevertheless,	O
it	O
remains	O
unclear	O
why	O
intraocular	O
reactive	O
sulfide	B
species	O
are	O
upregulated	O
in	O
DM,	O
as	O
the	O
current	O
study	O
found.	O

Best	O
results	O
were	O
obtained	O
using	O
0.5 mg/mL	O
PTAD	O
in	O
acetonitrile	B
solution,	O
and	O
the	O
reaction	O
was	O
fully	O
completed	O
after	O
1 h	O
at	O
room	O
temperature.	O

Glycine	B
can	O
also	O
be	O
generated	O
from	O
many	O
other	O
sources,	O
including	O
choline,	B
betaine,	B
dimethylglycine	B
and	O
sarcosine	B
(also	O
known	O
as	O
N-methylglycine),	B
through	O
a	O
series	O
of	O
reactions	O
that	O
involve	O
demethylation.	O

There	O
are	O
limits	O
to	O
know	O
an	O
exact	O
mechanism	O
with	O
our	O
information,	O
however,	O
we	O
suggest	O
a	O
possibility	O
based	O
on	O
our	O
findings:	O
activities	O
of	O
tyrosine	B
metabolism-related	O
enzymes	O
may	O
be	O
altered	O
before	O
LC	O
development.	O

To	O
address	O
these	O
issues	O
with	O
respect	O
to	O
sterols	O
and	O
vitamin	B
D	I
metabolites	O
(secosteroids),	O
we	O
developed	O
analytical	O
methods	O
to	O
measure	O
more	O
than	O
60	O
different	O
types	O
of	O
these	O
lipids	O
in	O
small	O
volumes	O
(<200	O
µL)	O
of	O
human	O
serum.	O

The	O
analysis	O
comprised	O
acylcarnitines,	B
diacyl-phosphatidylcholines	B
(PCaa),	O
acyl-alkyl-phosphatidylcholines	B
(PCae),	O
sphingomyelins	B
(SM),	O
lyso-phospholipids	B
(LPC)	O
and	O
amino	O
acids.	O

There	O
was	O
less	O
variability	O
in	O
serum	O
concentrations	O
of	O
estradiol	B
and	O
estrone	B
in	O
our	O
study	O
sample	O
compared	O
with	O
those	O
reported	O
in	O
previous	O
studies	O
of	O
postmenopausal	O
women	O
that	O
relied	O
on	O
immunoassays.	O

Phosphate-containing	O
compounds	O
included	O
sugar	O
phosphates	B
and	O
nucleotides	O
having	O
one	O
to	O
three	O
phosphoryl	O
groups.	O

PRMT,	O
arginine	O
N-methyltransferase;	O
PM,	O
plasma	O
membrane;	O
CATs,	O
cationic	O
amino	O
acid	O
transporters;	O
DDAH,	O
dimethylarginine	O
dimethylaminohydrolase;	O
DMA,	B
dimethylamine;	B
ADMA,	B
asymmetric	B
dimethylarginine;	I
SDMA,	O
symmetric	B
dimethylarginine;	I
NOS,	O
nitric	B
oxide	I
synthase;	O
NO,	O
nitric	B
oxide;	I
ARG,	O
arginase;	O
ODC,	O
ornithine	O
decarboxylase;	O
protein-CH_3	O
,	O
methylated	O
proteins.	O

(A)	O
Carboxymethyl	O
(CM)	O
column	O
1,	O
(B)	O
ceramic	O
hydroxyapatite	B
(HA)	O
column,	O
(C)	O
Superdex	O
200	O
column	O
1,	O
(D)	O
CM	O
column	O
2,	O
(E)	O
Superdex	O
200	O
column	O
2;	O
(F)	O
HA	B
column,	O
(G)	O
Superdex	O
200	O
column.	O

The	O
enzyme	O
glutaminase	O
converts	O
glutamine	B
to	O
glutamate,	B
which	O
can	O
be	O
used	O
by	O
alanine	O
aminotrasferase	O
to	O
produce	O
intermediates	O
of	O
the	O
TCA	O
cycle	O
or	O
for	O
the	O
synthesis	O
of	O
glutathione,	B
a	O
tripeptide	O
that	O
acts	O
as	O
an	O
important	O
antioxidant	O
in	O
cells.	O

Samples	O
were	O
monitored	O
for	O
PGF_2α	B
m/z	I
353.2 → 193.2)	O
and	O
PGE_2	O
(m/z	O
351.2 → 271.2)	O

Sphingolipids	B
modulate	O
several	O
beta-cell	O
signaling	O
pathways	O
involved	O
in	O
the	O
progression	O
of	O
diabetes	O
such	O
as	O
apoptosis,	O
cytokine	O
secretion,	O
ER	O
to	O
golgi	O
trafficking,	O
islet	O
autoimmunity	O
and	O
insulin	O
gene	O
expression	O
and	O
furthermore,	O
sphingolipid	B
metabolism	O
on	O
internal	O
membranes	O
is	O
also	O
implicated	O
in	O
the	O
regulation	O
of	O
beta-cell	O
apoptosis.	O

FE_i	O
	O
is	O
a	O
vector	O
of	O
fixed	O
effect	O
observations	O
for	O
individual	O
i	O
and	O
the	O
vector	O
B_2	O
compiles	O
the	O
regression	O
coefficients	O
for	O
each	O
adjustment	O
covariate;	O
for	O
model	O
1,	O
age,	O
gender,	O
phase,	O
and	O
ethnicity,	O
and	O
for	O
model	O
2,	O
we	O
additionally	O
correct	O
for	O
LDL	O
and	O
HDL	B
cholesterol,	I
lipids	O
and	O
blood	O
pressure	O
treatment,	O
systolic	O
blood	O
pressure,	O
smoking	O
status,	O
and	O
diabetes.	O

PBL	O
from	O
eight	O
healthy	O
subjects	O
were	O
incubated	O
with	O
kynurenine	B
(Kyn,	O
0.05,	O
0.1,	O
0.5,	O
and	O
1),	O
l-homocysteic	O
acid	O
(HCA,	O
100,	O
500 μM,	O
1 mM,	O
5 mM)	O
and	O
dibutyryl	O
cAMP	O
(db-cAMP,	O
500 μM)	O
for	O
24 h.	O

The	O
lower	O
derivatization	O
yield	O
in	O
SPE	O
is	O
probably	O
due	O
to	O
traces	O
of	O
protic	O
solvents	O
(water	O
and	O
methanol)	B
that	O
deactivate	O
PTAD	O
while	O
the	O
low	O
solubility	O
of	O
water	O
in	O
MTBE	B
makes	O
the	O
LLE	O
extracts	O
the	O
preferred	O
matrix	O
for	O
the	O
derivatization	O
reagent.	O

Aqueous	O
mixtures	O
containing	O
0.1%	O
formic	B
acid	I
and	O
5 mM	O
methylamine	B
provided	O
the	O
highest	O
signal	O
intensities	O
for	O
vitamin	B
D	I
compounds.	O

Three	O
other	O
minor	O
glucuronide	B
conjugates	O
of	O
hydroxylated	O
PhIP	O
metabolites	O
were	O
detected;	O
their	O
structures	O
are	O
unknown.	O

The	O
reduction	O
in	O
arginine	B
was	O
accompanied	O
by	O
an	O
accumulation	O
of	O
creatine,	B
but	O
also	O
by	O
the	O
absence	O
of	O
its	O
less	O
biologically-active	O
derivative,	O
creatinine.	B

Samples	O
were	O
reconstituted	O
in	O
200	O
μL	O
1	O
mM	O
ammonium	B
formate	I
pH	O
3.4	O
and	O
transferred	O
to	O
glass	O
autosampler	O
vials.	O

Glucose	B
(increased),	O
formate	B
(increased)	O
and	O
serine	B
(decreased)	O
in	O
rabies	O
CSF	O
moved	O
inversely	O
to	O
the	O
same	O
metabolites	O
measured	O
in	O
media	O
from	O
myotubes	O
intoxicated	O
with	O
rotenone	B
or	O
antimycin	B
A.	O
ATP	B
deficiency	O
from	O
mitochondrial	O
dysfunction	O
can	O
be	O
partially	O
offset	O
by	O
increased	O
glycolysis.	O

As	O
mentioned	O
above,	O
GSH	B
could	O
enhance	O
the	O
antioxidant	O
capacity	O
and	O
protect	O
cells	O
from	O
ROS.	O

They	O
found	O
that	O
only	O
seven	O
out	O
of	O
63	O
investigated	O
metabolites,	O
mainly	O
amino	O
acids,	O
were	O
altered	O
when	O
urine	O
was	O
stored	O
at	O
9	O
and	O
20	O
°C	O
for	O
24	O
h	O
but	O
not	O
2	O
or	O
8	O
h,	O
and	O
detected	O
a	O
statistically	O
significant	O
interaction	O
between	O
storage	O
duration	B
and	O
storage	O
temperature	O
on	O
metabolite	O
concentrations.	O

[Google	O
Scholar]	O
Watanabe	O
T,	O
Narumiya	O
S,	O
Shimizu	O
T,	O
Hayaishi	O
O.	O
Characterization	O
of	O
the	O
biosynthetic	O
pathway	O
of	O
prostaglandin	B
D2	I
in	O
human	O
platelet-rich	O
plasma.	O

(A)	O
2-Amino-3-methyl-1-butanol	B
was	O
continuously	O
up-regulated	O
in	O
the	O
LSIL,	O
HSIL	O
group	O
compared	O
with	O
CON.	O

Cells	O
were	O
fixed	O
with	O
4%	O
paraformaldehyde,	B
permeabilized	O
with	O
0.5%	O
Triton	O
X-100,	O
and	O
blocked	O
with	O
2%	O
BSA	O
for	O
1	O
h	O
at	O
room	O
temperature.	O

TG:	B
Triglycerides;	B
TC:	O
Total	O
cholesterol.	B

DCM	O
MTBE	B
Again,	O
precision	O
analyses	O
clarify	O
and	O
support	O
the	O
above	O
findings	O
on	O
dilution	O
and	O
PCT.	O

For	O
these	O
studies	O
we	O
chose	O
linoleic	B
acid,	I
the	O
NEFA	O
with	O
a	O
highest	O
increment	O
in	O
diabetic	O
plaques	O
(60%	O
increase	O
over	O
that	O
in	O
nondiabetic	O
subjects).	O

	O
Mass	O
spectrometry	O
for	O
purine	B
derivatives	O
of	O
adenosine	B
in	O
co-cultures	O
of	O
TEX	O
with	O
Treg	O
or	O
CD4_+	O
T	O
cells.	O

This	O
cluster	O
contained	O
12	O
putative	O
bile	O
acids,	O
including	O
matches	O
to	O
cholate,	B
chenodeoxycholate,	B
and	O
their	O
structural	O
variants.	O

Metabolites	O
in	O
this	O
pellet	O
were	O
extracted	O
with	O
1.0	O
mL	O
MTBE,	B
vortexed	O
vigorously	O
for	O
30	O
sec,	O
and	O
centrifuged	O
at	O
18000	O
×	O
g	O
0°C	O
for	O
15	O
min.	O

These	O
lysine	B
residues	O
are	O
known	O
to	O
form	O
acyl-linked	O
adducts	O
with	O
glucuronide	B
conjugates	O
of	O
tolmetin	B
and	O
permethrin._,	O
Lys_195	O
or	O
Lys_199	O
was	O
also	O
reported	O
to	O
form	O
an	O
adduct	O
with	O
2,4-dinitro-1-chlorobenzene,	B
and	O
both	O
lysine	B
residues	O
are	O
reactive	O
sites	O
in	O
SA	O
and	O
form	O
adducts	O
with	O
4-hydroxy-trans	B
-2-nonenal.	I

In	O
contrast,	O
the	O
levels	O
of	O
1,3-DAP,	B
PUT,	O
and	O
CAD	O
in	O
urine	O
were	O
significantly	O
lower	O
in	O
men	O
than	O
those	O
in	O
women	O
(p	O
<	O
0.01).	O

Therefore,	O
we	O
may	O
assume	O
that	O
the	O
association	O
between	O
poor	O
prognosis	O
and	O
higher	O
excretion	O
of	O
hippurate	B
did	O
not	O
reflect	O
a	O
deficient	O
empirical	O
antibiotic	O
strategy.	O

Mass	O
spectra	O
for	O
ZON	O
(m/z	O
 = 319.0,	O
a)	O
and	O
α-ZOL	B
(m/z	O
 = 317.1,	O
b)	O

SP	B
was	O
still	O
found	O
in	O
approximately	O
half	O
of	O
the	O
patients,	O
although	O
it	O
had	O
been	O
officially	O
abandoned	O
as	O
first-line	O
treatment	O
since	O
2006.	O

In	O
inflammation,	O
citrate	B
is	O
reduced	O
to	O
its	O
derivatives	O
in	O
the	O
cytosol	O
to	O
supply	O
components	O
to	O
altered	O
energy	O
and	O
intermediate	O
production.	O

Go	O
to:	O
Estrogens	O
can	O
become	O
endogenous	O
carcinogens	O
via	O
formation	O
of	O
catechol	B
estrogen	I
quinones,	I
which	O
react	O
with	O
DNA	O
to	O
form	O
specific	O
depurinating	O
estrogen-DNA	O
adducts.	O

Increased	O
levels	O
of	O
choline	B
and	O
phosphocholine	B
are	O
regarded	O
as	O
biomarkers	O
of	O
cellular	O
membranes	O
turnover	O
in	O
neoplasms,	O
demyelination	O
and	O
gliosis.	O

The	O
product	O
ion	O
spectrum	O
of	O
desamino-PhIP-K	B
contained	O
3	O
major	O
fragment	O
ions	O
at	O
m/z	O
337.2,	O
309.2	O
and	O
291.2,	O
corresponding	O
to	O
the	O
losses	O
of	O
NH_3	O
,	O
NH_3	O
+CO,	O
and	O
NH_3	O
+HCO_2	O
H,	O
respectively.	O

Phospholipids	B
analysis	O
of	O
HepG2	O
and	O
HepG2.2.15	O
cells.	O

The	O
majority	O
of	O
these	O
metabolites	O
were	O
found	O
to	O
be	O
significantly	O
associated	O
with	O
BMI	O
after	O
Bonferroni	O
correction	O
for	O
multiple	O
testing	O
(P	O
≤	O
4.55	O
×	O
10_−4	O
,	O
models	O
1	O
and	O
2);	O
exceptions	O
are	O
taurine,	B
serine,	B
asparagine,	B
glycine,	B
methionine,	B
and	O
arginine.	B

High	O
relative	O
abundances	O
of	O
cardiolipins	O
were	O
observed	O
in	O
normal	O
epithelial	O
tissue,	O
while	O
sphingomyelin	B
lipids	O
were	O
seen	O
in	O
higher	O
relative	O
abundance	O
in	O
normal	O
stroma	O
tissue.	O

It	O
is	O
well	O
known	O
that	O
mitochondria	O
can	O
compensate	O
for	O
decreased	O
energy	O
production	O
by	O
increasing	O
lactate	B
production	O
under	O
hypoxia.	O

Other	O
group	O
differences	O
included	O
for	O
T2DM	O
increased	O
mannose,	B
acetoacetate,	B
glycerol,	B
and	O
citrate	B
and	O
for	O
IGT	O
increased	O
pyruvate	B
and	O
glycerol	B
and	O
decreased	O
glycine.	B

The	O
contribution	O
of	O
estrogen	B
metabolism	O
to	O
the	O
development	O
of	O
breast	O
cancer	O
is	O
much	O
more	O
ambiguous	O
than	O
that	O
of	O
estradiol	B
and	O
estrone,	B
the	O
parent	O
estrogens.	O

The	O
AUC	O
values	O
of	O
the	O
three	O
metabolites	O
for	O
discriminating	O
HCC-C	O
from	O
HCC-B	O
were	O
0.89	O
(95%CI:	O
0.79-0.98,	O
P	O
<	O
0.0001)	O
for	O
glutamic	B
acid,	I
0.67	O

The	O
sum	O
of	O
the	O
diacylglycerols	B
(DGs)	O
served	O
to	O
localize	O
the	O
lipid	O
droplets	O
into	O
the	O
liver	O
tissue.	O

In	O
the	O
serum	O
of	O
IBD	O
patients	O
as	O
most	O
prominently	O
increased	O
there	O
were	O
reported:	O
N	B
-acetylated	I
glycoprotein,	I
lactate[],	B
methanol,	B
mannose,	B
formate,	B
3-methyl-2-oxovalerate,	B
2-hydroxybutyrate,	B
lysine,	B
creatine[],	B
3-hydroxybutyrate,	B
phenylalanine,	B
α	O
and	O
β-glucose[]	B
while	O
those	O
decreased	O
included:	O
lipids[,],	O
urea,	B
τ-methylhistidine,	B
valine,	B
tyrosine,	B
citrate,	B
choline,	B
creatinine,	B
dimethyl	B
sulfone[],	I
histidine,	B
tryptophan[]	O
and	O
alanine[].	B

(with	O
100	O
mg	O
pyridoxine	B
and	O
100	O
mg	O
thiamin)	B
to	O
27	O
community-dwelling	O
elderly	O
Chileans	O
(∼74	O
y	O
old)	O
with	O
vitamin	O
B-12	O
deficiency,	O
as	O
evaluated	O
with	O
serum	O
vitamin	O
B-12,	O
total	O
plasma	O
homocysteine	B
(tHcy),	O
methylmalonic	B
acid	I
(MMA),	O
and	O
holotranscobalamin.	O

z	O
range	O
of	O
700–910,	O
which	O
covered	O
the	O
intact	O
mass	O
range	O
of	O
almost	O
all	O
of	O
phospholipids	B
(PLs)	O
and	O
sphingomyelin	B
(SM),	O
which	O
is	O
a	O
class	O
of	O
sphingolipids	B
(SPs).	O

At	O
every	O
sample-to-solvent	O
ratio,	O
the	O
80%	O
methanol	B
protocol	O
yielded	O
a	O
higher	O
peak	O
area	O
for	O
the	O
metabolite	O
internal	O
standards	O
and	O
endogenous	O
species	O
compared	O
to	O
the	O
aqueous	O
phase	O
of	O
the	O
biphasic	O
methods	O
(	O
and	O
).	O

Urinary	O
carnosine	B
was	O
measured	O
using	O
an	O
internal	O
standard	O
and	O
a	O
triple	O
quadrupole	O
(TSQ	O
QUANTUM	O
ULTRA,	O
Thermo	O
Scientific,	O
Italy),	O
as	O
previously	O
described.	O

The	O
homeostasis	O
model	O
assessment	O
insulin	O
resistance	O
(HOMA-IR)	O
and	O
beta-cell	O
function	O
(HOMA-β)	O
were	O
used	O
to	O
assess	O
insulin	O
resistance	O
and	O
beta-cell	O
function.	O

The	O
resulting	O
datasets	O
had	O
22	O
metabolites	O
in	O
common	O
(alanine,	O
aspartate,	B
citrate,	B
glucose,	B
glutamate,	B
glutamine,	B
glycerol,	B
glycine,	B
histidine,	B
hypoxanthine,	B
isoleucine,	B
methionine,	B
ornithine,	B
phenylalanine,	B
proline,	B
pyroglutamate,	B
serine,	B
threonine,	B
tryptophan,	B
tyrosine,	B
urea,	B
and	O
valine).	B

Eicosanoids	B
consist	O
of	O
leukotrienes,	O
prostaglandins	B
and	O
thromboxanes	B
and	O
are	O
derived	O
from	O
arachidonic	B
acid	I
or	O
linoleate.	B

Using	O
a	O
liquid	O
chromatography-tandem	O
mass	O
spectrometry	O
method,	O
urinary	O
concentrations	O
of	O
15	O
estrogen	B
metabolites	O
were	O
determined	O
in	O
77	O
prostate	O
cancer	O
cases,	O
77	O
healthy	O
controls,	O
and	O
37	O
subjects	O
who	O
had	O
no	O
evidence	O
of	O
prostate	O
cancer	O
after	O
a	O
prostate	O
biopsy.	O

	O
Four	O
300	O
μL	O
serum	O
samples	O
were	O
mixed	O
with	O
methanol	B
in	O
a	O
1:2	O
ratio	O
(v/v),	O
vortexed,	O
and	O
incubated	O
at	O
−20	O
°C	O
for	O
20	O
min.	O

It	O
may	O
be	O
because	O
proliferating	O
cells	O
have	O
higher	O
metabolic	O
requirements	O
beyond	O
adenosine	B
triphosphate	I
production.	O

This	O
poses	O
the	O
question	O
of	O
the	O
appropriateness	O
of	O
normalising	O
the	O
ETS	O
urinary	O
biomarkers	O
with	O
creatinine.	B

There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
fatty	O
acid	O
and	O
phospholipid	B
and	O
lipoprotein	O
subclass	O
concentrations	O
between	O
the	O
groups.	O

A	O
high	O
level	O
of	O
all	O
estrogen	B
metabolites	O
and	O
17-ketosteroids	O
in	O
the	O
urine	O
of	O
these	O
patients	O
was	O
shown.	O

Moreover,	O
it	O
induces	O
deoxyribonucleic	B
acid	I
(DNA)	O
damage	O
by	O
increasing	O
intracellular	O
production	O
of	O
oxidative	O
stress	O
(,	O
).	O

in	O
which	O
cessation	O
was	O
for	O
only	O
one	O
day,	O
the	O
overall	O
results	O
show	O
a	O
relatively	O
slow	O
and	O
modest,	O
yet	O
significant,	O
decrease	O
in	O
8-iso	B
-PGF_2α	I
over	O
the	O
course	O
of	O
3	O
weeks	O
to	O
one	O
year,	O
while	O
the	O
only	O
other	O
study	O
to	O
report	O
the	O
effects	O
of	O
cessation	O
on	O
PGE-M	O
found	O
no	O
significant	O
decrease.	O

Glutamine-derived	O
glutamate	O
also	O
fulfills	O
the	O
role	O
of	O
a	O
primary	O
nitrogen	O
donor	O
for	O
the	O
synthesis	O
of	O
non-essential	O
amino	O
acids	O
and	O
is	O
a	O
precursor	O
of	O
the	O
major	O
cellular	O
antioxidant	O
glutathione	B
(GSH)	O

Whenever	O
a	O
molecule	O
of	O
alanine	B
is	O
formed	O
from	O
pyruvate	B
via	O
alanine	O
transaminase	O
a	O
molecule	O
of	O
glutamate	B
will	O
be	O
formed	O
from	O
α-ketoglutarate	B
(Eq	O
2),	O
and	O
that	O
in	O
turn	O
can	O
be	O
converted	O
(via	O
glutaminase,	O
Eq	O
4)	O
into	O
glutamine	B
(see	O
).	O

Interestingly	O
our	O
observation	O
that	O
urine	O
glucose	B
excretion	O
is	O
correlated	O
with	O
urinary	O
betaine	B
has	O
recently	O
been	O
reported	O
by	O
another	O
group	O
,	O
the	O
mechanisms	O
of	O
this	O
warrant	O
further	O
investigation.	O

The	O
replenishment	O
of	O
TCA	O
intermediates	O
was	O
due	O
of	O
glutaminolysis	O
(c)	O
a	O
stepwise	O
process	O
by	O
which	O
glutamine	B
is	O
converted	O
into	O
glutamate,	B
which	O
is	O
in	O
turn	O
transformed	O
into	O
α-ketoglutarate	B
and	O
aspartate,	B
which	O
are	O
converted	O
to	O
oxaloacetate.	B

The	O
tested	O
SFC	O
columns	O
included	O
both	O
the	O
recently	O
introduced	O
ACQUITY	O
UPC_2	O
Torus	O
columns,	O
designed	O
for	O
improved	O
robustness	O
and	O
stability	O
in	O
mixed	O
CO_2	B
-methanol	I
mobile	O
phases	O
,	O
,	O
and	O
the	O
older	O
ACQUITY	O
UPC_2	O
range.	O

Briefly,	O
tissue	O
samples	O
(100	O
micron	O
sections)	O
were	O
homogenized	O
using	O
Powergen-125	O
(Roche),	O
for	O
three	O
cycles	O
of	O
30	O
seconds	O
each	O
with	O
500	O
µL	O
of	O
prechilled	O
50%	O
methanol	B
containing	O
internal	O
standards	O
(10	O
µL	O
of	O
debrisoquine	B
and	O
50	O
µL	O
of	O
4-NBA	O
(1	O
mg	O
mL_−1	O
).	O

Few	O
studies,	O
however,	O
have	O
directly	O
assessed	O
the	O
associations	O
between	O
cannabis	B
use,	O
inflammation,	O
and	O
immune	O
activation	O
in	O
the	O
context	O
of	O
ART-treated	O
HIV	O
infection.	O

Node	O
color	O
was	O
grouped	O
according	O
to	O
SP	B
type	O
and	O
clinical	O
characteristic:	O
clinical	O
characteristic	O
nodes	O
are	O
gray,	O
Cer	B
nodes	O
are	O
red,	O
HexCer	O
nodes	O
are	O
blue,	O
Hex2Cer	O
nodes	O
are	O
green,	O
and	O
nodes	O
for	O
the	O
other	O
SPs	O
are	O
yellow.	O

We	O
note	O
several	O
differences	O
between	O
our	O
study	O
and	O
the	O
Hvidfeldt	O
study:	O
in	O
our	O
study	O
former	O
hormone	O
users	O
of	O
menopausal	O
hormone	O
therapy	O
were	O
excluded,	O
the	O
median	O
age	O
at	O
baseline	O
was	O
approximately	O
three	O
years	O
younger,	O
the	O
unadjusted	O
absolute	O
rate	O
of	O
breast	O
cancer	O
was	O
substantially	O
lower,	O
a	O
5	O
kg/m_2	O
increase	O
in	O
BMI	O
was	O
associated	O
with	O
a	O
smaller	O
relative	O
increase	O
in	O
estradiol	B
levels,	O
the	O
covariates	O
adjusted	O
for	O
were	O
not	O
identical,	O
and	O
different	O
estrogen	B
assays	O
were	O
used.	O

A	O
sublist	O
consisting	O
only	O
unsaturated	O
GPs	O
was	O
extracted	O
by	O
LOA	O
to	O
generate	O
a	O
precursor	O
ion	O
list	O
corresponding	O
to	O
their	O
PB	O
reaction	O
products	O
(_PB	O
M),	O
using	O
the	O
signature	O
58-unit	O
increase	O
in	O
m/z	O
due	O
to	O
single	O
acetone	B
addition.	O

Spearman	O
correlation	O
analyses	O
were	O
performed	O
to	O
determine	O
associations	O
between	O
serum	O
polyamine	B
levels	O
with	O
several	O
anthropometric	O
and	O
biochemical	O
variables.	O

The	O
interdependence	O
of	O
ascorbic	B
acid	I
metabolism	O
and	O
bacteria	O
in	O
the	O
GI	O
tract	O
is	O
one	O
example	O
of	O
many	O
ways	O
in	O
which	O
the	O
microbiome	O
and	O
metabolome	O
interact	O
in	O
health	O
and	O
disease.	O

(IBU,	O
ibuprofen;	B
M1,	B
2-hydroxy	I
ibuprofen;	I
M2,	B
1-hydroxy	I
ibuprofen;	I
M3,	B
3-hydroxy	I
ibuprofen;	I
M4,	O
carboxy	B
ibuprofen;	I
M5,	O
ibuprofen	B
glucuronide;	I
M6,	B
2-hydroxy	I
ibuprofen	I
glucuronide	I
conjugate;	O
M7,	O
carboxy	B
ibuprofen	I
glucuronide	I
conjugate;	O
M8,	B
3-hydroxy	I
iburprofen	I
glucuronide	I
conjugate;	O
and	O
M9,	B
1-hydroxy	I
ibuprofen	I
glucuronide	I
conjugate).	O

Wells	O
were	O
then	O
incubated	O
for	O
90	O
s	O
with	O
5	O
µl	O
of	O
a	O
50%	O
acetonitrile	B
(ACN)	O
and	O
0.1%	O
trifluoroacetic	B
acid	I
(TFA)	O
solution,	O
and	O
eluted	O
material	O
was	O
spotted	O
onto	O
a	O
target	O
plate,	O
allowed	O
to	O
completely	O
dry	O
(≈10	O
min),	O
after	O
which	O
0.5	O
µl	O
of	O
matrix	O
solution	O
(5	O
g/l	O
of	O
a-cyano-4-hydroxycinnamic	B
acid	I
(CHCA)	O
in	O
50%	O
ACN	O
and	O
0.1%	O
TFA)	O
which	O
was	O
spotted	O
on	O
the	O
target	O
plate	O
and	O
allowed	O
to	O
completely	O
dry.	O

The	O
long-term	O
stability	O
tests	O
suggested	O
that	O
the	O
stock	O
solution	O
of	O
FAU	O
and	O
FMAU	O
in	O
methanol	B
at	I
1	O
mg/ml	O
was	O
stable	O
at	O
−20°C	O
for	O
at	O
least	O
6	O
months,	O
and	O
FAU	O
(at	O
30	O
and	O
1600	O
ng/ml)	O
and	O
FMAU	O
(at	O
6	O
and	O
800	O
ng/ml)	O
were	O
stable	O
in	O
human	O
plasma	O
at	O
−80°C	O
for	O
at	O
least	O
2	O
months.	O

In	O
our	O
workflow,	O
individual	O
samples	O
were	O
labeled	O
using	O
_12	O
C-dansyl	B
chloride	I
and	O
a	O
pooled	O
sample	O
generated	O
by	O
mixing	O
small	O
aliquots	O
of	O
samples	O
was	O
labeled	O
by	O
_13	O
C-dansyl	B
chloride.	I

They	O
showed	O
that	O
patients	O
with	O
thyroid	O
cancer	O
had	O
much	O
higher	O
amounts	O
of	O
methionine,	B
leucine,	B
tyrosine,	B
and	O
lysine.	B

To-date,	O
there	O
has	O
been	O
no	O
effective	O
chiral	O
capillary	O
electrophoresis-mass	O
spectrometry	O
(CE-MS)	O
method	O
reported	O
for	O
the	O
simultaneous	O
enantioseparation	O
of	O
the	O
antidepressant	O
drug,	O
venlafaxine	B
(VX)	O
and	O
its	O
structurally-similar	O
major	O
metabolite,	O
O	B
-desmethylvenlafaxine	I
(O	O
-DVX).	O

Derivatization	O
with	O
1-methylimidazole-2-sulfonyl	B
chloride	I
was	O
carried	O
out	O
in	O
the	O
same	O
fashion	O
as	O
dansyl	B
chloride.	I

The	O
microbiome	O
features	O
along	O
with	O
endotoxin,	B
ammonia,	O
and	O
metabolomics	O
were	O
correlated	O
using	O
a	O
Spearman’s	O
correlation	O
function	O
and	O
then	O
filtered	O
for	O
correlations	O
>0.60	O
and	O
p<0.05.	O

As	O
shown	O
in	O
and	O
,	O
the	O
method	O
provides	O
a	O
suitable	O
selectivity,	O
a	O
satisfactory	O
control	O
of	O
matrix	O
effects	O
and	O
a	O
negligible	O
carryover	O
also	O
for	O
this	O
inactive	O
Met	O
amino.	B

Fatty	O
acids	O
are	O
esterified	O
to	O
phospholipids,	B
such	O
as	O
phophatidylcholine.	B

DHEA	O
and	O
its	O
oxygenated	O
metabolites	O
androstenediol	B
(AED),	O
androstenetriol	B
(AET)	O
and	O
7-oxo-DHEA	B
are	O
immunomodulatory	O
compounds	O
that	O
may	O
regulate	O
physiopathology	O
in	O
HIV-TB	O
co-infection.	O

The	O
homogenate	O
was	O
diluted	O
in	O
70%	O
isopropanol	B
to	O
a	O
concentration	O
of	O
2.0 mg	O
dry	O
weight/mL	O
(dw/mL)	O
for	O
further	O
analysis.	O

The	O
ribosyl-conjugated	B
methionine	I
scaffold	O
of	O
SAM	O
provides	O
functional	O
groups	O
for	O
various	O
enzymatic	O
reactions.	O

These	O
findings	O
build	O
on	O
a	O
previous	O
report	O
by	O
our	O
group	O
that	O
identified	O
between-group	O
differences	O
in	O
several	O
fatty	O
acids,	O
glycerol	B
and	O
gamma-aminobutyric	B
acid.	I

Compared	O
with	O
single	O
biomarker	O
models	O
using	O
phosphorylcholine,	B
glycocholic	B
acid,	I
arachidonic	B
acid	I
and	O
L-acetylcarnitine	B
individually,	O
a	O
model	O
comprising	O
the	O
aforementioned	O
four	O
metabolites	O
exhibited	O
improved	O
AUC	O
values,	O
sensitivity	O
and	O
specificity.	O

The	O
identity	O
of	O
our	O
SM(d18:2/18:1)	B
marker	O
needs	O
to	O
be	O
finally	O
proven	O
in	O
separate	O
studies,	O
and	O
if	O
the	O
assignment	O
is	O
correct	O
the	O
biological	O
and	O
especially	O
neurological	O
consequence	O
of	O
changing	O
the	O
usual	O
cis	B
-Δ3-sphingosines	I
by	O
an	O
aberrant	O
backbone	O
must	O
be	O
elucidated.	O

In	O
UC,	O
citrulline	B
was	O
the	O
only	O
metabolite	O
correlated	O
with	O
RI	B
(r	O
=	O
−0.38,	O
p	O
=	O
0.010);	O
other	O
metabolites	O
showed	O
no	O
significant	O
correlation	O
(p	O
=	O
0.132	O
for	O
SDMA,	O
p	O
=	O
0.578	O
for	O
DMA,	B
p	O
=	O
0.991	O
for	O
ADMA,	B
and	O
p	O
=	O
0.861	O
for	O
arginine).	B

	O
Batatasin	O
III,	O
piceatannol,	O
thunalbene,	B
and	O
pinostilbene	B
were	O
purchased	O
from	O
ChemFaces	O
(China)	O
at	O
98%	O
purity;	O
resveratrol,	B
oxyresveratrol,	B
and	O
[_13	O
C_6	O
]	O
trans	O
-resveratrol	O
were	O
obtained	O
from	O
Merck	O
(Darmstadt,	O
Germany)	O
at	O
98%	O
purity.	O

In	O
CKD	O
3–5,	O
TMAO	B
levels	O
were	O
associated	O
with	O
IL-6	O
(Rho	O
=	O
0.42;	O
p<0.0001),	O
fibrinogen	O
(Rho	O
=	O
0.43;	O
p<0.0001)	O
and	O
hsCRP	O

×	O
150mm),	O
which	O
consisted	O
of	O
water	O
containing	O
0.1	O
%	O
formic	B
acid	I
as	O
mobile	O
phase	O
A	O
and	O
acetonitrile	B
containing	O
0.1%	O
formic	B
acid	I
as	O
mobile	O
phase	O
B.	O
The	O
gradient,	O
which	O
is	O
initially	O
0%	O
B,	O
was	O
increased	O
to	O
100	O
%	O
B	O
in	O
60	O
min,	O
and	O
then	O
reverted	O
back	O
to	O
0%	O
B	O
in	O
1	O
min,	O
followed	O
by	O
equilibration	O
at	O
0%	O
B	O
for	O
14	O
min,	O
for	O
a	O
total	O
running	O
time	O
of	O
75	O
minutes.	O

300	O
ul	O
methyl	B
tert-butyl	I
ether	I
(MTBE)	O
was	O
then	O
added	O
into	O
the	O
mixture,	O
which	O
was	O
oscillated	O
at	O
1000	O
rpm	O
in	O
25°C	O
for	O
1	O
hour	O
and	O
was	O
further	O
added	O
by	O
75	O
μl	O
deionized	O
water,	O
vortex-mixed	O
for	O
1	O
min,	O
and	O
oscillated	O
at	O
1000	O
rpm	O
in	O
4°C	O
for	O
10	O
min,	O
then	O
the	O
final	O
mixture	O
was	O
centrifuged	O
at	O
12000.	O

The	O
anaerobic	O
metabolism	O
of	O
glucose	B
generates	O
lactate,	B
and	O
a	O
high	O
level	O
of	O
lactate	B
with	O
a	O
low	O
level	O
of	O
glucose	B
is	O
at	O
the	O
basis	O
of	O
the	O
cancer	O
glycolytic	B
shift	O
described	O
as	O
the	O
“Warburg	O
effect”.	O

All	O
clinical	O
definitions	O
and	O
recommendations	O
for	O
vitamin	B
D	I
sufficiency	O
are	O
based	O
on	O
total	O
25OHD	O
[,,].	O

(C)	O
Galactose	B
metabolism.	O

Given	O
the	O
fast	O
turnover	O
rate	O
and	O
minimal	O
storage	O
of	O
thiamin,	B
however,	O
the	O
effect	O
of	O
the	O
single	O
supplemental	O
dose	O
would	O
not	O
likely	O
be	O
seen	O
at	O
follow-up.	O

Several	O
studies	O
(for	O
review	O
see)	O
already	O
reported	O
associations	O
between	O
hippurate	B
and	O
obesity	O
as	O
well	O
as	O
T2DM.	O

After	O
further	O
adjustment	O
for	O
plasma	O
triglyceride	B
concentrations	O
(accounting	O
for	O
hypertriglyceridemic	B
waist),	O
acetylglycoproteins,	B
branched‐chain	O
amino	O
acids	O
(isoleucine,	O
leucine,	B
and	O
valine),	B
glutamine	B
(inversely),	O
and	O
serum	O
triglycerides	B
remained	O
significantly	O
associated	O
with	O
VAT	O
(nominal	O
P	O
<0.05	O
for	O
all,	O
Figure ).	O

ROC	O
analysis	O
of	O
Xanthine,	B
2HB	O
and	O
the	O
γ-glutamyl	O
peptides	O
demonstrates	O
that	O
these	O
oxidative	O
stress	O
metabolites	O
may	O
show	O
promise	O
as	O
ROS-related	O
metabolic	O
markers	O
of	O
HCC.	O

This	O
type	O
of	O
analysis	O
has	O
its	O
limitation	O
as	O
it	O
can	O
only	O
cover	O
approximately	O
10–15%	O
of	O
the	O
metabolome,	O
and	O
then	O
mainly	O
primary	O
metabolites	O
such	O
as	O
amino	O
acids,	O
fatty	O
acids,	O
other	O
organic	O
acids,	O
mono-	O
and	O
disaccharides.	B

This	O
may	O
explain	O
the	O
moderately	O
increased	O
levels	O
of	O
dihydrouracil	B
and	O
dihydrothymine	B
in	O
these	O
patients.	O

The	O
flow	O
rates	O
used	O
were	O
40	O
mL	O
min_−1	O
for	O
VOC,	O
30	O
mL	O
min_−1	O
for	O
1,3-butadiene	B
and	O
3	O
Lmin_−1	O
for	O
PAH.	O

ADPS,	O
1-alkyldihydroxyacetone-3-phosphate	B
synthetase;	O
AH,	B
denosylhomocysteinase;	O
AT,	O
acyltransferase;	O
BAD,	O
betaine	O
aldehyde	O
dehydrogenase;	O
BCKDC,	O
branched	O
chain	O
alpha-keto	O
acid	O
dehydrogenase	O
complex;	O
BHMT,	O
betaine-homocysteine	O
s-methyltransferase;	O
B12,	O
vitamin	O
B-12;	O
CAT,	O
carnitine-acylcarnitine	O
translocase;	O
CBS,	O
cystathionine	B
beta	O
synthase;	O
CDEP,	O
CDP-ethanolamine:1,2-diacylglycerol	O
ethanolaminephosphotransferase;	O
CDPT,	O
CDP-choline-diacylglycerol	B
phosphocholine	I
transferase;	O
CGL,	O
cystathionine	B
gamma	O
lyase;	O
CK,	O
choline	B
kinase;	O
CO,	O
choline	B
oxidase;	O
CS,	O
ceramide	B
synthase;	O
CTC,	O
CTP-choline	B
cytidylyltransferase;	O
CTP,	B
phosphoethanolamine	B
cytidylytransferase;	O
DGL,	O
diacylglyceride	B
lipase;	O
DHD,	O
dihydroceramide	B
desaturase;	O
DNMT,	O
DNA	O
(cytosine-5)-methyltransferase	O
1;	O
EK,	O
ethanolamine	B
kinase;	O
FAR1,	O
fatty	O
acyl-reductase;	O
GGS,	O
gamma-glutamylcysteine	B
synthase;	O
GS,	O
glutathione	B
synthase;	O
HMST,	O
homocysteine	O
s-methyltransferase;	O
HoloTC,	O
holotranscobalamin;	O
MAT,	O
s-adenosylmethionine	B
synthetase;	O
MCEE,	O
methylmalonyl-CoA/ethylmalonyl-CoA	B
epimerase;	O
MCH,	O
(S)-methylmalonyl-CoA	O
hydrolase;	O
Met,	O
methionine;	B
MGL,	O
monoacylglyceride	B
lipase;	O
MMA,	O
methylmalonic	B
acid;	I
MMCM,	O
methylmalonyl-CoA	B
mutase;	O
MMCS,	O
malonyl-CoA/methylmalonyl-CoA	O
synthetase;	O
MTAP,	O
MTA	O
phosphorylase;	O
OX,	O
oxidase;	O
PC,	O
phosphatidylcholine;	B
PCC,	O
propionyl-CoA	O
carboxylase;	O
PE,	O
phosphatidylethanolamine;	B
PENMT,	O
phosphatidylethanolamine	O
N-methyltransferase;	O
PNP,	O
purine-nucleoside	O
phosphorylase;	O
PSD,	O
phosphatidylserine	O
decarboxylase;	O
PSS,	O
phosphatidylserine	B
synthase;	O
ROS,	O
reactive	O
oxygen	O
species;	O
SAM,	O
S-adenosylmethionine;	B
SMS,	O
sphingomyelin	B
synthase;	O
SS,	O
spermidine	B
synthetase;	O
TGL,	O
triacylglyceride	B
lipase;	O
tHcy,	O
total	O
plasma	O
homocysteine;	B
VLCFA,	O
very-long-chain	O
FA.	B

SRM	O
traces	O
of	O
PhIP	O
and	O
its	O
glucuronide	B
metabolites	O
in	O
human	O
urine	O
before	O
and	O
after	O
consumption	O
of	O
cooked	O
beef.	O

The	O
Wilcoxon	O
signed-rank	O
test	O
was	O
used	O
to	O
test	O
for	O
significant	O
transcoronary	O
gradients	O
(i.e.	O
significant	O
myocardial	O
uptake	O
or	O
elution)	O
by	O
comparing	O
the	O
observed	O
AV	B
difference	O
with	O
the	O
null	O
hypothesis	O
(gradient	O
of	O
0).	O

Ultraviolet	O
(UV)	O
transparent	O
fluorinated	B
ethylene	I
propylene	I
(FEP)	O
tubing	O
(0.03-in.	O

Known	O
to	O
be	O
low	O
in	O
normal	O
physiological	O
conditions,	O
hypoxanthine	B
levels	O
increase	O
upon	O
tissue	O
damage.	O

Moreover,	O
both	O
substrates	O
and	O
enzymes	O
of	O
all	O
three	O
ceramide-biosynthesis	B
pathways	O
were	O
elevated	O
in	O
cancer	O
tissue,	O
and	O
ceramide	B
levels	O
were	O
inversely	O
associated	O
with	O
aggressive	O
phenotypes	O
of	O
breast	O
cancer.	O

All	O
of	O
these	O
metabolites	O
are	O
involved	O
in	O
glucose	B
metabolism,	O
amino	O
acid	O
metabolism,	O
or	O
oxidative	O
stress.	O

In	O
our	O
subjects,	O
there	O
was	O
no	O
difference	O
in	O
ascorbic	B
acid	I
intake	O
(dietary	O
and	O
supplemental)	O
between	O
cases	O
and	O
controls	O
(data	O
not	O
shown),	O
yet	O
decreased	O
levels	O
of	O
diketogulonic	O
acid	O
were	O
observed	O
in	O
cases.	O

Morphine-3-glucuronide	B
is	O
biologically	O
inactive	O
but	O
morphine-6-glucuronide	B
has	O
considerable	O
analgesic	O
activity.	O

The	O
LC	O
separation	O
of	O
lipid	O
extracts	O
prior	O
to	O
MS	O
analysis	O
is	O
an	O
important	O
component	O
of	O
the	O
analysis	O
as	O
it	O
prevents	O
signal	O
suppression	O
of	O
low	O
abundance	O
lipid	O
species	O
such	O
as	O
phosphatidic	B
acid	I
(PA),	O
bis(monoacylglycero)phosphate	B
(BMP)	O
and	O
GM3	B
by	O
lipids	O
that	O
are	O
typically	O
found	O
in	O
higher	O
abundance,	O
such	O
as	O
phosphatidylcholine	B
(PC)	O
and	O
phosphatidylethanolamine	B
(PE).	O

Increased	O
serum	O
17β-estradiol	B
in	O
men	O
or	O
postmenopausal	O
women	O
was	O
accepted	O
as	O
evidence	O
of	O
tumor-related	O
estrogen	B
excess.	O

Colors	O
represent	O
different	O
ratios	O
as	O
indicated	O
by	O
the	O
color	O
bar	O
Given	O
the	O
ubiquitous	O
existence	O
of	O
Δ9/Δ11	O
isomer	O
pair	O
in	O
all	O
C18:1-containing	O
lipids,	O
compositional	O
analysis	O
was	O
performed	O
for	O
29	O
pairs	O
of	O
PC	O
and	O
PE	B
isomers	I
from	O
normal	O
and	O
cancerous	O
breast	O
tissue	O
samples	O
(Supplementary	O
Fig.	O

To	O
confirm	O
the	O
mass	O
spectrometry	O
measurements	O
the	O
levels	O
of	O
malate	B
and	O
citrate	B
were	O
measured	O
by	O
alkali-enhanced	O
fluorescence	O
in	O
cell	O
lines	O
maintained	O
in	O
RPMI	O
1640	O
tissue	O
culture	O
medium	O
(usually	O
contains	O
11.1	O
mM	O
glucose	B
and	O
2mM	O
glutamine)	B
modified	O
to	O
contain	O
a	O
physiologically	O
normal	O
concentration	O
of	O
glucose	B
(5	O
mM)	O
(and	O
still	O
2	O
mM	O
glutamine)	B
for	O
one	O
day	O
followed	O
by	O
a	O
brief	O
starvation	O
period	O
in	O
the	O
presence	O
of	O
no	O
fuel	O
and	O
then	O
a	O
35	O
min	O
incubation	O
period	O
in	O
Krebs	O
Ringer	O
bicarbonate	O
buffer	O
solution	O
containing	O
10	O
mM	O
glucose.	B

This	O
study	O
shows	O
that	O
the	O
reduction	O
in	O
plasma	O
levels	O
of	O
LPC	O
plasmalogens	O
associated	O
with	O
an	O
increase	O
in	O
MDA	O
levels	O
may	O
indicate	O
increased	O
oxidative	O
stress	O
in	O
these	O
patients	O
and	O
identify	O
the	O
metabolite	O
LPC	O
(P-16:1)	O
as	O
a	O
putatively	O
novel	O
lipid	O
signature	O
for	O
RAC.	O

Moreover,	O
polyamines,	B
being	O
also	O
products	O
of	O
bacterial	O
metabolism,	O
can	O
be	O
directly	O
absorbed	O
from	O
the	O
gut	O
lumen	O
(reviewed	O
in).	O

Retinal	B
plays	O
an	O
essential	O
role	O
in	O
molecular	O
signaling	O
in	O
vision,	O
and	O
serves	O
mainly	O
as	O
a	O
retinoic	B
acid	I
(an	O
active	O
form	O
of	O
vitamin	O
A)	O
precursor	O
outside	O
the	O
eye.	O

Compared	O
with	O
healthy	O
control	O
subjects,	O
the	O
RA	O
cohort	O
showed	O
significantly	O
lower	O
levels	O
of	O
plasma	O
l-arginine	B
(46.11 ± 17.29	O
vs.	O
74.2 ± 22.53 μmol/L,	O

Aminoterminal	B
pro-B-type	O
natriuretic	O
peptide	O
(NT-proBNP)	O
levels	O
were	O
measured	O
by	O
the	O
Elecsys	O
platform	O
(Roche	O
Diagnostics,	O
Indianapolis	O
IN)	O

glycosylphosphatidylinositol-	B
(GPI-)	I
anchored	O
biosynthesis,	O
steroidal	O
biosynthesis,	O
and	O
glycerophospholipid	B
metabolism.	O

The	O
compounds	O
are	O
derived	O
from	O
phosphatidylcholine	B
(PC),	O
also	O
called	O
lecithin,	B
mainly	O
catalyzed	O
by	O
lecithin-cholesterol	B
acyltransferase	O

We	O
recognise	O
that	O
HOMA	O
IR	O
is	O
not	O
an	O
ideal	O
index	O
of	O
insulin	O
resistance	O
but	O
in	O
general	O
population	O
studies	O
it	O
is	O
often	O
impractical	O
to	O
perform	O
euglycemic	B
hyperinsulinemic	O
clamp	O
studies	O
in	O
all	O
subjects	O
and,	O
in	O
this	O
case,	O
HOMA	O
IR	O
and	O
fasting	O
insulin	O
are	O
satisfactory	O
surrogate	O
measures.	O

Based	O
on	O
the	O
non-targeted	O
metabolomics	O
results	O
obtained,	O
quantitative	O
targeted	O
analyses	O
using	O
Liposcale	O
(for	O
lipid	O
profiling,	O
deconvolution	O
of	O
phosphatidylcholines	B
and	O
glycoproteins)	B
and	O
Dolphin	O
(for	O
LMW	O
metabolite	O
profiling)	O
were	O
performed	O
(Fig.	O

0.025	O
M	O
Na_2	O
B_4	O
O_7	O
·10H_2	O
O,	O
1.77	O
mM	O
sodium	B
hydroxide	I
(NaOH),	O
pH	O
=	O
9.2)	O
were	O
vortexed	O
(1	O
min,	O
1100	O
rpm,	O
25	O
°C)	O
in	O
polypropylene	B
microtubes.	O

Glucose	B
is	O
the	O
primary	O
energy	O
source	O
for	O
the	O
central	O
nervous	O
system.	O

For	O
example,	O
taurine,	B
glutamine,	B
glutamic	B
acid,	I
phenyl	B
alanine,	I
proline,	B
serine,	B
valine,	B
asparagine,	B
glycine,	B
isoleucine,	B
lysine	B
were	O
all	O
up-regulated	O
while	O
orotate,	B
ketoglutarate	B
and	O
glyceraldehyde	B
3-phosphate	I
were	O
all	O
down-regulated	O
in	O
AA	O
serum	O
when	O
compared	O
to	O
EA	O
BLCA.	O

When	O
we	O
compare	O
late	O
stage	O
samples	O
from	O
rabies	O
survivors	O
to	O
nonsurvivors,	O
pyruvate	B
and	O
NAA	O
are	O
higher	O
in	O
individuals	O
that	O
die,	O
suggesting	O
deregulated	O
cerebral	O
volume	O
control	O
and	O
an	O
increased	O
energy	O
demand,	O
progressing	O
over	O
time.	O

Lactate,	B
alanine	B
and	O
t-choline	B
concentrations	O
were	O
significantly	O
elevated	O
in	O
high-grade	O
prostate	O
cancer	O
samples	O
when	O
compared	O
to	O
benign	O
samples	O
in	O
untreated	O
patients.	O

It	O
also	O
showed	O
high	O
specificity	O
to	O
the	O
choline	B
head	O
group	O
as	O
compared	O
to	O
other	O
fragments,	O
i.e.	O
loss	O
of	O
62	O
Da	O
(H_2	O
CO_3	O
);	O
therefore,	O
it	O
was	O
tested	O
for	O
profiling	O
of	O
PCs	O
from	O
complex	O
mixtures.	O

Lower	O
concentrations	O
of	O
isopropanol,	B
pyruvate,	B
lactate,	B
creatine	B
and	O
proline	B
and	O
higher	O
concentrations	O
of	O
acetate,	B
propionate	B
and	O
glycolate	B
in	O
mid/survivor	O
samples	O
separated	O
these	O
from	O
late	O
stage	O
rabies	O
samples.	O

These	O
included	O
both	O
metabolites	O
named	O
for	O
the	O
same	O
compound	O
across	O
platforms	O
as	O
well	O
as	O
unique	O
metabolites,	O
of	O
which	O
2	O
(nonanoylcarnitine	O
(C9)	O

To	O
50	O
μl	O
of	O
this	O
solution	O
was	O
added	O
450	O
μl	O
of	O
the	O
same	O
phosphate	B
buffer	O
and	O
400	O
μl	O
of	O
water.	O

In	O
terms	O
of	O
depicting	O
biomarkers	O
for	O
classifying	O
the	O
aggressive	O
state	O
of	O
CLL,	O
grouping	O
acetylcarnitines	B
was	O
promising;	O
however	O
this	O
panel	O
was	O
surpassed	O
by	O
the	O
combination	O
of	O
selected	O
acylcarnitines	B
and	O
fatty	O
acid	O
amides.	O

Mean	O
disease	O
duration	B
was	O
11.7 ± 9.6	O

Prostaglandin	B
E2.	I

The	O
multiple	O
level	O
of	O
replication	O
for	O
the	O
three	O
identified	O
genetic	O
signals,	O
individually	O
and	O
combined	O
in	O
the	O
response	O
score,	O
suggests	O
their	O
importance	O
as	O
predictors	O
of	O
hydrochlorothiazide	B
blood	O
pressure	O
response,	O
which	O
may	O
help	O
in	O
optimizing	O
the	O
selection	O
of	O
antihypertensive	O
therapy.	O

Bioelectrical	O
impedance	O
analysis	O
was	O
performed	O
in	O
duplicate	O
using	O
a	O
BF	O
906	O
Body	O
Fat	O
Analyzer	O
(Maltron,	O
Rayleigh,	O
United	O
Kingdom)	O
and	O
resting	O
in	O
a	O
supine	B
position	O
by	O
placing	O
2	O
electrodes	O
at	O
standardized	O
points	O
on	O
the	O
right	O
hand	O
and	O
2	O
electrodes	O
on	O
the	O
right	O
foot.	O

The	O
drop	O
of	O
levodopa	B
synthesis	O
may	O
be	O
the	O
result	O
of	O
the	O
hypersecretion	O
of	O
its	O
antagonist	O
prolactin,	O
as	O
observed	O
in	O
response	O
to	O
HS	O
in	O
goats,	O
ewes	O
and	O
cows.	O

The	O
elevated	O
level	O
of	O
2-aminobutyrate	B
further	O
indicates	O
a	O
higher	O
level	O
of	O
oxidative	O
stress	O
in	O
CRC	O
patients	O
compared	O
with	O
healthy	O
controls.	O

In	O
addition,	O
peak	O
areas	O
were	O
normalized	O
against	O
those	O
of	O
the	O
internal	O
standard	O
for	O
cations	O
(MetSul	O
[methionine	O
sulfone])	I
and	O
that	O
for	O
anions	O
(CSA	O
[D-camphor-10-sulfonic	O
acid])	O
and,	O
then,	O
the	O
resultant	O
relative	O
area	O
values	O
were	O
further	O
normalized	O
to	O
the	O
sample	O
amount.	O

The	O
levels	O
of	O
the	O
sphingolipids	B
including	O
sphingosine	B
(Sph),	O
dihydro-Sph	B
(DHSph),	O
S1P,	O
dihydro-S1P	O
(DHS1P)	O
were	O
determined	O
by	O
LC-ESI-MS/MS.	O

The	O
PAH	O
compound	O
that	O
shows	O
the	O
strongest	O
correlation	O
with	O
the	O
ETS	O
urinary	O
biomarkers	O
cotinine	B
(Pearson	O
R	O
=0.55,	O
p	O
<0.01)	O
and	O
trans	B
-3′-hydroxycotinine	I
(Pearson	O
R	O
=0.52,	O
p	O
<0.01)	O
is	O
chrysene.	O

In	O
fact,	O
SM	O
has	O
been	O
found	O
to	O
be	O
crucial	O
in	O
cell	O
apoptosis	O
by	O
hydrolyzing	O
into	O
ceramide().	B

BMI	O
(p	O
=	O
0.009),	O
GFR	O
(p	O
=	O
0.015)	O
and	O
2-oxoglutarate	B
were	O
included	O
in	O
a	O
logistic	O
regression	O
model	O
to	O
predict	O
response	O
to	O
lisinopril.	O

Urinary	O
excretion	O
of	O
phenylalanine	B
and	O
different	O
forms	O
of	O
hydroxyphenylacetic	B
acids	I
are	O
characteristic	O
of	O
this	O
disease.	O

Other	O
analgesics	O
such	O
as	O
ibuprofen	B
are	O
used	O
commonly	O
in	O
Western	O
countries;	O
for	O
example,	O
in	O
the	O
United	O
Kingdom,	O
total	O
ibuprofen	B
sales	O
of	O
46	O
tons	O
were	O
reported	O
in	O
2000.	O

We	O
focused	O
on	O
12	O
metabolites	O
that	O
have	O
previously	O
been	O
reported	O
to	O
be	O
biomarker	O
candidates;_13	O
,	O
_14	O
ie,	O
threonine,	B
methionine,	B
arabinose,	B
asparagine,	B
xylitol,	B
glutamine,	B
1,5‐AG,	B
lysine,	B
histidine,	B
tyrosine,	B
inositol	B
and	O
uric	B
acid.	I

The	O
citric	B
acid	I
cycle	O
(TCA	O
cycle)	O
or	O
Krebs	O
cycle	O
is	O
the	O
central	O
metabolic	O
process	O
of	O
the	O
cell.	O

MS/MS	O
analysis	O
identified	O
the	O
positive	O
ion	O
with	O
2450.9701	O
m	O
/z	O
as	O
a	O
transthyretin.	B

Our	O
findings	O
confirmed	O
a	O
clear	O
relationship	O
between	O
carotid	O
atherosclerosis	O
plaque	O
and	O
plasma	O
levels	O
of	O
20-HETE.	B

Folates	O
are	O
conjugated	O
pterines	O
that	O
contain	O
p-aminobenzoic	B
acid	I
and	O
L-glutamates	B
connected	O
to	O
the	O
methyl	B
group	I
at	O
position	O
6	O
of	O
the	O
pteridine	B
ring	O
system.	O

In	O
models	O
investigating	O
associations	O
and	O
potential	O
mechanisms,	O
after	O
adjusting	O
for	O
age,	O
sex	O
and	O
randomised	O
treatment,	O
phenylalanine	B
was	O
positively,	O
and	O
histidine	B
inversely,	O
associated	O
with	O
macrovascular	O
disease	O
risk.	O

For	O
oxalate,	B
m	O
/z	O
147	O
as	O
product	O
ion	O
resulted	O
in	O
the	O
highest	O
signal-to-noise	O
ratio	O
for	O
the	O
M+2	O
isotope,	O
whereas	O
for	O
glycolate,	B
m	O
/z	O
73	O
as	O
the	O
product	O
ion	O
resulted	O
in	O
the	O
highest	O
signal-to-noise	O
ratio	O
for	O
the	O
M+1	O
isotope.	O

The	O
detail	O
regulation	O
of	O
histidine-histamine	B
pathway	O
and	O
its	O
role	O
in	O
AD	O
need	O
more	O
research	O
to	O
evaluate.	O

The	O
negative	O
effects	O
of	O
Omega-3	B
on	O
glycemic	B
control	O
and	O
glucose	B
metabolism	O
were	O
prevented	O
by	O
Pio.	O

Focusing	O
on	O
the	O
child	O
population,	O
the	O
sum	O
of	O
the	O
phthalate	B
metabolites	O
in	O
the	O
Belgian	O
urine	O
samples	O
was	O
comparable	O
to	O
those	O
reported	O
from	O
Denmark,	O
Taiwan,	O
and	O
Canada	O
but	O
higher	O
than	O
in	O
the	O
CDC	O
study	O
and	O
lower	O
in	O
German	O
and	O
Korean	O
children.	O

1-methyl-histidine	B
(1M-His)	O
is	O
present	O
in	O
skeletal	O
muscles	O
as	O
a	O
precursor	O
of	O
anserine	B
(β-alanyl-N-methylhistidine).	I

A,	O
Metabolites	O
of	O
adrenal	O
androgen	O
precursors	O
and	O
active	O
androgens;	O
B,	O
metabolites	O
of	O
mineralocorticoids	O
and	O
their	O
precursors;	O
C,	O
metabolites	O
of	O
glucocorticoid	B
precursors;	O
D,	O
cortisol	B
and	O
cortisone	B
metabolites.	O

GP-tagged	O
7α,x	B
-dihydroxy-3-oxocholest-4-en-26-oic	I
acid	I
appears	O
as	O
syn	O
and	O
anti	O
conformers	O
appearing	O
at	O
2.67	O
and	O
3.79	O
min	O
in	O
RIC	O
(b	O
).	O

Pyridoxic	B
acid	I
has	O
received	O
little	O
attention	O
in	O
cardiovascular	O
research.	O

The	O
remaining	O
lipids	O
showed	O
positive	O
correlation	O
with	O
temperature,	O
although	O
significant	O
only	O
for	O
selected	O
phosphatidylcholines	B
and	O
sphingomyelins.	B

It	O
may	O
also	O
be	O
useful	O
to	O
have	O
HbA1_c	O
levels,	O
but	O
this	O
analysis	O
did	O
not	O
assess	O
the	O
effect	O
of	O
glycemic	B
control	O
on	O
NMR.	O

Patients	O
with	O
a	O
higher	O
extent	O
of	O
inflammation	O
had	O
lower	O
plasma	O
histidine	B
concentrations	O
(P	O
<0.001).	O

Finally,	O
the	O
enzyme	O
CPT2	O
reconverts	O
acylcarnitines	B
back	O
into	O
free	O
carnitine	B
and	O
long-chain	O
acyl-CoAs.	B

The	O
elevated	O
serum	O
levels	O
of	O
PG	B
(22:2(13Z,	I
16Z)/0:0)	I
may	O
be	O
attributed	O
to	O
high	O
concentrations	O
of	O
lipoproteins.	O

The	O
highest	O
prediction	O
power	O
was	O
reached	O
through	O
Naïve	O
Bayes	O
method	O
with	O
9	O
metabolites	O
combination,	O
including	O
valine,	B
leucine,	B
proline,	B
glyceic	B
acid,	I
pyroglutamate,	B
galactose,	B
glucopyranose,	B
palmitic	B
acid	I
and	O
heptadecylic	B
acid.	I

The	O
increased	O
postabsorptive	O
plasma	O
3-HIB	O
levels	O
in	O
our	O
subjects	O
with	O
diabetes	O
may	O
reflect	O
increased	O
protein	O
breakdown	O
as	O
a	O
consequence	O
of	O
relative	O
insulin	O
deficiency	O
due	O
to	O
insufficient	O
insulin	O
secretion	O
in	O
relation	O
to	O
insulin	O
resistance,	O
which	O
would	O
also	O
explain	O
increased	O
ketone	B
body	O
production.	O

DAG	B
34:2	I
and	O
DAG	B
36:2	I
were	O
robust	O
biomarkers	O
being	O
elevated	O
in	O
both	O
MCI	O
and	O
LOAD	O
patients	O
with	O
an	O
MMSE	O
score	O
of	O
10	O
to	O
18	O
while	O
DAG	B
36:2	I
also	O
was	O
elevated	O
in	O
MCI	O
and	O
LOAD	O
patients	O
with	O
an	O
MMSE	O
score	O
of	O
19	O
to	O
24.	O

The	O
buckets	O
presenting	O
the	O
largest	O
increases	O
when	O
cases	O
are	O
compared	O
with	O
controls	O
were	O
correlated	O
with	O
various	O
lipid	O
molecules,	O
whereas	O
the	O
highest	O
metabolite	O
reductions	O
were	O
observed	O
for	O
buckets	O
related	O
to	O
α/β-glucose.	B

IBS,	O
irritable	O
bowel	O
syndrome;	O
IBD,	O
inflammatory	O
bowel	O
disease;	O
CD,	O
Crohn’s	O
disease;	O
UC,	O
ulcerative	O
colitis;	O
F/M,	O
female	O
to	O
male	O
ratio;	O
yrs.,	O
years;	O
SD,	O
standard	O
deviation;	O
CDAI,	O
Crohn’s	O
disease	O
activity	O
index;	O
RI,	B
Rachmilewitz	O
index;	O
_1	O
for	O
comparison	O
between	O
controls	O
and	O
IBS	O
and	O
IBD	O
patients;	O
_2	O
for	O
comparison	O
between	O
controls	O
and	O
patients	O
with	O
IBS,	O
active	O
and	O
inactive	O
CD	O
and	O
active	O
and	O
inactive	O
UC;	O
_3	O
Χ_2	O
-test;	O
_4	O
one-way	O
ANOVA;	O
_5	O
Fisher’s	O
exact	O
test.	O

Increased	O
levels	O
of	O
choline	B
could	O
be	O
due	O
to	O
an	O
increase	O
in	O
the	O
membrane	O
activity,	O
particularly	O
due	O
to	O
enhanced	O
cellular	O
proliferation.	O

A	O
reproducible	O
and	O
sensitive	O
LC-MS/MS	O
method	O
for	O
the	O
simultaneous	O
quantitation	O
of	O
free	O
24S-OHC,	O
25-OHC,	O
27-OHC,	O
7β-OHC	B
and	O
7-KC	O
in	O
plasma	O
samples	O
was	O
developed	O
in	O
this	O
study.	O

Standard	O
compounds,	O
including	O
valine,	B
phenylalanine,	B
l-carnitine,	B
lactic	B
acid,	I
uric	B
acid,	I
cholic	B
acid,	I
linoleic	B
acid,	I
1-palmitoyl-sn	B
-glycero-3-phosphocholine,	I
and	O
1-stearoyl-sn	B
-glycero-3-phosphocholine	I
were	O
purchased	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
MO).	O

Correlation	O
plots	O
relating	O
A)	O
pre-intervention	O
levels	O
of	O
HOMA-IR	O
to	O
2-hydroxybutyric	B
acid	I
(2-HBA),	O
B)	O
decrease	O
in	O
HOMA-IR	O
to	O
decrease	O
in	O
2-HBA,	O
C)	O
pre-intervention	O
HOMA-IR	O
to	O
combined	O
branched-chain	O
amino	O
acids	O
(BCAA),	O
and	O
D)	O
decrease	O
in	O
HOMA-IR	O
to	O
decrease	O
in	O
BCAA.	O

It	O
was	O
possible	O
to	O
differentiate	O
endogenous	O
7α-hydroxy-3-oxocholest-4-en-26-oic	B
acid	I
from	O
that	O
generated	O
by	O
treatment	O
with	O
bacterial	O
cholesterol	B
oxidase,	O
as	O
the	O
abundance	O
of	O
the	O
GP-tagged	O
compound	O
did	O
not	O
change	O
when	O
derivatization	O
was	O
performed	O
in	O
the	O
presence	O
or	O
absence	O
of	O
the	O
bacterial	O
cholesterol	B
oxidase.	O

Top	O
and	O
bottom	O
spectra	O
show	O
the	O
presence	O
of	O
specific	O
glycerophospholipids	B
in	O
normal	O
and	O
cancerous	O
colon	O
tissue,	O
respectively.	O

Custom	O
Library	O
Search	O
for	O
all	O
known,	O
putative	O
known	O
and	O
putative	O
novel	O
oxylipins	B
was	O
performed	O
using	O
an	O
RT	O
tolerance	O
of	O
0.1	O
minutes	O
and	O
a	O
mass	O
tolerance	O
of	O
±5	O
ppm.	O

Principal	O
Component	O
Analysis	O
and	O
Partial	O
Least	O
Squares	O
Discriminant	O
Analysis	O
(PLS-DA)	O
were	O
used	O
to	O
evaluate	O
overall	O
discrimination	O
between	O
patients	O
and	O
controls	O
after	O
normalizing	O
to	O
1	O
mmol	O
of	O
urine	O
creatinine,	B
log	O
transformation,	O
and	O
autoscaling	O
(MetaboAnalyst	O
3.0;	O
www.metaboanalyst.ca).	O

The	O
application	O
of	O
this	O
approach	O
for	O
the	O
analysis	O
of	O
fatty	O
acids	O
in	O
human	O
serum	O
demonstrated	O
the	O
existence	O
of	O
two	O
double	O
bond	O
isomers	O
of	O
linolenic	B
acid	I
(i.e.	O
,	O
Δ_6,9,12	B
18:3,	I
γ-linolenic	B
acid	I
(GLA),	O
and	O
Δ_9,12,15	B
18:3,	I
α-linolenic	B
acid	I
(ALA)).	O

Samples	O
were	O
diluted	O
with	O
hexane,	B
and	O
tubes	O
were	O
centrifuged	O
to	O
remove	O
any	O
solid	O
particles	O
and	O
micro-particles.	O

Pyruvic	O
acid-meto-trimethylsilyl	O
(TMS),	O
glycolic	B
acid-2TMS,	O
lactic	O
acid-2TMS(/SI),	O
and	O
fumaric	O
acid-2TMS(/SI)	O
displayed	O
AUC	O
values	O
of	O
>0.8,	O
and	O
both	O
the	O
sensitivity	O
and	O
specificity	O
of	O
pyruvic	O
acid-meto-TMS	O
and	O
lactic	O
acid-2TMS(/SI)	O
were	O
>80%.	O

Retinal,	B
retinoic	B
acid,	I
and	O
β-apo-8′-carotenal	B
(Fluka)	O
were	O
used	O
as	O
obtained.	O

Only	O
cholesterol,	B
threonic	B
acid	I
and	O
inosine	B
show	O
a	O
lower	O
abundance	O
in	O
both	O
NP	O
and	O
CWP	O
while	O
arginine	B
and	O
aminomalonic	B
acid	I
show	O
increased	O
abundance	O
in	O
CWP	O
and	O
a	O
lower	O
in	O
NP.	O

LC-MS/MS	O
extracted	O
chromatograms	O
of	O
co-eluting	O
oxylipins	B
acquired	O
by	O
dynamic	O
MRM.	O

After	O
drying,	O
the	O
aliquots	O
were	O
reconstituted	O
with	O
0.1%	O
formic	B
acid,	I
for	O
LC/MS	O
positive	O
ion	O
mode,	O
and	O
with	O
6.5	O
mM	O
ammonium	B
bicarbonate	O
pH	O
8.0	O
for	O
negative	O
ion	O
mode.	O

In	O
addition,	O
we	O
noticed	O
a	O
negative	O
correlation	O
between	O
some	O
of	O
these	O
ketone	B
bodies	O
with	O
BMI	O
which	O
highlights	O
the	O
role	O
of	O
energy-related	O
metabolic	O
alterations	O
before	O
UC	O
relapse	O
(data	O
not	O
shown).	O

All	O
three	O
BCAAs	O
were	O
significantly	O
increased	O
in	O
the	O
T2DM	O
group	O
after	O
BMI	O
adjustment,	O
and	O
there	O
was	O
a	O
tendency	O
to	O
increase	O
for	O
all	O
BCAAs	O
in	O
the	O
IGT	O
group,	O
but	O
only	O
the	O
increase	O
in	O
leucine	B
was	O
significant.	O

Glycerol,	B
acetate,	B
methanol,	B
and	O
ethanol	B
were	O
detected	O
in	O
both	O
conditions	O
but	O
were	O
neither	O
quantified	O
nor	O
analyzed	O
because	O
they	O
are	O
either	O
volatile,	O
or	O
known	O
contaminants	O
from	O
filtration	O
(glycerol).	O

The	O
less	O
polar	O
compound,	O
hydrocortisone,	B
was	O
eluted	O
at	O
the	O
very	O
beginning	O
of	O
the	O
chromatography	O
run	O
(0.802 min)	O
while	O
the	O
quaternary	O
ammonium	B
compound	O
L-carnitine	B
was	O
strongly	O
retained	O
on	O
HILIC	O
column	O
and	O
eluted	O
with	O
a	O
retention	O
time	O
of	O
8.21 min,	O
towards	O
the	O
end	O
of	O
the	O
9-min	O
chromatographic	O
run.	O

Metabolite	O
profiling	O
identified	O
changes	O
in	O
succinate	B
associated	O
with	O
CE	O
stroke,	O
atrial	O
dysfunction,	O
and	O
stroke	O
recurrence,	O
revealing	O
a	O
putative	O
underlying	O
link	O
between	O
CE	O
stroke	O
and	O
energy	O
metabolism.	O

As	O
an	O
example,	O
compares	O
the	O
energy	O
coenzymes,	O
ATP,	B
ADP	B
and	O
AMP,	B
obtained	O
from	O
mouse	O
heart	O
tissue	O
samples	O
before	O
and	O
after	O
optimization	O
of	O
the	O
harvesting	O
and	O
extraction	O
method.	O

The	O
residue	O
was	O
mixed	O
with	O
810	O
μL	O
of	O
D_2	O
O,	O
methanol-d	B
_4	O
or	O
dimethyl	B
sulfoxide-d	I
_6	O
and	O
81	O
μL	O
of	O
an	O
acid/base/salt	O
solution	O
(0.1	O
M	O
HCl	O
(aq.),	O
0.1	O
M	O
NaOH	O
(aq.),	O
0.1	O
M	O
NaHCO_3	O
(aq.),	O
0.1	O
M	O
Na_2	O
CO_3	O

While	O
it	O
remains	O
likely	O
that	O
the	O
primary	O
mechanism	O
of	O
AGE	O
reduction	O
following	O
metformin	B
treatment	O
occurs	O
via	O
improved	O
glycemic	B
control,	O
the	O
unique	O
structure	O
of	O
metformin	B
also	O
facilitates	O
a	O
direct	O
scavenging	O
mechanism	O
to	O
directly	O
eliminate	O
MG	O
from	O
the	O
body.	O

Intensities	O
of	O
the	O
raw	O
peak	O
area	O
of	O
a	O
certain	O
ion	O
(GC–MS)	O
were	O
normalized	O
by	O
sum,	O
log-transformed,	O
and	O
auto-scaled	O
and	O
each	O
spectral	O
bin	O
(_1	O
H-NMR)	O
was	O
normalized	O
to	O
creatinine	B
(µmol/mmol	O
creatinine)	O
and	O
auto-scaled.	O

Relationship	O
between	O
Intestinal	O
Microflora-Dependent	O
Phosphatidylcholine	B
Metabolites	O
And	O
Diastolic	O
Dysfunction	O
in	O
Chronic	O
Systolic	O
Heart	O
Failure.	O
illustrates	O
the	O
Cox	O
proportional	O
hazard	O
models	O
of	O
TMAO,	B
choline,	B
and	O
betaine	B
for	O
long-term	O
adverse	O
clinical	O
outcomes.	O

The	O
transitions	O
of	O
m/z	O
436.3	O
→	O
285.2	O
for	O
SMV,	O
m/z	O
437.2	O
→	O
303.2	O
for	O
SMV-A,	O
m/z	O
559.2	O
→	O
440.3	O
for	O
ATV,	O
m/z	O
575.4	O
→	O
440.3	O
for	O
2-OH-ATV	B
and	O
4-OH-ATV,	B
m/z	O
482.3	O
→	O
258.1	O
for	O
RSV,	O
and	O
m/z	O
412.3	O
→	O
224.2	O
for	O
fluvastatin	B
(internal	O
standard,	O
IS)	O
were	O
determined	O
by	O
Selected	O
Reaction	O
Monitoring	O
(SRM)	O
method	O
to	O
detect	O
transitions	O
ions	O
in	O
the	O
positive	O
ion	O
mode.	O

The	O
dried	O
plasma	O
extracts	O
were	O
derivatized	O
with	O
25	O
µL	O
of	O
18	O
mg/mL	O
methoxyamine	B
hydrochloride	I
in	O
pyridine	B
at	O
50	O
°C	O
for	O
30	O
min,	O
followed	O
by	O
trimethylsilylation	O
with	O
75	O
µL	O
of	O
N	B
-methyl-N	I
-(trimethylsilyl)trifluoroacetamide	I

L1	O
comparing	O
to	O
L0	O
presented	O
higher	O
fasting	O
triglycerides	B
(P	O
 = 0.004),	O
insulin	O
(P	O
 = 0.002),	O
INS/GLU	O
(P	O
 = 0.003),	O
HOMA-IR	O
(P	O
 = 0.002),	O
GGTP	O

Of	O
the	O
745	O
unknown	O
experimental	O
tandem	O
mass	O
spectra,	O
362	O
spectra	O
were	O
chemically	O
networked	O
with	O
at	O
least	O
one	O
oxylipin	B
standard	O
and	O
did	O
not	O
form	O
secondary	O
connections	O
with	O
any	O
of	O
the	O
~50,000	O
non-oxylipin	O
compounds	O
present	O
in	O
the	O
library	O
repository,	O
thereby	O
classifying	O
these	O
362	O
metabolites	O
as	O
putative	O
known	O
oxylipins.	B

Plasma	O
F_2	B
-isoprostanes	I
were	O
determined	O
using	O
gas	O
chromatography	O
mass	O
spectrometry	O
(GC-MS)	O
.	O

Groups	O
did	O
not	O
differ	O
at	O
any	O
time	O
point	O
for	O
measures	O
included	O
in	O
the	O
chemistry	O
panel	O
(all	O
interaction	O
effects,	O
P>0.05)	O
despite	O
strong	O
exercise	O
induced	O
increases	O
for	O
many	O
of	O
these	O
including	O
blood	O
urea	B
nitrogen	I
(BUN),	O
bilirubin,	B
creatinine,	B
alkaline	O
phosphatase	O
(ALK),	O
and	O
aspartate	O
aminotransferase	O
(AST)	O
(time	O
effects,	O
P<0.001,	O
data	O
not	O
shown).	O

Phosphatidylcholine	B
is	O
required	O
for	O
breast	O
cancer	O
cell	O
survival.	O

7α,25-diHC	B
and	O
7α,(25R)26-diHC	B
share	O
CYP7B1	O
as	O
the	O
ultimate	O
enzyme	O
in	O
their	O
biosynthesis.	O

The	O
absolute	O
concentrations	O
(ng/ml)	O
of	O
each	O
PC	O
and	O
PE	O
were	O
calculated	O
based	O
on	O
the	O
peak	O
areas	O
of	O
the	O
PC	O
and	O
PE	O
identified	O
in	O
the	O
sample	O
and	O
the	O
peak	O
areas	O
of	O
the	O
internal	O
standards	O
of	O
PC(15:0/18:1)	B
and	O
PE(15:0/18:1)	B
corresponding	O
to	O
the	O
sample.	O

For	O
SUM1315MO2	O
cells,	O
10μM	O
C75	O
and	O
15μM	B
celecoxib	I
had	O
induced	O
significant	O
apoptosis	O
(Figure	O
and	O
)	O
when	O
compared	O
to	O
DMSO.	B

The	O
notion	O
that	O
the	O
malignant	O
plasma	O
cells	O
in	O
MM	O
are	O
the	O
direct	O
source	O
of	O
elevated	O
carnitine	B
(and	O
by	O
extension	O
its	O
acetylcarnitine)	B
is	O
further	O
supported	O
by	O
a	O
second	O
NMR	O
based	O
metabolomics	O
study	O
that	O
identified	O
increased	O
carnitine	B
release	O
by	O
mouse	O
myeloma	O
cells	O
associated	O
with	O
culture	O
in	O
conditions	O
that	O
promoted	O
enhanced	O
antibody	O
secretion	O
.	O

Consequently,	O
fraction	O
collection	O
and	O
analysis	O
conditions	O
for	O
evaluation	O
of	O
compounds	O
identified	O
as	O
sodium	B
phenylbutyrate	I
metabolites	O
had	O
to	O
be	O
transferred	O
to	O
an	O
MS-compatible	O
formate	B
buffer	O
system.	O

Oxysterols	B
were	O
enriched	O
on	O
Oasis	O
HLB	O
Prime	O
SPE	O
plates	O
(bed	O
wt.	O

The	O
mean-corrected	O
intensity	O
(i.e.,	O
residuals	O
removing	O
the	O
effect	O
of	O
possible	O
confounders:	O
phase	O
and	O
cohort,	O
see	O
Methods)	O
is	O
also	O
represented	O
(right	O
Y	O
axis)	O
for	O
the	O
samples	O
in	O
the	O
fifth	O
(blue	O
line)	O
and	O
95th	O
(green	O
line)	O
quantiles	O
of	O
the	O
residuals	O
log_10	O
glucose	B
levels	O
after	O
controlling	O
for	O
the	O
FRS	O
variables.	O

AUC,	O
area	O
under	O
the	O
curve;	O
CE,	O
cholesterol	B
esters;	I
SM,	O
sphingomyelin;	B
SqCC,	O
squamous	O
cell	O
lung	O
cancer.	O

Briefly,	O
methanol	B
(600 µl),	O
chloroform	O
(1,000 µl),	O
and	O
ultrapure	O
water	O
(500 µl)	O
were	O
added	O
sequentially	O
and	O
vortexed	O
each	O
time.	O

Each	O
tissue	O
sample	O
(about	O
15 mg)	O
was	O
individually	O
placed	O
in	O
D_2	O
O	O
saline	B
and	O
inserted	O
into	O
a	O
4 mm	O
diameter	O
zirconium	B
oxide	I
rotor	O
for	O
all	O
NMR	O
acquisitions.	O

The	O
key	O
limiting	O
enzyme	O
of	O
the	O
BCAA	O
catabolic	O
process,	O
branched-chain	O
α-keto	O
acid	O
dehydrogenase	O
(BCKDH),	O
is	O
activated	B
by	O
dephosphorylation	O
with	O
mitochondrial	O
targeted	O
2C-type	O
serine/threonine	O
protein	O
phosphatase	O
(PP2Cm).	O

Additionally,	O
in	O
vitro	O
exposure	O
of	O
PBMCs	O
to	O
palmitic	B
acid	I
(16:0)	O
enhanced,	O
whereas	O
PUFA-enriched	O
LPC	O
treatment	O
significantly	O
inhibited	O
LPS-induced	O
IL-6	O
production,	O
these	O
findings	O
suggest	O
HIV-associated	O
altered	O
lipid	O
profiles	O
may	O
exacerbate	O
the	O
inflammatory	O
consequences	O
of	O
microbial	O
translocation.	O

This	O
study	O
determined	O
whether	O
reductions	O
in	O
postprandial	O
plasma	O
FFA	O
flux	O
would	O
lead	O
to	O
reductions	O
in	O
plasma	O
acylcarnitine	B
(AC)	O
concentrations.	O

For	O
example,	O
3,	B
4dihydroxyphenylacetone,	I
a	O
significant	O
metabolite	O
in	O
the	O
PDND-PDID	O
comparison,	O
also	O
significantly	O
differentiated	O
PD	O
patients	O
from	O
the	O
healthy	O
controls.	O

Fold	O
change	O
was	O
obtained	O
by	O
comparing	O
mRNA	O
levels	O
obtained	O
in	O
treated	O
samples	O
by	O
DMSO	B
control.	O

These	O
metabolites	O
elute	O
early	O
under	O
the	O
reversed-phase	O
conditions	O
used	O
in	O
this	O
work,	O
giving	O
irregular	O
peak	O
shape	O
due	O
to	O
their	O
weak	O
retention	O
on	O
the	O
column,	O
and	O
their	O
analysis	O
by	O
UPLC–MS	O
would	O
require	O
the	O
use	O
of	O
a	O
different	O
stationary	O
phase	O
such	O
as	O
hydrophylic	B
interaction	O
liquid	O
chromatography	O
(HILIC).	O

MS/MS	O
spectra	O
reveal	O
the	O
characteristic	O
fragmentation	O
pattern	O
of	O
sphinganine.	B

Accordingly,	O
high	O
urinary	O
excretion	O
of	O
enterolactone	B
has	O
been	O
associated	O
with	O
a	O
high	O
diversity	O
of	O
the	O
gut	O
microbial	O
community.	O

LC/MS	O
grade	O
Acetonitrile	B
(ACN)	O
was	O
abtained	O
from	O
Carlo	O
Erba	O
(Van	O
de	O
Remil,	O
Paris,	O
France).	O

Another	O
possibility	O
is	O
that	O
cytoplasmic	O
lipid	O
droplets	O
contained	O
in	O
human	O
and	O
animal	O
gliomas	O
provide	O
a	O
dynamic	O
reservoir	O
of	O
substrate	O
for	O
the	O
production	O
of	O
acetyl-CoA	B
in	O
the	O
mitochondria.	O

Our	O
results	O
partially	O
validate	O
previous	O
reports	O
on	O
metabolomic	O
profiling	O
of	O
MTB-infected	O
murine	B
models	O
_,	O
	O
and	O
active	O
TB	O
patients	O
and	O
suggest	O
that	O
global	O
metabolic	O
profiling	O
could	O
provide	O
insight	O
into	O
TB	O
pathogenesis	O
in	O
relevant	O
hosts.	O

LC-MS	O
grade,	O
ammonium	B
acetate,	I
acetonitrile,	B
methanol,	B
and	O
acetic	B
acid	I
were	O
purchased	O
from	O
Fisher	O
Scientific	O
(Pittsburgh,	O
PA,	O
USA).	O

IDH1	O
and	O
IDH2	O
catalyze	O
the	O
oxidative	O
decarboxylation	O
of	O
isocitrate	B
to	O
α-ketoglutarate	B
(α-KG).	I

This	O
result	O
is	O
consistent	O
with	O
Ferreiro-Vera’s	O
results,	O
where	O
1,325	O
features	O
were	O
detected	O
using	O
ethanol	B
precipitation	O
versus	O
851	O
features	O
using	O
methanol	B
alone[].	O

Leucine	B
was	O
detected	O
only	O
in	O
the	O
lyophilized	O
samples	O
(C)	O
and	O
had	O
considerable	O
contribution	O
towards	O
differences	O
between	O
the	O
drying	O
techniques	O
as	O
it	O
had	O
the	O
highest	O
VIP	O
bucket.	O

(A)	O
MI	O
fractions	O
of	O
BCKA	O
and	O
branched-chain	O
acylcarnitine	B
species	O
from	O
deep	O
labeling	O
tracing	O
experiment.	O

This	O
was	O
also	O
seen	O
with	O
a	O
solution	O
of	O
10	O
mM	O
mannitol	B
plus	O
10	O
mM	O
borate,	O
where	O
a	O
peak	O
corresponding	O
to	O
free	O
mannitol	B
was	O
observed	O
at	O
m/z	O
181.08	O
and	O
a	O
borate-mannitol	B
complex	O
comprising	O
two	O
mannitol	B
molecules	O
plus	O
one	O
borate	O
molecule	O
at	O
m/z	O

Similarly,	O
pyruvate	B
positively	O
correlated	O
with	O
carnitine	B
(R	O
=	O
0.4),	O
TMAO	B
(R	O
=	O
0.4),	O
and	O
homocysteine	B

Except	O
for	O
inflammation	O
marker	O
Gp	B
(glycoprotein	I
acetylation)	I
(p	O
 = 4.12E_−8	O
)	O
(l),	O
TB	O
patients	O
only	O
displayed	O
elevated	O
levels	O
of	O
two	O
metabolites:	O
phenylalanine	B
(p	O

Phosphocholine	B
and	O
succinate	B
were	O
statistically	O
significant	O
at	O
a	O
p≤0.1	O
level.	O

As	O
with	O
the	O
clinical	O
samples,	O
there	O
was	O
no	O
evidence	O
for	O
a	O
difference	O
in	O
the	O
metabolism	O
of	O
sofosbuvir	B
based	O
on	O
gender;	O
similar	O
maximal	O
levels	O
of	O
GS-331007	O
triphosphate	B
were	O
observed	O
in	O
cells	O
isolated	O
from	O
males	O
and	O
females	O
(Fig.	O

This	O
could	O
also	O
explain	O
the	O
decreased	O
lipid	O
levels	O
and	O
increased	O
β-hydroxybutyrate	B
and	O
acetoacetate	B
levels	O
in	O
the	O
serum	O
of	O
lung	O
cancer	O
patients.	O

Correlation	O
between	O
apparent	O
formation	O
rate	O
of	O
hydroxyanastrozole	B
and	O
individual	O
P450	O
activity	O
was	O
tested	O
using	O
a	O
panel	O
of	O
characterized	O
HLMs.	O

According	O
to	O
an	O
NMR-based	O
metabolomics	O
study	O
in	O
adults,	O
lower	O
levels	O
of	O
triglycerides	B
in	O
T1DM	O
patients	O
may	O
also	O
be	O
attributable	O
to	O
treatment	O
with	O
insulin,	O
which	O
is	O
known	O
to	O
have	O
an	O
anti-lipolytic	O
action.	O

Furan	B
metabolites	O
were	O
eluted	O
from	O
the	O
cartridge	O
with	O
1%	O
(v/v)	O
formic	B
acid	I
containing	O
40%	O
(v/v)	O
methanol	B
(1,	O
6	O
as	O
[_2	O
H_3	O
]1,	O
[_13	O
C_6	O
_15	O
N_2	O
]1,	O
5,	O
3	O
as	O
[_2	O
H_3	O
]5,	O
and	O
[_13	O
C_6	O
_15	O
N_2	O
]5)	O
and	O
100%	O
methanol	B
(4,	O
[_2	O
H_3	O
]4,	O
[_13	O
C_6	O
_15	O
N_2	O
]4	O
and	O
[_13	O
C_6	O
_15	O
N_2	O
]2	O
as	O
[_13	O
C_6	O
_2	O
H_3	O
_15	O
N_2	O
]4).	O

In	O
this	O
study,	O
we	O
discovered	O
that	O
a	O
set	O
of	O
altered	O
metabolites	O
including	O
amino	O
acid	O
(isoleucine,	O
valine,	B
phenylalanine,	B
glutamine,	B
and	O
tyrosine),	B
energy	O
metabolism-related	O
molecules	O
(citrate	O
and	O
glucose)	B
and	O
other	O
metabolism	O
molecules	O
(N-acetyl-glycoproteins	O
and	O
TMAO)	O
that	O
would	O
be	O
the	O
potential	O
biomarkers.	O

shows	O
an	O
example	O
TOCSY	O
spectrum	O
of	O
a	O
polar	O
extract	O
of	O
A549	O
cells	O
grown	O
in	O
the	O
presence	O
of	O
[U–_13	B
C]-glucose.	I

There	O
was	O
a	O
significant	O
but	O
weak	O
inverse	O
correlation	O
between	O
cotinine	B
and	O
tryptophan	B
(r:	O
−0.13),	O
XA	O
(r:	O
−0.16),	O
HAA	O
(r:	O
−0.20),	O
riboflavin	B
(r:	O
−0.13)	O
and	O
total	O
vitamin	B
B6	I
levels	O
(r:	O
−0.16)	O
when	O
including	O
all	O
participants.	O

Urinary	O
furoylglycine	B
and	O
tiglylglycine	B
were	O
significantly	O
increased	O
in	O
patients	O
with	O
early-stage	O
PD.	O

A	O
stripped	O
sample	O
that	O
had	O
undergone	O
preparation	O
procedure	O
was	O
injected	O
into	O
the	O
column,	O
and	O
the	O
effect	O
of	O
matrix	O
suppression	O
on	O
the	O
response	O
of	O
the	O
infused	O
oxysterols	B
was	O
monitored.	O

The	O
VIP	O
plot	O
(Figure	O
),	O
sorted	O
by	O
importance,	O
showed	O
the	O
metabolites	O
tryptophan	B
and	O
3-hydroxybutanoic	B
acid	I
as	O
most	O
discriminatory	O
between	O
GDM	O
and	O
control.	O

Analysis	O
was	O
undertaken	O
in	O
all	O
patients,	O
and	O
by	O
treatment	O
arm	O
(paclitaxel	O
plus	O
lapatinib;	B
paclitaxel	O
plus	O
placebo).	O

Previously,	O
it	O
was	O
found	O
that	O
cortisol	B
levels	O
are	O
70%	O
sensitive	O
and	O
85%	O
specific	O
in	O
differentiating	O
acute	O
MI	O
from	O
angina	O
among	O
patients	O
admitted	O
to	O
an	O
intensive	O
care	O
unit.	O

Go	O
to:	O
3-Hydroxypropylmercapturic	B
acid	I
(3-HPMA)	O
and	O
3-hydroxy-1-methylpropylmercapturic	B
acid	I
(HMPMA)	O
are	O
urinary	O
metabolites	O
of	O
the	O
toxicants	O
acrolein	B
and	O
crotonaldehyde,	B
respectively.	O

In	O
the	O
assessment	O
of	O
changes	O
in	O
the	O
urine	O
samples,	O
the	O
decreased	O
trend	O
in	O
citrate,	B
acetone	B
and	O
3-hydroxybutyrate	B
level	O
for	O
the	O
FA	B
group	O
were	O
reported	O
in	O
both	O
studies	O
showed	O
metabolism	O
directed	O
towards	O
energy	O
demand.	O

Glycerophosphocholines	B
Glycerophosphoeserines	I
_*	O
fold	O
change	O
was	O
calculated	O
as	O
TNBC/CN.	O

The	O
major	O
recognized	O
altered	O
metabolic	O
pathways	O
are	O
mainly	O
referred	O
to	O
as	O
oxidative	O
stress	O
and	O
ischemia-induced	O
alterations	O
in	O
energy	O
metabolism,	O
amino	O
acids	O
metabolism,	O
fatty	O
acid	O
oxidation,	O
anaerobic	O
glycolysis,	O
urea	B
cycle	O
and	O
pathways	O
linked	O
to	O
endogenous	O
gasotransmitters.	O

In	O
the	O
stratified	O
analysis,	O
we	O
noted	O
that	O
the	O
positive	O
association	O
between	O
serum	O
TMAO	B
and	O
PLC	O
risk	O
became	O
insignificant	O
among	O
the	O
HBV-infected	O
patients,	O
alcohol	O
drinkers,	O
smokers	O
and	O
participants	O
with	O
Mets,	O
although	O
the	O
P	O
-interaction	O
was	O
only	O
significant	O
between	O
smokers	O
and	O
non-smokers.	O

The	O
most	O
strongly	O
differentiating	O
compounds	O
were	O
D-glucose,	B
creatinine,	B
L-valine,	B
propylene	B
glycol,	I
citric	B
acid,	I
formic	B
acid	I
and	O
L-alanine	B
(data	O
not	O
shown).	O

Choline	B
may	O
enter	O
the	O
homocysteine–methionine	B
cycle	O
through	O
its	O
oxidation	O
to	O
betaine	B
which	O
is	O
used	O
as	O
a	O
substrate	O
in	O
the	O
BHMT	O
reaction	O
that	O
links	O
choline	B
and	O
betaine	B
to	O
the	O
folate-dependent	O
methionine	O
pathway.	O

Gallic	B
acid	I
and	O
caffeic	B
acid	I
have	O
been	O
reported	O
to	O
repress	O
Clostridium	O
and	O
Bacteroides	O
species.	O

In	O
addition,	O
a	O
urinary	O
metabolite	O
biomarker	O
panel	O
consisting	O
of	O
lactate,	B
α-hydroxybutyrate,	B
phenylalanine,	B
for-mate,	O
and	O
arabinitol	B
was	O
identified.	O

Of	O
the	O
45	O
metabolites	O
reporting	O
at	O
least	O
30%	O
of	O
their	O
data	O
missing	O
or	O
BLD,	O
26	O
were	O
carnitines	B
indicating	O
that	O
the	O
typical	O
abundances	O
of	O
many	O
of	O
these	O
metabolites	O
in	O
blood	O
serum	O
or	O
plasma	O
were	O
below	O
the	O
operating	O
limits	O
of	O
the	O
assay.	O

For	O
each	O
AF	B
sample,	O
256	O
following	O
scans	O
were	O
collected	O
using	O
3.5	O
s	O
relaxation	O
delay	O
and	O
an	O
acquisition	O
time	O
of	O
1.36	O
s,	O
resulting	O
in	O
32k	O
data	O
points	O
and	O
a	O
spectral	O
width	O
of	O
20.01	O
ppm.	O

Concentrations	O
of	O
some	O
cytokines	O
and	O
inflammatory	O
markers	O
were	O
below	O
the	O
limit	O
of	O
detection	O
in	O
the	O
following	O
numbers	O
of	O
individuals—CRP:	O
n	O
=	O
52;	O
IL-1α:	B
n	O
=	O
9;	O
IL-1β:	B
n	O
=	O
45;	O
IL-2:	O
n	O
=	O
27;	O
IL-4:	O
n	O
=	O
2;	O
IL-10:	O
n	O
=	O
1;	O
IFNγ:	O
n	O
=	O
11;	O
and	O
TNFα:	O
n	O
=	O
1.	O

The	O
cells	O
were	O
maintained	O
in	O
DMEM	O
supplemented	O
with	O
10%	O
(v/v)	O
FBS,	O
100	O
units/ml	O
penicillin,	B
100	O
µg/ml	O
streptomycin,	B
and	O
0.5	O
µg/ml	O
puromycin.	B

The	O
buffer	O
pH	O
was	O
adjusted	O
to	O
7.00	O
using	O
a	O
calibrated	O
electronic	O
pH	O
meter	O
through	O
the	O
dropwise	O
addition	O
of	O
0.1	O
M	O
potassium	B
hydroxide	I
or	O
0.1	O
M	O
phosphoric	B
acid.	I

Briefly,	O
an	O
aliquot	O
of	O
50	O
μL	O
IS	O
(100	O
ng·mL_−1	O
)	O
and	O
250	O
μL	O
plasma	O
or	O
urine	O
sample	O
was	O
transferred	O
to	O
an	O
Eppendorf	O
microtube,	O
vortex-mixed	O
with	O
50	O
μL	O
methanol–water	O
(20:80,	O
v/v	O
)	O
for	O
30	O
s,	O
followed	O
by	O
protein	O
precipitation	O
by	O
adding	O
250	O
μL	O
methanol	B
(containing	O
0.1	O
%	O
acetic	O
acid),	O
mixing	O
for	O
5	O
min	O
and	O
centrifuging	O
for	O
3	O
min	O
at	O
15,000×	O
g	O
and	O
4	O
°C.	O

In	O
the	O
end,	O
we	O
selected	O
Waters	O
HLB	O
column	O
to	O
perform	O
sample	O
cleanup	O
and	O
oxylipins	B
were	O
eluted	O
with	O
1200	O
μl	O
MeOH	B
following	O
dryness	O
at	O
room	O
temperature.	O

Anti-hypertensive	O
medication,	O
particularly	O
angiotensin-converting	O
enzyme	O
inhibitors,	O
angiotensin	B
II	I
receptor	O
antagonists	O
and	O
diuretics,	O
alone	O
or	O
in	O
combination)	O
were	O
used	O
by	O
27	O
T2DM	O
subjects.	O

It	O
is	O
intriguing	O
that	O
whereas	O
Rtx	O
dramatically	O
reduced	O
TMAO	B
to	O
control	O
levels,	O
choline	B
and	O
betaine	B
levels	O
increased	O
even	O
further.	O

Interestingly,	O
the	O
source	O
of	O
citrulline	B
in	O
human	O
enterocytes	O
remains	O
uncertain,	O
although	O
studies	O
with	O
stable	O
isotopes	O
seem	O
to	O
point	O
at	O
glutamine	B
as	O
its	O
precursor	O
(reviewed	O
in).	O

Nevertheless,	O
we	O
did	O
not	O
detect	O
statistically	O
significant	O
association	O
between	O
serum	O
enterolactone	B
levels	O
and	O
the	O
BMI	O
of	O
CRC	O
patients.	O

In	O
pooled	O
samples	O
from	O
patients	O
with	O
sepsis	O
we	O
found	O
that	O
MeOH	B
ppt	O
+UF	O
offered	O
similar	O
recovery	O
and	O
variance	O
to	O
MeOH:	B

The	O
β-lactam	B
antibiotics,	O
such	O
as	O
amoxicillin	O
(AX),	O
are	O
among	O
the	O
most	O
widely	O
prescribed	O
drugs	O
and	O
frequently	O
elicit	O
allergic	O
reactions._,	O
The	O
covalent	O
adduction	O
of	O
AX,	O
other	O
antibiotics,	O
and	O
drugs	O
to	O
proteins	O
is	O
considered	O
a	O
key	O
process	O
for	O
the	O
allergic	O
response._,	O

patients	O
who	O
were	O
treated	O
by	O
depakine	B
(Sanofi	O
(Hangzhou)	O
Pharmaceutical	O
Co,	O
Ltd.,	O
Hangzhou,	O
China)	O
for	O
2 weeks.	O

Among	O
the	O
32	O
discriminant	O
lipids,	O
9	O
lipids	O
were	O
significantly	O
decreased	O
in	O
NASH,	O
mainly	O
ceramides	B
and	O
phospholipids.	B

Specially,	O
the	O
levels	O
of	O
serine	B
and	O
threonine	B
were	O
obviously	O
reduced	O
in	O
ovulatory	O
PCOS	O
subtype,	O
which	O
might	O
be	O
due	O
to	O
the	O
significantly	O
negative	O
correlations	O
of	O
serine	B
and	O
threonine	B
to	O
obesity	O
and	O
insulin	O
resistance	O
(Additional	O
files	O
and	O
).	O

Indeed,	O
we	O
observed	O
in	O
heavy	O
cannabis	B
users	O
lower	O
frequencies	O
of	O
IL-23_+	O
and	O
TNF-α_+	O
APCs.	O

S3	O
and	O
S4,	O
while	O
the	O
variation	O
in	O
retention	O
time	O
(as	O
measured	O
by%	O
RSD)	O
was	O
generally	O
quite	O
small,	O
at	O
<2%	O
in	O
all	O
conditions,	O
the	O
area	O
of	O
the	O
caffeine	B
peak	O
varied	O
significantly	O
both	O
across	O
modifiers	O
and	O
column	O
types.	O

The	O
relatively	O
low	O
concentration	O
of	O
lactate	B
and	O
creatine	B
indicated	O
an	O
increased	O
energy	O
metabolism	O
and	O
the	O
concomitant	O
decrease	O
in	O
the	O
concentration	O
of	O
amino	O
acids	O
may	O
not	O
imply	O
an	O
increased	O
rate	O
of	O
protein	O
biosynthesis,	O
but	O
an	O
increased	O
energy	O
consumption	O
at	O
the	O
expense	O
of	O
the	O
amino	O
acids.	O

Although	O
the	O
mechanisms	O
underlying	O
the	O
observed	O
sex	O
differences	O
remain	O
unclear,	O
our	O
results	O
suggest	O
that	O
12-LOX	O
is	O
more	O
active	O
in	O
women,	O
accounting	O
for	O
the	O
sex	O
difference	O
in	O
oxylipin	B
levels.	O

Nine	O
metabolites	O
identified	O
in	O
this	O
study,	O
prostaglandin	B
C1,	O
ricinoleic	B
acid,	I
oleic	B
acid	I
amide,	I
ethyl	O
docosahexaenoic,	O
hulupapeptide,	O
lysophosphatidylethanolamine	B
0:0/22:4,	I
cysteinyl-lysine,	B
methacholine,	B
and	O
vitamin	B
K2	I
made	O
up	O
to	O
the	O
prediction	O
model	O
NCT	O
outcome.	O

Conversely,	O
the	O
decreased	O
plasma	O
acetylcarnitine	B
observed	O
in	O
28-day	O
survivors	O
compared	O
to	O
non-survivors	O
would	O
indicate	O
a	O
general	O
more	O
efficient	O
use	O
of	O
substrates	O
for	O
energy	O
production	O
and	O
for	O
a	O
mitochondrial	O
damage	O
probably	O
reversible	O
in	O
survivors.	O

The	O
HCV	O
core	O
protein	O
is	O
also	O
known	O
to	O
activate	O
the	O
liver	O
X	O
receptor	O
alpha	O
(LXRα)	O
protein	O
which	O
activates	O
inflammatory	O
genes	O
resulting	O
in	O
lipogenesis.	O

Our	O
results	O
demonstrated	O
that	O
the	O
concentrations	O
of	O
circulating	O
leucine	B
and	O
isoleucine	B
were	O
higher	O
in	O
lung	O
cancer	O
patients	O
than	O
healthy	O
controls.	O

Each	O
1	O
ng/ml	O
decrement	O
in	O
24,25(OH)_2	B
D	O
was	O
associated	O
with	O
a	O
7%	O
higher	O
risk	O
of	O
microalbuminuria,	O
which	O
was	O
not	O
statistically	O
significant	O
(95%	O
confidence	O
interval,	O
1%	O
decreased	O
risk	O
to	O
16%	O
increased	O
risk;	O
P	O
=	O
0.09).	O

Statistical	O
differences	O
were	O
determined	O
using	O
Tukey’s	O
multiple	O
comparisons	O
where	O
significant	O
interactions	O
were	O
observed	O
BMI	O
body	O
mass	O
index,	O
TG	B
triglycerides,	I
LDL	O
low-density	O
lipoprotein,	O

At	O
the	O
start	O
of	O
the	O
day,	O
capillaries	O
were	O
flushed	O
with	O
deionized	O
water	O
for	O
15 min	O
at	O
930 mbar	O
and	O
with	O
0.1 M	O
sodium	B
hydroxide	I
for	O
15 min	O
at	O
930 mbar	O
and	O
then	O
with	O
deionized	O
water	O
for	O
15 min	O
at	O
930 mbar.	O

Tip	O
size	O
of	O
the	O
PicoChip_TM	O
nano	O
emitter	O
was	O
15	O
μm	O
and	O
NSI	O
source	O
parameters	O
were	O
as	O
follows:	O
source	O
voltage	O
1.9	O
kV,	B
source	O
current	O
100	O
μA,	O
sheath	O
gas	O
0,	O
aux	O
gas	O
0	O
and	O
capillary	O
temperature	O
275°C.	O

Some	O
of	O
the	O
increased	O
amino	O
acids	O
were	O
also	O
reported	O
to	O
be	O
increased	O
in	O
fecal	O
extracts	O
and	O
extracts	O
of	O
colon	O
mucosa	O
with	O
the	O
exception	O
of	O
isoleucine,	B
which	O
has	O
apparently	O
low	O
concentrations	O
in	O
colonic	O
mucosa	O
of	O
active	O
CD	O
and	O
UC.	O

For	O
instance,	O
N-AcPUT,	O
ORN,	O
N1,N12-DiAcSPM,	B
N1-AcSPD,	O
and	O
N8-AcSPD	O
have	O
comparable	O
signal	O
enhancement.	O

the	O
internal	O
standard	O
deuterated5-tamoxifen	B
(D_5	O
tam)	O
and	O
tamoxifen-N	B
-oxide	I
(TamNox)	O
from	O
Beta	O
Chem	O
Inc.	O

Consistent	O
with	O
this	O
observation,	O
we	O
observed	O
significant	O
upregulation	O
of	O
several	O
purine	B
and	O
pyrimidine	B
metabolites	O
in	O
HCC	O
vs.	O
DC,	O
including	O
a	O
near	O
two-fold	O
elevation	O
of	O
adenine	B
and	O
less	O
marked	O
but	O
still	O
significant	O
upregulation	O
of	O
uridine	B
and	O
xanthine	B
in	O
HCC	O
vs.	O
DC.	O

Samples	O
were	O
transferred	O
into	O
evacuated	O
tubes	O
that	O
contained	O
anticoagulant	O
sodium	B
dihydrogen	I
phosphate	I
(EDTA-K3),	O
centrifuged	O
at	O
2000g	O
for	O
10	O
minutes	O
at	O
4°C.	O

In	O
general,	O
excess	O
carbohydrate	O
is	O
converted	O
to	O
fatty	O
acids,	O
initially	O
palmitic	B
acid,	I
mostly	O
in	O
the	O
liver.	O

(E)	O
The	O
comparison	O
of	O
the	O
ratio	O
of	O
S1P	O
to	O
ceramide	B
in	O
breast	O
cancer	O
tissue	O
between	O
patients	O
with	O
high	O
Ki-67	O
index	O
and	O
patients	O
with	O
low	O
Ki-67	O
index.	O

There	O
was	O
no	O
consistent	O
pattern	O
to	O
the	O
direction	O
of	O
change	O
with	O
some	O
showing	O
markedly	O
reduced	O
levels	O
(e.g.	O
PC	B
ae	I
C38:1;	I
PC	B
aa	I
C34:1;	I
PC	O
aa	O
C30:0;	B
PC	O
aa	O
C28:1;	B
PC	O
aa	O
C40:4)	B
and	O
some	O
showing	O
elevated	O
levels	O
(e.g.	O
PC	B
aa	I
C36:5;	I
lysoPC	O
a	O
C17:0;	B
PC	B
ae	I
C30:2)	I
in	O
the	O
HD	O
sheep.	O

FAA,	O
fatty	O
acid	B
amide;	I
POEA,	B
palmitoleoyl	B
ethanolamide;	I
LPC,	O
lysophosphatidylcholine;	B
PC,	O
phosphatidylcholine;	B
PE,	O
phosphatidylethanolamine;	B
SM,	O
sphingomyelin;	B
Cer,	B
ceramide;	B
CE,	O
cholesterol	B
ester;	I
CoQ10,	O
coenzyme	B
Q10;	I
DGLA,	O
dihomo-γ-linoleic	B
acid;	I
AA,	O
arachidonic	B
acid;	I
8,9-DHET,	B
8,9-dihydroxy-5Z	B
,11Z	I
,14Z	I
-eicosatrienoic	I
acid;	I
EPA,	O
eicosapentaenoic	B
acid	I
(20:5;5Z	O
,8Z	O
,11Z	O
,14Z	O
,17Z	O
);	O
12-HEPE,	B
12-hydroxy-5Z	B
,8Z	I
,10E,14Z	I
,17Z	I
-eicosapentaenoic	I
acid;	I
12-LOX,	O
12-lipoxygenase;	O
PGE2,	O
prostaglandin	B
E2;	I
PGF2α,	B
prostaglandin	B
F2α;	I
PGF1α,	B
prostaglandin	B
1α;	I
TxB2,	O
thromboxane	B
B2;	I
TxA2,	O
thromboxane	B
A2;	I
mPGES-1,	O
microsomal	O
prostaglandin	B
E	I
synthase-1;	O
2OG,	O
2-oxoglutarate;	B
2HG,	O
(R	B
)-2-hydroxyglutarate;	I
DIC,	O
disseminated	O
intravascular	O
coagulation;	O
PGH2,	O
prostaglandin	B
H2	O

The	O
reaction	O
was	O
initiated	O
by	O
the	O
addition	O
of	O
the	O
substrate,	O
arachidonic	B
acid,	I
to	O
all	O
wells.	O

Increased	O
levels	O
of	O
4-methylcatechol	B
sulfate	I
in	O
post-BRB	O
urine	O
and	O
plasma	O
were	O
correlated	O
with	O
a	O
higher	O
level	O
of	O
apoptotic	O
marker	O
(TUNEL)	O
in	O
post-BRB	O
tumors.	O

It	O
is	O
considered	O
that	O
one	O
of	O
the	O
possible	O
reasons	O
for	O
this	O
beneficial	O
effect	O
of	O
empagliflozin	B
is	O
due	O
to	O
a	O
function	O
of	O
3-hydroxybutyric	B
acid	I
as	O
alternative	O
fuel	O
for	O
the	O
energy	O
metabolism	O
of	O
cells.	O

show	O
the	O
zoom-in	O
spectra	O
obtained	O
from	O
positive	O
and	O
negative	O
ionization	O
modes,	O
respectively,	O
in	O
the	O
m/z	O
range	O
of	O
700–910,	O
which	O
cover	O
the	O
intact	O
masses	O
of	O
almost	O
all	O
of	O
phospholipids	B
(PLs)	O
and	O
the	O
SM	O
class	O
of	O
SPs.	O

Since	O
clustering	O
is	O
favored	O
by	O
large	O
differences	O
in	O
the	O
geometrical	O
characteristics	O
in	O
the	O
head	O
group	O
of	O
the	O
complex	O
lipids,	O
GGs	O
that	O
have	O
a	O
much	O
more	O
hydrophilic	B
and	O
larger	O
head	O
group	O
than	O
the	O
neighboring	O
phospholipids	B
are	O
thought	O
to	O
be	O
especially	O
efficient	O
in	O
that	O
matter.	O

Labeling	O
of	O
ceramide	B
by	O
serine	B
from	O
PS	O
provides	O
evidence	O
for	O
a	O
new	O
metabolic	O
relationship	O
between	O
GPs	O
and	O
SPs.	O

Apart	O
from	O
the	O
correlations	O
with	O
clinical	O
chemistry	O
parameters,	O
the	O
above-mentioned	O
sphingomyelins	B
(except	O
SM	O
OH	B
C22:1)	I
were	O
negatively	O
correlated	O
with	O
BCAA-derived	O
AC	O
and	O
PCs	O
containing	O
36	O
carbons,	O
but	O
were	O
positively	O
correlated	O
with	O
the	O
PCs	O
containing	O
32	O
carbons.	O

Berger	O
and	O
Wilson	O
showed	O
that	O
baseline	O
resolution	O
of	O
drug	O
mixtures	O
(including	O
a	O
series	O
of	O
anti-depressants,	O
anti-psychotics	O
and	O
stimulants)	O
could	O
be	O
obtained	O
by	O
adding	O
0.5%	O
v/v	O
isopropylamine	B
to	O
a	O
methanol-based	O
SFC	O
mobile	O
phase	O
,	O
,	O
,	O
while	O
De	O
Klerck	O
et	O
al.	O
have	O
used	O
isopropylamine	B
in	O
conjunction	O
with	O
TFA	O
to	O
increase	O
enantioresolution	O
in	O
chiral	O
SFC	O
.	O

The	O
method	O
was	O
successfully	O
applied	O
to	O
determine	O
basal	O
concentrations	O
of	O
the	O
targeted	O
oxylipins	B
in	O
human	O
plasma	O
and	O
serum.	O

Virus	O
stocks	O
were	O
produced	O
in	O
fibroblasts	O
by	O
pooling	O
cell-free	O
and	O
cell-associated	O
virus,	O
concentrated	O
by	O
centrifugation	O
through	O
sorbitol	B
cushions,	O
resuspended	O
in	O
serum-free	O
medium,	O
and	O
titered	O
by	O
tissue	O
culture	O
infective	O
dose	O
(TCID_50	O
)	O
or	O
fluorescent	O
focus	O
assay.	O

All	O
the	O
QC	O
samples	O
were	O
prepared	O
in	O
human	O
plasma,	O
and	O
the	O
endogenous	O
levels	O
of	O
Cer(22:0)	B
and	O
Cer(24:0)	B
were	O
determined	O
by	O
mean	O
of	O
multiple	O
replicates	O
(n=12).	O

We	O
quantified	O
plasma	O
and	O
urinary	O
levels	O
of	O
TMAO	B
and	O
plasma	O
choline	B
and	O
betaine	B
levels	O
by	O
means	O
of	O
liquid	O
chromatography	O
and	O
online	O
tandem	O
mass	O
spectrometry	O
after	O
a	O
phosphatidylcholine	B
challenge	O
(ingestion	O
of	O
two	O
hard-boiled	O
eggs	O
and	O
deuterium	O
[d9]-labeled	O
phosphatidylcholine)	B
in	O
healthy	O
participants	O
before	O
and	O
after	O
the	O
suppression	O
of	O
intestinal	O
microbiota	O
with	O
oral	O
broad-spectrum	O
antibiotics.	O

The	O
effects	O
of	O
omega-3	B
fatty	O
acids	O
on	O
glucose	B
metabolism	O
in	O
insulin-sensitive	O
tissues	O
depend	O
on	O
energy	O
fuels.	O

A	O
likely	O
precursor	O
to	O
metabolite	O
9	O
is	O
N	B
-acetyl-S	I
-[1-(5-amino-5-carboxypentyl)-1H	I
-pyrrol-3-yl]-L-cysteine	I
sulfoxide	I
(12,	O
).	O

NMR	O
spectroscopy,	O
urine,	O
solvents,	O
methanol,	B
DMSO	B

Luminal	O
BCa	O
cell	O
lines	O
showed	O
elevated	O
levels	O
of	O
amino	O
acids,	O
like	O
phenylalanine,	B
tryptophan,	B
and	O
tyrosine,	B
and	O
branched	O
chain	O
amino	O
acids	O
like	O
leucine,	B
lysine,	B
and	O
valine,	B
as	O
well	O
as	O
higher	O
levels	O
of	O
lauric	B
acid	I
and	O
oleic	B
acid.	I

Within	O
this	O
study,	O
aspartate	B
and	O
serine	B
were	O
significantly	O
elevated	O
in	O
depressed	O
subjects	O
when	O
compared	O
with	O
controls.	O

In	O
our	O
results,	O
the	O
identified	O
six-metabolite	O
combination	O
showed	O
high	O
correlation	O
with	O
T2DM	O
and	O
diabetic	O
microangiopathy	O
both	O
in	O
CSF	O
and	O
plasma	O
samples,	O
and	O
is	O
mainly	O
composed	O
of	O
BCAAs	O
(leucine,	O
valine),	B
AAAs	O
(tyrosine),	O
glucogenic	O
amino	O
acids	O
(alanine,	O
histidine),	B
and	O
intermediates	O
of	O
glycolysis	O
(pyruvate).	O

The	O
thiolation	O
and	O
β-oxidation	O
reactions	O
are	O
carried	O
out	O
by	O
bile	O
acyl-CoA	B
synthetase	O
(liver-specific)	O
or	O
very	O
long	O
chain	O
acyl-CoA	B
synthetase	O
and	O
sterol	O
carrier	O
protein	O
x	O
,	O
respectively,	O
the	O
latter	O
two	O
of	O
which	O
are	O
expressed	O
in	O
rodent	O
brain	O
(Swiss-Prot	O
O35488,	O
P11915)._7	O
We	O
thus	O
searched	O
for	O
the	O
presence	O
of	O
C_24	O
precursors	O
of	O
primary	O
bile	O
acids	O
in	O
CSF.	O

no.	O
110611),	O
diacylglycerol	B
(18:1/2:0/0:0)	I
(cat.	O

However,	O
also	O
ε2	O
carriers	O
indicated	O
lower	O
cholesterol	B
levels	O
of	O
extremely	O
large	O
and	O
small	O
HDL-particles,	O
as	O
well	O
as	O
of	O
HDL3	O
subfractions.	O

K_2	O
HPO_4	O
>	O
98%,	O
KH_2	O
PO_4	O
>	O
98%,	O
D_2	O
O	O
99.9%,	O
and	O
DSS-d_6	O
(2,2-dimethyl-2-silapentane-5	O
sulfonate)	I
98%	O
were	O
purchased	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
MO,	O
USA).	O

In	O
the	O
present	O
study,	O
oxylipins	B
generated	O
from	O
ω-3	O
fatty	O
acids	O
had	O
notably	O
higher	O
levels	O
in	O
female	O
urine,	O
which	O
may	O
be	O
explained	O
by	O
the	O
previous	O
finding	O
that	O
the	O
ω-3	O
conversion	O
efficiency	O
from	O
linolenic	B
acid	I
(ALA)	O
to	O
longer-chain	O
PUFAs	O
is	O
greater	O
in	O
women	O
than	O
in	O
men.	O

Creatinine	B
analysis	O
was	O
performed	O
by	O
the	O
clinical	O
laboratory	O
SK-Lab	O
(Lucenec,	O
Slovakia)	O
using	O
an	O
enzymatic	O
procedure	O
with	O
the	O
use	O
of	O
the	O
Dimension	O
Vista_®	O
1500	O
system	O
(Siemens	O
Healthcare,	O
Erlangen,	O
Germany).	O

Branched-chain	O
amino	O
acids,	O
BCAA,	O
include	O
valine,	B
leucine	B
and	O
isoleucine.	B

In	O
this	O
sense,	O
other	O
groups	O
have	O
described	O
the	O
deficiency	O
of	O
ADSL	O
and	O
ATIC	O
as	O
affecting	O
the	O
formation	O
and	O
assembly	O
of	O
purinosome,	O
and	O
there	O
is	O
evidence	O
that	O
both	O
enzymes	O
are	O
key	O
in	O
the	O
regulation	O
of	O
the	O
synthesis	O
pathway	O
of	O
purines	B
during	O
tumor	O
development	O
(Baresova	O
et al	O
.,	O
2012;	O
Jurecka	O
et al	O
.,	O
2015).	O

In	O
addition	O
to	O
CYP2D6,	O
methadone	B
is	O
also	O
metabolized	O
by	O
CYP3A4	O
and	O
CYP2B6	O
enzymes.	O

Initiation	O
of	O
cancer	O
by	O
estrogens	O
is	O
based	O
on	O
estrogen	B
metabolism	O
in	O
which	O
the	O
homeostatic	O
balance	O
between	O
activating	O
and	O
deactivating	O
pathways	O
is	O
disrupted.	O

In	O
our	O
study,	O
endogenous	O
lactate	B
(δ	O
1.33	O
ppm)	O
in	O
serum	O
samples	O
was	O
used	O
as	O
an	O
internal	O
standard	O
reference,	O
and	O
the	O
relative	O
concentrations	O
of	O
the	O
metabolites	O
were	O
calculated	O
and	O
statistically	O
discriminated	O
by	O
integrating	O
their	O
signals	O
in	O
the	O
NMR	O
spectra.	O

Branched	O
chain	O
amino	O
acids,	O
particularly	O
Leu,	O
play	O
an	O
important	O
role	O
as	O
amino	B
group	O
donors	O
in	O
glutamic	B
acid	I
synthesis	O
in	O
the	O
brain.	O

Specifically	O
the	O
BCAA	O
factor	O
from	O
our	O
previous	O
study	O
(composed	O
of	O
phenylalanine,	B
tyrosine,	B
leucine/isoleucine,	O
methionine,	B
valine,	B
C5	O
acylcarnitine,	B
and	O
alanine),	B
grouped	O
into	O
three	O
different	O
factors	O
in	O
the	O
PCA	O
analysis	O
for	O
the	O
current	O
study,	O
namely	O
factor	O
6	O
(valine,	O
leucine/isoleucine,	O
methionine,	B
phenylalanine,	B
and	O
tyrosine),	B
factor	O
10	O
(valine,	O
leucine/isoleucine,	O
and	O
glutamate/glutamine),	O
and	O
factor	O
7	O
(C3	O
and	O
C5	O
acylcarnitines,	B
byproducts	O
of	O
mitochondrial	O
BCAA	O
catabolism).	O

PC	B
ae	I
40:3	I
was	O
detected	O
as	O
the	O
most	O
statistically	O
significant	O
decreased	O
lipid	O
among	O
all	O
the	O
phosphatidylcholines	B
(p	O
-value	O
of	O
2.79	O
×	O
10_−10	O
).	O

In	O
particular,	O
we	O
found	O
higher	O
fasting	O
α	B
-hydroxybutyrate	I
concentrations	O
and	O
higher	O
α	B
-hydroxybutyrate	I

However,	O
several	O
reports	O
have	O
indicated	O
that	O
BAIB	O
has	O
important	O
effects	O
on	O
energy	O
metabolism	O
including	O
pyrimidine	B
metabolism,	O
beta	O
oxidation,	O
and	O
glucose	B
homeostasis.	O

Briefly,	O
to	O
50	O
μl	O
serum	O
5	O
μl	O
of	O
internal	O
standard	O
(300	O
ppm	O
heptadecanoic	O
acid)	O
and	O
150	O
μl	O
methanol	B
chromasolv	O
grade	O
(Sigma)	O
were	O
added	O
and	O
tubes	O
were	O
vortexed	O
for	O
30	O
s.	O
Then,	O
750	O
μl	O
MTBE	B
chromasolv	O
grade	O
(Sigma)	O
were	O
added,	O
vortexed	O
and	O
an	O
incubation	O
for	O
30	O
minutes	O
in	O
a	O
ultrasound	O
(US)-assisted	O
water	O
bath	O
at	O
15°C	O
was	O
performed.	O

Phase	O
and	O
base-line	O
corrections	O
of	O
spectra	O
were	O
performed	O
by	O
operator	O
and	O
referenced	O
with	O
AMIX	O
software	O
to	O
methyl	O
resonance	O
of	O
TMPS,	O
lactate	B
or	O
TCB	O
for	O
diluted	O
plasma,	O
aqueous	O
fraction,	O
and	O
organic	O
fraction,	O
respectively.	O
_1	O
H	O
NMR	O
spectra	O
were	O
processed	O
using	O
the	O
TOPSPIN	O
(version	O
2.1,	O
Bruker	O
BioSpin	O
SA)	O
and	O
AMIX	O
(Bruker	O
Analytik)	O
software	O
packages.	O

Additionally,	O
some	O
abundant	O
non-sugar	O
compounds	O
always	O
present	O
in	O
urine,	O
such	O
as	O
creatinine,	B
were	O
also	O
captured.	O

The	O
mobile	O
phase	O
is	O
composed	O
of	O
(A)	O
0.1%	O
formic	B
acid	I
and	O
(B)	O
isopropanol,	B
acetonitrile	B
and	O
methanol	B
[20:40:40	I
(v/v)]	I
in	O
0.1%	O
formic	B
acid,	I
and	O
the	O
gradient	O
was	O
used	O
as	O
follows:	O
98–50%	O
(A)	O
and	O
2–50%	O
(B)	O
for	O
0–3.5	O
min;	O
50–0%	O
(A)	O
and	O
50–100%	O
(B)	O
for	O
3.5–20	O
min.	O

Therefore,	O
we	O
conclude	O
that	O
not	O
only	O
linear	O
but	O
more	O
complex	O
relations	O
may	O
exist	O
between	O
metabolites	O
and	O
the	O
fasting	O
glucose	B
development.	O

The	O
fatty	O
acid	O
composition	O
of	O
(A)	O
free	O
fatty	O
acids	O
and	O
(B)	O
lysophosphatidylcholine	B
(LPC)	O
are	O
displayed.	O

These	O
two	O
metabolites	O
demonstrated	O
levels	O
that	O
were	O
either	O
significantly	O
higher	O
(hexanoylcarnitine)	O
or	O
uniquely	O
present	O
(2-HG)	O
in	O
HNSCC	O
samples.	O

It	O
remains	O
intriguing	O
that	O
the	O
only	O
amino	O
acid	O
and	O
biogenic	O
amines	O
shown	O
here	O
to	O
increase	O
during	O
acute	O
sleep	O
deprivation	O
(serotonin,	O
tryptophan,	B
taurine)	B
have	O
been	O
implicated	O
in	O
the	O
etiology	O
of	O
depression	O
(,	O
,	O
,	O
,	O
).	O

Consistent	O
with	O
this,	O
serum	O
amyloid	O
P	O
components	O
have	O
been	O
shown	O
to	O
be	O
depleted	O
when	O
a	O
novel	O
palindromic	O
bis-D-proline	B
drug	O
was	O
prescribed.	O

We	O
also	O
found	O
the	O
concentration	O
of	O
erythritol	B
was	O
higher	O
in	O
the	O
group	O
with	O
higher	O
glycemia	O
compared	O
with	O
the	O
group	O
with	O
lower	O
glycemia	O
at	O
study	O
baseline.	O

Combined	O
mineralocorticoid	O
and	O
glucocorticoid	B
precursor	O
excess	O
was	O
found	O
in	O
4%	O
of	O
ACA	O
and	O
2%	O
of	O
ACC.	O

For	O
example,	O
the	O
pre-adjusted	O
association	O
estimate	O
of	O
higher	O
total	O
activity	O
with	O
lower	O
triglycerides	B
in	O
VLDL	O
particles	O
at	O
age	O
15y	O
(−0.03	O
mmol/l	O
or	O
−0.12	O
SD	O
units;	O
95%	O
CI	O
=	O
−0.18,	O
−0.06;	O
P	O
=	O
1.06	O
×	O
10_−4	O
)	O
was	O
essentially	O
unchanged	O
after	O
adjusting	O
for	O
triglycerides	B
in	O
VLDL	O
particles	O
at	O
age	O
8y	O
(−0.11	O
SD	O
units;	O
95%	O
CI	O
=	O
−0.17,	O
−0.04;	O
P	O
=	O
1.36	O
×	O
10_−3	O
).	O

The	O
upper	O
fraction	O
was	O
dried	O
down	O
at	O
30 °C	O
for	O
4 hours	O
using	O
a	O
vacuum	O
centrifuge	O
(Eppendorf	O
Concentrator	O
5301)	O
and	O
then	O
re-suspended	O
in	O
600 µl	O
of	O
the	O
following	O
NMR	O
buffer:	O
double	O
distilled	O
H_2	O
O	O
containing	O
5%	O
D_2	O
O	O
for	O
NMR	O
(Acros	O
organics,	O
CAS:	O
7789-20-0)	O
and	O
1 mM	O
3-trimethylsilyl-1-propanesulfonic	B
acid	I
sodium	I
salt	O
(DSS)	O

The	O
multiple	O
moderate	O
associations	O
between	O
indole-3	O
acetic	B
acid	I
and	O
psychological	O
measures	O
were	O
a	O
novel	O
finding.	O

However,	O
this	O
was	O
not	O
the	O
case	O
for	O
SP	B
or	O
SP	B
and	O
AL	O
taken	O
together.	O

DI	O
water	O
and	O
methanol	B
were	O
selected	O
for	O
extraction	O
evaluation.	O

The	O
developed	O
CE-MS/MS	O
method	O
was	O
successfully	O
used	O
to	O
control	O
patient	O
compliance	O
with	O
thiopurine	B
medication	O
and	O
relevant	O
co-medication.	O

GC-MS	O
samples	O
were	O
derivatized	O
using	O
bis(trimethylsilyl)	B
trifluoroacetiamide	I
under	O
nitrogen	B
gas.	I

In	O
our	O
initial	O
7-day	O
cross-over	O
study,	O
the	O
conversion	O
of	O
the	O
GR	O
following	O
hydrolysis,	O
absorption	O
and	O
conjugation	O
with	O
glutathione	B
varied	O
from	O
2%	O
to	O
50%	O
amongst	O
study	O
participants.	O

Pathway	O
enrichment	O
analysis	O
using	O
the	O
Mummichog	O
algorithm	O
showed	O
significant	O
enrichment	O
(p	O
<	O
0.05)	O
of	O
several	O
pathways	O
in	O
the	O
RCC	O
group	O
compared	O
with	O
those	O
in	O
healthy	O
controls,	O
including	O
galactose	B
metabolism,	O
linoleate	B
metabolism,	O
leukotriene	O
metabolism,	O
tryptophan	B
metabolism,	O
etc.	O
(;	O
).	O

Some	O
metabolites	O
found	O
by	O
_1	O
H	O
NMR	O
spectroscopy	O
have	O
signals	O
in	O
heavily	O
overlapping	O
spectral	O
regions	O
containing	O
resonances	O
from	O
compounds	O
such	O
as	O
ethanolamine,	B
3-methylhistidine,	B
and	O
lysine,	B
which	O
were	O
also	O
measured	O
independently	O
by	O
IEC.	O

The	O
drug	O
standards,	O
namely,	O
prednisone,	B
6-thioguanine,	B
6-mercaptopurine	B
monohydrate,	O
allopurinol,	B
azathioprine,	B
mesalazine,	B
and	O
6-methylmercaptopurine	B
were	O
purchased	O
from	O
Sigma-Aldrich	O
(Sigma-Aldrich,	O
Steinheim,	O
Germany).	O

Taurine	B
is	O
an	O
osmoprotectant	O
and	O
its	O
increased	O
level	O
was	O
observed	O
in	O
the	O
present	O
study	O
and	O
also	O
reported	O
from	O
studies	O
on	O
other	O
tumors.	O

No	O
significant	O
changes	O
were	O
observed	O
for	O
most	O
classes	O
of	O
glycerophospholipids	B
except	O
for	O
PG,	B
with	O
the	O
total	O
PG	B
level	O
being	O
significantly	O
higher	O
in	O
diabetic	O
monkeys	O
compared	O
to	O
normal	O
monkeys	O
under	O
fasting	O
condition.	O

The	O
best	O
MS/MS	O
transition	O
(Table	O
)	O
for	O
spironolactone	B
and	O
canrenone	B
found	O
(as	O
already	O
reported	O
by	O
others	O
[,	O
])	O
was	O
m/z	O
341	O

In	O
addition	O
to	O
the	O
above	O
metabolites,	O
the	O
WB	O
showed	O
the	O
presence	O
of	O
peaks	O
arising	O
from	O
aspartate,	B
glutathione	B
(GSSG,	O
oxidized	O
form)	O
and	O
cofactors	O
involved	O
in	O
the	O
cellular	O
redox	O
reactions	O
–	O
ATP,	B
ADP,	B
AMP,	B
NAD_+	O
,	O
and	O
NADP_+	O
.	O

As	O
revealed	O
by	O
CART	O
analysis,	O
the	O
final	O
regression	O
tree	O
for	O
plasma	O
water	O
T_2	O
included	O
three	O
biomarkers:	O
hepatocyte	O
growth	O
factor	O
receptor,	O
receptor	O
tyrosine	B
kinase	O
FLT3	O
(fms-like	O
tyrosine	B
kinase	O
3),	O
and	O
bone	O
sialoprotein	O
2	O
(Fig. ).	O

In	O
those	O
subjects	O
where	O
venous	O
glucose	B
levels	O
were	O
not	O
obtained,	O
capillary	O
glucose	B
measurements	O
were	O
used	O
to	O
calculate	O
corresponding	O
venous	O
values	O
as	O
described.	O

Negative	O
associations	O
are	O
revealed	O
between	O
eGFR	O
and	O
serum	O
cystatin	B
C	O
values	O
(CysC	O
)	O
(edge	O
weight = −0.76),	O
and	O
the	O
NMR	O
bucket	O
at	O
3.045 ppm	O
(edge	O
weight = −0.37),	O
corresponding	O
to	O
creatinine,	B
respectively.	O

For	O
hippurate	B
and	O
lactate	B
in	O
MeOD	O
and	O
DMSO	B
matrices	O
instead,	O
the	O
signal	O
positions	O
are	O
always	O
shifted	O
to	O
higher	O
ppm	O
values	O
for	O
all	O
added	O
solutions.	O

In	O
addition,	O
MRS	O
allows	O
for	O
assessment	O
of	O
the	O
metabolomic	O
profile	O
of	O
the	O
CNS,	O
having	O
found	O
significant	O
differences	O
in	O
metabolite	O
concentration	O
(e.g.,	O
glutamate,	B
N	B
-acetylaspartate,	I
γ-aminobutyric	B
acid,	I
and	O
aspartate)	O
between	O
patients	O
with	O
MS	O
and	O
controls.	O

A	O
broad	O
spectrum	O
of	O
metabolic	O
and	O
biochemical	O
changes	O
in	O
PCOS	O
subgroups	O
compared	O
with	O
the	O
control	O
group	O
were	O
indicated,	O
including	O
the	O
obviously	O
enhanced	O
triglyceride	B
and	O
low-density	O
lipoprotein	O
(LDL)	O
level	O
and	O
reduced	O
HDL	O
level,	O
a	O
marked	O
augment	O
in	O
serum	O
concentrations	O
of	O
androgens	O
such	O
as	O
androstenedione,	B
increased	O
ratio	O
of	O
luteinizing	O
hormone	O
(LH)	O
to	O
follicle-stimulating	O
hormone	O
(FSH).	O

The	O
oxidation	O
of	O
guanine	B
in	O
DNA	O
is	O
premutagenic,	O
leading	O
to	O
a	O
G:C	O
→	O
T:A	O
transversion	O
mutation	O
if	O
not	O
repaired,	O
because	O
an	O
oxidized	O
guanine	B
preferentially	O
pairs	O
with	O
adenine	B
instead	O
of	O
cytosine.	B

There	O
were	O
two	O
main	O
groups	O
of	O
outliers,	O
one	O
due	O
to	O
high	O
urinary	O
glucose	B
concentration	O
and	O
the	O
other	O
due	O
to	O
the	O
presence	O
of	O
acetaminophen	B
metabolites.	O

In	O
addition	O
to	O
the	O
metabolites	O
discussed	O
above	O
moderate	O
or	O
strong	O
suppression	O
of	O
PC	O
resulted	O
in	O
the	O
decreased	O
levels	O
of	O
α-ketoglutarate,	B
ADP-glucose,	B
GDP-fucose	B
and	O
GDP-mannose	O
while	O
decreases	O
in	O
the	O
levels	O
of	O
ribose-5-phosphate,	B
CTP,	B
hypoxanthine,	B
UDP	B
and	O
GDP	O
were	O
observed	O
only	O
in	O
the	O
strong	O
PC	O
suppression	O
cell	O
line	O
PC	O
2096	O
4B	O
(	O
and	O
).	O

At	O
week	O
48	O
there	O
was	O
no	O
significant	O
difference	O
across	O
treatment	O
arms	O
in	O
CD4	O
cell	O
count,	O
HIV	O
VL	B
or	O
proportion	O
of	O
participants	O
with	O
a	O
detectable	O
VL	B
(see	O
).	O

By	O
contrast,	O
11-dehydro-TXB2	B
did	O
not	O
change	O
significantly	O
in	O
the	O
sequential	O
catheter	O
samples	O
or	O
in	O
the	O
samples	O
drawn	O
by	O
separate	O
venipuncture.	O

Association	O
between	O
betaine	B
and	O
development	O
of	O
diabetes	O
in	O
4336	O
(224	O
cases)	O
subjects	O
of	O
the	O
Prevention	O
of	O
Renal	O
and	O
Vascular	O
End-Stage	O
Disease	O
(PREVEND)	O
study	O
as	O
a	O
continuous	O
variable	O
(_2	O
log-transformed)	O
and	O
according	O
to	O
tertiles	O
(T1-T3).	O

In	O
our	O
study,	O
phosphocreatine,	B
creatine,	B
dimethylgcine	B
and	O
betaine	B
were	O
down-regulated	O
in	O
rectal	O
cancer	O
tissues,	O
and	O
the	O
levels	O
of	O
methylamines	B
(methylamine,	I
DMA,	I
TMAO)	I
and	O
sarcosine	B
were	O
obviously	O
increased.	O

Univariate	O
and	O
multivariate	O
statistical	O
analyses	O
of	O
metabolomic	O
profiles	O
revealed	O
markers	O
such	O
as	O
2-hydroxybutanoic	B
acid	I
(AHBA),	O
3-hydroxybutanoic	B
acid	I
(BHBA),	O
amino	O
acids	O
valine	O
and	O
alanine,	B
the	O
glucose-alanine-cycle,	B
but	O
also	O
plant-derived	O
compounds	O
like	O
sitosterin	O
as	O
different	O
between	O
control	O
and	O
GDM	O
patients.	O

There	O
have	O
been	O
reports	O
demonstrating	O
the	O
role	O
of	O
ceramide	B
on	O
cancer	O
cell	O
biology	O
in	O
vivo	O
and	O
in	O
vitro	O
[,	O
].	O

Cotinine	B
is	O
divided	O
in	O
three	O
categories	O
corresponding	O
to	O
the	O
serum	O
level	O
in	O
non-smokers,	O
smokers	O
and	O
heavy	O
smokers.	O

Lactulose	B
or	O
rifaximin	O
therapy	O
was	O
not	O
considered	O
cause	O
for	O
exclusion.	O

After	O
loading	O
of	O
sample	O
on	O
plate,	O
the	O
phase	O
was	O
washed	O
with	O
2	O
×	O
200 μL	O
of	O
water	O
and	O
eluted	O
with	O
600 μL	O
of	O
methanol.	B

An	O
aliquot	O
of	O
100 μ	O
L	O
of	O
serum	O
was	O
mixed	O
with	O
400 μ	O
L	O
of	O
a	O
mixture	O
of	O
methanol	B
and	O
acetonitrile	B
[5 : 3,	O
(containing	O
0.1 mg/mL	O

An	O
intimate	O
relationship	O
between	O
dopamine	B
and	O
obesity	O
is	O
postulated	O
in	O
the	O
“reward	O
deficiency	O
syndrome”	O
(Blum	O
et	O
al.,	O
).	O

One	O
recently	O
published	O
study	O
showed	O
that	O
at	O
steady	O
state,	O
the	O
minimum	O
imatinib	B
levels	O
are	O
relatively	O
stable	O
over	O
time	O
and	O
proportional	O
to	O
the	O
dose	O
administered.	O

Consistent	O
with	O
a	O
previous	O
HCC	O
metabolomics	O
study	O
implicating	O
enhanced	O
γ-glutamyl	O
peptide	O
expression	O
in	O
HCC,	O
our	O
data	O
reveal	O
significant	O
elevation	O
of	O
oxidative	O
stress-related	O
metabolites	O
xanthine	B
and	O
several	O
γ-glutamyl	O
peptides	O
in	O
HCC	O
vs.	O
DC.	O

Among	O
the	O
subjects	O
who	O
experienced	O
CAD	O
during	O
follow	O
up	O
(males,	O
88%;	O
age,	O
66.3	O
±	O
6.1	O
years;	O
diabetes	O
duration,	B
17.2	O
±	O
10.1	O
years;	O
HbA1c,	O
7.1	O
±	O
0.7%),	O
10	O
(63%)	O
subjects	O
had	O
hypertension,	O
10	O
(63%)	O
had	O
dyslipidemia,	O
and	O
8	O
(53%)	O
had	O
a	O
smoking	O
habit.	O

Levels	O
of	O
3-HPMA	O
correlated	O
with	O
those	O
of	O
total	O
NNAL,	O
previously	O
measured	O
in	O
these	O
samples,	O
(R	O
=	O
0.55,	O
P	O
=	O
0.0009),	O
when	O
both	O
were	O
expressed	O
as	O
pmol/mg	O
creatinine.	B

Maintenance	O
of	O
intracellular	O
GSH	B
could	O
drive	O
cystine	B
transport	O
across	O
plasma	O
membrane	O
under	O
oxidative	O
stress.	O

The	O
strongest	O
positive	O
associations	O
with	O
disease	O
duration	B
was	O
found	O
for	O
4-acetamidobutanoate	B
and	O
indole-3-acetate;	B
EDSS:	O
glutarylcarnitine	B
and	O
methionine;	B
the	O
size	O
of	O
the	O
third	O
ventricle:	O
O	B
-succinyl-homoserine	I
and	O
ketoleucine;	B
the	O
size	O
of	O
spinal	O
cord:	O
caffeine	B
and	O
3-methoxytyramine.	B

It	O
is	O
also	O
possible	O
that	O
the	O
role	O
of	O
4-HPA	O
is	O
through	O
the	O
other	O
metabolites	O
of	O
colonic	O
microflora,	O
such	O
as	O
p	B
-hydroxybenzoic	I
acid,	I
phenylacetic	B
acid,	I
and	O
4-methoxyphenylacetic	B
acid.	I

Quantitative	O
analyses	O
of	O
succinic,	B
fumaric	O
and	O
itaconic	O
acids	O
were	O
carried	O
out	O
using	O
2,3,4,5,6-D_5	B
-benzoic	I
acid	I
as	O
an	O
internal	O
standard	O
according	O
to	O
the	O
equations	O
of	O
linear	O
functions.	O

Oleic	B
acid	I
was	O
higher	O
in	O
both	O
HBV	O
and	O
HCV	O
plasma	O
than	O
in	O
control	O
plasma,	O
while	O
isoleucine	B
was	O
lower	O
in	O
both	O
HBV	O
and	O
HCV	O
plasma	O
than	O
in	O
control	O
plasma.	O

The	O
incubation	O
of	O
morphine	B
with	O
liver	O
cytosol	O
extracts	O
resulted	O
in	O
the	O
formation	O
of	O
both	O
M3S	O
and	O
M6S.	O
Representative	O
chromatograms	O
from	O
an	O
incubation	O
of	O
morphine	B
with	O
adult	O
liver	O
cytosol	O
are	O
shown	O
in	O
Figure	O
.	O

Only	O
8	O
of	O
the	O
50	O
samples	O
investigated	O
had	O
2-	O
and	O
4-MeO-E_2	B
concentrations	O
>	O
LOD	O
in	O
serum.	O

Methanol,	B
though	O
evaluated	O
extensively	O
to	O
be	O
used	O
for	O
separation,	O
was	O
not	O
selected	O
due	O
to	O
the	O
decreased	O
stability	O
of	O
certain	O
arsenic	O
species	O
in	O
methanol.	B

Ceramides	B
are	O
associated	O
with	O
the	O
pathogenesis	O
of	O
Alzheimer’s	O
disease	O
(AD).	O

SPE	O
cartridges	O
were	O
activated	B
by	O
applying	O
0.8 ml	O
methanol	B
on	O
the	O
dry	O
bed,	O
followed	O
by	O
the	O
equilibration	O
with	O
0.8 ml	O
of	O
1%	O
formic	B
acid	I
in	O
water	O
(v/v,	O
pH~2)	O
using	O
the	O
consistent	O
flow	O
rate	O
of	O
1	O
drop/sec.	O

Hydroxyanastrozole	B
glucuronide	I
and	O
hydroxyanastrozole	B
were	O
quantified	O
as	O
the	O
major	O
metabolites	O
of	O
anastrozole	B
in	O
plasma	O
of	O
breast	O
cancer	O
patients.	O

Estrogen	B
metabolites,	O
Orbitrap	O
MS,	O
Dansyl	B
chloride,	I
1-Methylimidazole-2-sulfonyl	B
chloride	I

Finally,	O
the	O
high	O
levels	O
of	O
powerful	O
antioxidants	O
detected,	O
such	O
as	O
ascorbate	B
and	O
alpha/gamma‐tocopherol,	O
support	O
the	O
idea	O
that	O
an	O
accumulation	O
of	O
oxidative	O
stress	O
markers	O
and	O
antioxidants	O
takes	O
place	O
in	O
lung	O
tumors.	O

For	O
human	O
urine	O
analysis,	O
the	O
same	O
chromatographic	O
gradient	O
was	O
used	O
on	O
both	O
the	O
BEH	O
2-EP	O
and	O
the	O
Torus	O
Diol	B
columns	O
at	O
40 °C,	O
using	O
either	O
5%	O
water	O
in	O
methanol	B
or	O
20 mM	O
ammonium	B
formate	I
in	O
methanol	B
as	O
modifier;	O
1 μL	O
aliquots	O
of	O
1:3	O
urine:methanol	O
extract	O
were	O
injected	O
onto	O
the	O
column.	O

Consequently,	O
the	O
reduced	O
level	O
of	O
glycine	B
might	O
downregulate	O
the	O
expression	O
of	O
adiponectin	O
and	O
lead	O
to	O
the	O
inflammation	O
in	O
women	O
with	O
PCOS	O
independently	O
of	O
obesity.	O

Further,	O
increased	O
plasma	O
PFAS	O
concentrations	O
were	O
associated	O
with	O
changes	O
in	O
key	O
metabolic	O
pathways	O
(e.g.,	O
glycerophospholipids	B
and	O
tyrosine)	B
that	O
may	O
be	O
contributing	O
to	O
increased	O
NAFLD	O
severity.	O

The	O
polyaromatic	O
moiety	O
present	O
as	O
the	O
R_2	O
group	O
in	O
1a-a	O
was	O
shown	O
by	O
crystallography	O
to	O
exhibit	O
π-stacking	O
with	O
up	O
to	O
three	O
aromatic	O
residues	O
of	O
the	O
B.	O
anthracis	B
NMNAT	O
in	O
the	O
nicotinosyl	O
binding	O
pocket.	O

This	O
product	O
ion	O
is	O
a	O
diagnostic	O
ion	O
present	O
in	O
the	O
CID	O
of	O
PE	O
lipids	O
in	O
the	O
negative	O
ion	O
mode	O
and	O
corresponds	O
to	O
a	O
dehydrated	B
phosphoethanolamine	I
anion.	O

Glutamate	B
has	O
been	O
recognized	O
in	O
a	O
few	O
studies	O
as	O
a	O
potential	O
biomarker	O
related	O
to	O
various	O
types	O
of	O
cancers	O
and	O
more	O
recently	O
in	O
breast	O
tissues	O
as	O
a	O
tumor	O
biomarker	O
[–].	O

The	O
significant	O
changes	O
between	O
healthy	O
controls	O
and	O
patients	O
with	O
cirrhosis	O
in	O
terms	O
of	O
creatinine,	B
creatine	B
and	O
glutamate	B
suggest	O
that	O
changes	O
in	O
muscle	O
metabolism	O
are	O
being	O
reflected	O
in	O
the	O
urinary	O
metabolic	O
profile.	O

Intensive	O
insulin	O
therapy	O
has	O
been	O
shown	O
to	O
increase	O
triacylglycerol	B
and	O
weight	O
gain	O
in	O
the	O
DCCT	O
study	O
(Purnell	O
et	O
al.	O
).	O

Research	O
Network	O
identified	O
Etio-S	O
(etiocholan-3α-ol-17-one	O
sulfate)	I
to	O
discriminate	O
IC	O
patients	O
from	O
healthy	O
controls.	O

b	O
,	O
binding	O
affinities	O
of	O
β-apocarotenoids	B
to	O
RXRα	O
calculated	O
from	O
the	O
data	O
shown	O
in	O
a	O
.	O

The	O
product	O
ion	O
mobilities	O
in	O
both	O
positive	O
and	O
negative	O
ion	O
mode	O
are	O
very	O
different	O
from	O
that	O
of	O
the	O
precursor	O
phospholipid	B
ions,	O
which	O
is	O
not	O
only	O
due	O
to	O
the	O
lower	O
m/z	O
of	O
the	O
product	O
ions,	O
but	O
also	O
because	O
the	O
product	O
ions	O
tend	O
to	O
have	O
more	O
compact	O
structures.	O

The	O
exact	O
blood	O
sampling	O
times	O
and	O
blood	O
glucose	B
concentrations	O
after	O
ingestion	O
of	O
[U_13	B
C]glucose	I
were	O
monitored	O
by	O
an	O
in-house	O
Android	O
application	O
and	O
glucometers	B
(Diamond	O
Mini;	O
ForaCare).	O

The	O
most	O
altered	O
metabolites	O
included	O
ketones,	B
aldehydes	O
and	O
organic	O
acids.	O

Gardana	O
and	O
Simonetti29	O
identified	O
the	O
main	O
metabolite	O
of	O
equol	O
in	O
the	O
plasma	O
of	O
12	O
female	O
subjects	O
as	O
E‐7‐G	O
by	O
performing	O
cochromatography	O
with	O
an	O
authentic	O
standard,	O
while	O
double	O
conjugated	O
metabolites	O
such	O
as	O
diG,	O
diS,	O
and	O
sulfate‐glucuronide	B
were	O
not	O
found.	O

Early	O
research	O
comparing	O
the	O
choline	B
metabolites	O
in	O
breast	O
milk	O
and	O
infant	O
formula	O
suggested	O
that	O
infant	O
formula	O
had	O
lower	O
levels	O
of	O
PCho	O
than	O
breast	O
milk	O
,	O
;	O
however,	O
recent	O
data	O
from	O
Ilcol	O
and	O
the	O
present	O
study	O
results	O
indicate	O
that	O
there	O
is	O
a	O
large	O
range	O
in	O
PCho	O
in	O
both	O
breast	O
milk	O
(100	O
to	O
1200	O
µmol/L)	O
and	O
unprocessed	O
bovine	O
milk	O
(12	O
to	O
820	O
µmol/L).	O

For	O
cabozantinib	B
QCXL	O
was	O
also	O
included	O
in	O
this	O
analysis.	O

(1,1’	O
=	O
O	O
-DVX	O
and	O
2,2’	B
=	I
VX).	I

In	O
all	O
ten	O
patient	O
samples	O
we	O
also	O
detected	O
the	O
hitherto	O
unknown	O
toxins	B
DMSO_2	O
and	O
2-HIBA.	O

The	O
observation	O
of	O
the	O
levels	O
of	O
the	O
ketone	B
bodies	O
opens	O
such	O
possibility	O
and	O
allows	O
to	O
capture	O
the	O
patients	O
at	O
risk	O
of	O
the	O
greatest	O
decrease	O
in	O
the	O
body	O
weight	O
(Figs. ,	O
and	O
d).	O

Alanine,	B
a	O
non-essential	O
amino	O
acid,	O
is	O
an	O
end	O
product	O
of	O
glutamate	B
oxidation,	O
which	O
is	O
a	O
major	O
source	O
of	O
respiratory	O
energy	O
in	O
the	O
tumor	O
cell.	O

The	O
colorectal	O
cancer	O
patients	O
also	O
had	O
higher	O
plasma	O
levels	O
of	O
lactic	B
acid,	I
which	O
is	O
the	O
end	O
product	O
of	O
glycolysis,	O
than	O
the	O
healthy	O
volunteers.	O

Iron	O
overload	O
in	O
DIOS	O
was	O
associated	O
with	O
moderate	O
alterations	O
of	O
the	O
oxylipin	B
profile	O
suggesting	O
a	O
mild	O
inflammation,	O
but	O
larger	O
sample	O
size	O
would	O
be	O
necessary	O
to	O
confirm	O
results	O
from	O
this	O
pilot	O
study.	O

For	O
the	O
extraction	O
of	O
prokaryotic	O
microbes	O
(e.g.,	O
Escherichia	O
coli	O
),	O
eukaryotic	O
microbes	O
(e.g.,	O
Saccharomyces	O
cerevisiae	O
),	O
or	O
mammalian	O
cells	O
(e.g.,	O
MCF-7	O
breast	O
cancer	O
cells),	O
we	O
found	O
that	O
50%	O
MeOH	B
in	O
water	O
always	O
provided	O
the	O
best	O
extraction	O
efficiency,	O
whereas	O
50%	O
ACN	O
resulted	O
in	O
a	O
lower	O
extraction	O
efficiency	O
than	O
50%	O
MeOH,	B
and	O
1:1:1	O
ACN/MeOH/H_2	O
O	O
resulted	O
in	O
the	O
lowest	O
efficiency.	O

In	O
a	O
meta-analysis	O
of	O
11	O
articles,	O
the	O
levels	O
of	O
guanine,	B
cytosine,	B
thymine,	B
hypoxanthine,	B
uracil	B
and	O
ribose	B
were	O
found	O
to	O
be	O
elevated	O
in	O
the	O
urine	O
of	O
BC	O
patients,	O
indicating	O
a	O
higher	O
level	O
of	O
nucleotide	O
metabolism.	O

Inositol	B
might	O
therefore	O
play	O
a	O
role	O
in	O
cellular	O
signaling,	O
via	O
its	O
link	O
to	O
the	O
phosphoinositol-3-kinase	O
PI3K	O
pathway,	O
impacting	O
CRC	O
pathogenesis.	O

PLS-DA	O
analyses	O
to	O
discriminate	O
samples	O
obtained	O
before	O
ERCP	O
from	O
those	O
obtained	O
afterward	O
were	O
constructed	O
to	O
determine	O
whether	O
those	O
who	O
developed	O
AP	B
had	O
a	O
different	O
metabolic	O
response	O
to	O
the	O
procedure	O
than	O
those	O
who	O
did	O
not.	O

Clarifying	O
the	O
role	O
of	O
individual	O
compounds	O
as	O
well	O
as	O
patterns	O
of	O
estrogen	B
metabolism	O
in	O
breast	O
carcinogenesis	O
may,	O
therefore,	O
be	O
relevant	O
to	O
prevention	O
strategies.	O

Briefly,	O
urine	O
samples	O
were	O
diluted	O
25	O
times	O
with	O
eluent	O
A	O
(1:1	O
acetonitrile/aqueous	O
50	O
mM	O
ammonium	B
formate)	O
and	O
separated	O
by	O
an	O
inverse	O
acetonitrile	B
gradient	O
on	O
a	O
polar	O
HILIC	O
column	O
(Acquity	O
BEH	O
Amide,	B
100	O
×	O
2.1	O
mm,	O
1.7	O
µm,	O
Waters,	O
Eschborn,	O
Germany).	O

	O
LC-MS	O
grade,	O
ammonium	B
acetate,	I
acetonitrile,	B
methanol,	B
and	O
acetic	B
acid	I
were	O
purchased	O
from	O
Fisher	O
Scientific	O
(Pittsburgh,	O
PA,	O
USA).	O

Both	O
fasting	O
glycemia	O
and	O
HbA_1c	O
were	O
increased	O
by	O
Omega-3,	B
but	O
were	O
unchanged	O
by	O
Pio&	O
Omega-3.	B

We	O
also	O
compared	O
the	O
lipid	O
profiles	O
of	O
diabetic	O
monkeys	O
at	O
different	O
ages;	O
and	O
lipidomic	O
analysis	O
revealed	O
that	O
there	O
was	O
no	O
significant	O
correlation	O
between	O
the	O
levels	O
of	O
both	O
glycerophospholipids	B
and	O
sphingolipids	B
with	O
age	O
(12	O
to	O
20	O
years	O
old).	O

Some	O
of	O
the	O
metabolites	O
were	O
in	O
agreement	O
with	O
previously	O
published	O
data	O
that	O
compared	O
RA	O
patients	O
and	O
control	O
subjects,	O
such	O
as	O
decreased	O
levels	O
of	O
histidine,	B
methionine,	B
and	O
serine,	B
and	O
increased	O
levels	O
of	O
glyceric	B
acid,	I
phenylalanine,	B
and	O
tyrosine	B
in	O
RA	O
patients	O
[,,–].	O

In	O
another	O
research,	O
such	O
significant	O
difference	O
of	O
homocysteine	B
levels	O
was	O
not	O
observed.	O

Of	O
the	O
44	O
metabolites	O
with	O
significantly	O
changed	O
concentrations	O
at	O
RT,	O
35	O
showed	O
increasing	O
concentrations	O
after	O
24	O
h	O
(,	O
,	O
,	O
,	O
,	O
,	O
,	O
,	O
,	O
and	O
)	O
whereas	O
9	O
showed	O
decreasing	O
concentrations,	O
including	O
C4∶1,	O
arginine,	B
methionine,	B
serotonin*,	O
four	O
PC	O
aa’s	O
(PC	O
aa	O
C30∶0,	O
PC	O
aa	O
C32∶1,	O
PC	O
aa	O
C32∶2	O
and	O
PC	O
aa	O
C34∶3,	O
see	O
)	O
and	O
hexose.	B

The	O
patients	O
with	O
CAD	O
had	O
higher	O
serum	O
concentrations	O
of	O
fasting	O
glucose	B
and	O
lower	O
concentrations	O
of	O
HDL	B
cholesterol	I
and	O
triglycerides	B
than	O
did	O
the	O
controls.	O

Total	O
NNAL,	O
total	O
1-HOP,	O
total	O
NNN,	O
and	O
total	O
cotinine	B
were	O
expressed	O
per	O
milligram	O
creatinine	B
to	O
normalize	O
for	O
urinary	O
dilution.	O

However,	O
ER(+)	B
patients	O
apparently	O
exhibited	O
also	O
enhanced	O
level	O
of	O
cytokines	O
potentially	O
responsible	O
for	O
the	O
suppression	O
of	O
T-cells	O
as	O
IL-10,	O
IL-8,	O
and	O
transforming	O
growth	O
factor	O
(TGF)-β1,	O
and	O
lower	O
concentrations	O
of	O
both	O
T-cells	O
activating	O
factors	O
(IL-1α	O
and	O
IL-2),	O
and	O
mediators	O
of	O
the	O
inflammatory	O
response	O
as	O
IL-1β,	B
IL-6	O
and	O
GM-CSF.	O

However,	O
the	O
triglyceride	B
levels,	O
HbA1c,	O
and	O
blood	O
glucose	B
levels	O
were	O
significantly	O
higher	O
in	O
the	O
OW	O
group.	O

Four	O
mL	O
of	O
blood	O
was	O
collected	O
from	O
a	O
peripheral	O
vein	O
into	O
an	O
EDTA	O
tube	O
at	O
around	O
one	O
hour	O
later	O
under	O
ketamine	B
anesthesia.	O

For	O
NMR	O
analysis,	O
serum	O
samples	O
were	O
left	O
to	O
thaw,	O
and	O
aliquots	O
of	O
100	O
μL	O
were	O
mixed	O
with	O
200	O
μL	O
phosphate	B
buffer	O
(pH	O
7.0)	O
containing	O
5	O
mmol/L	O
TSP	O
(Trimethylsilyl	O
propionate)	I
and	O

Alb	O
adducts	O
of	O
SO	O
were	O
measured	O
in	O
48	O
workers	O
exposed	O
to	O
both	O
styrene	B
and	O
SO	O
in	O
a	O
boat	O
manufacturing	O
plant.	O

Higher	O
glycerol	B
and	O
free	O
fatty	O
acid	O
levels	O
in	O
the	O
blood	O
have	O
been	O
implicated	O
in	O
metabolic	O
disorders	O
and	O
obesity	O
.	O

This	O
suggests	O
that	O
the	O
creatinine	B
adjustment	O
method	O
may	O
not	O
adequately	O
reduce	O
the	O
measurement	O
variability	O
due	O
to	O
urine	O
dilution,	O
as	O
appears	O
to	O
occur	O
in	O
our	O
dataset.	O

Phosphatidylinositol	B
(PtdIns)	O
is	O
the	O
most	O
abundant	O
phosphoinositides	B
in	O
mammalian	O
cells,	O
and	O
its	O
dysregulation	O
has	O
been	O
implicated	O
in	O
a	O
number	O
of	O
human	O
diseases.	O

An	O
interesting	O
finding	O
of	O
our	O
study	O
was	O
that	O
taurine	B
levels	O
were	O
significantly	O
increased	O
due	O
to	O
prolonged	O
blood	O
incubation	O
at	O
RT.	O

The	O
histogram	O
is	O
expressed	O
as	O
mean ± SD,	O
n = 10,	O
detailed	O
data	O
of	O
phosphatidylcholines	B
are	O
shown	O
in	O
Table _S3	O
.	O

Indeed,	O
we	O
have	O
demonstrated	O
that	O
a	O
random	O
forests-based	O
mathematical	O
approach	O
was	O
enabled	O
to	O
characterize	O
hepatic	O
lipid	O
signature	O
specific	O
to	O
NASH	O
in	O
murine	B
models.	O

Characteristically,	O
the	O
1.3-ppm	O
and	O
2.2-ppm	O
peaks	O
are	O
considered	O
as	O
representative	O
of	O
triglyceride	B
and	O
unsaturated	O
fatty	O
acids,	O
but	O
actual	O
values	O
obtained	O
by	O
biochemical	O
measurements	O
(see	O
below)	O
suggest	O
the	O
combination	O
of	O
multiple	O
signals	O
from	O
other	O
compounds.	O

Key:	O
sEH,	O
soluble	O
epoxy	O
hydrolase;	O
CPT-I,	O
carnitine	B
palmitoyltransferase-I;	I
HO-1,	O
heme	B
oxygenase-1.	I

Within	O
the	O
CG,	O
urinary	O
concentration	O
of	O
hypoxanthine	B
significantly	O
changed	O
with	O
increasing	O
means	O
between	O
V1	O
and	O
V3	O
(p	O
=	O
0.0437)	O
and	O
V2	O
and	O
V3	O
(p	O
=	O
0.0442).	O

This	O
yielded	O
a	O
regression	O
equation	O
of	O
y	O
=	O
-0.94	O
-	O
7.97	O
C10	O
+	O
9.31	O
C10:1	B
-	I
2.71	I
C18:1	I
+	O
21.42	O
C3/Met	O
-	O
0.841	O
C3DC/C10	O
-	O
1.048	O
C4/C8	O
+	O
2.53	O
C4DC	O
+	O
188.6	O
C5-OH/C0	O
+	O
0.01624	O
Glu	O
-	O
0.0944	O
Thr	O
+	O
1.003	O
Val/Phe.	O

Gene-network	O
predictions	O
for	O
this	O
gene	O
included	O
functions	O
such	O
as	O
triglycerides	B
(TG)	O
and	O
lipoprotein	O
homeostasis.	O

We	O
found	O
that	O
the	O
intervention	O
with	O
the	O
more	O
robust	O
impact	O
on	O
glucose	B
homeostasis,	O
bariatric	O
surgery,	O
also	O
has	O
the	O
stronger	O
impact	O
on	O
lowering	O
circulating	O
levels	O
of	O
BCAAs	O
and	O
related	O
metabolites.	O

Concentrations	O
of	O
11-dehydro-TXB2	B
were	O
increased	O
in	O
patients	O
who	O
had	O
recently	O
suffered	O
a	O
pulmonary	O
embolism	O
to	O
a	O
greater	O
extent	O
than	O
either	O
the	O
11-dehydro-13,14-dihydro-15-keto-TXB2	B
or	O
the	O
2,3-dinor-TXB2	B
metabolites	O
in	O
plasma.	O

A	O
key	O
enzyme	O
in	O
the	O
conversion	O
of	O
cortisone	B
to	O
cortisol	B
is	O
11β-hydroxysteroid	B
dehydrogenase	I
(11β-HSD)	I
but	O
its	O
expression	O
levels	O
in	O
adipose	O
tissue	O
are	O
uncertain.	O

The	O
algorithm	O
correctly	O
identified	O
age,	O
gender,	O
and	O
serum	O
creatinine	B
in	O
the	O
first	O
order	O
neighborhood,	O
which	O
are	O
used	O
for	O
the	O
computation	O
of	O
eGFR	O
.	O

Interestingly,	O
we	O
found	O
in	O
this	O
study	O
that	O
several	O
metabolites	O
in	O
the	O
cysteine	B
and	O
methionine	B
metabolism	O
pathway,	O
which	O
is	O
upstream	O
of	O
the	O
taurine	B
and	O
hypotaurine	B
metabolism	O
pathway,	O
is	O
associated	O
with	O
RA	O
disease	O
activity.	O

Betaine	B
levels	O
may	O
be	O
useful	O
for	O
assessing	O
the	O
risk	O
of	O
future	O
T2DM.	O

Product	O
ion	O
mass	O
spectra	O
of	O
A)	O
C*PF	O
(C-[S=O]-PhIP)	O
sulfinamide	B
adduct	O
([M+H]_+	O
at	O
m/z	O
604.2)	O
recovered	O
from	O
HONH-PhIP-modified	O
SA;	O
B)	O
C*PF	O
(C-[S=O]-[_2	O
H_5	O
]-PhIP)	O
sulfinamide	B
adduct	O
([M+H]_+	O
at	O
m/z	O
609.2)	O
recovered	O
from	O
HONH-[_2	O
H_5	O
]-PhIP	O
modified	O
SA;	O
C)	O
C*PF	O

Gradient	O
elution	O
(solvent	O
A,	O
0.2%	O
FA	B
in	O
water;	O
solvent	O
B,	O
ACN)	O
was	O
used	O
according	O
to	O
the	O
following	O
program:	O
isocratic	O
step	O
that	O
holds	O
25%	O
solvent	O
B	O
from	O
0	O
to	O
2.2	O
min,	O
up	O
to	O
90%	O
solvent	O
B	O
in	O
1.5	O
min,	O
held	O
90%	O
solvent	O
B	O
to	O
4	O
min	O
and	O
column	O
reconditioning	O
at	O
25%	O
solvent	O
B	O
to	O
5	O
min	O
(total	O
analysis	O
time).	O

As	O
shown	O
in	O
&	O
,	O
synthetic	O
E_1	B
-9-N-Ade	I
and	O
E_2	B
-9-N-Ade	I
as	O
well	O
as	O
the	O
assay	O
mixtures	O
containing	O
E_1	O
or	O
E_2	O
showed	O
a	O
peak	O
(404.3>135.9)	O
at	O
R_t	O
of	O
∼1.9	O
min	O
and	O
a	O
peak	O
(406.3>271.02)	O
at	O
R_t	O
of	O
∼1.8	O
min,	O
confirming	O
the	O
formation	O
of	O
E_1	B
-9-N-Ade	I
and	O
E_2	B
-9-N-Ade.	I

Finally,	O
we	O
found	O
that	O
the	O
exogenous	O
glutathione	B
derivatives	O
at	O
these	O
concentrations	O
had	O
no	O
cytotoxic	O
effects	O
on	O
the	O
glutathione-depleted	O
RGC-5	O
cells.	O

We	O
have	O
also	O
observed	O
that	O
NO_2	O
-PhIP	O
is	O
formed	O
from	O
HONH-PhIP,	O
through	O
the	O
NO-PhIP	O
intermediate,	O
under	O
aerobic	O
conditions	O
in	O
phosphate	B
buffered	O
saline	B
(pH	O
7.4)	O
(Turesky	O
R,	O
unpublished	O
observations).	O

Among	O
these,	O
glutamine	B
and	O
glutamic	B
acid	I
were	O
suggested	O
as	O
the	O
most	O
distinctive	O
metabolites	O
for	O
the	O
presence	O
of	O
DR.	O

Adenine,	B
glycerol,	B
and	O
pyrophosphate	B
were	O
remarkably	O
increased	O
in	O
young	O
patients,	O
whereas	O
capric	B
acid	I
significantly	O
decreased	O
compared	O
with	O
normotensive	O
controls.	O

No	O
significant	O
differences	O
were	O
observed	O
for	O
aspartate	O
transaminase	O
(AST)	O
and	O
glucose	B
(GLU)	O
among	O
all	O
3	O
groups.	O

Nonlinear	O
correlations	O
of	O
ESR,	O
albumin,	O
transferrin,	O
HsCRP	O
and	O
fecal	O
calprotectin	O
with	O
selected	O
vitamin	B
D	I
parameters.	O
vs.:	O
versus.	O

Glutamine	B
is	O
one	O
of	O
the	O
most	O
abundant	O
metabolites	O
in	O
blood	O
and	O
is	O
a	O
precursor	O
as	O
well	O
as	O
end	O
product	O
central	O
to	O
numerous	O
important	O
metabolic	O
pathways.	O

Twenty-five	O
microliters	O
of	O
MTBSTFA	O
and	O
25	O
μL	O
acetonitrile	B
were	O
added,	O
and	O
the	O
mixture	O
was	O
incubated	O
for	O
30	O
min	O
at	O
80	O
°C.	O

For	O
example,	O
glucose	B
traits	O
and	O
the	O
inflammation	O
marker	O
glycoprotein	O
acetyls	O
were	O
similarly	O
associated	O
with	O
risk	O
of	O
ICH	O
as	O
to	O
risk	O
of	O
MI	O
and	O
IS.	O

In	O
future	O
studies,	O
we	O
plan	O
to	O
synthesize	O
additional	O
standards	O
of	O
K-E-LAs	O
to	O
expand	O
method	O
performance	O
evaluation,	O
and	O
to	O
incorporate	O
targeted	O
PUFAs	O
in	O
order	O
to	O
investigate	O
how	O
parent	O
PUFA	O
levels	O
relate	O
to	O
their	O
corresponding	O
oxylipin	B
derivatives.	O

Indeed,	O
measurement	O
of	O
T_1	O
times	O
on	O
a	O
separate	O
urine	O
sample	O
lyophylized	O
and	O
redissolved	O
in	O
the	O
various	O
solvents	O
indicates	O
relaxation	O
times	O
larger	O
than	O
2	O
s	O
for	O
almost	O
all	O
metabolites	O
investigated	O
in	O
D_2	O
O,	O
while	O
they	O
are	O
shorter	O
in	O
MeOD,	O
DMSO,	B
and	O
DMF	O
(Figure	O
S1).	O

CHCl_3	O
 = 2.5:1:1)	B
containing	O
10 μl	O
of	O
1.0 mg/ml	O
2-isopropylmalic	B
acid	I
dissolved	O
in	O
distilled	O
water	O
as	O
an	O
internal	O
standard.	O

The	O
detection	O
of	O
hypoxanthine	B
and	O
uridine	B
indicate	O
perturbations	O
to	O
purine/pyrimidine	O
catabolism.	O

Only	O
Glucose	B
and	O
pseudouridine	B
(PSI)	O
were	O
common	O
to	O
all	O
six	O
models.	O

The	O
30%	O
acetone	B
in	O
DCM	O
fraction	O
from	O
the	O
chromatography	O
of	O
the	O
crude	O
leaves	O
extract	O
was	O
rechromatographed	O
in	O
10%	O
EtOAc	O
in	O
petroleum	O
ether.	O

These	O
unconjugated	O
bile	O
acids	O
induce	O
oncogenesis	O
in	O
colonic	O
epithelial	O
cells	O
by	O
altering	O
muscarinic	O
3	O
receptor	O
(M3R)	O
and	O
Wnt/	O
β-catenin	B
signaling	O
and	O
thus	O
act	O
potential	O
promoters	O
of	O
colon	O
cancer.	O

The	O
diagnostic	O
utility	O
in	O
combining	O
measurement	O
of	O
the	O
up-regulated	O
(decanoylcarnitine,	O
lysoPC(16:0),	B
lysoPC(18:0),	B
lysoPC(16:1)	B
and	O
octanoylcarnitine)	B
with	O
the	O
down-regulated	O
(linoleic	O
acid	O
and	O
uric	O
acid)	O
was	O
relatively	O
high,	O
with	O
a	O
sensitivity	O
and	O
specificity	O
up	O
to	O
90.2%	O
and	O
96.0%,	O
respectively.	O

The	O
proton	O
chemical	O
shifts	O
were	O
referenced	O
to	O
CH_3	O
signal	O
of	O
lactate	B
at	O
1.33	O
ppm.	O

The	O
patients	O
reported	O
a	O
varied	O
drug	O
history:	O
the	O
majority	O
of	O
the	O
CHB	O
group	O
were	O
taking	O
multivitamins,	O
although	O
some	O
were	O
also	O
taking	O
an	O
oral	O
antiviral	O
drug	O
(n	O
=	O
10,	O
entecavir	O
or	O
tenofovir)	O
and/or	O
an	O
oral	O
proton	O
pump	O
inhibitor	O
(PPI)	O
(omeprazole,	O
pantoprazole);	B
the	O
CIR	O
group	O
reported	O
a	O
combination	O
of	O
non-absorbable	O
sugars	O
(lactulose),	O
PPI	B
(omeprazole,	I
pantoprazole),	I
oral	O
antiviral	O
(n	O
=	O
7,	O
entecavir,	O
tenofovir	O
or	O
telbivudine),	O
and/or	O
multivitamins;	O
and	O
the	O
HCC	O
cohort	O
reported	O
a	O
wider	O
range	O
of	O
medication,	O
including	O
an	O
oral	O
antiviral	O
(entecavir,	O
tenofovir),	O
hormonal	O
therapy	O
(tamoxifen),	O
PPI	B
(omeprazole,	I
pantoprazole),	I
beta	O
blockers,	O
non-absorbable	O
sugars	O
(lactulose),	O
multivitamins,	O
and	O
pain	O
killers	O
(including	O
tramadol).	O

When	O
the	O
sperm-toxic	O
T.	O
harzianum	O
extract	O
was	O
fractionated	O
with	O
solvents	O
of	O
different	O
polarities,	O
it	O
was	O
found	O
that	O
the	O
toxic	O
agent	O
was	O
insoluble	O
in	O
water	O
and	O
in	O
pentane	B
but	O
soluble	O
in	O
methanol.	B

A	O
YMC-Pack	O
Hydrosphere	B
C18	O
column	O
(3	O
μm	O
2.0	O
mm	O
×	O
150	O
mm)	O
was	O
used	O
with	O
a	O
flow	O
rate	O
of	O
0.225	O
ml/min	O
and	O
the	O
column	O
temperature	O
at	O
30°C	O
(Waters,	O
Milford,	O
MA).	O

This	O
study	O
highlighted	O
dysregulations	O
of	O
the	O
metabolic	O
pathway	O
involved	O
in	O
the	O
synthesis	O
of	O
fatty	O
acids	O
and	O
eicosanoid	B
precursors.	O

Sibutramine	B
hydrochloride	I
(SB)	O
was	O
purchased	O
from	O
Symed	O
labs.	O

M	O
acetic	B
acid	I
was	O
necessary	O
to	O
ensure	O
pH	O
of	O
the	O
sample	O
loaded	O
onto	O
the	O
SPE	O
was	O
well	O
below	O
the	O
sorbent	O
pK_a	O
(9.0).	O

Therefore,	O
phosphate	B
buffer	O
saline	B
(PBS)-methanol	I
containing	O
BHT/EDTA	O
was	O
used	O
as	O
a	O
surrogate	O
matrix	O
(referred	O
to	O
as	O
PMC).	O

After	O
centrifugation	O
at	O
4000×	O
g	O
for	O
30	O
min,	O
1	O
mL	O
of	O
the	O
upper	O
organic	O
layer	O
was	O
dried	O
by	O
centrifugal	O
vacuum	O
evaporation	O
and	O
dissolved	O
in	O
150	O
μL	O
of	O
isopropanol:methanol:chloroform	O
(4:2:1)	O
containing	O
15	O
mM	O
ammonium	B
acetate.	I

There	O
was	O
a	O
small,	O
albeit	O
significant	O
decreasing	O
effect	O
of	O
AXOS	O
on	O
serum	O
TMAO	B
(P	O
0.04).	O

Secondary	O
outcomes	O
in	O
this	O
study	O
include	O
changes	O
in	O
other	O
glycemic	B
parameters	O
such	O
as	O
fasting	O
glucose,	B
insulin,	O
fructosamine,	B
changes	O
in	O
lipid	O
profile	O
(triglyceride,	O
total	O
cholesterol,	B
HDL-cholesterol,	B
LDL-cholesterol),	B
changes	O
in	O
inflammation	O
(high-sensitivity	O
C-reactive	O
protein)	O
and	O
oxidative	O
stress	O
marker	O
(plasma	O
malondialdehyde),	B
changes	O
in	O
anthropometry	O
parameters	O
(BMI,	O
waist	O
circumference),	O
changes	O
in	O
metabolite	O
profile	O
(urine,	O
serum),	O
changes	O
in	O
safety	O
parameters	O
(liver	O
profile	O
and	O
renal	O
profile),	O
changes	O
in	O
blood	O
pressure,	O
dietary	O
pattern	O
and	O
physical	O
activity.	O

The	O
variables	O
in	O
the	O
equation	O
of	O
logic	O
regression	O
analysis	O
for	O
liver	O
cancer	O
plasma	O
(assigned	O
as	O
1	O
as	O
dependent)	O
and	O
lung	O
cancer	O
plasma	O
(assigned	O
for	O
2	O
as	O
dependent)	O
using	O
the	O
Conditional	O
Method	O
as	O
analytical	O
method.	O
_a	O
Variable(s)	O
entered	O
in	O
step	O
1:	O
putrescine;	B
_b	O
Variable(s)	O
entered	O
in	O
step	O
2:	O
spermidine;	B
_c	O
Variable(s)	O
entered	O
in	O
step	O
3:	O
N	B
-acetylspermine;	I
_d	O
Variable(s)	O
entered	O
in	O
step	O
4:	O
γ-aminobutyric	B
acid.	I

Cell	O
lysates	O
were	O
analyzed	O
for	O
(A)	O
AMPK	O
phosphorylation	O
and	O
protein	O
level	O
and	O
(B)	O
its	O
downstream	O
target	O
ACC	O
phosphorylation	O
and	O
β-actin	B
protein	O
expression.	O

For	O
the	O
transmethylation	O
of	O
cholesterol	B
esters,	I
the	O
samples	O
were	O
resuspended	O
in	O
400	O
μL	O
methyl	B
propionate,	I
and	O
600	O
μL	O
0.84	O
M	O
KOH	O
in	O
methanol	B
for	O
1	O
h	O
at	O
37	O
°C.	O

Our	O
experimental	O
data	O
showed	O
that	O
the	O
level	O
of	O
glucose	B
was	O
different	O
between	O
lung	O
cancer	O
and	O
control	O
plasma	O
samples.	O

The	O
tCho	O
pool	O
showed	O
a	O
strong	O
positive	O
correlation	O
with	O
lactate	B
in	O
astrocytomas	O
and	O
meningiomas	O
and	O
a	O
moderate	O
but	O
still	O
statistically	O
significant	O
positive	O
correlation	O
in	O
glioblastomas.	O

Bias	O
(%)	O
and	O
precision	O
(RSD)	O
for	O
quantification	O
of	O
PBTZ169	O
and	O
active	O
metabolites	O
in	O
plasma	O
with	O
different	O
anticoagulants	O
(EDTA	O
and	O
heparin)	B
and	O
in	O
serum	O
by	O
using	O
validated	O
citrated	O
plasma	O
calibration	O
were	O
assessed	O
with	O
QC	O
samples	O
(n	O
=	O
3)	O
spiked	O
at	O
10,	O
150	O
and	O
1500	O
ng/mL.	O
Additionally,	O
EDTA	O
plasma	O
spiked	O
at	O
calibrators	O
levels	O
were	O
also	O
quantified	O
using	O
reference	O
calibration	O
set	O
prepared	O
in	O
citrated	O
plasma.	O

The	O
antidepressants	O
presented	O
to	O
DT-MDD	O
subjects	O
were	O
primarily	O
selective	O
serotonin	B
reuptake	O
inhibitors	O
(SSRIs),	O
i.e.,	O
escitalopram,	B
fluoxetine,	B
fluvoxamine,	B
paroxetine,	B
and	O
sertraline.	B

Thus,	O
the	O
DCM	O
leaf	O
extract	O
exhibited	O
lower	O
(18.52%	O
±13.5%)	O
hypoglycemic	B
activity	O
than	O
the	O
aqueous	O
leaf	O
extract	O
(70.76%	O
±17.4%)	O
which	O
was	O
also	O
faster	O
acting	O
(0.5	O
h).	O

Dopamine	B
may	O
have	O
anti-angiogenic	O
effects,	O
inhibiting	O
vascular	O
endothelial	O
growth	O
factor	O
(VEGF)	O
in	O
vitro	O
.	O

The	O
clinical	O
utility	O
of	O
the	O
SID-LC/ESI/SRM/MS	O
method	O
for	O
the	O
quantification	O
of	O
keto-androgens	B
was	O
validated	O
by	O
its	O
application	O
to	O
human	O
serum	O
samples	O
from	O
patients	O
enrolled	O
in	O
the	O
TAPS	O
clinical	O
trial.	O

Specifically,	O
to	O
demonstrate	O
the	O
performance	O
of	O
the	O
new	O
method,	O
we	O
measured	O
cardiac	O
NADH	B
and	O
NAD_+	O
ratios	O
as	O
well	O
as	O
their	O
pool	O
sizes	O
in	O
heart	O
tissue	O
from	O
mouse	O
models	O
with	O
a	O
cardiac	O
specific	O
knockout	O
of	O
the	O
mitochondrial	O
Complex	O
I	O
Ndufs4	O
gene	O
(cKO).	O

One	O
of	O
these	O
features	O
was	O
attributed	O
to	O
either	O
lithocholic	B
acid	I
glycine	I
conjugate	I
or	O
any	O
of	O
eight	O
glycerophosphocholine	B
isomers	I
while	O
the	O
other	O
was	O
attributed	O
to	O
either	O
any	O
of	O
eighteen	O
glycerophosphocholine	B
lipids	O
containing	O
a	O
single	O
double	O
bond	O
or	O
to	O
any	O
of	O
thirty-two	O
lipids	O
containing	O
four	O
double	O
bonds.	O

mansoni	O
infection	O
consisted	O
of	O
reduced	O
levels	O
of	O
the	O
tricarboxylic	B
acid	I
cycle	O
intermediates,	O
including	O
citrate,	B
succinate,	B
and	O
2-oxoglutarate,	B
and	O
increased	O
levels	O
of	O
pyruvate,	B
suggesting	O
stimulated	O
glycolysis	O
[,].	O

H	O
There	O
is	O
a	O
significant	O
relationship	O
of	O
glucose	B
with	O
all	O
of	O
lipids	O
evident	O
from	O
the	O
NMR	O
study.	O

On	O
the	O
light	O
of	O
these	O
considerations,	O
tyrosine	B
levels	O
can	O
be	O
considered	O
an	O
important	O
serum	O
biomarker	O
for	O
HCC	O
progression.	O

Subjects	O
with	O
impaired	O
vascular	O
health,	O
therefore,	O
have	O
age-related	O
increase	O
in	O
CIMT	O
thickness	O
along	O
with	O
age-related	O
early-stage	O
decline	O
in	O
glucose	B
tolerance	O
and	O
renal	O
function	O
and	O
increased	O
glucose-mediated	O
protein	O
crosslinking.	O

Moreover,	O
lactate	B
is	O
a	O
major	O
biomarker	O
for	O
tissue	O
hypoxia	O
and	O
necrosis.	O

Metabolomic	O
standards	O
included	O
debrisoquine	B
sulfate,	I
4-nitrobenzoic	B
acid,	I
valine,	B
hypoxanthine,	B
carnitine,	B
proline,	B
tyrosine,	B
glucose,	B
uridine,	B
and	O
taurine	B
(all	O
Sigma-Aldrich,	O
St.	O
Louis,	O
MO).	O

BNP	O
brain	O
natriuretic	O
peptide;	O
NPR-A	O
natriuretic	O
peptide	O
receptor	O
A,	O
GTP	O
guanosine	B
triphosphate,	I
cGMP	O
cyclic	O
guanosine	O
monophosphate,	O
PKG	O
cGMP-dependent	O
protein	O
kinase,	O
HDL	O
high-density	O
lipoprotein,	O
VLDL	O
very	O
low-density	O
lipoprotein,	O
IDL	O
intermediate-density	O
lipoprotein,	O
LDL	O
low-density	O
lipoprotein	O

RCA = Right	O
coronary	O
artery;	O
ASA = Acetylsalicylic	B
acid;	I
ACEI = Angiotensin-converting	O
enzyme	O
(ACE)	O
inhibitors;	O
ARB = Angiotensin	O
II	O
receptor	O
blockers.	O

A	O
number	O
of	O
factors	O
potentially	O
explain	O
the	O
suggested	O
difference	O
in	O
glucose	B
handling	O
between	O
carriers	O
and	O
non-carriers	O
of	O
the	O
ACE	O
I-allele.	O

These	O
systems	O
were	O
controlled	O
by	O
Agilent	O
G2201AA	O
ChemStation	O
software	O
and	O
connected	O
by	O
a	O
fused	O
silica	B
capillary	O
(50	O
μm	O
i.d.	O

Each	O
of	O
the	O
three	O
male	O
ddY	O
mice	O
was	O
intra-peritoneally	B
administered	O
with	O
acetamiprid	B
(10	O
mg/kg),	O
imidacloprid	O
(10	O
mg/kg)	O
or	O
clothianidin	B
(20	O
mg/kg)	O
as	O
solutions	O
of	O
dimethyl	B
sulfoxide.	I

Conventional	O
cytogenetic	O
test	O
for	O
t(15:17)	B
was	O
performed	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
(FISH)	O
analysis	O
and	O
a	O
negative	O
FISH	O
result	O
was	O
considered	O
as	O
a	O
cytogenetic	O
complete	O
remission.	O

In	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease,	O
low	O
plasma	O
levels	O
of	O
several	O
sphingomyelins	B
relate	O
to	O
disease	O
severity.	O

Valine,	B
alanine, creatine	B
and	O
tyrosine	B
in	O
serum	O
samples	O
were	O
decreasing	O
in	O
TC,	O
whereas	O
the	O
aqueous	O
tissue	O
extract	O
showed	O
the	O
opposite	O
trend.	O

From	O
three	O
patients	O
undergoing	O
abiraterone	B
treatment,	O
fresh	O
samples	O
were	O
collected	O
by	O
venipuncture.	O

Significant	O
metabolites	O
according	O
to	O
the	O
jack-knife	O
confidence	O
intervals	O
were:	O
LPCs	O
(14:0),	O
(16:0),	O
(16:1),	O
(18:1),	O
(18:3),	O
(20:4),	O
(20:3);	O
phospchocholines:	B
(30:1),	O
(32:1),	O
(32:2),	O
(34:2),	O
(34:4),	O
(O-34:3)	O
and	O
sphingomyelins:	B
(33:1),	O
(32:1),	O
(38:1),	O
(39:1).	O

Free	O
and	O
conjugated	O
morphine	B
can	O
be	O
found	O
together	O
in	O
the	O
blood	O
and	O
urine	O
and	O
if	O
measured	O
together	O
it	O
is	O
referred	O
to	O
as	O
total	O
morphine.	B

(cholest-5-ene-3β,22(R	O
)-diol,	I
C_5	B
-3β,22R-diol;	I
10	O
μm)	O
a	O
known	O
LXRα	O
ligand	O
(,	O
),	O
or	O
the	O
acidic	O
compounds	O
indicated,	O
i.e.	O
3β-hydroxycholest-5-en-26-oic	B
acid,	I
CA_5	B
-3β-ol;	I
3β,7α-dihydroxycholest-5-en-26-oic	B
acid,	I
CA_5	B
-3β,7α-diol;	I
7α,12α-dihydroxy-3-oxo-5β-cholan-24-oic	B
acid,	I
5β-BA-7α,12α-diol-3-one;	B
7α-hydroxy-3-oxocholest-4-en-26-oic	B
acid,	I
CA_4	B
-7α-ol-3-one;	I
and	O
3-oxo-5β-cholan-24-oic	B
acid,	I
5β-BA-3-one.	B

a,	O
Sarcosine	B
levels	O
in	O
prostate	O
cancer	O
related	O
tissue	O
specimens	O
(n=89).	O

Circulating	O
PC	O
species,	O
containing	O
linoleic	B
and	O
α-linolenic	B
acids,	I
were	O
markedly	O
increased	O
in	O
NAFLD	O
patients	O
with	O
hypertension,	O
compared	O
to	O
NAFLD	O
patients	O
without	O
hypertension.	O

The	O
concentrated	O
supernatant	O
was	O
reconstituted	O
in	O
2	O
mL	O
0.1	O
M	O
phosphate	B
buffer,	O
pH	O
6.0.	O

Biochemical	O
identifications	O
were	O
based	O
on	O
(1)	O
retention	O
index	O
within	O
a	O
narrow	O
RI	B
window	O
of	O
the	O
proposed	O
identification,	O
(2)	O
accurate	O
mass	O
match	O
to	O
the	O
library	O
+/−	O
0.005	O

The	O
chemical	O
shifts	O
identified	O
(δ	O
4.38	O
(m)	O
and	O
δ	O
3.10	O
(m),	O
with	O
probability	O
>0.99)	O
indeed	O
come	O
from	O
the	O
same	O
metabolite;	O
however,	O
δ	O
3.30	O
(m)	O
was	O
not	O
observed	O
as	O
its	O
signals	O
are	O
heavily	O
overlapped	O
with	O
other	O
multiplets	O
(such	O
as	O
methylhistidines)	B
in	O
the	O
same	O
region.	O

Due	O
to	O
its	O
rather	O
low	O
concentration,	O
a	O
direct	O
confirmation	O
of	O
resulting	O
lowering	O
of	O
acetylcholine	B
in	O
CSF	O
could	O
be	O
demonstrated	O
only	O
in	O
the	O
mid-90s	O
.	O

Sample	O
preparation	O
involved	O
a	O
liquid-liquid	O
extraction	O
by	O
the	O
addition	O
of	O
0.25	O
ml	O
of	O
plasma	O
with	O
10μl	O
of	O
1M	O
NaOH	O
and	O
1.0	O
ml	O
ethyl	B
acetate	I
containing	O
50	O
ng/ml	O
of	O
the	O
internal	O
standard	O
zileuton.	O

Thus,	O
those	O
results	O
suggested	O
the	O
positive	O
associations	O
between	O
adipic	B
acid	I
and	O
L-leucine	B
might	O
contribute	O
to	O
the	O
inflammation	O
process	O
of	O
IBS.	O

The	O
serum	O
chiral	O
amino	O
acid	O
proportion,	O
creatinine;	B
total	O
cholesterol;	B
HDL-cholesterol;	B
triglyceride;	B
albumin;	O
white	O
blood	O
cell;	O
red	O
blood	O
cell;	O
haemoglobin;	O
haematocrit;	O
platelet;	O
mean	O
corpuscular	O
volume;	O
mean	O
corpuscular	O
haemoglobin;	O
mean	O
corpuscular	O
haemoglobin	O
concentration,	O
and	O
HbA1c	O
were	O
measured.	O

Glial	O
abnormalities	O
are	O
found	O
in	O
both	O
MS	O
and	O
NMOSD	O
while	O
astrocytes	O
are	O
especially	O
damaged	O
in	O
NMOSD,	O
which	O
may	O
be	O
linked	O
to	O
our	O
finding	O
of	O
altered	O
lactate	B
only	O
in	O
NMOSD	O
patients.	O

Factor	O
analysis	O
that	O
deliberately	O
excluded	O
primary	O
ketones,	B
urea	B
and	O
creatinine	B
from	O
analysis	O
still	O
identified	O
isopropanol	B
and	O
methanol,	B
both	O
downstream	O
metabolites	O
of	O
ketones,	B
as	O
discriminators	O
of	O
rabies.	O

Working	O
standard	O
solutions	O
of	O
mixed	O
estrogens	O
and	O
working	O
standard	O
solutions	O
of	O
internal	O
standards	O
(1	O
ng/mL)	O
were	O
prepared	O
by	O
dilutions	O
of	O
the	O
stock	O
solutions	O
with	O
methanol	B
containing	O
0.1%	O
(w/v)	O
L-ascorbic	B
acid.	I

Using	O
an	O
agnostic	O
metabolomics	O
approach	O
to	O
investigate	O
serum	O
biomarkers,	O
we	O
found	O
no	O
overall	O
association	O
between	O
serum	O
metabolites	O
and	O
colorectal	O
cancer;	O
although	O
a	O
suggestive	O
inverse	O
association	O
was	O
evident	O
for	O
serum	O
leucyl-leucine	B
and	O
colorectal	O
cancer	O
in	O
analyses	O
combining	O
both	O
genders	O
and	O
among	O
each	O
gender,	O
neither	O
reached	O
the	O
Bonferroni	O
corrected	O
level	O
of	O
statistical	O
significance.	O

This	O
raises	O
the	O
intriguing	O
possibility	O
of	O
whether	O
low	O
levels	O
of	O
oleic	B
acid	I
in	O
colorectal	O
tumors	O
may	O
bear	O
a	O
pathophysiological	O
consequence	O
and/or	O
constitute	O
a	O
metabolic	O
hallmark	O
of	O
the	O
disease.	O

_1	O
H	O
nuclear	O
magnetic	O
resonance	O
(NMR)	O
data	O
of	O
colorectal	O
cancer	O
(CRC)	O
biomarker	O
pool	O
(sample	O
A)	O
and	O
their	O
methyl	B
esters	I
*NMR	O
solvent	O
is	O
CDCl_3	O
,	O
signals	O
assigned	O
using	O
2D	O
NMR	O
experiments	O
(HMQC	O
and	O
HMBC)	O

It	O
is	O
conceivable	O
that	O
the	O
catechol	B
conjugates	O
are	O
poor	O
substrates	O
for	O
typical	O
β-glucuronidase/sulfates	O
enzymes	O
that	O
are	O
used	O
and	O
so	O
the	O
true	O
levels	O
could	O
be	O
higher.	O

Then	O
self-reported	O
questionnaire	O
data	O
on	O
current	O
analgesic	O
use	O
(yes/no)	O
for	O
all	O
17	O
INTERMAP	O
Western	O
population	O
samples	O
were	O
compared	O
with	O
the	O
presence/absence	O
of	O
_1	O
H	O
NMR-detected	O
urinary	O
acetaminophen	B
and	O
ibuprofen	B
metabolites	O
obtained	O
from	O
the	O
prediction	O
models,	O
by	O
country,	O
gender,	O
and	O
age	O
group.	O

Finally,	O
the	O
needle	O
and	O
the	O
needle	O
seat	O
were	O
flushed	O
with	O
the	O
initial	O
gradient	O
conditions	O
for	O
8	O
s.	O
Separations	O
were	O
performed	O
on	O
a	O
Kinetex_®	O
F5	O
column	O
(100	O
×	O
2.1	O
mm,	O
particle	O
size	O
1.7	O
µm)	O
from	O
Phenomenex	O
(Torrance,	O
CA,	O
USA)	O
with	O
a	O
flow	O
rate	O
of	O
0.4	O
mL	O
min_−1	O
and	O
an	O
injection	O
volume	O
of	O
2	O
µL.	O
H_2	O
O	O
+	O
0.1%	O
HCOOH	O
(A)	O
and	O
ACN:IPA	O
(2:1,	I
v	I
/v	I
)	I

[10μl	O
of	O
1mg/ml	O
debrisoquine	B
and	O
50μl	O
of	O
1mg/ml	O

gruberi	O
trophozoites,	O
whereas	O
4-monomethylsterols,	B
4,4-dimethyl	O
intermediates	O
and	O
14α-methylsterols	B
are	O
sparsely	O
represented.	O

Identification	O
of	O
hydroxybisoxocholestenoic	B
and	O
dihydroxyoxocholestenoic	B
acids.	I

The	O
average	O
duration	B
of	O
illness	O
was	O
21	O
(±3.0)	O
y	O
for	O
men	O
and	O
17	O
(±2.3)	O
y	O
for	O
women.	O

Finally,	O
in	O
contrast	O
to	O
the	O
AA	O
canonical	O
eicosanoid	B
cascade,	O
leading	O
to	O
the	O
metabolites	O
discussed	O
above,	O
data	O
from	O
the	O
parallel	O
pathway	O
starting	O
with	O
eicosapentaenoic	B
acid	I
(EPA;	O
20:5n-3)	O
was	O
also	O
collected	O
(Supplemental	O
Fig.	O
11C).	O

Analyses	O
by	O
classes	O
of	O
metabolite	O
for	O
model	O
1	O
revealed	O
that	O
nearly	O
all	O
variables	O
assigned	O
to	O
drug	O
derivative	O
(100%),	O
proteins	O
(98.7%),	O
and	O
carbohydrates	O
(92.1%)	O
were	O
associated	O
with	O
glucose	B
in	O
NOESY.	O

Their	O
positive	O
independent	O
correlations	O
with	O
CHD	O
were	O
further	O
quantified	O
using	O
a	O
logistic	O
regression	O
model:	O
palmitic	B
acid	I
(odds	O
ratio	O
[OR]:	O
7.24;	O
95%	O
CI:	O
(2.39,	O
21.912);	O

The	O
presented	O
method	O
can	O
be	O
used	O
to	O
increase	O
our	O
understanding	O
of	O
exposure	O
to	O
neonicotinoid	B
insecticides	O
and	O
DEET,	O
and	O
to	O
evaluate	O
the	O
potential	O
health	O
effects	O
from	O
such	O
exposures.	O

In	O
a	O
first	O
step	O
a	O
metabolite	O
heat	O
map	O
was	O
generated	O
solely	O
based	O
on	O
the	O
metabolite	O
ion	O
masses	O
of	O
the	O
pathways	O
of	O
α-linolenic	B
acid,	I
linoleic	B
acid,	I
arachidonic	B
acid,	I
and	O
biosynthesis	O
of	O
unsaturated	O
fatty	O
acids.	O

The	O
spectra	O
obtained	O
by	O
GC-MS	O
analysis,	O
indicated	O
a	O
decreased	O
presence	O
of	O
sugars	O
and	O
sorbitol	B
and	O
an	O
increased	O
concentration	O
of	O
glycerate	B
and	O
glutarate	B
in	O
the	O
dcSSc	O
samples	O
compared	O
to	O
lcSSc.	O

A	O
first	O
PCA	O
analysis	O
blindly	O
performed	O
on	O
all	O
samples	O
identified	O
five	O
outliers:	O
one	O
patient	O
had	O
very	O
high	O
lactate	B
plasma	O
level	O
probably	O
due	O
to	O
inadequate	O
blood	O
collection	O
or	O
manipulation,	O
two	O
presented	O
high	O
ethanol	B
levels	O
and	O
two	O
patients	O
showed	O
high	O
glucose	B
levels	O
due	O
to	O
non	O
insulin	O
dependent	O
diabetes.	O

In	O
the	O
study	O
reported	O
here,	O
we	O
have	O
solved	O
this	O
problem	O
by	O
analyzing	O
for	O
naturally	O
occurring	O
total	O
[_13	O
C]cotinine,	O
thus	O
developing	O
what	O
is	O
apparently	O
the	O
first	O
combined	O
method	O
for	O
analysis	O
of	O
total	O
NNAL	O
and	O
total	O
cotinine	B
in	O
urine.	O

There	O
are	O
strong	O
correlations	O
between	O
the	O
levels	O
of	O
C14:0,	B
C18:1,	B
and	O
C18:0	B
HexCer	O
(R_2	O
=	O
0.8461,	O
0.8988,	O
and	O
0.9373	O
respectively,	O
).	O

Metabolites	O
derived	O
from	O
both	O
sets	O
were	O
then	O
reconstituted	O
in	O
0.1%	O
formic	O
acid/50%	O
methanol	B
and	O
subjected	O
to	O
a	O
static	O
nanoelectrospray	O
ionization	O
coupled	O
to	O
an	O
LTQ	O
orbitrap	O
XL	O
hybrid	O
fourier	O
transform	O
mass	O
spectrometer	O
(FTMS).	O

[,	O
,	O
],	O
xanthine	B
(p	O
=	O
5.2E-03)	O

Amino	O
acids	O
were	O
mixed	O
at	O
a	O
concentration	O
of	O
2.5	O
µmol/mL	O
in	O
0.1	O
M	O
HCl	O
except	O
L-cystine	B
at	O
1.25	O
µmol/mL.	O
The	O
fatty	O
acids	O
and	O
organic	O
acids	O
were	O
prepared	O
by	O
mixing	O
the	O
0.5	O
mg/mL	O
fatty	O
acid	O
standards	O
and	O
0.5	O
mg/mL	O
organic	O
acid	O
standards	O
in	O
pyridine,	B
respectively.	O

Mobile	O
phase	O
additives	O
ammonium	B
formate,	I
ammonium	B
acetate	I
and	O
formic	B
acid	I
(99.9%	O
or	O
LC-MS	O
purity)	O
were	O
also	O
from	O
Fluka	O
or	O
Sigma-Aldrich.	O

Moreover,	O
the	O
identification	O
of	O
b-	O
and	O
y-series	O
ions	O
of	O
vasopressin	B
was	O
possible	O
using	O
MALDI	O
time-of-flight/time-of-flight	O
mass	O
spectrometry	O
(MALDI	O
TOF/TOF).	O

In	O
these	O
experiments,	O
paracetamol-β-d-glucuronide	B
was	O
added	O
as	O
an	O
internal	O
standard	O
for	O
the	O
control	O
of	O
the	O
deglucuronidation	O
and	O
p	B
-nitrocatechol	I
sulfate	I
for	O
the	O
control	O
of	O
the	O
desulfatation,	O
respectively.	O

Although	O
our	O
data	O
were	O
preliminary,	O
the	O
circadian	O
variation	O
of	O
cortisol	B
secretion	O
may	O
be	O
conserved	O
in	O
patients	O
with	O
AN	O
in	O
childhood	O
and	O
adolescence	O
after	O
recovery	O
of	O
body	O
weight	O
by	O
treatment.	O

Overview	O
of	O
tested	O
metabolite	O
extraction	O
protocols	O
from	O
plasma	O
A–G,	O
summarizing	O
the	O
composition	O
of	O
the	O
extraction	O
fluid	O
(EF),	O
the	O
required	O
volume,	O
the	O
duration	B
of	O
centrifugation,	O
and	O
the	O
transferred	O
volume	O
into	O
the	O
GC	O
vial.	O

Although	O
reference	O
intervals	O
for	O
commonly	O
measured	O
steroids,	O
such	O
as	O
cortisol	B
and	O
testosterone,	B
are	O
well	O
established	O
for	O
both	O
immunoassays	O
and	O
LC-MS/MS	O
measurements,	O
for	O
most	O
of	O
the	O
other	O
steroids	O
reference	O
intervals	O
are	O
mainly	O
derived	O
from	O
immunoassays	O
or	O
are	O
not	O
well	O
described	O
by	O
any	O
method.	O

Classification	O
of	O
significant	O
metabolites	O
(p < 0.001)	O
based	O
on	O
chemical	O
taxonomy	O
showed	O
that	O
lipids	O
and	O
lipid-derived	O
molecules	O
(38%)	O
formed	O
the	O
major	O
constituents	O
of	O
the	O
altered	O
metabolomic	O
profile	O
followed	O
by	O
organic	O
acids,	O
organo	O
heterocyclic	B
compounds,	O
benzenoids,	B
nucleotides	O
and	O
phytochemical	O
compounds	O
(Fig. ).	O

Since	O
resting	O
urinary	O
hypoxanthine	B
concentration	O
in	O
the	O
EG	O
was	O
still	O
lower	O
at	O
V3	O
than	O
pre-training	O
and	O
not	O
significantly	O
different	O
from	O
V2	O
(see	O
and	O
b),	O
the	O
possibility	O
exists	O
that	O
the	O
performed	O
training	O
induced	O
an	O
increase	O
in	O
purine	B
salvage	O
efficiency,	O
however	O
it	O
is	O
still	O
unclear	O
in	O
which	O
tissues	O
this	O
adaptation	O
occurred.	O

Analysis	O
of	O
the	O
metabolite	O
changes	O
that	O
correlated	O
with	O
LDL-C	O
response	O
in	O
the	O
full	O
range	O
group	O
identified	O
urea	B
cycle	O
intermediates	O
and	O
a	O
group	O
of	O
dibasic	O
amino	O
acids	O
related	O
by	O
shared	O
transporters.	O

Given	O
the	O
association	O
between	O
faster	O
nicotine	B
metabolism	O
and	O
greater	O
smoking	O
and	O
lung	O
cancer	O
risk,	O
these	O
findings	O
suggest	O
that	O
CYP2A6	O
may	O
contribute	O
to	O
an	O
elevated	O
risk	O
for	O
smoking	O
and	O
tobacco-related	O
disease	O
in	O
the	O
NP	O
compared	O
to	O
the	O
SW,	O
and	O
compared	O
to	O
other	O
ethnic	O
populations	O
in	O
the	O
United	O
States.	O

Comparing	O
the	O
combined	O
group	O
of	O
CD	O
patients	O
with	O
active	O
disease	O
and	O
remission	O
to	O
UC	O
patients	O
in	O
the	O
active	O
and	O
remission	O
phase	O
of	O
the	O
disease	O
we	O
found	O
a	O
significantly	O
increased	O
serum	O
concentration	O
of	O
alanine	B
and	O
N	O
-acetylated	O
compounds.	O

It	O
also	O
identified	O
triglycerides,	B
glycoproteins,	B
and	O
acetone	B
as	O
important	O
sources	O
of	O
energy.	O

An	O
increased	O
level	O
of	O
methionine	B
in	O
urine	O
is	O
clearly	O
seen	O
from	O
the	O
2D	O
HSQC	O
spectrum	O
of	O
derivatized	O
urine	O
of	O
HCY.	O

The	O
alteration	O
in	O
aldehydes	O
(e.g.	O
2-methylundecanal)	B
profiling	O
is	O
common	O
in	O
urine	O
of	O
PCa	O
patients	O
and	O
in	O
cancer	O
cell	O
lines	O
from	O
colon	O
and	O
lung.	O

The	O
sum	O
of	O
albumin-bound	O
and	O
free	O
25OHD	O
is	O
termed	O
“bioavailable	O
vitamin	O
D”,	O
while	O
the	O
sum	O
of	O
free,	O
albumin-bound	O
and	O
VDPB-bound	O
vitamin	B
D	I
fractions	O
is	O
known	O
as	O
“total	O
vitamin	O
D”.	O

The	O
target	O
analytes	O
were	O
eluted	O
with	O
methanol	B
(350	O
μL),	O
and	O
focused	O
on	O
a	O
Chromolith	O
HighResolution	O
RP-18	O
endcapped	O
guard	O
column	O
(5×4.6	O
mm,	O
Merck	O
KGaA,	O
Darmstadt,	O
Germany)	O
with	O
the	O
initial	O
HPLC	O
gradient.	O

The	O
major	O
component	O
(t	O
_ret	O
3.8 min)	O
was	O
purified	O
by	O
exhaustive	O
washing	O
with	O
hexane/ethyl	O
acetate	B
until	O
reaching	O
a	O
purity	O
of	O
98%	O
(Fig. )	O
and	O
this	O
was	O
characterized	O
by	O
NMR,	O
HRMS	O
and	O
IR.	O

The	O
biological	O
significance	O
of	O
this	O
change	O
in	O
glucose	B
without	O
corresponding	O
changes	O
in	O
glucose	B
metabolites	O
is	O
not	O
clear.	O

o	B
-Phenylenediamine	I
can	O
be	O
used	O
in	O
combination	O
with	O
MTBSTFA	O
and	O
undergoes	O
an	O
additional	O
reaction	O
with	O
oxalate.	B

Low	O
selectivity	O
was	O
observed	O
for	O
isobaric	O
sugars	O
such	O
as	O
hexoses	O
and	O
slightly	O
higher	O
selectivity	O
for	O
homologues	O
(pent-	O
vs.	I
hexoses).	O

Chemical	O
shifts	O
of	O
CPMG	O
spectra	O
were	O
referenced	O
to	O
the	O
left	O
peak	O
of	O
the	O
alanine	B
doublet	O
at	O
1.47	O
ppm.	O

Norepinephrine	B
and	O
Choline	B
are	O
precursors	O
for	O
Acetylcholine.	B

Oxalate	B
has	O
also	O
been	O
reported	O
to	O
be	O
augmented	O
in	O
recurrent	O
patients	O
when	O
compared	O
with	O
non-recurrent	O
patients.	O

The	O
contribution	O
of	O
selected	O
serum	O
inflammation	O
biomarker	O
and	O
cytokine	O
concentrations	O
as	O
independent	O
predictors	O
of	O
tryptophan,	B
its	O
metabolites,	O
and	O
pyridoxal	B
5′-phosphate	I
in	O
a	O
subset	O
of	O
healthy	O
young	O
adults	O
from	O
the	O
TSS_1	O

To	O
minimize	O
the	O
effects	O
of	O
the	O
endocannabinoids	B
potentially	O
present	O
in	O
normal	O
FBS,	O
we	O
cultivated	O
the	O
cells	O
in	O
RPMI	O
media	O
supplemented	O
with	O
charcoal/dextran-treated	O
FBS	O
(CFBS)	O
for	O
24	O
hours	O
before	O
and	O
after	O
treatment.	O

Phase	O
correction	O
and	O
baseline	O
correction	O
were	O
carefully	O
performed,	O
and	O
the	O
_1	O
H	O
chemical	O
shifts	O
referred	O
to	O
the	O
methyl	O
doublet	O
signal	O
of	O
lactate	B
(δ	O
1.33).	O

The	O
urine	O
sample	O
extracted	O
from	O
the	O
cotton	O
wool	O
after	O
squeezing	O
had	O
a	O
much	O
higher	O
concentration	O
of	O
acetone,	B
tert	B
-butanol,	I
and	O
isobutyl	B
alcohol	I
than	O
the	O
urine	O
obtained	O
via	O
centrifugation,	O
suggesting	O
that	O
manual	O
squeezing	O
of	O
cotton	O
wool	O
results	O
in	O
greater	O
destruction	O
of	O
the	O
cotton	O
wool	O
fibers	O
and	O
therefore	O
greater	O
release	O
of	O
contaminants	O
into	O
the	O
urine	O
sample.	O

The	O
regression	O
analysis	O
according	O
to	O
a	O
pseudo-first-order	O
kinetics	O
model	O
resulted	O
in	O
t	O
_1/2	O
<	O
1	O
min	O
for	O
25(OH)D_3	O
and	O
t	O
_1/2	O
~8	O
min	O
for	O
1α,25(OH)_2	B
D_3	O
.	O

The	O
estimates	O
for	O
cholesterol	B
concentrations	O
within	O
individual	O
lipoprotein	O
subclasses	O
were	O
very	O
similar	O
to	O
those	O
of	O
the	O
corresponding	O
lipoprotein	O
particle	O
concentrations.	O

Initial	O
samples	O
for	O
each	O
batch	O
were	O
shimmed	O
to	O
ensure	O
half-height	O
line	O
width	O
of	O
<1.1	O
Hz	O
for	O
the	O
dimethyl-silapentane-sulfonate	B
peak,	O
calibrated	O
to	O
0.0	O
ppm.	O

PC	B
aa	I
C40:2;	I
93.	O

For	O
estrogens,	O
estrogen	B
metabolites,	O
metabolic	O
pathway	O
groups,	O
and	O
metabolic	O
pathway	O
ratios,	O
the	O
statistical	O
significance	O
of	O
trends	O
in	O
risk	O
was	O
assessed	O
using	O
P	O
values	O
associated	O
with	O
the	O
log-transformed	O
continuous	O
measures.	O

Ceramides	B
are	O
associated	O
with	O
lipoprotein	O
aggregation,	O
inflammation,	O
reactive	O
oxygen	O
species	O
production	O
and	O
apoptosis,	O
and	O
seem	O
to	O
be	O
an	O
intermediate	O
link	O
between	O
over-nutrition	O
and	O
some	O
abnormalities	O
related	O
to	O
CV	O
risk	O
such	O
as	O
insulin	O
resistance	O
and	O
metabolic	O
syndrome.	O

In	O
the	O
positive	O
ion	O
mode	O
TOF	O
MS	O
analysis	O
we	O
identified	O
the	O
ceramide	B
species	O
at	O
m/z	O
552.5346.	O

Free	O
putrescine	B
might	O
be	O
present,	O
but	O
even	O
in	O
_1	O
H-_13	O
C	O
HSQC	O
the	O
peak	O
positions	O
are	O
almost	O
identical	O
to	O
those	O
of	O
spermidine	B
so	O
that	O
it	O
could	O
not	O
be	O
separately	O
observed.	O

Thus,	O
tryptophan	B
depletion	O
and	O
kynurenine	B
accumulation	O
cooperate	O
to	O
mediate	O
immunosuppression	O
in	O
tumors.	O

The	O
linear	O
regression	O
equation	O
for	O
acetamiprid	B
is	O
y	O
=	O
1.8636x	O
+	O
0.1263	O
(R_2	O
=	O
0.9995),	O
and	O
y	O
=	O
0.4887x	O
+	O
0.1996	O
(R_2	O
=	O
0.9946)	O
for	O
AM-2.	O

Data	O
on	O
vitamin	B
D	I
supplement	O
use	O
were	O
not	O
available.	O

Taking	O
the	O
diagnostic	O
criteria	O
of	O
the	O
Framingham	O
Heart	O
Study	O
(FHS)	O
as	O
the	O
benchmark,	O
receiver	O
operating	O
curves	O
(ROCs)	O
of	O
acetone,	B
3-hydroxybutyrate,	B
succinate	B
and	O
BNP	O
for	O
diagnosis	O
of	O
HF	O
were	O
compared.	O

In	O
the	O
male-only	O
validation	O
analysis	O
phytosphingosine	B
was	O
not	O
significant,	O
likely	O
owing	O
to	O
the	O
reduction	O
in	O
sample	O
size.	O

It	O
has	O
been	O
suggested	O
that	O
less	O
efficient	O
benzoate	B
conjugation	O
and	O
lower	O
urinary	O
hippurate	B
excretion	O
levels	O
may	O
result	O
from	O
reduced	O
hepatic	O
function	O
in	O
patients	O
with	O
HCC[].	O

Trigonelline	B
is	O
a	O
coffee	O
alkaloid,	O
and	O
has	O
previously	O
been	O
associated	O
with	O
pancreatic	O
cancer.	O

The	O
sensitivity,	O
specificity	O
and	O
AUC	O
values	O
for	O
C18:2	B
CE	O
were	O
62.5,	O
78.6	O
and	O
77.7%,	O
respectively,	O
and	O
for	O
SM	O
22:0	O
were	O
93.8,	O
89.3	O
and	O
91.5%,	O
respectively.	O

In	O
agreement	O
with	O
the	O
literature,	O
our	O
finding	O
revealed	O
that	O
TG,	B
PC,	O
and	O
SM	O
are	O
predominant	O
lipids	O
in	O
human	O
serum,	O
with	O
TG	B
comprising	O
over	O
50%	O
of	O
lipids	O
having	O
more	O
than	O
52	O
fatty	O
acyl	O
carbon	O
atoms	O
[,	O
].	O

In	O
addition,	O
a	O
large	O
fraction	O
of	O
the	O
plasma	O
_13	O
C-lactate	B
was	O
uniformly	O
labeled	O
in	O
_13	O
C,	O
as	O
evidenced	O
by	O
the	O
fine	O
splitting	O
structure	O
of	O
the	O
_13	O
C	O
satellites	O
of	O
the	O
3-methyl	O
protons	O
of	O
lactate	B
(Figures	O
and	O
)	O

 ),	O
suggesting	O
a	O
possible	O
reservoir	O
for	O
Methylobacterium	B
extorquens	O
toxic	O
activity	O
within	O
the	O
peripheral	O
blood.	O

a	O
shows	O
a	O
chromatogram	O
of	O
_15	O
N-ethanolamine	B
derivatized	O
urine	O
separated	O
on	O
a	O
TSKgel	O
Amide-18	B
HILIC	O
column.	O

L-alanine	B
shows	O
a	O
diminishing	O
effect	O
on	O
release	O
of	O
nor-epinephrine	O
from	O
cardiac	O
sympathetic	O
nerves	O
in	O
animal	O
models,	O
resulting	O
in	O
blood	O
pressure	O
elevation.	O

The	O
furan-derived	O
precursors	O
of	O
N	B
-(2-furoyl)glycine	I
and	O
cyclo(leu-pro)	B
are	O
probable	O
byproducts	O
of	O
coffee	O
roasting	O
(,	O
).	O

 ),	O
the	O
harmful	O
trimethylamine	B
had	O
a	O
strong	O
positive	O
correlation	O
with	O
the	O
portal	O
blood	O
proinflammatory	O
cytokines	O
IL6,	O
TNFα	O
and	O
IL1β	B
(r	I
_mean	O
 = 0.92/	O

Creatinine	B
was	O
quantified	O
using	O
a	O
Roche/Hitachi	O
Model	O
912	O
clinical	O
analyzer	O
(Dallas,	O
TX,	O
USA)	O
and	O
the	O
Creatinine	B
Plus	O
Assay.	O

Two	O
metabolites,	O
melatonin	B
and	O
5-Hydroxytryptophan,	B
which	O
are	O
involved	O
in	O
the	O
melatonin	B
biosynthesis	O
were	O
also	O
found	O
to	O
be	O
down-regulated	O
in	O
post-H.	O
pylori	O
eradication	O
groups.	O

We	O
did	O
not	O
directly	O
measure	O
choline	B
kinase	O
activity	O
in	O
this	O
study,	O
but	O
we	O
could	O
assume	O
that	O
the	O
increased	O
phosphatidylcholine	B
in	O
the	O
CSF	O
of	O
patients	O
with	O
LMC	O
results	O
from	O
increased	O
cell	O
membrane	O
turn-over	O
as	O
cancer	O
cells	O
proliferating	O
in	O
the	O
CSF	O
of	O
patients.	O

Interestingly,	O
some	O
of	O
these	O
typical	O
canonical	O
gut	O
microbial	O
derived	O
metabolites	O
(acetate,	O
TMAO,	B
and	O
3-indoxyl	B
sulfate)	I
were	O
significantly	O
affected	O
by	O
sleep	O
deprivation.	O

(A)	O
Results	O
of	O
linearity	O
study	O
(n	O
=	O
13),	O
(B)	O
Deming	O
regression	O
comparison	O
between	O
LC-MS/MS	O
and	O
NMR	O
measured	O
betaine	B
in	O
serum	O
samples	O
(n	O
=	O
24),	O
(C)	O

Subsequent	O
studies	O
by	O
Wang	O
et	O
al.	O
which	O
established	O
that	O
BRB	O
anthocyanins	B
prevent	O
esophageal	O
tumors	O
in	O
rats,	O
confirmed	O
the	O
in	O
vivo	O
applicability	O
of	O
Hecht	O
et	O
al.'s	O
in	O
vitro	O
bioassay	O
results.	O

However,	O
these	O
detection	O
limits	O
were	O
achieved	O
by	O
using	O
a	O
mobile	O
phase	O
consisting	O
of	O
25	O
mM	O
potassium	B
dihydrogen	I
phosphate,	I
0.4	O
mM	O
heptanesulfonic	B
acid,	I
and	O
50	O
mM	O
EDTA	O
and	O
adjusted	O
to	O
pH	O
2.5	O
with	O
85%	O
phosphoric	B
acid,	I
conditions	O
not	O
compatible	O
with	O
MS	O
even	O
while	O
operating	O
in	O
nanoelectrospray	O
mode.	O

Of	O
note,	O
HDL	O
and	O
Apo-A1	O
may	O
facilitate	O
monocyte	O
cholesterol	B
efflux	O
and	O
thereby	O
decrease	O
cholesterol	B
lipid	O
rafts.	O

On	O
the	O
contrary,	O
less	O
lactate	B
accumulated	O
in	O
supernatants	O
of	O
16HBE14o-	O
cells	O
during	O
rHla	O
treatment	O
with	O
levels	O
approximately	O
1.0	O
mmol/l	O
below	O
the	O
control	O
culture	O
after	O
120	O
min.	O

A	O
simple	O
and	O
sensitive	O
method	O
to	O
quantify	O
imatinib	B
and	O
its	O
metabolite	O
(CGP74588)	O
in	O
human	O
serum	O
was	O
developed	O
and	O
fully	O
validated	O
in	O
order	O
to	O
monitor	O
treatment	O
compliance.	O

Although	O
43	O
of	O
the	O
148	O
subjects	O
in	O
our	O
analysis	O
were	O
African-American,	O
we	O
did	O
not	O
observe	O
an	O
increase	O
in	O
ketone	B
bodies	O
in	O
relation	O
to	O
increased	O
glucose	B
levels.	O

There	O
is	O
also	O
evidence	O
that	O
hypertriglyceridemia	O
with	O
low	O
HDL-cholesterol	B
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
developing	O
mild	O
cognitive	O
impairment	O
(,	O
).	O

Thiazide	B
diuretics	O
have	O
been	O
the	O
mainstay	O
anti-HTN	O
therapy	O
for	O
decades	O
and	O
are	O
still	O
ranked	O
among	O
the	O
most	O
commonly	O
prescribed	O
medications	O
worldwide.	O

LOQ	O
data	O
(except	O
for	O
24,25-(OH)_2	B
D_3	O
)	O
are	O
shown	O
in	O
Table .	O

Indeed,	O
the	O
levels	O
of	O
Alb	O
adducts	O
formed	O
with	O
the	O
liver	O
carcinogen	O
AFB	O
and	O
carcinogenic	O
heterocyclic	B
aromatic	O
amines	O
(HAA)	O
are	O
far	O
greater	O
than	O
the	O
levels	O
of	O
adducts	O
formed	O
with	O
Hb,	O
a	O
fact	O
making	O
Alb	O
adducts	O
superior	O
biomarkers,	O
at	O
least	O
for	O
these	O
carcinogens._−	O
Many	O
studies	O
have	O
characterized	O
Alb	O
adducts	O
formed	O
in	O
vitro	O
with	O
environmental,	O
dietary,	O
and	O
tobacco	O
genotoxicants,	O
lipid	O
peroxide	B
products,	O
drug	O
medications,	O
and	O
pesticides,	O
among	O
others._,	O
However,	O
reports	O
on	O
other	O
Alb	O
adduct	O
studies	O
in	O
humans	O
are	O
relatively	O
few.	O

After	O
24	O
h,	O
cells	O
were	O
quickly	O
washed	O
with	O
1×PBS	O
and	O
fixed	O
with	O
a	O
pre-cooling	O
methanol	B
(HPLC-MS	O
grade,	O
Millipore)	O
for	O
30	O
min	O
at	O
-80°C.	O

They	O
found	O
that	O
the	O
plasma	O
cortisol	B
level	O
of	O
a	O
normal	O
person	O
was	O
decreased	O
throughout	O
the	O
day.	O

Elevation	O
of	O
the	O
level	O
of	O
myo-inositol	B
in	O
the	O
pure	O
DCIS	O
group	O
was	O
possibly	O
associated	O
with	O
the	O
chemopreventive	O
effect	O
of	O
myo-inositol.	B

HPHPA,	O
3HPA,	O
and	O
3HHA	O
were	O
completely	O
eliminated	O
in	O
35/50,	O
6/9,	O
and	O
12/17	O
cases	O
after	O
vancomycin	B
treatment,	O
respectively.	O

The	O
lower	O
limit	O
of	O
quantifications	O
were	O
0.02	O
and	O
0.08	O
μg/ml	O
for	O
Cer(22:0)	B
and	O
Cer(24:0),	B
respectively.	O

PCA	O
yielded	O
a	O
model	O
(Table S1	O
M1)	O
with	O
six	O
principal	O
components	O
(PCs),	O
in	O
which	O
samples	O
clustered	O
per	O
the	O
buffer	O
solution	O
used	O
(PC1/PC2;	O
A–2C),	O
with	O
higher	O
glucose	B
levels	O
in	O
samples	O
prepared	O
in	O
HBSS.	O

Levels	O
of	O
HDL	O
(δ0.85,	O
1.25,	O
1.26),	O
lactate	B
(δ1.32,	O
1.33,	O
4.1,	O
4.11),	O
PtdCho	O
(δ3.22),	O
Acetoacetate	B
(δ2.22)	O
and	O
LDL/VLDL	O
(δ1.29,	O
0.91)	O
were	O
higher	O
in	O
the	O
plasma	O
of	O
FD	B
patients.	O

HPLC	O
purifications	O
were	O
carried	O
out	O
on	O
a	O
10	O
×	O
250	O
mm	O
Phenomenex	O
Luna	O
5µ	B
C18	I
(2)	O
column	O
with	O
Waters	O
Delta	O
Prep	O
system	O
consisting	O
of	O
a	O
PDA	O
996	O
detector.	O

Peculiar	O
is	O
the	O
behavior	O
of	O
creatinine:	B
in	O
survivor-specific	O
network,	O
creatinine	B
shows	O
four	O
connections	O
with	O
mannose,	B
methionine,	B
leucine	B
and	O
isoleucine,	B
whereas	O
creatinine	B
in	O
deceased	O
patient-specific	O
network	O
is	O
completely	O
disconnected;	O
previous	O
studies	O
have	O
demonstrated	O
the	O
association	O
between	O
compromised	O
myocardial	O
flow	O
and	O
negative	O
prognosis	O
for	O
1	O
year	O
survival	O
and	O
a	O
high	O
level	O
of	O
creatinine	B
in	O
patients._,	O
Correlation	O
between	O
creatinine	B
and	O
mannose	B
has	O
been	O
previously	O
observed,	O
suggesting	O
an	O
association	O
between	O
insulin	O
resistance	O
and	O
diabetic	O
kidney	O
disease,	O
which	O
is	O
a	O
well-established	O
risk	O
factor	O
for	O
CVD	O
as	O
well	O
as	O
for	O
overt	O
diabetic	O
kidney	O
disease.	O

Of	O
the	O
indicated	O
pathways	O
just	O
2	O
(Polyamine	O
metabolism	O
and	O
L-arginine	B
metabolism)	O
were	O
common	O
between	O
to	O
control,	O
MCI	O
and	O
MCI_AD	O
subjects.	O

Liquid	O
chromatography-tandem	O
mass	O
spectrometry	O
was	O
used	O
to	O
measure	O
TMAO	B
and	O
dietary	O
choline	B
plasma	O
concentrations.	O

While	O
regression	O
analysis	O
did	O
not	O
show	O
any	O
differences	O
between	O
ADHD	O
patients	O
with	O
or	O
without	O
anxiety/depression	O
or	O
between	O
patients	O
with	O
or	O
without	O
bipolar	O
disorder,	O
we	O
cannot	O
rule	O
out	O
the	O
possibility	O
that	O
comorbid	O
conditions	O
also	O
could	O
affect	O
tryptophan	B
catabolism.	O

There	O
are	O
earlier	O
reports	O
of	O
HVA-G,	O
DOPAC-G,	O
5-HIAA-G	B
and	O
DOPAC-S	O
in	O
tissue	O
samples	O
of	O
the	O
human	O
brain	O
,	O
and	O
DA-G,	O
5-HT-G,	B
5-HT-S	B
and	O
DA-S	O
–,	O
,	O
have	O
been	O
found	O
in	O
human	O
CSF.	O

Similarly,	O
a	O
study	O
in	O
the	O
Shanghai	O
Women’s	O
Health	O
Study	O
reported	O
that	O
vitamin	B
E	I
supplementation,	O
and	O
also	O
plasma	O
levels	O
of	O
alpha-tocopherol,	B
were	O
significantly	O
inversely	O
associated	O
with	O
F_2	O
-IsoP-M,	O
but	O
not	O
F_2	O
-IsoPs.	O

Each	O
sample	O
and	O
QC	O
supernatant	O
was	O
concentrated	O
to	O
complete	O
dryness	O
at	O
50	O
°C	O
under	O
a	O
gentle	O
stream	O
of	O
nitrogen	B
gas	I
(Turbovap	O
LV,	O
Caliper	O
Life	O
Sciences).	O

3-DF,	O
3-deoxyfructose;	B
3-DPs,	O
3-deoxypentosone;	B
3-DP,	O
3-deoxypentulose;	B
MGH1,	O
methylglyoxal-derived	O
hydroimidazolone	O
1;	O
3-DGH,	O
3-deoxyglucosone-derived	O
hydroimidazolone;	O
CML,	B
carboxymethyl	B
lysine;	I
CEL,	O
carboxyethyl	B
lysine;	I
MetSO,	O
methionine	B
sulfoxide;	I
FruLys,	O
Nε-fructosyllysine.	B

The	O
FA	B
composition	O
of	O
the	O
phospholipids	B
fraction	O
of	O
erythrocytes	O
was	O
determined	O
by	O
GC.	O

The	O
first	O
woman	O
has	O
a	O
high	O
concentration	O
of	O
urinary	O
glucose	B
and	O
was	O
identified	O
as	O
diabetic.	O

This	O
observation	O
is	O
consistent	O
with	O
the	O
results	O
published	O
recently	O
by	O
Vuono	O
et	O
al	O
.,	O
who	O
using	O
GC-MS,	O
also	O
demonstrated	O
a	O
significant	O
decrease	O
in	O
serum	O
lathosterol	B
level	O
in	O
patients	O
after	O
sleeve	O
gastrectomy.	O

m	O
m	O
m	O
β-Apo-13-carotenone	B
is	O
a	O
potent	O
antagonist	O
of	O
retinoic	B
acid	I
receptor-mediated	O
induction	O
of	O
reporter	O
gene	O
expression	O
and	O
blocks	O
ATRA	O
induction	O
of	O
endogenous	O
gene	O
expression.	O

Visual	O
inspection	O
of	O
the	O
CPMG	O
spectra	O
revealed	O
higher	O
levels	O
of	O
glucose	B
and	O
lower	O
levels	O
of	O
lactate	B
in	O
LN/SLE	O
sera	O
compared	O
to	O
HC.	O

Therefore,	O
by	O
employing	O
a	O
hypothesis-free	O
tissue-based	O
metabolomics	O
study,	O
the	O
present	O
study	O
investigated	O
the	O
metabolic	O
signatures	O
of	O
BCa	O
and	O
found	O
that	O
bilirubin	B
and	O
retinal	B
may	O
be	O
involved	O
in	O
the	O
mechanism	O
underlying	O
the	O
biomolecular	O
action	O
of	O
submucosal	O
injection	O
of	O
gemcitabine	O
in	O
urothelial	O
BCa.	O

Metformin	B
hydrochloride	I
salt	O
was	O
added	O
to	O
5	O
mL	O
of	O
Milli-Q	O
water	O
at	O
4°C	O
to	O
a	O
final	O
concentration	O
of	O
200	O
mM.	O
Sodium	B
hydroxide	I
was	O
added	O
to	O
the	O
solution	O
to	O
a	O
final	O
concentration	O
of	O
200	O
mM.	O
Subsequently,	O
1.7	O
mL	O
of	O
40%	O
MG	O
solution	O
(Sigma-Aldrich)	O
was	O
added	O
to	O
the	O
metformin	B
solution	O
and	O
stirred	O
at	O
4°C	O
for	O
1	O
h	O
followed	O
by	O
4	O
h	O
at	O
20°C.	O

In	O
our	O
study,	O
which	O
includes	O
confirmation	O
of	O
DES	B
exposure	O
status	O
for	O
all	O
participants,	O
results	O
suggest	O
that	O
parent	O
estrogen	B
concentrations,	O
including	O
estradiol,	B
are	O
somewhat	O
greater	O
in	O
DES	B
exposed	O
postmenopausal	O
women.	O

In	O
normal	O
conditions	O
plasma	O
citrate	B
is	O
mostly	O
extracted	O
via	O
the	O
kidneys,	O
but	O
under	O
surgical	O
stress	O
the	O
hepatic	O
uptake	O
increases	O
and	O
leads	O
to	O
hypocitricemia.	O

Many	O
metabolites	O
which	O
were	O
lower	O
in	O
TB	O
patients	O
at	O
diagnosis	O
normalized	O
to	O
HC	O
levels	O
during	O
treatment	O
duration,	B
including	O
citrulline,	B
glutamine,	B
tryptophan,	B
histidine	B
and	O
ornithine,	B
while	O
glycylglycine	B
and	O
phenylalanine	B
were	O
decreased	O
as	O
a	O
result	O
of	O
therapy	O
after	O
previously	O
being	O
upregulated	O
in	O
TB	O
patients’	O
plasma.	O

Considering	O
each	O
urinary	O
steroid	O
metabolite	O
separately,	O
the	O
androgen	O
androstanediol	B
(5α3αdiol)	I
was	O
the	O
best	O
classifier	O
with	O
the	O
highest	O
AUC	O
in	O
the	O
ROC	O
analysis	O
(0.919,	O
95%	O
CI:	O
0.867–0.971;	O
).	O

In	O
addition	O
to	O
the	O
two	O
major	O
fragment	O
ions	O
present	O
at	O
m/z	O
169	O
and	O
m/z	O
183,	O
tandem	O
mass	O
spectra	O
of	O
AMPP-derivatized	O
saturated	O
FA	B
(18:0)	I
demonstrated	O
a	O
well-defined	O
series	O
of	O
fragment	O
ions	O
differing	O
by	O
14	O
Th.	O

In	O
addition,	O
the	O
levels	O
of	O
9	O
metabolites	O
(ornithine,	O
phenylalanine,	B
tyrosine,	B
aspartate	B
+	O
asparagine,	B
C3-carnitine,	B
C4-carnitine,	B
C8-carnitine,	B
C14-carnitine	B
and	O
C16-carnitine)	B
were	O
significantly	O
altered	O
in	O
the	O
patients	O
with	O
lung	O
cancer	O
only	O
in	O
the	O
2015	O
data	O
set.	O

Here,	O
oral	O
administration	O
of	O
limonene	B
resulted	O
in	O
significant	O
changes	O
in	O
several	O
metabolic	O
pathways.	O

FFPE	O
samples	O
showed	O
a	O
decrease	O
of	O
metabolites	O
with	O
characteristic	O
functional	O
groups,	O
such	O
as	O
secondary	O
carboxylic	B
acid	I
amide	I
(28%,	O
P	O
=	O
7.43	O
×	O
10_−12	O
;	O
FDR	O
=	O
6.42	O
×	O
10_−10	O
),	O
present	O
in	O
peptides	O
and	O
quaternary	O
ammonium	B
salts	O
(33%,	O
P	O
=	O
1.01	O
×	O
10_−3	O
;	O
FDR	O
=	O
2.30	O
×	O
10_−2	O
)	O
present	O
in	O
glycerophosphocholines	B
and	O
absent	O
in	O
glycerophosphoethanolamines.	B

The	O
fragmentation	O
analysis	O
for	O
the	O
sulfate	B
metabolites	O
was	O
observed	O
in	O
a	O
scan	O
mode	O
of	O
2–400 m/z	O
(A	O
and	O
B).	O

In	O
pregnancies	O
affected	O
by	O
fetal	O
growth	O
restriction	O
or	O
preeclampsia,	O
maternal	O
ADMA	B
concentrations	O
were	O
inversely	O
correlated	O
with	O
birth	O
weight.	O

ROC	O
curve	O
analysis	O
revealed	O
two	O
metabolites,	O
L-citrulline	B
and	O
D-aspartic	B
acid,	I
as	O
potential	O
biomarkers	O
that	O
can	O
distinguish	O
BDTT	O
from	O
other	O
bile	O
duct	O
diseases.	O

Some	O
crucial	O
pathways	O
such	O
as	O
glycerol	B
are	O
skewed.	O

This	O
is	O
supported	O
by	O
the	O
distribution	O
of	O
the	O
blood	O
levels	O
of	O
glucose,	B
which	O
is	O
right	O
skewed,	O
with	O
several	O
outlying	O
observations	O
(Figure	O
S-2A).	O

(LLC = 2.5	O
ng/mL)	O
and	O
none	O
chloroquine	B
(LLC = 2.5	O
ng/mL)	O
or	O
any	O
other	O
antimalarials	O
tested.	O

Creatine	B
may	O
be	O
degraded	O
by	O
intestinal	O
bacteria;	O
therefore,	O
it	O
is	O
conceivable	O
that	O
the	O
elevated	O
creatine	B
levels	O
may	O
even	O
result	O
from	O
reduced	O
bacterial	O
degradation	O
associated	O
with	O
microbial	O
dysbiosis.	O

Oxidative	O
stress	O
in	O
mitochondria	O
could	O
be	O
induced	O
by	O
reactive	O
oxygen	O
and	O
nitrogen	O
species	O
from	O
activated	B
microglia	O
[,	O
].	O

To	O
remove	O
the	O
effects	O
of	O
suppression	O
of	O
water	O
resonance	O
and	O
variation	O
in	O
the	O
urea	B
signal	O
caused	O
by	O
partial	O
cross-solvent	O
saturation	O
due	O
to	O
solvent-	O
exchanging,	O
proton	O
region	O
between	O
4.50	O
and	O
6.20 ppm	O
was	O
set	O
to	O
zero	O
integral	O
in	O
the	O
spectrum.	O

An	O
example	O
of	O
the	O
effect	O
of	O
normalisation	O
using	O
the	O
NIST	O
SRM	O
1950	O
(TS-06),	O
to	O
the	O
reported	O
values	O
of	O
SM	O
C24:0	B
by	O
each	O
laboratory,	O
for	O
our	O
primary	O
test	O
set	O
of	O
20	O
test	O
materials.	O

The	O
extent	O
to	O
which	O
this	O
prostaglandin	B
and	O
its	O
metabolite	O
Δ_12	O
-PGJ2	O
contribute	O
to	O
the	O
clinical	O
picture	O
in	O
certain	O
AML	O
patients	O
is	O
currently	O
unknown.	O

We	O
found	O
high	O
levels	O
of	O
concordance	O
for	O
self-reported	O
acetaminophen	B
and/or	O
ibuprofen	B
use	O
with	O
urinary	O
acetaminophen	B
and/or	O
ibuprofen	B
metabolites	O
detected	O
by	O
_1	O
H	O
NMR	O
spectroscopy.	O

No	O
statistically	O
significant	O
differences	O
between	O
males	O
and	O
females,	O
neither	O
for	O
the	O
AML	O
cases	O
nor	O
the	O
controls,	O
were	O
found	O
for	O
the	O
following	O
plasma	O
eicosanoids:	B
DHGLA	O
[20:3(8Z	O
,11Z	O
,14Z	O
)],	O
arachidonic	B
acid	I
[20:4(5Z	O
,	O
8Z	O
,11Z	O
,14Z	O
)],	O
EPA	O
[20:5(5Z	O
,	O
8Z	O
,11Z	O
,14Z	O
,17Z	O
)],	O
8,9-DHET,	B
11-dehydro-TxB2,	B
PGE2/8-isoPGE2,	B
12-HEPE,	I
11β-PGE2,	B
15-keto-PGF2α,	I
15-keto-PGE2,	B
8-iso-15-keto-PGF2α,	I
PGF1α,	B
and	O
PGF2α.	B

Abnormalities	O
of	O
urinary	O
benzoate	B
and	O
hippurate	B
may	O
reveal	O
clinically	O
significant	O
detoxification	O
or	O
dysbiosis	O
issues.	O

Dudzinska	O
et	O
al.	O
demonstrated	O
that	O
trained	O
subjects	O
had	O
a	O
significantly	O
higher	O
HGPRT	O
activity	O
in	O
erythrocytes	O
at	O
rest,	O
which	O
might	O
contribute	O
to	O
the	O
reduction	O
of	O
resting	O
plasma	O
as	O
well	O
as	O
urinary	O
hypoxanthine	B
levels	O
by	O
utilizing	O
more	O
hypoxanthine	B
for	O
IMP	B
formation.	O

As	O
expected,	O
because	O
PC	O
is	O
a	O
mitochondrial	O
enzyme	O
its	O
suppression	O
did	O
not	O
affect	O
the	O
levels	O
of	O
glycolytic	B
intermediates	O
as	O
glucose-6-phosphate,	B
fructose-6-phosphate	B
and	O
fructose	B
bisphosphate	I
were	O
not	O
altered	O
in	O
each	O
of	O
these	O
PC	O
knockdown	O
cell	O
lines.	O

Nile	O
red	O
staining	O
of	O
DMSO,	B
C75,	O
celecoxib	B
and	O
C75	O
+	O
celecoxib	B
treated	O
A.	O
SUM149PT	O
and	O
B.	O
SUM1315MO2	O
breast	O
cancer	O
cells	O
was	O
done	O
and	O
flow	O
cytometry	O
analysis	O
was	O
performed.	O

Researchers	O
who	O
observed	O
that	O
elevated	O
lithocholic	B
acid	I
levels	O
could	O
induce	O
hepatic	O
inflammation	O
in	O
cholestasis	O
also	O
uncovered	O
the	O
vascular	O
inflammatory	O
role	O
of	O
circulating	O
lithocholic	B
acid.	I

These	O
results	O
partially	O
confirm	O
previous	O
suggestions	O
of	O
a	O
7-	O
metabolite	O
urinary	O
signature	O
of	O
early	O
RCC,	O
particularly	O
regarding	O
the	O
increases	O
in	O
lactate	B
(not	O
statistically	O
relevant	O
here)	O
and	O
pyruvate	B
(here	O
with	O
p	O
-value	O
5.43 × 10_−7	O
,	O
compared	O
to	O
0.010	O
in	O
ref.	O
)	O
and	O
the	O
decrease	O
in	O
hippurate	B
(here	O
with	O
p	O
-value	O
4.60 × 10_−6	O
,	O
compared	O
to	O
0.023	O
in	O
ref.	O
).	O

Nevertheless,	O
our	O
results	O
corroborate	O
the	O
fact	O
that	O
lipids	O
of	O
various	O
classes	O
containing	O
a	O
fatty	O
acyl	O
side	O
chain	O
of	O
the	O
n-3	O
series	O
such	O
as	O
C22:6	B
and	O
C20:5	B
are	O
significantly	O
more	O
abundant	O
in	O
females	O
vs.	O
those	O
of	O
the	O
n	O
-6	O
series	O
such	O
as	O
C18:2,	B
C20:4	B
and	O
C22:4	B
that	O
are	O
more	O
abundant	O
in	O
males.	O

The	O
large	O
differences	O
may	O
be	O
due	O
to	O
the	O
duration	B
of	O
diabetes;	O
in	O
this	O
study,	O
patients	O
both	O
with	O
and	O
without	O
DR	O
had	O
suffered	O
from	O
type	O
2	O
diabetes	O
for	O
longer	O
than	O
20	O
years,	O
and	O
metabolic	O
changes	O
persistently	O
occurred	O
with	O
this	O
long-standing	O
disease.	O

In	O
contrast,	O
postprandial	O
TGRL	O
from	O
those	O
subjects	O
in	O
whom	O
triglycerides	B
increased	O
<120 mg/dl	O
reduced	O
or	O
had	O
a	O
neutral	O
effect	O
on	O
TNFα-stimulated	O
VCAM-1	O
surface	O
expression	O
in	O
HAEC	O
(Fig.	O

The	O
majority	O
of	O
intermediates	O
in	O
the	O
tricarboxylic	B
acid	I
(TCA)	O
cycle	O
(citric	O
acid,	O
α	B
-ketoglutarate,	I
fumaric	B
acid,	I
and	O
malic	O
acid)	O
were	O
elevated	O
in	O
both	O
serum	O
and	O
tissue	O
samples	O
from	O
the	O
EC	O
patients.	O

Results	O
firstly	O
observed	O
aberrant	O
levels	O
of	O
serine	B
and	O
glycine	B
in	O
the	O
blood	O
of	O
PCa	O
patients.	O

The	O
SAMe	O
methylation	O
is	O
a	O
critical	O
step	O
in	O
many	O
proteins	O
stabilization,	O
including	O
myelin.	B

The	O
correlation	O
analysis	O
of	O
LPC	O
with	O
PC	O
species	O
resulted	O
in	O
significant	O
positive	O
associations	O
in	O
most	O
cases,	O
except	O
for	O
LPC	O
14:0	O
and	O
PC	B
38:6.	I

Negative	O
ions	O
characteristic	O
of	O
grey	O
matter	O
(m/z	O
834,	O
[PS	O
40:6	O
–H]-	O
),	O
white	O
matter	O
(m/z	O
888,	O
[(3’-sulfo)GalCer	O
24:1	I
–H]-	O
),	O
and	O
glioma	O
(m/z	O
794,	O
[PC	O
34:1	O
+	O
Cl]-	O
)	O
were	O
also	O
observed	O
at	O
different	O
abundances.	O

Median	O
TMAO	B
levels,	O
choline,	B
and	O
betaine	B
levels	O
were	O
5.8	O
[3.6,	O
12.1]	O
μM,	O
10.9	O
[8.4,	O
14.0]	O
μM,	O
43.8	O
[37.1,	O
53.0]	O
μM,	O
respectively,	O
and	O
were	O
correlated	O
with	O
each	O
other	O
(all	O
p<0.0001	O
for	O
both).	O

4 × 1 μL	O
injections	O
of	O
caffeine	B
were	O
then	O
made,	O
and	O
the	O
observed	O
retention	O
time	O
stability	O
and	O
peak	O
area	O
variation	O
under	O
gradient	O
conditions	O
were	O
used	O
to	O
confirm	O
column	O
equilibration.	O

The	O
capillary	O
voltage	O
was	O
set	O
to	O
3.0	O
kV.	B
The	O
extraction	O
cone	O
was	O
set	O
at	O
4	O
V.	O

The	O
value	O
assignment	O
methods	O
employed	O
have	O
been	O
modified	O
from	O
those	O
utilized	O
for	O
the	O
previous	O
SRM,	O
and	O
all	O
three	O
approaches	O
now	O
incorporate	O
chromatographic	O
resolution	O
of	O
the	O
stereoisomers,	O
25(OH)D_3	O
and	O
3-epi-25(OH)D_3	B
.	O

Elevated	O
urinary	O
concentrations	O
of	O
acylcarnitine	B
metabolites	O
were	O
also	O
observed	O
in	O
individuals	O
with	O
gallstones.	O

However,	O
salivary	O
arginine	B
was	O
hardly	O
changed,	O
and	O
there	O
were	O
no	O
differences	O
among	O
the	O
groups	O
(Supplementary	O
Fig.	O

Geometric	O
means	O
of	O
non-normalized	O
BDCPP	O
and	O
DPP	O
were	O
148	O
and	O
1074	O
pg	B
mL_−1	O
,	O
respectively.	O

The	O
first	O
phosphopeptide	B
matched,	O
shown	O
in	O
line	O
1	O
shows	O
two	O
phosphorylations	B
on	O
threonine	B
and	O
serine,	B
and	O
is	O
matched	O
to	O
the	O
protein	O
serine/threonine-protein	B
kinase	O
MAK.	O

Carnitine	B
was	O
critical	O
in	O
lipid	O
metabolism,	O
which	O
could	O
transport	O
long-chain	O
fatty	O
acids	O
from	O
the	O
outer	O
membrane	O
of	O
mitochondria	O
to	O
the	O
inner	O
membrane	O
for	O
β-oxidation	O
to	O
generate	O
energy	O
in	O
the	O
form	O
of	O
acyl	B
carnitine.	I

The	O
levels	O
of	O
PE(16:0/16:1),	B
PE(16:0/18:3),	B
PE(16:0/18:2),	B
PE(18:0/16:0),	B
PE(17:0/18:2),	B
PE(18:0/17:1),	B
PE(17:0/18:1),	B
PE(20:5/16:0),	B
PE(18:0/18:1),	B
PE(18:1/20:4),	B
PE(18:0/20:3),	B
PC(15:0/18:1),	B
PC(16:1/20:5),	B
and	O
PC(18:0/20:1)	B
in	O
early-stage	O
NSCLC	O
were	O
significantly	O
increased	O
compared	O
with	O
HC	O
(p<0.05).	O

A	O
series	O
of	O
standard	O
samples	O
of	O
D-mannose	B
were	O
prepared	O
by	O
diluting	O
the	O
stock	O
solution	O
with	O
water	O
and	O
then	O
spiking	O
in	O
surrogate	O
blank	O
serum	O
(4%	O
BSA	O
in	O
PBS)	O
to	O
obtain	O
the	O
following	O
concentrations:	O
1,	O
2,	O
5,	O
20,	O
and	O
50	O
μg/mL.	O

Chemically	O
it	O
is	O
3-methyl-morphine.	B

B.	O
The	O
glycine,	B
serine	B
and	O
threonine	B
metabolism	O
pathway.	O

Subjects	O
received	O
deuterated	O
rac-(d_5	O
)	O
methadone	B
rectally	O
at	O
each	O
session,	O
together	O
with	O
rac-(d_0	O
)	O
intravenous	O
or	O
rac-(d_0	O
)	O
oral	O
methadone.	B

Interestingly,	O
we	O
found	O
that	O
there	O
is	O
no	O
correlation	O
in	O
the	O
levels	O
of	O
most	O
of	O
the	O
ceramide	B
species	O
between	O
breast	O
cancer	O
and	O
normal	O
breast	O
tissue	O
in	O
contrast	O
to	O
the	O
correlations	O
found	O
in	O
levels	O
of	O
S1P,	O
SM,	O
and	O
HexCer.	O

The	O
current	O
study	O
does,	O
however,	O
open	O
the	O
field	O
up	O
to	O
consideration	O
of	O
the	O
roles	O
played	O
by	O
elevations	O
in	O
brain	O
glucose	B
and	O
polyol-pathway	B
metabolites	O
and	O
associated	O
copper	O
deficiency	O
in	O
the	O
pathogenesis	O
of	O
AD.	O

Omega-3	B
fatty	O
acids	O
have	O
been	O
shown	O
to	O
have	O
a	O
favorable	O
impact	O
on	O
multiple	O
factors	O
related	O
to	O
CVD,	O
including	O
reduced	O
platelet	O
activation.	O

It	O
has	O
been	O
established	O
that	O
D2HGDH	O
and	O
l-2-hydroxyglutarate	O
dehydrogenase	O
(L2HGDH)	O
are	O
enzymes	O
that	O
convert	O
2-HG	O
to	O
α-KG.	B

The	O
neuroimmunological	O
kynurenine	B
pathway	O
(KP)	O
has	O
been	O
hypothesized	O
to	O
play	O
a	O
role	O
in	O
depressive/anhedonic	O
symptoms	O
and	O
related	O
CNS	O
disturbances.	O

The	O
impact-value	O
threshold	O
calculated	O
from	O
pathway	O
topology	O
analysis	O
was	O
set	O
to	O
0.10	O
,	O
and	O
two	O
unique	O
pathways	O
including	O
sphingolipid	B
metabolism	O
and	O
alanine,	B
aspartate	B
and	O
glutamate	B
metabolism	O
was	O
filtered	O
out	O
as	O
potential	O
targets	O
pathway	O
for	O
HAPE.	O

For	O
the	O
PtdCho	O
and	O
SM	O
panels,	O
12	O
μL	O
of	O
extract	O
B	O
was	O
mixed	O
with	O
108	O
μL	O
mobile	O
phase	O
and	O
15	O
μL	O
of	O
0.5ug/ml	O
PtdCho16:0(D31)/18:1	B
as	O
an	O
internal	O
standard.	O

r	B
-7,t	I
-8,9,c	I
-10-tetrahydroxy-7,8,9,10-tetrahydrobenzo[a	I
]pyrene	I
(trans,	O
anti	O
-BaPT),	O
r	B
-7,t	I
-8,9,10-tetrahydroxy-7,8,9,10-tetrahydrobenzo[a	I
]pyrene	I
(cis,	O
anti	O
-BaPT),	O
r	B
-7,t	I
-8,,c	I
-9,10-tetrahydroxy-7,8,9,10-tetrahydrobenzo[a	I
]pyrene	I
(cis,	O
syn	O
-BaPT),	O
r	B
-7,t	I
-8,c	I
-9,t	I
-10-tetrahydroxy-7,8,9,10-tetrahydrobenzo[a	I
]pyrene	I
(trans,	O
syn	O
-BaPT),	O
trans	B
-4,5-dihydro-4,5-dihydroxybenzo[a	I
]pyrene	I
(BaP-4,5-diol),	O
trans	B
-7,8-dihydro-7,8-dihydroxybenzo[a	I
]pyrene	I
(BaP-7,8-diol)	O
and	O
trans	B
-9,10-dihydro-9,10-dihydroxybenzo[a	I
]pyrene	I
(BaP-9,10-diol)	O
were	O
obtained	O
from	O
the	O
National	O
Cancer	O
Institute	O
Chemical	O
Carcinogen	O
Reference	O
Standard	O
Repository,	O
Midwest	O
Research	O
Institute	O
(Kansas	O
City,	O
MO).	O

Plasma	O
aliquots	O
were	O
stored	O
at	O
-80°C,	O
then	O
transported	O
on	O
dry	O
ice	O
to	O
the	O
Dr.	O
von	O
Hauner	O
Children’s	O
Hospital	O
(Munich,	O
Germany)	O
where	O
the	O
analyses	O
of	O
phospholipids	B
and	O
acyl-carnitines	B
using	O
flow-injection	O
mass	O
spectrometry	O
according	O
to	O
Uhl	O
et	O
al.	O

Intake	O
of	O
40 mg	O
simvastatin	B
for	O
3	O
months	O
reduced	O
the	O
level	O
of	O
these	O
oxysterols	B
to	O
the	O
levels	O
recorded	O
in	O
healthy	O
control	O
subjects.	O

The	O
upper	O
panel	O
represents	O
the	O
high	O
resolution	O
(unsigned)	O
Manhattan	O
plot	O
where	O
the	O
−log_10	O
p	O
-value	O
(left	O
Y	O
axis)	O
measuring	O
the	O
strength	O
of	O
association	O
each	O
between	O
peak	O
height	O
and	O
the	O
log_10	O
transformed	O
blood	O
glucose	B
level	O
is	O
represented	O
by	O
a	O
triangle	O
(down	O
pointing	O
for	O
negative	O
associations).	O

Changes	O
in	O
clinical	O
measures	O
after	O
simvastatin	B
treatment.	O

None	O
of	O
the	O
women	O
was	O
on	O
estrogen	B
therapy.	O

The	O
typical	O
total	O
ion	O
chromatograms	O
(TICs)	O
produced	O
from	O
urine	O
samples	O
by	O
LC-(±)ESI-MS	B
are	O
presented	O
in	O
.	O

Surge	O
in	O
the	O
percentage	O
of	O
lysine	B
and	O
arginine	B
has	O
been	O
observed	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
corresponding	O
to	O
dysfunction	O
of	O
diamino	B
transport	O
affecting	O
the	O
alveolar	O
epithelial	O
lining	O
fluid	O
and	O
alveolar	O
epithelial	O
cells.	O

The	O
amino	O
acid	O
focused	O
quintet	O
cysteine,	B
serine,	B
phenylalanine	B
and	O
tyrosine	B
together	O
with	O
uridine	B
has	O
an	O
AUC	O
value	O
of	O
0.799.	O

However,	O
mentioning	O
this	O
marginal	O
association	O
here	O
is	O
noteworthy	O
since	O
fibrinogen	O
is	O
a	O
blood-borne	O
glycoprotein.	B

The	O
likely	O
annotations	O
are	O
given	O
for	O
the	O
validated	O
peaks	O
and	O
the	O
m/z	O
value	O
of	O
the	O
adduct	O
in	O
the	O
LC-MS	O
experiment	O
is	O
given	O
for	O
the	O
other	O
peaks;	O
the	O
peak	O
labelled	O
testosterone	B
sulfate	I
may	O
be	O
dehydroepiandrosterone	B
sulfate	I
or	O
epitesterone	B
sulfate.	I

Creatinine	B
singlets	O
at	O
2.98	O
and	O
3.99	O
p.p.m.	O
and	O
urea	B
around	O
5.68	O
p.p.m.	O
have	O
a	O
strong	O
association	O
with	O
DKD	O
and	O
produce	O
similar	O
colorings	O
of	O
approximately	O
doubled	O
values	O
on	O
the	O
western	O
side	O
of	O
the	O
SOM	O
as	O
compared	O
with	O
the	O
eastern	O
side.	O

Butyrylcarnitine	B
and	O
2-hydroxybutyrate	B
(an	O
amino	B
acid),	O
for	O
example,	O
are	O
both	O
known	O
markers	O
of	O
excessive	O
fatty	O
acid	O
oxidation	O
(;	O
)	O
and	O
both	O
were	O
positively	O
associated	O
with	O
BMI.	O

Initial	O
baseline	O
(pre-operative)	O
and	O
post-operative	O
results	O
suggested	O
that	O
some	O
general	O
clinical	O
parameters	O
such	O
as	O
age,	O
BMI,	O
AC,	O
and	O
diabetes	O
duration	B
are	O
also	O
significantly	O
different	O
between	O
the	O
improved	O
and	O
non-improved	O
groups.	O

While	O
DG	O
species	O
were	O
detected	O
in	O
both	O
pellet	O
and	O
supernatant,	O
TG	B
species	O
were	O
found	O
in	O
three	O
of	O
the	O
samples	O
enriched	O
in	O
the	O
pellet.	O

All	O
the	O
prepared	O
solutions	O
were	O
prepared	O
in	O
MeOH,	B
and	O
two	O
sets	O
of	O
mixed	O
stock	O
solution	O
were	O
obtained	O
(2440,	O
2650,	O
and	O
1010	O
ng/mL	O
for	O
P,	O
P-1,	O
and	O
P-2,	O
and	O
2530,	O
2230,	O
and	O
1070	O
for	O
IP,	B
IP-1,	O
and	O
IP-2).	O

The	O
retention	O
time	O
(RT)	O
CV%	O
values	O
of	O
all	O
lipid	O
ISTDs	O
on	O
reverse	O
phase	O
chromatography	O
in	O
both	O
methanol	B
and	O
methanol-ethanol	B
precipitation	O
methods	O
are	O
below	O
1%	O
(Shown	O
in	O
).	O

Superoxides	B
easily	O
react	O
with	O
cellular	O
membrane	O
components	O
(i.e.	O
lipids	O
and	O
proteins)	O
and	O
DNA.	O

Previous	O
studies	O
have	O
found	O
that	O
AD	O
patients	O
had	O
higher	O
levels	O
of	O
ceramides	B
in	O
the	O
middle	O
frontal	O
cortex	O
and	O
white	O
matter	O
;	O
levels	O
peaked	O
in	O
early	O
mild	O
dementia	O
(CDR = 0.5)	O
.	O

Choline	B
chloride	I
(≥98%,	O
C7527	O
Sigma-Aldrich,	O
St.	O
Louis,	O
MO,	O
USA),	O
sodium	B
citrate	I
dehydrate	O
(≥99%,	O
W302600	O
Sigma-Aldrich,	O
St.	O
Louis,	O
MO,	O
USA)	O
and	O
creatine	B
monohydrate	O
(≥98%,	O
C3630	O
Sigma-Aldrich,	O
St.	O
Louis,	O
MO,	O
USA),	O
were	O
used	O
respectively	O
as	O
Cho,	O
Cit	O
and	O
Cr	O
source.	O

Previous	O
research	O
suggested	O
that	O
procyanidins	B
prevented	O
or	O
alleviated	O
type	O
2	O
diabetes	O
in	O
part	O
by	O
inhibiting	O
enzymatic	O
starch	O
digestion.	O

MetS_any	O
women	O
had	O
higher	O
levels	O
of	O
histidine	B
and	O
lysine	B
and	O
lower	O
levels	O
of	O
serine,	B
creatinine,	B
myo-inositol,	B
arginine,	B
acetoacetate	B
and	O
betaine	B
compared	O
with	O
MetS_zero	O
women.	O

This	O
finding	O
is	O
consistent	O
with	O
the	O
results	O
demonstrated	O
for	O
the	O
CSF	O
lactic	B
acid	I
levels.	O

Milk	O
fat,	O
protein	O
and	O
lactose	B
contents	O
varied	O
by	O
−9%,	O
−16%	O
and	O
−5%,	O
respectively	O
(;	O
P<0.01),	O
which	O
would	O
severely	O
compromise	O
the	O
milk	O
transformation	O
into	O
dairy	O
products.	O

ORs	O
of	O
potential	O
sphingolipid	B
biomarkers	O
for	O
T2DM	O
with	O
cardiovascular	O
complications.	O

 ,	O
we	O
show	O
the	O
LC-MS/MS	O
trace	O
for	O
PGF_2α	B
and	O
PGE_2	O
in	O
the	O
non-hydrolysed	O
urine	O
sample,	O
GUS	O
blank	O
samples	O
and	O
procedure	O
blank	O
sample	O
(water	O
sample	O
extracted	O
by	O
LLE,	O
no	O
enzyme	O
added).	O

Although	O
controversial,	O
plasma	O
increases	O
in	O
plant	O
sterols	O
(e.g.	O
campesterol	B
and	O
beta-sitosterol)	B
have	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
coronary	O
heart	O
disease	O
;	O
thus	O
our	O
data	O
may	O
suggest	O
RYGB	O
reduces	O
the	O
abundance	O
of	O
these	O
risk	O
factors.	O

Estrogen	B
and	O
estradiol	B
have	O
been	O
shown	O
to	O
increase	O
HDL-C	O
blood	O
concentrations,	O
which	O
is	O
a	O
protective	O
marker	O
for	O
cardiovascular	O
diseases.	O

Depletion	O
of	O
a	O
second	O
SNARE	O
component,	O
syntaxin	B
3,	O
has	O
also	O
been	O
found	O
to	O
reduce	O
the	O
yield	O
of	O
HCMV.	O

(E)	O
MI	O
fractions	O
from	O
cells	O
labeled	O
with	O
_13	O
C-isoleucine,	B
_13	O
C-leucine	B
and	O
_13	O
C-valine	B
simultaneously	O
for	O
48	O
h,	O
in	O
presence	O
(gray)	O
or	O
absence	O
(black)	O
of	O
unlabeled	O
BCKA.	O

1 ml	O
of	O
2%	O
potassium	B
chloride	I
was	O
added	O
and	O
the	O
contents	O
were	O
mixed	O
as	O
previously	O
described.	O

Creatinine	B
in	O
urine	O
was	O
measured	O
by	O
the	O
Jaffe	O
method	O
.	O

This	O
was	O
done	O
by	O
correlating	O
the	O
resolved	O
metabolic	O
information	O
against	O
the	O
exercise	O
phase	O
(pre-	O
vs.	I
post-	O
exercise)	O
and	O
predicting	O
independent	O
samples	O
with	O
known	O
phase	O
into	O
existing	O
models.	O

A	O
sucrose	B
tune	O
file	O
in	O
negative/positive	O
modes	O
at	O
normal	O
LC	O
flow	O
rate	O
was	O
used.	O

The	O
concentration	O
of	O
meso-erythritol	B
varied	O
by	O
tertiles	O
of	O
the	O
central	O
adiposity	O
score;	O
the	O
highest	O
meso-erythritol	B
concentration	O
was	O
in	O
the	O
lowest	O
central	O
adiposity	O
change	O
subgroup	O
(n	O
=	O
26),	O
and	O
the	O
pattern	O
indicated	O
lower	O
meso-erythritol	B
with	O
greater	O
central	O
adiposity	O
change.	O

During	O
CM,	O
we	O
found	O
a	O
depletion	O
in	O
amino	O
acids	O
including	O
arginine	B
(41	O
µM	O
vs	O
61	O
µM	O
p	O
=	O
0.109),	O
glutamate	B
(36	O
µM	O
vs	O
80	O
µM	O
p	O
=	O
0.078)	O
and	O
glycine	B
(131	O
µM	O
vs	O
278	O
µM	O
p	O
=	O
0.008).	O

We	O
report	O
application	O
of	O
this	O
platform	O
to	O
the	O
analysis	O
of	O
human	O
urine	O
from	O
patients	O
with	O
and	O
without	O
type	O
1	O
diabetes,	O
where	O
we	O
observed	O
statistically	O
significant	O
variations	O
in	O
the	O
concentration	O
of	O
disaccharides	B
and	O
previously	O
unreported	O
chemical	O
isomers.	O

biomarkers,	O
bioinformatics,	O
apoptosis,	O
oxidant	O
stress,	O
glutathione,	B
adenosine,	B
phosphatidylserine,	B
sphingomyelin,	B
myoinositol	B

Thus,	O
increased	O
levels	O
of	O
aspirin-triggered	O
epimeric	O
LXA_4	O
might	O
support	O
anti-inflammatory/pro-resolutive	O
pathways	O
and	O
thereby	O
be	O
more	O
specific	O
than	O
applying	O
additional	O
substrate	O
by	O
ω-3	B
&	I
ω-6	I
PUFA	I
supplemented	O
nutrition.	O

Multiple	O
hypotheses,	O
based	O
on	O
laboratory	O
experiments,	O
exist	O
about	O
the	O
role	O
of	O
specific	O
estrogen	B
metabolites	O
and	O
estrogen	B
metabolism	O
profiles	O
in	O
the	O
etiology	O
of	O
breast	O
cancer	O
[–].	O

As	O
observed	O
before,	O
Omega-3	B
PhL	O
Index	O
differed	O
between	O
individuals,	O
showing	O
up	O
to	O
~3-fold	O
differences	O
when	O
all	O
60	O
patients	O
were	O
compared	O
at	O
the	O
baseline	O
(Fig. ).	O

None	O
of	O
the	O
changes	O
in	O
breast	O
gene	O
expression	O
with	O
CER	B
were	O
seen	O
in	O
lymphocytes	O
in	O
the	O
IER	O
study	O
(Additional	O
file	O
2:	O
Figure	O
S1).	O

Additionally,	O
specific	O
bile	O
acids	O
were	O
associated	O
with	O
glycemic	B
control,	O
anti-hypertensive	O
medication,	O
statin	B
medication,	O
and	O
clinical	O
lipid	O
measurements.	O

The	O
increase	O
of	O
synaptic	O
inhibition	O
might	O
not	O
be	O
per	O
se	O
sufficient	O
in	O
contrasting	O
AEDs-resistant	O
epileptogenesis	O
since	O
the	O
brain	O
networks	O
under	O
sustained	O
seizure	O
activity	O
show	O
a	O
poor	O
affinity	O
of	O
GABA	B
receptors	O
(,	O
).	O

To	O
evaluate	O
the	O
benefit	O
of	O
the	O
applied	O
correction,	O
we	O
compared	O
MIDs	O
obtained	O
for	O
different	O
concentrations	O
(40	O
µM	O
and	O
200	O
µM),	O
and	O
_13	O
C	O
enrichments	O
(0.10%	O
and	O
0.01%)	O
of	O
glutamate	B
using	O
defined	O
mixtures	O
of	O
non-labeled	O
and	O
fully	O
labeled	O
glutamate	B
(U_13	O
C-glutamate)	B
in	O
aqueous	O
solution.	O

A	O
nucleoside,	O
putatively	O
identified	O
as	O
N-butenoyl-guanosine	B
(m/z	O
336,	O
RT	O
3.65	O
min),	O
was	O
found	O
using	O
positive	O
neutral	O
loss	O
scan	O
of	O
m/z	O
132	O
on	O
Acquity	O
UPLC-4000	O
QTrap	O
MS	O
in	O
pooled	O
urine	O
from	O
ccRCC	O
patients	O
(orange	O
line)	O
two-folds	O
higher	O
than	O
in	O
post-operative	O
controls	O
(grey	O
line).	O

Post-spike:	O
Internal	O
standard	O
spiked	O
into	O
MTBE	B
extracted	O
human	O
serum,	O
followed	O
by	O
derivatization.	O

These	O
findings	O
may	O
shed	O
light	O
on	O
the	O
increased	O
mortality	O
resulting	O
from	O
β-carotene	B
supplementation	O
in	O
the	O
ATBC	O
Study	O
and	O
call	O
attention	O
to	O
the	O
need	O
for	O
greater	O
understanding	O
of	O
possible	O
interactions	O
between	O
dietary	O
supplements	O
and	O
other	O
pharmacologic	O
agents.	O

csCaP,	O
clinically	O
significant	O
prostate	O
cancer;	O
Lip,	O
lipids/lipoproteins;	O
NMR,	O
nuclear	O
magnetic	O
resonance;	O
Pyr,	O
pyruvate;	B
Ser,	O
serine;	B
TMAO,	B
trimethylamine	B
N	I
-oxide;	I
PC,	O
principal	O
component.	O

For	O
patients	O
associated	O
with	O
“complete”	O
paralysis	O
(AIS	O
A),	O
the	O
elevation	O
in	O
citrulline	B
level	O
is	O
more	O
pronounced	O
compared	O
to	O
AIS	O
B	O
and	O
C.	O

In	O
positive	O
ionization	O
mode,	O
the	O
chromatographic	O
trace	O
477.2/301.1	O
was	O
used	O
for	O
both	O
3-O	O
-Gluc	O
and	O
7-O	O
-Gluc	O
while	O
3,7-O	B
-Digluc	I
was	O
monitored	O
on	O
the	O
transition	O
653.2/301.1	O
and	O
the	O
internal	O
standard,	O
buprenorphine-3-β-d-glucuronide,	B
on	O
the	O
transition	O
644.3/468.3;	O
the	O
injection	O
volume	O
was	O
2 μl.	O

Tetrabutylammonium	B
hydroxide	I
(Aldrich),	O
malonic	B
acid	I
(Aldrich),	O
and	O
high-performance	O
liquid	O
chromatography	O
(HPLC)	O
grade	O
methanol	B
(Fisher)	O
were	O
used	O
for	O
preparing	O
the	O
mobile	O
phase.	O

Although	O
PRA	O
decreases	O
soon	O
after	O
the	O
development	O
of	O
renal	O
artery	O
stenosis,	O
Ang	B
II	I
still	O
represents	O
a	O
primary	O
stimulus	O
via	O
activation	O
of	O
Ang	B
II	I
type	O
1	O
receptor	O
for	O
the	O
release	O
of	O
a	O
number	O
of	O
bioactive	O
compounds,	O
including	O
aldosterone,	B
endothelin,	O
and	O
eicosanoids,	B
that	O
independently	O
contribute	O
to	O
vasoconstriction,	O
salt	O
and	O
water	O
retention,	O
vascular	O
remodeling,	O
renal	O
fibrosis,	O
and	O
the	O
decline	O
in	O
glomular	O
filtration	O
rate	O
that	O
ultimately	O
determines	O
the	O
progression	O
of	O
the	O
disease.	O

In	O
a	O
small	O
interventional	O
study,	O
Dube	O
and	O
colleagues	O
reported	O
decreases	O
in	O
different	O
chain	O
length	O
ceramides	B
with	O
exercise	O
and	O
caloric	O
restriction	O
concomitant	O
with	O
improved	O
insulin	O
sensitivity,	O
and	O
while	O
C18:0	B
ceramide	I
decreased	O
with	O
exercise,	O
its	O
concentration	O
was	O
unchanged	O
with	O
caloric	O
restriction	O
26.	O

Based	O
on	O
the	O
observation	O
of	O
dose	O
linearity,	O
incubations	O
of	O
1,	O
5,	O
and	O
10	O
μM	O
sofosbuvir	B
were	O
dose-normalized	O
to	O
1	O
μM.	O
The	O
pulse	O
incubation	O
concentration	O
for	O
ribavirin	B
was	O
100	O
μM.	O
Results	O
are	O
means	O
±	O
standard	O
deviations	O
for	O
cells	O
from	O
14	O
(sofosbuvir)	O
or	O
2	O
(ribavirin)	O
donors,	O
with	O
results	O
at	O
each	O
time	O
point	O
taken	O
from	O
duplicate	O
incubations.	O

However,	O
the	O
same	O
metabolites	O
are	O
formed	O
from	O
nicotine;	B
therefore,	O
there	O
is	O
a	O
need	O
to	O
distinguish	O
the	O
NNK-	O
and	O
nicotine-derived	O
keto	O
and	O
hydroxy	B
acid	I
in	O
smokers’	O
urine.	O

In	O
gliomas,	O
the	O
oncometabolite	O
2-hydroxygluterate	B
was	O
detected	O
by	O
DESI-MSI	O
from	O
glioma	O
tissue	O
in	O
tumors	O
presenting	O
a	O
genetic	O
mutation	O
of	O
the	O
isocitrate	O
dehydrogenase	O
1	O
(IDH1)	O
enzyme.	O

Mobile	O
phase	O
A	O
was	O
acetonitrile.	B

For	O
170	O
of	O
the	O
175	O
(97.1	O
%)	O
spectra	O
selected	O
from	O
group	O
A,	O
presence	O
of	O
acetaminophen	B
metabolites	O
was	O
confirmed	O
whilst	O
270	O
of	O
the	O
275	O
spectra	O
(98.2	O
%)	O
selected	O
from	O
group	O
B	O
did	O
not	O
have	O
acetaminophen	B
metabolites	O
as	O
verified	O
visually.	O

Columns	O
represent	O
Gene	O
Ontology	O
(GO)	O
term,	O
Category	O
(being:	O
CC:	O
Cellular	O
Component,	O
MF:	O
Molecular	O
Function	O
and	O
BP:	O
Biological	O
Process),	O
the	O
number	O
of	O
genes	O
in	O
the	O
gene	O
set,	O
the	O
number	O
of	O
“differentially	O
methylated”	B
genes	O
(loose	O
P	O
 < 0.0005	O
cut-off),	O
the	O
P	O
-value,	O
and	O
False	O
Discovery	O
Rate	O
(FDR).	O

It	O
is	O
possible	O
that	O
some	O
of	O
the	O
PGs	O
observed	O
in	O
this	O
study	O
are	O
the	O
structural	O
isomers	O
BMPs,	O
as	O
some	O
of	O
the	O
PGs	O
and	O
putative	O
BMP	O
isomers	O
were	O
separated	O
by	O
the	O
same	O
retention	O
time	O
difference	O
observed	O
between	O
the	O
BMP	O
and	O
PG	B
analytical	O
standards.	O

Carbohydrate	O
standards	O
(C_4	O
sugar	O
1,	O
inositol	B
C,	O
talose,	O
mannose,	B
inositol	B
D,	O
glucose,	B
inositol	B
A,	O
arabinose,	B
xylose,	B
and	O
C_4	O
sugar	O
2)	O
were	O
purchased	O
from	O
Sigma	O
(St.	O
Louis,	O
MO,	O
USA).	O

Nadir	O
CD4+	O
T	O
cell	O
count	O
was	O
associated	O
with	O
the	O
dihexosylceramide	B
(DHC)	O
class	O
(β	O
coefficient	O
37.61	O
[95%	O
CI	O
16.81–58.42],	O
p	O
=	O
0.012)	O
only.	O

CAP	O
community-acquired	O
pneumonia,	O
DHEA-S	B
dehydroepiandrosterone	I
sulfate	I
Eight	O
metabolites	O
could	O
distinguish	O
patients	O
with	O
severe	O
CAP	O
from	O
those	O
with	O
non-severe	O
CAP	O
and	O
are	O
presented	O
in	O
Additional file 3:	O
Tables	O
S1	O
and	O
S4.	O

The	O
y_1	O
ion	O
observed	O
at	O
m/z	O
147.1	O
corresponds	O
to	O
lysine,	B
and	O
the	O
fragment	O
ions	O
observed	O
at	O
m/z	O
230.1	O
and	O
248.2	O
(y_2	O
and	O
y_2	O
-H_2	O
O)	O
in	O
the	O
spectra	O
for	O
both	O
NO_2	O
-PhIP-and	O
NO_2	O
-[_2	O
H_5	O
]-PhIP	O
modified	O
peptides	O
are	O
also	O
seen	O
in	O
the	O
spectrum	O
of	O
YTK	O
(data	O
not	O
shown).	O

Number	O
of	O
metabolites	O
in	O
the	O
major	O
biochemical	O
classes	O
detected	O
in	O
various	O
human	O
tissues	O
Adrenal	O
gland,	O
colon,	O
lung,	O
muscle,	O
pancreas,	O
small	O
intestine,	O
spleen,	O
and	O
stomach	O
samples	O
were	O
collected	O
from	O
beating	O
heart	O
donors	O
just	O
prior	O
to	O
the	O
withdrawal	O
of	O
support,	O
placed	O
immediately	O
in	O
80%	O
methanol	B
and	O
incubated	O
for	O
24	O
to	O
72	O
h	O
at	O
room	O
temperature.	O

Subsequent	O
addition	O
of	O
adenine	B
to	O
the	O
assay	O
mixture	O
lead	O
to	O
trapping	O
of	O
E_1	O
(E_2	O
)-QM,	O
resulting	O
in	O
formation	O
of	O
adenine	B
adducts	O
of	O
estrogens,	O
E_1	O
(E_2	B
)-9-N-Ade.	I

They	O
employed	O
Apollo-NADP_+	O
to	O
show	O
an	O
increase	O
in	O
Apollo-NADP_+	O
animosity	O
in	O
beta	O
cells	O
following	O
glucose	B
supplementation	O
consistent	O
with	O
stimulation	O
of	O
the	O
oxPPP	O
and	O
NADPH	B
production.	O

Only	O
higher	O
TMAO	B
levels	O
predicted	O
incident	O
adverse	O
clinical	O
events	O
independent	O
of	O
age,	O
eGFR,	O
mitral	O
E/septal	O
Ea,	O
and	O
NT-proBNP	O
levels	O
(HR	O
1.46	O
[1.03	O
2.14],	O
p=0.03).	O

Although	O
this	O
LOD	O
was	O
about	O
5	O
times	O
higher	O
than	O
that	O
obtained	O
from	O
PIS	O
m	O
/z	O
184	O
(phosphocholine	O
head	O
group	O
ion)	O
of	O
protonated	O
PC	B
16:0/18:1	I
(Fig.	O
S9b_†	O
),	O
it	O
was	O
significantly	O
more	O
sensitive	O
than	O
the	O
use	O
of	O
formate	B
or	O
acetate	B
anion	O
adduct	O
ions	O
(Fig.	O
S9c_†	O
).	O

ATP,	B
adenosine	B
triphosphate;	I
ADP,	B
adenosine	B
diphosphate;	I
AMP,	B
adenosine	B
monophosphate,	I
GMP,	O
guanosine	B
monophosphate.	I

We	O
could	O
therefore	O
speculate	O
that	O
an	O
increased	O
metabolism	O
of	O
these	O
amino	O
acids	O
(alanine,	O
glutamate	B
and	O
lysine)	B
can	O
be	O
considered	O
as	O
indicative	O
of	O
HCC	O
progression.	O

On	O
the	O
other	O
hand,	O
the	O
poor	O
correlation	O
of	O
sarcosine	B
may	O
arise	O
from	O
measurement	O
errors	O
due	O
to	O
its	O
weak	O
MRM	O
peak.	O

However,	O
treatment	O
failures	O
and	O
relapses	O
in	O
leukemia	O
are	O
most	O
often	O
present	O
in	O
the	O
bone	O
marrow,	O
where	O
our	O
results	O
show	O
that	O
increased	O
adiposity	O
could	O
reduce	O
available	O
anthracycline	B
levels.	O

Therefore,	O
some	O
pathways	O
downstream	O
of	O
cysteine	B
might	O
be	O
activated	B
and	O
the	O
increase	O
in	O
urinary	O
hypotaurine	B
may	O
represent	O
these	O
metabolic	O
changes	O
in	O
active	O
RA	O
disease.	O

Meanwhile,	O
men	O
have	O
higher	O
choline	B
and	O
betaine	B
levels	O
than	O
women	O
(p<0.001),	O
yet	O
levels	O
were	O
similar	O
between	O
those	O
with	O
versus	O
without	O
diabetes.	O

It’s	O
also	O
possible	O
that	O
reduced	O
levels	O
of	O
estrogen,	B
a	O
molecule	O
with	O
known	O
anti-inflammatory	O
properties,	O
contribute	O
to	O
aging-related	O
increases	O
in	O
urinary	O
PGE-M	O
levels.	O

Then	O
volume	O
was	O
made	O
up	O
to	O
the	O
mark	O
with	O
acetonitrile	B
to	O
obtain	O
a	O
solution	O
containing	O
500 μ	O
g/ml	O
sitagliptin.	B

Lower	O
glucose	B
and	O
higher	O
acetone	B
together	O
with	O
lower	O
citrate	B
in	O
MS	O
patients	O
and	O
higher	O
lactate	B
in	O
NMOSD	O
patients	O
may	O
suggest	O
an	O
impaired	O
TCA	O
cycle	O
in	O
mitochondria.	O

After	O
isolation,	O
cells	O
were	O
labeled	O
with	O
carboxyfluorescein	B
succinimidyl	I
ester	I
(CFSE,	O
Invitrogen)	O
according	O
to	O
manufacturer’s	O
instructions,	O
then	O
resuspended	O
in	O
RPMI	O
medium	O
containing	O
10%	O
FBS,	O
P/S,	O
non-essential	O
amino	O
acids,	O
sodium	B
pyruvate,	I
and	O
HEPES.	O

Freeze-dried	O
powder	O
of	O
KBR	O
and	O
NAB	O
and	O
a	O
color/flavor-matched	O
placebo	O
containing	O
lactose	B
were	O
provided	O
by	O
the	O
Korean	O
Rural	O
Development	O
Administration	O
(Suwon,	O
Gyunggi-do,	O
Korea).	O

In	O
PET-negative	O
patients,	O
a	O
relative	O
glutamate	B
level > 0.31	O
increases	O
the	O
specificity	O
of	O
PET	O
from	O
23%	O
to	O
58%	O
and	O
results	O
in	O
a	O
high	O
NPV	O
of	O
100%.	O

These	O
analyses	O
suggested	O
that	O
plasma	O
inosine	B
levels	O
are	O
reduced	O
more	O
notably	O
in	O
boys	O
and/or	O
in	O
those	O
with	O
more	O
severe	O
MDD	O
(Table S3).	O

For	O
statistical	O
details	O
see	O
Methods	O
section	O
While	O
no	O
association	O
with	O
bone	O
progression	O
was	O
established,	O
we	O
found	O
an	O
inverse	O
association	O
between	O
L-carnitine	B
(C0)	O
and	O
isovalerylcarnitine	B
(C5)	O
and	O
risk	O
of	O
lymph	O
node	O
progression	O
(p	O
 = 0.006	O
and	O
p	O
 = 0.027,	O
respectively,	O
median	O
cut-off,	O
Log-Rank	O

Hedman	O
et	O
al	O
.	O
developed	O
a	O
highly	O
sensitive	O
assay	O
for	O
1,25(OH)_2	B
D_3/2	O
using	O
Amplifex	O
labeling	O
without	O
specifically	O
mentioning	O
the	O
epimeric	O
products.	O

The	O
increased	O
endocannabinoid	B
levels	O
detected	O
in	O
IGT	O
patients	O
in	O
the	O
present	O
study	O
is	O
consistent	O
with	O
these	O
data.	O

Our	O
findings	O
suggest	O
that	O
chemotherapy	O
recipients	O
experience	O
changes	O
in	O
lipid	O
metabolism,	O
leading	O
to	O
a	O
transient	O
inflammatory	O
lipid	O
profile	O
consisting	O
of	O
high	O
triglycerides,	B
VLDL,	O
increased	O
small	O
LDL,	O
low	O
HDL,	O
triglyceride	B
enrichment	O
of	O
LDL	O
and	O
HDL	O
and	O
increased	O
sphingolipids.	B

While	O
there	O
was	O
a	O
slight	O
reduction	O
in	O
free	O
cholesterol,	B
we	O
observed	O
a	O
substantial	O
elevation	O
of	O
cholesterol-derived	O
bile	O
acids	O
and	O
some	O
of	O
their	O
metabolites	O
(glycochenodeoxycholate	O
sulphate	I
and	O
deoxycholic	B
acid	I
3-glucuronide).	O

In	O
this	O
study,	O
we	O
compared	O
the	O
effects	O
of	O
acetonitrile	B
and	O
methanol	B
on	O
the	O
metabolic	O
profile	O
of	O
urine	O
samples.	O

Cot	O
cotinine	B

The	O
diagnosis	O
was	O
suspected	O
in	O
light	O
of	O
a	O
normal	O
testosterone	B
level	O
with	O
undetectable	O
gonadotropins	O
just	O
after	O
a	O
bilateral	O
testicular	O
surgery.	O

Other	O
studies	O
suggested	O
a	O
role	O
for	O
hypotaurine	B
as	O
an	O
antioxidant	O
and	O
protective	O
agent	O
under	O
physiological	O
conditions	O
[,].	O

Hz,	O
H1),	O
3.25-3.23	O
(m,	O
2H,	O
Cys	O
β-CH_2	B
),	O
2.22	O
(t,	O
2H,	O
J	O
=7.5	O

Interestingly,	O
1.74-fold	O
higher	O
levels	O
(borderline	O
significance;	O
p-adjusted	O
0.07)	O
of	O
a	O
metabolite	O
similar	O
to	O
cadaverine	B
was	O
also	O
observed	O
in	O
pre-surgery	O
CRC	O
patients.	O

This	O
suggests	O
that	O
the	O
balance	O
of	O
SP	B
metabolism,	O
rather	O
than	O
ceramide	B
accumulation,	O
is	O
associated	O
with	O
the	O
pathology	O
of	O
obesity.	O

The	O
treatment	O
was	O
a	O
single	O
injection	O
of	O
10	O
mg	O
vitamin	O
B-12	O
with	O
100	O
mg	O
pyridoxine	B
and	O
100	O
mg	O
thiamin.	B

The	O
developed	O
method	O
was	O
used	O
to	O
analyze	O
92	O
urine	O
samples	O
obtained	O
from	O
patients	O
with	O
T2DM	O
prescribed	O
metformin.	B

For	O
each	O
HCC	O
case	O
identified,	O
the	O
histology,	O
methods	O
used	O
to	O
diagnose	O
the	O
cancer,	O
and	O
α-fetoprotein	B
(AFP)	O
levels	O
were	O
reviewed	O
to	O
exclude	O
metastatic	O
cases	O
or	O
other	O
types	O
of	O
primary	O
liver	O
cancers.	O

Faecal	O
acetate	B
and	O
n-heptanoate	B
were	O
negatively	O
related	O
to	O
portal	O
blood	O
proinflammatory	O
cytokines,	O
indicating	O
a	O
protective	O
role.	O

Proliferation	O
of	O
TRT-HU1	O
cells	O
treated	O
with	O
varying	O
doses	O
of	O
2-oxoglutarate	B
(0,	O
1,	O
10,	O
or	O
25	O
mM)	O
was	O
measured	O
over	O
time	O
(days	O
0,	O
1,	O
2,	O
and	O
3).	O

The	O
alterations	O
are	O
related	O
to	O
the	O
down-regulation	O
of	O
the	O
tricarboxylic	B
acid	I
(TCA)	O
cycle	O
(e.g.,	O
the	O
Warburg	O
effect)	O
and	O
the	O
increased	O
energy	O
request	O
in	O
tumors.	O

Hepatitis-infected	O
HCC	O
cases	O
presented	O
(1)	O
higher	O
levels	O
of	O
AAA,	O
glucose,	B
and	O
citrate	B
and	O
(2)	O
lower	O
VLDL	O
and	O
unsaturated	O
lipids	O
levels,	O
while	O
on	O
the	O
other	O
hand	O
HCC	O
hepatitis-free	O
cases	O
were	O
characterized	O
by	O
(1)	O
higher	O
levels	O
in	O
ethanol	B
and	O
glutamate	B
and	O
(2)	O
lower	O
levels	O
in	O
glutamine,	B
BCAA,	O
and	O
choline.	B

Hasler	O
et	O
al	O
found	O
reduced	O
prefrontal	O
glutamate/glutamine	O
level	O
in	O
depressed	O
patients,	O
which	O
was	O
similar	O
to	O
our	O
findings	O
that	O
the	O
d-glutamine	B
and	O
d-glutamate	B
metabolism	O
was	O
affected	O
in	O
depressed	O
postpartum	O
women.	O

The	O
estrogen	B
(ER	O
+/−)	O
and	O
progesterone	B
(PR	O
+/−)	O
receptors	O
data	O
were	O
available	O
for	O
40	O
breast	O
cancer	O
patients.	O

Furthermore,	O
some	O
phospholipase	O
A2	O
enzymes	O
are	O
predominantly	O
active	O
on	O
oxidized	O
phosphatidylcholines	B
that	O
may	O
derive	O
from	O
oxidation	O
processes	O
upon	O
long-term	O
storage.	O

The	O
metabolites	O
used	O
for	O
study	O
were:	O
2-nitro-1-methyl-6-phenylimidazo[4,5-b	B
]pyridine	I
(NO_2	O
-PhIP),	O
2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b	B
]pyridine	I
(HONH-PhIP),	O
or	O
N	B
-acetyloxy-2-amino-1-methyl-6-phenylimidazo[4,5-b	I
]pyridine	I
(N	O
-acetoxy-PhIP).	I

Our	O
data	O
suggest	O
that	O
patients	O
with	O
higher	O
pretreatment	O
levels	O
of	O
coprostanoligenic	B
bacteria	O
will	O
respond	O
more	O
robustly	O
to	O
the	O
LDL-C	O
lowering	O
effects	O
of	O
simvastatin.	B

Given	O
that	O
the	O
inverse	O
relationship	O
observed	O
between	O
phosphocholine	B
and	O
choline	B
is	O
due	O
to	O
PAP-mediated	O
hydrolysis,	O
a	O
reaction	O
which	O
was	O
not	O
inhibited	O
in	O
these	O
samples,	O
choline-based	O
metabolites	O
(choline,	O
phosphocholine,	B
and	O
glycerophosphocholine)	B
were	O
excluded	O
to	O
remove	O
their	O
effect	O
of	O
unbalanced	O
regulation	O
on	O
the	O
MVSA.	O

Most	O
of	O
the	O
intermediates	O
of	O
important	O
plant	O
metabolic	O
pathways	O
(Krebs'	O
cycle,	O
fatty	O
acid	O
biosynthesis	O
and	O
glucosinolate	B
biosynthesis)	O
were	O
detected	O
(A	O
Inset	O
and	O
).	O

In	O
smokers,	O
counts	O
indicating	O
carotenoid	B
levels	O
increased	O
an	O
average	O
of	O
15,055.25	O
±	O
11,674.18	O
photon	O
units	O
at	O
week	O
12;	O
in	O
non-smokers,	O
levels	O
increased	O
an	O
average	O
of	O
16,640.59	O
±	O
13,595.16	O
units	O
at	O
week	O
12.	O

The	O
major	O
objective	O
of	O
this	O
study	O
was	O
to	O
perform	O
the	O
first	O
side-by-side	O
comparison	O
of	O
three	O
conventional	O
solvent	O
precipitation	O
methods	O
to	O
test	O
the	O
effect	O
of	O
small	O
changes	O
in	O
solvent	O
polarity	O
(methanol,	O
methanol-ethanol,	B
and	O
methanol-MTBE),	B
one	O
LLE	O
(MTBE)	O
method	O
and	O
three	O
post-deproteinization	O
SPE	O
methods	O
(C18,	O
mixed	O
cation-anion	O
exchange	O
(IEX)	O
and	O
divinylbenzene-pyrrolidone	B
(PEP2))	O
for	O
LC-MS	O
metabolomics	O
of	O
human	O
plasma.	O

Serial	O
dilutions	O
(from	O
300	O
to	O
3	O
ng/ml)	O
of	O
the	O
standards	O
in	O
MeOH	B
were	O
prepared	O
and	O
injected	O
into	O
the	O
mass	O
spectrometer	O
in	O
decreasing	O
order.	O

The	O
total	O
lipids	O
of	O
the	O
soy	O
drink,	O
mostly	O
derived	O
from	O
added	O
vegetable	O
fat	O
composed	O
of	O
palm	O
and	O
palm	O
kernel	O
oil,	O
consisted	O
of	O
the	O
following	O
four	O
most	O
abundant	O
fatty	O
acids:	O
lauric	B
acid	I
C12:0	I
(22%),	O
linoleic	B
acid	I
C18:2	I
(21%),	O
palmitic	B
acid	I
C16:0	I
(13%),	O
and	O
stearic	B
acid	I
C18:0	I
(12.1%).	O

The	O
ACE	O
Excel	O
Super	O
C18	O
with	O
its	O
unique	O
encapsulated	O
bonding	O
technology	O
and	O
ACE	O
Excel	O
C18-AR	O
with	O
its	O
integrated	O
phenyl	O
capacity	O
chosen	O
for	O
added	O
selectivity	O
for	O
aromatic	O
compounds	O
still	O
did	O
not	O
resolve	O
the	O
methoxyestrogen	B
metabolites.	O

In	O
the	O
subgroup	O
analysis	O
by	O
the	O
effect	O
of	O
the	O
24-week-intervention	O
(see	O
∆-values	O
in	O
Table ),	O
both	O
Pio	O
and	O
Pio&	O
Omega-3	B
increased	O
body	O
weight	O
and	O
BMI	O
compared	O
with	O
Placebo	O
or	O
Omega-3	B
(except	O
for	O
Placebo	O
vs.	O
Pio	O
in	O
the	O
case	O
of	O
body	O
weight;	O
p	O
 = 0.10).	O

The	O
analysed	O
metabolic	O
traits	O
were	O
fasting	O
plasma	O
glucose,	B
fasting	O
plasma	O
insulin,	O
glycated	O
hemoglobin	O
A1c	O
(HbA1c),	O
the	O
homeostasis	O
model	O
assessment	O
of	O
β-cell	O
function	O
(HOMA2-B)	O
and	O
of	O
insulin	O
sensitivity	O
(HOMA2-S)	O
and	O
their	O
product	O
called	O
HOMA2-BS.	O

Each	O
of	O
the	O
BA	O
products	O
generated	O
had	O
a	O
corresponding	O
glucuronide.	B

10	O
to	O
20	O
µg	O
of	O
anti-BChE	O
antibodies	O
were	O
biotinylated	O
through	O
the	O
activated	B
succinimidyl	I
ester	I
in	O
an	O
aqueous	O
solution	O
at	O
pH	O
7.8.	O

In	O
contrast	O
to	O
etiocholanolone,	B
which	O
originates	O
almost	O
exclusively	O
from	O
the	O
classic	O
pathways,	O
androsterone	B
may	O
be	O
derived	O
additionally	O
from	O
the	O
backdoor	O
pathway.	O

In	O
light	O
of	O
our	O
previous	O
global	O
metabolomics	O
data	O
linking	O
α-OG	B
to	O
cell	O
cycle	O
arrest	O
and	O
proliferation	O
suppression,	O
we	O
first	O
investigated	O
the	O
effects	O
of	O
α-OG	B
in	O
immortalized	O
normal	O
bladder	O
epithelial	O
cells.	O

Furthermore,	O
we	O
found	O
that	O
creatinine	B
increased	O
in	O
the	O
atrial	O
appendage	O
samples	O
of	O
AF	B
patients.	O

The	O
serum	O
samples	O
were	O
deproteinized	O
using	O
methanol	B
at	O
a	O
final	O
concentration	O
of	O
20%	O
prior	O
to	O
measurement.	O

For	O
instance,	O
in	O
a	O
cohort	O
of	O
patients	O
with	O
sepsis	O
caused	O
by	O
the	O
malaria	O
parasite	O
Plasmodium	O
falciparum,	O
ADMA	B
was	O
increased	O
and	O
associated	O
with	O
mortality.	O

The	O
elevated	O
glycolysis	O
in	O
lung	O
cancer	O
cell	O
results	O
in	O
a	O
higher	O
production	O
of	O
fructose-6-phosphate,	B
a	O
metabolite	O
that	O
can	O
branch	O
of	O
the	O
glycolysis	O
to	O
enter	O
the	O
hexosamine	B
biosynthesis	O
pathway	O
(HBP)	O
where	O
it	O
becomes	O
converted	O
into	O
intermediate	O
products	O
like	O
UDP-N-acetylglucosamine	B
that	O
are	O
critical	O
for	O
post-translational	O
modifications	O
of	O
proteins,	O
such	O
as	O
protein	O
glycosylation	O
to	O
NAGs.	O

Reactive	O
catechol	B
estrogen	I
metabolites,	O
metabolites	O
with	O
adjacent	O
hydroxyl	O
groups	O
on	O
the	O
steroid	O
ring,	O
are	O
formed	O
through	O
2-hydroxylation	O
and	O
4-hydroxylation,	O
but	O
can	O
be	O
converted	O
to	O
less	O
reactive	O
compounds	O
by	O
methylation.	O

The	O
plasma	O
was	O
acidified	O
by	O
adding	O
100	O
μL	O
of	O
2M	O
HCl	O
followed	O
by	O
addition	O
of	O
5.0	O
mL	O
of	O
n-hexane:methylene	O
chloride	B
(1:1	O
v/v).	O

Quantitative,	O
targeted	O
mass-spectrometry	O
based	O
metabolite	O
profiling,	O
was	O
used	O
to	O
measure	O
levels	O
of	O
45	O
acylcarnitines,	B
15	O
amino	O
acids	O
and	O
three	O
conventional	O
metabolites	O
(ketones,	O
nonesterified	O
fatty	O
acids	O
and	O
β-hydroxybutyrate)	B
as	O
a	O
part	O
of	O
the	O
main	O
MURDOCK	O
CV	O
study.	O

Virus-coded	O
IE-1	O
and	O
pUL99	O
were	O
assayed	O
to	O
confirm	O
the	O
progression	O
of	O
infection,	O
and	O
β-actin	B
was	O
used	O
as	O
a	O
loading	O
control.	O

The	O
ether	O
phase	O
was	O
transferred	O
to	O
a	O
new	O
glass	O
tube	O
and	O
evaporated	O
to	O
dryness	O
under	O
a	O
stream	O
of	O
nitrogen	B
gas	I
at	O
room	O
temperature	O
in	O
a	O
fume	O
hood.	O

Thus,	O
based	O
on	O
insulin	O
sensitivity	O
and	O
glucose	B
tolerance	O
subjects	O
were	O
classified	O
into	O
four	O
categories:	O
NGT	O
insulin	O
sensitive	O
(NGT-IS);	O
NGT	O
insulin	O
resistant	O
(NGT-IR);	O
IFG;	O
and	O
IGT.	O

,	O
Our	O
results	O
provide	O
further	O
evidence	O
that	O
alterations	O
in	O
urea	B
cycle	O
metabolites,	O
particularly	O
arginine	B
and	O
citrulline,	B
are	O
associated	O
with	O
DR.	O

Quantification	O
of	O
neonicotinoid	B
metabolites	O
was	O
performed	O
only	O
for	O
AM-2,	O
because	O
standard	O
compounds	O
were	O
not	O
available	O
for	O
imidacloprid	O
or	O
clothianidin,	B
i.e.	O
IM-1,	O
IM-3,	O
IM-7	O
or	O
CM-1.	O

Methanol	B
(250	O
μL)	O
containing	O
10	O
mM	O
ammonium	B
formate	I
was	O
added	O
to	O
each	O
well	O
in	O
the	O
analytical	O
plate.	O

Anastrozole	B
and	O
the	O
internal	O
standard	O
were	O
separated	O
on	O
a	O
100	O
×	O
2	O
mm	O
Luna	O
3	O
µ	O
C18(2)	O
100A	O
stainless	O
steel	O
column	O
(Phenomenex,	O
Torrance,	O
CA).	O

There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
levels	O
of	O
serum	O
albumin,	O
total	O
bilirubin,	B
aspartate	O
aminotransferase,	O
alanine	O
aminotransferase,	O
fasting	O
blood	O
glucose,	B
γ-glutamyl	O
transferase,	O
creatinine,	B
platelet	O
count,	O
Fib-4	O
index,	O
elevated	O
AFP	O
or	O
DCP,	O
between	O
the	O
two	O
groups.	O

These	O
perturbed	O
levels	O
of	O
SAM	O
and	O
SAH	O
indicate	O
switching	O
off	O
methionine	B
salvage	O
pathways	O
to	O
adenine	B
metabolism,	O
which	O
is	O
indicated	O
in	O
the	O
NMR	O
spectra	O
of	O
EH	O
subjects	O
in	O
accordance	O
with	O
KEGG	O
pathways	O
(M00034;	O
map	O
00270).	O

Enzymatic	O
test	O
(hexokinase	O
method)	O
was	O
used	O
for	O
the	O
quantitative	O
determination	O
of	O
glucose	B
(Beckman	O
Coulter).	O

Indeed,	O
patients	O
with	O
rectal	O
cancer	O
(n = 38)	O
had	O
similar	O
enterolactone	B
concentrations	O
to	O
controls	O
(glucuronide:	O
median	O
5.39 nM	O
vs.	O
6.32 nM,	O
P = 0.357;	O
sulfate:	B
median	O
0.19 nM	O
vs.	O
0.17 nM,	O
P = 0.452,	O
Table ),	O
whereas	O
the	O
patients	O
with	O
colon	O
cancer	O
(n = 77)	O
had	O
significantly	O
lower	O
concentrations	O
of	O
both	O
enterolactone	B
forms	O
compared	O
with	O
control	O
subjects	O
(glucuronide:	O
median	O
2.61 nM	O
vs.	O
6.32 nM,	O
P < 0.001;	O
sulfate:	B
median	O
0.13 nM	O
vs.	O
0.17 nM,	O
P = 0.002,	O
Table ).	O

These	O
included	O
adenosine,	B
inosine	B
and	O
hypoxanthine.	B

For	O
this	O
phosphate	B
compound	O
there	O
was	O
a	O
standard	O
and	O
known	O
retention	O
time;	O
therefore,	O
data	O
were	O
not	O
collected	O
for	O
that	O
fraction.	O

MS/MS	O
fragmentation	O
experiments	O
with	O
pure	O
reference	O
standards	O
for	O
N-acetylaspartyl	B
glutamate	I
and	O
glycerol-3-phosphoinositol,	B
confirmed	O
the	O
identities	O
of	O
Unknown	O
1	O
and	O
Unknown	O
2	O
(Supplementary	O
Figs _S2	O
and	O
_3	O
).	O

Phenylethylamine,	B
tyramine,	B
and	O
dopamine	B
are	O
substrates	O
of	O
MaoA	O
and	O
PadA,	O
leading	O
to	O
formation	O
of	O
the	O
corresponding	O
aromatic	O
acids,	O
that	O
is,	O
phenylacetic	B
acid,	I
4-hydroxyphenylacetic	B
acid,	I
and	O
3,4-dihydroxyphenylacetic	B
acid,	I
respectively	O
[,	O
].	O

Serum	O
random	O
glucose	B
levels,	O
measured	O
with	O
glucose	B
oxidase	O
method,	O
did	O
not	O
show	O
a	O
significant	O
change	O
and	O
were	O
79	O
(SD = 22.65)	O
mg/dL,	O
75.75	O
(SD = 20.29)	O
mg/dL,	O
and	O
79.75	O
(SD = 16.26)	O
mg/dL	O
at	O
pre‐surgery,	O
at	O
2 weeks	O
and	O
6 months	O
post‐surgery,	O
respectively	O
(P	O
 > 0.05,	O
n	O
 = 8).	O

We	O
therefore	O
hypothesized	O
that	O
glutaminase	O
activity	O
of	O
plasma-treated	O
leukemia	O
cells	O
was	O
reduced	O
and	O
glutamine	B
could	O
not	O
be	O
normally	O
metabolized	O
and	O
converted	O
to	O
glutamic	B
acid,	I
which	O
suppressed	O
the	O
proliferation	O
of	O
leukemia	O
cells	O
and	O
even	O
leaded	O
to	O
leukemia	O
cells	O
apoptosis.	O

There	O
was	O
a	O
trend	O
towards	O
reduced	O
oxidized	O
LDL	B
cholesterol	I
in	O
the	O
OEP-treated	O
group,	O
but	O
this	O
was	O
not	O
significant	O
either	O
with	O
respect	O
to	O
time	O
or	O
compared	O
to	O
the	O
control	O
treatment.	O

If	O
AF	B
was	O
not	O
terminated,	O
self-adhesive	O
skin	O
electrodes	O
(ZOLL	O
Stat-padz®,	O
ZOLL	O
Medical	O
Corporation)	O
were	O
applied	O
in	O
anterior–posterior	O
position,	O
using	O
a	O
200	O
J	O
energy	O
shock.	O

A	O
gradient	O
elution	O
of	O
mobile	O
phase	O
A	O
(10	O
mM	O
ammonium	B
formate	I
and	O
0.04%	O
formic	B
acid	I
in	O
water)	O
and	O
mobile	O
phase	O
B	O
(acetonitrile)	O
was	O
used	O
with	O
a	O
flow	O
rate	O
of	O
0.4	O
ml/min	O
and	O
run	O
time	O
of	O
5	O
min.	O

ulcerative	O
colitis,	O
tryptophan,	B
mucosal	O
healing	O

The	O
recovery	O
of	O
six	O
estrogens	O
after	O
extraction,	O
derivatization,	O
and	O
purification	O
from	O
LQC,	O
MQC,	O
and	O
HQC	O
samples	O
(n=5)	O
was	O
84–98%	O
for	O
E2,	O
92–106%	O
for	O
16α-OH-E2,	B
99–109%	O
for	O
4-MeO-E2,	B
98–112%	O
for	O
2-MeO-E2,	B
95–109%	O
for	O
4-OH-E2,	B
and	O
90–100%	O
for	O
2-OH-E2.	B

Unlike	O
findings	O
in	O
plasma	O
in	O
OIR	O
versus	O
Lean,	O
only	O
DG(18:2_18:2)	B
was	O
significantly	O
different	O
between	O
groups	O
in	O
muscle	O
and,	O
contrary	O
to	O
DG	O
in	O
plasma,	O
was	O
lower.	O

Comparison	O
of	O
the	O
median	O
values	O
of	O
the	O
urinary	O
estrogen-related	O
compounds	O
from	O
NHL	O
cases	O
and	O
healthy	O
controls	O
indicated	O
that	O
the	O
androstenedione	B
and	O
testosterone	B
levels	O
were	O
higher	O
(p	O
<0.0001)	O
in	O
control	O
men.	O

The	O
significance	O
of	O
riboflavin	B
was	O
discussed	O
in	O
many	O
publications	O
[,	O
].	O

This	O
correlation	O
was	O
also	O
corroborated	O
by	O
Yan	O
et	O
al	O
who	O
found	O
that	O
therapeutic	O
administration	O
of	O
lyso-PC	B
after	O
induction	O
of	O
sepsis	O
effectively	O
inhibited	O
lethality	O
in	O
mouse	O
models.	O

Maximum	O
concentrations	O
were	O
845	O
ng/mL	O
for	O
JWH-018	O
5-hydroxypentyl,	O
284	O
ng/mL	O
for	O
JWH-018	O
pentanoic	B
acid,	I
315	O
ng/mL	O
for	O
JWH-073	O
butanoic	B
acid,	I
10	O
ng/mL	O
for	O
JWH-018	B
6-hydroxyindole,	I
and	O
6.2	O
ng/mL	O
for	O
JWH-073	O
4-hydroxybutyl.	O

We	O
note	O
that	O
citrate,	B
which	O
showed	O
significant	O
variation	O
at	O
W4,	O
does	O
no	O
longer	O
contribute	O
to	O
the	O
discrimination	O
at	O
W7	O
(Figure	O
).	O

Other	O
metabolites	O
that	O
were	O
present	O
in	O
normal	O
tissues	O
only	O
include	O
PE-Cer(d14:1(4E)/23:0)	B

The	O
column	O
temperature	O
was	O
35	O
°C	O
with	O
a	O
flow	O
rate	O
of	O
0.35	O
mL/min	O
and	O
the	O
autosampler	O
cooler	O
temperature	O
was	O
set	O
at	O
4	O
°C	O
with	O
an	O
injection	O
volume	O
of	O
5	O
µL.	O
Analytes	O
were	O
eluted	O
with	O
a	O
mobile	O
phase	O
composed	O
of	O
0.1%	O
formic	B
acid	I
in	O
water	O
(A)	O
and	O
acetonitrile	B
with	O
0.1%	O
formic	B
acid	I
(B).	O

Participants	O
were	O
between	O
46	O
and	O
75	O
years,	O
had	O
a	O
BMI	O
between	O
23	O
and	O
35 kg/m_2	O
and	O
no	O
diabetes	O
(fasting	O
glucose	B
<7.0 mmol/L).	O

N-methyl-N-(trimethylsilyl)	B
trifluoroacetamide	I
(MSTFA)	O
with	O
1%	O
trimethylchlorosilane	B
(TMCS)	O
and	O
methoxyamine	B
hydrochloride	I
in	O
pyridine	B
(MOX)	O
were	O
products	O
of	O
Thermo	O
Fisher	O
Scientific.	O

Mitochondria	O
(0.5	O
mg	O
protein/mL)	O
were	O
incubated	O
in	O
2	O
mL	O
of	O
medium	O
containing	O
125	O
mM	O
KCl,	O
15	O
mM	O
HEPES,	O
pH	O
7.4	O
in	O
the	O
presence	O
of	O
1	O
mM	O
cyanide,	B
20	O
μL	O
of	O
10%	O
Triton	O
X-100,	O
100	O
μM	O
DCPIP.	O

Both	O
extracts	O
were	O
concentrated	O
in	O
vacuo	O
and	O
then	O
diluted	O
to	O
the	O
desired	O
volume	O
with	O
methanol.	B

[N	O
-acetyl-D_3	I
]3-HPMA	O
and	O
500	O
ng	O

Plasma	O
levels	O
of	O
TMAO,	B
choline,	B
and	O
betaine	B
were	O
compared	O
across	O
categorical	O
variables	O
using	O
the	O
Wilcoxon	O
rank-sum	O
or	O
Kruskal-Wallis	O
test.	O

DGLA	O
also	O
has	O
been	O
shown	O
to	O
compete	O
with	O
arachidonic	B
acid	I
(AA)	O
synthesis	O
through	O
the	O
expression	O
(or	O
lack	O
thereof)	O
of	O
FADS1	O
,	O
which	O
converts	O
DGLA	O
to	O
AA.	O

v	O
,	O
NaH,	O
dialdehyde	B
shown,	O
CH_2	O
Cl_2	O
,	O
0	O
°C	O
to	O
room	O
temperature,	O
48	O
h	O
(59%).	O

Thus,	O
increased	O
levels	O
of	O
plasma	O
nervonic	B
acid	I
might	O
reflect	O
white	O
matter	O
dysfunction	O
in	O
patients	O
with	O
MDD.	O

The	O
differential	O
expression	O
of	O
aspartate	B
and	O
3-hydroxyanthranilic	B
acids	I
observed	O
in	O
our	O
DOCK8-deficient	O
patients	O
is	O
supported	O
by	O
recently	O
reported	O
data	O
[,].	O

Purification	O
and	O
partial	O
characterization	O
of	O
prostaglandin	B
D2	I
11-keto	O
reductase	O
in	O
rabbit	O
liver.	O

e.g.	O
24(S	O
)-hydroxycholesterol,	I
and	O
oxocholesterols,	B

Triiodothyronine	B
(T3)	O
and	O
thyroxine	B
(T4)	O
as	O
the	O
main	O
secretion	O
products	O
of	O
the	O
thyroid	O
affect	O
nearly	O
every	O
human	O
tissue	O
and	O
are	O
involved	O
in	O
a	O
broad	O
range	O
of	O
processes	O
ranging	O
from	O
energy	O
expenditure	O
and	O
lipid	O
metabolism	O
to	O
glucose	B
homeostasis.	O

Regarding	O
the	O
LC	O
system,	O
hydrophilic	B
interaction	O
chromatography	O
(HILIC)	O
was	O
employed	O
for	O
lipid	O
class	O
separation	O
and	O
the	O
PB	O
reagent,	O
acetone,	B
was	O
directly	O
employed	O
in	O
the	O
mobile	O
phase.	O

In	O
this	O
study,	O
we	O
found	O
that	O
heavy	O
cannabis	B
use,	O
as	O
defined	O
by	O
plasma	O
quantity	O
of	O
THC-COOH,	O
in	O
HIV-infected,	O
ART-treated	O
individuals	O
was	O
associated	O
with	O
lower	O
frequencies	O
of	O
activated	B
(HLA-DR_+	O
CD38_+	O
)	O
CD4_+	O
and	O
CD8_+	O
T	O
cells	O
compared	O
to	O
frequencies	O
of	O
these	O
cells	O
in	O
non-cannabis-using	O
individuals.	O

Butylated	B
hydroxytoluene	I
(BHT)	O
and	O
Discovery	O
DSC18	O
cartridges	O
were	O
from	O
Sigma-Aldrich,	O
UK.	O

The	O
femoral	O
artery	O
of	O
the	O
exercise	O
leg	O
was	O
cannulated	O
under	O
local	O
anesthetic	O
treatment	O
(lidocaine,	O
1%).	O

Referring	O
to	O
such	O
compounds	O
as	O
uremic	O
solutes	O
rather	O
than	O
uremic	O
toxins	B
may	O
serve	O
as	O
a	O
reminder	O
of	O
this	O
distinction.	O

Urinary	O
citrate	B
excretion	O
is	O
a	O
common	O
tool	O
in	O
the	O
differential	O
diagnosis	O
of	O
renal	O
tubular	O
acidosis	O
(Buckalew	O
).	O

[]	O
Literature	O
has	O
also	O
suggested	O
that	O
the	O
total	O
solvent	O
volume	O
of	O
2:1	O
CHCl_3	O
:MeOH	O
(v/v)	O
be	O
17	O
times	O
higher	O
than	O
the	O
tissue	O
volume	O
to	O
effectively	O
extract	O
lipids	O
as	O
well	O
as	O
to	O
associate	O
weak	O
hydrogen	O
bonds	O
between	O
chloroform	B
and	O
water.	O

(F)	O
N-methyl-α-aminobutyric	B
acid	I
present	O
only	O
in	O
the	O
lyophilized	O
AsPC-1	O
samples.	O

The	O
Waters	O
UPC_2	O
was	O
coupled	O
to	O
a	O
Waters	O
Quattro	O
Premier	O
tandem	O
mass	O
spectrometer	O
via	O
a	O
purpose-built,	B
two-part	O
stainless	O
steel	O
splitter	O
supplied	O
by	O
Waters.	O

To	O
further	O
validate	O
this	O
method,	O
it	O
will	O
be	O
critical	O
to	O
establish	O
the	O
relationship	O
of	O
the	O
breathprint	O
to	O
other	O
current	O
circadian	O
phase-markers	O
like	O
melatonin	B
or	O
cortisol	B
as	O
well	O
as	O
other	O
potential	O
or	O
already	O
confirmed	O
biomarkers	O
for	O
metabolism	O
and/or	O
disease.	O

Arginine	B
is	O
a	O
semi-essential	O
amino	O
acid	O
and	O
can	O
be	O
synthesized	O
from	O
glutamine.	B

However,	O
glutamine	B
can	O
also	O
be	O
exported	O
out	O
of	O
the	O
cell	O
by	O
antiporters	O
in	O
exchange	O
for	O
other	O
non-essential	O
amino	O
acids	O
through	O
the	O
L-type	O
amino-acid	B
transporter.	O

Urinary	O
citrate	B
was	O
also	O
validated	O
to	O
be	O
indicative	O
for	O
chronic	O
kidney	O
disease	O
in	O
general	O
(Posada-Ayala	O
et	O
al.	O
).	O

Serum	O
concentrations	O
of	O
tamoxifen	B
and	O
its	O
metabolites	O
correlate	O
with	O
age	O
_a	O
 4OHtam	O
4-hydroxytamoxifen,	B
4OHNDtam	O
4-hydroxy-N	B
-demethyltamoxifen,	I
NDtam	O
N	B
-demethyltamoxifen,	I
NDDtam	O
N	B
-dedimethyltamoxifen,	I
tamNox	O
tamoxifen-N	B
-oxide,	I
Wt/Wt	O
EM	O
wild	O
type/wild	O
type	O
extensive	O
metabolizer	O
CYP2D6	O
_b	O
 Median	O
(range)	O
_c	O
 R	O
and	O
p	O
values	O
are	O
derived	O
from	O
two-tailed	O
Spearman	O
correlation	O
rank	O
test	O
To	O
circumvent	O
effects	O
of	O
CYP2D6	O
polymorphisms	O
we	O
also	O
studied	O
these	O
correlations	O
exclusively	O
in	O
EMs.	O

The	O
parameters	O
used	O
for	O
1D	O
CPMG	O
pulse	O
sequence	O
were	O
as	O
follows:	O
spectral	O
sweep	O
width:	O
12 ppm;	O
data	O
points:	O
32 K;	O
flip	O
angle	O
of	O
radiofrequnecy	O
pulse:	O
90°;	O
total	O
relaxation	O
delay	O
(RD):	O
5 sec;	O
T_2	O
filtering	O
was	O
obtained	O
with	O
an	O
echo	O
time	O
of	O
200 μs	O
repeated	O
300	O
times,	O
resulting	O
in	O
a	O
total	O
duration	B
of	O
effective	O
echo	O
time	O
of	O
60 ms;	O
number	O
of	O
scans:	O
128;	O
window	O
function:	O
exponential	O
and	O
line	O
broadening:	O
0.3 Hz.	O

Following	O
radiation	O
treatment,	O
an	O
obvious	O
increase	O
in	O
OCR	O
was	O
observed	O
in	O
radiation-resistant	O
cells	O
after	O
PA	O
stimulation,	O
which	O
was	O
then	O
inhibited	O
by	O
ethyl	B
2-[6-(4-chlorophenoxy)	I
hexyl]	I
oxirane-2-carboxylate	I
(Etomoxir,	O
ETO),	O
a	O
specific	O
FAO	O
inhibitor	O
(Figure	O
F	O
and	O
Figure	O
D).	O

A	O
group	O
of	O
sulfated	O
steroids	O
were	O
elevated	O
after	O
hydrochlorothiazide	B
administration.	O

The	O
maximum	O
CV	O
of	O
the	O
IS-normalized	O
MF	O
calculated	O
from	O
the	O
six	O
different	O
plasma	O
samples	O
for	O
the	O
low	O
and	O
the	O
high	O
concentration	O
was,	O
respectively,	O
1.0%	O
and	O
0.9%	O
for	O
enzalutamide	B
and	O
1.0%	O
and	O
2.7%	O
for	O
N-desmethylenzalutamide,	B
fulfilling	O
the	O
acceptance	O
criteria	O
of	O
<15%.	O

Incremental	O
improvements	O
in	O
NADPH	B
production	O
could	O
theoretically	O
be	O
supported	O
by	O
interventions	O
directed	O
at	O
folate,	B
B12,	O
glycine,	B
and	O
serine	B
pools,	O
and	O
B6	O
metabolism,	O
however	O
the	O
safety	O
and	O
efficacy	O
of	O
these	O
manipulations	O
have	O
not	O
yet	O
been	O
tested	O
in	O
a	O
rigorously	O
designed	O
clinical	O
trial.	O

On	O
the	O
other	O
hand,	O
the	O
challenge	O
for	O
ex	O
vivo	O
analysis	O
of	O
GSH	B
is	O
that	O
it	O
is	O
extremely	O
labile	O
and	O
it	O
readily	O
oxidizes	O
to	O
GSSG.	O

The	O
ratio	O
of	O
UDP-galactose	B
to	O
UDP-glucose	B
was	O
decreased,	O
suggesting	O
that	O
UDP-galactose	B
is	O
limiting	O
for	O
N-glycan	B
biosynthesis	O
(see	O
the	O
).	O

The	O
urine	O
was	O
treated	O
with	O
β-glucuronidase	O
and	O
sulfatase,	O
and	O
then	O
trans,	O
anti	O
-BaPT	O
was	O
enriched	O
by	O
solid-phase	O
extraction	O
with	O
polymeric	O
reversed	O
phase	O
and	O
phenylboronic	B
acid	I
cartridges.	O

TMAO	B
levels	O
were	O
increased	O
in	O
CLI	O
compared	O
to	O
IC	O
(P < 0.001).	O

and	O
IFG	O
by	O
fasting	O
glucose	B
between	O
5.6	O
and	O
6.9	O
mmol/	O

Inositol	B
(1,2-)cyclic	I
phosphate	I
belongs	O
to	O
the	O
class	O
of	O
organic	O
compounds	O
known	O
as	O
cyclitols.	O

Also,	O
our	O
short-term	O
results	O
are	O
in	O
line	O
with	O
a	O
recently	O
published	O
study	O
which	O
showed	O
an	O
increase	O
of	O
PC38:6	B
in	O
the	O
first	O
42	O
days	O
after	O
bariatric	O
surgery.	O

Methanol,	B
acetonitrile,	B
sodium	B
phosphate,	I
monobasic	O
(NaH_2	O
PO_4	O
),	O
sodium	B
phosphate,	I
dibasic	O
(Na_2	O
HPO_4	O
),	O
and	O
3-(trimethylsilyl)propionic	B
acid-2,2,3,3-d	I
_4	O
sodium	O
salt	O
(TSP)	O
were	O
obtained	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
MO).	O

The	O
top	O
and	O
bottom	O
bars	O
(“whiskers”)	O
represent	O
the	O
entire	O
spread	O
of	O
the	O
data	O
points	O
for	O
α-HB	B
and	O
each	O
group,	O
excluding	O
“extreme”	O
points,	O
which	O
are	O
indicated	O
with	O
black	O
squares.	O

The	O
column	O
was	O
eluted	O
isocratically	O
at	O
a	O
flow	O
rate	O
of	O
400	O
μL/min	O
with	O
25%	O
mobile	O
phase	O
A	O
(0.1%	O
formic	B
acid	I
in	O
water)	O
for	O
1	O
minute	O
followed	O
by	O
a	O
linear	O
gradient	O
to	O
100%	O
mobile	O
phase	O
B	O
(acetonitrile	O
with	O
0.1%	O
formic	O
acid)	O
over	O
11	O
minutes.	O

These	O
data	O
show	O
that	O
once	O
taken	O
up	O
by	O
tissues,	O
_13	O
C-glucose	B
was	O
metabolized	O
quickly	O
to	O
_13	O
C-lactate	B
and	O
secreted	O
back	O
into	O
the	O
blood.	O

Glutamate	B
was	O
found	O
to	O
be	O
elevated	O
in	O
patients	O
with	O
high	O
IP_3	O
R	O
while	O
there	O
was	O
no	O
significant	O
difference	O
between	O
low	O
IP_3	O
R	O
group	O
and	O
healthy	O
control.	O

Blood	O
samples	O
were	O
taken	O
at	O
three	O
time	O
points	O
of	O
the	O
oGTT	O
(0,	O
60,	O
and	O
120	O
min	O
after	O
glucose	B
intake).	O

Utilizing	O
a	O
Speedvac	O
(Christ,	O
Osterode,	O
Germany),	O
the	O
extract	O
was	O
evaporated	O
to	O
dryness	O
until	O
only	O
the	O
glycerol	B
plug	O
was	O
left.	O

BEN	O
is	O
an	O
alkylating	O
agent	O
currently	O
being	O
investigated	O
in	O
phase	O
I	O
clinical	O
trials,	O
with	O
structural	O
similarities	O
to	O
busulfan	B
and	O
melphalan.	B

As	O
anticipated,	O
these	O
diagnostic	O
fragment	O
ions	O
are	O
specific	O
to	O
the	O
locations	O
of	O
double	O
bonds	O
and	O
are	O
therefore	O
least	O
affected	O
by	O
the	O
length	O
of	O
the	O
saturated	O
aliphatic	B
portion	O
after	O
the	O
last	O
double	O
bond.	O

Meanwhile,	O
DMA	B
and	O
TMA,	O
the	O
products	O
of	O
choline	B
metabolism,	O
remarkable	O
increased.	O

The	O
zoomed-in	O
region	O
in	O
shows	O
two	O
pairs	O
of	O
CC	O
diagnostic	O
ions	O
(m	O
/z	O
171,	O
197;	O
m	O
/z	O
199,	O
225)	O
of	O
C18:1,	B
suggesting	O
that	O
PC	B
18:1/16:0	I
contains	O
two	O
CC	O
isomers,	O
PC	B
18:1(Δ9)/16:0	I
and	O
PC	B
18:1(Δ11)/16:0.	I

The	O
NMR	O
sample	O
contained	O
final	O
100	O
mmol/L	O
potassium	B
phosphate	I
(pH	O
7.0)	O
and	O
1	O
mM	O
DSS	O
as	O
a	O
chemical	O
shift	O
reference.	O

This	O
indicates	O
that	O
factors	O
affecting	O
P450	O
2E1	O
metabolism	O
exerted	O
a	O
greater	O
role	O
on	O
the	O
production	O
of	O
1,4-BQ	B
than	O
BO.	O

The	O
drug	O
vehicle	O
propylene	B
glycol	I
was	O
removed	O
from	O
the	O
list	O
of	O
metabolites	O
prior	O
to	O
analysis	O
to	O
eliminate	O
impact	O
on	O
metabolic	O
interpretations.	O

Except	O
methionine	B
sulfoxide,	I
all	O
159	O
investigated	O
metabolites	O
of	O
this	O
panel	O
had	O
stable	O
concentrations	O
after	O
one	O
freeze-thaw	O
cycle.	O

During	O
development,	O
the	O
limit	O
of	O
quantification	O
of	O
cabozantinib	B
was	O
expanded	O
from	O
300	O
to	O
100 μg/L	O
to	O
cover	O
the	O
full	O
range	O
of	O
clinically	O
relevant	O
plasma	O
concentrations.	O

This	O
is	O
consistent	O
with	O
the	O
findings	O
of	O
a	O
long-term	O
intervention	O
trial	O
in	O
which	O
220	O
premenopausal	O
women	O
were	O
randomized	O
to	O
a	O
soy	O
intervention	O
or	O
control	O
arm;	O
in	O
this	O
study	O
investigators	O
found	O
no	O
differences	O
between	O
groups	O
in	O
circulating	O
estrone,	B
estradiol,	B
or	O
free	O
estradiol	B
at	O
four	O
time	O
points	O
up	O
to	O
24	O
months.	O

Because	O
non-smokers	O
with	O
no	O
prior	O
exposure	O
to	O
cigarette	O
smoking	O
and	O
no	O
detectable	O
nicotine	B
metabolites	O
are	O
unlikely	O
to	O
develop	O
COPD,	O
non-smokers	O
were	O
excluded	O
from	O
COPD	O
model	O
generation.	O

Both	O
ethyl	B
acetate	I
(used	O
for	O
liquid–liquid	O
extraction)	O
and	O
MTBSTFA	O
turned	O
out	O
to	O
be	O
especially	O
important	O
sources	O
of	O
contamination	O
as	O
they	O
contained	O
both	O
oxalate	B
and	O
glycolate.	B

We	O
identified	O
novel	O
associations	O
of	O
RV-PV	O
dysfunction	O
with	O
circulating	O
indoleamine	O
2,3-dioxygenase	O
(IDO)–dependent	O
tryptophan	B
metabolites	O
(TMs),	O
tricarboxylic	B
acid	I
intermediates,	O
and	O
purine	B
metabolites	O
and	O
confirmed	O
previously	O
described	O
associations	O
with	O
arginine–nitric	B
oxide	I
metabolic	O
pathway	O
constituents.	O

Mass	O
spectrum	O
and	O
RI	B
of	O
individual	O
peaks	O
in	O
samples	O
were	O
compared	O
with	O
that	O
of	O
the	O
standard	O
references	O
to	O
verify	O
the	O
results.	O

CE,	O
cholesterol	B
esters;	I
SM,	O
sphingomyelin;	B
SqCC,	O
squamous	O
cell	O
lung	O
cancer.	O

Our	O
data	O
indicate	O
that	O
potential	O
exists	O
for	O
similar	O
glucose-driven	B
damage	O
mechanisms	O
to	O
occur	O
in	O
AD	O
brain,	O
consistent	O
with	O
co-localization	O
there	O
of	O
AGEs	O
with	O
Aβ-containing	O
plaque.	O

Metabolic	O
syndrome	O
(Mets)	O
was	O
diagnosed	O
based	O
on	O
WC,	O
BP,	O
TG,	B
HDL-C	O
and	O
FBG,	O
according	O
to	O
International	O
Diabetes	O
Federation	O
criteria.	O

On	O
the	O
right	O
is	O
shown	O
the	O
energy	O
minimized	O
then	O
docked	O
conformations	O
of	O
ATRA	O
(red	O
)	O
and	O
β-apo-13-carotenone	B
(purple	O
)	O
overlaid	O
onto	O
the	O
conformation	O
of	O
the	O
agonist	O
tetramethyl	B
tetrahydronaphthalenyl	I
propenyl	I
benzoic	I
acid	I
(TTNPB)	O
(white	O
)	O
as	O
observed	O
in	O
the	O
x-ray	O
structure.	O

However,	O
it	O
is	O
also	O
found	O
in	O
alfalfa	O
sprouts,	O
lentils,	O
chickpeas,	O
oats	O
and	O
fenugreek	O
,	O
and	O
is	O
a	O
plasma	O
and	O
urinary	O
metabolite	O
of	O
niacin	B
(vitamin	O
B3).	O

Oxylipins	B
were	O
eluted	O
with	O
2 mL	O
ethyl	B
acetate	I
after	O
wetting	O
the	O
cartridge	O
with	O
0.5 mL	O
methanol.	B

Inclusion	O
of	O
current	O
exercise,	O
smoking,	O
alcohol	O
consumption,	O
red	O
meat	O
consumption,	O
parity,	O
and	O
spontaneous	O
abortion	O
history	O
in	O
the	O
analyses	O
did	O
not	O
affect	O
the	O
relationships	O
between	O
creatinine-adjusted	O
aMT6s	O
and	O
8-oxodG	B
or	O
8-oxoGua	O
(data	O
not	O
shown).	O

(LLC = 0.5	O
ng/mL),	O
15	O
(10.1%)	O
pyrimethamine	B
(LLC = 0.5	O
ng/mL),	O
16	O
(10.8%)	O
quinine	O

In	O
inactive	O
CD	O
and	O
UC,	O
ADMA	B
is	O
correlated	O
exclusively	O
with	O
SDMA	O
and	O
arginine	B
becomes	O
positively	O
correlated	O
with	O
citrulline,	B
while	O
a	O
tendency	O
towards	O
a	O
negative	O
association	O
between	O
DMA	B
and	O
citrulline	B
could	O
be	O
found,	O
especially	O
in	O
inactive	O
UC.	O

Here,	O
brain-fructose	O
levels	O
were	O
elevated	O
in	O
all	O
cases,	O
consistent	O
with	O
the	O
findings	O
for	O
glucose	B
and	O
sorbitol	B
(	O
and	O
a;	O
).	O

One	O
issue	O
with	O
8-oxodG	B
as	O
an	O
oxidative	O
stress	O
biomarker	O
is	O
that	O
it	O
is	O
affected	O
by	O
DNA	O
repair	O
capacity,	O
and	O
therefore	O
low	O
levels	O
many	O
not	O
necessarily	O
reflect	O
low	O
oxidative	O
damage,	O
but	O
instead	O
impaired	O
DNA	O
repair.	O

Due	O
to	O
disease	O
persistence,	O
after	O
surgery	O
the	O
patient	O
required	O
treatment	O
with	O
somatostatin	B
analogs	O
(lanreotide	O
120	O
mg/4	O
weeks).	O

Plasma	O
lipoproteins	O
were	O
measured	O
via	O
nuclear	O
magnetic	O
resonance	O
(NMR)	O
spectroscopy	O
(,	O
),	O
while	O
total	O
cholesterol,	B
triglycerides,	B
LDL	B
cholesterol,	I
and	O
HDL	B
cholesterol	I
were	O
measured	O
using	O
standard	O
automated	O
methods.	O

Similarly,	O
Jobard	O
et al.	O
demonstrated	O
higher	O
levels	O
of	O
histidine	B
in	O
early	O
compared	O
with	O
metastatic	O
breast	O
cancer	O
patients,	O
while	O
levels	O
of	O
several	O
metabolites	O
including	O
phenylalanine,	B
pyruvate,	B
glutamate	B
and	O
glycerol	B
were	O
relatively	O
higher	O
in	O
metastatic	O
patients.	O

Deuterium	O
exchange	O
could	O
have	O
been	O
problematic	O
because	O
methanol	B
was	O
used	O
as	O
stock	O
solvent	O
for	O
NNAL	O
and	O
deuterated	O
NNAL	O
and	O
acidic	O
conditions	O
were	O
employed	O
for	O
purifying	O
the	O
derivative	O
from	O
the	O
urine.	O

However,	O
univariate	O
analysis	O
suggests	O
elevated	O
mean	O
citrate	B
concentrations	O
with	O
increasing	O
hyperglycemia.	O

Then,	O
820	O
μL	O
of	O
supernatant	O
was	O
dried	O
with	O
N_2	O
(l),	O
dissolved	O
in	O
100	O
μL	O
of	O
cold	O
10%	O
methanol	B
(J.T.Baker,	O
HPLC	O
grade),	O
mixed	O
by	O
vortexing	O
for	O
1	O
min,	O
and	O
centrifuged	O
at	O
10,000	O
rpm	O
for	O
5	O
min	O
at	O
4°C.	O

In	O
this	O
scenario,	O
our	O
results	O
point	O
to	O
DHA,	O
EPA	O
and	O
stearic,	O
a	O
Th1-promoter	O
NEFA	O
associated	O
with	O
disease	O
duration,	B
as	O
relevant	O
mediators	O
of	O
this	O
phenomenon,	O
as	O
they	O
hallmarked	O
the	O
NEFA_low	O
profile.	O

The	O
compound	O
DHPM8	O
has	O
the	O
methoxy	B
group	O
at	O
the	O
second	O
and	O
fourth	O
positions	O
on	O
the	O
benzyl	O
ring	O
and	O
exhibited	O
half-maximal	O
inhibitory	O
concentration	O
values	O
of	O
0.92±0.09	O
μM	O
and	O
1.97±0.08	O
μM	O
against	O
MCF-7	O
and	O
UACC-62	O
cell	O
lines,	O
respectively,	O
according	O
to	O
.	O

Interestingly,	O
at	O
5/5	O
time	O
points,	O
γ-butyrobetaine,	B
a	O
metabolite	O
downstream	O
of	O
TMLHE	O
and	O
the	O
precursor	O
of	O
l-carnitine,	B
was	O
significantly	O
decreased.	O

Comparing	O
job	O
titles,	O
engine	O
operators	O
were	O
similar	O
to	O
foremen,	O
while	O
coke	O
markers	O
had	O
significantly	O
higher	O
concentrations	O
(about	O
2–3	O
fold)	O
of	O
PHEMA	O
and	O
SPMA	O
than	O
foremen,	O
thus	O
showing	O
that	O
the	O
task	O
of	O
coke	O
markers	O
was	O
associated	O
with	O
higher	O
exposure	O
to	O
styrene	B
and	O
benzene.	B

TRP	O
and	O
its	O
metabolites,	O
including	O
melatonin,	B
have	O
shown	O
a	O
pattern	O
of	O
variability	O
that	O
is	O
modified	O
by	O
light	O
as	O
well	O
as	O
food,	O
and	O
thus	O
sampling	O
time	O
needs	O
to	O
be	O
considered	O
before	O
comparisons	O
across	O
studies	O
can	O
be	O
made.	O

The	O
primary	O
aldosteronism	O
group	O
showed	O
significantly	O
increased	O
excretion	O
of	O
all	O
metabolites	O
of	O
the	O
mineralocorticoid	O
and	O
glucocorticoid	B
synthesis	O
pathways.	O

In	O
our	O
study,	O
choline	B
did	O
not	O
show	O
an	O
ability	O
to	O
predict	O
GDM.	O

Likewise,	O
these	O
results	O
also	O
confirm	O
that	O
Tem	O
needs	O
to	O
be	O
biotransformed	O
in	O
order	O
to	O
inhibit	O
human	O
RBC	O
AChE.	O
Further	O
studies	O
are	O
needed	O
to	O
determine	O
the	O
ability	O
of	O
biotransformation	O
products	O
of	O
Tem	O
to	O
inhibit	O
AChE.	O
In	O
vitro	O
determination	O
of	O
IC_50	O
of	O
RCB AChE	O
(a)	O
in	O
the	O
presence	O
of	O
Tem-oxidized	O
metabolites	O
and	O
ethyl-paraoxon	B
and	O
BuChE	O
(b)	O
in	O
the	O
presence	O
of	O
Tem-dox-SO_2	O
and	O
ethyl-paraoxon.	B

In	O
this	O
study	O
we	O
found	O
that	O
citric	B
acid,	I
hippuric	B
acid,	I
ketoleucine,	B
phenylacetylglutamine,	B
p	O
-cresol	O
sulfate,	B
and	O
proline	B
betaine	I
were	O
inversely	O
correlated	O
with	O
BMI,	O
and	O
N	B
-acetylneuraminic	I
acid,	I
creatinine,	B
and	O
acetylcarnitine	B
were	O
directly	O
correlated	O
with	O
BMI,	O
which	O
underpins	O
previous	O
findings.	O

fowleri	O
trophozoites	O
per	O
sample	O
were	O
exposed	O
for	O
24	O
h	O
to	O
0.5%	O
DMSO	B
or	O
an	O
inhibitor	O
at	O
EC_50	O
concentration	O
prior	O
to	O
lipid	O
extraction.	O

Three	O
metabolites	O
were	O
selected	O
in	O
all	O
models:	O
PC	B
ae	I
C40:2,	I
PC	B
ae	I
C38:0	I
and	O
alanine.	B

(i),	O
phosphatidylcholine	B
(p	O
 = 0.054),	O
total	O
cholines	B
(p	O
 = 0.017)	O

Next,	O
we	O
tested	O
whether	O
the	O
prediction	O
accuracy	O
can	O
be	O
improved	O
by	O
combining	O
the	O
serotonin	B
data	O
from	O
urine	O
analysis.	O

As	O
higher	O
consumption	O
of	O
glutamine	B
in	O
tumor	O
cells	O
has	O
been	O
reported	O
to	O
be	O
essential	O
for	O
the	O
production	O
of	O
macromolecules	O
such	O
as	O
fatty	O
acid	O
and	O
nuclear	O
acids,_,	O
more	O
circulating	O
glutamate	B
may	O
be	O
transformed	O
to	O
glutamine	B
in	O
CRC	O
patients	O
to	O
compensate	O
the	O
higher	O
consumption	O
in	O
tumor	O
tissue	O
cells.	O

= 35)	O
containing	O
predominantly	O
LC	O
n-3	O
PUFAs	O
(1.3 g	O
eicosapentaenoic	B
acid	I
(EPA)	O
and	O
2.9	O

Lower	O
levels	O
of	O
palmitic	B
(p<0.0001),	O
palmitoleic	B
(p	O
=	O
0.002),	O
oleic	O
(p	O
=	O
0.010),	O
arachidonic	O
(p	O
=	O
0.027),	O
EPA	O
(p<0.0001)	O
and	O
DHA	O
(p<0.0001)	O
were	O
found	O
in	O
RA	O
patients,	O
some	O
NEFA	O
being	O
altered	O
at	O
onset.	O

For	O
comparison	O
between	O
AIS	O
A	O
and	O
AIS	O
B,	O
AUC	O
values	O
of	O
greater	O
than	O
0.8	O
were	O
observed	O
for	O
N1,	O
N12-diacetylspermine,	B
lactic	B
acid	I
and	O
glycerol	B
used	O
individually,	O
and	O
a	O
larger	O
AUC	O
value	O
(0.875)	O
was	O
obtained	O
when	O
these	O
metabolites	O
were	O
used	O
together.	O

Tamoxifen	B
dosage	O
is	O
based	O
on	O
the	O
one-dose-fits-all	B
approach.	O

Comparison	O
of	O
Self-Reported	O
Acetaminophen	B
and	O
Ibuprofen	B
Use	O
With	O
Detection	O
of	O
Acetaminophen	B
and/or	O
Ibuprofen	B
Metabolites	O
in	O
Urine	O
Specimens	O
of	O
Belfast	O
and	O
Chicago	O
Participants,	O
by	O
Gender	O
and	O
Age,	O
International	O
Study	O
of	O
Macro-/Micro-Nutrients	O
and	O
Blood	O
Pressure,	O
1996–1999	O
Abbreviation:	O
CI,	O
confidence	O
interval.	O

In	O
addition	O
there	O
are	O
a	O
few	O
models	O
that	O
add	O
urea,	B
glucose	B
and/or	O
glucuronate	B
to	O
that	O
core	O
feature	O
set	O

Comparison	O
of	O
endogenous	O
levels	O
of	O
oxylipins	B
in	O
human	O
plasma	O
and	O
serum	O
determined	O
by	O
our	O
method	O
with	O
those	O
previously	O
reported	O
measurement	O
[–,,	O
–,]	O
NQ:	O
not	O
quantifiable,	O
the	O
concentration	O
is	O
below	O
the	O
LOQ	O
or	O
out	O
of	O
the	O
linear	O
range	O
or	O
not	O
detected	O
from	O
the	O
matrix,	O
−:	O
not	O

Given	O
that	O
others	O
have	O
reported	O
higher	O
kynurenine	B
and	O
lower	O
tryptophan	B
levels	O
in	O
breast	O
cancer	O
patients	O
compared	O
to	O
healthy	O
donors,	O
our	O
finding	O
of	O
a	O
strong	O
maintenance	O
of	O
balanced	O
levels	O
of	O
substrate	O
to	O
catabolite	O
in	O
plasma	O
from	O
both	O
breast	O
cancer	O
patients	O
and	O
cancer-free	O
donors	O
was	O
unexpected.	O

Cytotoxic	O
ceramides	B
originating	O
from	O
the	O
liver	O
(or	O
other	O
organs/tissues)	O
which	O
enter	O
the	O
peripheral	O
blood	O
can	O
cross	O
the	O
blood-brain	O
barrier	O
and	O
exert	O
neurotoxic	O
and	O
neurodegenerative	O
effects	O
in	O
the	O
brain.	O

Plasma	O
levels	O
of	O
choline	B
plasmalogens	O
in	O
PTB	O
positive	O
versus	O
negative	O
cows	O
(N = 12	O
per	O
group).	O

This	O
figure	O
shows	O
a	O
relative	O
reduction	O
of	O
hippurate	B
and	O
a	O
further	O
increase	O
of	O
aromatic	O
amino	O
acids	O
in	O
the	O
T2DM	O
patient	O
group.	O

 creatine	B
(Cr) + phosphocreatine	I
(PCr)],	O
taurine,	B
myo-inositol	B
and	O
polyamines	B
were	O
measured	O
in	O
benign	O
prostate	O
tissue	O
samples	O
(n = 10),	O
in	O
prostate	O
cancer	O
specimens	O
from	O
untreated	O
patients	O
(n = 7)	O
and	O
prostate	O
cancer	O
specimens	O
from	O
patients	O
treated	O
with	O
Degarelix	O
(n = 6).	O

The	O
mean	O
fasting	O
TG	B
level	O
for	O
the	O
first	O
measurement	O
was	O
103	O
mg/dL	O
in	O
the	O
NTG	O
group	O
compared	O
with	O
220	O
mg/dL	O
in	O
the	O
HTG	O
group.	O

The	O
gradient	O
consisted	O
of	O
2	O
solutions:	O
1)	O
water	O
with	O
0.1%	O
formic	B
acid	I
and	O
2)	O
acetonitrile.	B

Pooled	O
human	O
milk	O
was	O
used	O
to	O
evaluate	O
and	O
validate	O
the	O
Biocrates	O
AbsoluteIDQ®	O
p180	O
kit	O
for	O
human	O
milk	O
metabolomics	O
(40	O
acylcarnitines,	B
42	O
acids/biogenic	O
amines,	O
91	O
phospholipids,	B
15 sphingolipids,	B
sum	O
of	O
hexoses)	O
using	O
an	O
ABSciex	O
5500QTRAP	O
mass	O
spectrometer	O
in	O
LC-MS/MS	O
and	O
flow	O
injection	O
analysis	O
(FIA)	O
mode.	O

Score	O
plot	O
from	O
PLS-DA	O
of	O
targeted	O
metabolite	O
concentrations	O
in	O
adults	O
with	O
high	O
or	O
low	O
plasma	O
cystathionine	B
concentration.	O

It	O
should	O
be	O
noted	O
that	O
the	O
picolinic	B
acid	I
analytical	O
standards	O
showed	O
signs	O
of	O
long-term	O
instability	O
in	O
solution	O
(83.3%	O
after	O
2	O
weeks	O
at	O
−20	O
°C).	O

Full	O
mass	O
spectra	O
were	O
obtained	O
by	O
using	O
the	O
FT	B
analyser	O
(Orbitrap)	O
at	O
60,000	O
resolution	O
(at	O
m/z	O
400).	O

PfNMNAT	O
was	O
found	O
to	O
have	O
a	O
K_m	O
of	O
19.9±6.7	O
µM	O
for	O
ATP	B
and	O
35.8±5.1	O
µM	O
for	O
NaMN,	O
which	O
is	O
comparable	O
to	O
the	O
K_m	O
constants	O
reported	O
for	O
Bacillus	O
anthracis	B
(44	O
µM	O
for	O
ATP	B
and	O
25	O
µM	O
for	O
NaMN)	O
and	O
other	O
bacterial	O
versions	O
of	O
this	O
enzyme	O
,	O
.	O

Solvent	O
A	O
consisted	O
of	O
an	O
89:5:5:1	O
mixture	O
of	O
water,	O
isopropyl	B
alcohol,	I
acetonitrile	B
and	O
500 mM	O
ammonium	B
acetate	I
respectively.	O

Association	O
between	O
increase	O
in	O
serum	O
glycine	B
and	O
colon	O
cancer	O
has	O
been	O
shown	O
in	O
many	O
studies.	O

Proline	B
was	O
reduced	O
(P	O
<	O
0.05	O
after	O
the	O
FDR	O
procedure),	O
whereas	O
some	O
lyso-phospholipids	B
increased	O
(6:0,	O
24:0,	O
26:0,	O
28:0,	O
28:1)	O
and	O
others	O
decreased	O
(14:0,	O
16:0,	O
18:0,	O
18:1,	O
18:2)	O
(P	O
<	O
0.05	O
after	O
the	O
FDR	O
procedure).	O

Study	O
supplement	O
usage	O
was	O
confirmed	O
by	O
increases	O
in	O
subjects'	O
palmar	O
skin	O
carotenoid	B
levels,	O
as	O
measured	O
by	O
Raman	O
spectroscopy.	O

Together,	O
these	O
findings	O
support	O
the	O
premise	O
that	O
enhanced	O
insulin	O
action	O
per	O
se	O
is	O
responsible	O
for	O
the	O
changes	O
in	O
these	O
functional	O
pairs	O
of	O
AA/AA	O
metabolites,	O
rather	O
than	O
being	O
attributable	O
to	O
a	O
more	O
direct	O
effect	O
of	O
the	O
pharmacological	O
agents,	O
pioglitazone	B
and/or	O
metformin.	B

The	O
series	O
of	O
citric	B
acid	I
cycle	O
metabolites	O
were	O
tentatively	O
identified	O
from	O
the	O
data	O
as	O
being	O
differentially	O
expressed	O
in	O
the	O
ACO2	O
cohort	O
plasma	O
versus	O
the	O
matched	O
control	O
plasma	O
samples.	O

For	O
creatinine	B
levels,	O
the	O
median	O
and	O
interquartile	O
range	O
are	O
presented,	O
and	O
comparisons	O
were	O
made	O
by	O
Wilcoxon	O
rank	O
sum	O
test.	O

Our	O
present	O
findings	O
suggest	O
that	O
increased	O
activation	O
of	O
the	O
neurotrophic	O
branch	O
of	O
the	O
KP	B
relative	O
to	O
the	O
neurotoxic	O
branch	O
(i.e.,	O
KA/QUIN	O
ratio	O
levels)	O
is	O
associated	O
with	O
increased	O
connectivity	O
between	O
these	O
regions,	O
which	O
may	O
potentially	O
impact	O
their	O
functioning.	O

Neopterin	B
in	O
its	O
unchanged	O
form	O
is	O
excreted	O
via	O
the	O
kidney	O
and	O
its	O
levels	O
correlate	O
with	O
the	O
extent	O
of	O
disease	O
or	O
infection.	O

For	O
Level	O
4	O
of	O
SRM	O
972,	O
which	O
contains	O
3-epi-25(OH)D_3	B
,	O
a	O
second	O
LC-MS	O
approach	O
was	O
developed	O
to	O
allow	O
the	O
quantification	O
of	O
25(OH)D_3	O
and	O
3-epi-25(OH)D_3	B
.	O

More	O
extensive	O
studies	O
are	O
needed	O
in	O
future	O
to	O
confirm	O
the	O
feasibility	O
of	O
testing	O
succinic	B
acid	I
in	O
the	O
blood	O
as	O
a	O
target	O
for	O
assessing	O
the	O
degree	O
of	O
mitochondrial	O
dysfunction	O
in	O
sepsis,	O
while	O
monitoring	O
sepsis-associated	O
microbial	O
metabolites	O
to	O
control	O
targeted	O
therapy.	O

This	O
finding	O
indicates	O
that	O
substantive	O
disturbance	O
of	O
brain	O
glucose	B
and	O
polyol	O
pathway	O
regulation	O
may	O
antedate	O
the	O
onset	O
of	O
clinical	O
dementia,	O
possibly	O
by	O
a	O
considerable	O
period.	O

The	O
indoor	O
isolate	O
of	O
T.	O
harzianum	O
ES39	O
produced	O
peptaibols	O
when	O
grown	O
on	O
2%	O
malt	O
extract	O
agar	O
but	O
not	O
on	O
DG-18	O
agar	O
culture	O
of	O
lower	O
water	O
activity,	O
consistent	O
with	O
the	O
previously	O
reported	O
effect	O
of	O
low	O
water	O
activity	O
of	O
the	O
growth	O
substrate	O
on	O
toxin	B
production	O
by	O
fungi.	O

In	O
utilized	O
HPLC-LIT-MS_3	O
to	O
screen	O
for	O
multiple	O
DNA	O
adducts	O
formed	O
in	O
primary	O
human	O
hepatocyte	O
cultures	O
by	O
an	O
untargeted	O
Data-Dependent	O
Constant	O
Neutral	O
Loss	O
(DD-CNL)	O
method,	O
where	O
the	O
loss	O
of	O
dR	O
(m/z	O
116)	O
triggered	O
the	O
MS_3	O
fragmentation	O
of	O
the	O
aglycone	B
adducts.	O

Citric	B
acid	I
is	O
clearly	O
detected	O
following	O
ultrafiltration	O
with	O
a	O
symmetrical	O
quadruplet,	O
generally	O
referred	O
to	O
as	O
an	O
AB-system,	O
at	O
2.94	O
ppm;	O
whereas,	O
resonance	O
signals	O
are	O
low	O
in	O
the	O
spectral	O
region	O
δ	O
7.00–8.00.	O

China,	O
metabolomics,	O
histidine,	B
energy	O
homeostasis,	O
inflammation,	O
chronic	O
obstructive	O
pulmonary	O
disease	O

The	O
HCT116	O
cell	O
line	O
was	O
maintained	O
in	O
DMEM	O
(Dulbecco’s	O
Modified	O
Eagle	O
Medium,	O
Thermo	O
Fischer	O
Scientific,	O
Waltham,	O
MA,	O
USA)	O
supplemented	O
with	O
10%	O
or	O
20%	O
FCS	O
(Thermo	O
Fischer	O
Scientific,	O
Waltham,	O
MA,	O
USA),	O
1%	O
penicillin/streptomycin	O
(Thermo	O
Fischer	O
Scientific,	O
Waltham,	O
MA,	O
USA),	O
2	O
mM	O
glutamine	B
(Thermo	O
Fischer	O
Scientific,	O
Waltham,	O
MA,	O
USA)	O
and	O
1	O
g/L	O
glucose	B
(Sigma-Aldrich,	O
St.	O
Louis,	O
MO,	O
USA).	O

Higher	O
RER	O
values	O
are	O
indicative	O
of	O
an	O
increased	O
glucose	B
oxidation.	O

It	O
is	O
notable	O
that	O
for	O
the	O
BMI	O
analysis	O
there	O
was	O
significant	O
interaction	O
with	O
D-mannose	B
in	O
modifying	O
CRC	O
risk.	O

Evaluating	O
inter-relationships	O
between	O
tryptophan	B
catabolism	O
and	O
inflammation	O
markers	O
in	O
the	O
merged	O
HIV	O
dataset	O
(n=40	O
subjects)	O
identified	O
strong	O
associations	O
between	O
kynurenine	B
and	O
the	O
IFN-gamma-induced	O
chemokines	O
CXCL9	O
and	O
CXCL10	O
(p<0.05,	O
FDR<10%).	O

The	O
loadings	O
plot	O
of	O
this	O
model	O
was	O
dominated	O
by	O
the	O
spectral	O
regions	O
that	O
belonged	O
to	O
one	O
of	O
the	O
most	O
commonly	O
used	O
over-the-counter	O
analgesic,	O
paracetamol	B
(Supplementary	O
Fig.	O

As	O
such,	O
cancer	O
cells	O
rapidly	O
consume	O
NAD,	B
which	O
means	O
that	O
they	O
need	O
more	O
energy	O
and	O
require	O
alternative	O
NAD	B
synthesis	O
pathways	O
to	O
the	O
pathway	O
involving	O
nicotinamide[].	B

After	O
40 mg	O
simvastatin	B
treatment	O
per	O
day	O
for	O
3	O
months,	O
the	O
subjects	O
with	O
hypercholesterolaemia	O
showed	O
a	O
35%	O
reduction	O
in	O
cholesterol	B
levels	O
and	O
there	O
was	O
no	O
significant	O
difference	O
observed	O
in	O
other	O
measurements	O
between	O
the	O
two	O
groups.	O

Previous	O
research	O
showed	O
that	O
pyruvate	B
and	O
lactate	B
are	O
metabolized	O
to	O
produce	O
ATP	B
and	O
are	O
good	O
energy	O
substrates	O
for	O
sperm	O
survival	O
and	O
movement	O
[,].	O

The	O
elevated	O
levels	O
of	O
methyl	B
arginine,	I
methyl	B
histidine,	I
methyl	B
alanine,	I
methyl	B
nicotinamide,	I
serine,	B
and	O
glycine	B
indicate	O
dysregulation	O
of	O
the	O
one-carbon	O
metabolism	O
in	O
AA	O
with	O
BLCA.	O

Elevated	O
level	O
of	O
fatty	O
acids,	O
glucose	B
and	O
acids	O
were	O
observed	O
in	O
lung	O
cancer	O
in	O
comparison	O
with	O
control	O
groups	O
apparently	O
due	O
to	O
enhanced	O
glycolysis,	O
gluconeogenesis,	O
lipogenesis	O
and	O
acidosis,	O
indicating	O
the	O
metabolic	O
signature	O
for	O
lung	O
cancer.	O

Therefore,	O
we	O
aimed	O
to	O
verify	O
the	O
identity	O
of	O
the	O
detected	O
metabolite	O
using	O
a	O
reference	O
standard.	O
_1	O
H-NMR	O
of	O
the	O
authentic	O
compound	O
p-cresyl	B
sulphate	I
in	O
H_2	O
O	O
at	O
pH	O
2.5	O
showed	O
a	O
singlet	O
at	O
2.33	O
ppm	O
(CH_3	O
group)	O
and	O
a	O
doublet	O
at	O
both	O
7.19	O
ppm	O
and	O
7.27	O
ppm	O
(aromatic	O
ring	O
protons).	O

The	O
solvent	O
was	O
removed	O
under	O
reduced	O
pressure,	O
the	O
residue	O
was	O
dissolved	O
in	O
1	O
mL	O
H_2	O
O	O
and	O
extracted	O
with	O
1	O
mL	O
ethyl	B
acetate	I
3	O
times.	O

Pellets	O
were	O
resuspended	O
in	O
buffered	O
saline,	B
and	O
virions	O
were	O
resolved	O
by	O
centrifugation	O
in	O
sodium	B
tartrate	I
gradients.	O

We	O
have	O
previously	O
reported	O
the	O
effect	O
of	O
smoking,	O
alcohol	O
intake	O
and	O
oral	O
contraceptive	O
use	O
on	O
tryptophan	B
metabolism.	O

Based	O
on	O
our	O
results,	O
plasma	O
treatment	O
could	O
inhibit	O
the	O
purine	B
metabolism	O
and	O
thus	O
lowers	O
the	O
level	O
of	O
uric	B
acid,	I
which	O
might	O
be	O
benefit	O
for	O
gout-related	O
diseases.	O

Matrix	O
effect	O
on	O
the	O
IS	O
was	O
assessed	O
using	O
the	O
plasma	O
with	O
high	O
triglyceride	B
levels.	O

Go	O
to:	O
Polycyclic	B
aromatic	O
hydrocarbons	B
(PAH)	O
are	O
environmental	O
carcinogens	O
implicated	O
as	O
causes	O
of	O
cancer	O
in	O
certain	O
industrial	O
settings	O
and	O
in	O
cigarette	O
smokers.	O

The	O
powder	O
sample	O
was	O
dissolved	O
in	O
1100	O
μL	O
20	O
mM	O
sodium	B
phosphate	I
buffer	O
at	O
pH	O
7.0.	O

The	O
levels	O
of	O
Methionine,	B
2-Methylglutaric	B
acid,	I
L-Alanine	B
and	O
Glycolic	B
acid	I
were	O
lower	O
in	O
the	O
urine	O
of	O
HIV-infected	O
persons;	O
these	O
were	O
reduced	O
further	O
following	O
ART.	O

MAILD	O
TOF/MS	O
positive-ion	O
spectra	O
for	O
250	O
pmol	O
of	O
triethylamine	B
(A	O
),	O
diisopropylamine	B
(B	O
),	O
ethyldiisopropylamine	B
(C	O
),	O
1,8-diazabicyclo[5.4.0]undec-7-ene	B
(D	O
).	O

Multiple	O
variants	O
in	O
CYP39A1	O
,	O
which	O
encodes	O
an	O
oxysterol	O
7α-hydroxylase,	O
were	O
strongly	O
associated	O
with	O
increased	O
levels	O
of	O
the	O
oxysterol	B
24S	I
-hydroxycholesterol.	I

Hydroxycholesterols	B
may	O
also	O
be	O
called	O
bile	O
alcohols,	O
as	O
many	O
are	O
intermediates	O
in	O
the	O
biosynthesis	O
of	O
bile	O
acids	O
from	O
cholesterol.	B

The	O
low	O
level	O
of	O
glucose	B
could	O
be	O
explained	O
by	O
impaired	O
intestinal	O
absorption	O
due	O
to	O
the	O
inflammation,	O
which	O
is	O
more	O
profound	O
in	O
CD	O
than	O
UC.	O

The	O
V	O
mode	O
was	O
used	O
for	O
the	O
mass	O
spectrometer	O
and	O
data	O
were	O
collected	O
in	O
the	O
centroid	O
mode	O
with	O
a	O
scan	O
accumulation	O
of	O
0.2 s.	O
Leucine	B
encephalin	O
was	O
used	O
as	O
reference	O
lock	O
mass	O
(m	O
/z	O
554.2615)	O
by	O
independent	O
LockSpray	O
interference.	O

RBCs,	O
for	O
instance,	O
exhibited	O
large	O
amounts	O
of	O
lactate,	B
glucose,	B
glutathione,	B
ATP/ADP,	O
ascorbic	B
acid,	I
creatine	B
and	O
phospholipids.	B

Levels	O
of	O
hypoxanthine	B
were	O
higher	O
in	O
PTSD	O
compared	O
to	O
controls	O
(Discovery	O
group:	O
p	O
=	O
0.013,	O
q	O
=	O
0.25;	O
Test	O
group:	O
p	O
=	O
0.016,	O
q	O
=	O
0.13).	O

We	O
demonstrated	O
the	O
importance	O
of	O
both	O
amino	O
acids	O
and	O
dicarboxylic	B
acids	I
in	O
differentiating	O
between	O
the	O
depressed	O
and	O
non-depressed	O
groups	O
with	O
a	O
predictive	O
accuracy	O
of	O
78.2%.	O

The	O
gradient	O
elution	O
consisted	O
of	O
0.1%	O
acetic	B
acid	I
in	O
water	O
(solvent	O
A)	O
and	O
0.1%	O
acetic	B
acid	I
in	O
acetonitrile	B
(solvent	O
B).	O

Serum	O
metabolomics	O
of	O
lipoprotein	O
subfractions	O
and	O
their	O
contents	O
of	O
cholesterol,	B
free	O
cholesterol,	B
phospholipids,	B
apolipoprotein-A1	O
and	O
apolipoprotein-A2,	O
were	O
assessed	O
using	O
nuclear	O
magnetic	O
resonance.	O

One	O
important	O
bioactivation	O
pathway	O
involves	O
the	O
P450	O
oxidation	O
of	O
the	O
4-methyl	O
substituent	O
to	O
4-hydroxymethyl-NVP	B
(12-OH-NVP).	I

The	O
women	O
who	O
were	O
included	O
were	O
likely	O
exposed	O
to	O
a	O
high	O
cumulative	O
dose	O
of	O
DES	B
in	O
utero	O
,	O
and	O
the	O
majority	O
had	O
VEC,	O
which	O
is	O
associated	O
with	O
high	O
DES	B
dose	O
and	O
early	O
exposure	O
in	O
pregnancy.	O

It	O
can	O
be	O
hypothesized	O
that	O
the	O
lower	O
level	O
of	O
valine	B
in	O
the	O
plasma	O
of	O
the	O
GR	O
patients	O
may	O
contribute	O
to	O
limit	O
the	O
cancer	O
cell	O
viability,	O
improving	O
the	O
pharmacological	O
effect	O
of	O
NATC.	O

Pearson’s	O
correlation	O
coefficients	O
were	O
determined,	O
and	O
no	O
statistically	O
significant	O
correlation	O
was	O
found	O
between	O
betaine	B
and	O
TMAO	B
in	O
either	O
the	O
normal	O
healthy	O
population	O
study	O
that	O
was	O
used	O
for	O
the	O
reference	O
interval	O
determination	O
(r	O
=	O
0.065,	O

The	O
first	O
admission	O
included	O
an	O
insulin-modified,	O
frequently-sampled,	O
intravenous	O
glucose	B
tolerance	O
test	O
(FSIVGTT)	O
performed	O
after	O
a	O
12-h	O
overnight	O
fast	O
[–]	O
and	O
body	O
composition	O
measurements	O
by	O
DEXA	O
(Hologic	O
Discovery	O
W,	O
QDR	O
series).	O

In	O
order	O
to	O
achieve	O
this,	O
we	O
assessed	O
three	O
different	O
columns:	O
a	O
Phenomenex	O
Luna	O
C18(2)	O
150	O
×	O
2	O
mm,	O
Phenomenex	O
Synergi	O
4µ	B
Polar-RP	I
100	O
×	O
2	O
mm	O
and	O
a	O
Phenomenex	O
Synergi	O
4µ	O
Hydro-RP	O
100	O
×	O
2	O
mm.	O

Protein	O
precipitation	O
with	O
MeOH	B
was	O
carried	O
out	O
by	O
adding	O
167	O
µL	O
of	O
MeOH,	B
and	O
the	O
supernatant	O
was	O
transferred	O
to	O
a	O
new	O
tube.	O

For	O
GC-MS	O
analysis,	O
50	O
mg	O
tissue	O
and	O
50	O
μl	O
serum	O
with	O
internal	O
standard	O
2-	B
isopropyl-malic	I
acid	I
(15	O
μl	O
from	O
1.0	O
mg/mL)	O
was	O
taken	O
and	O
metabolites	O
were	O
extracted	O
similar	O
to	O
LC-MS.	O

The	O
intervention-induced	O
effects	O
described	O
above	O
were	O
less	O
pronounced	O
in	O
the	O
glucose-derived	O
M2	O
isotopologues	O
of	O
citrate	B
and	O
glutamate	B
(,	O
middle	O
panel;	O
see	O
for	O
atom	O
transitions	O
and	O
isotopologue	O
formation).	O

Our	O
result	O
is	O
in	O
line	O
with	O
previous	O
reports	O
on	O
failing	O
myocardium,	O
which	O
is	O
found	O
to	O
show	O
reduction	O
in	O
fatty	O
acid	O
oxidation	O
and	O
respiratory	O
chain	O
activity,	O
as	O
well	O
as	O
increased	O
glycolysis	O
and	O
glucose	B
oxidation.	O

Intriguingly,	O
2-HG	O
is	O
a	O
known	O
bacterial	O
product	O
of	O
2-hydroxyglutarate	B
synthase	O
.	O

Metabolites	O
of	O
the	O
glycine/serine/threonine	O
subgroup	O
include	O
these	O
amino	O
acids	O
as	O
well	O
as	O
n-acetlylserine	B
and	O
betaine.	B

Finally,	O
branched-chain	O
amino	O
acids	O
(BCAAs),	O
particularly	O
leucine	B
but	O
also	O
isoleucine	B
and	O
valine,	B
regulate	O
protein	O
translation	O
and,	O
therefore,	O
amino	O
acid	O
levels,	O
involving	O
mTORC1	O
activation	O
by	O
the	O
HBV	O
HBx	O
protein.	O

Go	O
to:	O
We	O
recently	O
demonstrated	O
that	O
reconstituted	O
high-density	O
lipoprotein	O
(rHDL)	O
modulates	O
glucose	B
metabolism	O
in	O
humans	O
via	O
both	O
AMP-activated	O
protein	O
kinase	O
(AMPK)	O
in	O
muscle	O
and	O
by	O
increasing	O
plasma	O
insulin.	O

In	O
the	O
present	O
study,	O
we	O
also	O
observed	O
an	O
increase	O
in	O
plasma	O
N,N-dimethylglycine	B
after	O
the	O
RB	O
period,	O
which	O
may	O
indicate	O
an	O
increase	O
in	O
BHMT-R.	O
Homocysteine	B
and	O
methionine,	B
the	O
other	O
metabolites	O
involved	O
in	O
this	O
pathway,	O
are	O
present	O
in	O
low	O
concentrations	O
and	O
have	O
overlapping	O
signals	O
with	O
other	O
metabolites	O
on	O
the	O
NMR	O
spectrum,	O
which	O
obstructs	O
their	O
measurement	O
by	O
NMR.	O

Although	O
detection	O
of	O
the	O
necessary	O
bioactivating,	O
Phase	O
II	O
and	O
efflux	O
transporter	O
enzymes	O
in	O
human	O
oral	O
tissues	O
supports	O
the	O
feasibility	O
for	O
intraoral	O
anthocyanin	B
enteric	O
recycling,	O
their	O
mere	O
presence	O
does	O
not	O
confirm	O
ongoing	O
activity.	O

We	O
have	O
recently	O
reported	O
that	O
glutamic	B
acid	I
in	O
CSF	O
is	O
highly	O
susceptible	O
to	O
sampling	O
variables	O
and	O
in	O
particular	O
to	O
storage	O
temperature	O
(−20°C	O
versus	O
−80°C)	O
.	O

	O
1,5-Anhydroglucitol	B
(1,5-AG)	I
increased	O
after	O
leptin	O
replacement.	O

Another	O
recent	O
metabolomic	O
analysis	O
of	O
successful	O
cognitive	O
aging	O
found	O
lower	O
levels	O
of	O
serum	O
arginine	B
in	O
participants	O
with	O
superior	O
memory	O
(Mapstone	O
et	O
al.,	O
);	O
(3)	O
in	O
CSF,	O
there	O
are	O
also	O
controversial	O
findings.	O

Further,	O
we	O
performed	O
GC-MS	O
to	O
denote	O
fatty	O
acids	O
altered	O
in	O
PCa	O
patients	O
and	O
found	O
that	O
alpha-linolenic	B
acid	I
(ALA)	O
levels	O
are	O
altered	O
in	O
PCa.	O

The	O
derivatization	O
reagent	O
3n	O
butanolic	B
HCl	O
was	O
made	O
in-house	O
by	O
mixing	O
4:1 v/v	O
of	O
1-butanol	B
(for	O
spectroscopy)	O
from	O
Merck	O
(Darmstadt,	O
Germany)	O
and	O
acetyl	B
chloride	I
(p.a.)	O
from	O
Sigma-Aldrich	O
(Steinheim,	O
Germany).	O

Ethanolamine	B
ammonia-lyase	O
(EC	O
4.3.1.7)	O
was	O
similarly	O
enriched	O
in	O
the	O
IBD	O
gut.	O

Creatine	B
and	O
creatinine	B
phosphate	I
are	O
present	O
in	O
blood,	O
muscles	O
and	O
organs,	O
while	O
phosphocreatine	B
is	O
a	O
phosphate	B
donor	O
for	O
the	O
generation	O
of	O
ATP.	B

The	O
results	O
showed	O
that	O
glutamine,	B
alanine,	B
proline,	B
HDL,	O
β-glucose,	B
α-glucose	B
and	O
LDL/VLDL	O
levels	O
were	O
significantly	O
altered	O
in	O
FD	B
patients.	O

Cholesterol	B
oxidase	O
converts	O
sterols	O
with	O
a	O
3β-hydroxy-5-ene	B
function	O
to	O
3-oxo-4-ene	B
analogues	O
(Scheme	O
2)	O
and	O
a	O
3β-hydroxy-5α-hydrogen	B
function	O
to	O
a	O
3-oxo	O
function.	O

Our	O
previous	O
analysis	O
of	O
estrogen	B
metabolism	O
and	O
breast	O
cancer	O
risk	O
included	O
277	O
histologically	O
confirmed	O
invasive	O
breast	O
cancer	O
cases	O
diagnosed	O
between	O
January	O
1,	O
1993	O
and	O
June	O
30,	O
2005	O
and	O
423	O
controls	O
who	O
were	O
free	O
of	O
breast	O
cancer	O
as	O
of	O
June	O
30,	O
2005.	O

Briefly,	O
a	O
set	O
of	O
8	O
metabolites,	O
including	O
β-hydroxybutyrate,	B
lysine,	B
glutamine,	B
citrate,	B
creatinine,	B
lactate,	B
glucose	B
and	O
an	O
unknown	O
molecule	O
were	O
statistically	O
significant	O
(p	O
<0.05),	O
and	O
higher	O
levels	O
of	O
each	O
of	O
those	O
metabolites	O
in	O
the	O
EAC	O
specimens	O
were	O
observed.	O

Comparison	O
of	O
the	O
estrogen	B
metabolic	O
profiles	O
of	O
these	O
two	O
groups	O
clearly	O
shows	O
that	O
the	O
median	O
4-OCH_3	O
E_1	O
(E_2	O
)	O
and	O
4-OHE_1	O
(E_2	B
)-thiol	I
conjugate	O
(GSH,	O
Cys,	O
NAcCys)	O
values	O
were	O
higher	O
in	O
healthy	O
controls	O
compared	O
with	O
NHL	O
cases.	O

To	O
the	O
best	O
of	O
our	O
knowledge,	O
this	O
study	O
reports	O
the	O
largest	O
population-based,	O
high-resolution	O
analysis	O
of	O
the	O
sphingolipidome,	B
allowing	O
for	O
an	O
accurate	O
evaluation	O
of	O
the	O
associations	O
between	O
plasma	O
SP	B
content	O
and	O
obesity-	O
and	O
diabetes-related	O
characteristics,	O
such	O
as	O
BMI,	O
blood	O
lipids,	O
and	O
HOMA-IR.	O

The	O
higher	O
plasma	O
content	O
of	O
acyl-carnitine	B
C3.0	O
in	O
infants	O
receiving	O
the	O
standard	O
formula	O
may	O
be	O
a	O
result	O
of	O
the	O
higher	O
amino	O
acid	O
content	O
in	O
this	O
formula.	O

Taurine	B
was	O
found	O
to	O
exhibit	O
a	O
much	O
higher	O
intra-individual	O
variability	O
than	O
sulfate.	B

5-MTHF-_13	B
C_5	O
was	O
purchased	O
from	O
Merck	O
(Schaffhausen,	O
Switzerland).	O

Wu	O
et	O
al[],	O
in	O
their	O
study	O
based	O
on	O
urinary	O
gas	O
chromatography	O
mass	O
spectrometry	O
of	O
20	O
HCC	O
patients,	O
founda	O
marker	O
set	O
of	O
18	O
metabolites	O
(including	O
octanedioic	B
acid,	I
glycine	B
and	O
hypoxanthine)	B
distinguishing	O
HCC	O
and	O
healthy	O
Chinese	O
controls,	O
but	O
a	O
disease	O
control	O
group	O
of	O
cirrhotic	O
patients	O
was	O
not	O
considered[].	O

Considering	O
previous	O
reports	O
about	O
deconjugation	O
of	O
Δ9-tetrahydrocannabinol	B
metabolites,_,	O
we	O
were	O
concerned	O
that	O
beta-glucuronidase	O
may	O
not	O
be	O
effective	O
for	O
hydrolyzing	O
ester-	O
and	O
ether-linked	O
synthetic	O
cannabinoid	B
glucuronide	I
metabolites.	O

Interestingly,	O
in	O
the	O
present	O
study,	O
glucose,	B
the	O
precursor	O
in	O
glycolysis	O
is	O
not	O
detected	O
in	O
any	O
of	O
the	O
head	O
and	O
neck	O
and	O
lymph	O
node	O
metastatic	O
tissues.	O

In	O
measured	O
DNA	O
base	O
adducts	O
of	O
B[a	O
]P,	O
7-(benzo[a	B
]pyren-6-yl)-adenine	I
(BP-6-N	O
7-Ade)	O
and	O
7-(benzo[a	B
]pyren-6-yl)-guanine	I
(BP-6-N	O
7-Gua)	O
in	O
urine.	O

PPARγ,	O
a	O
key	O
heterodimer	O
partner	O
with	O
RXRs,	O
was	O
shown	O
to	O
participate	O
in	O
the	O
regulation	O
of	O
cholesterol	B
metabolism	O
and	O
exert	O
protective	O
effects	O
against	O
atherosclerosis	O
in	O
humans,	O
mice	O
and	O
rabbits.	O

Our	O
results	O
presented	O
here	O
showed	O
that	O
taurine	B
increased	O
about	O
1.8-fold	O
when	O
blood	O
samples	O
were	O
centrifuged	O
after	O
6	O
h	O
post-blood	O
draw	O
compared	O
with	O
30	O
min	O
of	O
coagulation.	O

The	O
most	O
commonly	O
prescribed	O
opioids	O
in	O
this	O
group	O
include	O
oxycodone,	B
oxymorphone,	B
hydrocodone,	B
hydromorphone	B
and	O
dihydrocodeine,	B
all	O
chemical	O
variants	O
of	O
morphine.	B

Hemoglobin	O
A1c	O
(HbA1c),	O
a	O
marker	O
of	O
usual	O
glycemia	O
and	O
long-term	O
glycemic	B
control,	O
was	O
measured	O
in	O
whole	O
blood	O
using	O
the	O
Dimension	O
Xpand	O
Plus	O
Integrated	O
Chemistry	O
System	O
(Siemens).	O

The	O
usefulness	O
of	O
1-methyladenosine	B
for	O
a	O
diagnostic	O
marker	O
of	O
HCC	O
was	O
first	O
reported	O
by	O
Chen	O
et	O
al	O

These	O
are	O
the	O
same	O
people	O
who	O
exhibited	O
high	O
insulin	O
sensitivity,	O
low	O
postprandial	O
nadir	O
FFA	O
concentrations,	O
and	O
a	O
switch	O
to	O
glucose	B
oxidation	O
in	O
the	O
fed	O
state.	O

No	O
significant	O
difference	O
was	O
detected	O
in	O
the	O
metabolic	O
pattern	O
within	O
1	O
hr	O
duration	B
of	O
NMR	O
measurement,	O
which	O
is	O
in	O
agreement	O
with	O
previous	O
observations	O
for	O
oral	O
cancer	O
and	O
other	O
types	O
of	O
tissues.	O

In	O
addition,	O
the	O
derivatization	O
reaction	O
was	O
also	O
investigated	O
prior	O
to	O
SPE,	O
but	O
solid-phase	O
extraction	O
of	O
the	O
derivatized	O
vitamin	B
D	I
compounds	O
resulted	O
in	O
very	O
low	O
analyte	O
recovery	O
rates	O
as	O
compared	O
with	O
post-extraction	O
derivatization	O
(Fig.	O

We	O
used	O
mass	O
spectrometry	O
imaging	O
(MSI)	O
in	O
the	O
positive	O
ion	O
mode	O
to	O
analyze	O
the	O
intensities	O
of	O
various	O
phosphatidylcholines	B
(PCs)	O
and	O
sphingomyelins	B
(SMs)	O
in	O
the	O
cancer	O
and	O
adjacent	O
non-cancer	O
areas	O
in	O
MF	O
patient	O
tissue	O
sections.	O

Moreover,	O
in	O
accordance	O
with	O
previous	O
studies,	O
both	O
ω-3	B
PUFAs	I
(EPA,	O
ALA)	O
andω-6	B
PUFAs	O
(AA,	O
LA)	O
were	O
also	O
reduced	O
in	O
MDD	O
subjects.	O

Indeed,	O
elevations	O
in	O
insulin	O
secretion	O
associated	O
with	O
sitagliptin	B
therapy	O
lead	O
to	O
reduced	O
circulating	O
BCAA	O
concentrations	O
following	O
a	O
mixed	O
meal	O
in	O
patients	O
with	O
T2D.	O
Our	O
findings	O
are	O
also	O
consistent	O
with	O
a	O
previous	O
report	O
in	O
which	O
it	O
was	O
shown	O
that	O
an	O
alteration	O
in	O
insulin	O
action	O
on	O
glucose	B
metabolism	O
following	O
insulin	O
treatment	O
may	O
not	O
be	O
accompanied	O
by	O
a	O
change	O
in	O
the	O
insulin	O
effect	O
on	O
protein	O
metabolism.	O

1-(1-methylsulfonyl-piperidin-4-yl)-3-(4-trifluoromethoxy-phenyl)-urea	B
(sEH	O
inhibitor)	O
in	O
methanol/water	O
(50/50,	O
v/v)].	O

Additional	O
metabolites	O
related	O
to	O
the	O
degradation	O
of	O
caffeine	B
(e.g.,	O
1,3-dimethylurate	B
and	O
7-methylxanthine),	B
chlorogenic	B
acids	I
(e.g.,	O
hippurate),	O
and	O
trigonelline	B
(e.g.,	O
nicotinamide)	B
that	O
did	O
not	O
withstand	O
Bonferroni	O
correction	O
did	O
meet	O
nominal	O
significance	O
(P	O
<	O
0.05)	O
(data	O
not	O
shown).	O

A	O
hypothesized	O
mechanism	O
linking	O
increased	O
levels	O
of	O
BCAAs	O
and	O
type	O
2	O
diabetes	O
involved	O
leucine-mediated	O
activation	O
of	O
the	O
mammalian	O
target	O
of	O
rapamycin	B
complex	O
1	O
(mTORC1),	O
which	O
resulted	O
in	O
the	O
uncoupling	O
of	O
insulin	O
signalling	O
at	O
an	O
early	O
stage.	O

2	O
×	O
10_4	O
cells	O
of	O
the	O
PC-knockdown	O
MDA-MB-231	O
or	O
the	O
scrambled	O
shRNA	O
control	O
cell	O
line	O
were	O
plated	O
into	O
35	O
mm_2	O
dishes	O
and	O
cultured	O
in	O
complete	O
DMEM	O
supplemented	O
with	O
1.0	O
µg/ml	O
puromycin	B
at	O
37	O
°C	O
with	O
5%	O
CO_2	O
.	O

Individuals	O
who	O
self-reported	O
as	O
non-cannabis-using	O
individuals,	O
yet	O
who	O
had	O
detectable	O
levels	O
of	O
≥2	O
plasma	O
cannabis	B
metabolites	O
(n	O
=	O
5),	O
and	O
individuals	O
who	O
reported	O
as	O
daily	O
cannabis	B
users,	O
yet	O
who	O
had	O
detectable	O
levels	O
of	O
≤2	O
cannabis	B
metabolites	O
(n	O
=	O
8),	O
were	O
excluded	O
from	O
their	O
respective	O
groups	O
and	O
from	O
all	O
future	O
analysis	O
(shown	O
in	O
red,	O
).	O

 	O
the	O
levels	O
of	O
2-HB,	O
3-HB,	O
lactate,	B
tyrosine,	B
and	O
citrate,	B
but	O
not	O
of	O
alanine,	B
valine,	B
and	O
glucose,	B
were	O
significantly	O
different	O
(increased)	O
in	O
patients	O
who	O
died	O
compared	O
to	O
those	O
who	O
survived	O
the	O
first	O
three	O
months	O
after	O
onset	O
of	O
AHF.	O

This	O
assay	O
was	O
validated	O
for	O
clinical	O
use	O
and	O
was	O
applied	O
to	O
blood	O
samples	O
from	O
patients	O
taking	O
mercaptopurine	B
(6MP).	O

High	O
performance	O
liquid	O
chromatography-electrospray	O
ionization-tandem	O
mass	O
spectrometry	O
multiple	O
reaction	O
monitoring	O
(negative	O
ion	O
mode)	O
chromatographic	O
profiles	O
of	O
estrogen	B
steroids	O
corresponding	O
to	O
100	O
pg/mL	O
in	O
standard	O
solution	O
(4%(w/w)	O
bovine	O
albumin).	O

Regarding	O
the	O
pyrimidine	B
metabolism,	O
SPMS	O
patients	O
had	O
altered	O
levels	O
of	O
uridine	B
and	O
deoxyuridine	B
compared	O
with	O
RRMS	O
and	O
controls,	O
and	O
altered	O
thymine	B
and	O
glutamine	B
compared	O
with	O
RRMS	O
patients.	O

Arachidonic	B
acid	I
and	O
precursors	O
were	O
elevated	O
in	O
AML,	O
particularly	O
in	O
patients	O
with	O
high	O
bone	O
marrow	O
(BM)	O
or	O
peripheral	O
blasts	O
and	O
unfavorable	O
prognostic	O
risk.	O

Studies	O
conducted	O
over	O
20	O
years	O
ago	O
showed	O
that	O
Alb	O
forms	O
adducts	O
with	O
the	O
human	O
carcinogens	O
aflatoxin	B
B_1	O
and	O
benzene,	B
which	O
were	O
successfully	O
used	O
as	O
biomarkers	O
in	O
molecular	O
epidemiology	O
studies	O
designed	O
to	O
address	O
the	O
role	O
of	O
these	O
chemicals	O
in	O
cancer	O
risk.	O

We	O
observed	O
a	O
significant	O
increase	O
in	O
the	O
levels	O
of	O
essential	O
fatty	O
acids	O
such	O
as	O
dihomo‐linolenate	O
and	O
arachidonate.	B

Interestingly,	O
tauroursodeoxycholic	B
acid	I
(TUDCA)	O
has	O
been	O
shown	O
to	O
protect	O
photoreceptors	O
from	O
cell	O
death	O
in	O
murine	B
models	O
of	O
retinitis	O
pigmentosa	O
and	O
retinal	B
detachment	O
,	O
as	O
well	O
as	O
to	O
suppress	O
choroidal	O
neovascularization	O
in	O
a	O
laser-treated	O
rat	O
model	O
.	O

In	O
this	O
regard	O
the	O
overshoot	O
of	O
serum	O
glucose	B
post	O
exercise	O
in	O
ACE-DD	O
genotypes	O
is	O
of	O
interest	O
as	O
these	O
subjects	O
may	O
miss	O
a	O
vasodilatatory	O
response	O
post-exercise.	O

The	O
correlation	O
between	O
acetaminophen	B
and	O
its	O
sulfate	B
conjugate	O
is	O
weaker	O
than	O
the	O
correlation	O
between	O
the	O
acetaminophen	B
parent	O
and	O
the	O
glucuronide.	B

N-acetylneuraminic	B
acid-9-phosphate	I
and	O
β-nicotinamide	B
mononucleotide	O
related	O
metabonomics	O
study	O
has	O
not	O
been	O
reported.	O

This	O
is	O
substantiated	O
by	O
comparison	O
of	O
metabolite	O
levels	O
for	O
the	O
same	O
blood	O
sample	O
obtained	O
after	O
extraction	O
using	O
methanol	B
and	O
chloroform	B
(1:2:2)	I
or	O
only	O
methanol	B
(1:2).	I

Interestingly,	O
we	O
noticed	O
that	O
L-citrulline	B
and	O
D-aspartic	B
acid	I
are	O
not	O
only	O
can	O
be	O
used	O
to	O
distinguish	O
BDTT	O
from	O
Stone,	O
they	O
are	O
also	O
effective	O
in	O
separating	O
BDTT	O
from	O
two	O
other	O
diseases.	O

Interestingly,	O
low	O
fibrosis	O
was	O
reported	O
as	O
an	O
intriguing	O
hallmark	O
of	O
β-catenin	B
mutated	O
tumors	O
[,].	O

(97.5 %)	O
and	O
d_4	B
-paracetamol	I

Regarding	O
the	O
role	O
of	O
glutamate	B
in	O
discriminating	O
lung	O
cancer	O
patients	O
from	O
controls,	O
the	O
relative	O
glutamate	B
concentrations	O
are	O
not	O
significantly	O
different.	O

OPLS-DA	O
score	O
plot	O
of	O
pre-treatment	O
(ESCC)	O
and	O
post-treatment	O
(ESCC-P)	O
patients	O
based	O
on	O
data	O
from	O
RRLC-(+)ESI-MS	B
(A	O
)	O
●	O
ESCC	O
and	O
■	O
ESCC-P;	O
all	O
patients,	O
(C	O
)	O

Rinse	O
II	O
also	O
included	O
chlorhexidine	B
gluconate	I
(0.12%	O
final	O
concentration).	O

The	O
GG	O
pattern	O
of	O
the	O
brain	O
was	O
very	O
different	O
from	O
the	O
other	O
tissues	O
with	O
the	O
absence	O
of	O
GM3	B
and	O
the	O
abundance	O
of	O
tetraosylGG:	O
GM1,	O
GD1a,	O
GD1b	O
and	O
GT1b	O
which	O
represented	O
respectively	O
23%,	O
15%,	O
35%	O
and	O
26%	O
of	O
the	O
total	O
nmoles	O
of	O
GGs	O
detected.	O

dihydroceramide	B

Macro-albuminuria,	O
which	O
is	O
an	O
indicator	O
of	O
kidney	O
disease,	O
was	O
associated	O
with	O
elevated	O
GCDCA	B
and	O
GDCA,	O
Tyr,	O
Trp,	O
and	O
decreased	O
Kynu	O
(,	O
).	O

Many	O
laboratories	O
haves	O
studied	O
the	O
regulation	O
of	O
ceramide	B
biosynthesis	O
(–);	O
however,	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
sphingolipids	B
in	O
cornea	O
and	O
even	O
less	O
is	O
known	O
about	O
their	O
role	O
in	O
the	O
diabetic	O
cornea.	O

No	O
associations	O
between	O
antenatal	O
serum	O
phthalate	B
metabolite	O
concentrations	O
and	O
adult	O
male	O
serum	O
inhB,	O
E_1	O
,	O
or	O
E_2	O
concentrations	O
were	O
found.	O

PC	B
aa	I
C34:2;	I
65.	O

In	O
the	O
present	O
study,	O
the	O
total	O
ceramide	B
means	O
refers	O
to	O
the	O
sum	O
of	O
ceramides	B
from	O
C_14:0	B
to	O
C_26:1	B
,	O
not	O
including	O
ceramide-1-phosphate	B
(C1P).	O

Indeed,	O
we	O
identified	O
two	O
metabolites	O
in	O
plasma,	O
histidine	B
and	O
guanidoacetic	B
acid,	I
and	O
one	O
metabolite,	O
hypotaurine,	B
in	O
urine,	O
as	O
possible	O
biomarkers	O
that	O
may	O
be	O
closely	O
associated	O
with	O
RA	O
disease	O
activity.	O

In	O
HIV-positive	O
subjects,	O
acylcarnitines	B
and	O
other	O
markers	O
of	O
mitochondrial	O
function	O
correlated	O
inversely	O
with	O
tryptophan	B
catabolism,	O
a	O
marker	O
of	O
IFN	O
responses,	O
suggesting	O
inter-relationships	O
between	O
inflammatory	O
pathways,	O
tryptophan	B
catabolism,	O
and	O
metabolic	O
alterations	O
associated	O
with	O
depression.	O

As	O
a	O
control,	O
synthetic	O
triglycerides	B
were	O
irradiated	O
at	O
the	O
ion	O
dose	O
used	O
for	O
analysis.	O

In	O
plasma	O
the	O
mean	O
total	O
recovery	O
of	O
abiraterone	B
was	O
76%	O
with	O
a	O
CV	O
of	O
1%	O
and	O
for	O
the	O
internal	O
standard	O
the	O
mean	O
recovery	O
was	O
72%	O
with	O
CV%	O
of	O
1%.	O

SUM	O
159	O
PT	O
was	O
grown	O
in	O
Ham	O
F12,	O
5%	O
insulin	O
hydrocortisone	B
(Life	O
Technologies).	O

m	O
The	O
samples	O
destined	O
for	O
GC/MS	O
analysis	O
were	O
re‐dried	O
under	O
vacuum	O
desiccation	O
for	O
a	O
minimum	O
of	O
24 h	O
prior	O
to	O
being	O
derivatized	O
under	O
dried	O
nitrogen	O
using	O
bis‐trimethylsilyl‐trifluoroacetamide.	B

A	O
total	O
of	O
103	O
SNPs	O
were	O
selected,	O
from	O
PEAR	O
HCTZ	O
monotherapy	O
SBP	O
and	O
DBP	B
GWAS	O
analyses,	O
based	O
on	O
our	O
suggestive	O
cut	O
off	O
p-value	O
(i.e.	O
p<5×10_−5	O
).	O

In	O
the	O
model,	O
the	O
increased	O
ceramide	B
mass	O
levels	O
might	O
result	O
either	O
from	O
the	O
accelerated	O
SM	O
hydrolysis,	O
which	O
would	O
involve	O
either	O
the	O
increased	O
levels	O
or	O
activities	O
of	O
sphingomyelinase	O
(SMase)	O
or	O
increased	O
biosynthesis,	O
which	O
would	O
be	O
largely	O
associated	O
with	O
serine	O
palmitoyltransferase.	O

α-HB,	B
alpha-hydroxybutyrate;	B
α-KB,	B
alpha-ketobutyrate;	B
BCAA,	O
branched	O
chain	O
amino	O
acids;	O
BCKDH,	O
branched	O
chain	O
alpha	O
keto	O
acid	O
dehydrogenase;	O
CBS,	O
cystathionine-beta-synthase;	O
CGL,	O
cystathionine	B
gamma-lyase;	O
HBDH,	O
α-hydroxybutyrate	O
dehydrogenase;	O
LDH,	O
lactate	O
dehydrogenase;	O
SAH,	O
S-adenosyl-L-homocysteine;	B
SAM,	O
S-adenosyl	B
Methionine.	I

The	O
method	O
was	O
tested	O
and	O
stability	O
was	O
studied	O
in	O
real	O
life	O
patients	O
with	O
metastatic	O
castration-resistant	O
prostate	O
cancer	O
patients	O
treated	O
with	O
enzalutamide.	B

Patients	O
underwent	O
blood	O
and	O
urine	O
laboratory	O
tests	O
that	O
included	O
fasting	O
plasma	O
glucose,	B
total	O
cholesterol,	B
triglycerides,	B
High	O
density	O
lipoprotein	O
cholesterol	B
(HDL-c),	O
Low	O
density	O
lipoprotein	O
cholesterol	B
(LDL-c)	O
serum	O
creatinine,	B
and	O
HbA1c.	O

A	O
total	O
of	O
nine	O
modifier	O
additives	O
were	O
tested	O
during	O
method	O
development;	O
of	O
these,	O
water,	O
formic	B
acid,	I
acetic	B
acid	I
and	O
the	O
ammonium	B
salts	O
were	O
MS-compatible.	O

Recently	O
it	O
has	O
been	O
shown	O
that	O
cholesteryl	B
linoleate	I
C(18:2)CE	I
can	O
be	O
oxidized	O
to	O
form	O
compounds	O
9-ON-secoA	B
and	O
9-ON-secoB,	B
both	O
of	O
which	O
have	O
been	O
found	O
to	O
exhibit	O
strong	O
cytotoxicity	O
against	O
human	O
leukemia	O
HL-60	O
cells.	O

CHB	O
infection	O
has	O
been	O
associated	O
with	O
alterations	O
in	O
lipid	O
metabolism	O
and	O
a	O
recent	O
study	O
showed	O
that	O
HBV	O
infection	O
altered	O
the	O
metabolic	O
gene	O
expression	O
in	O
a	O
human	O
liver-chimeric	O
mouse	O
model	O
by	O
altering	O
bile	O
acid	O
and	O
cholesterol	B
metabolism	O
as	O
a	O
consequence	O
of	O
impaired	O
bile	O
acid	O
uptake.	O

In	O
this	O
study,	O
perturbed	O
glycerophospholipid	B
metabolism,	O
glycerolipid	B
metabolism	O
and	O
fatty	O
acid	O
metabolism	O
were	O
firstly	O
discovered	O
in	O
AIS	O
patients,	O
validating	O
the	O
postulation	O
of	O
disturbed	O
energy	O
metabolism	O
of	O
AIS	O
by	O
some	O
researchers_,	O
.	O

The	O
measured	O
particulate-phase	O
PAH	O
were	O
acenaphthylene	B
(Ac),	O
acenaphthene	O
(Ace),	O
fluorene	B
(Fl),	O
phenanthrene	B
(Phe),	O
anthracene	B
(Ant),	O
fluoranthene	B
(Fluo),	O
pyrene	O
(Pyr),	O
benzo(a)anthracene	B
(BaA),	O
chrysene	O
(Chry),	O
benzo(b)	B
fluouranthene	O
(BbF),	O
benzo(k)fl	B
uoranthene	O
(BkF),	O
benzo(a)pyrene	B
(BaP),	O
indeno(1,2,3-cd)	B
pyrene	O
(Ind),	O
benzo(ghi)perylene	B
(BghiP),	O
dibenzo(ah)anthracene	B
(DahA)	O
and	O
coronene	O
(Cor).	O

Even	O
though	O
smoking	O
history	O
is	O
believed	O
to	O
be	O
a	O
risk	O
factor	O
of	O
NSCLC,	O
no	O
association	O
of	O
plasma	O
concentration	O
in	O
cholesteryl	B
esters	I
has	O
been	O
observed	O
between	O
smokers	O
and	O
non-smokers	O
at	O
a	O
large	O
scale	O
of	O
lipidomics	O
analysis.	O

Second,	O
LCACs	O
stimulate	O
reactive	O
oxygen	O
species	O
production	O
and	O
promote	O
cellular	O
stress	O
through	O
activation	O
of	O
c‐Jun	O
amino‐terminal	B
kinase,	O
p38	O
mitogen‐activated	O
protein	O
kinase,	O
and	O
the	O
apoptotic	O
caspase‐3	O
protein.56,	O
63	O
Third,	O
LCACs	O
may	O
promote	O
malignant	O
arrhythmias	O
by	O
(1)	O
modulating	O
deactivation	O
kinetics	O
of	O
voltage‐gated	O
potassium	O
channels	O
and	O
(2)	O
broadly	O
increasing	O
intracellular	O
calcium	O
concentrations	O
by	O
promoting	O
net	O
calcium	O
efflux	O
from	O
the	O
sarcoplasmic	O
reticulum.66,	O
67,	O
68	O
Last,	O
LCACs	O
may	O
not	O
only	O
reflect,	O
but	O
also	O
exacerbate	O
IR	O
by	O
inducing	O
serine	O
phosphorylation	O
of	O
insulin	O
receptor	O
substrate	O
1.56	O
Through	O
these	O
actions	O
and	O
potential	O
downstream	O
effects	O
on	O
the	O
cyclic	O
guanosine	O
monophosphate/protein	O
kinase	O
G	O
pathway,	O
elevated	O
LCACs	O
may	O
reflect,	O
promote,	O
or	O
exacerbate	O
myocardial	O
and	O
peripheral	O
pathologies	O
contributing	O
to	O
the	O
HF	O
phenotype.9	O
Proposed	O
model	O
for	O
plasma	O
long‐chain	O
acylcarnitine	B
contributions	O
to	O
the	O
heart	O
failure	O
phenotype.	O

From	O
the	O
kynurenine	B
pathway,	O
KYNA	O
(↑	O
SP-RR)	O
is	O
directly	O
generated	O
through	O
deamination	O
of	O
KYN	O
(↑	O
SP-RR,	O
↑	O
SP-C)	O
and	O
has	O
been	O
identified	O
as	O
a	O
neuroprotective	O
agent	O
involved	O
in	O
the	O
neurotoxic	O
processes	O
and	O
degenerative	O
mechanisms	O
of	O
MS.	O

The	O
film	O
was	O
digitized	O
using	O
a	O
high-resolution	O
scanner	O
and	O
the	O
image	O
density	O
of	O
appropriate	O
bands	O
(130	O
kDa	O
for	O
PC	O
and	O
50	O
kDa	O
for	O
α-tubulin)	B
was	O
analyzed	O
using	O
Image	O
J	O
(NIH,	O
Bethesda,	O
MD).	O

The	O
estrogen	B
metabolites,	O
conjugates	O
and	O
depurinating	O
DNA	O
adducts	O
were	O
identified	O
and	O
quantified	O
by	O
using	O
ultra-performance	O
liquid	O
chromatography/tandem	O
mass	O
spectrometry.	O

Correlation	O
heatmaps	O
between	O
skeletal	O
muscle	O
glucose	B
uptake	O
(GU)	O
and	O
whole-body	O
insulin	O
sensitivity	O
(M-value)	O
with	O
different	O
lipoprotein	O
subclasses:	O
HDL	O
particles	O
and	O
lipids	O
(a)	O
and	O
HDL	O
lipid	O
fractions	O
(b).	O

As	O
shown	O
in	O
,	O
the	O
recovery	O
of	O
creatinine-d_3	B
is	O
about	O
10%	O
higher	O
when	O
methanol-ethanol	B
is	O
used	O
compared	O
to	O
methanol	B
alone,	O
with	O
%CV	O
around	O
20%	O
for	O
both	O
methods.	O

Interestingly,	O
our	O
recent	O
gastric	O
bypass	O
surgery	O
study[]	O
(n	O
=	O
33)	O
showed	O
that	O
baseline	O
serum	O
tryptophan	B
level	O
was	O
negatively	O
associated	O
with	O
diabetes	O
duration.	B

∑nmi=1	O
∑nmi=1	O
∑	O
∑	O
nm	O
nm	O
nm	O
nm	O
n	O
n	O
m	O
m	O
	O
i=1	O
i=1	O
i	O
=	O
1	O
(	O
RVHU+NAFLDmi	O
RVHU+NAFLDmi	O
RV	B
RV	I

Three	O
metabolites	O
which	O
can	O
be	O
indicators	O
of	O
mitochondrial	O
TCA	O
cycle	O
activity,	O
3-hydroxybutyrate	B
[BHBA],	O
2-hydroxybutyrate	B
[AHB],	O
and	O
acetylcarnitine	B
were	O
elevated	O
in	O
cohort	O
1	O
BCa	O
urines.	O

An	O
exception	O
was	O
the	O
analysis	O
of	O
alpha-PEP	B
in	O
HILIC/negative	O
mode	O
(Figure _S8	O
).	O

ESR:	O
erythrocyte	O
sedimentation	O
rate,	O
TSAT:	O
transferrin	O
saturation,	O
VDBP:	O
vitamin	B
D	I
binding	O
protein,	O
p	O
:	O
Mann	O
Whitney	O
U	O
test	O
significance;	O
*	O
p	O
<	O
0.05,	O
**	O
p	O
<	O
0.001.	O

The	O
derivatization	O
reagent	O
PTAD	O
was	O
dissolved	O
in	O
acetonitrile	B
or	O
ethyl	B
acetate	I
at	O
different	O
concentrations,	O
and	O
samples	O
were	O
incubated	O
at	O
room	O
temperature	O
at	O
various	O
incubation	O
times.	O

Total	O
cholesterol	B
levels	O
were	O
measured	O
by	O
photometry	O
(Dimension	O
VISTA,	O
Siemens	O
Healthcare	O
Diagnostics,	O
Eschborn,	O
Germany).	O

Furthermore,	O
an	O
exaggerated	O
systemic	O
inflammatory	O
response	O
in	O
NR	O
would	O
be	O
in	O
accordance	O
with	O
the	O
high	O
levels	O
of	O
kynurenine,	B
supporting	O
the	O
role	O
of	O
an	O
accelerated	O
tryptophan	B
catabolism	O
along	O
the	O
kynurenine	B
pathway	O
in	O
sepsis	O
outcome.	O

Coming	O
back	O
to	O
the	O
focus	O
of	O
this	O
study,	O
it	O
can	O
be	O
concluded	O
that	O
neither	O
free	O
nor	O
bioavailable	O
25OHD	O
seems	O
to	O
be	O
an	O
optimal	O
sole	O
marker	O
of	O
vitamin	B
D	I
status	O
in	O
patients	O
with	O
chronic	O
inflammatory	O
disease.	O

In	O
particular,	O
a	O
comparison	O
of	O
the	O
postprandial	O
kinetics	O
of	O
lactose	B
after	O
milk	O
intake	O
(peak	O
value	O
at	O
2	O
h),	O
3-phenyllactic	B
acid	I
after	O
cheese	O
intake	O
(peak	O
value	O
at	O
2	O
h),	O
and	O
pinitol	B
after	O
soy	O
intake	O
(peak	O
value	O
at	O
4	O
h),	O
under	O
cross-over	O
study	O
conditions,	O
provides	O
interesting	O
insights	O
into	O
the	O
intestinal	O
processing	O
of	O
these	O
molecules.	O

While	O
it	O
has	O
been	O
previously	O
thought	O
that	O
efavirenz	O
induced	O
dyslipidaemia	O
was	O
not	O
atherogenic	O
in	O
nature	O
due	O
to	O
a	O
balanced	O
increase	O
in	O
LDL	O
and	O
HDL	O
(and	O
hence	O
no	O
alteration	O
in	O
LDL/HDL	B
ratio),	O
a	O
recent	O
analysis	O
from	O
the	O
large	O
veterans	O
affairs	O
database	O
in	O
the	O
US	O
has	O
found	O
an	O
increased	O
risk	O
of	O
cardiovascular	O
events	O
with	O
current	O
exposure	O
to	O
efavirenz	O
(OR	O
=	O
1.40;	O
95%	O
CI	O
1.19–1.66)	O
although	O
this	O
has	O
not	O
been	O
seen	O
in	O
other	O
prospective	O
cohort	O
studies.	O

Tissue	O
was	O
collected	O
just	O
prior	O
to	O
the	O
withdrawal	O
of	O
support	O
and	O
placed	O
immediately	O
in	O
80%	O
methanol	B
to	O
fix	O
the	O
tissue	O
for	O
histological	O
analysis	O
and	O
to	O
extract	O
metabolites.	O

The	O
prepared	O
phosphate	B
buffer	O
solution	O
was	O
stored	O
at	O
4°C.	O

Carnitine	B
and	O
acylcarnitines	B
are	O
essential	O
for	O
the	O
transport	O
of	O
long	O
chain	O
fatty	O
acids	O
across	O
the	O
mitochondrial	O
membrane	O
for	O
degradation	O
and	O
energy	O
production,	O
and	O
that	O
they	O
have	O
the	O
ability	O
to	O
shuttle	O
short	O
chain	O
fatty	O
acids	O
from	O
the	O
inside	O
of	O
the	O
mitochondria	O
to	O
the	O
cytosol.	O

One-	O
and	O
2-dimensional	O
NMR	O
analyses	O
demonstrated	O
that	O
this	O
derivatized	O
product	O
is	O
N	B
-acetyl-S	I
-[1-(5-methoxyimino-5-carboxypentyl)-1H	I
-pyrrol-3-yl]-L-cysteine	I
sulfoxide	I
(11,	O
and	O
).	O

In	O
this	O
article	O
we	O
present	O
bio-markers	O
of	O
risk	O
that	O
are	O
related	O
to	O
the	O
hypothesized	O
first	O
critical	O
step	O
in	O
the	O
initiation	O
of	O
breast	O
cancer,	O
namely,	O
the	O
reaction	O
of	O
catechol	B
estrogen	I
quinone	I
metabolites	O
with	O
DNA.	O

In	O
elevated	O
oxidative	O
stress	O
conditions,	O
the	O
flow	O
of	O
cysteine	B
for	O
the	O
formation	O
of	O
GSH	B
is	O
increased.	O

[]	O
It	O
has	O
also	O
been	O
reported	O
that	O
the	O
oxidation	O
of	O
methionine	B
residues	O
could	O
play	O
an	O
important	O
role	O
in	O
the	O
aggregation	O
of	O
normally	O
soluble	O
α-synuclein	B
in	O
PD.	O

The	O
pathways	O
identified	O
as	O
relevant	O
in	O
our	O
models,	O
have	O
been	O
previously	O
reported	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
resting	O
or	O
activated	B
T	O
cells.	O

We	O
focused	O
on	O
silica	B
nanoparticles	O
in	O
this	O
work,	O
but	O
quantum	O
dots	O
or	O
other	O
nanoparticles,	O
such	O
as	O
gold	O
or	O
silver	O
based	O
nanoparticles,	O
are	O
likely	O
to	O
work	O
as	O
well.	O

Further	O
characterization	O
of	O
the	O
reactivity	O
of	O
Alb	O
toward	O
4-hydroxy-trans	B
-2-nonenal	I
(HNE),	O
by	O
ion	O
trap	O
mass	O
spectrometry,	O
also	O
showed	O
that	O
Cys34	O
and	O
Lys199	O
were	O
the	O
most	O
reactive	O
adduction	O
sites	O
of	O
Alb	O
in	O
plasma	O
reactions	O
with	O
limiting	O
concentrations	O
of	O
HNE	O
and	O
resulted	O
in	O
the	O
formation	O
of	O
a	O
Michael	O
and	O
Schiff	O
base	O
adducts,	O
respectively.	O

Carnosine	B
levels	O
in	O
muscle	O
contribute	O
to	O
better	O
performances	O
of	O
high-intensity	O
exercise.	O

This	O
deduction	O
is	O
consistent	O
with	O
previous	O
work	O
that	O
has	O
found	O
evidence	O
of	O
reduced	O
brain	O
catecholamine	B
levels	O
in	O
the	O
pathophysiology	O
of	O
PSD._,	O

ANOVA	O
of	O
normalized	O
concentration	O
data	O
with	O
Tukey’s	O
post-hoc	O
test	O
showed	O
that	O
the	O
concentrations	O
of	O
23	O
compounds	O
were	O
significantly	O
different	O
(post	O
hoc	O
p	O
-values	O
≤	O
0.05)	O
between	O
MeOH	B
ppt	O
+UF	O
and	O
MeOH:	B

As	O
expected,	O
the	O
glucose	B
infusion	O
rate	O
was	O
inversely	O
correlated	O
with	O
the	O
BCAA:	O
leucine	B
(ρ=−0.52,	O
p=0.007),	O
isoleucine	B
(ρ=−0.41,	O
p=0.043),	O
and	O
valine	B
(ρ=−0.51,	O
p=0.010);	O
and	O
AAA:	O
phenylalanine	B
(ρ=−0.70,	O
p=0.007),	O
tyrosine	B
(ρ=−0.55,	O
p=0.005).	O

Other	O
fatty	O
acids,	O
such	O
as	O
myristic,	B
oleic,	O
palmitoleic,	B
and	O
stearic	B
acid	I
were	O
more	O
represented	O
in	O
both	O
MM	O
and	O
HL,	B
and	O
plasma	O
samples	O
from	O
HL	B
patients	O
were	O
also	O
characterized	O
by	O
an	O
increased	O
amount	O
of	O
linoleic	B
and	O
palmitic	B
acid.	I

Finally,	O
the	O
volume	O
of	O
concentrated	O
SNPs	O
was	O
adjusted	O
back	O
to	O
1	O
mL	O
using	O
the	O
same	O
phosphate	B
buffer,	O
with	O
a	O
recovery	O
rate	O
of	O
70%,	O
quantified	O
by	O
gravimetric	O
analysis	O
after	O
completely	O
solvent	O
evaporation.	O

The	O
reduced	O
concentrations	O
of	O
lactate	B
and	O
t-choline	B
metabolites	O
due	O
to	O
Degarelix	O
could	O
in	O
principle	O
be	O
monitored	O
by	O
in	O
vivo	O
_1	O
H	O
MRS,	O
which	O
suggests	O
that	O
it	O
would	O
be	O
possible	O
to	O
monitor	O
the	O
effects	O
of	O
physical	O
or	O
chemical	O
castration	O
in	O
patients	O
by	O
that	O
non-invasive	O
method.	O

Using	O
the	O
concentrations	O
of	O
these	O
three	O
metabolites,	O
a	O
diagnostic	O
equation	O
of	O
y	O
=	O
lysoPC	O
a	O
C16:0	B
×	O
1.034	O
+	O
PC	B
ae	I
C42:5	I
×	O
44.248	O
−	O
PC	B
aa	I
C34:2	I
×	O
0.585	O
−	O
37.002	O
was	O
established.	O

	O
Water,	O
methanol,	B
acetonitrile,	B
formic	B
acid,	I
ammonium	B
bicarbonate,	O
ammonium	B
hydroxide	I
solution,	O
and	O
ammonium	B
acetate	I
(99.999%)	O
were	O
purchased	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
MO)	O
and	O
were	O
LC-MS	O
grade	O
except	O
as	O
noted.	O

In	O
all,	O
1,828	O
molecular	O
features	O
were	O
found	O
in	O
the	O
MTBE	B
extracted	O
lipid	O
fraction,	O
and	O
1,410	O
features	O
were	O
found	O
when	O
methanol	B
alone	O
was	O
used	O
in	O
conjunction	O
with	O
RPC.	O

When	O
compared	O
with	O
FDR,	O
the	O
levels	O
of	O
the	O
acylcarnitine:	B
C2,	O
C16	O
and,	O
C18:1	B
were	O
found	O
to	O
be	O
higher	O
in	O
GC	O
as	O
well	O
as	O
in	O
NHL	O
and	O
breast	O
cancer	O
groups.	O

The	O
method	O
is	O
robust	O
down	O
to	O
0.2–4	O
pg	B
on	O
column,	O
depending	O
on	O
the	O
androgen	O
metabolite	O
quantified,	O
and	O
can	O
also	O
quantify	O
dehydroepiandrosterone	B
sulfate	I
(DHEA-S)	O
in	O
only	O
1	O
μL	O
of	O
serum.	O

From	O
these	O
primary	O
solutions,	O
working	O
solutions	O
were	O
prepared	O
as	O
mixtures	O
of	O
imatinib	B
and	O
its	O
metabolite	O
(CGP74588)	O
at	O
a	O
final	O
concentration	O
of	O
200	O
µg/mL;	O
these	O
mixtures	O
were	O
the	O
precursor	O
solutions	O
for	O
preparing	O
the	O
calibration	O
curves	O
and	O
the	O
quality	O
controls.	O

Up-regulation	O
of	O
3-hydroxyanthranilic	B
acid	I
was	O
observed	O
in	O
the	O
DOCK8-deficient	O
cohort	O
compared	O
with	O
Ctrl	O
and	O
AD,	O
while	O
aspartic	B
acid	I
was	O
up-regulated	O
in	O
DOCK8-deficient	O
cohort	O
compared	O
with	O
Ctrl	O
and	O
hypotaurine	B
was	O
down-regulated	O
in	O
DOCK8	O
deficiency	O
compared	O
with	O
the	O
AD.	O

The	O
result	O
of	O
our	O
correlation	O
analysis	O
shows	O
that	O
valine	B
has	O
a	O
moderate	O
and	O
strong	O
positive	O
correlation	O
with	O
isoleucine	B
in	O
both	O
HCC	O
cases	O
and	O
cirrhotic	O
controls,	O
respectively,	O
suggesting	O
its	O
connection	O
not	O
only	O
to	O
cancer	O
but	O
other	O
liver	O
diseases	O
such	O
as	O
cirrhosis	O
as	O
previously	O
reported.	O

Therefore,	O
our	O
results	O
indicate	O
that	O
the	O
relationship	O
between	O
vitamin	B
D	I
deficiency	O
and	O
cardiometabolic	O
diseases	O
is	O
unlikely	O
to	O
merely	O
reflect	O
pathomechanisms	O
related	O
to	O
obesity.	O

We	O
found	O
that	O
in	O
healthy	O
premenopausal	O
women,	O
an	O
exercise	O
regimen	O
of	O
150	O
minutes	O
of	O
moderate-to-vigorous	O
aerobic	O
exercise	O
per	O
week	O
for	O
16	O
weeks	O
resulted	O
in	O
significant	O
changes	O
in	O
estrogen	B
metabolism	O
in	O
a	O
direction	O
consistent	O
with	O
reduction	O
of	O
breast	O
cancer	O
risk.	O

Chromatograms	O
of	O
dabrafenib	O
in	O
lowest	O
patient	O
sample	O
(A	O
,	O
75 ng/mL)	O
and	O
at	O
LLOQ	O
(B	O
,	O
5 ng/mL)	O
compared	O
to	O
blank	O
(C	O
)	O
and	O
the	O
internal	O
standard	O
D6-erlotinib	B
(D	O
)	O
Typical	O
chromatogram	O
of	O
patient	O
sample.	O

Full	O
PI	O
and	O
PS	O
profiles	O
appeared	O
to	O
be	O
a	O
key	O
to	O
the	O
cell	O
line	O
discrimination,	O
while	O
FA	B
composition	O
of	O
discriminating	O
MW	O
species	O
appeared	O
to	O
be	O
specific	O
for	O
individual	O
PL	O
classes,	O
as	O
shown	O
in	O
.	O

PhIP/nmol	O
SA,	O
based	O
on	O
the	O
assumption	O
that	O
N	B
-acetoxy-PhIP-SA	I
adducts	O
possess	O
molar	O
absorption	O
coefficients	O
that	O
are	O
comparable	O
to	O
that	O
of	O
PhIP	O
(315	O
nm;	O
ε	O
(M_−1	O
cm_−1	O
)	O
at	O
22,220).	O

Specifically,	O
the	O
UK	O
population	O
samples	O
replicated	O
25	O
of	O
the	O
29	O
structurally	O
identified	O
significant	O
BMI-metabolite	O
associations	O
at	O
a	O
5%	O
ST-FDR;	O
the	O
exceptions	O
were	O
citrate,	B
NMNA,	O
proline	B
betaine,	I
and	O
3-hydroxymandelate,	B
possibly	O
reflecting	O
reduced	O
statistical	O
power	O
for	O
these	O
analyses	O
because	O
of	O
the	O
smaller	O
sample	O
size	O
in	O
the	O
UK	O
cohort.	O

The	O
amount	O
of	O
sphingolipid	B
metabolites	O
in	O
the	O
tissue	O
were	O
determined	O
by	O
mass	O
spectrometry.	O

The	O
points	O
and	O
horizontal	O
lines	O
indicate	O
the	O
regression	O
coefficient	O
slopes	O
(β	O
)	O
for	O
testosterone	B
with	O
their	O
95%	O
confidence	O
intervals	O
in	O
cases	O
and	O
controls.	O

Arginine	B
and	O
its	O
products	O
are	O
critical	O
for	O
the	O
growth	O
of	O
several	O
cancers	O
by	O
enhancing	O
tumour	O
growth,	O
and	O
arginine	B
depletors	O
have	O
been	O
shown	O
effective	O
as	O
anti-cancer	O
drugs	O
in	O
several	O
cancers	O
including	O
PCa	O
(;	O
;	O
).	O

The	O
undesirable	O
contribution	O
of	O
glycerol	B
associated	O
with	O
the	O
membrane	O
in	O
the	O
centrifugal	O
filters	O
has	O
been	O
reported	O
earlier.	O

The	O
changes	O
in	O
metabolic	O
gene	O
expression	O
profiles	O
in	O
the	O
11	O
responders	O
to	O
IER	O
resembled	O
changes	O
in	O
women	O
undertaking	O
a	O
60 %	O
CER	B
for	O
one	O
menstrual	O
cycle	O
from	O
our	O
previous	O
study	O
whilst	O
the	O
9	O
non-responders	O
resembled	O
the	O
non-dieting	O
controls	O
in	O
this	O
study.	O

The	O
Sigma-Aldrich	O
oligosaccharides	B
kit	O
was	O
prepared	O
in	O
acetonitrile:water	O
(1:1,	O
v/v).	O

In	O
Table	O
are	O
reported	O
the	O
general	O
characteristics	O
and	O
the	O
plasma	O
levels	O
of	O
24S-OH-Chol	B
in	O
patients	O
with	O
LOAD,	O
VD,	O
CIND,	O
and	O
in	O
C.	O

Of	O
all	O
differential	O
lipids,	O
FA	B
(18:3)	I
was	O
identified	O
as	O
α	O
linolenic	B
acid	I
(ALA).	O

Cationic	O
metabolites	O
were	O
separated	O
through	O
a	O
fused	O
silica	B
capillary	O
(50 μm	O
internal	O
diameter × 80 cm	O
total	O
length)	O
preconditioned	O
with	O
a	O
commercial	O
buffer	O
(H3301-1001,	O
Human	O
Metabolome	O
Technologies	O
Inc.	O
(HMT),	O
Tsuruoka,	O
Japan)	O
and	O
filled	O
with	O
1 M	O
formic	B
acid	I
as	O
electrolyte,	O
and	O
a	O
commercial	O
sheath	O
liquid	O
(H3301-1020,	O
HMT)	O
was	O
delivered	O
at	O
a	O
rate	O
of	O
10 μl/min.	O

Direct	O
measurements	O
of	O
CSF	O
glucose	B
levels	O
(performed	O
immediately	O
after	O
sample	O
collection)	O
confirmed	O
a	O
highly	O
significant	O
increase	O
in	O
glucose	B
levels	O
in	O
drug-naïve	O
patients	O
with	O
schizophrenia	O
in	O
the	O
first	O
cohort	O
(6.5%	O
increase,	O
p	O
=	O
0.005;	O
).	O

Median	O
concentrations	O
of	O
sofosbuvir	B
and	O
ribavirin	B
metabolites	O
in	O
human	O
liver	O
sections	O
after	O
3	O
to	O
52	O
weeks	O
of	O
treatment	O
with	O
sofosbuvir	B
and	O
ribavirin.	B

As	O
expected,	O
and	O
as	O
previously	O
described[,	O
],	O
those	O
with	O
history	O
of	O
diabetes	O
mellitus	O
or	O
renal	O
insufficiency	O
witnessed	O
higher	O
levels	O
of	O
TMAO,	B
choline,	B
and	O
betaine	B
compared	O
to	O
those	O
without.	O

Two	O
of	O
the	O
six	O
markers	O
were	O
identified	O
as	O
imidazoleacetic	B
acid	I
whose	O
relation	O
to	O
bladder	O
cancer	O
has	O
certain	O
degree	O
of	O
supporting	O
evidence.	O

The	O
amount	O
of	O
N	B
-acetoxy-PhIP	I
was	O
about	O
100-fold	O
greater	O
than	O
the	O
amount	O
of	O
its	O
inactive	O
isomer,	O
the	O
hydroxamic	B
acid,	I
N	B
-hydroxy-N	I
-(1-methyl-6-phenylimidazo[4,5-b	I
]pyridin-2-yl)-acetamide	I
(N	O
-hydroxy-N	I
-acetyl-PhIP),	I
assuming	O
comparable	O
ionization	O
efficiencies	O
of	O
the	O
compounds	O
by	O
ESI/MS.	O

It	O
also	O
appears	O
that	O
A_2A	O
R-mediated	O
signals	O
delivered	O
to	O
Treg	O
by	O
TEX	O
were	O
significantly	O
more	O
effective	O
in	O
stimulating	O
inosine	B
production	O
than	O
were	O
the	O
TEX	O
parent	O
cells,	O
emphasizing	O
the	O
importance	O
of	O
exosomes	O
in	O
mediating	O
intercellular	O
communication.	O

This	O
finding	O
is	O
in	O
concordance	O
with	O
the	O
inverse	O
association	O
between	O
hsCRP	O
and	O
glutamine	B
in	O
the	O
present	O
study.	O

Given	O
that	O
PC	B
16:0/18:1	I
was	O
the	O
dominant	O
component	O
(94%),	O
HILIC-PB-MS_2	O
CID	O
in	O
positive	O
ion	O
mode	O
readily	O
provided	O
CC	O
location	O
information,	O
viz.	O

On	O
the	O
other	O
hand,	O
MTBE	B
and	O
C18	O
extraction	O
methods	O
demonstrated	O
the	O
worst	O
repeatability	O
independent	O
of	O
LC-MS	O
analysis.	O

The	O
stock	O
solutions	O
of	O
QA,	O
PA,	O
3-hydroxy-PA,	B
2-hydroxynicolinic	B
acid,	I
tyramine,	B
tryptamine,	B
tyrosine	B
and	O
baclofen	O
were	O
prepared	O
at	O
10	O
mM	O
in	O
triply	O
deionized	O
water.	O

Since	O
muscle	O
ATP	B
levels	O
are	O
not	O
differentiating	O
between	O
the	O
two	O
groups,	O
FS	O
animals	O
appeared	O
to	O
rely	O
more	O
heavily	O
on	O
this	O
non-oxidative	O
mode	O
of	O
ATP	B
generation.	O

In	O
our	O
study,	O
glycoprotein	O
acetyls	O
consisted	O
mostly	O
of	O
alpha-1-acid	B
glycoprotein	I
(AGP,	O
also	O
known	O
as	O
orosomucoid).	O

Uric	B
acid	I
is	O
biologically	O
active	O
and	O
can	O
stimulate	O
oxidative	O
stress,	O
endothelial	O
dysfunction,	O
inflammation	O
and	O
vasoconstriction.	O

High-density	O
lipoprotein	O
cholesterol	B
(HDL)	O
and	O
low-density	O
lipoprotein	O
were	O
measured	O
using	O
Cobas	O
agents,	O
HDL-cholesterol,	B
no	O
pretreatment,	O
and	O
LDL-cholesterol,	B
no	O
pretreatment,	O
in	O
homogeneous	O
enzymatic	O
colorimetric	O
assay.	O

No	O
assays	O
of	O
estrogens	O
or	O
estrogen	B
metabolites	O
in	O
this	O
study	O
resulted	O
in	O
non-detectable	O
readings.	O

We	O
also	O
detected	O
bisethane,	B
but	O
it	O
appears	O
to	O
be	O
artefact	O
of	O
chemical	O
derivatization	O
and	O
is	O
not	O
a	O
urine	O
metabolite.	O

The	O
levels	O
of	O
TG,	B
TC,	O
LDL-C,	O
and	O
HDL-C	O
differed	O
significantly	O
in	O
the	O
groups	O
with	O
abnormal	O
plasma	O
lipid	O
levels	O
(P	O
<	O
0.001).	O

Additional	O
studies	O
are	O
needed	O
to	O
determine	O
whether	O
the	O
observed	O
postprandial	O
enrichment	O
of	O
EPA-derived	O
oxylipins	B
that	O
mark	O
pro-TGRL	O
are	O
themselves	O
proactive	O
mediators	O
of	O
inflammation.	O

Compared	O
with	O
the	O
controls,	O
three	O
metabolites	O
(histidine,	O
leucine	B
and	O
C5-carnitine)	B
were	O
increased	O
in	O
the	O
patients	O
with	O
lung	O
cancer	O
in	O
the	O
2015	O
data	O
set,	O
but	O
decreased	O
in	O
the	O
2017	O
data	O
set.	O

Citrate	B
molecules	O
are	O
signaling	O
molecules	O
in	O
inflammation	O
processes	O
and	O
in	O
the	O
beginnings	O
of	O
the	O
non-alcoholic	O
fatty	O
liver	O
disease.	O

Plasma	O
glucose	B
_13	O
C-labeling	O
from	O
the	O
patient	O
presented	O
in	O
,	O
C.	O
_13	O
C-_13	O
C	O
doublets	O
C1D12	O
and	O
C2D23	O
are	O
due	O
to	O
[1,2-_13	O
C]	I
and	O
[2,3-_13	O
C]	I
isotopomers	O
of	O
_13	O
C	O
labeled	O
glucose	B
respectively.	O

The	O
two	O
groups	O
were	O
similar	O
in	O
age	O
(p=0.78),	O
but	O
semi-vegetarians	O
had	O
a	O
lower	O
BMI	O
(23.9±5.1	O
vs	O
26.3±5.3	O
kg/m_2	O
;	O
p=0.01)	O
and	O
non-significantly	O
lower	O
urinary	O
creatinine	B
(868±372	O
vs.	O
1140±152	O

Hence,	O
the	O
observed	O
changes	O
in	O
serum	O
concentration	O
of	O
phospholipids	B
were	O
not	O
directly	O
associated	O
with	O
the	O
treatment-related	O
loss	O
of	O
patients’	O
body	O
mass.	O

Isoleucine	B
acts	O
a	O
nutrient	O
regulator	O
of	O
glucose	B
metabolism	O
and	O
isoleucine	B
signaling	O
is	O
involved	O
in	O
the	O
acceleration	O
of	O
metabolism	O
of	O
glucose.	B

Interestingly,	O
urinary	O
concentrations	O
of	O
metabolite	O
downstream	O
of	O
this	O
compound	O
(quinolinic	O
acid	O
and	O
xanthurenic	B
acid)	O
are	O
elevated	O
in	O
autistic	O
children,	O
whereas	O
metabolite	O
upstream	O
of	O
3-hydroxykinurenine	B
(kynurenine	O
and	O
kynurenic	O
acid)	O
are	O
higher	O
among	O
controls	O
(Fig.	O

Using	O
a	O
dummy	O
matrix	O
of	O
the	O
graded	O
criteria,	O
PLS-DA	O
yielded	O
Q_2	O
 = 2%	O
for	O
the	O
pronounced	O
hyperglycemia	O
class	O
G2	O
at	O
visit	O
V2,	O
involving	O
citrate,	B
glucose	B
and	O
the	O
unidentified	O
signal	O
at	O
1.08	O
ppm.	O

Analysis	O
of	O
healthy	O
tissue	O
samples	O
adjacent	O
to	O
the	O
tumors	O
revealed	O
the	O
presence	O
of	O
13	O
glycerophospholipid	B
species	O
containing	O
9-HSA	O
(A).	O

Nervonic	B
acid	I

Unadjusted	O
linear	O
regression	O
correlations	O
between	O
PAF	O
species	O
and	O
depressive	O
symptoms	O
in	O
CAD	O
patients	O
(n=26)	O
Notes:	O
Nomenclature	O
adheres	O
to	O
the	O
recent	O
reorganization	O
of	O
ontologies	O
for	O
lipid	O
classes	O
and	O
the	O
curated	O
list	O
of	O
lipid	O
species	O
identified	O
by	O
the	O
CIHR	O
Training	O
Program	O
in	O
Neurodegenerative	O
Lipidomics	O
(CTPNL)	O
teams._,	O
PC(O	B
-20:4/2:0),	I
for	O
example,	O
defines	O
a	O
lipid	O
species	O
with	O
a	O
phosphocholine	B
(PC)	O
polar	O
head	O
group,	O
an	O
ether	O
linkage	O
at	O
the	O
sn	O
-1	O
position	O
(O	O
-)	O
with	O
a	O
chain	O
of	O
20	O
carbons,	O
and	O
2	O
carbons	O
linked	O
by	O
an	O
ester	O
linkage	O
at	O
the	O
sn	O
-2	O
position,	O
of	O
which	O
the	O
sn	O
-1	O
chain	O
has	O
four	O
degrees	O
of	O
unsaturation	O
(indicated	O
as:	O
4)	O
whereas	O
the	O
sn	O
-2	O
chain	O
is	O
characterized	O
by	O
fully	O
saturated	O
acetyl	O
group	O
(referred	O
to	O
by:	O
0).	O

The	O
cartridge	O
was	O
then	O
eluted	O
with	O
four	O
1	O
mL	O
aliquots	O
of	O
90%	O
MeOH	B
and	O
2%	O
HCOOH	O
to	O
collect	O
the	O
analytes.	O

The	O
blank	O
plasma	O
sample	O
was	O
obtained	O
from	O
donor's	O
blood	O
treated	O
with	O
sodium	B
heparin.	I

[PubMed]	O
[Google	O
Scholar]	O
Prostaglandins.	B
1972	O
Oct;2(4):251–263.	O

We	O
have	O
established	O
and	O
validated	O
a	O
simple,	O
fast,	O
and	O
reproducible	O
assay	O
for	O
directly	O
quantitating	O
the	O
urinary	O
conjugated	O
vitamin	B
E	I
metabolites	O
and	O
shown	O
unequivocally	O
for	O
the	O
first	O
time	O
that	O
conjugates	O
of	O
α-TL	B
were	O
real	O
metabolites	O
and	O
not	O
artifacts	O
of	O
the	O
methodological	O
procedure.	O

Furthermore,	O
high	O
ketone	B
levels	O
also	O
inhibit	O
hepatic	O
gluconeogenesis,	O
stimulate	O
splanchnic	O
protein	O
synthesis,	O
and	O
may	O
or	O
may	O
not	O
inhibit	O
muscle	O
protein	O
degradation	O
,	O
.	O

Increased	O
catabolism	O
of	O
tryptophan	B
to	O
kynurenine	B
has	O
been	O
found	O
in	O
patients	O
with	O
depression	O
[,	O
],	O
schizophrenia	O
[,	O
],	O
women	O
with	O
postpartum	O
depression	O
and	O
women	O
with	O
preeclampsia.	O

For	O
arylamine	B
adducts	O
with	O
PP,	O
the	O
amounts	O
hydrolyzed	O
varied	O
from	O
0	O
to	O
58%	O
of	O
the	O
bound	O
adduct.	O

These	O
pathways	O
were	O
pyrimidine	B
metabolism;	O
alanine,	B
aspartate	B
and	O
glutamate	B
metabolism;	O
caffeine	B
metabolism;	O
beta-alanine	B
metabolism;	O
purine	B
metabolism;	O
cysteine	B
and	O
methionine	B
metabolism;	O
sulfur	O
metabolism;	O
sphingolipid	B
metabolism;	O
arginine	B
and	O
proline	B
metabolism;	O
63	O
metabolites	O
(Additional	O
file	O
2)	O
were	O
identified	O
in	O
the	O
aforementioned	O
9	O
pathways	O
and	O
a	O
corresponding	O
heatmap	O
is	O
shown	O
in	O
Fig.	O

Valine	B
excretion	O
was	O
associated	O
with	O
both	O
proteinuria	O
and	O
decreasing	O
sodium	O
levels.	O

We	O
found	O
a	O
relationship	O
(inverse)	O
with	O
BMI	O
of	O
the	O
gut	O
microbial-host	O
co-metabolite	O
4-cresyl	B
sulfate	I
(P	O
=	O
8.09	O
×	O
10_−11	O
),	O
a	O
hepatic	O
phase	O
2	O
α	O
conjugation	O
(detoxification)	O
product	O
of	O
4-cresol,	B
which	O
is	O
a	O
distal	O
colonic	O
bacterial	O
degradation	O
product	O
of	O
tyrosine.	B

Measurement	O
of	O
additional	O
isoleucine	B
spectral	O
regions	O
with	O
no	O
lipoprotein	O
overlap	O
was	O
prevented	O
by	O
the	O
histopaque	O
contaminant	O
present	O
in	O
these	O
samples.	O

As	O
shown	O
in	O
,	O
the	O
mean	O
concentrations	O
for	O
a	O
number	O
of	O
these	O
metabolites	O
including	O
formate,	B
histidine,	B
proline,	B
N-acetyl-glycine	B
and	O
3-hydroxy-2-methyl-butanoic	B
acid	I
decrease	O
significantly	O
in	O
recurrent	O
cancer.	O

Adults	O
in	O
good	O
general	O
health	O
without	O
a	O
history	O
of	O
major	O
chronic	O
illnesses	O
were	O
randomized	O
into	O
a	O
placebo-controlled	O
trial	O
for	O
assessing	O
the	O
pharmacokinetics	O
and	O
pharmacodynamics	O
of	O
a	O
beverage	O
enriched	O
with	O
GR	O
and	O
SF	B
from	O
broccoli	O
sprouts.	O

A	O
notable	O
exception	O
involved	O
the	O
C16	O
ceramides	B
(Cer	O
d18:1/16:0	B
and	O
Cer	B
d18:2/16:0),	I
which	O
did	O
not	O
cluster	O
with	O
the	O
other	O
ceramides.	B

Increasing	O
methionine	B
levels	O
were	O
also	O
associated	O
with	O
an	O
increasing	O
trend	O
in	O
the	O
risk	O
of	O
pancreatic	O
cancer.	O

One	O
normally	O
expects	O
cancer	O
cells	O
to	O
be	O
forming	O
lactate	B
for	O
host	O
cells	O
to	O
oxidise,	O
but	O
Lisanti	O
has	O
described	O
a	O
“reverse	O
Warburg	O
effect”	O
in	O
which	O
cancer	O
cells	O
oxidise	O
lactate	B
formed	O
in	O
host	O
cells.	O

We	O
found	O
that	O
glucose	B
was	O
upregulated	O
in	O
sepsis	O
patients,	O
which	O
is	O
in	O
line	O
with	O
a	O
previous	O
pediatric	O
sepsis	O
study.	O

Then,	O
the	O
solid	O
was	O
washed	O
with	O
2x100	O
mL	O
of	O
acetone,	B
dried	O
and	O
placed	O
in	O
a	O
furnace.	O

Interestingly,	O
recent	O
work	O
reported	O
a	O
therapeutic	O
effect	O
of	O
lysine	B
administration	O
in	O
T2DM	O
patients	O
to	O
counteract	O
the	O
production	O
of	O
glycated	O
lysozyme.	O

R	O
_2	O
(squared	O
correlation	O
coefficient)	O
represents	O
the	O
proportion	O
of	O
variation	O
in	O
total	O
diosmetin	B
that	O
is	O
accounted	O
by	O
the	O
diosmetin	B
after	O
digestion,	O
and	O
it	O
is	O
presented	O
here	O
as	O
a	O
ratio.	O

So,	O
the	O
increase	O
in	O
aromatic	O
hydrocarbons	B
in	O
cancer	O
cell	O
lines	O
media	O
can	O
be	O
an	O
indicator	O
of	O
an	O
increase	O
in	O
ROS	O
activity,	O
which	O
could	O
lead	O
to	O
lipid	O
peroxidation	O
and	O
consequently	O
to	O
cell	O
membrane	O
damage.	O

Percent	O
changes	O
in	O
serum	O
kynurenine	B
metabolites	O
in	O
patients	O
affected	O
by	O
CH	O
with	O
respect	O
to	O
healthy	O
controls.	O

Differences	O
in	O
3-hydroxyisovalerate,	B
2-aminoisobutyrate	B
and	O
glycine	B
could	O
be	O
clearly	O
reproduced,	O
while	O
changes	O
in	O
inosine,	B
β-alanine	B
and	O
acetate	B
were	O
less	O
significant.	O

The	O
instrument	O
sensitivity	O
was	O
checked	O
daily	O
by	O
injecting	O
the	O
lowest	O
calibration	O
standard	O
(1	O
pg	B
injected	O
on	O
column	O
for	O
1-NAP	O
and	O
2-NAP	O
and	O
250	O
fg	B
for	O
the	O
remaining	O
analyte).	O

Over	O
3	O
times	O
more	O
17:0	O
Cer	O
and	O
17:0	O
PE	O
were	O
extracted	O
using	O
the	O
methanol-ethanol	B
method	O
compared	O
to	O
the	O
methanol	B
method.	O

A	O
doublet	O
at	O
2.63–2.68	O
ppm	O
indicated	O
that	O
methionine	B
was	O
discriminative	O
between	O
dairy	O
products	O
(i.e.,	O
milk	O
and	O
cheese)	O
and	O
the	O
soy	O
drink.	O

We	O
identified	O
situations	O
suggesting	O
an	O
overproduction	O
occurring	O
at	O
a	O
systemic	O
level	O
(Cit)	O
and	O
situations	O
of	O
urinary	O
retention	O
(ADMA)	O
and	O
urinary	O
excretion	O
(proline).	O

In	O
summary,	O
this	O
metabolomics	O
analysis	O
demonstrates	O
that	O
arginine	B
metabolism	O
is	O
dysregulated	O
in	O
DR	O
and	O
that	O
fatty	O
acid	O
metabolism	O
is	O
altered	O
in	O
PDR.	O

Bile	O
acids	O
which	O
have	O
important	O
roles	O
as	O
signaling	O
molecules	O
controlling	O
glucose,	B
lipid,	O
and	O
energy	O
metabolism	O
were	O
significantly	O
different	O
in	O
subjects	O
with	O
macro-albuminuria,	O
and	O
they	O
were	O
further	O
associated	O
with	O
glycemic	B
control.	O

Using	O
β-actin	B
as	O
an	O
internal	O
reference,	O
PCR	O
was	O
preceded	O
using	O
FastStart	O
Universal	O
SYBR	O
Green	O
Master	O
(F.	O
Hoffmann-La	O
Roche	O
Ltd.,	O
Basel,	O
Switzerland).	O

An	O
ESI-MS/MS	O
analysis	O
of	O
low-mass	O
ions	O
in	O
urine	O
identified	O
137.08	O
m/z	O
as	O
hypoxanthine	B
(Figure	O
and	O
).	O

Interestingly,	O
the	O
neighborhood	O
with	O
the	O
most	O
severe	O
insulin	O
resistance	O
did	O
not	O
coincide	O
with	O
the	O
highest	O
values	O
of	O
creatinine	B
and	O
urea,	B
which	O
suggests	O
that	O
there	O
is	O
a	O
subtle	O
systematic	O
difference	O
between	O
the	O
two	O
clinical	O
conditions.	O

Biliverdin.	B

Methoxyamination	O
was	O
performed	O
by	O
adding	O
60	O
μL	O
methoxyamine.	B

Metabolites	O
from	O
top	O
to	O
bottom	O
are:	O
creatinine;	B
creatine	B
phosphate;	I
leucine;	B
glucose;	B
proline;	B
phosphocholine;	B
choline;	B
creatine+creatine	B
phosphate;	I
albumin;	O
trimethylamine;	B
citrate+dimethylamine;	B
glutamine;	B
3-hydroxyisovalerate;	B
pyruvate;	B
N-acetylglutamine;	B
lipids	O
( = CH-CH2-CH2-)+aminobutyrate;	B
isoleucine;	B
lipids	O
(βCH2);	O
alanine;	B
lactate;	B
lipids	O
(-CH2-)n;	O
valine;	B
valine+isoleucine;	B
leucine+isoleucine;	B
lipids	O
(-CH3)	O
and	O
cholesterol.	B

As	O
summarized	O
in	O
and	O
,	O
-hydroxybutyrate	B
(3-HBA)	O
and	O
acetoacetate	B
(AcAc)	O
were	O
elevated	O
in	O
PSPC	O
versus	O
placebo	O
at	O
the	O
recovery	O
time	O
point	O
(fold	O
differences,	O
1.75	O
and	O
1.60,	O
respectively,	O
both	O
contrasts,	O
P<0.01,	O
with	O
Q-values	O
of	O
0.265	O
and	O
0.246,	O
respectively),	O
indicative	O
of	O
increased	O
fatty	O
acid	O
oxidation	O
and	O
ketone	B
synthesis.	O

These	O
findings	O
are	O
consistent	O
with	O
those	O
of	O
Lazarus	O
&	O
Sun	O
who,	O
citing	O
their	O
unpublished	O
results,	O
reported	O
that	O
UGT1A4	O
was	O
the	O
main	O
enzyme	O
responsible	O
for	O
anastrozole	B
N-glucuronidation	O
in	O
vitro	O
,	O
with	O
an	O
average	O
K	O
_m	O
value	O
of	O
∼637	O
µm,	O
which	O
was	O
close	O
to	O
the	O
results	O
of	O
the	O
present	O
study.	O

The	O
gradient	O
system	O
used	O
to	O
separate	O
the	O
phosphopeptides	B
was	O
the	O
following:	O

Serine	B
not	O
only	O
activates	O
this	O
enzyme	O
upon	O
binding,	O
but	O
depletion	O
of	O
serine	B
results	O
in	O
an	O
attenuation	O
of	O
PKM2	O
activity.	O

Others	O
have	O
demonstrated	O
increased	O
urine	O
lactate	B
levels	O
and	O
TCA	O
cycle	O
disturbances	O
in	O
rats	O
treated	O
with	O
streptozotocin	B
.	O

We	O
accomplished	O
this	O
with	O
the	O
addition	O
of	O
0.2	O
M	O
ammonium	B
acetate	I
buffer.	O

It	O
is	O
this	O
imbalance	O
in	O
estrogen	B
metabolism,	O
leading	O
to	O
relatively	O
high	O
levels	O
of	O
estrogen-DNA	O
adducts,	O
that	O
may	O
be	O
a	O
critical	O
determinant	O
of	O
breast	O
cancer	O
initiation.	O

Two	O
subjects	O
were	O
being	O
treated	O
for	O
diabetes,	O
6	O
for	O
high	O
cholesterol,	B
and	O
24	O
for	O
high	O
blood	O
pressure.	O

The	O
sample	O
(1	O
mL)	O
was	O
neutralized	O
to	O
pH	O
7	O
with	O
NH_4	O
OH	O
and	O
loaded	O
onto	O
an	O
Oasis	O
MAX	O
cartridge	O
(1	O
mL,	O
30	O
mg,	O
Waters)	O
previously	O
equilibrated	O
using	O
1	O
mL	O
MeOH,	B
and	O
1	O
mL	O
2%	O
aqueous	O
NH_4	O
OH.	O

In	O
males,	O
over	O
50%	O
(16/30)	O
of	O
the	O
sphingolipids	B
that	O
were	O
decreased	O
were	O
ceramides,	B
and	O
47%	O
(14/30)	O
were	O
sphingomyelin	B
species.	O

Lactate	B
was	O
found	O
to	O
be	O
significantly	O
higher	O
in	O
patients	O
with	O
high	O
tissue	O
expression	O
of	O
IP_3	O
R	O
when	O
compared	O
to	O
patients	O
with	O
low	O
tissue	O
expression	O
of	O
IP_3	O
R	O
and	O
healthy	O
control.	O

Included	O
were	O
18	O
patients	O
with	O
early	O
septic	O
shock	O
(<12	O
h)	O
and	O
high	O
need	O
for	O
high	O
doses	O
of	O
norepinephrine	B
(>0.4	O
μg/kg/min)	O
that	O
were	O
neither	O
pregnant,	O
aged	O
<18	O
years	O
nor	O
had	O
an	O
end-stage	O
chronic	O
disease.	O

BPHL	O
had	O
almost	O
no	O
activity	O
for	O
any	O
of	O
these	O
substrates	O
except	O
for	O
p	B
-nitrophenyl	I
butyrate,	I
for	O
which	O
it	O
had	O
only	O
low	O
activity.	O

We	O
also	O
found	O
significantly	O
increased	O
levels	O
of	O
the	O
endocannabinoid-like	O
lipid,	O
monoacylglycerol	B
2-oleoylglycerol	I
(2-OG),	O
in	O
the	O
serum	O
of	O
DLBCL	O
cases	O
(138	O
±	O
17%,	O
P	O
<	O
0.05)	O
compared	O
to	O
controls	O
that	O
did	O
not	O
vary	O
by	O
sex.	O

Two	O
LMIs	O
(496.3 m	O
/z	O
,	O
retention	O
time	O
(RT)	O
of	O
18.9 min	O
a	O
and	O
544.3 m	O
/z	O
,	O
RT	O
of	O
18.3 min	O
b	O
were	O
identified	O
as	O
LysoPC(16,0)	B
and	O
LysoPC(20:4(5Z,8Z,11Z,14Z))	B
according	O
to	O
the	O
tandem	O
mass	O
spectrometry	O
(MS/MS)	O
patterns	O
of	O
serum	O
samples	O
of	O
BTC	O
patients	O
Amounts	O
of	O
LysoPC(16:0)	B
and	O
LysoPC(20:4(5Z,8Z,11Z,14Z))	B
in	O
the	O
serum	O
of	O
PC	O
and	O
BTC	O
patients.	O

Also	O
depicted	O
in	O
panel	O
B	O
is	O
the	O
malate/Asp	O
shuttle	O
across	O
the	O
mitochondrial	O
membrane,	O
where	O
the	O
export	O
of	O
[_13	B
C-1,2,3]-Asp	I
into	O
the	O
cytosol	O
leads	O
to	O
the	O
synthesis	O
of	O
[_13	B
C-1,2,3]-malate.	I

Patterns	O
5–8	O
and	O
15	O
denote	O
the	O
presence	O
of	O
_13	O
C-2-Glu-GSSG	B
and	O
_13	O
C-2-Glu	O
while	O
patterns	O
16	O
and	O
17	O
indicate	O
the	O
presence	O
of	O
_13	O
C-2-Asp.	O

2-	O
and	O
3-hydroxybutanoic	B
acid	I
(α-	O
and	O
β-hydroxybutyric	B
acid,	I
AHBA	O
and	O
BHBA)	O
differ	O
significantly	O
(see	O
boxplots	O
Supplementary	O
Figure	O
).	O

It	O
was	O
found	O
that	O
among	O
the	O
70	O
metabolites	O
included	O
in	O
the	O
analysis,	O
34	O
(18	O
of	O
known	O
identity	O
and	O
9	O
of	O
known	O
chemical	O
class)	O
and	O
3	O
(urea,	O
glycerol	B
3-phosphate	I
and	O
1	O
unknown)	O
metabolites	O
were,	O
respectively,	O
of	O
significantly	O
higher	O
(positively	O
significant)	O
or	O
lower	O
(negatively	O
significant)	O
concentration	O
in	O
the	O
ICSI	O
than	O
the	O
NC	O
group.	O

	O
displays	O
box	O
plots	O
of	O
several	O
lipid	O
hydroperoxides,	B
namely	O
PC	B
hydroperoxides	I
(A–C),	O
triacylglyceride	B
(TAG)	O
hydroperoxides	B
(D,	O
E),	O
and	O
a	O
cholesterylester	O
(C,	O
E)	O
hydroperoxide	B
(F),	O
that	O
were	O
all	O
affected	O
by	O
longer	O
storage	O
within	O
subject	O
age	O
groups	O
and	O
showed	O
increased	O
concentrations	O
over	O
time.	O

The	O
synthesis	O
of	O
bile	O
acids	O
(BAs)	O
is	O
the	O
key	O
pathway	O
of	O
cholesterol	B
catabolism	O
in	O
human.	O

Sub-hazard	O
ratios	O
(SHR)	O
are	O
effects	O
sizes	O
for	O
a	O
doubling	O
of	O
TMAO	B
in	O
plasma.	O

The	O
study	O
cohorts	O
were	O
composed	O
of	O
34	O
POAG	O
and	O
30	O
age-	O
and	O
sex-matched	O
control	O
individuals	O
whose	O
recruitment	O
criteria	O
and	O
clinical	O
features	O
were	O
recently	O
described	O
in	O
a	O
study	O
focused	O
on	O
a	O
quantitative	O
dosage	O
of	O
nicotinamide.	B

The	O
levels	O
of	O
serum	O
S1P	O
and	O
urine	O
sphingosine	B
at	O
the	O
basal	O
status	O
before	O
the	O
ASA-BPT	O
test	O
were	O
significantly	O
correlated	O
with	O
a	O
greater	O
decrease	O
in	O
FEV_1	O
(%)	O
values	O
during	O
the	O
ASA-BPT	O
(r	O
 = 0.451,	O
P	O
 < 0.001;	O
r	O
 = 0.553,	O
P	O
 < 0.001,	O
respectively,	O
).	O

Significant	O
associations	O
were	O
found	O
for	O
the	O
following	O
lipid	O
subclasses	O
for	O
(i)	O
sex:	O
di-	O
and	O
triacylglycerols,	B
ceramides,	B
PE,	O
PI	O
and	O
Glc/Gal-Cer,	O
and	O
for	O
their	O
fatty	O
acyl	O
side	O
chains:	O
C18:2,	B
C20:5,	B
C22:4	B
and	O
C22:6,	B
and	O
(ii)	O
age:	O
diacylglycerols,	B
SM,	O
PCO-,	O
PE,	O
PI,	O
LPE	O
and	O
for	O
their	O
fatty	O
acyl	O
side	O
chains	O
C18:2	B
and	O
C22:5.	B

Using	O
this	O
strategy,	O
103	O
thiol	B
candidates	O
were	O
discovered	O
in	O
all	O
the	O
cancer	O
urines	O
and	O
6	O
thiol	B
candidates	O
in	O
urines	O
were	O
confirmed	O
as	O
Cys,	O
HCys,	O
Nac,	O
γ-GluCys,	B
GSH	B
and	O
pantetheine	O
by	O
standards.	O

These	O
five	O
subjects	O
(referred	O
to	O
hereon	O
as	O
the	O
OB/D	O
group)	O
were	O
treated	O
with	O
metformin	B
and	O
hypolipemic	O
drugs	O
(either	O
fibrates	O
or	O
statins).	O

For	O
both	O
pre-	O
and	O
post-PM	O
cases,	O
uracil	B
and	O
sarcosine	B
correlate	O
positively,	O
while	O
kynurenic	B
acid	I
correlates	O
negatively	O
with	O
biopsy	O
results.	O

In	O
addition,	O
glutamate,	B
one	O
of	O
the	O
most	O
abundant	O
amino	O
acids	O
in	O
the	O
human	O
body,	O
was	O
significantly	O
increased	O
in	O
NDMM	O
patients	O
compared	O
to	O
healthy	O
controls,	O
suggesting	O
that	O
MM	O
cells	O
in	O
the	O
bone	O
marrow	O
secrete	O
or	O
detoxify	O
glutamate.	B

Homocysteine	B
can	O
be	O
metabolized	O
to	O
cysteine	B
and	O
the	O
observed	O
increased	O
levels	O
of	O
cysteine	B
could	O
reflect	O
a	O
misbalance	O
in	O
the	O
homocysteine	B
metabolic	O
system.	O

In	O
addition	O
to	O
glucose,	B
also	O
leucine,	B
glutamate,	B
lysine,	B
valine,	B
and	O
isoleucine	B
resulted	O
the	O
top	O
five	O
important	O
metabolites,	O
based	O
on	O
their	O
frequency	O
selection	O
during	O
cross-validation	O
(C).	O

We	O
found	O
that	O
this	O
genetic	O
response	O
score,	O
by	O
itself,	O
explained	O
11.3%	O
and	O
11.9%	O
of	O
HCTZ	O
SBP	O
and	O
DBP	B
responses,	O
respectively.	O

Recently,	O
it	O
was	O
demonstrated	O
that	O
2-hydroxybutyrate	B
is	O
an	O
early	O
marker	O
of	O
both	O
insulin	O
resistance	O
and	O
impaired	O
glucose	B
regulation,	O
and	O
it	O
was	O
suggested	O
that	O
the	O
underlying	O
biochemical	O
mechanisms	O
might	O
involve	O
increased	O
lipid	O
oxidation	O
and	O
oxidative	O
stress	O
.	O

0.388,	O
P	O
 < 0.05);	O
Energy	O
adjusted	O
folate	B
and	O
vitamin	B
B12	I
intake	O
had	O
positive	O
correlation	O
(r	O
 = 0.184).	O

Intriguingly,	O
our	O
data	O
demonstrated	O
that	O
vitamin	O
B_6	O
metabolism	O
is	O
one	O
of	O
the	O
three	O
most-significantly	O
altered	O
pathways	O
in	O
patients	O
receiving	O
HTK	O
solution,	O
showing	O
that	O
urinary	O
4-pyridoxic	B
acid,	I
which	O
is	O
the	O
major	O
catabolite	O
of	O
vitamin	O
B_6	O
,	O
was	O
significantly	O
reduced.	O

To	O
control	O
for	O
multiple	O
comparisons	O
(n = 947	O
retinol-metabolite	B
associations),	O
we	O
applied	O
the	O
Bonferroni	O
correction	O
using	O
p	O
 = 0.05/947 = 5.3	O

Interestingly,	O
omega-3	B
fatty	O
acids,	O
which	O
showed	O
decreased	O
levels	O
associated	O
with	O
migraine	O
in	O
male	O
participants,	O
have	O
also	O
been	O
shown	O
to	O
be	O
vasoprotective	O
and	O
have	O
been	O
deemed	O
to	O
generate	O
anti-inflammatory	O
resolvins.	O

Urinary	O
estrogens	O
(E_1	O
,	O
E_2	O
,	O
and	O
E_3	O
)	O
and	O
their	O
metabolites	O
(2-OHE_1	O
,	I
2-OHE_2	I
,	I
16α-OHE_1	I
,	O
4-OHE_1	O
,	O
4-OHE_2	O
,	O
2-MeOE_1	O
,	O
2-MeOE_2	O
,	O
4-MeOE_1	O
,	O
and	O
4-MeOE_2	O
)	O
were	O
analyzed	O
in	O
the	O
mid-follicular	O
phase	O
of	O
baseline	O
and	O
follow-up	O
cycles	O
by	O
liquid	O
chromatography/tandem	O
mass	O
spectrometry	O

hi	B
h	O

However,	O
in	O
order	O
to	O
validate	O
the	O
nicotinamide	B
deficiency,	O
we	O
previously	O
measured	O
the	O
level	O
of	O
this	O
vitamin	O
using	O
a	O
targeted	O
LC-MS/MS	O
method	O
specifically	O
designed	O
for	O
the	O
quantification	O
of	O
nicotinamide.	B

An	O
internal	O
standard	O
(DL-alanine-2,3,3,3-d4:	O
DL-d4-Ala)	O
was	O
purchased	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(Dallas,	O
TX,	O
USA).	O

Second,	O
only	O
limited	O
additional	O
benefits	O
of	O
pioglitazone	B
and/or	O
Omega-3	B
may	O
be	O
expected	O
in	O
metformin	B
treated	O
T2D	O
patients.	O

Nonetheless,	O
the	O
most	O
direct	O
evidence	O
comes	O
from	O
mouse	O
knockout	O
studies	O
in	O
which	O
genetic	O
ablation	O
of	O
key	O
enzymes	O
in	O
Cer	B
synthesis	O
mitigates	O
atherosclerosis	O
,	O
insulin	O
resistance	O
,	O
and	O
T2DM	O
among	O
other	O
metabolic-related	O
disease	O
phenotypes.	O

The	O
chaotrope	O
disrupts	O
the	O
shell	O
of	O
hydration	O
around	O
the	O
biomolecules	O
and	O
silica,	B
which	O
allows	O
cations	O
from	O
the	O
solution	O
to	O
form	O
a	O
salt	O
bridge	O
between	O
the	O
negatively	O
charged	O
DNA	O
backbone	O
and	O
the	O
negatively	O
charged	O
silica.	B

This	O
may	O
reflect	O
the	O
role	O
of	O
PLP	O
as	O
a	O
cofactor	O
for	O
SHMT,	O
which	O
catalyzes	O
the	O
reversible	O
conversion	O
of	O
serine	B
and	O
tetrahydrofolate	B
to	O
feed	O
into	O
nucleotide	O
biosynthesis.	O

The	O
analytical	O
methods	O
were	O
validated	O
for	O
quantification	O
of	O
the	O
BRB	O
anthocyanins	B
and	O
cyanidin	B
in	O
human	O
saliva	O
by	O
using	O
an	O
internal	O
standard	O
(malvidin	O
3-glucoside)	B
and	O
BRB	O
standards	O
“spiked”	O
with	O
human	O
saliva.	O

Investigations	O
of	O
blank	O
samples	O
for	O
ultrafiltration	O
revealed	O
that	O
the	O
filter	O
membrane	O
contributed	O
to	O
glycerol	B
and	O
lactate	B
apart	O
from	O
methanol	B
and	O
an	O
unidentified	O
peak	O
as	O
predominant	O
contaminants	O
(see	O
Figure	O
S2	O
in	O
the	O
Supporting	O
Information).	O

Regarding	O
our	O
exposure	O
of	O
interest,	O
paracetamol	B
has	O
a	O
short	O
biologic	O
half-life,	O
such	O
that	O
24	O
h	O
post-ingestion,	O
85–95%	O
of	O
the	O
chemical	O
has	O
been	O
excreted	O
by	O
the	O
kidneys.	O

The	O
metabolism	O
of	O
SL	B
is	O
a	O
complex	O
pathway	O
that	O
generates	O
sphingosine-1-phosphate	B
(S1P)	O
from	O
various	O
precursors,	O
using	O
ceramide	B
as	O
a	O
backbone.	O

Many	O
studies	O
have	O
shown	O
that	O
TCM,	O
such	O
as	O
Radix	O
Astragali,	O
Radix	O
Rehmanniae,	O
and	O
Radix	O
Trichosanthis,	O
also	O
has	O
hypoglycemic	B
effects.	O

We	O
placed	O
an	O
episomal	O
copy	O
of	O
PfNMNAT	O
into	O
the	O
nadD	O
deletion	O
strain	O
under	O
the	O
control	O
of	O
the	O
arabinose	B
promoter,	O
which	O
is	O
induced	O
in	O
the	O
presence	O
of	O
arabinose	B
and	O
repressed	O
in	O
the	O
presence	O
of	O
the	O
competitive	O
inhibitor	O
fucose	B
.	O

Acetoacetate;	B
15.α-glucose;	B
16.	O

Isoleucine	B
was	O
present	O
in	O
both	O
samples	O
but	O
at	O
a	O
higher	O
abundance	O
in	O
those	O
dried	O
by	O
lyophilization	O
(D).	O

In	O
brief,	O
1	O
mL	O
methanol	B
(cooled	O
at	O
−80°C)	O
was	O
added	O
into	O
250	O
μ	O
L	O
of	O
plasma	O
or	O
cell	O
medium	O
followed	O
by	O
vortex-mixing	O
and	O
centrifugation	O
(at	O
10	O
000	O
rpm,	O
4°C	O
for	O
10	O
minutes).	O

As	O
observed	O
for	O
the	O
medium	O
(see	O
above),	O
the	O
myocytes	O
showed	O
a	O
lower	O
degree	O
of	O
enrichment	O
than	O
the	O
Rh30	O
cells,	O
especially	O
for	O
Ala,	O
consistent	O
with	O
a	O
substantially	O
lower	O
glycolytic	B
rate	O
in	O
the	O
primary	O
cells.	O

By	O
comparing	O
the	O
glycerophospholipid	B
composition	O
of	O
HCMV	O
virions	O
with	O
published	O
datasets,	O
we	O
noted	O
a	O
resemblance	O
to	O
synaptic	O
vesicles.	O

For	O
our	O
discussion,	O
we	O
selected	O
metabolites	O
involved	O
in	O
major	O
biophysiological	O
pathways	O
such	O
as	O
the	O
TCA	O
cycle,	O
methionine	B
metabolism,	O
and	O
glutathione	B
(GSH)	O
biosynthesis.	O

Taking	O
into	O
account	O
the	O
confounding	O
factors	O
that	O
may	O
limit	O
the	O
diagnostic	O
utility	O
of	O
these	O
cardiac	O
peptides,	O
the	O
addition	O
of	O
measuring	O
acetoacetate	B
along	O
with	O
plasma	O
natriuretic	O
peptides	O
may	O
be	O
of	O
clinical	O
importance;	O
although	O
they	O
still	O
cannot	O
be	O
used	O
to	O
accurately	O
differentiate	O
between	O
HFrEF	O
and	O
HFpEF	O
patients.	O

The	O
periods	O
were	O
as	O
follows:	O
period	O
1—COT,	O
HYM,	O
MOR,	O
NIC,	O
OHCOT,	O
and	O
pOHMAMP;	O
period	O
2—6AM,	O
AMP,	B
COD,	O
HYC,	O
MAMP,	O
mOHBE,	O
and	O
OXY;	O
period	O
3—BE,	O
CE,	O
COC,	O
EDDP,	O
and	O
MTD.	O

Indeed,	O
pathway	O
analysis	O
of	O
metabolites	O
indicated	O
compounds	O
of	O
caffeine	B
metabolism	O
altered	O
significantly	O
from	O
controls	O
to	O
PLP	O
and	O
CRC.	O

The	O
mobile	O
phase	O
consisted	O
of	O
a	O
linear	O
gradient	O
elution,	O
previously	O
described,	O
and	O
was	O
performed	O
at	O
0.4	O
mL/min	O
using	O
0.1%	O
formic	B
acid	I
in	O
water	O
and	O
in	O
acetonitrile.	B

As	O
shown	O
in	O
Table	O
,	O
higher	O
levels	O
of	O
1,5‐AG,	B
asparagine,	B
tyrosine	B
and	O
uric	B
acid	I
showed	O
a	O
decreasing	O
trend	O
in	O
the	O
risk	O
of	O
pancreatic	O
cancer	O
(P	O
for	O
trend	O
=	O
.04,	O
.04,	O
.04	O
and	O
.02,	O
respectively),	O
even	O
after	O
adjustment	O
for	O
smoking,	O
BMI,	O
and	O
past	O
history	O
of	O
DM.	O

Patients	O
with	O
low	O
albuminemia	O
had	O
increased	O
plasma	O
citrulline	B
but	O
lower	O
tryptophan	B
concentrations	O
(both	O
P	O
≤0.001)	O
(Supplemental	O
Figure	O
1A).	O

The	O
short-term	O
patient	O
sample	O
stability	O
was	O
demonstrated	O
for	O
enzalutamide	B
and	O
N-desmethylenzalutamide	B
for	O
at	O
least	O
23	O
days	O
in	O
plasma	O
at	O
ambient	O
temperature	O
and	O
at	O
4	O
°C.	O

Once	O
charge-tagged	O
by	O
the	O
GP	B
reagent,	O
oxysterols	B
can	O
be	O
analyzed	O
by	O
LC-electrospray	O
ionization-MS_n	O
	O
with	O
high	O
sensitivity	O
(<	O
pg	B
injected),	O
and	O
the	O
oxysterol	B
content	O
of	O
CSF	O
was	O
initially	O
probed	O
by	O
generation	O
of	O
exact	O
mass	O
(5	O
ppm)	O
RICs	O
for	O
all	O
potential	O
oxysterols	B
with	O
one	O
to	O
five	O
additional	O
oxygen	O
functions	O
on	O
the	O
cholesterol	B
skeleton	O
(see	O
supplemental	O
Table	O
S2).	O

Of	O
the	O
nine	O
remaining	O
candidates,	O
choline	B
has	O
clearly	O
been	O
demonstrated	O
to	O
be	O
representative	O
of	O
direct	O
dietary	O
intake	O
of	O
choline	B
containing	O
foods.	O

They	O
also	O
found	O
changes	O
in	O
some	O
SM	O
species,	O
such	O
as	O
an	O
increase	O
in	O
SM16:0	B
and	O
a	O
decrease	O
in	O
SM20:0	B
concentration.	O

Moreover,	O
NEFAs	O
showed	O
moderate	O
to	O
strong	O
correlations	O
with	O
acylcarnitines.	B

Of	O
these,	O
the	O
greatest	O
fold	O
change	O
between	O
experimental	O
groups	O
was	O
for	O
orotate,	B
which	O
was	O
significantly	O
elevated	O
in	O
ICC	O
patient	O
samples	O
(fold-change	O
39,	O
p	O
-value	O
0.006).	O

Like	O
VIP	O
plot	O
between	O
BTUT	O
(β-thalassemia	O
untreated)	O
and	O
healthy	O
comprises	O
different	O
classes	O
of	O
lipids	O
and	O
amino	O
acids,	O
glucose,	B
glycerol	B
and	O
acid,	O
a	O
similar	O
trend	O
of	O
metabolites	O
is	O
followed	O
in	O
discrimination	O
of	O
BTUT	O
and	O
BTT	O
(β-thalassemia	O
treated)	O
groups.	O

Consistent	O
with	O
our	O
findings	O
that	O
breast	O
cancer	O
cells	O
have	O
elevated	O
tryptophan	B
catabolism	O
during	O
anchorage	O
independence,	O
we	O
also	O
found,	O
using	O
the	O
Curtis	O
et	O
al	O
dataset,	O
that	O
the	O
gene	O
encoding	O
the	O
amino	O
acid	O
transporter	O
LAT1	O
(SLCA5)	O
(which	O
uptakes	O
tryptophan	B
and	O
other	O
large	O
neutral	O
amino	O
acids	O
from	O
the	O
microenvironment	O
into	O
the	O
cell)	O
was	O
significantly	O
elevated	O
in	O
breast	O
cancer	O
versus	O
normal	O
breast,	O
in	O
ER-negative	O
versus	O
ER-positive	O
disease,	O
and	O
in	O
higher	O
grade	O
breast	O
cancer.	O

Subsequently,	O
the	O
ions	O
monitored	O
for	O
anastrozole	B
glucuronide	I
(analyte)	O
and	O
testosterone	B
(IS)	O
were	O
m/z	O
470.2/225.2	O
and	O
m/	O

Two	O
internal	O
standards,	O
tridecanoic	B
acid	I
and	O
chlorophenylalanine	B
were	O
also	O
included	O
to	O
monitor	O
the	O
extraction	O
efficiency.	O

Another	O
novel	O
finding	O
is	O
a	O
reduction	O
of	O
serum	O
butyrate	B
at	O
6 months	O
post	O
RYGB	O
compared	O
with	O
pre‐surgery	O
values.	O

	O
Retinoic	B
acid	I
receptors	O
(like	O
other	O
type	O
II	O
nuclear	O
receptors)	O
function	O
in	O
the	O
regulation	O
of	O
endogenous	O
gene	O
expression	O
by	O
binding	O
as	O
heterodimers	O
with	O
retinoid	B
X	O
receptors	O
(,	O
).	O

This	O
observation	O
fits	O
with	O
the	O
notion	O
that	O
purine	B
and	O
pyrimidine	B
nucleotide	O
degradation	O
occurs	O
following	O
cellular	O
DNA	O
double-strand	O
breaks	O
induced	O
by	O
irinotecan/SN-38.	O

All	O
kynurenine	B
metabolites	O
were	O
positively	O
correlated	O
to	O
kynurenine	B
levels	O
[Spearman’s	O
rho	O
(r):	O
0.24–0.58]	O
(Table ).	O

With	O
regard	O
to	O
low	O
molar	O
mass	O
metabolites,	O
the	O
OPLS-DA	O
loadings	O
with	O
high	O
VIP	O
values	O
(>1.0)	O
were	O
because	O
of	O
glycerol,	B
few	O
amino	O
acids	O
like	O
(histidine,	O
alanine,	B
valine,	B
lysine,	B
proline,	B
glutamine,	B
and	O
arginine),	B
formate,	B
acetate,	B
citrate,	B
adipic	B
acid,	I
fucose	B
and	O
glucose,	B
signifying	O
their	O
state	O
of	O
prominence	O
between	O
healthy	O
control	O
and	O
disease,	O
when	O
weighing	O
up	O
their	O
concentrations.	O

Ethyl	B
acetate	I
(6	O
mL)	O
was	O
added,	O
vortex-mixed,	O
the	O
tubes	O
centrifuged,	O
and	O
the	O
upper	O
ethyl	B
acetate	I
layer	O
was	O
discarded.	O

Mice	O
were	O
anesthetized	O
with	O
ketamine	B
and	O
xylazine,	B
and	O
intra-cardiac	O
perfusion	O
performed	O
with	O
PBS	O
until	O
liver	O
clearing	O
prior	O
to	O
harvesting	O
of	O
tissues.	O

The	O
stimulating	O
effect	O
of	O
lipids	O
on	O
BC	O
tumor	O
growth	O
seems	O
also	O
be	O
sustained	O
by	O
the	O
observation	O
that	O
high	O
levels	O
of	O
LDL-cholesterol	B
at	O
the	O
time	O
of	O
diagnosis	O
may	O
have	O
a	O
negative	O
prognostic	O
value.	O

In	O
this	O
subgroup	O
analysis,	O
the	O
increases	O
in	O
the	O
excretion	O
of	O
the	O
mercapturic	O
acids	O
of	O
benzene,	B
acrolein,	B
and	O
crotonaldehyde	B
for	O
the	O
broccoli	O
sprout	O
versus	O
placebo	O
group	O
were	O
+54.7%	O
(+27.2%,	O
+88.1%),	O
+21.7%	O
(+1.8%,	O
45.5%),	O
and	O
+2.0%	O
(−13.7%,	O
+20.4%),	O
respectively.	O

The	O
use	O
of	O
ascorbic	B
acid	I
increased	O
the	O
deconjugation	O
speed,	O
most	O
likely	O
by	O
preventing	O
the	O
oxidative	O
damage	O
of	O
β-glucuronidase	O
and	O
sulfatase,	O
and	O
thus	O
reduced	O
deconjugation	O
time	O
required	O
to	O
achieve	O
maximal	O
yield	O
from	O
overnight	O
to	O
3	O
hour.	O

Interestingly	O
and	O
surprisingly,	O
the	O
concentration	O
of	O
kynurenine	B
was	O
also	O
significantly	O
lower	O
in	O
the	O
plasma	O
of	O
women	O
with	O
breast	O
cancer	O
(mean	O
=	O
7.12	O
μM)	O
compared	O
to	O
normal	O
controls	O
(mean	O
=	O
9.02	O
μM).	O

Therefore,	O
it	O
is	O
described	O
as	O
‘pyruvate+oxalacetic	B
acid’	O
in	O
the	O
Supporting	O
tables	O
and	O
as	O
‘pyruvate’,	O
which	O
was	O
actually	O
detected	O
by	O
GC/MS	O
analysis,	O
in	O
this	O
manuscript.	O

Since	O
nearly	O
all	O
of	O
the	O
SL's	O
analyzed	O
associated	O
significantly	O
in	O
univariate	O
analysis	O
with	O
the	O
presence	O
of	O
HCC,	O
we	O
intended	O
to	O
conduct	O
a	O
multivariate	O
analysis	O
to	O
evaluate	O
if	O
SL	B
parameters	O
constitute	O
independent	O
diagnostic	O
predictors	O
of	O
HCC.	O

In	O
a	O
recent	O
investigation,	O
4-HPA	O
was	O
confirmed	O
to	O
participate	O
in	O
the	O
intermediate	O
step	O
of	O
tyrosine	B
degradation.	O

Calibration	O
curve	O
details	O
of	O
sibutramine,	B
N-des	O
methyl	B
sibutramine,	I
N-di	O
des	B
methyl	I
sibutramine.	I

In	O
a	O
recent	O
study,	O
several	O
genes	O
involved	O
in	O
BCAA	O
catabolism	O
were	O
downregulated	O
in	O
muscle	O
from	O
insulin-resistant	O
subjects;	O
the	O
highest	O
correlation	O
was	O
seen	O
with	O
MUT	O
and	O
ALDH6A1	O
,	O
both	O
involved	O
in	O
valine	B
catabolism	O
downstream	O
of	O
3-HIB.	O

S-adenosylhomocysteine	B
and	O
S-adenosylmethionine	B
plasma	O
level	O
were	O
decreased	O
according	O
to	O
Pogribna	O
and	O
Coll.,	O
and	O
increased	O
according	O
to	O
Obeid	O
and	O
Coll..	O

Women	O
were	O
excluded	O
if	O
they	O
(a)	O
had	O
a	O
history	O
of	O
organic	O
GI	O
disease,	O
cardiac	O
arrhythmia,	O
or	O
renal	O
or	O
gynecological	O
issues;	O
(b)	O
were	O
taking	O
medications	O
for	O
GI	O
symptoms;	O
(c)	O
were	O
taking	O
any	O
medications	O
daily	O
that	O
would	O
alter	O
5-HT;	O
(d)	O
had	O
a	O
body	O
mass	O
index	O
(BMI)	O
>	O
35	O
kg/m_2	O
;	O
(e)	O
worked	O
during	O
the	O
late	O
evening	O
or	O
night;	O
(f)	O
had	O
a	O
known	O
sleep	O
disorder;	O
(g)	O
had	O
severe	O
comorbid	O
pain	O
or	O
psychiatric	O
conditions;	O
or	O
(h)	O
drank	O
caffeine-containing	O
beverages	O
(>300	O
mg	O
caffeine)	B
in	O
the	O
afternoon/evening	O
or	O
≥3	O
servings	O
of	O
alcohol/day.	O

The	O
resulting	O
sample	O
was	O
dried	O
and	O
dissolved	O
in	O
200	O
µL	O
methanol,	B
resulting	O
in	O
a	O
neutral	O
lipid	O
fraction.	O

Homocysteine,	B
a	O
compound	O
reported	O
previously	O
as	O
elevated	O
in	O
the	O
plasma	O
of	O
COPD	O
subjects	O
(among	O
other	O
diseases),	O
may	O
also	O
be	O
an	O
indirect	O
rather	O
than	O
direct	O
causal	O
player	O
in	O
the	O
disease.	O

16	O
patients	O
with	O
a	O
blood	O
glucose	B
level	O
(BGL)	O
over	O
100	O
mg/dL	O
showed	O
higher	O
levels	O
of	O
serum	O
PE,	O
which	O
was	O
due	O
to	O
a	O
significant	O
elevation	O
of	O
MUFA-PE,	O
whereas	O
PUFA-PE	O
remained	O
unchanged	O
(B).	O

In	O
addition,	O
assessment	O
of	O
Erythronic	B
acid	I
and	O
N-Acetylaspartic	B
acid	I
abundance	O
in	O
urine	O
are	O
already	O
routinely	O
performed,	O
via	O
DNA	O
mutation	O
screenings	O
for	O
Transaldolase	O
and	O
Aspartoacylase	O
correspondently.	O

The	O
short-term	O
evaluation	O
of	O
an	O
intervention	O
formula	O
with	O
a	O
lower	O
protein	O
content,	O
containing	O
alpha-lactalbumin	B
enriched	O
whey	B
and	O
LC-PUFA,	O
showed	O
differential	O
growth	O
effects	O
compared	O
to	O
a	O
normal	O
protein	O
control	O
formula	O
up	O
to	O
the	O
age	O
of	O
4	O
months.	O

Similarly,	O
signals	O
corresponding	O
to	O
methionine,	B
whose	O
levels	O
were	O
not	O
detected	O
in	O
other	O
flour,	O
bread	O
or	O
dough	O
samples,	O
were	O
clearly	O
present	O
in	O
the	O
spectra	O
from	O
the	O
sourdough	O
samples.	O

However,	O
sarcosine	B
levels	O
were	O
elevated	O
only	O
in	O
tissue	O
biopsies	O
with	O
a	O
Gleason	O
pattern	O
of	O
8	O
or	O
worse	O
in	O
the	O
McDunn	O
et	O
al	O
report.	O

Besides,	O
we	O
showed	O
that	O
KP	B
metabolism	O
is	O
altered	O
in	O
PRE	O
and	O
TRM	O
samples	O
from	O
CMM	O
patients	O
treated	O
with	O
MAPKIs,	O
as	O
reflected	O
by	O
changes	O
in	O
plasma	O
levels	O
of	O
downstream	O
metabolites.	O

Impaired	O
urea	B
metabolism	O
leads	O
to	O
decreased	O
ammonia	O
detoxification	O
and	O
is	O
responsible	O
for	O
the	O
increase	O
levels	O
of	O
glutamine	B
and	O
glutamate.	B

Three	O
parent	O
compounds,	O
metformin–MG	O
imidazolinone	B
(A),	O
metformin	B
(B),	O
and	O
metformin-d	O
_6	O
(C),	O
are	O
monitored	O
in	O
a	O
metformin-treated	O
T2DM	O
urine	O
sample.	O

Estrogens	O
and	O
estrogen	B
metabolites	O
were	O
analyzed	O
individually,	O
in	O
groups	O
representing	O
metabolic	O
pathways,	O
and	O
as	O
ratios	O
of	O
metabolic	O
pathways.	O

It	O
is	O
also	O
important	O
to	O
note	O
that	O
the	O
use	O
of	O
amino	O
acid	O
acylation	O
pathways	O
has	O
been	O
successfully	O
exploited	O
in	O
empiric	O
studies	O
of	O
patients	O
with	O
inborn	O
errors	O
of	O
urea	B
synthesis	O
(e.g.,	O
carbamyl	B
phosphate	I
synthetase	O
(CAD)	O
deficiency).	O

For	O
paliperidone,	B
a	O
drug	O
that	O
is	O
only	O
available	O
as	O
ER	O
formulation,	O
and	O
for	O
aripiprazole,	B
a	O
drug	O
with	O
a	O
half‐life	O
of	O
60	O
to	O
80	O
hours,1	O
no	O
%differences	O
of	O
>100%	O
were	O
observed.	O

In	O
particular	O
ion	O
number	O
8	O
([M−H]_−	O
 = 145.0606	O
m/z	O
,	O
retention	O
time	O
of	O
2.764	O
min),	O
ion	O
number	O
9	O
([M+H]_+	O
 = 101.0356	O
m/z	O
,	O
retention	O
time	O
of	O
0.2948	O
min),	O
ion	O
number	O
10	O
([M+H]_+	O
 = 335.0676	O
m/z	O
,	O
retention	O
time	O
of	O
2.3983	O
min),	O
ion	O
number	O
11	O
([M+H]_+	O
 = 241.0326	O
m/z	O
,	O
retention	O
time	O
of	O
3.9999	O
min),	O
and	O
ion	O
number	O
12	O
([M+H]_+	O
 = 243.0986	O
m/z	O
,	O
retention	O
time	O
of	O
0.3166	O
min)	O
were	O
tested	O
against	O
L-glutamine,	B
alanyl-glycine	B
(Ala-Gly),	O
adipic	B
acid,	I
and	O
D-glutamine	B
for	O
ion	O
8,	O
hydantoin	O
for	O
ion	O
9,	O
b-nicotinamide	B
mononucleotide	O
for	O
ion	O
10,	O
L-cystine	B
for	O
ion	O
11,	O
and	O
b-thymidine	B
for	O
ion	O
12.	O

AUC_0–120min	O
of	O
the	O
metabolite	O
levels	O
of	O
glucose,	B
lactate,	B
alanine,	B
citrate	B
and	O
glutamate	B
were	O
calculated	O
with	O
R	O
(version	O
3.4.4)	O
using	O
the	O
package	O
“DescTools”	O
with	O
the	O
trapezoidal	O
rule.	O

These	O
differences	O
included	O
the	O
two	O
prostaglandin	B
parent	O
molecules	O
arachidonate	B
(20:4n6),	I
which	O
was	O
significantly	O
elevated	O
in	O
HCC	O
vs.	O
DC,	O
but	O
downregulated	O
in	O
DC	O
vs.	O
NHC,	O
and	O
dihomolinoleate	B
(20:2n6),	I
which	O
also	O
showed	O
significant	O
elevation	O
in	O
HCC	O
vs.	O
DC.	O

Although	O
not	O
analyzed	O
in	O
the	O
present	O
study,	O
a	O
depletion	O
of	O
muscular	O
adenine	B
nucleotide	O
content	O
in	O
the	O
course	O
of	O
the	O
10-day	O
HIIT	O
is	O
also	O
presumable	O
due	O
to	O
the	O
high	O
intensity	O
and	O
frequency	O
of	O
training.	O

 180.1 μM	O
in	O
venous	O
plasma,	O
),	O
followed	O
by	O
amino	O
acids	O
(glutamine,	O
glutamate)	B
also	O
detected	O
in	O
high	O
concentrations	O
(≥100 μM)	O
in	O
arterial	O
and	O
venous	O
plasma.	O

Patients	O
reported	O
that	O
they	O
were	O
taking	O
medications	O
including	O
5-aminosalicylate	B
(5-ASA)	O
drugs	O
(3	O
CD	O
and	O
15	O
UC),	O
azathiopurine	B
(7	O
CD	O
and	O
5	O
UC),	O
and	O
corticosteroids	O
(15	O
CD	O
and	O
16	O
UC).	O

One	O
of	O
the	O
most	O
consistently	O
reported	O
surrogate	O
metabolites	O
is	O
hippurate.	B

Yij=βoj+Xi1β1j+Xi2β2j+…+Xipβpj+εij	B

Choline	B
forms	O
phosphocholine	B
via	O
choline	B
kinase.	O

Other	O
factors,	O
including	O
malabsorption	O
and	O
changes	O
in	O
microbiota,	O
also	O
can	O
be	O
a	O
reason	O
related	O
to	O
altered	O
circulation	O
levels	O
of	O
ω-3	B
PUFAs.	I

Tandem	O
Mass	O
Spectrometry:	O
Optimized	O
tune	O
parameters	O
of	O
methylpiperazine	B
derivatives	O
of	O
estrogens	O
and	O
their	O
retention	O
times.	O

MS2	O
does	O
not	O
distinguish	O
the	O
sn1	O
and	O
sn2	O
acyl	O
positions	O
of	O
glycerolipids,	B
nor	O
the	O
position	O
of	O
unsaturations	O
in	O
acyl	O
chains	O
and	O
acyl	O
branching.	O

Fifty	O
microlitres	O
of	O
methoxyamine	B
hydrochloride	I
(20 mg/mL	O
pyridine)	B
was	O
used	O
to	O
dissolve	O
dried	O
residue,	O
which	O
stayed	O
at	O
20°C	O
for	O
24 h.	O

All	O
of	O
the	O
metabolites	O
were	O
up-regulated	O
in	O
CIN	O
and	O
cervical	O
cancer,	O
except	O
for	O
proline	B
metabolite	O
in	O
the	O
CIN1	O
group.	O

(D)	O
Manual	O
annotation	O
of	O
spectral	O
fragments	O
of	O
m/z	O
367	O
at	O
1.62	O
minutes	O
and	O
how	O
they	O
relate	O
to	O
the	O
structure	O
of	O
12-oxo-LTB4	B
with	O
blue	O
arrows	O
indicating	O
identical	O
fragments	O
and	O
orange	O
arrows	O
indicating	O
a	O
shift	O
of	O
+CH_4	O
O	O
between	O
carbons	O
11	O
and	O
13.	O

Potential	O
mechanisms	O
included	O
reduced	O
processing	O
of	O
acetyl-CoA	B
via	O
the	O
tricarboxylic	B
acid	I
(TCA)	O
cycle	O
due	O
to	O
the	O
inhibition	O
of	O
citrate	B
formation	O
and/or	O
changes	O
in	O
the	O
NADH/NAD_+	O
ratio	O
due	O
to	O
efflux	O
of	O
aspartate.	B

We	O
used	O
mass	O
spectrometry	O
to	O
quantify	O
glycerophospholipids	B
in	O
mock-infected	O
and	O
virus-infected	O
fibroblasts,	O
as	O
well	O
as	O
in	O
virions.	O

With	O
a	O
purpose	O
of	O
selecting	O
biomarkers	O
that	O
were	O
positively	O
correlated	O
with	O
state	O
of	O
psychological	O
suboptimal	O
health	O
and	O
forming	O
a	O
biomarker	O
panel,	O
6	O
metabolites	O
containing	O
phenylalanine,	B
glutamine,	B
tyrosine,	B
TMAO,	B
N-acetyl-glycoproteins	B
and	O
citrate	B
were	O
selected	O
and	O
defined	O
as	O
a	O
biomarker	O
panel	O
from	O
the	O
9	O
potential	O
biomarkers.	O

In	O
order	O
to	O
assess	O
whether	O
the	O
DNA	O
methylome	B
is	O
changed	O
by	O
α-OG,	B
EPIC	O
array	O
was	O
performed.	O

These	O
analyses	O
revealed	O
that	O
the	O
metabolic	O
profile	O
associated	O
with	O
obese	O
patients	O
was	O
characterized	O
by	O
increased	O
levels	O
of	O
2-aminoisobutyrate,	B
β-alanine,	B
inosine	B
and	O
acetate,	B
and	O
decreased	O
levels	O
of	O
3-hydroxyisovalerate	B
and	O
glycine.	B

Metabolic	O
alterations	O
have	O
long	O
been	O
associated	O
with	O
cancer,	O
prominently	O
including	O
the	O
Warburg	O
effect,	O
shifting	O
energy	O
production	O
toward	O
aerobic	O
glycolysis	O
and	O
generation	O
of	O
lactic	B
acid.	I

The	O
50:50	O
methanol:	O
water	O
composition	O
used	O
to	O
obtain	O
the	O
mass	O
spectra	O
of	O
M1	O
or	O
M2	O
is	O
approximately	O
similar	O
to	O
the	O
composition	O
of	O
mobile	O
phase	O
at	O
their	O
elution	O
times	O
through	O
the	O
chromatographic	O
gradient,	O
which	O
is,	O
55:	O
45	O
methanol:	B
water.	O

LC-MS/MS	O
was	O
performed	O
as	O
described	O
above	O
by	O
employing	O
HILIC	O
chromatography	O
and	O
electrospray	O
ionization	O
in	O
positive	O
mode	O
(Waters,	O
Xevo	O
TQ-Smicro	O
triple	O
quad)	O
on	O
a	O
C18	O
BEH	O
Amide	B
1.7um	O
50mmx2.1mm	O
column	O
(Waters).	O

This	O
test	O
provides	O
information	O
about	O
the	O
size,	O
lipid	O
concentration	O
(cholesterol	O
and	O
triglycerides)	B
and	O
number	O
of	O
particles	O
for	O
the	O
main	O
classes	O
of	O
lipoproteins	O
[very-low	O
density	O
lipoprotein	O
(VLDL),	O
low-density	O
lipoprotein	O
(LDL),	O
intermediate-density	O
lipoprotein	O
(IDL)	O
and	O
high-density	O
lipoprotein	O
(HDL)],	O
as	O
well	O
as	O
the	O
concentration	O
of	O
particles	O
in	O
their	O
subclasses	O
(large,	O
median,	O
small).	O

The	O
fact	O
that,	O
in	O
our	O
models,	O
3-hydroxybutyrate	B
levels	O
were	O
higher	O
in	O
EAC	O
patients	O
than	O
in	O
controls	O
or	O
Barrett's	O
patients	O
could	O
be	O
a	O
starvation	O
effect.	O

Data	O
points	O
in	O
red	O
indicate	O
individuals	O
who	O
were	O
excluded	O
from	O
future	O
analysis	O
due	O
to	O
detection	O
of	O
≥2	O
cannabis	B
metabolites	O
in	O
noncannabis	O
users	O
and	O
≤2	O
metabolites	O
in	O
cannabis	B
users.	O

Creatinine	B
is	O
easily	O
detectable	O
by	O
_1	O
H	O
NMR	O
as	O
two	O
singlets	O
at	O
2.98	O
and	O
3.99	O
p.p.m	O
accordingly,	O
the	O
non-NMR	O
measurement	O
in	O
closely	O
matches	O
the	O
NMR-derived	O
creatinine	B
(and	O
biologically	O
correlated	O
urea)	O
in	O
(P	O
=9.2	O
×	O
10_−7	O
).	O

The	O
mitochondria-generated	O
acetyl	O
coenzyme	O
A	O
could	O
be	O
exported	O
to	O
the	O
cytoplasm	O
through	O
the	O
citrate	B
transporter	O
and	O
citrate	B
lyase.	O

Components	O
of	O
the	O
serotonin	B
(5-HT)	O
system	O
have	O
been	O
shown	O
to	O
be	O
present	O
in	O
human	O
ejaculate.	O

The	O
attenuation	O
of	O
a	O
number	O
of	O
metabolites	O
such	O
as	O
lactate,	B
histidine,	B
tyrosine,	B
and	O
phenylalanine	B
has	O
thus	O
been	O
described	O
earlier	O
using	O
NMR	O
of	O
intact	O
blood	O
serum/plasma._−	O

The	O
previously-mentioned	O
phosphocreatine-dependent	O
uptake	O
of	O
glutamate	B
forms	O
part	O
of	O
a	O
cyclic	O
glutamate	O
and	O
glutamine	B
shuttle	O
between	O
astrocytes	O
and	O
neurons	O
in	O
the	O
normal	O
brain.	O

Besides,	O
we	O
describe	O
the	O
presence	O
of	O
d16:1	B
LCB,	O
mainly	O
in	O
plasma	O
as	O
previously	O
reported,	O
but	O
also	O
in	O
the	O
retina.	O

In	O
patients	O
undergoing	O
planned	O
withdrawal	O
from	O
lactulose,	B
cognition	O
was	O
linked	O
to	O
stool	O
Prevotella	O
spp.	O

The	O
reductions	O
in	O
plasma	O
glycine,	B
cysteine,	B
serine,	B
threonine	B
and	O
glutamine	B
during	O
CM	O
could	O
be	O
secondary	O
to	O
parasite	O
uptake	O
and/or	O
host	O
utilization.	O

The	O
finding	O
reported	O
here	O
that	O
are	O
most	O
relevant	O
to	O
the	O
biology	O
of	O
AML	O
are	O
the	O
differential	O
levels	O
in	O
AML	O
and	O
control	O
plasma	O
of	O
the	O
measured	O
PUFAs	O
and	O
their	O
eicosanoid	B
metabolites.	O

Subjects	O
from	O
Group	O
3	O
and	O
of	O
the	O
TT	O
genotype	O
of	O
the	O
rs3803	O
polymorphism,	O
19	O
subjects,	O
had	O
a	O
lower	O
prevalence	O
of	O
DM2	O
(5.3%	O
vs	O
24.2%;	O
p	O
=	O
0.009)	O
compared	O
to	O
the	O
CC	O
genotype	O
(151	O
subjects,	O
25.8%)	O
although	O
they	O
were	O
predominantly	O
male	O
and	O
had	O
higher	O
values	O
of	O
plasma	O
creatinine	B
(1.37	O
±	O
0.2	O
mmol/L	O
vs	O
0.91	O
±	O
0.24	O
mmol/L)	O

Alterations	O
in	O
cholesterol	B
metabolism	O
could	O
influence	O
COH	O
accumulation.	O

Ammonium	B
formate	I
(AF)	O
for	O
LC/MS	O
was	O
purchased	O
from	O
Thermo	O
Fischer	O
Scientific	O
(Waltham,	O
MA,	O
USA).	O

Nevertheless,	O
PCA	O
analysis	O
identified	O
the	O
importance	O
of	O
ketone	B
bodies	O
in	O
identifying	O
rabies.	O

During	O
the	O
method	O
development	O
process	O
for	O
Level	O
4	O
of	O
SRM	O
972,	O
several	O
samples	O
of	O
the	O
other	O
three	O
levels	O
of	O
SRM	O
972	O
were	O
also	O
analyzed	O
on	O
the	O
cyano	B
column.	O

Acetamiprid	B
was	O
found	O
in	O
Case	O
#2,	O
N	B
-desmethyl-acetamiprid	I
(AM-2)	O
in	O
Cases	O
1	O
and	O
3,	O
and	O
N	B
-(6-chloronicotinoyl)-glycine	I
(CPM-8)	O
in	O
the	O
all	O
three	O
cases.	O

Using	O
a	O
targeted	O
metabolomics	O
platform	O
with	O
which	O
we	O
evaluated	O
12	O
sterols	O
and	O
14	O
bile	O
acids,	O
we	O
observed	O
in	O
the	O
randomly	O
selected	O
(FR)	O
subjects	O
a	O
very	O
strong	O
correlation	O
between	O
a	O
lower	O
pretreatment	O
level	O
of	O
several	O
endogenous	O
primary	O
and	O
secondary	O
bile	O
acids—taurocholic	O
acid	O
(TCA),	O
glycocholic	B
acid	I
(GCA),	O
taurochenodeoxycholic	B
acid	I
(TCDCA),	O
glycochenodeoxycholic	B
acid,	I
(GCDCA)	O
and	O
glycoursodeoxycholic	B
acid	I
(GUDCA)	O
—and	O
greater	O
response	O
to	O
the	O
LDL	O
lowering	O
effects	O
of	O
simvastatin	B
(	O
and	O
).	O

A	O
representative	O
ion	O
chromatogram	O
of	O
the	O
anastrozole	B
metabolite	O
is	O
shown	O
in	O
.	O

Isoleucine,	B
leucine,	B
valine,	B
alanine	B
and	O
proline	B
showed	O
a	O
decrease	O
with	O
shorter	O
sitting	O
time	O
in	O
both	O
the	O
original	O
and	O
replication	O
analysis.	O

In	O
the	O
Prostate,	O
Lung,	O
Colorectal,	O
and	O
Ovarian	O
Cancer	O
Screening	O
Trial	O
(PLCO)	O
cohort,	O
the	O
serum	O
ratio	O
of	O
2-hydroxylation	O
pathway	O
metabolites	O
to	O
parent	O
estrogens	O
was	O
associated	O
with	O
a	O
28%	O
reduction	O
in	O
breast	O
cancer	O
risk	O
across	O
extreme	O
deciles	O
(p-trend=.05),	O
after	O
adjusting	O
for	O
unconjugated	O
estradiol	B
and	O
breast	O
cancer	O
risk	O
factors.	O

In	O
addition,	O
choline	B
is	O
found	O
in	O
various	O
water-	O
and	O
lipid-soluble	O
forms	O
in	O
milk,	O
which	O
can	O
differ	O
in	O
their	O
absorption,	O
transport	O
and	O
metabolism	O
in	O
the	O
nursing	O
infant	O
.	O

In	O
particular,	O
lactose	B
could	O
not	O
be	O
detected	O
in	O
the	O
urine	O
samples	O
of	O
subjects	O
11	O
and	O
20,	O
as	O
well	O
as	O
in	O
the	O
QC	O
samples	O
of	O
the	O
batches	O
co-analysed	O
with	O
these	O
samples.	O

After	O
extraction,	O
the	O
aqueous	O
layer	O
was	O
discarded	O
and	O
the	O
organic	O
solvent	O
portion	O
was	O
transferred	O
to	O
a	O
clean	O
glass	O
tube	O
and	O
evaporated	O
to	O
dryness	O
at	O
60°C	O
under	O
a	O
stream	O
of	O
nitrogen	B
gas.	I

Thus,	O
the	O
low	O
levels	O
of	O
IL-2	O
and	O
IL-10	O
in	O
ER(+)	B
BC	O
relapsed	O
patients	O
could	O
reflect	O
a	O
reduced	O
ability	O
to	O
exert	O
a	O
proper	O
response	O
to	O
therapy.	O

Tumor	O
lactate	B
_13	O
C-labeling	O
in	O
a	O
patient	O
with	O
GBM	O
(A	O
and	O
C)	O
and	O
a	O
patient	O
with	O
lung	O
metastasis	O
to	O
brain	O
(B,	O
D).	O
_13	O
C-_13	O
C	O
doublets	O
C2D12	O
and	O
C3D23	O
correspond	O
to	O
[1,2-_13	O
C]	I
and	O
[2,3-_13	O
C]	I
isotopomers	O
of	O
_13	O
C	O
labeled	O
lactate	B
respectively.	O

There	O
was	O
substantial	O
overlap	O
in	O
features	O
between	O
IL-6	O
and	O
hs-CRP	O
separately	O
between	O
IL-1β	B
and	O
IL-8.	O

Profiling	O
PCs	O
at	O
the	O
isomer	O
level,	O
however,	O
remains	O
challenging	O
in	O
lipidomic	O
settings,	O
especially	O
for	O
characterizing	O
the	O
positions	O
of	O
fatty	O
acyls	O
on	O
the	O
glycerol	B
backbone	O
(sn	O
-positions)	O
and	O
the	O
locations	O
of	O
carbon–carbon	O
double	O
bonds	O
(CCs)	O
in	O
unsaturated	O
acyl	O
chains.	O

(Struck-Lewicka	O
et	O
al.	O
)	O
have	O
reported	O
decreased	O
levels	O
of	O
glycine,	B
in	O
a	O
study	O
performed	O
by	O
liquid	O
chromatography–mass	O
spectrometry	O
(LC–MS)	O
and	O
gas	O
chromatography–mass	O
spectrometry	O
(GC–MS),	O
when	O
comparing	O
the	O
urinary	O
metabolomic	O
profiles	O
of	O
PCa	O
patients	O
and	O
healthy	O
individuals.	O

Both	O
studies	O
suggest	O
that	O
a	O
portion	O
of	O
the	O
BMI-ER+	O
breast	O
cancer	O
association	O
is	O
mediated	O
by	O
estradiol	B
levels,	O
but	O
that	O
a	O
substantial	O
portion	O
may	O
be	O
mediated	O
by	O
other	O
factors.	O

These	O
relationships	O
were	O
observed	O
when	O
classifiers	O
based	O
on	O
all	O
low/intermediate-risk	O
patients,	O
determined	O
by	O
biopsy	O
or	O
RP,	B
were	O
performed	O
(D,	O
5E;	O
Table S1	O
M6).	O

It	O
is	O
known	O
that	O
under	O
prolonged	O
fasting	O
brain	O
switches	O
to	O
the	O
utilization	O
of	O
ketone	B
body	O
(BHB)	O
as	O
an	O
energy	O
substrate	O
which	O
directly	O
enters	O
the	O
citric	B
acid	I
cycle	O
in	O
the	O
mitochondria.	O

Ammonium	B
acetate,	I
acetonitrile	B
(CH_3	O
CN),	O
methanol	B
and	O
water	O
(H_2	O
O)	O
of	O
Optima	O
LC/MS	O
grade	O
were	O
all	O
from	O
Fisher	O
Scientific,	O
France.	O

In	O
this	O
setting,	O
24,25(OH)_2	B
D	O
concentration	O
appears	O
to	O
provide	O
little	O
information	O
beyond	O
25(OH)D	O
concentration.	O

Protein	O
mannosylation	O
is	O
a	O
common	O
glycosylation	O
pattern	O
for	O
HCV,	O
and	O
threonine	B
protein	O
residues	O
are	O
a	O
principal	O
site	O
of	O
mannosylation.	O

PC	B
aa	I
C34:3;	I
120.	O

Anhydrous	B
methanol	I
and	O
chloroform	B
were	O
purchased	O
from	O
Mallinkrodt	O
Baker	O
(Phillipsburg,	O
NJ,	O
USA).	O

Moreover,	O
Ducker	O
et	O
al.	O
traced	O
[2,3,3-_2	B
H]-serine	I
into	O
palmitate	B
and	O
proline	B
to	O
differentiate	O
between	O
cytosolic	O
and	O
mitochondrial	O
folate	B
metabolism	O
and	O
show	O
a	O
compensatory	O
exchange	O
between	O
these	O
distinct	O
one-carbon	O
pools	O
when	O
the	O
mitochondrial	O
system	O
was	O
lost	O
in	O
colorectal	O
cancer.	O

A	O
Cyclone	O
MAX	O
anion-exchange	O
column	O
(Thermo	O
Fisher	O
Scientific,	O
Franklin,	O
MA)	O
was	O
used	O
for	O
the	O
extraction,	O
and	O
a	O
Waters	O
Xbridge	O
C8	O
(Waters	O
Corporation,	O
Milford,	O
MA)	O
was	O
used	O
for	O
separation	O
from	O
other	O
prostaglandins.	B

In	O
this	O
study,	O
the	O
ratio	O
of	O
the	O
2-hydroxylation	O
pathway	O
to	O
the	O
16-hydroxylation	O
pathway	O
was	O
associated	O
with	O
a	O
non-statistically	O
significantly	O
decreased	O
risk	O
of	O
breast	O
cancer	O
after	O
adjustment	O
for	O
unconjugated	O
estradiol	B
(HR	O
=	O
0.69;	O

For	O
both	O
cohorts,	O
the	O
exclusion	O
criteria	O
were:	O
diagnosis	O
of	O
any	O
other	O
vitreoretinal	O
disease,	O
active	O
uveitis	O
or	O
ocular	O
infection,	O
significant	O
media	O
opacities	O
that	O
precluded	O
the	O
observation	O
of	O
the	O
ocular	O
fundus,	O
refractive	O
error	O
equal	O
or	O
greater	O
than	O
6	O
diopters	O
of	O
spherical	O
equivalent,	O
past	O
history	O
of	O
retinal	B
surgery,	O
history	O
of	O
any	O
ocular	O
surgery	O
or	O
intra-ocular	O
procedure	O
(such	O
as	O
laser	O
and	O
intra-ocular	O
injections)	O
within	O
the	O
90	O
days	O
prior	O
to	O
enrolment,	O
and	O
diagnosis	O
of	O
diabetes	O
mellitus.	O

bolus	O
of	O
BEN	O
(2	O
mg/mL	O
in	O
50	O
%	O
hydroxyl-propyl-β-cyclodextrin	B
in	O
saline)	B
or	O
50	O
%	O
hydroxyl-propyl-β-cyclodextrin	B
vehicle	O
at	O
0.01	O
mL/g	O
body	O
weight.	O

Guanosine	B
network	O
generated	O
by	O
Metscape	O
2	O
in	O
which	O
the	O
abundant	O
metabolites	O
of	O
ARDS	O
BALF,	O
xanthine	B
and	O
hypoxanthine,	B
are	O
components	O
and	O
urate	B
(uric	O
acid)	O
is	O
a	O
product.	O

Underlying	O
mechanisms	O
for	O
the	O
higher	O
sorbitol	B
are	O
unknown,	O
but	O
it	O
might	O
be	O
associated	O
with	O
glucose	B
metabolism.	O

Trimethylamine	B
N	I
-oxide	I
is	O
produced	O
in	O
the	O
liver	O
by	O
intestinal	O
bacteria	O
from	O
dietary	O
quaternary	O
amines,	O
such	O
as	O
choline	B
and	O
carnitine	B
trough	O
trimethylamine	B
(TMA)	O
via	O
flavin-containing	O
monooxygenase	O
(FMO3),	O
and	O
the	O
levels	O
in	O
urine	O
or	O
plasma	O
are	O
used	O
to	O
determine	O
FMO_3	O
deficiency	O
[,,,,].	O

Compliance	O
was	O
monitored	O
by	O
breath	O
CO	O
and	O
urinary	O
and	O
saliva	O
cotinine.	B

Furthermore,	O
no	O
interfering	O
peaks	O
were	O
observed	O
in	O
the	O
chromatogram,	O
which	O
validated	O
the	O
use	O
of	O
acetonitrile	B
in	O
three	O
volumes	O
for	O
protein	O
precipitation.	O

Vitamin	B
E	I
is	O
as	O
a	O
fat-soluble	O
antioxidant;	O
it	O
can	O
be	O
effective	O
at	O
scavenge	O
free	O
radicals	O
at	O
the	O
cellular	O
level	O
and	O
can	O
be	O
also	O
prevented	O
a	O
great	O
deal	O
of	O
the	O
resultant	O
scarring	O
during	O
CD.	O

In	O
order	O
to	O
evaluate	O
the	O
linear	O
response	O
of	O
the	O
MS/MS_ALL	O
technique	O
and	O
its	O
dynamic	O
quantification	O
range	O
based	O
on	O
sphingosine-derived	O
fragment	O
ions,	O
we	O
prepared	O
a	O
serial	O
dilution	O
of	O
the	O
CER	B
d17:1/18:0	I
in	O
human	O
plasma	O
while	O
the	O
concentration	O
of	O
CER	B
d18:1/17:0	I
was	O
kept	O
constant.	O

One	O
such	O
example	O
is	O
an	O
unknown	O
compound	O
m/z	O
347.2600,	O
which	O
corresponds	O
to	O
the	O
chemical	O
formula	O
C_22	O
H_36	O
O_3	O
,	O
and	O
was	O
spectrally	O
matched	O
as	O
an	O
analog	O
to	O
the	O
octadecanoid	B
13-HoTrE.	O
Comparison	O
of	O
the	O
tandem	O
MS	O
fragmentation	O
patterns	O
between	O
the	O
unknown	O
and	O
known	O
compounds	O
revealed	O
that	O
all	O
carboxyl-containing	O
fragments	O
from	O
carbons	O
C7	O
to	O
C1	O
were	O
identical	O
between	O
the	O
two	O
compounds	O
while	O
carboxyl-containing	O
fragments	O
from	O
carbons	O
C12/C13	O
to	O
C1	O
were	O
shifted	O
by	O
54.0472	O
daltons.	O

Furthermore,	O
the	O
catabolism	O
of	O
BCAAs	O
also	O
provides	O
an	O
important	O
source	O
for	O
the	O
generation	O
of	O
amino	O
acids,	O
especially	O
glutamine	B
and	O
alanine.	B

The	O
four	O
most	O
significantly	O
altered	O
pathways	O
were	O
pyrimidine	B
metabolism	O
(impact	O
value:	O
0.48,	O
P	O
 < 0.001),	O
purine	B
metabolism	O
(impact	O
value:	O
0.35,	O
P	O
 < 0.001),	O
histidine	B
metabolism	O
(impact	O
value:	O
0.35,	O
P	O
 = 0.002),	O
and	O
alanine,	B
aspartate,	B
and	O
glutamate	B
metabolism	O
(impact	O
value:	O
0.49,	O
P	O
 = 0.003).	O

ASA	O
and	O
statin	B
medication	O
was	O
also	O
taken	O
on	O
the	O
day	O
of	O
the	O
colonoscopy.	O

Our	O
experiment	O
utilizes	O
an	O
efficient	O
Latin	B
square	O
design,	O
which	O
allows	O
one	O
to	O
compare	O
the	O
performance	O
of	O
statistical	O
methods	O
using	O
a	O
range	O
of	O
fold	O
changes	O
over	O
a	O
range	O
of	O
concentration	O
baselines.	O

The	O
results	O
of	O
our	O
study	O
showed	O
that	O
total	O
cholesterol,	B
LDL,	O
eight	O
lysoPCs	O
and	O
glycerophosphocholine	B
were	O
significantly	O
lower	O
in	O
cirrhosis	O
group,	O
correlated	O
with	O
the	O
Child-Pugh	O
score	O
(P<0.001),	O
which	O
suggesting	O
that	O
lipid	O
metabolism	O
was	O
overall	O
impaired	O
in	O
patients	O
with	O
hepatitis	O
B	O
cirrhosis.	O

We	O
provide	O
first	O
evidence	O
that	O
the	O
ability	O
to	O
achieve	O
clinically	O
relevant	O
(Z)‐endoxifen	B
plasma	O
concentrations	O
during	O
breast	O
cancer	O
tamoxifen	B
treatment	O
is	O
cooperatively	O
influenced	O
by	O
treatment	O
adherence	O
behavior,	O
CYP2D6	O
genomic	O
background,	O
and	O
pharmacokinetic	O
capacity.	O

As	O
for	O
the	O
tamNox	O
to	O
tamoxifen	B
ratio	O
was	O
inversely	O
related	O
with	O
CYP2C19	O
predicted	O
activity	O
(p	O
=	O
0.001,	O
figure	O
).	O

We	O
can	O
prove	O
pyridoxine	B
responsiveness	O
by	O
finding	O
a	O
lower	O
endogenous	O
oxalate	B
production	O
(from	O
glycolate)	B
as	O
compared	O
to	O
non-B6	O
responders,	O
but	O
more	O
importantly	O
we	O
can	O
also	O
prove	O
that	O
the	O
conversion	O
of	O
1-_13	O
C-glyoxylate	B
to	O
1-_13	O
C-glycine	B
occurs.	O

The	O
protection	O
from	O
CRC	O
in	O
individuals	O
treated	O
with	O
aspirin	B
becomes	O
visible	O
in	O
the	O
rates	O
of	O
CRC	O
incidence	O
8–10	O
years	O
after	O
the	O
beginning	O
of	O
aspirin	B
administration.	O

The	O
inter-run	O
precision	O
was	O
in	O
the	O
range	O
of	O
3.2%CV	O
and	O
3.6%CV	O
for	O
Cer(22:0)	B
and	O
Cer(24:0),	B
respectively.	O

_,	O
Unlike	O
eukaryotes,	O
bacteria	O
can	O
synthesize	O
trp	O
and	O
some	O
bacteria	O
can	O
also	O
produce	O
serotonin.	B

Then,	O
200 μL	O
of	O
Milli-Q	O
water	O
and	O
500 μL	O
chloroform	B
were	O
added,	O
and	O
the	O
solution	O
was	O
centrifuged	O
at	O
2300 g	O
for	O
5 min	O
at	O
4 °C.	O

	O
Blood	O
for	O
cortisol	B
determination	O
was	O
collected	O
peripherally	O
via	O
intravenous	O
(IV)	O
catheter	O
1	O
hr	O
after	O
sleep	O
onset	O
in	O
silicone-coated	O
tubes,	O
centrifuged,	O
and	O
the	O
serum	O
layer	O
removed.	O

Cysteine	B
is	O
also	O
supplied	O
through	O
the	O
diet	O
but	O
it	O
can	O
additionally	O
result	O
from	O
the	O
conversion	O
of	O
methionine	B
via	O
the	O
transsulfuration	O
pathway.	O

FAs	O
are	O
then	O
incorporated	O
into	O
complex	O
glycerophospholipids,	B
which	O
further	O
promote	O
biomass	O
growth	O
by	O
providing	O
building	O
blocks	O
and	O
suitable	O
physical	O
properties	O
to	O
dividing	O
cell	O
membranes,	O
acting	O
as	O
signaling	O
mediators	O
and	O
regulating	O
energy	O
metabolism	O
in	O
cells.	O

sodium-3-(tri-methylsilyl)-2,2,3,3-tetradeuterio-propionate	B
(TSP;	O
Cambridge	O
Isotope	O
Laboratories,	O
Andover,	O
MA)	O
as	O
an	O
internal	O
standard.	O

CaP,	O
prostate	O
cancer;	O
Cit,	O
citrate;	B
Fru,	B
fructose;	B
Lip,	O
lipids/lipoproteins;	O
PC,	O
principal	O
component;	O
Ser,	O
serine;	B
Spe,	O
spermine.	B

Steroid	O
conjugates	O
were	O
enzymatically	O
hydrolyzed,	O
re-extracted,	O
and	O
chemically	O
derivatized	O
to	O
form	O
methyloxime	B
trimethyl	I
silyl	I
ethers.	I

The	O
mobile	O
phase	O
was	O
0.1%	O
formic	B
acid	I
in	O
water	O
and	O
methanol.	B

This	O
study	O
indicates	O
that	O
the	O
_1	O
H-NMR-derived	O
relative	O
plasma	O
concentration	O
of	O
glutamate	B
allows	O
discrimination	O
between	O
lung	O
cancer	O
and	O
lung	O
inflammation.	O

Fasting	O
blood	O
glucose	B
will	O
be	O
performed	O
with	O
a	O
hexokinase-based	O
method	O
(Abbott	O
Laboratories,	O
USA).	O

(LCFA)	O
esterified	O
to	O
carnitine.	B

The	O
mean	O
level	O
of	O
8-iso	B
-PGF_2α	I
at	O
Week	O
4	O
was	O
1.34	O
±	O
1.08	O
(S.D.)	O
pmol/mg	O
creatinine	B
(N	O
=	O
226)	O
while	O
that	O
of	O
PGE-M	O
was	O
73.7	O
±	O
113	O
(S.D.)	O
pmol/mg	O
creatinine	B
(N	O
=	O
232).	O

All	O
were	O
postmenopausal	O
and	O
not	O
currently	O
using	O
hormone	O
therapy	O
at	O
baseline,	O
had	O
no	O
other	O
cancers	O
other	O
than	O
non-melanoma	O
skin	O
cancer	O
diagnosed	O
during	O
follow-up,	O
had	O
sufficient	O
baseline	O
serum	O
for	O
biochemical	O
analyses,	O
and	O
did	O
not	O
have	O
extreme	O
values	O
for	O
the	O
sum	O
of	O
all	O
estrogens	O
and	O
estrogen	B
metabolites.	O

Each	O
participant	O
underwent	O
a	O
75-g	O
oral	O
glucose	B
tolerance	O
test	O
(OGTT)	O
with	O
blood	O
sampling	O
at	O
30-minute	O
intervals	O
for	O
2	O
hours.	O

STOCSY	O
was	O
performed	O
on	O
the	O
subset	O
of	O
samples	O
from	O
acetaminophen	B
users.	O

After	O
correction	O
for	O
adult	O
height,	O
BMI,	O
presence	O
of	O
a	O
varicocele	O
and	O
exposure	O
to	O
maternal	O
smoking	O
mono-iso-nonyl	B
phthalate	I
(MiNP)	O
(r	O
 = −0.22)	O
and	O
sums	O
of	O
DEHP	O
and	O
DiNP	O
metabolites	O
(r	O
 = −0.24)	O
and	O
the	O
sum	O
of	O
the	O
metabolites	O
of	O
the	O
high	O
molecular	O
weight	O
phthalates	O
(r	O
 = −0.21)	O
were	O
negatively	O
correlated	O
with	O
TV	O
(all	O
p	O
 < 0.05).	O

We	O
also	O
established	O
a	O
correlation	O
between	O
high	O
plasma	O
levels	O
of	O
TMAO	B
and	O
an	O
increased	O
risk	O
of	O
incident	O
major	O
adverse	O
cardiovascular	O
events	O
that	O
is	O
independent	O
of	O
traditional	O
risk	O
factors,	O
even	O
in	O
low-risk	O
cohorts.	O

The	O
endogenous	O
level	O
+	O
6/24	O
μg/mL	O
QC,	O
which	O
is	O
also	O
referred	O
to	O
as	O
a	O
dilution	O
quality	O
control	O
(DQC)	O
sample,	O
was	O
higher	O
than	O
the	O
upper	O
limit	O
of	O
quantification	O
(ULOQ:	O
4/16	O
μg/mL	O
of	O
Cer(22:0)/Cer(24:0)),	B
and	O
thus	O
was	O
diluted	O
1:4	O
with	O
5%	O
BSA	O
prior	O
to	O
extraction.	O

BCAAs,	O
including	O
leucine,	B
isoleucine,	B
and	O
valine,	B
are	O
essential	O
amino	O
acids	O
and	O
are	O
acquired	O
from	O
the	O
diet.	O

The	O
effect	O
of	O
statin	B
treatment	O
on	O
eicosanoid	B
formation	O
is	O
controversial,	O
with	O
studies	O
demonstrating	O
increased	O
eicosanoid	B
formation	O
due	O
to	O
statin	B
use	O
(–)	O
as	O
compared	O
with	O
other	O
data	O
indicating	O
suppression	O
of	O
eicosanoid	B
formation	O
(–).	O

When	O
using	O
concentrated	O
solutions,	O
interference	O
from	O
IS	O
to	O
spironolactone’s	B
transitions	O
and	O
vice	O
versa	O
was	O
significant.	O

Only	O
one	O
molecule,	O
isocitrate,	B
achieved	O
statistical	O
signiﬁcance	O
between	O
patients	O
with	O
strictures	O
and	O
healthy	O
controls.	O

However,	O
most	O
amino	O
acid	O
degradation	O
takes	O
place	O
in	O
extrahepatic	O
tissues,	O
which	O
lack	O
the	O
enzymes	O
of	O
the	O
urea	B
cycle.	O

A	O
MALDI	O
micro	O
MX	O
mass	O
spectrometer	O
(Waters/Micromass)	O
fitted	O
with	O
a	O
nitrogen	O
laser	O
(337-nm,	O
4-ns	O
laser	O
pulse	O
duration,	B
max	O
330	O
μJ	O
per	O
laser	O
pulse,	O
max	O
20-Hz	O
repetition	O
rate)	O
was	O
used	O
in	O
reflectron	O
mode	O
and	O
negative	O
polarity	O
for	O
data	O
acquisition.	O

Consistent	O
with	O
previous	O
studies	O
in	O
man,	O
pioglitazone	B
in	O
the	O
present	O
study	O
enhanced	O
adipocyte	O
sensitivity	O
to	O
the	O
antilipolytic	O
effect	O
of	O
insulin,	O
leading	O
to	O
a	O
decrease	O
in	O
fasting	O
plasma	O
FFA	O
concentration	O
and	O
improved	O
insulin-mediated	O
suppression	O
of	O
plasma	O
FFA	O
concentration.	O

The	O
levels	O
of	O
SM(36:3)	B
and	O
PC(40:7)	B
were	O
increased	O
at	O
w16	O
and	O
declined	O
to	O
the	O
levels	O
observed	O
before	O
intervention	O
(w0)	O
at	O
w28	O
for	O
the	O
TFA	O
group,	O
whereas	O
there	O
was	O
no	O
change	O
for	O
the	O
CTR	O
group.	O

The	O
current	O
work	O
therefore	O
outlines,	O
for	O
the	O
first	O
time,	O
a	O
rapid,	O
comprehensive	O
method	O
for	O
simultaneously	O
assaying	O
metformin	B
and	O
the	O
metformin–MG	O
scavenged	O
IMZ	O
metabolite	O
in	O
urine	O
from	O
metformin-treated	O
T2DM	O
patients.	O

The	O
samples	O
were	O
centrifuged	O
at	O
3000	O
rpm	O
for	O
20	O
min,	O
and	O
1.5	O
mL	O
of	O
the	O
hexane	B
layer	O
was	O
removed	O
and	O
transferred	O
to	O
a	O
separate	O
glass	O
tube	O
with	O
a	O
cap.	O

Interestingly,	O
when	O
the	O
pH	O
was	O
adjusted	O
to	O
10	O
with	O
ammonium	B
hydroxide,	I
a	O
decrease	O
in	O
the	O
signal	O
intensity	O
occurred.	O

The	O
metabolite	O
with	O
the	O
strongest	O
positive	O
association	O
with	O
TB	O
was	O
3-methoxytyrosine,	B
a	O
metabolite	O
of	O
levodopa	B
which	O
is	O
mostly	O
associated	O
with	O
aromatic	O
L-amino	O
acid	O
decarboxylase	O
(AADC)	O
deficiency.	O

Another	O
possible	O
explanation	O
for	O
the	O
association	O
between	O
plasma	O
citrulline	B
and	O
OCN	O
might	O
be	O
found	O
in	O
energy	O
metabolism.	O

In	O
a	O
twin	O
study,	O
consisting	O
of	O
14	O
pairs	O
of	O
young-adult	O
monozygotic	O
twins	O
discordant	O
for	O
obesity,	O
several	O
TG	B
species	O
correlated	O
significantly	O
with	O
BMI	O
and	O
subcutaneous	O
fat	O
measurement.	O

Samples	O
were	O
re-constituted	O
in	O
70%	O
aqueous	O
acetonitrile,	B
of	O
which	O
5ul	O
was	O
injected	O
for	O
LC-MS/MS	O
analysis.	O

The	O
cartridges	O
were	O
conditioned	O
by	O
flushing	O
the	O
tips	O
ten	O
times	O
with	O
100	O
µl	O
methanol	B
followed	O
by	O
100	O
µl	O
of	O
water	O
acidified	O
with	O
formic	B
acid	I
(100	O
µl	O
water	O
and	O
5	O
µl	O
25%	O
formic	O
acid).	O

It	O
correlates	O
with	O
dietary	O
purine	B
uptake,	O
indicating	O
disturbances	O
in	O
the	O
purine	B
metabolism	O
in	O
IBD.	O

a	O
Analysis	O
of	O
effect	O
of	O
adding	O
Lactate.	B

Among	O
them,	O
the	O
derivatives	O
of	O
pyridine-3-sulfonyl	B
chloride	I
appears	O
to	O
be	O
more	O
diagnostically	O
valuable	O
by	O
showing	O
estrogen-specific	O
fragmentations	O
by	O
ESI	O
MRM	O
using	O
triple	O
quadrupole	O
MS	O
with	O
a	O
LOD	O
of	O
10	O
pg/mL	O
for	O
E2.	O

We	O
treated	O
colon	O
cancer	O
cells	O
lines	O
with	O
epacadostat	O
or	O
680C91	O
for	O
3	O
d,	O
after	O
which	O
the	O
cells	O
were	O
harvested	O
and	O
stained	O
with	O
propidium	O
iodide	B
(PI)	O

A	O
separate	O
study	O
showed	O
that	O
4-HPA	O
reduced	O
inflammatory	O
cytokine	O
levels	O
through	O
suppressing	O
hypertonicity-	O
and	O
hypoxia-induced	O
HIF-1α	B
in	O
macrophages.	O

Any	O
additional	O
folate	B
supplementation	O
was	O
self-reported	O
by	O
subjects	O
at	O
study	O
enrollment,	O
12	O
wk,	O
and	O
34	O
wk.	O

Some	O
of	O
the	O
top	O
20	O
variables	O
are	O
also	O
located	O
in	O
the	O
[3.966	O
–3.984]	O
region	O
which	O
corresponds	O
to	O
the	O
aliphatic	B
doublet	O
of	O
hippurate,	B
while	O
most	O
of	O
the	O
variables	O
ranked	O
between	O
20	O
and	O
100	O
are	O
located	O
in	O
the	O
remaining	O
three	O
hippurate	B
regions.	O

Hence	O
we	O
have	O
combined	O
all	O
the	O
values	O
of	O
2-catechol	B
conjugates	O
and	O
4-catechol	B
conjugates	O
,	O
.	O

Methanol,	B
acetonitrile,	B
perchloric	B
acid	I
(PCA),	O
trichloroacetic	O
acid	O
(TCA),	O
hydrochloric	B
acid	I
(HCl),	O
sodium	B
hydroxide	I
(NaOH),	O
(2-bromoethyl)	B
trimethylammonium	I
bromide,	I
dimethylformamide	B

PC	B
ae	I
C40:2;	I
51.	O

Due	O
to	O
their	O
similar	O
structures,	O
citric	B
acid	I
and	O
isocitric	B
acid	I
were	O
detected	O
at	O
the	O
same	O
retention	O
time	O
by	O
our	O
system.	O

μg/24	O
h	O
in	O
healthy	O
controls;	O
P	O
<	O
0.001),	O
with	O
similar	O
findings	O
for	O
cortisol	B
excretion	O
(SI	O
Appendix	O
and	O
).	O

More	O
recently	O
fecal	O
biomarkers	O
such	O
as	O
fecal	O
calprotectin	O
and	O
lactoferrin	B
have	O
shown	O
promising	O
results	O
in	O
differentiating	O
IBD	O
from	O
IBS,	O
monitoring	O
disease	O
activity	O
and	O
predicting	O
the	O
relapse	O
in	O
IBD	O
,	O
.	O

We	O
found	O
that	O
HCC	O
was	O
associated	O
with	O
increased	O
plasma	O
levels	O
of	O
glycodeoxycholate,	B
deoxycholate	B
3-sulfate	I
and	O
bilirubin.	B

The	O
potential	O
mechanism	O
by	O
which	O
altered	O
GM3	B
levels	O
may	O
be	O
associated	O
with	O
PD	O
was	O
investigated	O
in	O
a	O
few	O
models.	O

This	O
might	O
be	O
due	O
to	O
a	O
differential	O
expression	O
of	O
adenylate	B
kinase	O
catalyzing	O
the	O
reaction,	O
2ADP ↔ ATP + AMP,	O
which	O
is	O
undetectable	O
in	O
adult	O
prostate	O
but	O
shows	O
activity	O
along	O
with	O
its	O
malignant	O
alteration	O
(Hall	O
et	O
al.	O
).	O

Two	O
volatile	O
metabolites	O
(4-heptanone	O
and	O
2,6-dimethyl-7-octen-2-ol)	B
were	O
detected	O
to	O
able	O
to	O
significantly	O
discriminate	O
early-stage	O
lymphoma	O
from	O
advanced	O
lymphoma.	O

Venous	O
blood	O
samples	O
were	O
drawn	O
for	O
measurement	O
of	O
blood	O
glucose,	B
serum	O
creatinine,	B
cholesterol	B
as	O
well	O
as	O
“classical”	O
markers	O
of	O
inflammation	O
such	O
as	O
high	O
sensitivity	O
C-reactive	O
protein	O
(hs-CRP)	O
and	O
interleukin-6	O
(hs-IL-6).	O

Metabolites	O
that	O
have	O
only	O
one	O
or	O
two	O
cross-peaks,	O
such	O
as	O
methylguanidine	B
or	O
dimethylglycine	B
can	O
be	O
easily	O
misassigned	O
due	O
to	O
peak	O
overlaps.	O

At	O
low	O
pH	O
and	O
up	O
to	O
9.5,	O
ZDV-TP	O
was	O
better	O
ionized	O
in	O
the	O
negative	O
mode	O
than	O
in	O
the	O
positive	O
mode,	O
due	O
to	O
the	O
inability	O
of	O
the	O
thymine	B
base	O
to	O
accept	O
an	O
extra	O
proton	O
unless	O
conditions	O
are	O
extremely	O
basic	O
(thymidine	O
nucleoside	O
and	O
nucleotide	O
pK	O
_a	O
>	O
9.5).	O

Example	O
shown	O
for	O
1,25(OH)_2	B
D_3.	O

Our	O
MTBE	B
results	O
are	O
in	O
contrast	O
to	O
good	O
precision	O
obtained	O
when	O
using	O
MTBE	B
with	O
in-vial	O
dual	O
extraction	O
method	O
where ≥ 80%	O
of	O
features	O
had	O
RSD ≤ 30%	O
for	O
n = 3	O
extraction	O
replicates.	O

For	O
both	O
2-pathway	O
catechols	B
and	O
the	O
single	O
4-pathway	O
catechol,	B
breast	O
cancer	O
risk	O
was	O
elevated	O
in	O
the	O
fourth	O
quartile,	O
compared	O
to	O
the	O
first,	O
and	O
reduced	O
for	O
two	O
of	O
the	O
three	O
2-pathway	O
methylated	B
catechols	I
and	O
both	O
4-pathway	O
methylated	B
catechols.	I

Lyophilised	O
ClinCal	O
and	O
ClinCheck	O
25-OH-Vitamin	B
D_2	O
/D_3	O
serum	O
calibrators	O
(level	O
0-III)	O
and	O
quality	O
control	O
sera	O
(level	O
I,	O
II)	O
were	O
from	O
Recipe	O
(Munich,	O
Germany)	O
and	O
reconstituted	O
in	O
water	O
prior	O
to	O
use.	O

A	O
targeted	O
search	O
for	O
C15:0	B
and	O
C17:0	B
revealed	O
the	O
presence	O
of	O
these	O
two	O
free	O
fatty	O
acids	O
in	O
the	O
serum	O
samples	O
of	O
our	O
study.	O

High	O
concentrations	O
(10,000	O
ng/g)	O
of	O
cocaine	O
metabolites,	O
ecgonine	O
ethyl	B
ester,	I
ecgonine	B
methyl	I
ester,	I
and	O
anhydroecgonine	B
methyl	I
ester	I
were	O
chosen	O
to	O
far	O
exceed	O
observed	O
meconium	O
concentrations.	O

In	O
order	O
to	O
determine	O
more	O
precisely	O
the	O
extent	O
of	O
ethanol	B
production	O
after	O
24	O
h	O
of	O
fermentation	O
in	O
these	O
2	O
groups,	O
the	O
area	O
under	O
the	O
ethanol	B
resonance	O
of	O
the	O
methyl	O
protons	O
at	O
1.18	O
ppm	O
was	O
integrated	O
at	O
0	O
h	O
and	O
24	O
h.	O

Emericellene	B
A	O
(2):	O
colorless	O
amorphous	O
solid;	O
[α]_25	O
_D	O
15.7	O
(c	O
0.05,	O
MeOH);	O
UV	O
(MeOH)	O

At	O
low	O
glutamate	B
concentration	O
and	O
0.10%	O
_13	O
C	O
enrichment,	O
the	O
labeling	O
was	O
slightly	O
overestimated,	O
and	O
we	O
calculated	O
an	O
M5	O
abundance	O
of	O
0.14%	O
instead	O
of	O
0.1%.	O

Aspartate	B
is	O
produced	O
directly	O
from	O
oxaloacetate	B
catalyzed	O
by	O
aspartate	O
aminotransferase.	O

Tryptophan	B
was	O
also	O
one	O
of	O
the	O
metabolites	O
with	O
highest	O
p(corr)	O
values	O
in	O
an	O
OPLS-DA	O
model	O
between	O
pre-symptomatic	O
individuals	O
and	O
controls.	O

In	O
whole	O
blood,	O
but	O
not	O
in	O
plasma,	O
BEN	O
was	O
rapidly	O
converted	O
to	O
its	O
carboxylic	B
acid	I
analog	O
BA,	O
suggesting	O
conversion	O
by	O
an	O
enzyme	O
present	O
in	O
red	O
blood	O
cells.	O

Lipids	O
were	O
extracted	O
using	O
chloroform,	B
methanol,	B
and	O
isopropanol	B
(Sigma	O
Aldrich,	O
St.	O
Louis,	O
MO,	O
USA)	O
and	O
ultrapure	O
water	O
(Millipore).	O

Among	O
them	O
were	O
the	O
most	O
abundant	O
acylcarnitines,	B
namely,	O
C0,	O
C2	O
and	O
C3.	O

BEN	O
metabolism,	O
Alkylators,	B
Degradation,	O
Renal	O
cell	O
carcinoma,	O
HPLC,	O
Mass	O
spectrometry,	O
Metabolism,	O
Aldehyde	O
dehydrogenase,	O
Stability,	O
Cell	O
lines,	O
Cancer	O

Activity	O
was	O
most	O
strongly	O
associated	O
with	O
cholesterol	B
content	O
in	O
VLDL	O
and	O
HDL	O
lipoprotein	O
particles,	O
with	O
triglyceride	B
content	O
in	O
all	O
particle	O
types,	O
and	O
with	O
inflammatory	O
glycoprotein	O
acetyls.	O

Standards	O
were	O
commercially	O
available	O
(Avanti	O
Polar	O
Lipids,	O
Alabaster,	O
AL)	O
for	O
three	O
of	O
the	O
tentatively	O
identified	O
lipids	O
of	O
interest,	O
1-0-1’-(Z)-Octadecenyl-2-Arachidonoyl-sn-Glycero-3-Phosphoethanolamine,	B
1-Palmitoyl-2-Linoleoyl-sn-Glycero-3-Phosphocholine,	B
and	O
1-octadecanoyl-2-(5Z,	B
8Z,	I
11Z,	I
14Z-eicosatetraenoyl)-sn-Glycero-3-Phospho-(1’-myo-inositol))and	I
we	O
performed	O
MS/MS	O
on	O
those	O
available	O
to	O
confirm	O
our	O
tentative	O
identifications.	O

Meanwhile,	O
a	O
number	O
of	O
previous	O
studies	O
have	O
confirmed	O
that	O
lower	O
circulating	O
PLP	O
concentrations	O
or	O
lowering	O
vitamin	B
B6	I
intake	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
CHD,	O
hypertension,	O
diabetes	O
or	O
stroke.	O

b	O
Colored	O
according	O
to	O
the	O
logarithm	O
of	O
absolute	O
concentration	O
of	O
paracetamol–glucuronide	B
(Color	O
figure	O
online)	O

The	O
elevated	O
concentrations	O
of	O
lactate	B
in	O
PTSD	O
may	O
have	O
synergistic	O
anti-lipolytic	O
effects,	O
reducing	O
the	O
availability	O
of	O
long	O
chain	O
fatty	O
acids	O
for	O
energy	O
metabolism,	O
which	O
may	O
also	O
lead	O
to	O
the	O
increased	O
adiposity	O
and	O
BMI	O
seen	O
in	O
these	O
subjects.	O

Short‐term	O
stability	O
experiment	O
in	O
treated	O
patients	O
on	O
1000	O
mg	O
once	O
daily	O
abiraterone	B
acetate.	I

Chronic	O
prednisone	B
treatment	O
caused	O
increase	O
in	O
membrane	O
associated	O
glycerophospholipids,	B
which	O
may	O
be	O
associated	O
with	O
certain	O
adverse	O
effects.	O

The	O
mobile	O
phase	O
was	O
0.1%	O
formic	B
acid	I
in	O
water	O
(A)	O
and	O
0.1%	O
formic	B
acid	I
in	O
70%	O
acetonitrile	B
and	O
30%	O
methanol	B
(B).	O

In	O
our	O
study,	O
the	O
levels	O
of	O
PC(15:0/18:1),	B
PC(16:1/20:5),	B
and	O
PC(18:0/20:1)	B
in	O
early-stage	O
NSCLC	O
patients	O
were	O
significantly	O
increased	O
compared	O
with	O
LBD	O
patients	O
and	O
HC.	O

Serum	O
follistatin	B
and	O
myostatin	B
during	O
pre-event,	O
C1,	O
C2,	O
and	O
post-event.	O

After	O
that,	O
the	O
mixture	O
of	O
salts	O
containing	O
4	O
g	O
MgSO_4	O
,	O
1	O
g	O
NaCl,	O
1	O
g	O
sodium	B
citrate	I
and	O
0.5	O
g	O
disodium	B
citrate	I
sesquihydrate,	O
was	O
poured	O
and	O
immediately	O
shaken	O
for	O
1	O
min,	O
and	O
then	O
centrifuged	O
at	O
4400	O
rpm	O
for	O
5	O
min.	O

Abbreviations:	O
ASD,	O
autism	O
spectrum	O
disorders;	O
DUP,	O
duration	B
of	O
untreated	O
psychosis;	O
FESZ,	O
first-episode	O
schizophrenia;	O
GAF,	O
the	O
global	O
assessment	O
of	O
functioning;	O
NA,	O
not	O
applicable;	O
PANSS,	O
the	O
positive	O
and	O
negative	O
symptom	O
scale.	O

We	O
determined	O
that	O
6	O
weeks	O
of	O
daily	O
simvastatin	B
treatment	O
increased	O
plasma	O
glucose	B
and	O
insulin	O
in	O
some	O
subjects,	O
indicating	O
development	O
of	O
insulin	O
resistance.	O

Vitamin-D3	O
derivatives,	O
sphingolipids,	B
PC,	O
and	O
phosphatidylethanolamines	B
(PE)	O
were	O
only	O
found	O
in	O
methanol-ethanol	B
extracted	O
samples,	O
while	O
hydroxyl-	B
or	O
bromo-modified	O
fatty	O
acid	O
and	O
carnitine	B
analogs	O
were	O
found	O
only	O
when	O
the	O
methanol-only	B
method	O
was	O
used.	O

This	O
feature	O
was	O
putatively	O
assigned	O
to	O
riboflavin.	B

First,	O
it	O
seems	O
that	O
changes	O
in	O
serum	O
metabolomics	O
profiles	O
reflect	O
activation	O
or	O
impairment	O
in	O
several	O
biologic	O
pathways,	O
mainly	O
energetic	O
metabolism	O
involving	O
glutamine/glutamate,	O
carbohydrates,	O
ketone	B
bodies,	O
and	O
lipids.	O

Notably,	O
when	O
we	O
predicted	O
the	O
successful	O
management	O
of	O
the	O
blood	O
glucose	B
based	O
on	O
the	O
predicted	O
HbA1c	O
values	O
(a	O
dichotomic	O
decision:	O
successful	O
management	O
of	O
HbA1c≤7.0;	O
unsuccessful	O
management	O
of	O
HbA1c>7.0),	O
the	O
model	O
correctly	O
classified	O
the	O
management	O
status	O
in	O
17	O
out	O
of	O
21	O
patients	O
(81%	O
correct).	O

The	O
ratio	O
of	O
the	O
2-hydroxylation	O
pathway	O
to	O
parent	O
estrogens	O
(HR	O
=	O
0.66,	O
95%	O
CI	O
=	O
0.51	O
to	O
0.87)	O
and	O
the	O
ratio	O
of	O
4-hydroxylation	O
pathway	O
catechols	B
to	O
4-hydroxylation	O
pathway	O
methylated	B
catechols	I
(HR	O
=	O
1.34,	O
95%	O
CI	O
=	O
1.04	O
to	O
1.72)	O
were	O
statistically	O
significantly	O
associated	O
with	O
the	O
risk	O
of	O
breast	O
cancer	O
and	O
remained	O
so	O
after	O
adjustment	O
for	O
unconjugated	O
estradiol.	B

%Methylated	B
catechols,	I
like	O
%catechols,	B
increased	O
significantly	O
across	O
the	O
range	O
of	O
soy	O
intake	O
(p_trend	O
<	O
0.01).	O

Some	O
of	O
the	O
increased	O
amino	O
acids	O
were	O
also	O
reported	O
to	O
be	O
increased	O
in	O
fecal	O
extracts	O
and	O
extracts	O
of	O
colon	O
mucosa	O
with	O
the	O
exception	O
of	O
isoleucine,	B
which	O
has	O
apparently	O
low	O
concentrations	O
in	O
colonic	O
mucosa	O
of	O
active	O
CD	O
and	O
UC.	O

There	O
are	O
no	O
direct	O
data	O
in	O
animals	O
on	O
the	O
effect	O
of	O
DES	B
on	O
estrogen	B
metabolism.	O

In	O
particular,	O
eight	O
metabolites	O
showed	O
a	O
similar	O
upward	O
or	O
downward	O
change	O
in	O
DLBCL	O
and	O
CLL	O
cases	O
compared	O
to	O
the	O
controls,	O
namely	O
2-aminoadipic	B
acid,	I
2-aminoheptanedioic	B
acid,	I
4-hydroxyproline,	B
erythritol,	B
glucoheptonic	B
acid,	I
inositol-like	O
(an	O
inositol	B
isomer	I
other	O
than	O
myo-,	O
scyllo-	O
and	O
chiro-inositol),	O
threitol,	B
and	O
unknown	O
1910.	O

Betaine	B
was	O
quantified	O
from	O
the	O
acquired	O
spectra	O
using	O
a	O
proprietary	O
deconvolution	O
algorithm	O
that	O
resolved	O
the	O
betaine	B
region	O
into	O
its	O
spectral	O
components.	O

Oxysterols	B
can	O
be	O
defined	O
as	O
oxygenated	O
forms	O
of	O
cholesterol,	B
and	O
this	O
definition	O
includes	O
hydroxycholesterols,	B

For	O
example,	O
in	O
the	O
current	O
study,	O
taurine	B
is	O
significantly	O
higher	O
in	O
most	O
of	O
the	O
treated	O
and	O
untreated	O
patient	O
samples	O
in	O
comparison	O
with	O
the	O
control	O
(Table	O
S1),	O
and	O
it	O
is	O
tempting	O
to	O
conclude	O
that	O
taurine	B
is	O
an	O
important	O
disease	O
marker,	O
given	O
its	O
anti-inflammatory	O
effects.	O

*	O
indicates	O
p	O
≤	O
0.05	O
between	O
MeOH:CHCl_3	B
ppt	O
versus	O
MeOH:	B

An	O
alternative	O
explanation	O
is	O
that	O
tamoxifen	B
and	O
its	O
metabolites	O
inhibit	O
enzymes	O
that	O
are	O
involved	O
in	O
the	O
degradation	O
of	O
estrogens.	O

Tetradecenoylcarnitine;	B
6.	O

Likewise,	O
the	O
biomarker	O
of	O
pro-inflammatory	O
event	O
(IL-1β)	O
in	O
sputum	O
supernatant	O
was	O
significantly	O
increased	O
in	O
asthmatic	O
subjects	O
with	O
obesity	O
compared	O
with	O
lean	O
ones.	O

Correlation	O
of	O
the	O
basal	O
status	O
of	O
serum	O
S1P	O
and	O
urine	O
sphingosine	B
levels	O
with	O
(b)	O
the	O
decline	O
of	O
FEV_1	O
(%)	O
following	O
the	O
ASA-BPT,	O
and	O
(c)	O
serum	O
periostin	O
level.	O

Tryptophan	B
metabolism	O
demonstrated	O
strong	O
relevance	O
as	O
it	O
achieved	O
the	O
highest	O
impact	O
in	O
the	O
comparison	O
between	O
SPMS	O
and	O
controls	O
and	O
the	O
second	O
highest	O
in	O
the	O
comparison	O
with	O
RRMS	O
patients.	O

The	O
low	O
levels	O
of	O
succinate	B
found	O
in	O
urine	O
samples	O
after	O
meals	O
with	O
blueberries	O
can,	O
therefore,	O
suggest	O
the	O
effect	O
of	O
blueberries	O
in	O
the	O
regulation	O
of	O
glucose	B
metabolism	O
and	O
inflammatory	O
pathways.	O

Glucometer	B
and	O
strips	O
will	O
be	O
given	O
to	O
the	O
patients	O
to	O
record	O
three	O
values	O
daily	O
(after	O
fasting,	O
before	O
a	O
meal	O
and	O
two	O
hours	O
after	O
a	O
meal).	O

As	O
these	O
data	O
reflect	O
total	O
anthocyanins	B
and	O
account	O
for	O
saliva	O
volumes,	O
the	O
differences	O
don't	O
reflect	O
volume	O
dilutions	O
in	O
the	O
Rinse	O
II	O
and	O
III	O
samples.	O

In	O
previous	O
studies,	O
we	O
showed	O
that	O
human	O
serum	O
extracts	O
enriched	O
for	O
selected	O
GTAs	O
protected	O
against	O
inflammation	O
through	O
the	O
down-regulation	O
of	O
NFκB	O
and	O
several	O
pro-inflammatory	O
markers	O
in	O
both	O
human	O
colon	O
cancer	O
and	O
RAW264.3	O
mouse	O
macrophage	O
cells	O
exposed	O
to	O
lipopolysaccharide.	B

Some	O
of	O
the	O
depleted	O
molecules	O
have	O
important	O
neuroprotective	O
roles,	O
such	O
as	O
indolepriopionate	O
and	O
the	O
depletion	O
of	O
other	O
molecules	O
such	O
as	O
glutamate	B
can	O
impair	O
immunologic	O
function.	O

Extracts	O
reconstituted	O
in	O
acidic	O
conditions	O
were	O
gradient	O
eluted	O
using	O
water	O
and	O
methanol	B
both	O
containing	O
0.1%	O
formic	B
acid,	I
while	O
the	O
basic	O
extracts,	O
which	O
also	O
used	O
water/methanol,	O
contained	O
6.5	O
mM	O
ammonium	B
bicarbonate.	O

The	O
dihydrooxepine	B
and	O
epitetrathiodioxopiperazine	B
partial	O
structures	O
and	O
all	O
the	O
above	O
moieties	O
were	O
joined	O
together	O
with	O
the	O
help	O
of	O
HMBC	O
correlations	O
suggesting	O
that	O
secoemestrin	O
D	O
is	O
an	O
epitetrathiodioxopiperizine	B
analogue	O
with	O
the	O
gross	O
structure	O
as	O
depicted	O
in	O
1.	O

A	O
corresponding	O
increase	O
in	O
plasma	O
NEFA	O
during	O
placebo	O
(26	O
±	O
13%,	O
P	O
=	O
0.06)	O
was	O
also	O
observed	O
with	O
a	O
reduction	O
in	O
triglycerides	B
(−11	O
±	O
4.6%,	O
P	O
=	O
0.03).	O

MEDFSDO,	O
coded	O
0–6	O
by	O
increasing	O
dose	O
of	O
statin	B
type.	O

HDL-c:	O
High-density	O
lipoprotein	O
cholesterol;	B
LDL-c:	O
Low-density	O
lipoprotein	O
cholesterol;	B
FBG:	O
fasting	O
plasma	O
glucose;	B
2	O
h-PG:	O
2	O
h	O
Postprandial	O
plasma	O
glucose;	B
HOMA-IR:	O
Homeostasis	O
model	O
assessment	O
of	O
insulin	O
resistance.	O

Treatment	O
with	O
glutamate	B
could	O
potentially	O
improve	O
outcomes	O
as	O
supplemental	O
glutamate	B
increased	O
survival	O
in	O
the	O
animal	O
model	O
of	O
cerebral	O
malaria	O
through	O
modulation	O
of	O
CD8+	O
effector	O
T	O
cell	O
function.	O

Mass	O
spectrometry	O
parameters,	O
MRM	O
transitions,	O
diagnostic	O
ions,	O
and	O
retention	O
times	O
of	O
targeted	O
oxylipins	B
and	O
matching	O
internal	O
standards	O
DP,	O
declustering	O
potential;	O
CE,	O
collision	O
energies;	O
CXP,	O
collision	O
cell	O
exit	O
potential;	O
IS,	O
internal	O
standard	O

Furthermore,	O
as	O
the	O
carnitine	B
of	O
the	O
carrier	O
of	O
the	O
internal	O
and	O
external	O
material	O
exchange	O
of	O
the	O
mitochondrial	O
membrane	O
was	O
synthesized	O
to	O
raw	O
lysine,	B
and	O
participated	O
in	O
the	O
folded	O
leucine	B
of	O
protein	O
space,	O
so	O
that	O
papillary	O
thyroid	O
carcinoma	O
was	O
increased.	O

The	O
low	O
energy	O
yield	O
of	O
glucose	B
metabolism	O
forces	O
cells	O
to	O
use	O
fat	O
as	O
an	O
energy	O
source	O
and	O
release	O
ketone	B
bodies	O
as	O
end	O
products.	O

Valine,	B
showing	O
an	O
AUROC	O
=	O
0.88,	O
a	O
Cliff’s	O
delta	O
effect	O
size	O
of	O
−0.75	O
(large	O
effect)	O
and	O
a	O
p	O
-value	O
of	O
0.003	O
(p	O
=	O
0.05	O
after	O
FDR	O
correction)	O
(A)	O
resulted	O
to	O
be	O
the	O
metabolite	O
most	O
significantly	O
associated	O
with	O
the	O
discrimination	O
between	O
GR	O
and	O
PR	O
patients.	O

Nonetheless,	O
when	O
we	O
evaluated	O
potential	O
risk	O
models	O
accounting	O
LysoPC(16:0),	B
it	O
did	O
not	O
add	O
a	O
significant	O
value	O
over	O
the	O
clinical	O
parameters	O
explained	O
by	O
ABCD2	O
and	O
LAA	O
presence.	O

Additionally,	O
88.6%	O
(39	O
of	O
44)	O
of	O
subjects	O
in	O
this	O
study	O
had	O
TxB_2	O
<500	O
pg/mg	O
creatinine,	B
consistent	O
with	O
a	O
normal	O
response	O
to	O
aspirin.	B

Proton	O
NMR	O
spectroscopy	O
provides	O
simultaneous	O
quantification	O
of	O
lipids,	O
lipoprotein	O
subclass	O
profiling	O
with	O
lipid	O
concentrations	O
within	O
14	O
subclasses,	O
fatty	O
acid	O
composition	O
and	O
various	O
low‐molecular	O
metabolites,	O
including	O
amino	O
acids,	O
ketone	B
bodies	O
and	O
gluconeogenesis‐related	O
metabolites	O
in	O
molar	O
concentration	O
units.	O

Seven	O
VOCs,	O
namely	O
2-methylpentane-1,3-diol,	B
1-(3,5-dimethylfuran-2-yl)ethanone,	B
methyl	B
benzoate,	I
nonanoic	B
acid,	I
cyclohexanone,	B
4-methylbenzaldehyde	B
(Fig.	O
),	O
and	O
4-methylheptan-2-one	B
were	O
significantly	O
decreased	O
in	O
the	O
extracellular	O
medium	O
of	O
all	O
PCa	O
cell	O
lines	O
when	O
compared	O
with	O
normal	O
cell	O
line	O
(Table	O
).	O

Bladder	O
tissue	O
samples	O
were	O
collected	O
from	O
the	O
same	O
patient	O
immediately	O
prior	O
to	O
and	O
30	O
min	O
after	O
submucosal	O
injection	O
of	O
gemcitabine	O
(50	O
mg,	O
dissolved	O
in	O
20	O
ml	O
normal	O
saline).	B

We	O
found	O
a	O
significant	O
difference	O
in	O
phthalate	B
exposure	O
according	O
to	O
age	O
and	O
gender.	O

Jannson	O
et	O
al.	O
found	O
that	O
tyrosine	B
and	O
its	O
metabolites	O
as	O
well	O
as	O
phenylalanine	B
and	O
tryptophan	B
were	O
significantly	O
higher	O
in	O
CD	O
patients.	O

The	O
mean	O
values	O
of	O
most	O
traits	O
fell	O
within	O
the	O
normal	O
range,	O
with	O
the	O
exception	O
of	O
low-density	O
lipoprotein	O
(LDL)	O
cholesterol	B
(121	O
mg/dL),	O
which	O
was	O
higher	O
than	O
the	O
level	O
recommended	O
by	O
the	O
National	O
Cholesterol	B
Education	O
Program	O
of	O
the	O
United	O
States	O
(<	O
100	O
mg/dL).	O

Increased	O
concentrations	O
of	O
citrulline,	B
arginine,	B
carnosine,	B
t4-hydroxy-proline	B
(t4-OH-proline),	I
kynurenine,	B
asymmetric	B
dimethylarginine	I
(ADMA),	O
alpha-aminoadipic	B
acid	I
(alpha-AAA)	O
and	O
symmetric	B
dimethylarginine	I
(SDMA)	O
and	O
decreased	O
concentrations	O
of	O
amino	O
acids	O
(particularly	O
the	O
branched	O
chain	O
amino	B
acids),	O
acylcarnitines,	B
sarcosine	B
and	O
sphingolipids	B
were	O
observed	O
in	O
the	O
HD	O
sheep.	O

Measurements	O
of	O
vitamin	B
D	I
metabolites	O
were	O
performed	O
on	O
an	O
Agilent	O
Technologies	O
(Palo	O
Alto,	O
CA,	O
USA)	O
1100	O
series	O
LC	O
coupled	O
to	O
an	O
SL	B
series	O
mass	O
spectrometric	O
detector.	O

The	O
serum	O
ALP,	O
gamma-glutamyltransferase	B
(γ-GT),	I
total	O
bile	O
acid	O
(TBA)	O
and	O
direct	O
bilirubin	B
(DBIL)	O
levels	O
significantly	O
differed	O
between	O
the	O
PBC	O
and	O
HBC	O
patients	O
(P < 0.05),	O
but	O
no	O
significant	O
differences	O
were	O
found	O
in	O
the	O
age,	O
liver	O
ultrasonic	O
score,	O
and	O
Child-Pugh	O
score	O
between	O
the	O
PBC	O
and	O
HBC	O
patients	O
(P > 0.05).	O

The	O
capillary	O
voltage	O
was	O
−2.5	O
kV.	B

IC_50	O
value	O
of	O
1	O
and	O
Doxorubicin	B
against	O
a	O
human	O
cancer	O
cell	O
line	O
colon	O
carcinoma	O
116	O
and	O
a	O
noncancer	O
cell	O
line	O
Chinese	O
hamster	O
ovary	O
cells	O
(AA8)	O

The	O
Metabolon	O
platform	O
has,	O
among	O
other	O
studies,	O
been	O
successfully	O
applied	O
in	O
the	O
analysis	O
of	O
the	O
adult	O
human	O
plasma	O
metabolome	O
identification	O
of	O
sarcosine	B
as	O
a	O
biomarker	O
for	O
prostate	O
cancer	O
,	O
and	O
biomarkers	O
of	O
insulin	O
resistance	O
in	O
a	O
nondiabetic	O
population	O
.	O

The	O
CSF/plasma	O
ratios	O
of	O
glucose	B
and	O
insulin	O
were	O
50.45%	O
and	O
4.92%	O
in	O
T2DM	O
patients	O
and	O
59.00%	O
and	O
5.13%	O
in	O
control	O
group.	O

Representative	O
_1	O
H	O
NMR	O
spectra	O
of	O
aqueous	O
methanol	B
extracts	O
of	O
whole	O
blood	O
(WB)	O
showing	O
signals	O
arising	O
from	O
cofactors	O
ATP,	B
ADP,	B
AMP,	B
NAD_+	O
,	O
and	O
NADP_+	O
in	O
LH/FSH-secreting	O
pituitary	O
tumor,	O
prolactinoma,	O
and	O
NF	O
pituitary	O
tumor	O
patients.	O

In	O
addition,	O
quetiapineis	B
metabolized	O
by	O
CYP3A4	O
although	O
aldehyde	O
oxidase	O
is	O
the	O
enzyme	O
responsible	O
for	O
most	O
of	O
its	O
metabolism.	O

Concerning	O
renal	O
cell	O
carcinoma,	O
Catchpole	O
et	O
al.	O
observed	O
an	O
increased	O
level	O
of	O
α-tocopherol	B
in	O
RCC	O
tumour	O
tissues	O
compared	O
with	O
normal	O
renal	O
cortex	O
tissue,	O
consistent	O
with	O
the	O
findings	O
of	O
Nikiforova	O
et	O
al.	O

A	O
small	O
number	O
of	O
metabolites	O
including	O
octanoylcarnitine,	B
arginine,	B
asparagine,	B
LysoPC(C18:2),	B
and	O
SM(C20:2)	B
was	O
able	O
to	O
discriminate	O
HFpEF	O
patients	O
from	O
the	O
non-HF	O
controls.	O

The	O
concentrations	O
of	O
putrescine,	B
spermidine	B
and	O
spermine	B
tended	O
to	O
be	O
inversely	O
correlated	O
with	O
sperm	O
immotility.	O

While	O
some	O
studies	O
linked	O
the	O
downregulation	O
of	O
FA	B
oxidation	O
with	O
HCC,	O
others	O
associated	O
increased	O
catabolism	O
of	O
certain	O
saturated	O
lipids	O
with	O
high	O
AFP	O
levels	O
in	O
the	O
serum	O
of	O
HCC	O
patients,	O
concluding	O
that	O
lipidomics	O
analysis	O
may	O
provide	O
new	O
biomarkers	O
for	O
HCC	O
[-].	O

Glucuronidase	O
(from	O
bovine	O
liver),	O
sulfatase	O
(from	O
Abalone	O
entrails),	O
p	B
-nitrocatecholsulfate,	I
4-nitrocatechol,	B
and	O
d-saccharic	B
acid	I
1,4-lactone	I
monohydrate	O
were	O
provided	O
by	O
Sigma	O
(Deisenhofen,	O
Germany).	O

N:	O
_1	O
H-nuclear	O
magnetic	O
resonance	O
spectroscopy,	O
G:	O
gas	O
chromatography	O
mass	O
spectrometry,	O
C:	O
combined	O
dataset,	O
Coeff:	O
regression	O
coefficient	O
for	O
given	O
X	O
variable	O
(metabolite)	O
in	O
the	O
modeled	O
Y	O
variable	O
(malignant	O
versus	O
benign),	O
positive	O
values	O
associated	O
with	O
malignancy	O
and	O
negative	O
values	O
associated	O
with	O
benign	O
disease;	O
SE:	O
standard	O
error;	O
RI:	B
retention	O
index,	O
QI:	O
quantification	O
ions;	O
VIP:	O
variable	O
importance	O
to	O
projection	O
expresses	O
overall	O
contribution	O
to	O
the	O
model.	O

Furthermore,	O
to	O
maximize	O
metabolic	O
changes	O
between	O
centenarians	O
and	O
elderly,	O
we	O
applied	O
pair-wise	O
Multiple	O
Regression/Correlation	O
(MRC)	O
analysis	O
between	O
these	O
two	O
age	O
groups	O
displaying	O
increased	O
serum	O
concentration	O
levels	O
of	O
8,9-epoxyeicosatrienoic	B
(8,9-EET)	I
in	O
centenarians.	O

The	O
lab	O
values	O
of	O
urea	B
(obtained	O
with	O
a	O
Gem	O
Premier	O
3000	O
blood	O
gas	O
analyzer)	O
are	O
reported	O
instead	O
of	O
NMR	O
values	O
since	O
the	O
water	O
suppression	O
in	O
the	O
CPMG	O
pulse	O
sequence	O
compromises	O
the	O
urea	B
signal.	O

The	O
metabolites	O
are	O
numbered	O
accordingly:	O
1:	O
valine,	B
2:	O
3-hydroxyisobutyrate,	O
3:	O
4-deoxyerythronic	O
acid	O
(4-DEA),	O
4:	O
3-aminoisobutyrate,	O
5:	O
4-deoxythreonic	O
acid	O
(4-DTA),	O
6:	O
3-hydroxyisovalerate,	O
7:	O
threonine/lactate,	O
8:	O
2/alfa-hydroxyisobutyrate,	O
9:	O
alanine,	B
10:	O
acetate,	B
11:	O
phenylacetylglutamine,	B
12:	O
p-cresol	B
sulfate,	I
13:	O
citrate,	B
14:	O
dimethylamine,	B
15:	O
creatine,	B
16:	O
creatinine,	B
17:	O
proline	B
betaine,	I
18:	O
carnitine,	B
19:	O
trimethylamine-N-oxide	B
(TMAO),	O
20:	O
taurine,	B
21:	O
glycine,	B
22:	O
hippurate,	B
23:	O
trigonelline,	B
24:	O
ascorbate,	B
25:	O
xylose,	B
26:	O
allantoin,	B
27:	O
urea*,	O
28:	O
4-hydroxyphenylacetate,	O
29:	O
tyrosine,	B
30:	O
3-indoxyl	O
sulfate,	O
31:	O
histidine,	B
32:	O
formate,	B
33:	O
trigonelline,	B
*urea	O
peak	O
was	O
not	O
quantified.	O

To	O
facilitate	O
further	O
exploration	O
of	O
the	O
contribution	O
of	O
individual	O
differences	O
in	O
estrogen	B
metabolism	O
to	O
cancer	O
etiology,	O
Regina	O
Ziegler,	O
Larry	O
Keefer,	O
Xia	O
Xu,	O
and	O
Timothy	O
Veenstra	O
developed	O
a	O
novel	O
LC-MS/MS	O
method	O
for	O
measuring	O
concurrently	O
the	O
approximately	O
15	O
endogenous	O
estrogens	O
and	O
estrogen	B
metabolites	O
(;	O
all	O
15	O
referred	O
to	O
as	O
EM)	O
in	O
human	O
urine	O
and	O
serum	O
[,].	O

We	O
evaluated	O
the	O
specificity	O
of	O
the	O
method	O
by	O
comparing	O
the	O
chromatograms	O
obtained	O
from	O
the	O
analytes	O
in	O
a	O
solution	O
of	O
MeOH	B
with	O
an	O
extracted	O
plasma	O
sample,	O
both	O
fortified	O
with	O
standards	O
and	O
IS.	O

Cachectic	O
patients	O
have	O
lower	O
total	O
body	O
skeletal	O
muscle	O
mass	O
and	O
therefore	O
lower	O
levels	O
of	O
urinary	O
creatinine.	B

A	O
significant	O
body	O
of	O
literature	O
indicates	O
that	O
melatonin,	B
a	O
hormone	O
primarily	O
produced	O
nocturnally	O
by	O
the	O
pineal	O
gland,	O
is	O
an	O
important	O
scavenger	O
of	O
hydroxyl	O
radicals	O
and	O
other	O
reactive	O
oxygen	O
species.	O

The	O
dataset	O
comprises	O
617	O
compounds	O
of	O
known	O
identity	O
that	O
were	O
measured	O
in	O
plasma	O
samples	O
of	O
approximately	O
40	O
individuals	O
after	O
1-month	O
treatment	O
of	O
amlodipine	B
(5	O
mg	O
daily),	O
bisoprolol	O
(5	O
mg	O
daily),	O
hydrochlorothiazide	B
(25	O
mg	O
daily)	O
and	O
losartan	O
(50	O
mg	O
daily),	O
each	O
as	O
a	O
monotherapy	O
in	O
a	O
rotational	O
double-blind	O
fashion,	O
and	O
after	O
the	O
preceding	O
and	O
intervening	O
1-month	O
placebo	O
periods	O
(the	O
average	O
values	O
of	O
three	O
placebo	O
periods	O
were	O
used	O
as	O
the	O
baseline	O
reference).	O

A	O
significant	O
down-regulation	O
of	O
creatine	B
kinase	O
reported	O
in	O
oral	O
squamous	O
cell	O
carcinoma	O
further	O
supports	O
our	O
observation	O
of	O
elevated	O
level	O
of	O
creatine.	B

We	O
also	O
demonstrate	O
the	O
use	O
of	O
matrix	O
assisted	O
laser	O
desorption	O
ionization-time	O
of	O
flight	O
mass	O
spectrometry	O
to	O
estimate	O
the	O
incorporation	O
ratio	O
of	O
glucose	B
to	O
albumin	O
during	O
glycation.	O

To	O
verify	O
the	O
accuracy	O
of	O
the	O
quantitation	O
of	O
FA	B
double	O
bond	O
positional	O
isomers	O
by	O
the	O
developed	O
method,	O
two	O
isomeric	O
mixtures	O
were	O
prepared	O
from	O
the	O
authentic	O
18:3	O
FA	O
isomers	O
at	O
the	O
designated	O
ratios	O
(i.e.	O
,	O
12%	O
or	O
45%	O
of	O
GLA	O
in	O
the	O
mixtures).	O

Along	O
with	O
the	O
marked	O
weight	O
loss	O
and	O
clinical	O
improvements,	O
RYGB	O
induced	O
specific	O
alterations	O
in	O
plasma	O
acylcarnitines,	B
bile	O
acid	O
and	O
phospholipid	B
levels.	O

The	O
authors	O
found	O
that	O
serial	O
measurements	O
of	O
lyso-PC	B
helped	O
in	O
the	O
prediction	O
of	O
28-day	O
mortality	O
in	O
ICU	O
patients	O
with	O
severe	O
sepsis	O
or	O
septic	O
shock.	O

However,	O
in	O
the	O
present	O
study,	O
the	O
phosphorylcholine	B
levels	O
in	O
patients	O
with	O
GCA	O
were	O
significantly	O
reduced	O
compared	O
with	O
healthy	O
subjects,	O
suggesting	O
a	O
weakened	O
immune	O
response.	O

The	O
most	O
common	O
inclusion	O
criteria	O
failed	O
to	O
be	O
met	O
was	O
confirmation	O
of	O
adequate	O
aspirin	B
therapy	O
or	O
a	O
sufficient	O
time	O
period	O
for	O
enrollment	O
prior	O
to	O
coronary	O
angiography	O
procedure.	O

Arginine	B
and	O
citrulline	B
concentrations	O
declined	O
in	O
response	O
to	O
insulin	O
sensitizer	O
therapy	O
(	O
and	O
),	O
but	O
the	O
underlying	O
mechanism(s)	O
are	O
not	O
yet	O
clear.	O

Using	O
this	O
validated	O
method,	O
the	O
estrogen	B
levels	O
in	O
human	O
serum	O
samples	O
from	O
20	O
female	O
patients	O
and	O
20	O
male	O
patients	O
were	O
analyzed	O
and	O
compared.	O

This	O
study	O
used	O
joint	O
metagenomics	O
and	O
metabolomics	O
analyses	O
to	O
elucidate	O
the	O
relationship	O
between	O
gut	O
microbiota	O
and	O
faecal	O
metabolites	O
in	O
different	O
glycemic	B
groups,	O
and	O
the	O
result	O
suggested	O
that	O
metabolic	O
disorders	O
and	O
gut	O
microbiota	O
dysbiosis	O
occurred	O
in	O
Uyghur	O
T2DM	O
and	O
IGR.	O

FASN	O
can	O
be	O
regulated	O
by	O
other	O
lipid	O
metabolism	O
associated	O
genes	O
such	O
as	O
SREBP-2,	O
SREBP1c,	O
Acyl-CoA,	B
CPT1a	O
and	O
HMG-CoA	O
synthase.	O

The	O
same	O
trend	O
can	O
be	O
seen	O
for	O
alanine	B
and	O
creatinine	B
but	O
with	O
stronger	O
variations	O
in	O
the	O
signal	O
position	O
within	O
individual	O
solvents.	O

H	O
Note:	O
HbA1c,	O
glycated	O
hemoglobin;	O
TC,	O
total	O
cholesterol;	B
LDL,	O
low	O
density	O
lipoprotein;	O
HDL,	O
high	O
density	O
lipoprotein;	O
r	O
,	O
Pearson	O
correlation	O
coefficient.	O

In	O
contrast	O
with	O
the	O
positive	O
relationship	O
between	O
most	O
ceramides	B
and	O
diabetes-related	O
characteristics,	O
our	O
study	O
found	O
a	O
significant	O
negative	O
correlation	O
between	O
hexosylceramides	B
and	O
diabetes-related	O
characteristics.	O

Of	O
the	O
plasma	O
metabolites	O
most	O
important	O
for	O
the	O
correct	O
prediction	O
of	O
menopausal	O
status	O
only	O
few	O
were	O
identical	O
to	O
the	O
ones	O
important	O
for	O
the	O
prediction	O
of	O
continuous	O
age	O
in	O
women,	O
and	O
include	O
ornithine,	B
choline,	B
glucuronic	B
acid,	I
and	O
cholesterol.	B

Sample	O
analysis	O
was	O
carried	O
out	O
using	O
two	O
quantitative	O
approaches:	O
i)	O
the	O
Biocrates’s	O
AbsoluteIDQ®	O
p180	O
kit	O
(Biocrates	O
Life	O
Sciences	O
AG,	O
Innsbruck,	O
Austria)	O
and	O
ii)	O
a	O
novel	O
method	O
for	O
the	O
quantification	O
of	O
29	O
analytes	O
including	O
tryptophan	B
and	O
phenylalanine	B
metabolites.	O

On	O
the	O
other	O
hand,	O
elevated	O
glycine	B
could	O
be	O
attributed	O
to	O
increased	O
activity	O
of	O
3-phosphoglycerate	O
dehydrogenase,	O
which	O
catalyzes	O
the	O
formation	O
of	O
the	O
glycine	B
for	O
de	O
novo	O
purine	B
and	O
pyrimidine	B
biosynthesis.	O

The	O
metabolites	O
in	O
the	O
catecholamine	B
pathway	O
were	O
excluded	O
in	O
order	O
to	O
avoid	O
the	O
interference	O
of	O
levodopa	B
medication.	O

Pentadecanoic	B
acid	I
(C15:0)	O
and	O
heptadecanoic	B
acid	I
(C17:0)	O
were	O
evaluated	O
in	O
the	O
GC-MS	O
data	O
in	O
a	O
targeted	O
approach	O
by	O
assessing	O
the	O
response	O
of	O
their	O
quantifier	O
ions	O
at	O
known	O
retention	O
time	O
normalised	O
with	O
the	O
quantifier	O
ion	O
of	O
internal	O
standard.	O

Besides,	O
phosphatidylinositol/phosphatidylcholine	O
transfer	O
proteins-β(PITP-β)	B
is	O
also	O
very	O
important	O
in	O
the	O
glycerophospholipid	B
metabolism.	O

It	O
is	O
the	O
final	O
product	O
of	O
heme	B
catabolism.	O

The	O
combination	O
of	O
reduced	O
glucose	B
uptake	O
and	O
impaired	O
insulin	O
signaling	O
in	O
these	O
HCV	O
protein	O
expressing	O
mice	O
was	O
interpreted	O
as	O
the	O
cause	O
of	O
insulin	O
resistance.	O

We	O
analyzed	O
estrogens	O
and	O
estrogen	B
metabolites	O
individually,	O
in	O
groups	O
representing	O
metabolic	O
pathways,	O
and	O
as	O
ratios	O
of	O
metabolic	O
pathway	O
groups.	O

For	O
preparation	O
of	O
the	O
mobile	O
phase	O
and	O
sample	O
pre-treatment,	O
methanol	B
plus	O
(MeOH)	O
for	O
LC/MS	O
and	O
distilled	O
water	O
plus	O
(H_2	O
O)	O
for	O
LC/MS	O
were	O
purchased	O
from	O
Kanto	O
Chemical	O
Co.,	O
Inc.	O

One	O
set	O
was	O
reconstituted	O
in	O
0.1%	O
formic	B
acid,	I
whereas	O
the	O
other	O
in	O
6.5 mM	O
ammonium	B
bicarbonate,	O
both	O
of	O
which	O
were	O
then	O
subjected	O
to	O
mass	O
spectrometric	O
analysis	O
in	O
the	O
negative	O
mode.	O

The	O
extract	O
from	O
T.	O
harzianum	O
strain	O
ES39	O
was	O
added	O
as	O
a	O
methanolic	B
solution	O
during	O
stirring	O
to	O
the	O
cis	O
side.	O

However,	O
accumulation	O
of	O
1-methylhistidine	B
in	O
patients	O
treated	O
with	O
hemodialysis	O
has	O
been	O
demonstrated	O
by	O
HPLC	O
previously	O
.	O

5-Methylcytidine,	B
octanoylcarnitine,	B
glycocholic	B
acid	I
and	O
decanoylcarnitine	B
were	O
purchased	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
MO).	O

0.7	O
mg/kg	O
·	O
min;	O
P	O
<	O
0.01),	O
and	O
insulin-mediated	O
suppression	O
of	O
endogenous	O
glucose	B
production,	O
determined	O
during	O
the	O
210-	O
to	O
240-min	O
period	O
of	O
the	O
euglycemic	B
insulin	O
clamp	O
(0.15	O
±	O
0.05	O
vs	O
.	O
0.05	O
±	O
0.00	O
mg/kg	O
·	O
min;	O
P	O
<	O
0.05)	O
were	O
enhanced	O
after	O
pioglitazone	B
treatment.	O

-hydroxycholesterol	B

However,	O
overall,	O
sperm	O
mtDNAcn	O
and	O
mtDNAdel	O
were	O
not	O
associated	O
with	O
urinary	O
concentrations	O
of	O
phthalate	B
metabolites	O
or	O
isoprostane,	B
a	O
marker	O
of	O
lipid	O
peroxidation	O
in	O
this	O
study.	O

All	O
these	O
results	O
might	O
indicate	O
that	O
low	O
serum	O
levels	O
of	O
2,4-hexadienoic	B
acid,	I
4-methylphenyl	B
dodecanoate	I
and	O
glycerol	B
tributanoate	I
may	O
be	O
independent	O
prognostic	O
factors	O
of	O
GC.	O

Moreover,	O
outside	O
the	O
TCA	O
cycle,	O
new	O
biological	O
roles	O
for	O
succinate	B
have	O
been	O
demonstrated	O
as	O
a	O
key	O
signal	O
in	O
multiple	O
cellular	O
functions,	O
including	O
the	O
transcription	O
factor	O
hypoxia-inducible	O
factor-1α	B
(HIF-1α)	I
stabilization,	O
the	O
succinate	B
and	O
succinate	B
receptor	O
1	O
(SUCNR1,	O
termed	O
G	O
protein	O
coupled	O
receptor	O
91)	O
signaling	O
during	O
inflammation	O
and	O
the	O
post-translational	O
modification	O
(PTM)	O
of	O
proteins	O
by	O
succinylation.	O

BMI,	O
body	O
mass	O
index;	O
2-HB,	O
2-Hydroxybutyrate;	B
3-HB,	O
3-Hydroxybutyrate;	B
CI,	O
confidence	O
interval;	O
LDL,	O
low-density	O
lipoprotein;	O
MAP,	O
mean	O
arterial	O
pressure;	O
NT-proBNP,	O
N-terminal	O
pro	O
brain	O
natriuretic	O
peptide;	O
OR,	O
odds	O
ratio.	O

The	O
model	O
obtained	O
for	O
total	O
choline	B
yield	O
in	O
milk	O
(γ;	O
g/d)	O
was	O

ARA:	O
Arachidonic	B
acid;	I
EPA:	O
Eicosapentaenoic	B
acid;	I
DHA:	O
Docosahexaenoic	B
acid;	I
PUFA:	O
Poly-unsaturated	O
fatty	O
acids;	O
MUFA:	O
Mono-unsaturated	O
fatty	O
acids.	O

The	O
Waters	O
UPC_2	O
was	O
coupled	O
to	O
a	O
Waters	O
Quattro	O
Premier	O
tandem	O
mass	O
spectrometer	O
via	O
a	O
purpose-built,	B
two-part	O
stainless	O
steel	O
splitter	O
supplied	O
by	O
Waters.	O

These	O
elevated	O
metabolites	O
were	O
associated	O
with	O
highly	O
active	O
glycolysis,	O
increased	O
amino	O
acids	O
influx	O
(anaplerosis)	O
into	O
the	O
TCA	O
cycle,	O
altered	O
energy	O
metabolism,	O
membrane	O
choline	B
phospholipid	I
metabolism,	O
and	O
oxidative	O
and	O
osmotic	O
defense	O
mechanisms.	O

In	O
addition,	O
to	O
analyze	O
whether	O
erythritol	B
is	O
oxidized	O
to	O
erythronate	B
in	O
vivo,	O
erythritol	B
and	O
erythronate	B
levels	O
were	O
quantified	O
by	O
standard	O
addition.	O

The	O
differential	O
cytokines	O
profile	O
analysis	O
between	O
GR	O
and	O
PR	O
within	O
the	O
ER(+)	B
group	O
indicates	O
that	O
TNF-α	O
levels	O
were	O
significantly	O
higher	O
in	O
GR	O
patients,	O
presenting	O
an	O
AUROC	O
=	O
0.84,	O
a	O
Cliff’s	O
delta	O
effect	O
size	O
of	O
0.68	O
(large	O
effect)	O
and	O
a	O
p	O
-value	O
of	O
0.007	O
(p	O
=	O
0.04	O
after	O
FDR	O
correction)	O

We	O
defined	O
impaired	O
metabolic	O
health	O
herein	O
by	O
reference	O
to	O
detection	O
of	O
impaired	O
glucose	B
tolerance	O
by	O
increased	O
A1C	O
and	O
to	O
insulin	O
resistance	O
represented	O
by	O
the	O
HOMA-IR.	O

There	O
is	O
a	O
negative	O
correlation	O
between	O
HDL	B
cholesterol	I
and	O
serum	O
triglycerides,	B
so	O
any	O
linear	O
model	O
that	O
includes	O
both	O
the	O
two	O
is	O
likely	O
to	O
emphasize	O
one	O
at	O
the	O
expense	O
of	O
the	O
other.	O

Postmenopausal	O
estrogen	B
synthesis	O
and	O
metabolism:	O
alterations	O
caused	O
by	O
aromatase	O
inhibitors	O
used	O
for	O
the	O
treatment	O
of	O
breast	O
cancer.	O

In	O
healthy	O
donors,	O
C16:0	B
species	O
were	O
the	O
highest	O
followed	O
by	O
C24:0,	B
C24:1,	B
and	O
C22:0.	B

However,	O
metabolomics	O
revealed	O
far	O
more	O
extensive	O
differences	O
between	O
SLE	O
and	O
LN	O
than	O
could	O
be	O
learnt	O
from	O
a	O
simple	O
serum	O
creatinine	B
test.	O

Vitamin	B
D,	I
Metabolites,	O
Plasma,	O
UHPLC,	O
Tandem	O
mass	O
spectrometry,	O
Quantification,	O
Multiple	O
reaction	O
monitoring	O
(MRM)	O

Accumulation	O
of	O
ADMA	B
can	O
either	O
due	O
to	O
increased	O
production	O
(i.e.	O
increase	O
in	O
PRMT)	O
or	O
reduced	O
degradation	O
(i.e.	O
decrease	O
in	O
DDAH).	O

Changes	O
in	O
sarcosine	B
but	O
not	O
dimethylglycine	B
suggest	O
that	O
increased	O
activity	O
of	O
GNMT	O
might	O
have	O
been	O
present	O
in	O
the	O
recurrent	O
group.	O

Separately,	O
five	O
portions	O
of	O
serum	O
(350	O
μ	O
L	O
each)	O
were	O
subjected	O
to	O
ultrafiltration;	O
the	O
filtrates	O
were	O
mixed	O
with	O
a	O
15	O
μ	O
L	O
solution	O
of	O
phosphate	B
buffer	O
(100	O
mM)	O
in	O
D_2	O
O	O
containing	O
0.1	O
mM	O
TSP,	O
and	O
200	O
μ	O
L	O
was	O
transferred	O
to	O
3	O
mm	O
NMR	O
tubes.	O

Importantly,	O
the	O
retinol	B
metabolism	O
pathway	O
was	O
shown	O
to	O
possess	O
the	O
strongest	O
discriminative	O
power	O
for	O
LMCAD	O
phenotype	O
despite	O
the	O
fact	O
that	O
the	O
glycerophospholipid	B
metabolism	O
pathway	O
was	O
shown	O
to	O
be	O
the	O
most	O
altered	O
pathway	O
(Fig.	O

Abbeviations:	O
NO = nitric	O
oxide,	O
ADMA = asymmetric	O
dimethylarginine	B
(a)	O
Leucine,	B
(b)	O
isoleucine,	B
(c)	O
valine.	B

Furthermore,	O
glycine	B
serine	I
and	O
threonine	B
metabolism	O
as	O
well	O
as	O
glyoxylate	B
and	O
dicarboxylate	B
metabolism,	O
cyanoamino	O
acid	O
metabolism	O
and	O
glutathione	B
metabolism,	O
where	O
glycine	B
is	O
also	O
involved	O
in,	O
were	O
listed	O
by	O
the	O
joint	O
pathway	O
analysis	O
as	O
significantly	O
altered	O
in	O
EG	O
group.	O

Eight	O
PS	O
lipids	O
were	O
identified	O
and	O
were	O
statistically	O
(P	O
value	O
<0.05)	O
higher	O
in	O
fatalities	O
in	O
our	O
study,	O
with	O
the	O
exception	O
of	O
PS(18:0_20:4)	B
(	O
and	O
SI	O
Appendix	O
,	O
Table	O
S2).	O

In	O
the	O
fasting	O
state,	O
plasma	O
glucose	B
level	O
is	O
mainly	O
maintained	O
by	O
glycogenolysis	O
(glycogen	O
breakdown)	O
and	O
glycogenesis	O
(synthesis	O
of	O
glucose	B
from	O
glucogenic	B
amino	I
acids).	O

The	O
altered	O
choline	B
metabolism	O
we	O
observed	O
is	O
possibly	O
due	O
to	O
an	O
overexpression	O
of	O
Chk-α.	O

Metabolites	O
were	O
separated	O
on	O
nanoAquity	O
UPLC	O
(Waters)	O
equipped	O
with	O
a	O
BEH-Amide	B
capillary	O
column	O
(200	O
μm	O
x	O
150	O
mm,	O
1.7	O
μm	O
particle	O
size,	O
Waters),	O
applying	O
a	O
gradient	O
of	O
0.5	O
μM	O
ammoniumacetate	B
in	O
acetonitril	B
(A)	O
and	O
0.5	O
μM	O
ammoniumacetate	B
in	O
water	O
(B)	O
from	O
90%	O
A	O
to	O
50%	O
A.	O

The	O
efficacy	O
of	O
abiraterone	B
acetate	I
in	O
CRPC	O
patients	O
confirms	O
the	O
Geller	O
hypothesis	O
that	O
these	O
prostate	O
tumors	O
are	O
still	O
androgen	O
dependent.	O

The	O
duration	B
of	O
diabetes	O
in	O
these	O
5	O
subjects	O
was	O
7.4±1.0	O
years	O
(range	O
between	O
5–11	O
years).	O

The	O
positive	O
control	O
was	O
diluted	O
5-fold	O
with	O
acidic,	O
neutral	O
or	O
basic	O
SPE	O
For	O
neutral	O
SPE,	O
the	O
mixture	O
of	O
20	O
μL	O
of	O
the	O
mouse	O
urine	O
and	O
480	O
μL	O
of	O
water	O
was	O
loaded	O
in	O
a	O
pre-conditioned	O
SPE	O
cartridge	O
(Plexa,	O
30	O
mg,	O
40	O
μm,	O
Varian,	O
Palo	O
Alto,	O
CA),	O
washed	O
with	O
1	O
mL	O
of	O
water	O
and	O
extracted	O
with	O
500	O
μL	O
of	O
acetonitrile.	B

Therefore,	O
inosine	B
and	O
chenodeoxycholic	B
acid	I
should	O
be	O
further	O
investigated	O
as	O
potential	O
markers	O
for	O
HCC	O
stratification.	O

Enrichment	O
analysis	O
showed	O
that	O
amino	O
acid	O
metabolism	O
and	O
the	O
pentose	B
phosphate	I
pathway	O
were	O
related	O
to	O
p‐GDM	O
status.	O

TCM	O
has	O
played	O
an	O
important	O
role	O
in	O
lowering	O
blood	O
glucose	B
and	O
controlling	O
the	O
development	O
of	O
DM.	O

The	O
delivery	O
of	O
these	O
drugs	O
to	O
the	O
liver	O
reflects	O
trapping	O
of	O
polar	O
phosphorylated	O
metabolites	O
for	O
both	O
drugs,	O
prodrug	O
activation	O
for	O
sofosbuvir,	B
and	O
nucleoside	O
transport	O
for	O
ribavirin.	B

Paracetamol–glucuronide	B
was	O
quantified	O
based	O
on	O
the	O
resonance	O
at	O
5.10 ppm	O
(d	O
,	O
7.1 Hz);	O
for	O
other	O
compounds	O
the	O
signal	O
with	O
high	O
intensity	O
and	O
low	O
degree	O
of	O
overlapping	O
was	O
chosen	O
for	O
quantification.	O

One	O
of	O
the	O
most	O
pronounced	O
differences	O
between	O
the	O
EG	O
and	O
RG	O
groups	O
concerns	O
the	O
NAGs,	O
mainly	O
N-acetylglucosamine	B
and	O
N-acetylneuramic	B
acid	I
–	O
they	O
are	O
acute	O
phase	O
proteins	O
with	O
anti-inflammatory	O
properties	O
and	O
are	O
expressed	O
more	O
during	O
inflammation	O
and	O
immune	O
responses.	O

SBP:	O
systolic	O
blood	O
pressure;	O
DBP:	B
diastolic	O
blood	O
pressure;	O
HbA1c:	O
hemoglobin	O
A1c;	O
HDL:	O
high	O
density	O
lipoprotein;	O
LDL:	O
low	O
density	O
lipoprotein	O
TC:	O
total	O
cholesterol;	B
TG:	B
triglyceride;	B
BUA:	O
blood	O
uric	B
acid;	I
CR:	O
creatinine;	B
ALT:	O
alanine	O
transaminase;	O
AST:	O
aspartate	O
transaminase;	O
γGT:	O
γ	O
glutamyl	O
transferase.	O

Concordantly,	O
we	O
had	O
observed	O
that	O
four	O
dihydroceramide	B
species	O
(18:0,	O
20:0,	O
22:0,	O
and	O
24:1)	O
were	O
significantly	O
associated	O
with	O
waist	O
circumference	O
in	O
Mexican	O
Americans	O
and	O
here	O
we	O
find	O
that	O
clusters	O
5	O
and	O
7	O
(which	O
contain	O
these	O
four	O
lipid	O
species)	O
showed	O
significant	O
association	O
with	O
central	O
obesity	O
again	O
indicating	O
a	O
possible	O
genetic	O
basis	O
to	O
the	O
previously	O
reported	O
associations.	O

We	O
found	O
that	O
plasma	O
levels	O
of	O
betaine,	B
methionine	B
and	O
N-acetyl	B
glycoprotein	I
(NAG)	O
were	O
noticeably	O
increased.	O

Samples	O
were	O
evaporated	O
for	O
1	O
h	O
using	O
an	O
RC10.22	O
vacuum	O
concentrator	O
(Jouan,	O
Winchester,	O
VA,	B
USA),	O
and	O
100	O
μL	O
0.75	O
mg/mL	O
PTAD	O
in	O
acetonitrile	B
was	O
added	O
to	O
the	O
residue	O
followed	O
by	O
1	O
min	O
of	O
mixing.	O

level,	O
the	O
ratio	O
of	O
reduced	B
glutathione	I
(GSH)	O
to	O
GSSG	O
(q	O
=	O
0.039)	O
in	O
erythrocytes,	O
malondialdehyde	B
(MDA,	O
q	O
=	O
0.006)	O
and	O
interleukin-6	O
(q	O
=	O
0.006)	O
levels	O
in	O
plasma,	O
and	O
seventeen	O
NMR	O
metabolites	O
in	O
urine	O
compared	O
with	O
those	O
in	O
the	O
placebo	O
group.	O

All	O
baseline	O
and	O
24 h	O
post-reperfusion	O
samples	O
were	O
taken	O
at	O
the	O
same	O
moment	O
during	O
the	O
day,	O
between	O
12:00	O
noon	O
and	O
2:00 p.m.,	O
to	O
reduce	O
the	O
potential	O
impact	O
of	O
circadian	O
rhythm-dependent	O
cycling	O
which	O
can	O
affect	O
several	O
oxylipins.	B

Moreover,	O
it	O
is	O
the	O
endogenous	O
selective	O
estrogen	B
receptor	O
modulator	O
(SERM)	O
for	O
estrogen	B
receptor	O
α	O
(ERα)	O
and	O
β(ERβ),	B
which	O
can	O
inhibit	O
inflammation	O
and	O
demyelination,	O
respectively	O
[,].	O

In	O
KS	O
etiology,	O
we	O
hypothesized	O
that	O
the	O
kynurenine	B
pathway	O
might	O
promote	O
KS	O
by	O
decreasing	O
immune	O
surveillance.	O

For	O
example,	O
similar	O
to	O
our	O
study,	O
Adamko	O
et	O
al.	O
found	O
that	O
betaine	B
was	O
elevated	O
in	O
children	O
with	O
RSV	O
infection	O
compared	O
to	O
both	O
non-infected	O
children	O
and	O
children	O
with	O
non-RSV	O
infection.	O

The	O
stock	O
solutions	O
of	O
each	O
compound	O
were	O
diluted	O
in	O
an	O
equal	O
volume	O
of	O
ammonia	O
(0.1%)	O
and	O
dansyl	B
chloride	I
in	O
acetonitrile	B
(0.5	O
mg/mL)	O
at	O
a	O
final	O
concentration	O
of	O
0.02	O
µM	O
(tuning	O
solution).	O

Typical	O
_1	O
H	O
NMR	O
spectra	O
highlighting	O
the	O
cyclization	O
of	O
glutamine	B
to	O
pyroglutamic	B
acid	I
in	O
both	O
ultrafiltered	O
serum	O
and	O
protein	O
precipitated	O
serum	O
are	O
shown	O
in	O
.	O

Interestingly,	O
some	O
metabolites	O
such	O
as	O
inosine	B
and	O
chenodeoxycholic	B
acid	I
altered	O
differently	O
at	O
stage	O
II,	O
presumably	O
because	O
of	O
the	O
fact	O
that	O
stage	O
II	O
and	O
III	O
have	O
drastically	O
different	O
pathological	O
phenotypes,	O
such	O
as	O
lymph	O
node	O
invasion.	O

Accumulation	O
of	O
BCAAs	O
has	O
been	O
shown	O
to	O
suppress	O
glucose	B
metabolism	O
and	O
sensitize	O
the	O
heart	O
to	O
ischemic	O
injury.	O

It	O
is	O
important	O
to	O
underline	O
that	O
the	O
increment	O
of	O
pyruvate,	B
succinate,	B
formate	B
and	O
creatine	B
are	O
significant	O
in	O
terms	O
of	O
p_FDR	O
and	O
classified	O
as	O
medium	O
or	O
large	O
in	O
terms	O
of	O
Cliff’s	O
delta	O
(Tables 	O
and	O
).	O

We	O
then	O
tested	O
the	O
effects	O
of	O
tyramine	B
and	O
2-oxoglutarate	B
on	O
cell	O
proliferation	O
in	O
the	O
hTERT-immortalized	O
urothelial	O
cell	O
line	O
TRT-HU1	O
(Figure	O
F).	O

Both	O
regions	O
have	O
high	O
rates	O
of	O
chronic	O
HBV	O
infection	O
and	O
have	O
had,	O
in	O
the	O
past,	O
high	O
rates	O
of	O
aflatoxin	B
B_1	O
(AFB_1	O
)	O
contamination	O
of	O
staple	O
foods.	O

Hepatocellular	O
carcinoma;	O
TMA:	O
Trimethylamineoxide;	B
OPLS:	O

Urinary	O
pseudouridine	B
levels	O
probably	O
reflect	O
the	O
overall	O
cellular	O
proliferation	O
in	O
tumorigenesis	O
and	O
are	O
not	O
specific	O
for	O
HCC,	O
since	O
have	O
also	O
been	O
shown	O
to	O
be	O
elevated	O
in	O
other	O
cancers,	O
such	O
as	O
non-Hodgkin’s	O
lymphoma.	O

According	O
to	O
the	O
manufacturer’s	O
product	O
insert,	O
the	O
minimum	O
detectable	O
concentration	O
of	O
IL-6,	O
IL-1α	B
and	O
TNF-	O
α	O
were	O
7.8 pg/mL,	O
3.9 pg/mL	O
and	O
7.8 pg/mL,	O
respectively.	O

Citrate,	B
together	O
with	O
glycine,	B
is	O
also	O
involved	O
in	O
glyoxylate	B
and	O
dicarboxylate	B
metabolism	O
which	O
we	O
found	O
significantly	O
altered	O
in	O
terms	O
of	O
the	O
pathway	O
enrichment.	O

The	O
present	O
data	O
derived	O
from	O
spot	O
plasma	O
concentrations	O
suggest	O
that	O
anastrozole	B
exposure	O
among	O
postmenopausal	O
patients	O
may	O
vary	O
widely	O
and	O
this,	O
in	O
turn,	O
may	O
contribute	O
to	O
differences	O
in	O
the	O
effects	O
of	O
anastrozole.	B

These	O
24	O
OTUs	O
represented	O
21	O
bacterial	O
genera,	O
in	O
which	O
Alistipes	O
(median,	O
1.894	O
versus	O
0.024),	O
Oscillibacter	O
(median,	O
1.234	O
versus	O
0.009),	O
Bacteroides	O
(median,	O
0.847	O
versus	O
0.097),	O
Pseudoflavonifractor	O
(median,	O
0.012	O
versus	O
0)	O
and	O
Succinivibrio	B
(median,	O
0.23	O
versus	O
0)	O
being	O
identified	O
as	O
the	O
top	O
five	O
most	O
differentially	O
abundant	O
genera.	O

No	O
unconjugated	O
4-hydroxy	B
catechol	I
estrogens	O
were	O
detected	O
in	O
any	O
of	O
the	O
NCI-60	O
tumor	O
cells.	O

However,	O
when	O
the	O
reaction	O
of	O
NO_2	O
-PhIP	O
with	O
SA	O
was	O
performed	O
with	O
a	O
limiting	O
amount	O
of	O
carcinogen,	O
desamino-PhIP-Y*TK	B
adduct	O
formation	O
at	O
Tyr_411	O
accounted	O
for	O
about	O
99%	O
of	O
the	O
total	O
ion	O
counts	O
of	O
SA	O
adducts.	O

In	O
a	O
normal	O
situation,	O
lipids	O
undergo	O
β-oxidation	O
eventually	O
resulting	O
in	O
the	O
accumulation	O
of	O
acetyl-CoA	B
which	O
may	O
then	O
enter	O
the	O
TCA	O
cycle	O
for	O
energy	O
production.	O

Typical	O
uremic	O
retention	O
solutes	O
uniquely	O
cleared	O
by	O
HFD	O
rather	O
than	O
HD	O
were	O
guanidine,	B
hippuric	B
acid,	I
amino	O
acids	O
and	O
alkalines.	B

L-Aspartate.	B

Two	O
300	O
μL	O
serum	O
samples	O
were	O
made	O
up	O
to	O
550	O
μL	O
with	O
phosphate	B
buffer	O
in	O
D_2	O
O	O
and	O
transferred	O
to	O
5	O
mm	O
NMR	O
tubes	O
for	O
direct	O
analysis.	O

In	O
other	O
studies,	O
vitamin	B
D	I
levels	O
were	O
shown	O
to	O
be	O
lower	O
in	O
patients	O
with	O
late	O
AMD	O
and	O
were	O
associated	O
with	O
poorer	O
visual	O
acuity	O
in	O
older	O
adults	O
.	O

Lower	O
urinary	O
N-methyl	B
nicotinic	I
acid	I
levels	O
predicted	O
the	O
presence	O
of	O
OHE	O
and	O
these	O
nucleotide	O
pathways	O
should	O
be	O
further	O
evaluated.	O

The	O
most	O
significant	O
change	O
is	O
protein	O
biosynthesis	O
according	O
to	O
fold	O
enrichment	O
(>15)	O
followed	O
by	O
alanine	B
metabolism	O
and	O
phenylanine	B
tyrosine	I
metabolism.	O

A	O
study	O
on	O
the	O
characterization	O
of	O
the	O
human	O
CSF	O
metabolome	O
has	O
previously	O
been	O
performed	O
by	O
Wishart	O
et	O
al.,	O
showing	O
that	O
lysophospholipids	B
are	O
present	O
at	O
very	O
low	O
concentrations	O
in	O
CSF.	O

The	O
Phenomenex	O
Strata-X	O
polymeric	O
10mg/mL	O
96-well	O
SPE	O
plate	O
was	O
washed	O
by	O
sequentially	O
adding	O
and	O
vacuum	O
assisted	O
eluting	O
600	O
μL	O
of	O
methanol	B
and	O
600μL	O
of	O
ethanol	B
and	O
equilibrated	O
by	O
addition	O
of	O
1.2mL	O
of	O
water	O
per	O
well.	O

In	O
this	O
study,	O
we	O
found	O
decreased	O
EC	O
serum	O
and	O
increased	O
tissue	O
tryptophan	B
levels,	O
along	O
with	O
the	O
elevated	O
kynurenic	B
acid	I
concentrations	O
in	O
EC	O
tissues,	O
suggesting	O
an	O
enhanced	O
cancer	O
cell	O
immune	O
escape	O
in	O
EC.	O

Notably,	O
saliva	O
and/or	O
oral	O
epithelia	O
also	O
contributed	O
to	O
β-glucosidase	O
activity	O
in	O
10	O
of	O
11	O
donors,	O
as	O
indicated	O
by	O
retention	O
of	O
appreciable	O
functional	O
activity	O
following	O
rinsing	O
with	O
chlorhexidine	B
gluconate.	I

Based	O
on	O
previous	O
work	O
in	O
prostate	O
cancer	O
showing	O
that	O
glucose	B
levels	O
are	O
high	O
while	O
citrate	B
is	O
low,	O
we	O
found	O
that	O
measurement	O
of	O
the	O
glucose/citrate	B
ion	O
signal	O
ratio	O
accurately	O
predicted	O
cancer	O
when	O
this	O
ratio	O
exceeds	O
1.0	O
and	O
normal	O
prostate	O
when	O
the	O
ratio	O
is	O
less	O
than	O
0.5.	O

(D)	O
Fold	O
change	O
of	O
cellular	O
acylcarnitine	B
levels	O
in	O
CNE2-IR	O
cells	O
compared	O
with	O
CNE2	O
cells.	O

Briefly,	O
after	O
the	O
addition	O
of	O
internal	O
standard	O
and	O
sodium	B
acetate	I
buffer	O
to	O
3 mL	O
of	O
previously	O
centrifuged	O
urine,	O
the	O
samples	O
were	O
hydrolyzed	O
overnight	O
at	O
37°C	O
using	O
Helix	O
pomatia	O
glucuronidase.	O

If	O
the	O
average	O
mainstream	O
delivery	O
of	O
acrolein	B
were	O
50	O
µg	O
per	O
cigarette,	O
then	O
a	O
smoker	O
of	O
1	O
pack	O
per	O
day	O
would	O
excrete	O
a	O
maximum	O
of	O
about	O
4	O
mg	O
per	O
day	O
of	O
3-HPMA.	O

Under	O
our	O
UPLC-MS/MS	O
system,	O
five	O
out	O
of	O
seven	O
synthesized	O
standards	O
were	O
observed	O
to	O
contain	O
a	O
mixture	O
of	O
the	O
related	O
isomers:	O
four	O
peaks	O
for	O
11-H-9-E-LA	B
(3b,	O
3c,	O
3d,	O
3e),	O
three	O
for	O
11-H-12-ELA	B
(3g,	O
3h,	O
3i),	O
four	O
for	O
13-K-9-E-LA	B
(3j,	O
3k,	O
3l,	O
3m),	O
three	O
for	O
11-K-9-E-LA	B
(3n,	O
3o,	O
3p),	O
and	O
three	O
for	O
11-K-12-E-LA	B
(3r,	O
3s,	O
3t),	O
and	O
one	O
peak	O
for	O
both	O
13-H-9-E-LA	B
(3a)	O
and	O
9-H-12-E-LA	B
(3f).	O

There	O
was	O
a	O
significant	O
increase	O
in	O
plasma	O
GLP-1	O
and	O
reduction	O
of	O
plasma	O
GIP-1	O
between	O
baseline	O
and	O
4	O
hour	O
after	O
both	O
aspartame	B
and	O
control	O
preparation	O
in	O
all	O
study	O
participants.	O

Caveolin	B
and	O
LAMP-2A	O
blotting	O
were	O
performed	O
on	O
the	O
non-chloroquine	O
treated	O
extracts	O
only.	O

The	O
MS_3	O
spectra	O
correspond	O
to	O
GP-tagged	O
3β-hydroxycholest-5-en-26-oic	B
(c	O
)	O
and	O
7α-hydroxy-3-oxocholest-4-en-26-oic	B
acids	I
(d	O
).	O

Replicate	O
analysis	O
of	O
a	O
laboratory	O
reference	O
serum	O
(n = 7)	O
analyzed	O
in	O
conjunction	O
with	O
the	O
Pennington	O
Research	O
Center	O
samples	O
showed	O
excellent	O
precision,	O
72%	O
of	O
the	O
oxylipins	B
and	O
67%	O
of	O
the	O
acyl-glycerol/amides	O
showed	O
relative	O
standard	O
deviations	O
of	O
<30%	O
for	O
analytes	O
with	O
a	O
signal-to-noise	O
ratio	O
>2.	O

Initially,	O
a	O
range	O
of	O
concentrations	O
(5,	O
10,	O
20,	O
and	O
50	O
mM)	O
of	O
ammonium	B
acetate	I
and	O
ammonium	B
hydroxide	I
mixture	O
were	O
tested.	O

These	O
data	O
would	O
suggest	O
that	O
the	O
addition	O
of	O
bicalutamide	B
has	O
no	O
beneficial	O
effect	O
on	O
serum	O
ketoandrogens	O
as	O
might	O
be	O
expected	O
with	O
an	O
AR	O
antagonist.	O

The	O
CSF	O
was	O
tapped	O
as	O
part	O
of	O
the	O
initial	O
clinical	O
investigation	O
before	O
treatment	O
with	O
riluzole	B
was	O
initiated.	O

After	O
the	O
start	O
of	O
insulin,	O
no	O
glucose	B
was	O
infused	O
until	O
the	O
plasma	O
glucose	B
concentration	O
declined	O
to	O
5.55	O
mmol/liter,	O
at	O
which	O
level	O
it	O
was	O
maintained.	O

The	O
total	O
concentration	O
in	O
essential	O
AA	O
(EAAs)	O
was	O
defined	O
as	O
the	O
sum	O
of	O
10	O
EAAs	O
(histidine,	O
isoleucine,	B
leucine,	B
lysine,	B
methionine,	B
phenylalanine	B
[Phe],	O
threonine,	B
tryptophan	B
[Trp],	O
tyrosine	B
[Tyr],	O
and	O
valine	B

15-HETE,	B
a	O
major	O
AA	O
metabolite,	O
was	O
also	O
present	O
at	O
higher	O
levels	O
in	O
the	O
urine	O
of	O
young	O
women.	O

The	O
only	O
amino	O
acid	O
that	O
showed	O
markedly	O
decreased	O
t	O
-values	O
after	O
prolonged	O
blood	O
incubation	O
was	O
arginine,	B
which	O
was	O
probably	O
due	O
to	O
the	O
arginase	O
activity	O
of	O
erythrocytes.	O

In	O
the	O
large	O
waist	O
circumference	O
stratum,	O
the	O
concentration	O
of	O
phospholipids,	B
cholesterol,	B
free	O
cholesterol	B
and	O
cholesterol	B
esters	I
in	O
HDL	O
subclasses	O
were	O
significantly	O
(P	O
<0.002)	O
decreased,	O
as	O
well	O
as	O
the	O
diameter	O
and	O
concentration	O
of	O
HDL	O
particles.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
perform	O
metabolic	O
profiling	O
in	O
urine	O
from	O
patients	O
with	O
MODY	O
due	O
to	O
mutations	O
in	O
the	O
genes	O
encoding	O
glucokinase	O
(GCK)	O
or	O
hepatocyte	O
nuclear	O
factor	O
1	O
alpha	O
(HNF1A),	O
type	O
2	O
diabetes	O
(T2D)	O
and	O
normoglycaemic	B
control	O
subjects.	O

NPDR	O
is	O
characterized	O
by	O
retinal	B
microaneurysms	O
and	O
hemorrhages	O
and	O
may	O
progress	O
to	O
PDR,	O
which	O
is	O
defined	O
by	O
retinal	B
neovascularization	O
with	O
the	O
potential	O
for	O
severe	O
vision	O
loss.	O

The	O
composition	O
of	O
selected	O
probiotic	O
and	O
predominant	O
bacterial	O
groups	O
such	O
as	O
Bacteroidetes	O
,	O
Bifidobacter	O
,	O
Clostridium	O
coccoides	O
and	O
Lactobacillus	B
groups	O
was	O
studied	O
using	O
group-specific	O
amplifications	O
to	O
compare	O
the	O
individual	O
communities	O
with	O
the	O
total	O
bacteria.	O

The	O
highest	O
significances	O
(p < 10_−3	O
)	O
were	O
found	O
for	O
LPC(20:0/0:0),	B
ChoE(20:5),	B
and	O
ChoE(22:5),	B
whose	O
levels	O
decreased	O
in	O
F2	O
patients	O
when	O
compared	O
with	O
F1.	O

Only	O
6	O
metabolites	O
were	O
below	O
the	O
detection	O
limit	O
in	O
the	O
control	O
urine	O
samples	O
including	O
gamma-glutamylcysteine,	B
a	O
precursor	O
of	O
glutathione,	B
which	O
was	O
found	O
in	O
all	O
of	O
the	O
uEV	O
samples.	O

The	O
upper	O
aqueous	O
phase	O
was	O
evaporated	O
under	O
vacuum	O
and	O
reconstituted	O
in	O
200	O
µl	O
acetonitrile:H_2	O
O	B
(66:34)	I
containing	O
internal	O
standards	O
for	O
normalization	O
(2	O
µM	O
debrisoquine	B
sulfate,	I
30	O
µM	O
4-nitrobenzoic	B
acid).	O

collision	O
energy	O
12	O
eV,	O
8iPGF_3	O
351.0	O
->193.0,	O
collision	O
energy	O
22	O
eV,	O
20-COOH-LTB_4	B
365.0	O
->195.0,	O
collision	O
energy	O
13	O
eV,	O
RvD1,	O
RvD2	O
375.0	O
->141.3,	O
collision	O
energy	O
13	O
eV;	O
RvE1	O
375.1	O
->141.3,	O
collision	O
energy	O
13	O
eV;	O
from	O
9.0–12.5	O
min	O
for	O
13-HODE	B
294.7	O
->170.7,	O
collision	O
energy	O
16	O
eV;	O
9-HODE	B
294.7	O
->194.7,	O
collision	O
energy	O
16	O
eV;	O
5-HEPE	B
317.0	O
->115.0,	O
collision	O
energy	O
17	O
eV;	O
12-HEPE	B
317.0	O
->179.0,	O
collision	O
energy	O
17	O
eV;	O
15-HEPE	B
317.0	O
->219.0,	O
collision	O
energy	O
17	O
eV,	O
LTC_4	O
623.9	O
->272.0,	O
collision	O
energy	O
14	O
eV	O
from	O
12.5–16.0	O
min	O
for	O
LA	O
279.3	O
->279.0,	O
collision	O
energy	O
10	O
eV;	O
8-HEPE	O
317.0	O
->255.0,	O
collision	O
energy	O
17	O
eV,	O
18-HEPE	B
317.0	O
->259.0,	O
collision	O
energy	O
17	O
eV;	O
5-oxoETE,	B
12-oxoETE	B
and	O
15-oxoETE	B
317.0	O
->273.0,	O
collision	O
energy	O
17	O
eV,	O
20-HETE	B
319.0	O
>245.0,	O
collision	O
energy	O
10	O
eV;	O
LTC_4	O
623.9	O
->272.0,	O
collision	O
energy	O
14	O
eV;	O
LTE_4	O
438.0	O
->333.0,	O
collision	O
energy	O
13	O
eV	O
from	O
12.5–16.0	O
min	O
for	O
LA	O
279.3	O
->59.2,	O
collision	O
energy	O
25	O
eV;	O
EPA	O
301.0	O
->203.2,	O
collision	O
energy	O
12	O
eV;	O
AA	O
303.0	O
->259.3,	O
collision	O
energy	O
11	O
eV,	O
DHA	O
327.1	O
->29.3,	O
collision	O
energy	O
14	O
eV.	O
Method	O
B	O
from	O
0.0–9.8	O
min	O
for	O
PGE_2	O
,	O
d15d12PGD_2	O
,	O
PGD_2	O
,	O
d15d12PGJ_2	O
,	O
PGJ_2	O
315.0	O
->271.3,	O
collision	O
energy	O
13	O
eV;	O
LTB_5	O
333.0	O
->195.0,	O
collision	O
energy	O
13	O
eV;	O
LTB_4	O
335.0	O
->195.0,	O
collision	O
energy	O
13	O
eV;	O
RvE_1	O
349.1	O
->195.3,	O
collision	O
energy	O
13	O
eV;	O
HXA_3	O
,	O
HXB_3	B
,	I
20-COOH-AA	I
335.0	O
->273.3,	O
collision	O
energy	O
13	O
eV;	O
LXA_5	O
349.0	O
->115.0,	O
collision	O
energy	O
12	O
eV;	O
20-OH-LTB_4	B
351.0	O
->195.0,	O
collision	O
energy	O
13	O
eV;	O
MaR	O
359.0	O
->250.0,	O
collision	O
energy	O
13	O
eV;	O
from	O
9.8–12.5	O
min	O
for	O
5-HETE	B
318.7	O
->115.0,	O
collision	O
energy	O
14	O
eV;	O
8-HETE	B
319.0	O
->155.0,	O
collision	O
energy	O
14	O
eV;	O
11-HETE	B
319.0	O
->167.0,	O
collision	O
energy	O
14	O
eV;	O
12-HETE	B
319.0	O
->179.0,	O
collision	O
energy	O
14	O
eV;	O
15-HETE	B
319.0	O
->218.9,	O
collision	O
energy	O
11	O
eV;	O
4-HDHA	O
343.0	O
->101.0,	O
collision	O
energy	O
10	O
eV;	O
10-HDHA	O
343.0	O
->181.0,	O
collision	O
energy	O
10	O
eV;	O
14-HDHA	O
343.0	O
->205.0,	O
collision	O
energy	O
10	O
eV;	O
17-HDHA	B
343.0	O
->245.0,	O
collision	O
energy	O
14	O
eV,	O
20-HDHA	O
343.0	O
->285.0,	O
collision	O
energy	O
10	O
eV;	O
13-oxoODE	B
293.0	O
->249.0,	O
collision	O
energy	O
17	O
eV	O
and	O
from	O
12.5–16.0	O
min	O
for	O
LA	O
279.3	O
->59.2,	O
collision	O
energy	O
25	O
eV;	O
EPA	O
301.0	O
->203.2,	O
collision	O
energy	O
12	O
eV,	O
AA	O
303.0	O
->259.3,	O
collision	O
energy	O
11	O
eV,	O
DHA	O
327.1	O
->229.3,	O
collision	O
energy	O
14	O

This	O
data	O
illustrates	O
of	O
metabolites	O
such	O
as	O
glutamine,	B
proline,	B
valine,	B
threonine	B
and	O
tyramine	B
being	O
differentially	O
abundant	O
in	O
the	O
population	O
of	O
patients	O
who	O
survived	O
therapy	O
where	O
metabolites	O
such	O
as	O
hydroxylamine	B
and	O
octadecan-1-ol	B
being	O
at	O
a	O
higher	O
concentration	O
in	O
patients	O
who	O
did	O
not	O
survive	O
therapy.	O

For	O
validation,	O
cholesterol	B
stripped	O
serum	O
and	O
CSF	O
were	O
used	O
because	O
each	O
OHC	O
is	O
normally	O
present	O
in	O
human	O
samples	O
at	O
different	O
concentrations.	O

With	O
our	O
method,	O
peak	O
areas	O
obtained	O
in	O
spiked	O
and	O
clinical	O
samples	O
for	O
ISTD	O
11526102	O
and	O
Met	O
amino-d11	B
perfectly	O
matched,	O
with	O
an	O
overall	O
RSD	O
below	O
2%,	O
confirming	O
the	O
reliability	O
of	O
the	O
method	O
for	O
measuring	O
not	O
only	O
PBTZ169	O
but	O
also	O
six	O
known	O
metabolites	O
in	O
real	O
human	O
plasma	O
samples	O
collected	O
from	O
healthy	O
volunteers.	O

The	O
method	O
development	O
study	O
described	O
herein	O
indicates	O
that	O
of	O
the	O
tested	O
Waters	O
columns,	O
the	O
Torus	O
range	O
should	O
be	O
the	O
first	O
choice	O
for	O
the	O
analysis	O
of	O
any	O
class	O
of	O
polar	O
metabolite;	O
similarly,	O
the	O
use	O
of	O
either	O
ammonium	B
salts	O
or	O
water	O
as	O
modifier	O
additives	O
should	O
be	O
considered	O
when	O
analysing	O
such	O
compounds	O
using	O
SFC.	O

After	O
incubation,	O
the	O
samples	O
were	O
brought	O
to	O
room	O
temperature	O
and	O
the	O
internal	O
standard	O
GP	B
(7.5	O
ng)	O
was	O
added.	O

Collection	O
b	O
was	O
negatively	O
associated	O
with	O
methamphetamine,	B
L-alanine,	B
L-proline	B
and	O
hexanoic	B
acid.	I

The	O
high	O
detection	O
frequency	O
of	O
paracetamol	B
in	O
our	O
cohort	O
among	O
both	O
men	O
and	O
women	O
(93	O
and	O
97%,	O
respectively)	O
from	O
two	O
geographically	O
different	O
states	O
may	O
corroborate	O
the	O
variety	O
of	O
potential	O
sources	O
of	O
paracetamol	B
exposure.	O

Regarding	O
metabolite	O
subclasses,	O
reliability	O
was	O
lowest	O
for	O
acylcarnitines	B
both	O
in	O
serum	O
and	O
plasma,	O
as	O
hydroxyacylcarnitines	B
showed	O
low	O
reliability	O
due	O
to	O
low	O
concentrations.	O

In	O
particular,	O
we	O
targeted	O
(identified	O
and	O
quantified)	O
a	O
subset	O
of	O
oxylipins	B
(n = 76),	O
acyl-glycines	B
(n = 2),	O
acyl-ethanolamides	B
(n = 12),	O
and	O
mono-acylglycerols	B
(n = 6).	O

P	O
values	O
were	O
generated	O
evaluating	O
each	O
vitamin	B
D	I
metabolite	O
as	O
a	O
continuous	O
variable.	O

Interestingly	O
of	O
the	O
74	O
lipid	O
species	O
found	O
to	O
be	O
associated	O
with	O
future	O
cardiovascular	O
events	O
in	O
HIV	O
positive	O
individuals	O
only	O
14	O
(predominantly	O
from	O
the	O
ceramide	B
and	O
phosphatidylcholine	B
classes)	O
were	O
observed	O
to	O
change	O
with	O
initiation	O
of	O
antiretroviral	O
therapy	O
in	O
this	O
current	O
project.	O

1-methylhistidine	B
is	O
produced	O
from	O
the	O
metabolism	O
of	O
anserine	B
(a	O
dipeptide)	O
which	O
is	O
commonly	O
found	O
in	O
meats	O
,	O
.	O

Nevertheless,	O
some	O
significant	O
correlations	O
were	O
observed	O
between	O
FA	B
PBMC	O
content	O
and	O
metabolic	O
biomarkers.	O

The	O
latter	O
seems	O
to	O
be	O
triggered	O
in	O
some	O
samples	O
by	O
addition	O
of	O
isopropanol	B
and	O
matches	O
lipolytic	O
activities	O
observed	O
in	O
organic	O
solvents	O
[,	O
].	O

In	O
addition,	O
in	O
both	O
European-Americans	O
and	O
African-Americans,	O
high	O
hexadecanedioate	B
levels	O
were	O
related	O
to	O
high	O
systolic	O
blood	O
pressure	O
and	O
diastolic	O
blood	O
pressure	O
levels,	O
which	O
are	O
important	O
risk	O
factors	O
for	O
HF	O
(all	O
P	O
<	O
0.004;	O
table	O
S4).	O

In	O
addition,	O
an	O
upregulation	O
of	O
the	O
genes	O
LPCAT1	O
and	O
LCAT	O
(B)	O
that	O
encode	O
enzymes	O
involved	O
in	O
the	O
synthesis	O
of	O
phosphatidylcholine	B
and	O
cholesteryl	B
esters,	I
respectively,	O
was	O
also	O
observed.	O

Anastrozole	B
(10	O
µm)	O
was	O
incubated	O
for	O
30	O
min	O
at	O
37°C	O
with	O
HLMs	O
(0.5	O
mg	O
ml_−1	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
chemical	O
inhibitors.	O

Waagepetersen	O
and	O
coworkers	O
have	O
demonstrated	O
that	O
alanine	B
has	O
an	O
important	O
role	O
as	O
a	O
carrier	O
of	O
nitrogen	B
glutamatergic	I
neurons	O
to	O
astrocytes.	O

The	O
reversed	O
phase	O
chromatographic	O
conditions	O
were	O
adapted	O
from	O
Hu	O
et	O
al..	O
Methanol	B
was	O
preferred	O
to	O
acetonitrile	B
since	O
it	O
has	O
been	O
observed	O
that	O
it	O
decreased	O
the	O
carryover	O
of	O
most	O
apolar	O
lipid	O
species	O
(data	O
not	O
shown).	O

A	O
novel	O
estrogen	B
biomarker,	O
the	O
estrogen	B
DNA	O
adduct	O
(EDA)	O
ratio,	O
was	O
shown	O
to	O
be	O
elevated	O
in	O
women	O
at	O
high-risk	O
of	O
BC	O
and	O
among	O
BC	O
cases.	O

Collectively,	O
all	O
these	O
data	O
tend	O
to	O
link	O
fatty	O
acid	O
transport	O
and	O
oxidation	O
mechanisms	O
to	O
blood	O
pressure	O
regulation	O
and,	O
possibly,	O
to	O
the	O
antihypertensive	O
action	O
of	O
some	O
antihypertensive	O
drugs	O
including	O
amlodipine.	B

Glutamine	B
is	O
an	O
amino	O
acid	O
that	O
is	O
largely	O
used	O
in	O
cancer	O
cells,	O
as	O
its	O
withdrawal	O
from	O
the	O
extracellular	O
environment	O
can	O
significantly	O
affect	O
tumor	O
growth.	O

These	O
modified	O
metabolites	O
revealed	O
disturbance	O
of	O
glycolysis,	O
glutaminolysis,	O
TCA,	O
amino	O
acids	O
and	O
choline	B
metabolism,	O
which	O
were	O
correlated	O
with	O
the	O
occurrence	O
and	O
development	O
of	O
human	O
gastric	O
cancer.	O

Half	O
(2/4)	O
of	O
the	O
latter	O
group	O
(phenylalanine	O
and	O
serine)	B
were	O
decreased,	O
while	O
the	O
other	O
2	O
(aspartic	O
acid	I
and	O
methionine)	B
were	O
increased.	O

Albeit,	O
several	O
publications	O
suggested	O
that	O
the	O
anthocyanins	B
are	O
promising	O
dietary	O
bioactive	O
compounds	O
in	O
prevention	O
and	O
treatment	O
of	O
DMT2	O
[,,]	O
and	O
the	O
management	O
of	O
MetS	O
[,,],	O
the	O
results	O
of	O
the	O
studies	O
on	O
the	O
blueberry	O
anti-inflammatory	O
effects	O
in	O
these	O
chronic	O
diseases	O
are	O
contradictory.	O

Given	O
the	O
small	O
odds	O
ratio	O
for	O
tryptophan,	B
we	O
also	O
dichotomized	O
tryptophan	B
concentration	O
by	O
its	O
75_th	O
percentile	O
(94.87	O
mol)	O
and	O
found	O
an	O
odds	O
ratio	O
for	O
advanced	O
atherosclerosis	O
of	O
.06	O
(95%	O
confidence	O
interval	O
.013–.254;	O
P=.0002),	O
again	O
suggesting	O
that	O
tryptophan	B
greatly	O
reduces	O
the	O
risk	O
of	O
advanced	O
atherosclerosis.	O

In	O
addition,	O
sleep	O
restriction	O
was	O
accompanied	O
by	O
alterations	O
in	O
tryptophan	B
metabolism	O
including	O
elevations	O
in	O
glycosylated	B
tryptophan	I
and	O
the	O
neurotransmitter	O
serotonin	B
which	O
is	O
derived	O
from	O
tryptophan.	B

Briefly,	O
100 μ	O
L	O
of	O
serum	O
samples	O
was	O
thawed	O
at	O
4°C	O
and	O
mixed	O
with	O
300 μ	O
L	O
of	O
methanol	B
to	O
precipitate	O
protein.	O

WC,	O
waist	O
circumference;	O
AUC,	O
area	O
under	O
the	O
curve;	O
SBP,	O
systolic	O
blood	O
pressure;	O
DBP,	B
diastolic	O
blood	O
pressure;	O
CRF,	O
cardiorespiratory	O
fitness.	O

Although	O
our	O
focus	O
was	O
on	O
how	O
circulating	O
vitamin	B
D	I
metabolites	O
affect	O
risk	O
of	O
kidney	O
disease,	O
it	O
is	O
clear	O
that	O
kidney	O
disease	O
also	O
determines	O
vitamin	B
D	I
metabolism.	O

 )	O
were	O
presented	O
estradiol-17beta	B
3-sulfate	I
(353 ± 1	O

Also	O
noted	O
was	O
the	O
less	O
significant	O
correlation	O
between	O
_13	O
C-succinate	B
and	O
_13	O
C-lactate	B
for	O
the	O
lung	O
tumor	O
tissues	O
(Table	O
).	O

MTBE	B
extraction	O
also	O
resulted	O
in	O
improved	O
recovery	O
of	O
15:0	O
PC	O
(p=0.00136),	O
PC(19:0/15:1)	B
(p<0.001)	O
and	O
17:0	O
Cer	O
(p=0.00173)	O
compared	O
to	O
methanol.	B

Furthermore,	O
in	O
the	O
setting	O
of	O
tamoxifen	B
treatment	O
that	O
is	O
routinely	O
administered	O
to	O
ER +	O
patients,	O
RRM2	O
was	O
able	O
to	O
distinguish	O
patients	O
who	O
were	O
resistant	O
to	O
treatment	O
from	O
those	O
who	O
responded	O
to	O
the	O
therapy.	O

From	O
each	O
sample,	O
5	O
μL	O
was	O
injected	O
onto	O
a	O
reverse-phase	O
50	O
×	O
2.1	O
mm	O
ACQUITY	O
1.7-μm	O
C18	O
column	O
(Waters	O
Corp,	O
Milford,	O
MA)	O
using	O
an	O
ACQUITY	O
UPLC	O
system	O
(Waters)	O
with	O
a	O
gradient	O
mobile	O
phase	O
consisting	O
of	O
2%	O
ACN	O
in	O
water	O
containing	O
0.1%	O
formic	B
acid	I
(A)	O
and	O
2%	O
water	O
in	O
ACN	O
containing	O
0.1%	O
formic	B
acid	I
(B).	O

Once	O
charge-tagged	O
by	O
the	O
GP	B
reagent,	O
oxysterols	B
can	O
be	O
analyzed	O
by	O
LC-electrospray	O
ionization-MS_n	O
	O
with	O
high	O
sensitivity	O
(<	O
pg	B
injected),	O
and	O
the	O
oxysterol	B
content	O
of	O
CSF	O
was	O
initially	O
probed	O
by	O
generation	O
of	O
exact	O
mass	O
(5	O
ppm)	O
RICs	O
for	O
all	O
potential	O
oxysterols	B
with	O
one	O
to	O
five	O
additional	O
oxygen	O
functions	O
on	O
the	O
cholesterol	B
skeleton	O
(see	O
supplemental	O
Table	O
S2).	O

Kynurenine,	B
the	O
lipid	O
signal	O
at	O
1.55–1.60	O
ppm,	O
ADMA,	B
2	O
phosphatidylcholines	B
(PC	O
aa	O
C38:3,	B
PC	B
ae	I
C42:1),	I
alpha-aminoadipic	B
acid,	I
hexoses	O
and	O
sphingolipids	B
were	O
increased	O
in	O
chemotherapy	O
recipients	O
after	O
6	O
months.	O

The	O
3-methyl	O
resonances	O
of	O
both	O
Ala	O
and	O
lactate	B
(doublets	O
at	O
1.53	O
and	O
1.4	O
ppm,	O
respectively)	O
display	O
pairs	O
of	O
_13	O
C	O
satellite	O
peaks	O
displaced	O
126	O

In	O
the	O
comparison	O
between	O
Tae-Eum	O
and	O
So-Yang	O
types,	O
levels	O
of	O
lactate	B
and	O
glutamate	B
were	O
higher	O
in	O
serum	O
samples	O
of	O
Tae-Eum	O
type	O
than	O
those	O
in	O
So-Yang	O
type	O
(see	O
).	O

The	O
association	O
to	O
kynurenine	B
points	O
towards	O
a	O
pro-inflammatory	O
state	O
with	O
increasing	O
OCN.	O

There	O
is	O
a	O
controversial	O
discussion	O
of	O
whether	O
patients	O
with	O
PKU	O
have	O
an	O
additional	O
risk	O
for	O
atherosclerosis	O
due	O
to	O
interference	O
of	O
Phe	O
with	O
cholesterol	B
synthesis	O
and	O
LDL-cholesterol	B
regulation.	O

Increased	O
alanine	B
and	O
lactate	B
levels	O
have	O
previously	O
been	O
observed	O
in	O
brain	O
tumours,	O
and	O
they	O
were	O
also	O
attributed	O
to	O
increased	O
glycolysis.	O

In	O
a	O
comparison	O
of	O
self-reported	O
acetaminophen	B
and	O
ibuprofen	B
use	O
with	O
_1	O
H	O
NMR-detected	O
acetaminophen	B
and	O
ibuprofen	B
metabolites	O
among	O
496	O
participants	O
from	O
Chicago,	O
Illinois,	O
and	O
Belfast,	O
Northern	O
Ireland,	O
the	O
overall	O
rate	O
of	O
concordance	O
was	O
81%–84%;	O
the	O
rate	O
of	O
underreporting	O
was	O
15%–17%;	O
and	O
the	O
rate	O
of	O
underdetection	O
was	O
approximately	O
1%.	O

Except	O
for	O
tryptophan	B
(peak	O
no.	O
46	O
in	O
Figure	O
),	O
the	O
identity	O
for	O
all	O
other	O
additional	O
peaks	O
is	O
yet	O
to	O
be	O
ascertained.	O

These	O
data	O
indicate	O
that	O
hydrogen	B
sulphide	I
could	O
be	O
an	O
important	O
factor	O
in	O
the	O
progress,	O
development	O
and	O
diagnosis	O
of	O
colorectal	O
cancer.	O

The	O
injected	O
sample	O
volume	O
was	O
1	O
μ	O
L.	O
Data	O
acquisition	O
and	O
processing	O
were	O
performed	O
with	O
the	O
acquisition	O
software	O
Analyst	O
TF	O
(version	O
1.7.1,	O
AB	O
SCIEX,	O
USA),	O
which	O
could	O
acquire	O
high	O
resolution	O
MS	O
and	O
tandem-MS	O
data	O
simultaneously	O
by	O
TOF	O
MS	O
full	O
scan	O
and	O
information-dependent	O
acquisition	O
(IDA)	O
in	O
both	O
ESI(+)	B
and	O
ESI(−)	O
modes.	O

_,	O
Reduced	O
1,25(OH)_2	B
D_3	O
production	O
is	O
due	O
to	O
reduced	O
renal	O
mass	O
as	O
well	O
as	O
downregulation	O
of	O
the	O
renal	O
1-α	O
hydroxylase	O
enzyme	O
(CYP27B1)	O
by	O
fibroblast	O
growth	O
factor	O
23	O
(FGF-23),	O
phosphorous	O
excess,	O
and	O
metabolic	O
acidosis._	O

A	O
substantial	O
decrease	O
in	O
lysophosphatidylcholines	B
and	O
lysophosphatidylethanolamines	B
plasma	O
content	O
was	O
found	O
between	O
T1	O
and	O
T2.	O

Methanol,	B
isopropanol,	B
and	O
2,6-di-tert	B
-butyl-4-methylphenol	I
(butylated	I
hydroxytoluene)	I
were	O
purchased	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
MO),	O
and	O
HPLC-grade	O
solvents	O
were	O
products	O
of	O
Fisher	O
Scientific	O
(Pittsburgh,	O
PA).	O

Orešič	O
and	O
colleagues	O
reported	O
decreased	O
levels	O
of	O
ether	B
PC	I
in	O
individuals	O
with	O
T1DM	O
relative	O
to	O
controls;	O
we	O
identified	O
4	O
ether	B
PC	I
molecular	O
species	O
that	O
were	O
significantly	O
decreased	O
in	O
recently	O
diagnosed	O
T1DM.	O

To	O
further	O
elucidate	O
mechanistic	O
differences	O
between	O
the	O
tested	O
isoflavones	B
and	O
to	O
compare	O
AhR	O
transcriptional	O
activation	O
by	O
isoflavones,	B
XRE-luciferase	O
reporter	O
activity	O
was	O
analyzed	O
(A	O
and	O
S2).	O

Data	O
were	O
mass	O
corrected	O
during	O
acquisition	O
using	O
a	O
leucine	B
enkephalin	I
reference	O
spray	O
(LockSpray)	O
infused	O
at	O
3 μL	O
min_−1	O
.	O

Tryptophan	B
metabolism,	O
as	O
well	O
as	O
phenylalanine,	B
nitrogen,	O
arginine,	B
proline,	B
alanine	B
and	O
histidine	B
metabolisms	O
and	O
phenylalanine,	B
tyrosine	B
and	O
tryptophan	B
biosynthesis	O
pathways	O
were	O
found	O
significantly	O
altered	O
(false	O
discovery	O
rate	O
(FDR)	O
adjusted	O
p	O
-value < 0.05)	O

Furthermore,	O
we	O
observed	O
that	O
7-ketocholesterol	B
levels	O
were	O
significantly	O
higher	O
in	O
the	O
second	O
sampling	O
compared	O
to	O
the	O
first	O
sampling	O
of	O
the	O
subgroup	O
of	O
patients	O
with	O
tumors	O
expressing	O
estrogen	B
receptor,	O
as	O
well	O
as	O
in	O
patients	O
treated	O
with	O
tamoxifen-based	O
regimens.	O

An	O
alternative	O
pathway	O
to	O
excrete	O
ammonia	O
excess	O
is	O
through	O
AKG	O
to	O
glutamic	B
acid,	I
glutamine	B
and	O
phenylacetylglutamine	B
(PAG),	O
which	O
then	O
exits	O
the	O
body	O
via	O
the	O
urine.	O

Saude	O
et	O
al.	O
used	O
the	O
concentration	O
of	O
creatinine	B
as	O
a	O
normalization	O
factor	O
in	O
an	O
attempt	O
to	O
compensate	O
for	O
the	O
effect	O
of	O
liquid	O
consumption	O
and	O
subsequent	O
urine	O
volume	O
on	O
metabolite	O
concentrations	O
and	O
concluded	O
that	O
that	O
subject	O
hydration	O
was	O
not	O
a	O
major	O
factor	O
contributing	O
to	O
variance.	O

The	O
background	O
[_12	O
C_6	O
]	O
adducts	O
of	O
1,2-	B
and	O
1,4-BQ	B
in	O
F344	O
rats	O
were	O
2.7	O
and	O
11.4	O
nmol/g.	O

The	O
methoxy	B
estrogen	I
4-MeOE2,	O
on	O
the	O
other	O
hand,	O
was	O
the	O
least	O
abundant	O
metabolite	O
detected	O
in	O
the	O
urine	O
of	O
all	O
the	O
groups	O
followed	O
by	O
other	O
methoxy	B
estrogens.	O

The	O
sphingosine	B
pathway	O
plays	O
an	O
important	O
role	O
in	O
signaling	O
and	O
is	O
finely	O
regulated.	O

[]	O
Using	O
an	O
immunoassay,	O
they	O
observed	O
a	O
rapid	O
decrease	O
in	O
8-iso	B
-PGF_2α	I
which	O
reached	O
statistical	O
significance	O
within	O
3	O
days	O
of	O
quitting,	O
and	O
decreased	O
by	O
40%	O
from	O
the	O
baseline	O
value	O
within	O
2	O
weeks.	O

Some	O
of	O
the	O
significantly	O
changed	O
metabolites	O
are	O
found	O
in	O
the	O
glucose-L-alanine	B
cycle,	O
which	O
plays	O
a	O
role	O
in	O
glycolysis	O
and	O
gluconeogenesis.	O

Of	O
particular	O
relevance	O
to	O
this	O
study,	O
a	O
variety	O
of	O
N-acylethanolamines	B
have	O
been	O
confirmed	O
to	O
be	O
peroxisome	O
proliferator-activated	O
receptor	O
(PPAR)	O
ligands,	O
which	O
play	O
key	O
roles	O
in	O
essential	O
physiological	O
processes	O
such	O
as	O
lipid	O
metabolism	O
and	O
inflammation	O
response_,	O
.	O

The	O
results	O
showed	O
that	O
these	O
metabolites	O
were	O
primarily	O
involved	O
in	O
1)	O
pyruvate	B
metabolism	O
(lactate	O
and	O
formate);	O
2)	O
propanoate	B
metabolism	O
(lactate	O
and	O
α-hydroxybutyrate);	B
3)	O
nitrogen	O
metabolism	O
(phenylalanine	O
and	O
formate);	O
and	O
4)	O
d-glutamine	B
and	O
d-glutamate	B
metabolism	O
(α-glucose).	O

For	O
example,	O
it	O
is	O
unclear	O
whether	O
the	O
doublet	O
of	O
C2,5	O
of	O
citrate	B
represents	O
_13	O
C1,_13	O
C2/_13	O
C5,_13	O
C6,_13	O
C2,_13	O
C3/_13	O
C3,_13	O
C5	O
or	O
both	O
(cf.	O
for	O
numbering	O
of	O
citrate).	O

l	O
l	O
l	O
Elevated	O
l-arginine	B
metabolites	O
in	O
plasma	O
are	O
associated	O
with	O
rheumatoid	O
arthritis	O
incidence	O
l	O
l	O
l	O
l	O
Abbreviations:	O
ADMA	B
Asymmetric	I
dimethylarginine,	I
SDMA	O
Symmetric	B
dimethylarginine,	I
ArgMI	O
Arginine	O
methylation	O
index	O
(i.e.,	O
ADMA	B
+	O
SDMA/l-N	O
_G	B
-monomethyl	I
arginine),	I
GABR	O
Global	O
arginine	B
bioavailability	O
ratio	O
(i.e.,	O
ratio	O
of	O
l-arginine	B
to	O
l-ornithine	B
+	O
l-citrulline)	O
l	O
l	O
l	O
l	O
Adjusted	O
for	O
age,	O
sex,	O
and	O
decreased	O
renal	O
function	O
(creatinine	O
> 1.4	O

Using	O
relative	O
quantitation	O
of	O
PE	B
16:0_18:1	I
as	O
an	O
example,	O
RSDs	O
from	O
three	O
technical	O
repeats	O
of	O
one	O
individual	O
are	O
all	O
round	O
8%	O
for	O
normal	O
control	O
and	O
T2D	O
samples	O
(Fig.	O

A	O
peak	O
metabolite,	O
identified	O
as	O
5-methyl-2-furoic	B
acid,	I
was	O
significantly	O
associated	O
with	O
lower	O
lung	O
cancer	O
risk	O
(odds	O
ratio,	O
0.57	O

Two	O
mesenchymal	O
stem	O
cell	O
mediums	O
were	O
tested	O
for	O
the	O
conditioning,	O
namely,	O
PromoCell	O
medium	O
(LabClinics,	O
Promocell,	O
C-28010,	O
so	O
called	O
commercial	O
medium	O
further	O
on)	O
and	O
Dulbecco's	O
Modified	O
Eagle	O
Medium	O
(DMEM,	O
Gibco)	O
supplemented	O
with	O
10%	O
of	O
fetal	O
bovine	O
serum	O
(FBS,	O
Gibco),	O
2	O
mM	O
glutamine	B
(Sigma),	O
100	O
U/ml	O
of	O
penicillin	B
and	O
100	O
µg/ml	O
of	O
streptomycin	B
(Sigma).	O

They	O
reported	O
that	O
a	O
multitude	O
of	O
uremic	O
toxins	B
were	O
retained	O
including	O
myo	O
-inositol	O
and	O
3-methylhistidine,	B
similar	O
to	O
our	O
findings	O
in	O
non-dialysis	O
CKD	O
patients.	O

The	O
results	O
revealed	O
that	O
disruptions	O
in	O
glycerophospholipid	B
and	O
linoleic	B
acid	I
metabolism	O
and	O
fatty	O
acid	O
and	O
primary	O
bile	O
acid	O
biosynthesis	O
were	O
significantly	O
associated	O
with	O
the	O
development	O
of	O
GCA.	O

Levels	O
of	O
beta-alanine,	B
alpha-hydroxyisovalerate,	B
tryptophan,	B
and	O
hexanoylcarnitine	B
were	O
elevated	O
in	O
HNSCC	O
oral	O
washes	O
compared	O
to	O
healthy	O
controls	O
(range	O
7.8-12.2-fold).	O

In	O
ruminants	O
dietary	O
choline	B
is	O
extensively	O
degraded	O
in	O
the	O
rumen	O
,	O
,	O
which	O
may	O
explain	O
the	O
low	O
and	O
constant	O
levels	O
of	O
free	O
choline	B
in	O
plasma	O
during	O
lactation	O
in	O
the	O
present	O
study.	O

In	O
these	O
cases,	O
glycerophosphocholines	B
were	O
identified	O
through	O
accurate	O
mass	O
and	O
MS/MS	O
product	O
ions	O
m/z	O
104	O
and	O
m/z	O
184.	O

Prediabetes	O
are	O
associated	O
with	O
low	O
vitamin	B
D	I
levels	O
,	O
and	O
the	O
risk	O
of	O
developing	O
diabetes	O
is	O
much	O
greater	O
for	O
prediabetes	O
who	O
are	O
vitamin	B
D	I
deficient	O
,	O
.	O

Eleven	O
patients	O
(55%)	O
were	O
diagnosed	O
to	O
have	O
pancolitis	O
and	O
13	O
(65%)	O
subjects	O
were	O
on	O
either	O
oral	O
or	O
rectal	O
5-aminosalicylic	B
acid	I
(5-ASA)	O
medications.	O

Glucose-1-phosphate	B
is	O
generated	O
during	O
glycogenolysis.	O

Interestingly,	O
sarcosine,	B
and	O
its	O
proximal	O
regulatory	O
enzymes,	O
appear	O
to	O
play	O
an	O
intermediary	O
role	O
in	O
neoplastic	O
progression	O
modulating	O
cell	O
invasion	O
and	O
migration.	O

For	O
the	O
purpose	O
of	O
obtaining	O
pure	O
cyclododecyl	O
2,4-dihydroxybenzoate,	O
its	O
synthesis	O
was	O
modified	O
by	O
annealing	O
silica	B
gel	O
at	O
120 °C	O
for	O
24 h	O
until	O
the	O
purification	O
stage.	O

Consistent	O
with	O
our	O
in	O
vitro	O
data,	O
hydroxyanastrozole	B
was	O
detected	O
and	O
quantified	O
in	O
plasma	O
mainly	O
as	O
the	O
conjugated	O
and,	O
to	O
a	O
small	O
extent,	O
as	O
the	O
unconjugated	O
(free)	O
form,	O
suggesting	O
that	O
once	O
formed	O
by	O
oxidation,	O
the	O
hydroxylated	O
metabolite	O
is	O
then	O
subsequently	O
efficiently	O
conjugated	O
probably	O
by	O
UGTs.	O

Although	O
the	O
mechanisms	O
by	O
which	O
the	O
deregulated	O
metabolites	O
of	O
glycosylated	B
ceramide	I
contribute	O
to	O
drug	O
resistance	O
and/or	O
metastasis	O
are	O
undefined,	O
such	O
alterations	O
are	O
widely	O
observed	O
and	O
warrant	O
investigation	O
(Byrnes	O
et	O
al.,	O
2009;	O
Saltz	O
et	O
al.,	O
2008).	O

In	O
the	O
first	O
step	O
a	O
mixture	O
of	O
20	O
deuterated	O
IS	O
(20	O
nM	O
each,	O
including	O
_2	O
H_5	O
-RvD1,	O
_2	O
H_5	O
-RvD2,	O
_2	O
H_5	O
-LXA_4	O
,	O
_2	O
H_4	O
-LTB_4	O
,	O
and	O
_2	O
H_4	B
-9,10-DiHOME),	I
antioxidant	O
mixture	O
(0.2	O
mg/mL	O
BHT,	O
100	O
μM	O
indomethacin,	B
100	O
μM	O
soluble	O
epoxide	O
hydrolase	O
inhibitor	O
trans	B
-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic	I
acid	I
(t	O
-AUCB)	O
in	O
MeOH)	O
were	O
added	O
to	O
500	O
μL	O
of	O
plasma/serum	O
or	O
1,200	O
μL	O
of	O
PD	O
exudates.	O

In	O
terms	O
of	O
the	O
average	O
results	O
for	O
the	O
hUCBP	O
samples	O
and	O
in	O
contrast	O
with	O
the	O
culture	O
and	O
conditioned	O
media,	O
it	O
was	O
possible	O
to	O
detect	O
lipids,	O
scyllo-inositol,	B
β-hidroxibutirate	B
and	O
purines.	B

It	O
reveals	O
retinal	B
specificities	O
in	O
both	O
GG	O
class	O
and	O
ceramide	B
pattern,	O
especially	O
using	O
a	O
lipidomic	O
approach	O
based	O
on	O
LC/MS.	O

TCDD	O
and	O
1,2,3,7,8-pentaCDD	B
were	O
so	O
highly	O
correlated	O
that	O
one	O
of	O
them	O
was	O
used	O
in	O
either	O
model	O
group	O
1	O
or	O
2	O
to	O
prevent	O
overadjustment.	O

Therefore,	O
reducing	O
the	O
accumulation	O
of	O
toxic	O
long-chain	O
acylcarnitines	B
may	O
be	O
important	O
to	O
attenuate	O
AMS.	O

To	O
successfully	O
quantify	O
the	O
new	O
platform	O
of	O
amines,	O
it	O
was	O
first	O
important	O
that	O
the	O
methylarginines,	B
ADMA,	B
L-NMMA	B
and	O
SDMA	O
could	O
be	O
distinguished	O
and	O
identified	O
individually	O
in	O
human	O
plasma	O
samples.	O

Several	O
anthropometrical	O
parameters	O
and	O
biochemical	O
analyses	O
including	O
glucose,	B
high-density	O
lipoproteins	O
(HDL),	O
low-density	O
lipoproteins	O
(LDL),	O
triglycerides	B
(TG),	O
the	O
BMI,	O
waist,	O
insulin,	O
and	O
the	O
homeostasis	O
model	O
assessment	O
of	O
insulin	O
resistance	O
(HOMA-IR)	O
were	O
measured.	O

A	O
novel	O
in	O
vivo	O
radiometric	O
method	O
had	O
been	O
developed	O
in	O
order	O
to	O
measure	O
the	O
total	O
oxidative	O
metabolism	O
of	O
estrogen,	B
independent	O
of	O
further	O
biotransformations	O
and	O
conjugation	O
pathways.	O

Bars	O
represent	O
mean	O
value	O
of	O
plasmalogen	O
ethanolamine	B
16:0/22:6	I
normalized	O
to	O
phosphatidyl	B
ethanolamine	I
16:0/18:3.	I

We	O
compared	O
the	O
rate	O
of	O
nicotine	B
metabolism	O
(i.e.	O
CYP2A6	O
activity),	O
determined	O
by	O
NMR,	O
between	O
NP	O
and	O
SW	O
smokers,	O
and	O
with	O
additional	O
populations	O
of	O
different	O
ethnic	O
backgrounds.	O

Ethanolamine	B
phosphate	I
cytidylyltransferase	O
and	O
choline	B
phosphate	I
cytidylyltransferase	O
homologs	O
were	O
identified	O
in	O
trypanosomatids	O
.	O

HbA1c:	O
glycosylated	O
hemoglobin,	O
T-chol:	O
total	O
cholesterol,	B
UN:	O
urea	B
nitrogen.	I

Eight	O
microliters	O
per	O
milligram	O
of	O
chloroform	B
and	O
4	O
μl/mg	O
of	O
water	O
were	O
subsequently	O
added	O
to	O
each	O
vial.	O

Markers	O
related	O
to	O
inﬂammatory	O
status,	O
as	O
well	O
as	O
to	O
perturbations	O
in	O
bile	O
acid	O
metabolism	O
(elevations	O
in	O
cholesterol,	B
unconjugated,	O
conjugated	O
and	O
sulfated	O
bile	O
acid),	O
lipid	O
metabolism	O
(elevations	O
in	O
fatty	O
acids,	O
ketone	B
bodies	O
and	O
several	O
acylcarnitines)	B
and	O
protein	O
metabolism	O
(depletion	O
in	O
dipeptides),	O
were	O
associated	O
with	O
the	O
PSC	O
patient’s	O
metabolome,	O
compared	O
to	O
healthy	O
controls.	O

A	O
similar	O
_13	O
C	O
enrichment	O
pattern	O
of	O
Ala,	O
lactate,	B
succinate	B
and	O
citrate	B
in	O
lung	O
tumor	O
tissues	O
was	O
observed	O
in	O
all	O
five	O
patients	O
where	O
_13	O
C	O
labeling	O
in	O
these	O
metabolites	O
was	O
sufficient	O
to	O
be	O
quantified	O
by	O
GC-MS.	O

,	O
citrate,	B
EDTA	O
and	O
heparin)	B
and	O
serum	O
was	O
performed	O
using	O
whole	O
blood	O
from	O
the	O
same	O
human	O
donor.	O

Asp	O
may	O
be	O
actively	O
consumed	O
as	O
a	O
precursor	O
for	O
nucleic	O
acids	O
and	O
these	O
TCA	O
cycle	O
intermediates,	O
because	O
tumor	O
concentrations	O
of	O
malate,	B
fumarate	B
and	O
succinate	B
were	O
significantly	O
higher	O
than	O
the	O
normal	O
levels.	O

THC,	O
11-OH-THC,	B
THCCOOH,	O
THCCOOH-gluc,	O
CBD,	O
CBN,	O
d_3	O
-THC,	O
d_3	B
-11-OH-THC,	I
d_9	O
-THCCOOH,	O
d_3	O
-CBD,	O
d_3	O
-CBN	O
and	O
d_3	O
-THCCOOH-gluc	O
(d_3	O
-THCCOOH-gluc)	O
were	O
purchased	O
from	O
Cerilliant	O
(Round	O
Rock,	O
TX,	O
USA).	O

The	O
median	O
serum	O
concentration	O
of	O
retinol	B
was	O
579	O
μg/L.	O

Cn,	O
creatinine;	B
Cr,	O
creatine;	B
DHT,	O
dihydrothymine;	B
DMG,	B
N,	O
N-dimethylglycine;	B
EA,	O
ethanolamine;	B

In	O
addition	O
to	O
the	O
oncometabolite	O
2-hydroxyglutarate,	B
at	O
least	O
42	O
more	O
metabolites	O
were	O
identified	O
from	O
our	O
series	O
of	O
NMR	O
experiment.	O

The	O
most	O
significant	O
decreases	O
in	O
the	O
post-partum	O
period	O
were	O
obviously	O
observed	O
for	O
17-OHP,	B
PROG,	O
E2,	O
E1,	O
and,	O
surprisingly,	O
also	O
for	O
CORT,	O
as	O
highlighted	O
in	O
and	O
in	O
.	O

The	O
amino	O
acid	O
(AA)	O
lower	O
level	O
of	O
quantitation	O
(LOQ)	O
was	O
0.5	O
μM	O
and	O
the	O
acylcarnitine	B
(AC)	O
LOQ	O
was	O
0.015	O
μM.	O

The	O
Kruskal–Wallis	O
test	O
showed	O
statistical	O
differences	O
in	O
the	O
serum	O
levels	O
of	O
tamoxifen,	B
4OHtam,	O
NDtam,	O
and	O
NDDtam	O
between	O
the	O
age	O
groups	O
of	O
30–49,	O
50–69,	O
and	O
>69 years	O
(data	O
not	O
shown).	O

These	O
very	O
low	O
levels	O
in	O
plasma	O
may	O
be	O
due	O
to	O
enhanced	O
peroxisomal	O
β-oxidation	O
of	O
VLCFAs	O
under	O
the	O
control	O
of	O
the	O
peroxisome	O
proliferator	O
activated	B
receptor	O
alpha	O
(PPARα)	O
and	O
as	O
a	O
result	O
of	O
enhanced	O
lignoceryl-CoA	B
ligase	O
activity	O
or	O
as	O
a	O
result	O
of	O
activation	O
of	O
liver	O
X	O
receptor	O
α	O
(LXRα).	O

Finally,	O
targeted	O
UPLC-MS/MS	O
based	O
metabolomic	O
analysis	O
was	O
performed	O
on	O
human	O
breast	O
tissues	O
to	O
investigate	O
total	O
estrogen	B
anabolic/catabolic	O
pathways	O
using	O
total	O
42	O
steroids	O
and	O
estrogen	B
related	O
reference	O
standards.	O

NO_2	O
-PhIP,	O
HONH-PhIP,	O
and	O
N	B
-acetoxy-PhIP	I
are	O
reactive	O
species	O
that	O
contribute	O
to	O
the	O
deleterious	O
biological	O
effects	O
of	O
PhIP	O
through	O
DNA	O
and	O
protein	O
adduct	O
formation.	O

Several	O
studies	O
have	O
reported	O
reduced	O
levels	O
of	O
tryptophan	B
and	O
increased	O
levels	O
of	O
kynurenine	B
(an	O
increased	O
kynurenine:tryptophan	B
ratio)	O
in	O
patients	O
with	O
RA	O
in	O
comparison	O
to	O
control	O
subjects	O
[–],	O
confirming	O
activation	O
of	O
kynurenine	B
pathway	O
in	O
RA	O
as	O
an	O
attempt	O
(albeit	O
not	O
sufficiently	O
effective)	O
to	O
down-regulate	O
the	O
immune	O
system.	O

Two-hydroxybutyric	B
acid	I
and	O
3-hydroxybutyric	B
acid	I
(a	O
ketone	B
body),	O
both	O
synthesized	O
in	O
the	O
liver,	O
decreased	O
in	O
survivors	O
with	O
time	O
and	O
increased	O
in	O
fatalities	O
compared	O
with	O
healthy	O
controls.	O

Furthermore,	O
the	O
improvement	O
in	O
insulin	O
sensitivity	O
after	O
pioglitazone	B
treatment	O
was	O
associated	O
with	O
a	O
reduction	O
in	O
almost	O
all	O
skeletal	O
muscle	O
LC-FACoAs	O
including	O
stearate	B
CoA	O
(18:0),	O
palmityl	O
CoA	O
(16:0),	O
palmitoleate	B
CoA	O
(16:1),	O
oleate	B
CoA	O
(18:1),	O
and	O
linoleate	B
CoA	O
(18:2).	O

Notably,	O
ketone	B
bodies	O
have	O
recently	O
been	O
reported	O
to	O
be	O
immune	O
suppressors,	O
and	O
elevations	O
in	O
these	O
metabolites	O
may	O
contribute	O
to	O
a	O
negative	O
response	O
in	O
critical	O
illness.	O

l	O
l	O
l	O
l	O
_a	O
Variable(s)	O
entered	O
in	O
step	O
1:	O
S	B
-adenosyl-l-methionine.	I

Five	O
compounds	O
were	O
identified	O
in	O
three	O
classes	O
of	O
lipids:	O
sphingolipids	O
(sphinganine,	O
Galα1-3(Fucα1-2)Galβ1-4Glcβ-Cer(d18:1/16:0)),	O
endocannabinoids	B
(docosatetraenoylethanolamide	I
[DEA]),	I
and	O
glycerophospholipids	B
(PE	O
18:2(9Z,12Z)/0:0)	O
and	O
PC	B
(18:1(9Z)/0:0)).	I

In	O
summary,	O
changes	O
in	O
L-tryptophan	B
in	O
the	O
GDM	O
group	O
pointed	O
to	O
an	O
altered	O
serotonin	B
metabolism	O
which	O
indeed	O
is	O
changed	O
in	O
GDM	O
patients.	O

This	O
decrease	O
is	O
most	O
likely	O
due	O
to	O
low	O
glycogen	B
levels	O
in	O
FS	O
animals	O
connected	O
to	O
an	O
overnight	O
fast	O
[–].	O

Figure	O
)	O
and	O
possibly	O
involving	O
a	O
different	O
pool	O
of	O
pyruvate	B
as	O
has	O
been	O
observed	O
in	O
other	O
cells	O
[,].	O

From	O
this	O
panel,	O
the	O
light-sensitive	O
metabolites	O
S-adenosylmethionine	B
and	O
S-adenosylhomocysteine	B
were	O
excluded	O
as	O
the	O
DBS	O
cards	O
were	O
not	O
specifically	O
protected	O
from	O
light.	O

In	O
only	O
200	O
μL	O
urine,	O
we	O
simultaneously	O
quantified	O
11	O
cannabinoids	B
at	O
low	O
μg/L	O
concentrations	O
within	O
clinically	O
relevant	O
linear	O
ranges.	O

The	O
sample	O
was	O
then	O
dried	O
under	O
nitrogen	O
and	O
methoximised	O
using	O
60	O
µL	O
methoxyamine	B
(20	O
mg/mL	O
in	O
pyridine)	B
for	O
17	O
h	O
at	O
RT.	O

Plasma	O
levels	O
of	O
metabolites	O
in	O
healthy	O
subjects	O
and	O
in	O
patients	O
who	O
underwent	O
carotid	O
endarterectomy	O
(CE):	O
(a)	O
ATP;	B
(b)	O
ADP;	B
(c)	O
3’,5’-cyclic-AMP;	B
(d)	O
3’,5’-cyclic-GMP.	B

A	O
similar	O
trend	O
was	O
observed	O
for	O
the	O
much	O
weaker	O
base,	O
DMA	B
(	O
A	O
and	O
B	O
),	O
suggesting	O
that	O
these	O
phenomena	O
might	O
be	O
rather	O
general.	O

We	O
note	O
that	O
the	O
ratio	O
between	O
creatine	B
and	O
creatinine	B
may	O
also	O
serve	O
as	O
a	O
possible	O
biomarker,	O
as	O
it	O
generally	O
appears	O
to	O
increase	O
in	O
DMD	O
patients	O
and	O
decrease	O
in	O
controls	O
and	O
is	O
more	O
significantly	O
associated	O
with	O
DMD	O
status	O
than	O
either	O
creatine	B
or	O
creatinine	B
individually.	O

Glutamate	B
takes	O
part	O
in	O
the	O
energy	O
supply,	O
and	O
has	O
an	O
important	O
role	O
as	O
an	O
excitotoxic	O
substance	O
promoting	O
glioma	O
invasiveness	O
[,].	O

Of	O
the	O
quantified	O
metabolites,	O
IAA	O
was	O
the	O
only	O
metabolite	O
to	O
show	O
significant	O
correlation	O
with	O
the	O
PHQ9	O
overall	O
score	O
(R	O
 = 0.39,	O
P	O
 < 0.05),	O
owing	O
to	O
low-moderate	O
associations	O
with	O
the	O
subscales	O
sleep	O
(R	O
 = 0.49,	O
P	O
 < 0.01)	O
and	O
depression	O
mood	O
(R	O
 = 0.50,	O
P	O
 < 0.01)	O
which	O
also	O
correlated	O
with	O
3-OH	O
anthranilic	B
acid	I
(R	O
 = 0.40,	O
P	O
 < 0.05).	O

We	O
did	O
not	O
detect	O
kynurenine	B
in	O
our	O
urinary	O
samples	O
but	O
noted	O
a	O
catabolite,	O
xanthurenate,	B
to	O
be	O
lowered	O
in	O
CRC	O
patients	O
prior	O
to	O
surgery	O
compared	O
to	O
post-surgery	O
patients.	O

Regression	O
of	O
unconjugated	O
estradiol	B
on	O
corrected	O
BMI	O
and	O
other	O
covariates	O
resulted	O
in	O
a	O
relative	O
increase	O
in	O
unconjugated	O
estradiol	B
of	O
12.2%	O
for	O
each	O
5kg/m_2	O
increase	O
in	O
BMI	O
(as	O
compared	O
to	O
12.8%	O
for	O
uncorrected	O
data	O
–	O
).	O

MID	O
calculation	O
of	O
glutamine	B
M5	O
obtained	O
from	O
labeled	O
A549	O
cell	O
extract	O
diluted	O
in	O
plasma	O
(0.1,	O
0.2,	O
0.5,	O
and	O
1%	O
of	O
the	O
original	O
_13	O
C	O
enrichment)	O
with	O
(gray)	O
and	O
without	O
model	O
peak	O
correction	O
(red)—(a)	O
Barplot	O
of	O
calculated	O
(saturated)	O
and	O
estimated	O
(transparent)	O
glutamine	B
M5	O
abundance	O
with	O
(gray)	O
and	O
without	O
(red)	O
model	O
peak	O
correction;	O
(b)	O
scatter	O
plot	O
of	O
estimated	O
vs	O
measured	O
glutamine	B
M5	O
abundance,	O
with	O
(gray)	O
and	O
without	O
(red)	O
model	O
peak	O
correction	O
for	O
linear	O
regression	O
analysis.	O

The	O
lysophilized	O
sample	O
was	O
resuspended	O
in	O
10%	O
methanol.	B

We	O
hypothesized	O
that	O
Phe-epoxides,	B
the	O
primary	O
metabolites	O
of	O
Phe,	O
were	O
detoxified	O
by	O
glutathione	B
conjugate	O
formation,	O
which	O
would	O
result	O
ultimately	O
in	O
the	O
excretion	O
of	O
the	O
corresponding	O
mercapturic	O
acids	O
in	O
urine.	O

The	O
dominant	O
effect	O
of	O
Etanercept	O
treatment	O
was	O
observed	O
in	O
normalizing	O
the	O
plasma	O
levels	O
of	O
a	O
large	O
cluster	O
of	O
positively	O
correlated	O
metabolites	O
consisting	O
of	O
ornithine,	B
arginine,	B
proline,	B
citrulline,	B
glycine,	B
glutamine,	B
threonine,	B
and	O
methionine	B
(Figure	O
),	O
specifically	O
within	O
the	O
arginine/proline	B
and	O
glycine,	B
serine,	B
and	O
threonine	B
pathways	O
(Table	O
S9).	O

Insulin	O
resistance	O
was	O
estimated	O
by	O
the	O
HOMA	O
method	O
using	O
the	O
following	O
equation:	O
HOMA-IR was	O
calculated	O
using	O
the	O
following	O
equation: 	O
HOMA-IR = [fasting	O
insulin	O
(μIU/mL)	O
×	O
fasting	O
glucose	B
(mmol/L)]/22.5.	O

Finally,	O
the	O
_31	O
P	O
NMR	O
spectrum	O
revealed	O
the	O
presence	O
of	O
a	O
phosphate	B
group	O
at	O
(δ	O
_P	O
66.1),	O
similar	O
to	O
that	O
of	O
Tem	O
(δ	O
_P	O
66.3).	O

In	O
both	O
extraction	O
methods	O
(UE	O
and	O
ASE)	O
used	O
to	O
isolate	O
ZON	O
and	O
α-ZOL,	B
the	O
most	O
satisfactory	O
results	O
were	O
reported	O
in	O
respect	O
of	O
ACN/H_2	O
O	B
(84:16%	I
v	I
/v	I
)	I
and	O

This	O
had	O
an	O
effect	O
of	O
detuning	O
the	O
tryptophan	B
transition	O
for	O
sensitivity	O
with	O
the	O
benefit	O
of	O
negating	O
the	O
effect	O
of	O
in-source	O
saturation,	O
resulting	O
in	O
linearity	O
of	O
the	O
calibration	O
over	O
the	O
desired	O
range	O
(Figure	O
S3).	O

Regarding	O
the	O
level	O
of	O
maltose,	B
it	O
was	O
highest	O
in	O
the	O
BT	O
group,	O
followed	O
by	O
PP	O
and	O
GP;	B
this	O
trend	O
might	O
be	O
associated	O
with	O
tumor	O
formation	O
and	O
recurrence.	O

For	O
example,	O
metabolites	O
derived	O
from	O
the	O
same	O
parent	O
compound,	O
e.g.,	O
acetaminophen,	B
acetaminophen	B
glucuronide,	I
acetaminophen	B
sulfate,	I
and	O
N	B
-acetyl	I
cysteine	I
acetaminophen,	I
all	O
show	O
correlations	O
that	O
vary	O
in	O
strength	O
according	O
to	O
the	O
degree	O
of	O
overlap	O
with	O
other	O
endogenous	O
or	O
exogenous	O
signals.	O

SMs	O
can	O
be	O
hydrolyzed	O
back	O
to	O
ceramides	B
by	O
SMase	O
action.	O

Considering	O
that	O
several	O
metabolic	O
processes	O
taking	O
place	O
following	O
glucose	B
ingestion	O
are	O
mediated	O
by	O
insulin,	O
we	O
hypothesized	O
that	O
insulin	O
sensitivity	O
could	O
be	O
reflected	O
not	O
only	O
by	O
changes	O
in	O
glucose	B
but	O
also	O
by	O
the	O
OGTT	O
response	O
of	O
multiple	O
other	O
metabolites.	O

In	O
brief,	O
the	O
filtrate	O
volume	O
was	O
brought	O
up	O
to	O
650 μL,	O
using	O
a	O
DSS-containing	O
sodium	B
phosphate	I
buffer	O
(130 μL,	O
0.5 M),	O
the	O
antibacterial	O
compound	O
sodium	O
azide	O
(10 μL,	O
1 M)	O
and	O
deuterium	O
oxide.	O

Bile	O
acids	O
have	O
long	O
been	O
known	O
to	O
be	O
essential	O
in	O
dietary	O
lipid	O
absorption	O
and	O
cholesterol	B
catabolism,	O
and	O
have	O
a	O
role	O
in	O
regulating	O
thyroid	O
hormone	O
signaling	O
and	O
energy	O
homeostasis.	O

Glutamine	B
is	O
one	O
of	O
the	O
major	O
amino	O
acids	O
used	O
by	O
tumor	O
cells	O
for	O
biosynthesis.	O

After	O
a	O
long	O
MD	O
equilibration	O
in	O
the	O
presence	O
of	O
explicit	O
solvent	O
and	O
the	O
detergent	O
micelle,	O
a	O
unique	O
α-helix	B
was	O
found	O
for	O
the	O
same	O
portion,	O
with	O
an	O
additional	O
round	O
of	O
3_10	O
-helix	O
between	O
the	O
5th	O
and	O
the	O
7th	O
position	O
only	O
in	O
50%	O
of	O
the	O
conformers.	O

Analysis	O
was	O
blinded	O
to	O
aspartame	B
consumption	O
and	O
subject	O
group	O
(AS	O
or	O
NS).	O

The	O
urine	O
samples	O
were	O
prepared	O
with	O
chemical	O
product	O
from	O
Sigma	O
(Sigma	O
Aldrich,	O
Saint	O
Quentin	O
Fallavier,	O
France)	O
to	O
obtain	O
a	O
final	O
volume	O
of	O
600	O
μ	O
L	O
(400	O
μ	O
L	O
of	O
urine;	O
160	O
μ	O
L	O
of	O
200	O
mM	O
phosphate	B
buffer	O
at	O
pH	O
7.4,	O
1	O
mM	O
of	O
TSP	B
-Trimethyl	I
silyl	I
propionate	I
of	O
sodium	O
salt	O
as	O
the	O
NMR	O
chemical	O
shift	O
reference-,	O
6	O
mM	O
of	O
NaN_3	O
;	O
40	O
μ	O
L	O
D_2	O
O).	O

In	O
addition,	O
reserpine	B
was	O
also	O
spiked	O
in	O
samples	O
as	O
internal	O
standard	O
for	O
QC	O
purpose.	O

Using	O
a	O
comprehensive	O
battery	O
of	O
psychological	O
tests,	O
biochemistry	O
and	O
state	O
of	O
the	O
art	O
metabonomics	O
there	O
was	O
no	O
evidence	O
of	O
any	O
acute	O
adverse	O
responses	O
to	O
aspartame.	B

An	O
excellent	O
separation	O
with	O
minimal	O
overlapping	O
was	O
observed	O
between	O
positive	O
and	O
negative	O
prognosis	O
in	O
the	O
Urine-0h	B
model.	O

Spearman	O
rank	O
correlation	O
between	O
metabolites	O
in	O
the	O
kynurenine	B
pathway	O
and	O
FSS	O
in	O
the	O
entire	O
SLE	O
cohort	O
and	O
in	O
the	O
selection	O
of	O
patients	O
with	O
severe	O
fatigue	O
Fatigue	O
Severity	O
Scale	O
(FSS)	O
data	O
were	O
obtained	O
from	O
129	O
of	O
132	O
patients	O
with	O
SLE.	O

Threonine	B
plays	O
an	O
important	O
role	O
in	O
the	O
TCA	O
cycle.	O

A	O
number	O
of	O
lipid	O
metabolites	O
including	O
arachidonic,	O
palmitoleic	B
and	O
linoleic	B
acids,	I
were	O
also	O
increased.	O

Zhao	O
et	O
al.	O
reported	O
that	O
L-proline	B
was	O
one	O
of	O
the	O
amino	O
acid	O
which	O
its	O
plasma	O
concentration	O
was	O
found	O
to	O
be	O
decreased	O
in	O
LCPs,	O
compared	O
with	O
control	O
group	O
(p	O
 < 0.001).	O

The	O
first	O
class	O
of	O
lipids	O
we	O
analyzed	O
was	O
glycerolipids;	B
subclasses	O
TG,	B
DG,	O
and	O
MG.	O

Two	O
fatty	O
acyl	B
amides	I
(FAAs),	O
oleamide	B
and	O
POEA,	B
were	O
detected	O
in	O
AML	O
plasma	O
but	O
were	O
not	O
detected	O
in	O
any	O
control	O
plasma.	O

(A)	O
Contribution	O
of	O
a	O
_1	O
H	O
NMR	O
characteristic	O
signal	O
of	O
lactate	B
at	O
1.36	O
ppm	O
to	O
the	O
spectrum	O
of	O
aqueous	O
fraction	O
of	O
the	O
plasma	O
extract	O
(Aq	O
spectrum).	O

When	O
querying	O
the	O
spectrum	O
against	O
the	O
database,	O
arginine	B
could	O
not	O
be	O
identified.	O

The	O
MPPZ	O
derivatives	O
of	O
E1	O
and	O
17βE2	B
fragmented	O
to	O
give	O
two	O
specific	O
product	O
ions	O
m/z	O
549 → 502	O
and	O
551 → 504	O
by	O
loss	O
of	O
NO_2	O
.	O

After	O
small	O
HCC	O
tumors	O
were	O
removed	O
by	O
RFA	O
treatment,	O
we	O
noted	O
a	O
remarkable	O
upregulation	O
of	O
glycerol	B
accompanied	O
by	O
increased	O
levels	O
of	O
various	O
fatty	O
acids	O
that	O
should	O
contribute	O
to	O
HCV-induced	O
insulin	O
resistance	O
and	O
hinder	O
the	O
synthesis	O
of	O
TG.	B

It	O
was	O
the	O
result	O
of	O
an	O
oxidation	O
of	O
the	O
pyrrolidine	B
ring.	O

GABA	B
is	O
produced	O
from	O
glutamic	B
acid	I
by	O
glutamic	O
acid	O
decarboxylase.	O

Excellent	O
recoveries	O
of	O
Cer(22:0)	B
and	O
Cer(24:0)	B
from	O
plasma	O
and	O
from	O
BSA	O
were	O
obtained	O
(see	O
).	O

When	O
the	O
components	O
of	O
the	O
major	O
adverse	O
cardiovascular	O
events	O
were	O
analyzed	O
separately,	O
increased	O
levels	O
of	O
TMAO	B
remained	O
significantly	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
death	O
(hazard	O
ratio,	O
3.37;	O
95%	O
CI,	O
2.39	O
to	O
4.75;	O
P<0.001)	O
and	O
nonfatal	O
myocardial	O
infarction	O
or	O
stroke	O
(hazard	O
ratio,	O
2.13;	O
95%	O
CI,	O
1.48	O
to	O
3.05;	O
P<0.001).	O

Plasma	O
20-HETE	B
was	O
highest	O
in	O
subjects	O
with	O
renovascular	O
disease	O
(median:	O
1.20	O
ng/mL;	O
range:	O
0.42	O
to	O
1.92	O
ng/mL)	O
compared	O
with	O
subjects	O
with	O
essential	O
hypertension	O
(median:	O
0.90	O
ng/mL;	O
range:	O
0.40	O
to	O
2.17	O
ng/mL)	O
and	O
control	O
subjects	O
(median:	O
0.45	O
ng/mL;	O
range:	O
0.14	O
to	O
1.70	O
ng/mL;	O
P	O
<0.05).	O

Elevated	O
acylcarnitine	B
production	O
can	O
occur	O
when	O
β-oxidation	O
rates	O
are	O
in	O
excess	O
of	O
complete	O
oxidation	O
to	O
carbon	B
dioxide	I
through	O
the	O
tricarboxylic	B
acid	I
cycle.	O

It	O
was	O
therefore	O
decided	O
to	O
profile	O
the	O
HCC	O
and	O
control	O
plasmas	O
for	O
LPA(16:0),	B
a	O
product	O
of	O
LPD/autotaxin.	O

(A)	O
C2:	O
acetylcarnitine;	B
Total	O
AC:	O
sum	O
of	O
all	O
quantified	O
acylcarnitines;	B
medium	O
chain:	O
sum	O
of	O
acylcarnitines	B
with	O
6	O
to	O
14	O
carbons;	O
long	O
chain:	O
sum	O
of	O
acylcarnitines	B
with	O
16–18	O
carbons;	O
(B)	O
BCAA_AC:	O
sum	O
of	O
acylcarnitines	B
derived	O
from	O
branched-chain	O
amino	O
acid	O
catabolism	O
(C3,	O
2M-C3,	O
2M-C4,	O
3M-C4	O
and	O
C4DC);	O
FA_AC	O
=	O
sum	O
of	O
medium-chain	O
acylcarnitines	O
derived	O
from	O
fatty	O
acid	O
catabolism	O
(C6,	O
C8,	O
C10,	O
C12,	O
C14,	O
C16,	O
C16:1,	B
C:18,	O
C18:1,	B
C18:2;	B
C0	O
=	O
L-carnitine.	B

HPLC-grade	O
methanol,	B
acetonitrile,	B
ammonium	B
hydroxide	I
(NH_4	O
OH),	O
and	O
ammonium	B
acetate	I
(NH_4	O
CH_3	O
COOH)	O
were	O
obtained	O
from	O
Fisher	O
Scientific	O
International,	O
Inc.	O
(Pittsburgh,	O
PA).	O

A	O
qualitative	O
profiling	O
of	O
urinary	O
metabolites	O
was	O
performed	O
using	O
liquid	O
chromatography/time-of-flight	O
mass	O
spectrometry	O
(LC/TOFMS)	O
with	O
a	O
database	O
of	O
nominal	O
molecular	O
weights	O
of	O
57	O
known	O
metabolites	O
of	O
three	O
neonicotinoid	B
pesticides	O
(acetamiprid,	O
Imidacloprid,	O
and	O
clothianidin),	B
as	O
well	O
as	O
the	O
parent	O
compounds.	O

100μl	O
of	O
1-butanol/methanol	O
(1:1	O
v/v)	O
containing	O
5	O
mM	O
ammonium	B
formate	I
was	O
then	O
added	O
to	O
the	O
sample.	O

Most	O
amino	O
acids	O
including	O
glutamine,	B
glutamate,	B
asparagine,	B
aspartate,	B
tyrosine	B
histidine,	I
cysteine,	B
isoleucine,	B
and	O
leucine	B
were	O
elevated	O
in	O
the	O
serum	O
of	O
lung	O
cancer	O
patients.	O

Although	O
choline	B
is	O
involved	O
in	O
multiple	O
metabolic	O
pathways,	O
it	O
has	O
a	O
predominant	O
role	O
in	O
cell	O
membrane	O
integrity,	O
methyl	O
metabolism	O
and	O
lipid-cholesterol	B
transport	O
.	O

Alanine	O
aminotransferase	O
(ALT),	O
aspartate	O
aminotransferase	O
(AST),	O
γ-GT,	B
cholinesterase	O
(ChE),	O
blood	O
urea	B
nitrogen	I
(BUN),	O
creatinine	B
(Cr),	O
and	O
uric	B
acid	I
(UA)	O
were	O
assessed	O
on	O
an	O
automatic	O
analyzer	O
(7600–020	O
biochemistry	O
automatic	O
analyzer,	O
Hitachi,	O
Tokyo,	O
Japan).	O

Here,	O
we	O
showed	O
that	O
the	O
metabolic	O
profiles	O
in	O
subjects	O
with	O
improved	O
glycemic	B
control	O
could	O
be	O
differentiated	O
from	O
those	O
without	O
improvement	O
as	O
early	O
as	O
7	O
days	O
after	O
metabolic	O
surgery,	O
and	O
that	O
the	O
metabolic	O
profile	O
is	O
correlated	O
with	O
HbA1c	O
values	O
at	O
3	O
months	O
after	O
surgery.	O

Rank	O
is	O
based	O
on	O
estrogen	B
metabolite	O
concentration	O
There	O
was	O
insufficient	O
urine	O
volume	O
for	O
5	O
participants	O
(1	O
case,	O
3	O
healthy	O
controls,	O
2	O
biopsy	O
controls)	O
to	O
assay	O
for	O
creatinine,	B
therefore	O
estrogen	B
metabolite	O
measurements	O
are	O
not	O
presented	O
for	O
these	O
subjects.	O

Plasma	O
samples	O
(300	O
μL)	O
were	O
mixed	O
with	O
cold	O
methanol	B
(1:2,	I
vol:vol)	I
in	O
1.5-mL	O
microcentrifuge	O
tubes	O
on	O
ice,	O
vortexed	O
and	O
incubated	O
at	O
–20°C	O
for	O
20	O
min,	O
and	O
centrifuged	O
at	O
14,000	O
×	O
g	O
for	O
30	O
min	O
at	O
4°C.	O

With	O
respect	O
to	O
adipose	O
tissue	O
distribution,	O
a	O
study	O
in	O
mice	O
suggested	O
a	O
body	O
fat	O
lowering	O
effect	O
and	O
piperine-treatment	B
of	O
3T3-L1	O
cells	O
reduced	O
lipid	O
storage	O
as	O
well	O
as	O
blocked	O
their	O
differentiation	O
into	O
adipocytes.	O

Final	O
extracts	O
were	O
than	O
analyzed	O
by	O
LC-MS/MS	O
for	O
amino	O
acids	O
and	O
bioactive	O
amines	O
PTC-derivatives	O
using	O
a	O
Zorbax	O
SB	O
100	O
×	O
2.1	O
mm	O
column	O
(Agilent,	O
Santa	O
Clara	O
CA,	O
USA),	O
while	O
direct	O
flow	O
injection	O
analysis	O
(FIA-MS/MS)	O
was	O
used	O
for	O
the	O
analysis	O
of	O
acylcarnitine	B
and	O
phospolipides.	O

L-2-chlorophenylalanine	B
(Shanghai	O
Hengbai	O
Biotech.	O

vastus	O
lateralis	O
of	O
ACE-DD	O
genotypes;	O
indicates	O
that	O
capillarisation	O
is	O
a	O
possible	O
limiting	O
factor	O
for	O
glucose	B
supply	O
during	O
endurance	O
exercise	O
in	O
this	O
genotype.	O

f	O
Pyruvate;	B
g	O
Trimethylamine	B
N	I
-oxide;	I
h	O
Glutamine;	B
i	O
Isoleucine;	B
j	O
Succinate.	B

There	O
is	O
variability	O
in	O
patient	O
consumption	O
of	O
food	O
(amount,	O
composition,	O
and	O
timing)	O
and	O
adherence	O
to	O
medications	O
(e.g.	O
statins	B
and	O
antihyperglycemics),	O
relative	O
to	O
when	O
blood	O
is	O
drawn,	O
and	O
food	O
consumption	O
and	O
medication	O
adherence	O
may	O
differ	O
by	O
disease	O
status	O
in	O
unknown	O
ways.	O

The	O
fact	O
that	O
medium-chain	O
acylcarnitines	O
and	O
suberic	B
acid	I
were	O
both	O
elevated	O
in	O
the	O
same	O
samples	O
in	O
this	O
study,	O
might	O
reflect	O
the	O
metabolic	O
state	O
of	O
more	O
aggressive	O
prostate	O
cancers.	O

Metabolomics	O
also	O
revealed	O
an	O
influence	O
of	O
vitamin	O
B-12	O
on	O
primary	O
intermediates	O
of	O
one-carbon	O
metabolites	O
and	O
the	O
Krebs	O
cycle,	O
as	O
well	O
as	O
on	O
a	O
number	O
of	O
carbohydrates,	O
amino	O
acids,	O
amides,	B
organic	O
acids,	O
nucleotides,	O
lipids,	O
and	O
sterols.	O

Lastly,	O
bacteria	O
are	O
capable	O
of	O
converting	O
kynurenine	B
to	O
KYNA.	O

P	O
_mean	O
 = 3.7_*	O
10_−6	O
),	O
while	O
two	O
SCFAs,	O
acetate	B
and	O
n-heptanoate,	B
were	O
negatively	O
correlated	O
with	O
these	O
cytokines	O
(r	O
_mean	O
 = −0.46/P	O
_mean	O
 = 0.037),	O
thus	O
performing	O
a	O
protective	O
role.	O

Limited	O
by	O
the	O
case-control	O
design,	O
this	O
study	O
could	O
not	O
definitively	O
conclude	O
whether	O
elevated	O
serum	O
TMAO	B
was	O
involved	O
in	O
liver	O
carcinogenesis,	O
or	O
if	O
liver	O
cancer	O
caused	O
the	O
elevation	O
in	O
serum	O
TMAO.	B

Simultaneously,	O
compounds	O
with	O
acidic	O
groups	O
may	O
interact	O
with	O
the	O
amino-sorbent.	B

Threonine;	B
31.	O

In	O
the	O
case	O
of	O
creatinine,	B
a	O
gender	O
imbalance	O
in	O
the	O
two	O
patient	O
cohorts	O
may	O
be	O
reducing	O
its	O
significance	O
(vide	O
infra	O
).	O

The	O
metabolites	O
holding	O
differential	O
power	O
primarily	O
belonged	O
to	O
a	O
range	O
of	O
amino	O
acids,	O
microbiota-related	O
short	O
chain	O
fatty	O
acids,	O
and	O
lactate	B
suggestive	O
of	O
an	O
inflammation-driven	O
malabsorption	O
and	O
dysbiosis	O
of	O
the	O
normal	O
bacterial	O
ecology.	O

Lactate,	B
was	O
measured	O
together	O
with	O
glucose,	B
as	O
the	O
most	O
abundant	O
among	O
the	O
quantified	O
metabolites	O
(1453 ± 109.4 μM	O
in	O
arterial	O
and	O
1728 ±	O

Within	O
the	O
ERF	O
population,	O
we	O
found	O
that	O
BMI	O
correlated	O
positively	O
with	O
carnitine	B
(r = 0.136,	O
P-value	O
 = 4.40×10_−11	O
),	O
proline	B
(r = 0.123,	O
P-value	O
 = 2.80×10_−9	O
),	O
pyruvate	B
(r = 0.240,	O
P-value	O
 = 5.40×10_−32	O
),	O
lysine	B
(r = 0.132,	O
P-value	O
 = 1.45×10_−10	O
),	O
and	O
valine	B
(r = 0.383,	O
P-value	O
 = 2.05×10_−82	O
),	O
whereas	O
BMI	O
correlated	O
negatively	O
with	O
glycine	B
(r = −0.178,	O
P-value	O
 = 4.19×10_−18	O
).	O

We	O
also	O
witnessed	O
significant	O
elevation	O
of	O
purine	B
and	O
pyrimidine	B
metabolites	O
in	O
HCC	O
vs.	O
DCs.	O

20-HETE	B
activation	O
of	O
small-GTPase	O
Ras	O
is	O
consistent	O
with	O
previous	O
findings	O
by	O
others	O
that	O
20-HETE	B
can	O
act	O
as	O
a	O
second	O
messenger	O
in	O
the	O
mitogenic	O
actions	O
of	O
some	O
growth	O
factors	O
and	O
activate	O
the	O
ERK	O
and	O
PI3K-Akt	O
cascades.	O

A	O
targeted	O
quantification	O
UPLC–MS/MS	O
method	O
for	O
seven	O
amino	B
compounds	O
in	O
plasma,	O
including	O
L-carnitine,	B
choline,	B
and	O
trimethylamine-N-oxide	B
(TMAO)	O
was	O
established	O
using	O
an	O
Acquity	O
UPLC	O
H-Class	O
system	O
coupled	O
to	O
a	O
Xevo	O
TQD	O
triple	O
quadrupole	O
MS	O
(both	O
from	O
Waters,	O
Eschborn,	O
Germany).	O

Panels	O
A	O
and	O
B	O
show	O
the	O
hormonal	O
fluctuations	O
of	O
pregnancy,	O
in	O
order	O
to	O
define	O
the	O
distribution	O
of	O
data	O
in	O
each	O
trimester	O
of	O
pregnancy	O
and	O
in	O
the	O
post-partum	O
period:	O
with	O
the	O
exception	O
for	O
CORT	O
and	O
ADIONE	B
in	O
T3,	O
a	O
gradual	O
increase	O
in	O
each	O
trimester	O
of	O
pregnancy	O
was	O
observed	O
for	O
all	O
the	O
steroids	O
and	O
estrogens	O
we	O
monitored,	O
while	O
an	O
important	O
decrease	O
was	O
revealed	O
in	O
the	O
post-partum	O
period,	O
as	O
highlighted	O
by	O
the	O
significance	O
of	O
the	O
post	O
hoc	O
test	O
between	O
T3	O
and	O
post-partum.	O

High	O
performance	O
liquid	O
chromatography	O
(HPLC)-grade	O
methanol,	B
ethanol,	B
hexane	B
and	O
2-propanol	B
were	O
purchased	O
from	O
Burdick	O
&	O
Jackson	O
(Ulsan,	O
Korea).	O

Some	O
metabolites	O
could	O
not	O
be	O
analyzed	O
reliably	O
enough	O
due	O
to	O
sample	O
irregularities	O
(mainly	O
related	O
to	O
low	O
protein	O
content,	O
polysaccharides,	B
and	O
abnormal	O
macromolecule	O
A)	O
or	O
they	O
were	O
rejected	O
by	O
the	O
automatic	O
sample	O
and	O
measurement	O
quality	O
control	O
(Table	O
S1).	O

High	O
levels	O
of	O
tryptophan	B
have	O
also	O
been	O
shown	O
in	O
urine	O
from	O
ADHD	O
children	O
along	O
with	O
low	O
HAA/HK	O
ratios	O
which	O
made	O
the	O
authors	O
suggest	O
that	O
this	O
was	O
due	O
to	O
a	O
low	O
activity	O
of	O
B6-dependent	O
enzymes.	O

As	O
for	O
the	O
de	O
novo	O
pathway,	O
the	O
levels	O
of	O
all	O
dihydroceramide	B
species,	O
which	O
serve	O
as	O
the	O
precursor	O
of	O
ceramide	B
in	O
the	O
de	O
novo	O
pathway,	O
were	O
significantly	O
higher	O
in	O
cancer	O
tissue	O
than	O
that	O
in	O
peri-tumor	O
or	O
normal	O
breast	O
tissue	O
(Figure	O
).	O

These	O
abnormalities	O
are	O
related	O
to	O
several	O
defects	O
in	O
insulin-signaling	O
mechanisms	O
and	O
several	O
steps	O
in	O
regulating	O
glucose	B
metabolism	O
(transport	O
and	O
key	O
enzymes	O
of	O
glycogen	B
synthesis	O
or	O
mitochondrial	O
oxidation).	O

Extraction	O
efficiency,	O
matrix	O
effect,	O
and	O
process	O
efficiency	O
for	O
buprenorphine,	B
norbuprenorphine,	B
and	O
conjugated	O
metabolites	O
in	O
urine	O
by	O
LCMSMS	O
%RSD	O
is	O
given	O
in	O
parentheses	O
.	O

Patients	O
were	O
classified	O
as	O
suffering	O
from	O
overt	O
Cushing’s	O
syndrome	O
if	O
they	O
had	O
at	O
least	O
3	O
abnormal	O
biochemical	O
test	O
results	O
indicative	O
of	O
Cushing’s,	O
in	O
addition	O
to	O
insufficiently	O
suppressed	O
serum	O
cortisol	B
levels	O
(>5	O
μg/dl	O

Elevation	O
of	O
hypoxanthine	B
has	O
also	O
been	O
reported	O
during	O
septic	O
shock	O
and	O
may	O
reflect	O
early	O
high	O
energy	O
nucleotide	O
failure	O
.	O

_,	O
We	O
can	O
hypothesize	O
that	O
the	O
onset	O
of	O
metabolic	O
ketosis	O
may	O
influence	O
the	O
patient	O
prognosis	O
but	O
whether	O
the	O
increase	O
of	O
ketone	B
bodies	O
is	O
an	O
adaptive	O
response	O
necessary	O
for	O
supporting	O
cell	O
metabolism	O
or	O
it	O
is	O
a	O
trigger	O
for	O
disease	O
progression	O
has	O
to	O
be	O
ascertained.	O

1,25-(OH)_2	B
D	O
may	O
be	O
circulating	O
at	O
levels	O
as	O
low	O
as	O
0.2 pg/mL.	O
Thus,	O
analyte	O
enrichment	O
would	O
be	O
required,	O
which	O
is	O
easily	O
incorporated	O
into	O
the	O
developed	O
sample	O
preparation	O
protocol.	O

Thus,	O
the	O
MeOH	B
curve	O
proved	O
precise	O
and	O
accurate	O
in	O
quantifying	O
the	O
analytes	O
in	O
the	O
matrix	O
studied.	O

In	O
addition,	O
we	O
bought	O
BSTFA	O
(including	O
1%	O
TMCS,	O
v/v)	O
from	O
REGIS	O
Technologies	O
Inc	O
(Morton	O
Grove,	O
IL,	O
USA)	O
and	O
methanol	B
(HPLC	O
grade)	O
from	O
ANPEL	O
Laboratory	O
Technologies	O
Inc	O
(Shanghai,	O
China).	O

Prior	O
to	O
analysis	O
the	O
samples	O
were	O
re-dissolved	O
with	O
sonication	O
in	O
10	O
µL	O
of	O
methanol	B
and	O
then	O
40	O
µL	O
of	O
15	O
mM	O
ammonium	B
acetate	I
was	O
added.	O

Impaired	O
metabolism	O
of	O
cholesterol,	B
phospholipids,	B
bilirubin	B
and	O
bile	O
acids	O
is	O
known	O
to	O
be	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
gallstone	O
disease.	O

Tryptophan	B
and	O
the	O
seven	O
kynurenines,	O
kynurenine,	B
kynurenic	B
acid	I
(KA),	O
anthranilic	B
acid	I
(AA),	O
xanthurenic	B
acid	I
(XA),	O
3-hydroxykynurenine	B
(HK),	O
3-hydroxyanthranilic	B
acid	I
(HAA)	O
and	O
quinolinic	B
acid	I
(QA),	O
as	O
well	O
as	O
riboflavin	B
(vitamin	O
B2),	O
B6	O
vitamers	O
pyridoxal	B
(PL)	O
and	O
pyridoxal-5′-phosphate	B
(PLP),	O
and	O
the	O
nicotine	B
metabolite	O
cotinine,	B
were	O
measured	O
using	O
stable	O
isotope	O
dilution	O
liquid	O
chromatography-tandem	O
mass	O
spectrometry,	O
as	O
described.	O

-butyldimethylsilyl-N	B
-methyltrifluoroacetamide	I
(MTBSTFA)	O
for	O
analyte	O
derivatization.	O

Finally,	O
we	O
used	O
CKD-EPI	O
cystatin	B
equations	O
as	O
alternative	O
reference	O
equations.	O

Moreover,	O
the	O
microbiome	O
could	O
be	O
impacted	O
by	O
cannabis	B
use	O
and	O
the	O
different	O
routes	O
by	O
which	O
it	O
is	O
taken,	O
which	O
may	O
also	O
contribute	O
to	O
alterations	O
in	O
levels	O
of	O
inflammation.	O

U_13	O
C-Glutamate,	B
U_13	O
C-glucose,	B
and	O
U_13	O
C-glutamine	B
were	O
purchased	O
from	O
CIL	O
Inc.,	O
Tewksbury,	O
MA,	O
USA.	O

Elevated	O
glycine	B
levels	O
in	O
CSF	O
have	O
previously	O
been	O
observed	O
in	O
multiple	O
sclerosis	O
patients,	O
possibly	O
due	O
to	O
oxidative	O
stress	O
(Ďurfinová	O
et	O
al.	O
;	O

Finally,	O
we	O
conducted	O
PLS-DA	O
analysis	O
on	O
the	O
targeted	O
metabolite	O
data	O
set,	O
omitting	O
all	O
postprandial	O
subjects	O
from	O
the	O
high–cystathionine	B
concentration	O
group.	O

Venous	O
blood	O
samples	O
were	O
collected	O
for	O
population	O
pharmacokinetic	O
(PK)	O
modeling	O
from	O
all	O
patients	O
in	O
the	O
aripiprazole,	B
olanzapine,	B
and	O
quetiapine	B
cohorts	O
at	O
8	O
scheduled	O
times	O
within	O
the	O
dosing	O
interval.	O

Changes	O
in	O
the	O
branched	O
chain	O
amino	O
acids	O
leucine	O
and	O
isoleucine,	B
and	O
UDP-GlcNAc	B
were	O
inversely	O
associated	O
with	O
changes	O
in	O
CRF	O
(ml/kg/min),	O
whereas	O
change	O
in	O
the	O
TCA	O
cycle	O
intermediate,	O
isocitric	B
acid,	I
was	O
positively	O
correlated.	O

VLDL5-free	O
cholesterol,	B
VLDL5-cholesterol,	B
VLDL5-phospholipids,	B
and	O
VLDL4-free	O
cholesterol	B
showed	O
a	O
significant	O
(p	O
 < 0.05)	O
negative	O
correlation	O
with	O
concurrent	O
Phe	O
level.	O

The	O
doublet	O
pattern	O
of	O
the	O
γ-	B
(C-4)	I
and	O
α-	B
(C-2)	I
carbons	O
of	O
Glu	O
suggests	O
the	O
presence	O
of	O
_13	O
C-4,5-Glu	B
and/or	O
_13	O
C-3,4-Glu	B
as	O
well	O
as	O
_13	O
C-1,2-Glu	B
and/or	O
_13	O
C-2,3-Glu	B
isotopomers,	O
respectively.	O

Tarim	O
et	O
al.	O
reported	O
triacylglycerols	B
were	O
higher	O
in	O
women	O
with	O
GDM.	O

In	O
terms	O
of	O
amino	O
acid	O
metabolism,	O
GM	O
(including	O
pyroglutamic	B
acid	I
and	O
glycine)	B
and	O
GSTM	O
(including	O
glycine)	B
increased	O
in	O
SA	O
groups.	O

Arginine	B
is	O
an	O
amino	O
acid	O
of	O
the	O
urea	B
cycle	O
and	O
was	O
inversely	O
associated	O
with	O
hsCRP	O
in	O
the	O
present	O
study.	O

The	O
supernatant	O
after	O
centrifugation	O
was	O
analyzed	O
by	O
injection	O
onto	O
a	O
silica	B
column	O
interfaced	O
with	O
an	O
API	O
4000	O
Q-TRAP	O
mass	O
spectrometer	O
(AB	O
SCIEX,	O
Framingham,	O
MA,	O
USA).	O

Perfusion	O
of	O
the	O
catheters	O
was	O
performed	O
using	O
artificial	O
CSF	O
(Perfusion	O
Fluid	O
CNS,	O
M	O
Dialysis	O
AB),	O
containing	O
NaCl	O
147	O
mM,	O
CaCl_2	O
1.7	O
mM,	O
KCl	O
2.7	O
mM,	O
MgCl	O
0.85	O
mM,	O
total	O
chloride	B
contents	O
153.8	O
mM,	O
osmolarity	O
305	O
mOsm/kg),	O
delivered	O
at	O
a	O
rate	O
of	O
0.3	O
µL/min	O
by	O
using	O
a	O
microdialysis	O
pump	O
(106	O
MD	O
Pump,	O
M	O
Dialysis	O
AB).	O

Intriguingly,	O
Hanse	O
et	O
al.	O
used	O
[4-_2	B
H]-glucose	I
to	O
label	O
cytosolic	O
NADH	B
and	O
demonstrated	O
that	O
malate	O
dehydrogenase	O
1	O
(MDH1)	O
regenerates	O
NAD_+	O
to	O
sustain	O
glycolysis	O
in	O
the	O
presence	O
of	O
biosynthetic	O
diversion	O
of	O
glycolytic	B
intermediates	O
upstream	O
of	O
lactate.	B

While	O
acetate,	B
2-hydroxybutyrate,	B
pimelyl	B
carnitine,	I
and	O
phosphatidyl	B
choline	I
diacyl	I
C40:4	I
were	O
used	O
for	O
the	O
combined	O
metabolites	O
and	O
NT-proBNP	O
panel.	O

MeOH	B
ppt	O
+UF	O
offers	O
both	O
good	O
recovery	O
and	O
consistent	O
measurement	O
of	O
metabolites	O
in	O
serum,	O
particularly	O
when	O
NMR	O
spectra	O
are	O
obtained	O
with	O
a	O
500	O
MHz	O
magnet	O
and	O
fewer	O
scans	O
than	O
suggested	O
by	O
some	O
protocols	O
[,].	O

-streptomycin	B
(Sigma	O
Aldrich,	O
UK)	O
at	O
5%	O
CO_2	O
and	O
37 °C.	O

Isopropanol	B
was	O
present	O
at	O
higher	O
concentration	O
in	O
UF	O
samples	O
than	O
in	O
MeOH	B
ppt	O
+UF	O
or	O
MeOH:CHCl_3	B
:water	O
ext	O
+UF	O
serum	O
because	O
it	O
was	O
partially	O
removed	O
during	O
lyophilization	O
in	O
precipitated	O
and	O
extracted	O
samples,	O
while	O
UF	O
samples	O
were	O
not	O
lyophilized.	O

The	O
analysis	O
distinguished	O
between	O
patients	O
with	O
or	O
without	O
carotid	O
atheroma	O
plaque	O
with	O
an	O
accuracy	O
of	O
60%	O
and	O
revealed	O
plasma	O
20-HETE	B
as	O
the	O
primary	O
differentiator	O
in	O
a	O
list	O
of	O
metabolites	O
ranked	O
in	O
order	O
of	O
importance	O
in	O
the	O
classification	O
scheme.	O

The	O
advantage	O
of	O
analyzing	O
adducts	O
at	O
the	O
deoxynucleoside	O
level	O
is	O
that	O
the	O
near	O
universal	O
loss	O
of	O
the	O
deoxyribose	B
(dR)	O
moiety	O
([M+H]_+	O
>	O
[M+H-116]_+	O
)	O
upon	O
MS_2	O
fragmentation	O
can	O
be	O
monitored	O
for	O
targeted	O
adduct	O
analysis	O
or	O
non-targeted	O
screening	O
in	O
DNA	O
adductomics	O
(;	O
).	O

Furan	B
is	O
toxic	O
and	O
carcinogenic	O
in	O
laboratory	O
animals.	O

Thiacloprid	B
was	O
detected	O
in	O
ASG	O
(6.3%,	O
0.1	O
ppb).	O

On	O
the	O
other	O
hand,	O
an	O
increased	O
excretion	O
of	O
terpenes	B
in	O
the	O
urine	O
could	O
be	O
detected	O
in	O
the	O
control	O
group,	O
although	O
this	O
relationship	O
is	O
not	O
significant.	O

To	O
1.0	O
mL	O
of	O
the	O
urine	O
sample	O
in	O
the	O
glass	O
vials,	O
400	O
μL	O
of	O
concentrated	O
hydrochloric	B
acid	I
was	O
added.	O

Through	O
analysis,	O
five	O
serum	O
metabolites	O
[threonine	O
(VIP	O
predicted	O
values:	O
1.04),	O
arginine	B
(VIP	O
predicted	O
values:	O
1.47),	O
glutamate	B
(VIP	O
predicted	O
values:	O
1.89),	O
proline	B
(VIP	O
predicted	O
values:	O
1.97),	O
and	O
leucine-isoleucine	B
(VIP	O
predicted	O
values:	O
2.46)]	O
were	O
screened	O
out,	O
which	O
were	O
closely	O
related	O
to	O
the	O
recovery	O
level	O
of	O
stroke	O
(VIP	O
>	O
1).	O

To	O
examine	O
the	O
distributions	O
of	O
SG-corrected	O
urinary	O
phthalate	B
metabolite	O
and	O
isoprostane	B
concentrations,	O
geometric	O
means	O
and	O
selected	O
percentiles	O
were	O
calculated.	O

Cannabinoids,	B
JWH-018,	O
JWH-073,	O
synthetic	O
cannabinoids,	B
aminoalkylindole	B
metabolism	O

TRP	O
and	O
its	O
metabolites	O
such	O
as	O
serotonin	B
(5-hydroxytryptophan	I
[5-HT]),	I
melatonin,	B
and	O
kynurenine	B
(KYN)	O
have	O
multiple	O
effects	O
impacting	O
pain	O
perception,	O
mood,	O
gut	O
motility,	O
and	O
sleep/arousal	O
(;	O
).	O

The	O
sample	O
was	O
then	O
reconstituted	O
in	O
100	O
μl	O
of	O
5%	O
water	O
in	O
acetonitrile,	B
mixed	O
by	O
pipetting	O
twice,	O
and	O
transferred	O
to	O
a	O
150	O
μl	O
96-well	O
PCR	O
plate	O
and	O
sealed.	O

During	O
endoscopy,	O
antral	O
biopsies	O
for	O
histology	O
and	O
for	O
rapid	O
urease	O
test	O
(JATROX	O
HP	B
test	O
CHR	O
Heim	O
Arzneimittel	O
GmbH,	O
Germany)	O
were	O
obtained.	O

The	O
pathway	O
analysis	O
also	O
revealed	O
the	O
significance	O
of	O
the	O
purine	B
metabolic	O
pathway,	O
which	O
plays	O
an	O
important	O
role	O
in	O
providing	O
cellular	O
energy,	O
and	O
indicates	O
cancer	O
cell	O
survival	O
and	O
proliferation	O
(,).	O

Incubation	O
using	O
100	O
μ	O
mol/L	O
morphine	B
for	O
15	O
or	O
35	O
min	O
gave	O
1.7	O
times	O
increase	O
in	O
M3S	O
formation	O
(P	O
<	O
0.05).	O

Secondly,	O
metabolite	O
profiling	O
revealed	O
that	O
glucose	B
was	O
greater	O
in	O
OB/D	O
subjects	O
compared	O
to	O
OB	O
subjects	O
at	O
all	O
three	O
time	O
points	O
(p<0.05).	O

The	O
same	O
process	O
may	O
normally	O
allow	O
recovery	O
of	O
methionine	B
from	O
N-formyl-L-methionine	B
which	O
is	O
an	O
initiating	O
residue	O
in	O
mitochondrial	O
protein	O
synthesis.	O

In	O
contrast,	O
the	O
cross-peaks	O
of	O
glutamate	B
and	O
the	O
glutamyl	O
moiety	O
of	O
glutathione	B
(GSH)	O
displayed	O
more	O
complex	O
patterns,	O
that	O
correspond	O
to	O
a	O
mixture	O
of	O
four	O
isotopomers	O
comprising	O
the	O
fragments	O
_12	O
C3_12	O
C4,	O
_13	O
C3_13	O
C4	O
(Glu-H3/4_sat	O
),	O
_12	O
C3_13	O
C4	O
(Glu-H4_sat	O
),	O
and	O
_13	O
C3_12	O
C4	O
(Glu-H3_sat	O
).	O

A	O
flowchart	O
representing	O
possible	O
dynamics	O
of	O
metabolites	O
describing	O
results	O
and	O
implications	O
of	O
elevated	O
blood	O
pressure	O
(green	O
colour	O
represents	O
decreased	O
concentrations	O
and	O
red	O
colour	O
represents	O
elevated	O
concentration	O
in	O
EH	O
milieu;	O
DDAH;	O
dimethylarginine	O
dimethylamino-hydrolase,	O
ADMA;	B
asymmetrical	O
dimethyl	B
arginine,	I
NO;	O
Nitric	B
oxide,	I
NOS;	O
NO	O
synthase,	O
PRMT;	O
protein	O
methyltransferase,	O
ROS;	O
reactive	O
oxygen	O
species,	O
SAM;	O
S-adenosylmethionine,	B
SAH;	O
S-adenosylhomocysteine).	O

CID,	O
collision-induced	O
dissociation;	O
cps,	O
counts	O
per	O
second;	O
E1,	O
estrone;	B
OHE1/2,	O
hydroxyestr-one/adiol;	O
MeOE1/2,	O
methoxyestr-one/adiol;	O
ESI,	O
electrospray	O
ionization;	O
FA,	B
formic	B
acid;	I
IS,	O
internal	O
standards;	O
LC-MS,	O
liquid	O
chromatography-mass	O
spectrometry;	O
LC-MS/MS,	O
liquid	O
chromatography	O
tandem	O
mass	O
spectrometry;	O
LODs,	O
limits	O
of	O
detection;	O
LLOQ/ULOQs,	O
lower/upper	O
limits	O
of	O
quantitation;	O
PPZ,	O
1-(5-fluoro-2,4-dinitrophenyl)-4-methylpiperazine;	B
MPPZ,	O
methyl-PPZ-;	B
MRM,	O
multiple	O
reaction	O
monitoring;	O
PAH,	O
pulmonary	O
arterial	O
hypertension;	O
RME,	O
relative	O
mean	O
error;	O
RSD,	O
relative	O
standard	O
deviation;	O
SD,	O
standard	O
deviation;	O
SNR,	O
signal/noise;	O

Methanol	B
LiChroSolv,	O
hypergrade,	O
purchased	O
from	O
Merck/VWR	O
(Darmstadt,	O
Germany)	O
was	O
used	O
for	O
liquid	O
chromatography.	O

Moreover,	O
we	O
also	O
observed	O
the	O
accumulation	O
of	O
kynurenine	B
(Kyn),	O
which	O
is	O
a	O
product	O
of	O
tryptophan	B
catabolism	O
(Aune	O
and	O
Pogue	O
)	O
and	O
regulator	O
of	O
the	O
PPP	O
(Fabregat	O
et	O
al.	O
).	O

Highlighted	O
candidate	O
markers	O
are:	O
1)	O
Acetate,	B
2)	O

These	O
observational	O
data	O
in	O
humans	O
are	O
consistent	O
with	O
recent	O
feeding	O
studies	O
in	O
rats,	O
showing	O
that	O
adding	O
hexadecanedioate	B
to	O
the	O
diet	O
increased	O
blood	O
pressure	O
levels.	O

The	O
upper	O
aqueous	O
phase	O
was	O
transferred	O
into	O
a	O
clean	O
polypropylene	B
tube	O
and	O
re-extracted	O
by	O
addition	O
of	O
200	O
μl	O
MTBE	B
as	O
described	O
above.	O

Samples	O
were	O
collected	O
by	O
a	O
registered	O
medical	O
technician	O
using	O
a	O
plasma-collecting	O
tube	O
with	O
heparin	B
as	O
the	O
anticoagulant	O
in	O
Qilu	O
Hospital	O
of	O
Shandong	O
University.	O

Glycerol	B
is	O
the	O
backbone	O
of	O
triglyceride	B
molecules,	O
and	O
its	O
fasting	O
blood	O
levels	O
are	O
strongly	O
influenced	O
by	O
adipose	O
tissue	O
lipolysis	O
[,	O
].	O

Twenty-four	O
hours	O
after	O
admission	O
in	O
the	O
ICU,	O
the	O
urinary	O
catheter	O
was	O
blocked	O
to	O
collect	O
the	O
second	O
urine	O
sample	O
(Urine-24h).	O

We	O
used	O
a	O
selective	O
analytic	O
platform	O
to	O
assay	O
levels	O
of	O
sterol	O
metabolites	O
in	O
plasma	O
of	O
participants	O
in	O
a	O
trial	O
of	O
simvastatin	B
treatment	O
in	O
order	O
to	O
identify	O
biomarkers	O
that	O
correlate	O
with	O
statin	B
lipid-modifying	O
efficacy.	O

Muscle	O
glucose	B
uptake	O
(GU)	O
was	O
measured	O
directly	O
using	O
[_18	O
F]FDG-PET.	O

Tae-Eum	O
type	O
showed	O
higher	O
lactate	B
levels	O
in	O
serum	O
than	O
So-Yang	O
type	O
for	O
similar	O
BMI	O
groups,	O
suggesting	O
that	O
the	O
levels	O
of	O
serum	O
lactate	B
might	O
be	O
dependent	O
on	O
the	O
SC	O
type	O
regardless	O
of	O
BMI.	O

Lines	O
indicate	O
median	O
concentrations	O
of	O
sofosbuvir	B
(70.3	O
μM;	O
range,	O
0.382	O
to	O
252	O
μM)	O
and	O
ribavirin	B
(329	O
μM;	O
range,	O
10.1	O
to	O
1,800	O
μM)	O
in	O
the	O
30	O
patients.	O

Indeed,	O
lactate	B
might	O
be	O
a	O
predictive	O
marker	O
for	O
assessing	O
the	O
response	O
of	O
tumor	O
cells	O
to	O
neoadjuvant	O
chemotherapy.	O

200	O
μl	O
of	O
2-chloro-phenylalanine	B
(0.3	O
g/L)	O
served	O
as	O
internal	O
standard.	O

At	O
inclusion,	O
cases	O
with	O
type	O
2	O
diabetes	O
were	O
matched	O
with	O
normoglycemic	B
controls	O
on	O
age	O
and	O
BMI.	O

On	O
the	O
contrary,	O
C5:1,	B
Phe/Tyr,	O
(C0	B
+	I
C2	I
+	I
C3	I
+	I
C16	I
+	I
C18:1)/Cit,	I
and	O
Met/Leu	O
were	O
of	O
lower	O
levels	O
in	O
the	O
CI	O
group	O
(Fig.	O
).	O

Serum	O
of	O
the	O
EG	O
patients	O
had	O
higher	O
levels	O
of	O
creatine/phosphocreatine	O
than	O
in	O
the	O
reference	O
subjects	O
but	O
the	O
differences	O
in	O
the	O
creatinine	B
levels	O
were	O
out	O
of	O
detection.	O

Also	O
levels	O
of	O
the	O
BCAAs	O
containing	O
valine	B
and	O
isoleucine	B
declined	O
sharply,	O
suggesting	O
their	O
consumption	O
in	O
large	O
quantities	O
for	O
energy	O
supply,	O
meanwhile	O
isoleucine	B
deficiency	O
is	O
marked	O
by	O
muscle	O
tremors.	O

The	O
odds	O
ratio	O
for	O
progression	O
to	O
ESRD	O
for	O
a	O
one	O
standard	O
deviation	O
increase	O
in	O
the	O
plasma	O
concentration	O
of	O
leucine	B
was	O
0.5	O
(95%	O
CI;	O
0.3,	O
0.8)	O
and	O
odds	O
ratios	O
for	O
the	O
remaining	O
5	O
amino	O
acids	O
were	O
similar	O
.	O

Hypoxanthine	B
and	O
xanthine	B
are	O
the	O
precursors	O
of	O
uric	B
acid	I
and	O
uric	B
acid	I
was	O
also	O
elevated	O
in	O
the	O
plasma	O
of	O
pneumonia	O
patients,	O
although	O
not	O
statistically	O
significant.	O

Similarly,	O
reported	O
that	O
24–48	O
hours	O
of	O
exposure	O
to	O
selective	O
serotonin	B
reuptake	O
inhibitors	O
or	O
tricyclic	B
antidepressant	O
medications	O
stimulated	O
the	O
de	O
novo	O
synthesis	O
of	O
KynA	O
and	O
decreased	O
3HK	O
production	O
in	O
astroglial	O
cultures,	O
thus	O
resulting	O
in	O
an	O
increase	O
in	O
the	O
KynA	O
to	O
3HK	O
ratio.	O

In	O
the	O
present	O
study,	O
decreasing	O
isoleucine	B
levels	O
were	O
not	O
matched	O
by	O
changes	O
in	O
the	O
levels	O
of	O
leucine	B
or	O
valine	B
to	O
the	O
same	O
extent,	O
as	O
these	O
amino	O
acids	O
did	O
not	O
meet	O
the	O
model	O
criteria.	O

There	O
were	O
significant	O
correlations	O
between	O
proteinuria	O
and	O
urinary	O
excretion	O
of	O
12	O
AAs	O
(ρ=0.74–0.29	O
for	O
proline,	B
citrulline,	B
asparagine,	B
valine,	B
alanine,	B
threonine,	B
lysine,	B
phenylalanine,	B
methionine,	B
serine,	B
tyrosine,	B
and	O
tryptophan;	B
P	O
<0.05).	O

Hecogenin	O
at	O
5	O
µm	O
inhibited	O
anastrozole	B
glucuronidation	O
activity	O
by	O
38.4%	O
in	O
pooled	O
HLMs	O
(P	O
<	O
0.01)	O
and	O
62.2%	O
in	O
expressed	O
UGT1A4	O
(P	O
<	O
0.01).	O

Univariate	O
tests	O
showed	O
a	O
highly	O
significant	O
increase	O
in	O
total	O
plasma	O
triglycerides,	B
as	O
well	O
as	O
lipids	O
and	O
apolipoproteins	O
associated	O
with	O
VLDL,	O
IDL	O
and	O
LDL	O
4–6	O
after	O
6	O
months	O
(Supplementary	O
Table 2).	O

Moreover,	O
previous	O
studies	O
in	O
E.	O
coli	O
revealed	O
copper	O
overload	O
inactivated	O
ISC	O
enzymes	O
such	O
as	O
isopropyl	B
malate	I
dehydratase,	O
fumarase	O
A,	O
and	O
6-phospho-gluconate	B
dehydratase.	O

Furthermore,	O
we	O
adjusted	O
for	O
cystatin	B
C	O
concentrations	O
and	O
found	O
that	O
IDO-TM,	O
but	O
not	O
other	O
TMs	O
such	O
as	O
indoxysulfate,	B
remained	O
strongly	O
predictive	O
of	O
pulmonary	O
hemodynamic	O
measurements.	O

Briefly,	O
150	O
mg	O
of	O
the	O
epoxide	B
was	O
dissolved	O
in	O
200	O
μL	O
THF	O
and	O
added	O
to	O
a	O
solution	O
of	O
32	O
mg	O
of	O
KOH	O
and	O
59	O
mg	O
of	O
NAC	O
in	O
200	O
μL	O
of	O
MeOH	B
kept	O
at	O
0	O
°C.	O

X-axis	O
indicates	O
the	O
mean	O
uric	B
acid	I
concentrations	O
(μmol/L)	O
of	O
capillary	O
electrophoresis-mass	O
spectrometry	O
(CE-MS)	O
and	O
clinical	O
assay,	O
and	O
Y-axis	O
indicates	O
percentage	O
of	O
differences	O
between	O
these	O
two	O
methods.	O
and	O
show	O
results	O
by	O
sex	O
and	O
age.	O

Muscle	O
linolenate	B
CoA	O
[18:3;	O
from	O
0.40	O
±	O
0.04	O
to	O
0.36	O
±	O
0.12	O
nmol/g;	O
P	O
=	O
not	O
significant	O
(NS)]	O
did	O
not	O
decrease	O
after	O
pioglitazone	B
treatment.	O

Gluconolactone	B
and	O
threonic	B
acid	I
are	O
metabolites	O
produced	O
by	O
the	O
PPP	O
from	O
glucose	B
and	O
xylitol,	B
respectively.	O

Notwithstanding	O
that	O
both	O
PET	O
parameters	O
correlate	O
most	O
strongly	O
with	O
threonine	B
as	O
shown	O
in	O
Table ,	O
the	O
correlation	O
remains	O
modest.	O

However,	O
the	O
high	O
dose	O
of	O
vitamin	O
B-12	O
might	O
have	O
also	O
limited	O
the	O
availability	O
of	O
homocysteine	B
for	O
cystathione	B
B	O
synthase	O
by	O
stimulating	O
catalytic	O
conversion	O
of	O
homocysteine	B
to	O
methionine	B
by	O
methionine	B
synthase.	O

S1P	O
and	O
sphingosine	B
in	O
both	O
serum	O
and	O
urine	O
samples	O
were	O
quantified	O
using	O
the	O
Mass	O
Hunter	O
Quantitative	O
Analysis	O
B.07.00	O
system	O
(Agilent	O
Technologies,	O
Santa	O
Clara,	O
CA,	O
USA).	O

NADPH	B
is	O
utilized	O
by	O
both	O
the	O
glutathione	B
and	O
thioredoxin	B
systems	O
in	O
the	O
parasite	O
to	O
deal	O
with	O
oxidative	O
stress	O
.	O

Intake	O
of	O
ascorbic	B
acid	I
has	O
been	O
disputed	O
as	O
protective	O
against	O
CRC,_,	O
and	O
very	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
diketogulonic	O
acid	O
in	O
CRC.	O

Therefore,	O
the	O
low	O
average	O
intake	O
of	O
foods	O
rich	O
in	O
choline	B
and	O
l-carnitine	B
among	O
our	O
participants	O
may	O
be	O
the	O
leading	O
cause	O
of	O
lower	O
plasma	O
TMAO	B
in	O
our	O
study.	O

The	O
combination	O
of	O
tissue	O
and	O
mitochondrial	O
pathways	O
contributing	O
to	O
an	O
increase	O
in	O
the	O
level	O
of	O
succinic	B
acid	I
in	O
the	O
blood	O
of	O
septic	O
patients.	O

Interestingly,	O
we	O
found	O
similar	O
decreased	O
concentrations	O
of	O
hypoxanthine	B
and	O
xanthine	B
in	O
the	O
plasma	O
of	O
patients	O
with	O
Dominant	O
Optic	O
Atrophy	O
related	O
to	O
OPA1	O
mutations.	O

Buprenorphine	B
has	O
extremely	O
long	O
half	O
life	O
therefore	O
it	O
can	O
be	O
administered	O
once	O
every	O
2-3	O
days.	O

GDM,	O
gestational	O
diabetes	O
mellitus;	O
TMAO,	B
trimethylamine-N	B
-oxide.	I

Our	O
laboratory’s	O
previous	O
urine	O
method	O
was	O
updated	O
with	O
four	O
new	O
cannabinoids	B
and	O
metabolites,	O
simplified	O
sample	O
preparation	O
and	O
a	O
shorter	O
run	O
time.	O

For	O
two	O
metabolites,	O
nicotine	B
and	O
cotinine,	B
we	O
used	O
reported	O
smoking	O
status	O
of	O
the	O
participants	O
from	O
the	O
metadata	O
to	O
obtain	O
strong	O
correlation	O
and	O
regression	O
parameters	O
(Table	O
1)	O
only	O
for	O
the	O
samples	O
collected	O
from	O
the	O
smokers	O
(Figure	O
S-5A,B).	O

Through	O
the	O
Dean’s	O
switch,	O
the	O
flow	O
was	O
either	O
directed	O
to	O
the	O
mass	O
spectrometer	O
(uncoated	O
fused	O
silica	B
capillary,	O
1.8	O
m,	O
0.180	O
mm)	O
or	O
to	O
waste	O
(uncoated	O
fused	O
silica	B
capillary,	O
1.3	O
m,	O
0.180	O
mm).	O

In	O
principle,	O
either	O
mechanism	O
could	O
result	O
in	O
a	O
positive	O
correlation	O
between	O
lactate	B
and	O
tCr.	O

Cholesterol	B
can	O
be	O
transformed	O
to	O
adrenocortical	O
hormone,	O
such	O
as	O
corticosterone.	B

We	O
also	O
developed	O
a	O
similar	O
assay	O
using	O
glucose-6-phosphate,	B
which	O
we	O
anticipated	O
would	O
bypass	O
the	O
enzyme	O
defect	O
in	O
phosphoglucomutase	O
1	O
deficiency.	O

BRB	O
rinses	O
provided	O
higher	O
salivary	O
levels	O
of	O
both	O
total	O
BRB	O
anthocyanins	B
as	O
well	O
as	O
the	O
predominant	O
anthocyanin	B
(cyanidin-3	I
rutinoside)	I
relative	O
to	O
topical	O
gel	O
application.	O

This	O
study	O
provides	O
a	O
comprehensive	O
metabolic	O
endotypes	O
(lysine,	O
arginine,	B
tyrosine,	B
threonine	B
and	O
branched	O
chain	O
amino	O
acids	O
proline,	O
glutamate,	B
phenylalanine	B
and	O
valine)	B
associated	O
with	O
ARDS	O
subtype,	O
complementing	O
clinical	O
score	O
and	O
significant	O
predictability	O
in	O
outcome.	O

BMI	O
Body	O
mass	O
index,	O
ER:Estrogen	O
receptors,	O
PgR:	O
progesterone	B
receptors.	O

Dysregulation	O
of	O
the	O
kynurenine	B
metabolic	O
route	O
has	O
been	O
reported	O
in	O
multiple	O
neurological	O
conditions	O
including	O
dementia,_−	O
depression,_−	O
schizophrenia,_,	O
and	O
anorexia.	O

Only	O
3-hydroxybutyrate	B
was	O
increased	O
(P	O
 < .05)	O
in	O
the	O
normal	O
tissue	O
of	O
the	O
EAC	O
patients	O
compared	O
with	O
the	O
normal	O
tissue	O
of	O
the	O
Barrett's	O
patients.	O

Importantly,	O
the	O
TG	B
within	O
all	O
apolipoprotein	O
B	O
and	O
most	O
HDL	O
particles	O
were	O
associated	O
with	O
higher	O
risk	O
of	O
MI	O
and,	O
to	O
a	O
slightly	O
lesser	O
extent,	O
of	O
IS.	O

Increased	O
circulating	O
levels	O
of	O
acylcarnitines,	B
particularly	O
long-chain	O
acylcarnitines,	B
have	O
been	O
previously	O
linked	O
to	O
increased	O
risk	O
to	O
predict	O
cardiovascular	O
events	O
in	O
patients	O
at	O
risk	O
for	O
coronary	O
heart	O
disease	O
[–].	O

For	O
calibration,	O
commercially	O
available	O
standards	O
of	O
resveratrol,	B
dihydroresveratrol,	B
oxyresveratrol,	B
piceatannol,	O
thunalbene,	B
batatasin	O
III	O
and	O
pinostilbene	B
were	O
used	O
each	O
at	O
6	O
concentration	O
levels	O
in	O
the	O
range	O
of	O
20–1000	O
ng/mL.	O
As	O
an	O
internal	O
standard,	O
20	O
μL	O
of	O
trans	O
-[_13	O
C_6	O
]	O
resveratrol	B
at	O
a	O
concentration	O
of	O
2	O
μg/mL	O
was	O
used.	O

A	O
consisted	O
of	O
33.3%	O
methanol,	B
16.7%	O
acetonitrile	B
containing	O
0.1%	O
formic	B
acid,	I
and	O
mobile	O
phase	O
B	O
consisted	O
of	O
63.3%	O
methanol	B
31.7%	O
acetonitrile	B
containing	O
0.1%	O
formic	B
acid.	I

e,	O
Assessment	O
of	O
cell	O
invasiveness	O
of	O
prostate	O
epithelial	O
cells	O
upon	O
exogenous	O
administration	O
of	O
alanine,	B
glycine,	B
or	O
sarcosine	B
(mean	O
+/−	O
s.e.m.,	O
n=3).	O

Among	O
the	O
compounds	O
found	O
significantly	O
altered	O
in	O
the	O
urine	O
of	O
RCC	O
patients	O
compared	O
to	O
controls,	O
three	O
alcohols	B
(2‐methylpropan‐2‐ol,	I
isobutanol	I
and	O
2‐methylbutan‐2‐ol)	B
were	O
found	O
significantly	O
increased	O
in	O
the	O
urine	O
of	O
RCC	O
patients	O
compared	O
with	O
controls,	O
showing	O
strong	O
positive	O
correlations	O
between	O
them.	O

Unlike	O
previously	O
reported	O
with	O
human	O
milk	O
we	O
found	O
no	O
correlation	O
between	O
plasma	O
free	O
choline	B
concentration	O
and	O
milk	O
choline	B
metabolites.	O

Because	O
of	O
the	O
high	O
glucose	B
consumption	O
of	O
cancer	O
cells,	O
glucose	B
availability	O
for	O
other	O
cells	O
within	O
the	O
tumor	O
is	O
likely	O
limited.	O

Ion	O
ratios	O
of	O
analyte	O
to	O
respective	O
internal	O
standard	O
computed	O
from	O
centroided	O
spectra	O
were	O
converted	O
to	O
concentrations	O
using	O
calibrators	O
constructed	O
from	O
authentic	O
aliphatic	B
acylcarnitines	I
and	O
amino	O
acids	O
(Sigma,	O
MO,	O
USA;	O
Larodan	O
Sweden)	O
and	O
Bovine	O
Adult	O
Serum	O
(Sigma,	O
MO,	O
USA).	O

In	O
light	O
of	O
the	O
high	O
detection	O
frequency	O
of	O
paracetamol	B
in	O
urine	O
and	O
the	O
stark	O
gender	O
differences	O
in	O
urinary	O
concentrations	O
of	O
paracetamol,	B
with	O
the	O
highest	O
distribution	O
being	O
among	O
the	O
females	O
in	O
the	O
LIFE	O
study,	O
the	O
lack	O
of	O
association	O
between	O
female	O
urinary	O
concentrations	O
of	O
paracetamol	B
and	O
TTP	O
is	O
worthy	O
of	O
further	O
consideration.	O

The	O
pH	O
needs	O
to	O
be	O
alkaline;	B
however,	O
it	O
has	O
been	O
described	O
that	O
at	O
a	O
pH	O
higher	O
than	O
10,	O
dansyl	B
chloride	I
reacts	O
highly	O
with	O
water	O
or	O
the	O
other	O
hydroxyl	O
groups	O
present	O
in	O
the	O
environment.	O

Higher	O
levels	O
of	O
tryptophan	B
were	O
detected	O
in	O
patients	O
with	O
prednisolone	B
treatment	O
compared	O
with	O
patients	O
without	O
prednisolone	B
(60 µM,	O
SD=25	O
vs	O
52 µM,	O
SD=19,	O
p=0.03),	O
although	O
glucocorticoids	B
are	O
known	O
to	O
stimulate	O
IDO,	O
that is	O
increase	O
tryptophan	B
consumption.	O

The	O
identification	O
of	O
feline-specific	B
pre-clinical	O
biomarkers	O
of	O
NSAID-induced	O
toxicity	O
would	O
be	O
extremely	O
valuable	O
for	O
optimizing	O
individualized	O
drug	O
therapies.	O

Not	O
all	O
validation	O
parameters	O
could	O
be	O
determined	O
because	O
calibrators	O
consisting	O
of	O
dTG	O
incorporated	O
into	O
DNA	O
are	O
not	O
obtainable	O
and	O
it	O
is	O
not	O
possible	O
to	O
have	O
a	O
processed	O
sample	O
containing	O
the	O
DNA	O
matrix	O
without	O
the	O
presence	O
of	O
dA.	O
As	O
dA	O
is	O
always	O
present	O
in	O
processed	O
DNA	O
samples,	O
the	O
absence	O
of	O
dTG	O
in	O
negative-control	O
MOLT4	O
cells	O
and	O
in	O
patients	O
not	O
on	O
thiopurine	B
therapy	O
indicates	O
selectivity.	O

The	O
lowest	O
concentration	O
that	O
could	O
be	O
reliably	O
detected	O
using	O
NMR	O
was	O
12.3	O
µM	O
(for	O
malonic	O
acid)	O
and	O
14.5	O
µM	O
(for	O
choline).	B

3-Succinoylpyridine	B
(3SP)	O
a	O
nicotine	B
metabolite	O
and	O
by-product	O
of	O
N-nitrosamine	B
formed	O
by	O
the	O
action	O
of	O
cytochrome	O
P450.	O

Extracted	O
characteristic	O
peak	O
pairs	O
from	O
the	O
two	O
precursor	O
ion	O
scan	O
(PI)	O
spectra	O
and	O
assigned	O
them	O
as	O
potential	O
thiol	B
candidates.	O

We	O
confirmed	O
this	O
aspect	O
for	O
sample	O
storage	O
and	O
further	O
found	O
that	O
asparagine,	B
cysteine	B
and	O
cystine,	B
which	O
are	O
not	O
included	O
in	O
their	O
work,	O
were	O
all	O
significantly	O
reduced	O
in	O
concentration	O
during	O
storage.	O

Cold	O
increased	O
plasma	O
cholesterols,	B
apolipoproteins,	O
total	O
fatty	O
acids,	O
glutamine,	B
acetate	B
and	O
albumin	O
(Figure B),	O
whereas	O
cold	O
had	O
no	O
effect	O
on	O
other	O
metabolites	O
(Figure B).	O

Model	O
adjsutment	O
for	O
age,	O
race,	O
smoking	O
status,	O
physical	O
activity,	O
education,	O
menopause	O
status,	O
hormone	O
replacement	O
therapy,	O
systolic	O
blood	O
pressure,	O
anti–hypertensive	O
treatment,	O
body	O
mass	O
index,	O
family	O
history	O
of	O
diabetes,	O
HbA1c,	O
log	O
hs-CRP,	O
HDL-c,	O
LDL-c	O
and	O
log	O
triglycerides	B
(Trigl.).	O

A	O
10µL	O
aliquot	O
was	O
vortexed	O
with	O
40µL	O
of	O
water	O
and	O
extracted	O
in	O
equal	O
volumes	O
of	O
chloroform,	B
methanol	B
and	O
water.	O

Similarly,	O
we	O
prepared	O
the	O
initial	O
stock	O
solutions	O
of	O
stable	O
isotope-labeled	O
internal	O
standards	O
in	O
acetonitrile.	B

Interestingly,	O
3-hydroxyisobutyrate	B
was	O
found	O
by	O
NMR	O
in	O
higher	O
concentrations	O
in	O
the	O
serum	O
of	O
our	O
subjects	O
after	O
cheese	O
intake.	O

With	O
longer	O
exposure	O
times	O
(6	O
and	O
24	O
hours),	O
the	O
accumulation	O
of	O
amino	O
acid	O
metabolites	O
(eg,	O
N-α	B
-acetyllysine,	I
aminoadipic	B
acid,	I
and	O
cystathionine)	B
and	O
acylcarnitines	B
became	O
more	O
pronounced,	O
and	O
in	O
addition,	O
a	O
number	O
of	O
pyrimidine/purine	O
nucleosides	O
(eg,	O
uridine,	B
thymidine,	B
inosine,	B
guanosine,	B
deoxyinosine,	B
and	O
deoxyguanosine)	B
and	O
nucleobases	O
(eg,	O
thymine,	B
uracil,	B
hypoxanthine,	B
xanthine,	B
adenine,	B
and	O
guanine)	O
were	O
significantly	O
accumulated	O
in	O
the	O
medium,	O
particularly	O
at	O
24	O
hours.	O

The	O
hormones	O
dehydroepiandrosterone	B
(DHEA),	O
androstenediol	B
(AED),	O
androstenetriol	B
(AET),	O
7-oxo-DHEA	B
and	O
the	O
compound	O
used	O
as	O
an	O
internal	O
standard	O
(IS)	O
are	O
represented.	O

4-Methyl-phenol	B
(p-cresol)	O
seemed	O
to	O
be	O
over-synthesized	O
in	O
IgAN	O
patients.	O

The	O
Mann-Whitney	O
U	O
test,	O
Chi-square	O
test,	O
and	O
Kruskal-Wallis	O
test	O
were	O
used	O
to	O
evaluate	O
differences	O
between	O
demographic	O
data,	O
such	O
as	O
age	O
and	O
gender,	O
region,	O
and	O
each	O
level	O
of	O
phthalate	B
metabolites	O
for	O
continuous	O
and	O
categorical	O
variables,	O
respectively.	O

We	O
have	O
used	O
the	O
EI	B
library	O
and/or	O
standards	O
to	O
identify	O
the	O
fatty	O
acids.	O

The	O
assays	O
were	O
analyzed	O
as	O
per	O
the	O
manufacturers’	O
protocol	O
(http://www.mesoscale.com).	O

The	O
high	O
triglycerides	B
were	O
assumed	O
not	O
to	O
be	O
related	O
to	O
PKU	O
or	O
BMI	O
(27.5	O
and	O
23.6 kg/m_2	O
,	O
respectively).	O

Our	O
pathway	O
analysis	O
emphasized	O
that	O
creatine	B
is	O
involved	O
in	O
arginine	B
and	O
proline	B
metabolism	O
and	O
the	O
glycine,	B
serine	B
and	O
threonine	B
metabolism	O
which	O
were	O
both	O
associated	O
with	O
MPO	O
gains.	O

Androgens	O
regulate	O
key	O
enzymes	O
involved	O
in	O
fatty	O
acid	O
and	O
cholesterol	B
synthesis	O
and	O
prostate	O
cancer	O
cells	O
show	O
altered	O
lipid	O
synthesis,	O
including	O
the	O
conversion	O
of	O
citrate	B
to	O
acetyl	O
CoA.	O
Metabolite	O
profiles	O
have	O
been	O
associated	O
with	O
localized	O
and	O
metastatic	O
prostate	O
tissues.	O

Only	O
one	O
participant	O
had	O
low	O
serum	O
folate	B
(<10	O
nmol/L)	O
at	O
baseline.	O

eGFR	O
is	O
strongly	O
negatively	O
associated	O
with	O
serum	O
creatinine	B
(crea	O
)	O
(edge	O
weight = −11.19),	O
strongly	O
positively	O
associated	O
with	O
male	O
gender	O
(gender	O
)	O
(edge	O
weight = 7.51),	O
and	O
negatively	O
associated	O
with	O
age	O
(age	O
)	O
(edge	O
weight = −2.71).	O

An	O
aliquot	O
of	O
each	O
sample	O
(1	O
mL)	O
was	O
sent	O
to	O
an	O
outside	O
laboratory	O
for	O
determination	O
of	O
urinary	O
creatinine	B
and	O
specific	O
gravity	O
levels.	O

Moreover,	O
we	O
found	O
that	O
PAG	B
is	O
positively	O
correlated	O
to	O
%FFM	O
and	O
urine	O
creatinine,	B
but	O
negatively	O
correlated	O
to	O
urinary	O
urea	B
and	O
inflammatory	O
markers	O
CRP	O
and	O
calprotectin.	O

Glutarylcarnitine;	B
53.	O

It	O
also	O
supports	O
recent	O
human	O
in	O
vivo	O
evidence	O
showing	O
increased	O
cerebral	O
serotonin	B
2A	O
receptor	O
binding	O
during	O
24	O
h	O
of	O
wakefulness.	O

The	O
upper	O
polar	O
phase	O
mainly	O
consists	O
of	O
methanol	B
and	O
water,	O
whereas	O
the	O
bottom	O
(nonpolar)	O
phase	O
is	O
rich	O
in	O
chloroform,	B
and	O
lipids	O
dissolve	O
there.	O

The	O
CerS2	O
and	O
CerS4	O
in	O
liver	O
probably	O
have	O
more	O
specificity	O
toward	O
24:0	O
acyl-CoA	O
than	O
22:0	O
acyl-CoA.	O
Measurement	O
of	O
Cer(22:0)	B
and	O
Cer(24:0)	B
in	O
human	O
plasma.	O

The	O
affinity	O
of	O
binding	O
for	O
β-apo-14′-carotenal	B
and	O
β-apo-14′-carotenoic	B
acid	I
to	O
RARs	O
was	O
in	O
the	O
15–60	O
nm	O
range,	O
whereas	O
those	O
of	O
β-apo-10′-	B
and	O
β-apo-12′-carotenoic	B
acids	I
were	O
>300	O
nm.	O

(A)	O
STOCSY	O
plot	O
derived	O
from	O
the	O
correlation	O
matrix	O
between	O
all	O
data	O
points	O
and	O
the	O
data	O
point	O
at	O
the	O
peak	O
maxima	O
relating	O
to	O
the	O
combined	O
resonances	O
from	O
2-hydroxy	B
signal	O
of	O
ibuprofen	B
and	O
its	O
glucuronide	B
resonance	O
(δ	O
1.21),	O
as	O
indicated	O
by	O
the	O
arrow.	O

Endogenous	O
estrogens	O
and	O
estrogen	B
metabolites	O
were	O
found	O
in	O
all	O
NCI-60	O
human	O
tumor	O
cell	O
lines	O
and	O
some	O
were	O
substantially	O
elevated	O
and	O
exceeded	O
the	O
levels	O
found	O
in	O
well	O
known	O
estrogen-dependent	O
and	O
estrogen	B
receptor-positive	O
tumor	O
cells	O
such	O
as	O
MCF-7	O
and	O
T-47D.	O
While	O
estrogens	O
were	O
expected	O
to	O
be	O
present	O
at	O
high	O
levels	O
in	O
cell	O
lines	O
representing	O
the	O
female	O
reproductive	O
system	O
(that	O
is,	O
breast	O
and	O
ovarian),	O
other	O
cell	O
lines,	O
such	O
as	O
leukemia	O
and	O
colon,	O
also	O
contained	O
very	O
high	O
levels	O
of	O
these	O
steroid	O
hormones.	O

MeOH	B
(A),	O
ACN	O
(B),	O
EtOH	B
(C)	O
and	O
IPA	O
(D).	O

For	O
17-hydroxyprogesterone,	B
a	O
relationship	O
with	O
age	O
requiring	O
age-specific	O
reference	O
intervals	O
was	O
present	O
for	O
males,	O
whereas	O
for	O
females	O
there	O
was	O
need	O
to	O
consider	O
post-menopausal	O
and	O
pre-menopausal	O
status	O
(	O
panels	O
G	O
&	O
H).	O

Thymol	B
was	O
bought	O
from	O
Science	O
Lab	O
(Houston,	O
TX,	O
USA).	O

Patients	O
with	O
an	O
outcome	O
(death,	O
overt	O
HE,	O
transplant	O
or	O
hospitalization),	O
largely	O
had	O
a	O
higher	O
MELD	O
score,	O
lactulose,	B
SBP	O
prophylaxis	O
and	O
prior	O
HE	O
compared	O
to	O
the	O
rest.	O

Short	O
gestational	O
age	O
is	O
in	O
itself	O
related	O
to	O
type	O
1	O
diabetes	O
(Dahlquist	O
and	O
Kallén	O
),	O
and	O
it	O
can	O
be	O
speculated	O
that	O
low	O
levels	O
of	O
triacylglycerol	B
might	O
be	O
an	O
accelerator-	O
or	O
sign	O
of	O
metabolic	O
deviations	O
leading	O
to	O
type	O
1	O
diabetes	O
at	O
very	O
early	O
ages.	O

Nonlinear	O
regression	O
analysis	O
of	O
the	O
log	O
transformed	O
fentanyl	O
CL	O
and	O
midazolam	B
CL_met	O
(Fig.	O

Research	O
has	O
shown	O
that	O
arginine	B
was	O
required	O
for	O
sperm	O
production,	O
and	O
arginine	B
supplementation	O
can	O
help	O
to	O
boost	O
healthy	O
sperm	O
count	O
and	O
improve	O
fertility.	O

The	O
mobile	O
phases	O
consisted	O
of	O
a	O
combination	O
of	O
solution	O
A	O
(0.1%	O
formic	B
acid	I
in	O
water)	O
and	O
solution	O
B	O
(0.1%	O
formic	B
acid	I
in	O
100%	O
acetonitrile).	O

Similar	O
results	O
were	O
obtained	O
for	O
M5	O
glutamine	B
and	O
M5	O
valine	B
(Supplementary	O
Figure	O
S2).	O

For	O
optimum	O
sensitivity,	O
the	O
following	O
parameters	O
were	O
set:	O
fragmentor	O
voltage	O
of	O
50	O
V	O
for	O
GLY	O
and	O
GP,	B
250	O
V	O
for	O
M1	O
and	O
M2,	O
capillary	O
voltage	O
5000	O
V,	O
drying	O
gas	O
temperature	O
350°	O
C,	O
drying	O
gas	O
flow	O
10	O
L/min	O
and	O
nebulizer	O
pressure	O
25	O
psig	O
(172.4	O
KPa).	O

Increased	O
glutamine	B
levels	O
were	O
also	O
observed	O
in	O
early	O
stage	O
CRC	O
urine	O
samples,	O
suggesting	O
augmented	O
glutaminalysis.	O

In	O
comparison,	O
the	O
four-metabolite	O
profile	O
did	O
not	O
add	O
significantly	O
to	O
the	O
model	O
containing	O
a	O
clinically	O
utilized	O
marker	O
for	O
HCC,	O
alpha-fetoprotein	B
(AFP).	O

Model	O
3:	O
adjusted	O
for	O
hypertension	O
at	O
sampling,	O
antiphospholipid	B
antibody	O
syndrome,	O
and	O
use	O
of	O
heparin/aspirin	O
at	O
sampling.	O

This	O
suggests	O
that	O
the	O
exchange	O
is	O
intermediate	O
on	O
the	O
NMR	O
time-scale	O
and	O
apparently	O
faster	O
than	O
that	O
for	O
the	O
borate-citrate	B
complex.	O

Many	O
cancer	O
cells	O
are	O
glutamine	B
dependent	O
in	O
culture	O
as	O
pyruvate	B
gets	O
converted	O
into	O
lactate,	B
and	O
glutaminolysis	O
becomes	O
an	O
important	O
anaplerotic	O
source	O
for	O
the	O
Krebs	O
cycle,	O
thus	O
promoting	O
oxidative	O
phosphorylation	O
and	O
replenishing	O
oxalEACetate	B
lost	O
to	O
anabolism.	O

We	O
further	O
conclude	O
that	O
lipoproteins	O
such	O
as	O
TGRL	O
can	O
serve	O
as	O
a	O
depot	O
for	O
fatty	O
acids	O
and	O
oxylipins,	B
and	O
propose	O
that	O
these	O
bioactive	O
fatty	O
acid	O
metabolites	O
transported	O
in	O
TGRL	O
could	O
act	O
remotely	O
to	O
directly	O
modulate	O
an	O
endothelial	O
inflammatory	O
response.	O

This	O
observation	O
also	O
supports	O
the	O
thesis	O
of	O
an	O
early	O
effect	O
of	O
aspirin	B
treatment	O
on	O
healthy	O
colonic	O
mucosa.	O

The	O
inability	O
of	O
skeletal	O
muscles	O
to	O
quickly	O
use	O
glycogen	B
for	O
the	O
anaerobic	O
production	O
of	O
energy	O
leads	O
to	O
exercise	O
intolerance	O
and	O
potentially	O
to	O
rhabdomyolysis.	O

These	O
findings	O
may	O
suggest	O
a	O
cross-talk	O
between	O
SL	B
and	O
eicosanoid	B
metabolism	O
in	O
the	O
pathogenesis	O
of	O
AERD	O
in	O
which	O
platelet	O
activation	O
and	O
subsequent	O
platelet-leukocyte	O
aggregates	O
might	O
be	O
involved;	O
however,	O
further	O
studies	O
are	O
required	O
to	O
elucidate	O
the	O
relationship	O
between	O
circulating	O
S1P	O
and	O
the	O
underlying	O
systemic	O
inflammation	O
of	O
AERD	O
patients,	O
as	O
well	O
as	O
the	O
downstream	O
effects	O
of	O
S1P	O
in	O
AERD	O
pathogenesis.	O

Another	O
group	O
that	O
analyzed	O
plasma	O
of	O
patients	O
with	O
IBD	O
with	O
the	O
aim	O
to	O
investigate	O
differences	O
in	O
metabolites	O
demonstrated	O
that	O
amino	O
acid	O
profiles	O
evaluated	O
by	O
a	O
novel	O
statistical	O
data	O
modelling	O
(aminogram)	O
discriminated	O
between	O
IBD	O
and	O
healthy	O
and	O
between	O
UC	O
and	O
CD.	O

In	O
addition,	O
Leu/Ile	O
also	O
works	O
jointly	O
with	O
valine	B
in	O
various	O
biological	O
reactions	O
and	O
is	O
necessary	O
in	O
the	O
biosynthesis	O
of	O
reduced	B
glutathione	I
hormone	O
(GSH).	O

Samples	O
were	O
incubated	O
with	O
0.5 mL	O
of	O
20%	O
acetic	B
acid,	I
pH	O
3.5,	O
and	O
0.5 mL	O
of	O
0.78%	O
aqueous	O
solution	O
of	O
thiobarbituric	B
acid.	I

However,	O
the	O
isotopic	O
data-dependent	O
scanning	O
was	O
not	O
successful	O
in	O
detecting	O
SA	O
adducts	O
of	O
N	B
-acetoxy-PhIP,	I
irrespective	O
of	O
the	O
enzymatic	O
digestion	O
conditions.	O

VIP:	O
Variable	O
Importance	O
of	O
Projection;	O
Sa:	O
Sphinganine;	B
Sa1P:	O
Sphinganine-1-Phosphate;	B
C16Cer:	O
Ceramide	B
(d18:1/16:0);	I
C24dHCer:	O
Dihydroceramide	B
(d18:1/24:1):	I
C0:	O
Free	O
Carnitine;	B
So1P:	O
Sphingosine-1-Phosphate;	B
C16GlcCer:	O
Glucosylceramide	B
(d18:1/16:0);	I
C24:	O
Tetracosanoylcarnitine;	B
C2:	O
Acetylcarnitine;	B
C18Cer:	O
Ceramide	B
(d18:1/18:0);	I
C18:1:	B
Octadecenoylcarnitine.	B

For	O
cabozantinib	B
total	O
extraction	O
recovery	O
was	O
additionally	O
determined	O
for	O
QCXL	O
in	O
duplicate.	O

As	O
shown	O
in	O
this	O
study,	O
cysteine,	B
which	O
is	O
the	O
rate-limiting	O
factor	O
of	O
de	O
novo	O
GSH	B
synthesis	O
(Lu	O
),	O
was	O
profoundly	O
diminished	O
in	O
lupus	O
PBL.	O

Many	O
of	O
the	O
biomarker	O
associations	O
were	O
comparable	O
with	O
or	O
even	O
stronger	O
than	O
those	O
of	O
traditional	O
risk	O
markers	O
of	O
fatty	O
liver,	O
such	O
as	O
BMI,	O
liver	O
enzymes,	O
insulin	O
resistance	O
index,	O
and	O
serum	O
triglycerides	B
and	O
HDL	B
cholesterol	I
(Table	O
and	O
Fig.	O
).	O

Oral	O
BCAA	O
administration	O
activates	O
mammalian	O
target	O
of	O
rapamycin	B
(mTOR)	O
signalling	O
and	O
exacerbates	O
cardiac	O
dysfunction	O
and	O
remodelling	O
in	O
mice	O
with	O
surgically	O
induced	O
MI.	O

d	O
d	O
d	O
d	O
d	O
For	O
the	O
calibrators	O
and	O
QC	O
samples,	O
spiked	O
directly	O
with	O
diosmetin,	B
a	O
deconjugation	O
is	O
not	O
needed;	O
therefore,	O
these	O
samples	O
were	O
not	O
incubated	O
with	O
enzymes	O
but	O
just	O
diluted	O
with	O
0.3 mL	O
sodium	B
acetate	I
0.2 M,	O
pH	O
4.5	O
and	O
further	O
processed	O
as	O
described	O
in	O
“Extraction	O
procedure	O
for	O
the	O
determination	O
of	O
diosmetin	B
in	O
plasma.”	O

9-HODE	B
and	O
12,13-DiHOME	B
reduce	O
VCAM-1	O
surface	O
expression	O
in	O
TNFα-stimulated	O
HAEC.	O

A	O
,	O
The	O
levels	O
of	O
glucose-6-phosphate	B
(G6P)	O
plus	O
fructose-6-phosphate	B
(F6P)	O
before	O
the	O
uniformly	O
labeled	O
glucose	B
or	O
glutamine	B
was	O
added	O
(zero	O
time	O
point).	O

Based	O
on	O
the	O
distribution	O
of	O
Y-predicted	O
scores	O
of	O
the	O
model	O
PCT,	O
415	O
(4.9	O
%)	O
of	O
the	O
remaining	O
8,436	O
urine	O
spectra	O
were	O
predicted	O
as	O
containing	O
acetaminophen	B
metabolites;	O
the	O
remaining	O
8,021	O
(95.1	O
%)	O
urine	O
spectra	O
were	O
predicted	O
as	O
not	O
containing	O
acetaminophen	B
metabolites.	O

The	O
main	O
common	O
feature	O
of	O
the	O
TAGs	O
subgroup	O
compared	O
to	O
other	O
species	O
from	O
this	O
class	O
was	O
lower	O
total	O
length	O
and	O
a	O
higher	O
degree	O
of	O
saturation	O
of	O
the	O
FA	B
chains	O
(average	O
46.3	O
vs.	O
53.8	O
carbon	O
atoms	O
and	O
1.1	O
versus	O
4.4	O
double	O
bonds	O
per	O
molecule	O
for	O
TAGs	O
with	O
negative	O
and	O
positive	O
p(corr)	O
value	O
respectively),	O
which	O
are	O
to	O
some	O
extent	O
correlated	O
with	O
each	O
other	O
(more	O
possible	O
double	O
bonds	O
can	O
exist	O
in	O
the	O
longer	O
fatty	O
acid	O
chain).	O

Studying	O
the	O
difference	O
between	O
the	O
post-exercise	O
period	O
by	O
the	O
three	O
sampling	O
points	O
at	O
70,	O
220	O
and	O
370	O
min	O
after	O
exercise	O
indicated	O
that	O
the	O
overall	O
effect	O
of	O
intake	O
of	O
milk	O
protein	O
(whey	O
or	O
calcium	B
caseinate)	I
compared	O
to	O
a	O
non-caloric	O
drink	O
is	O
higher	O
levels	O
of	O
lipids	O
and	O
cholines	B
in	O
the	O
blood.	O

Further	O
analysis	O
identified	O
a	O
potential	O
biomarker	O
panel	O
consisting	O
of	O
five	O
potential	O
biomarkers	O
–	O
formate,	B
succinate,	B
1-methylhistidine,	B
α-glucose	B
and	O
dimethylamine.	B

Glucose	B
uptake	O
was	O
analyzed	O
using	O
{2-[N	O
-(7-Nitrobenz-2-oxa-1,	O
3-diazol-4-yl]	O
Amino}-2-Deoxyglucose	O
(NBDG),	O
a	O
fluorescently	O
labeled	O
deoxy	B
glucose	I
analogue	O
as	O
a	O
probe	O
for	O
detection	O
of	O
glucose	B
taken	O
up	O
by	O
cultured	O
cells.	O

This	O
in	O
turn	O
may	O
diminish	O
the	O
uptake	O
and	O
utilization	O
of	O
glucose,	B
whose	O
energy	O
producing	O
efficiency	O
outperforms	O
that	O
of	O
3-HB.	O

There	O
was	O
a	O
significant	O
reduction	O
of	O
both	O
phenylalanine	B
and	O
tyrosine	B
4	O
hours	O
after	O
ingestion	O
of	O
both	O
aspartame	B
and	O
control	O
bars.	O

Immunoreactions	O
were	O
visualized	O
using	O
the	O
DAB	O
substrate,	O
followed	O
by	O
hematoxylin	B
counterstaining.	O

Compared	O
to	O
elderly,	O
centenarians	O
also	O
presented	O
depletion	O
of	O
eicosapentanoic	B
acid	I
(EPA),	O
an	O
omega-3	B
fatty	O
acid,	O
which	O
can	O
be	O
synthesized	O
in	O
humans	O
from	O
alpha-linoleic	B
acid	I
or	O
in	O
greater	O
amount	O
directly	O
from	O
oily	O
fishes.	O

Total	O
NEFA	O
levels	O
were	O
similar	O
in	O
patients	O
and	O
controls	O
but	O
palmitic,	B
palmitoleic,	B
oleic,	O
AA,	O
EPA	O
and	O
DHA	O
were	O
decreased	O
in	O
RA	O
patients.	O

The	O
chloroform–methanol	B
extraction	O
platform	O
provided	O
coverage	O
over	O
glycerolipids,	B
cholesterol	B
esters,	I
sphingolipids,	B
diacylglycerophospholipids,	B
and	O
acyl-ether-glycerophospholipids.	B

In	O
addition,	O
a	O
shift	O
towards	O
elevated	O
Krebs	O
cycle	O
intermediates,	O
including	O
malate,	B
seemed	O
to	O
emerge	O
when	O
sleep	O
was	O
curtailed.	O

From	O
a	O
pathway	O
topology	O
analysis	O
perspective,	O
arginine	B
and	O
proline	B
metabolism;	O
alanine,	B
aspartate,	B
and	O
glutamine	B
metabolism;	O
and	O
glycine,	B
serine,	B
and	O
threonine	B
metabolism	O
are	O
the	O
pathways	O
with	O
the	O
highest	O
impact.	O

Odds	O
ratios	O
represent	O
the	O
change	O
in	O
odds	O
of	O
moderate	O
to	O
severe	O
endoscopic	O
inflammation	O
(Mayo	O
2	O
or	O
3)	O
or	O
histologic	O
inflammation	O
(moderate	O
or	O
severe)	O
per	O
1	O
unit	O
change	O
in	O
the	O
metabolite	O
ratio	O
to	O
tryptophan	B
and	O
1-	O
fold	O
change	O
in	O
the	O
mRNA	O
expression	O
compared	O
to	O
normal	O
controls,	O
respectively.	O

Analytical	O
liquid	O
chromatography	O
was	O
performed	O
using	O
1	O
g/L	O
ammonium	B
acetate	I
(pH	O
5.5,	O
adjusted	O
by	O
glacial	B
acetic	I
acid)	I

Total	O
cholesterol	B
and	O
LDL	O
were	O
actually	O
lower	O
in	O
the	O
diabetes	O
group,	O
possibly	O
a	O
consequence	O
of	O
lipid	O
lowering	O
medication.	O

*	O
α-Ketoglutaric	B
acid	I
was	O
determined	O
qualitatively	O
and	O
its	O
quantitative	O
analysis	O
is	O
presumably	O
limited	O
to	O
the	O
conditions	O
of	O
sample	O
preparation.	O

(E)	O
The	O
inclusion	O
of	O
LysoPC	O
(20:4)	O
levels	O
to	O
age,	O
blood	O
pressure,	O
clinical	O
features,	O
duration	B
of	O
symptoms,	O
and	O
diabetes	O
scale	O
(ABCD2)	O
and	O
LAA	O
score	O
to	O
receiver	O
operating	O
characteristic	O
curve	O
increase	O
the	O
predictive	O
power	O
of	O
stroke	O
recurrence	O
(areas:	O
ABCD2	O
=	O
0.646,	O
p	O
=	O
0.0.05;	O
ABCD2	O
+	O
LAA	O
=	O
0.678,	O
p	O
=	O
0.001;	O

Succinate	B
accumulation	O
has	O
been	O
associated	O
with	O
severe	O
HIE,	O
possibly	O
evidencing	O
HIF-1α	O
mediated	O
neurological	O
injury.	O

A	O
close	O
evaluation	O
of	O
the	O
spectra	O
showed	O
that	O
although	O
glutamine	B
did	O
not	O
cyclize	O
in	O
intact	O
serum,	O
a	O
very	O
significant	O
cyclization	O
of	O
glutamine	B
to	O
pyroglutamic	B
acid	I
occurred	O
in	O
ultrafiltered	O
and	O
protein	O
precipitated	O
serum.	O

_a	O
OPLS-DA	O
models	O
selected	O
based	O
on	O
multivariate	O
statistical	O
analysis	O
(Controls	O
vs	O
Specific	O
Cases)	O
Hazard	O
ratio	O
(95%	O
confidence	O
interval)	O
and	O
Kaplan	O
Meier	O
curves	O
for	O
the	O
association	O
of	O
acylcarnitines	B
with	O
PSA	O
progression.	O

Polyamines	B
are	O
involved	O
in	O
the	O
regulation	O
of	O
many	O
cellular	O
functions	O
and	O
are	O
promising	O
biomarkers	O
of	O
numerous	O
physiological	O
conditions.	O

It	O
is	O
a	O
metabolite	O
of	O
lysine	B
found	O
in	O
human	O
physiological	O
fluids	O
such	O
as	O
urine	O
and	O
serum.	O

One	O
possible	O
explanation	O
for	O
this	O
behavior	O
is	O
that	O
exogenous	O
25(OH)D	O
is	O
incorporated	O
into	O
the	O
serum	O
matrix	O
by	O
binding	O
to	O
various	O
components	O
including	O
albumin	O
and	O
vitamin	B
D	I
binding	O
protein	O
(DBP).	O

exp(12∑ps=1∑pt=1βstxsxt+∑ps=1αsxs	B
exp(12∑ps=1∑pt=1βstxsxt+∑ps=1αsxs	I
exp(12∑ps=1∑pt=1βstxsxt+∑ps=1αsxs	I
exp(12∑ps=1∑pt=1βstxsxt+∑ps=1αsxs	I
exp	O
(12∑ps=1∑pt=1βstxsxt+∑ps=1αsxs	O
(	O
(	O
12∑ps=1∑pt=1βstxsxt+∑ps=1αsxs	B
12	O
12	O
1	O
1	O
2	O
2	O
	O
	O
∑ps=1	O
∑ps=1	O
∑	O
∑	O
p	O
p	O
s=1	O
s=1	O
s	O
=1	O
	O
∑pt=1	O
∑pt=1	O
∑	O
∑	O
p	O
p	O
t=1	O
t=1	O
t	O
=1	O
	O
βst	O
βst	O

The	O
concentrations	O
of	O
REG	O
(blue	O
diamonds)	O
and	O
the	O
active	O
REG	O
metabolites	O
demethylated	O
REG	O
N-oxide	B
(red	O
squares)	O
and	O
REG	O
N-oxide	B
(black	O
triangles)	O
are	O
depicted.	O

The	O
sphingolipid,	B
ceramide,	B
has	O
been	O
studied	O
extensively	O
under	O
normal	O
and	O
pathological	O
conditions,	O
ranging	O
from	O
skin	O
development	O
to	O
lung	O
cancer.	O

The	O
mixture	O
was	O
extracted	O
with	O
240 μl	O
of	O
ice-cold	O
methanol	B
and	O
then	O
80 μl	O
of	O
ice-cold	O
methanol.	B

An	O
analytical	O
method	O
to	O
detect	O
exposure	O
to	O
five	O
nerve	O
agents,	O
including	O
VX,	O
VR	B
(Russian	O
VX),	O
GB	O
(sarin),	O
GD	O
(soman)	O
and	O
GF	O
(cyclosarin),	O
through	O
the	O
analysis	O
of	O
the	O
hydrolysis	O
products,	O
which	O
are	O
the	O
primary	O
metabolites,	O
in	O
serum	O
has	O
been	O
developed	O
and	O
characterized.	O

Sensitivity	O
and	O
specificity	O
of	O
UPLC-MS	O
profiles,	O
AFP	O
and	O
individual	O
peaks	O
for	O
HCC	O
diagnosis	O
ROC	O
receiver	O
operating	O
characteristic,	O
AUC	O
area	O
under	O
the	O
curve,	O
HCC	O
hepatocellular	O
carcinoma,	O
LC	O
liver	O
cirrhosis,	O
AFP	O
alpha-fetoprotein,	B
UPLC	O
ultra	O
performance	O
liquid	O
chromatography,	O
MS	O
mass	O
spectrometry,	O
CHB	O
chronic	O
hepatitis	O
B,	O
RT	O
retention	O
time,	O
n	O
neutral,	O
m/z	O
mass	O
to	O
charge	O
ratio,	O
HS	O
healthy	O
subjects.	O

Tryptophan,	B
which	O
is	O
the	O
precursor	O
of	O
serotonin,	B
is	O
a	O
widely	O
expressed	O
metabolite	O
and	O
transmitter	O
throughout	O
the	O
gut.	O

The	O
non-adjusted	O
p	O
values	O
of	O
these	O
correlations	O
indicate	O
that	O
they	O
may	O
be	O
affected	O
by	O
statin	B
treatment	O
and	O
should	O
be	O
further	O
investigated.	O

It	O
was	O
previously	O
reported	O
that	O
endocannabinoid	B
anandamide	I
could	O
mediate	O
hypoxic	O
pulmonary	O
vasoconstriction	O
via	O
fatty	O
acid	O
amide	O
hydrolase	O
(FAAH)-dependent	O
metabolites	O
and	O
hypoxia	O
could	O
cause	O
elevated	O
anandamide	B
in	O
the	O
lung.	O

It	O
was	O
reported	O
that	O
glycine	B
could	O
stimulate	O
the	O
release	O
of	O
dopamine	B
and	O
acetylcholine	B
from	O
tissue_,	O
.	O

Acetone	B
is	O
an	O
end	O
product	O
of	O
ketosis,	O
a	O
metabolic	O
state	O
that	O
produces	O
ketone	B
bodies	O
for	O
use	O
as	O
another	O
fuel	O
for	O
the	O
brain.	O

Fasting	O
insulin,	O
glucose,	B
low-dendity	O
lipoprotein	O
(LDL),	O
high-density	O
lipoprotein	O
(HD)L,	O
cholesterol	B
and	O
triglycerides	B
were	O
analysed	O
in	O
the	O
Biochemistry	O
Department	O
at	O
the	O
University	O
Hospital	O
of	O
South	O
Manchester	O
as	O
described	O
previously.	O

As	O
AAPs	O
are	O
known	O
to	O
have	O
a	O
varying	O
propensity	O
to	O
cause	O
adverse	O
metabolic	O
side	O
effects,	O
medication	O
use	O
was	O
further	O
described	O
by	O
risk	O
group,	O
as	O
follows:	O
high	O
(olanzapine	O
or	O
clozapine),	B
moderate	O
(quetiapine,	O
risperidone,	B
iloperidone,	B
or	O
paliperidone),	B
and	O
low	O
(aripiprazole,	O
ziprasidone,	B
and	O
lurasidone).	B

In	O
addition,	O
three	O
downregulated	O
LPCs,	O
LPC(14:0),	B
LPC(20:3),	B
and	O
LPC(22:6),	B
were	O
found	O
for	O
this	O
comparison	O
of	O
patient	O
classes	O
by	O
random	O
forests.	O

All	O
of	O
the	O
metabolic	O
abnormalities	O
that	O
we	O
identified	O
in	O
CFS	O
were	O
either	O
directly	O
regulated	O
by	O
redox	O
or	O
the	O
availability	O
of	O
NADPH.	B

Such	O
decrease	O
in	O
citrulline	B
levels	O
is	O
likely	O
to	O
be	O
mediated	O
via	O
the	O
preservation	O
of	O
the	O
citric	B
acid	I
cycle	O
intermediates	O
to	O
defend	O
ATP	B
production	O
in	O
the	O
myocardium.	O

Urinary	O
concentrations	O
of	O
nine	O
phthalate	B
metabolites	O
were	O
measured	O
by	O
online	O
solid	O
phase	O
extraction	O
coupled	O
to	O
high	O
performance	O
liquid	O
chromatography-isotope-dilution	O
tandem	O
mass	O
spectrometry.	O

Specifically,	O
we	O
observed	O
significant	O
concentration	O
changes	O
in	O
the	O
glycolysis	O
intermediates	O
lactate	B
and	O
acetate	B
and	O
the	O
ketone	B
bodies	O
3-hydroxybutyrate	B
and	O
acetoacetate.	B

Hexanes	B
(10	O
ml)	O
were	O
added	O
to	O
each	O
tube,	O
and	O
the	O
mixture	O
was	O
sonicated	O
again.	O

In	O
brief,	O
5	O
mg	O
muscle	O
tissue	O
was	O
extracted	O
in	O
cold	O
MetOH:	O
MTBE:	B
H20	O
=	O
360:	O
1200:	O
348	O
using	O
a	O
full	O
glass	O
Potter	O
type	O
homogeniser.	O

Affinity	O
labeling	O
of	O
cysteine	B
282	O
with	O
N-(2,3-epoxypropyl)-N-amidinoglycine.	B

FA	B
is	O
mainly	O
catalyzed	O
to	O
acyl-coenzyme	B
A	O
(acyl-CoA)	O
by	O
long-chain	O
acyl-CoA	B
synthetase	O
in	O
the	O
mitochondrial	O
outer	O
membrane	O
in	O
the	O
skeletal	O
muscles,	O
but	O
acyl-CoA	B
is	O
unable	O
to	O
penetrate	O
mitochondrial	O
membranes.	O

In	O
the	O
diabetes	O
group	O
we	O
observe	O
highly	O
increased	O
concentrations	O
of	O
the	O
ketone	B
3-hydroxybutyrate	I
(BHBA).	O

It	O
is	O
unclear	O
whether	O
the	O
elevation	O
of	O
arachidonic	B
acid	I
is	O
due	O
to	O
the	O
disruption	O
of	O
the	O
cell	O
membrane	O
or	O
to	O
downstream	O
interruption	O
of	O
its	O
metabolic	O
pathways.	O

Other	O
metabolites	O
determined	O
included	O
Trp	O
and	O
its	O
metabolites	O
3-hydroxykynurenine	B
(HK),	O
nicotinamide	B
(NAM),	O
5-HT,	O
kynurenine	B
(KYN),	O
xanthurenic	B
acid,	I
kynurenic	B
acid	I
(KA),	O
anthranilic	B
acid	I
(AA),	O
3-hydroxyanthranilic	B
acid	I
(HAA),	O
5-hydroxyindole-3-acetic	B
acid	I
(HIAA),	O
indole-3-lactic	B
acid	I
(ILA),	O
indole-3-acetic	B
acid	I
(IAA)	O
and	O
indole-3-propionic	B
acid	I
(IPA).	O

Hypoxanthine	B
also	O
showed	O
an	O
increased	O
risk	O
of	O
developing	O
CIN2/3	O
compared	O
with	O
CIN1	O
(OR,	O
7.90;	O
CI,	O
2.00–31.3).	O

Participants	O
with	O
an	O
outcome	O
present	O
at	O
the	O
time	O
of	O
vitamin	B
D	I
metabolite	O
measurement	O
(prevalent	O
cases)	O
were	O
excluded	O
from	O
analyses	O
of	O
that	O
outcome.	O

Inverse	O
normal-rank	O
transformations	O
were	O
applied	O
to	O
the	O
cytokines,	O
tryptophan	B
metabolites,	O
KTR,	O
and	O
PLP	O
to	O
make	O
them	O
satisfy	O
the	O
normality	O
assumption	O
before	O
examination	O
of	O
associations	O
with	O
any	O
of	O
the	O
cytokines	O
through	O
multiple	O
linear	O
regression	O
analysis.	O

Modifiable	O
factors	O
may	O
impact	O
the	O
EDA	O
ratio,	O
with	O
studies	O
demonstrating	O
that	O
resveratrol	B
reduces	O
EDA	O
ratio	O
in	O
vitro	O
.	O

The	O
top	O
regression	O
model	O
identified	O
consisted	O
of	O
the	O
excursions	O
in	O
Leu/Ile	O
and	O
glycerol	B
(R	O
_2	O
_adj	O
=0.54,	O
P	O
=0.0001).	O

The	O
most	O
discriminating	O
PC	O
species	O
(eight)	O
included	O
both	O
lower	O
MW	O
species	O
(MW	O
705.8–741.8),	O
containing	O
short	O
saturated	O
and/or	O
mono-unsaturated	O
FA	B
chains	O
(C	O
30–34,	O
0–2	O
DB),	O
and	O
higher	O
MW	O
species	O
(809.8–835.8)	O
containing	O
longer	O
and	O
more	O
unsaturated	O
FA	B
chains	O
(C	O
38–40,	O
3–6	O
DB).	O

Those	O
who	O
developed	O
diabetes	O
were	O
older	O
and	O
had	O
higher	O
BMI,	O
waist/hip	O
ratio,	O
blood	O
pressure,	O
blood	O
triglycerides,	B
C-reactive	O
protein,	O
fasting	O
insulin,	O
and	O
HbA1c.	O

Decanoylcarnitine	B
(15),	O
was	O
also	O
over-expressed	O
in	O
the	O
cancer	O
tissue,	O
though	O
at	O
much	O
lower	O
abundance.	O

Taken	O
together	O
with	O
changes	O
in	O
PAG	B
and	O
the	O
Krebs	O
cycle,	O
this	O
urinary	O
pattern	O
describes	O
a	O
further	O
remodeling	O
of	O
energy,	O
amino	O
acid	O
and	O
fatty	O
acid	O
metabolism	O
in	O
relation	O
to	O
the	O
altered	O
metabolic	O
requirements	O
of	O
UC	O
pediatric	O
patients.	O

When	O
we	O
compared	O
with	O
our	O
data	O
of	O
MDD	O
with	O
a	O
previous	O
blood	O
study	O
of	O
bipolar	O
disorder	O
using	O
CE-TOFMS,	O
increased	O
Glu	O
levels	O
and	O
decreased	O
cis-Aconitic	B
acid	I
levels,	O
which	O
is	O
an	O
intermediate	O
product	O
of	O
the	O
citric	B
acid	I
cycle,	O
have	O
been	O
commonly	O
observed	O
between	O
studies.	O

S1P:	O
sphingosine	B
1-phosphate,	I
SA1P:	O
sphinganine	B
1-phosphate.	I

All	O
solvents	O
used	O
to	O
reconstitute	O
the	O
analytes	O
prior	O
to	O
analysis,	O
including	O
water	O
(H2O),	O
metha-nol	B
(MeOH),	O
acetonitrile	B
(ACN),	O
isopropanol	B
(IPA),	O
and	O
chloroform	B
(CHCl3)	O
were	O
Optima	O
LC-MS	O
grade	O
purchased	O
from	O
Fisher	O
Scientific	O
(Fair	O
Lawn,	O
NJ).	O

	O
Urine	O
creatinine	B
was	O
measured	O
at	O
the	O
University	O
of	O
Minnesota	O
Medical	O
Center	O
using	O
Vitros	O
Crea	O
slides	O
(Ortho-Clinical	O
Diagnostics,	O
Rochester,	O
NY)	O

The	O
output	O
CSV	O
files	O
are	O
provided	O
in	O
the	O
data	O
record	O
(adni1-lipidomics-eics.zip)	O
in	O
Data	O
Citation	O
3.	O

The	O
chemotherapy	O
regimens	O
used	O
were	O
either	O
fluorouracil,	B
epirubicine	B
and	O
cyclophosphamide	O
(FEC)	O
every	O
third	O
week	O
for	O
6	O
cycles,	O
or	O
4	O
cycles	O
of	O
either	O
FEC	O
followed	O
by	O
12	O
weeks	O
of	O
either	O
docetaxel	O
every	O
third	O
week	O
or	O
paclitaxel	O
every	O
week.	O

The	O
VIPs	O
and	O
p(corr)	O
extracted	O
from	O
the	O
OPLS-DA	O
plot	O
and	O
the	O
values	O
of	O
p	O
and	O
q	O
obtained	O
from	O
one	O
way	O
ANOVA	O
also	O
revealed	O
patients	O
with	O
FSGS	O
mainly	O
characterized	O
by	O
high	O
levels	O
of	O
Glc,	O
DMA,	B
TMA,	O
and	O
decreased	O
excretion	O
of	O
Pyr,	O
Hip,	O
PAG,	B
Ile,	O
Val,	O
Tyr,	O
Cit,	O
3-HIV	O
and	O
3-me-	B

Also,	O
one	O
study	O
showed	O
that	O
low	O
circulating	O
levels	O
of	O
1,25(OH)_2	B
D	O
are	O
associated	O
with	O
increased	O
risk	O
of	O
CAC.	O

Metabolism	O
of	O
prostaglandin	B
D2	I
in	O
the	O
monkey.	O

Therefore,	O
glycine	B
could	O
be	O
a	O
useful	O
biomarker	O
for	O
early	O
tumor	O
detection	O
(Zhao	O
et	O
al.,	O
).	O

For	O
calibration,	O
a	O
standard	O
mixture	O
of	O
polyphenol	O
metabolites	O
was	O
serially	O
diluted	O
in	O
aqueous	O
methanol	B
(50:50)	I
at	O
a	O
concentration	O
range	O
of	O
0.01–20	O

These	O
results	O
suggest	O
an	O
altered	O
pattern	O
of	O
phosphatidylinositol	B
metabolism	O
in	O
smokers.	O

Digested	O
β-casein	B
fractions	O
were	O
collected	O
off-line	O
and	O
no	O
additional	O
sample	O
preparation	O
was	O
performed	O
prior	O
to	O
the	O
fraction	O
being	O
injected	O
into	O
the	O
CHIP	O
system.	O

2-Oxoglutarate	B
also	O
inhibits	O
angiogenesis-related	O
proteins,	O
such	O
as	O
HIF-1α,	B
erythropoietin,	B
and	O
VEGF,	O
under	O
hypoxic	O
conditions	O
in	O
tumor	O
cells.	O

Intriguingly,	O
steroid	O
pathway	O
analysis	O
revealed	O
evidence	O
for	O
additional	O
autonomous	O
production	O
of	O
11β-hydroxyandrostenedione,	B
which	O
is	O
a	O
major	O
product	O
of	O
adrenal	O
steroidogenesis	O
and	O
a	O
direct	O
precursor	O
to	O
potent	O
androgens	O
(,	O
).	O

To	O
the	O
combined	O
effluent,	O
9	O
ml	O
of	O
water	O
was	O
added	O
to	O
give	O
19	O
ml	O
of	O
∼17.5%	O
methanol.	B

Risk	O
of	O
a	O
Major	O
Adverse	O
Cardiovascular	O
Event	O
at	O
3	O
Years,	O
According	O
to	O
Quartile	O
of	O
TMAO	B
Level._	O

A	O
3-oxo-4-ene	B
functionality	O
was	O
generated	O
by	O
oxidation	O
of	O
the	O
native	O
3β-hydroxy-5-ene	B
function	O
by	O
cholesterol	B
oxidase	O
prior	O
to	O
treatment	O
with	O
GP	B
reagent.	O

The	O
reaction	O
of	O
HONH-PhIP	O
with	O
oxygen	O
results	O
in	O
the	O
production	O
of	O
NO-PhIP	O
and	O
superoxide	B
anion.	O

More	O
polar	O
species	O
preferred	O
MTBE;	B
more	O
hydrophobic	O
compounds	O
preferred	O
DCM.	O

The	O
second	O
phosphopeptide	B
matched	O
shows	O
phosphorylation	O
only	O
on	O
serine	B
and	O
is	O
from	O
the	O
C-type	O
lectin	O
domain	O
family	O
9	O
member	O
A	O
protein.	O

Leucine,	B
isoleucine	B
and	O
valine	B
are	O
essential	O
amino	O
acids	O
whose	O
carbon	O
structures	O
are	O
marked	O
by	O
branch	O
points	O
(BCAA).	O

For	O
example,	O
if	O
we	O
observed	O
L-valine	B
2	O
as	O
statistically	O
significant,	O
we	O
included	O
L-valine	B
1	O
in	O
the	O
list.	O

On	O
the	O
other	O
hand,	O
total	O
cholesterol	B
is	O
higher	O
in	O
the	O
southeast	O
(4.9	O
versus	O
5.7	O
mmol/l),	O
so	O
the	O
difference	O
in	O
the	O
ratio	O
of	O
HDL_2	O
to	O
total	O
cholesterol	B
is	O
less	O
pronounced.	O

Stock	O
solutions	O
(20	O
mM)	O
for	O
the	O
synthetic	O
analogues	O
of	O
all	O
these	O
28	O
metabolites	O
and	O
internal	O
standards,	O
DSS	O
(5	O
mM),	O
maleic	B
acid	I
(20	O
mM)	O
and	O
ethanolamine	B
(20	O
mM),	O
were	O
prepared.	O

Through	O
glia	O
cells,	O
glutamate	B
is	O
converted	O
to	O
glutamine	B
and	O
released	O
into	O
the	O
extracellular	O
fluid	O
from	O
which	O
it	O
is	O
reabsorbed	O
into	O
presynaptic	O
terminals	O
and	O
converted	O
back	O
to	O
glutamate	B
via	O
the	O
action	O
of	O
neuronal	O
glutaminase.	O

α-Keto	B
acids	I
are	O
products	O
of	O
BCAA	O
catabolism	O
that	O
occurs	O
in	O
the	O
mitochondria.	O

In	O
such	O
cases,	O
only	O
dedicated	O
experiments	O
(similar	O
to	O
the	O
one	O
for	O
the	O
carnitine/SLC16A9	O
association	O
mentioned	O
above)	O
could	O
validate	O
the	O
connection	O
of	O
ethanolamine	B
to	O
the	O
gene	O
product.	O

Differences	O
in	O
phospholipid	B
metabolism	O
can	O
reflect	O
the	O
growth	O
and	O
turnover	O
of	O
tissue	O
as	O
well	O
as	O
the	O
increase	O
after	O
degradation	O
of	O
membranes	O
during	O
apoptosis	O
(Beloribi‐Djefaflia	O
et al	O
.,	O
2016;	O
Santos	O
and	O
Schulze,	O
2012).	O

HDL	B
cholesterol	I
was	O
assayed	O
by	O
a	O
homogeneous	O
enzymatic	O
colorimetric	O
test	O
(Roche/Hitachi,	O
cat.no	O
04713214).	O

Generation	O
of	O
models	O
like	O
partial	O
least	O
square	O
discriminant	O
analysis	O
(PLS-DA)	O
and	O
orthogonal	O
projections	O
to	O
latent	O
structures	O
discriminant	O
analysis	O
(OPLS-DA)	O
based	O
on	O
different	O
metabolites	O
including	O
lipids,	O
amino	O
acids,	O
glucose,	B
fucose,	B
isobutyrate,	B
and	O
glycerol	B
revealed	O
satisfactory	O
outcomes	O
with	O
85.2%	O
and	O
91.1%	O
classification	O
rates,	O
respectively.	O

Therefore,	O
the	O
salivary	O
choline–creatinine	B
ratio	O
showed	O
oral	O
cancer-specific	O
elevation	O
(Supplementary	O
Table S2	O
and	O
Fig.	O

With	O
the	O
exception	O
of	O
phenylacetic	B
acid,	I
the	O
microbially-derived	O
solutes	O
are	O
conjugates.	O

After	O
a	O
90-minute	O
treatment	O
with	O
hydrogen	B
peroxide,	I
the	O
viability	O
of	O
the	O
cells	O
was	O
evaluated	O
with	O
an	O
Alamar	O
Blue	O
assay	O
(Invitrogen,	O
Carlsbad,	O
CA).	O

Additionally,	O
the	O
simple	O
aqueous-methanolic	B
sample	O
extraction	O
technique	O
used	O
failed	O
to	O
capture	O
most	O
of	O
the	O
nonpolar	O
fatty	O
acids,	O
i.e.,	O
SCFAs,	O
unconjugated	O
secondary	O
bile	O
acids	O
and	O
other	O
specialized	O
metabolites	O
and	O
volatiles	O
that	O
are	O
typically	O
released	O
by	O
the	O
gut	O
microbiome	O
and	O
the	O
host's	O
gut	O
cellular	O
landscape	O
.	O

The	O
gradient	O
program	O
was:	O
90%	O
methanol	B
for	O
1.5	O
min,	O
decreased	O
to	O
75%	O
methanol	B
over	O
1	O
min	O
and	O
hold	O
for	O
3	O
min,	O
decreased	O
to	O
35%	O
methanol	B
over	O
3	O
min	O
and	O
hold	O
for	O
3	O
min,	O
then	O
decreased	O
to	O
10%	O
methanol	B
over	O
1.5	O
min	O
and	O
hold	O
for	O
3	O
min,	O
and	O
back	O
to	O
90%	O
methanol	B
over	O
1	O
min	O
and	O
hold	O
for	O
5	O
min	O
to	O
re-equilibrate	O
the	O
column.	O

The	O
supernatant	O
was	O
evaporated	O
and	O
reconstituted	O
with	O
5%	O
acetonitrile	B
aqueous	O
solution	O
followed	O
by	O
filtrating	O
through	O
a	O
0.22 µm	O
membrane	O
and	O
analyzed.	O

In	O
the	O
pathway	O
analysis	O
we	O
found	O
three	O
biochemical	O
pathways	O
that	O
were	O
affected	O
in	O
SPMS	O
compared	O
with	O
controls:	O
tryptophan	B
metabolism;	O
phenylalanine	B
metabolism	O
and	O
caffeine	B
metabolism	O
(f,	O
).	O

Although	O
several	O
hundred	O
metabolites	O
remain	O
to	O
be	O
identified,	O
a	O
panel	O
of	O
six	O
metabolites	O
namely	O
sarcosine,	B
uracil,	B
kynurenine,	B
glycerol-3-phosphate,	B
leucine,	B
and	O
proline	B
showed	O
a	O
statistically	O
significant	O
increase	O
in	O
abundance	O
in	O
localized	O
and	O
metastatic	O
PCa,	O
as	O
compared	O
to	O
benign	O
tissues.	O

In	O
fact,	O
it	O
has	O
already	O
been	O
postulated	O
that	O
AIS	O
has	O
a	O
dysfunctional	O
energy	O
balance	O
involving	O
a	O
complex	O
systems	O
including	O
white	O
adipose	O
tissue,	O
the	O
adipose-tissue	O
derived	O
hormone	O
leptin	O
and	O
other	O
cytokine-hormones,	B
hypothalamus	O
and	O
neuroendocrine	O
axes.	O

Elevated	O
ADMA	B
concentrations	O
have	O
been	O
previously	O
reported	O
to	O
be	O
associated	O
with	O
pregnancy-related	O
hypertension	O
and	O
preeclampsia.	O

Urinary	O
metabolic	O
profiling	O
by	O
Nuclear	O
Magnetic	O
Resonance	O
(NMR)	O
and	O
ultra	O
performance	O
liquid	O
chromatography	O
hyphenated	O
to	O
Q-TOF	O
mass	O
spectrometry	O
(UPLC-MS)	O
was	O
performed	O
in	O
a	O
Discovery	O
set	O
of	O
subjects	O
with	O
HNF1A-MODY	O
(n = 14),	O
GCK-MODY	O
(n = 17),	O
T2D	O
(n = 14)	O
and	O
normoglycaemic	B
controls	O
(n = 34).	O

Our	O
results	O
showed	O
that	O
arginine	B
levels	O
in	O
the	O
PR	O
group	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
the	O
GR	O
group.	O

TMAO	B
enhances	O
the	O
accumulation	O
of	O
cholesterol	B
in	O
macro-phages,	O
the	O
accumulation	O
of	O
foam	O
cells	O
in	O
artery	O
walls,	O
and	O
atherosclerosis,	O
all	O
factors	O
that	O
are	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
heart	O
attack,	O
stroke,	O
and	O
death.	O

Effect	O
of	O
metreleptin	O
therapy	O
on	O
1,5-anhydroglucitol	B
levels	O
and	O
metabolites	O
in	O
the	O
pregnenolone	B
pathway.	O

In	O
conclusion,	O
urinary	O
myo-inositol	B
differentiates	O
FSGS	O
patients	O
from	O
MCD	O
patients	O
and	O
correlates	O
with	O
various	O
clinical	O
parameters	O
of	O
FSGS	O
patients.	O

Kynurenine	B
pathway,	O
resting-state	O
functional	O
connectivity,	O
adolescence,	O
major	O
depressive	O
disorder,	O
anhedonia	O

The	O
metabolites	O
comprised	O
of	O
the	O
amino	O
acids	O
phenylalanine	O
and	O
proline,	B
and	O
seven	O
phosphocholines.	B

The	O
injected	O
samples	O
were	O
equilibrated	O
with	O
water	O
containing	O
0.1%	O
formic	B
acid.	I

Upon	O
receipt	O
of	O
fasted,	O
baseline	O
plasma	O
samples	O
from	O
HI	B
clamps,	O
aliquots	O
were	O
prepared	O
and	O
immediately	O
frozen	O
at	O
−80°C	O
until	O
time	O
of	O
analysis.	O

In	O
particular,	O
glucose,	B
5-OH-TRP,	B
and	O
TRP	O
were	O
lower	O
in	O
the	O
patients	O
with	O
MS,	O
whereas	O
3-OH-butyrate,	B
acetoacetate,	B
acetone,	B
alanine,	B
and	O
choline	B
had	O
higher	O
concentrations	O
in	O
the	O
patients	O
with	O
MS.	O

Although	O
active	O
tobacco	O
smoking	O
was	O
an	O
exclusion	O
criterion,	O
the	O
analysis	O
of	O
urinary	O
cotinine	B
showed	O
that	O
three	O
control	O
subjects	O
had	O
cotinine	B
levels	O
greater	O
than	O
50	O
µg/L	O
(212,	O
195,	O
668	O
µg/L),	O
which	O
was	O
considered	O
as	O
the	O
cutoff	O
to	O
distinguish	O
active	O
smokers	O
from	O
persons	O
exposed	O
to	O
passive	O
smoke.	O

The	O
mean	O
concentration	O
of	O
urinary	O
PGE-M	O
was	O
17.9	O
±	O
12.9	O
ng/mg	O
creatinine	B
for	O
HNSCC	O
cases	O
and	O
14.0	O
±	O
12.2	O
ng/mg	O
creatinine	B
for	O
healthy	O
controls.	O

It	O
is	O
difficult	O
to	O
compare	O
our	O
findings	O
with	O
others	O
reports	O
since	O
the	O
initial	O
study	O
by	O
Sreekumar	O
et	O
al	O
differ	O
in	O
the	O
methodology	O
of	O
sarcosine	B
measurement	O
,	O
sample	O
source	O
,	O
,	O
and	O
importantly	O
criteria	O
defining	O
recurrence	O
–.	O

Therefore,	O
we	O
also	O
concluded	O
that	O
the	O
product	O
of	O
pyridinium	B
dichromate	O
oxidation	O
of	O
10	O
generated	O
9.	O

A	O
pilot	O
study	O
was	O
carried	O
out	O
on	O
five	O
obese/overweight	O
patients	O
suffering	O
from	O
metabolic	O
syndrome,	O
with	O
the	O
aim	O
to	O
evaluate	O
postprandial	O
effects	O
of	O
high	O
fat/high	O
glycemic	B
load	O
meals	O
enriched	O
by	O
blueberries.	O

The	O
mass	O
error	O
calculated	O
against	O
their	O
theoretical	O
masses	O
was	O
shown	O
to	O
be	O
below	O
1.5	O
ppm,	O
thus	O
aiding	O
in	O
unambiguous	O
identification	O
of	O
both	O
ceramide	B
molecular	O
species.	O

In	O
this	O
work,	O
_13	O
C	O
atoms	O
in	O
various	O
metabolites	O
deriving	O
exclusively	O
from	O
[U-_13	B
C]-glucose	I
were	O
monitored	O
by	O
NMR	O
or	O
mass	O
spectrometry,	O
which	O
represented	O
de	O
novo	O
metabolic	O
transformations	O
originating	O
from	O
glucose.	B

The	O
increase	O
of	O
arginase	O
activity	O
will	O
decrease	O
the	O
catalytic	O
activity	O
of	O
arginine	B
for	O
NO	O
production	O
and	O
lead	O
to	O
the	O
uncoupling	O
of	O
eNOS,	O
while	O
uncoupled	O
eNOS	O
can	O
induce	O
the	O
transfer	O
of	O
electrons	O
from	O
NADPH	B
to	O
oxygen	O
molecules	O
to	O
form	O
superoxide	B
anions	O
(O2-).	O

BaP	O
carcinogenicity	O
is	O
believed	O
to	O
occur	O
mainly	O
through	O
its	O
covalent	O
modification	O
of	O
DNA,	O
resulting	O
in	O
the	O
formation	O
of	O
BPDE--dG,	O
an	O
adduct	O
formed	O
between	O
deoxyguanosine	B
and	O
a	O
diol	B
epoxide	I
metabolite	O
of	O
BaP,	O
with	O
subsequent	O
mutation	O
of	O
critical	O
growth	O
control	O
genes.	O

For	O
LLE	O
standard	O
addition	O
experiments	O
400	O
μL	O
pooled	O
human	O
serum	O
was	O
aliquoted	O
into	O
2	O
mL	O
plastic	O
tubes	O
and	O
each	O
group	O
(n	O
=4)	O
was	O
spiked	O
with	O
10	O
μL	O
blank,	O
1.0,	O
3.0	O
and	O
10.0	O
ng/mL	O
1α,25(OH)_2	B
D_3	O
as	O
well	O
as	O
125,	O
250	O
or	O
500	O
ng/mL	O
25(OH)D_3	O
.	O

The	O
levels	O
of	O
TXB_2	O
,	O
the	O
stable	O
hydrolysis	O
product	O
of	O
TXA_2	O
,	O
were	O
lower	O
compared	O
to	O
the	O
prostaglandins	B
and	O
thus	O
indicate	O
lower	O
levels	O
of	O
TXA_2	O
.	O

Desmethyldiazepam	B
(20	O
µl	O
of	O
250	O
ng	O
ml_−1	O
)	O
was	O
added	O
as	O
an	O
internal	O
standard	O
to	O
the	O
incubation	O
sample	O
which	O
was	O
then	O
vortex	O
mixed	O
for	O
30	O
s,	O
and	O
centrifuged	O
at	O
14	O
000	O
rev	O
min_−1	O
for	O
5	O
min	O
in	O
an	O
Eppendorf	O
model	O
5415D	O
centrifuge	O
(Brinkmann	O
Instruments,	O
Westbury,	O
NY).	O

Plasma	O
concentrations	O
of	O
parathyroid	O
hormone	O
and	O
fibroblast	O
growth	O
factor-23	O
were	O
measured	O
concurrently	O
with	O
vitamin	B
D	I
metabolites	O
in	O
a	O
subset	O
of	O
300	O
participants	O
using	O
immunoassay	O
and	O
ELISA,	O
respectively.	O

pH	O
11.0,	O
–15	O
kV	B
was	O
used	O
on	O
AMPS	O
and	O
VBTA	O
coated	O
capillary,	O
respectively.	O

These	O
metabolites	O
included	O
corticosteroids,	O
bilirubin,	B
amino	O
acids,	O
acylcarnitines,	B
and	O
lysophospholipids.	B

Among	O
the	O
seven	O
metabolites	O
that	O
showed	O
highly	O
significant	O
differences	O
in	O
the	O
individual	O
metabolite	O
analysis,	O
aspartic	B
acid	I
was	O
present	O
in	O
6	O
groups,	O
glyceraldehyde	B
and	O
hippuric	B
acid	I
were	O
present	O
in	O
one	O
group	O
each,	O
and	O
xanthine,	B
xanthosine,	B
orotate	B
and	O
hydroxyproline/aminolevulinate	O
were	O
present	O
in	O
two	O
groups	O
each,	O
as	O
shown	O
in	O
the	O
.	O

Arguing	O
against	O
a	O
role	O
of	O
acrolein	B
in	O
smoking	O
induced	O
lung	O
cancer	O
is	O
its	O
weak	O
carcinogenic	O
activity.	O

Based	O
on	O
the	O
ischemic	O
insult	O
severity,	O
elevation	O
of	O
catecholamine	B
levels	O
can	O
be	O
observed	O
for	O
prolonged	O
periods	O
of	O
up	O
to	O
24 h.	O

The	O
bottom	O
chloroform	B
phase	O
was	O
transferred	O
to	O
GC	O
vials	O
containing	O
~100	O
mg	O
of	O
anhydrous	B
sodium	I
sulfate.	I

The	O
running	O
time	O
for	O
every	O
sample	O
(injection	O
volume:	O
15	O
μl	O
for	O
Cer	B
and	O
dhCer	O
determination	O
and	O
10	O
μl	O
for	O
the	O
other	O
sphingolipids)	B
was	O
16	O
min.	O

We	O
selected	O
8	O
metabolites	O
(lactic	O
acid,	O
5-methoxytryptamine,	B
pyruvic	B
acid,	I
phenylalanine,	B
proline,	B
alanine,	B
threonine,	B
and	O
3-hydroxybutyric	B
acid)	O
that	O
were	O
quantitatively	O
measured	O
by	O
LC-MS	O
analysis.	O

Citrate	B
contributes	O
to	O
the	O
production	O
of	O
prostaglandin,	B
reactive	O
oxygen	O
species	O
(ROS),	O
and	O
nitric	B
oxide	I
(NO),	O
which	O
have	O
a	O
remarkable	O
role	O
in	O
inflammation	O
and	O
cell	O
damage.	O

Leucine,	B
is	O
involved	O
in	O
the	O
induction	O
of	O
muscle	O
biogenesis	O
and	O
is	O
an	O
independent	O
predictor	O
of	O
muscle	O
protein	O
synthesis	O
[,	O
].	O

(A	O
)	O
Erythritol	B
(Ery)	O
is	O
synthesized	O
from	O
glucose	B
via	O
the	O
PPP	O
from	O
glucose-6-phosphate	B
(G6P).	O

Previous	O
work	O
suggests	O
that	O
sphingolipid	B
metabolism	O
may	O
be	O
disrupted	O
in	O
IBD,	O
resulting	O
in	O
an	O
accumulation	O
of	O
specific	O
sphingolipid	B
compounds	O
that	O
promote	O
an	O
inflammatory	O
state_–	O
.	O

The	O
mixture	O
was	O
then	O
extracted	O
and	O
deproteinized	O
by	O
adding	O
100	O
μL	O
of	O
acetonitrile	B
and	O
vortex	O
mixed	O
for	O
30	O
s.	O

Because	O
FAO	O
feeds	O
the	O
Krebs	O
cycle	O
with	O
abundant	O
acetyl-CoA,	B
increased	O
amounts	O
of	O
citrate	B
will	O
be	O
generated,	O
which	O
is	O
the	O
starting	O
point	O
for	O
de	O
novo	O
fatty	O
acid	O
synthesis	O
for	O
new	O
membrane	O
components	O
.	O

The	O
amount	O
of	O
lysophosphatidylethanolamine	B
(LPE)	O
was	O
significantly	O
decreased	O
in	O
NAFL	O
and	O
NASH	O
patients	O
in	O
comparison	O
to	O
controls	O
(E).	O

On	O
the	O
other	O
hand,	O
others	O
have	O
reported	O
that	O
AKR	O
expression	O
contributes	O
to	O
DOX	O
resistance	O
in	O
breast	O
cancer	O
cells,	O
even	O
in	O
the	O
absence	O
of	O
detectible	O
doxorubicinol	B
accumulation	O
in	O
these	O
cells	O
or	O
media.	O

PC	B
ae	I
C40:1;	I
125.	O

An	O
additional	O
68	O
unique	O
features	O
were	O
found	O
when	O
negative	O
mode	O
was	O
used	O
to	O
analyze	O
the	O
MTBE	B
aqueous	O
fraction.	O

Here,	O
we	O
have	O
also	O
observed	O
increased	O
PC	O
with	O
MW	O
731.7	O
(which	O
corresponds	O
to	O
PC	B
16:0/16:1).	I

The	O
increased	O
urinary	O
betaine	B
excretion	O
seen	O
in	O
those	O
with	O
metabolic	O
syndrome	O
means	O
we	O
would	O
expect	O
that	O
subjects	O
with	O
T2D	O
would	O
have	O
higher	O
urine	O
betaine	B
as	O
we	O
saw	O
in	O
the	O
extended	O
study.	O

Figure	O
1b,	O
the	O
catechol	B
estrogens:	O
2-hydroxyestrone	B
(2-OHE_1	O
),	O
2-hydroxyestradiol	B
(2-OHE_2	O
),	O
and	O
4-hydroxyestrone	B
(4-OHE_1	O
);	O
Figure	O
1c,	O
the	O
16α	B
pathway	I
estrogens:	O
16α-hydroxyestrone	B
(16α-OHE_1	I
),	I
17-epiestriol	O
17-epiE_3	O
),	O
estriol	B
(E3),	O
16-ketoestradiol	O
16-ketoE_2	O
)	O
and	O
16-epiestriol	B
(16epiE_3	O
);	O
Figure	O
1d,	O
the	O
methoxy	B
estrogens:	O
2-methoxyestrone	B
(2-MeOE_1	O
),	O
2-methoxyestradiol	B
(2-MeOE_2	O
),	O
2-hydroxyestrone-3-methyl	B
ether	I
(3-MeOE_1	O
),	O
4-methoxyestrone	B
(4-MeOE_1	O
),	O
and	O
4-methyoxyestradiol	B
(4-MeOE_2	O
).	O

This	O
suggests	O
that	O
the	O
previously	O
unrecognized	O
glucocorticoid	B
excess	O
in	O
primary	O
aldosteronism	O
is	O
a	O
major	O
determinant	O
of	O
metabolic	O
risk.	O

Comparison	O
of	O
tryptophan	B
(C)	O
and	O
kynurenine	B
(D)	O
concentrations	O
in	O
plasma	O
from	O
normal	O
women,	O
all	O
breast	O
cancer	O
patients	O
in	O
the	O
cohort,	O
and	O
ER+	O
versus	O
ER-breast	O
cancer	O
patients.	O

The	O
spray	O
voltage	O
was	O
set	O
at	O
+1.8	O
kV;	B
the	O
temperature	O
of	O
the	O
capillary	O
was	O
set	O
at	O
200°C;	O
the	O
capillary	O
voltage	O
was	O
set	O
at	O
+20	O
V;	O
the	O
tube	O
lens	O
voltage	O
was	O
set	O
at	O
+100	O
V;	O
and	O
the	O
auxiliary	O
gas	O
was	O
set	O
to	O
zero.	O

Previous	O
animal	O
and	O
human	O
studies	O
have	O
shown	O
higher	O
concentrations	O
of	O
circulating	O
triglycerides,	B
as	O
well	O
as	O
an	O
altered,	O
pro-atherogenic	O
lipid	O
and	O
cholesterol	B
metabolism	O
in	O
growth-restricted	O
fetuses.	O

A	O
consisted	O
of	O
0.1 %	O
formic	B
acid	I
in	O
water	O
(HPLC	O
grade,	O
Tedia,	O
Ohio,	O
USA)	O
and	O
mobile	O
phase	O
B	O
was	O
0.1 %	O
formic	B
acid	I
in	O
acetonitrile	B
(HPLC	O
grade,	O
Tedia,	O
Ohio,	O
USA).	O

In	O
contrast,	O
median	O
concentrations	O
for	O
androstenedione	B
averaged	O
60%	O
higher	O
in	O
the	O
present	O
study	O
than	O
in	O
the	O
earlier	O
study	O
with	O
parallel	O
differences	O
in	O
reference	O
intervals.	O

Citrulline.	B

Tentative	O
identification	O
of	O
the	O
metabolites	O
found	O
to	O
be	O
unique	O
to	O
the	O
MTBE	B
lipid	O
fraction	O
was	O
performed.	O

fowleri	O
trophozoites	O
treated	O
with	O
(A)	O
0.5%	O
DMSO,	B
(B)	O
0.2	O
μM	O
posaconazole,	B
(C)	O
5.4	O
μM	O
epiminolanosterol,	B
and	O
(D)	O
5.6	O
μM	O
AY9944.	O

The	O
aromatic	O
amino	O
acids	O
Phe	O
and	O
Tyr	O
are	O
the	O
biosynthetic	O
precursors	O
of	O
the	O
monoamine	B
neurotransmitters	O
(dopamine	O
(DA)	O
and	O
noradrenaline	B
(NA)).	O

However,	O
leptin’s	O
effects	O
on	O
11βHSD1	B
in	O
nonadipose	O
tissues	O
is	O
less	O
clear.	O

Uridine	B
is	O
produced	O
from	O
cytidine	B
by	O
cytidine	O
deaminase.	O

In	O
the	O
mass	O
spectrometry	O
experiments	O
using	O
either	O
LC-MS/MS	O
or	O
GCMS,	O
metabolite	O
levels	O
were	O
measured	O
in	O
the	O
cell	O
lines	O
immediately	O
before	O
(zero	O
time	O
control)	O
and	O
then	O
60	O
min	O
after	O
10	O
mM	O
[U-_13	B
C]glucose	I
or	O
2	O
mM	O
[U-_13	B
C]glutamine	I
were	O
added	O
to	O
the	O
cells.	O

When	O
plasma	O
metabolome	O
from	O
Baseline	O
was	O
compared	O
with	O
post-H.	O
pylori	O
eradication	O
groups,	O
a	O
number	O
of	O
fatty	O
acids	O
and	O
sphingolipids	B
involved	O
in	O
biosynthesis	O
of	O
unsaturated	O
fatty	O
acids	O
and	O
sphingolipid	B
metabolism	O
respectively	O
were	O
down-	O
regulated	O
post-H.	O
pylori	O
eradication.	O

The	O
AUC	O
of	O
the	O
panel	O
for	O
low-grade	O
NMIBC	O
samples,	O
which	O
consisted	O
of	O
3-hydroxy-cis-5-tetradecenoylcarnitine,	B
6-ketoestriol,	O
beta-cortolone,	B
tetrahydrocorticosterone,	B
and	O
heptylmalonic	O
acid,	O
was	O
0.899.	O

In	O
this	O
study,	O
several	O
of	O
the	O
true	O
positive	O
metabolites	O
such	O
as	O
1-methlyhistidine	B
and	O
2-aminobutyric	B
acid	I
had	O
a	O
uniqueness	O
value	O
0,	O
which	O
would	O
have	O
been	O
missed	O
if	O
the	O
uniqueness	O
filter	O
had	O
been	O
applied	O
in	O
the	O
HSQC-based	O
query.	O

In	O
the	O
corresponding	O
loading	O
plot,	O
several	O
metabolites,	O
such	O
as	O
taurine,	B
lactate,	B
glucose	B
and	O
several	O
others	O
can	O
be	O
identified.	O

After	O
normalization	O
of	O
data	O
using	O
creatinine	B
as	O
internal	O
standard,	O
a	O
number	O
of	O
differentially	O
expressed	O
compounds	O
with	O
p	O
values	O
of	O
<0.05	O
were	O
selected	O
by	O
statistical	O
analysis	O
to	O
construct	O
a	O
PCA	O
model	O
for	O
assessment	O
of	O
the	O
clustering	O
of	O
the	O
ASDs	O
group	O
and	O
the	O
control	O
group.	O

The	O
lipids	O
were	O
extracted	O
from	O
milk	O
and	O
soy	O
drink	O
samples	O
after	O
an	O
ammonia-alkaline	B
digestion	O
at	O
room	O
temperature	O
with	O
a	O
mixture	O
of	O
diethyl	B
ether	I
and	O
n-pentane.	B

Moreover,	O
obese	O
young	O
breast	O
cancer	O
patients	O
were	O
found	O
to	O
have	O
larger	O
tumors,	O
higher	O
grade,	O
and	O
were	O
more	O
often	O
ER	O
negative	O
and	O
PgR	O
negative,	O
and	O
the	O
oxysterol,	B
27OH-Cholesterol,	B
is	O
associated	O
with	O
hormone	O
receptor	O
positive	O
breast	O
cancer	O
cell	O
proliferation.	O

Further,	O
these	O
results	O
should	O
contribute	O
to	O
the	O
development	O
of	O
well-designed	O
clinical	O
studies	O
that	O
will	O
allow	O
us	O
to	O
substantiate	O
and	O
better	O
understand	O
the	O
effects	O
of	O
equol	O
and	O
isoflavone	B
on	O
health.	O

These	O
would	O
have	O
had	O
a	O
severe	O
adverse	O
impact	O
on	O
the	O
identification	O
of	O
C=C	O
locations	O
in	O
PE	B
39:4	I
if	O
PB–MS/MS	O
analysis	O
was	O
directly	O
applied	O
to	O
the	O
lipid	O
extract.	O

Accordingly	O
the	O
apparent	O
formation	O
rate	O
of	O
hydroxyanastrozole	B
from	O
anastrozole	B
(0.5–200	O
µm)	O
in	O
HLMs	O
exhibited	O
biphasic	O
kinetic	O
behaviour	O
in	O
Eadie-Hofstee	O
plots,	O
which	O
suggested	O
the	O
involvement	O
of	O
at	O
least	O
two	O
enzymatic	O
activities	O
that	O
were	O
best	O
described	O
by	O
high-affinity	O
(K	O
_m1	O
and	O
V	O
_max1	O
)	O
and	O
low-affinity	O
(K	O
_m2	O
and	O
V	O
_max2	O
)	O
components.	O

All	O
phospholipids	B
correlated	O
positively	O
with	O
sphingolipids	B
Cer,	I
SM,	O
and	O
So,	O
which	O
are	O
also	O
components	O
of	O
lipoprotein	O
membranes.	O

(a)	O
Heat-map	O
of	O
fold	O
change	O
of	O
56	O
differential	O
metabolites;	O
(b)	O
Discrimination	O
of	O
T2DM	O
in	O
the	O
training	O
set	O
using	O
Linolenic	B
Acid	I
(1),	O
deoxycholic	B
acid	I
(2),	O
and	O
the	O
combination	O
of	O
them	O
(3).	O

On	O
filtering	O
out	O
exogenous	O
plasma	O
metabolites	O
that	O
were	O
not	O
produced	O
by	O
the	O
human	O
body,	O
two	O
hopanoids	B
produced	O
by	O
Proteobacteria	O
in	O
the	O
plasma,	O
bacteriohopane-,32,33,34-triol-35-cyclitolguanine	B
and	O
2-methyl-32,35-anhydrobacteriohopanetetrol,	B
were	O
detected	O
that	O
may	O
be	O
correlated	O
with	O
the	O
Proteobacteria	O
hopanoid	B
(32,35-anhydrobacteriohopaneterol)	I
found	O
in	O
fecal	O
lipidome.	O

Therefore,	O
2-hydroxybutyrate	B
would	O
not	O
be	O
produced	O
in	O
the	O
blood	O
by	O
lactate	O
dehydrogenase,	O
but	O
the	O
enzymatic	O
production	O
of	O
2-hydroxybutyrate	B
by	O
α-hydroxybutyrate	O
dehydrogenase	O
might	O
be	O
caused	O
in	O
blood	O
and/or	O
2-hydroxybutyrate	B
would	O
be	O
secreted	O
from	O
cells.	O

At	O
24	O
h,	O
the	O
triphosphate	B
metabolites	O
accounted	O
for	O
approximately	O
70%	O
of	O
the	O
total	O
intracellular	O
metabolites	O
for	O
both	O
sofosbuvir	B
and	O
ribavirin.	B

Comparison	O
of	O
a	O
portion	O
of	O
800	O
MHz,	O
cryo-probe	O
_1	O
H	O
NMR	O
spectra	O
of	O
the	O
same	O
pooled	O
human	O
serum	O
sample	O
obtained	O
by	O
suppressing	O
protein	O
signals	O
(a)	O
by	O
ultrafiltration	O
using	O
3	O
kDa	O
cutoff	O
filter	O
and	O
(b)	O
by	O
protein	O
precipitation	O
using	O
methanol	B
(1:2).	I

After	O
informed	O
consent	O
was	O
obtained,	O
first	O
morning	O
urine	O
samples	O
(20	O
mL)	O
were	O
collected	O
using	O
a	O
PP	O
container	O
and	O
transferred	O
into	O
an	O
acetonitrile	B
(ACN)-prewashed	O
amber	O
glass	O
bottle	O
and	O
stored	O
at	O
-20	O
℃.	O

By	O
applying	O
the	O
quantitation	O
procedure	O
described	O
earlier,	O
PC	B
16:0/18:1	I
was	O
determined	O
to	O
be	O
1.7	O
±	O
0.1	O

SM	B
C26:1;	I
25.	O

In	O
our	O
experiments,	O
bilirubin	B
was	O
significantly	O
increased	O
in	O
the	O
AMS-S	O
group	O
compared	O
with	O
the	O
AMS-R	O
group,	O
which	O
indicates	O
the	O
AMS-S	O
group	O
may	O
have	O
experienced	O
stronger	O
oxidative	O
stress	O
and	O
neurologic	O
damage.	O

[Google	O
Scholar]	O
Salzman	O
PM,	O
Salmon	O
JA,	O
Moncada	O
S.	O
Prostacyclin	B
and	O
thromboxane	B
A2	I
synthesis	O
by	O
rabbit	O
pulmonary	O
artery.	O

Acylcarnitine	B
metabolites	O
were	O
also	O
decreased	O
in	O
UC	O
as	O
compared	O
with	O
control,	O
but	O
did	O
not	O
reach	O
significance.	O

AhR	O
antagonism	O
would	O
interfere	O
with	O
kynurenine-mediated	O
AhR	O
activation,	O
but	O
would	O
not	O
abrogate	O
tryptophan	B
depletion.	O

Deoxyinosine	B
correlated	O
with	O
cAMP	O
(r = 0.52;	O

95%	O
CI:	O
0.942–3.561,	O
P = 0.075	O
and	O
sulfate:	B
HR:	O
0.96,	O
95%	O
CI	O
0.502–1.823,	O
P = 0.892)	O
or	O
overall	O
survival	O
(glucuronide:	O
HR:	O
1.71,	O
95%	O
CI:	O
0.986–2.968,	O
P = 0.056	O
and	O
sulfate:	B
HR:	O
1.05,	O
95%	O
CI:	O
0.611–1.796,	O
P = 0.865).	O

We	O
conducted	O
for	O
the	O
first	O
time	O
an	O
exhaustive	O
and	O
simultaneous	O
assessment	O
of	O
all	O
metabolisms	O
and	O
simplified	O
the	O
correlation	O
among	O
altered	O
glucose,	B
protein	O
and	O
lipid	O
metabolism.	O

In	O
addition,	O
statin	B
group	O
has	O
a	O
higher	O
percentage	O
of	O
males	O
and	O
lower	O
percentage	O
of	O
females	O
compared	O
to	O
the	O
non-statin	O
group.	O

Significant	O
inverse	O
associations	O
were	O
limited	O
to	O
glycerophosphocholine,	B
cotinine	B
and	O
catechol	B
sulfate	I
(Fig.	O

They	O
also	O
exist	O
in	O
outer	O
plasma	O
membrane	O
mostly	O
in	O
lipid	O
rafts,	O
in	O
conjunction	O
with	O
cholesterol.	B

The	O
unique	O
oxylipin	B
profile	O
observed	O
in	O
urine	O
can	O
be	O
attributed	O
to	O
the	O
specific	O
function	O
that	O
the	O
kidneys	O
perform	O
by	O
concentrating	O
certain	O
metabolites	O
from	O
blood.	O

By	O
using	O
combination	O
of	O
LysoPC(16:0)	B
and	O
7-Dehydrocholesterol-1	B
with	O
or	O
without	O
Diosgenin-1,	O
which	O
were	O
top	O
3	O
metabolites	O
with	O
higher	O
AUC	O
in	O
this	O
analysis,	O
PSP	O
was	O
distinguished	O
with	O
higher	O
accuracy.	O

For	O
example	O
study	O
by	O
Tana	O
et	O
al	O
observed	O
the	O
altered	O
profile	O
of	O
intestinal	O
microbiota,	O
especially	O
Lactobacilli	B
and	O
Veillonella	O
;	O
and	O
unbalanced	O
fecal	O
organic	O
acid	O
levels	O
in	O
IBS.	O

Regarding	O
xylitol	B
in	O
the	O
urine	O
of	O
HBV	O
patients,	O
this	O
polyol	O
was	O
found	O
to	O
exhibit	O
the	O
largest	O
decline	O
of	O
any	O
urinary	O
metabolite	O
detected	O
between	O
control	O
samples	O
and	O
liver	O
cirrhosis/hepatocellular	O
carcinoma	O
patients	O
in	O
Egypt.	O

Low	O
levels	O
of	O
coenzyme	O
PLP	O
in	O
plasma	O
have	O
been	O
associated	O
with	O
their	O
recruitment	O
to	O
inflammatory	O
sites	O
for	O
degradation	O
of	O
tryptophan	B
via	O
the	O
kynurenine	B
pathway,	O
metabolism	O
of	O
sphingolipids,	B
immunomodulatory,	O
and	O
proliferation	O
of	O
immune	O
cells.	O

It	O
may	O
be	O
produced	O
from	O
methionine	B
oxidation	O
by	O
reactive	O
oxygen	O
species.	O

The	O
ROC	O
curve	O
of	O
the	O
4-variable	O
panel	O
including	O
age,	O
proline,	B
glutamate,	B
and	O
arginine—The	O
values	O
of	O
mean	O
AUC	O
of	O
the	O
panel	O
including	O
age,	O
proline,	B
glutamate,	B
and	O
arginine	B
in	O
the	O
training	O
set	O
(A)	O
is	O
0.962	O
(95%	O
CI:0.961,	O
0.963)	O
and	O
0.871	O

[Google	O
Scholar]	O
Kinoshita	O
F,	O
Nakai	O
Y,	O
Katakami	O
H,	O
Imura	O
H,	O
Shimizu	O
T,	O
Hayaishi	O
O.	O
Suppressive	O
effect	O
of	O
prostaglandin	B
(PG)D2	O
on	O
pulsatile	O
luteinizing	O
hormone	O
release	O
in	O
conscious	O
castrated	O
rats.	O

However,	O
as	O
betaine	B
functions	O
as	O
an	O
organic	O
osmolyte	O
and	O
methyl	O
donor,	O
its	O
importance	O
for	O
exercise	O
performance	O
has	O
recently	O
been	O
discussed.	O

The	O
complete	O
series	O
of	O
steps	O
from	O
neuronal	O
glutamate	B
release	O
to	O
resynthesis	O
of	O
glutamate	B
from	O
glutamine	B
is	O
called	O
the	O
Glu-Gln	O
cycle,	O
and	O
the	O
Gln/Glu	O
ratio	O
is	O
regarded	O
as	O
a	O
potentially	O
useful	O
index	O
for	O
Glu-Gln	O
cycle	O
in	O
neuronal-glial	O
interactions	O
and	O
the	O
balance	O
of	O
glutamatergic	B
metabolites.	O

We	O
next	O
sought	O
to	O
identify	O
metabolites	O
whose	O
baseline	O
levels	O
were	O
predictive	O
of	O
LDL-C	O
response	O
to	O
simvastatin	B
in	O
the	O
full	O
range	O
group.	O

All	O
PULSE	O
tubes	O
were	O
washed	O
with	O
MeOH	B
and	O
dried	O
prior	O
to	O
the	O
experiment.	O

25-Hydroxyvitamin	B
D_3	O
was	O
obtained	O
from	O
the	O
U.S.	O
Pharmacopeia	O
(USP,	O
Rockville,	O
MD).	O

Because	O
vitamin	B
D	I
metabolites	O
are	O
endogenous	O
compounds,	O
we	O
studied	O
method	O
accuracy	O
and	O
precision	O
using	O
the	O
addition	O
of	O
known	O
quantities	O
of	O
vitamin	B
D	I
metabolites	O
to	O
human	O
serum	O
and	O
extracted	O
it	O
by	O
LLE	O
and	O
SPE.	O

Low-density	O
lipoproteins	O
(LDL)	O
are	O
one	O
of	O
the	O
five	O
major	O
groups	O
of	O
lipoproteins,	O
which	O
facilitate	O
transport	O
of	O
multiple	O
different	O
lipid	O
molecules,	O
including	O
cholesterol,	B
triglyceride,	B
and	O
glycosphingolipids,	B
and	O
mediate	O
lipid	O
catabolism.	O

An	O
additional	O
plate	O
was	O
set	O
up	O
concurrently	O
and	O
a	O
crystal	O
violet	O
assay	O
was	O
performed	O
to	O
normalise	O
ATP	B
measurements	O
to	O
cell	O
number.	O

Plasma	O
was	O
extracted	O
in	O
acetonitrile	B
and	O
applied	O
to	O
an	O
Acquity	O
UPLC	O
HILIC	O
(1.7μm	O
x	O
2.1	O
x	O
100	O
mm)	O
column	O
coupled	O
to	O
a	O
Xevo	O
G2	O
QTof	O
mass	O
spectrometer	O
using	O
a	O
previously	O
optimised	O
method.	O

A	O
high-fat	O
and	O
low-carbohydrate	O
diet	O
that	O
elevates	O
circulating	O
levels	O
of	O
ketone	B
bodies	O
(i.e.,	O
acetoacetate,	B
β-hydroxybutyrate,	B
and	O
acetone)	O
diminish	O
the	O
overall	O
energetic	O
health	O
of	O
pancreatic	O
cancer	O
cells	O
by	O
reducing	O
glucose	B
uptake,	O
lactate	B
release,	O
glutamine	B
uptake,	O
cellular	O
ATP	B
content,	O
and	O
ROS	O
levels.	O

T2DM	O
and	O
IFG	O
were	O
defined	O
by	O
the	O
American	O
Diabetes	O
Association	O
criteria,	O
T2DM	O
by	O
fasting	O
glucose	B

Its	O
increased	O
urinary	O
excretion	O
closely	O
mirrors	O
the	O
decreased	O
levels	O
of	O
urinary	O
urea	B
and	O
cis	O
-aconitate.	O

Haemodialysis	O
is	O
rather	O
limited	O
in	O
improving	O
the	O
clearance	O
of	O
indole-based	O
uraemic	O
toxins	B
produced	O
by	O
gut	O
microflora,	O
depending	O
on	O
their	O
conjugates	O
and	O
affinity	O
to	O
albumin.	O

(Pio&	O
Omega-3).	B

The	O
urinary	O
levels	O
of	O
α	O
1-microglobulin,	O
β	O
2-microglobulin,	O
transferrin,	O
and	O
retinol	B
binding	O
protein	O
were	O
measured	O
with	O
kits	O
from	O
Siemens	O
using	O
a	O
Siemens	O
Dabe	O
Behring	O
BN	O
II	O
Nephelometer	O
Analyzer	O
(Siemens	O
HeathCare	O
GmbH,	O
Erlangen,	O
Germany).	O

Increased	O
concentrations	O
of	O
modiﬁed	O
nucleotides	O
(such	O
as	O
pseudouridine,	B
1-methyladenosine	B
and	O
1-methylguanosine)	B
in	O
the	O
urine	O
of	O
cancer	O
patients	O
are	O
reﬂective	O
of	O
high	O
whole-body	O
RNA	O
turnover	O
or	O
oxidative	O
DNA	O
damage.	O

To	O
determine	O
the	O
groups	O
that	O
showed	O
significantly	O
different	O
levels	O
of	O
nervonic	B
acid,	I
we	O
reanalyzed	O
the	O
samples	O
for	O
nervonic	B
acid	I
using	O
GC-TOFMS,	O
which	O
is	O
more	O
sensitive	O
than	O
LC-TOFMS,	O
to	O
obtain	O
more	O
precise	O
data.	O

Recent	O
studies	O
suggest	O
that	O
statins	B
prevent	O
CRC	O
and	O
improve	O
survival	O
after	O
diagnosis.	O

The	O
observed	O
plasma	O
metabolic	O
signature	O
in	O
patients	O
was	O
well	O
replicated	O
in	O
the	O
culture	O
medium	O
of	O
HepatoCells,	O
whereby	O
SN-38	O
exposure	O
induced	O
concentration-	O
and	O
time-dependent	O
accumulation	O
of	O
amino	O
acid	O
metabolites,	O
acylcarnitines,	B
as	O
well	O
as	O
pyrimidine/purine	O
nucleosides	O
and	O
nucleobases.	O

Compounds	O
6,	O
9,	O
13,	O
and	O
16	O
(each	O
as	O
a	O
mixture	O
of	O
unseparable	O
diastereomers)	O
were	O
synthesized	O
by	O
reaction	O
of	O
the	O
epoxides	B
2	O
and	O
12	O
with	O
N	B
-acetyl-L-cysteine	I
(NAC).	O

OPLS-DA	O
analysis	O
on	O
a	O
subset	O
of	O
70	O
samples	O
from	O
the	O
two	O
groups	O
(acetaminophen	O
users	O
or	O
nonusers)	O
generated	O
a	O
scores	O
plot	O
showing	O
clear	O
differentiation	O
of	O
the	O
spectra	O
based	O
on	O
acetaminophen	B
intake	O
of	O
the	O
participants.	O

Similarly,	O
we	O
observed	O
an	O
increase	O
in	O
cystathionine,	B
cysteine	B
and	O
glycine,	B
which	O
are	O
limiting	O
components	O
of	O
glutathione	B
synthesis	O
(Fig.	O

However,	O
the	O
remaining	O
30	O
patients	O
had	O
normal	O
T	O
levels,	O
either	O
in	O
the	O
presence	O
of	O
HA	B
(HA/NT;	O
n	O
=	O
20)	O
or	O
normal	O
A	O
(NA/NT;	O
n	O
=	O
10).	O

The	O
corresponding	O
molecular	O
species	O
PE	B
16:0/20:4	I
and	O
PE	B
18:2/18:2	I
were	O
determined	O
by	O
MS/MSALL	O
to	O
2.7	O
and	O
0.5	O
µM	O
respectively,	O
which	O
adds	O
up	O
to	O
precisely	O
the	O
same	O
amount	O
as	O
by	O
the	O
QqQ	O
analysis.	O

LDLC,	O
Low-Density	O
Lipoprotein	O
Cholesterol;	B
NIST,	O
National	O
Institute	O
of	O
Standards	O
and	O
Technology.	O

Thus,	O
one	O
may	O
hypothesize	O
that	O
decan-1-ol	B
can	O
be	O
associated	O
with	O
the	O
synthesis	O
of	O
a	O
medium-chain	O
fatty	O
acid,	O
namely	O
capric	B
acid	I
(C10:0),	O
for	O
energy	O
production.	O

For	O
example,	O
female	O
hormone	O
replacement	O
therapy	O
has	O
been	O
seriously	O
reconsidered	O
or	O
even	O
abandoned	O
by	O
many	O
women	O
following	O
data	O
indicating	O
that	O
the	O
oral	O
combination	O
of	O
estrogens	O
and	O
a	O
progestin	B
causes	O
a	O
26%	O
increase	O
in	O
the	O
incidence	O
of	O
breast	O
cancer	O
with	O
a	O
negative	O
impact	O
on	O
cardiovascular	O
events.	O

The	O
acidic	O
pathway	O
starts	O
with	O
26-hydroxylation	O
of	O
cholesterol	B
by	O
CYP27A1,	O
and	O
the	O
24(S	O
)-hydroxycholesterol	I
pathway	O
by	O
24(S	O
)-hydroxylation	O
of	O
cholesterol	B
by	O
CYP46A1.	O

As	O
shown	O
in	O
,	O
dietary	O
phenylalanine	B
firstly	O
is	O
converted	O
into	O
m	B
-tyrosine,	I
o	B
-tyrosine,	I
and	O
2,3-dihydroxyphenylalanine	B
by	O
gut	O
microbiota,	O
for	O
example,	O
chloridazon-degrading	O
bacteria.	O

The	O
peptides	O
were	O
eluted	O
using	O
a	O
50	O
min	O
gradient	O
of	O
2–32%	O
acetonitrile	B
gradient	O
in	O
0.1%	O
formic	B
acid,	I
at	O
250	O
nL/min,	O
and	O
analyzed	O
by	O
an	O
LTQ-Orbitrap	O
(Thermo	O
Fisher	O
Scientific).	O

Leucine,	B
isoleucine,	B
and	O
valine	B
are	O
branched-chain	O
amino	O
acids	O
(BCAAs),	O
which	O
are	O
primarily	O
catabolized	O
in	O
the	O
extrahepatic	O
tissues,	O
notably	O
the	O
cardiac	O
muscle,	O
and	O
are	O
essential	O
for	O
normal	O
growth	O
and	O
function	O
at	O
the	O
cellular	O
and	O
the	O
organ	O
levels._,	O
BCAA	O
catabolism	O
plays	O
a	O
fundamental	O
role	O
in	O
normal	O
cardiac	O
physiology	O
and	O
cellular	O
viability,	O
and	O
defective	O
BCAA	O
catabolism	O
has	O
been	O
reported	O
to	O
promote	O
dilated	O
cardiomyopathy	O
in	O
humans.	O

Vitamin	B
D	I
metabolites	O
are	O
known	O
to	O
be	O
stable	O
during	O
long-term	O
storage.	O

The	O
top	O
20	O
metabolites	O
with	O
the	O
lowest	O
P-values	O
are	O
shown	O
in	O
;	O
the	O
lowest	O
P-value	O
was	O
for	O
leucyl-leucine	B
(OR=0.50;	O
95%	O
CI=0.32-0.80;	O
P-value=0.003),	O
although	O
this	O
did	O
not	O
reach	O
the	O
Bonferroni-corrected	O
level	O
of	O
statistical	O
significance.	O

To	O
additionally	O
test	O
the	O
reliability	O
of	O
the	O
lipid	O
quantitation,	O
we	O
analyzed	O
one	O
serum	O
sample	O
in	O
triplicate	O
and	O
the	O
following	O
CVs	O
(%)	O
were	O
obtained:	O
for	O
acylcarnitines	B
13.4%,	O
for	O
lysoPC	O
11.1%,	O
for	O
PC	O
aa	O
9.3%,	O
for	O
PC	B
ae	I
11.4%,	O
for	O
sphingomyelins	B
9.2%.	O

Immediately	O
after	O
the	O
collection,	O
samples	O
were	O
aliquoted	O
and	O
frozen	O
at	O
−20°C	O
since	O
the	O
phthalate	B
metabolites	O
were	O
demonstrated	O
to	O
be	O
stable	O
in	O
these	O
conditions	O
for	O
at	O
least	O
one	O
year	O
and	O
parabens	O
and	O
BP3	O
for	O
6	O
months.	O

High	O
SDMA	O
levels	O
(adjusted	O
odds	O
ratio	O
[OR]	O
1.6,	O
95%CI,	O
1.1-2.6,	O
p<0.001),	O
low	O
MMA	O
(adjusted	O
OR	O
0.5,	O
95%CI	O
0.4-0.8,	O
p=0.007),	O
but	O
not	O
ADMA	B
(adjusted	O
OR	O
1.3,	O
95%CI	O
0.88-2.0,	O
p=0.177)	O
were	O
associated	O
with	O
increased	O
prevalence	O
of	O
significantly	O
obstructive	O
CAD.	O

These	O
results	O
help	O
highlight	O
the	O
differential	O
lipid	O
patterns	O
between	O
RP	B
and	O
NRP	O
sera	O
and	O
are	O
summarized	O
in	O
.	O

Sofosbuvir	B
(Gilead	O
Sciences,	O
Foster	O
City,	O
CA)	O
at	O
400	O
mg	O
was	O
administered	O
once	O
daily,	O
along	O
with	O
ribavirin	B
(Ribasphere;	O
Kadmon,	O
Warrendale,	O
PA)	O
administered	O
twice	O
daily	O
and	O
dosed	O
according	O
to	O
body	O
weight	O
(1,000	O
mg/day	O
for	O
patients	O
weighing	O
<75	O
kg	O
and	O
1,200	O
mg/day	O
for	O
those	O
weighing	O
≥75	O
kg).	O

In	O
a	O
univariate	O
analysis	O
of	O
each	O
metabolite	O
and	O
ABI	O
in	O
the	O
entire	O
cohort,	O
higher	O
indole,	B
trp,	O
I3P,	O
I3A,	O
and	O
hippuric	B
acid	I
were	O
significantly	O
associated	O
with	O
higher	O
ABI,	O
or	O
less	O
severe	O
PAD,	O
while	O
the	O
kyn/trp	O
ratio	O
and	O
3-hydroxyanthranilic	B
acid	I
were	O
negatively	O
associated	O
with	O
ABI,	O
as	O
shown	O
in	O
.	O

The	O
culture	O
medium	O
RPMI	O
1640	O
(#51800–035,	O
Gibco)	O
contained	O
HEPES,	O
antibiotic/antimycotic	O
mix	O
(#15240–062,	O
Gibco),	O
NaHCO_3,	O
insulin,	O
hydrocortisone	B
and	O
5%	O
FBS.	O

The	O
chemical	O
shifts	O
of	O
lactate	B
and	O
Ala	O
reflected	O
the	O
acidic	O
pH	O
of	O
the	O
TCA	O
extract.	O

This	O
study	O
demonstrates	O
that	O
arginine	B
and	O
citrulline-related	O
pathways	O
are	O
dysregulated	O
in	O
DR,	O
and	O
fatty	O
acid	O
metabolism	O
is	O
altered	O
in	O
PDR	O
patients	O
compared	O
with	O
NPDR	O
patients.	O

We	O
found	O
that	O
the	O
ATP	B
levels	O
were	O
significantly	O
decreased	O
in	O
FTD	O
compared	O
to	O
controls	O
(Fig. ),	O
supporting	O
our	O
lipid	O
data.	O

Correlation	O
between	O
apparent	O
formation	O
rate	O
of	O
hydroxyanastrozole	B
and	O
individual	O
P450	O
activity	O
was	O
tested	O
using	O
a	O
panel	O
of	O
characterized	O
HLMs.	O

Though	O
it	O
remains	O
unclear	O
how	O
much	O
glucuronide	B
was	O
present	O
initially,	O
these	O
results	O
indicate	O
that	O
this	O
analyte	O
is	O
glucuronidated	O
and	O
that	O
we	O
successfully	O
hydrolyzed	O
the	O
conjugated	O
species.	O

In	O
particular,	O
in	O
the	O
investigation	O
of	O
cancer,	O
interest	O
in	O
targeting	O
the	O
NAD	B
metabolism	O
as	O
a	O
new	O
therapeutic	O
approach	O
for	O
cancer	O
treatment	O
is	O
increasing	O
owing	O
to	O
the	O
close	O
association	O
of	O
the	O
NAD	B
metabolome	O
with	O
cancer	O
cell	O
biology	O
[,,].	O

Previous	O
studies	O
indicate	O
that	O
furan	B
is	O
oxidized	O
to	O
a	O
reactive	O
α,	O
β-unsaturated	B
dialdehyde,	I
cis	B
-2-butene-1,4-dial	I
(BDA),	O
in	O
a	O
reaction	O
catalyzed	O
by	O
cytochrome	O
P450.	O

A	O
quadratic	O
curve	O
with	O
1/x	O
as	O
weighing	O
factor	O
was	O
used	O
to	O
quantify	O
enzalutamide	B
and	O
N-desmethylenzalutamide	B
that	O
resulted	O
in	O
a	O
better	O
fit	O
than	O
a	O
more	O
simple	O
linear	O
relationship.	O

The	O
MTBE	B
layers	O
were	O
combined	O
for	O
analysis.	O

compares	O
the	O
nanoESI-MS	O
spectra	O
of	O
PC	B
16:0/18:1	I
(2	O
μM)	O
in	O
negative	O
ion	O
mode	O
derived	O
from	O
solutions	O
containing	O
5	O
mM	O
NH_4	O
HCO_3	O
and	O
NH_4	O
COOH,	O
respectively.	O

Taurine,	B
citrulline	B
and	O
trans-4-hydroxyproline	B
were	O
previously	O
identified	O
in	O
human	O
blood	O
plasma	O
by	O
NMR._,	O
The	O
Metabolomics	O
Standards	O
Initiative	O
(MSI)	O
categorizes	O
the	O
confidence	O
of	O
metabolite	O
identification	O
according	O
to	O
four	O
different	O
levels,	O
where	O
level	O
1	O
(highest	O
confidence	O
level)	O
is	O
achieved	O
by	O
spiking	O
of	O
authentic	O
standards	O
into	O
the	O
original	O
sample.	O

While	O
prednisolone	B
can	O
result	O
in	O
increased	O
glucose	B
levels,	O
it	O
should	O
be	O
noted	O
that	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
number	O
of	O
our	O
patients	O
on	O
steroids	O
in	O
the	O
high	O
UCEIS	O
group	O
compared	O
to	O
the	O
low	O
UCEIS	O
group.	O

This	O
analysis	O
revealed	O
a	O
relative	O
increase	O
in	O
1-methylhistidine	B
levels	O
24 h	O
after	O
surgery.	O

N-acetyl-lysine	B
and	O
FFA	O
14:0	O
were	O
present	O
in	O
less	O
than	O
half	O
of	O
the	O
RF	O
models,	O
which	O
indicated	O
that	O
these	O
metabolites	O
should	O
be	O
rejected	O
as	O
candidate	O
biomarkers.	O

In	O
the	O
metabolic	O
profile,	O
decreased	O
levels	O
of	O
glucose	B
and	O
elevated	O
levels	O
of	O
lactate	B
were	O
observed	O
in	O
the	O
cachexia	O
patients'	O
sera,	O
consistent	O
with	O
previous	O
reports.17,	O
18	O
Enhanced	O
glucose	B
metabolism	O
in	O
cancer	O
has	O
been	O
associated	O
with	O
glycolysis,	O
leading	O
to	O
greater	O
pyruvate	B
and	O
lactate	B
formation	O
via	O
non‐oxidative	O
pathways.	O

Several	O
recent	O
studies	O
of	O
erythritol	B
loading	O
reported	O
no	O
effect	O
on	O
glucose	B
(,	O
),	O
consistent	O
with	O
our	O
findings.	O

Each	O
peak	O
in	O
the	O
spectrum	O
corresponds	O
to	O
different	O
metabolite	O
from	O
the	O
carboxylic	B
acid	I
class.	O

These	O
changes	O
are	O
consistent	O
with	O
the	O
pathway	O
analysis	O
in	O
Fig.	O
,	O
indicating	O
reduced	O
degradation	O
of	O
branched	O
chain	O
amino	O
acids	O
and	O
lysine,	B
as	O
well	O
as	O
changes	O
in	O
energy	O
metabolism.	O

BMI,	O
body	O
mass	O
index;	O
DM,	O
diabetes	O
mellitus;	O
1,5‐AG,	B
1,5‐anhydro‐d‐glucitol.	B

Since	O
the	O
glycation	O
occurred	O
at	O
lysine	B
residues,	O
we	O
also	O
used	O
endoproteinase	O
Glu-C	O
to	O
degrade	O
GA	O
besides	O
of	O
trypsin.	O

The	O
limit	O
of	O
detection	O
was	O
50	O
pg	B
ml_−1	O
and	O
the	O
limit	O
of	O
quantification	O
was	O
100	O
pg	B
ml_−1	O
.	O

The	O
standard	O
addition	O
was	O
performed	O
for	O
urine	O
by	O
co-injecting	O
standard	O
solutions	O
of	O
taurine	B
and	O
sulfate	B
with	O
concentrations	O
within	O
the	O
range	O
of	O
2.5-15,	O
and	O
125-750	O
μg	O
S	O
ml-1	O
,	O
respectively	O
3)	O

The	O
developed	O
chromatographic	O
method	O
for	O
taurine	B
analysis	O
in	O
human	O
urine	O
and	O
serum	O
offers	O
the	O
advantages	O
of	O
speed	O
and	O
simplicity,	O
and	O
can	O
be	O
used	O
in	O
future	O
large-scale	O
clinical	O
trials	O
in	O
order	O
to	O
establish	O
the	O
cardioprotective	O
roles	O
of	O
taurine	B
in	O
humans	O
and	O
justify	O
its	O
potential	O
usage	O
as	O
a	O
dietary	O
supplement.	O

This	O
may	O
be	O
partly	O
explained	O
by	O
significantly	O
high	O
tumor	O
levels	O
of	O
S386	O
phosphorylation	O
in	O
phosphofructokinase,	O
which	O
enhances	O
its	O
activity	O
(Brand	O
and	O
Soling	O
),	O
and	O
thus	O
the	O
overall	O
glycolytic	B
flux	O
because	O
it	O
is	O
a	O
bottleneck	O
enzyme.	O

In	O
this	O
work	O
we	O
also	O
identified	O
significant	O
dysregulation	O
of	O
other	O
pathways	O
related	O
to	O
neurodegeneration,	O
namely	O
of	O
taurine	B
and	O
hypotaurine.	B

Neither	O
study,	O
however,	O
measured	O
free	O
or	O
bioavailable	O
estradiol,	B
which	O
may	O
be	O
more	O
important	O
mediators	O
of	O
the	O
BMI-breast	O
cancer	O
association.	O

Overall,	O
although	O
a	O
large	O
portion	O
of	O
consumed	O
erythritol	B
was	O
assumed	O
to	O
be	O
excreted	O
in	O
urine,	O
about	O
5–10%	O
was	O
oxidized	O
through	O
the	O
pathway	O
to	O
erythronate.	B

Importantly,	O
the	O
loss	O
of	O
cysteine	B
was	O
associated	O
with	O
the	O
accumulation	O
of	O
its	O
oxidized	O
product,	O
cystine,	B
as	O
well	O
as	O
Met-SO	O
(Haenold	O
et	O
al.	O
)	O
and	O
HCA	O
(Boldyrev	O
;	O
Go	O
and	O
Jones	O
),	O
all	O
of	O
which	O
represent	O
metabolic	O
evidence	O
of	O
oxidative	O
stress	O
in	O
SLE.	O

Although	O
polar	O
lipids	O
seem	O
to	O
be	O
vital	O
for	O
health	O
of	O
obese	O
subjects,	O
only	O
few	O
previous	O
studies	O
addressed	O
bariatric	O
surgery-related	O
changes	O
in	O
serum	O
phospholipids.	B

Both	O
the	O
level	O
of	O
3-hydroxybutyrate	B
(nonsignificant,	O
p-	O
value	O
>	O
0.05,	O
not	O
shown)	O
and	O
acetone	B
were	O
higher	O
in	O
patients	O
than	O
healthy	O
people	O
in	O
our	O
analysis.	O

Interestingly,	O
plasma	O
SM	O
levels	O
(SM	O
36:1,	O
SM	B
38:1,	I
and	O
SM	B
40:1),	I
which	O
are	O
related	O
with	O
fatty	O
liver	O
and	O
insulin	O
resistance	O
as	O
well	O
as	O
obesity,	O
were	O
significantly	O
elevated	O
in	O
pre-diabetic	O
individuals	O
with	O
AO	O
when	O
compared	O
to	O
normal	O
individuals	O
with	O
AO	O
or	O
pre-diabetic	O
without	O
AO	O
(	O
and	O
).	O

We	O
focus	O
on	O
the	O
mediating	O
effect	O
of	O
unconjugated	O
estradiol	B
on	O
ER+	O
positive	O
breast	O
cancer	O
for	O
the	O
following	O
reasons:	O
although	O
several	O
metabolic	O
pathway	O
ratios	O
confounded	O
the	O
BMI-breast	O
cancer	O
association	O
to	O
a	O
similar	O
degree	O
as	O
unconjugated	O
estradiol	B
when	O
unconjugated	O
estradiol	B
was	O
not	O
included	O
in	O
the	O
model,	O
unconjugated	O
estradiol	B
was	O
the	O
strongest	O
predictor	O
of	O
ER+	O
breast	O
cancer	O
in	O
our	O
analysis,	O
it	O
was	O
more	O
highly	O
correlated	O
with	O
BMI	O
than	O
other	O
estrogens,	O
estrogen	B
metabolites,	O
and	O
metabolic	O
pathway	O
ratios,	O
and	O
additional	O
adjustment	O
of	O
the	O
BMI-breast	O
cancer	O
association	O
for	O
metabolic	O
pathway	O
ratios	O
after	O
adjustment	O
for	O
unconjugated	O
estradiol	B
did	O
not	O
change	O
the	O
BMI	O
risk	O
estimate.	O

When	O
overwhelming	O
oxidative	O
stress	O
eclipses	O
glutathione	B
antioxidant	O
capacity,	O
the	O
liver	O
produces	O
antioxidant	O
2HB	O
through	O
an	O
‘emergency’	O
transsulfuration	O
pathway.	O

Covalent	O
binding	O
of	O
zomepirac	O
glucuronide	B
to	O
proteins:	O
evidence	O
for	O
a	O
Schiff	O
base	O
mechanism.	O

All	O
PULSE	O
tubes	O
were	O
washed	O
with	O
MeOH	B
and	O
dried	O
prior	O
to	O
the	O
experiment.	O

Some	O
metabolites,	O
such	O
as	O
cortisol	B
and	O
melatonin,	B
fluctuate	O
by	O
the	O
hour	O
in	O
a	O
given	O
day	O
,	O
;	O
while	O
other	O
metabolites,	O
such	O
as	O
female	O
hormones	O
and	O
vitamin	B
D,	I
may	O
fluctuate	O
by	O
month	O
or	O
season.	O

Therefore,	O
oxylipin	B
solubilities	O
in	O
methanol	B
at	O
the	O
concentrations	O
used	O
in	O
our	O
work	O
will	O
not	O
be	O
a	O
problem.	O

A.C.S.	O
Spectrophotometric	O
grade	O
dimethyl	B
sulfoxide	I
(>99.9%	O
pure)	O
was	O
purchased	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
MO).	O

The	O
acquired	O
NMR	O
spectra	O
were	O
manually	O
phased,	O
baseline	O
corrected	O
and	O
referenced	O
to	O
the	O
methyl	B
lactate	I
resonance	O
at	O
δ	O
1.33.	O
m	O

The	O
algorithm	O
assessed	O
the	O
relevance	O
of	O
the	O
160	O
metabolites	O
identified	O
for	O
the	O
prediction	O
performances	O
of	O
Partial	O
Least	O
Squares-Discriminant	O
Analysis	O
(PLS-DA),	O
Random	O
Forest	O
(RF),	O
and	O
Support	O
Vector	O
Machines	O
(SVM)	O
classifier	O
models	O
and	O
subsequently	O
identified	O
2	O
robust	O
‘S	O
tier’	O
features,	O
i.e.,	O
nicotinamide	B
and	O
N-acetyl	B
L-leucine.	I

Indeed,	O
serine	B
is	O
an	O
active	O
component	O
of	O
the	O
serine	B
proteases,	O
a	O
group	O
of	O
enzymes	O
that	O
cleave	O
peptides.	O

The	O
sample	O
was	O
acidified	O
with	O
the	O
addition	O
of	O
2.5	O
µL	O
of	O
trifluoroacetic	B
acid	I
(TFA),	O
and	O
the	O
extraction	O
step	O
with	O
250	O
µL	O
of	O
ethyl	B
acetate	I
was	O
repeated.	O

Longer	O
term	O
studies	O
should	O
be	O
designed	O
to	O
confirm	O
the	O
involvement	O
of	O
TMAO	B
in	O
PAD	O
mortality.	O

The	O
itaconic	B
acid	I
is	O
a	O
thiol-reactive	O
metabolite	O
which	O
forms	O
adducts	O
with	O
cysteine	B
thiols.	I

Despite	O
endorsement	O
by	O
regulatory	O
bodies	O
of	O
over-the-counter	O
analgesics	O
as	O
safe	O
and	O
effective	O
for	O
use	O
without	O
a	O
physician’s	O
prescription,	O
approximately	O
40%	O
of	O
reported	O
cases	O
of	O
liver	O
injury	O
in	O
the	O
United	O
States	O
in	O
2005	O
were	O
due	O
to	O
over-the-counter	O
acetaminophen.	B

From	O
the	O
spectral	O
regions	O
corresponding	O
to	O
these	O
metabolites,	O
specific	O
spectral	O
peaks	O
undergoing	O
the	O
largest	O
degree	O
of	O
change	O
were	O
identified	O
as:	O
1.31ppm	O
for	O
lactate	B
(27.4%	O
increase),	O
3.35ppm	O
for	O
glucose	B
(52.4%	O
decrease)	O
and	O
0.92	O
ppm	O
for	O
isoleucine	B
(60.5%	O
decrease).	O

Based	O
on	O
a	O
creatinine	B
clearance	O
rate	O
of	O
0.163 mmol/(d.kg),	O
daily	O
urinary	O
isoflavone	B
excretions	O
were	O
calculated.	O

Lastly,	O
palmitic	B
acid	I
is	O
cytotoxic	O
to	O
β-cells	O
in	O
models	O
of	O
obesity	O
and	O
diabetes,	O
as	O
well	O
as	O
normal	O
β-cells	O
and	O
has	O
been	O
shown	O
to	O
induce	O
apoptosis	O
in	O
exocrine	O
pancreatic	O
AR42J	O
cells.	O

To	O
define	O
the	O
minimal	O
number	O
of	O
metabolites	O
needed	O
to	O
discriminate	O
the	O
2	O
groups,	O
only	O
the	O
metabolites	O
with	O
a	O
p	O
<	O
0.05	O
(5-OH-TRP,	O
acetoacetate,	B
acetone,	B
glucose,	B
TRP,	O
3-OH-butyrate,	B
choline,	B
and	O
alanine)	B
and	O
then	O
with	O
a	O
p	O
<	O
0.01	O
(5-OH-TRP,	O
acetoacetate,	B
acetone,	B
TRP,	O
and	O
3-OH-butyrate)	B
were	O
used.	O

The	O
pathway	O
analysis	O
shows	O
perturbations	O
in	O
the	O
biosynthesis	O
of	O
aminoacyl-tRNA	B
and	O
several	O
amino	O
acids,	O
as	O
well	O
as	O
in	O
the	O
metabolism	O
of	O
fatty	O
acids,	O
glycerolipids	B
and	O
glycerophospholipids	B
(	O
and	O
).	O

Models	O
shown	O
on	O
the	O
right-hand	O
side	O
were	O
adjusted	O
for	O
log-transformed	O
(to	O
the	O
base	O
1.2)	O
continuous	O
unconjugated	O
estradiol.	B

The	O
high	O
PCho	O
levels	O
in	O
early	O
lactation	O
have	O
also	O
been	O
seen	O
in	O
the	O
human	O
and	O
porcine	B
and	O
may	O
be	O
of	O
importance	O
in	O
ensuring	O
a	O
rapidly	O
bioavailable	O
form	O
of	O
choline	B
for	O
the	O
nursing	O
young.	O

The	O
blank	O
matrix	O
(serum	O
and	O
urine)	O
was	O
prepared	O
by	O
treating	O
fetal	O
bovine	O
serum	O
(FBS,	O
Omega	O
Scientific	O
Inc.,	O
Tarzana,	O
CA)	O
or	O
mixed	O
urine	O
collected	O
from	O
six	O
volunteers	O
with	O
10%	O
(w/v)	O
with	O
activated	B
charcoal	O
to	O
remove	O
BAs.	O

Extracts	O
reconstituted	O
in	O
acidic	O
conditions	O
were	O
gradient	O
eluted	O
using	O
water	O
and	O
methanol	B
containing	O
0.1 %	O
formic	B
acid,	I
while	O
the	O
basic	O
extracts,	O
which	O
also	O
used	O
water/methanol,	O
contained	O
6.5 mM	O
ammonium	B
bicarbonate.	O

Estrone	B
(E1);	O
estradiol	B
(17	O
α/β	O
E2);	O
16-hydroxyestrone	B
(16OHE1);	O
16-hydroxyestradiol	B
(16OHE2);	O
2	O
or	O
4-methoxyestrone	B
(2	O
or	O
4-MeOE1);	O
2	O
or	O
4-methoxyestradiol	B
(2	O
or	O
4-MeOE2);	O
2,3,4–_13	B
C_3	I
-estrone	I
(_13	O
CE1);	O
2,3,4–_13	B
C_3	I
-estradiol	I
(_13	O
C_3	O
-E2);	O
2,3,4–_13	B
C_3	I
-estriol	I
(_13	O
C_3	O
-16OHE2);	O
13,14,15,16,17,18-_13	B
C_6	I
-2-methoxyestrone	I
(_13	O
C_6	O
-2MeOE1)	O
and	O
13,14,15,16,17,18-_13	B
C_6	I
-4-methoxyestradiol	I
(_13	O
C_6	O
-4MeOE2).	O

580.3745	O
with	O
a	O
retention	O
time	O
compatible	O
with	O
a	O
GP-tagged	O
dihydroxy-3-oxocholest-4-en-26-oic	B
acid.	I

Plasma	O
samples	O
(0.2 mL)	O
were	O
diluted	O
with	O
2.0 mL	O
of	O
a	O
0.05 mol/L	O
phosphoric	B
acid	I
solution	O
prior	O
to	O
extraction	O
using	O
an	O
Oasis_®	O
HLB	O
cartridge	O
(3 cc,	O
60 mg	O
packing;	O
Waters)	O
according	O
to	O
a	O
previously	O
reported	O
method.16	O

Because	O
of	O
its	O
importance	O
in	O
sleep	O
we	O
conjectured	O
that	O
melatonin	B
would	O
either	O
be	O
lower	O
and/or	O
its	O
pattern	O
across	O
the	O
night	O
would	O
be	O
different	O
in	O
the	O
IBS	O
as	O
compared	O
to	O
HCs.	O

Moreover,	O
the	O
prospective	O
association	O
of	O
low	O
betaine	B
levels	O
with	O
future	O
T2DM	O
in	O
DPP	O
remained	O
significant	O
after	O
adjusting	O
for	O
risk	O
factors	O
such	O
as	O
age,	O
sex,	O
BMI,	O
hypertension,	O
ethnicity	O
and	O
FPG.	O

In	O
contrast,	O
a	O
significant	O
increase	O
of	O
the	O
final	O
metabolic	O
product,	O
homocarnosine,	B
has	O
been	O
observed	O
in	O
all	O
three	O
injury	O
groups.	O

There	O
was	O
a	O
weak	O
inverse	O
correlation	O
of	O
25(OH)D	O
concentration	O
with	O
diastolic	O
blood	O
pressure	O
at	O
the	O
time	O
of	O
biomarker	O
measurement,	O
but	O
25(OH)D	O
was	O
not	O
correlated	O
with	O
systolic	O
blood	O
pressure,	O
and	O
24,25(OH)_2	B
D	O
and	O
1,25(OH)_2	B
D	O
were	O
not	O
correlated	O
with	O
systolic	O
or	O
diastolic	O
blood	O
pressure.	O

We	O
did	O
not	O
observe	O
statistically	O
significant	O
differences	O
in	O
the	O
levels	O
of	O
metabolites	O
in	O
samples	O
obtained	O
via	O
LP	B
versus	O
OM	O
(Table	O
).	O

The	O
alanine	B
is	O
the	O
product	O
of	O
pyruvate	B
metabolism.	O

For	O
each	O
of	O
the	O
hydrophilic	B
and	O
hydrophobic	O
standard	O
mixtures,	O
50	O
standards	O
were	O
prepared	O
at	O
a	O
final	O
concentration	O
of	O
20	O
µg/mL.	O
Ammonium	B
acetate	I
(NH_4	O
Ac),	O
ammonium	B
hydroxide	I
(NH_4	O
OH),	O
ammonium	B
fluoride	I
(NH_4	O
F),	O
ammonium	B
carbonate	I
((NH_4	O
)_2	O
CO_3	O
)	O
and	O
ammonium	B
formate	I
(NH_4	O
HCOO)	O
were	O
purchased	O
from	O
Sigma	O
Aldrich.	O

In	O
subgroup	O
analysis	O
of	O
patients	O
with	O
functional	O
CYP2D6	O
(EM/EM)	O
treatment	O
adherence	O
was	O
significantly	O
correlated	O
with	O
tamoxifen	B
metabolites	O
at	O
all	O
three	O
time	O
points	O
(Figure	O
c,	O
data	O
shown	O
for	O
months	O
3	O
and	O
12).	O

Glutamic	B
acid	I
changed	O
from	O
negative	O
to	O
positive	O
with	O
Lachnospiraceae	O
.	O

A	O
shows	O
the	O
variation	O
in	O
peak	O
base	O
widths	O
and	O
B	O
the	O
differences	O
in	O
the	O
sum	O
of	O
resolutions	O
(across	O
water,	O
ammonium	B
formate	I
and	O
formic	O
acid-containing	O
modifiers	O
and	O
all	O
evaluated	O
temperatures)	O
by	O
column.	O

Separation	O
between	O
low-	O
(green	O
dots)	O
and	O
intermediate-	B
(yellow	I
diamonds)	I
risk	O
patients	O
based	O
on	O
RP	B
histology	O
due	O
to	O
elevated	O
lactate,	B
lipids/lipoproteins	O
and	O
pyruvate	B
and	O
reduced	O
citrate,	B
fructose,	B
myo-inositol,	B
and	O
spermine	B
in	O
intermediate-risk	B
samples	O
(A,C).	O

Higher	O
metabolite	O
concentrations	O
of	O
endoxifen	B
were	O
related	O
to	O
26%	O
lower	O
breast	O
cancer	O
recurrence	O
rate.	O

Three	O
plasma	O
metabolites	O
meet	O
the	O
criterion,	O
including	O
ratio	O
of	O
L-asparagine	B
to	O
L-aspartic	B
acid,	I
vanillylmandelic	B
acid	I
and	O
glutaric	B
acid.	I

No	O
single	O
metabolite	O
without	O
demographics	O
performed	O
better	O
than	O
eGFRcr	O
in	O
the	O
AASK,	O
while	O
two	O
metabolites	O
performed	O
better	O
than	O
eGFRcr	O
in	O
the	O
MESA	O
(N	O
-acetylthreonine	I
and	O
pseudouridine).	B

Purified	B
water	I
was	O
provided	O
ad	O
libitum	O
to	O
all	O
animals	O
and	O
food	O
consumption	O
evaluated	O
at	O
least	O
twice	O
daily.	O

N	B
-Acetyl-S	I
-methyl-cysteine-sulfoxide	I
(NAcSMCSO)	O
is	O
the	O
major	O
urinary	O
metabolite	O
after	O
consumption	O
of	O
cruciferous	O
and	O
other	O
vegetables.	O

In	O
addition	O
to	O
well-known	O
clinical	O
risk	O
factors,	O
BCAAs	O
and	O
3-hydroxyisobyturate	B
are	O
potential	O
markers	O
to	O
be	O
evaluated	O
as	O
predictors	O
of	O
metabolic	O
risk	O
after	O
pregnancy	O
complicated	O
by	O
GDM.	O

The	O
betaine	B
peak	O
at	O
3.22	O
ppm,	O
as	O
well	O
as	O
the	O
glucose	B
peaks	O
on	O
either	O
side,	O
were	O
mathematically	O
modeled	O
using	O
lognormal	O
and	O
Lorentzian	O
peak	O
shapes.	O

We	O
found	O
negative	O
correlations	O
between	O
insulin	O
sensitivity	O
and	O
BCAAs	O
(leucine,	O
isoleucine,	B
valine)	B
and	O
aromatic	O
amino	O
acids	O
(phenylalanine,	O
tyrosine),	B
whereas	O
glycine	B
and	O
glutamine	B
had	O
positive	O
correlation.	O

As	O
shown	O
in	O
Figure	O
S1,	O
compared	O
with	O
the	O
control	O
sample	O
(general	O
anaerobic	O
medium	O
(GAM)	O
and	O
IP)	O
and	O
blank	O
sample	O
(incubation	O
solution	O
without	O
analyses),	O
two	O
metabolites	O
from	O
IP	B
were	O
obtained.	O

In	O
addition,	O
the	O
pathway	O
analysis	O
showed	O
that	O
purine,	B
tyrosine,	B
and	O
histidine	B
metabolism	O
was	O
affected	O
by	O
pharmacological	O
responses	O
to	O
glimepiride.	O

water/75%	O
acetonitrile	B
mixture.	O

Uric	B
acid	I
is	O
the	O
end-product	O
of	O
the	O
purine	B
oxidative	O
degradation,	O
deriving	O
from	O
hypoxanthine	B
through	O
xanthine	B
by	O
a	O
NAD-dependent	O
oxidoreductase	O
(https://www.genome.jp/dbget-bin/www_bget?rn:R01768;	O
https://www.genome.jp/dbget-bin/www_bget?rn:R02103).	O

Importantly,	O
oxylipins	B
are	O
susceptible	O
to	O
non-enzymatic	O
processing,	O
including	O
oxidation,	O
and	O
are	O
therefore	O
sensitive	O
to	O
specific	O
collection,	O
storage,	O
processing	O
and	O
analysis	O
methodologies	O
(;	O
;	O
).	O

Cytochrome	O
P450	O
metabolizes	O
AA	O
to	O
cell	O
signaling	O
molecules	O
such	O
as	O
epoxyeicosatrienoic	B
acids,	I
HETEs	O
and	O
hydroperoxyeicosatetraenoic	B
acids	I
.	O

Since	O
2006,	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
and	O
the	O
European	O
Medicines	O
Agency	O
have	O
approved	O
the	O
use	O
of	O
seven	O
targeted	O
therapies	O
for	O
mRCC,	O
five	O
of	O
them	O
being	O
directed	O
to	O
VEGF	O
or	O
its	O
receptors	O
(sunitinib,	O
sorafenib,	O
pazopanib,	B
axitinib,	B
bevacizumab)	O
and	O
two	O
corresponding	O
to	O
inhibitors	O
of	O
the	O
mTOR	O
complex	O
(temsirolimus	O
and	O
everolimus).	O

The	O
m/z	O
for	O
isoniazid	O
and	O
pyrazinamide	B
were	O
detected	O
at	O
low	O
intensity	O
in	O
some,	O
but	O
not	O
all,	O
individuals	O
with	O
TB	O
disease.	O

For	O
example,	O
the	O
predicted	O
λ	O
_b:a	O
	O
for	O
2-hexenal	B
was	O
111,	O
therefore	O
exchanges	O
almost	O
exclusively	O
in	O
the	O
airways.	O

Secondary	O
endpoints	O
included	O
the	O
changes	O
in	O
fasting	O
glycemia	O
and	O
HbA_1c	O
,	O
and	O
postprandial	O
change	O
in	O
glucose,	B
NEFA	O
and	O
triacylglycerol	B
levels	O
(meal	O
test),	O
metabolic	O
flexibility	O
assessed	O
by	O
indirect	O
calorimetry,	O
and	O
inflammatory	O
markers.	O

The	O
buffer	O
contained	O
the	O
chemical	O
shift	O
reference	O
3-(trimethylsilyl)-propionic	B
acid-D4,	O
sodium	O
salt	O
and	O
NaN_3	O
.	O

Our	O
study	O
provides	O
evidence	O
that	O
the	O
cancer	O
metabolome	O
is	O
reflected	O
in	O
body	O
fluids	O
and	O
measuring	O
blood	O
histidine	B
concentration,	O
a	O
precursor	O
for	O
histamine,	B
can	O
provide	O
a	O
valuable	O
information	O
due	O
to	O
its	O
association	O
with	O
the	O
presence	O
of	O
cancer.	O

The	O
IP	B
values	O
reflect,	O
in	O
fact,	O
the	O
importance	O
of	O
terms	O
in	O
the	O
model	O
both	O
with	O
respect	O
to	O
Y,	O
that	O
is,	O
its	O
correlation	O
with	O
all	O
the	O
responses,	O
and	O

Alcohol,	O
alcohol	O
intake	O
gram/week;	O
ApoA,	O
apolipoprotein	O
A1;	O
ApoB,	O
apolipoprotein	O
B;	O
CRP,	O
c-reactive	O
protein;	O
DBP,	B
diastolic	O
blood	O
pressure;	O
eGFR,	O
estimated	O
glomerular	O
filtration	O
rate;	O
Gluc0,	O
fasting	O
glucose;	B
Gluc120,	O
120	O
min	O
oral	O
glucose	B
tolerance	O
test	O
(OGTT)	O
glucose	B
level;	O
HOMA-B,	O
homeostasis	O
model	O
assessment	O
of	O
beta-cell	O
function;	O
HOMA-IR,	O
homeostasis	O
model	O
assessment	O
of	O
insulin	O
resistance;	O
LAEI,	O
large	O
artery	O
elasticity	O
index;	O
SAEI,	O
small	O
artery	O
elasticity	O
index;	O
SBP,	O
systolic	O
blood	O
pressure;	O
SHBG,	O
sex	O
hormone	O
binding	O
globulin;	O
TAG,	O
triacylglycerides;	B
WHR,	O
waist/hip-ratio.	O

Biliverdin.	B

GDM	O
was	O
diagnosed	O
independently	O
according	O
to	O
two	O
separate	O
sets	O
of	O
criteria:	O
The	O
first	O
set	O
are	O
the	O
criteria	O
of	O
the	O
World	O
Health	O
Organization	O
(WHO)	O
which	O
define	O
GDM	O
as	O
FPG	O
≥7.0	O
or	O
2-h	O
PG	B
≥7.8 mmol/L.	O

Compounds	O
involved	O
in	O
oxidative	O
stress,	O
such	O
as	O
cysteine	B
and	O
lysophosphatidylcholine,	B
may	O
serve	O
as	O
causal	O
in	O
lung	O
function	O
decline.	O

We	O
identified	O
only	O
one	O
study	O
on	O
the	O
association	O
of	O
F_2	B
-isoprostanes	I
with	O
clinical	O
characteristics	O
and	O
modifiable	O
factors	O
among	O
breast	O
cancer	O
survivors.	O

fowleri	O
by	O
drug	O
combinations:	O
tamoxifen	B
and	O
isavuconazole	B
(A),	O
epiminlanosterol	B
and	O
tamoxifen	B
(B),	O
and	O
epiminolanosterol	B
and	O
isavuconazole	B
(C).	O

The	O
association	O
between	O
the	O
metabolic	O
profiles	O
and	O
TBC	O
was	O
further	O
confirmed	O
in	O
the	O
subjects	O
aged	O
between	O
26	O
and	O
40	O
(in	O
whom	O
there	O
was	O
no	O
correlation	O
between	O
cholesterol	B
and	O
age),	O
and	O
also	O
by	O
comparing	O
subjects	O
with	O
high	O
cholesterol	B
concentrations	O
with	O
matched	O
subjects	O
who	O
had	O
desirable	O
cholesterol	B
concentrations	O
and	O
similar	O
values	O
for	O
the	O
other	O
clinical	O
metadata	O
(gender,	O
menopausal	O
status,	O
age,	O
BMI,	O
glycemia,	O
and	O
blood	O
pressure).	O

The	O
observed	O
inverse	O
correlation	O
of	O
the	O
serotonin	B
concentration	O
in	O
sperm	O
with	O
the	O
sperm	O
concentration	O
is	O
consistent	O
with	O
the	O
results	O
of	O
former	O
studies	O
in	O
which	O
it	O
was	O
shown	O
that	O
hyperserotonemia	O
leads	O
to	O
azoospermia	O
and	O
that	O
increased	O
serotonin	B
concentration	O
in	O
the	O
spermatic	O
vein	O
is	O
correlated	O
with	O
significantly	O
lower	O
sperm	O
quality.	O

Mean	O
relative	O
serum	O
levels	O
of	O
glutamate	B
are	O
0.159	O
(SD	O
0.156)	O
in	O
cancer;	O
0.485	O
(SD	O
0.237)	O
in	O
inflammation	O
and	O
0.152	O
(SD	O
0.113)	O
in	O
controls.	O

The	O
parent	O
was	O
tentatively	O
identified	O
as	O
atractyligenin	O
glucuronide	B
based	O
on	O
the	O
accurate	O
masses	O
of	O
the	O
parent	O
and	O
in-source	O
fragments	O
observed	O
in	O
the	O
mass	O
spectra	O
obtained	O
with	O
high	O
resolution	O
mass	O
spectrometry	O
analysis	O
of	O
urine	O
samples.	O

Because	O
ERα	O
can	O
suppress	O
AhR	O
activation,	O
the	O
MCF-7	O
cells	O
were	O
pretreated	O
with	O
ICI	O
182,780	O
before	O
isoflavone	B
treatments	O
and	O
XRE-luciferase	O
activity	O
was	O
determined.	O

Compared	O
to	O
stroke	O
and	O
HC	O
subjects,	O
the	O
levels	O
of	O
the	O
following	O
five	O
metabolites	O
were	O
significantly	O
increased	O
in	O
the	O
urine	O
of	O
PSD	O
subjects:	O
carnosine,	B
arabinitol,	B
α-glucose,	B
phenylalanine,	B
and	O
formate.	B

We	O
used	O
linear	O
regression	O
to	O
evaluate	O
the	O
effects	O
of	O
cotinine,	B
arsenic,	O
and	O
phthalates	O
on	O
the	O
change	O
in	O
tumor	O
size	O
after	O
treatment,	O
adjusted	O
for	O
confounding	O
variables.	O

The	O
limit	O
of	O
detection	O
for	O
β-apo-13-carotenone	B
was	O
280	O
pm.	O

1.3	O
ppm	O
peak	O
is	O
mainly	O
associated	O
with	O
triglycerides	B
(C)	O
while	O
2.2	O
ppm	O
peak	O
is	O
associated	O
with	O
unsaturations	O
(D).	O

Since	O
apoptotic	O
cells	O
that	O
release	O
intracellular	O
ceramides	B
at	O
cell	O
lysis	O
are	O
considered	O
the	O
major	O
source	O
of	O
ceramides	B
in	O
the	O
cancer	O
tissue,	O
the	O
production	O
of	O
ceramides	B
appears	O
to	O
occur	O
independently	O
from	O
the	O
condition	O
of	O
the	O
host.	O

Alternatively,	O
the	O
superoxide	B
anion	O
generated	O
over	O
the	O
time,	O
by	O
HONH-PhIP,	O
may	O
have	O
oxidized	O
a	O
portion	O
of	O
the	O
N	O
_2	B
-[cystein-S-yl-PhIP]-S-oxide	I
linkage	O
to	O
the	O
sulfonamide	B
structure;	O
the	O
oxidation	O
of	O
N	O
_2	B
-[cystein-S-yl-PhIP]-S-oxide	I
to	O
the	O
sulfonamide	B
adduct	O
during	O
enzymatic	O
digestion	O
also	O
cannot	O
be	O
excluded.	O

Dabrafenib	O
was	O
dissolved	O
in	O
DMSO	B
to	O
a	O
concentration	O
of	O
1 mg/mL.	O
Internal	O
standard	O
erlotinib-d6	B
was	O
dissolved	O
in	O
DMSO	B
to	O
a	O
concentration	O
of	O
1.9 mg/mL.	O
Calibration	O
and	O
quality	O
control	O
(QC)	O
working	O
stock	O
solutions	O
were	O
prepared	O
from	O
the	O
stock	O
solutions	O
by	O
dilution	O
in	O
an	O
acetonitrile/water	O
(50:50,	O
v	O
/v	O
)	O
mixture.	O

The	O
more	O
complex	O
the	O
oligosaccharide	B
chain,	O
the	O
lower	O
proportion	O
of	O
ceramides	B
with	O
2	O
or	O
3	O
unsaturations	O
was	O
observed.	O

All	O
1D	O
spectra	O
were	O
processed	O
with	O
a	O
line	O
broadening	O
of	O
0.3 Hz	O
and	O
automatically	O
phase	O
corrected	O
(in	O
Topspin	O
software	O
from	O
Bruker	O
Biospin),	O
referenced	O
to	O
the	O
methyl	O
doublet	O
of	O
alanine	B
at	O
1.5 ppm	O
and	O
bucketed	O
over	O
the	O
region	O

The	O
final	O
SFC	O
method	O
was	O
based	O
on	O
a	O
CO_2	O
(A)	O
methanol-ammonium	B
formate	I
(B)	O
gradient.	O

We	O
found	O
a	O
relationship	O
(inverse)	O
of	O
BMI	O
with	O
the	O
gut	O
microbial-host	O
co-metabolite	O
phenylacetylglutamine	B
(P	O
=	O
1.39	O
×	O
10_−8	O
),	O
a	O
bacterial	O
degradation	O
product	O
of	O
phenylalanine.	B

The	O
platform	O
utilizes	O
hydrophilic	B
interaction	O
chromatography	O
(HILIC)	O
at	O
pH	O
=	O
9.0	O
(,	O
).	O

ADMA	B
and	O
L-arginine	B
levels	O
in	O
clinical	O
samples	O
were	O
determined	O
using	O
a	O
commercially	O
available	O
ELISA	O
(DLD	O
Diagnostika,	O
Germany),	O
as	O
described	O
previously.	O

Racemic	O
Phe	O
epoxides	B
2	O
and	O
12	O
were	O
prepared	O
as	O
described.	O

Utilizing	O
the	O
GC-MS	O
data,	O
pairs	O
of	O
biosynthetically-related	O
_13	O
C-labeled	O
metabolites	O
in	O
tumor	O
and	O
non-cancerous	O
tissues	O
were	O
tested	O
for	O
precursor-product	O
relationships,	O
as	O
illustrated	O
in	O
Figure	O
and	O
Table	O
.	O
_13	O
C-succinate,	B
_13	O
C-citrate	O
and	O
_13	O
C-Glu	O
are	O
products	O
of	O
the	O
Krebs	O
cycle	O
while	O
_13	O
C-Ala	O
is	O
derived	O
from	O
pyruvate,	B
the	O
end	O
product	O
of	O
glycolysis	O
(cf.	O

In	O
our	O
study,	O
as	O
a	O
result	O
of	O
the	O
lability	O
of	O
GSH,	B
high	O
levels	O
of	O
GSSG	O
were	O
detected	O
in	O
whole	O
blood	O
extracts	O
arising	O
from	O
the	O
conversion	O
of	O
GSH	B
to	O
GSSG	O
(Figures	O
and	O
).	O

bis	B
-Trimethylsilyltrifluoroacetamide	I
(BSTFA)	O
was	O
purchased	O
from	O
Regis	O
Technologies	O
(Morton	O
Grove,	O
IL).	O

(Isotec,	O
St.	O
Louis,	O
MO)	O
at	O
pH	O
7.2	O
(uncorrected);	O
50	O
μM	O
of	O
3-(trimethylsilyl)	B

Daily	O
calibration	O
standards	O
were	O
made	O
by	O
first	O
preparing	O
an	O
intermediate	O
working	O
solution	O
in	O
DMSO	B
(0.5	O
μg	O
/mL),	O
followed	O
by	O
serial	O
dilution	O
with	O
blank	O
human	O
urine	O
and	O
DMSO	B
(50%	O
final	O
concentration)	O
to	O
yield	O
final	O
analytical	O
standards	O
ranging	O
from	O
0.05	O
to	O
100	O
ng/mL.	O
Blank	O
human	O
urine	O
was	O
collected	O
from	O
untimed	O
urine	O
collections	O
provided	O
by	O
volunteers.	O

Mean	O
unconjugated	O
serum	O
E2	O
was	O
2.9	O
pg/mL	O
in	O
postmenopausal	O
women	O
Mean	O
unconjugated	O
serum	O
E2	O
was	O
9.1	O
pg/mL	O
in	O
older	O
men	O
Conjugated	O
serum	O
4-MeO-E2	B
is	O
potential	O
cancer	O
biomarker.	O

Isoprene	O
is	O
the	O
basic	O
unit	O
of	O
terpenes	B
and	O
is	O
generated	O
during	O
the	O
cholesterol	B
biosynthesis	O
in	O
the	O
mevalonate	B
pathway.	O

Thus,	O
the	O
study	O
was	O
double	O
blind	O
for	O
EPA + DHA	O
and	O
open-label	O
for	O
pioglitazone.	B

×	O
100	O
%	O
where	O
Response_post-extraction	O
spike	O
is	O
the	O
mean	O
peak	O
area	O
count	O
for	O
the	O
proline	B
spiked	O
into	O
extracted	O
matrix	O
after	O
the	O
extraction	O
procedure,	O
and	O
Response_matrix-free	O
spike	O
is	O
for	O
the	O
same	O
concentration	O
of	O
proline	B
in	O
water.	O

Thus,	O
to	O
investigate	O
only	O
the	O
short-term	O
influence	O
of	O
intake	O
of	O
either	O
whey	B
or	O
calcium	B
caseinate	I
protein	O
drinks	O
after	O
a	O
single	O
bout	O
of	O
heavy	O
resistance,	O
OPLS-DA	O
models	O
were	O
performed	O
in	O
comparison	O
with	O
the	O
intake	O
of	O
the	O
non-caloric	O
drink	O
at	O
70	O
min	O
after	O
intake.	O

However,	O
our	O
study	O
demonstrated	O
that	O
patients	O
receiving	O
HTK	O
had	O
higher	O
levels	O
of	O
pyrimidine	B
degradation	O
products,	O
but	O
lower	O
levels	O
of	O
purine	B
degradation	O
products.	O

Two	O
3-oxo-Δ_4	B
-bile	I
acids,	I
that	O
are	O
intermediates	O
in	O
the	O
synthesis	O
of	O
chenodeoxycholic	B
acid	I
from	O
cholesterol	B
and	O
generally	O
considered	O
to	O
be	O
fetal	O
bile	O
acids	O
(–),	O
7α-hydroxy-3-oxochol-4-en-24-oic	B
acid	I
and	O
3-oxochola-4,6-dien-24-oic	B
acid,	I
were	O
upregulated	O
in	O
HCC	O
relative	O
to	O
AML.	O

Since	O
MUC16	O
knockdown	O
cells	O
also	O
demonstrate	O
decreased	O
secretion	O
of	O
lactate,	B
which	O
is	O
known	O
to	O
regulate	O
tumor	O
cell	O
motility,	O
we	O
next	O
studied	O
if	O
supplementation	O
of	O
culture	O
media	O
with	O
lactate	B
could	O
restore	O
cell	O
migration	O
in	O
MUC16	O
knockdown	O
cells.	O

Our	O
results	O
furthermore	O
show	O
increased	O
serum	O
choline	B
concentrations	O
in	O
G4	O
vs.	O
G0	O
patients.	O

Columns	O
indicate	O
Map	O
of	O
the	O
Human	O
Methylome	B
identifiers,	O
Ensemble	O
id,	O
Gene	O
Symbol,	O
log	O
fold-change	O
(logFC),	O
t-statistic,	O
P-value,	O
and	O
False	O
Discovery	O
Rate	O
(FDR).	O

Choline	B
(p	O
 = 0.0150),	O
ethanolamine	B
(p	O
 = 0.0078),	O
lactate	B
(p	O
 = 0.0360),	O
and	O
phenylalanine	B
(p	O
 = 0.0055)	O
were	O
statistically	O
significant	O
between	O
long-term	O
and	O
short-term	O
survival	O
in	O
patients	O
with	O
PA	O
(Table ).	O

Six	O
metabolites	O
emerged	O
as	O
markers	O
of	O
key	O
differences	O
between	O
the	O
two	O
groups:	O
uric	B
acid,	I
L-histidine,	B
hypoxanthine,	B
glutamic	B
acid,	I
L-tryptophan,	B
and	O
ADP.	B

This	O
pilot	O
study	O
is	O
the	O
first	O
report	O
in	O
depressed	O
adolescents	O
demonstrating	O
associations	O
between	O
the	O
KP	B
and	O
anhedonia/depression-associated	O
brain	O
networks.	O

The	O
OW/OB	O
group	O
had	O
significantly	O
higher	O
levels	O
of	O
the	O
five	O
AAs	O
compared	O
to	O
the	O
HL	B
group	O
(fold	O
change	O
range	O
1.07–1.19).	O

Declines	O
in	O
xanthine	B
and	O
urate	B
may	O
be	O
attributable	O
to	O
the	O
consumption	O
of	O
purines	B
during	O
the	O
replication	O
of	O
DNA.	O

Thus,	O
relatively	O
low	O
leukocyte	O
number,	O
which	O
may	O
be	O
associated	O
with	O
low	O
levels	O
of	O
5-HETE	B
and	O
leukotriene	O
B_4	O
,	O
may	O
lead	O
to	O
an	O
improper	O
inflammatory/immune	O
function	O
against	O
future	O
LC	O
progression.	O

Serum	O
11-ketoandrostenedione	B
(11KA4)	O
was	O
quantified	O
using	O
an	O
ACQUITY	O
UPC_2	O
system	O
(Waters)	O
coupled	O
to	O
a	O
mass	O
spectrometer	O
(Xevo	O
TQ-S;	O
Waters)	O
as	O
previously	O
reported.	O

Statistically	O
significant	O
single	O
metabolites	O
or	O
metabolites	O
within	O
a	O
specific	O
biochemical	O
class	O
(LysoPCs,	O
PCs,	O
Sphingomyelins,	B
Acylcarnitines)	B
are	O
highlighted	O
in	O
blue	O
and	O
red.	O

In	O
this	O
study,	O
serum	O
concentrations	O
of	O
unconjugated	O
estradiol,	B
unconjugated	O
estrone,	B
conjugated	O
estrone,	B
and	O
many	O
estrogen	B
metabolites	O
were	O
statistically	O
significantly	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
postmenopausal	O
breast	O
cancer.	O

Novel	O
findings	O
also	O
show	O
that	O
C17:0	B
is	O
synthesized	O
in	O
vivo	O
and	O
would	O
therefore	O
not	O
be	O
a	O
suitable	O
FIB.	O

The	O
mobile	O
phase	O
for	O
the	O
elution	O
of	O
the	O
ACE	O
C4	O
column	O
consisted	O
of	O
1	O
mM	O
acetic	B
acid	I
in	O
water	O
(A)	O
and	O
1	O
mM	O
acetic	B
acid	I
in	O
acetonitrile	B
(B)	O
at	O
a	O
flow	O
rate	O
of	O
0.4	O
mL/min.	O

Although	O
exclusion	O
of	O
hepatitis-positive	O
cases	O
attenuated	O
some	O
of	O
our	O
findings	O
and	O
resulted	O
in	O
loss	O
of	O
significance	O
for	O
specific	O
metabolites,	O
strong	O
associations	O
were	O
observed	O
for	O
glutamate	B
and	O
glutamine.	B

These	O
data	O
provide	O
the	O
first	O
evidence	O
suggesting	O
a	O
role	O
of	O
the	O
kynurenine	B
pathway	O
of	O
tryptophan	B
catabolism	O
in	O
KS	O
pathogenesis	O
and	O
may	O
explain	O
why	O
some	O
KSHV-infected	O
individuals	O
with	O
advanced	O
AIDS	O
fail	O
to	O
develop	O
KS.	O

Intensities	O
were	O
log_10	O
transformed	O
and	O
variables	O
were	O
mean-centered	O
and	O
unit-variance	O
scaled,	O
prior	O
to	O
principal	O
component	O
analysis	O
(PCA)	O
and	O
partial	O
least-squares	O
(PLS)	O
analysis	O
with	O
two	O
components	O
(with	O
the	O
storage	O
duration	B
as	O
Y	O
response).	O

Thus,	O
although	O
there	O
seems	O
to	O
be	O
an	O
association	O
between	O
higher	O
age,	O
lower	O
tryptophan	B
and	O
increased	O
KTR,	O
low	O
level	O
of	O
tryptophan	B
in	O
the	O
ADHD	O
group	O
cannot	O
be	O
fully	O
explained	O
by	O
higher	O
IDO	O
or	O
TDO	O
activity.	O

TG,	B
triglyceride;	B
PS,	O
phosphatidylserine;	B
PG,	B
phosphatidylglycerol;	B
MGDG,	O
monogalactosyldiacylglycerol;	B
SiE,	O
sitosteryl	B
ester.	I

TEMs	O
show	O
thin	O
sections	O
of	O
the	O
middle	O
piece	O
of	O
boar	O
spermatozoa	O
exposed	O
for	O
3	O
days	O
to	O
T.	O
harzianum	O
strain	O
ES39	O
extract	O
(a)	O
or	O
to	O
reagents	O
only	O
(1%	O
methanol)	B
(b).	O

Interestingly,	O
those	O
acylcarnitines	B
that	O
were	O
not	O
significantly	O
correlated	O
with	O
sperm	O
concentration	O
were	O
linked	O
to	O
sperm	O
motility.	O

Blood	O
for	O
the	O
generation	O
of	O
WB	O
samples	O
was	O
collected	O
into	O
tubes	O
containing	O
sodium	B
heparin	I
(Vacutainer®,	O
Becton	O
Dickinson),	O
which	O
were	O
immediately	O
placed	O
in	O
an	O
ice-water	O
bath	O
for	O
10	O
min	O
during	O
which	O
aliquots	O
(500μL)	O
were	O
generated;	O
the	O
samples	O
were	O
then	O
promptly	O
transferred	O
to	O
the	O
freezer	O
(-80°C).	O

In	O
addition,	O
pyroglutamic	B
acid	I
could	O
improve	O
the	O
learning	O
and	O
memory	O
capacities	O
in	O
old	O
rat;	O
this	O
effect	O
could	O
also	O
be	O
related	O
to	O
an	O
activation	O
of	O
cholinergic	B
mechanisms.	O

Derivatization	O
of	O
vitamin	B
D	I
metabolites	O
results	O
in	O
an	O
approximately	O
100-fold	O
increase	O
in	O
the	O
analytical	O
signal	O
in	O
MRM	O
mode,	O
as	O
shown	O
for	O
1α,25(OH)_2	B
D_3	O
in	O
.	O

While	O
none	O
of	O
the	O
sphingolipids	B
were	O
specifically	O
associated	O
with	O
baseline	O
HIV	O
viral	O
load	O
levels	O
or	O
change	O
in	O
viral	O
load	O
with	O
treatment	O
it	O
is	O
plausible	O
that	O
the	O
effect	O
seen	O
in	O
the	O
atazanavir/r	O
and	O
zidovudine/abacavir	O
arms	O
may	O
be	O
the	O
consequence	O
of	O
HIV	O
suppression	O
rather	O
than	O
a	O
direct	O
effect	O
of	O
the	O
agents	O
themselves	O
on	O
lipid	O
metabolism	O
(i.e.	O
a	O
“return	O
to	O
health”	O
phenomena).	O

Our	O
data	O
show	O
a	O
short-term	O
increase	O
of	O
PC38:6	B
but	O
the	O
increase	O
was	O
lower	O
at	O
the	O
long-term	O
visit	O
relative	O
to	O
baseline,	O
resulting	O
in	O
a	O
Ʌ-pattern.	O

To	O
purify	O
the	O
derivatized	O
analytes,	O
two	O
methods	O
were	O
tested:	O
LLE	O
with	O
ethyl	B
acetate	I
and	O
SPE.	O

The	O
metabolite	O
most	O
significantly	O
different	O
between	O
good	O
and	O
poor	O
responders	O
at	O
baseline	O
was	O
the	O
purine	B
metabolite	O
xanthine,	B
which	O
is	O
implicated	O
in	O
oxidative	O
stress	O
cascades.	O

GlyOH3P	O
glycerol-3-phosphate,	B
all	O
other	O
abbreviations	O
and	O
numbering	O
were	O
the	O
same	O
as	O
in	O
The	O
HCCH-TOCSY	O
experiment	O
also	O
reduces	O
spectral	O
crowding	O
by	O
selecting	O
only	O
those	O
isotopomers	O
that	O
contains	O
at	O
least	O
two	O
contiguous	O
_13	O
C	O
in	O
the	O
same	O
molecule.	O

Representative	O
product	O
ion	O
spectrum	O
of	O
Cer(22:0)	B
and	O
proposed	O
structures	O
of	O
main	O
product	O
ions	O
of	O
Cer(22:0),	B
Cer(24:0),	B
[_2	B
H_4	I
]Cer(22:0)	I
and	O
[_2	B
H_4	I
]Cer(24:0)	I

We	O
selected	O
four	O
metabolites	O
as	O
the	O
potential	O
predictive	O
biomarkers	O
for	O
survival,	O
based	O
on	O
CC<0.5	O
between	O
each	O
selected	O
metabolite,	O
which	O
were	O
Kynurenine,	B
Acetylcarnitine,	B
PC	B
(42:11),	I
and	O
LPE(22:0/0:0)	B
(Table	O
).	O

Cold	O
atmospheric	O
plasma,	O
Acute	O
myeloid	O
leukemia,	O
Metabolite	O
profiling,	O
Alanine,	B
aspartate	B
and	O
glutamate	B
metabolism,	O
d-Glutamine	B
and	O
d-glutamate	B
metabolism	O
d	O
d	O

Only	O
oleic	B
acid	I
was	O
common	O
on	O
all	O
platforms.	O

Factor	O
3’s	O
(medium	O
chain	O
acylcarnitines)	B
metabolite	O
profile	O
scores	O
were	O
higher	O
among	O
NW	O
participants	O
than	O
among	O
Ov/Ob	O
with	O
or	O
without	O
MetS.	O
Factor	O
3	O
was	O
negatively	O
associated	O
with	O
glucose	B
levels	O
among	O
the	O
Ov/Ob	O
with	O
MetS.	O
Factor	O
1	O
seems	O
to	O
be	O
associated	O
with	O
a	O
deteriorated	O
metabolic	O
profile	O
that	O
corresponds	O
to	O
obesity,	O
whereas	O
Factors	O
2	O
and	O
3	O
seem	O
to	O
be	O
rather	O
associated	O
with	O
a	O
healthy	O
metabolic	O
profile.	O

Go	O
to:	O
Arsenic	B
trioxide	I
has	O
been	O
successfully	O
used	O
as	O
a	O
therapeutic	O
in	O
the	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
(APL).	O

Although	O
the	O
same	O
dose	O
of	O
arsenic	B
trioxide	I
was	O
administered	O
to	O
all	O
APL	O
patients,	O
the	O
mean	O
concentrations	O
of	O
arsenicals	O
differed	O
among	O
individual	O
APL	O
patients.	O

Precast	O
10%	O
acrylamide	B
gels	O
were	O
obtained	O
from	O
Bio-Rad	O
Laboratories	O
(Hercules,	O
California,	O
USA).	O

Circulating	O
unconjugated	O
estradiol	B
levels	O
partially	O
mediate	O
the	O
BMI-breast	O
cancer	O
association,	O
but	O
other	O
potentially	O
important	O
estrogen	B
mediators	O
(e.g.	O
bioavailable	O
estradiol)	O
were	O
not	O
evaluated.	O

Briefly,	O
proton	O
NMR	O
spectra	O
were	O
recorded	O
at	O
300 K	O
using	O
a	O
700 MHz	O
Bruker	O
Avance	O
AV	B
III	O
spectrometer.	O

Then	O
2 mL	O
chloroform	B
per	O
gram	O
of	O
specimen	O
was	O
added	O
and	O
the	O
sample	O
was	O
vortexed	O
again,	O
followed	O
keeping	O
on	O
ice	O
for	O
30 min.	O

The	O
mixture	O
was	O
incubated	O
at	O
37	O
°C	O
for	O
1	O
h	O
and	O
then	O
quenched	O
with	O
2	O
ml	O
of	O
methanol	B
(Scheme	O
1,	O
route	O
B	O
,	O
and	O
Scheme	O
2).	O

The	O
glycosidic	B
linkage	O
of	O
the	O
DNA	O
adduct	O
is	O
normally	O
the	O
most	O
facile	O
bond	O
to	O
undergo	O
cleavage	O
in	O
the	O
gas	O
phase.	O

However,	O
these	O
biomarkers	O
may	O
not	O
adequately	O
capture	O
tissue	O
1,25(OH)_2	B
D_3	O
function:	O
25(OH)D_3	O
is	O
relatively	O
inactive	O
and	O
requires	O
regulated	O
conversion	O
to	O
1,25(OH)_2	B
D_3	O
for	O
full	O
hormonal	O
activity,	O
while	O
PTH	O
reflects	O
functional	O
1,25(OH)_2	B
D_3	O
deficiency	O
at	O
only	O
one	O
of	O
many	O
relevant	O
biological	O
sites	O
and	O
is	O
influenced	O
by	O
factors	O
other	O
than	O
1,25(OH)_2	B
D_3	O
,	O
such	O
as	O
calcium.	O

Among	O
them,	O
N-acetylaspartate	B
and	O
creatinine	B
have	O
been	O
reported	O
to	O
be	O
critical	O
for	O
cancer	O
metabolism.	O

Normally	O
associated	O
with	O
disorders	O
in	O
energy	O
metabolism	O
,	O
oxidative	O
status	O
,	O
and	O
aging	O
,	O
more	O
recently	O
these	O
metabolites	O
have	O
been	O
associated	O
with	O
breast	O
(beta-alanine)	O
and	O
liver	O
cancers	O
,	O
.	O

In	O
present	O
study,	O
HOMA-IR,	O
L-octanoylcarnitine,	B
and	O
decanoylcarnitine	B
were	O
increased	O
in	O
overweight	O
group	O
after	O
3-year	O
follow-up,	O
which	O
are	O
coincide	O
with	O
previous	O
studies.	O

The	O
partial	O
least-square	O
discriminant	O
analysis	O
of	O
urinary	O
metabolome	O
correctly	O
allocated	O
children	O
based	O
on	O
their	O
obesity,	O
NAFLD,	O
visceral	O
fat,	O
pathological	O
IP	B
and	O
SIBO.	O

Working	O
Group	O
for	O
the	O
Standardization	O
of	O
Serum	O
Cystatin	B
C	O
and	O
the	O
Institute	O
for	O
Reference	O
Materials	O
and	O
Measurements	O
certified	O
reference	O
materials	O
and	O
in	O
the	O
AASK	O
F48	O
using	O
a	O
particle-enhanced	O
immunonephelometric	O
assay	O
(N	O
Latex	O
Cystatin	B
C,	O
Dade	O
Behring,	O
IL,	O
USA)	O
at	O
the	O
Cleveland	O
Clinic	O
Foundation	O
(CCF)	O
laboratory	O
(calibrated	O
to	O
IFCC	O
values	O
using	O
published	O
methods;	O
1.12 × (0.105 + 0.848 × CCF	O
cystatin	B
C).	O

Specifically,	O
BCAAs,	O
methionine	B
sulfoxide,	I
α-aminoadipic	B
acid,	I
and	O
multiple	O
phosphatidylcholines	B
were	O
all	O
altered	O
in	O
association	O
with	O
changes	O
in	O
the	O
HAM-D_17	O
scores	O
at	O
a	O
level	O
that	O
equaled	O
or	O
exceeded	O
a	O
correlation	O
coefficient	O
of	O
0.4.	O

Surprisingly,	O
sphingolipids	B
show	O
the	O
most	O
significant	O
results	O
in	O
the	O
classification	O
of	O
pregnancy	O
and	O
post-partum	O
period	O
in	O
MuS	O
patients.	O

In	O
both	O
cases,	O
the	O
baseline	O
resolution	O
between	O
the	O
isomers	O
was	O
obtained	O
by	O
addition	O
of	O
a	O
modifier	O
(organic	O
solvent-methanol).	B

From	O
a	O
biochemical	O
perspective	O
our	O
study	O
has	O
demonstrated	O
elevated	O
levels	O
of	O
phosphatidyl‐choline	B
PC(16:0–18:1),	I
LysoPC(16:0)	B
and	O
LysoPC(18:1)	B
in	O
cancerous	O
tissue	O
regions.	O

PCA	O
has	O
detected	O
a	O
group	O
of	O
distinct	O
outliers	O
corresponding	O
to	O
ketone	B
bodies	O
(3HB,	O
Ace,	O
AceAce).	O

Therefore,	O
we	O
focused	O
on	O
the	O
quantification	O
of	O
TG	B
and	O
DG.	O

The	O
findings	O
are	O
of	O
high	O
interest	O
as	O
hippurate	B
levels	O
were	O
recently	O
shown	O
to	O
correlate	O
with	O
the	O
presence	O
of	O
Clostridia	O
in	O
the	O
gut	O
and	O
Clostridia	O
bacteria	O
have	O
been	O
found	O
widely	O
in	O
CD	O
patients.	O

Plasma	O
levels	O
of	O
phosphatidylcholines	B
in	O
PTB	O
positive	O
versus	O
negative	O
cows	O
(N = 12	O
per	O
group).	O

The	O
decreased	O
valine	B
levels	O
in	O
ESCC	O
patients	O
indicate	O
the	O
need	O
for	O
glutamine	B
biosynthesis,	O
related	O
to	O
the	O
TCA	O
cycle,	O
in	O
response	O
to	O
higher	O
energy	O
requirements	O
for	O
tumour	O
proliferation.	O

Nevertheless,	O
compared	O
to	O
Quehenberger	O
et	O
al.,	O
who	O
quantified	O
588	O
lipids	O
with	O
multiple	O
platforms	O
using	O
a	O
targeted	O
approach,	O
we	O
cover	O
(i)	O
more	O
lipid	O
(sub)classes	O
with	O
numerous	O
isomeric	O
forms	O
such	O
as	O
glycerophospholipids	B
(212	O
vs.	O
160)	O
and	O
glycerolipids	B
(112	O
vs.	O
73),	O
but	O
(ii)	O
less	O
low	O
abundant	O
ones	O
such	O
as	O
fatty	O
acyls,	O
which	O
include	O
acylcarnitines	B
and	O
eicosanoids	B
(8	O
vs.	O
107),	O
or	O
prenols	O
(1	O
vs.	O
8),	O
since	O
we	O
are	O
limited	O
by	O
the	O
signal	O
intensity	O
dynamic	O
range	O
of	O
our	O
single	O
instrument.	O

Endogenous	O
biosynthesis	O
of	O
prostacyclin	B
and	O
thromboxane	B
and	O
platelet	O
function	O
during	O
chronic	O
administration	O
of	O
aspirin	B
in	O
man.	O

An	O
entirely	O
novel	O
change	O
identified	O
in	O
the	O
aqueous	O
metabolites	O
was	O
a	O
decrease	O
in	O
the	O
essential	O
branched-chain	O
amino	O
acid	O
(BCAA)	O
isoleucine	B
with	O
ascent.	O

Low	O
24,25(OH)_2	B
D_3	O
relative	O
to	O
25(OH)D_3	O
may	O
better	O
reflect	O
impaired	O
vitamin	B
D	I
metabolic	O
function	O
and	O
therefore	O
provide	O
a	O
stronger	O
indication	O
for	O
treatment.	O

In	O
contrast,	O
there	O
were	O
no	O
clear	O
associations	O
of	O
concentrations	O
of	O
any	O
of	O
the	O
lipoprotein	O
particles	O
or	O
their	O
cholesterol	B
or	O
TG	B
constituents	O
with	O
ICH.	O

All	O
patients	O
received	O
atropine	B
before	O
anesthesia	O
was	O
induced	O
with	O
thiopental.	B

Decreased	O
isoleucine	B
is	O
of	O
particular	O
interest	O
as	O
a	O
potential	O
contributor	O
to	O
muscle	O
catabolism	O
observed	O
with	O
exposure	O
to	O
hypoxia	O
at	O
altitude.	O

By	O
the	O
detection	O
of	O
under-	O
and	O
over-collected	O
urine	O
samples	O
on	O
the	O
basis	O
of	O
the	O
lower	O
and	O
upper	O
limit	O
of	O
the	O
95%	O
CI	O
of	O
the	O
24-hour	O
creatinine	B
excretion	O
at	O
least	O
extreme	O
collection	O
errors	O
could	O
be	O
excluded	O
from	O
the	O
analyses.	O

Aliquots	O
of	O
CD4_+	O
T	O
cells	O
or	O
CD4_+	O
CD39_+	O
Treg	O
isolated	O
from	O
PBMC	O
of	O
ND	O
as	O
described	O
above	O
were	O
co-incubated	O
with	O
TEX	O
(10 μg	O
protein	O
added	O
to	O
10_5	O
cells/well	O
in	O
96-well	O
plates)	O
or	O
PCI-13	O
cells	O
in	O
the	O
presence	O
of	O
exogenous	O
ATP	B
(20 μM)	O
for	O
16 h.	O
Control	O
wells	O
contained	O
T	O
cells	O
alone	O
or	O
tumor	O
cells	O
alone.	O

This	O
subclass	O
of	O
glycerophospholipids	B
is	O
less	O
abundant	O
than	O
PC,	O
PE	O
and	O
PI	O
and	O
probably	O
resulted	O
in	O
too	O
low	O
signal	O
intensity	O
for	O
their	O
robust	O
detection	O
using	O
our	O
injection	O
volume,	O
which	O
was	O
selected	O
to	O
limit	O
MS	O
signal	O
saturation	O
of	O
abundant	O
lipids	O
(cf.	O
section	O
“Worfklow	O
Validation”).	O

As	O
has	O
been	O
reported	O
previously,	O
we	O
confirmed	O
an	O
increase	O
in	O
levels	O
of	O
isovalerate,	B
isobutyrate	B
and	O
valerate	B
that	O
could	O
originate	O
from	O
an	O
increase	O
in	O
intestinal	O
slough	O
cells	O
utilisation	O
or	O
an	O
increase	O
in	O
mucolytic	O
activity	O
from	O
a	O
subset	O
of	O
microbes.	O

The	O
significant	O
metabolites	O
proposed	O
from	O
the	O
correlation	O
coefficients	O
were	O
further	O
validated	O
and	O
compared	O
with	O
the	O
use	O
of	O
a	O
simple	O
Student’s	O
t	O
test	O
and	O
by	O
ANOVA	O
and	O
subsequently	O
corrected	O
for	O
multiple	O
testing	O
using	O
Bonferroni	O
and	O
Tamhane,	B
respectively	O
(Table ).	O

The	O
only	O
literature	O
we	O
found	O
relating	O
IAA	O
to	O
psychiatry	O
research	O
included	O
early	O
studies	O
in	O
severely	O
depressed	O
patients,	O
showing	O
no	O
change	O
in	O
urinary	O
excretion	O
of	O
IAA	O
throughout	O
the	O
stages	O
of	O
disease	O
and	O
recovery,	O
despite	O
a	O
drop	O
in	O
tryptamine	B
excretion	O
or	O
plasma	O
tryptophan.	B

Elevated	O
histamine	B
can	O
aggravate	O
bronchoconstriction	O
and	O
shrink	O
airway	O
smooth	O
muscle.	O

The	O
range	O
of	O
LOQ	O
was	O
between	O
0.3	O
and	O
102 nM.	O
For	O
the	O
majority	O
of	O
the	O
targets	O
(81 %),	O
the	O
LOQ	O
was	O
below	O
10 nM,	O
for	O
56 %	O
it	O
was	O
below	O
3 nM.	O
Relatively	O
high	O
LOQs	O
were	O
observed	O
for	O
5,6-Lipoxin	B
A4	O
with	O
values	O
higher	O
than	O
80 nM.	O

The	O
oxidation	O
of	O
the	O
pyrrolidine	B
ring	O
was	O
additionally	O
found	O
at	O
a	O
different	O
retention	O
time	O
using	O
HILIC	O
(M216T114	O
in	O
Table )	O
implying	O
that	O
this	O
compound	O
was	O
not	O
formed	O
within	O
the	O
ion	O
source.	O

These	O
compounds	O
constitute	O
a	O
large	O
proportion	O
of	O
ethanolamine	O
glycerophospholipids—≥50%	O
in	O
the	O
brain,	O
heart,	O
neutrophils,	O
and	O
eosinophils,	B
and	O
up	O
to	O
∼90%	O
of	O
ethanolamine	B
derivatives	O
in	O
some	O
regions	O
of	O
the	O
brain.	O

Therefore,	O
we	O
propose	O
that	O
limiting	O
cellular	O
kynurenine	B
or	O
its	O
downstream	O
targets	O
could	O
present	O
a	O
new	O
strategy	O
to	O
reduce	O
the	O
proliferation	O
of	O
MYC-dependent	O
cancer	O
cells.	O

In	O
all	O
spectra,	O
the	O
aliphatic	O
region	O
at	O
0.6-4.5	O
ppm	O
included	O
prominent	O
signals	O
from	O
water-soluble	O
metabolites,	O
such	O
as	O
amino	O
acids	O
(e.g.,	O
leucine,	B
isoleucine,	B
valine,	B
alanine,	B
lysine,	B
dimethylglycine,	B
asparate,	O
tyrosine,	B
glutamate,	B
proline,	B
succinate),	B
SCFAs	O
(e.g.,	O
acetate,	B
propionate,	B
butyrate),	B
creatinine,	B
ethanol,	B
choline,	B
lactate	B
and	O
glucose	B
components.	O

Bindzil	O
2040	O
silica	B
nanoparticles	O
(SNPs)	O
were	O
obtained	O
from	O
AkzoNobel	O
and	O
Eka	O
Chemicals	O
with	O
an	O
average	O
diameter	O
of	O
20	O
nm	O
(characterized	O
previously)	O
and	O
a	O
negative	O
surface	O
charge	O
at	O
pH	O
7.4	O
(ζ-potential	O
=	O
−40.7	O
±	O
5.9	O
mV,	O
see	O
).	O

Furthermore,	O
AF4	O
separations	O
are	O
performed	O
in	O
a	O
50	O
mM	O
phosphate	B
buffer	O
which	O
is	O
preferred	O
for	O
biological	O
systems	O
(rather	O
than	O
the	O
3	O
M	O
KBr	O
used	O
in	O
UC	O
lipoprotein	O
isolation).	O

A	O
large	O
body	O
of	O
evidence	O
resulted	O
from	O
MRS-based	O
studies	O
(,	O
,	O
)	O
to	O
show	O
alterations	O
of	O
phospholipid	B
metabolism	O
in	O
PA	O
tumor	O
samples	O
as	O
evidenced	O
by	O
high	O
levels	O
of	O
phosphoetanolamine,	B
phosphatidylcholine	B
(,	O
)	O
and	O
phosphatidylinositol	B
concentrations	O
(Table	O
).	O

The	O
remainder	O
was	O
extracted	O
with	O
200	O
μL	O
of	O
methanol,	B
and	O
the	O
supernatant	O
was	O
combined	O
with	O
the	O
first	O
step	O
extraction	O
supernatant.	O

Meikle	O
and	O
colleagues	O
have	O
reported	O
that	O
THC	O
was	O
inversely	O
associated	O
with	O
obesity,	O
plasma	O
glucose	B
level	O
and	O
decreased	O
with	O
prediabetes	O
and	O
T2DM.	O

Vascular	O
health	O
impairment	O
was	O
associated	O
with	O
increased	O
urinary	O
excretion	O
of	O
glucosepane.	B

Although	O
in	O
smaller	O
proportion,	O
other	O
increased	O
lipids	O
in	O
patients	O
with	O
preeclampsia	O
were	O
Glycerophosphates-GP10	B
(PAc)	O
(p<0.0001),	O
Phosphosphingolipids-SP03	B
(SM)	O
(p<0.0001),	O
Neutral	O
glycosphingolipids-SP05	B
(p<0.0001)	O
and	O
Steroid	O
conjugates-ST05	O
(p<0.0002).	O

Hence,	O
the	O
commercially	O
available	O
1-methylimidazole-2-sulfonyl	B
chloride	I
(ISCl)	O
and	O
2-(1H-1,2,4-triazol-1-yl)-3-pyridinesulfonyl	B
chloride	I
were	O
selected	O
to	O
derivatize	O
steroids.	O

The	O
mobile	O
phase	O
is	O
composed	O
of	O
(A)	O
0.1%	O
formic	B
acid	I
and	O
(B)	O
isopropanol,	B
acetonitrile	B
and	O
methanol	B
[20:40:40	I
(v/v)]	I
in	O
0.1%	O
formic	B
acid,	I
and	O
the	O
gradient	O
was	O
used	O
as	O
follows:	O
98–50%	O
(A)	O
and	O
2–50%	O
(B)	O
for	O
0–3.5	O
min;	O
50–0%	O
(A)	O
and	O
50–100%	O
(B)	O
for	O
3.5–20	O
min.	O

Edoxaban	B
is	O
a	O
substrate	O
for	O
these	O
transporters.	O

Our	O
results	O
showed	O
that	O
PG	B
and	O
PI	O
could	O
be	O
detected	O
by	O
all	O
six	O
protocols.	O

Correlation	O
analyses	O
adjusted	O
for	O
cotinine	B
and	O
age	O
showed	O
significant	O
inverse	O
correlations	O
between	O
the	O
serum	O
concentration	O
of	O
tryptophan	B
and	O
kynurenine	B
and	O
the	O
current	O
and	O
past	O
ADHD	O
symptom	O
scores	O
ASRS	O
and	O
WURS,	O
when	O
including	O
all	O
participants	O
(N = 264)	O
(Table ).	O

Sphingolipid	B
metabolites	O
in	O
healthy	O
controls	O
stratified	O
by	O
the	O
absence/presence	O
of	O
central	O
obesity.	O

HPLC-grade	O
methanol	B
and	O
acetic	B
acid	I
were	O
purchased	O
from	O
Fisher	O
Scientific	O
(Pittsburgh,	O
PA).	O

GABA	B
is	O
an	O
important	O
inhibitory	O
neurotransmitter.	O

The	O
data	O
showed	O
that	O
after	O
16 h	O
of	O
co-incubation,	O
adenosine	B
is	O
consumed	O
and	O
inosine	B
is	O
the	O
main	O
product	O
of	O
enzymatic	O
ATP	O
hydrolysis.	O

In	O
mice,	O
disruption	O
of	O
Nrf2	O
signaling	O
obviates	O
the	O
cancer	O
chemopreventive	O
actions	O
of	O
SF.	B

AFP,	O
alpha-fetoprotein;	B
HBsAg,	O
hepatitis	O
B	O
surface	O
antigen;	O
ALP,	O
alkaline	O
phosphatase;	O
ALT,	O
alanine	O
aminotransferase;	O
AST,	O
aspartate	O
transaminase;	O
D-BIL,	O
direct	O
bilirubin;	B
T-BIL,	O
total	O
bilirubin.	B

Citric	B
acid	I
and	O
flavin	B
adenine	I
dinucleotide	I
(FAD),	O
an	O
intermediate	O
and	O
a	O
cofactor	O
of	O
the	O
tricarboxylic	B
acid	I
cycle	O
(TCA),	O
were	O
changed	O
post-H.	O
pylori	O
eradication.	O

,	O
where	O
saturated	O
ammonium	B
sulfate	I
(0.75	O
mL)	O
was	O
slowly	O
added	O
to	O
plasma	O
or	O
serum	O
(0.5	O
mL)	O
on	O
ice.	O

Abbreviations:	O
5AAs-Combined	O
score:	O
the	O
combined	O
score	O
derived	O
from	O
the	O
abundance	O
of	O
5	O
AAs	O
(valine,	O
leucine,	B
isoleucine,	B
tyrosine,	B
and	O
phenelalanine);	B
6AAs-Combined	O
score:	O
the	O
combined	O
score	O
derived	O
from	O
the	O
abundance	O
of	O
6	O
AAs	O
(valine,	O
leucine,	B
isoleucine,	B
tyrosine,	B
phenelalanine,	B
and	O
tryptophan).	O

Although	O
glutamine	B
massively	O
cyclizes	O
to	O
pyroglutamic	B
acid,	I
the	O
sum	O
of	O
glutamine	B
and	O
pyroglutamic	B
acid	I
is	O
the	O
same	O
in	O
all	O
the	O
portions	O
of	O
serum	O
samples	O
(CV	O
<	O
3%).	O

The	O
glucuronide	B
levels	O
(A	O
and	O
D	O
in	O
)	O
and	O
sulfonated	O
compounds	O
(H,	O
I,	O
J	O
in	O
)	O
reflect	O
modified	O
patterns	O
of	O
kidney	O
and	O
liver	O
function.	O

They	O
also	O
noticed	O
low	O
hippurate	B
levels	O
in	O
urine	O
of	O
IBD	O
patients	O
suggesting	O
that	O
hippurate	B
may	O
be	O
a	O
biomarker	O
candidate.	O

We	O
found	O
16	O
metabolites	O
meeting	O
the	O
two	O
criteria	O
of	O
interest:	O
correlation	O
with	O
storage	O
duration	B
in	O
the	O
RT	O
samples,	O
and	O
identical	O
statistical	O
significance	O
between	O
the	O
two	O
experiments	O
(when	O
available)	O
in	O
both	O
the	O
RT	O
and	O
4 °C	O
conditions	O
(Fig.	O

[0.0002]	O
vs	O
0.0019	O
[0.0003]	O
arbitrary	O
units	O
[AU];	O
p	O
=	O
0.041);	O
formate	B
(0.0027	O
[0.0006]	O
vs	O
0.0019	O
[0.0006]	O
AU;	O
p	O
=	O
0.010)	O
(AU).	O

The	O
low	O
(L),	O
medium	O
(M)	O
and	O
high	O
(H)	O
plasma	O
quality	O
control	O
(QC)	O
samples	O
were	O
prepared	O
by	O
spiking	O
Cer(22:0)	B
and	O
Cer(24:0)	B
working	O
solution	O
to	O
yield	O
endogenous	O
level	O
+	O
0/0,	O
endogenous	O
level	O
+	O
1.5/6,	O
and	O
endogenous	O
level	O
+	O
3/12	O
μg/mL,	O
respectively.	O

Completeness	O
of	O
24-hour	O
urine	O
collection	O
was	O
assessed	O
based	O
on	O
the	O
amount	O
of	O
urinary	O
creatinine	B
excretion	O
as	O
recently	O
published.	O

Interestingly,	O
3-phosphoglycerolphosphate	B
(G3P)	O
does	O
not	O
participate	O
in	O
glycerol	B
shuttle,	O
which	O
is	O
strongly	O
reduced,	O
because	O
G3P	O
is	O
mainly	O
used	O
to	O
produce	O
triglycerides	B
(TGs).	O

This	O
intensity	O
ratio	O
is	O
reduced	O
to	O
0.06,	O
0.3	O
and	O
0.2	O
(see	O
discussion	O
below)	O
in	O
the	O
tandem	O
mass	O
spectra	O
of	O
Δ_9	O
18:1	O
FA,	O
Δ_9,12	B
18:2	I
FA	I
and	O
Δ_9,12,15	B
18:3	I
FA,	I
respectively.	O

The	O
position	O
of	O
the	O
oxo	O
group	O
was	O
again	O
determined	O
in	O
ortho	O
to	O
the	O
pyrrolidine	B
nitrogen	I
due	O
to	O
the	O
above-mentioned	O
characteristics.	O

Octadecenoylcarnitine;	B
12.	O

Adjusting	O
for	O
age,	O
BMI,	O
current	O
smoking,	O
race,	O
and	O
measurement	O
batch,	O
urinary	O
monocarboxy-isononyl	B
phthalate	I
(MCNP)	O
concentrations	O
were	O
positively	O
associated	O
with	O
mtDNAcn	O
(β	O
=	O
1.63,	O
95%	O
CI:	O
0.14,	O
3.11).	O

Although	O
higher	O
concentration	O
levels	O
of	O
formic	B
acid	I
in	O
the	O
sheath	O
liquid	O
tended	O
to	O
partially	O
increase	O
the	O
signal	O
intensity	O
of	O
analyzed	O
amino	O
acids,	O
the	O
stability	O
of	O
the	O
analytical	O
signal	O
was	O
decreased.	O

Primary	O
aldosteronism	O
patients	O
were	O
compared	O
to	O
5	O
comparator	O
cohorts:	O
healthy	O
controls	O
(n	O
=	O
162);	O
patients	O
with	O
endocrine-inactive	O
adrenal	O
adenoma	O
(n	O
=	O
56);	O
patients	O
with	O
adrenal	O
adenomas	O
associated	O
with	O
mild,	O
subclinical	O
Cushing’s	O
syndrome	O
(n	O
=	O
104);	O
and	O
patients	O
with	O
overt	O
clinical	O
Cushing’s	O
syndrome	O
(n	O
=	O
47)	O
due	O
to	O
a	O
cortisol-producing	B
adrenal	I
adenoma.	O

It	O
is	O
of	O
note	O
that,	O
despite	O
cholesterol	B
and	O
fatty	O
acids	O
being	O
abundant	O
classes	O
observed	O
in	O
the	O
mixed-mode	O
LC,	O
we	O
did	O
not	O
perform	O
identification	O
of	O
these	O
two	O
classes	O
at	O
the	O
molecular	O
level.	O

The	O
repeatability	O
and	O
selectivity/orthogonality	O
of	O
extraction	O
methods	O
were	O
compared	O
using	O
both	O
targeted	O
metabolites	O
and	O
on	O
global	O
basis	O
in	O
combination	O
with	O
RP	B
and	O
mixed-mode	O
IEX/RP	O
(Scherzo)	O
LC-MS.	O

For	O
the	O
FDA-compliant	O
validation	O
of	O
the	O
chemotyping	O
assay,	O
vitamin	O
D-free	O
blank	O
serum	O
samples	O
were	O
spiked	O
with	O
varying	O
amounts	O
of	O
the	O
investigated	O
vitamin	B
D	I
compounds.	O

Indeed,	O
the	O
inhibition	O
of	O
CPT-I-regulated	O
fatty	O
acid	O
β-oxidation	O
promotes	O
an	O
up-regulation	O
of	O
ceramide	B
levels	O
which	O
have	O
been	O
associated	O
with	O
a	O
ceramide-mediated	O
apoptotic	O
pathway	O
via	O
the	O
peroxisome	O
proliferator-activated	O
receptor	O
(PPAR)	O
gamma,	O
induction	O
of	O
proapoptotic	O
genes	O
BNIP3,	O
tumour	O
necrosis	O
factor	O
(TNF)-related	O
apoptosis-inducing	O
ligand	O
(TNSF10)	O
and	O
death-associated	O
protein	O
kinase	O
2	O
(DAPK2)	O
,	O
.	O

Therefore,	O
for	O
the	O
variables	O
concerned	O
[HDL	O
triacylglycerol	B
(-CH	O
_2	O
-)_n	O
,	O
and	O
total	O
unsaturated	O
-CH_2	O
-CH	O
_2	O
-CH=	O
functions],	O
this	O
observation	O
may	O
be	O
ascribable	O
to	O
the	O
‘masking’	O
of	O
information	O
by	O
relatively	O
large	O
numbers	O
of	O
uninformative	O
variables,	O
a	O
lack	O
of	O
overlap	O
between	O
the	O
univariate	O
and	O
MV	O
testing	O
approaches	O
utilised,	O
and/or	O
complications	O
with	O
the	O
provision	O
of	O
reliable	O
estimates	O
of	O
covariances,	O
notably	O
when	O
there	O
are	O
large	O
numbers	O
of	O
potential	O
predictor	O
variables	O
and	O
relatively	O
smaller	O
sample	O
sizes	O
(although	O
in	O
this	O
case	O
there	O
was	O
a	O
very	O
favourable	O
high	O
sample	O
size	O
to	O
NMR	O
chemical	O
shift	O
bin	O
variable	O
ratio,	O
i.e.	O
ca	O
.	O

Thus,	O
these	O
studies	O
suggest	O
that	O
both	O
glycolysis	O
and	O
glutaminolysis	O
are	O
important	O
energy	O
determinants	O
in	O
HNSCC;	O
however,	O
glucose	B
metabolism	O
may	O
be	O
more	O
important	O
for	O
survival	O
and	O
proliferation,	O
whereas	O
glutamine/glutamate	O
metabolism	O
may	O
be	O
critical	O
for	O
subsequent	O
aggressive	O
transitions,	O
such	O
as	O
acquiring	O
stemness	O
properties	O
and	O
metastatic	O
potential.	O

Moreover,	O
we	O
found	O
that	O
early	O
impairment	O
of	O
insulin	O
sensitivity	O
alters	O
the	O
minute-to-minute	O
metabolic	O
processing	O
of	O
α	B
-hydroxybutyrate	I
under	O
glucose-induced	O
hyperinsulinemia,	O
as	O
evident	O
from	O
different	O
plasma	O
time	O
courses	O
in	O
response	O
to	O
a	O
glucose	B
challenge	O
between	O
individuals	O
with	O
different	O
degrees	O
of	O
insulin	O
sensitivity.	O

Publications,	O
such	O
as	O
that	O
by	O
Samejima	O
et	O
al.,	O
have	O
used	O
N1-AcSPD-	B
and	O
N1,12-DiAcSPM-labeled	O
internal	O
standards;	O
Stevens	O
et	O
al.	O
used	O
ORN-,	O
PUT-,	O
SPD-,	O
and	O
SPM-labeled	O
internal	O
standards;	O
Häkkinen	O
et	O
al.	O
used	O
14	O
labeled	O
polyamines	B
and	O
acetylated	B
polyamines;	I
and	O
Tomita	O
et	O
al.	O
used	O
numerous	O
labeled	O
polyamines	B
and	O
amino	O
acids.	O

10 cc	O
venous	O
blood	O
(10 cc),	O
of	O
fasting	O
patients,	O
was	O
collected	O
in	O
lithium-heparin	B
tubes	O
and	O
stored	O
within	O
5 min	O
at	O
4 °C.	O

(C)	O
DNMT	O
and	O
(D)	O
TET	O
activity	O
were	O
measured	O
in	O
response	O
to	O
α-OG	B
treatment.	O

HPLC	O
grade	O
acetonitrile,	B
ethyl	B
acetate	I
and	O
ammonium	B
acetate	I
were	O
obtained	O
from	O
Fisher	O
Scientific	O
Co.	O
(Fair	O
Lawn,	O
NJ,	O
USA).	O

Tryptophan	B
itself,	O
as	O
well	O
as	O
5-hydroxytryptophan,	B
an	O
intermediate	O
in	O
the	O
indoleamine	B
pathway,	O
has	O
also	O
been	O
used	O
to	O
treat	O
depressive	O
disorder	O
(,	O
).	O

Citrate,	B
another	O
metabolite	O
related	O
to	O
cellular	O
energetics,	O
was	O
negatively	O
correlated	O
with	O
glutamate	B
during	O
insulin	O
deprivation	O
but	O
the	O
relationship	O
between	O
these	O
two	O
metabolites	O
became	O
positive	O
with	O
insulin	O
treatment.	O

Metabolomic	O
analyses	O
of	O
bronchoalveolar	O
lavage	O
fluid	O
from	O
dexamethasone	B
treated,	O
experimentally	O
induced	O
asthma	O
mouse	O
model	O
identified	O
a	O
similar	O
increase	O
in	O
PC	O
level	O
associated	O
with	O
a	O
decrease	O
in	O
choline	B
level	O
.	O

In	O
the	O
_1	O
H-NMR	O
spectra	O
of	O
sera,	O
the	O
lipids	O
were	O
detected	O
as	O
broad	O
resonances	O
of	O
fatty-acid	O
methyl	O
and	O
methylene	B
moieties	O
at	O
0.8	O
and	O
1.24	O
ppm,	O
respectively,	O
and	O
the	O
N-trimethyl	O
moiety	O
of	O
choline	B
was	O
included	O
in	O
phospholipids	B
at	O
3.2	O
ppm.	O

A	O
decreased	O
level	O
of	O
glucose	B
has	O
also	O
been	O
shown	O
in	O
PA	O
without	O
neoadjuvant	O
chemotherapy.	O

Pathway	O
analysis	O
revealed	O
that	O
these	O
dysregulated	O
metabolites	O
were	O
potentially	O
related	O
to	O
the	O
metabolic	O
pathways	O
of	O
sphingolipid,	B
arginine	B
and	O
proline,	B
pyruvate	B
and	O
inositol	B
phosphate.	I

These	O
enzymes	O
catalyze	O
the	O
conversion	O
of	O
various	O
aldehydes	O
and	O
ketones	B
to	O
their	O
corresponding	O
alcohols	O
by	O
utilizing	O
NADH	B
and/or	O
NADPH	B
as	O
cofactors.	O

Exemestane-d3,	B
17β-hydroxyexemestane-d3	I
and	O
17β-hydroxyexemestane-d3–17-O-β-D-glucuronide,	B
the	O
stable	O
isotope-labelled	O
internal	O
standards	O
(IS),	O
were	O
also	O
purchased	O
from	O
Toronto	O
Research	O
Chemicals	O
Inc.	O
(North	O
York,	O
Ontario,	O
Canada).	O

Cells	O
were	O
incubated	O
with	O
uniformly	O
labeled	O
_13	O
C_16	B
-palmitate,	I
and	O
the	O
abundance	O
of	O
_13	O
C-labeled	O
palmitoyl-carnitine	B
(C16),	O
myristoyl-carnitine	B
(C14)	O
and	O
lauroyl-carnitine	B
(C12)	O
were	O
measured	O
by	O
ultra-high-performance	O
liquid	O
chromatography-tandem	O
mass	O
spectrometry	O
(UPLC-MS/MS;	O
Figure	O
E).	O

After	O
LC–TOFMS	O
analysis,	O
the	O
samples	O
were	O
derivatized	O
with	O
N	B
,O	I
-bis(trimethylsilyl)trifluoroacetamide	I
(BSTFA)	O
and	O
analyzed	O
by	O
gas	O
chromatography	O
time-of-flight	O
mass	O
spectrometry	O
(GC–TOFMS,	O
Leco	O
Corporation,	O
St.	O
Joseph,	O
MI).	O

Component	O
1	O
(interleukin-1	O
receptor	O
antagonist,	O
QA,	O
and	O
kynurenine)	O
was	O
significantly	O
elevated	O
in	O
MDD	O
participants	O
versus	O
the	O
HCs,	O
whereas	O
component	O
2	O
(KA,	O
tryptophan,	B
and	O
kynurenine)	O
was	O
positively	O
correlated	O
with	O
hippocampal	O
and	O
amygdala	O
volume	O
within	O
the	O
MDD	O
group.	O

In	O
the	O
present	O
study,	O
higher	O
levels	O
of	O
trans-aconitate	B
(urine),	O
3-hydroxybutyrate	B
(serum),	O
acetoacetate	B
(serum),	O
and	O
acetone	B
(serum)	O
were	O
found	O
in	O
the	O
patients	O
who	O
relapsed	O
within	O
12	O
mo.	O

In	O
fact	O
within	O
the	O
NMOSD-like	O
subgroup	O
alone,	O
patients	O
on	O
immunosuppressants	O
had	O
higher	O
levels	O
of	O
myoinositol	B
(on	O
immunosuppressant,	O
0.0020	O

All	O
cases	O
and	O
control	O
subjects	O
had	O
no	O
history	O
of	O
self-reported	O
prior	O
doctor-diagnosed	O
CHD,	O
stroke,	O
transient	O
ischemic	O
attack,	O
and	O
cancer,	O
and	O
were	O
not	O
using	O
statin	B
therapy	O
at	O
baseline.	O

3-indoxyl	B
sulfate	I
is	O
a	O
well-known	O
uremic	O
toxin	B
accumulating	O
in	O
the	O
blood	O
of	O
chronic	O
kidney	O
disease	O
(CKD)	O
patients	O
due	O
to	O
inadequate	O
renal	O
clearance_,	O
,	O
and	O
has	O
been	O
associated	O
with	O
increased	O
risk	O
of	O
CVD	O
in	O
these	O
patients_,	O
,	O
possibly	O
through	O
increased	O
oxidative	O
stress_,	O
.	O

,	O
there	O
was	O
a	O
significantly	O
increased	O
concentration	O
of	O
creatinine	B
in	O
sepsis	O
sera	O
compared	O
to	O
the	O
healthy	O
controls’	O
sera.	O

While	O
most	O
of	O
the	O
significant	O
metabolites	O
have	O
been	O
previously	O
reported	O
in	O
literature,	O
a	O
few	O
of	O
them	O
(e.g.,	O
N-acetyl-L-histidine,	B
octanoylcarnitine)	B
were	O
uniquely	O
discovered	O
for	O
the	O
first	O
time	O
in	O
this	O
Asian	O
female	O
TNBC	O
population.	O

Tryptophan	B
(Trp)	O
is	O
an	O
essential	O
amino	O
acid	O
for	O
protein	O
synthesis,	O
and	O
its	O
metabolism	O
can	O
give	O
rise	O
to	O
serotonin	B
and	O
metabolites	O
in	O
the	O
kynurenine	B
(Kyn)	O
pathway.	O

CRP	O
was	O
negatively	O
associated	O
with	O
PLP	O
(P	O
=	O
0.005),	O
and	O
monocyte	O
chemoattractant	O
protein	O
1	O
was	O
positively	O
associated	O
with	O
tryptophan	B
(P	O
=	O
0.003).	O

In	O
the	O
current	O
method,	O
urine	O
ultrafiltrate	O
is	O
mixed	O
with	O
stable	O
isotopic	O
standards	O
in	O
0.1%	O
trifluoroacetic	B
acid	I
which	O
stabilizes	O
analytes	O
from	O
risk	O
of	O
degradation	O
at	O
neutral	O
and	O
high	O
pH;	O
all	O
are	O
stable	O
at	O
low	O
pH	O
and	O
ambient	O
temperature.	O

Studies	O
have	O
shown	O
that	O
polyphenols	O
(epigalocatechin	O
gallate,	I
oenothelin	O
B,	O
ellagitanin,	O
and	O
resveratrol)	O
augment	O
NK	O
cell	O
cytotoxicity	O
[–];	O
however,	O
a	O
study	O
of	O
hesperidin	B
showed	O
no	O
effects	O
in	O
healthy,	O
well-nourished	O
humans.	O

Serum	O
hypoxanthine	B
levels	O
were	O
also	O
elevated	O
in	O
a	O
heterogeneous	O
group	O
of	O
hemolymphatic	O
malignancies,	O
including	O
acute	O
myeloid	O
leukemia,	O
NHL	O
and	O
CLL,	O
and	O
in	O
rectal	O
cancer	O
patients	O
who	O
underwent	O
chemoradiotherapy.	O

Preliminary	O
analysis	O
revealed	O
glucose	B
at	O
sometimes	O
dominant	O
levels	O
in	O
most	O
samples.	O

Myristic	B
acid	I
(C14:0),	O
palmitic	B
acid	I
(C16:0),	O
palmitoleic	B
acid	I
(C16:1n-7),	O
vaccenic	B
acid	I
(C18:1n-7)	O
and	O
oleic	B
acid	I
(C18:1n-9)	O
were	O
all	O
obtained	O
from	O
Sigma	O
(Ref#	O
M3128,	O
43051,	O
S4751,	O
P9417,	O
V0384,	O
O1257,	O
respectively).	O

The	O
resonances	O
assigned	O
in	O
the	O
CPMG	O
HRMAS	O
spectrum	O
of	O
sample	O
G	O
are:	O
mannitol	B
(Man),	O
glycine	B
(Gly),	O
choline	B
and	O
phosphocholine	B
(Cho),	O
creatine	B
(Cr),	O
alanine	B
(Ala),	O
lactate	B
(Lac),	O
and	O
lipids	O
(Lip).	O

A	O
previous	O
study	O
found	O
elevated	O
serum	O
enterolactone	B
levels	O
in	O
patients	O
with	O
diabetic	O
nephropathy	O
and	O
a	O
strong	O
correlation	O
between	O
serum	O
enterolactone	B
and	O
creatinine	B
levels.	O

ATP	B
adenosine	I
triphosphate,	I
Fatty	O
acids	O
capric	O
acid,	O
cis-9-palmitoleic	B
acid,	I
dodecanoic	B
acid,	I
oleic	B
acid,	I
palmitic	B
acid	I
or	O
stearic	B
acid,	I
MDD	O
major	O
depressive	O
disorder,	O
PUFAs	O
eicosapentaenoic	B
acid	I
(EPA,	O
ω-3)	O
and	O
arachidonic	B
acid	I
(AA,	O
ω-6),	O
SAM	O
S-adenosylmethionine,	B

The	O
levels	O
of	O
adenosine,	B
guanosine,	B
and	O
uridine	B
did	O
not	O
differ	O
significantly	O
between	O
the	O
CRC	O
and	O
normal	O
tissue	O
samples.	O

-hydroxybenoylecgonine,	B
MOR	O
morphine,	B
MTD	O
methadone,	B
NBUP	O
norbuprenorphine,	B
NIC	O
nicotine,	B
OHCOT	O
trans	B
-3′-hydroxycotinine,	I
OXY	B
oxycodone,	I
pOHMAMP	O
p	B
-hydroxymethamphetamine	I
Calibration	O
with	O
matched	O
deuterated	O
internal	O
standardization	O
was	O
possible	O
for	O
all	O
analytes	O
except	O
mOHBE	O
and	O
pOHMAMP.	O

Both	O
tissues	O
also	O
exhibit	O
increased	O
levels	O
of	O
BCAA	O
(isoleucine,	O
leucine,	B
valine),	B
suggesting	O
more	O
proteolysis	O
during	O
shock	O
than	O
at	O
baseline.	O

Enacted	O
restrictions	O
and	O
regulations	O
could	O
effectively	O
reduce	O
phthalate	B
exposure	O
in	O
the	O
general	O
population;	O
however,	O
continuous	O
biomonitoring	O
surveillance	O
is	O
necessary	O
to	O
detect	O
the	O
long-term	O
level	O
variation.	O

These	O
photographs	O
were	O
subsequently	O
examined	O
independently	O
by	O
2	O
qualified	O
retinal	B
photography	O
graders	O
in	O
accordance	O
with	O
quality	O
assurance	O
protocols.	O

More	O
recently,	O
kidney-relevant	O
properties	O
have	O
also	O
been	O
disclosed;	O
for	O
example,	O
serine	B
is	O
a	O
major	O
methyl	B
group	I
provider,	O
and	O
it	O
also	O
has	O
direct	O
blood	O
pressure–lowering	O
effects.	O

Associations	O
between	O
C_18	O
H_3	O
and	O
C_26	O
H_3	O
_1	O
H	O
NMR	O
signals	O
for	O
total	O
cholesterol	B
(A),	O
C_18	O
H_3	O
_1	O
H	O
NMR	O
signal	O
for	O
total	O
cholesterol	B
and	O
serum	O
cholesterol	B
concentration	O
determined	O
routinely	O
at	O
a	O
clinical	O
laboratory	O
(B),	O
C_26	O
H_3	O
_1	O
H	O
NMR	O
signal	O
for	O
total	O
cholesterol	B
and	O
serum	O
cholesterol	B
concentration	O
determined	O
routinely	O
at	O
a	O
clinical	O
laboratory	O
(C)	O
in	O
the	O
study	O
subjects.	O

Proinflammatory	O
cytokines	O
associated	O
with	O
SLE	O
and	O
disease	O
activity,	O
that	O
is,	O
IP-10,	O
TNF-α	O
and	O
IL-16,	O
correlated	O
with	O
kynurenine,	B
quinolinic	B
acid	I
and	O
kynurenine/tryptophan	B
ratio,	O
but	O
not	O
with	O
tryptophan,	B
in	O
our	O
study.	O

Decreased	O
serum	O
levels	O
of	O
these	O
metabolites	O
may	O
be	O
associated	O
with	O
the	O
increased	O
uptake	O
of	O
circulating	O
glycine,	B
valine,	B
methionine	B
and	O
citrulline	B
for	O
the	O
rapid	O
biosynthesis	O
of	O
proteins	O
(,,).	O

Lower	O
levels	O
of	O
TG(49∶3)	B
do	O
not	O
depend	O
on	O
the	O
lamin	O
mutation	O
(panel	O
D)	O
but	O
are	O
DCM	O
specific	O
(panel	O
E).	O

To	O
characterize	O
specifically	O
the	O
presence	O
of	O
4-OH-E_1	B
-1-N	I
3Ade	O
from	O
breast-tissue	O
extract,	O
the	O
analyses	O
were	O
carried	O
out	O
with	O
an	O
ion-trap	O
instrument	O
to	O
monitor	O
alternatively	O
the	O
product	O
ions	O
generated	O
from	O
precursor	O
ions	O
of	O
m/z	O
420	O
(native	O
analyte)	O
and	O
425	O
([4-OH-E_1	O
-1-N	I
3(U-_15	I
N)Ade	I
+	I
H]_+	I
).	O

There	O
are	O
plausible	O
mechanisms	O
whereby	O
indole	B
metabolites	O
may	O
contribute	O
to	O
IBS	O
pathophysiology,	O
such	O
as	O
activation	O
of	O
argyl	B
hydrocarbon	I
receptor	O
and	O
subsequent	O
inflammation	O
and	O
afferent	O
pain	O
fiber	O
stimulation._,	O
However,	O
validation	O
of	O
these	O
mechanisms	O
was	O
beyond	O
the	O
scope	O
of	O
the	O
present	O
study.	O

Additionally,	O
we	O
excluded	O
participants	O
for	O
whom	O
urinary	O
EM	O
or	O
urinary	O
creatinine	B
was	O
not	O
assayed	O
(n=16);	O
participants	O
who	O
reported	O
recent	O
(<6	O
months)	O
exogenous	O
hormone	O
use	O
(n=83),	O
pregnancy	O
(n=12)	O
or	O
lactation	O
(n=5);	O
and	O
participants	O
with	O
missing	O
data	O
on	O
adult	O
soy	O
intake	O
(n=2).	O

The	O
stock	O
solutions	O
(1	O
mg/mL)	O
of	O
Abi	O
and	O
its	O
metabolites	O
were	O
prepared	O
by	O
dissolving	O
the	O
synthesized	O
powder	O
in	O
100%	O
methanol.	B

PC(40:7)	B
(A)	O
and	O
SM(36:3)	B
(B)	O
at	O
w0,	O
w16	O
and	O
w28.	O

This	O
method	O
was	O
then	O
successfully	O
applied	O
to	O
detect	O
the	O
adducts	O
in	O
subjects	O
who	O
had	O
taken	O
high	O
levels	O
of	O
acetaminophen.	B

Assuming	O
that	O
TAG(54:5)	B
contains	O
fatty	O
acid	O
22:5	O
this	O
means	O
there	O
is	O
an	O
inverse	O
correlation	O
of	O
the	O
amount	O
of	O
22:5	O
in	O
WAT	O
and	O
serum.	O

Incubation	O
of	O
human	O
mammary	O
epithelial	O
MCF-7	O
and	O
MCF-10A	O
cells	O
with	O
dioxins	B
resulted	O
in	O
a	O
concentration-dependent	O
decrease	O
in	O
the	O
ratio	O
of	O
4-methoxy-E_2	B
(4-MeO-E_2	I
)	I
to	O
2-methoxy-E_2	B
(2-MeO-E_2	I
)	I
as	O
an	O
indication	O
of	O
decreased	O
4-OH-E_2	B
:2-OH-E_2	I
.	O

Plasma	O
glucose	B
levels	O
were	O
derived	O
from	O
the	O
collected	O
SCAN	O
data.	O

Lipoprotein	O
profiles	O
showed	O
significantly	O
lower	O
plasma	O
concentrations	O
of	O
cholesterol-intermediate	B
density	O
lipoprotein	O
(IDL),	O
triglycerides-IDL	B
and	O
high-density	O
lipoprotein	O
(HDL)	O
in	O
mothers	O
of	O
growth-restricted	O
fetuses	O
compared	O
to	O
controls	O
(p < 0.05).	O

Here	O
we	O
studied	O
the	O
utility	O
of	O
the	O
androgen	O
precursor	O
serum	O
androstenedione	B
(A)	O
in	O
conjunction	O
with	O
serum	O
T	O
for	O
predicting	O
metabolic	O
dysfunction	O
in	O
PCOS.	O

The	O
urea	B
was	O
degraded	O
for	O
60 min	O
at	O
37°C.	O

ORs	O
for	O
Developing	O
Pancreatic	O
Cancer	O
in	O
Different	O
Glutamine	B
and	O
Histidine	B
Strata	O

Estrone	B
sulfate:	I
a	O
potential	O
source	O
of	O
estradiol	B
in	O
human	O
breast	O
cancer	O
tissues.	O

CRP-	O
and	O
IL-6	O
levels	O
before	O
and	O
after	O
surgery;	O
(a)	O
CRP	O
levels	O
(n	O
 = 5),	O
after	O
surgery	O
the	O
CRP	O
levels	O
increased	O
dramatically;	O
(b)	O
IL-6	O
levels	O
(n	O
 = 5),	O
also	O
for	O
IL-6	O
levels	O
a	O
significant	O
increment	O
after	O
surgery	O
was	O
observed	O
The	O
pairplot	O
demonstrates	O
the	O
abundance	O
of	O
the	O
two	O
monohydroxy	B
fatty	O
acids	O
12-HETE	O
and	O
5-HETE	B
at	O
baseline	O
levels	O
before	O
the	O
surgery	O
(T0)	O
and	O

This	O
partitioning	O
is	O
attributed	O
to	O
the	O
diversion	O
of	O
upper	O
glycolytic	B
intermediates	O
towards	O
the	O
pentose	B
phosphate	I
pathway	O
for	O
the	O
synthesis	O
of	O
ribose-5-phosphate	B
and	O
NADPH	B
and	O
the	O
lower	O
intermediate	O
towards	O
the	O
TCA	O
cycle	O
or	O
one-carbon	O
metabolism.	O

Finally,	O
there	O
were	O
18	O
metabolic	O
signatures	O
associated	O
both	O
with	O
obesity	O
and	O
asthma,	O
which	O
were	O
pyrophosphate	B
3,	O
d-glucoheptose	B
1,	O
shikimic	B
acid,	I
aspartic	B
acid,	I
beta-glutamic	B
acid	I
1,	I
4-aminobutyric	I
acid	I
1,	O
phytosphingosine	B
2,	O
xanthine,	B
3-aminopropionitrile	B
1,	I
3-hydroxybutyric	I
acid,	I
gly-pro	B
in	O
sputum	O
(n	O
=	O
11),	O
and	O
valine,	B
uric	B
acid,	I
d-glyceric	B
acid,	I
N-Methyl-DL-alanine	B
in	O
serum	O
(n	O
=	O
4),	O
and	O
linolenic	B
acid,	I
3-hydroxynorvaline	B
2,	O
isoleucine	B
in	O
PBMCs	O
samples	O
(n	O
=	O
3).	O

Regarding	O
the	O
HLP	O
group,	O
TC	O
was	O
positively	O
associated	O
with	O
changes	O
in	O
valine,	B
serine,	B
isoleucine	B
and	O
asparagine	B
between	O
0	O
and	O
120	O
min	O
during	O
the	O
OGTT	O
(p	O
<	O
0.05).	O

However,	O
it	O
has	O
not	O
been	O
reported	O
that	O
free	O
threonine	B
can	O
be	O
mannosylated	O
or	O
if	O
the	O
amino	O
acid	O
can	O
inhibit	O
protein	O
mannosylation,	O
despite	O
the	O
fact	O
that	O
O	B
-α-D-mannopyranosyl-L-threonine	I
is	O
available	O
from	O
several	O
commercial	O
sources.	O

β-actin	B
was	O
regarded	O
as	O
a	O
standard	O
reference.	O

This	O
solution	O
represents	O
the	O
MTBE	B
lipid	O
fraction	O
used	O
for	O
analysis.	O

These	O
findings	O
are	O
consistent	O
with	O
animal	O
models,	O
where	O
PCs	O
and	O
other	O
phospholipids	B
were	O
found	O
to	O
be	O
lower	O
in	O
heart	O
tissues	O
from	O
Syrian	O
hamsters	O
with	O
hereditary	O
cardiomyopathy	O
compared	O
to	O
normal	O
hamsters.	O

As	O
expected	O
metabonomics	O
failed	O
to	O
detect	O
methanol	B
or	O
significant	O
increases	O
in	O
formate	B
in	O
blood	O
or	O
urine	O
as	O
constitutive	O
levels	O
would	O
mask	O
any	O
change.	O

Although	O
the	O
difference	O
between	O
serum	O
and	O
plasma	O
should	O
be	O
taken	O
into	O
account,	O
our	O
preliminary	O
study	O
showed	O
that	O
the	O
metabolites	O
detected	O
in	O
serum	O
samples	O
included	O
all	O
the	O
metabolites	O
detected	O
in	O
plasma,	O
and	O
metabolite	O
concentrations	O
in	O
EDTA	O
plasma	O
and	O
serum	O
correlate	O
well	O
with	O
the	O
exception	O
of	O
some	O
metabolites	O
such	O
as	O
hypoxanthine	B
and	O
lactic	B
acid	I
[,].	O

In	O
C	O
it	O
was	O
shown	O
the	O
MS/MS	O
ion	O
fragmentation	O
of	O
the	O
major	O
9-HSA-containing	O
species,	O
PE(O-18:0/9-HSA).	B

 999,	O
package	O
‘boot’)	O
on	O
Δ_AUROC	O
,	O
constructing	O
CIs	O
thereof,	O
and	O
testing	O
for	O
embracement	B
of	O
Δ_0	O
by	O
the	O
Δ_AUROC	O
’s	O
CI	O
according	O
to	O
the	O
methods	O
proposed	O
by	O
Liu	O
et	O
al.	O

Another	O
possibility	O
is	O
that	O
significant	O
and/or	O
prolonged	O
exposure	O
to	O
acetemiprid	O
or	O
thiamethoxam	B
caused	O
neo-nicotinic	O
symptoms	O
with	O
abnormal	O
electrocardiogram,	O
an	O
increased	O
excretion	O
of	O
DMAP	O
or	O
thiamethoxam	B
and	O
a	O
reduced	O
renal	O
tubular	O
reabsorption.	O

Additional	O
participants	O
were	O
excluded	O
from	O
the	O
reference	O
sample	O
group	O
for	O
the	O
following	O
reasons:	O
urine	O
under-	O
or	O
over-collection,	O
pregnancy,	O
self-reported	O
bilateral	O
oophorectomy	O
or	O
bilateral	O
oophorectomy	O
with	O
hysterectomy,	O
Addison’s	O
disease	O
(the	O
presence	O
of	O
other	O
hormone	O
disorders	O
was	O
not	O
reported	O
in	O
the	O
cohort),	O
self-reported	O
diagnosis	O
of	O
active	O
malignant	O
disease,	O
self-reported	O
liver	O
disease,	O
estimated	O
glomerular	O
filtration	O
rate	O
less	O
than	O
30	O
mL/min	O
per	O
1.73	O
m_2	O
calculated	O
by	O
CKD-EPI	O
formula,	O
missing	O
data	O
for	O
serum	O
creatinine	B
or	O
urinary	O
creatinine,	B
body	O
mass	O
index	O
<16	O
kg/	O
m_2	O
or	O
>	O
40	O
kg/m_2	O
,	O
>3	O
fold	O
elevated	O
γ-glutamyltransferase	O
(>120	O
U/L	O
for	O
female	O
and	O
>180	O
U/L	O
for	O
male),	O
aspartate	B
or	O
alanine	O
aminotransferases	O
(>105	O
U/L	O
for	O
female	O
and	O
>	O
150	O
U/L	O
for	O
male),	O
intake	O
of	O
the	O
following	O
drugs	O
(current	O
intake	O
or	O
in	O
the	O
two	O
previous	O
weeks):	O
hormonal	O
contraceptives,	O
hormones	O
to	O
suppress	O
menstrual	O
bleeding,	O
hormonal	O
menopause	O
treatment,	O
systemic	O
glucocorticoids	B
or	O
mineralocorticoids,	O
5α-reductase	O
inhibitors,	O
aromatase	O
inhibitors,	O
antiepileptic	O
agents,	O
systemic	O
azole	B
derivatives.	O

Among	O
the	O
variables	O
selected	O
by	O
the	O
global	O
model,	O
only	O
the	O
following	O
two	O
variables	O
were	O
not	O
metabolomic	O
data:	O
the	O
age	O
and	O
the	O
urinary	O
retinol	B
binding	O
protein	O
concentration.	O

On	O
the	O
other	O
hand,	O
in	O
cirrhotic	O
controls	O
phosphoric	B
acid	I
shows	O
positive	O
correlation	O
with	O
linoleic	B
acid	I
which	O
presents	O
also	O
a	O
moderate	O
and	O
strong	O
negative	O
correlation	O
with	O
a	O
furanose	O
sugar.	O

The	O
difference	O
in	O
color	O
intensity	O
before	O
and	O
after	O
the	O
addition	O
of	O
acid	O
is	O
a	O
direct	O
estimate	O
of	O
creatinine	B
concentration	O
in	O
the	O
sample.	O

Mass	O
levels	O
of	O
many	O
sphingomyelin	B
and	O
ceramide	B
species	O
were	O
correlated	O
with	O
AD	O
severity.	O

The	O
patient	O
continued	O
treatment	O
with	O
120	O
mg	O
enzalutamide	B
until	O
October	O
2016.	O

Lanthionine	B
and	O
homolanthionine	B
plasma	O
concentrations	O
were	O
determined	O
by	O
GC-MS	O
(Thermo	O
DSQII)	O
in	O
the	O
Food	O
Science	O
and	O
Human	O
Nutrition	O
Department	O
at	O
the	O
University	O
of	O
Florida.	O

Furthermore,	O
it	O
is	O
known	O
that	O
pyrimidines	B
play	O
an	O
important	O
role	O
in	O
the	O
modulation	O
of	O
the	O
CNS	O
and	O
alterations	O
in	O
pyrimidine	B
metabolism	O
have	O
been	O
shown	O
in	O
Alzheimer’s	O
disease	O
[,].	O

Another	O
compound	O
significantly	O
increased	O
in	O
ARDS	O
BALF,	O
hippurate,	B
is	O
a	O
known	O
metabolite	O
of	O
the	O
gut	O
microbiome,	O
an	O
abundant	O
urine	O
metabolite,	O
and	O
a	O
uremic	O
toxin.	B

Spearman’s	O
correlation	O
analysis	O
between	O
metabolites	O
with	O
high	O
VIP	O
values	O
and	O
parameters	O
of	O
clinical	O
chemistry	O
indicated	O
that	O
these	O
metabolites	O
significantly	O
correlated	O
to	O
alterations	O
in	O
cholesterol,	B
triacylglycerol	B
and	O
glucose	B
plasma	O
concentrations.	O

It	O
is	O
present	O
in	O
tobacco	O
smoke	O
and	O
undergoes	O
metabolism	O
to	O
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol	B
(NNAL)	O
in	O
the	O
lungs.	O

(2019),	O
extract	O
from	O
F.	O
oxysporum	B
with	O
strong	O
antimutagenic	O
activity	O
was	O
found	O
to	O
be	O
composed	O
of	O
gibepyrone	B
A,	O
pyrrolo	O
[1,	O
2-a]	O
pyrazine-1,4-dione,	B
hexahydro-3-(2-methylpropyl)	B
and	O
indoleacetic	B
acid	I
as	O
major	O
components.	O

Samples	O
(0.1 μg	O
mL_−1	O
)	O
dissolved	O
in	O
H_2	O
O:	O
CH_3	O
CN	B
(70:30)	I
were	O
infused	O
2	O
μL/min	O

In	O
the	O
H	O
group,	O
Firmicutes	O
(Bacillus,	O
Solibacillus	O
and	O
Lactococcus	B
)	O
were	O
grouped	O
with	O
sugars	O
(d-galactose,	O
sedoheptulose),	O
sugar	O
alcohols,	O
and	O
organic	O
acids,	O
such	O
as	O
nonanoic	B
acid,	I
benzoic	B
acid	I
and	O
others	O
(hexane,	O
1-acetyl-2-methyl-azetidine).	B

Mobile	O
phase	O
consisted	O
of	O
water	O
(solvent	O
A)	O
and	O
ACN	O
(solvent	O
B),	O
both	O
with	O
0.1%	O
formic	B
acid	I
as	O
additive	O
to	O
improve	O
electrospray	O
ionization.	O

In	O
IBS	O
only,	O
we	O
explored	O
whether	O
Trp	O
metabolites	O
are	O
associated	O
with	O
IBS	O
symptoms	O
and	O
subjective	O
and	O
objective	O
sleep	O
indices,	O
serum	O
cortisol,	B
plasma	O
adrenocorticotropic	O
hormone	O
(ACTH),	O
and	O
cortisol/ACTH	B
levels.	O

The	O
spray	O
voltage	O
was	O
5	O
kV.	B

Formate	B
was	O
added	O
as	O
the	O
internal	O
standard	O
(I.S.)	O
in	O
all	O
samples.	O

Moreover,	O
untargeted	O
metabolites	O
in	O
tissue	O
and	O
plasma	O
were	O
compared	O
to	O
determine	O
whether	O
the	O
differential	O
metabolites	O
could	O
be	O
potential	O
biomarkers	O
for	O
AF	B
diagnosis	O
or	O
prediction.	O

Briefly,	O
tissue	O
cryo-sections	O
of	O
10 μm	O
were	O
thaw-mounted	O
onto	O
ITO	O
coated	O
glass	O
slides	O
(Delta	O
Technologies,	O
Loveland,	O
CO)	O
and	O
1,5-diaminonapthalene	B
(DAN)	O
matrix	O
(Sigma	O
Aldrich,	O
Oakville,	O
CA)	O
was	O
sublimated	O
on	O
the	O
slide.	O

The	O
methanol,	B
2-chloro-phenylalanine,	B
methoxyamine	B
and	O
pyridine	B
were	O
bought	O
from	O
Aladdin	O
(Shanghai,	O
China).	O

Despite	O
this,	O
some	O
samples	O
were	O
also	O
analyzed	O
using	O
pooled	O
plasma	O
as	O
matrix	O
curve,	O
also	O
finding	O
significant	O
differences	O
for	O
DHEA,	O
AET	O
and	O
7-oxo-DHEA	B
between	O
HD	O
and	O
HIV-TB	O
(data	O
not	O
shown).	O

The	O
RT	O
index	O
(RI)	O
method	O
was	O
used	O
for	O
peak	O
identification,	O
and	O
the	O
RI	B
tolerance	O
was	O
5,000.	O

Using	O
the	O
current	O
method’s	O
hydrolysis	O
conditions	O
achieved	O
similar	O
JWH-018	O
N-5-hydroxypentyl-glucuronide	O
hydrolysis	O
as	O
observed	O
during	O
development	O
of	O
the	O
previous	O
qualitative	O
synthetic	O
cannabinoid	B
assay	O
inferring	O
that	O
the	O
current	O
conditions	O
would	O
also	O
achieve	O
optimal	O
hydrolysis	O
of	O
JWH-073,	O
JWH-122,	O
JWH-210,	O
JWH-250,	O
AM2201	O
and	O
RCS-4	O
metabolites.	O

Decanoylcarnitine	B
and	O
octanoylcarnitine	B
were	O
identified	O
using	O
the	O
single-variant	O
test,	O
and	O
the	O
remains	O
were	O
identified	O
using	O
the	O
gene-based	O
burden	O
test.	O

Estrogen	B
metabolite	O
data	O
were	O
analyzed	O
as	O
both	O
nmol/day	O
and	O
ng/mg	O

-hydroxycholesterol.	B

The	O
PEAR	O
investigators	O
reported	O
certain	O
racial	O
differences	O
in	O
blood	O
metabolite	O
profile	O
following	O
antihypertensive	O
drug	O
administration	O
and	O
found	O
that	O
the	O
levels	O
of	O
a	O
number	O
of	O
organic	O
acids,	O
including	O
oleic,	O
linoleic,	B
palmitoleic,	B
palmitic,	B
BHBA	O
and	O
myristic	B
acid,	I
were	O
significantly	O
decreased	O
upon	O
atenolol	B
treatment	O
of	O
white	O
and,	O
to	O
slightly	O
lesser	O
extent,	O
of	O
black	O
patients.	O

To	O
identify	O
metabolites	O
that	O
are	O
associated	O
with	O
the	O
development	O
of	O
fasting	O
plasma	O
glucose	B
levels,	O
we	O
calculated	O
the	O
Spearman's	O
rank	O
correlation	O
coefficient	O
between	O
the	O
single	O
metabolites	O
and	O
Δglucose	B
.	O

The	O
amount	O
of	O
aspartate	B
released	O
by	O
16HBE14o_−	O
cells	O
during	O
2	O
h	O
of	O
treatment	O
with	O
rHla	O
correlates	O
with	O
approximately	O
13%	O
of	O
the	O
amount	O
of	O
consumed	O
glutamine	B
and	O
would	O
therefore	O
match	O
the	O
missing	O
portion	O
of	O
the	O
precursor	O
glutamate	B
that	O
has	O
not	O
been	O
released	O
directly.	O

First,	O
we	O
compared	O
metabolites	O
found	O
in	O
the	O
supernatant	O
(n	O
=	O
132)	O
with	O
those	O
found	O
in	O
the	O
extracts	O
from	O
frozen	O
samples	O
(n	O
=	O
437),	O
as	O
described	O
in	O
to	O
identify	O
those	O
that	O
are	O
soluble	O
in	O
formalin	B
and	O
could,	O
as	O
a	O
result,	O
be	O
lost	O
in	O
the	O
analysis.	O

After	O
vortexing	O
and	O
placing	O
on	O
ice	O
for	O
30 min,	O
1 mL	O
water	O
and	O
0.9 mL	O
dichloromethane	B
were	O
added,	O
and	O
the	O
mixture	O
was	O
centrifuged	O
(1500 rpm,	O
10 min,	O
room	O
temperature).	O

However,	O
contrary	O
to	O
previous	O
studies,	O
our	O
research	O
showed	O
that	O
compared	O
with	O
the	O
controls,	O
deoxyinosine,	B
one	O
of	O
the	O
most	O
common	O
precursors	O
of	O
DNA,	O
was	O
decreased	O
in	O
the	O
cancer	O
groups.	O

Although	O
the	O
concentrations	O
of	O
some	O
amino	O
acids	O
were	O
primarily	O
affected	O
by	O
co-variables	O
such	O
as	O
fasting	O
status,	O
many	O
other	O
amino	O
acids,	O
such	O
as	O
phenylalanine,	B
threonine,	B
tyrosine,	B
lysine,	B
tryptophan,	B
asparagine	B
and	O
glycine	B
for	O
example,	O
were	O
excreted	O
at	O
lower	O
concentrations	O
in	O
pre-surgery	O
CRC	O
patients’	O
urine.	O

To	O
verify	O
and	O
quantify	O
the	O
self-reported	O
cannabis	B
usage	O
of	O
all	O
individuals,	O
the	O
level	O
of	O
4	O
cannabis	B
metabolites,	O
including	O
THC,	O
11-OH-THC,	B
THC-COOH,	O
and	O
THC-COOH	O
glucuronide,	B
were	O
quantified	O
in	O
plasma.	O

The	O
six	O
differential	O
metabolites	O
were	O
pseudouridine,	B
malic	B
acid,	I
hypoxanthine,	B
3,4-dihydroxybutyric	B
acid,	I
fructose	B
and	O
inositol.	B

Interestingly,	O
the	O
increase	O
in	O
creatinine	B
levels	O
for	O
females	O
was	O
highly	O
significant	O
(Table	O
S4).	O

After	O
phase-position	O
and	O
baseline	O
one-dimensional	O
1H	O
NMR	O
spectra	O
were	O
collected	O
with	O
Bruker	O
TopSpin	O
software	O
(Bruker,	O
Switzerland),	O
lactate	B
was	O
used	O
for	O
calibration	O
with	O
two	O
peaks	O
in	O
the	O
high	O
field	O
(1.33	O
ppm).	O

L-leucine;	B
7,	O
glycerol;	B
8,	O
phosphoric	B
acid;	I
9,	O
L-isoleucine;	B
10,	O
L-proline;	B
11,	O
glycine;	B
12,	O

Chromatographic	O
separation	O
was	O
achieved	O
with	O
a	O
30	O
m	O
0.25	O
mm	O
CP-Sil	O
8	O
CB	O
fused	O
silica	B
capillary	O
GC	O
column	O
with	O
1.00	O
µm	O
film	O
thickness	O
from	O
Agilent	O
(Agilent,	O
J&W	O
Scientific,	O
Folsom,	O
CA,	O
USA),	O
with	O
helium	O
as	O
carrier	O
gas.	O

The	O
concentrations	O
of	O
spermine,	B
citrate	B
and	O
the	O
ratio	O
CCP/C	O
[(total	O
choline + creatine + polyamines)/citrate]	I
obtained	O
from	O
HRMAS	O
_1	O
H	O
NMR	O
of	O
human	O
prostate	O
tissues	O
samples	O
data	O
using	O
the	O
peak	O
assignment	O
and	O
quantification	O
program	O
LCModel	O
(Linear	O
Combination	O
Model)	O
showed	O
that	O
the	O
cancer	O
tissues	O
could	O
be	O
distinguished	O
from	O
normal	O
tissue	O
with	O
a	O
sensitivity	O
of	O
86.9 %	O
and	O
specificity	O
of	O
85.2 %.	O

Among	O
the	O
potential	O
urinary	O
biomarkers,	O
acetoacetate,	B
glutamine,	B
asparagine,	B
and	O
cysteine	B
had	O
relatively	O
high	O
AUC,	O
sensitivity,	O
and	O
specificity	O
values	O
for	O
distinguishing	O
early	O
stage	O
CRC	O
patients	O
from	O
HCs.	O

Separate	O
studies	O
have	O
also	O
suggested	O
the	O
association	O
of	O
acylcarnitines	B
with	O
bladder	O
cancer	O
,	O
,	O
as	O
well	O
as	O
with	O
esophageal	O
squamous	O
cell	O
carcinoma	O
.	O

This	O
network	O
model	O
consisted	O
of	O
β-CATENIN	B
(CTNNB1),	O
PKD1	O
(polycystin	O
1),	O
CDH18	O
(cadherin	O
18),	O
SMARCA4	O
(SWI/SNF	O
related,	O
matrix	O
associated,	O
actin	O
dependent	O
regulator	O
of	O
chromatin,	B
subfamily	O
A,	O
member	O
4),	O
HDAC4	O
(histone	O
deacetylase	O
4),	O
ARID1A	O
(AT-rich	O
interactive	O
domain	O
1A),	O
PBRM1	O
(Polybromo-1,	O
a	O
component	O
of	O
the	O
PBAF	O
(Polybromo-associated-BRG1-	O
or	O
BRM-associated	O
factors)	O
chromatin	B
remodeling	O
complex)	O
et	O
al	O
.	O

In	O
addition,	O
bilirubin	B
was	O
found	O
to	O
be	O
elevated	O
in	O
HCC	O
compared	O
to	O
AML	O
and	O
LC	O
and	O
biliverdin	B
in	O
HCC	O
compared	O
to	O
LC	O
only.	O

Lactate	B
and	O
total	O
cholesterol	B
concentration	O
were	O
determined	O
by	O
a	O
routine	O
laboratory	O
method	O
using	O
a	O
COBAS	O
MIRA+	O
autoanalyzer	O
according	O
to	O
the	O
manufacturer's	O
instructions	O
(HORIBA	O
ABX	O
diagnostic,	O
Montpellier,	O
France).	O

The	O
product	O
ion	O
spectra	O
of	O
this	O
pair	O
of	O
modified	O
peptides	O
contained	O
almost	O
the	O
complete	O
series	O
of	O
b-	O
and	O
y-ions	O
and	O
the	O
immonium	O
ions	O
for	O
the	O
desamino-PhIP	B
modified	O
tyrosine,	B
which	O
confirmed	O
that	O
Tyr_138	O
was	O
the	O
amino	O
acid	O
modified	O
in	O
this	O
sequence.	O

Sixty	O
atrial	O
appendage	O
samples	O
(AF	O
group:	O
30;	O
non-AF	O
group:	O
30)	O
and	O
163	O
plasma	O
samples	O
(AF	O
group:	O
48;	O
non-AF	O
group:	O
115)	O
from	O
49	O
AF	B
patients	O
and	O
116	O
non-AF	O
patients	O
were	O
subjected	O
to	O
liquid	O
chromatography	O
positive	O
ion	O
electrospray	O
ionization	O
tandem	O
mass	O
spectrometry	O
(LC-ESI-MS/MS)	O
metabolomics	O
analysis.	O

The	O
liquid	O
chromatography-mass	O
spectrometry	O
analysis	O
of	O
methanol	B
extract	O
from	O
endophyte	O
F.	O
tricinctum	O
isolated	O
from	O
the	O
fruits	O
of	O
Hordeum	O
sativum	O
revealed	O
the	O
presence	O
of	O
six	O
antibiotic	O
compounds,	O
enniatins	B
A,	O
A1,	O
B,	O
B1,	O
B2,	O
and	O
Q	O
(Zaher	O
et	O
al.	O
2014).	O

Abbreviations:	O
LPC = lysophosphatidylcholine;	B
PC = phosphatidylcholine;	B
SM = sphingomyelin.	B

Furthermore,	O
elevated	O
levels	O
of	O
kynurenate,	B
1-methylimidazoleacetate	B
and	O
dimethylarginine	B
are	O
associated	O
with	O
mortality	O
in	O
both	O
conditions	O
[–].	O

We	O
obtained	O
identical	O
MS_2	O
and	O
MS_3	O
fragmentation	O
patterns	O
when	O
we	O
subjected	O
purified	O
l-α-hydroxyglutaric	B
acid	I
to	O
tandem	O
MS	O
experiments.	O

Importantly,	O
we	O
investigated	O
the	O
use	O
of	O
AD	O
treatment	O
drugs	O
(cholinesterase	O
inhibitors	O
and	O
memantine),	O
as	O
well	O
as	O
antidepressants,	O
antipsychotics,	O
anxiolytics,	O
corticosteroids	O
and	O
statins	B
to	O
identify	O
metabolites	O
that	O
might	O
potentially	O
be	O
associated	O
with	O
drug	O
metabolism	O
and/or	O
response.	O

From	O
the	O
SQC	O
well,	O
a	O
series	O
of	O
dilution	O
quality	O
controls	O
(dQC)	O
were	O
prepared	O
by	O
dilution	O
with	O
50%	O
methanol	B
(water/methanol	O
=	O
50/50,	O
v/v	O
%)	O
containing	O
0.1%	O
formic	B
acid	I
as	O
follows:	O
dilution	O
by	O
2-fold	O
(d2QC),	O
4-fold	O
(d4QC),	O
8-fold	O
(d8QC),	O
and	O
16-fold	O
(d16QC).	O

Additionally,	O
we	O
studied	O
plasma	O
from	O
patients	O
with	O
pulmonary	O
arterial	O
hypertension	O
(PAH)	O
as	O
it	O
has	O
previously	O
been	O
reported	O
that	O
estrogen	B
levels	O
are	O
elevated	O
in	O
these	O
patients	O
and	O
metabolites	O
may	O
be	O
pathogenic	O
[,,].	O

For	O
example,	O
tri-	O
and	O
diorganophosphates	B
(e.g.,	O
adenosine	B
triphosphate	I
and	O
adenosine	B
diphosphate)	I
were	O
readily	O
degraded	O
into	O
a	O
mono-organophosphate	B
(e.g.,	O
adenosine	B
monophosphate)	I
during	O
heating.	O

Low	O
plasma	O
concentrations	O
of	O
25(OH)D	O
and	O
24,25-dihydroxyvitamin	B
D	I
are	O
associated	O
with	O
increased	O
risk	O
of	O
microalbuminuria	O
in	O
type	O
1	O
diabetes.	O

However,	O
its	O
utility	O
in	O
personalizing	O
thiopurine	B
treatment	O
has	O
remained	O
controversial,	O
particularly	O
in	O
multiethnic	O
Asian	O
population	O
in	O
Singapore	O
where	O
TPMT	O
variant	O
alleles	O
have	O
only	O
been	O
shown	O
to	O
occur	O
at	O
a	O
low	O
overall	O
frequency	O
of	O
2.5%.	O

mean	O
MVPA	O
duration	B
was	O
23.6	O
(SD	O
=	O
17.9)	O
min/d,	O
and	O
mean	O
sedentary	O
time	O
was	O
522.1	O
(SD	O
=	O
66.0)	O
min/d.	O

The	O
expression	O
of	O
GSK3β	B
and	O
GAD1	O
was	O
significantly	O
decreased	O
in	O
CSCC	O
and	O
CIN	O
II-III	O
compared	O
with	O
NC	O
group	O
[p	O
<	O
0.05].	O

The	O
inclusion	O
criteria	O
were	O
as	O
follows:	O
at	O
least	O
one	O
side	O
of	O
the	O
thyroid	O
after	O
lobectomy	O
was	O
pathologically	O
confirmed	O
with	O
PTC;	O
no	O
cervical	O
lymph	O
nodes	O
or	O
distant	O
metastasis	O
were	O
present;	O
after	O
surgery,	O
levothyroxine	B
sodium	I
tablets	O
(L-T4)	O
were	O
regularly	O
consumed	O
over	O
3	O
months;	O
TSH	O
levels	O
were	O
less	O
than	O
0.1	O
IU/L;	O
and	O
free	O
triiodothyronine	B
(FT3)	O
and	O
free	O
thyroxine	B
(FT4)	O
levels	O
were	O
normal.	O

It	O
is	O
well	O
known	O
that	O
12,13-DiHOME	B
is	O
produced	O
in	O
humans	O
from	O
linoleic	B
acid,	I
via	O
its	O
oxidation	O
(by	O
P450	O
monoxygenase)	O
to	O
the	O
protoxin	B
12,13-EpOME	I
(isoleukotoxin),	O
followed	O
by	O
conversion	O
to	O
12,13-DiHOME	B
via	O
the	O
12,13-EpOME	B
by	O
sEH.	O

The	O
time	O
course	O
of	O
biotransformation	O
of	O
P	O
(A)	O
and	O
IP	B
(B)	O
by	O
active	O
human	O
intestinal	O
flora	O
(n	O
=	O
3,	O
mean	O
±	O
standard	O
deviation	O
(SD).	O

The	O
sera	O
were	O
drawn	O
after	O
an	O
overnight	O
fasting	O
and	O
a	O
24-hour	O
long	O
serotonin-free	O
diet,	O
refraining	O
patients	O
and	O
controls	O
from	O
eating	O
anything	O
that	O
might	O
include	O
serotonin	B
or	O
its	O
precursor	O
such	O
as	O
nuts,	O
banana,	O
avocado,	O
plum,	O
kiwi,	O
pineapple,	O
grape,	O
melons,	O
date,	O
tomato,	O
eggplant	O
and	O
blue	O
cheese.	O

In	O
pyrimidine	B
metabolism,	O
orotate,	B
β-alanine,	B
and	O
cytosine	B
were	O
upregulated;	O
however,	O
certain	O
compounds,	O
such	O
as	O
glutamine,	B
urea	B
and	O
cytidine	B
were	O
downregulated	O
in	O
tumor	O
tissues.	O

cAMP	O
correlated	O
with	O
taurine	B
(r = 0.58;	O
FDR	O
p = 0.003)	O
and	O
48	O
other	O
metabolites,	O
including	O
GPP	O
(r = 0.57;	O
FDR	O
p = 0.003),	O
CDP-choline	B
(r = 0.57;	O
FDR	O
p = 0.003),	O
kynurenic	B
acid	I
(r = 0.56;	O

Preconception	O
LNS	O
significantly	O
decreased	O
the	O
level	O
of	O
ADMA,	B
a	O
metabolite	O
which	O
has	O
been	O
implicated	O
in	O
intrauterine	O
growth	O
restriction	O
and	O
preeclampsia.	O

The	O
urinary	O
ribose	B
and	O
citrate	B
negative	O
correlation	O
(d)	O
may	O
be	O
a	O
direct	O
effect	O
of	O
the	O
HCV	O
virus.	O

In	O
contrast,	O
two	O
microbial	O
metabolites,	O
p	O
-cresol	O
and	O
its	O
glucuronide	B
(p	I
-cresol-β	I
-O	I
-glucuronide),	I
were	O
found	O
to	O
be	O
excreted	O
in	O
higher	O
concentrations	O
in	O
patients	O
pre-surgery	O
(p-adjusted	O
<	O
0.05	O
<	O
FDR).	O

In	O
some	O
cases,	O
urine	O
(100	O
μL)	O
from	O
control	O
rats	O
and	O
[_12	O
C_4	O
]furan-	O
or	O
[_13	O
C_4	O
]furan-treated	O
rats	O
was	O
reacted	O
with	O
methyoxyamine	B
(10	O
mg)	O
at	O
37	O
°C	O
for	O
2	O
hours	O
before	O
centrifugation	O
at	O
5,000	O
rpm	O
for	O
3	O
min	O
to	O
remove	O
any	O
solids.	O

Mothers	O
and	O
daughters	O
did	O
not	O
differ	O
in	O
measures	O
of	O
adiposity,	O
insulin	O
resistance,	O
serum	O
triglycerides,	B
fatty	O
acids	O
or	O
amino	O
acids.	O

Hence,	O
the	O
enhanced	O
plasma	O
availability	O
of	O
lysophosphatidylcholine	B
and	O
tryptophan	B
and	O
the	O
reduction	O
of	O
plasma	O
leucine	B
support	O
the	O
idea	O
of	O
a	O
prolonged	O
and	O
unexplained	O
fasting-like	O
metabolic	O
state	O
in	O
severely	O
affected	O
CMT1A	O
patients.	O

Various	O
α-keto	B
acids,	I
which	O
are	O
the	O
byproducts	O
of	O
BCAA	O
catabolism,	O
such	O
as	O
3-methyl-2-oxovalerate,	B
increased	O
after	O
leptin	O
therapy	O
(2.4-fold)	O
and	O
levels	O
of	O
3-methyl-2-oxobutyrate	B
(11-fold)	O
tended	O
to	O
increase	O
(	O
and	O
).	O

The	O
precursor	O
of	O
RvE1	B
18-HEPE	I
may	O
represent	O
the	O
EPA-derived	O
resolving	O
capacity	O
.	O

To	O
our	O
knowledge,	O
our	O
study	O
is	O
the	O
largest	O
experience	O
to	O
date	O
to	O
address	O
the	O
clinical	O
significance	O
of	O
assessing	O
systemic	O
levels	O
of	O
arginine	B
metabolites	O
for	O
cardiovascular	O
risks	O
in	O
humans.	O

We	O
hypothesized	O
that	O
a	O
less	O
complex	O
sample	O
would	O
also	O
result	O
in	O
few	O
overlapping	O
compounds,	O
and	O
reduced	O
ion	O
suppression	O
of	O
metabolites	O
when	O
RPC	O
was	O
used	O
for	O
lipids	O
and	O
HILIC	O
was	O
used	O
for	O
hydrophilic	B
compounds.	O

Briefly,	O
100	O
µL	O
of	O
serum	O
samples	O
were	O
extracted	O
with	O
300	O
µL	O
of	O
cold	O
methanol	B
in	O
an	O
Eppendorf	O
microcentrifuge	O
tube,	O
and	O
placed	O
in	O
a	O
−20	O
°C	O
freezer	O
for	O
30	O
min.	O

The	O
relatively	O
low	O
value	O
we	O
measured	O
is	O
likely	O
due	O
to	O
the	O
fact	O
that	O
the	O
literature	O
value	O
of	O
trans-ferulic	B
acid	I
reported	O
in	O
was	O
measured	O
for	O
people	O
on	O
a	O
special	O
diet	O
.	O

In	O
the	O
photosynthesis	O
and	O
metabolism	O
of	O
vitamin	B
D,	I
the	O
substrate	O
vitamin	B
D	I
is	O
transported	O
to	O
the	O
liver,	O
where	O
it	O
undergoes	O
the	O
first	O
hydroxylation	O
step	O
at	O
C-25	O
(catalysed	O
by	O
CYP2R1	O
and	O
CYP27A1)	O
to	O
give	O
25(OH)D.	O
This	O
is	O
followed	O
by	O
CYP27B1	O
conversion	O
to	O
the	O
active	O
form	O
1,25(OH)_2	B
D	O
in	O
the	O
kidneys.	O

3-Chloroperoxybenzoic	B
acid	I
and	O
dithiothreitol	B
were	O
purchased	O
from	O
TCI	O
America	O
(Portland,	O
OR).	O

After	O
adding	O
15	O
μL	O
of	O
N	B
-methyl-N	I
-trimethylsilyl-trifluoroacetamide	I
(Macherey-Nagel),	O
samples	O
were	O
incubated	O
at	O
40	O
°C	O
for	O
30	O
min	O
under	O
continuous	O
shaking.	O

Briefly,	O
for	O
CE-TOFMS	O
analysis,	O
50	O
μl	O
plasma	O
samples	O
were	O
added	O
to	O
450	O
μl	O
methanol	B
containing	O
internal	O
standards	O
(H3304-1002,	O
HMT)	O
on	O
ice,	O
and	O
then	O
mixed	O
with	O
500	O
μl	O
chloroform	B
and	O
200	O
μl	O
Milli-Q	O
water.	O

For	O
NMR	O
spectra	O
recorded	O
in	O
tissue	O
samples,	O
Spectra	O
were	O
phased,	O
baseline	O
corrected,	O
and	O
referenced	O
to	O
Alanine's	B
signal	O
at	O
1.47	O
ppm	O
in	O
Chenomx	O
NMR	O
Suite	O
8.1	O
(Chenomx	O
Inc.,	O
Edmonton,	O
Canada).	O

Rats	O
fed	O
on	O
diet	O
rich	O
in	O
medium-chain	O
fatty	O
acids	O
had	O
smaller	O
fat	O
pads,	O
reduced	O
adipose	O
tissue	O
lipoprotein	O
lipase	O
activity	O
and	O
improved	O
insulin	O
sensitivity	O
and	O
glucose	B
tolerance.	O

Valine,	B
leucine	B
and	O
isoleucine	B
biosynthesis.	O

Panel	O
B	O
shows	O
the	O
_13	O
C	O
satellite	O
pattern	O
of	O
the	O
3-methyl	O
group	O
of	O
lactate	B
(_13	O
C-CH_3	O
-lac)	O
in	O
the	O
1-D	O
_	O

However,	O
after	O
normalizing	O
the	O
concentration	O
of	O
8-oxo-dG	B
in	O
urine	O
with	O
the	O
creatinine	B
content,	O
there	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
8-oxo-dG	B
levels	O
among	O
the	O
healthy	O
male	O
and	O
female	O
volunteers.	O

Some	O
of	O
these	O
changes,	O
such	O
as	O
those	O
in	O
tryptophan	B
metabolism	O
and	O
TCA	O
cycle,	O
were	O
also	O
observed	O
in	O
other	O
studies	O
of	O
experimental	O
IBD	O
[,].	O

Assay	O
performance	O
data	O
of	O
enzalutamide	B
and	O
N-desmethylenzalutamide	B
in	O
human	O
plasma	O
at	O
validated	O
quality	O
control	O
concentration	O
levels	O
The	O
recovery,	O
covering	O
sample	O
preparation,	O
and	O
stability,	O
were	O
determined	O
at	O
three	O
concentration	O
levels	O
(1000,	O
15000,	O
and	O
40000	O
ng/mL)	O
in	O
duplicate,	O
for	O
enzalutamide	B
and	O
N-desmethylenzalutamide	B
and	O
for	O
the	O
internal	O
standard	O
D_6	B
-enzalutamide.	I

lysoPC	O
a	O
C20:4;	B
80.	O

It	O
will	O
be	O
important	O
in	O
the	O
future	O
to	O
account	O
for	O
host	O
factors,	O
use	O
of	O
other	O
drugs	O
of	O
abuse,	O
cannabis	B
types/routes,	O
cigarette	O
smoking,	O
microbiome,	O
and	O
HCV	O
and	O
other	O
coinfection	O
status,	O
and	O
to	O
perform	O
longitudinal	O
observations,	O
in	O
order	O
to	O
accurately	O
evaluate	O
relationships	O
between	O
drug	O
level	O
and	O
immunological	O
readouts.	O

In	O
conclusion,	O
the	O
present	O
study	O
quantifies	O
the	O
eight	O
major	O
choline	B
metabolites	O
in	O
blood	O
and	O
milk	O
during	O
lactation	O
in	O
the	O
dairy	O
cow.	O

White	O
bars,	O
awake,	O
90	O
lx,	O
free	O
to	O
move;	O
gray	O
bars,	O
awake,	O
<5	O
lx,	O
semirecumbent;	O
black	O
bars,	O
sleeping	O
with	O
eye	O
masks,	O
0	O
lx,	O
supine.	B

This	O
finding	O
suggests	O
that	O
a	O
substantial	O
portion	O
of	O
the	O
N	B
-acetoxy-PhIP	I
had	O
bound	O
to	O
Cys_34	O
as	O
unstable	O
adducts	O
that	O
underwent	O
hydrolysis	O
to	O
form	O
PhIP	O
and	O
5-HO-PhIP,	B
during	O
proteolytic	O
digestion.	O

The	O
31	O
significantly	O
altered	O
plasma	O
metabolites	O
in	O
both	O
CT	O
and	O
SH	O
patients	O
(adjusted	O
p	O
<	O
0.05,	O
Supporting	O
Information	O
Figure	O
S1A)	O
include	O
amino	O
acids,	O
carbohydrates,	O
lipids,	O
nucleosides,	O
organic	O
acids,	O
aromatic	O
heteropolycyclic	B
compounds,	O
aliphatic	B
acyclic	I
compounds,	O
and	O
aliphatic	B
heteromonocyclic	I
compounds	O
(Table	O
2	O
and	O
Supporting	O
Information	O
Figure	O
S1A).	O

The	O
differentiating	O
metabolites	O
were	O
involved	O
in	O
glycerolipid,	B
glycerophospholipid,	B
amino	O
acid	O
and	O
fatty	O
acid	O
metabolism.	O

Among	O
them,	O
two	O
saturated	O
fatty	O
acids	O
(myristic	O
and	O
palmitic	B
acids)	O
were	O
found	O
significantly	O
higher	O
in	O
aggressive	O
CLL	O
than	O
in	O
controls.	O

All	O
of	O
the	O
patients	O
had	O
been	O
diagnosed	O
with	O
CINs	B
or	O
cervical	O
cancers	O
histologically.	O

β-alanine,	B
azelaic	B
acid,	I
and	O
α-hydroxybutyrate	B
were	O
increased,	O
while	O
pseudouridine	B
and	O
2,4-dihydroxypyrimidine,	B
were	O
decreased	O
in	O
BD	O
subjects.	O

We	O
hypothesize	O
that	O
individuals	O
belonging	O
to	O
the	O
low	O
prevalence	O
cluster	O
for	O
diabetes,	O
dyslipidemia	O
and	O
hypertension	O
generally	O
do	O
not	O
experience	O
the	O
“double	O
jeopardy”	O
of	O
elevated	O
postprandial	O
levels	O
of	O
circulating	O
fatty	O
acids	O
and	O
leucine,	B
which	O
may	O
synergistically	O
activate	O
different	O
inflammation	O
pathways	O
and	O
thereby	O
increase	O
disease	O
susceptibility.	O

Inflammatory	O
bowel	O
disease;	O
TCA:	O
Taurocholic	B
acid;	I
bUCA:	O
Beta-ursocholic	O
acid;	O
GUDCA:	O
Glycoursodeoxycholic	B
acid;	I
THCA:	O
Taurohyocholate;	B
UDCA:	O
Ursodeoxycholic	B
acid;	I
GHDCA:	O
Glycohyodeoxycholate.	B

These	O
analyses	O
suggest	O
that	O
the	O
association	O
of	O
an	O
elevated	O
cystathionine	B
concentration	O
with	O
CVD	O
risk	O
in	O
epidemiological	O
studies	O
is	O
associated	O
with	O
several	O
factors,	O
including	O
higher	O
plasma	O
glucose,	B
total	O
homocysteine,	B
BCAAs,	O
and	O
trimethylamine	B
oxide,	I
evidence	O
of	O
inflammation,	O
and	O
lower	O
total	O
glutathione,	B
lower	O
kidney	O
function,	O
along	O
with	O
modest	O
impairment	O
of	O
vitamin	O
B-6	O
status	O
associated	O
with	O
increased	O
B-6	O
catabolism.	O

Therefore,	O
we	O
hypothesize	O
that	O
main	O
effect	O
of	O
rifaximin	O
may	O
be	O
to	O
inhibit	O
bacterial	O
growth	O
and	O
reduce	O
endotoxin	B
absorption	O
in	O
the	O
small	O
bowel.	O

Except	O
for	O
pentanoic	B
acid	I
methyl	I
ester,	I
heptanoic	B
acid	I
1,	I
1-dimethylethyl	I
ester,	I
hexyl	B
n-valerate,	I
heptanoic	B
acid	I
1-methylethyl	I
ester,	I
benzoic	B
acid	I
hexadecyl	I
ester,	I
and	O
phthalic	B
acid	I
methyl	I
neopentyl	I
ester,	I
the	O
levels	O
of	O
esters	O
were	O
significantly	O
(P	O
<0.05)	O
higher	O
in	O
the	O
fecal	O
samples	O
of	O
NP	O
and	O
P	O
than	O
in	O
those	O
from	O
HC.	O

For	O
metabolomic	O
profiling	O
of	O
the	O
entire	O
sample	O
set,	O
all	O
individual	O
samples	O
were	O
labeled	O
with	O
_12	O
C-dansyl	B
chloride,	I
and	O
the	O
pooled	O
CSF	O
and	O
pooled	O
serum	O
samples	O
were	O
labeled	O
with	O
_13	O
C-dansyl	B
chloride.	I

Furthermore,	O
it	O
is	O
likely	O
that	O
this	O
has	O
functional	O
significance	O
because	O
generation	O
of	O
these	O
ceramides	B
by	O
CERS4	O
is	O
associated	O
with	O
glucolipotoxicity	O
in	O
pancreatic	O
β	O
cells	O
in	O
vitro.	O

Two	O
XBridge	O
Amide	B
columns	O
were	O
run	O
in	O
parallel	O
using	O
alternating	O
column	O
regeneration,	O
with	O
one	O
column	O
devoted	O
to	O
metabolites	O
with	O
negative	O
ionization	O
character,	O
hence	O
negative	O
polarity	O
detection,	O
and	O
the	O
second	O
column	O
for	O
positive	O
polarity	O
detection.	O

Mobile	O
phase	O
B	O
was	O
5	O
mM	O
ammonium	B
acetate	I
in	O
water,	O
adjusted	O
to	O
pH	O
9.9	O
with	O
ammonium	B
hydroxide.	I

In	O
particular,	O
elevated	O
levels	O
of	O
glycerol-3-phosphate,	B
sarcosine,	B
kynurenine,	B
proline,	B
threonine,	B
and	O
uracil	B
were	O
found	O
to	O
be	O
a	O
characteristic	O
feature	O
of	O
metastatic	O
PCa	O
in	O
both_,	O
untargeted	O
metabolomics	O
studies.	O

PB	O
proline	B
betaine,	I
4	O
-HPB	O
4-hydroxy-proline	B
betaine;	I
Log10/TIC,	O
normalization	O
using	O
sample	O
total	O
ion	O
count	O
(TIC)	O
and	O
logarithmic	O
transformation	O
of	O
data;	O
‘PRE’,	O
pool	O
of	O
the	O
pre-test	O
day	O
over-night	O
urine	O
voids;	O
‘0’,	O
fasting	O
spot	O
urine	O
sample	O
after	O
a	O
12 h	O
(minimum)	O
fast;	O
‘2’,	O
‘4’,	O
‘6’	O
and	O
‘8’,	O
postprandial	O
urine	O
samples	O
(with	O
a	O
light	O
lunch	O
consumed	O
after	O
the	O
4 h	O
sample	O
collection)	O

Compared	O
with	O
the	O
AUC	O
of	O
simple	O
metabolites	O
in	O
and	O
,	O
thus,	O
the	O
combination	O
of	O
uric	B
acid,	I
sphinganine,	B
and	O
adrenoyl	B
ethanolamide	I
was	O
selected	O
as	O
the	O
candidate	O
biomarkers	O
with	O
highest	O
AUC	O
for	O
diagnosis	O
of	O
IS.	O

Therefore,	O
we	O
concluded	O
that	O
among	O
targeted	O
metabolites,	O
phospholipids	B
appeared	O
to	O
be	O
significantly	O
altered	O
compared	O
with	O
others.	O

Thus,	O
we	O
cannot	O
exclude	O
associations	O
between	O
TCF7L2	O
genotype	O
and	O
other	O
metabolic	O
products	O
of	O
carbohydrate	O
or	O
protein	O
metabolism,	O
e.g.	O
metabolites	O
from	O
the	O
tricarboxylic	B
acid	I
cycle.	O

For	O
proteomics	O
extraction,	O
although	O
the	O
14	O
most	O
abundant	O
plasma	O
proteins	O
[albumin,	O
α1-antitrypsin,	O
transferrin,	O
haptoglobin,	O
α2-macroglobulin,	O
α1-acid	O
glycoprotein	B
(orosomucoid),	O
fibrinogen,	O
complement	O
C3,	O
IgG,	O
IgA,	O
IgM,	O
HDL	O
(apolipoproteins	O
A-I	O
and	O
A-II),	O
and	O
LDL	O
(mainly	O
apolipoprotein	O
B)]	O
were	O
simultaneously	O
immunodepleted	O
by	O
using	O
Seppro	O
IgY14	O
spin	O
columns	O
(Sigma-Aldrich),	O
apolipoproteins	O
were	O
still	O
identified	O
and	O
quantified	O
(SI	O
Appendix	O
,	O
Table	O
S8)	O
as	O
complete	O
depletion	O
is	O
difficult	O
to	O
achieve.	O

Adiposity	O
and	O
inflammation	O
have	O
both	O
been	O
hypothesized	O
to	O
increase	O
estrogen	B
production.	O

The	O
presence	O
of	O
elevated	O
brain-glucose	B
levels	O
in	O
AD	O
accords	O
with	O
impaired	O
intracellular	O
glucose	B
utilization	O
through	O
glycolysis	O
and	O
the	O
tricarboxylic	B
acid	I
(TCA)	O
cycle:	O
consistently,	O
there	O
is	O
substantive	O
evidence	O
for	O
defects	O
in	O
AD	O
of	O
TCA-related	O
mitochondrial	O
enzymes	O
including	O
the	O
pyruvate	O
dehydrogenase	O
complex,	O
the	O
α-ketoglutarate	O
dehydrogenase	O
complex,	O
and	O
cytochrome	O
c	O
oxidase/complex	O
IV.	O

The	O
MRM	O
transitions	O
monitored	O
were:	O
8-iso	B
-PGF_2α	I
,	O
m/z	O
353	O
→	O
m/z	O
193	O
(quantifier)	O
and	O
m/z	O
353	O
→	O
m/z	O
173	O
(qualifier);	O
8-iso	B
-PGF_2α	I

PC	B
aa	I
C38:3;	I
57.	O

Bariatric	O
surgery	O
has	O
induced	O
a	O
global	O
down-regulation	O
of	O
kynurenine	B
metabolites,	O
associated	O
with	O
weight	O
loss.	O

Moreover,	O
high	O
levels	O
of	O
gut-derived	O
uremic	O
toxins	B
seem	O
to	O
affect	O
both	O
the	O
cellular	O
protein	O
expression	O
and	O
the	O
activity	O
of	O
the	O
cyclooxygenase-2	O
(COX-2)	O
enzyme,	O
which	O
plays	O
a	O
major	O
role	O
in	O
the	O
regulation	O
of	O
inflammation	O
through	O
the	O
production	O
of	O
prostaglandins;	B
so,	O
when	O
COX-2	O
activity	O
is	O
sped	O
up,	O
inflammation	O
increases.	O

These	O
results	O
suggest	O
that	O
epiandrosterone	B
sulfate	I
might	O
be	O
the	O
most	O
potent	O
biomarker	O
of	O
DED.	O

Odds	O
ratios	O
and	O
95%	O
CI	O
for	O
prostate	O
cancer	O
in	O
relation	O
to	O
16-KE2	O
and	O
17-epiE3	O
estrogen	B
metabolites	O
OR=Odds	O
Ratio,	O
adjusted	O
for	O
age,	O
race,	O
smoking	O
status,	O
presence	O
of	O
benign	O
prostatic	O
hyperplasia	O
and	O
time	O
of	O
urine	O
collection	O

The	O
use	O
of	O
sucrose	B
as	O
a	O
sweetening	O
agent	O
in	O
food	O
and	O
beverages	O
is	O
becoming	O
increasingly	O
frequent.	O

On	O
the	O
other	O
hand,	O
considering	O
that	O
increased	O
glucose	B
metabolism	O
is	O
often	O
used	O
as	O
a	O
clinical	O
indication	O
for	O
cancer	O
diagnosis,	O
our	O
result	O
deserves	O
further	O
investigation.	O

Dietary	O
interventions,	O
specifically	O
the	O
Mediterranean	O
diet,	O
are	O
effective	O
in	O
mitigating	O
the	O
deleterious	O
effects	O
of	O
ceramides	B
on	O
CV	O
risk,	O
as	O
shown	O
by	O
a	O
recent	O
report	O
from	O
the	O
PREDIMED	O
Trial.	O

Finally,	O
a	O
correlation	O
analysis	O
was	O
performed	O
between	O
phenylalanine	B
and	O
tyrosine	B
as	O
phenylalanine	B
is	O
related	O
to	O
the	O
tyrosine	B
metabolism	O
and	O
was	O
found	O
up-regulated	O
in	O
IBD.	O

Bile	O
acids	O
are	O
steroidal	O
amphipathic	O
molecules,	O
derived	O
from	O
the	O
catabolism	O
of	O
cholesterol.	B

Prenatal	O
diethylstilbestrol	B
(DES)	O
exposure	O
is	O
associated	O
with	O
adverse	O
reproductive	O
outcomes	O
and	O
cancer	O
of	O
the	O
breast	O
and	O
vagina/cervix	O
in	O
adult	O
women.	O

Multivariate	O
Model	O
for	O
PGE-M.	O
Estimated	O
fold	O
change	O
in	O
PGE-M	O
(and	O
95%	O
CI)	O
with	O
respect	O
to	O
covariates	O
in	O
the	O
multivariable	O
linear	O
regression	O
model	O
(an	O
indicator	O
variable	O
of	O
statin	B
use	O
was	O
also	O
included	O
in	O
the	O
final	O
model	O
but	O
its	O
effect	O
was	O
not	O
statistically	O
significant).	O

L1	O
patients	O
showed	O
higher	O
5α-reductase	O
and	O
21-hydroxylase	O
activity	O
(the	O
highest	O
in	O
L1_A	O
and	O
L1_AL	O
)	O
and	O
lower	O
activity	O
of	O
11βHSD1	B
than	O
L0	O
(P	O
 = 0.041,	O
P	O
 = 0.009,	O
P	O
 = 0.019).	O

Both	O
metabolic	O
routes	O
produce	O
sulfide	B
metabolites	O
that	O
are	O
oxidized	O
to	O
sulfoxides	B
in	O
reactions	O
catalyzed	O
by	O
either	O
cytochrome	O
P450	O
or	O
flavin	O
mono-oxygenase	O
(,).	O

A	O
net	O
reclassification	O
index	O
(NRI)	O
analysis	O
demonstrated	O
that	O
the	O
addition	O
of	O
SM	B
d16:1/18:0	I
and	O
SM	B
d18:1/18:0	I
to	O
the	O
current	O
clinical	O
standard	O
of	O
HbA1c	O
or	O
HbA1c	O
plus	O
BMI	O
provides	O
moderately	O
improved	O
accuracy	O
of	O
the	O
prediction	O
of	O
diabetes	O
incidence	O
for	O
38%–40%	O
of	O
individuals.	O

The	O
first	O
source	O
of	O
variation	O
in	O
the	O
metabolic	O
profile—held	O
by	O
the	O
PC1	O
–seemed	O
related	O
to	O
total	O
blood	O
cholesterol	B
(TBC).	O

Many	O
metabolites	O
have	O
been	O
shown	O
to	O
correlate	O
with	O
breast	O
cancer,	O
including	O
choline,	B
lipids,	O
glucose,	B
lactate	B
and	O
amino	O
acids.	O

In	O
the	O
end,	O
30	O
μl	O
heptane,	B
including	O
methyl	B
stearate	I
(15	O
ng/μl),	O
as	O
an	O
injection	O
standard,	O
was	O
added.	O

Here,	O
systemic	O
citrulline	B
was	O
elevated,	O
which,	O
as	O
already	O
mentioned,	O
is	O
consistent	O
with	O
concomitantly	O
elevated	O
DMA	B
and	O
up-regulated	O
expression	O
of	O
DDAHs,	O
observed	O
both	O
in	O
small	O
and	O
large	O
bowel.	O

To	O
investigate	O
erythritol	B
metabolism	O
in	O
humans,	O
an	O
ex	O
vivo	O
stable	O
isotope-assisted	O
blood	O
incubation	O
experiment	O
was	O
performed	O
on	O
five	O
healthy	O
male	O
volunteers.	O

Contrary	O
to	O
this,	O
ADMA	B
levels	O
have	O
been	O
shown	O
to	O
be	O
chronically	O
elevated	O
in	O
survivors	O
of	O
acute	O
lymphoblastic	O
leukaemia,	O
suggesting	O
an	O
increased	O
risk	O
of	O
cardiovascular	O
disease.	O

Typical	O
chromatograms	O
for	O
the	O
analysis	O
of	O
N	B
-propyl-NNAL	I
in	O
the	O
urine	O
of	O
a	O
smoker	O
before	O
and	O
after	O
treatment	O
with	O
β-glucuronidase	O
are	O
shown	O
in	O
.	O

Low-density	O
lipoprotein	O
(LDL)	O
cholesterol	B
was	O
measured	O
using	O
enzymatic	O
colorimetric	O
methods	O
(Roche,	O
Mannheim,	O
Germany).	O

Species	O
matched	O
to	O
an	O
entity	O
in	O
the	O
GOLM	O
database	O
that	O
does	O
not	O
yet	O
have	O
an	O
associated	O
chemical	O
name	O
were	O
labelled	O
with	O
the	O
word	O
“Match”,	O
their	O
retention	O
index	O
(RI)	O
value,	O
and	O
the	O
list	O
of	O
m	O
/z	O
values	O
for	O
quantified	O
ions	O
(e.g.,	O
“Match:	O
RI	B
1416.54,	O
Ions	O
110	O
134	O
184	O
217	O
228”);	O
and	O
species	O
not	O
matched	O
to	O
any	O
entity	O
in	O
the	O
GOLM	O
database	O
were	O
labelled	O
with	O
the	O
word	O
“Unmatched”,	O
their	O
RI	B
value,	O
and	O
the	O
list	O
of	O
m	O
/z	O
values	O
for	O
quantified	O
ions	O
(e.g.,	O
“Unmatched:	O
RI	B
2475.33,	O
Ions	O
73	O
375	O
376”).	O

The	O
pyruvate	O
dehydrogenase	O
complex	O
(PDH)	O
oxidizes	O
and	O
decarboxylates	B
pyruvate	I
to	O
acetyl-CoA,	B
which	O
enters	O
the	O
TCA	O
cycle.	O

Most	O
uEVs	O
detected	O
with	O
the	O
EM	O
were	O
spheroids	O
with	O
a	O
single	O
membrane,	O
but	O
also	O
some	O
multi-membrane-layer	B
EVs	O
were	O
found	O
(Fig.	O

Similarly,	O
the	O
_13	O
C-NMR	O
signal	O
for	O
the	O
3-methyl	O
group	O
of	O
8	O
resonated	O
at	O
42.0	O
ppm	O
whereas	O
the	O
same	O
carbon	O
atom	O
in	O
7	O
appeared	O
at	O
20.7	O
ppm;	O
there	O
was	O
little	O
difference	O
in	O
the	O
chemical	O
shift	O
of	O
the	O
methylene	B
carbon	O
attached	O
to	O
the	O
pyrrole	B
nitrogen	I
(7:	O
49.4	O
ppm;	O
8:	O
49.8	O
ppm).	O

These	O
latter	O
observations	O
are	O
of	O
interest	O
given	O
that	O
the	O
enzyme	O
activity	O
of	O
ACE	O
is	O
regulated	O
by	O
shear	O
stress	O
acting	O
on	O
the	O
endothelial	O
lumen	O
such	O
a	O
during	O
exercise	O
induced	O
hyperemia	O
and	O
because	O
angiotensin	B
2	I
which	O
increases	O
in	O
function	O
of	O
exercise	O
intensity	O
affects	O
arterio-venous	O
glucose	B
extraction	O
and	O
glucose	B
utilisation	O
in	O
contracting	O
muscle	O
[,].	O

Although	O
the	O
incidence	O
of	O
TET2	O
mutations	O
was	O
low	O
overall,	O
no	O
patient	O
with	O
an	O
identified	O
IDH	O
mutation	O
had	O
a	O
co-occurring	O
TET2	O
mutation,	O
as	O
has	O
been	O
reported	O
previously._,	O
Clinical	O
characteristics	O
and	O
patient	O
outcome	O
of	O
study	O
cohort	O
DNR,	O
daunorubicin;	B
dx,	O
diagnosis;	O
FLT3-ITD	O
,	O
FLT3	O
internal	O
tandem	O
duplication;	O
FLT3-TKD	O
,	O
FLT3	O
tyrosine	B
kinase	O
domain;	O
PLT,	O
platelet	O

DMA	B
(V49)	O
and	O
in	O
particular	O
TMA	O
(V47)	O
levels	O
significantly	O
decreased	O
after	O
meals	O
with	O
blueberries.	O

To	O
predict	O
HOMA-IR	O
variance,	O
follow-up	O
variables	O
that	O
correlated	O
with	O
HOMA-IR	O
but	O
are	O
not	O
direct	O
measurements	O
of	O
glucose	B
metabolism	O
were	O
analysed	O
in	O
a	O
regression	O
model.	O

Baseline	O
characteristics	O
of	O
these	O
two	O
groups	O
differed	O
in	O
prevalence	O
of	O
hypertension,	O
smoking,	O
statin	B
use,	O
median	O
LDL	O
and	O
HDL	B
cholesterol,	I
and	O
in	O
median	O
lowest	O
ABI.	O

Samples	O
were	O
prepared	O
by	O
mixing	O
400	O
μl	O
serum	O
with	O
300	O
μl	O
of	O
a	O
1.5	O
mM	O
3-(trimethylsilyl)	B
propionic-(2,2,3,3-d_4	I
)	I
acid	I
sodium	I
salt	O
(TSP)	O
solution	O
(in	O
D_2	O
O),	O
in	O
which	O
TSP	O
was	O
used	O
as	O
the	O
frequency	O
standard	O
(δ=0.00	O
ppm).	O

Our	O
results	O
are	O
supported	O
by	O
previous	O
small	O
metabolomics	O
studies	O
in	O
the	O
serum	O
of	O
patients	O
with	O
MS,	O
which	O
have	O
identified	O
differences	O
in	O
levels	O
of	O
phosphatidyl-choline,	B
phosphatidyl-inositol,	B
glutamate,	B
and	O
other	O
amino	O
acids	O
between	O
patients	O
and	O
controls.	O

The	O
electrospray	O
voltage	O
was	O
set	O
to	O
5	O
kV.	B
Nitrogen	O
sheath	O
and	O
auxiliary	O
gas	O
flow	O
rates	O
were	O
set	O
at	O
60	O
and	O
20	O
arbitrary	O
units,	O
respectively.	O

Similarly	O
to	O
the	O
subject	O
characteristics	O
of	O
the	O
Guatemalan	O
women,	O
subject	O
characteristics	O
of	O
the	O
Pakistani	O
women	O
showed	O
no	O
significant	O
differences	O
between	O
the	O
+LNS	O
and	O
−LNS	O
groups,	O
with	O
the	O
exception	O
of	O
folate	B
supplementation	O
at	O
34	O
wk.	O

For	O
example,	O
according	O
to	O
the	O
QqQ	O
analyses,	O
human	O
plasma	O
contained	O
approximately	O
3.2	O
µM	O
PE	B
36:4.	I

Over	O
the	O
course	O
of	O
time,	O
glycerol	B
increased	O
in	O
serum	O
by	O
an	O
average	O
of	O
52%	O
and	O
in	O
WB,	O
decreased	O
by	O
an	O
average	O
of	O
28%	O
(data	O
not	O
shown).	O

8-Nitro-cGMP	B
seems	O
to	O
regulate	O
the	O
redox-sensor	O
signaling	O
protein	O
Keap1,	O
a	O
potent	O
repressor	O
of	O
Nrf2-dependent	O
transcription,	O
via	O
S-guanylation	O
of	O
the	O
highly	O
nucleophilic	O
cysteine	O
sulfhydryls	O
of	O
Keap1,	O
and	O
the	O
metabolism	O
of	O
8-nitro-cGMP	B
may	O
thus	O
also	O
be	O
valuable	O
in	O
the	O
development	O
of	O
new	O
approaches	O
to	O
the	O
diagnosis	O
and	O
treatment	O
of	O
diseases	O
related	O
to	O
oxidative	O
stress	O
and	O
redox	O
metabolism.	O

This	O
method,	O
comparable	O
to	O
previous	O
methods	O
in	O
sensitivity,	O
enables	O
the	O
direct	O
detection	O
of	O
a	O
cytotoxic	O
thiopurine	B
metabolite	O
without	O
derivatisation	O
in	O
an	O
easily	O
obtainable,	O
stable	O
sample	O
and	O
will	O
facilitate	O
a	O
better	O
understanding	O
of	O
the	O
mechanisms	O
of	O
action	O
of	O
these	O
inexpensive	O
yet	O
effective	O
drugs.	O

All	O
spectra	O
were	O
phased,	O
baseline	O
corrected	O
(using	O
a	O
3_rd	O
degree	O
polynomial),	O
and	O
chemical	O
shifts	O
referenced	O
to	O
the	O
lactate-CH_3	B
doublet	O
resonance	O
at	O
δ =	O

In	O
addition,	O
lysophosphatidylcholine	B
increases	O
intracellular	O
calcium	O
concentrations	O
in	O
macrophages,	O
ultimately	O
enhancing	O
parasite	O
invasion.	O

d	O
HMDB	O
number	O
of	O
the	O
LMI	O
with	O
147.0764 m/z.	O
Based	O
on	O
the	O
MS/MS	O
analytic	O
pattern,	O
three	O
metabolic	O
compounds—HMDB00641	O
(_L	O
-glutamine),	I
HMDB02031	O
(ureidoisobutyric	O
acid)	O
and	O
HMDB03423	O
(_D	B
-glutamine)—for	I
the	O
LMI	O
with	O
147.0764 m/z	O
were	O
selected	O
Identification	O
of	O
the	O
LMI	O
with	O
496.3398 m/z.	O
a	O
Mass	O
spectra	O
of	O
496.3398 m/z.	O
MS	O
and	O
MS/MS	O
pattern	O
analyses	O
were	O
performed	O
using	O
a	O
Triple-TOF	O
mass	O
spectrometer.	O

Interestingly,	O
the	O
high-HE-risk	O
consortium	O
Methylobacterium	B
extorquens	O
/Stenotrophomonas	O
pavanii	O
in	O
the	O
peripheral	O
blood	O
was	O
positively	O
correlated	O
with	O
the	O
MELD	O
score	O
(r	O
_mean	O
 = 0.48/	O

Brain	O
glucose	B
uptake	O
in	O
AD	O
is	O
lower	O
in	O
severely	O
affected	O
regions	O
and	O
occurs	O
early	O
in	O
disease	O
development.	O

T2D	O
was	O
defined	O
by	O
HbA1c	O
levels	O
≥	O
6.5%	O
or	O
fasting	O
plasma	O
glucose	B
≥	O
126	O
mg/dL	O
according	O
to	O
the	O
American	O
Diabetes	O
Association	O
(ADA)	O
guidelines.	O

(B)	O
Positive	O
ionization	O
mode	O
ion	O
images	O
of	O
m/	O
z	O
703.57	O
(SM(d18:1/16:0))	O
in	O
red	O
and	O
m/	O
z	O
744.57	O
PC	B
(p-16:0/18:1)	I
in	O
green.	O

In	O
our	O
previous	O
study,	O
we	O
found	O
that	O
there	O
were	O
different	O
postprandial	O
glucose	B
profiles	O
during	O
OGTTs	O
between	O
HLP	O
and	O
control	O
groups.	O

Whether	O
xanthine	B
production	O
from	O
hypoxanthine,	B
plays	O
a	O
role	O
in	O
T2D	O
development	O
due	O
to	O
increased	O
XO	O
activity	O
or	O
due	O
to	O
xanthine	B
production	O
in	O
parallel	O
with	O
the	O
consequent	O
decrease	O
in	O
hypoxanthine,	B
requires	O
further	O
investigation.	O

In	O
addition	O
to	O
the	O
novel	O
associations,	O
there	O
were	O
19	O
additional	O
metabolite-BMI	O
associations	O
that	O
had	O
been	O
previously	O
reported	O
upon,	O
including	O
branched	O
chain	O
amino	O
acids	O
like	O
valine,	B
aromatic	O
amino	O
acids	O
like	O
tyrosine,	B
markers	O
of	O
glucose	B
control	O
like	O
mannose	B
and	O
1–5-anhydroglucitol,	B
and	O
markers	O
of	O
lipid	O
metabolism	O
like	O
glycerol	B
and	O
lathosterol.	B

Importantly,	O
as	O
anticipated	O
based	O
on	O
the	O
_15	O
N-ethanolimane	O
tagging	O
approach	O
shown	O
earlier	O
in	O
our	O
laboratory,	O
the	O
_15	O
N-cholamine	B
tagging	O
of	O
metabolites	O
in	O
human	O
serum	O
provided	O
a	O
rich	O
NMR	O
spectrum	O
due	O
to	O
the	O
large	O
number	O
of	O
carboxyl-containing	O
metabolites	O
normally	O
present	O
in	O
blood.	O

Post-ERCP	O
increases	O
in	O
serum	O
glucose	B
levels	O
in	O
the	O
current	O
study	O
corroborate	O
this	O
interpretation.	O

Plasma	O
(10	O
μL)	O
was	O
mixed	O
with	O
10	O
μL	O
of	O
water	O
(LiChrosolv;	O
Merck	O
KGaA,	O
Darmstadt,	O
Germany)	O
and	O
80	O
μL	O
of	O
methanol	B
(Fluka,	O
Munich,	O
Germany).	O

μg/L	O
for	O
11-OH-THC,	B
CBD,	O
CBN,	O
THCAA	O
and	O
THC-gluc,	O
1–100	O
μg/L	O
for	O
CBG,	O
THCV	O
and	O
THCVCOOH	O
and	O
5–500	O
μg/L	O
for	O
THCCOOH-gluc	O
(R_2	O
>0.99).	O

Typical	O
ESI(+)-MS	B
of	O
erythrocyte	O
membrane	O
showing	O
lipid	O
profiles	O
for	O
(A)	O
healthy	O
and	O
(B)	O
septic	O
patients.	O

These	O
combined	O
100	O
spectra	O
were	O
used	O
to	O
predict	O
the	O
presence	O
or	O
absence	O
of	O
ibuprofen	B
metabolites	O
from	O
the	O
remaining	O
270	O
spectra.	O

Even	O
though	O
our	O
present	O
report	O
presents	O
a	O
statistical	O
association	O
between	O
the	O
presence	O
of	O
estrogen	B
metabolites	O
in	O
the	O
urine	O
of	O
S.	O
haematobium	O
-infected	O
females	O
and	O
sub-fertility,	O
several	O
confounding	O
variables	O
may	O
weaken	O
our	O
hypothesis.	O

For	O
5-azacytidine	B
(aza)–based	O
studies,	O
TAM-R	O
cells	O
were	O
plated	O
onto	O
96-well	O
and	O
six-well	O
plates	O
for	O
assessing	O
cell	O
survival	O
and	O
RRM2	O
protein	O
levels,	O
respectively.	O

creatinine,	B
estimating	O
equations,	O
GFR,	O
kidney	O
function,	O
metabolomics	O

Alanine,	B
aspartate	B
and	O
glutamate	B
metabolism,	O
and	O
the	O
metabolism	O
of	O
each	O
of	O
phenylalanine,	B
pyruvate,	B
sphingolipid,	B
glycerophospholipid,	B
and	O
D-glutamine	B
and	O
D-glutamate	B
were	O
found	O
to	O
be	O
disturbed	O
in	O
the	O
AMS-S	O
group	O
(	O
and	O
).	O

Previous	O
studies	O
revealed	O
that	O
OCN	O
is	O
influencing	O
K_+	O
_V	O
-channels	O
and	O
GPRC6A	O
in	O
pancreatic	O
islet	O
cells,	O
but	O
the	O
exact	O
role	O
of	O
citrulline	B
in	O
energy	O
metabolism	O
remains	O
unclear.	O

Consistent	O
with	O
the	O
previous	O
MRS	O
findings	O
that	O
decreasing	O
myo-inositol	B
level	O
was	O
associated	O
with	O
increasing	O
aggressiveness	O
of	O
the	O
glioma	O
phenotype,	O
our	O
data	O
also	O
showed	O
that	O
the	O
tumor	O
size	O
in	O
our	O
cohort	O
negatively	O
correlated	O
with	O
myo-inositol	B
levels	O
in	O
the	O
CSF.	O

Conclusions:	O
In	O
healthy	O
young	O
adults	O
with	O
no	O
apparent	O
inflammatory	O
conditions,	O
serum	O
tryptophan	B
metabolites	O
are	O
significantly	O
associated	O
with	O
key	O
immune	O
system	O
biomarkers.	O

Notably,	O
these	O
urinary	O
caffeine	B
metabolites	O
have	O
been	O
used	O
to	O
assess	O
the	O
enzymatic	O
activities	O
of	O
xanthine	B
oxidase	O
(XO)	O

The	O
pyrrolidine	B
ring	O
underwent	O
metabolism	O
resulting	O
in	O
an	O
oxo	O
and	O
a	O
dihydroxy	B
metabolite	O
as	O
well	O
as	O
a	O
ring	O
opened	O
hydroxy	B
metabolite.	O

Then,	O
the	O
plate	O
was	O
washed	O
with	O
0.7	O
mL	O
of	O
2%	O
aqueous	O
formic	B
acid,	I
which	O
was	O
discarded.	O

We	O
first	O
investigated	O
the	O
differences	O
in	O
serum	O
lipidomes	O
and	O
cine	B
MR	O
image	O
data	O
between	O
the	O
LMNA	O
carriers	O
not	O
diagnosed	O
with	O
DCM,	O
and	O
matched	O
healthy	O
controls.	O

Homocysteine	B
was	O
also	O
increased	O
in	O
patients	O
with	O
glioblastoma.	O

Only	O
one	O
of	O
the	O
34	O
carbohydrates	O
and	O
hexose	B
amines	O
in	O
the	O
library	O
was	O
well	O
retained	O
on	O
RP-C18	O
column	O
A	O
and	O
only	O
two	O
on	O
MM-RP	O
column	O
C.	O

Although	O
an	O
association	O
with	O
glucocorticoid	B
usage	O
may	O
have	O
been	O
expected,	O
low	O
doses	O
of	O
corticoids	O
prescribed	O
to	O
RA	O
patients	O
may	O
explain	O
our	O
findings.	O

In	O
addition,	O
administration	O
of	O
valproic	B
acid,	I
which	O
we	O
previously	O
demonstrated	O
to	O
be	O
associated	O
with	O
larger	O
amygdala	O
volumes	O
in	O
patients	O
with	O
bipolar	O
disorder	O
(BD),	O
reportedly	O
increased	O
the	O
levels	O
of	O
KA	O
in	O
the	O
rat	O
brain.	O

1–5)	O
have	O
been	O
recognized	O
as	O
Cys,	O
HCys,	O
Nac,	O
γ-GluCys,	B
and	O
GSH	B
by	O
the	O
standards,	O
and	O
12	O
(No.	O
6–17)	O
were	O
given	O
the	O
possible	O
structures	O
by	O
the	O
MS/MS	O
and	O
QTOF-MS	O
information	O
from	O
our	O
previous	O
work.	O

These	O
DHB	O
adduct	O
ions	O
were	O
consistent	O
with	O
the	O
previous	O
studies	O
using	O
0.5 M	O
DHB	O
in	O
methanol	B
with	O
0.1%	O
TFA	O
as	O
the	O
matrix	O
solution,	O
and	O
thus	O
were	O
used	O
to	O
normalize	O
the	O
abundance	O
of	O
each	O
lipid	O
species	O
identified	O
in	O
this	O
study.	O

In	O
addition,	O
an	O
upregulation	O
of	O
the	O
genes	O
LPCAT1	O
and	O
LCAT	O
(B)	O
that	O
encode	O
enzymes	O
involved	O
in	O
the	O
synthesis	O
of	O
phosphatidylcholine	B
and	O
cholesteryl	B
esters,	I
respectively,	O
was	O
also	O
observed.	O

H	O
A	O
corresponding	O
PCA	O
analysis	O
then	O
performed	O
on	O
the	O
clinical	O
chemistry	O
lipid	O
profile	O
dataset	O
(all	O
variables	O
this	O
time	O
normalised	O
to	O
total	O
triacylglycerol	B
concentrations	O
prior	O
to	O
analysis)	O
demonstrated	O
that	O
the	O
three	O
variables	O
investigated	O
were	O
predominantly	O
segregated	O
into	O
two	O
orthogonal	O
components,	O
the	O
first	O
(PC1*)	O
containing	O
the	O
total	O
cholesterol	B
and	O
LDL-cholesterol	B
(LDL-c)	O
variables	O
(loading	O
scores	O
vectors	O
0.80	O
and	O
0.93	O
respectively),	O
the	O
second	O
(PC2*)	O
HDL-cholesterol	B
(HDL-c)	O
alone	O
(0.91),	O
as	O
might	O
be	O
expected	O
in	O
view	O
of	O
the	O
commonly	O
observed	O
higher	O
LDL-	O
to	O
HDL-cholesterol	B
concentration	O
ratios	O
of	O
blood	O
plasma	O
samples.	O

Lipoproteins,	O
Subfractions,	O
HDL,	O
Breast	O
cancer,	O
Tumor,	O
Progesterone	B
receptor,	O
Ki67	O

The	O
odd-carbon	O
chain	O
structural	O
analog	O
internal	O
standards	O
were	O
cholesterol	B
ester	I
(CE)	O
CE(19:0),	B
phosphatidylcholine	B
PC(19:0/19:0),	I
phosphatidylethanolamine	B
PE(17:0/17:0),	I
and	O
lysophosphatidylcholine	B
(LPC)	O
LPC(19:0).	B

The	O
following	O
type	O
strains	O
were	O
obtained	O
from	O
the	O
Korean	O
Agricultural	O
Culture	O
Collection	O
(KACC)	O
or	O
Korean	O
Collection	O
for	O
Type	O
Cultures	O
(KCTC):	O
Bacteroides	O
fragilis	O
(KCTC	O
3688),	O
Bacteroides	O
vulgatus	O
(KCTC	O
2639),	O
Bifidobacterium	O
breve	O
(KCTC	O
3220),	O
Bifidobacterium	O
longum	O
(KACC	O
20597),	O
Campylobacter	O
jejuni	O
(KCTC	O
5327),	O
Clostridium	O
clostridioforme	O
(KCTC	O
5572),	O
Enterococcus	O
faecalis	O
(KACC	O
13807),	O
Escherichia	O
coli	O
(KCTC	O
1682),	O
Lactobacillus	B
acidophilus	O
(KACC	O
12419),	O
Lactobacillus	B
casei	O
(KACC	O
12413)	O
and	O
Ruminococcus	O
productus	O
(KCTC	O
3695).	O

Finally,	O
a	O
1-mM	O
ammonium	B
acetate	I
aqueous	O
solution	O
(A)	O
and	O
acetonitrile	B
(ACN;	O
B)	O
were	O
chosen	O
as	O
the	O
mobile	O
phase,	O
which	O
produced	O
the	O
best	O
response	O
and	O
sensitivity.	O

MS	O
or	O
rabies	O
could	O
be	O
identified	O
from	O
controls	O
with	O
100%	O
sensitivity	O
and	O
76%	O
specificity	O
by	O
high	O
2-hydroxybutyrate	B
or	O
low	O
2-hydroxybutyrate	B
and	O
high	O
carnitine.	B

Pearson’s	O
correlation	O
coefficients	O
based	O
on	O
univariate	O
logistic	O
regression	O
were	O
calculated	O
between	O
each	O
SP	B
species	O
and	O
relevant	O
clinical	O
characteristics	O
and	O
depicted	O
as	O
a	O
heatmap.	O

(A)	O
Principal	O
component	O
analysis	O
of	O
serotonin	B
metabolic	O
intermediates.	O

The	O
spectrum	O
shows	O
resonances	O
of	O
p-cresyl	B
sulphate.	I

RV	B
hypertrophy	O
was	O
confirmed	O
by	O
an	O
elevated	O
Fulton	O
ratio	O
of	O
0.35	O
±	O
0.02	O
in	O
the	O
hypoxia	O
group	O
versus	O
0.22	O
±	O
0.02	O
in	O
controls	O
(p	O
<	O
0.001).	O

Nine	O
estrogen	B
metabolites	O
were	O
measured	O
in	O
urine	O
by	O
liquid	O
chromatography	O
mass	O
spectrometry.	O

On	O
the	O
other	O
hand,	O
formate	B
may	O
be	O
formed	O
by	O
intestinal	O
bacteria,	O
such	O
as	O
enterobacteria.	O

We	O
note	O
that	O
our	O
ICC	O
values	O
are	O
higher	O
in	O
males	O
than	O
in	O
females;	O
0.56	O
for	O
8-iso	B
-PGF_2α	I
and	O
0.43	O
for	O
PGE-M,	O
which	O
however	O
are	O
still	O
lower	O
than	O
those	O
reported	O
by	O
Wu	O
et	O
al	O
for	O
males	O
only.	O

The	O
hyperparameters	O
themselves	O
are	O
initialized	O
from	O
the	O
observation	O
mean	O
(μ_z	O
)	O
and	O
variance	O
(σ_z	O
_2	O
)	O
as	O
vague	O
priors	O
(p	O
(λ)	O
∼	O
φ_0,1	B
(μ_z	I
,	I
σ_z	I
_2	I
);	I
p	O
(r	O
)	O
∼	O
Γ(1,	O
σ_z	O
_2	O
);	O
p	O
(γ_–1	O
)	O
∼	O
Γ(1,	O
1);	O
p	O
(β)	O
∼	O
Γ(1,	O
σ_z	O
_–2	O
)).	O

However,	O
there	O
is	O
also	O
co-elution	O
of	O
neutral	O
and	O
lipid	O
compounds;	O
testosterone-d_2	B
co-eluted	O
with	O
17:0	O
Cer,	O
and	O
PC(19:0/15:1)	B
co-eluted	O
with	O
an	O
unknown	O
compound	O
with	O
a	O
similar	O
m/	O

Insulin	O
and	O
c-peptide	O
concentrations	O
increased	O
in	O
several	O
subjects	O
following	O
simvastatin	B
treatment,	O
as	O
did	O
HOMA-IR	O
and	O
HOMA-beta	O
scores.	O

Conversely,	O
total	O
cholesterol	B
concentration	O
was	O
significantly	O
lower	O
in	O
patients	O
who	O
were	O
dead	O
at	O
30	O
days	O
than	O
in	O
patients	O
alive	O
at	O
30	O
days	O
with	O
2.37	O
±	O
0.67	O
(n = 28)	O
vs	O
3.23	O
±	O
1.01	O
mM	O
(n = 98),	O
(p<0.001),	O
respectively.	O

Additionally,	O
excess	O
sorbitol	B
has	O
been	O
associated	O
with	O
diabetic-related	O
microvascular	O
complications	O
and	O
retinopathy,	O
and	O
its	O
accumulation	O
was	O
associated	O
with	O
osmotic	O
and	O
oxidative	O
stress	O
damage	O
to	O
the	O
endothelium.	O

Our	O
study	O
revealed	O
that	O
tryptophan	B
and	O
KPm	O
concentrations	O
significantly	O
decreased	O
one	O
year	O
after	O
bariatric	O
surgery	O
and	O
were	O
correlated	O
with	O
the	O
decrease	O
of	O
the	O
well-known	O
marker	O
of	O
systemic	O
inflammation	O
usCRP.	O

AP,	B
acute	O
pancreatitis;	O
ERCP,	O
endoscopic	O
retrograde	O
cholangiopancreatography;	O
IPMN,	O
intraductal	O
papillary	O
mucinous	O
neoplasm;	O
PJ,	O
pancreaticojejunostomy;	O
SOD,	O
sphincter	O
of	O
oddi	O
dysfunction.	O

In	O
the	O
present	O
study,	O
we	O
observed	O
significantly	O
decreased	O
concentrations	O
of	O
unsaturated	O
LPC,	O
LPC18:2,	B
LPC18:1,	B
LPC20:2,	B
LPC20:1,	B
and	O
LPC20:0	B
in	O
obese	O
adolescents,	O
which	O
were	O
not	O
affected	O
by	O
traditional	O
clinical	O
plasma	O
lipid	O
levels.	O

Other	O
studies	O
aimed	O
at	O
sphingosine	B
kinase	O
inhibition	O
have	O
shown	O
abrogation	O
of	O
HCC	O
development	O
when	O
used	O
in	O
combination	O
with	O
sorafenib	O
(,	O
).	O

After	O
optimisation	O
the	O
chip	O
voltage	O
was	O
set	O
to	O
1.6	O
kV,	B
and	O
a	O
backpressure	O
of	O
0.5	O
psi	O
was	O
used.	O

NAFL	O
and	O
NASH	O
can	O
be	O
induced	O
in	O
mice	O
by	O
using	O
specific	O
high-fat	O
diet	O
(HFD)	O
and	O
methionine-choline	B
deficient	O
diet	O
(MCDD),	O
respectively_,	O
_,	O
_,	O
_,	O
_,	O
.	O

However,	O
it	O
remains	O
unclear	O
how	O
metabolic	O
changes	O
occurring	O
in	O
cancer	O
patients	O
influence	O
plasma	O
amino-acid	B
profiles	O
systemically.	O

Protein	O
precipitation	O
of	O
five	O
aliquots	O
(100	O
μL)	O
of	O
the	O
human	O
serum	O
were	O
performed	O
with	O
cold	O
methanol	B
according	O
to.	O

d	O
PG	B
(22:2(13Z,16Z)/0:0),	I
S	B
-(3-methylbutanoyl)-dihydrolipoamide-E,	I
S-succinyl	B
glutathione	I
and	O
glycerophosphocholine	B
may	O
reflect	O
the	O
possibility	O
of	O
death	O
of	O
critically	O
ill	O
patients	O
with	O
sepsis.	O

On	O
the	O
other	O
hand,	O
cohort	O
differences	O
in	O
relation	O
to	O
variations	O
in	O
particular	O
low-M_w	O
compounds	O
(e.g.	O
glutamine,	B
alanine,	B
creatine,	B
dimethyl	B
sulfone,	I
pyruvate)	O
may	O
reflect	O
the	O
potential	O
importance	O
of	O
local	O
nutritional	O
and	O
lifestyle	O
effects	O
on	O
the	O
suggested	O
AMD	O
metabolic	O
fingerprints.	O

Positive	O
correlations	O
were	O
also	O
observed	O
between	O
the	O
N	O
-acetyl	O
of	O
the	O
glucuronide	B
conjugate	O
and	O
the	O
aromatic	O
protons	O
of	O
the	O
sulfate	B
conjugate	O
at	O
δ	O
7.31	O
and	O
7.46	O
(r	O
=	O
0.76;	O
95%	O
CI	O
of	O
0.66−0.83	O
and	O
0.90;	O
95%	O
CI	O
of	O
0.85−0.93,	O
respectively).	O

Several	O
carnitine-conjugated	O
derivatives	O
increased	O
following	O
leptin	O
treatment,	O
including	O
isovalerylacarnitine,	B
tiglyl	B
carnitine,	I
isobutryrylcarnitine,	B
butyrylcarnitine,	B
propionylcarnitine,	B
and	O
steroylcarnitine.	B

However,	O
the	O
CV%	O
values	O
of	O
17:0	O
Cer	O
and	O
17:0	O
PE	O
are	O
significantly	O
lower	O
when	O
the	O
methanol	B
method	O
is	O
used	O
(25%	O
and	O
30%	O
versus	O
47%	O
and	O
49%).	O

However,	O
in	O
this	O
study,	O
we	O
find	O
that	O
the	O
HCC	O
patient	O
group,	O
which	O
does	O
have	O
a	O
significantly	O
larger	O
number	O
of	O
males	O
compared	O
to	O
the	O
HCV	O
group,	O
actually	O
exhibits	O
a	O
lower	O
concentration	O
of	O
creatinine,	B
indicating	O
a	O
definitive	O
pathological	O
role	O
for	O
creatinine.	B

In	O
brief,	O
phospholipids	B
were	O
extracted	O
by	O
chloroform.	B

Data	O
was	O
collected	O
over	O
a	O
mass	O
range	O
of	O
m/z	O
67-1000,	O
using	O
a	O
sheath	O
gas	O
flow	O
rate	O
of	O
40	O
units,	O
auxillary	O
gas	O
flow	O
rate	O
of	O
20	O
units,	O
sweep	O
gas	O
flow	O
rate	O
of	O
2	O
units,	O
spray	O
voltage	O
of	O
3.5	O
and	O
2.5	O
kV	B
for	O
positive	O
and	O
negative	O
ion	O
modes	O
(respectively),	O
capillary	O
inlet	O
temperature	O
of	O
275	O
°C,	O
auxillary	O
gas	O
heater	O
temperature	O
of	O
350	O
°C	O
and	O
an	O
S-lens	O
RF	O
level	O
of	O
45.	O

Internal	O
standard	O
(ISTD)	O
compounds:	O
creatinine-d_3	B
(hydrophilic)	I
was	O
purchased	O
from	O
CDN	O
Isotopes	O
(Pointe-Claire,	O
Canada);	O
lysine-d_4	B
(hydrophilic)	I
and	O
testosterone-d_2	O
(hydrophobic)	O
were	O
purchased	O
from	O
Cambridge	O
Isotope	O
Laboratories	O
(Andover,	O
Massachusetts);	O
heptadecanoic	B
acid	I
(17:0	O
FA)	O
and	O
cis	O
-10-nonadecenoic	O
acid	O
(19:1	O
FA)	O
were	O
purchased	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
Missouri).	O

Carnitine	B
can	O
be	O
both	O
absorbed	O
from	O
food	O
intake	O
and	O
synthesized	O
in	O
the	O
liver,	O
kidney	O
and	O
brain	O
,	O
.	O

Formation	O
of	O
methylpiperazine	B
(MPPZ)	O
derivative	O
of	O
phenolic	O
estrogens;	O
showing	O
an	O
example	O
of	O
derivatization	O
of	O
17β-estradiol	B
with	O
1-(5-fluoro-2,4-dinitrophenyl)-4-methylpiperazine	B
(PPZ)	O
in	O
the	O
presence	O
of	O
sodium	O
bicarbonate	O
(NaHCO_3	O
)	O
followed	O
by	O
reaction	O
with	O
methyl	B
iodide	I
(CH_3	O
I)	O
to	O
create	O
the	O
charged	O
moiety.	O

The	O
data	O
showed	O
that	O
metabolites	O
involved	O
in	O
tryptophan	B
metabolism	O
were	O
upregulated	O
in	O
the	O
high-grade	O
NMIBC	O
patients	O
when	O
compared	O
with	O
the	O
metabolites	O
for	O
the	O
low-grade	O
patients.	O

Also,	O
purine	B
metabolism	O
was	O
found	O
to	O
convey	O
sizable	O
discriminative	O
power,	O
because	O
ASD	O
cases	O
display	O
higher	O
urinary	O
concentrations	O
of	O
many	O
purine	B
metabolites	O
compared	O
to	O
controls,	O
including,	O
among	O
others,	O
inosine,	B
hypoxanthine,	B
and	O
xanthosine	B
(Fig.	O

Non‐eligible	O
patients	O
for	O
this	O
study	O
included	O
those	O
with	O
active	O
infection,	O
uncontrolled	O
diabetes,	O
receiving	O
glucocorticoid	B
therapy,	O
or	O
having	O
esophageal‐gastrointestinal	O
obstructions	O
responsible	O
for	O
feeding	O
limitations.	O

Native	O
1α,25(OH)_2	B
D_3	O
a;	O

If	O
plasma	O
sphingolipids	B
herald	O
incipient	O
neurodegeneration,	O
it	O
may	O
be	O
useful	O
as	O
a	O
predictive	O
biomarker.	O

Keys:	O
1-MH:	O
1-Methylhistidene;	B
AA:	O
Acetoacetate;	B
Ace:	O
Acetate;	B
Act:	O
Acetone;	B
Ala:	O
Alanine;	B
Cr:	O
Creatine;	B
Eth:	O
Ethanol;	B
For:	O
Formate;	B
Gln:	O
Glutamine;	B
Glu:	O
Glutamate;	B
Gly:	O
Glycine;	B
GPC:	B
Glycerolphosphocholine;	B
Ileu:	O
Isoleucine;	B
L1:	O
LDL,	O
CH3-	B
(CH2)n-;	I
L2:	O
VLDL,	O
CH3-	B
(CH2)n-;	I
L3:	O
LDL,	O
CH3-	B
(CH2)n-;	I
L4:	O
VLDL,	O
CH3-	B
(CH2)n-;	I
L5:	O
VLDL,	O
-CH2-CH2-C=O;	B
L6:	O

Interestingly,	O
within	O
our	O
data	O
set	O
we	O
identified	O
PE	B
(phosphoethanolamine)	I
plasmalogens	O
to	O
be	O
associated	O
with	O
both	O
tumor	O
areas	O
and	O
areas	O
of	O
inflammation,	O
whereas	O
PC	O
plasmalogens	O
are	O
exclusively	O
abundant	O
in	O
areas	O
of	O
UN.	O

Putatively	O
identified	O
discriminant	O
metabolites	O
showing	O
a	O
VIP > 1	O
in	O
the	O
BC	O
vs	O
CTRL	O
model	O
summarized	O
in	O
Table _S1	O
reflected	O
alterations	O
in	O
the	O
metabolic	O
pathways	O
of	O
arginine,	B
proline,	B
fatty	O
acids,	O
phenylalanine,	B
purine,	B
pyrimidine,	B
and	O
tryptophan,	B
among	O
others	O
(see	O
Table ).	O

Estrogen	B
exposure	O
plays	O
a	O
role	O
in	O
breast	O
cancer	O
(BC)	O
development.	O

This	O
indicates	O
that	O
a	O
rather	O
complex	O
non-linear	O
pattern	O
allows	O
the	O
prediction	O
of	O
Δglucose	B
.	O

There	O
are	O
no	O
gold-standard	O
measurements	O
to	O
help	O
validate	O
plasma	O
metabolomics	O
in	O
this	O
setting,	O
but	O
for	O
at	O
least	O
1	O
marker	O
(glucose),	O
a	O
relatively	O
good	O
association	O
was	O
shown	O
between	O
hospital-based	O
methods	O
and	O
MS-based	O
methods.	O

Sphingolipid	B
and	O
glycosphingolipid	B
abnormalities	O
explained	O
55%	O
of	O
the	O
metabolic	O
impact	O
in	O
males	O
and	O
44%	O
in	O
females	O
(	O
and	O
).	O

In	O
contrast,	O
sn	O
-position	O
analysis	O
revealed	O
that	O
both	O
PC	B
16:0_17:1	I
and	O
PC	B
15:0_18:1	I
contained	O
sn	O
-isomers	O
and	O
each	O
pair	O
of	O
isomers	O
showed	O
significant	O
changes	O
between	O
cancerous	O
and	O
normal	O
breast	O
tissues.	O

Nicotinate	B
and	O
nicotinamide	B
metabolic	O
pathways	O
were	O
specifically	O
decreased	O
in	O
infants	O
with	O
RSV	O
ARI	O
compared	O
to	O
healthy	O
controls.	O

In	O
our	O
method,	O
these	O
four	O
metabolites	O
were	O
annotated,	O
demonstrated	O
by	O
the	O
correct	O
diagnosis	O
of	O
guanidinoacetic	O
acid	O
methyltransferase	O
deficiency,	O
methylmalonic	B
aciduria	O
and	O
very	O
long-chain	O
acyl-CoA	O
dehydrogenase	O
deficiency.	O

These	O
compounds	O
included	O
pantothenic	B
acid	I
and	O
riboflavin	B
which	O
the	O
patients	O
were	O
receiving	O
in	O
a	O
vitamin	O
supplement	O
and	O
pyridoxic	B
acid,	I
a	O
metabolite	O
of	O
pyridoxine	B
contained	O
in	O
the	O
supplement.	O

Interestingly,	O
a	O
significant	O
decrease	O
in	O
LPC	B
(18:1)	I
was	O
observed	O
in	O
non-advanced	O
CRC	O
patients	O
but	O
an	O
increase	O
in	O
our	O
patients	O
with	O
metastatic	O
CRC,	O
suggesting	O
that	O
this	O
metabolite	O
may	O
potentially	O
be	O
useful	O
as	O
a	O
biomarker	O
of	O
the	O
progression	O
of	O
this	O
disease.	O

If	O
enhanced	O
2-hydroxylation	O
of	O
parent	O
estrogens	O
really	O
does	O
reduce	O
the	O
risk	O
of	O
breast	O
cancer,	O
we	O
will	O
want	O
to	O
know	O
how	O
genetics	O
and	O
lifestyle	O
determine	O
individual	O
estrogen	B
metabolism	O
profiles,	O
and	O
whether	O
we	O
can	O
modify	O
the	O
profiles.	O

Hippurate.	B

Three	O
hours	O
later,	O
a	O
significant	O
fraction	O
(8.3–32%)	O
of	O
the	O
plasma	O
glucose	B
remained	O
_13	O
C-labeled	O
but	O
by	O
12	O
hrs,	O
the	O
%	O
_13	O
C	O
enrichment	O
dropped	O
to	O
2–5%,	O
as	O
illustrated	O
for	O
four	O
patients.	O

Green	O
tea	O
extract	O
contains	O
caffeine	B
with	O
a	O
relatively	O
short	O
half-life,	O
and	O
the	O
post-exercise	O
increases	O
probably	O
reflects	O
acute	O
ingestion	O
of	O
the	O
supplement	O
product	O
just	O
before	O
and	O
one	O
hour	O
into	O
the	O
running	O
bouts.	O

Modified	O
tumor	O
regression	O
grading	O
(mTRG):	O
All	O
52	O
lesions	O
were	O
stained	O
(detailed	O
in	O
)	O
to	O
identify	O
areas	O
and	O
relative	O
percentage	O
of	O
viable	O
liver	O
cells,	O
fibrosis,	O
inflammation,	O
mucin,	B
usual	O
necrosis	O
and	O
infarct	O
like	O
necrosis.	O

SCSA	O
DFI,	O
sperm	O
chromatin	B
structural	O
assay	O
DNA	O
fragmentation	O
index	O
.	O

In	O
the	O
RAC	O
group,	O
ions	O
of	O
m/z	O
734	O
and	O
756	O
identified	O
as	O
PC	O
or	O
PE;	O
and	O
ions	O
of	O
m/	O
z	O
792,	O
820	O
identified	O
as	O
PC	O
plasmalogen	O
(PCP)	O
or	O
1-alkyl	B
PC	I
(PCO)	O
were	O
up-regulated,	O
while	O
lisophosphatidylcholine	B
(LPC)	O
metabolites	O
(m/z	O
496	O
and	O
524)	O
and	O
three	O
LPC	O
plasmalogens	O
(m/z	O
478,	O
506	O
and	O
504)	O
were	O
downregulated	O
compared	O
with	O
healthy	O
subjects.	O

In	O
contrast	O
to	O
arginine	B
pathway	O
metabolites,	O
the	O
association	O
of	O
IDO-TMs	O
with	O
PH	O
in	O
humans	O
has	O
not	O
been	O
established.	O

Comparison	O
of	O
saliva	O
samples	O
obtained	O
before	O
and	O
after	O
rinsing	O
with	O
the	O
antimicrobial	O
chlorhexidine	B
gluconate	I
demonstrated	O
a	O
decrease	O
in	O
β-glucosidase	O
in	O
all	O
donors'	O
saliva	O
following	O
rinsing	O
[69.43%	O
±7.24	O
(mean	O
±	O
s.e.m),	O
extent	O
of	O
inhibition	O
ranged	O
from	O
25	O
to	O
100%,	O
n=11,	O
p<0.001].	O

A	O
volume	O
of	O
1200 μL	O
of	O
the	O
separated	O
chloroform	B
phase	O
was	O
transferred	O
into	O
a	O
sample	O
vial	O
by	O
a	O
pipetting	O
robot	O
(Tecan	O
Genesis	O
RSP	O
150)	O
and	O
evaporated	O
to	O
dryness	O
in	O
a	O
vacuum	O
concentrator.	O

Dilution	O
integrity	O
(1:5)	O
was	O
assessed	O
with	O
three	O
meconium	O
specimens	O
fortified	O
with	O
high	O
QC	O
solution	O
and	O
internal	O
standards	O
and	O
homogenized	O
in	O
acidic	O
methanol	B
as	O
previously	O
described.	O

Bovine	O
serum	O
albumin	O
(≥	O
96%),	O
phosphate-buffered	B
saline	I
(PBS),	O
25(OH)D_2	O
and	O
25(OH)D_3	O
were	O
obtained	O
from	O
Sigma	O
(St.	O
Louis,	O
MO).	O

We	O
analyzed	O
serum,	O
platelet	O
rich	O
plasma	O
(PRP),	O
platelet	O
poor	O
plasma	O
(PPP),	O
and	O
platelet	O
free	O
plasma	O
(PFP),	O
collected	O
from	O
8	O
non-fasting	O
apparently	O
healthy	O
women,	O
using	O
untargeted	O
standard	O
1D	O
and	O
CPMG	O
_1	O
H	O
NMR	O
and	O
reverse	O
phase	O
and	O
hydrophilic	B
(HILIC)	O
UPLC-MS.	O

Specifically,	O
3-hydroxybutyrate,	B
hypoxanthine,	B
phosphocholine,	B
and	O
glycerophosphocholine	B
increased,	O
whereas	O
glutamine	B
and	O
alanine	B
decreased.	O

Proline;	B
87.PC	O
ae	B
C44:6;	I
88.	O

This	O
closely	O
eluting	O
peak	O
is	O
likely	O
4-cishydroxy	B
glyburide,	I
as	O
the	O
elution	O
time	O
is	O
consistent	O
with	O
that	O
observed	O
in	O
the	O
recent	O
in	O
vitro	O
study	O
with	O
human	O
liver	O
microsomes.	O

Meanwhile,	O
IDO	O
activity	O
(indexed	O
by	O
the	O
KYN/TRP	O
ratio),	O
previously	O
linked	O
to	O
a	O
worsening	O
of	O
depressive	O
symptoms	O
by	O
way	O
of	O
the	O
neurotoxic	O
branch	O
of	O
the	O
KP	B
(;	O
;	O
)	O
was	O
associated	O
with	O
decreased	O
connectivity	O
between	O
the	O
right	O
dACC	O
and	O
the	O
right	O
precuneus.	O

Examined	O
in	O
the	O
context	O
of	O
our	O
results,	O
euricoyl-sphingomyelin	B
could	O
play	O
a	O
role	O
along	O
the	O
causal	O
pathway	O
between	O
25(OH)D	O
and	O
T2D.	O
Sphingolipids	B
are	O
also	O
associated	O
with	O
multiple	O
sclerosis	O
and	O
a	O
small	O
randomized	O
pilot	O
trial	O
showed	O
pleiotropic	O
immunomodulatory	O
effects	O
of	O
high-dose	O
supplementation	O
with	O
vitamin	O
D_3	O
(i.e.	O
10 400	O
IU/day),	O
increasing	O
naïve	O
and	O
central-memory	O
CD4+	O
T	O
cells	O
and	O
decreasing	O
production	O
of	O
IL-17.	O

Urinary	O
EM	O
and	O
d-EM	O
were	O
hydrolyzed	O
using	O
β-glucuronidase/sulfatase	O
from	O
Helix	O
pomatia	O
,	O
and	O
then,	O
following	O
a	O
20-hour	O
incubation,	O
extracted	O
with	O
dichloromethane.	B

The	O
derivatization	O
reagent	O
3n	O
butanolic	B
HCl	O
was	O
made	O
in-house	O
by	O
mixing	O
4:1 v/v	O
of	O
1-butanol	B
(for	O
spectroscopy)	O
from	O
Merck	O
(Darmstadt,	O
Germany)	O
and	O
acetyl	B
chloride	I
(p.a.)	O
from	O
Sigma-Aldrich	O
(Steinheim,	O
Germany).	O

Chloroform	B
(CHCl_3	O
)	O
and	O
methanol	B
(CH_3	O
OH)	O
were	O
obtained	O
from	O
SDS,	O
France.	O

Acyl-carnitine,	B
essential	O
for	O
the	O
import	O
of	O
fatty	O
acids	O
into	O
mitochondria,	O
was	O
produced	O
from	O
acetyl-CoA	B
to	O
a	O
lesser	O
extent	O
compared	O
to	O
controls	O
(Fig.	O

Among	O
our	O
477	O
metabolites,	O
the	O
10	O
compounds	O
that	O
make	O
up	O
the	O
final	O
panel	O
include	O
two	O
sphingomyelins,	B
one	O
phosphatidylcholine,	B
one	O
sphinganine-phosphate	B
and	O
one	O
ceramide.	B

Baseline	O
characteristics	O
of	O
the	O
SATIN	B
and	O
GLYNDIET	O
studies.	O

As	O
such,	O
3-phenyllactic	B
acid	I
was	O
not	O
only	O
identified	O
after	O
cheese	O
intake	O
(this	O
report)	O
but	O
also	O
after	O
the	O
intake	O
of	O
yoghurt.	O

Overall,	O
the	O
human	O
and	O
cell	O
studies	O
of	O
erythritol	B
support	O
the	O
heretofore	O
unrecognized	O
metabolism	O
of	O
glucose	B
to	O
erythritol.	B

The	O
BPHL	O
specific	O
inhibitors	O
valacyclovir	O
and	O
L-proline	B
benzyl	I
ester	I
decreased	O
human	O
liver	O
HCTLase	O
activity	O
by	O
74%	O
and	O
88%,	O
respectively.	O

These	O
metabolites	O
included	O
lactate,	B
threonine,	B
acetate,	B
glutathione,	B
uracil,	B
succinate,	B
serine,	B
formate,	B
lysine,	B
tyrosine,	B
myo-inositol,	B
taurine,	B
phosphocreatine,	B
creatine,	B
betaine,	B
dimethylglycine,	B
which	O
are	O
known	O
to	O
be	O
involved	O
in	O
multiple	O
metabolic	O
processes,	O
especially	O
in	O
energy	O
and	O
amino	O
acid	O
metabolism	O
[,].	O

Metabolite	O
levels	O
were	O
quantitated	O
using	O
commercially	O
available	O
standards	O
(CS	O
and	O
NANA),	O
whereas	O
CR	O
was	O
semi-quantitated	O
to	O
creatine	B
equivalents,	O
and	O
561+	O
to	O
CS	O
equivalents	O
due	O
to	O
lack	O
of	O
commercially	O
available	O
standards.	O

The	O
spike-in	O
experiment	O
was	O
performed	O
by	O
spiking	O
1	O
mM	O
isoleucine,	B
2	O
mM	O
triglyceric	B
acid,	I
2	O
mM	O
trigonelline,	B
and	O
2	O
mM	O
2-aminobutyric	B
acid	I
into	O
a	O
fresh	O
serum	O
sample	O
followed	O
by	O
the	O
collection	O
of	O
the	O
same	O
2D	O
NMR	O
data	O
sets	O
for	O
comparison	O
with	O
the	O
original	O
serum	O
sample.	O

The	O
variable	O
core	O
was	O
mainly	O
composed	O
of	O
prenol	B
lipids,	O
amino	O
acids,	O
glycerolipids,	B
steroids,	O
phenols,	O
fatty	O
acids	O
and	O
derivatives,	O
benzoic	B
acid	I
and	O
derivatives,	O
flavonoids,	B
glycerophospholipids,	B
benzopyrans,	B
and	O
quinolines.	B

The	O
principle	O
was	O
to	O
measure	O
the	O
rate	O
of	O
ammonia	O
production	O
from	O
glutamine	B
catalyzed	O
by	O
GLS	O
to	O
calculate	O
the	O
enzymatic	O
activity.	O

Concentrations	O
of	O
cotinine	B
and	O
trans	B
-3′-hydroxycotinine	I
in	O
urine	O
were	O
determined	O
using	O
liquid	O
chromatography–tandem	O
mass	O
spectrometry	O
(LC-MS/MS).	O

Notably,	O
levels	O
of	O
choline	B
and	O
betaine	B
increased	O
after	O
12	O
months	O
of	O
dialysis,	O
which	O
may	O
reflect	O
guideline	O
recommendations	O
of	O
increased	O
protein	O
intake	O
for	O
dialysis	O
patients.	O

Follistatin	B
was	O
increased	O
at	O
C1	O
(1,715	O
±	O
876	O
pg/ml)	O
in	O
comparison	O
to	O
baseline.	O

Expression	O
of	O
GSTM1	O
and	O
GSTA1	O
and	O
measurement	O
of	O
GST	O
activity	O
by	O
conjugation	O
of	O
1-chloro-2,4-dinitrobenzene	B
(CDNB)	O
were	O
carried	O
out	O
as	O
described	O
previously.	O

We	O
also	O
found	O
that	O
a	O
higher	O
baseline	O
concentration	O
of	O
plasma	O
fructose	B
was	O
associated	O
with	O
the	O
incident	O
central	O
adiposity	O
gain	O
phenotype.	O

Citrate	B
can	O
be	O
converted	O
into	O
cytosolic	O
acetyl-CoA	B
without	O
passing	O
through	O
the	O
conventional	O
clockwise	O
steps	O
of	O
the	O
TCA	O
cycle.	O

The	O
unmedicated	O
BD	O
group	O
did	O
not	O
receive	O
any	O
psychotropic	O
medications	O
for	O
at	O
least	O
3	O
weeks	O
(8	O
for	O
fluoxetine)	B
prior	O
to	O
the	O
blood-draw	O
and	O
MRI	O
scanning	O
(mean	O
length	O
of	O
time	O
off	O
medication:	O
39.6±30.0	O
months;	O
6	O
participants	O
treatment-naïve).	O

3-	O
to	O
109-fold	O
dose	O
reduction	O
for	O
epiminolanosterol	B
and	O
2-	O
to	O
16-fold	O
dose	O
reduction	O
for	O
tamoxifen;	B
and	O
finally,	O
the	O
highest	O
synergy	O
with	O
4-	O
to	O
265-fold	O
dose	O
reduction	O
for	O
isavucanazole	B
and	O
13-	O
to	O
132-fold	O
dose	O
reduction	O
for	O
epiminolanosterol	B
is	O
indicated	O
for	O
the	O
isavuconazole-epiminolanosterol	B
pair.	O

DMG	B
significantly	O
decreased	O
in	O
stage	O
III,	O
and	O
the	O
changes	O
of	O
DMA	B
and	O
histidine	B
were	O
significant	O
only	O
in	O
stage	O
IV	O
in	O
comparison	O
to	O
normal	O
mucosae.	O

Alb	O
forms	O
adducts	O
with	O
many	O
therapeutic	O
drugs	O
or	O
their	O
reactive	O
metabolites	O
such	O
as	O
β-lactam	B
antibiotics,	O
acetylsalicylic	B
acid,	I
acetaminophen,	B
nonsteroidal	O
anti-inflammatory	O
drugs,	O
chemotherapeutic	O
agents,	O
and	O
antiretroviral	O
therapy	O
drugs.	O

Glutamate	B
can	O
then	O
be	O
converted	O
to	O
α-ketoglutarate,	B
a	O
precursor	O
of	O
the	O
citric	B
acid	I
cycle,	O
which	O
correlates	O
with	O
the	O
occurrence	O
of	O
histidine	B
as	O
the	O
predominant	O
free	O
amino	O
acid	O
in	O
R.	O
prolixus	O
feces	O
.	O

The	O
dry	O
extract	O
was	O
reconstituted	O
with	O
200	O
μL	O
of	O
a	O
solution	O
of	O
2%	O
aqueous	O
MeOH	B
(initial	O
conditions	O
of	O
the	O
chromatographic	O
elution	O
gradient).	O

chronic	O
lymphocytic	O
leukaemia,	O
metabolomics,	O
disease	O
staging,	O
biomarker,	O
acylcarnitines	B

Furthermore,	O
urinary	O
dopamine,	B
a	O
downstream	O
metabolite	O
of	O
tyrosine,	B
was	O
found	O
to	O
be	O
diminished	O
in	O
patients	O
still	O
bearing	O
a	O
tumor.	O

Acetone	B
is	O
a	O
breakdown	O
product	O
of	O
acetoacetate	B
through	O
the	O
action	O
of	O
gut	O
microflora	O
and	O
is	O
also	O
found	O
in	O
the	O
urine	O
during	O
ketosis.	O

LC-MS	O
and	O
MRM-MS	O
confirmed	O
that	O
the	O
soy	O
bar	O
contained	O
malonyl	O
and	O
acetyl	B
β-glucosides	I
of	O
daidzein	B
and	O
genistein,	B
as	O
well	O
as	O
non-esterified	O
β-glucosides.	B

Fatty	O
acids	O
were	O
transformed	O
into	O
methyl	B
esters,	I
using	O
either	O
TMS-diazomethane	B
or	O
methanolic	B
transesterification	O
for	O
NEFA	O
and	O
TFA,	O
respectively.	O

The	O
improved	O
properties	O
obtained	O
by	O
the	O
use	O
of	O
2	O
mM	O
ammonium	B
phosphate	I
versus	O
ammonium	B
hydrogen	I
carbonate	I
could	O
be	O
explained	O
by	O
its	O
rank	O
in	O
the	O
Hofmeister	O
series,	O
where	O
the	O
carbonate	B
ions	O
are	O
placed	O
lower	O
than	O
phosphate	B
ions._,	O
Carbonate	B
ions	O
would	O
have	O
a	O
lower	O
propensity	O
to	O
retain	O
protonated	O
amines,	O
such	O
as	O
HMA,	O
than	O
phosphate	B
ions,	O
explaining	O
the	O
necessity	O
to	O
raise	O
the	O
concentration	O
of	O
ammonium	B
hydrogen	I
carbonate.	I

Examination	O
of	O
the	O
relationship	O
between	O
FA	B
levels	O
and	O
metabolic	O
markers	O
revealed	O
several	O
significant	O
correlations.	O

Both	O
2-HG	O
and	O
lactate	B
have	O
higher	O
abundance	O
in	O
patient	O
samples	O
with	O
circulating	O
IDH1	O
mutation	O
(box	O
plots:	O
n	O
=	O
8	O
ICC	O
patient	O
samples,	O
n	O
=	O
6	O
controls,	O
boxes	O
extend	O
from	O
the	O
25th	O
to	O
the	O
75th	O
percentile	O
with	O
the	O
median	O
line	O
in	O
the	O
middle.	O

In	O
the	O
PC	O
knockdown	O
MDA-MB-231	O
cells,	O
the	O
depleted	O
levels	O
of	O
malate	B
and	O
citrate	B
caused	O
by	O
the	O
chronic	O
suppression	O
of	O
PC	O
may	O
slow	O
down	O
the	O
overall	O
pyruvate	O
cycling	O
rate,	O
resulting	O
in	O
the	O
low	O
level	O
of	O
pyruvate.	B

Altogether,	O
24	O
metabolites	O
were	O
identified	O
in	O
the	O
EDTA	O
plasma	O
samples,	O
including	O
alcohols,	O
amides,	B
amines,	O
amino	O
acid	O
derivatives,	O
amino	O
acids,	O
aromatic	O
compounds,	O
fatty	O
acids,	O
food/drug	O
components,	O
organic	O
acids	O
and	O
sugars.	O

The	O
subjects	O
had	O
mild	O
to	O
moderate	O
MG	O
with	O
serum	O
antibodies	O
to	O
the	O
acetylcholine	B
receptor	O
antibodies.	O

Nevertheless,	O
levels	O
were	O
still	O
lower	O
if	O
compared	O
with	O
smoking	O
subjects,	O
for	O
which	O
median/mean	O
values	O
close	O
to	O
1	O
µg/g	O
creatinine	B
have	O
been	O
reported	O
[,].	O

This	O
same	O
study	O
showed	O
decreased	O
levels	O
of	O
4-OHE_1	O
during	O
use	O
of	O
isoflavone	B
supplements	O
at	O
both	O
doses.	O

Andronesi	B
et	O
al.	O
attempted	O
to	O
classify	O
brain	O
biopsies	O
by	O
using	O
a	O
HRMAS	O
_1	O
H	O
2D-NMR	O
method	O
called	O
adiabatic	O
TOBSY	O
(total	O
correlation	O
through	O
bond	O
spectroscopy)	O
which	O
has	O
provided	O
enhanced	O
sensitivity	O
for	O
several	O
metabolites	O
[,	O
].	O

After	O
returning	O
the	O
samples	O
at	O
room	O
temperature,	O
91μL	O
of	O
MSTFA	O
+	O
RI	B
standards	O
was	O
added,	O
vortexed	O
and	O
incubated	O
at	O
80°C	O
for	O
20	O
minutes.	O

PSPC	O
intake	O
was	O
linked	O
to	O
some	O
direct	O
increases	O
in	O
plant	O
constituents	O
such	O
as	O
arabinose	B
and	O
caffeine.	B

Increased	O
alanine	B
and	O
lactate	B
levels	O
have	O
previously	O
been	O
observed	O
in	O
brain	O
tumours,	O
and	O
they	O
were	O
also	O
attributed	O
to	O
increased	O
glycolysis.	O

Metabolite	O
levels	O
were	O
quantitated	O
using	O
commercially	O
available	O
standards	O
(CS	O
and	O
NANA),	O
whereas	O
CR	O
was	O
semi-quantitated	O
to	O
creatine	B
equivalents,	O
and	O
561+	O
to	O
CS	O
equivalents	O
due	O
to	O
lack	O
of	O
commercially	O
available	O
standards.	O

Data	O
acquisition	O
was	O
performed	O
through	O
a	O
parent	O
ion	O
scan	O
of	O
m/z	O
=	O
184	O
Da,	O
which	O
corresponds	O
to	O
the	O
choline	B
fragment,	O
allowing	O
the	O
MS/MS	O
detection	O
of	O
PCs,	O
SMs	O
and	O
the	O
respective	O
Lyso-forms	O
(LPCs	O
and	O
LSMs).	O

We	O
observed	O
significant	O
positive	O
associations	O
between	O
serum	O
interleukin-10	O
(IL-10)	O
and	O
serum	O
kynurenine	B
(P	O
=	O
0.0002),	O
the	O
kynurenine-to-tryptophan	O
ratio	O
(KTR)	O

Metabolomic	O
equations,	O
preferably	O
excluding	O
creatinine	B
and	O
demographic	O
characteristics,	O
should	O
be	O
tested	O
for	O
robustness	O
and	O
generalizability	O
as	O
a	O
potential	O
confirmatory	O
test	O
when	O
eGFRcr	O
is	O
unreliable.	O

In	O
the	O
present	O
study,	O
glutamine,	B
glutamate,	B
aspartate	B
and	O
asparagine	B
were	O
measured	O
simultaneously	O
using	O
a	O
fast	O
LC-MS/MS	O
method.	O

Another	O
limitation	O
is	O
that	O
we	O
were	O
only	O
able	O
to	O
measure	O
circulating	O
levels	O
of	O
kynurenine-pathway	B
metabolites,	O
and	O
it	O
therefore	O
remains	O
unclear	O
whether	O
the	O
hippocampal	O
and	O
amygdalar	O
concentrations	O
of	O
KynA,	O
3HK,	O
and	O
QA	O
in	O
the	O
brains’	O
of	O
the	O
volunteers	O
were	O
sufficient	O
to	O
exert	O
neurotoxic	O
or	O
neuroprotective	O
effects.	O

Moreover,	O
the	O
decline	O
in	O
pyruvate	B
levels	O
has	O
been	O
supported	O
in	O
previous	O
study	O
conducted	O
on	O
a	O
limited	O
number	O
of	O
hypertensive	O
individuals.	O

Levels	O
of	O
sphingosine-1-phosphate	B
(S1P)	O
and	O
other	O
sphingolipids	B
in	O
breast	O
cancer	O
and	O
normal	O
breast	O
tissue.	O

Several	O
of	O
these	O
disturbances	O
could	O
be	O
interconnected	O
through	O
reduced	O
regeneration	O
of	O
tetrahydrofolate	B
and	O
tetrahydrobiopterin.	B

Indoor	O
air	O
PAHs	O
identified	O
are	O
Napthalene,	B
fluorine,	O
acenaphthene,	O
phenanthrene,	B
pyrene,	O
chrysene	O
and	O
indeno	O
[1,2,3-cd)	O
pyrene.	O

The	O
increased	O
levels	O
of	O
nervonic	B
acid	I
in	O
patients	O
with	O
major	O
depressive	O
disorder	O
compared	O
with	O
controls	O
and	O
patients	O
with	O
bipolar	O
disorder	O
in	O
cohort	O
1	O
were	O
replicated	O
in	O
the	O
independent	O
sample	O
set	O
(cohort	O
2).	O

Nine	O
of	O
the	O
patients	O
(47%)	O
were	O
classified	O
as	O
having	O
developed	O
cardiac	O
ischemia	O
at	O
peak	O
pacing	O
by	O
either	O
lactate	B
elution	O
or	O
hs-cTnT	O
criteria.	O

Carnitine	B
availability	O
is	O
essential	O
for	O
these	O
processes	O
and	O
depends	O
on	O
dietary	O
intake	O
and	O
endogenous	O
synthesis.	O

One	O
proposed	O
route	O
for	O
primary	O
fatty	O
acid	B
amide	I
biosynthesis	O
is	O
the	O
ammonolysis	O
of	O
fatty	O
acyl-CoA	B
thioesters.	I

Univariate	O
correlation	O
with	O
time	O
storage	O
duration	B
was	O
tested	O
by	O
using	O
the	O
nonparametric	O
Spearman	O
coefficient	O
of	O
rank	O
correlation	O
(Kvam	O
and	O
Vidakovic	O
)	O
and	O
controlling	O
the	O
false	O
discovery	O
rate	O
(Benjamini	O
and	O
Hochberg	O
)	O
at	O
a	O
0.01	O
threshold.	O

We	O
were	O
not	O
able	O
to	O
measure	O
the	O
nervonic	B
acid	I
in	O
the	O
remaining	O
21	O
subjects,	O
because	O
sufficient	O
sample	O
volumes	O
were	O
not	O
available.	O

	O
High	O
sample	O
throughput	O
(≤	O
16	O
min	O
total	O
cycle	O
time	O
per	O
sample,	O
<7	O
min	O
for	O
MS1	O
portion)	O
was	O
achieved	O
using	O
the	O
nanoelectrospray	O
TriVersa	O
NanoMate	O
(Advion	O
Biosciences,	O
Ithaca,	O
NY,	O
USA)	O
with	O
1.5	O
kV	B
electrospray	O
voltage	O
and	O
0.4	O
psi	O
head	O
pressure.	O

N-(9-Fluorenylmethoxycarbonyl)-glycine	B
(FMOC-glycine)	I
and	O
N-methyl-N-trimethyl-silyl-trifluoroacetamide	B
(MSTFA)	O
were	O
purchased	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
MO,	O
USA).	O

Levels	O
of	O
the	O
three	O
BCAAs	O
leucine,	B
isoleucine	B
and	O
valine	B
were	O
all	O
higher	O
in	O
cohort	O
1	O
BCa	O
urines	O
relative	O
to	O
the	O
normal	O
and	O
BCa	O
history	O
controls.	O

Acetonitrile	B
(ACN),	O
methanol	B
(MeOH),	O
ethanol	B
(EtOH),	O
trichloroethylene	O
(TCE)	O
and	O
n	B
-hexane	I
(HEX)	O
were	O
purchased	O
from	O
Merck	O
(Darmstadt,	O
Germany).	O

Enzyme	O
abbreviations	O
used	O
are	O
CH25H	O
cholesterol	O
25-hydroxylase,	O
CYP	O
cytochrome	O
P450,	O
HSD	O
hydroxysteroid	O
dehydrogenase	O
In	O
agreement	O
with	O
some,	O
but	O
not	O
all,	O
earlier	O
studies,	O
the	O
level	O
of	O
24S-hydroxycholesterol	B
(24S-HC)	O
is	O
reduced	O
in	O
plasma	O
from	O
the	O
group	O
of	O
patients	O
with	O
either	O
AD	O
or	O
PD	O
compared	O
to	O
CP	O
(10.51 ± 2.18 ng/mL	O
cf.	O

The	O
concentrations	O
of	O
all	O
three	O
statins	B
and	O
their	O
active	O
metabolites	O
(ng/ml)	O
were	O
converted	O
to	O
the	O
molar	O
concentration	O
(nM),	O
then	O
were	O
normalized	O
by	O
dose/body	O
weight	O
[(nM)/(mg/Kg)].	O

Since	O
they	O
are	O
derived	O
from	O
cellular	O
BDA	O
reaction	O
products,	O
these	O
metabolites	O
are	O
markers	O
of	O
furan	B
exposure	O
and	O
bioactivation	O
and	O
could	O
be	O
explored	O
as	O
potential	O
biomarkers	O
in	O
human	O
studies.	O

The	O
decreasing	O
levels	O
of	O
four	O
PC	O
aa’s	O
and	O
increasing	O
levels	O
of	O
eight	O
lysoPCs	O
during	O
storage	O
at	O
RT	O
could	O
be	O
explained	O
by	O
the	O
hydrolysis	O
of	O
phosphatidylcholine	B
to	O
yield	O
a	O
lysophospholipid	B
and	O
free	O
fatty	O
acid,	O
catalyzed	O
by	O
a	O
phospholipase	O
.	O

Oropharyngeal	O
candidiasis	O
caused	O
by	O
C.	O
albicans	O
,	O
which	O
produces	O
Ethanol	B
via	O
anaerobic	O
fermentation,	O
is	O
the	O
most	O
prevalent	O
opportunistic	O
infection	O
in	O
HIV/AIDS	O
.	O

Acylcarnitines	B
accumulate	O
and	O
are	O
released	O
into	O
the	O
circulation	O
due	O
to	O
FAO	O
defects	O
and	O
can	O
also	O
be	O
reflective	O
of	O
incomplete	O
long-chain	O
FAO,	O
as	O
it	O
occurs	O
in	O
type	O
2	O
diabetes	O
and	O
in	O
insulin	O
resistance.	O

PtdCho	O
indicates	O
phosphatidylcholine	B
in	O
cell	O
membranes	O
which	O
is	O
invisible	O
to	O
HRMAS	O
_1	O
H	O
NMR.	O

However,	O
while	O
observational	O
and	O
animal	O
studies	O
have	O
found	O
positive	O
associations	O
between	O
omega-3	B
FAs	O
and	O
insulin	O
sensitivity,	O
trials	O
using	O
omega-3	B
FA	I
supplementation	O
in	O
humans	O
have	O
shown	O
no	O
benefit	O
on	O
improving	O
insulin	O
sensitivity,	O
which	O
agrees	O
with	O
our	O
finding.	O

Phospholipid	B
abnormalities	O
constituted	O
16%	O
of	O
the	O
metabolic	O
disturbances	O
in	O
males	O
and	O
26%	O
in	O
females	O
(	O
and	O
).	O

Unique	O
associations	O
with	O
fibrinogen	O
were	O
observed	O
for	O
plasma	O
levels	O
of	O
pregnanediol-3-glucuronide	B
(positively)	O
and	O
phosphatidylcholines	B
with	O
fatty	O
acid	O
residues	O
bound	O
to	O
one	O
acyl	O
and	O
one	O
alkyl	O
group	O
(inversely).	O

MeOH	B
(A),	O
ACN	O
(B),	O
EtOH	B
(C)	O
and	O
IPA	O
(D).	O

The	O
present	O
method	O
is	O
the	O
first	O
LC–MS/MS	O
assay	O
with	O
spectral	O
library	O
searching	O
for	O
qualitative	O
confirmation	O
of	O
9	O
synthetic	O
cannabinoids	B
and	O
20	O
metabolites.	O

An	O
example	O
is	O
illustrated	O
in	O
for	O
tryptamine.	B

Three	O
metabolites	O
had	O
distinct	O
patterns	O
in	O
the	O
2	O
populations:	O
taurine,	B
an	O
AA	O
not	O
used	O
in	O
protein	O
synthesis	O
but	O
which	O
is	O
important	O
for	O
fetal	O
growth	O
and	O
placental	O
function;	O
threonine,	B
an	O
essential	O
AA;	O
and	O
choline,	B
a	O
major	O
component	O
of	O
cell	O
membranes	O
that	O
is	O
critical	O
for	O
fetal	O
brain	O
development	O
(,	O
).	O

Artefact	O
peaks	O
resulting	O
from	O
the	O
derivatization	O
process	O
and	O
interferences	O
due	O
to	O
urea	B
were	O
removed	O
from	O
the	O
dataset.	O

Elevated	O
urinary	O
glucose	B
in	O
HNF1A-MODY	O
is	O
consistent	O
with	O
the	O
previously	O
reported	O
low	O
renal	O
threshold	O
for	O
glucose	B
in	O
this	O
genetic	O
subtype.	O

In	O
this	O
study,	O
even	O
before	O
LC	O
development,	O
the	O
LC	O
group	O
showed	O
higher	O
levels	O
of	O
palmitoylcarnitine	B
and	O
oleoylcarnitine	B
than	O
the	O
control	O
group.	O

This	O
finding	O
was	O
somewhat	O
surprising	O
given	O
that	O
studies	O
in	O
rat	O
hepatocytes	O
indicated	O
that	O
the	O
formation	O
of	O
glutathione-BDA-lysine	B
metabolites	O
occurred	O
to	O
a	O
much	O
greater	O
extent	O
than	O
metabolite	O
1;_,	O
glutathione-BDA-lysine	B
is	O
likely	O
a	O
major	O
precursor	O
to	O
metabolites	O
2	O
–	O
5._,	O
A	O
likely	O
explanation	O
for	O
this	O
discrepancy	O
is	O
that	O
we	O
are	O
not	O
accounting	O
for	O
all	O
of	O
the	O
cysteine-BDA-lysine-derived	O
metabolites	O
reported	O
in	O
rat	O
urine.	O

These	O
results	O
indicate	O
that	O
patients	O
with	O
an	O
eGFR	O
<	O
60	O
ml/min/1.73m_2	O
have	O
at	O
the	O
same	O
time	O
low	O
concentrations	O
of	O
3-hydroxyisovalerate	B
and	O
dimethylsulfone,	B
with	O
a	O
mirror	O
profile	O
for	O
patients	O
with	O
an	O
eGFR	O
≥	O
60	O
ml/min/1.73m_2	O
.	O

Studies	O
investigating	O
the	O
relationship	O
between	O
adult	O
urinary	O
concentrations	O
of	O
paracetamol	B
and	O
TTP	O
are	O
lacking.	O

Low	O
plasma	O
uric	B
acid	I
levels	O
at	O
presentation	O
with	O
hepatic	O
or	O
neurologic	O
manifestations	O
in	O
patients	O
with	O
WD	O
have	O
been	O
previously	O
described	O
and	O
may	O
be	O
due	O
to	O
renal	O
tubular	O
failure	O
and	O
reduced	O
uric	B
acid	I
synthesis	O
in	O
the	O
liver	O
(;	O
;	O
;	O
).	O

According	O
to	O
the	O
OPLS-DA	O
VIP	O
score,	O
there	O
was	O
an	O
increase	O
in	O
the	O
allantoin	B
serum	O
level	O
in	O
the	O
osteopenia	O
group	O
while	O
the	O
osteoporosis	O
groups	O
presented	O
higher	O
serum	O
levels	O
of	O
cholesterol,	B
lactate	B
and	O
unsaturated	O
lipids.	O

Conversely,	O
acetate,	B
ketone	B
bodies,	O
carnosine,	B
m-hydroxyphenylacetate,	B
phenylacetyglycine,	B
pyruvate	B
and	O
α-ketoglutarate	B
exhibited	O
enhanced	O
expression	O
levels	O
in	O
COPD	O
patients	O
relative	O
to	O
healthy	O
subjects.	O

Multiple	O
regression	O
analyses	O
were	O
performed	O
to	O
identify	O
the	O
major	O
plasma	O
metabolites	O
associated	O
with	O
the	O
fasting	O
TG	B
level.	O

Ethyl	B
acetate	I
(1	O
ml)	O
was	O
then	O
added,	O
and	O
the	O
mixture	O
was	O
vortexed	O
for	O
3	O
minutes.	O

Increased	O
level	O
of	O
DMA	B
and	O
TMA	O
indicated	O
the	O
up-regulation	O
of	O
the	O
methylamine	B
methylamine.	I

Importantly,	O
this	O
is	O
in	O
the	O
range	O
of	O
normal	O
concentrations	O
of	O
retinoic	B
acid	I
in	O
plasma	O
and	O
approximately	O
the	O
same	O
as	O
the	O
binding	O
constant	O
of	O
the	O
compound	O
for	O
the	O
retinoid	B
receptors.	O

Our	O
data	O
showed	O
that	O
the	O
metabolite	O
most	O
strongly	O
associated	O
with	O
vitamin	B
D	I
among	O
the	O
55	O
lipid	O
metabolites	O
was	O
CMPF.	O

The	O
estrogen	B
metabolite	O
4-OHE1	O
ranked	O
slightly	O
higher	O
among	O
cases	O
than	O
the	O
2	O
control	O
groups;	O
however,	O
there	O
was	O
no	O
difference	O
in	O
the	O
median	O
concentration	O
of	O
the	O
metabolite	O
among	O
the	O
3	O
groups.	O

Each	O
aliquot	O
was	O
supplemented	O
with	O
a	O
1	O
M	O
[U_13	B
C]glucose,	I
[6-_13	B
C_1	I
]glucose,	I
[1,2-_13	B
C_2	I
]glucose,	I
or	O
[3,4-_13	B
C_2	I
]glucose	I
(CLM-1396-1,	O
CLM-2717-PK,	O
CLM-504,	O
or	O
CLM-6750-MPT-PK;	O
Cambridge	O
Isotopes)	O
solution	O
to	O
a	O
final	O
total	O
glucose	B
(labeled	O
+	O
unlabeled)	O
concentration	O
of	O
15	O
mM.	O
The	O
volume	O
of	O
the	O
1	O
M	O
tracer	O
solution	O
added	O
to	O
the	O
blood	O
depended	O
on	O
the	O
blood	O
glucose	B
concentration	O
measured	O
before	O
and	O
was	O
adjusted	O
to	O
reach	O
a	O
final	O
concentration	O
of	O
15	O
mM	O
glucose	B
in	O
all	O
samples.	O

Signal	O
assignment:	O
1-lactate;	B
2-alanine;	B
3	B
-glutamine;	I
4-glucose;	B
5-isoleucine;	B
6-leucine;	B
7-valine;	B
8-lysine;	B
9-acetate;	B
10-pyruvate;	O
11-citrate;	O
12-creatine;	B
13-creatinine;	O
14-dimethyl	B
sulfone;	I
15-TMAO,	O
trimethylamine-N	B
-Oxide;	I
16,proline;	B
17-methanol;	B
18-glycine;	B
19-tyrosine;	B
20-histidine;	B
21-	B
phenylalanine;	I
22-formate;	O
23-C18H	O
cholesterol;	B
24-CH_3	O
lipids;	O
25-(CH_2	O
)_n	O
lipids;	O
26-CH_2	O
CH_2	O
CO	O
lipids;	O
27-CH_2	O
CH_2	O
C	O
=	O
C	O
lipids;	O
28-CH_2	O
C	O
=	O
C	O
lipids;	O
29-CH_2	O
CO	O
lipids;	O
30-C	O
=	O

γ	B
-Aminobutyric	I
acid	I
formed	O
by	O
decarboxylation	O
of	O
glutamate	B
is	O
an	O
inhibitory	O
neurotransmitter	O
in	O
organisms	O
widely	O
present	O
in	O
the	O
body	O
[,	O
].	O

demonstrates	O
detection	O
of	O
the	O
pharmaceutical	O
tiabendazole	B
(TAE),	O
which	O
was	O
spiked	O
into	O
human	O
plasma	O
and	O
urine,	O
at	O
a	O
concentration	O
of	O
1	O
nM.	O
TAE	O
occurred	O
during	O
the	O
3-s	O
SPE-IMS-MS	O
peak	O
elution	O
time	O
and	O
each	O
sample	O
was	O
analyzed	O
using	O
a	O
10-s	O
sample-to-sample	O
cycle	O
time	O
to	O
account	O
for	O
cartridge	O
equilibration	O
and	O
sample	O
loading.	O

Other	O
main	O
lipid	O
classes	O
reduced	O
in	O
preeclampsia	O
group	O
were:	O
Glycerophosphoglycerols-GP04	B
(PG)	O
(p<0.003),	O
Sterols-ST01	B
(p<0.0001)	O
and	O
Other	O
acyl	O
sugars-SL05	O
(p<0.0001).	O

Propionylcarnitine	B
and	O
other	O
BCAA-derived	O
AC,	O
as	O
well	O
as	O
the	O
phosphatidylcholines	B
PCae	O
C36:3,	B
PCaa	O
C36:2	B
and	O
sphingomyelin	B
SM	O
OH	B
C22:1	I
had	O
higher	O
concentrations	O
in	O
samples	O
collected	O
before	O
surgery,	O
while	O
SM	O
16:0,	O
SM	O
18:0,	O
SM	B
18:1,	I
the	O
acylcarnitine	B
3-Hydroxybutyrylcarnitine	I
(C4:OH)	O
and	O
the	O
phosphatidylcholines	B
PCaa	O
C32:2	B
and	O
PCae	O
C32:1	B
were	O
increased	O
in	O
blood	O
collected	O
90	O
days	O
after	O
the	O
RYGB	O
surgery.	O

Therefore	O
one	O
important	O
step	O
in	O
developing	O
requirements	O
for	O
dairy	O
cattle	O
is	O
increasing	O
the	O
understanding	O
of	O
the	O
incorporation	O
of	O
choline	B
in	O
milk	O
and	O
how	O
this	O
varies	O
through	O
lactation.	O

Our	O
results	O
are	O
consistent	O
with	O
other	O
literature	O
in	O
finding	O
positive	O
correlations	O
between	O
circulating	O
estrogen	B
levels	O
and	O
BMI	O
in	O
post-menopausal	O
women	O
(,	O
-);	O
others	O
have	O
not	O
examined	O
correlations	O
for	O
the	O
full	O
range	O
of	O
estrogens	O
and	O
estrogen	B
metabolites.	O

The	O
system	O
was	O
calibrated	O
routinely	O
with	O
LTQ	O
FT	B
calibration	O
solution	O
prepared	O
according	O
to	O
the	O
instrument	O
instructions.	O

After	O
adjusting	O
for	O
BMI,	O
age,	O
sex,	O
race,	O
and	O
Tanner	O
stage,	O
the	O
significant	O
associations	O
between	O
DI	O
and	O
C3,	O
C4,	O
and	O
C5	O
acylcarnitine	B
and	O
between	O
IS	O
and	O
C4	O
and	O
C5	O
acylcarnitine,	B
methionine	B
and	O
tyrosine	B
disappeared.	O

PUFA	O
levels	O
were	O
reduced	O
significantly	O
in	O
HIV+	O
individuals,	O
and	O
many	O
individual	O
PUFA	O
species	O
levels	O
were	O
inversely	O
related	O
to	O
markers	O
of	O
monocyte	O
activation,	O
such	O
as	O
tissue	O
factor,	O
TLR4,	O
CD69,	O
and	O
SR-A.	O
Also	O
in	O
HIV+	O
individuals,	O
the	O
composition	O
of	O
lysophosphatidylcholine	B
(LPC)	O
was	O
enriched	O
for	O
SaFAs;	O
LPC	O
species	O
containing	O
SaFAs	O
were	O
directly	O
associated	O
with	O
IL-6	O
levels	O
and	O
monocyte	O
activation.	O

In	O
this	O
study,	O
the	O
glucose	B
levels	O
significantly	O
decreased	O
and	O
lactate,	B
as	O
the	O
end	O
product	O
of	O
glycolysis,	O
apparently	O
increased	O
in	O
the	O
LNM-negative	O
and	O
LNM-positive	O
GC	O
specimens	O
compared	O
with	O
controls,	O
which	O
was	O
not	O
surprised	O
because	O
of	O
the	O
well-known	O
Warburg	O
effect	O
(Vander	O
Heiden	O
et	O
al.	O
).	O

Related	O
studies	O
have	O
indicated	O
that	O
N-carbamyl-β-alanine	B
and	O
N-carbamyl-β-aminoisobutyric	B
acid	I
were	O
weak	O
inhibitors	O
of	O
dihydropyrimidinase.	O

Odds	O
of	O
recurrence	O
were	O
2.44	O
(95%	O
CI:	O
1.07	O
to	O
5.56,	O
p = 0.03)	O
times	O
higher	O
when	O
cystathionine	B
levels	O
were	O
increased	O
from	O
139	O
(Q1)	O
to	O
200	O
(Q3).	O

Ice-cold	O
methanol	B
(2.7	O
mL)	O
and	O
2.7	O
mL	O
cold	O
H_2	O
O	O
(4	O
°C)	O
were	O
added	O
to	O
the	O
cells	O
to	O
quench	O
the	O
metabolism.	O

The	O
HPLC-grade	O
solvents	O
methanol,	B
acetonitrile,	B
ethyl	B
acetate,	I
formic	B
acid,	I
and	O
acetic	B
acid	I
were	O
bought	O
from	O
Fisher	O
Chemicals	O
(Loughborough,	O
UK).	O

The	O
amino	O
acid	O
homocysteine,	O
a	O
derivative	O
of	O
methionine,	B
functions	O
in	O
one-carbon	O
metabolism	O
reactions,	O
which	O
are	O
important	O
for	O
nucleotide	O
synthesis	O
and	O
DNA	O
methylation.	O

In	O
the	O
DCCT,	O
MESA,	O
CHS,	O
and	O
SKS,	O
serum	O
creatinine	B
concentrations	O
were	O
measured	O
using	O
methods	O
traceable	O
to	O
isotope	O
dilution	O
mass	O
spectrometry.	O

The	O
elemental	O
compositions	O
determined	O
here	O
for	O
the	O
precursor	O
and	O
product	O
ions	O
of	O
metabolite	O
b	O
led	O
to	O
its	O
assignment	O
as	O
another	O
known	O
SPB	O
metabolite,	O
4-phenyl-trans	B
-crotonate,	I
whose	O
structure	O
had	O
been	O
determined	O
in	O
SPB	O
studies	O
that	O
investigated	O
the	O
mechanism	O
of	O
3-hydroxy-4-	B
phenylbutyrate	I
formation	O
in	O
SPB-perfused	O
rat	O
livers.	O

Alternatively,	O
carnitine	B
can	O
induce	O
formation	O
of	O
TMAO	B
and	O
carnitine	B
is	O
often	O
promoted	O
as	O
a	O
weight	O
loss	O
inducing	O
supplement.	O

Also	O
citrate	B
can	O
be	O
converted	O
to	O
Acetyl-CoA	B
by	O
ATP	B
citrate	I
lyase	O
(ACL)	O
and	O
participate	O
in	O
the	O
synthesis	O
of	O
fatty	O
acids	O
and	O
cholesterol,	B
which	O
are	O
essential	O
components	O
of	O
cancer	O
cell	O
membranes,	O
lipid	O
raft	O
and	O
lipid-modified	O
signalling	O
molecules.	O

The	O
urea	B
cycle	O
(UC)	O
is	O
a	O
part	O
of	O
APM.	O

Participants	O
were	O
followed	O
for	O
a	O
total	O
of	O
6	O
weeks	O
on	O
simvastatin	B
therapy	O
(40	O
mg	O
at	O
bedtime)	O
and	O
were	O
seen	O
at	O
clinic	O
visits	O
conducted	O
at	O
two-week	O
intervals.	O

Ketone	B
bodies,	O
mainly	O
acetoacetate,	B
but	O
also	O
3-hydroxibutyrate	B
were	O
significantly	O
downregulated	O
in	O
cirrhotic	O
patients.	O

The	O
glycerol	B
signal	O
was	O
assigned	O
using	O
the	O
Chenomx	O
Reference	O
Compound	O
library.	O

As	O
the	O
baseline	O
levels	O
in	O
serum	O
and	O
urine	O
were	O
below	O
the	O
limit	O
of	O
detection,	O
3-phenyllactic	B
acid	I
may	O
be	O
a	O
suitable	O
FIB	O
for	O
fermented	O
foods,	O
during	O
the	O
first	O
6	O
h	O
after	O
intake	O
as	O
it	O
is	O
then	O
excreted	O
non-metabolized	O
into	O
urine.	O

MTBE	B
was	O
the	O
most	O
efficient	O
solvent	O
to	O
extract	O
all	O
estrogens	O
tested;	O
furthermore,	O
it	O
removed	O
many	O
of	O
the	O
co-eluting	O
interfering	O
peaks.	O

C10:	O
decanoylcarnitine;	B
C3DC/C10:	O
malonylcarnitine/decanoylcarnitine;	O
C10:1:	B
decenoylcarnitine;	B
C18:1:	B
octadecenoylcarnitine;	B
Glu:	O
glutamate;	B
Thr:	O
Threonine;	B
Val/Phe:	O
valine/phenylalanine;	O
C5-OH/C0:	O
3-Hydroxy-isovalerylcarnitine/carnitine;	O
C4DC:	O
Methylmalonylcarnitine;	B
C4/C8:	O
butyrylcarnitine/octanoylcarnitine	O
and	O
C3/Met:	O
propionylcarnitine/methionine.	O

Plasma	O
malondialdehyde	B
(MDA)	O
was	O
measured	O
from	O
thiobarbituric	B
acid-reactive	O
substances	O
(TBARS)	O
using	O
the	O
TBARS	O
Assay	O
Kit	O
(ZeptoMetrix	O
Co.,	O
Buffalo,	O
NY,	O
USA).	O

The	O
sample	O
size	O
calculations	O
were	O
based	O
on	O
a	O
separate	O
candidate-gene	B
study,	O
conducted	O
as	O
part	O
of	O
the	O
broader	O
“Topography	O
and	O
Genetics	O
of	O
Smoking	O
and	O
Nicotine	B
Dependence	O
in	O
American	O
Indians”	O
study.	O

The	O
gradient	O
program	O
contained	O
5.0	O
mM	O
of	O
ammonium	B
formate	I
with	O
0.05%	O
formic	B
acid	I
(solvent	O
A)	O
and	O
acetonitrile	B
(solvent	O
B).	O

Moreover,	O
at	O
the	O
3-year	O
follow-up	O
the	O
overweight	O
group	O
showed	O
an	O
increase	O
in	O
waist	O
circumference,	O
SBP	O
and	O
DBP,	B
FFA,	O
insulin,	O
HOMA-IR,	O
and	O
ba-PWV	O
compared	O
with	O
baseline	O
levels,	O
and	O
the	O
changes	O
in	O
waist	O
circumference,	O
SBP,	O
DBP,	B
triglyceride,	B
FFA,	O
glucose,	B
insulin,	O
HOMA-IR,	O
hs-CRP,	O
and	O
ba-PWV	O
observed	O
in	O
the	O
overweight	O
group	O
were	O
significantly	O
different	O
from	O
those	O
in	O
the	O
normal	O
weight	O
group	O
after	O
adjusting	O
for	O
baseline	O
levels.	O

Interestingly	O
metabolites	O
such	O
as	O
threonine	B
and	O
citrate	B
were	O
part	O
of	O
up	O
the	O
_1	O
H-NMR	O
metabolite	O
data;	O
were	O
not	O
picked	O
by	O
the	O
GCMS.	O

Based	O
on	O
this	O
evidence,	O
it	O
appears	O
that	O
high-grade	O
gliomas	O
have	O
higher	O
levels	O
of	O
citric	B
acid	I
than	O
low-grade	O
gliomas.	O

With	O
this	O
mechanistic	O
relevance	O
and	O
our	O
data	O
showing	O
the	O
correlation	O
with	O
the	O
prognosis	O
at	O
3	O
months,	O
the	O
[3-HB]/[glucose]	B
ratio	O
might	O
be	O
a	O
useful	O
prognostic	O
marker	O
for	O
future	O
glycemic	B
control,	O
if	O
our	O
results	O
are	O
reproduced	O
in	O
larger	O
studies.	O

In	O
addition,	O
we	O
have	O
shown	O
that	O
anastrozole	B
is	O
hydroxlated	O
to	O
form	O
hydroxyanastrozole.	B

_a	O
solubilised	O
in	O
SBE-β-CD	B
Blocking	O
two	O
essential	O
enzymes	O
in	O
the	O
ergosterol	B
pathway	O
is	O
more	O
detrimental	O
for	O
unicellular	O
organisms	O
than	O
inhibiting	O
one.	O

Tryptophan,	B
which	O
is	O
an	O
essential	O
amino	O
acid,	O
is	O
critical	O
for	O
cell	O
proliferation.	O

Interestingly,	O
plasma	O
phenylalanine	B
concentration	O
has	O
been	O
shown	O
to	O
be	O
increased	O
in	O
inflammatory	O
diseases,	O
including	O
uremia.	O

 ,	O
1-methyladenosine	B
displayed	O
higher	O
AUC	O
value	O
than	O
that	O
of	O
AFP	O
or	O
HBV-DNA.	O

Similarly,	O
stably	O
suppressing	O
glutaminase	O
expression	O
in	O
these	O
cells	O
with	O
lentiviral	O
shRNA	O
also	O
abrogated	O
HNSCC	O
tumorsphere	O
formation	O
and	O
glutamate	B
levels	O
in	O
HNSCC	O
cells	O
in	O
vitro	O
.	O

We	O
discovered	O
that	O
LoF	O
mutation	O
in	O
CD36	O
influences	O
serum	O
octanoylcarnitine	B
and	O
decanoylcarnitine	B
levels—two	O
acylcarnitine	B
biomarkers	O
of	O
medium-chain	O
acyl–coenzyme	O
A	O
dehydrogenase	O
(MCAD)	O
deficiency—and	O
replicated	O
this	O
mutation.	O

During	O
fatty	O
acid	O
oxidation,	O
acylcarnitines	B
are	O
generated	O
as	O
intermediates;	O
and	O
their	O
accumulation	O
is	O
caused	O
by	O
metabolic	O
dysfunctions	O
as	O
a	O
consequence	O
of	O
the	O
insufficient	O
integration	O
between	O
β-oxidation	O
and	O
Krebs	O
cycle.	O

(D)	O
Extracted	O
ion	O
chromatograms	O
for	O
all	O
134	O
spectral	O
peaks	O
observed	O
in	O
pooled	O
plasma	O
that	O
were	O
matched	O
to	O
commercial	O
oxylipin	B
standards.	O

A	O
biomarker	O
for	O
elevated	O
diabetes	O
risk,	O
2-aminoadipic	B
acid,	I
was	O
found	O
to	O
positively	O
correlate	O
to	O
baseline	O
HOMA	O
and	O
to	O
glucose/c-peptide	B
ratio,	O
but	O
not	O
to	O
baseline	O
glucose,	B
c-peptide	O
or	O
insulin	O
levels.	O

compared	O
patients	O
on	O
day	O
0	O
and	O
28	O
(n=27)	O
after	O
the	O
beginning	O
of	O
endocrine	O
therapy	O
with	O
tamoxifen	B
or	O
aromatase	O
inhibitors	O
and	O
observed	O
a	O
number	O
of	O
significant	O
changes	O
between	O
both	O
samplings,	O
but	O
none	O
for	O
7-ketocholesterol	B
and	O
27-hydroxycholesterol.	B

In	O
addition,	O
levels	O
of	O
γ-glutamyl	O
amino	O
acids	O
(γ-glutamylleucine	O
and	O
γ-glutamylglutamine)	B
were	O
found	O
to	O
be	O
significantly	O
elevated	O
in	O
depressed	O
subjects	O
in	O
comparison	O
to	O
control	O
subjects.	O

The	O
robustness	O
of	O
our	O
method	O
for	O
the	O
sensitive	O
detection	O
and	O
quantitation	O
of	O
the	O
17	O
metabolites	O
and	O
co-factors	O
of	O
methionine	B
metabolism	O
was	O
assessed	O
in	O
biological	O
materials	O
collected	O
from	O
healthy	O
donors	O
and	O
patients	O
diagnosed	O
with	O
Alzheimer’s	O
disease.	O

Therefore,	O
aberrant	O
expression	O
of	O
genes	O
involved	O
in	O
the	O
methionine	B
metabolism	O
could	O
explain	O
the	O
excessive	O
accumulation	O
of	O
circulating	O
methionine	B
in	O
patients	O
with	O
liver	O
disease.	O

It	O
is	O
possible	O
that	O
the	O
decreased	O
hepatic	O
function,	O
as	O
evidenced	O
by	O
higher	O
Child–Pugh	O
scores	O
in	O
patients	O
with	O
HCC	O
translates	O
into	O
less	O
efficient	O
benzoate	B
conjugation	O
and	O
subsequently	O
lower	O
urinary	O
hippurate	B
excretion	O
levels.	O

In	O
patients	O
with	O
ACLF,	O
increased	O
lactate	B
concentration	O
may	O
be	O
related	O
to	O
the	O
superimposed	O
impairment	O
of	O
hepatic	O
lactate	B
catabolism	O
and	O
increased	O
production	O
of	O
lactate	B
caused	O
by	O
hypoxia	O
and	O
liver	O
necrosis.	O

The	O
impact	O
of	O
additive	O
selection	O
upon	O
peak	O
base	O
widths	O
and	O
resolution	O
in	O
SFC-MS	O
mode	O
is	O
shown	O
in	O
:	O
the	O
three	O
ammonium	B
salts	O
reduce	O
the	O
median	O
peak	O
base	O
width	O
considerably	O
when	O
compared	O
to	O
the	O
acidic	O
additives.	O

All	O
of	O
them	O
were	O
positively	O
associated	O
with	O
a	O
standard	O
deviation	O
(SD)	O
increase	O
in	O
retinol,	B
except	O
for	O
the	O
peptide	O
metabolite	O
adsgegdfxaegggvr	O
(fibrinopeptide	O
A)	O
that	O
showed	O
an	O
inverse	O
association	O
(β = −0.16).	O

The	O
lowest	O
concentrations	O
of	O
standard	O
solution	O
for	O
acetamiprid	B
and	O
AM-2	O
were	O
set	O
based	O
on	O
the	O
approximately	O
10-fold	O
difference	O
in	O
their	O
instrumental	O
detection	O
limits.	O

Glycerin	B
was	O
included	O
in	O
the	O
enhanced	O
rinse	O
formulations	O
to	O
augment	O
rinse	O
viscosity	O
and	O
therefore	O
increase	O
opportunity	O
for	O
the	O
adherence	O
of	O
BRB	O
compounds	O
to	O
oral	O
mucosal	O
tissues.	O

Table 	O
shows	O
results	O
of	O
multivariable	O
CLR	O
additionally	O
adjusted	O
for	O
liver	O
function	O
score	O
for	O
which	O
only	O
citrate	B
(OR = 1.88;	O
95 %	O
CI,	O
1.14–3.11)	O
and	O
phenylalanine	B
(OR = 1.75;	O
95 %	O
CI,	O
1.04–2.94)	O
remained	O
significantly	O
associated	O
with	O
HCC	O
risk.	O

Moreover,	O
PA	O
urinary	O
level	O
has	O
been	O
linked	O
also	O
to	O
2-phenyletilamine	B
metabolism,	O
mainly	O
related	O
to	O
monoamine	B
oxidase	O
activity.	O

The	O
present	O
study	O
aimed	O
to	O
determine	O
the	O
profile	O
of	O
omega-3	B
or	O
n3-	O
as	O
well	O
as	O
omega-6	B
or	O
n6-	O
polyunsaturated	O
fatty	O
acids	O
(PUFAs)	O
and	O
PUFA-metabolites	O
of	O
linoleic	B
acid,	I
arachidonic	B
acid	I
(AA),	O
eicosapentaenoic	B
acid	I
(EPA)	O
and	O
docosahexaenoic	B
acid	I
(DHA)	O
in	O
gingival	O
crevicular	O
fluid	O
(GCF),	O
saliva	O
and	O
serum	O
in	O
AgP	O
patients	O
and	O
healthy	O
controls.	O

In	O
addition,	O
it	O
has	O
been	O
demonstrated	O
that	O
children	O
developing	O
T1DM	O
before	O
4 years	O
of	O
age	O
have	O
low	O
cord-blood	O
levels	O
of	O
phospholipids,	B
mainly	O
phosphatidylcholines.	B

Thus	O
patients	O
not	O
able	O
to	O
take	O
methadone	B
orally	O
may	O
require	O
prolonged	O
hospitalization	O
or	O
more	O
intensive	O
home	O
health	O
care	O
to	O
enable	O
intravenous	O
dosing.	O

We	O
observed	O
large	O
AUC	O
values	O
(AUC ≥ 0.9)	O
between	O
AIS	O
A	O
and	O
C	O
for	O
four	O
metabolites	O
used	O
alone:	O
N1,	O
N12-diacetylspermine,	B
lactic	B
acid,	I
citrulline	B
and	O
glycerol,	B
with	O
good	O
sensitivity	O
and	O
specificity	O
at	O
the	O
cut-off	O
threshold.	O

Serum	O
prostate-specific	B
antigen	O
(PSA)	O
is	O
currently	O
the	O
most	O
used	O
biomarker	O
in	O
clinical	O
practice	O
for	O
prostate	O
cancer	O
(PCa)	O
detection.	O

Thus,	O
the	O
observed	O
alteration	O
in	O
propionate	B
metabolism	O
appears	O
to	O
be	O
consistent	O
with	O
a	O
recent	O
view	O
that	O
MS	O
may	O
also	O
be	O
associated	O
with	O
dysfunction	O
in	O
lipid	O
metabolism.	O

However,	O
arachidonic	B
acid	I
(ARA,	O
20:4)	O
and	O
docosahexaenoic	B
acid	I
(DHA	O
22:6),	O
which	O
are	O
long-chain	O
polyunsaturated	O
acids	O
(PUFAs),	O
were	O
decreased	O
in	O
R_AT	O
and	O
R_BT	O
,	O
respectively	O
(Shown	O
in	O
Figures	O
,	O
).	O

Peaks	O
represent	O
the	O
trimethylsilyl	B
ethers	I
of	O
OH-PAHs	O
and	O
Me-OHNs.	O

Thus,	O
the	O
level	O
of	O
tryptophan	B
and	O
its	O
catabolic	O
product	O
in	O
the	O
tumour	O
microenvironment	O
may	O
contribute	O
to	O
modulate	O
the	O
immunocytoxic	O
side	O
activity	O
induced	O
by	O
Trastuzumab.	O

A	O
panel	O
excluding	O
creatinine	B
and	O
demographics	O
still	O
performed	O
well	O
[1-P_30	O
6.4%	O
(P = 0.11)	O
and	O
3.4%	O
(P < 0.001)	O
in	O
the	O
AASK	O
and	O
MESA]	O
versus	O
eGFRcr.	O

Moreover,	O
we	O
could	O
not	O
study	O
changes	O
in	O
the	O
retinal	B
metabolome,	O
which	O
is	O
very	O
important	O
for	O
the	O
understanding	O
of	O
DM,	O
due	O
to	O
ethical	O
considerations.	O

A	O
study	O
also	O
proposed	O
the	O
PA:(PL + PLP)	O
ratio	O
(PAr)	O
as	O
an	O
indicator	O
of	O
vitamin	B
B6	I
catabolism	O
and	O
confirmed	O
that	O
the	O
PAr	O
is	O
a	O
predictor	O
for	O
all-cause	O
mortality.	O

Inclusion	O
criteria	O
for	O
CM	O
patients	O
were:	O
(i)	O
age	O
between	O
18	O
and	O
75 years;	O
(ii)	O
patients	O
treated	O
with	O
OnabotulinumtoxinA	O
for	O
the	O
prophylactic	O
therapy	O
(iii)	O
patients	O
treated	O
with	O
triptans	B
or	O
any	O
other	O
analgesics	O
during	O
the	O
headache	O
attacks.	O

Among	O
them,	O
proline	B
and	O
xanthosine	B
were	O
the	O
two	O
of	O
the	O
most	O
downregulated	O
metabolites	O
by	O
plasma	O
treatment.	O

The	O
specific	O
decrease	O
of	O
serum	O
threonine	B
and	O
histidine	B
levels	O
observed	O
in	O
NSCLC	O
patients,	O
compared	O
with	O
healthy	O
individuals,	O
most	O
probably	O
reflects	O
the	O
up-regulation	O
of	O
the	O
glycine/serine/threonine	O
and	O
pyrimidine	B
metabolic	O
pathways,	O
respectively,	O
that	O
have	O
been	O
described	O
as	O
metabolic	O
hallmarks	O
of	O
NSCLC	O
tumor-initiating	O
cells.	O

As	O
the	O
ribose-5-phosphate	B
is	O
also	O
the	O
backbone	O
of	O
nucleotides,	O
the	O
lowered	O
level	O
of	O
total	O
ribose-5-phosphate	B
in	O
the	O
knockdown	O
cells	O
as	O
shown	O
in	O
and	O
may	O
also	O
contribute	O
to	O
the	O
decreased	O
levels	O
of	O
some	O
nucleotides	O
and	O
their	O
derivatives	O
i.e.	O
hypoxanthine,	B
ADP-glucose,	B
UDP,	B
GDP,	O
GDP-mannose	O
and	O
GDP-fucose.	B

It	O
was	O
revealed	O
that	O
the	O
identified	O
metabolites	O
are	O
responsible	O
for	O
sphingolipid	B
metabolism,	O
alanine,	B
aspartate	B
and	O
glutamate	B
metabolism,	O
methionine	B
metabolism,	O
D-Glutamine	B
and	O
D-glutamate	B
metabolism,	O
valine,	B
leucine	B
and	O
isoleucine	B
biosynthesis,	O
purine	B
metabolism,	O
fatty	O
acid	O
metabolism	O
and	O
phospholipid	B
metabolism.	O

The	O
MS_3	O
spectra	O
correspond	O
to	O
GP-tagged	O
3β-hydroxycholest-5-en-26-oic	B
(c	O
)	O
and	O
7α-hydroxy-3-oxocholest-4-en-26-oic	B
acids	I
(d	O
).	O

The	O
mobile	O
phase	O
consisted	O
of	O
acetonitrile/water	O
(40:60	O
v/v)	O
with	O
10	O
mM	O
ammonium	B
acetate	I
(solvent	O
A)	O
and	O
acetonitrile/water/isopropanol	O
(10:5:85	O
v/v)	O
with	O
10	O
mM	O
ammonium	B
acetate	I
(solvent	O
B).	O

Prostaglandin	B
Thromboxane	I
Leukot	O
Res.	O

Of	O
these	O
pathways,	O
the	O
linoleic	B
acid	I
metabolism,	O
galactose	B
metabolism,	O
arachidonic	B
acid	I
metabolism,	O
glycine/serine/threonine	O
metabolism,	O
and	O
phenylalanine	B
metabolism	O
pathways	O
were	O
most	O
relevant	O
to	O
post-TBI	O
cognitive	O
impairment	O
revealed,	O
as	O
indicated	O
by	O
the	O
MetaboAnalyst	O
tool;	O
this	O
service	O
is	O
a	O
free,	O
web-based	O
tool	O
that	O
combines	O
the	O
results	O
from	O
powerful	O
pathway	O
enrichment	O
analysis	O
and	O
data	O
from	O
the	O
studied	O
conditions.	O

	O
Of	O
the	O
373	O
biochemicals	O
identified	O
in	O
CSF,	O
benzoate	B
was	O
the	O
only	O
one	O
with	O
a	O
change	O
in	O
concentration	O
from	O
baseline	O
to	O
final	O
that	O
provided	O
even	O
moderate	O
prediction	O
of	O
ΔUPDRS2	O
+	O
3	O
(0.48,	O
p	O
=	O
0.00045).	O

Samples	O
were	O
reconstituted	O
in	O
100	O
μL	O
of	O
15	O
mM	O
ammonium	B
acetate	I
containing	O
1%	O
(v/v)	O
methanol	B
for	O
LC-MS/MS	O
analysis.	O

L-Tyrosine	B
is	O
one	O
of	O
the	O
standard	O
amino	O
acids	O
that	O
are	O
useful	O
by	O
cells	O
to	O
synthesize	O
proteins.	O

Of	O
note,	O
measured	O
plasma	O
levels	O
were	O
multiplied	O
by	O
the	O
factor	O
1.1	O
accounting	O
for	O
the	O
blood	O
10:1	O
dilution	O
due	O
to	O
citrate	B
solution.	O

The	O
buffer	O
solution	O
solvated	O
in	O
a	O
mixture	O
of	O
water	O
and	O
D_2	O
O	O
consists	O
of	O
2,85	B
mM	I
TSP,	O
6.92	O
mM	O
sodium	O
azide	O
(NaN_3	O
)	O
and	O
42.08	O
mM	O
sodium	B
phosphate	I
dibasic	O
dehydrate	O
(Na_2	O
HPO_4	O
•2H_2	O
O).	O

The	O
second	O
UHPLC-TOF-MS	O
platform	O
was	O
optimized	O
for	O
the	O
analysis	O
of	O
chloroform/methanol	O
extracts,	O
covering	O
glycerolipids,	B
glycerophospholipids,	B
cholesteryl	B
esters,	I
sphingolipids,	B
and	O
primary	O
fatty	O
acid	O
amides.	O

CE,	O
cholesterol	B
esters;	I
SM,	O
sphingomyelin;	B
SqCC,	O
squamous	O
cell	O
lung	O
cancer.	O

In	O
MBC	O
patients,	O
we	O
observed	O
a	O
drop	O
in	O
all	O
the	O
already	O
identified	O
AAS	O
but	O
glycine,	B
with	O
the	O
worsening	O
of	O
the	O
disease,	O
potentially	O
reflecting	O
the	O
exhausted	O
MBC	O
patient	O
metabolism.	O

Our	O
findings	O
support	O
the	O
suggestion	O
that	O
high	O
serum	O
hypoxanthine	B
levels	O
may	O
be	O
indicative	O
of	O
OVC	O
(	O
and	O
).	O

Marked	O
changes	O
are	O
reported	O
in	O
cellular	O
phospholipid	B
metabolism,	O
glycolysis	O
and	O
amino	O
acid	O
metabolism	O
(Aboagye	O
and	O
Bhujwalla,	O
1999;	O
Katz‐Brull	O
et al.,	O
2002;	O
Li	O
et al.,	O
2011;	O
Griffin	B
and	O
Shockcor,	O
2004).	O

Fasting	O
glucose,	B
insulin,	O
proinsulin,	O
and	O
C-peptide	O
levels	O
were	O
also	O
similar	O
in	O
both	O
study	O
groups.	O

(H,	O
I)	O
Correlation	O
between	O
the	O
ceramide	B
level	O
in	O
breast	O
cancer	O
tissue	O
and	O
that	O
in	O
serum	O
(H)	O
or	O
plasma	O
(I)	O
were	O
compared.	O

Metabolites	O
interaction	O
in	O
tryptophan	B
metabolism.	O

In	O
addition,	O
ciPTEC	O
were	O
also	O
exposed	O
for	O
48	O
h	O
to	O
1	O
mM	O
1-methylhistidine,	B
3-methylhistidine	B
(both	O
as	O
negative	O
control)	O
or	O
indoxyl	B
sulphate	I
as	O
a	O
positive	O
control.	O

P,	O
P-1,	O
P-2,	O
IP,	B
IP-1,	O
IP-2,	O
and	O
I.S.	O
were	O
eluted	O
at	O
3.351,	O
0.768,	O
3.873,	O
3.421,	O
0.842,	O
4.030,	O
and	O
6.245	O
min	O
in	O
an	O
LQC	O
sample,	O
respectively.	O

In	O
addition,	O
a	O
study	O
in	O
rats	O
suggested	O
that	O
tryptophan	B
suppresses	O
the	O
elevation	O
of	O
blood	O
glucose	B
and	O
lessens	O
the	O
burden	O
associated	O
with	O
insulin	O
secretion	O
from	O
β-cells.	O

Samples	O
were	O
then	O
loaded	O
onto	O
5	O
mL	O
ChemElut	O
cartridges	O
(Agilent	O
Tech.),	O
and	O
the	O
[D_4	O
]4	O
methyl	B
ester	I
was	O
eluted	O
with	O
25	O
mL	O
of	O
CH_2	O
Cl_2	O
.	O

These	O
3	O
differential	O
metabolites	O
were	O
cholesterol,	B
linoleic	B
acid	I
and	O
glycine.	B

The	O
NMR	O
data	O
were	O
further	O
analyzed	O
by	O
principal	O
component	O
analysis	O
(PCA)	O
using	O
the	O
full,	O
processed	O
_1	O
H	O
NMR	O
spectra	O
with	O
glucose	B
regions	O
removed	O
to	O
differentiate	O
the	O
plasma	O
of	O
insulin-deprived	O
type	O
1	O
diabetic	O
people	O
from	O
insulin-treated	O
T1D	O
and	O
non-diabetic	O
controls.	O

3-MPST,	O
3-mercaptopyruvate	O
sulfurtransferase;	O
APS,	O
adenosine	B
5′-phosphosulfate;	I
ATPS,	O
ATP	O
sulfurylase;	O
APK,	O
APS	O
kinase;	O
CAT,	O
cysteine	O
aminotransferase;	O
CDO,	O
cysteine	O
dioxygenase;	O
AST,	O
aspartate	O
(cysteinesulfinate)	O
aminotransferase;	O
CSD,	O
Cysteine	O
sulfinic	O
acid	O
decarboxylase;	O
CSE,	O
cystathionine	O
γ-lyase;	O
CBS,	O
cystathionine	O
β-synthase;	O
GCL,	O
glutamate-cysteine	B
ligase;	O
GSS,	O
glutathione	B
synthetase;	O
HTDH,	O
hypotaurine	O
dehydrogenase;	O
PAPS,	O
3′-phosphoadenosine-5′-phosphosulfate;	B
Rhd,	O
rhodanese;	O
SO,	O
sulfite	B
oxidase;	O
SQR,	O
sulfide	B
quinone	I
reductase;	O
SQR-S-SH,	O
SQR-bound	O
persulfide;	B
TMT,	O
thiol	O
S	O
-methyltransferase;	O
TEMT,	O
thioether	O
S	O
-methyltransferase.	O

The	O
validation	O
set	O
confirmed	O
that	O
myo-inositol	B
concentrations	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
FSGS	O
than	O
in	O
healthy	O
controls	O
(2.35-fold;	O
P = 0.008)	O
and	O
MCD	O
patients	O
(1.69-fold;	O
P = 0.042)	O

Almost	O
all	O
metabolomics	O
studies	O
concerning	O
CHD	O
thus	O
far	O
have	O
mentioned	O
acylcarnitines.	B

Hb	O
adduct	O
formation	O
for	O
many	O
aromatic	O
amines	O
occurs	O
as	O
a	O
sulfinamide	B
linkage	O
formed	O
by	O
reaction	O
of	O
the	O
arylnitroso	B
intermediates	O
with	O
the	O
β-Cys	B
chain	O
of	O
Hb._−	O
These	O
adducts	O
undergo	O
hydrolysis	O
with	O
base	O
or	O
acid	O
in	O
vitro,	O
and	O
the	O
liberated	O
amines	O
can	O
be	O
assayed	O
by	O
GC	O
methods.	O

For	O
quality	O
control,	O
a	O
mixture	O
of	O
four	O
standard	O
compounds	O
(acetaminophen,	O
sulfadimethoxine,	B
terfenadine,	B
and	O
reserpine)	O
was	O
injected	O
every	O
ten	O
samples.	O

Pharmacokinetic	O
and	O
metabolic	O
parameters	O
of	O
fentanyl	O
and	O
midazolam	B
presented	O
as	O
mean ± SD.	O
_	O

However,	O
only	O
glycerolphosphocholine	B
(GPC)	O
was	O
elevated	O
in	O
COPD	O
patients.	O

The	O
methionine	B
metabolites	O
further	O
supplemented	O
known	O
clinical	O
variables	O
to	O
provide	O
superior	O
sensitivity	O
and	O
specificity	O
in	O
multivariable	O
prediction	O
models	O
for	O
rapid	O
biochemical	O
recurrence	O
following	O
prostatectomy.	O

SAM	O
and	O
methionine	B
were	O
intermediate	O
metabolites	O
in	O
one-carbon	O
metabolites	O
starting	O
from	O
choline.	B

N-acetylneuraminic	B
acid-9-phosphate	I
is	O
involved	O
in	O
the	O
metabolism	O
of	O
amino	B
sugars	O
and	O
it	O
is	O
a	O
condensation	O
of	O
N-acetylmannosamine	B
and	O
phosphoenolpyruvate	B
catalyzed	O
by	O
N-acetylneuraminic	B
acid-9-phosphate	I
synthase.	O

In	O
the	O
negative	O
ion	O
mode,	O
signals	O
were	O
also	O
acquired	O
with	O
auto-calibration,	O
using	O
standard	O
solutions	O
of	O
2-hydroxybenzoic	B
acid	I
and	O
trioxymethylanthraquinone,	B
which	O
were	O
introduced	O
by	O
post-column	O
mixing	O
at	O
concentrations	O
of	O
2	O
ng/μl	O
and	O
a	O
flow	O
rate	O
of	O
10	O
μl/min,	O
generating	O
[M-H]_−	O
ions	O
of	O
m	O
/z	O
137.0244	O
and	O
m	O
/z	O
269.0455.	O

As	O
previously	O
described,	O
we	O
used	O
targeted,	O
quantitative	O
tandem	O
flow	O
injection	O
mass	O
spectrometry	O
(MS/MS)	O
to	O
determine	O
levels	O
of	O
60	O
metabolites	O
(45	O
acylcarnitines	B
and	O
15	O
amino	B
acids)	O
and	O
standard	O
assays	O
for	O
measurement	O
of	O
ketones,	B
β-hydroxybutyrate,	B
and	O
non-esterified	O
fatty	O
acids._,	O
For	O
MS/MS	O
analyses,	O
plasma	O
samples	O
were	O
spiked	O
with	O
a	O
cocktail	O
of	O
heavy-isotope	O
internal	O
standards	O
(Cambridge	O
Isotope	O
Laboratories,	O
MA,	O
USA;	O
CDN	O
Isotopes,	O
Canada)	O
and	O
deproteinated	O
with	O
methanol.	B

The	O
goal	O
of	O
this	O
North	O
Carolina-based	O
cross-sectional	O
study	O
was	O
to	O
explore	O
if	O
the	O
programming	O
fidelity	O
of	O
the	O
sperm	O
DNA	O
methylation	O
was	O
adversely	O
affected	O
by	O
exposure	O
to	O
environmental	O
factors,	O
including	O
indoor	O
toxins	B
but	O
also	O
factors	O
such	O
as	O
being	O
overweight	O
or	O
obese.	O

RQ	O
values	O
corresponding	O
to	O
EC_50	O
(50_th	O
percentile	O
value)	O
on	O
each	O
of	O
the	O
curves	O
were	O
obtained	O
and	O
the	O
difference	O
between	O
this	O
RQ	O
value	O
assessed	O
during	O
the	O
clamp	O
and	O
fasting,	O
respectively,	O
was	O
used	O
as	O
a	O
marker	O
of	O
metabolic	O
flexibility	O
to	O
glucose	B
(PRCF	O
curve	O
shift;	O
Placebo,	O
0.04;	O
Pio,	O
0.06;	O
Omega-3,	B
0.06;	O
Pio&	O
Omega-3,	B
0.07)	O

Significantly	O
elevated	O
levels	O
of	O
2-hydroxybutyrate,	B
2-oxobutyrate,	B
and	O
2-aminobutyrate	B
were	O
observed	O
in	O
our	O
study.	O

Moreover,	O
in	O
most	O
cases	O
is	O
positively	O
correlated	O
with	O
its	O
precursor	O
3-hydroxybutyrate	B
(except	O
tissue	O
TC	O
vs	O
HC).	O

Plasma	O
malondialdehyde	B
(MDA;	O
intra-Coefficients	O
of	O
Variance	O
(CV):	O
13.1%;	O
inter-CV:	O
5.2%)	O
levels	O
were	O
determined	O
by	O
HPLC	O
fluorescence	O
(emission	O
=	O
515	O
nm,	O
excitation	O
=	O
553	O
nm;	O
SHISEIDO,	O
Tokyo,	O
Japan)	O
with	O
a	O
Capcell	O
Pak	O
C18	O
column	O
(UG120	O
type,	O
5	O
μm	O
×	O
4.6	O
mm	O
×	O
150	O
mm,	O
Shiseido).	O

The	O
extracted	O
ion	O
chromatograms	O
for	O
a	O
few	O
typical	O
carboxylic	B
acids	I
detected	O
in	O
serum	O
with	O
_15	O
N-cholamine	B
tag	O
are	O
shown	O
in	O
the	O
.	O

From	O
lysoPC	O
species,	O
lysophosphatidic	B
acids	I
(LPAs)	O
are	O
generated	O
by	O
enzymes,	O
autotaxin	B
(ATX)	O
which	O
has	O
lysophospholipase	O
D	O
activity.	O

Disruptions	O
in	O
tryptophan	B
metabolism	O
have	O
been	O
associated	O
with	O
various	O
neurological	O
and	O
psychological	O
disorders.	O

Hypotaurine	B
is	O
considered	O
to	O
play	O
a	O
protective	O
role	O
for	O
scavenging	O
free	O
radicals	O
caused	O
by	O
oxygen	O
and	O
biological	O
antioxidants.	O

At	O
present,	O
we	O
are	O
unable	O
to	O
explain	O
the	O
underlying	O
mechanism	O
for	O
the	O
change	O
in	O
hypoxanthine,	B
but	O
one	O
possibility	O
may	O
be	O
found	O
in	O
alterations	O
of	O
purine	B
metabolism	O
that	O
occur	O
during	O
tumor	O
development.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
pyruvic	B
acid,	I
phenylalanine,	B
proline,	B
alanine,	B
threonine,	B
and	O
3-hydroxybutyric	B
acid	I
between	O
groups.	O

Lyso-PC18:2	B
was	O
almost	O
as	O
abundant	O
as	O
Lyso-PC	B
16:0	I
and	O
was	O
elevated	O
by	O
1.75	O
fold.	O

The	O
higher	O
levels	O
of	O
hFA-sphingolipids	B
indicate	O
a	O
higher	O
expression	O
level	O
of	O
fatty	O
acid	O
2-hydroxylase,	O
which	O
may	O
affect	O
cancer	O
cell	O
growth	O
in	O
breast	O
cancer	O
patients.	O

Blocking	O
the	O
interaction	O
between	O
AHR	O
and	O
kynurenine	B
with	O
CH223191	O
reduced	O
the	O
proliferation	O
of	O
colon	O
cancer	O
cells.	O

Our	O
data	O
suggests	O
that	O
statins	B
significantly	O
lowered	O
levels	O
of	O
both	O
SM	O
and	O
ceramides	B
in	O
both	O
AD	O
and	O
controls.	O

Lysine	B
is	O
an	O
essential	O
amino	O
acid	O
converted	O
to	O
acetyl	O
CoA	O
and	O
a	O
precursor	O
of	O
carnitine,	B
which	O
contributes	O
to	O
the	O
transportation	O
of	O
long-chain	O
fatty	O
acids	O
into	O
the	O
mitochondria.	O

Therefore,	O
in	O
clinic,	O
we	O
not	O
only	O
need	O
to	O
control	O
fasting	O
blood-glucose,	B
blood	O
pressure,	O
blood	O
lipid	O
levels	O
and	O
obesity,	O
but	O
also	O
should	O
pay	O
attention	O
to	O
the	O
risk	O
factor	O
of	O
hyperuricemia	O
and	O
give	O
relative	O
intervention	O
measures	O
in	O
a	O
timely	O
fashion.	O

The	O
serum	O
concentration	O
of	O
sphinganine	B
in	O
severe	O
CAP	O
patients	O
is	O
higher	O
than	O
that	O
in	O
non-severe	O
CAP	O
patients,	O
and	O
lower	O
than	O
controls,	O
but	O
the	O
AUC	O
to	O
distinguish	O
between	O
non-severe	O
CAP	O
and	O
severe	O
CAP	O
was	O
0.821	O
and	O
it	O
correlated	O
positively	O
with	O
CURB-65,	O
PSI	O
and	O
APACHE	O
II	O
scores.	O

The	O
raw	O
abundances	O
(peak	O
areas)	O
were	O
normalised	O
by	O
dividing	O
each	O
peak	O
area	O
by	O
the	O
raw	O
abundance	O
of	O
the	O
corresponding	O
internal	O
standard	O
for	O
that	O
lipid	O
class	O
e.g.	O
all	O
ceramides	B
were	O
normalised	O
using	O
Cer(d18:1/12:0).	B

LC-grade	O
acetonitrile	B
and	O
methanol	B
were	O
obtained	O
from	O
Merck	O
(LiChrosolv_®	O
,	O
Darmstadt,	O
Germany).	O

It	O
should	O
also	O
be	O
noted	O
that	O
many	O
studies	O
have	O
used	O
plasma	O
levels	O
and	O
urinary	O
levels	O
of	O
F2-isoprostanes	B
interchangeably	O
as	O
biomarkers	O
of	O
oxidative	O
status,	O
despite	O
evidence	O
that	O
they	O
may	O
differ.	O

As	O
indicated	O
in	O
,	O
the	O
assay	O
is	O
more	O
sensitive	O
for	O
the	O
neurotransmitter	O
DA,	O
detecting	O
reproducibly	O
down	O
to	O
25	O
ng/mL,	O
which	O
translates	O
to	O
0.625	O
ng	O
of	O
material	O
on	O
column	O
of	O
which	O
0.13	O
and	O
500	O
pg	B
are	O
delivered	O
to	O
the	O
MS	O
and	O
EC-array,	O
respectively.	O

The	O
derivatization	O
procedure	O
was	O
repeated	O
with	O
the	O
addition	O
of	O
50	O
μl	O
ethyl	B
chloroformate	I
into	O
the	O
aforementioned	O
products.	O

As	O
in	O
serum	O
from	O
UC	O
patients,	O
significant	O
increases	O
were	O
measured	O
for	O
mannose,	B
formate,	B
3-methyl-2-oxovalerate,	B
2-hydroxybutyrate,	B
creatine,	B
isoleucine,	B
and	O
lysine,	B
while	O
urea,	B
tau-methylhistidine,	B
valine,	B
tyrosine,	B
choline	B
and	O
creatinine	B
were	O
decreased	O
in	O
both	O
serum	O
and	O
plasma	O
as	O
compared	O
to	O
control	O
subjects.	O

(E)	O
PAF	B
16:1p	I
levels	O
were	O
increased	O
in	O
FTD.	O

((1R	O
,2R	I
,3R	I
,4R	I
,5R	I
,6R	I
)-Cyclohexane-1,2,3,4,5,6-hexol),	I
based	O
on	O
the	O
spectral	O
data	O
of	O
the	O
compound	O
at	O
(δ_1	O
H,	O
δ_13	O
C)	O
=	O
(3.332,	O
76.298)	O
ppm	O
in	O
BioMagResBank.	O

Taurochenodeoxycholate	B
(TCDCA),	O
taurocholate	B
(TCA),	O
glycohyocholate	B
(GHCA)	O
and	O
glycocholate	B
(GCA)	O
were	O
17.8-,	O
15-,	O
6.6-	O
and	O
4-fold	O
upregulated	O
in	O
DC	O
vs.	O
NHC	O
respectively.	O

Furthermore,	O
several	O
Krebs	O
cycle	O
intermediates	O
such	O
as	O
citrate,	B
succinate,	B
and	O
formate	B
were	O
less	O
concentrated	O
in	O
patients	O
with	O
disease	O
suggesting	O
a	O
suppressed	O
Krebs	O
cycle.	O

For	O
example,	O
lower	O
circulating	O
concentrations	O
of	O
the	O
PC(O	B
-36:4)	I
were	O
associated	O
with	O
greater	O
depressive	O
symptom	O
severity	O
in	O
a	O
community-based	O
cohort	O
study.	O

All	O
other	O
steroids	O
were	O
extracted	O
from	O
400	O
μL	O
serum	O
using	O
2	O
mL	O
methyl	B
tert	I
-butyl	I
ether	I
as	O
previously	O
described.	O

EMPA,	O
ethyl-D_5	B
;	O
IMPA,	O
isopropyl-_13	B
C_3	O
;	O
PMPA,	O
trimethylpropyl-_13	B
C_6	O
;	O
CMPA,	O
cyclohexyl-_13	O
C_6	O
;	O
IMPA,	O
methylphosphonyl-_13	B
C.	O

Additionally,	O
“pyruvate + oxaloacetic	B
acid”	O
represents	O
the	O
combined	O
signal	O
from	O
both	O
metabolites,	O
which	O
cannot	O
be	O
discriminated	O
using	O
the	O
technology	O
in	O
this	O
present	O
study.	O

The	O
circulating	O
glucose	B
is	O
filtrated	O
by	O
the	O
glomerulus	O
and	O
absorbed	O
by	O
the	O
renal	O
tubules.	O

Using	O
mediation	O
analysis,	O
we	O
found	O
that	O
25%	O
of	O
the	O
association	O
between	O
soy	O
consumption	O
and	O
higher	O
lung	O
cancer	O
risk	O
was	O
significantly	O
mediated	O
via	O
5-methyl-2-furoic	B
acid.	I

[25(OH)D],	O
1,25-dihydroxyvitamin	B
D,	I
and	O
24,25-dihydroxyvitamin	B
D	I
by	O
mass	O
spectrometry	O
at	O
the	O
end	O
of	O
the	O
DCCT.	O

Among	O
the	O
increased	O
annotated	O
metabolites,	O
sorbitol	B
was	O
augmented	O
more	O
than	O
3-fold	O
in	O
WD.	O

Glycerophospholipids	B
in	O
mock-infected	O
vs.	O
HCMV-infected	O
fibroblasts.	O

In	O
the	O
metabolomic	O
analysis,	O
hsa-miR-122-5p	O
levels	O
were	O
found	O
to	O
independently	O
predict	O
apoB,	O
small	O
VLD,	O
IDL,	O
and	O
large	O
LDL	O
component	O
levels,	O
while	O
hsa-miR-885-5p	O
levels	O
were	O
inversely	O
associated	O
with	O
very	O
large	O
HDL	O
total	O
lipid,	O
phospholipid	B
and	O
cholesterol	B
content.	O

A	O
decrease	O
in	O
serine	B
and	O
threonine	B
content	O
of	O
the	O
cartilage	O
proteoglycan	B
in	O
antigen-induced	O
arthritis	O
of	O
rabbit,	O
supporting	O
our	O
findings	O
showing	O
the	O
decreased	O
levels	O
of	O
isovalerylsarcosine	O
in	O
AOSD	O
patients	O
with	O
chronic	O
articular	O
pattern	O
of	O
disease	O
outcome.	O

The	O
amount	O
of	O
glucose	B
remaining	O
in	O
the	O
medium	O
and	O
the	O
amounts	O
of	O
lactate	B
and	O
Ala	O
that	O
were	O
secreted	O
by	O
the	O
cells	O
are	O
readily	O
measured	O
by	O
_1	O
H	O
NMR	O
and/or	O
GC-MS.	O

Previous	O
work	O
exploring	O
the	O
role	O
of	O
metformin	B
in	O
reducing	O
MG	O
concentrations	O
identified	O
the	O
primary	O
product	O
of	O
the	O
metformin–MG	O
reaction	O
as	O
a	O
seven-membered,	O
triazepinone-based	O
structure.	O

An	O
analysis	O
of	O
each	O
individual	O
species	O
showed	O
that	O
97	O
TG	B
species	O
were	O
significantly	O
increased	O
in	O
bvFTD	O
compared	O
to	O
control	O
(Figure	O
A;	O
Table	O
),	O
whereas	O
only	O
10	O
TG	B
species	O
were	O
significantly	O
increased	O
in	O
AD	O
compared	O
to	O
control	O
(Figure	O
B;	O
Table	O
).	O

In	O
particular,	O
ion	O
number	O
3	O
with	O
[M−H]_−	O
 = 167.0202	O
m/z	O
,	O
retention	O
time	O
of	O
0.3179	O
min	O
was	O
verified	O
as	O
uric	B
acid,	I
which	O
as	O
mentioned	O
earlier	O
is	O
involved	O
in	O
the	O
purine	B
metabolism.	O

In	O
addition	O
to	O
measuring	O
α-HB	B
by	O
absolute	O
quantitation,	O
targeted	O
assays	O
were	O
also	O
developed	O
for	O
candidate	O
IR	O
biomarkers	O
identified	O
by	O
RF	O
and	O
correlation	O
analyses,	O
with	O
examples	O
of	O
representative	O
biochemical	O
classes	O
highlighted	O
in	O
.	O

In	O
much	O
of	O
the	O
literature,	O
this	O
compound	O
is	O
known	O
by	O
the	O
non-systematic	O
name	O
27-hydroxycholesterol	B
Sterol	I
metabolism	O
via	O
the	O
cholesterol	B
24S-	O
and	O
25-hydroxylase	O
pathways	O
in	O
CNS.	O

continuous	O
(0.25	O
μCi/min)]	O
to	O
quantitate	O
insulin-stimulated	O
glucose	B
disposal	O
and	O
measurement	O
of	O
muscle	O
fat	O
content	O
with	O
magnetic	O
resonance	O
spectroscopy	O
(n	O
=	O
7);	O
they	O
were	O
subsequently	O
treated	O
with	O
45	O
mg	O
pioglitazone	B
per	O
day	O
for	O
4	O
months,	O
and	O
the	O
insulin	O
clamp	O
and	O
magnetic	O
resonance	O
spectroscopy	O
studies	O
for	O
insulin	O
sensitivity	O
and	O
muscle	O
fat	O
content,	O
respectively,	O
were	O
repeated.	O

Standardized	O
β-estimates	B
from	O
linear	O
regression	O
analyses	O
with	O
the	O
amount	O
of	O
visceral	O
(VAT;	O
left	O
panel)	O
or	O
subcutaneous	O
(SAT;	O
right	O
panel)	O
adipose	O
tissue	O
as	O
exposure	O
and	O
plasma	O
metabolites	O
as	O
outcome	O
conducting	O
either	O
the	O
whole	O
population	O
(square),	O
only	O
men	O
(circle)	O
or	O
women	O
(diamond).	O

Immediately	O
post	O
PPCI	O
(Fig. ),	O
when	O
compared	O
to	O
pre	O
PPCI,	O
metabolic	O
pathways	O
for	O
valine,	B
leucine	B
and	O
isoleucine	B
biosynthesis,	O
vitamin	B
B6	I
metabolism	O
and	O
glutathione	B
metabolism	O
were	O
observed	O
to	O
have	O
significant	O
change.	O

Meanwhile,	O
for	O
myeloma	O
patients	O
we	O
have	O
observed	O
that	O
fumarate,	B
uridine,	B
and	O
S-adenosylmethioninamine	B
which	O
are	O
under	O
the	O
oxidative	O
phosphorylation	O
pathway,	O
pyrimidine	B
metabolism,	O
and	O
cysteine	B
and	O
methionine	B
metabolism	O
were	O
some	O
of	O
the	O
metabolites	O
potentially	O
affected	O
by	O
the	O
disease.	O

Hydrolysis	O
of	O
S-adenosylhomocysteine	B
by	O
S-adenosylhomocysteine	O
hydrolase	O
(SAH)	O
leads	O
to	O
the	O
formation	O
of	O
homocysteine	B
and	O
adenosine.	B

As	O
expected,	O
the	O
advanced	O
atherosclerosis	O
cohort	O
(n=100)	O
had	O
a	O
greater	O
prevalence	O
of	O
diabetes,	O
hypertension,	O
smoking,	O
and	O
history	O
of	O
MI	O
and	O
stroke;	O
lower	O
high	O
density	O
lipoprotein	O
(HDL)	O
cholesterol;	B
more	O
frequent	O
use	O
of	O
statins;	B
and	O
worse	O
median	O
lowest	O
ABI	O
than	O
the	O
control	O
cohort	O
(n=22).	O

,	O
(2015)	O
have	O
also	O
reported	O
increased	O
levels	O
of	O
glycine,	B
stearic	B
acid,	I
oleic	B
acid	I
and	O
cholesterol,	B
in	O
a	O
study	O
performed	O
by	O
LC/MS	O
and	O
GC/MS,	O
when	O
comparing	O
the	O
urinary	O
metabolomic	O
profiles	O
of	O
CHB	O
patients	O
and	O
control	O
groups.	O

These	O
compounds	O
were	O
involved	O
in	O
various	O
pathways,	O
such	O
as	O
purine	B
metabolism,	O
oxidative	O
phosphorylation,	O
glycerolipid	B
metabolism,	O
and	O
fatty	O
acid	O
biosynthesis.	O

12-HpETE,	B
15-HpETE,	B
9-HpODE,	O
13-HpODE,	B
and	O
PGF_3α	O
need	O
to	O
be	O
noted	O
(Electronic	O
Supplementary	O
Material	O
Table	O
S-3).	O

Unfortunately,	O
we	O
do	O
not	O
have	O
data	O
on	O
s-adenosyl-methionine	B
and	O
SAH	O
in	O
nephrosclerosis,	O
and	O
the	O
interpretation	O
of	O
the	O
related	O
epigenome	O
literature	O
is	O
also	O
difficult.	O

Exclusion	O
criteria	O
for	O
all	O
participants	O
included	O
use	O
of	O
antibiotics	O
within	O
two	O
months	O
of	O
study	O
participation,	O
and	O
regular	O
use	O
of	O
NSAIDS,	O
statins,	B
or	O
probiotics.	O

Covariance	O
simultaneous	O
component	O
analysis	O
(COVSCA)	O
is	O
a	O
recently	O
introduced	O
model	O
to	O
analyze	O
communalities	O
and	O
differences	O
across	O
a	O
set	O
of	O
(k	O
=	O
1,2,...,	B
K	O
)	O
covariance	O
matrices	O
simultaneously.	O

The	O
increase	O
of	O
oxidative	O
stress	O
(Reactive	O
Oxygen	O
Species	O
production)	O
leads	O
the	O
cells	O
towards	O
the	O
glycolytic	B
way	O
with	O
lactate	B
production	O
and	O
the	O
two	O
effects	O
seem	O
to	O
be	O
strongly	O
linked	O
and	O
coexist.	O

Its	O
high	O
level	O
and	O
lipid	O
and	O
glycerol	B
low	O
levels	O
may	O
suggest	O
that	O
the	O
cancer	O
cells	O
enhanced	O
fatty	O
acid	O
β	O
-oxidation	O
to	O
support	O
the	O
energy	O
demand	O
of	O
cancer	O
cell	O
proliferation.	O

Stock	O
solutions	O
of	O
EMs	O
and	O
SI-EMs	O
were	O
each	O
prepared	O
at	O
80	O
μg/ml	O
by	O
dissolving	O
2	O
mg	O
of	O
the	O
estrogen	B
powders	O
in	O
methanol	B
with	O
0.1%	O
L-ascorbic	B
acid	I
to	O
a	O
final	O
volume	O
of	O
25	O
ml	O
in	O
a	O
volumetric	O
flask.	O

TDO2,	O
breast	O
cancer,	O
kynurenine,	B
T	O
cell,	O
immunotherapy	O

Interestingly,	O
fatigue	O
correlated	O
weakly	O
with	O
measures	O
of	O
enhanced	O
tryptophan	B
metabolism,	O
while	O
depression	O
did	O
not.	O

HILIC	O
Comparison	O
of	O
molecular	O
features	O
detected	O
by	O
LC-TOF	O
on	O
HILIC	O
when	O
methanol	B
(MeOH)	O
or	O
methanol-ethanol	B
(MeOH-EtOH)	O
precipitation	O
methods	O
were	O
used.	O

Reductions	O
in	O
lactate	B
and	O
alanine	B
suggest	O
a	O
gluconeogenic	B
shift	O
in	O
the	O
provision	O
of	O
circulating	O
glucose,	B
but	O
they	O
are	O
not	O
conclusive	O
due	O
to	O
the	O
inability	O
to	O
assess	O
glucose	B
kinetics	O
in	O
this	O
environmental	O
setting.	O

Fasting	O
plasma	O
lipids	O
[total	O
cholesterol,	B
triglyceride,	B
high-density	O
lipoprotein	O
(HDL)	O
cholesterol,	B
and	O
low-density	O
lipoprotein	O
(LDL)	O
cholesterol]	B
were	O
measured	O
monthly.	O

The	O
amino	O
acids	O
serine,	O
glycine	B
and	O
alanine	B
can	O
either	O
originate	O
from	O
starch	O
via	O
glycolysis	O
or	O
from	O
protein	O
hydrolysis,	O
both	O
pathways	O
will	O
result	O
in	O
identical	O
isotopologues.	O

In	O
contrast	O
to	O
that,	O
in	O
16HBE14o_−	O
cells,	O
intracellular	O
NTPs	O
and	O
NDPs	O
were	O
already	O
reduced	O
after	O
30	O
min	O
of	O
rHla	O
addition	O
to	O
35%	O
of	O
the	O
corresponding	O
control	O
for	O
ATP,	B
53%	O
for	O
GTP,	O
26%	O
for	O
UTP	O
and	O
30%	O
for	O
CTP.	B

Visual	O
examination	O
of	O
these	O
selected	O
spectra	O
confirmed	O
that	O
100	O
of	O
the	O
104	O
spectra	O
contained	O
ibuprofen	B
metabolites	O
(from	O
here	O
on,	O
these	O
100	O
spectra	O
are	O
referred	O
to	O
as	O
‘I’	O
class).	O

This	O
discovery	O
is	O
significant	O
due	O
to	O
the	O
importance	O
of	O
the	O
accurate	O
quantitation	O
of	O
blood	O
metabolites,	O
especially,	O
the	O
growing	O
need	O
to	O
understand	O
the	O
key	O
roles	O
of	O
glutamine	B
metabolism	O
in	O
health	O
and	O
numerous	O
diseases.	O

Lipid	O
peroxidation	O
injury	O
is	O
considered	O
to	O
be	O
the	O
reason	O
for	O
increased	O
concentration	O
in	O
serum	O
uric	B
acid	I
related	O
to	O
the	O
pathogenesis	O
of	O
NAFLD	O

The	O
pyruvate	B
metabolism	O
and	O
glycerolipid	B
metabolism	O
were	O
activated	B
in	O
colorectal	O
polyps.	O

(B)	O
Glucocorticoid	B
metabolites	O
in	O
order	O
of	O
increasing	O
amounts	O
of	O
cortisol	B
excretion.	O

A	O
total	O
of	O
2	O
volatile	O
metabolites	O
(2-methylbutanal	O
and	O
decanoic	O
acid)	O
were	O
able	O
to	O
distinguish	O
the	O
patients	O
with	O
CD20_−	O
B-NHL	O
and	O
CD20_+	O
B-NHL	O
with	O
significantly	O
higher	O
concentration	O
levels	O
in	O
patients	O
with	O
CD20_−	O
B-NHL.	O

As	O
compared	O
to	O
controls,	O
IBS	O
patients	O
had	O
higher	O
citrulline	B
and	O
DMA	B
and	O
lower	O
SDMA	O
concentrations.	O

The	O
first	O
three	O
of	O
these	O
are	O
expected	O
to	O
be	O
elevated	O
in	O
diabetics	O
while	O
cholesterol	B
is	O
usually	O
lower	O
than	O
controls	O
due	O
to	O
statin	B
therapy.	O

IS	O
induces	O
free	O
radicals	O
in	O
vascular	O
smooth	O
muscle	O
cells	O
and	O
vascular	O
endothelial	O
cells,	O
inhibits	O
viability	O
and	O
nitric	B
oxide	I
production	O
of	O
vascular	O
endothelial	O
cells,	O
and	O
promotes	O
aortic	O
calcification	O
and	O
aortic	O
wall	O
thickening	O
in	O
hypertensive	O
rats.	O

Further	O
study	O
of	O
estrogen	B
metabolism	O
and	O
EM	O
phenotypes	O
in	O
relation	O
to	O
cancer	O
risk	O
will	O
provide	O
more	O
information	O
about	O
the	O
mechanisms	O
by	O
which	O
soy	O
can	O
modify	O
breast	O
cancer	O
risk.	O

Oncometabolic	O
activities	O
of	O
2-hydroxyglutarate	B
have	O
recently	O
been	O
discovered:	O
2-hydroxyglutarate	B
can	O
promote	O
epigenetically	O
driven	O
carcinogenesis	O
by	O
directly	O
inhibiting	O
histone	O
lysine	O
demethylases	O
and	O
5-methylcytosine	O
hydroxylases.	O

Considering	O
the	O
higher	O
rates	O
of	O
glucose	B
uptake	O
and	O
lactate	B
secretion	O
in	O
16HBE14o_−	O
cells,	O
we	O
presume	O
that	O
the	O
glycolytic	B
flux	O
may	O
be	O
33%	O
higher	O
in	O
16HBE14o_−	O
than	O
in	O
S9	O
cells.	O

In	O
addition,	O
EDTA,	O
which	O
irreversibly	O
inhibits	O
human	O
PON1,	O
had	O
no	O
effect	O
on	O
BPHL	O
activity	O
at	O
a	O
concentration	O
of	O
10	O
mM.	O
Other	O
BPHL	O
substrates,	O
VC	O
and	O
L-proline	B
benzyl	I
ester,	I
the	O
latter	O
reported	O
to	O
be	O
the	O
best	O
substrate	O
for	O
human	O
valacyclovirase	O
,	O
inhibited	O
the	O
HCTLase	O
activity	O
of	O
BPHL.	O

This	O
observation	O
agrees	O
with	O
reports	O
in	O
the	O
literature	O
[,],	O
[,]	O
which	O
indicate	O
that	O
choline	B
and	O
tyrosine	B
concentrations	O
decreased	O
in	O
patient	O
with	O
osteoporosis.	O

Then,	O
retinal	B
inflammation	O
was	O
induced	O
by	O
the	O
method	O
of	O
Kapin	O
et	O
al.	O

With	O
regard	O
to	O
the	O
quantification	O
of	O
conjugated	O
androgens,	O
a	O
major	O
concern	O
during	O
the	O
development	O
of	O
this	O
method	O
was	O
that	O
the	O
levels	O
would	O
saturate	O
the	O
MS	O
detector,	O
as	O
baseline	O
levels	O
of	O
DHEA-S	B
are	O
at	O
least	O
three	O
orders	O
of	O
magnitude	O
higher	O
than	O
unconjugated	O
androgens.	O

While	O
many	O
lipid	O
species	O
were	O
found	O
to	O
increase	O
in	O
subjects	O
post	O
RYGB,	O
several	O
lipids	O
were	O
of	O
particular	O
interest,	O
namely	O
nervonic	B
acid	I
and	O
various	O
sphingosine	B
species	O
(3-O-methylsphingosine,	O
threo-sphingosine,	B
erythro-sphingosine,	B
and	O
5-O-methylsphingosine).	B

Tyrosine	B
is	O
also	O
one	O
predominant	O
amino	O
acid	O
in	O
casein.	B

The	O
concentrations	O
of	O
fourteen	O
analytes	O
in	O
polyamine	B
metabolite	O
profiles	O
in	O
lung	O
and	O
liver	O
cancer	O
patients,	O
including	O
1,3-diaminopropane,	B
putrescine,	B
cadaverine,	B
spermidine,	B
spermine,	B
agmatine,	B
N	B
-acetylputrescine,	I
N	B
-acetylspermine,	I
N	B
-acetylspermidine,	I
l-ornithine,	B
lysine,	B
l-arginine,	B
S	B
-adenosyl-l-methionine,	I
γ-aminobutyric	B
acid,	I
were	O
determined	O
by	O
UHPLC-MS/MS	O
detection.	O

Total	O
levels	O
of	O
Ceramides	B
in	O
human	O
cadaver	O
corneas	O
from	O
Healthy,	O
T1DM,	O
and	O
T2DM	O
donors.	O

Mediation	O
analysis	O
revealed	O
that	O
the	O
lipids	O
LysoPC(P-15:0),	B
PC(P-34:4),	B
and	O
PC(38:6)	B
may	O
mediate	O
the	O
effects	O
of	O
ascites	O
on	O
recurrence.	O

In	O
the	O
magnetic	O
beads	O
technology,	O
the	O
magnetic	O
or	O
paramagnetic	O
core	O
is	O
encapsulated	O
by	O
a	O
layer	O
of	O
silica,	B
which	O
will	O
bind	O
the	O
DNA,	O
followed	O
by	O
purification	O
employing	O
the	O
same	O
solvent	O
conditions	O
described	O
above.	O

Plasma	O
samples	O
were	O
prepared	O
from	O
blood	O
collected	O
into	O
10-mL	O
lithium	B
heparin	I
tubes.	O

However,	O
more	O
recently	O
Reemtsma	O
et	O
al.	O
reported	O
a	O
median	O
of	O
1300	O
pg	B
mL_−1	O
and	O
95%	O
percentile	O
of	O
28,600	O
pg	O
mL_−1	O
DPP	O
in	O
human	O
urine	O
in	O
Germany.	O

The	O
hypothesis	O
considers	O
the	O
facilitation	O
of	O
tumor	O
initiation	O
by	O
dysregulation	O
of	O
lipid	O
metabolism	O
and	O
the	O
increased	O
utilization	O
of	O
glucose	B
for	O
energy	O
as	O
the	O
hallmarks	O
of	O
many	O
proliferating	O
tumors.	O

It	O
is	O
interesting	O
that	O
methanol	B
was	O
highly	O
increased	O
in	O
both	O
UC	O
and	O
CD.	O

The	O
first	O
treatment	O
regimen	O
of	O
patients	O
in	O
the	O
PP	O
and	O
GP	B
groups	O
were	O
mainly	O
surgery	O
and	O
chemoradiotherapy,	O
and	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
2	O
groups.	O

Both	O
the	O
total	O
polyphenolic	O
levels	O
and	O
individual	O
catechin	B
contents	O
remained	O
unchanged	O
after	O
12	O
months	O
storage	O
at	O
5°C	O
in	O
the	O
dark	O
indicating	O
a	O
stable	O
protein	O
polyphenolic	O
matrix.	O

These	O
results,	O
combined	O
with	O
the	O
observed	O
higher	O
blood	O
triglyceride	B
levels,	O
suggest	O
that	O
impaired	O
lipid	O
metabolism	O
is	O
a	O
trait	O
that	O
is	O
shared	O
by	O
diseased	O
subjects	O
in	O
Clusters	O
2	O
and	O
4.	O

An	O
extraction	O
with	O
diethyl	B
ether	I
was	O
carried	O
out	O
(2	O
×	O
1	O
mL).	O

Serum	O
samples	O
from	O
the	O
same	O
patients	O
were	O
collected	O
in	O
10	O
mL	O
plain	O
glass	O
blood-tubes	O
(BD	O
Vacutainer_®	O
)	O
spun	O
down,	O
fractionated	O
and	O
frozen	O
in	O
2	O
mL	O
polypropylene	B
vials	O
(Sarstedt	O
AG	O
&	O
Co.)	O
at	O
−20	O
°C	O
within	O
45	O
min.	O

SIBO	O
was	O
increased	O
in	O
all	O
obese	O
children	O
(p	O
=	O
0.0022),	O
IP	B
preferentially	O
in	O
those	O
with	O
NAFLD	O
(p	O
=	O
0.0002).	O

For	O
example,	O
ω-oxidation	O
of	O
fatty	O
acids	O
is	O
known	O
to	O
occur	O
in	O
liver	O
microsomes	O
through	O
a	O
NADPH-	O
and	O
cytochrome	O
P450-dependent	O
process	O
by	O
which	O
the	O
omega	O
carbon	O
of	O
a	O
fatty	O
acid	O
is	O
oxidized	O
to	O
an	O
alcohol	O
then	O
to	O
a	O
carboxylic	B
acid,	I
thereby	O
generating	O
a	O
dicarboxylic	B
acid	I
(DCA).	O

Due	O
to	O
the	O
absence	O
of	O
a	O
certified	O
urine	O
or	O
serum	O
for	O
taurine	B
and	O
sulfate	B
concentration,	O
accuracy	O
was	O
assessed	O
by	O
spiking	O
a	O
series	O
of	O
eight	O
urine	O
and	O
serum	O
samples	O
with	O
two	O
different	O
levels	O
of	O
taurine	B
and	O
sulfate	B
and	O
by	O
determining	O
the	O
recovery	O
of	O
the	O
spiking	O
(Table	O
).	O

Our	O
main	O
finding	O
was	O
that	O
the	O
human	O
liver	O
tissue	O
can	O
execute	O
sulfation	O
of	O
morphine	B
both	O
at	O
position	O
3	O
and	O
6,	O
even	O
in	O
the	O
newborn	O
period.	O

The	O
time	O
course	O
(0–8	O
h)	O
of	O
plasma	O
concentrations	O
of	O
the	O
methadone	B
metabolite	O
EDDP	O
(mean	O
(s.d.))	O
in	O
seven	O
healthy	O
subjects	O
after	O
IV-rectal,	O
and	O
oral-rectal	O
administration	O
of	O
methadone-HCl	B
(5	O
mg	O
IV,	O
10	O
mg	O
rectally	O
(deuterated	O
methadone)	B
and	O
orally).	O

The	O
urinary	O
metabolite	O
3’-sialyllactose	B
showed	O
the	O
strongest	O
association	O
and	O
was	O
positively	O
related	O
to	O
all	O
investigated	O
traits.	O

The	O
internal	O
standards	O
of	O
known	O
concentration,	O
formate	B
and	O
deuterated	O
4,4-dimethyl-4-silapentane-1-sulfonic	B
acid	I
(DSS-d_6	O
;	O
IS-2,	O
Chenomx	O
Internal	O
Standard),	O
were	O
used	O
for	O
quantification	O
of	O
metabolites	O
for	O
serum	O
and	O
WB,	O
respectively.	O

Medium-chain	O
acylcarnitines	O
(C6-C12)	O
were	O
positively	O
associated	O
with	O
the	O
risk	O
of	O
PSA	O
progression	O
(p	O
 = 0.036,	O
median	O
cut-off)	O
while	O
long-chain	O
acylcarnitines	B
(C14-C16)	O
were	O
inversely	O
associated	O
with	O
local	O
(p	O
 = 0.034)	O
and	O
bone	O
progression	O
(p	O
 = 0.0033).	O

The	O
level	O
of	O
Amadori-phosphatidylethanolamine	B
products	O
is	O
higher	O
in	O
foods	O
with	O
high	O
lipid	O
and	O
sugar	O
concentrations	O
that	O
have	O
high	O
temperatures	O
in	O
processing.	O

Volunteers	O
who	O
failed	O
the	O
first-line	O
eradication	O
regimen	O
were	O
offered	O
second-line	O
eradication	O
therapy	O
with	O
a	O
2-week	O
twice	O
daily	O
regime	O
(amoxicillin	O
1,000	O
mg,	O
levofloxacin	B
500	O
mg	O
and	O
rabeprazole	B
20	O
mg)	O

(C)	O
Tandem	O
mass	O
spectra	O
from	O
one	O
of	O
these	O
missing	O
entries	O
(C_22	O
H_34	O
O_3	O
)	O
was	O
found	O
to	O
be	O
highly	O
similar	O
to	O
the	O
tandem	O
mass	O
spectra	O
for	O
10-HDoHE	B
with	O
both	O
sharing	O
common	O
fragments	O
(blue	O
arrows)	O
as	O
well	O
as	O
analogous	O
fragments	O
that	O
were	O
shifted	O
by	O
the	O
mass	O
of	O
two	O
hydrogens	O
(orange	O
arrows).	O

Alternatively,	O
they	O
may	O
reflect	O
a	O
feedback	O
response	O
to	O
the	O
high	O
fat	O
meal	O
in	O
hypertriglyceridemic	B
subjects	O
to	O
mitigate	O
inflammation.	O

Phosphatidylserine	B
species	O
that	O
were	O
significantly	O
altered	O
in	O
(A)	O
behavioral	O
variant	O
frontotemporal	O
dementia	O
(bvFTD)	O
and	O
(B)	O
Alzheimer’s	O
disease	O
(AD)	O
compared	O
to	O
control.	O

After	O
the	O
analysis	O
of	O
our	O
results	O
suggested	O
that	O
glucocorticoid	B
excess	O
represents	O
a	O
prevalent	O
and	O
highly	O
relevant	O
feature	O
in	O
primary	O
aldosteronism,	O
we	O
prospectively	O
assessed	O
the	O
pre-	O
and	O
postoperative	O
adrenal	O
function	O
in	O
a	O
confirmatory	O
cohort	O
of	O
46	O
consecutively	O
recruited	O
patients	O
with	O
unilateral	O
aldosterone-producing	O
adenoma.	O

As	O
a	O
supplement,	O
17	O
biomarkers	O
(shown	O
in	O
)	O
were	O
analyzed	O
by	O
KEGG	O
and	O
2	O
metabolic	O
pathways	O
were	O
identified,	O
including	O
glutathione	B
metabolism	O
(GM),	O
and	O
tricarboxylic	B
acid	I
cycle	O
(TCA).	O

Because	O
baseline	O
TAG	O
levels	O
were	O
different	O
between	O
progressors	O
and	O
nonprogressors,	O
the	O
glycerolipid	B
factors	O
and	O
their	O
upstream	O
regulators	O
(FFAs	O
and	O
ACs)	O
were	O
tested	O
for	O
their	O
correlation	O
with	O
corresponding	O
renal	O
tissue	O
transcripts.	O

Firstly,	O
most	O
gastric	O
cancer	O
cells	O
produce	O
energy	O
primarily	O
through	O
Valsalva	O
effect	O
instead	O
of	O
the	O
citric	B
acid	I
cycle	O
and	O
will	O
change	O
the	O
serum	O
levels	O
of	O
the	O
metabolites	O
of	O
the	O
citric	B
acid	I
cycles.	O

Portions	O
of	O
800	O
MHz	O
_1	O
H	O
NMR	O
spectra	O
of	O
human	O
whole	O
blood	O
and	O
blood	O
plasma	O
from	O
the	O
same	O
individual	O
obtained	O
after	O
extraction	O
using	O
methanol	B
and	O
chloroform	B
in	O
a	O
1:2:2	O
ratio	O
(v/v/v)	O
highlighting	O
detection	O
of	O
reduced	B
glutathione	I
(GSH)	O
and	O
oxidized	B
glutathione	I
(GSSG),	O
and	O
significantly	O
high	O
concentrations	O
for	O
certain	O
metabolites	O
such	O
as	O
aspartic	B
acid,	I
creatine,	B
choline,	B
acetylcarnite,	B
and	O
betaine	B
in	O
whole	O
blood	O
compared	O
to	O
blood	O
plasma.	O

It	O
is	O
known	O
that	O
mothers	O
can	O
become	O
hypoglycemic	B
even	O
though	O
their	O
gluconeogenesis	O
rates	O
are	O
increased.	O

The	O
decline	O
in	O
glucose	B
oxidation	O
during	O
ischemia	O
requires	O
the	O
rapid	O
acceleration	O
in	O
the	O
conversion	O
of	O
pyruvate	B
to	O
lactate	B
in	O
order	O
to	O
regenerate	O
NAD_+	O
under	O
oxygen	O
limiting	O
conditions,	O
which	O
is	O
required	O
to	O
sustain	O
glycolysis.	O

2HG	O
competitively	O
inhibits	O
the	O
normal	O
functions	O
of	O
α-KG	B
and	O
is	O
found	O
in	O
high	O
levels	O
in	O
several	O
cancers.	O

Aspartic	B
acid	I
is	O
involved	O
in	O
protein	O
synthesis	O
and	O
degradation	O
and	O
also	O
acts	O
in	O
transamination	O
reactions.	O

Our	O
findings	O
may	O
be	O
of	O
pathophysiological	O
relevance	O
since	O
lysophosphatidylcholines,	B
byproducts	O
of	O
phospholipase	O
A2-catalyzed	O
phospholipid	O
hydrolysis,	O
are	O
preferred	O
carriers	O
of	O
polyunsaturated	O
fatty	O
acids	O
across	O
the	O
blood-brain	O
barrier.	O

This	O
study	O
is	O
the	O
first	O
to	O
successfully	O
quantify	O
urinary	O
DIM,	O
a	O
biomarker	O
of	O
I3C	O
uptake,	O
after	O
feeding	O
Brassica	O
vegetables,	O
and	O
the	O
first	O
to	O
show	O
that	O
higher	O
glucobrassicin	B
exposure	O
from	O
food	O
consistently	O
results	O
in	O
higher	O
urinary	O
DIM	O
levels.	O

The	O
mammalian	O
target	O
of	O
rapamycin	B
complex	O
1	O
(mTORC1)	O
is	O
an	O
attractive	O
target	O
for	O
HER-2	O
positive	O
breast	O
cancer	O
therapy	O
because	O
of	O
its	O
key	O
role	O
in	O
protein	O
translation	O
regulation,	O
cell	O
growth	O
and	O
metabolism.	O

Two	O
groups	O
of	O
cardiovascular	O
disease	O
patients,	O
an	O
AF	B
group	O
(49	O
AF	B
patients)	O
and	O
a	O
non-AF	O
group	O
(116	O
non-AF	O
patients),	O
were	O
included	O
in	O
the	O
present	O
study.	O

The	O
FAHFA	O
fraction	O
was	O
redissolved	O
in	O
50	O
µL	O
methanol,	B
and	O
40	O
µL	O
was	O
injected	O
into	O
an	O
Agilent	O
1260	O
Infinity	O
high-performance	O
liquid	O
chromatograph	O
equipped	O
with	O
an	O
Agilent	O
G1311C	O
quaternary	O
pump	O
and	O
an	O
Agilent	O
G1329B	O
autosampler.	O

This	O
trend	O
of	O
increased	O
taurine	B
concentration	O
is	O
also	O
visible	O
in	O
a	O
plot	O
of	O
mean	O
taurine	B
concentrations	O
over	O
time.	O

Important	O
features	O
of	O
the	O
new	O
vitamin	B
D	I
chemotyping	O
assay	O
were:	O
(1	O
)	O
it	O
required	O
only	O
50 μL	O
of	O
human	O
serum	O
and	O
was	O
conducted	O
in	O
parallel	O
96-well	O
plate	O
format;	O
(2	O
)	O
metabolites	O
were	O
derivatised	O
for	O
enhanced	O
response.	O

The	O
BCAAs	O
leucine,	B
isoleucine	B
and	O
valine	B
were	O
inversely	O
associated	O
with	O
age,	O
HDL-cholesterol	B
and	O
NT-proBNP	O
but	O
were	O
positively	O
associated	O
with	O
CVD,	O
male	O
sex,	O
BMI,	O
triacylglycerols	B
and	O
HbA_1c	O
.	O

Four	O
milliliters	O
of	O
serum	O
from	O
patients	O
receiving	O
the	O
therapeutic	O
drug	O
sodium	B
phenyl	I
butyrate	I
was	O
precipitated	O
with	O
16	O
mL	O
of	O
ACN/0.4%	O
glacial	B
acetic	I
acid,	I
vortexed	O
for	O
20	O
s,	O
and	O
centrifuged	O
for	O
30	O
min/12000g	O
at	O
−2	O
°C.	O

Then	O
100	O
μM	O
palmitoyl-CoA	B
and	O
5	O
mM	O
L-carnitine	B
were	O
added	O
to	O
the	O
mixture.	O

A	O
20	O
µL	O
solution	O
of	O
0.4	O
M	O
ammonium	B
bicarbonate	O
(pH	O
7.5)	O
and	O
8	O
M	O
urea	B
was	O
added	O
to	O
the	O
dissolved	O
casein.	B

This	O
mass	O
corresponds	O
to	O
a	O
[M]_+	O
ion	O
with	O
elemental	O
composition	O
C_33	O
H_48	O
N_3	O
O_3	O
_+	O
,	O
which	O
prior	O
to	O
GP	B
tagging	O
fits	O
a	O
sterol	O
of	O
elemental	O
composition	O
C_26	O
H_40	O
O_3	O
.	O

Non-polar	O
metabolites	O
were	O
separated	O
on	O
an	O
Acquity	O
HSS	O
T3	O
column	O
(150	O
×	O
2.1	O
mm,	O
1.8	O
μm—Waters,	O
Milford,	O
MA,	O
USA)	O
at	O
45	O
°C	O
using	O
a	O
seventeen	O
minute	O
gradient	O
method	O
at	O
300	O
μl/min	O
(unless	O
where	O
noted)	O
and	O
mobile	O
phases	O
containing	O
IPA	O
(isopropanol,	O
A:	O
72:25	O
H_2	O
O:ACN	O
5	O
mM	O
NH_4	O
OAc,	O
B:	B
50:45:5	I
IPA:ACN:H_2	O
O	O
5	O
mM	O
NH_4	O
OAc)	O
for	O
negative	O
ion	O
mode.	O

Further,	O
a	O
marginal	O
improvement	O
in	O
metabolite	O
recovery	O
(average	O
concentration	O
3.9%)	O
could	O
be	O
observed	O
when	O
multiple	O
extractions	O
were	O
performed	O
using	O
methanol	B
solvent.	O

The	O
spray	O
voltage	O
was	O
2.2	O
kV,	B
capillary	O
temperature	O
was	O
200	O
°C,	O
and	O
the	O
tube	O
lens	O
was	O
100	O
V.	O

While	O
the	O
fish	O
oil	O
supplementation	O
increased	O
the	O
proportion	O
of	O
various	O
phospholipid	B
species,	O
previously	O
reported	O
reductions	O
in	O
total	O
triacylglycerides	B
(TAGs)	O
upon	O
fish	O
oil	O
intake	O
were	O
shown	O
to	O
be	O
driven	O
by	O
a	O
reduction	O
in	O
a	O
specific	O
subset	O
of	O
the	O
measured	O
TAGs.	O

In	O
one	O
case,	O
metabolite	O
associations	O
with	O
genetic	O
variants	O
at	O
the	O
SGPP1	O
locus	O
did	O
not	O
match	O
in	O
name	O
for	O
PC	O
aa	O
C28:1	B
(Biocrates)	O
and	O
1-stearoylglycerol	B
(Metabolon).	O

Although	O
proximal	O
tubular	O
cells	O
are	O
highly	O
oxygen	O
demanding	O
under	O
physiological	O
condition,	O
it	O
is	O
logical	O
to	O
expect	O
that	O
when	O
HK-2	O
cells	O
have	O
sufficient	O
glucose	B
in	O
their	O
environment,	O
they	O
use	O
the	O
glycolytic	B
pathway	O
for	O
energy	O
supply.	O

From	O
these	O
findings,	O
tumor	O
cells,	O
particularly	O
hypoxic	O
tumor	O
cells,	O
appear	O
to	O
predominantly	O
produce	O
and	O
release	O
lactic	B
acid.	I

We	O
found	O
11	O
metabolites	O
that	O
were	O
significantly	O
different	O
between	O
RSV	O
ARI,	O
HRV	O
ARI,	O
and	O
healthy	O
control	O
infant	O
groups:	O
1-methylnicotinamide,	B
4-deoxythreonic	B
acid,	I
citrate,	B
creatine,	B
hypoxanthine,	B
alanine,	B
succinate,	B
3-hydroxyisovalerate,	B
acetone,	B
valine,	B
and	O
2-aminobutyrate	B
(	O
and	O
).	O

Chemiluminescence	O
using	O
the	O
automated	O
Immulite	O
Analyzer	O
(Diagnostic	O
Products	O
Co,	O
Los	O
Angeles,	O
CA,	O
USA)	O
was	O
used	O
to	O
measure	O
serum	O
cortisol	B
levels.	O

For	O
further	O
elucidation	O
of	O
significantly	O
increased	O
and	O
decreased	O
thiols	B
in	O
cancer	O
(	O
and	O
),	O
3	O
compounds	O
(pantetheine,	O
HCys	O
and	O
γ-GluCys)	B
were	O
successfully	O
identified	O
by	O
comparing	O
to	O
the	O
standards;	O
and	O
2	O
compounds	O
(compound	O
11	O
and	O
12)	O
were	O
given	O
the	O
possible	O
structures	O
by	O
MS/MS	O
and	O
QTOF-MS	O
information.	O

The	O
mean	O
glucobrassicin	B
concentration	O
was	O
significantly	O
higher	O
in	O
Brussels	O
sprouts	O
than	O
in	O
cabbage	O
Abbreviations:	O
gfw	O
=	O
gram	O
food	O
weight	O

A	O
previous	O
nested	O
case-control	O
study	O
demonstrated	O
that	O
higher	O
concentrations	O
of	O
S1P	O
and	O
total	O
ceramide	B
in	O
plasma	O
were	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
lung	O
cancer.	O

However,	O
have	O
argued	O
that	O
the	O
levels	O
of	O
kynurenine	B
metabolites	O
in	O
the	O
plasma/serum	O
are	O
substantially	O
diluted	O
relative	O
to	O
the	O
extracellular	O
spaces	O
that	O
are	O
in	O
close	O
proximity	O
to	O
activated	B
macrophages	O
in	O
the	O
periphery,	O
and	O
microglia	O
and	O
astrocytes	O
in	O
the	O
CNS.	O

In	O
89%	O
of	O
samples,	O
levels	O
of	O
DPP	O
(non-normalized)	O
were	O
higher	O
than	O
those	O
of	O
BDCPP,	O
ranging	O
from	O
287	O
to	O
7443	O
pg	B
mL_−1	O
,	O
with	O
a	O
median	O
of	O
803	O
pg	B
mL_−1	O
.	O

PBMCs	O
were	O
isolated	O
from	O
peripheral	O
blood	O
(diluted	O
1.6	O
times	O
with	O
10%	O
phosphate	B
buffered	O
saline)	B
by	O
density	O
gradient	O
centrifugation	O
(800	O
×	O
g	O
for	O
25	O
min	O
at	O
room	O
temperature)	O
over	O
Isolymph	O
(specific	O
gravity	O
1.077)	O
(CT	O
Scientific	O
Supply	O
Corp.,	O
Deer	O
Park,	O
NY,	O
USA)	O
in	O
Leucosep	O
tubes	O
(Greiner	O
Bio-One,	O
Tokyo	O
Japan)	O
for	O
use	O
in	O
the	O
NK	O
cell	O
activity	O
assay.	O

Further	O
research	O
is	O
needed	O
to	O
understand	O
the	O
meaning	O
of	O
these	O
findings,	O
including	O
the	O
interplay	O
between	O
variation	O
in	O
endogenous	O
erythritol	B
synthesis	O
and	O
exogenous	O
exposure	O
to	O
erythritol-containing	O
foods.	O

The	O
absence	O
of	O
metabolites	O
such	O
as	O
trimethylamine	B
in	O
the	O
lyophilized	O
samples	O
was	O
potentially	O
due	O
to	O
chemical	O
degradation.	O

Gray	O
matter	O
volume	O
in	O
both	O
females	O
and	O
males	O
was	O
more	O
strongly	O
correlated	O
with	O
serum	O
24S	B
-hydroxycholesterol	I
levels,	O
whereas	O
the	O
association	O
with	O
white	O
matter	O
volume	O
was	O
weaker	O
than	O
that	O
for	O
gray	O
matter	O
but	O
statistically	O
significant.	O

Levels	O
of	O
ribavirin	B
in	O
PBMC	O
were	O
approximately	O
10-fold	O
lower.	O

These	O
altered	O
metabolites	O
clearly	O
revealed	O
dysregulation	O
of	O
multiple	O
metabolic	O
events,	O
including	O
aerobic	O
glycolysis	O
(Warburg	O
effect),	O
oxidative	O
phosphorylation	O
(Pasteur’s	O
effect),	O
energy	O
metabolism,	O
TCA	O
cycle	O
anaplerotic	O
flux,	O
hexosamine	B
pathway,	O
osmoregulatory,	O
and	O
antioxidant	O
mechanisms.	O

Increased	O
expression	O
of	O
the	O
proteins	O
containing	O
certain	O
forms	O
of	O
C-glycosylated	B
tryptophan	I
in	O
the	O
aortic	O
vessels	O
have	O
been	O
reported	O
in	O
the	O
diabetic	O
rats.	O

We	O
found	O
that	O
AD	O
patients	O
had	O
increased	O
levels	O
of	O
C14:1,	B
C15:1,	B
C16:1n7,	O
C20:1n9,	O
C22:1n9,	O
C18:3n3,	O
C18:3n6,	O
and	O
total	O
omega-6/	B
total	O
omega-3	B
ratio	O
while	O
they	O
had	O
lower	O
levels	O
of	O
total	O
omega-3	B
fatty	O
acids,	O
C12:0,	B
C17:0,	B
C18:0	B
in	O
a	O
statistically	O
significant	O
manner.	O

_†	O
Chronic	O
home	O
medication	O
or	O
within	O
24	O
hours	O
preceding	O
enrollment	O
(prior	O
to	O
T0	O
sample	O
collection)	O
except	O
for	O
warfarin,	O
statins,	B
ACE	O
Inhibitors	O
/	O
ARBs	O
and	O
beta	O
blockers	O
which	O
are	O
home	O
use	O
only.	O
_	O

In	O
blood,	O
the	O
upper	O
and	O
lower	O
reference	O
levels	O
for	O
lipid	O
content	O
are	O
well	O
described	O
for	O
only	O
a	O
few	O
lipids,	O
such	O
as	O
that	O
of	O
blood	O
cholesterol	B
and	O
triacylglycerol.	B

GP-tagged	O
7α-hydroxy-3-oxocholest-4-en-26-oic	B
acid	I
appears	O
as	O
syn	O
and	O
anti	O
conformers	O
in	O
RIC	O
(b	O
).	O

Furthermore,	O
there	O
was	O
<0.02	O
min	O
separation	O
between	O
the	O
deuterium	O
and	O
protium	O
forms	O
of	O
the	O
NNAL	O
propionate	B
derivatives,	O
which	O
would	O
minimize	O
any	O
differential	O
suppression	O
of	O
ionization	O
between	O
the	O
analyte	O
and	O
its	O
deuterated	O
internal	O
standard.	O

Glycolic	B
acid	I
decreased	O
significantly	O
(p<0.0005,	O
q<0.039),	O
and	O
this	O
decrease	O
was	O
correlated	O
in	O
the	O
full	O
range	O
group	O
with	O
a	O
decrease	O
in	O
hydroxylamine	B
(0.598,	O
p<.002)(not	O
shown).	O

A	O
recent	O
plasma	O
lipidomic	O
analysis	O
in	O
rat	O
and	O
mouse	O
models,	O
and	O
22	O
veterans	O
with	O
GWI	O
showed	O
elevations	O
in	O
phospholipids.	B

For	O
sphingolipids	B
in	O
particular	O
the	O
effect	O
was	O
dramatic:	O
of	O
a	O
total	O
of	O
300	O
sphingolipid	B
inter-laboratory	O
CVs	O
calculated,	O
270	O
CVs	O
were	O
>30%	O
before	O
normalisation	O
and	O
272	O
CVs	O
<20%	O
post	O
normalisation.	O

The	O
metabolites	O
that	O
lost	O
their	O
rhythmicity	O
on	O
day	O
2	O
(wake/wake;	O
n	O
=	O
31,	O
28%)	O
were	O
14	O
acylcarnitines,	B
13	O
glycerophospholipids,	B
one	O
sphingolipid	B
[SM	O
(OH)	O
C14:1],	B
hexose,	B
total	O
dimethylarginine,	B
and	O
taurine.	B

Further,	O
succinate	O
dehydrogenase	O
is	O
the	O
only	O
enzyme	O
shared	O
by	O
the	O
electron	O
transport	O
chain	O
and	O
the	O
TCA	O
cycle;	O
in	O
cardiac	O
myocytes,	O
this	O
link	O
between	O
substrate	O
utilization	O
and	O
the	O
electron	O
transport	O
chain	O
has	O
been	O
reinforced	O
by	O
experiments	O
showing	O
that	O
mitochondrial	O
rate	O
reserve	O
respiratory	O
capacity	O
(the	O
ability	O
of	O
mitochondria	O
to	O
increase	O
ATP	B
production	O
as	O
demand	O
increases)	O
was	O
abolished	O
by	O
the	O
absence	O
of	O
succinate	O
dehydrogenase	O
activity.	O

They	O
identified	O
three	O
discriminatory	O
metabolites,	O
2-hydroxyisobutyrate,	B
3-indoxylsulfate	B
and	O
alanine.	B

The	O
supernatant	O
was	O
mixed	O
with	O
500	O
μl	O
of	O
pure	O
water	O
and	O
250	O
μl	O
of	O
chloroform,	B
and	O
was	O
centrifuged	O
at	O
4,000	O
rpm	O
for	O
15	O
minutes.	O

For	O
both	O
abiraterone	B
as	O
D_4	B
-abiraterone	I
the	O
following	O
optimized	O
settings	O
on	O
the	O
mass	O
spectrometer	O
were	O
used	O
capillary	O
voltage	O
was	O
3.76	O
kV,	B
cone	O
voltage	O
was	O
47	O
V,	O
desolvation	O
temperature	O
was	O
550°	O
C	O
desolvation	O
gas	O
flow	O
was	O
1000L/h.	O
Colision	O
energy	O
was	O
46	O
V,	O
dwell	O
time	O
was	O
0,07	B
ms	I
and	O
typical	O
retention	O
time	O
for	O
abiraterone	B
was	O
4.69min	O
and	O
for	O
D_4	B
-abiraterone	I
4.64min.	O

The	O
purpose	O
of	O
this	O
testing	O
was	O
to	O
ensure	O
that	O
naturally	O
produced	O
glucuronide	B
and	O
sulfate	B
metabolites	O
did	O
not	O
interfere	O
in	O
the	O
method.	O

The	O
Direct	O
Flow	O
Infusion	O
(DFI)	O
MS/MS	O
targeted	O
analysis	O
using	O
the	O
Biocrates	O
AbsoluteIDQ	O
kit	O
provided	O
quantitative	O
results	O
for	O
139	O
metabolites	O
(24	O
acylcarnitines.	B

The	O
branched-chain	O
acylcarnitines	B
have	O
recently	O
been	O
shown	O
to	O
be	O
precursors	O
of	O
fatty	O
acid	O
synthesis	O
in	O
human	O
preadipocytes	O
(;	O
;	O
),	O
and	O
are	O
associated	O
with	O
growth	O
phenotypes	O
in	O
C.Elegans	O
,	O
but	O
have	O
not	O
previously	O
been	O
observed	O
in	O
cancer	O
cells.	O

As	O
a	O
consequence,	O
oxalate	B
and	O
glycolate	B
concentrations	O
present	O
in	O
these	O
pooled	O
plasma	O
samples	O
were	O
inbetween	O
the	O
concentration	O
ranges	O
for	O
healthy	O
volunteers	O
and	O
PH1	O
patients.	O

This	O
profile	O
was	O
characterized	O
by	O
higher	O
total	O
cholesterol,	B
triglyceride	B
and	O
ApoB	O
levels	O
and	O
lower	O
HDLc	O
levels	O
in	O
pre-symptomatic	O
individuals	O
compared	O
to	O
controls.	O

Dramatic	O
increases	O
in	O
plasma	O
triacylglyceride	B
levels	O
in	O
diabetic	O
monkeys	O
were	O
also	O
observed,	O
while	O
there	O
were	O
no	O
significant	O
changes	O
for	O
the	O
levels	O
of	O
cholesterol,	B
HDL-cholesterol	B
and	O
LDL-cholesterol.	B

(b)	O
3-hydroxykynurenine.	B

Methanol,	B
acetonitrile,	B
and	O
ammonium	B
hydroxide	I
were	O
purchased	O
from	O
Fisher	O
Scientific	O
(Pittsburgh,	O
PA,	O
USA),	O
and	O
formic	B
acid,	I
acetic	B
acid,	I
and	O
ammonium	B
acetate	I
were	O
purchased	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
MO,	O
USA).	O

When	O
overlaid	O
with	O
loadings	O
vectors,	O
the	O
scores	O
plot	O
of	O
the	O
first	O
two	O
PCs	O
revealed	O
two	O
patterns	O
of	O
metabolites	O
among	O
infectious	O
diseases,	O
one	O
characterized	O
by	O
higher	O
levels	O
of	O
ketone	B
bodies	O
and	O
the	O
other	O
by	O
higher	O
levels	O
of	O
pyruvate,	B
glutamate,	B
2-oxoglutarate,	B
carnitine,	B
and	O
glycine.	B

The	O
concentration	O
of	O
protein	O
in	O
the	O
vitreous	O
body	O
was	O
significantly	O
reduced	O
in	O
rabbits	O
that	O
had	O
received	O
a	O
subcutaneous	O
injection	O
of	O
indomethacin	B
(P	O
 = 0.0064,	O
Dunnett's	O
test,	O
one-side).	O

Assessment	O
of	O
individual	O
donor	O
responsiveness	O
to	O
the	O
respective	O
rinses	O
i.e.	O
which	O
rinse	O
provided	O
the	O
highest	O
intra-donor	O
levels	O
of	O
the	O
parent	O
anthocyanin	B
at	O
time	O
points	O
was	O
determined	O
by	O
the	O
Friedman	O
Two-Way	O
Analysis	O
of	O
Variance	O
by	O
Ranks.	O

NAD	B
is	O
one	O
of	O
the	O
cofactors	O
essential	O
for	O
redox	O
reactions.	O

Furthermore,	O
creatinine	B
and	O
betaine,	B
or	O
acetic	B
acid,	I
creatine	B
and	O
1-methylnicotinamide	B
were	O
related	O
to	O
TSH	O
levels	O
in	O
Inter99	O
or	O
Health2006/08,	O
respectively.	O

Thirty-six	O
of	O
62	O
of	O
the	O
metabolites	O
were	O
independent	O
of	O
these	O
measures	O
(P	O
<0.05;	O
Figure	O
A	O
and	O
Table	O
II	O
in	O
the	O
online-only	B
Data	O
Supplement),	O
and	O
network	O
analysis	O
indicated	O
2	O
main	O
clusters	O
with	O
hub	O
metabolites,	O
including	O
again,	O
among	O
others,	O
N2,N2-dimethylguanosine	B
(Figure	O
B).	O

For	O
lipidomic	O
analyses,	O
type	O
2	O
diabetes	O
patients	O
(n	O
 = 21)	O
and	O
individuals	O
treated	O
with	O
lipid‐lowering	O
medications	O
(statins	O
[n	O
 = 8]	O
or	O
ezetimibe	O
[n	O
 = 1])	O
were	O
excluded;	O
therefore,	O
findings	O
for	O
n	O
 = 51	O
are	O
reported.	O

The	O
150 μl	O
filtrate	O
was	O
lyophilized	O
and	O
dissolved	O
in	O
25 μl	O
of	O
Milli-Q	O
water	O
containing	O
a	O
reference	O
compound	O
(200 μM	O
of	O
3-aminopyrrolidine	B
and	O
trimesate)	O
prior	O
to	O
CE-time-of-flight	O
(TOF)-MS	O
analysis.	O

While	O
a	O
phenotyping	O
method	O
for	O
the	O
mercapturic	O
acids	O
resulting	O
from	O
detoxification	O
of	O
anti	O
-	O
PheDE	O
by	O
GSTs	O
would	O
likely	O
be	O
a	O
more	O
direct	O
way	O
of	O
assessing	O
this	O
detoxification	O
pathway	O
in	O
humans,	O
we	O
have	O
carried	O
out	O
our	O
initial	O
work	O
on	O
PheO-NAC	O
because	O
studies	O
in	O
laboratory	O
animals	O
indicated	O
that	O
this	O
mercapturic	B
acid	I
might	O
be	O
more	O
readily	O
detected.	O

LPC(17:0),	B
the	O
only	O
odd	O
chain	O
LPC	O
detected	O
in	O
our	O
study,	O
showed	O
different	O
behavior	O
than	O
other	O
LPCs,	O
with	O
non-significant	O
correlation	O
with	O
the	O
disease	O
and	O
negative	O
correlation	O
to	O
the	O
parasitaemia	O
values.	O

Normally,	O
glomerular	O
filtration	O
followed	O
by	O
reabsorption	O
and	O
hydrolysis	O
in	O
the	O
proximal	O
tubule	O
cells	O
allows	O
recovery	O
of	O
the	O
native	O
amino	B
acids[,	O
].	O

The	O
method	O
described	O
by	O
was	O
adopted	O
for	O
extraction	O
of	O
oxysterols	B
from	O
plasma.	O

The	O
chemical	O
structures	O
were	O
evident	O
by	O
their	O
spectra	O
of	O
infrared	O
ray	O
(IR),	O
liquid	O
chromatography-mass	O
spectrometry	O
(LC-MS),	O
_1	O
hydrogen-nuclear	B
magnetic	O
resonance	O
(_1	O
H-NMR),	O
_13	O
carbon	O
nuclear	O
magnetic	O
resonance	O
spectroscopy	O
(_13	O
C-NMR),	O
heteronuclear	O
multiple	O
quantum	O
coherence	O
(HMQC),	O
heteronuclear	O
multiple	O
bond	O
correlation	O
(HMBC),	O
and	O
heteronuclear	O
single	O
quantum	O
correlation	O
(HSQC),	O
and	O
compared	O
with	O
the	O
data	O
reported	O
in	O
the	O
published	O
paper,	O
which	O
were	O
consistent	O
with	O
the	O
structure,	O
being	O
6,7-furano-hydrocoumaric	B
acid	I
(P-1),	O
6,7-furano-hydrocoumaric	B
acid	I
methyl	I
ester	I
(P-2),	O
and	O
5,6-furano-hydrocoumaric	B
acid	I
(IP-1).	O

Glycine	B
is	O
a	O
precursor	O
substance	O
of	O
glutathione	B
in	O
GM.	O

 )	O
resulted	O
in	O
detection	O
of	O
a	O
group	O
of	O
the	O
distinct	O
outliers—they	O
are	O
mainly	O
due	O
to	O
the	O
ketone	B
bodies	O
(3HB,	O
Ace,	O
AceAce),	O
lactate	B
and	O
glucose.	B

Furan	B
is	O
a	O
rodent	O
hepatotoxicant	O
and	O
carcinogen.	O

For	O
TMAO	B
quantification,	O
before	O
the	O
analysis,	O
each	O
sample	O
was	O
added	O
with	O
TMAO-d9	O
as	O
internal	O
standard	O
and	O
then	O
extracted	O
with	O
acidified	O
acetonitrile,	B
as	O
previously	O
described.	O

Cotinine	B
is	O
divided	O
into	O
three	O
categories	O
corresponding	O
to	O
the	O
serum	O
level	O
in	O
non-smokers,	O
smokers	O
and	O
heavy	O
smokers.	O

The	O
defined	O
integration	O
regions	O
aim	O
to	O
capture	O
the	O
following	O
broad	O
lipid	O
resonances:	O
CH_3	O
–(CH_2	O
)_n	O
–in	O
the	O
fatty	O
acid	O
chain	O
(FAC),	O
–CH_3	O
–(CH_2	O
)_n	O
–in	O
the	O
FAC	O
(captured	O
using	O
two	O
integration	O
regions	O
in	O
the	O
900	O
MHz	O
analysis),	O
–CH_2	O
–CH_2	O
–C	O
=	O
O	O
or	O
–CH_2	O
–CH_2	O
–CH	O
=	O
CH–in	O
the	O
FAC,	O
–CH_2	O
–CH	O
=	O
CH–in	O
the	O
FAC	O
and	O
CH_3	O
in	O
N-acetylated	B
glycoproteins	I
(NAG),	O
–CH_2	O
–C	O
=	O
O	O
or	O
–CH_2	O
–CH	O
=	O
CH–in	O
FAC,	O
=	O
CH–CH_2	O
–CH	O
=	O
in	O
FAC,	O
lysyl,	O
and	O
–CH	O
=	O
CH–in	O
FAC.	O

Our	O
analysis	O
revealed	O
a	O
significant	O
reduction	O
of	O
alanine,	B
glutamine,	B
glutamate,	B
leucine,	B
lysine,	B
methionine,	B
tyrosine,	B
and	O
phenylalanine	B
in	O
T2DM	O
patients	O
with	O
respect	O
to	O
non-diabetic	O
subjects.	O

The	O
mixture	O
was	O
preincubated	O
with	O
alamethicin	B
(50	O
μg/mg	O
protein)	O
on	O
ice	O
for	O
15	O
min.	O

As	O
the	O
plasma	O
sample-to-solvent	O
ratio	O
decreased	O
from	O
1:4,	O
1:10,	O
1:20,	O
and	O
1:100	O
(v/v),	O
many	O
of	O
the	O
Cer,	B
LPC,	O
PC,	O
and	O
PE	O
lipid	O
species	O
increased	O
in	O
peak	O
area	O
for	O
the	O
Bligh-Dyer,	O
Folch,	O
and	O
Matyash	O
methods	O
as	O
shown	O
in	O
.	O

We	O
found	O
many	O
small	O
aromatic	O
components,	O
such	O
as	O
guajacol,	O
three	O
derivatives	O
of	O
hydroxyhippuric	B
acids,	I
pyrogallol	B
and	O
hydroquinone	B
lower	O
in	O
CRC	O
patients	O
prior	O
to	O
surgery	O
compared	O
to	O
post-surgery	O
timepoints.	O

It	O
is	O
a	O
byproduct	O
of	O
the	O
pathway	O
from	O
methionine	B
to	O
glutathione.	B

Taken	O
together,	O
our	O
data	O
suggest	O
that	O
enzymatic	O
downregulation	O
and	O
metabolite	O
deficiency	O
in	O
the	O
phenylalanine-tyrosine-dopamine	B
axis	O
is	O
found	O
in	O
early	O
hypertensive	O
nephrosclerosis.	O

Subsequent	O
concentration	O
and	O
reconstruction	O
were	O
performed	O
as	O
described	O
above	O
(b),	O
as	O
well	O
as	O
the	O
acidic/basic	O
SPE	O
except	O
for	O
adding	O
2.5	O
μL	O
of	O
formic	B
acid	I
for	O
acidic	O
SPE	O
and	O
20	O
μL	O
of	O
25	O
%	O
ammonium	B
hydroxide	I
for	O
basic	O
SPE	O
to	O
the	O
human	O
urine.	O

Representative	O
chromatogram	O
of	O
m/z	O
302.3042	O
in	O
a	O
biological	O
sample	O
(A)	O
and	O
sphinganine	B
standard	O
(B)	O
at	O
10.13 min.	O

We	O
found	O
significantly	O
increased	O
levels	O
of	O
methionine	B
sulfoxide,	I
decreased	O
levels	O
of	O
Met,	O
and	O
altered	O
Met/methionine	O
sulfoxide	I
ratio	O
in	O
samples	O
of	O
blood	O
plasma	O
collected	O
from	O
medication-free	O
MDD	O
patients.	O

Metabolic	O
alterations	O
have	O
long	O
been	O
associated	O
with	O
cancer	O
shifting	O
energy	O
production	O
toward	O
aerobic	O
glycolysis	O
and	O
generation	O
of	O
lactic	B
acid.	I

Accurate	O
mass	O
was	O
maintained	O
by	O
introduction	O
of	O
LockSpray	O
interface	O
of	O
sulfadimethoxine	B
(311.0814	O
[M+H]_+	O
or	O
309.0658	O
[M-H]_−	O
)	O
at	O
a	O
concentration	O
of	O
250	O
pgμL_−1	O
in	O
50%	O
aqueous	O
ACN	O
and	O
a	O
rate	O
of	O
150	O
μLmin_−1	O
.	O

Briefly,	O
the	O
cells	O
were	O
scraped	O
using	O
chilled	O
phosphate-buffered	B
saline	I
(PBS),	O
washed	O
3×	O
in	O
cold	O
PBS	O
buffer,	O
and	O
then	O
stored	O
in	O
−80	O
°C	O
prior	O
to	O
cell	O
extraction.	O

To	O
formally	O
assess	O
the	O
sensitivity	O
of	O
our	O
MWSL	O
estimates	O
to	O
distributional	O
features	O
of	O
the	O
outcome,	O
we	O
also	O
simulated	O
continuous	O
responses	O
from	O
gamma	O
and	O
several	O
Gaussian	O
distributions	O
and	O
compared	O
resulting	O
MWSL	O
estimates	O
to	O
those	O
obtained	O
using	O
measured	O
glucose	B
levels.	O

The	O
results	O
showed	O
that	O
all	O
of	O
the	O
four	O
PCOS	O
phenotypes	O
had	O
higher	O
levels	O
of	O
very	O
low-density	O
lipoprotein	O
(VLDL),	O
LDL,	O
fatty	O
acids,	O
unsaturated	O
fatty	O
acids	O
and	O
an	O
unidentified	O
sugar	O
(δ	O
3.74	O
ppm),	O
but	O
had	O
lower	O
levels	O
of	O
phosphatidylcholine	B
and	O
lysyl-albumin	B
as	O
compared	O
with	O
the	O
control	O
group,	O
respectively,	O
which	O
indicated	O
the	O
aberrance	O
of	O
lipid	O
metabolism	O
in	O
PCOS.	O

The	O
filtrates	O
were	O
then	O
transferred	O
to	O
clean	O
microcentrifuge	O
tubes	O
and	O
phosphate	B
buffer,	O
sodium	O
azide	O
and	O
D_2	O
O	O
were	O
added.	O

2-methylerythritol-4-phosphate	B
is	O
an	O
intermediate	O
in	O
isoprenoid	B
biosynthesis	O
and	O
has	O
been	O
found	O
to	O
be	O
quite	O
abundant	O
in	O
certain	O
plants	O
.	O

In	O
the	O
metastatic	O
cases	O
we	O
also	O
detected	O
a	O
remarkable	O
strong	O
and	O
significant	O
inverse	O
correlation	O
between	O
medium-chain	O
acylcarnitines	O
and	O
tryptophan	B
detected	O
in	O
positive	O
and	O
negative	O
ionization	O
mode	O
(this	O
effect	O
was	O
consistent	O
also	O
in	O
primary	O
cases).	O

While	O
ARG1-generated	O
ornithine	B
may	O
be	O
used	O
in	O
polyamine	B
synthesis,	O
ARG2-synthesized	O
ornithine	B
fuels	O
citrulline	B
or	O
proline	B
formation,	O
with	O
both	O
polyamines	B
and	O
proline	B
facilitating	O
tissue	O
regeneration	O
[,].	O

While	O
we	O
did	O
not	O
record	O
correlations	O
reaching	O
P	O
values	O
<	O
2	O
x	O
10_−5	O
,	O
we	O
observed	O
a	O
trend	O
for	O
higher	O
plasma	O
levels	O
of	O
a	O
number	O
of	O
aromatic	O
amino	O
acids	O
(including	O
phenylpyruvate,	B
phenylalanine	B
and	O
N-acetylphenylalanine)	B
to	O
predict	O
better	O
antihypertensive	O
responses	O
to	O
bisoprolol	O
(with	O
r	O
values	O
-0.48	O
to	O
-0.31,	O
and	O
P	O
values	O
0.002	O
to	O
0.06),	O
and	O
lower	O
levels	O
of	O
plasma	O
serotonin	B
and	O
phosphoethanolamine	B
to	O
predict	O
a	O
better	O
systolic	O
response	O
to	O
amlodipine	B
(with	O
r	O
values	O
0.50	O
and	O
0.48,	O
and	O
P	O
values	O
0.002	O
and	O
0.003,	O
respectively).	O

To	O
confirm	O
their	O
identity,	O
two	O
marker	O
fatty	O
acids,	O
arachidonic	B
acid	I
and	O
eicosatrienoic	B
acid,	I
were	O
matched	O
against	O
the	O
retention	O
times	O
of	O
their	O
corresponding	O
standards	O
on	O
a	O
C4	O
reversed	O
phase	O
column.	O

The	O
inverse	O
associations	O
of	O
choline	B
and	O
PLC	O
risk	O
were	O
not	O
significantly	O
modified,	O
although	O
stronger	O
among	O
non-smokers	O
than	O
smokers	O
(P	O
-trend	O
 < 0.001,	O
P	O
-interaction	O
 = 0.001),	O
and	O
stronger	O
among	O
women	O
than	O
men	O
(P	O
-trend	O
 < 0.001,	O

For	O
instance,	O
an	O
imbalance	O
of	O
this	O
metabolic	O
pathway,	O
marked	O
by	O
hyperhomocysteinemia	O
and/or	O
an	O
altered	O
SAM/SAH	O
ratio,	O
is	O
a	O
hallmark	O
of	O
memory	O
loss	O
and	O
cognitive	O
decline	O
in	O
elderly	O
populations	O
[,	O
]	O
This	O
loss	O
of	O
metabolic	O
homeostasis	O
may	O
result	O
from	O
deficiency	O
in	O
metabolites	O
and	O
co-factors—such	O
as	O
vitamin	O
B_12	O
or	O
folic	O
acid—directly	O
and	O
indirectly	O
involved	O
in	O
the	O
methylation	O
of	O
homocysteine.	B

Due	O
to	O
availability	O
of	O
lactate	B
and	O
pyruvate	B
in	O
PL	O
and	O
AF,	B
a	O
lactate	B
to	O
pyruvate	B
ratio	O
(L/P)	O
was	O
calculated.	O

In	O
order	O
to	O
maintain	O
the	O
_15	O
N	O
amide	B
protonation	O
for	O
_1	O
H	O
NMR	O
detection,	O
the	O
pH	O
was	O
adjusted	O
to	O
5.0	O
by	O
adding	O
1	O
M	O
HCl	O
or	O
1	O
M	O
NaOH.	O

Indeed,	O
pretreatment	O
assessment	O
of	O
TPMT	O
genotype	O
status	O
has	O
been	O
recommended	O
in	O
clinical	O
practice	O
guidelines	O
to	O
guide	O
the	O
initial	O
thiopurine	B
doses	O
[,].	O

Thus,	O
in	O
the	O
case	O
of	O
elevated	O
25-hydroxyvitamin	O
D	O
1α-hydroxylase	O
activity	O
that	O
is	O
associated	O
with	O
some	O
disease	O
states,	O
excess	O
25(OH)D_3	O
may	O
lead	O
to	O
1α,25(OH)_2	B
D_3	O
-associated	O
toxicity.	O

10	O
mL	O
N-methyl-N-	B
(trimethyl-silyl)	I
three	O
fussol	O
solution	O
and	O
100	O
μL	O
chlorotrimethylsilane	B
solution	O
were	O
mixed.	O

Control	O
samples	O
had	O
significantly	O
lower	O
levels	O
of	O
FFA	B
(22:6)	I
than	O
the	O
10	O
Gy	O
group.	O

Since	O
citrate	B
and	O
malate	B
are	O
the	O
two	O
major	O
citric	B
acid	I
cycle	O
intermediates	O
that	O
are	O
capable	O
of	O
exiting	O
mitochondria	O
for	O
the	O
biosynthesis	O
of	O
lipids,	O
nucleic	O
acids	O
and	O
certain	O
amino	O
acids,	O
the	O
reduction	O
in	O
the	O
cellular	O
levels	O
of	O
nucleotides	O
(	O
and	O
),	O
aspartate,	B
glycine,	B
serine	B
and	O
lower	O
glucose	B
carbon	O
incorporation	O
into	O
palmitate	B
are	O
consistent	O
with	O
the	O
anaplerotic/cataplerotic	O
role	O
of	O
PC	O
in	O
growth	O
of	O
breast	O
cancer	O
cells.	O

The	O
transitions	O
monitored	O
were:	O
337.2>207.1	O
and	O
337.2>319.3	O
for	O
14(15)-DiHET	O
(rt:	O
5.4	O
min),	O
337.2>167.0	O
and	O
337.2>319.3	O
for	O
11(12)-DiHET	O
(rt:	O
5.7	O
min),	O
319.2>275.3,	O
319.2>301.3	O
and	O
319.2>289.2	O
for	O
20-HETE	B
(rt:	O
6.6	O
min),	O
319.2>219.2,	O
319.2>301.3	O
and	O
319.2>175.0	O
for	O
15-HETE	B
(rt:	O
7.6	O
min),	O
319.2>179.2,	O
319.2>301.3	O
and	O
319.2>257.2	O
for	O
12-HETE	B
(rt:	O
8.2	O
min),	O
303.2>259.2,	O
303.2>205.1	O
and	O
303.2>58.7	O
for	O
AA	O
(rt:	O
15.1	O
min)	O
and	O
311.3>267.3	O
for	O
AA-d8	O
(rt:	O
14.9	O
min).	O

Plasma	O
BCAA	O
concentrations	O
may	O
not	O
have	O
changed	O
due	O
to	O
opposing	O
effects	O
of	O
metformin	B
and	O
pioglitazone.	B

The	O
effect	O
of	O
phenylacetylglutamine	B
was	O
similar,	O
but	O
slightly	O
less	O
than	O
that	O
of	O
p-cresol	B
sulfate.	I

However,	O
total	O
glucocorticoid	B
excretion	O
was	O
higher	O
in	O
the	O
PCOS	O
group	O
(9624	O
±	O
4214	O
vs	O
6821	O
±	O
3572	O
μg	O
per	O
24	O
h,	O
P	O
=	O
.01).	O

Abbreviations:	O
ALT	O
(Alanine	O
Transaminase,	O
normal	O
upper	O
value	O
threshold	O
<26	O
U/L	O
boys;	O
22	O
U/L	O
girls),	O
AST	O
(Aspartate	O
Transaminase),	O
BMI	O
(Body	O
Mass	O
Index),	O
HOMA-IR	O
(Homeostatic	O
Model	O
Assessment	O
–	O
Insulin	O
Resistance),	O
L/M	O
(Lactulose	O
to	O
Mannitol	B
ratio),	O
NW	O
(Normal	O
Weight),	O
SDS	O
(Standard	O
Deviation),	O
SIBO	O
(Small	O
Intestine	O
Bacterial	O
Overgrowth),	O
wo	O
(without),	O
WtHR	O
(Waist	O
to	O
Height	O
Ratio).	O

Incomplete	O
β-oxidation	O
of	O
fatty	O
acids	O
under	O
mitochondrial	O
fatty	O
acid	O
overload	O
in	O
obesity	O
produces	O
even-chain	O
acyl-carnitines	B
(C6	O
to	O
C22)	O
(Fig.	O
).	O

The	O
significant	O
features	O
identified	O
in	O
the	O
incubations	O
using	O
alpha-PEP	B
consisted	O
of	O
seven	O
isotopes,	O
four	O
artifacts,	O
nine	O
metabolites,	O
two	O
impurities,	O
one	O
endogenous	O
compound,	O
and	O
two	O
yet	O
unidentified	O
compounds.	O

Together,	O
these	O
findings	O
highlight	O
the	O
potential	O
role	O
of	O
choline	B
metabolism	O
in	O
the	O
pathogenesis	O
of	O
both	O
HFpEF	O
and	O
HFrEF.	O

Statistical	O
comparison	O
of	O
total	O
excretion	O
per	O
steroid	O
subclass	O
revealed	O
that	O
ACC	O
patients	O
exhibited	O
significantly	O
increased	O
excretion	O
of	O
metabolites	O
derived	O
from	O
the	O
precursors	O
of	O
androgen,	O
mineralocorticoid,	O
and	O
glucocorticoid	B
synthesis	O
(all	O
P	O
<	O
0.001	O
vs.	O
controls;	O
).	O

-PGF_2α	B
-d_4	I
dissolved	O
in	O
80%	O
aqueous	O
methanol	B
and	O
20	O
μL	O
of	O
formic	B
acid	I
(ACS	O
grade,	O
≥98%).	O

This	O
is	O
in	O
contrast	O
to	O
the	O
consistent	O
associations	O
of	O
TG	B
and	O
cholesterol	B
in	O
apolipoprotein	O
B–containing	O
lipoproteins	O
with	O
risk	O
of	O
MI	O
or	O
IS.	O

During	O
a	O
starvation	O
response	O
due	O
to	O
critical	O
illness,	O
lipolysis	O
of	O
adipose	O
tissue	O
increases,	O
converting	O
TG	B
to	O
free	O
fatty	O
acids,	O
glycerol,	B
and	O
DG	O
but	O
also	O
resulting	O
in	O
enhanced	O
recycling	O
of	O
the	O
fatty	O
acids	O
back	O
into	O
TGs.	O

Elevated	O
serum	O
ceramide	B
and	O
sphingomyelin	B
species	O
in	O
veterans	O
with	O
GWI	O
represents	O
a	O
new	O
finding	O
(,	O
,	O
).	O

We	O
confirmed	O
the	O
reproducibility	O
of	O
the	O
results	O
in	O
the	O
medicated	O
condition	O
and	O
the	O
effects	O
of	O
psychotropic	O
medication	O
on	O
nervonic	B
acid	I
by	O
measuring	O
the	O
levels	O
of	O
nervonic	B
acid	I
using	O
GC-TOFMS	O
in	O
an	O
independent	O
sample	O
set.	O

An	O
imbalance	O
between	O
the	O
fatty	O
acid	O
uptake	O
and	O
the	O
oxidation	O
due	O
to	O
defects	O
or	O
alterations	O
in	O
mitochondrial	O
respiratory	O
complex	O
activities	O
arises	O
in	O
intracellular	O
concentration	O
of	O
acylcarnitines	B
that	O
may	O
be	O
reflected	O
at	O
the	O
serum	O
level.	O

Citrate	B
is	O
likewise	O
upregulated	O
in	O
G4	O
patient	O
serum	O
suggesting	O
alterations	O
in	O
the	O
metabolic	O
Krebs	O
cycle.	O

In	O
terms	O
of	O
T_H	O
2_high	O
cytokines,	O
the	O
IL-4	O
level	O
was	O
inversely	O
associated	O
with	O
shikimic	B
acid	I
(r	O
=	O
−0.598;	O
P	O
=	O
0.024),	O
meanwhile	O
IL-5	O
positively	O
correlated	O
to	O
gly-pro	B
(r	O
=	O
0.651;	O
P	O
=	O
0.012)	O
and	O

To	O
obtain	O
wide	O
coverage	O
of	O
endogenous	O
metabolites	O
and	O
metabolic	O
activities	O
in	O
human	O
cells,	O
we	O
synthesized	O
a	O
growth	O
medium	O
where	O
glucose	B
and	O
all	O
amino	O
acids	O
were	O
fully	O
_13	O
C,	O
while	O
choline	B
and	O
the	O
various	O
vitamins	O
were	O
_12	O
C.	O

Furthermore,	O
compared	O
to	O
that	O
of	O
normal	O
donors,	O
higher	O
concentrations	O
of	O
spermine	B
and	O
spermidine	B
were	O
reported	O
in	O
the	O
seminal	O
plasma	O
of	O
obese	O
men	O
(BMI	O
>	O
30)	O
with	O
a	O
poor	O
spermiogram.	O

The	O
elevated	O
levels	O
of	O
this	O
anti-oxidant	O
molecule	O
are	O
compatible	O
with	O
oxidative	O
stress	O
previously	O
described	O
in	O
ALS	O
and	O
could	O
also	O
be	O
linked	O
to	O
ascorbic	B
acid	I
release	O
from	O
astrocytes	O
after	O
glutamate	B
stimulation	O
,	O
.	O

Furthermore,	O
an	O
in	O
vitro	O
experiment	O
confirmed	O
that	O
palmitic	B
acid	I
could	O
induce	O
vascular	O
endothelial	O
dysfunction	O
by	O
triggering	O
inflammatory	O
signals	O
and	O
provided	O
novel	O
insight	O
on	O
the	O
mechanisms	O
underlying	O
the	O
correlation	O
between	O
palmitic	B
acid	I
and	O
atherosclerosis.	O

1α,25(OH)_2	B
D_3	O
[25	O
to	O
128	O
pg/mL;	O
25	O
to	O
108	O
pg/mL],	O
and	O
(c)	O
24R	O
,25(OH)	O
_2	O
D_3	O
[0.9	O
to	O
9.6	O
ng/mL;	O
0.3	O
to	O
4.3	O
ng/mL]	O
in	O
two	O
different	O
groups	O
of	O
healthy	O
subjects	O
studied	O
in	O
fall	O
(black	O
bars	O
;	O
n	O
=17)	O
and	O
winter	O
(gray	O
bars	O
;	O
n	O
=17).	O

Consequently,	O
glycerol-3-phosphate	B
does	O
not	O
participate	O
in	O
glycerol	B
shuttling	O
(Fig. ),	O
as	O
indicated	O
by	O
the	O
accumulation	O
of	O
dihydroxyacetone	B
in	O
IR	O
hypogonadism	O
with	O
a	O
parallel	O
lower	O
NADH	B
production.	O

We	O
cannot	O
exclude	O
the	O
possibility	O
that	O
the	O
development	O
of	O
PLC	O
may	O
itself	O
affect	O
concentrations	O
of	O
serum	O
choline	B
and	O
TMAO,	B
even	O
though	O
we	O
recruited	O
only	O
newly	O
diagnosed	O
patients	O
and	O
conducted	O
blood	O
collection	O
as	O
soon	O
as	O
possible.	O

For	O
example,	O
the	O
zwitterionic	O
HILIC	O
method	O
E	O
successfully	O
retains	O
a	O
large	O
portion	O
of	O
the	O
amino	O
acid	O
subgroup	O
((),	O
presumably	O
through	O
double	O
ion	O
pairing	O
with	O
the	O
phosphorylcholine	B
moiety.	O

Additionally,	O
the	O
folate	B
cycle	O
is	O
intimately	O
tied	O
to	O
FA	B
metabolism,	O
as	O
it	O
is	O
needed	O
to	O
contribute	O
methyl	O
groups	O
for	O
carnitine	O
methylation	O
and	O
FA	B
chain	O
elongation	O
and	O
desaturation.	O

Our	O
study	O
suggests	O
for	O
evaluating	O
RRM2-associated	O
metabolites	O
as	O
noninvasive	O
markers	O
for	O
tamoxifen	B
resistance	O
and	O
its	O
pharmacological	O
inhibition	O
as	O
a	O
novel	O
approach	O
to	O
overcome	O
tamoxifen	B
resistance	O
in	O
BCa.	O

Potency	O
of	O
fluoxetine	B
(EC_50	O
of	O
32	O
μM)	O
exceeded	O
that	O
of	O
miltefosine	O
(54	O
μM).	O

As	O
a	O
consequence,	O
these	O
regions	O
of	O
the	O
spectra	O
were	O
omitted	O
from	O
our	O
analysis,	O
a	O
process	O
unfortunately	O
resulting	O
in	O
a	O
significant	O
loss	O
of	O
information	O
from	O
a	O
large	O
number	O
of	O
metabolite	O
resonances,	O
including	O
those	O
ascribable	O
to	O
the	O
molecularly-mobile-N_+	O
(CH_3	O
)_3	O
function	O
of	O
HDL,	O
free	O
choline,	B
betaine,	B
acetoacetate,	B
and	O
glucose.	B

(A	O
and	O
B)	O
Box	O
plots	O
showing	O
the	O
levels	O
of	O
glutamate	B
and	O
glutamine	B
in	O
metastatic	O
HNSCC	O
(Mets;	O
n	O
=	O
26),	O
primary	O
HNSCC	O
(n	O
=	O
26),	O
and	O
normal	O
control	O
(n	O
=	O
24)	O
tissues	O
based	O
on	O
isotope	O
dilution	O
GC-MS.	O

Dried	O
cell	O
extracts	O
were	O
dissolved	O
in	O
15	O
µL	O
of	O
methoxyamine	B
hydrochloride	I
solution	O
(40	O
mg/mL	O
in	O
pyridine)	B
and	O
incubated	O
for	O
90	O
min	O
at	O
30	O
°C	O
with	O
constant	O
shaking,	O
followed	O
by	O
the	O
addition	O
of	O
50	O
µL	O
of	O
N	B
-methyl-N-[trimethylsilyl]trifluoroacetamide	I
(MSTFA)	O
and	O
incubation	O
at	O
37	O
°C	O
for	O
60	O
min.	O

In	O
the	O
tryptophan	B
metabolic	O
pathway,	O
the	O
mRNA	O
expression	O
of	O
TPH1	O
and	O
IDO1	O
was	O
significantly	O
lower	O
in	O
NIMBC	O
patients	O
than	O
in	O
controls	O
(p	O
<0.05).	O

Regarding	O
the	O
myelination	O
of	O
axons,	O
ATP	B
liberated	O
from	O
axons	O
can	O
facilitate	O
myelination	O
by	O
mature	O
oligodendrocytes	O
through	O
a	O
cytokine,	O
leukemia	O
inhibitory	O
factor	O
(LIF)	O
released	O
from	O
astrocytes.	O

The	O
results	O
of	O
previous	O
experiments	O
were	O
similar	O
to	O
the	O
present	O
study	O
that	O
the	O
levels	O
of	O
norepinephrine	B
and	O
epinephrine	B
in	O
the	O
blood	O
of	O
hypertensive	O
patients	O
with	O
YDYHS	O
were	O
higher	O
than	O
that	O
of	O
healthy	O
people	O
and	O
YYDS	O
patients.	O

A	O
comparison	O
of	O
the	O
endocrine	O
effects	O
of	O
low	O
dose	O
aminoglutethimide	B
with	O
and	O
without	O
hydrocortisone	B
in	O
postmenopausal	O
breast	O
cancer	O
patients.	O

In	O
addition,	O
the	O
significantly	O
higher	O
intensity	O
of	O
the	O
resonance	O
signals	O
of	O
α-glucose	B
and	O
β-glucose	B
in	O
1H-	O
NMR	O
spectra	O
of	O
hUCBP	O
compared	O
with	O
the	O
CM	O
reveals	O
the	O
significantly	O
higher	O
concentration	O
of	O
α-	O
and	O
β-glucose	B
in	O
hUCBP.	O

Creatinine	B
is	O
derived	O
from	O
creatine	B
and	O
phosphocreatine.	B

Therefore,	O
the	O
[M+2	O
picolinic	B
acid+Na]_+	O
(m/z	O
635)	O
and	O
[M+picolinic	O
acid+Na]_+	O
(m/z	O
512)	O
ions	O
were	O
selected	O
as	O
a	O
monitoring	O
ion	O
pair	O
(Q1/Q3)	O
for	O
OHC	O
derivatives.	O

Glutamine	B
is	O
an	O
alternative	O
source	O
of	O
energy	O
for	O
living	O
cells	O
which	O
is	O
converted	O
to	O
glutamate	B
and	O
fed	O
into	O
the	O
TCA	O
cycle	O
via	O
α-ketoglutarate	B
for	O
energy	O
and	O
biomass	O
production,	O
most	O
dividing	O
cells	O
in	O
turn	O
utilize	O
glutamate	B
in	O
nucleotide	O
synthesis.	O

Two	O
deuterated	O
internal	O
standards,	O
estriol-,	B
estrone-	B
were	O
purchased	O
from	O
C/D/N	O
Isotopes,	O
Inc.	O
(Pointe-Claire,	O
Quebec,	O
Canada),	O
estradiol-	B
was	O
supplied	O
by	O
Cambridge	O
Isotope	O
Laboratories,	O
Inc.	O
(Andover,	O
MA,	O
USA)	O
and	O
aldosterone-	B
(used	I
as	I
internal	I
standard	I
for	I
16-OHE1)	I
was	O
custom	O
synthesized	O
by	O
IsoSciences,	O
LLC	O
(King	O
of	O
Prussia,	O
PA,	O
USA).	O

In	O
addition	O
to	O
one	O
participant	O
with	O
an	O
outlying	O
25(OH)D	O
concentration,	O
we	O
excluded:	O
nine	O
participants	O
with	O
more	O
than	O
20%	O
missing	O
values	O
in	O
at	O
least	O
one	O
of	O
the	O
metabolomics	O
platforms;	O
eight	O
participants	O
who	O
were	O
pregnant	O
or	O
had	O
a	O
fasting	O
duration	B
of	O
less	O
than	O
8 h	O
at	O
the	O
time	O
of	O
the	O
examination;	O
and	O
one	O
participant	O
with	O
missing	O
information	O
in	O
the	O
covariables;	O
leaving	O
a	O
study	O
population	O
of	O
1726	O
participants.	O

Cells	O
were	O
incubated	O
for	O
18	O
hrs	O
in	O
growth	O
medium	O
supplemented	O
with	O
2.5	O
mg/ml	O
fluorescein-rhodamine	B
labeled	O
dextran	O

This	O
correlation	O
matrix	O
visualises	O
not	O
only	O
the	O
significant	O
correlations	O
between	O
Δ	O
glucose	B
and	O
the	O
metabolites	O
(first	O
row/column)	O
but	O
also	O
the	O
correlation	O
among	O
the	O
metabolites.	O

LPC18:1	B
level	O
was	O
negatively	O
correlated	O
with	O
TC	O
level.	O

Relative	O
to	O
the	O
study	O
presented	O
here,	O
the	O
Huynh	O
et	O
al.	O
study	O
quantified	O
a	O
larger	O
number	O
of	O
metabolites	O
(636	O
species),	O
across	O
more	O
lipid	O
classes	O
(SPs,	O
phospholipids,	B
cholesterols,	B
acylcarnitines),	B
in	O
fewer	O
individuals	O
(640	O
samples),	O
whereas	O
the	O
Lemaitre	O
et	O
al.	O
study	O
evaluated	O
fewer	O
SPs	O
(15	O
species)	O
on	O
a	O
similar	O
number	O
of	O
individuals	O
(2086	O
samples).	O

As	O
early	O
as	O
30	O
years	O
ago,	O
Harkness	O
et	O
al.	O
described	O
that	O
purine	B
degradation	O
is	O
increased	O
under	O
ATP	B
depleting	O
conditions	O
and	O
small	O
changes	O
in	O
hypoxanthine	B
may	O
reflect	O
alterations	O
of	O
ATP	B
turnover.	O

These	O
findings	O
are	O
sufficient	O
to	O
conclude	O
that	O
a	O
significant	O
number	O
of	O
patients	O
had	O
taken	O
SP	B
for	O
a	O
previous	O
febrile	O
episode,	O
which	O
is	O
against	O
the	O
standard	O
treatment	O
recommendations.	O

The	O
role	O
of	O
acylcarnitines	B
in	O
NSCLC	O
requires	O
in-depth	O
investigation;	O
however,	O
our	O
study	O
demonstrated	O
the	O
value	O
of	O
this	O
group	O
of	O
metabolites	O
in	O
lung	O
cancer	O
biomarker	O
studies.	O

A	O
recent	O
study	O
suggests	O
an	O
up-regulated	O
glycolysis	O
and	O
higher	O
alanine	B
concentration	O
in	O
T2DM	O
patients	O
(Huang	O
and	O
Joseph,	O
).	O

Both	O
are	O
degradation	O
products	O
of	O
tryptophan	B
from	O
two	O
major	O
pathways	O
by	O
which	O
this	O
molecule	O
is	O
metabolized	O
in	O
humans	O
(kynurenine	O
pathway	O
or	O
via	O
a	O
series	O
of	O
indoles,	O
respectively).	O

Xanthine.	B

Stable	O
isotope-labeled	O
internal	O
standards,	O
25(OH)D_2	O
-d	O
_3	O
,	O
25(OH)D_3	O
-d	O
_6	O
,	O
and	O
3-epi-25(OH)D_3	B
-d	I
_3	O
,	O
were	O
obtained	O
from	O
IsoSciences,	O
Medical	O
Isotopes,	O
Inc.	O
(Pelham,	O
NH),	O
and	O
Cerilliant	O
(Round	O
Rock,	O
TX).	O

The	O
medium	O
was	O
changed	O
to	O
DMEM	O
without	O
FBS	O
modified	O
to	O
contain	O
10	O
mM	O
_13	O
C_6	B
-glucose	I
plus	O
2	O
mM	O
glutamine	B
or	O
2	O
mM	O
_13	O
C_5	B
-glutamine	I
plus	O
10	O
mM	O
glucose.	B

There	O
were	O
no	O
consistent	O
or	O
significant	O
increases	O
in	O
concentrations	O
of	O
the	O
α-TL	B
conjugates	O
or	O
decreases	O
in	O
the	O
α-CEHC	B
conjugates.	O

The	O
lack	O
of	O
lactate	B
level	O
changes	O
in	O
the	O
comparison	O
TC	O
vs	O
HC	O
can	O
be	O
caused	O
by	O
strong	O
local	O
tissue	O
changes	O
and/or	O
the	O
limited	O
flow	O
between	O
these	O
two	O
compartments.	O

The	O
kynurenine	B
and	O
kynurenic	B
acid	I
were	O
associated	O
with	O
ACTH	O
(positively)	O
and	O
cortisol/ACTH	O
(negatively).	O

Dose-response	B
relationships	O
between	O
workplace	O
air	O
measures	O
of	O
benzene	B
and	O
urinary	O
excretion	O
of	O
SPMA	O
have	O
been	O
reported.	O

Previous	O
studies	O
using	O
pure	O
compounds	O
have	O
shown	O
that	O
glutamine	B
undergoes	O
spontaneous	O
cyclization	O
to	O
form	O
pyroglutamic	B
acid	I
under	O
extreme	O
conditions	O
of	O
pH	O
and	O
temperature;_–	O
however,	O
identification	O
of	O
significant	O
cyclization	O
of	O
glutamine	B
to	O
pyroglutamic	B
acid	I
in	O
human	O
blood	O
serum	O
under	O
mild	O
conditions	O
typically	O
used	O
in	O
the	O
metabolomics	O
of	O
human	O
serum/plasma	O
is	O
new.	O

Cold	O
methanol	B
(4°	O
C;	O
9.6	O
mL)	O
was	O
added	O
to	O
4.8	O
mL	O
of	O
the	O
NIST	O
plasma,	O
vortexed,	O
and	O
then	O
kept	O
for	O
30	O
min	O
at	O
-20	O
°C.	O

Future	O
studies	O
should	O
investigate	O
whether	O
plasma	O
glutamine	B
can	O
serve	O
as	O
a	O
biomarker	O
to	O
identify	O
AD	O
patients	O
susceptible	O
to	O
excitotoxicity.	O

Similarly,	O
alterations	O
in	O
the	O
pyrimidine	B
pathway	O
were	O
detected.	O

Our	O
results	O
revealed	O
that	O
the	O
combinational	O
marker	O
comprised	O
of	O
D-glutamic	B
acid,	I
creatinine,	B
and	O
choline	B
had	O
an	O
AUC	O
value	O
of	O
0.927	O
(95%	O
CI:	O
0.875–0.979,	O
P < 0.001),	O
while	O
the	O
diagnostic	O
effectiveness	O
of	O
this	O
combinational	O
biomarker	O
achieved	O
90.5%	O
sensitivity	O
and	O
83.3%	O
specificity,	O
demonstrating	O
that	O
its	O
ability	O
to	O
predict	O
AF	B
in	O
plasma	O
samples	O
was	O
satisfactory	O
(Fig.	O

Twenty-eight	O
of	O
the	O
metabolites	O
showed	O
good	O
discriminatory	O
power	O
for	O
non-diabetic	O
versus	O
diabetic	O
subjects,	O
with	O
an	O
area	O
under	O
the	O
curve	O
(AUC) > 0.7,	O
except	O
for	O
urea	B
(9)	O
and	O
two	O
lysoPCs	O
of	O
C14:0	B
(21)	O
and	O
C20:3	B
(29)	O
(Tables	O
S2,	O
S3	O
and	O
Figs.	O

Ala	O
could	O
increase	O
brain	O
carnosine	B
content	O
24,	O
which	O
exerted	O
neuroprotective	O
effects	O
by	O
attenuating	O
autophage	O
taking	O
place	O
in	O
ischemic	O
damaged	O
brain	O
25.	O

An	O
important	O
factor	O
that	O
needs	O
consideration	O
is	O
arginine	B
paradox.	O

For	O
example,	O
a	O
variant	O
in	O
CYP27A1	O
(rs114768494),	O
which	O
specifies	O
sterol	O
27-hydroxylase,	O
was	O
significantly	O
associated	O
(P	O
=	O
6.9	O
×	O
10_−20	O
)	O
with	O
decreased	O
serum	O
27-hydroxycholesterol	B
levels.	O

The	O
frozen	O
tissue	O
samples	O
ranged	O
from	O
150	O
to	O
400 mg	O
were	O
weighed	O
and	O
suspended	O
in	O
methanol	B
(4 ml	O
per	O
gram	O
of	O
tissue)	O
and	O
double	O
distilled	O
water	O
(0.85 ml	O
per	O
gram	O
of	O
tissue).	O

The	O
initial	O
focus	O
of	O
this	O
work	O
was	O
on	O
the	O
identification	O
and	O
relative	O
quantification	O
of	O
oxysterols	B
in	O
CSF.	O

Both	O
sympathetic	O
nerve	O
system	O
activity	O
[,	O
]	O
and	O
activating	O
renin-angiotensin-aldosterone	B
system	O
caused	O
by	O
insulin	O
resistance	O
play	O
critical	O
roles	O
in	O
the	O
pathological	O
mechanism	O
of	O
EH	O
[,	O
].	O

Nine	O
samples	O
from	O
one	O
patient	O
included	O
extreme	O
concentrations	O
of	O
ethylene	B
glycol	I
suggesting	O
intoxication	O
from	O
local	O
remedies	O
or	O
counterfeit	O
medications.	O

On	O
the	O
VBTA	O
coated	O
capillary,	O
anodic	O
electroosmotic	O
flow	O
(EOF)	O
was	O
generated	O
by	O
applying	O
a	O
voltage	O
of	O
–15	O
kV.	B
Because	O
QA	O
contains	O
one	O
more	O
ionizable	O
carboxyl	O
group	O
than	O
PA	O
(see	O
inset),	O
it	O
is	O
not	O
too	O
surprising	O
that	O
QA	O
acquires	O
more	O
effective	O
negative	O
charge	O
than	O
PA.	O

In	O
PsA	O
and	O
SLE,	O
patients	O
with	O
higher	O
disease	O
activity	O
had	O
lower	O
levels	O
of	O
citrate	B
(P	O
 = 1.8 × 10_–5	O
and	O
P	O
 = 1.3	O

LysoPC	O
16:0	O
and	O
palmitoleamide	B
emerged	O
as	O
the	O
primary	O
metabolites	O
able	O
to	O
discriminate	O
the	O
HTG	O
group	O
from	O
the	O
NTG	O
group	O
in	O
a	O
partial	O
least-squares	O
discriminant	O
analysis	O
and	O
were	O
positively	O
associated	O
with	O
the	O
fasting	O
triglyceride	B
levels.	O

For	O
example,	O
DMA_III	O
has	O
the	O
high	O
potency	O
of	O
being	O
oxidized	O
to	O
DMA_V	O
without	O
the	O
presence	O
of	O
relatively	O
high	O
concentrations	O
of	O
GSH,	B
so	O
it	O
is	O
difficult	O
to	O
accurately	O
quantify	O
this	O
species	O
in	O
the	O
absence	O
of	O
GSH.	B

In	O
addition,	O
several	O
essential	O
acylcarnitine	B
metabolites	O
were	O
decreased	O
in	O
CD	O
compared	O
with	O
both	O
control	O
and	O
UC	O
(	O
and	O
).	O

Combining	O
the	O
cleanest	O
available	O
chemicals	O
with	O
a	O
reduction	O
in	O
the	O
volume	O
of	O
ethyl	B
acetate	I
during	O
liquid–liquid	O
extraction	O
and	O
reducing	O
the	O
volume	O
of	O
MTBSTFA	O
by	O
adding	O
acetonitrile	B
during	O
the	O
derivatization,	O
we	O
managed	O
to	O
significantly	O
reduce	O
contamination.	O

The	O
results	O
for	O
individual	O
urinary	O
estrogens,	O
metabolic	O
pathways,	O
and	O
the	O
2/16α-OH	B
ratio	O
remained	O
non-significant	O
in	O
these	O
sensitivity	O
analyses.	O

Blockage	O
of	O
polyamine	B
synthesis	O
can	O
result	O
in	O
a	O
significant	O
reduction	O
of	O
cancer	O
proliferation	O
rates	O
in	O
various	O
cancers	O
and	O
therefore,	O
alpha-difluoromethylornithine	B
(DFMO)	O
has	O
been	O
clinically	O
evaluated	O
for	O
inhibiting	O
the	O
rate	O
limiting	O
enzyme	O
of	O
polyamine	B
synthesis,	O
ornithine	O
decarboxylase	O
(ODC)	O
[EC	O
4.1.1.17].	O

Thus,	O
we	O
are	O
unable	O
to	O
relate	O
changes	O
in	O
metabolites	O
to	O
blood	O
or	O
tissue	O
levels	O
of	O
limonene.	B

Formic	B
acid	I
was	O
obtained	O
from	O
Sigma-Aldrich	O
(Zwijndrecht,	O
The	O
Netherlands).	O

PAG	B
is	O
a	O
glycine	B
conjugate,	O
which	O
is	O
expected	O
to	O
respond	O
in	O
the	O
same	O
direction	O
with	O
glycine.	B

FA	B
synthesis	O
is	O
the	O
initial	O
step	O
in	O
de	O
novo	O
lipid	O
biosynthesis	O
required	O
for	O
cancer	O
cell	O
proliferation	O
and	O
survival.	O

The	O
other	O
product	O
of	O
PC	O
metabolism,	O
arachidonic	B
acid,	I
can	O
be	O
metabolized	O
by	O
cyclooxygenases	O
and	O
lipooxygenases,	O
forming	O
various	O
eicosanoids	B
such	O
as	O
prostaglandins,	B
thromboxanes,	B
leukotrienes	O
and	O
lipoxins	B
that	O
participate	O
in	O
the	O
inflammatory	O
response.	O

However,	O
a	O
large	O
reduction	O
in	O
all	O
urea	B
cycle	O
metabolites,	O
including	O
arginine	B
and	O
citrulline,	B
was	O
observed,	O
which	O
does	O
not	O
support	O
the	O
modulation	O
of	O
NOS	O
activity	O
as	O
a	O
mode	O
of	O
action	O
of	O
treatment.	O

This	O
paper	O
reports	O
the	O
results	O
of	O
a	O
study	O
relating	O
the	O
level	O
of	O
overnight	O
melatonin	B
production	O
to	O
the	O
overnight	O
excretion	O
of	O
the	O
two	O
primary	O
urinary	O
metabolites	O
of	O
the	O
repair	O
of	O
oxidatively	O
damaged	O
guanine	B
in	O
DNA.	O

Phosphatidylethanolamines	B
(PEs)	O
are	O
the	O
primary	O
lipid	O
components	O
of	O
the	O
inner	O
bacterial	O
membrane,	O
and	O
an	O
increase	O
in	O
PE	O
levels	O
is	O
indicative	O
of	O
significant	O
cell	O
injury.	O

A	O
further	O
analysis	O
combining	O
both	O
inflammatory	O
status	O
and	O
type	O
of	O
disease	O
to	O
classify	O
the	O
patients	O
produced	O
similar	O
results;	O
vitamin	B
D	I
markers	O
did	O
not	O
significantly	O
differ	O
between	O
CD	O
and	O
UC	O
patients,	O
regardless	O
of	O
whether	O
inflammation	O
was	O
present.	O

A	O
pattern	O
of	O
higher	O
levels	O
of	O
essential	O
amino	O
acids	O
appears	O
when	O
considering	O
that	O
2-ketoisocaproic	B
acid	I
(p<0.027,	O
q<0.12)	O
and	O
2-aminoadipic	B
acid	I
(p<0.039,	O
q<0.13),	O
intermediates	O
in	O
the	O
degradation	O
of	O
leucine	B
and	O
lysine	B
respectively,	O
were	O
both	O
increased	O
by	O
simvastatin	B
treatment.	O

A	O
200-mg	O
Sep-Pak	O
tC_18	O
cartridge	O
(SPE2)	O
was	O
washed	O
with	O
6	O
ml	O
of	O
100%	O
methanol,	B
6	O
ml	O
of	O
10%	O
methanol	B
and	O
conditioned	O
with	O
4	O
ml	O
of	O
70%	O
methanol.	B

The	O
prevalence	O
of	O
CAC	O
tended	O
to	O
be	O
lower—not	O
higher—with	O
lower	O
concentrations	O
of	O
each	O
vitamin	B
D	I
metabolite,	O
though	O
none	O
of	O
these	O
trends	O
were	O
statistically	O
significant	O
(Supplementary	O
Table	O
3).	O

In	O
contrast,	O
however,	O
when	O
adenine	B
is	O
present	O
in	O
excess,	O
xanthine	B
oxidase	O
is	O
activated,	B
inducing	O
oxidative	O
stress	O
by	O
hydroxyl	O
free	O
radicals	O
and	O
hydrogen	B
peroxide.	I

For	O
injection,	O
samples	O
were	O
reconstituted	O
in	O
50	O
μL	O
of	O
5%	O
aqueous	O
CH_3	O
CN	O
with	O
0.1%	O
formic	B
acid.	I

The	O
proline	B
pathway	O
was	O
linked	O
with	O
hypoxia	O
in	O
pancreatic	O
cancer	O
and	O
triggered	O
a	O
hypoxic	O
stress	O
response.	O

The	O
cardioprotective	O
and	O
anti-inflammatory	O
effects	O
of	O
long	O
chain	O
omega-3	B
polyunsaturated	O
fatty	O
acids	O
(n3	O
PUFA)	O
are	O
believed	O
to	O
be	O
partly	O
mediated	O
by	O
their	O
oxygenated	O
metabolites	O
(oxylipins).	O

The	O
classic	O
Kovats	O
RI	B
parameter	O
also	O
makes	O
possible	O
a	O
wider	O
application	O
by	O
different	O
laboratories	O
in	O
different	O
GC	O
separation	O
conditions.	O

Figure 	O
shows	O
the	O
_1	O
H	O
NMR	O
spectral	O
profile	O
of	O
metabolites	O
in	O
the	O
aqueous-methanolic	B
extract	O
of	O
serum	O
from	O
LH/FSH-secreting,	O
prolactinoma,	O
and	O
NF	O
pituitary	O
tumor	O
patients.	O

and	O
of	O
urea	B
is	O
17–52 mg/dl.	O

The	O
established	O
prediction	O
model	O
was	O
composed	O
of	O
4	O
metabolites;	O
i.e.,	O
2-hydroxybutyrate,	B
aspartic	B
acid,	I
kynurenine,	B
and	O
cystamine	B
(cysteamine+cystamine).	I

These	O
7	O
metabolites	O
were	O
acetone,	B
2-butanone,	B
4-heptanone,	B
dimethyl	B
disulfide,	I
furan,	B
2-methylbutanal	B
and	O
2-methylpyrazine.	B

In	O
our	O
study,	O
sarcosine	B
was	O
detected	O
in	O
high	O
abundance.	O

CYP2A6,	O
genetic	O
variation,	O
nicotine	B
metabolism,	O
nicotine	B
metabolite	O
ratio	O
(NMR),	O

Glucocorticoid	B
excess	O
in	O
mild,	O
subclinical	O
adrenal	O
Cushing’s	O
syndrome	O
is	O
associated	O
with	O
overnight	O
dexamethasone	B
test	O
results	O
that	O
are	O
regularly	O
abnormal,	O
while	O
24-hour	O
urine	O
glucocorticoid	B
excretion	O
is	O
often	O
normal.	O

The	O
Ov/Ob	O
subjects	O
with	O
the	O
MetS	O
had	O
a	O
more	O
deteriorated	O
plasma	O
lipid	O
profile	O
including	O
increased	O
plasma	O
TG	B
levels	O
and	O
decreased	O
plasma	O
HDL-C	O
levels	O
compared	O
to	O
Ov/Ob	O
without	O
MetS	O
or	O
NW	O
individuals.	O

To	O
determine	O
if	O
M1	O
and	O
M2	O
were	O
excreted	O
in	O
the	O
urine	O
as	O
glucuronide	B
conjugates,	O
we	O
incubated	O
a	O
study	O
subject’s	O
urine	O
(0.1	O
mL)	O
at	O
37	O
°C	O
with	O
0,	O
500,	O
1000	O
or	O
2000	O
U/mL	O
of	O
β-glucuronidase	O
for	O
2,	O
16	O
or	O
36	O
hr.	O

Water,	O
acetonitrile,	B
and	O
methanol	B
(LC-MS	O
grade)	O
were	O
obtained	O
from	O
Merck	O
Millipore	O
(Warsaw,	O
Poland).	O

Other	O
Torus	O
columns	O
such	O
as	O
the	O
2-PIC	O
can	O
be	O
used	O
instead	O
of	O
the	O
Diol	B
without	O
a	O
significant	O
loss	O
of	O
resolution	O
or	O
peak	O
symmetry,	O
and	O
the	O
combination	O
of	O
ammonium	B
formate	I
and	O
water	O
as	O
modifier	O
additives	O
might	O
improve	O
separation	O
more	O
than	O
the	O
use	O
of	O
either	O
one	O
by	O
itself.	O

Emergent	O
fungi	O
were	O
isolated	O
into	O
pure	O
culture	O
on	O
2%	O
MEA,	O
vouchered	O
in	O
sterile	B
water,	I
and	O
deposited	O
as	O
living	O
vouchers	O
at	O
the	O
Robert	O
L.	O
Gilbertson	O
Mycological	O
Herbarium	O
at	O
the	O
University	O
of	O
Arizona.	O

shows	O
the	O
same	O
information	O
presented	O
in	O
,	O
age-adjusted	O
percent	O
change	O
in	O
geometric	O
means	O
between	O
the	O
prenatally	O
DES	B
exposed	O
and	O
the	O
unexposed	O
in	O
parent	O
estrogens,	O
estrogen	B
metabolites,	O
metabolite	O
pathways	O
and	O
ratios.	O

The	O
estimated	O
daily	O
intake	O
is	O
69-fold	O
to	O
104-fold	O
less	O
than	O
the	O
Acceptable	O
Daily	O
Intake	O
(ADI)	O
for	O
acetamiprid	B
(0.071	O
mg/kg).	O

Summary	O
of	O
significant	O
changes	O
in	O
LC-MS	O
peaks	O
between	O
groups	O
Note	O
:	O
Tentative	O
(low	O
abundance/no	O
MS/MS)	O
or	O
ambiguous	O
identifications	O
are	O
in	O
italics	O
TAG	O
triacylglycerol,	B
DAG	O
diacylglycerol,	B
PC	B
glycerophosphatidyl	I
choline,	I
PS	O
glycerophosphoserine,	B
PE	B
glycerophospho	I
ethanolamine,	I
PA	O
glycerophospatydic	B
acid,	I
SM	O
sphingomyeline	B
_a	O
Denotes	O
signals	O
at	O
very	O
low	O
abundance	O
in	O
the	O
raw	O
data	O
In	O
terms	O
of	O
the	O
class	O
of	O
lipid	O
species	O
affected	O
the	O
largest	O
decreases	O
on	O
fish	O
oil	O
supplementation	O
were	O
associated	O
with	O
TAGs,	O
suggesting	O
that	O
this	O
class	O
of	O
lipids	O
had	O
decreased	O
in	O
general,	O
which	O
has	O
been	O
published	O
before	O
(Harris	O
;	O
Krebs	O
et	O
al.	O
).	O

This	O
indicates	O
the	O
importance	O
of	O
diet/lifestyle	O
parameters	O
in	O
determining	O
the	O
relationship	O
of	O
hippurate	B
and	O
cancer.	O

α	B
-hydroxybutyrate	I
profiles	O
throughout	O
the	O
OGTT.	O

Levels	O
of	O
carnitine-related	O
metabolites,	O
including	O
acetyl	B
carnitine,	I
decanoyl	B
carnitine,	I
and	O
hexanoyl	B
carnitine,	I
were	O
significantly	O
higher	O
in	O
the	O
BS	O
pattern	O
than	O
the	O
non-BS	O
pattern	O
patients	O
(P	O
<	O
0.05).	O

A	O
significant	O
difference	O
between	O
the	O
6h-iAUC	O
was	O
found	O
for	O
C15:0,	B
but	O
not	O
for	O
C17:0,	B
based	O
on	O
a	O
Kruskal-Wallis	O
test	O
of	O
the	O
three	O
food	O
groups.	O

In	O
the	O
glycolysis-associated	O
metabolites,	O
a	O
good	O
positive	O
correlation	O
between	O
lactate	B
and	O
alanine	B
was	O
observed	O
in	O
all	O
brain	O
tumour	O
types	O
except	O
oligodendrogliomas	O
(	O
and	O
).	O

Because	O
beta-methyl-L-amino-alanine	B
(BMAA)	O
has	O
been	O
recently	O
reported	O
by	O
several	O
authors	O
as	O
potentially	O
involved	O
in	O
the	O
etiology	O
of	O
ALS,	O
we	O
searched	O
for	O
its	O
presence	O
.	O

Thus	O
both	O
lactate	B
and	O
alanine	B
will	O
tend	O
to	O
be	O
present	O
in	O
high	O
or	O
low	O
concentration,	O
all	O
other	O
things	O
(such	O
as	O
the	O
presence	O
of	O
co-substrates	O
necessary	O
for	O
the	O
synthesis	O
and	O
breakdown	O
reactions)	O
being	O
equal.	O

13:0,	O
lysophosphatidylethanolamine	B
(LPE)	O
14:0,	O
lysophosphatidylinositol	B
(LPI)	O

Although	O
these	O
results	O
seem	O
to	O
be	O
inconsistent	O
with	O
our	O
data,	O
the	O
direct	O
impact	O
of	O
hypoxanthine	B
on	O
atherosclerosis	O
and	O
detailed	O
mechanism	O
are	O
still	O
unclear.	O

Identification	O
of	O
hydroxycholestenoic	B
and	O
hydroxyoxocholestenoic	B
acids	I
in	O
CSF.	O

(b)	O
HIV-TB	O
patients	O
with	O
pulmonar	O
TB	O
exhibited	O
higher	O
7-oxo-DHEA	B
concentrations	O
compared	O
to	O
those	O
with	O
extrapulmonar	O
TB.	O

Altogether	O
the	O
anti-diabetic	O
effects	O
of	O
OCN	O
and	O
citrulline	B
seem	O
congruent	O
with	O
each	O
other.	O

Recent	O
research	O
suggested	O
a	O
metabolic	O
implication	O
of	O
osteocalcin	B
(OCN)	O
in	O
e.g.	O
insulin	O
sensitivity	O
or	O
steroid	O
production.	O

Second,	O
these	O
metabolomic	O
signatures	O
may	O
reflect	O
changes	O
in	O
the	O
CNS	O
lipid	O
composition	O
due	O
to	O
myelin	B
destruction	O
(mainly	O
composed	O
by	O
sphingolipids)	B
and	O
astroglia	O
proliferation	O
(mainly	O
requiring	O
phospholipids).	B

This	O
could	O
also	O
potentially	O
be	O
used	O
to	O
screen	O
for	O
additional	O
vitamin	B
D	I
metabolites	O
and	O
other	O
conjugated	O
dienes	O
using	O
the	O
precursor	O
ion	O
scan	O
function.	O

However,	O
a	O
tendency	O
for	O
lower	O
%differences	O
was	O
observed	O
for	O
drugs	O
with	O
less	O
fluctuation,	O
that	O
is,	O
for	O
the	O
ER	O
and	O
LAI	O
formulations	O
and	O
for	O
aripiprazole,	B
a	O
drug	O
with	O
a	O
long	O
half‐life.	O

P	O
and	O
IP	B
were	O
separately	O
incubated	O
with	O
the	O
bacterial	O
suspension	O
anaerobically,	O
and	O
the	O
metabolic	O
samples	O
were	O
incubated	O
for	O
12,	O
24,	O
and	O
48	O
h,	O
then	O
extracted	O
with	O
ethyl	B
acetate	I
(EtOAc),	O
and	O
analyzed	O
by	O
HPLC.	O

Specifically,	O
the	O
role	O
of	O
HIF	O
in	O
the	O
regulation	O
of	O
cellular	O
glucose	B
flux	O
and	O
shunting	O
of	O
pyruvate	B
from	O
the	O
TCA	O
cycle	O
towards	O
lactate	B
production	O
in	O
renal	O
cancer	O
cells	O
becomes	O
apparent.	O

eNO	O
was	O
measured	O
using	O
a	O
NIOX	O
Mino	O
(Circassia)	O
and	O
FEV_1	O
was	O
measured	O
using	O
a	O
handheld	O
spirometer.	B

Briefly,	O
a	O
phosphate	B
buffer	O
solution	O
(pH	O
7.4)	O
was	O
prepared	O
with	O
sodium	B
phosphate	I
dibasic	O
(Na_2	O
HPO_4	O
;	O
99.95%	O
trace	O
metals	O
basis,	O
anhydrous,	O
Sigma-Aldrich	O
Merck;	O
Darmstadt	O
Germany),	O
sodium	B
phosphate	I
monobasic	O
(NaH_2	O
PO_4	O
;	O
99.95%	O
trace	O
metals	O
basis,	O
anhydrous,	O
Sigma-Aldrich	O
Merck)	O
and	O
sodium	O
azide	O
(NaN_3	O
;	O
Sigma-Aldrich	O
Merck).	O

Our	O
hypothesis	O
is	O
that	O
glucose	B
preferred	O
to	O
attack	O
unmodified	O
HSA	O
instead	O
of	O
already	O
glycated	O
HSA.	O

The	O
method	O
developed	O
in	O
this	O
study	O
was	O
successfully	O
validated	O
and	O
is	O
being	O
efficiently	O
used	O
to	O
measure	O
imatinib	B
concentrations	O
in	O
samples	O
from	O
chronic	O
myeloid	O
leukemia	O
patients	O
to	O
check	O
treatment	O
compliance.	O

Tamoxifen	B
treatment	O
may	O
be	O
further	O
improved	O
by	O
dose	O
adjustment	O
based	O
on	O
direct	O
measurement	O
of	O
the	O
active	O
tamoxifen	B
metabolites.	O

Our	O
data	O
showed	O
that	O
the	O
level	O
of	O
glutamine	B
was	O
increased	O
in	O
the	O
HTK	O
group.	O

P = 0.0001),	O
linoleic	B
acid	I
(OR:	O
6.13;	O
95%	O
CI:	O
(2.367,	O
15.893);	O
P = 0.0005),	O
4-pyridoxic	B
acid	I
(OR:	O
4.879;	O
95%	O
CI:	O
(2.158,	O
11.035);	O
P = 0.0002),	O
phosphatidylglycerol	B
(20:3/2:0)	I
(OR:	O
3.938;	O
95%	O
CI:	O
(1.891,	O
8.204);	O
P = 0.0001),	O
carnitine	B
(14:1)	I
(OR:	O
3.379;	O
95%	O
CI:	O
(1.913,	O
5.967);	O
P < 0.0001),	O
and	O
lithocholic	B
acid	I
(OR:	O
2.791;	O
95%	O
CI:	O
(1.74,	O
4.477);	O
P = 0.0003)	O
(Table ).	O

Clinical	O
parameters,	O
such	O
as	O
TG,	B
TC,	O
LDL-c,	O
HDL-c,	O
fasting	O
insulin,	O
2-h	O
insulin	O
and	O
HOMA-IR,	O
were	O
associated	O
with	O
changes	O
in	O
metabolite	O
levels.	O

After	O
5 min,	O
the	O
reactions	O
were	O
terminated	O
by	O
addition	O
of	O
an	O
equal	O
volume	O
of	O
acetonitrile	B
(v/v)	O
containing	O
an	O
appropriate	O
internal	O
standard.	O

To	O
remove	O
membrane	O
lipids	O
and	O
triglycerides,	B
dried	O
samples	O
were	O
reconstituted	O
with	O
acetonitrile/water	O
(1:1),	O
decanted	O
and	O
taken	O
to	O
dryness	O
under	O
reduced	O
pressure.	O

There	O
was	O
a	O
good	O
correlation	O
between	O
the	O
NMR	O
peak	O
heights	O
and	O
the	O
assayed	O
levels	O
of	O
xanthurenic	B
acid	I
(r	O
=	O
0.73	O

Makrecka	O
et	O
al	O
.	O
showed	O
that	O
long-chain	O
acylcarnitine	B
could	O
regulate	O
the	O
metabolism	O
of	O
pyruvate–lactate	B
and	O
long-chain	O
fatty	O
acids	O
in	O
the	O
mitochondria,	O
and	O
the	O
increase	O
of	O
long-chain	O
acylcarnitine	B
could	O
impair	O
glucose	B
metabolism.	O

Sterols	O
were	O
extracted	O
with	O
hexane	B
(3	O
x	O
1	O
ml)	O
and	O
dried	O
under	O
an	O
N_2	O
stream.	O

Continuing	O
with	O
this	O
notation,	O
the	O
95%	O
confidence	O
limits	O
for	O
α	O
′	O
can	O
be	O
deterministically	O
approximated	O
by	O
qnα±nα(1−α)√.	B
qnα±nα(1−α)√	B
qnα±nα(1−α)√	I
qnα±nα(1−α)√	I
qnα±nα(1−α)√	I
qnα±nα(1−α)√	I
qnα±nα(1−α)√	I
qnα±nα(1−α)√	I
qnα±nα(1−α)√	I
q	O
q	O
q	O
	O
nα±nα(1−α)√	B
nα±nα(1−α)√	I
n	O
α	O
±	O
nα(1−α)√	B
nα(1−α)√	I
nα(1−α)	I
nα(1−α)	I
nα(1−α)	I

The	O
urinary	O
levels	O
of	O
α	O
1-microglobulin,	O
β	O
2-microglobulin,	O
transferrin,	O
and	O
retinol	B
binding	O
protein	O
were	O
measured	O
with	O
kits	O
from	O
Siemens	O
using	O
a	O
Siemens	O
Dabe	O
Behring	O
BN	O
II	O
Nephelometer	O
Analyzer	O
(Siemens	O
HeathCare	O
GmbH,	O
Erlangen,	O
Germany).	O

This	O
observation	O
may,	O
however,	O
reflect	O
inconsistent	O
cortisol	B
levels	O
in	O
the	O
small	O
cohort	O
due	O
to	O
medications	O
(i.e.	O
ACE	O
inhibitors),	O
circadian	O
variations	O
and	O
possible	O
glucocorticoids	B
resistance	O
in	O
some	O
patients.	O

As	O
a	O
result,	O
we	O
do	O
not	O
recommend	O
routine	O
measurements	O
of	O
circulating	O
vitamin	B
D	I
metabolites	O
or	O
routine	O
treatment	O
with	O
vitamin	B
D	I
on	O
the	O
basis	O
of	O
these	O
results.	O

_,	O
The	O
C677T	O
polymorphism	O
in	O
the	O
methylenetetrahydrofolate	B
reductase	O
gene	O
is	O
a	O
risk	O
factor	O
for	O
hyperhomocysteinemia_,	O
and	O
is	O
associated	O
with	O
psychiatric	O
diseases	O
such	O
as	O
bipolar	O
disorders,	O
depression_,	O
and	O
schizophrenia.	O

Indeed,	O
LLE	O
with	O
TFA	O
highly	O
improved	O
the	O
recoveries	O
of	O
ARG	O
and	O
GABA	B
but	O
diminished	O
the	O
recoveries	O
of	O
some	O
polyamines.	B

McAnulty	O
et	O
al.	O
,	O
for	O
example,	O
showed	O
that	O
ingestion	O
of	O
250	O
g/day	O
blueberries	O
for	O
6	O
weeks	O
prior	O
to	O
2.5	O
h	O
of	O
intensive	O
running	O
attenuated	O
exercise-induced	O
increases	O
in	O
F_2	B
-isoprostanes.	I

Detection	O
frequency,	O
median,	O
and	O
concentration	O
range	O
for	O
DEET	O
and	O
neonicotinoid	B
biomarkers	O
measured	O
in	O
60	O
anonymous	O
adult	O
volunteers	O
Limit	O
of	O
detection	O
(LOD)	O
in	O
μg/L:	O
acetamiprid	B
and	O
clothianidin	B
=	O
0.1;	O
N-desmethyl-acetamiprid	B
and	O
5-hydroxyimidacloprid=	B
0.03;	O
imidacloprid	O
and	O
ECBA	O
=	O
0.05;	O
DCBA	O
=	O
0.06;	O
and	O
thiacloprid	B
=	O
0.01	O
NA	O
,	O
not	O
applicable	O
The	O
LODs	O
ranged	O
from	O
0.01	O
to	O
0.1	O

Also,	O
to	O
search	O
for	O
any	O
secondary	O
cause	O
of	O
hypertension,	O
the	O
patients	O
were	O
advised	O
to	O
obtain	O
for	O
a	O
set	O
of	O
biochemical	O
tests	O
including	O
electrolyte	O
levels	O
(Na_+	O
,	O
K_+	O
),	O
glycosylated	O
hemoglobin,	O
blood	O
urea,	B
serum	O
creatinine,	B
lipid	O
profile,	O
hematocrite	O
and	O
urinalysis.	O

A	O
method	O
to	O
analyze	O
mercapturic	O
acids	O
of	O
acrolein	B
and	O
crotonaldehyde	B
is	O
described	O
The	O
method	O
was	O
validated	O
for	O
accuracy	O
and	O
precision	O
The	O
method	O
was	O
applied	O
in	O
the	O
analysis	O
of	O
more	O
than	O
2600	O
urine	O
samples	O
from	O
smokers	O
Mean	O
smokers’	O
urinary	O
levels	O
were	O
4800±5358	O
(3-HPMA)	O
and	O
3302±3341	O
pmol/ml	O
(HMPMA)	O

Caffeine,	B
first	O
proposed	O
as	O
a	O
marker	O
of	O
intake	O
some	O
decades	O
ago	O
,	O
was	O
indeed	O
a	O
discriminant	O
of	O
coffee	O
intake	O
in	O
the	O
SU.VI.MAX2	O
cohort,	O
although	O
a	O
relatively	O
weak	O
one	O
(p-value = 0.0266;	O
VIP = 1.65),	O
and	O
a	O
moderately	O
intense	O
signal	O
was	O
found	O
even	O
in	O
the	O
urine	O
of	O
the	O
low	O
consumers.	O

Combination	O
with	O
these	O
three	O
methods,	O
we	O
hope	O
we	O
can	O
discover	O
potential	O
biomarkers	O
of	O
FD	B
in	O
a	O
more	O
robust	O
and	O
consistent	O
way.	O

Serum	O
samples	O
were	O
collected	O
with	O
BD	O
Vacutainer	O
serum	O
tubes,	O
processed	O
according	O
to	O
the	O
standard	O
BD	O
Vacutainer	O
protocol,	O
and	O
stored	O
at	O
−80°	O
C.	O
Concentrations	O
of	O
tryptophan	B
(TRP),	O
kynurenine	B
(KYN),	O
kynurenic	B
acid	I
(KynA),	O
3-hydroxykynurenine	B
(3HK),	O
and	O
quinolinic	B
acid	I
(QA)	O
were	O
measured	O
blind	O
to	O
diagnosis	O
by	O
Brains	O
Online,	O
LLC	O
(www.brainsonline.org/home).	O

We	O
observed	O
that	O
the	O
concentrations	O
of	O
valine	B
and	O
tryotophan	O
were	O
generally	O
elevated	O
in	O
PCOS	O
groups.	O

In	O
addition	O
to	O
proline	B
(positive	O
correlation),	O
alanine	B
(positive	O
correlation)	O
and	O
glycine	B
(negative	O
correlation),	O
c-peptide	O
levels	O
post	O
treatment	O
also	O
correlated	O
to	O
lactic	B
acid	I
(positive	O
correlation),	O
succinic	B
acid	I
(negative	O
correlation),	O
lauric	B
acid	I
(negative	O
correlation)	O
and	O
aminomalonate	B
(negative	O
correlation).	O

We	O
identified	O
matches	O
for	O
glutamine	B
and	O
m/z	O
246.9550;	O
plasma	O
and	O
CSF	O
levels	O
were	O
modestly	O
correlated	O
for	O
glutamine	B
(rho	O
 = 0.26,	O
P	O
 = 0.03)	O
but	O
not	O
for	O
m/z	O
246.9550	O
(rho	O
 = −0.04,	O
P	O
 = 0.72).	O

Similarly,	O
9	O
metabolites	O
(Phytosphingosine,	O
PC(22:6),	B
PE(20:3),	B
2-keto	O
valericacid,	O
Sphinganine-phosphate,	B
Cholic	B
acid,	I
Deoxycholic	B
acid,	I
3-Methylxanthine/7-Methylxanthine/1-Methylxanthine,	B
Uridine	B
monophosphate)	I
were	O
selected	O
from	O
33	O
metabolites	O
(heat-map	O
displayed	O
in	O
)	O
between	O
T2DM	O
and	O
DACD	O
patients.	O

Model	O
4(M4):	O
M	O
3	O
plus	O
lipid	O
parameters	O
not	O
contemplated	O
by	O
LPIR	O
(HDL-c,	O
LDL-c	O
and	O
triglycerides	B
logarithm).	O

Ceramides	B
are	O
also	O
intermediates	O
linking	O
inflammatory	O
cytokines	O
to	O
insulin	O
resistance	O
and	O
subclinical	O
atherosclerosis	O
,	O
;	O
all	O
of	O
which	O
are	O
associated	O
with	O
AD	O
pathogenesis.	O

In	O
this	O
work,	O
we	O
developed	O
a	O
novel	O
strategy	O
by	O
combing	O
IL	O
with	O
LC-MS	O
in	O
the	O
DPI	O
and	O
MRM	O
mode	O
for	O
non-targeted	O
profiling	O
and	O
targeted	O
quantitation	O
of	O
thiols	B
from	O
the	O
urine	O
sample	O
of	O
cancer	O
patients.	O

In	O
CSF,	O
these	O
metabolites	O
were	O
uridine,	B
imidazoleacetic	B
acid,	I
methionine	B
sulfoxide,	I
arginine,	B
cystathionine	B
and	O
homocarnosine.	B

,	O
In	O
this	O
study,	O
we	O
also	O
identified	O
the	O
significantly	O
changed	O
azelaic	B
acid	I
in	O
depressed	O
patients.	O

It	O
is	O
tempting	O
to	O
speculate	O
that	O
lower	O
levels	O
of	O
glycolate	B
may	O
be	O
associated	O
with	O
reduced	O
inhibition	O
of	O
calcium	O
dependent	O
ATPase,	O
perhaps	O
contributing	O
to	O
CRF	O
regulation.	O

The	O
following	O
drugs	O
and	O
metabolites	O
were	O
examined:	O
cocaine,	O
benzoylecgonine,	B
norcocaine,	O
norbenzoylecgonine,	B
ecgo-nine	O
ethyl	B
ester,	I
ecgonine	B
methyl	I
ester,	I
anhydroecgonine	B
methyl	I
ester,	I
ecgonine,	O
cocaethylene,	B
norcocaethylene,	B
m	B
-hydroxycocaine,	I
p	B
-hydroxycocaine,	I
m	B
-hydroxybenzoylecgonine,	I
p	B
-hydroxybenzoylecgonine,	I
methadone,	B
2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline,	B
2-ethyl-1,5-dimethyl-3,	B
3-diphenylpyrrolinium,	I
methadol,	B
Δ_9	B
-tetrahydrocannabinol,	I
11-hydroxy-Δ_9	B
-tetrahydrocannabinol,	I
11-nor-9-carboxy	B

nuclei	O
have	O
documented	O
increased	O
levels	O
of	O
total	O
choline	B
containing	O
compounds,	O
phosphomonoesters	B
and	O
phosphodiesters	B
in	O
human	O
breast	O
cancer	O
tissues,	O
which	O
is	O
indicative	O
of	O
altered	O
choline	B
and	O
phospholipid	B
metabolism.	O

In	O
contrast,	O
a	O
subset	O
of	O
metabolites	O
specifically	O
changed	O
during	O
the	O
first	O
2	O
months	O
of	O
intensive	O
treatment,	O
of	O
which	O
the	O
strongly	O
increased	O
concentrations	O
of	O
methionine	B
sulfone	I
and	O
putrescine	B
were	O
especially	O
striking.	O

Glucose	B
is	O
the	O
only	O
metabolite	O
to	O
exhibit	O
higher	O
levels	O
in	O
the	O
serum	O
of	O
CPF	O
animals	O
when	O
compared	O
to	O
FS	O
animals	O
at	O
baseline.	O

NT-proBNP	O
=	O
amino-terminal	B
pro-B-type	O
natriuretic	O
peptide	O
Cox	O
Proportional	O
Hazard	O
Analyses	O
of	O
Adverse	O
Clinical	O
Outcomes	O
Choline	B
Betaine	I
Trimethylamine	I
N	I
-oxide	I
Adjusted	O
for	O
age,	O
estimated	O
glomerular	O
filtration	O
rate,	O
mitral	O
septal	O
E/Ea,	O
and	O
aminoterminal	B
pro-B-type	O
natriuretic	O
peptide	O

Water,	O
acetonitrile	B
containing	O
0.1%	O
formic	B
acid	I
and	O
water	O
containing	O
0.1%	O
formic	B
acid,	I
were	O
of	O
CHROMASOLV	O
grade.	O

Hence,	O
we	O
took	O
the	O
product	O
of	O
putrescine	B
and	O
spermidine	B
as	O
argument	O
to	O
characterize	O
liver	O
and	O
lung	O
cancerous	O
plasma.	O

The	O
presence	O
of	O
S-(−)equol	O
will	O
depend	O
upon	O
whether	O
or	O
not	O
the	O
gut	O
microflora	O
was	O
exposed	O
to	O
any	O
daidzein	B
through	O
usual	O
food	O
intakes.	O

However,	O
observations	O
from	O
these	O
two	O
papers	O
are	O
likely	O
to	O
be	O
more	O
relevant	O
for	O
the	O
aggregation	O
of	O
extracellular	O
pools	O
of	O
α-synuclein	B
than	O
for	O
aggregation	O
of	O
intracellular	O
α-synuclein.	B

Comparison	O
of	O
general	O
sequencing	O
characteristics	O
between	O
the	O
soymilk	O
and	O
control	O
groups	O
revealed	O
significant	O
differences	O
in	O
coverage	O
(P	O
 = 0.009),	O
number	O
of	O
mapped	O
fragments	O
(P	O
 = 0.012)	O
and	O
library	O
size	O
upon	O
data	O
summary	O
(P	O
 = 0.003),	O
despite	O
sample	O
randomization	O
before	O
gDNA	O
extraction	O
and	O
MethylCap-seq.	B

The	O
dietary	O
sterols,	O
β-sitosterol	B
(β-SITO),	I
stigmasterol	B
(STIG),	O
and	O
campesterol	B
(CAMP)	O
were	O
highly	O
positively	O
correlated	O
with	O
each	O
other,	O
and	O
were	O
negatively	O
correlated	O
with	O
most	O
cholesterol	B
biosynthesis	O
metabolites,	O
and	O
bile	O
acids.	O

Previous	O
studies	O
have	O
suggested	O
that	O
levels	O
of	O
total	O
4-MeO-E2	B
in	O
serum	O
from	O
postmenopausal	O
women	O
are	O
below	O
1	O
pg/mL	O
and	O
so	O
analysis	O
of	O
this	O
molecule	O
cannot	O
really	O
be	O
justified.	O

Lower	O
Figure:	O
Validation	O
study	O
of	O
plasma	O
levels	O
(100	O
μL)	O
of	O
VLCDCA	B
28:4	I
in	O
controls	O
(Con;	O
N	O
=	O
16)	O
and	O
patients	O
with	O
colorectal	O
(CRC;	O
N	O
=	O
26),	O
kidney	O
(Kid;	O
N	O
=	O
9),	O
or	O
pancreatic	O
(Pan;	O
N	O
=	O
45)	O
cancers.	O

The	O
calibration	O
of	O
the	O
standard	O
mixture	O
was	O
performed	O
with	O
a	O
mixture	O
of	O
FA	B
methyl	I
esters	I
(47885-U;	O
Supelco-Sigma-Aldrich,	O
St.	O
Louis,	O
MO,	O
USA).	O

Lipids	O
were	O
extracted	O
from	O
tissue,	O
and	O
sphingolipids	B
were	O
quantified	O
by	O
LC-ESIMS/MS	O
(4000	O
QTRAP,	O
ABI)	O
as	O
described	O
previously	O
by	O
our	O
group	O
[,	O
].	O

It	O
was	O
hypothesized	O
that	O
changes	O
in	O
the	O
gut	O
microbial	O
profile	O
accounted	O
for	O
differences	O
in	O
plasma	O
TMAO	B
concentrations.	O

Histidine,	B
glutamine,	B
tyrosine,	B
and	O
creatine	B
came	O
up	O
as	O
the	O
top	O
four	O
metabolites	O
showing	O
significant	O
alterations	O
in	O
tissue	O
for	O
this	O
comparative	O
study.	O

Therefore,	O
it	O
appears	O
that	O
nitroso-derivatives	O
are	O
a	O
minor	O
component	O
in	O
the	O
plasma	O
and	O
are	O
likely	O
generated	O
from	O
the	O
arylhydroxlamines	B
within	O
the	O
erythrocytes._,	O
This	O
can	O
be	O
explained	O
by	O
the	O
fact	O
that	O
N	B
-hydroxyarylamines	I
can	O
be	O
readily	O
transformed	O
to	O
nitrosoarenes	O
by	O
a	O
co-oxidation	O
reaction	O
with	O
oxyHb	B
in	O
the	O
erythrocytes.	O

For	O
instance	O
valine	B
is	O
strongly	O
metabolised	O
inside	O
the	O
mitochondria	O
(approximately	O
by	O
80%)	O
to	O
produce	O
propionyl-CoA,	B
which	O
is	O
finally	O
transformed	O
into	O
OAA	O
(Fig.	O

Our	O
data	O
suggest	O
that	O
carnosine	B
may	O
have	O
beneficial	O
effects	O
on	O
the	O
plasma	O
lipidome.	O

gruberi	O
trophozoites	O
on	O
the	O
U_13	O
C-glucose-containing	O
growth	O
medium	O
identified	O
an	O
exogenous	O
origin	O
of	O
cholesterol,	B
while	O
7-dehydrocholesterol	B
(7DHC)	O
had	O
enriched	O
_13	O
C-content,	O
suggesting	O
a	O
dual	O
origin	O
of	O
this	O
metabolite	O
both	O
from	O
de	O
novo	O
biosynthesis	O
and	O
metabolism	O
of	O
scavenged	O
cholesterol.	B

Overall,	O
our	O
data	O
suggests	O
that	O
a	O
decrease	O
of	O
serum	O
glycoproteins	B
may	O
be	O
associated	O
to	O
fibrosis.	O

In	O
our	O
study,	O
α-CEHC	B
was	O
upregulated	O
in	O
cancer	O
patients	O
compared	O
to	O
that	O
in	O
the	O
healthy	O
controls,	O
and	O
the	O
fold	O
change	O
was	O
4.38,	O
which	O
confirms	O
an	O
accelerated	O
vitamin	B
E	I
metabolism.	O

It	O
is	O
also	O
thought	O
that	O
the	O
α-ketoglutarate	B
formed	O
in	O
this	O
pathway	O
can	O
pass	O
backwards	O
(i.e.	O
anticlockwise)	O
through	O
the	O
TCA	O
to	O
citrate	B
which	O
can	O
be	O
bled	O
off	O
to	O
form	O
fatty	O
acids.	O

In	O
contrast,	O
phosphatidylglycerols	B
(PG)	O
were	O
found	O
in	O
cluster	O
two,	O
indicating	O
the	O
presence	O
of	O
mucus	O
in	O
mucinous	O
subtype	O
colorectal	O
malignant	O
tissue_,	O
as	O
PGs	O
generally	O
serve	O
as	O
surfactants	O
in	O
the	O
human	O
body.	O

After	O
having	O
been	O
vortexed	O
for	O
10	O
s,	O
samples	O
were	O
applied	O
to	O
Strata-XC	O
solid	O
phase	O
extraction	O
(SPE)	O
columns	O
(60	O
mg/3	O
mL)	O
(Phenomenex,	O
Torrance,	O
CA,	O
USA)	O
preconditioned	O
with	O
1	O
mL	O
methanol	B
followed	O
by	O
1	O
mL	O
0.1%	O
perchloric	B
acid.	I

×	O
RT_2	O
+	O
(21.61	O
×	O
RT)	O
+	O
507.9,	O
with	O
the	O
RIs	O
of	O
FAMES	O
defined	O
as	O
800	O
for	O
methyl	B
octanoate,	I
900	O
for	O
methyl	B
nonanoate,	I
and	O
so	O
on.	O

Tyrosine	B
levels	O
showed	O
a	O
unique	O
correlation	O
with	O
diabetic	O
microangiopathy	O
in	O
T2DM	O
patients	O
compared	O
to	O
any	O
other	O
single	O
marker.	O

Because	O
the	O
effect	O
of	O
RCE	O
and	O
its	O
isoflavones	B
on	O
estrogen	B
metabolism	O
had	O
not	O
been	O
previously	O
investigated,	O
we	O
studied	O
their	O
effects	O
in	O
two	O
different	O
cell	O
lines.	O

The	O
score	O
plot	O
(Figure A)	O
and	O
S‐plot	O
(Figure B)	O
revealed	O
the	O
metabolic	O
effect	O
of	O
tumours,	O
including	O
elevated	O
levels	O
of	O
glycocholate,	B
citrulline,	B
succinate,	B
cis‐aconitate,	O
malate,	B
glutamine,	B
pyruvate,	B
methionine,	B
citrate,	B
tyrosine,	B
myo‐inositol,	O
acetone,	B
valine,	B
isoleucine,	B
n‐acetylcysteine,	B
anserine,	B
alanine,	B
methylmalonate,	B
taurine,	B
glutamate,	B
n‐acetylglutamate,	B
fatty	O
acid,	O
leucine,	B
lactate,	B
and	O
1‐methylhistidine	B
and	O
decreased	O
levels	O
of	O
choline,	B
glucose,	B
carnitine,	B
and	O
glycine.	B

Either	O
deficient	O
or	O
excessive	O
renal	O
production	O
of	O
20-HETE	B
was	O
reported	O
to	O
elevate	O
blood	O
pressure.	O

The	O
BMI	O
was	O
not	O
associated	O
with	O
the	O
serum	O
concentration	O
of	O
the	O
8	O
analyte	O
sphingolipids.	B

Abbreviations:	O
BMI,	O
body	O
mass	O
index;	O
FA,	B
fatty	O
acid;	O
HDL,	O
high-density	O
lipoprotein.	O

In	O
addition,	O
overall	O
retention	O
was	O
reduced,	O
which	O
could	O
be	O
due	O
to	O
either	O
the	O
different	O
packing	O
materials	O
(B:	O
polymer,	O
E:	O
silica)	O
or	O
the	O
absence	O
of	O
a	O
terminal	O
acid	O
moiety	O
on	O
the	O
surface	O
of	O
E.	O
On	O
amide	B
column	O
F,	O
we	O
observed	O
inconsistent	O
elution	O
sequences	O
of	O
the	O
nucleobases	O
(U<T≪G~A<C)	O
compared	O
to	O
the	O
respective	O
nucleosides	O
(U<A<C,	O
G	O
not	O
detected)	O
and	O
deoxynucleosides	O
(T<dU<dC<dG~dA).	O

In	O
case	O
of	O
sulfatase,	O
only	O
modest	O
levels	O
(<5 %	O
of	O
sulfatase + glucorindase	O
concentrations)	O
were	O
observed	O
in	O
the	O
last	O
three	O
urine	O
fractions;	O
no	O
diosmetin	B
concentrations	O
were	O
measured	O
in	O
the	O
undigested	O
samples.	O

The	O
higher	O
area	O
under	O
curve	O
value	O
was	O
achieved	O
in	O
1-methyladenosine	B
group	O
than	O
AFP	O
group	O
(0.802	O
vs.	O
0.592),	O
and	O
the	O
diagnostic	O
model	O
combining	O
1-methyladenosine	B
with	O
AFP	O
exhibited	O
significant	O
improved	O
sensitivity,	O
which	O
could	O
identify	O
those	O
patients	O
who	O
missed	O
the	O
diagnosis	O
of	O
HCC	O
by	O
determining	O
serum	O
AFP	O
alone.	O

To	O
determine	O
whether	O
20-HETE	B
can	O
activate	O
small	O
GTPase	O
Ras,	O
HRPTEC	O
cells	O
were	O
treated	O
with	O
20	O
μM	O
WIT003	O
(20-HETE	O
agonist)	O
and	O
incubated	O
with	O
Ras	O
binding	O
domain	O
(RBD)	O
of	O
Raf1,	O
to	O
specifically	O
isolate	O
the	O
active	O
GTP-bound	O
form	O
of	O
Ras.	O

Furthermore,	O
higher	O
levels	O
of	O
circulating	O
LPC	O
could	O
reflect	O
a	O
lower	O
rate	O
of	O
atherogenic	O
lysophosphatidic	B
acid	I
production	O
via	O
autotaxin-mediated	O
LPC	O
hydrolysis,	O
thus	O
conferring	O
a	O
net	O
protective	O
effect	O
on	O
CVD	O
.	O

Interestingly,	O
hVDAC2(12–36)	O
showed	O
the	O
smallest	O
full-width	O
at	O
half-maximum	O
(FWHM)	O
among	O
the	O
three	O
hVDAC	O
peptides,	O
with	O
a	O
value	O
of	O
48	O
cm_–1	O
,	O
whereas	O
the	O
amide	B
I	O
bands	O
of	O
hVDAC3(1–25)	O
and	O
hVDAC1(1–25)	O
were	O
slightly	O
larger,	O
with	O
FWHM	O
of	O
50	O
and	O
53	O
cm_–1	O
,	O
respectively.	O

In	O
general,	O
the	O
results	O
in	O
suggest	O
that	O
conjugation	O
with	O
sulfonate	B
is	O
the	O
major	O
phase	O
II	O
metabolism	O
pathway	O
in	O
the	O
human	O
brain.	O

A	O
clear	O
peak	O
corresponding	O
to	O
the	O
accurate	O
mass	O
of	O
the	O
analyte,	O
matching	O
the	O
retention	O
time	O
of	O
sulfoxide	B
standards	O
8,	O
11,	O
15	O
and	O
18	O
was	O
observed	O
in	O
all	O
samples	O
of	O
creosote	O
workers’	O
urine.	O

AV	B
differences,	O
expressed	O
as	O
percentages	O
of	O
extraction	O
or	O
release,	O
were	O
generated	O
by	O
taking	O
the	O
difference	O
of	O
the	O
[metabolite]_peripheral	O
–	O
[metabolite]_CS	O
and	O
dividing	O
by	O
the	O
[metabolite]_peripheral	O
.	O

Elevated	O
levels	O
of	O
amino	O
acids	O
(alanine	O
and	O
pyroglutamic	B
acid)	O
and	O
phenolic	O
compounds	O
(hydroxyphenyl	O
acetate	I
and	O
hydroxyphenyl	B
propionate)	I
were	O
found	O
in	O
IBS.	O

Sample	O
injection	O
was	O
performed	O
hydrodynamically	B
for	O
80 s	O
at	O
50 mbar.	O

The	O
metformin–MG	O
imidazolinone	B
identified	O
herein	O
therefore	O
warrants	O
further	O
study	O
with	O
respect	O
to	O
its	O
pharmacokinetic	O
and	O
potential	O
pharmacodynamic	O
properties,	O
its	O
ability	O
to	O
exhibit	O
ligand	O
activity	O
at	O
I1R,	O
and	O
whether	O
insulin	O
sensitivity	O
may	O
be	O
enhanced	O
as	O
a	O
result.	O

In	O
this	O
case,	O
long-term	O
treatment	O
with	O
low	O
concentration	O
of	O
several	O
long-lived	O
species	O
by	O
plasma	O
might	O
be	O
suppressed	O
and	O
would	O
be	O
benefit	O
to	O
those	O
diseases	O
that	O
have	O
abnormal	O
high	O
level	O
of	O
glutamate	B
and	O
purine	B
metabolism.	O

Our	O
metabolomics	O
analysis	O
revealed	O
that	O
the	O
Krebs	O
cycle	O
is	O
significantly	O
hindered	O
at	O
the	O
citrate-isocitrate	B
level,	O
which	O
is	O
used	O
for	O
lipogenesis	O
in	O
IR;	O
thus,	O
less	O
energy	O
is	O
produced	O
through	O
the	O
Krebs	O
cycle.	O

Abbreviations:	O
body	O
mass	O
index	O
(BMI),	O
mini-mental	O
examination	O
(MMSE),	O
waist-hip	O
ratio	O
(WHR),	O
low	O
density	O
lipoprotein	O
cholesterol	B
(LDL-C),	O
high	O
density	O
lipoprotein	O
cholesterol	B
(HDL-C).	O

Conversely,	O
in	O
moderate	O
to	O
severe	O
steatosis,	O
the	O
levels	O
of	O
triglyceride,	B
oleic	B
acid,	I
and	O
some	O
amino	O
acids	O
were	O
high	O
but	O
there	O
was	O
a	O
significant	O
depletion	O
of	O
PUFA.	O

Two	O
independent	O
enzalutamide	B
and	O
N-desmethylenzalutamide	B
stocks	O
were	O
used:	O
one	O
for	O
the	O
preparation	O
of	O
calibration	O
standards	O
and	O
one	O
for	O
the	O
quality	O
control	O
samples	O
(QC).	O

In	O
a	O
small	O
controlled	O
study,	O
the	O
number	O
of	O
individuals	O
with	O
faecal	O
calprotectin	O
levels	O
below	O
50	O
μg/g	O
stool	O
were	O
greater	O
in	O
those	O
randomized	O
to	O
an	O
increased	O
dose	O
of	O
mesalazine.	B

(CH_3	O
OH);	O
perdeuterated	O
water,	O
99%	O
D	O
(D_2	O
O);	O
phosphate	B
buffer	O
saline	B
(PBS)	O
was	O
prepared	O
at	O
10	O
mM	O
total	O
phosphate	B
concentration	O
(KH_2	O
PO_4	O
+	O
K_2	O
HPO_4)	O
and	O
150	O
mM	O
NaCl,	O
pH	O
7.4.	O

Patients	O
with	O
Killip	O
class > I	O
on	O
admission,	O
heart	O
failure,	O
serum	O
creatinine	B
>250	O
µmol/L,	O
alanine	O
aminotransferase	O
>135 U/L,	O
severe	O
fatty	O
liver	O
or	O
liver	O
cirrhosis,	O
or	O
malignant	O
tumours	O
were	O
excluded,	O
as	O
were	O
patients	O
who	O
had	O
taken	O
amino	O
acid	O
supplements	O
in	O
the	O
preceding	O
3	O
months.	O

The	O
chromatographic	O
conditions	O
of	O
LC-MS/MS	O
were	O
improved	O
quantitatively	O
for	O
maximum	O
analytical	O
peak	O
quality	O
with	O
short	O
run	O
time,	O
using	O
a	O
mobile	O
phase	O
prepared	O
by	O
mixing	O
of	O
70%	O
methanol	B
and	O
30%	O
of	O
a	O
mixture	O
of	O
20 mM	O
ammonium	B
acetate	I
and	O
0.2 mM	O
formic	B
acid	I
and	O
was	O
eluted	O
isocratically	O
with	O
a	O
flow	O
rate	O
of	O
1 mL	O
min_−1	O
through	O
ACE™	O
C18	O
(50	O
×	O
2.1 mm,	O
5 μ	O
m)	O
column	O
for	O
LC-MS/MS.	O

A	O
comparison	O
of	O
the	O
postprandial	O
response	O
to	O
the	O
foods	O
shows	O
that	O
the	O
levels	O
of	O
C15:0,	B
C17:0,	B
and	O
unknown	O
C17	O
acid	O
were	O
higher	O
4	O
h	O
after	O
milk	O
and	O
cheese	O
intake	O
when	O
compared	O
to	O
soy	O
drink	O
intake,	O
and	O
were	O
higher	O
6	O
h	O
after	O
milk	O
intake	O
when	O
compared	O
to	O
soy	O
drink	O
intake	O
(see	O
lower	O
graph	O
of	O
panels	O
in	O
and	O
Tables	O
S3	O
and	O
S4).	O

Moreover,	O
tyrosine	B
has	O
been	O
identified	O
as	O
the	O
only	O
metabolite	O
significantly	O
associated	O
with	O
HOMA	O
in	O
obesity-independent	O
models	O
[,].	O

Alanine	B
produced	O
by	O
transamination	O
of	O
pyruvate	B
in	O
muscles	O
is	O
transported	O
to	O
the	O
liver	O
where	O
it	O
enters	O
neo-glycogenesis	O
after	O
inverse	O
transamination	O
to	O
pyruvate.	B

We	O
found	O
a	O
strong	O
inverse	O
association	O
of	O
urinary	O
hippurate	B
across	O
the	O
range	O
of	O
BMI	O
(P	O
=	O
1.52	O
×	O
10_−14	O
,	O
);	O
a	O
weak	O
inverse	O
association	O
with	O
adiposity	O
has	O
been	O
reported	O
previously	O
only	O
in	O
morbidly	O
obese	O
humans	O
as	O
well	O
as	O
in	O
dogs	O
and	O
mice	O
(,	O
).	O

For	O
instance,	O
urinary	O
phosphatidylcholines	B
concentrations	O
were	O
significantly	O
higher	O
both	O
in	O
glomerulonephritis	O
and	O
tubulointerstitial	O
injury	O
than	O
in	O
healthy	O
controls.	O

Fasting	O
blood	O
samples	O
were	O
collected	O
and	O
HbA1c	O
and	O
serum	O
total	O
and	O
HDL-cholesterol	B
levels	O
were	O
measured	O
using	O
standard	O
laboratory	O
protocols.	O

Methylated	B
catechols	I
of	O
the	O
2-pathway	O
increased	O
as	O
a	O
proportion	O
of	O
total	O
EM	O
across	O
soy	O
tertiles	O
(p_trend	O
<0.01)	O
while	O
%methylated	B
catechols	I
in	O
the	O
4-hydroxylation	O
pathway	O
showed	O
no	O
linear	O
trend	O
(p_trend	O
=0.80).	O

In	O
two	O
nested	O
case-control	O
clinical	O
trials,	O
women	O
in	O
the	O
highest	O
vs	O
lowest	O
quintiles	O
of	O
plasma	O
levels	O
of	O
DHEA-S	B
and	O
androgens	O
had	O
greater	O
risk	O
of	O
developing	O
breast	O
cancer	O
[,	O
].	O

For	O
S1P	O
analysis,	O
the	O
extracted	O
lipids	O
underwent	O
an	O
additional	O
trimethylsilyl-diazomethane	B
derivatization	O
step.	O

Low-flow,	O
ion-pairing	O
liquid	O
chromatography-tandem	O
mass	O
spectrometry	O
(LC–MS-MS)	O
was	O
used	O
to	O
separate	O
and	O
detect	O
the	O
metabolites	O
of	O
sofosbuvir	B
and	O
ribavirin	B
(see	O
Fig.	O

We	O
tried	O
using	O
both	O
50%	O
MeOH	B
and	O
80%	O
MeOH	B
as	O
quenching	O
buffers,	O
followed	O
by	O
an	O
extraction	O
using	O
different	O
ratios	O
and	O
volumes	O
of	O
CHCl_3	O
and	O
polar	O
phases	O
in	O
cells	O
cultured	O
with	O
20%	O
FCS	O
compared	O
to	O
standard	O
cell	O
culture	O
conditions.	O

The	O
systems	O
level	O
alteration	O
of	O
metabolites	O
in	O
glycerophospholipid	B
metabolism	O
pathway	O
is	O
consistent	O
with	O
metabolomics	O
studies	O
of	O
BC	O
in	O
other	O
populations.	O

α	B
-Hydroxybutyrate	I
and	O
BCAA	O
levels	O
were	O
consistently	O
increased	O
throughout	O
the	O
OGTT	O
in	O
adolescents	O
with	O
lower	O
WBISI	O
(WBISI	O
effect,	O
P	O
<	O
0.03	O
for	O
all).	O

The	O
extracted	O
solution	O
was	O
evaporated	O
to	O
dryness	O
under	O
gentle	O
flow	O
of	O
nitrogen	O
and	O
reconstituted	O
with	O
HPLC	O
grade	O
acetonitrile	B
up	O
to	O
1.0	O
mL.	O
Before	O
injection,	O
the	O
extracted	O
samples	O
were	O
filtered	O
through	O
PTFE	O
membrane	O
(pore	O
size:	O
0.45μm,	O
Millipore).	O

Mass	O
calibration	O
was	O
done	O
with	O
perfluorotributylamine	B
(PFTBA).	O

We	O
previously	O
reported	O
a	O
weaker	O
vitamin	O
B-12	O
biochemical	O
response	O
to	O
vitamin	O
B-12	O
treatment	O
in	O
participants	O
from	O
this	O
study	O
who	O
had	O
moderately	O
high	O
and	O
high	O
folate	B
at	O
baseline.	O

200	O
µL	O
of	O
the	O
supernatant	O
were	O
transferred	O
to	O
a	O
GC	O
autosampler	O
vial	O
and	O
spiked	O
with	O
20	O
µl	O
of	O
myristic	B
acid-d27	O
(Sigma	O
Aldrich),	O
used	O
as	O
the	O
internal	O
standard	O
for	O
retention	O
time	O
lock	O
(RTL	O
system	O
provided	O
in	O
Agilent’s	O
ChemStation	O
Software),	O
and	O
lyophilized	O
overnight	O
(Lyotrap	O
freeze	O
dryer).	O

In	O
the	O
DM	O
patients	O
(n	O
 = 11),	O
the	O
aqueous	O
and	O
vitreous	O
concentrations	O
of	O
GSSSG,	O
cystine	B
and	O
CysSSH	O
were	O
correlated	O
(r = 0.63,	O
P	O
 < 0.05;	O
r = 0.73,	O
P	O
 = 0.01;	O
r = 0.72,	O
P	O
 = 0.01),	O
although	O
the	O
aqueous	O
and	O
vitreous	O
concentrations	O
of	O
Cys	O
were	O
not	O
(lower).	O

This	O
finding	O
served	O
as	O
an	O
internal	O
control	O
confirming	O
quality	O
of	O
metabolite	O
extraction	O
and	O
analytic	O
pipeline	O
given	O
that	O
our	O
tissue	O
samples	O
were	O
extracted	O
with	O
citrate	B
buffer.	O

The	O
liver	O
is	O
central	O
to	O
galactose	B
metabolism;	O
however,	O
there	O
are	O
no	O
reported	O
alterations	O
in	O
galactose	B
metabolism	O
in	O
tumor	O
cells.	O

Neutral	O
loss	O
scan	O
mode	O
and	O
precursor	O
ion	O
scan	O
mode,	O
respectively,	O
were	O
used	O
for	O
specific	O
detection	O
of	O
respective	O
lipid	O
classes:	O
precursor	O
scan	O
at	O
m/z	O
184	O
for	O
phosphatidylcholines	B
(PC);	O
neutral	O
loss	O
scan	O
at	O
m/z	O
115	O
for	O
phosphatidic	B
acids,	I
at	O
m/z	O
141	O
for	O
phosphatidylethanolamines	B
(PE),	O
at	O
m/z	O
185	O
for	O
phosphatidylserines	B
(PS),	O
and	O
at	O
m/z	O
277	O
for	O
phosphatidylinositols	B
(PI).	O

Chemical	O
shifts	O
were	O
referenced	O
to	O
the	O
glycine	B
peak	O
in	O
the	O
HSQC	O
spectra.	O

Histidine,	B
glutamine,	B
tyrosine,	B
creatine,	B
phenylalanine,	B
lactic	B
acid,	I
and	O
adonitol	B
showed	O
an	O
elevated	O
concentration	O
and	O
3,7-cholest-5-ene	B
showed	O
reduced	O
concentration	O
from	O
control	O
to	O
benign	O
to	O
IDC.	O

Figures	O
and	O
show	O
the	O
Kaplan-Meier	O
time-to-event	O
curves	O
for	O
the	O
occurrence	O
of	O
MACE	O
for	O
each	O
quartile	O
of	O
GABR	O
and	O
citrulline,	B
respectively.	O

We	O
collected	O
a	O
set	O
of	O
relevant	O
clinical	O
variables	O
at	O
baseline,	O
including	O
age	O
at	O
study	O
inclusion,	O
sex,	O
disease	O
subtype,	O
disease	O
duration,	B
and	O
EDSS	O
score.	O

Weak	O
wash	O
solvent	O
was	O
H_2	O
O-methanol	B
(1:1,	O
v/v)	O
and	O
strong	O
wash	O
solvent	O
was	O
acetonitrile/isopropanol	O
(3:1,	O
v/v).	O

The	O
present	O
study	O
adds	O
new	O
knowledge	O
to	O
a	O
recent	O
study	O
in	O
Europeans	O
by	O
demonstrating	O
consistent	O
associations	O
of	O
cholesterol	B
and	O
TG	B
when	O
present	O
in	O
apolipoprotein	O
B–containing	O
lipoproteins,	O
yet	O
differential	O
associations	O
of	O
cholesterol	B
and	O
TG	B
when	O
present	O
in	O
HDL	O
lipoproteins.	O

Higher	O
BMI	O
also	O
increases	O
estrogen	B
production.	O

Age,	O
age	O
at	O
partus;	O
BMI,	O
BMI	O
at	O
start	O
of	O
pregnancy	O
(kg/m_2	O
);	O
ethnic,	O
%	O
Nordic	O
ethnicity;	O
glucose,	B
fasting	O
p-glucose	B
(mM)	O
at	O
time	O
of	O
GDM	O
diagnosis;	O
diagnose,	O
gestational	O
age	O
at	O
time	O
of	O
GDM	O
diagnosis;	O
and	O
insulin	O
req,	O
required	O
insulin	O
treatment	O
during	O
GDM	O
pregnancy.	O
_∗	O
P	O
<	O
0.05	O
versus	O
NGT.	O

Using	O
0.025‐mL	O
aliquots	O
of	O
sample	O
for	O
analysis,	O
the	O
lower	O
limits	O
of	O
quantification	O
for	O
plasma	O
assays	O
were	O
as	O
follows:	O
0.100	O
ng/mL	O
for	O
risperidone,	B
paliperidone	B
(9‐hydroxyrisperidone),	I
and	O
olanzapine;	B
2.00	O
ng/mL	O
for	O
quetiapine,	B
and	O
1.00	O
ng/mL	O
for	O
aripiprazole	B
and	O
dehydroaripiprazole.	B

In	O
particular,	O
high	O
levels	O
of	O
cholesterol,	B
myo-inositol-1-phosphate,	B
citric	B
acid,	I
fumarate,	B
glycerol-3-phosphate,	B
and	O
fatty	O
acids	O
were	O
found	O
in	O
PCa	O
bone	O
metastases	O
samples	O
compared	O
to	O
normal	O
bone.	O

All	O
differentially	O
regulated	O
plasma	O
metabolites	O
were	O
phospholipids	B
with	O
the	O
most	O
pronounced	O
differences	O
observed	O
in	O
SMs.	O

These	O
portions	O
of	O
the	O
spectra	O
are	O
principally	O
related	O
to	O
LDL1	O
lipoproteins,	O
mainly	O
associated	O
to	O
cholesterol,	B
phospholipids	B
and	O
Apo-B	O
subfractions,	O
and	O
to	O
creatinine	B
signals	O
(B).	O

The	O
spectral	O
peaks	O
of	O
the	O
associated	O
protons	O
of	O
ATP	B
(i-iii)	O
and	O
aspartate	B
(vi)	O
are	O
shown	O
in	O
the	O
whole	O
blood	O
spectrum.	O

Among	O
all	O
potential	O
biomarkers,	O
2-amino-3-methyl-1-butanol,	B
L-carnitine,	B
Asn	O
Asn	O
Gln	O
Arg,	O
Ala	O
Cys	O
Ser	O
Trp,	O
Soladulcidine,	B
Ala	O
Ile	O
Gln	O
Arg,	O
2-amino-3	B
-Methyl-1-butanol,	I
L-carnitine,	B
Asn	O
Asn	O
Gln	O
Arg,	O
Ala	O
Cys	O
Ser	O
Trp,	O
Soladulcidine,	B
Ala	O
Ile	O
Gln	O
Arg	O
can	O
be	O
used	O
as	O
predictors	O
of	O
precancerous	O
lesions	O
at	O
different	O
stages	O
of	O
CC.	O

Conceivably	O
more	O
sensitive	O
markers	O
of	O
anhedonia	O
such	O
behavioral	O
or	O
neurophysiological	O
responses	O
to	O
reward	O
and/or	O
positively-valenced	O
stimuli,	O
which	O
have	O
been	O
shown	O
to	O
be	O
abnormal	O
in	O
rMDD	O
subjects	O
(;	O
;	O
),	O
might	O
have	O
shown	O
associations	O
with	O
kynurenine	B
metabolites	O
in	O
the	O
rMDD	O
group.	O

Escobar-Morreale	O
et	O
al	O
.	O
found	O
PCOS	O
was	O
associated	O
with	O
decreased	O
alanine	B
concentrations,	O
but	O
GC/TOF-MS	O
analysis	O
in	O
our	O
data	O
revealed	O
obviously	O
elevated	O
levels	O
of	O
alanine	B
in	O
PCOS	O
plasma.	O

_–	O
Nuclear	O
magnetic	O
resonance	O
(NMR)	O
spectroscopy	O
and	O
mass	O
spectrometry	O
(MS)	O
enable	O
reliable	O
identification	O
and	O
quantitation	O
of	O
a	O
large	O
number	O
of	O
blood	O
metabolites	O
(including	O
glutamine)	B
on	O
a	O
routine	O
basis._,	O
However,	O
numerous	O
investigations	O
using	O
standard	O
compounds	O
have	O
shown	O
that	O
under	O
abnormal	O
conditions,	O
the	O
glutamine	B
molecule	O
is	O
not	O
stable.	O

The	O
relationship	O
between	O
gradient	O
duration,	B
peak	O
capacity	O
and	O
the	O
number	O
of	O
mass	O
spectrometric	O
features	O
(ions)	O
detected	O
using	O
columns	O
of	O
30,	O
75	O
or	O
150 mm	O
in	O
length	O
and	O
either	O
UPLC/MS	O
or	O
UPLC/IMS/MS	O
(constructed	O
from	O
the	O
data	O
presented	O
in	O
).	O

Mixture	O
of	O
C_7	O
–C_40	O
n-alkanes,	O
each	O
at	O
1000 g L_−1	O
were	O
acquired	O
from	O
Sigma-Aldrich	O
Química	O
SL	B
(Madrid,	O
Spain).	O

In	O
diabetic	O
patients,	O
ketone	B
body	O
concentration	O
is	O
high	O
and	O
their	O
detection	O
in	O
urine	O
is	O
a	O
danger	O
marker	O
which	O
suggests	O
a	O
poorly	O
controlled	O
diabetes.	O

During	O
ischemia,	O
increased	O
degradation	O
of	O
adenosine	B
triphosphate	I
and	O
activity	O
of	O
xanthine	B
oxidase	O
may	O
lead	O
to	O
the	O
formation	O
of	O
xanthine	B
and	O
uric	B
acid.	I

Effects	O
of	O
inter-individual	O
differences	O
in	O
urinary	O
creatinine	B
clearance	O
on	O
NNAL	O
concentrations	O
were	O
then	O
assessed	O
and	O
three	O
metabolizer	O
phenotypes	O
were	O
identified	O
in	O
the	O
60	O
subjects	O
from	O
the	O
ratio	O
of	O
urinary	O
NNAL	O
glucuronides/free	O
NNAL.	O

9-hydroxyphenanthrene	B
and	O
3-hydroxyfluoranthene	B
could	O
also	O
be	O
separated	O
from	O
the	O
other	O
target	O
metabolites	O
(data	O
not	O
shown).	O

In	O
contrast,	O
there	O
was	O
no	O
difference	O
between	O
the	O
two	O
groups	O
in	O
the	O
level	O
of	O
methyl-lysine	B
(2.21	O
μM	O
vs	O
2.17	O
μM,	O
p	O
=	O
0.45).	O

p < 0.0001),	O
linoleic	B
acid	I
(β = 0.133;	O
p < 0.0001),	O
4-pyridoxic	B
acid	I
(β = 0.142;	O
p < 0.0001),	O
phosphatidylglycerol	B
(20:3/2:0)	I
(β = 0.287;	O

Various	O
enzymes	O
are	O
involved	O
in	O
this	O
alteration	O
of	O
choline	B
pathways,	O
including	O
glycerophosphocholine	O
phosphodiesterases	O
(GDPDs).	O

In	O
this	O
regard,	O
aggressive	O
risk	O
factor	O
modification	O
in	O
patients	O
with	O
AF	B
can	O
reverse	O
adverse	O
atrial	O
remodeling.	O

It	O
is	O
possible	O
that	O
some	O
or	O
all	O
of	O
the	O
PG	B
lipids	O
identified	O
are	O
actually	O
monoacylglycerophosphomonoradylglycerols	B
(LBPAs)	O

All	O
values	O
represent	O
the	O
mean	O
and	O
standard	O
deviation	O
of	O
the	O
sample	O
size	O
denoted,	O
except	O
for	O
the	O
DHEA-G	O
in	O
the	O
goserelin	O
and	O
bicalutamide	B
arm	O
where	O
the	O
individual	O
values	O
are	O
listed.	O

For	O
example,	O
the	O
ratio	O
between	O
intercellular	O
ATP	B
and	O
AMP	B
has	O
been	O
used	O
to	O
estimate	O
the	O
malfunction	O
of	O
the	O
mitochondria	O
dysfunction	O
during	O
aging	O
and	O
pathology.	O

It	O
is	O
widely	O
recognized	O
that	O
endogenous	O
estrogen	B
is	O
associated	O
with	O
increased	O
risk	O
of	O
postmenopausal	O
breast	O
cancer.	O

Methionine	B
is	O
an	O
essential	O
amino	O
acid	O
and	O
a	O
precursor	O
of	O
homocysteine,	B
a	O
metabolite	O
also	O
shown	O
highly	O
elevated	O
in	O
plasma	O
and	O
colonic	O
mucosa	O
from	O
UC	O
and	O
CD	O
patients.	O

Nevertheless,	O
the	O
AUC	O
of	O
clinical	O
risk	O
factors	O
in	O
normoglycaemic	B
individuals	O
was	O
still	O
>	O
80%,	O
slightly	O
higher	O
than	O
reported	O
in	O
other	O
recent	O
studies	O
[,	O
].	O

12-HETE	B
and	O
15-HETE	B
are	O
products	O
of	O
lipoxygenase	O
and	O
cytochrome	O
P450	O
enzymes	O
and	O
exert	O
both	O
pro	O
and	O
anti-inflammatory	O
effects.	O

Lower	O
levels	O
of	O
tryptophan	B
were	O
also	O
correlated	O
with	O
higher	O
WURS	O
score.	O

Lysophosphatidylcholine	B
(18:0)	I
were	O
purchased	O
from	O
Larodan	O
AB	O
(Malmö,	O
Sweden).	O

The	O
module	O
MEturquoise	O
of	O
metabolites	O
was	O
significantly	O
associated	O
with	O
the	O
frequency	O
of	O
abdominal	O
pain	O
(R	O
=	O
0.59,	O
p	O
=	O
6e-04),	O
the	O
frequency	O
of	O
abdominal	O
discomfort	O
(R	O
=	O
0.6,	O
p	O
=	O
5e-04),	O
defections	O
(R	O
=	O
0.59,	O
p	O
=	O
6e-04),	O
stool	O
trait	O
(R	O
=	O
0.62,	O
p	O
=	O
3e-04),	O
post-surgical	O
relief	O
of	O
abdominal	O
pain	O
(R	O
=	O
−0.41,	O
p	O
=	O
0.02),	O
and	O
duration	B
of	O
symptoms	O
(R	O
=	O
0.51,	O
p	O
=	O
0.004).	O

Separately,	O
the	O
model	O
was	O
also	O
tested	O
on	O
the	O
recurrent	O
breast	O
cancer	O
patients	O
based	O
on	O
the	O
stage	O
of	O
the	O
cancer	O
at	O
the	O
initial	O
diagnosis,	O
the	O
type	O
of	O
recurrence,	O
estrogen	B
(ER)	O
and	O
progesterone	B
(PR)	O
receptors	O
status.	O

Similarly	O
in	O
the	O
IBS	O
category,	O
the	O
majority	O
of	O
patients	O
were	O
either	O
on	O
mebeverine	O
or	O
loperamide.	B

Matrix	O
effect	O
and	O
recovery	O
were	O
assessed	O
in	O
three	O
replicates	O
at	O
three	O
concentration	O
levels	O
(low,	O
mid,	O
and	O
high)	O
for	O
paclitaxel	O
(50.0,	O
250.0,	O
and	O
1250 ng/mL),	O
docetaxel	O
and	O
SN-38	O
(20.0,	O
100.0,	O
and	O
500.0 ng/mL),	O
vinorelbine	O
and	O
pemetrexed	O
(200.0,	O
1000.0,	O
and	O
5000.0 ng/mL),	O
vinblastine	B
and	O
irinotecan	O
(50.0,	O
500.0,	O
and	O
5000.0 ng/mL),	O
cyclophosphamide	O
and	O
ifosfamide	B
(5.0,	O
50.0,	O
and	O
500.0 ng/mL),	O
and	O
carboplatin,	B
etoposide,	B
and	O
gemcitabine	O
(100.0,	O
500.0,	O
and	O
2500.0 ng/mL).	O

On	O
the	O
contrary,	O
αHCA	O
and	O
HDCA,	O
the	O
hepatic	O
6α-hydroxylated	O
metabolites	O
of	O
CDCA	O
and	O
LCA,	O
were	O
inclined	O
to	O
be	O
excreted	O
in	O
urine	O
and	O
existed	O
in	O
urine	O
mainly	O
as	O
sulfates	B
and/or	O
glucuronides.	O

Although	O
differential	O
cytokine	O
patterns	O
between	O
the	O
two	O
groups	O
are	O
observed,	O
these	O
differences	O
did	O
not	O
reach	O
statistical	O
significance,	O
likely	O
due	O
to	O
the	O
wide	O
inter-patient	O
cytokine	O
variability	O
(Figure	O
S2).This	O
apparently	O
negative	O
result	O
does	O
not	O
exclude	O
specific	O
immunological	O
interactions	O
since	O
TILs,	O
that	O
characterizes	O
the	O
ER(−)	O
better	O
than	O
the	O
ER(+)	B
tumor	O
tissue	O
[,],	O
could	O
contribute	O
to	O
determine	O
local	O
specific	O
interactions	O
that	O
can	O
be	O
better	O
decoded	O
by	O
the	O
circulatory	O
metabolomics	O
profiles.	O

In	O
individuals	O
with	O
normal	O
fasting	O
glucose	B
who	O
progressed	O
to	O
type	O
2	O
diabetes,	O
we	O
identified	O
19	O
metabolites	O
associated	O
with	O
type	O
2	O
diabetes	O
incidence	O
Information	O
from	O
these	O
19	O
metabolites	O
improved	O
the	O
predictive	O
capability	O
of	O
incident	O
type	O
2	O
diabetes	O
beyond	O
conventional	O
clinical	O
risk	O
factors	O
These	O
metabolites	O
identify	O
alterations	O
in	O
nitrogen	O
metabolism	O
pathways	O
that	O
may	O
contribute	O
to	O
the	O
earliest	O
stages	O
of	O
type	O
2	O
diabetes	O
pathogenesis	O
If	O
these	O
findings	O
are	O
confirmed	O
in	O
other	O
populations,	O
we	O
would	O
have	O
confidence	O
that	O
measurement	O
of	O
a	O
defined	O
set	O
of	O
metabolites	O
could	O
help	O
identify	O
individuals	O
at	O
risk	O
for	O
future	O
type	O
2	O
diabetes,	O
even	O
when	O
they	O
appear	O
clinically	O
at	O
low	O
risk	O

Another	O
study	O
from	O
the	O
same	O
group	O
(Medina-Gomez	O
)	O
identified	O
a	O
major	O
decrease	O
of	O
TAG(48:2)	B
in	O
the	O
POKO	O
mouse	O
(a	O
double	O
gene	O
deletion	O
of	O
the	O
leptin	O
receptor	O
and	O
PPARγ)	B
and	O
a	O
minor	O
decrease	O
in	O
white	O
adipose	O
tissue	O
(WAT)	O
from	O
ob/ob	O
mice.	O

Purification	O
was	O
performed	O
on	O
a	O
52	O
×	O
2.5	O
cm	O
Sephadex	O
LH-20	O
column	O
using	O
methanol	B
as	O
the	O
eluting	O
solvent.	O

Interestingly,	O
2-hydroxybutyrate	B
showed	O
significant	O
increases	O
in	O
serum	O
and	O
plasma	O
of	O
both	O
UC	O
and	O
CD	O
patients	O
as	O
compared	O
to	O
control	O
subjects.	O

For	O
the	O
comparison	O
between	O
cachectic	O
and	O
pre-cachectic	O
patients,	O
glycerol	B
phosphate	I
shuttle,	O
and	O
alanine	B
and	O
riboflavin	B
metabolism	O
were	O
identified.	O

Liu	O
et	O
al.	O
suggested	O
a	O
possible	O
prognostic	O
value	O
of	O
preoperative	O
serum	O
TMAO	B
level	O
in	O
108	O
colorectal	O
cancer	O
patients.	O

Plasma	O
concentrations	O
of	O
TMAO,	B
choline,	B
betaine,	B
creatinine,	B
and	O
L-carnitine	B
were	O
measured	O
by	O
LC-MS.	O

For	O
GC,	O
in	O
contrast,	O
hydrophilic	B
metabolite	O
separation	O
must	O
be	O
conducted	O
after	O
derivatization	O
(e.g.,	O
trimethylsilylation)	O
of	O
hydrophilic	B
residues	O
to	O
increase	O
volatility.	O

However,	O
the	O
consistency	O
of	O
the	O
erythritol	B
results	O
in	O
both	O
the	O
central	O
adiposity	O
and	O
usual	O
glycemia	O
comparisons	O
lends	O
strength	O
to	O
the	O
findings,	O
and	O
the	O
cluster	O
of	O
metabolites	O
has	O
biological	O
plausibility.	O

The	O
statin-like	O
effect	O
of	O
high	O
Phe	O
may	O
also	O
be	O
the	O
cause	O
of	O
higher	O
concentrations	O
of	O
citrate	B
and	O
glutamic	B
acid	I
in	O
patients	O
compared	O
to	O
controls,	O
as	O
inhibition	O
of	O
HMGR	O
leads	O
to	O
an	O
increase	O
of	O
HMG-CoA	O
which	O
feeds	O
acetyl	O
CoA	O
into	O
the	O
citric	O
cycle.	O

In	O
16HBE14o_−	O
cells,	O
the	O
top	O
six	O
affected	O
amino	O
acids	O
after	O
30	O
min	O
ranked	O
as	O
follows:	O
glycine	B
(decrease	O
by	O
91%),	O
aspartate	B
(91%),	O
proline	B
(84%),	O
5-oxo-proline	B
(83%)	O
and	O
glutamate	B
(75%).	O

These	O
two	O
α,	O
β-unsaturated	B
aldehydes	I
have	O
been	O
previously	O
quantified	O
in	O
cigarette	O
smoke._,	O
Levels	O
of	O
metabolite	O
3	O
are	O
significantly	O
associated	O
with	O
both	O
HPMA	O
(ρ	O
=	O
0.631,	O
p	O
-value	O
=	O
0.011)	O
and	O
HMPMA	O
(ρ	O
=	O
0.615,	O
p	O
-value	O
=	O
0.014).	O

Protein	O
filtered	O
from	O
serum	O
samples	O
were	O
washed	O
with	O
an	O
additional	O
100	O
μL	O
of	O
D_2	O
O.	O
The	O
filtrates	O
(volume	O
ranging	O
from	O
100–150	O
μL)	O
were	O
then	O
transferred	O
to	O
clean	O
microcentrifuge	O
tubes	O
and	O
the	O
final	O
volume	O
brought	O
to	O
400	O
μL	O
by	O
the	O
addition	O
of	O
80	O
μL	O
of	O
phosphate	B
buffer	O
(0.5	O
M	O
NaH_2	O
PO_4	O
buffer	O
solution	O
at	O
pH	O
7.0)	O
containing	O
2.5	O
mM	O
2,2-dimethyl-2-	B
silapentane-5-sulfonate	I
(DSS,	O
final	O
concentration	O
0.5	O
mM),	O
10	O
μL	O
of	O
1M	O
sodium	O
azide	O
to	O
prevent	O
bacterial	O
growth,	O
and	O
D2O.	O
The	O
final	O
concentration	O
of	O
DSS	O
(0.5	O
mM	O
for	O
each	O
sample)	O
was	O
used	O
for	O
NMR	O
chemical	O
shift	O
reference	O
and	O
concentration	O
calibration.	O

A	O
primary	O
objective	O
of	O
developing	O
a	O
reference	O
material	O
for	O
vitamin	B
D	I
metabolites	O
is	O
to	O
improve	O
the	O
accuracy	O
and	O
comparability	O
of	O
routine	O
measurement	O
methods	O
for	O
these	O
analytes	O
in	O
serum.	O

The	O
sole	O
presence	O
of	O
9-HSA	O
among	O
hydroxy	B
fatty	O
acids	O
in	O
tumors	O
raises	O
another	O
significant	O
question	O
as	O
to	O
what	O
are	O
the	O
biochemical	O
mechanisms	O
that	O
support	O
the	O
cellular	O
levels	O
of	O
this	O
fatty	O
acid	O
in	O
cells,	O
i.e.,	O
synthesis	O
and	O
clearance,	O
and	O
whether	O
specific	O
alteration	O
of	O
these	O
routes	O
could	O
be	O
envisioned	O
as	O
an	O
effective	O
manner	O
to	O
manipulate	O
the	O
levels	O
of	O
9-HSA.	O

Collectively	O
the	O
obtained	O
results	O
propose	O
the	O
presence	O
of	O
PC	B
17:0/20:5,	I
PC	B
P-18:0/20:4,	I
PC	B
O-18:0/20:5	I
and	O
PC	B
O-16:0/22:5.	I

After	O
incubation	O
of	O
sofosbuvir	B
for	O
1	O
h,	O
followed	O
by	O
removal	O
of	O
extracellular	O
compound,	O
the	O
intermediate	O
metabolite	O
X	O
was	O
rapidly	O
formed	O
intracellularly.	O

Microsomal	O
mediated	O
UDP-glucuronosyltransferases	O
catalyze	O
the	O
bioactivation	O
of	O
NSAIDS	O
by	O
the	O
formation	O
of	O
acyl	B
glucuronide	I

For	O
3-PGDH	O
we	O
could	O
not	O
demonstrate	O
the	O
accuracy	O
of	O
the	O
method	O
in	O
DBS,	O
as	O
the	O
sample	O
was	O
drawn	O
under	O
serine	B
supplementation,	O
normalizing	O
the	O
level	O
of	O
serine.	B

Of	O
interest	O
in	O
this	O
study,	O
trypanosomatids	O
synthesize	O
lipids	O
from	O
acetyl-CoA	B
and	O
glycerolipids	B
from	O
glycerol	B
through	O
the	O
mevalonate	B
pathway	O
.	O

Fifty	O
microliters	O
aliquots	O
of	O
plasma	O
was	O
thawed	O
and	O
precipitated	O
with	O
200 μL	O
of	O
internal	O
standard	O
mixture	O
containing	O
erlotinib-d6	B
(200 ng/mL)	O
in	O
acetonitrile.	B

As	O
recently	O
suggested	O
by	O
Meiser	O
and	O
Vazquez,	O
the	O
increase	O
in	O
formate	B
may	O
relate	O
to	O
its	O
role	O
in	O
one-carbon	O
metabolism.	O

A	O
prominent	O
finding	O
in	O
the	O
current	O
study	O
was	O
the	O
marked	O
decrease	O
in	O
plasma	O
sphingolipids	B
in	O
HD	O
sheep	O
compared	O
to	O
controls.	O

no.	O
110544),	O
diacylglycerol	B
(12:0/12:0/0:0)	I
(cat.	O

The	O
signal	O
with	O
two	O
sialic	B
acid	I
residues	O
presumably	O
arises	O
from	O
a	O
mixture	O
of	O
transferrin	O
molecules	O
that	O
have	O
one	O
unoccupied	O
glycosylation	O
site	O
as	O
well	O
as	O
transferrin	O
molecules	O
that	O
are	O
occupied	O
at	O
both	O
sites	O
by	O
glycans	B
but	O
have	O
only	O
two	O
terminal	O
sialic	B
acid	I
residues.	O

Cysteine	B
metabolism	O
partly	O
fed	O
into	O
increases	O
in	O
hypotaurine	B
and	O
taurine	B
in	O
SCC	O
samples.	O

In	O
contrast	O
to	O
the	O
other	O
selected	O
oxylipins,	B
LTE_4	O
contains	O
a	O
cysteinyl	O
group,	O
and	O
like	O
LTDs	O
and	O
LTCs,	O
it	O
belongs	O
to	O
the	O
cysteinyl	O
leukotriens.	O

At	O
T2	O
the	O
plasma	O
levels	O
of	O
six	O
species	O
of	O
lysophosphatidylcholines	B
(lysoPCs),	O
seven	O
diacyl-phosphatidylcholines	B
(PCaa),	O
two	O
acyl-alkyl	B
phosphatidylcholines	I
(PCae),	O
two	O
long-chain	O
sphingomyelins	B
(SM)	O
and	O
glutamic	B
acid	I
were	O
lower	O
in	O
NR	O
than	O
in	O
R,	O
whereas	O
there	O
was	O
greater	O
abundance	O
in	O
NR	O
for	O
aminoacids	B
such	O
as	O
alanine,	B
methionine,	B
phenylalanine	B
and	O
histidine	B
(Table 	O
and	O
Fig.	O

Possible	O
fragmentation	O
mechanisms	O
leading	O
to	O
formation	O
of	O
those	O
smaller	O
fragment	O
ions	O
include	O
1,4-hydrogen	B
elimination	O
followed	O
by	O
homolytic	O
scission	O
and	O
subsequent	O
radical	O
elimination_,	O
.	O

Furthermore,	O
the	O
second	O
strongest	O
glycine-associated	O
SNP	O
rs1047891	O
causes	O
a	O
non-synonymous	O
mutation	O
(Thr>Asn)	O
in	O
the	O
C-terminal	O
domain	O
of	O
the	O
CPS1	O
polypeptide,	O
which	O
hosts	O
the	O
binding	O
site	O
for	O
the	O
allosteric	O
activator	O
N-acteyl-L-glutamate	B
(NAG).	O

Except	O
for	O
arginine,	B
significantly	O
different	O
between	O
patients	O
with	O
endoscopically	O
inactive	O
and	O
the	O
most	O
active	O
disease,	O
systemic	O
metabolite	O
concentrations	O
were	O
not	O
related	O
to	O
the	O
endoscopic	O
activity	O
of	O
UC	O
expressed	O
in	O
terms	O
of	O
the	O
Mayo	O
endoscopic	O
activity	O
score.	O

The	O
advantage	O
of	O
having	O
MS	O
detector	O
in	O
MRM	O
mode	O
over	O
conventional	O
high	O
pressure	O
liquid	O
chromatography	O
analysis	O
is	O
that	O
number	O
of	O
channels	O
in	O
the	O
detector	O
could	O
be	O
set	O
to	O
specifically	O
and	O
separately	O
identify	O
all	O
the	O
estrogen	B
related	O
compounds.	O

Comparable	O
loss	O
of	O
cell	O
invasion	O
and	O
reduction	O
in	O
sarcosine	B
levels	O
were	O
also	O
apparent	O
in	O
DU145	O
cancer	O
cells	O
upon	O
knock-down	O
of	O
DMGDH.	O

In	O
summary,	O
50	O
μl	O
of	O
serum,	O
saliva	O
extract	O
or	O
GCF	O
and	O
150	O
μl	O
acetonitrile	B
were	O
shaken	O
for	O
3	O
min,	O
the	O
precipitated	O
protein	O
was	O
centrifuged	O
at	O
13.000	O
rpm,	O
4°C	O
for	O
6	O
min,	O
130	O
μL	O
of	O
the	O
resulting	O
supernatant	O
was	O
spiked	O
with	O
10	O
μl	O
isotope	O
supernatant	O
mix,	O
evaporated	O
in	O
Eppendorf	O
reaction	O
vials	O
with	O
an	O
Eppendorf	O
concentrator	O
at	O
30°C	O
for	O
∼60	O
min	O
until	O
the	O
sample	O
volume	O
was	O
∼10	O
µl.	O

Therefore,	O
25(OH)D_3	O
was	O
the	O
only	O
vitamin	B
D	I
metabolite	O
detected	O
in	O
SRM	O
909c.	O

Dihydrothymine	B
particularly	O
was	O
selected	O
as	O
a	O
new	O
feasible	O
biomarker	O
associated	O
with	O
tumor	O
occurrence.	O

Interestingly,	O
orotate	B
levels	O
could	O
be	O
divided	O
into	O
two	O
groups	O
within	O
the	O
ICC	O
patient	O
cohort:	O
those	O
where	O
orotate	B
levels	O
were	O
significantly	O
elevated	O
(Patients	O
2	O
and	O
4)	O
and	O
those	O
which	O
showed	O
similar	O
levels	O
to	O
healthy	O
controls	O
(Patients	O
1	O
and	O
3).	O

With	O
these	O
assumptions	O
in	O
mind,	O
the	O
data	O
imply	O
that	O
tumors	O
oxidize	O
other	O
substrates	O
in	O
addition	O
to	O
blood-borne	O
glucose.	B

In	O
a	O
previous	O
study,	O
we	O
found	O
that	O
expression	O
of	O
KYNU,	O
the	O
gene	O
encoding	O
kynureninase	O
(an	O
enzyme	O
downstream	O
of	O
TDO)	O
is	O
elevated	O
in	O
suspended	O
TNBC	O
cell	O
lines	O
and	O
in	O
the	O
context	O
of	O
increased	O
inflammatory	O
signaling,	O
which	O
would	O
be	O
consistent	O
with	O
tryptophan	B
catabolism	O
further	O
down	O
the	O
pathway.	O

Moreover,	O
cortisol	B
is	O
present	O
at	O
higher	O
concentrations	O
in	O
samples	O
from	O
cachectic	O
patients.	O

In	O
that	O
study	O
of	O
urine	O
metabolome,	O
carnitine	B
was	O
upregulated,	O
while	O
some	O
medium-chain	O
acylcarnitines	O
were	O
downregulated	O
in	O
cancer	O
patients	O
when	O
compared	O
to	O
the	O
control	O
group.	O

The	O
increased	O
arginine	B
in	O
APS	O
patients	O
might	O
be	O
induced	O
by	O
the	O
physiological	O
condition	O
of	O
APS	O
and	O
be	O
positive	O
on	O
the	O
body.	O

Equol	O
mostly	O
exists	O
in	O
human	O
plasma	O
as	O
its	O
conjugated	O
metabolites	O
such	O
as	O
glucuronides	O
and	O
sulfates.	B

One	O
patient	O
showed	O
a	O
somewhat	O
low	O
sum	O
of	O
cortisol	B
metabolites	O
during	O
the	O
daytime.	O

Intermittent	O
hypoxemia	O
(IH)	O
could	O
activate	O
the	O
sympathetic	O
nervous	O
system,	O
and	O
the	O
activated	B
sympathetic	O
nervous	O
system	O
could	O
stimulate	O
adipose	O
tissue	O
lipolysis.	O

Whole	O
genome	O
sequence	O
data	O
were	O
examined	O
for	O
SNVs	O
and	O
copy	O
number	O
variants	O
(CNVs)	O
relating	O
to	O
four	O
genes	O
of	O
the	O
pyrimidine	B
metabolism	O
pathway:	O
CAD	O
(tri-functional	O
enzyme,	O
carbamoyl-phosphate	B
synthetase	O
2	O
(CPS2),	O
aspartate	O
transcarbamylase	O
(ATCase),	O
and	O
dihydroorotase	O
(DHOase));	O
DHODH	O
(dihydroorotate	O
dehydrogenase);	O
UMPS	O
(bi-functional	O
enzyme,	O
orotate	O
phosphoribosyltransferase	O
and	O
OMP	O
decarboxylase);	O
and	O
TYMS	O
(thymidylate	O
synthase).	O

[0.977–1.000]),	O
followed	O
by	O
histidine	B
and	O
glycine.	B

Taurine	B
levels	O
in	O
the	O
L2	O
group	O
were	O
lower	O
than	O
those	O
in	O
the	O
L1	O
group.	O

Seven	O
out	O
of	O
eight	O
targeted	O
hydroxy-epoxy-octadecenoic	B
acid	I
(H-E-LAs)	O
and	O
keto-epoxy-octadecenoic	B
acid	I
(K-E-LAs)	O
are	O
not	O
commercially	O
available.	O

The	O
solution	O
was	O
centrifuged	O
at	O
2,300	O
×g	O
for	O
5	O
min	O
at	O
4°C	O
and	O
the	O
supernatant	O
was	O
applied	O
to	O
a	O
Hybrid	O
SPE	O
phospholipid	B
cartridge	O
(55261-U,	O
Sigma-Aldrich).	O

Subsequently,	O
80	O
μl	O
of	O
N-methyl-N-(trimethylsilyl)	B
trifluoroacetamide	I
(MSTFA)	O
(Macherey	O
Nagel,	O
Germany)	O
were	O
added	O
and	O
incubated	O
for	O
30	O
min	O
at	O
37°C.	O

One	O
explanation	O
is	O
that	O
estrogen	B
metabolites	O
cause	O
mutations	O
by	O
reacting	O
with	O
DNA,	O
leading	O
to	O
depurination.	O

In	O
the	O
present	O
study,	O
the	O
reason	O
why	O
the	O
LC	O
group	O
had	O
lower	O
levels	O
of	O
ω-3	B
PUFAs	I
than	O
the	O
control	O
group	O
was	O
hard	O
to	O
know	O
because	O
of	O
limited	O
information.	O

The	O
fifth	O
component,	O
however,	O
resulted	O
from	O
covalent	O
bond	O
formation	O
and	O
was	O
identified	O
as	O
a	O
tetrapeptide	O
containing	O
3-tryptophanyl-4-acetyl-ABP,	B
the	O
amino	O
acid	O
sequence	O
of	O
which	O
was	O
H_2	O
N-Ala-Trp-Ala-Val.	O

Health	O
beneficial	O
effects	O
of	O
betaine	B
have	O
been	O
recently	O
reported.	O

Glutathione	B
(GSH)	O
is	O
a	O
tripeptide	O
(L-γ-glutamyl-L-cysteinyl-glycine)	O
that	O
is	O
synthesized	O
in	O
the	O
cytosol	O
from	O
the	O
precursor	O
amino	O
acids	O
glutamate,	O
cysteine	B
and	O
glycine.	B

Being	O
expected	O
from	O
molecular	O
structures,	O
the	O
_4	O
CH_2	O
peak	O
of	O
GABA	B
showed	O
extensive	O
overlap	O
with	O
_6	O
CH_2	O
peak	O
of	O
lysine,	B
although	O
GABA	B
tends	O
to	O
be	O
more	O
abundant	O
than	O
lysine	B
in	O
typical	O
human	O
brain.	O

Olive	O
product,	O
Prebiotic,	O
Polyphenols,	O
Metabolomic,	O
Tyrosol	B
glucoside,	I
Tyrosol	B
group	O

The	O
serum	O
levels	O
of	O
γ-tocopherol	B
and	O
S27	O
were	O
significantly	O
higher	O
after	O
soy	O
drink	O
intake	O
than	O
after	O
milk	O
and	O
cheese	O
intake	O
at	O
4	O
and	O
6	O
h.	O
Of	O
note,	O
despite	O
apparent	O
postprandial	O
increases	O
at	O
late	O
time	O
points	O
(i.e.,	O
6	O
and	O
24	O
h),	O
the	O
serum	O
levels	O
of	O
catechol	B
and	O
guaiacol	B
were	O
not	O
discriminative	O
at	O
specific	O
time	O
points	O
based	O
on	O
the	O
Kruskal-Wallis	O
sum	O
rank	O
test,	O
although	O
a	O
trend	O
was	O
indicated	O
by	O
the	O
significantly	O
higher	O
6	O
h	O
values	O
of	O
catechol	B
after	O
soy	O
drink	O
intake	O
compared	O
to	O
cheese	O
intake.	O

The	O
pattern	O
of	O
fatty	O
acid	O
increase	O
after	O
rifaximin	O
were	O
a	O
higher	O
level	O
of	O
saturated	O
fatty	O
acids	O
[caprylic	O
(8∶0),	O
myristic	B
(14∶0)	I
and	O
palimitic	O
acid	O
(16∶0)]	O
which	O
after	O
the	O
action	O
of	O
stearoyl-CoA	B
desaturase	O
can	O
be	O
turned	O
into	O
palmitoleic	B
acid	I
(16∶1n7),	O
oleic	O
(18∶1n9)	O
and	O
eicosanoic	B
acid	I
(20∶1n9).	O

;	O
glycerophosphoinositol	B
34:1,	I
PI	B
(16:1/18:0)	I
at	O
m	O
/z	O
835.6;	O
and	O
glycerophosphoinositol	B
36:2,	I
PI	B
(18:2/18:0)	I
at	O
m	O
/z	O
861.6	O
(SI	O
Appendix	O
,	O
Fig.	O

Ascorbic	B
acid,	I
tryptophan,	B
tyrosine,	B
phenylalanine,	B
uric	B
acid,	I
UDP,	B
creatine,	B
and	O
pyruvate	B
showed	O
reduced	O
concentration	O
in	O
IDC	O
against	O
benign	O
and	O
control.	O

In	O
addition,	O
peak	O
distribution	O
measured	O
by	O
r−	O
(A)	O
followed	O
a	O
different	O
trend,	O
with	O
the	O
most	O
even	O
distribution	O
seen	O
for	O
ammonium	B
acetate	I
(median	O
r−	O
of	O
0.39,	O
mean	O
of	O
0.42),	O
and	O
the	O
most	O
uneven	O
observed	O
for	O
ammonium	B
formate	I
and	O
water,	O
with	O
median	O
r−	O
values	O
of	O
0.23	O
and	O
0.20	O
respectively.	O

–	O
Lactate	B
is	O
typically	O
interpreted	O
as	O
a	O
marker	O
of	O
anaerobic	O
metabolism,	O
but	O
this	O
may	O
not	O
be	O
true	O
in	O
rabies.	O

Plasma	O
LDL-cholesterol	B
was	O
calculated.	O

The	O
lipoproteins	O
identified	O
and	O
their	O
concentrations	O
(i.e.	O
triglycerides	B
and	O
cholesterol),	B
strongly	O
correlated	O
to	O
the	O
enzymatic	O
colorimetric	O
methods	O
quantifications	O
for	O
the	O
same	O
subjects	O
(Fig.	O

Suppressing	O
the	O
expression	O
of	O
OSBPL2	O
may	O
be	O
hypothesized	O
to	O
be	O
the	O
biological	O
pathway	O
through	O
which	O
elevated	O
hsa-miR-885-5p	O
is	O
associated	O
with	O
decreased	O
levels	O
of	O
large	O
HDL	B
cholesterol.	I

The	O
levels	O
of	O
AIR,	O
hypoxanthine	B
and	O
inosine	B
were	O
significantly	O
increased	O
with	O
bladder	O
cancer	O
progression	O
(from	O
healthy	O
subjects	O
to	O
LG	O
BC	O
patients	O
and	O
then	O
to	O
HG	O
BC	O
patients),	O
which	O
suggested	O
that	O
purine	B
metabolism	O
was	O
upregulated	O
in	O
BC	O
patients,	O
especially	O
in	O
HG	O
BC	O
patients.	O

The	O
six	O
estrogen	B
derivatives	O
were	O
baseline	O
separated	O
within	O
a	O
20	O
min	O
chromatographic	O
run	O
time.	O

Equal	O
amounts	O
(30	O
μg)	O
of	O
cell	O
lysate	O
protein	O
were	O
loaded	O
onto	O
12.5%	O
polyacrylamide	B
gels,	O
eletrophoresed,	O
and	O
transfered	O
to	O
nitocellulose	O
membranes.	O

The	O
SP	B
with	O
m/z	O
704.82635	O
and	O
857.11525	O
were	O
hyper	O
represented	O
in	O
the	O
control	O
group,	O
while	O
the	O
SPs	O
with	O
m/	O

Our	O
findings	O
suggest	O
a	O
multifactorial	O
origin	O
for	O
such	O
abnormal	O
phospholipids	B
metabolism,	O
in	O
which	O
dysregulation	O
of	O
phospholipases,	O
catabolism	O
of	O
LPC,	O
peroxisomal	O
dysfunction,	O
imbalance	O
in	O
the	O
levels	O
of	O
saturated/unsaturated	O
fatty	O
acids	O
could	O
all	O
be	O
involved.	O

The	O
presence	O
of	O
α-zearalenol	B
and	O
zearalenone	B
in	O
neoplastically	O
changed	O
tissue	O
from	O
the	O
tissue	O
corpus	O
of	O
the	O
uterus	O
was	O
confirmed	O
by	O
ions	O
with	O
m/z	O
ratios	O
of	O
317.1	O
and	O
319.0,	O
respectively.	O

The	O
relationship	O
between	O
proline	B
and	O
stroke	O
is	O
unclear.	O

This	O
finding	O
indicates	O
that	O
loss	O
of	O
GSTM1	O
function	O
may	O
lead	O
to	O
increased	O
levels	O
of	O
isothiocyanates	B
which	O
induces	O
expression	O
of	O
GST-alpha,	O
while	O
GST-alpha	O
in	O
turn	O
possesses	O
much	O
less	O
activity	O
to	O
degrade	O
isothiocyanates	B
than	O
GSTM1.	O

Formic	B
acid	I
(FA)	O
for	O
LC/MS	O
was	O
purchased	O
from	O
Fujifilm	O
Wako	O
Pure	O
Chemical	O
Corporation	O
(Osaka,	O
Japan).	O

Aspirin	B
challenge,	O
for	O
instance	O
the	O
ASA-BPT,	O
is	O
the	O
gold	O
standard	O
for	O
confirming	O
aspirin	B
hypersensitivity,	O
however,	O
there	O
are	O
still	O
risks	O
for	O
bronchospasm	O
as	O
well	O
as	O
various	O
contraindications.	O

Furthermore,	O
there	O
is	O
a	O
significant	O
decrease	O
of	O
average	O
1,5-anhydroglucitol	B
concentrations	O
by	O
37.8%	O
(p = 5.1×10_−6	O
)	O
in	O
participants	O
with	O
diabetes	O
when	O
compared	O
to	O
the	O
control	O
group.	O

Collectively,	O
these	O
data	O
suggest	O
a	O
role	O
of	O
the	O
guanosine	B
network	O
in	O
ARDS,	O
which	O
could	O
be	O
a	O
potential	O
avenue	O
for	O
future	O
investigation.	O

ZON,	O
α-ZOL,	B
2,2'-azobisisobutyronitrile,	B
1-allyl-piperazine	B
(1-ALPP)	O
(96%),	O
trimethylolpropane	B
trimethacrylate	I
(TRIM;	O
techn.),	O
cyclododecanol,	O
1,1’-carbonyldiimidazole	B
(≥90%),	O
dimethyl	B
fumarate,	I
2,4-dihydroxybenzoate	B
acid	I
(97%),	O
1,8-diazabicyclo[5.4.0]undec-7-ene	B
were	O
purchased	O
from	O
Fluka	O
(Sigma-Aldrich	O
Chemie,	O
Steinheim,	O
Germany).	O

To	O
quantify	O
the	O
metabolite	O
concentrations,	O
DSS	O
(4,4-dimethyl-4-silapentane-1-sulfonic	O
acid)	O
was	O
used	O
as	O
an	O
internal	O
standard.	O

The	O
potential	O
application	O
of	O
proline	B
as	O
the	O
biomarkers	O
for	O
BC	O
diagnosis	O
and	O
prognosis	O
has	O
been	O
previously	O
suggested,	O
though	O
the	O
mechanisms	O
leading	O
to	O
its	O
perturbance	O
are	O
unclear.	O

Particularly,	O
the	O
understanding	O
of	O
the	O
up-regulation	O
of	O
long	O
chain	O
fatty	O
acyl	B
carnitines	I
and	O
the	O
down-regulation	O
of	O
cyclic	O
phosphatidic	O
acid	O
(cPA).	O

The	O
precipitated	O
material	O
into	O
the	O
well	O
plate	O
was	O
washed	O
twice	O
with	O
800μL	O
of	O
a	O
solution	O
of	O
MeOH:	B

metabolomics,	O
urinary	O
metabolome,	O
hypoxanthine,	B
high-intensity	O
interval	O
training,	O
NMR	O
spectroscopy,	O
LC-MS	O

Adjusted	O
effect	O
estimates	O
(95%	O
CI)	O
for	O
urinary	O
phthalate	B
metabolite	O
and	O
isoprostane	B
concentrations	O
and	O
mtDNAdel	O
levels.	O

The	O
TMAO	B
level	O
of	O
the	O
stroke	O
and	O
TIA	O
patients	O
showed	O
a	O
result	O
that	O
was	O
the	O
opposite	O
of	O
our	O
initial	O
expectations.	O

Arginine	B
and	O
citrulline	B
are	O
key	O
components	O
of	O
nitric	B
oxide	I
biosynthesis	O
and	O
the	O
urea.	B

For	O
example,	O
breakdown	O
products	O
of	O
acetylglycoproteins,	B
such	O
as	O
mannose,	B
are	O
elevated	O
in	O
individuals	O
with	O
insulin	O
resistance30	O
and	O
associated	O
with	O
incident	O
type	O
2	O
diabetes	O
mellitus	O
and	O
CVD.31	O

BMI,	O
body	O
mass	O
index;	O
BP,	O
blood	O
pressure;	O
ACE,	O
angiotensin-converting	O
enzyme;	O
ARB,	O
angiotensin	B
receptor	O
blocker	O

Groupe	O
Hospitalier	O
Paris	O
Seine-Saint-Denis	B
BB-0033–00027”.	O

Three	O
metabolic	O
pathway	O
of	O
importance	O
including	O
metabolism	O
of	O
xenobiotics	O
by	O
cytochrome	O
P450,	O
phenylalanine	B
metabolism,	O
amino	B
sugar	O
and	O
nucleotide	O
sugar	O
metabolism	O
were	O
found	O
to	O
be	O
disturbed	O
in	O
HBV	O
patients.	O

The	O
triglyceride	B
signals	O
were	O
indicated	O
as	O
‘TG’.	O

The	O
statistical	O
significance	O
of	O
different	O
spectral	O
regions	O
containing	O
resonances	O
of	O
BCAA	O
and	O
related	O
metabolites,	O
like	O
3-OH-isovalerate,	B
supports	O
the	O
association.	O

Kyn	O
can	O
also	O
function	O
as	O
an	O
endogenous	O
ligand	O
for	O
the	O
basic	O
helix–loop–helix	O
(bHLH)-PAS	O
transcription	O
factor	O
aryl	B
hydrocarbon	I
receptor	O
(AHR),	O
suggesting	O
a	O
cell-autonomous	O
role.	O

Our	O
data	O
demonstrate	O
that	O
comparable	O
to	O
the	O
small	O
intestine,	O
the	O
requisite	O
hydrolytic,	B
Phase	O
II	O
and	O
efflux	O
transporting	O
enzymes	O
necessary	O
for	O
local	O
enteric	O
recycling	O
are	O
present	O
and	O
functional	O
in	O
human	O
oral	O
mucosa.	O

Thus,	O
our	O
work	O
suggests	O
that	O
cannabinoids	B
may	O
have	O
an	O
immunological	O
benefit	O
in	O
the	O
context	O
of	O
HIV	O
infection,	O
as	O
lowering	O
the	O
frequency	O
of	O
activated	B
T	O
cells	O
could	O
limit	O
the	O
risk	O
of	O
development	O
of	O
non-AIDS-associated	O
comorbidities	O
[,	O
].	O

This	O
approach	O
has	O
revealed	O
specific	O
metabolites	O
for	O
each	O
HCC,	O
as	O
an	O
increased	O
level	O
of	O
β-HB	B
and	O
aromatic	O
amino	O
acids	O
in	O
HCC-Cirrhosis	O
and	O
overexpression	O
of	O
Gln/Glu	O
in	O
HCC-NAFLD.	O

To	O
100 µL	O
of	O
plasma,	O
900 µL	O
of	O
extraction	O
solution	O
(methanol/water	O
(8:1))	O
with	O
4	O
internal	O
standards	O
(Val-Tyr-Val,	O
Leu-Enk,	O
Sulfadimetoxin,	B
Reserpine)	O
was	O
added	O
and	O
the	O
samples	O
were	O
vigorously	O
extracted	O
at	O
a	O
frequency	O
of	O
30 Hz	O
for	O
2 min	O
using	O
a	O
MM301	O
vibration	O
Mill	O
(Retsch	O
GmbH	O
&	O
Co.	O
KG,	O
Haan,	O
Germany).	O

Absolute	O
concentrations	O
of	O
the	O
metabolites	O
alanine,	B
lactate,	B
glutamine,	B
glutamate,	B
citrate,	B
choline	B
compounds	O
[t-choline =	O

Blood	O
lactate	B
was	O
found	O
elevated	O
among	O
obese,	O
IR	O
and	O
T2D	O
subjects	O
and	O
decreased	O
following	O
weight	O
loss.	O

Given	O
the	O
reported	O
anti-tumor	O
effects	O
of	O
enterolactone,	B
we	O
hypothesized	O
that	O
high	O
serum	O
enterolactone	B
could	O
be	O
associated	O
with	O
improved	O
patient	O
outcome.	O

The	O
desmosterol	B
pathway	O
corresponds	O
to	O
the	O
stress-inducible	O
arm	O
of	O
de	O
novo	O
cholesterol	B
and	O
sterol	O
synthesis.	O

A	O
similar	O
effect	O
is	O
attributed	O
to	O
glutamate;	B
its	O
actions	O
are	O
mediated	O
through	O
two	O
main	O
receptors	O
predominantly	O
expressed	O
in	O
the	O
brain:	O
ionotropic	O
glutamate	B
receptors	O
(iGluRs)	O
and	O
metabotropic	O
glutamate	B
receptors	O
(mGluRs).	O

There	O
was	O
however	O
a	O
correlation	O
between	O
betaine	B
levels	O
and	O
gender.	O

Compared	O
with	O
samples	O
from	O
patients	O
with	O
CIN,	O
the	O
plasma	O
of	O
CSCC	O
patients	O
had	O
higher	O
levels	O
of	O
acetate,	B
formate,	B
lactate,	B
isoleucine,	B
leucine,	B
valine,	B
alanine,	B
glutamine,	B
histidine,	B
tyrosine,	B
acetylcysteine,	B
myo-inositol,	B
glycoprotein,	B
α-glucose	B
and	O
β-glucose,	B
together	O
with	O
lower	O
levels	O
of	O
acetone,	B
unsaturated	O
lipid	O
and	O
carnitine.	B

The	O
remaining	O
aqueous	O
extract	O
was	O
concentrated	O
by	O
evaporation,	O
reconstituted	O
in	O
5%	O
DI	O
water	O
in	O
acetonitrile,	B
and	O
analyzed	O
by	O
HILIC	O
LC-MS/MS.	O

Pleiotropic	O
effects	O
of	O
acetone	B
including	O
the	O
regulation	O
of	O
inflammation,	O
oxidative	O
stress,	O
and	O
anti-catabolic	O
effects	O
in	O
human	O
skeletal	O
muscle	O
have	O
been	O
described	O
previously.	O

In	O
the	O
present	O
study,	O
guanosine	B
was	O
also	O
positively	O
correlated	O
to	O
HOMA-IR.	O

CAD	O
is	O
a	O
hexameric	O
protein	O
and	O
each	O
polypeptide	O
chain	O
is	O
composed	O
of	O
three	O
domains,	O
each	O
encoding	O
a	O
different	O
enzymatic	O
step	O
in	O
the	O
pyrimidine	B
biosynthesis	O
pathway	O
(CPS2,	O
DHOase,	O
ATCase).	O

The	O
metabolites	O
included	O
FFAs,	O
BAs,	O
amino	O
acids	O
(AAs),	O
organic	O
acids,	O
lipids,	O
organooxygen	B
compounds,	O
pyridines	B
and	O
others.	O

Multiple	O
investigators	O
have	O
studied	O
the	O
impact	O
of	O
glycine	B
on	O
glucose	B
and	O
insulin	O
levels	O
in	O
healthy	O
and	O
diabetic	O
individuals.	O

In	O
addition,	O
hydrogen	O
bonding	O
and	O
π-π	B
interactions	I
between	O
AQC	O
and	O
the	O
chiral	O
stationary	O
phase	O
of	O
the	O
ZWIX	O
(+)	O
column	O
may	O
also	O
contribute	O
to	O
enantiomer	O
separation.	O

We	O
presented	O
group	O
differences	O
in	O
sleep	O
indices	O
and	O
cortisol	B
levels	O
in	O
a	O
previous	O
publication.	O

Several	O
of	O
the	O
metabolites	O
possibly	O
altered	O
in	O
response	O
to	O
β-carotene	B
supplementation	O
provided	O
potential	O
biologic	O
insights	O
into	O
the	O
trial	O
findings	O
for	O
β-carotene	B
in	O
the	O
ATBC	O
Study	O
and	O
Beta-Carotene	B
and	O
Retinol	B
Efficacy	O
Trial.	O

Twenty	O
three	O
metabolites	O
related	O
to	O
glycerophospholipid	B
metabolism,	O
oxidation	O
and	O
antioxidation	O
were	O
associated	O
with	O
the	O
process	O
from	O
pre-DM	O
to	O
NGR,	O
while	O
twenty	O
two	O
metabolites	O
related	O
to	O
amino	O
acid	O
metabolism,	O
glycerophospholipid	B
metabolism	O
and	O
mitochondrial	O
β-oxidation	O
played	O
important	O
roles	O
in	O
the	O
progression	O
to	O
DM.	O

In	O
conclusion,	O
our	O
results	O
confirm	O
that	O
orally	O
administered	O
doses	O
of	O
sofosbuvir	B
and	O
ribavirin	B
used	O
in	O
clinical	O
practice	O
efficiently	O
load	O
the	O
liver.	O

The	O
analysis	O
with	O
forward	O
selection	O
was	O
represented	O
by	O
risk	O
of	O
APO = 5.55 + (1816.18	O
*	O
LysoPC	O
C22:5)	B

Although	O
the	O
chance	O
is	O
low	O
that	O
this	O
individual	O
will	O
father	O
a	O
child	O
carrying	O
this	O
particular	O
mark,	O
on	O
a	O
population	O
level	O
this	O
could	O
be	O
translated	O
in	O
an	O
increase	O
of	O
0.4%	O
offspring	O
carrying	O
at	O
least	O
one	O
affected	O
CpG	O
site,	O
caused	O
by	O
paternal	O
exposure	O
to	O
this	O
particular	O
environmental	O
toxin.	B

Also,	O
future	O
research	O
characterizing	O
specific	O
foods	O
or	O
food	O
groups	O
that	O
contribute	O
to	O
exogenous	O
erythritol	B
exposure,	O
or	O
variation	O
in	O
human	O
endogenous	O
erythritol	B
synthesis,	O
could	O
improve	O
the	O
understanding	O
of	O
erythritol	B
exposure,	O
and	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
factors	O
contributing	O
to	O
endogenous	O
erythritol	B
concentration,	O
increased	O
adiposity,	O
or	O
both.	O

In	O
contrast,	O
pyruvate	O
carboxylation	O
leads	O
to	O
the	O
production	O
of	O
_13	O
C-2,3-Glu	B
via	O
the	O
Krebs	O
cycle,	O
which	O
is	O
distinct	O
from	O
the	O
PDH	O
pathway	O
(cf.	O

The	O
presence	O
of	O
glucose	B
and	O
lactate	B
as	O
well	O
as	O
the	O
non-glycolytic	O
end	O
products	O
of	O
glucose	B
(mannose	O
and	O
1,6-anhydro-β-D-glucose)	B
in	O
the	O
urine	O
suggest	O
that	O
the	O
ingested	O
carbohydrate	O
load	O
was	O
greater	O
that	O
the	O
physiologic	O
capacity	O
to	O
aerobically	O
process	O
the	O
load.	O

For	O
metabolite	O
derivatization,	O
50	O
μl	O
of	O
methoxyamine-hydrochloride	B
in	O
pyridine	B
solution	O
(20	O
mg/ml)	O
was	O
added	O
to	O
each	O
tube.	O

Several	O
acyl	B
carnitines	I
were	O
significantly	O
lower	O
following	O
ADT,	O
including	O
deoxycarnitine,	B
acetylcarnitine,	B
hexanoylcarnitine,	B
octanoylcarnitine,	B
decanoylcarnitine,	B
laurylcarnitine,	B
palmitoylcarnitine,	B
stearoylcarnitine	B
and	O
oleoylcarnitine	B
(p<0.05	O
for	O
each	O
compound).	O

d	O
ROC	O
curve	O
of	O
glutamine	B
to	O
glutamic	B
acid	I
ratio.	O

Regression	O
models	O
were	O
adjusted	O
for	O
age,	O
(sex),	O
smoking	O
behavior,	O
alcohol	O
consumption,	O
LDL-cholesterol,	B
systolic	O
blood	O
pressure,	O
and	O
estimated	O
glomerular	O
filtration	O
rate.	O

Melatonin,	B
N-acetylserotonin,	B
Autism	O
Spectrum	O
Disorder,	O
Nanoflow	O
LC-MS/MS	O

GBM–glioblastoma,	O
AST—astrocytoma,	O
MN—meningioma,	O
ODG-	O
oligodendroglioma,	O
MET—metastasis;	O
Lac–lactate,	B
Ala—alanine,	O
Gln–glutamine,	B
Glu—glutamate,	O
tGlut–glutamine	B
+	O
glutamate,	B
GPC–glycerophosphocholine,	B
PCho–phosphocholine,	B
tCho–choline	B
+	O
phosphocholine	B
+	O
glycerophosphocholine,	B
Lip1.3a	O
and	O
Lip1.3b	O
–fatty	O
acids	O
at	O
1.3ppm	O
(fatty	O
acids),	O
tCr—creatine	O
+	O
phosphocreatine,	B
Lip	O
0.9	O
–fatty	O
acid	O
at	O
0.9ppm	O
(triglycerides),	O
Lip	O
2.0	O
–fatty	O
acid	O
at	O
2.0ppm.	O

Effect	O
of	O
pH	O
on	O
the	O
simultaneous	O
enantioseparation	O
of	O
1,1’	B
=	I
ODVX,	I
and	O
2,2’	B
=	I
VX.	I

CMPF	O
has	O
a	O
correlation	O
of	O
r	O
 = 0.39,	O
whereas	O
palimitoyl-oleoyl-GPPG-2	B
has	O
r	O
 = 0.28.	O

In	O
multivariate	O
regression	O
models,	O
the	O
plasma	O
levels	O
of	O
citrulline,	B
tryptophan,	B
ADMA,	B
and	O
OH-Kyn	O
were	O
significantly	O
associated	O
with	O
eGFR.	O

Immediately	O
as	O
the	O
MeOH	B
solution	O
was	O
added	O
to	O
the	O
culture	O
plate,	O
cells	O
were	O
scraped	O
into	O
the	O
methanol	B
solution	O
and	O
the	O
methanolic	B
lysates	O
were	O
collected.	O

For	O
example,	O
sulfatides	B
and	O
galactoceramides,	B
observed	O
in	O
low-grade	O
astrocytomas	O
(histological	O
grades	O
II	O
and	O
III),	O
were	O
undetectable	O
in	O
high-grade	O
astrocytomas	O
(histological	O
grade	O
IV,	O
or	O
glioblastomas)	O
by	O
DESI-MSI.	O

The	O
concentrations	O
of	O
4-AP	O
that	O
were	O
evaluated	O
(0.03,	O
0.1,	O
0.3,	O
1,	O
3,	O
10,	O
and	O
30 μM)	O
are	O
∼0.1–100-times	O
the	O
average	O
plasma	O
4-AP	O
concentration	O
(30 ng/mL;	O
0.32 μM)	O
that	O
was	O
measured	O
in	O
a	O
clinical	O
trial	O
of	O
the	O
therapeutic	O
dose	O
of	O
dalfampridine-ER	B
(10 mg	O
administered	O
twice	O
daily)2.	O

The	O
T	O
_max	O
	O
for	O
berberine,	B
jatrorrhizine,	B
and	O
palmatine	B
was	O
4 hours	O
in	O
the	O
African	O
volunteers	O
corresponding	O
to	O
the	O
results	O
in	O
rat	O
model.	O

Patient	O
2,	O
who	O
had	O
elevated	O
orotate	B
and	O
orotidine,	B
had	O
several	O
variants	O
that,	O
when	O
combined,	O
may	O
explain	O
the	O
accumulation	O
of	O
these	O
metabolites.	O

(2017),	O
only	O
7-desmethylscorpinone	B
(68)	O
and	O
7-desmethyl-6-methylbostrycoidin	B
(69)	O
among	O
compounds	O
produced	O
by	O
F.	O
solani	O
isolated	O
from	O
Aponogeton	O
undulates	O
were	O
strongly	O
potent	O
against	O
four	O
human	O
tumour	O
cell	O
lines,	O
MDA	O
MB	O
231,	O
MIA	O
PaCa2,	O
HeLa,	O
and	O
NCI	O
H1975	O
(IC_50	O
0.34–30.72µM).	O

The	O
present	O
study	O
has	O
revealed	O
that	O
the	O
mean	O
level	O
is	O
in	O
fact	O
slightly	O
higher	O
at	O
8.2	O
pg/mL	O
(,	O
),	O
suggesting	O
that	O
total	O
serum	O
4-MeO-E2	B
might	O
be	O
a	O
useful	O
biomarker	O
of	O
catechol	B
formation.	O

The	O
high	O
observed	O
tamoxifen	B
nonadherence	O
rate	O
within	O
the	O
first	O
year	O
may	O
reflect	O
the	O
socioeconomic	O
condition	O
of	O
this	O
population	O
and	O
the	O
high	O
percentage	O
of	O
young	O
women	O
(two‐thirds)	O
known	O
to	O
be	O
at	O
increased	O
risk	O
to	O
stop	O
medication._10	O

Moreover	O
it	O
allows	O
to	O
measure	O
some	O
additional	O
serum	O
lipids	O
–	O
PE	O
as	O
well	O
as	O
lathosterol,	B
which	O
can	O
serve	O
as	O
a	O
marker	O
of	O
cholesterol	B
production	O
rate	O
in	O
human	O
organism.	O

PBMCs	O
also	O
produced	O
more	O
IL-6	O
following	O
exposure	O
to	O
palmitic	B
acid	I
(16:0)	O
and	O
stearic	B
acid	I
(18:0).	O

Amino	O
acid	O
AUROCs	O
and	O
their	O
95%	O
CIs	O
for	O
the	O
differentiation	O
of	O
colon	O
cancer	O
patients	O
and	O
controls	O
AUROCs	O
and	O
95%	O
CIs	O
for	O
the	O
different	O
amino	O
acids	O
with	O
respect	O
to	O
the	O
discriminatory	O
power	O
between	O
colon	O
cancer	O
patients	O
and	O
healthy	O
controls	O
ROC	O
curves,	O
95%	O
confidence	O
bands	O
(B	O
 = 999)	O
and	O
AUROCs	O
for	O
CEA	O
(red	O
),	O
the	O
model	O
consisting	O
of	O
CEA	O
and	O
principal	O
component	O
1	O
(PC1	O
orange	O
),	O
and	O
the	O
model	O
consisting	O
of	O
CEA,	O
glycine,	B
and	O
tyrosine	B
(green	O
).	O

Although	O
fumarate	B
is	O
also	O
used	O
as	O
a	O
food	O
additive,	O
both	O
fumarate	B
and	O
succinate	B
are	O
involved	O
in	O
energy	O
production	O
as	O
intermediates	O
in	O
the	O
Krebs	O
cycle.	O

Seven	O
metabolites	O
(AMP,	O
aspartate,	B
glutamate,	B
hypoxanthine,	B
lactate,	B
proline,	B
and	O
pyroglutamate)	B
were	O
discriminated	O
between	O
CINs	B
and	O
cervical	O
cancer	O
versus	O
normal	O
(area	O
under	O
the	O
curve	O
(AUC)	O
value	O
>	O
0.8).	O

And	O
sarcosine	B
can	O
be	O
converted	O
into	O
glycine	B
by	O
sarcosine	O
dehydrogenase.	O

A	O
volume	O
of	O
400	O
µL	O
ice-cold	O
methanol	B
or	O
methanol-ethanol	B
(1:1)	I
was	O
added	O
to	O
plasma	O
sample	O
aliquots	O
containing	O
internal	O
standards,	O
and	O
vigorously	O
vortexed	O
for	O
15	O
min	O
at	O
room	O
temperature.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
metabolic	O
health	O
and	O
inflammatory	O
parameters	O
measured	O
Biochemical	O
markers	O
of	O
subjects	O
in	O
the	O
vitamin	B
D3	I
supplemented	O
and	O
placebo	O
groups	O
(Study	O
1).	O

Trimethylamine	B
N-oxide	I
(TMAO),	O
Choline,	B
Gut	O
microbiota	O
metabolite,	O
Liver	O
cancer,	O

Instrument	O
conditions:	O
Chromatographic	O
separation	O
was	O
performed	O
on	O
a	O
Phenomenex	O
Luna	O
C18	O
column	O
(50	O
x	O
2	O
mm;	O
3	O
µm)	O
using	O
a	O
water	O
and	O
methanol	B
gradient	O
for	O
the	O
mobile	O
phase;	O
both	O
the	O
methanol	B
and	O
water	O
were	O
supplemented	O
with	O
the	O
modifiers	O
ammonium	B
acetate	I
(10	O
mM)	O
and	O
formic	B
acid	I
(0.1%).	O

Cotinine	B
range	O
was	O
1,074	O
to	O
2,657	O
ng/mg	O
creatinine	B
in	O
cases	O
and	O
1,033	O
to	O
2,051	O
ng/mg	O
creatinine	B
in	O
controls	O
(P	O
=	O
0.583).	O

Significant	O
alterations	O
were	O
also	O
observed	O
in	O
two	O
sphingolipids:	B
sphinganine	B
and	O
a	O
neutral	O
glycosphingolipid.	B

Methionine	B
is	O
converted	O
into	O
homocysteine	B
via	O
a	O
3-step	O
process	O
in	O
which	O
demethylation	O
of	O
s-adenosyl-methionine	B
to	O
s-adenosyl-homocysteine	B
(SAH).	O

However,	O
a	O
bottleneck	O
is	O
the	O
lack	O
of	O
understanding	O
of	O
the	O
NAD	B
metabolome	O
specifically	O
at	O
the	O
subcellular	O
level,	O
which	O
in	O
turn	O
is	O
due	O
to	O
the	O
lack	O
of	O
a	O
reliable	O
analytical	O
method.	O

However,	O
the	O
opposite	O
change	O
has	O
been	O
observed	O
in	O
patients	O
with	O
inflammatory	O
disorders:	O
nonesterified	O
carnitine	B
was	O
extremely	O
decreased,	O
while	O
acylcarnitines	B
were	O
significantly	O
increased	O
in	O
patient	O
plasma.	O

However,	O
the	O
nonenzymatic	O
formation	O
of	O
11-dehydro-TXB2	B
was	O
not	O
a	O
practical	O
limitation	O
to	O
its	O
use	O
as	O
an	O
index	O
of	O
TX	O
biosynthesis.	O

Cysteine	B
instability	O
can	O
be	O
explained	O
by	O
rapid	O
oxidation	O
to	O
cystine.	B

_11	O
%RA	O
against	O
7α-hydroxy-3-oxocholest-4-en-26-oic	B
acid	I
(n	O
=	O
9).	O

We	O
estimate	O
that	O
these	O
experiments	O
detect	O
>	O
50	O
nmol	O
of	O
phosphorylated	O
compound,	O
which	O
translates	O
roughly	O
to	O
a	O
concentration	O
of	O
20	O
μM	O
in	O
the	O
cell,	O
in	O
line	O
with	O
reported	O
concentrations	O
of	O
common	O
phosphometabolites	B
in	O
cells	O
(;	O
).	O

BMI:	O
25.1 kg/m_2	O
;	O
total-Cholesterol:	B
5.74 mmol/L;	O
HDL-Cholesterol:	B
1.78 mmol/L;	O
Low-Density	O
Lipoprotein	O
(LDL)-Cholesterol:	B
3.45 mmol/L;	O
triglycerides:	B
1.18 mmol/	O

Incubations	O
were	O
carried	O
out	O
for	O
12	O
or	O
24	O
h.	O
We	O
used	O
high-performance	O
liquid	O
chromatography-electrospray	O
ionization-tandem	O
mass	O
spectrometry-selected	O
reaction	O
monitoring	O
at	O
m/z	O
464	O
→	O
m/z	O
317	O
to	O
analyze	O
the	O
incubation	O
mixtures	O
for	O
the	O
mercapturic	B
acid	I
products	O
that	O
would	O
result	O
from	O
glutathione	B
conjugation.	O

The	O
internal	O
standard	O
Phe-9-hydroxy-10-NAC	B
was	O
added	O
to	O
a	O
0.2	O
ml	O
of	O
aliquots	O
of	O
incubation	O
medium,	O
and	O
the	O
mixture	O
was	O
applied	O
to	O
a	O
Strata-X	O
polymeric	O
sorbent	O
cartridge	O
(33	O
μm,	O
30	O
mg/1	O
ml;	O
Phenomenex,	O
Torrance,	O
CA)	O
that	O
had	O
been	O
activated	B
with	O
1	O
ml	O
of	O
CH_3	O
OH	O
and	O
1	O
ml	O
of	O
H_2	O
O.	O

Statins	B
are	O
widely	O
prescribed	O
for	O
reducing	O
LDL-cholesterol	B
(C)	O
and	O
risk	O
for	O
cardiovascular	O
disease	O
(CVD),	O
but	O
there	O
is	O
considerable	O
variation	O
in	O
therapeutic	O
response.	O

LC-TOFMS	O
analysis	O
was	O
conducted	O
by	O
an	O
Agilent	O
1200	O
series	O
RRLC	O
system	O
SL	B
and	O
an	O
Agilent	O
6230	O
TOFMS	O
(Agilent	O
Technologies)	O
equipped	O
with	O
ODS	O
column	O
(2	O
×	O
50	O
mm,	O
2	O
μm).	O

PACK	O
was	O
obscured	O
in	O
chronic	O
stages	O
of	O
schizophrenia,	O
suggesting	O
that	O
the	O
leak	O
of	O
creatine	B
kinase	O
from	O
muscle	O
to	O
blood	O
occurred	O
especially	O
around	O
the	O
onset	O
of	O
schizophrenia.	O

There	O
is	O
further	O
evidence	O
that	O
mitochondrial	O
dysfunction	O
in	O
skeletal	O
muscle	O
leads	O
to	O
increased	O
cellular	O
glycine	B
production,	O
which	O
in	O
turn	O
is	O
protective	O
against	O
muscle	O
wasting	O
conditions,	O
such	O
as	O
cachexia	O
(reviewed	O
in	O
[,]).	O

B.	O
Box	O
plot	O
of	O
α-HB	B
concentrations	O
measured	O
using	O
targeted	O
isotopic	O
dilution	O
assays	O
(targeted	O
data).	O

FFPE	O
samples	O
showed	O
a	O
decrease	O
of	O
metabolites	O
with	O
characteristic	O
functional	O
groups,	O
such	O
as	O
secondary	O
carboxylic	B
acid	I
amide	I
(28%,	O
P	O
=	O
7.43	O
×	O
10_−12	O
;	O
FDR	O
=	O
6.42	O
×	O
10_−10	O
),	O
present	O
in	O
peptides	O
and	O
quaternary	O
ammonium	B
salts	O
(33%,	O
P	O
=	O
1.01	O
×	O
10_−3	O
;	O
FDR	O
=	O
2.30	O
×	O
10_−2	O
)	O
present	O
in	O
glycerophosphocholines	B
and	O
absent	O
in	O
glycerophosphoethanolamines.	B

Interestingly,	O
when	O
we	O
added	O
glutamate	B
to	O
the	O
experimental	O
group	O
containing	O
20 µM/L	O
BPTES	O
for	O
48 h,	O
relative	O
cell	O
activity	O
had	O
a	O
certain	O
increase	O
(Fig.	O

Metabolite	O
concentrations	O
entered	O
the	O
model	O
as	O
the	O
dependent	O
variable,	O
participant	O
identity	O
as	O
the	O
random	O
effect	O
and	O
the	O
following	O
clinical	O
variables	O
as	O
fixed	O
effects:	O
albuminuria	O
group,	O
age,	O
BMI,	O
estimated	O
globular	O
filtration	O
rate	O
(eGFR;	O
kidney	O
function),	O
glycated	O
hemoglobin	O
(HbA1c;	O
glycemic	B
control),	O
sex,	O
systolic	O
blood	O
pressure,	O
total	O
cholesterol,	B
total	O
triglycerides.	B

Fatty	O
acid	O
and	O
oxylipin	B
data	O
were	O
categorized	O
into	O
non-esterified	O
and	O
esterified	O
fatty	O
acid	O
pools	O
and	O
metabolites	O
were	O
grouped	O
by	O
their	O
parent	O
fatty	O
acids.	O

Muscle-ISI	O
and	O
WB-ISI	O
had	O
a	O
significant	O
correlation	O
with	O
the	O
actual	O
measurement	O
among	O
subgroups	O
of	O
subjects	O
with	O
metformin	B
(n = 19)	O
or	O
statin	B
therapy	O
(n	O

We	O
also	O
show	O
that	O
anastrozole	B
is	O
directly	O
glucuronidated	O
in	O
vitro	O
predominantly	O
by	O
UGT1A4,	O
although	O
the	O
contribution	O
of	O
this	O
route	O
in	O
vivo	O
remains	O
to	O
be	O
clarified	O
through	O
measurement	O
of	O
metabolites	O
in	O
urine.	O

Urine	O
samples	O
were	O
centrifuged	O
at	O
12,000	O
g	O
for	O
4	O
min	O
and	O
diluted	O
two-fold	O
with	O
Milli-Q	O
purified	B
water.	I

Nevertheless,	O
a	O
complex	O
relationship	O
has	O
been	O
shown	O
between	O
mTOR	O
activity	O
and	O
cancer,	O
and	O
that	O
leucine	B
or	O
a	O
leucine	B
derivative	O
may	O
be	O
involved	O
in	O
mTOR	O
activity.	O

β-Apocarotenoids	B
do	O
not	O
transactivate	O
retinoic	B
acid	I
receptors.	O

Among	O
the	O
23	O
differential	O
metabolites	O
in	O
this	O
study,	O
two	O
metabolites	O
related	O
to	O
oxidative	O
stress,	O
5-oxoproline	B
and	O
diketogulonic	O
acid,	O
were	O
significantly	O
decreased	O
in	O
adenoma	O
cases	O
compared	O
with	O
nonadenoma	O
controls.	O

The	O
ROC	O
curves	O
from	O
all	O
models	O
based	O
on	O
cross	O
validation	O
performance	O
indicated	O
that	O
Model	O
5	O
entered	O
10	O
features,	O
including	O
9cRA,	O
dehydrophytosphingosine,	B
1H-Indole-3-carboxaldehyde	B
and	O
seven	O
variants	O
of	O
lysophosphatidylcholines	B
(LysoPCs).	O

It	O
should	O
also	O
be	O
noted	O
that	O
the	O
Leu/Ile	O
values	O
include	O
contributions	O
from	O
allo-isoleucine	B
and	O
hydroxyproline.	B

Mean	O
serum	O
level	O
of	O
carnitine	B
in	O
the	O
NSCLC	O
patients	O
was	O
higher	O
than	O
in	O
healthy	O
controls,	O
while	O
the	O
rest	O
of	O
the	O
identified	O
metabolites	O
had	O
mean	O
levels	O
lower	O
in	O
the	O
NSCLC	O
group	O
as	O
compared	O
to	O
the	O
control	O
group	O
(Table ;	O
Fig.	O

The	O
higher	O
level	O
of	O
circulatory	O
TNF-α	O
observed	O
in	O
the	O
GR	O
patients	O
within	O
the	O
ER(+)	B
group	O
seems	O
to	O
support	O
the	O
hypothesis	O
of	O
a	O
more	O
proficient	O
immune	O
system	O
in	O
these	O
patients.	O

Additionally,	O
another	O
disadvantage	O
of	O
the	O
high	O
level	O
of	O
hippuric	B
acid	I
is	O
its	O
inhibition	O
of	O
glucose	B
utilization	O
in	O
the	O
muscles.	O

To	O
our	O
knowledge,	O
elevation	O
of	O
plasma	O
malate	B
levels	O
due	O
to	O
glucose	B
ingestion	O
has	O
not	O
been	O
previously	O
reported.	O

However,	O
additional	O
longitudinal	O
studies	O
are	O
needed	O
to	O
validate	O
these	O
results	O
before	O
further	O
conclusions	O
on	O
the	O
biological	O
mechanisms	O
linked	O
to	O
vitamin	B
D	I
can	O
be	O
drawn.	O

The	O
possibility	O
also	O
exists	O
that	O
C_27	O
bile	O
acids	O
could	O
be	O
formed	O
in	O
brain	O
from	O
cholesterol	B
itself.	O

_a	O
Abbreviations:	O
MBzP:	O
mono-benzyl	B
phthalate;	I
MiBP:	O
mono-iso-butyl	B
phthalate;	I
MnBP:	O
mono-n	B
-butyl	I
phthalate,	I
MCMHP:	O
mono-(2-carboxymethylhexyl)	B
phthalate,	I
MEP:	O
mono-ethyl	B
phthalate,	I
MECPP:	O
mono-(2-ethyl-5-carboxypentyl)	B
phthalate;	I
MEHP:	O
mono-ethylhexyl	B
phthalate;	I
MEHHP:	O
mono-(2-ethyl-5-hydroxyhexyl)	B
phthalate;	I
MEOHP:	O
mono-(2-ethyl-5-oxo-hexyl)	B
phthalate;	I
MMP:	O
mono-methyl	B
phthalate;	I
MiNP:	O
mono-iso-nonyl	B
phthalate;	I
unadjusted	O
level	O
of	O
each	O
phthalate	B
metabolite	O
was	O
shown	O
in	O
the	O
parentheses;	O
ND:	O
not	O
detectable;	O
Detectable	O
rate	O
=	O
number	O
of	O
urine	O
sample	O
with	O
level	O
of	O
each	O
phthalate	B
metabolite	O
above	O
detection	O
limit/	O
all	O
analyzed	O
urine	O
samples.	O

Selective	O
depletion	O
of	O
tumor	O
ATP	B
by	O
2-deoxyglucose	B
and	O
insulin,	O
detected	O
by	O
31P	O
magnetic	O
resonance	O
spectroscopy.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
serum	O
triglycerides	B
(p	O
 = 0.62),	O
LDL	O
(p	O
 = 0.94)	O
or	O
HDL	O
(p	O
 = 0.12)	O
at	O
baseline.	O

Plasma	O
protein	O
was	O
precipitated	O
by	O
the	O
addition	O
of	O
cold	O
acetonitrile.	B

Twenty	O
plasma	O
metabolites	O
were	O
identified	O
based	O
on	O
their	O
characteristic	O
chemical	O
shifts	O
and	O
multiplicities	O
and	O
quantified	O
by	O
integrating	O
peak	O
areas	O
relative	O
to	O
a	O
reference	O
signal	O
from	O
3-(Trimethylsilyl)propionic	B
acid-d_4	O
sodium	O
salt	O
(TSP).	O

Unlike	O
itaconic	B
acid,	I
which	O
acts	O
as	O
an	O
inhibitor	O
of	O
the	O
catalytic	O
subunit	O
of	O
SDH,	O
PhCAs	O
most	O
likely	O
act	O
on	O
the	O
ubiquinone-binding	O
site	O
of	O
the	O
respiratory	O
chain.	O

Separation	O
was	O
performed	O
using	O
eluent	O
A:	O
20	O
mM	O
ammonium	B
acetate	I
+	O
20	O
mM	O
ammonium	B
hydroxide	I
in	O
95:5	O
water:	O
acetonitrile,	B
pH	O
9.45;	O
Eluent	O
B:	O
acetonitrile.	B

All	O
the	O
participants	O
gave	O
their	O
written	O
informed	O
consent	O
before	O
entering	O
the	O
study,	O
which	O
was	O
approved	O
by	O
the	O
relevant	O
national	O
authority	O
(l’Agence	O
nationale	O
de	O
sécurité	O
du	O
medicament	O
et	O
des	B
produits	O
de	O
santé)	O
and	O
by	O
the	O
Ile	O
de	O
France	O
VII	O
ethics	O
committee.	O

We	O
have	O
developed	O
a	O
new	O
method	O
to	O
quantify	O
abiraterone	B
in	O
human	O
plasma,	O
using	O
more	O
convenient	O
protein	O
precipitation	O
as	O
sample	O
preparation,	O
and	O
applying	O
a	O
deuterated	O
isotope	O
as	O
the	O
internal	O
standard.	O

The	O
elevation	O
of	O
plasma	O
nonesterified	O
FA	B
levels	O
has	O
been	O
reported	O
to	O
produce	O
important	O
myocardial	O
damage,	O
arrhythmias,	O
and	O
reduction	O
in	O
heart	O
rate	O
variability	O
in	O
septic	O
patients.	O

()	O
Three	O
additional	O
solute	O
derivatives	O
of	O
amino	O
acids	O
that	O
are	O
synthesized	O
in	O
the	O
gut,	O
phenol	B
sulfate,	I
indoleacetate	B
and	O
3-indoxyl	B
sulfate,	I
were	O
elevated	O
in	O
plasma	O
of	O
progressors	O
compared	O
to	O
non-progressors,	O
however,	O
the	O
differences	O
did	O
not	O
reach	O
statistical	O
significance	O
(see	O
).	O

We	O
found	O
a	O
strong	O
direct	O
association	O
of	O
urinary	O
24-hour	O
creatinine	B
excretion	O
with	O
BMI	O
(P	O
=	O
8.88	O
×	O
10_−14	O
,	O
);	O
adjustment	O
for	O
creatinine	B
(model	O
3,	O
)	O
greatly	O
attenuated	O
the	O
association	O
of	O
BMI	O
with	O
3-methylhistidine,	B
the	O
most	O
strongly	O
associated	O
(P	O
=	O
8.28	O

The	O
relationship	O
between	O
urinary	O
myo-inositol	B
and	O
eGFR	O
was	O
closer	O
and	O
more	O
significant	O
in	O
the	O
FSGS	O
patients	O
than	O
in	O
the	O
MCD	O
patients	O
(Fig. ).	O

In	O
conclusion,	O
we	O
found	O
tyrosine	B
metabolism,	O
including	O
the	O
dopaminergic	O
species,	O
to	O
be	O
altered	O
in	O
manifest	O
HD	O
patients.	O

To	O
our	O
best	O
knowledge,	O
there	O
are	O
very	O
few	O
studies	O
about	O
the	O
metabolites	O
of	O
P	O
and	O
IP;	B
through	O
the	O
research	O
about	O
the	O
microbial	O
transformation	O
of	O
P,	O
which	O
was	O
performed	O
with	O
the	O
fungus	O
Glomerella	O
cingulate	O
,	O
Shinsuke	O
et	O
al.	O
obtained	O
P-1	O
for	O
the	O
first	O
time,	O
and	O
the	O
β-secretase	O
inhibitory	O
activity	O
of	O
P-1	O
and	O
P-2	O
in	O
vitro	O
were	O
proceeded.	O

d.	O
Ratio	O
of	O
Plasmalogen	O
ethanolamine	B
16:0/22:6	I
to	O
phosphatidyl	B
ethanolamine	I
16:0/18:3	I
in	O
Multiple	O
Sclerosis.	O

Critically,	O
this	O
study	O
identified	O
and	O
validated	O
a	O
type	O
II	O
biomarker	O
for	O
the	O
RR	O
to	O
SP	B
transition	O
in	O
patients	O
with	O
MS.	O

200	O
ll	B
aliquots	O
of	O
serum	O
from	O
each	O
study	O
subject,	O
stored	O
at	O
−80°C,	O
were	O
thawed	O
on	O
ice	O
and	O
each	O
aliquot	O
was	O
split	O
into	O
three	O
equal	O
parts:	O
One	O
aliquot	O
for	O
GC/MS,	O
one	O
aliquot	O
for	O
the	O
ESI-positive	O
mode	O
of	O
the	O
UPLC/MS-MS	O
analysis	O
and	O
the	O
third	O
aliquot	O
for	O
the	O
ESI-negative	O
mode.	O

This	O
confirms	O
previous	O
assessments	O
performed	O
in	O
plasma	O
or	O
urine	O
[,	O
–],	O
while	O
lending	O
further	O
support	O
to	O
blunted	O
melatonin	B
synthesis	O
possibly	O
due	O
to	O
reduced	O
ASMT	O
enzyme	O
activity	O
in	O
ASD	O
[,	O
].	O

This	O
was	O
appropriate	O
here,	O
because	O
the	O
study	O
sought	O
any	O
evidence	O
of	O
aspartame	B
symptoms,	O
even	O
if	O
these	O
would	O
not	O
be	O
consequential	O
in	O
the	O
general	O
population.	O

In	O
the	O
CTS	O
analysis	O
of	O
PA	O
and	O
PS,	O
the	O
product	O
ion	O
at	O
m/z	O
153,	O
which	O
is	O
a	O
1,2-cyclic	B
phosphodiester	I
of	O
glycerol,	B
had	O
low	O
CCS	O
value	O
of	O
108	O
Å_2	O
.	O

The	O
residual	O
water	O
signal	O
in	O
the	O
regions	O
of	O
δ	O
4.20–5.20	O
was	O
discarded	O
prior	O
to	O
data	O
analyses	O
together	O
with	O
ethanol	B
resonances	O
(δ	O
1.14–1.18,	O
δ	O
3.62–3.70),	O
which	O
were	O
probably	O
introduced	O
during	O
sample	O
collections.	O

Strong	O
positive	O
correlations	O
existed	O
within	O
lipid	O
classes,	O
such	O
as	O
those	O
between	O
sterol	O
synthesis	O
intermediates	O
and	O
total	O
serum	O
cholesterol	B
and	O
lipoprotein	O
levels.	O

The	O
presence	O
of	O
glutamate,	B
pyruvate	B
and	O
alanine	B
only	O
in	O
the	O
commercial	O
medium	O
and	O
corresponding	O
CM	O
(24	O
h	O
and	O
48	O
h	O
Com.	O

Blood	O
concentrations	O
of	O
vinorelbine	O
and	O
its	O
metabolite,	O
4′-O	B
-deacetylvinorelbine,	I
were	O
quantified	O
by	O
a	O
validated	O
liquid	O
chromatography–tandem	O
mass	O
spectrometry	O
method	O
at	O
SIMM	O
Bioanalytical	O
Laboratory	O
(Shanghai,	O
China).	O

In	O
the	O
present	O
study,	O
the	O
levels	O
of	O
creatinine,	B
creatine,	B
glycine,	B
DMG	B
and	O
choline	B
significantly	O
decreased	O
in	O
esophageal	O
cancer	O
tissues.	O

Support	O
for	O
the	O
ACE	O
I/D	O
polymorphism-dependent	O
modification	O
of	O
glucose	B
metabolism	O
in	O
working	O
muscle	O
was	O
presented	O
by	O
a	O
reduced	O
RER	O
during	O
the	O
exhaustive	O
exercise	O
in	O
ACE-DD	O
genotypes	O
(Figs	O
and	O
).	O

The	O
limit	O
of	O
detection	O
for	O
the	O
plasma	O
melatonin	B
assay	O
was	O
3.9 ± 0.8 pg/	O

Isopropanol	B
(LC-MS	O
grade,	O
Fluka),	O
methanol,	B
water	O
and	O
_13	O
C-	B
cholic	I
acid	I
(internal	O
standard)	O
were	O
from	O
Sigma-Aldrich	O
(Milwaukee,	O
WI,	O
USA).	O

The	O
loading	O
plot	O
shows	O
increased	O
concentrations	O
of	O
glycine,	B
taurine,	B
trimethylamine-N-oxide	B
(TMAO),	O
carnitine	B
and	O
citrate,	B
and	O
decreased	O
concentrations	O
of	O
creatinine	B
(mean	O
concentration	O
of	O
creatinine	B
over	O
time	O
is	O
shown	O
in	O
)	O
and	O
dimethylamine	B
during	O
sleep	O
deprivation.	O

The	O
normalized	O
measured	O
and	O
predicted	O
migration	O
times	O
were	O
8.16 min	O
and	O
7.78 min	O
(0.38 min)	O
for	O
ethanolamine,	B
11.61 min	O
and	O
10.42 min	O
(1.19 min)	O
for	O
burimamide,	B
8.75 min	O
and	O
7.78 min	O
(0.97 min)	O
for	O
choline,	B
8.16 min	O
and	O
7.78 min	O
(0.38 min)	O
for	O
ethanolamine,	B
10.012 min	O
and	O
10.10 min	O
(0.98 min)	O
for	O
methylimidazoleacetic	B
acid,	I
8.78 min	O
and	O
7.84 min	O
(0.94 min)	O
for	O
piperidine,	B
12.90 min	O
and	O
13.09 min	O
(0.19 min)	O
for	O
pyrroline	B
hydroxycarboxylic	I
acid,	I
and	O
7.61 min	O
and	O
8.26 min	O
(0.65 min)	O
for	O
trimethylamine.	B

The	O
dry	O
residue	O
was	O
reconstituted	O
in	O
60	O
μl	O
of	O
acetonitrile	B
(brief	O
vortex),	O
followed	O
by	O
20	O
μl	O
of	O
high	O
purity	O
grade	O
water	O
(brief	O
vortex),	O
and	O
then	O
centrifuged	O
again	O
at	O
3000	O
×	O
g	O
for	O
10	O
min	O
at	O
4	O
°C.	O

The	O
following	O
metabolites	O
were	O
characterized:	O
sterol	O
lipid	O
(n	O
=	O
8),	O
sphingolipids	B
(n	O
=	O
6),	O
prenol	B
lipids	O
(n	O
=	O
4),	O
polyketides	O
(n	O
=	O
11),	O
organooxygen	B
compounds	O
(n	O
=	O
1),	O
lactones	B
(n	O
=	O
1),	O
glycerophospholipids	B
(n	O
=	O
10),	O
glycerolipids	B
(n	O
=	O
5),	O
flavonoids	B
(n	O
=	O
1),	O
fatty	O
acyls	O
(n	O
=	O
22),	O
coumarins	O
and	O
derivatives	O
(n	O
=	O
1),	O
and	O
carboxylic	B
acids	I
and	O
derivatives	O
(n	O
=	O
2).	O

The	O
data	O
showed	O
that	O
metabolites	O
involved	O
in	O
purine	B
biosynthesis	O
and	O
fatty	O
acid	O
metabolism	O
were	O
upregulated	O
in	O
the	O
low-grade	O
NMIBC	O
patients,	O
whereas	O
metabolites	O
involved	O
in	O
steroid	O
hormone	O
biosynthesis	O
and	O
protein	O
digestion	O
were	O
downregulated.	O

To	O
avoid	O
any	O
effects	O
of	O
heparin,	B
such	O
as	O
increased	O
levels	O
of	O
oxylipins	B
by	O
heparin	B
induced	O
phopholipase	O
A2	O
activity,	O
described	O
in	O
literature	O
[,	O
],	O
samples	O
collected	O
during	O
the	O
period	O
in	O
which	O
heparin	B
was	O
administered	O
to	O
the	O
patient	O
were	O
not	O
used.	O

Thus,	O
there	O
is	O
a	O
common	O
mechanism	O
accounting	O
for	O
the	O
elevated	O
lysoglycerophospholipid	B
levels	O
in	O
EVs	O
but	O
it	O
has	O
not	O
yet	O
been	O
elucidated.	O

Recently,	O
blood	O
branch-chained	O
amino	O
acids	O
(BCAAs),	O
glutamine	B
and	O
glycine	B
have	O
been	O
shown	O
to	O
robustly	O
associate	O
with	O
prediabetes	O
and	O
type	O
2	O
diabetes	O
(T2DM)	O
and	O
predict	O
the	O
risk	O
of	O
T2DM.	O

Two	O
hundred	O
microliter	O
MeOH	B
were	O
added	O
to	O
precipitate	O
proteins,	O
and	O
then	O
the	O
mixture	O
was	O
incubated	O
at	O
−20°C	O
for	O
20	O
minutes.	O

It	O
was	O
also	O
noted	O
that	O
one	O
endogenous	O
metabolite,	O
uridine,	B
was	O
present	O
at	O
lower	O
levels	O
in	O
both	O
CSF	O
and	O
serum	O
of	O
the	O
SCI	O
patients.	O

Individuals	O
with	O
type	O
1	O
DM	O
(T1DM)	O
at	O
follow-up,	O
confirmed	O
with	O
antibody	O
tests	O
(GADA	O
and	O
IA-2A),	O
were	O
excluded	O
from	O
the	O
main	O
analysis	O
but	O
were	O
included	O
in	O
a	O
subgroup	O
analysis	O
of	O
ketone	B
metabolism.	O

These	O
observations	O
are	O
supported	O
by	O
a	O
recent	O
finding	O
that	O
a	O
factor	O
secreted	O
by	O
adipocytes	O
could	O
inhibit	O
2-hydroxylation	O
of	O
estradiol	B
by	O
MCF-7	O
cells.	O

summarizes	O
metabolites	O
that	O
changed	O
with	O
limonene	B
intervention.	O

Urine-0h	B
samples	O
were	O
collected	O
from	O
the	O
first	O
urine	O
after	O
catheterization	O
for	O
each	O
patient	O
on	O
the	O
day	O
of	O
admission.	O

A	O
mixture	O
containing	O
0.1 mL	O
of	O
human	O
serum,	O
3.0 mL	O
of	O
phosphate	B
buffer	O
(0.1 M,	O
pH	O
7.4),	O
and	O
0.10 mL	O
of	O
DTNB	O
(10 mM)	O
was	O
incubated	O
at	O
37 °C	O
for	O
10 min.	O

The	O
performance	O
of	O
the	O
developed	O
UHPLC-MS/MS	O
method	O
was	O
compared	O
with	O
other	O
LC-MS/MS	O
methods	O
registered	O
with	O
the	O
vitamin	B
D	I
External	O
Quality	O
Assessment	O
Scheme	O
(DEQAS,	O
http://www.deqas.org)	O
by	O
blind	O
measurement	O
of	O
12	O
samples	O
in	O
duplicate	O
and	O
comparison	O
of	O
the	O
results	O
using	O
regression	O
and	O
Bland	O
and	O
Altman	O
analysis.	O

Resonance	O
assignments	O
and	O
concentrations	O
of	O
uremic	O
toxins	B
measured	O
by	O
_1	O
H-NMR	O
are	O
summarized	O
in	O
and	O
chemical	O
structures	O
can	O
be	O
found	O
in	O
.	O

GGs	O
corresponding	O
to	O
commercial	O
standards	O
were	O
detected,	O
confirming	O
the	O
identification	O
previously	O
made	O
by	O
HPTLC:	O
GM3,	B
GD3,	O
GD1a,	O
GD1b,	O
GT1b	O
and	O
GQ1b.	O

The	O
unconjugated	O
steroids	O
were	O
extracted	O
from	O
serum	O
with	O
1.5	O
mL	O
methyl	B
tert-butyl	I
ether	I
(MtBE)	O
by	O
vortexing	O
at	O
1800	O
rpm	O
for	O
2	O
min.	O

We	O
found	O
a	O
direct	O
association	O
of	O
urinary	O
glucose	B
with	O
BMI	O
(r	O
=	O
0.14,	O
P	O
=	O
3.27	O
×	O
10_−9	O
),	O
which	O
is	O
materially	O
unchanged	O
when	O
dietary	O
glucose	B
intake,	O
total	O
sugar,	O
or	O
total	O
carbohydrate	O
intake	O
are	O
added	O
to	O
the	O
regression	O
model,	O
indicating	O
possible	O
latent	O
insulin	O
resistance	O
and	O
undiagnosed	O
diabetes	O
related	O
to	O
adiposity	O
(,	O
,	O
,	O
).	O

The	O
aqueous	O
methanolic	B
layer	O
was	O
collected	O
and	O
dried	O
completely.	O

Examination	O
of	O
the	O
MS/MS	O
data	O
for	O
the	O
C28	O
series	O
(masses	O
446,	O
448,	O
450,	O
464,	O
466	O
and	O
448)	O
revealed	O
a	O
consistent	O
113	O
Da	O
daughter	O
ion,	O
which	O
we	O
conjecture	O
to	O
represent	O
the	O
carboxy-terminus	B
chain	O
fragment	O
-CH_2	O
-CH=CH-CH_2	O
-CH_2	O
-COOH.	O

We	O
also	O
assessed	O
whether	O
associations	O
between	O
log-transformed	O
measures	O
of	O
estrogen	B
and	O
estrogen	B
metabolism	O
and	O
the	O
risk	O
of	O
breast	O
cancer	O
were	O
modified	O
by	O
the	O
time	O
from	O
blood	O
draw	O
to	O
diagnosis	O
(≤1327	O
days	O
[median]	O
vs	O
>1327	O
days),	O
by	O
the	O
period	O
of	O
blood	O
draw	O
(January	O
26,	O
1994,	O
to	O
September	O
29,	O
1997,	O
vs	O
September	O
30,	O
1997,	O
to	O
October	O
17,	O
2001),	O
by	O
age	O
at	O
study	O
entry	O
on	O
10-year	O
groups	O
(55–64	O
vs	O
65–74	O
years),	O
or	O
by	O
history	O
of	O
menopausal	O
hormone	O
therapy	O
before	O
study	O
entry	O
(ever	O
vs	O
never).	O

Metabolite	O
concentrations	O
were	O
normalized	O
to	O
urinary	O
creatinine	B
and	O
subjected	O
to	O
univariate	O
statistical	O
analysis.	O

Vinorelbine	O
doses	O
administered,	O
blood	O
sampling	O
timepoints,	O
duration	B
of	O
study,	O
and	O
bioanalytical	O
methods	O
used	O
were	O
similar	O
in	O
both	O
studies.	O

_8	O
x	B
-Hydroxy-3-oxocholesta-4,6-dien-26-oic	I
acid	I
is	O
a	O
likely	O
dehydration	O
product	O
of	O
7α-x	B
-dihydroxy-3-oxocholest-4-en-26-oic	I
acid.	I

An	O
increase	O
of	O
the	O
total	O
choline-containing	O
compounds	O
(e.g.,	O
glycerophosphocholine,	B
phosphocholine,	B
and	O
choline)	B
has	O
been	O
reported	O
as	O
the	O
most	O
common	O
feature	O
in	O
a	O
large	O
variety	O
of	O
tumors	O
demonstrating	O
biosynthetic	O
and/or	O
catabolic	O
phosphatidylcholine-cycle	B
pathways	O
of	O
cell	O
membrane	O
turnover	O
[,	O
]	O
and	O
was	O
proposed	O
as	O
fingerprints	O
of	O
tumor	O
progression	O
and/or	O
as	O
endpoints	O
of	O
therapeutic	O
treatment	O
[,	O
–,	O
].	O

Five	O
metabolites	O
had	O
robust	O
changes	O
(increased	O
creatine	B
and	O
decreased	O
betaine,	B
nonanoic	B
acid,	I
benzoic	B
acid	I
and	O
perillic	O
acid)	O
in	O
two	O
independent	O
sample	O
sets.	O

Trihexosylceramide	B
was	O
inversely	O
related	O
with	O
fasting	O
insulin	O
(r = −0.6,	O
p = 0.002),	O
insulin	O
resistance	O
(r = −0.6,	O
p = 0.003),	O
insulin	O
secretion	O
(r = −0.4,	O
p = 0.05)	O
and	O
serum	O
carnosinase	O
1	O
activity	O
(r = −0.3,	O
p = 0.05).	O

The	O
significant	O
alteration	O
in	O
the	O
levels	O
of	O
4-methylheptan-2-one	B
study	O
is	O
in	O
concordance	O
with	O
previously	O
reported	O
in	O
urines	O
from	O
head	O
and	O
neck	O
cancer	O
patients.	O

Again,	O
the	O
liver	O
is	O
known	O
to	O
actively	O
take	O
up	O
glutamine	B
and	O
convert	O
it	O
to	O
glutamate,	B
making	O
it	O
available	O
for	O
gluconeogenesis	O
or	O
for	O
subsequent	O
conversion	O
to	O
other	O
amino	O
acids.	O

Briefly,	O
a	O
300	O
μL-volume	O
of	O
methanol	B
containing	O
internal	O
standards	O
at	O
40	O
ng/mL	O
was	O
added	O
to	O
100-μL	O
aliquot	O
of	O
human	O
plasma	O
(or	O
serum)	O
for	O
plasma	O
protein	O
precipitation	O
in	O
1.5	O
mL	O
safe-lock	O
PP	O
tubes.	O

(+)ESI	B
MS/MS	O
spectrum	O
and	O
proposed	O
fragmentation	O
of	O
abiraterone,	B
transitions	O
monitored	O
for	O
quantification	O
are	O
350→156	O
for	O
abiraterone	B
and	O
354→160	O
for	O
D_4	O
‐abiraterone.	B

Of	O
particular	O
interest	O
was	O
the	O
observed	O
accumulation	O
of	O
carnitine	B
and/or	O
acetylcarnitine	B
in	O
blood	O
serum	O
of	O
MM	O
patients	O
both	O
at	O
diagnosis	O
and	O
after	O
relapse,	O
suggesting	O
these	O
metabolites	O
as	O
candidate	O
blood	O
serum	O
biomarkers	O
associated	O
with	O
active	O
MM	O
disease.	O

According	O
to	O
biomarker	O
analysis	O
through	O
receiver-operating	O
characteristic	O
curves,	O
9-cis-retinoic	B
acid	I
(9cRA)	O
dominated	O
the	O
first	O
page	O
of	O
biomarkers,	O
with	O
area	O
under	O
the	O
curve	O
(AUC)	O
value	O
0.888.	O

We	O
not	O
only	O
measured	O
elevated	O
concentrations	O
of	O
p	O
-cresol	O
and	O
its	O
glucuronide	B
in	O
the	O
late	O
stages	O
of	O
CRC,	O
but,	O
moreover,	O
surgical	O
intervention	O
markedly	O
reduced	O
the	O
levels	O
in	O
patients	O
after	O
surgery	O
by	O
approximately	O
50	O
%.	O

Patients	O
with	O
echolucent	O
plaque	O
showed	O
significantly	O
higher	O
levels	O
of	O
20-HETE	B
and	O
DiHETEs	O
but	O
lower	O
levels	O
of	O
EETs.	O

These	O
metabolites	O
included	O
three	O
previously	O
identified	O
biomarkers	O
(α-hydroxybutyrate,	B
N-methylnicotinamide,	I
and	O
2,4-dihydroxypyrimidine)_,	B
.	O

Thus,	O
the	O
metabolism	O
of	O
the	O
membrane	O
phospholipids	B
caused	O
by	O
accelerated	O
cell	O
proliferation	O
could	O
be	O
a	O
reason	O
for	O
elevated	O
choline	B
in	O
the	O
sera	O
of	O
HCC	O
patients.	O

Among	O
them,	O
generally	O
heightened	O
fatty	O
acids	O
were	O
found	O
in	O
the	O
recurrent	O
cases,	O
except	O
for	O
arachidonic	B
acid	I
(ARA,	O
FFA	B
20:4),	I
similar	O
to	O
the	O
fatty	O
acid-related	O
findings	O
with	O
BT.	O

HDL-cholesterol	B
and	O
triglyceride	B
were	O
associated	O
with	O
TPA	O
levels.	O

The	O
vials	O
stored	O
at	O
25	O
°C	O
remained	O
on	O
a	O
lab	O
benchtop	O
under	O
room	O
light	O
for	O
the	O
duration	B
of	O
the	O
testing	O
period.	O

Treatment	O
of	O
C4–2B4	O
and	O
PC-3 M-Pro4	O
cells	O
with	O
palmitic	B
acid	I
(PA)	O
(range	O
between	O
50	O
and	O
200 μM)	O
resulted	O
in	O
increased	O
proliferation	O
(Fig.	O

Three	O
other	O
metabolites	O
involved	O
in	O
androgen	O
metabolism,	O
4-androsten-3beta,17beta-diol	B
disulfate	I
1	O
and	O
2,	O
and	O
dehydroepiandrosterone	B
sulfate,	I
were	O
the	O
next	O
most	O
strongly	O
associated	O
of	O
the	O
222	O
metabolites,	O
but	O
did	O
not	O
reach	O
metabolome-wide	O
significance.	O

Another	O
discriminant	O
strongly	O
correlated	O
with	O
coffee	O
intake	O
was	O
the	O
alkaloid	O
trigonelline	B
(m/	O

There	O
are	O
no	O
natural	O
sources	O
of	O
saccharin	B
and	O
acetaminophen,	B
so	O
accumulation	O
of	O
saccharin	B
and	O
2-hydroxyacetaminophen	B
sulfate	I
in	O
renal	O
failure	O
is	O
presumably	O
due	O
exclusively	O
to	O
intake	O
of	O
the	O
synthetic	O
compounds.	O

Cancer	O
cells,	O
being	O
highly	O
proliferative,	O
show	O
significant	O
alterations	O
in	O
metabolic	O
pathways	O
such	O
as	O
glycolysis,	O
respiration,	O
the	O
tricarboxylic	B
acid	I
(TCA)	O
cycle,	O
oxidative	O
phosphorylation,	O
lipid	O
metabolism,	O
and	O
amino	O
acid	O
metabolism.	O

For	O
this	O
study,	O
we	O
have	O
employed	O
an	O
UPLC-MS	O
method	O
(Supplementary	O
Figure	O
S1)	O
capable	O
of	O
detecting	O
consistently	O
the	O
105	O
identified	O
metabolites	O
listed	O
in	O
Supplementary	O
Table	O
S1,	O
that	O
includes	O
fatty	O
acyls,	O
glycerolipids,	B
glycerophospholipids,	B
sterol	O
lipids	O
and	O
sphingolipids.	B

As	O
it	O
is	O
broken	O
down	O
into	O
its	O
constituents	O
fructose	B
and	O
glucose	B
and	O
its	O
increase	O
in	O
blood	O
indicates	O
metabolic	O
syndrome,	O
mostly	O
in	O
β-thalassemia	O
patients	O
glucose	B
homeostasis	O
is	O
abnormal	O
this	O
may	O
result	O
in	O
its	O
elevation.	O

The	O
ethyl	O
radical	O
then	O
abstracts	O
C3–H	O
on	O
the	O
glycerol	B
backbone;	O
subsequent	O
β-cleavage	B
gives	O
rise	O
to	O
neutral	O
loss	O
of	O
sn	O
-2	O
fatty	O
acyl	O
as	O
˙R_2	O
and	O
CO_2	O
and	O
forms	O
a	O
double	O
bond	O
between	O
C2	O
and	O
C3	O
on	O
the	O
glycerol	B
backbone.	O

Since	O
acyl	O
side	O
chain	O
positions	O
were	O
not	O
validated	O
with	O
synthetic	O
standards,	O
glycerophospholipids	B
and	O
glycerolipids	B
were	O
annotated	O
along	O
with	O
the	O
identified	O
structure	O
for	O
the	O
acyl	O
side	O
chains	O
using	O
the	O
underscore	O
convention,	O
and	O
reported	O
with	O
their	O
highest	O
intensity	O
MS/MS	O
fragment.	O

For	O
IHC,	O
tissues	O
were	O
fixed	O
in	O
10%	O
methanol/buffered	O
formalin	B
for	O
12 h	O
and	O
were	O
processed	O
routinely.	O

A	O
greater	O
ratio	O
of	O
saturated	O
stearic	B
acid	I
FA	I
(18:0)	I
(m	O
/z	O
283.3)	O
(SI	O
Appendix	O
,	O
Fig.	O

Some	O
confusion	O
may	O
arise	O
concerning	O
the	O
nomenclature	O
of	O
27-hydroxycholesterol	B
and	O
related	O
compounds.	O

The	O
recoveries	O
of	O
all	O
polyamine	B
and	O
precursors	O
were	O
above	O
82%	O
in	O
the	O
serum	O
matrix.	O

An	O
aliquot	O
of	O
the	O
lipid	O
extract	O
was	O
then	O
extracted	O
with	O
hexane	B
to	O
isolate	O
triglycerides	B
(TGs)	O
from	O
the	O
total	O
chloroform	B
extract,	O
followed	O
by	O
base	O
hydrolysis	O
to	O
release	O
FAs	O
from	O
TGs.	O

Valine	B
and	O
leucine	B
were	O
decreased	O
in	O
late	O
IUGR	O
samples.	O

These	O
characteristics	O
are	O
also	O
seen	O
with	O
glycogen	B
storage	O
disease	O
Ia,	O
in	O
which	O
there	O
is	O
a	O
defect	O
in	O
hepatic	O
glucose-6-phosphatase.	O

Some	O
amino	O
acids	O
are	O
correlated	O
with	O
violence	O
in	O
previous	O
studies,	O
especially	O
tryptophan,	B
which	O
is	O
the	O
amino	O
acid	O
precursor	O
of	O
5-HT	O
biosynthesis.	O

Patients	O
who	O
developed	O
AP	B
had	O
significantly	O
higher	O
levels	O
of	O
amylase	O
(P	O
=0.006)	O
and	O
lipase	O
(P	O
=0.004)	O
after	O
ERCP	O
than	O
those	O
who	O
did	O
not	O
(	O
and	O
).	O

These	O
differences	O
in	O
lanthionine	B
concentrations	O
may	O
partly	O
result	O
from	O
higher	O
precursor	O
concentrations,	O
because	O
cysteine	B
concentrations	O
were	O
higher	O
in	O
subjects	O
with	O
high	O
cystathionine	B
concentrations	O
(P	O
=	O
0.024;	O
).	O

Palmitic	B
acid	I
(16:0)	O
levels	O
were	O
positively	O
associated	O
with	O
inflammatory	O
monocyte	O
(CD14_+	O
CD16_+	O
)	O
surface	O
expression	O
of	O
the	O
innate	O
immune	O
receptor,	O
TLR4,	O
and	O
myristic	B
acid	I
(14:0)	O
was	O
positively	O
associated	O
with	O
levels	O
of	O
CD36,	O
a	O
scavenger	O
receptor	O
involved	O
in	O
immune	O
signaling	O
and	O
lipid	O
uptake.	O

Urinary	O
creatinine	B
concentrations	O
were	O
measured	O
using	O
a	O
Roche-Cobas	O
MiraPlus	O
clinical	O
chemistry	O
autoanalyzer	O
(Roche	O
Diagnostics,	O
Switzerland).	O

It	O
has	O
been	O
reported	O
that	O
the	O
level	O
of	O
serum	O
proline	B
in	O
patients	O
with	O
acute	O
ischemic	O
stroke	O
is	O
significantly	O
lower	O
than	O
that	O
in	O
normal	O
controls.	O

This	O
disease	O
is	O
characterized	O
by	O
elevated	O
levels	O
of	O
methionine	B
and	O
homocysteine	B
in	O
plasma	O
and	O
urine.	O

Model	O
2:	O
model	O
1	O
adjustments	O
plus	O
smoking,	O
alcohol	O
consumption,	O
caloric	O
expenditure,	O
family	O
history	O
of	O
diabetes,	O
dietary	O
kilocalories,	O
dietary	O
protein,	O
and	O
fasting	O
blood	O
glucose.	B

A	O
57-year-old	O
male	O
patient	O
with	O
mCRPC	O
started	O
enzalutamide	B
therapy	O
in	O
January	O
2015.	O

One	O
of	O
the	O
low	O
abundance	O
metabolites	O
identified	O
in	O
serum	O
was	O
trigonelline.	B

Since	O
a	O
subset	O
of	O
patients	O
were	O
treated	O
with	O
oral	O
nitrates	B
or	O
sodium	O
nitroprusside	O
at	O
the	O
time	O
of	O
blood	O
draws,	O
confirmation	O
of	O
NO	O
deficiency	O
with	O
direct	O
measurements	O
of	O
nitrate	B
levels	O
(NOx)	O
cannot	O
be	O
a	O
reliable	O
estimate	O
of	O
systemic	O
NO	O
production.	O

β-Apocarotenoids.	B

In	O
addition,	O
the	O
hypertriglyceridemia	O
and	O
hyperglycaemia	B
result	I
in	O
high	O
levels	O
of	O
glucose	B
and	O
glutamine	B
in	O
the	O
serum.	O

Urinary	O
cotinine	B
was	O
analyzed	O
by	O
LC-MS/MS.	O

Given	O
that	O
this	O
radical	O
fragmentation	O
channel	O
is	O
not	O
observed	O
from	O
CID	O
of	O
formate	B
or	O
acetate	B
adduct	O
anions	O
of	O
PCs,	O
we	O
hypothesize	O
that	O
the	O
–OH	O
group	O
in	O
bicarbonate	O
may	O
form	O
a	O
relatively	O
strong	O
hydrogen	O
bond	O
with	O
phosphate	B
oxygen	I
in	O
PC	O
molecules	O
(possible	O
interaction	O
is	O
indicated	O
in	O
).	O

When	O
stratified	O
according	O
to	O
the	O
optimal	O
ROC	O
cut-off	O
value	O
of	O
6.1	O
μM	O
for	O
TMAO	B
and	O
median	O
NT-proBNP	O
(1,473	O
pg/mL)	O
for	O
this	O
cohort,	O
the	O
subset	O
of	O
patients	O
with	O
both	O
elevated	O
TMAO	B
and	O
NT-proBNP	O
demonstrated	O
the	O
greatest	O
risk	O
of	O
future	O
adverse	O
cardiac	O
events.	O

These	O
findings	O
are	O
in	O
agreement	O
with	O
previous	O
studies	O
demonstrating	O
that	O
eGFR	O
is	O
an	O
unsuitable	O
tool	O
to	O
predict	O
levels	O
of	O
uremic	O
toxins	B
from	O
different	O
classes	O
(e.g.	O
middle	O
weight	O
and	O
protein-bound)	O
in	O
CKD	O
patients	O
,	O
.	O

We	O
identified	O
associations	O
between	O
indexes	O
of	O
RV-PV	O
dysfunction	O
and	O
the	O
catecholamine	B
vanillylmandelic	I
acid,	I
as	O
well	O
as	O
aminoisobutyric	B
acid	I
and	O
cyclic	O
adenosine	O
monophosphate,	O
2	O
additional	O
metabolites	O
potentially	O
related	O
to	O
sympathetic	O
nervous	O
system	O
activation	O
(,).	O

Each	O
increase	O
in	O
plasma	O
triglycerides	B
of	O
100 mg/dl	O
corresponded	O
to	O
a	O
12.5%	O
increase	O
in	O
TNFα-stimulated	O
VCAM-1	O
expression.	O

Glucocorticoid	B
inhibits	O
prostaglandin	B
synthesis	O
by	O
inhibiting	O
translation	O
of	O
PG	B
synthase	O
enzyme	O
.	O

Patients	O
were	O
randomized	O
to	O
sequential	O
treatment	O
with	O
prebiotic	O
arabinoxylan	B
oligosaccharides	I
(AXOS)	O
(10	O
g	O
twice	O
daily)	O
and	O
maltodextrin	O
for	O
4	O
weeks,	O
or	O
vice	O
versa,	O
with	O
a	O
4-week	O
wash-out	O
period	O
between	O
both	O
intervention	O
periods.	O

PCYT1A	O
is	O
a	O
rate-limiting	O
enzyme	O
for	O
PC	O
synthesized	O
via	O
the	O
Kennedy	O
pathway,	O
which	O
converts	O
phosphocholine	B
to	O
CDP-choline.	B

The	O
SATIN	B
study	O
is	O
a	O
multicentre	O
2-month	O
weight-loss	O
trial	O
and	O
it	O
was	O
used	O
as	O
a	O
training	O
set	O
for	O
the	O
analysis.	O

Of	O
five	O
identified	O
metabolites	O
that	O
differed	O
significantly	O
among	O
groups	O
by	O
Kruskal-Wallis	O
test,	O
four	O
remained	O
significant	O
after	O
evaluation	O
by	O
Wilcoxon	O
rank-sum	O
tests	O
with	O
Bonferroni	O
correction	O
(acetone,	O
adenosine,	B
citrate,	B
ribose).	O

In	O
particular	O
creatinine	B
is	O
strongly	O
correlated	O
with	O
pyroglutamic	B
acid/glutamic	I
acid,	O
alpha-D-glucosamine	B
1-phosphate	I
and	O
lauric	B
acid.	I

A	O
100 μL	O
of	O
the	O
serum	O
sample	O
was	O
mixed	O
with	O
300 μL	O
of	O
methanol	B
(HPLC	O
grade,	O
Merck,	O
Darmstadt,	O
Germany),	O
thoroughly	O
vortexed	O
for	O
30 s,	O
and	O
subsequently	O
centrifuged	O
at	O
12000 rpm	O
and	O
4 °C	O
for	O
15 min	O
to	O
pellet	O
the	O
protein	O
contents.	O

Methionine	B
is	O
susceptible	O
to	O
oxidative	O
modification	O
by	O
reactive	O
oxygen	O
species	O
(ROS),	O
and	O
high	O
levels	O
of	O
oxidized	O
methionine	B
are	O
therefore	O
regarded	O
as	O
a	O
marker	O
of	O
oxidative	O
stress.	O

For	O
instance,	O
the	O
relative	O
standard	O
deviation	O
(RSD)	O
for	O
the	O
majority	O
of	O
the	O
analytes	O
for	O
PCA	O
extraction	O
is	O
over	O
40%,	O
with	O
the	O
highest	O
being	O
74.1%	O
for	O
N1-AcSPM,	O
69.7%	O
for	O
AGM,	O
and	O
62.3%	O
for	O
SPM	O
(data	O
shown	O
in	O
Figure	O
S1);	O
whereas	O
for	O
CHCl_3	O
:MeOH	O
extraction,	O
the	O
RSD	O
was	O
lower	O
than	O
20%	O
for	O
all	O
the	O
compounds,	O
with	O
the	O
exception	O
of	O
AGM	O
(28.6%)	O
and	O
N1,N12-DiAcSPM	B

Excitingly	O
though,	O
we	O
have	O
observed	O
that	O
Polyamine	B
metabolism	O
is	O
differentially	O
affected	O
in	O
stable	O
MCI	O
subjects	O
and	O
AD	O
converting	O
subjects	O
which	O
provides	O
a	O
new	O
insight.	O

Sunitinib	B
is	O
an	O
oral,	O
smallmolecule,	O
multi-targeted	O
inhibitor	O
of	O
receptor	O
tyrosine	B
kinases	O
(e.g.,	O
platelet-derived	O
growth	O
factor	O
receptors	O
(PDGFR)	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
receptors	O
(VEGFR)),	O
some	O
of	O
which	O
are	O
implicated	O
in	O
tumour	O
growth,	O
pathologic	O
angiogenesis,	O
and	O
metastatic	O
progression	O
of	O
cancer.	O

Higher	O
ornithine	B
and	O
citrulline	B
levels	O
were	O
also	O
associated	O
with	O
higher	O
prevalence	O
of	O
CAD.	O

Overall,	O
parent	O
BRB	O
anthocyanins	B
showed	O
the	O
greatest	O
decrease	O
in	O
Rinse	O
III	O
over	O
time.	O

Since	O
choline	B
is	O
involved	O
in	O
the	O
synthesis	O
of	O
cellular	O
membranes,	O
a	O
decrease	O
in	O
choline	B
level	O
may	O
be	O
attributed	O
to	O
cell	O
proliferation.	O

In	O
addition	O
to	O
higher	O
levels	O
of	O
glutamate	B
among	O
HTK	O
users,	O
we	O
also	O
observed	O
an	O
almost	O
15-fold	O
increase	O
in	O
glutamine	B
compared	O
with	O
that	O
among	O
non-HTK	O
users.	O

Finally,	O
tyrosine	B
displayed	O
significant	O
correlations	O
to	O
TMS,	O
SI,	O
CVF	O
and	O
SDMT,	O
while	O
lumichrome	O
only	O
displayed	O
a	O
significant	O
correlation	O
to	O
the	O
five	O
year	O
risk	O
of	O
onset	O
in	O
premanifest	O
HD	O
subjects.	O

The	O
two	O
minor	O
products	O
probably	O
resulted	O
from	O
cis	O
-	O
ring	O
opening	O
of	O
the	O
syn	O
-	O
and	O
anti	B
-9,10-diol-7,8-epoxides,	I
but	O
this	O
was	O
not	O
pursued.	O

The	O
chromatographic	O
separation	O
was	O
performed	O
in	O
gradient	O
elution	O
with	O
ultrapure	O
water,	O
and	O
10	O
mM	O
ammonium	B
acetate	I
(A)	O
and	O
acetonitrile	B
(B)	O
as	O
the	O
mobile	O
phases,	O
at	O
a	O
flow	O
rate	O
of	O
0.5	O
mL/min.	O

We	O
would	O
suggest	O
that	O
the	O
drop	O
in	O
the	O
lactate	B
plasma	O
levels	O
observed	O
in	O
EBC,	O
associated	O
with	O
the	O
modifications	O
of	O
pyruvate	B
and	O
alanine,	B
is	O
a	O
clue	O
of	O
the	O
activation	O
of	O
the	O
lactate	B
cycle	O
(Cori	O
cycle)	O
and	O
liver	O
neo-glycogenesis.	O

This	O
is	O
supported	O
by	O
experimental	O
observations	O
in	O
animals	O
and	O
humans;	O
supplementation	O
of	O
lArg	O
in	O
rabbits	O
can	O
restore	O
vascular	O
relaxation	O
and	O
endothelial	O
function,	O
whereas	O
in	O
humans	O
infusion	O
of	O
ADMA	B
results	O
in	O
increased	O
systemic	O
vascular	O
resistance	O
(SVR)	O
and	O
mean	O
arterial	O
blood	O
pressure	O
(MAP)	O

Iida	O
et	O
al.	O
reported	O
that	O
trichokindins	O
induced	O
Ca_2+	O
-dependent	O
catecholamine	B
secretion	O
from	O
bovine	O
adrenal	O
medullary	O
chromaffin	B
cells	O
at	O
a	O
concentration	O
of	O
10	O
μM.	O
To	O
our	O
knowledge,	O
other	O
activities	O
of	O
trichokindins	O
have	O
not	O
been	O
reported.	O

Differences	O
between	O
groups	O
in	O
urinary	O
betaine	B
concentration	O
at	O
V3	O
could	O
also	O
be	O
due	O
to	O
uncontrolled	O
variation	O
in	O
the	O
CG.	O

The	O
concentrations	O
of	O
succinic	B
acid,	I
ascorbic	B
acid,	I
and	O
carnitine	B
were	O
consistent	O
across	O
the	O
9	O
plates	O
within	O
acceptable	O
ranges.	O

Alanine	B
transfer	O
its	O
amino	B
group	O
by	O
the	O
action	O
of	O
alanine	O
aminotransferase	O
to	O
α-ketoglutarate,	B
forming	O
pyruvate	B
and	O
glutamate,	B
pyruvate	B
regenerated	O
forms	O
glucose	B
through	O
gluconeogenesis.	O

It	O
increases	O
fasting	O
glucose	B
concentrations	O
and	O
HOMA-IR.	O

SPCSO	O
is	O
the	O
major	O
flavor	O
precursor	O
in	O
Allium	O
cepa	O
and	O
precursor	O
to	O
the	O
main	O
lachrymatory	O
factor	O
(Z	B
)-propanethial-sulfoxide.	I

Increased	O
levels	O
of	O
arginine	B
and	O
C16-carnitine	B
were	O
observed	O
in	O
the	O
serum	O
of	O
patients	O
with	O
lung	O
cancer	O
compared	O
with	O
the	O
controls	O
in	O
the	O
present	O
study.	O

The	O
ion	O
at	O
m/z	O
104	O
in	O
the	O
low	O
mass	O
region	O
corresponds	O
to	O
the	O
choline	B
group.	O

In	O
β-glucuronidase	O
treated	O
patient	O
samples,	O
anastrozole	B
and	O
hydroxyanastrozole	B
concentrations	O
in	O
plasma	O
were	O
47.1	O
±	O
17.1	O
ng	O
ml_−1	O
(range	O
17.0–90.9,	O
5-fold)	O
and	O
0.62	O
±	O
0.27	O
ng	O
ml_−1	O
(range	O
0.22–1.5,	O
7-fold),	O
respectively.	O

In	O
addition,	O
the	O
roles	O
of	O
other	O
metabolites	O
identified	O
in	O
this	O
research,	O
for	O
example,	O
benzoic	B
acid,	I
l-aspartyl-l-phenylalanine,	B
pipecolic	B
acid,	I
pyroglutamic	B
acid,	I
N	B
-phenylacetamide,	I
phenylpyruvate,	B
and	O
aminobutyric	B
acids,	I
which	O
were	O
all	O
increased	O
as	O
the	O
result	O
of	O
BSP	O
consumption	O
are	O
not	O
understood	O
at	O
this	O
time	O
and,	O
thus,	O
requires	O
further	O
studies	O
to	O
elucidate	O
the	O
underlying	O
mechanism.	O

In	O
contrast,	O
the	O
levels	O
of	O
tryptophan	B
and	O
methionine	B
were	O
reduced	O
in	O
these	O
patients.	O

Ascorbic	B
acid	I
is	O
a	O
component	O
of	O
several	O
medications,	O
for	O
example,	O
mixtures	O
with	O
paracetamol	B
used	O
to	O
treat	O
fever	O
and	O
pain,	O
the	O
metabolites	O
of	O
which	O
detected	O
by	O
DI-nESI-HRMS	O
were	O
higher	O
in	O
urine	O
samples	O
from	O
the	O
USA	O
population.	O

The	O
mass	O
spectrometer	O
was	O
operating	O
in	O
the	O
positive	O
ion	O
mode	O
and	O
configured	O
in	O
multiple	O
reaction	O
monitoring	O
(MRM)	O
mode	O
for	O
quantification	O
of	O
abiraterone	B
and	O
its	O
internal	O
standard	O
(m/z	O
350	O
→	O
156	O
and	O
354	O
→	O
160).	O

The	O
methanol	B
contained	O
four	O
recovery	O
standards	O
(DL-2-fluorophenylglycine,	O
tridecanoic	B
acid,	I
d6-cholesterol	B
and	O
4-chlorophenylalanine)	B
to	O
allow	O
confirmation	O
of	O
extraction	O
efficiency.	O

Methyl	B
tert	I
-butyl	I
ether	I
was	O
purchased	O
from	O
J.T.	O
Baker	O
(Center	O
Valley,	O
Pennsylvania);	O
isopropanol	B
and	O
water	O
were	O
from	O
Burdick	O
and	O
Jackson	O
(Morristown,	O
New	O
Jersey);	O
and	O
ammonium	B
acetate	I
was	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
Missouri).	O

Linolenic	B
acid	I
and	O
linoleic	B
acid,	I
both	O
belonging	O
to	O
n-6	O
polyunsaturated	O
FAs,	O
are	O
also	O
increased	O
in	O
patients	O
with	O
triple-negative	O
breast	O
cancer	O
in	O
our	O
study.	O

In	O
the	O
schizophrenia	O
cohort,	O
significant	O
differences	O
were	O
apparent	O
in	O
several	O
saturated	O
FA,	B
such	O
as	O
16:0	O
(palmitic	O
acid),	O
14:0	O
(myristic	O
acid),	O
24:0	O
(lignoceric	O
acid),	O
and	O
the	O
unsaturated	O
essential	O
FA	B
18:2	I
(linoleic	O
acid).	O

Given	O
that	O
subjects	O
with	O
HNF1A-MODY	O
are	O
known	O
to	O
have	O
a	O
low	O
renal	O
threshold	O
for	O
glucose,	B
we	O
calculated	O
both	O
urinary	O
glucose/creatinine	B
(UG/Cr)	O
ratio	O
and	O
plasma	O
glucose	B
to	O
urinary	O
glucose/creatinine	B
ratio	O
PG/(UG/Cr).	O

Our	O
study	O
sample	O
set	O
had	O
the	O
significant	O
differences	O
in	O
the	O
plasma	O
levels	O
of	O
total	O
cholesterol,	B
triglyceride,	B
glucose,	B
total	O
bilirubin	B
and	O
AST	O
between	O
the	O
colorectal	O
cancer	O
patients	O
and	O
healthy	O
volunteers,	O
so	O
it	O
is	O
impossible	O
to	O
completely	O
deny	O
the	O
involvement	O
of	O
these	O
factors’	O
alterations	O
in	O
the	O
establishment	O
of	O
our	O
model	O
at	O
this	O
time.	O

In	O
fact,	O
arsenic	O
bound	O
to	O
high	O
molecular	O
weight	O
proteins	O
(MW	O
>	O
10-kDa)	O
has	O
been	O
detected	O
in	O
livers	O
and	O
kidneys	O
in	O
rats	O
after	O
an	O
intravenous	O
injection	O
of	O
arsenite.	B

All	O
members	O
were	O
negatively	O
correlated	O
to	O
HAM-D_17	O
changes,	O
with	O
the	O
BCAA	O
valine	B
and	O
the	O
known	O
oxidative	O
stress	O
biomarker	O
methionine	B
sulfoxide	I
perturbations	O
showing	O
the	O
strongest	O
correlations	O
with	O
HAM-D_17	O
changes	O
(R	O
_2	O
<	O
–0.40,	O
p	O
<	O
0.05).	O

In	O
this	O
study	O
there	O
were	O
no	O
strong	O
correlations	O
between	O
pretreatment	O
bile	O
acid	O
metabolites	O
and	O
HDL-C	O
response	O
to	O
simvastatin	B
(data	O
not	O
shown),	O
which	O
further	O
supports	O
the	O
specificity	O
of	O
the	O
relationship	O
between	O
the	O
concentration	O
of	O
the	O
bile	O
acid	O
metabolites	O
and	O
LDL-C	O
response.	O

In	O
an	O
earlier	O
study	O
by	O
Williams	O
et al.,	O
breast	O
cancer	O
cells	O
were	O
found	O
to	O
contain	O
relatively	O
increased	O
concentrations	O
of	O
PC	B
(16:0/18:1)	I
compared	O
to	O
healthy	O
counterparts	O
(Williams	O
et al.,	O
1993	O
Apr).	O

Biofactors	O
35,	O
239–248);	O
thus,	O
cholesterol	B
metabolites	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
etiology	O
of	O
Alzheimer	O
disease.	O

Elevated	O
alanine	B
but	O
low	O
N-acetyl-aspartate	B
concentrations	O
were	O
reported	O
in	O
PA,	O
nonetheless,	O
a	O
similar	O
pattern	O
was	O
apparent	O
in	O
meningioma	O
and	O
gliomas	O
(,	O
).	O

A	O
previous	O
study	O
has	O
shown	O
a	O
decrease	O
in	O
resting	O
muscular	O
adenine	B
nucleotide	O
levels	O
after	O
one	O
week	O
of	O
high-intensity	O
intermittent	O
training.	O

In	O
the	O
current	O
study,	O
folate	B
status	O
was	O
considered	O
adequate	O
in	O
both	O
groups,	O
although	O
lower	O
concentrations	O
were	O
observed	O
among	O
subjects	O
in	O
the	O
high–cystathionine	B
concentration	O
group.	O

Taurine	B
is	O
related	O
to	O
bile	O
acid	O
conjugation	O
and	O
also	O
aids	O
lipid	O
absorption.	O

The	O
third	O
aliquot	O
was	O
prepared	O
with	O
treatment-3	O
(T3),	O
in	O
which	O
150	O
uL	O
buffer	O
containing	O
50	O
U	O
of	O
SUL1	O
and	O
500	O
U	O
of	O
GLU1	O
were	O
added	O
to	O
hydrolyze	O
the	O
sulfates	B
and	O
glucuronides.	O

Also,	O
lysophosphatidylcholine	B
(22:5)	I
at	O
m/z	O
569.3440n	O
(ESI+,	O
RT	O
=	O
1.01	O
min)	O
showed	O
a	O
slight	O
decrease	O
in	O
T2D	O
and	O
prediabetes	O
(P	O
=	O
0.027,	O
FDR	O
=	O
0.310),	O
while	O
no	O
significant	O
associations	O
with	O
HOMA-IR	O
or	O
other	O
diabetes-related	O
indices	O
were	O
observed.	O

Tubes	O
were	O
vortexed	O
10	O
sec	O
prior	O
to	O
addition	O
of	O
(i)	O
2.5	O
mL	O
MTBE	B
and	O
(ii)	O
deionized	O
water	O
(625	O
μL),	O
followed	O
each	O
time	O
by	O
mixing	O
with	O
a	O
multi-pulse	O
vortexer	O
(Glas-Col,	O
Terre-Haute,	O
IN,	O
USA)	O
for	O
5	O
and	O
3	O
min,	O
respectively.	O

With	O
regard	O
to	O
past	O
and	O
present	O
isoflavone	B
intakes,	O
the	O
study	O
population	O
consisted	O
of	O
mostly	O
non-consumers	O
(80%),	O
with	O
only	O
2	O
subjects	O
consuming	O
soy-derived	O
products	O
on	O
a	O
daily-to-weekly	O
basis	O
(soymilk:	O
1;	O
control:	O
1).	O

Thus,	O
[M–18+H]_+	O
was	O
used	O
as	O
a	O
precursor	O
ion	O
for	O
all	O
vitamin	B
D	I
metabolites	O
hydroxylated	O
at	O
position	O
25.	O

We	O
also	O
confirmed	O
different	O
metabolic	O
signatures	O
resulting	O
from	O
acute	O
inflammatory	O
responses	O
and	O
upregulated	O
sphingolipid	B
and	O
glycerophospholipid	B
in	O
patients	O
with	O
MI.	O

Similarly,	O
three	O
NMR	O
signals	O
specific	O
for	O
triacylglycerols	B
correlated	O
strongly	O
with	O
one	O
another,	O
as	O
well	O
as	O
with	O
serum	O
concentration	O
of	O
triacylglycerols	B
determined	O
routinely	O
at	O
our	O
laboratory	O
(Fig. ).	O

Upregulated	O
levels	O
of	O
hypoxanthine	B
and	O
xanthine	B
could	O
be	O
connected	O
to	O
increased	O
catabolism	O
of	O
nucleotides	O
in,	O
for	O
example,	O
hypoxia	O
conditions.	O

With	O
further	O
study	O
of	O
linkage	O
between	O
metabolic	O
pattern	O
and	O
other	O
environmental	O
risk	O
factors,	O
such	O
as	O
diet	O
pattern,	O
oxidative	O
stress,	O
etc.,	O
it	O
may	O
prompt	B
new	O
couples	O
how	O
to	O
increase	O
chances	O
to	O
have	O
a	O
baby.	O

A	O
set	O
of	O
recovery	O
standards,	O
tridecanoic	B
acid,	I
chloro-phenylalanine,	B
D6-cholesterol,	B
and	O
fluoro-phenylglycine	B
was	O
added	O
prior	O
to	O
the	O
first	O
step	O
in	O
the	O
extraction	O
process	O
for	O
quality	O
control	O
purposes,	O
with	O
final	O
extraction	O
standard	O
concentrations	O
ranging	O
from	O
2.5	O
to	O
25 μg/mL.	O
Sample	O
preparation	O
was	O
conducted	O
using	O
a	O
methanol	B
extraction	O
to	O
remove	O
the	O
protein	O
fraction	O
while	O
allowing	O
the	O
maximum	O
recovery	O
of	O
small	O
molecules.	O

However,	O
this	O
finding	O
needs	O
to	O
be	O
interpreted	O
with	O
care	O
because	O
choline	B
is	O
a	O
nutrient	O
present	O
in	O
most	O
foods.	O

Vitamin	O
B-12	O
deficiency	O
is	O
associated	O
with	O
the	O
redistribution	O
of	O
carnitine	B
and	O
a	O
consequent	O
higher	O
loss	O
due	O
to	O
the	O
formation	O
of	O
propionyl	O
and	O
other	O
carnitine	B
derivatives.	O

The	O
2-h	O
time	O
point	O
has	O
clinical	O
significance,	O
and	O
can	O
aid	O
in	O
the	O
diagnosis	O
of	O
impaired	O
glucose	B
tolerance	O
and	O
diabetes.	O

We	O
have	O
demonestrated	O
that THC	O
levels	O
were	O
maintained	O
after	O
carnosine	B
supplementation	O
compared	O
to	O
placebo,	O
which	O
showed	O
a	O
relative increase	O
in	O
the	O
carnosine	B
group.	O

The	O
top	O
three	O
compounds	O
contributing	O
to	O
group	O
separation	O
when	O
objective	O
hardship	O
was	O
included	O
(Fig. )	O
were	O
malonate,	B
2-hydroxy-3-methylvalerate,	B
and	O
adenine,	B
with	O
VIP	O
scores	O
of	O
1.71,	O
1.18,	O
and	O
1.04,	O
respectively	O
(Table ).	O

All	O
ten	O
statin-naïve,	O
hypercholesterolaemic	B
subjects	O
were	O
prescribed	O
simvastatin	B
intervention	O
(40 mg/day),	O
whereas	O
normolipidaemic	O
subjects	O
maintained	O
habitual	O
diets	O
and	O
lifestyles	O
without	O
intervention.	O

By	O
using	O
Principal	O
Component	O
Analysis	O
(PCA),	O
in	O
combination	O
with	O
uni-	O
and	O
multivariable	O
linear	O
regression	O
analyses,	O
total	O
plasma	O
apolipoprotein-A1	O
and	O
the	O
contents	O
of	O
cholesterol,	B
free	O
cholesterol,	B
apolipoprotein-A1,	O
apolipoprotein-A2,	O
and	O
phospholipids	B
of	O
HDL,	O
HDL-1,	O
HDL-2	O
and	O
HDL-3,	O
were	O
associated	O
with	O
tumor	O
PgR	O
expression	O
(Table ).	O

The	O
simple	O
metabolic	O
pathway	O
for	O
metabolism	O
of	O
[1,2-_13	B
C]acetate	I
in	O
a	O
brain	O
tumor	O
is	O
its	O
conversion	O
to	O
acetyl-CoA	B
and	O
oxidation	O
to	O
CO_2	O
in	O
the	O
citric	B
acid	I
cycle,	O
and	O
thus	O
providing	O
no	O
direct	O
mechanism	O
for	O
_13	O
C	O
entry	O
into	O
the	O
lactate	B
pool	O
of	O
the	O
tumor.	O

Bisphenol	B
A	O
(211.11,	O
[M + H-H_2	O
O]_+	O
),	O
retinol	B
(287.23,	O
[M + H]_+	O
)	O
and	O
L-proline	B
(116.07,	O
[M + H]_+	O
)	O
were	O
among	O
the	O
significant	O
compounds	O
found	O
to	O
have	O
contributed	O
in	O
the	O
discrimination	O
between	O
these	O
groups,	O
suggesting	O
that	O
these	O
compounds	O
might	O
be	O
related	O
in	O
the	O
development	O
of	O
lung	O
cancer.	O

A	O
simple	O
and	O
fast	O
test	O
to	O
confirm	O
the	O
fullness	O
of	O
the	O
active	O
detection	O
cell	O
is	O
done	O
by	O
acquiring	O
a	O
flow	O
cell	O
profile	O
(Figure	O
A)	O
that	O
is	O
routinely	O
implemented	O
for	O
every	O
injected	O
sample	O
by	O
FIA-NMR.	O
_1	O
H	O
NMR	O
metabolomics	O
profiles	O
of	O
urine,	O
acquired	O
as	O
a	O
routine	O
analysis	O
by	O
FIA-NMR:	O
(A)	O
flow	O
cell	O
profile;	O
(B)	O
_1	O
H	O
NMR	O
NOESY-1D;	O
(C)	O
_1	O
H	O
J	O
-Res-2D;	O
citric	B
acid	I
signal	O
in	O
_1	O
H	O
NMR	O
NOESY-1D	O
and	O

Stability	O
of	O
buprenorphine,	B
norbuprenorphine,	B
and	O
conjugated	O
metabolites	O
in	O
urine	O
LCMSMS;	O
percentage	O
difference	O
from	O
fresh	O
controls	O
A	O
chromatogram	O
of	O
a	O
patient	O
specimen	O
containing	O
all	O
four	O
analytes	O
can	O
be	O
seen	O
in	O
.	O

Aspartate	B
is	O
a	O
metabolite	O
of	O
the	O
urea	B
cycle,	O
involved	O
in	O
gluconeogenesis,	O
being	O
derived	O
from	O
asparaginase.	O

Go	O
to:	O
It	O
has	O
been	O
suggested	O
that	O
the	O
concentrations	O
of	O
tamoxifen	B
and	O
its	O
demethylated	O
metabolites	O
increase	O
with	O
age.	O

We	O
suggest	O
that	O
this	O
may	O
also	O
be	O
responsible	O
for	O
the	O
reduced	O
salivary	O
Vitamin	B
E,	I
which	O
was	O
reversed	O
on	O
ART.	O

In	O
our	O
lipidomics	O
analysis,	O
TG	B
56:4	I
was	O
the	O
second	O
most	O
significantly	O
increased	O
TG	B
species	O
with	O
a	O
p	O
value	O
of	O
0.0006.	O

Columns	O
indicate	O
Map	O
of	O
the	O
Human	O
Methylome	B
identifiers,	O
Ensemble	O
id,	O
Gene	O
Symbol,	O
log	O
fold-change	O
(logFC),	O
t-statistic,	O
P-value,	O
and	O
False	O
Discovery	O
Rate	O
(FDR).	O

The	O
extracellular	O
aspartate	B
concentration	O
in	O
S9	O
cells	O
was	O
only	O
marginally	O
affected	O
over	O
time	O
under	O
control	O
conditions	O
or	O
under	O
the	O
influence	O
of	O
rHla,	O
respectively.	O

These	O
are	O
palmitic	B
acid,	I
stearic	B
acid,	I
oleic	B
acid,	I
benzoic	B
acid,	I
butanoic	B
acid,	I
cholesterol,	B
glycine,	B
3-heptanone,	B
4-heptanone,	B
hexanal,	B
1-tetradecanol	B
and	O
naphthalene	B
.	O

Since	O
the	O
other	O
glucuronide	B
metabolites	O
were	O
not	O
commercially	O
available,	O
it	O
was	O
not	O
possible	O
to	O
evaluate	O
hydrolysis	O
efficiency	O
for	O
the	O
six	O
remaining	O
compounds.	O

In	O
addition,	O
Pre-DM	O
patients	O
with	O
AO	O
had	O
significantly	O
higher	O
levels	O
of	O
SM36:1,	B
SM38:1	B
and	O
SM40:1	B
than	O
normal	O
subjects	O
with	O
AO.	O

Choline	B
is	O
also	O
important	O
for	O
pancreatic	O
cell	O
function,	O
as	O
pancreatic	O
acinar	O
cell	O
integrity	O
and	O
the	O
generation	O
of	O
digestive	O
enzymes	O
and	O
insulin	O
secretion	O
are	O
dependent	O
upon	O
high	O
choline	B
phospholipid	I
metabolism.	O

Fasting	O
glucose	B
levels	O
were	O
measured	O
by	O
the	O
glucose-oxidase	O
method	O
with	O
a	O
Beckman	O
Glucose	B
Analyzer	O
(Beckman	O
Instruments,	O
Irvine,	O
CA,	O
USA).	O

(A)	O
Significantly	O
increased	O
levels	O
of	O
3-[3-(sulfooxy)	B
phenyl]	I
propanoic	I
acid,	I
N-acetylproline,	B
3-hydroxyphenylacetate,	B
5-hydroxymethyl-2-furoic	B
acid	I
and	O
anthranilate	B
in	O
post-BRB	O
urine.	O

A.	O
Resorcinol-stained	O
HPTLC	O
plate	O
of	O
GGs	O
extracted	O
from	O
retina,	O
retinal	B
pigment	O
epithelium	O
(RPE)/choroid,	O
ciliary	O
body,	O
optic	O
nerve,	O
brain	O
and	O
plasma.	O

Abbreviations:	O
THS,	O
tetrahydro-11-deoxycortisol;	B
5-PD,	O
5-pregnenediol;	O
PD,	O
pregnanediol;	B
PT,	O
pregnanetriol;	B
5-PT,	O
5-pregnenetriol;	O
THDOC,	O
tetrahydrodeoxycorticosterone;	B
Etio,	O
etiocholanolone;	B
5α-THA,	B
5α-tetrahydro-11-dehydrocorticosterone.	B

The	O
biomarker	O
candidate	O
contains	O
galactose	B
as	O
a	O
saccharide	B
in	O
addition	O
to	O
glucose.	B

The	O
urinary	O
biomarkers	O
of	O
nicotine	B
exposure	O
(cotinine	O
and	O
trans	B
-3′-hydroxycoti-nine)	I
and	O
the	O
personal	O
exposure	O
concentrations	O
of	O
selected	O
VOC	O
(3-EP	O
and	O
BUT)	O
and	O
some	O
non-parent	O
PAH	O
compounds	O
were	O
higher	O
in	O
the	O
ETS-exposed	O
sub-sample	O
compared	O
with	O
the	O
non-ETS	O
at	O
the	O
p	O
<0.05	O
level.	O

Control	O
(n	O
 = 73),	O
OVC	O
(n	O
 = 13),	O
and	O
GC	O
(n	O
 = 9)	O
samples	O
were	O
further	O
analyzed	O
using	O
Triple-TOF	O
MS	O
for	O
semi-quantitation	O
of	O
the	O
three	O
identified	O
LMIs	O
[a	O
_D,l	B
-glutamine,	I
b	O
LPC	O
16:0,	O
and	O
c	O
fibrinogen	O
alpha	O
chain	O
fragment].	O

A	O
vs	O
I	O
-	B
(+)/(−)	I
means	O
increased/decreased	O
abundance	O
in	O
CLL	O
patients	O
in	O
aggressive	O
state	O
in	O
comparison	O
to	O
CLL	O
patients	O
in	O
indolent	O
of	O
the	O
disease.	O

ALA	O
in	O
biological	O
systems	O
provides	O
important	O
insights	O
into	O
the	O
effects	O
of	O
dietary	O
manipulation	O
on	O
the	O
production	O
of	O
downstream	O
ω-3/ω-6	B
products	I
that	O
likely	O
can	O
serve	O
as	O
novel	O
biomarkers	O
and	O
therapeutic	O
targets	O
for	O
lipid-related	O
metabolic	O
diseases.	O

We	O
identified	O
metabolic	O
rewiring	O
networks,	O
including	O
the	O
suppression	O
of	O
the	O
oxidative	O
pentose	B
pathway	O
and	O
found	O
that	O
the	O
normal	O
tricarboxylic	B
acid	I
(TCA)	O
cycle	O
were	O
decoupled	O
from	O
increases	O
in	O
glycolysis	O
and	O
glutamine	B
reductive	O
carboxylation.	O

The	O
normal	O
range	O
of	O
serum	O
creatinine	B
is	O
0.5–1.6 mg/dl	O

A	O
metabolite	O
profile	O
study	O
of	O
subjects	O
at	O
risk	O
for	O
CVD	O
showed	O
changes	O
in	O
amino	O
acid	O
patterns	O
and	O
acylcarnitine	B
patterns	O
associated	O
with	O
CVD	O
development.	O

As	O
noted	O
in	O
the	O
advanced	O
atherosclerosis	O
cohort	O
as	O
a	O
whole,	O
the	O
carotid	O
stenosis	O
subgroup	O
also	O
had	O
significantly	O
lower	O
indole,	B
trp,	O
kyn,	O
I3P,	O
and	O
I3A,	O
and	O
higher	O
plasma	O
levels	O
of	O
3-hydroxyanthranilic	B
acid.	I

To	O
assist	O
in	O
the	O
chemical	O
characterization,	O
the	O
oxidation	O
product	O
was	O
reacted	O
with	O
methoxyamine	B
prior	O
to	O
its	O
isolation.	O

Sterol	O
analysis	O
included	O
the	O
free	O
and	O
esterified	O
plant	O
sterols	B
brassicasterol	I
(BR),	O
campesterol	B
(CA),	O
β-sitosterol	B
(SI)	O
and	O
stigmasterol	B
(ST),	O
the	O
cholesterol	B
biosynthesis	O
precursors	O
lanosterol	B
(LA)	O
as	O
well	O
as	O
the	O
sum	O
parameter	O
including	O
desmosterol,	B
zymosterol,	B
7-dehydrocholesterol	B
(DEZY7DHC),	O
and	O
cholesterol	B
itself	O
(CH).	O

lung	O
cancer,	O
liquid	O
chromatography-tandem	O
mass	O
spectrometry,	O
amino	O
acids,	O
acylcarnitines,	B
metabolomics	O

However,	O
the	O
percentage	O
of	O
subjects	O
(77.8%)	O
receiving	O
heparin	B
at	O
time	O
of	O
enrollment	O
(T0)	O
was	O
identical	O
between	O
thrombotic	O
and	O
non-thrombotic	O
MI	O
subjects,	O
and	O
the	O
pattern	O
of	O
change	O
between	O
enrollment	O
and	O
follow-up	O
in	O
heparin	B
was	O
also	O
the	O
same	O
for	O
thrombotic	O
and	O
non-thrombotic	O
MI	O
subjects	O
and	O
therefore	O
should	O
not	O
explain	O
metabolic	O
differences	O
observed	O
between	O
these	O
two	O
groups.	O

In	O
the	O
present	O
study	O
we	O
demonstrated	O
that	O
treatment	O
of	O
HepG2	O
cells	O
with	O
“safe”	O
dose	O
of	O
BPA:	O
(1)	O
increases	O
of	O
proliferation	O
rate	O
only	O
in	O
presence	O
of	O
high	O
glucose	B
concentration;	O
(2)	O
regulate	O
the	O
ERK/MAPK	O
and	O
the	O
PI3K/AKT	O
pathways;	O
(3)	O
induces	O
an	O
increase	O
of	O
oxidative	O
stress	O
and	O
4)	O
induces	O
an	O
increase	O
of	O
steroid	O
hormones	O
oxidation.	O

In	O
addition,	O
both	O
studies	O
showed	O
the	O
level	O
of	O
homocysteine	B
elevated	O
in	O
the	O
IBS	O
group.	O

The	O
carnitine	B
supply	O
from	O
cow’s	O
milk-based	O
infant	O
formula	O
is	O
comparable	O
or	O
slightly	O
higher	O
compared	O
to	O
that	O
of	O
human	O
milk.	O

Initial	O
sample	O
clustering	O
is	O
observed	O
due	O
to	O
the	O
difference	O
in	O
buffer	O
solutions	O
and	O
resulting	O
sample	O
glucose	B
content	O
(principal	O
component	O
1)	O
and	O
intersample	O
differences	O
in	O
metabolite	O
(citrate,	O
choline,	B
lipids/lipoproteins	O
and	O
phosphocholine)	B
variation	O
(principal	O
component	O
2).	O

This	O
difference	O
in	O
fasting	O
α	B
-hydroxybutyrate	I
concentrations	O
remained	O
statistically	O
significant	O
after	O
correction	O
for	O
age,	O
sex,	O
ethnicity,	O
and	O
BMI	O

Although	O
we	O
cannot	O
directly	O
draw	O
conclusions	O
on	O
endogenous	O
production	O
and	O
disposal,	O
these	O
processes	O
obviously	O
need	O
to	O
be	O
adjusted	O
in	O
vivo	O
in	O
order	O
to	O
maintain	O
the	O
observed	O
unaffected	O
plasma	O
levels	O
of	O
lactate	B
and	O
alanine.	B

An	O
especially	O
remarkable	O
upregulation	O
of	O
DCAs	O
was	O
seen	O
in	O
the	O
comparison	O
of	O
cirrhosis	O
controls	O
vs.	O
NHC,	O
where	O
non-anedioate	O
(azelate),	O
undecanedioate	B
and	O
decanedioate	B
(sebacate)	O
showed	O
a	O
strongly	O
significant	O
respective	O
overexpression	O
of	O
54-,	O
36-	O
and	O
26-fold	O
in	O
cirrhosis	O
vs.	O
NHC.	O

For	O
the	O
separation	O
of	O
analytes	O
in	O
human	O
urine,	O
urine	O
samples	O
were	O
obtained	O
from	O
healthy	O
individuals	O
and	O
pooled	O
to	O
form	O
a	O
reference	O
urine	O
sample;	O
this	O
was	O
spiked	O
with	O
caffeine,	B
uridine	B
and	O
cytosine	B
as	O
aqueous	O
stock	O
solutions.	O

Therefore,	O
the	O
CSF	O
lactic	B
acid	I
level	O
appears	O
to	O
reflect	O
the	O
metabolic	O
condition	O
of	O
the	O
glioma	O
cells.	O

In	O
the	O
following	O
experiments,	O
different	O
conditions	O
for	O
the	O
post-extraction	O
derivatization	O
reaction	O
of	O
vitamin	B
D	I
compounds	O
were	O
evaluated.	O

Anastrozole	B
(0–200	O
µm)	O
was	O
incubated	O
for	O
30	O
min	O
at	O
37°C	O
with	O
HLMs	O
(0.5	O
mg	O
ml_−1	O
).	O

LASSO-LR	O
identified	O
three	O
discriminatory	O
metabolites:	O
2-hydroxyisobutyrate,	B
3-indoxylsulfate,	B
and	O
alanine,	B
which	O
produced	O
a	O
discriminatory	O
model	O
with	O
an	O
area	O
under	O
the	O
ROC	O
of	O
0.95.	O

Albeit	O
preliminary,	O
this	O
study	O
introduces	O
an	O
interesting	O
scenario	O
about	O
the	O
actual	O
role	O
of	O
TMAO	B
in	O
modulating	O
functions	O
of	O
the	O
central	O
nervous	O
system.	O

Betaine	B
levels	O
were	O
inversely	O
correlated	O
with	O
both	O
IL-6	O
(Rho	O
=	O
-0.21;	O
p	O
=	O
0.029)	O
and	O
fibrinogen	O
(Rho	O
-0.34;	O
p<0.0001).	O

OmniTrace	B
glacial	I
acetic	I
acid	I
and	O
ammonium	B
hydroxide	I
were	O
obtained	O
from	O
EMD	O
Chemicals.	O

Glutamine	B
metabolism	O
provides	O
intermediate	O
products	O
for	O
tricarboxylic	B
acid	I
cycle,	O
which	O
not	O
only	O
offers	O
material	O
for	O
biosynthesis	O
but	O
also	O
supplies	O
energy	O
for	O
cell	O
metabolism,	O
thereby	O
promoting	O
tumor	O
growth.	O

For	O
example,	O
the	O
concentration	O
of	O
glutamate	B
was	O
more	O
than	O
3X	O
higher	O
in	O
WB	O
than	O
in	O
serum	O
and	O
is	O
known	O
to	O
be	O
10X	O
higher	O
in	O
RBC	O
than	O
in	O
plasma.	O

FT-ICR	O
Rp	B
=	O
40,000,000).	O

The	O
conditions	O
of	O
synthesis	O
of	O
N	B
-acetoxy-PhIP	I
were	O
optimized	O
to	O
produce	O
this	O
reactive	O
intermediate	O
in	O
high	O
yield	O
with	O
minimal	O
side-reaction	O
products.	O

Although	O
a	O
chromatographic	O
peak	O
that	O
was	O
consistent	O
with	O
an	O
anastrozole	B
oxidative	O
metabolite	O
was	O
identified	O
using	O
the	O
UV	O
detection	O
method,	O
the	O
amount	O
of	O
metabolite	O
formed	O
was	O
too	O
low	O
to	O
perform	O
further	O
kinetic	O
characterization	O
or	O
to	O
conduct	O
structural	O
elucidation.	O

We	O
examined	O
the	O
serum	O
metabolite	O
profile	O
associated	O
with	O
serum	O
25-hydroxyvitamin	B
D	I
levels	O
in	O
metabolites	O
obtained	O
from	O
both	O
a	O
nuclear	O
magnetic	O
resonance	O
spectroscopy	O
(NMR)-	O
and	O
a	O
mass	O
spectrometry	O
(MS)-based	O
platform.	O

Plasma	O
betaine	B
was	O
correlated	O
inversely	O
with	O
triglycerides	B
and	O
positively	O
with	O
HDL	B
cholesterol.	I

Hydroxyhexadecenoylcarnitine;	B
32.	O

(B)	O
Comparison	O
of	O
total	O
mol	O
fraction	O
of	O
phospholipid	B
and	O
sphingolipids	B
species	O
in	O
Human	O
(n = 10)	O
and	O
normal,	O
fed	O
Monkey	O
plasma	O
(n = 8).	O

Whether	O
these	O
relationships	O
were	O
independent	O
of	O
unconjugated	O
estradiol	B
was	O
not	O
explored	O
because	O
unconjugated	O
estradiol	B
was	O
only	O
weakly	O
associated	O
with	O
risk	O
(RR=1.06).	O

Aliquots	O
of	O
1	O
µL	O
were	O
injected	O
onto	O
a	O
HP-5	O
MS	O
fused	O
silica	B
column	O
(30	O
m	O
×	O
0.25	O
mm;	O
0.25	O
µm	O
film	O
thickness	O
of	O
the	O
5	O
%	O
phenyl	O
95	O
%	O
dimethylpolysiloxane	B
stationary	O
phase;	O
Agilent	O
J&W	O
Scientific)	O
in	O
splitless	O
mode.	O

Furthermore,	O
regeneration	O
is	O
also	O
connected	O
with	O
the	O
folate	B
cycle,	O
which	O
we	O
also	O
found	O
to	O
be	O
suppressed.	O

The	O
other	O
assessed	O
endocannabinoids	B
and	O
analogs,	O
2-arachidonoyl	B
glycerol	I
(2-AG),	O
and	O
palmitoylethanolamide	B
(PEA),	O
were	O
unchanged.	O

The	O
most	O
prominent	O
metabolites	O
in	O
the	O
_1	O
H	O
NMR	O
blood	O
serum	O
spectra	O
are	O
fat	O
(methylene-	O
and	O
methyl-moieties	B
from	O
the	O
lipoproteins),	O
amino	O
acids,	O
lactate	B
and	O
glucose.	B

Furthermore,	O
we	O
identified	O
the	O
presence	O
of	O
several	O
anthracycline	B
metabolizing	O
enzymes	O
in	O
adipocytes,	O
but	O
have	O
not	O
identified	O
the	O
individual	O
contribution	O
that	O
each	O
enzyme	O
has	O
on	O
DNR	O
metabolism.	O

The	O
levels	O
of	O
metabolites	O
involved	O
in	O
the	O
propanediol	O
pathway	O
via	O
dihydroxyacetone	B
phosphate	I
were	O
not	O
changed.	O

High	O
physical	O
activity	O
[42+	O
metabolic	O
equivalent-hours	O
(MET-hours)/week	O
vs.	O
<3	O
MET-hours/week]	O
was	O
associated	O
with	O
an	O
11%	O
lower	O
level	O
of	O
urinary	O
parent	O
estrogens	O
(p-trend=.16)	O
and	O
a	O
15%	O
lower	O
level	O
of	O
urinary	O
estradiol	B
(p-trend=.03),	O
which	O
is	O
consistent	O
with	O
the	O
inverse	O
relationships	O
reported	O
by	O
cohort	O
studies	O
of	O
luteal	O
phase	O
circulating	O
parent	O
estrogens	O
and	O
physical	O
activity.	O

The	O
QC	O
stock	O
solution	O
was	O
diluted	O
with	O
ACN	O
to	O
yield	O
QC	O
concentration	O
levels	O
of	O
1000,	O
15000,	O
and	O
40000	O
ng/mL	O
enzalutamide	B
and	O
N-desmethylenzalutamide,	B
which	O
were	O
also	O
subsequently	O
diluted	O
ten-fold	O
with	O
the	O
albuman	O
solution/plasma	O
(90:10).	O

Glycerophospholipids,	B
lyso	O
phospholipids	B
and	O
diacylglycerol	B
(DAG)	O
were	O
annotated	O
as	O
<lipid	O
abbreviation>	O
<total	O
fatty	O
acyl	O
chain	O
length>:<total	O
number	O
of	O
unsaturated	O
bonds>.	O

Lipidomics,	O
Microbiome,	O
Feces,	O
Triglyceride,	B
Diglyceride,	B
High-resolution	O
mass	O
spectrometry	O

Online	O
Table 1	O
shows	O
the	O
correlation	O
coefficients	O
of	O
lipids	O
(total	O
cholesterol,	B
LDL-C,	O
HDL-C,	O
and	O
TG),	O
apolipoproteins	O
A1	O
and	O
B,	O
creatinine,	B
and	O
albumin	O
as	O
measured	O
by	O
clinical	O
chemistry	O
and	O
NMR	O
spectroscopy.	O

Similarly,	O
the	O
excretion	O
of	O
the	O
urinary	O
metabolite	O
of	O
11OHA4,	B
11β	I
-OH-An,	I
was	O
significantly	O
increased	O
in	O
patients	O
with	O
PCOS	O
[595	O
(IQR,	O
347	O
to	O
861)	O
vs	O
353	O
(IQR,	O
171	O
to	O
487)	O
in	O
control	O
subjects;	O
P	O
<	O
0.001).	O

As	O
a	O
direct	O
link	O
between	O
plasma	O
pipecolate	B
levels	O
and	O
composition	O
of	O
the	O
gut	O
microbiota	O
has	O
not	O
been	O
available	O
up	O
to	O
now,	O
further	O
studies	O
are	O
needed	O
to	O
investigate	O
this	O
possible	O
line	O
of	O
explanation	O
in	O
more	O
detail.	O

In	O
the	O
whole	O
group,	O
betaine	B
(r	O
 = −0.144,	O
p	O
 = 0.12)	O
and	O
LCAT	O
activity	O
(r	O
 = 0.072,	O
p	O
 = 0.43)	O
were	O
unrelated	O
to	O
age,	O
but	O
PLTP	O
activity	O
tended	O
to	O
be	O
higher	O
with	O
advancing	O
age	O
(r	O
 = 0.164,	O
p	O
 = 0.073).	O

Mass	O
spectrometry	O
was	O
performed	O
on	O
a	O
Quadrupole-time-of-flight	O
mass	O
spectrometer	O
operating	O
in	O
either	O
negative	O
or	O
positive	O
electrospray	O
ionization	O
mode	O
with	O
a	O
capillary	O
voltage	O
of	O
3.2	O
KV	B
and	O
a	O
sampling	O
cone	O
voltage	O
of	O
35	O
V.	O

For	O
instance,	O
the	O
Relative	O
Intensity%	O
(Rel.	O
Int.%)	O
of	O
PE	B
39:4	I
(monoisotopic	O
molecular	O
mass:	O
781.5622	O
Da,	O
m/z	O
782.6)	O
was	O
less	O
than	O
2%	O
of	O
the	O
most	O
abundant	O
species	O
in	O
the	O
subclass	O
(PE	O
38:4,	O
m/z	O
768.6)	O
(Fig.	O

However,	O
in	O
contrast	O
to	O
the	O
lower	O
concentrations	O
of	O
amino	O
acids,	O
lactate	B
and	O
creatine	B
in	O
CSCC	O
compared	O
with	O
the	O
healthy	O
controls,	O
the	O
ratio	O
of	O
these	O
metabolites	O
was	O
reversely	O
correlated	O
between	O
CSCC	O
and	O
CIN	O
and	O
may	O
not	O
follow	O
the	O
pathological	O
order	O
from	O
normal	O
and	O
CIN	O
to	O
CSCC,	O
revealing	O
a	O
more	O
complex	O
mechanism	O
of	O
CIN	O
development	O
as	O
a	O
unique	O
disease	O
rather	O
than	O
a	O
precursor	O
of	O
the	O
cancer.	O

When	O
column	O
performance	O
was	O
compared	O
in	O
individual	O
co-solvents	O
(D)	O
it	O
became	O
apparent	O
that	O
the	O
overall	O
trends	O
observed	O
in	O
A	O
and	O
B	O
were	O
also	O
applicable	O
in	O
specific	O
cases:	O
the	O
Diol	B
column	O
had	O
the	O
lowest	O
median	O
peak	O
widths	O
in	O
the	O
presence	O
of	O
water	O
and	O
ammonium	B
formate	I
(12.6	O
and	O
11.3 s	O
respectively),	O
while	O
the	O
2-PIC	O
column	O
had	O
the	O
lowest	O
median	O
width	O
in	O
formic	B
acid	I
(13.7 s).	O

Plasma	O
samples	O
were	O
spiked	O
with	O
isotope-labeled	O
internal	O
standards	O
and	O
pretreated	O
using	O
protein	O
precipitation,	O
solid-phase	O
extraction	O
(SPE)	O
and	O
a	O
Diels–Alder	O
derivatization	O
step	O
with	O
4-phenyl-1,2,4-triazoline-3,5-dione.	B

Aspartame	B
is	O
a	O
commonly	O
used	O
intense	O
artificial	O
sweetener,	O
being	O
approximately	O
200	O
times	O
sweeter	O
than	O
sucrose.	B

We	O
set	O
out	O
to	O
investigate	O
the	O
metabolomic	O
profile	O
of	O
reactive	O
persulfides	B
and	O
polysulfides	B
in	O
the	O
aqueous	O
and	O
vitreous	O
humors.	O

Metabolites	O
found	O
to	O
be	O
most	O
strongly	O
correlated	O
with	O
change	O
in	O
depressive	O
symptoms	O
were	O
branched	O
chain	O
amino	O
acids,	O
acylcarnitines,	B
methionine	B
sulfoxide,	I
and	O
α-aminoadipic	B
acid	I
(negative	O
correlations	O
with	O
symptom	O
change)	O
as	O
well	O
as	O
several	O
lipids,	O
particularly	O
the	O
phosphatidlylcholines	B
(positive	O
correlation).	O

The	O
proportion	O
of	O
positive	O
HBV	O
desoxyribonucleic	B
acid	I
(HBV-DNA)	O
was	O
higher	O
in	O
CHB	O
group	O
than	O
that	O
in	O
either	O
the	O
HBV-associated	O
cirrhosis	O
or	O
HBV-associated	O
HCC	O
groups.	O

	O
Using	O
mass	O
spectrometry,	O
we	O
monitored	O
146	O
unique	O
glycerophospholipids,	B
with	O
acyl	O
chains	O
containing	O
a	O
total	O
of	O
30–42	O
carbons,	O
over	O
the	O
course	O
of	O
the	O
HCMV	O
replication	O
cycle.	O

Organic	O
acids,	O
comprised	O
particularly	O
of	O
amino	O
acids,	O
represented	O
the	O
largest	O
individual	O
group,	O
but	O
also	O
purine	B
metabolites	O
in	O
the	O
nucleotide	O
group,	O
as	O
well	O
as	O
fatty	O
acyl	B
carnitines	I
in	O
the	O
carnitine	B
group	O
were	O
common.	O

We	O
have	O
successfully	O
quantified	O
urinary	O
DIM	O
after	O
uptake	O
of	O
I3C	O
from	O
food,	O
and	O
demonstrated	O
that	O
differences	O
in	O
glucobrassicin	B
exposure	O
are	O
reflected	O
in	O
urinary	O
DIM	O
levels.	O

For	O
males	O
the	O
negative	O
relationship	O
of	O
testosterone	B
with	O
age	O
was	O
weaker	O
and	O
did	O
not	O
remain	O
significant	O
after	O
adjustment	O
for	O
body	O
mass	O
index.	O

Another	O
analysis	O
to	O
characterize	O
relapse	O
and	O
remission	O
status	O
showed	O
that	O
isoleucine	B
and	O
valine	B
were	O
down-regulated	O
in	O
MS	O
relapse	O
compared	O
to	O
MS	O
remission.	O

However,	O
these	O
results	O
were	O
not	O
consistent	O
by	O
the	O
relative	O
abundance,	O
such	O
that	O
the	O
asparagine,	B
2-aminoadipate,	B
alpha-hydroxyisovalerate,	B
deoxycholate,	B
7-ketodeoxycholate,	B
sorbitol	B
and	O
cys-gly,	B
oxidized	O
had	O
higher	O
expression	O
in	O
adjacent	O
mucosa	O
compared	O
to	O
CRC,	O
whereas	O
isobar:	O
betaine	B
aldehyde,	I
N-methyldiethanolamine	B
had	O
higher	O
expression	O
in	O
CRC	O
than	O
in	O
adjacent	O
mucosa	O
in	O
this	O
study.	O

Dialyses	O
with	O
membrane	O
of	O
100–200	O
Daltons	O
cut	O
off	O
(Spectra/por	O
100–200	O
Da	O
MWCO	O
dialysis	O
membrane,	O
Spectrum	O
Laboratories	O
Inc.,	O
UK)	O
were	O
used	O
to	O
remove	O
monosaccharides	B
from	O
the	O
pre-digested	O
breads.	O

#	O
59623–23)	O
and	O
was	O
spiked	O
with	O
120	O
pmol	O
PGEM-d_6	O
(Cayman	O
Chemical,	O
Ann	O
Harbor,	O
MI)	O
dissolved	O
in	O
10%	O
aqueous	O
formic	B
acid	I
and	O
40	O
μL	O
of	O
formic	B
acid	I
(ACS	O
grade	O
≥98%).	O

Therefore,	O
we	O
tested	O
the	O
three	O
β-apocarotenoids	B
resulting	O
from	O
cleavage	O
of	O
the	O
C13–C14	O
double	O
bond	O
of	O
β-carotene	B
for	O
their	O
binding	O
to	O
purified	O
recombinant	O
RXRα.	O

Limonene	B
has	O
also	O
been	O
shown	O
to	O
inhibit	O
proliferation	O
through	O
a	O
cyclin	O
D1	O
dependent	O
mechanism	O
in	O
breast	O
cancer	O
cell	O
lines.	O

The	O
column	O
was	O
equilibrated	O
with	O
mobile	O
phase	O
A	O
(250	O
mM	O
ammonium	B
acetate	I
containing	O
50	O
mM	O
magnesium	B
chloride	I
and	O
5%	O
ethanol,	B
pH	O
8.5)	O
at	O
flowrate	O
of	O
1	O
mL/min.	O

Furthermore,	O
we	O
tested	O
whether	O
these	O
newly	O
identified	O
alterations	O
related	O
to	O
IR	O
could	O
predict	O
deteriorations	O
of	O
glycemic	B
control	O
in	O
youth.	O

Percent	O
change	O
(compared	O
with	O
baseline,	O
0	O
hr)	O
in	O
levels	O
of	O
plasma	O
(A)	O
glycerol	B
(actual	O
baseline	O
values;	O
rHDL,	O
46	O
±	O
11	O
μM;	O
Placebo,	O
44	O
±	O
9	O
μM);	O
(B)	O
NEFA	O
(actual	O
baseline	O
values;	O
rHDL,	O
388	O
±	O
76	O
μM;	O
Placebo,	O
384	O
±	O
39	O
μM);	O
and	O
(C)	O
TG	B
(actual	O
baseline	O
values;	O
rHDL,	O
1.86	O
±	O
0.36	O
mM;	O
Placebo,	O
1.56	O
±	O
0.23	O
mM)	O
during	O
4	O
hr	O
rHDL	O
(solid	O
lines)	O
and	O
placebo	O
(dotted	O
lines)	O
infusion.	O

These	O
included	O
the	O
same	O
types	O
of	O
molecules	O
listed	O
above	O
for	O
the	O
methanol	B
method.	O

R=Z−C(C−1Z)whereR=[x˜Y˜],Z=[XjY],andCi=[1Mi]	B

Betaine	B
and	O
choline	B
levels	O
are	O
also	O
greater	O
in	O
CPF	O
animals.	O

This	O
matches	O
our	O
finding	O
of	O
the	O
down	O
regulation	O
of	O
oleoyl	B
carnitine	I
in	O
HCC	O
and	O
supports	O
the	O
hypothesis	O
that	O
cancer	O
cell	O
changes	O
energy	O
metabolism	O
by	O
promoting	O
glycolysis	O
and	O
suppressing	O
the	O
TCA	O
cycle,	O
in	O
which	O
the	O
relative	O
accumulation	O
of	O
C2-acylcarnitine	B
and	O
other	O
medium	O
and	O
short-chain	O
acylcarnitines	B
would	O
be	O
detected	O
in	O
HCC	O
compared	O
with	O
cirrhosis.	O

Electrospray	O
ionization	O
(ESI)	O
in	O
the	O
positive	O
ion	O
mode	O
provided	O
high	O
ionization	O
efficiency	O
for	O
5-HT,	O
DA,	O
5-HT-glucuronide	B
(5-HT-G),	I
5-HT-sulfate	B
(5-HT-S),	I
and	O
DA-glucuronide	O
(DA-G),	O
whereas	O
the	O
negative	O
ion	O
mode	O
provided	O
better	O
ionization	O
efficiency	O
for	O
DA-3-O-S	B
and	O
DA-4-O-S,	B
as	O
well	O
as	O
for	O
DOPAC,	O
HVA,	O
5-HIAA,	B
and	O
their	O
glucuronide	B
and	O
sulfate	B
conjugates.	O

The	O
total	O
sum	O
of	O
cysteine-BDA-lysine	B
derived	O
metabolites	O
(2	O
–	O
5)	O
was	O
less	O
than	O
the	O
BDA-lysine	B
metabolite	O
1.	O

The	O
SL	B
metabolic	O
pathway	O
is	O
an	O
important	O
cellular	O
pathway	O
that	O
represents	O
a	O
highly	O
coordinated	O
system	O
in	O
which	O
S1P	O
induces	O
cell	O
survival,	O
while	O
ceramide	B
induces	O
programmed	O
cell	O
death.	O

Briefly,	O
to	O
the	O
dry	O
lipid	O
extract,	O
1	O
mL	O
of	O
methanol,	B
1	O
mL	O
of	O
BF3	O
methanol	B
and	O
40	O
µL	O
of	O
BHT	O
were	O
added.	O

It	O
is	O
now	O
well	O
known	O
that	O
hydrogen	B
sulphide	I
is	O
endogenous	O
and	O
is	O
produced	O
by	O
both	O
enzymatic	O
reaction	O
and	O
microbiota	O
in	O
the	O
gut.	O

For	O
example,	O
strong	O
correlation	O
values	O
describing	O
the	O
relationship	O
between	O
the	O
2-hydroxy	O
ibuprofen	O
methyl	O
at	O
δ	O
1.21	O
and	O
resonances	O
of	O
the	O
carboxy	B
ibuprofen	I
were	O
found;	O
CH_3	O
(δ	O
1.40,	O
r	O
=	O
0.97;	O

A	O
total	O
of	O
34	O
key	O
metabolites	O
associated	O
with	O
BCa	O
were	O
identified;	O
ii)	O
three	O
metabolic	O
pathways,	O
namely	O
glutathione,	B
purine	B
and	O
thiamine	B
metabolism,	O
were	O
altered	O
in	O
BCa,	O
and	O
glutathione	B
metabolism	O
was	O
the	O
consistently	O
altered	O
pathway	O
in	O
enrichment	O
and	O
pathway	O
analyses	O
(	O
and	O
,	O
and	O
);	O
iii)	O
among	O
the	O
34	O
cancer-associated	O
metabolites,	O
the	O
levels	O
of	O
bilirubin	B
and	O
retinal	B
recovered	O
after	O
gemcitabine	O
injection,	O
suggesting	O
that	O
these	O
two	O
are	O
likely	O
the	O
targets	O
of	O
gemcitabine	O
treatment	O
(,	O
);	O
iv)	O
the	O
effects	O
of	O
gemcitabine	O
on	O
normal	O
bladder	O
tissues	O
were	O
also	O
investigated,	O
and	O
it	O
was	O
deduced	O
that	O
histamine	B
may	O
have	O
the	O
ability	O
to	O
protect	O
against	O
disease	O
recurrence,	O
whereas	O
thiamine	B
may	O
be	O
involved	O
in	O
the	O
side	O
effects	O
of	O
treatment	O
(,	O
),	O
which	O
requires	O
further	O
confirmation	O
in	O
future	O
studies.	O

In	O
this	O
study,	O
we	O
analyzed	O
the	O
plasma	O
samples	O
of	O
patients	O
from	O
each	O
BT,	O
PP,	O
and	O
GP	B
group.	O

In	O
the	O
“Test	O
group”	O
of	O
31	O
PTSD-negative	O
and	O
31	O
PTSD-positive	O
subjects,	O
demographic	O
and	O
clinical	O
characteristics	O
were	O
similar	O
to	O
the	O
Discovery	O
group,	O
except	O
there	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
BMI,	O
glucose,	B
insulin,	O
HOMA-IR,	O
creatinine,	B
hemoglobin,	O
or	O
hematocrit	O
between	O
the	O
PTSD-positive	O
and	O
-negative	O
groups.	O

_b	O
Dimethyl	B
sulfoxide	I
was	O
the	O
vehicle	O
for	O
4-aminopyridine,	B
omeprazole,	B
phenobarbital,	O
and	O
rifampin.	O

(a)	O
Arginine,	B
(b)	O
urea,	B
(c)	O
ornithine,	B
(d)	O
citrulline.	B

Our	O
findings	O
that	O
urinary	O
biomarkers	O
for	O
flame-retardants	O
or	O
organochlorine	B
pollutants	O
are	O
associated	O
with	O
male	O
reproductive	O
health	O
and	O
sperm	O
parameters	O
are	O
consistent	O
with	O
previous	O
studies	O
[,	O
,	O
].	O

The	O
pathways	O
related	O
to	O
purine	B
metabolism	O
and	O
fatty	O
acid	O
biosynthesis	O
were	O
directly	O
identified	O
as	O
those	O
that	O
might	O
have	O
been	O
perturbed	O
by	O
the	O
development	O
of	O
BAV.	O

Metabolic	O
profiling	O
analysis	O
was	O
limited	O
to	O
those	O
subjects	O
with	O
normal	O
fasting	O
glucose	B
concentrations	O
(below	O
100	O
mg/100	O
ml)	O
and	O
normal	O
glucose	B
tolerance	O
(2-h	O
glucose	B
concentration	O
below	O
140	O
mg/100	O
ml).	O

ADMA,	B
asymmetric	B
dimethylarginine;	I
Arg,	O
arginine;	B
Cit,	O
citrulline;	B
EAA,	O
essential	O
amino	O
acid;	O
NEAA,	O
nonessential	O
amino	O
acid;	O
OH-Kyn,	O
hydroxykynurenine;	B
Orn,	O
ornithine;	B
Phe,	O
phenylalanine;	B
Pro,	O
proline;	B
SDMA,	O
symmetric	B
dimethylarginine;	I
Trp,	O
tryptophan;	B
Tyr,	O
tyrosine.	B

Analytes	O
were	O
kept	O
at	O
10	O
°C	O
in	O
the	O
autosampler	O
and	O
injected	O
hydrodynamically	B
at	O
the	O
pressure	O
of	O
5	O
mbar	O
for	O
100	O
s.	O
Unless	O
otherwise	O
stated,	O
the	O
following	O
ESI-MS/MS	O
conditions	O
were	O
used:	O
sheath	O
liquid,	O
MeOH/H_2	O
O	O
(80/20,	O
v/v)	O
containing	O
40	O
mM	O
HOAc;	O
sheath	O
liquid	O
flow	O
rate,	O
5	O
μL/min;	O
capillary	O
voltage,	O
+3500	O
V;	O
drying	O
gas	O
flow	O
rate,	O
5.0	O
L/min;	O
drying	O
gas	O
temperature,	O
200	O
°C;	O
nebulizer	O
pressure,	O
7	O
psi;	O
collision	O
cell	O
gas	O
(N_2	O
)	O
pressure	O
was	O
~30	O
psi.	O

Taurine,	B
alanine,	B
3-aminoisobutyrate	B
showed	O
very	O
high	O
AUC	O
scores.	O

However,	O
direct	O
comparison	O
of	O
arylamine	B
adduct	O
formation	O
with	O
Hb	O
and	O
PP	O
has	O
been	O
determined	O
only	O
in	O
a	O
few	O
studies.	O

For	O
those	O
kynurenine	B
metabolites	O
that	O
were	O
statistically	O
correlated	O
with	O
hippocampal	O
and/or	O
amygdalar	O
volume	O
and/or	O
the	O
clinical	O
rating	O
scales,	O
we	O
subsequently	O
conducted	O
a	O
linear	O
regression	O
analysis	O
to	O
control	O
for	O
the	O
potential	O
confounds,	O
age,	O
sex,	O
BMI,	O
and	O
ICV	O
(model	O
3).	O

Representative	O
fields	O
of	O
control	O
cells	O
(growth	O
medium)	O
or	O
cells	O
following	O
3	O
hrs	O
incubation	O
in	O
DMEM	O
medium	O
with	O
no	O
glucose	B
or	O
glutamine	B
stained	O
with	O
LC3	O
antibody.	O

Additionally,	O
2-methylpyrazine	B
was	O
detected	O
at	O
higher	O
concentration	O
in	O
patients	O
with	O
high	O
IPI	O
score	O
B-NHL	O
compared	O
with	O
those	O
with	O
low	O
IPI	O
score	O
B-NHL.	O

Studies	O
have	O
suggested	O
that	O
indole-3-acetate	B
directly	O
modulates	O
inflammatory	O
responses	O
in	O
hepatocytes	O
and	O
macrophages	O
by	O
attenuation	O
of	O
the	O
release	O
of	O
pro-inflammatory	O
cytokines	O
and	O
induction	O
of	O
the	O
liver	O
to	O
synthesize	O
free	O
fatty	O
acids.	O

Sterol,	O
Oxysterol,	B
Bile	O
acid,	O
CNS,	O
Inflammation,	O
HPLC,	O
MS	O

This	O
hypothesis	O
is	O
consistent	O
with	O
the	O
decreased	O
amounts	O
of	O
both	O
acetoacetate	B
and	O
3-hydroxy-butyrate	B
(3-HBA),	O
also	O
components	O
of	O
ketone	B
bodies,	O
found	O
in	O
cancer	O
patients	O
compared	O
to	O
controls	O
(metabolites	O
not	O
discriminant	O
according	O
to	O
their	O
VIP	O
value).	O

Ethanol	B
was	O
excluded	O
from	O
the	O
correlation	O
coefficient	O
calculation.	O

Serum	O
metabolic	O
profiling	O
identified	O
a	O
series	O
of	O
12	O
metabolites	O
with	O
significant	O
alterations,	O
and	O
the	O
related	O
metabolic	O
pathways	O
involved	O
glycerophospholipid,	B
sphingolipid,	B
phospholipid,	B
fat	O
acid,	O
acylcarnitine,	B
heme,	B
and	O
purine	B
metabolism.	O

PCA	O
analysis	O
of	O
only	O
the	O
lipoprotein	O
triacylglycerol	B
_1	O
H	O
NMR	O
resonances	O
normalised	O
to	O
that	O
of	O
the	O
total	O
triacylglycerol-CH	B
_3	O
function	O
signal	O
revealed	O
that	O
the	O
variables	O
were	O
clearly	O
segregated	O
into	O
four	O
major	O
orthogonal	O
components	O
(loading	O
scores	O
vectors	O
in	O
brackets):	O
(1)	O
PC1,	O
encompassing	O
the	O
VLDL-(CH	O
_2	O
)_n	O
-	O
function	O
(0.91),	O
the	O
triacylglycerol-CH	B
_2	O
CO-	O
group	O
(0.88),	O
and	O
both	O
vinylic	B
proton	O
triacylglycerol	B
signals	O
1	O
and	O
2	O
(0.83	O
and	O
0.92	O
respectively);	O
(2)	O
PC2,	O
involving	O
HDL-CH	O
_3	O
and	O
-(CH	O
_2	O
)_n	O
-	O
signals	O
(0.95	O
and	O
0.91	O
respectively),	O
and	O
the	O
VLDL-CH	O
_3	O
function	O
(−0.93);	O
(3)	O
PC3,	O
exclusively	O
featuring	O
the	O
triacylglycerol-CH_2	B
-CH	I
_2	O
-CH=	O
resonance	O
alone	O
(0.96);	O
and	O
(4)	O
PC4,	O
involving	O
the	O
LDL-associated	O
triacylglycerol-(CH	B
_2	I
)	I
_n	O
-	O
signal	O
alone	O
(0.97).	O

Of	O
these,	O
2	O
were	O
affixed	O
onto	O
glass	O
slides	O
and	O
stained	O
with	O
either	O
hematoxylin	B
and	O
eosin	B
(H&E)	O
or	O
CD4	O
immunohistochemical	O
staining	O
to	O
determine	O
cancer	O
and	O
non-cancer	O
areas	O
in	O
each	O
MF	O
patient	O
samples.	O

A	O
mobile	O
phase	O
containing	O
50 mM	O
sodium	B
acetate	I
(pH	O
6.2)	O
and	O
7 %	O
acetonitrile	B
was	O
pumped	O
through	O
the	O
reverse-phase	O
column	O
at	O
a	O
flow	O
rate	O
of	O
0.5 mL/min.	O

More	O
recent	O
work	O
provided	O
evidence	O
for	O
higher	O
cortisol	B
secretion	O
from	O
SAT	O
rather	O
than	O
VAT	O
in	O
humans.	O

Then,	O
60 μL	O
of	O
buffer	O
solution	O
(1.5 M	O
phosphate	B
buffer	O
pH	O
7.0	O
in	O
D_2	O
O)	O
containing	O
0.1%	O
of	O
3-trimethylsilyl-propionate	B
(TSP),	O
used	O
as	O
chemical	O
shift	O
reference,	O
were	O
added	O
to	O
540 μL	O
of	O
each	O
urine	O
sample.	O

Perhaps,	O
the	O
deprotonation	O
of	O
substituted	O
hydroxyl	O
proton	O
located	O
in	O
the	O
benzene	B
ring	O
of	O
O	O
-DVX	O
begins	O
at	O
pH	O
9.5	O
(resulting	O
in	O
electrostatic	O
repulsion	O
with	O
the	O
poly-L,L	O
-SULA).	O

1-methylnicotinamide,	B
creatine,	B
citrate,	B
4-deoxythreonic	B
acid,	I
and	O
2-aminobutyrate,	B
in	O
the	O
order	O
listed,	O
were	O
the	O
five	O
most	O
important	O
metabolites	O
in	O
separating	O
the	O
healthy	O
controls	O
and	O
RSV	O
ARI	O
groups.	O

Among	O
these	O
metabolites,	O
glutamine	B
in	O
serum	O
and	O
ethanolamine	B
and	O
1,3‐diphosphoglycerate	B
in	O
urine	O
showed	O
>0.80	O
AUC_ROC	O
values	O
in	O
the	O
prediction	O
model	O
for	O
discrimination	O
between	O
the	O
p‐GDM	O
and	O
control	O
groups	O
(Table ).	O

Altered	O
glucose	B
metabolism	O
or	O
aerobic	O
glycolysis	O
generates	O
a	O
tumor	O
friendly	O
niche,	O
especially	O
by	O
creating	O
an	O
acidic	O
tumor	O
microenvironment	O
through	O
increased	O
lactate	B
secretion.	O

Although	O
not	O
statistically	O
significant,	O
there	O
was	O
a	O
trend	O
toward	O
a	O
positive	O
relationship	O
between	O
uPCr	O
and	O
log-transformed	O
urinary	O
myo-inositol	B
in	O
the	O
FSGS	O
patients.	O

R	O
script	O
to	O
generate	O
the	O
lipidomics	O
dataset	O
from	O
the	O
extracted	O
ion	O
chromatograms	O
is	O
provided	O
in	O
data	O
record	O
(adni1-lipidomics-script.r).	O

HDL3	O
apolipoproteins	O
showed	O
strong	O
positive	O
correlations	O
with	O
tyrosine	B
(r	O
=	O
0.95;	O
P	O
<	O
0.0001)	O
and	O
creatinine	B
(r	O
=	O
0.49;	O
P	O
<	O
0.0001)	O
whereas	O
valine	B
showed	O
strong	O
negative	O
correlation	O
with	O
creatinine	B
(r	O
=	O
–0.64;	O
P	O
<	O
0.0001)	O
and	O
fatty	O
acid	O
with	O
αCH2	O
(r	O
=	O
–0.68;	O
P	O
<	O
0.0001;	O
).	O

The	O
method	O
was	O
applied	O
to	O
different	O
doses	O
of	O
imatinib	B
in	O
serum	O
samples	O
from	O
308	O
patients	O
whose	O
BCR-ABL	O
gene	O
measurements	O
had	O
been	O
quantified	O
(to	O
monitor	O
disease	O
progression	O
based	O
on	O
treatment	O
consisting	O
of	O
400	O
mg/day	O
imatinib).	B

It	O
is	O
demonstrated	O
how	O
serum	O
protein	O
can	O
be	O
efficiently,	O
cost-effectively,	O
and	O
environmentally	O
friendly	O
removed	O
at	O
physiological	O
pH	O
(pH	O
7.4)	O
through	O
attractive	O
interactions	O
with	O
silica	B
nanoparticles.	O

F_2α	B
-isoprostanes	I
are	O
generally	O
considered	O
to	O
be	O
the	O
most	O
reliable	O
markers	O
of	O
in	O
vivo	O
oxidative	O
stress	O
[,	O
].	O

The	O
concentration	O
of	O
these	O
metabolites	O
and	O
lipoproteins	O
were	O
all	O
higher	O
in	O
the	O
ER(+)	B
group	O
as	O
compared	O
to	O
those	O
observed	O
in	O
the	O
ER(−)	O
group	O
(Figure	O
S1).	O

As	O
expected,	O
the	O
Me-OHNs	O
eluted	O
shortly	O
after	O
the	O
naphthols	O
and	O
before	O
the	O
hydroxyfluorenes.	B

Phosphatidylcholines	B
and	O
sphingomyelins	B
were	O
analyzed	O
by	O
flow	O
injection	O
analysis	O
(FIA)	O
into	O
the	O
analytical	O
system	O
which	O
was	O
comprised	O
of	O
a	O
Nexera	O
UHPLC	O
system	O
(Shimadzu)	O
coupled	O
to	O
an	O
API	O
QTRAP®	O
5500	O
mass	O
spectrometer	O
(AB	O
Sciex,	O
Darmstadt,	O
Germany).	O

Owing	O
to	O
increased	O
angiogenesis	O
and	O
tissue	O
growth	O
in	O
women	O
with	O
advanced	O
stages	O
of	O
endometriosis,	O
it	O
is	O
likely	O
that	O
the	O
formate	B
molecules	O
are	O
incorporated	O
into	O
the	O
purine	B
nucleotide	O
synthesis	O
leading	O
to	O
its	O
depletion.	O

Several	O
additional	O
carnitines	B
were	O
putatively	O
identified	O
in	O
this	O
work	O
(14–28).	O

The	O
concentrations	O
of	O
lysophosphatidic	B
acid	I
and	O
multiple	O
kinds	O
of	O
LysoPCs	O
were	O
noted	O
to	O
be	O
significantly	O
down-regulated	O
and	O
sphingosines	B
significantly	O
up-regulated	O
in	O
STEMI	O
compared	O
to	O
the	O
PSM	O
healthy	O
controls.	O

Reboldi	O
et	O
al.	O
suggested	O
that	O
this	O
may	O
be	O
through	O
reducing	O
the	O
cellular	O
content	O
of	O
sterols	O
generated	O
via	O
the	O
mevalonate	B
pathway.	O

For	O
both	O
dried	O
blood	O
spots	O
(DBS)	O
and	O
plasma	O
three	O
acylcarnitine	B
biomarkers,	O
three	O
amino	O
acids	O
and	O
three	O
other	O
metabolites	O
are	O
demonstrated	O
as	O
representative	O
examples	O
of	O
compounds	O
with	O
high	O
Z-scores	O
that	O
contributed	O
to	O
the	O
assigned	O
most	O
probable	O
diagnosis.	O

A	O
specific	O
dietary	O
habit	O
(benzoate-rich	O
diet	O
for	O
example)	O
may	O
have	O
contributed	O
to	O
this	O
high	O
level	O
of	O
hippurate.	B

Plasma	O
levels	O
of	O
tamoxifen	B
and	O
the	O
inactive	O
major	O
metabolite	O
DM‐Tam	O
as	O
well	O
as	O
active	O
metabolites	O
(Z)‐endoxifen	B
and	O
(Z)‐4‐OH‐Tam)	O
were	O
measured	O
by	O
liquid	O
chromatography	O
tandem	O
mass	O
spectrometry	O
as	O
previously	O
described._17	O

And	O
the	O
glycolysis	O
and	O
glycine,	B
serine,	B
and	O
threonine	B
metabolism	O
were	O
activated	B
in	O
CRC.	O

 a,	O
NAC	O
treatment	O
markedly	O
increased	O
NADPH	B
(+281 ± 57 %,	O
p = 0.035),while	O
it	O
diminished	O
Kyn	O
(−55 ±	O

A	O
significant	O
increase	O
in	O
1,5-anhydrosorbitol	B
(1,5-AG)	I
occurred	O
at	O
T6	O
vs.	O
T0	O
in	O
OB/D	O
subjects,	O
while	O
a	O
non-significant	O
increase	O
was	O
seen	O
in	O
OB	O
subjects	O
(group:time	O
interaction	O
was	O
allowed	O
for	O
by	O
the	O
linear	O
model).	O

For	O
example,	O
glycine	B
concentrations	O
have	O
previously	O
been	O
shown	O
to	O
be	O
linked	O
with	O
whole	O
body	O
glucose	B
uptake	O
and	O
thus	O
insulin	O
responsiveness,	O
as	O
assessed	O
by	O
hyperinsulinemic-euglycemic	B
glucose	I
clamps.	O

After	O
removing	O
ketones	B
and	O
creatinine,	B
factor	O
analysis	O
of	O
z-scores	O
did	O
not	O
separate	O
cleanly	O
between	O
disease	O
groups.	O

For	O
positive	O
mode	O
calibration,	O
a	O
mixture	O
of	O
PEG	B
200	O
and	O
600	O
was	O
used.	O

For	O
PA,	O
metabolites	O
of	O
interest	O
were	O
propionylcarnitine,	B
glycine,	B
and	O
propionylglycine.	B

Quality	O
and	O
concentration	O
of	O
DNA	O
extracts	O
were	O
determined	O
using	O
1%	O
agarose-0.5X	B
TBE	O
gels,	O
which	O
were	O
stained	O
with	O
Gel	O
Red	O
10,000X	O
(Biotium,	O
Inc.)	O
and	O
analyzed	O
through	O
spectrophotometric	O
measurements	O
at	O
260,	O
280	O
and	O
230	O
nm,	O
using	O
the	O
NanoDrop	O
ND-1000	O
Spectrophotometer	O
(ThermoFisher	O
Scientific	O
Inc.,	O
MI,	O
Italy).	O

()	O
Two	O
studies	O
in	O
children	O
also	O
showed	O
that	O
PFAS	O
levels	O
in	O
blood	O
were	O
associated	O
with	O
significant	O
alterations	O
in	O
glycophospholipid	B
metabolism	O
and	O
several	O
amino	O
acid	O
pathways	O
such	O
as	O
tyrosine,	B
aspartate	B
and	O
asparagine.	B

Deoxycholic	B
acid,	I
one	O
of	O
the	O
bile	O
acids	O
is	O
seen	O
to	O
be	O
higher	O
in	O
the	O
serum	O
of	O
individuals	O
with	O
adenoma.	O

In	O
this	O
study,	O
the	O
RRLC-MS	O
analysis	O
by	O
ESI	O
in	O
both	O
positive	O
and	O
negative	O
ion	O
modes	O
(RRLC-(±)ESI-MS)	O
raw	O
data	O
were	O
converted	O
into	O
mzData	O
format.	O

The	O
spray	O
voltage	O
was	O
4.5	O
kV	B
for	O
the	O
positive	O
mode	O
and	O
4.0	O
kV	B
for	O
negative	O
mode,	O
while	O
the	O
ion	O
transfer	O
capillary	O
temperature	O
was	O
275	O
°C.	O

Tandem	O
mass	O
spectrometric	O
fragmentation	O
fingerprints	O
of	O
standards	O
for	O
each	O
of	O
these	O
metabolic	O
classes	O
were	O
therefore	O
generated	O
including	O
5S,6S-(7E,9E,11Z,14Z)-dihydroxyeicosatetraenoic	B
acid	I
(1),	O
15S-Hydroxy-(5Z,8Z,11Z,13E)-eicosatetraenoic	B
acid	I
(2)	O
and	O
8R-Hydroxy-(5Z,9E,11Z,14Z)-eicosatetraenoic	B
acid	I
(3),	O
α-tocopherol	B
(4)	O
γ-tocopherol	B
(5),	O
13-(6-hydroxy-2,7,8-trimethylchroman-2-yl)-2,6,10-trimethyltridecanoic	B
acid	I
(6),	O
16-(4,5-dimethyl-3,6-dioxo	B
cyclohexa-1,4-dienyl)-2,6,10,14-tetramethylhexadecanoic	I
acid	I
(7),	O
6-hydroxy-2,7-dimethyl-2-(4,8,12-trimethyltridecyl)chroman-8-carbaldehyde	B
(8),	O
6-hydroxy-2,7-dimethyl-2-(4,8,12-trimethyltridecyl)chroman-8-carboxylic	B
acid	I
(9),	O
calciferol	B
(10),	O
cholecalciferol	B
(11),	O
ergosterol	B
(12),	O
phylloquinone	B
(13),	O
retinol	B
(14)	O
and	O
3β,7α-dihydroxy-5-cholestenoic	B
acid	I
(15)	O
(Table	O
).	O

As	O
such,	O
fewer	O
samples	O
had	O
a	O
result	O
for	O
glutamine.	B

In	O
addition,	O
the	O
levels	O
of	O
glutamine	B
have	O
been	O
inversely	O
associated	O
with	O
insulin	O
resistance	O
and	O
diabetes	O
risk,35,	O
38	O
and	O
here	O
the	O
glutamine	B
concentration	O
in	O
serum	O
was	O
also	O
inversely	O
associated	O
with	O
the	O
presence	O
of	O
fatty	O
liver.	O

Impaired	O
brain-glucose	B
regulation	O
has	O
been	O
tentatively	O
attributed	O
to	O
a	O
functional	O
defect	O
of	O
glucose	B
transporter	O
(GLUT)-mediated	O
glucose	B
uptake,	O
but	O
neuronal	O
loss	O
may	O
be	O
responsible	O
for	O
some	O
of	O
this	O
effect,	O
and	O
there	O
is	O
ongoing	O
argument	O
concerning	O
the	O
contribution	O
of	O
this	O
mechanism	O
to	O
defective	O
brain-glucose	B
uptake	O
and	O
neurodegeneration.	O

Leucine	B
was	O
elevated	O
in	O
cancer	O
patients	O
and	O
decreased	O
in	O
cachexia	O
patients.	O

In	O
the	O
six	O
patients	O
in	O
this	O
study	O
who	O
received	O
dietary	O
supplementation	O
with	O
galactose,	B
some	O
potentially	O
important	O
clinical	O
changes	O
were	O
seen.	O

Heptadecanoic	B
acid	I
(C17:0)	O
belongs	O
to	O
the	O
odd-chain	O
fatty	O
acids,	O
and	O
although	O
it	O
has	O
been	O
widely	O
used	O
as	O
a	O
biomarker	O
of	O
dairy	O
intake	O
(Yakoob	O
et	O
al.,	O
),	O
there	O
is	O
recent	O
evidence	O
that	O
it	O
is	O
related	O
to	O
metabolic	O
diseases	O
and	O
gut	O
microbiome	O
imbalance	O
(Jenkins	O
et	O
al.,	O
).	O

Furthermore,	O
the	O
fact	O
that	O
reactive	O
sulfide	B
species,	O
which	O
might	O
protect	O
retinal	B
cells	O
from	O
oxidative	O
stress	O
damage,	O
are	O
upregulated	O
in	O
eyes	O
with	O
diabetic	O
retinopathy	O
leads	O
us	O
to	O
believe	O
that	O
these	O
reactive	O
sulfide	B
species	O
may	O
be	O
promising	O
target	O
molecules	O
for	O
therapy	O
to	O
treat	O
diabetic	O
retinopathy.	O

This	O
is	O
in	O
line	O
with	O
the	O
Randle	O
cycle,	O
which	O
draws	O
attention	O
to	O
competition	O
between	O
glucose	B
and	O
fatty	O
acids	O
for	O
their	O
oxidation,	O
and	O
pharmacological	O
models	O
of	O
mitochondrial	O
impairment,	O
which	O
stimulates	O
insulin	O
sensitivity	O
and	O
protects	O
against	O
diet-induced	O
obesity,	O
NAFLD	O
and	O
insulin	O
resistance[,].	O

The	O
ratio	O
of	O
metabolites	O
to	O
parent	O
estrogen	B
increased	O
statistically	O
significantly	O
across	O
quintiles	O
of	O
whole-tree	O
phylogenetic	O
diversity	O
(P	O
for	O
trend	O
=	O
.004)	O
but	O
not	O
for	O
observed	O
species	O
(P	O
for	O
trend	O
=	O
0.22),	O
Shannon	O
index	O
(P	O
for	O
trend	O
=	O
.24),	O
or	O
Inverse	O
Simpson	O
(P	O
for	O
trend	O
=	O
.77).	O

The	O
dried	O
material	O
was	O
reconstituted	O
in	O
0.1%	O
formic	B
acid	I
in	O
water	O
for	O
LC-MS	O
analysis	O
in	O
positive	O
and	O
negative	O
ionization	O
modes.	O

Sulfonation	O
to	O
p-cresol	B
sulfate	I
occurs	O
in	O
the	O
liver.	O

By	O
simultaneously	O
measuring	O
both	O
methylarginines	B
and	O
methyl-lysine	B
levels,	O
this	O
“internal	O
control”	O
further	O
validates	O
the	O
important	O
contribution	O
of	O
arginine	O
methylation	O
pathways	O
in	O
the	O
disease	O
progression	O
of	O
long-term	O
cardiovascular	O
disease.	O

Our	O
unexpected	O
observation	O
of	O
significant	O
associations	O
between	O
the	O
anti-inflammatory	O
cytokine	O
IL-10	O
and	O
kynurenine	B
metabolites	O
indicates	O
that	O
interactions	O
between	O
tryptophan	B
catabolism	O
and	O
immune	O
system	O
cytokines	O
occur	O
even	O
in	O
the	O
presence	O
of	O
minimal	O
inflammation	O
and	O
suggests	O
that	O
this	O
pathway	O
may	O
serve	O
as	O
a	O
mechanism	O
to	O
promote	O
negative	O
regulation	O
as	O
part	O
of	O
normal	O
immune	O
homeostasis.	O

Plasma	O
total	O
cholesterol,	B
LDL-C,	O
HDL-C	O
and	O
TG	B
were	O
measured	O
by	O
enzymatic	O
assay	O
at	O
SEALS	O
pathology	O
(Prince	O
of	O
Wales	O
Hospital)	O
as	O
previously	O
described,	O
using	O
a	O
Beckman	O
LX20	O
Analyzer	O
with	O
a	O
timed-endpoint	O
method	O
(Fullerton,	O
CA).	O

Women	O
with	O
breast	O
cancer	O
who	O
met	O
eligibility	O
criteria	O
were	O
prescribed	O
1	O
mg	O
day_−1	O
anastrozole	B
to	O
be	O
taken	O
orally.	O

Briefly,	O
cystine	B
(5.3	O
mmol)	O
was	O
added	O
to	O
13	O
ml	O
of	O
a	O
1.5	O
M	O
NaOH	O
solution	O
and	O
the	O
mixture	O
was	O
cooled	O
in	O
an	O
ice	O
bath	O
with	O
stirring.	O

Pasikanti,	O
et	O
al.	O
showed	O
elevated	O
concentrations	O
of	O
tryptophan	B
metabolites	O
in	O
the	O
urine	O
of	O
BCA	O
patients.	O

Then,	O
80	O
µL	O
of	O
methoxyamine	B
hydrochloride	I
(15	O
mgm	O
L_−1	O
in	O
pyridine)	B
was	O
used	O
to	O
dissolve	O
dried	O
residue,	O
and	O
stayed	O
at	O
37	O
°C	O
for	O
90	O
min.	O

A	O
Synergi	O
Hydro‐RP	B
column	O
was	O
employed	O
(150 × 2.0 mm	O
i.d.	O

The	O
flow	O
rate	O
was	O
350 μL/min	O
and	O
the	O
injection	O
volume	O
was	O
4 μL.	O
An	O
Agilent	O
6530	O
Accurate-Mass	B
Quadrupole	O
Time-of-Flight	O
(Q-TOF)	O
mass	O
spectrometer	O
(Agilent,	O
USA)	O
was	O
used	O
in	O
the	O
study.	O

By	O
comparing	O
the	O
fragmentation	O
patterns	O
of	O
the	O
standards	O
against	O
those	O
from	O
our	O
samples,	O
we	O
confirmed	O
the	O
identities	O
of	O
valine,	B
isoleucine,	B
leucine,	B
alpha	B
tocopherol,	I
citric	B
acid,	I
lactic	B
acid,	I
glutamic	B
acid,	I
and	O
cholesterol.	B

In	O
addition	O
to	O
β-HB,	B
accumulation	O
in	O
aromatic	O
amino	O
acids	O
levels	O
suggests	O
impairment	O
of	O
mitochondrial	O
function	O
and	O
inflammatory	O
status	O
in	O
HCC-cirrhosis.	O

Abbreviations:	O
BMI	O
=	O
body	O
mass	O
index;	O
Glucose0	B
=	O
fasting	O
plasma	O
glucose;	B
Glucose120	O
=	O
2	O
h	O
plasma	O
glucose;	B
INS0	O
=	O
fasting	O
insulin;	O
INS120	O
=	O
2	O
h	O
insulin;	O
HDL	O
=	O
high-density	O
lipoprotein;	O
LDL	O
=	O
low-density	O
lipoprotein;	O
SP	B
=	O
systolic	O
blood	O
pressure;	O
DP	O
=	O
diastolic	O
blood	O
pressure;	O
TC	O
=	O
total	O
cholesterol;	B
TG	B
=	O
total	O
triglycerides;	B
HOMA-IR	O
=	O
homeostatic	O
model	O
assessment	O
of	O
insulin	O
resistance	O
(FPG*INS0/22.5);	O
Matsuda	O
index	O
=	O
10000/(Glucose0×INS0×Glucose120×INS120)_0.5	O
;	O
HOMA-Beta	O
=	O
homeostatic	O
model	O
assessment	O
of	O
beta-cell	O
function	O
(20*INS0/(Glucose0-3.5);	O
First-phase	O
secretion	O
=	O
2032+4.681*INS0-135*Glucose120+0.995*INS120+27.99*BMI-269.1*Glucose0;	O
Second-phase	O
secretion	O
=	O
277+0.8*INS0-42.79*Glucose120+0.321*INS120+5.338*BMI.	O

To	O
our	O
knowledge,	O
this	O
is	O
the	O
first	O
study	O
investigating	O
the	O
response	O
of	O
α	B
-hydroxybutyrate	I
concentrations	O
during	O
an	O
OGTT	O
in	O
youth.	O

We	O
observed	O
an	O
increase	O
in	O
serum	O
arginine	B
levels	O
of	O
EH	O
patients	O
compared	O
to	O
HC.	O

al.,	O
found	O
both	O
PM	O
extracts	O
from	O
a	O
roadside	O
monitor	O
and	O
a	O
simulated	O
metal	O
solution,	O
including	O
Al,	O
Fe,	O
and	O
Pb,	O
increased	O
IL-6	O
and	O
TNF-α	O
in	O
murine	B
bronchoalveolar	O
fluid	O
over	O
a	O
24-hour	O
period	O
with	O
returns	O
to	O
baseline	O
by	O
the	O
48-hr	O
measurement.	O

The	O
decrease	O
in	O
Krebs	O
cycle	O
intermediates	O
(such	O
as	O
succinate	B
and	O
citrate)	O
and	O
molecules	O
involved	O
in	O
energy	O
metabolism	O
(such	O
as	O
acetate)	B
in	O
IBD	O
patients	O
may	O
indicate	O
the	O
demand	O
and	O
rapid	O
utilization	O
of	O
metabolites	O
that	O
feed	O
energy	O
producing	O
pathways.	O

Trauma	O
patients	O
showed	O
relatively	O
lower	O
substrates	O
for	O
ribonucleic	O
acid	O
and	O
DNA	O
synthesis	O
(mean	O
[IQR],	O
adenylosuccinate	B
concentrations:	O
0.08	O
[0.04–0.12]	O
relative	O
units	O
fortrauma	O
patients	O
vs	O
0.15	O
[0.14–0.17]	O
relative	O
units	O
for	O
healthy	O
volunteers,	O
P	O
=	O
.02;	O
and	O
cytidine	B
concentrations:	O
1.44	O
[0.95–1.73]	O
relative	O
units	O
for	O
trauma	O
patients	O
vs	O
1.74	O
[1.62–1.98]	O
relative	O
units	O
for	O
healthy	O
volunteers,	O
P	O
=	O
.05;	O
).	O

The	O
energy	O
metabolites	O
that	O
are	O
detected	O
using	O
_31	O
P	O
MRS	O
include	O
nucleotide	O
triphosphates	B
(NTPs),	O
phosphocreatine	B
(PCr),	O
and	O
inorganic	O
phosphate	B
(Pi).	O

The	O
serum	O
metabolic	O
network	O
associated	O
with	O
those	O
who	O
developed	O
AP	B
has	O
fewer	O
connections	O
(green	O
lines)	O
than	O
the	O
serum	O
metabolic	O
network	O
associated	O
with	O
patients	O
who	O
did	O
not	O
develop	O
AP	B
(gray	O
lines).	O

Blocking	O
of	O
IP_3	O
R	O
by	O
XeC	O
as	O
well	O
as	O
siRNA	O
silencing	O
of	O
IP_3	O
R2	O
and	O
IP_3	O
R3	O
in	O
MCF-7	O
cells	O
and	O
MDA	O
MB-	O
231	O
resulted	O
in	O
significant	O
reduction	O
in	O
a	O
key	O
metabolic	O
process	O
such	O
as	O
%	O
glucose	B
uptake.	O

Notably,	O
three	O
patients	O
diagnosed	O
with	O
AP	B
voluntarily	O
chose	O
not	O
to	O
be	O
admitted	O
to	O
the	O
hospital;	O
one	O
patient	O
without	O
AP	B
was	O
admitted	O
to	O
the	O
hospital	O
because	O
of	O
pain.	O

Our	O
findings	O
have	O
some	O
similarity	O
with	O
the	O
recent	O
study	O
by	O
Langley	O
et	O
al	O
,	O
which	O
also	O
demonstrated	O
that	O
the	O
different	O
profiles	O
of	O
metabolites	O
clustered	O
into	O
fatty	O
acid	O
transport	O
and	O
β-oxidation,	O
gluconeogenesis	O
and	O
the	O
citric	B
acid	I
cycle.	O

The	O
visualized	O
S-plot	O
(Fig. )	O
and	O
the	O
variables	O
with	O
high	O
VIPs	O
indicated	O
33	O
metabolites,	O
including	O
increasing	O
levels	O
of	O
phenylacetylglycine,	B
2-oxoisoleucine,	B
threonate,	B
4-hydroxyproline,	B
gluconate,	B
glucose,	B
glycylproline,	B
3-hydroxyisovalerate,	B
2-aminoadipate,	B
glycerol,	B
glutamate,	B
tyrosine,	B
alanine,	B
3-hydroxyisobutyrate,	B
homocitrulline,	B
isoleucine,	B
hippurate,	B
urocanate,	B
thymidine,	B
inosine,	B
and	O
tiglylglycine	B
and	O
decreasing	O
levels	O
of	O
5-hydroxyindoleacetate,	B
valine,	B
phenylalanine,	B
citrulline,	B
histidine,	B
cysteine,	B
citrate,	B
ornithine,	B
taurine,	B
carnitine,	B
trimethylamine	B
n-oxide,	I
and	O
n-acetylcysteine.	B

Glycerophospholipids	B
are	O
further	O
differentiated	O
with	O
respect	O
to	O
the	O
presence	O
of	O
ester	O
(a)	O
and	O
ether	O
(e)	O
bonds	O
in	O
the	O
glycerol	B
moiety,	O
where	O
two	O
letters	O
(aa	O
=	O
diacyl,	O
ae	B
=	O
acyl-alkyl,	O
ee	O
=	O
dialkyl)	O
denote	O
that	O
two	O
glycerol	B
positions	O
are	O
bound	O
to	O
a	O
fatty	O
acid	O
residue,	O
while	O
a	O
single	O
letter	O
(a	O
=	O
acyl	O
or	O
e	O
=	O
alkyl)	O
indicates	O
the	O
presence	O
of	O
a	O
single	O
fatty	O
acid	O
residue.	O

This	O
is	O
achieved	O
by	O
augmenting	O
the	O
expression	O
and	O
activation	O
of	O
specific	O
transcription	O
factors	O
that	O
activate	O
the	O
synthesis	O
of	O
FA,	B
triglycerides	B
and	O
cholesterol,	B
causing	O
their	O
accumulation	O
in	O
the	O
liver.	O

Previous	O
studies	O
have	O
found	O
that	O
citrate	B
is	O
present	O
at	O
lower	O
concentrations	O
in	O
the	O
urine	O
of	O
inflammatory	O
bowel	O
disease	O
(IBD)	O
patients	O
compared	O
to	O
controls	O
[,	O
].	O

A	O
special	O
attention	O
has	O
been	O
paid	O
to	O
the	O
comparability	O
of	O
the	O
data:	O
the	O
same	O
year	O
of	O
inclusion	O
was	O
selected	O
for	O
all	O
the	O
women	O
to	O
consider	O
a	O
similar	O
likelihood	O
of	O
pesticide	O
exposure	O
according	O
to	O
the	O
agricultural	O
use,	O
and	O
to	O
avoid	O
the	O
potential	O
variability	O
induced	O
by	O
different	O
duration	B
of	O
storage	O
of	O
biological	O
samples	O
,	O
.	O

In	O
addition,	O
the	O
Krebs	O
cycle	O
intermediate	O
fumarate	B
demonstrates	O
markedly	O
depleted	O
levels	O
in	O
BCC	O
aggregates	O
probably	O
owing	O
to	O
the	O
increased	O
rate	O
of	O
cataplerosis	O
in	O
tumor.	O

[FDR	O
P	O
=0.116],	O
0.6-fold),	O
proline	B
(P	O
=0.021	O

We	O
measured	O
plasma	O
vitamin	B
D	I
metabolite	O
concentrations	O
for	O
all	O
non-pregnant	O
participants	O
with	O
available	O
frozen	O
samples	O
collected	O
at	O
or	O
near	O
the	O
end	O
of	O
the	O
DCCT	O
(N=1193).	O

Capillaries	O
are	O
a	O
main	O
effector	O
for	O
the	O
vasodilatative	O
action	O
of	O
insulin	O
and	O
the	O
degree	O
of	O
glucose	B
tolerance	O
is	O
positively	O
correlated	O
with	O
capillary	O
density	O
in	O
skeletal	O
muscle.	O

The	O
HMBC	O
correlations	O
of	O
each	O
of	O
the	O
CH_2	O
protons	O
of	O
this	O
terminal	O
oxirane	O
moiety	O
to	O
C-11	O
and	O
C-13	O
and	O
H-11	O
to	O
the	O
remaining	O
carbon	O
(C-12)	O
of	O
this	O
moiety	O
suggested	O
that	O
the	O
terminal	O
CH_2	O
of	O
the	O
spin	O
system	O
A	O
is	O
connected	O
to	O
the	O
CH	O
terminal	O
of	O
the	O
spin	O
system	O
C	O
via	O
C-12	O
generating	O
a	O
[9,3,1]	B
bicarbocyclic	I
ring	O
similar	O
to	O
that	O
of	O
verticillane-type	B
diterpenenoids.	I

There	O
was	O
also	O
no	O
significant	O
correlation	O
between	O
the	O
concentrations	O
of	O
the	O
α-TL	B
conjugates	O
and	O
the	O
HbA1c	O
levels	O
in	O
all	O
the	O
diabetic	O
patients.	O

Since	O
glutaminolysis	O
leads	O
to	O
an	O
activation	O
of	O
the	O
malate	B
aspartate	I
cycle,	O
greater	O
amounts	O
of	O
NADH	B
and	O
ATP	B
with	O
respect	O
to	O
the	O
control	O
were	O
recorded.	O

The	O
quantified	O
metabolites	O
were	O
put	O
into	O
biochemical	O
context	O
via	O
the	O
schematic	O
overview	O
of	O
tryptophan	B
metabolism	O
illustrated	O
in	O
Fig.	O

This	O
is	O
particularly	O
relevant	O
to	O
young	O
patients,	O
as	O
their	O
risk	O
to	O
discontinue	O
tamoxifen	B
is	O
among	O
the	O
highest_4	O
,	O
_10	O
with	O
tamoxifen	B
currently	O
being	O
the	O
sole	O
standard‐of‐care	O
treatment	O
in	O
this	O
patient	O
group.	O

The	O
m/z	O
feature	O
129.0661	O
was	O
identified	O
by	O
MS_2	O
as	O
glutamine.	B

Mass	O
chromatograms	O
of	O
methylpiperazine	B
(MPPZ)	O
derivatives	O
of	O
estrogens	O
and	O
their	O
metabolites	O
following	O
analysis	O
of	O
an	O
extracted	O
solution	O
of	O
Standards,	O
2000	O
pg	B
mL-1	O
.	O

Urine	O
concentrations	O
are	O
not	O
creatinine	B
normalized.	O

Despite	O
the	O
amount	O
of	O
labeled	O
NAD_+	O
increasing	O
by	O
almost	O
100%	O
in	O
the	O
iRBC	O
during	O
development,	O
only	O
a	O
small	O
fraction	O
of	O
this	O
pool	O
is	O
phosphorylated	O
to	O
generate	O
labeled	O
NADP_+	O
,	O
with	O
only	O
7%	O
containing	O
any	O
labeled	O
ribose.	B

Taurine	B
has	O
also	O
been	O
found	O
at	O
altered	O
levels	O
in	O
the	O
plasma	O
of	O
depressed	O
patients,	O
at	O
increased	O
concentrations	O
in	O
some	O
cases,	O
and	O
at	O
lower	O
concentrations	O
compared	O
with	O
controls	O
in	O
others.	O

Based	O
on	O
a	O
set	O
of	O
51	O
detectable	O
urinary	O
cis-diol	B
metabolites	O
in	O
the	O
applied	O
sample	O
volume	O
of	O
1	O
mL	O
urine,	O
we	O
first	O
attempted	O
to	O
define	O
a	O
valid	O
metabolic	O
profile.	O

Increases	O
were	O
detected	O
in	O
cholate,	B
glycocholate,	B
taurocholate,	B
chenodeoxycholate,	B
taurochenodeoxycholate,	B
ursodeoxycholate,	B
hyodeoxycholate,	B
deoxycholate,	B
taurodeoxycholate	B
glycodeoxycholate,	I
glycochenodeoxycholate,	B
7-ketodeoxycholate,	B
glycochenodeoxycholate,	B
glycolithocholate	B
sulfate,	I
and	O
taurolithocholate	B
3-sulfate.	I

The	O
Sigma-Aldrich	O
oligosaccharides	B
kit	O
was	O
prepared	O
in	O
acetonitrile:water	O
(1:1,	O
v/v).	O

Another	O
collateral	O
effect	O
observed	O
by	O
these	O
authors	O
was	O
the	O
biosynthesis	O
of	O
phosphatidylcholine	B
and	O
diacylglycerol	B
by	O
epimastigotes,	O
as	O
well	O
as	O
the	O
activation	O
of	O
protein	O
kinase	O
C,	O
as	O
a	O
consequence	O
of	O
free	O
fatty	O
acid	O
accumulation	O
due	O
to	O
the	O
digestion	O
of	O
blood	O
phospholipids	B
by	O
an	O
intestinal	O
phospholipase.	O

The	O
cartridge	O
was	O
then	O
washed	O
with	O
the	O
following	O
solutions	O
(%	O
in	O
H_2	O
O):	O
1	O
mL	O
of	O
2%	O
NH_4	O
OH,	O
1	O
mL	O
MeOH,	B
1	O
mL	O
2%	O
HCOOH,	O
1	O
mL	O
30%	O
MeOH	B
and	O
2%	O
HCOOH,	O
1	O
mL	O
50%	O
MeOH	B
and	O
2%	O
HCOOH.	O

Notably,	O
an	O
abnormally	O
high	O
lactate	B
concentration	O
(approximately	O
4-fold	O
higher	O
than	O
control)	O
was	O
observed.	O

During	O
this	O
step,	O
the	O
first	O
carbon	O
atom	O
of	O
glucose	B
is	O
lost	O
as	O
CO_2	O
.	O

Percent	O
of	O
maximal	O
activation	O
of	O
cells	O
treated	O
with	O
10_−5	O
m	O
ATRA	O
alone	O
(left	O
most	O
bar	O
in	O
each	O
histogram)	O
or	O
co-treated	O
with	O
10_−5	O
m	O
ATRA	O
and	O
10_−5	O
m	O
of	O
the	O
β-apocarotenoids	B
resulting	O
from	O
cleavage	O
at	O
the	O
a,	O
b,	O
c,	O
or	O
d	O
sites	O
are	O
shown	O
in	O
a,	O
b,	O
c,	O
and	O
d,	O
respectively	O
(n	O
=	O
3	O
to	O
6);	O

1-	O
and	O
3-Methylhistidine	B
are	O
abundant	O
in	O
actin,	O
formed	O
by	O
post-translational	O
methylation,	O
and	O
are	O
considered	O
markers	O
of	O
myofibrillar	O
protein	O
degradation.	O

All	O
glucocorticoid	B
degradation	O
metabolites	O
were	O
higher	O
in	O
the	O
PCOS	O
group	O
than	O
in	O
controls.	O

Nonetheless,	O
we	O
cover	O
metabolites	O
from	O
multiple	O
classes,	O
including	O
amino	O
acids,	O
lipids	O
and	O
acylcarnitines,	B
all	O
of	O
which	O
are	O
involved	O
in	O
central	O
metabolic	O
processes.	O

DNA	O
samples	O
were	O
quantified	O
using	O
a	O
Qubit	O
3.0	O
Fluorometer.	B

[FDR	O
P	O
=0.160],	O
0.5-fold),	O
and	O
tyrosine	B
(P	O
=0.006	O

The	O
latter	O
study	O
reported	O
dose-specific	B
effects	O
of	O
a	O
longer	O
supplementation	O
phase	O
(one	O
menstrual	O
cycle	O
vs	O
.	O
5	O
days)	O
in	O
a	O
different	O
study	O
population,	O
treated	O
with	O
different	O
sources	O
of	O
isoflavones	B
(soy	O
supplements	O
vs	O
.	O
soymilk).	O

The	O
gradient	O
system	O
used	O
to	O
separate	O
the	O
phosphopeptides	B
was	O
the	O
following:	O

The	O
variation	O
of	O
the	O
anomeric	O
proton	O
δ_H	O
of	O
sucrose	B
in	O
QC	O
samples	O
was	O
calculated	O
for	O
this	O
study,	O
and	O
the	O
variation	O
obtained	O
was	O
2	O
×	O
10_–3	O
%,	O
Figure	O
D.	O

Derivatized	O
sterols	O
were	O
then	O
eluted	O
in	O
three	O
1-ml	O
portions	O
of	O
100%	O
methanol	B
(SPE2-Fr-1,	I
Fr-2,	I
and	O
Fr-3)	B
followed	O
by	O
1	O
ml	O
of	O
99.9%	O
ethanol	B
(SPE2-Fr-4).	I

An	O
increased	O
concentration	O
of	O
glycine	B
was	O
linked	O
to	O
neuroectodermal	O
tumors,	O
while	O
neurinomas,	O
glioblastomas	O
and	O
ependymomas	O
showed	O
a	O
high	O
peak	O
of	O
myo-inositol.	B

Other	O
significant	O
metabolites	O
included	O
guanosine,	B
xanthine	B
and	O
hypoxanthine.	B

The	O
methanol/chloroform	O
extract	O
was	O
mixed	O
(1:12,	O
v/v)	O
with	O
an	O
α-cyano-4-hydroxycinnamic	B
acid	I
solution	O
in	O
50 %	O
acetonitrile/0.1 %	O
TFA,	O
and	O
1 μL	O
of	O
the	O
mixture	O
was	O
spotted	O
on	O
the	O
MALDI	O
target	O
for	O
analysis.	O

Concentrations	O
for	O
glycine	B
and	O
total	O
homocysteine	B
are	O
in	O
micromolars	O
and	O
for	O
SAH	O
and	O
SAM	O
in	O
nanomolars.	O

In	O
addition,	O
although	O
there	O
were	O
no	O
significant	O
differences	O
in	O
serum	O
levels	O
of	O
creatinine	B
among	O
the	O
three	O
groups	O
(controls	O
vs	O
MSA,	O
p	O
=	O
0.472;	O
controls	O
vs	O
PSP,	O
p	O
=	O
0.625	O
by	O
Wilcoxon’s	O
test),	O
because	O
plasma	O
levels	O
of	O
SDMA	O
are	O
strongly	O
correlated	O
with	O
renal	O
function,	O
we	O
cannot	O
completely	O
exclude	O
the	O
possibility	O
that	O
renal	O
function	O
affected	O
SDMA	O
levels	O
in	O
the	O
current	O
study.	O

We	O
identified	O
significant	O
associations	O
between	O
SPs	O
and	O
obesity/T2DM	O
characteristics,	O
specifically,	O
those	O
of	O
hexosylceramides,	B
d16:1	B
SPs,	O
and	O
d18:2	B
SPs.	O

Comparison	O
of	O
free,	O
conjugated	O
and	O
total	O
urinary	O
NNAL	O
for	O
60	O
smokers:	O
(A)NNAL	O
(nM)	O
and	O
(B)	O
NNAL	O
pmol/mg	O
creatinine.	B

Phenylacetylglutamine,	B
a	O
normal	O
constituent	O
of	O
human	O
urine,	O
forms	O
in	O
the	O
liver	O
following	O
the	O
condensation	O
of	O
glutamine	B
with	O
phenylacetyl-CoA.	B

Boar	O
spermatozoa	O
have	O
been	O
found	O
to	O
be	O
sensitive	O
indicators	O
in	O
detecting	O
microbial	O
toxins	B
in	O
indoor	O
building	O
materials	O
(,	O
)	O
as	O
well	O
as	O
in	O
detecting	O
bacteria	O
producing	O
toxic	O
depsipeptides	O
in	O
indoor	O
environments	O
and	O
in	O
foods.	O

After	O
the	O
samples	O
had	O
passed	O
through	O
the	O
cartridges,	O
they	O
were	O
washed	O
with	O
6	O
mL	O
of	O
10%	O
methanol	B
and	O
eluted	O
with	O
6	O
mL	O
of	O
methanol	B
containing	O
0.0004%	O
w/v	O
BHT	O
into	O
a	O
glass	O
tube	O
that	O
had	O
10	O
μL	O
of	O
30%	O
glycerol	B
in	O
methanol.	B

Xylose	B
is	O
the	O
connection	O
unit	O
between	O
the	O
sugar	O
chain	O
and	O
serine	B
or	O
threonine	B
as	O
a	O
combined	O
form	O
in	O
vivo.	O

In	O
fact,	O
butanedioic	B
acid	I
(1),	O
5alpha,	O
8alpha-epidioxyergosta-6,	B
22-dien-3beta-ol	I
(2),	O
and,	O
22-dien-3beta,	B
5alpha,	O
6beta,	O
7alpha-tetraol	B
(3),	O
displaying	O
antimicrobial	O
activity	O
were	O
isolated	O
from	O
active	O
petroleum	O
extract	O
of	O
Fusarium	O
sp.	B

HCC-cirrhosis	O
was	O
characterized	O
by	O
increased	O
level	O
β-HB	B
(β-hydroxybutyrate)	I
(signal	O
1.18	O
ppm	O
with	O
p	O
(corr)	O
>	O
0.5	O
and	O
signal	O
1.19–1.20	O
ppm	O
with	O
p	O
(corr)	O
=	O
0.45),	O
Tyr	O
(tyrosine)	O
(signals	O
3.94–3.95	O
ppm,	O
6.88–6.91	O
ppm	O
with	O
p	O
(corr)	O
>	O
0.5	O
;	O
signal	O
7.17–7.18	O
ppm	O
with	O
p	O
(corr)	O
=	O
0.45),	O
Phe	O
(phenylalanine)	O
(signal	O
7.34–7.37	O
ppm	O
with	O
p	O
(corr)	O
>	O
0.5	O
;	O
signal	O
7.40–7.44	O
ppm	O
with	O
p	O
(corr)	O
=	O
0.45)	O
and	O
His	O
(histidine)	O
(signal	O
7.07–7.09	O
ppm	O
with	O
p	O
(corr)	O
>	O
0.5)	O
;	O
signal	O
7.91	O
ppm	O
with	O
p	O
(corr)	O
=	O
0.45)	O
(box	O
on	O
the	O
right	O
of	O
horizontal	O
axis).	O

The	O
samples	O
were	O
resuspended	O
in	O
8μL	O
of	O
methanol,	B
placed	O
in	O
duplicate	O
of	O
1μL	O
per	O
spot	O
on	O
MTP	O
384	O
plate	O
(Bruker	O
Daltonics,	O
Bremen,	O
Germany)	O
and	O
topped	O
with	O
1μL	O
of	O
2,5-dihydroxybenzoic	B
acid	I
(DHB)	O
and	O
4-hydroxycinnamic	B
acid	I
(CHCA),	O
both	O
at	O
the	O
concentration	O
of	O
7mg/ml,	O
0.01%	O
trifluoroacetic	B
acid	I
(TFA),	O
dissolved	O
in	O
70%	O
methanol	B
and	O
30%	O
water.	O

Moreover,	O
the	O
risk	O
of	O
hypothyroidism	O
was	O
higher	O
in	O
subjects	O
with	O
high	O
baseline	O
trigonelline	B
or	O
low	O
lactic	B
acid,	I
alanine	B
or	O
glycine	B
values.	O

These	O
events	O
suggested	O
fumaric	B
acid	I
may	O
play	O
a	O
role	O
in	O
tissue	O
oxidative	O
stress.	O

the	O
maximum	O
calculated	O
(MarvinSketch,	O
www.chemaxon.com)	O
logD	O
for	O
S	B
-[2-[(hydroxyethyl)thio]ethyl]Cys-Pro-Phe	I
(HETE-CPF)	O
is	O
−1.97	O
at	O
pH	O
5.5	O
versus	O
the	O
unmodified	O
CPF	O
at	O
logD	O
=	O
−1.94.	O

Acetic	B
acid	I
(≥99.7%)	O
and	O
all	O
the	O
standard	O
metabolites	O
(≥97%)	O
used	O
in	O
this	O
study	O
(see	O
)	O
were	O
purchased	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
MO).	O

For	O
instance,	O
the	O
higher	O
sensitivity	O
of	O
the	O
CHCl_3	O
:MeOH	O
extraction	O
is	O
noteworthy	O
in	O
analytes,	O
such	O
as	O
N1-AcSPM,	O
CAD,	O
or	O
N1,N8-DiAcSPD,	B
because	O
of	O
its	O
low	O
concentration	O
in	O
serum	O
samples.	O

Likewise,	O
the	O
expression	O
of	O
proteins	O
of	O
glycolysis	O
(GAPDH,	O
PK-M2	O
and	O
LDHA)	O
and	O
of	O
the	O
pentose	B
phosphate	I
pathway	O
(G6PDH)	O
was	O
not	O
affected.	O

Arginase	O
(also	O
present	O
in	O
the	O
brain)	O
is	O
an	O
enzyme	O
that	O
catalyzes	O
the	O
conversion	O
of	O
arginine	B
to	O
ornithine,	B
competing	O
with	O
eNOS	O

The	O
commercial	O
standard	O
mixture	O
consisted	O
of	O
50	O
μM	O
carboxymethylcysteine,	B
10	O
μM	O
nicotinic	B
acid,	I
8	O
μM	O
adenosine,	B
80	O
μM	O
benzoic	B
acid,	I
100	O
μM	O
N-benzoyltyrosine,	B
20	O
μM	O
glutaric	B
acid,	I
20	O
μM	O
glucose-cysteine,	B
20	O
μM	O
leucine,	B
phenylalanine,	B
20	O
μM	O
pantothenic	B
acid	I
and	O
20	O
μM	O
methyl-2-aminobenzoic	B
acid,	I
in	O
water.	O

An	O
essential	O
amino	O
acid	O
is	O
valine	B
that	O
must	O
be	O
ingested.	O

Tryptophan	B
and	O
kynurenine	B
metabolite	O
concentrations	O
were	O
significantly	O
decreased	O
one	O
year	O
after	O
bariatric	O
surgery	O
and	O
were	O
correlated	O
with	O
the	O
decrease	O
of	O
the	O
usCRP	O
in	O
both	O
groups.	O

Thus,	O
eicosapentaenoic	B
acid	I
(C20:5)	O
and	O
5-HEPE	B
may	O
become	O
a	O
potent	O
biomarker	O
for	O
prediction	O
LC	O
development.	O

 ),	O
we	O
observed	O
that	O
the	O
HIV-TB	O
cohort	O
exhibited	O
not	O
only	O
higher	O
DHEA	O
plasma	O
levels,	O
but	O
also	O
higher	O
AET	O
and	O
7-oxo-DHEA	B
concentrations	O
compared	O
with	O
HD.	O

Participants	O
from	O
the	O
SATIN	B
study	O
were	O
community-dwelling	O
adults	O
recruited	O
in	O
Spain	O
and	O
Denmark	O
from	O
2015	O
to	O
2016.	O

These	O
indicate	O
that	O
there	O
were	O
differences	O
in	O
both	O
the	O
fatty	O
acid	O
and	O
purine	B
metabolism	O
pathways	O
in	O
children	O
and	O
adolescent	O
with	O
DN-MDD	O
compared	O
with	O
HCs.	O

A	O
unique	O
α-helix	B
comprising	O
residues	O
from	O
10	O
to	O
21	O
resulted	O
from	O
SA,	O
then	O
MD	O
revealed	O
an	O
additional	O
helical	O
round	O
up	O
to	O
the	O
24th	O
position	O
in	O
80%	O
of	O
the	O
frames.	O

At	O
the	O
time	O
of	O
extraction,	O
spent	O
medium	O
was	O
collected	O
and	O
cells	O
were	O
rapidly	O
washed	O
twice	O
with	O
cold	O
phosphate	B
buffered	O
saline	B
to	O
remove	O
contaminating	O
medium.	O

Urate	B
also	O
showed	O
non-significant	O
elevation	O
in	O
BE	O
versus	O
GERD	O
(P=0.12),	O
while	O
homocysteine	B
was	O
similarly	O
non-significantly	O
elevated	O
in	O
HGD/EA	O
versus	O
BE	O
(P=0.17).	O

Homocysteine	B
is	O
an	O
intermediary	O
metabolite	O
in	O
methionine/cysteine	O
metabolism.	O

We	O
observed	O
that	O
DHA,	O
DPA,	O
UA	O
and	O
9,10-EOA	B
were	O
associated	O
with	O
autism.	O

Distribution	O
of	O
specific	O
gravity-adjusted	O
urinary	O
phthalate	B
metabolite	O
and	O
isoprostane	B
concentrations	O
(ng/mL)	O
and	O
sperm	O
mtDNAcn	O
and	O
mtDNAdel	O
levels	O
(n	O
=	O
99).	O

The	O
breast	O
metastasis	O
also	O
produced	O
glycine	B
from	O
glucose	B
(,	O
multiplet	O
#7).	O

Of	O
them,	O
most	O
of	O
the	O
fatty	O
acids	O
and	O
metabolomics	O
profiling	O
of	O
phospholipid	B
biosynthesis	O
increased	O
significantly.	O

Compared	O
with	O
control	O
subjects,	O
the	O
RA	O
cohort	O
had	O
significantly	O
lower	O
levels	O
of	O
l-arginine	B
(43.2	O
vs.	O
71.7 μmol/L,	O
p	O
 < 0.001)	O

Upon	O
collection,	O
the	O
CSF	O
was	O
immediately	O
frozen	O
in	O
1	O
ml	O
polypropylene	B
tubes	O
to	O
−80°C	O
as	O
described	O
.	O

Leucine	B
enkephalin	I
was	O
used	O
as	O
the	O
lock	O
mass	O
(m/z	O
556.2771	O
in	O
ES+	O
mode	O
and	O
554.2615	O
in	O
ES-	O
mode)	O
at	O
a	O
concentration	O
of	O
100	O
ng/ml	O
and	O
flow	O
rate	O
of	O
0.2	O
ml/min	O
for	O
all	O
analyses.	O

Chromatograms	O
of	O
urine	O
extracts	O
containing	O
NNAL,	O
NNAL	O
acetate,	B
and	O
NNAL	O
hexanoate.	B

The	O
key	O
step	O
of	O
tryptophan	B
degradation	O
is	O
catalyzed	O
by	O
an	O
enzyme	O
called	O
indoleamin	O
2,3-dioxygenase	O
1	O
(IDO1).	O

On	O
the	O
other	O
hand,	O
the	O
mean	O
levels	O
of	O
the	O
rest	O
of	O
oxysterols	B
we	O
analyzed	O
are	O
comparable	O
to	O
other	O
published	O
data	O
in	O
humans.	O

Triterpene	B
1	O
was	O
cytotoxic	O
against	O
human	O
colon	O
carcinoma	O
116	O
with	O
an	O
IC_50	O
value	O
of	O
28.7	O
but	O
did	O
not	O
exhibit	O
cytotoxicity	O
against	O
A549.	O

In	O
addition,	O
the	O
decreased	O
acetone	B
urinary	O
levels	O
found	O
suggest	O
the	O
inhibition	O
of	O
ketogenesis,	O
consistent	O
with	O
the	O
reported	O
preferential	O
use	O
of	O
acetyl	O
coenzyme	O
A	O
(acetyl-CoA)	O
by	O
cancer	O
cells	O
as	O
precursor	O
of	O
lipids/cholesterol/isoprenoids	O
over	O
the	O
ketogenic	O
pathway.	O

The	O
reaction	O
products	O
with	O
ISCl	O
were	O
separated	O
using	O
an	O
Ascentis	O
C18	O
column	O
with	O
0.1%	O
formic	B
acid	I
in	O
water	O
and	O
0.1%	O
formic	B
acid	I
in	O
acetonitrile	B
as	O
mobile	O
phase,	O
similar	O
to	O
the	O
chromatographic	O
conditions	O
of	O
dansyl	O
derivatives.	O

The	O
HPLC	O
mobile	O
phases	O
consisted	O
of	O
water-:formic	O
acid	O
(100:0.1,	O
v/v)	O
(A)	O
and	O
acetonitrile-:tetrahydrofuran-:formic	B
acid	I
(50:50:0.1,	O
v/v/v)	O
(B).	O

PSG	O
=	O
polysomnography;	O
REM	O
=	O
rapid	O
eye	O
movement;	O
TRP	O
=	O
tryptophan;	B
5-HTP	O
=	O
5-hydroxytryptophan;	B
KYN	O
=	O
kynurenine;	B
KYNA	O
=	O
kynurenate;	B
3-HKYN	O
=	O
3-hydroxykynurenine.	B

Glutamate	B
is	O
derives	O
from	O
2-oxoglutarate	B
by	O
transamination	O
or	O
reductive	O
amination	O
(Glu	O
dehydrogenase)	O
in	O
mammalian	O
cells.	O

Glycine	B
is	O
an	O
essential	O
amino	O
acid	O
required	O
by	O
proliferating	O
cancer	O
cells	O
for	O
energetic	O
purposes	O
and	O
performs	O
a	O
similar	O
function	O
as	O
serine	B
in	O
sustaining	O
the	O
one-carbon	O
metabolic	O
pathway	O
which	O
supplies	O
precursors	O
for	O
the	O
biosynthesis	O
of	O
biomolecules	O
essential	O
for	O
cancer	O
cell	O
growth.	O

The	O
HP	B
fractogram	O
shown	O
in	O
exhibits	O
a	O
large	O
peak	O
with	O
several	O
smaller	O
peaks	O
(at	O
~10	O
and	O
19	O
minutes)	O
on	O
the	O
tailing	O
edge.	O

ROC	O
curves	O
for	O
the	O
combination	O
of	O
3-hydroxyphenylacetic	B
acid	I
and	O
3-methyl-3-hydroxybutyric	B
acid.	I

The	O
final	O
volume	O
of	O
filtrate	O
ranged	O
from	O
100	O
to	O
400	O
μL.	O
Samples	O
were	O
brought	O
to	O
650	O
μL	O
by	O
addition	O
of	O
D_2	O
O,	O
130	O
μL	O
of	O
sodium	B
phosphate	I
buffer	O
(final	O
concentration	O
0.1	O
M)	O
containing	O
dimethyl-silapentane-sulfonate	B
(final	O
concentration	O
0.5	O
mM)	O
for	O
NMR	O
chemical	O
shift	O
reference	O
and	O
concentration	O
calibration,	O
and	O
10	O
μL	O
of	O
1	O
M	O
sodium	O
azide	O
to	O
prevent	O
growth	O
of	O
bacteria.	O

For	O
LLE,	O
separate	O
experiments	O
for	O
1α,25(OH)_2	B
D_3	O
and	O
25(OH)D_3	O
standard	O
spikes	O
were	O
performed,	O
while	O
for	O
SPE,	O
serum	O
was	O
spiked	O
with	O
a	O
mixture	O
of	O
24R	O
,25(OH)_2	O
D_3	B
,	I
1α,25(OH)_2	I
D_3	O
,	O
25(OH)D_2	O
and	O
25(OH)D_3	O
.	O

However,	O
a	O
negative	O
impact	O
of	O
Phe	O
on	O
cholesterol,	B
LDL-cholesterol,	B
VLDL-cholesterol	B
(except	O
HDL-cholesterol)	B
and	O
their	O
subclasses	O
indicate	O
a	O
key	O
role	O
of	O
elevated	O
Phe	O
on	O
the	O
lipoprotein	O
profile	O
with	O
great	O
similarities	O
to	O
that	O
seen	O
in	O
patients	O
with	O
high	O
cholesterol	B
using	O
statins.	B

papaya	O
L.	O
(including	O
fruit	O
skins	O
and	O
seeds)	O
was	O
extracted	O
in	O
the	O
Philippines	B
and	O
exported	O
to	O
Japan	O
where	O
it	O
was	O
fermented	O
for	O
approximately	O
one	O
year	O
with	O
E	O
.	O
faecalis	O
,	O
followed	O
by	O
approximately	O
six	O
months	O
with	O
A	O
.	O
oryzae	O
,	O
and	O
then	O
dried.	O

Six	O
metabolites	O
were	O
detected	O
in	O
both	O
HILIC-MS	O
and	O
_1	O
H-NMR	O
to	O
be	O
significantly	O
different	O
between	O
civilian	O
and	O
veteran	O
sarcoidosis	O
subjects:	O
arginine,	B
glutamine,	B
creatinine,	B
glycine,	B
taurine,	B
and	O
methionine.	B

Quattro	O
Micro	O
triple	O
quadrupole	O
mass	O
spectrometer	O
by	O
using	O
electrospray	O
ionization	O
(ESI)	O
in	O
positive	O
ion	O
(PI)	O
and	O
negative	O
ion	O
(NI)	O
mode,	O
with	O
an	O
ESI-MS	O
capillary	O
voltage	O
of	O
3.0	O
kV,	B
an	O
extractor	O
cone	O
voltage	O
of	O
2	O
V,	O
and	O
a	O
detector	O
voltage	O
of	O
650	O
V.	O
Desolvation	O
gas	O
flow	O
was	O
maintained	O
at	O
600	O
l/h.	O
Cone	O
gas	O
flow	O
was	O
set	O
at	O
60	O
l/h.	O
Desolvation	O
temperature	O
and	O
source	O
temperature	O
were	O
set	O
to	O
200	O
and	O
100°C,	O
respectively.	O

The	O
following	O
criteria	O
was	O
used	O
to	O
diagnose	O
diabetes:	O
early-morning	O
fasting	O
plasma	O
glucose	B
(PG)	O
≥	O
126	O
mg/dl,	O
two-hour	O
PG	B
after	O
75	O
g	O
glucose	B
load	O
≥	O
200	O
mg/dl,	O
or	O
causal	O
plasma	O
glucose	B
load	O
≥	O
200	O
mg/dl.	O

The	O
ratio	O
of	O
all	O
estrogen	B
metabolites	O
to	O
parent	O
estrogen	B
was	O
directly	O
associated	O
with	O
the	O
order	O
Clostridiales	O
(r	O
=	O
0.32,	O
P	O
=	O
.02)	O
and,	O
among	O
the	O
Clostridiales	O
,	O
with	O
the	O
family	O
Ruminococcaceae	O
(r	O
=	O
0.37,	O
P	O
=	O
.005).	O

ER	O
together	O
with	O
PgR	O
immunohistochemical	O
analysis	O
was	O
performed	O
on	O
4	O
mm	O
section	O
of	O
each	O
paraffin	B
block	O
from	O
biopsy	O
or	O
tumor	O
tissues	O
adequately	O
stained	O
with	O
haematoxylin-eosin.	B

The	O
results	O
suggest	O
that	O
a	O
new	O
generation	O
of	O
stationary	O
phases,	O
specifically	O
designed	O
for	O
improved	O
robustness	O
in	O
mixed	O
CO_2	B
-methanol	I
mobile	O
phases,	O
can	O
improve	O
peak	O
shape,	O
peak	O
capacity	O
and	O
resolution	O
for	O
all	O
classes	O
of	O
polar	O
analytes.	O

The	O
mass	O
spectral	O
data	O
demonstrate	O
that	O
bond	O
formation	O
adduct	O
occurred	O
between	O
the	O
4-HO	O
group	O
of	O
tyrosine	B
and	O
the	O
C-2	O
imidazole	B
atom	O
of	O
PhIP.	O

=	O
not	O
significant;	O
OHC	O
=	O
hydroxycholesterol,;	B
WBC_CSF	O
=	O
number	O
of	O
white	O
blood	O
cells	O
in	O
the	O
CSF.	O

Glucose	B
concentration	O
assessed	O
just	O
before	O
the	O
meal	O
was	O
5.5	O
±	O
0.1	O
mmol/L	O
and	O
rose	O
to	O
7.7	O
±	O
0.4	O
mmol/	O

The	O
spectra	O
were	O
binned	O
into	O
0.005	O
ppm	O
buckets	O
between	O
0.5–10	O
ppm	O
and	O
mean	O
centered	O
for	O
multivariate	O
analysis	O
and	O
normalized	O
to	O
total	O
aliphatic	B
spectral	O
area	O
(0.5–4.4	O
ppm)	O
to	O
eliminate	O
differences	O
in	O
metabolite	O
total	O
concentration.	O

Results	O
from	O
four	O
urine	O
specimens	O
collected	O
after	O
individuals	O
reportedly	O
self-administered	O
either	O
JWH-018	O
or	O
a	O
mixture	O
of	O
JWH-018	O
and	O
JWH-073	O
showed	O
the	O
following:	O
1)	O
all	O
tested	O
metabolites	O
were	O
excreted	O
in	O
high	O
concentrations,	O
2)	O
(ω)-	B
and	O
(ω-1)-hydroxyl	O
metabolites	O
were	O
exclusively	O
excreted	O
as	O
glucuronic	B
acid	I
conjugates,	O
and	O
3)	O
approximately	O
5–80%	O
of	O
the	O
(ω)-carboxyl	O
metabolites	O
were	O
excreted	O
as	O
glucuronic	B
acid	I
conjugates.	O

Homocysteine	B
induces	O
inflammatory	O
cytokine	O
production	O
in	O
cultured	O
human	O
cells,	O
and	O
has	O
been	O
mechanistically	O
linked	O
to	O
inflammatory	O
bowel	O
disease	O
(IBD)	O
and	O
atherosclerosis	O
(,	O
).	O

Treating	O
SK-Mel	O
23	O
melanoma	O
cells	O
with	O
E_2	O
has	O
been	O
shown	O
to	O
inhibit	O
their	O
growth,	O
while	O
pre-treating	O
the	O
cells	O
with	O
tamoxifen	B
(an	O
anti-estrogen)	O
blocks	O
the	O
effects	O
of	O
E_2	O
.	O

The	O
rest	O
of	O
the	O
ceramide	B
species	O
were	O
not	O
significantly	O
different	O
between	O
the	O
AD	O
and	O
control	O
groups.	O

In	O
brief,	O
frozen	O
tissues,	O
saliva,	O
plasma,	O
or	O
cell	O
lysate	O
pellets	O
were	O
homogenized	O
in	O
methanol	B
after	O
spiking	O
with	O
labeled	O
internal	O
standards	O
(d	O
_5	B
-glutamic	I
acid	I
and	O
d	O
_4	B
-glutamine)	I
and	O
extracted	O
overnight	O
at	O
4	O
°C,	O
with	O
constant	O
shaking.	O

(B)	O
Schematic	O
illustration	O
of	O
oxidation	O
of	O
lysyl	O
residues	O
to	O
2-aminoadipic	B
acid	I
under	O
oxidized	O
conditions.	O

After	O
60	O
min,	O
the	O
amounts	O
of	O
NTPs	O
in	O
16HBE14o_−	O
cells	O
declined	O
even	O
further	O
to	O
18%	O
for	O
ATP,	B
6%	O
for	O
UTP,	O
10%	O
for	O
CTP	B
and	O
46%	O
for	O
GTP	O
and	O
remained	O
at	O
these	O
levels	O
up	O
to	O
120	O
min.	O

_,	O
As	O
mitochondrial	O
dysfunction	O
has	O
been	O
implicated	O
in	O
MS	O
pathogenesis,	O
it	O
is	O
of	O
interest	O
to	O
note	O
the	O
higher	O
formate	B
levels	O
in	O
patients	O
with	O
MS.	O

(B)	O
Discriminators	O
with	O
glycerolipid	B
metabolism	O
and	O
the	O
fatty	O
acids	O
included	O
in	O
the	O
discrimination	O
between	O
NRAT	O
and	O
RAT.	O
_*	O
:	O
p	O
<	O
0.05,	O
_**	O
:	O
p	O
<	O
0.01.	O

Serum	O
albumin,	O
total	O
cholesterol,	B
LDL,	O
LysoPCs,	O
glycerophosphocholine,	B
ornithine,	B
glucuronic	B
acid,	I
glycerophosphoserine	B
and	O
taurocholic	B
acid	I
were	O
correlated	O
with	O
the	O
Child-Pugh	O
score	O
(P	O
<0.01).	O

The	O
solutions	O
were	O
then	O
made	O
up	O
to	O
550	O
μL	O
with	O
the	O
phosphate	B
buffer	O
in	O
D_2	O
O	O
and	O
transferred	O
to	O
5	O
mm	O
NMR	O
tubes.	O

The	O
most	O
interesting	O
finding	O
to	O
emerge	O
from	O
the	O
fatty	O
acid	O
profiling	O
of	O
HCC	O
and	O
control	O
plasma	O
was	O
the	O
highly	O
statistically	O
significant	O
quenching	O
of	O
the	O
two	O
VLCFAs	O
lignoceric	B
acid	I
(24:0)	O
and	O
nervonic	B
acid	I
(24:1).	O

Additional	O
file	O
3),	O
since	O
metformin	B
is	O
known	O
to	O
exert	O
anti-inflammatory	O
action.	O

It	O
is	O
therefore	O
highly	O
likely	O
that	O
11KT	O
is	O
a	O
major	O
player	O
in	O
PCOS-related	O
androgen	O
excess,	O
especially	O
given	O
that	O
11KT	O
can	O
activate	O
the	O
androgen	O
receptor	O
in	O
a	O
similar	O
manner	O
to	O
T,	O
and	O
can	O
be	O
converted	O
to	O
the	O
even	O
more	O
potent	O
androgen	O
11-ketodihydrotestosterone	B
in	O
peripheral	O
target	O
tissue.	O

Cells	O
were	O
cultured	O
in	O
Dulbecco’s	O
modified	O
Eagle’s	O
medium	O
(DMEM),	O
containing	O
10%	O
fetal	O
bovine	O
serum	O
(FBS,	O
Invitrogen),	O
1%	O
penicillin/streptomycin,	O
and	O
1%	O
L-glutamine	B
(Sigma,	O
St.	O
Louis,	O
MO)	O
in	O
a	O
37 °C	O
humidified	O
incubator	O
with	O
5%	O
CO_2	O
.	O

However,	O
no	O
significant	O
differences	O
in	O
creatinine	B
and	O
urea	B
levels	O
were	O
observed	O
between	O
the	O
non-survivor	O
and	O
survivor	O
groups.	O

They	O
were	O
freshly	O
prepared	O
and	O
used	O
for	O
calibration	O
curves	O
after	O
the	O
removal	O
of	O
cholesterol	B
from	O
the	O
serum	O
and	O
CSF.	O

The	O
protein	O
was	O
loaded	O
into	O
Leadit	O
2.1.2,	O
and	O
the	O
receptor	O
components	O
were	O
chosen	O
by	O
selection	O
of	O
chain	O
A	O
as	O
a	O
main	O
chain,	O
which	O
is	O
complexed	O
with	O
arachidonic	B
acid.	I

PC = phosphatidylcholine.	B

In	O
fact,	O
the	O
absence	O
of	O
a	O
change	O
in	O
non-esterified	O
cholesterol	B
levels	O
in	O
CSF	O
in	O
all	O
disease	O
groups,	O
except	O
those	O
with	O
PBI	O
or	O
ALS,	O
highlights	O
its	O
tight	O
regulation	O
in	O
CNS.	O

Spermine	B
has	O
been	O
described	O
as	O
a	O
decapacitation	O
factor	O
for	O
sperm	O
that	O
ensures	O
the	O
proper	O
timing	O
of	O
the	O
acrosome	O
reaction	O
and	O
capacitation.	O

For	O
both	O
studies,	O
aliquots	O
of	O
human	O
plasma	O
were	O
deproteinated	O
with	O
methanol,	B
dried,	O
methoxymated,	O
trimethylsilylated,	O
and	O
run	O
on	O
a	O
6890N	O
GC/5975	O
Inert	O
MS	O
(Agilent	O
Technologies,	O
Santa	O
Clara,	O
CA,	O
USA).	O

The	O
elevated	O
expression	O
of	O
GSH,	B
glutathione	B
peroxidase	O
and	O
glutatione	B
reductase	O
were	O
reported	O
in	O
the	O
tissues	O
of	O
oral	O
squamous	O
cell	O
carcinoma_,	O
	O
and	O
other	O
various	O
human	O
cancer	O
such	O
as	O
colorectal,	O
breast,	O
ovarian	O
and	O
brain	O
tumor.	O

In	O
contrast	O
to	O
suppression	O
of	O
PC	O
expression	O
in	O
pancreatic	O
beta	O
cells,	O
in	O
which	O
the	O
knockdown	O
cells	O
showed	O
a	O
metabolic	O
crossover	O
point	O
with	O
increased	O
levels	O
of	O
pyruvate	B
and	O
low	O
levels	O
of	O
malate	B
and	O
citrate,	B
suppression	O
of	O
PC	O
in	O
MDA-MB-231	O
cell	O
lines	O
showed	O
lowered	O
levels	O
of	O
pyruvate	B
and	O
lactate	B
when	O
cells	O
were	O
maintained	O
in	O
the	O
presence	O
of	O
a	O
high	O
concentration	O
of	O
glucose	B
(25	O
mM)	O
(in	O
DMEM	O
cell	O
culture	O
medium)	O
prior	O
to	O
the	O
experiment.	O

Associations	O
between	O
phthalate	B
metabolites	O
and	O
their	O
sums	O
were	O
performed	O
using	O
Pearson	O
correlation	O
coefficients.	O

A	O
weak,	O
but	O
significant,	O
correlation	O
was	O
observed	O
between	O
TMAO	B
and	O
hsCRP	O
(Rho	O
=	O
0.17;	O
p	O
=	O
0.022),	O
but	O
not	O
for	O
choline	B
or	O
betaine.	B

GABA	B
can	O
modulate	O
the	O
immune	O
response	O
via	O
secretion	O
of	O
cytokines,	O
activation,	O
proliferation	O
and	O
migration	O
of	O
immune	O
cells.	O

Mozier	O
et	O
al.	O
detected	O
TMS	O
in	O
the	O
urine	O
of	O
rats	O
treated	O
with	O
250 μmol/kg	O
of	O
dimethylsulfide	B
and	O
[methyl	O
-_3	I
H]	O
methionine,	B
but	O
the	O
endogenous	O
levels	O
of	O
TMS	O
in	O
animals	O
and	O
whether	O
it	O
is	O
significantly	O
produced	O
without	O
administration	O
of	O
the	O
parent	O
thioether	B
is	O
not	O
known.	O

Inadequate	O
vitamin	O
B-12	O
availability	O
results	O
in	O
a	O
reduced	O
remethylation	O
potential	O
of	O
homocysteine,	B
thereby	O
limiting	O
methionine	B
pools	O
and	O
redirection	O
of	O
homocysteine	B
into	O
the	O
transsulfuration	O
pathway,	O
a	O
source	O
of	O
free	B
cysteine	I
for	O
glutathione	B
synthesis	O
(1).	O

daytime	O
DBP	B
(p=0.0051,	O
p=8.62×10_−6	O
,	O
p=0.0057),	O
respectively.	O

L	O
DTT	O
as	O
a	O
stabilizing	O
medium	O
for	O
TPN	O
in	O
RBC	O
lysates}	O
demonstrated	O
the	O
suitability	O
of	O
such	O
protocol	O
for	O
a	O
well-defined	O
and	O
reliable	O
routine	O
use	O
in	O
studies	O
on	O
thiopurines	B
TDM.	O

The	O
most	O
recent	O
published	O
assay	O
of	O
Alyamani	O
et	O
a.l	O
use	O
liquid-liquid	O
extraction	O
as	O
sample	O
preparation	O
method	O
with	O
D_4	B
-abiraterone	I
as	O
an	O
internal	O
standard().	O

Adjusted	O
hazard	O
ratios	O
and	O
corresponding	O
95%	O
confidence	O
intervals	O
were	O
generated	O
for	O
each	O
category	O
of	O
vitamin	B
D	I
metabolite,	O
and	O
P	O
values	O
were	O
generated	O
evaluating	O
each	O
vitamin	B
D	I
metabolite	O
as	O
a	O
continuous	O
variable.	O

A	O
1:10	O
ratio	O
of	O
internal	O
standard	O
(2,2-dimethyl-2-silapentane-5-sulfonate)	O
and	O
urine	O
was	O
buffered	O
to	O
pH	O
6.7–6.8,	O
and	O
then	O
placed	O
in	O
a	O
Wilmad	O
528-pp	O
4-inch	O
nuclear	O
magnetic	O
resonance	O
tube	O
(Wilmad,	O
Buena,	O
NJ).	O

These	O
pathways	O
contain	O
testosterone	B
sulfate	I
and	O
dehydroepiandrosterone	B
sulfate.	I

Moreover,	O
in	O
MESA,	O
LPIR	O
was	O
associated	O
with	O
T2D	O
largely	O
independent	O
of	O
glucose,	B
insulin,	O
and	O
Homeostasis	O
Model	O
Assessment	O
–	O
Insulin	O
Resistance,	O
which	O
reinforces	O
the	O
LPIR	O
unique	O
risk	O
information.	O

This	O
substantiates	O
the	O
previous	O
discussion	O
that	O
mannose	B
may	O
be	O
a	O
pivotal	O
player	O
for	O
the	O
prediction	O
of	O
mortality	O
following	O
AMI	O
and	O
of	O
CVD	O
in	O
general.	O

Some	O
of	O
the	O
changes	O
in	O
mitochondrial	O
metabolites	O
could	O
be	O
attributed	O
to	O
thiamin,	B
given	O
that	O
this	O
vitamin	O
is	O
a	O
cofactor	O
for	O
1	O
)	O
α-ketoglutarate	O
dehydrogenase	O
in	O
the	O
Krebs	O
cycle,	O
which	O
catalyses	O
the	O
formation	O
of	O
succinyl-CoA;	B
and	O
2	O
)	O
the	O
branched-chain	O
α-ketoacid	O
dehydrogenase	O
complex,	O
which	O
catalyzes	O
the	O
formation	O
of	O
branched-chain	O
acyl-CoA.	B

Recently,	O
urine	O
metabolic	O
profiling	O
of	O
NSCLC	O
patients	O
revealed	O
significant	O
alterations	O
of	O
carnitine	B
and	O
11	O
acylcarnitines	B
(Wu	O
et	O
al.	O
).	O

On	O
the	O
morning	O
of	O
study	O
day	O
2,	O
fasting	O
plasma	O
samples	O
were	O
collected	O
by	O
drawing	O
blood	O
into	O
9	O
mL	O
ethylenediaminetetraacetic	B
acid	I
(EDTA)	O
plasma	O
tubes	O
(S-Monovette,	O
Sarstedt,	O
Nümbrecht,	O
Germany)	O
from	O
an	O
antecubital	O
vein.	O

We	O
used	O
reporter	O
gene	O
assays	O
to	O
show	O
that	O
none	O
of	O
the	O
β-apocarotenoids	B
significantly	O
activated	B
RARs.	O

The	O
quantifications	O
were	O
performed	O
with	O
the	O
transitions	O
of	O
m/z	O
436.3	O
→	O
285.2	O
for	O
SMV,	O
m/z	O
437.2	O
→	O
303.2	O
for	O
SMV-A,	O
m/z	O
559.2	O
→	O
440.3	O
for	O
ATV,	O
m/z	O
575.4	O
→	O
440.3	O
for	O
2-OH-ATV	B
and	O
4-OH-ATV,	B
m/z	O
482.3	O
→	O
258.1	O
for	O
RSV,	O
and	O
m/z	O
412.3	O
→	O
224.2	O
for	O
fluvastatin	B
(IS).	O

No	O
other	O
statistically	O
significant	O
associations	O
were	O
found	O
between	O
mtDNAcn	O
and	O
urinary	O
phthalate	B
metabolite	O
or	O
isoprostane	B
concentrations.	O

The	O
Liposcale	O
analysis	O
showed	O
that	O
mothers	O
of	O
SGA	O
fetuses	O
had	O
significantly	O
lower	O
concentrations	O
of	O
cholesterol-IDL	B
compared	O
to	O
controls	O
(p = 0.02).	O

Plasma	O
lipids	O
specific	O
to	O
obesity‐related	O
insulin	O
resistance	O
(i.e.,	O
different	O
between	O
OIS	O
and	O
OIR,	O
but	O
not	O
between	O
OIR	O
and	O
Lean)	O
included	O
DG(14:1_16:0),	B
CE(22:4)	B
and	O
PC(O‐35:4)	B
(higher)	O
and	O
Hex2Cer(d18:1/22:0),	O
Hex2Cer(d18:1/24:0)	O
and	O
LPC(22:0)	B
(lower).	O

The	O
expected	O
changes	O
included	O
decreased	O
free	O
cholesterol	B
in	O
individuals	O
selected	O
from	O
both	O
the	O
full	O
range	O
of	O
LDL-C	O
response	O
and	O
those	O
selected	O
from	O
the	O
10%	O
tail	O
of	O
good	O
responders,	O
but	O
not	O
from	O
the	O
poor	O
response	O
tail.	O

Although	O
the	O
BMI	O
of	O
each	O
group	O
was	O
non-significantly	O
different	O
(HCC = 25.9 kg/m_2	O
and	O
cirrhosis = 27.25 kg/m_2	O
,	O
P	O
 = 0.23)	O
it	O
may	O
be	O
that	O
the	O
slight	O
difference	O
in	O
weight	O
is	O
due	O
to	O
reduced	O
muscle	O
mass	O
in	O
HCC	O
patients,	O
which	O
is	O
reflected	O
in	O
lower	O
urinary	O
creatinine	B
levels.	O

The	O
ACE	O
Excel	O
Super	O
C18	O
with	O
its	O
unique	O
encapsulated	O
bonding	O
technology	O
and	O
ACE	O
Excel	O
C18-AR	O
with	O
its	O
integrated	O
phenyl	O
capacity	O
chosen	O
for	O
added	O
selectivity	O
for	O
aromatic	O
compounds	O
still	O
did	O
not	O
resolve	O
the	O
methoxyestrogen	B
metabolites.	O

Kynurenic	O
acid/tryptophan	O
ratio	O
(KYNA/T)	O
and	O
expression	O
of	O
indolamine	O
2,3-dioxygenase	O
1	O
(IDO1),	O
tryptophan	O
2,3-dioxygenase,	O
kynurinase,	O
and	O
kynurenine	O
monooxygenase	O
correlated	O
positively	O
with	O
endoscopic	O
subscore.	O

(a–c)	O
Regions	O
of	O
800	O
MHz	O
_1	O
H	O
NMR	O
spectra	O
of	O
different	O
sample	O
portions	O
from	O
the	O
same	O
pool	O
of	O
human	O
serum	O
obtained	O
under	O
virtually	O
identical	O
conditions	O
after	O
protein	O
precipitation	O
using	O
methanol	B
(1:2	O
v/v).	O

The	O
association	O
remained	O
significant	O
even	O
after	O
adjusting	O
for	O
multiple	O
clinical	O
covariates	O
and	O
T2DM	O
risk	O
factors,	O
including	O
fasting	O
glucose.	B

Finally,	O
considering	O
the	O
21	O
VOCs	O
signature	O
of	O
RCC	O
patients,	O
no	O
correlations	O
were	O
found	O
for	O
α‐methylstyrene,	B
2‐carene,	O
retinol	B
acetate,	I
DHEA‐S	O
and	O
VOC_6	O
.	O

The	O
spectral	O
regions	O
containing	O
water	O
and	O
urea	B
resonances	O
(δ	O
4.5	O
–	O
6.4)	O
were	O
eliminated	O
to	O
remove	O
variation	O
in	O
water	O
suppression	O
and	O
in	O
the	O
integral	O
of	O
the	O
urea	B
signal	O
due	O
to	O
partial	O
cross-saturation	O
with	O
water	O
via	O
deuterium	O
solvent	O
exchangeable	O
protons.	O

Serum	O
levels	O
of	O
alanine	O
aminotransferase	O
(ALT),	O
aspartate	O
aminotransferase	O
(AST),	O
bilirubin	B
(total	O
and	O
direct),	O
albumin,	O
alkaline	O
phosphatase,	O
gamma-glutamyl	O
transferase	O
(GGT),	O
blood	O
urea	B
nitrogen	I
(BUN)	O
and	O
creatinine	B
were	O
assessed.	O

Glutamine,	B
increased	O
in	O
patients	O
with	O
lcSSc,	O
is	O
a	O
relevant	O
energy	O
substrate	O
for	O
cells	O
of	O
the	O
immune	O
system,	O
playing	O
an	O
important	O
role	O
in	O
their	O
function	O
and	O
homeostasis.	O

The	O
assay	O
method	O
may	O
be	O
the	O
source	O
of	O
variations	O
in	O
oxysterols	B
between	O
the	O
studies,	O
e.g.,	O
the	O
observed	O
median	O
of	O
27-hydroxycholesterol	B
was	O
between	O
55.6–58.7	O
ng/ml	O
in	O
the	O
previous	O
study	O
and	O
27.9–31.7	O
in	O
the	O
present	O
one.	O

For	O
example,	O
DESI-MSI	O
of	O
testicular	O
cancers	O
revealed	O
that	O
lipids	O
from	O
a	O
specific	O
class	O
exclusive	O
to	O
germ	O
line	O
cells,	O
the	O
seminolipids	O
[seminolipid	O
(16:0/16:0)	O
and	O
semino-lipid	B
(30:0)],	I
were	O
present	O
in	O
normal	O
tubule	O
testis	O
tissue	O
while	O
undetectable	O
in	O
seminoma	O
tissue.	O

For	O
smokers,	O
detection	O
frequencies	O
were	O
97%	O
for	O
1-OH-PYR,	B
53%	O
for	O
4-OH-PHE,	B
and	O
100%	O
for	O
the	O
rest	O
of	O
analytes.	O

In	O
addition,	O
especially,	O
depletion	O
of	O
docosahexaenoic	B
acid	I
(C22:6)	O
may	O
influence	O
on	O
homeostasis	O
of	O
liver	O
tissue,	O
likely	O
fibrosis	O
progression.	O

We	O
previously	O
developed	O
a	O
unique	O
methodology	O
based	O
on	O
the	O
use	O
of	O
[pyridine-D_4	O
]	O

Adenosine	B
and	O
formate	B
were	O
not	O
detected	O
after	O
MeOH:CHCl_3	O
ppt.	O

Another	O
important	O
observation	O
was	O
the	O
decrease	O
in	O
glutamine	B
levels,	O
revealing	O
an	O
alteration	O
in	O
glutaminolysis,	O
a	O
process	O
that	O
occurs	O
at	O
high	O
rates	O
in	O
immune	O
system	O
cells.	O

Therefore,	O
reducing	O
C16-carnitine	B
concentration	O
may	O
be	O
a	O
novel	O
approach	O
to	O
cancer	O
therapy.	O

The	O
protein	O
is	O
transported	O
to	O
the	O
Golgi	O
apparatus,	O
and	O
the	O
glycans	B
are	O
modified	O
in	O
multiple	O
steps.	O

Two	O
solid	O
core	O
C18	O
columns	O
(Phenomenex	O
Kinetex	O
C18,	O
150	O
×	O
4.6	O
mm)	O
in	O
series	O
were	O
used	O
to	O
achieve	O
chromatographic	O
separation	O
of	O
the	O
F2-isoprostane	B
isomers.	I

In	O
cases	O
of	O
contradictory	O
results	O
i.e.	O
SUV_max	O
 ≥ 2.5	O
and	O
relative	O
glutamate	B
level > 0.31	O
or	O
SUV_max	O
 < 2.5	O
and	O
relative	O
glutamate	B
level ≤ 0.31,	O
19%	O
of	O
the	O
cancer	O
diagnoses	O
are	O
missed.	O

In	O
conclusion,	O
AF	B
patients	O
showed	O
discernible	O
lipid	O
profiles	O
compared	O
to	O
healthy	O
controls:	O
levels	O
of	O
SFA	O
were	O
elevated,	O
while	O
PUFA	O
levels	O
were	O
decreased	O
in	O
plasma	O
from	O
AF	B
patients.	O

For	O
our	O
primary	O
outcome	O
of	O
T2DM,	O
we	O
selected	O
multi-marker	O
panels	O
constructed	O
from	O
significant	O
metabolites	O
in	O
CSF	O
and	O
plasma	O
with	O
the	O
highest	O
AUC	O
value	O
for	O
correlation	O
with	O
the	O
presence	O
of	O
T2DM	O
and	O
compared	O
to	O
CSF	O
glucose,	B
plasma	O
glucose,	B
plasma	O
HbA1c,	O
and	O
HOMA-IR.	O

Our	O
cohort	O
of	O
smokers	O
with	O
HNSCC	O
demonstrates	O
higher	O
levels	O
of	O
TSNA-derived	O
oral	O
DNA	O
damage	O
in	O
the	O
setting	O
of	O
similar	O
exposure	O
to	O
nicotine	B
and	O
tobacco	O
carcinogens.	O

polyamines,	B
diabetes,	O
insulin,	O
HbA1c,	O
case-control	O

()	O
[_2	B
H_2	I
]Formaldehyde	I
(20%	O
w/w	O
aqueous	O
solution;	O
1.5	O
mL)	O
was	O
added	O
to	O
indole	B
(1.17	O
mg,	O
0.01	O
mol)	O
suspended	O
in	O
a	O
mixture	O
of	O
glacial	B
acetic	I
acid	I
(0.6	O
g,	O
0.01	O
mol)	O
in	O
2.5	O
mL	O
of	O
D_2	O
O.	O
The	O
mixture	O
was	O
vigorously	O
stirred	O
under	O
nitrogen	O
at	O
90°C	O
for	O
5	O
h,	O
cooled,	O
and	O
purified	O
using	O
the	O
HPLC	O
system	O
below.	O

However,	O
it	O
has	O
two	O
major	O
disadvantages;	O
first,	O
it	O
is	O
only	O
a	O
singlet,	O
and	O
thus	O
assignment	O
can	O
be	O
ambiguous,	O
but	O
second,	O
and	O
more	O
importantly,	O
the	O
chemical	O
shift	O
of	O
dimethylsulfone	B
is	O
in	O
a	O
region	O
of	O
the	O
NMR	O
spectrum	O
where	O
there	O
are	O
many	O
other	O
di-	O
and	O
trimethyl	O
signals	O
that	O
may	O
confound	O
this	O
metabolite	O
identification.	O

4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone	B
(NNK),	O
a	O
carcinogenic	O
nitrosamine	B
produced	O
upon	O
curing	O
tobacco,	O
is	O
present	O
at	O
relatively	O
high	O
concentrations	O
in	O
tobacco	O
smoke.	O

They	O
described	O
that	O
the	O
late	O
TCA	O
intermediates	O
fumarate	B
and	O
malate	B
were	O
reduced	O
in	O
IDH	O
mutant-expressing	O
cells.	O

β-Thalassemia	O
is	O
a	O
common	O
congenital	O
haematological	O
disorder	O
which	O
is	O
characterized	O
by	O
dysregulation	O
in	O
the	O
synthesis	O
of	O
the	O
β-globin	B
chain,	O
one	O
of	O
the	O
major	O
constituents	O
of	O
adult	O
haemoglobin	O
(HbA).	O

This	O
result	O
proved	O
that	O
surrogate	O
serum	O
was	O
equivalent	O
to	O
real	O
human	O
serum	O
in	O
this	O
LC–MS/MS	O
analysis	O
of	O
D-mannose.	B

These	O
metabolites	O
are	O
also	O
correlated	O
with	O
AST	O
levels	O
in	O
AP	B
patients	O
only.	O

Sphingolipid	B
related	O
transcripts	O
in	O
the	O
PBMCs,	O
ceramide	B
lipids	O
in	O
the	O
plasma	O
as	O
well	O
as	O
l-serine	B
from	O
the	O
plasma	O
are	O
displayed	O
on	O
the	O
sphingolipid	B
metabolic	O
pathway.	O

However,	O
the	O
mechanism	O
about	O
vitamin	B
K2	I
antitumor	O
is	O
still	O
disputed,	O
it	O
may	O
act	O
by	O
involving	O
in	O
mitochondrial	O
electron	O
signal	O
transmission,	O
affecting	O
the	O
Bcl-2	O
protein,	O
inducing	O
cell	O
apoptosis	O
of	O
caspase	O
family,	O
adjusting	O
the	O
G1	O
phase-relevant	O
molecular	O
expression	O
of	O
cell	O
cycle,	O
etc.	O

After	O
removing	O
from	O
the	O
−	O
80	O
°C	O
freezer,	O
50	O
μL	O
of	O
the	O
IS	O
working	O
solution	O
and	O
20	O
μL	O
of	O
methanol	B
were	O
added	O
to	O
all	O
samples.	O

Although	O
BRB	O
anthocyanins	B
are	O
structurally	O
distinct	O
from	O
chlorhexidine	B
gluconate,	I
the	O
post-rinse	O
data,	O
which	O
show	O
sustained	O
salivary	O
levels	O
of	O
anthocyanins,	B
suggest	O
that	O
BRB	O
anthocyanins	B
may	O
also	O
be	O
adsorbed	O
to	O
oral	O
tissues	O
and/or	O
oral	O
microflora	O
present	O
in	O
plaque.	O

(A)	O
Glycerophospholipid	B
metabolism.	O

Finally,	O
our	O
study	O
provides	O
the	O
most	O
comprehensive	O
analysis	O
on	O
the	O
effects	O
of	O
exercise	O
on	O
estrogen	B
metabolism	O
to	O
date.	O

Lipid	O
analysis	O
was	O
performed	O
by	O
liquid	O
chromatography	O
mass	O
spectrometry	O
in	O
24	O
overweight	O
and	O
obese	O
adults:	O
13	O
were	O
randomly	O
assigned	O
to	O
2 g	O
carnosine	B
daily	O
and	O
11	O
to	O
placebo,	O
and	O
treated	O
for	O
12	O
weeks.	O

The	O
metabolites	O
with	O
significance	O
were	O
creatine,	B
glycine,	B
serine,	B
and	O
trimethylamine	B
N-oxide.	I

[Google	O
Scholar]	O
Patrono	O
C,	O
Ciabattoni	O
G,	O
Remuzzi	O
G,	O
Gotti	O
E,	O
Bombardieri	O
S,	O
Di	O
Munno	O
O,	O
Tartarelli	O
G,	O
Cinotti	O
GA,	O
Simonetti	O
BM,	O
Pierucci	O
A.	O
Functional	O
significance	O
of	O
renal	O
prostacyclin	B
and	O
thromboxane	B
A2	I
production	O
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus.	O

Finally,	O
CoQ_10	O
,	O
which	O
is	O
a	O
key	O
component	O
of	O
the	O
mitochondrial	O
electron	O
transport	O
chain	O
that	O
generates	O
ATP	B
by	O
aerobic	O
respiration	O
and	O
also	O
a	O
component	O
of	O
serum	O
lipoproteins	O
,	O
was	O
40%	O
reduced	O
in	O
AML	O
plasma	O

In	O
addition,	O
smaller	O
capillary–venous	O
differences	O
were	O
observed	O
for	O
extended‐release	O
and	O
long‐acting	O
intramuscular	O
formulations	O
and	O
for	O
aripiprazole,	B
a	O
drug	O
with	O
a	O
long	O
half‐life,	O
compared	O
with	O
drugs	O
administered	O
as	O
an	O
immediate‐release	O
formulation	O
(risperidone,	O
olanzapine).	B

Following	O
the	O
recommendations	O
of	O
Pechlivanis	O
et	O
al.,	O
the	O
spectral	O
regions	O
of	O
histidine,	B
1-metylhistidine,	B
and	O
3-methylhistidine	B
(δ	O
=	O
8.17–7.87,	O
δ	O
=	O
7.15–7.01,	O
and	O
δ	O
=	O
3.77–3.71	O
ppm,	O
respectively)	O
were	O
also	O
removed	O
because	O
of	O
the	O
sensitivity	O
to	O
small	O
pH	O
differences	O
among	O
urine	O
samples.	O

At	O
this	O
point,	O
it	O
is	O
not	O
clear	O
whether	O
humans	O
can	O
demethylate	B
JWH-018	O
to	O
produce	O
JWH-073	O
and	O
the	O
corresponding	O
oxidized	O
metabolites	O
or	O
whether	O
the	O
subjects	O
studied	O
had	O
a	O
non-reported,	O
prior	O
exposure	O
to	O
JWH-073.	O

The	O
supernatant	O
was	O
dissolved	O
in	O
20%	O
aqueous	O
methanol	B
containing	O
caffeine	B
for	O
ultraperformance	O
liquid	O
chromatography-quadrupole	O
time-of-flight	O
mass	O
spectrometry	O
(UPLC-Q-TOF-MS)	O
analysis.	O

Sarcosine	B
was	O
further	O
validated	O
as	O
a	O
potential	O
biomarker	O
for	O
early	O
disease	O
detection	O
and	O
as	O
a	O
predictor	O
of	O
aggressiveness	O
because	O
it	O
was	O
undetectable	O
in	O
any	O
benign	O
tissue	O
samples.	O

Significant	O
changes	O
of	O
bacterial	O
genera	O
mainly	O
in	O
the	O
metastats-based	O
comparison	O
of	O
Control-iUC	B
groups.	O

We	O
determined	O
that	O
the	O
analysis	O
of	O
circulating	O
xanthine,	B
hypoxanthine	B
and	O
D-Mannose	B
levels	O
has	O
the	O
potential	O
to	O
distinguish	O
patients	O
with	O
PLP	O
and	O
CRC	O
from	O
those	O
without	O
cancer.	O

Although	O
the	O
serum	O
lactate	B
level	O
of	O
both	O
EAR	O
and	O
ADV	O
patients	O
is	O
normally	O
higher	O
than	O
in	O
control	O
subjects	O
(data	O
not	O
shown),	O
ADV	O
patients	O
had	O
lower	O
serum	O
lactate	B
than	O
EAR	O
patients,	O
when	O
compared	O
to	O
each	O
other.	O

In	O
the	O
urine,	O
metabolites	O
related	O
to	O
saturated	O
FAs,	O
pentoses,	O
Indoles,	O
amino	O
acids	O
(basic,	O
cyclic,	O
acidic	O
and	O
basic),	O
purines	B
malates,	I
disaccharides,	B
dicarboxylic	B
acids,	I
hexuronic	O
acids,	O
hexoses,	O
phenylacetate	B
and	O
citrates	O
were	O
associated	O
with	O
higher	O
death.	O

The	O
following	O
MS	O
parameters	O
were	O
used:	O
capillary	O
voltage	O
0.8	O
kV,	B
source	O
block	O
temperature	O
150	O
°C,	O
probe	O
temperature	O
600	O
°C,	O
cone	O
voltage	O
15–30	O
V.	O
A	O
computer	O
with	O
the	O
MassLynx	O
software	O
(Waters,	O
Prague,	O
Czech	O
Republic)	O
was	O
used	O
for	O
the	O
acquisition	O
and	O
processing	O
of	O
data	O
from	O
the	O
LC-MS	O
apparatus.	O

However,	O
clinical	O
trials	O
regarding	O
glutamine	B
supplementation	O
and	O
reduced	O
mortality	O
have	O
yielded	O
seemingly	O
inconsistent	O
results.	O

Thus,	O
we	O
suggest	O
that	O
SPE	O
is	O
the	O
preferred	O
technique	O
for	O
samples	O
in	O
clinical	O
settings	O
where	O
precise	O
measurements	O
of	O
1α,25(OH)_2	B
D_2	I
,	I
1α,25(OH)_2	I
D_3	O
,	O
25(OH)D_2	O
and	O
25(OH)D_3	O
are	O
critical.	O

NMN	O
is	O
metabolites	O
of	O
nicotinic	B
acid	I
and	O
nicotinamide	B
in	O
mammals	O
.	O

Correlations	O
between	O
α	B
-hydroxybutyrate	I
AUC	O
and	O
plasma	O
concentration	O
at	O
fasting,	O
90	O
minutes,	O
and	O
120	O
minutes	O
during	O
an	O
OGTT	O
at	O
study	O
onset	O
and	O
Change	O
of	O
(a)	O
DI	O
and	O
(b)	O
2-hour	O
glucose	B
tolerance	O
after	O
2.3	O
±	O
0.6	O
years	O
of	O
follow-up	O
in	O
adolescent	O
subjects	O
(n	O
=	O
16).	O

In	O
this	O
study,	O
sarcosine	B
was	O
measured	O
by	O
gas	O
chromatography–mass	O
spectrometry	O
and	O
sarcosine	B
values	O
were	O
normalized	O
to	O
urine	O
creatinine.	B

The	O
higher	O
level	O
of	O
citrate	B
in	O
the	O
plasma	O
samples	O
of	O
the	O
subjects	O
in	O
the	O
state	O
of	O
psychological	O
suboptimal	O
health	O
is	O
indicative	O
of	O
TCA	O
cycle	O
dysfunction.	O

Glimepiride	O
is	O
a	O
widely	O
used	O
antihyperglycemic	B
agent	O
to	O
treat	O
patients	O
with	O
T2DM.	O

Our	O
aims	O
were	O
as	O
follows:	O
1)	O
to	O
identify	O
metabolic	O
signatures	O
that	O
could	O
distinguish	O
patients	O
with	O
PDR	O
from	O
those	O
with	O
long	O
duration	B
but	O
without	O
DR,	O
and	O
2)	O
to	O
identify	O
the	O
metabolic	O
pathways	O
that	O
respond	O
to	O
DR.	O

The	O
ratios	O
of	O
2-hydroxyestrone	B
to	O
16α-hydroxyestrone	B
(2-OHE_1	O
/16α-OHE_1	B
)	O
and	O
2-OHE_1	O
to	O
4-hydroxyestrone	B
(2-	O
OHE_1	O
/4-OHE_1	O
)	O
were	O
also	O
calculated.	O

Since	O
this	O
IR72	O
is	O
not	O
increased	O
in	O
case	O
of	O
inflammation,	O
we	O
assign	O
the	O
increase	O
of	O
IR89	O
in	O
case	O
of	O
inflammation	O
to	O
an	O
increase	O
in	O
glutamate.	B

GDM,	O
gestational	O
diabetes	O
mellitus;	O
TMAO,	B
trimethylamine-N	B
-oxide.	I
_2	O
Tests	O
for	O
linear	O
trend	O
were	O
conducted	O
by	O
using	O
the	O
median	O
value	O
for	O
each	O
quartile	O
and	O
treating	O
it	O
as	O
a	O
continuous	O
variable	O
in	O
the	O
conditional	O
logistic	O
regression.	O

Thus,	O
because	O
cows	O
do	O
not	O
have	O
very	O
many	O
active	O
sweat	O
glands,	O
we	O
speculate	O
that	O
a	O
greater	O
portion	O
of	O
urea	B
may	O
be	O
lost	O
in	O
the	O
sweat	O
of	O
goats	O
when	O
compared	O
to	O
cows.	O

Insulin	O
resistance	O
not	O
only	O
increases	O
uric	B
acid	I
synthesis	O
and	O
reduces	O
the	O
renal	O
excretion	O
of	O
uric	B
acid	I
but	O
also	O
promotes	O
lipolysis	O
of	O
peripheral	O
adipose	O
tissue	O
and	O
increases	O
free	O
fatty	O
acid	O
influx	O
into	O
the	O
liver,	O
leading	O
to	O
NAFLD	O

The	O
surplus	O
of	O
lipids	O
due	O
to	O
hyperlipidemia	O
correlates	O
with	O
an	O
excess	O
of	O
ketone	B
bodies	O
(acetoacetate	O
and	O
acetone),	O
which	O
are	O
the	O
end-products	O
of	O
lipid	O
metabolism	O
in	O
the	O
blood.	O

Of	O
these	O
metabolites,	O
changes	O
in	O
cholesterol	B
levels	O
were	O
most	O
remarkable.	O

PC	B
aa	I
C40:3;	I
49.	O

The	O
insulin	O
sensitivity	O
indices	O
of	O
obese	O
children	O
with	O
liver	O
disease	O
are	O
marked	O
by	O
higher	O
postprandial	O
glucose	B
and	O
insulin,	O
higher	O
insulin/glucose	O
ratio	O
and	O
higher	O
HOMA-IR	O
than	O
those	O
with	O
no	O
liver	O
disease.	O

Briefly,	O
layers	O
of	O
the	O
two-phase	O
mixture	O
of	O
chloroform	B
and	O
methanol	B
were	O
transferred	O
to	O
individual	O
tubes.	O

The	O
loadings	O
for	O
the	O
predicted	O
component	O
indicates	O
a	O
higher	O
intensity	O
of	O
beta-hydroxybutyrate	B
and	O
lipids	O
at	O
220	O
min	O
and	O
a	O
higher	O
intensity	O
of	O
alanine,	B
branched	O
amino	O
acids,	O
creatine,	B
glucose,	B
glutamate/glutamine,	O
histidine	B
and	O
tyrosine	B
at	O
70	O
min	O
after	O
resistance	O
exercise	O
((b)).	O

On	O
the	O
other	O
hand,	O
the	O
EVs	O
had	O
higher	O
lysoglycerophospholipid	B
(LPCs,	O
LPCes,	O
and	O
LPEs)	O
content	O
than	O
LDL/VLVL	O
and	O
HDL,	O
as	O
seen	O
in	O
C.	O
Moreover,	O
the	O
levels	O
of	O
PCe,	O
PE,	O
PEe	O
were	O
lower	O
in	O
the	O
EVs	O
than	O
the	O
lipoproteins.	O

Multifly	O
needle	O
sets	O
and	O
polypropylene	B
serum	O
monovettes	O
with	O
clotting	O
activators	O
were	O
also	O
obtained	O
from	O
Sarstedt.	O

C	O
and	O
D	O
,	O
Upon	O
adding	O
the	O
labeled	O
glucose	B
or	O
glutamine	B
to	O
the	O
culture	O
media,	O
the	O
metabolites	O
were	O
extracted	O
and	O
analyzed	O
by	O
LC-MS/MS	O
spectroscopy.	O

2-Aminobutyric	B
acid	I
(2-ABA)	O
and	O
3-HBA	O
were	O
also	O
significant	O
for	O
the	O
six-month	O
correlations,	O
but	O
not	O
for	O
correlations	O
with	O
HOMA-IR	O
at	O
baseline.	O

B12,	O
vitamin	O
B-12;	O
cB12,	O
combined	O
indicator	O
of	O
vitamin	O
B-12	O
status;	O
holoTC,	O
holotranscobalamin;	O
MMA,	O
methylmalonic	B
acid;	I
post,	O
after;	O
pre,	O
before;	O
tHcy,	O
total	O
plasma	O
homocysteine.	B

This	O
hypothesis	O
is	O
supported	O
here	O
by	O
the	O
identification	O
in	O
CSF	O
of	O
7α-hydroxy-3-oxochol-4-en-24-oic	B
acid,	I
an	O
immediate	O
precursor	O
of	O
chenodeoxycholic	B
acid,	I
and	O
the	O
partial	O
identification	O
of	O
7α,x	B
-dihydroxy-3-oxocholest-4-en-26-oic	I
and	O
7α-hydroxy-3,x	B
-bisoxocholest-4-en-26-oic	I
acids,	I
and	O
7α-hydroxy-26-norcholest-4-ene-3,x	B
-dione	I
(26-nor-C_4	I
-7α-ol-3,x	I
-dione),	I
where	O
x	O
may	O
be	O
position	O
24,	O
i.e.	O
giving	O
7α,24-dihydroxy-3-oxocholest-4-en-26-oic	B
acid,	I
7α-hydroxy-3,24-bisoxocholest-4-en-26-oic	B
acid,	I
and	O
7α-hydroxy-26-norcholest-4-ene-3,24-dione.	B

A	O
significant	O
increase	O
of	O
fully	O
labeled	O
erythritol	B
was	O
observed	O
after	O
120	O
min	O
compared	O
with	O
the	O
time	O
point	O
before	O
adding	O
the	O
[U_13	B
C]glucose	I
tracer	O
(−5	O
min).	O

Area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
(AUC)	O
logistic	O
regression	O
approach	O
identified	O
kynurenine	B
(AUC = 0.859),	O
dCTP	O
(AUC	O

This	O
observation	O
indicated	O
that	O
H.	O
pylori	O
eradication	O
may	O
affect	O
the	O
biosynthesis	O
of	O
NAD	B
in	O
nicotinate	B
and	O
nicotinamide	B
metabolism	O
and	O
hence,	O
it	O
corroborated	O
with	O
our	O
previous	O
finding	O
that	O
H.	O
pylori	O
eradication	O
may	O
affect	O
the	O
regulation	O
of	O
energy	O
metabolism	O
in	O
the	O
human	O
body	O
(Yap	O
et	O
al.,	O
).	O

Interestingly,	O
NMR	O
detects	O
20	O
compounds	O
that	O
GC-MS	O
methods	O
cannot	O
detect	O
while	O
GC-MS	O
detects	O
45	O
compounds	O
that	O
NMR	O
cannot	O
routinely	O
detect,	O
including	O
3	O
very	O
high	O
abundance	O
compounds	O
(phosphoric	O
acid/phosphate,	I
uric	B
acid	I
and	O
N-acetyl-glycine).	B

Incubations	O
were	O
performed	O
with	O
0.5	O
mg	O
ml_−1	O
microsomal	O
protein	O
and	O
500	O
µm	O
anastrozole	B
for	O
90	O
min	O
at	O
37°C.	O

Within	O
the	O
first	O
24 h	O
after	O
inclusion,	O
plasma	O
samples	O
were	O
taken	O
to	O
measure	O
lArg,	O
hArg,	O
and	O
ADMA.	B

The	O
residue	O
was	O
reconstituted	O
with	O
580 μl	O
of	O
D_2	O
O	O
containing	O
30 μM	O
phosphate	B
buffer	O
solution	O
(PBS,	O
pH = 7.4)	O
and	O
0.01 mg/ml	O
sodium	B
(3-trimethylsilyl)-2,	I
2,	I
3,	I
3-tetradeuteriopropionate	I
(TSP)	O
as	O
a	O
chemical	O
shift	O
reference	O
(δ0.0).	O

Experiments	O
were	O
performed	O
on	O
the	O
cells	O
between	O
passages	O
30	O
and	O
40,	O
during	O
which	O
proximal	O
tubule	O
characteristics,	O
such	O
as	O
albumin	O
uptake	O
and	O
phosphate	B
reabsorption,	O
were	O
maintained	O
.	O

Despite	O
the	O
certain	O
technical	O
limitations	O
of	O
our	O
analytical	O
approach,	O
we	O
identified	O
potential	O
differentiating	O
metabolites	O
of	O
ARDS	O
as	O
evidenced	O
by	O
the	O
over	O
four-fold	O
increase	O
in	O
L-lactate	B
and	O
changes	O
in	O
other	O
metabolites	O
associated	O
with	O
energy	O
metabolism	O
(e.g.,	O
citrate,	B
creatine,	B
creatinine).	O

Although	O
diet	O
restriction	O
is	O
a	O
considerably	O
less	O
dramatic	O
weight	O
loss	O
situation	O
than	O
RYGB,	O
the	O
authors	O
found	O
that	O
diet-induced	O
weight	O
loss	O
led	O
to	O
decreases	O
in	O
triglycerides	B
and	O
phospholipids,	B
but	O
no	O
changes	O
to	O
lysophosphatidylcholine	B
(LPC)	O
and	O
sphingolipid	B
species	O
.	O

It	O
has	O
been	O
confirmed	O
in	O
relevant	O
reports	O
that	O
lack	O
of	O
leucine	B
can	O
promote	O
the	O
metabolism	O
of	O
peripheral	O
fats	O
and	O
energy.	O

 ),	O
for	O
the	O
synthesis	O
of	O
triglycerides.	B

Glucose	B
(_13	O
C)	O
and	O
glutamine	B
(_13	O
C,	O
_15	O
N)	O
tracers	O
have	O
been	O
used	O
extensively	O
to	O
demonstrate	O
the	O
importance	O
of	O
central	O
carbon	O
metabolism	O
in	O
meeting	O
the	O
bioenergetic	O
demands	O
of	O
tumors_,	O
.	O

A	O
significant	O
inter-patient	O
variability	O
in	O
metabolite	O
plasma	O
levels	O
was	O
observed,	O
especially	O
for	O
hydroxy-dabrafenib	B
as	O
seen	O
in	O
Table	O
.	O

Moreover,	O
as	O
summarized	O
by	O
Pudenz	O
et	O
al	O
.,	O
in	O
vitro	O
data	O
suggests	O
an	O
impact	O
of	O
soy	O
isoflavones	B
on	O
GSTP1,	O
SCGB3A1	O
(HIN-1),	O
TERT,	O
BRCA1,	O
BRCA2,	O
ATM,	O
APC,	O
PTEN	O
and	O
SERPINB5	O
promoter	O
methylation	O
and	O
BRCA1	O
(exon	O
1)	O
and	O
BRCA2	O
(exon	O
2)	O
exon	O
methylation	O
in	O
breast	O
(cancer)	O
cells.	O

Urinary	O
levels	O
of	O
N-acetyl-S-phenyl-L-cysteine	B
(SPMA)	O
(metabolite	O
of	O
benzene),	B
N-acetyl-S-(2-hydroxy-1/2-phenylethyl)-L-cysteine	B
(PHEMA)	O
(metabolite	B
of	I
styrene),	I
N-acetyl-S-(2-cyanoethyl)-L-cysteine	I
(CEMA)	I
(metabolite	I
of	I
acrylonitrile),	I
N-acetyl-S-[1-(hydroxymethyl)-2-propen-1-yl)-L-cysteine	I
and	O
N-acetyl-S-(2-hydroxy-3-buten-1-yl)-L-cysteine	B
(MHBMA)	O
(metabolites	O
of	O
1,3-butadiene)	B
were	O
2–10	O
fold	O
higher	O
in	O
workers	O
than	O
in	O
controls	O
(p	O
<	O
0.05).	O

Nonetheless,	O
it	O
demonstrated	O
a	O
pattern	O
of	O
results	O
consistent	O
with	O
a	O
relative	O
decrease	O
in	O
levels	O
of	O
2-hydroxylation	O
pathway	O
metabolites	O
and	O
in	O
the	O
ratio	O
of	O
these	O
to	O
total	O
parent	O
estrogens	O
and	O
to	O
16-hydroxylation	O
pathway	O
metabolites	O
in	O
the	O
prenatally	O
DES	B
exposed	O
compared	O
with	O
unexposed	O
women.	O

The	O
prognostic	O
value	O
of	O
elevated	O
plasma	O
levels	O
of	O
TMAO	B
for	O
cardiovascular	O
risk	O
remained	O
significant	O
in	O
various	O
subgroups	O
associated	O
with	O
a	O
reduced	O
overall	O
risk	O
of	O
major	O
adverse	O
cardiovascular	O
events.	O

There	O
are	O
several	O
qualitative	O
and	O
quantitative_–	O
liquid	O
chromatography	O
tandem	O
mass	O
spectrometry	O
(LC–MS/MS)	O
methods	O
for	O
synthetic	O
cannabinoids	B
in	O
urine,	O
primarily	O
for	O
JWH-018	O
and	O
JWH-073.	O

It	O
turned	O
out	O
that	O
higher	O
concentrations	O
of	O
succinic	B
acid	I
and	O
PhCAs	O
corresponded	O
to	O
higher	O
levels	O
of	O
lactic	B
acid.	I

Additionally,	O
we	O
found	O
an	O
association	O
of	O
BMI	O
with	O
N	B
-acetyl	I
neuraminate	I
(P	O
=	O
2.02	O
×	O
10_−16	O
),	O
a	O
hydrolytic	B
breakdown	O
product	O
of	O
urinary	O
glycoproteins	B
with	O
sialic	B
acid	I
subunits;	O
the	O
assignment	O
was	O
confirmed	O
by	O
N	O
-acetyl	O
neuraminidase	O
incubation	O
experiments.	O

We	O
determined	O
urinary	O
phthalate	B
monoester	O
metabolites	O
of	O
dibutyl	B
phthalate	I
(DBP),	O
including	O
mono-butyl	B
phthalate	I
(MBP),	O
benzyl-butyl	B
phthalate	I
(BzBP),	O
including	O
mono-benzyl	B
phthalate	I
(MBzP),	O
and	O
di-ethylhexyl	B
phthalate	I
(DEHP),	O
including	O
mono-(2-ethylhexyl)	B
phthalate	I
(MEHP),	O
mono-(2-ethyl-5-hydroxyhexyl)	B
phthalate	I
(MEHHP),	O
and	O
mono-(2-ethyl-5-oxo-hexyl)	B
phthalate	I
(MEOHP),	O
based	O
on	O
a	O
recently	O
published	O
method.	O

In	O
addition	O
to	O
confirming	O
the	O
retention	O
of	O
several	O
previously	O
identified	O
uremic	O
toxins,	B
including	O
p-cresyl	B
sulphate,	I
two	O
novel	O
uremic	O
retentions	O
solutes	O
were	O
detected,	O
namely	O
dimethyl	B
sulphone	I
(DMSO_2	O
)	O
and	O
2-hydroxyisobutyric	B
acid	I
(2-HIBA).	O

Analytes	O
in	O
the	O
samples	O
were	O
quantified	O
from	O
linear	O
calibration	O
curves	O
relating	O
the	O
ratio	O
of	O
varying	O
amounts	O
of	O
3-HPMA	O
or	O
HMPMA	O
and	O
a	O
constant	O
amount	O
of	O
[N	O
-acetyl-D_3	I
]3-HPMA	O
or	O
[N	O
-acetyl-D_3	I
]HMPMA	O
to	O
the	O
area	O
ratio	O
of	O
the	O
appropriate	O
analyte:internal	O
standard	O
MS/MS	O
transitions.	O

The	O
mechanisms	O
underlying	O
the	O
actions	O
of	O
SF	B
on	O
benzene	B
metabolism	O
or	O
its	O
myriad	O
of	O
other	O
protective	O
effects	O
are	O
unclear.	O

The	O
liver	O
of	O
an	O
adult	O
with	O
normal	O
liver	O
and	O
kidney	O
functions	O
will	O
metabolize	O
propylene	B
glycol	I
into	O
lactate,	B
acetate,	B
and	O
pyruvate	B
within	O
several	O
hours.	O

NanoSep	O
microcentrifuge	O
filters;	O
Pall,	O
Inc.,	O
East	O
Hills,	O
NY,	O
USA)	O
of	O
serum	O
samples	O
(V = 250 μL)	O
was	O
followed	O
by	O
adding	O
to	O
the	O
filtrated	O
samples	O
80 μL	O
of	O
phosphate-buffered	O
solution	O
(0.5 M	O
NaH_2	O
PO_4	O
containing	O
2.5 mM	O
2,2-dimethyl-2-silapentane-5-sulfonate,	B
DSS),	O
10 μL	O
of	O
sodium	O
azide	O
(1 M	O
NaN_3	O
)	O
and	O
D_2	O
O.	O

Changes	O
in	O
cholesterol	B
metabolism,	O
glucose	B
metabolism	O
and	O
prostaglandin	B
metabolism	O
were	O
indicated.	O

In	O
our	O
study,	O
untargeted	O
GC-MS	O
was	O
used	O
to	O
detect	O
disturbance	O
of	O
metabolism	O
occurs	O
in	O
RSA	O
and	O
targeted	O
LC-MS	O
further	O
was	O
used	O
to	O
show	O
that	O
plasma	O
concentrations	O
of	O
two	O
metabolites	O
(lactic	O
acid	O
and	O
5-methoxytryptamine)	B
were	O
different	O
in	O
the	O
RSA	O
compared	O
to	O
the	O
control	O
group.	O

In	O
the	O
RP	B
UPLC-MS	O
analysis,	O
PE(18:0/18:2)	B
and	O
PC(P-16:0/20:4)	B
were	O
higher	O
in	O
PRP	O
than	O
PFP.	O

The	O
MDLs	O
were	O
between	O
0.004	O
and	O
0.4	O
nM	O
for	O
the	O
polyamines	B
(AGM,	O
PUT,	O
SPD,	O
SPM,	O
1,3-DAP,	B
CAD,	O
and	O
acetylated	O
derivatives)	O
and	O
between	O
0.8	O
and	O
22.0	O
nM	O
for	O
the	O
amino	O
acids	O
(ARG,	O
LYS,	O
ORN,	O
and	O
GABA).	O

We	O
previously	O
published	O
results	O
from	O
29	O
of	O
the	O
dMDD	O
subjects	O
and	O
20	O
of	O
the	O
HCs	O
making	O
up	O
the	O
current	O
sample	O
in	O
the	O
context	O
of	O
a	O
study	O
examining	O
associations	O
between	O
kynurenine	B
metabolites	O
and	O
gray	O
matter	O
volumes	O
of	O
the	O
hippocampus	O
and	O
amygdala.	O

Urinary	O
acylcarnitine	B
pattern	O
and	O
excess	O
excretion	O
of	O
urinary	O
bile	O
acids	O
were	O
comparable	O
between	O
the	O
two	O
groups.	O

Amino	O
acids	O
with	O
significant	O
24	O
h	O
rhythms	O
irrespective	O
of	O
the	O
presence	O
or	O
absence	O
of	O
sleep	O
included	O
the	O
branched	O
chain	O
amino	O
acids	O
(BCAAs)	O
isoleucine	B
and	O
valine,	B
glutamate,	B
ornithine,	B
and	O
proline,	B
all	O
peaking	O
at	O
night	O
between	O
21.28	O
and	O
01.45	O
decimal	O
h	O
on	O
day	O
1.	O

Cer = Ceramide.	B

Levels	O
of	O
tryptophan	B
(Trp)	O
and	O
5-hydroxyindolacetic	B
acid	I
(5-HIAA)	O
were	O
also	O
detected.	O

The	O
codeine	B
:	O
morphine	B
ratio	O
in	O
urine	O
will	O
remain	O
>1	O
during	O
the	O
first	O
24	O
hours	O
after	O
codeine	B
administration,	O
but	O
then	O
it	O
will	O
“flip”,	O
or	O
become	O
<1,	O
between	O
24-30	O
hours	O
post	O
dose.	O

Spearman's	O
rank	O
correlation	O
was	O
used	O
to	O
evaluate	O
the	O
associations	O
among	O
plasma	O
xylitol,	B
1,5‐AG,	B
histidine,	B
inositol,	B
threonine,	B
methionine,	B
arabinose,	B
asparagine,	B
glutamine,	B
lysine,	B
tyrosine,	B
and	O
uric	B
acid	I
levels.	O

Secondly,	O
the	O
targeted	O
relative	O
quantification	O
of	O
the	O
thiols	B
between	O
the	O
cancer	O
and	O
healthy	O
control	O
was	O
investigated	O
by	O
the	O
IL-LC-MRM-MS	O
method.	O

Stability	O
of	O
BEN	O
(a)	O
and	O
BA	O
(b)	O
in	O
plasma	O
at	O
room	O
temperature	O
(open	O
circle),	O
4	O
°C	O
(filled	O
square	O
)	O
and	O
at	O
room	O
temperature	O
with	O
5	O
%	O
(v/v	O
)	O
2	O
M	O
sulfuric	B
acid	I
(open	O
triangle	O
)	O

Therefore,	O
the	O
m/z	O
162.1123	O
was	O
identified	O
as	O
carnitine	B
according	O
to	O
the	O
elemental	O
composition,	O
retention	O
time	O
and	O
fragmentation	O
information.	O

More	O
generally,	O
Acetylcarnitine	B
participates	O
in	O
the	O
oxidation	O
of	O
fatty	O
acids	O
by	O
the	O
means	O
of	O
facilitating	O
the	O
uptakes	O
of	O
acetyl-CoA	B
into	O
the	O
mitochondria	O
and	O
produces	O
energy	O
to	O
maintain	O
the	O
process	O
of	O
cancer.	O

Dietary	O
betaine	B
can	O
serve	O
as	O
a	O
substrate	O
for	O
bacteria	O
to	O
form	O
TMA	O
and	O
presumably	O
TMAO.	B

This	O
will	O
disrupt	O
the	O
sodium	B
ion	I
homeostasis	O
in	O
the	O
astrocytes,	O
which	O
will	O
then	O
be	O
re-established	O
by	O
the	O
action	O
of	O
sodium/potassium	O
ATPase,	O
an	O
energy-consuming	O
process.	O

In	O
a	O
double-blinded	O
randomized	O
controlled	O
parallel-group	O
study,	O
52	O
overweight	O
postmenopausal	O
women	O
received	O
either	O
partially	O
hydrogenated	O
soybean	O
oil,	O
providing	O
15.7	O
g/day	O
of	O
TFA	O
(trans	O
18:1)	O
or	O
control	O
oil	O
with	O
mainly	O
oleic	B
acid	I
for	O
16	O
weeks.	O

Based	O
on	O
the	O
optimal	O
parameters,	O
models	O
for	O
acetaminophen	B
and	O
ibuprofen	B
showed	O
sensitivity	O
greater	O
than	O
98%	O
in	O
identifying	O
urine	O
specimens	O
containing	O
acetaminophen	B
and	O
ibuprofen	B
metabolites.	O

Serum	O
insulin	O
concentration	O
was	O
measured	O
by	O
a	O
double	O
antibody	O
radioimmunoassay	O
(Phadeseph	O
Insulin	O
RIA	O
kit,	O
Pharmacia	O
&	O
Upjohn,	O
Uppsala,	O
Sweden),	O
fluoroimmunometric	B
assay	O
(AutoDELFIA,	O
PerkinElmer	O
Inc,	O
Turku,	O
Finland)	O
or	O
automatized	O
electro-chemiluminescence	O
immunoassay	O
(Cobas	O
8000,	O
Roche	O
Diagnostics	O
GmbH,	O
Mannheim,	O
Germany).	O

The	O
albumin-like	O
protein	O
of	O
Atlantic	B
cod	O
is	O
therefore	O
small	O
in	O
comparison	O
to	O
most	O
reported	O
albumin/albumin-like	O
proteins.	O

Accordingly,	O
we	O
previously	O
showed	O
that	O
the	O
enzyme	O
which	O
catalyzes	O
the	O
synthesis	O
of	O
picolinic	B
acid	I
is	O
not	O
expressed	O
in	O
the	O
human	O
adipose	O
tissue	O
which	O
may	O
explain	O
our	O
current	O
data	O
obtained	O
after	O
adiposity	O
reduction.	O

After	O
additional	O
adjustment	O
for	O
BMI,	O
we	O
observed	O
that	O
pyruvate,	B
lysine	B
and	O
valine	B
correlated	O
positively	O
with	O
risk	O
factors	O
of	O
T2DM,	O
whereas	O
glycine	B
correlated	O
negatively	O
with	O
triglycerides	B
and	O
C-reactive	O
protein	O
(CRP).	O

As	O
shown	O
in	O
,	O
1,669	O
features	O
were	O
found	O
when	O
methanol	B
alone	O
was	O
used	O
to	O
precipitate	O
proteins	O
compared	O
to	O
1,831	O
features	O
when	O
methanol-ethanol	B
was	O
used.	O

Notably,	O
there	O
was	O
significant	O
interaction	O
between	O
BMI	O
and	O
D-mannose	B
level	O
in	O
modifying	O
CRC	O
risk	O
(P	O
interaction	O
<0.001)().	O

More	O
extensive	O
2-hydroxylation	O
of	O
parent	O
estrogens	O
is	O
associated	O
with	O
lower	O
risk,	O
and	O
less	O
extensive	O
methylation	O
of	O
potentially	O
genotoxic	O
4-hydroxylation	O
pathway	O
catechols	B
is	O
associated	O
with	O
higher	O
risk	O
of	O
postmenopausal	O
breast	O
cancer.	O

Enzalutamide	B
and	O
N-desmethylenzalutamide	B
and	O
the	O
internal	O
standard	O
(D_6	O
-enzalutamide)	I
were	O
stable	O
for	O
at	O
least	O
11	O
months	O
in	O
stock	O
solution	O
at	O
−40	O
°C.	O

Glycolysis	O
could	O
produce	O
large	O
amounts	O
of	O
lactic	B
acid,	I
leading	O
to	O
a	O
high	O
lactic	B
acid	I
level.	O

Taurine	B
is	O
currently	O
seen	O
as	O
a	O
physiological	O
stabilizer	O
of	O
photoreceptor	O
membranes,	O
and	O
studies	O
have	O
shown	O
that,	O
in	O
its	O
absence,	O
there	O
is	O
a	O
degeneration	O
of	O
both	O
ganglion	O
cells,	O
photoreceptors	O
and	O
RPE	O
[,].	O

lysoPC	O
a	O
C18:0;	B
107.	O

Combining	O
with	O
the	O
results	O
of	O
pathway	O
analysis	O
and	O
the	O
multi-ROC	O
analysis,	O
the	O
metabolites	O
involved	O
with	O
glycerolipid	B
metabolism	O
may	O
become	O
the	O
potential	O
biomarkers	O
for	O
colorectal	O
polyps.	O

Plasma	O
heparin	B
samples	O
were	O
obtained	O
after	O
a	O
12	O
h	O
fast	O
and	O
stored	O
at	O
-80°C.	O

In	O
line	O
with	O
the	O
cross-sectional	O
positive	O
association	O
of	O
FT4	O
(p	O
=	O
0.03)	O
as	O
well	O
as	O
inverse	O
association	O
of	O
log(TSH)	O
(p<0.01)	O
with	O
urinary	O
glucose	B
in	O
Inter99,	O
former	O
studies	O
already	O
showed	O
a	O
major	O
role	O
of	O
THs	O
in	O
the	O
regulation	O
of	O
glucose	B
homeostasis	O
by	O
e.g.	O
increasing	O
gluconeogenesis	O
in	O
the	O
kidney	O
and	O
liver	O
but	O
also	O
glucose	B
absorption	O
and	O
utilization	O
in	O
target	O
cells	O
[,	O
].	O

LysoPE	O
which	O
is	O
a	O
lyso-type	O
phospholipid,	B
is	O
a	O
metabolic	O
product	O
of	O
phosphatidylethanolamine	B
(PE,	O
a	O
minor	O
constituent	O
of	O
cell	O
membranes)	O
generated	O
by	O
phospholipase	O
A2.	O

Therefore,	O
the	O
abundance	O
and	O
types	O
of	O
lipids	O
available	O
to	O
T.	O
cruzi	O
during	O
vector	O
infection	O
will	O
affect	O
its	O
ability	O
to	O
synthesize	O
eicosanoids,	B
which	O
can	O
have	O
a	O
direct	O
impact	O
on	O
both	O
the	O
parasite	O
itself	O
and	O
on	O
the	O
vector	O
host.	O

Information	O
regarding	O
the	O
age,	O
gender,	O
the	O
duration	B
of	O
illness,	O
laboratory	O
indices,	O
liver	O
ultrasonic	O
score,	O
Child-Pugh	O
score	O
and	O
previous	O
diseases	O
was	O
collected.	O

As	O
shown	O
in	O
,	O
there	O
were	O
no	O
oxypilins	B
showing	O
age-related	O
difference	O
within	O
women	O
and	O
men	O
groups.	O

Definitions	O
of	O
hyperuricemia	O
were	O
high	O
fasting	O
serum	O
uric	B
acid	I
(SUA)	O
(>420μmol/L)	O
at	O
physiological	O
temperature	O
(37°C)	O
and	O
neutral	O
pH.	O
The	O
diagnosis	O
of	O
NAFLD	O
was	O
based	O
on	O
the	O
findings	O
of	O
abdominal	O
ultrasound,	O
clinical	O
chemistry	O
according	O
to	O
conventional	O
criteria	O
and	O
alcohol	O
consumption	O
of	O
<20g⁄day	O
in	O
the	O
last	O
year.	O

Unlike	O
ADMA,	B
SDMA	O
is	O
not	O
a	O
substrate	O
for	O
DDAHs,	O
the	O
up-regulated	O
expression	O
of	O
which	O
would	O
have	O
explained	O
the	O
reduction	O
in	O
its	O
level.	O

Enhanced	O
catabolism	O
of	O
several	O
lipid	O
classes	O
increases	O
prognostic	O
risk	O
while	O
plasma	O
PGF2α	B
may	O
be	O
a	O
marker	O
for	O
reduced	O
prognostic	O
risk	O
in	O
AML.	O

Methionine	B
is	O
an	O
essential	O
amino	O
acid	O
participating	O
in	O
protein	O
synthesis	O
and	O
the	O
transfer	O
of	O
methyl	O
groups	O
to	O
histones	O
and	O
DNA.	O

However	O
3-methyl-2-oxobutyrate,	B
3-methyl-2-oxovalerate	B
and	O
4-methyl-2-oxopentanoate,	B
which	O
are	O
associated	O
with	O
valine,	B
leucine	B
and	O
isoleucine	B
metabolism,	O
were	O
not	O
found	O
to	O
be	O
significantly	O
altered	O
in	O
depressed	O
subjects.	O

LysoPC	O
resulted	O
from	O
the	O
partial	O
hydrolysis	O
of	O
phosphatidylcholines,	B
which	O
removes	O
one	O
of	O
the	O
fatty	O
acid	O
groups;	O
LysoPC	O
can	O
activate	O
endothelial	O
cells	O
during	O
early	O
atherosclerosis	O
and	O
can	O
stimulate	O
phagocyte	O
recruitment	O
when	O
they	O
were	O
released	O
by	O
apoptotic	O
cells	O
[–].	O

Associations	O
of	O
vitamin	B
D	I
metabolites	O
with	O
IMT	O
were	O
estimated	O
using	O
linear	O
regression.	O

(a)	O
Portion	O
of	O
typical	O
800	O
MHz	O
NMR	O
spectra	O
of	O
mouse	O
heart	O
tissue	O
extracts	O
highlighting	O
characteristic	O
NAD_+	O
and	O
NADH	B
peaks	O
in	O
(a)	O

To	O
investigate	O
the	O
effect	O
of	O
H.	O
pylori	O
infection	O
on	O
the	O
observed	O
metabolic	O
differences	O
among	O
GC	O
and	O
FDR,	O
all	O
samples	O
were	O
categorized	O
according	O
to	O
the	O
H.	O
pylori	O
-infection	O
status	O
and	O
their	O
sphingomyelins	B
or	O
acylcarnitines	B
serum	O
levels.	O

Although	O
milk	O
samples	O
from	O
CD	O
mothers	O
appeared	O
to	O
have	O
higher	O
succinate	B
at	O
PP3,	O
this	O
difference	O
was	O
not	O
significant.	O

After	O
the	O
solution	O
was	O
cooled	O
to	O
room	O
temperature,	O
5	O
µL	O
of	O
100	O
mM	O
idoacetamide	B
was	O
added,	O
after	O
which,	O
it	O
was	O
left	O
in	O
the	O
dark	O
at	O
room	O
temperature	O
for	O
15	O
min.	O

PC	O
was	O
the	O
largest	O
number	O
in	O
glycerophospholipid	B
class	O
and	O
PC	B
(34:2;	I
16:0/18:2)	I
was	O
the	O
most	O
abundant	O
PC.	O

Self-reported	O
current	O
acetaminophen	B
or	O
ibuprofen	B
use	O
was	O
compared	O
with	O
the	O
presence/absence	O
of	O
_1	O
H	O
NMR-detected	O
urinary	O
acetaminophen	B

and	O
UR-144	O
N-5-hydroxypentyl	B
alkyl	I
hydroxy	I
metabolite	O
standards,	O
but	O
since	O
isomeric	O
separation	O
was	O
not	O
possible,	O
we	O
can	O
only	O
identify	O
these	O
peaks	O
as	O
alkyl	B
hydroxy	I
metabolites	O
without	O
assigning	O
hydroxy	B
position	O
on	O
the	O
side	O
chain.	O

The	O
approach	O
clearly	O
highlights	O
the	O
importance	O
of	O
five	O
metabolites,	O
consisting	O
of	O
three	O
plasma	O
metabolites,	O
lysoPC	O
18:2,	O
adenosine	B
5’-phosphate,	I
and	O
glutamate,	B
as	O
well	O
as	O
two	O
urine	O
metabolites,	O
C-mannosyltryptophan	B
and	O
3’-sialyllactose.	B

PC	O
(1029.85 ± 105.98 μ	O
mol/L),	O
CE	O
(979.72 ± 110.87 μ	O
mol/L),	O
COH	O
(485.83 ± 76.38 μ	O
mol/L),	O
TG	B
(157.56 ± 60.78 μ	O
mol/L),	O
SM	O
(207.74 ± 22.08 μ	O
mol/L),	O
and	O
LPC	O
(155.74 ± 19.72 μ	O
mol/L)	O
were	O
the	O
most	O
abundant	O
lipids	O
in	O
the	O
normal-weight	O
normal	O
plasma	O
lipid	O
level	O
group.	O

Intermediates	O
of	O
proline	B
catabolism	O
were	O
associated	O
with	O
OCN	O
reflecting	O
the	O
implication	O
in	O
bone	O
metabolism.	O

CPR	O
levels	O
(r:	O
0.33;	O
p:	O
0.001);	O
no	O
significant	O
correlations	O
emerged	O
with	O
age,	O
Barthel	O
index,	O
and	O
creatinine	B
levels.	O

Functional	O
differences	O
in	O
serum	O
metabolic	O
networks	O
related	O
to	O
aspartate	B
metabolism	O
were	O
identified	O
in	O
patients	O
with	O
AP.	B

Therefore,	O
a	O
postoperative	O
decrease	O
in	O
the	O
concentration	O
of	O
this	O
FA	B
might	O
reflect	O
lower	O
rate	O
of	O
liver	O
lipogenesis	O
and	O
FA	B
desaturation	O
after	O
bariatric	O
surgery.	O

For	O
α(R)-OHB	B
and	O
α(S)-OHB,	B
only	O
three	O
measuring	O
points	O
could	O
be	O
used	O
due	O
to	O
the	O
high	O
LOD	O
of	O
these	O
analytes.	O

Metabolites	O
with	O
>25%	O
of	O
values	O
reported	O
as	O
“0”	O
(i.e.	O
below	O
the	O
lower	O
limits	O
of	O
quantification)	O
were	O
not	O
further	O
analyzed	O
(C6	O
and	O
C7-DC	O
acylcarnitines).	B

If	O
_13	O
C-glutamine	B
entered	O
the	O
tumor	O
from	O
the	O
interstitial	O
space,	O
and	O
then	O
was	O
converted	O
to	O
glutamate,	B
the	O
fractional	O
enrichment	O
in	O
glutamine	B
would	O
exceed	O
that	O
of	O
glutamate.	B

Diphenyl	B
phosphate	I
(DPhP),	O
DPhP-d_10	O
,	O
di-o	B
-cresylphosphate	I
(DoCP),	O
DoCP-d_14	O
,	O
di-p	B
-cresylphosphate	I
(DpCP),	O
DpCP-d_14	O
,	O
bis-(1-chloro-2-propyl)	B
phosphate	I
(BCPP),	O
BCPP-d_12	O
,	O
bis-2-chloroethyl	B
phosphate	I
(BCEtP),	O
and	O
BCEtP-d_8	O
were	O
purchased	O
from	O
Toronto	O
Research	O
Chemicals,	O
TRC	O
(Toronto,	O
Canada).	O

Error	O
in	O
the	O
glutathione	B
synthetase	O
leads	O
to	O
reduced	O
level	O
of	O
GSH	B
and	O
accumulation	O
of	O
γ-glutamylcysteine.	B

In	O
conclusion,	O
this	O
study	O
demonstrated	O
that	O
several	O
key	O
relations	O
between	O
cytokines	O
and	O
tryptophan	B
metabolites	O
reported	O
in	O
inflammatory	O
conditions	O
are	O
also	O
present	O
in	O
healthy	O
young	O
adults	O
without	O
acute	O
or	O
chronic	O
inflammatory	O
disease.	O

Our	O
goal	O
in	O
this	O
study	O
was	O
to	O
identify	O
novel	O
glomerular	O
filtration–related	O
markers	O
using	O
metabolomics	O
that	O
are	O
better	O
than	O
or	O
equal	O
to	O
creatinine,	B
the	O
most	O
established	O
metabolite	O
in	O
use	O
for	O
GFR	O
estimation.	O

For	O
example	O
TG	B
(58:8)	I
[M + NH_4	O
]_+	O
has	O
m	O
/z	O
value	O
948.8015	O
and	O
expected	O
retention	O
time	O
10.167 min	O
in	O
the	O
ion	O
database.	O

Formate	B
is	O
the	O
simplest	O
of	O
the	O
carboxylic	B
acids,	I
and	O
an	O
intermediate	O
of	O
several	O
metabolic	O
processes.	O

This	O
oxysterol	B
is	O
synthesized	O
in	O
the	O
brain	O
by	O
a	O
neuronal	O
enzyme	O
(cholesterol	O
24-hydroxylase,	O
CYP46A1	O
)	O
and	O
thereafter	O
secreted	O
into	O
the	O
circulation	O
where	O
it	O
associates	O
with	O
circulating	O
lipoproteins.	O

Besides	O
that,	O
alteration	O
of	O
cytidine	B
could	O
induce	O
the	O
abnormality	O
of	O
the	O
salvage	O
pathway	O
of	O
pyrimidine	B
nucleotide,	O
followed	O
by	O
the	O
dysfunction	O
of	O
phospholipid.	B

The	O
spray	O
voltage	O
was	O
5	O
kV.	B

Rather,	O
these	O
correlations	O
suggest	O
that	O
a	O
more	O
complex	O
derangement	O
of	O
SP	B
metabolism	O
results	O
from	O
increased	O
adiposity	O
and/or	O
contributes	O
to	O
susceptibility	O
to	O
obesity.	O

The	O
most	O
relevant	O
resonances	O
for	O
evaluating	O
renal	O
function	O
after	O
transplantation	O
in	O
our	O
hands	O
were	O
those	O
of	O
citrate,	B
lactate,	B
alanine,	B
and	O
urea	B
normalized	O
to	O
creatinine	B
excretion.	O

HIV+	O
participants	O
had	O
significantly	O
reduced	O
proportions	O
of	O
the	O
PUFA	O
α-linolenic	B
acid	I
(18:3);	O
proportions	O
of	O
dihomo-γ-linolenic	B
acid	I
(20:3)	O
and	O
arachidonic	B
acid	I
(20:4)	O
also	O
tended	O
to	O
be	O
decreased	O
in	O
HIV+	O
individuals.	O

The	O
elevation	O
of	O
arachidonate	B
may	O
be	O
of	O
associated	O
with	O
increased	O
liberation	O
of	O
free	O
fatty	O
acids	O
from	O
phospholipids	B
either	O
in	O
the	O
tumor	O
or	O
in	O
adjacent	O
tissue.	O

The	O
present	O
study	O
pointed	O
out	O
that	O
the	O
HER2-positve/ER(+)group	O
is	O
characterized	O
by	O
high	O
level	O
of	O
cholesterol-phospholipid	B
lipoprotein	O
subfractions	O
that	O
potentially	O
could	O
be	O
negatively	O
associated	O
to	O
the	O
clinical	O
outcomes	O
of	O
the	O
therapeutic	O
interventions.	O

The	O
eluate	O
was	O
evaporated	O
to	O
dryness	O
under	O
a	O
gentle	O
stream	O
of	O
nitrogen	O
at	O
45°C	O
and	O
then	O
resuspended	O
in	O
500 µ	O
L	O
methanol	B
for	O
the	O
further	O
analysis.	O

Dihydroresveratrol,	B
with	O
only	O
one	O
hydroxyl	O
group	O
on	O
ring	O
B	O
in	O
para	O
position,	O
was	O
not	O
further	O
metabolized	O
or	O
degraded,	O
and	O
it	O
was	O
the	O
end-product	O
of	O
resveratrol	B
colon	O
metabolism.	O

shows	O
an	O
example	O
EIC	O
of	O
valine	B
1	O
retrieved	O
using	O
our	O
in-house	O
tool	O
and	O
the	O
mixed	O
similarity	O
scores	O
based	O
on	O
AUC	O
and	O
peak	O
apex.	O

This	O
shows	O
that	O
the	O
current	O
lower	O
limit	O
of	O
detection	O
for	O
metabolites	O
in	O
urine	O
is	O
in	O
the	O
low	O
pM/mM	O
creatinine	B
range	O
and	O
that	O
the	O
concentration	O
range	O
of	O
analytes	O
in	O
urine	O
spans	O
nearly	O
11	O
orders	O
of	O
magnitude.	O

These	O
findings	O
were	O
independent	O
of	O
traditional	O
cardiovascular	O
risk	O
factors,	O
renal	O
function,	O
markers	O
of	O
inflammation,	O
and	O
even	O
when	O
accounting	O
for	O
levels	O
of	O
the	O
endogenous	O
NO	O
synthase	O
inhibitor	O
ADMA.	B

Creatinine	B
is	O
subsequently	O
produced	O
via	O
a	O
biological	O
system	O
involving	O
creatine,	B
phosphocreatine,	B
and	O
adenosine	B
triphosphate	I
(ATP),	O
whereas	O
hippurate	B
and	O
citrate	B
are	O
derived	O
from	O
phenylalanine	B
metabolism	O
and	O
the	O
citrate	B
cycle.	O

The	O
metabolomics	O
profiling	O
of	O
steroidogenesis,	O
spermine	B
biosynthesis,	O
tryptophan	B
metabolism,	O
and	O
porphyrin	O
metabolism	O
were	O
altered	O
significantly	O
(,	O
VIP > 1	O
and	O
p	O
 < 0.05,	O
respectively).	O

The	O
ABCD2	O
+	O
LAA	O
+	O
LysoPC(20:4)	B
model	O
showed	O
the	O
highest	O
calibration	O
(χ_2	O
3.58,	O
p	O
=	O
0.309),	O
whereas	O
the	O
ABCD2	O
+	O
LAA	O
+	O
LysoPC(16:0)	B
model	O
showed	O
the	O
lowest	O
calibration	O
values	O
(χ_2	O
17.33,	O
p	O

No	O
significant	O
interference	O
was	O
observed	O
in	O
the	O
blank	O
plasma	O
chromatograms	O
(in	O
plasma	O
with	O
either	O
low	O
or	O
high	O
triglyceride	B
levels)	O
at	O
the	O
retention	O
times	O
of	O
SMV	O
(3.8	O
min),	O
SMV-A	O
(3.6	O
min),	O
ATV	O
(3.2	O
min),	O
2-OH-ATV	B
(3.1	O
min),	O
4-OH-ATV	B
(2.8	O
min),	O
RSV	O
(2.9	O
min)	O
and	O
the	O
IS	O
(3.3	O
min)	O
as	O
shown	O
in	O
.	O

Glycerol	B
3-phosphate	I
is	O
a	O
phosphoric	B
ester	I
of	O
glycerol	B
that	O
controls	O
the	O
flux	O
through	O
the	O
glycerolipid/free	O
fatty	O
acid	O
cycle,	O
phospholipid	B
biosynthesis	O
and	O
many	O
other	O
cellular	O
functions.	O

Second,	O
it	O
has	O
been	O
suggested	O
that	O
omega-3	B
fatty	O
acids	O
and	O
certain	O
HDL	O
subclasses	O
can	O
travel	O
across	O
the	O
blood–brain	O
barrier,	O
which	O
may	O
have	O
effects	O
on	O
a	O
neuronal	O
level.	O

The	O
bar	O
graphs	O
represent	O
the	O
relative	O
peak	O
area	O
on	O
LC–MS	O
analysis	O
for	O
tyramine	B
(D)	O
and	O
2-oxoglutarate	B
(E).	O

The	O
figures	O
show	O
that	O
the	O
broad	O
protein	O
peaks	O
have	O
been	O
largely	O
removed	O
by	O
both	O
methods,	O
although	O
after	O
treatment	O
with	O
methanol	B
alone,	O
residual	O
protein	O
signals	O
cause	O
a	O
well-visible	O
curved	O
baseline	O
under	O
the	O
crowded	O
peak	O
regions	O
as	O
well	O
as	O
a	O
broad	O
lipid	O
feature	O
around	O
1.2	O
ppm.	O

Univariate	O
analysis	O
showed	O
higher	O
concentrations	O
of	O
CSF	O
ascorbate	B
in	O
ALS	O
patients.	O

Cluster	O
B	O
links	O
the	O
naphthalene	B
derivatives	O
(TDN,	O
1,1,5,6‐tetramethyl‐1,2‐dihydronaphthalene	B
and	O
2,5,8‐trimethyl‐1,2,3,4‐tetrahydronaphthalen‐1‐ol)	B
with	O
(E)‐1‐(2,3,6‐trimethylphenyl)buta‐1,3‐diene.	B

Centrifugal	O
filters	O
(3 kDa	O
cutoff;	O
Vivospin	O
Turbo	O
4,	O
VS04T91,	O
Sartorius)	O
were	O
first	O
washed	O
with	O
1000 μl	O
phosphate	B
buffer	O
in	O
triple	O
distilled	O
water	O
at	O
10,000 rpm	O
for	O
30 min.	O

Nitric	B
oxide,	I
coronary	O
artery	O
disease,	O
prognosis	O

The	O
findings	O
argue	O
against	O
the	O
conventional	O
perception	O
of	O
metabolism	O
in	O
_18	O
FDG-PET-positive	O
tumors:	O
that	O
tumor	O
glucose	B
handling	O
is	O
dominated	O
by	O
production	O
of	O
the	O
end	O
products	O
lactate	B
and	O
alanine.	B

We	O
now	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
systemic	O
arginine	B
bioavailability	O
(estimated	O
by	O
GABR)	O
in	O
patients	O
with	O
ADHF	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
CHF	O
patients.	O

These	O
results	O
suggest	O
that	O
all	O
of	O
the	O
monohexocylceramide	B
species	O
as	O
well	O
as	O
the	O
total	O
amount	O
of	O
monohexocylceramides	B
were	O
significantly	O
higher	O
in	O
cancer.	O

(A)	O
uric	B
acid	I
(AUROC	O
=	O
0.74),	O
(B)	O
cholylglycine	B
(AUROC	O
=	O
0.83),	O
(C)	O
3-hydroxycapric	B
acid	I
(AUROC	O
=	O
0.73),	O
(D)	O
D-leucic	O
acid	O
(AUROC	O
=	O
0.79),	O
(E)	O
xanthine	B
(AUROC	O
=	O
0.74),	O
(F)	O
arachidonyl	O
lysolecithin	O
(AUROC	O
=	O
0.88),	O
(G)	O
dioleoylphosphatidylcholine	B
(AUROC	O
=	O
0.84).	O

The	O
majority	O
of	O
PLs	O
identified	O
in	O
this	O
work,	O
including	O
different	O
PCs	O
and	O
LPCs	O
as	O
well	O
as	O
SM(34:1),	B
belong	O
to	O
the	O
most	O
abundant	O
in	O
their	O
classes	O
measured	O
in	O
human	O
plasma	O
samples;	O
SM(38:3)	B
and	O
Cer(36:2)	B
are	O
less	O
common	O
species.	O

In	O
rat	O
brain	O
tissue,	O
the	O
activation	O
of	O
the	O
anaerobic	O
flux	O
during	O
hypoxia-ischemia	O
and	O
increased	O
glycolysis	O
has	O
been	O
reported	O
with	O
all	O
rate-limiting	O
enzymes	O
activated,	B
being	O
the	O
transport	O
of	O
glucose	B
across	O
the	O
blood-brain	O
barrier	O
the	O
major	O
rate-limiting	O
step	O
of	O
this	O
process.	O

Before	O
NMR	O
acquisition,	O
the	O
tissue	O
extracts	O
were	O
resuspended	O
in	O
650 μl	O
NMR	O
buffer	O
(100 mM	O
sodium	B
phosphate	I
buffer,	O
pH	O
7.4,	O
in	O
deuterated	O
water	O
(D_2	O
O),	O
containing	O
1 mM	O
sodium	O
salt	O
of	O
3-(trimethylsilyl)	O
propionic-2,2,3,3,d4	O
acid	O
(TSP).	O

Total	O
levels	O
of	O
sofosbuvir	B
and	O
ribavirin	O
nucleoside	O
and	O
nucleotide	O
metabolites	O
were	O
high	O
in	O
liver	O
tissue.	O

Glutamate	B
was	O
initially	O
identified	O
as	O
having	O
a	O
significantly	O
elevated	O
level	O
within	O
depressed	O
subjects;	O
however,	O
ANCOVA	O
analysis	O
later	O
indicated	O
that	O
there	O
was	O
a	O
significant	O
age	O
effect	O
associated	O
with	O
glutamate.	B

It	O
is	O
possible	O
that	O
vitamin	B
D	I
metabolites	O
are	O
lost	O
along	O
with	O
vitamin	B
D	I
binding	O
protein	O
with	O
high	O
levels	O
of	O
albuminuria.	O

Thyroxine	B
and	O
dopamine	B
also	O
correlated	O
with	O
the	O
five	O
year	O
risk	O
of	O
onset	O
in	O
premanifest	O
HD	O
subjects.	O

The	O
chromatographic	O
peak	O
corresponding	O
to	O
serine-2TMS	B
is	O
weak	O
and	O
overlaps	O
slightly	O
with	O
the	O
urea	B
peak.	O

First,	O
we	O
compared	O
the	O
predictive	O
and	O
discriminant	O
performances	O
of	O
tryptophan	B
with	O
the	O
other	O
5	O
AAs	O
(valine,	O
leucine,	B
isoleucine,	B
phenylalanine,	B
and	O
tyrosine)	B
which	O
were	O
recently	O
reported	O
as	O
new	O
biomarkers	O
for	O
T2D	O
risk.	O

There	O
were	O
no	O
interactions	O
of	O
plasma	O
BCAAs	O
and	O
sex,	O
obesity,	O
and	O
glucose	B
tolerance	O
status	O
with	O
any	O
other	O
outcomes	O
in	O
either	O
linear	O
or	O
logistic	O
regression	O
models.	O

Lysophospholipids	B
increased	O
after	O
radiation	O
exposure.	O

ARG,	O
arginase;	O
DDAH,	O
dimethylarginine	O
dimethylaminohydrolase,	O
NOS,	O
nitric	B
oxide	I
synthase;	O
ODC,	O
ornithine	O
decarboxylase;	O
PRMT,	O
arginine	O
N-methyltransferase;	O
CD_i,	O
inflamed	O
tissue	O
obtained	O
from	O
patients	O
with	O
Crohn’s	O
disease;	O
CD_q,	O
quiescent	O
tissue	O
obtained	O
from	O
patients	O
with	O
Crohn’s	O
disease;	O
UC_n,	O
normal	O
small	O
bowel	O
tissue	O
obtained	O
from	O
patients	O
with	O
ulcerative	O
colitis;	O
_a	O
significantly	O
different	O
from	O
CD_q;	O
_b	O
significantly	O
different	O
from	O
UC_n;	O
_c	O
significantly	O
different	O
from	O
CD_i.	O

Up	O
to	O
now,	O
only	O
one	O
work	O
on	O
lactic	B
acid	I
and	O
short	O
chain	O
fatty	O
acids	O
have	O
revealed	O
how	O
dietary-derived	O
products	O
may	O
exert	O
(potentially	O
adverse)	O
neurological	O
effects.	O

C3D23	O
tumor	O
lactate	B
value	O
(0.17±0.02)	O
is	O
same	O
to	O
the	O
value	O
of	O
C1D12	O
of	O
plasma	O
glucose	B
(0.17±0.04),	O
which	O
suggests	O
that	O
_13	O
C	O
labeled	O
glucose	B
from	O
[1,2-_13	B
C]acetate	I
metabolism	O
in	O
the	O
liver	O
is	O
the	O
main	O
source	O
of	O
[2,3-_13	B
C]lactate	I
in	O
the	O
brain	O
tumor.	O

LOQ	O
for	O
the	O
analytes	O
ranged	O
from	O
0.05	O
ng/mL	O
(thiacloprid)	O
to	O
3.0	O
ng/mL	O
(imidacloprid).	O

Cardiovascular	O
risk	O
factor	O
profile	O
has	O
been	O
associated	O
with	O
high	O
choline	B
in	O
plasma	O
suggesting	O
a	O
disruption	O
of	O
choline	B
oxidation	O
to	O
betaine	B
as	O
part	O
of	O
the	O
mitochondrial	O
dysfunction.	O

Other	O
urinary	O
metabolites	O
contributing	O
to	O
the	O
correct	O
prediction	O
of	O
sex	O
included	O
creatinine,	B
leucine,	B
dimethylamine,	B
2-hydroxyphenylacetic	B
acid,	I
chloride,	B
and	O
sodium	O
with	O
higher	O
concentrations	O
in	O
men;	O
and	O
citrate,	B
fructose,	B
and	O
p	O
-cresol	O
with	O
higher	O
concentrations	O
in	O
women.	O

Most	O
of	O
the	O
unknown	O
tri-hydroxyl	O
species,	O
such	O
as	O
TBA01	O
(50),	O
TBA02	O
(51),	O
TBA05	O
(55),	O
TBA07	O
(57),	O
TBA09	O
(60),	O
TBA10	O
(61),	O
TBA13	O
(66)	O
and	O
TBA18	O
(74)	O
employed	O
distinctive	O
CID	O
dissociation	O
routes	O
including	O
dehydration,	O
loss	O
of	O
carbon	O
monoxide/carbon	O
dioxide,	B
dehydrogenation	O
and	O
cleavages	O
of	O
the	O
steroid	O
skeleton.	O

Internal	O
standards	O
2,3,4–_13	B
C_3	I
-estrone	I
(_13	O
C_3	O
-E1),	O
2,3,4–_13	B
C_3	I
-estradiol	I
(_13	O
C_3	O
-E2),	O
formic	B
acid	I
(FA)	O
and	O
methyl	B
iodide	I
(CH_3	O
I;	O
≥99%)	O
were	O
from	O
Sigma-Aldrich,	O
Inc.	O
(St.	O
Louis,	O
USA).	O

Fatty	O
acid	O
amides	O
are	O
bioactive	O
signalling	O
lipids	O
and	O
FAAH	O
catalyses	O
the	O
hydrolysis	O
of	O
these	O
bioactive	O
compounds	O
such	O
as	O
oleamide	B
and	O
palmitoylethanolamide.	B

For	O
CV2,	O
Xi	O
matrices	O
were	O
randomly	O
split	O
into	O
2	O
submatrices	O
Xical	O
(A,	O
J)	O
and	O
Xitest	O
(B,	O
J),	O
with	O
A	O
=	O
17,	O
12,	O
or	O
9,	O
and	O
B	O
=	O
5,	O
4,	O
or	O
2,	O
for	O
either	O
risperidone,	B
olanzapine,	B
and	O
quetiapine,	B
respectively.	O

The	O
resulting	O
sections	O
were	O
then	O
stained	O
with	O
hematoxylin	B
and	O
eosin.	B

The	O
collective	O
findings	O
of	O
the	O
present	O
and	O
recent	O
studies	O
_,	O
	O
indicate	O
that	O
the	O
inverse	O
observational	O
associations	O
of	O
cholesterol	B
in	O
HDL	O
particles	O
are	O
limited	O
to	O
large	O
and	O
medium	O
subclasses.	O

Chemical	O
shifts	O
were	O
referenced	O
to	O
the	O
TSP	O
signal	O
for	O
_1	O
H	O
1D	O
or	O
2D	O
spectra	O
or	O
the	O
derivatized	O
formic	B
acid	I
signal	O
(_1	O
H,	O
8.05	O
ppm;	O
_15	O
N,	O
123.93	O
ppm)	O
in	O
HSQC	O
spectra	O
for	O
isotope	O
labeled	O
samples.	O

In	O
these	O
rapidly	O
proliferating	O
cells	O
glutamine	B
can	O
be	O
taken	O
up	O
and	O
converted	O
first	O
to	O
glutamate	B
via	O
glutaminase	O
	O
and	O
then	O
to	O
α-ketoglutarate	B
via	O
aspartate	O
aminotransferase	O
	O
followed	O
by	O
a	O
passage	O
through	O
part	O
of	O
the	O
tricarboxylic	B
acid	I
cycle	O
(TCA)	O
to	O
form	O
oxaloacetate	B
which	O
is	O
converted	O
via	O
malate	O
dehydrogenase	O
and	O
malate	O
decarboxylase	O
to	O
pyruvate	B
	O
	O
which	O
can	O
then	O
be	O
converted	O
to	O
alanine	B
or	O
lactate	B
via	O
Eqs	O
1	O
or	O
2	O
(see	O
).	O

Currently	O
there	O
is	O
no	O
standard	O
treatment	O
to	O
eliminate	O
kynurenines,	O
and	O
this	O
emphasizes	O
the	O
need	O
to	O
reduce	O
kynurenines	O
formation	O
via	O
control	O
of	O
inflammation	O
and	O
other	O
factors	O
which	O
contribute	O
to	O
tryptophan	B
catabolism	O
into	O
kynurenines,	O
including	O
reduced	O
consumption	O
of	O
tryptophan.	B

For	O
the	O
amniotic	O
fluid	O
analysis,	O
200	O
μL	O
of	O
0.5	O
M	O
sodium	B
phosphate	I
buffer	O
(pH	O
=	O
7	O
containing	O
33.3%	O
of	O
D_2	O
O,	O
0.5	O
mM	O
3-(trimethylsilyl)-2,2’,3,3’-tetradeuteropropionate	B
sodium	I
salt	O
TSP-d4	O
(TSP)	O
as	O
an	O
internal	O
standard	O
and	O
3	O
mM	O
sodium	O
azide	O
to	O
prevent	O
microbial	O
contamination)	O
was	O
added	O
to	O
400	O
μL	O
of	O
AF.	B

Triglycerides	B
tended	O
to	O
be	O
elevated	O
in	O
T2DM	O
(p	O
 = 0.081).	O

According	O
to	O
the	O
KEGG	O
database	O
and	O
other	O
references,	O
several	O
enzymes,	O
including	O
glutathion	B
S-transferases	O
(GSTs),	O
leucine	O
aminopeptidase	O
(LAP),	O
cyclooxygenase	O
(COX),	O
hormone-sensitive	O
lipase	O
(HSL),	O
and	O
fatty	O
acid	O
synthase	O
(FAS)	O
are	O
involved	O
in	O
the	O
biosynthesis	O
and	O
degradation	O
of	O
valine,	B
leucine	B
and	O
isoleucine.	B

Training-induced	O
changes	O
in	O
serum	O
metabolites	O
lack	O
consensus,	O
but	O
have	O
been	O
reported	O
to	O
include	O
decreases	O
in	O
hippuric	B
acid,	I
lactate,	B
pyruvate,	B
and	O
hypoxanthine,	B
and	O
increases	O
in	O
creatinine,	B
dimethylamine,	B
3-methylxanthine,	B
TCA	O
cycle	O
intermediates,	O
and	O
phospholipids.	B

Arachidonic	O
acid-derived	O
eicosanoids	B
12-HETE	I
and	O
15-HETE,	B
several	O
γ-glutamyl	O
peptides,	O
cell	O
turnover	O
metabolite	O
sphingosine,	B
amino	O
acids	O
serine	O
and	O
glycine,	B
and	O
several	O
acylcarnitines	B
were	O
most	O
significantly	O
associated	O
with	O
HCC.	O

The	O
serum	O
levels	O
of	O
tyrosine	B
at	O
admission	O
were	O
also	O
higher	O
in	O
patients	O
who	O
died	O
within	O
three	O
months	O
compared	O
to	O
those	O
who	O
were	O
alive	O
three	O
months	O
after	O
onset	O
of	O
AHF.	O

The	O
hydrolyzed	O
sample	O
was	O
subsequently	O
neutralized	O
to	O
pH	O
7	O
with	O
75	O
μL	O
of	O
phosphoric	B
acid.	I

z,	O
with	O
a	O
scan	O
time	O
of	O
0.4	O
s	O
and	O
an	O
interscan	O
delay	O
of	O
0.1	O
s.	O
To	O
avoid	O
possible	O
contamination	O
and	O
keep	O
the	O
signal	O
stable,	O
the	O
Q-TOF	O
mass	O
spectrometer	O
system	O
was	O
tuned	O
for	O
optimum	O
accuracy	O
and	O
reproducibility	O
using	O
leucine	B
enkephalin	I
for	O
the	O
positive	O
ESI	O
mode	O
([M+H]_+	O
=	O
556.2771)	O
and	O
negative	O
ESI	O
mode	O
([M–H]_−	O
=	O
554.2615).	O

In	O
DC	O
vs.	O
NHC,	O
medium	O
chain	O
acylcarnitines	B
averaged	O
two-fold	O
overexpression,	O
while	O
long	O
chain	O
acylcarnitines	B
trended	O
downward	O
in	O
HCC	O
vs.	O
DC.	O

The	O
most	O
abundant	O
FA	B
in	O
the	O
cells	O
were	O
as	O
follows	O
(given	O
in	O
descending	O
order):	O
C20:4n6,	O
C18:0,	B
C16:0	B
and	O
C18:1n9c	O
and	O
comprised	O
around	O
85%	O
of	O
the	O
total	O
FA	B
present	O
in	O
the	O
PBMC	O
cell.	O

Samples	O
that	O
were	O
used	O
directly	O
were	O
diluted	O
with	O
300	O
μL	O
solution	O
containing	O
250	O
mM	O
phosphate	B
buffer	O
(pH	O
7.4),	O
5	O
mM	O
formate	B
and	O
10%	O
D_2	O
O.	O
Ultrafiltration	O
was	O
performed	O
using	O
Millipore	O
centrifugal	O
devices	O
(Millipore	O
Microcon	O
YM-10)	O
with	O
a	O
10,000	O
molecular	O
weight	O
cutoff.	O

Ketone	B
bodies	O
can	O
migrate	O
into	O
the	O
bloodstream	O
for	O
use	O
in	O
peripheral	O
tissues	O
where	O
they	O
are	O
metabolized	O
for	O
the	O
production	O
of	O
ATP,	B
especially	O
3-OH-butyrate.	B

Oral	O
glucose	B
tolerance	O
test	O
(5	O
g/kg	O
BW)	O
was	O
performed	O
on	O
normoglycemic	B
mice	O
(n	O
=	O
9),	O
followed	O
by	O
measurement	O
of	O
blood	O
glucose	B
level	O
(mg/dl)	O
using	O
OneTouch	O
Horizon	O
(Lifescan,	O
Johnson	O
and	O
Johnson,	O
USA).	O

(p<0.02),	O
creatinine	B
(p<0.01),	O
pulse	O
rate	O
(p<0.01),	O
hemoglobin	O
(p<0.02),	O
and	O
hematocrit	O
(p<0.03),	O
compared	O
to	O
the	O
PTSD-negative	O
subjects.	O

Small	O
molecules,	O
including	O
formate,	B
phenylalanine,	B
tyrosine,	B
creatine/	O
phosphocreatine,	O
histidine,	B
1-methylhistidine,	B
alanine,	B
glycine,	B
citrate,	B
glutamate,	B
glutamine,	B
methionine,	B
acetate,	B
succinate,	B
valine,	B
lactate,	B
leucine,	B
lysine,	B
isoleucine,	B
2-hydroxyisobutyrate,	B
3-hydroxybutyrate	B
and	O
others,	O
were	O
also	O
observed.	O

A	O
YSI	O
2900	O
Bioanalyzer	O
was	O
used	O
to	O
determine	O
the	O
absolute	O
concentration	O
of	O
glutamine,	B
glutamate,	B
glucose,	B
and	O
lactate	B
in	O
plasma,	O
according	O
to	O
manufacturer’s	O
instructions.	O

Specifically,	O
the	O
locations	O
of	O
proximal	O
double	O
bonds	O
in	O
AMPP-derivatized	O
fatty	O
acids	O
are	O
identified	O
by	O
diagnostic	O
fragment	O
ions	O
resulting	O
from	O
the	O
markedly	O
reduced	O
1,4-hydrogen	B
elimination	O
from	O
the	O
proximal	O
olefinic	O
carbons.	O

Acylcarnitines	B
are	O
carnitine	B
esters	I
derived	O
from	O
fatty	O
acids	O
or	O
amino	O
acids	O
that	O
are	O
transferred	O
into	O
the	O
mitochondria.	O

Beta-alanine	B
appeared	O
to	O
act	O
via	O
glycine	B
and	O
GABA	B
(A)	O
receptors	O
(both	O
inhibitory	O
neurotransmitters)	O
with	O
comparable	O
efficacy	O
to	O
glycine	B
and	O
GABA	B
themselves.	O

Metabolites	O
selected	O
using	O
both	O
approaches	O
mostly	O
comprised	O
amino	O
acids	O
and	O
lipid	O
species	O
such	O
as	O
SMs,	O
lysophosphatidylcholines	B
(LPC),	O
PCs,	O
TGs	O
and	O
phosphatidylethanolamines	B
(PE).	O

Relative	O
effectiveness	O
of	O
4-aminopyridine	B
compared	O
with	O
the	O
prototypical	O
inducers	O
(positive	O
controls	O
expressed	O
as	O
100%	O
for	O
their	O
respective	O
enzymes).	O

When	O
the	O
arms	O
containing	O
goserelin	O
and	O
dutasteride	O
are	O
compared	O
with	O
the	O
arms	O
that	O
contained	O
goserelin,	O
dutasteride	O
and	O
bicalutamide,	B
the	O
effect	O
of	O
these	O
drug	O
combinations	O
were	O
similar.	O

With	O
respect	O
to	O
TSH	O
levels,	O
mixed	O
model	O
analyses	O
revealed	O
significant	O
associations	O
with	O
DMA	B
(,	O
).	O

Calculated	O
concentrations	O
of	O
estrone	B
and	O
estradiol	B
were	O
compared	O
to	O
reported	O
biological	O
concentrations	O
and	O
fall	O
within	O
the	O
expected	O
ranges	O
(E1/17βE2 = 73.4	O
–	O
1725.3 pmol L_−1	O
)	O
whereas	O
metabolites	O
were	O
only	O
detected	O
in	O
PAH	O
patient	O
plasma	O
(27.8	O
-	O
734.2	O
pmol	O
L-1	O
),	O
albeit	O
only	O
small	O
numbers	O
of	O
samples	O
were	O
analyzed.	O

The	O
aliquots	O
dissolved	O
in	O
basic	O
conditions	O
were	O
eluted	O
in	O
a	O
separate	O
dedicated	O
C18	O
column	O
and	O
using	O
a	O
gradient	O
of	O
methanol,	B
water,	O
and	O
6.5	O
mM	O
ammonium	B
bicarbonate.	O

The	O
increased	O
arginine	B
concentration	O
in	O
POAG	O
plasma	O
was	O
evidenced	O
by	O
three	O
of	O
the	O
four	O
data	O
methods	O
and	O
was	O
already	O
reported	O
in	O
the	O
targeted	O
metabolomics	O
study,	O
together	O
with	O
that	O
of	O
methionine	B
and	O
tyrosine,	B
which	O
were	O
also	O
identified	O
here	O
by	O
the	O
univariate	O
analysis,	O
thus	O
attesting	O
the	O
reproducibility	O
of	O
the	O
results	O
obtained	O
with	O
two	O
different	O
mass	O
spectrometry	O
approaches.	O

It	O
has	O
been	O
shown	O
that	O
ceramide	B
is	O
a	O
key	O
regulator	O
of	O
the	O
taxane-mediated	O
spindle	O
assembly	O
checkpoint	O
and	O
taxane-induced	O
cell	O
death.	O

These	O
findings	O
together	O
directly	O
link	O
activation	O
of	O
the	O
sarcosine	B
pathway	O
to	O
AR	O
and	O
ETS	O
gene	O
fusion	O
regulation,	O
two	O
key	O
mediators	O
of	O
prostate	O
cancer	O
progression.	O

For	O
example,	O
taurochenodeoxycholic	B
acid,	I
which	O
increased	O
in	O
the	O
serum	O
of	O
rapid	O
fibrosers,	O
has	O
been	O
described	O
as	O
potential	O
biomarker	O
for	O
liver	O
cirrhosis	O
in	O
hepatitis	O
B	O
virus	O
(HBV)	O
patients.	O

Plasma	O
concentrations	O
for	O
all	O
other	O
steroids	O
were	O
higher	O
in	O
men	O
than	O
women,	O
with	O
the	O
largest	O
difference	O
(P < 0.0001)	O
observed	O
for	O
testosterone,	B
which	O
showed	O
no	O
overlap	O
between	O
males	O
and	O
females.	O

Over	O
time	O
several	O
alterations	O
on	O
metabolite	O
concentrations	O
have	O
been	O
described	O
in	O
the	O
blood	O
of	O
DS	O
in	O
comparison	O
with	O
control	O
subjects:	O
i)	O
increased	O
levels	O
of	O
phenylalanine	B
and	O
tyrosine	B
in	O
blood	O
serum	O
following	O
1-phenylalanine	B
load	O
and	O
due	O
to	O
lower	O
hydroxylation	O
rate	O
of	O
phenylalanine;	B
ii)	O
lower	O
plasma	O
levels	O
of	O
free	O
histidine,	B
lysine,	B
tyrosine,	B
phenylalanine,	B
leucine,	B
isoleucine	B
and	O
tryptophan;	B
iii)	O
increased	O
plasma	O
concentrations	O
of	O
leucine,	B
isoleucine,	B
cysteine	B
and	O
phenylalanine	B
at	O
an	O
age	O
vulnerable	O
to	O
Alzheimer	O
changes;	O
iv)	O
decreased	O
plasma	O
concentration	O
of	O
serine	B
at	O
any	O
age,	O
possibly	O
due	O
to	O
a	O
dosage	O
effect	O
of	O
the	O
gene	O
for	O
cystathionine	B
beta	O
synthase	O
(CSB),	O
located	O
on	O
Hsa21;	O
v)	O
increased	O
plasma	O
lysine	B
concentration	O
in	O
patients	O
above	O
10	O
years	O
old,	O
possibly	O
due	O
to	O
premature	O
aging.	O

It	O
is	O
known	O
that	O
lactate	B
is	O
increased	O
under	O
both	O
aerobic	O
and	O
anaerobic	O
conditions	O
in	O
many	O
cancers	O
relative	O
to	O
normal	O
tissue.	O

The	O
system	O
utilized	O
a	O
DB-5MS	O
capillary	O
column	O
coated	O
with	O
5%	O
diphenyl	O
cross-linked	O
with	O
95%	O
dimethylpolysiloxane	B
(30 m × 250	O

Contrarily,	O
the	O
Dhrs	O
enzyme	O
family	O
converts	O
retinaldehyde	B
back	O
to	O
retinol,	B
thereby	O
regulating	O
the	O
amount	O
of	O
available	O
substrate	O
for	O
9cRA	O
production.	O

20-HETE	B
exhibits	O
both	O
pressor	O
and	O
antipressor	O
activities._,	O
20-HETE	B
mediates	O
renal	O
circulatory	O
autoregulation	O
and	O
contributes	O
to	O
pressure	O
natriuresis.	O

Overall,	O
treatment	O
with	O
simvastatin	B
lowered	O
low-density	O
lipoprotein	O
(LDL)	O
cholesterol	B
by	O
54	O
mg/dl	O
and	O
increased	O
high-density	O
lipoprotein	O
(HDL)	O
cholesterol	B
by	O
2	O
mg/dl.	O

We	O
analysed	O
17	O
CSF	O
metabolites	O
in	O
ALS	O
and	O
non	O
ALS	O
patients,	O
defined	O
as	O
follows:	O
amino-acids	B
(alanine,	O
glutamine,	B
tyrosine),	B
organic	O
acids	O
(citrate,	O
acetate,	B
α-hydroxybutyrate	B
(AHBT)),	O
ketone	B
bodies	O
(β-hydroxybutyrate	O
(BHBT),	O
acetone,	B
acetoacetate),	B
glucose,	B
fructose,	B
metabolites	O
involved	O
in	O
glucose	B
metabolism	O
(pyruvate,	O
lactate,	B
creatinine	B
and	O
creatine,	B
recently	O
identified	O
as	O
markers	O
of	O
mitochondrial	O
dysfunction	O
,	O
the	O
anti-oxidant	O
molecule	O
ascorbate,	B
and	O
formate	B
as	O
well	O
as	O
ethanol.	B

D-Glutamine	B
and	O
D-glutamate	B
metabolism,	O
6.	O

Lactic	B
acid	I
and	O
pyruvate,	B
which	O
were	O
increased	O
in	O
serum,	O
but	O
decreased	O
in	O
tissues	O
of	O
the	O
EC	O
patients,	O
revealed	O
enhanced	O
gluconeogenesis	O
of	O
EC	O
cells,	O
consistent	O
with	O
gastric	O
cancer.	O

Ethyl-4-hydroxy-2-quinolinecarboxylate	B
was	O
used	O
as	O
an	O
internal	O
standard.	O

The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
investigate	O
the	O
peripheral	O
concentration	O
of	O
cytokines	O
and	O
tryptophan	B
and	O
kynurenine	B
metabolites	O
in	O
patients	O
with	O
unipolar	O
treatment-resistant	O
depression	O
before	O
and	O
after	O
electroconvulsive	O
therapy	O
(ECT),	O
the	O
most	O
effective	O
treatment	O
for	O
depression.	O

The	O
LLOQ	O
and	O
HLOQ	O
were	O
selected	O
at	O
the	O
outer	O
range	O
of	O
the	O
concentration	O
levels	O
measured	O
in	O
patients	O
treated	O
with	O
abiraterone	B
1000	O
mg	O
OD.	O

For	O
instance,	O
C=C	O
isomer	O
compositional	O
analysis	O
revealed	O
that	O
PE	B
34:1	I
consisted	O
of	O
two	O
C=C	O
location	O
isomers,	O
PE	B
16:0_18:1(Δ9)	I
and	O
PE	B
16:0_18:1(Δ11)	I

For	O
semi-quantification	O
of	O
other	O
metabolites,	O
100	O
μl	O
of	O
serum	O
was	O
mixed	O
with	O
two	O
internal	O
standard	O
solutions	O
(10	O
μl	O
of	O
l-2-chlorophenylalanine	B
in	O
water,	O
0.3	O
mg/ml;	O
10	O
μl	O
of	O
heptadecanoic	B
acid	I
in	O
methanol,	B
1	O
mg/ml)	O
and	O
300	O
μl	O
of	O
methanol/chloroform	B
(v/v	O
=	O
3/1).	O

Oxalate	B
overproduction	O
may	O
cause	O
calcium-oxalate	B
crystal	O
formation	O
leading	O
to	O
kidney	O
stones,	O
nephrocalcinosis,	O
and	O
ultimately	O
kidney	O
failure.	O

The	O
isomeric	O
glucuronide	B
conjugates	O
of	O
HONH-PhIP	O
and	O
their	O
isotopically	O
labelled	O
internal	O
standards	O
were	O
monitored	O
by	O
use	O
of	O
the	O
transitions	O
[M+H]_+	O
→	O
[M+H–192]_+	O
and	O
[M+H–193]_+	O
,	O
which	O
are	O
attributed	O
to	O
the	O
loss	O
of	O
the	O
glucuronide	B
moiety	O
and	O
an	O
oxygen	O
atom	O
or	O
loss	O
of	O
the	O
glucuronide	B
moiety	O
and	O
the	O
hydroxyl	O
group.	O

Aspartate	B
(p	O
 = 0.0017)	O
was	O
statistically	O
significant	O
between	O
PA	O
samples	O
from	O
patients	O
who	O
received	O
neoadjuvant	O
chemotherapy	O
and	O
those	O
who	O
did	O
not	O
(Table ).	O

They	O
are	O
synthesized	O
from	O
cytosol	O
compounds	O
and	O
acetyl-CoA	B
from	O
cytosol	O
or	O
mitochondria.	O

Cross-calibration	O
diagrams	O
for	O
25-OH	O
D:	O
a	O
in-house	O
UHPLC-MS/MS	O
versus	O
DEQAS	O
LC-MS	O
and	O
DEQAS	O
ALTM	O
values	O
for	O
12	O
DEQAS	O
samples;	O
b	O
Bland–Altman	O
plots	O
(bottom	O
)	O
Finally,	O
the	O
circulating	O
concentration	O
of	O
1,25-(OH)_2	B
D_3	O
is	O
usually	O
in	O
the	O
range	O
50–200 pmol/L	O
(20–100 pg/mL)	O
for	O
normal	O
adults	O
and	O
usually	O
at	O
least	O
10×	O
less	O
for	O
1,25-(OH)_2	B
D_2	O
;	O
values	O
for	O
25-OH	O
D	O
in	O
the	O
population	O
are	O
typically	O
between	O
0.5	O
and	O
200 nmol/L	O
(0.2–80 ng/mL),	O
and	O
levels	O
of	O
0.5–20 nmol/L	O
(0.2–83 ng/mL)	O
are	O
seen	O
for	O
24,25-OH	B
D_3	O
.	O

Correlation	O
scatter	O
plots	O
for	O
total	O
sphingomyelin	B
(SM)	O
level	O
with	O
(A)	O
WHR,	O
(B)	O
CE,	O
(C)	O
Ceramide	B
and	O
(D)	O
Plasmanyl	B
PC	I
in	O
all	O
participants.	O

256	O
[Google	O
Scholar]	O
Granström	O
E,	O
Westlund	O
P,	O
Kumlin	O
M,	O
Nordenström	O
A.	O
Monitoring	O
thromboxane	B
production	O
in	O
vivo:	O
metabolic	O
and	O
analytical	O
aspects.	O

Low	O
serum	O
folate	B
was	O
defined	O
as	O
<10	O
nmol/L.	O
Vitamin	O
B-12	O
status	O
was	O
defined	O
based	O
on	O
the	O
“combined	O
indicator	O
of	O
vitamin	O
B-12	O
status”	O
(cB-12),	O
a	O
novel	O
approach	O
that	O
combines	O
serum	O
vitamin	O
B-12,	O
serum	O
holotranscobalamin,	O
tHcy,	O
and	O
serum	O
MMA	O
into	O
1	O
parameter:	O
cB-12	O
=	O
log_10	O
[(holotranscobalamin	O
·	O
B-12)/(MMA	O
·	O
tHcy)]	O

Interestingly,	O
the	O
higher	O
activity	O
of	O
creatine	B
kinases	O
in	O
serum	O
is	O
already	O
reported	O
indicating	O
its	O
role	O
in	O
invasive	O
breast	O
cancer.	O

In	O
contrast,	O
in	O
two	O
observational	O
studies,	O
investigators	O
found	O
that	O
high	O
soy	O
intake	O
was	O
associated	O
with	O
reduced	O
serum	O
estrone	B
in	O
postmenopausal	O
Chinese	O
women	O
and	O
reduced	O
serum	O
estradiol	B
in	O
Japanese	O
premenopausal	O
women.	O

The	O
serum	O
levels	O
of	O
valine,	B
leucine,	B
isoleucine,	B
tyrosine,	B
and	O
phenylalanine	B
were	O
measured	O
in	O
a	O
longitudinal	O
and	O
a	O
cross	O
sectional	O
studies	O
with	O
a	O
total	O
of	O
429	O
Chinese	O
participants	O
at	O
different	O
stages	O
of	O
diabetes	O
development,	O
using	O
an	O
ultra-performance	O
liquid	O
chromatography	O
triple	O
quadruple	O
mass	O
spectrometry	O
platform.	O

Addition	O
of	O
the	O
4-pathway	O
catechols:4-pathway	B
methylated	I
catechols	I
ratio	O
to	O
a	O
model	O
containing	O
unconjugated	O
estradiol	B
changed,	O
by	O
at	O
least	O
14%,	O
the	O
absolute	O
risk	O
estimate	O
for	O
30%	O
of	O
the	O
women.	O

Representative	O
600	O
MHz	O
_1	O
H	O
nuclear	O
magnetic	O
resonance	O
(NMR)	O
spectrum	O
of	O
a	O
plasma	O
sample	O
70	O
min	O
after	O
a	O
bout	O
of	O
heavy	O
resistance	O
and	O
intake	O
of	O
protein	O
drink	O
(calcium	O
caseinate)	B
(Red	O
line).	O

M3S	O
was	O
present	O
in	O
urine	O
and	O
plasma	O
from	O
all	O
study	O
groups	O
although	O
at	O
lower	O
concentrations	O
than	O
morphine-3-glucuronide	B
(M3G).	O

Under	O
this	O
partition	O
function	O
if	O
FA	B
(22:3)	I
is	O
≥	O
0.045	O
ppm	O
and	O
PC	B
(39:6)	I
is	O
≥	O
0.145	O
ppm,	O
100%	O
sensitivity	O
(18	O
control	O
samples	O
classified	O
correctly	O
PCa)	O
and	O
77.7%	O
specificity	O
(of	O
18	O
tumor	O
samples	O
4	O
samples	O
are	O
misclassified)	O
could	O
be	O
achieved	O
in	O
classification	O
of	O
cancer	O
patients	O
from	O
the	O
corresponding	O
normal	O
group.	O

The	O
mixtures	O
were	O
then	O
extracted	O
3	O
times	O
with	O
50 mL	O
ethyl	B
acetate.	I

A	O
20	O
mM	O
sucrose	B
solution,	O
0.5	O
mM	O
TSP,	O
2	O
mM	O
NaN_3	O
in	O
90%	O
H_2	O
O/10%	O
D_2	O
O	O
(v/v)	O
was	O
used	O
for	O
line-shape	O
assessment,	O
system	O
equilibration,	O
and	O
quality	O
control.	O

L-arginine	B
and	O
ADMA	B
levels	O
measured	O
in	O
plasma	O
by	O
both	O
UHPLC-MS/MS	O
or	O
ELISA	O
showed	O
similar	O
relative	O
concentrations	O
and	O
patterns	O
of	O
change	O
after	O
bypass	O
surgery	O
(Fig. ).	O

In	O
the	O
experiments	O
with	O
buffer	O
we	O
tried	O
to	O
minimize	O
these	O
losses	O
by	O
using	O
high	O
metabolite	O
concentrations,	O
but	O
clearly	O
adsorptive	O
losses	O
were	O
still	O
considerable	O
especially	O
for	O
metabolites	O
such	O
as	O
thyroxine,	B
cortisone	B
and	O
cortisol.	B

Histidine’s	B
affinity	O
for	O
a	O
number	O
of	O
metal	O
ions	O
is	O
well	O
known	O
(Maley	O
and	O
Mellor	O
).	O

Yet,	O
under	O
these	O
conditions,	O
obese	O
and	O
diabetic	O
subjects	O
maintained	O
higher	O
acylcarnitine	B
concentrations	O
than	O
lean	O
controls.	O

Serum	O
levels	O
of	O
glucose,	B
insulin,	O
alanine	O
transaminase	O
(ALT),	O
aspartate	O
transaminase	O
(AST),	O
and	O
homeostatic	O
model	O
assessment-insulin	O
resistance	O
(HOMA-IR)	O
were	O
recorded.	O

AERD	O
is	O
well	O
known	O
as	O
a	O
distinct	O
phenotype	O
and	O
endotype	O
of	O
asthma;	O
it	O
is	O
characterized	O
by	O
eosinophilic	B
inflammation,	O
enhanced	O
leukotriene	O
production	O
and	O
activation	O
of	O
airway	O
mast	O
cells_,	O
.	O

In	O
the	O
accompanying	O
manuscript,	O
we	O
have	O
found	O
that	O
serum	O
levels	O
of	O
all	O
kynurenine	B
metabolites	O
are	O
altered	O
in	O
patients	O
with	O
chronic	O
migraine.	O

A	O
subset	O
(20	O
of	O
53)	O
of	O
the	O
metabolites	O
distinguished	O
patients	O
with	O
PAH	O
from	O
disease	O
control	O
subjects	O
after	O
correction	O
for	O
potential	O
confounders	O
(P	O
<0.05;	O
Table	O
I	O
in	O
the	O
online-only	B
Data	O
Supplement).	O

There	O
was	O
no	O
difference	O
between	O
the	O
3	O
groups	O
for	O
cholesterol	B
plasma	O
levels	O
(Fig.	O
).	O

The	O
significance	O
of	O
differences	O
in	O
cell	O
viability	O
under	O
oxidative	O
stress	O
with	O
and	O
without	O
reactive	O
polysulfide	B
species	O
was	O
evaluated	O
with	O
the	O
Tukey-Kramer	O
test.	O

Interestingly,	O
mass	O
spectrometry/liquid	O
chromatography	O
analyses	O
of	O
HNSCC	O
cell	O
lines	O
by	O
another	O
group	O
indicated	O
that	O
glucose	B
rather	O
than	O
glutamine	B
is	O
the	O
dominant	O
energy	O
source	O
required	O
for	O
proliferation	O
and	O
survival	O
of	O
HNSCC	O
cells.	O

The	O
phenolic	O
OH	O
of	O
AFB-Lys	O
and	O
AFB-dialdehyde	B
is	O
deprotonated	O
at	O
pH	O
7.4	O
(bathochromic	O
shift	O
of	O
the	O
UV-spectra	O
pH	O
4.0	O
to	O
pH	O
7.4).	O

To	O
ensure	O
stabilization	O
of	O
urinary	O
pH,	O
500	O
µl	O
of	O
urine	O
was	O
mixed	O
with	O
100	O
µl	O
of	O
phosphate	B
buffer	O
(90%	O
D2O,	O
1	O
mM	O
3-trimethylsilyl-1-[2,2,3,3-_2	B
H4]	I
propionate	I
(TSP),	O
and	O
3	O
mM	O
sodium	O
azide;	O
pH	O
7.4).	O

It	O
is	O
suggestive	O
that	O
some	O
kinds	O
of	O
population-related	O
metabolic	O
alteration	O
are	O
associated	O
with	O
HCC	O
state,	O
but	O
a	O
series	O
of	O
biological	O
behaviors	O
caused	O
by	O
high	O
glucose	B
consumption	O
have	O
become	O
a	O
common	O
feature.	O

Serum	O
cytokine	O
concentrations,	O
including	O
IL-1α,	B
IL-1β,	B
IL-2,	O
IL-4,	O
IL-6,	O
IL-8,	O
and	O
IL-10,	O
in	O
addition	O
to	O
IFNγ,	O
TNFα,	O
and	O
monocyte	O
chemoattractant	O
protein	O
1,	O
were	O
measured	O
with	O
the	O
use	O
of	O
a	O
high-sensitivity	O
ELISA	O
kit	O
(Randox	O
Laboratories).	O

In	O
Ta/T1	O
stage	O
disease,	O
when	O
comparing	O
pre-gemcitabine	O
normal	O
vs.	O
pre-gemcitabine	O
BCa	O
tissues,	O
bilirubin	B
was	O
decreased	O
significantly	O
in	O
the	O
BCa	O
tissues	O
(P=4.15E-2)	O
(Table	O
SI	O
and	O
),	O
while	O
this	O
decrease	O
recovered	O
to	O
an	O
insignificant	O
level	O
following	O
submucosal	O
injection	O
of	O
gemcitabine	O
(P=5.40E-1)	O
(Table	O
SI	O
and	O
);	O
however,	O
at	O
this	O
stage,	O
the	O
decrease	O
of	O
retinal	B
in	O
the	O
tumor	O
was	O
still	O
not	O
statistically	O
significant	O
(P=4.76E-1)	O
(Table	O
SI).	O

Previous	O
studies	O
have	O
shown	O
that	O
elevations	O
in	O
troponin	O
(Troponin	O
T)	O
and	O
creatine	B
kinase	O
(CK)	O
or	O
its	O
specific	O
MB	O
(CKMB)	O
isoform	O
after	O
primary	O
PCI	O
represent	O
larger	O
infarct	O
size	O
and	O
are	O
clearly	O
associated	O
with	O
increased	O
early	O
and	O
late	O
mortality.	O

In	O
the	O
present	O
study,	O
1-methyladenosine	B
clearly	O
discriminated	O
HCC	O
in	O
cluster	O
pattern	O
Y,	O
therefore,	O
it	O
is	O
expected	O
to	O
become	O
an	O
indicator	O
in	O
this	O
type	O
of	O
HCC.	O

Glucose	B
levels	O
trended	O
higher	O
in	O
regions	O
more	O
prone	O
to	O
tissue-damage	O
in	O
AD,	O
consistent	O
with	O
insufficient	O
clearance	O
via	O
glycolysis	O
with	O
consequent	O
up-regulation	O
of	O
the	O
alternative	O
polyol	O
pathway.	O

The	O
same	O
group	O
also	O
studied	O
changes	O
in	O
skeletal	O
muscle	O
metabolite	O
concentrations	O
after	O
exercise	O
training	O
and	O
found	O
nominally	O
(p	O
<	O
0.05)	O
significant	O
increases	O
in	O
even-chain	O
acylcarnitines	B
and	O
TCA	O
cycle	O
intermediates,	O
whereas	O
skeletal	O
muscle	O
concentrations	O
of	O
amino	O
acids,	O
glycolytic	B
metabolites	O
(lactate	O
and	O
pyruvate)	O
and	O
all	O
other	O
TCA	O
cycle	O
intermediates	O
did	O
not	O
change.	O

Recently,	O
MALDI-MSI	O
has	O
been	O
successfully	O
implemented	O
in	O
differentiation	O
of	O
brain	O
tumor	O
vs.	O
healthy	O
brain	O
tissue	O
on	O
a	O
murine	B
model	O
of	O
high-grade	O
glioblastoma.	O

The	O
resulting	O
aqueous	O
extract	O
contained	O
about	O
5	O
mM	O
GR,	O
the	O
biogenic	O
precursor	O
of	O
SF.	B

Glycogen	B
was	O
measured	O
on	O
20	O
μl	O
muscle	O
homogenate	O
against	O
a	O
glycogen	B
standard	O
with	O
the	O
Assay	O
Kit	O
(abcam,	O
Cambridge,	O
UK)	O
according	O
to	O
the	O
instructions.	O

When	O
counting	O
Δ9/Δ11	O
relative	O
isomer	O
ratios	O
for	O
PE	B
16:0_18:1,	I
the	O
RSDs	O
(8%)	O
of	O
the	O
technique	O
repeats	O
are	O
quite	O
comparable	O
to	O
that	O
of	O
subclass	O
quantitation;	O
however,	O
individual-to-individual	O
variation	O
is	O
significantly	O
reduced,	O
at	O
10%	O
for	O
normal	O
control	O
(I	O
_Δ9	O
/I	O
_Δ11	O
 = 5.0 ± 0.5)	O
and	O
11%	O
for	O
T2D	O
(I	O
_Δ9	O
/I	O
_Δ11	O
 = 3.8 ± 0.4).	O

On	O
the	O
other	O
hand,	O
comparison	O
of	O
the	O
non-esterified	O
or	O
free	O
fatty	O
acids	O
quantitative	O
results	O
between	O
the	O
TLC/GC-FID	O
and	O
the	O
GC-(+)EI	B
MS	O
platforms	O
shows	O
that	O
the	O
GC-(+)EI	B
MS	O
concentrations	O
of	O
palmitic	B
acid,	I
vaccinic	O
acid,	O
oleic	B
acid,	I
linoleic	B
acid,	I
dihomo-γ-linolenic	B
acid	I
and	O
docosapenta-(4,7,10,13,16)-enoic	B
acid	I
are	O
generally	O
higher	O
than	O
those	O
measured	O
by	O
TLC/GC-FID	O
(	O
and	O
).	O

Methanol	B
and	O
isopropanol	B
(gradient	O
grade)	O
were	O
purchased	O
from	O
Merck	O
(Darmstadt,	O
Germany).	O

Xanthine	B
on	O
the	O
other	O
hand	O
was	O
not	O
identified	O
as	O
a	O
marker	O
through	O
the	O
statistical	O
analysis.	O

Lithocholic	B
acid	I
(LCA)	O
belongs	O
to	O
the	O
bile	O
acid	O
family,	O
which	O
is	O
composed	O
of	O
molecules	O
that	O
are	O
essential	O
for	O
the	O
absorption	O
of	O
dietary	O
fats	O
and	O
the	O
regulation	O
of	O
cholesterol	B
homeostasis.	O

Using	O
all	O
identified	O
metabolites,	O
the	O
top	O
three	O
pathways	O
identified	O
were:	O
Glycerol	B
phosphate	I
shuttle,	O
ketone	B
body	O
metabolism,	O
and	O
glycine	B
and	O
serine	B
metabolism.	O

Nomenclature:	O
1,	O
lipid;	O
2,	O
beta-hydroxy	B
butyrate;	I
3,	O
branched	O
amino	O
acids;	O
4,	O
alanine;	B
5,	O
glutamate/glutamine;	O
6,	O
creatine;	B
7,	O
glucose;	B
8,	O
tyrosine;	B
9,	O
histidine.	B

Spectral	O
changes	O
corresponding	O
to	O
glutamine	B
and	O
alanine	B
resulted	O
from	O
a	O
pH-dependent	O
change	O
in	O
the	O
chemical	O
shift	O
of	O
these	O
resonances.	O

To	O
the	O
best	O
of	O
our	O
knowledge,	O
4	O
of	O
these	O
16	O
metabolites	O
(N-carbamoyl-β-alanine,	O

These	O
classes	O
were	O
prenol	B
lipids	O
(Pm/Rp&Ti:	O
7.8%,	O
Rp/Pm&Ti:	O
11.4%,	O
Ti/Pm&Rp:	O
8.1%),	O
glycerolipids	B
(Pm/Rp&Ti:	O
5.5%,	O
Rp/Pm&Ti:	O
5.2%,	O
Ti/Pm&Rp:	O
5.6%),	O
amino	O
acids	O
(Pm/Rp&Ti:	O
5.3%,	O
Rp/Pm&Ti:	O
6.5%,	O
Ti/Pm&Rp:	O
6.1%),	O
fatty	O
acid	O
esters	O
(Pm/Rp&Ti:	O
5.3%,	O
Rp/Pm&Ti:	O
4.2%,	O
Ti/Pm&Rp:	O
3.9%),	O
fatty	O
acids	O

Clearly,	O
the	O
optical	O
isomers	O
of	O
10-OH-WAR	B
was	O
better	O
separated	O
using	O
the	O
mobile	O
phase	O
of	O
ACN	O
/	O
H_2	O
O	O
(45/55,	O
v/v)	O
containing	O
10	O
mM	O
NH_4	O
OAc	O
at	O
pH	O
4.0	O
compared	O
to	O
the	O
mobile	O
composition	O
of	O
ACN	O
/	O
MeOH/	O
H_2	O
O	O
(30/50/20,	O
v/v/v).	O

We	O
next	O
determined	O
the	O
levels	O
of	O
each	O
species	O
of	O
SM	O
(C14:0,	O
C16:0,	B
C18:1,	B
C18:0,	B
C20:0,	B
C22:0,	B
C24:1,	B
C24:0,	B
C26:1	B
and	O
C26:0)	B
in	O
the	O
breast	O
cancer	O
and	O
normal	O
breast	O
tissue.	O

Product	O
ion	O
mass	O
spectra	O
of	O
A)	O
C*PF	O
(C-[S=O]-PhIP)	O
sulfinamide	B
adduct	O
([M+H]_+	O
at	O
m/z	O
604.2)	O
recovered	O
from	O
HONH-PhIP-modified	O
SA;	O
B)	O
C*PF	O
(C-[S=O]-[_2	O
H_5	O
]-PhIP)	O
sulfinamide	B
adduct	O
([M+H]_+	O
at	O
m/z	O
609.2)	O
recovered	O
from	O
HONH-[_2	O
H_5	O
]-PhIP	O
modified	O
SA;	O
C)	O
C*PF	O

Kynurenine	B
has	O
been	O
recently	O
linked	O
to	O
oxidative	O
damage	O
in	O
the	O
eye	O
(Linetsky	O
et	O
al.	O
).	O

In	O
summary,	O
treatment	O
of	O
type	O
2	O
diabetic	O
patients	O
with	O
a	O
PPAR-γ	O
agonist	O
(pioglitazone)	O
is	O
associated	O
with	O
a	O
reduction	O
in	O
both	O
intramyocellular	O
triglyceride	B
content	O
and	O
skeletal	O
muscle	O
LC-FACoAs	O
and	O
the	O
lack	O
of	O
an	O
effect	O
on	O
skeletal	O
muscle	O
DAG.	O

Lignoceric	B
acid	I
underwent	O
a	O
7.5-fold	O
decline	O
in	O
HCC	O
patients	O
relative	O
to	O
LC	O
(P<0.01).	O

At	O
the	O
same	O
time,	O
we	O
found	O
only	O
two	O
statistically	O
relevant	O
differences	O
in	O
serum	O
metabolomic	O
profiles	O
between	O
IBD	O
patients	O
with	O
quiescent	O
disease	O
and	O
healthy	O
control	O
subjects	O
(a	O
higher	O
level	O
of	O
dimethylamine	B
and	O
a	O
lower	O
level	O
of	O
dimethyl	B
sulfone)	I
and	O
in	O
this	O
case	O
it	O
was	O
not	O
possible	O
to	O
distinguish	O
the	O
cohorts	O
by	O
multivariate	O
modeling.	O

Phosphoethanolamine,	B
N-acetyl	B
aspartate	I
and	O
myo-inositol	B
are	O
down	O
regulated	O
in	O
prolactinoma,	O
whereas	O
aspartate,	B
glutamate	B
and	O
glutamine	B
are	O
up	O
regulated.	O

The	O
one	O
year	O
delta	O
of	O
quinolinic	B
acid	I
concentrations	O
was	O
negatively	O
associated	O
with	O
the	O
delta	O
of	O
fasting	O
glucose	B
(p	O
=	O
0.019)	O
and	O
HbA1c	O
(p	O
=	O
0.014),	O
whereas	O
the	O
delta	O
of	O
xanthurenic	B
acid	I
was	O
positively	O
associated	O
with	O
the	O
delta	O
of	O
insulin	O
sensitivity	O
index	O
(p	O
=	O
0.0018).	O

The	O
ions	O
observed	O
at	O
m/z	O
291.1	O
and	O
m/z	O
296.1,	O
respectively,	O
in	O
the	O
spectrum	O
of	O
NO_2	O
-PhIP-	O
and	O
NO_2	O
-[_2	O
H_5	O
]-PhIP-modified	O
ASSAKQR	O
are	O
at	O
the	O
same	O
m/z	O
observed	O
in	O
the	O
spectra	O
of	O
desamino-PhIP-K	B
([K*-NH_3	O
-HCO_2	O
H]_+	O
,	O
suggesting	O
that	O
NO_2	O
-PhIP	O
had	O
bound	O
to	O
lysine.	B

A	O
400	O
µmol/L	O
and	O
40	O
µmol/L-solution	O
of	O
4-hydroxybenzophenone	B
in	O
methanol	B
was	O
used	O
as	O
internal	O
standard	O
in	O
the	O
quantitative	O
analyses	O
of	O
urine,	O
serum,	O
and	O
breast	O
tissue,	O
respectively.	O

As	O
β-hydroxybutyrate	B
is	O
not	O
retained	O
as	O
a	O
significant	O
metabolite	O
in	O
Table 	O
of	O
our	O
study,	O
we	O
controvert	O
its	O
importance.	O

≥ 7.0	O
mmol/L,	O
2-hour	O
glucose	B

The	O
platform	O
was	O
designed	O
to	O
include	O
as	O
many	O
polar	O
metabolites	O
that	O
we	O
could	O
that	O
cover	O
major	O
metabolic	O
pathways	O
including	O
glycolysis,	O
TCA	O
cycle,	O
the	O
pentose	B
phosphate	I
pathway,	O
amino	O
acid	O
metabolism,	O
nucleotide	O
metabolism,	O
etc.	O
to	O
study	O
cancer	O
cell	O
metabolism.	O

(A,	O
B),	O
Levels	O
of	O
total	O
ceramide	B
(Cer)	O

Pairwise	O
correlations	O
between	O
sterol	O
and	O
vitamin	B
D	I
levels	O
revealed	O
evidence	O
for	O
shared	O
metabolic	O
pathways,	O
additional	O
substrates	O
for	O
known	O
enzymes,	O
and	O
transcriptional	O
regulatory	O
networks.	O

N-des-methyl	B
sibutramine	I
hydrochloride	I
(DSB),	O
N-di-desmethyl	B
sibutramine	I
hydrochloride	I
(DDSB),	O
sibutramine	B
d7	O
hydrochloride	B
(SB	O
d7),	O
N-des-methyl	B
sibutramine	I
d7	O
hydrochloride	B
(DSB	O
d7),	O
N-di-des	O
methyl	B
sibutramine	I
d7	O
hydrochloride	B
(DDSB	O
d7)	O
were	O
obtained	O
from	O
Toronto	O
Research	O
Chemicals,	O
Canada.	O

For	O
GC-MS	O
analysis,	O
dried	O
serum	O
lipid	O
extracts	O
were	O
directly	O
subjected	O
to	O
methylation	O
using	O
diazomethane	B
reagent,	O
by	O
which	O
the	O
non-volatile	O
fatty	O
acids	O
present	O
in	O
the	O
serum	O
samples	O
were	O
converted	O
into	O
volatile	O
FAMEs.	O

The	O
correlation	O
coefficients	O
for	O
the	O
acylcarnitine	B
concentrations	O
in	O
sperm	O
with	O
those	O
in	O
seminal	O
plasma	O
are	O
presented	O
in	O
.	O

In	O
addition,	O
analysing	O
66	O
invasive	O
ovarian	O
carcinomas	O
and	O
9	O
borderline	O
tumour	O
tissues	O
by	O
gas	O
chromatography/time-of-flight	O
mass	O
spectrometry,	O
Denkert,	O
et	O
al.	O
discovered	O
that	O
α-tocopherol	B
2	O
was	O
elevated	O
in	O
cancers,	O
and	O
the	O
fold	O
change	O
(of	O
cancer	O
vs	O
borderline	O
tumour)	O
was	O
2.5.	O

Without	O
using	O
demographic	O
characteristics,	O
a	O
number	O
of	O
metabolites	O
performed	O
as	O
well	O
or	O
better	O
in	O
RMSE	O
than	O
creatinine	B
alone	O
(N	O
-acetylthreonine,	I
pseudouridine	B
and	O
N	B
-acetylserine	I
in	O
both	O
studies	O
and	O
meso-erythritol,	B
arabitol,	B
myo-inositol	B
and	O
N	B
-acetylalanine	I
in	O
the	O
MESA	O
only).	O

Acetoacetate;	B
15.α-glucose;	B
16.	O

All	O
the	O
plasma	O
samples	O
were	O
thawed	O
at	O
4°C	O
and	O
a	O
volume	O
of	O
200	O
μl	O
of	O
plasma	O
was	O
mixed	O
with	O
600	O
μl	O
of	O
acetonitrile	B
at	O
4°C.	O

Hence,	O
we	O
conclude	O
that	O
neither	O
stearic	O
nor	O
oleic	B
acid	I
are	O
biosynthetic	O
precursors	O
of	O
9-HSA	O
in	O
colon	O
cancer	O
cells.	O

 m_2	O
(deduced	O
from	O
increased	O
serum	O
creatinine	B
by	O
the	O
Modification	O
of	O
Diet	O
in	O
Renal	O
Disease	O
Study	O
equation),	O
and	O
clinical	O
chemistry	O
tests	O
within	O
the	O
normal	O
range	O
±	O
10%.	O

Our	O
sample	O
of	O
the	O
general	O
Taiwanese	O
population	O
provided	O
some	O
evidence	O
of	O
decreasing	O
DEHP	O
and	O
DBP	B
levels	O
after	O
enacted	O
restrictions	O
and	O
regulations.	O

In	O
our	O
study,	O
we	O
observed	O
high	O
level	O
of	O
fumaric	B
acid	I
in	O
the	O
PDR	O
group,	O
and	O
the	O
AUC	O
for	O
detecting	O
diabetic	O
retinopathy	O
was	O
0.96	O
(95%	O
CI,	O
0.91–1).	O

After	O
the	O
intake	O
of	O
all	O
the	O
three	O
foods,	O
levels	O
after	O
1	O
h	O
were	O
significantly	O
lower	O
when	O
compared	O
to	O
baseline	O
based	O
on	O
a	O
paired	O
Wilcoxon	O
signed	O
rank	O
test,	O
after	O
milk	O
intake	O
(C15:0	O
p	O
=	O
9.8	O
×	O
10_−4	O
,	O
C17:0	B
p	O
=	O
2.9	O
×	O
10_−3	O
,	O
unknown	O
C17	O
p	O
=	O
1.9	O
×	O
10_−3	O
),	O
after	O
cheese	O
intake	O
(C15:0	O
p	O
=	O
2.9	O
×	O
10_−3	O
,	O
C17:0	B
p	O
=	O
1.4	O
×	O
10_−2	O
,	O
unknown	O
C17	O
p	O
=	O
1.4	O
×	O
10_−2	O
),	O
and	O
after	O
soy	O
drink	O
intake	O
(C15:0	O
p	O
=	O
9.8	O
×	O
10_−4	O
,	O
C17:0	B
p	O
=	O
2.9	O
×	O
10_−3	O
,	O
unknown	O
C17	O
p	O
=	O
9.8	O
×	O
10_−4	O
).	O

Thus,	O
it	O
is	O
not	O
surprising	O
that	O
β-alanine	B
is	O
a	O
popular	O
supplement	O
used	O
primarily	O
by	O
strength	O
and	O
power	O
athletes	O
to	O
enhance	O
their	O
performance,	O
as	O
well	O
as	O
for	O
training	O
aimed	O
at	O
improving	O
muscle	O
growth,	O
strength	O
and	O
power.	O

Investigation	O
has	O
been	O
conducted	O
in	O
accordance	O
with	O
the	O
ethical	O
standards	O
and	O
according	O
to	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
to	O
national	O
and	O
international	O
guidelines	O
and	O
has	O
been	O
accepted	O
by	O
the	O
members	O
of	O
the	O
institutional	O
review	O
board:	O
The	O
Ethics	O
Committee	O
of	O
Ambroise	B
Paré	O
Hospital	O
(Mons,	O
Belgium)	O
approved	O
this	O
study	O
on	O
May	O
2012	O
according	O
to	O
the	O
international	O
and	O
Belgian	O
laws.	O

Our	O
analyses	O
suggest	O
that	O
osteoporosis	O
is	O
related	O
to	O
testosterone	B
deficiency_–	O
and	O
is	O
independent	O
from	O
insulin	O
activity.	O

pOHMAMP	O
p	B
-hydroxymethamphetamine	I

The	O
strongest	O
individual	O
biomarkers	O
not	O
only	O
for	O
the	O
presence	O
of	O
fatty	O
liver	O
but	O
also	O
for	O
its	O
future	O
risk	O
were	O
VLDL	O
particles	O
and	O
the	O
related	O
triglyceride	B
concentrations.	O

d	O
l	O
During	O
our	O
profiling	O
studies	O
for	O
oxysterols,	B
we	O
monitored	O
the	O
MRM	O
transition	O
534→455→	O

The	O
highest	O
rate	O
of	O
anastrozole	B
glucuronide	I
formation	O
after	O
normalization	O
by	O
protein	O
content	O
was	O
observed	O
with	O
UGT1A4	O
(mean	O
anastrozole	B
glucuronide	I
formation	O
=	O
3863	O
nmol	O
min	O
_−1	O
mg_−1	O
),	O
followed	O
by	O
UGT1A3	O
(150	O
pmol	O
min_−1	O
mg_−1	O
),	O
and	O
UGT2B7	O
(57	O
pmol	O
min_−1	O
mg_−1	O
).	O

Among	O
the	O
20	O
candidate	O
lipid	O
markers,	O
decreasing	O
levels	O
were	O
observed	O
in	O
18	O
lipid	O
species	O
in	O
SqCC	O
patients;	O
however,	O
2	O
lipid	O
species,	O
PC(38:6)	B
and	O
PI(38:4),	B
presented	O
an	O
increased	O
level	O
in	O
SqCC	O
plasma	O
when	O
compared	O
with	O
the	O
controls.	O

The	O
most	O
sound	O
biological	O
subgroup	O
was	O
the	O
group	O
of	O
patients	O
with	O
HER2‐positive	O
disease	O
who	O
received	O
paclitaxel	O
plus	O
the	O
HER2‐targeted	O
treatment,	O
lapatinib.	B

Furthermore,	O
Case	O
#1	O
may	O
be	O
exposed	O
to	O
other	O
neonicotinoid	B
pesticides,	O
which	O
were	O
not	O
scrutinized	O
in	O
this	O
study.	O

Given	O
that	O
TCA	O
cycle-associated	O
metabolites	O
and	O
lactate	B
were	O
found	O
elevated	O
in	O
the	O
recurrent	O
group	O
after	O
RFA	O
therapy,	O
this	O
decrease	O
in	O
PPP	O
metabolites	O
might	O
result	O
from	O
down-regulation	O
of	O
the	O
energy	O
supply	O
from	O
this	O
pathway.	O

AER	O
was	O
measured	O
yearly	O
during	O
the	O
DCCT	O
and	O
every	O
other	O
year	O
during	O
EDIC	O
by	O
4-h	O
timed	O
urine	O
collection	O
using	O
fluoroimmunoassay	B
(coefficient	O
of	O
variation,	O
9.4%).	O

Two	O
studies	O
have	O
previously	O
reported	O
a	O
weak	O
increase	O
in	O
the	O
activities	O
of	O
20α-HSD	B
and	O
20β-HSD	B
in	O
lean	O
women	O
with	O
PCOS._,	O
When	O
separately	O
analyzing	O
the	O
activities	O
of	O
20α-HSD	B
and	O
20β-HSD,	B
we	O
found	O
a	O
highly	O
significant	O
increase	O
in	O
the	O
former	O
and	O
a	O
normal	O
activity	O
in	O
the	O
latter	O
in	O
the	O
PCOS	O
group.	O

Consistent	O
with	O
our	O
study,	O
a	O
decrease	O
in	O
the	O
concentration	O
of	O
glutamine	B
was	O
also	O
documented	O
in	O
the	O
plasma	O
of	O
patients	O
with	O
early	O
stage	O
head	O
and	O
neck	O
cancer.	O

The	O
serum	O
was	O
transferred	O
into	O
a	O
bar-coded	O
13 mL	O
polypropylene	B
transfer	O
tube,	O
capped	O
and	O
frozen	O
in	O
dry	O
ice.	O

This	O
enzyme	O
catalyzes	O
two	O
reactions	O
of	O
the	O
histidine	B
metabolism,	O
in	O
particular	O
the	O
degradation	O
of	O
N-formimino-L-glutamic	B
acid	I
to	O
form	O
5,10-methenyltetrahydrofolate,	B
L-glutamate,	B
and	O
ammonia	O
(KEGG	O
pathway	O
2.1.2.5,	O
Supplementary	O
Table _S4	O
).	O

We	O
hypothesised	O
that	O
the	O
reportedly	O
lower	O
aerobic	O
performance	O
in	O
non-carriers	O
compared	O
to	O
carriers	O
of	O
the	O
ACE	O
I-allele,	O
i.e.	O
ACE-DD	O
vs.	O
ACE-ID/ACE-II	O
genotype,	O
is	O
associated	O
with	O
alterations	O
in	O
activity-induced	O
glucose	B
metabolism	O
and	O
capillarisation	O
in	O
exercise	O
muscle.	O

5-ASA	O
=	O
5-Aminosalicylic	B
Acid	I
Based	O
Medications,	O
TNFα	O
=	O
tumor	O
necrosis	O
factor	O
alpha,	O
NS	O
=	O
Not	O
Significant	O

On	O
D7,	O
KYN	O
and	O
PC	B
aa	I
C42:4	I
were	O
positively	O
correlated	O
to	O
28-day	O
mortality,	O
while	O
PC	B
aa	I
C40:1	I
and	O
PC	B
ae	I
C40:1	I
are	O
negatively	O
correlated.	O

Test	O
vs.	O
reference	O
pharmacokinetic	O
parameters	O
of	O
sibutramine,	B
N-des	O
methyl	B
sibutramine	I
and	O
N-di	O
des	B
methyl	I
sibutramine	I
after	O
administration	O
of	O
15 mg	O
of	O
test	O
and	O
reference	O
products	O
in	O
40	O
healthy	O
human	O
volunteers.	O

Abbreviations:	O
U,	O
unknown;	O
PO4,	O
phosphate;	B
Met,	O
L-methionine;	B
1,5-AS,	B
1,5-anhydro-D-sorbitol;	B
Phe,	O
phenylalanine;	B
4-HMA,	O
4-hydroxymandelic	B
acid;	I
N-AAA,	O
N-acetylaspartic	B
acid;	I
2,5-FDCA,	B
2,5-furandicarboxylic	B
acid;	I
ism,	O
isomer;	O
3-AIBA,	O
3-aminoisobutyric	B
acid.	I

The	O
breakdown	O
of	O
stored	O
TG	B
is	O
largely	O
regulated	O
by	O
ATGL	O
and	O
HSL.	O

This	O
metabolomic	O
analysis	O
confirmed	O
lactate	B
and	O
creatinine	B
as	O
markers	O
of	O
asphyxia	O
and	O
discovered	O
new	O
metabolites	O
including	O
succinic	B
acid	I
and	O
malate	B
(intermediates	O
in	O
the	O
Krebs	O
cycle)	O
and	O
arachidonic	B
acid	I
(a	O
brain	O
fatty	O
acid	O
and	O
inflammatory	O
marker)	O
as	O
potential	O
biomarkers.	O

Next,	O
the	O
column	O
was	O
eluted	O
with	O
800	O
µL	O
2%	O
acetic	B
acid	I
in	O
diethyl	B
ether	I
to	O
a	O
new	O
tube,	O
dried	O
by	O
N_2	O
,	O
and	O
dissolved	O
in	O
200	O
µL	O
methanol,	B
resulting	O
in	O
a	O
fatty	O
acids	O
fraction.	O

For	O
MALDI‐MSI	O
analysis,	O
a	O
uniform	O
coating	O
of	O
α‐cyano‐4‐hydroxycinnamic	B
acid	I
(CHCA)	O
matrix	O
solution	O
(Huwiler	O
et al.,	O
2003	O
Dec)	O
was	O
applied	O
to	O
designated	O
tissue	O
sections	O
using	O
an	O
automated	O
spray	O
system	O
(TM	O
Sprayer,	O
HTX	O
Technologies,	O
NC,	O
USA).	O

CPMG	O
acquisitions	O
provided	O
clear	O
delineation	O
of	O
2HG	O
from	O
neighboring	O
metabolites	O
γ-aminobutyric	B
acid	I
(GABA),	O
glutamine	B
(Gln),	O
and	O
Glu	O
and	O
were	O
therefore	O
used	O
for	O
all	O
further	O
analyses	O
in	O
this	O
study.	O

The	O
HPLC	O
grade	O
reagents,	O
methanol,	B
acetonitrile,	B
deionized	O
water,	O
Bovine	O
serum	O
albumin	O
(BSA),	O
Potassium	B
Phosphate,	I
12×75mm	O
polystyrene	O
tubes	O
from	O
Fisher	O
Scientific,	O
Pittsburg,	O
PA,	O
USA.	O

This	O
argues	O
that	O
cortisol	B
may	O
reflect	O
early	O
pathological	O
changes	O
in	O
the	O
brain.	O

Data	O
indicated	O
that	O
faecal	O
decreased	O
metabolites	O
such	O
as	O
matricin,	B
protorifamycin	B
I,	O
and	O
epothilone	B
A	O
were	O
negatively	O
correlated	O
with	O
Actinobacteria	O
,	O
matricin	B
and	O
PA	O
were	O
positively	O
correlated	O
with	O
Bacteroides	O
,	O
epothilone	B
A	O
was	O
positively	O
correlated	O
with	O
Firmicutes	O
,	O
and	O
PA	O
was	O
negatively	O
correlated	O
with	O
Firmicutes	O
(Supplementary	O
).	O

The	O
mass	O
spectrometer	O
was	O
operated	O
in	O
the	O
negative	O
mode	O
with	O
a	O
3.0	O
kV	B
capillary	O
voltage.	O

Higher	O
PTH	O
was	O
associated	O
with	O
a	O
significantly	O
lower	O
mean	O
24,25(OH)_2	B
D_3	O
concentration	O
at	O
a	O
25(OH)D_3	O
of	O
20	O
ng/mL	O
in	O
SKS,	O
but	O
not	O
MESA	O
or	O
CHS.	O

A,	O
palmitic	B
acid	I
(16:0);	O
B,	O
stearic	B
acid	I
(18:0);	O
C,	O
oleic	B
acid	I
(18:1n-9);	O
D,	O
linoleic	B
acid	I
(18:2n-6);	O
E,	O
eicosadienoic	B
acid	I
(20:2n-6);	O
F,	O
eicosatrienoic	B
acid	I
(20:3n-6);	O
G,	O
arachidonic	B
acid	I
(20:4n-6);	O
H,	O
eicosapentaenoic	B
acid	I
(20:5n-3);	O
I,	O
lignoceric	B
acid	I
(24:0);	O
J,	O
cholesterol.	B

Given	O
that	O
most	O
metabolites	O
have	O
relatively	O
short	O
half-lives,	O
the	O
weak	O
correlation	O
between	O
5-methyl-2-furoic	B
acid	I
and	O
dietary	O
soy	O
intake	O
may	O
have	O
been	O
stronger	O
if	O
we	O
had	O
questionnaire	O
or	O
diary	O
data	O
for	O
the	O
last	O
few	O
days	O
before	O
urine	O
was	O
collected.	O

2-Amino-1-methyl-6-[_2	B
H_5	I
]-phenylimidazo[4,5-b	I
]pyridine	I
([_2	O
H_5	O
]-PhIP,	O
99%	O
isotopic	O
purity)	O
was	O
a	O
gift	O
from	O
Dr.	O
Mark	O
Knize	O
and	O
Dr.	O
Kristen	O
Kulp,	O
(Lawrence	O
Livermore	O
National	O
Laboratory,	O
Livermore,	O
CA).	O

genistein,	B
total	O
daidizein	O
and	O
total	O
isoflavone	B
concentrations	O
was	O
assessed	O
for	O
these	O
20	O
regions	O
in	O
the	O
treatment	O
group	O
(Table ),	O
again	O
without	O
significant	O
results	O
(likewise	O
for	O
Pearson	O
correlations).	O

Metabolomic	O
profiling	O
(lipids	O
and	O
amino	B
acids)	O
was	O
performed	O
by	O
ultra-high-performance	O
liquid	O
chromatography	O
coupled	O
to	O
mass	O
spectrometry	O
in	O
serum	O
samples.	O

Tear	O
lipidomics	O
showed	O
30	O
phospholipids	B
significantly	O
modulated	O
and,	O
notably,	O
many	O
sphingomyelins	B
resulted	O
lower	O
in	O
MuS.	O
Moreover,	O
the	O
metabolomics	O
approach	O
carried	O
out	O
both	O
on	O
tears	O
and	O
serum	O
highlighted	O
the	O
diagnostic	O
potential	O
of	O
specific	O
aminoacids	B
and	O
acylcarnitines.	B

Preliminary	O
synthetic	O
cannabinoids	B
recovery	O
studies	O
were	O
conducted	O
in	O
triplicate	O
during	O
method	O
development	O
to	O
evaluate	O
potential	O
sample	O
preparation	O
approaches	O
with	O
Resprep	O
C18	O
columns,	O
Strata	O
C8	O
columns	O
and	O
SLE.	O

Griffin	B
et	O
al	O
.	O
reported	O
that	O
the	O
main	O
metabolic	O
changes	O
monitored	O
using	O
NMR	O
in	O
CVD	O
patients	O
were	O
derived	O
from	O
lipids	O
in	O
lipoproteins,	O
as	O
well	O
as	O
choline.	B

Subjects	O
in	O
the	O
highest	O
tertile	O
of	O
betaine	B
had	O
lower,	O
total	O
cholesterol,	B
TG	B
and	O
C-reactive	O
protein	O
(CRP).	O

Ethyl	B
2-methylacetoacetate,	I
4-hydroxybenzoic	B
acid,	I
benzil	B
and	O
hippuric	B
acid	I
were	O
diluted	O
in	O
the	O
anhydrous	B
ethanol.	I

Plasma	O
lipid	O
profiles,	O
including	O
367	O
lipid	O
species	O
from	O
13	O
classes	O
of	O
phospholipids	B
and	O
1	O
class	O
of	O
CE,	O
were	O
identified	O
by	O
lipidomics	O
from	O
a	O
total	O
of	O
194	O
plasma	O
samples	O
(84	O
with	O
breast	O
cancer	O
and	O
110	O
with	O
benign	O
breast	O
disease).	O

The	O
total	O
serum	O
lipid	O
levels	O
were	O
calculated	O
by	O
adding,	O
from	O
free	O
cholesterol,	B
total	O
cholesterol,	B
phospholipids	B
and	O
triglycerides,	B
as	O
previous	O
described	O
.	O

In	O
urine,	O
citrate	B
and	O
acetone	B
were	O
statistically	O
important,	O
and	O
it	O
followed	O
the	O
same	O
decreasing	O
trend	O
as	O
in	O
the	O
tissue	O
extract.	O

After	O
removing	O
plasma	O
and	O
the	O
upper	O
layer	O
of	O
packed	O
RBCs,	O
the	O
remaining	O
RBCs	O
were	O
washed	O
with	O
saline	B
and	O
centrifuged	O
twice	O
at	O
1000g	O
for	O
10	O
minutes.	O

_,	O
It	O
has	O
also	O
been	O
shown	O
that	O
the	O
elevation	O
of	O
2-aminoadipic	B
acid	I
after	O
long-term	O
hyperglycemia	O
of	O
endothelial	O
cells	O
is	O
a	O
sign	O
of	O
lysine	B
breakdown	O
through	O
oxidative	O
stress	O
and	O
reactive	O
oxygen	O
species.	O

For	O
example,	O
many	O
products	O
of	O
cholesterol	B
metabolism	O
were	O
identified	O
but	O
testosterone	B
itself	O
was	O
not.	O

After	O
12	O
h	O
overnight	O
fast,	O
subjects	O
ingested	O
75	O
g	O
glucose	B
in	O
solution.	O

First,	O
clinical	O
symptoms	O
of	O
FD	B
were	O
evaluated	O
using	O
the	O
Nepean	O
Dyspepsia	O
Index	O
(NDI),	O
and	O
plasma	O
metabolic	O
profiles	O
were	O
measured	O
by	O
_1	O
H	O
NMR.	O

The	O
final	O
4-min	O
period	O
was	O
maintained	O
at	O
5%	O
solution	O
A,	O
95%	O
acetonitrile.	B

Calibration	O
curves	O
were	O
constructed	O
in	O
plasma	O
with	O
low	O
and	O
high	O
triglyceride	B
levels.	O

The	O
association	O
studies	O
of	O
differentially	O
abundant	O
microbes	O
and	O
metabolites	O
showed	O
that	O
microbes	O
were	O
significantly	O
correlated	O
with	O
each	O
other,	O
and	O
4	O
metabolites	O
(homocysteine,	O
putrescine,	B
glycine,	B
and	O
ornithine)	O
were	O
strongly	O
associated	O
with	O
several	O
microbes	O
(Clostridium,	O
Lachnospira,	O
Intestinibacter	B
,	O
and	O
et	O
al.).	O

Acetyl-CoA	B
enrichment	O
was	O
positively	O
correlated	O
with	O
plasma	O
glucose	B
enrichment.	O

In	O
the	O
test	O
sample,	O
we	O
detected	O
206	O
glycerophospholipids	B
and	O
105	O
sphingolipids.	B

If	O
not	O
stated	O
otherwise	O
solvents	O
were	O
purchased	O
from	O
Sigma-Aldrich	O
(Austria)	O
in	O
high	O
quality	O
(CHROMASOLV®,	O
HPLC	O
grade),	O
formic	B
acid	I
(ROTIPURAN®)	O
was	O
purchased	O
from	O
Carl	O
Roth	O
(Germany),	O

Chief	O
among	O
them	O
are	O
several	O
GPLs	O
that	O
are	O
believed	O
to	O
have	O
biological	O
significance	O
in	O
cancer	O
physiology,	O
including	O
PC(32:1),	B
PC(34:1),	B
PS(38:5),	B
PE(38:6),	B
PC(32:3),	B
and	O
PC(34:2)._5	B
,	O

The	O
Biocrates	O
AbsoluteIDQ	O
p180	O
kit	O
allows	O
the	O
identification	O
and	O
measurement	O
of	O
more	O
than	O
180	O
metabolites,	O
including	O
amino	O
acids,	O
biogenic	O
amines,	O
acylcarnitines,	B
lysophosphatidylcholines,	B
phosphatidylcholines,	B
sphingomyelins	B
and	O
the	O
sum	O
of	O
hexoses	O
(one	O
resultant	O
metabolite).	O

Ac	O
(10 mM,	O
aqueous)	O
(40/40/20,	O
v/v/v)),	O
the	O
PB	O
reactions	O
of	O
a	O
variety	O
of	O
GP	B
standards,	O
belonging	O
to	O
different	O
subclasses	O
and	O
containing	O
different	O
degrees	O
of	O
unsaturation,	O
could	O
all	O
reach	O
a	O
steady	O
state	O
in	O
40 s	O
with	O
moderate	O
yields	O
(20–30%).	O

Compound	O
2	O
was	O
obtained	O
at	O
75%	O
yield	O
after	O
recrystallization	O
using	O
methanol.	B

The	O
CID	O
mass	O
spectrum	O
of	O
the	O
protonated	O
[M + H]_+	O
ion	O
confirmed	O
the	O
presence	O
of	O
the	O
phosphocholine	B
polar	O
head	O
(c),	O
whereas	O
the	O
CID	O
mass	O
spectrum	O
of	O
the	O
formate	B
adduct	O
[M − H + CHO_2	O
]_−	O
ion	O
enabled	O
the	O
detection	O
of	O
the	O
two	O
FA	B
C18:1	I
(m/z	O
281.2487)	O
and	O
FA	B
C16:0	I
(m/z	O
255.2329)	O
associated	O
fatty	O
acids	O
(d),	O
leading	O
to	O
an	O
improved	O
structural	O
characterization	O
of	O
this	O
lipid	O
species	O
The	O
characterization	O
of	O
isomeric	O
lipid	O
species	O
constitutes	O
another	O
critical	O
issue,	O
not	O
only	O
of	O
“shotgun	O
lipidomic	O
approaches”,	O
but	O
also	O
of	O
hyphenated	O
liquid	O
chromatography	O
coupled	O
mass	O
spectrometry.	O

haematobium	O
catechol	B
estrogen	I
and	O
related	O
molecules	O
identified	O
previously	O
in	O
Santos	O
et	O
al	O
.	O

However,	O
decreased	O
concentrations	O
of	O
amino	O
acids	O
can	O
be	O
detected	O
by	O
this	O
method,	O
as	O
illustrated	O
by	O
the	O
repeatedly	O
decreased	O
concentration	O
of	O
lysine	B
in	O
a	O
sample	O
of	O
a	O
patient	O
affected	O
with	O
LPI	O
(	O
and	O
).	O

In	O
a	O
study	O
by	O
Uchiyama	O
et	O
al.	O
based	O
on	O
capillary	O
electrophoresis/mass	O
spectrometry,	O
in	O
which	O
14	O
stage	O
I	O
colorectal	O
cancer	O
patients	O
and	O
14	O
stage	O
II	O
colorectal	O
cancer	O
patients	O
were	O
included	O
in	O
the	O
sample	O
set,	O
the	O
serum	O
level	O
of	O
benzoic	B
acid	I
showed	O
sensitivity,	O
specificity,	O
and	O
AUC	O
values	O
of	O
1.0,	O
0.98,	O
and	O
0.98,	O
respectively,	O
for	O
stage	O
I	O
colorectal	O
cancer,	O
and	O
0.93,	O
0.90,	O
and	O
0.95,	O
respectively,	O
for	O
stage	O
II	O
colorectal	O
cancer.	O

Absolute	O
concentrations	O
of	O
free	O
radical	O
dependent	O
oxysterols,	B
7β-OHC	B
and	O
7-KC	O
were	O
significantly	O
increased	O
(P < 0.0001)	O
in	O
hypercholesterolaemic	B
men	O
at	O
baseline	O
and	O
after	O
3	O
months	O
intervention	O
with	O
simvastatin,	B
oxysterol	B
concentrations	O
in	O
plasma	O
were	O
similar	O
to	O
those	O
of	O
healthy	O
subjects.	O

Furthermore,	O
the	O
mechanisms	O
underlying	O
blueberry	O
effects,	O
such	O
as	O
reduction	O
of	O
oxidative	O
stress	O
and	O
inflammation,	O
improvement	O
of	O
endothelial	O
dysfunction,	O
regulation	O
of	O
cholesterol	B
accumulation	O
and	O
trafficking,	O
along	O
with	O
potentially	O
influence	O
of	O
gut	O
microbiota,	O
were	O
discussed	O
in	O
a	O
recent	O
review	O
showing	O
the	O
health	O
benefits	O
related	O
to	O
blueberries	O
consumption.	O

Identification	O
of	O
metabolites	O
was	O
conducted	O
based	O
on	O
fragmentation	O
patterns	O
of	O
NIST	O
library,	O
RI	B
value,	O
and	O
other	O
researcher's	O
experimental	O
data	O
using	O
the	O
same	O
method.	O

A	O
recent	O
study	O
has	O
also	O
revealed	O
the	O
important	O
role	O
that	O
glutamine,	B
as	O
a	O
nitrogen	O
source	O
for	O
the	O
synthesis	O
of	O
nucleotides	O
and	O
amino	O
acids,	O
plays	O
in	O
these	O
conditions.	O

After	O
centrifugation	O
at	O
200	O
g	O
and	O
4	O
°C	O
for	O
10	O
min	O
(Allegra	O
X15R,	O
Beckman	O
Coulter,	O
Brea,	O
CA),	O
the	O
culture	O
media	O
was	O
carefully	O
removed	O
and	O
the	O
cells	O
were	O
washed	O
twice	O
with	O
50	O
mL	O
freshly-prepared	O
phosphate	B
buffered	O
saline	B
(PBS).	O

Concentrations	O
of	O
cotinine	B
and	O
trans	B
-3′-hydroxycotinine	I
in	O
urine	O
were	O
determined	O
using	O
liquid	O
chromatography–tandem	O
mass	O
spectrometry	O
(LC-MS/MS).	O

Ketone	B
bodies	O
3-hydroxybutyrate	B
(BHBA)	O
and	O
acetoacetate	B
were	O
significantly	O
lower	O
following	O
ADT	O
(p<0.05	O
for	O
each).	O

In	O
the	O
present	O
study,	O
the	O
overweight	O
group	O
showed	O
glucose,	B
insulin,	O
HOMA-IR,	O
and	O
hs-CRP	O
than	O
control	O
group,	O
indicating	O
insulin	O
resistance	O
and	O
increased	O
inflammatory	O
status	O
than	O
controls.	O

The	O
serum	O
levels	O
of	O
tamoxifen	B
were	O
positively	O
associated	O
with	O
the	O
serum	O
levels	O
of	O
E2	O
and	O
E1	O
(R	O
=	O
0.295,	O
and	O
0.297,	O
p	O
=	O
0.025	O
and	O
p	O
=	O
0.020,	O
respectively,	O
Table	O
).	O

[,	O
],	O
where	O
patients	O
with	O
relapse	O
showed	O
higher	O
lactate	B
levels	O
compared	O
with	O
patients	O
with	O
remission.	O

(H)	O
acetate	B
at	O
1.86	O
p.p.m.	O

In	O
human	O
HCA-7	O
CRC	O
cells,	O
the	O
incorporation	O
of	O
EPA	O
from	O
cell-culture	O
medium	O
resulted	O
in	O
reduced	O
synthesis	O
of	O
prostaglandin	B
E_2	O
.The	O

AUC	O
was	O
0.81	O
(95%	O
CI	O
0.77,	O
0.86)	O
for	O
the	O
type	O
2	O
diabetes	O
risk	O
score	O
and	O
0.902	O
(95%	O
CI	O
0.87,	O
0.94)	O
for	O
the	O
type	O
2	O
diabetes	O
risk	O
score	O
+	O
metabolites	O
(p	O
=	O
1.1×10_−4	O
)	O
Metabolites	O
prioritised	O
≥10	O
times	O
in	O
the	O
training	O
set	O
for	O
type	O
2	O
diabetes	O
incidence	O
differentiation	O
Nineteen	O
metabolites	O
were	O
selected	O
ten	O
or	O
more	O
times	O
out	O
of	O
100	O
iterations	O
in	O
the	O
training	O
set	O
with	O
tenfold	O
cross	O
validation	O
at	O
minimum	O
mean	O
cross-validated	O
error	O
CE,	O
cholesteryl	B
ester;	I
DAG,	O
diacylglycerol;	B
HMDB-ID,	O
Human	O
Metabolome	O
Database	O
identification;	O
LPC,	O
lysophosphatidylcholine;	B
SM,	O
sphingomyelin;	B
PC,	O
phosphatidylcholine	B
Next,	O
we	O
used	O
the	O
set	O
of	O
19	O
metabolites	O
to	O
identify	O
enriched	O
metabolic	O
pathways.	O

The	O
concerted	O
changes	O
in	O
arginine	B
and	O
methylarginine	B
concentrations	O
did	O
not	O
significantly	O
alter	O
ADMA:	B
arginine	B
ratio	O
but	O
did	O
increase	O
L-NMMA:	B
arginine	B
and	O
SDMA:	O
arginine	B
ratios	O
after	O
bypass	O
surgery.	O

Another	O
case	O
report	O
reported	O
improvement	O
in	O
DED	O
signs	O
and	O
symptoms	O
in	O
a	O
patient	O
who	O
received	O
testosterone	B
cream	O
applied	O
to	O
the	O
eyelids	O
for	O
3	O
months.	O

Because	O
of	O
skewed	O
distribution,	O
logarithmically	O
transformed	O
values	O
of	O
triglycerides	B
were	O
used.	O

Some	O
investigators	O
have	O
hypothesized	O
that	O
statins	B
are	O
beneficial	O
in	O
PLWH	O
with	O
elevated	O
CV	O
risk	O
regardless	O
of	O
their	O
cholesterol	B
levels.	O

Insulin	O
resistance	O
that	O
develops	O
in	O
adipose	O
tissue	O
results	O
in	O
altered	O
ability	O
of	O
insulin	O
signaling	O
cascade	O
to	O
store	O
triglycerides.	B

For	O
the	O
indicators	O
that	O
reflected	O
the	O
severity	O
of	O
sepsis	O
(2-Phenylacetamide,	O
Ne,	O
Ne	O
dimethyllysine,	B
glyceryl-phosphoryl-ethanolamine	B
and	O
d-cysteine),	O
the	O
AUCs	O
were	O
determined	O
to	O
be	O
0.804	O
(95%	O
CI	O
0.647	O
to	O
0.962),	O
0.782	O
(95%	O
CI	O
0.602	O
to	O
0.962),	O

Columns	O
represent	O
KEGG	O
pathway,	O
the	O
number	O
of	O
genes	O
in	O
a	O
pathway,	O
the	O
number	O
of	O
“differentially	O
methylated”	B
genes	O
(loose	O
P	O
 < 0.0005	O
cut-off),	O
the	O
P	O
-value,	O
and	O
False	O
Discovery	O
Rate	O
(FDR).	O

The	O
levels	O
of	O
SL	B
metabolites	O
in	O
serum	O
and	O
urine	O
samples	O
from	O
45	O
AERD	O
patients	O
and	O
45	O
aspirin-tolerant	O
asthma	O
(ATA)	O
patients	O
were	O
quantified	O
through	O
mass	O
spectrometry.	O

Following	O
the	O
quantification	O
of	O
different	O
serum	O
sphingolipids	B
and	O
ceramides	B
by	O
LC-MS/MS	O
analysis,	O
many	O
interesting	O
alterations	O
in	O
sphingolipid	B
metabolism	O
were	O
identified	O
during	O
the	O
trimesters	O
of	O
pregnancy	O
and	O
in	O
the	O
post-partum	O
period.	O

The	O
rat	O
liver	O
microsomes	O
catalyzed	O
low	O
levels	O
of	O
glucuronidation	O
of	O
PhIP	O
at	O
both	O
the	O
endocyclic	B
N	O
3	O
and	O
exocyclic	B
N	O
_2	O
atoms	O
of	O
PhIP.	O

These	O
results	O
suggest	O
that	O
while	O
acylcarnitine	B
levels	O
were	O
not	O
strongly	O
associated	O
with	O
TB	O
or	O
TB-DM	O
in	O
the	O
initial	O
regression	O
analysis,	O
some	O
could	O
specifically	O
be	O
affected	O
in	O
individuals	O
with	O
severe	O
disease.	O

HMPMA	O
diastereomers	O
were	O
collected	O
by	O
HPLC	O
using	O
the	O
Synergi	O
column	O
described	O
above	O
with	O
elution	O
by	O
isocratic	O
95%	O
15	O
mM	O
NH_4	O
OAc,	O
5%	O
methanol.	B

Glycerophospholipids	B
not	O
only	O
constitute	O
the	O
backbone	O
of	O
neural	O
membranes,	O
but	O
also	O
provide	O
the	O
membrane	O
with	O
fluidity	O
and	O
ion	O
permeability.	O

Thus,	O
the	O
changes	O
observed	O
could	O
be	O
due	O
to	O
different	O
degrees	O
of	O
acetate	B
uptake	O
impairment	O
by	O
astrocytes.	O

 a;	O
median	O
absolute	O
difference	O
between	O
the	O
AUC	O
of	O
the	O
models	O
with	O
lactate	B
and	O
their	O
counterparts	O
without	O
lactate	B
was	O
0.096	O
for	O
the	O
strict	O
setting).	O

Association	O
of	O
rs11687765	O
with	O
HOMA-insulin	O
resistance	O
dropped	O
when	O
adjusted	O
by	O
the	O
valine	B
level	O
itself	O
(P-value	O
 = 0.122).	O

In	O
line	O
with	O
the	O
proinflammatory	O
character	O
of	O
PRMTs	O
overexpression,	O
all	O
PRMTs	O
evaluated	O
in	O
the	O
current	O
study	O
were	O
correlated	O
with	O
local	O
expression	O
of	O
inflammatory	O
cytokines,	O
more	O
pronouncedly	O
in	O
quiescent	O
tissue,	O
and	O
were	O
positively	O
correlated	O
with	O
the	O
clinical	O
activity	O
disease	O
indices,	O
CDAI	O
and	O
RI.	B

They	O
were	O
maintained	O
in	O
Dulbecco’s	O
Modified	O
Eagle	O
medium	O
supplemented	O
with	O
10%	O
(v/v)	O
fetal	O
bovine	O
serum,	O
2	O
mM	O
glutamine,	B
penicillin	B
(100	O
units/mL),	O
and	O
streptomycin	B
100	O
μg/mL.	O

The	O
absorption	O
of	O
hesperidin	B
and	O
narirutin	O
takes	O
place	O
in	O
the	O
colon	O
only	O
after	O
hydrolysis	O
by	O
rhamnosidases	O
originating	O
from	O
microflora	O
and	O
so	O
provides	O
distinctive	O
urinary	O
excretion	O
markers	O
to	O
indicate	O
the	O
onset	O
of	O
colonic	O
fermentation.	O

The	O
synthesis	O
of	O
Tem-SO	O
was	O
described	O
by	O
Leesch	O
and	O
Fukuto	O
via	O
the	O
several-steps	O
reaction	O
between	O
4,4′-dihydroxydiphenyl	O
and	O
sulfoxide	B
dimethyl	I
phosphorochlorhydrate.	I

Also,	O
downregulation	O
of	O
FASN	O
contributes	O
to	O
the	O
chemopreventive	O
effect	O
of	O
the	O
COX-2	O
inhibitor	O
celecoxib	B
[,	O
].	O

The	O
dominant	O
finding	O
from	O
the	O
pathway	O
analysis	O
was	O
that	O
sphingolipid	B
abnormalities	O
constituted	O
close	O
to	O
50%	O
of	O
all	O
of	O
the	O
metabolic	O
disturbances	O
associated	O
with	O
CFS	O
in	O
both	O
males	O
and	O
females.	O

When	O
we	O
saw	O
the	O
pronounced	O
increase	O
in	O
Cit	O
and	O
Arg	O
concentrations,	O
we	O
added	O
urea	B
measurement	O
to	O
our	O
testing	O
protocol.	O

An	O
example	O
of	O
a	O
spectra-like	O
STOCSY	O
plot	O
illustrated	O
in	O
shows	O
the	O
correlation	O
of	O
the	O
signal	O
at	O
m	O
/z	O
170.10	O
detected	O
in	O
positive	O
ion	O
mode	O
with	O
the	O
signals	O
at	O
m	O
/z	O
141.07,	O
m	O
/z	O
126.10,	O
and	O
m	O
/z	O
96.07	O
that	O
are	O
in-source	O
fragments	O
of	O
1-	O
and	O
3-methylhistidine.	B

This	O
molecular	O
mass	O
corresponds	O
to	O
the	O
mass	O
of	O
the	O
amino	O
acid	O
sequence	O
191–197	O
of	O
SA	O
(ASSAKQR,	O
[M+H]_+	O
at	O
m/z	O
747.4)	O
plus	O
desamino-PhIP	B
or	O
desamino-[_2	B
H_5	I
]-PhIP,	I
respectively	O
(addition	O
of	O
207	O
or	O
212	O
Da).	O

Green	O
dots	O
on	O
the	O
left	O
panels	O
are	O
samples	O
from	O
untreated	O
patients	O
(C	O
)	O
and	O
blue	O
dots	O
are	O
samples	O
from	O
Degarelix-treated	O
patients	O
(T	O
)	O
Figure 	O
shows	O
that	O
lactate	B
and	O
t-choline	B
[choline + phosphocholine	I
(PC) + glycerophosphocholine	I
(GPC)]	I
concentrations	O
were	O
significantly	O
higher	O
in	O
the	O
prostate	O
cancer	O
samples	O
compared	O
to	O
benign	O
samples.	O

Our	O
findings	O
of	O
low	O
LDL-cholesterol	B
and	O
low	O
LDL	O
subclass	O
levels	O
in	O
these	O
patients	O
suggest	O
this	O
may	O
protect	O
them	O
from	O
early	O
atherosclerosis	O
and	O
the	O
lipoprotein	O
profile	O
is	O
non-atherogenic.	O

The	O
organic	O
solvents	O
acetonitrile	B
and	O
methanol	B
(LC	O
grade)	O
were	O
purchased	O
from	O
Merck	O
(Darmstadt,	O
Germany).	O

There	O
were	O
15	O
cholesteryl	B
ester	I
(CE),	O
16	O
ceramide	B
(Cer),	O
7	O
diacylglycerol	B
(DG),	O
10	O
dihexosylceramide	B
(Hex2Cer),	O
7	O
hexosylceramide	B
(HexCer),	O
1	B
2-monoglyceride	I
(MG),	O
16	O
phosphatidic	B
acid	I
(PA),	O
214	O
PCs,	O
14	O
PCs	O
with	O
alkyl	O
substituent	O
(PC-O),	O
61	O
PCs	O
with	O
alkenyl	O
substituent	O
(PC-P),	O
72	O
PEs,	O
21	O
PE	O
with	O
alkenyl	O
substituent	O
(PE-P),	O
22	O
phosphatidylglycerol	B
(PG),	O
45	O
phosphatidylinositol	B
(PI),	O
43	O
sphingomyelin	B
(SM),	O
1	O
sphingosine	B
(SP),	O
and	O
129	O
triglyceride	B
(TG).	O

Thus	O
these	O
models	O
were	O
more	O
predictive	O
than	O
models	O
normalized	O
to	O
total	O
spectral	O
area	O
(PCT1	O
to	O
PCT6),	O
or	O
to	O
the	O
creatinine	B
peak	O
(PCT19	O
to	O
PCT24).	O

Branched	O
chain	O
amino	O
acids	O
(valine	O
and	O
leucine)	B
were	O
lower	O
following	O
short-term	O
acute	O
exercise	O
in	O
the	O
control	O
group.	O

The	O
line	O
shape	O
of	O
the	O
methyl	O
and	O
methylene	B
fatty-acid	O
resonances,	O
at	O
0.8	O
and	O
1.24	O
ppm,	O
depended	O
on	O
the	O
size	O
of	O
the	O
lipoprotein	O
particles.	O

The	O
bootstrapping	O
process	O
was	O
repeated	O
for	O
all	O
353	O
samples	O
containing	O
ibuprofen	B
and	O
its	O
metabolites.	O

In	O
the	O
present	O
study,	O
PRA	O
correlated	O
positively	O
with	O
plasma	O
levels	O
of	O
20-HETE	B
in	O
subjects	O
with	O
RVD.	O

An	O
immediate	O
increase	O
in	O
erythritol	B
blood	O
concentrations	O
was	O
observed,	O
followed	O
by	O
an	O
increase	O
of	O
erythronate	B
blood	O
concentrations.	O

At	O
3 months	O
of	O
treatment,	O
patients	O
with	O
good	O
adherence	O
had	O
26%	O
higher	O
tamoxifen	B
concentrations	O
than	O
patients	O
with	O
medium	O
adherence	O
(318 ± 97 nM	O
vs.	O
236 ± 115 nM;	O
P	O
 < .001;	O
Figure	O
a).	O

Considering	O
a	O
second	O
set	O
of	O
independent	O
samples	O
(from	O
the	O
same	O
geographic	O
origin),	O
analysed	O
under	O
the	O
same	O
conditions	O
but	O
approximately	O
1 year	O
before,	O
from	O
the	O
21	O
compounds,	O
only	O
15	O
were	O
detected	O
and	O
3	O
(2‐oxopropanal,	O
2,2‐dimethylpropionic	B
acid	I
butyl	I
ester,	I
and	O
2,5,8‐trimethyl‐1,2,3,4‐tetrahydronaphthalen‐1‐ol)	B
were	O
significant	O
and	O
in	O
agreement	O
with	O
the	O
results	O
from	O
the	O
untargeted	O
approach.	O

The	O
phenolic	O
HO	O
group	O
of	O
tyrosine	B
has	O
a	O
pK	O
a	O
of	O
~10,	O
whereas	O
the	O
pK	O
a	O
of	O
phenolic	O
HO	O
group	O
of	O
Tyr_411	O
is	O
lowered	O
to	O
7.9	O
due	O
to	O
the	O
electrostatic	O
interaction	O
with	O
guanidinium	B
ω-NH	I
of	O
Arg_410.	O

The	O
resulting	O
solution	O
was	O
again	O
applied	O
to	O
the	O
column	O
followed	O
by	O
a	O
wash	O
of	O
1	O
ml	O
of	O
17%	O
methanol.	B

Therefore,	O
high	O
serum	O
concentration	O
of	O
long-chain	O
acylcarnitines	B
in	O
HFpEF	O
patients	O
may	O
corroborate	O
the	O
findings	O
that	O
show	O
inflammation	O
is	O
strongly	O
associated	O
with	O
diastolic	O
dysfunction.	O

Furthermore,	O
experimental	O
studies	O
confirmed	O
a	O
relationship	O
between	O
ADMA	B
and	O
thyroid	O
function	O
by	O
showing	O
a	O
down-regulation	O
of	O
the	O
DDAH1	O
gene	O
in	O
mice	O
liver	O
following	O
T3	O
treatment	O
as	O
well	O
as	O
the	O
production	O
of	O
endogenous	O
ADMA	B
in	O
primary	O
human	O
thyrocytes.	O

The	O
level	O
of	O
citric	B
acid	I
(the	O
signals	O
at	O
2.55	O
and	O
2.7	O
ppm)	O
is	O
significantly	O
decreased	O
in	O
EG	O
as	O
compared	O
to	O
the	O
non-epileptic	O
reference	O
group,	O
whereas	O
the	O
choline	B
changes	O
are	O
not	O
important	O
after	O
the	O
age	O
related	O
correction.	O

However,	O
a	O
recently	O
published	O
study	O
showed	O
that	O
only	O
certain	O
species	O
of	O
phosphatidylethanolamine	B
(PE)	O
and	O
phosphatidylcholine	B
(PC),	O
but	O
not	O
GM3,	B
are	O
affected	O
by	O
food	O
intake	O
and	O
time	O
of	O
sample	O
collection.	O

The	O
abundances	O
of	O
Anaerotruncus	O
,	O
Intestinimonas	O
and	O
Oscillibacter	O
exhibited	O
significant	O
relationships	O
with	O
both	O
steroid	O
biosynthesis	O
and	O
sesquiterpenoid	B
and	O
triterpenoid	B
biosynthesis	O
pathways	O
in	O
both	O
tumor	O
and	O
normal	O
tissue	O
samples	O
with	O
Anaerotruncus	O
showing	O
the	O
most	O
significant	O
associations	O
(p	O
-values	O
<	O
0.0001)	O
(;	O
).	O

Go	O
to:	O
Dichlorodiphenyltrichloroethane	O
(p,p’	O
-DDT),	O
an	O
organochlorine	B
pesticide	O
known	O
to	O
have	O
deleterious	O
health	O
effects	O
in	O
humans,	O
has	O
been	O
linked	O
to	O
hepatocellular	O
carcinoma	O
(HCC)	O
in	O
rodents.	O

This	O
state	O
is	O
consistent	O
with	O
the	O
observed	O
higher	O
concentration	O
of	O
alpha-tocopherol,	B
the	O
biologically	O
active	O
form	O
of	O
the	O
lipophilic	O
vitamin	B
E	I
,	O
which	O
is	O
positively	O
correlated	O
with	O
blood	O
lipid	O
levels	O
and	O
adiposity	O
.	O

Three	O
of	O
the	O
5	O
OB/D	O
subjects	O
demonstrated	O
a	O
resolution	O
of	O
diabetes,	O
as	O
suggested	O
by	O
the	O
normalization	O
of	O
glucose	B
levels	O
and	O
the	O
fact	O
they	O
no	O
longer	O
needed	O
anti-diabetic	O
and	O
dyslipidemia	O
treatments	O
after	O
3	O
months.	O

In	O
the	O
case	O
of	O
MUFAs,	O
Cis-10-pentadecanoic	B
acid	I
(C15:1),	O
Cis-11-eicosenoic	B
acid	I
(C20:1n9)	O
and	O
erucic	B
acid	I
(C22:1n9)	O
were	O
demonstrated	O
as	O
potent	O
biomarkers	O
by	O
our	O
predictive	O
model.	O

The	O
six-metabolite	O
combination	O
of	O
alanine,	B
histidine,	B
leucine,	B
pyruvate,	B
tyrosine,	B
and	O
valine	B
displayed	O
superior	O
correlation	O
with	O
T2DM	O
in	O
both	O
CSF	O
and	O
plasma	O
samples	O
compared	O
to	O
clinical	O
parameters	O
such	O
as	O
HbA1c,	O
HOMA-IR.	O

On	O
the	O
next	O
day,	O
1	O
mL	O
of	O
freshly	O
prepared	O
3%	O
(v/v)	O
concentrated	O
H_2	O
SO_4	O
in	O
MeOH	B
was	O
added	O
to	O
the	O
dry	O
residue,	O
followed	O
by	O
sonication	O
and	O
vortexing	O
to	O
completely	O
dissolve	O
the	O
sample.	O

Higher	O
urinary	O
paracetamol	B
concentrations	O
among	O
male	O
partners	O
were	O
associated	O
with	O
a	O
longer	O
TTP.	O

In	O
a	O
scores	O
plot	O
of	O
the	O
first	O
two	O
components,	O
PC	O
2	O
identified	O
an	O
apparent	O
outlier	O
in	O
the	O
WNV	O
group,	O
which	O
upon	O
closer	O
examination	O
was	O
observed	O
to	O
have	O
extremely	O
low	O
levels	O
of	O
citrate,	B
lactate,	B
and	O
amino	O
acids	O
coupled	O
with	O
markedly	O
high	O
glutamate,	B
pyruvate,	B
acetate	B
and	O
2-oxoglutarate	B
compared	O
to	O
the	O
rest	O
of	O
the	O
samples.	O

Moreover,	O
in	O
in-vitro	O
experiments,	O
supplemental	O
histidine	B
lowered	O
the	O
expression	O
of	O
IL-6,	O
TNF-α	O
and	O
nuclear	O
factor	O
kappa-B	O
(NF-κB)	O
in	O
adipocytes.	O

Therefore,	O
the	O
relationships	O
between	O
urinary	O
nitrogen	O
excretion	O
through	O
urea,	B
hippurate,	B
and	O
PAG	B
may	O
be	O
a	O
potential	O
readout	O
for	O
CAD-NOD2	O
activity	O
in	O
pediatric	O
IBD.	O

For	O
sample	O
5	O
significantly	O
higher	O
variations	O
were	O
observed	O
especially	O
for	O
TG	B
species	O
concentrations	O
(see	O
also	O
“Evaluation	O
of	O
reproducibility	O
issues”).	O

A	O
downregulation	O
of	O
the	O
aforementioned	O
pathways	O
would	O
result	O
from	O
low	O
concentrations	O
of	O
these	O
sphingolipids,	B
favoring	O
metastasization.	O

A	O
high	O
positive	O
peak	O
(correlation)	O
belongs	O
to	O
a	O
corresponding	O
peak	O
in	O
the	O
NMR	O
spectrum	O
of	O
a	O
metabolite	O
that	O
has	O
a	O
relatively	O
high	O
concentration	O
in	O
the	O
Type	O
2	O
diabetes	O
mellitus	O
(T2DM)	O
placebo-treated	O
group,	O
and	O
a	O
relative	O
low	O
concentration	O
in	O
the	O
T2DM	O
rosiglitazone	B
(RSG)-treated	O
group.	O

Bovine	O
serum	O
albumin	O
(≥	O
96%),	O
phosphate-buffered	B
saline	I
(PBS),	O
25(OH)D_2	O
and	O
25(OH)D_3	O
were	O
obtained	O
from	O
Sigma	O
(St.	O
Louis,	O
MO).	O

Finally,	O
a	O
significant	O
inter-individual	O
variability	O
is	O
observed	O
in	O
the	O
postprandial	O
behaviour	O
of	O
the	O
candidate	O
FIBs,	O
its	O
extent	O
being	O
different	O
from	O
one	O
metabolite	O
to	O
the	O
other	O
as	O
illustrated	O
for	O
the	O
unmetabolized	O
lactose,	B
3-phenylalanine,	B
and	O
pinitol.	B

The	O
PIS	O
of	O
m/z	O
183	O
of	O
human	O
serum	O
samples	O
identified	O
the	O
complete	O
serum	O
FA	B
profiles	O
with	O
extremely	O
low	O
background	O
noise	O
and	O
high	O
sensitivity	O
(	O
top	O
panels).	O

The	O
eight	O
metabolites	O
were	O
N-acetylneuraminic	B
acid-9-phosphate,	I
5’-methioadenosine,	B
uric	O
acid-3-nucleoside,	O
pseudouridine,	B
L-valine,	B
succinic	B
acid,	I
L-proline	B
and	O
β-nicotinamide	B
mononucleotide.	O

Indeed,	O
plasma	O
acylcarnitine	B
concentrations	O
are	O
reduced	O
during	O
an	O
oral	O
glucose	B
tolerance	O
test	O
and	O
during	O
a	O
euglycemic-hyperinsulinemic	B
clamp,	O
both	O
procedures	O
that	O
reduce	O
plasma	O
FFA	O
concentrations	O
significantly	O
[,].	O

	O
Stock	O
solutions	O
of	O
BEN,	O
BEN-Cl_2	O
BA,	O
BA-Cl_2	O
BEN-(OH)_2	O
and	O
BA-(OH)_2	O
were	O
prepared	O
separately	O
at	O
1.0	O
mg/	O
mL	O
in	O
acetonitrile	B
containing	O
0.1	O
%	O
formic	B
acid.	I

Although	O
we	O
did	O
find	O
a	O
negative	O
association	O
between	O
cortisol	B
and	O
the	O
ratio	O
of	O
cortisol/ACTH	B
with	O
Trp,	O
there	O
was	O
no	O
association	O
with	O
melatonin.	B

Standard	O
clinical	O
laboratory	O
tests	O
including	O
bacteriological,	O
biochemical	O
analyses	O
of	O
CSF	O
and	O
blood	O
glucose	B
levels	O
were	O
collected	O
for	O
each	O
subject.	O

To	O
these	O
wells	O
were	O
added	O
100	O
μL	O
of	O
Griess	O
reagent	O
and	O
the	O
plate	O
was	O
read	O
at	O
540	O
nm	O
after	O
14	O
min	O
to	O
quantitate	O
nitrite	B
released	O
into	O
the	O
medium	O
after	O
induction	O
of	O
nitric	B
oxide	I
synthase	O
by	O
LPS.	B

Estrogen	B
metabolites,	O
conjugates	O
and	O
depurinating	O
DNA	O
adducts	O
were	O
identified	O
and	O
quantified	O
in	O
spot	O
urine	O
samples	O
from	O
15	O
men	O
with	O
NHL	O
and	O
30	O
healthy	O
control	O
men	O
by	O
using	O
ultraperformance	O
liquid	O
chromatography/tandem	O
mass	O
spectrometry.	O

Moreover,	O
choline,	B
betaine,	B
and	O
trimethylamine	B
N-oxide	I
(TMAO)	O
seem	O
to	O
be	O
upregulated	O
metabolites	O
in	O
both	O
liver	O
and	O
plasma	O
of	O
rodents	O
after	O
feeding	O
them	O
with	O
diets	O
provoking	O
fatty	O
liver.	O

The	O
SM/PC	O
ratio	O
for	O
healthy	O
and	O
septic	O
patients	O
was	O
determined	O
dividing	O
the	O
combine	O
pool	O
of	O
SM(d18:1/16:0,	B
d18:1/24:1,	I
d18:1/24:0,	I
d16:1/24:1,	I
16:1/24:0)	I
by	O
combined	O
pool	O
of	O
PC	O
from	O
healthy	O
and	O
septic	O
patients.	O

In	O
plasma	O
subtype	O
analyses,	O
isoleucine,	B
leucine,	B
valine,	B
phenylalanine,	B
glutamate,	B
and	O
pyruvate	B
were	O
higher	O
among	O
PRP	O
samples	O
compared	O
with	O
PPP	O
and	O
PFP	O
by	O
NMR	O
while	O
lipids	O
in	O
VLDL/LDL,	O
citrate,	B
and	O
glutamine	B
were	O
lower.	O

Further	O
analysis	O
indicated	O
that	O
a	O
panel	O
made	O
up	O
of	O
1-hydroxy-2-oxopropyl	B
tetrahydropterin,	I
1-acetoxy-2-hydroxy-16-heptadecyn-4-one,	B
1,2-dehydrosalsolinol	B
and	O
L-tyrosine	B
exhibited	O
the	O
best	O
capacity	O
to	O
distinguish	O
the	O
independent	O
subgroups.	O

In	O
a	O
multivariate	O
analysis	O
that	O
included	O
diabetes,	O
kyn/trp,	O
and	O
hippuric	B
acid,	I
only	O
the	O
kyn/trp	O
ratio	O
remained	O
significantly	O
associated	O
with	O
a	O
post-operative	O
cardiac	O
complication	O
(OR	O
44.1;	O
95%	O
CI	O
3.3–587.1;	O
P=.004).	O

Leucine	B
is	O
an	O
essential	O
amino	O
acid	O
in	O
humans	O
and	O
contributes	O
to	O
regulation	O
of	O
blood-sugar	O
levels.	O

The	O
fact	O
that	O
both	O
guanidinosuccinate	B
and	O
N-acetylneuramine	B
were	O
identified	O
as	O
predictors	O
for	O
kidney	O
deterioration	O
in	O
this	O
study	O
may	O
suggest	O
the	O
potential	O
roles	O
of	O
glycomodulation	O
in	O
the	O
progression	O
of	O
kidney	O
diseases.	O

(D)	O
Glycine	B
and	O
(E)	O
creatine	B
are	O
examples	O
of	O
metabolites	O
that	O
are	O
common	O
to	O
serum	O
and	O
whole	O
blood	O

More	O
in	O
detail,	O
MetPA	O
software	O
analysis	O
of	O
NMR	O
data	O
showed	O
a	O
significant	O
perturbation	O
of	O
alanine,	B
glutamine	B
and	O
glutamate	B
metabolism	O
in	O
both	O
T2DM	O
groups	O
(T2DM-C	O
and	O
T2DM-NC)	O
of	O
patients	O
(,	O
Tables	O
S1–S3).	O

α-Tocopherol	B
is	O
believed	O
to	O
be	O
the	O
main	O
source	O
found	O
in	O
supplements	O
and	O
in	O
the	O
European	O
diet,	O
whereas	O
γ-tocopherol	B
is	O
the	O
most	O
common	O
form	O
in	O
the	O
American	O
diet.	O

Mobile	O
phase	O
B	O
was	O
100%	O
acetonitrile.	B

This	O
suggests	O
acetate	B
has	O
a	O
critical	O
role	O
in	O
myelin	B
lipid	O
biosynthesis	O
in	O
MS	O
and	O
NMOSD.	O

I	O
(CPT-I)	O
converts	O
acyl-CoA	B
and	O
carnitine	B
to	O
acylcarnitine	B
which	O
is	O
then	O
transported	O
to	O
the	O
inner	O
mitochondrial	O
matrix.	O

1-HOP	O
levels	O
were	O
similar	O
between	O
cases	O
and	O
controls,	O
ranging	O
from	O
0.554	O
to	O
1.240	O
pmol/mg	O
creatinine	B
and	O
undetectable	O
to	O
1.105	O
pmol/mg	O
creatinine	B
(P	O
=	O
0.681),	O
respectively.	O

The	O
plate	O
was	O
then	O
dried,	O
the	O
samples	O
were	O
derivatized	O
with	O
phenyl	B
isothiocyanate	I
for	O
the	O
amino	O
acids	O
and	O
biogenic	O
amines.	O

This	O
difference	O
can	O
be	O
mainly	O
explained	O
by	O
the	O
influence	O
of	O
protein	O
signals	O
in	O
the	O
total	O
area	O
under	O
some	O
of	O
the	O
peaks,	O
especially	O
lactate	B
H7-9,	O
both	O
valine	B
peaks,	O
and	O
α-glucose	B
H19.	O

Phospholipids	B
were	O
extracted	O
from	O
an	O
average	O
of	O
3.4	O
×	O
10_6	O
TCID_50	O
of	O
purified	O
virions	O
by	O
using	O
acidified	O
methanol	B
followed	O
by	O
chloroform	B
extraction,	O
as	O
described	O
for	O
cells	O
above.	O

A	O
validated	O
and	O
reported	O
stable	O
isotope	O
dilution	O
high-performance	O
liquid	O
chromatography	O
tandem	O
mass	O
spectrometry	O
(HPLC-MS/MS)	O
assay	O
was	O
employed	O
to	O
measure	O
15	O
estrogens	O
and	O
estrogen	B
metabolites,	O
including	O
estrone,	B
estradiol,	B
2-hydroxyestrone,	B
2-methoxyestrone,	B
2-hydroxyestradiol,	B
2-methoxyestradiol,	B
2-hydroxyestrone-3-methyl	B
ether,	I
4-hydroxyestrone,	B
4-methoxyestrone,	B
4-methoxyestradiol,	B
16α-hydroxyestrone,	B
16-ketoestradiol,	O
estriol,	B
17-epiestriol,	O
and	O
16-epiestriol,	B
in	O
serum	O
as	O
previously	O
described_,	O
with	O
updated	O
instrumentations	O
and	O
additional	O
stable	O
isotope	O
labeled	O
estrogen	B
metabolites.	O

The	O
exclusion	O
criteria	O
were	O
presence	O
or	O
history	O
of	O
neurological	O
illness,	O
traumatic	O
brain	O
injury	O
with	O
any	O
known	O
cognitive	O
consequences	O
or	O
loss	O
of	O
consciousness	O
for	O
>5 min,	O
a	O
history	O
of	O
electroconvulsive	O
therapy,	O
low	O
premorbid	O
IQ	O
(<70),	O
previous	O
history	O
of	O
alcohol	O
addiction,	O
previous	O
continuous	O
illegal	O
substance	O
use	O
(for	O
example,	O
cannabis)	B
and	O
clearly	O
diagnosed	O
as	O
ASD	O
and	O
dissociative	O
disorders.	O

For	O
instance,	O
glycerol,	B
the	O
most	O
significantly	O
altered	O
metabolite	O
in	O
the	O
preeclampsia	O
case	O
study,	O
showed	O
moderate	O
level	O
of	O
decrease	O
in	O
SLE	O
compared	O
to	O
controls	O
in	O
our	O
study.	O

Ham's	O
F-12	O
supplemented	O
with	O
1×	O
penicillin/streptomycin	O
and	O
1×/2	O
mM	O
glutamax.	B

Venn	O
diagrams	O
represent	O
metabolite	O
frequencies	O
(numbers	O
in	O
circles)	O
and	O
their	O
share	O
among	O
replicates	O
(circles)	O
for	O
each	O
triatomine	O
species	O
(A:	O
T.	O
infestans	O
or	O
Ti,	O
B:	O
R.	O
prolixus	O
or	O
Rp,	B
C:	O
P.	O
megistus	O
or	O
Pm).	O

Alc	O
–	O
Higher	O
Alcohols,	O
Ald	B
-	I
Aldehydes,	I
Benz	B
-	I
Benzene	I
derivatives,	O
CTRL	O
–	O
control,	O
Est	O
–	O
Esters,	O
Fur	O
–	O
Furans,	O
HC	O
–	O
Hydrocarbons,	B
LC	O
–	O
patients	O
with	O
colon	O
cancer,	O
Napht	B
-	I
Naphthalene	I
derivatives,	O
Oth	O
–	O
Others,	O
Phen	O
–	O
Phenols,	O
Sulf	B
–	O
Organosulphurs,	O
Terp	B
-	I
Terpene	I
derivatives.	O

These	O
results	O
are	O
surprising	O
in	O
view	O
of	O
the	O
well-established	O
activity	O
of	O
this	O
pathway	O
based	O
on	O
in	O
vitro	O
studies	O
and	O
the	O
ease	O
of	O
detection	O
of	O
urinary	O
mercapturic	O
acids	O
of	O
other	O
xenobiotics	O
such	O
as	O
acrolein,	B
acrylonitrile,	O
and	O
benzene.	B

The	O
expected	O
dansylated	O
precursor	O
ion	O
was	O
observed	O
with	O
an	O
error	O
lower	O
than	O
5	O
ppm,	O
and	O
the	O
main	O
fragment	O
from	O
the	O
loss	O
of	O
dansylated	O
GABA	B
at	O
100.0753	O
m/z	O

Neither	O
of	O
these	O
fatty	O
acids	O
correlates	O
with	O
any	O
TAG	O
reduction	O
indicating	O
that	O
the	O
decrease	O
in	O
18:3	O
and	O
20:3	O
fatty	O
acids	O
preferentially	O
affect	O
PC	O
lipids	O
rather	O
than	O
triglycerides.	B

The	O
samples	O
destined	O
for	O
GC/MS	O
analysis	O
were	O
re‐dried	O
under	O
vacuum	O
desiccation	O
for	O
a	O
minimum	O
of	O
24 h	O
prior	O
to	O
being	O
derivatized	O
under	O
dried	O
nitrogen	O
using	O
bis‐trimethylsilyl‐trifluoroacetamide.	B

The	O
samples	O
were	O
boiled	O
for	O
20	O
min	O
and	O
methyl	B
esters	I
were	O
extracted	O
by	O
the	O
addition	O
of	O
2	O
mL	O
hexane	B
and	O
2	O
mL	O
deionised	O
water.	O

The	O
acidic	O
pathway	O
starts	O
with	O
26-hydroxylation	O
of	O
cholesterol	B
by	O
CYP27A1,	O
and	O
the	O
24(S	O
)-hydroxycholesterol	I
pathway	O
by	O
24(S	O
)-hydroxylation	O
of	O
cholesterol	B
by	O
CYP46A1.	O

The	O
IBD	O
patients	O
in	O
remission	O
were	O
characterized	O
by	O
a	O
significantly	O
higher	O
concentration	O
of	O
dimethylamine	B
and	O
a	O
lower	O
level	O
of	O
dimethyl	B
sulfone.	I

_1	O
H	O
NMR	O
studies	O
on	O
urinary	O
excretion	O
of	O
diagnostic	O
amino	O
acids	O
such	O
as	O
phenylalanine	B
in	O
phenylketonuria	O
(PKU),	O
branched	O
chain	O
amino	O
acids	O
(leucine,	O
valine,	B
isoleucine)	B
in	O
maple	O
syrup	O
urine	O
disease,	O
N	B
-acetyl	I
aspartic	I
acid	I
in	O
Canavan	O
disease,	O
and	O
tyrosine	B
and	O
N	B
-acetyl	I
tyrosine	I
in	O
tyrosinemia	O
type	O
I	O
have	O
been	O
reported	O
(,	O
).	O

These	O
findings	O
point	O
to	O
the	O
possibility	O
of	O
increased	O
RRM2	O
expression	O
as	O
being	O
a	O
downstream	O
consequence	O
of	O
activated	B
ESR1	O
in	O
patients,	O
a	O
hypothesis	O
that	O
needs	O
to	O
be	O
validated.	O

This	O
observation	O
might	O
indicate	O
the	O
interest	O
of	O
the	O
use	O
in	O
vivo	O
of	O
spectroscopy	O
combined	O
to	O
MRI	O
to	O
detect	O
hepatic	O
lesions	O
potentially	O
β-catenin	B
mutated.	O

Whiskers	O
indicate	O
range,	O
*	O
indicates	O
significant	O
difference	O
between	O
ACC	O
and	O
other	O
groups	O
ROC-analysis	O
demonstrated	O
that	O
15	O
steroid	O
metabolites	O
had	O
a	O
sensitivity	O
>90 %	O
for	O
detecting	O
ACC,	O
of	O
which	O
7	O
had	O
a	O
sensitivity	O
of	O
100 %	O
(i.e.,	O
tetrahydro-11-deoxycortisol	B
(THS),	O
pregnanediol	B
(P2),	O
pregnanetriol	B
(P3),	O
etiocholanolone	B
(E),	O
androsterone,	B
tetrahydrocortisol,	B
and	O
tetrahydrocortisone;	B
Table ).	O

Most	O
of	O
them	O
were	O
medium-and	O
long-chain	O
acylcarnitines,	B
indicating	O
the	O
compromised	O
mitochondrial	O
β-oxidation	O
functions.	O

Glutamate	B
is	O
an	O
important	O
energy	O
sourse	O
via	O
anaplerotic	O
input	O
into	O
the	O
the	O
tricarboxylic	B
acid	I
(TCA)	O
cycle	O
after	O
conversion	O
to	O
α-ketoglutarate.	B

A	O
significantly	O
higher	O
level	O
of	O
uracil	B
in	O
the	O
tumor	O
tissue	O
found	O
in	O
this	O
work	O
may	O
result	O
in	O
the	O
accumulation	O
of	O
genomic	O
uracil.	B

Most	O
of	O
the	O
94	O
metabolites	O
that	O
were	O
significantly	O
associated	O
with	O
TBC	O
in	O
both	O
KORA	O
and	O
TwinUK	O
samples	O
also	O
showed	O
significant	O
associations	O
with	O
TBC	O
in	O
the	O
present	O
study	O
(mainly	O
phosphatidylcholines	B
and	O
sphingomyelins).	B

Increasing	O
plasma	O
folate	B
level	O
was	O
positive	O
correlated	O
with	O
late	O
tumor	O
stage	O
(r	O
 = 0.108).	O

Glutathione	B
(A)	O
and	O
polyamines	B
(B)	O
metabolism	O
pathways.	O

The	O
mobile	O
phase,	O
operating	O
at	O
a	O
flow	O
rate	O
of	O
200	O
µL/min,	O
consisted	O
of	O
methanol	B
as	O
solvent	O
A	O
and	O
0.1%	O
(v/v)	O
formic	B
acid	I
in	O
water	O
as	O
solvent	O
B.	O
A	O
linear	O
gradient	O
changing	O
A	O
from	O
72%	O
to	O
85%	O
in	O
75	O
min	O
was	O
employed.	O

Furthermore,	O
we	O
observed	O
a	O
trend	O
of	O
increasing	O
ethanol	B
concentration	O
from	O
0.070	O
to	O
0.203 mM	O
(mean)	O
in	O
the	O
aliquots	O
of	O
method	O
3,	O
which	O
was	O
related	O
to	O
the	O
time	O
the	O
cryotubes	O
were	O
uncapped	O
during	O
aliquoting.	O

The	O
PFPP	O
column	O
offers	O
peak	O
shape	O
and	O
efficiency	O
that	O
are	O
comparable	O
with	O
the	O
C18	O
column,	O
but	O
it	O
has	O
the	O
advantage	O
of	O
resolving	O
25(OH)D_3	O
and	O
3-epi-25(OH)D_3	B
.	O

A	O
broad	O
peak	O
was	O
observed	O
for	O
DMA_III	O
,	O
but	O
in	O
human	O
cells	O
DMA_III	O
is	O
likely	O
present	O
in	O
GSH	B
complexed	O
form	O
which	O
can	O
be	O
detected	O
as	O
a	O
separate	O
species	O
(see	O
section	O
3.3).	O

Extraction	O
efficiencies	O
and	O
matrix	O
effects	O
for	O
synthetic	O
cannabinoids	B
in	O
urine	O
are	O
presented	O
in	O
.	O

Previous	O
studies	O
reported	O
that	O
plasma	O
FA	B
levels	O
were	O
increased	O
in	O
PD	O
[,	O
].	O

The	O
least	O
abundant	O
(detectable)	O
metabolites	O
in	O
serum	O
include	O
several	O
diacylglycerols	B
(DGs),	O
(>1	O
pM),	O
LPS-o-antigen	O
(2pM),	O
vitamin	B
K1	I
2,3-epoxide	I
(2	O
pM),	O
13,14-dihydro	B
prostaglandin	I
E1	I
(PGE1)	O
(3	O
pM),	O
substance	B
P	I
and	O
prostaglandin	B
E1	I
(4	O
pM),	O
various	O
glycerophospholipids	B
(4–100	O
pM),	O
vasopressin	B
(5	O
pM),	O
11-trans-Leukotriene	B
C4	I
(10	O
pM),	O
nitric	B
oxide	I
(12	O
pM),	O
LPS	B
core	I
(14	O
pM),	O
thyroxine	B
(15	O
pM),	O
3,5-diiodothyronine	B
(16	O
pM),	O
epietiocholanolone,	B
thromboxane	B
B3	I
and	O
cotinine	B
N-oxide	I
(17	O
pM),	O
thyroxine	B
sulfate	I
and	O
11b-hydroxyprogesterone	B
(∼20	O
pM).	O

The	O
fatty	O
acid	O
is	O
removed	O
from	O
the	O
sn-2	O
position	O
of	O
the	O
three-carbon	O
backbone	O
of	O
the	O
phospholipid	B
by	O
phospholipase	O
A2	O
to	O
produce	O
the	O
intermediate	O
LPC.	O

PKU	O
patients	O
also	O
had	O
lower	O
levels	O
of	O
22	O
LDL	O
subclasses	O
with	O
the	O
greatest	O
differences	O
in	O
LDL2	O
Apo-B,	O
LDL2	O
Particle	O
Number,	O
LDL2-phospholipids,	B
and	O
LDL2-cholesterol	B
(p	O
 < 0.0001).	O

Conversely,	O
high	O
glucose	B
levels	O
can	O
activate	O
the	O
pentose	B
phosphate	I
pathway_56	O
.	O

Chromatographic	O
separation	O
of	O
critical	O
isomer	O
pairs:	O
PGE_2	O
and	O
PGD_2	O
(upper),	O
PGF_2α	B
and	O
8-isoPGF_2α	B
(middle),	I
and	O
PD1	O
and	O
PDX	O
(bottom).	O

We	O
further	O
performed	O
Spearman	O
correlation	O
analysis	O
between	O
lysoPC	O
a	O
C20:3	B
and	O
Child-Pugh	O
scores,	O
as	O
well	O
as	O
ALT,	O
AST,	O
TBIL,	O
DBIL,	O
ALP,	O
GGT,	O
TP,	O
ALB,	O
LDH,	O
TBA,	O
CHE,	O
TC,	O
TG,	B
CREA,	O
GLU,	O
PT,	O
INR,	O
AFP,	O
CEA,	O
Viral	O
load,	O
RBC,	O
HGB,	O
and	O
PLT.	O

Acetylation	O
of	O
polyamines	B
is	O
catalyzed	O
by	O
spermidine/spermine	O
N1–acetyltransferase	O
(SSAT)	O
as	O
part	O
of	O
the	O
polyamine	B
catabolism	O
process.	O

The	O
main	O
source	O
of	O
choline	B
is	O
absorption	O
from	O
the	O
food,	O
however,	O
to	O
a	O
lower	O
extent,	O
it	O
can	O
also	O
be	O
produced	O
via	O
the	O
hepatic	O
phosphatidylethanolamine	O
N-methyltransferase	O
pathway	O
in	O
the	O
liver	O
or	O
through	O
hydrolysis	O
of	O
membrane	O
lipids	O
(PCs	O
and	O
SMs).	O

kg/m_2	O
among	O
cases	O
and	O
controls,	O
respectively;	O
median	O
serum	O
levels	O
(5_th	O
-95_th	O
percentile)	O
of	O
unconjugated	O
estradiol	B
were	O
15.7	O
(14.5-16.9)	O

Guanidoacetic	B
acid	I
is	O
involved	O
in	O
the	O
arginine	B
metabolism	O
pathway.	O

Eleven	O
weeks	O
after	O
induction,	O
we	O
euthanized	O
rats	O
by	O
terminal	O
isoflurane	B
anesthesia,	O
excised	O
brains,	O
and	O
stored	O
them	O
at	O
−80 °C	O
until	O
analysis.	O

The	O
MCTs	O
used	O
in	O
the	O
study	O
were	O
caprylic	O
(C8:0),	O
capric	O
(C10:0),	O
and	O
lauric	O
(C12:0)	B
acids.	I

Intakes	O
of	O
choline	B
and	O
betaine	B
were	O
lower	O
in	O
Pakistan,	O
although	O
intakes	O
in	O
both	O
the	O
Pakistani	O
and	O
Guatemalan	O
populations	O
were	O
well	O
below	O
the	O
estimated	O
average	O
requirement.	O

The	O
LODs	O
(at	O
S/N	O
≥	O
3)	O
were	O
measured	O
from	O
standard	O
samples	O
and	O
are	O
remarkably	O
different	O
for	O
different	O
analytes,	O
with	O
the	O
lowest	O
LOD	O
being	O
<	O
2.5	O
ng	O
mL_−1	O
(being	O
the	O
lowest	O
measured	O
concentration)	O
for	O
Ala,	O
AzelA,	O
GCDCA,	B
GDCA,	O
Leu,	O
Ile,	O
N-MNA,	O
Phe,	O
and	O
TCA.	O

When	O
CAC	O
in	O
multiple	O
categories	O
was	O
examined	O
as	O
the	O
outcome,	O
lower	O
circulating	O
levels	O
of	O
all	O
three	O
vitamin	B
D	I
metabolites	O
were	O
associated	O
with	O
lower	O
mean	O
CAC.	O

In	O
the	O
patients	O
with	O
schizophrenia,	O
glycine	B
(A)	O
concentration	O
trended	O
lower	O
but	O
was	O
increased	O
in	O
obese	O
BMI	O
controls	O
compared	O
with	O
nonobese	O
BMI	O
controls	O
(B).	O

However,	O
whether	O
kynurenine	B
metabolism	O
is	O
a	O
pathogenic	O
factor	O
in	O
sepsis	O
or	O
rather	O
an	O
epiphenomenon	O
needs	O
further	O
evaluation.	O

Considering	O
a	O
VIP	O
value	O
greater	O
than	O
2.5,	O
we	O
identified	O
three	O
spectral	O
regions	O
responsible	O
for	O
the	O
discrimination:	O
(1)	O
δ	O
1.28–1.36	O
ppm,	O
attributed	O
to	O
methyl	B
group	I
from	O
lactate;	B
(2)	O
δ	O
1.16–1.24	O
ppm,	O
attributed	O
to	O
methylene	B
groups	O
from	O
HDL	B
cholesterol;	I
and	O
(3)	O
δ	O
0.76–0.80	O
ppm,	O
attributed	O
to	O
methyl	O
groups	O
of	O
HDL	B
cholesterol.	I

Second,	O
obesity-related	O
changes	O
in	O
enzymes	O
regulating	O
plasma	O
and	O
membrane	O
phospholipids	B
may	O
also	O
increase	O
levels	O
of	O
circulating	O
polar	O
lipids	O
[,	O
]	O
(Fig.	O
).	O

The	O
performance	O
of	O
atractyligenin	O
glucuronide	B
and	O
caffeine	B
is	O
illustrated	O
in	O
.	O

Based	O
on	O
these	O
findings,	O
other	O
strong	O
genetic	O
associations	O
shown	O
in	O
may	O
identify	O
substrates	O
of	O
enzymes	O
specified	O
by	O
variant	O
alleles,	O
including	O
8-dehydrocholesterol	B
and	O
SDR42E1	O
,	O
which	O
encodes	O
a	O
short	O
chain	O
dehydrogenase/reductase,	O
and	O
7-dehydrocholesterol	B
and	O
24-oxocholesterol	B
with	O
CYP39A1	O
.	O

Activation	O
of	O
mGlu2	O
receptors	O
causes	O
analgesia	O
by	O
negatively	O
modulating	O
glutamate	B
release	O
from	O
primary	O
afferent	O
fibers,	O
and	O
preliminary	O
data	O
demonstrate	O
the	O
analgesic	O
activity	O
of	O
XA	O
in	O
rodents	O
(M.	O
Bernabucci	O
and	O
F.	O
Fazio,	O
unpublished	O
observation).	O

High-level	O
concordance	O
(>60%)	O
was	O
observed	O
between	O
self-reported	O
analgesic	O
use	O
and	O
_1	O
H	O
NMR-detected	O
urinary	O
acetaminophen	B
and/or	O
ibuprofen	B
metabolites	O
for	O
all	O
Western	O
population	O
samples,	O
with	O
concordance	O
being	O
lowest	O
for	O
Pittsburgh	O
(60.6%,	O
95%	O
CI:	O
54.6,	O
66.5)	O
and	O
an	O
overall	O
concordance	O
of	O
70.5%	O
(95%	O
CI:	O
68.7,	O
72.2).	O

Nitrogen	B
gas	I
was	O
used	O
for	O
both	O
nebulizing	O
and	O
drying.	O

Abbreviations:	O
TCDCA,	O
taurochenodeoxycholic	B
acid;	I
GCDCA,	B
glycochenodeoxycholic	B
acid;	I
GCA,	O
glycocholic	B
acid.	I

Because	O
of	O
the	O
large	O
orifice	O
of	O
the	O
instrument,	O
which	O
is	O
a	O
major	O
difference	O
compared	O
to	O
older	O
models	O
of	O
the	O
type	O
of	O
instrument,	O
only	O
little	O
influence	O
on	O
the	O
signal	O
results	O
for	O
oxylipins	B
within	O
a	O
DP	O
between	O
−40	O
and	O
−60	O
V.	O
Therefore,	O
a	O
standard	O
DP	O
of	O
−60	O
V	O
could	O
be	O
selected	O
for	O
all	O
oxylipins,	B
even	O
though	O
we	O
used	O
the	O
optimal	O
parameters	O
for	O
the	O
SPMs.	O

We	O
found	O
that	O
plasma	O
3-methylhistidine	B
(3-MH)	O
levels	O
were	O
similar	O
in	O
insulin	O
treated	O
and	O
deprived	O
T1D,	O
suggesting	O
that	O
myofibrillar	O
protein	O
degradation	O
is	O
not	O
likely	O
to	O
be	O
affected	O
by	O
short-term	O
insulin	O
deprivation.	O

0.4 ml	O
methanol	B
and	O
50 μl	O
of	O
L-2-Chlorophenylalanine	B
(0.1 mg/ml	O
stock	O
in	O
dH2O,	O
Shanghai	O
Hengbai	O
chemdrug	O
biotechnology	O
Co.,	O
Ltd,	O
Shanghai,	O
China),	O
which	O
is	O
used	O
as	O
an	O
internal	O
standard,	O
were	O
added	O
to	O
100 μl	O
sample	O
serum,	O
and	O
vortex	O
for	O
10s.	O

The	O
ESI-MS/MS	O
spectrum	O
of	O
PC	B
(37:3)	I
is	O
shown	O
in	O
as	O
an	O
example.	O

The	O
molecular	O
species	O
of	O
amino	O
acids	O
were	O
eluted	O
in	O
the	O
order	O
of	O
basicity,	O
neutrality,	O
and	O
acidity,	O
whereas	O
they	O
were	O
not	O
retained	O
in	O
reversed-phase	O
conditions	O
using	O
methanol	B
solvent.	O

What	O
makes	O
our	O
study	O
unique	O
is	O
that	O
the	O
phospholipids	B
analyzed	O
comprise	O
not	O
only	O
of	O
those	O
found	O
in	O
plasma	O
but	O
also	O
those	O
in	O
blood	O
cell	O
membranes	O
and	O
in	O
lipoproteins;	O
nevertheless,	O
the	O
reported	O
changes	O
go	O
in	O
the	O
same	O
direction	O
as	O
most	O
of	O
the	O
previously	O
published	O
studies.	O

These	O
include	O
amino	O
acid	O
metabolism,	O
bile	O
acid	O
biosynthesis	O
and	O
the	O
urea	B
cycle.	O

2-Ketobutyric	B
acid	I
is	O
a	O
substance	O
that	O
is	O
involved	O
in	O
the	O
metabolism	O
of	O
many	O
amino	O
acids,	O
such	O
as	O
glycine,	B
methionine,	B
valine,	B
leucine,	B
serine,	B
threonine	B
and	O
isoleucine.	B

In	O
order	O
to	O
investigate	O
the	O
potential	O
effects	O
of	O
long-term	O
storage	O
on	O
the	O
metabolome,	O
human	O
ethylenediaminetetraacetic	B
acid	I
(EDTA)	O
plasma	O
samples	O
stored	O
for	O
up	O
to	O
16	O
years	O
were	O
analyzed	O
by	O
gas	O
and	O
liquid	O
chromatography-tandem	O
mass	O
spectrometry-based	O
metabolomics.	O

Adrenoyl	B
ethanolamide	I
is	O
an	O
N-acylethanolamine	B
(NAE).	O

Cold	O
(−20°C)	O
ethanol	B
containing	O
20	O
deuterated	O
oxylipin	B
internal	O
standards	O
was	O
used	O
to	O
precipitate	O
proteins	O
and	O
non-polar	O
lipids	O
as	O
well	O
as	O
extract	O
bioactive	O
lipids	O
from	O
the	O
plasma	O
through	O
the	O
addition	O
of	O
1:4	O
plasma:ethanol-standard	O
mixture	O
to	O
each	O
well,	O
shaking	O
at	O
500rpm	O
at	O
4	O
°C	O
for	O
15	O
minutes,	O
and	O
centrifugation	O
at	O
4200	O
rpm	O
at	O
4	O
°C	O
for	O
10	O
minutes.	O

Asterisks	O
show	O
co-eluting	O
second	O
regioisomers	O
from	O
4-OH-E2	B
and	O
2-OH-E2.	B

The	O
sample	O
was	O
inserted	O
hydrodynamically	B
with	O
a	O
pressure	O
of	O
50	O
mbar	O
for	O
10	O
s.	O

After	O
being	O
cooled	O
to	O
45	O
°C,	O
6	O
mg	O
hematin	B
chloride	I
and	O
1	O
mg	O
vitamin	B
K	I
were	O
added	O
in	O
the	O
broth.	O

It	O
seems	O
that	O
phosphoethanolamine	B
down	O
regulation	O
is	O
involved	O
in	O
tumor	O
genesis,	O
given	O
that	O
pharmacologic	O
administration	O
of	O
phosphoethanolamine	B
suppressed	O
tumor	O
growth	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
performed	O
in	O
mice	O
bearing	O
melanoma.	O

Norepinephrine	B
sulfate	I
(NE	O
sulfate)	B
showed	O
significant	O
increases	O
both	O
in	O
cancer	O
tissue	O
and	O
urine	O
samples	O
from	O
patients	O
with	O
kidney	O
cancer	O
(2,	O
Fig.	O
).	O

Urine	O
samples	O
were	O
thawed	O
at	O
room	O
temperature	O
and	O
400 μL	O
were	O
transferred	O
to	O
1.5 mL	O
microvial	O
tube	O
to	O
which	O
200 μL	O
of	O
phosphate	B
buffer	O
solution	O
(pH	O
7.4),	O
containing	O
1 mM	O
trimethyl	B
silyl	I
phosphate	I
(TSP),	O

Phospholipids	B
containing	O
unsaturated,	O
long	O
fatty	O
acyl	O
chains	O
have	O
been	O
shown	O
to	O
be	O
associated	O
with	O
a	O
reduced	O
risk	O
for	O
future	O
T2D,	O
whereas	O
phospholipid	B
species	O
with	O
shorter,	O
saturated	O
acyl	O
chains	O
were	O
associated	O
with	O
an	O
increased	O
risk.	O

Some	O
reports	O
disclosed	O
an	O
elevated	O
urinary	O
p-cresol	B
in	O
colorectal	O
cancer,	O
valine	B
in	O
bladder	O
cancer,	O
proline	B
in	O
ovarian	O
cancer,	O
glycine,	B
threonine	B
and	O
tyrosine	B
in	O
liver	O
cancer	O
[,	O
].	O

We	O
were	O
also	O
interested	O
in	O
potential	O
alterations	O
in	O
myostatin	B
and	O
follistain	O
in	O
conjunction	O
with	O
this	O
event.	O

For	O
instance,	O
the	O
mass	O
difference	O
between	O
the	O
total	O
PC	B
37:5	I
(total	O
number	O
of	O
carbons:total	O
number	O
of	O
double	O
bonds	O
in	O
attached	O
fatty	O
acids)	O
and	O
total	O
PC-O	O
38:5	O
is	O
only	O
about	O
36	O
mDa.	O

Hydrophilic	B
ISTDs	O
were	O
dissolved	O
in	O
50%	O
methanol-water	O
to	O
form	O
a	O
solution	O
at	O
40	O
µg/mL;	O
hydrophobic	O
and	O
lipid	O
ISTDs	O
were	O
dissolved	O
in	O
chloroform-methanol	B
(1:1)	I
at	O
40	O
µg/mL.	O

eGFR	O
was	O
significantly	O
correlated	O
with	O
plasma	O
citrulline	B
(Spearman	O
ρ=−0.65,	O
P	O
<0.001),	O
ADMA	B
(ρ=−0.64,	O
P	O
<0.001),	O
tryptophan	B
(Pearson	O
r	O
=0.58,	O
P	O
<0.001),	O
and	O
hydroxykynurenine	B
(ρ=−0.90,	O
P	O
<0.001)	O
concentrations.	O

After	O
acetylchloride	B
catalyzed	O
methylation,	O
methyl	B
esters	I
of	O
all	O
fatty	O
acids	O
were	O
separated,	O
identified	O
and	O
quantified	O
on	O
a	O
Shimadzu	O
GCMS-QP2010Plus	O
spectrometer	O
(Shimadzu	O
Scientific	O
Instruments,	O
USA)	O
equipped	O
with	O
a	O
GC	O
system,	O
a	O
mass	O
spectrometer	O
with	O
an	O
EI	B
source	O
and	O
a	O
flame	O
ionization	O
detector	O
(FID).	O

Such	O
new	O
roles	O
include	O
gene	O
regulation:	O
PC	B
16:0/18:1	I
have	O
been	O
described	O
as	O
an	O
endogenous	O
ligand	O
for	O
the	O
nuclear	O
receptor	O
PPAR	O
alpha	O
in	O
hepatocytes,	O
a	O
transcription	O
factor	O
regulating	O
the	O
expression	O
of	O
many	O
genes	O
that	O
govern	O
lipid	O
metabolism.	O

Filled	O
circles	O
illustrate	O
retention	O
time	O
of	O
the	O
authentic	O
standards,	O
PC(18:1/18:1),	B
PC(18:0/20:4)	B
and	O
PC(18:0/22:6),	B
confirming	O
the	O
predicted	O
pattern.	O

The	O
MRM	O
transitions	O
of	O
[M]_+	O
 → 218.1	O
and	O
[M + 7]_+	O
 → 225.1	O
for	O
BQB	O
and	O
BQB-d	O
_7	O
	O
labeled	O
thiols,	B
respectively,	O
were	O
applied	O
in	O
the	O
developed	O
IL-LC-MRM-MS	O
method.	O

Ace,	O
acetate;	B
Ala,	O
alanine;	B
Gln,	O
glutamine;	B
Glu,	O
glutamate;	B
Gly,	O
glycine;	B
Lac,	O
lactate;	B
myo-I,	O
myo-inositol;	B
scyllo-I,	O
scylloinositol;	O
Tau,	O
taurine.	B

Recent	O
surveys	O
on	O
availability	O
of	O
antimalarials	O
have	O
shown	O
that	O
sick	O
people	O
were	O
getting	O
SP	B
from	O
drugs	O
shops,	O
public	O
and	O
private	O
health	O
facilities	O
(Alba	O
S	O
et	O
al	O
.,	O
in	O
preparation),	O
especially	O
so	O
when	O
clinicians	O
were	O
doubtful	O
about	O
the	O
diagnosis	O
of	O
malaria.	O

The	O
liver	O
is	O
the	O
major	O
site	O
of	O
glutathione	B
(GSH)	O
synthesis	O
and	O
is	O
the	O
principal	O
organ	O
of	O
oxidative	O
stress	O
homoeostasis.	O

The	O
ICC	O
values	O
of	O
0.51	O
for	O
8-iso	B
-PGF_2α	I
and	O
0.36	O
for	O
PGE-M	O
are	O
relatively	O
low.	O

The	O
research	O
results	O
show	O
that,	O
the	O
content	O
of	O
lactic	B
acid	I
was	O
increased	O
for	O
the	O
person	O
with	O
papillary	O
thyroid	O
carcinoma	O
compared	O
to	O
a	O
healthy	O
person.	O

Abbreviations:	O
Ahr:	O
aryl	B
hydrocarbon	I
receptor;	O
BPA:	O
bisphenol	B
A;	O
CTR:	O
controls;	O
SIL:	O
silybin;	O
p-ERK:	O
phosphorilized	O
extracellular	O
signal-regulated	O
kinase;	O
ERK:	O
extracellular	O
signal-regulated	O
kinase;	O
AKT:	O
protein	O
kinase	O
B;	O
Sil:	O
silybin.	O

The	O
first	O
step	O
of	O
the	O
sample	O
preparation	O
procedure	O
was	O
the	O
precipitation	O
of	O
any	O
proteins	O
from	O
the	O
specimens	O
by	O
adding	O
10	O
µl	O
of	O
sulfosalicylic	B
acid	I
to	O
40	O
µl	O
of	O
the	O
serum	O
sample.	O

The	O
gradient	O
program	O
of	O
the	O
clean-up	O
column	O
was	O
listed	O
as	O
follows:	O
100%	O
solution	O
A	O
(5%	O
ACN	O
+	O
0.1%	O
FA)	B

Within	O
the	O
sphingolipid	B
pathway,	O
ceramide	B
synthase	O
(CERS)3	O
and	O
CERS6	O
were	O
32	O
and	O
19%	O
upregulated	O
in	O
OIR	O
versus	O
OIS,	O
respectively	O
and	O
24	O
and	O
15%	O
in	O
OIR	O
versus	O
Lean,	O
respectively.	O

We	O
analyzed	O
the	O
association	O
of	O
urinary	O
myo-inositol	B
with	O
baseline	O
clinical	O
parameters	O
at	O
the	O
time	O
of	O
kidney	O
biopsy.	O

Lipids	O
were	O
separated	O
using	O
a	O
Kinetex	O
HILIC	O
column	O
with	O
a	O
mobile	O
phase	O
A	O
of	O
acetonitrile	B
and	O
B	O
with	O
10 mM	O
ammonium	B
formate	I
in	O
water	O
at	O
pH	O
3.2	O
following	O
a	O
gradient	O
and	O
the	O
injection	O
volume	O
was	O
5 μL.	O
Sample	O
solutions	O
were	O
analyzed	O
using	O
an	O
Agilent	O
1290	O
UPLC	O
system	O
coupled	O
to	O
a	O
G6460	O
triple	O
quadrupole	O
mass	O
spectrometer	O
(Agilent	O
Technologies)	O
and	O
using	O
MassHunter	O
software	O
(Agilent	O
Technologies)	O
for	O
data	O
acquisition	O
and	O
analysis.	O

Both	O
T2D	O
and	O
prediabetes	O
displayed	O
relatively	O
higher	O
concentrations	O
of	O
several	O
short-	O
and	O
long-chain	O
AcylCNs,	O
such	O
as	O
L-acetylcarnitine	B
(C2)	O
at	O
m/z	O
203.1160n	O
(ESI+,	O
RT	O
=	O
0.57	O
min;	O
P	O
=	O
6.66E-04,	O
FDR	O
=	O
0.066),	O
tetradecanoylcarnitine	B
(C14)	O
at	O
m/z	O
372.3115	O
(ESI+,	O
RT	O
=	O
0.99	O
min;	O
P	O
=	O
1.46E-03,	O
FDR	O
=	O
0.094),	O
2-hydroxyhexadecanoylcarnitine	B
(C16OH)	O
at	O
m/z	O
416.3371	O
(ESI+,	O
RT	O
=	O
1.02	O
min;	O
P	O
=	O
1.60E-04,	O
FDR	O
=	O
0.044),	O
and	O
12-hydroxy-12-octadecanoylcarnitine	B
(C18OH)	O
at	O
m/z	O
444.3667	O
(ESI+,	O
RT	O
=	O
1.38	O
min;	O
P	O
=	O
5.70E-04,	O
FDR	O
=	O
0.066)	O
(KW	O
test,	O
).	O

Erythronic	B
acid	I
has	O
therefore	O
been	O
proposed	O
to	O
be	O
generated	O
by	O
an	O
as	O
yet	O
unknown	O
alternative	O
pathway	O
to	O
the	O
PPP	O
[,].	O

The	O
decreased	O
levels	O
of	O
cortisol	B
in	O
the	O
ICSI	O
compared	O
to	O
the	O
NC	O
group	O
within	O
the	O
subset	O
of	O
girls	O
analyzed	O
using	O
metabolomics	O
is	O
consistent	O
with	O
a	O
recent	O
publication	O
reporting	O
lower	O
salivary	O
cortisol	B
levels	O
in	O
the	O
ICSI-conceived	O
girls	O
.	O

Previous	O
studies	O
have	O
identified	O
changes	O
in	O
the	O
BCAA	O
degradation	O
pathways	O
related	O
to	O
acute	O
and	O
chronic	O
exercise	O
training	O
in	O
younger	O
men._,	O
Further,	O
isoleucine	B
is	O
previously	O
proposed	O
as	O
a	O
metabolite	O
biomarkers	O
for	O
acute	O
ischemic	O
stroke.	O

Four	O
standard	O
glutamine	B
solutions	O
in	O
deionized	O
water	O
(0.25	O
mM)	O
(without	O
serum)	O
were	O
also	O
subjected	O
to	O
protein	O
precipitation	O
or	O
ultrafiltration	O
protocols	O
and	O
NMR	O
analysis.	O

It	O
increases	O
the	O
expression	O
of	O
key	O
glycolytic	B
genes	O
and	O
activates	O
glycolysis	O
in	O
several	O
types	O
of	O
cancer.	O

Phosphocholine	B
is	O
both	O
a	O
precursor	O
and	O
a	O
breakdown	O
product	O
of	O
phosphatidylcholine,	B
which,	O
together	O
with	O
other	O
phospholipids	B
such	O
as	O
phosphatidylethanolamine	B
and	O
neutral	O
lipids,	O
forms	O
the	O
characteristic	O
bilayer	O
structure	O
of	O
cellular	O
membranes	O
and	O
regulates	O
membrane	O
integrity.	O

The	O
streptavidin	O
magnetic	O
beads	O
with	O
average	O
size	O
~800	O
nm	O
consist	O
of	O
an	O
outer	O
core	O
hydrophilic	B
polymer	O
surface	O
covalently	O
cross-linked	O
to	O
streptavidin	O
and	O
encapsulate	O
a	O
paramagnetic	O
core	O
as	O
designed	O
by	O
the	O
manufacturer	O
(SoluLink).	O

For	O
the	O
tyrosine	B
metabolism,	O
we	O
found	O
very	O
similar	O
reduction	O
for	O
phenylalanine	B
(−51%,	O
P	O
 =	O
0.004),	O
tyrosine	B
(−45%,	O
P	O
 =	O
0.04),	O
and	O
dopamine	B
(−28%,	O
P	O
 = 0.05).	O

The	O
line-shape	O
test	O
using	O
the	O
conventional	O
standard	O
sample	O
(1%	O
chloroform	B
in	O
acetone-d	B
_6	O
)	O
gave	O
the	O
following	O
results:	O
hump	O
6.9/11.9	O

Mean	O
elevations	O
in	O
glucose	B
fold-change,	O
9.5	O
(3.0–30.4)	O
were	O
significantly	O
higher	O
across	O
all	O
regions	O
in	O
AD	O
brain	O
than	O
those	O
for	O
sorbitol	B
and	O
fructose	B
(P	O
 = 0.0002).	O

Eleven	O
lipid	O
metabolites	O
related	O
to	O
the	O
sphingolipid	B
pathway	O
(SM,	O
Cer,	B
Glucer,	O
DG,	O
and	O
PC)	O
showed	O
a	O
positive	O
correlation	O
with	O
hs-CRP	O
before	O
and	O
after	O
adjustment	O
for	O
confounding	O
factors	O
in	O
patients	O
with	O
MI	O
(	O
and	O
).	O

Tyrosine	B
was	O
identified	O
as	O
marker	O
metabolite	O
by	O
Qiu	O
et	O
al.	O

Lovreglio	O
and	O
co-workers,	O
assessing	O
SPMA	O
levels,	O
revealed	O
that	O
coke	O
oven	O
workers	O
were	O
exposed	O
to	O
a	O
low	O
level	O
of	O
benzene	B
and	O
reported	O
a	O
median	O
level	O
of	O
SPMA	O
in	O
the	O
end-shift	O
urine	O
equal	O
to	O
0.50	O
µg/g	O
creatinine	B
(from	O
0.10	O
to	O
6.89	O
µg/g	O
creatinine);	O
they	O
also	O
reported	O
higher	O
concentrations	O
in	O
oven	O
standpipe	O
workers	O
than	O
in	O
byproduct	O
workers.	O

Paracetamol	B
is	O
a	O
commonly	O
used	O
analgesic	O
among	O
women	O
and	O
men	O
of	O
all	O
ages.	O

Mannose,	B
an	O
intermediate	O
metabolite	O
of	O
galactose	B
metabolism	O
pathway,	O
plays	O
an	O
essential	O
role	O
in	O
N-linked	O
glycosylation,	O
which	O
modified	O
certain	O
proteins	O
at	O
the	O
post-translational	O
step.	O

Analytical	O
grade	O
flavin	B
mononucleotide	I
(FMN),	O
folic	B
acid	I
(FA),	O
pyridoxine	B
(B_6	O
),	O
pyridoxal	B
(PL)	O
hydrochloride,	B
pyridoxamine	B
(PM)	O
dihydrochloride,	B
4-pyridoxic	B
acid	I
(4PA),	O
zinc	O
sulphate,	B
and	O
tris(2-carboxyethyl)phosphine	B
(TCEP)	O
were	O
purchased	O
from	O
Sigma	O
(St	O
Louis,	O
MO,	O
USA);	O
riboflavin	B
(B_2	O
)	O
was	O
purchased	O
from	O
Alfa	O
Aesar,	O
and	O
5-methyltetrahydrofolate	B
(5MTHF),	O
dihydrofolate	B
(DHF)	O
and	O
tetrahydrofolate	B
(THF)	O
were	O
purchased	O
from	O
Cayman	O
Chemicals	O
(Ann	O
Arbor,	O
MI,	O
USA).	O

However,	O
adjustment	O
of	O
the	O
models	O
for	O
total	O
estradiol	B
did	O
not	O
change	O
estimates	O
by	O
>10%.	O

We	O
did	O
note	O
a	O
change	O
in	O
N-methyl	B
nicotinic	I
acid	I
levels	O
in	O
patients	O
with	O
cirrhosis	O
and	O
between	O
those	O
with	O
or	O
without	O
OHE.	O

The	O
major	O
loadings	O
for	O
the	O
first	O
principle	O
component	O
are	O
attributable	O
to	O
glucose	B
derivatives,	O
two	O
unknowns	O
(retention	O
times	O
of	O
27.8	O
min	O
and	O
30.0	O
min)	O
and	O
a	O
methylxanthine	B
possibly	O
from	O
purine	B
degradation.	O

Rahimi	O
and	O
colleagues	O
found	O
GDM	O
mothers	O
had	O
higher	O
plasma	O
concentrations	O
of	O
arginine,	B
glycine	B
and	O
methionine,	B
however,	O
these	O
glucogenic	B
AAs	O
showed	O
no	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
in	O
our	O
research.	O

Additionally,	O
increased	O
levels	O
of	O
PCs	O
may	O
be	O
correlated	O
with	O
the	O
overexpression	O
of	O
choline	B
kinase	O
in	O
various	O
cancers.	O

This	O
suggests	O
that	O
samples	O
E	O
and	O
F	O
contained	O
an	O
unusually	O
high	O
proportion	O
of	O
high	O
glucose	B
contributions	O
due	O
to	O
disease	O
(such	O
as	O
diabetes)	O
or	O
uncontrolled	O
dietary	O
intake.	O

Then,	O
an	O
increase	O
of	O
alanine	B
(Ala)	O
(1.5 ppm)	O
is	O
observed	O
close	O
to	O
the	O
3	O
o’clock	O
position.	O

However,	O
In	O
contrast	O
to	O
their	O
measure	O
in	O
late	O
postprandial	O
urine	O
pools,	O
serum	O
guaiacol	B
and	O
catechol	B
could	O
not	O
significantly	O
differentiate	O
soy	O
drink	O
intake	O
from	O
dairy	O
intake	O
at	O
24	O
h.	O

In	O
this	O
study,	O
we	O
have	O
comprehensively	O
evaluated	O
the	O
performance	O
of	O
protein	O
precipitation	O
using	O
methanol,	B
acetonitrile,	B
perchloric	B
acid,	I
and	O
trichloroacetic	O
acid	O
and	O
ultrafiltration	O
approaches	O
using	O
1D	O
and	O
2D	O
NMR,	O
based	O
on	O
the	O
identification	O
and	O
absolute	O
quantitation	O
of	O
44	O
human	O
blood	O
metabolites,	O
including	O
a	O
few	O
identified	O
for	O
the	O
first	O
time	O
in	O
the	O
NMR	O
spectra	O
of	O
human	O
serum.	O

Increased	O
TMAO	B
levels	O
are	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
incident	O
major	O
adverse	O
cardiovascular	O
events.	O

For	O
the	O
DCM	O
method,	O
the	O
PULSE	O
Tubes	O
were	O
modified	O
with	O
(DCM-resistant)	O
ultrahigh	O
purity	O
fluoropolymer	B
O-rings.	O

Since	O
we	O
were	O
interested	O
in	O
covering	O
the	O
entirety	O
of	O
the	O
polyamine	B
metabolism,	O
we	O
tried	O
acidifying	O
the	O
sample	O
with	O
TFA	O
before	O
the	O
LLE	O
to	O
achieve	O
better	O
recoveries	O
of	O
the	O
more	O
polar	O
analytes.	O

Risk	O
of	O
GDM	O
according	O
to	O
quartiles	O
of	O
plasma	O
TMAO	B
concentration	O
measured	O
before	O
20	O
wk	O
of	O
gestation:	O
nested	O
case-control	O
study	O
within	O
a	O
prospective	O
cohort_1	O
	O
_1	O
Values	O
are	O
ORs	O
(95%	O
CIs).	O

The	O
placement	O
of	O
the	O
best	O
pose	O
of	O
the	O
most	O
active	O
compound	O
DHPM7	O
inside	O
the	O
active	O
site	O
was	O
compared	O
to	O
that	O
of	O
arachidonic	B
acid.	I

To	O
establish	O
the	O
concentration	O
of	O
20	O
biogenic	O
amino	O
acids	O
and	O
their	O
selected	O
derivatives	O
(ADMA,	O
SDMA,	O
NMMA,	O
creatinine,	B
taurine,	B
1-methyl-histidine,	B
betaine,	B
and	O
gamma-aminobutyric	B
acid),	O
an	O
aliquot	O
of	O
20	O
µL	O
serum	O
was	O
extracted	O
with	O
acetonitrile	B
in	O
proportion	O
1:2.4	O
with	O
the	O
addition	O
of	O
the	O
internal	O
standard	O
solution	O
(2-chloroadenosine).	O

The	O
plate	O
was	O
washed	O
with	O
0.7	O
mL	O
2%	O
NH_4	O
OH	O
and	O
0.7	O
mL	O
MeOH,	B
then	O
dried	O
with	O
a	O
stream	O
of	O
N_2	O
for	O
5	O
min.	O

Urinary	O
analytes	O
were	O
normalised	O
to	O
urinary	O
creatinine	B
because	O
spot	O
urine	O
samples	O
were	O
used.	O

It	O
has	O
also	O
recently	O
been	O
suggested	O
that	O
elevated	O
threonic	B
acid,	I
as	O
an	O
oxidative	O
metabolite	O
of	O
ascorbic	B
acid,	I
is	O
a	O
measure	O
of	O
an	O
attenuated	O
oxidative	O
stress	O
response.	O

Initial	O
experiments	O
were	O
carried	O
out	O
with	O
unlabeled	O
glucose,	B
followed	O
by	O
full	O
metabolite	O
profile	O
experiments	O
using	O
[U-_13	B
C]-glucose.	I

HVA	O
can	O
be	O
glucuronidated	O
both	O
at	O
the	O
phenolic	O
hydroxyl	O
and	O
the	O
carboxylic	B
acid	I
group	O
sites.	O

([M+H-HCO_2	O
H]_+	O
)	O
contained	O
the	O
prominent	O
fragment	O
ion	O
at	O
m/z	O
226.1,	O
attributed	O
to	O
2-HO-PhIP	B
(m/z	O
231.1	O
for	O
2-HO-[_2	B
H_5	I
]-PhIP),	I
as	O
was	O
observed	O
in	O
the	O
spectra	O
of	O
desamino-PhIP-Y.	B
Accurate	O
mass	O
measurement	O
of	O
the	O
monoisotopic	O
elemental	O
mass	O
of	O
synthetic	O
Y*TK	O
and	O
its	O
product	O
ion	O
spectra	O
confirmed	O
the	O
assignment.	O

Rats	O
fed	O
a	O
high-fat,	O
obesogenic	O
diet	O
for	O
12	O
weeks	O
had	O
an	O
accumulation	O
of	O
hexosylceramides	B
in	O
adipose	O
tissue	O
but	O
a	O
depletion	O
in	O
muscle.	O

These	O
results	O
indicate	O
that	O
OPLS-DA	O
models	O
derived	O
from	O
the	O
RRLC-(±)ESI-MS	B
data	O
had	O
good	O
predictive	O
ability	O
and	O
were	O
reliable.	O

 ),	O
showing	O
significant	O
effects	O
on	O
valine,	B
leucine,	B
and	O
isoleucine	B
(BCAA)	O
biosynthesis/degradation	O
(p < 0.01),	O
propanoate	B
metabolism	O
(p < 0.001),	O
and	O
ketone	B
body	O
biosynthesis/degradation	O
(p > 0.01).	O

Resulting	O
data	O
showed	O
313	O
known	O
and	O
putative	O
oxylipins	B
were	O
observed	O
in	O
the	O
fresh	O
plasma	O
sample	O
with	O
minimal	O
change	O
in	O
signal	O
presence	O
and	O
stability	O
due	O
to	O
the	O
addition	O
of	O
BHT	O
during	O
the	O
sample	O
preparation	O
process.	O

The	O
anion,	O
succinate,	B
is	O
a	O
component	O
of	O
the	O
citric	B
acid	I
cycle	O
capable	O
of	O
donating	O
electrons	O
to	O
the	O
electron	O
transfer	O
chain.	O

Dicarboxylic	B
acids:	I
ω-oxidation	O
is	O
a	O
secondary	O
pathway	O
to	O
fatty	O
acid	O
metabolism.	O

Liquid	O
chromatography	O
grade	O
acetonitrile,	B
methanol	B
(MeOH),	O
MTBE,	B
and	O
dichloromethane	B
were	O
purchased	O
from	O
Merck	O
(Darmstadt,	O
Germany).	O

Our	O
study	O
identified	O
a	O
large	O
number	O
of	O
metabolites	O
in	O
various	O
metabolic	O
pathways	O
associated	O
with	O
serum	O
retinol	B
concentration,	O
some	O
of	O
which	O
directly	O
relate	O
to	O
prostate	O
cancer	O
risk	O
associations	O
and	O
other	O
known	O
biological	O
functions.	O

In	O
the	O
present	O
study,	O
lower	O
levels	O
of	O
myristic	B
acid	I
(C14:0)	O
observed	O
in	O
the	O
LC	O
group	O
might	O
be	O
due	O
to	O
its	O
rapid	O
metabolism	O
in	O
hepatocyte;	O
and	O
the	O
rapid	O
metabolism	O
might	O
contribute	O
to	O
accumulation	O
of	O
palmitic	B
acid	I
(C16:0)	O
in	O
the	O
LC	O
group.	O

The	O
paracrine-driven	B
phase	O
eventually	O
leads	O
to	O
an	O
autonomous	O
phase	O
that	O
is	O
no	O
longer	O
androgen	O
dependent	O
and	O
is	O
characterized	O
by	O
cell	O
cycle	O
changes	O
in	O
an	O
advanced	O
metastatic	O
form	O
of	O
the	O
disease.	O

Then,	O
cells	O
were	O
cultured	O
for	O
48	O
h	O
in	O
48-well	O
plates	O
at	O
2·10_6	O
cells/ml	O
in	O
RPMI	O
1640	O
(Bio	O
Witthaker)	O
with	O
10%	O
heat-inactivated	O
FCS	O
(PAA)	O
and	O
100	O
μg/ml	O
streptomycin	B
and	O
ampicillin	O
(Sigma)	O
in	O
the	O
presence	O
of	O
different	O
concentrations	O
of	O
stearic,	O
DHA	O
and	O
EPA	O
fatty	O
acids	O
dissolved	O
in	O
DMSO	B
(Sigma)	O
under	O
resting	O
conditions	O
or	O
with	O
2.5	O
μg/ml	O
phytohaemagglutinin	O
A	O
(PHA)	O
(Sigma).	O

Spectra	O
in	O
D	O
and	O
E	O
show	O
only	O
copious	O
matrix	O
clusters	O
with	O
no	O
signal	O
for	O
the	O
deprotonated	O
stearate	B
ion	O
at	O
m	O
/z	O
283	O
(transparent	O
red	O
bar);	O
single	O
ion	O
at	O
m	O
/z	O
283	O
corresponding	O
to	O
stearate	B
anion	O
is	O
observed,	O
with	O
no	O
additional	O
matrix	O
peaks	O
(F	O
).	O

The	O
4-year	O
FU	O
of	O
the	O
BeMIM	O
study	O
showed	O
that	O
the	O
administration	O
of	O
a	O
new	O
formula	O
with	O
a	O
lower	O
protein	O
content,	O
a	O
higher	O
content	O
of	O
alpha-lactalbumin	B
enriched	O
whey	B
and	O
containing	O
LC-PUFA	O
does	O
not	O
produce	O
measurable	O
growth	O
differences	O
in	O
children	O
compared	O
with	O
children	O
receiving	O
a	O
standard	O
protein	O
content	O
formula	O
during	O
the	O
first	O
4	O
months	O
of	O
life.	O

Characteristics	O
of	O
Participants	O
by	O
Prenatal	O
DES	B
Exposure.	O

The	O
higher	O
levels	O
of	O
antioxidant	O
metabolites,	O
such	O
as	O
cystathionine,	B
cysteine,	B
hypotaurine,	B
taurine,	B
and	O
ascorbic	B
acid,	I
in	O
CRC	O
tissues	O
might	O
protect	O
CRC	O
from	O
oxidative	O
stress.	O

-hydroxycholesterol	B

A	O
postoperative	O
decrease	O
in	O
serum	O
levels	O
of	O
various	O
lipids	O
likely	O
reflected	O
their	O
reduced	O
dietary	O
intake,	O
as	O
well	O
as	O
lower	O
rate	O
of	O
cholesterol	B
production,	O
and	O
less	O
intense	O
liver	O
synthesis	O
and	O
desaturation	O
of	O
fatty	O
acids	O
in	O
obese	O
patients	O
subjected	O
to	O
bariatric	O
surgeries.	O

In	O
cross-sectional	O
studies,	O
we	O
have	O
demonstrated	O
significant	O
impairment	O
in	O
DI	O
in	O
obese	O
youth	O
across	O
the	O
spectrum	O
of	O
glucose	B
tolerance	O
(,	O
–).	O

The	O
retention	O
time	O
variation	O
of	O
the	O
3-dehydroCDCA	B
standard	O
in	O
runs	O
lasting	O
for	O
8	O
days	O
was	O
as	O
narrow	O
as	O
10.91±0.00	O
min.	O

Sphingolipids	B
constitute	O
a	O
class	O
of	O
lipids	O
that	O
are	O
essential	O
for	O
the	O
cellular	O
structural	O
integrity	O
and	O
play	O
a	O
role	O
in	O
regulating	O
lipid	O
bilayer	O
fluidity.	O

Sphingolipids,	B
which	O
represent	O
less	O
than	O
20 %	O
of	O
total	O
lipid	O
species	O
in	O
CSF,	O
are	O
of	O
particular	O
importance	O
in	O
the	O
context	O
of	O
biomarker	O
discovery	O
for	O
neurological	O
diseases,	O
such	O
as	O
lysosomal	O
or	O
unknown	O
neurometabolic	O
diseases.	O

Regardless	O
of	O
the	O
specimen	O
type,	O
sarcosine	B
was	O
significantly	O
higher	O
in	O
PCa	O
patients	O
than	O
in	O
controls,	O
but	O
there	O
was	O
no	O
correlation	O
with	O
the	O
Gleason	O
score	O
or	O
clinical	O
stage.	O

Metabolic	O
pathways	O
of	O
arginine.	B

Triglycerides	B
in	O
the	O
larger	O
VLDL	O
subclasses,	O
the	O
serum	O
concentration	O
of	O
VLDL	O
particles,	O
the	O
VLDL	O
mean	O
diameter	O
as	O
well	O
as	O
the	O
phospholipids	B
and	O
total	O
lipids	O
in	O
VLDL	O
subclasses	O
(ranging	O
from	O
medium	O
to	O
extremely	O
large	O
particles),	O
and	O
the	O
total	O
cholesterol,	B
cholesterol	B
esters	I
and	O
free	O
cholesterol	B
in	O
large	O
VLDL	O
subclasses	O
were	O
all	O
positively	O
associated	O
with	O
testosterone	B
levels	O
(β	O
>0.73,	O
P	O
<1.4	O
×	O
10_−3	O
).	O

CO_2	O
(44	O
Da)	O
from	O
[M-H]-	O
ions	O
in	O
addition	O
to	O
the	O
product	O
ion	O
at	O
m/z	O
59	O
corresponding	O
to	O
the	O
acetate	B
ion	O
(CH_3	O
COO-	O
).	O

The	O
remaining	O
lower	O
fraction	O
was	O
mixed	O
with	O
200 μL	O
of	O
MTBE	B
and	O
vigorously	O
vortexed	O
for	O
60 s.	O

The	O
highest	O
rate	O
of	O
anastrozole	B
glucuronide	I
formation	O
after	O
normalization	O
by	O
protein	O
content	O
was	O
observed	O
with	O
UGT1A4	O
(mean	O
anastrozole	B
glucuronide	I
formation	O
=	O
3863	O
nmol	O
min	O
_−1	O
mg_−1	O
),	O
followed	O
by	O
UGT1A3	O
(150	O
pmol	O
min_−1	O
mg_−1	O
),	O
and	O
UGT2B7	O
(57	O
pmol	O
min_−1	O
mg_−1	O
).	O

This	O
may	O
be	O
because	O
arginine	B
metabolism	O
is	O
associated	O
with	O
several	O
pain	O
mechanisms,	O
as	O
pain	O
is	O
the	O
hallmark	O
of	O
the	O
β-thalassemic	B
condition	O
and	O
patients	O
experience	O
pain	O
virtually	O
all	O
the	O
time.	O

[kg/m_2	O
],	O
fasting	O
blood	O
glucose	B

PC	O
is	O
formed	O
from	O
phosphocholines	B
and	O
catabolised	O
back	O
to	O
phosphocholines.	B

Plasma	O
concentrations	O
of	O
eight	O
amino	O
acids	O
and	O
carnitine	B
differed	O
between	O
asthmatics	O
and	O
non-asthmatics.	O

Long-chain	O
dicarboxylic	B
acids,	I
in	O
turn,	O
are	O
formed	O
from	O
the	O
correspondent	O
fatty	O
acids	O
by	O
ω-oxidation	O
in	O
the	O
microsomial	O
membranes	O
or	O
are	O
consumed	O
with	O
a	O
diet	O
rich	O
in	O
vegetables.	O

Formic	B
acid	I
and	O
acetonitrile	B
(ACN)	O
were	O
obtained	O
from	O
Sigma-Aldrich;	O
Merck	O
KGaA	O
(Darmstadt,	O
Germany).	O

Bile	O
acids	O
with	O
both	O
a	O
7-hydroxy-4-ene	B
and	O
7-hydroxy-5-ene	B
structure	O
are	O
known	O
to	O
be	O
labile	O
and	O
to	O
dehydrate	O
to	O
give	O
conjugated	O
dienes.	O

The	O
serum	O
extracts	O
that	O
remained	O
on	O
the	O
bench-top	O
for	O
24	O
h	O
at	O
room	O
temperature	O
displayed	O
an	O
average	O
of	O
101.5%	O
of	O
proline	B
compare	O
to	O
the	O
freshly	O
prepared	O
ones,	O
which	O
indicated	O
that	O
the	O
processed	O
proline	B
serum	O
extracts	O
were	O
stable	O
at	O
room	O
temperature	O
at	O
least	O
for	O
24	O
h.	O

In	O
our	O
study	O
cohort,	O
a	O
combination	O
of	O
three	O
metabolites	O
namely	O
pentadecanoic	B
acid	I
(15:0),	O
linoleoyl	B
carnitine	I
(18:2	O
carnitine)	O
and	O
1-linoleoylglycerophosphocholine	B
(18:2	I
lysoPC)	I
exhibited	O
good	O
separating	O
capability	O
in	O
discriminating	O
small	O
and	O
large	O
infarct	O
size	O
patients	O
with	O
an	O
AUC	O
value	O
of	O
86	O
based	O
on	O
peak	O
troponin	O
concentration	O
(Fig. )	O
and	O
with	O
an	O
AUC	O
value	O
of	O
82	O
(Fig.	O

The	O
urine	O
samples	O
were	O
prepared	O
with	O
chemical	O
product	O
from	O
Sigma	O
(Sigma	O
Aldrich,	O
Saint	O
Quentin	O
Fallavier,	O
France)	O
to	O
obtain	O
a	O
final	O
volume	O
of	O
600	O
μ	O
L	O
(400	O
μ	O
L	O
of	O
urine;	O
160	O
μ	O
L	O
of	O
200	O
mM	O
phosphate	B
buffer	O
at	O
pH	O
7.4,	O
1	O
mM	O
of	O
TSP	B
-Trimethyl	I
silyl	I
propionate	I
of	O
sodium	O
salt	O
as	O
the	O
NMR	O
chemical	O
shift	O
reference-,	O
6	O
mM	O
of	O
NaN_3	O
;	O
40	O
μ	O
L	O
D_2	O
O).	O

Psoriasis	O
severity	O
was	O
associated	O
with	O
an	O
increase	O
in	O
three	O
intermediates	O
of	O
the	O
urea	B
cycle	O
(citrulline,	O
ornithine,	B
and	O
arginine).	B

For	O
all	O
the	O
models	O
tested,	O
two	O
were	O
relevant	O
to	O
predict	O
SVC	O
from	O
SM	B
C24:1	I
in	O
group	O
O	O
and	O
the	O
other	O
to	O
predict	O
SVC	O
from	O
SM	O
OH	B
C22:2	I
and	O
SM	B
C16:1	I
in	O
group	O
P+O.	O

Proteomic	O
studies	O
have	O
shown	O
upregulations	O
of	O
glyceraldehyde-3-phosphate	O
dehydrogenase	O
(GAPDH)	O
and	O
malate	O
dehydrogenase	O
(MDH)	O
but	O
down-regulations	O
of	O
phosphoenolpyruvate	O
carboxykinase	O
(PEPCK),	O
UDP-glucose	O
pyrophosphorylase	O
2	O
(UGP2)	O
and	O
aconitate	B
hydratase	O
in	O
CRC	O
tissues	O
compared	O
to	O
these	O
in	O
adjacent	O
normal	O
mucosa	O
indicating	O
the	O
CRC-associated	O
alterations	O
in	O
multiple	O
metabolic	O
pathways	O
such	O
as	O
glycolysis/gluconeogenesis,	O
glucuronate	B
pathway	O
and	O
tricarboxylic	B
acid	I
cycle_,	O
_,	O
.	O

Bar	O
graphs	O
of	O
urinary	O
metabolite	O
levels	O
of	O
A)	O
creatine	B
riboside	I
(CR),	O
B)	O
N	B
-acetylneuraminic	I
acid	I
(NANA),	O
C)	O
cortisol	B
sulfate	I
(CS)	O
and	O
D)	O
metabolite	O
561+	O
quantitatively	O
measured	O
by	O
UPLC-MS/MS	O
in	O
Intrahepatic	O
Cholangiocarcinoma	O
(ICC)	O
cases	O
in	O
comparison	O
to	O
unaffected	O
population	O
controls	O
and	O
high-risk	O
subjects	O
in	O
the	O
TIGER-LC	O
cohort.	O

The	O
pathway	O
analysis	O
showed	O
significantly	O
altered	O
alanine,	B
aspartate,	B
and	O
glutamate	B
metabolic	O
pathways	O
(FDR	O
p	O
-value	O
<	O
0.05)	O
in	O
both	O
the	O
discovery	O
and	O
validation	O
phases.	O

Muscle	O
linolenate	B
CoA	O
[18:3;	O
from	O
0.40	O
±	O
0.04	O
to	O
0.36	O
±	O
0.12	O
nmol/g;	O
P	O
=	O
not	O
significant	O
(NS)]	O
did	O
not	O
decrease	O
after	O
pioglitazone	B
treatment.	O

3-HBA:	O
3-hydroxy-butyrate;	B
HIVA:	O
3-hydroxy-isovalerate;	B
4-DTA:	O
4-deoxythreonic	B
acid:	I
GAA:	O
guanidinoacetate;	B
TMA:	O
trimethylamine;	B
TMAO:	B
trimethylamine-N-oxide.	B

Significant	O
differences	O
between	O
the	O
intake	O
of	O
the	O
three	O
foods	O
after	O
6	O
h	O
were	O
found	O
in	O
case	O
of	O
galactonate,	B
galactitol,	B
and	O
galactono-1,5-lactone	B
(see	O
Tables	O
S3	O
and	O
S4).	O

3-Hydroxyisovalerate,	B
adenosine,	B
methionine,	B
succinate,	B
and	O
threonine	B
were	O
detected	O
in	O
MeOH:	B

Neither	O
of	O
the	O
recent	O
studies	O
evaluated	O
longitudinal	O
diabetes	O
incidence	O
data;	O
however,	O
Huynh	O
et	O
al.	O
demonstrated	O
a	O
significant	O
correlation	O
between	O
1	O
of	O
our	O
putative	O
prognostic	O
markers,	O
SM	B
d18:1/18:0,	I
and	O
fasting	O
glucose.	B

The	O
[_2	O
H_3	O
]acetylation	O
reaction	O
also	O
resulted	O
in	O
the	O
conversion	O
of	O
the	O
BDA-lysine	B
reaction	O
product	O
6	O
to	O
[_2	O
H_3	O
]1	O
and	O
metabolite	O
3	O
to	O
[_2	O
H_3	O
]5.	O

Our	O
data	O
also	O
supports	O
that	O
dietary	O
intake	O
of	O
linolenic	B
acid	I
are	O
associated	O
with	O
decreased	O
airway	O
inflammation	O
and	O
improved	O
asthma	O
control.	O

Interestingly,	O
the	O
human	O
retina	O
presented	O
five	O
types	O
of	O
long	O
chain	O
bases:	O
mostly	O
d18:1	B
but	O
also	O
d16:1,	B
d18:2	B
and	O
d20:1	B
quite	O
prominently	O
while	O
d17:0	B
was	O
frequently	O
present	O
in	O
minor	O
proportions.	O

Briefly,	O
150 μl	O
of	O
blood	O
plasma	O
were	O
mixed	O
with	O
600 μl	O
methanol:	B
chloroform	B
(2:1).	I

In	O
the	O
first	O
study	O
(phosphatidylcholine	O
challenge),	O
we	O
enrolled	O
40	O
healthy	O
adults	O
who	O
had	O
no	O
chronic	O
illnesses	O
(including	O
a	O
known	O
history	O
of	O
heart,	O
renal,	O
pulmonary,	O
or	O
hematologic	O
disease),	O
had	O
no	O
active	O
infections,	O
and	O
had	O
not	O
taken	O
antibiotics	O
or	O
probiotics	O
within	O
the	O
past	O
month.	O

However,	O
if	O
the	O
levels	O
of	O
acetyl-CoA	B
reach	O
a	O
point	O
such	O
that	O
they	O
exceed	O
the	O
requirements	O
of	O
the	O
TCA	O
cycle	O
then	O
the	O
excess	O
is	O
directed	O
towards	O
the	O
formation	O
of	O
ketone	B
bodies	O
such	O
as	O
3-hydroxybutyrate.	B

In	O
1990,	O
a	O
study	O
using	O
a	O
modified	O
ELISA	O
assay,	O
showed	O
the	O
presence	O
of	O
transforming	O
growth	O
factor	O
α	O
(TGFα)	O
in	O
the	O
urine	O
of	O
patients	O
affected	O
by	O
HCC[].	O

We	O
could	O
not	O
detect	O
an	O
effect	O
of	O
bile	O
acids	O
on	O
basal	O
or	O
insulin-stimulated	O
glucose	B
uptake,	O
however,	O
in	O
cultured	O
adipocytes	O
(data	O
not	O
shown).	O

glucobrassicin	B

Dicarboxylic	B
acids	I
(glutarate,	O
dihydroxyfumarate	B
and	O
others),	O
aromatic	O
and	O
heterocyclic	B
acids	I
and	O
α-hydroxycarboxylic	B
acids	I
also	O
eluted	O
ahead	O
of	O
or	O
close	O
to	O
t	O
_0	O
,	O
which	O
hints	O
at	O
electrostatic	O
repulsion	O
phenomena.	O

Infant	O
formula	O
derived	O
from	O
bovine	O
milk	O
contains	O
a	O
number	O
of	O
metabolic	O
forms	O
of	O
choline,	B
all	O
contribute	O
to	O
the	O
growth	O
and	O
development	O
of	O
the	O
newborn.	O

Levels	O
are	O
expressed	O
as	O
area	O
of	O
the	O
metabolite	O
of	O
interest	O
divided	O
with	O
respect	O
total	O
aliphatic	B
spectral	O
area.*p	O
<	O
0.05;	O
**p	O
<	O
0.01;***p	O
<	O
0.001.	O

The	O
levels	O
of	O
nervonic	B
acid	I
were	O
higher	O
in	O
the	O
dMDD	O
patients	O
(0.65±0.45	O
µM)	O
compared	O
with	O
the	O
rMDD	O
patients	O
(0.40±0.17	O
µM;	O
effect	O
size	O
of	O
Cohen’s	O
d	O
=0.75;	O
P=	O
.0091).	O

HDL_2	O
cholesterol	B
and	O
(D)	O
serum	O
creatinine.	B

Among	O
these	O
pro-inﬂammatory	O
cytokines,	O
IFN-γ,	O
IL-1α,	B
IL-6,	O
IL-8,	O
and	O
IL-21	O
are	O
predominantly	O
abundant	O
in	O
IBD	O
mothers’	O
breast	O
milk.	O

Several	O
amino	O
acids	O
are	O
part	O
of	O
the	O
identified	O
metabolic	O
signature	O
for	O
GDM	O
such	O
as	O
methionine,	B
glutamine,	B
alanine,	B
serine,	B
and	O
tryptophan.	B

N	B
-Methyl-N-trimethylsilyltrifluoroacetamide	I
(MSTFA)	O
with	O
1%	O
trimethylchlorosilane	B
(TMCS)	O
and	O
pyridine	B
(silylation	I
grade)	I
were	O
purchased	O
from	O

Results	O
of	O
the	O
assays	O
using	O
triterpene	B
(1)	O
in	O
95%	O
EtOH	B
and	O
in	O
DCM,	O
the	O
DCM	O
and	O
aqueous	O
leaf	O
extracts	O
in	O
concentrations	O
that	O
ranged	O
from	O
30	O
μg/ml	O
to	O
10	O
mg/ml	O
showed	O
the	O
absence	O
of	O
antimicrobial	O
activities	O
against	O
all	O
the	O
test	O
samples.	O

This	O
four-carbon	O
hydroxy	B
acid	I
was	O
also	O
increased	O
in	O
plasma	O
from	O
hepatocellular	O
carcinoma	O
cases,	O
and	O
it	O
was	O
suggested	O
as	O
a	O
potential	O
biomarker	O
of	O
insulin	O
resistance	O
and	O
impaired	O
glucose	B
regulation	O
[,].	O

but,	O
unlike	O
itaconic	B
acid	I
which	O
acts	O
as	O
a	O
competitive	O
inhibitor	O
of	O
SDH,	O
microbial	O
metabolites	O
most	O
likely	O
act	O
on	O
the	O
ubiquinone	B
binding	O
site	O
of	O
the	O
respiratory	O
chain.	O

In	O
addition,	O
we	O
observed	O
a	O
significant	O
increase	O
of	O
long-chain	O
fatty	O
acylcarnitines	B
in	O
the	O
PAH	O
group.	O

Major	O
metabolic	O
pathways	O
were	O
branched-chain	O
amino	O
acid	O
metabolism	O
(partially	O
independent	O
of	O
insulin	O
resistance),	O
surrogate	O
markers	O
of	O
oxidative	O
stress	O
and	O
gut	O
microbial	O
diversity,	O
and	O
cortisol	B
metabolism.	O

The	O
relative	O
expanded	O
uncertainty	O
for	O
3-epi-25(OH)D_3	B
in	O
Level	O
3	O
is	O
>	O
10%,	O
and	O
we	O
elected	O
to	O
make	O
this	O
a	O
reference	O
value.	O

Arginine	B
metabolism	O
has	O
been	O
linked	O
to	O
several	O
cancer	O
types	O
that	O
rely	O
on	O
extracellular	O
arginine	B
to	O
maintain	O
rapid	O
tumor	O
growth	O
[,].	O

Alternatively,	O
the	O
differences	O
in	O
levels	O
of	O
24S-OH-Chol	B
between	O
LOAD	O
and	O
VD	O
might	O
reflect	O
the	O
different	O
pathogenetic	O
mechanisms	O
and/or	O
evolution	O
of	O
these	O
two	O
forms	O
of	O
dementia.	O

All	O
other	O
organic	O
acid	O
standards	O
including	O
lactic	B
acid,	I
beta-hydroxybutyric	B
acid,	I
alpha-ketoglutaric	B
acid,	I
citric	B
acid,	I
butyric	B
acid,	I
isobutyric	B
acid,	I
propionic	B
acid,	I
p-hydroxyhippuric	B
acid,	I
succinic	B
acid,	I
fumaric	B
acid,	I
pyruvic	B
acid,	I
hippuric	B
acid,	I
methylmalonic	B
acid,	I
homovanillic	B
acid,	I
indole-3-acetic	B
acid,	I
uric	B
acid,	I
and	O
their	O
isotope-labeled	O
standards	O
were	O
purchased	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
MO,	O
USA).	O

Quantitative	O
measurement	O
and	O
comparison	O
of	O
seven	O
bile	O
acids	O
among	O
benign	O
liver	O
tumor	O
patients	O
with	O
liver	O
cirrhosis	O
and	O
hepatitis,	O
HCC	O
patients	O
with	O
liver	O
cirrhosis	O
and	O
hepatitis,	O
HCC	O
patients	O
without	O
liver	O
cirrhosis	O
and	O
hepatitis,	O
and	O
healthy	O
controls	O
revealed	O
that	O
the	O
abnormal	O
levels	O
of	O
glycochenodeoxycholic	B
acid,	I
glycocholic	B
acid,	I
taurocholic	B
acid,	I
and	O
chenodeoxycholic	B
acid	I
are	O
associated	O
with	O
liver	O
cirrhosis	O
and	O
hepatitis.	O

In	O
addition	O
to	O
glucose,	B
amino	O
acids	O
are	O
have	O
an	O
important	O
role	O
for	O
T	O
cells	O
as	O
a	O
prime	O
source	O
of	O
energy	O
and	O
as	O
a	O
substrate	O
for	O
protein	O
and	O
nucleic	O
acid	O
biosynthesis.	O

Three	O
of	O
these	O
peaks	O
were	O
validated	O
as	O
being	O
creatinine,	B
creatine,	B
and	O
5a-DHT.	B

In	O
addition,	O
patients	O
with	O
MN	O
and	O
MCD	O
had	O
a	O
higher	O
level	O
of	O
serum	O
cholesterol	B
and	O
lower	O
albumin	O
than	O
that	O
in	O
FSGS	O
and	O
IgAN.	O

B.	O
Adipose	O
tissue	O
aldo-keto	O
reductase	O
activity	O
in	O
the	O
presence	O
of	O
two	O
putative	O
AKR	O
inhibitors,	O
indomethacin	B
and	O
luteolin,	B
measured	O
by	O
PQ	O
reduction	O
(n=5).	O

FS	O
animals	O
raise	O
the	O
baseline	O
degree	O
of	O
proteolysis	O
to	O
provide	O
additional	O
amino	O
acids	O
for	O
energy	O
production	O
while	O
CPF	O
animals	O
rely	O
on	O
both	O
glucose	B
and,	O
to	O
a	O
lesser	O
extent,	O
amino	O
acids.	O

Previous	O
studies	O
involving	O
isotopic	O
enrichment	O
below	O
1%	O
were	O
mainly	O
focused	O
on	O
single	O
or	O
a	O
few	O
target	O
metabolites	O
e.g.,	O
glucose,	B
cholesterol	B
in	O
different	O
species,	O
or	O
phenylalanine	B
and	O
leucine	B
in	O
muscle	O
protein	O
synthesis.	O

Sphingolipids	B
that	O
were	O
lower	O
in	O
OIR	O
versus	O
Lean	O
included	O
the	O
most	O
and	O
second	O
most	O
abundant	O
Hex2Cer(d18:1/16:0)	O
and	O
Hex2Cer(d18:1/24:1),	O
5	O
of	O
6	O
Hex3Cer	O
including	O
the	O
most	O
abundant	O
Hex3Cer(d18:1/16:0)	O
and	O
the	O
two	O
most	O
abundant	O
GM3	B
GM3(d18:1/16:0)	I
and	O
GM3(d18:1/24:1).	B

Unfortunately,	O
even	O
when	O
we	O
used	O
a	O
12	O
min	O
LC	O
gradient,	O
the	O
19-HETE	O
cannot	O
be	O
fully	O
resolved	O
from	O
20-HETE.	B

We	O
observed	O
some	O
overlap	O
between	O
the	O
plasma	O
profiles	O
of	O
patients	O
with	O
malignancy	O
and	O
those	O
with	O
TB	O
in	O
that	O
the	O
levels	O
of	O
lactate,	B
pyruvate,	B
and	O
ketone	B
bodies	O
were	O
elevated	O
relative	O
to	O
healthy	O
controls,	O
although	O
the	O
mechanism	O
may	O
be	O
very	O
different.	O

Methods	O
such	O
as	O
positron	O
emission	O
tomography	O
(PET)	O
already	O
use	O
such	O
an	O
approach	O
in	O
which	O
metabolite	O
tracers	O
that	O
are	O
radiolabeled	O
are	O
monitored	O
for	O
their	O
ability	O
to	O
accumulate	O
in	O
cancer	O
tissue._18	O
F-fluoro-2-deoxyglucose	B
(FDG)	O
and	O
_11	O
C-	O
or	O
_18	O
F-labeled	O
choline	B
can	O
be	O
used	O
for	O
PCa	O
detection	O
using	O
PET	O
imaging.	O

Sulfide,	B
allyl	O
methyl	O
had	O
the	O
largest	O
AUC	O
value	O
which	O
was	O
0.552,	O
with	O
a	O
sensitivity	O
of	O
0.933	O
and	O
a	O
specificity	O
of	O
0.810	O
at	O
the	O
best	O
cut-off	O
point.	O

After	O
stepwise	O
adjustment	O
for	O
the	O
combination	O
of	O
age,	O
sex,	O
NT-proBNP,	O
cystatin	B
C,	O
and	O
IL-6,	O
IDO-TM	O
scores	O
remained	O
significantly	O
associated	O
with	O
RAP,	O
mPAP,	O
PVR,	O
exercise	O
PVR,	O
and	O
ΔPQ	O
(p	O
≤	O
0.01	O
for	O
all).	O

Conversely,	O
Wettersten	O
et	O
al.,	O
found	O
that	O
the	O
accumulation	O
of	O
acylcarnitine	B
did	O
not	O
overlap	O
with	O
upregulation	O
of	O
fatty	O
acid	O
oxidation	O
enzymes	O
in	O
RCC.	O

However,	O
Allott	O
et	O
al	O
.	O
reported	O
that	O
higher	O
levels	O
of	O
triglycerides	B
the	O
blood	O
of	O
male	O
patients	O
were	O
associated	O
with	O
increased	O
risk	O
for	O
prostate	O
cancer	O
recurrence,	O
which	O
presented	O
a	O
reverse	O
trend	O
to	O
that	O
in	O
our	O
study.	O

[25(OH)D]	O
and	O
940	O
serum	O
metabolites	O
were	O
measured	O
in	O
392	O
men	O
from	O
eight	O
nested	O
cancer	O
case–control	O
studies	O
in	O
the	O
Alpha-Tocopherol,	B
Beta-Carotene	B
Cancer	O
Prevention	O
Study	O
of	O
Finnish	O
male	O
smokers	O
(aged	O
50–69	O
years).	O

Statistical	O
analysis	O
was	O
not	O
performed	O
to	O
compare	O
ADMA	B
concentrations	O
in	O
the	O
hypertensive	O
compared	O
with	O
the	O
normotensive	O
subjects	O
due	O
to	O
the	O
small	O
number	O
of	O
subjects	O
involved.	O

The	O
_1	O
H-NMR	O
analyses	O
revealed	O
elevated	O
plasma	O
glucose,	B
ketones,	B
and	O
branched-chain	O
amino	O
acids	O

High	O
levels	O
of	O
tryptophan,	B
KA,	O
XA,	O
HAA	O
and	O
riboflavin	B
were	O
associated	O
with	O
lower	O
odds	O
ratio	O
for	O
ADHD.	O

Metabolic	O
remodeling	O
is	O
a	O
predominant	O
phenotype	O
of	O
malignant	O
tumor	O
cells	O
(Warburg	O
effect)	O
and	O
refers	O
to	O
the	O
alteration	O
of	O
the	O
utilization	O
and/or	O
synthesis	O
of	O
important	O
metabolites,	O
including	O
glucose,	B
fatty	O
acids,	O
and	O
amino	O
acids,	O
by	O
tumor	O
cells.	O

DNA	O
replication	O
in	O
tumour	O
cells	O
rapidly	O
exhausts	O
thymine	B
levels;	O
hence,	O
decreased	O
dihydrothymine	B
could	O
be	O
a	O
feasible	O
new	O
biomarker	O
associated	O
with	O
tumour	O
initiation.	O

Furthermore,	O
we	O
found	O
significant	O
and	O
inverse	O
association	O
between	O
hsa-miR-885-5p	O
and	O
OSBPL2,	O
a	O
protein	O
known	O
to	O
affect	O
efflux	O
of	O
cholesterol.	B

The	O
heatmaps	O
clearly	O
show	O
that	O
the	O
metabolic	O
profiles	O
of	O
the	O
AF	B
group	O
were	O
more	O
easily	O
distinguished	O
from	O
those	O
of	O
the	O
non-AF	O
group	O
in	O
the	O
atrial	O
appendage	O
samples	O
than	O
in	O
the	O
plasma	O
samples.	O

(Sigma)	O
was	O
added	O
to	O
1	O
ug	O
of	O
purified	O
enzyme	O
(rhAKR1C3	O
from	O
R&D	O
Systems,	O
rhCBR1	O
from	O
MyBiosource,	O
San	O
Diego,	O
CA)	O
or	O
5	O
ug	O
lysates	O
(mouse	O
3T3-L1	O
adipocytes,	O
human	O
breast	O
adipose	O
tissue)	O
in	O
sodium	B
phosphate	I
buffer	O
(0.1M,	O
pH	O
6.0)	O
in	O
a	O
final	O
volume	O
of	O
100	O
ul/well.	O

Lipid	O
classes	O
with	O
statistically	O
significant	O
associations	O
with	O
total	O
cholesterol	B
(defined	O
as	O
p	O
<0.05	O
following	O
adjustment	O
for	O
multiple	O
comparisons	O
using	O
the	O
Benjamini-Hochberg	O
method)	O
for	O
each	O
arm	O
where—Efavirenz:	O
free	O
cholesterol	B
(p	O
=	O
0.015),	O
cholesterol	B
ester	I
(p	O
=	O
0.013).	O

We	O
further	O
assessed	O
the	O
effect	O
of	O
adding	O
α	B
-hydroxybutyrate	I
AUC	O
or	O
its	O
concentrations	O
at	O
either	O
fasting,	O
90	O
minutes,	O
and	O
120	O
minutes	O
on	O
the	O
ability	O
of	O
the	O
model	O
to	O
predict	O
deteriorations	O
of	O
glucose	B
control.	O

Unfortunately,	O
we	O
had	O
to	O
exclude	O
serine	B
from	O
the	O
analyses	O
due	O
to	O
severe	O
spectral	O
overlap	O
and	O
we	O
were	O
unable	O
to	O
replicate	O
the	O
findings	O
from	O
prior	O
studies	O
[,].	O

Gouin-Thibault	O
et	O
al	O
showed	O
no	O
significant	O
influence	O
of	O
rs2032582	O
and	O
rs1045642	O
ABCB1	O
polymorphisms	O
on	O
rivaroxaban	B
pharmacokinetics:	O
the	O
AUC	O
ratio	O
between	O
carriers	O
of	O
allelic	O
variants	O
and	O
wild	O
genotype	O
was	O
1.20	O
(95%	O
CI:	O
0.96–1.51).	O

In	O
the	O
polar	O
solvents	O
MeOD,	O
DMSO,	B
and	O
DMF	O
most	O
of	O
the	O
substances	O
could	O
be	O
dissolved	O
and	O
there	O
was	O
only	O
a	O
minor	O
residue	O
in	O
the	O
centrifuge	O
tube.	O

CLL	O
cells	O
have	O
been	O
reported	O
to	O
exhibit	O
a	O
greater	O
dependency	O
on	O
peroxisome	O
proliferator	O
activated	B
receptor	O
–	O
alpha	O
(PPAR-α)	O
regulated	O
oxidation	O
of	O
fatty	O
acids	O
leading	O
to	O
these	O
cells	O
having	O
a	O
higher	O
fat-burning	O
rate	O
than	O
such	O
as	O
myocytes,	O
that	O
is	O
not	O
related	O
to	O
diet.	O

To	O
test	O
the	O
applicability	O
of	O
this	O
assay,	O
enzalutamide	B
and	O
N-desmethylenzalutamide	B
concentrations	O
were	O
quantified	O
in	O
samples	O
collected	O
from	O
a	O
patient	O
participating	O
in	O
a	O
clinical	O
trial	O
who	O
was	O
treated	O
with	O
160	O
mg	O
enzalutamide	B
once	O
daily	O
and	O
had	O
reached	O
steady-state	O
pharmacokinetics.	O

DHT,	O
trifluoroacetic	B
acid,	I
Escherichia	O
coli	O
β-glucuronidase	O
Type	O
VII	O
A	O

Galactose	B
and	O
galactonate	B
were	O
exclusively	O
detected	O
after	O
the	O
intake	O
of	O
milk	O
while	O
lactose	B
was	O
also	O
identified	O
after	O
cheese	O
and	O
soy	O
drink	O
intake,	O
although	O
its	O
level	O
was	O
significantly	O
increased	O
after	O
milk	O
intake.	O

The	O
relatively	O
weak	O
signals	O
for	O
some	O
coenzymes	O
such	O
as	O
NADH	B
and	O
NADPH,	B
due	O
to	O
their	O
low	O
concentrations	O
of	O
a	O
few	O
μ	O
M	O
(Figures	O
and	O
),	O
added	O
to	O
the	O
challenge.	O

Comparison	O
of	O
PC	O
and	O
benign	O
pancreatitis	O
cases	O
showed	O
upregulation	O
of	O
3-hydroxybutyrate	B
and	O
phenylalanine	B
in	O
PC,	O
while	O
lysine,	B
asparagine,	B
and	O
threonine	B
were	O
down-regulated.	O

The	O
uniform	O
core	O
was	O
composed	O
of	O
metabolites	O
of	O
various	O
categories,	O
including	O
fatty	O
acids,	O
steroids,	O
glycerolipids,	B
nucleotides,	O
sugars,	O
and	O
others.	O

Two	O
enzymes	O
control	O
the	O
pyruvate	B
flux:	O
the	O
kinase,	O
PDK1	O
that	O
phosphorylates	B
PDH,	O
thereby	O
inactivating	O
it,	O
and	O
the	O
phosphatase,	O
PDP2	O
that	O
activates	O
PDH.	O

(A)	O
NMR	O
peaks	O
at	O
3.0212	O
and	O
3.0157	O
ppm	O
were	O
annotated	O
as	O
2-oxoglutarate,	B
and	O
those	O
at	O
3.2485,	O
3.243,	O
and	O
2.924	O
ppm	O
were	O
annotated	O
as	O
tyramine,	B
using	O
a	O
500	O
MHz	O
machine	O
(VNMRS500)	O
at	O
Varian	O
Inc.,	O
Korea.	O

Interestingly,	O
among	O
the	O
methylated	B
arginine	I
parameters	O
examined	O
(ie	O
ADMA,	B
SDMA,	O
MMA	O
and	O
ArgMI),	O
the	O
integrated	O
methylation	O
index,	O
ArgMI,	O
remained	O
the	O
most	O
robust	O
independent	O
predictor	O
of	O
significantly	O
obstructive	O
CAD	O
status	O
after	O
adjustments	O
for	O
traditional	O
risk	O
factors,	O
renal	O
function,	O
and	O
hsCRP,	O
demonstrating	O
odds	O
ratios	O
of	O
[adjusted	O
OR	O
(95%	O
CI):	O
1.63	O
(1.09-2.46),	O
p=0.019]	O
for	O
the	O
third	O
quartile	O
and	O
[adjusted	O
OR	O
(95%	O
CI):	O
2.64	O
(1.71-	O
4.08),	O
p<0.001]	O
for	O
fourth	O
quartile.	O

At	O
the	O
time	O
of	O
biomarker	O
measurement	O
(at	O
or	O
near	O
the	O
end	O
of	O
the	O
DCCT),	O
mean	O
age	O
was	O
32.4	O
yr,	O
mean	O
duration	B
of	O
diabetes	O
was	O
7.5	O
yr,	O
mean	O
iothalamate	O
GFR	O
was	O
132.9	O
ml/min/1.73	O

Bars	O
represent	O
mean	O
value	O
of	O
the	O
ratio	O
of	O
phosphatidyl	B
ethanolamine	I
16:0/28:0	I
to	O
the	O
internal	O
standard.	O

Interestingly,	O
butyrate,	B
with	O
its	O
potential	O
association	O
to	O
CRC	O
was	O
the	O
metabolite	O
that	O
is	O
most	O
important	O
in	O
separating	O
patients	O
with	O
adenoma	O
from	O
normal.	O

Calibration	O
was	O
performed	O
for	O
the	O
entire	O
mass	O
range	O
with	O
cluster	O
ions	O
produced	O
from	O
a	O
solution	O
of	O
acetonitrile	B
containing	O
0.1%	O
phosphoric	B
acid.	I

As	O
previously	O
reported,	O
methylamines,	B
important	O
osmoregulatory	O
compounds,	O
are	O
produced	O
from	O
choline,	B
introduced	O
with	O
the	O
diet,	O
that	O
give	O
rise	O
to	O
DMA	B
and	O
TMA	O
by	O
specific	O
gut	O
microflora	O
[,].	O

Compared	O
to	O
healthy	O
people,	O
in	O
the	O
serum	O
samples	O
of	O
papillary	O
thyroid	O
cancer	O
patients	O
the	O
valine,	B
leucine,	B
isoleucine,	B
lactate,	B
alanine,	B
glutamine,	B
and	O
glycine	B
levels	O
were	O
increased,	O
while	O
lipids,	O
choline,	B
and	O
tyrosine	B
levels	O
were	O
reduced.	O

Furthermore,	O
estrogen	B
levels	O
in	O
these	O
tumor	O
cell	O
lines	O
were	O
substantially	O
elevated	O
and	O
even	O
exceeded	O
the	O
levels	O
typically	O
found	O
in	O
well	O
characterized	O
estrogen-dependent	O
and	O
ER-positive	O
tumor	O
cells	O
such	O
as	O
MCF-7	O
and	O
T-47D.	O
Levels	O
of	O
unconjugated	O
endogenous	O
estrogens	O
(picograms)	O
found	O
in	O
NCI-60	O
cell	O
lines	O
Data	O
are	O
expressed	O
as	O
mean	O
(standard	O
deviation)	O
of	O
three	O
replicated	O
analyses	O
of	O
10_6	O
cells.	O

It	O
has	O
been	O
long	O
known	O
that	O
several	O
plant	O
materials	O
(including	O
coffee,	O
tea,	O
and	O
cocoa)	O
are	O
rich	O
in	O
niacin	B
(vitamin	O
B3)	O
and	O
some	O
of	O
its	O
major	O
metabolic	O
products,	O
including	O
NMNA.	O

The	O
NTDs	O
used	O
in	O
this	O
work,	O
“NeedleEx”,	O
were	O
custom	O
manufactured	O
by	O
Shinwa	O
Ltd.,	O
Japan	O
(60 mm × 0:41 mm	O
id,	O
0.72 mm	O
od,	O
triple	O
bed	O
configuration	O
Divinylbenzene/Carboxen	O
X/Carbopack	O
1000	O
-	O
DVB/CarX/Car1000)	O
and	O
purchased	O
from	O
PAS	O
Technology	O
(Magdala,	O
Germany).	O

It	O
has	O
also	O
been	O
established	O
that	O
especially	O
the	O
N-glycosite	B
occupancy	O
of	O
a	O
protein	O
is	O
associated	O
with	O
the	O
enzymatic	O
activity	O
and	O
the	O
physical	O
stability	O
of	O
glycoproteins,	B
which	O
might	O
contribute	O
to	O
the	O
metastasis	O
of	O
HCC.	O

Patients	O
with	O
mild	O
insulin	O
resistance	O
are	O
more	O
likely	O
to	O
develop	O
full	O
insulin	O
resistance	O
after	O
simvastatin	B
treatment,	O
which	O
may	O
drive	O
their	O
metabolism	O
towards	O
a	O
more	O
gluconeogenic	B
state.	O

On	O
the	O
contrary,	O
in	O
the	O
advanced	O
stages	O
of	O
the	O
disease	O
low	O
levels	O
of	O
24S-OH-Chol	B
in	O
CNS	O
(and	O
consequently	O
in	O
the	O
circulation),	O
would	O
even	O
accelerate	O
beta-amyloid	O
deposition	O
and	O
the	O
progression	O
of	O
LOAD.	O

Finally,	O
a	O
stock	O
solution	O
of	O
sodium	B
(3-trimethylsilyl)-2,2,3,3-tetradeuteriopropionate	I
(TSP)/D_2	O
O	O
(50	O
μL)	O
was	O
added	O
to	O
each	O
supernatant	O
prior	O
to	O
analysis	O
via	O
_1	O
H	O
NMR	O
spectroscopy.	O

(Solvent	O
1	O
:	O
A,	O
0.1%	O
formic	B
acid	I
in	O
H_2	O
O	O
and	O
B,	O
0.1%	O
formic	B
acid	I
in	O
methanol.	B

In	O
addition,	O
a	O
subset	O
of	O
patients	O
were	O
also	O
subjected	O
to	O
chemotherapy	O
with	O
the	O
following	O
distribution:	O
AC	O
(Adriamycin+	O
Cyclophosphamide	I
(AC)	O
(Sigma,	O
St	O
Louis,	O
MO,	O
USA))	O

Here,	O
we	O
labeled	O
metabolites	O
with	O
dansyl	B
chloride,	I
which	O
increases	O
the	O
hydrophobicity	O
to	O
an	O
extent	O
that	O
the	O
labeled	O
metabolites	O
can	O
be	O
efficiently	O
retained	O
and	O
separated	O
in	O
RPLC	O
and	O
enhances	O
ionization	O
efficiency	O
by	O
1–3	O
orders	O
of	O
magnitude,	O
enabling	O
us	O
to	O
systematically	O
investigate	O
hydrophilic	B
metabolites	O
as	O
well	O
as	O
hydrophobic	O
metabolites.	O

Significantly	O
altered	O
metabolites	O
caused	O
by	O
high	O
temperature	O
(40	O
°C)	O
in	O
urine	O
samples	O
with	O
no	O
preservative	O
or	O
preserved	O
with	O
thymol	B
in	O
the	O
PABA	O
group.	O

Cells	O
were	O
plated	O
in	O
24-well	O
plates	O
(5	O
×	O
10_5	O
cells/well)	O
24	O
h	O
before	O
transfection	O
and	O
transfected	O
with	O
1	O
μg	O
of	O
plasmid	O
DNA/well	O
complexed	O
with	O
2	O
μl	O
of	O
Lipofectamine	B
2000	O
(Invitrogen).	O

The	O
significant	O
decrease	O
of	O
acetone	B
in	O
CSF	O
might	O
imply	O
that	O
the	O
decreased	O
flux	O
from	O
acetyl-CoA	B
into	O
acetoacetyl-CoA	B
resulted	O
in	O
lower	O
production	O
of	O
acetone	B
or	O
a	O
reduced	O
efflux	O
through	O
the	O
blood-brain	O
barrier	O
(BBB)	O
and	O
higher	O
consumption	O
in	O
the	O
brain.	O

DUP,	O
duration	B
of	O
untreated	O
schizophrenia	O
(week).	O

Our	O
studies	O
show	O
free	O
methyl-lysine	B
levels	O
demonstrate	O
limited	O
prognostic	O
value	O
regarding	O
either	O
prevalence	O
of	O
significantly	O
obstructive	O
CAD	O
or	O
the	O
prediction	O
of	O
future	O
cardiovascular	O
events	O
in	O
the	O
population	O
examined.	O

Increased	O
glutamate	B
(Glu)	O
levels	O
and	O
decreased	O
glutamine	B
(Gln)	O
levels	O
were	O
found	O
in	O
the	O
MDD	O
group	O
(FDR	O
q = 3.7 × 10_−7	O
and	O
4.8 × 10_−7	O
,	O
respectively)	O

As	O
expected,	O
adolescents	O
with	O
lower	O
insulin	O
sensitivity	O
(first	O
WBISI	O
tertile)	O
had	O
higher	O
BMI,	O
BMI	O
z	O
-score,	O
fasting	O
and	O
2-hour	O
glucose	B
levels,	O
fasting	O
insulin	O
level,	O
hemoglobin	O
A1C,	O
IGI,	O
triglyceride	B
levels,	O
transaminase	O
levels,	O
and	O
lower	O
DI	O
and	O
HDL	B
cholesterol	I
levels	O
than	O
adolescents	O
with	O
higher	O
insulin	O
sensitivity	O
(third	O
WBISI	O
tertile).	O

Soluble	O
fms-like	O
tyrosine	B
kinase-1	O
(sFlt-1)/Placental	O
growth	O
factor	O
(PlGF)	O
were	O
measured	O
with	O
high-sensitive	O
multiplex	O
array	O
(Meso	O
Scale	O
Discovery	O
(MSD)	O
V-PLEX	O
Angiogenesis	O
Panel	O
1	O
Human	O
kit,	O
MSD,	O
USA),	O
according	O
to	O
the	O
manufacturer’	O
instruction.	O

In	O
summary,	O
the	O
final	O
modified	O
50_HIGH	O
quenching,	O
extraction,	O
and	O
normalization	O
method	O
(50%	O
MeOH	B
for	O
harvest	O
followed	O
by	O
extraction	O
using	O
a	O
1:1:1,	O
v/v/v	O
MeOH:CHCl_3	B
:H_2	O
O	O
ratio	O
and	O
collection	O
of	O
6	O
mL	O
polar	O
phase)	O
can	O
be	O
recommended	O
for	O
the	O
investigation	O
of	O
intracellular	O
metabolites	O
from	O
adherent	O
human	O
cells	O
grown	O
under	O
standard	O
(10%)	O
or	O
high	O
(20%)	O

In	O
this	O
study	O
we	O
observed	O
an	O
increase	O
in	O
only	O
a	O
single,	O
minor	O
SM	O
having	O
two	O
C18	O
chains	O
with	O
one	O
and	O
two	O
double	O
bonds,	O
respectively,	O
either	O
SM(d18:2/18:1)	B
or	O
SM(d18:1/18:2).	B

Baseline	O
serum	O
polyamine	B
levels	O
of	O
the	O
study	O
subjects,	O
according	O
to	O
the	O
presence	O
or	O
absence	O
of	O
T2D.	O
Data	O
are	O
mean	O
±	O
SD	O
or	O
n	O
(%).	O

The	O
data	O
could	O
mean	O
that	O
our	O
patient	O
population	O
had	O
previously	O
undetected	O
metastasis	O
or	O
that	O
the	O
elevated	O
methionine	B
metabolism	O
is	O
a	O
precursor	O
for	O
metastasis.	O

In	O
tumour	O
samples,	O
this	O
apparently	O
was	O
linked	O
to	O
increases	O
in	O
glutathione,	B
glutathione	B
derivatives,	O
(lactoyl-	O
glutathione	I
and	O
hydroxylmethytl	B
glutathione),	I
and	O
also	O
taurine.	B

Both	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
have	O
shown	O
that	O
polyamine	B
pathway	O
plays	O
a	O
major	O
role	O
in	O
energy	O
homeostasis	O

We	O
observed	O
statistically	O
significant	O
changes	O
in	O
threitol	B
and	O
aminomalonic	B
acid	I
in	O
PAH	O
patients,	O
which	O
could	O
provide	O
new	O
biochemical	O
insights	O
into	O
the	O
pathogenesis	O
of	O
the	O
disease.	O

We	O
assessed	O
the	O
contribution	O
of	O
muscle	O
metabolism	O
to	O
the	O
suggested	O
difference	O
in	O
glucose	B
consumption	O
with	O
exhaustive	O
endurance	O
exercise.	O

Only	O
the	O
creatine,	B
replenishing	O
energy	O
in	O
ADP-ATP	O
cycle	O
metabolite,	O
which	O
increased	O
level	O
is	O
observed	O
in	O
the	O
TC	O
group	O
matched	O
with	O
the	O
changes	O
from	O
the	O
previous	O
study.	O

While	O
these	O
higher	O
amounts	O
were	O
most	O
notable	O
for	O
15-HETE	B
and	O
17-HDHA,	B
even	O
these	O
differences	O
were	O
not	O
significant.	O

It	O
was	O
positively	O
correlated	O
with	O
lactate	B
concentration	O
in	O
glioblastomas,	O
astrocytomas	O
and	O
meningiomas	O
while	O
in	O
oligodendrogliomas	O
these	O
metabolites	O
showed	O
a	O
moderate	O
correlation	O
that	O
lay	O
just	O
outside	O
statistical	O
significance	O
(p	O
=	O
0.07).	O

Inositol	B
might	O
therefore	O
play	O
a	O
role	O
in	O
cellular	O
signaling,	O
via	O
its	O
link	O
to	O
the	O
phosphoinositol-3-kinase	O
PI3K	O
pathway,	O
impacting	O
CRC	O
pathogenesis.	O

They	O
showed	O
that	O
C52:1	B
TG	I
was	O
linked	O
with	O
an	O
increased	O
risk	O
of	O
T2D,	O
whereas	O
C38:6	B
PC	I
was	O
linked	O
with	O
a	O
decreased	O
risk.	O

We	O
also	O
found	O
abnormal	O
choline	B
metabolism	O
in	O
AS.	O

High	O
concentrations	O
of	O
vitamin	B
B6	I
are	O
seen	O
to	O
stimulate	O
IGBF1,	O
p53,	O
and	O
p21	O
which	O
are	O
defensive	O
factors	O
against	O
colon	O
cancer.	O

Sterols	O
and	O
glycerolipids	B
were	O
separated	O
with	O
reverse-phase	O
HPLC	O
using	O
an	O
isocratic	O
mobile	O
phase	O
as	O
before	O
except	O
with	O
an	O
Agilent	O
Zorbax	O
Eclipse	O
XDB-C18	O
column	O
(4.6	O
x	O
100	O
mm).	O

Sphinganine	B
is	O
an	O
intermediate	O
in	O
sphingolipid	B
metabolism.	O

Myo-inositol,	B
alanine,	B
lactate,	B
ornithine	B
and	O
urea	B
were	O
also	O
identified	O
as	O
biomarkers.	O

FIA	O
is	O
used	O
for	O
the	O
semi-quantitative	O
measurement	O
of	O
146	O
hydrophobic	O
molecules	O
such	O
as	O
acylcarnitines,	B
sphingomyelins	B
(SM:	O
type	O
of	O
sphingolipid	B
consisting	O
of	O
phosphorylcholine	B
and	O
ceramide.)	B
and	O
phospholipids	B
(lyso-,	O
diacyl-	B
and	O
acyl-	B
alkyl	I
phosphatidylcholines	I
(PC)).	O

For	O
example,	O
a	O
6	O
fold	O
increase	O
in	O
hydroxyspheroidenone,	B
involved	O
in	O
carotenoid	B
biosynthesis	O
was	O
found	O
that	O
is	O
not	O
known	O
to	O
be	O
related	O
to	O
steroid	O
treatment	O
or	O
myasthenia	O
gravis.	O

In	O
addition	O
to	O
our	O
findings	O
for	O
these	O
metabolites,	O
our	O
results	O
also	O
show	O
the	O
known	O
associations	O
of	O
higher	O
HDL-cholesterol	B
and	O
lower	O
triglyceride	B
concentration	O
with	O
physical	O
activity.	O

This	O
is	O
the	O
first	O
study	O
to	O
elucidate	O
the	O
clinical	O
relevance	O
of	O
ceramide	B
metabolism	O
in	O
breast	O
cancer	O
patients.	O

Findings	O
from	O
correlation	O
analyses	O
and	O
size	O
effect	O
(Hedges’s	O
statistic)	O
were	O
considered	O
to	O
choose	O
candidate	O
individual	O
FA	B
for	O
in	O
vitro	O
assays.	O

Parallel	O
to	O
changes	O
in	O
HNSCC	O
tissues,	O
studies	O
of	O
unmatched	O
saliva	O
and	O
plasma	O
samples	O
from	O
patients	O
with	O
HNSCC	O
showed	O
that	O
glutamate	B
levels	O
were	O
also	O
significantly	O
elevated	O
in	O
samples	O
derived	O
from	O
HNSCC	O
patients	O
compared	O
to	O
healthy	O
controls.	O

_1	O
H	O
NMR-detected	O
acetaminophen	B
and	O
ibuprofen	B
use	O
was	O
low	O
(∼4%)	O
among	O
East	O
Asian	O
population	O
samples	O
and	O
higher	O
(>16%)	O
in	O
Western	O
population	O
samples.	O

PtdCho	O
indicates	O
phosphatidylcholine	B
in	O
cell	O
membranes	O
which	O
is	O
invisible	O
to	O
HRMAS	O
_1	O
H	O
NMR.	O

Altered	O
PC	O
metabolism	O
has	O
been	O
suggested	O
in	O
asthma	O
with	O
increase	O
in	O
level	O
of	O
PC	O
and	O
decrease	O
in	O
level	O
of	O
lyso-PC	B
and	O
Crohn’s	O
disease	O
where	O
phospholipids	B
were	O
increased	O
.	O

The	O
studies	O
discussed	O
above	O
present	O
a	O
comprehensive	O
and	O
authoritative	O
examination	O
of	O
PAH	O
diol	B
epoxide	I
conjugation	O
catalyzed	O
by	O
GSTs.	O

Meanwhile,	O
only	O
a	O
single	O
lipid	O
metabolism	O
(sphingolipid	O
metabolism)	O
was	O
found	O
to	O
be	O
increased.	O

In	O
vitro	O
functional	O
characterization	O
of	O
DHT	O
and	O
palmitate	B
(PA)	O
stimulation	O
on	O
AR	O
positive	O
and	O
negative	O
PCa	O
cells.	O

The	O
two-compartment	O
model	O
is	O
consistent	O
with	O
the	O
fact	O
that	O
it	O
took	O
several	O
days	O
to	O
months	O
for	O
the	O
majority	O
of	O
TSG	O
before	O
the	O
onset	O
of	O
symptoms	O
and	O
for	O
the	O
recovery	O
of	O
their	O
neo-nicotinic	O
symptoms,	O
in	O
contrast	O
to	O
that	O
of	O
the	O
acute	O
case	O
of	O
acetamiprid	B
intoxication,	O
which	O
was	O
within	O
24	O
hours.	O

Box	O
plots	O
of	O
C18:2	B
CE	O
and	O
SM	B
22:0	I
concentrations	I
in	O
the	O
training	O
and	O
validation	O
SqCC	O
cohorts	O
and	O
high-risk	O
controls.	O

Correlations	O
of	O
circulating	O
vitamin	B
D	I
metabolites	O
with	O
clinical	O
characteristics	O
and	O
other	O
biomarkers	O
were	O
assessed	O
using	O
Kendall's	O
τ	O
statistic.	O

This	O
points	O
to	O
differences	O
in	O
sample	O
processing	O
between	O
the	O
two	O
sample	O
types	O
as	O
a	O
possible	O
explanation	O
for	O
the	O
higher	O
creatine	B
levels	O
in	O
WB	O
compared	O
with	O
serum.	O

This	O
residue	O
is	O
thought	O
to	O
either	O
hydrogen	O
bond	O
with	O
the	O
adenosine	B
monophosphate	I
during	O
the	O
adenylyltransferase	O
reaction	O
or	O
help	O
with	O
essential	O
Mg_+2	O
coordination	O
during	O
catalysis	O
,	O
.	O

Stilbenoids	B
were	O
fermented	O
in	O
an	O
in	O
vitro	O
faecal	O
fermentation	O
system	O
using	O
fresh	O
faeces	O
from	O
five	O
different	O
donors	O
as	O
an	O
inoculum.	O

Chemical	O
shifts	O
were	O
referenced	O
to	O
the	O
anomeric	O
proton	O
of	O
α-glucose	B
at	O
δ5.233	O
and	O
the	O
spectra	O
were	O
put	O
into	O
2,834	O
integrated	O
regions	O
of	O
0.003	O
ppm,	O
corresponding	O
to	O
δH=9.0,	O
to	O
0.5	O
ppm.	O

The	O
most	O
significant	O
difference	O
observed	O
for	O
emericellene	B
B	O
(3)	O
was	O
the	O
absence	O
of	O
signals	O
at	O
δ_H	O
9.28	O

NEFAs	O
have	O
been	O
linked	O
to	O
changes	O
in	O
matrix	O
proteoglycans	B
leading	O
to	O
an	O
increased	O
lipoprotein	O
uptake	O
on	O
the	O
arterial	O
wall.	O

A	O
number	O
of	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
have	O
been	O
identified	O
in	O
the	O
MTHFD2L	O
gene	O
that	O
correlate	O
with	O
the	O
CDR	O
and	O
interleukin	O
1β	B
(IL1β)	I

Increased	O
pyrimidine	B
and	O
metabolite	O
levels	O
in	O
urine	O
were	O
detected	O
by	O
GC–MS.	O

Although	O
it	O
has	O
been	O
suggested	O
that	O
the	O
sn	O
-2	O
position	O
is	O
preferred	O
by	O
polyunsaturated	O
acyl	O
chains,,	O
our	O
data	O
quantitatively	O
show	O
that	O
many	O
of	O
them	O
still	O
consist	O
of	O
minor	O
sn	O
-isomers,	O
such	O
as	O
PC	B
20:4/16:0	I
(4%)	O
and	O
PC	B
22:4/18:0	I
(9%).	O

Conversely,	O
effective	O
PTSD	O
treatments	O
such	O
as	O
SSRI	O
antidepressants	O
may	O
have	O
beneficial	O
effects	O
on	O
these	O
dysregulated	O
biochemical	O
pathways,	O
in	O
addition	O
to	O
the	O
observed	O
behavioral	O
manifestations	O
of	O
PTSD,	O
as	O
noted	O
in	O
an	O
animal	O
study	O
where	O
fluoxetine	B
pre-treatment	O
averted	O
some	O
physiological	O
sequellae	O
of	O
stress	O
(energy	O
metabolism).	O

Bivariate	O
relationships	O
of	O
24,25(OH)_2	B
D_3	O
concentration	O
with	O
25(OH)D_3	O
concentration	O
were	O
examined	O
using	O
scatterplots,	O
locally-weighted	O
scatterplot	O
smoothing	O
(LOWESS),	O
Pearson	O
correlation,	O
and	O
linear	O
regression.	O

Stable	O
isotope-labeled	O
internal	O
standards,	O
25(OH)D_3	O
-d	O
_6	O
and	O
3-epi-25(OH)D_3	B
-d	I
_3	O
were	O
obtained	O
from	O
Medical	O
Isotopes,	O
while	O
25(OH)D_2	O
-d	O
_3	O
was	O
obtained	O
from	O
IsoSciences.	O

Samples	O
were	O
then	O
vortex	O
mixed	O
and	O
extracted	O
with	O
ethyl	B
acetate	I
(2	O
×	O
2	O
ml).	O

In	O
conclusion,	O
our	O
results	O
raise	O
the	O
possibility	O
that	O
BD-associated	O
abnormalities	O
in	O
kynurenine	B
metabolism	O
may	O
negatively	O
impact	O
the	O
hippocampus	O
and	O
possibly	O
the	O
amygdala,	O
structures	O
that	O
have	O
been	O
shown	O
to	O
be	O
both	O
functionally	O
impaired	O
and	O
reduced	O
in	O
volume	O
in	O
unmedicated	O
patients	O
with	O
BD.	O

Exact	O
masses,	O
calculated	O
cations,	O
and	O
the	O
ppm	O
mass	O
error	O
for	O
the	O
cations	O
monitored	O
by	O
high-resolution	O
mass	O
spectrometry	O
for	O
PtdC	O
and	O
SM.	O
ppm:	O
parts	O
per	O
million	O
mass	O
error;	O
PtdC:	O
phosphatidylcholines;	B
PlsC:	O
choline	B
plasmalogens;	O
SM:	O
sphingomyelins.	B

One	O
is	O
that	O
something	O
other	O
than	O
NN	O
interfered	O
with	O
the	O
renal	O
tubular	O
reabsorption	O
of	O
DMAP	O
and	O
thiamethoxam,	B
and	O
caused	O
an	O
increase	O
in	O
DMAP	O
and	O
thiamethoxam	B
excretion	O
in	O
urine	O
and	O
neo-nicotinic	O
symptoms,	O
while	O
the	O
environmental	O
acetemiprid	O
and	O
thiamethoxam	B
exposure	O
was	O
in	O
the	O
normal	O
ranges.	O

A	O
study	O
reported	O
that	O
plasma	O
glutamine	B
and	O
alanine	B
were	O
lower	O
in	O
HCC	O
patients	O
when	O
compared	O
with	O
normal	O
subjects	O
and	O
patients	O
with	O
liver	O
cirrhosis,	O
indicating	O
that	O
the	O
consumption	O
of	O
these	O
amino	O
acids	O
increased	O
in	O
HCC.	O

As	O
expected,	O
cats	O
in	O
the	O
meloxicam	O
group	O
had	O
increased	O
serum	O
BUN	O
and	O
creatinine	B
concentrations	O
(Supplementary	O
Figs _S1	O
and	O
_S2	O
).	O

Urine	O
samples	O
from	O
100	O
subjects	O
were	O
collected	O
and	O
concentrations	O
of	O
monophenolic	O
metabolites	O
of	O
naphthalene,	B
fluorene,	B
phenanthrene,	B
and	O
pyrene	O
and	O
the	O
nicotine	B
metabolites	O
cotinine	B
and	O
trans	B
-3′-hydroxycotinine	I
were	O
measured	O
using	O
liquid	O
chromatography–tandem	O
mass	O
spectrometry	O
(LC-MS/MS)	O
to	O
assess	O
PAH	O
and	O
ETS	O
exposures.	O

Furthermore,	O
neither	O
sex	O
nor	O
distance	O
from	O
health	O
facilities	O
or	O
pharmacies	O
showed	O
a	O
significant	O
effect	O
on	O
residual	O
levels	O
of	O
SP,	B
AL	O
or	O
both	O
at	O
study	O
entry.	O

Dashed	O
boxes	O
indicate	O
pools	O
of	O
metabolites:	O
tCr,	O
total	O
creatines	B
(creatine	I
+	I
phosphocreatine);	I
tCho,	O
total	O
cholines	B
(choline	I
+	I
phosphocholine	I
+	I
glycerophosphocholine).	I

Down-regulation	O
of	O
acetate	B
in	O
the	O
disease	O
groups	O
and	O
down-regulation	O
of	O
citrate	B
in	O
MS	O
patients	O
may	O
indicate	O
a	O
decrease	O
of	O
fatty	O
acid	O
metabolism,	O
particularly	O
in	O
myelin	B
synthesis.	O

Equal	O
amounts	O
of	O
cell	O
proteins	O
were	O
resolved	O
on	O
(SDS)-polyacrylamide	B
gels	O
and	O
transferred	O
to	O
nitrocellulose	O
membrane	O
by	O
Trans-blot	B
turbo	O
transfer	O
system	O
(Bio-Rad,	O
Hercules,	O
CA	O
USA).	O

However,	O
it	O
is	O
still	O
unclear	O
if	O
the	O
oxidization	O
of	O
C(18:2)CE	B
is	O
involved	O
in	O
tumorogenesis	O
of	O
lung	O
cancer.	O

Besides	O
the	O
slight	O
but	O
significant	O
correlation	O
between	O
BP3	O
and	O
parabens	O
(r	O
=	O
0.27–0.37	O
P	O
<	O
0.001)	O
already	O
observed	O
in	O
a	O
previous	O
study,	O
BP3	O
seemed	O
to	O
be	O
weakly	O
correlated	O
with	O
some	O
phthalate	B
metabolites,	O
mainly	O
MnBP,	O
MiBP,	O
5-OH-MEHP,	B
and	O
5-oxo-MEHP	B
(r	O
=	O
0.33–0.37	O

Among	O
the	O
34	O
metabolites	O
associated	O
with	O
BCa,	O
the	O
levels	O
of	O
bilirubin	B
and	O
retinal	B
recovered	O
in	O
BCa	O
tissues	O
treated	O
with	O
gemcitabine.	O

Further	O
aberrations	O
in	O
lipid	O
metabolism	O
were	O
witnessed	O
through	O
strong	O
elevations	O
in	O
bile	O
acids	O
TCDCA,	O
TCA,	O
GHCA	B
and	O
GCA	O
in	O
DC	O
vs.	O
NHC.	O

a	O
Schematic	O
representation	O
of	O
experimental	O
set-up	O
to	O
test	O
for	O
air	O
diffusion	O
of	O
ethanol.	B

Our	O
findings	O
on	O
urinary	O
creatine	B
suggest	O
that	O
it	O
is	O
elevated	O
in	O
HCC	O
in	O
comparison	O
to	O
ethnically-matched	O
healthy	O
controls	O
but	O
is	O
reduced	O
in	O
CIR	O
patients	O
in	O
comparison	O
to	O
the	O
same	O
controls.	O

The	O
phospholipids	B
FA	I
profile	O
is	O
also	O
less	O
affected	O
by	O
fat	O
intake	O
than	O
other	O
plasma	O
lipids,	O
ie,	O
triacylglycerols	B
or	O
nonesterified	O
FAs.	O

[,	O
,	O
]	O
Disturbance	O
in	O
the	O
metabolic	O
pathways	O
of	O
bile	O
acid	O
derivatives	O
such	O
as	O
sulfolithocholylglycine	B
could	O
contribute	O
to	O
the	O
changes	O
in	O
cholylglycine,	B
while	O
variation	O
in	O
3-hydroxyacyl-CoA	O
dehydrogenase	O
activity	O
might	O
be	O
responsible	O
for	O
relative	O
differences	O
of	O
3-hydroxycapric	B
acid	I
we	O
observe	O
in	O
HCC/HCV	O
patients.	O

The	O
mobile	O
phases	O
were:	O
(A)	O
water + 0.1%	O
formic	B
acid	I
and	O
(B)	O
methanol + 0.1%	B
formic	I
acid.	I

Models	O
were	O
adjusted	O
for	O
variables	O
(measured	O
at	O
the	O
time	O
of	O
plasma	O
collection)	O
that	O
could	O
confound	O
associations	O
of	O
circulating	O
vitamin	B
D	I
metabolites	O
with	O
study	O
outcomes:	O
age	O
(continuous),	O
sex,	O
race	O
(white	O
vs.	O
non-white),	O
duration	B
of	O
diabetes	O
(categories),	O
DCCT	O
treatment	O
assignment	O
(allowing	O
separate	O
baseline	O
hazards	O
in	O
Cox	O
models),	O
season	O
(May-October	O
vs.	O
November-April),	O
solar	O
irradiation	O
of	O
DCCT	O
site	O
(continuous),	O
body	O
mass	O
index	O
(continuous),	O
AER	O
(continuous),	O
and	O
eGFR	O

As	O
seen	O
in	O
,	O
significant	O
differences	O
in	O
the	O
microbial	O
transformation	O
among	O
stilbene	B
derivatives	O
were	O
observed.	O

Pertaining	O
to	O
heart	O
failure,	O
several	O
studies	O
have	O
identified	O
dysregulated	O
arginine	B
metabolism	O
is	O
present	O
in	O
patients	O
with	O
heart	O
failure	O
compared	O
to	O
healthy	O
controls.	O

g	O
docosahexaenoic	B
acid	I
(DHA)).	O

p(x,y;Θ)	B
p(x,y;Θ)	I
p(x,y;Θ)	I
p(x,y;Θ)	I
p(x,y;Θ)	I
p(x,y;Θ)	I

Carnitine	B
and	O
acylcarnitines,	B
which	O
are	O
intermediates	O
in	O
the	O
key	O
energy	O
metabolic	O
pathways	O
of	O
fatty	O
acid	O
β-oxidation,	O
are	O
present	O
at	O
different	O
concentrations	O
in	O
the	O
urine	O
of	O
ESCC	O
patients	O
than	O
in	O
the	O
urine	O
of	O
matched	O
control	O
patients.	O

A	O
previous	O
study	O
also	O
reported	O
that	O
the	O
early-life	O
maltreatment	O
may	O
induce	O
high	O
level	O
of	O
cholesterol	B
in	O
the	O
adulthood	O
of	O
non-human	O
primate	O
.	O

Hypoglycemia	O
was	O
defined	O
as	O
a	O
fasting	O
glucose	B
level	O
of	O
less	O
than	O
2.2	O
mmol	O
per	O
liter	O
(40	O
mg	O
per	O
deciliter).	O

The	O
function	O
of	O
GSK3β	B
is	O
tightly	O
regulated	O
by	O
its	O
phosphorylation	O
state,	O
i.e.	O
this	O
enzyme	O
is	O
active	O
with	O
phosphotyrosine	O
(GSK3β_tyr216	O
)	O
and	O
inactive	O
with	O
phosphoserine	B
(GSK3β_ser9	I
).	I

Previous	O
studies	O
have	O
shown	O
that	O
humans	O
are	O
capable	O
of	O
converting	O
furan	B
to	O
its	O
reactive	O
metabolite,	O
cis	B
-2-butene-1,4-dial	I
(BDA),	O
and	O
therefore	O
may	O
be	O
susceptible	O
to	O
furan	B
toxicity.	O

562.3639	O
(580.3745	O
−	O
H_2	O
O)	O
and	O
546.3690	O
(564.3796	O
−	O
H_2	O
O)	O
assigned	O
to	O
hydroxy-3-oxocholesta-4,6-dien-26-oic	B
acid	I
(CA_4,6	O
-x	I
-ol-3-one,	I
0.453	O
±	O
0.204	O
ng/ml)	O
and	O
3-oxocholesta-4,6-dien-26-oic	B
acid	I

Structure	O
characteristics	O
of	O
the	O
albumin-like	O
protein	O
of	O
Atlantic	B
cod	O
(Gadus	O
morhua).	O

Publicly	O
available	O
data	O
revealed	O
that	O
high	O
TDO2,	O
the	O
gene	O
encoding	O
TDO,	O
correlates	O
with	O
poor	O
breast	O
cancer	O
clinical	O
outcomes,	O
including	O
overall	O
survival	O
and	O
distant	O
metastasis-free	O
survival,	O
while	O
expression	O
of	O
the	O
gene	O
encoding	O
the	O
more	O
commonly	O
studied	O
tryptophan	B
catabolizing	O
enzyme	O
IDO1	O
did	O
not.	O

Excretion	O
rates	O
for	O
testosterone	B
and	O
17β-estradiol	B
have	O
not	O
been	O
found	O
to	O
be	O
different	O
in	O
women	O
but	O
to	O
be	O
lower	O
at	O
night	O
time	O
in	O
men.	O

The	O
LLE	O
with	O
the	O
ethyl	B
acetate	I
method	O
had	O
very	O
good	O
recoveries	O
(over	O
90%)	O
for	O
all	O
the	O
analytes	O
except	O
for	O
ARG	O
and	O
GABA,	B
and	O
the	O
recoveries	O
for	O
these	O
analytes	O
were	O
very	O
low.	O

Circulating	O
20-HETE	B
was	O
positively	O
correlated	O
with	O
PRA	O
in	O
RVD	O
and	O
may	O
contribute	O
to	O
elevation	O
of	O
blood	O
pressure	O
by	O
increasing	O
vasomotion	O
and	O
enhancing	O
vascular	O
reactivity.	O

Our	O
analyses	O
found	O
specific	O
amino	O
acids,	O
acylcarnitines,	B
phosphatidylcholines,	B
and	O
sphingomyelins	B
were	O
associated	O
with	O
the	O
depressed	O
state	O
and	O
with	O
changes	O
after	O
CBT	O
treatment.	O

Low	O
cholesterol	B
and	O
LDL-cholesterol	B
have	O
also	O
been	O
observed	O
by	O
Couce	O
et	O
al.	O

1	O
Isoleucine;	B
2	O
Leucine;	B
3	O
Valine;	B
4	O
Isobutyrate;	B
5	O
Ethanol;	B
6	B
3-Hydroxybutyrate;	I
7	O
Lactate;	B
8	O
Alanine;	B
9	O
Lysine;	B
10	O
Acetate;	B
11	O
Proline;	B
12	O
Glycoprotein;	B
13	O
Glutamate;	B
14	O
Glutamine;	B
15	O
Methionine;	B
16	O
Acetoacetate;	B
17	O
Pyruvate;	B
18	O
Succinate;	B
19	O
Aspartate;	B
20	O
Asparagine;	B
21	O
Phosphocreatine;	B
22	O
Choline;	B
23	O
O-Acetylcholine;	B
24	O
O-Phosphocholine;	B
25	O
TMAO;	B
26	O
Taurine;	B
27	O
Glucose;	B
28	O
Glycine;	B
29	O
Threonine;	B
30	O
Glycerol;	B
31	O
dCTP;	O
32	O
Tyrosine;	B
33	O
Phenylalanine;	B
34	O
Tryptophan;	B
35	O
Histidine;	B
36	O
Tyramine;	B
37	O
Formate	B
Potential	O
serum	O
biomarkers	O
identified	O
by	O
_1	O
H	O
NMR	O
and	O
their	O
variations	O
among	O
NSCLC	O
patients,	O
MWA	O
treated	O
patients	O
and	O
healthy	O
controls	O
_1	O
H–NMR	O
1H–nuclear	O
magnetic	O
resonance,	O
NSCLC	O
non-small-cell	O
lung	O
cancer,	O
MWA	O
microwave	O
ablation,	O
TMAO	B
trimethylamine	I
N-oxide.	I

shows	O
the	O
product	O
ion	O
scan	O
spectra	O
of	O
proline	B
and	O
IS.	O

Precursor–product	O
relationships	O
explained	O
several	O
positive	O
correlations,	O
such	O
as	O
that	O
between	O
27-hydroxycholesterol	B
and	O
7α,27-dihydroxycholesterol,	B
which	O
are	O
sequential	O
intermediates	O
in	O
the	O
alternate	O
pathway	O
of	O
bile	O
acid	O
synthesis,	O
and	O
that	O
between	O
7-dehydrocholesterol	B
and	O
8-dehydrocholesterol.	B

A	O
mixture	O
of	O
1 mM	O
disodium	B
3-hydroxynaphthalene-2,7-disulfonate	I
(Wako,	O
Japan),	O
trimesic	O
acid	O
(Wako,	O
Japan),	O
N,N-diethyl-2-phenylacetamide	B
(Wako,	O
Japan),	O
and	O
3-aminopyrrolidine	B
dihydrochloride	I
(Aldrich,	O
USA)	O
in	O
water	O
was	O
used	O
as	O
internal	O
standard	O
solution	O
3	O
(ISS3).	O

The	O
glutathione	B
pathway	O
is	O
seen	O
after	O
increasing	O
glycine.	B

In	O
the	O
urine	O
of	O
the	O
patients,	O
the	O
classes	O
of	O
hydrocarbons,	B
phenols,	O
acids	O
and	O
sulfur-containing	O
compounds	O
are	O
significantly	O
increased	O
compared	O
to	O
healthy	O
controls.	O

The	O
current	O
study	O
evaluated	O
the	O
effects	O
of	O
red	O
clover,	O
a	O
popular	O
BDS	O
used	O
for	O
women’s	O
health,	O
and	O
its	O
isoflavones,	B
biochanin	B
A	O
(BA),	O
formononetin	B
(FN),	O
genistein	B
(GN),	O
and	O
daidzein	B
(DZ),	O
on	O
estrogen	B
metabolism.	O

Noteworthy,	O
although	O
in	O
the	O
first	O
stage	O
of	O
treatment	O
(B-A)	O
the	O
decrease	O
of	O
body	O
mass	O
corresponded	O
to	O
the	O
general	O
decrease	O
of	O
serum	O
phospholipids,	B
no	O
statistically	O
significant	O
correlation	O
was	O
observed	O
between	O
both	O
parameters	O
for	O
individual	O
patients	O
(A).	O

In	O
deionized	O
water,	O
we	O
observed	O
degradation	O
of	O
5-hydroxy-imidacloprid	B
at	O
25	O
°C	O
and	O
37	O
°C,	O
and,	O
to	O
a	O
lesser	O
degree,	O
of	O
acetamiprid,	B
but	O
only	O
at	O
37	O
°C.	O

Correspondingly,	O
pseudo	O
sample	O
for	O
lactate,	B
glucose	B
and	O
citrate	B
measured	O
by	O
NMR	O
and	O
GC-MS	O
display	O
comparable	O
trajectories	O
along	O
concentration	O
range.	O

Accordingly	O
the	O
apparent	O
formation	O
rate	O
of	O
hydroxyanastrozole	B
from	O
anastrozole	B
(0.5–200	O
µm)	O
in	O
HLMs	O
exhibited	O
biphasic	O
kinetic	O
behaviour	O
in	O
Eadie-Hofstee	O
plots,	O
which	O
suggested	O
the	O
involvement	O
of	O
at	O
least	O
two	O
enzymatic	O
activities	O
that	O
were	O
best	O
described	O
by	O
high-affinity	O
(K	O
_m1	O
and	O
V	O
_max1	O
)	O
and	O
low-affinity	O
(K	O
_m2	O
and	O
V	O
_max2	O
)	O
components.	O

The	O
loading	O
analysis	O
of	O
the	O
first	O
component	O
PCA-CA	O
of	O
the	O
ER(+)	B
group	O
revealed	O
that	O
the	O
GR	O
and	O
PR	O
subgroups	O
were	O
mainly	O
discriminated	O
by	O
the	O
3.99–3.93	O
ppm,	O
3.05–3.03	O
ppm,	O
2.75–2.71	O
ppm,	O
2.05–1.99	O
ppm,	O
1.57–1.55	O
ppm,	O
1.31–1.23	O
ppm,	O
1.05–1.03	O
ppm	O
and	O
0.99–0.85	O
ppm	O
_1	O
H	O
NMR	O
spectral	O
regions,	O
corresponding	O
to	O
cholesterol	B
and	O
phospholipid	B
subfractions	O
belonging	O
to	O
ApoB,	O
VLDL,	O
LDL	O
lipoproteins	O
and	O
to	O
isoleucine,	B
valine,	B
and	O
ethanol	B
signals.	O

The	O
models	O
closely	O
agree	O
with	O
measured	O
chemical	O
shifts	O
in	O
most	O
cases,	O
although	O
one	O
of	O
the	O
citrate	B
peaks	O
(Fig.	O

 0.1]	O
and	O
sphingolipids	B
[SM(d30:0),	I
FC = 0.5].	I

Reduced	O
melatonin	B
production	O
may	O
contribute	O
to	O
the	O
pathophysiology	O
of	O
IBS	O
via	O
a	O
decrease	O
in	O
analgesia,	O
altered	O
motility,	O
and/or	O
increased	O
intestinal	O
secretion	O
in	O
those	O
with	O
IBS-D.	O
Researchers	O
have	O
shown	O
that	O
melatonin	B
has	O
GI	O
protective	O
effects.	O

The	O
fasting	O
TG	B
level	O
correlated	O
positively0020with	O
N-ethyldodecanamide,	B
N-propyldodecanamide,	B
palmitoleamide,	B
and	O
lysoPCs	O
containing	O
14:0	O
and	O
16:0	O
and	O
correlated	O
negatively	O
with	O
cis	O
-4-octenedioic	O
acid	O
and	O
docosanamide.	B

Interestingly,	O
there	O
was	O
also	O
a	O
decrease	O
in	O
the	O
kynurenine	B
catabolite	O
kynurenic	B
acid	I
in	O
stage	O
3/4	O
breast	O
cancer	O
patients	O
compared	O
to	O
patients	O
with	O
stage	O
1/2	O
disease.	O

Phospholipids	B
can	O
be	O
analyzed	O
as	O
either	O
positive	O
or	O
negative	O
molecular	O
ions	O
and	O
CID	O
of	O
these	O
molecular	O
ions	O
yields	O
different	O
information	O
relevant	O
to	O
the	O
nature	O
of	O
the	O
intact	O
precursor	O
ion	O
species	O
and	O
product	O
ions.	O

A	O
linear	O
regression	O
of	O
the	O
combined	O
IER	O
and	O
CER	B
datasets	O
including	O
both	O
these	O
factors	O
explained	O
38 %	O
of	O
the	O
variation	O
in	O
fat	O
cell	O
size.	O

The	O
internal	O
standard	O
deuterated	O
(-d11)	O
of	O
amino	B
metabolite,	O
available	O
only	O
at	O
the	O
end	O
of	O
the	O
present	O
method	O
validation,	O
was	O
then	O
used	O
throughout	O
all	O
subsequent	O
analyses,	O
also	O
providing	O
robust	O
and	O
accurate	O
quantitative	O
results	O
for	O
Met	O
amino	B
in	O
human	O
plasma	O
by	O
correcting	O
matrix	O
effects,	O
bioanalytical	O
variability	O
and	O
analyte	O
degradation	O
potentially	O
occurring	O
in	O
post-preparative	O
samples.	O

There	O
was	O
a	O
slight	O
negative	O
correlation	O
of	O
total	O
cholesterol	B
and	O
LDL-cholesterol	B
with	O
concurrent	O
Phe	O
level.	O

This	O
consequently	O
leads	O
to	O
changes	O
in	O
fatty	O
acid	O
synthesis	O
and	O
glucose	B
utilization.	O

ROC	O
analysis	O
for	O
differentiating	O
PSP	O
from	O
controls	O
confirmed	O
that	O
the	O
predictive	O
accuracy	O
was	O
moderate	O
(AUC	O
>	O
0.7)	O
for	O
seven	O
of	O
eight	O
metabolites,	O
excluding	O
acylcarnitine	B
(AC)	O
(13:1).	O

A	O
series	O
of	O
glutamine	B
containing	O
compounds	O
is	O
one	O
of	O
those	O
clusters	O
and	O
fragmentation	O
spectra	O
are	O
consistent	O
with	O
a	O
family	O
of	O
acylglutamines,	B
i.e.,	O
glutamine-based	O
analogues	O
of	O
acylcarnitines	B
with	O
different	O
acyl	O
chains.	O

H=∑ni=1βi ⋅Vi	B
H	O
=	O
∑ni=1βi ⋅Vi	B
∑ni=1βi ⋅Vi	I
∑ni=1	O
∑ni=1	O
∑	O
∑	O
n	O
n	O
i=1	O
i=1	O
i	O
=	O
1	O
βi ⋅Vi	O
βi	O

Thus,	O
lactate	B
is	O
a	O
mediator	O
of	O
metabolic	O
information	O
in	O
addition	O
to	O
being	O
a	O
metabolic	O
substrate.	O

Human	O
malignant	O
melanoma	O
tumours	O
were	O
sliced	O
into	O
10 µm	O
thick	O
sections	O
on	O
a	O
cryotome,	O
dried	O
for	O
15 min	O
at	O
37 °C	O
and	O
fixed	O
with	O
100%	O
MeOH.	B

We	O
discovered	O
that	O
multiple	O
ether-linked	O
phospholipids	B
were	O
significantly	O
higher	O
in	O
the	O
obese	O
group	O
compared	O
to	O
control	O
and	O
were	O
driving	O
group	O
separation	O
in	O
the	O
OPLS-DA	O
model.	O

In	O
addition	O
to	O
succinylacetone,	B
levels	O
of	O
tyrosine,	B
methionine,	B
and	O
phenylalanine	B
also	O
have	O
been	O
reported	O
to	O
increase	O
in	O
genetic	O
deficiency	O
of	O
FAH-induced	O
type	O
1	O
tyrosinemia.	O

Furthermore,	O
an	O
oral	O
glucose	B
tolerance	O
test	O
(OGTT)	O
was	O
systematically	O
performed	O
before	O
RYGB	O
and	O
confirmed	O
that	O
all	O
patients	O
in	O
the	O
OB	O
group	O
had	O
glucose	B
levels	O
less	O
than	O
11	O
mmol/l	O
(200	O
mg/dl)	O
in	O
the	O
two	O
hours	O
following	O
a	O
75	O
g	O
oral	O
glucose	B
challenge.	O

These	O
observations	O
probably	O
complimented	O
with	O
the	O
down-regulation	O
of	O
fecal	O
pytosphingosine	B
post-	O
H.	O
pylori	O
eradication.	O

R	O
_2	O
=	O
0.27)],	O
and	O
4-OH-E_2	B
concentrations	O

Then,	O
particular	O
alterations,	O
rather	O
than	O
a	O
global	O
impairment	O
on	O
FA	B
metabolism,	O
may	O
cause	O
these	O
profiles.	O

When	O
fasting	O
subjects	O
were	O
selected,	O
the	O
same	O
metabolites	O
were	O
also	O
found	O
to	O
be	O
significantly	O
increased	O
or	O
decreased	O
in	O
DS,	O
with	O
the	O
exception	O
of	O
acetoacetate	B
and	O
lysine,	B
which	O
resulted	O
not	O
significantly	O
different	O
(Table ).	O

The	O
methanol	B
used	O
for	O
extraction	O
was	O
spiked	O
with	O
the	O
following	O
compounds,	O
chosen	O
to	O
encompass	O
most	O
of	O
the	O
retention	O
time-m/z	O
space	O
covered	O
by	O
the	O
method,	O
while	O
being	O
undetected	O
in	O
nonspiked	O
human	O
serum	O
extracts:	O
tryptophan-d_5	O
(indole-d_5	O
),	O
PC(13:0/0:0),	B
NEFA(19:0),	B
and	O
dehydrocholic	B
acid.	I

An	O
exploration	O
of	O
its	O
production	O
provides	O
additional	O
support	O
for	O
the	O
anabolic	O
state	O
associated	O
with	O
glucose	B
provision.	O

Pyruvate	B
enters	O
the	O
mitochondrion	O
where	O
it	O
is	O
converted	O
into	O
acetyl-CoA	B
by	O
pyruvate	O
dehydrogenase	O
(PDH).	O

The	O
internal	O
standards	O
used	O
were	O
succinic	B
d_4	O
acid,	O
glycerol	B
_13	O
C_3	O
,	O
norvaline,	B
L-methionine-(carboxy-_13	B
C,methyl-d_3	I
),	I
D-glucose	B
_13	O
C_6	O
,	O
myristic-d_27	O
acid	O
and	O
alpha-tocopherol	B
d_6	O
.	O

Urinary	O
creatinine	B
was	O
measured	O
using	O
a	O
Creatinine	B
Assay	O
Kit,	O
catalog	O
no.	O

Urinary	O
N	B
-desmethyl-acetamiprid,	I
as	O
well	O
as	O
5-hydroxy-Imidacloprid	B
and	O
N	B
-desmethyl-clothianidin,	I
may	O
be	O
a	O
good	O
biomarker	O
for	O
neonicotinoid	B
exposure	O
in	O
humans	O
and	O
warrants	O
further	O
investigation.	O

The	O
results	O
show	O
that	O
a	O
mixture	O
of	O
blood/methanol/chloroform	O
in	O
a	O
ratio	O
of	O
1:2:2	O
enabled	O
the	O
detection	O
of	O
all	O
the	O
coenzymes,	O
while	O
the	O
other	O
combinations	O
failed	O
to	O
detect	O
unstable	O
coenzymes,	O
NADH	B
and	O
NADPH	B
in	O
particular.	O

It	O
is	O
of	O
interest	O
that	O
all	O
9	O
of	O
the	O
xenobiotic	O
metabolites	O
among	O
the	O
top	O
17	O
metabolites	O
increased	O
with	O
β-carotene	B
supplementation.	O

The	O
spectra	O
were	O
aligned	O
towards	O
the	O
right	O
peak	O
of	O
alanine	B
doublet,	O
set	O
to	O
1.473	O
ppm,	O
and	O
the	O
signals	O
of	O
water	O
and	O
urea	B
were	O
removed.	O

Sphingolipids	B
that	O
contain	O
VLCFA	O
are	O
a	O
major	O
component	O
of	O
myelin,	B
along	O
with	O
cholesterol	B
and	O
phospholipids.	B

It	O
was	O
surprising	O
that	O
three	O
of	O
the	O
high	O
concentration	O
metabolites,	O
namely,	O
creatinine,	B
creatine,	B
and	O
citric	B
acid,	I
were	O
not	O
as	O
accurate	O
and	O
precise	O
as	O
expected	O
according	O
to	O
the	O
acceptance	O
criteria	O
of	O
our	O
study.	O

PAF	O
is	O
a	O
class	O
of	O
endogenous	O
bioactive	O
phospholipids.	B

eGFR,	O
estimated	O
GFR;	O
CRP,	O
C-reactive	O
protein;	O
ADMA,	B
asymmetric	B
dimethylarginine;	I
EAA,	O
sum	O
of	O
essential	O
amino	O
acids;	O
NEAA,	O
sum	O
of	O
nonessential	O
amino	O
acids;	O

Thus,	O
even	O
without	O
the	O
influence	O
of	O
the	O
growth	O
factor	O
in	O
FCS,	O
Rh30	O
cells	O
grown	O
in	O
BSA	O
still	O
exhibited	O
a	O
greater	O
turnover	O
of	O
[U-_13	B
C]-glucose	I
through	O
glycolysis,	O
Krebs'	O
cycle,	O
and	O
pyrimidine	B
nucleotide	O
biosynthesis	O
than	O
the	O
primary	O
myocytes.	O

_B	O
sqC:	O
squamous	O
cell	O
carcinoma;	O
adenoC:	O
adenocarcinoma;	O
N:	O
non-cancerous;	O
C:	O
cancer;	O
Cit:	O
citrate;	B
Lac:	O
lactate;	B
Succ:	O
succinate	B
_C	O
_	O
13	O
C	O
enrichment	O
in	O
excess	O
of	O
natural	O
abundance;	O
values	O
in	O
bold	O
represent	O
enhanced	O
enrichment	O
in	O
cancer	O
over	O
its	O
non-cancerous	O
counterpart	O
_D	O
_	O
13	O
C	O
mass	O
isotopomer	O
of	O
Asp	O
with	O
three	O
carbons	O
labeled;	O
detection	O
limit	O
was	O
0.004	O
μmole/g	O
dry	O
weight.	O

NMDA	O
receptors	O
are	O
activated	B
or	O
inhibited	O
by	O
neuroactive	O
compounds	O
generated	O
by	O
tryptophan	B
metabolism	O
through	O
the	O
kynurenine	B
pathway.	O

A	O
lock	O
mass	O
function	O
was	O
used	O
with	O
a	O
peak	O
derived	O
from	O
polydimethylsiloxane	B
as	O
a	O
lock	O
mass	O
for	O
the	O
LTQ-Orbitrap	O
to	O
obtain	O
constant	O
mass	O
accuracy	O
during	O
gradient	O
analysis	O
(Olsen	O
et	O
al.	O
).	O

A	O
100 μl	O
aliquot	O
of	O
plasma	O
sample	O
was	O
spiked	O
with	O
two	O
internal	O
standards	O
(10 μl	O
L-2-chlorophenylalanine	B
in	O
water)	O
and	O
vortexed	O
for	O
10 s,	O
followed	O
by	O
the	O
addition	O
of	O
400 μl	O
of	O
methanol/acetonitrile/acetone	O
(1:1:1,	O
v/v/v)	O
into	O
the	O
tube.	O

Numerous	O
stimuli	O
implicated	O
in	O
insulin	O
resistance	O
induce	O
sphingolipid	B
metabolism	O
and	O
determine	O
ceramide	B
metabolic	O
fate.	O

Endothelial	O
cells	O
are	O
a	O
major	O
site	O
of	O
EET	O
incorporation,	O
a	O
process	O
greatly	O
enhanced	O
by	O
preventing	O
hydrolysis	O
of	O
EETs	O
by	O
sEH,	O
because	O
DHETs	O
show	O
negligible	O
incorporation	O
into	O
phospholipids.	B

The	O
excretion	O
of	O
uric	B
acid	I
can	O
be	O
related	O
to	O
the	O
consumption	O
of	O
seafood.	O

The	O
production	O
of	O
4-cresol	B
from	O
4-hydroxyphenylacetic	B
acid	I
is	O
a	O
purely	O
microbial	O
enzymatic	O
conversion	O
performed	O
by	O
clostridial	O
species	O
(Firmicutes)	O
and	O
reflects	O
variation	O
in	O
microbial	O
genomic	O
activity	O
and	O
composition.	O

These	O
data	O
suggest	O
that	O
fusarithioamide	B
A	O
and	O
B	O
could	O
be	O
a	O
good	O
starting	O
point	O
to	O
provide	O
promising	O
anticancer	O
candidate	O
molecules	O
for	O
drug	O
development.	O

The	O
metabolite	O
with	O
the	O
highest	O
increase	O
was	O
cortisol	B
(FC = 1.6).	O

In	O
each	O
sample,	O
the	O
cortisol	B
metabolites	O
were	O
measured	O
by	O
GC/MS	O
in	O
SIM.	O

To	O
500 μl	O
urine,	O
100 μl	O
of	O
a	O
solution	O
of	O
1 M	O
acetic	B
acid	I
(adjusted	O
to	O
pH	O
6.0	O
with	O
sodium	B
hydroxide),	I
50 μl	O
of	O
the	O
internal	O
standards	O
mix	O
(valine-d8,	O
phenylalanine-d5,	B
tryptophan-d5,	O
thymine-d4	B
and	O
reserpine	B
in	O
water	O
at	O
a	O
concentration	O
of	O
60,	O
60,	O
60,	O
100,	O
20 μg/ml,	O
respectively)	O
and	O
a	O
varying	O
volume	O
of	O
the	O
calibration	O
mix	O
(phenylalanine,	O
tryptophan	B
and	O
salicylamide	B
in	O
water	O
at	O
a	O
concentration	O
of	O
100 μg/ml)	O
were	O
added.	O

 399,	O
top	O
spectrum	O
)	O
and	O
PTAD-derivatized	O
1,25-(OH)_2	B
D_3	O
(M	O
+	O
CH_3	O
NH_3	O
_+	O
at	O
m	O
/z	O

However,	O
this	O
is	O
unlikely	O
to	O
have	O
been	O
a	O
major	O
factor,	O
since	O
we	O
previously	O
demonstrated	O
that	O
the	O
acetaminophen	B
and	O
ibuprofen	B
prediction	O
models	O
each	O
had	O
a	O
sensitivity	O
greater	O
than	O
98%;	O
furthermore,	O
detailed	O
data	O
on	O
analgesic	O
use	O
from	O
Belfast	O
and	O
Chicago	O
participants	O
indicated	O
an	O
underdetection	O
rate	O
of	O
approximately	O
1%.	O

Reduced	O
histidine	B
can	O
cause	O
recession	O
of	O
anti-oxidant	O
and	O
anti-inflammatory	O
processes,	O
both	O
of	O
which	O
contribute	O
to	O
the	O
pathogenesis	O
and	O
development	O
of	O
COPD	O
or	O
emphysema.	O

Choline	B
is	O
one	O
of	O
the	O
major	O
cell	O
membrane	O
phos-pholipids[]	O
and	O
is	O
overexpressed	O
and	O
highly	O
active	O
in	O
tumor	O
tissues	O
and	O
cell	O
lines.	O

Common	O
to	O
both	O
forms	O
of	O
IBD	O
are	O
decreases	O
in	O
urea	B
(more	O
prominent	O
in	O
UC	O
than	O
CD),	O
citrate	B
and	O
acetate.	B

Consistent	O
with	O
this,	O
the	O
phospholipid	B
catabolism	O
product	O
glycerol-3-phosphocholine	B
was	O
30	O
%	O
_13	O
C_0	O
,	O
indicating	O
turnover	O
of	O
the	O
glycerol	B
backbone	O
from	O
serum-derived	O
lipids.	O

MeMP-d3	O
was	O
used	O
as	O
an	O
internal	O
standard	O
as	O
it	O
was	O
the	O
only	O
deuterated	O
thiopurine	B
metabolite	O
available	O
commercially	O
at	O
the	O
time.	O

Integrating	O
those	O
103	O
SNPs	O
with	O
the	O
thirteen	O
significant	O
metabolites	O
identified	O
the	O
netrin	O
signaling	O
pathway	O
as	O
the	O
only	O
significant	O
pathway	O
(p=1.54×10_−5	O
),	O
after	O
adjusting	O
for	O
multiple	O
comparisons	O
(FDR<0.05),	O
with	O
rs2727563	O
in	O
PRKAG2	O
and	O
rs12604940	O
in	O
DCC	O
converging	O
with	O
the	O
arachidonic	B
acid	I
metabolite	O
in	O
the	O
same	O
pathway.	O

A	O
few	O
representative	O
tandem	O
MS	O
spectra	O
for	O
identification	O
and	O
second	O
step	O
quantification	O
of	O
PC,	O
PE,	O
SM,	O
and	O
ceramide	B
species	O
were	O
shown	O
in	O
.	O

These	O
complications	O
can	O
be	O
seen	O
from	O
,	O
where,	O
unlike	O
the	O
presentations	O
of	O
metabolite	O
maps	O
previously	O
shown	O
for	O
brain	O
tumors,	O
a	O
spectroscopist	O
or	O
trained	O
radiologist	O
has	O
to	O
evaluate	O
not	O
only	O
where	O
the	O
spectra	O
were	O
measured	O
from	O
the	O
prostate	O
but	O
also	O
the	O
relative	O
ratios	O
between	O
different	O
metabolic	O
regions,	O
such	O
as	O
evaluations	O
of	O
the	O
proposed	O
indicator,	O
(C+C)/C	O
(spectral	O
intensities	O
of	O
regions	O
between	O
creatine	B
and	O
choline	B
over	O
citrate)	B

The	O
association	O
with	O
total	O
cholesterol	B
was	O
not	O
affected.	O

In	O
comparison	O
to	O
their	O
healthy	O
co-twins,	O
the	O
patients	O
had	O
elevated	O
triglycerides	B
and	O
were	O
more	O
insulin	O
resistant.	O

As	O
shown	O
in	O
,	O
the	O
recovery	O
of	O
creatinine-d_3	B
is	O
about	O
10%	O
higher	O
when	O
methanol-ethanol	B
is	O
used	O
compared	O
to	O
methanol	B
alone,	O
with	O
%CV	O
around	O
20%	O
for	O
both	O
methods.	O

For	O
example,	O
3-hydroxy-3-methylglutaryl-CoA	B
reductase	O
reduced	O
glucose	B
levels	O
in	O
an	O
experimental	O
type	O
II	O
diabetes	O
animal	O
model	O
[,].	O

The	O
other	O
purine	O
nucleoside,	O
guanosine,	B
is	O
cleaved	O
to	O
form	O
guanine	B
that	O
is	O
subsequently	O
deaminated	O
via	O
guanine	O
deaminase	O
to	O
form	O
xanthine	B
and	O
then	O
uric	B
acid.	I

The	O
CV	O
of	O
each	O
metabolite	O
was	O
as	O
follows:	O
tetradecane	B
(−1.14783E-05),	O
alpha-D-glucopyranoside	B
(−4.47826E-06),	O
methyl	B
stearate	I
(−6.08696E-06),	O
dodecane	B
(−7.6087E-06),	O
1-4-benzene	B
(1.44348E-05),	O
D-galactose	B
(−2.6087E-06)	O
and	O
octadecanoic	B
acid	I
(1.02609E-05).	O

Results:	O
We	O
measured	O
489	O
metabolites,	O
and	O
17	O
changed	O
significantly	O
(P	O
<	O
0.05)	O
in	O
response	O
to	O
β-carotene	B
supplementation.	O

Since	O
the	O
metabolite	O
standard	O
was	O
not	O
available	O
to	O
us,	O
quantification	O
of	O
this	O
metabolite	O
was	O
made	O
using	O
standard	O
curves	O
generated	O
with	O
anastrozole.	B

The	O
first	O
and	O
third	O
components	O
account	O
mostly	O
for	O
the	O
separation	O
among	O
survivor	O
and	O
deceased	O
patients	O
and	O
are	O
dominated	O
by	O
amino	O
acids	O
(histidine,	O
leucine,	B
isoleucine,	B
and	O
valine).	B

Additionally,	O
HD	O
patients	O
had	O
lower	O
concentrations	O
in	O
alanine	B
(P	O
<0.001),	O
arginine	B
(P	O
<0.001),	O
serine	B
(P	O
=0.003),	O
and	O
glutamine	B
(P	O
=0.04).	O

The	O
results	O
showed	O
that	O
aMCI	O
patients	O
had	O
a	O
significant	O
reduced	O
ratio,	O
suggesting	O
that	O
the	O
arginine	B
catabolism	O
of	O
aMCI	O
patients	O
is	O
increased,	O
consistent	O
with	O
previous	O
results	O
from	O
a	O
community	O
cohort.	O

In	O
addition,	O
compared	O
with	O
the	O
ascites	O
of	O
non	O
malignant	O
disease,	O
lysophospholipid	B
metabolism	O
in	O
ascites	O
in	O
patients	O
with	O
ovarian	O
cancer	O
significantly	O
increases.	O

Baseline	O
characteristics	O
were	O
compared	O
between	O
the	O
No-AE	O
and	O
AE	B
groups	O
using	O
Mann–Whitney	O
U	O
-tests	O
for	O
continuous	O
variables	O
and	O
χ_2	O
tests	O
for	O
categorical	O
variables.	O

Since	O
cysteamine	B
was	O
converted	O
to	O
cystamine	B
during	O
the	O
pre-treatment	O
procedure,	O
cysteamine	B
was	O
detected	O
as	O
cystamine	B
by	O
our	O
system.	O

Partner-specific	O
models	O
were	O
further	O
adjusted	O
for	O
chronic	O
health	O
conditions,	O
namely,	O
hypothyroidism	O
(;	O
;	O
)	O
and	O
hypertension	O
(;	O
;	O
),	O
in	O
an	O
attempt	O
to	O
control	O
for	O
differences	O
in	O
the	O
use	O
of	O
paracetamol	B
medication.	O

MethylCap-seq	B
was	O
performed	O
by	O
NXTGNT	O
(Ghent,	O
Belgium)	O
as	O
outlined	O
earlier,	O
with	O
following	O
modifications:	O
(a)	O
500 ng	O
input	O
material	O
was	O
used	O
for	O
the	O
affinity	O
purification	O
step	O
(MethylCap	O
kit,	O
Diagenode,	O
Liege,	O
Belgium),	O
(b)	O
paired-end	O
(2 × 51	O
nt,	O
excluding	O
adapters	O
and	O
multiplex	O
identifiers)	O
massive	O
parallel	O
sequencing	O
was	O
performed	O
on	O
the	O
Illumina	O
HiSeq2000	O
platform.	O

This	O
pathway	O
is	O
activated	B
by	O
netrins,	O
a	O
class	O
of	O
proteins	O
that	O
play	O
a	O
crucial	O
role	O
in	O
neuronal	O
migration	O
and	O
in	O
axon	O
guidance.	O

From	O
this	O
analysis,	O
several	O
species	O
exhibited	O
no	O
change	O
between	O
any	O
of	O
the	O
extraction	O
methods,	O
such	O
as	O
the	O
Cer	B
and	O
diglycerides	B
(DGs).	O

The	O
methanolic	B
extracts	O
were	O
analyzed	O
for	O
metabolites	O
on	O
GC/MS	O
and	O
LC/MS	O
platforms.	O

Setting	O
the	O
AUC	O
value	O
for	O
GDM	O
at	O
0.6	O
and	O
fold	O
change	O
between	O
the	O
two	O
groups	O
at	O
1.2	O
to	O
identify	O
variables	O
for	O
testing	O
in	O
the	O
multivariate	O
models,	O
we	O
selected	O
six	O
metabolites	O
such	O
as	O
C16:1	B
(cis-7),	I
6,7-diketoLCA,	B
alanine,	B
n-acetylaspartic	B
acid,	I
2-oxo-4-methylvaleric	B
acid	I
and	O
1-monooleoylglycerol.	B

The	O
CSF	O
levels	O
of	O
citric	O
and	O
isocitric	B
acid,	I
which	O
are	O
TCA	O
cycle	O
metabolites,	O
were	O
significantly	O
elevated	O
in	O
GBMs	O
compared	O
with	O
grades	O
I–II	O
or	O
III	O
gliomas.	O

Some	O
of	O
the	O
exceptions	O
were	O
oxalic	B
acid,	I
phosphate	B
and	O
uric	B
acid,	I
each	O
of	O
which	O
was	O
detected	O
by	O
GC-MS	O
but	O
not	O
by	O
NMR.	O

E‐7G‐4′S	O
was	O
synthesized	O
from	O
4′‐O	O
‐benzyldaidzein‐7‐O	B
‐triacetylglucuronide	I
methyl	I
ester	I
according	O
to	O
a	O
previously	O
reported	O
method21,	O
23	O
with	O
the	O
following	O
minor	O
modifications.	O

Prostate	O
cancer	O
cells	O
also	O
show	O
increased	O
uptake	O
of	O
choline,	B
in	O
part	O
due	O
to	O
increased	O
expression	O
of	O
choline	B
transporters.	O

Four	O
metabolites	O
of	O
the	O
purine	B
compound	O
caffeine	B
were	O
among	O
the	O
biochemicals	O
found	O
to	O
be	O
biomarkers	O
of	O
PD	O
progression:	O
theobromine,	B
theophylline,	B
paraxanthine,	B
and	O
1-methylxanthine.	B

Notably,	O
we	O
detected	O
tamoxifen	B
and	O
its	O
metabolites	O
in	O
all	O
serum	O
samples	O
[range	O
31-247	O
ng/ml	O
for	O
tamoxifen]	B
indicating	O
good	O
compliance	O
for	O
the	O
patients	O
included	O
(Table	O
).	O

Correlations	O
for	O
six-month	O
changes	O
for	O
these	O
metabolites	O
are	O
less	O
compelling	O
however,	O
the	O
exception	O
being	O
BCAA,	O
driven	O
predominantly	O
by	O
valine.	B

DHT	O
was	O
diluted	O
in	O
ethanol	B
(EtOH)	O
and	O
administered	O
at	O
a	O
final	O
concentration	O
of	O
10 nmol/L.	O
EtOH	B
was	O
used	O
as	O
control.	O

Solvents	O
A	O
and	O
B	O
consisted	O
of	O
acetonitrile:MilliQ	O
water	O
(6:4	O
v/v)	O
and	O
isopropanol:acetonitrile	O
(9:1	O
v/v)	O
respectively,	O
both	O
containing	O
10	O
mM	O
ammonium	B
formate	I
and	O
0.1%	O
formic	B
acid.	I

We	O
recapitulated	O
earlier	O
findings	O
that	O
H.	O
pomatia	O
extract	O
leads	O
to	O
the	O
conversion	O
of	O
DHEA-S	B
to	O
Δ_4	O
-AD	O

After	O
mapping	O
the	O
metabolites	O
into	O
general	O
biochemical	O
pathway	O
illustrated	O
in	O
the	O
Kyoto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes,	O
it	O
became	O
clear	O
that	O
the	O
levels	O
of	O
intermediates	O
involved	O
in	O
glycolysis,	O
the	O
pentose	B
pathway,	O
glutathione	B
biosynthesis,	O
and	O
the	O
tryptophan	B
kynurenine	I
(TK)	O
pathway	O
were	O
significantly	O
higher	O
in	O
the	O
CRC	O
tissue	O
samples.	O

For	O
example,	O
lactate	B
and	O
several	O
amino	O
acids	O
such	O
as	O
tyrosine	B
and	O
leucine	B
were	O
found	O
to	O
be	O
differential	O
metabolites	O
in	O
the	O
serum	O
of	O
CRC	O
patients	O
in	O
our	O
previous	O
study,	O
but	O
not	O
identified	O
as	O
biomarkers	O
in	O
the	O
current	O
study.	O

This	O
decrease	O
in	O
hepatotoxicity	O
with	O
treatment	O
duration	B
might	O
be	O
explained	O
with	O
similar	O
concepts	O
of	O
duration-related	O
decreased	O
myelosuppression,	O
such	O
as	O
noncompliance	O
or	O
resistance	O
to	O
the	O
drugs.	O

The	O
relative	O
amounts	O
of	O
the	O
metabolites	O
derived	O
from	O
cysteine-BDA-lysine	B
cross-links	O
was	O
sulfoxide	B
5	O
>	O
sulfide	B
2	O
≅	O
sulfoxide	B
4	O
>	O
sulfide	B
3	O
with	O
the	O
sum	O
of	O
these	O
four	O
metabolites	O
less	O
than	O
the	O
levels	O
of	O
the	O
BDA-lysine	B
derived	O
metabolite,	O
1.	O

The	O
expression	O
of	O
L-DOPA-decarboxylase	O
for	O
conversion	O
of	O
L-DOPA	B
to	O
dopamine	B
was	O
also	O
strongly	O
downregulated	O
in	O
our	O
patients	O
with	O
nephrosclerosis,	O
and	O
mice	O
with	O
reduced	O
renal	O
expression	O
of	O
L-DOPA-decarboxylase	O
demonstrate	O
reduced	O
renal	O
and	O
urine	O
dopamine	B
concentrations,	O
leading	O
to	O
reduced	O
salt	O
and	O
water	O
excretion,	O
activation	O
of	O
renin-angiotensin	O
system,	O
and	O
increased	O
blood	O
pressure.	O

The	O
main	O
above-mentioned	O
ways	O
leading	O
to	O
an	O
increase	O
of	O
succinic	B
acid	I
and	O
microbial	O
PhCA	O
levels	O
in	O
the	O
blood	O
in	O
sepsis	O
are	O
presented	O
in	O
.	O

Glc	O
glucose,	B
Gln	O
glutamine,	B
GPC	B
glycerophosphocholine,	I
Gly	O
glycine,	B
HDL	O
high-density	O
lipoproteins,	O
His	O
histidine,	B
Lac	O
lactate,	B
NAG	O
N-acetyl	B
glycoprotein,	I
Phe	O
phenylalanine,	B
U1	O
,	O
U2	O
,	O
U3	O
unknown	O
metabolite,	O
Val	O
valine,	B
VLDL	O
very-low	O
density	O
lipoproteins,	O
CD	O
Crohn’s	O
disease,	O
UC	O
ulcerative	O
colitis,	O
Rem	O
remission	O
Significant	O
up	O
and	O
down-regulated	O
metabolites	O
(0),	O
before	O
1st	O
infusion	O
of	O
infliximab	O
at	O
week	O
0;	O
(2),	O
before	O
2nd	O
infusion	O
at	O
week	O
2;	O
(6),	O
before	O
3rd	O
infusion	O
at	O
week	O
6;	O
(14),	O
before	O
4th	O
infusion	O
at	O
week	O
14	O
	O
increased	O
or	O
↓	O
decreased	O
compared	O
to	O
controls	O
(The	O
coefficients	O
from	O
the	O
OPLS-DA	O
results,	O
positive	O
and	O
negative	O
signs,	O
indicate	O
positive	O
and	O
negative	O
correlation	O
in	O
the	O
concentrations,	O
respectively.	O

In	O
addition,	O
higher	O
levels	O
of	O
cotinine	B
were	O
strongly	O
associated	O
with	O
ADHD.	O

Isopropyl	B
alcohol	I
was	O
obtained	O
from	O
Fluka.	O

The	O
observed	O
reduction	O
of	O
polyunsaturated	O
fatty	O
acid	O
containing	O
PCs	O
is	O
of	O
great	O
importance	O
since	O
arachidonic	B
acid	I
and	O
its	O
downstream	O
products	O
are	O
important	O
mediators	O
of	O
inflammatory	O
processes	O
and	O
hence	O
studies	O
aimed	O
at	O
detecting	O
biomarkers	O
in	O
inflammatory	O
diseases	O
should	O
always	O
account	O
for	O
storage	O
time	O
as	O
a	O
potential	O
confounder	O
for	O
their	O
results.	O

In	O
adjusted	O
Cox	O
proportional	O
hazard	O
models,	O
the	O
type	O
2	O
diabetes	O
risk	O
per	O
1	O
SD	O
increase	O
in	O
glycine,	B
taurine	B
and	O
phenylalanine	B
was	O
0.65	O
(95%	O
CI	O
0.54,	O
0.48),	O
0.73	O
(95%	O
CI	O
0.59,	O
0.9)	O
and	O
1.35	O
(95%	O
CI	O
1.11,	O
1.65),	O
respectively.	O

Protein	O
precipitation	O
was	O
performed	O
by	O
adding	O
600	O
μL	O
methanol	B
to	O
200	O
μL	O
to	O
each	O
serum	O
sample.	O

Lower	O
baseline	O
levels	O
of	O
xanthine	B
(p<0.0001,	O
q<0.00068),	O
2-hydroxyvaleric	B
acid	I
(p<0.0001,	O
q<0.0013),	O
succinic	B
acid	I
(p<0.0009,	O
q<0.017)	O
and	O
stearic	B
acid	I
(p<0.0039,	O
q<0.037)	O
were	O
all	O
significantly	O
correlated	O
with	O
greater	O
LDL-C	O
response.	O

The	O
least	O
abundant	O
compounds	O
were	O
carnitine	B
(46	O
µM),	O
acetic	B
acid	I
(42	O
µM),	O
creatine	B
(37	O
µM),	O
L-cysteine	B
(34	O
µM),	O
propylene	B
glycol	I
(22	O
µM)	O
and	O
L-aspartic	B
acid	I
(21	O
µM).	O

Ribavirin	B
levels	O
did	O
not	O
drop	O
to	O
the	O
extent	O
that	O
sofosbuvir	B
levels	O
did	O
in	O
patients	O
who	O
had	O
been	O
off	O
treatment	O
prior	O
to	O
liver	O
transplantation,	O
a	O
finding	O
consistent	O
with	O
the	O
fact	O
that	O
ribavirin	B
and	O
its	O
phosphorylated	O
metabolites	O
have	O
half-lives	O
of	O
approximately	O
9	O
to	O
14	O
days	O
in	O
plasma,	O
serum,	O
red	O
blood	O
cells	O
(RBC),	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
(PBMC)	O
(,	O
).	O

In	O
the	O
control	O
wells,	O
DMSO	B
and	O
media	O
were	O
added.	O

Pyruvate	B
concentration	O
was	O
low,	O
while	O
possible	O
precursors	O
of	O
pyruvate,	B
such	O
as	O
cysteine,	B
tyrosine	B
and	O
alanine,	B
increased	O
significantly	O
in	O
plasma	O
ruling	O
out	O
their	O
involvement	O
in	O
pyruvate	B
production.	O

Among	O
these	O
compounds,	O
six	O
belong	O
to	O
phospholipids	B
(PLs).	O

Supplementation	O
of	O
the	O
knockdown	O
cancer	O
cells	O
with	O
aspartate	B
rescued	O
this	O
slow	O
growth	O
phenotype.	O

The	O
previously	O
known	O
57	O
metabolites	O
were	O
studied,	O
which	O
might	O
develop	O
in	O
the	O
positive	O
control	O
mouse	O
urine	O
by	O
acetamiprid,	B
imidacloprid,	O
or	O
clothianidin	B
[-].	O

The	O
butanol	B
layer	O
was	O
dried	O
by	O
Speed-vac	O
evaporation	O
and	O
reconstituted	O
by	O
vortexing	O
in	O
10	O
μL	O
of	O
10%	O
CH_3	O
CN.	O

prostate	O
cancer,	O
HRMAS,	O
MRSI,	O
inositol,	B
Gleason	O
score,	O
Ki67	O

The	O
injected	O
samples	O
were	O
equilibrated	O
with	O
water	O
containing	O
0.1%	O
formic	B
acid.	I

High	O
extent	O
of	O
lipids	O
referring	O
to	O
this	O
type	O
apparently	O
resulted	O
from	O
both	O
chosen	O
conditions	O
of	O
serum	O
extraction,	O
which	O
favored	O
glycerophospholipids,	B
sphingolipids,	B
sterols	O
and	O
prenols,	O
and	O
positive	O
mode	O
of	O
MALDI	O
ionization,	O
which	O
narrowed	O
the	O
ionization	O
of	O
glycerophospholipids	B
to	O
neutral	O
(zwitterionic)	O
representatives,	O
such	O
as	O
phosphatidylocholines	B
and	O
phosphatidylethanolamines.	B

Patients	O
on	O
statins	B
had	O
a	O
mean	O
age	O
significantly	O
older	O
than	O
that	O
of	O
patients	O
not	O
on	O
statins.	B

Furthermore,	O
3	O
of	O
the	O
14	O
metabolites	O
(C8-ceramide,	O
sphingosine	B
and	O
glutamine)	B
were	O
selected	O
as	O
candidate	O
diagnostic	O
biomarkers	O
for	O
HAPE	O
using	O
metabolic	O
pathway	O
impact	O
analysis.	O

Among	O
the	O
other	O
38%	O
of	O
thiols	B
not	O
being	O
quantified,	O
which	O
have	O
lower	O
signals	O
or	O
the	O
signals	O
were	O
originally	O
near	O
the	O
limit	O
of	O
quantifications	O
(LOQs),	O
were	O
largely	O
affected	O
by	O
the	O
instrument	O
signal	O
fluctuations.	O

(4S	O
)-2-(Substituted-phenyl/or	O
benzyl)-4-(4-chlorophenyl)-6-methyl-5-methyl	I
carboxylate-1,4-dihydropyrimidine	I
enantiomer	O
was	O
used	O
for	O
docking	O
process.	O

Adduct	O
levels	O
were	O
less	O
than	O
proportional	O
to	O
benzene	B
exposure,	O
suggesting	O
saturable	O
P450	O
2E1	O
metabolism	O
of	O
benzene.	B

The	O
rest	O
of	O
oxysterols	B
did	O
not	O
differ	O
between	O
samplings	O
of	O
tamoxifen-treated	O
patients.	O

The	O
mixture	O
was	O
reduced	O
to	O
dryness	O
under	O
OFN	O
and	O
dissolved	O
in	O
H_2	O
O/CH_3	O
CN	B
(70:30;	I
70 μL).	I

This	O
problem	O
has	O
been	O
previously	O
addressed	O
by	O
addition	O
of	O
sodium	B
ascorbate	I
to	O
the	O
enzymatic	O
hydrolysis	O
reaction.	O

To	O
assess	O
associations	O
between	O
the	O
50	O
altered	O
metabolites	O
and	O
clinical	O
measures,	O
the	O
metabolites	O
were	O
associated	O
to	O
radiological	O
data,	O
EDSS,	O
and	O
disease	O
duration,	B
and	O
grouped	O
using	O
hierarchical	O
clustering.	O

⋅	O
Vi	B
	O
where	O
β_i	O
is	O
the	O
estimated	O
beta	O
coefficient	O
for	O
variable	O
V_i	O
and	O
n	O
accounts	O
for	O
the	O
total	O
number	O
of	O
variables	O
considered.	O

A	O
major	O
caveat	O
remains	O
the	O
contribution	O
of	O
different	O
precursors	O
on	O
endogenous	O
oxalate	B
production,	O
which	O
could	O
be	O
answered	O
with	O
a	O
multiple	O
tracer	O
infusion.	O

Ranitidine	B
is	O
available	O
in	O
the	O
UK	O
both	O
as	O
prescription	O
and	O
over-the-counter	O
formulations.	O

The	O
four	O
serum	O
androstenediol	B
(adiol)	O
sulfate	B
metabolites	O
positively	O
related	O
to	O
serum	O
retinol	B
could	O
serve	O
as	O
androgenic	O
mediators	O
and	O
confer	O
the	O
vitamin	O
A-prostate	O
cancer	O
association.	O

On	O
the	O
other	O
hand,	O
the	O
discrepancy	O
noted	O
on	O
the	O
methionine	B
results	O
between	O
the	O
GC-MS	O
and	O
NMR	O
results	O
raises	O
the	O
issue	O
of	O
the	O
analytical	O
validation	O
of	O
metabolites	O
derived	O
from	O
untargeted	O
metabolomics	O
methods	O
as	O
subsequent	O
steps	O
in	O
the	O
validation	O
of	O
candidate	O
FIBs	O
need	O
to	O
include	O
harmonized	O
sample	O
preparation	O
procedures	O
as	O
well	O
as	O
analytical	O
methods	O
whose	O
performance	O
(sensitivity,	O
precision)	O
are	O
well	O
characterized.	O

Another	O
study	O
compared	O
benign	O
controls	O
against	O
patients	O
with	O
active	O
prostate	O
cancer	O
and	O
found	O
that	O
urine	O
sarcosine	B
was	O
only	O
a	O
modest	O
predictor	O
of	O
disease,	O
but	O
when	O
added	O
to	O
other	O
new	O
markers	O
such	O
as	O
prostate	O
cancer	O
antigen	O
3	O
and	O
percent-free	O
PSA	O
improved	O
diagnostic	O
power	O
.	O

One	O
outlier	O
with	O
5.5	O
ng/ml	O
(closest	O
value	O
1.6)	O
of	O
25-hydroxycholesterol	B
from	O
the	O
first	O
sampling,	O
one	O
with	O
2.2	O
ng/ml	O
(14.6)	O
of	O
27-hydroxycholesterol	B
from	O
the	O
second	O
sampling,	O
one	O
with	O
8.4	O
ng/ml	O
of	O
7α	B
-hydroxycholesterol	I
(6.7	O
from	O
the	O
first	O
sampling)	O
and	O
one	O
with	O
10.9	O
ng/ml	O
(7.7	O
from	O
the	O
second	O
sampling),	O
two	O
with	O
27.6	O
and	O
22.5	O
ng/ml	O
7-ketocholesterol	B
(14.6	O
from	O
the	O
first	O
sampling)	O
and	O
one	O
with	O
16.1	O
ng/ml	O
(12.1	O
from	O
the	O
second	O
sampling)	O
were	O
removed	O
from	O
the	O
analysis.	O

Conclusions:	O
Male	O
smokers	O
supplemented	O
with	O
β-carotene	B
developed	O
metabolomic	O
profiles	O
consistent	O
with	O
the	O
induction	O
of	O
cytochrome	O
P450	O
enzymes,	O
the	O
primary	O
metabolizers	O
of	O
xenobiotics	O
in	O
humans.	O

Lactate,	B
pyruvate,	B
alanine	B
levels	O
were	O
significantly	O
higher	O
and	O
acetate,	B
glucose	B
and	O
glutamine	B
levels	O
were	O
significantly	O
lower	O
in	O
cluster	O
LR-1	O
compared	O
to	O
clusters	O
LR-2	O
and	O
LR-3.	O

The	O
dose	O
levels	O
used	O
in	O
these	O
two	O
studies	O
effectively	O
defined	O
the	O
maximum	O
tolerated	O
doses	O
of	O
GR,	O
SF	B
or	O
the	O
two	O
combined.	O

This	O
mixture	O
is	O
designed	O
as	O
an	O
internal	O
standard	O
for	O
human	O
plasma,	O
and	O
as	O
such	O
contains	O
a	O
cross	O
section	O
of	O
different	O
lipid	O
classes,	O
including	O
the	O
glycerophospholipids	B
LPC	O
[_2	B
H_7	I
]18:1(n	I
-9,	I
cis	I
),	I
LPE	O
[_2	B
H_7	I
]18:1(n	I
-9,	I
cis	I
),	I
PC	B
15:0/[_2	I
H_7	I
]18:1(n	I
-9,	I
cis	I
),	I
PE	B
15:0/[_2	I
H_7	I
]18:1(n	I
-9,	I
cis	I
),	I
PI	B
15:0/[_2	I
H_7	I
]18:1(n	I
-9,	I
cis	I
),	I
PG	B
15:0/[_2	I
H_7	I
]18:1(n	I
-9,	I
cis	I
),	I
PS	B
15:0/[_2	I
H_7	I
]18:1(n	I
-9,	I
cis	I
),	I
PA	B
15:0/[_2	I
H_7	I
]18:1(n	I
-9,	I
cis	I
);	I
the	O
sphingomyelin	B
SM	O
[_2	B
H_9	I
]18:1(n	I
-9,	I
cis	I
);	I
the	O
glycerolipids	B
TG	I
15:0/[_2	I
H_7	I
]18:1(n	I
-9,	I
cis	I
)/15:0,	I
DG	B
15:0_[_2	I
H_7	I
]18:1(n	I
-9,	I
cis	I
)	I
and	O
MG	O
[_2	B
H_7	I
]18:1(n	I
-9,	I
cis	I
);	I
and	O
the	O
cholesterol	B
ester	I
CE	O
[_2	B
H_7	I
]18:1(n	I
-9,	I
cis	I
).	I

As	O
shown	O
by	O
the	O
extensive	O
lipoprotein	O
subclass	O
analysis,	O
they	O
had	O
lower	O
total	O
cholesterol	B
and	O
LDL-cholesterol	B
but	O
not	O
HDL-cholesterol.	B

It	O
is	O
noteworthy	O
that	O
in	O
the	O
non-targeted	O
metabolomics	O
approach	O
of	O
the	O
present	O
study,	O
lipid	O
molecules,	O
branched-chain	O
amino	O
acids,	O
and	O
acylcarnitines	B
were	O
also	O
featured	O
among	O
the	O
top	O
30	O
metabolites	O
that	O
RF	O
analysis	O
associated	O
with	O
the	O
M	O
value.	O

Levels	O
of	O
TMAO	B
in	O
urine	O
were	O
adjusted	O
for	O
urinary	O
dilution	O
by	O
analysis	O
of	O
the	O
urine	O
creatinine	B
level.	O

Moreover,	O
we	O
observed	O
the	O
decrease	O
in	O
serum	O
concentration	O
of	O
albumin	O
that,	O
during	O
the	O
first	O
stage	O
of	O
treatment,	O
correlated	O
with	O
the	O
decrease	O
of	O
serum	O
phospholipids.	B

Deuterium	O
oxide	O
(D_2	O
O)	O
and	O
a	O
mixture	O
of	O
uniformly	O
13C,_15	O
N-labeled	O
(97–99%	O
enrichment)	O
standard	O
amino	O
acids	O
that	O
included	O
leucine,	B
methionine,	B
tryptophan,	B
and	O
tyrosine	B
were	O
obtained	O
from	O
Cambridge	O
Isotope	O
laboratories,	O
Inc.	O

These	O
data	O
suggest	O
that	O
ERα	O
specifically	O
influences	O
the	O
effect	O
of	O
isoflavones	B
on	O
CYP1A1	O
expression,	O
without	O
altering	O
CYP1B1.	O

Previous	O
relationships	O
between	O
urinary	O
urea	B
nitrogen	I
excretion	O
and	O
appearance	O
of	O
urine	O
hippurate	B
and/or	O
PAG	B
nitrogen	I
were	O
reported	O
in	O
normal	O
subjects	O
given	O
sodium	B
benzoate	I
or	O
sodium	B
phenylacetate,	I
respectively.	O

Post-rinse	O
anthocyanin	B
levels	O
showed	O
rinse-related	O
differences,	O
with	O
saliva	O
collected	O
following	O
Rinse	O
I	O
containing	O
the	O
highest	O
levels	O
of	O
BRB	O
parent	O
anthocyanins	B
over	O
the	O
time	O
course	O
of	O
the	O
study.	O

Levels	O
of	O
capric	B
acid,	I
cis-9-palmitoleic	B
acid,	I
dodecanoic	B
acid,	I
oleic	B
acid	I
and	O
palmitic	B
acid	I
were	O
decreased	O
in	O
children	O
and	O
adolescents	O
with	O
MDD	O
who	O
were	O
drug-naive	O
compared	O
with	O
healthy	O
controls.	O

Lipidomic	O
analysis	O
of	O
rHDL	O
infusate	O
COH-CE,	O
cholesterol	B
and	O
cholesterol	B
ester;	I
DAG,	O
diacylglycerol;	B
rHDL,	O
reconstituted	O
HDL;	O
LPC,	O
lysophosphatidylcholine;	B
PC,	O
phosphatidylcholine.	B

Given	O
that	O
betaine	B
has	O
been	O
described	O
as	O
being	O
a	O
precursor	O
to	O
TMAO,	B
it	O
seems	O
counterintuitive	O
that	O
lower	O
betaine	B
levels	O
would	O
coincide	O
with	O
higher	O
TMAO	B
levels	O
and	O
vice	O
versa.	O

Propylene	B
glycol	I
seems	O
to	O
be	O
an	O
exogenous	O
contaminant,	O
as	O
it	O
is	O
widely	O
used	O
as	O
a	O
solvent	O
in	O
many	O
pharmaceuticals	O
(Psychogios	O
et	O
al.	O
).	O

Three	O
compounds	O
identified	O
as	O
3-(3-hydroxyphenyl)-3-hydroxypropionic	B
acid	I
(HPHPA),	O
3-hydroxyphenylacetic	B
acid	I
(3HPA),	O
and	O
3-hydroxyhippuric	B
acid	I
(3HHA)	O
were	O
found	O
in	O
higher	O
concentrations	O
in	O
autistic	O
children	O
than	O
in	O
the	O
controls	O
(p	O
<	O
0.001).	O

Tyrosine	B
was	O
diluted	O
in	O
hydrochloricacid.	B

In	O
citrate/cis-aconitate	B
ratio,	O
both	O
metabolites	O
are	O
in	O
the	O
citric	B
acid	I
cycle	O
pathway;	O
cis-aconitate	B
is	O
an	O
intermediate	O
metabolite	O
during	O
conversion	O
of	O
citrate	B
to	O
isocitrate.	B

Further	O
investigation	O
of	O
the	O
effect	O
of	O
season,	O
age	O
and	O
gender	O
on	O
the	O
levels	O
of	O
creatinine,	B
cotinine	B
and	O
trans	B
-3′-hydroxycotinine	I
by	O
means	O
of	O
a	O
General	O
Linear	O
Model	O
suggests	O
a	O
mild	O
interaction	O
of	O
gender	O
(males)	O
plus	O
age	O
and	O
the	O
interaction	O
of	O
gender	O
(males)	O
plus	O
season	O
(winter)	O
as	O
factors	O
affecting	O
creatinine	B
levels	O
(p	O
<0.10),	O
whilst	O
no	O
effect	O
was	O
flagged	O
for	O
cotinine	B
or	O
trans	B
-3′-hydroxycotinine	I
concentrations.	O

In	O
addition	O
to	O
peptides,	O
serum	O
myoinositol,	B
dimethyluric	B
acid	I
and	O
N-methylnicotinate	B
were	O
significantly	O
increased	O
in	O
COPD	O
smokers,	O
as	O
compared	O
with	O
both	O
healthy	O
smokers	O
and	O
non-smokers.	O

REE,	O
resting	O
energy	O
expenditure;	O
RQ,	O
respiratory	O
quotient;	O
GDR,	O
glucose	B
disposal	O
rate	O
(indirect	O
calorimetry).	O

Deuterated	O
chloroform	B
was	O
applied	O
as	O
the	O
solvent,	O
and	O
trimethylsilane	B
was	O
the	O
reference	O
standard	O
(Fig. ).	O

 ,	O
which	O
shows	O
the	O
extracted	O
ion	O
chromatogram	O
for	O
m/z	O
137.071	O
(C_7	O
H_9	O
N_2	O
O;	O
tentative	O
annotation	O
methylnicotinamide).	B

To	O
determine	O
whether	O
there	O
were	O
other	O
CYP39A1	O
variants	O
associated	O
with	O
serum	O
24S	B
-hydroxycholesterol	I
levels,	O
the	O
12	O
exons	O
of	O
this	O
gene	O
were	O
sequenced	O
in	O
the	O
30	O
DHS	O
individuals	O
with	O
the	O
highest	O
normalized	O
24S	B
-hydroxycholesterol	I
levels.	O

Pisarenko	O
et	O
al	O
.	O
observed	O
that	O
ATP	B
and	O
phosphocreatine	B
levels	O
significantly	O
decreased	O
in	O
the	O
isolated	O
heart,	O
and	O
succinate	B
level	O
was	O
significantly	O
increased	O
in	O
the	O
myocardial	O
perfusate	O
early	O
following	O
reperfusion	O
of	O
the	O
Guinea	O
pig	O
model.	O

The	O
internal	O
standard	O
L-2	O
chlorophenylalanine	B
was	O
obtained	O
from	O
Ark	O
Pharm,	O
Inc.	O
and	O
ultrapure	O
water	O
was	O
purchased	O
from	O
EMD	O
Millipore.	O

Typical	O
average	O
total	O
cotinine	B
concentrations	O
in	O
urine	O
are	O
about	O
5000–15 000	O
times	O
greater	O
than	O
those	O
of	O
total	O
NNAL,	O
which	O
can	O
introduce	O
problems	O
associated	O
with	O
dynamic	O
range.	O

In	O
addition	O
to	O
the	O
11	O
common	O
metabolites,	O
we	O
identified	O
26	O
metabolites	O
associated	O
only	O
with	O
prevalent	O
type	O
2	O
diabetes,	O
including	O
5	O
LPIs,	O
9	O
NEFAs,	O
and	O
12	O
acylcarnitines.	B

Pharmacological	O
agents	O
that	O
modulate	O
pyrimidine	B
metabolism	O
are	O
prescribed	O
in	O
neurologic	O
conditions,	O
such	O
as	O
multiple	O
sclerosis,	O
due	O
to	O
their	O
immunosuppressive	O
effects,	O
which	O
appears	O
to	O
delay	O
the	O
progression	O
of	O
disability.	O

Additionally,	O
low	O
levels	O
of	O
NAAG	B
in	O
brain	O
tissue	O
and	O
increased	O
levels	O
in	O
CSF	O
are	O
associated	O
with	O
human	O
amyotrophic	O
lateral	O
sclerosis	O
(ALS).	O

The	O
stability	O
of	O
the	O
DEET	O
and	O
neonicotinoid	B
biomarkers	O
in	O
human	O
urine	O
and	O
water	O
was	O
assessed	O
under	O
several	O
storage/	O
handling	O
conditions.	O

PAG = Phenylacetylglutamine,	B
PCS = p-cresol-sulfate,	B
2HB = 2-hydroxybenzoate.	B

Vascular-free	O
EETs	O
can	O
be	O
increased	O
by	O
release	O
from	O
endothelial	O
phospholipids;	B
eg,	O
bradykinin	B
stimulates	O
phospholipase	O
activity	O
to	O
increase	O
unbound	O
EETs	O
that	O
exert	O
antipressor	O
effects	O
by	O
relaxing	O
vascular	O
smooth	O
muscle.	O

Solvent	O
A	O
was	O
6:4	O
acetonitrile:water	O
and	O
Solvent	O
B	O
was	O
1:9	O
acetonitrile:isopropanol,	O
both	O
with	O
10 mM	O
ammonium	B
formate	I
and	O
0.1%	O
formic	B
acid.	I

Ora-Sweet	O
SF	B
™:	O

OPLS-DA	O
score	O
plots	O
based	O
on	O
the	O
data	O
from	O
RRLC-(+)ESI-MS	B
of	O
the	O
ESCC,	O
ESCC-M	O
and	O
ESCC-P	O
patients	O
and	O
controls.	O

We	O
also	O
stratified	O
the	O
analysis	O
by	O
follow-up	O
time	O
(<9	O
years	O
[the	O
median	O
duration	B
of	O
follow-up]	O
or	O
≥9	O
years)	O
and	O
major	O
lung	O
cancer	O
subtypes	O
(adenocarcinoma,	O
nonadenocarcinoma).	O

Our	O
data	O
limit	O
further	O
the	O
clinical	O
indication	O
of	O
liver	O
biopsy	O
in	O
obese	O
patients	O
for	O
those	O
with	O
the	O
additional	O
presence	O
of	O
known	O
factors	O
affecting	O
the	O
progression	O
of	O
liver	O
disease	O
such	O
as	O
alcohol	O
or	O
drugs	O
consumption,	O
toxin	B
exposure	O
or	O
viral	O
disease.	O

The	O
chloroform	B
layers	O
were	O
combined	O
for	O
analysis.	O

In	O
addition,	O
the	O
rapid	O
proliferation	O
of	O
malignant	O
tumor	O
cells	O
requires	O
the	O
synthesis	O
of	O
a	O
large	O
number	O
of	O
nucleotides	O
and	O
proteins,	O
leading	O
to	O
the	O
increase	O
of	O
glycine	B
as	O
the	O
synthesis	O
of	O
purine	B
nucleotides.	O

No	O
differences	O
were	O
detected	O
on	O
age,	O
sex,	O
systolic	O
blood	O
pressure	O
(SBP),	O
urea,	B
creatine	B
(Cr)	O
or	O
sodium	O
(Na)	O
between	O
any	O
two	O
groups	O
among	O
acute	O
AD,	O
chronic	O
AD,	O
total	O
AD	O
and	O
CHD	O
patients.	O

Plasma	O
levels	O
of	O
carnitine	B
are	O
significantly	O
increased	O
in	O
PDR	O
compared	O
with	O
NPDR	O
patients.	O

From	O
a	O
35	O
year	O
old	O
healthy	O
control	O
(CTR)	O
(A,	O
A’);	O
a	O
22	O
year	O
old	O
male	O
with	O
chronic	O
hepatitis-B	O
related	O
liver	O
disease	O
(CHB)	O
(B,	O
B’);	O
a	O
36	O
year	O
old	O
male	O
with	O
hepatitis	O
B	O
virus	O
(HBV)-cirrhosis	O
(C,	O
C’);	O
and	O
a	O
50	O
year	O
old	O
male	O
with	O
HBV-hepatocellular	O
carcinoma	O
(AFP	O
>	O
30000	O
mg/dL)	O
displaying	O
(A-D)	O
the	O
aliphatic	B
region	O
0.5-4.5	O
ppm	O
and	O
(A’-D’)	O
the	O
aromatic	O
region	O
6.4-9.5	O
ppm	O
(D,	O
D’).	O

Our	O
data	O
provide	O
insight	O
into	O
colonic	O
lipid	O
metabolism	O
under	O
the	O
influence	O
of	O
ASA	O
medication	O
in	O
healthy	O
humans	O
and	O
supports	O
the	O
widely	O
hypothesized	O
anti-tumorigenic	O
effect	O
due	O
to	O
aspirin’s	O
effect	O
on	O
PG	B
suppression.	O

Finally,	O
serum	O
uric	B
acid	I
has	O
long	O
been	O
known	O
as	O
a	O
significant	O
risk	O
factor	O
for	O
excessive	O
cancer	O
risk,	O
recurrence,	O
and	O
mortality.	O

A	O
previous	O
study	O
reported	O
that	O
certain	O
adducts	O
formed	O
between	O
N	B
-acetoxy-PhIP	I
and	O
rat	O
SA	O
were	O
unstable	O
and	O
underwent	O
hydrolysis	O
to	O
produce	O
5-HO-PhIP.	B

High	O
phosphatidylcholine	B
levels	O
have	O
been	O
consistently	O
observed	O
in	O
tissues	O
from	O
various	O
types	O
of	O
cancers	O
(e.g.,	O
breast,	O
colorectal,	O
and	O
thyroid	O
papillary	O
cancer).	O

The	O
plasma-saline	B
mixture	O
was	O
left	O
to	O
stand	O
at	O
room	O
temperature	O
for	O
10	O
min	O
and	O
was	O
then	O
centrifuged	O
at	O
10,000	O
rpm	O
for	O
10	O
min.	O

The	O
resulting	O
analysis	O
revealed	O
that	O
46	O
of	O
the	O
184	O
putative	O
compounds	O
clustered	O
with	O
at	O
least	O
one	O
known	O
oxylipin	B
standard	O
and	O
none	O
of	O
the	O
50,000	O
non-oxylipin	O
metabolites,	O
indicating	O
structural	O
similarity	O
is	O
present	O
between	O
these	O
putative	O
compounds	O
with	O
known	O
members	O
of	O
oxylipin	B
families.	O

After	O
the	O
different	O
treatments,	O
the	O
cells	O
were	O
lysed	O
in	O
ice-cold	O
buffer	O
containing	O
20	O
mM	O
Tris-HCl	O
(pH	O
7.4),	O
150	O
mM	O
NaCl,	O
0.5%	O
Triton	O
X-100,	O
100	O
mM	O
Na_3	O
VO_4	O
,	O
1	O
mM	O
phenyl	B
methyl	I
sulfonyl	I
fluoride,	I
and	O
protease	O
inhibitor	O
cocktail	O
(Sigma).	O

Elevated	O
level	O
of	O
citrate	B
is	O
tightly	O
associated	O
with	O
energy	O
production	O
via	O
the	O
TCA	O
by	O
fatty	O
acid	O
β-oxidation	O
in	O
the	O
mitochondria.	O

Numerous	O
metabolites,	O
covering	O
important	O
metabolic	O
pathways	O
(Krebs'	O
cycle,	O
fatty	O
acid	O
and	O
glucosinolate	B
biosynthesis),	O
were	O
detected	O
in	O
extracts,	O
biofluids,	O
and/or	O
in	O
biological	O
tissues	O
(Arabidopsis	O
thaliana	O
,	O
Drosophila	O
melanogaster	O
,	O
Acyrthosiphon	O
pisum	O
,	O
and	O
human	O
blood).	O

The	O
level	O
of	O
serum	O
sphingosine	B
at	O
the	O
basal	O
status	O
was	O
negatively	O
correlated	O
with	O
the	O
level	O
of	O
serum	O
SMs	O
(d18:0/16:0,	O
d18:0/18:0,	B
d18:0/18:1,	B
Lyso	O
SM)	O
(,	O
b1–4,	O
Table	O
E1).	O

The	O
abundance	O
of	O
48%	O
(83	O
of	O
172)	O
of	O
the	O
measured	O
metabolites	O
changed	O
significantly	O
within	O
the	O
first	O
3	O
months	O
post	O
RYGB	O
(p<0.05),	O
including	O
sphingosines,	B
unsaturated	O
fatty	O
acids,	O
and	O
branched	O
chain	O
amino	O
acids.	O

It	O
is	O
interesting	O
that	O
HOMA-IR	O
and	O
homeostatic	O
model	O
assessment	O
of	O
insulin	O
sensitivity	O
values	O
were	O
still	O
unfavorable	O
in	O
the	O
NA/NT	O
group,	O
suggestive	O
perhaps	O
of	O
impaired	O
fasting	O
indices	O
but	O
preserved	O
ability	O
to	O
handle	O
an	O
oral	O
glucose	B
load.	O

The	O
urine	O
levels	O
of	O
1-methyladenosine	B
has	O
been	O
reported	O
to	O
be	O
higher	O
in	O
preoperative	O
patients	O
with	O
ovarian	O
or	O
breast	O
cancer	O
[,	O
].	O

spike:	O
Internal	O
standard	O
spiked	O
into	O
human	O
serum,	O
followed	O
by	O
MTBE	B
extraction	O
and	O
derivatization.	O

Regarding	O
the	O
serine	B
metabolism,	O
our	O
top	O
hit,	O
we	O
found	O
that	O
cases	O
had	O
70%	O
lower	O
urine	O
excretion	O
of	O
serine	B
in	O
this	O
cohort	O
compared	O
with	O
their	O
controls	O
(P	O
 <	O
0.001),	O
and	O
glycine	B
excretion	O
was	O
36%	O
lower	O
(P	O
 <	O
0.001).	O

In	O
this	O
exploratory	O
analysis,	O
we	O
have	O
demonstrated	O
for	O
the	O
first	O
time	O
an	O
effect	O
of	O
supplementation	O
with	O
carnosine	B
on	O
THC,	O
PC	O
and	O
COH	O
levels	O
which	O
are	O
likely	O
to	O
have	O
biological	O
roles	O
in	O
the	O
development	O
of	O
insulin	O
resistance,	O
T2DM	O
and	O
CVD.	O

Analyte	O
specific	O
product	O
ions	O
were	O
assigned	O
for	O
EI	B
and	O
E2,	O
however,	O
certain	O
metabolites	O
generated	O
similar	O
fragments	O
through	O
the	O
loss	O
of	O
the	O
derivative	O
function.	O

The	O
study	O
by	O
Bjerrum	O
is	O
in	O
agreement	O
with	O
our	O
results	O
except	O
for	O
the	O
tyrosine	B
levels,	O
which	O
were	O
consistently	O
lower.	O

The	O
serum	O
of	O
LN	O
patients	O
was	O
characterized	O
by	O
lower	O
levels	O
of	O
amino	O
acids	O
(such	O
as	O
leucine,	B
valine,	B
alanine,	B
glutamate,	B
proline,	B
histidine	B
and	O
glycine),	B
citrate,	B
acetate,	B
lactate	B
and	O
choline	B
compared	O
with	O
HC,	O
whereas	O
levels	O
of	O
creatinine,	B
lipoproteins	O
(LDL	O
and	O
VLDL),	O
Lipids	O
(L5-L9),	O
N-acetyl	B
glycoprotein	I
and	O
α/β	O
glucose	B
were	O
significantly	O
elevated	O
in	O
sera	O
of	O
LN	O
patients	O
(	O
and	O
).	O

However,	O
the	O
stratification	O
of	O
TMAO	B
levels	O
according	O
to	O
the	O
neurological	O
diagnoses	O
revealed	O
no	O
differences	O
among	O
the	O
three	O
groups.	O

Lignoceric	O
(C24:0)	O
is	O
a	O
very	O
long	O
chain	O
fatty	O
acid	O
along	O
with	O
behenic	B
acid	I
(C22:0)	O
and	O
arachidic	B
acid	I
(C20:0).	O

The	O
biomarker	O
most	O
commonly	O
associated	O
with	O
tryptophan	B
metabolites	O
was	O
neopterin,	B
which	O
had	O
positive	O
associations	O
with	O
the	O
KTR,	O
kynurenine	B
(both	O
P	O
<	O
0.0001),	O
and	O
anthranilic	B
acid	I
(P	O
=	O
0.004).	O

In	O
support	O
of	O
this,	O
are	O
our	O
data	O
on	O
Cer.	B

The	O
advantage	O
of	O
the	O
derivatization	O
is	O
that	O
it	O
increases	O
the	O
retention	O
of	O
the	O
amino	O
acids	O
and	O
thus	O
allows	O
the	O
use	O
of	O
reversed-phase	O
LC,	O
which	O
is	O
more	O
robust	O
than,	O
for	O
example,	O
hydrophilic	O
interaction	O
chromatography,	O
particularly	O
when	O
the	O
goal	O
is	O
to	O
simultaneously	O
analyze	O
very	O
polar	O
(e.g.,	O
small	O
amino	B
acids)	O
and	O
relatively	O
non-polar	O
compounds	O
(e.g.,	O
bile	O
acids).	O

Neurotoxicity	O
of	O
ACO2	O
deficiency	O
may	O
be	O
promoted	O
by	O
both	O
increased	O
glutamate	B
and	O
reduced	O
AKG	O
levels.	O

Subjects	O
with	O
body	O
mass	O
index	O
(BMI) > 25	O
kg/m_2	O
(n	O
 = 28)	O
were	O
stratified	O
based	O
on	O
median	O
glucose	B
infusion	O
rate	O
during	O
a	O
hyperinsulinemic‐euglycemic	B
clamp	O
into	O
insulin‐sensitive	O
and	O
insulin‐resistant	O
groups	O
(above	O
and	O
below	O
median,	O
obesity/insulin‐sensitive	O
and	O
obesity/insulin‐resistant,	O
respectively).	O

Björkhem	O
and	O
colleagues	O
have	O
found	O
that	O
patients	O
with	O
PD	O
or	O
AD	O
can	O
have	O
higher	O
CSF	O
levels	O
of	O
(25R)26-HC	B
than	O
the	O
controls	O
[,	O
,	O
].	O

Addition	O
of	O
the	O
2-pathway:parent	O
estrogens	O
ratio	O
to	O
a	O
model	O
containing	O
unconjugated	O
estradiol	B
increased	O
or	O
decreased,	O
by	O
at	O
least	O
14%,	O
the	O
absolute	O
breast	O
cancer	O
risk	O
estimate	O
for	O
36%	O
of	O
the	O
women.	O

To	O
determine	O
whether	O
there	O
was	O
a	O
distinct	O
border	O
of	O
the	O
relative	O
quantities	O
of	O
glucose	B
and	O
citrate	B
between	O
normal	O
and	O
malignant	O
prostate	O
tissues,	O
we	O
set	O
our	O
DESI	O
probe	O
to	O
scan	O
along	O
a	O
single	O
line	O
over	O
a	O
prostate	O
tissue	O
specimen.	O

One	O
part	O
(1050	O
μ	O
L)	O
was	O
dried	O
using	O
an	O
Eppendorf	O
Vacufuge-Plus	O
vacuum	O
concentrator;	O
the	O
resulting	O
residue	O
was	O
mixed	O
with	O
300	O
μ	O
L	O
of	O
phosphate	B
buffer	O
(0.1	O
M)	O
in	O
D_2	O
O	O
containing	O
50	O
μ	O
M	O
TSP.	O

The	O
result	O
of	O
literature	O
mining	O
in	O
PubMed	O
suggested	O
that	O
1-methyladenosine	B
is	O
associated	O
with	O
liver	O
cancer	O
(PMID:	O
19399767,	O
7562399,	O
1823269,	O
3711674,	O
and	O
7139605).	O

Using	O
these	O
HPLC	O
assays,	O
we	O
measured	O
a	O
total	O
of	O
4	O
thiols	B
and	O
6	O
isoflavones	B
in	O
urine.	O

Regarding	O
the	O
use	O
of	O
1,25OH2D	O
and	O
24,25OH2D	O
as	O
markers	O
of	O
vitamin	B
D	I
status,	O
our	O
results	O
identified	O
a	O
significant	O
inverse	O
correlation	O
between	O
1,25OH2D	O
and	O
hsCRP,	O
and	O
a	O
significant	O
positive	O
correlation	O
between	O
24,25OH2D	O
and	O
ESR.	O

p	B
-Hydroxyphenyl-acetic	I
and	O
3-(3’-hydroxyphenyl)-3-hydropropionic	B
acids	I
are	O
produced	O
by	O
gut	O
microbial	O
dehydrogenation	O
of	O
some	O
bioactive	O
compounds	O
such	O
as	O
proanthocyanidins	B
and	O
procyanidins,	B
present	O
in	O
elevated	O
quantity	O
in	O
blueberry	O
fruits.	O

When	O
plasma	O
spiked	O
with	O
triglycerides	B
to	O
reach	O
levels	O
higher	O
than	O
300	O
mg/dl	O
(352–	O
403	O
mg/dl)	O
was	O
used	O
in	O
the	O
matrix	O
effect	O
test,	O
the	O
matrix	O
effect	O
ranged	O
92–103%,	O
similar	O
to	O
those	O
with	O
plasma	O
of	O
low	O
triglyceride	B
levels.	O

Besides	O
ornithine,	B
the	O
blood	O
levels	O
of	O
most	O
essential	O
and	O
nonessential	O
amino	O
acids	O
(such	O
as	O
threonine,	B
valine,	B
isoleucine,	B
leucine,	B
glycine,	B
tyrosine,	B
and	O
phenylalanine)	B
were	O
found	O
to	O
be	O
lower	O
in	O
the	O
cancer	O
patients.	O

Sodium	B
hydroxide,	I
sodium	O
bicarbonate	O
and	O
anhydrous	B
sodium	I
sulfate	I
were	O
of	O
analytical	O
grade	O
and	O
obtained	O
from	O
JT	O
Baker	O
Co.	O
(Phillipsburg,	O
NJ).	O

Conversion	O
of	O
VLCFAs	O
to	O
dicarboxylic	B
acids	I
first	O
involves	O
ω-hydroxylation	O
of	O
the	O
fatty	O
acid	O
by	O
microsomal	O
CYP4A/4F	O
enzyme	O
systems	O
(CYP4A11,	O
CYP4F2,	O
CYP4F3A,	O
CYP4F3B)	O

PC	O
847	O
2C	O
and	O
PC	O
2096	O
4B	O
cell	O
lines	O
or	O
the	O
shRNA	O
scramble	O
control	O
cell	O
line	O
were	O
maintained	O
in	O
DMEM	O
for	O
24	O
h	O
or	O
longer	O
without	O
labeled	O
glucose	B
of	O
glutamine	B
(the	O
same	O
as	O
the	O
zero	O
time	O
control	O
shown	O
in	O
).	O

Consequently,	O
a	O
down-regulation	O
of	O
the	O
peroxisomal	O
lignoceryl-CoA	B
ligase	O
activity	O
might	O
be	O
hypothesized.	O

The	O
blots	O
were	O
stripped	O
and	O
probed	O
for	O
housekeeper	O
proteins	O
transferrin	O
(serum)	O
or	O
β-actin	B
(tissue	O
lysate).	O

The	O
levels	O
found	O
suggested	O
that	O
for	O
amino	O
acid	O
crosslinks,	O
glucosepane	B
had	O
the	O
highest	O
urinary	O
excretion,	O
and	O
for	O
oxidized	O
amino	O
acids,	O
GSA	O
had	O
the	O
high	O
urinary	O
excretion.	O

Our	O
study	O
showed	O
that	O
the	O
chiral	O
column	O
had	O
high	O
specificity	O
and	O
selectivity	O
for	O
separating	O
proline	B
from	O
serum	O
components.	O

Two	O
300	O
μL	O
serum	O
samples	O
were	O
cooled	O
in	O
an	O
ice	O
bath	O
and	O
mixed	O
with	O
perchloric	B
acid	I
(30	O
μL;	O
4	O
M),	O
vortexed,	O
and	O
kept	O
aside	O
for	O
10	O
min,	O
then	O
centrifuged	O
at	O
11 000	O
rpm	O
for	O
30	O
min	O
to	O
pellet	O
proteins.	O

Similar	O
FRET-based	O
sensors	O
that	O
capitalize	O
on	O
the	O
metabolite	O
binding	O
properties	O
of	O
bacterial	O
or	O
yeast	O
proteins	O
have	O
been	O
developed	O
for	O
the	O
measurement	O
of	O
other	O
metabolite	O
fluxes,	O
including	O
mitochondrial	O
pyruvate	B
uptake_,	O
,	O
changes	O
in	O
the	O
ATP:ADP	O
ratio,	O
and	O
glutamate,	B
phosphate	B
and	O
tryptophan	B
transport	O
(Table ).	O

Indeed,	O
we	O
detected	O
higher	O
levels	O
of	O
lipids	O
(m/z	O
200–1,000)	O
in	O
PCa	O
compared	O
with	O
normal	O
prostate	O
tissues,	O
a	O
finding	O
consistent	O
with	O
metabolic	O
reprogramming	O
in	O
PCa	O
associated	O
with	O
increased	O
expression	O
and	O
activity	O
of	O
several	O
lipogenic	O
enzymes	O
including	O
FA	B
synthase	O
(FASN).	O

All	O
the	O
metabolites	O
were	O
quantified	O
by	O
using	O
an	O
Agilent	O
1200	O
HPLC	O
system	O
(Agilent	O
Technologies,	O
Santa	O
Clara,	O
CA)	O
coupled	O
to	O
a	O
6410	O
Triple	O
Quadrupole	O
(QQQ)	O
mass	O
spectrometer	O
(Agilent	O
Technologies)	O
except	O
myo-inositol,	B
which	O
was	O
measured	O
using	O
an	O
Agilent	O
7890	O
GC	O
system	O
(Agilent	O
Technologies)	O
coupled	O
to	O
a	O
7000B	O
QQQ	O
mass	O
spectrometer	O
(Agilent	O
Technologies).	O

Liang	O
and	O
Patel	O
have	O
demonstrated	O
that	O
persistent	O
seizures	O
(status	O
epilepticus)	O
cause	O
oxidative	O
damage	O
to	O
DNA	O
and	O
cellular	O
membrane	O
components	O
leading	O
to	O
protein	O
carbonylation,	O
nitric	B
oxide	I
formation	O
and	O
lipid	O
peroxidation.	O

A	O
total	O
of	O
29	O
moderately	O
to	O
severely	O
depressed	O
unmedicated	O
subjects	O
who	O
met	O
DSM-IV	O
criteria	O
for	O
MDD	O
and	O
20	O
healthy	O
controls	O
(HCs)	O
completed	O
a	O
structural	O
MRI	O
scan	O
and	O
provided	O
blood	O
sample	O
for	O
kynurenine	B
metabolite	O
analysis,	O
performed	O
using	O
high-performance	O
liquid	O
chromatography	O
with	O
tandem	O
mass	O
spectrometry.	O

However,	O
glycerophosphocholine	B
was	O
negatively	O
correlated	O
(degree	O
of	O
correlation:	O
−1.0)	O
with	O
creatinine	B
(Fig. ).	O

Thirdly,	O
apart	O
from	O
CYP2D6,	O
other	O
factors	O
and	O
drug-metabolizing	O
enzymes,	O
such	O
as	O
polymorphic	O
CYP2C9,	O
CYP3A5,	O
CYP2B6,	O
CYP2C19,	O
SULT1A2	O
and	O
UGTs,	O
age,	O
body	O
mass	O
index	O
[,],	O
and	O
seasonal	O
variation	O
may	O
also	O
influence	O
the	O
steady	O
level	O
of	O
(Z)-endoxifen.	B

Overall,	O
we	O
observed	O
that	O
peptides	O
(78%,	O
P	O
=	O
2.29	O
×	O
10_−19	O
;	O
FDR	O
=	O
1.84	O
×	O
10_−18	O
)	O
and	O
carbohydrates	O
(47%,	O
P	O
=	O
4.09	O
×	O
10_−3	O
;	O
FDR	O
=	O
1.09	O
×	O
10_−2	O
)	O
probably	O
reacted	O
with	O
formaldehyde.	B

Formic	B
acid,	I
methanol	B
and	O
acetonitrile	B
(ACN)	O
were	O
purchased	O
from	O
Thermo	O
Fisher	O
Scientific	O
(Pittsburgh,	O
PA,	O
USA).	O

The	O
NMR	O
spectrum	O
from	O
each	O
sample	O
was	O
aligned	O
with	O
reference	O
to	O
the	O
TSP	O
(3-(trimethylsilyl)	O
propionic-(2,2,3,3-d4)	I
acid	I
sodium	I
salt)	O
signal	O
at	O
0	O
ppm.	O

First,	O
the	O
strongest	O
associations	O
were	O
found	O
with	O
raised	O
serum	O
triglycerides.	B

Two	O
were	O
used	O
for	O
_1	O
H	O
1D	O
NMR	O
and	O
the	O
other	O
two	O
samples	O
were	O
used	O
for	O
detecting	O
carboxyl	O
class	O
of	O
metabolites	O
after	O
tagging	O
with	O
_15	O
N-cholamine.	B

Butanoic	B
acid	I
is	O
a	O
short-chain	O
fatty	O
acids	O
mainly	O
generated	O
from	O
dietary	O
cellulose,	O
starch	O
and	O
other	O
undigested	O
substances	O
under	O
microbial	O
fermentation	O
in	O
the	O
cecum	O
or	O
colon	O
(Mao	O
et	O
al.,	O
2012).	O

For	O
instance,	O
decreased	O
uridine	B
diphosphate	I
N-acetylglucosamine	I
(UDP-GlcNAc)	O
concentrations	O
were	O
associated	O
with	O
improvements	O
in	O
anthropometric	O
and	O
insulin	O
resistance	O
traits,	O
whereas	O
increased	O
levels	O
were	O
associated	O
with	O
worse	O
CRF.	O

Compounds	O
identified	O
in	O
include	O
lactate	B
(4.14	O
ppm,	O
q,	O
1.35	O
ppm,	O
d),	O
creatine	B
(3.94	O
ppm,	O
s,	O
3.04	O
ppm,	O
s),	O
methionine	B
(3.86	O
ppm,	O
t),	O
glucose	B
(3.75	O
ppm,	O
m),	O
glycine	B
(3.57	O
ppm,	O
s),	O
myo	O
-inositol/glycerol	O
(3.56	O
ppm),	O
taurine	B
(3.43	O
ppm,	O
t,	O
3.25	O
ppm,	O
t),	O
trimethylamine	B
oxide	I
(TMAO)/betaine	O
(3.27	O
ppm,	O
s),	O
acetone	B
(2.25	O
ppm,	O
s),	O
alanine	B
(1.49	O
ppm,	O
d),	O
and	O
hydroxybutyrate	B
(1.17	O
ppm,	O
d).	O

According	O
to	O
the	O
literature,	O
elevation	O
of	O
N-Acetylaspartic	B
acid	I
could	O
be	O
regulated	O
by	O
the	O
Ras	O
homolog	O
gene	O
family,	O
member	O
C	O
guanosine	O
triphosphatase,	O
which	O
is	O
essential	O
in	O
transforming	O
growth	O
factor	O
beta	O

PCA	O
was	O
performed	O
on	O
the	O
baseline-subtracted	O
femoral	O
arterial	O
plasma	O
samples	O
for	O
both	O
whey	B
protein	O
and	O
calcium	B
caseinate.	I

However,	O
NMR	O
analysis	O
of	O
standard	O
glutamine	B
solutions	O
after	O
subjecting	O
to	O
either	O
protein	O
precipitation	O
or	O
ultrafiltration	O
showed	O
no	O
conversion	O
to	O
pyroglutamic	B
acid.	I

Many	O
genes	O
partly	O
contribute	O
to	O
severe	O
AMS	O
pathogenesis,	O
e.g.	O
genes	O
of	O
the	O
renin–angiotensin–aldosterone	B
system,	O
the	O
heat-shock	O
protein	O
70	O
family	O
and	O
endothelial	O
nitric	B
oxide	I
synthase_,	O
_,	O
.	O

That	O
is,	O
nominal	O
mass	O
losses	O
for	O
the	O
aldehyde	O
and	O
Criegee	O
ions	O
are	O
expected	O
at	O
117	O
and	O
101	O
Da	O
for	O
the	O
_2	O
H_7	O
-labelled	O
lipids	O
and	O
119	O
and	O
103	O
Da	O
for	O
the	O
_2	O
H_9	O
-labelled	O
SM.	O
illustrates	O
the	O
m/z	O
and	O
drift	O
time	O
extracted	O
XICs	O
of	O
six	O
lipid	O
precursor	O
ions	O
and	O
their	O
OzID	O
products	O
in	O
positive	O
mode	O
and	O
six	O
in	O
negative	O
mode,	O
with	O
the	O
extracted	O
ion	O
chromatograms	O
for	O
PE	B
15:0/[_2	I
H_7	I
]18:1(n	I
-9,	I
cis	I
)	I
shown	O
in	O
both	O
polarities.	O

A	O
(70%	O
water,	O
30%	O
acetonitrile	B
and	O
0.1%	O
acetic	O
acid)	O
and	O
B	O
(50%	O
acetonitrile,	B
50%	O
isopropanol,	B
0.02%	O
acetic	O
acid)	O
running	O
the	O
following	O
gradient:	O
1%	O
B	O
from	O
−1.00	O
to	O
0.25	O
minutes,	O
1%	O
to	O
55%	O
B	O
from	O
0.25	O
to	O
5.00	O
minutes,	O
55%	O
to	O
99%	O
B	O
from	O
5.00	O
to	O
5.50	O
minutes,	O
and	O
99%	O
B	O
from	O
5.50	O
to	O
7.00	O
minutes.	O

For	O
positive	O
ionization,	O
the	O
aqueous	O
mobile	O
phase	O
(mobile	O
phase	O
A)	O
was	O
water	O
with	O
0.1%	O
formic	B
acid	I
and	O
the	O
organic	O
mobile	O
phase	O
(mobile	O
phase	O
B)	O
was	O
acetonitrile	B
with	O
0.1%	O
formic	B
acid.	I

Additionally,	O
PUT’s	O
behavior	O
is	O
very	O
similar	O
to	O
the	O
behavior	O
of	O
CAD	O
and	O
1,3-DAP,	B
and	O
GABA	B
and	O
N1,N8-DiAcSPD	B
show	O
similar	O
signal	O
suppression.	O

The	O
parasite	O
genome	O
encodes	O
for	O
a	O
nicotinamidase	O
(PFC0910w,	O
EC	O
3.5.1.19),	O
nicotinate	O
phosphoribosyltransferase	O
(PFF1410c,	O
EC	O
2.4.2.11),	O
nicotinate	B
mononucleotide	O
adenylyltransferase	O
(PF13_0159,	O
EC	O
2.7.7.18),	O
and	O
NAD_+	O
synthase	O
(PFI1310w,	O
EC	O
6.3.5.1).	O

The	O
sphingolipid,	B
SM,	O
and	O
Cer	B
signaling	O
pathway	O
is	O
altered	O
by	O
stress,	O
including	O
oxidative	O
stress,	O
and	O
is	O
critically	O
involved	O
in	O
cell	O
proliferation	O
and	O
death	O
as	O
well	O
as	O
the	O
contraction	O
of	O
cardiomyocytes	O
and	O
vascular	O
smooth	O
muscle	O
cells	O
[,].	O

Although	O
we	O
did	O
not	O
find	O
significantly	O
different	O
levels	O
of	O
citrate	B
between	O
tumor	O
and	O
non-tumor	O
urines,	O
low	O
concentrations	O
of	O
this	O
metabolite	O
have	O
been	O
reported	O
in	O
bladder	O
tumors,	O
suggesting	O
the	O
role	O
of	O
β-oxidation	O
as	O
source	O
of	O
energy.	O

In	O
the	O
RA	O
cohort,	O
we	O
also	O
found	O
elevated	O
levels	O
of	O
ADMA	B
(0.76	O
vs.	O
0.61 μmol/L,	O
p	O
 < 0.001)	O

Since	O
it	O
readily	O
forms	O
covalent	O
adducts	O
and	O
reversible	O
complexes	O
with	O
hydroxyl	O
and	O
carboxylate	B
groups,	O
the	O
effects	O
of	O
borate	O
preservation	O
in	O
_1	O
H	O
NMR	O
spectroscopy-based	O
metabolic	O
profiling	O
of	O
human	O
urine	O
samples	O
have	O
been	O
assessed.	O

Metabolites	O
were	O
separated	O
using	O
C18-RP	O
(ACQUITY	O
UPLC	O
HSS	O
T3	O
1.8	O
μm,	O
Waters)	O
for	O
ESI	O
+ and	O
C18-RP	O
(ACQUITY	O
UPLC	O
BEH	O
1.7	O
μm)	O
for	O
ESI−.	O
When	O
the	O
instrument	O
was	O
operated	O
in	O
positive	O
ionization	O
mode,	O
the	O
solvent	O
system	O
was	O
A = 0.1%	O
formic	B
acid	I
in	O
water	O
and	O
B = 0.1%	O
formic	B
acid	I
in	O
acetonitrile.	B

The	O
variables	O
responsible	O
for	O
the	O
discrimination	O
were	O
found	O
at	O
around	O
1.35	O
and	O
3.70	O
ppm	O
tentatively	O
assigned	O
to	O
lactate	B
and	O
glucose	B
respectively	O
(Fig. ).	O

The	O
Flavonoids	B
are	O
known	O
for	O
their	O
antioxidant	O
properties	O
,	O
.	O

After	O
oxidative	O
decarboxylation	O
by	O
gluconate-6-phosphate	O
dehydrogenase,	O
ribulose-5-phosphate	B
is	O
produced.	O

A	O
significant	O
difference	O
between	O
the	O
6h-iAUC	O
was	O
found	O
for	O
C15:0,	B
but	O
not	O
for	O
C17:0,	B
based	O
on	O
a	O
Kruskal-Wallis	O
test	O
of	O
the	O
three	O
food	O
groups.	O

Further	O
analysis	O
of	O
across	O
LC-MS	O
methods	O
demonstrated	O
inferior	O
reproducibility	O
of	O
Scherzo	O
analysis	O
comparative	O
to	O
RP.	B

HCC-cirrhosis	O
was	O
characterized	O
by	O
high	O
levels	O
of	O
β-hydroxybutyrate,	B
tyrosine,	B
phenylalanine	B
and	O
histidine	B
whereas	O
HCC-NAFLD	O
was	O
characterized	O
by	O
high	O
levels	O
of	O
glutamine/glutamate.	O

The	O
expression	O
of	O
genes	O
related	O
to	O
the	O
other	O
sphingolipid	B
metabolic	O
pathways	O
in	O
The	O
Cancer	O
Genome	O
Atlas	O
(TCGA)	O
cohort	O
(n=112)	O
were	O
analyzed.	O

Subsequently,	O
produced	O
formazan	O
crystals	O
were	O
dissolved	O
in	O
DMSO	B
and	O
extinction	O
was	O
measured	O
at	O
570	O
nm.	O

4:	O
Phospholipid	B
synthesis	O
occurs	O
in	O
the	O
endoplasmic	O
reticulum.	O

All	O
(12/12)	O
metabolites	O
were	O
increased	O
in	O
the	O
GCS = 15	O
points	O
group,	O
including	O
8	O
organic	O
acids	O
(4-HPA,	O
(2-(4-(2-acetoxyethyl)-2,5-dimethoxyphenyl)acetic	O
acid	I
(methyl	O
ester),	O
2-hydroxybutyric	B
acid,	I
methyl	B
(R	I
)-(−)-3-hydroxy-2-methyl-propionate,	I
1,2-cyclopentanedicarboxylic	B
acid	I
(dimethyl),	O
3-hydroxypropionic	B
acid,	I
2-oxovaleric	B
acid,	I
and	O
dipicolinic	B
acid),	O
2	O
TCA	O
cycle	O
intermediates	O
(malic	O
acid	O
and	O
oxalic	B
acid),	O
and	O
one	O
saturated	O
fatty	O
acid	O
(hexanoic	O
acid).	O

Glycine	B
metabolism	O
intermediates,	O
urea	B
cycle	O
intermediates,	O
branched	O
chain	O
amino	O
acids	O
and	O
long	O
to	O
medium	O
chain	O
fatty	O
acids	O
should	O
form	O
the	O
focus	O
of	O
future	O
directed	O
metabolomic	O
strategies.	O

Twelve	O
of	O
the	O
SVMRFE_NL-selected	O
features	O
from	O
the	O
multimode	O
dataset	O
were	O
tentatively	O
identified	O
as	O
endogeneous	O
carboxylic	B
acids,	I
peptides,	O
glycerophospholipids	B
and	O
hormones.	O

Non-targeted	O
GC-MS	O
and	O
subsequent	O
statistical	O
analysis	O
of	O
single	O
time	O
points	O
further	O
revealed	O
a	O
significant	O
reduction	O
of	O
fructose	B
(GG2:	O
13%,	O
GG4:	O
6%),	O
gluconic	B
acid	I
(GG2:	O
5%,	O
GG4:	O
22%)	O
and	O
two	O
unidentified	O
metabolites	O
(RI	O
2028:	O
GG2:	O
6%,	O
GG4:	O
12%;	O
RI	B
1958:	O
GG2:	O
11.6%,	O
GG4:	O
11.4%)	O
at	O
the	O
time	O
point	O
of	O
maximal	O
level	O
(T_max	O
)	O
(Suppl.	O

The	O
strongly	O
positive	O
correlation	O
of	O
lactate	B
level	O
to	O
insulin	O
resistance	O
further	O
suggested	O
insulin	O
stimulated	O
glucose	B
uptake	O
and	O
consumption	O
in	O
the	O
muscle	O
of	O
these	O
PCOS	O
patients	O
(Additional	O
files	O
and	O
).	O

This	O
result	O
is	O
likely	O
due	O
to	O
the	O
fact	O
that	O
4-hydroxy	B
catechol	I
estrogens	O
are	O
quickly	O
transformed	O
into	O
other	O
reactive	O
species	O
such	O
as	O
their	O
quinones	B
and	O
semi-quinones,	B
which	O
could	O
damage	O
DNA	O
and	O
lead	O
to	O
tumor	O
initiation	O
[,,].	O

One	O
of	O
their	O
enzymatic	O
reactions	O
is	O
the	O
conversion	O
of	O
phosphatidic	B
acid	I
to	O
diacylglycerol	B
which	O
is	O
a	O
central	O
lipid	O
for	O
glycerophospholipids,	B
triacylglycerols	B
and	O
sphingolipid	B
metabolisms.	O

Males	O
had	O
higher	O
ICC	O
values	O
than	O
females	O
for	O
both	O
8-iso	B
-PGF_2α	I
(0.56,	I
95%	I
CI	I
[0.48,	I
0.64]	I
for	I
males	I
vs.	I
0.46	I
[0.37,	I
0.56]	I
for	I
females)	I
and	O
PGE-M	O
(0.43	O
[0.34,	O
0.51]	O
for	O
males	O
vs	O
0.26	O
[0.18,	O
0.37]	O
for	O
females).	O

These	O
data	O
augment	O
our	O
findings	O
that	O
sarcoidosis	O
patients	O
exhibit	O
an	O
increase	O
in	O
β-oxidation	O
pathway	O
along	O
with	O
decreased	O
intermediates	O
of	O
the	O
TCA	O
cycle,	O
such	O
as	O
succinate.	B

Specifically,	O
validation	O
of	O
this	O
BRCA1-like	O
metabolic	O
profile	O
in	O
TNBC	O
could	O
aid	O
in	O
the	O
prediction	O
of	O
resistance	O
to	O
taxanes	B
and	O
the	O
sensitivity	O
to	O
platinum	O
and	O
PARP	O
inhibitor	O
agents.	O

Interestingly,	O
among	O
the	O
metabolites	O
detected	O
by	O
SUR	O
analysis,	O
three	O
metabolites	O
including	O
phenylalanine,	B
xanthosine	B
and	O
epinephrine	B
were	O
unique	O
in	O
that	O
their	O
association	O
with	O
polyps	O
is	O
shown	O
here	O
for	O
the	O
first	O
time.	O

The	O
first	O
fraction	O
which	O
was	O
eluted	O
with	O
40%	O
(v/v)	O
methanol	B
contained	O
1,	O
6	O
(as	O
[_2	O
H_3	O
]1),	O
3	O
(as	O
[_2	O
H_3	O
]5)	O
and	O
5.	O

In	O
our	O
study,	O
following	O
H.	O
pylori	O
eradication,	O
the	O
down-regulation	O
of	O
S1P,	O
sphinganine	B
1-phosphate	I
and	O
phytosphingosine	B
could	O
probably	O
be	O
related	O
to	O
the	O
reduction	O
of	O
sub-clinical	O
inflammation	O
in	O
the	O
stomach	O
lining.	O

More	O
specifically,	O
beta-sitosterol	B
and	O
campesterol	B
were	O
decreased,	O
and	O
lycopene	B
and	O
beta-carotene	B
were	O
increased.	O

An	O
aliquot	O
of	O
human	O
plasma	O
(50	O
μL)	O
was	O
added,	O
and	O
the	O
PP	O
tube	O
was	O
vortexed	O
for	O
30	O
s.	O
Proteins	O
were	O
precipitated	O
by	O
addition	O
of	O
150	O
uL	O
of	O
acetonitrile	B
subsequently	O
and	O
the	O
PP	O
tube	O
was	O
vortexed	O
for	O
another	O
30	O
s.	O
Next,	O
the	O
PP	O
tube	O
was	O
centrifuged	O
at	O
35,000	O
×	O
g	O
for	O
10	O
min	O
at	O
4°C.	O

Following	O
evaporation	O
at	O
70 °C	O
for	O
40 min,	O
we	O
added	O
60 μL	O
of	O
3n	O
butanolic-HCl	B
for	O
derivatization	O
at	O
65 °C	O
for	O
18 min.	O

To	O
predict	O
which	O
metabolites	O
were	O
involved	O
in	O
the	O
progression	O
from	O
HU	O
to	O
HU+NAFLD,	O
we	O
designed	O
two	O
novel	O
indicators:	O
RV	B
represents	O
the	O
power	O
of	O
the	O
metabolites	O
to	O
reflect	O
the	O
abnormality	O
of	O
the	O
disease,	O
and	O
TI	O
reveals	O
the	O
ability	O
of	O
the	O
metabolites	O
to	O
indicate	O
the	O
progression.	O

Furthermore,	O
the	O
exogenous	O
metabolites	O
5-aminosalicylic	B
acid	I
and	O
N	B
-acetyl-5-aminosalicylic	I
acid	I
were	O
detected	O
in	O
the	O
samples	O
from	O
UC	O
patients	O
and	O
in	O
two	O
CD	O
samples,	O
and	O
originated	O
from	O
the	O
medication	O
Mesalazine	B
taken	O
by	O
all	O
of	O
the	O
UC	O
patients	O
and	O
two	O
CD	O
patients	O
(Table ).	O

Our	O
analysis	O
demonstrated	O
a	O
significant	O
increase	O
in	O
TCAIs	O
(malate,	O
citrate,	B
succinate,	B
fumarate	B
and	O
α-ketoglutarate)	B
in	O
the	O
control	O
subjects	O
in	O
response	O
to	O
exercise.	O

A	O
receiver	O
operating	O
characteristic	O
(ROC)	O
curve	O
analysis	O
indicated	O
that	O
cadaverine	B
(area	O
under	O
the	O
curve	O
(AUC),	O
0.764;	O
p	O
=	O
5.4512E-5)	O
and	O
putrescine	B
(AUC,	O
0.672;	O
p	O
=	O
0.015449)	O
were	O
significantly	O
associated	O
with	O
CRC	O
samples	O
(Figure	O
D).	O

Available	O
information	O
suggests	O
that	O
anastrozole	B
is	O
predominantly	O
cleared	O
by	O
hepatic	O
metabolism	O
via	O
oxidation	O
and	O
glucuronidation	O
in	O
humans	O
to	O
pharmacologically	O
inactive	O
metabolites	O
that	O
include	O
triazole,	B
hydroxyanastrozole	B
(free	O
and	O
glucuronide	B
conjugated)	O
as	O
well	O
as	O
anastrozole	B
N-glucuronide	O
[–].	O

Compounds	O
with	O
similar	O
core	O
structure	O
including	O
stachybogrisephenone	B
B,	O
grisephenone	B
A,	O
and	O
3,6,8-Trihydroxy-1-methylxanthine,	B
isolated	O
from	O
the	O
cultures	O
of	O
sponge-derived	O
fungus	O
Stachybotry	O
sp.	B

For	O
the	O
graphitic	O
carbon	O
cartridge,	O
the	O
polar	O
urine	O
extracts	O
were	O
loaded	O
using	O
the	O
same	O
mobile	O
phase	O
A	O
as	O
used	O
for	O
C18	O
cartridge,	O
but	O
the	O
small	O
molecules	O
were	O
eluted	O
using	O
a	O
combination	O
of	O
0.1%	O
formic	B
acid,	I
25%	O
acetonitrile,	B
25%	O
acetone	B
and	O
49.9%	O
water	O
(v/v/v/v)	O
(mobile	O
phase	O
B,	O
flow	O
rate	O
at	O
0.6	O
mL/min).	O

The	O
increase	O
in	O
serum	O
concentration	O
of	O
ketone	B
bodies	O
(like	O
acetoacetate	B
and	O
3-hydroxybutyric	B
acid)	O
used	O
as	O
an	O
alternative	O
source	O
of	O
energy	O
when	O
glucose	B
level	O
is	O
insufficient[,],	O
as	O
well	O
as	O
the	O
decrease	O
in	O
the	O
concentration	O
of	O
Krebs	O
cycle	O
intermediates	O
(such	O
as	O
citrate	B
and	O
succinate)	B
and	O
creatine	B
(that	O
serves	O
as	O
an	O
energy	O
reservoir[])	O
indicate	O
a	O
high	O
demand	O
of	O
the	O
organism	O
for	O
energy	O
and	O
rapid	O
utilization	O
of	O
metabolites[,].	O

Additionally,	O
ascorbic	B
acid	I
(HMDB00044)	O
has	O
been	O
linked	O
to	O
other	O
kinds	O
of	O
cancers.	O

Even	O
though	O
disaccharides	B
were	O
believed	O
not	O
to	O
cross	O
the	O
intestinal	O
brush	O
border	O
due	O
to	O
the	O
absence	O
of	O
an	O
active	O
transport	O
system,	O
lactose	B
has	O
previously	O
been	O
detected	O
after	O
the	O
intake	O
of	O
a	O
dairy	O
shake	O
in	O
blood	O
and,	O
more	O
recently,	O
after	O
the	O
intake	O
of	O
milk	O
and	O
even	O
yoghurt	O
[,].	O

Typical	O
LC/SRM-MS	O
chromatographic	O
profiles	O
of	O
the	O
six	O
estrogen-NMPS	O
derivatives	O
together	O
with	O
their	O
corresponding	O
six	O
internal	O
standards	O
are	O
shown	O
for	O
the	O
LLOQ	O
standard	O
of	O
0.5	O
pg/mL	O
for	O
E2,	O
16	O
α	B
-OH-E2,	I
4-MeO-E2	I
and	O
2-MeOE2,	O
and	O
5	O
pg/mL	O
for	O
4	O
and	O
2-OH-E2.	B

The	O
γ-glutamyl	O
cyclotransferase	O
(γ-GCT)	O
generates	O
pyroglutamate	B
from	O
γ-glutamylcysteine.	B

Glucose	B
intolerance	O
and	O
hyperglycemia	O
are	O
common	O
side	O
effects	O
of	O
mTOR	O
inhibitors	O
used	O
to	O
treat	O
cancer,	O
due	O
to	O
their	O
critical	O
role	O
in	O
glucose	B
homeostasis	O
[,	O
,	O
].	O

Thirteen	O
metabolites	O
including	O
Trp,	O
serotonin,	B
melatonin,	B
kynurenine,	B
kynurenic	B
acid,	I
anthranilic	B
acid,	I
tryptamine,	B
nicotinic	B
acid,	I
nicotinamide,	B
indole,	B
indole-acetic	O
acid,	O
indole-pyruvate,	O
and	O
indole-3-lactic	B
acid	I
were	O
identified.	O

Stable	O
isotope	O
products	O
for	O
each	O
metabolite;	O
ie,	O
l‐threonine	B
[13C4,	O
97%‐99%],	O
l‐methionine	B

Heat	O
map	O
of	O
Spearman	O
correlation	O
coefficients	O
between	O
AAs	O
and	O
metabolic	O
markers	O
(a),	O
relationship	O
between	O
combined	O
score	O
and	O
HOMA-IR	O
(b),	O
Scatter	O
plot	O
of	O
combined	O
score	O
(c)	O
and	O
HOMA-IR	O
(d)	O
in	O
HL,	B
OW/OB,	O
and	O
DM	O
individuals	O
from	O
cross	O
sectional	O
study.	O

For	O
phenylalanine,	B
in	O
addition	O
to	O
some	O
interfering	O
protein	O
signal,	O
the	O
different	O
results	O
can	O
be	O
explained	O
by	O
low	O
signal-to-noise	O
(S/N)	O
and	O
the	O
longer	O
T_2	O
filters	O
that	O
further	O
reduce	O
the	O
S/N.	O
Second,	O
increasing	O
the	O
length	O
of	O
the	O
T_2	O
filter	O
in	O
intact	O
plasma	O
tends	O
toward	O
the	O
values	O
from	O
the	O
CPMG	O
of	O
the	O
extracted	O
plasma.	O

The	O
function	O
of	O
this	O
protein	O
is	O
unknown	O
but	O
believed	O
to	O
serve	O
as	O
a	O
nucleation	O
site	O
for	O
hydroxyapatite	B
crystals.	O

Currently,	O
monitoring	O
of	O
these	O
patients	O
mostly	O
relies	O
on	O
the	O
measurement	O
of	O
serum	O
creatinine	B
and	O
clinical	O
evaluation.	O

Note	O
that	O
uric	B
acid	I
has	O
also	O
been	O
positively	O
associated	O
with	O
gout	O
in	O
our	O
study.	O

Taken	O
together,	O
the	O
observed	O
higher	O
GSH	B
levels	O
in	O
the	O
present	O
study	O
could	O
be	O
helpful	O
in	O
further	O
understanding	O
of	O
oxidative	O
stress	O
mechanism	O
in	O
HNSCC	O
biology.	O

Comparing	O
subjects	O
diagnosed	O
in	O
the	O
first	O
0‐6	O
years,	O
higher	O
levels	O
of	O
1,5‐AG,	B
asparagine,	B
tyrosine	B
and	O
uric	B
acid	I
showed	O
a	O
decreasing	O
trend	O
for	O
pancreatic	O
cancer	O
risk	O
(P	O
for	O
trend	O
=	O
.04,	O
.04,	O
.04	O
and	O
.02,	O
respectively),	O
even	O
after	O
adjustment	O
for	O
potential	O
confounders.	O

Other	O
mechanisms	O
include	O
decreased	O
hepatic	O
clearance	O
of	O
IgA1	O
and	O
decreased	O
activity	O
of	O
β1,	O
3-galactosyl	O
transferase	O
that	O
normally	O
adds	O
galactose	B
to	O
IgA1	O
molecule.	O

We	O
also	O
observed	O
an	O
increase	O
in	O
Cox	O
2	O
staining	O
of	O
the	O
pancreatic	O
tumor	O
tissue	O
as	O
compared	O
to	O
matched	O
normal	O
tissue	O
which	O
was	O
suggestive	O
of	O
diversion	O
of	O
arachidonic	B
acid	I
pathway	O
towards	O
the	O
production	O
of	O
pro-inflammatory	O
mediators	O
known	O
to	O
be	O
associated	O
with	O
malignant	O
progression.	O

Lipoprotein	O
profiles,	O
inflammatory	O
markers,	O
albumin	O
and	O
creatinine	B
levels	O
were	O
determined	O
at	O
the	O
Clinical	O
Chemistry	O
Laboratory,	O
Lund	O
University.	O

The	O
elution	O
from	O
the	O
column	O
was	O
introduced	O
to	O
Quadrupole	O
Time	O
of	O
flight	O
Mass	O
spectrometer	O
(Waters	O
G2-	O
Qtof)	O
by	O
electrospray	O
Ionization	O
in	O
both	O
positive	O
and	O
negative	O
mode	O
at	O
a	O
capillary	O
voltage	O
of	O
3.5	O
kV	B
and	O
sampling	O
cone	O
voltage	O
of	O
35	O
V.	O

To	O
0.5	O
mL	O
of	O
[_13	B
C_3	I
]glycerol	I
in	O
a	O
25	O
mL	O
2-neck	O
flask	O
was	O
added	O
100	O
mg	O
NaHSO_4	O
.	O

These	O
metabolic	O
characteristics	O
are	O
exacerbated	O
in	O
women	O
with	O
PCOS	O
and	O
abdominal	O
obesity	O
(WC⩾0.98)	O
suggesting	O
an	O
interaction	O
between	O
testosterone	B
and	O
abdominal	O
obesity	O
that	O
putatively	O
affect	O
metabolic	O
risk	O
factors	O
of	O
cardiovascular	O
disease.	O

Quality	O
control	O
samples	O
(QCs)	O
were	O
prepared	O
in	O
10-fold	O
diluted	O
human	O
urine	O
at	O
three	O
concentration	O
levels—15	O
(low),	O
150	O
(medium)	O
and	O
400	O
(high)	O
µM	O
for	O
each	O
of	O
19	O
amino	O
acids	O
except	O
from	O
7.5	O
(low),	O
75	O
(medium)	O
and	O
200	O
(high)	O
µM	O
for	O
cysteine.	B

During	O
periods	O
of	O
oxidative	O
stress,	O
mitochondria	O
become	O
less	O
capable	O
in	O
converting	O
ADP	B
to	O
ATP.	B

Taken	O
together,	O
these	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
indicate	O
that	O
ceramide	B
increases	O
apoptosis	O
in	O
a	O
dose	O
dependent	O
manner,	O
regardless	O
of	O
the	O
cancer	O
cell	O
origin.	O

The	O
supernatant	O
and	O
methanol	B
was	O
mixed	O
for	O
10	O
min.	O

Total	O
cholesterol,	B
HDL,	O
and	O
triglycerides	B
were	O
measured	O
using	O
diagnostic	O
kits	O
from	O
Roche	O
(Germany).	O

Serum	O
creatinine	B
levels	O
were	O
analyzed	O
with	O
nuclear	O
magnetic	O
resonance	O
metabolomics	O
platform,	O
equipped	O
with	O
Bruker	O
AVANCE	O
III	O
500 MHz	O
and	O
Bruker	O
AVANCE	O
III	O
600 MHz	O
spectrometers	O
(Bruker,	O
Billerica,	O
MA,	O
USA).	O

Phenylalanine	B
levels	O
were	O
also	O
found	O
associated	O
in	O
ARDS	O
caused	O
by	O
H1N1	O
pneumonia	O
by	O
virtue	O
of	O
resultant	O
viral	O
and	O
bacterial	O
infections.	O

The	O
loss	O
of	O
motility	O
and	O
penetration	O
of	O
propidium	O
iodide	B
into	O
boar	O
spermatozoa	O
were	O
detected	O
as	O
early	O
as	O
5	O
min	O
after	O
exposure.	O

The	O
GSH	B
conjugates	O
of	O
estrogen	B
quinones	I
are	O
further	O
converted	O
to	O
cysteine	B
and	O
N-acetyl-cysteine	B
via	O
the	O
mercapturic	B
acid	I
biosynthesis	O
pathway	O
.	O

MS/MS	O
analysis	O
on	O
features	O
810.597	O
at	O
RT	O
25.11	O
(peak	O
#3)	O
and	O
RT	O
25.58	O
(peak	O
#4)	O
identified	O
two	O
PC(18:0_20:4)	B
with	O
a	O
similar	O
MS/MS	O
signal	O
intensity	O
pattern	O
for	O
the	O
two	O
fragments	O
corresponding	O
to	O
their	O
fatty	O
acyl	O
side	O
chain:	O
higher	O
at	O
m/z	O
303.23	O
for	O
C20:4,	B
most	O
likely	O
on	O
sn-2	O
position,	O
and	O
lower	O
at	O
m/z	O
283.26	O
for	O
C18:0.	B

P	O
values	O
were	O
generated	O
evaluating	O
each	O
vitamin	B
D	I
metabolite	O
as	O
a	O
continuous	O
variable.	O

Additionally	O
palmitoylcarnitine	B
increases	O
with	O
apoptosis	O
consistent	O
with	O
our	O
observed	O
effect.	O

shows	O
forest	O
plots	O
of	O
hazard	O
ratios	O
for	O
breast	O
cancer	O
by	O
quintiles	O
of	O
unconjugated	O
estradiol,	B
total	O
estrogens,	O
and	O
estrogen	B
metabolites,	O
and	O
the	O
three	O
measures	O
that	O
showed	O
evidence	O
of	O
estradiol-independent	O
associations	O
with	O
the	O
risk	O
of	O
breast	O
cancer	O
(ie,	O
the	O
ratio	O
of	O
the	O
2-hydroxylation	O
pathway	O
to	O
parent	O
estrogens,	O
the	O
ratio	O
of	O
the	O
2-hydroxylation	O
pathway	O
to	O
the	O
16-hydroxylation	O
pathway,	O
and	O
the	O
ratio	O
of	O
4-hydroxylation	O
pathway	O
catechols	B
to	O
4-hydroxylation	O
pathway	O
methylated	B
catechols).	I

Similar	O
to	O
the	O
NPC1	O
patients,	O
the	O
key	O
variables	O
responsible	O
for	O
discrimination	O
between	O
HET	O
and	O
HC	O
samples	O
are	O
dominated	O
by	O
lipoprotein-associated	O
triacylglycerol	B
resonances	O
(Fig.	O

We	O
showed	O
that,	O
even	O
in	O
a	O
young	O
healthy	O
population,	O
PLP	O
has	O
significant	O
negative	O
correlations	O
with	O
neopterin	B
and	O
CRP.	O

Statins,	B
widely	O
prescribed	O
drugs	O
for	O
treatment	O
of	O
cardiovascular	O
disease,	O
inhibit	O
the	O
biosynthesis	O
of	O
low	O
density	O
lipoprotein	O
cholesterol	B
(LDL-C).	O

Briefly,	O
this	O
study	O
was	O
designed	O
to	O
examine	O
genetic	O
and	O
non-genetic	O
factors	O
affecting	O
the	O
response	O
to	O
simvastatin	B
therapy	O
in	O
healthy,	O
drug-naïve	O
patients	O
.	O

Similarly,	O
in	O
negative	O
MS	O
mode,	O
100%	O
of	O
the	O
lipids	O
identified	O
in	O
FFA,	O
CerP,	O
LPE,	O
S4E,	O
PA,	O
PC,	O
PG,	B
PI,	O
pPE,	O
and	O
PS	O
lipid	O
classes	O
of	O
the	O
samples	O
prepared	O
by	O
the	O
UC	O
method	O
are	O
also	O
detected	O
in	O
samples	O
prepared	O
by	O
the	O
SP-AF4	O
method	O
in	O
both	O
the	O
LDL	O
and	O
HDL	O
fractions.	O

First,	O
the	O
infusion	O
protocol	O
yielded	O
low	O
oxalate	B
enrichments	O
in	O
this	O
group,	O
making	O
enrichment	O
measurements	O
subject	O
to	O
imprecisions	O
inherent	O
in	O
the	O
method.	O

A	O
positive	O
correlation	O
of	O
factor	O
1	O
with	O
plasma	O
total-C	O
and	O
TG	B
levels	O
was	O
observed	O
in	O
each	O
group.	O

Stubbs	O
et	O
al	O
.	O
showed	O
CKD	O
patients’	O
altered	O
ability	O
to	O
increase	O
serum	O
24,25(OH)_2	B
D_3	O
after	O
vitamin	O
D_3	O
therapy,	O
suggesting	O
decreased	O
24-hydroxylase	O
activity.	O

The	O
enrichment	O
kinetics	O
of	O
lactate	B
and	O
alanine	B
were	O
very	O
similar,	O
suggesting	O
a	O
close	O
metabolic	O
coupling	O
of	O
these	O
metabolites.	O

We	O
compared	O
the	O
pattern	O
of	O
ganglioside	B
classes	O
and	O
ceramide	B
molecular	O
species	O
of	O
this	O
tissue	O
with	O
other	O
ocular	O
structures	O
and	O
with	O
brain	O
and	O
plasma	O
in	O
elderly	O
human	O
individuals.	O

Aliquots	O
of	O
chloroform	B
extracts	O
were	O
analyzed	O
directly	O
by	O
electrospray	O
as	O
described	O
in	O
method	O
section.	O

Arginine	B
is	O
one	O
of	O
the	O
most	O
versatile	O
amino	O
acids	O
in	O
animal	O
cells,	O
serving	O
as	O
a	O
precursor	O
for	O
the	O
synthesis	O
not	O
only	O
of	O
proteins	O
but	O
also	O
of	O
nitric	B
oxide,	I
urea,	B
polyamines,	B
proline,	B
glutamate,	B
creatine	B
and	O
agmatine.	B

Creatinine	B
was	O
measured	O
using	O
the	O
Vitros	O
CREA	O
Slide	O
(Ortho-Clinical	O
Diagnostics,	O
Inc.)	O
method.	O

Box-whisker	O
plots	O
of	O
the	O
concentrations	O
of	O
(A)	O
4-heptanone,	B
(B)	O
2-methylpyrazine,	B
(C)	O
2-methylbutanal,	B
(D)	O
2,6-dimethyl-7-octen-2-ol	B
and	O
(E)	O
decanoic	B
acid.	I

Although	O
levels	O
of	O
trimethylamine	B
N-oxide	I
were	O
higher	O
in	O
ulcerative	O
colitis	O
patients,	O
they	O
did	O
not	O
achieve	O
statistical	O
significance	O
in	O
active	O
ulcerative	O
colitis	O
and	O
inactive	O
ulcerative	O
colitis	O
groups.	O

With	O
regards	O
to	O
LMW	O
metabolites,	O
maternal	O
plasma	O
concentrations	O
of	O
alanine,	B
citrate,	B
2-oxoisovaleric	B
acid	I
and	O
pyruvate	B
were	O
significantly	O
lower	O
in	O
mothers	O
of	O
small	O
fetuses	O
compared	O
to	O
controls	O
(all	O
p	O
values < 0.05)	O

In	O
NMR	O
analyses,	O
VLDL/LDL	O
fatty	O
acyl	O
groups,	O
lactate,	B
glutamine,	B
and	O
37	O
lipoprotein	O
subclasses	O
(mainly	O
from	O
the	O
HDL	O
fractions)	O
were	O
higher	O
in	O
serum	O
than	O
plasma	O
while	O
glucose	B
and	O
some	O
VLDL,	O
LDL,	O
and	O
IDL	O
subclasses	O
were	O
lower.	O

Multiple	O
hypothesis	O
correction	O
was	O
performed	O
using	O
standard	O
false	O
discovery	O
rate	O
(FDR),	O
and	O
oxylipins	B
were	O
statistically	O
associated	O
with	O
common	O
clinical	O
features	O
linked	O
to	O
systemic	O
inflammation,	O
including	O
advancing	O
age,	O
obesity	O
(measured	O
by	O
body	O
mass	O
index	O
[BMI]),	O
and	O
circulating	O
high	O
sensitivity	O
C-reactive	O
protein	O
(CRP)	O
levels,	O
a	O
well-established	O
marker	O
of	O
systemic	O
inflammation	O
(;	O
).	O

Acetonitrile	B
(ACN)	O
and	O
methanol	B
were	O
purchased	O
from	O
Thermo	O
Fisher	O
Scientific,	O
USA.	O

ADMA	B
has	O
been	O
shown	O
to	O
attenuate	O
starvation-induced	O
apoptosis	O
in	O
vitro,	O
and	O
is	O
therefore	O
suggested	O
to	O
contribute	O
to	O
blocking	O
apoptosis	O
in	O
response	O
to	O
chemotherapy.	O

That	O
negative	O
relationship	O
may	O
be	O
relevant	O
to	O
PAFs	O
as	O
membrane	O
phospholipids	B
such	O
as	O
PC(O	B
-36:4)	I
may	O
be	O
cleaved	O
to	O
produce	O
PAFs	O
and	O
arachidonic	B
acid	I
(20:4)	O
during	O
periods	O
of	O
increased	O
inflammation,	O
leading	O
to	O
reduced	O
circulating	O
concentrations	O
of	O
the	O
precursor	O
lipid.	O

Plasma	O
samples	O
were	O
thawed	O
on	O
ice	O
and	O
extracted	O
using	O
a	O
dual	O
methanol-chloroform	B
extraction	O
(for	O
protein	O
precipitation	O
and	O
separation	O
of	O
hydrophilic	B
and	O
lipophilic	O
fractions)	O
as	O
previously	O
described.	O

Standards	O
of	O
3-indoleacetonitrile	O
(Kioto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes	O
(KEGG)	O
number	O
C02938),	O
quinolinic	B
acid	I
(C03722),	O
aminophenol	B
(C01987),	O
3-hydroxykynurenine	B
(C03227),	O
p-tyrosine	B
(C0082),	O
m-tyrosine	B
(HMDB59720),	O
o-tyrosine	B
(HMDB06050),	O
serotonin	B
(C00780),	O
5-hydroxytryptophan	B
(C00643),	O
L-kynurenine	B
(C00328),	O
phenylalanine	B
(C00079),	O
hydroxyanthranillic	B
acid	I
(C00632),	O
tryptophan	B
(C00078),	O
xanthurenic	B
acid	I
(C02470),	O
tryptamine	B
(C00398),	O
kynurenic	B
acid	I
(C01717),	O
N-acetylserotonin	B
(C00978),	O
phenylacetylglutamine	B
(PAGN)	O
(C04148),	O
indole-3-acetamide	B
(C02693),	O
anthranillic	B
acid	I
(C00108),	O
melatonin	B
(C01598),	O
3-indoleacetic	B
acid	I
(KEGG	O
C00954),	O
tryptophol	B
(00955),	O
indolelactic	B
acid	I
(C02043)	O
were	O
obtained	O
from	O
Sigma	O
Aldrich	O
Quimica.	O

Bile	O
acids	O
serve	O
many	O
important	O
physiological	O
functions,	O
including	O
cholesterol	B
homeostasis,	O
lipid	O
absorption	O
and	O
generation	O
of	O
bile	O
flow,	O
that	O
help	O
in	O
the	O
excretion	O
and	O
recirculation	O
of	O
drugs,	O
vitamins	O
and	O
endogenous	O
and	O
exogenous	O
toxins.	B

On	O
the	O
basis	O
of	O
the	O
values	O
of	O
VIPs,	O
p(corr),	O
p	O
and	O
q,	O
the	O
metabolites	O
that	O
predominantly	O
contributed	O
to	O
the	O
separation	O
of	O
the	O
FSGS	O
from	O
the	O
IgAN	O
group	O
were	O
higher	O
levels	O
of	O
TMAO	B
and	O
Tau,	O
and	O
lower	O
levels	O
of	O
NMN	O
and	O
3-HB,	O
(,).	O

In	O
one	O
recent	O
study,	O
we	O
found	O
that	O
when	O
cigarette	O
smokers	O
stopped	O
smoking	O
for	O
12	O
weeks,	O
their	O
levels	O
of	O
8-iso	O
-PGF_2α	O
decreased	O
significantly	O
but	O
modestly	O
(27%	O
reduction)	O
from	O
1.05	O
pmol/mg	O
creatinine	B
to	O
0.73	O
pmol/mg	O
creatinine.	B

Lithocholyltaurine	B
and	O
7-alpha-hydroxy-3-oxochol-4-en-24-oic	B
acid	I
are	O
bile	O
acid	O
conjugation	O
molecules.	O

The	O
group	O
that	O
was	O
prescribed	O
statins	B
(n	O
 = 18)	O
displayed	O
significantly	O
lower	O
anxiety	O
(total	O
BAI	O
score	O
mean	O
of	O
4.5	O
vs.	O
12.4;	O
P	O
 = 0.003)	O
and	O
also	O
better	O
cognitive	O
functioning	O
(mean	O
of	O
91	O
vs.	O
76;	O
P =	O
 0.02).	O

This	O
higher	O
level	O
was	O
assigned	O
to	O
an	O
increased	O
gluconeogenesis	O
in	O
normal	O
cells	O
to	O
overcome	O
the	O
higher	O
glucose	B
uptake	O
by	O
malignant	O
tissue.	O

Glutamic	B
acid	I
positively	O
correlated	O
to	O
glucose,	B
insulin	O
and	O
HOMA-IR	O
with	O
q	O
<	O
0.2.	O

In	O
brief,	O
GSH	B
(20 mM)	O
was	O
reacted	O
with	O
20 mM	O
NaHS	O
in	O
the	O
presence	O
of	O
I_2	O
(20 mM)	O
in	O
20 mM	O
Tris-HCl	O
buffer	O
(pH	O
7.4)	O
at	O
room	O
temperature	O
for	O
15 min.	O

In	O
addition,	O
the	O
concentration	O
of	O
homocysteine,	B
γ-glutamylcysteine	B
and	O
pantetheine	O
enhanced	O
more	O
than	O
two	O
folds	O
in	O
cancer	O
patients	O
compared	O
to	O
healthy	O
controls.	O

The	O
reported	O
linearity	O
of	O
this	O
LC-MS	O
/MS	O
method	O
is	O
250ng/mL	O
for	O
Tamoxifen	B
and	O
endoxifen,	B
500ng/mL	O
for	O
ND-tamoxifen	B
and	O
6ng/mL	O
for	O
4	O
hydroxy	B
–tamoxifen.	I

The	O
specimens	O
were	O
histologically	O
stained	O
after	O
imaging	O
using	O
hematoxylin	B
and	O
eosin	B
(H&E)	O
procedure	O
for	O
unfixed	O
tissue.	O

These	O
included	O
steroid	O
lipids,	O
diacylglycerol,	B
free	O
fatty	O
acids,	O
glucose,	B
glycine	B
derivative,	O
and	O
some	O
glycophospholipids.	B

Log-transformed	O
urinary	O
myo-inositol	B
significantly	O
increased	O
as	O
eGFR	O
decreased	O

Then,	O
the	O
samples	O
were	O
extracted	O
three	O
times	O
by	O
2.5	O
mL	O
ethyl	B
acetate	I
(VWR	O
Chemicals,	O
Stribrna	O
Skalice,	O
Czech	O
Republic).	O

The	O
injected	O
sample	O
volume	O
was	O
1	O
μ	O
L.	O
Data	O
acquisition	O
and	O
processing	O
were	O
performed	O
with	O
the	O
acquisition	O
software	O
Analyst	O
TF	O
(version	O
1.7.1,	O
AB	O
SCIEX,	O
USA),	O
which	O
could	O
acquire	O
high	O
resolution	O
MS	O
and	O
tandem-MS	O
data	O
simultaneously	O
by	O
TOF	O
MS	O
full	O
scan	O
and	O
information-dependent	O
acquisition	O
(IDA)	O
in	O
both	O
ESI(+)	B
and	O
ESI(−)	O
modes.	O

For	O
quality	O
assurance,	O
4	O
different	O
quality-control	O
samples	O
with	O
TMAO	B
concentrations	O
ranging	O
between	O
4	O
and	O
400	O
μg/L	O
were	O
used	O
for	O
the	O
evaluation	O
of	O
accuracy	O
and	O
precision.	O

Twenty	O
patients	O
were	O
not	O
on	O
any	O
statin	B
and	O
were	O
used	O
as	O
a	O
control	O
group	O
for	O
the	O
pharmacodynamic	O
parameters.	O

ATP	B
is	O
mainly	O
produced	O
through	O
metabolism	O
of	O
glucose	B
under	O
normoxia	O
condition,	O
which	O
is	O
composed	O
of	O
three	O
relay	O
pathways:	O
citric	B
acid	I
cycle	O
(TCA	O
cycle,	O
Krebs	O
cycle),	O
oxygen-independent	O
pathway	O
of	O
glucose	B
to	O
pyruvate	B
in	O
cytoplasm	O
and	O
oxygen-dependent	O
electron	O
transfer	O
chain,	O
respectively.	O

Consistent	O
with	O
a	O
previous	O
report,	O
as	O
choline	B
demand	O
increases	O
in	O
tumor	O
tissues,	O
blood	O
choline	B
levels	O
drop,	O
leading	O
to	O
decreased	O
urinary	O
choline	B
in	O
CRC	O
patients.	O

The	O
synthetic	O
product	O
was	O
obtained	O
by	O
the	O
acylase	O
catalyzed	O
deacetylation	O
of	O
the	O
reaction	O
product	O
of	O
N	O
_α	B
-acetyl-l-lysine	I
with	O
AFB-dibromo	B
and	O
characterized	O
by	O
UV,	O
fluorescence,	O
_1	O
H	O
NMR,	O
_13	O
C	O
NMR,	O
and	O
fast	O
atom	O
bombardment	O
mass	O
spectrometry.	O

Alkanes,	O
methylated	O
alkanes,	O
alcohols,	O
aldehydes,	O
ketones,	B
pentanes	O
or	O
olefins	O
have	O
also	O
been	O
identified	O
as	O
breast	O
cancer	O
markers.	O

Other	O
measurements	O
included	O
height	O
and	O
weight	O
to	O
calculate	O
body	O
mass	O
index	O
(BMI),	O
blood	O
pressure,	O
and	O
routine	O
blood	O
tests	O
conducted	O
in	O
the	O
check-up,	O
including	O
serum	O
triglyceride,	B
cholesterols,	B
hemoglobin	O
A1c,	O
and	O
plasma	O
glucose.	B

L-2-chlorophenylalanine	B
was	O
used	O
as	O
an	O
internal	O
quality	O
standard.	O

 ,	O
two	O
NMR	O
signals	O
for	O
total	O
cholesterol	B
correlated	O
strongly	O
with	O
each	O
other,	O
and	O
showed	O
a	O
strong	O
positive	O
correlation	O
with	O
serum	O
concentration	O
of	O
cholesterol	B
determined	O
using	O
routine	O
laboratory	O
method.	O

No	O
significant	O
interaction	O
between	O
group:time	O
was	O
identified	O
for	O
ascorbic	B
acid.	I

As	O
regards	O
the	O
tricarboxylic	B
acid	I
pathway	O
metabolites,	O
we	O
observed	O
an	O
increase	O
in	O
several	O
intermediate	O
metabolites,	O
such	O
as	O
fumarate	B
and	O
malate	B
in	O
both	O
tumor	O
subtypes,	O
and	O
oxalacetate	B
in	O
SCC.	O

During	O
this	O
process,	O
carnitine	B
is	O
esterified	O
to	O
form	O
acylcarnitine	B
derivatives	O
catalyzed	O
by	O
acetyl-CoA.	B

The	O
need	O
of	O
glutamate	B
in	O
the	O
synthesis	O
of	O
GSH	B
and	O
macromolecules	O
such	O
as	O
lipids	O
and	O
polynucleotides,	O
may	O
explain	O
the	O
lower	O
levels	O
of	O
glutamate	B
in	O
the	O
plasma	O
of	O
cancer	O
patients	O
compared	O
to	O
patients	O
with	O
lung	O
inflammation.	O

With	O
the	O
exception	O
of	O
2-MeOE_1	O
,	O
concentrations	O
of	O
the	O
methoxy	B
estrogens	O
tended	O
to	O
be	O
very	O
low	O
for	O
all	O
groups,	O
comprising	O
less	O
than	O
10%	O
of	O
total	O
urinary	O
EM.	O

The	O
spray	O
voltage	O
was	O
5	O
kV.	B

Data	O
analyses	O
were	O
performed	O
using	O
Stata	O
V.14	O
(StatCorp	O
LP,	B
USA).	O

These	O
phosphate	B
metabolites	O
are	O
involved	O
in	O
malignant	O
transformation,	O
tumor	O
biology,	O
and	O
cell	O
destruction	O
through	O
apoptotic	O
mechanisms	O
[,].	O
_31	O
P	O
MRS	O
studies	O
have	O
shown	O
increased	O
levels	O
of	O
PME	O
and	O
PDE	O
resonance	O
that	O
are	O
metabolic	O
characteristics	O
of	O
breast	O
cancer.	O

The	O
identified	O
differences	O
in	O
serum	O
glucose	B
concentration	O
between	O
ACE	O
genotypes	O
after	O
the	O
lab	O
test	O
were	O
remarkably	O
well	O
confirmed	O
by	O
the	O
pronounced	O
rise	O
in	O
serum	O
glucose	B
after	O
the	O
field	O
test.	O

Take	O
100	O
μL	O
of	O
plasma	O
sample	O
and	O
add	O
600	O
μL	O
of	O
methanol	B
(containing	O
1	O
mM	O
butylhydroxytoluene)	B
was	O
for	O
5	O
min	O
ultrasonic	O
processing.	O

The	O
increased	O
levels	O
of	O
the	O
glycerophospholipid	B
PC-O	O
(34:0)	O
in	O
SPMS	O
patients	O
has	O
to	O
our	O
knowledge	O
not	O
been	O
demonstrated	O
previously,	O
but	O
altered	O
levels	O
of	O
lipid	O
composition	O
in	O
multiple	O
sclerosis	O
patients	O
has	O
recently	O
been	O
found	O
in	O
other	O
cohorts	O
of	O
patients	O
also	O
(Nogueras	O
et	O
al.	O

As	O
hypothesized,	O
we	O
observed	O
positive	O
associations	O
between	O
the	O
serum	O
levels	O
of	O
estrogens	O
(E1	O
and	O
E2)	O
and	O
tamoxifen,	B
as	O
well	O
as	O
two	O
of	O
its'	O
non-hydroxylated	O
metabolites	O
(NDDtam	O
and	O
tamNox).	O

Simvastatin	B
has	O
been	O
shown	O
previously	O
to	O
reduce	O
alpha-tocopherol	B
levels	O
in	O
plasma	O
following	O
both	O
short-term	O
and	O
long-term	O
exposure	O
.	O

The	O
addition	O
of	O
tryptophan	B
provided	O
complementary	O
value	O
to	O
the	O
existing	O
amino	O
acid	O
predictors.	O

The	O
main	O
models	O
for	O
those	O
metabolites	O
that	O
were	O
associated	O
with	O
25(OH)D	O
at	O
P	O
 < 1	O
.20 x 10_−4	O
were	O
re-examined	O
using	O
vitamin	B
D	I
quartiles.	O

This	O
is	O
consistent	O
with	O
high	O
activity	O
of	O
both	O
biosynthetic	O
(choline	O
kinase)	O
and	O
catabolic	O
(phosphatidylcholine-PLC/PLD)	O
enzymes	O
observed	O
in	O
ovarian	O
carcinoma	O
contributing	O
to	O
the	O
observed	O
choline-containing	O
compounds	O
accumulation	O
in	O
CRC	O
tumor.	O

The	O
bias	O
of	O
the	O
calibration	O
was	O
tested	O
against	O
certified	O
reference	O
material	O
for	O
E1	O
and	O
17βE2;	B
Bias,	O
(Average	O
Interday	O
concentration	O
–	O
reference	O
material	O
concentration).	O

There	O
was	O
a	O
non-significant	O
tendency	O
towards	O
lower	O
proinsulin	O
concentrations	O
and	O
increased	O
proinsulin	O
to	O
insulin	O
ratio	O
in	O
the	O
TCF7L2	O
risk	O
group	O
after	O
intravenous	O
glucose	B
injection.	O

Serum	O
levels	O
of	O
total	O
bilirubin	B
(TBIL),	O
alkaline	O
phosphatase	O
(ALP),	O
total	O
bile	O
acid	O
(TBA),	O
prothrombin	O
time	O
(PT),	O
international	O
normalized	O
ratio	O
(INR),	O
carcino	O
embryonie	O
antigen	O
(CEA)	O
and	O
model	O
for	O
end-stage	O
liver	O
disease	O
(MELD)	O
Score	O
were	O
lower	O
in	O
CHB	O
group	O
than	O
HBV-associated	O
cirrhosis	O
and	O
HBV-associated	O
HCC	O
groups,	O
while	O
levels	O
of	O
total	O
protein	O
(TP),	O
albumin	O
(ALB),	O
lactate	O
dehydrogenase	O
(LDH),	O
choline	B
esterase	O
(CHE),	O
cholesterol	B
(TC),	O
triglyceride	B
(TG),	O
red	O
blood	O
cell	O
(RBC),	O
platelet	O
(PLT)	O
were	O
higher	O
for	O
CHB	O
relative	O
to	O
HBV-associated	O
cirrhosis	O
and	O
HBV-associated	O
HCC	O
groups.	O

The	O
model	O
was	O
adjusted	O
for	O
age,	O
sex,	O
BMI,	O
T2DM,	O
NT-proBNP,	O
GFR,	O
MAP	O
and	O
LDL-cholesterol.	B

Metabolic	O
pathway	O
analysis	O
revealed	O
alteration	O
in	O
multiple	O
pathways	O
including	O
glycolysis,	O
pyruvate,	B
propanoate,	B
glycerophospholipid,	B
galactose,	B
fatty	O
acid,	O
starch	O
and	O
sucrose	B
metabolism	O
along	O
with	O
fatty	O
acid	O
elongation	O
in	O
mitochondria,	O
glycerolipid,	B
glyoxylate	B
and	O
dicarboxylate	B
metabolism	O
pointing	O
towards	O
the	O
shift	O
of	O
metabolism	O
in	O
β-thalassemia	O
patients	O
in	O
comparison	O
to	O
healthy	O
individuals.	O

The	O
concentrations	O
of	O
the	O
saturates	O
C14:0,	B
C16:0,	B
and	O
C18:0	B
remained	O
steady,	O
while	O
the	O
mono-	O
and	O
polyunsaturates	O
fell	O
significantly.	O

CD4_+	O
and	O
CD8_+	O
T-cell	O
frequencies	O
and	O
phenotype	O
in	O
cannabis	B
users	O
and	O
nonusers.	O

Decreased	O
levels	O
of	O
creatine	B
and	O
lactate	B
were	O
shown	O
in	O
long-term	O
survival	O
patients	O
too.	O

The	O
possible	O
causes	O
were	O
as	O
follows:	O
first,	O
dietary	O
deficiency	O
may	O
affect	O
the	O
intake	O
of	O
choline	B
because	O
of	O
the	O
damage	O
of	O
the	O
stomach.	O

The	O
same	O
11	O
markers	O
were	O
top	O
ranked	O
by	O
logistic	O
regression,	O
with	O
the	O
exception	O
of	O
nonanedioic	B
acid,	I
which	O
was	O
ranked	O
13_th	O
overall.	O

Twenty	O
cirrhotics	O
with	O
MHE	O
underwent	O
cognitive	O
testing,	O
endotoxin	B
analysis,	O
urine/serum	O
metabolomics	O
(GC	O
and	O
LC-MS)	O
and	O
fecal	O
microbiome	O
assessment	O
(multi-tagged	O
pyrosequencing)	O
at	O
baseline	O
and	O
8	O
weeks	O
post-rifaximin	O
550	O
mg	O
BID.	O

Association	O
of	O
TMAO	B
(µmol/L)	O
with	O
CV	O
death.	O
_a	O
Log-transformed	O
variable.	O

Three	O
of	O
these	O
genera	O
consume	O
partly	O
reduced	O
fermentation	O
products	O
(e.g.	O
lactate)	B
and	O
reduce	O
sulfate	B
to	O
sulfide,	B
whilst	O
the	O
other	O
two	O
are	O
hydrogen	O
consuming	O
[,	O
].	O

A	O
second	O
aliquot	O
of	O
the	O
original	O
serum	O
samples,	O
not	O
previously	O
thawed,	O
were	O
assayed	O
by	O
another	O
LC-MS/MS	O
method	O
at	O
the	O
Mayo	O
Medical	O
Laboratories	O
(Rochester,	O
MN),	O
and	O
the	O
obtained	O
results	O
showed	O
concordance	O
for	O
tamoxifen,	B
endoxifen,	B
and	O
ND-tamoxifen,	B
but	O
less	O
concordance	O
for	O
4-OH-tamoxifen.	B

Plasma	O
levels	O
of	O
threonine	B
(p<0.0060,	O
q<0.055),	O
alanine	B
(p<0.010,	O
q<0.069),	O
and	O
phenylalanine	B
(p<0.011,	O
q<0.069),	O
were	O
increased	O
following	O
simvastatin	B
treatment.	O

Specifically,	O
glycolytic	B
and	O
nucleotide	O
metabolite	O
pools	O
were	O
significantly	O
decreased.	O

For	O
example,	O
the	O
separation	O
of	O
the	O
control	O
and	O
UTI	O
groups	O
was	O
seen	O
in	O
the	O
first	O
two	O
principal	O
components	O
of	O
PCA;	O
however,	O
this	O
discrimination	O
was	O
not	O
disease-related,	O
but	O
the	O
result	O
of	O
patients	O
taking	O
the	O
antipyretic	O
and	O
analgesic	O
drug	O
paracetamol.	B

Regarding	O
the	O
positive	O
correlation	O
between	O
citric	B
acid	I
and	O
erythronic	B
acid	I
in	O
HCV	O
urine	O
(d),	O
the	O
literature	O
gives	O
little	O
guidance	O
on	O
this,	O
except	O
that	O
both	O
were	O
uncorrelated	O
in	O
the	O
plasma	O
of	O
patients	O
with	O
acute	O
ischemic	O
stroke	O
and	O
that	O
urinary	O
erythronic	B
acid	I
was	O
massively	O
elevated	O
in	O
the	O
transaldolase	O
deficiency	O
of	O
the	O
PPP.	O

Increased	O
dietary	O
folate	B
intake	O
has	O
been	O
strongly	O
linked	O
with	O
a	O
decrease	O
in	O
CRC	O
risk.	O

LMI	O
was	O
positively	O
associated	O
with	O
Sphingosine-1	B
phosphate.	I

Recent	O
evidence	O
suggests	O
that	O
obesity	O
is	O
associated	O
with	O
altered	O
adipose	O
tissue	O
metabolism,	O
which	O
in	O
turn	O
affects	O
systemic	O
glucose	B
homeostasis	O
and	O
induces	O
insulin	O
resistance	O
in	O
skeletal	O
muscle_,	O
.	O

m	O
m	O
m	O
m	O
m	O
m	O
Correlation	O
between	O
formation	O
rate	O
of	O
hydroxyanastrozole	B
and	O
individual	O
P450-isoform	O
contents	O
in	O
a	O
panel	O
of	O
HLMs	O
m	O
m	O
T,	O
testosterone	O
6β-hydroxylation;	O
M,	O
midazolam	O
1′-hydroxylation.	O

This	O
is	O
often	O
referred	O
to	O
as	O
having	O
approximately	O
“50%	O
cross	O
reactivity”	O
with	O
hydrocodone	B
or	O
hydromorphone.	B

The	O
relative	O
levels	O
of	O
2	O
and	O
3	O
depended	O
on	O
the	O
individuals	O
in	O
this	O
group	O
with	O
sulfide	B
2	O
was	O
greater	O
than	O
sulfoxide	B
3	O
in	O
some	O
individuals	O
and	O
3	O
was	O
more	O
abundant	O
than	O
2	O
in	O
others.	O

Eicosanoids	B
consist	O
of	O
leukotrienes,	O
prostaglandins	B
and	O
thromboxanes	B
and	O
are	O
derived	O
from	O
arachidonic	B
acid	I
or	O
linoleate.	B

In	O
addition,	O
there	O
was	O
a	O
mixed	O
group	O
of	O
18	O
patients	O
with	O
a	O
variety	O
of	O
diagnoses:	O
benign	O
myelolipoma	O
(n	O
 = 4),	O
metastasis	O
from	O
an	O
extra-adrenal	O
primary	O
tumor	O
(n	O
 = 4),	O
adrenal	O
hyperplasia	O
(n	O
 = 2),	O
multinodular	O
hyperplasia	O
(n	O
 = 2),	O
cavernous	O
lymphangioma	O
(n	O
 = 1),	O
ganglioneuroma	B
(n	O
 = 1),	O
hemangioma	O
(n	O
 = 1),	O
cyst	O
(n	O
 = 1),	O
non-Hodgkin	O
lymphoma	O
(n	O
 = 1)	O
and	O
leiomyosarcoma	O
(n	O
 = 1).	O

We	O
did	O
not	O
conduct	O
the	O
analyte	O
long-term	O
storage	O
stability	O
(−	O
80	O
°C)	O
in	O
the	O
methanol	B
working	O
solution.	O

Serum	O
metabolite	O
clusters	O
increased	O
in	O
patients	O
who	O
were	O
hospitalized	O
were	O
pyridines	B
and	O
pyrimidines,	B
sugar	O
acids,	O
sugar	O
alcohols,	O
amino	O
acids	O
and	O
sulfur	O
amino	O
acids,	O
phenylacetates,	B
disaccharides,	B
monosaccharides,	B
hexoses,	O
uronic	O
acid	O
and	O
glutarates.	B

[]	O
8-iso	B
-PGF_2α	I
and	O
8-iso	B
-PGF_2α	I

First,	O
the	O
ratios	O
of	O
glucuronate	B
to	O
choline,	B
hippuric	B
acid	I
and	O
niacinamide	B
were	O
up	O
to	O
26-fold	O
lower	O
in	O
the	O
pre-prostatectomy	O
samples	O
than	O
in	O
the	O
other	O
groups	O
separately	O
or	O
combined	O
(all	O
p	O
<	O
0.05).	O

These	O
changes	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
the	O
2-OHE_1	O
/16α-OHE_1	B
ratio.	O

Samples	O
were	O
derivatized	O
under	O
nitrogen	O
using	O
bistrimethyl-silyltrifluoroacetamide	B
and	O
separated	O
on	O
a	O
5 %	O
diphenyl/95	O

Plasma	O
analysis	O
of	O
patients	O
with	O
preeclampsia	O
revealed	O
the	O
main	O
class	O
of	O
Glycerophosphoserines-GP03	B
(PS)	O
as	O
the	O
most	O
prevalent	O
lipid,	O
representing	O
52.30%	O
of	O
the	O
total	O
lipid	O
composition,	O
followed	O
by	O
Glycerophosphoethanolamines-GP02	B
(PEt),	O
Glycerophosphocholines-GP01	B
(PC)	O
and	O
Flavanoids-PK12	O
(FLV).	O

Under	O
neutral	O
conditions,	O
there	O
exists	O
presumably	O
a	O
strong	O
counterion	O
effect	O
from	O
the	O
internal	O
phosphate	B
moiety	O
on	O
the	O
carboxylates.	B

While	O
the	O
sensitivity	O
for	O
glucose,	B
galactose,	B
and	O
cysteine	B
+	O
cystine	B
was	O
≥85%,	O
that	O
for	O
nonanoic	B
acid	I
was	O
79%.	O

In	O
the	O
active	O
MS	O
group	O
the	O
intermediate,	O
AA-derived	O
molecule	O
15-hydroxyeicosatetraenoic	B
acid	I
(15-HETE)	O
reached	O
significantly	O
higher	O
levels	O
(4.4	O
pg/ml	O
±0.8	O
[mean	O
±	O
SEM]	O
vs.	O
2.2	O
pg/ml	O
±0.63,	O
P<	O
0.05),	O
and	O
this	O
was	O
also	O
the	O
case	O
with	O
the	O
pleiotropic	O
inflammatory	O
mediator	O
PGE_2	O
(1.27	O
pg/ml	O
±0.27	O
vs.	O
0.65	O
pg/ml	O
±0.12,	O
P<	O
0.01),	O
Thromboxanes,	B
leukotrienes	O
and	O
prostaglandin	B
D2	I
remained	O
unchanged.	O

The	O
supernatant	O
was	O
dried	O
under	O
a	O
gentle	O
nitrogen	O
flow	O
using	O
MULTIVAP	O
nitrogen	O
evaporator	O
(Organomation	O
Associates,	O
Inc.,	O
Berlin,	O
MA,	O
USA)	O
and	O
then	O
reconstituted	O
by	O
adding	O
100 μL	O
of	O
0.1%	O
formic	B
acid	I
in	O
water	O
followed	O
by	O
incubation	O
on	O
an	O
ice	O
bath	O
for	O
15 min.	O

During	O
the	O
discovery	O
phase,	O
the	O
results	O
repeatedly	O
pointed	O
to	O
metabolites	O
and	O
ratios	O
linked	O
to	O
metabolism	O
affecting	O
acylcarnitine	O
hydroxylation	O
and	O
carboxylation	O
as	O
well	O
as	O
the	O
catabolism	O
of	O
branched	O
chain	O
amino	O
acids,	O
lysine,	B
organic	O
acids,	O
and	O
tryptophan.	B

This	O
suggests	O
that	O
the	O
ETS	O
urinary	O
biomarkers	O
studied	O
are	O
good	O
biological	O
indicators	O
of	O
personal	O
exposure	O
to	O
high	O
molecular	O
weight	O
polycyclic	B
aromatic	O
hydrocarbons,	B
including	O
carcinogenic	O
PAHs	O
such	O
as	O
benzo(a)pyrene,	B
in	O
our	O
study	O
population.	O

 	O
where	O
a	O
correlation	O
graph	O
between	O
the	O
obtained	O
diosmetin	B
concentrations	O
is	O
presented.	O

Direction	O
of	O
changes	O
and	O
statistical	O
significance	O
of	O
analyzed	O
hydrophilic	B
compounds	O
of	O
CSF	O
fluid	O
for	O
MS	O
vs	O
control	O
group	O
The	O
multivariate	O
OPLS-DA	O
modeling	O
was	O
employed	O
using	O
the	O
knowledge	O
of	O
patient’s	O
classification.	O

Galactose	B
supplementation	O
in	O
fibroblast	O
cultures	O
and	O
dietary	O
supplementation	O
in	O
the	O
patients	O
were	O
studied	O
to	O
determine	O
the	O
effect	O
on	O
glycosylation.	O

First,	O
we	O
confirmed	O
the	O
potential	O
prognostic	O
utility	O
of	O
ADMA	B
in	O
significantly	O
obstructive	O
CAD	O
severity	O
and	O
related	O
events	O
in	O
a	O
large	O
cohort	O
of	O
patients	O
undergoing	O
elective	O
diagnostic	O
cardiac	O
catheterization.	O

High	O
levels	O
of	O
proline	B
can	O
inhibit	O
ALT	O
enzyme	O
and	O
cause	O
alanine	B
concentration	O
reduction.	O

For	O
this	O
purpose,	O
melanoma	O
cell	O
lines	O
(A375	O
and	O
A375R)	B
were	O
treated	O
with	O
IFNγ	O
(50	O
ng/ml)	O
and	O
TNF-	O
α	O
(10	O
ng/ml).	O

Impairment	O
of	O
the	O
methyl	O
cycle	O
has	O
been	O
actually	O
documented	O
and	O
also	O
affects	O
mitochondrial	O
methyl	O
availability	O
and	O
glutathione	B
levels	O
in	O
DS.	O

We	O
next	O
sought	O
to	O
identify	O
metabolites	O
whose	O
baseline	O
levels	O
were	O
predictive	O
of	O
LDL-C	O
response	O
to	O
simvastatin	B
in	O
the	O
full	O
range	O
group.	O

Our	O
findings	O
and	O
theirs	O
suggest	O
the	O
possibility	O
that	O
pelargonic	B
acid	I
is	O
related	O
to	O
the	O
onset	O
of	O
CAD	O
under	O
diabetic	O
conditions.	O

Lack	O
of	O
direct	O
pharmacokinetic	O
measurements	O
of	O
vitamin	B
D	I
catabolism.	O

The	O
concentration	O
of	O
glutamic	B
acid	I
in	O
non-DR	O
subjects	O
was	O
165.86 ± 62.55	O
and	O
150.16 ± 63.99 nmol/mL	O
in	O
DR	O
subjects	O
(p	O
 = 0.242).	O

At	O
baseline,	O
the	O
overweight	O
group	O
showed	O
higher	O
BMI,	O
waist	O
circumference,	O
triglyceride,	B
free	O
fatty	O
acid	O
(FFA),	O
glucose,	B
insulin,	O
and	O
hs-CRP,	O
and	O
lower	O
HDL-cholesterol	B
than	O
controls.	O

There	O
were	O
7	O
significantly	O
altered	O
pathways	O
(P < 0.05)	O
involving	O
atrial	O
appendage	O
sample	O
metabolism	O
(Table ):	O
‘aminoacyl-tRNA	B
biosynthesis’,	O
‘arginine	B
and	O
proline	B
metabolism’,	O
‘glycine,	B
serine,	B
and	O
threonine	B
metabolism’,	O
‘purine	B
metabolism’,	O
‘taurine	B
and	O
hypotaurine	B
metabolism’,	O
‘pantothenate	B
and	O
CoA	O
biosynthesis’,	O
and	O
‘beta-alanine	B
metabolism’,	O
all	O
of	O
which	O
showed ≥ 2	O
hits.	O

In	O
two	O
previous	O
studies,	O
adjusting	O
for	O
free	O
and/or	O
bioavailable	O
estradiol	B
reduced	O
the	O
BMI-breast	O
cancer	O
association	O
more	O
than	O
did	O
adjusting	O
for	O
total	O
estradiol	B
(,	O
).	O

The	O
chromatographic	O
column	O
Zebron	O
ZB-5	O
(30	O
m	O
×	O
0.25	O
mm	O
×	O
0.25	O
µm	O
of	O
5%	O
phenyl-	B
95%	I
dimethylpolysiloxane)	I
supplied	O
by	O
Phenomenex	O
(Torrance,	O
CA,	O
USA)	O
was	O
used.	O

After	O
a	O
treatment	O
with	O
10	O
mg/kg	O
of	O
quinine	O
dihydrochloride	B
administered	O
8-hourly	O
orally	O
for	O
7	O
days,	O
the	O
plasma	O
quinine	O
levels	O
had	O
fallen	O
to	O
below	O
0.4	O
µg/mL	O
in	O
almost	O
all	O
patients	O
40	O
h	O
after	O
the	O
last	O
dose	O
on	O
Day	O
7	O
.	O

3-(N	B
-acetylcysteinyl)phenanthrene	I
sulfoxide	I
(15).	O

Therefore,	O
increased	O
glutamate	B
along	O
with	O
depleted	O
glutamine	B
in	O
EC	O
tissue	O
could	O
suggest	O
changes	O
in	O
glutaminolytic	B
activity	O
for	O
EC	O
development.	O

Decrease	O
of	O
AA	O
and	O
AA	O
derived	O
pro-inflammatory	O
eicosanoids	B
demonstrate	O
that	O
immunosuppression	O
by	O
corticosteroid	O
is	O
via	O
suppression	O
of	O
pro-inflammatory	O
pathways.	O

Mobile	O
phases	O
were	O
water	O
and	O
acetonitrile	B
containing	O
0.1	O
%	O
formic	B
acid	I
with	O
a	O
linear	O
gradient.	O

	O
Aliquots	O
of	O
100	O
µL	O
of	O
serum	O
or	O
urine	O
and	O
5	O
µL	O
of	O
IS	O
were	O
transferred	O
to	O
a	O
LoBind	O
Eppendorf	O
microcentrifuge	O
tube	O
and	O
vortexed	O
for	O
30	O
s.	O
For	O
protein	O
precipitation,	O
we	O
proposed	O
the	O
use	O
of	O
chloroform:	B
methanol	B
(CHCl_3	O
:MeOH)	O
(2:1,	O
v	O
/v	O
)	O
and	O
we	O
compared	O
it	O
with	O
the	O
three	O
following	O
methodologies:	O
PCA,	O
MeOH,	B
and	O
ACN.	O

The	O
concentration	O
of	O
urinary	O
AM-2	O
in	O
Case	O
#1,	O
3.2	O
ng/mL,	O
is	O
equivalent	O
to	O
0.015	O
μM.	O
In	O
literature,	O
the	O
blood	O
concentration	O
of	O
acetamiprid	B
in	O
3	O
cases	O
of	O
acute	O
severe	O
poisoning	O
was	O
2.39–59.83	O
μg/mL	O
(10.7–269	O
μM),	O
whereas	O
that	O
of	O
imidacloprid	O
in	O
7	O
cases	O
of	O
acute	O
poisoning	O
was	O
2.05–12.5	O
μg/mL	O

The	O
hydroxylated	B
estrogen	I
metabolite,	O
3,4-catechol-estrogen	B
quinone,	I
can	O
react	O
with	O
DNA,	O
to	O
form	O
4-hydroxyestrogen-1-N	B
7-guanine	O
(4-OH-E_1	O
-1-N	I
7-Gua)	O
and	O
4-hydroxyestrogen-1-N	B
3-adenine	O
(4-OH-E_1	O
-1-N	I
3-Ade),	O
which	O
are	O
labile	O
and	O
undergo	O
depurination.	O

As	O
depicted	O
in	O
a,	O
taurine	B
levels	O
did	O
not	O
change	O
after	O
prolonged	O
EDTA	O
blood	O
incubation	O
for	O
4	O
h	O
to	O
8	O
h.	O

Within	O
PC,	O
saturated	O
and	O
monounsaturated	O
lower	O
MW	O
species,	O
as	O
well	O
as	O
higher	O
unsaturated	O
MW	O
species	O
were	O
significantly	O
increased	O
in	O
tumor	O
epithelial	O
cells	O
(for	O
their	O
expected	O
FA	B
composition,	O
see	O
).	O

In	O
the	O
present	O
study,	O
sarcosine	B
was	O
significantly	O
enhanced,	O
especially	O
in	O
stage	O
IV	O
of	O
rectal	O
cancer	O
tissues.	O

We	O
investigated	O
alterations	O
in	O
plasma	O
metabolites	O
associated	O
with	O
borderline-to-moderate	O
HTG	O
(triglycerides	O
(TG)	O
150-500	O
mg/dL).	O

Connections	O
between	O
metabolites	O
(indicated	O
by	O
lines)	O
and	O
functional	O
groupings	O
of	O
metabolites	O
(indicated	O
by	O
node	O
colors)	O
differ	O
between	O
the	O
two	O
groups,	O
indicating	O
different	O
functional	O
metabolic	O
states	O
between	O
those	O
with	O
AP	B
and	O
those	O
without.	O

Between	O
the	O
two	O
laboratories	O
that	O
did	O
measure	O
sarcosine	B
the	O
agreement	O
was	O
within	O
~10%	O
(data	O
not	O
shown).	O

The	O
metabolites	O
identified	O
are	O
associated	O
with	O
various	O
metabolic	O
pathways	O
including	O
glycolysis,	O
pentose	B
phosphate	I
pathway	O
(PPP),	O
lipid	O
and	O
fatty	O
acid	O
metabolism,	O
amino	O
acid	O
metabolism,	O
tricarboxilic	O
acid	O
(TCA)	O
cycle	O
and	O
urea	B
cycle.	O

Acetic	B
acid,	I
ammonium	B
hydroxide,	I
ammonium	B
acetate	I
and	O
2-proponal	O
were	O
acquired	O
from	O
Sigma-Aldrich	O
(Zwijndrecht,	O
the	O
Netherlands).	O

*	O
After	O
adjustment	O
for	O
traditional	O
risk	O
factors	O
and	O
other	O
baseline	O
covariates,	O
elevated	O
plasma	O
levels	O
of	O
TMAO	B
remained	O
a	O
significant	O
predictor	O
of	O
the	O
risk	O
of	O
major	O
adverse	O
cardiovascular	O
events.	O

After	O
the	O
PCR	O
step,	O
the	O
amplified	O
product	O
was	O
digested	O
with	O
AluI,	O
DdeI	O
and/or	O
HinfI	O
as	O
restriction	O
enzymes	O
(Promega,	O
Madison,	O
USA)	O
and	O
visualized	O
after	O
electrophoresis	O
run	O
in	O
ethidium	O
bromide	B
stained	O
12%	O
polyacrylamide	B
gel.	O

Then	O
the	O
target	O
components	O
were	O
eluted	O
in	O
1.0 ml	O
of	O
5%	O
aqueous	O
methanol.	B

Aliquots,	O
dried	O
under	O
nitrogen	O
and	O
vacuum-desiccated,	O
were	O
subsequently	O
either	O
reconstituted	O
in	O
50	O
µL	O
0.1%	O
formic	B
acid	I
in	O
water	O
(acidic	O
conditions)	O
or	O
in	O
50	O
µL	O
6.5	O
mM	O
ammonium	B
bicarbonate	O
in	O
water,	O
pH	O
8	O
(basic	O
conditions)	O
for	O
the	O
two	O
UHPLC/MS/MS_2	O
analyses	O
or	O
derivatized	O
to	O
a	O
final	O
volume	O
of	O
50	O
µL	O
for	O
GC/MS	O
analysis	O
using	O
equal	O
parts	O
bistrimethyl-silyl-trifluoroacetamide	B
and	O
solvent	O
mixture	O
acetonitrile:dichloromethane:cyclohexane	O
(5∶4:1)	O
with	O
5%	O
triethylamine	B
at	O
60°C	O
for	O
1	O
h.	O

Certain	O
nucleic	O
acids	O
are	O
overexpressed	O
in	O
GC	O
(hypoxanthine,	O
uridine,	B
guanosine),	O
indicating	O
active	O
replication	O
(;	O
;	O
).	O

Numbers	O
in	O
parentheses	O
denote	O
number	O
of	O
carbons,	O
excluding	O
the	O
CoA	O
or	O
carnitine	B
moieties.	O

The	O
concentrations	O
of	O
glycolic	B
acid	I
and	O
mannose	B
were	O
higher	O
in	O
SIBO-positive	O
children,	O
whereas	O
the	O
concentrations	O
of	O
valine,	B
p-cresylsulphate	B
(PCS),	O
butyrate	B
and	O
adipic	B
acid	I
were	O
higher	O
in	O
SIBO-negative	O
children.	O

Elaidic	B
acid	I
is	O
the	O
trans	O
isomer	O
of	O
monounsaturated	O
C18	O
oleic	B
acid,	I
naturally	O
present	O
in	O
ruminant	O
fat,	O
meat,	O
margarine,	O
and	O
baked	O
products;	O
its	O
plasma	O
level	O
has	O
been	O
associated	O
with	O
an	O
increase	O
in	O
total	O
mortality	O
and	O
in	O
cardiovascular	O
mortality,	O
and	O
a	O
diet	O
high	O
in	O
trans	O
fatty	O
acids	O
has	O
been	O
associated	O
with	O
an	O
increase	O
in	O
NHL	O
risk.	O

Sphingolipid	B
metabolites	O
in	O
healthy	O
controls	O
stratified	O
by	O
LMI.	O

For	O
individuals	O
with	O
high	O
NMR,	O
smoking	O
cessation	O
therapy	O
may	O
be	O
enhanced	O
by	O
tailoring	O
treatment	O
based	O
on	O
rates	O
of	O
nicotine	B
metabolism.	O

The	O
same	O
consideration	O
should	O
be	O
applied	O
to	O
glycerol,	B
which	O
is	O
known	O
to	O
be	O
below	O
0.1	O
mmol/kg	O
in	O
normal	O
brain	O
but	O
might	O
have	O
been	O
generated	O
from	O
the	O
degradation	O
of	O
glycerophosphorylcholine	B
during	O
the	O
pretreatment	O
of	O
the	O
samples.	O

The	O
most	O
relevant	O
result	O
from	O
their	O
studies	O
is	O
the	O
altered	O
levels	O
of	O
specific	O
phospholipids	B
in	O
the	O
MS	O
group	O
compared	O
to	O
the	O
OND	O
group.	O

 ),	O
whereas	O
the	O
relative	O
amounts	O
of	O
D,L-glutamine	B
and	O
fibrinogen	O
alpha	O
chain	O
fragment	O
were	O
significantly	O
higher	O
in	O
the	O
OVC	O
group	O
compared	O
to	O
the	O
control	O
group	O
(Fig.	O

Box	O
plots	O
displayed	O
the	O
median	O
levels	O
of	O
xanthine,	B
hypoxanthine	B
and	O
D-mannose	B
according	O
to	O
colorectal	O
cancer	O
(CRC),	O
adenoma	O
polyp	O
(PLP),	O
and	O
control	O
(CTRL)	O
groups	O
in	O
both	O
discovery	O
and	O
validation	O
phases.	O

However,	O
contrary	O
to	O
other	O
microbial	O
and	O
chemical	O
products	O
such	O
as	O
hydrogen	B
sulphide,	I
p-cresol,	B
phenol,	B
haem	B
iron,	O
N-nitroso	O
compounds,	O
polycyclic	B
aromatic	O
hydrocarbons,	B
and	O
heterocyclic	B
amines	O
which	O
are	O
reported	O
to	O
be	O
detrimental	O
[,	O
,	O
],	O
the	O
isoacids	O
although	O
indicative	O
of	O
putrescible	O
fermentation,	O
are	O
not	O
associated	O
with	O
cell	O
toxicity.	O

For	O
the	O
urine	O
samples	O
from	O
RA	O
patients,	O
which	O
were	O
collected	O
at	O
a	O
random	O
time	O
of	O
day,	O
we	O
used	O
the	O
urinary	O
creatinine	B
level	O
for	O
correcting	O
the	O
oxidised	O
lipids	O
for	O
sample	O
dilution.	O

As	O
a	O
major	O
class	O
of	O
mammalian	O
lipids,	O
phosphatidylcholines	B
(PCs)	O
often	O
contain	O
mixtures	O
of	O
structural	O
isomers,	O
resulting	O
from	O
different	O
lipogenesis	O
pathways.	O

Abbreviations:	O
Cer = ceramide;	B
LPC = lysophosphatidylcholine;	B
SM = sphingomyelin.	B

Cox	O
proportional	O
hazard	O
analysis	O
for	O
3-year	O
major	O
adverse	O
clinical	O
events	O
for	O
arginine	O
methylation	O
and	O
global	O
arginine	B
bioavailability,	O
adjusted	O
for	O
renal	O
function	O
and	O
cardiac	O
risk	O
factors	O
as	O
well	O
as	O
stratified	O
according	O
to	O
primary	O
and	O
secondary	O
prevention	O
cohorts.	O

Increased	O
urea	B
also	O
had	O
many	O
adverse	O
influences	O
on	O
complications	O
because	O
it	O
was	O
closely	O
related	O
to	O
carbamylation	O
in	O
vivo	O
.	O

LP-1	O
cells	O
were	O
grown	O
in	O
Roswell	O
Park	O
Memorial	O
Institute	O
(RPMI)	O
1640	O
medium	O
supplemented	O
with	O
10%	O
fetal	O
calf	O
serum,	O
100 U/mL	O
penicillin,	B
and	O
50 µg/mL	O
streptomycin	B
(Gibco-Invitrogen,	O
Carlsbad,	O
CA,	O
15140-122).	O

The	O
MS/MS	O
spectrum	O
of	O
[M-H]-	O
ion	O
of	O
FA	B
(20:4)	I
is	O
shown	O
in	O
.	O

Until	O
we	O
conducted	O
the	O
analysis,	O
we	O
did	O
not	O
know	O
that	O
the	O
urea	B
cycle	O
or	O
NO	O
system	O
might	O
be	O
perturbed	O
in	O
the	O
HD	O
sheep,	O
and	O
we	O
could	O
not	O
measure	O
NO	O
levels	O
in	O
the	O
plasma	O
retrospectively.	O

The	O
developed	O
method	O
was	O
successfully	O
applied	O
for	O
the	O
assay	O
of	O
the	O
targeted	O
drugs	O
and	O
their	O
selected	O
metabolites	O
in	O
urine	O
samples	O
collected	O
from	O
patients	O
suffering	O
from	O
inflammatory	O
bowel	O
disease	O
(IBD)	O
and	O
receiving	O
azathioprine	B
therapy.	O

Moreover,	O
a	O
highly	O
sensitive	O
ultra-performance	O
liquid	O
chromatography	O
tandem	O
mass	O
spectrometry	O
(UPLC-MS/MS)	O
method	O
was	O
used	O
to	O
characterize	O
the	O
metabolic	O
pathways	O
of	O
P,	O
IP,	B
and	O
their	O
bio-transforming	O
products	O
in	O
the	O
reaction	O
samples.	O

Although	O
it	O
has	O
been	O
reported	O
that	O
some	O
species	O
of	O
Clostridia	O
produce	O
phenol	B
and	O
p-cresol	B
together	O
with	O
ammonia	O
and	O
hydrogen	O
by	O
anaerobic	O
degradation	O
of	O
aromatic	O
amino	O
acids	O
,	O
our	O
data	O
suggest	O
that	O
Proteobacteria	O
might	O
also	O
contribute	O
to	O
the	O
pool	O
of	O
PAG	B
and	O
PCS.	O

Acetate	B
used	O
for	O
myelin	B
lipid	O
biosynthesis	O
in	O
oligodendrocytes	O
is	O
mainly	O
produced	O
from	O
N-acetylaspartate	B
(NAA)	O
degradation	O
by	O
aspartoacylase	O
(ASPA)	O

Ladenson	O
et	O
al.	O
found	O
a	O
5%	O
lower	O
glucose	B
concentration	O
in	O
plasma	O
compared	O
to	O
serum	O
.	O

Glutamate,	B
which	O
was	O
elevated	O
in	O
NDMM	O
patients,	O
is	O
a	O
nonessential	O
amino	O
acid	O
and	O
serves	O
as	O
the	O
major	O
bioenergetic	O
substrate	O
for	O
proliferating	O
normal	O
but	O
also	O
neoplastic	O
cells.	O

This	O
finding	O
is	O
very	O
similar	O
to	O
that	O
for	O
another	O
phytochemical,	O
isothiocyanates.	B

C	B
18:0	I
(C),	I
and	O
C	B
20:4	I
(D).	O

Average	O
levels	O
of	O
this	O
metabolite	O
were	O
0.34	O
fmol/mg	O
creatinine	B
in	O
non-smokers,	O
and	O
0.71	O
fmol/mg	O
creatinine	B
in	O
smokers.	O

Serum	O
concentrations	O
of	O
significative	O
sphingomyelins	B
phospholipids	I
(a)	O
and	O
acylcarnitines	B
derivatives	O
(b)	O
in	O
FDR	O
and	O
GC	O
patients	O
according	O
to	O
H.	O
pylori	O
infection.	O

In	O
response	O
to	O
exercise,	O
both	O
groups	O
had	O
increased	O
concentrations	O
of	O
gluconeogenic	B
precursors	O
(alanine	O
and	O
lactate)	B
and	O
tricarboxylic	B
acid	I
cycle	O
intermediates	O
(citrate,	O
malate,	B
fumarate	B
and	O
succinate).	B

Extraction	O
of	O
estrogen	B
and	O
metabolites	O
using	O
Oasis_®	O
MCX	O
separation	O
columns	O
with	O
the	O
manufacturer's	O
generic	O
protocol	O
allowed	O
high	O
recovery	O
(93–108%)	O
of	O
the	O
9	O
target	O
metabolites.	O

Glucose	B
metabolism	O
is	O
only	O
slightly	O
downregulated,	O
with	O
activation	O
of	O
the	O
PPP.	O

Specifically,	O
concentrations	O
of	O
creatine,	B
glycine,	B
histidine,	B
and	O
threonine	B
were	O
reduced	O
in	O
COPD	O
compared	O
to	O
NCS	O
subjects.	O

The	O
_13	O
C-positional	O
isotopomer	O
information	O
obtained	O
from	O
the	O
TOCSY	O
analysis	O
was	O
confirmed	O
by	O
the	O
HSQC	O
analysis,	O
including	O
the	O
positional	O
isotopomers	O
of	O
_13	O
C-3-Ala,	O
_13	O
C-3-lactate,	B
_13	O
C-3-Glu,	O
_13	O
C-3-Gln	O
_13	O
C-3-Glu-GSSG,	B
_13	O
C-2-Glu-GSSG,	B
_13	O
C-2-Glu,	O
and	O
_13	O
C-2-Asp	O
(cf.	O
respectively	O

Exceptions	O
in	O
FINRISK	O
1997	O
were	O
2-aminobutyrate	B
(M)	O
and	O
urea	B
(M).	O

Urinary	O
NMR	O
from	O
HCC	O
differed	O
across	O
a	O
range	O
of	O
metabolites,	O
including	O
reduced	O
hippurate	B
and	O
creatinine	B
and	O
increased	O
carnitine	B
levels,	O
consistent	O
with	O
the	O
diverse	O
effects	O
of	O
liver	O
cancer	O
on	O
metabolic	O
pathways	O
and	O
the	O
interrelationship	O
with	O
the	O
gut	O
microbiome.	O

Moreover,	O
a	O
change	O
in	O
the	O
balance	O
of	O
methylamine	B
metabolism	O
with	O
an	O
increment	O
in	O
TMA	O
concentrations	O
was	O
observed	O
in	O
diabetic	O
rats.	O

Mycotoxin	B
exposure	O
assessment:	O
traditional	O
food	O
analysis	O
compared	O
to	O
the	O
innovative,	O
complementary	O
biomarker	O
approach	O

Although	O
the	O
clinical	O
parameters	O
of	O
the	O
patients	O
with	O
AML	O
are	O
remarkably	O
heterogeneous,	O
the	O
serum	O
metabolic	O
profiles	O
from	O
patients	O
still	O
fall	O
into	O
distinct	O
clusters	O
which	O
were	O
related	O
with	O
their	O
different	O
responses	O
to	O
chemotherapy	O
with	O
cytarabine	O
and	O
anthracycline.	B

We	O
verified	O
the	O
identities	O
of	O
selected	O
putative	O
identifications	O
including	O
glycholic	B
acid	I
(GCA),	O
glycodeoxycholic	B
acid	I
(GDCA),	O
3beta,	O
6beta-dihydroxy-5beta-cholan-24-oic	B
acid,	I
oleoyl	B
carnitine,	I
and	O
Phe-Phe.	B

For	O
similar	O
analysis	O
of	O
CSF,	O
benzoate	B
was	O
the	O
only	O
compound	O
selected	O
by	O
LASSO;	O
hence,	O
its	O
result	O
was	O
the	O
same	O
as	O
that	O
shown	O
by	O
univariate	O
analysis	O
(0.48,	O
p	O
=	O
0.00045).	O

By	O
using	O
a	O
bootstrap	O
cross-validation	O
method	O
on	O
in	O
vivo	O
_1	O
H	O
MRS	O
data	O
of	O
brain	O
tumours	O
from	O
35	O
children,	O
medulloblastomas	O
were	O
characterized	O
by	O
high	O
taurine,	B
phosphocholine	B
and	O
glutamate	B
and	O
low	O
glutamine;	B
astrocytomas	O
by	O
low	O
creatine	B
and	O
high	O
N-acetylaspartate;	B
and	O
ependymomas	O
by	O
high	O
myo-inositol	B
and	O
glycerophosphocholine.	B

After	O
the	O
intake	O
of	O
all	O
the	O
three	O
foods,	O
levels	O
after	O
1	O
h	O
were	O
significantly	O
lower	O
when	O
compared	O
to	O
baseline	O
based	O
on	O
a	O
paired	O
Wilcoxon	O
signed	O
rank	O
test,	O
after	O
milk	O
intake	O
(C15:0	O
p	O
=	O
9.8	O
×	O
10_−4	O
,	O
C17:0	B
p	O
=	O
2.9	O
×	O
10_−3	O
,	O
unknown	O
C17	O
p	O
=	O
1.9	O
×	O
10_−3	O
),	O
after	O
cheese	O
intake	O
(C15:0	O
p	O
=	O
2.9	O
×	O
10_−3	O
,	O
C17:0	B
p	O
=	O
1.4	O
×	O
10_−2	O
,	O
unknown	O
C17	O
p	O
=	O
1.4	O
×	O
10_−2	O
),	O
and	O
after	O
soy	O
drink	O
intake	O
(C15:0	O
p	O
=	O
9.8	O
×	O
10_−4	O
,	O
C17:0	B
p	O
=	O
2.9	O
×	O
10_−3	O
,	O
unknown	O
C17	O
p	O
=	O
9.8	O
×	O
10_−4	O
).	O

The	O
control	O
group	O
encompassed	O
patients	O
with	O
the	O
following	O
diseases	O
:	O
sarcoidosis	O
(one	O
patient),	O
psychiatric	O
disorders	O
(three	O
patients),	O
cerebellar	O
syndrome	O
(one	O
patient),	O
peripheral	O
neuropathy	O
(thirteen	O
patients),	O
chronic	O
inflammatory	O
demyelinating	O
polyneuropathy	O
(six	O
patients),	O
muscular	O
cramps	O
(one	O
patient),	O
facial	O
paralysis	O
(one	O
patient),	O
traumatic	O
cerebral	O
injury	O
(one	O
patient),	O
ataxia	O
with	O
axonal	O
neuropathy	O
(one	O
patient),	O
normal	O
pressure	O
hydrocephalus	B
(two	O
patients),	O
paresthesia	O
(two	O
patients),	O
epileptic	O
seizures	O
(one	O
patient),	O
spinal	O
cord	O
infarction	O
(one	O
patient),	O
cervical	O
spondylotic	O
myelopathy	O
(three	O
patients),	O
adrenomyeloneuropathy	O
(one	O
patient),	O
non-organic	O
hypoesthesia	O
(one	O
patient),	O
neuroborreliosis	O
(one	O
patient),	O
dystonia	O
(one	O
patient),	O
Hallervorden-Spatz	O
syndrome	O
(one	O
patient),	O
non	O
neurologic	O
deafness	O
(one	O
patient),	O
and	O
oculomotor	O
paralysis	O
(one	O
patient).	O

In	O
total,	O
levels	O
of	O
31/53	O
amines	O
(58.5%)	O
and	O
5/21	O
acylcarnitines	B
(23.8%)	O
were	O
significantly	O
different	O
in	O
TB	O
patients	O
compared	O
to	O
HC	O
based	O
on	O
a	O
linear	O
regression	O
model	O
(Fig. ).	O

The	O
best	O
match	O
for	O
the	O
band	O
at	O
≈34	O
kDa	O
was	O
hydroxyacyl-Coenzyme	B
A	O
dehydrogenase,	O
with	O
a	O
56.4%	O
sequence	O
coverage.	O

Methanol,	B
acetonitrile,	B
water,	O
and	O
formic	B
acid	I
were	O
LC–MS	O
grade,	O
methyl	O
tertiary	O
butyl	B
ether	I
(MTBE)	O
was	O
HPLC	O
grade	O
and	O
all	O
were	O
from	O
Fisher	O
Scientific	O
(Fair	O
Lawn,	O
NJ).	O

The	O
combination	O
of	O
UE-MISPE-LC	O
(ultrasonic	O
extraction	O
-	O
molecularly	O
imprinted	O
solid-phase	O
extraction	O
-	O
liquid	O
chromatography)	O
produced	O
high	O
(R	O
 ≈ 95–98%)	O
and	O
repeatable	O
(RSD < 3%)	O
recovery	O
values	O
for	O
ZON	O
and	O
α-ZOL.	B

(A)	O
Formation	O
rate	O
of	O
anastrozole	B
glucuronide	I
from	O
anastrozole	B
single	O
concentration	O
in	O
a	O
panel	O
of	O
purified	O
human	O
UGTs.	O

With	O
enabled	O
model	O
peak	O
correction,	O
the	O
minimal	O
determined	O
enrichment	O
for	O
glutamine	B
M5	O
was	O
0.026%,	O
with	O
an	O
acceptable	O
accuracy	O
(0.002%,	O
injections	O
of	O
same	O
sample,	O
n	O
=	O
3)	O
and	O
reproducibility	O
(0.014%,	O
sample	O
extraction,	O
n	O
=	O
3).	O

The	O
metabolites	O
that	O
result	O
from	O
direct	O
reaction	O
of	O
BDA	O
with	O
lysine	B
(BDA-N	O
_α	B
-acetyllysine)	I
and	O
from	O
cysteine-BDA-lysine	B
cross-links	O
(N	O
-acetylcysteine-BDA-lysine,	I
N	B
-acetylcysteine-BDA-N	I
_α	I
-acetyllysine	I
and	O
their	O
sulfoxides)	B
were	O
targeted	O
in	O
this	O
study.	O

CYP2A6	O
is	O
also	O
responsible	O
for	O
the	O
metabolism	O
of	O
nicotine:	B
It	O
mediates	O
the	O
conversion	O
of	O
nicotine	B
to	O
cotinine	B
and	O
the	O
subsequent	O
conversion	O
of	O
cotinine	B
to	O
3′-hydroxycotinine.	B

Taurine	B
is	O
an	O
amino	B
sulfonic	I
acid	I
derived	O
from	O
cysteine.	B

The	O
enzyme	O
GMPR	O
catalyzes	O
a	O
reverse	O
reaction	O
which	O
turns	O
GMP	O
into	O
IMP,	B
keeping	O
these	O
metabolite	O
levels	O
high.	O

Taken	O
together,	O
glutamic	B
acid/glutamate	O
may	O
play	O
a	O
permissive	O
role	O
in	O
the	O
regulation	O
of	O
gluconeogenesis.	O

The	O
mouse	O
and	O
rat	O
samples	O
yielded	O
highly	O
significant	O
multivariate	O
classification	O
models,	O
with	O
disease-correlated	O
increases	O
of	O
urinary	O
citrate,	B
DMA	B
and	O
lactate.	B

This	O
application	O
was	O
subsequently	O
implemented	O
to	O
assess	O
the	O
rates	O
of	O
glucose	B
depletion	O
as	O
well	O
as	O
lactate	B
production	O
via	O
the	O
lactate	B
biosensor,	O
Laconic,	O
to	O
indicate	O
glycolytic	B
metabolism	O
in	O
response	O
to	O
hypoxia	O
in	O
breast	O
cancer	O
cells.	O

Effect	O
of	O
nebulizer	O
pressure	O
on	O
the	O
simultaneous	O
enantioseparation	O
of	O
1,1’	B
=	I
O	I
-DVX	I
and	O
2,2’	B
=	I
VX.	I

Depressed	O
subjects	O
had	O
reduced	O
levels	O
of	O
ketone	B
body	O
formation	O
along	O
with	O
increased	O
levels	O
of	O
dicarboxylic	B
acid	I
(DCA)	O
formation	O
which	O
suggested	O
reduced	O
β-oxidation	O
and	O
enhanced	O
ω-oxidation	O
of	O
fatty	O
acids	O
in	O
depressed	O
subjects.	O

Within	O
systems	O
that	O
trigger	O
coagulation,	O
such	O
as	O
virus	O
infection,	O
sepsis,	O
and	O
inflammation,	O
cellular	O
precursors	O
of	O
MVs	O
(e.g.,	O
monocytes,	O
platelets,	O
and	O
endothelial	O
cells)	O
become	O
activated,	B
moving	O
PS	O
lipids	O
from	O
the	O
inner	O
to	O
the	O
outer	O
plasma	O
membrane	O
through	O
the	O
action	O
of	O
scramblases	O
(,	O
,	O
).	O

a:	O
arginine	B
and	O
proline	B
metabolism;	O
b:	O
glycerolipid	B
metabolism;	O
c:	O
inositol	B
phosphate	I
metabolism;	O
d:	O
pyruvate	B
metabolism;	O
e:	O
glyoxylate	B
and	O
dicarboxylate	B
metabolism;	O
f:	O
glycine,	B
serine	B
and	O
threonine	B
metabolism.	O

Due	O
to	O
the	O
degree	O
of	O
noise	O
present,	O
the	O
aromatic	O
region	O
was	O
excluded	O
and	O
only	O
the	O
aliphatic	B
spectral	O
region	O
analysed.	O

This	O
finding	O
suggests	O
that	O
exercise	O
training	O
may	O
reverse	O
the	O
effect	O
of	O
cold	O
to	O
substantially	O
reduce	O
triglycerides.	B

These	O
data	O
serve	O
as	O
a	O
basis	O
to	O
design	O
clinical	O
drug	O
interaction	O
and	O
pharmacogenetic	O
studies	O
with	O
CYP3A4	O
and	O
UGT1A4	O
aimed	O
at	O
predicting	O
anastrozole	B
clearance.	O

One	O
of	O
three	O
patients	O
with	O
MDR-TB	O
had	O
concomitantly	O
detectable	O
D-series	O
resolvin(s)	O
and	O
the	O
trehalose-6-mycolate	B
and	O
PI	O
metabolites.	O

Different	O
stationary	O
phases	O
were	O
investigated	O
for	O
the	O
separation	O
of	O
25(OH)D_3	O
and	O
3-epi-25(OH)D_3	B
including	O
phenyl,	O
PFPP,	O
and	O
two	O
CN-based	O
columns.	O

Finally,	O
the	O
high	O
production	O
of	O
KBs	O
in	O
patients	O
with	O
frequent	O
seizure	O
could	O
be	O
important	O
to	O
balance	O
the	O
increase	O
of	O
glutamate	B
through	O
the	O
modification	O
of	O
the	O
behavior	O
of	O
vesicular	O
glutamate	B
transporters.	O

To	O
prepare	O
the	O
antibody-coded	O
magnetic	O
beads,	O
the	O
anti-BChE	O
antibody	O
was	O
first	O
labeled	O
with	O
the	O
ChromaLink™	O
biotin	B
protein	O
labeling	O
kit,	O
which	O
efficiently	O
reacted	O
with	O
protein	O
amine	O
groups	O
through	O
the	O
aromatic	O
water	O
soluble	O
N-hydroxy-sulfosuccinimidyl	B
ester	I
functional	O
group	O
in	O
the	O
reagent.	O

Similarly,	O
formate	B
strong	O
upregulation	O
was	O
observed	O
in	O
blood	O
serum	O
and	O
tissue	O
however	O
due	O
to	O
the	O
high	O
RSD	O
it	O
is	O
hard	O
at	O
this	O
stage	O
to	O
consider	O
this	O
molecule	O
as	O
a	O
potential	O
biomarker.	O

Retinol	B
has	O
been	O
seen	O
to	O
have	O
a	O
correlation	O
with	O
smoking	O
while	O
both	O
bisphenol	B
A	O
and	O
L-proline	B
were	O
found	O
to	O
be	O
unrelated.	O

Instead,	O
they	O
arise	O
from	O
different	O
types	O
of	O
carbon-hydrogen	B
bond	O
in	O
all	O
fatty	O
acyl	O
chains:	O
0.9ppm–CH_3	O
;	O
1.3ppm–(CH_2	O
)_n	O
-;	O
2.0ppm–CH_2	O
-CH	O
=	O
CH-CH_2	O
-.	O

1-(N	B
-acetylcysteinyl)phenanthrene	I
sulfoxide	I
(8).	O

In	O
the	O
CER	B
study,	O
baseline	O
subcutaneous	O
abdominal	O
fat	O
adipocytes	O
were	O
significantly	O
larger	O
than	O
breast	O
adipocytes	O
(4066 μm_2	O
vs.	O

Gut	O
microbiota	O
can	O
directly	O
participate	O
in	O
the	O
metabolism	O
of	O
protein,	O
fat,	O
and	O
carbohydrate	O
and	O
also	O
take	O
part	O
in	O
the	O
metabolism	O
of	O
energy	O
and	O
biochemical	O
metabolism	O
of	O
bile	O
acid	O
and	O
bilirubin.	B

Fasting	O
glucose	B
concentrations	O
were	O
higher	O
in	O
obese	O
NAFLD	O
patients	O
as	O
compared	O
to	O
normal	O
liver	O
subjects,	O
reaching	O
statistical	O
significance	O
in	O
the	O
obese	O
class	O
I–II	O
cohort	O
(lean,	O
K-W=0.89,	O
p-value=0.64;	O
obese,	O
K-W=9.75,	O
p-value=0.01;	O
morbidly	O
obese,	O
K-W=5.79,	O
p-value=0.06).	O

The	O
levels	O
of	O
7α-hydroxy-3-oxocholest-4-en-26-oic	B
and	O
3β-hydroxycholest-5-en-26-oic	B
acid	I
in	O
CSF	O
were	O
found	O
to	O
be	O
7.170	O
±	O
2.826	O
and	O
0.416	O
±	O

Similarly,	O
Patient	O
4,	O
who	O
also	O
had	O
elevated	O
orotate	B
levels,	O
had	O
four	O
SNVs	O
in	O
three	O
genes	O
of	O
the	O
pyrimidine	B
biosynthesis	O
pathway	O
that	O
we	O
examined,	O
including	O
two	O
somatic	O
heterozygous	O
mutations	O
in	O
CAD	O
(C92R	O
and	O
D2047fs)	O
and	O
a	O
somatic	O
variant	O
in	O
DHODH	O
(A375S)	O
as	O
well	O
as	O
a	O
mild	O
germline	O
variant	O
in	O
TYMS	O
(G5S).	O

These	O
pathways	O
included	O
alanine,	B
aspartate	B
and	O
glutamate	B
metabolism,	O
D-glutamine	B
and	O
D-glutamate	B
metabolism,	O
lysine	B
degradation,	O
aminoacyl-tRNA	B
biosynthesis,	O
and	O
carbohydrate	O
metabolism	O
(starch	O
and	O
sucrose	B
metabolism,	O
glycolysis,	O
or	O
gluconeogenesis).	O

These	O
dibasic	O
amino	O
acids	O
share	O
plasma	O
membrane	O
transporters	O
with	O
arginine,	B
the	O
rate-limiting	O
substrate	O
for	O
nitric	B
oxide	I
synthase	O
(NOS),	O
a	O
critical	O
mediator	O
of	O
cardiovascular	O
health.	O

	O
C_27	O
bile	O
acids,	O
including	O
3β-hydroxycholest-5-en-26-oic	B
acid,	I
3β,7α-dihydroxycholest-5-en-26-oic,	B
and	O
7α-hydroxy-3-oxocholest-4-en-26-oic	B
acid,	I
are	O
prevalent	O
in	O
blood	O
(,	O
)	O
(see	O
supplemental	O
Table	O
S1)	O
and	O
have	O
been	O
identified	O
in	O
cells	O
of	O
the	O
rodent	O
central	O
nervous	O
system	O
following	O
incubation	O
with	O
27-hydroxycholesterol,	B
whereas	O
7α-hydroxy-3-oxocholest-4-en-26-oic	B
acid	I
has	O
been	O
identified	O
as	O
an	O
export	O
product	O
from	O
human	O
brain	O
into	O
plasma.	O

Monohydroxy	B
fatty	O
acids,	O
dicarboxylic	B
fatty	O
acids	O
(DCA),	O
glycerophospholipids,	B
sphingolipids	B
and	O
acylcarnitines	B
all	O
trended	O
higher	O
in	O
HCC	O
vs.	O
DC.	O

Taking	O
urea	B
as	O
an	O
example,	O
its	O
relative	O
intensity	O
increased	O
in	O
the	O
pre-dialysis	O
groups	O
versus	O
controls	O
(17.30 ± 3.68	O
in	O
pre-HFD,	O
FC = 3.74	O
and	O
17.90 ± 3.28	O
in	O
pre-HD,	O
FC = 3.86	O
vs.	O
4.63 ± 1.12	O
in	O
control)	O
and	O
then	O
dramatically	O
decreased	O
to	O
7.87 ± 2.36	O
in	O
post-HFD,	O
FC = 1.70	O
and	O
7.66 ± 1.92	O
in	O
post-HD,	O
FC = 1.66.	O

Metabolites	O
(methanol	O
and	O
ethanol)	O
that	O
were	O
biased	O
due	O
to	O
reagents	O
used	O
in	O
the	O
collection	O
and	O
preparation	O
of	O
samples	O
were	O
not	O
considered	O
for	O
further	O
analysis.	O

The	O
subset	O
of	O
samples	O
was	O
randomly	O
assigned	O
based	O
on	O
plasma	O
cystathionine	B
concentration	O
after	O
initial	O
screening	O
based	O
on	O
cystathionine	B
concentration.	O

Urinary	O
furan	B
metabolites	O
were	O
initially	O
identified	O
by	O
spiking	O
the	O
urine	O
samples	O
with	O
stable	O
isotopically	O
labeled	O
forms	O
of	O
the	O
metabolites,	O
[_13	O
C_6	O
_15	O
N_2	O
]1,	O
[_13	O
C_6	O
_15	O
N_2	O
]2,	O
[_13	O
C_6	O
_15	O
N_2	O
]4,	O
and	O
[_13	O
C_6	O
_15	O
N_2	O
]5	O
and	O
investigating	O
whether	O
there	O
were	O
unlabeled	O
forms	O
of	O
the	O
metabolites	O
in	O
the	O
urine	O
samples	O
that	O
co-eluted	O
with	O
the	O
internal	O
standards.	O

We	O
also	O
investigated	O
the	O
possible	O
presence	O
of	O
3-epi-25(OH)D_2	B
in	O
the	O
SRM	O
serum	O
pools	O
using	O
a	O
similar	O
approach	O
to	O
that	O
used	O
for	O
3-epi-25(OH)D_3	B
,	O
but	O
none	O
was	O
detected.	O

The	O
isolated	O
EVs	O
were	O
resuspended	O
in	O
phosphate-buffered	B
saline	I
(PBS)	O
and	O
used	O
in	O
the	O
subsequent	O
assays.	O

Depending	O
on	O
the	O
medium	O
used	O
in	O
culture-based	O
protocols,	O
either	O
reductions	O
in	O
Bifidobacteria	O
or	O
no	O
differences	O
in	O
their	O
concentration	O
were	O
observed	O
in	O
stool	O
samples	O
from	O
IBS	O
patients,	O
while	O
the	O
level	O
of	O
the	O
genus	O
Lactobacillusis	B
was	O
either	O
increased	O
or	O
reduced	O
in	O
IBS	O
fecal	O
samples.	O

For	O
enzymes	O
with	O
unspecific	O
substrate	O
or	O
product	O
annotations,	O
such	O
as	O
‘a	O
carboxylate’,	B
specific	O
annotations,	O
e.g.,	O
4-hydroxyphenylacetate,	B
were	O
added	O
manually.	O

The	O
addition	O
of	O
acetonitrile	B
in	O
the	O
ratio	O
of	O
2 : 1	O
to	O
a	O
biofluid	O
sample	O
was	O
found	O
to	O
be	O
most	O
efficient	O
in	O
removing	O
protein	O
from	O
the	O
sample	O
(efficiency	O
>	O
96%).	O

Serum	O
glucose	B
concentrations	O
were	O
higher	O
in	O
the	O
high–cystathionine	B
concentration	O
group	O
(P	O
=	O
0.026),	O
whereas	O
glycated	O
hemoglobin	O
concentrations	O
did	O
not	O
differ	O
between	O
groups.	O

In	O
total,	O
six	O
metabolites	O
(glycine,	O
valine,	B
methionine,	B
citrulline,	B
arginine	B
and	O
C16-carnitine)	B
were	O
considered	O
to	O
be	O
potential	O
biomarkers	O
for	O
lung	O
cancer.	O

The	O
sensitivity	O
is	O
achieved	O
by	O
using	O
ammonium	B
fluoride	I
as	O
an	O
eluent	O
additive,	O
which	O
in	O
our	O
case	O
amplifies	O
the	O
signal	O
from	O
our	O
analytes	O
in	O
the	O
plasma	O
solution	O
on	O
average	O
about	O
70	O
times.	O

	O
Sixteen	O
300	O
μL	O
serum	O
samples	O
were	O
mixed	O
with	O
methanol	B
in	O
1:1,	O
1:2,	O
1:3	O
or	O
1:4	O
ratios	O
(v/v)	O

Metabolites	O
whose	O
change	O
correlated	O
with	O
LDL-C	O
lowering	O
response	O
to	O
simvastatin	B
in	O
the	O
full	O
range	O
responders	O
included	O
cystine,	B
urea	B
cycle	O
intermediates,	O
and	O
the	O
dibasic	O
amino	O
acids	O
ornithine,	O
citrulline	B
and	O
lysine.	B

In	O
murine	B
peritonitis	O
models	O
SPM	O
formation	O
was	O
reduced	O
after	O
the	O
initiation	O
of	O
inflammation	O
(highest	O
after	O
2–6	O
h,	O
reduced/not	O
detectable	O
after	O
9–24	O
h)	O

The	O
metabolites	O
are	O
numbered	O
accordingly:	O
1:	O
decanoylcarnitine	B
(C10);	O
2:	O
tetradecenoylcarnitine	B
(C14 : 1);	O
3:	O
octanoylcarnitine	B
(C8);	O
4:	O
nonanoylcarnitine	B
(C9);	O
5:	O
arginine;	B
6:	O
kynurenine;	B
7:	O
lysophosphatidylcholine	O
acyl	O
(lysoPC	O
a)	O
C16 : 0;	O
8:	O
lysoPC	O
a	O
C18 : 0;	O
9:	O
lysoPC	O
a	O
C20 : 4;	O
10:	O
phosphatidylcholine	O
diacyl	O
(PC	O
aa)	O

The	O
Kruskal-Wallis	O
ANOVA,	O
followed	O
by	O
the	O
Dunns'	O
Multiple	O
Comparison	O
test,	O
was	O
used	O
to	O
evaluate	O
the	O
anthocyanin	B
levels	O
at	O
respective	O
time	O
points	O
in	O
the	O
donor	O
population	O
as	O
a	O
whole.	O

After	O
adjusting	O
for	O
tryptophan	B
levels,	O
only	O
3-hydroxyanthranilic	B
acid	I
and	O
cotinine	B
remained	O
significant.	O

However,	O
no	O
functional	O
role	O
of	O
urinary	O
2-oxoglutarate	B
has	O
been	O
proposed	O
in	O
the	O
setting	O
of	O
bladder	O
wall	O
abnormalities	O
or	O
bladder	O
diseases,	O
and	O
no	O
correlations	O
have	O
been	O
previously	O
described.	O

First,	O
the	O
dried	O
samples	O
were	O
dissolved	O
in	O
100	O
µl	O
of	O
a	O
solution	O
of	O
methoxyamine	B
hydrochloride	I
in	O
pyridine	B
(20	O
mg	O
ml_−1	O
;	O
Sigma)	O
and	O
incubated	O
at	O
75	O
°C	O
for	O
30	O
min.	O

However,	O
DG	O
and	O
Cer	B
species	O
have	O
a	O
different	O
mass	O
range	O
from	O
phospholipids.	B

Lactate	B
and	O
creatinine	B
are	O
currently	O
the	O
two	O
primary	O
metabolites	O
used	O
clinically	O
to	O
assess	O
the	O
degree	O
of	O
hypoxic-ischemic	O
injury	O
due	O
to	O
perinatal	O
asphyxia.	O

While	O
these	O
data	O
collectively	O
suggest	O
that	O
artefactual,	O
non-enzymatic	O
modification	O
of	O
oxylipins	B
during	O
sample	O
collection,	O
storage,	O
processing	O
and	O
analysis	O
does	O
not	O
likely	O
contribute	O
significantly	O
to	O
the	O
species	O
observed	O
herein,	O
such	O
processes	O
cannot	O
be	O
ruled	O
out	O
completely	O
and	O
must	O
be	O
considered	O
with	O
follow-up	O
biological	O
experiments.	O

With	O
respect	O
to	O
their	O
correlations	O
with	O
BMI	O
and	O
HOMA-IR,	O
d16:1	B
SPs	O
are	O
uniformly	O
higher	O
and	O
d18:2	B
SPs	O
are	O
often	O
lower	O
than	O
that	O
of	O
the	O
canonical	O
d18:1	B
species.	O

"All	O
spectra	O
showed	O
a	O
series	O
of	O
b_n	O
-type	O
ions	O
and	O
a	O
characteristic	O
complementary	O
ion	O
pair	O
identified	O
as	O
b_12	O
/y""_6	O
,	O
suggesting	O
a	B
proline	I
residue	O
at	O
position	O
13."	O

Significant	O
decrease	O
of	O
methylamines,	B
acetoacetate,	B
acetone	B
and	O
succinate,	B
known	O
indicators	O
of	O
type	O
2	O
diabetes	O
mellitus,	O
were	O
observed	O
after	O
the	O
intake	O
of	O
meals	O
enriched	O
with	O
blueberries.	O

Non-esterified	O
oxylipins	B
were	O
isolated	O
directly	O
from	O
TGRL	O
solution	O
in	O
PBS	O
using	O
solid	O
phase	O
extraction.	O

We	O
further	O
defined	O
a	O
panel	O
of	O
four	O
lipid	O
markers	O
(LPE(18:1),	O
ePE(40:4),	B
C(18:2)CE	B
and	O
SM(22:0))	B
for	O
prediction	O
of	O
early	O
cancer	O
with	O
a	O
accuracy	O
of	O
82.3%	O
AUC	O

The	O
metabonomic	O
data	O
obtained	O
were	O
normalized	O
using	O
internal	O
standard	O
p	B
-chlorophenylalanine	I
and	O
calibrated	O
using	O
QC	O
samples.	O

The	O
greatest	O
inter-donor	O
variability	O
was	O
noted	O
at	O
the	O
early	O
(0,	O
5	O
and	O
30	O
minutes)	O
time	O
points,	O
and	O
most	O
apparent	O
in	O
the	O
cyanidin	B
3-rutinoside	I
(predominant	O
BRB	O
anthocyanin)	B
and	O
protocatechuic	B
acid	I
(stabilized	O
metabolite)	O
samples.	O

Recently,	O
the	O
pentose	B
phosphate	I
pathway	O
has	O
been	O
reportedly	O
associated	O
with	O
adiposity,	O
a	O
higher	O
glycemic	B
phenotype_52	O
and	O
diabetes	O
complications_48	O
.	O

Then,	O
their	O
free	O
species	O
were	O
preconcentrated	O
into	O
20%	O
toluene	B
in	O
pentane,	B
derivatized	O
and	O
quantified	O
by	O
GC-MS/MS.	O

Metabolite	O
levels	O
were	O
normalized	O
to	O
creatinine	B
to	O
control	O
for	O
kidney	O
function.	O

It	O
is	O
important	O
to	O
mention	O
that	O
rs2008720	O
maps	O
to	O
first	O
exon	O
of	O
PRODH	O
(PRODH-001	O
isoform)	O
resulting	O
the	O
amino-acid	B
change	O
Pro19Gln,	O
whereas	O
it	O
also	O
maps	O
to	O
the	O
promoter	O
regulatory	O
region	O
of	O
another	O
PRODH	O
isoform	O
(PRODH-004	O
).	O

While	O
mercapturic	B
acid	I
sulfoxides	I
have	O
been	O
reported	O
for	O
a	O
number	O
of	O
compounds	O
in	O
rodent	O
urine,	O
most	O
human	O
urinary	O
biomarker	O
studies	O
focus	O
on	O
the	O
mercapturic	B
acid	I
metabolites	O
of	O
environmental	O
chemicals.	O

Albumin,	O
triglyceride,	B
total	O
cholesterol,	B
HDL,	O
LDL	O
and	O
FBS	O
were	O
determined	O
by	O
automatic	O
biochemical	O
analyzer.	O

The	O
reaction	O
mixtures	O
were	O
adjusted	O
to	O
pH	O
4	O
with	O
1	O
mol/L	O
of	O
HCl	O
and	O
extracted	O
with	O
2	O
mL	O
of	O
ethyl	B
acetate	I
twice.	O

In	O
the	O
ACLF	O
group,	O
lipid	O
metabolism,	O
lactate,	B
amino-acid	B
metabolism,	O
and	O
urea	B
metabolism	O
were	O
affected	O
by	O
impaired	O
liver	O
function.	O

NAA	O
is	O
synthesized	O
in	O
neuronal	O
mitochondria	O
and	O
transferred	O
to	O
oligodendrocytes,	O
where	O
ASPA	O
liberates	O
the	O
acetate	B
moiety	O
to	O
be	O
used	O
for	O
myelin	B
lipid	O
synthesis.	O

The	O
lower	O
layer	O
was	O
dried	O
by	O
N_2	O
,	O
and	O
then	O
reconstituted	O
in	O
100	O
µL	O
water	O
followed	O
by	O
400	O
µL	O
methanol.	B

Catecholamines	B
are	O
normally	O
at	O
very	O
low	O
concentrations	O
in	O
plasma,	O
but	O
the	O
levels	O
excreted	O
in	O
urine	O
are	O
generally	O
much	O
higher.	O

Those	O
data	O
indicated	O
that	O
the	O
developed	O
LC-MS/MS	O
method	O
was	O
validated	O
to	O
be	O
accurate	O
and	O
precise	O
in	O
analysis	O
of	O
human	O
serum	O
samples	O
with	O
proline	B
concentration	O
from	O
2.5	O
to	O
100	O
μg/mL.	O

Here,	O
we	O
observed	O
a	O
number	O
of	O
dysregulated	O
metabolic	O
pathways,	O
such	O
as	O
metabolism	O
of	O
xenobiotics	O
by	O
cytochrome	O
P450,	O
phenylalanine	B
metabolism,	O
amino	B
sugar	O
and	O
nucleotide	O
sugar	O
metabolism.	O

The	O
proposed	O
glucuronide	B
metabolite	O
structure	O
also	O
explains	O
the	O
absence	O
of	O
any	O
EC-array	O
signal	O
at	O
18.4	O
min	O
since	O
its	O
functional	O
groups	O
are	O
not	O
expected	O
to	O
undergo	O
redox	O
reaction	O
at	O
the	O
voltages	O
employed.	O

Next,	O
we	O
also	O
examined	O
the	O
possibility	O
that	O
stearic	B
acid,	I
not	O
oleic	B
acid,	I
was	O
the	O
biosynthetic	O
precursor	O
of	O
9-HSA.	O

Accordingly,	O
we	O
found	O
that	O
the	O
glycerol-3-phosphate	B
level	O
was	O
lower	O
in	O
GBM	O
compared	O
to	O
oligodendrogliomas	O
as	O
well	O
as	O
lower	O
in	O
short	O
surviving	O
patients,	O
which	O
would	O
be	O
expected	O
in	O
highly	O
proliferating	O
tumors.	O

Serum	O
levels	O
of	O
total	O
bilirubin	B
(TBIL),	O
direct	O
bilirubin	B
(DBIL),	O
indirect	O
bilirubin	B
(IDBIL),	O
alanine	O
aminotransferase	O
(ALT),	O
aspartate	O
aminotransferase	O
(AST),	O
gamma	O
glutamyl	O
transferase	O
(GGT),	O
and	O
albumin	O
(ALB)	O
were	O
measured	O
by	O
an	O
automatic	O
biochemical	O
analyzer	O
(Model	O
LX-20;	O
Beckman,	O
Fullerton,	O
USA).	O

In	O
the	O
discovery	O
cohort,	O
three	O
metabolites	O
–	O
citrate,	B
hippurate,	B
and	O
3-hydroxyisovalerate	B
–	O
were	O
found	O
to	O
be	O
significantly	O
associated	O
with	O
disease	O
activity	O
in	O
CD	O
after	O
multiple-test	O
correction	O
(Fig.	O

Metabolite	O
keys:	O
1,	O
isoleucine;	B
2,	O
leucine;	B
3,	O
valine;	B
4,	O
lactate;	B
5,	O
threonine;	B
6,	O
alanine;	B
7,	O
lysine;	B
8,	O
arginine;	B
9,	O
proline;	B
10,	O
glutamate;	B
11,	O
methionine;	B
12,	O
glutamine;	B
13,	O
creatine;	B
14,	O
choline;	B
15,	O
glycine;	B
16,	O
tyrosine;	B
17,	O
phenylalanine;	B
18,	O
scyllo	O
-inositol;	O
19,	O
lipid;	O
20,	O
aspartate;	B
21,	O
asparagine;	B
22,	O
glutathione;	B
23,	O
cysteine;	B
24,	O
phosphorylcholine/glycerophosphocholine;	O
25,	O
taurine;	B
26,	O
myo	O
-inositol;	O
27,	O
phosphoethanolamine;	B
28,	O
uracil;	B
29,	O
cytosine;	B
30,	O
isocytosine;	O
31,	O
acetate;	B
32,	O
fumarate;	B
33,	O
inosine;	B
34,	O
formate.	B

In	O
glycolysis,	O
hexokinase	O
and	O
phosphofructokinase	O
catalyse	O
reactions	O
where	O
ATP	B
is	O
the	O
phosphate-group	O
donor.	O

Stars	O
in	O
boxplots	O
indicate	O
significant	O
differences	O
in	O
concentration	O
between	O
methionine	B
sulfoxide	I
in	O
serum	O
W	O
tubes	O
with	O
clotting	O
activator	O
and	O
serum	O
gel-barrier	O
tubes.	O

shows	O
that	O
many,	O
but	O
no	O
all,	O
of	O
the	O
participants	O
who	O
experienced	O
an	O
absolute	O
change	O
in	O
2-OHE_1	O
/16α-OHE_1	B
ratio	O
greater	O
than	O
100	O
had	O
a	O
high	O
baseline	O
2-OHE_1	O
/16α-OHE_1	B
ratio.	O

Based	O
on	O
comparison	O
of	O
the	O
metabolic	O
profiles	O
for	O
the	O
three	O
arms	O
of	O
the	O
TORAVA	O
trial,	O
a	O
significant	O
discrimination	O
is	O
only	O
observed	O
between	O
the	O
experimental	O
arm	O
and	O
arm	O
B	O
(sunitinib)	O
after	O
several	O
weeks	O
of	O
treatment.	O

Oxysterols	B
and	O
bile	O
acids	O
in	O
CSF	O

Cluster	O
2,	O
comprised	O
predominantly	O
of	O
C18-derived	O
esterified	O
diols	O
(12,13-DiHOME,	O
9,10-	B
DiHOME,	I
15,16-DiHODE,	B
9,10-DiHODE),	B
negatively	O
correlated	O
with	O
VCAM-1	O
expression.	O

This	O
may	O
be	O
a	O
consequence	O
of	O
increased	O
activation	O
of	O
xanthine	B
oxidase	O
and	O
adenosine	O
deaminase.	O

The	O
severe	O
deregulation	O
in	O
acylcarnitine	B
and	O
sphingomyelin	B
metabolism	O
suggests	O
that	O
HIV	O
infection	O
leads	O
to	O
deficiencies	O
in	O
mitochondrial	O
function.	O

Among	O
the	O
9	O
metabolites,	O
lysoPC	O
a	O
C20:3	B
was	O
found	O
significantly	O
lower	O
in	O
Class	O
C	O
than	O
in	O
Class	O
A	O
and	O
Class	O
B	O
in	O
both	O
HBV-associated	O
cirrhosis	O
and	O
HBV-associated	O
HCC	O
groups.	O

The	O
method	O
of	O
Miller	O
et	O
al.	O
did	O
not	O
identify	O
guanidinoacetic	B
acid,	I
methylmalonic	B
acid	I
and	O
C14:1	B
and	O
C14:2	B
carnitine.	I

The	O
y	O
-intercept	O
represents	O
the	O
amount	O
present	O
in	O
each	O
pooled	O
sample	O
before	O
addition	O
of	O
cotinine	B
or	O
NNAL.	O

Thus,	O
H.	O
pylori	O
infection	O
may	O
partially	O
explain	O
the	O
higher	O
serum	O
level	O
of	O
specific	O
acylcarnitine	B
metabolites	O
shown	O
in	O
our	O
patients.	O

Then	O
90 ul	O
of	O
N-methyl-N-trimethylsilyltrifluoroacetamide	B
(MSTFA)	O
was	O
added	O
and	O
shaken	O
at	O
37 °C	O
for	O
30 min.	O

Sphingosine	B
is	O
a	O
potent	O
bioactive	O
signalling	O
lipid	O
involved	O
in	O
the	O
regulation	O
of	O
processes	O
such	O
as	O
cell	O
growth,	O
differentiation,	O
and	O
apoptosis.	O

After	O
mixing	O
for	O
5	O
min,	O
the	O
plate	O
was	O
centrifuged	O
for	O
30	O
min	O
at	O
−5	O
°C,	O
and	O
then	O
0.96	O
mL	O
mixtures	O
from	O
each	O
well	O
was	O
transferred	O
onto	O
the	O
96-well	O
SPE	O
plate,	O
pre-equilibrated	O
with	O
1.0	O
mL	O
of	O
methanol	B
and	O
1.0	O
mL	O
of	O
buffer	O
(5	O
mM	O
ammonium	B
formate,	I
0.05%	O
formic	O
acid).	O

Polypoidal	O
choroidal	O
vasculopathy	O
(PCV)	O
is	O
a	O
disease	O
characterized	O
by	O
a	O
branching	O
choroidal	O
network	O
with	O
terminal	O
polypoidal	O
dilatations	O
of	O
the	O
choroidal	O
vessels	O
in	O
the	O
macular	O
and/or	O
peripapillary	O
area,	O
which	O
cause	O
episodic	O
leakage	O
and	O
bleeding	O
under	O
the	O
retinal	B
pigment	O
epithelium	O
(RPE)	O
and	O
neurosensory	O
retina_,	O
_,	O
.	O

The	O
concentration	O
values	O
of	O
polyamines,	B
precursors,	O
and	O
catabolites	O
measured	O
by	O
the	O
current	O
method	O
are	O
shown	O
in	O
and	O
Supplementary	O
Figure	O
S2	O
and	O
are	O
in	O
accordance	O
with	O
those	O
reported	O
in	O
the	O
literature	O
in	O
serum	O
[,,]	O
and	O
urine	O
[,,].	O

Intriguingly,	O
cosecretion	O
of	O
glucocorticoids	B
could	O
also	O
potentially	O
explain	O
the	O
recent	O
finding	O
that	O
adrenal	O
vein	O
sampling	O
performs	O
less	O
well	O
than	O
previously	O
assumed	O
in	O
differentiating	O
unilateral	O
from	O
bilateral	O
adrenal	O
causes	O
of	O
primary	O
aldosteronism,	O
as	O
this	O
test	O
relies	O
on	O
the	O
assumption	O
of	O
an	O
increase	O
in	O
the	O
aldosterone	B
over	O
cortisol	B
ratio	O
in	O
unilateral	O
disease,	O
which	O
may	O
be	O
diluted	O
in	O
adenomas	O
with	O
cosecretion.	O

For	O
intracellular	O
cytokine	O
staining,	O
cells	O
were	O
stimulated	O
with	O
phorbol	O
myristate	B
acetate	I
(PMA;	O
5	O
ng/mL;	O
Sigma-Aldrich,	O
St	O
Louis,	O
Missouri)	O
and	O
ionomycin	B
(1	O
μM/mL;	O
Thermo	O
Fisher	O
Scientific)	O
for	O
10–14	O
hours,	O
in	O
the	O
presence	O
of	O
brefeldin	O
A	O
(1	O
μg/mL;	O
Sigma-Aldrich).	O

Pyridinium	B
dichromate	O
(1.3	O
mg,	O
3.5	O
μmol)	O
was	O
added	O
directly	O
to	O
a	O
solution	O
of	O
either	O
N	B
-acetyl-S	I
-[1-(5-hydroxy-5-carboxypentyl)-1H	I
-pyrrol-3-yl]-L-cysteine	I
or	O
N	O
-acetyl-S	O
-[1-(5-hydroxy-5-carboxypentyl)-1H	O
-pyrrol-3-yl]-L-cysteine	O
sulfoxide(3.5	O
μmol)	O
in	O
0.5	O
mL	O
dichloromethane-dimethylformamide	B
(1:1)	I
at	O
0	O
°C.	O

Conclusions:	O
Despite	O
a	O
pronounced	O
caloric	O
deficit	O
and	O
sustained	O
activity	O
under	O
extreme	O
cold	O
conditions,	O
FFM	O
was	O
preserved	O
with	O
an	O
increase	O
in	O
serum	O
follistatin	B
and	O
acetoacetate.	B

Phosphatidic	B
acid	I
is	O
the	O
most	O
representative	O
metabolite	O
in	O
both	O
HU	O
and	O
HU+NAFLD.	O

There	O
were	O
six	O
main	O
findings	O
of	O
this	O
study	O
in	O
relation	O
to	O
HCC	O
versus	O
controls,	O
(1)	O
that	O
two	O
bile	O
acid	O
conjugates	O
and	O
two	O
fetal	O
bile	O
acids	O
were	O
elevated,	O
(2)	O
that	O
bilirubin	B
and	O
biliverdin	B
were	O
elevated,	O
(3)	O
that	O
11	O
lysophospholipids	B
were	O
attenuated,	O
(4)	O
that	O
two	O
very	O
long-chain	O
fatty	O
acids	O
were	O
attenuated,	O
(5)	O
that	O
LPA(16:0)	B
was	O
considerably	O
elevated	O
in	O
4/20	O
HCC	O
patients,	O
and	O
(6)	O
that	O
in	O
the	O
HCC	O
group	O
as	O
a	O
whole	O
LPA(16:0)	B
was	O
strongly	O
correlated	O
with	O
plasma	O
AFP	O
concentration.	O

The	O
four	O
metabolites	O
(valine,	O
methionine,	B
citrulline	B
and	O
arginine)	B
were	O
altered	O
significantly	O
in	O
the	O
patients	O
with	O
lung	O
cancer	O
in	O
the	O
two	O
data	O
sets,	O
and	O
these	O
results	O
suggested	O
their	O
potential	O
to	O
distinguish	O
the	O
metabolites	O
in	O
patients	O
with	O
lung	O
cancer.	O

This	O
primate’s	O
initial	O
blood	O
gas	O
(pH	O
6.78,	O
base	O
excess	O
of	O
−25)	O
and	O
peak	O
lactate	B
(15.8	O
mmol/l)	O
were	O
on	O
the	O
severe	O
end	O
of	O
the	O
spectrum	O
of	O
values	O
in	O
the	O
asphyxia	O
group.	O

Spearman	O
correlation	O
(ρ)	O
of	O
methylation	O
degrees	O
(log-cpm)	O
and	O
(a)	O
genistein,	B
(b)	O
daidzein	B
and	O
(c)	O
total	O
isoflavone	B
concentrations.	O

Lysates	O
were	O
prepared	O
from	O
mixed	O
stage	O
culture	O
and	O
separated	O
on	O
10%	O
denaturing	O
Tris-glycine	B
gels.	O

The	O
JECS	O
is	O
a	O
multi‐region,	O
multi‐facility	O
cohort	O
study;	O
thus,	O
we	O
could	O
not	O
review	O
the	O
accuracy	O
of	O
the	O
diagnostic	O
process	O
or	O
oral	O
glucose	B
tolerance	O
test	O
results	O
for	O
all	O
enrolled	O
participants.	O

Furthermore,	O
Burton	O
and	O
Ma	O
analyzed	O
the	O
literature	O
investigating	O
the	O
use	O
of	O
urinary	O
metabolomics	O
to	O
develop	O
cancer	O
biomarkers,	O
and	O
reported	O
a	O
significant	O
number	O
of	O
altered	O
metabolic	O
pathways	O
and	O
putative	O
biomarkers,	O
including	O
pteridines,	B
modified	O
nucleosides,	O
and	O
acylcarnitines,	B
which	O
are	O
all	O
involved	O
in	O
cancer	O
development	O
and	O
progression.	O

The	O
levels	O
of	O
carnitine	B
were	O
found	O
to	O
be	O
increased	O
by	O
dietary	O
intervention,	O
too.	O

Five	O
of	O
the	O
19	O
patients	O
had	O
no	O
significant	O
CAD	O
and	O
no	O
net	O
lactate	B
elution	O
after	O
pacing,	O
strongly	O
suggesting	O
the	O
absence	O
of	O
cardiac	O
ischemia.	O

Hyperactivity	O
of	O
the	O
HPA	O
axis	O
and	O
increased	O
cortisol	B
levels	O
in	O
CSF	O
and	O
serum	O
of	O
AD	O
patients	O
has	O
been	O
described	O
previously	O
in	O
AD	O
patients	O
in	O
several	O
studies	O
,	O
,	O
.	O

This	O
process	O
is	O
less	O
efficient,	O
so	O
cancer	O
cells	O
must	O
enhance	O
glucose	B
uptake	O
to	O
meet	O
the	O
energy	O
requirement	O
maintaining	O
their	O
quickly	O
growth	O
and	O
proliferation.	O

Compared	O
with	O
unilateral	O
thyroidectomy,	O
total	O
thyroidectomy	O
reversed	O
some	O
highly	O
increased	O
metabolite	O
levels	O
(e.g.,	O
taurine	B
and	O
betaine).	O

To	O
confirm	O
the	O
previously	O
reported	O
reference	O
interval	O
for	O
betaine,	B
two	O
studies	O
were	O
evaluated.	O

The	O
mobile	O
phase,	O
delivered	O
at	O
a	O
flow	O
rate	O
of	O
0.5	O
ml/min	O
at	O
40°C,	O
consisted	O
of	O
a	O
gradient	O
of	O
0.1%	O
formic	B
acid	I
in	O
MQ	O
water	O
(A)	O
and	O
MeOH	B
(B).	O

MRS=1−S0(t)e∑pi=1βˆi(Xi−X¯¯¯i)=1−exp{−λˆγˆ}e∑pi=1βˆi(Xi−X¯¯¯i)	B
MRS=1−S0(t)e∑pi=1βˆi(Xi−X¯¯¯i)=1−exp{−λˆγˆ}e∑pi=1βˆi(Xi−X¯¯¯i)	I

A	O
∼10	O
mg	O
colon	O
biopsy	O
was	O
used	O
for	O
a	O
two-step	O
metabolite	O
extraction	O
with	O
4-chlorophenylalanine	B
(used	O
as	O
an	O
internal	O
standard).	O

Steroidal	O
signature	O
of	O
liver	O
disease	O
in	O
childhood	O
obesity:	O
differences	O
between	O
z-transformed	O
concentrations	O
of	O
steroid	O
metabolites	O
(androgens,	O
glucocorticoids	B
and	O
mineralocorticoids)	O
in	O
liver	O
diseases	O
(L1)	O
and	O
with	O
non-liver	O
disease	O
features	O
(L0)	O
patients.	O

Box	O
plots	O
of	O
C18:2	B
CE	O
and	O
SM	B
22:0	I
concentrations	I
in	O
the	O
training	O
and	O
validation	O
SqCC	O
cohorts	O
and	O
high-risk	O
controls.	O

All	O
metabolite	O
standards	O
(Sigma-Aldrich)	O
were	O
brought	O
to	O
100	O
mM	O
in	O
DMSO	B
(Sigma-Aldrich,	O
D2438)	O
prior	O
to	O
dilution	O
for	O
dose	O
assays.	O

The	O
serum	O
levels	O
of	O
dodecanoic	B
acid,	I
pinitol,	B
maltol,	B
sucrose,	B
and	O
S13	O
were	O
significantly	O
higher	O
after	O
soy	O
drink	O
intake	O
than	O
after	O
milk	O
and	O
cheese	O
intake	O
at	O
1,	O
2,	O
and	O
4	O
h	O
(see	O
Tables	O
S3	O
and	O
S4).	O

A	O
positive	O
correlation	O
was	O
observed	O
for	O
proline.	B

Benzoate	B
is	O
formed	O
from	O
dietary	O
aromatic	O
compounds	O
via	O
gut	O
microbial	O
metabolism.	O

Concentrations	O
and	O
acyl	O
combinations	O
of	O
DG	O
and	O
TG	B
species	O
in	O
human	O
feces	O
from	O
20	O
different	O
samples.	O

Previously,	O
RARB	O
and	O
CCND2	O
promoter	O
hypermethylation	O
has	O
been	O
associated	O
with	O
in	O
vivo	O
serum	O
genistein	B
concentrations.	O

In	O
particular,	O
disruption	O
of	O
the	O
gut	O
microbiota	O
may	O
alter	O
estrogen	B
reabsorption	O
and	O
also	O
contribute	O
to	O
obesity-related	O
phenotypes	O
by	O
reduced	O
integrity	O
of	O
the	O
gut	O
mucosa,	O
allowing	O
bacterial	O
translocation	O
into	O
circulation	O
and,	O
as	O
a	O
consequence,	O
chronic	O
low-grade	O
systemic	O
inflammation.	O

The	O
combination	O
of	O
serum	O
dodecanamide	B
and	O
LTB4-DMA	O
given	O
an	O
effective	O
predictor	O
for	O
chemosensitivity.	O

The	O
high	O
voltage	O
employed	O
in	O
electrospray	O
ionization	O
should	O
also	O
be	O
considered	O
a	O
hazard,	O
and	O
the	O
safety	O
interlocks	B
provided	O
by	O
the	O
instrument	O
manufacturer	O
should	O
not	O
be	O
altered.	O

However,	O
only	O
higher	O
plasma	O
TMAO	B
levels	O
was	O
associated	O
with	O
poor	O
prognosis	O
after	O
adjustment	O
for	O
cardio-renal	O
indices.	O

The	O
mobile	O
phases	O
were	O
tested	O
with	O
different	O
organic	O
modifiers	O
(acetonitrile	O
and	O
acetonitrile/water	B
mixtures	O
at	O
various	O
concentrations	O
in	O
water)	O
and	O
a	O
low	O
amount	O
of	O
formic	B
acid	I
or	O
acetic	B
acid.	I

Blood	O
plasma	O
of	O
patients	O
with	O
MATV_WTB	O
 ≥ 48.1 cm³	O
and	O
TLG_WTB	O
 ≥ 276.2 cm³	O
is	O
characterized	O
by	O
higher	O
concentrations	O
of	O
glucose,	B
glycerol,	B
NAG,	O
threonine,	B
aspartate	B
and	O
valine,	B
but	O
lower	O
levels	O
of	O
sphingomyelin	B
(SM)	O
and	O
phosphatidylcholine	B
(PC).	O

Consistent	O
with	O
these	O
reports,	O
the	O
current	O
study	O
showed	O
significant	O
increases	O
in	O
ba-PWV,	O
serum	O
IL-6	O
levels,	O
and	O
lipid	O
peroxides	B
including	O
8-epi	B
-PGF_2α	I
and	O
MDA	O
in	O
the	O
prehypertensive	O
group,	O
and	O
positive	O
correlations	O
among	O
lysoPC	O
(16:0),	O
IL-6,	B
8-epi	I
-PGF_2α	I
,	O
and	O
MDA.	O

In	O
our	O
study	O
the	O
β-glucuronide	B
and	O
sulfate	B
conjugates	O
(total	O
E2	O
-	O
unconjugated	O
E2)	O
corresponded	O
to	O
18	O
pg/mL	O
suggesting	O
that	O
the	O
sulfate	B
was	O
the	O
major	O
conjugate	O
of	O
E2	O
that	O
was	O
present	O
in	O
the	O
serum.	O

On	O
the	O
contrary	O
aspartate	B
has	O
been	O
found	O
to	O
be	O
discriminant	O
in	O
systemic	O
sclerosis	O
but	O
not	O
in	O
the	O
other	O
inflammatory	O
and	O
autoimmune	O
disorders.	O

Demographic	O
and	O
clinical	O
characteristics	O
and	O
serum	O
kynurenine	B
pathways	O
metabolites	O
levels	O
in	O
the	O
study	O
groups	O
LC/MS-MS	O
analysis	O
of	O
kynurenine	B
metabolites	O
showed	O
significant	O
reductions	O
in	O
serum	O
levels	O
of	O
KYN	O
(-36 %),	O
KYNA	O
(-34 %),	O
3-HK	O
(-51 %),	O
3-HANA	O
(-54 %),	O
XA	O
(-25 %),	O
5-HIAA	B
(-39 %)	O
and	O
QUINA	O
(-43 %)	O
in	O
the	O
serum	O
of	O
the	O
overall	O
population	O
of	O
patients	O
affected	O
by	O
CH,	O
as	O
compared	O
to	O
HCs	O
(Table ,	O
Fig.	O

The	O
best	O
cut-off	O
was	O
found	O
at	O
the	O
value	O
of	O
134.38	O
μM,	O
where	O
palmitic	B
acid	I
achieved	O
a	O
sensitivity	O
of	O
100%	O
and	O
a	O
specificity	O
of	O
100%.	O

Severe	O
deregulation	O
in	O
acylcarnitine	B
and	O
sphingomyelin	B
metabolism	O
compatible	O
with	O
mitochondrial	O
deficiencies	O
was	O
observed.	O

P	O
_1	O
-values	O
were	O
derived	O
from	O
an	O
independent	O
t-test	O
after	O
adjusting	O
for	O
age,	O
BMI,	O
waist-to-hip	O
ratio,	O
smoking,	O
drinking,	O
systolic	O
and	O
diastolic	O
blood	O
pressure,	O
total-	O
and	O
LDL-cholesterol,	B
glucose,	B
and	O
insulin.	O

Upregulation	O
of	O
proline	B
and	O
cysteine	B
pathways	O
have	O
also	O
been	O
associated	O
with	O
proliferation	O
and	O
cell	O
cycle	O
in	O
HCC.	O

In	O
PET-negative	O
patients,	O
a	O
high	O
relative	O
glutamate	B
concentration	O
excludes	O
lung	O
cancer	O
in	O
all	O
patients	O
(NPV	O
100%).	O

Specifically,	O
both	O
amino	O
acids	O
and	O
amino	B
acid-related	O
analytes,	O
as	O
well	O
as	O
specific	O
bile	O
acids,	O
were	O
associated	O
with	O
macro-albuminuria.	O

_,	O
For	O
3-hydroxybutyrate,	B
we	O
found	O
increased	O
serum	O
levels	O
(Table	O
2)	O
in	O
deceased	O
patients,	O
whereas	O
no	O
difference	O
in	O
connectivity	O
is	O
present.	O

Upon	O
cleavage,	O
FFA	B
(20:4)	I
is	O
the	O
parent	O
molecule	O
from	O
which	O
many	O
prostaglandins,	B
leukotrienes,	O
and	O
other	O
inflammatory	O
molecules	O
are	O
produced.	O

m	O
The	O
internal	O
standard	O
of	O
bile	O
acids	O
(BAs)	O
included	O
cholic	O
acid-D4,	O
ursodeoxycholic	B
acid-D4,	O
lithocholic	B
acid,	I
glycocholic	B
acid-D4,	O
and	O
glycodeoxycholic	B
acid-D4.	O

Considering	O
that	O
NO	O
is	O
potent	O
immunomodulators,	O
arginine	B
metabolism	O
play	O
significant	O
roles	O
in	O
physiological	O
and	O
pathological	O
conditions.	O

Also	O
citrate	B
can	O
be	O
converted	O
to	O
Acetyl-CoA	B
and	O
contribute	O
in	O
the	O
synthesis	O
of	O
fatty	O
acids	O
and	O
cholesterol,	B
essential	O
components	O
of	O
cancer	O
cell	O
membranes.	O

N	B
-Acetoxy-PhIP,	I
a	O
penultimate	O
metabolite	O
of	O
PhIP	O
that	O
reacts	O
with	O
DNA	O
to	O
form	O
covalent	O
adducts,	O
did	O
not	O
appear	O
to	O
form	O
stable	O
adducts	O
with	O
SA;	O
instead,	O
PhIP	O
and	O
2-amino-1-methyl-6-(5-hydroxy)-phenylimidazo[4,5-b	B
]pyridine,	I
an	O
aqueous	O
reaction	O
product	O
of	O
the	O
proposed	O
nitrenium	O
ion	O
of	O
PhIP,	O
were	O
recovered	O
during	O
the	O
proteolysis	O
of	O
N	O
-acetoxy-PhIP-modified	O
SA.	O

The	O
human	O
RMS	O
cell	O
line	O
Rh30	O
(established	O
at	O
St.	O
Jude	O
Hospital),	O
and	O
human	O
primary	O
myocytes	O
were	O
cultured	O
in	O
pyruvate	B
and	O
glucose-free	O
RPMI	O
1640	O
(Invitrogen,	O
11879-020),	O
supplemented	O
with	O
100	O
IU/ml	O
penicillin,	B
10	O
μg/ml	O
streptomycin,	B
and	O
50	O
μg/ml	O
neomycin	B
(Life	O
Technologies,	O
Inc.,	O
Grand	O
Island,	O
NY)	O
in	O
the	O
presence	O
of	O
10%	O
heat-inactivated	O
FCS	O
(Life	O
Technologies)	O
and	O
0.2%	O
glucose.	B

The	O
estimated	O
levels	O
of	O
ribavirin	B
triphosphate	I
also	O
approach	O
the	O
reported	O
binding	O
constant	O
of	O
500	O
to	O
700	O
μM	O
for	O
incorporation	O
as	O
an	O
ATP	B
or	O
GTP	O
analog	O
by	O
HCV	O
NS5B.	O
In	O
a	O
previous	O
study	O
of	O
sofosbuvir	B
pharmacokinetics	O
in	O
HCV-infected	O
patients,	O
Rower	O
et	O
al.	O

We	O
confirmed	O
the	O
specificity	O
of	O
these	O
three	O
replicated	O
signals	O
to	O
HCTZ	O
BP	O
response	O
by	O
testing	O
them	O
in	O
whites	O
treated	O
with	O
other	O
antihypertensives	O
like	O
atenolol	B
in	O
PEAR	O
and	O
candesartan	O
in	O
GERA.	O

As	O
expected,	O
choline	B
was	O
the	O
superior	O
biomarker	O
for	O
TB-DM	O
versus	O
HC	O
from	O
our	O
dataset	O
(AUC:	O
0.991	O

1,25(OH)_2	B
D	O
suppresses	O
gene	O
transcription	O
by	O
binding	O
to	O
vitamin	B
D	I
receptor	O
(VDR),	O
with	O
CYP3A4	O
being	O
the	O
most	O
important	O
cytochrome	O
P450	O
species	O
supressed	O
by	O
1,25(OH)_2	B
D.	O

The	O
average	O
difference	O
was	O
8.73	O
pmol/mg	O
creatinine	B
(95%	O
CI	O
5.36,	O
12.10,	O
p=0.00002).	O

Finally,	O
the	O
compounds	O
were	O
eluted	O
using	O
1000	O
μL	O
of	O
25%	O
water	O
in	O
acetonitrile	B
and	O
collected	O
in	O
a	O
2	O
mL	O
96-well	O
NUNC	O
plate.	O

Differences	O
in	O
free	O
choline	B
and	O
PC	O
level	O
in	O
serum	O
have	O
been	O
associated	O
with	O
early	O
markers	O
of	O
risk	O
of	O
having	O
cardiovascular	O
disease	O
(CVD)	O
.	O

Tables 	O
and	O
,	O
shows	O
the	O
lipoproteins	O
identified	O
and	O
their	O
concentrations,	O
phosphatidylcholines	B
and	O
glycoprotein	B
properties,	O
as	O
well	O
as	O
LMW	O
metabolites	O
for	O
each	O
clinical	O
phenotype	O
(SGA	O
and	O
FGR)	O
in	O
maternal	O
and	O
cord	O
blood,	O
respectively.	O

They	O
include	O
4	O
essential	O
FAs,	O
17	O
long-chain	O
FAs,	O
3	O
monohydroxy	B
FAs,	O
4	O
dicarboxylate	B
acids,	I
and	O
5	O
carnitine	B
metabolites.	O

The	O
plasma	O
proteins	O
were	O
precipitated	O
with	O
the	O
addition	O
of	O
400	O
μL	O
of	O
cold	O
20%	O
0.2M	O
ZnSO4	O
in	O
methanol	B
and	O
kept	O
at	O
−20_o	O
C	O
for	O
30	O
min.	O

The	O
predictive	O
values	O
of	O
C18:2	B
CE	O
and	O
SM	O
22:0	O
were	O
analyzed	O
separately	O
and	O
combined.	O

The	O
level	O
of	O
tyrosine	B
was	O
decreased	O
in	O
the	O
urine	O
of	O
postpartum	O
depressed	O
patients	O
in	O
this	O
study,	O
which	O
was	O
consistent	O
with	O
the	O
previous	O
studies	O
that	O
showed	O
the	O
decrease	O
in	O
the	O
blood	O
of	O
depressed	O
patients	O
and	O
supported	O
the	O
hypothesis	O
that	O
dopaminergic	O
factors	O
are	O
involved	O
in	O
clinical	O
depression.	O

For	O
example,	O
it	O
has	O
been	O
estimated	O
that	O
ethanol,	B
which	O
has	O
a	O
high	O
blood	O
solubility	O
(λ	O
_b:a	O
 = 1,803),	O
can	O
show	O
a	O
20%	O
lower	O
concentration	O
than	O
alveolar	O
air	O
after	O
a	O
complete	O
prolonged	O
exhalation.	O

In	O
their	O
system,	O
murine	B
memory	O
T	O
cells	O
display	O
a	O
distinct	O
metabolic	O
profile	O
as	O
compared	O
to	O
effector	O
T	O
cells.	O

After	O
successive	O
washing	O
with	O
solution	O
A	O
and	O
solution	O
B	O
(0.1 %	O
TFA	O
and	O
80 %	O
acetonitrile),	O
0.5 %	O
piperidine	B
was	O
used	O
for	O
elution.	O

Aqueous	O
metabolites	O
will	O
be	O
dried	O
under	O
vacuum,	O
and	O
then	O
derivatized	O
using	O
methoxyamine	B
and	O
MSTFA.	O

In	O
the	O
AASK,	O
mGFR	O
was	O
computed	O
as	O
the	O
weighted	O
mean	O
of	O
four	O
clearance	O
periods	O
of	O
25–35 min	O
duration.	B

During	O
ischemia	O
5'-nucleotidase	O
acts	O
on	O
AMP	B
to	O
generate	O
adenosine,	B
a	O
potential	O
vasodilator.	O

Patients	O
with	O
long-term	O
survival	O
showed	O
increased	O
plasma	O
relative	O
intensity	O
of	O
LPE	B
(20:0/0:0)	I
and	O
decreased	O
relative	O
intensity	O
of	O
Kynurenine,	B
Acetylcarnitine,	B
and	O
PC(42:11).	B

The	O
inclusion	O
of	O
uric	B
acid,	I
xanthine,	B
and	O
cholylglycine	B
resulted	O
in	O
model	O
performance	O
with	O
a	O
sensitivity	O
and	O
specificity	O
of	O
95%	O
and	O
62%,	O
respectively,	O
with	O
a	O
calculated	O
AUROC	O
of	O
0.89.	O

Boers	O
et	O
al.	O
demonstrated	O
that	O
guar	O
gum	O
supplementation	O
slightly	O
reduced	O
the	O
rate	O
of	O
appearance	O
of	O
exogenous	O
glucose,	B
but	O
the	O
intervention	O
additionally	O
induced	O
a	O
reduced	O
rate	O
of	O
endogenous	O
glucose	B
production	O
and	O
glucose	B
disposal	O
resulting	O
in	O
lowered	O
glucose	B
levels.	O

The	O
ability	O
of	O
the	O
acidic	O
cholesterol	B
metabolites	O
3β-hydroxycholest-5-en-26-oic,	B
3β,7α-dihydroxycholest-5-en-26-oic,	B
7α-hydroxy-3-oxocholest-4-en-26-oic,	B
7α,12α-dihydroxy-3-oxo-5β-cholan-24-oic	B
(5β-BA-7α,12α-	I
diol-3-one),	I
and	O
3-oxo-5β-cholan-24-oic	B
(5β-BA-3-one)	I
acids	I
to	O
activate	O
several	O
nuclear	O
receptors	O
was	O
tested	O
in	O
luciferase	O
assays.	O

Low	O
serum	O
carnosinase	O
1	O
activity	O
increases	O
circulating	O
carnosine	B
in	O
humans.	O

Human	O
plasma	O
total	O
lipid	O
extracts	O
were	O
spiked	O
with	O
the	O
isobaric	O
CER	B
d18:1/17:0	I
and	O
CER	B
d17:1/18:0	I
standards	O
and	O
analyzed	O
as	O
described	O
in	O
the	O
Experimental	O
section.	O

Pipette	O
tips	O
were	O
engaged	O
with	O
the	O
ESI-Chip	O
to	O
deliver	O
the	O
sample	O
using	O
nitrogen	B
gas	I
pressure	O
at	O
0.5	O
psi	O
and	O
a	O
spray	O
voltage	O
of	O
1.6	O
kV.	B
For	O
each	O
sample	O
new	O
pipette	O
tips	O
and	O
nozzles	O
were	O
used	O
to	O
prevent	O
any	O
cross-contamination	O
or	O
carryover.	O

Nevertheless,	O
only	O
42%	O
of	O
our	O
women	O
visited	O
a	O
primary	O
care	O
physician	O
for	O
aftercare	O
during	O
the	O
study	O
period,	O
confirming	O
the	O
reported	O
low	O
rates	O
of	O
follow-up	O
with	O
glucose	B
testing	O
and	O
primary	O
care	O
visits	O
after	O
delivery.	O

Metabolites	O
with	O
significant	O
treatment-associated	O
effects	O
in	O
both	O
groups	O
were	O
glutamine,	B
gamma-glutamylglutamine,	B
gamma-glutamylalanine,	B
histidine,	B
citrulline,	B
proline,	B
O-acetylserine	B
and	O
glutamate.	B

GCB	O
removes	O
pigments,	O
sterols	O
and	O
non-polar	O
interferences,	O
and	O
may	O
be	O
added	O
to	O
assist	O
the	O
cleanup	O
of	O
intensively	O
colored	O
extracts	O
due	O
to	O
a	O
high	O
content	O
of	O
carotenoids	B
(e.g.,	O
carrots,	O
red	O
sweet	O
pepper)	O
or	O
chlorophyll	B
(e.g.,	O
spinach,	O
rucola,	O
lettuce).	O

The	O
following	O
urinary	O
phthalate	B
and	O
DINCH	O
metabolites	O
and	O
were	O
analyzed:	O
Mono(2-ethylhexyl)	B
phthalate	I
(MEHP);	O
Mono(2-ethyl-5-hydroxyhexyl)	B
phthalate	I
(MEHHP);	O
Mono(2-ethyl-5-oxohexyl)	B
phthalate	I
(MEOHP);	O
Mono(2-ethyl-5-carboxypentyl)	B
phthalate	I
(MECPP);	O
Monocarbxyisooctyl	B
phthalate	I
(MCOP);	O
Mono-isononyl	B
phthalate	I
(MNP);	O
Monobenzyl	B
phthalate	I
(MBzP);	O
Mono	O
(3-carboxypropyl)	O

The	O
predictive	O
power	O
of	O
C18:2	B
CE	O
in	O
the	O
diagnosis	O
of	O
early-stage	O
SqCC	O
exerted	O
a	O
sensitivity	O
of	O
86.4%,	O
a	O
specificity	O
of	O
54.5%	O
and	O
an	O
area	O
under	O
the	O
curve	O
(AUC)	O
value	O
of	O
72.5%.	O

 ,	O
we	O
detected	O
a	O
significant	O
decrease	O
in	O
the	O
levels	O
of	O
various	O
glycolysis	O
metabolites	O
involved	O
in	O
both	O
tumor	O
subtypes,	O
such	O
as	O
glucose,	B
3‐	O
and	O
2‐phosphoglycerate	B
and	O
phosphoenolpyruvate.	B

NA,	O
not	O
applicable;	O
LDL,	O
low-density	O
lipoprotein;	O
MI,	O
myocardial	O
infarction;	O
5-HETE,	B
5-hydroxyicosatetraenoic	B
acid;	I
CHD,	O
coronary	O
heart	O
disease;	O
CVD,	O
cardiovascular	O
disease;	O
MCAD,	O
medium-chain	O
acyl-CoA	O
dehydrogenase.	O

In	O
the	O
resulting	O
model,	O
PC1	O
and	O
PC2	O
cumulatively	O
accounted	O
for	O
38.9	O
percent	O
of	O
the	O
variation,	O
and	O
when	O
loadings	O
vectors	O
were	O
overlaid	O
with	O
PC	O
scores,	O
the	O
resulting	O
Gabriel’s	O
biplot	O
revealed	O
the	O
most	O
important	O
metabolites	O
to	O
be	O
ketone	B
bodies,	O
glutamine,	B
glutamate,	B
and	O
threonine.	B

Mannose	B
is	O
a	O
sugar	O
monomer	O
of	O
the	O
aldohexose	O
series	O
of	O
carbohydrates	O
and	O
a	O
C-2	O
epimer	O
of	O
glucose.	B

IL-17B-induced	O
expression	O
of	O
TNF	O
and	O
IL-1β	B
results	I
in	O
monocytic	O
chemotaxis,	O
a	O
phenomenon	O
that	O
is	O
well	O
described	O
in	O
colorectal	O
liver	O
metastases	O
[,].	O

(R)-3-Hydroxybutanoate.	B

As	O
DDAH	O
enzymes	O
are	O
known	O
mostly	O
as	O
ADMA-metabolizing	O
enzymes	O
and	O
ADMA	B
is	O
primarily	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
cardiovascular	O
diseases,	O
little,	O
if	O
not	O
nothing,	O
is	O
known	O
on	O
DDAHs	O
in	O
IBD.	O

The	O
supernatant,	O
containing	O
proteins	O
and	O
lipids	O
dissolved	O
in	O
HFIP,	O
was	O
then	O
transferred	O
to	O
15	O
ml	O
polypropylene	B
centrifuge	O
tubes.	O

and	O
Eubacteria	O
(universal)	O
were	O
observed,	O
while	O
the	O
abundances	O
of	O
Escherichia	O
coli	O
,	O
Clostridium	O
sp.,	B
and	O
Bacteroides	O
sp.	B
were	O
also	O
increased	O
but	O
the	O
results	O
did	O
not	O
reach	O
statistical	O
significance.	O

Some	O
classes	O
of	O
membrane	O
lipids	O
preferentially	O
ionize	O
in	O
the	O
positive	O
ion	O
mode	O
(e.g.,	O
PC	O
and	O
SM)	O
and	O
others	O
in	O
the	O
negative	O
ion	O
mode	O
(e.g.,	O
phosphatidic	B
acids,	I
PI,	O
and	O
PS)	O
depending	O
largely	O
on	O
the	O
functionality	O
of	O
the	O
polar	O
headgroup.	O

An	O
association	O
with	O
the	O
urine	O
excretion	O
of	O
trigonelline	B
was	O
previously	O
reported	O
with	O
respect	O
to	O
the	O
TH	O
metabolite	O
3,5-T2	B
in	O
a	O
large	O
sample	O
of	O
euthyroid	O
subjects.	O

Decreased	O
dopamine	B
(and	O
its	O
metabolites)	O
and	O
increased	O
MAO	O
activity	O
have	O
been	O
reported	O
in	O
the	O
basal	O
ganglia	O
of	O
SIV-infected	O
macaques	O
and	O
HIV	O
patients	O
with	O
neurological	O
disease	O
[-];	O
these	O
alterations	O
also	O
correlated	O
with	O
neuroinflammation	O
and	O
oxidative	O
stress.	O

Furthermore,	O
since	O
endogenous	O
LXA_4	O
synthesis	O
is	O
limited	O
despite	O
sufficient	O
substrate	O
(15-HETE)	O
which	O
is	O
in	O
line	O
with	O
a	O
defective	O
“lipid	O
mediator	O
class	O
switch”	O
,	O
it	O
might	O
be	O
worthwhile	O
analyzing	O
whether	O
aspirin-triggered	O
epimeric	O
LXA_4	O
levels	O
can	O
also	O
be	O
boosted	O
in	O
the	O
CSF	O
of	O
MS	O
patients,	O
as	O
has	O
been	O
demonstrated	O
in	O
the	O
serum	O
of	O
healthy	O
subjects	O
taking	O
low-dose	O
aspirin.	B

Having	O
modeled	O
the	O
spectral	O
features	O
characterizing	O
acetaminophen	B
ingestion,	O
statistical	O
correlation	O
was	O
performed	O
for	O
prominent	O
acetaminophen-related	O
resonances	O
to	O
determine	O
correlations	O
between	O
protons	O
within	O
the	O
same	O
molecule	O
and	O
to	O
ascertain	O
the	O
statistical	O
relationship	O
between	O
resonances	O
from	O
the	O
parent	O
compound	O
and	O
resonances	O
from	O
acetaminophen	B
metabolites.	O

The	O
tripeptide,	O
GSH	B
is	O
a	O
ubiquitous	O
intra-	O
and	O
extracellular	O
protective	O
antioxidant	O
against	O
oxidative/nitrosative	O
stress,	O
which	O
plays	O
a	O
vital	O
role	O
against	O
pro-inflammatory	O
processes.	O

The	O
top	O
2	O
discriminatory	O
metabolites,	O
myoinositol	B
and	O
formate,	B
are	O
identified	O
by	O
their	O
high	O
VIP	O
scores.	O

In	O
the	O
samples	O
from	O
cancer	O
patients,	O
the	O
levels	O
of	O
valine,	B
ethanol,	B
lactate,	B
alanine,	B
acetate,	B
citrate,	B
phenylalanine,	B
tyrosine,	B
methanol,	B
formaldehyde,	B
and	O
formic	B
acid	I
were	O
reduced	O
compared	O
with	O
those	O
of	O
healthy	O
controls,	O
whereas	O
signals	O
arising	O
from	O
glucose,	B
pyruvate,	B
acetone,	B
acetoacetate,	B
3-hydroxybutyrate	B
and	O
2-hydroxybutyrate,	B
choline,	B
betaine,	B
and,	O
to	O
a	O
lesser	O
degree,	O
dimethylglycine,	B
sarcosine,	B
asparagine,	B
and	O
ornithine	B
showed	O
enhanced	O
loadings.	O

(a)	O
SN,	O
normal	O
serum;	O
SP,	B
patient	O
serum.	O

Compounds	O
were	O
dissolved	O
in	O
75	O
mM	O
ammonium	B
citrate	I
and	O
12.5	O
mM	O
ascorbic	B
acid	I
(pH	O
6)	O
buffer.	O

Thus,	O
higher	O
levels	O
of	O
TMAO	B
and	O
TNFa/IL6/IL1b	O
levels	O
could	O
lead	O
to	O
a	O
synergistic	O
feedback	O
loop	O
in	O
liver	O
failure.	O

We	O
propose	O
the	O
–CH_2	O
–/–CH_3	O
ratio	O
from	O
plasma	O
aliphatic	B
lipid	O
chains	O
as	O
a	O
biomarker	O
for	O
the	O
diagnosis	O
of	O
left	O
ventricular	O
remodeling	O
in	O
hypertension.	O

	O
β	B
-glucose	I
was	O
absent	O
in	O
all	O
cases	O
of	O
serous	O
cancer	O
tissues.	O

It	O
should	O
also	O
be	O
noted	O
that	O
glycerol-3-P	B
and	O
F6P	O
could	O
not	O
be	O
unambiguously	O
assigned	O
in	O
_1	O
H	O
and	O
_13	O
C-edited	O
experiments	O
due	O
to	O
their	O
low	O
abundance	O
and/or	O
spectral	O
crowding	O
(cf.	O
).	O

It	O
is	O
noteworthy	O
that	O
in	O
the	O
published	O
clinical	O
trials	O
for	O
treatment	O
of	O
CRPC	O
patients	O
with	O
P450	O
17	O
inhibitors,	O
rigorous	O
SID-LC/ESI/SRM/MS	O
methods	O
were	O
not	O
used	O
in	O
their	O
entirety	O
and	O
in	O
some	O
instances	O
mixed	O
methods	O
were	O
used	O
including	O
immunoassays	O
for	O
DHEA-S.	B

Since	O
all	O
of	O
our	O
study	O
participants	O
experienced	O
a	O
decrease	O
in	O
body	O
weight,	O
percent	O
body	O
fat,	O
and	O
blood	O
triglyceride	B
levels,	O
this	O
result	O
is	O
unexpected	O
as	O
uric	B
acid	I
is	O
widely	O
known	O
to	O
be	O
an	O
indicator	O
for	O
obesity.	O

Mobile	O
phases	O
A	O
and	O
B	O
were	O
water	O
and	O
acetonitrile	B
respectively,	O
both	O
containing	O
formic	B
acid	I
0.1%.	O

The	O
individual	O
daily	O
dose	O
was	O
600	O
μmol	O
of	O
GR	O
and	O
40	O
μmol	O
of	O
SF.	B

In	O
agreement	O
with	O
the	O
GC-MS	O
data	O
on	O
linoleic	B
acid	I
(see	O
Section	O
3.5),	O
the	O
NMR	O
region	O
from	O
2.74	O
to	O
2.83	O
ppm,	O
containing	O
signals	O
assigned	O
to	O
polyunsaturated	O
lipid	O
“=CH–CH2–CH=”,	O
increased	O
between	O
4	O
and	O
6	O
h	O
after	O
intake	O
of	O
the	O
soy	O
drink.	O

In	O
baseline	O
samples,	O
valine,	B
isobutyrate,	B
phenylalanine,	B
2-oxoglutarate,	B
tyrosine,	B
and	O
formate	B
significantly	O
decreased	O
from	O
F4	O
to	O
F0/F1,	O
and	O
glutamine	B
only	O
increased	O
from	O
F4	O
to	O
F0/F1.	O

(2018)	O
reported	O
the	O
free	O
radical	O
scavenging	O
potential	O
of	O
methanol-extract	B
of	O
F.	O
lateritium	O
endophyte	O
of	O
Rhizophora	O
mucronata	O
.	O

Following	O
urinary	O
toxicology	O
screening	O
for	O
cannabinoids,	B
cocaine,	O
barbiturates,	O
benzodiazepine,	B
opiates,	O
methadone,	B
amphetamines,	B
and	O
phencyclidine,	B
blood	O
was	O
collected	O
for	O
complete	O
blood	O
count,	O
electrolytes,	O
glucose,	B
urea	B
nitrogen,	I
creatinine,	B
glycated	O
hemoglobin	O
(HbA1c)	O
and	O
the	O
liver	O
function	O
tests	O
as	O
specified	O
by	O
a	O
CLIA	O
certified	O
clinical	O
laboratory.	O

Thus,	O
high	O
levels	O
of	O
unbound	O
EETs	O
in	O
the	O
endothelium	O
presumably	O
will	O
increase	O
circulating	O
EETs	O
that	O
are	O
mainly	O
esterified	O
in	O
the	O
phospholipids	B
of	O
circulating	O
lipoproteins.	O

Identification	O
of	O
hydroxycholestenoic	B
and	O
hydroxyoxocholestenoic	B
acids	I
in	O
CSF.	O

The	O
decreased	O
levels	O
of	O
two	O
lysoPCs	O
would	O
largely	O
contribute	O
to	O
the	O
lower	O
concentration	O
of	O
total	O
lysoPCs	O
in	O
plasma,	O
which	O
was	O
previously	O
reported	O
to	O
be	O
associated	O
with	O
an	O
activated	B
inflammatory	O
status	O
in	O
cancer	O
patients.	O

Second,	O
a	O
putative	O
sulfur	O
dioxygenase	O
oxidizes	O
the	O
persulfide	B
group	O
producing	O
sulfite.	B

Glycerophospholipids	B
are	O
the	O
main	O
components	O
of	O
the	O
cell	O
membranes	O
and	O
play	O
a	O
major	O
role	O
in	O
cell	O
signaling,	O
membrane	O
anchoring,	O
and	O
substrate	O
transport.	O

Although	O
currently	O
limited	O
by	O
lack	O
of	O
quality	O
antibodies	O
for	O
IHC,	O
it	O
is	O
likely	O
that	O
measurement	O
of	O
TDO/IDO	O
protein	O
levels	O
or	O
activity	O
in	O
primary	O
tumor	O
and/or	O
circulating	O
tumor	O
cells	O
would	O
be	O
more	O
informative	O
than	O
plasma	O
levels	O
of	O
tryptophan	B
and	O
kynurenine.	B

In	O
terms	O
of	O
fatty	O
acid	O
metabolism,	O
a	O
low	O
level	O
of	O
glucose	B
may	O
provide	O
a	O
metabolic	O
environment	O
in	O
which	O
fatty	O
acid	O
degradation	O
into	O
acetyl-CoA	B
(beta-oxidation)	O
is	O
facilitated.	O

Threitol	B
and	O
erythritol	B
are	O
four-carbon	O
polyols	O
differing	O
by	O
the	O
configuration	O
of	O
only	O
one	O
chiral	O
carbon	O
(i.e.,	O
they	O
are	O
diastereomers),	O
and	O
both	O
were	O
more	O
abundant	O
in	O
DLBCL	O
and	O
CLL	O
cases	O
compared	O
to	O
the	O
controls.	O

Compared	O
to	O
women,	O
men	O
had	O
higher	O
diastolic	O
blood	O
pressure,	O
serum	O
creatinine	B
and	O
triglycerides.	B

The	O
pathophysiologcial	O
significance	O
of	O
increased	O
lactate	B
in	O
PTSD	O
is	O
unknown,	O
but	O
to	O
the	O
extent	O
that	O
lactate	B
contributes	O
to	O
PTSD	O
symptoms	O
[–],	O
several	O
potential	O
mechanisms	O
are	O
proposed,	O
as	O
described	O
below.	O

Correlation	O
testing	O
in	O
the	O
whole	O
population	O
showed	O
positive	O
correlations	O
between	O
insulin	O
sensitivity	O
and	O
glycine	B
and	O
glutamine,	B
whereas	O
alanine,	B
isoleucine,	B
leucine,	B
valine,	B
phenylalanine	B
and	O
tyrosine	B
had	O
negative	O
correlation	O
with	O
insulin	O
sensitivity.	O

Specifically,	O
the	O
study	O
population	O
comparatively	O
lower	O
in	O
asparagine,	B
citrulline,	B
glutamine,	B
leucine/isoleucine,	O
and	O
tryptophan	B
while	O
glutamate	B
and	O
proline	B
were	O
comparatively	O
higher	O
than	O
HMDB	O
values.	O

Myristic	B
acid–d27	O
(366889),	O
Alkane	O
standard	O
mixture	O
(68281),	O
fatty	O
acid	O
methyl	O
ester	O
standards	O
(FAMEs),	O
C8	O
(260673),	O
C9	O
(245895),	O
C10	O
(299030),	O
C12	O
(234591),	O
C14	O
(P5177),	O
C16	O
(P5177),	O
C18	O
(S5376),	O
C20	O
(10941),	O
C22	O
(11940),	O
C24	O
(87115),	O
C26	O
(H6389),	O
C28	O
(74701),	O
except	O
for	O
the	O
C30,	O
were	O
purchased	O
from	O
TCI	O
chemicals	O
(T0812),	O
while	O
methoxyamine	B
hydrochloride	I
(226904)	O
and	O
pyridine	B
(360570)	O
were	O
purchased	O
from	O
Sigma	O
Aldrich.	O

In	O
vivo	O
spectroscopy	O
of	O
tumors	O
provides	O
a	O
sum	O
of	O
total	O
choline-containing	O
compounds	O
and	O
cannot	O
determine	O
individual	O
signals,	O
such	O
as	O
GPC	B
and	O
PC,	O
due	O
to	O
resolution	O
limitations.	O

Interestingly,	O
complex	O
SPs	O
(SMs,	O
HexCer,	O
and	O
Hex2Cer)	O
containing	O
a	O
d18:2	B
sphingoid	I
base	O
preferentially	O
demonstrated	O
significantly	O
higher	O
levels	O
in	O
women.	O

It	O
is	O
clear	O
that	O
the	O
use	O
of	O
discriminatory	O
models	O
on	O
plasma	O
metabolites	O
or	O
conventional	O
MRI	O
can	O
distinguish	O
patients	O
with	O
relapsing-remitting	O
MS	O
(RRMS)	O
from	O
those	O
with	O
aquaporin-4	O
antibody	O
(AQP4-Ab)	O
NMOSD	O
and	O
RRMS	O
from	O
myelin	B
oligodendrocyte	O
glycoprotein	B
antibody	O
(MOG-Ab)	O
disease	O
remarkably	O
accurately._,	O

Additionally,	O
given	O
its	O
tight	O
regulation	O
by	O
parathyroid	O
hormone	O
(PTH),	O
calcium	O
and	O
phosphate,	B
its	O
relatively	O
short	O
half-life,	O
and	O
its	O
ability	O
to	O
be	O
synthesized	O
locally,	O
the	O
added	O
benefit	O
of	O
measuring	O
1,25OH2D	O
remains	O
uncertain	O
[,].	O

As	O
for	O
the	O
levels	O
of	O
metabolites	O
involved	O
in	O
nucleotide	O
metabolism,	O
the	O
concentrations	O
of	O
adenine,	B
xanthine	B
hypoxanthine,	I
uracil,	B
and	O
thymine	B
were	O
higher,	O
and	O
the	O
level	O
of	O
uric	B
acid	I
was	O
lower	O
in	O
the	O
CRC	O
tissue	O
samples.	O

Lower	O
level	O
of	O
leucine	B
and	O
isoleucine	B
reflect	O
malabsorption	O
of	O
necessary	O
amino	O
acid	O
in	O
FD	B
female	O
patients.	O

Relative	O
lipid	O
concentration	O
(mol%)	O
of	O
sphingolipids	B
(B)	O
and	O
glycerophospholipids	B
(C).	O

However,	O
we	O
observed	O
slightly	O
higher	O
levels	O
of	O
cis-aconitate,	B
a	O
TCA	O
cycle	O
intermediate	O
produced	O
by	O
the	O
dehydration	O
of	O
citrate,	B
in	O
CRC	O
patient	O
urine.	O

In	O
the	O
comparison	O
of	O
case	O
(AD	O
plus	O
CRC)	O
versus	O
C	O
groups,	O
significant	O
metabolites	O
were	O
found	O
mainly	O
in	O
Cer,	B
ChoE,	O
PE	O
and	O
SM	O
families.	O

The	O
FIDs	O
were	O
multiplied	O
by	O
an	O
exponential	O
weighing	O
function	O
corresponding	O
to	O
a	O
line	O
broadening	O
of	O
0.5	O
Hz	O
prior	O
to	O
FT.	B

Allantoin	B
is	O
produced	O
from	O
the	O
non-enzymatic	O
oxidation	O
of	O
uric	B
acid	I
(Fig.	O

Based	O
on	O
previous	O
reports,	O
serum	O
CRP	O
>10	O
mg/L	O
and	O
neopterin	B
>10	O
nmol/L	O
were	O
considered	O
to	O
be	O
clinically	O
relevant	O
indicators	O
of	O
current	O
inflammation	O
(–).	O

Recent	O
data	O
have	O
linked	O
increased	O
glycine	B
levels	O
and	O
decreased	O
urea	B
cycle	O
metabolites	O
with	O
a	O
chromosomal	O
locus	O
and	O
identified	O
a	O
strong	O
association	O
with	O
decreased	O
risk	O
of	O
atherosclerosis.	O

Studies	O
of	O
ESRD	O
have	O
shown	O
that	O
CMPF	O
indirectly	O
inhibits	O
the	O
activity	O
of	O
cytochrome	O
P450	O
3A4	O
(CYP3A4)._,	O
An	O
important	O
drug-metabolizing	O
enzyme,	O
CYP3A4	O
activity	O
is	O
altered	O
in	O
patients	O
afflicted	O
with	O
ESRD	O
through	O
its	O
association	O
with	O
the	O
VDR,	O
with	O
CYP3A4	O
expression	O
being	O
controlled	O
by	O
both	O
VDR	O
and	O
the	O
pregnane	O
X	O
receptor	O
(PXR)	O
which	O
are	O
induced	O
by	O
1,25(OH)D._,	B
In	O
cases	O
of	O
ESRD,	O
increases	O
in	O
uremic	O
toxins	B
of	O
10-fold	O
or	O
more	O
limit	O
the	O
ability	O
of	O
VDR	O
to	O
bind	O
to	O
vitamin	B
D	I
response	O
elements	O
and	O
inhibit	O
CYP3A4	O
activity.	O
CYP3A4	O
is	O
also	O
known	O
to	O
play	O
a	O
role	O
in	O
the	O
catabolism	O
of	O
vitamin	B
D,	I
with	O
the	O
hepatic	O
23-	O
and	O
24-hydroxylation	O
of	O
vitamin	B
D	I
being	O
CYP3A4-dependent._,	O
It	O
is	O
therefore	O
possible	O
that	O
higher	O
circulating	O
CMPF	O
down-regulates	O
hydroxylation	O
and	O
metabolism	O
of	O
25(OH)D,	O
leading	O
to	O
increased	O
concentrations	O
of	O
the	O
latter.	O

The	O
plasma	O
concentration	O
of	O
LPC(20:4)	B
in	O
HCC	O
was	O
statistically	O
significantly	O
lower	O
than	O
in	O
HV	B
controls	O
(P<0.05)	O
and	O
in	O
LC	O
controls	O
(P<0.05).	O

To	O
test	O
the	O
applicability	O
of	O
this	O
assay,	O
abiraterone	B
concentrations	O
were	O
quantified	O
in	O
samples	O
collected	O
in	O
a	O
patient	O
that	O
was	O
treated	O
pre-chemotherapy	O
with	O
1000	O
mg	O
abiraterone	B
QD	O
and	O
had	O
reached	O
steady-state	O
pharmacokinetics.	O

Thus,	O
increased	O
tryptophan	B
catabolism	O
via	O
the	O
kynurenine	B
pathway	O
may	O
contribute	O
to	O
depression	O
not	O
only	O
by	O
effects	O
on	O
serotonin	B
biosynthesis,	O
but	O
also	O
by	O
production	O
of	O
neurotoxic	O
metabolites	O
and	O
possible	O
effects	O
on	O
the	O
glutamatergic	B
system.	O

Sphingolipid	B
measurements	O
were	O
performed	O
according	O
to	O
a	O
previously	O
published	O
protocol.	O

It	O
was	O
noticed	O
that	O
short-chain	O
acylcarnitines	B
tended	O
to	O
be	O
risk	O
factors	O
for	O
HCC.	O

Among	O
the	O
assayed	O
circulating	O
metabolites,	O
the	O
major	O
differences	O
between	O
cancer	O
and	O
non-cancer	O
subjects	O
were	O
observed	O
in	O
the	O
group	O
of	O
phosphatidylcholines	B
and	O
lysophosphatidylcholines	B
(Table ,	O
Fig.	O

Unlike	O
in	O
vitro	O
NMR	O
which	O
requires	O
the	O
extraction	O
of	O
metabolites	O
(using	O
perchloric	B
acid,	I
methanol,	B
etc.),	O
which	O
can	O
alter	O
the	O
nature	O
of	O
tissues;	O
HRMAS	O
NMR	O
can	O
be	O
performed	O
with	O
intact	O
tissues.	O

The	O
Seahorse	O
system	O
permits	O
the	O
simultaneous	O
assessment	O
of	O
glycolytic	B
and	O
oxidative	O
metabolism	O
through	O
the	O
coupled	O
sensing	O
of	O
oxygen	O
consumption	O
and	O
extracellular	O
acidification.	O

Whether	O
increased	O
levels	O
of	O
3-indoxyl	B
sulfate	I
might	O
be	O
involved	O
in	O
the	O
increased	O
risk	O
of	O
CVD	O
linked	O
to	O
sleep	O
deprivation	O
merits	O
further	O
investigation.	O

A	O
previous	O
study	O
suggests	O
that	O
an	O
increase	O
in	O
inflammatory	O
cytokines	O
might	O
facilitate	O
the	O
uptake	O
of	O
cholesteryl	B
ester	I
enriched	O
lipoproteins	O
into	O
the	O
tissues	O
in	O
otherwise	O
normolipidemic	O
type	O
1	O
diabetes	O
patients,	O
and	O
this	O
connection	O
also	O
explains	O
the	O
increased	O
risk	O
of	O
atherogenesis	O
in	O
type	O
1	O
diabetes	O
patients	O
(Ruan	O
et	O
al.	O
).	O

In	O
animal	O
and	O
human	O
studies,	O
pharmacologic	O
melatonin	B
reduces	O
visceral	O
sensitivity._,	O
Whether	O
and	O
how	O
melatonin	B
degradation	O
contributes	O
to	O
the	O
link	O
between	O
poor	O
sleep	O
and	O
pain	O
symptoms	O
requires	O
further	O
rigorous	O
study.	O

Alterations	O
in	O
amino	O
acid,	O
lipid	O
(glycerolipid,	O
fatty	O
acid,	O
sphingolipid),	B
endocannabinoid,	B
and	O
carnitine	B
pathways	O
were	O
characteristic	O
of	O
IBD	O
subjects	O
compared	O
to	O
controls.	O

Liquid	O
chromatography–tandem	O
mass	O
spectrometry	O
(LC-MS/MS)	O
was	O
performed,	O
and	O
the	O
diagnosis	O
of	O
CAH	O
was	O
suspected,	O
given	O
a	O
high	O
level	O
of	O
17-hydroxyprogesterone	B
(17OHP)	O
and	O
its	O
metabolites.	O

Research	O
using	O
differential	O
centrifugation	O
to	O
separate	O
genomic	O
DNA	O
from	O
fecal	O
samples	O
detected	O
reduced	O
members	O
of	O
Lactobacillus	B
in	O
all	O
IBS	O
subgroups,	O
less	O
abundant	O
Actinobacteria	O
in	O
IBS-C	O
and	O
IBS-D	O
patients,	O
higher	O
levels	O
of	O
Ruminococcus	O
in	O
IBS-C	O
and	O
IBS-M	O
patients,	O
and	O
higher	O
levels	O
of	O
Streptococcus	O
in	O
IBS-D	O
patients.	O

Interestingly,	O
many	O
of	O
these	O
metabolites	O
are	O
involved	O
in	O
tryptophan	B
and	O
histidine	B
metabolism.	O

[Google	O
Scholar]	O
Harris	O
AL,	O
Dowsett	O
M,	O
Smith	O
IE,	O
Jeffcoate	B
S.	O
Hydrocortisone	B
alone	O
vs	B
hydrocortisone	I
plus	O
aminoglutethimide:	B
a	O
comparison	O
of	O
the	O
endocrine	O
effects	O
in	O
postmenopausal	O
breast	O
cancer.	O

The	O
plasma	O
concentration	O
of	O
nervonic	B
acid	I
in	O
HCC	O
was	O
very	O
statistically	O
significantly	O
(P<0.01)	O
lower	O
concentration	O
that	O
LC	O
plasma	O
and	O
highly	O
statistically	O
significantly	O
(P<0.001)	O
below	O
the	O
concentration	O
in	O
HV	B
plasma.	O

A	O
large	O
number	O
of	O
malignant	O
tumor	O
cells	O
need	O
a	O
large	O
and	O
rapid	O
supply	O
of	O
oxygen,	O
but	O
even	O
when	O
the	O
supply	O
of	O
oxygen	O
is	O
sufficient,	O
the	O
cancer	O
cells	O
still	O
rely	O
on	O
obtaining	O
a	O
large	O
number	O
to	O
consume	O
the	O
glucose,	B
for	O
anaerobic	O
fermentation,	O
and	O
convert	O
it	O
to	O
lactic	B
acid	I
so	O
that	O
it	O
can	O
obtain	O
the	O
energy	O
rapidly	O
under	O
the	O
function	O
of	O
lactate	O
dehydrogenase,	O
known	O
as	O
the	O
Warburg	O
effect.	O

They	O
found,	O
as	O
we	O
did,	O
that	O
3-hydroxybutyrate	B
correlated	O
with	O
the	O
later	O
development	O
of	O
sepsis.	O

The	O
use	O
of	O
separate	O
methods	O
presumably	O
is	O
related	O
in	O
part	O
to	O
the	O
huge	O
difference	O
in	O
concentrations	O
of	O
total	O
cotinine	B
versus	O
total	O
NNAL	O
in	O
urine.	O

All	O
analytes	O
were	O
individually	O
dissolved	O
in	O
a	O
solution	O
of	O
PTAD	O
(0.5	O
mg/mL)	O
in	O
acetonitrile	B
at	O
100	O
ng/mL	O
and	O
allowed	O
to	O
react	O
at	O
room	O
temperature	O
for	O
4	O
h	O
to	O
form	O
the	O
corresponding	O
PTAD	O
Diels–Alder	O
conjugate.	O

Finally,	O
428	O
different	O
lipids	O
were	O
identified,	O
namely	O
9	O
fatty	O
acyls,	O
227	O
glycerophospholipids,	B
54	O
sphingolipids,	B
15	O
sterols,	O
122	O
glycerolipids	B
and	O
1	O
prenol	B
lipid.	O

_,	O
_,	O
The	O
20α-HSD	B
excess	O
has	O
not	O
been	O
investigated,	O
and	O
therefore,	O
attributing	O
to	O
it	O
a	O
role	O
in	O
the	O
PCOS	O
suppression	O
of	O
luteal	O
progesterone	B
generation	O
and	O
menstrual	O
dysregulation	O
remains	O
speculative.	O

For	O
both,	O
total	O
and	O
free	O
oxidised	O
lipids,	O
the	O
extraction	O
was	O
performed	O
by	O
the	O
same	O
ethyl	B
acetate	I
liquid-liquid	O
extraction (LLE)	O
procedure.	O

We	O
also	O
followed	O
up	O
10	O
patients	O
who	O
received	O
a	O
naturalistic	O
course	O
of	O
treatment	O
with	O
an	O
antidepressant	O
(paroxetine	O
n = 4,	O
duloxetine	B
n = 2,	O
mirtazapine	B
n = 1,	O
or	O
sertraline	B
n = 3).	O

The	O
technical	O
aspects	O
of	O
our	O
iCPET	O
and	O
exercise	O
protocol	O
have	O
been	O
described	O
in	O
detail	O
previously._,	O
RHC	O
was	O
performed	O
in	O
the	O
supine	B
position	O
with	O
a	O
5-port	O
pacing	O
PA	O
catheter	O
(Edwards	O
LifeSciences,	O
Irvine,	O
CA,	O
USA)	O
inserted	O
percutaneously	O
under	O
ultrasound	O
and	O
fluoroscopic	B
guidance	O
into	O
the	O
internal	O
jugular	O
vein	O
and	O
a	O
5Fr	O
radial	O
artery	O
catheter	O
contemporaneously	O
placed	O
in	O
the	O
radial	O
artery.	O

The	O
medium	O
was	O
similarly	O
treated	O
with	O
TCA	O
in	O
the	O
same	O
way	O
for	O
measuring	O
secreted	O
metabolites	O
(predominantly	O
lactate	B
and	O
Ala),	O
and	O
to	O
assay	O
the	O
glucose	B
utilization	O
during	O
the	O
experiment.	O
_13	O
C-glucose	B
was	O
quantified	O
at	O
t	O
=	O
0	O
and	O
at	O
harvest	O
(t)	O

Many	O
other	O
compounds	O
annotated	O
in	O
these	O
three	O
patients,	O
representing	O
major	O
chemical	O
classes	O
of	O
metabolites	O
such	O
as	O
acylcarnitines,	B
amino	O
acids,	O
and	O
organic	O
acids,	O
were	O
found	O
to	O
have	O
satisfactory	O
RSDs	O
(all	O
data	O
is	O
available	O
on	O
request).	O

And,	O
the	O
functional	O
enrichment	O
analysis	O
found	O
that	O
some	O
related	O
functions	O
of	O
amino	O
acid	O
metabolism,	O
such	O
as	O
methylhistidine	B
metabolism,	O
ammonia	O
recycling	O
and	O
amino	B
sugar	O
metabolism,	O
were	O
affected	O
in	O
dHB.	O

However,	O
only	O
TG	B
(49:1)	I
and	O
TG	B
(51:1)	I
were	O
identified	O
as	O
putative	O
biomarkers	O
when	O
the	O
lipidome	O
was	O
compared	O
between	O
meloxicam-	O
and	O
saline-treated	O
cats	O
and	O
within	O
the	O
meloxicam	O
group	O
(post-treatment	O
vs	O
baseline	O
lipidome)	O

The	O
prehypertension	O
group	O
also	O
had	O
higher	O
lipoprotein-associated	O
phospholipase	O
A_2	O
(Lp-PLA_2	O
)	O
activity,	O
plasma	O
malondialdehyde	B
(MDA),	O
urinary	O
excretion	O
of	O
8-epi	B
-PGF_2α	I
,	O
ba-PWV,	O
and	O
serum	O
interleukin	O
6	O
before	O
and	O
after	O
adjusting	O
for	O
BMI,	O
WHR,	O
smoking,	O
alcohol	O
consumption,	O
serum	O
lipid	O
profiles,	O
glucose,	B
and	O
insulin.	O

On	O
the	O
other	O
hand,	O
branched	O
chain	O
amino	O
acid	O
(BCAA)	O
dietary	O
supplementation	O
including	O
valine	B
in	O
mice	O
upregulated	O
expression	O
mitochondrial	O
ROS	O
defence	O
enzymes	O
and	O
promoted	O
longevity.	O

The	O
presence	O
of	O
signals	O
due	O
to	O
a	O
dihydrooxepine	B
moiety	O
[δ_H	O
6.58	O
(1H,	O
brd,	O
J	O
=	O
1.6	O
Hz),	O
δ_c	O
138.6	O
(CH);	O
δ_H	O
6.28	O
(1H,	O
dd,	O
J	O
=	O
2.4,	O
8.0	O
Hz),	O
δ_c	O
139.4	O
(CH);	O
δ_H	O
4.82	O
(1H,	O
dd,	O
J	O
=	O
2.0,	O
8.4	O
Hz),	O
δ_c	O
106.6	O
(CH);	O
δ_H	O
5.46	O
(1H,	O
ddd,	O
J	O
=	O
2.0,	O
2.4,	O
8.4	O
Hz),	O
δ_c	O
71.5	O
(CH);	O
δ_H	O
5.33	O
(1H,	O
dd,	O
J	O
=	O
2.0,	O
8.4	O
Hz),	O
δ_c	O
61.7	O
(CH);	O
and	O
δ_c	O
108.2	O
(C)],	O
and	O
a	O
prominent	O
peak	O
at	O
m/z	O
465	O
(C_19	O
H_17	O
N_2	O
O_4	O
S_4	O
)	O
in	O
the	O
HREIMS	O
due	O
to	O
the	O
facile	O
loss	O
of	O
the	O
hydroxy	B
and	O
methoxy-substituted	B
benzoic	I
acid	I
moiety	O
from	O
[M	O
+	O
H]_+	O
suggested	O
that	O
the	O
structure	O
of	O
1	O
closely	O
resembled	O
that	O
of	O
secoemestrin	O
C_1	O
.	O

Leucine	B
was	O
among	O
the	O
most	O
released	O
amino	O
acids	O
during	O
the	O
ripening	O
of	O
Gruyère.	O

Notably	O
at	O
MSI	O
level	O
4,	O
the	O
abundance	O
of	O
hydroxybutyric	B
acid	I
at	O
m/z	O
103.0391	O
(ESI–,	O
RT	O
=	O
0.61	O
min)	O
was	O
also	O
higher	O
in	O
T2D	O
patients	O
than	O
in	O
both	O
prediabetic	O
and	O
NGT	O
individuals	O
(KW	O
test,	O
P	O
=	O
2.38E-8,	O
FDR	O
=	O
1.01E-5)	O
in	O
this	O
study.	O

However,	O
we	O
did	O
not	O
find	O
significant	O
differences	O
in	O
the	O
shape	O
of	O
BCAA	O
profiles	O
between	O
insulin-sensitive	O
and	O
insulin-resistant	O
subjects	O
(i.e.,	O
a	O
blunted	O
suppression	O
of	O
BCAA	O
levels	O
during	O
the	O
glucose	B
challenge	O
in	O
insulin-resistant	O
individuals).	O

As	O
well	O
as	O
being	O
markers	O
of	O
the	O
aggressive	O
form,	O
acetylcarnitine	B
and	O
hexannoylcarnitine	B
were	O
also	O
distinguishable	O
markers	O
of	O
indolent	O
and	O
control	O
subjects.	O

In	O
this	O
study,	O
we	O
used	O
a	O
targeted	O
GC-MS	O
metabolomics	O
platform	O
to	O
measure	O
a	O
panel	O
of	O
metabolites	O
within	O
cholesterol	B
synthesis,	O
dietary	O
sterol	O
absorption,	O
and	O
bile	O
acid	O
formation	O
to	O
determine	O
metabolite	O
signatures	O
that	O
may	O
predict	O
variation	O
in	O
statin	B
LDL-C	O
lowering	O
efficacy.	O

These	O
findings	O
demonstrate	O
that	O
alteration	O
of	O
SL	B
metabolism	O
(shifting	O
SM	O
into	O
sphingosine	B
and	O
S1P)	O
may	O
be	O
involved	O
in	O
the	O
underlying	O
mechanism	O
of	O
AERD.	O

The	O
anionic	O
SNPs	O
were	O
extensively	O
dialyzed	O
in	O
50	O
mM	O
sodium	B
phosphate	I
buffer	O
before	O
they	O
were	O
added	O
to	O
serum.	O

Kynurenine,	B
which	O
is	O
produced	O
by	O
oxidation	O
of	O
tryptophan,	B
was	O
increased	O
2.2-fold	O
in	O
the	O
BS	O
pattern	O
patients	O
(P	O
=	O
0.010).	O

This	O
is	O
associated	O
with	O
exposure	O
to	O
increased	O
glucose	B
concentrations	O
as	O
judged	O
by	O
continuous	O
glucose	B
monitoring	O
studies.	O

Historically,	O
epidemiologic	O
and	O
clinical	O
studies	O
of	O
estradiol	B
have	O
relied	O
on	O
radioimmunoassays	O
and	O
EIA,	O
which	O
could	O
include	O
extraction	O
and/or	O
chromatography	O
(indirect	O
methods)	O
or	O
no	O
purification	O
(direct	O
methods).	O

(C)	O
MR	O
spectrum	O
obtained	O
from	O
area	O
of	O
imaging	O
abnormality	O
in	O
the	O
right	O
peripheral	O
zone	O
demonstrates	O
elevated	O
choline	B
and	O
reduced	O
citrate,	B
a	O
pattern	O
consistent	O
with	O
definite	O
cancer.	O

However,	O
adducts	O
formed	O
with	O
benzene	B
and	O
4ABP	O
(sulfonamide-adduct	O
with	O
sulfur	O
of	O
Cys)	O
yield	O
logD	O
values	O
of	O
−0.17	O
and	O
−0.12,	O
respectively,	O
at	O
pH	O
5.5.	O

Data	O
processing	O
method	O
files	O
are	O
provided	O
in	O
the	O
data	O
record	O
(adni1-qual-method.zip).	O

For	O
both	O
enzalutamide	B
and	O
N-desmethylenzalutamide,	B
the	O
following	O
optimized	O
settings	O
on	O
the	O
mass	O
spectrometer	O
were	O
used:	O
capillary	O
voltage	O
was	O
4.2	O
kV,	B
cone	O
voltage	O
was	O
65	O
V,	O
desolvation	O
temperature	O
was	O
500	O
°C,	O
desolvation	O
gas	O
flow	O
was	O
1000	O
L/hour.	O

and	O
it	O
is	O
a	O
glycine	B
conjugate	O
of	O
phenylacetic	B
acid,	I
which	O
is	O
normally	O
a	O
minor	O
metabolite	O
of	O
fatty	O
acids	O
,	O
so	O
decreased	O
level	O
of	O
PAG	B
indicated	O
the	O
decreased	O
catabolism	O
of	O
lipid.	O

The	O
reduction	O
in	O
cysteine	B
and	O
cystine	B
coupled	O
with	O
elevations	O
in	O
methionine	B
sulfoxide,	I
an	O
oxidation	O
product	O
of	O
methionine,	B
implicates	O
altered	O
redox	O
status,	O
which	O
may	O
be	O
linked	O
to	O
the	O
observed	O
changes	O
in	O
circulating	O
acyl	B
carnitines.	I

Kinetic	O
analysis	O
for	O
the	O
formation	O
of	O
hydroxyanastrozole	B
from	O
anastrozole	B
was	O
studied	O
in	O
four	O
different	O
HLM	O
preparations.	O

Being	O
expected	O
from	O
molecular	O
structures,	O
the	O
_4	O
CH_2	O
peak	O
of	O
GABA	B
showed	O
extensive	O
overlap	O
with	O
_6	O
CH_2	O
peak	O
of	O
lysine,	B
although	O
GABA	B
tends	O
to	O
be	O
more	O
abundant	O
than	O
lysine	B
in	O
typical	O
human	O
brain.	O

Betaine	B
levels	O
are	O
increased	O
in	O
liver	O
diseases	O
characterised	O
by	O
the	O
development	O
of	O
fatty	O
liver,	O
especially	O
non-alcoholic	O
fatty	O
liver	O
disease.	O

None	O
of	O
the	O
control	O
patients	O
had	O
tested	O
positive	O
on	O
urine	O
drug	O
screen	O
and	O
no	O
change	O
in	O
CSF	O
metabolites	O
was	O
observed	O
between	O
healthy	O
volunteers	O
who	O
reported	O
moderate	O
(20–50	O
times	O
per	O
lifetime)	O
or	O
low/no	O
(<5	O
times	O
per	O
lifetime)	O
cannabis	B
use	O
(unpublished	O
data).	O

Microalbuminuria	O
and	O
increased	O
urine	O
albumin	O
to	O
creatinine	B
ratio	O
are	O
regarded	O
as	O
early	O
predictors	O
of	O
kidney	O
damage.	O

Urinary	O
creatinine	B
was	O
assayed	O
by	O
the	O
Hagerstown	O
Medical	O
Laboratory,	O
Hagerstown,	O
MD.	O

Correlation	O
between	O
levels	O
of	O
sphingosine-1-phosphate	B
(S1P)	O
and	O
other	O
sphingolipids	B
in	O
breast	O
cancer	O
and	O
those	O
in	O
normal	O
breast	O
tissue.	O

The	O
down-regulation	O
of	O
Biliverdin	B
IX,	I
which	O
acts	O
as	O
the	O
precursor	O
of	O
biosynthesis	O
of	O
bilirubin,	B
as	O
well	O
as	O
uribilinoids	B
(Mesobilirubinogen	I
and	O
L-Urobilinogen)	B
and	O
urobilins	O
(I-Urobilin	O
and	O
L-Urobilin),	O
which	O
are	O
by-products	O
of	O
bilirubin	B
degradation	O
could	O
be	O
associated	O
with	O
the	O
down-regulation	O
of	O
cellular	O
antioxidant	O
activity.	O

spray	O
voltage,	O
3.6	O
kV;	B
Capillary	O
temperature,	O
320	O
°C;	O
S-lens	O
RF	O
level,	O
70	O
and	O
heater	O
temperature	O
450	O
°C.	O

Like	O
other	O
such	O
quinones,	B
AQ	O
is	O
capable	O
of	O
forming	O
reactive	O
oxygen	O
species	O
with	O
pathological	O
consequences.	O

Fasting	O
plasma	O
glucose	B
level	O
was	O
significantly	O
higher	O
in	O
both	O
T2DM	O
groups	O
compared	O
to	O
CG	O
and	O
significantly	O
different	O
(p	O
<	O
0.05)	O
between	O
T2DM	O
groups.	O

The	O
current	O
base	O
width	O
data	O
supports	O
the	O
use	O
of	O
water	O
as	O
an	O
additive	O
to	O
improve	O
peak	O
shapes	O
for	O
acids	O
and	O
sugars,	O
while	O
its	O
use	O
has	O
previously	O
been	O
demonstrated	O
to	O
give	O
sharper	O
peaks	O
for	O
nucleobases	O
on	O
a	O
variety	O
of	O
stationary	O
phases,	O
including	O
diol,	B
cyanopropyl	O
and	O
2-EP	O
.	O

Phthalic	B
acid	I
esters	I
(PAEs),	O
as	O
common	O
environmental	O
endocrine	O
disruptors,	O
can	O
enter	O
the	O
body	O
through	O
the	O
respiratory	O
system	O
and	O
skin,	O
interfering	O
with	O
the	O
endocrine	O
system.	O

The	O
differences	O
between	O
patients	O
and	O
controls	O
suggested	O
that	O
the	O
metabolism	O
of	O
several	O
substances—including	O
glucose	B
and	O
acetate—might	O
be	O
altered	O
in	O
the	O
brains	O
of	O
patients	O
with	O
schizophrenia	O
or	O
brief	O
psychotic	O
disorder.	O

The	O
concentration	O
of	O
the	O
DSS	O
solution	O
was	O
calibrated	O
using	O
_1	O
H	O
NMR	O
against	O
a	O
primary	O
stoichiometric	O
standard,	O
tris(hydroxymethyl)aminomethane	B
(22.4	O
mM),	O
prepared	O
in	O
the	O
lab.	O

Y]	O
allowed	O
to	O
have	O
dynamic	O
modifications	O
of	O
207.1	O
and	O
212.1	O
amu;	O
peptides	O
modified	O
with	O
HONH-PhIP	O
and	O
HONH-[_2	O
H_5	O
]-PhIP	O
or	O
their	O
N	B
-acetoxy	I
derivatives	O
were	O
allowed	O
to	O
have	O
dynamic	O
modifications	O
at	O
[C,K,Y,S,T,W,H]	O
of	O
222.1	O
and	O
227.1	O
amu,	O
for	O
adduction	O
with	O
PhIP,	O
or	O
dynamic	O
modifications	O
at	O
[C]	O
of	O
238.1	O
and	O
243.1	O
amu	O
for	O
adduction	O
with	O
NO-PhIP	O
(sulfinamide	O
adducts);	O
and	O
254.1	O
and	O
259.1	O
amu	O
(sulfonamide	O
adducts).	O

To	O
that	O
extent,	O
we	O
measured	O
CR	O
and	O
NANA	B
in	O
a	O
tissue	O
set	O
from	O
the	O
TIGER-LC	O
cohort	O
comprising	O
48	O
ICC	O
and	O
51	O
HCC	O
cases	O
with	O
a	O
goal	O
of	O
detecting	O
these	O
metabolites	O
in	O
tumor	O
tissue,	O
as	O
well	O
as	O
evaluating	O
their	O
levels	O
when	O
ICC	O
was	O
compared	O
to	O
HCC.	O

In	O
the	O
gonads	O
and	O
the	O
adrenals	O
3αHSD	B
catalyzes	O
the	O
conversion	O
of	O
5α-androstanedione	B
to	O
androsterone	B
and	O
from	O
17α-OH-dihydro-progesterone	B
to	O
17α-OH-allopregnanolone	B
in	O
the	O
backdoor	O
pathway.	O

In	O
our	O
case,	O
the	O
levels	O
of	O
PC(20:4/0:0),	B
PC(22:6/0:0),	B
were	O
increased	O
in	O
the	O
serum	O
of	O
rapid	O
fibrosers	O
when	O
compared	O
with	O
slow	O
fibrosers;	O
in	O
contrast,	O
the	O
levels	O
of	O
PC(18:2/20:4),	B
and	O
PC(40:8)	B
decreased.	O

The	O
pattern	O
of	O
phospholipids	B
did	O
not	O
differ	O
between	O
NAFLD	O
patients	O
with	O
diabetes	O
and	O
those	O
without	O
diabetes.	O

At	O
each	O
fludarabine	O
concentration	O
and	O
time	O
point,	O
1.25×10_6	O
cells	O
were	O
incubated	O
in	O
RPMI	O
media	O
(not	O
containing	O
phenol	B
red)	O
at	O
37°C,	O
and	O
washed	O
and	O
resuspended	O
in	O
1	O
mL	O
PBS.	O

Factors	O
that	O
may	O
be	O
involved	O
include:	O
decreased	O
PC	O
availability	O
due	O
to	O
loss	O
of	O
PEMT	O
activity,	O
decreased	O
expression	O
of	O
phospholipase-α2	B
(PLA2)	O
and/or	O
lecithin-cholesterol	B
acyltransferase	O

However,	O
they	O
share	O
a	O
common	O
mechanism	O
of	O
action	O
associated	O
with	O
the	O
interaction	O
with	O
thiol	B
groups.	O

Our	O
samples	O
were	O
quantified,	O
using	O
LC-MS/MS	O
to	O
identify	O
the	O
major	O
species	O
present	O
in	O
different	O
classes	O
of	O
sphingolipids.	B
,	O
,	O
and	O
shows	O
all	O
major	O
species	O
of	O
Cer,	B
MHC,	O
and	O
SM	O
respectively.	O

This	O
ISTD	O
spiking	O
solution	O
also	O
contained	O
4-methylumbelliferyl-β	B
-D-glucuronide	I
hydrate	O
and	O
4-methylumbelliferone-_13	B
C_4	O
at	O
concentrations	O
that	O
resulted	O
in	O
1	O
and	O
0.35	O
mg/L	O
urine,	O
respectively.	O

p < 0.0001),	O
carnitine	B
(14:1)	I
(β = 0.332;	O
p < 0.0001)	O
and	O
lithocholic	B
acid	I
(β = 0.224;	O
p < 0.0001);	O
of	O
these,	O
4-pyridoxic	B
acid,	I
lithocholic	B
acid	I
and	O
phosphatidylglycerol	B
(20:3/2:0)	I
were,	O
to	O
the	O
best	O
of	O
our	O
knowledge,	O
first	O
reported	O
in	O
this	O
study.	O

Transthyretin,	B
meanwhile,	O
is	O
a	O
supportive	O
marker	O
for	O
colorectal	O
adenoma	O
and	O
cancer	O
that	O
represents	O
nutritional	O
status._,	O
Including	O
these	O
two	O
proteins,	O
the	O
combination	O
of	O
unidentified	O
metabolic	O
compounds	O
may	O
serve	O
to	O
characterize	O
CRC.	O

The	O
identified	O
pathways	O
were	O
glycerophospholipids	B
metabolism,	O
sphingolipids	B
metabolism	O
and	O
the	O
glycosylphosphatidylinositol	B
(GPI)-anchor	O
biosynthesis	O
pathway	O
suggesting	O
that	O
these	O
pathways	O
could	O
be	O
altered	O
in	O
colorectal	O
cancer	O
(Supplementary	O
Figure	O
S4).	O

[]	O
It	O
may	O
have	O
an	O
increased	O
concentration	O
in	O
PD	O
via	O
conversion	O
from	O
VMA	O
or	O
homovanillic	B
acid.	I

When	O
alkylamines	B
were	O
used	O
as	O
modifier	O
additives,	O
the	O
UPC_2	O
was	O
used	O
in	O
stand-alone	O
mode	O
i.e.	O
with	O
UV–vis	O
detection	O
only.	O

In	O
the	O
metastatic	O
trial,	O
premenopausal	O
patients	O
with	O
ER_+	O
MBC	O
were	O
randomized	O
to	O
undergo	O
oophorectomy	O
surgery	O
as	O
palliative	O
endocrine	O
therapy	O
in	O
either	O
the	O
follicular	O
or	O
the	O
luteal	O
phase	O
of	O
the	O
menstrual	O
cycle,	O
followed	O
by	O
tamoxifen.	B

These	O
included	O
11	O
glycerophospholipids,	B
2	O
acylcarnitines,	B
tyrosine,	B
and	O
aspartate.	B

With	O
respect	O
to	O
GDM,	O
higher	O
levels	O
of	O
homocysteine	B
have	O
been	O
found	O
by	O
Guven	O
et	O
al.	O
.	O

For	O
cabozantinib	B
an	O
additional	O
extra	O
low	O
quality	O
control	O
sample	O
(QCXL)	O
was	O
included.	O

In	O
fact,	O
all	O
of	O
the	O
enzymes	O
necessary	O
for	O
the	O
biosynthesis	O
of	O
the	O
primary	O
bile	O
acid	O
chenodeoxycholic	O
acid	O
by	O
the	O
24(S	O
)-hydroxycholesterol	I
pathway	O
are	O
expressed	O
in	O
brain	O
(Scheme	O
4).	O

For	O
LC-MS	O
analysis,	O
frozen	O
serum	O
samples	O
were	O
thawed,	O
and	O
the	O
protein	O
was	O
precipitated	O
by	O
mixing	O
100	O
µL	O
serum	O
and	O
200	O
µL	O
cold	O
methanol.	B

In	O
the	O
LC	O
group,	O
18	O
metabolites	O
had	O
significantly	O
lower	O
peak	O
intensities	O
than	O
in	O
the	O
control	O
group;	O
glycolic	B
acid	I
(q	O
=	O
1.112	O
×	O
10_–11	O
),	O
myristic	B
acid	I
(q	O
=	O
0.019),	O
3-hydroxytetradecanedioic	B
acid	I
(q	O
=	O
0.025),	O
α-linolenic	B
acid	I
(q	O
=	O
1.877	O
×	O
10_–5	O
),	O
linoleic	B
acid	I
(q	O
=	O
3.805	O
×	O
10_–5	O
),	O
oleic	B
acid	I
(q	O
=	O
0.025),	O
9-HOTE	B
(q	O
=	O
0.001),	O
13S-hydroxyoctadecadienoic	B
acid	I
(q	O
=	O
3.326	O
×	O
10_–5	O
),	O
9-cis-retinoic	B
acid	I
(q	O
=	O
7.158	O
×	O
10_–6	O
),	O
eicosapentaenoic	B
acid	I
(q	O
=	O
5.311	O
×	O
10_–5	O
),	O
5-HEPE	B
(q	O
=	O
3.021	O
×	O
10_–6	O
),	O
5-HETE	B
(q	O
=	O
4.986	O
×	O
10_–7	O
),	O
leukotriene	O
B_4	O
(q	O
=	O
3.412	O
×	O
10_–4	O
),	O
17-HdoHE	B
(q	O
=	O
4.587	O
×	O
10_–7	O
),	O
dehydroepiandrosterone	B
sulfate	I
(q	O
=	O
9.100	O
×	O
10_–4	O
),	O
LPA	B
(16:0)	I
(q	O
=	O
0.005),	O
LPA	B
(18:1)	I
(q	O
=	O
2.097	O
×	O
10_–5	O
),	O
and	O
PE	B
(P-16:0e)	I
(q	O
=	O
4.878	O
×	O
10_–5	O
).	O

LM-1000),	O
d	O
_7	B
-cholesterol	I
(cat.	O

On	O
the	O
other	O
hand,	O
Hirayama	O
et	O
al.	O
found	O
that	O
colorectal	O
cancer	O
tissue	O
contained	O
lower	O
levels	O
of	O
pyruvic	B
acid	I
than	O
normal	O
colon	O
tissue,	O
although	O
the	O
concentration	O
of	O
lactic	B
acid	I
was	O
increased	O
in	O
the	O
colorectal	O
cancer	O
tissue.	O

The	O
evidence	O
regarding	O
soy	O
intake	O
and	O
levels	O
of	O
these	O
estrogen	B
metabolites	O
is	O
not	O
conclusive.	O

However,	O
the	O
response	O
rate	O
to	O
anti-EGFR	O
target	O
therapy	O
in	O
HER2-positive	O
BC	O
could	O
be	O
also	O
influenced	O
by	O
the	O
ER	O
status,	O
being	O
lower	O
in	O
ER(+)	B
as	O
compared	O
to	O
ER(−)	O
patients	O
independently	O
from	O
the	O
kind	O
of	O
target	O
chemotherapy	O
schedule	O
performed	O
[,,].	O

Glutamate	B
levels	O
differentially	O
increased	O
in	O
both	O
biofluids	O
while	O
glutamine	B
reduced	O
in	O
serum.	O

We	O
observed	O
a	O
significant	O
positive	O
correlation	O
of	O
the	O
tyrosine	B
serum	O
levels	O
with	O
AST	O
and	O
a	O
significant	O
negative	O
correlation	O
with	O
serum	O
fibrinogen	O
levels	O
in	O
the	O
present	O
study.	O

Furthermore,	O
there	O
were	O
distinctness	O
increase	O
of	O
all	O
branched-chain	O
amino	O
acids	O
(BCAAs)	O
in	O
plasma	O
of	O
GCT	O
patients,	O
including	O
valine,	B
leucine,	B
and	O
isoleucine.	B

They	O
identified	O
a	O
27-metabolite	O
panel	O
discriminating	O
glycemic	B
improvers	O
(i.e.	O
Matsuda	O
index	O
improvements	O
≥40.36%)	O
with	O
an	O
AUC	O
(95%	O
CI)	O
of	O
0.77	O
(0.70–0.85).	O

Multivariate	O
analysis	O
showed	O
that	O
MTX	O
dose	O
and	O
duration	B
of	O
treatment	O
were	O
the	O
most	O
predictive	O
factors	O
for	O
ALT	O
and	O
AST	O
elevation.	O

A	O
Spearman	O
correlation	O
coefficient	O
was	O
calculated	O
to	O
summarize	O
the	O
correlation	O
between	O
GABR	O
and	O
ADMA.	B

[]	O
As	O
expected,	O
cycloartenol,	O
ergosta-5,7-dienol	B
and	O
ergosterol	B
made	O
by	O
amoeba	O
biosynthetically,	O
had	O
the	O
highest	O
_13	O
C-isotope	O
content.	O

Effect	O
of	O
carnosine	B
supplementation	O
on	O
the	O
plasma	O
lipidome.	O

Atazanavir/r:	O
ceramide	B
(p	O
=	O
0.002),	O
trihexosylceramide	B
(p	O
=	O
0.006),	O
free	O
cholesterol	B
(p	O
=	O
0.006),	O
monohexosylceramide	B
(p	O
=	O
0.006),	O
GM3	B
ganglioside	I
(p	O
=	O
0.012),	O
alkenylphosphatidylcholine	B
(p	O
=	O
0.014),	O
sphingomyelin	B
(p	O
=	O
0.021),	O
phosphatidylcholine	B
(p	O
=	O
0.021),	O
alkylphosphatidylethanolamine	B
(p	O
=	O
0.021),	O
cholesteryl	B
ester	I
(p	O
=	O
0.021),	O
lysophosphatidylcholine	B
(p	O
=	O
0.025).	O

Interestingly,	O
when	O
comparing	O
each	O
of	O
the	O
individual	O
stages	O
of	O
MS	O
against	O
the	O
controls,	O
2	O
metabolites	O
were	O
consistent	O
across	O
the	O
groups:	O
glucose	B
(δ_x-y	O
=	O
3.25,	O
3.75,	O
3.91)	O
and	O
phosphocholine	B
(δ_x-y	O
=	O
3.23)	O
were	O
both	O
reduced.	O

Because	O
no	O
analyte-free	O
urine	O
was	O
available,	O
blank	O
extractions	O
were	O
conducted	O
using	O
HPLC-grade	O
water	O
acidified	O
with	O
0.1	O
M	O
acetic	B
acid.	I

Glutamine;	B
7	O
NAc;	O
8.	O

GSH	B
was	O
labeled	O
in	O
the	O
Glu	O
residue	O
in	O
Rh30	O
cells	O
and	O
the	O
extent	O
of	O
this	O
labeling	O
was	O
much	O
stronger	O
in	O
Rh30	O
cells	O
than	O
in	O
the	O
myocytes	O
(cf.	O

Individual	O
levels	O
of	O
oxysterols	B
in	O
patients	O
with	O
two	O
samplings	O
All	O
levels	O
in	O
ng/ml	O
of	O
plasma.	O

The	O
composite	O
score	O
increased	O
with	O
higher	O
HDL3	O
apolipoproteins,	O
tyrosine,	B
fatty	O
acid	O
with	O
αCH2	O
and	O
creatinine,	B
and	O
decreased	O
with	O
higher	O
glucose	B
and	O
valine.	B

A)	O
Analysis	O
for	O
sulfoxides	B
8,	O
11,	O
15,	O
and	O
18	O
in	O
creosote	O
worker’s	O
urine.	O

Elevated	O
levels	O
of	O
these	O
sphingolipids	B
in	O
tissues	O
and	O
in	O
the	O
circulation	O
have	O
been	O
associated	O
with	O
insulin	O
resistance	O
and	O
diabetes.	O

Among	O
them,	O
aspartic	B
acid	I
and	O
phenylalanine	B
were	O
increased,	O
but	O
serine	B
was	O
decreased.	O

Na	O
deoxycholic	B
acid,	I
1 mM	O
EGTA,	O
1%	O
NP40)	O
containing	O
protease	O
and	O
phosphatase	O
inhibitors,	O
and	O
sonicated	O
3 × 10 sec.	O

Our	O
study	O
therefore	O
justifies	O
an	O
extended	O
analysis	O
of	O
existing	O
MM	O
blood	O
serum	O
archives	O
to	O
further	O
dissect	O
and	O
define	O
the	O
association	O
of	O
carnitine	B
with	O
MM	O
and	O
its	O
clinical	O
course	O
and	O
in	O
particular	O
its	O
relative	O
association	O
with	O
kidney	O
and	O
bone	O
disease.	O

As	O
it	O
can	O
be	O
seen,	O
no	O
diosmetin	B
was	O
detected	O
without	O
digestion	O
and	O
as	O
well	O
after	O
sulfatase	O
degradation.	O

Organophosphate	B
pesticides	O
are	O
inhibitors	O
of	O
acetylcholinesterase.	O

The	O
CerS2	O
and	O
CerS4	O
are	O
responsible	O
for	O
production	O
of	O
Cer(22:0)	B
and	O
Cer(24:0).	B

An	O
inverse	O
association	O
between	O
serum	O
choline	B
and	O
PLC	O
risk	O
was	O
found.	O

(Abcam,	O
MA,	O
USA),	O
anti-cleaved-PARP,	O
anti-cleaved	O
caspase	O
3,	O
anti-normal	O
rabbit	O
IgG	O
and	O
anti-normal	O
mouse	O
IgG	O
(Cell	O
Signaling	O
Technologies,	O
MA,	O
USA),	O
anti-Rab14,	O
anti-Rab7A,	O
anti-MLKL	O
and	O
anti-β-actin	B
(Sigma-Aldrich,	O
Darmstadt,	O
Germany),	O
anti-HSP60	O
(Santa	O
Cruz,	O
CA,	O
USA),	O
and	O
anti-LC3	O
I/II	O
(Novus	O
Biologicals,	O
CA,	O
USA).	O

Upon	O
soy	O
consumption,	O
isoflavone	B
metabolites	O
attain	O
bioactive	O
concentrations	O
in	O
breast	O
tissue	O
possibly	O
affecting	O
health.	O

The	O
established	O
biomarker	O
for	O
hepatocellular	O
carcinoma	O
(HCC),	O
serum	O
α-fetoprotein	B
(AFP),	O
has	O
suboptimal	O
performance	O
in	O
early	O
disease	O
stages.	O

The	O
following	O
gradient	O
was	O
used	O
with	O
pure	O
CO_2	O
as	O
solvent	O
A	O
and	O
methanol	B
(MeOH)	O
with	O
30 mM	O
ammonium	B
formate	I
(1.892 g	O
dissolved	O
prior	O
in	O
5 mL	O
water	O
for	O
1 L	O
MeOH)	O
as	O
modifier	O
(solvent	O
B):	O
0–4.0 min	O
5%	O
B,	O
4.0–17.0 min	O
ramp	O
to	O
55%	O
B,	O
17.0–25.0 min	O
55%	O
B,	O
25.0–25.5 min	O
ramp	O
down	O
to	O
5%	O
B,	O
and	O
25.5–27.0 min	O
5%	O
B	O
as	O
equilibration	O
step.	O

For	O
example,	O
we	O
detected	O
a	O
strong	O
and	O
significant	O
positive	O
correlation	O
between	O
medium-chain	O
acylcarnitines	O
and	O
suberic	B
acid,	I
which	O
is	O
present	O
in	O
the	O
urine	O
of	O
patients	O
with	O
fatty	O
acid	O
oxidation	O
disorders	O
and	O
was	O
elevated	O
in	O
individuals	O
with	O
perturbations	O
in	O
ACADM.	O

Plasma	O
lArg,	O
hArg,	O
and	O
ADMA	B
concentrations	O
were	O
determined	O
by	O
liquid	O
chromatography	O
(LC)-tandem	O
mass	O
spectrometry	O
(MS)	O
analysis	O
as	O
described	O
previously	O
[,	O
].	O

The	O
clearest	O
increases	O
in	O
these	O
groups	O
of	O
compounds	O
were	O
also	O
observed	O
in	O
the	O
morbidly	O
obese	O
subject	O
cohort	O
where	O
all	O
but	O
2	O
of	O
the	O
28	O
monoetherglycerophosphocholine	B
and	O
monoetherglycerophosphoethanolamine	B
species	O
profiled	O
were	O
significantly	O
increased	O
in	O
NASH	O
as	O
compared	O
to	O
steatosis	O
patients.	O

Discarded	O
the	O
supernatant	O
and	O
resuspend	O
with	O
100	O
μl	O
PBS,	O
then	O
500	O
μl	O
cooled	O
75%	O
ethanol	B
were	O
added	O
into	O
EP	O
tubes	O
after	O
centrifugation.	O

A,	O
urinary	O
PGE-M	O
levels	O
[median	O
(range)]	O
are	O
not	O
significantly	O
elevated	O
in	O
58	O
HNSCC	O
cases	O
[15.4	O
(2.4–69.7)	O
ng/mg	O
creatinine]	O
compared	O
with	O
29	O
healthy	O
controls	O
[12.6	O
(1.5–68.5)	O
ng/mg	O
creatinine,	B
P	O
=	O
0.07].	O

Validating	O
this	O
response	O
score	O
in	O
another	O
independent	O
study	O
emphasized	O
the	O
importance	O
of	O
considering	O
this	O
score	O
and	O
its	O
signals	O
in	O
future	O
models	O
for	O
guiding	O
the	O
selection	O
of	O
hydrochlorothiazide	B
therapy.	O

In	O
terms	O
of	O
the	O
circadian	O
variation	O
of	O
cortisol	B
secretion,	O
our	O
findings	O
were	O
consistent	O
with	O
their	O
report,	O
although	O
our	O
patients	O
had	O
been	O
treated	O
and	O
their	O
body	O
weights	O
had	O
recovered.	O

Serine	B
is	O
generated	O
from	O
the	O
glycolytic	B
intermediate	O
3-phosphoglycerate	B
generated	O
by	O
3-phosphoglycerate	O
dehydrogenase	O
(PHGDH).	O

However,	O
as	O
new	O
information	O
apoE	O
ε4	O
allele	O
also	O
presented	O
a	O
consistent	O
atherogenic	O
effect	O
across	O
all	O
measured	O
apoE-	O
(chylomicron	O
remnants,	O
VLDL,	O
IDL,	O
HDL)	O
and	O
apoB-containing	O
(VLDL-,	O
IDL-,	O
LDL)	O
lipoproteins	O
along	O
with	O
their	O
subfractions,	O
showing	O
an	O
influence	O
on	O
particle	O
concentrations	O
of	O
free/esterified	O
cholesterol,	B
triglycerides,	B
phospholipids	B
and	O
total	O
lipid	O
contents,	O
as	O
well	O
as	O
on	O
LDL	O
and	O
VLDL	O
particle	O
sizes	O
in	O
serum.	O

Dimethyl‐sulfoxide	B
(DMSO,	O
Seccosolv)	O
and	O
acetonitrile	B
(ACN,	O
Lichrosolv)	O
were	O
purchased	O
from	O
Merck	O
(Darmstadt,	O
Germany).	O

The	O
reaction	O
of	O
catechol	B
estrogen	I
quinones	I
with	O
DNA	O
to	O
form	O
depurinating	O
estrogen-DNA	O
adducts	O
is	O
hypothesized	O
to	O
initiate	O
this	O
process.	O

Interestingly,	O
this	O
pleiotropic	O
and	O
proinflammatory	O
cytokine	O
is	O
also	O
involved	O
in	O
glucose	B
metabolism	O
and	O
in	O
the	O
development	O
of	O
diabetes,	O
insulin	O
resistance	O
and	O
obesity	O
which	O
is	O
a	O
known	O
risk	O
factor	O
for	O
BC	O
and	O
recurrence	O
of	O
this	O
disease	O
[–].	O

non-alcoholic	O
fatty	O
liver	O
disease,	O
NAFLD,	O
phospholipids,	B
metabolic	O
disease	O

Since	O
polyamines	B
mediate	O
the	O
complex	O
interplay	O
between	O
bacterial	O
infection	O
and	O
the	O
host	O
immune	O
response_,	O
this	O
might	O
suggest	O
an	O
altered	O
regulation	O
of	O
pathogen-host	O
interactions	O
in	O
these	O
patients.	O

Reporter	O
vectors	O
used	O
were	O
Renilla	O
luciferase	O
under	O
the	O
control	O
of	O
the	O
thymidine	B
kinase	O
promoter	O
and	O
firefly	O
luciferase	O
under	O
the	O
control	O
of	O
RARE.	O

This	O
score	O
explained	O
11.3%	O
and	O
11.9%	O
of	O
the	O
variability	O
in	O
HCTZ	O
SBP	O
and	O
DBP	B
responses,	O
respectively,	O
and	O
was	O
further	O
validated	O
in	O
another	O
independent	O
study	O
of	O
196	O
whites	O
treated	O
with	O
HCTZ	O
(DBP-score	O
p=0.03,	O
SBP-score	O
p=0.07).	O

For	O
example,	O
an	O
increase	O
in	O
lactate	B
(visible	O
at	O
1.33	O
and	O
4.13	O
ppm),	O
ketone	B
bodies	O
(acetoacetate	O
[visible	O
at	O
2.23	O
ppm],	O
and	O
β-hydroxybutyrate	B
[visible	O
at	O
1.19	O
ppm]),	O
and	O
a	O
decrease	O
in	O
lipids	O
and	O
glucose	B
(visible	O
at	O
5.23	O
[α-glucose]	O
and	O
4.68	O
ppm	O
[β-glucose],	O
respectively)	O
were	O
observed.	O

ALT,	O
Alanine	O
transaminase;	O
AST,	O
Aspartate	O
transaminase;	O
TBIL,	O
Total	O
bilirubin;	B
DBIL,	O
direct	O
bilirubin;	B
IBIL,	O
indirect	O
bilirubin;	B
ALP,	O
alkaline	O
phosphatase;	O
GGT,	O
gamma-glutamyl	O
transferase;	O
GLB,	O
globin;	O
TP,	O
Total	O
Protein;	O
ALB,	O
Albumin;	O
PALB,	O
prealbumin;	O
TBA,	O
Total	O
bile	O
acid;	O
CREA,	O
creatinine;	B
BUN,	O
Blood	O
urea	B
nitrogen;	I
CHOL,	O
cholesterol;	B
TG,	B
Triglyceride;	B
HDLC,	O
High-Density	O
Lipoprotein	O
Cholesterol;	B
LDLC,	O
low-density	O
lipoprotein	O
cholesterol;	B
GLU,	O
Glucose;	B
RBC,	O
red	O
blood	O
cell;	O
WBC,	O
white	O
blood	O
cell;	O
HCT,	O
hematocrit;	O
HGB,	O
hemoglobin;	O
MCH,	O
mean	O
corpuscular	O
hemoglobin;	O
MCHC,	O
Mean	O
corpuscular	O
hemoglobin	O
concentration;	O
MPV,	O
Mean	O
platelet	O
volume;	O
PLT,	O
platelet;	O
PCT,	O
plateletocrit;	O
PDW,	O
platelet	O
distribution	O
width	O
Clinical	O
information	O
and	O
characteristics	O
of	O
liver	O
cirrhotic	O
patients	O
in	O
the	O
discovery	O
set.	O

 _S2	O
)	O
and	O
visual	O
inspection	O
of	O
the	O
derived	O
metabolic	O
network	O
revealed	O
a	O
cluster	O
containing	O
the	O
annotated	O
metabolite	O
piperine	B
(Fig. ).	O

Methodological	O
limitations	O
have	O
challenged	O
the	O
analysis	O
of	O
free	O
oxysterols	B
to	O
date.	O

The	O
current	O
study	O
found	O
positive	O
correlations	O
between	O
lysoPCs,	O
fasting	O
TG	B
levels,	O
and	O
several	O
amides,	B
including	O
palmitoleamide.	B

Since	O
hundreds	O
of	O
different	O
glycerophospholipids	B
have	O
been	O
observed	O
in	O
plasma	O
lipoproteins	O
(Lp	O
(a))	O
and	O
atherosclerotic	O
plaques,	O
our	O
finding	O
was	O
not	O
unexpected.	O

An	O
isocratic	O
LC	O
separation	O
of	O
the	O
targeted	O
metabolites	O
(succinic	O
acid,	I
ascorbic	B
acid,	I
and	O
carnitine)	B
was	O
performed	O
using	O
a	O
Waters	O
ACQUITY	O
UPLC	O
BEH	O
C18	O
column	O
(2.1	O
mm	O
×	O
150	O
mm,	O
1.7	O
µm)	O
with	O
95:5	O
water:acetonitrile	O
(10	O
mM	O
Ammonium	B
formate,	I
pH3)	O
as	O
mobile	O
phase	O
and	O
a	O
flowrate	O
of	O
0.3	O
mL/min.	O

Carnitine	B
and	O
ACs	O
are	O
involved	O
in	O
FA	B
oxidation	O
and	O
organic	O
acid	O
metabolism,	O
and	O
are	O
considered	O
important	O
biomarkers	O
for	O
metabolic	O
disorders	O
such	O
as	O
obesity,	O
diabetes,	O
hepatic	O
encephalopathy	O
and	O
cardiomyopathy_,	O
.	O

The	O
analytical	O
chemistry	O
validation	O
data	O
reported	O
here	O
were	O
important	O
for	O
our	O
study	O
of	O
the	O
longitudinal	O
stability	O
of	O
8-iso	B
-PGF_2α	I
and	O
PGE-M.	O

Since	O
D-mannose	B
is	O
an	O
endogenous	O
compound,	O
both	O
the	O
LLOQ	O
and	O
ULOQ	O
were	O
determined	O
based	O
on	O
the	O
level	O
of	O
D-mannose	B
found	O
in	O
normal	O
human	O
serum.	O

A	O
mixture	O
of	O
D6-25-OH	B
D_3	O
,	O
D6-25-OH	B
D_2	O
,	O
D6-1,25-(OH)_2	B
D_3	O
,	O
and	O
D6-1,25-(OH)_2	B
D_2	O
was	O
prepared;	O
four	O
different	O
amounts	O
were	O
spiked	O
into	O
plasma	O
and	O
incubated	O
at	O
room	O
temperature	O
for	O
10	O
to	O
120 min.	O

Total	O
nicotine	B
equivalents	O
(TNE)	O
were	O
calculated	O
as	O
the	O
sum	O
of	O
nicotine,	B
COT,	O
and	O
3HC.	O

Ketones,	B
β-hydroxybutyrate,	B
total	O
NEFA,	O
glucose	B
and	O
insulin	O
were	O
measured	O
by	O
standard	O
methods.	O

4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol	B
(NNAL)	O
and	O
4-(methyl-[_2	B
H_3	I
]-nitrosamino)-1-(3-pyridyl)-1-butanol	I
([_2	O
H_3	O
]-NNAL)	O
were	O
obtained	O
from	O
Toronto	O
Research	O
Chemicals	O
(Toronto,	O
Canada).	O

This	O
finding	O
was	O
confirmed	O
in	O
a	O
historical	O
study	O
by	O
Pitkänen	O
E,	O
reporting	O
that	O
the	O
urinary	O
appearance	O
of	O
myo-inositol	B
was	O
closely	O
related	O
to	O
kidney	O
function,	O
and	O
the	O
estimation	O
of	O
urinary	O
myo-inositol	B
was	O
useful	O
in	O
the	O
evaluation	O
of	O
kidney	O
function.	O

All	O
of	O
the	O
top	O
coffee	O
metabolites	O
were	O
positively	O
correlated	O
with	O
each	O
other;	O
correlations	O
between	O
caffeine,	B
theophylline,	B
paraxanthine,	B
and	O
1,7-dimethylurate	B
were	O
especially	O
strong	O
(>0.7).	O

The	O
spectra	O
were	O
normalized	O
to	O
total	O
aliphatic	B
spectral	O
area	O
to	O
eliminate	O
differences	O
in	O
metabolite	O
total	O
concentration.	O

2,4-dihydroxypyrimidine	B
was	O
decreased	O
in	O
BD	O
patients.	O

The	O
pediatric	O
study	O
was	O
the	O
only	O
one	O
to	O
find	O
altered	O
lactate	B
levels	O
in	O
sepsis	O
compared	O
to	O
healthy	O
controls.	O

The	O
D_2	O
O	O
contained	O
0.05%	O
v/v	O
trimethylsilylpropanoic	B
acid	I
(TSP)	O
as	O
a	O
chemical	O
shift	O
reference	O
for	O
_1	O
H	O
NMR	O
spectroscopy.	O

Moreover,	O
in	O
the	O
pancreas,	O
GABA	B
is	O
produced	O
primarily	O
by	O
insulin-secreting	O
beta	O
cells,	O
and	O
the	O
release	O
of	O
GABA	B
from	O
these	O
cells	O
appears	O
to	O
be	O
regulated	O
by	O
glucose.	B

In	O
positive	O
ionization	O
mode,	O
there	O
were	O
1,297	O
features	O
detected	O
in	O
the	O
aqueous	O
fraction	O
following	O
MTBE	B
extraction,	O
compared	O
to	O
1,669	O
features	O
detected	O
in	O
the	O
methanol	B
supernatant.	O

For	O
example,	O
recovery	O
of	O
PC(19:0/15:1)	B
(p<0.001)	O
increased	O
by	O
40%,	O
and	O
PE(20:3/18:1)	B
(p=0.012)	O
increased	O
by	O
58%.	O

In	O
these	O
women,	O
testosterone	B
levels	O
were	O
positively	O
associated	O
with	O
serum	O
TG	B
as	O
well	O
as	O
with	O
PL,	O
TG	B
and	O
TC	O
in	O
larger	O
VLDL	O
subclasses,	O
which	O
is	O
consistent	O
with	O
other	O
reported	O
studies	O
in	O
women	O
with	O
PCOS.	O

Since	O
HIV	O
infection	O
of	O
primary	O
oral	O
epithelial	O
cells	O
in	O
culture	O
is	O
increased	O
significantly	O
by	O
alcohol	O
,	O
we	O
suggest	O
that	O
increased	O
levels	O
of	O
Ethanol	B
in	O
the	O
oral	O
cavity	O
may	O
also	O
increase	O
the	O
risk	O
of	O
continuous	O
oral	O
reinfection.	O

In	O
addition,	O
the	O
levels	O
of	O
octadecanoylcarnitine,	B
ADMA	B
and	O
six	O
PCs	O
were	O
significantly	O
different	O
between	O
RRMM	O
and	O
MGUS	O
patients.	O

TMAO	B
determination	O
showed	O
increased	O
levels	O
of	O
TMAO	B
in	O
CLI	O
subjects	O
compared	O
to	O
IC	O
[median:	O
1.30(0.83–2.25)	O
IC	O
vs	O
2.77(1.45–7.16)	O
µmol/L	O
CLI,	O

All	O
signals	O
within	O
the	O
GLU2,	O
GLU3	O
and	O
GLU4	O
multiplets	O
were	O
resolved	O
well	O
enough	O
to	O
integrate	O
peak	O
areas	O
with	O
high	O
confidence,	O
so	O
it	O
was	O
possible	O
to	O
perform	O
a	O
complete	O
analysis	O
of	O
glutamate	B
isotopomers	O
to	O
determine	O
enrichments	O
and	O
relative	O
fluxes	O
related	O
to	O
core	O
pathways	O
of	O
glucose	B
metabolism.	O

The	O
most	O
commonly	O
detected	O
neonicotinoid	B
biomarkers	O
were	O
N-desmethyl-acetamiprid	B
(90%),	O
5-hydroxy-imidacloprid	B
(42%),	O
clothianidin	B
(37%),	O
and	O
imidacloprid	O
(30%).	O

Figs	O
and	O
in	O
revealed	O
a	O
moderate	O
to	O
high	O
positive	O
correlation	O
among	O
most	O
of	O
androgen	O
and	O
progesterone	B
metabolites	O
and	O
a	O
low	O
to	O
moderate	O
positive	O
correlation	O
among	O
most	O
of	O
glucocorticoid	B
metabolites	O
in	O
men	O
and	O
women.	O

In	O
the	O
present	O
study,	O
both	O
eicosapentaenoic	B
acid	I
(C20:5)	O
and	O
5-HEPE	B
were	O
significantly	O
lower	O
in	O
the	O
LC	O
group	O
than	O
the	O
control	O
group;	O
moreover,	O
the	O
former	O
was	O
revealed	O
as	O
an	O
independent	O
factor	O
for	O
incidence	O
of	O
LC.	O

Recent	O
evidence	O
further	O
highlights	O
that	O
AF	B
episodes	O
are	O
often	O
temporally	O
dissociated	O
from	O
thromboembolism.	O

In	O
detail,	O
32	O
females	O
and	O
30	O
males,	O
between	O
30	O
and	O
65 years	O
old,	O
with	O
BMI	O
from	O
20	O
to	O
29.9	O
(average	O
24 ± 3.4)	O
and	O
total	O
cholesterol	B
ranging	O
between	O
180	O
and	O
240 mg/dl	O
completed	O
the	O
study.	O

The	O
tubes	O
were	O
previously	O
degreased	O
by	O
sulfuric	B
acid	I
and	O
washed	O
with	O
ethanol.	B

The	O
profiles	O
of	O
patients	O
with	O
sepsis	O
48 h	O
before	O
death	O
illustrated	O
an	O
obvious	O
state	O
of	O
metabolic	O
disorder,	O
such	O
that	O
S	B
-(3-methylbutanoyl)-dihydrolipoamide-E,	I
phosphatidylglycerol	B
(22:2	I
(13Z,	I
16Z)/0:0),	I
glycerophosphocholine	B
and	O
S	B
-succinyl	I
glutathione	I
were	O
significantly	O
decreased	O
(p<0.05).	O

Sample	O
extraction	O
was	O
conducted	O
by	O
using	O
aqueous	O
methanol,	B
delivered	O
by	O
an	O
automated	O
liquid	O
handler	O
to	O
remove	O
the	O
protein	O
fraction	O
while	O
allowing	O
maximum	O
recovery	O
of	O
small	O
molecules.	O

Generalized	O
estimating	O
equations	O
were	O
used	O
to	O
examine	O
eGFR	O
(intercept)	O
and	O
its	O
change	O
over	O
time	O
(slope)	O
by	O
categories	O
of	O
vitamin	B
D	I
metabolites.	O

Our	O
data	O
suggests	O
that	O
if	O
soy	O
decreases	O
breast	O
cancer	O
risk,	O
its	O
effects	O
are	O
not	O
mediated	O
by	O
effects	O
on	O
absolute	O
levels	O
of	O
estrogens	O
or	O
total	O
estrogens	O
and	O
estrogen	B
metabolites.	O

No	O
other	O
DMARDs	O
were	O
allowed	O
within	O
the	O
4	O
weeks	O
prior	O
to	O
commencing	O
treatment,	O
but	O
prednisolone	B
was	O
allowed	O
provided	O
the	O
dose	O
remained	O
stable	O
and	O
did	O
not	O
exceed	O
10	O
mg	O
daily.	O

Moreover,	O
the	O
ER	O
status	O
itself	O
has	O
been	O
found	O
to	O
dramatically	O
influence	O
the	O
lipid	O
profiles,	O
with	O
the	O
highest	O
levels	O
of	O
membrane	O
phospholipids	B
detected	O
in	O
the	O
most	O
aggressive	O
tumors	O
[,].	O

This	O
study	O
suggests	O
that	O
plasma	O
metabolic	O
profiling	O
has	O
great	O
potential	O
in	O
differentiating	O
RSA	O
patients	O
from	O
control	O
patients,	O
and	O
the	O
metabolism	O
of	O
lactic	B
acid	I
and	O
5-methoxytryptamine	B
is	O
significantly	O
different	O
between	O
RSA	O
and	O
control	O
groups,	O
implying	O
that	O
the	O
differential	O
metabolites	O
might	O
be	O
novel	O
biomarkers	O
of	O
RSA.	O

In	O
addition,	O
investigations	O
of	O
breast	O
cancer	O
cells	O
showed	O
increased	O
levels	O
of	O
threonine,	B
under	O
hypoxic	O
conditions,	O
and	O
such	O
an	O
increase	O
is	O
attributed	O
to	O
impaired	O
protein	O
synthesis	O
due	O
to	O
hypoxia	O
(Weljie	O
et al.,	O
2011).	O

Given	O
the	O
implication	O
these	O
results	O
have	O
for	O
breast	O
cancer	O
prevention	O
efforts,	O
future	O
studies	O
should	O
not	O
only	O
attempt	O
to	O
corroborate	O
our	O
results,	O
but	O
also	O
investigate	O
the	O
exact	O
mechanisms	O
by	O
which	O
exercise	O
leads	O
to	O
these	O
favorable	O
estrogen	B
metabolism	O
changes.	O

Characteristic	O
MS/MS	O
spectra	O
of	O
m/z	O
522.3451	O
in	O
a	O
biological	O
sample	O
(C)	O
and	O
PC	B
(18:1(9Z)/0:0)	I
standard	O
(D)	O
at	O
11.75 min.	O

Human	O
plasma	O
samples	O
(100 μL)	O
were	O
extracted	O
using	O
400 μL	O
of	O
cold	O
MeOH:ACN	O
(1:1,	O
v/v)	O
to	O
maintain	O
MeOH:ACN:H_2	O
O	O

We	O
tested	O
the	O
influence	O
of	O
therapy	O
duration	B
(12	O
or	O
24	O
weeks),	O
administration	O
of	O
ribavirin	B
(RBV),	O
HCV	O
genotypes	O
and	O
METAVIR	O
score	O
on	O
the	O
metabolic	O
fingerprint.	O

Signal	O
intensity	O
in	O
the	O
water	O
region	O
(4.5	O
–	O
5.0	O
ppm)	O
and	O
water	O
+	O
urea	B
region	O
(4.5	O
–	O
6.0	O
ppm)	O
was	O
set	O
to	O
0	O
in	O
the	O
spectra	O
of	O
all	O
cell	O
line	O
and	O
urine	O
samples,	O
respectively.	O

Both	O
estrogen	B
receptor-mediated	O
mechanisms	O
involving	O
increased	O
mitosis	O
and	O
proliferation	O
and	O
estrogen	B
receptor-independent	O
mechanisms	O
involving	O
direct	O
DNA	O
damage	O
have	O
been	O
proposed.	O

The	O
tandem	O
mass	O
spectra	O
in	O
panels	O
(a)	O
and	O
(f)	O
are	O
from	O
18:3	O
FA	O
isomers,	O
Δ_9,12,15	B
(i.e.,	I
ALA)	I
and	O
Δ_6,9,12	B
(i.e.,	I
GLA),	I
respectively.	O

Though	O
most	O
oxylipins	B
are	O
stable	O
during	O
storage	O
at	O
−80°C	O
(Jonasdottir	O
et	O
al.,	O
)	O
lower	O
SPM	O
levels	O
have	O
been	O
reported	O
in	O
plasma	O
which	O
was	O
stored	O
for	O
a	O
longer	O
period	O
of	O
time	O
(Colas	O
et	O
al.,	O
).	O

Therefore,	O
the	O
observed	O
association	O
between	O
mtDNA	O
and	O
tyrosine	B
might	O
be	O
due	O
to	O
overlapping	O
resonances	O
arising	O
from	O
HDL3	O
apolipoproteins	O
and	O
tyrosine	B
metabolites.	O

In	O
the	O
case	O
when	O
sulfatase	O
was	O
used,	O
0.05 mL	O
of	O
the	O
incubated	O
mixture	O
were	O
transferred	O
in	O
a	O
mictrotiter	O
plate,	O
treated	O
with	O
0.05 mL	O
NaOH	O
1 M	O
and	O
the	O
obtained	O
p	B
-nitrocatechol	I
was	O
measured	O
at	O
490 nm	O
to	O
appreciate	O
the	O
desulfatation	O
process	O
efficiency	O
against	O
a	O
standard	O
of	O
p	B
-nitrocatechol	I
in	O
water	O
(concentration	O
of	O
0.32	O
mMol/L,	O
corresponding	O
to	O
the	O
expected	O
levels	O
of	O
p	B
-nitrocatechol	I
achievable	O
in	O
the	O
samples	O
with	O
a	O
complete	O
enzymatic	O
degradation).	O

Past	O
studies	O
have	O
also	O
reported	O
on	O
inverse	O
associations	O
between	O
estrogen	B
metabolites	O
and	O
fruit	O
and	O
vegetable	O
intake	O
in	O
population-based	O
studies	O
[,	O
–].	O

Indeed,	O
the	O
ratio	O
of	O
quinolinic	B
acid	I
over	O
xanthurenic	B
acid	I
is	O
positively	O
associated	O
with	O
better	O
insulin	O
sensitivity	O
and	O
glucose	B
control.	O

The	O
method	O
described	O
here	O
for	O
the	O
simultaneous	O
detection	O
of	O
five	O
oxysterols	B
has	O
been	O
optimised	O
for	O
analysis	O
of	O
non-esterified	O
plasma	O
oxysterols	B
through	O
a	O
simple	O
solid	O
phase	O
preparative	O
procedure.	O

Similarly,	O
the	O
UPLC	O
chromatograms	O
for	O
representative	O
samples	O
with	O
high	O
concentration	O
of	O
acetaminophen	B
(m	O
/z	O
=	O
150.05,	O
rt	O
=	O
4.45	O
min)	O
and	O
its	O
metabolites	O
(acetaminophen	O
glucuronide	I
(m	O
/z	O
=	O
326.09,	O
rt	O
=	O
2.45	O
min),	O
acetaminophen	B
sulfate	I
(m	O
/z	O
=	O
230.01,	O
rt	O
=	O
2.62	O
min))	O

Therefore,	O
especially	O
the	O
1,2-NPQ-Alb	B
adduct	O
is	O
unstable.	O

The	O
18	O
unique	O
metabolites	O
of	O
WB	O
included	O
adenosine,	B
AMP,	B
ADP	B
and	O
ATP,	B
which	O
are	O
associated	O
with	O
RBC	O
metabolism.	O

At	O
first,	O
matrix	O
effect	O
was	O
performed	O
with	O
plasma	O
from	O
six	O
different	O
individuals	O
with	O
triglyceride	B
levels	O
of	O
52–103	O
mg/dL.	O
The	O
test	O
was	O
repeated	O
with	O
plasma	O
that	O
was	O
spiked	O
with	O
a	O
known	O
concentration	O
of	O
triglycerides	B
to	O
reach	O
concentrations	O
more	O
than	O
300	O
mg/dl	O
(352–403	O
mg/dl).	O

For	O
both	O
cohorts,	O
the	O
exclusion	O
criteria	O
were:	O
diagnosis	O
of	O
any	O
other	O
vitreoretinal	O
disease,	O
active	O
uveitis	O
or	O
ocular	O
infection,	O
significant	O
media	O
opacities	O
that	O
precluded	O
the	O
observation	O
of	O
the	O
ocular	O
fundus,	O
refractive	O
error	O
equal	O
or	O
greater	O
than	O
6	O
diopters	O
of	O
spherical	O
equivalent,	O
past	O
history	O
of	O
retinal	B
surgery,	O
history	O
of	O
any	O
ocular	O
surgery	O
or	O
intra-ocular	O
procedure	O
(such	O
as	O
laser	O
and	O
intra-ocular	O
injections)	O
within	O
the	O
90	O
days	O
prior	O
to	O
enrolment,	O
and	O
diagnosis	O
of	O
diabetes	O
mellitus.	O

Signature	O
score	O
is	O
defined	O
as	O
the	O
normalized	O
sum	O
of	O
metabolite	O
intensity	O
of	O
the	O
citric	B
acid	I
cycle	O
components	O
(succinate,	O
fumarate,	B
alpha-ketoglutarate,	B
malate,	B
oxaloacetate,	B
isocitrate,	B
and	O
citrate).	O

The	O
levels	O
of	O
p	B
-hydroxyphenyl-acetic	I
and	O
3-(3’-hydroxyphenyl)-3-hydropropionic	B
acids	I
increased	O
in	O
patients’	O
urine	O
after	O
blueberry	O
meals	O
intake,	O
in	O
particular	O
after	O
four	O
hours.	O

Chloroform	B
was	O
from	O
Rathburn	O
Chemicals	O
Ltd	O
(Walkerburn,	O
UK).	O

These	O
results	O
suggest	O
that	O
N-formylkynurenine	B
could	O
be	O
significant	O
as	O
a	O
potentially	O
useful	O
metabolite	O
for	O
RCC	O
distinction	O
from	O
healthy	O
controls	O
and	O
benign	O
controls.	O

Dressen	O
et	O
al	O
.	O
recently	O
reported	O
an	O
LC-MS/MS	O
method	O
capable	O
of	O
detecting	O
and	O
measuring	O
several	O
AAI	O
and	O
other	O
similar	O
synthetic	O
cannabinoids	B
in	O
human	O
serum.	O

Transformed	O
spectra	O
were	O
automatically	O
corrected	O
for	O
phase	O
and	O
baseline	O
distortions	O
and	O
calibrated	O
(anomeric	O
glucose	B
signal	O
5.24	O
ppm)	O
using	O
TopSpin	O
3.2	O
(Bruker	O
BioSpin	O
GmbH,	O
Rheinstetten,	O
Germany).	O

Perturbation	O
of	O
fatty	O
acid	O
synthesis	O
and	O
metabolism	O
could	O
lead	O
to	O
abnormal	O
levels	O
of	O
free	O
carboxylates.	B

(a)	O
Arginine	B
and	O
proline	B
metabolism	O
(b)	O
Glycine,	B
serine	B
and	O
threonine	B
metabolism,	O
(c)	O
Alanine,	B
aspartate	B
and	O
glutamate	B
metabolism,	O
(d)	O
Pyruvate	B
metabolism.	O

The	O
product	O
ion	O
of	O
126.0906	O
m/z	O
has	O
also	O
been	O
described	O
by	O
Fitzgerald	O
et	O
al..	O
N1-acetylisoputreanine	B
(N1-AcIsoPUTR)	O
product	O
ion	O
spectrum	O
at	O
30	O
V	O
of	O
collision	O
energy.	O

A	O
key	O
finding	O
from	O
the	O
molecular	O
process	O
analysis	O
is	O
the	O
relevance	O
of	O
nitric	B
oxide	I
(NO)	O
in	O
ARB	O
response,	O
as	O
illustrated	O
by	O
the	O
direct	O
interference	O
of	O
ARB	O
molecular	O
mechanism	O
of	O
action	O
and	O
DKD	O
molecular	O
model	O
by	O
the	O
enzyme	O
NOS3,	O
and	O
further	O
reflected	O
by	O
the	O
inclusion	O
of	O
ADMA	B
and	O
citrulline	B
in	O
the	O
serum	O
metabolite	O
classifier.	O

Guo	O
et	O
al.	O
evaluated	O
the	O
antioxidant	O
activities	O
of	O
six	O
compounds,	O
including	O
psoralidin,	B
from	O
PC	O
extract,	O
which	O
exhibited	O
strong	O
antioxidant	O
activities;	O
however,	O
P	O
and	O
IP	B
do	O
not	O
possess	O
any	O
antioxidant	O
activities	O
either,	O
which	O
is	O
consistent	O
with	O
the	O
results	O
of	O
our	O
experiments.	O

It	O
is	O
likely	O
that	O
the	O
observed	O
matrix	O
effects	O
were	O
due	O
to	O
the	O
short	O
retention	O
time	O
of	O
citrulline	B
and	O
its	O
SIL	O
internal	O
standard.	O

The	O
PAH	O
compound	O
that	O
shows	O
the	O
strongest	O
correlation	O
with	O
the	O
ETS	O
urinary	O
biomarkers	O
cotinine	B
(Pearson	O
R	O
=0.55,	O
p	O
<0.01)	O
and	O
trans	B
-3′-hydroxycotinine	I
(Pearson	O
R	O
=0.52,	O
p	O
<0.01)	O
is	O
chrysene.	O

This	O
fragment	O
was	O
divided	O
in	O
3	O
smaller	O
pieces	O
of	O
1×1	O
cm,	O
washed	O
in	O
saline	B
solution	O
and	O
immediately	O
frozen	O
and	O
stored	O
at	O
−80°C	O
for	O
further	O
processing	O
and	O
lipid	O
extraction.	O

The	O
dissociation	O
between	O
TMAO	B
and	O
choline/betaine	O
in	O
terms	O
of	O
relationships	O
with	O
markers	O
of	O
endothelial	O
dysfunction	O
further	O
suggests	O
that	O
the	O
metabolic	O
defect	O
associated	O
with	O
elevated	O
TMAO	B
may	O
even	O
be	O
independent	O
of	O
traditional	O
measures	O
of	O
vascular	O
dysfunction	O
that	O
has	O
known	O
to	O
impact	O
diastolic	O
dysfunction[,	O
].	O

 	O
and	O
the	O
chromatograms	O
of	O
extracts	O
obtained	O
from	O
the	O
synthesis	O
of	O
sulfoxides	B
are	O
presented.	O

Interestingly,	O
azelaic	B
acid,	I
a	O
dicarboxylic	B
acid	I
found	O
in	O
wheat,	O
rye	O
and	O
barley	O
that	O
has	O
been	O
shown	O
to	O
reverse	O
diabetic	O
symptoms	O
following	O
a	O
high-fat	O
diet	O
in	O
mice,	O
decreased	O
in	O
relation	O
to	O
increased	O
glucose,	B
insulin,	O
c-peptide	O
and	O
HOMA	O
in	O
all	O
analyses.	O

3-HPMA,	O
[N	O
-acetyl-D_3	I
]3-HPMA	O
dicyclohexylamine	B
salt,	O
HMPMA	O
dicyclohexylamine	B
salt,	O
and	O
[N	O
-acetyl-D_3	I
]HMPMA	O
dicyclohexylamine	B
salt	O
were	O
obtained	O
from	O
Toronto	O
Research	O
Chemicals.	O

For	O
the	O
ultraLC	O
separation,	O
the	O
sample	O
was	O
loaded	O
into	O
an	O
Atlantis	O
T3	O
sentry	O
guard	O
cartridge	O
(3 μm,	O
2.1 × 10 mm;	O
Waters),	O
and	O
then	O
separation	O
was	O
performed	O
in	O
an	O
Atlantis	O
T3	O
column	O
(3 μm,	O
2.1 × 100 mm;	O
Waters)	O
in	O
a	O
two-step	O
linear	O
gradient	O
(solvent	O
A,	O
0.1 %	O
FA	B
in	O
water;	O
solvent	O
B,	O
100 %	O
Acetonitrile;	B
with	O
1 %	O
solvent	O
B	O
for	O
2 min,	O
1	O
to	O
30 %	O
B	O
for	O
6 min,	O
30	O
to	O
90 %	O
B	O
for	O
8 min,	O
90 %	O
B	O
for	O
4 min,	O
90	O
to	O
1 %	O
B	O
for	O
1 min	O
and	O
9 min	O
in	O
1 %	O
B).	O

However,	O
in	O
the	O
previous	O
metabonomics	O
research	O
on	O
esophageal	O
cancer,	O
none	O
of	O
the	O
paper	O
reported	O
the	O
identification	O
of	O
NAA	O
and	O
acetate.	B

hypercholesterolaemic	B
group = 6.72 ± 0.78 mM;	O
p < 0.001,	O
).	O

This	O
association	O
remained	O
after	O
adjustment	O
for	O
chronic	O
health	O
conditions,	O
hypothyroidism	O
and	O
hypertension	O
and	O
female	O
partner's	O
urinary	O
paracetamol	B
concentration	O
[FOR	O
=	O
0.65;	O
95%	O
CI	O
=	O
(0.45,	O
0.94)].	O

Through	O
urinary	O
data	O
analysis,	O
metabolites	O
were	O
grouped	O
according	O
to	O
BMI,	O
hypertension,	O
diabetes,	O
total	O
cholesterol	B
(TC),	O
and	O
triacylglycerol	B
(TG)	O
indexes.	O

Further,	O
we	O
detected	O
greater	O
amounts	O
of	O
poly-	O
and	O
monounsaturated	O
fatty	O
acids	O
and	O
deoxycholic	B
acid	I
in	O
the	O
H	O
group,	O
which	O
are	O
known	O
to	O
be	O
present	O
in	O
fecal	O
samples	O
from	O
healthy	O
adults	O
_,	O
.	O

[1,2-_13	O
C]	I
(C1D12)	O
in	O
plasma	O
glucose	B
are	O
0.23±0.05,	O
0.17±0.04	O
respectively.	O

Increased	O
glucose	B
exposure	O
was	O
rather	O
reflected	O
in	O
increased	O
urinary	O
excretion	O
of	O
the	O
glucose-dependent	O
glycation-derived	O
crosslink,	O
glucosepane.	B

Then,	O
extract	O
solution	O
(2.85 ml/g	O
distilled	O
water + 4 ml/g	O
methanol	B
and	O
chloroform)	B
was	O
added.	O

In	O
RA	O
and	O
SLE,	O
citrate	B
has	O
also	O
been	O
found	O
to	O
be	O
in	O
lower	O
levels	O
in	O
the	O
serum	O
of	O
patients	O
compared	O
to	O
controls	O
[,	O
].	O

For	O
example,	O
increased	O
plasmanylcholine	B
and	O
TAG	O
levels	O
and	O
decreased	O
plasmenyl-ethanolamine	B
lipids	O
have	O
been	O
observed	O
in	O
metastatic	O
SW620	O
cells,	O
as	O
compared	O
to	O
the	O
primary	O
colon	O
cancer	O
SW480	O
cell	O
line.	O

TNBC,	O
Triple	O
negative	O
breast	O
cancer;	O
CN,	O
healthy	O
controls;	O
ER−,	O
negative	O
expression	O
of	O
estrogen	B
receptor;	O
PR−,	O
negative	O
expression	O
of	O
progesterone	B
receptor;	O
HER2−,	O
negative	O
expression	O
of	O
human	O
epidermal	O
growth	O
factor	O
receptor.	O

Aliquots	O
of	O
each	O
sample	O
(300 μl)	O
were	O
mixed	O
with	O
300 μl	O
of	O
sodium	B
phosphate	I
buffer	O
for	O
immediate	O
analysis.	O

Enzymatic	O
methods	O
(Randox	O
Laboratories	O
Ltd.,	O
Crumlin,	O
UK)	O
were	O
employed	O
to	O
analyze	O
the	O
levels	O
of	O
serum	O
cholesterol,	B
triglycerides,	B
HDL-cholesterol,	B
glucose,	B
and	O
glycosylated	O
hemoglobin	O
(HbA1c)	O
using	O
a	O
Dimension	O
Vista	O
autoanalyzer	O
(Siemens	O
Healthcare	O
Diagnostics,	O
Erlangen,	O
Germany).	O

Among	O
the	O
five	O
identified	O
potential	O
metabolite	O
biomarkers,	O
the	O
levels	O
of	O
lactate	B
and	O
α-hydroxybutyrate	B
were	O
increased	O
and	O
the	O
levels	O
of	O
phenylalanine,	B
formate,	B
and	O
arabinitol	B
were	O
decreased	O
in	O
the	O
urine	O
of	O
PSD	O
subjects.	O

However,	O
our	O
results	O
are	O
supported	O
by	O
several	O
observational	O
studies	O
linking	O
cholesterol	B
and	O
lipoproteins	O
to	O
breast	O
cancer	O
development	O
[,	O
]	O
and	O
survival.	O

Glutamate	B
links	O
the	O
tricarboxylic	B
acid	I
(TCA)	O
cycle	O
with	O
amino	O
acid	O
biosynthesis	O
and	O
degradation.	O

Whole	O
cell	O
protein	O
lysates	O
were	O
prepared	O
by	O
lysis	O
in	O
radio-immunoprecipitation	O
assay	O
buffer	O
(150 mM	O
NaCl,	O
2 %	O
NP-40,	O
0.5 %	O
sodium	B
deoxycholate,	I
0.1 %	O
SDS,	O

Acetone,	B
choline,	B
urea,	B
1,3-dimethylurate,	B
creatinine,	B
isoleucine,	B
myo-inositol,	B
leucine,	B
and	O
3-OH	O
butyrate;	B
saturated	O
and	O
monounsaturated	O
acyl	O
groups	O
of	O
ω–9,	O
ω–7,	O
ω–6,	O
ω–3,	O
and	O
fatty	O
acid,	O
triglycerides,	B
1,3-DG,	B
1-MG,	O
and	O
unassigned	O
component	O
signal	O
at	O
3.33 ppm	O
were	O
the	O
most	O
important	O
signal	O
compounds	O
in	O
group	O
separation.	O

Nonetheless,	O
our	O
study	O
represents	O
the	O
largest	O
cohort	O
of	O
patients	O
used	O
to	O
investigate	O
the	O
levels	O
of	O
and	O
potential	O
role	O
of	O
ceramide	B
in	O
human	O
breast	O
cancer.	O

Similarly,	O
urinary	O
excretion	O
of	O
flavonols,	O
particularly	O
kaempferol,	B
also	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
breast	O
cancer	O
among	O
those	O
with	O
at	O
least	O
one	O
copy	O
of	O
GSTM1	O
(P	O
for	O
trend,	O
0.05).	O

Cotinine	B
values	O
demonstrated	O
that	O
15	O
of	O
38	O
subjects	O
quit	O
smoking	O
for	O
the	O
entire	O
84	O
day	O
period.	O

Schematic	O
diagram	O
of	O
the	O
metabolism	O
of	O
phosphorylcholine,	B
L-acetylcarnitine,	B
arachidonic	B
acid	I
and	O
glycocholic	B
acid.	I

CHCl_3	O
:water	O
ext	O
+UF,	O
n	O
=	O
8	O
for	O
MeOH	B
ppt	O
samples),	O
or	O
simply	O
differences	O
in	O
collection	O
procedures.	O

The	O
levels	O
of	O
2-hydroxybutyrate,	B
a	O
biomarker	O
for	O
insulin	O
resistance	O
and	O
a	O
metabolite	O
of	O
threonine	B
catabolism,	O
were	O
increased	O
in	O
GG2	O
and	O
GG4	O
(Supp.	O

One	O
pulse	O
sequence	O
was	O
applied	O
to	O
hydrophilic	B
and	O
hydrophobic	O
CSF	O
compounds	O
in	O
_1	O
H-NMR	O
examinations.	O

Chromatograms	O
of	O
100	O
ng/mL	O
calibrator	O
in	O
serum	O
containing	O
five	O
nerve	O
agent	O
metabolites	O
in	O
different	O
mobile	O
phase	O
compositions:	O
a)	O
8%	O
ammonium	B
fluoride	I
(1	O
mM)/92%	O
acetonitrile,	B
and	O
b)	O
14%	O
ammonium	B
acetate	I
(20	O
mM)/86%	O
acetonitrile	B
Percent	O
of	O
peak	O
area	O
response	O
relative	O
to	O
the	O
buffer	O
composition	O
of	O
14%	O
ammonium	B
acetate	I
(20	O
mM)	O
with	O
86%	O
acetonitrile	B

Oleic	B
acid	I
is	O
produced	O
by	O
stearoyl-CoA	B
desaturase	O
(SCD1),	O
which	O
is	O
an	O
enzyme	O
localized	O
in	O
the	O
endoplasmic	O
reticulum	O
that	O
converts	O
palmitoyl-CoA	B
(C16:0)	I
and	O
stearoyl-CoA	B
(C18:0)	I
to	O
palmitoleoyl-CoA	B
(16:1)	I
and	O
oleoyl-CoA	B
(18:1),	I
respectively,	O
with	O
stearoyl-CoA	B
being	O
the	O
main	O
substrate.	O

The	O
participants	O
in	O
this	O
present	O
study	O
were	O
generally	O
overweight	O
and	O
might	O
have	O
influenced	O
their	O
current	O
diabetes	O
status,	O
however,	O
we	O
did	O
not	O
find	O
significant	O
correlations	O
between	O
phthalate	B
concentrations	O
and	O
obesity,	O
measured	O
by	O
BMI,	O
thus,	O
it	O
is	O
unlikely	O
that	O
obesity	O
be	O
on	O
the	O
casual	O
pathway	O
that	O
may	O
explain	O
our	O
results.	O

The	O
gradient	O
program	O
was:	O
85%	O
methanol	B
for	O
3	O
min,	O
decreased	O
to	O
40%	O
methanol	B
over	O
4.5	O
min	O
and	O
hold	O
for	O
2	O
min,	O
then	O
decreased	O
to	O
15%	O
methanol	B
over	O
3	O
min	O
and	O
hold	O
for	O
5	O
min,	O
and	O
back	O
to	O
85%	O
methanol	B
over	O
1	O
min	O
and	O
hold	O
for	O
5	O
min	O
to	O
re-equilibrate.	O

In	O
contrast,	O
lactate	B
showed	O
a	O
good	O
to	O
moderate	O
negative	O
correlation	O
with	O
the	O
1.3ppm	O
fatty	O
acid	O
peak	O
in	O
all	O
the	O
5	O
tumour	O
types.	O

Models	O
were	O
further	O
adjusted	O
for	O
hypothyroidism	O
and	O
hypertension	O
as	O
an	O
attempt	O
to	O
account	O
for	O
possible	O
indications	O
of	O
paracetamol	B
medication	O
use.	O

This	O
is	O
consistent	O
with	O
a	O
low	O
glutaminolysis	O
(Gln	O
to	O
lactate)	B
capacity	O
that	O
we	O
found	O
in	O
human	O
NSCLC	O
A549	O
cells	O
(A.N.	O
Lane,	O
T.	O
W-M.	O
Fan,	O
M.M.	O
McKinney	O
and	O
J.L.	O
Tan,	O
unpublished	O
data),	O
in	O
contrast	O
to	O
the	O
findings	O
for	O
glioblastoma	O
cells.	O

Trypsin/chymotrypsin	O
digestion:	O
The	O
denatured	O
and	O
alkylated	O
PhIP-modified	O
SA	O
(5	O
μ	O
g,	O
75	O
pmol,	O
in	O
35	O
μ	O
L	O
50	O
mM	O
ammonium	B
bicarbonate	O
buffer	O
(pH	O
8.5)	O
containing	O
CaCl_2	O
(1	O
mM)	O
was	O
digested	O
with	O
trypsin	O
at	O
a	O
protease:protein	O
ratio	O
of	O
1:50	O
(w/w)	O
and	O
chymotrypsin	O
at	O
a	O
protease:SA	O
ratio	O
of	O
1:12.5	O
(w/w).	O

We	O
found	O
that	O
baseline	O
valine	B
and	O
tyrosine	B
were	O
significantly	O
correlated	O
to	O
baseline	O
insulin	O
levels	O
and	O
that	O
both,	O
as	O
well	O
as	O
leucine,	B
were	O
correlated	O
with	O
HOMA	O
at	O
baseline;	O
phenylalanine,	B
but	O
not	O
the	O
others,	O
significantly	O
correlated	O
to	O
insulin	O
secretion	O
at	O
baseline.	O

Each	O
participant's	O
insulin	O
sensitivity	O
was	O
measured	O
using	O
the	O
hyperinsulinemic	O
euglycemic	B
(HI)	O
clamp;	O
the	O
distribution	O
of	O
M_FFM	O
(M_FFM	O
 = insulin-mediated	O
glucose	B
disposal	O
rate,	O
µmol·min_−1	O
·kg_FFM	O
_−1	O
)	O
in	O
the	O
399	O
RISC	O
subjects	O
analyzed	O
is	O
shown	O
in	O
.	O

BMI:	O
body	O
mass	O
index;	O
HR:	O
heart	O
rate;	O
EF:	O
ejection	O
fraction;	O
LAD:	O
left	O
atrial	O
diameter;	O
LVEDD:	O
left	O
ventricular	O
end	O
diastolic	O
diameter;	O
Ccr:	O
creatinine	B
clearance	O
rate;	O
COPD:	O
chronic	O
obstructive	O
pulmonary	O
disease;	O
MACCE:	O
major	O
adverse	O
cardiac	O
and	O
cerebrovascular	O
events;	O
NYHA:	O
New	O
York	O
Heart	O
Association.	O

L-glutamic	B
acid,	I
a	O
key	O
molecule	O
in	O
cellular	O
metabolism,	O
has	O
signals	O
that	O
are	O
difficult	O
to	O
detect	O
without	O
ambiguity	O
in	O
the	O
_1	O
H-NMR	O
spectrum	O
of	O
human	O
urine	O
owing	O
to	O
extensive	O
peak	O
overlap	O
and	O
its	O
low	O
concentration.	O

From	O
our	O
data,	O
N-Glycoloylganglioside	B
GM2	I
(GGM),	O
a	O
ganglioside,	B
was	O
abundant	O
in	O
advanced	O
cases.	O

This	O
study	O
was	O
powered	O
for	O
changes	O
in	O
blood	O
LDL	B
cholesterol	I
and	O
changes	O
in	O
faecal	O
bifidobacteria.	O

While	O
below	O
the	O
level	O
of	O
statistical	O
significance,	O
we	O
observed	O
increases	O
in	O
fructose	B
and	O
the	O
sugar	O
acids	O
pentonic	O
acid	O
and	O
hexaric	B
acid	I
that	O
correlated	O
with	O
change	O
in	O
LDL-C	O
in	O
the	O
good	O
responder	O
group	O
(data	O
not	O
shown)	O
and	O
were	O
opposite	O
to	O
the	O
effects	O
seen	O
for	O
these	O
metabolites	O
in	O
poor	O
responders.	O

LC-MS/MS	O
analysis	O
of	O
reference	O
standards	O
BMP(14:0/14:0)	B
and	O
PG(14:0/14:0)	B
revealed	O
that	O
BMPs	O
eluted	O
1.9	O
min	O
earlier	O
than	O
PG	B
(SI	O
Appendix	O
,	O
Fig.	O

The	O
spectral	O
resolution	O
is	O
assessed	O
by	O
the	O
shimming	O
quality;	O
therefore,	O
this	O
parameter	O
was	O
inspected	O
by	O
comparing	O
the	O
valley-to-peak	O
ratio	O
(%v	O
/p	O
,	O
Figure	O
A)	O
of	O
the	O
anomeric	O
proton	O
of	O
sucrose	B
present	O
in	O
the	O
QC	O
sample,	O
Figure	O
C.	O

In	O
human	O
serum	O
albumin,	O
PAH	O
adducts	O
bind	O
almost	O
exclusively	O
within	O
a	O
binding	O
pocket	O
of	O
subdomain	O
1B	O
[,	O
],	O
and	O
based	O
on	O
the	O
model	O
prediction,	O
the	O
albumin-like	O
protein	O
of	O
Atlantic	B
cod	O
may	O
present	O
similar	O
binding	O
pocket	O
conformations.	O

These	O
results	O
suggested	O
that	O
nervonic	B
acid	I
levels	O
can	O
be	O
used	O
as	O
a	O
biomarker	O
to	O
discriminate	O
the	O
depressive	O
state	O
of	O
patients	O
with	O
MDD	O
from	O
the	O
euthymic	O
state	O
of	O
patients	O
with	O
MDD	O
or	O
the	O
depressive	O
state	O
of	O
patients	O
with	O
BD.	O

-hydroxycholesterol	B

The	O
finding	O
of	O
sustained	O
plasma	O
and	O
urinary	O
oestrogens	O
at	O
20-40%	O
compared	O
to	O
their	O
control	O
levels	O
indirectly	O
support	O
a	O
hypothesis	O
of	O
alternative	O
oestrogen	O
sources	O
in	O
postmenopausal	O
breast	O
cancer	O
patients	O
on	O
treatment	O
with	O
4-hydroxyandrostenedione.	B

Methadone	B
is	O
therefore	O
often	O
preferred	O
when	O
morphine	B
fails,	O
either	O
due	O
to	O
lack	O
of	O
adequate	O
analgesia	O
or	O
intolerable	O
side-effects.	O

Fibrinogen	O
alpha/beta	O
chain	O
(A	O
and	O
B)	O
and	O
N1,	O
N12-diacetylspermine	B
(C)	O
are	O
one	O
of	O
the	O
components	O
in	O
LOME	O
1-33;	O
phosphatidylcholine	B
(D)	O
is	O
in	O
LOME	O
2-21.	O

The	O
presence	O
of	O
specific	O
chemical	O
substituents	O
seems	O
to	O
have	O
a	O
clear	O
importance	O
with	O
regards	O
to	O
the	O
ability	O
to	O
detect	O
of	O
metabolites	O
in	O
FFPE	O
samples	O
as	O
suggested	O
by	O
the	O
inferior	O
levels	O
of	O
lysophosphatidylcholines	B
(36%,	O
P	O
=	O
1.00;	O
FDR	O
=	O
1.00)	O
when	O
compared	O
with	O
lysophosphatidylethanolamines	B
(89%,	O
P	O
=	O
4.01	O
×	O
10_−3	O
;	O
FDR	O
=	O
3.07	O
×	O
10_−2	O
).	O

Neopterin	B
is	O
a	O
protein	O
released	O
from	O
macrophages	O
during	O
the	O
inflammatory	O
response.	O

By	O
comprehensive	O
metabolic	O
pathway	O
analysis	O
with	O
the	O
KEGG	O
pathway,	O
we	O
showed	O
that	O
alanine,	B
aspartate,	B
glutamate,	B
and	O
purine	B
metabolism	O
pathways	O
were	O
the	O
most	O
significantly	O
suppressed	O
after	O
gas	O
plasma	O
treatment	O
in	O
human	O
endothelial	O
cells.	O

First,	O
the	O
quantification	O
of	O
diosmetin,	B
free	O
and	O
after	O
deconjugation,	O
was	O
carried	O
out	O
by	O
high-performance	O
liquid	O
chromatography	O
coupled	O
with	O
tandem	O
mass	O
spectrometry,	O
on	O
an	O
Ascentis	O
RP-Amide	B
column	O
(150 × 2.1 mm,	O
5 μm),	O
in	O
reversed-phase	O
conditions,	O
after	O
enzymatic	O
digestion.	O

SDMA	O
is	O
generally	O
considered	O
to	O
be	O
biologically	O
inert,	O
although	O
some	O
studies	O
have	O
suggested	O
that	O
it	O
may	O
compete	O
with	O
arginine	B
for	O
transport	O
into	O
cells.	O

Glutathione	B
scavenging	O
of	O
ROS	O
is	O
catalysed	O
by	O
glutathione	B
s-transferase	O
P1	O
(GSTP1)	O
and	O
studies	O
show	O
that	O
impairment	O
of	O
GSTP1	O
promotes	O
HCC	O
(,	O
).	O

Importantly,	O
proline,	B
p-cresol	B
and	O
4-hydroxybenzoic	B
acid	I
disclose	O
outcome-prediction	O
value	O
by	O
means	O
of	O
survival	O
analysis.	O

Changes	O
in	O
cognition,	O
endotoxin,	B
serum/urine	O
metabolites	O
(and	O
microbiome	O
were	O
analyzed	O
using	O
recommended	O
systems	O
biology	O
techniques.	O

Consistent	O
with	O
these	O
findings,	O
3-HIB	O
had	O
a	O
strong	O
linear	O
correlation	O
with	O
triglycerides,	B
glycerol,	B
FFA,	O
and	O
ADIPO-IR.	O

The	O
significant	O
fold	O
change	O
was	O
LPC	B
(20:0)	I
(fold-change	O
=	O
4.08).	O

The	O
regions	O
of	O
the	O
spectra	O
containing	O
the	O
water	O
(δ	O
4.7−4.9)	O
and	O
urea	B
(δ	O
5.6−6.0)	O
resonances	O
were	O
removed	O
to	O
eliminate	O
both	O
the	O
variation	O
in	O
water	O
suppression	O
and	O
the	O
variation	O
in	O
the	O
integral	O
of	O
the	O
urea	B
signal	O
due	O
to	O
partial	O
cross-saturation	O
via	O
the	O
solvent	O
exchanging	O
protons.	O

Given	O
their	O
unique	O
chemical	O
properties,	O
we	O
reasoned	O
additional	O
systems	O
chemistry	O
approaches	O
may	O
prove	O
useful	O
in	O
identification	O
of	O
unknown	O
oxylipins.	B

Inhibition	O
of	O
reabsorption	O
by	O
glucose	B
can	O
occur	O
in	O
hyperglycemia.	O

Pretreatment	O
of	O
SA	O
with	O
the	O
selective	O
thiol	B
reagents	O
4-CMB	O
or	O
NEM	O
prior	O
to	O
reaction	O
with	O
N	B
-acetoxy-PhIP,	I
decreased	O
the	O
amounts	O
of	O
PhIP	O
and	O
5-HO-PhIP	B
recovered	O
from	O
the	O
proteolytic	O
digest	O
by	O
3-fold.	O

The	O
levels	O
of	O
glutamate	B
and	O
glutamine	B
were	O
assessed	O
in	O
tissues,	O
cell	O
lines,	O
saliva,	O
and	O
plasma	O
samples	O
using	O
isotype	O
dilution	O
GC-MS	O
as	O
described	O
previously.	O

The	O
CID	O
mass	O
spectrum	O
of	O
the	O
protonated	O
[M + H]_+	O
ion	O
confirmed	O
the	O
presence	O
of	O
the	O
phosphocholine	B
polar	O
head	O
(c),	O
whereas	O
the	O
CID	O
mass	O
spectrum	O
of	O
the	O
formate	B
adduct	O
[M − H + CHO_2	O
]_−	O
ion	O
enabled	O
the	O
detection	O
of	O
the	O
two	O
FA	B
C18:1	I
(m/z	O
281.2487)	O
and	O
FA	B
C16:0	I
(m/z	O
255.2329)	O
associated	O
fatty	O
acids	O
(d),	O
leading	O
to	O
an	O
improved	O
structural	O
characterization	O
of	O
this	O
lipid	O
species	O

The	O
later	O
eluting	O
isomer	O
of	O
PC(38:4)	B
coeluted	O
with	O
our	O
standard,	O
PC(18:0/20:4).	B

AA	O
is	O
an	O
important	O
polyunsaturated	O
FA	B
for	O
cell	O
signaling,	O
and	O
it	O
is	O
also	O
a	O
precursor	O
of	O
prostaglandin	B
E2	I
(PGE2).	O

[1.94–1.95]	O
respectively,	O
since	O
contributions	O
towards	O
these	O
from	O
lipoprotein-associated	O
triacylglycerols	B
cannot	O
be	O
excluded.	O

Atmospheric	O
pressure	O
chemical	O
ionization	O
(APCI)	O
in	O
the	O
positive	O
ion	O
mode	O
and	O
multiple	O
reaction	O
monitoring	O
(MRM)	O
mode	O
were	O
used,	O
and	O
the	O
following	O
transitions	O
were	O
monitored	O
for	O
quantification:	O
m/z	O
401	O
→	O
m/z	O
383	O
for	O
25(OH)D_3	O
and	O
3-epi-25(OH)D_3	B
;	O
m/z	O
407	O
→	O
m/z	O
389	O
for	O
25(OH)D_3	O
-d	O
_6	O
;	O
m/z	O
404	O
→	O
m/z	O
386	O
for	O
3-epi-25(OH)D_3	B
-d_3	I
;	O
m/z	O
413	O
→	O
m/z	O
395	O
for	O
25(OH)D_2	O
;	O
and	O
m/z	O
416	O
→	O
m/z	O
398	O
for	O
25(OH)D_2	O
-d	O
_3	O
.	O

Since	O
the	O
annotated	O
pathways	O
of	O
arachidonic,	O
linoleic	B
and	O
α-linolenic	B
acid	I
as	O
well	O
as	O
the	O
biosynthesis	O
of	O
unsaturated	O
fatty	O
acids	O
are	O
interrelated	O
and	O
comprise	O
a	O
high	O
number	O
of	O
metabolites	O
with	O
altered	O
intensities	O
we	O
focussed	O
in	O
more	O
detail	O
on	O
the	O
metabolite	O
ion	O
masses	O
of	O
those	O
pathways.	O

For	O
example,	O
cholesterol,	B
phospholipid,	B
sphingolipid,	B
and	O
purine	B
metabolism	O
are	O
all	O
decreased	O
in	O
CFS	O
and	O
dauer	O
but	O
are	O
increased	O
in	O
metabolic	O
syndrome	O
and	O
the	O
stereotyped	O
CDR.	O

In	O
a	O
previous	O
study,	O
the	O
authors	O
demonstrated	O
a	O
strong	O
relationship	O
between	O
serum	O
fatty	O
acid	O
composition	O
with	O
the	O
risk	O
of	O
type	O
1	O
diabetes-associated	O
autoimmunity	O
(Niinistö	O
et	O
al.,	O
).	O

DMAP	O
and	O
NNs	O
were	O
eluted	O
with	O
2	O
mL	O
of	O
acetonitrile;	B
and	O
the	O
eluate	O
was	O
dried	O
under	O
a	O
stream	O
of	O
nitrogen	O
until	O
complete	O
dryness.	O

Hypertensive	O
men	O
received	O
in	O
a	O
double-blind	O
rotational	O
fashion	O
amlodipine,	B
bisoprolol,	O
hydrochlorothiazide	B
and	O
losartan,	O
each	O
as	O
a	O
monotherapy	O
for	O
one	O
month,	O
with	O
intervening	O
one-month	O
placebo	O
cycles.	O

[GP03]-(PS):	O
Glycerophosphoserines	B
or	O
Phosphatidylserines;	B
[GP02]-(PEt):	O
Glycerophosphoethanolamines	B
or	O
Phosphatidylethonolamines;	B
[PK12]-(FLV):	O
Flavonoids;	B
[GP01]-(PC):	O
Glycerophosphocholines	B
or	O
Phosphatidylcholines.	B

The	O
supernatant	O
(600	O
µL)	O
was	O
removed,	O
dried,	O
and	O
reconstituted	O
in	O
50	O
µL	O
of	O
ammonia	O
(0.1%)	O
plus	O
0.5	O
mg/mL	O
dansyl	B
chloride	I
in	O
acetonitrile	B
(50	O
µL).	O

FA,	B
fatty	O
acids;	O
OH-butyrate,	B
hydroxybutyrate;	B
PL,	O
phospholipids;	B
PUFA,	O
polyunsaturated	O
fatty	O
acids;	O
TAG,	O
triacylglycerol;	B
UFA,	O
unsaturated	O
fatty	O
acids.	O

Fasting	O
serum	O
samples	O
at	O
75	O
g	O
oral	O
glucose	B
tolerance	O
test	O
were	O
used	O
for	O
metabolites	O
by	O
ultra	O
performance	O
liquid	O
chromatography-quadrupole-time	O
of	O
flight-mass	O
spectrometry,	O
ultra	O
performance	O
liquid	O
chromatography-triple	O
triple-quadrupole-mass	O
spectrometry	O
and	O
gas	O
chromatography-	O
time-of-	O
flight	O
mass	O
spectrometry	O
platforms.	O

The	O
design	O
of	O
multiple-dose-multiple-NSAID	B
studies	O
could	O
assist	O
to	O
discover	O
biomarker	O
candidates	O
for	O
monitoring	O
the	O
administration	O
of	O
NSAIDs.	O

After	O
oral	O
limonene	B
intervention,	O
there	O
were	O
also	O
elevations	O
in	O
markers	O
indicative	O
of	O
collagen	O
remodeling	O
or	O
degradation,	O
glycine,	B
proline,	B
hydroxyproline,	B
and	O
proline-hydroxyproline.	B

Evidence	O
suggests	O
that	O
linolenic	B
acid	I
may	O
influence	O
the	O
proliferation,	O
differentiation,	O
and	O
prognosis	O
of	O
breast	O
cancer,	O
and	O
genes	O
involved	O
in	O
the	O
regulation	O
of	O
linolenic	B
acid	I
metabolism	O
were	O
associated	O
with	O
breast	O
cancer	O
risk	O
in	O
a	O
genome-wide	O
association	O
study	O
of	O
breast	O
cancer.	O

200 μL	O
of	O
water	O
and	O
200 μL	O
of	O
chloroform	B
were	O
then	O
added.	O

We	O
hypothesized	O
that	O
at	O
least	O
some	O
of	O
the	O
erythritol	B
production	O
takes	O
place	O
in	O
blood	O
cells	O
because,	O
after	O
transport	O
by	O
the	O
enterocytes,	O
these	O
cells	O
are	O
the	O
first	O
that	O
are	O
in	O
contact	O
with	O
the	O
tracer,	O
and	O
the	O
finding	O
that	O
these	O
primary	O
human	O
blood	O
cells	O
can	O
synthesize	O
detectable	O
amounts	O
of	O
isotopic	O
labeled	O
erythritol	B
after	O
incubation	O
with	O
stable	O
isotope	O
tracers	O
supported	O
this	O
hypothesis.	O

According	O
to	O
these	O
observations,	O
their	O
presence	O
should	O
result	O
in	O
increased	O
membrane	O
rigidity	O
compared	O
to	O
the	O
ciliary	O
body	O
which	O
expresses	O
mainly	O
d18:1.	B

For	O
positive	O
ion	O
mode	O
(ES+)	O
where	O
A	O
=	O
water	O
with	O
0.1%	O
formic	B
acid	I
and	O
B	O
=	O
acetonitrile	B
with	O
0.1%	O
formic	B
acid,	I
whereas	O
A	O
=	O
water	O
and	O
B	O
=	O
acetonitrile	B
for	O
negative	O
ion	O
mode	O
(ES-).	O

PC	O
species	O
in	O
the	O
rHDL	O
infusate	O
and	O
plasma	O
PC	O
species	O
after	O
4	O
h	O
infusion	O
of	O
rHDL	O
or	O
saline	B
placebo	O
rHDL,	O
reconstituted	O
HDL;	O
PC,	O
phosphatidylcholine;	B
ND,	O
not	O
detectable.	O

96-well	O
polypropylene	B
microtiter	O
plates	O
were	O
purchased	O
from	O
Greiner	O
Bio-One	O
(Frickenhausen,	O
Germany).	O

Common	O
to	O
both	O
forms	O
of	O
IBD	O
are	O
decreases	O
in	O
urea	B
(more	O
prominent	O
in	O
UC	O
than	O
CD),	O
citrate	B
and	O
acetate.	B

Proton	O
nuclear	O
magnetic	O
resonance	O
spectroscopy	O
(_1	O
H	O
NMR),	O
hydrophilic	B
interaction	O
liquid	O
chromatography	O
mass	O
spectrometry	O
(HILIC-MS)	O
and	O
inductively	O
coupled	O
plasma	O
mass	O
spectrometry	O
(ICP-MS)	O
were	O
applied	O
to	O
quantify	O
metabolites	O
and	O
metal	O
elements	O
in	O
plasma	O
samples.	O

The	O
formation	O
of	O
ROS,	O
as	O
measured	O
by	O
the	O
red	O
fluorescence	O
resulting	O
from	O
the	O
oxidation	O
of	O
dihydroethidium	B
by	O
superoxide,was	O
detected	O
in	O
HepatoCells	O
but	O
not	O
in	O
cancer	O
cells.	O

_*	O
signal	O
at	O
5.61	O
ppm,	O
most	O
likely	O
glucose-	B
or	O
galactose-1-phosphate.	B

We	O
observed	O
significant	O
changes	O
in	O
molecules	O
that	O
could	O
impact	O
neurologic	O
function	O
during	O
CM;	O
these	O
include	O
increased	O
levels	O
of	O
kynurenate	B
and	O
decreased	O
indolepropionate,	B
glutamate,	B
arginine	B
and	O
glutamine.	B

An	O
unknown	O
fraction	O
of	O
the	O
genome	O
participates	O
in	O
the	O
metabolism	O
of	O
sterols	O
and	O
vitamin	B
D,	I
two	O
classes	O
of	O
lipids	O
with	O
diverse	O
physiological	O
and	O
pathophysiological	O
roles.	O

The	O
method	O
proposed	O
to	O
quantify	O
imatinib	B
in	O
human	O
serum	O
is	O
based	O
on	O
a	O
protein	O
precipitation	O
extraction	O
technique	O
associated	O
with	O
an	O
instrumental	O
analysis	O
using	O
ultrafast	O
liquid	O
chromatography	O
coupled	O
with	O
mass	O
spectrometry	O
(UFLC-MS),	O
which	O
has	O
been	O
fully	O
validated.	O

Specifically	O
ADMA	B
impacting	O
eNOS	O
activity	O
appears	O
to	O
be	O
a	O
relevant	O
factor	O
in	O
ARB	O
response.	O

Deuterium	O
oxide	O
(D_2	O
O,	O
99.9%)	O
and	O
_15	O
N-ethanolamine	B
were	O
obtained	O
from	O
Cambridge	O
isotope	O
Laboratories	O
Inc	O
(Andover,	O
MA).	O

Although	O
BA	O
and	O
FN	O
increased	O
estrogen	B
metabolism,	O
it	O
is	O
important	O
to	O
note	O
that	O
they	O
are	O
not	O
bioavailable	O
and	O
are	O
rapidly	O
metabolized	O
to	O
GN	O
and	O
DZ	O
in	O
vivo	O
.	O

Demographics	O
of	O
healthy	O
control	O
and	O
hypercholesterolaemic	B
patients	O
at	O
baseline	O
and	O
3	O
month	O
follow	O
up	O
visit.	O

After	O
deleting	O
outliers,	O
there	O
were	O
55	O
atrial	O
appendage	O
samples	O
(25	O
from	O
AF	B
patients	O
and	O
30	O
from	O
non-AF	O
patients)	O
and	O
120	O
plasma	O
samples	O
(36	O
from	O
AF	B
patients	O
and	O
84	O
from	O
non-AF	O
patients)	O
in	O
our	O
metabolomics	O
analysis	O
study.	O

5-ASA,	O
5-aminosalicylic	B
acid;	I
TNF,	O
tumour	O
necrosis	O
factor.	O

In	O
contrast	O
to	O
T	O
cells,	O
resting	O
or	O
activated	B
B	O
cells,	O
effectively	O
internalized	O
TEX	O
or	O
DEX,	O
and	O
the	O
uptake	O
by	O
activated	B
B	O
cells	O
was	O
greater	O
(p	O
=	O
0.03)	O
than	O
that	O
by	O
resting	O
B	O
cells	O
(Fig.	O

This	O
would	O
have	O
furnished	O
an	O
explanation	O
for	O
the	O
negative	O
correlation	O
between	O
mannose	B
and	O
threonine.	B

(b)	O
Decrease	O
of	O
methionine	B
concentration	O
due	O
to	O
its	O
conversion	O
to	O
homocysteine;	B
homocysteine	B
increases	O
as	O
a	O
result	O
of	O
the	O
cofactor	O
pyridoxal	B
5′-phosphate	I
inhibition	O
by	O
inflammatory	O
mediators	O
(C-reactive	O
protein);	O
decrease	O
of	O
pyridoxal	B
5′-phosphate	I
due	O
to	O
its	O
migration	O
to	O
inflammatory	O
sites.	O

Protein	O
samples	O
were	O
denatured	O
at	O
95	O
°C	O
for	O
5	O
min	O
in	O
2X	O
treatment	O
buffer	O
(0.125	O
M	O
Tris-HCl,	O
4%	O
SDS,	O
20%	O
glycerol,	B
10%	O
2-mercaptoethanol,	O
pH	O
6.8).	O

The	O
increase	O
in	O
pentadecan-2-one	B
observed	O
in	O
all	O
PCa	O
cell	O
lines	O
is	O
in	O
accordance	O
with	O
previously	O
reported	O
increase	O
in	O
ketone	B
levels	O
in	O
urine	O
from	O
PCa	O
patients,	O
as	O
well	O
as	O
in	O
other	O
cancer	O
cell	O
lines.	O

1-Methyladenosine	B
is	O
a	O
methylated	O
nucleotide	O
containing	O
purine	B
bases.	O

The	O
present	O
study	O
extended	O
the	O
results	O
from	O
previous	O
studies	O
by	O
revealing	O
significant	O
reductions	O
in	O
the	O
levels	O
of	O
the	O
unsaturated	O
LPC	O
subclass	O
and	O
five	O
LPC	O
species	O
(LPC18:2,	O
LPC18:1,	B
LPC20:2,	B
LPC20:1,	B
and	O
LPC20:0)	B
in	O
obese	O
adolescents	O
that	O
were	O
independent	O
of	O
changes	O
in	O
traditional	O
clinical	O
plasma	O
lipid	O
levels.	O

Ammonium	B
formate	I
(purity > 99.0%)	O
was	O
purchased	O
from	O
Sigma-Aldrich	O
(Vienna,	O
Austria).	O

Accumulation	O
of	O
ceramides	B
in	O
tissues	O
is	O
determined	O
by	O
complex	O
biosynthetic	O
and	O
degradative	O
pathways.	O

Catabolism	O
of	O
PGE_2	O
is	O
initiated	O
by	O
15-prostaglandin	O
dehydrogenase	O
(15-PGDH)	O
and	O
results	O
in	O
a	O
stable	O
end	O
metabolite,	O
11-α	B
-hydroxy-9,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic	I
acid	I
(PGE-M)	O
that	O
is	O
excreted	O
in	O
the	O
urine	O
(;	O
refs.	O

Similarly,	O
no	O
peak	O
interferences	O
were	O
observed	O
for	O
the	O
studied	O
hemolyzed	O
matrix	O
and	O
additives	O
matrix	O
containing	O
lithium	B
heparin,	I
EDTA	O
and	O
citric	B
acid.	I

PE	O
(14 : 0/20 : 3)	O
is	O
one	O
kind	O
of	O
glycerophosphoethanolamines.	B

Consequently,	O
the	O
total	O
number	O
of	O
phosphatidylcholines,	B
sphingolipids	B
and	O
lysophosphatidylcholines	B
structures	O
identified	O
by	O
this	O
method	O
was	O
458,	O
19	O
and	O
6,	O
respectively.	O

Briefly,	O
the	O
chromatographic	O
separation	O
of	O
biological	O
phospholipids	B
was	O
obtained	O
by	O
HILIC	O
retention.	O

The	O
metabolites	O
in	O
included	O
isopropanol,	B
glycine,	B
alanine,	B
arginine,	B
proline,	B
glutamine,	B
acetate,	B
glucose,	B
creatine,	B
3-methylhistidine,	B
creatinine,	B
isoleucine,	B
tyrosine,	B
valine,	B
threonine	B
and	O
leucine,	B
and	O
the	O
importance	O
decreased	O
in	O
this	O
order,	O
while	O
the	O
VLDL/LDL	O
was	O
rejected	O
as	O
it	O
made	O
little	O
contribution	O
to	O
distinguish	O
the	O
T2DM-CHD	O
and	O
HC.	O

Androstenedione,	B
7-alpha-hydroxy-3-oxochol-4-en-24-oic	B
acid	I
and	O
lithocholyltaurine	B
are	O
the	O
most	O
significantly	O
differentially	O
detected	O
metabolites	O
that	O
have	O
good	O
prediction	O
accuracy	O
between	O
RCC	O
and	O
healthy	O
controls,	O
likely	O
playing	O
important	O
roles	O
during	O
RCC	O
occurrence.	O

All	O
metabolite	O
and	O
biochemical	O
measurements	O
were	O
from	O
fasting	O
samples	O
(glucose	O
from	O
plasma	O
and	O
others	O
from	O
serum).	O

These	O
plots	O
show	O
the	O
same	O
trends	O
(increased	O
or	O
decreased)	O
as	O
all	O
samples	O
with	O
the	O
exception	O
of	O
glutamic	B
acid,	I
which	O
shows	O
the	O
same	O
trend	O
for	O
females,	O
but	O
not	O
for	O
males.	O

The	O
mass	O
spectrum	O
of	O
GLY,	O
GP	B
(25	O
μg/mL),	O
M1	O
and	O
M2	O
(10	O
μg/mL)	O
was	O
determined	O
by	O
direct	O
injection	O
of	O
neat	O
solutions	O
of	O
each	O
compound	O
in	O
1:1	O
methanol:	O
water	O
into	O
a	O
mass	O
spectrometer	O
set	O
in	O
a	O
positive	O
ion	O
mode.	O

Ang	B
II	I
can	O
activate	O
the	O
release	O
of	O
renal	O
20-HETE	B
by	O
stimulating	O
the	O
synthesis	O
of	O
20-HETE	B
at	O
critical	O
sites	O
in	O
the	O
kidney:	O
the	O
preglomerular	O
microvessels	O
that	O
determine	O
renovascular	O
resistance	O
and	O
a	O
nephron	B
segment,	O
the	O
medullary	O
thick	O
ascending	O
limb,	O
that	O
contributes	O
decisively	O
to	O
salt	O
and	O
water	O
balance.	O

Although	O
lactate	B
and	O
phenylalanine	B
are	O
identified,	O
further	O
t	O
-test	O
eliminates	O
the	O
latter	O
(Table	O
).	O

The	O
up-regulation	O
of	O
N1,N12-diacetylspermine	B
at	O
6	O
and	O
12	O
months	O
post-eradication	O
but	O
with	O
no	O
significant	O
changes	O
at	O
18	O
months-post	O
eradication	O
may	O
indicate	O
the	O
dysregulation	O
of	O
polyamine	B
metabolism	O
which	O
could	O
be	O
a	O
potential	O
predictive	O
signature	O
of	O
metabolic	O
disorders	O
such	O
as	O
obesity.	O

Sphingolipids,	B
comprised	O
of	O
Cers,	O
SMs,	O
and	O
their	O
reduced	O
forms	O
(dhCers	O
and	O
dhSMs),	O
were	O
positively	O
associated	O
with	O
obesity	O
and	O
dysglycemia.	O

The	O
method	O
was	O
designed	O
for	O
analysis	O
of	O
urine	O
specimens	O
collected	O
in	O
a	O
controlled	O
cannabis	B
administration	O
study	O
to	O
investigate	O
new	O
urinary	O
markers	O
for	O
recent	O
cannabis	B
intake.	O

The	O
pellets	O
were	O
extracted	O
two	O
more	O
times	O
with	O
200	O
μl	O
methanol:water	O
(2:1)	O
containing	O
0.005%	O
BHT	O
and	O
0.01	O
mM	O
acetic	B
acid.	I

Two	O
letters	O
indicate	O
that	O
the	O
first	O
and	O
second	O
positions	O
of	O
glycerol	B
unit	O
are	O
bound	O
to	O
a	O
fatty	O
acid	O
residue,	O
while	O
a	O
single	O
letter	O
(a	O
or	O
e)	O
indicates	O
a	O
bond	O
with	O
only	O
one	O
fatty	O
acid	O
residue.	O

Concentrations	O
(logarithmic	O
scale)	O
of	O
(A–D)	O
glutamine	B
and	O
(E–H)	O
histidine	B
in	O
the	O
blood	O
circulation	O
in	O
controls	O
and	O
cases,	O
that	O
is,	O
those	O
individuals	O
who	O
developed	O
pancreatic	O
cancer	O
within	O
a	O
time	O
window	O
after	O
blood	O
sampling.	O

Internal	O
standards	O
solution	O
for	O
plasma	O
processing	O
(plasma	O
protein	O
precipitation)	O
was	O
prepared	O
in	O
PP	O
tube	O
by	O
diluting	O
50-fold	O
in	O
MeOH	B
the	O
internal	O
standards	O
WS	O
to	O
obtain	O
a	O
final	O
concentration	O
for	O
all	O
internal	O
standards	O
of	O
40	O
ng/mL.	O

However,	O
the	O
nervonic	B
acid	I
concentrations	O
positively	O
correlated	O
with	O
the	O
duration	B
of	O
illness	O
in	O
the	O
patients	O
with	O
MDD	O
(ρ	O
=0.55,	O
P=	O
.0011).	O

The	O
day	O
of	O
the	O
biopsy,	O
the	O
following	O
multi-source	O
patient	O
data	O
were	O
recorded	O
using	O
an	O
information-based	O
data	O
warehouse:	O
clinical	O
(age,	O
sex,	O
body	O
mass	O
index,	O
arterial	O
hypertension),	O
demographic	O
(ethnicity),	O
clinical	O
chemistry	O
(urinary	O
total	O
protein,	O
urinary	O
albumin,	O
urinary	O
retinol	B
binding	O
protein,	O
urinary	O
β	O
2-microglobulin,	O
urinary	O
α	O
1-microglobulin,	O
urinary	O
transferrin,	O
serum	O
creatinine),	O
renal	O
pathology	O
(interstitial	O
fibrosis	O
extent)	O
and	O
urine	O
metabolomic	O
(_1	O
H	O
NMR	O
spectra)	O
data.	O

Minimizing	O
formation	O
of	O
catechol	B
estrogen	I
quinones	I
and/or	O
their	O
reaction	O
with	O
DNA	O
should	O
reduce	O
the	O
risk	O
of	O
developing	O
breast	O
cancer.	O

The	O
accuracies	O
of	O
the	O
PLS-DA	O
and	O
SVM	O
models	O
on	O
the	O
final	O
S	O
signature	O
were	O
respectively	O
73.7%	O
and	O
71.1%	O
for	O
nicotinamide	B
and	O
N-acetyl	B
L-leucine.	I

Acetoacetate,	B
glutamine,	B
asparagine,	B
and	O
cysteine	B
had	O
relatively	O
high	O
AUC	O
values,	O
sensitivities,	O
and	O
specificities	O
in	O
distinguishing	O
early	O
stage	O
CRC	O
patients	O
from	O
HCs.	O

In	O
the	O
full	O
CAP	O
study	O
population,	O
this	O
SNP	O
was	O
strongly	O
associated	O
with	O
fasting	O
simvastatin	B
acid	I
concentration	O
(p<0.0001,	O
r = 0.23,	O
R.	O
Krauss,	O
personal	O
communication),	O
consistent	O
with	O
earlier	O
observations	O
.	O

Significant	O
reduction	O
of	O
2‐aminobutyric	B
acid	I
and	O
2‐hydroxybutyrate	B
(α‐hydroxybutyrate)	I
was	O
observed	O
at	O
6 months	O
post‐RYGB	O
compared	O
with	O
pre‐surgery.	O

Weak	O
wash	O
solvent	O
was	O
H_2	O
O-methanol	B
(1:1,	O
v/v)	O
and	O
strong	O
wash	O
solvent	O
was	O
acetonitrile/isopropanol	O
(3:1,	O
v/v).	O

Neither	O
L-glutamine	B
nor	O
L-glutamic	B
acid	I
could	O
be	O
accurately	O
quantified	O
or	O
identified	O
by	O
GC-MS.	O

Surgery	O
stress	O
might	O
increase	O
the	O
levels	O
of	O
hormones,	O
such	O
as	O
glucagon,	O
cortisol,	B
and	O
growth	O
hormone,	O
and	O
enhance	O
the	O
sympathetic	O
nerve.	O

The	O
study	O
presented	O
here	O
also	O
identified	O
significant	O
reductions	O
in	O
urinary	O
p-cresol	B
sulfate,	I
a	O
metabolite	O
which	O
was	O
not	O
discriminatory	O
in	O
previous	O
studies.	O

Correlations	O
between	O
individual	O
treatment-related	O
changes	O
of	O
total	O
phospholipid	B
concentration	O
(PC,	O
lysoPC,	O
and	O
SM),	O
serum	O
albumin	O
concentration,	O
and	O
body	O
mass	O
during	O
the	O
first	O
stage	O
of	O
a	O
treatment	O
(the	O
B-A	O
difference)	O
in	O
CCRT	O
and	O
RT	O
samples	O
marked	O
in	O
blue	O
and	O
orange,	O
respectively.	O

All	O
metabolite	O
and	O
biochemical	O
measurements	O
were	O
from	O
fasting	O
samples	O
(glucose	O
from	O
plasma	O
and	O
others	O
from	O
serum).	O

Differences	O
between	O
the	O
tertiles	O
of	O
betaine	B
were	O
tested	O
by	O
ANOVA	O
or	O
Kruskal	O
Wallis	O
for	O
continuous	O
variables	O
and	O
with	O
χ_2	O
-	O
test	O
for	O
categorical	O
variables.	O

Therefore,	O
the	O
observed	O
associations	O
may	O
be	O
confounded	O
by	O
differences	O
in	O
paracetamol	B
exposure	O
source;	O
such	O
information	O
(e.g.	O
self-report	O
of	O
occupational	O
versus	O
environmental	O
exposures)	O
was	O
not	O
collected	O
and	O
therefore	O
was	O
not	O
included	O
in	O
regression	O
models.	O

Such	O
an	O
adaptation	O
seems	O
advantageous,	O
because	O
a	O
lower	O
loss	O
of	O
purines	B
results	O
in	O
a	O
lower	O
reliance	O
on	O
the	O
comparably	O
slow	O
and	O
metabolically	O
expensive	O
replacement	O
of	O
adenine	B
nucleotides	O
by	O
the	O
purine	B
de	O
novo	O
synthesis	O
pathway.	O

In	O
analyses	O
in	O
which	O
we	O
adjusted	O
for	O
age,	O
sex,	O
diabetes	O
status,	O
BMI	O
and	O
lipoprotein	O
variables	O
(representing	O
variables	O
to	O
which	O
betaine,	B
PLTP	O
and/or	O
LCAT	O
activity	O
were	O
correlated	O
in	O
age-,	O
sex-	O
and	O
diabetes	O
status-adjusted	O
analysis	O
as	O
shown	O
in	O
Table ),	O
PLTP	O
activity	O
was	O
independently	O
and	O
inversely	O
associated	O
with	O
betaine	B
(Table ,	O
model	O
1).	O

A	O
group	O
of	O
31	O
breast	O
cancer	O
patients	O
(age = 45.55 ± 9.31	O
years,	O
age	O
range	O
25	O
years	O
to	O
70	O
years)	O
with	O
history	O
of	O
pre-operative	O
neoadjuvant	O
chemotherapy	O
comprising	O
of	O
TAC	O
regimen	O
(Taxotere	O
75 mg/m_2	O
 + doxorubicin	B
50 mg/m_2	O
 + cyclophosphamide	B
500 mg/m_2	O
IV	O
given	O
once	O
every	O
3	O
weeks	O
with	O
a	O
total	O
of	O
6	O
cycles)	O
were	O
also	O
included.	O

Therefore,	O
it	O
was	O
decided	O
not	O
to	O
include	O
DMA.	B

However,	O
we	O
found	O
no	O
statistically	O
significant	O
interactions	O
with	O
either	O
cigarettes	O
smoked	O
per	O
day	O
or	O
alcohol	O
intake,	O
particularly	O
the	O
associations	O
between	O
the	O
metabolites	O
known	O
to	O
result	O
from	O
CYP1A2-	O
or	O
CYP2E1-mediated	O
metabolism	O
discussed	O
above,	O
and	O
β-carotene	B
supplementation	O
did	O
not	O
differ	O
by	O
either	O
smoking	O
(<20	O
compared	O
with	O
≥20	O
cigarettes/d:	O
3,7-dimethylurate	B
β_<20	O
=	O
0.29,	O
β_≥20	O
=	O
0.26,	O
P	O
=	O
0.88;	B
1-methylurate	I
β_<20	O
=	O
0.31,	O
β_≥20	O
=	O
0.23,	O
P	O
=	O
0.73;	B
2-hydroxyacetaminophen	I
sulfate	I
β_<20	O
=	O
0.41,	O
β_≥20	O
=	O
0.40,	O
P	O
=	O
0.98)	O
or	O
alcohol	O
intake	O
(<median	O
compared	O
with	O
≥median	O
intake:	O
3,7-dimethylurate	B
β_low	O
=	O
0.43,	O
β_high	O
=	O
0.22,	O
P	O
=	O
0.46;	B
1-methylurate	I
β_low	O
=	O
0.25,	O
β_high	O
=	O
0.36,	O
P	O
=	O
0.70;	B
2-hydroxyacetaminophen	I
sulfate	I
β_low	O
=	O
0.41,	O
β_high	O
=	O
0.24,	O
P	O
=	O
0.57).	O

These	O
data	O
support	O
that	O
there	O
is	O
a	O
lipid	O
profile	O
characteristic	O
of	O
newly	O
diagnosed	O
T1DM	O
and	O
that	O
this	O
profile	O
may	O
be	O
useful	O
in	O
the	O
diagnosis	O
of	O
the	O
disease	O
and	O
exploration	O
of	O
potential	O
beta-cell	O
lipotoxins.	B

Ring-deuterated	O
rac-d_5	B
-methadone-HCl	I
was	O
synthesized	O
in	O
our	O
laboratory	O
as	O
described	O
previously.	O

Stock	O
solution	O
stability	O
was	O
established	O
by	O
quantification	O
of	O
samples	O
from	O
dilution	O
of	O
two	O
stock	O
solutions	O
that	O
have	O
been	O
stored	O
at	O
−20	O
°C	O
for	O
38	O
days	O
and	O
at	O
room	O
temperature	O
on	O
the	O
bench	O
for	O
4	O
hours,	O
respectively,	O
to	O
the	O
final	O
ULOQ	O
solution	O
(4/16	O
μg/mL	O
of	O
Cer(22:0)/Cer(24:0)	B
in	O
isopropanol).	O

The	O
variable	O
index	O
consists	O
of	O
the	O
following:	O
(1)	O
C_4	O
sugar	O
1,	O
(2)	O
inositol	B
C,	O
(3)	O
talose,	O
(4)	O
mannose,	B
(5)	O
inositol	B
D,	O
(6)	O
glucose,	B
(7)	O
inositol	B
A,	O
(8)	O
arabinose,	B
(9)	O
xylose,	B
and	O
(10)	O
C_4	O
sugar	O
2.	O

Finally,	O
measuring	O
the	O
levels	O
of	O
arginine	B
and	O
its	O
related	O
metabolites	O
poses	O
challenges	O
due	O
to	O
the	O
influence	O
of	O
food	O
intake	O
and	O
analytical	O
constraints	O
on	O
amino	O
acid	O
levels.	O

Structural	O
identification	O
of	O
the	O
glycerophospholipids	B
was	O
achieved	O
by	O
looking	O
at	O
the	O
fragments	O
and/or	O
neutral	O
losses	O
obtained	O
in	O
product-ion	O
scan	O
experiments.	O

Mapping	O
these	O
inter-related	O
metabolites	O
to	O
metabolic	O
pathways	O
(KEGG	O
and	O
SMPDB)	O
and	O
bio-functions	O
(HMDB)	O
identified	O
alterations	O
in	O
pathways	O
involved	O
in	O
monoamine	B
metabolism	O
(phenylalanine	O
and	O
tyrosine	B
metabolism,	O
tryptophan	B
metabolism,	O
serotonin	B
biosynthesis,	O
dopamine	B
synthesis,	O
and	O
catecholamine	B
synthesis),	O
mitochondrial	O
function	O
and	O
energy	O
production	O
(TCA	O
cycle,	O
Nicotinamide	B
and	O
NAD+	B
synthesis,	O
fatty	O
acid	O
metabolism,	O
BCAA	O
metabolism),	O
and	O
immune	O
function	O
and	O
inflammation	O
(tryptophan	O
metabolism).	O

This	O
assignment	O
is	O
further	O
supported	O
by	O
the	O
data	O
of	O
Bruengraber	O
et	O
al.,	O
who	O
recently	O
reported	O
on	O
the	O
formation	O
of	O
a	O
phenylbutyryl-β	B
-glucuronate	I
metabolite	O
indirectly	O
by	O
incubating	O
PB	O
patient	O
urine	O
with	O
β	O
-glucuronidase	O
and	O
monitoring	O
the	O
increase	O
in	O
PB	O
concentration.	O

First,	O
we	O
now	O
have	O
a	O
strong	O
tool	O
that	O
will	O
play	O
a	O
pivotal	O
role	O
in	O
further	O
elucidating	O
and	O
mapping	O
of	O
glyoxylate	B
metabolism.	O

Most	O
of	O
the	O
detected	O
thiols	B
contain	O
single	O
charge,	O
indicating	O
that	O
most	O
of	O
thiols	B
only	O
have	O
one	O
sulfhydryl	O
group.	O

Accordingly,	O
a	O
third	O
PLS-DA	O
analysis	O
was	O
performed	O
in	O
which	O
samples	O
were	O
pooled	O
regardless	O
of	O
AP	B
status.	O

By	O
contrast,	O
these	O
subjects	O
had	O
higher	O
HDL-C	O
levels,	O
and	O
significantly	O
higher	O
HDL-C	O
to	O
LDL-C	O
ratio	O
(HLR),	O
and	O
had	O
lower	O
levels	O
of	O
Cer(d18:0/X)	B
(dihydroceramides)	I
and	O
trended	O
lower	O
Cer	B
and	O
CE(18:X)	O
levels	O
(p	O
=	O
0.07)	O
compared	O
to	O
their	O
drug	O
naïve	O
counterparts.	O

The	O
thiolation	O
and	O
β-oxidation	O
reactions	O
are	O
carried	O
out	O
by	O
bile	O
acyl-CoA	B
synthetase	O
(liver-specific)	O
or	O
very	O
long	O
chain	O
acyl-CoA	B
synthetase	O
and	O
sterol	O
carrier	O
protein	O
x	O
,	O
respectively,	O
the	O
latter	O
two	O
of	O
which	O
are	O
expressed	O
in	O
rodent	O
brain	O
(Swiss-Prot	O
O35488,	O
P11915)._7	O
We	O
thus	O
searched	O
for	O
the	O
presence	O
of	O
C_24	O
precursors	O
of	O
primary	O
bile	O
acids	O
in	O
CSF.	O

Using	O
the	O
program	O
AMIX	O
3.9.14	O
(Bruker	O
BioSpin	O
GmbH,	O
Rheinstetten,	O
Germany)	O
plasma	O
spectra	O
were	O
then	O
referenced	O
to	O
the	O
ethylenediaminetetraacetic	B
acid	I
(EDTA)	O
signal	O
at	O
2.5809	O
ppm	O
and	O
bucketed	O
graphically,	O
such	O
that	O
buckets	O
wherever	O
possible	O
contained	O
only	O
one	O
signal	O
or	O
group	O
of	O
signals	O
and	O
no	O
peaks	O
were	O
split	O
between	O
buckets.	O

Anastrozole	B
(0–100	O
µm)	O
was	O
incubated	O
for	O
30	O
min	O
at	O
37°C	O
with	O
each	O
isoform	O
(52	O
pmol	O
ml_−1	O
).	O

Methyl	B
heptadecanoate,	I
methyl	O
tricosanate,	O
and	O
acetyl	B
chloride	I
(99.0%)	O
were	O
purchased	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
MO)	O
whereas	O
3,5-Di-tert-butyl–4-hydroxytoluene	B
(BHT)	O
and	O
a	O
mixed	O
standard	O
methyl	B
esters	I
of	O
37	O
fatty	O
acids	O
were	O
obtained	O
from	O
Supelco	O
(Bellefonte,	O
PA).	O

Only	O
ADMA,	B
arginine,	B
glutathione,	B
and	O
methionine	B
did	O
not	O
statistically	O
change	O
from	O
preconception	O
through	O
34	O
wk	O
of	O
pregnancy.	O

Two	O
metabolites	O
were	O
putatively	O
matched	O
through	O
matching	O
mass	O
in	O
HMDB	O
to	O
be	O
4-hydroxyproline	B
and	O
5-hydroxylysine.	B

Proline	B
can	O
feed	O
the	O
TCA	O
cycle	O
through	O
the	O
urea	B
cycle	O
and	O
is	O
oxidized	O
by	O
proline	O
dehydrogenase	O
to	O
form	O
reactive	O
oxygen	O
species	O
(ROS).	O

GP	B
IIb/IIIa	O
inhibitors	O
were	O
not	O
used	O
in	O
this	O
cohort.	O

These	O
findings	O
demonstrate	O
the	O
potential	O
influence	O
of	O
leptin	O
on	O
tryptophan,	B
kynurenine	B
and	O
serotonin	B
metabolism,	O
gut	O
microbiome,	O
and	O
immunomodulation.	O

To	O
the	O
best	O
of	O
our	O
knowledge,	O
this	O
is	O
the	O
first	O
report	O
showing	O
the	O
simultaneous	O
measurement	O
of	O
DHEA,	O
AED,	O
AET	O
and	O
7-oxo-DHEA	B
in	O
plasma	O
from	O
HIV-TB	O
individuals	O
using	O
HPLC-MS/MS	O
technology.	O

Since	O
the	O
same	O
internal	O
standard	O
is	O
used	O
for	O
all	O
analytes,	O
the	O
reduction	O
in	O
the	O
IS’s	O
signal	O
is	O
responsible	O
for	O
the	O
apparent	O
increase	O
in	O
7-alpha-methylthiospironolactone’s	B
and	O
canrenone’s	O
intensities.	O

Spearman’s	O
correlations	O
for	O
ADHD	O
symptom	O
scores	O
and	O
serum	O
variables,	O
adjusted	O
for	O
cotinine	B
and	O
age	O
The	O
18-item	O
ASRS	O
(Adult	O
ADHD	O
Self-report	O
Scale)	O
is	O
used	O
to	O
assess	O
current	O
ADHD	O
symptom	O
burden,	O
with	O
nine	O
questions	O
specific	O
to	O
hyperactivity/impulsivity	O
and	O
nine	O
questions	O
specific	O
to	O
inattentiveness.	O

Participants	O
were	O
randomized	O
to	O
three	O
months	O
of	O
pioglitazone	B
(45	O
mg	O
per	O
day)	O
plus	O
metformin	B
(1000	O
mg	O
twice	O
per	O
day,	O
N	O
=	O
12	O
participants)	O
or	O
placebo	O
(N	O
=	O
13).	O

To	O
eliminate	O
this	O
influence,	O
levels	O
of	O
urinary	O
creatinine	B
were	O
used	O
to	O
correct	O
for	O
dilution.	O

The	O
studied	O
group	O
included	O
28	O
epilepsy	O
patients	O
(median	O
age	O
12	O
months)	O
examined	O
with	O
a	O
diagnostic	O
protocol	O
including	O
EEG,	O
videoEEG,	O
24-hour-EEG,	B
tests	O
for	O
inborn	O
errors	O
of	O
metabolism,	O
chromosomal	O
analysis	O
and	O
molecular	O
study.	O

A	O
step	O
gradient	O
consisting	O
of	O
A= Milli-Q	O
water	O
and	O
B = 100 mM	O
ammonium	B
acetate	I
buffer	O
with	O
pH = 9.0	O
(adjusted	O
with	O
ammonia)	O
was	O
used	O
as	O
follows:	O
0–5 min	O
7%	O
B;	O
5–10 min	O
100%	O
B;	O
10–15 min	O
7%	O

Prior	O
work	O
has	O
proposed	O
that	O
purine	B
metabolism	O
might	O
act	O
as	O
alternative	O
pathway	O
to	O
overcome	O
inadequate	O
glucose	B
supply	O
and	O
energy	O
crisis	O
in	O
neurodegeneration.	O

To	O
achieve	O
this	O
goal,	O
we	O
first	O
used	O
a	O
liquid	O
chromatography	O
electrospray	O
ionization	O
tandem	O
mass	O
spectrometry	O
(LC-ESI-MS/MS)-based	O
metabolomic	O
method	O
(polysulfidomics)	O
to	O
profile	O
low-molecular	O
weight	O
reactive	O
polysulfides	B
and	O
their	O
related	O
molecular	O
species	O
in	O
the	O
aqueous	O
humor	O
and	O
vitreous	O
of	O
DM	O
patients	O
with	O
DR,	O
and	O
then	O
examined	O
the	O
effect	O
of	O
the	O
reactive	O
sulfide	B
species	O
we	O
identified	O
on	O
the	O
viability	O
of	O
cultured	O
retinal	B
cells	O
under	O
oxidative	O
stress.	O

We	O
therefore	O
conclude	O
that	O
a	O
significant	O
reduction	O
in	O
the	O
_13	O
C-enrichment	O
found	O
for	O
lactate	B
and	O
alanine	B
does	O
not	O
necessarily	O
result	O
in	O
a	O
reduced	O
appearance	O
rate.	O

To	O
evaluate	O
the	O
extent	O
of	O
conjugation	O
by	O
UGTs	O
in	O
vivo	O
,	O
anastrozole	B
and	O
hydroxyanastrozole	B
were	O
measured	O
with	O
and	O
without	O
deconjugation	O
using	O
β-glucuronidase.	O

but	O
also	O
with	O
5-oxo-MEHP	B
and	O
5-OH-MEHP	B
(r	O
=	O
0.54–0.62	O

Prior	O
to	O
analysis,	O
800	O
µL	O
of	O
80%	O
acetonitrile	B
was	O
added	O
to	O
100	O
µL	O
of	O
plasma,	O
mixed	O
by	O
vortexing,	O
and	O
centrifuged	O
at	O
10,000	O
rpm	O
for	O
5	O
minutes	O
at	O
4°C.	O

For	O
subjects	O
with	O
serum	O
triglyceride	B
levels	O
≥400	O
mg/dL,	O
LDL-cholesterol	B
concentrations	O
were	O
measured	O
indirectly.	O

Compared	O
to	O
the	O
80%	O
methanol	B
extraction	O
method,	O
the	O
Folch	O
and	O
Bligh-Dyer	O
method	O
yielded	O
the	O
closest	O
results	O
at	O
a	O
1:20	O
(v/v)	O
sample-to-solvent	O
ratio	O
and	O
the	O
Bligh-Dyer	O
method	O
was	O
closest	O
at	O
a	O
1:100	O
(v/v)	O
sample-to-solvent	O
ratio.	O

FA	B
–	O
Fatty	O
acid.	O

Erythronate	B
was	O
shown	O
to	O
be	O
produced	O
from	O
erythritol,	B
and	O
there	O
was	O
no	O
evidence	O
that	O
glucose	B
metabolism	O
was	O
perturbed	O
after	O
ingestion	O
of	O
50	O
g	O
of	O
erythritol.	B

With	O
elongation	O
and	O
desaturation,	O
palmitate	B
is	O
converted	O
to	O
longer	O
unsaturated	O
fatty	O
acids,	O
which	O
are	O
incorporated	O
into	O
complex	O
lipids	O
(e.g.,	O
glycerolipids).	B

The	O
recovery	O
of	O
the	O
analytes	O
from	O
plasma	O
samples	O
with	O
low	O
triglyceride	B
levels	O
was	O
between	O
98–100%	O
for	O
SMV,	O
88–96%	O
for	O
SMV-A,	O
97–100%	O
for	O
ATV,	O
92–98	O
for	O
2-OH-ATV,	B
97–99%	O
for	O
4-OH-ATV,	B
and	O
88–95	O
for	O
RSV.	O

However,	O
only	O
the	O
prognostic	O
value	O
of	O
TMAO	B
remained	O
statistically	O
significant	O
following	O
adjustments	O
with	O
age,	O
eGFR,	O
mitral	O
E/septal	O
Ea,	O
and	O
NT-proBNP	O
levels	O
(adjusted	O
HR	O
1.46,	O
95%	O
confidence	O
interval	O
1.03–2.14,	O
p=0.031).	O

A	O
medical	O
history	O
and	O
clinical	O
parameters	O
were	O
obtained	O
from	O
all	O
study	O
subjects	O
including	O
age,	O
blood	O
pressure	O
levels,	O
presence	O
of	O
any	O
definite	O
cause	O
of	O
hypertension,	O
serum	O
creatinine	B
and	O
urea	B
levels,	O
lipid	O
profile,	O
Na_+	O
and	O
K_+	O
levels,	O
symptoms	O
of	O
hypertension	O
and	O
family	O
history.	O

The	O
sterol	O
fractions	O
from	O
above	O
were	O
reconstituted	O
in	O
100	O
μl	O
of	O
propan-2-ol,	B
and	O
a	O
solution	O
of	O
1	O
ml	O
of	O
50	O
mm	O
phosphate	B
buffer	O
(KH_2	O
PO_4	O
,	O
pH	O
7)	O
containing	O
3.0	O
μl	O
of	O
cholesterol	B
oxidase	O
(2	O
mg/ml	O
in	O
H_2	O
O,	O
44	O
units/mg	O
of	O
protein)	O
was	O
added	O
to	O
each.	O

Again,	O
although	O
these	O
tumors	O
contained	O
[1,2-_13	B
C]acetyl-CoA,	I
the	O
measured	O
fractional	O
enrichment	O
in	O
acetyl-CoA	B
was	O
far	O
lower	O
than	O
the	O
plasma	O
glucose	B
enrichment.	O

Unique	O
positive	O
associations	O
regarding	O
VAT	O
and	O
urine	O
metabolites	O
in	O
women	O
included	O
several	O
steroids,	O
e.g.	O
tetrahydrocrotisone	B
and	O
likely	O
related	O
unknown	O
compounds	O
as	O
indicated	O
from	O
the	O
estimated	O
metabolic	O
network	O
(see	O
Methods,	O
Figs.	O

Comparison	O
of	O
total	O
ion	O
current	O
of	O
iurine	B
samples	O
prepared	O
bythe	O
conditions	O
of	O
oximate	O
1,	O
2	O
and	O
3.	O

It	O
can	O
also	O
be	O
highlighted	O
that	O
the	O
majority	O
of	O
metabolites	O
were	O
down-regulated	O
relatively	O
to	O
the	O
BC	O
group,	O
except	O
formate,	B
α-hydroxybutyrate	B
hippurate,	I
and	O
phenylalanine,	B
that	O
were	O
up-regulated,	O
being	O
also	O
identified	O
in	O
a	O
study	O
developed	O
by	O
Carrola	O
et	O
al.	O

Identification	O
of	O
the	O
albumin-like	O
protein	O
of	O
Atlantic	B
cod	O
(Gadus	O
morhua)	O
in	O
plasma.	O

Therefore,	O
it	O
is	O
necessary	O
to	O
determine	O
how	O
the	O
three	O
biological	O
components	O
of	O
the	O
triatomine-T.	B
cruzi	O
host-parasite	O
interaction	O
may	O
affect	O
the	O
developmental	O
success	O
of	O
the	O
parasite.	O

LDL	B
cholesterol	I
was	O
measured	O
using	O
enzymatic	O
colorimetric	O
methods	O
(Roche,	O
Mannheim,	O
Germany).	O

Baseline	O
arterialized	O
venous	O
blood	O
samples	O
for	O
determination	O
of	O
plasma	O
glucose,	B
FFA,	O
and	O
insulin	O
concentrations	O
were	O
drawn	O
at	O
−30,	O
−20,	O
−10,	O
−5,	O
and	O
0	O
min.	O

LC-MS/MS,	O
morphine,	B
morphine-3-sulfate,	B
morphine-6-sulfate,	B
plasma,	O
urine	O

The	O
bag	O
was	O
filled	O
with	O
hydrocarbon	B
free	O
air	O
and	O
placed	O
in	O
the	O
incubator	O
for	O
45	O
minutes.	O

A	O
60	O
m	O
×	O
0.25	O
mm	O
_1	O
×	O
0.25	O
µm	O
_1	O
,	O
DB-5	O
ms	O
UI	O
GC	O
capillary	O
column	O
(phenyl	O
arylene	I
polymer	O
virtually	O
equivalent	O
to	O
a	O
(5%-phenyl)-methylpolysiloxane)	B
(Agilent	O
Technologies)	O
was	O
used	O
for	O
the	O
GC-MS	O
analysis.	O

For	O
example,	O
hydroxyacylcarnitines	B
found	O
such	O
as	O
hydroxybutyrylcarnitine	B
(18)	O
and	O
hydroxypropionylcarnitine	B
(17)	O
were	O
found	O
in	O
tissue	O
with	O
2.3	O
and	O
3.1	O
cancer-to-control	O
ratios,	O
respectively.	O

Subjects	O
consisted	O
of	O
29	O
subjects	O
with	O
impaired	O
fasting	O
glucose	B
and/or	O
impaired	O
glucose	B
tolerance.	O

Pathophysiologically,	O
very	O
early	O
insulin	O
resistance	O
enhances	O
VLDL-triglyceride	B
secretion	O
in	O
the	O
liver	O
when	O
its	O
glucose	B
metabolism	O
is	O
normally	O
responsive	O
to	O
insulin.	O

Then,	O
receiver	O
operating	O
characteristic	O
analysis	O
revealed	O
that	O
a	O
two-metabolite	O
set	O
(glycine	O
and	O
PAG)	O
had	O
the	O
strongest	O
prognostic	O
relevance	O
for	O
future	O
interventions	O
against	O
oxidative	O
stress	O
(the	O
area	O
under	O
the	O
curve	O
(AUC)	O

Lactate	B
on	O
the	O
other	O
hand,	O
is	O
in	O
the	O
current	O
study	O
only	O
found	O
in	O
greater	O
abundance	O
in	O
active	O
UC—a	O
result	O
that	O
parallels	O
previous	O
studies	O
(Hove	O
et	O
al.	O
;	O

Upregulated	O
lipid	O
subclasses	O
have	O
been	O
described	O
between	O
normal,	O
localized,	O
and	O
metastatic	O
prostatic	O
cells,	O
with	O
choline	B
kinase	O
α	O
implicated	O
in	O
de	O
novo	O
lipogenesis	O
in	O
aggressive	O
metastatic	O
cells.	O

This	O
could	O
explain	O
the	O
higher	O
PC	O
and	O
SM	O
concentrations	O
in	O
HC	O
females	O
compared	O
to	O
those	O
in	O
males	O
and	O
non-HC	O
females,	O
as	O
they	O
are	O
the	O
most	O
abundant	O
phospholipids	B
in	O
lipoproteins.	O

Moreover,	O
lower	O
plasma	O
betaine	B
concentrations	O
have	O
been	O
reported	O
in	O
subjects	O
with	O
type	O
2	O
diabetes	O
mellitus	O
(T2DM).	O

The	O
combined	O
EtOAc	O
layer	O
was	O
evaporated,	O
and	O
the	O
residue	O
was	O
dissolved	O
by	O
MeOH.	B

The	O
sodium	B
phosphate	I
buffer	O
for	O
preparation	O
of	O
the	O
faecal	O
slurries	O
was	O
made	O
of	O
1.77	O
g	O
KH_2	O
PO_4	O
in	O
195	O
mL	O
distilled	O
water	O
and	O
3.62	O
g	O
of	O
Na_2	O
HPO_4	O
in	O
305	O
mL	O
distilled	O
water	O
(both	O
1/15	O
M).	O

Based	O
on	O
the	O
overall	O
metabolite	O
profiles,	O
control	O
and	O
MUC16	O
knockdown	O
cultured	O
cells,	O
as	O
well	O
as	O
MUC16-high	O
and	O
MUC16-low	O
human	O
pancreatic	O
tumors,	O
segregated	O
in	O
distinct	O
clusters,	O
in	O
a	O
MUC16	O
expression-dependent	O
manner,	O
in	O
the	O
respective	O
2D-PLS-DA	B
(partial	O
least	O
squares	O
discriminant	O
analysis)	O
plots	O
(Figure	O
).	O

The	O
serum	O
spectra	O
contained	O
high-intensity	O
signals	O
from	O
the	O
small	O
molecules	O
lactate,	B
alanine,	B
creatine,	B
taurine,	B
glycine,	B
and	O
glucose.	B

Although	O
opiates	O
were	O
part	O
of	O
the	O
original	O
NIDA	O
5	O
group	O
only	O
morphine	B
and	O
codeine	B
cutoffs	O
are	O
regulated.	O

Abnormal	O
metabolism	O
induced	O
by	O
hyperglycemia	O
could	O
also	O
result	O
in	O
the	O
overproduction	O
of	O
free	O
radicals	O
that	O
can	O
lead	O
to	O
oxidative	O
stress	O
and	O
damage	O
to	O
tissues	O
in	O
and	O
around	O
retinal	B
vessels.	O

In	O
total	O
200	O
μL	O
of	O
serum	O
was	O
added	O
into	O
a	O
vial	O
and	O
extracted	O
with	O
methanol	B
(600	O
μL),	O
followed	O
by	O
vigorous	O
vortex	O
for	O
2	O
min	O
and	O
then	O
by	O
centrifugation	O
at	O
14	O
000g	O
for	O
10	O
min	O
at	O
4°C.	O

Our	O
data	O
reveal	O
up-regulation	O
of	O
1-methylhistidine,	B
acetoacetate,	B
acetone,	B
glutamate,	B
glutamine,	B
isoleucine,	B
lactate,	B
lysine,	B
nicotinate,	B
phenylalanine,	B
pyruvate,	B
and	O
tyrosine	B
and	O
down-regulation	O
of	O
alanine,	B
formate,	B
glycine,	B
glycerolphosphocholine,	B
and	O
low-density	O
lipoproteins	O
(LDL)	O
in	O
TB	O
patients	O
relative	O
to	O
healthy	O
controls.	O

Regions	O
of	O
800	O
MHz	O
_1	O
H	O
NMR	O
spectra	O
of	O
the	O
same	O
pooled	O
intact	O
human	O
serum:	O
(a)	O
serum	O
before	O
spiking	O
with	O
pyroglutamic	B
acid	I
(pGlu);	O
(b–d)	O
serum	O
spiked	O
with	O
standard	O
solution	O
of	O
pyroglutamic	B
acid	I
so	O
that	O
the	O
added	O
concentration	O
is	O
86,	O
172	O
and	O
1032	O
μ	O
M,	O
respectively.	O

One	O
of	O
the	O
end	O
products	O
of	O
protein	O
catabolism	O
is	O
urea.	B

These	O
metabolites	O
were	O
correlated	O
with	O
the	O
five	O
top	O
canonical	O
pathways,	O
including	O
purine	B
nucleotide	O
degradation	O
II,	O
liver	O
X	O
receptor/retinoic	O
X	O
receptor	O
(LXR/RXR)	O
activation,	O
phospholipases,	O
serotonin	B
receptor	O
signaling	O
and	O
purine	B
nucleotides	O
de	O
novo	O
biosynthesis	O
II.	O

For	O
fluorescence	O
quantitation	O
standardized	O
fluorochrome	B
microspheres	O
were	O
used	O
as	O
recommended	O
by	O
the	O
company	O
(Quantum™	O
FITC-5	O
MESF,	O
555,	O
Bangs	O
Laboratories,	O
Fishers,	O
Indiana,	O
USA).	O

To	O
distinguish	O
the	O
two	O
in	O
the	O
text,	O
AC	O
notation	O
will	O
be	O
preceded	O
by	O
a	O
capital	O
letter	O
C	O
(e.g.,	O
C18:1),	B
while	O
fatty	O
acids	O
will	O
not	O
(e.g.,	O
18:1).	O

In	O
our	O
lipidomics	O
analyses,	O
we	O
did	O
not	O
monitor	O
circulating	O
levels	O
of	O
diacyl-phosphatidic	B
acids	I
in	O
control	O
or	O
infected	O
cows.	O

	O
Metabolites	O
were	O
extracted	O
by	O
adding	O
four	O
volumes	O
of	O
cold	O
methanol	B
to	O
the	O
plasma	O
sample	O
(10 μL);	O
samples	O
were	O
vortexed	O
and	O
incubated	O
at	O
−20 °C	O
for	O
1 h.	O

5-methoxytryptamine	B
is	O
biosynthesized	O
via	O
the	O
deacetylation	O
of	O
melatonin,	B
which	O
occurs	O
naturally	O
in	O
the	O
body	O
at	O
low	O
levels.	O

ACM	O
from	O
obese	O
EAC	O
patients	O
induced	O
a	O
metabolic	O
shift	O
to	O
glycolysis	O
in	O
EAC	O
cells,	O
which	O
was	O
coupled	O
with	O
significantly	O
increased	O
sensitivity	O
to	O
the	O
glycolytic	B
inhibitor	O
2-deoxyglucose.	B

Furthermore,	O
indole,	B
another	O
metabolite	O
associated	O
with	O
Component	O
5,	O
is	O
derived	O
from	O
dietary	O
tryptophan	B
in	O
the	O
gut.	O

All	O
one-dimensional	O
_1	O
H	O
NMR	O
spectra	O
were	O
manually	O
corrected	O
for	O
phase	O
using	O
TOPSPIN	O
3.1	O
(BioSpin,	O
Bruker)	O
and	O
corrected	O
for	O
baseline	O
distortions,	O
and	O
referenced	O
to	O
the	O
left	O
signal	O
peak	O
of	O
α-glucose	B
at	O
5.236 ppm	O
using	O
Mnova	O
8.1	O
(Mestrelab	O
Research,	O
Santiago	O
de	O
Compostela,	O
Spain).	O

Quantification	O
was	O
performed	O
with	O
the	O
commercial	O
standards	O
arginine,	B
ornithine,	B
N_1	B
-acetylspermidine,	I
N_8	B
-acetylspermidine,	I
N-acetylputrescine,	B
N-acetylspermine,	B
spermine,	B
spermidine,	B
putrescine,	B
N_1	B
,N_12	I
-diacetylspermine,	I
and	O
N_1	O
,	O

Fatty	O
acids	O
are	O
a	O
valuable	O
energy	O
source	O
for	O
mitochondrial	O
oxidation	O
and	O
ATP	B
cell	O
generation	O
(Lehner	O
and	O
Quiroga,	O
2016).	O

The	O
highest	O
number	O
of	O
significantly	O
affected	O
metabolites	O
was	O
observed	O
in	O
the	O
T3	O
vs.	O
T2	O
comparison,	O
in	O
which	O
sixteen	O
metabolites	O
in	O
the	O
AF	B
(leucine,	I
valine,	I
isoleucine,	I
alanine,	I
methionine,	I
tyrosine,	I
phenylalanine,	I
N	I
,N	I
-dimethylglycine,	I
carnitine,	I
creatinine,	I
succinate,	I
pyruvate,	I
urocanate,	I
glucose,	I
choline	I
and	O
AU2)	B
and	O
five	O
metabolites	O
in	O
the	O
PL	O
(pyruvate,	O
3-hydroxybutyrate,	B
acetoacetate,	B
glycerol,	B
and	O
choline)	B
were	O
found.	O

This	O
is	O
depicted	O
in	O
,	O
where	O
the	O
offset	O
of	O
the	O
leftmost	O
peak	O
from	O
the	O
center	O
of	O
the	O
double	O
doublet	O
of	O
aspartate	B
is	O
half	O
of	O
the	O
sum	O
of	O
the	O
two	O
J-coupling	O
constants.	O

P	O
 =	O
0.000000029;	O
epiandrosterone	B
sulfate,	I
P	O
 = 0.0000040;	O
4-androsten-3beta,17beta-diol	O
disulfate	O
1,	O
P	O
 =	O
0.000016;	O
4-androsten-3beta,17beta-diol	O
disulfate	O
2,	O
P	O
 =	O
0.000064;	O
and	O
dehydroepiandrosterone	B
sulfate,	I
P	O
 =	O
0.00011).	O

Dietary	O
lignan	O
derived	O
enterolactone	B
has	O
been	O
reported	O
to	O
possess	O
anti-cancer	O
activities	O
and	O
to	O
be	O
associated	O
with	O
lowered	O
risk	O
of	O
prostate	O
cancer	O
and	O
breast	O
cancer.	O

For	O
example,	O
the	O
relative	O
abundance	O
of	O
several	O
monophosphates	B
(i.e.,	O
AMP,	B
CMP,	B
GMP,	O
and	O
UMP)	O
experienced	O
an	O
increase	O
during	O
the	O
first	O
60	O
s	O
and	O
then	O
decreased	O
dramatically	O
up	O
to	O
300	O
s	O
(-C	O
and	O
D	O
and	O
Table	O
S-1),	O
suggesting	O
that	O
triphosphates	B
and	O
diphosphates	B
could	O
be	O
degraded	O
into	O
monophosphate	B
analogues	O
as	O
suggested	O
in	O
-A.	O

Continued	O
degradation	O
of	O
HX	O
produces	O
uric	B
acid	I
that	O
gets	O
excreted	O
in	O
the	O
urine.	O

Tiabendazole	B
at	O
1	O
nM	O
was	O
detected	O
in	O
both	O
human	O
plasma	O
and	O
urine	O
extracts	O
with	O
similar	O
signal	O
intensities.	O

In	O
conclusion,	O
as	O
shown	O
in	O
,	O
the	O
development	O
of	O
steatosis	O
in	O
HU	O
is	O
characterized	O
by	O
up-regulated	O
phosphatidic	B
acid	I
and	O
CE	B
(18:0)	I
and	O
down-regulated	O
inosine.	B

The	O
advent	O
of	O
_2	O
H-tracing	O
has	O
also	O
enhanced	O
the	O
investigation	O
of	O
the	O
fate	O
of	O
the	O
critical	O
redox	O
cofactors	O
nicotinamide	B
adenine	I
dinucleotide	I
(NAD[H])	O
and	O
nicotinamide	B
adenine	I
dinucleotide	I
phosphate	I
(NADP[H]).	O

In	O
addition,	O
unlike	O
most	O
normal	O
tissues,	O
malignant	O
tumor	O
cells	O
convert	O
most	O
glucose	B
into	O
lactic	B
acid,	I
regardless	O
of	O
whether	O
oxygen	O
is	O
available	O
to	O
support	O
mitochondrial	O
oxidative	O
phosphorylation.	O

In	O
_1	O
H-NMR	O
serum	O
profiling,	O
lower	O
intensities	O
of	O
LDL/VLDL,	O
lipids,	O
and	O
choline	B
in	O
YDS-HCC	O
than	O
NYDS-HCC	O
patients	O
are	O
correlated	O
to	O
lipid	O
metabolism.	O

AS	O
=	O
Aspartame	B
sensitive,	O
NS	O
=	O
Non	O
sensitive.	O

The	O
results	O
of	O
mass	O
spectrometry	O
of	O
the	O
intact	O
transferrin	O
protein	O
and	O
corresponding	O
transferrin	O
IEF	O
profiles	O
are	O
shown	O
before	O
(Panel	O
A)	O
and	O
after	O
(Panel	O
B)	O
the	O
intake	O
of	O
supplementary	O
galactose.	B

who	O
did	O
not	O
observe	O
an	O
association	O
between	O
smoking	O
status	O
and	O
urinary	O
2-OHE1	B
but	O
reported	O
increased	O
levels	O
of	O
urinary16α-OHE1	B
among	O
current	O
smokers	O
compared	O
to	O
never/former	O
smokers.	O

For	O
picolinic	B
acid,	I
untreated	O
UC	O
and	O
treated	O
UC	O
groups	O
showed	O
a	O
decrease	O
in	O
concentration	O
compared	O
with	O
controls	O
(control	O
→	O
UC	O
treated	O
p	O
=	O
0.060,	O
control	O
→	O
UC	O
untreated	O
p	O
=	O
0.009).	O

Concentrations	O
of	O
esterified	O
and	O
non-esterified	O
fatty	O
acids	O
and	O
oxylipins	B
in	O
TGRL	O
were	O
quantified	O
by	O
mass	O
spectrometry.	O

The	O
prediction	O
models	O
indicated	O
that	O
644	O
(7.0%)	O
of	O
9,260	O
urine	O
spectra	O
contained	O
acetaminophen	B
metabolites	O
and	O
382	O
(4.1%)	O
contained	O
ibuprofen	B
metabolites.	O

Steady-state	O
modeling	O
again	O
revealed	O
significant	O
anaplerosis	O
and	O
enrichment	O
in	O
acetyl-CoA	B
that	O
was	O
much	O
lower	O
than	O
blood	O
glucose.	B

Furthermore,	O
strong	O
negative	O
associations	O
between	O
IS	O
and	O
a	O
combination	O
of	O
BCAAs,	O
the	O
AAAs,	O
methionine,	B
glutamate/glutamine,	O
and	O
C3	O
and	O
C5	O
acylcarnitines	B
are	O
observed	O
in	O
obese	O
adults	O
(with	O
and	O
without	O
T2DM)	O
and	O
in	O
insulin-resistant	O
lean	O
men	O
(–,	O
).	O

DeFilippis	O
et	O
al.	O
demonstrated	O
19	O
metabolites	O
with	O
an	O
intra-subject	O
fold	O
change	O
from	O
time	O
of	O
acute	O
thrombotic	O
MI	O
presentation	O
to	O
the	O
quiescent	O
state,	O
including	O
lipids	O
2-hydroxybutyrate,	B
and	O
amino	O
acids.	O

Our	O
observations	O
might	O
suggest	O
that	O
the	O
level	O
of	O
total	O
4-MeO-E2	B
could	O
be	O
a	O
potential	O
biomarker	O
for	O
breast	O
cancer	O
cases.	O

The	O
pHbA1c	O
ratio	O
reflects	O
the	O
two	O
to	O
three	O
month	O
average	O
plasma	O
glucose	B
level	O
and	O
is	O
here	O
associated	O
with	O
elevated	O
blood	O
sugar	O
independently	O
of	O
diagnosed	O
diabetes.	O

3-Hydroxycinnamate	B
shows	O
weak	O
correlation	O
(C).	O

Main	O
components	O
in	O
the	O
residue	O
of	O
the	O
polar	O
solvents	O
MeOD,	O
DMSO,	B
and	O
DMF	O
are	O
most	O
likely	O
salts	O
that	O
are	O
only	O
completely	O
soluble	O
in	O
water.	O

The	O
result	O
of	O
the	O
quantitative	O
analysis	O
showed	O
N	B
-desmethyl-acetamiprid	I
was	O
determined	O
in	O
the	O
urine	O
of	O
one	O
case,	O
which	O
had	O
been	O
collected	O
on	O
the	O
first	O
visit,	O
at	O
a	O
concentration	O
of	O
3.2	O
ng/mL.	O

These	O
450	O
selected	O
spectra	O
were	O
chosen	O
as	O
representative	O
of	O
groups	O
A	O
and	O
B	O
(see	O
),	O
and	O
were	O
subsequently	O
examined	O
visually	O
to	O
confirm	O
presence	O
or	O
absence	O
of	O
acetaminophen	B
metabolite	O
signals.	O

According	O
to	O
these	O
results	O
it	O
can	O
be	O
stated	O
that	O
our	O
CE-MS	O
method	O
is	O
able	O
to	O
save	O
approximately	O
17%	O
of	O
the	O
time	O
of	O
analysis	O
and	O
is	O
characterized	O
by	O
a	O
resolution	O
between	O
isoleucine	B
and	O
leucine	B
isomers	I
which	O
is	O
satisfactory	O
for	O
their	O
quantification	O
purposes.	O

Sulfaphenazole	B
was	O
obtained	O
from	O
Ultrafine	B
Chemicals	O
(Manchester,	O
UK).	O

It	O
is	O
unclear	O
whether	O
the	O
duration	B
of	O
these	O
physiological	O
challenges	O
emerged	O
as	O
a	O
primary	O
factor	O
in	O
the	O
deterioration	O
of	O
physical	O
function.	O

As	O
shown	O
in	O
Table ,	O
bariatric	O
surgery	O
contributed	O
to	O
a	O
significant	O
decrease	O
in	O
the	O
levels	O
of	O
all	O
analyzed	O
lipids,	O
by	O
57%	O
for	O
triacylglycerols,	B
by	O
40–45%	O
for	O
SM,	O
PC,	O
PE	O
and	O
by	O
42%	O
for	O
total	O
PL.	O

Q1–Q4	O
median	O
enzalutamide	B
+	O
N-desmethylenzalutamide	B
concentration	O
levels	O
from	O
the	O
analysis	O
of	O
Gibbons	O
et	O
al	O
(n=704).	O

The	O
recovery	O
testing	O
was	O
performed	O
by	O
manually	O
spiking	O
900	O
μL	O
of	O
urine	O
with	O
100	O
μL	O
of	O
standard	O
solutions,	O
producing	O
a	O
spiking	O
level	O
of	O
5	O
μg	O
S	O
ml-1	O
(L1)	O
and	O
25	O
μg	O
S	O
ml-1	O
(L2)	O
of	O
taurine,	B
and	O
250	O
μg	O
S	O
ml-1	O
(L1)	O
and	O
1250	O
μg	O
S	O
ml-1	O
(L2)	O
of	O
sulfate	B
4)	O
Precision	O
is	O
expressed	O
as	O
the	O
%RSD	O
5)	O

l	O
l	O
l	O
l	O
l	O
Quantification	O
of	O
l-arginine	B
and	O
l-arginine	B
metabolites	O
in	O
human	O
plasma.	O

This	O
study	O
identified	O
the	O
branched-chain	O
amino	O
acids	O
valine,	O
leucine,	B
and	O
isoleucine	B
as	O
potential	O
prognostic	O
biomarkers	O
for	O
pancreatic	O
cancer.	O

When	O
compared	O
with	O
tenofovir,	O
zidovudine	B
and	O
abacavir	O
are	O
both	O
associated	O
with	O
small	O
increases	O
in	O
total-	O
and	O
LDL-	B
cholesterol	I
although	O
the	O
total-	O
to	O
HDL-	B
cholesterol	I
ratio	O
is,	O
in	O
general,	O
the	O
same	O
across	O
the	O
three	O
agents	O
[–].	O

Other	O
pathways	O
related	O
to	O
urea	B
cycle	O
and	O
amino	O
acid	O
metabolism	O
were	O
different	O
between	O
PTSD	O
subjects	O
and	O
controls	O
in	O
the	O
‘Discovery’	O
but	O
not	O
in	O
the	O
smaller	O
‘Test’	O
group.	O

The	O
LLODs	O
of	O
P,	O
P-1,	O
P-2,	O
IP,	B
IP-1,	O
and	O
IP-2	O
were	O
2.24,	O
2.65,	O
1.01,	O
2.53,	O
2.23,	O
and	O
1.07	O
ng/mL,	O
respectively,	O
and	O
the	O
LLOQs	O
of	O
P,	O
P-1,	O
P-2,	O
IP,	B
IP-1,	O
and	O
IP-2	O
were	O
4.88,	O
5.30,	O
2.02,	O
5.06,	O
4.46,	O
2.14	O
ng/mL,	O
respectively,	O
which	O
were	O
suitable	O
as	O
the	O
thresholds	O
for	O
the	O
quantitation	O
of	O
the	O
components.	O

Glucose	B
concentration	O
was	O
measured	O
in	O
the	O
first	O
minute	O
after	O
collection.	O

Their	O
combined	O
contribution	O
to	O
acetate	B
metabolism	O
in	O
the	O
brain	O
tumors	O
was	O
less	O
than	O
4.0%,	O
significantly	O
lower	O
than	O
the	O
direct	O
oxidation	O
of	O
acetate	B
in	O
the	O
citric	B
acid	I
cycle	O
in	O
tumors.	O

Here,	O
NMR	O
spectroscopy	O
was	O
used	O
to	O
determine	O
how	O
the	O
metabolic	O
profiles	O
of	O
hydrophilic	B
extracts	O
of	O
three	O
human	O
pancreatic	O
cancer	O
cell	O
lines,	O
MiaPaCa-2,	O
Panc-1	O
and	O
AsPC-1,	O
were	O
influenced	O
by	O
the	O
choice	O
of	O
drying	O
technique.	O

These	O
measures	O
showed	O
a	O
significant	O
difference	O
across	O
the	O
three	O
groups,	O
with	O
the	O
least	O
urinary	O
glucose	B
found	O
in	O
those	O
with	O
GCK-MODY	O
and	O
the	O
most	O
in	O
those	O
with	O
HNF1A-MODY.	O

Sphingomyelin	B
is	O
a	O
major	O
component	O
of	O
the	O
outer	O
plasma	O
membranes	O
of	O
cells	O
.	O

Of	O
the	O
21	O
amino	O
acids	O
quantified	O
in	O
the	O
targeted	O
analysis,	O
only	O
tryptophan	B
was	O
found	O
to	O
vary	O
significantly	O
with	O
sleep	O
status,	O
with	O
increased	O
levels	O
during	O
acute	O
sleep	O
deprivation.	O

To	O
25	O
μL	O
of	O
plasma,	O
100	O
μL	O
of	O
methanol	B
and	O
5	O
μL	O
of	O
internal	O
standard	O
(AA-d8	O
)	O
were	O
added.	O

In	O
summary	O
our	O
mass	O
spectrometry-based	O
metabolomic	O
profiling	O
of	O
pancreatic	O
cancer	O
patients	O
and	O
normal	O
subjects	O
allowed	O
us	O
to	O
identify	O
four	O
metabolites	O
(oleanoic	O
acid,	O
palmitic	B
acid,	I
taurochenodeoxycholate	B
and	O
d-sphingosine)	B
with	O
highly	O
discriminative	O
potential.	O

Also	O
for	O
hVDAC2(12–36),	O
the	O
α-helix	B
region	O
of	O
the	O
Ramachandran	O
plot	O
was	O
populated	O
by	O
residues	O
from	O
P5	O
to	O
K20	O
with	O
the	O
only	O
exception	O
of	O
residue	O
G11	O
in	O
this	O
case.	O

The	O
elevated	O
level	O
of	O
pyruvate	B
in	O
the	O
sera	O
of	O
TB	O
patients	O
suggests	O
increased	O
catabolism	O
of	O
all	O
three	O
major	O
nutrients,	O
as	O
well	O
as	O
increased	O
energy	O
consumption.	O

Major	O
proteins	O
are	O
apoA1	O
(70%)	O
and	O
apoA2	O
(20%)	O
together	O
with	O
proteins	O
such	O
as	O
apoA4,	O
apoE,	O
apoJ,	O
haptoglobin,	O
paraoxanase,	O
α2-macroglobulin,	O
and	O
lecithin	B
cholesterol	I
acyltransferase.	O

The	O
capillary	O
voltage	O
was	O
set	O
to	O
3.2	O
kV	B
and	O
3	O
kV,	B
and	O
the	O
cone	O
voltage	O
of	O
30V	O
and	O
20	O
V,	O
respectively.	O

Effect	O
of	O
the	O
concentration	O
of	O
poly-L,L	O
-SULA	O
on	O
the	O
simultaneous	O
enantioseparation	O
of	O
1,1’	B
=	I
O	I
-DVX	I
and	O
2,2’	B
=	I
VX.	I

MCRI	O
was	O
calculated	O
as	O
the	O
ratio	O
of	O
the	O
insulin	O
dose	O
over	O
the	O
incremental	O
area	O
under	O
the	O
curve	O
of	O
insulin	O
from	O
20	O
min	O
to	O
infinity	O
using	O
the	O
following	O
equation:	O
where	O
Dose	O
represents	O
the	O
amount	O
of	O
insulin	O
injected	O
at	O
20	O
min,	O
Ins(t)	O
the	O
plasma	O
insulin	O
concentration	O
in	O
standard	O
units	O
at	O
each	O
FSIGTT	O
sampling	O
point,	O
and	O
Ins(0)	O
the	O
fasting	O
plasma	O
insulin	O
concentration	O
determined	O
before	O
injection	O
of	O
glucose	B
in	O
the	O
FSIGTT.	O

Briefly,	O
lipids	O
were	O
extracted	O
from	O
serum	O
samples	O
by	O
substituting	O
chloroform	B
with	O
dichloromethane	B
(DCM)	O

Go	O
to:	O
Glimepiride,	O
a	O
third	O
generation	O
sulfonylurea,	B
is	O
an	O
antihyperglycemic	B
agent	O
widely	O
used	O
to	O
treat	O
type	O
2	O
diabetes	O
mellitus.	O

When	O
objective	O
hardship	O
was	O
included,	O
3-chlorotyrosine,	B
3-hydroxymandelate,	B
and	O
isoleucine	B
contributed	O
most	O
(Fig. ),	O
with	O
VIP	O
scores	O
of	O
1.39,	O
1.31,	O
and	O
1.31,	O
respectively	O
(Table ).	O

The	O
column	O
was	O
eluted	O
with	O
500	O
µL	O
methanol	B
to	O
new	O
tube,	O
dried	O
by	O
SpeedVac	O
at	O
35°C,	O
and	O
dissolved	O
in	O
200	O
µL	O
methanol,	B
resulting	O
in	O
a	O
phospholipids	B
fraction.	O

However,	O
we	O
did	O
find	O
a	O
significant	O
inverse	O
relationship	O
between	O
kynurenic	B
acid	I
and	O
sleep	O
efficiency.	O

Acetone,	B
acetonitrile,	B
ethanol,	B
hydrochloric	B
acid,	I
methanol,	B
perchloric	B
acid,	I
potassium	B
chloride,	I
potassium	B
hydroxide,	I
sodium	B
chloride	I
and	O
sodium	B
hydroxide	I
were	O
purchased	O
from	O
Fisher	O
Scientific	O
(Pittsburgh,	O
PA).	O

The	O
results	O
showed	O
that	O
the	O
progression	O
was	O
associated	O
with	O
disturbances	O
of	O
phospholipase	O
metabolism,	O
purine	B
nucleotide	O
degradation	O
and	O
Liver	O
X	O
receptor/retinoic	O
X	O
receptor	O
activation	O
as	O
characterized	O
by	O
up-regulated	O
phosphatidic	B
acid,	I
cholesterol	B
ester	I
(18:0)	I
and	O
down-regulated	O
inosine.	B

108	O
participants	O
with	O
pre-DM	O
from	O
a	O
longitudinal	O
cohort	O
study	O
were	O
followed	O
up	O
for	O
ten	O
years	O
and	O
were	O
divided	O
into	O
3	O
groups	O
according	O
to	O
different	O
glycemic	B
outcomes.	O

A	O
free	O
fatty	O
acid	O
(11-dodecenoic	O
acid)	O
showed	O
higher	O
levels	O
in	O
RCC,	O
and	O
the	O
oxidation	O
intermediate	O
2,6-dimethylheptanoyl	B
carnitine	I
showed	O
lower	O
levels,	O
indicating	O
a	O
high	O
energy	O
requirement	O
in	O
RCC.	O

LC–MS	O
grade	O
acetonitrile,	B
methanol,	B
and	O
water	O
were	O
purchased	O
from	O
Burdick	O
and	O
Jackson	O
(VWR	O
International,	O
West	O
Chester,	O
PA,	O
USA).	O

secondary	O
analysis	O
was	O
performed	O
in	O
216	O
middle-aged	O
abdominally	O
obese	O
men	O
and	O
women	O
([mean	O
(SD)],	O
52.4	O
(8.0)	O
years)	O
randomized	O
into	O
one	O
of	O
four	O
groups	O
varying	O
in	O
exercise	O
amount	O
and	O
intensity	O
for	O
6	O
months	O
duration:	B
high	O
amount	O
high	O
intensity,	O
high	O
amount	O
low	O
intensity,	O
low	O
amount	O
low	O
intensity,	O
and	O
control.	O

These	O
catechol	B
estrogens	O
and	O
the	O
catechol-estrogen-DNA	B
adducts	O
can	O
be	O
isolated	O
from	O
sera	O
of	O
people	O
infected	O
with	O
S.	O
haematobium	O
.	O

 ),	O
which	O
is	O
one	O
of	O
the	O
most	O
neurotoxic	O
organophosphorus	B
pesticides.	O

5-OH	O
IAA	O
also	O
highly	O
correlated	O
with	O
KYN/TRP,	O
and	O
was	O
moderately	O
correlated	O
with	O
neopterin	B
and	O
indoxyl	B
sulfate	I
(see	O
Table ).	O

It	O
might	O
also	O
be	O
noted	O
that,	O
in	O
addition	O
to	O
the	O
production	O
of	O
gut-derived	O
uremic	O
toxins	B
from	O
dietary	O
aromatic	O
amino	O
acids	O
by	O
the	O
gastrointestinal	O
microbiota,	O
Phe	O
is	O
known	O
to	O
be	O
an	O
essential	O
amino	O
acid	O
for	O
most	O
animals,	O
including	O
ruminants.	O

In	O
the	O
present	O
study,	O
NMR-based	O
metabolomics	O
was	O
used	O
to	O
study	O
the	O
metabolic	O
effects	O
of	O
intervention	O
with	O
rye	O
bran-enriched	O
rye	O
bread	O
(RB)	O
in	O
postmenopausal	O
women	O
with	O
slightly	O
elevated	O
serum	O
cholesterol.	B

Interestingly,	O
SPTLC3	O
has	O
been	O
shown	O
to	O
generate	O
d16:1	B
SPs	O
in	O
the	O
heart,	O
where	O
high	O
levels	O
of	O
d16:1	B
SPs	O
were	O
found	O
to	O
induce	O
cardiomyocyte	O
apoptosis	O
(,	O
),	O
thus	O
identifying	O
a	O
potential	O
mechanistic	O
link	O
between	O
T2DM	O
and	O
congestive	O
heart	O
failure.	O

In	O
particular,	O
distinct	O
clusters	O
were	O
observed	O
for	O
phosphatidylcholines	B
(PCs),	O
lyso-PCs	O
(LPCs),	O
lyso-phosphatidylethanolamines	B
(LPEs),	O
purines,	B
amino	O
acids,	O
medium-	O
and	O
long-chain	O
acylcarnitines.	B

Moreover,	O
glutathione	B
(GSH),	O
the	O
most	O
abundant	O
endogenous	O
antioxidant	O
in	O
the	O
brain,	O
is	O
decreased	O
in	O
AD	O
and	O
aging.	O

Our	O
aim	O
was	O
to	O
identify	O
and	O
quantify	O
abiraterone	B
which	O
requires	O
separation	O
of	O
abiraterone	B
from	O
its	O
potential	O
metabolites.	O

Besides	O
free	O
fatty	O
acids,	O
pyruvate	B
is	O
one	O
of	O
the	O
major	O
sources	O
of	O
acetyl-CoA	B
for	O
TCA	O
cycle.	O

Threonic	B
acid	I
is	O
elevated	O
in	O
the	O
serum	O
of	O
mice	O
with	O
experimental	O
intestinal	O
ischemia,	O
which	O
may	O
have	O
been	O
the	O
result	O
of	O
altered	O
gut	O
floral	O
metabolism.	O

Plasma	O
miR-146a	O
was	O
also	O
differentially	O
associated	O
with	O
plasma	O
amino	O
acids,	O
as	O
well	O
as	O
skeletal	O
muscle	O
long-chain	O
acylcarinitines	O
and	O
pyruvate,	B
both	O
key	O
substrates	O
for	O
muscle	O
energy	O
generation,	O
compared	O
to	O
control	O
subjects.	O

[]	O
Finally,	O
posaconazole	B
and	O
itraconazole	B
were	O
found	O
superior	O
to	O
AmpB,	O
a	O
cornerstone	O
of	O
PAM	O
therapy	O
and	O
a	O
standard	O
of	O
care	O
for	O
CNS	O
infections	O
caused	O
by	O
molds,	O
against	O
N	O
.	O

Freeze–thaw	O
stability	O
experiments	O
did	O
not	O
demonstrate	O
degradation	O
of	O
enzalutamide	B
and	O
N-desmethylenzalutamide	B
over	O
three	O
freeze–thaw	O
cycles.	O

The	O
changes	O
in	O
the	O
composition	O
of	O
the	O
non-esterified	O
pool	O
were	O
predominantly	O
associated	O
with	O
sEH-	O
and	O
LOX-derived	O
oxylipins	B
originating	O
from	O
the	O
C18	O
PUFA,	O
linoleic	O
(LA)	O
and	O
alpha-linolenic	B
acid	I
(ALA)	O

Undiluted	O
serum	O
sample	O
(25 μL)	O
and	O
100 μL	O
of	O
2 mM	O
hydrogen	B
peroxide	I
was	O
added	O
to	O
freshly	O
prepared	O
reaction	O
mixture	O
consisting	O
of	O
755 μL	O
of	O
0.1 M	O
sodium	B
phosphate	I
buffer	O
(pH	O
7.0),	O
100 μL	O
of	O
2 mM	O
nicotinamide	B
adenine	I
dinucleotide	I
phosphate	I
(NADPH),	O
10 μL	O
glutathione	B
reductase	O
(2 μL	O
in	O
500 μL	O
buffer)	O
and	O
10 μL	O
reduced	B
glutathione	I
(9.22 mg/mL)	O
kept	O
in	O
cuvette	O
of	O
1 mL	O
capacity.	O

In	O
summary,	O
unique	O
putative	O
metabolites	O
with	O
potential	O
value	O
as	O
biomarkers	O
were	O
identified	O
in	O
this	O
study;	O
when	O
these	O
metabolites	O
are	O
completely	O
validated,	O
the	O
molecules	O
and	O
associated	O
proteins	O
could	O
be	O
further	O
characterised	O
and	O
studied	O
for	O
future	O
use	O
as	O
therapeutic	O
or	O
diagnostic	O
targets,	O
or	O
in	O
vaccine	B
development.	O

This	O
further	O
confirms	O
an	O
increase	O
in	O
the	O
extraction	O
of	O
hydrophobic	O
lipids	O
when	O
ethanol-methanol	B
is	O
used.	O

The	O
levels	O
of	O
PGF_2α	B
in	O
E.	O
coli	O
and	O
bovine	O
liver	O
GUS	O
samples	O
were	O
lower	O
compared	O
with	O
the	O
high	O
PGF_2α	O
background	O
present	O
in	O
H.	O
pomatia	O
.	O

This	O
resulted	O
in	O
selection	O
of	O
134,	O
36,	O
and	O
119	O
m/z	O
signals	O
for	O
the	O
olanzapine,	B
risperidone,	B
and	O
quetiapine	B
treatment	O
groups,	O
respectively	O
out	O
of	O
more	O
than	O
1,600	O
compounds	O
in	O
total	O
(Table	O
).	O

GC-MS	O
analysis	O
also	O
revealed	O
a	O
significant	O
presence	O
of	O
mass	O
isotopomers	O
of	O
lactate	B
with	O
one	O
or	O
two	O
_13	O
C	O
labels	O
for	O
patients	O
#8–10,	O
which	O
is	O
consistent	O
with	O
an	O
active	O
Cori	O
cycle.	O

Metabolites	O
1	O
and	O
6	O
are	O
products	O
of	O
the	O
reaction	O
of	O
BDA	O
with	O
lysine	B
whereas	O
metabolites	O
2	O
–	O
5	O
are	O
derived	O
from	O
the	O
crosslinking	O
of	O
cysteine	B
to	O
lysine	B
by	O
this	O
reactive	O
compound.	O

In	O
this	O
metabolomics	O
study,	O
we	O
also	O
identified	O
a	O
metabolomics	O
profiling	O
panel	O
consisting	O
of	O
metabolites	O
(4-hydroxypentenoic	O
acid,	I
arabinose,	B
glycochenodeoxycholate-3-sulfate,	B
isoleucine,	B
serine,	B
and	O
xanthine)	B
with	O
moderate	O
power	O
for	O
diagnosing	O
adult	O
OSA.	O

For	O
plasma,	O
validation	O
was	O
performed	O
in	O
aliquots	O
containing	O
endogenous	O
estrone	B
and	O
estradiol	B
and	O
enriched	O
with	O
metabolites.	O

Plasma	O
(5	O
μL)	O
was	O
added	O
to	O
60	O
μL	O
of	O
50%	O
methanol	B
and	O
incubated	O
at	O
room	O
temperature	O
for	O
15	O
min	O
with	O
constant	O
agitation.	O

The	O
standard	O
internal	O
mixture	O
(200	O
μl	O
methyl	B
non-adecanoate	I
in	O
hexane	B
containing	O
BHT)	O
was	O
added	O
to	O
the	O
100	O
μl	O
plasma.	O

The	O
lower	O
level	O
of	O
specific	O
serum	O
phospholipids	B
in	O
GC	O
serum	O
could	O
reflect	O
alterations	O
at	O
tumor	O
tissue.	O

The	O
virion	O
PE	O
population	O
contained	O
plasmalogen	O
species	O
(Fig.	O
S2A	O
),	O
consistent	O
with	O
the	O
elevation	O
of	O
its	O
dihydroxyacetone	B
phosphate	I
precursor	O
in	O
infected	O
cells,	O
and	O
plasmalogens	O
support	O
fusion.	O

All	O
80 μl	O
samples	O
were	O
mixed	O
with	O
10 μl	O
solutions	O
containing	O
the	O
internal	O
quality	O
standards	O
leucine-d3,	B
glutamic	B
acid-d3,	O
phenylalanine-d5	B
and	O
cholic	O
acid-d4	O
(each	O
present	O
at	O
a	O
concentration	O
of	O
about	O
250 μg/ml	O
in	O
methanol/water	O
(1:4	O
v/v))	O
and	O
subsequently	O
lyophilized	O
at	O
−37°C	O
in	O
autosampler	O
vials.	O

Stuebe	O
et	O
al	O
found	O
a	O
lower	O
plasma	O
oxytocin	B
concentration	O
in	O
the	O
last	O
trimester	O
of	O
women	O
at	O
risk	O
of	O
PPD.	O

A	O
higher	O
free	O
fatty	O
acids	O
concentration	O
was	O
indeed	O
recorded_,	O
,	O
which	O
shifts	O
glycerol	B
consumption	O
toward	O
triglyceride	B
formation.	O

The	O
cholesterol	B
metabolites	O
3β-HCA	B
(P	O
 < 0.05)	O
and	O
7αH,3O–CA	B
(P	O
 < 0.01)	O
of	O
the	O
“acidic	O
pathway”	O
are	O
elevated	O
in	O
the	O
AD	O
and	O
PD	O
group,	O
while	O
in	O
the	O
ALS	O
group	O
7α,(25R)26-diHCO	B

For	O
example,	O
lactate	B
and	O
the	O
ribose	B
moieties	O
of	O
the	O
free	O
nucleotides	O
show	O
isotopomers	O
with	O
either	O
no	O
_13	O
C	O
(central	O
cross-peak)	O
or	O
both	O
atoms	O
are	O
_13	O
C	O
(square	O
array)	O

Therefore,	O
their	O
pathological	O
states	O
could	O
be	O
confirmed	O
by	O
enhanced	O
glucose	B
consumption	O
and	O
lactate	B
production.	O

The	O
elute	O
dried	O
by	O
nitrogen	B
gas	I
flow	O
at	O
60°C	O
and	O
30	O
L/min.	O

Previous	O
studies	O
in	O
diabetes	O
have	O
also	O
indicated	O
that	O
impaired	O
glucocorticoid	B
receptor	O
(GR)	O
signaling	O
induces	O
sorbitol	B
accumulation	O
via	O
polyol	O
pathways	O
(;	O
;	O
)	O
and	O
there	O
is	O
evidence	O
showing	O
a	O
positive	O
correlation	O
between	O
blood	O
copper	O
level	O
and	O
risk	O
for	O
developing	O
diabetes	O
mellitus,	O
possibly	O
due	O
to	O
augmented	O
copper-induced	O
oxidative	O
stress.	O

In	O
contrast	O
to	O
prior	O
studies	O
(,	O
),	O
circulating	O
vitamin	B
D	I
metabolites	O
were	O
not	O
significantly	O
related	O
to	O
blood	O
pressure	O
in	O
cross-section	O
or	O
to	O
risk	O
of	O
hypertension	O
during	O
follow-up.	O

Individual	O
oxylipins	B
including	O
9-HODEs	O
and	O
12/15-HETEs	O
induced	O
ER	O
stress	O
in	O
macrophages	O
and	O
adipocytes,	O
respectively.	O

The	O
collision	O
induced	O
fragmentation	O
mass	O
spectrum	O
of	O
this	O
metabolite	O
contained	O
fragment	O
ions	O
that	O
were	O
characteristic	O
for	O
an	O
N	B
-acetylcysteine	I
sulfoxide	I
substituted	O
pyrrole	B
moiety	O
(neutral	O
loss	O
of	O
77,	O
95,	O
147	O
and	O
177,	O
,	O
).	O

Given	O
that	O
thymol	B
was	O
the	O
only	O
preservative	O
found	O
to	O
be	O
effective	O
under	O
40	O
°C	O
storage	O
conditions,	O
only	O
thymol	B
was	O
included	O
for	O
significance	O
testing.	O

After	O
quantification	O
and	O
quality	O
control	O
analyses,	O
Wilcoxon	O
rank-sum	O
test	O
was	O
used	O
to	O
compare	O
the	O
proline	B
concentration	O
levels	O
between	O
the	O
EAC	O
cases	O
and	O
healthy	O
controls.	O

Respectively,	O
red	O
color	O
indicates	O
the	O
regions	O
that	O
showed	O
increased	O
wall	O
thickening/motion	O
related	O
to	O
the	O
TG(49∶3)	B
concentration	O
decrease	O
in	O
LMNA	O
mutation.	O

The	O
LAC2	O
multiplet	O
also	O
contained	O
small	O
2–3	O
and	O
1–2	O
doublets,	O
demonstrating	O
that	O
not	O
all	O
of	O
the	O
lactate	B
in	O
the	O
tumor	O
was	O
uniformly	O
labeled.	O

The	O
cohort	O
in	O
which	O
we	O
initially	O
discovered	O
ethanol	B
contamination	O
consisted	O
of	O
human	O
CSF	O
samples	O
that	O
were	O
collected	O
for	O
research	O
purposes,	O
namely	O
to	O
investigate	O
the	O
pathophysiology	O
of	O
migraine.	O

reported	O
that	O
24–48 h	O
of	O
exposure	O
to	O
selective	O
serotonin	B
reuptake	O
inhibitors	O
or	O
tricyclic	B
antidepressant	O
medications	O
stimulated	O
the	O
de	O
novo	O
synthesis	O
of	O
KA	O
and	O
decreased	O
3HK	O
production	O
in	O
astroglial	O
cultures,	O
thus	O
resulting	O
in	O
an	O
increase	O
in	O
the	O
KA	O
to	O
3HK	O
ratio.	O

We	O
identified	O
as	O
major	O
factors:	O
(i)	O
solubility	O
in	O
formalin	B
solution,	O
(ii)	O
covalent	O
bonding	O
to	O
cellular	O
component	O
(e.g.,	O
protein,	O
DNA/RNA),	O
and	O
(iii)	O
solubility	O
in	O
ethanol	B
and	O
xylene.	B

The	O
highest	O
serine	B
concentrations	O
were	O
seen	O
for	O
MetS_zero	O
women	O
with	O
the	O
highest	O
PAL_DLW	O
,	O
attesting	O
to	O
the	O
importance	O
of	O
engaging	O
in	O
physical	O
activity	O
even	O
for	O
normal	O
weight	O
and	O
healthy	O
women.	O

Formate	B
was	O
markedly	O
decreased	O
in	O
the	O
sera	O
of	O
TB	O
patients	O
in	O
this	O
study.	O

Ornithine	B
represents	O
a	O
metabolite	O
found	O
in	O
the	O
urea	B
cycle,	O
which	O
can	O
use	O
amino	O
acid	O
breakdown	O
products	O
to	O
feed	O
into	O
the	O
Krebs	O
cycle.	O

Malignant	O
cells	O
transport	O
glutamine	B
across	O
the	O
cytoplasmic	O
membrane	O
to	O
form	O
glutamate	B
at	O
a	O
faster	O
rate	O
than	O
their	O
non-malignant	O
counterparts.	O

On	O
the	O
other	O
hand,	O
the	O
amino	O
acid	O
concentration-based	O
model	O
was	O
superior	O
in	O
selectivity	O
[without	O
taking	O
misclassification	O
costs	O
into	O
account	O
(Klawonn	O
et	O
al.	O
)],	O
suggesting	O
that	O
PCs	O
might	O
not	O
serve	O
as	O
optimal	O
modeling	O
variables	O
when	O
Occam’s	O
razor	B
is	O
strictly	O
availed.	O

LIMA1	O
may	O
modulate	O
plasma	O
low-density	O
lipoprotein	O
cholesterol	B
level	O
by	O
regulating	O
intestinal	O
cholesterol	B
absorption.	O

Since	O
the	O
cells	O
have	O
sufficient	O
energy	O
from	O
glycolysis,	O
TCA	O
cycle	O
is	O
turned	O
off,	O
resulting	O
in	O
the	O
reduction	O
in	O
TCA	O
metabolites,	O
including	O
citric	B
acid,	I
α-ketoglutaric	B
acid,	I
and	O
fumaric	B
acid.	I

The	O
standards	O
including	O
lysoPC	O
(16:0),	O
lysoPC	O
(17:0),	O
lysoPC	O
(18:0)	O
and	O
taurocholate	B
were	O
purchased	O
from	O
Sigma-Aldrich	O
(USA).	O

Creatinine	B
is	O
a	O
breakdown	O
product	O
of	O
muscular	O
creatine	B
phosphate,	I
and	O
may	O
thus	O
reflect	O
the	O
higher	O
levels	O
of	O
physical	O
activity	O
in	O
these	O
subjects.	O

The	O
difference	O
of	O
216	O
and	O
248 Da	O
compared	O
to	O
Tem-dox-SO	O
and	O
Tem-SO	O
suggested	O
that	O
this	O
compound	O
lacks	O
thiophosphate	B
and	O
phosphate	B
groups.	O

The	O
others,	O
[2-(4-(2-acetoxyethyl)-2,5-dimethoxyphenyl)acetic	O
acid	I
(methyl	O
ester),	O
2-hydroxybutyric	B
acid,	I
carbamic	B
acid,	I
and	O
malonic	B
acid,	I
were	O
decreased.	O

Reagents	O
and	O
solvents	O
included	O
methanol,	B
hexane	B
(Tedia,	O
Tediaway,	O
Fairfield,	O
USA),	O
myristic-d_27	O
acid,	O
N,O	B
-bis(trimethylsilyl)	I
trifluoroacetamide	I
(BSTFA)	O
with	O
trimethylchlorosilane	B
(TMCS)	O
(Sigma-Aldrich,	O
St.	O
Louis,	O
Missouri,	O
USA),	O
methoxylamine	O
hydrochloric	O
(Acros	O
Organic,	O
New	O
Jersey,	O
USA),	O

Dashed	O
boxes	O
indicate	O
pools	O
of	O
metabolites:	O
tCr,	O
total	O
creatines	B
(creatine	I
+	I
phosphocreatine);	I
tCho,	O
total	O
cholines	B
(choline	I
+	I
phosphocholine	I
+	I
glycerophosphocholine);	I
tGlut,	O
glutamate	B
+	O
glutamine	B
pool;	O
PtdCho,	O
phosphatidylcholine.	B

Ketone	B
bodies	O
mainly	O
produced	O
from	O
fatty	O
acids	O
β-oxidation,	O
exhibit	O
different	O
patterns	O
of	O
alteration	O
in	O
cancer	O
studies.	O

Additionally,	O
some	O
concerns	O
arise	O
on	O
the	O
design	O
of	O
FA	B
supplements,	O
since	O
not	O
only	O
dosages	O
but	O
also	O
ratios	O
among	O
FA	B
are	O
crucial,	O
following	O
our	O
results.	O

Tryptophan	B
was	O
detected	O
at	O
lower	O
levels	O
in	O
patients	O
compared	O
with	O
controls	O
in	O
the	O
combined	O
metabolic	O
profile,	O
but	O
the	O
difference	O
reached	O
significance	O
(p=0.02)	O
only	O
in	O
one	O
of	O
the	O
analysed	O
batches	O
of	O
samples.	O

Since	O
carbonic	B
acid	I
is	O
a	O
weak	O
acid,	O
not	O
all	O
carbonic	B
acid	I
is	O
dissociated,	O
and	O
we	O
estimate	O
that	O
25	O
mM	O
concentration	O
is	O
just	O
a	O
lower	O
estimate	O
for	O
the	O
amount	O
of	O
dissolved	O
CO_2	O
.	O

In	O
this	O
regard,	O
the	O
differences	O
we	O
have	O
observed	O
in	O
the	O
oxylipin	B
composition	O
between	O
pro-	O
and	O
anti-TGRL	O
may	O
exacerbate	O
an	O
inflammatory	O
response	O
in	O
endothelium	O
exposed	O
to	O
these	O
particles	O
for	O
a	O
prolonged	O
period.	O

No	O
plasma	O
vitamin	B
D	I
metabolite	O
was	O
associated	O
with	O
mean	O
IMT	O
measured	O
in	O
1994	O
only	O
(evaluated	O
using	O
linear	O
regression)	O
or	O
with	O
change	O
in	O
IMT	O
from	O
1994	O
to	O
2000/2001	O
(evaluated	O
using	O
generalized	O
estimating	O
equations	O
including	O
time–by–vitamin	O
D	O
metabolite	O
interactions).	O

Another	O
1 ml	O
blood	O
sample	O
will	O
be	O
taken	O
in	O
tubes	O
containing	O
ethylenediaminetetraacetic	B
acid	I
(EDTA)	O
for	O
HbA1C.	O

In	O
another	O
example,	O
median	O
concentrations	O
of	O
donor	O
AO	O
with	O
respect	O
to	O
creatinine,	B
3-hydroxyisovalerate,	B
alanine,	B
citrate,	B
dimethylamine,	B
glycine,	B
isoleucine,	B
lactate/threonine,	O
leucine,	B
and	O
valine	B
are	O
consistently	O
at	O
the	O
lower	O
end	O
within	O
the	O
panel.	O

Interestingly,	O
a	O
positive	O
correlation	O
was	O
found	O
between	O
age	O
and	O
sphingomyelins	B
and	O
total	O
phosphatidylcholines	B
concentrations,	O
two	O
classes	O
of	O
molecules	O
with	O
essential	O
roles	O
in	O
cell	O
membrane	O
integrity	O
and	O
function.	O

Most	O
of	O
the	O
profiling	O
studies	O
performed	O
on	O
brain	O
GGs	O
of	O
different	O
species	O
(mouse,	O
bovine,	O
porcine,	B
human)	O
using	O
MS	O
do	O
not	O
report	O
on	O
GT3	O
or	O
AcGT3	O
[–].	O

The	O
3-epimer	O
of	O
25(OH)D_3	B
,	I
3-epi-25(OH)D_3	I
,	O
was	O
obtained	O
from	O
IsoSciences.	O

During	O
a	O
two-week	O
lead-in	O
period,	O
participants	O
were	O
recommended	O
to	O
maintain	O
their	O
usual	O
dietary	O
and	O
exercise	O
habits	O
and	O
to	O
avoid	O
high-flavonoid	B
foods	O
and	O
beverages	O
including	O
berries,	O
fruits,	O
vegetables,	O
juices,	O
microalgae,	O
and	O
teas	O
for	O
minimizing	O
between-subject	O
variability	O
of	O
bioactive	O
components	O
at	O
baseline.	O

Samples	O
were	O
reconstituted	O
with	O
50	O
μL	O
of	O
5%	O
acetonitrile	B
for	O
LC-MS/MS	O
analysis.	O

Preclinical	O
studies	O
have	O
shown	O
that	O
limonene	B
causes	O
apoptosis	O
in	O
multiple	O
cell	O
types	O
through	O
indirect	O
mechanisms	O
[,	O
].	O

Unadjusted	O
Spearman’s	O
correlations	O
Significance:	O
<0.05	O
‘*’	O
Trp	O
tryptophan,	B
Kyn	O
kynurenine,	B
KTR	O
kynurenine/tryptophan	B
ratio,	O
HK	O
3-hydroxykynurenine,	B
KA	O
kynurenic	B
acid,	I
XA	O
xanthurenic	B
acid,	I
AA	O
anthranilic	B
acid,	I
HAA	O
3-hydroxyanthranilic	B
acid,	I
QA	O
quinolinic	B
acid,	I
Cot	O
cotinine	B
There	O
was	O
a	O
significant	O
inverse	O
correlation	O
between	O
age	O
and	O
tryptophan	B
in	O
this	O
material	O
as	O
a	O
whole	O
(r:	O
−0.24)	O
and	O
in	O
the	O
patient	O
group	O
(r:	O
−0.30)	O
in	O
particular.	O

As	O
the	O
standard	O
arsenic	O
compounds,	O
sodium	O
arsenate	O
(As(V)),	O
sodium	B
arsenite	I
(As(III)),	O
methylarsonic	B
acid	I
(MA(V)),	O
dimethylarsinic	B
acid	I
(DMA(V))	O
and	O
arsenobetaine	B
(AB)	O
were	O
purchased	O
from	O
Tri	O
Chemical	O
Laboratories	O
Inc.	O
(Yamanashi,	O
Japan).	O

The	O
analysis	O
of	O
plasma	O
samples	O
from	O
newborns	O
with	O
HIE	O
revealed	O
a	O
decrease	O
of	O
lactate,	B
pyruvate	B
and	O
β-hydroxybutyrate	B
concentrations,	O
whereas	O
rising	O
malate	B
concentrations	O
were	O
observed.	O

The	O
kit	O
allows	O
the	O
targeted	O
analysis	O
of	O
up	O
to	O
189	O
metabolites	O
(see	O
)	O
in	O
the	O
metabolite	O
classes	O
of	O
amino	O
acids,	O
biogenic	O
amines,	O
acylcarnitines,	B
glycerophospholipids,	B
sphingolipids	B
and	O
sum	O
of	O
hexoses,	O
covering	O
a	O
wide	O
range	O
of	O
analytes	O
and	O
metabolic	O
pathways	O
in	O
one	O
targeted	O
assay.	O

Data	O
also	O
indicate	O
new,	O
multifactorial	O
roles	O
for	O
acylcarnitines	B
in	O
neuroprotection	O
through	O
mechanisms	O
that	O
include	O
modifying	O
synthesizing	O
lipids,	O
stabilizing	O
membrane	O
composition,	O
modulating	O
genes	O
and	O
proteins,	O
increasing	O
antioxidant	O
activity,	O
and	O
enhancing	O
cholinergic	B
neurotransmission.	O

Values	O
are	O
reported	O
as	O
mean	O
(range)	O
with	O
units	O
of	O
μmol/mmol	O
creatinine.	B

Carnosine;	B
126.	O

Proline	B
oxidase	O
(POX),	O
an	O
inner	O
mitochondrial	O
membrane	O
enzyme,	O
catalyzes	O
the	O
released	O
proline	B
to	O
P5C;	O
this	O
process	O
generates	O
electrons	O
that	O
are	O
donated	O
to	O
electron	O
transport	O
chain	O
in	O
mitochondria	O
and	O
generate	O
ATP.	B

These	O
findings	O
help	O
illustrate	O
the	O
contribution	O
of	O
physical	O
activity	O
to	O
glucose	B
homeostasis.	O

Both	O
UPLC–HRMS	O
and	O
DI–nESI–HRMS	O
showed	O
higher	O
levels	O
of	O
several	O
acylcarnitines	B
in	O
positive	O
ion	O
mode	O
and	O
steroid	O
metabolites	O
in	O
negative	O
ion	O
mode	O
in	O
urine	O
samples	O
obtained	O
from	O
men,	O
indicating	O
differences	O
in	O
lipid	O
metabolism,	O
which	O
is	O
consistent	O
with	O
previously	O
reported	O
data	O
on	O
sex-specific	O
urine	O
and	O
serum	O
metabolome.	O

The	O
PhIP	O
sulfinamide	B
linkage	O
at	O
Cys_34	O
of	O
SA	O
undergoes	O
hydrolysis	O
to	O
produce	O
PhIP,	O
by	O
heat	O
and	O
treatment	O
with	O
DTT	O
during	O
the	O
denaturation	O
of	O
SA	O
(Peng,	O
L.,	O
unpublished	O
observations).	O

The	O
analysis	O
of	O
alpha-PEP	B
using	O
HILIC	O
and	O
negative	O
ionization	O
mode	O
revealed	O
three	O
significant	O
features.	O

At	O
enrolment,	O
high	O
density	O
lipoprotein	O
(HDL-C)	O
was	O
measured	O
in	O
EDTA	O
plasma	O
on	O
the	O
Roche/Hitachi	O
911	O
Automatic	O
Analyzer	O
(Roche	O
Diagnostics	O
Corporation,	O
Indianapolis,	O
IN),	O
and	O
low	O
density	O
lipoprotein	O
(LDL-C)	O
was	O
calculated	O
using	O
the	O
Friedewald	O
equation,	O
together	O
with	O
fasting	O
serum	O
glucose	B
using	O
the	O
glucose	B
oxidase	O
method	O
on	O
the	O
Vitros	O
analyzer	O
(Johnson	O
and	O
Johnson	O
Clinical	O
Diagnostics).	O

Phosphatidylcholines	B
and	O
sphingomyelins	B
are	O
the	O
main	O
phospholipids	B
in	O
mammalian	O
plasma	O
membranes	O
and	O
circulating	O
lipoproteins.	O

20	O
µL	O
of	O
DMSO,	B
instead	O
of	O
the	O
tested	O
compound,	O
was	O
added	O
to	O
the	O
negative	O
control	O
vials,	O
and	O
2	O
mL	O
of	O
the	O
sodium	B
phosphate	I
buffer,	O
instead	O
of	O
the	O
faecal	O
slurry,	O
was	O
added	O
to	O
the	O
positive	O
control	O
vials.	O

NMDA	O
receptor,	O
Cytokines,	O
ECT,	O
Quinolinic	B
acid,	I
Inflammation,	O
IL-6,	O
Kynurenic	B
acid,	I
Treatment-resistant	O
depression	O

HPLC	O
grade	O
2-propanol,	B
acetonitrile	B
and	O
water	O
were	O
used	O
for	O
metabolites	O
extraction.	O

Significant	O
differences	O
between	O
the	O
intake	O
of	O
the	O
three	O
foods	O
after	O
6	O
h	O
were	O
found	O
in	O
case	O
of	O
galactonate,	B
galactitol,	B
and	O
galactono-1,5-lactone	B
(see	O
Tables	O
S3	O
and	O
S4).	O

Trimethylsilylation	O
was	O
subsequently	O
performed	O
by	O
adding	O
50	O
μL	O
of	O
N-methyl-N-trimethylsilyl-trifluoroacetamide	B
(MSTFA+1%	O
TMCS,	O
Sigma-Aldrich),	O
incubating	O
for	O
1	O
h	O
at	O
65°C	O
and	O
centrifuged	O
at	O
13000	O
rpm	O
X	O
10	O
min	O
at	O
RT.	O

In	O
order	O
to	O
do	O
this,	O
we	O
first	O
measured	O
a	O
total	O
of	O
10	O
main	O
class	O
of	O
phospholipids	B
in	O
patients	O
and	O
cells.	O

In	O
the	O
current	O
study,	O
we	O
found	O
evidence	O
that	O
women	O
who	O
were	O
prenatally	O
exposed	O
to	O
DES	B
compared	O
with	O
those	O
who	O
were	O
not	O
had	O
less	O
metabolism	O
of	O
parent	O
estrogens	O
in	O
the	O
2	O
pathway;	O
this	O
association	O
remained	O
after	O
adjustment	O
for	O
total	O
estrogens	O
and	O
adjustment	O
for	O
some	O
other	O
factors	O
that	O
may	O
influence	O
estrogen	B
metabolism,	O
such	O
as	O
BMI,	O
parity,	O
years	O
since	O
menopause	O
or	O
recent	O
alcohol	O
use.	O

The	O
sample	O
(1	O
mL)	O
was	O
neutralized	O
to	O
pH	O
7	O
with	O
NH_4	O
OH	O
and	O
loaded	O
onto	O
an	O
Oasis	O
MAX	O
cartridge	O
(1	O
mL,	O
30	O
mg,	O
Waters)	O
previously	O
equilibrated	O
using	O
1	O
mL	O
MeOH,	B
and	O
1	O
mL	O
2%	O
aqueous	O
NH_4	O
OH.	O

MS,	O
we	O
rapidly	O
detect	O
the	O
tumor	O
metabolite	O
2-hydroxyglutarate	B
(2-HG)	O
from	O
tissue	O
sections	O
of	O
surgically	O
resected	O
gliomas,	O
under	O
ambient	O
conditions	O
and	O
without	O
complex	O
or	O
time-consuming	O
preparation.	O

CSF	O
samples	O
were	O
thawed	O
on	O
ice	O
and	O
100 µL	O
was	O
mixed	O
with	O
410 µL	O
ice-cold	O
methanol	B
(MeOH)	O
supplemented	O
with	O
internal	O
standards	O
at	O
a	O
final	O
concentration	O
of	O
0.25 µM.	O
The	O
samples	O
were	O
vortexed	O
for	O
15 s	O
and	O
incubated	O
at	O
−20 °C	O
for	O
30 minutes,	O
followed	O
by	O
centrifugation	O
at	O
20400 g	O
for	O
12 minutes	O
at	O
4 °C.	O

The	O
difference	O
of	O
unit	O
mass	O
between	O
the	O
fragment	O
ions	O
of	O
m/z	O
250/251	O
and	O
m/z	O
280/281	O
between	O
methoxy	B
and	O
hydroxy	B
metabolites	O
respectively	O
suggests	O
a	O
block	O
to	O
proton	O
migration	O
from	O
the	O
2′	O
or	O
4’	O
position	O
of	O
estrogen	B
due	O
to	O
the	O
methylated	O
group.	O

Three	O
specific	O
amino	O
acids,	O
leucine/isoleucine	O
and	O
valine,	B
play	O
a	O
role	O
in	O
IR	O
hypogonadism.	O

Subjects	O
exhibited	O
a	O
broad	O
range	O
in	O
BMI	O
(19.81–30.25 kg/m_2	O
)	O
and	O
waist	O
circumference	O
(24.5–43.0	O
in),	O
and	O
ranged	O
from	O
normal	O
to	O
hypertriglyceridemic	B
(fasting	O
triglycerides	B
30–279 mg/dl).	O

The	O
items	O
that	O
cluster	O
on	O
the	O
same	O
components	O
suggest	O
that	O
component	O
1	O
(IL-1RA,	O
QA,	O
and	O
KYN)	O
represents	O
inflammation-related	O
activation	O
of	O
the	O
QA	O
branch	O
of	O
the	O
kynurenine	B
pathway.	O

Thus,	O
these	O
changed	O
carnitine	B
esters	I
might	O
mirror	O
the	O
impaired	O
mitochondrial	O
oxidation	O
functions.	O

Sabatine	B
et	O
al.	O
published	O
the	O
earliest	O
report	O
on	O
metabolomic	O
analysis	O
of	O
patients	O
undergoing	O
cardiac	O
stress	O
testing.	O

Purification	O
of	O
the	O
intermediate	O
was	O
achieved	O
using	O
methanol	B
as	O
a	O
solvent	O
for	O
recrystallization	O
method	O
and	O
the	O
yield	O
obtained	O
was	O
found	O
to	O
be	O
66%.	O

Alb	O
is	O
critical	O
for	O
maintaining	O
colloidal	O
osmotic	O
pressure	O
and	O
reversibly	O
binds	O
hormones,	O
nonesterified	O
long	O
chain	O
fatty	O
acids,	O
cholesterol,	B
billirubin,	O
hemin,	O
and	O
many	O
xenobiotic	O
compounds,	O
including	O
therapeutic	O
drugs._,	O
Many	O
commonly	O
used	O
drugs	O
contain	O
acidic	O
or	O
basic	O
functional	O
groups,	O
such	O
as	O
warfarin,	O
diazepam,	B
and	O
ibuprofen.	B

The	O
residue	O
was	O
transferred	O
to	O
a	O
0.25	O
mL	O
autosampler	O
vial	O
with	O
2	O
×	O
80	O
µL	O
of	O
80:20	O
acetonitrile:	O
MeOH,	B
and	O
the	O
solvents	O
were	O
removed	O
on	O
the	O
Speed-Vac.	O

Finally,	O
lysophosphatidylcholine	B
inhibits	O
nitric	B
oxide	I
production	O
in	O
macrophages	O
stimulated	O
by	O
T.	O
cruzi	O
and	O
thus	O
interferes	O
with	O
the	O
immune	O
system	O
of	O
the	O
vertebrate	O
host	O
.	O

There	O
was	O
a	O
significant	O
inverse	O
relationship	O
between	O
urinary	O
3-HPMA	O
and	O
α-hydroxy-PdG	B
(3)	O
but	O
not	O
γ-hydroxy-PdG	B
(4)	O
or	O
total	O
adduct	O
levels.	O

Additionally,	O
sarcosine	B
levels	O
correlated	O
well	O
with	O
cell	O
invasiveness	O
(Spearman’s	O
correlation	O
coefficient:	O
0.943,	O
P	O
=0.0048).	O

Urine	O
hippurate	B
levels,	O
along	O
with	O
other	O
putative	O
metabolites	O
of	O
microbial	O
origin	O
such	O
as	O
indolepropionate	B
(plasma)	O
or	O
2-methylhippurate	B
(urine),	O
were	O
inversely	O
associated	O
with	O
VAT	O
consistently	O
in	O
both	O
sexes.	O

Metabolites	O
were	O
composed	O
of	O
67	O
Glycerophospholipids	B
(GPs),	O
12	O
Acylcarnitines	B
(ACs),	O
10	O
Sphingolipids	B
(SGs)	O
and	O
6	O
amino	O
acids	O
(AA).	O

The	O
40	O
analytes	O
included	O
the	O
androgens	O
androstenedione	B
and	O
testosterone;	B
the	O
estrogens	O
E_1	O
sulfate,	B
E_1	O
and	O
E_2	O
;	O
the	O
catechol	B
estrogens	O
2-OHE_1	O
(E_2	O
)	O
and	O
4-OHE_1	O
(E_2	O
);	O
the	O
16α-OHE_1	B
(E_2	O
);	O
the	O
methylated	O
2-	O
and	O
4-catechol	B
estrogens;	O
the	O
2-	O
and	O
4-catechol	B
estrogens	O
conjugated	O
with	O
GSH,	B
cysteine	B
(Cys)	O
or	O
N	B
-acetylcys-teine	I
(NAcCys);	O
and	O
the	O
depurinating	O
DNA	O
adducts	O
of	O
4-OHE_1	O
(E_2	O
)	O
and	O
2-OHE_1	O
(E_2	O
).	O

The	O
specific	O
multiple	O
reaction	O
monitoring	O
transitions	O
employed	O
for	O
38	O
eicosanoids	B
and	O
10	O
deuterated	O
internal	O
standards,	O
together	O
with	O
their	O
retention	O
times,	O
are	O
given	O
in	O
Supplemental	O
Table	O
.	O

For	O
the	O
crystal	O
violet	O
staining	O
cell	O
proliferation	O
assay,	O
cells	O
were	O
stained	O
with	O
0.5%	O
crystal	O
violet	O
(Sigma-Aldrich	O
Corp.,	O
St.	O
Louis,	O
MO,	O
USA)	O
in	O
30%	O
ethanol	B
for	O
10 minutes	O
at	O
room	O
temperature.	O

The	O
most	O
characteristic	O
indication	O
for	O
tumor-associated	O
alterations	O
in	O
the	O
reaction	O
of	O
SAM-induced	O
carboxyaminopropyltransfer	B
and	O
SAM-induced	O
methyltransfer	B
is	O
reflected	O
by	O
feature	O
combination	O
7	O
(acp_3	O
U/m_3	O
U).	O

Urinary	O
creatinine	B
is	O
considered	O
as	O
a	O
“house-keeping	O
metabolite”,	O
integrals	O
of	O
bins	O
in	O
every	O
sample	O
were	O
subtracted	O
by	O
the	O
level	O
of	O
bin	O
including	O
the	O
urinary	O
creatinine.	B

Excluding	O
the	O
ACS	O
classification	O
risk,	O
only	O
low-risk	O
patients	O
show	O
significant	O
differences	O
in	O
the	O
connectivity	O
of	O
mannose:	B
we	O
observed	O
a	O
progressive	O
decrease	O
of	O
the	O
connectivity	O
of	O
mannose	B
with	O
BCAA,	O
alanine,	B
creatinine,	B
and	O
acetone	B
going	O
from	O
survivor	O
low-risk	O
patients	O
to	O
high-risk	O
ones	O
to	O
low-risk	O
deceased	O
and	O
finally	O
to	O
high-risk	O
deceased	O
patients.	O

Similarly,	O
after	O
3	O
years	O
the	O
overweight	O
group	O
showed	O
higher	O
BMI,	O
waist	O
circumference,	O
systolic	O
and	O
diastolic	O
blood	O
pressure	O
(SBP	O
and	O
DBP),	O
triglyceride,	B
FFA,	O
glucose,	B
insulin,	O
HOMA-IR,	O
and	O
ba-PWV,	O
and	O
lower	O
HDL-cholesterol	B
than	O
controls.	O

It	O
is	O
tempting	O
to	O
speculate	O
that	O
similar	O
mechanisms	O
may	O
be	O
involved	O
here;	O
whereas	O
an	O
overexposure	O
to	O
glucocorticoids	B
is	O
involved	O
in	O
chronic	O
stress,	O
it	O
may	O
as	O
well	O
play	O
an	O
important	O
role	O
in	O
this	O
clinical	O
subform	O
of	O
IUGR.	O

Urinary	O
concentrations	O
of	O
the	O
conjugated	O
metabolites	O
of	O
α-tocopherol	B
(nmol/mmol	O
creatinine).	O

The	O
standard	O
L-1,2,3,4-Tetrahydro-beta-carboline-3-carboxylic	B
acid	I
is	O
listed	O
as	O
“cyclomethyltryptophan.”	B

Pulverized	O
and	O
lyophilized	O
lung	O
tissues	O
were	O
extracted	O
twice	O
in	O
chloroform:methanol	O
(2:1)	O
plus	O
1	O
mM	O
butylated	B
hydroxytoluene	I
to	O
remove	O
lipids,	O
which	O
interfered	O
with	O
the	O
extraction	O
of	O
PC.	O

Participants	O
were	O
instructed	O
to	O
refrain	O
from	O
exercise	O
and	O
alcohol	O
consumption	O
for	O
the	O
preceding	O
48	O
h	O
from	O
caffeine	B
consumption	O
for	O
a	O
minimum	O
of	O
12	O
h.	O

Metabolite	O
abnormalities:	O
Creatinine	B
(1	O
and	O
2),	O
1-methylhistidine	B
(3),	O
3-methylhistidine	B
(4),	O
myo	O
-Inositol	O
(5),	O
trimethylamine	B
N	I
-oxide	I
(6),	O
dimethyl	B
sulphone	I
(7),	O
N,N	B
-dimethylglycine	I

Compounds	O
were	O
analysed	O
on	O
a	O
fully-porous	O
3.00 × 100 mm,	O
1.7 μm	O
ACQUITY	O
UPC_2	O
BEH	O
2-ethylpyridine	B
(BEH	O
2-EP)	O
column	O
maintained	O
at	O
35 °C,	O
using	O
a	O
mobile	O
phase	O
composed	O
of	O
CO_2	O
(solvent	O
A)	O
and	O
the	O
selected	O
organic	O
modifier	O
(solvent	O
B)	O
with	O
the	O
following	O
14.65 min	O
gradient	O
elution	O
method:	O
the	O
mobile	O
phase	O
composition	O
changed	O
from	O
98%	O

CV1	O
and	O
CV2	O
were	O
determined	O
for	O
a	O
urine	O
volume	O
of	O
1.5	O
mL.	O
OH:	O
hydroxy,	B
DH:	O
dihydro,	B
TH:	O
tetrahydro.	B

The	O
second	O
reaction	O
was	O
conducted	O
in	O
a	O
glass	O
tube	O
for	O
24h	O
at	O
37	O
°C	O
and	O
contained	O
200	O
mM	O
sodium	B
acetate,	I
pH	O
5.0,	O
200	O
pg	B
of	O
[_13	O
C_3	O
]-T/-DHT,	O
90U	O
of	O
E.	O
coli	O
β-glucuronidase,	O
30U	O
of	O
Abalone	O
entrails	O
sulfatase	O
and	O
1	O
μL	O
of	O
the	O
aqueous	O
fraction,	O
a	O
fresh	O
aliquot	O
of	O
30	O
U	O
of	O
Abalone	O
entrails	O
sulfatase	O
was	O
added	O
at	O
the	O
12	O
h	O
time	O
point.	O

Identification	O
of	O
glyceric	B
acid	I
with	O
the	O
COLMARm	O
web	O
server	O
by	O
uploading	O
(A)	O
HSQC,	O
(B)	O
TOCSY	O
and	O
(C)	O
HSQC-TOCSY	O
of	O
human	O
serum	O
as	O
input.	O

50	O
μL	O
serum	O
was	O
spiked	O
with	O
1	O
pmol	O
of	O
isotope	O
labeled	O
internal	O
standards,	O
extracted	O
by	O
1	O
mL	O
chilled	O
methanol,	B
vortexed	O
and	O
incubated	O
for	O
10	O
min	O
on	O
ice.	O

N-Acetylaspartic	B
acid	I
is	O
synthesized	O
from	O
Aspartate	B
and	O
Acetyl-CoA	B
and	O
via	O
hydrolysis	O
of	O
N-Acetyl-aspartylglutamate.	B

The	O
changes	O
in	O
lysophosphatidylcholine	B
(lysoPC)	O
16:0	O
levels	O
were	O
positively	O
related	O
to	O
those	O
of	O
lysoPC	O
15:0	O
(r	O
=	O
0.90,	O
P	O
<	O
0.001)	O
and	O
lysoPC	O
18:0	O
(r	O
=	O
0.76,	O
P	O
<	O
0.001),	O
while	O
that	O
of	O
lysoPC	O
18:0	O
was	O
closely	O
related	O
to	O
that	O
of	O
lysoPC	O
15:0	O
(r	O
=	O
0.77,	O
P	O
<	O
0.001).	O

A	O
recent	O
study	O
has	O
reported	O
that	O
p,p’	O
-DDT	O
and	O
its	O
most	O
persistent	O
metabolite,	O
dichlorodiphenyldichloroethylene	B
(p,p’	O
-DDE),	O
may	O
also	O
be	O
associated	O
with	O
HCC	O
in	O
humans.	O

At	O
V2,	O
hypoxanthine	B
(p	O
=	O
0.0210)	O
showed	O
significantly	O
different	O
urinary	O
concentrations	O
between	O
the	O
EG	O
and	O
the	O
CG,	O
whereas	O
at	O
V3,	O
urinary	O
concentrations	O
of	O
betaine	B
(p	O
=	O
0.0055),	O
hypoxanthine	B
(p	O
=	O
0.0006)	O
and	O
isoleucine	B
(p	O
=	O
0.0285)	O
significantly	O
differed	O
between	O
both	O
groups.	O

SMs	O
species	O
are	O
important	O
cellular	O
membrane	O
constituents	O
which	O
are	O
tightly	O
associated	O
with	O
cholesterol	B
in	O
construction,	O
metabolism	O
and	O
transport,	O
and	O
which	O
are	O
enriched	O
in	O
lipid	O
rafts.	O

Choline	B
allows	O
discriminating	O
between	O
G4	O
and	O
G0	O
groups:	O
patients	O
with	O
cirrhosis	O
significantly	O
show	O
lower	O
choline	B
signal	O
than	O
patients	O
in	O
the	O
G0	O
group.	O

In	O
the	O
present	O
work	O
we	O
have	O
evaluated	O
whether	O
a	O
metabolomics	O
approach	O
by	O
_1	O
H	O
NMR	O
can	O
discriminate	O
between	O
HCV	O
patients	O
with	O
advanced	O
LF	B
(group	O
G4)	O
and	O
those	O
with	O
no	O
signs	O
of	O
LF	B
(group	O
G0).	O

The	O
CKD-EPI	O
(CKD	O
Epidemiology	O
Collaboration)	O
equation	O
was	O
used	O
to	O
estimate	O
GFR	O
from	O
serum	O
creatinine	B
and	O
demographic	O
variables.	O

Aerobic	O
Exercise,	O
Estrogen	B
Metabolism,	O
Randomized	O
Clinical	O
Trial,	O
Breast	O
Cancer	O
Risk	O

These	O
results	O
show	O
similar	O
changes	O
in	O
these	O
metabolites	O
(increase	O
or	O
decrease)	O
in	O
both	O
studies	O
with	O
the	O
exception	O
of	O
glutamic	B
acid,	I
which	O
shows	O
an	O
increase	O
in	O
Study	O
1	O
and	O
a	O
decrease	O
in	O
Study	O
2.	O

Because	O
of	O
the	O
observations	O
above	O
of	O
very	O
low	O
24:0	O
and	O
24:1	O
fatty	O
acids	O
in	O
HCC	O
and	O
AML,	O
it	O
was	O
decided	O
to	O
profile	O
the	O
corresponding	O
LPC	O
of	O
24:0,	O
LPC(24:0)	B
by	O
UPLC-ESI-TQMS.	O

Initial	O
lactate	B
levels	O
are	O
a	O
useful	O
biochemical	O
marker	O
to	O
assess	O
the	O
degree	O
of	O
birth	O
asphyxia.	O

Moreover,	O
the	O
high-resolution	O
spectrum	O
revealed	O
_13	O
C	O
coupling	O
patterns	O
of	O
βG6P	O
carbons,	O
i.e.	O
doublet	O
for	O
C1,	O
triplet	O
for	O
C3-5,	O
as	O
well	O
as	O
doublet	O
for	O
C6,	O
which	O
indicate	O
the	O
presence	O
of	O
uniformly	O
labeled	O
βG6P	O
and	O
thus	O
its	O
origin	O
from	O
[U-_13	B
C]-glucose.	I

It	O
provides	O
protection	O
against	O
cellular	O
stress	O
and	O
converts	O
haem	B
into	O
carbon	B
monoxide,	I
free	O
iron	O
and	O
biliverdin,	B
the	O
latter	O
of	O
which	O
that	O
is	O
later	O
converted	O
to	O
potent	O
antioxidant	O
bilirubin.	B

Box	O
plots	O
of	O
concentrations	O
for	O
urinary	O
estrogens	O
and	O
estrogen	B
metabolites	O
(EM)	O
in	O
urine	O
(y	O
axis)	O
for	O
10	O
premenopausal	O
follicular	O
phase	O
women,	O
10	O
premenopausal	O
luteal	O
phase	O
women,	O
15	O
postmenopausal	O
women,	O
and	O
10	O
men	O
(x	O
axis).	O

In	O
tumor	O
cells,	O
an	O
excessive	O
increase	O
in	O
plasma	O
choline	B
levels	O
in	O
patients	O
with	O
breast	O
cancer	O
was	O
also	O
shown	O
(Katz-Brull	O
et	O
al.	O
).	O

It	O
is	O
generally	O
believed	O
that	O
the	O
dysfunction	O
of	O
serotonergic	O
system	O
contributes	O
to	O
the	O
development	O
of	O
depression,	O
and	O
the	O
synthesis	O
of	O
serotonin	B
in	O
the	O
CNS	O
is	O
dependent	O
on	O
the	O
utilization	O
of	O
tryptophan—the	O
biochemical	O
precursor	O
of	O
serotonin—from	O
plasma	O
to	O
brain.	O

If	O
these	O
ratios	O
of	O
estrogen	B
metabolism	O
pathways	O
are	O
confirmed	O
as	O
predictors	O
of	O
breast	O
cancer	O
risk,	O
they	O
might	O
provide	O
clues	O
to	O
mechanisms	O
of	O
breast	O
carcinogenesis	O
and	O
suggest	O
targets	O
for	O
preventive	O
interventions.	O

[more	O
commonly	O
known	O
as	O
bis(monoacylglycerol)phosphate	B
(BMP)],	O
a	O
structural	O
isomer	O
of	O
PG	B
since	O
PG	B
and	O
BMP	O
lipids	O
have	O
very	O
similar	O
tandem	O
mass	O
spectra.	O

HbA_1c	O
was	O
measured	O
twice	O
during	O
the	O
last	O
week	O
of	O
pioglitazone	B
treatment.	O

Changes	O
in	O
several	O
metabolite	O
modules,	O
containing	O
primarily	O
short-chain	O
acylcarnitines	B
and	O
α-aminoadipic	B
acid	I
(purple	O
module)	O
as	O
well	O
as	O
branched-chain	O
and	O
neurotransmitter-related	O
amino	O
acids	O
(yellow	O
module)	O
and	O
lipids	O
(green-yellow	O
module),	O
were	O
significantly	O
associated	O
with	O
changes	O
in	O
depressive	O
symptom	O
severity	O
over	O
the	O
12-weeks	O
of	O
CBT	O
treatment.	O

During	O
the	O
method	O
validation,	O
a	O
partially	O
co-eluting	O
interference	O
affecting	O
4-hydroxyphenanthrene	B
was	O
present	O
in	O
certain	O
urine	O
samples.	O

Surprisingly,	O
however,	O
although	O
we	O
identified	O
an	O
increase	O
in	O
lactate	B
in	O
postmortem	O
brain	O
tissue,	O
we	O
observed	O
a	O
significant	O
decrease	O
in	O
CSF	O
lactate	B
levels	O
in	O
patients	O
with	O
first-onset	O
schizophrenia.	O

Serum	O
non‐esterified	O
free	O
FA	B
(NEFA)	O
were	O
measured.	O

Those	O
significant	O
metabolites	O
are	O
the	O
compounds	O
whose	O
change	O
is	O
associated	O
with	O
statin	B
response	O
of	O
LDL-C.	O
For	O
predicting	O
response	O
of	O
LDL-C	O
to	O
simvastatin,	B
baseline	O
metabolite	O
levels	O
were	O
correlated	O
with	O
statin	B
response	O
of	O
LDL-C	O
by	O
calculating	O
their	O
Spearman’s	O
correlation	O
coefficients	O
with	O
post-treatment	O
level	O
of	O
LDL-C,	O
adjusting	O
for	O
pre-treatment	O
level	O
of	O
LDL-C	O
using	O
the	O
same	O
aforementioned	O
method.	O

Both	O
ceramides	B
and	O
their	O
salvage	O
precursor	O
sphingomyelins	B
(SMs)	O
were	O
increased.	O

A	O
similar	O
reduction	O
in	O
acyl	B
carnitine	I
metabolites	O
was	O
found	O
in	O
low-grade	O
NMIBC	O
samples	O
compared	O
to	O
the	O
control	O
group.	O

3-indoxyl	B
sulfate	I
is	O
a	O
metabolite	O
of	O
dietary	O
tryptophan.	B

This	O
is	O
in	O
distinction	O
to	O
the	O
observed	O
changes	O
in	O
e.g.	O
(b)	O
purine	B
metabolites,	O
(c)	O
tryptophan	O
hydrolase	O
metabolites,	O
(d)	O
aminoisobutyric	B
acid,	I
or	O
(e)	O
the	O
bile	O
acids.	O

Recently,	O
linoleate	B
induction	O
of	O
cytokine	O
expression	O
by	O
monocytes	O
has	O
been	O
reported.	O

Alternatively,	O
the	O
SGGP1	O
genetic	O
variant	O
(rs7157785)	O
has	O
also	O
been	O
associated	O
with	O
sphingomyelin	B
14:0	I
in	O
a	O
separate	O
study.	O

Tested	O
against	O
DBP	B
response	O
in	O
the	O
GERA	O
study.	O

Intestinal	O
barrier	O
damage	O
was	O
diagnosed	O
based	O
on	O
IP	B
assessed	O
by	O
HPLC	O
analysis	O
of	O
lactulose	B
and	O
mannitol	B
urinary	O
values	O
5	O
h	O
after	O
sugar	O
ingestion	O
in	O
fasting	O
children.	O

Moriyama et al	O
.	O
also	O
compared	O
the	O
intracellular	O
levels	O
of	O
thioguanine	B
incorporated	O
into	O
DNA	O
in	O
NUDT15	O
-knockdown	O
and	O
control	O
human	O
lymphoid	O
cells	O
and	O
demonstrated	O
the	O
accumulation	O
of	O
active	O
metabolites	O
in	O
NUDT15	O
-knockdown	O
cells,	O
which	O
indicate	O
the	O
role	O
of	O
NUDT15	O
in	O
inactivating	O
thiopurine	B
metabolites	O
and	O
leading	O
to	O
the	O
postulation	O
that	O
NUDT15	O
modulates	O
thiopurine-induced	O
myelosuppression	O
via	O
accumulation	O
of	O
6-TGN.	O

With	O
GC-MS	O
it	O
has	O
often	O
been	O
noted	O
that	O
L-cystine	B
can	O
be	O
converted	O
to	O
L-cysteine	B
during	O
derivatization,	O
while	O
L-cysteine	B
might	O
be	O
oxidized	O
to	O
L-cystine	B
during	O
prolonged	O
storage	O
of	O
the	O
standard	O
solution	O
,	O
confounding	O
the	O
identification	O
of	O
L-cystine	B
and	O
L-cysteine.	B

*p<0.05,	O
versus	O
monocyclic	B
systemic	O
pattern	O
or	O
polycyclic	B
systemic	O
pattern.	O

The	O
caffeine	B
peak	O
eluted	O
relatively	O
early	O
in	O
all	O
conditions,	O
when	O
the	O
mobile	O
phase	O
consisted	O
predominantly	O
of	O
CO_2	O
(rather	O
than	O
the	O
organic	O
modifier).	O

For	O
instance,	O
a	O
stable	O
isotopic	O
plateau	O
was	O
not	O
attained	O
in	O
all	O
PH	O
patients,	O
and	O
the	O
rate	O
of	O
appearance	O
of	O
oxalate	B
was	O
higher	O
than	O
expected	O
and	O
did	O
not	O
match	O
24-h	O
oxalate	B
excretion	O
rates	O
in	O
the	O
healthy	O
volunteers.	O

Acetamide	B
is	O
the	O
amide	B
of	O
acetic	B
acid.	I

Stock	O
solutions	O
for	O
native	O
acetamiprid,	B
N-desmethyl-acetamiprid,	B
clothianidin,	B
imidacloprid,	O
and	O
thiacloprid	B
were	O
purchased	O
as	O
certified	O
solutions	O
at	O
1	O
mg/mL	O
in	O
acetonitrile,	B
except	O
imidacloprid	O
which	O
was	O
in	O
acetone.	B

However,	O
the	O
difference	O
we	O
found	O
in	O
GM3	B
concentration	O
between	O
PD	O
and	O
control	O
is	O
14.5%.	O

However,	O
both	O
caffeine	B
and	O
theophylline	B
were	O
measured	O
as	O
part	O
of	O
the	O
metabolomic	O
profile,	O
and	O
neither	O
changed	O
with	O
β-carotene	B
supplementation	O
(caffeine:	O
P	O
=	O
0.75;	O
theophylline:	B
P	O
=	O
0.33;	O
see	O
Supplemental	O
Table	O
1	O
under	O
“Supplemental	O
data”	O
in	O
the	O
online	O
issue).	O

A	O
Wilcoxon	O
rank	O
sum	O
test	O
was	O
performed	O
to	O
compare	O
creatinine	B
values	O
between	O
the	O
respective	O
groups	O
as	O
these	O
values	O
were	O
not	O
normally	O
distributed	O
within	O
the	O
groups.	O

The	O
influence	O
of	O
intramuscular	O
4-hydroxyandrostenedione	B
on	O
peripheral	O
aromatisation	O
in	O
breast	O
cancer	O
patients.	O

(R)-3-Hydroxybutyric	B
acid	I
is	O
very	O
important	O
in	O
butanoate	B
metabolism.	O

methanol	B
final	O
proportion	O
1:2).	O

Chromatograms	O
of	O
SRM	O
972	O
Level	O
3	O
obtained	O
with	O
the	O
SB-CN	O
column	O
and	O
isocratic	O
elution	O
with	O
68%	O
methanol,	B
32%	O
water	O
(volume	O
fractions)	O
and	O
a	O
column	O
temperature	O
of	O
45	O
°C.	O

We	O
are	O
not	O
aware	O
of	O
a	O
derivatization	O
technique	O
that	O
provides	O
a	O
pre-ionized	O
derivative	O
of	O
estradiol	B
in	O
a	O
single	O
step.	O

As	O
a	O
result,	O
the	O
lipid	O
metabolite	O
profile	O
was	O
restricted	O
to	O
a	O
total	O
of	O
104	O
metabolites	O
(7	O
acylcarnitines,	B
15	O
sphingolipids	B
and	O
81	O
glycerophospholipids)	B
(Online	O
Resource).	O

6d,	O
JWH-210	B
5-hydroxyindole;	I
6e,	O
JWH-210	O
pentanoic	B
acid;	I
7a,	O
JWH-250;	O
7b,	O
JWH-250	O
5-hydroxypentyl;	O
7c,	O
JWH-250	O
4-hydroxypentyl;	O
7d,	O
JWH-250	B
5-hydroxyindole;	I
7e,	O
JWH-250	O
pentanoic	B
acid;	I
8a,	O
RCS-4;	O
8b,	O
RCS-4	O
5-hydroxypentyl;	O
8c,	O
RCS-4	O
pentanoic	B
acid;	I
9a,	O
AM2201;	O
9b,	O
AM2201	O
4-hydroxypentyl;	O
9c,	O
AM2201	O
6-ydroxyindole;	O
10a,	O
MAM2201.	O

Changes	O
detected	O
in	O
gamma‐glutamyl	O
amino	O
acid	O
levels	O
suggest	O
an	O
alteration	O
in	O
the	O
levels	O
of	O
glutathione.	B

Urinary	O
creatinine	B
levels	O
were	O
measured	O
by	O
spectrophotometric	O
methods,	O
with	O
picric	O
acid	O
as	O
a	O
reactive	O
compound	O
for	O
reading	O
at	O
520	O
nm	O
measurement	O
(Beckman;	O
DXC	O
800).	O

Likewise,	O
5-acetyl-2-methoxy-1,4,6-trihydroxy-anthraquinone	B
(81),	O
isolated	O
from	O
the	O
culture	O
of	O
the	O
endophytic	O
fungus	O
Fusarium	O
sp.	B

Here	O
we	O
showed	O
that	O
in	O
NR	O
patients	O
specific	O
lysophosphatidylcholines	B
species	O
(lysoPC	O
C16:0,	B
C16:1,	B
C18:0,	B
C18:1,	B
C18:2,	B
C20:3)	B
did	O
not	O
significantly	O
change	O
from	O
T1	O
and	O
T2,	O
whereas	O
in	O
R	O
patients	O
they	O
significantly	O
increased	O
and	O
were	O
markedly	O
higher	O
than	O
in	O
NR	O
at	O
T2	O
(see	O
Fig.	O

Levels	O
of	O
high-density	O
lipoprotein	O
(HDL)	O
in	O
serum	O
samples	O
of	O
So-Eum	O
type	O
were	O
higher	O
than	O
those	O
in	O
Tae-Eum	O
type	O
whereas	O
levels	O
of	O
lactate,	B
fatty	O
acids	O
(FAs),	O
and	O
low-density	O
lipoprotein	O
(LDL)	O
were	O
lower	O
in	O
serum	O
samples	O
of	O
So-Eum	O
type	O
(see	O
).	O

Plot	O
of	O
the	O
reproducibility	O
of	O
determining	O
spike-in	O
fold	O
changes	O
for	O
taurine	B
from	O
the	O
Latin-square	O
spike-in	O
dataset	O
without	O
normalization	O
(upper	O
left	O
),	O
after	O
Cyclic	O
Loess	O
(upper	O
right	O
),	O
Quantile	O
(lower	O
left	O
)	O
and	O
Li-Wong	O
Normalization	O
(lower	O
right	O
).	O

Treatment	O
of	O
urine	O
with	O
methoxyamine	B
led	O
to	O
the	O
disappearance	O
of	O
the	O
m/z	O
373	O
metabolite	O
and	O
the	O
formation	O
of	O
a	O
new	O
compound	O
with	O
a	O
molecular	O
ion	O
(m/z	O
402)	O
and	O
retention	O
time	O
similar	O
to	O
the	O
synthetic	O
standard	O
for	O
11	O
(,	O
).	O

The	O
fragmentation	O
patterns	O
were	O
matched	O
with	O
the	O
fragmentation	O
patterns	O
of	O
standard	O
E_1	B
-9-N-Ade	I
and	O
E_2	B
-9-N-Ade	I
(	O
&	O
,	O
insets).	O

Of	O
the	O
33	O
SM	O
species	O
tested,	O
we	O
found	O
that	O
8	O
SM	O
molecular	O
species,	O
particularly	O
those	O
containing	O
long	O
aliphatic	B
chains	O
such	O
as	O
22	O
and	O
24	O
carbon	O
atoms,	O
were	O
significantly	O
lower	O
(p	O
<0.05)	O
in	O
AD	O
patients	O
as	O
compared	O
to	O
the	O
age-matched	O
cognitively	O
normal	O
controls.	O

The	O
specimens	O
were	O
thawed	O
at	O
room	O
temperature,	O
methanol	B
was	O
added	O
to	O
the	O
serum	O
samples	O
according	O
to	O
the	O
ratio	O
1:3	O
(200:600	O
µl).	O

Moreover,	O
in	O
the	O
unmatched	O
disease	O
model,	O
from	O
the	O
21	O
variables	O
that	O
showed	O
to	O
be	O
significant	O
(P 	O
< 	O
0.05)	O
after	O
the	O
BH‐FDR	O
correction,	O
only	O
two	O
(VOC_2	O
and	O
1,1,6‐trimethyl‐1,2‐dihydronaphthalene)	B
with	O
possible	O
bias	O
from	O
the	O
age	O
model	O
were	O
present.	O

The	O
positive	O
association	O
of	O
tyrosine	B
concentration	O
with	O
ppBMI	O
seen	O
in	O
Guatemala	O
was	O
replicated	O
(P	O
 = 0.0167);	O
isoleucine	B
was	O
positively	O
associated	O
with	O
ppBMI	O
(P	O
 = 0.0014)	O
in	O
Pakistan	O
but	O
not	O
in	O
Guatemala.	O

Therefore,	O
the	O
ratio	O
between	O
medium-chain	O
(MC)	O
and	O
long-chain	O
acylcarnitines	B
(LC)	O
may	O
be	O
used	O
as	O
an	O
indicator	O
of	O
FA	B
catabolism.	O

In	O
this	O
metabolomics	O
analysis	O
of	O
participants	O
from	O
a	O
large,	O
randomized	O
trial	O
of	O
male	O
smokers,	O
we	O
found	O
that	O
the	O
metabolomic	O
profiles	O
of	O
response	O
to	O
β-carotene	B
supplementation	O
point	O
to	O
induction	O
of	O
CYP1A2	O
and	O
CYP2E1	O
and,	O
possibly,	O
to	O
dysregulated	O
glycemic	B
control.	O

To	O
prove	O
whether	O
storage	O
under	O
the	O
above	O
mentioned	O
conditions	O
leads	O
to	O
a	O
measurable	O
amount	O
of	O
CO_2	O
or	O
hydrogen	B
carbonate	I
in	O
the	O
solution,	O
we	O
employed	O
infrared	O
spectroscopy.	O

The	O
UV	O
spectrum	O
of	O
human	O
SA	O
modified	O
with	O
N	B
-acetoxy-PhIP	I
displays	O
a	O
maximum	O
at	O
320	O
–	O
325	O
nm,	O
whereas	O
non-modified	O
SA	O
does	O
not	O
possess	O
a	O
chromophore	O
around	O
these	O
wavelengths.	O

One	O
subtype	O
identified	O
contained	O
metabolites	O
enriched	O
in	O
citric	B
acid	I
cycle	O
components.	O

Four	O
differentially	O
expressed	O
metabolites	O
including	O
2-indolecarboxylic	B
acid,	I
hypotaurine	B
(HTAU),	O
pipecolic	B
acid,	I
and	O
progesterone	B
between	O
DM	O
patients	O
with	O
excess	O
and	O
deficiency	O
syndrome	O
were	O
found.	O

Briefly,	O
50 µl	O
of	O
samples	O
and	O
standards	O
were	O
added	O
to	O
96-well	O
plates	O
containing	O
the	O
ATP	B
reaction	O
mix	O
and	O
incubated	O
at	O
room	O
temperature	O
in	O
the	O
dark	O
for	O
30 min.	O

The	O
serum	O
levels	O
of	O
fumaric	B
acid	I
at	O
an	O
early	O
stage	O
of	O
sepsis	O
were	O
less	O
than	O
10	O
µM	O
and,	O
in	O
most	O
cases	O
(in	O
44	O
samples,	O
92%),	O
did	O
not	O
exceed	O
4.4	O
µM.	O
The	O
correlation	O
between	O
the	O
concentration	O
of	O
succinic	B
acid	I
and	O
the	O
SOFA	O
score	O
(r	O
=	O
0.38)	O
was	O
revealed.	O

In	O
the	O
present	O
study,	O
we	O
used	O
a	O
targeted	O
mass	O
spectrometry-based	O
quantitative	O
metabolomics	O
approach	O
focusing	O
our	O
attention	O
on	O
several	O
series	O
of	O
metabolites,	O
such	O
as	O
glycerophospholipids,	B
aminoacids,	B
biogenic	O
amines	O
and	O
acylcarnitines,	B
some	O
of	O
which	O
have	O
already	O
been	O
identified	O
as	O
part	O
of	O
key	O
biochemical	O
pathways	O
in	O
septic	O
shock.	O

Role	O
of	O
vitamin	O
B-12	O
in	O
the	O
mitochondria	O
(acyl-CoA	O
utilization).	O

It	O
is	O
not	O
so	O
easy	O
to	O
understand	O
why	O
tGlut,	O
a	O
substrate	O
of	O
both	O
pathways,	O
should	O
be	O
positively	O
correlated	O
with	O
one	O
product,	O
lactate,	B
and	O
negatively	O
correlated	O
with	O
the	O
other,	O
fatty	O
acids.	O

MS/MS	O
fragmentation	O
of	O
PC(40:7)	B
lead	O
to	O
its	O
identification	O
as	O
PC(18:1/22:6)	B
based	O
on	O
the	O
fragment	O
ions	O
550.3	O
([M+Li-R1′CHCO]+)	O
and	O
556.3	O
([M+Li-R1CO2Li]+).	O

Lysolipids	O
are	O
very	O
abundant	O
in	O
plasma	O
and	O
Lyso-PC	B
16:0	I
was	O
the	O
most	O
abundant	O
compound	O
by	O
response	O
in	O
this	O
set	O
of	O
samples;	O
an	O
increase	O
of	O
1.34	O
fold	O
between	O
≥5%	O
WL	O
and	O
WS	O
patients	O
represents	O
a	O
major	O
shift	O
in	O
metabolic	O
output.	O

As	O
can	O
be	O
seen	O
from	O
statistical	O
analyzes	O
in	O
Tables 	O
and	O
,	O
patients	O
with	O
a	O
high	O
maximal	O
glucose	B
uptake	O
(SUV_max	O
),	O
a	O
large	O
metabolic	O
active	O
tumor	O
volume	O
(MATV_WTB	O
)	O
or	O
a	O
high	O
glycolytic	B
burden	O
(TLG_WTB	O
)	O
have	O
a	O
significant	O
increase	O
in	O
the	O
plasma	O
concentration	O
of	O
N-acetylated	B
glycoproteins	I
or	O
NAGs.	O

Diacylglycerols	B
were	O
measured	O
in	O
a	O
mass	O
rage	O
m/z	O
450–800	O
and	O
triacylglycerols	B
in	O
a	O
range	O
of	O
m/z	O
750–1200.	O

The	O
levels	O
of	O
PE(18:0/18:2)	B
and	O
PC(15:0/18:1)	B
in	O
early-stage	O
NSCLC	O
were	O
significantly	O
increased	O
compared	O
with	O
LBD	O
(p<0.05).	O

The	O
AUC	O
values	O
indicate	O
the	O
diagnostic	O
potentials	O
of	O
the	O
metabolites	O
as	O
unique	O
biomarkers	O
for	O
identification	O
of	O
CINs	B
and	O
cervical	O
cancers.	O

Those	O
who	O
developed	O
AP	B
were	O
matched	O
1:2	O
by	O
age	O
and	O
gender	O
with	O
controls	O
who	O
did	O
not	O
develop	O
AP	B
for	O
comparison	O
via	O
metabolomics.	O

These	O
are	O
three	O
enzymatically	O
formed	O
oxysterols,	B
24(S	O
)	O

Peak	O
height	O
for	O
the	O
internal	O
standard	O
was	O
<5%	O
of	O
the	O
normal	O
response	O
of	O
D_4	B
-abiraterone.	I

The	O
6	O
samples	O
were	O
diluted	O
using	O
phosphate	B
buffer	O
(PH=7.4,	O
final	O
concentration	O
of	O
0.2M)	O
to	O
prepare	O
three	O
sets	O
of	O
mixtures	O
with	O
three	O
dilution	O
levels	O
:	O
a	O
set	O
of	O
6	O
non-diluted	O
samples,	O
the	O
same	O
6	O
samples	O
diluted	O
two-fold,	O
and	O
the	O
same	O
6	O
samples	O
diluted	O
four-fold.	O

The	O
overall	O
result	O
is	O
an	O
increase	O
in	O
circulating	O
lactate	B
after	O
ischemia,	O
as	O
clearly	O
evident	O
from	O
our	O
results.	O

Comparisons	O
of	O
the	O
43	O
metabolites	O
showed	O
a	O
mean	O
correlation	O
coefficient	O
(r)	O
of	O
0.44	O
with	O
a	O
maximum	O
correlation	O
for	O
octanoylcarnitine	B
(r	O
=	O
0.92),	O
minimum	O
correlation	O
for	O
1-docosahexaenoylglycerophosphocholine	B
(r	O
=	O
0),	O
and	O
weak	O
correlations	O
(0<r<0.2)	O
for	O
7	O
metabolites,	O
which	O
included	O
lipids	O
and	O
an	O
amino	O
acid.	O

This	O
separation	O
was	O
due	O
to	O
a	O
higher	O
content	O
of	O
ethanol	B
and	O
taurine	B
in	O
the	O
controls	O
and	O
of	O
proline	B
in	O
the	O
IBS	O
samples.	O

Insulin	O
sensitivity	O
was	O
measured	O
using	O
a	O
hyperinsulinemic-euglycemic	B
clamp	O
as	O
previously	O
described.	O

Other	O
clinical	O
CSF	O
parameters,	O
such	O
as	O
white	O
blood	O
cell	O
(WBC)	O
count,	O
total	O
protein	O
level,	O
glucose	B
level,	O
LDH	O
level,	O
and	O
cytology	O
were	O
also	O
tabulated.	O

Significant	O
changes	O
in	O
the	O
serum	O
amino	O
acids	O
laboratory	O
profiles	O
(increased	O
glycine	B
and	O
glutamine	B
and	O
decreased	O
levels	O
of	O
arginine,	B
BCAAs,	O
histidine,	B
methionine,	B
phenylalanine,	B
taurine,	B
threonine	B
and	O
tryptophan)	O
in	O
epileptic	O
patients	O
treated	O
with	O
AEDs	O
were	O
found	O
by	O
Rao	O
et	O
al	O
..	O

LLOQ	O
for	O
prednisone	B
and	O
other	O
analytes	O
in	O
urine	O
were	O
0.5	O
μg·mL_−1	O
and	O
0.25	O
μg·mL_−1	O
,	O
respectively.	O

Increased	O
CSF	O
lactate	B
levels	O
have	O
been	O
reported	O
on	O
Days	O
1	O
through	O
9	O
following	O
experimental	O
spinal	O
cord	O
injury	O
on	O
cat	O
models,	O
indicating	O
continuing	O
hypoxia	O
in	O
the	O
spinal	O
cord	O
tissue.	O

In	O
addition	O
to	O
urinary	O
p	O
-cresol,	O
found	O
elevated	O
in	O
these	O
same	O
urine	O
samples	O
both	O
here	O
(Fig. )	O
and	O
previously	O
using	O
a	O
different	O
technology,	O
we	O
also	O
detect	O
a	O
significant	O
increase	O
in	O
indole	B
derivatives	O
of	O
bacterial	O
tryptophan	B
including	O
indolyl	O
3-acetic	O
acid,	O
indoxyl	B
sulfate,	I
and	O
most	O
prominently,	O
indolyl	B
lactate	I
(Fig.	O

The	O
extraction	O
solvent	O
was	O
spiked	O
with	O
compounds	O
not	O
detected	O
in	O
unspiked	O
human	O
stool	O
samples	O
[SM(d18:1/16:0),	O
PE(17:0/17:0),	B
PC(19:0/19:0),	B
TAG(13:0/13:0/13:0),	B
Cer(d18:1/17:0)	B
and	O
ChoE(12:0)].	B

Kaplan-Meier	O
analysis	O
of	O
metabolites	O
divided	O
in	O
tertiles	O
revealed	O
that	O
levels	O
of	O
TMAO,	B
but	O
not	O
choline	B
or	O
betaine,	B
were	O
associated	O
with	O
decreased	O
survival.	O

On	O
the	O
other	O
hand,	O
branched	O
chain	O
amino	O
acids	O
typically	O
associated	O
with	O
lower	O
ammonia	O
production,	O
and	O
glutamine,	B
that	O
represents	O
ammonia	O
capture	O
with	O
glutamate	B
were	O
protective[,	O
].	O

There	O
was	O
also	O
a	O
trend	O
toward	O
higher	O
monohydroxy	B
metabolites	O
derived	O
from	O
AA,	O
EPA,	O
DHA,	O
and	O
LA,	O
such	O
as	O
11-HETE,	B
15-HEPE,	B
18-HEPE,	B
and	O
9-HODE.	B

Although	O
smoking	O
history	O
is	O
thought	O
to	O
be	O
a	O
risk	O
factor	O
of	O
SqCC,	O
in	O
a	O
large-scale	O
lipidomics	O
analysis	O
no	O
associations	O
were	O
identified	O
for	O
the	O
plasma	O
concentration	O
in	O
cholesteryl	B
esters	I
between	O
smokers	O
and	O
non-smokers.	O

Citrate,	B
as	O
a	O
potential	O
biomarker	O
which	O
is	O
related	O
to	O
energy	O
metabolism,	O
is	O
a	O
dominant	O
intermediate	O
of	O
the	O
tricarboxylic	B
acid	I
cycle	O
(TCA).	O

In	O
addition,	O
gene	O
expression	O
changes	O
of	O
chromatin	B
remodeling	O
genes	O
were	O
identified	O
in	O
human	O
bladder	O
epithelial	O
cells	O
from	O
patients	O
with	O
IC.	O

Choline	B
and	O
betaine	B
levels	O
increased	O
with	O
dialysis	O
and	O
Rtx	O
whereas	O
TMAO	B
levels	O
remained	O
unchanged	O
during	O
dialysis	O
and	O
normalized	O
after	O
Rtx.	O

l	O
We	O
compared	O
the	O
l-arginine,	B
l-arginine	B
catabolic	O
products,	O
and	O
methylated	B
arginine	I
derivatives	O
in	O
patients	O
with	O
RA	O
and	O
age-	O
and	O
sex-matched	O
control	O
subjects	O
(Fig. ).	O

The	O
y-axis	O
shows	O
the	O
ratio	O
of	O
the	O
intensities	O
of	O
spectral	O
peaks	O
at	O
the	O
m/z	O
250.25	O
and	O
264.27	O
and	O
the	O
x-axis	O
represents	O
the	O
absolute	O
concentration	O
of	O
CER	B
d18:1/17:0	I
from	O
three	O
independent	O
calibration	O
data	O
series	O
(six	O
different	O
concentrations).	O

Fractions	O
of	O
different	O
isotopomers	O
of	O
U-_13	O
C	O
glucose-6-phosphate	B
plus	O
U-_13	O
C	O
fructose-6-phosphate	B
or	O
fructose-biphosphate	B
are	O
shown	O
within	O
the	O
bars.	O

and	O
Pseudobutyrivibrio	B
ruminis	O
,	O
were	O
lower	O
in	O
stool	O
samples	O
from	O
CRC	O
patients	O
compared	O
to	O
healthy	O
controls.	O

In	O
the	O
case	O
a	O
V˙O2	O
plateau	O
did	O
not	O
manifest	O
during	O
the	O
test,	O
the	O
ergospirometry	B
was	O
repeated	O
on	O
a	O
subsequent	O
day.	O

For	O
some	O
conjugated	O
alcohols,	O
the	O
hydroxyl	O
group	O
behaves	O
like	O
a	O
phenol	B
group	O
and	O
thus	O
can	O
be	O
labeled	O
by	O
dansylation.	O

All	O
solutions	O
contained	O
0.05%	O
(v/v)	O
butylated	B
hydroxytoluene	I
to	O
prevent	O
autoxidation.	O

Lipid	O
peroxidation,	O
quantitation,	O
4-hydroxy-2-nonenal,	B
4-oxo-2-nonenal,	B
mass	O
spectrometry,	O
smoking	O

Upon	O
incorporation	O
into	O
the	O
uracil	B
ring,	O
these	O
Asp	O
isotopomers	O
should	O
yield	O
the	O
following	O
_13	O
C	O
isotopomers	O
respectively	O
(see	O
for	O
uracil	B
ring	O
numbering):	O
_12	O
C5,_13	O
C6-uracil,	O
_13	O
C5,_12	O
C6-uracil,	O
and	O
_13	O
C5,_13	O
C6-uracil.	O

The	O
present	O
study	O
was	O
performed	O
to	O
compare	O
capillary	O
and	O
venous	O
plasma	O
concentrations	O
of	O
risperidone,	B
paliperidone,	B
quetiapine,	B
olanzapine,	B
and	O
aripiprazole	B
and	O
selected	O
metabolites	O
after	O
repeated	O
dosing	O
in	O
patients.	O

Data	O
points	O
between	O
4.2	O
and	O
5.0	O
p.p.m.	O
were	O
omitted	O
and	O
the	O
intensities	O
between	O
3.22	O
and	O
3.88	O
p.p.m.	O
were	O
given	O
only	O
0.1%	O
weight	O
in	O
the	O
SOM	O
algorithm	O
to	O
attenuate	O
the	O
effect	O
of	O
glucose.	B

For	O
example,	O
an	O
increase	O
in	O
ceramide	B
d18:1/20:0	I
was	O
positively	O
correlated	O
with	O
24	O
other	O
ceramides.	B

Ammonium	B
acetate,	I
ammonium	B
hydroxide,	I
and	O
acetic	B
acid	I
were	O
the	O
highest	O
purity	O
grade	O
available	O
from	O
Sigma-Aldrich.	O

Without	O
the	O
contribution	O
from	O
pyruvate	O
recycling	O
and	O
the	O
hepatic	O
gluconeogenesis	O
contributions,	O
Fc1	O
should	O
be	O
at	O
the	O
_13	O
C	O
isotope	O
natural	O
abundance	O
value	O
of	O
1.1%.	O
_13	O
C	O
fractional	O
enrichment	O
of	O
plasma	O
glucose	B
is	O
4.0%±1.0%	O
(from	O
_1	O
H	O
NMR	O
spectra	O
of	O
plasma	O
glucose,	B
data	O
not	O
shown)	O
and	O
its	O
contribution	O
to	O
the	O
total	O
Fc1	O
cannot	O
exceed	O
more	O
than	O
0.8%.	O

Second,	O
as	O
expected,	O
twofold-labeled	O
(M2)	O
erythritol	B
isotopologs	O
emerged	O
after	O
addition	O
of	O
the	O
[1,2-_13	B
C_2	I
]glucose	I
tracer	O
to	O
the	O
blood	O
cells.	O

CDG-I	O
defects	O
are	O
easily	O
identified	O
owing	O
to	O
the	O
occurrence	O
of	O
transferrin	O
isoforms	O
with	O
two	O
or	O
no	O
sialic	B
acid	I
residues	O
detected	O
by	O
means	O
of	O
IEF.	O

The	O
mean	O
±	O
standard	O
deviations	O
of	O
amino	O
acid	O
and	O
acylcarnitine	B
concentrations	O
were	O
calculated	O
for	O
patients	O
with	O
lung	O
cancer	O
and	O
healthy	O
controls	O
in	O
the	O
two	O
data	O
sets.	O

The	O
lower	O
level	O
malic	O
enzyme	O
in	O
two	O
cell	O
lines	O
with	O
severely	O
knocked	O
down	O
PC	O
is	O
consistent	O
with	O
lower	O
pyruvate	O
cycling	O
and	O
lower	O
malate,	B
citrate	B
and	O
pyruvate	B
levels	O
(–)	O
in	O
these	O
cell	O
lines	O
(means	O
±	O
SE,	O
_a	O
p	O
<	O
0.01	O
vs	O
scramble	O
control).	O

Partial	O
metabolic	O
clearance	O
of	O
midazolam	B
(CL_met	O
)	O
was	O
derived	O
using	O
the	O
established	O
equation	O
CL_met	O

Clothianidin	B
was	O
only	O
detected	O
in	O
ASG	O
(6.3%,	O
not	O
quantified),	O
and	O
in	O
NSG	O
(2.0%,	O
1.6	O
ppb).	O

In	O
addition,	O
methylarginine	B
(ADMA,	O
L-NMMA	B
and	O
SDMA)	O
stock	O
solutions	O
(10 mM)	O
were	O
prepared	O
and	O
diluted	O
with	O
50:50	O
water/methanol	O
(v/v)	O
to	O
give	O
concentrations	O
of	O
0,	O
0.05,	O
0.1,	O
0.19,	O
0.38,	O
0.76,	O
1.5	O
and	O
3 μM.	O
All	O
standards	O
were	O
run	O
at	O
the	O
beginning	O
and	O
end	O
of	O
the	O
sample	O
batch.	O

The	O
dipicolinyl	O
derivative	O
of	O
VLCDCA	B
28:4	I
isolated	O
from	O
3	O
mL	O
of	O
human	O
plasma,	O
semipurified	O
by	O
basic	O
anion	O
exchange,	O
was	O
generated.	O

Besides,	O
previous	O
metabolomic	O
studies	O
have	O
identified	O
an	O
association	O
between	O
low	O
tyrosine	B
concentration	O
and	O
diabetic	O
nephropathy,	O
which	O
substantiates	O
our	O
finding	O
that	O
tyrosine	B
level	O
had	O
a	O
significant	O
correlation	O
with	O
diabetic	O
microangiopathy.	O

The	O
most	O
significant	O
disease	O
related	O
effects	O
pertain	O
to	O
the	O
proteins	O
Tau/p-Tau	O
(increase)	O
and	O
amyloid	O
beta42	O
(decrease)	O
as	O
well	O
as	O
several	O
analytes	O
identified	O
by	O
metabolite	O
profiling,	O
particularly	O
cysteine,	B
several	O
unknowns,	O
cortisol	B
and	O
ornithine,	B
including	O
minor	O
components	O
arginine	B
and	O
citrulline,	B
most	O
of	O
which	O
are	O
best	O
correlated	O
with	O
light	O
AD.	O

Automated	O
densitometry	O
was	O
used	O
to	O
quantify	O
the	O
levels	O
of	O
mTOR	O
substrate	O
protein	O
expression	O
relative	O
to	O
β-actin	B
using	O
a	O
Kodak	O
Image	O
Station	O
440CF	O
with	O
Kodak	O
1D	O
Image	O
Analysis	O
Software	O
(Eastman	O
Kodak	O
Company,	O
Rochester,	O
NY).	O

In	O
summary,	O
we	O
report	O
that	O
elevated	O
TMAO	B
levels	O
are	O
strongly	O
associated	O
with	O
degree	O
of	O
renal	O
function	O
in	O
CKD	O
and	O
normalize	O
after	O
Rtx.	O

However,	O
since	O
a	O
combined	O
reduction	O
in	O
levels	O
of	O
NAAG,	B
N-acetylalanine,	B
N-acetylthreonine	B
and	O
N-acetylserine	B
hasn’t	O
been	O
previously	O
recognized	O
as	O
associated	O
with	O
any	O
inborn	O
error	O
of	O
metabolism,	O
we	O
speculate	O
that	O
this	O
pattern	O
of	O
change	O
can	O
serve	O
as	O
a	O
unique	O
identifier	O
of	O
CLN2	O
disease.	O

Paraffin	B
sections	O
with	O
a	O
thickness	O
of	O
5	O
μm	O
were	O
stained	O
with	O
hematoxylin	B
and	O
eosin	B
method.	O

These	O
findings,	O
which	O
highlight	O
the	O
ability	O
of	O
tryptophan	B
to	O
identify	O
high	O
risk	O
individuals	O
before	O
the	O
onset	O
of	O
T2D,	O
and	O
even	O
before	O
significant	O
variations	O
of	O
metabolic	O
markers,	O
are	O
noteworthy.	O

Entry	O
criteria	O
included:	O
age,	O
30	O
to	O
70	O
yr;	O
stable	O
body	O
weight	O
(±1	O
kg)	O
for	O
at	O
least	O
3	O
months	O
before	O
study;	O
and	O
fasting	O
plasma	O
glucose	B
(FPG),	O
126–260	O
mg/dl.	O

Group	O
differences	O
in	O
acyl-carnitine	B
concentrations	O
in	O
our	O
study	O
may	O
be	O
explained	O
by	O
a	O
compositional	O
difference	O
in	O
the	O
study	O
formulae.	O

A	O
previous	O
pretreatment	O
procedure	O
was	O
developed	O
jointly	O
using	O
PPT	O
by	O
methanol	B
for	O
pemetrexed,	O
gemcitabine,	O
carboplatin	B
and	O
LLE	O
by	O
ethyl	B
acetate	I
for	O
irinotecan,	O
cyclophosphamide,	O
ifosfamide,	B
etoposide,	B
and	O
mixed	O
ether-dichloromethane	B
(7 : 3,	O
V : V)	O
for	O
the	O
remaining	O
analytes	O
to	O
maximize	O
recovery	O
and	O
reduce	O
matrix	O
effect	O
of	O
all	O
analytes,	O
but	O
it	O
was	O
an	O
low	O
efficiency	O
way	O
for	O
extraction	O
of	O
analytes.	O

To	O
evaluate	O
the	O
relative	O
amount	O
of	O
product	O
excreted	O
as	O
glucuronic	B
acid	I
conjugates,	O
40	O
μL	O
of	O
human	O
urine	O
samples	O
were	O
incubated	O
in	O
the	O
presence	O
and	O
absence	O
of	O
β-glucuronidase	O
(Bovine	O
liver,	O
Type	O
B-10,	O
Sigma-Aldrich,	O
St.	O
Louis,	O
MO)	O
at	O
37	O
°C,	O
with	O
constant	O
shaking	O
for	O
30	O
or	O
60	O
minutes,	O
by	O
adding	O
160	O
μL	O
of	O
0.1	O
M	O
pH	O
5.0	O
sodium	B
acetate	I
buffer	O
containing	O
β-glucuronidase	O
(1.6	O
units/μl	O
final	O
concentration).	O

The	O
cysteinyl	O
leukotrienes,	O
LTC4,	B
LTD4,	B
and	O
LTE4,	O
are	O
created	O
from	O
the	O
enzymatic	O
reactions	O
of	O
LTA4	O
and	O
glutathione.	B

Serum	O
folate	B
concentrations	O
were	O
significantly	O
lower	O
in	O
the	O
high–cystathionine	B
concentration	O
group,	O
but	O
the	O
subjects	O
were	O
not	O
considered	O
deficient.	O

The	O
metabolites	O
of	O
importance	O
included	O
up-regulated	O
N	B
-acetylglycoprotein	I
in	O
CD	O
patients,	O
and	O
down-regulated	O
LDL	O
and	O
HDL	B
cholesterol,	I
unsaturated	O
lipids,	O
choline,	B
isoleucine	B
and	O
alanine.	B

L,	O
HDL-cholesterol	B
of	O
1.78 mmol/L,	O
LDL-cholesterol	B
of	O
3.45 mmol/L,	O
and	O
Triglycerides	B
of	O
1.18 mmol/	O

Example	O
of	O
a	O
calibration	O
curve	O
for	O
the	O
enrichment	O
of	O
_13	O
C_2	B
-oxalate.	I

Of	O
potential	O
importance	O
was	O
the	O
observation	O
that	O
PGF2α	B
was	O
elevated,	O
in	O
particular	O
in	O
relation	O
to	O
AML	O
with	O
low	O
BM	O
and	O
peripheral	O
blast	O
and	O
with	O
a	O
favorable	O
prognostic	O
risk.	O

We	O
found	O
that	O
pathways	O
involved	O
in	O
the	O
transport	O
of	O
inorganic	O
cations/anions	O
and	O
amino	B
acids/oligopeptides,	O
creatine	B
metabolism,	O
amino	O
acid	O
synthesis,	O
and	O
interconversion	O
(transamination),	O
amino	O
acid	O
transport	O
across	O
the	O
plasma	O
membrane,	O
transport	O
of	O
glycerol	B
from	O
adipocytes	O
to	O
the	O
liver	O
by	O
aquaporins,	O
glycerophospholipid	B
catabolism,	O
and	O
GABA	B
biosynthesis,	O
metabolism,	O
and	O
catabolism	O
could	O
be	O
the	O
most	O
relevant	O
biological	O
networks	O
that	O
differ	O
between	O
veterans	O
and	O
civilians	O
with	O
sarcoidosis.	O

FTCD	O
enzyme	O
is	O
involved	O
in	O
the	O
most	O
common	O
inborn	O
error	O
of	O
folate	B
metabolism	O
due	O
to	O
an	O
autosomal	O
recessive	O
disorder	O
causing	O
a	O
glutamate	B
formiminotransferase	O
deficiency.	O

shows	O
principal	O
component	O
analysis	O
results	O
for	O
all	O
extraction	O
and	O
LC-MS	O
methods	O
further	O
illustrating	O
that	O
IEX	O
and	O
MTBE	B
are	O
the	O
most	O
complementary	O
methods	O
to	O
methanol-based	O
solvent	O
precipitation.	O

More	O
prospective	O
studies	O
are	O
needed	O
to	O
verify	O
the	O
causality	O
between	O
TMAO	B
and	O
PLC.	O

The	O
THC	O
precursor,	O
THCAA,	O
was	O
evaluated	O
as	O
a	O
marker	O
for	O
differentiating	O
illicit	O
cannabis	B
intake	O
from	O
licit	O
THC	O
pharmacotherapy.	O

For	O
HDL,	O
LPCa	O
C16:1,	B
LPCa	O
C20:3,	B
LPCa	O
C20:5,	B
LPCa	O
C22:5,	B
LPCe	O
C18:0,	B
NEFA	B
C24:5,	I
PCaa	O
C38:0,	B
PCaa	O
C38:6,	B
PCaa	O
C40:5,	B
PCaa	O
C40:6,	B
PCae	O
C40:0,	B
PCae	O
C40:6	B
and	O
SMa	O
C42:6	B
were	O
significantly	O
different	O
between	O
males,	O
hormonal	O
contraceptive-taking	O
females	O
and	O
non-hormonal	O
contraceptive-taking	O
females.	O

Elevated	O
levels	O
of	O
glucopyranoside,	B
tetradecane,	B
mannose	B
and	O
benzene	B
1,2	I
dicarboxylic	I
acid	I
were	O
found	O
to	O
differentiate	O
between	O
different	O
grades,	O
stages	O
and	O
neoadjuvant	O
status.	O

The	O
Cancer	O
Genome	O
Atlas	O
was	O
used	O
to	O
analyze	O
gene	O
expression	O
related	O
to	O
the	O
sphingolipid	B
metabolism.	O

Urinary	O
metabolites	O
reduced	O
in	O
patients	O
with	O
HCC	O
included	O
citrate	B
double	O
doublet	O
(2.56 ppm	O
and	O
2.68 ppm,	O
P	O
 =	O

Briefly,	O
plasma	O
and	O
CSF	O
samples	O
are	O
extracted	O
with	O
methanol	B
and	O
applied	O
to	O
a	O
capillary-flow	O
HPLC	O
column	O
interfaced	O
with	O
a	O
TOF	O
mass	O
spectrometer	O
equipped	O
with	O
an	O
electrospray	O
source.	O

After	O
the	O
two	O
successive	O
derivatization	O
steps,	O
300 μl	O
of	O
dichloromethane	B
was	O
added	O
and	O
shaken	O
for	O
10 s	O
for	O
separating	O
the	O
MCF	O
derivatives.	O

There	O
were	O
several	O
key	O
findings	O
that	O
emerged:	O
First,	O
we	O
demonstrated	O
significant	O
reductions	O
of	O
sphingomyelin	B
mass	O
and	O
significant	O
increases	O
in	O
ceramide	B
content	O
in	O
plasma	O
of	O
AD	O
patients.	O

Our	O
results	O
indicate	O
an	O
increased	O
metabolism	O
of	O
tryptophan	B
that	O
can	O
most	O
probably	O
be	O
related	O
to	O
the	O
biological	O
activity	O
of	O
its	O
metabolites,	O
especially	O
in	O
connection	O
with	O
immune	O
activation.	O

The	O
mean	O
extraction	O
recovery	O
for	O
D-mannose	B
was	O
104.13,	O
105.53,	O
and	O
104.84,	O
for	O
the	O
low,	O
medium,	O
and	O
high	O
QC	O
concentrations,	O
respectively.	O

For	O
PG	B
and	O
PI,	O
MS	O
analysis	O
in	O
negative	O
ion	O
mode	O
was	O
applied.	O

The	O
DHFR-TS	O
used	O
by	O
trypanosomatids	O
can	O
exclusively	O
reduce	O
folic	B
acid;	I
the	O
reductase	O
PTR1	O
shows	O
a	O
much	O
broader	O
range	O
of	O
activity,	O
catalyzing	O
successive	O
reductions	O
of	O
conjugated	O
(folate)	O
and	O
unconjugated	O
(biopterin)	O
pterins.	O

The	O
residue	O
was	O
mixed	O
with	O
1000	O
μL	O
of	O
a	O
deuterated	O
solvent	O
(D_2	O
O,	O
methanol-d	B
_4	O
(MeOD),	O
acetonitrile-d	O
_3	O
(MeCN),	O
dimethyl	B
sulfoxide-d	I
_6	O
(DMSO),	O
CDCl_3	O
,	O
acetone-d	B
_6	O
,	O
dichloromethane-d	B
_2	O
(DCM),	O
dimethyl	B
formamide-d	I
_7	O
(DMF))	O
and	O
shaken	O
for	O
10	O
min	O
(neolab	O
Intelli	O
Mixer,	O
program:	O
u1,	O
speed:	O
85	O
rpm).	O

Several	O
studies	O
also	O
suggested	O
the	O
relationship	O
between	O
2-hydroxybutyrate	B
and	O
neurodegenerative	O
disorders	O
such	O
as	O
dihydrolipoyl	O
dehydrogenase	O
(E3)	O
deficiency	O
and	O
cerebral	O
lactic	O
acidosis.	O

LPI	O
is	O
a	O
bioactive	O
lipid	O
produced	O
from	O
membrane	O
phosphatidylinositol	B
(PI)	O
through	O
the	O
catalytic	O
activity	O
of	O
the	O
phospholipase	O
A	O
(PLA)	O
family	O
of	O
lipases,	O
including	O
PLA1	O
and	O
PLA2.	O

Uridine	B
is	O
a	O
glycosylated	O
form	O
of	O
uracil	B
and	O
is	O
a	O
nitrogenous	O
base	O
found	O
in	O
RNA.	O

For	O
instance,	O
for	O
human	O
urine,	O
identification	O
of	O
creatine	B
solely	O
based	O
on	O
_13	O
C-_1	O
H	O
HSQC	O
alone	O
was	O
challenging.	O

LC/MS-grade	O
water	O
and	O
MeOH	B
(Honeywell)	O
were	O
used	O
for	O
the	O
LC/MS-MS	O
mobile	O
phase.	O

Ethanolamine	B
is	O
an	O
important	O
fatty	O
acid	O
for	O
cellular	O
membranes[],	O
and	O
its	O
decreased	O
levels	O
in	O
EC	O
urine	O
could	O
suggest	O
increased	O
consumption	O
for	O
biosynthesis	O
of	O
cellular	O
membranes	O
and	O
indicate	O
activation	O
of	O
fatty	O
acid	O
metabolism.	O

As	O
previously	O
shown,	O
GSH	B
is	O
depleted	O
in	O
lupus	O
PBL	O
(Gergely	O
et	O
al.	O
)	O
and	O
its	O
reversal	O
by	O
treatment	O
with	O
NAC	O
was	O
safe	O
and	O
effective	O
in	O
reducing	O
disease	O
activity	O
in	O
patients	O
with	O
SLE	O
(Lai	O
et	O
al.	O
).	O

Most	O
importantly,	O
carnosine	B
supplementation	O
has	O
been	O
shown	O
to	O
diminish	O
the	O
activity	O
of	O
SREBPs,	O
reduce	O
hepatic	O
triglycerides,	B
and	O
improve	O
insulin	O
sensitivity	O
in	O
mice.	O

Sex-stratified	O
analyses	O
of	O
the	O
association	O
of	O
betaine	B
as	O
a	O
continuous	O
variable	O
and	O
according	O
to	O
tertiles	O
with	O
the	O
development	O
of	O
T2DM.	O

([M–2+H]_+	O
)	O
and	O
diketo-	B

The	O
intra-day	O
accuracy	O
and	O
precision	O
values	O
for	O
plasma	O
with	O
low	O
triglycerides	B
ranged	O
from	O
96	O
to	O
104%	O
and	O
4	O
to	O
8%	O
for	O
SMV,	O
95	O
to	O
103%	O
and	O
5	O
to	O
12%	O
for	O
SMV-A,	O
95	O
to	O
109%	O
and	O
5	O
to	O
12%	O
for	O
ATV,	O
98	O
to	O
104%	O
and	O
4	O
to	O
11%	O
for	O
2-OH-ATV,	B
95	O
to	O
106%	O
and	O
4	O
to	O
10%	O
for	O
4-OH-ATV,	B
96	O
to	O
105%	O
and	O
3	O
to	O
13%	O
for	O
RSV.	O

Other	O
tryptophan	B
degradation	O
products,	O
indolelactate	B
(1.2-fold)	O
and	O
indolepropionate	B
(2.2-fold),	O
related	O
to	O
microbiome	O
metabolic	O
origin	O
tended	O
to	O
increase	O
(	O
and	O
).	O

Recently,	O
rapamycin	B
has	O
attracted	O
interest	O
for	O
the	O
clinical	O
treatment	O
of	O
organ	O
transplant	O
rejection	O
and	O
autoimmune	O
diseases	O
.	O

Cells	O
and	O
supernatants	O
were	O
collected	O
and	O
prepared	O
for	O
measurements	O
of	O
purines	B
by	O
mass	O
spectrometry	O
as	O
described	O
in	O
Methods.	O

Total	O
triglycerides,	B
the	O
ratio	O
of	O
triglycerides	B
to	O
phosphoglycerides,	B
omega-9	B
and	O
saturated	O
fatty	O
acids,	O
the	O
ratio	O
of	O
omega-9	B
and	O
saturated	O
fatty	O
acids	O
to	O
total	O
fatty	O
acids	O
and	O
the	O
average	O
number	O
of	O
methylene	B
groups	O
per	O
double	O
bond	O
showed	O
positive	O
association	O
with	O
levels	O
of	O
testosterone	B
in	O
PCOS	O
women	O
but	O
not	O
in	O
controls	O
(β	O
>0.17,	O
P	O
<1.9	O
×	O
10_−3	O
).	O

Among	O
the	O
sphingolipid	B
metabolites,	O
So1P	O
was	O
associated	O
with	O
sex	O
and	O
lean	O
mass	O
index,	O
but	O
not	O
with	O
the	O
body	O
mass	O
index.	O

Multiple	O
reaction	O
monitoring	O
chromatogram	O
of	O
β-apo-13-carotenone	B
in	O
blood	O
plasma	O
(top	O
)	O
and	O
a	O
standard	O
(bottom	O
)	O
as	O
analyzed	O
by	O
atmospheric	O
pressure	O
chemical	O
ionization	O
in	O
positive	O
mode	O
after	O
C30	O
HPLC.	O

Cell	O
culture	O
experiments	O
also	O
suggest	O
that	O
exposure	O
to	O
PE	O
alters	O
the	O
plasma	O
membrane	O
bilayer	O
with	O
total	O
loss	O
of	O
asymmetrical	O
aminophospholipids	B
and	O
promotes	O
apoptosis	O
and	O
autophagy.	O

ADMA	B
(r_p	O
=	O
0.77,	O
p	O
<	O
0.001)	O
was	O
an	O
independent	O
predictor	O
of	O
serum	O
arginine	B
concentrations	O
in	O
IBS	O
patients,	O
explaining	O
60%	O
in	O
its	O
variability	O
(R_2	O
=	O
0.596;	O
F	O
=	O
23.6,	O
p	O
<	O
0.001).	O

Derivatized	O
sterols	O
were	O
then	O
eluted	O
in	O
three	O
1-ml	O
portions	O
of	O
100%	O
methanol	B
(SPE2-Fr-1,	I
Fr-2,	I
and	O
Fr-3)	B
followed	O
by	O
1	O
ml	O
of	O
99.9%	O
ethanol	B
(SPE2-Fr-4).	I

Although	O
the	O
number	O
of	O
metabolites	O
profiled	O
in	O
this	O
study	O
was	O
significantly	O
lower	O
and	O
the	O
metabolic	O
variation	O
of	O
TB	O
patients	O
was	O
different	O
from	O
the	O
previous	O
study,	O
the	O
altered	O
metabolic	O
pathways	O
are	O
congruent	O
with	O
our	O
study,	O
including	O
histidine	B
metabolism,	O
bile	O
acid	O
metabolism,	O
glutathione	B
metabolism,	O
urea	B
cycle,	O
phenylalanine	B
and	O
tyrosine	B
metabolism.	O

Initial	O
evaluation	O
of	O
a	O
protein	O
precipitation	O
using	O
acetonitrile	B
or	O
acetone	B
for	O
the	O
sample	O
preparation	O
of	O
these	O
compounds	O
from	O
serum	O
resulted	O
in	O
lower	O
sensitivities	O
than	O
desired.	O

Many	O
investigators	O
cite	O
problems	O
of	O
albumin	O
interference	O
with	O
the	O
Ellman	O
assay	O
and	O
degradation	O
of	O
HCTL	O
at	O
alkaline	B
pH	O
as	O
a	O
rationale	O
for	O
using	O
GTBL,	O
which	O
has	O
been	O
used	O
as	O
a	O
lactonase	O
substrate	O
for	O
analysis	O
of	O
PON1	O
activity	O
,	O
,	O
,	O
,	O
.	O

We	O
extended	O
our	O
studies	O
to	O
compare	O
Kyn	O
levels	O
in	O
the	O
epithelial	O
human	O
retinal	B
epithelial	O
cell	O
line	O
ARPE	O
and	O
normal	O
human	O
foreskin	O
fibroblasts	O
(HFFs)	O
expressing	O
empty	O
vector	O
or	O
MYC	O
(G).	O

Indeed,	O
KYN	O
level	O
at	O
day	O
7	O
was	O
almost	O
doubled	O
in	O
28-day	O
NS	O
compared	O
to	O
S.	O
To	O
date	O
a	O
clear	O
relation	O
has	O
been	O
made	O
between	O
accelerated	O
tryptophan	B
catabolism	O
along	O
the	O
KYN	O
pathway	O
and	O
inflammatory	O
reactions.	O

In	O
the	O
quantitation	O
experiments	O
based	O
on	O
deconjugation,	O
to	O
measure	O
diosmetin	B
in	O
plasma,	O
digestion	O
either	O
with	O
β-d-glucuronidase,	O
or	O
with	O
sulfatase,	O
or	O
with	O
both	O
enzymes	O
together	O
was	O
performed.	O

Arachidonic	B
acid	I
metabolism	O
by	O
COX-2	O
provides	O
one	O
potential	O
mechanism	O
for	O
explaining	O
pro-tumorigenic	O
effects	O
downstream	O
of	O
FASN	O
[,	O
].	O

Fasting	O
insulin,	O
postprandial	O
glucose,	B
INS/GLU	O
and	O
HOMA-IR	O
were	O
highest	O
in	O
L1_L	O
and	O
L1_AL	O

2-oxobutyrate	B
can	O
be	O
produced	O
by	O
the	O
direct	O
catabolism	O
of	O
threonine	B
or	O
methionine	B
metabolism	O
through	O
homocysteine	B
and	O
cystathionine.	B

Another	O
example	O
of	O
a	O
metabolite	O
found	O
to	O
be	O
increased	O
in	O
the	O
pre-diabetic	O
group	O
(ISI_Matsuda	O
<15)	O
compared	O
to	O
the	O
group	O
with	O
normal	O
insulin	O
sensitivity	O
is	O
the	O
metabolite	O
ion	O
possibly	O
assigned	O
to	O
sphingomyelin.	B

For	O
some	O
steroids	O
(11-deoxycorticosterione	O
and	O
cortisone	B
in	O
both	O
genders,	O
17-hydroxypgrogesterone	B
and	O
androstenedione	B
in	O
males	O
and	O
corticosterone	B
and	O
pregnenolone	B
in	O
females)	O
there	O
was	O
evidence	O
of	O
peaks	O
in	O
plasma	O
concentrations	O
at	O
21	O
to	O
23 years	O
of	O
age,	O
suggesting	O
lower	O
concentrations	O
at	O
ages	O
younger	O
than	O
21 years.	O

Triglycerides	B
were	O
measured	O
by	O
an	O
enzymatic	O
color	O
test	O
(GPO-PAP-method,	O
TGL	O
Flex,	O
Dade	O
Behring).	O

In	O
the	O
cross-sectional	O
analysis	O
of	O
ARIC	O
(Atherosclerosis	O
Risk	O
in	O
Communities),	O
arteries	O
appear	O
to	O
become	O
stiffer	O
at	O
increasing	O
concentrations	O
of	O
fasting	O
glucose	B
and	O
insulin,	O
independent	O
of	O
race	O
or	O
gender.	O

Comparison	O
of	O
levels	O
of	O
methylthioguanosine	B
and	O
thioguanosine	B
nucleotides	O
(diagrams	O
in	O
upper	O
half)	O
and	O
methylthioinosine	B
nucleotides	O
and	O
thioinosine	B
nucleotides	O
(diagrams	O
in	O
lower	O
half)	O
in	O
the	O
RBC	O
samples	O
washed	O
and	O
diluted	O
with	O
the	O
saline	B
or	O
PBS	O
and	O
hold	O
for	O
4	O
h	O
to	O
the	O
samples	O
processed	O
immediately	O
(expressed	O
as	O
%).	O

Ceramides	B
ordered	O
after	O
the	O
number	O
of	O
hydroxyl	O
groups	O
in	O
the	O
three	O
fractions,	O
where	O
ceramides	B
were	O
identified	O
(fraction	O
7–9).	O

TG,	B
triglyceride;	B
TC,	O
total	O
cholesterol;	B
LDL-C,	O
low-density	O
lipoprotein	O
cholesterol;	B
HDL-C,	O
high-density	O
lipoprotein	O
cholesterol.	B

MiaPaCa-2	O
and	O
Panc-1	O
were	O
grown	O
in	O
high	O
glucose	B
Dulbecco’s	O
Modified	O
Eagle	O
Medium,	O
(DMEM)	O
and	O
AsPC-1	O
cells	O
were	O
grown	O
in	O
Roswell	O
Park	O
Memorial	O
Institute	O
(RPMI)	O
medium.	O

However,	O
overexpression	O
of	O
glucose-6-phosphate	O
dehydrogenase,	O
a	O
rate-limiting	O
enzyme	O
of	O
the	O
pentose	B
phosphate	I
pathway,	O
promotes	O
oxidative	O
stress	O
and	O
expression	O
of	O
pro-inflammatory	O
cytokines	O
in	O
macrophages,	O
which	O
induce	O
insulin	O
resistance	O
in	O
adipocyte.	O

The	O
chromatographic	O
analysis	O
of	O
human	O
urine	O
using	O
a	O
15 cm	O
length	O
column	O
and	O
eluted	O
with	O
a	O
linear	O
solvent	O
gradient	O
from	O
5	O
to	O
60%	O
acetonitrile	B
over	O
15 min	O
(at	O
a	O
flow	O
rate	O
of	O
600 μL/min)	O
enabled	O
the	O
detection	O
of	O
in	O
excess	O
of	O
16,000	O
features	O
in	O
positive	O
ion	O
electrospray	O
ionization	O
with	O
Data	O
Independent	O
Acquisition	O
(DIA)	O
ESI	O
mode	O
(using	O
medium	O
peak	O
detection	O
settings).	O

Detailed	O
quantification	O
of	O
the	O
_13	O
C-isotopomers	O
of	O
intracellular	O
lactate	B
and	O
Ala	O
by	O
NMR	O
and	O
GC-MS	O
is	O
given	O
in	O
Table	O
and	O
Fig.	O
.	O

A549	O
cells	O
were	O
exposed	O
to	O
serial	O
dilutions	O
of	O
methanolic	B
metabolites	O
produced	O
by	O
T.	O
harzianum	O
strain	O
ES39	O
for	O
24	O
h	O
at	O
37°C.	O

Thus,	O
antioxidant	O
materials	O
could	O
have	O
activated	B
glycerol-phosphate	I
oxidation	O
in	O
mitochondria,	O
a	O
process	O
that	O
would	O
explain	O
the	O
observed	O
reduction	O
of	O
glycerol	B
levels.	O

Reduced	O
circulating	O
24,25(OH)_2	B
D_3	O
concentration	O
may	O
therefore	O
be	O
a	O
sign	O
of	O
reduced	O
net	O
tubular	O
CYP24A1	O
function.	O

Knockdown	O
of	O
glycine-N-methyl	O
transferase	O
(GNMT),	O
the	O
enzyme	O
that	O
generates	O
sarcosine	B
from	O
glycine,	B
attenuated	O
prostate	O
cancer	O
invasion.	O

During	O
hypoxia,	O
because	O
of	O
decreased	O
oxygen,	O
adenosine	B
triphosphate	I
is	O
generated	O
by	O
conversion	O
of	O
glucose	B
to	O
lactate	B
via	O
glycolysis.	O

In	O
addition,	O
citric	B
acid,	I
an	O
important	O
intermediate	O
in	O
citrate	B
cycle,	O
was	O
observed	O
to	O
be	O
reduced	O
in	O
BC	O
subjects,	O
which	O
suggested	O
that	O
citrate	B
cycle	O
were	O
impaired	O
in	O
BC	O
patients.	O

To	O
test	O
whether	O
_13	O
C	O
label	O
originating	O
from	O
infused	O
[1,2-_13	B
C]acetate	I
could	O
enter	O
hepatic	O
gluconeogenesis,	O
plasma	O
from	O
the	O
patient	O
was	O
obtained	O
at	O
the	O
time	O
of	O
tumor	O
excision.	O

One	O
hundred	O
and	O
fifty	O
(150)	O
microlitre	O
of	O
absolute	B
ethanol	I
was	O
added	O
and	O
the	O
samples	O
were	O
mixed	O
by	O
inversion	O
and	O
immediately	O
stored	O
at	O
− 20 °C.	O

Additional	O
CPMG	O
experiments	O
for	O
intact	O
serum	O
were	O
performed	O
after	O
spiking	O
with	O
standard	O
pyroglutamic	B
acid.	I

− 0.116)	O
and	O
18-hydroxycortisol	B
(r_s	O
 =	O

Heparin	B
plasma	O
and	O
serum	O
were	O
obtained	O
by	O
centrifugation	O
(1620g,	O
10	O
min),	O
and	O
red	O
blood	O
cells	O
were	O
separated	O
from	O
EDTA	O
whole	O
blood	O
by	O
centrifugation	O
(10000g,	O
1	O
min)	O
and	O
washed	O
with	O
NaCl.	O

Therefore,	O
0.1%	O
FA	B
was	O
chosen	O
as	O
our	O
mobile	O
phase	O
additive.	O

Some	O
downstream	O
metabolites,	O
8-iso-13,14-dihydro-PGF_2α	B
and	O
13,14-dihydro-PGF_2α	B
,	O
were	O
exclusively	O
detected	O
after	O
GUS	O
hydrolysis	O
(Fig.	O

Regarding	O
the	O
baseline	O
differences,	O
there	O
was	O
low	O
taurine	B
in	O
the	O
HLP	O
group	O
compared	O
with	O
the	O
healthy	O
control	O
(p	O
<	O
0.05).	O

The	O
separation	O
was	O
performed	O
on	O
CAPCELL	O
PAC	O
C18	O
MG	O
II	O
with	O
10	O
mM	O
butane	B
sulfonic	I
sodium,	I
4	O
mM	O
malonic	B
acid,	I
4	O
mM	O
tetramethylammonium	B
hydroxide,	I
and	O
0.5%	O
methanol	B
(pH	O
2.0).	O

The	O
significant	O
changed	O
amino	O
acids	O
were	O
glutamate	B
and	O
phenylalanine	B
in	O
acute	O
AD	O
patients	O
comparing	O
with	O
chronic	O
AD	O
patients.	O

By	O
analyzing	O
samples	O
in	O
parallel	O
by	O
routes	O
A	O
(without	O
cholesterol	B
oxidase)	O
and	O
B	O
(with	O
cholesterol	B
oxidase),	O
analytes	O
possessing	O
a	O
3-oxo	O
group	O
are	O
differentiated	O
from	O
those	O
oxidized	O
to	O
contain	O
one	O
(i.e.	O
3β-hydroxy-5-ene	B
or	O
3β-hydroxy-5α-hydrogen	B
sterols/bile	O
acids).	O

Monohydroxy	B
metabolites	O
of	O
naphthalene,	B
fluorene,	B
phenanthrene,	B
and	O
pyrene	O
were	O
determined	O
by	O
the	O
method	O
of	O
.	O

Alterations	O
of	O
glycolipid	B
and	O
glycoprotein	B
biosynthesis	O
and	O
degradation	O
could	O
possibly	O
lead	O
to	O
increased	O
serum	O
concentrations	O
of	O
complex	O
sugars,	O
containing	O
N-acetylglucosamine	B
and	O
sialic	B
acid	I
moieties.	O

Although	O
7-alpha-methylthiospironolactone	B
was	O
quantified	O
on	O
different	O
transition,	O
it	O
was	O
still	O
present	O
in	O
noticeable	O
amounts	O
on	O
this	O
one.	O

We	O
can	O
only	O
speculate	O
that	O
an	O
increase	O
in	O
metabolism	O
of	O
vitamin	B
E	I
and	O
particularly	O
oxidation	O
occurs	O
as	O
a	O
result	O
of	O
the	O
underlying	O
condition.	O

As	O
far	O
as	O
PCaa	O
are	O
concerned,	O
Oberbach	O
et	O
al	O
.	O
showed	O
an	O
increase	O
of	O
several	O
PCaa	O
including	O
C32:0,	B
C32:1	B
and	O
C40:5	B
levels	O
among	O
obese	O
as	O
compared	O
to	O
lean	O
individuals	O
[,],	O
a	O
trend	O
that	O
was	O
also	O
observed	O
for	O
PCaa	O
C32:1	B
and	O
C40:5	B
in	O
the	O
present	O
study.	O

The	O
100	O
genes	O
with	O
the	O
highest	O
variance	O
in	O
changed	O
gene	O
expression	O
in	O
breast	O
tissue	O
following	O
IER	O
are	O
shown	O
in	O
a.	O
The	O
same	O
genes	O
in	O
the	O
lymphocytes	O
from	O
IER	O
participants	O
(b),	O
the	O
breast	O
in	O
women	O
undertaking	O
CER	B
(c)	O
and	O
subcutaneous	O
abdominal	O
fat	O
(d)	O
in	O
women	O
undertaking	O
CER	B
are	O
shown	O
for	O
comparison.	O

At	O
the	O
end-point	O
of	O
the	O
study,	O
no	O
significant	O
differences	O
in	O
the	O
biochemical	O
characteristics	O
were	O
found	O
among	O
the	O
three	O
groups,	O
except	O
for	O
fasting	O
glucose,	B
2-h	O
glucose	B
and	O
HbA1c	O
(Table ).	O

Plasmalogens	O
are	O
a	O
unique	O
class	O
of	O
glycerophospholipids	B
containing	O
a	O
fatty	B
alcohol	I
linked	O
by	O
a	O
vinyl-ether	B
moiety	O
at	O
the	O
sn −	O
 1	O
position	O
of	O
the	O
glycerol	B
backbone.	O

ADMA	B
is	O
the	O
most	O
studied	O
methylarginine	B
and	O
elevated	O
plasma	O
levels	O
have	O
been	O
associated	O
with	O
cardiovascular	O
disease,	O
sepsis	O
and	O
inhibition	O
of	O
cyclooxygenase-2	O
by	O
pain	O
medications.	O

Since	O
proline	B
is	O
endogenous	O
compound,	O
and	O
the	O
concentration	O
of	O
free	O
proline	B
in	O
normal	O
human	O
serum	O
was	O
reported	O
to	O
be	O
15.8	O
–	O
29.1	O
μg/mL,	O
the	O
LLOQ	O
selected	O
in	O
this	O
work	O
was	O
2.5	O
μg/mL,	O
which	O
was	O
more	O
than	O
6	O
times	O
lower	O
than	O
the	O
normal	O
level.	O

These	O
glycoproteins	B
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
growth,	O
differentiation	O
and	O
metastasis.	O

After	O
excluding	O
glass	O
binding	O
and	O
photodegradation	O
(data	O
not	O
shown),	O
we	O
tested	O
ascorbic	B
acid	I
as	O
an	O
antioxidant	O
to	O
prevent	O
potential	O
degradation	O
by	O
hydroxyl	O
and	O
superoxide	B
radicals	O
[–],	O
and	O
found	O
that	O
ascorbic	B
acid	I
effectively	O
stabilized	O
the	O
Me-OHNs	O
during	O
the	O
hydrolysis	O
process	O
by	O
preventing	O
the	O
oxidation	O
of	O
the	O
deconjugated	O
Me-OHNs.	O

Over	O
85%	O
(448)	O
features	O
were	O
found	O
in	O
common	O
between	O
the	O
methods	O
and	O
there	O
were	O
64	O
features	O
unique	O
to	O
the	O
methanol	B
method	O
and	O
78	O
features	O
unique	O
to	O
the	O
methanol-ethanol	B
method.	O

The	O
study	O
was	O
approved	O
at	O
individual	O
participating	O
institutions	O
in	O
the	O
Philippines,	B
Vietnam,	O
and	O
Morocco	O
and/or	O
by	O
supervising	O
Institutional	O
Review	O
Boards	O
for	O
these	O
institutions	O
and	O
at	O
lead	O
investigator’s	O
American	O
institutions.	O

Sodium	B
thiomethoxide,	I
BDA	O
and	O
N	B
-acetyl-L-lysine	I
were	O
combined	O
to	O
generate	O
S	B
-[1-(5-acetylamino-5-carboxypentyl)-1H	I
-pyrrol-3-yl]methanethiol.	I

Product	O
ion	O
mass	O
spectra	O
of	O
A)	O
5-HO-PhIP	B
([M+H]_+	O
at	O
m/z	O
241.2)	O
recovered	O
from	O
N	O
-acetoxy-PhIP-modified	O
SA	O
(upper	O
panel)	O
and	O
5-HO-[_2	B
H_5	I
]-PhIP	I
(([M+H]_+	O
at	O
m/z	O
246.2)	O
recovered	O
from	O
N	B
-acetoxy-[_2	I
H_5	I
]-PhIP-modified	I
SA	O
(bottom	O
panel)	O
digested	O
with	O
Pronase	O
E,	O
leucine	O
aminopeptidase,	O
and	O
prolidase.	O

Glucosepane	B
is	O
formed	O
from	O
the	O
degradation	O
of	O
FL	O
and	O
is	O
not	O
repaired	O
enzymatically,	O
potentially	O
providing	O
greater	O
sensitivity	O
for	O
detection	O
of	O
dysglycemia.	O

Only	O
high-density	O
lipoprotein	O
cholesterol	B
(HDL)	O
content	O
was	O
inversely	O
associated	O
with	O
the	O
three	O
diseases,	O
which	O
is	O
consistent	O
with	O
its	O
proposed	O
role	O
as	O
a	O
protective	O
factor.	O

Progesterone,	B
17-hydroxyprogesterone	B
and	O
11-deoxycorticosterone	B
were	O
55%	O
to	O
98%	O
lower	O
(P < 0.01)	O
in	O
postmenopausal	O
than	O
younger	O
women	O
who	O
were	O
not	O
taking	O
oral	O
contraceptives.	O

Together	O
with	O
3-phenyllatic	B
acid,	I
which	O
was	O
detected	O
postprandially	O
in	O
urine	O
after	O
the	O
intake	O
of	O
cheese,	O
each	O
of	O
these	O
metabolites	O
was	O
higher	O
after	O
cheese	O
intake,	O
compared	O
to	O
milk	O
and	O
soy	O
drink.	O

Four	O
examples	O
including	O
1,	O
2	O
and	O
3	O
protonation	O
sites,	O
(acetate,	O
alanine,	B
threonine	B
and	O
TTMethylHistidine)	B
are	O
shown	O
in	O
Table	O
and	O
Fig.	O
.	O

For	O
HILIC–LC–ESI–MS	O
analysis,	O
oligosaccharides	B
were	O
used	O
as	O
retention	O
time	O
index	O
standards	O
because	O
they	O
eluted	O
in	O
the	O
order	O
of	O
increasing	O
monomer	O
units,	O
with	O
larger	O
oligomers	O
eluting	O
as	O
the	O
latest	O
ones.	O

Since	O
increasing	O
evidence	O
indicates	O
that	O
inflammation	O
and	O
oxidative	O
stress	O
play	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	O
of	O
PAH,	O
aminomalonic	B
acid	I
emerges	O
as	O
a	O
potential	O
biomarker	O
regarding	O
the	O
inflammatory/oxidative	O
extent.	O

K07147:	O
methionine	B
sulfoxide	I
reductase	O
catalytic	O
subunit	O
msrP	O
[EC:1.8.-.-].	O

Lipids	O
are	O
a	O
group	O
of	O
naturally	O
occurring	O
molecules	O
such	O
as	O
types	O
of	O
vitamins,	O
monoglycerides,	B
and	O
others.	O

Piperine	B
has	O
been	O
shown	O
to	O
be	O
neuroprotective	O
in	O
AD	O
mouse	O
models,64,	O
65,	O
66,	O
67,	O
68	O
but	O
to	O
our	O
knowledge,	O
this	O
is	O
the	O
first	O
report	O
of	O
an	O
association	O
between	O
piperine	B
and	O
AD	O
in	O
a	O
human	O
study.	O

Increased	O
glycolysis	O
is	O
proposed	O
to	O
be	O
associated	O
with	O
many	O
tumors	O
and	O
with	O
cancer	O
cell	O
growth,	O
cancer	O
cells	O
prefer	O
to	O
utilize	O
1	O
molecule	O
glucose	B
through	O
glycolysis	O
to	O
generate	O
2	O
molecules	O
ATP	B
instead	O
of	O
36	O
molecules	O
ATP	B
through	O
oxidative	O
phosphorylation	O
even	O
in	O
presence	O
of	O
ample	O
oxygen.	O

In	O
essence,	O
PCA	O
showed	O
excellent	O
clustering	O
of	O
metabolomic	O
changes	O
for	O
different	O
treatment	O
conditions,	O
and	O
exposure	O
to	O
glucose	B
at	O
5	O
and	O
25 mM	O
lead	O
to	O
distinct	O
metabolomic	O
profiles	O
as	O
compared	O
to	O
samples	O
treated	O
with	O
serum-free	O
medium	O
or	O
mannitol	B
as	O
osmotic	O
control.	O

The	O
reagent	O
used	O
for	O
derivatisation	O
of	O
the	O
vitamin	B
D	I
compounds	O
was	O
Amplifex	O
Diene	O
Reagent	O
Kit,	O
consisting	O
of	O
two	O
components,	O
Diene	O
Reagent	O
and	O
Diene	O
Dilution.	O

The	O
median	O
metabolite	O
excretion	O
by	O
sex	O
compared	O
by	O
Mann–Whitney	O
U	O
test	O
revealed	O
a	O
significant	O
higher	O
excretion	O
for	O
almost	O
all	O
metabolites	O
in	O
men	O
than	O
in	O
women	O
as	O
shown	O
in	O
,	O
with	O
the	O
exception	O
of	O
pregnanediol	B
(206	O
vs.	O
204	O

Specifically,	O
we	O
have	O
shown	O
that	O
excursions	O
in	O
Leu/Ile	O
and	O
glycerol,	B
reflecting	O
the	O
sensitivity	O
of	O
proteolysis	O
and	O
lipolysis	O
to	O
the	O
action	O
of	O
insulin,	O
are	O
jointly	O
predictive	O
of	O
fasting	O
insulin,	O
with	O
each	O
of	O
the	O
two	O
excursions	O
offering	O
complementary	O
and	O
significant	O
explanatory	O
power.	O

In	O
preparation	O
for	O
the	O
recording	O
of	O
NMR	O
spectra,	O
75μl	O
of	O
phosphate	B
buffer	O
were	O
added	O
to	O
675μl	O
of	O
urine	O
to	O
set	O
the	O
pH	O
to	O
7.0	O
(+/-	O
0.35).	O

Peak	O
assignments:	O
0,	O
unidentified;	O
1,	O
cholesterol;	B
2,	O
lipids	O
(–CH_3	O
)	O
(mainly	O
LDL/VLDL);	O
3,	O
leucine;	B
4,	O
valine;	B
5,	B
3-hydroxybutyrate;	I
6,	O
lipids	O
(CH_2	O
)n	O
(mainlyLDL/VLDL);	O
7,	O
lactate;	B
8,	O
alanine;	B
9,	O
adipicacid;	O
10,	O
arginine;	B
11,	O
lysine;	B
12,	O
acetate;	B
13,	O
lipids	O
(CH_2	O
–C=C);	O
14,	O
acetyl	O
signals	O
from	O
glycoproteins;	B
15,	O
glutamine;	B
16,	O
lipids	O
(CH_2	O
–CO);	O
17,	O
citrate;	B
18,	O
lipids	O
(CH=CH–CH_2	O
–CH=CH–);	O
19,	O
Albumin	O
lysyl;	O
20,	O
creatine;	B
21,	O
choline;	B
22,	O
Trimethylamine	B
N-oxide;	I
23,	O
Proline;	B
24,	O
glucose;	B
25,	O
glycerol;	B
26,	O
Myo-inositol;	B
27,	O
creatinine;	B
28,	O
threonine;	B
29,	O
β-glucose;	B
30,	O
glycerol	B
of	O
lipids;	O
31,	O
α-glucose;	B
32,	O
lipids	O
(–CH=CH–);	O
33,	O
tyrosine;	B
34,	O
phenylalanine;	B
35,	O
histidine;	B
36,	B
1-methylhistidine;	I
37,	O
formate.	B

In	O
the	O
CTS	O
analysis	O
of	O
phospholipid	B
standards,	O
the	O
ions	O
with	O
largest	O
CCS	O
ranging	O
from	O
271	O
to	O
303	O
Å_2	O
corresponded	O
to	O
the	O
molecular	O
ion	O
[M−H]_−	O
for	O
PA,	O
PI,	O
PE,	O
and	O
PS	O
and	O
the	O
[M−15]_−	O
ion	O
for	O
PC	O
and	O
SM.	O

Models	O
analyzed	O
using	O
the	O
0.01ppm	O
width	O
were	O
marginally	O
better	O
with	O
respect	O
to	O
predictive	O
ability	O
for	O
the	O
acetaminophen	B
models,	O
thus,	O
the	O
0.01	O
ppm	O
bin	O
width	O
was	O
used	O
for	O
the	O
data	O
normalized	O
to	O
total	O
spectral	O
area.	O

Of	O
these	O
perturbed	O
metabolic	O
pathways,	O
linoleic	B
acid	I
metabolism	O
is	O
of	O
particular	O
note.	O

Similarly,	O
homovanillic	B
acid	I
and	O
DOPAC	O
are	O
both	O
involved	O
in	O
the	O
dopamine	B
pathway	O
and	O
have	O
been	O
shown	O
to	O
mediate	O
other	O
physiological	O
effects	O
including	O
ameliorating	O
age-related	O
decline	O
in	O
muscle	O
function	O
and	O
brain	O
function.	O

The	O
positive	O
correlations	O
of	O
CML	B
and	O
GSA	O
with	O
pyrraline	B
suggest	O
that	O
urinary	O
increases	O
of	O
these	O
metabolites	O
were	O
linked	O
to	O
increased	O
food	O
consumption.	O

Further,	O
we	O
observed	O
a	O
strongly	O
significant	O
downregulation	O
of	O
serine,	B
glycine,	B
aspartate,	B
glutamate	B
and	O
phenylalanine	B
in	O
cirrhosis	O
patients	O
vs.	O
healthy	O
controls,	O
consistent	O
with	O
the	O
notion	O
that	O
an	O
emergent	O
HCC	O
would	O
intensify	O
anabolic	O
demands.	O

(5-hydroxymethyl-2-furancarboxylic	O
acid,	I
benzoic	B
acid	I
and	O
hippuric	O
acid).	O

The	O
instrument	O
was	O
calibrated	O
before	O
analysis	O
with	O
0.5	O
mmol	O
L-1	O
sodium	B
formate	I
solution.	O

Moreover,	O
GABA	B
had	O
anti-oxidative	O
effects,	O
and	O
acute	O
hyperglycemia	O
after	O
a	O
meal	O
or	O
glucose	B
load	O
increases	O
oxidative	O
stress.	O

Oxysterols	B
are	O
more	O
soluble	O
than	O
cholesterol	B
and	O
are	O
reported	O
to	O
exert	O
inflammatory,	O
cytoprotective	O
and	O
apoptotic	O
effects	O
according	O
to	O
concentration	O
and	O
species.	O

In	O
our	O
studies,	O
glutamine	B
was	O
positively	O
associated	O
with	O
APOE‐ε4	O
status	O
and	O
CSF	O
t‐Tau	O
and	O
p‐Tau_181	O
levels.	O

Using	O
models	O
that	O
corrected	O
for	O
age	O
and	O
gender,	O
body	O
mass	O
index	O
showed	O
weak	O
negative	O
relationships	O
with	O
corticosterone,	B
21-deoxycortisol,	B
cortisol,	B
cortisone,	B
testosterone,	B
progesterone,	B
17-hydroxyprogesterone	B
and	O
11-deoxycorticosterone,	B
but	O
a	O
positive	O
relationship	O
with	O
18-hydroxycortisol.	B

PE	B
34:2	I
–	O
PIS	B
18:2)	I
was	O
used	O
to	O
calculate	O
the	O
additional	O
acyl	O
chain	O
(e.g.	O
PE	B
34:2 = 18:2 + 16:0).	I

However,	O
this	O
study	O
revealed	O
further	O
details,	O
providing	O
qualitative	O
and	O
quantitative	O
measurements	O
of	O
lipoproteins,	O
their	O
cholesterol	B
and	O
triglyceride	B
concentration,	O
as	O
well	O
as	O
the	O
number	O
of	O
sub-fraction	O
particles	O
and	O
their	O
size.	O

In	O
order	O
to	O
baseline	O
correct	O
for	O
this	O
linear	O
increase	O
in	O
taurine	B
levels	O
over	O
time,	O
the	O
difference	O
in	O
taurine	B
levels	O
between	O
the	O
time	O
interval	O
of	O
interest	O
and	O
the	O
last	O
time	O
interval	O
before	O
sleep	O
or	O
sleep	O
deprivation	O
(19:00–23:00 h)	O
was	O
used	O
as	O
input	O
for	O
statistical	O
analysis	O
by	O
LMM.	O

Several	O
studies	O
have	O
related	O
an	O
increased	O
serum	O
level	O
of	O
cholesterol	B
to	O
work-related	O
tendon	O
disorders,	O
for	O
example	O
in	O
frozen	O
shoulder	O
and	O
rotator	O
cuff	O
tear.	O

The	O
recovery	O
of	O
each	O
unconjugated	O
estrogen	B
was	O
determined	O
at	O
the	O
LQC,	O
MQC	O
and	O
HQC	O
(n=5).	O

Under	O
normal	O
homeostasis	O
conditions,	O
carnitine	B
is	O
eliminated	O
by	O
excretion	O
in	O
urine,	O
in	O
both	O
free	O
and	O
esterified	O
forms,	O
mainly	O
as	O
acetylcarnitine	B
(Chalmers	O
et	O
al.	O
).	O

AC:	O
AC	B
C18:2,	I
AC	O
C3-OH.	O

According	O
to	O
previous	O
data	O
showing	O
ROS	O
generation	O
after	O
exposure	O
to	O
organophosphorous	O
or	O
pyrethroids	O
,	O
,	O
we	O
hypothesize	O
that	O
the	O
increase	O
in	O
urinary	O
glycine	B
could	O
result	O
from	O
a	O
protective	O
mechanism	O
against	O
the	O
oxidative	O
stress	O
induced	O
by	O
a	O
more	O
complex	O
exposure	O
to	O
pesticides.	O

The	O
triglyceride	B
cluster	O
LC5	O
is	O
positively	O
correlated	O
with	O
gray	O
matter	O
density	O
in	O
lateral	O
temporal	O
surfaces	O
on	O
both	O
sides	O
and	O
medial	O
occipital	O
and	O
parietal	O
surfaces	O
on	O
the	O
right	O
side.	O

We	O
aimed	O
to	O
compare	O
CYP2A6	O
genetic	O
variation	O
and	O
CYP2A6	O
enzyme	O
activity	O
(representative	O
of	O
the	O
rate	O
of	O
nicotine	B
metabolism)	O
between	O
the	O
two	O
tribal	O
populations,	O
as	O
these	O
have	O
previously	O
been	O
associated	O
with	O
differences	O
in	O
smoking,	O
quitting,	O
and	O
lung	O
cancer	O
risk.	O

1.4 g	O
oleic	B
acid	I
(provided	O
as	O
five	O
1 g	O
oil	O
capsules	O
per	O
day),	O
with	O
no	O
weight	O
loss	O
program	O
(n	O
 = 26).	O

In	O
other	O
analyses	O
of	O
STEMI	O
patients,	O
lysophosphatidylcholines,	B
caffeine,	B
glycolysis,	O
tryptophan	B
and	O
sphingomyelin	B
metabolism	O
and	O
minerals	O
were	O
found	O
to	O
be	O
disrupted	O
compared	O
to	O
healthy	O
controls.	O

Additionally,	O
glucose	B
and	O
Krebs	O
cycle	O
intermediates	O
imported	O
from	O
urine	O
could	O
be	O
used	O
as	O
energy	O
substrates	O
by	O
proximal	O
tubular	O
cells	O
.	O

In	O
a	O
rodent	O
sepsis	O
model	O
in	O
which	O
metabolic	O
markers	O
in	O
rat	O
liver	O
tissue	O
were	O
examined,	O
an	O
increased	O
TCA	O
cycle	O
with	O
peripheral	O
release	O
of	O
amino	O
acids	O
like	O
glycine	B
for	O
the	O
liver	O
metabolism	O
and	O
an	O
increase	O
in	O
TCA	O
intermediate	O
products	O
including	O
citrate	B
were	O
reported.	O

Briefly,	O
urine	O
samples	O
were	O
diluted	O
25	O
times	O
with	O
eluent	O
A	O
(1:1	O
acetonitrile/aqueous	O
50	O
mM	O
ammonium	B
formate)	O
and	O
separated	O
by	O
an	O
inverse	O
acetonitrile	B
gradient	O
on	O
a	O
polar	O
HILIC	O
column	O
(Acquity	O
BEH	O
Amide,	B
100	O
×	O
2.1	O
mm,	O
1.7	O
µm,	O
Waters,	O
Eschborn,	O
Germany).	O

As	O
shown	O
in	O
,	O
HCC-induced	O
metabolic	O
perturbations	O
were	O
strongly	O
related	O
to	O
ammonia	O
recycling,	O
the	O
urea	B
cycle,	O
and	O
the	O
metabolism	O
of	O
glycine	B
and	O
serine,	B
methionine,	B
and	O
arginine	B
and	O
proline.	B

Glutamine	B
has	O
also	O
been	O
considered	O
a	O
conditionally	O
essential	O
amino	O
acid	O
in	O
certain	O
catabolic	O
states	O
because	O
its	O
utilization	O
exceeds	O
its	O
de	O
novo	O
synthesis	O
during	O
critical	O
illnesses.	O

However,	O
we	O
noted	O
significant	O
and	O
consistent	O
decreases	O
in	O
the	O
circulating	O
pools	O
of	O
PtdC,	O
PlsC,	O
and	O
sphingomyelins.	B

Most	O
patients	O
received	O
AZA	O
(n	O
=	O
127,	O
98.4%)	O
and	O
were	O
on	O
concurrent	O
5-aminosalicylates	B
(n	O
=	O
83,	O
64.3%)	O
and	O
steroids	O
(n	O
=	O
87,	O
67.4%)	O
at	O
the	O
time	O
of	O
thiopurine	B
initiation.	O

In	O
all	O
5	O
AN	O
patients	O
in	O
childhood	O
and	O
adolescence,	O
the	O
circadian	O
variation	O
of	O
the	O
sum	O
of	O
cortisol	B
metabolites	O
was	O
observed	O
and	O
was	O
similar	O
to	O
that	O
in	O
healthy	O
young	O
adults.	O

Dried	O
samples	O
were	O
dissolved	O
in	O
15	O
μL	O
of	O
pyridine,	B
containing	O
20	O
mg/mL	O
methoxyamine	B
hydrochloride,	I
at	O
40	O
°C	O
for	O
90	O
min	O
under	O
shaking.	O

On	O
the	O
other	O
hand,	O
the	O
NO	O
and	O
citrulline	B
levels	O
are	O
also	O
regulated	O
by	O
activation	O
of	O
arginase,	O
an	O
enzyme	O
that	O
catalyzes	O
a	O
competing	O
reaction	O
and	O
consumes	O
arginine.	B

Supernatants	O
were	O
subsequently	O
derivatised	O
using	O
AccQ·Fluor	B
reagent.	O

The	O
importance	O
of	O
the	O
acipimox-induced	O
decrease	O
in	O
the	O
intramyocellular	O
LC-FACoA	O
concentration	O
is	O
underscored	O
by	O
its	O
strong	O
correlation	O
with	O
improved	O
whole-body	O
(primarily	O
muscle)	O
glucose	B
disposal	O
during	O
the	O
hyperinsulinemic	O
euglycemic	B
clamp.	O

In	O
studies	O
involving	O
a	O
cohort	O
of	O
university	O
students,	O
it	O
was	O
shown	O
using	O
glucose	B
tolerance	O
tests	O
that	O
alterations	O
in	O
the	O
pentose	B
phosphate	I
pathway	O
were	O
associated	O
with	O
glucose	B
metabolism_30	O
,	O
_53	O
.	O

The	O
least	O
stable	O
of	O
these	O
metabolites	O
was	O
dihydropiceatannol,	B
which	O
had	O
two	O
hydroxyl	O
groups	O
in	O
para	O
and	O
meta	O
position	O
on	O
ring	O
B.	O

However,	O
there	O
is	O
an	O
alternative	O
metabolic	O
pathway	O
in	O
which	O
D-xylulose	B
is	O
metabolized	O
by	O
phosphofructokinase	O
(PFK	O
).	O

Serine	B
is	O
one	O
of	O
the	O
important	O
amino	O
acids	O
in	O
cancer	O
metabolism.	O

For	O
LC-TOFMS	O
measurements,	O
approximately	O
100	O
mg	O
of	O
FPP	O
was	O
plunged	O
into	O
500	O
μL	O
of	O
methanol	B
containing	O
an	O
internal	O
standard	O
solution	O
(20	O
μM;	O
#H3304-1002;	O
HMTI)	O
at	O
0°C	O
to	O
inactivate	O
enzymes.	O

Also,	O
the	O
fatty	O
acid	O
composition	O
of	O
these	O
two	O
species	O
is	O
different	O
(primary	O
constituent	O
of	O
PC	B
38:6a	I
is	O
PC	B
16:0/22:6	I
while	O
that	O
for	O
PC	B
38:6b	I
is	O
PC	B
18:2/20:4).	I

×	O
100	O
cm)	O
filled	O
with	O
200	O
mmol/L	O
ammonium	B
acetate	I
(pH	O
3.3)	O
as	O
the	O
run	O
buffer[].	O

Changes	O
in	O
levels	O
of	O
tryptophan	B
catabolites	O
were	O
related	O
to	O
mitochondrial	O
disturbances	O
and	O
impairment	O
of	O
brain	O
energy	O
metabolism	O
involved	O
in	O
the	O
development	O
of	O
neurodegenerative	O
disease.	O

Therefore,	O
an	O
increase	O
in	O
arginine	B
can	O
cause	O
an	O
increase	O
in	O
glutamate,	B
and	O
arginine	B
itself	O
may	O
also	O
trigger	O
this	O
synergistic	O
effect.	O

Citric	B
acid,	I
in	O
excess,	O
acts	O
as	O
an	O
antioxidant	O
and	O
a	O
preservative	O
in	O
solution.	O

(c)	O
PLS-DA	O
score	O
plot	O
of	O
fever	O
duration	B
6–12.	O

Since	O
cells	O
in	O
vivo	O
are	O
exposed	O
to	O
a	O
suite	O
of	O
fatty	O
acids,	O
oxylipins,	B
and	O
other	O
metabolites	O
present	O
in	O
lipoproteins	O
which	O
could	O
have	O
opposing	O
effects	O
on	O
inflammation,	O
characterizing	O
the	O
integrated	O
response	O
to	O
the	O
native	O
oxylipin	B
profile	O
and	O
evaluating	O
correlative	O
trends	O
with	O
inflammatory	O
response	O
ex-vivo	O
provides	O
physiological	O
relevance.	O

Arginine	B
and	O
the	O
arginine	B
metabolites	O
ornithine,	B
citrulline,	B
MMA,	O
ADMA	B
and	O
SDMA,	O
were	O
quantified	O
in	O
plasma	O
by	O
stable-isotope-dilution	O
HPLC	O
with	O
online	O
tandem	O
mass	O
spectrometry.	O

The	O
lower	O
concentrations	O
and	O
more	O
limited	O
ranges	O
observed	O
in	O
this	O
study	O
are	O
consistent	O
with	O
the	O
improved	O
specificity	O
of	O
our	O
assay,	O
as	O
shown	O
in	O
a	O
recent	O
comparison	O
of	O
urinary	O
estrogen	B
and	O
estrogen	B
metabolite	O
measures	O
obtained	O
using	O
traditional	O
immunoassays	O
and	O
the	O
LC/MS/MS	O
technique	O
used	O
in	O
this	O
study.	O

-hydroxycholesterol.	B

Data	O
on	O
vitamin	B
D	I
supplement	O
use	O
were	O
not	O
available.	O

We	O
have	O
developed	O
a	O
sensitive	O
assay	O
to	O
quantify	O
deoxythioguanosine	B
(dTG)	O
without	O
derivatisation	O
in	O
the	O
DNA	O
of	O
nucleated	O
blood	O
cells.	O

Serum	O
acetoacetate	B
was	O
increased	O
substantially	O
at	O
post-event	O
(Table	O
).	O

[2,	O
2,	O
3,	O
3-d4]	O
propionate	B
(TSP)	O
9.9	O
mmol/l,	O
MnSO_4	O
0.47	O
mmol/l	O
in	O
99.9%	O
D_2	O
O)	O
was	O
placed	O
coaxially	O
into	O
the	O
NMR	O
sample	O
tube	O
(o.d.	O

Cells	O
were	O
transfected	O
at	O
70%	O
confluency	O
with	O
luciferase	O
and	O
renilla	O
plasmids	O
(Promega,	O
Madison,	O
WI),	O
XRE	O
pGL4.43,	O
and	O
pRL-TK,	O
respectively,	O
using	O
Lipofectamine	B
2000	O
reagent	O
for	O
6	O
h.	O
Cells	O
were	O
treated	O
with	O
the	O
RCE/isoflavones	O
for	O
24	O
h	O
and	O
lysed	O
with	O
buffer.	O

a,	O
linoleic	B
acid	I
metabolism;	O
b,	O
arachidonic	B
acid	I
metabolism;	O
c,	O
pyruvate	B
metabolism;	O
d,	O
inositol	B
phosphate	I
metabolism;	O
e,	O
phenylalanine	B
metabolism;	O
f,	O
citrate	B
cycle.	O

The	O
increased	O
levels	O
of	O
urinary	O
cortisol,	B
dihydrocortisol	B
and	O
hydroxyprogesterone	B
were	O
observed	O
in	O
the	O
all	O
stages	O
of	O
PD	O
while	O
urinary	O
21-deoxycortisol	B
was	O
only	O
significantly	O
altered	O
in	O
the	O
mid-	O
and	O
advanced-	O
stages	O
PD	O

The	O
proximity	O
of	O
these	O
two	O
resonance	O
and	O
the	O
–CH_3	O
moiety	O
of	O
sialic	B
acid	I
or	O
N-acetyl	O
groups	O
of	O
glycoproteins	B
(2.06	O
to	O
2.1 ppm)	O
may	O
potentially	O
lead	O
to	O
some	O
confusion	O
in	O
vivo 	O
	O
_1	O
H-MR	O
spectroscopy	O
[,	O
,	O
,	O
]	O
or	O
non-HRMAS_5	O
ex	O
vivo	O
NMR	O
studies	O
of	O
ovarian	O
carcinoma	O
cases.	O

Simultaneous	O
measurements	O
of	O
metformin	B
concentrations	O
were	O
in	O
the	O
range	O
of	O
0.17	O
μ	O
M	O
to	O
23.0	O
mM.	O
IMZ	O
was	O
also	O
detectable	O
in	O
a	O
plasma	O
sample	O
(from	O
the	O
patient	O
with	O
the	O
highest	O
urinary	O
concentration	O
of	O
IMZ),	O
analyzed	O
at	O
a	O
1:1000	O
dilution,	O
suggesting	O
that	O
the	O
method	O
can	O
be	O
expanded	O
to	O
other	O
biological	O
matrices.	O

Then	O
BSTFA	O
was	O
added	O
with	O
1%	O
trimethylchlorosilane	B
(TCMS)	O
and	O
placed	O
at	O
70°Cfor	O
60 min	O
to	O
form	O
trimethylsilyl	O
(TMS)	O
derivatives.	O

Even	O
though	O
each	O
of	O
the	O
phospholipid	B
standards	O
has	O
17:0	O
at	O
the	O
sn	O
-1	O
position	O
and	O
20:4	O
esterified	O
to	O
sn	O
-2	O
position	O
of	O
the	O
glycerol	B
backbone,	O
different	O
ion	O
mobility	O
was	O
observed	O
for	O
each	O
lipid	O
class	O
molecular	O
ion	O
due	O
to	O
the	O
size	O
and	O
shape	O
of	O
the	O
polar	O
headgroup.	O

Glutamine	B
plays	O
a	O
role	O
in	O
upregulation	O
of	O
mTOR	O
signalling	O
pathway	O
to	O
facilitate	O
proliferation	O
in	O
tumor	O
cell	O
growth	O
and	O
interestingly	O
export	O
of	O
glutamine	B
to	O
the	O
extracelular	O
space	O
via	O
the	O
L-type	O
amino	O
acid	O
transportes	O
such	O
as	O
LAT1,	O
which	O
is	O
coupled	O
with	O
the	O
import	O
of	O
essential	O
amino	O
acids	O
such	O
as	O
BCAAs.	O

TMAO	B
plasma	O
concentrations	O
were	O
reduced	O
in	O
UC	O
compared	O
to	O
healthy	O
controls	O
(UC:	O
1.027 ± 0.896,	O
C:	O
5.478 ± 3.655,	O
p	O
<0.001)	O
and	O
when	O
adjusted	O
for	O
dietary	O
choline	B
plasma	O
concentrations	O
(UC:	O
0.149 ± 0.232,	O
C:0.643 ± 0.388,	O
p<0.0001).	O

Total	O
levels	O
of	O
monohexosylceramides	B
in	O
human	O
cadaver	O
corneas	O
from	O
Healthy,	O
T1DM,	O
and	O
T2DM	O
donors.	O

Interestingly	O
1	O
matching	O
metabolite,	O
lysoPC	O
a	O
C20:4	B
[Biocrates]	O
/	O
1—arachidonoylglycerophosphocholine	O
[Metabolon],	O
showed	O
low	O
heritability	O
in	O
one	O
platform	O
(0.09	O
in	O
Metabolon	O
and	O
0.59	O
in	O
Biocrates	O
platform)	O
and	O
showed	O
relatively	O
low	O
correlation	O
(r	O
=	O
0.29)	O
across	O
platforms,	O
but	O
was	O
still	O
identified	O
to	O
associate	O
with	O
the	O
same	O
locus	O
from	O
both	O
platforms	O
at	O
genome-wide	O
significance.	O

SM	B
(d18:2/24:1),	I
which	O
was	O
inversely	O
associated	O
with	O
dyslipidemia	O
in	O
cross-sectional	O
analysis,	O
was	O
directly	O
associated	O
with	O
longitudinal	O
change	O
in	O
HDL-C.	O
Single	O
marker	O
associations	O
with	O
longitudinal	O
changes	O
in	O
metabolic	O
risk	O
factors.	O

For	O
antigen	O
retrieval,	O
slides	O
were	O
heated	O
in	O
the	O
steamer	O
for	O
either	O
40	O
or	O
60 minutes	O
in	O
citrate	B
buffer	O
(pH 6.0)	O
(Biocare	O
Medical,	O
(Concord,	O
CA)	O

Water,	O
Optima_TM	O
LC/MS	O
grade	O
was	O
obtained	O
from	O
Fisher	O
Scientific	O
(Leicester,	O
U.K.),	O
LC-MS	O
grade	O
solvents	O
and	O
formic	B
acid	I
were	O
from	O
Sigma-Aldrich	O
(Gillingham,	O
U.K.)	O
and	O
the	O
AccQTag	O
Ultra	O
reagents	O
including	O
borate	O
buffer	O
from	O
Waters	O
Corporation	O
(Milford,	O
MA,	O
U.S.A.).	O

Wang	O
et	O
al.	O
indicated	O
that	O
asparagine	B
supplementation	O
improves	O
energy	O
status	O
and	O
attenuates	O
the	O
changes	O
in	O
serum	O
biochemical	O
parameters	O
in	O
weaned	O
piglets	O
after	O
the	O
administration	O
of	O
a	O
lipopolysaccharide	B
challenge.	O

After	O
adding	O
1.8	O
mL	O
mixture	O
containing	O
0.6	O
mL	O
distilled	O
water	O
(2	O
mL/g	O
tissue)	O
and	O
1.2	O
mL	O
methanol	B
(4	O
mL/g	O
tissue),	O
the	O
resulting	O
mixture	O
was	O
homogenized	O
at	O
16000	O
rpm	O
for	O
80	O
s.	O
After	O
homogenization,	O
the	O
mixture	O
was	O
added	O
to	O
chloroform	B
(4	O
mL/g	O
tissue)	O
and	O
distilled	O
water	O
(4	O
mL/g	O
tissue)	O
and	O
vortexed	O
for	O
60	O
s.	O

Stable	O
isotope-labeled	O
estrogens	O
(SI-EM),	O
including	O
estradiol-13,14,15,16,17,18-_13	B
C_6	O
(_13	O
C_6	O
-E_2	O
)	O
and	O
estrone-13,14,15,16,17,18-_13	B
C_6	O
(_13	O
C_6	O
-E_1	O
)	O
were	O
purchased	O
from	O
Cambridge	O
Isotope	O
Laboratories,	O
Inc.	O
(Andover,	O
MA,	O
USA);	O
estriol-2,4,17-d	B
_3	O
(d_3	O
-E_3	O
),	O
2-hydroxyestradiol-1,4,16,16,17-d	B
_5	O
(d_5	O
-2-OHE_2	O
),	O
and	O
2-methoxyestradiol-1,4,16,16,17-d	B
_5	O
(d_5	O
-2-MeOE_2	O
),	O
were	O
obtained	O
from	O
C/D/N	O
Isotopes,	O
Inc.	O

All	O
standards	O
were	O
purchased	O
from	O
Sigma-Aldrich,	O
except	O
for	O
phenylalanine-d5,	B
which	O
was	O
from	O

As	O
demonstrated	O
in	O
,	O
this	O
fragment	O
ion	O
(i.e.	O
,	O
AMPP-derivatized	O
prop-2-enoic	O
acid)	O
arises	O
from	O
the	O
cleavage	O
of	O
C3–C4	O
bond	O
through	O
1,4-hydrogen	B
elimination	O
(i.e.	O
,	O
from	O
C2	O
and	O
C5),	O
and	O
is	O
stabilized	O
by	O
the	O
resultant	O
α,β-unsaturated	B
amide	I
leading	O
to	O
its	O
relatively	O
high	O
abundance.	O

The	O
metabolism	O
of	O
oxyresveratrol	B
was	O
similar	O
to	O
resveratrol,	B
and	O
one	O
metabolite,	O
2′,3,4′,5-tetrahydroxybibenzyl,	O
formed	O
by	O
double	O
bond	O
reduction,	O
was	O
detected.	O

Prostaglandin	B
E2	I
(PGE2),	O
another	O
typical	O
proteinoid,	B
has	O
been	O
verified	O
to	O
induce	O
tumor	O
cell	O
invasion	O
in	O
the	O
EP4-mediated	O
pathway,	O
which	O
would	O
account	O
for	O
a	O
worse	O
clinical	O
outcome.	O

For	O
example,	O
the	O
significantly	O
decreased	O
levels	O
of	O
amino	O
acids	O
(glycine,	O
valine,	B
isoleucine,	B
glutamine,	B
proline,	B
threonine,	B
and	O
5-hydroxytryptophan	B
as	O
well	O
as	O
L-arginine,	B
deoxycholic	B
acid	I
glycine	I
conjugate,	I
etc.	O
)	O
were	O
observed	O
in	O
both	O
diseases,	O
despite	O
their	O
pathological	O
and	O
histological	O
features	O
being	O
so	O
different.	O

Comparing	O
within	O
each	O
BMI	O
cohort,	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
histology	O
groups	O
in	O
fasting	O
serum	O
total	O
cholesterol	B
(lean,	O
K-W=1.38,	O
p-value=0.50;	O
obese,	O
K-W=4.14,	O
p-value=0.13;	O
morbidly	O
obese,	O
K-W=3.84,	O
p-value=0.15).	O

Patients	O
who	O
take	O
oxycodone	B
for	O
chronic	O
pain	O
relief	O
might	O
have	O
urine	O
oxycodone	B
concentrations	O
above	O
the	O
2,500	O
ng/mL	O
on	O
occasion,	O
immediately	O
after	O
the	O
last	O
dose,	O
but	O
oxycodone	B
and	O
its	O
metabolites	O
will	O
be	O
present	O
below	O
the	O
2,500	O
ng/mL	O
limit	O
most	O
of	O
the	O
time,	O
leading	O
to	O
false	O
negative	O
laboratory	O
result.	O

It	O
is	O
also	O
a	O
product	O
of	O
degradation	O
from	O
cellulose	O
acetate	B
films.	O

Large	O
differences	O
in	O
peripheral	O
concentrations	O
of	O
adenosine	B
(ischemic	O
+130%	O
vs	O
non-ischemic	O
+15%	O
at	O
180-minutes,	O
p = 0.006)	O
and	O
5-hydroxytryptophan	B
concentrations	O
(ischemic	O
+120%	O
vs	O
non-ischemic	O
−1%	O
at	O
180-minutes,	O
p = 0.03)	O
were	O
observed.	O

The	O
finding	O
that	O
phosphatidylcholine	B
oxidation	O
products	O
that	O
have	O
been	O
shown	O
in	O
vitro	O
to	O
induce	O
disease	O
related	O
phenotypic	O
changes	O
in	O
endothelial	O
cells	O
were	O
not	O
elevated	O
in	O
our	O
obese	O
subjects	O
was	O
unexpected.	O

Furthermore,	O
the	O
metabolomic	O
profile	O
of	O
good	O
responders	O
differed	O
from	O
that	O
of	O
moderate	O
responders	O
mainly	O
in	O
the	O
levels	O
of	O
3-hydroxybutyrate	B
and	O
1-methyl-hystidine,	B
which	O
were	O
significantly	O
higher,	O
and	O
in	O
the	O
level	O
of	O
alanine,	B
which	O
was	O
significantly	O
lower.	O

Biosynthesis	O
of	O
prostaglandin	B
D2.	I

For	O
the	O
protein	O
precipitation,	O
acidic	O
conditions	O
were	O
chosen,	O
as	O
protein	O
precipitation	O
with	O
methanol	B
or	O
acetonitrile	B
would	O
have	O
required	O
evaporation	O
of	O
the	O
solvent	O
prior	O
to	O
derivatization	O
and	O
analysis.	O

250	O
µL	O
of	O
urine	O
is	O
combined	O
with	O
500	O
µL	O
of	O
acetate	B
buffer	O
(pH	O
4.6),	O
50	O
µL	O
of	O
50	O
mg/mL	O
ascorbic	B
acid,	I
and	O
glucuronidase/sulfatase	O
(β-Glucuronidase	O
from	O
Helix	O
pomatia,	O
Sigma).	O

mL.	O
A	O
solution	O
of	O
the	O
internal	O
standard,	O
GP,	B
was	O
prepared	O
in	O
methanol	B
(1.0	O
mg/mL)	O
and	O
further	O
diluted	O
with	O
methanol:water	B
(1:1	O
v/v)	O
to	O
achieve	O
a	O
final	O
concentration	O
of	O
50	O
ng/mL	O
All	O
the	O
calibrators	O
and	O
QCs	O
were	O
aliquoted	O
and	O
stored	O
at	O
−80°C	O
along	O
with	O
clinical	O
study	O
samples.	O

A	O
previous	O
study	O
investigated	O
metabolism	O
of	O
platelet	O
concentrates	O
during	O
sample	O
storage	O
and	O
reported	O
correlations	O
with	O
hypoxanthine,	B
malate,	B
lactate,	B
and	O
glucose.	B

Fishman	O
J.	O
Uterine	O
estrogen	B
receptor	O
binding	O
of	O
catecholestrogens	B
and	O
of	O
estetrol	O
(1,3,5(10)-estratriene-3,15alpha,16alpha,17beta-tetrol).	O

However,	O
there	O
was	O
no	O
significant	O
difference	O
beween	O
ischemic	O
and	O
nonischemic	O
subjects	O
in	O
transcoronary	O
elution	O
of	O
either	O
5-hydroxytryptophan	B
(e.g.	O
−16%	O
vs	O
−1%	O
at	O
60-minutes,	O
p = 0.92)	O
or	O
adenosine	B
(e.g.	O
−41%	O
vs	O
−21%	O
at	O
60-minutes,	O
p = 0.92)	O
at	O
any	O
timepoint	O
after	O
pacing	O
implying	O
a	O
non-cardiac	O
source	O
for	O
this	O
differential	O
response.	O

(C)	O
Schematic	O
illustration	O
of	O
accumulation	O
of	O
asymmetric	B
dimethylarginine	I
(ADMA)	O
because	O
of	O
inactivation	O
of	O
dimethylargine	O
dimethylaminohydrolases	O
(DDAH),	O
a	O
major	O
enzyme	O
responsible	O
for	O
the	O
metabolism	O
of	O
ADMA,	B
under	O
oxidative	O
stress.	O

We	O
conclude	O
that	O
in	O
response	O
to	O
high	O
glucose,	B
HK-2	O
cells	O
characteristic	O
metabolomic	O
changes,	O
including	O
increase	O
in	O
lactate-to-pyruvate	O
ratio,	O
reduction	O
in	O
Krebs	O
cycle	O
metabolites,	O
reduction	O
in	O
glutathione	B

When	O
the	O
different	O
late-IUGR	O
subsets	O
were	O
considered	O
in	O
regard	O
to	O
glutamine	B
levels,	O
thought-provoking	O
differences	O
were	O
found:	O
while	O
vasodilated	O
late-IUGR	O
cases	O
did	O
not	O
show	O
any	O
significant	O
change,	O
there	O
was	O
a	O
significant	O
decrease	O
in	O
the	O
non-vasodilated	O
late-IUGR	O
cases.	O

This	O
metabolite	O
peak	O
depended	O
on	O
the	O
NADPH-generating	O
system,	O
duration	B
of	O
incubation	O
and	O
microsomal	O
protein	O
and	O
substrate	O
concentrations	O
(data	O
not	O
shown).	O

Using	O
these	O
metabolites	O
we	O
could	O
reach	O
a	O
higher	O
predictive	O
value	O
than	O
using	O
only	O
Resolvin	B
D1.	I

Spectrum	O
of	O
serum	O
from	O
patients	O
and	O
healthy	O
subjects	O
shows	O
the	O
presence	O
of	O
metabolites	O
including	O
amino	O
acids	O
like	O
alanine,	B
lysine,	B
glutamine,	B
glutamate,	B
other	O
branched	O
chain	O
amino	O
acids,	O
metabolites	O
like	O
lactate,	B
N-acetyl	B
glycoproteins	I
(NAG),	O
glucose,	B
lipids,	O
creatinine,	B
acetate,	B
pyruvate,	B
citrate	B
and	O
lipoproteins	O
(HDL,	O
LDL	O
and	O
VLDL).	O

Additionally,	O
FSGS	O
patients	O
had	O
lower	O
urine	O
N-methylnicotinamide	B
levels	O
compared	O
with	O
other	O
glomerulopathies.	O

For	O
example,	O
levels	O
of	O
hexadecanedioate,	B
and	O
octadecanedioate	B
were	O
significantly	O
higher	O
in	O
C-P	O
(fold	O
changes:	O
1.72	O
and	O
1.64)	O
and	O
C-3N	O
(fold	O
changes:	O
1.71	O
and	O
1.72)	O
subjects	O
than	O
C-C	O
subjects	O
after	O
the	O
adjustment	O
of	O
multiple	O
comparisons.	O

Our	O
_1	O
H-NMR-based	O
metabolomic	O
findings	O
identified	O
distinct	O
disturbances	O
to	O
CRC	O
patient	O
urine	O
metabolites,	O
even	O
at	O
stage	O
I/II,	O
compared	O
with	O
HCs,	O
including	O
elevated	O
acetoacetate,	B
guanidoacetate,	B
cis-aconitate,	B
trans-aconitate,	B
glutamine,	B
and	O
homocycteine,	O
and	O
reduced	O
creatinine,	B
phosphorylcholine,	B
dimethyl	B
sulfone,	I
asparagine,	B
alanine,	B
isocitrate,	B
hippurate,	B
methylamine,	B
cysteine,	B
and	O
phenylalanine	B
(Table	O
).	O

We	O
also	O
had	O
estrogen	B
measurements	O
at	O
only	O
one	O
point	O
in	O
time.	O

The	O
PPP	O
is	O
tightly	O
linked	O
to	O
cysteine	B
metabolism	O
and	O
GSH	B
homeostasis	O
by	O
providing	O
NADPH,	B
which	O
is	O
essential	O
for	O
the	O
regeneration	O
of	O
GSH	B
from	O
its	O
oxidized	O
form,	O
GSSG	O
(Perl	O
)	O
(Fig. ).	O

Finally,	O
we	O
describe	O
the	O
potential	O
clinical	O
significance	O
of	O
this	O
intestinal	O
microbiota-dependent	O
metabolite	O
by	O
showing	O
that	O
fasting	O
plasma	O
TMAO	B
levels	O
predict	O
the	O
risk	O
of	O
incident	O
major	O
adverse	O
cardiovascular	O
events	O
independently	O
of	O
traditional	O
cardiovascular	O
risk	O
factors	O
and	O
the	O
presence	O
or	O
extent	O
of	O
coronary	O
artery	O
disease	O
and	O
within	O
multiple	O
low-risk	O
subgroups,	O
including	O
both	O
participants	O
without	O
angiographic	O
evidence	O
of	O
substantial	O
coronary	O
artery	O
disease	O
(i.e.,	O
stenosis	O
of	O
<50%	O
in	O
major	O
coronary	O
vessels)	O
and	O
those	O
with	O
low-risk	O
lipid	O
and	O
apolipoprotein	O
levels.	O

We	O
observed	O
markedly	O
decreased	O
C_6	O
-sugar	O
phosphates	B
and	O
phosphoenolpyruvate	B
indicating	O
impaired	O
glycolysis.	O

iii	O
,	O
MnO_2	O
,	O
Celite,	O
CH_2	O
Cl_2	O
,	O
room	O
temperature,	O
4	O
h	O
(73%,	O
β-ionylideneacetaldehyde;	B
36%,	O
β-apo-10′-carotenal;	B
6%,	O
β-apo-14′-carotenal).	B

Betaine,	B
PLTP	O
and	O
LCAT	O
activity	O
were	O
not	O
different	O
between	O
men	O
and	O
women	O
(p	O
 > 0.10	O
for	O
each;	O
data	O
not	O
shown).	O

The	O
metabolic	O
differences	O
were	O
highlighted	O
in	O
multiple	O
metabolic	O
pathways	O
involving	O
energy	O
metabolism,	O
protein	O
biosynthesis,	O
and	O
metabolisms	O
of	O
fatty	O
acids	O
and	O
choline,	B
which	O
probably	O
involved	O
biosynthesis	O
of	O
cell	O
membranes.	O

In	O
a	O
separate	O
method,	O
3-O	O
-Gluc,	O
7-O	O
-Gluc,	O
and	O
3,7-O	B
-Digluc	I
were	O
isolated	O
from	O
plasma	O
by	O
a	O
solid-phase	O
extraction	O
(SPE)	O
procedure.	O

Go	O
to:	O
The	O
aminoalkylindole	B
agonists	O
JWH-018	O
and	O
JWH-073	O
are	O
contained	O
in	O
“K2/SPICE”	O
products	O
sold	O
as	O
“legal	O
marijuana”.	O

The	O
pH	O
of	O
the	O
CSF	O
NMR	O
sample	O
was	O
adjusted	O
to	O
around	O
7	O
(7.0–7.1)	O
by	O
the	O
buffering	O
capacity	O
of	O
the	O
phosphate	B
in	O
the	O
buffer	O
solution.	O

OPLS-DA	O
revealed	O
fecal	O
marker	O
metabolites	O
(e.g.,	O
fructose,	B
linoleic	B
acid,	I
and	O
nicotinic	O
acid)	O
that	O
provided	O
novel	O
insights	O
into	O
the	O
tumorigenesis	O
of	O
CRC.	O

The	O
pH	O
of	O
lysosomes	O
in	O
7	O
NF/CAF	O
pairs	O
determined	O
by	O
ratiometric	O
fluorescence	O
microscopy	O
of	O
endocytosed	O
rhodamine-fluorescein	B
(R/F)	O
labeled	O
dextran.	O

However,	O
women	O
showed	O
a	O
more	O
benficial	O
lipid	O
profile,	O
mainly	O
due	O
to	O
higher	O
HDL-cholesterol	B
values,	O
compared	O
to	O
men.	O

Breast	O
cancer	O
risk	O
for	O
women	O
in	O
the	O
highest	O
tertile	O
of	O
kaempferol	B
have	O
more	O
than	O
doubled	O
(OR=2.41	O
(1.04–5.59)	O
that	O
for	O
women	O
in	O
the	O
lowest	O
tertile(data	O
not	O
shown).	O

PS	O
is	O
a	O
glycerophospholipid	B
in	O
which	O
a	O
phosphorylserine	B
moiety	O
occupies	O
a	O
glycerol	B
substitution	O
site.	O

Furthermore,	O
the	O
12-LOX	O
pathway	O
metabolites	O
like	O
12-HETE,	B
12-hydroxyeicosapentaenoic	B
acid	I
(12-HEPE),	O
9-hydroxyoctadecanoic	B
acid	I
(9-HODE)	O
and	O
14-hydroxydocosahexaenoic	B
acid	I
(14-HDHA);	O
the	O
15-LOX	O
metabolites	O
15-HETE,	B
13-HODE,	B
15-HEPE	B
and	O
17-HDHA	B
and	O
various	O
other	O
PUFA	O
metabolites	O
like	O
11-HETE,	B
20-COOH-AA	B
and	O
the	O
oxidative	O
stress	O
marker	O
8iPGF_2	O
were	O
all	O
present	O
at	O
enhanced	O
concentrations	O
(significantly	O
different)	O
in	O
AgP	O
patient	O
samples.	O

Model	O
1	O
adjusts	O
for	O
demographic	O
variables:	O
age,	O
gender,	O
and	O
sample;	O
model	O
2	O
adds	O
medical	O
and	O
life-style	O
factors:	O
history	O
of	O
heart	O
disease	O
or	O
stroke,	O
moderate	O
to	O
heavy	O
physical	O
activity	O
(hours/day),	O
medication	O
for	O
hypertension,	O
prescribed	O
lipidlowering	O
drugs,	O
NSAID	O
use,	O
dietary	O
supplement	O
use,	O
special	O
diet,	O
smoking	O
status,	O
years	O
of	O
education,	O
and	O
total	O
energy	O
intake	O
per	O
day	O
(kcal/day);	O
and	O
model	O
3	O
adds	O
24-hour	O
urinary	O
creatinine	B
(mmol/day).	O

In	O
multiple	O
regression	O
analysis	O
of	O
potential	O
determinants	O
for	O
the	O
metabolites,	O
chosen	O
to	O
reflect	O
nutritional	O
status	O
(SGA>1,	O
plasma	O
albumin),	O
DM	O
and	O
renal	O
function	O
in	O
the	O
total	O
CKD	O
cohort,	O
mGFR	O
was	O
the	O
most	O
dominant	O
variable	O
for	O
TMAO	B
(β	O
=	O
-0.41,	O
p<0.001),	O
choline	B
(β	O
=	O
-0.38,	O
p<0.001),	O
and	O
betaine	B
(β	O
=	O
0.45,	O
p<0.001)	O
levels,	O
respectively.	O

Altered	O
plasma	O
levels	O
of	O
macrophage	O
inflammatory	O
protein	O
(MIP)	O
1α	O
in	O
plasma	O
of	O
heavy	O
cannabis	B
users	O
compared	O
with	O
noncannabis	O
users.	O

To	O
account	O
for	O
this	O
asymmetrical	O
distribution,	O
we	O
first	O
applied	O
a	O
log_10	O
transformation	O
to	O
glucose	B
levels	O
(Figure	O
S-2B).	O

For	O
each	O
well,	O
60	O
μL	O
of	O
1-butanol	B
and	O
acetyl	B
chloride	I
mixture	O
(90:10,	O
v/v)	O
was	O
added	O
and	O
incubated	O
at	O
65°C	O
for	O
20	O
minutes	O
for	O
metabolite	O
derivatization.	O

Concentration	O
of	O
acetone	B
trended	O
higher	O
(p = 0.015),	O
and	O
those	O
of	O
pyruvate	B
(p = 0.002)	O
and	O
ascorbate	B
(p = 0.003)	O
were	O
higher	O
in	O
the	O
ALS	O
group.	O

A	O
total	O
of	O
13	O
types	O
of	O
amino	O
acids	O
and	O
8	O
types	O
of	O
acylcarnitines	B
were	O
measured	O
using	O
the	O
LC-MS/MS	O
method	O
as	O
described	O
previously.	O

Thus,	O
our	O
results	O
also	O
help	O
to	O
clarify	O
some	O
controversies	O
regarding	O
the	O
effects	O
of	O
EPA + DHA	O
on	O
glucose	B
homeostasis	O
in	O
T2D	O
patients	O
(see	O
Background).	O

In	O
contrast,	O
myo	O
-inositol,	O
arabitol,	B
isocitric	B
acid,	I
glucuronic	B
acid,	I
l-ornithine,	B
TMAO,	B
SM	B
C16:1,	I
l-tyrosine,	B
hippuric	B
acid,	I
choline,	B
pseudouridine,	B
and	O
potassium	O
show	O
positive	O
weights	O
and	O
therefore	O
tend	O
to	O
have	O
a	O
higher	O
concentration	O
in	O
older	O
men.	O

Higher	O
serum	O
homocysteine,	B
cystathionine,	B
and	O
cysteine	B
concentrations	O
independently	O
predicted	O
risk	O
of	O
early	O
biochemical	O
recurrence	O
and	O
aggressiveness	O
of	O
disease	O
in	O
a	O
nested	O
case	O
control	O
study.	O

It	O
has	O
been	O
demonstrated	O
that	O
plasma	O
LysoPC(16:0)	B
can	O
inhibit	O
Lp-PLA2	O
activity	O
both	O
in	O
vitro	O
and	O
in	O
vivo,	O
thereby	O
suppressing	O
their	O
neuroinflammative	O
properties.	O

The	O
fecal	O
extracts	O
were	O
finally	O
prepared	O
by	O
mixing	O
4 µl	O
of	O
D_2	O
O/500 µM	O
TSP	O
(3-trimethylsilyl-2,2,3,3-tetradeuterosodium	O
propionate,	I
final	O
TSP =	O

TB	O
patients	O
were	O
further	O
characterized	O
by	O
relatively	O
high	O
levels	O
of	O
several	O
metabolites	O
including	O
the	O
L-DOPA	B
metabolite	O
3-methoxytyrosine,	B
whereas	O
only	O
putrescine,	B
a	O
polyamine	B
associated	O
with	O
DM,	O
was	O
found	O
to	O
be	O
specifically	O
elevated	O
in	O
TB-DM.	O

Estrone	B
and	O
estradiol	B
in	O
blood	O
remain	O
stable	O
for	O
years	O
during	O
long-term	O
storage	O
at	O
−70°C	O
or	O
lower.	O

Ammonium	B
fluoride	I
has	O
been	O
reported	O
to	O
result	O
in	O
the	O
ionization	O
of	O
additional	O
compounds	O
and	O
may	O
in	O
fact	O
enhance	O
ionization	O
when	O
using	O
negative	O
electrospray	O
[,	O
].	O

An	O
example	O
is	O
the	O
now	O
famous	O
CARET	O
trial,	O
which,	O
based	O
on	O
observational	O
epidemiology,	O
explored	O
whether	O
supplemental	O
β-carotene	B
would	O
decrease	O
incidence	O
of	O
lung	O
cancer	O
in	O
a	O
highly	O
susceptible	O
population,	O
namely	O
smokers	O
and	O
asbestos	O
workers	O
(,	O
).	O

The	O
androgen	O
metabolites	O
were	O
subsequently	O
tested	O
for	O
an	O
association	O
with	O
incidence	O
of	O
DED,	O
and	O
epiandrosterone	B
sulfate	I
(P	O
 = 0.0076)	O
appeared	O
to	O
be	O
the	O
most	O
strongly	O
associated,	O
with	O
the	O
other	O
4	O
androgens	O
showing	O
nominal	O
significance	O
levels,	O
before	O
multiple	O
testing	O
correction:	O
4-androsten-3beta,17beta-diol	B
disulfate	I
1,	O
P	O
 =	O
0.046;	O
androsterone	B
sulfate,	I
P	O
 =	O
0.055;	O
dehydroepiandrosterone	B
sulfate,	I
P	O
 =	O
0.063;	O
and	O
4-androsten-3beta,17beta-diol	B
disulfate	I
2,	O
P	O
 =	O
0.085.	O

In	O
addition,	O
lower	O
relative	O
abundances	O
of	O
phytosphingosine	B
and	O
sphinganine	B
were	O
observed	O
in	O
the	O
non-severe	O
CAP	O
group	O
compared	O
to	O
the	O
severe	O
CAP	O
group	O
and	O
controls.	O

The	O
PS	O
ratio	O
trend	O
remained	O
similar	O
when	O
PS(18:0_20:4)	B
was	O
divided	O
by	O
the	O
sum	O
of	O
all	O
PS	O
lipids	O
(SI	O
Appendix	O
,	O
Fig.	O

Cats	O
in	O
the	O
control	O
group	O
received	O
a	O
0.1 mL/kg	O
body	O
weight	O
of	O
saline	B
subcutaneously	O
every	O
24 h.	O

Our	O
solution	O
to	O
the	O
problem	O
of	O
a	O
huge	O
dynamic	O
range,	O
which	O
can	O
inhibit	O
quantitation	O
of	O
both	O
of	O
these	O
important	O
compounds,	O
was	O
to	O
decrease	O
the	O
sensitivity	O
of	O
cotinine	B
detection	O
by	O
analysis	O
of	O
naturally	O
occurring	O
[_13	O
C]cotinine	O
in	O
the	O
samples.	O

Clearly,	O
only	O
tyramine	B
showed	O
good	O
peak	O
shape	O
and	O
was	O
well	O
separated	O
from	O
PA	O
and	O
QA.	O

The	O
mass	O
spectrometer	O
was	O
operated	O
in	O
the	O
electron	O
impact	O
mode	O
at	O
70eV.	O
A	O
fused	O
silica,	B
nonpolar,	O
capillary	O
column	O
(Restek,	O
Bellefont,	O
PA,	O
USA),	O
RTX-5MS	O
model	O
30m	O
x	O
0.25mm,	O
id.	O
x	O

GP-tagged	O
oxysterols	B
offer	O
three	O
advantages	O
for	O
this	O
type	O
of	O
analysis	O
as	O
follows:	O
(i)	O
charge	O
tagging	O
improves	O
parent	O
molecule	O
ionization	O
by	O
2–3	O
orders	O
of	O
magnitude;	O
(ii)	O
GP-tagged	O
oxysterols	B
give	O
an	O
abundant	O
[M	O
−	O
79]_+	O
ion	O
upon	O
MS_2	O

In	O
contrast,	O
we	O
revealed	O
significantly	O
higher	O
levels	O
of	O
L-phenylalanine	B
in	O
patients	O
compared	O
with	O
the	O
control	O
group.	O

Thus,	O
lysophospholipid	B
metabolism	O
in	O
cancer	O
might	O
vary	O
depending	O
on	O
the	O
type	O
and	O
stage	O
of	O
cancer.	O

Consequently,	O
since	O
there	O
is	O
a	O
correlation	O
between	O
lactate	B
and	O
testosterone	B
production	O
in	O
rat	O
Leydig	O
cells,	O
in	O
these	O
patients,	O
testosterone	B
production	O
can	O
be	O
further	O
reduced	O
upon	O
time.	O

DSS-d6,	O
sodium	B
2,2-dimethyl-2-silapentane-5-sulfonate-d6.	I

1,6-anhydro-β-D-glucose,	B
and	O
the	O
glycolytic	B
end	O
product,	O
lactate).	B

It	O
has	O
been	O
proved	O
that	O
BCAAs	O
can	O
promote	O
the	O
proliferation	O
of	O
tumor	O
cells	O
by	O
activating	O
mammalian	O
target	O
of	O
rapamycin	B
signaling.	O

Values	O
represent	O
ATP	B
concentration	O
mean	O
values	O
±	O
S.D.	O
of	O
3	O
independent	O
experiments	O
(*p	O
<	O
0.05,	O
**p	O
<	O
0.01,	O
**	O

In	O
line	O
with	O
the	O
described	O
inhibition	O
of	O
BNP	O
on	O
angiotensin	B
II	I
induced	O
steroidogenesis,	O
the	O
strong	O
inverse	O
association	O
with	O
NT-proBNP	O
may	O
be	O
a	O
consequence	O
of	O
affected	O
cortisol	B
synthesis.	O

The	O
selected	O
compounds	O
covered	O
a	O
cLogP	O
range	O
(calculated	O
using	O
ChemAxon	O
)	O
from	O
+1.2	O
to	O
−6.5,	O
a	O
cLogD	O
range	O
(calculated	O
using	O
a	O
pH	O
of	O
5.5	O
and	O
the	O
ACD/Labs	O
Percepta	O
platform	O
)	O
from	O
0.3	O
to	O
−6.2,	O
and	O
molecular	O
weights	O
up	O
to	O
505 Da	O
5 mL	O
stock	O
solutions	O
of	O
each	O
of	O
the	O
60	O
analytes	O
were	O
prepared	O
in	O
water	O
or	O
methanol	B
and	O
stored	O
at	O
−20 °C	O
before	O
use.	O

An	O
association	O
of	O
decreased	O
neurogenesis	O
in	O
the	O
hippocampus	O
and	O
the	O
dysregulation	O
of	O
sphingomyelin	B
metabolic	O
pathway	O
has	O
been	O
suggested	O
to	O
play	O
a	O
role	O
in	O
depression,	O
and	O
antidepressants	O
have	O
been	O
postulated	O
to	O
enhance	O
neurogenesis	O
by	O
inhibiting	O
the	O
acid	O
sphingomyelinase/ceramide	O
system,	O
which	O
is	O
part	O
of	O
the	O
sphingomyelin	B
metabolic	O
pathway.	O

Eight	O
male	O
and	O
eight	O
female	O
T2DM	O
patients	O
uncontrolled	O
by	O
diet	O
alone,	O
aged	O
between	O
40	O
and	O
75	O
years,	O
with	O
a	O
body	O
mass	O
index	O
>25	O
kg	O
m_−2	O
,	O
increased	O
fasting	O
plasma	O
glucose	B
concentrations	O
>7.0	O
mm	O
and	O
C-peptide	O
>0.17	O
nmol	O
l_−1	O
were	O
included	O
in	O
the	O
study.	O

It	O
should	O
be	O
noted	O
that	O
measurement	O
of	O
3-epi-25(OH)D_3	B
was	O
not	O
included	O
in	O
the	O
CDC	O
method,	O
and	O
the	O
chromatographic	O
method	O
employed	O
did	O
not	O
resolve	O
25(OH)D_3	O
from	O
3-epi-25(OH)D_3	B
.	O

SLC1A5	O
is	O
known	O
as	O
a	O
glutamine	B
transporter	O
but	O
can	O
also	O
import	O
alanine,	B
threonine,	B
serine,	B
leucine,	B
valine,	B
asparagine,	B
methionine,	B
isoleucine,	B
Trp,	O
histidine,	B
and	O
phenylalanine	B
but	O
not	O
glutamate,	B
lysine,	B
arginine,	B
and	O
branched	O
chain	O
amino	O
acids.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
redox	O
homeostasis	O
is	O
crucial	O
to	O
cancer	O
initiation	O
and	O
progression	O
and	O
that	O
the	O
ratio	O
of	O
glutathione	B
(GSH)	O
and	O
its	O
oxidized	O
form	O
(GSSG)	O
is	O
an	O
important	O
indicator	O
of	O
redox	O
balance.	O

For	O
example,	O
5’-methioadenosine	B
was	O
detected	O
in	O
the	O
urine	O
of	O
patients	O
with	O
lymphoma	O
by	O
Li	O
HY	O
et	O
al..	O

Our	O
hypothesis	O
was	O
that	O
prenatal	O
exposure	O
to	O
DES	B
effects	O
estrogen	B
metabolism	O
and	O
that	O
alterations	O
in	O
estrogen	B
metabolism	O
persist	O
after	O
menopause.	O

Two	O
subjects	O
that	O
consumed	O
JWH-018	O
primarily	O
excreted	O
glucuronidated	O
conjugates	O
of	O
5-(3-(1-naphthoyl)-1H	B
-indol-1-yl)-pentanoic	I
acid	I
(>	O
50	O
ng/ml)	O
and	O
(1-(5-hydroxypentyl)-	B
1H	I
-indol-3-yl)(naphthalene-1-yl)-methanone	I
(>	O
30	O
ng/ml).	O

Among	O
metabolites	O
measured	O
in	O
both	O
the	O
AASK	O
and	O
MESA,	O
tryptophan	B
was	O
the	O
most	O
positively	O
correlated	O
with	O
mGFR	O
in	O
the	O
AASK	O
(r	O
 = 0.58,	O
P <10_−	O
_15	O
)	O
and	O
MESA	O
(r	O
 = 0.34,	O
P = 10_−	O
_8	O
;	O
).	O

Due	O
to	O
their	O
broad	O
physiological	O
function	O
of	O
bile	O
acids	O
in	O
the	O
human	O
body,	O
and	O
their	O
implication	O
in	O
cholesterol,	B
glucose	B
and	O
lipid	O
metabolism	O
there	O
is	O
a	O
clear	O
need	O
to	O
investigate	O
bile	O
acid	O
metabolites	O
in	O
AD.	O

The	O
activity	O
of	O
5α-R	B
is	O
enhanced	O
only	O
through	O
the	O
backdoor	O
pathway.	O

Interestingly,	O
the	O
S1P	O
pathway	O
was	O
significantly	O
enriched	O
in	O
the	O
prostaglandin	B
E2	I
expression	O
signature;	O
thirteen	O
up-regulated	O
and	O
eight	O
down-regulated	O
genes	O
in	O
response	O
to	O
PGE2	O
treatment	O
were	O
determined	O
to	O
be	O
part	O
of	O
the	O
S1P	O
pathway.	O

To	O
systematically	O
characterize	O
the	O
normal	O
biochemical	O
response	O
to	O
glucose	B
ingestion	O
in	O
humans,	O
we	O
obtained	O
plasma	O
samples	O
for	O
metabolic	O
profiling	O
from	O
an	O
ongoing	O
study,	O
Metabolic	O
Abnormalities	O
in	O
College	O
Students	O
(MACS,	O
see	O
Materials	O
and	O
methods).	O

Urine	O
analysis	O
in	O
a	O
pre-surgical	O
patient	O
population	O
suggested	O
products	O
of	O
methionine	B
catabolism	O
might	O
correlate	O
with	O
prostate	O
cancer	O
progression	O
status.	O

The	O
chronic	O
use	O
of	O
beta-blockers,	O
lactulose,	B
proton	O
pump	O
inhibitors	O
(PPI)	O
and	O
other	O
drugs	O
with	O
the	O
potential	O
to	O
influence	O
the	O
gut	O
microbiota	O
was	O
recorded.	O

These	O
studies	O
revealed	O
that	O
under	O
conditions	O
of	O
high	O
dietary	O
β-carotene	B
and	O
the	O
oxidative	O
stress	O
of	O
smoking,	O
there	O
was	O
a	O
clear	O
increase	O
in	O
preneoplastic	O
lung	O
cancer	O
lesions	O
in	O
the	O
animals.	O

The	O
modest	O
correlation	O
of	O
hydroxyproline	B
with	O
PASI	O
score	O
may	O
indicate	O
different	O
susceptibility	O
of	O
subjects,	O
and	O
further	O
investigations	O
are	O
necessary	O
to	O
examine	O
if	O
this	O
susceptibility	O
is	O
reflected	O
with	O
incidence	O
of	O
psoriatic	O
arthritis.	O

A	O
high	O
arginine	B
concentration	O
can	O
increase	O
arginase	O
activity,	O
which	O
leads	O
to	O
an	O
uncoupling	O
of	O
eNOS	O
and	O
induces	O
more	O
neurotoxic	O
substance	O
(imaginary	O
line).	O

The	O
relatively	O
increased	O
creatine	B
levels	O
that	O
were	O
also	O
seen	O
in	O
our	O
previously	O
described	O
DSS	O
mouse	O
model	O
of	O
UC	O
may	O
indicate	O
the	O
need	O
of	O
ATP	B
and	O
fatty	O
acids	O
as	O
energy	O
supply	O
during	O
the	O
states	O
of	O
the	O
disease.	O

Note	O
that	O
after	O
the	O
sample	O
was	O
labeled	O
using	O
dansylation,	O
the	O
labeled	O
AMP	B
was	O
found	O
to	O
be	O
very	O
stable.	O

In	O
addition,	O
several	O
other	O
metabolites,	O
including	O
cis	O
-4-octenedioic	O
acid	O
and	O
docosanamide,	B
exhibited	O
decreased	O
levels	O
in	O
HTG	O
subjects	O
compared	O
with	O
NTG	O
controls.	O

A	O
new	O
oxysporidinone	B
analogue	O
and	O
a	O
new	O
3-hydroxyl-2-piperidinone	B
derivative,	O
along	O
with	O
(−)-4,6′-anhydrooxysporidinone,	B
(+)-fusarinolic	B
acid,	I
gibepyrone	B
D,	O
beauvercin,	B
cerevisterol,	B
fusaruside,	O
and	O
(2S,2′R,3R,3′E,4E,8E)-1-O-D-glucopyranosyl-2-N-(2′-hydroxy-3′-octadecenoyl)-3-hydroxy-9-methyl-4,8-sphingadienine	B
isolated	O
from	O
F.	O
oxysporum	B
were	O
evaluated	O
for	O
cytotoxicity	O
against	O
PC-3,	O
PANC-1,	O
and	O
A549	O
cancer	O
cell	O
lines	O
and	O
only	O
beauvericin	B
(21)	O
showed	O
potency	O
with	O
IC_50	O
ranging	O
from	O
10.4	O
to	O
49.5μM	O
(Wang	O
et	O
al.	O
2011).	O

We	O
observed	O
that	O
glycine,	B
serine,	B
threonine,	B
galactose	B
and	O
pyrimidine	B
metabolisms	O
are	O
the	O
most	O
perturbed	O
pathways	O
in	O
both	O
mono	O
and	O
co-infection	O
conditions.	O

Interestingly,	O
we	O
detected	O
increased	O
amounts	O
of	O
glutamate	B
in	O
the	O
cell	O
culture	O
media	O
of	O
S9	O
as	O
well	O
as	O
16HBE14o_−	O
cells	O
during	O
rHla	O
treatment.	O

The	O
inhibition	O
of	O
KMO	O
has	O
suggested	O
that	O
KMO	O
regulates	O
the	O
production	O
of	O
downstream	O
KP	B
metabolites.	O

The	O
results	O
of	O
correlation	O
coefficients	O
(R	O
)	O
and	O
calibration	O
ranges	O
for	O
all	O
targeted	O
50	O
oxylipins	B
are	O
listed	O
in	O
.	O

Nervonic	B
acid	I
levels	O
were	O
higher	O
in	O
the	O
depressive	O
state	O
in	O
the	O
patients	O
with	O
MDD	O
compared	O
with	O
the	O
remission	O
state	O
in	O
the	O
patients	O
with	O
MDD	O
and	O
the	O
depressive	O
state	O
of	O
patients	O
with	O
bipolar	O
disorder,	O
suggesting	O
state-dependent	O
alterations.	O

The	O
healthy	O
controls	O
showed	O
17	O
enriched	O
KEGG	O
level-3	O
functional	O
orthologues,	O
which	O
were	O
related	O
to	O
Amino	O
Acid	O
Metabolism	O
(arginine	O
and	O
proline	B
metabolism	O
ko00330,	O
histidine	B
metabolism	O

Furthermore,	O
even	O
if	O
an	O
antibiotic	O
initially	O
suppressed	O
TMAO	B
levels,	O
the	O
durability	O
of	O
that	O
effect	O
with	O
long-term	O
use	O
remains	O
unknown.	O

Furthermore,	O
a	O
higher	O
hypoxanthine	B
concentration	O
correlated	O
with	O
a	O
good	O
chemoresponse	O
in	O
patients	O
with	O
locally	O
advanced	O
rectal	O
cancer.	O

The	O
urinary	O
hypoxanthine	B
level	O
may	O
be	O
a	O
marker	O
of	O
gastrointestinal	O
tumors	O
[,].	O

;	O
Restek)	O
at	O
a	O
temperature	O
of	O
50°C,	O
with	O
a	O
mobile	O
phase	O
consisted	O
of	O
MeOH/CH_3	O
CN/H_2	O
O	O
45/45/10+	O
0.1%	O
acetic	B
acid	I
(phase	O
A)	O
and	O
CH_2	O
Cl/MeOH	O
(80/20	O
v/v)	O
(phase	O
B).	O

[Google	O
Scholar]	O
Gullino	O
PM,	O
Grantham	O
FH,	O
Courtney	O
AH.	B

Only	O
2/34	O
altered	O
metabolites	O
were	O
depleted,	O
cysteine	B
and	O
inosine	B
Metabolome	O
effects	O
of	O
lupus	O
by	O
quantitative	O
enrichment	O
analysis	O
of	O
209	O
metabolites	O
in	O
PBL	O
of	O
SLE	O
patients	O
in	O
comparison	O
to	O
those	O
of	O
healthy	O
controls	O
matched	O
for	O
age	O
within	O
10 years,	O
gender,	O
and	O
ethnic	O
background	O

Several	O
early	O
studies	O
have	O
showed	O
that	O
PD	O
patients	O
have	O
slightly	O
decreased	O
concentrations	O
of	O
leucine	B
and	O
isoleucine	B
in	O
their	O
CSF	O
and	O
plasma.	O

Glucose	B
was	O
involved	O
with	O
the	O
glycolysis,	O
which	O
was	O
abnormal	O
in	O
CRC.	O

Recently,	O
researchers	O
have	O
paid	O
much	O
attention	O
to	O
the	O
nonapeptide	O
oxytocin	B
for	O
its	O
potential	O
involvement	O
in	O
depression.	O

The	O
PCA,	O
PLS-DA,	O
and	O
OPLS-DA	O
score	O
plots	O
revealed	O
significant	O
differences	O
between	O
the	O
BT	O
and	O
GP	B
groups	O
(Fig.	O

Solid-phase	O
DNA	O
extraction	O
(silica-based)	O
methods	O
are	O
commonly	O
used	O
in	O
commercial	O
kits,	O
which	O
have	O
higher	O
throughput	O
than	O
the	O
solution-phase	O
extraction	O
with	O
phenol-chloroform.	B

For	O
glucose	B
isotope	O
tracing	O
experiment,	O
HCT116,	O
MCF7	O
and	O
HeLa	O
cells	O
were	O
cultured	O
in	O
6-well	O
plates	O
with	O
custom	O
made	O
RPMI	O
1640	O
media	O
with	O
the	O
stabled	O
isotope	O
1-_13	O
C_1	B
-glucose	I
or	O
2-_13	O
C_1	B
-glucose	I
for	O
48	O
h.	O

A	O
significantly	O
higher	O
concentration	O
of	O
myo-inositol	B
was	O
noted	O
in	O
our	O
pure	O
DCIS	O
group	O
than	O
in	O
the	O
DCIS	O
accompanying	O
invasive	O
carcinoma	O
group.	O

Glucose	B
and	O
many	O
related	O
carbohydrate	O
metabolites	O
were	O
readily	O
confirmed	O
as	O
a	O
diabetes	O
biomarker.	O

Good’s	O
buffers,	O
a	O
class	O
of	O
zwitterionic	O
N	O
-substituted	O
aminosulfonic	B
acid	I
buffers,	O
have	O
been	O
considered	O
to	O
have	O
weak	O
metal	O
complexation	O
properties;	O
however	O
some	O
reports	O
suggest	O
that	O
many	O
of	O
these	O
buffers	O
in	O
fact	O
strongly	O
bind	O
metals	O
(Mash	O
et	O
al.	O
).	O

Surfactant	O
protein	O
C	O
is	O
one	O
of	O
the	O
widely	O
studied	O
marker	O
which	O
is	O
mainly	O
composed	O
of	O
valine,	B
leucine	B
and	O
isoleucine	B
forming	O
the	O
bulk	O
of	O
its	O
hydrophobic	O
residues.	O

Our	O
study	O
has	O
several	O
limitations,	O
such	O
as	O
a	O
medium	O
population	O
size	O
(especially	O
size	O
of	O
the	O
matched	O
NGT	O
group)	O
due	O
to	O
the	O
strict	O
criterion	O
for	O
samples	O
selection,	O
and	O
the	O
short	O
of	O
tryptophan	B
level	O
after	O
diabetes	O
onset.	O

The	O
latter	O
two	O
were	O
also	O
correlated	O
with	O
fish	O
consumption	O
(r	O
 = 0.27	O
and	O
0.33,	O
respectively),	O
as	O
was	O
CMPF	O
(r	O
 = 0.36),	O
palimitoyl-oleoyl-GPPG-2	B
(r	O
 = 0.31)	O
and	O
25(OH)D	O
(r	O
 = 0.29).	O

This	O
group	O
of	O
patients	O
in	O
a	O
relatively	O
early	O
state	O
of	O
the	O
disease	O
is	O
likely	O
most	O
similar	O
to	O
our	O
group	O
of	O
individuals	O
who	O
were	O
diagnosed	O
in	O
<2	O
years	O
after	O
blood	O
sampling	O
and	O
had	O
the	O
lowest	O
histidine	B
levels	O
of	O
all	O
cases.	O

It	O
is	O
the	O
commonest	O
polar	O
head	O
group	O
of	O
phospholipids	B
and	O
sphingomyelins,	B
the	O
major	O
amphipathic	O
constituents	O
of	O
cells	O
membranes,	O
the	O
latter	O
especially	O
in	O
the	O
myelin	B
sheath	O
that	O
electrically	O
insulates	O
the	O
nerve	O
cell	O
axons.	O

High	O
performance	O
liquid	O
chromatography	O
(HPLC)	O
grade	O
methanol	B
was	O
purchased	O
from	O
the	O
Tedia	O
Company	O
(Inc.,	O
Fairfield,	O
USA).	O

At	O
1d	O
post-treatment	O
12.5μM	O
C75	O
had	O
induced	O
significant	O
apoptosis	O
in	O
SUM149PT	O
cells	O
(Figure	O
and	O
)	O
when	O
compared	O
to	O
DMSO.	B

Analysis	O
of	O
the	O
data	O
showed	O
that	O
duration	B
of	O
limonene	B
treatment	O
did	O
not	O
affect	O
the	O
observed	O
metabolite	O
changes	O
(data	O
not	O
shown).	O

A	O
calibration	O
curve	O
generated	O
by	O
standard	O
addition	O
of	O
_15	O
N	O
isotope	O
labeled	O
glutamic	B
acid	I
into	O
a	O
sample	O
of	O
derivatized	O
urine	O
shows	O
a	O
good	O
linear	O
relationship	O
between	O
the	O
concentration	O
of	O
derivatized	O
L-glutamic	B
acid	I
and	O
the	O
NMR	O
peak	O
area	O
with	O
a	O
coefficient	O
of	O
regression	O
(R_2	O
)	O
of	O
~0.99.	O

In	O
terms	O
of	O
chemoresistance,	O
ALDHs	O
are	O
capable	O
of	O
direct	O
enzymatic	O
inactivation	O
of	O
alkylating	O
agents,	O
such	O
as	O
cyclophosphamide._,	O
ALDHs	O
can	O
also	O
confer	O
resistance	O
to	O
other	O
chemotherapeutic	O
drugs,	O
such	O
as	O
cisplatin	B
and	O
doxorubicin,	B
although	O
the	O
mechanisms	O
have	O
not	O
been	O
fully	O
delineated._,	O
Other	O
evidence	O
reveals	O
that	O
ALDH	O
is	O
often	O
coexpressed	O
with	O
antioxidant	O
factors.	O

Individual	O
and	O
grouped	O
estrogens	O
and	O
estrogen	B
metabolites	O
were	O
log-transformed	O
using	O
base	O
1.2	O
because	O
in	O
the	O
study	O
cohort,	O
serum	O
concentrations	O
increased	O
by	O
approximately	O
20%	O
between	O
the	O
10th	O
and	O
90th	O
percentiles	O
for	O
most	O
of	O
these	O
measures.	O

Putrescine	B
acts	O
on	O
S	B
-adenosylmethionine	I
(SAMe),	O
a	O
methylating	O
molecule,	O
to	O
produce	O
spermine,	B
which	O
in	O
turn	O
acts	O
on	O
further	O
SAMe	O
molecules	O
to	O
produce	O
spermidine[].	O

One	O
hundred	O
fifty	O
microliters	O
of	O
the	O
plasma	O
supernatant	O
was	O
then	O
diluted	O
with	O
450	O
μL	O
of	O
75	O
mM	O
sodium	B
phosphate	I
buffer	O
prepared	O
in	O
D_2	O
O	O

In	O
the	O
case	O
of	O
the	O
purine	B
xanthosine,	I
there	O
were	O
positive	O
and	O
negative	O
correlations	O
with	O
both	O
purine	B
and	O
non-purine	O
metabolites.	O

Dithiolethiones,	B
including	O
oltipraz	O
and	O
the	O
unsubstituted	O
molecule	O
1,2-dithiole-3-thione,	B
are	O
potent	O
inhibitors	O
of	O
AFB-induced	O
hepatic	O
tumorigenesis	O
in	O
rats._−	O
In	O
rats	O
fed	O
1,2-dithiole-3-thione,	B
the	O
overall	O
reduction	O
in	O
the	O
levels	O
of	O
hepatic	O
DNA	O
adducts,	O
urinary	O
AFB-guanine,	O
and	O
AFB-Alb	O
adducts	O
over	O
the	O
2-week	O
exposure	O
period	O
were	O
76%,	O
62%,	O
and	O
66%,	O
respectively.	O

The	O
derivatization	O
regents,	O
MCF	O
and	O
ECF,	O
as	O
well	O
as	O
HPLC	O
grade	O
solvents	O
including	O
methanol,	B
ethanol,	B
chloroform	B
and	O
pyridine	B
were	O
purchased	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
MO,	O
USA).	O

Abbreviations:	O
PPD,	O
postpartum	O
depression;	O
TCA,	O
tricarboxylic	B
acid.	I

PC	O
847	O
2C	O
and	O
PC	O
2096	O
4B	O
cell	O
lines	O
or	O
the	O
shRNA	O
scramble	O
control	O
cell	O
line	O
were	O
maintained	O
in	O
the	O
presence	O
of	O
U-_13	O
C_6	O
glucose	B
or	O
U-_13	O
C_5	O
glutamine	B
for	O
1	O
h	O
in	O
the	O
same	O
experiment	O
described	O
in	O
.	O

Each	O
sample	O
was	O
spiked	O
with	O
200 μl	O
of	O
2-chloro-phenylalanine	B
(0.3 g/L)	O
as	O
an	O
internal	O
standard	O
and	O
600 μl	O
of	O
methanol.	B

In	O
support	O
of	O
this	O
concept,	O
it	O
has	O
recently	O
been	O
shown	O
that	O
the	O
production	O
of	O
eicosanoids	B
during	O
T.	O
cruzi	O
infections	O
of	O
mammalian	O
hosts	O
has	O
an	O
effect	O
on	O
parasite	O
burden,	O
and	O
this	O
may	O
also	O
be	O
true	O
during	O
triatomine	O
infections	O
.	O

Previous	O
studies	O
with	O
whole	O
plant	O
foods	O
or	O
oat-derived	O
beta-glucan	O
in	O
particular,	O
have	O
shown	O
significant	O
and	O
clinically	O
meaningful	O
reductions	O
in	O
cholesterol	B
upon	O
ingestion.	O

A	O
major	O
limitation	O
of	O
the	O
C18	O
method	O
is	O
that	O
it	O
is	O
unable	O
to	O
separate	O
25(OH)D_3	O
and	O
3-epi-25(OH)D_3	B
,	O
which	O
was	O
fortified	O
to	O
be	O
a	O
major	O
component	O
of	O
SRM	O
972	O
Level	O
4.	O

The	O
results	O
indicate	O
a	O
strong	O
increase	O
in	O
in	O
the	O
uptake	O
of	O
glutamine	B
and	O
subsequent	O
hydrolysis	O
to	O
glutamate	B
during	O
rHla-treatment,	O
especially	O
in	O
16HBE14o_−	O
cells.	O

Fewer	O
lipid	O
classes	O
were	O
associated	O
with	O
baseline	O
HDL	O
(9	O
classes;	O
70	O
species)	O
or	O
triglycerides	B
(7	O
classes;	O
128	O
species).	O

Glutamine	B
is	O
lysed	O
to	O
glutamate,	B
which	O
can	O
be	O
converted	O
to	O
α-ketoglutarate	B
to	O
increase	O
transit	O
through	O
the	O
citric	B
acid	I
cycle,	O
providing	O
sustainable	O
energy	O
required	O
for	O
rapid	O
cell	O
proliferation	O
[,	O
].	O

In	O
conclusion,	O
from	O
a	O
panel	O
of	O
>30 000	O
metabolomics	O
features,	O
acetylglycoproteins,	B
branched‐chain	O
amino	O
acids,	O
lactate,	B
glutamine,	B
and	O
markers	O
of	O
atherogenic	O
dyslipidemia	O
emerged	O
as	O
strong	O
markers	O
of	O
visceral	O
adiposity.	O

Indeed,	O
we	O
believe	O
that	O
the	O
most	O
promising	O
source	O
of	O
biomarkers	O
of	O
retinal	B
diseases	O
is	O
the	O
vitreous	O
humor,	O
because	O
the	O
vitreous	O
humor	O
is	O
particularly	O
easy	O
to	O
extract	O
during	O
surgery	O
and	O
because	O
it	O
is	O
in	O
anatomical	O
contact	O
with	O
the	O
retina.	O

The	O
first	O
(good/poor	O
responders,	O
GPR)	O
consisted	O
of	O
24	O
individuals	O
selected	O
from	O
the	O
top	O
10%	O
of	O
the	O
LDL-C	O
response	O
distribution	O
who	O
were	O
matched	O
for	O
body	O
mass	O
index	O
(BMI),	O
race,	O
and	O
gender	O
to	O
24	O
individuals	O
in	O
the	O
lowest	O
10%	O
of	O
responders,	O
with	O
response	O
to	O
therapy	O
defined	O
as	O
the	O
percentage	O
change	O
in	O
LDL	B
cholesterol	I
from	O
pretreatment	O
levels.	O

Several	O
studies	O
have	O
assessed	O
the	O
degree	O
to	O
which	O
estrogens	O
mediate	O
the	O
relationship	O
between	O
BMI	O
and	O
risk	O
of	O
all	O
breast	O
cancer	O
by	O
adjusting	O
the	O
BMI-breast	O
cancer	O
association	O
for	O
circulating	O
estradiol	B
levels	O
(-).	O

Moreover,	O
the	O
metabolites	O
associated	O
with	O
disability	O
status	O
(EDSS	O
<3.0	O
compared	O
with	O
patients	O
reaching	O
EDSS	O
>4.5	O
after	O
2	O
years	O
follow-up)	O
included	O
glutamic	B
acid,	I
tryptophan,	B
eicosapentaenoic	B
acid	I
(timnodonic	O
acid),	O
13S-hydroxyoctadecadienoic	B
acid,	I
lysophosphatidylcholine	B
(20:5/0:0),	I
and	O
lysophosphatidylethanolamine	B
(20:5/0:0).	I

However,	O
while	O
this	O
study	O
highlights	O
the	O
capacity	O
for	O
rHDL	O
to	O
modulate	O
fatty	O
acid	O
metabolism	O
in	O
adipocytes,	O
the	O
phospholipid	B
component	O
of	O
the	O
rHDL	O
infusate	O
did	O
directly	O
increase	O
circulating	O
NEFA.	O

Microbial	O
polyphenol	O
metabolism	O
produces	O
a	O
relatively	O
small	O
number	O
of	O
metabolites	O
from	O
the	O
extremely	O
diverse	O
population	O
of	O
dietary	O
polyphenols	O
arriving	O
in	O
the	O
colon,	O
and	O
these	O
include	O
simple	O
phenols	O
and	O
derivatives	O
of	O
benzoic	B
acid,	I
phenylacetic	B
acid,	I
mandelic	B
acid,	I
phenylpropionic	B
acid,	I
and	O
cinnamic	B
acid	I
.	O

Here,	O
we	O
employed	O
a	O
mass	O
spectrometry-based	O
metabolomic	O
approach	O
to	O
confirm	O
that	O
P.	O
falciparum	O
lacks	O
the	O
ability	O
to	O
synthesize	O
NAD_+	O
de	O
novo	O
and	O
is	O
reliant	O
on	O
the	O
uptake	O
of	O
exogenous	O
niacin.	B

Again,	O
hexadecanedioate	B
was	O
positively	O
and	O
significantly	O
related	O
to	O
incident	O
HF	O
risk	O
in	O
European-Americans	O
(HR,	O
1.09;	O
P	O
=	O
0.005).	O

Briefly,	O
10	O
μL	O
aliquots	O
of	O
plasma	O
and	O
10	O
μL	O
of	O
internal	O
lipid	O
standards	O
(Avanti	O
SPLASH	O
Lipidomix)	O
that	O
had	O
been	O
first	O
diluted	O
1:10	O
in	O
1-butanol/methanol	O
were	O
added	O
to	O
160	O
μl	O
of	O
ice-cold	O
methanol	B
followed	O
by	O
addition	O
of	O
320	O
μl	O
of	O
ice-cold	O
chloroform	B
and	O
vortexed	O
(10	O
s),	O
then	O
sonicated	O
(1	O
h).	O

Accumulation	O
of	O
uremic	O
toxins	B
due	O
to	O
inadequate	O
renal	O
clearance	O
is	O
a	O
hallmark	O
of	O
CKD.	O

In	O
healthy	O
corneas	O
C16:0	B
Cer	I
accounts	O
for	O
the	O
highest	O
levels	O
of	O
the	O
ceramide	B
subspecies,	O
followed	O
by	O
C24:0,	B
C24:1,	B
and	O
C22:0.	B

However,	O
similarly	O
to	O
the	O
biochemical	O
markers,	O
no	O
significant	O
changes	O
in	O
the	O
FA	B
profile	O
of	O
the	O
PBMC	O
were	O
observed,	O
presumably	O
due	O
to	O
the	O
short	O
length	O
of	O
the	O
intervention.	O

This	O
result	O
corroborates	O
with	O
studies	O
correlating	O
taurine	B
as	O
an	O
osteoclast	O
formation	O
inhibitor	O
and	O
osteoblast	O
inductor	O
[,,].	O

The	O
percentage	O
of	O
16α-Oxo-E_1	B
was	O
significantly	O
decreased	O
in	O
Sil	O
and	O
BPA/Sil	O
treated	O
H-HepG2	O
cells	O
of	O
15	O
and	O
2-fold	O
respectively	O
compared	O
to	O
the	O
BPA	O
H-HepG2	O
cells.	O

We	O
also	O
assessed	O
breast	O
biopsy	O
composition	O
in	O
samples	O
from	O
the	O
previous	O
CER	B
study	O
for	O
comparison.	O

The	O
level	O
of	O
serum	O
uric	B
acid	I
is	O
closely	O
related	O
to	O
the	O
occurrence	O
of	O
stroke.	O

Plasma	O
choline	B
concentrations	O
were	O
also	O
higher	O
in	O
subjects	O
with	O
high	O
cystathionine	B
concentrations	O
(P	O
<	O
0.001),	O
as	O
were	O
those	O
of	O
trimethylamine	B
oxide	I
(TMAO)	O

Since	O
the	O
concentration	O
of	O
lactate	B
in	O
the	O
blood	O
remains	O
one	O
of	O
the	O
main	O
indicators	O
of	O
sepsis,	O
we	O
compared	O
simultaneously,	O
in	O
the	O
same	O
serum	O
samples	O
from	O
septic	O
patients,	O
the	O
concentration	O
of	O
lactic,	O
succinic	B
acids	I
and	O
Sum3.	O

We	O
included	O
outcome	O
data	O
from	O
all	O
study	O
visits	O
that	O
occurred	O
after	O
measurement	O
of	O
vitamin	B
D	I
metabolites,	O
including	O
DCCT	O
study	O
visits	O
when	O
vitamin	B
D	I
metabolites	O
were	O
measured	O
before	O
DCCT	O
closeout,	O
through	O
EDIC	O
year	O
16	O
(September	O
2009	O
to	O
April	O
2010).	O

Increases	O
in	O
both	O
BCAA	O
and	O
AAA	O
levels	O
in	O
normoglycemic	B
individuals	O
during	O
long-term	O
follow-up	O
were	O
identified	O
in	O
several	O
large	O
cohorts	O
to	O
have	O
high	O
predictive	O
accuracy	O
for	O
the	O
future	O
development	O
of	O
T2DM,	O
suggesting	O
that	O
dampened	O
metabolism	O
of	O
BCAAs	O
and	O
AAAs	O
play	O
a	O
pivotal	O
role	O
in	O
insulin	O
resistance	O
and	O
the	O
development	O
of	O
T2DM	O
[,].	O

Nevertheless,	O
the	O
use	O
of	O
these	O
medications	O
did	O
not	O
appear	O
as	O
predictors	O
in	O
the	O
models	O
created	O
here	O
and	O
the	O
models	O
were	O
relatively	O
robust	O
for	O
the	O
use	O
of	O
statins	B
or	O
metformin	B
when	O
tested	O
separately	O
in	O
subgroups	O
using	O
these	O
medications	O
and	O
compared	O
to	O
HOMA-IR	O
and	O
revised	O
QUICKI.	O

When	O
this	O
same	O
data	O
set	O
was	O
evaluated	O
in	O
regards	O
to	O
amino	O
acid	O
contributions	O
to	O
variation	O
in	O
response	O
to	O
simvastatin,	B
N	B
-methylalanine	I
was	O
found	O
to	O
strongly	O
correlate	O
to	O
the	O
branched-chain	O
amino	O
acid	O
valine	O
while	O
negatively	O
correlating	O
with	O
oxalic	B
acid,	I
nicotinic	B
acid,	I
phosphoric	B
acid,	I
asparagine,	B
oxoproline,	B
hexadecanol	B
and	O
octadecanol.	B

Inserts	O
were	O
introduced	O
into	O
zirconium	B
oxide	I
rotors	O
for	O
analysis.	O

 choline + phosphocholine	B
(PC) + glycerophosphocholine	I
(GPC)],	O
creatine	B
compounds	O
[t-creatine =	O

Chloroform	B
(CHCl3)	O
and	O
methanol	B
(MeOH)	O
were	O
purchased	O
from	O
Burdick	O
&	O
Jackson	O
(Muskegon,	O
MI,	O
USA).	O

Mannose	B
is	O
involved	O
in	O
glycoprotein	B
biosynthesis	O
and	O
is	O
present	O
at	O
increased	O
levels	O
in	O
patients	O
with	O
T2DM	O
and	O
diabetic	O
retinopathy.	O

Our	O
study	O
is	O
noteworthy	O
for	O
its	O
finding	O
that,	O
in	O
a	O
random	O
sample	O
of	O
healthy,	O
postmenopausal	O
women,	O
microbial	O
diversity	O
in	O
the	O
distal	O
gut	O
was	O
positively	O
associated	O
with	O
the	O
ratio	O
of	O
hydroxylated	B
estrogen	I
metabolites	O
to	O
parent	O
estrogens	O
even	O
after	O
adjustment	O
for	O
age,	O
BMI,	O
and	O
study	O
design	O
variables.	O

Finally,	O
our	O
observation	O
about	O
the	O
consistent	O
negative	O
association	O
of	O
cluster	O
10	O
with	O
several	O
risk	O
factors	O
of	O
CVD	O
indicates	O
a	O
likely	O
genetic	O
explanation	O
for	O
the	O
reported	O
association	O
of	O
reduced	O
levels	O
of	O
plasma	O
lysophsophatidylcholine	B
with	O
obesity	O
and	O
type	O
2	O
diabetes.	O

and	O
the	O
slope	O
was	O
determined	O
based	O
on	O
the	O
serial	O
creatinine	B
measurements	O
over	O
7.6	O
(6.5-12.4)	O
years.	O

While	O
the	O
intensities	O
of	O
C14:0	B
and	O
C16:0	B
saturated	O
fatty	O
acids	O
(SFAs)	O
were	O
significantly	O
lower	O
in	O
AF	B
patients,	O
the	O
intensities	O
of	O
longer	O
SFAs,	O
such	O
as	O
C18:0,	B
C20:0,	B
and	O
C22:0,	B
were	O
significantly	O
higher	O
in	O
AF	B
patients.	O

The	O
slope	O
of	O
melatonin	B
over	O
the	O
night	O
correlated	O
with	O
several	O
self-reported	O
measures,	O
with	O
better	O
sleep	O
quality	O
associated	O
with	O
a	O
steeper	O
decrease	O
in	O
melatonin.	B

Specifically,	O
myoinositol	B
was	O
inversely	O
associated	O
with	O
VFD	O
(ρ	O
=	O
−0.73,	O
P	O
=	O
0.005,	O
q	O
=	O
0.01).	O

Increased	O
2-HB	O
levels	O
have	O
been	O
shown	O
to	O
reflect	O
insulin	O
resistance	O
and	O
tricarboxylic	B
acid	I
(TCA)	O
cycle	O
overload	O
as	O
well	O
as	O
increased	O
oxidative	O
stress.	O

The	O
mobile	O
phase	O
consisted	O
of	O
water	O
including	O
0.1%	O
formic	B
acid	I
(solvent	O
A)	O
and	O
acetonitrile	B
including	O
0.1%	O
formic	B
acid	I
(solvent	O
B).	O

Three	O
additional	O
patients	O
had	O
17β-estradiol	B
excess,	O
in	O
combination	O
with	O
glucocorticoid	B
and	O
adrenal	O
androgen	O
excess	O
in	O
two	O
and	O
one,	O
respectively.	O

Of	O
the	O
remaining	O
seven	O
patients	O
all	O
had	O
significant	O
CAD,	O
but	O
no	O
net	O
lactate	B
release,	O
suggesting	O
either	O
absence	O
of	O
ischemia	O
or	O
an	O
area	O
of	O
ischemia	O
that	O
was	O
too	O
small	O
to	O
result	O
in	O
a	O
net	O
lactate	B
release	O
detectable	O
in	O
the	O
CS	O
given	O
uptake	O
in	O
the	O
remainder	O
of	O
the	O
non-ischemic	O
myocardium.	O

After	O
cheese	O
intake,	O
four	O
amino	O
acids	O
were	O
discriminating	O
based	O
on	O
an	O
OPLS-DA	O
analysis	O
of	O
their	O
6h-iAUC	O
(see	O
Figure	O
S4)	O
and	O
their	O
subsequent	O
targeted	O
quantification,	O
namely	O
methionine,	B
proline,	B
leucine,	B
and	O
glutamic	B
acid.	I

In	O
this	O
study,	O
for	O
healthy	O
term	O
newborns	O
at	O
two	O
days	O
of	O
age	O
ranges	O
(percentile	O
10	O
to	O
90)	O
between	O
300	O
and	O
1000	O
and	O
6	O
and	O
50	O
μmol	O
L_−1	O
(see	O
Table )	O
were	O
obtained	O
for	O
lactate	B
and	O
pyruvate,	B
respectively.	O

This	O
observation	O
was	O
in	O
agreement	O
with	O
recent	O
results	O
reporting	O
increased	O
levels	O
of	O
four	O
tryptophan	B
metabolites	O
(kynurenine,	O
acetyl-N-formyl-5-methoxykynurenamine,	B
indoleacetic	B
acid	I
and	O
indolelactic	O
acid)	O
in	O
serum	O
samples	O
of	O
BC	O
patients	O
compared	O
to	O
healthy	O
controls,	O
and	O
previous	O
studies	O
in	O
BC	O
tissue	O
and	O
urine	O
that	O
suggested	O
the	O
potential	O
role	O
of	O
kynurenine	B
in	O
the	O
malignancy	O
BC	O
associated	O
to	O
IDO	O
and	O
IDO2,	O
two	O
tryptophan-metabolizing	O
enzymes	O
that	O
control	O
the	O
tryptophan	B
catabolism-signaling	O
pathway.	O

Metabolomic	O
profiling	O
of	O
serum	O
samples	O
showed	O
statistically	O
significant	O
changes	O
in	O
glycerophospholipid	B
metabolism	O
(p≤0.05),	O
in	O
response	O
to	O
prednisone	B
treatment.	O

Coffee	O
represents	O
a	O
complex	O
mixture	O
of	O
more	O
than	O
1000	O
partly	O
bioactive	O
compounds	O
including	O
beside	O
caffeine	B
and	O
its	O
metabolites	O
paraxanthine,	B
theobromine	B
and	O
theophylline,	B
a	O
high	O
number	O
of	O
further	O
molecules	O
like	O
trigonelline,	B
phenolic	O
acids,	O
kahweol	O
or	O
cafestol.	O

Similarly	O
for	O
21-deoxycortisol,	B
plasma	O
concentrations	O
are	O
low,	O
often	O
not	O
detectable	O
and	O
the	O
reference	O
intervals	O
described	O
here	O
require	O
further	O
validation	O
using	O
more	O
sensitive	O
measurements.	O

Cancer	O
cells	O
take	O
up	O
cystine	B
from	O
the	O
blood	O
and	O
maintain	O
high	O
levels	O
of	O
intracellular	O
glutathione	B
and,	O
thus,	O
their	O
proliferative	O
capacity.	O

In	O
the	O
present	O
study,	O
we	O
analyzed	O
the	O
target	O
metabolome	O
using	O
a	O
gradient	O
of	O
mobile	O
phase	O
A	O
(20 mmol/L	O
ammonium	B
hydroxide/20 mmol/L	O
ammonium	B
acetate	I

The	O
reasons	O
for	O
such	O
wide	O
interpatient	O
variability	O
in	O
response	O
to	O
anastrozole	B
are	O
likely	O
to	O
be	O
multiple.	O

2D	O
HSQC	O
spectra	O
of	O
plasma	O
samples	O
tagged	O
with	O
_15	O
N	O
and	O
_13	O
C	O
isotopes	O
provide	O
resolved	O
peaks	O
for	O
a	O
much	O
larger	O
number	O
of	O
carboxylic	B
acid	I
and	O
amine	O
containing	O
metabolites.	O

The	O
only	O
significant	O
correlations	O
of	O
HDL-C	O
with	O
lipid	O
class	O
were	O
negative	O
correlations	O
with	O
DG	O
and	O
TG,	B
(r	O
=	O
-0.33	O
and	O
r	O
=	O
-0.23,	O
respectively,	O
p<0.05).	O

Adrenochrome	O
(also	O
Adrenochrome-O-quinone;	B
AQ),	O
is	O
a	O
toxic	O
quinone	B
metabolite	O
of	O
catecholamines,	B
specifically	O
epinephrine.	B

d	O
Many	O
significant	O
metabolites,	O
not	O
present	O
in	O
human	O
biochemical	O
pathways,	O
were	O
presumably	O
of	O
microbial	O
origin,	O
for	O
example	O
2,3-butanediol,	B
maleamate,	O
hydroquinone,	B
guajacol,	O
pyrogallol	B
and	O
the	O
hippuric	B
acid	I
derivatives	O

Blood	O
samples	O
were	O
obtained	O
and	O
used	O
for	O
the	O
determination	O
of	O
glucose,	B
insulin,	O
HbA1c,	O
alanine	O
aminotransferase	O
(ALT),	O
aspartate	O
aminotransferase	O
(AST),	O
triglycerides	B
(TG),	O
high-density	O
lipoprotein	O
(HDL)	O
cholesterol,	B
and	O
low-density	O
lipoprotein	O
(LDL)	O
cholesterol.	B

48	O
h	O
myoctye	O
cells	O
and	O
24	O
h	O
Rh30	O
cells	O
grown	O
in	O
the	O
presence	O
of	O
[U-_13	B
C]-glucose	I
were	O
extracted	O
as	O
described	O
in	O
the	O
methods.	O

Other	O
workers	O
have	O
reported	O
that	O
acute	O
hypoxia	O
caused	O
the	O
inhibition	O
of	O
FFA	O
oxidation,	O
which	O
resulted	O
in	O
the	O
accumulation	O
of	O
long-chain	O
acylcarnitines.	B

They	O
represent	O
the	O
proportions	O
of	O
several	O
variables:	O
(36:1	O
+	O
38:1),	O
(40:1	B
+	I
42:2	I
+	I
42:1)	I
ceramides	I
and	O
other	O
molecular	O
species;	O
ceramides	B
with	O
1,	O
2	O
and	O
3	O
unsaturations;	O
ceramides	B
with	O
34	O
carbons	O
or	O
less,	O
42	O
carbons	O
or	O
more	O
and	O
other	O
molecular	O
species,	O
as	O
well	O
as	O
confidence	O
ellipses.	O

Decreased	O
levels	O
of	O
glucose	B
(α-	I
and	O
β-glucose),	B
lipids,	O
unsaturated	O
lipids,	O
phospholipids	B
intermediates	O
(choline,	O
phosphocholine,	B
and	O
glycerophosphocholine),	B
TMAO,	B
and	O
betaine	B
were	O
observed	O
in	O
lung	O
cancer	O
patients	O
compared	O
to	O
healthy	O
controls.	O

Further,	O
these	O
findings	O
translated	O
to	O
examination	O
of	O
the	O
pathophysiological	O
roles	O
for	O
this	O
class	O
of	O
lipids,	O
where	O
PE-(P-18:0/20:4(5Z,8Z,11Z,14Z))	B
induces	O
cell	O
adhesion	O
molecule	O
expression	O
in	O
coronary	O
artery	O
endothelial	O
cells.	O

The	O
Warburg	O
effect,	O
excess	O
metabolism	O
of	O
glucose	B
to	O
lactate	B
in	O
the	O
presence	O
of	O
oxygen,	O
is	O
a	O
hallmark	O
of	O
cancer	O
cells	O
in	O
culture.	O

The	O
hydrolysis	O
and	O
extraction	O
process	O
were	O
performed	O
as	O
follows:	O
diluted	O
RBC	O
solution	O
(250	O
µL)	O
was	O
mixed	O
with	O
20	O
µL	O
of	O
IS,	O
20	O
µL	O
of	O
1.1	O
M	O
dithiothreitol,	B
and	O
50	O
µL	O
of	O
DW,	O
vortexed	O
for	O
30	O
seconds,	O
and	O
spun	O
down.	O

LysoPC	O
(16:0)	O
was	O
the	O
most	O
important	O
plasma	O
metabolite	O
for	O
evaluating	O
the	O
difference	O
between	O
control	O
and	O
prehypertensive	O
groups,	O
with	O
a	O
variable	O
important	O
in	O
the	O
projection	O
(VIP)	O
value	O
of	O
17.173,	O
and	O
it	O
showed	O
a	O
positive	O
and	O
independent	O
association	O
with	O
DBP	B
and	O
SBP.	O

Histidine;	B
81.	O

Our	O
observation	O
of	O
a	O
significantly	O
elevated	O
plasma	O
level	O
of	O
glutamate	B
is	O
in	O
accordance	O
with	O
serum	O
analyses	O
of	O
PC	O
by	O
Bathe	O
et	O
al.	O

The	O
supernatant	O
was	O
then	O
neutralized	O
to	O
pH	O
7.4	O
with	O
2 M	O
potassium	B
carbonate	I
and	O
left	O
on	O
ice	O
for	O
30 min	O
to	O
precipitate	O
the	O
potassium	B
perchlorate	I
salts.	O

Finally,	O
the	O
spectral	O
region	O
1.04–1.08	O
ppm,	O
containing	O
a	O
doublet	O
originating	O
from	O
3-hydroxyisobutyrate,	B
also	O
had	O
increased	O
signals	O
after	O
cheese	O
intake,	O
compared	O
to	O
milk	O
and	O
soy	O
drink	O
intake.	O

In	O
cervical	O
cancer	O
patients	O
relative	O
to	O
CIN2/3	O
patients,	O
the	O
lactate	B
metabolites	O
levels	O
were	O
slightly	O
reduced.	O

In	O
addition,	O
the	O
correlation	O
between	O
changes	O
in	O
2-HBA	O
and	O
HOMA-IR	O
was	O
strongly	O
significant	O
(P	O
=	O
0.0016),	O
whereas	O
that	O
between	O
changes	O
in	O
2-HBA	O
and	O
BMI	O
was	O
not	O
(P	O
=	O
0.067),	O
indicating	O
the	O
association	O
is	O
with	O
glycemic	B
improvement	O
and	O
not	O
weight	O
loss.	O

The	O
ROC	O
curves	O
for	O
mucosal	O
KP	B
mRNA	O
expression	O
are	O
depicted	O
in	O
.	O

General	O
linear	O
model	O
tests	O
were	O
applied	O
to	O
the	O
clinical	O
variables	O
to	O
adjust	O
for	O
potential	O
confounding	O
factors,	O
including	O
age,	O
BMI,	O
WHR,	O
smoking,	O
drinking,	O
systolic	O
and	O
diastolic	O
BP,	O
total-	O
and	O
LDL-cholesterol,	B
glucose,	B
and	O
insulin.	O

Because	O
of	O
the	O
toxicity	O
of	O
benzoic	B
acid,	I
it	O
is	O
conjugated	O
with	O
glycine	B
in	O
the	O
mitochondrial	O
matrix	O
of	O
the	O
liver	O
and	O
renal	O
cortex	O
to	O
form	O
hippuric	B
acid	I
[,	O
],	O
which	O
is	O
later	O
filtered	O
in	O
the	O
kidneys	O
and	O
finally	O
excreted	O
in	O
urine	O
as	O
hippurate	B
[,	O
].	O

Based	O
on	O
early	O
results	O
(see	O
below),	O
the	O
benzoic	B
acid	I
analog	O
of	O
BEN	O
(BA)	O
and	O
its	O
products	O
were	O
included	O
in	O
further	O
studies.	O

The	O
highest	O
recovery	O
values	O
were	O
reported	O
for	O
4 ml,	O
reaching	O
97.9%	O
for	O
zearalenone	B
(±0.8%)	O
and	O
95.4%	O
for	O
α-zearalenol	B
(±1.4%).	O

However,	O
the	O
D2047fs	O
is	O
in	O
the	O
latter	O
half	O
of	O
the	O
ATCase	O
domain	O
of	O
CAD	O
,	O
which	O
is	O
activated	B
by	O
co-operative	O
binding.	O

Our	O
results	O
demonstrate	O
down-regulation	O
of	O
glycolytic	B
genes	O
as	O
well	O
as	O
reduced	O
activation	O
of	O
Akt	O
and	O
mTORC1,	O
which	O
can	O
regulate	O
c-MYC	O
expression	O
[,	O
],	O
in	O
MUC16	O
knockdown	O
pancreatic	O
cancer	O
cells.	O

(2019)	O
demonstrated	O
that	O
endophytic	O
Fusarium	O
sp.	B

The	O
slope	O
of	O
the	O
curve	O
for	O
all	O
compounds	O
was	O
close	O
to	O
the	O
theoretical	O
value	O
of	O
0.01	O
and	O
within	O
the	O
predefined	O
maximum	O
allowable	O
deviation	O
(average	O
slope	O
of	O
curves,	O
derivatized	O
and	O
analyzed	O
on	O
five	O
different	O
days:	O
glyoxylate	B
0.0114,	O
glycolate	B
0.0119,	O
and	O
oxalate	B
0.0110).	O

NAGs	O
are	O
secreted	O
from	O
lung	O
cancer	O
cells	O
into	O
surrounding	O
biological	O
fluids	O
such	O
as	O
plasma,	O
explaining	O
the	O
higher	O
levels	O
when	O
the	O
glycolytic	B
activity	O
increases.	O

PC	O
aa	O
indicates	O
that	O
glycerol	B
is	O
bound	O
to	O
two	O
fatty	O
acid	O
residues,	O
while	O
PC	B
ae	I
indicates	O
the	O
presence	O
of	O
a	O
fatty	O
acid	O
residue	O
and	O
a	O
fatty	B
alcohol	I
residual.	O

Pathway	O
analysis	O
revealed	O
six	O
pathways	O
namely,	O
Glycine,	B
serine	B
and	O
threonine	B
metabolism	O
(p-value = 8.16E-05),	O
Galactose	B
metabolism	O
(p-value = 0.0072443),	O
Starch	O
and	O
sucrose	B
metabolism	O
(p-value = 0.012559),	O
Glyoxylate	B
and	O
dicarboxylate	B
metabolism	O
(p-value = 0.012559),	O
Pentose	B
phosphate	I
pathway	O
(p-value = 0.0394)	O
and	O
Propanoate	B
metabolism	O
(p-value = 0.046418)	O
to	O
be	O
significantly	O
regulated.	O

It	O
has	O
been	O
reported	O
that	O
urinary	O
levels	O
of	O
methylguanidine	B
are	O
significantly	O
increased	O
in	O
chronic	O
pancreatitis	O
patients,	O
yet	O
this	O
metabolite	O
has	O
not	O
been	O
studied	O
in	O
PC	O
to	O
date.	O

Citric	B
acid,	I
trioxymethylanthraquinone,	B
2-hydroxybenzoic	B
acid,	I
levofloxacin,	B
hesperidin,	B
and	O
rhein	O
were	O
purchased	O
from	O
the	O
National	O
Institute	O
for	O
the	O
Control	O
of	O
Pharmaceutical	O
and	O
Biological	O
Products	O
(Beijing,	O
China).	O

Figure a	O
shows	O
the	O
change	O
in	O
relative	O
abundance	O
at	O
genus	O
level	O
for	O
Bifidobacterium,	O
Ruminococcus	O
and	O
Lactobacillus	B
for	O
OEP	O
and	O
CTRL	O
treatments	O
between	O
V1	O
and	O
V2.	O

When	O
all	O
subjects	O
were	O
considered	O
irrespectively	O
of	O
the	O
fasting	O
state,	O
acetate,	B
acetoacetate,	B
acetone,	B
creatine,	B
formate,	B
L-glutamine,	B
glycerol,	B
pyruvate, succinate	B
and	O
Unk3	O
(an	O
unknown	O
metabolite,	O
Supplementary	O
Figure _S2	O
)	O
were	O
significantly	O
increased	O
in	O
DS	O
plasma	O
with	O
a	O
DS/CTRL	O
ratio > 1;	O
instead,	O
lysine	B
and	O
tyrosine	B
were	O
significantly	O
reduced	O
in	O
DS	O
with	O
a	O
DS/CTRL	O
ratio < 1	O
(Table ).	O

Choline	B
phospholipid	I
metabolites	O
including	O
choline,	B
phosphocholine,	B
and	O
glycerophosphocholine,	B
as	O
well	O
as	O
ketone	B
bodies	O
such	O
as	O
β-hydroxybutyrate	B
and	O
acetoacetate	B
were	O
also	O
detected.	O

The	O
slope	O
of	O
melatonin	B
was	O
positively	O
associated	O
with	O
slow	O
wave	O
sleep	O
(P	O
<	O
0.01).	O

p	O
 = 0.002),	O
HDL	B
cholesterol	I
(β	O
0.09,	O
p	O
 < 0.001),	O

In	O
addition,	O
adipic	B
acid	I
and	O
L-leucine	B
have	O
been	O
identified	O
as	O
key	O
factors	O
of	O
anti-inflammation	O
mechanism	O
of	O
forsythiae	B
fructus	O
in	O
rats	O
(Yuan	O
et	O
al.,	O
).	O

The	O
concomitant	O
elevation	O
of	O
hypoxanthine	B
in	O
our	O
HCC	O
vs.	O
DC	O
comparison	O
suggests	O
overactivity	O
of	O
xanthine	B
oxidase	O
in	O
HCC.	O

Baseline	O
ethanolamine	B
negatively	O
correlated	O
to	O
post-treatment	O
insulin	O
and	O
threonine	B
positively	O
correlated	O
to	O
insulin	O
and	O
HOMA-IR.	O

Despite	O
this,	O
all	O
of	O
the	O
four	O
transformation	O
products	O
were	O
obtained	O
by	O
our	O
research	O
for	O
probing	O
into	O
the	O
biotransformation	O
mechanism	O
of	O
P	O
and	O
IP	B
in	O
the	O
human	O
intestinal	O
flora,	O
which	O
will	O
be	O
further	O
discussed	O
in	O
the	O
Discussion	O
section.	O

The	O
total	O
concentration	O
in	O
branched	O
chain	O
AAs	O
(BCAAs)	O
was	O
defined	O
as	O
the	O
sum	O
of	O
leucine,	B
isoleucine,	B
and	O
Val.	O

daily	O
variation,	O
acylcarnitines,	B
amino	O
acids,	O
metabolomics,	O
biomarkers	O

GAD1	O
is	O
a	O
rate-limiting	O
enzyme	O
in	O
the	O
production	O
of	O
γ-aminobutyric	B
acid	I
(GABA)	O
and	O
found	O
in	O
the	O
GABAergic	O
neurons	O
in	O
the	O
central	O
nervous	O
system.	O

Detection	O
of	O
neonicotinoid	B
and	O
metabolites	O
in	O
human	O
urine:	O
Regarding	O
peaks	O
in	O
the	O
human	O
urine,	O
data	O
mining	O
and	O
analysis	O
was	O
conducted	O
with	O
four	O
sets	O
of	O
mass	O
spectra	O
for	O
each	O
human	O
urine	O
sample	O
data	O
combined	O
with	O
positive	O
controls	O
and	O
the	O
database	O
of	O
neonicotinoid	B
pesticides,	O
known	O
metabolites	O
and	O
biological	O
chemicals.	O

With	O
regards	O
to	O
lipid	O
metabolites,	O
we	O
observed	O
increases	O
in	O
specific	O
sphingosines,	B
unsaturated	O
fatty	O
acids,	O
and	O
phospholipids,	B
while	O
ceramide	B
(d18:1,	I
C24:0),	I
triglycerides,	B
and	O
saturated	O
fatty	O
acids	O
decreased	O
following	O
RYGB.	O

This	O
mixture	O
of	O
enzymes	O
efficiently	O
digests	O
a	O
variety	O
of	O
different	O
classes	O
of	O
DNA	O
adducts,	O
including	O
those	O
formed	O
with	O
aromatic	O
amines,	O
heterocyclic	B
aromatic	O
amines,	O
aristolochic	O
acid,	O
polycyclic	B
aromatic	O
hydrocarbons,	B
tobacco	O
specific	O
N-nitroso	O
compounds,	O
and	O
lipid	O
peroxidation	O
adducts	O
(;	O
;	O
;	O
;	O
).	O

For	O
digestion,	O
20	O
µg	O
of	O
trypsin	O
was	O
dissolved	O
in	O
200	O
µL	O
of	O
50	O
mM	O
acetic	B
acid	I
(as	O
a	O
resuspension	O
buffer).	O

While	O
nicotinic	O
and	O
picolinic	B
acids	I
shared	O
the	O
same	O
quantification	O
transition	O
(124.1	O
→	O
78.1),	O
they	O
were	O
fully	O
resolved	O
chromatographically.	O

In	O
addition,	O
Wang	O
et	O
al.	O
recently	O
have	O
implicated	O
enteric	O
bacteria	O
and	O
phosphatidylcholine	B
metabolism	O
in	O
the	O
pathogenesis	O
of	O
cardiovascular	O
disease	O
.	O

One-mL	O
stock	O
solutions	O
(1	O
mM)	O
of	O
the	O
coenzymes/antioxidants	O
(NAD_+	O
,	O
NADH,	B
NADP_+	O
,	O
NADPH,	B
ATP,	B
ADP,	B
AMP,	B
GSH,	B
and	O
GSSG)	O
were	O
prepared	O
in	O
D_2	O
O	O
by	O
diluting	O
their	O
50	O
mM	O
solutions,	O
which	O
were	O
first	O
prepared	O
by	O
weighing	O
each	O
compound	O
and	O
dissolving	O
it	O
in	O
D_2	O
O.	O
A	O
60	O
μ	O
L	O
solution	O
of	O
each	O
compound	O
was	O
mixed	O
with	O
540	O
μ	O
L	O
of	O
phosphate	B
buffer	O
to	O
obtain	O
solutions	O
of	O
100	O
μ	O
M	O
concentration,	O
which	O
were	O
transferred	O
to	O
5	O
mm	O
NMR	O
tubes.	O

Again,	O
using	O
a	O
combination	O
of	O
exact	O
mass,	O
retention	O
time,	O
MS_2	O
and	O
MS_3	O
spectra,	O
and	O
comparison	O
with	O
authentic	O
standards,	O
the	O
C_27	O
bile	O
acids	O
3β-hydroxycholest-5-en-26-oic	O
acid	O
and	O
7α-hydroxy-3-oxocholest-4-en-26-oic	B
acid	I
were	O
identified.	O

The	O
analytical	O
method	O
analyzes	O
17	O
metabolites	O
involved	O
in	O
the	O
homocysteine–methionine	B
cycle.	O

Moreover,	O
a	O
higher	O
BCAA	O
level	O
has	O
been	O
found	O
in	O
retinal	B
Müller	O
cells	O
from	O
diabetic	O
compared	O
to	O
euglycemic	B
rats.	O

The	O
stability	O
study	O
demonstrated	O
a	O
strong	O
instability	O
for	O
glutamic	B
acid	I
and	O
aspartic	B
acid.	I

Altered	O
glucose	B
metabolism	O
in	O
metastatic	O
carcinoma	O
has	O
been	O
known	O
since	O
as	O
long	O
as	O
1975.	O

Plasma	O
PLTP	O
and	O
LCAT	O
activity	O
were	O
expectedly	O
elevated	O
in	O
T2DM,	O
and	O
both	O
protein	O
factors	O
were	O
correlated	O
positively	O
with	O
triglycerides	B
[,	O
,	O
,	O
].	O

For	O
example,	O
Patassini	O
et	O
al	O
.	O
showed	O
that	O
brain	O
urea	B
levels	O
increased	O
significantly,	O
Graham	O
et	O
al	O
.	O
found	O
that	O
they	O
decreased.	O

The	O
measured	O
betaine	B
values	O
agreed	O
well	O
with	O
expected	O
concentrations	O
(slope = 0.998,	O
intercept = 0.890,	O
r_2	O
 = 0.996).	O

Accordingly,	O
increased	O
levels	O
of	O
GDPDs	O
in	O
metastatic	O
CRC	O
would	O
be	O
associated	O
with	O
decreased	O
levels	O
of	O
GPC	B
and	O
PE.	O

The	O
2	O
lipids	O
C18:2	B
CE	O
and	O
SM	B
22:0	I
shown	I
in	O
bold	O
were	O
selected	O
for	O
further	O
study	O
in	O
the	O
validation	O
stage.	O

Several	O
cytotoxic	O
compounds	O
including	O
dihydronaphthalenone	B
(73),	O
5-hydroxydihydrofusarubins	B
A	O
(74),	O
5-hydroxydihydrofusarubins	B
B	O
(75),	O
5-methoxydihydrofusarubin	B
B	O
(76),	O
and	O
5-hydroxydihydrofusarubin	B
C	O
(77)	O
were	O
also	O
reported	O
by	O
Kornsakulkarn	O
et	O
al.	O

Multiple	O
logistic	O
regression	O
analysis	O
(adjusted	O
for	O
age,	O
gender	O
and	O
body	O
weight	O
index)	O
revealed	O
that	O
serum	O
putrescine	B
and	O
spermine	B
levels	O
were	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
T2D.	O
Conclusions:	O
Our	O
study	O
suggests	O
that	O
polyamine	B
metabolism	O
is	O
dysregulated	O
in	O
T2D,	O
and	O
that	O
serum	O
levels	O
of	O
putrescine	B
and	O
spermine	B
are	O
associated	O
with	O
glycemic	B
control	O
and	O
circulating	O
insulin	O
levels,	O
respectively.	O

Hydrogen	B
peroxide	I
does	O
not	O
appear	O
to	O
react	O
directly	O
with	O
DNA,	O
but	O
does	O
undergo	O
chemical	O
reactions	O
within	O
the	O
cell	O
nucleus	O
which	O
produces	O
_•	O
OH,	O
e.g.,	O
reaction	O
with	O
Fe_+2	O
.	O

The	O
high	O
abundance	O
of	O
P-choline	B
in	O
Rh30	O
compared	O
with	O
the	O
myocytes	O
(Figure	O
)	O
appears	O
to	O
be	O
a	O
distinct	O
feature	O
of	O
proliferating	O
cells	O
[,,-].	O

A	O
mixture	O
of	O
10	O
μg/ml	O
each	O
(SMV,	O
SMV-A,	O
ATV,	O
2-OH-ATV,	B
4-OH-ATV,	B
RSV)	O
was	O
prepared	O
from	O
the	O
stock	O
solutions	O
by	O
a	O
dilution	O
with	O
acetonitrile.	B

The	O
major	O
route	O
for	O
primary	O
fatty	O
acid	B
amide	I
degradation	O
in	O
vivo	O
is	O
the	O
hydrolysis	O
of	O
fatty	O
acids	O
and	O
ammonia,	O
a	O
reaction	O
that	O
is	O
catalyzed	O
by	O
fatty	O
acid	O
amide	O
hydrolase.	O

2-Amino-1-methyl-6-phenylimidazo[4,5-b	B
]pyridine	I
(PhIP)	O
is	O
a	O
carcinogenic	O
heterocyclic	B
aromatic	O
amine	O
that	O
is	O
produced	O
in	O
cooked	O
meats.	O

Only	O
fragmentation	O
experiments	O
in	O
the	O
negative	O
ion	O
mode	O
enabled	O
to	O
distinguish	O
between	O
the	O
alkyl-acyl	O
form	O
PC32e:1	O
by	O
the	O
presence	O
of	O
the	O
FA	B
16:1	I
(m/z	O
253.2172)	O
at	O
9.0 min	O
(Fig.	O

Participants	O
represent	O
a	O
subset	O
of	O
subjects	O
from	O
a	O
previously	O
published	O
resting-state	O
study	O
that	O
had	O
blood	O
samples	O
to	O
be	O
analyzed	O
for	O
KP	B
metabolites.	O

Additional	O
measures	O
were	O
the	O
analyses	O
of	O
the	O
anthropometric	O
indices,	O
the	O
fasting	O
plasma	O
insulin,	O
glucose	B
and	O
C-reactive	O
protein	O
(CRP)	O
and	O
the	O
analysis	O
of	O
isoprostane	B
F2	O
in	O
urine.	O

These	O
differences	O
may	O
suggest	O
that	O
the	O
conversion	O
of	O
aspartate	B
to	O
asparagine	B
is	O
occurring	O
in	O
AP	B
patients	O
and	O
not	O
in	O
those	O
without	O
AP.	B

Moreover,	O
bradykinin	B
production	O
leads	O
to	O
the	O
release	O
of	O
various	O
cytokines,	O
e.g.,	O
IL-6,	O
which	O
further	O
activates	O
the	O
innate	O
immune	O
system	O
and,	O
thereby,	O
CRP	O
release	O
from	O
the	O
liver.	O

As	O
hypertriglyceridemia	O
has	O
been	O
suggested	O
as	O
a	O
risk	O
factor	O
for	O
PCa,	O
the	O
opposite	O
result	O
would	O
have	O
been	O
expected,	O
and	O
the	O
significantly	O
increased	O
triglyceride	B
levels	O
might	O
be	O
a	O
result	O
of	O
the	O
control	O
group	O
not	O
consisting	O
of	O
healthy	O
men,	O
but	O
men	O
diagnosed	O
with	O
BPH.	O

For	O
the	O
elevated	O
PG	B
lipids	O
in	O
fatalities,	O
we	O
hypothesize	O
that	O
since	O
these	O
lipids	O
are	O
required	O
for	O
BMP	O
synthesis,	O
which	O
takes	O
place	O
in	O
late	O
endosomes,	O
they	O
are	O
elevated	O
during	O
enhanced	O
endosomal	O
pathway	O
activity.	O

Together,	O
these	O
results	O
suggest	O
that	O
we	O
have	O
identified	O
a	O
metabolite	O
related	O
to	O
oxidative	O
stress	O
that	O
is	O
robustly	O
correlated	O
to	O
LDL	O
response	O
to	O
simvastatin.	B

The	O
overall	O
metabolic	O
network	O
involved	O
metabolism	O
of	O
glucose	B
to	O
lactate	B
through	O
glycolysis	O
and	O
through	O
more	O
complex	O
metabolic	O
pathways	O
involving	O
part	O
of	O
the	O
TCA	O
cycle	O
and/or	O
the	O
pentose	B
phosphate	I
pathway	O
(data	O
not	O
shown).	O

Nonetheless,	O
adapting	O
two	O
different	O
reconstitution	O
solvent	O
involves	O
an	O
additional	O
partition	O
step	O
to	O
divide	O
the	O
plasma	O
sample	O
equally	O
into	O
two	O
portions:	O
one	O
reconstituted	O
in	O
0.1%	O
formic	B
acid	I
for	O
the	O
positive	O
mode;	O
the	O
other	O
in	O
ammonium	B
bicarbonate	O
for	O
the	O
negative	O
mode.	O

Dried	O
extracts	O
were	O
reconstituted	O
in	O
100	O
μL	O
85:15	O
mobile	O
phase	O
A	O
(0.1%	O
formic	B
acid	I
and	O
water)	O
and	O
mobile	O
phase	O
B	O
(0.1%	O
formic	B
acid	I
in	O
acetonitrile)	O
and	O
15	O
μL	O
was	O
injected	O
into	O
the	O
mass	O
spectrometer.	O

However,	O
similar	O
to	O
donor	O
D1,	O
these	O
microbiota	O
were	O
not	O
able	O
to	O
metabolize	O
thunalbene	B
to	O
isoresveratrol.	O

However,	O
these	O
two	O
precursor	O
amino	O
acids	O
were	O
not	O
altered	O
by	O
thiazide	B
therapy.	O

The	O
positive	O
controls	O
used	O
were	O
doxorubicin	B
and	O
camptothecin	B
at	O
50	O
μg/mL.	O
The	O
plates	O
were	O
incubated	O
at	O
37°C	O
with	O
5%	O
CO_2	O
for	O
48	O
hours.	O

As	O
shown	O
in	O
Additional	O
file	O
9,	O
the	O
decreasing	O
L-proline	B
occurred	O
in	O
all	O
parameters	O
that	O
were	O
analyzed,	O
suggesting	O
that	O
this	O
compound	O
is	O
possible	O
to	O
act	O
as	O
biomarker	O
for	O
lung	O
cancer,	O
regardless	O
of	O
smoking	O
habit.	O

We	O
have	O
optimized	O
a	O
combined	O
liquid-liquid	O
and	O
solid	O
phase	O
extraction	O
method	O
for	O
plasma	O
and	O
have	O
compared	O
that	O
to	O
traditional	O
methanol	B
precipitation	O
using	O
spiked	O
internal	O
standards	O
as	O
controls.	O

Data	O
are	O
shown	O
as	O
pg/mL.	O
Individuals	O
are	O
classified	O
as	O
noncannabis	O
users	O
or	O
cannabis	B
users	O
stratified	O
by	O
moderate	O
or	O
heavy	O
cannabis	B
use	O
as	O
determined	O
by	O
plasma	O
quantities	O
of	O
11-nor-carboxy-tetrahydrocannabinol.	B

Formate	B
can	O
be	O
linked	O
to	O
the	O
production	O
of	O
GSH	B
through	O
tetrahydrofolate	B
(THF)	O
metabolism	O
and	O
the	O
malfunction	O
of	O
GSH	B
production	O
possibly	O
affects	O
or	O
causes	O
the	O
increase	O
of	O
formate.	B

To	O
increase	O
the	O
sample	O
size	O
used	O
in	O
our	O
previous	O
publication	O
between	O
phthalates	O
and	O
isoprostane	B
(N	O
=	O
50),	O
we	O
analyzed	O
an	O
additional	O
49	O
samples.	O

Our	O
findings	O
of	O
higher	O
myoinositol	B
levels	O
in	O
RRMS	O
and	O
MS-like	O
patients	O
compared	O
with	O
Ab-NMOSD	O
and	O
NMOSD-like	O
patients	O
are	O
in	O
agreement	O
with	O
these	O
observations.	O

The	O
overall	O
receiver	O
operator	O
characteristic	O
(ROC)	O
curves	O
for	O
sarcosine	B
suggest	O
its	O
predictive	O
value	O
is	O
modest	O
with	O
AUCs	O
of	O
0.71	O
and	O
0.67	O
for	O
urine	O
sediments	O
and	O
supernatants,	O
respectively.	O

However,	O
it	O
is	O
still	O
noticeable	O
that	O
PC(40:7)	B
is	O
so	O
abundant.	O

Comparing	O
cachectic	O
to	O
non-cachectic	O
patients,	O
higher	O
levels	O
of	O
metabolites	O
such	O
as	O
acetone	B
(Fold	O
change	O
(FC)	O
=	O
3.17;	O
p	O
=	O
0.02)	O
and	O
arginine	B
(FC	O
=	O
0.33;	O
p	O
=	O
0.04)	O
were	O
observed.	O

The	O
signal	O
in	O
lactate	B
carbon	O
2	O
(LAC2)	O
showed	O
a	O
large	O
doublet	O
of	O
doublets,	O
reflecting	O
labeling	O
at	O
all	O
three	O
lactate	B
carbons.	O

Testosterone	B
(T),	O
and	O
progesterone	B
(Prog)	O
were	O
purchased	O
from	O
Sigma–Aldrich	O
(St.	O
Louis,	O
MO).	O

Since	O
the	O
immune	O
system	O
is	O
the	O
first	O
candidate	O
responsible	O
for	O
cancer–host	O
interaction,	O
we	O
investigated	O
serum	O
cytokines	O
profile	O
among	O
the	O
ER(−)	O
and	O
ER(+)	B
groups	O
in	O
an	O
attempt	O
to	O
reveal	O
potential	O
interactions	O
between	O
the	O
cancer	O
and	O
the	O
host	O
immune	O
system.	O

**PE(18:2(9Z,12Z)/0:0):	B
1-(9Z,12Z-Octadecadienoyl)-glycero-3-phosphoethanolamine;	B
PC	B
(18:1(9Z)/0:0):	I
1-(9Z)-Octadecenoyl-sn-glycero-3-phosphocholine.	B

We	O
have	O
also	O
identified	O
glycerol	B
and	O
lactate	B
to	O
be	O
differentially	O
expressed	O
among	O
three	O
injury	O
groups.	O

In	O
the	O
present	O
study,	O
we	O
discovered	O
and	O
validated	O
that	O
arginine	B
in	O
urine	O
is	O
a	O
potential	O
diagnostic	O
biomarker	O
for	O
aMCI.	O

This	O
agrees	O
with	O
the	O
methylation	O
and	O
reduced	O
expression	O
of	O
the	O
GABA	B
receptor	O
GABBR2	O
in	O
LC.	O

Notably,	O
inter-patient	O
differences	O
in	O
anthocyanin	B
bioactivation	O
and	O
capacities	O
for	O
enteric	O
recycling	O
would	O
impact	O
treatment	O
as	O
retention	O
of	O
bioactivated	O
chemopreventives	O
at	O
the	O
target	O
site	O
would	O
sustain	O
therapeutic	O
effectiveness.	O

This	O
strain	O
was	O
initially	O
grown	O
in	O
the	O
presence	O
of	O
arabinose	B
and	O
then	O
back	O
diluted	O
into	O
LB	O
containing	O
arabinose,	B
fucose,	B
or	O
no	O
inducer.	O

A	O
simple	O
and	O
rapid	O
estrogen	B
measurement	O
by	O
LC-MS/MS	O
is	O
important	O
in	O
clinical	O
and	O
research	O
laboratories,	O
and	O
we	O
developed	O
such	O
a	O
method	O
by	O
taking	O
advantage	O
of	O
the	O
superior	O
analytical	O
sensitivity	O
offered	O
by	O
API	O
5000	O
triple-quadrupole	O
tandem	O
mass	O
spectrometer.	O

Inspection	O
of	O
the	O
complete	O
IsoP,	O
PG	B
and	O
NO_2	O
-FA	O
target	O
panel	O
found	O
that	O
H.	O
pomatia	O
GUS	O
contained	O
the	O
highest	O
blank	O
effect	O
compared	O
with	O
E.	O
coli	O
and	O
bovine	O
liver	O
(see	O
ESM	O
Table	O
S7).	O

While	O
correction	O
for	O
multiple	O
hypothesis	O
testing	O
indicates	O
that	O
these	O
changes	O
are	O
not	O
statistically	O
significant,	O
we	O
report	O
the	O
entire	O
dataset	O
since	O
these	O
metabolites	O
are	O
connected	O
by	O
the	O
enzymatic	O
reaction	O
of	O
pseudouridine	B
synthase.	O

The	O
acquired	O
CPMG	O
_1	O
H-NMR	O
spectra	O
were	O
phased,	O
baseline-corrected	O
and	O
referenced	O
to	O
the	O
chemical	O
shift	O
of	O
the	O
α-glucose	B
anomeric	O
proton	O
doublet	O
at	O
5.23	O
ppm.	O

Future	O
analyses	O
of	O
glutaminolytic-ALDH	B
driven	O
mechanisms	O
underlying	O
tumorigenic	O
transitions	O
may	O
help	O
in	O
the	O
development	O
of	O
targeted	O
therapies	O
for	O
head	O
and	O
neck	O
cancer	O
and	O
its	O
CSC	O
compartment.	O

The	O
plasma	O
concentrations	O
of	O
tamoxifen	B
and	O
its	O
two	O
major	O
active	O
metabolites	O
were	O
determined	O
by	O
liquid	O
chromatography	O
tandem	O
mass	O
spectrometry	O
(LC-MS).	O

The	O
mobile	O
phase,	O
operating	O
at	O
a	O
flow	O
rate	O
of	O
4	O
μl/minute,	O
consists	O
of	O
methanol	B
as	O
solvent	O
A	O
and	O
0.1%	O
(v/v)	O
formic	B
acid	I
in	O
water	O
as	O
solvent	O
B.	O
A	O
linear	O
gradient	O
from	O
72	O
to	O
85%	O
solvent	O
B	O
in	O
75	O
minutes	O
was	O
employed	O
for	O
separation	O
of	O
EMs	O
and	O
SI-EMs.	O

SAM	O
plays	O
a	O
pivotal	O
role	O
as	O
a	O
methyl	O
donor,	O
being	O
formed	O
from	O
methionine	B
and	O
converted	O
into	O
SAH	O
after	O
donating	O
its	O
methyl	B
group.	I

There	O
were	O
no	O
significant	O
differences	O
in	O
HbA1c,	O
cholesterol,	B
HDL,	O
LDL,	O
triglycerides,	B
waist-to-hip	O
ratios,	O
sodium,	O
calcium,	O
CO_2	O
,	O
blood	O
urea	B
nitrogen	I
or	O
liver	O
function	O
tests.	O

Remarkably,	O
both	O
ERG-and	O
ETV1-induced	O
invasion	O
were	O
associated	O
with	O
a	O
3-fold	O
sarcosine	B
elevation	O
in	O
benign	O
RWPE	O
cells.	O

They	O
found	O
that	O
impaired	O
SPT	O
activity	O
induced	O
decreased	O
serum	O
ceramides	B
and	O
sphingosine	B
levels,	O
finally	O
resulting	O
in	O
bronchial	O
hyperreactivity.	O

(A)	O
UPLC-ESI/MS	O
analysis	O
of	O
reaction	O
products	O
formed	O
by	O
reaction	O
of	O
HONH-PhIP	O
with	O
acetic	B
anhydride,	I
following	O
SPE.	O

There	O
was	O
a	O
significant	O
increase	O
in	O
serum	O
saturated	O
(myristic,	O
caprylic,	O
palmitic,	B
palmitoleic,	B
oleic	O
and	O
eicosanoic)	B
and	O
unsaturated	O
(linoleic,	O
linolenic,	O
gamma-linolenic	O
and	O
arachnidonic)	O
fatty	O
acids	O
post-rifaximin.	O

In	O
order	O
to	O
understand	O
how	O
T2D	O
can	O
influence	O
polyamine	B
metabolism	O
(or	O
vice	O
versa),	O
further	O
studies	O
are	O
needed.	O

While	O
glucose	B
is	O
used	O
in	O
ribose	B
production	O
of	O
proliferating	O
cells	O
through	O
pentose	B
phosphate	I
pathway,	O
it	O
can	O
be	O
converted	O
to	O
citrate	B
via	O
glycolysis	O
and	O
Krebs	O
cycle.	O

renal	O
cell	O
carcinoma,	O
metabolomics,	O
benign	O
tumors,	O
biomarker,	O
tryptophan	B
metabolism	O

Groups	O
of	O
ACs,	O
important	O
to	O
evaluate	O
mitochondrial	O
function,	O
were	O
also	O
computed	O
by	O
summing	O
(Total	O
AC,	O
C2+C3,	O
C16+C18,	O
C16+C18:1,	B
C16-OH+C18:1-OH).	B

In	O
addition,	O
the	O
rate	O
of	O
nicotine	B
metabolism	O
was	O
again	O
higher	O
among	O
NP	O
relative	O
to	O
SW	O
smokers	O
when	O
analyses	O
were	O
restricted	O
to	O
the	O
*1B/*1B	O
group	O
(P	O
=0.02;	O
).	O

Biological	O
actions	O
of	O
linoleic	B
acid	I
were	O
studied	O
in	O
cultured	O
vascular	O
smooth	O
muscle	O
cells	O
(VSMCs).	O

BMI	O
indicates	O
body	O
mass	O
index;	O
CAD,	O
coronary	O
artery	O
disease;	O
Cr,	O
creatinine;	B
GLU,	O
glucose;	B
HBP,	O
high	O
blood	O
pressure;	O
HDL,	O
high‐density	O
lipoprotein;	O
HLP,	O
hyperlipidemia;	O
LAA,	O
large‐artery	O
atherosclerosis;	O
LDL,	O
low‐density	O
lipoprotein;	O
NA,	O
not	O
applicable	O
due	O
to	O
selection	O
criteria;	O
TC,	O
total	O
cholesterol;	B
TG,	B
triglycerides;	B
TIA,	O
transient	O
ischemic	O
attack;	O
TMAO,	B
trimethylamine	B
N‐oxide;	I
UA,	O
uric	B
acid;	I
VLDL,	O
very	O
low‐density	O
lipoprotein;	O
WBC,	O
white	O
blood	O
cell	O
count.	O

Apo,	O
apolipoprotein;	O
CI,	O
confidence	O
interval;	O
DHA,	O
docosahexaenoic	B
acid;	I
FA,	B
fatty	O
acid;	O
HOMA‐IR,	O
homeostatic	O
model	O
assessment	O
of	O
insulin	O
resistance;	O
IDL,	O
intermediate‐density	O
lipoprotein;	O
LDL,	O
low‐density	O
lipoprotein;	O
MUFA,	O
monounsaturated	O
fatty	O
acid;	O
PUFA,	O
polyunsaturated	O
fatty	O
acid;	O
SFA,	O
saturated	O
fatty	O
acid.	O

Thus,	O
bile	O
acids	O
might	O
serve	O
global	O
anti-apoptotic	O
or	O
anti-angiogenic	O
roles	O
that	O
are	O
critical	O
to	O
retinal	B
function.	O

Tryptophan	B
depletion	O
is	O
related	O
to	O
T-cell	O
anergy	O
and	O
apoptosis,	O
whereas	O
kynurenine	B
suppresses	O
T-cell	O
differentiation	O
and	O
function.	O

Hypoxanthine,	B
a	O
purine	B
base	I
generated	O
from	O
degradation	O
of	O
adenine	B
and	O
guanine	B
nucleotides,	O
decreased	O
in	O
MACS	O
by	O
39%	O
within	O
2	O
h	O
of	O
glucose	B
ingestion,	O
and	O
this	O
pattern	O
was	O
replicated	O
in	O
FOS-NGT.	O

While	O
there	O
are	O
multiple	O
sources	O
of	O
lactate	B
represented	O
in	O
the	O
blood	O
during	O
critical	O
illness	O
and	O
because	O
lactate	B
is	O
normally	O
detected	O
in	O
the	O
blood,	O
blood	O
lactate	B
is	O
not	O
a	O
specific	O
marker	O
of	O
lung	O
injury	O
and	O
the	O
precise	O
range	O
of	O
lactate	B
concentrations	O
associated	O
with	O
overall	O
illness	O
severity	O
has	O
not	O
been	O
defined.	O

Pyrimidine	B
metabolism–associated	O
RRM2	O
is	O
differently	O
expressed	O
in	O
breast	O
cancer	O
subtypes	O
and	O
is	O
a	O
predictor	O
of	O
outcome.	O

Hypoxanthine	B
levels	O
decrease	O
to	O
a	O
small	O
extent	O
in	O
the	O
liver	O
of	O
CPF	O
animals	O
but	O
increase	O
in	O
the	O
liver	O
of	O
FS.	O

In	O
a	O
previous	O
study,	O
various	O
amino	O
acids	O
including	O
aspartic	B
acid	I
displayed	O
higher	O
levels	O
in	O
colorectal	O
tumor	O
tissues	O
than	O
in	O
normal	O
colorectal	O
tissues	O
,	O
,	O
,	O
indicating	O
that	O
tumor	O
cells	O
may	O
need	O
the	O
nutrient.	O

The	O
correlations	O
between	O
MRS	O
measured	O
and	O
laboratory	O
measured	O
of	O
triglycerides,	B
cholesterol,	B
LDL	O
and	O
HDL	O
were	O
r	O
=0.98,	O
0.97,	O
0.95	O
and	O
0.97,	O
respectively.	O

Associations	O
between	O
plasma	O
levels	O
of	O
AGEs	O
and	O
fasting	O
glucose,	B
fasting	O
insulin	O
and	O
HOMA-IR	O
were	O
weak	O
(r	O
between	O
-0.2	O
and	O
0.2)	O
and	O
not	O
statistically	O
significant	O
(all	O
p>0.05).	O

As	O
shown	O
in	O
,	O
after	O
normalizing	O
to	O
that	O
of	O
0.1%	O
FA,	B
0.1%	O
FA	B
and	O
10mM	O
AF	B
exhibited	O
higher	O
average	O
responses	O
compared	O
to	O
0.1%	O
HOAc	O
and	O
20mM	O
AF,	B
with	O
0.1%	O
FA	B
showing	O
less	O
variation	O
in	O
comparison	O
to	O
10	O
mM	O
AF.	B

5-HETE	B
and	O
leukotriene	O
B_4	O
are	O
metabolites	O
associated	O
with	O
arachidonic	B
acid	I
(C20:4)	O
metabolism.	O

The	O
levels	O
of	O
these	O
free	O
oxysterols	B
in	O
CSF	O
were	O
very	O
low	O
ranging	O
from	O
0.009	O
±	O
0.005	O
ng/ml	O
for	O
7β-hydroxycholesterol	B
(cholest-5-ene-3β,7β-diol,	I
C_5	I
-3β,7β-diol)	I
to	O
0.026	O
±	O
0.018	O
ng/ml	O
for	O
6-hydroxycholesterol	B
(cholest-4-ene-3β,6-diol,	I
C_4	I
-3β,6-diol,	I
or	I
cholest-5-ene-3β,6-diol,	I
C_5	I
-3β,6-diol)	I
and	O
0.034	O
±	O
0.017	O
ng/ml	O
for	O
7-oxocholesterol.	B

However,	O
after	O
multivariable	O
adjustments	O
incorporating	O
CrCl	O
and	O
hsCRP,	O
analytes	O
of	O
arginine	O
methylation	O
pathways	O
alternative	O
to	O
ADMA	B
(e.g.	O
SDMA)	O
and	O
the	O
integrated	O
methylation	O
index,	O
ArgMI,	O
still	O
demonstrated	O
independent	O
prognostic	O
value	O
for	O
cardiovascular	O
events.	O

Serine	B
is	O
a	O
nutritionally	O
nonessential	O
amino	O
acid,	O
but	O
it	O
is	O
metabolically	O
indispensable	O
and	O
has	O
received	O
increasing	O
attention	O
over	O
the	O
past	O
years.	O

The	O
third	O
metabolite	O
found	O
to	O
be	O
associated	O
with	O
CHD	O
in	O
this	O
study	O
is	O
pyridoxic	B
acid,	I
which	O
is	O
the	O
end	O
product	O
of	O
vitamin	B
B6	I
catabolism.	O

Additionally,	O
this	O
deficiency	O
was	O
closely	O
related	O
to	O
the	O
deactivation	O
of	O
peroxisome	O
proliferator‐activated	O
receptor	O
α	O
(PPARα)	O
29.	O

All	O
patients	O
had	O
chosen	O
prostatectomy	O
as	O
primary	O
treatment,	O
and	O
cases	O
for	O
inclusion	O
were	O
selected	O
simply	O
based	O
upon	O
whether	O
adequate	O
tumor	O
and	O
appropriate	O
non-tumor	O
methanol	B
extracts	O
were	O
available	O
upon	O
review	O
of	O
the	O
histologic	O
sections	O
that	O
corresponded	O
to	O
the	O
samples.	O

Covariance	O
simultaneous	O
component	O
analysis	O
(COVSCA)	O
is	O
a	O
recently	O
introduced	O
model	O
to	O
analyze	O
communalities	O
and	O
differences	O
across	O
a	O
set	O
of	O
(k	O
=	O
1,2,...,	B
K	O
)	O
covariance	O
matrices	O
simultaneously.	O

In	O
contrast	O
to	O
our	O
results,	O
older	O
studies	O
have	O
shown	O
that	O
blood	O
ketone	B
bodies	O
are	O
higher	O
in	O
HF	O
patients	O
than	O
in	O
healthy	O
control	O
subjects	O
after	O
8–12	O

We	O
found	O
important	O
correlations	O
between	O
the	O
levels	O
of	O
BCAA-derived	O
acylcarnitines	B
and	O
specific	O
sphingomyelins	B
with	O
plasma	O
cholesterol	B
and	O
triacylglycerol	B
concentrations.	O

The	O
key	O
enzyme	O
of	O
pentose	B
phosphate	I
pathway,	O
glucose‐6‐phosphate	O
dehydrogenase,	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
insulin	O
resistance_54	O
.	O

Previous	O
attempts	O
to	O
predict	O
the	O
variability	O
of	O
(Z)‐endoxifen	B
levels	O
relied	O
on	O
pharmacokinetic	O
and	O
pharmacogenomic	O
knowledge,_17	O
,	O
_38	O
,	O
_39	O
which	O
has	O
been	O
implemented	O
into	O
therapeutic	O
recommendations	O
based	O
on	O
CYP2D6	O
genotyping._14	O
Although	O
a	O
recent	O
drug	O
monitoring	O
study	O
showed	O
that	O
tamoxifen	B
metabolites	O
may	O
be	O
predictive	O
of	O
side	O
effects,	O
such	O
as	O
nausea	O
and	O
vaginal	O
dryness,_40	O
clinical	O
tamoxifen	B
outcome	O
studies	O
as	O
of	O
yet	O
provided	O
controversial	O
results	O
possibly	O
due	O
to	O
the	O
influence	O
of	O
unidentified	O
confounders._22	O
,	O
_23	O
,	O
_24	O
,	O
_26	O
,	O
_27	O
,	O
_28	O
Because	O
it	O
is	O
well	O
known	O
that	O
women	O
stop	O
taking	O
their	O
medication	O
before	O
completing	O
the	O
standard	O
5‐year	O
regimen,	O
we	O
investigated	O
patients'	O
adherence	O
behavior	O
during	O
the	O
first	O
year	O
of	O
tamoxifen	B
treatment	O
in	O
relation	O
to	O
their	O
metabolic	O
capacity	O
for	O
achieving	O
relevant	O
(Z)‐endoxifen	B
concentrations.	O

Tulipani	O
et	O
al.	O
concluded	O
that	O
plasma	O
concentrations	O
of	O
LPC17:0,	B
LPC18:1,	B
and	O
LPC18:2	B
show	O
inverse	O
correlations	O
with	O
BMI,	O
body	O
weight,	O
and	O
waist	O
and	O
hip	O
circumference	O
in	O
morbidly	O
obese	O
subjects	O
[,	O
].	O

Go	O
to:	O
Background:	O
Gut	O
microbiota-related	O
metabolites,	O
trimethylamine-N-oxide	B
(TMAO),	O
choline,	B
and	O
betaine,	B
have	O
been	O
shown	O
to	O
be	O
associated	O
with	O
cardiovascular	O
disease	O
(CVD)	O
risk.	O

A	O
study	O
on	O
Chinese	O
patients	O
reported	O
that	O
the	O
levels	O
of	O
triglycerides,	B
total	O
cholesterol,	B
and	O
low-	O
and	O
high-density	O
lipoproteins	O
in	O
seminal	O
plasma	O
were	O
higher	O
in	O
individuals	O
with	O
oligo-,	O
astheno-	O
or	O
teratozoospermia	O
than	O
in	O
individuals	O
with	O
normal	O
sperm	O
concentration,	O
motility	O
and	O
morphology.	O

To	O
facilitate	O
continued	O
testing	O
in	O
population-based	O
studies	O
of	O
the	O
multiple	O
laboratory-based	O
hypotheses	O
about	O
the	O
roles	O
of	O
estrogen	B
metabolites,	O
a	O
novel	O
liquid	O
chromatography-tandem	O
mass	O
spectrometry	O
(LC-MS/MS)	O
assay	O
was	O
developed	O
to	O
measure	O
concurrently	O
all	O
15	O
estrogens	O
and	O
estrogen	B
metabolites	O
in	O
human	O
serum	O
and	O
urine,	O
as	O
unconjugated	O
and	O
total	O
(glucuronidated+sulfated+unconjugated)	O
concentrations.	O

The	O
use	O
of	O
capillary	O
liquid	O
chromatography	O
coupled	O
to	O
inductively	O
coupled	O
plasma	O
mass	O
spectrometry	O
(capLC-ICPMS)	O
for	O
screening	O
using	O
_31	O
P	O
as	O
the	O
internal	O
elemental	O
tag	O
atom	O
at	O
ultratrace	O
levels,	O
in	O
combination	O
with	O
molecular	O
mass	O
spectrometry	O
using	O
Spectrum	O
Mill	O
and	O
MASCOT	O
database	O
search	O
engines	O
for	O
peptide	O
identification,	O
is	O
a	O
novel	O
approach	O
in	O
its	O
application	O
to	O
CSF	O
relevant	O
phosphopeptides	B
and	O
phosphorylated	O
proteins.	O

There	O
is	O
no	O
consensus	O
in	O
the	O
literature	O
on	O
the	O
correct	O
levels	O
of	O
total	O
serum	O
16α-OH-E2	B
–	O
reported	O
values	O
span	O
a	O
wide	O
range	O
from	O
27.9	O
pg/mL	O
to	O
126.0	O
pg/mL.	O

In	O
particular,	O
several	O
investigations	O
have	O
focused	O
on	O
establishing	O
breast	O
cancer	O
biomarkers	O
using	O
metabolomics	O
approach	O
and	O
numerous	O
metabolites	O
including	O
glucose,	B
lactate,	B
lipids,	O
choline	B
and	O
amino	O
acids	O
are	O
shown	O
to	O
correlate	O
with	O
breast	O
cancer	O
(-).	O

On	O
the	O
other	O
hand,	O
citrate	B
is	O
a	O
substrate	O
for	O
production	O
itaconate	B
via	O
cisaconitate,	O
which	O
acts	O
as	O
a	O
negative	O
regulator	O
of	O
inflammation	O
by	O
modulating	O
the	O
synthesis	O
of	O
the	O
inflammatory	O
mediators.	O

We	O
found	O
that	O
neither	O
of	O
these	O
SNPs	O
were	O
significantly	O
associated	O
with	O
atenolol	B
BP	O
response	O
(rs2727563	O
SBP	O
p=0.24,	O
DBP	B
p=0.47;	O
rs12604940	O
SBP	O
p=0.96,	O
DBP	B
p=0.79;	O
rs13262930	O
SBP	O
p=0.56,	O
DBP	B
p=0.93)	O
nor	O
with	O
candesartan	O
BP	O
response	O
(rs2727563	O
SBP	O
p=0.64,	O
DBP	B
p=0.71;	O
rs12604940	O
SBP	O
p=0.37,	O
DBP	B
p=0.29;	O
rs13262930	O
SBP	O
p=0.81,	O
DBP	B
p=0.77).	O

In	O
particular,	O
mass	O
errors	O
of	O
adrenic	B
acid	I
and	O
UA	O
were	O
21.13	O
and	O
23.95,	O
respectively,	O
and	O
were	O
identified	O
using	O
both	O
databases	O
and	O
reference	O
compounds,	O
suggesting	O
that	O
the	O
analysis	O
was	O
appropriate	O
for	O
compound	O
identification.	O

In	O
particular,	O
the	O
increased	O
levels	O
of	O
acetoacetate,	B
acetone,	B
acetate	B
as	O
well	O
as	O
n-butyrate,	B
α-hydroxy-n	B
-butyrate,	I
and	O
β-hydroxybutyrate,	B
derive	O
from	O
β-oxidation	O
process.	O

(E)	O
AL-conjugated	O
protein	O
levels	O
were	O
increased	O
in	O
the	O
superior	O
frontal	O
cortex	O
of	O
FTD	O
brain	O
(N = 10)	O
compared	O
to	O
control	O
brain	O
(N = 11)	O
as	O
detected	O
by	O
western	O
blotting;	O
normalized	O
by	O
the	O
housekeeper	O
β-actin	B
(β-a)	I
(F)	O
AL-conjugated	O
protein	O
levels	O
were	O
increased	O
in	O
the	O
superior	O
frontal	O
cortex	O
of	O
AD	O
brain	O
(N = 10)	O
compared	O
to	O
control	O
brain	O
(N = 11).	O

Analytical	O
experiments	O
confirm	O
the	O
identity	O
of	O
N	B
-acetyl-S	I
-(1Z	I
)-propenyl-cysteine-sulfoxide	I
(NAcSPCSO)	O
as	O
a	O
urinary	O
biomarker	O
of	O
onion	O
intake.	O

Pathway	O
enrichment	O
analysis	O
indicated	O
that	O
tryptophan	B
metabolism	O
was	O
an	O
important	O
pathway	O
in	O
RCC.	O

Increased	O
phospholipid	B
content	O
is	O
demonstrated	O
in	O
transformed	O
cells	O
and	O
during	O
tumor	O
progression.	O

This	O
is	O
consistent	O
with	O
reports	O
in	O
oligospermic	O
men	O
showing	O
that	O
treatment	O
with	O
S-adenosylmethionine,	B
a	O
polyamine	B
precursor,	O
leads	O
to	O
an	O
increase	O
in	O
polyamine	B
content	O
and	O
improved	O
sperm	O
motility.	O

Chenomx	O
NMR	O
Suite	O
Professional	O
Software	O
package	O
(version	O
5.1;	O
Chenomx	O
Inc.,	O
Edmonton,	O
Alberta,	O
Canada)	O
was	O
used	O
for	O
absolute	O
quantitation	O
of	O
glutamine	B
and	O
pyroglutamic	B
acid.	I

Intra-	O
and	O
inter-day	O
accuracy	O
and	O
precision	O
for	O
abiraterone	B
and	O
its	O
metabolites	O
in	O
LLOQ	O
and	O
QC	O
samples.	O

Results:	O
In	O
all	O
three	O
protocols,	O
pioglitazone	B
similarly	O
reduced	O
(all	O
P	O
<	O
0.05)	O
the	O
glycosylated	O
hemoglobin	O
(Δ	O
=	O
0.8–1.2%),	O
fasting	O
plasma	O
glucose	B
(39–76	O
mg/dl),	O
fasting	O
free	O
fatty	O
acid	O
(132–236	O
μmol/liter),	O
and	O
increased	O
insulin-stimulated	O
glucose	B
disposal	O
(by	O
25–56%).	O

The	O
Zhang	O
study	O
could	O
differentiate	O
between	O
healthy	O
subjects	O
and	O
overt	O
T2DM	O
cases	O
using	O
NMR	O
spectra	O
of	O
plasma,	O
but	O
could	O
not	O
identify	O
the	O
milder	O
cases	O
with	O
impaired	O
glucose	B
regulation.	O

In	O
addition	O
a	O
decrease	O
in	O
TAG(52:1)	B
was	O
detected.	O

A	O
direct	O
association	O
with	O
BMI	O
of	O
phenylalanine	B
(P	O
=	O
8.35	O
×	O
10_−19	O
,	O
),	O
based	O
on	O
the	O
IEC	O
amino	O
acid	O
analysis	O
data,	O
confirmed	O
previous	O
findings	O
linking	O
obesity	O
with	O
the	O
blood	O
concentration	O
of	O
phenylalanine	B
(–,	O
).	O

Stability	O
of	O
abiraterone	B
and	O
its	O
metabolites	O
after	O
preparation	O
and	O
in	O
serum.	O

Pyruvate	B
showed	O
increased	O
levels	O
during	O
the	O
whole	O
examined	O
time	O
period	O
and	O
concentrations	O
also	O
decreased	O
with	O
time	O
although	O
remaining	O
elevated	O
as	O
compared	O
to	O
the	O
control	O
group	O
at	O
48 h	O
of	O
life	O
(see	O
Fig.	O

The	O
levels	O
of	O
sphingomyelin	B
(C14:0,	I
C16:0,	I
C18:1,	I
C18:0,	I
C20:0,	I
C22:0,	I
C24:1,	I
C24:0,	I
C26:1,	I
C26:0)	I
were	O
determined	O
by	O
LC-ESI-MS/MS.	O

In	O
HILIC,	O
chloride	B
anions	O
and	O
other	O
salts	O
are	O
retained	O
by	O
the	O
column	O
and	O
elute	O
over	O
a	O
broad	O
retention	O
time	O
range	O
(from	O
6–17	O
minutes	O
of	O
the	O
20	O
minute	O
run),	O
thereby	O
causing	O
substantial	O
ion	O
suppression	O
of	O
later-eluting	O
peaks.	O

(254.1	O
or	O
259.1	O
Da),	O
where	O
the	O
amine	O
group	O
of	O
the	O
side	O
chain	O
of	O
lysine	B
displaced	O
the	O
nitro	O
moiety	O
of	O
PhIP.	O

Through	O
subsequent	O
targeting	O
of	O
CPS-1,	O
they	O
demonstrated	O
that	O
these	O
KL	B
cells	O
rely	O
on	O
the	O
urea	B
cycle	O
to	O
drive	O
pyrimidine	B
synthesis	O
from	O
ammonia,	O
which	O
may	O
serve	O
as	O
a	O
metabolic	O
vulnerability	O
to	O
target	O
therapeutically.	O

In	O
particular,	O
we	O
found	O
that	O
a	O
characteristic	O
change	O
depends	O
on	O
the	O
degree	O
of	O
unsaturation	O
of	O
fatty	O
acids	O
in	O
the	O
specific	O
lipid	O
classes,	O
including	O
FFAs	O
and	O
phospholipids.	B

However,	O
other	O
resolvins	O
and	O
lipoxin	B
A_4	O
were	O
only	O
detected	O
when	O
their	O
amounts	O
reached	O
the	O
minimal	O
detection	O
limits	O
in	O
one	O
or	O
two	O
samples,	O
thus	O
they	O
were	O
not	O
considered	O
for	O
biomarker	O
potentials.	O

Labeling	O
in	O
glutamate	B
carbon	O
2	O
and	O
glutamate	B
carbon	O
3	O
is	O
consistent	O
with	O
turnover	O
of	O
the	O
TCA	O
cycle.	O

It	O
has	O
been	O
reported	O
that	O
trans	O
-acyl	O
chains	O
adopt	O
extended	O
configurations	O
similar	O
to	O
saturated	O
acyl	O
chains,	O
allowing	O
better	O
interaction	O
with	O
the	O
cholesterol	B
molecule	O
compared	O
with	O
their	O
cis	O
analogs	O
.	O

For	O
example,	O
we	O
found	O
40.2%	O
of	O
unique	O
compounds	O
in	O
arachidonic	B
acid	I
metabolism,	O
61.9%	O
in	O
steroid	O
hormone	O
biosynthesis,	O
40.9%	O
in	O
bile	O
acid	O
biosynthesis,	O
69.2%	O
and	O
45%,	O
respectively	O
for	O
α-linolenic	B
acid	I
metabolism	O
and	O
linoleic	B
acid	I
metabolism,	O
and	O
38.9%	O
in	O
the	O
pathway	O
of	O
the	O
biosynthesis	O
of	O
unsaturated	O
fatty	O
acids.	O

A	O
similar	O
trend	O
was	O
observed	O
by	O
using	O
25μM	B
celecoxib	I
for	O
treating	O
SUM149PT	O
cells	O
(Figure	O
and	O
).	O

Maternal	O
thyroxine	B
is	O
crucial	O
in	O
fetal	O
development	O
due	O
to	O
it	O
supplies	O
thyroid	O
hormone-dependent	O
tissues	O
in	O
critical	O
periods	O
during	O
the	O
first	O
trimester	O
of	O
pregnancy.	O

Interestingly,	O
iodoacetamide,	B
a	O
reported	O
Blmh	O
inhibitor	O
,	O
decreased	O
human	O
liver	O
HCTL	O
hydrolysis	O
by	O
∼50%.	O

Briefly,	O
sample	O
extraction	O
was	O
conducted	O
by	O
using	O
aqueous	O
methanol,	B
delivered	O
by	O
an	O
automated	O
liquid	O
handler	O
to	O
remove	O
the	O
protein	O
fraction	O
while	O
allowing	O
maximum	O
recovery	O
of	O
small	O
molecules.	O

[13C6,	O
97%‐99%],	O
l‐tyrosine	B

Imbalance	O
between	O
oxygen	O
delivery	O
and	O
consumption	O
leads	O
to	O
anaerobic	O
metabolism	O
and	O
lactate	B
production.	O

In	O
this	O
study,	O
cysteine	B
+	O
cystine	B
levels	O
were	O
high	O
in	O
the	O
OSCC	O
group	O
compared	O
to	O
the	O
OD	O
group,	O
and	O
pre-	O
and	O
postoperative	O
comparisons	O
of	O
OSCC	O
revealed	O
a	O
high	O
value	O
of	O
cysteine	B
+	O
cystine.	B

After	O
30	O
minutes	O
of	O
intensive	O
exercise,	O
glucose	B
levels	O
varied	O
differently	O
according	O
to	O
diabetic	O
condition.	O

Valine	B
is	O
characterized	O
by	O
linearity	O
and	O
monotonicity	O
in	O
its	O
low	O
range,	O
and	O
non-linearity	O
in	O
its	O
high	O
range.	O

Our	O
platform	O
highlighted	O
small	O
molecules	O
previously	O
associated	O
with	O
RV-PV	O
dysfunction,	O
including	O
arginine-NO	B
pathway	O
intermediates,	O
catecholamines,	B
and	O
indicators	O
of	O
oxidative	O
stress.	O

In	O
some	O
cases,	O
methoxyamine	B
(20	O
mmol)	O
was	O
added	O
after	O
1	O
hour	O
to	O
derivatize	O
all	O
carbonyl	O
groups.	O

The	O
IBD	O
patients	O
had	O
significantly	O
higher	O
citrulline	B
and	O
higher	O
DMA	B
concentrations	O
than	O
healthy	O
controls.	O

The	O
majority	O
of	O
amino	O
acid	O
(alanine,	O
valine,	B
leucine,	B
isoleucine,	B
glutamate,	B
glutamine,	B
aspartate,	B
phenylalanine,	B
tryptophan,	B
tyrosine	B
and	O
gamma-amino	B
butyric	I
acid	I
(GABA,	O
a	O
non-protein	O
amino	B
acid)	O
were	O
present	O
in	O
higher	O
concentrations	O
in	O
the	O
sourdough	O
samples	O
and	O
in	O
some	O
cases	O
also	O
the	O
bread	O
made	O
using	O
this	O
process.	O

Uric	B
acid,	I
another	O
purine	B
metabolite,	O
showed	O
higher	O
levels	O
in	O
CLL	O
and	O
MM,	O
and	O
lower	O
in	O
DLBCL	O
and	O
HL	B
when	O
compared	O
to	O
the	O
controls.	O

NMDA	O
receptors	O
also	O
require	O
the	O
additional	O
binding	O
of	O
glycine	B
or	O
serine	B
as	O
a	O
co-agonist	O
for	O
functional	O
opening	O
of	O
the	O
ion	O
channel.	O

A	O
volume	O
of	O
334	O
μL	O
of	O
chloroform	B
was	O
added	O
and	O
the	O
mixture	O
was	O
vortexed	O
for	O
1	O
min	O
and	O
centrifuged	O
for	O
10	O
min	O
at	O
15,000	O
rpm	O
and	O
4	O
°C.	O

The	O
effect	O
of	O
carnosine	B
on	O
human	O
plasma	O
lipidome	O
has	O
thus	O
far	O
not	O
been	O
investigated.	O

During	O
nutritional	O
stress,	O
Pro	O
is	O
easily	O
released	O
by	O
extracellular	O
matrix	O
degradation,	O
and	O
this	O
degradation	O
can	O
result	O
in	O
adenosine	B
triphosphate	I
(ATP)	O
production.	O

All	O
SP	B
measurements	O
were	O
performed	O
on	O
baseline	O
plasma	O
samples.	O

As	O
an	O
example,	O
buckets	O
2.6	O
and	O
2.72,	O
which	O
represent	O
citrate,	B
are	O
found	O
in	O
high	O
concentration	O
in	O
urines	O
of	O
aAIP	O
individuals	O
compared	O
with	O
a	O
far	O
lower	O
concentration	O
in	O
urines	O
of	O
individuals	O
with	O
s/fPCT	O
(and	O
without	O
overlap).	O

The	O
silver	B
ion	I
is	O
a	O
soft	O
Lewis	O
acid,	O
and	O
carbon–carbon	O
double	O
bonds	O
in	O
unsaturated	O
compounds	O
are	O
soft	O
Lewis	O
bases	O
and	O
serve	O
as	O
likely	O
sites	O
for	O
π	O
complex	O
formation	O
which	O
is	O
charged	O
complex.	O

All	O
analyses	O
were	O
performed	O
on	O
a	O
Waters	O
(Milford,	O
MA,	O
USA)	O
Quattro	O
Micro	O
triple	O
quadrupole	O
mass	O
spectrometer	O
by	O
using	O
electrospray	O
ionization	O
(ESI)	O
in	O
positive	O
ion	O
(PI)	O
and	O
negative	O
ion	O
(NI)	O
mode,	O
with	O
an	O
ESI-MS	O
capillary	O
voltage	O
of	O
3.0	O
kV,	B
an	O
extractor	O
cone	O
voltage	O
of	O
2	O
V,	O
and	O
a	O
detector	O
voltage	O
of	O
650	O
V.	O
Desolvation	O
and	O
cone	O
gas	O
flow	O
were	O
maintained	O
at	O
400	O
and	O
60	O
l	O
h_−1	O
,	O
respectively.	O

Associations	O
with	O
inflammatory	O
markers	O
were	O
more	O
reliably	O
driven	O
by	O
higher	O
MVPA	O
than	O
lower	O
sedentary	O
time	O
duration.	B

In	O
the	O
first	O
study	O
(Study	O
1),	O
eight	O
healthy	O
males	O
and	O
females	O
aged	O
40–65	O
years	O
were	O
randomly	O
selected	O
for	O
this	O
study	O
from	O
the	O
subjects	O
receiving	O
either	O
15	O
µg	O
of	O
vitamin	B
D3	I
or	O
placebo	O
in	O
a	O
capsule	O
form	O
for	O
4	O
weeks,	O
as	O
described	O
elsewhere.	O

The	O
studies	O
about	O
human	O
hepatocellular	O
carcinoma	O
also	O
showed	O
uric	B
acid	I
was	O
elevated	O
in	O
urine	O
sample	O
of	O
patients	O
but	O
not	O
obvious	O
variation	O
in	O
serum	O
sample.	O

Dialister	O
was	O
also	O
found	O
to	O
be	O
significantly	O
associated	O
with	O
formylmethionyl-leucyl-phenylalanine	B
methyl	I
ester	I
(p	O
-value	O
<	O
0.01).	O

Pittsburgh,	O
Pennsylvania,	O
and	O
Corpus	O
Christi,	O
Texas	O
(non-Hispanic	O
participants)	O
showed	O
the	O
highest	O
prevalence	O
of	O
analgesic	O
use,	O
with	O
acetaminophen	B
and/or	O
ibuprofen	B
metabolites	O
being	O
detected	O
in	O
more	O
than	O
20%	O
of	O
the	O
first	O
and	O
second	O
urine	O
collections.	O

Since	O
cysteine	B
is	O
also	O
a	O
required	O
component	O
of	O
assembly	O
proteins	O
that	O
form	O
ISCs,	O
reduced	O
cysteine	B
levels	O
can	O
further	O
compound	O
ISC	O
damage	O
as	O
glutathione	B
is	O
required	O
for	O
maturation	O
of	O
cytosolic	O
ISC	O
proteins	O
thus	O
creating	O
a	O
continuously	O
detrimental	O
cycle	O
of	O
ISC/amino	O
acid/glutathione	O
damage	O
and	O
reduction.	O

These	O
metabolites,	O
annotated	O
by	O
the	O
Kyoto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes	O
(KEGG)	O
database,	O
represent	O
key	O
metabolic	O
pathways	O
involving	O
branched	O
chain	O
amino	O
acid	O
metabolism,	O
glycine	B
derivation,	O
tryptophan	B
metabolism,	O
phenylalanine	B
metabolism,	O
lysine	B
metabolism,	O
histidine	B
metabolism,	O
citrate	B
cycle	O
and	O
steroid	O
hormone	O
biosynthesis.	O

This	O
study	O
is	O
the	O
first	O
report	O
of	O
the	O
abundance	O
of	O
Adrenochrome-o-quinone	B
and	O
NNK	O
by-product	O
3SP	O
in	O
urogenital	O
schistosomiasis.	O

(LCAT),	O
increased	O
expression	O
of	O
lysophosphatidylcholine	B
acyltransferase	O
1–4	O
(LPCAT1–4)	O
or	O
increased	O
expression	O
of	O
autotaxin	B
(ATX).	O

The	O
reactions	O
were	O
stopped	O
after	O
30	O
min	O
by	O
addition	O
and	O
extraction	O
with	O
1	O
ml	O
of	O
chloroform.	B

These	O
effects	O
could	O
be	O
contributing	O
factors	O
in	O
modulating	O
cholesterol	B
homeostasis,	O
and	O
as	O
such,	O
may	O
be	O
part	O
of	O
the	O
explanation	O
of	O
the	O
elevation	O
of	O
LDL	B
cholesterol	I
by	O
a	O
TFA-rich	O
diet	O
which	O
was	O
demonstrated	O
by	O
NMR.	O

The	O
concentration	O
of	O
free	O
choline	B
is	O
typically	O
an	O
order	O
of	O
magnitude	O
smaller	O
than	O
the	O
other	O
two	O
species,	O
although	O
significantly	O
enhanced	O
in	O
case	O
of	O
tumors	O
[,	O
].	O

Associations	O
between	O
baseline	O
metabolic	O
alterations	O
and	O
longitudinal	O
changes	O
in	O
glucose	B
control	O
were	O
tested	O
in	O
16	O
subjects	O
after	O
a	O
mean	O
follow-up	O
of	O
2.3	O
years.	O

To	O
determine	O
the	O
influence	O
of	O
these	O
covariates	O
on	O
the	O
relationship	O
between	O
SPs	O
and	O
BMI,	O
we	O
performed	O
a	O
multivariate	O
analysis	O
correcting	O
for	O
age,	O
sex,	O
LDL,	O
HDL,	O
and	O
triglycerides	B
(	O
and	O
).	O

A	O
positive	O
test	O
for	O
aggregation,	O
indicating	O
incomplete	O
inhibition	O
of	O
COX-1,	O
was	O
defined	O
as	O
a	O
>10%	O
increase	O
in	O
light	O
transmission	O
in	O
response	O
to	O
≥1	O
mmol/L	O
arachidonic	B
acid.	I

On	O
the	O
other	O
hand,	O
serum	O
after	O
protein	O
precipitation	O
using	O
methanol	B
provided	O
the	O
most	O
optimal	O
NMR	O
spectra	O
in	O
terms	O
of	O
both	O
the	O
number	O
of	O
metabolites	O
detected	O
as	O
well	O
as	O
their	O
peak	O
intensities.	O

Two	O
secondary	O
bile	O
acid	O
metabolites	O
(7-ketodeoxycholate	O
and	O
deoxycholate)	B
showed	O
higher	O
expression	O
in	O
adjacent	O
mucosa	O
compared	O
with	O
CRC	O
and	O
were	O
detectable	O
across	O
sample	O
matrices	O
(Additional	O
file	O
1:	O
Table	O
S1).	O

Two	O
possible	O
structures	O
for	O
the	O
metformin–methylglyoxal	B
reaction	O
product.	O

According	O
to	O
KEGG	O
analysis,	O
these	O
marker	O
metabolites	O
were	O
primarily	O
related	O
to	O
fat	O
metabolism,	O
intestinal	O
microbial	O
metabolism,	O
glucose	B
metabolism	O
and	O
choline	B
metabolism	O
pathways,	O
and	O
they	O
were	O
also	O
probably	O
associated	O
with	O
immune	O
regulation.	O

Dipeptides	O
leucyl-phenylalanine	B
and	O
glycyl-phenylalanine	B
are	O
up-regulated	O
in	O
AD	O
patients	O
compared	O
with	O
DOCK8-deficient	O
(E,	O
F,	O
respectively).	O

AUC	O
values	O
of	O
C18:2	B
CE	O
and	O
SM	O
22:0	O
for	O
SqCC	O
prediction	O
in	O
the	O
training	O
and	O
validation	O
cohorts.	O

In	O
the	O
present	O
study,	O
the	O
median	O
sarcosine	B
and	O
kynurenic	B
acid	I
values	O
were	O
found	O
to	O
be	O
lower	O
in	O
PCa	O
patients	O
than	O
in	O
participants	O
without	O
malignancy,	O
in	O
accordance	O
to	O
previously	O
published	O
results	O
[,].	O

We	O
also	O
observed	O
an	O
increase	O
in	O
creatine	B
and	O
a	O
decrease	O
in	O
creatinine	B
in	O
the	O
urine	O
from	O
MS	O
patients.	O

Since	O
these	O
fractions	O
were	O
more	O
polar	O
than	O
both	O
the	O
identified	O
4-phenyl-trans	B
-crotonate	I
metabolite	O
and	O
the	O
parent	O
SPB	O
drug,	O
they	O
eluted	O
earlier	O
than	O
these	O
compounds	O
and	O
it	O
was	O
only	O
necessary	O
to	O
record	O
data	O
for	O
20	O
min.	O

In	O
the	O
validation	O
phase,	O
levels	O
of	O
xanthine	B
and	O
hypoxanthine	B
in	O
CRC	O
and	O
PLP	O
were	O
lower	O
than	O
controls,	O
while	O
D-mannose	B
of	O
CRC	O
and	O
PLP	O
groups	O
displayed	O
higher	O
levels	O
than	O
controls	O
(P	O
<0.01),	O
consistent	O
with	O
discovery	O
set.	O

Thus,	O
equimolar	O
amounts	O
of	O
d_6	B
-dimethylsulfide	I
(324 μL,	O
purity	O
99%,	O
isotopic	O
purity	O
99	O
atom	O
D	O
%,	O
Sigma-Aldrich,	O
Vienna,	O
Austria)	O
and	O
iodomethane	B
(250 μL,	O
purity	O
99.5%,	O
Sigma-Aldrich,	O
Vienna,	O
Austria)	O
were	O
combined	O
in	O
a	O
capped	O
10 ml	O
glass	O
test	O
tube;	O
the	O
mixture	O
was	O
left	O
overnight	O
at	O
room	O
temperature	O
whereupon	O
it	O
yielded	O
a	O
white	O
precipitate	O
of	O
d_6	B
-trimethylsulfonium	I
iodide.	I

Moreover,	O
it	O
is	O
well	O
described,	O
how	O
before	O
entering	O
the	O
urea	B
cycle,	O
glycine	B
can	O
be	O
conjugated	O
with	O
benzoic	B
acid	I
to	O
form	O
hippurate,	B
and	O
be	O
subsequently	O
excreted	O
in	O
urine.	O

Successive	O
analyses	O
identified	O
distinct	O
disturbances	O
to	O
fecal	O
metabolites	O
of	O
CRC	O
patients	O
at	O
various	O
stages,	O
compared	O
with	O
those	O
in	O
cancer	O
free	O
controls,	O
including	O
reduced	O
levels	O
of	O
acetate,	B
butyrate,	B
propionate,	B
glucose,	B
glutamine,	B
and	O
elevated	O
quantities	O
of	O
succinate,	B
proline,	B
alanine,	B
dimethylglycine,	B
valine,	B
glutamate,	B
leucine,	B
isoleucine	B
and	O
lactate.	B

Lung	O
cancer,	O
Lung	O
inflammation,	O
_1	O
H-NMR,	O
Metabolic	O
phenotype,	O
Glutamate,	B
ROC	O

Heptane	B
was	O
purchased	O
from	O
Fisher	O
Scientific	O
(Loughborough,	O
UK).	O

The	O
samples	O
from	O
fermentations	O
were	O
centrifuged	O
(5	O
min;	O
15,000	O
rpm/min),	O
and	O
400	O
μL	O
of	O
supernatant	O
was	O
diluted	O
with	O
2	O
mL	O
of	O
ultra-pure	O
water	O
(Milipore,	O
Bedford,	O
MA,	O
United	O
States	O
of	O
America);	O
20	O
μL	O
of	O
[_13	O
C_6	O
]	O
trans	O
-resveratrol	O
solution	O
in	O
methanol	B
(2	O
μg/mL)	O
was	O
added	O
as	O
an	O
internal	O
standard.	O

The	O
data	O
dependent	O
collision-induced	O
dissociation	O
spectrum	O
of	O
the	O
ion	O
of	O
m/z	O
329.1	O
has	O
shown	O
the	O
most	O
abundant	O
peak	O
with	O
m/z	O
153,	O
corresponding	O
to	O
the	O
deprotonated	O
protocatechuic	B
acid	I
via	O
the	O
labile	O
cleavage	O
of	O
glycosidic	B
bond,	O
along	O
with	O
two	O
minor	O
peaks	O
with	O
m/z	O
175.0	O
and	O
113.2.	O

Furthermore,	O
in	O
vitro	O
studies	O
of	O
human	O
platelets	O
demonstrate	O
reductions	O
in	O
TxA_2	O
production	O
in	O
the	O
presence	O
of	O
omega-3	B
fatty	O
acids.	O

For	O
the	O
data	O
presented	O
here	O
an	O
optimized	O
bin	O
size	O
of	O
0.01 ppm	O
was	O
applied	O
and	O
bins	O
were	O
generated	O
in	O
the	O
regions	O
from	O
9.5	O
to	O
6.5 ppm	O
and	O
from	O
4.5	O
to	O
0.5 ppm,	O
respectively,	O
to	O
exclude	O
the	O
water	O
artifact	O
and	O
the	O
broad	O
urea	B
signal,	O
leaving	O
701	O
bins	O
for	O
further	O
analysis.	O

Next,	O
we	O
examined	O
the	O
suitability	O
of	O
lactate	B
as	O
an	O
element	O
of	O
our	O
model.	O

	O
10-(N	B
-Acetylcysteinyl)-9-hydroxy-9,10-dihydrophenanthrene	I
(Phe-9-hydroxy-10-NAC)	I
was	O
prepared	O
as	O
described	O
previously.	O

Metabolic	O
pathways	O
including	O
arginine	B
and	O
proline	B
metabolism,	O
pyruvate	B
metabolism,	O
aminoacyl-tRNA	B
biosynthesis,	O
and	O
D-glutamine	B
and	O
D-glutamate	B
metabolism	O
were	O
statistically	O
related	O
(impact	O
>	O
0.1,	O
FDR	O
p	O
-value	O
<	O
0.05).	O

Participants	O
with	O
baseline	O
HbA1c	O
>	O
5.05%	O
had	O
21-fold	O
(95%	O
CI:	O
19.84,	O
21.41)	O
higher	O
blood	O
erythritol	B
compared	O
with	O
participants	O
with	O
lower	O
HbA1c	O
(P	O
<	O
0.001,	O
FDR	O
=	O
0.00016).	O

Negative	O
control	O
incubations	O
were	O
run	O
in	O
parallel	O
that	O
included	O
exclusion	O
of	O
anastrozole,	B
a	O
NADPH-generating	O
system	O
or	O
microsomes	O
(bovine	O
serum	O
albumin	O
was	O
used	O
instead)	O
from	O
the	O
incubation	O
mixture.	O

Urinaly	O
oxylipin	B
levels	O
were	O
compared	O
between	O
the	O
young	O
and	O
elderly	O
subjects	O
of	O
both	O
sex.	O

However,	O
a	O
small	O
proportion	O
of	O
the	O
drug	O
is	O
bioactivated	O
by	O
P450s	O
to	O
produce	O
the	O
highly	O
reactive	O
N	B
-acetyl-p	I
-benzoquinoneimine	I
(NAPQI)	O
intermediate,	O
which	O
is	O
detoxicated	O
by	O
conjugation	O
with	O
glutathione.	B

A	O
gradient	O
elution	O
was	O
used	O
using	O
mobile	O
phase	O
A:	O
0.1%	O
aqueous	O
formic	B
acid	I
and	O
mobile	O
phase	O
B:	O
methanol.	B

All	O
subjects	O
underwent	O
an	O
oral	O
glucose	B
tolerance	O
test	O
(OGTT)	O
by	O
ingesting	O
a	O
75-g	O
glucose	B
solution	O
after	O
a	O
12-hour	O
overnight	O
fast.	O

Glycine	B
has	O
been	O
detected	O
by	O
MRS	O
at	O
higher	O
concentrations	O
in	O
high	O
grade	O
gliomas	O
and	O
therefore	O
been	O
suggested	O
as	O
a	O
possible	O
diagnostic	O
marker.	O

The	O
extraction	O
of	O
FA	B
methyl	I
esters	I
was	O
performed	O
using	O
hexane,	B
and	O
they	O
were	O
transferred	O
to	O
GC	O
injection	O
vials	O
with	O
a	O
crimp	O
cap.	O

The	O
multivariate	O
analysis	O
performed	O
on	O
serum	O
metabolic	O
profiles	O
also	O
showed	O
and	O
allowed	O
to	O
quantify	O
significant	O
differences	O
in	O
the	O
levels	O
of	O
isoleucine,	B
lysine,	B
tyrosine,	B
and	O
valine	B
in	O
T2DM-C	O
with	O
respect	O
to	O
CG	O
patients	O
and	O
between	O
the	O
two	O
diabetic	O
groups.	O

Approximately	O
7-10%	O
of	O
the	O
effect	O
of	O
overweight,	O
12-15%	O
of	O
the	O
effect	O
of	O
obesity,	O
and	O
19-20%	O
of	O
the	O
effect	O
of	O
a	O
5	O
kg/m_2	O
BMI	O
increase	O
on	O
ER+	O
breast	O
cancer	O
risk	O
was	O
mediated	O
through	O
unconjugated	O
estradiol.	B

A	O
cluster	O
of	O
purine	B
degradation	O
products	O
(i.e.,	O
purine-Ms:	B
allantoin,	B
xanthosine,	B
inosine,	B
xanthine,	B
uric	O
acid)	O
was	O
also	O
closely	O
related	O
to	O
RV-PV	O
dysfunction.	O

A	O
subsequent	O
generalized	O
linear	O
mixed	O
model	O
analysis	O
showed	O
linear	O
correlations	O
between	O
baseline	O
urinary	O
glycine	B
and	O
N-phenylacetylglycine	B
(PAG)	O
and	O
changes	O
in	O
the	O
GSH:GSSG	O
ratio	O
(p	O
=	O
0.008	O
and	O
0.004)	O
as	O
well	O
as	O
between	O
baseline	O
urinary	O
adenine	B
and	O
changes	O
in	O
MDA	O
(p	O
=	O
0.018).	O

N-methyl-α-aminobutyric	B
acid	I
was	O
detected	O
only	O
in	O
the	O
lyophilized	O
samples	O
(F).	O

On	O
the	O
other	O
hand,	O
myo-inositol	B
treatment	O
ameliorated	O
the	O
decreased	O
expression	O
of	O
synaptopodin	O
and	O
ZO-1	O
(see	O
Supplementary	O
Fig.	O

This	O
product	O
ion	O
at	O
m/z	O
153	O
is	O
observed	O
in	O
the	O
CID	O
of	O
the	O
[M−H]_−	O
of	O
all	O
phospholipids	B
at	O
high	O
collision	O
energy	O
(~50	O
V),	O
however	O
the	O
current	O
analyses	O
were	O
performed	O
at	O
a	O
collision	O
energy	O
of	O
35	O
V	O
and	O
this	O
product	O
ion	O
was	O
only	O
observed	O
in	O
the	O
PA	O
and	O
PS	O
standards.	O

Increased	O
metabolites	O
included	O
arginine,	B
creatine	B
and	O
unknown	O
compounds	O
at	O
m/z	O
of	O
357	O
and	O
312	O
while	O
decreased	O
metabolites	O
included	O
creatinine,	B
androgen	O
derivatives	O
and	O
other	O
unknown	O
yet	O
to	O
be	O
identified	O
compounds.	O

(CLM-2264-0),	O
_13	O
C_6	B
-isoleucine	I

An	O
in	O
vitro	O
study	O
carried	O
out	O
on	O
cancer	O
cells	O
by	O
metabolite	O
profiling	O
indicates	O
key	O
role	O
of	O
glycine	B
in	O
cancer	O
cell	O
proliferation.	O

A	O
(25 mM	O
uridine-5′-diphospho-glucoronic	B
acid	I
(UGDPA)),	O
and	O
UGT	O
mixture	O
solution	O
B	O
(250 mM	O
Tris-HCl,	O
40 mM	O
MgCl_2	O
,	O
and	O
0.125 mg/mL	O
alamethicin,	B
pH 7.5)	O
were	O
purchased	O
from	O
BD	O
Bioscience	O
(Stockholm,	O
Sweden).	O

Mannitol,	B
maltose,	B
threonic	O
acid-1,4-lactone	O
and	O
alanine	B
were	O
all	O
higher	O
in	O
relative	O
concentration	O
in	O
grade	O
III	O
oligodendrogliomas,	O
while	O
lysine	B
and	O
1-monohexadecanoylglycerol	B
were	O
found	O
in	O
lower	O
relative	O
concentrations	O
in	O
grade	O
III	O
as	O
compared	O
to	O
grade	O
II	O
oligodendrogliomas.	O

While	O
several	O
bile	O
acids	O
such	O
as	O
lithicolic	O
acid	O
and	O
deoxycholic	B
acid	I
have	O
been	O
associated	O
with	O
tumorigenesis,	O
UDCA	O
has	O
shown	O
chemopreventive	O
effects	O
in	O
preclinical	O
and	O
animal	O
models	O
of	O
CRC	O
.	O

The	O
resulting	O
sample	O
was	O
dried	O
and	O
dissolved	O
in	O
200	O
µL	O
methanol,	B
resulting	O
in	O
a	O
neutral	O
lipid	O
fraction.	O

RV	B
HU+NAFLD	O
HU+NAFLD	O
H	O

Data	O
were	O
collected	O
every	O
20 s,	O
and	O
acquired	O
volume	O
of	O
oxygen	O
(V	O
O_2	O
)	O
and	O
carbon	B
dioxide	I
(V	O
CO_2	O
)	O
were	O
converted	O
to	O
REE	O
(kcal/24 h)	O
using	O
the	O
equation	O
of	O
Weir	O
(3.940 × V	O
O_2	O
 + 1.106 × V	O
CO_2	O
)	O

The	O
assay	O
limit	O
of	O
detection	O
(LOD)	O
providing	O
estrogen	B
signal-to-noise	O
ratio	O
greater	O
than	O
3-to-1	O
was	O
100	O
fg/mL	O
(approximately	O
0.33–0.37	O
pmol/L).	O

In	O
our	O
current	O
study,	O
possibly	O
due	O
to	O
the	O
larger	O
sample	O
size	O
facilitating	O
resolution	O
of	O
clustered	O
metabolites,	O
this	O
factor	O
was	O
split	O
into	O
three	O
components,	O
each	O
with	O
biological	O
plausibility:	O
factor	O
6	O
(combination	O
of	O
BCAA	O
and	O
aromatic	O
acids,	O
which	O
may	O
be	O
reporting	O
on	O
the	O
pathway	O
of	O
shared	O
transport);	O
factor	O
7	O
(C3	O
and	O
C5	O
acylcarnitines,	B
which	O
include	O
byproducts	O
of	O
mitochondrial	O
BCAA	O
catabolism);	O
and	O
factor	O
10	O
(BCAA,	O
and	O
glutamate/glutamine,	O
the	O
byproduct	O
of	O
the	O
initial	O
step	O
of	O
mitochondrial	O
BCAA	O
metabolism).	O

 	O
together	O
with	O
main	O
PK	O
parameters;	O
the	O
data	O
were	O
obtained	O
analyzing	O
nondigested	O
samples	O
(evaluation	O
of	O
free	O
diosmetin),	O
following	O
glucuronidase	O
digestion	O
(diosmetin	O
glucuronides	O
levels),	O
sulfatase	O
digestion	O
(diosmetin	O
sulfate	I
levels),	O
and	O
combined	O
sulfatase	O
with	O
glucuronidase	O
digestion	O
(total	O
conjugated	O
diosmetin).	O

Our	O
findings	O
showed	O
that	O
50	O
metabolites	O
were	O
significantly	O
altered	O
in	O
PLP	O
and	O
CRC	O
patients	O
in	O
the	O
discovery	O
phase	O
using	O
metabolomic	O
profiling,	O
which	O
were	O
mapped	O
to	O
eight	O
superpathways	O
(nucleotide,	O
carbohydrate,	O
peptide,	O
amino	O
acid,	O
lipid,	O
energy,	O
carnitine	B
metabolism,	O
and	O
xenobiotics)	O
and	O
thirty-one	O
subpathways	O
associated	O
with	O
metabolism.	O

In	O
the	O
urine,	O
clusters	O
related	O
to	O
pentoses,	O
purines,	B
disaccharides,	B
phenylacetates,	B
sugar	O
alcohols,	O
amino	O
acids	O
(cyclic,	O
basic,	O
acidic,	O
sulfur	O
and	O
aromatic),	O
glutarates,	B
hexuronates,	O
malates,	B
hexoses,	O
sugar	O
acids,	O
citrates,	O
indoles,	O
saturated	O
FA,	B
dicarboxylates,	B
purinones	B
were	O
associated	O
with	O
hospitalizations.	O

Samples	O
were	O
reconstituted	O
with	O
acetonitrile/water	O
(20:80),	O
with	O
and	O
without	O
either	O
5	O
%	O
2	O
M	O
H_2	O
SO_4	O
or	O
0.1	O
%	O
formic	B
acid.	I

Each	O
of	O
the	O
rabbits	O
in	O
Groups	O
1	O
through	O
5	O
had	O
50	O
µL	O
of	O
a	O
topical	O
application	O
of	O
the	O
NSAID	O
or	O
saline	B
3	O
times/day	O
for	O
4	O
days.	O

We	O
also	O
acknowledge	O
that,	O
other	O
than	O
arginases	O
and	O
NOS,	O
levels	O
of	O
l-arginine,	B
l-citrulline,	B
and	O
l-ornithine	B
can	O
be	O
altered	O
by	O
the	O
aberrant	O
release/uptake	O
of	O
these	O
molecules	O
in	O
and	O
out	O
of	O
the	O
circulation	O
and	O
dysregulation	O
of	O
enzymes	O
that	O
participate	O
in	O
their	O
biosynthesis.	O

Pathway	O
analysis	O
using	O
discriminating	O
features	O
revealed	O
alterations	O
in	O
multiple	O
pathways,	O
including	O
the	O
metabolism	O
of	O
multiple	O
amino	O
acids,	O
leukotrienes,	O
niacin,	B
pyrimidine,	B
and	O
purine.	B

GP-tagged	O
7α-hydroxy-26-norcholest-4-ene-3,x	B
-dione	I
appears	O
in	O
chromatograms	O
(a	O
and	O
b	O
)	O
as	O
syn	O
and	O
anti	O
conformers	O
(peaks	O
1	O
and	O
2	O
).	O

Pipecolic	B
acid	I
(piperidine-2-carboxylic	O
acid),	O
the	O
carboxylic	B
acid	I
of	O
piperidine,	B
is	O
a	O
small	O
organic	O
molecule	O
which	O
accumulates	O
in	O
pipecolic	B
acidemia.	O

As	O
such	O
sugars	O
are	O
not	O
carcinogenic,	O
however,	O
among	O
eight	O
different	O
sugars,	O
sorbose	B
showed	O
mild	O
sarcomas	O
in	O
rats.	O

prediction,	O
fasting	O
glucose,	B
type	O
2	O
diabetes,	O
metabolomics,	O
plasma,	O
random	O
forest,	O
metabolite,	O
regression,	O
biomarker	O

This	O
study	O
tends	O
to	O
confirm	O
that	O
CQ,	O
replaced	O
by	O
SP	B
as	O
first-line	O
treatment	O
in	O
2001,	O
has	O
been	O
effectively	O
withdrawn.	O

Groups	O
are	O
defined	O
by	O
median-cut	O
off	O
of	O
normalized	O
abundances	O
(vs	O
L-carnitine)	B
of	O
high	O
acetylcarnitine	B
(C2	O
High,	O
blue	O
solid	O
line)	O
vs	O
low	O
acetylcarnitne	B
(C2	O
Low,	O
red	O
dotted	O
line).	O

There	O
are	O
data	O
in	O
the	O
literature	O
supporting	O
a	O
link	O
between	O
some	O
indole	B
derivatives	O
and	O
atherosclerosis.	O

However,	O
to	O
date,	O
the	O
sphingolipid	B
profile	O
of	O
diabetic	O
patients	O
with	O
CVD	O
has	O
remained	O
to	O
be	O
investigated.	O

Sarcosine	B
is	O
a	O
naturally	O
occurring	O
derivative	O
of	O
glycine,	B
formed	O
by	O
the	O
enzymes	O
glycine	O
N	O
-methyl	O
transferase	O
(GNMT)	O
or	O
dimethylglycine	O
dehydrogenase	O
(DMGDH),	O
and	O
converted	O
back	O
into	O
glycine	B
via	O
sarcosine	O
dehydrogenase	O
(SARDH).	O

Moreover,	O
with	O
the	O
exception	O
of	O
tryptophan,	B
which	O
is	O
a	O
major	O
constituent	O
of	O
serum	O
and	O
therefore	O
yielded	O
major	O
differences	O
in	O
analyte	O
signal,	O
the	O
MS	O
response	O
for	O
all	O
analytes	O
at	O
a	O
given	O
concentration	O
showed	O
much	O
less	O
variability	O
between	O
the	O
neat	O
solutions	O
and	O
the	O
serum	O
samples.	O

We	O
found	O
that	O
glucuronic	B
acid	I
levels	O
were	O
significantly	O
reduced	O
in	O
patients	O
with	O
cirrhosis,	O
which	O
directly	O
affected	O
the	O
metabolism	O
of	O
bilirubin.	B

Cis-11-eicosenoic	B
acid	I
(C20:1n9)	O
originates	O
from	O
oleic	B
acid	I
(C18:1n9cis)	O
and	O
can	O
be	O
elongated	O
to	O
produce	O
erucic	B
acid	I
(C22:1n9)	O
(	O

Trimethylsilylation	O
was	O
subsequently	O
performed	O
by	O
adding	O
50	O
μL	O
of	O
N-methyl-N-trimethylsilyl-trifluoroacetamide	B
(MSTFA+1%	O
TMCS,	O
Sigma-Aldrich),	O
incubating	O
for	O
1	O
h	O
at	O
65°C	O
and	O
centrifuged	O
at	O
13000	O
rpm	O
X	O
10	O
min	O
at	O
RT.	O

Exclusion	O
criteria	O
included	O
scan-detectable	O
bone	O
metastases,	O
Karnofsky	O
performance	O
status	O
less	O
than	O
90,	O
history	O
of	O
diabetes	O
or	O
glucose	B
intolerance,	O
treatment	O
with	O
medications	O
known	O
to	O
alter	O
glucose	B
or	O
insulin	O
levels,	O
and	O
history	O
of	O
prior	O
hormonal	O
therapy	O
for	O
prostate	O
cancer	O
within	O
the	O
past	O
year.	O

The	O
six-metabolite	O
combination	O
identified	O
was	O
alanine,	B
histidine,	B
leucine,	B
pyruvate,	B
tyrosine,	B
and	O
valine.	B

Sarcosine,	B
an	O
N-methyl	O
derivative	O
of	O
the	O
amino	O
acid	O
glycine,	O
was	O
significantly	O
up-regulated	O
in	O
stage	O
IV.	O

These	O
findings	O
identify	O
this	O
novel	O
metabolic	O
association	O
and	O
further	O
support	O
the	O
role	O
of	O
the	O
KP	B
in	O
regulating	O
mucosal	O
inflammation	O
in	O
UC.	O

Only	O
trace	O
amounts	O
of	O
Cer(18:0/24:1),	B
cholesterol,	B
and	O
TG(17:2/17:2/18:0)	B
were	O
found	O
in	O
methanol-ethanol	B
samples	O
and	O
these	O
compounds	O
were	O
not	O
detected	O
when	O
only	O
methanol	B
was	O
used.	O

Frozen	O
tumor	O
samples	O
were	O
powdered	O
in	O
a	O
mortar	O
under	O
liquid	O
nitrogen	O
with	O
4%	O
perchloric	B
acid	I
(1:4	O
w/v),	O
thawed,	O
and	O
centrifuged	O
at	O
47,800	O
g	O
for	O
15	O
min.	O

For	O
biotinylation,	O
20-fold	O
molar	O
ratio	O
of	O
the	O
ChromaLink	O
biotin	B
to	O
antibody	O
was	O
incubated	O
for	O
90	O
min	O
at	O
room	O
temperature.	O

In	O
the	O
absence	O
of	O
convincing	O
evidence	O
for	O
significant	O
levels	O
of	O
detoxification	O
of	O
either	O
the	O
simple	O
Phe-epoxides	B
2	O
and	O
12	O
or	O
the	O
diol	B
epoxides	I
4	O
and	O
20	O
by	O
the	O
GST	O
pathway,	O
how	O
can	O
we	O
account	O
for	O
the	O
effect	O
of	O
GSTM1	O
null	O
status	O
on	O
levels	O
of	O
Phe-tetraols	O
5	O
and	O
21?	O

Results:	O
Our	O
results	O
showed	O
that	O
serum	O
putrescine,	B
directly	O
generated	O
from	O
ornithine	B
by	O
the	O
catalytic	O
action	O
of	O
the	O
biosynthetic	O
enzyme	O
ornithine	O
decarboxylase,	O
was	O
significantly	O
elevated	O
in	O
patients	O
with	O
T2D	O
compared	O
to	O
those	O
without	O
T2D,	O
and	O
that	O
it	O
significantly	O
correlated	O
with	O
the	O
levels	O
of	O
glycosylated	O
hemoglobin	O
(HbA1c).	O

The	O
exclusion	O
criteria	O
were	O
active	O
acute	O
or	O
chronic	O
illness	O
(history/diagnosis	O
or	O
CRP	O
≥10),	O
diabetes	O
(history/diagnosis	O
or	O
fasting	O
glucose	B
≥125	O

These	O
were	O
bilirubin	B
and	O
retinal,	B
which	O
may	O
be	O
the	O
candidate	O
targets	O
of	O
gemcitabine	O
for	O
the	O
prevention	O
of	O
recurrence	O
of	O
urothelial	O
BCa.	O

THCV	O
and	O
its	O
metabolite	O
THCVCOOH	O
also	O
were	O
targeted	O
for	O
distinguishing	O
intake	O
of	O
illicit	O
cannabis	B
and	O
Marinol,	O
synthetic	O
THC	O
indicated	O
for	O
treatment	O
of	O
weight	O
loss	O
and	O
nausea.	O

(D)	O
TMAO	B
levels	O
of	O
the	O
Control,	O
iUC	O
and	O
aUC	O
patients.	O

Serum	O
total	O
25OHD	O
concentration	O
was	O
the	O
only	O
vitamin	B
D	I
parameter	O
found	O
to	O
have	O
no	O
specific	O
correlation	O
with	O
any	O
of	O
the	O
inflammatory	O
markers.	O

A	O
classic	O
example	O
involves	O
fructose-6-phosphate,	B
glucose-6-phosphate,	B
and	O
glucose-1-phosphate,	B
which	O
are	O
all	O
endogenous	O
metabolites	O
of	O
importance	O
in	O
glucose	B
metabolism.	O

(E)	O
(left)	O
Phase	O
contrast	O
images;	O
(right)	O
graph	O
showing	O
fold	O
tumorsphere	O
induction	O
(total	O
area)	O
of	O
UM-SCC-14A	O
cells	O
cultured	O
in	O
the	O
presence	O
or	O
absence	O
of	O
glutamine	B
(30	O
μ	O
g/mL)	O
under	O
suspension	O
conditions	O
in	O
glutamine	B
free	O
media	O
for	O
the	O
indicated	O
time	O
points.	O

Significant	O
features	O
of	O
alpha-PEP	B
after	O
untargeted	O
analysis	O
using	O
a	O
reversed	O
phase	O
(PhenylHexyl)	O
column.	O

Prostate	O
cancer,	O
Abiraterone,	B
LC–MS/MS,	O
Method	O
validation,	O
Metabolites	O

In	O
summary,	O
our	O
findings	O
highlight	O
the	O
potential	O
role	O
of	O
GM3	B
in	O
idiopathic	O
PD.	O

d	O
The	O
low	O
level	O
of	O
alanine	B
and	O
pyroglutamic	B
acid	I
in	O
nIBS	O
indicates	O
a	O
lowered	O
level	O
of	O
bacterial	O
protease	O
and	O
peptide	O
catabolism,	O
whereas	O
Lactobacillus	B
activity	O
is	O
increased	O
in	O
IBS,	O
indicated	O
by	O
the	O
elevated	O
levels	O
of	O
faecal	O
alanine	B
released	O
by	O
protein	O
catabolism.	O

High	O
concentrations	O
of	O
arginine	B
and	O
glutamate	B
may	O
lead	O
to	O
stronger	O
neuroexcitotoxicity	O
through	O
synergistic	O
action	O
(,	O
).	O

(Cx:y),	O
hydroxylacylcarnitines(C(OH)x:y)	O
and	O
dicarboxylacylcarnitines	B
(Cx:y-DC);	O
40	O
amino	O
acids	O
and	O
biogenic	O
amines;	O
one	O
sugar;	O
10	O
sphingomyelins	B
(SMx:y)	O
and	O
sphingomyelin-derivatives	O
(SM(OH)x:y);	O
and	O
90	O
glycerophospholipids	B
(PC).	O

OPLS-DA	O
score	O
plots	O
based	O
on	O
the	O
data	O
from	O
(A	O
)	O
RRLC-(+)ESI-MS	B
and	O
(B	O
)	O
RRLC-(-)ESI-MS	B
of	O
the	O
ESCC	O
patients	O
and	O
controls	O
(ESCC	O
and	O
NC).	O

a Primary	O
BJ	O
cells,	O
HUH7	O
and	O
c CAKI2	O
cancer	O
cells	O
were	O
treated	O
with	O
PPARα	O
agonist	O
or	O
DMSO	B
as	O
a	O
control.	O

The	O
heatmap	O
displays	O
data	O
related	O
to	O
amino	O
acids	O
(AAs),	O
free	O
carnitine	B
(C0),	O
acylcarnitines	B
(ACCs),	O
succinyl	B
acetone	I
(SA),	O
nucleosides,	O
and	O
lysophospholipids	B
(LPCs)	O
in	O
the	O
form	O
of	O
colored	O
cells.	O

Additionally,	O
a	O
comparison	O
of	O
CP	O
and	O
PC	O
diagnostic	O
groups	O
yielded	O
3-hydroxybutyrate,	B
lactate,	B
valine,	B
tyrosine,	B
phenylalanine,	B
lysine,	B
isoleucine,	B
histidine,	B
glutamine,	B
glutamate,	B
and	O
alanine	B
as	O
being	O
up-regulated	O
in	O
chronic	O
pancreatitis.	O

The	O
following	O
metabolites	O
are	O
identified:	O
1,	O
Unk_1;	B
2,	I
3-Hydroxyisobutyrate;	I
3,	B
3-Methyl-2-oxovalerate;	I
4,	O
Isopropanol;	B
5,	B
3-Hydroxybutyrate;	I
6,	O
Methylmalonate;	B
7,	O
Fucose;	B
8,	B
3-Hydroxyisovalerate;	I
9,	O
Lactate;	B

Two	O
of	O
the	O
bacterial	O
genera	O
overrepresented	O
in	O
CRC,	O
Phascolarctobacterium	O
and	O
Acidiminobacter	O
showed	O
a	O
strong	O
positive	O
association	O
with	O
the	O
amino	O
acids	O
phenylalanine	O
and	O
glutamate,	B
and	O
were	O
moderately	O
correlated	O
with	O
increased	O
serine	B
and	O
threonine.	B

CNI	O
values	O
were	O
generated	O
from	O
a	O
linear	O
regression–based	O
algorithm	O
and	O
represent	O
the	O
changes	O
in	O
choline	B
and	O
NAA	O
levels	O
relative	O
to	O
normal	O
voxels.	O

Samples	O
analyzed	O
via	O
the	O
LC-MS/MS	O
method	O
were	O
injected	O
at	O
a	O
flow	O
rate	O
of	O
0.8	O
ml/min	O
to	O
a	O
4.6	O
×	O
250	O
mm,	O
5	O
µm	O
Luna	O
silica	B
column	O
interfaced	O
with	O
an	O
AB	O
SCIEX	O
5000	O
triple	O
quadrupole	O
mass	O
spectrometer	O
using	O
d9-(trimethyl)-labeled	O
internal	O
standards.	O

Our	O
results	O
for	O
estriol	B
are	O
very	O
close	O
to	O
the	O
immunoassay	O
All	O
Method	O
Mean	O
and	O
the	O
correlation	O
coefficient	O
was	O
r	O
=0.992.	O

At	O
24	O
hours	O
after	O
DOX	O
injection,	O
the	O
F2-isoprostanes	B
returned	O
to	O
their	O
baseline	O
levels,	O
whereas	O
the	O
levels	O
of	O
allantoin	B
continued	O
increasing,	O
although	O
the	O
difference	O
between	O
allantoin	B
levels	O
at	O
T24	O
vs.	O
T0	O
was	O
not	O
statistically	O
significant.	O

shows	O
the	O
distributions	O
for	O
measured	O
urinary	O
cotinine,	B
arsenic,	O
and	O
phthalates	O
levels	O
on	O
a	O
creatinine	B
basis.	O

GDCA,	O
GCA,	O
3	O
sulfo-GCDCA,	B
TCA	O
and	O
TCDCA	O
are	O
conjugated	O
bile	O
acids	O
that	O
enable	O
absorption	O
of	O
lipids,	O
cholesterol,	B
and	O
fat-soluble	O
vitamin.	O

In	O
contrast	O
to	O
the	O
low	O
vs	O
high	O
UCEIS	O
model,	O
neither	O
isoleucine,	B
valine	B
nor	O
glucose	B
were	O
selected	O
as	O
discriminatory	O
variables	O
for	O
the	O
disease	O
outcome	O
model	O
above,	O
confirming	O
that	O
the	O
metabolite	O
profile	O
which	O
distinguishes	O
low	O
from	O
high	O
UCEIS	O
is	O
distinct	O
from	O
the	O
metabolite	O
profile	O
which	O
predicts	O
improved/worsened	O
disease.	O

Kynurenine	B
stimulated	O
mTOR	O
activity	O
in	O
healthy	O
control	O
PBL	O
in	O
vitro.	O

A	O
similar	O
analysis	O
with	O
LASSO	O
was	O
carried	O
out	O
for	O
compounds	O
in	O
the	O
baseline	O
CSF	O
profiles,	O
which	O
identified	O
2	O
biochemicals,	O
benzoate	B
and	O
N-6-trimethyllysine,	B
that	O
best	O
predicted	O
ΔUPDRS2	O
+	O
3.	O

Significant	O
differences	O
by	O
disease	O
group	O
were	O
found	O
in	O
the	O
CSF	O
concentrations	O
of	O
several	O
metabolites	O
known	O
to	O
be	O
involved	O
in	O
the	O
synthesis	O
of	O
the	O
antioxidant	O
glutathione	B
(GSH)	O
and	O
related	O
pathways,	O
including	O
glycine,	B
formate,	B
pyroglutamate,	B
and	O
2-hydroxybutyrate.	B

Based	O
on	O
the	O
definition	O
of	O
the	O
WHO	O
concerning	O
the	O
120	O
min	O
blood	O
glucose	B
concentration	O
during	O
an	O
oGTT	O
four	O
subjects	O
were	O
diagnosed	O
to	O
have	O
type	O
2	O
diabetes	O
and	O
were	O
excluded	O
from	O
the	O
study.	O

The	O
two	O
dhSMs	O
positively	O
associated	O
with	O
obesity	O
–	O
SM	O
36:0	O
and	O
SM	B
(d18:0/24:0)	I
–	O
were	O
also	O
positively	O
associated	O
with	O
dysglycemia,	O
along	O
with	O
Cer	B
(d18:0/24:0).	I

Glutamate	B
metabolism	O
has	O
been	O
linked	O
to	O
immunomodulation	O
with	O
its	O
prominent	O
role	O
as	O
glutamate	B
receptors	O
in	O
mediating	O
T-cell	O
mediated	O
immunity.	O

The	O
derivative	O
of	O
vanillic	B
acid,	I
vanillic	B
acid	I
[-CO],	O
was	O
also	O
a	O
unique	O
metabolite	O
in	O
the	O
PD	O
group.	O

Therefore,	O
additional	O
studies	O
are	O
required	O
to	O
further	O
clarify	O
the	O
significance	O
of	O
the	O
decreased	O
serum	O
enterolactone	B
levels	O
in	O
colon	O
cancer	O
patients.	O

This	O
assumption	O
is	O
further	O
supported	O
by	O
high	O
partial	O
correlation	O
between	O
X-10510	O
and	O
other	O
Metabolon	O
sphingolipid	B
molecules	O
and	O
genetic	O
associations	O
to	O
a	O
second	O
sphingolipid	B
related	O
gene	O
in	O
Shin	O
et	O
al	O
..	O

D	O
(diol)	O
and	O
F	O
(amide)	O
are	O
“neutral”	O
HILIC	O
methods.	O

When	O
the	O
severe	O
group	O
only	O
was	O
considered,	O
two	O
lipid	O
metabolites	O
(TAG(42:2)	O
and	O
TAG(42:1)),	B
were	O
positively	O
correlated	O
with	O
parasitaemia	O
and	O
16	O
exhibited	O
a	O
negative	O
correlation.	O

This	O
finding	O
is	O
reasonable	O
because	O
trigonelline	B
is	O
an	O
alkaloid	O
produced	O
by	O
the	O
metabolism	O
of	O
niacin	B
(vitamin	O
B3),	O
which	O
is	O
excreted	O
in	O
the	O
urine	O
and	O
might	O
protect	O
against	O
renal	O
oxidative	O
stress	O
and	O
apoptotic	O
cell	O
death	O
and	O
slow	O
the	O
progression	O
of	O
diabetic	O
nephropathy.	O

Additionally,	O
all	O
UC	O
patients	O
were	O
treated	O
with	O
5-aminosalicylic	B
acid;	I
hence	O
the	O
resonances	O
from	O
5-aminosalicylic	B
acid	I
and	O
its	O
metabolite,	O
N	B
-acetyl-5-aminosalicylic	I
acid,	I
which	O
include	O
the	O
entire	O
aromatic	O
region	O
and	O
δ	O
2.12–2.26,	O
were	O
removed	O
whenever	O
group	O
comparisons	O
involved	O
UC	O
patients.	O

We	O
observed	O
a	O
positive	O
enrichment	O
of	O
α-linoleic	B
acid	I
and	O
linoleic	B
acid	I
metabolism	O
in	O
both	O
frozen	O
and	O
FFPE	O
tumor	O
tissues	O
(P	O
=	O
0.012	O
and	O
FDR	O
=	O
0.064	O
in	O
frozen	O
tissues	O
and	O
P	O
=	O
0.050	O
and	O
FDR	O
=	O
0.166	O
in	O
FFPE	O
tissues),	O
whereas	O
the	O
protein	O
synthesis	O
pathway	O
was	O
statistically	O
significant	O
only	O
in	O
FFPE	O
samples	O
(P	O
=	O
0.009	O
and	O
FDR	O
=	O
0.048).	O

Similarly,	O
lipid	O
species	O
such	O
as	O
acylcarnitines	B
and	O
lysoglycerophospholipids	B
also	O
distinguish	O
NGT-IS	O
and	O
NGT-IR	O
subjects	O
and	O
NGT-IS	O
from	O
IGT,	O
with	O
high	O
statistical	O
significance.	O

A	O
putatively	O
identified	O
metabolite,	O
20-OH-LTB4,	B
decreased	O
after	O
in-vehicle	O
exposure	O
to	O
particulate	O
metals,	O
suggesting	O
a	O
subclinical	O
immune	O
response.	O

The	O
samples	O
of	O
metabolized	O
stilbenoids	B
were	O
collected	O
at	O
0,	O
2,	O
4,	O
8,	O
24,	O
and	O
48	O
h.	O
Significant	O
differences	O
in	O
the	O
microbial	O
transformation	O
among	O
stilbene	B
derivatives	O
were	O
observed	O
by	O
liquid	O
chromatography	O
mass	O
spectrometry	O
(LC/MS).	O

Only	O
salivary	O
L-Lactic	B
acid	I
levels	O
were	O
higher	O
following	O
infection	O
and	O
remained	O
so	O
on	O
therapy.	O

Moreover,	O
Ishikawa	O
et	O
al.	O
showed	O
a	O
comparable	O
SMs	O
level	O
in	O
young	O
and	O
elderly	O
women	O
(55–64	O
years	O
old),	O
despite	O
a	O
markedly	O
decreased	O
estrogen	B
level	O
in	O
postmenopausal	O
elderly	O
women.	O

Studies	O
on	O
retinol	B
report	O
an	O
inverse	O
association	O
with	O
25(OH)D,	O
suggesting	O
a	O
possible	O
interaction._,	O
A	O
recent	O
nested	O
case–control	O
study	O
supports	O
an	O
interaction,	O
showing	O
that	O
increased	O
25(OH)D	O
is	O
inversely	O
associated	O
with	O
colon	O
cancer	O
risk	O
among	O
those	O
with	O
lower	O
levels	O
of	O
retinol.	B

A	O
hydrophilic	B
head	O
group	O
of	O
lipid	O
is	O
important	O
for	O
selective	O
extraction	O
by	O
various	O
solvents.	O

Rectal,	O
oral	O
and	O
relative	O
rectal/oral	O
bioavailabilities_*	O
(mean,	O
95%	O
CI,	O
and	O
90%CI	O
_#	O
)	O
for	O
methadone	B
after	O
IV	O
(5	O
mg	O
methadone-HCl)	B
and	O
oral	O
and	O
rectal	O
(10	O
mg	O
methadone	B
HCl)	O
in	O
7	O
human	O
subjects	O
The	O
time	O
course	O
(0–96	O
h)	O
of	O
plasma	O
concentrations	O
of	O
methadone	B
(mean	O
(s.d.))	O
in	O
seven	O
healthy	O
subjects	O
after	O
IV-rectal,	O
and	O
oral-rectal	O
administration	O
of	O
methadone-HCl	B
(5	O
mg	O
IV,	O
10	O
mg	O
rectally	O
(deuterated	O
methadone)	B
and	O
orally).	O

Synthesis	O
and	O
platelet	O
aggregation	O
inhibiting	O
activity	O
of	O
prostaglandin	B
D	O
analogues.	O

UV	O
spectra	O
and	O
plot	O
presenting	O
decay	O
of	O
estrone	B
quinone	I
methide	O
(E_1	O
QM)	O
(A)	O
and	O
estradiol	B
quinone	I
methide	O
(E_2	O
QM)	O
(B).	O

Actually,	O
GG	O
properties	O
rely	O
both	O
on	O
their	O
hydrophilic	B
oligosaccharide	I
chain	O
and	O
on	O
their	O
hydrophobic	O
ceramide	O
moiety	O
and	O
their	O
redistribution	O
within	O
the	O
plasma	O
membrane	O
might	O
thus	O
be	O
crucial	O
for	O
signaling	O
events	O
occurring	O
at	O
the	O
cell	O
surface.	O

Each	O
model	O
was	O
run	O
separately	O
for	O
each	O
mercapturic	B
acid	I
(µg/L),	O
which	O
was	O
imputed	O
as	O
dependent	O
variable	O
using	O
the	O
log_10	O
-transformed	O
data.	O

The	O
pooled	O
extracts	O
were	O
dried	O
under	O
nitrogen	B
gas.	I

Cyclic	O
Guanosine	O
monophosphate	O
(cGMP)	O
is	O
a	O
second	O
messenger	O
that	O
mediates	O
incretin	B
effects;	O
potentiates	O
glucose-stimulated	O
insulin	O
secretion;	O
promotes	O
proper	O
beta-cells	O
differentiation,	O
and	O
prevents	O
beta-cells	O
apoptosis,	O
cooperating	O
with	O
biotin.	B

The	O
increase	O
of	O
omega-6	B
fatty	O
acids	O
observed	O
from	O
incident	O
to	O
prevalent	O
type	O
2	O
diabetes	O
could	O
have	O
indicated	O
an	O
important	O
role	O
of	O
omega-6	B
fatty	O
acid–mediated	O
inflammation	O
in	O
the	O
pathogenesis	O
of	O
type	O
2	O
diabetes.	O

The	O
identified	O
biomarker	O
candidates	O
of	O
phosphatidylcholines	B
(PCs)	O
and	O
phosphatidylethanolamines	B
(PEs)	O
were	O
further	O
externally	O
validated	O
in	O
a	O
cohort	O
including	O
30	O
early-stage	O
NSCLC,	O
30	O
LBD,	O
and	O
30	O
HC	O
by	O
a	O
targeted	O
lipidomic	O
analysis.	O

Each	O
15 mg	O
tissue	O
sample	O
was	O
homogenized	O
individually	O
in	O
cold	O
methanol	B
using	O
a	O
TissueLyser	O
(20 Hz,	O
90 s).	O

Replicate	O
injections	O
of	O
urine	O
samples	O
spiked	O
at	O
different	O
concentrations	O
were	O
performed	O
and	O
accuracy	O
ranged	O
for	O
sarcosine	B
from	O
90%	O
to	O
95%,	O
for	O
uracil	B
from	O
89%	O
to	O
96%,	O
and	O
for	O
kynurenic	B
acid	I
from	O
90%	O
to	O
98%	O
while	O
relative	O
standard	O
deviation	O
(RSD,	O
%)	O
was	O
found	O
to	O
range	O
from	O
4.2%	O
to	O
11%	O
for	O
sarcosine,	B
from	O
2.7%	O
to	O
10%	O
for	O
uracil,	B
and	O
from	O
4.2%	O
to	O
10.5%	O
for	O
kynurenic	B
acid.	I

In	O
this	O
study,	O
plasma	O
glucose	B
was	O
decreased,	O
which	O
might	O
be	O
a	O
result	O
of	O
the	O
over-expression	O
of	O
INSR.	O

In	O
recent	O
years	O
it	O
has	O
become	O
widely	O
recognized	O
that	O
many	O
radioimmunoassays	O
for	O
unconjugated	O
estradiol,	B
particularly	O
direct	O
radioimmonassays	O
(-),	O
are	O
not	O
sufficiently	O
specific,	O
especially	O
at	O
the	O
low	O
concentrations	O
characteristic	O
of	O
postmenopausal	O
women.	O

These	O
include	O
isoleucine,	B
leucine,	B
and	O
valine,	B
which	O
can	O
regulate	O
various	O
signaling	O
pathways	O
such	O
as	O
protein	O
synthesis,	O
lipid	O
synthesis,	O
cell	O
growth,	O
and	O
autophagy.	O

The	O
fatty	O
acids,	O
or	O
ethanol	B
(EtOH)	O
vehicle	O
control,	O
were	O
added	O
(10	O
μM	O
final	O
concentration)	O
to	O
fresh	O
RPMI	O
1640	O
supplemented	O
with	O
5%	O
autologous	O
serum,	O
and	O
incubated	O
for	O
30	O
min	O
prior	O
to	O
stimulation	O
of	O
PBMCs.	O

Disruption	O
of	O
this	O
correlation	O
could	O
indicate	O
a	O
possible	O
impairment	O
or	O
re-wiring	O
of	O
mannose	B
metabolism,	O
which	O
has	O
been	O
considered	O
as	O
a	O
potential	O
biomarker	O
for	O
the	O
prediction	O
of	O
CVD.	O

Hippurate.	B

Similar	O
amino-acid	B
(tyrosine,	O
aspartate	B
and	O
asparagine,	B
lysine,	B
glycine,	B
serine,	B
alanine,	B
and	O
threonine)	B
and	O
lipid	O
pathways	O
(glycerophospholipid)	O
were	O
significantly	O
associated	O
with	O
the	O
outcome	O
(NASH)	O
(data	O
not	O
shown).	O

Each	O
sample	O
was	O
investigated	O
for	O
changes	O
in	O
sphingolipids	B
as	O
previously	O
described	O
(–)	O
using	O
a	O
targeted	O
lipidomics	O
approach	O
as	O
previously	O
described	O
(–).	O

Our	O
study	O
suggests	O
that	O
exposure	O
to	O
PCDDs/PCDFs	O
significantly	O
affects	O
estrogen	B
metabolism.	O

We	O
hypothesized	O
that	O
regular	O
cannabis	B
use	O
would	O
be	O
associated	O
with	O
decreased	O
frequencies	O
of	O
inflammatory	O
cells	O
and	O
lowered	O
expression	O
of	O
markers	O
of	O
immune	O
activation	O
and	O
dysfunction.	O

The	O
oleic	O
acid-isoleucine	O
negative	O
correlation	O
(a)	O
is	O
consistent	O
with	O
the	O
observations	O
that	O
plasma	O
oleic	B
acid	I
was	O
greater	O
in	O
HBV	O
than	O
in	O
the	O
controls	O
and	O
that	O
plasma	O
isoleucine	B
was	O
lower	O
in	O
HBV	O
than	O
in	O
the	O
controls.	O

This	O
open‐label,	O
parallel‐group	O
study	O
was	O
performed	O
to	O
compare	O
finger‐stick‐based	O
capillary	O
with	O
corresponding	O
venous	O
plasma	O
concentrations	O
for	O
risperidone,	B
paliperidone,	B
quetiapine,	B
olanzapine,	B
and	O
aripiprazole	B
and	O
their	O
major	O
metabolites	O
after	O
repeated	O
dosing	O
in	O
patients	O
with	O
schizophrenia	O
or	O
related	O
illnesses.	O

Ingested	O
phosphatidylcholine	B
(lecithin),	O
the	O
major	O
dietary	O
source	O
of	O
total	O
choline,	B
is	O
acted	O
on	O
by	O
intestinal	O
lipases	O
to	O
form	O
a	O
variety	O
of	O
metabolic	O
products,	O
including	O
the	O
choline-containing	O
nutrients	O
glycerophosphocholine,	B
phosphocholine,	B
and	O
choline.	B

Tumor	O
lesions	O
are	O
characterized	O
by	O
increases	O
in	O
metabolite	O
intensities	O
of	O
choline	B
and	O
decreases	O
in	O
NAA,	O
while	O
the	O
localized	O
metabolite	O
changes	O
coincide	O
with	O
the	O
lesions	O
reflected	O
by	O
hyperintensities	O
in	O
T_2	O
-weighted	O
MRI.	O

Indeed,	O
our	O
group	O
and	O
others	O
have	O
demonstrated	O
the	O
clinical	O
significance	O
of	O
elevated	O
plasma	O
ADMA	B
levels	O
in	O
cardiovascular	O
risks(,-).	O

4-[bis[2–hydroxy-ethyl]amino]-2-methyl-benzoic	B
acid	I
(BA-(OH)_2	O
)	O
was	O
generated	O
by	O
heating	O
13.2	O

It	O
also	O
included	O
27	O
carbohydrate	O
metabolites	O
representing	O
aminosugar,	B
disaccharides	B
and	O
oligosaccharides,	B
fructose,	B
mannose,	B
and	O
galactose,	B
glycogen,	B
glycolysis,	O
gluconeogenesis,	O
and	O
pyruvate,	B
pentose,	B
and	O
metabolic	O
pathways.	O

Urine	O
measurement	O
is	O
preferred	O
as	O
the	O
F_2	O
-IsoPs	O
are	O
not	O
subject	O
to	O
artifactual	O
generation	O
by	O
autoxidation	O
of	O
arachidonic	B
acid	I
during	O
processing	O
and	O
storage.	O

We	O
identified	O
patients	O
on	O
ASA	O
and/or	O
statin	B
treatment	O
undergoing	O
routine	O
colonoscopy	O
and	O
measured	O
eicosanoid	B
levels	O
in	O
colonic	O
mucosa	O
with	O
targeted	O
metabolomics	O
technology	O
(LC-MS/MS).	O

All	O
are	O
found	O
in	O
conjugated	O
forms,	O
attached	O
to	O
sulfate	B
or	O
glucuronide	B
moieties;	O
five	O
(ie,	O
estrone,	B
estradiol,	B
2-methoxyestrone,	B
2-methoxyestradiol,	B
and	O
estriol)	O
also	O
exist	O
in	O
unconjugated	O
form.	O

As	O
would	O
be	O
anticipated	O
from	O
a	O
pre-surgical	O
carbohydrate	O
feed,	O
glucose	B
levels	O
are	O
higher	O
in	O
all	O
four	O
compartments	O
at	O
baseline	O
in	O
pre-fed	O
animals.	O

The	O
significance	O
of	O
this	O
finding	O
remains	O
obscure,	O
as	O
sulfated	O
steroids	O
as	O
such	O
are	O
proposed	O
to	O
act	O
as	O
a	O
steroid	O
reservoir	O
in	O
blood	O
plasma,	O
with	O
no	O
ability	O
as	O
hydrophilic	B
molecules	O
to	O
penetrate	O
target	O
cell	O
membrane	O
and	O
to	O
interact	O
with	O
steroid	O
receptors	O
[,].	O

_1	O
H	O
NMR	O
([_2	O
H_6	O
]DMSO)	O
showed	O
absence	O
of	O
methylene	B
protons,	O
isotopic	O
purity	O
>99%).	O

Fiszmann	O
in	O
a	O
recent	O
study	O
found	O
a	O
glutamate	B
concentration	O
around	O
0.6–0.9	O
µM	O
in	O
control	O
CSF	O
and	O
2.6–6.1	O
µM	O
in	O
ALS	O
CSF.	O

HPLC	O
grade	O
acetonitrile	B
was	O
purchased	O
from	O
BDH	O
chemicals	O
(purity > 99.9%,	O
HiPerSolv	O
CHROMANORM_®	O
,	O
BDH	O
chemicals,	O
Poole,	O
UK).	O

For	O
TG	B
concentrations	O
within	O
lipoprotein	O
subclasses,	O
there	O
were	O
strong	O
positive	O
associations	O
with	O
risk	O
of	O
MI	O
for	O
TG	B
in	O
all	O
apolipoprotein	O
B–containing	O
(VLDL,	O
IDL,	O
and	O
LDL)	O
lipoprotein	O
particles.	O

CE	B
(18:0)	I
is	O
a	O
cholesterol	B
fatty	O
acid	O
ester	O
and	O
can	O
be	O
hydrolyzed	O
by	O
cholesterol	B
esterase	O
to	O
produce	O
cholesterol	B
and	O
free	O
fatty	O
acids.	O

Threonine	B
was	O
positively	O
linked	O
(blue	O
edges)	O
with	O
Escherichia	O
fergusonii	O
(Otu4)	O
and	O
Enterobacter	O
cloacae	O
(Otu13)	O
but	O
negatively	O
related	O
(red	O
edges)	O
to	O
Bacteroides	O
vulgatus	O
(Otu1)	O
and	O
Bacteroides	O
uniformis	O
(Otu8).	O

MS/MS	O
analysis	O
on	O
features	O
810.597	O
at	O
RT	O
25.11	O
(peak	O
#3)	O
and	O
RT	O
25.58	O
(peak	O
#4)	O
identified	O
two	O
PC(18:0_20:4)	B
with	O
a	O
similar	O
MS/MS	O
signal	O
intensity	O
pattern	O
for	O
the	O
two	O
fragments	O
corresponding	O
to	O
their	O
fatty	O
acyl	O
side	O
chain:	O
higher	O
at	O
m/z	O
303.23	O
for	O
C20:4,	B
most	O
likely	O
on	O
sn-2	O
position,	O
and	O
lower	O
at	O
m/z	O
283.26	O
for	O
C18:0.	B

In	O
summary,	O
out	O
of	O
22	O
ER(+)	B
patients,	O
one	O
false	O
positive	O
(92.9%	O
specificity)	O
and	O
no	O
false	O
negative	O
(100%	O
sensitivity	O
)	O
were	O
obtained,	O
with	O
an	O
accuracy	O
of	O
95.5%.	O

This	O
is	O
intriguing	O
as	O
animal	O
experiments	O
in	O
global	O
DDAH2-knockout	O
mice	O
have	O
shown	O
unchanged	O
systemic	O
ADMA	B
and	O
NO	O
concentrations	O
compared	O
to	O
wild-type	O
mice.	O

The	O
repeatability	O
and	O
reproducibility	O
were	O
below	O
20%	O
for	O
most	O
of	O
the	O
compounds,	O
except	O
for	O
1,3-DAP	B
reproducibility,	O
which	O
was	O
21.2%.	O

Other	O
urinary	O
phthalate	B
metabolite	O
and	O
isoprostane	B
concentrations	O
were	O
not	O
associated	O
with	O
sperm	O
mtDNAcn	O
or	O
mtDNAdel.	O

Healthy	O
controls	O
(Group	O
III)	O
were	O
characterized	O
by	O
low	O
(less	O
than	O
2	O
µM)	O
levels	O
of	O
all	O
PhCAs:	O
benzoic	B
acid	I
(BA),	O
phenylpropionic	B
acid	I
(PhPA),	O
PhLA,	O
p	O
-HPhLA	O
which	O
were	O
described	O
in	O
our	O
previous	O
paper.	O

Identities	O
of	O
the	O
majority	O
of	O
the	O
metabolites	O
selected	O
by	O
LASSO	O
were	O
confirmed	O
by	O
analysis	O
of	O
authentic	O
compounds	O
purchased	O
from	O
Sigma	O
Aldrich:	O
L-valine	B
(PHR1172),	O
glycine	B
(G7403),	O
DL-isoleucine	B
(298689),	O
creatinine	B
(C4255),	O
L-pyroglutamic	B
acid	I
(83160)	O
/	O

Response_matrix-freespike	O
is	O
the	O
mean	O
peak	O
area	O
count	O
for	O
the	O
same	O
concentration	O
of	O
D-mannose	B
in	O
water.	O

Acrolein,	B
a	O
highly	O
reactive	O
α	O
,β	O
-unsaturated	O
aldehyde,	O
is	O
an	O
ubiquitous	O
environmental	O
contaminant	O
and	O
lipid	O
peroxidation	O
product	O
produced	O
endogenously.	O

Tyrosine	B
is	O
also	O
reported	O
to	O
likely	O
be	O
useful	O
for	O
the	O
diagnosis	O
of	O
pancreatic	O
cancer._31	O
Catecholamines,	B
which	O
are	O
metabolically	O
produced	O
from	O
tyrosine,	B
increased	O
proliferation	O
of	O
pancreatic	O
cancer	O
cells._35	O

Methionine	B
sulfoxide	I
(MetSO)	O
increased	O
as	O
methionine	B
(Met)	O
decreased,	O
and	O
aspartate	B
(Asp)	O
increased	O
as	O
asparagine	B
(Asn)	O
decreased	O
(Fig.	O

Indeed,	O
AC	O
concentrations	O
are	O
higher	O
in	O
the	O
fasting	O
state	O
in	O
insulin	O
resistant	O
populations	O
and	O
decrease	O
less	O
during	O
glucose	B
challenge	O
tests	O
[,	O
].	O

The	O
scores	O
plot	O
(A)	O
and	O
the	O
loadings	O
plot	O
(B)	O
indicate	O
the	O
key	O
resonances	O
contributing	O
to	O
the	O
separation:	O
lactate,	B
glucose,	B
glutamine,	B
and	O
citrate.	B

After	O
a	O
12-hour	O
fasting	O
period,	O
avoid	O
12-hours	O
of	O
intake	O
meal	O
including	O
alcohol	O
and	O
caffeine	B
consumption,	O
venous	O
blood	O
specimens	O
were	O
collected	O
in	O
EDTA-treated	O
and	O
plain	O
tubes	O
and	O
centrifuged	O
to	O
yield	O
plasma	O
or	O
serum,	O
which	O
were	O
stored	O
at	O
-70°C	O
until	O
analysis.	O

Low	O
myoinositol	B
levels	O
have	O
been	O
observed	O
in	O
AQP4-Ab	O
NMOSD	O
compared	O
with	O
MS	O
after	O
transverse	O
myelitis	O
using	O
_1	O
H	O
magnetic	O
resonance	O
spectroscopy	O
(MRS)	O
of	O
the	O
spinal	O
cord,	O
reflecting	O
astrocytic	O
necrosis.	O

Samples	O
were	O
analyzed	O
for	O
peripheral	O
blood	O
mononuclear	O
cell	O
(PBMC)	O
count,	O
total	O
serum	O
protein,	O
serum	O
albumin,	O
serum	O
globulin,	O
and	O
liver	O
function	O
(total	O
bilirubin,	B
glutamic	O
oxaloacetic	O
transaminase	O
(GOT),	O
guanosine	O
triphosphatase	O
(GPT),	O
gamma	O
glutamyl-transpeptidase	O
(γGTP),	O
alkaline	O
phosphatase	O
(ALP),	O
cholinesterase,	O
leucine	O
aminopeptidase	O
(LAP),	O
and	O
lactic	O
acid	O
dehydrogenase	O
(LDH)).	O

Training	O
increased	O
docosahexaenoic	B
acid	I
and	O
citrate	B
concentration	O
(Figure A).	O

Methoxyestrogens	B
are	O
considered	O
as	O
potential	O
therapeutic	O
agents	O
due	O
to	O
their	O
antitumor	O
activity	O
via	O
induction	O
of	O
apoptosis	O
and	O
inhibition	O
of	O
angiogenesis	O
[–].	O

When	O
chemically	O
synthetized	O
by	O
the	O
reduction	O
of	O
PBTZ169	O
with	O
NaBH_4	O
,	O
a	O
mixture	O
of	O
two	O
position	O
o	O
-	O
and	O
p	B
-	I
isomers	I
of	O
H_2	O
-PBTZ169	O
is	O
formed,	O
yet	O
only	O
the	O
p	O
-isomer	O
is	O
found	O
in	O
vivo	O
.	O

Although	O
we	O
could	O
not	O
confirm	O
renal	O
abnormalities	O
as	O
a	O
diagnosis	O
for	O
the	O
subjects	O
that	O
are	O
in	O
the	O
biopsy	O
control	O
group,	O
our	O
observations	O
prompted	O
us	O
to	O
investigate	O
abnormal	O
protein-to-creatinine	O
ratio	O
in	O
relation	O
to	O
estrogen	B
concentrations.	O

Overall,	O
it	O
seems	O
reasonable	O
to	O
conjecture	O
that	O
suppressed	O
immune	O
responses	O
and	O
increased	O
atherosclerosis	O
risk	O
in	O
uremic	O
patients	O
may	O
be	O
partially	O
caused	O
by	O
increased	O
activity	O
of	O
AHR	O
and	O
accumulated	O
kynurenine.	B

The	O
majority	O
of	O
metabolites	O
were	O
small	O
(64	O
%	O
had	O
10	O
carbons	O
or	O
less),	O
but	O
we	O
also	O
detected	O
larger	O
species	O
of	O
up	O
to	O
64	O
carbons,	O
most	O
of	O
which	O
were	O
likely	O
phospholipids.	B

Fasting	O
insulin	O
(pmol/L),	O
homeostatic	O
model	O
assessment	O
insulin	O
resistance	O
(HOMA-IR),	O
2-hour	O
glucose	B
(mmol/L)	O
and	O
insulin	O
area	O
under	O
the	O
curve	O
(AUC)	O
were	O
derived	O
from	O
a	O
2-hour,	O
75-g	O
oral	O
glucose	B
tolerance	O
test	O
(OGTT)	O
at	O
baseline,	O
16	O
and	O
24	O
weeks.	O

The	O
standard	O
mixtures	O
used	O
for	O
the	O
external	O
calibration	O
of	O
the	O
MS	O
instrument	O
(Calmix-positive,	O
for	O
the	O
positive-ionization	O
mode,	O
consisting	O
of	O
caffeine,	B
L-methionyl-arginyl-phenylalanyl-alanine	B
acetate,	I
and	O
Ultramark	O
1621;	O
Calmix-negative,	O
for	O
the	O
negative-ionization	O
mode,	O
consisting	O
of	O
same	O
mixture	O
plus	O
sodium	B
dodecyl	I
sulfate	I
and	O
sodium	O
taurocholate)	O
were	O
from	O
Thermo	O
Fisher	O
Scientific	O
(Les	O
Ulis,	O
France).	O

The	O
effect	O
of	O
the	O
TCEP	O
and	O
BQB	O
contents	O
on	O
reduction	O
efficiencies	O
of	O
disulfide	B
bonds	O
and	O
chemical	O
labeling	O
were	O
investigated.	O

Levels	O
of	O
25OHD	O
and	O
vitamin	O
D-binding	O
protein	O
(VDBP)	O
were	O
determined	O
by	O
ELISA,	O
and	O
1,25-dihydroxyvitamin	B
D	I
(1,25OHD)	I
and	O
dihydroxycholecalciferol	B
(24,25OHD)	I
by	O
LC-MS/MS.	O

There	O
was	O
no	O
evidence	O
of	O
carryover	O
for	O
synthetic	O
cannabinoids.	B

Spiked	O
spectra	O
were	O
acquired	O
on	O
the	O
400	O
MHz	O
and	O
900	O
MHz	O
spectrometers	O
for	O
37	O
metabolites:	O
alanine,	B
arginine,	B
asparagine,	B
aspartate,	B
cysteine,	B
glutamine,	B
glutamate,	B
glycine,	B
histidine,	B
isoleucine,	B
leucine,	B
lysine,	B
methionine,	B
phenylalanine,	B
proline,	B
serine,	B
threonine,	B
tryptophan,	B
tyrosine,	B
valine,	B
glucose,	B
myo-inositol,	B
acetate,	B
acetoacetate,	B
α	B
-ketoglutarate,	I
β	B
-hydroxybutyrate,	I
citrate,	B
lactate,	B
pyruvate,	B
succinate,	B
creatine,	B
creatinine,	B
acetone,	B
betaine,	B
choline,	B
glycerol,	B
and	O
methanol.	B

Of	O
note,	O
omega-3	B
fatty	O
acid	O
supplements,	O
due	O
to	O
their	O
anti-inflammatory	O
action,	O
have	O
been	O
investigated	O
in	O
migraine	O
attack	O
prevention.	O

This	O
was	O
an	O
expected	O
result,	O
due	O
to	O
the	O
presence	O
of	O
three	O
glycine	B
residues	O
located	O
in	O
the	O
C-terminal	O
portion	O
of	O
each	O
peptide.	O

Uric	B
acid	I
(Panel	O
A)	O
is	O
upregulated	O
in	O
pneumonia	O
plasma	O
levels,	O
although	O
not	O
statistically	O
significant	O
(p = 0.119).	O

e.g.	O
7-	B
oxocholesterol	I
(7-oxocholest-5-en-3β-ol,	I
C_5	I
-3β-ol-7-one).	I

No	O
subject	O
was	O
taking	O
a	O
melatonin	B
supplement.	O

Cysteinyl	O
adducts	O
of	O
Alb	O
with	O
NPO	O
and	O
1,2-	B
and	O
1,4-NPQ	B
were	O
produced	O
in	O
a	O
dose-dependent	O
manner.	O

However,	O
besides	O
the	O
monitored	O
similarities	O
between	O
both	O
model	O
systems,	O
differing	O
absolute	O
amounts	O
of	O
intracellular	O
metabolites	O
were	O
observed	O
in	O
particular	O
for	O
myo-inositol	B
(25.85	O
nmol/10_6	O
S9	O
cells	O
and	O
4.79	O
nmol/10_6	O
16HBE14o_−	O
cells),	O
but	O
also	O
for	O
lactate	B
(4.16	O
and	O
12.67	O
nmol/10_6	O
cells),	O
glutamate	B
(25.33	O
and	O
34.14	O
nmol/10_6	O
cells),	O
glutamine	B
(10.23	O
and	O
18.54	O
nmol/10_6	O
cells)	O
and	O
glucose	B
(15.23	O
and	O
11.15	O
nmol/10_6	O
cells)	O
one	O
hour	O
after	O
fresh	O
medium	O
was	O
supplied.	O

However,	O
the	O
similarity	O
in	O
fragmentation	O
pattern,	O
particularly	O
in	O
the	O
relative	O
abundances	O
of	O
daughter	O
ions	O
resulting	O
from	O
losses	O
of	O
CO_2	O
and	O
H_2	O
O,	O
and	O
chain	O
cut	O
ions	O
from	O
the	O
hPULCFAs	O
to	O
known	O
hydroxy	B
fatty	O
acid	O
standards	O
as	O
well	O
as	O
other	O
fatty	O
acids	O
reported	O
in	O
the	O
literature	O
such	O
as	O
the	O
resolvins	O
and	O
protectins	O
(discussed	O
below),	O
allowed	O
for	O
the	O
identification	O
of	O
the	O
metabolites	O
as	O
hydroxylated	O
polyunsaturated	O
ultra	O
long-chain	O
fatty	O
acids.	O

Previous	O
studies	O
have	O
found	O
varying	O
amounts	O
of	O
hemoglobin	O
even	O
in	O
normal	O
serum	O
and	O
the	O
hemoglobin	O
correlated	O
positively	O
with	O
many	O
metabolites	O
including	O
ATP,	B
which	O
is	O
a	O
product	O
of	O
hemolysis;_,	O
these	O
results	O
indicate	O
the	O
deleterious	O
confounding	O
effects	O
of	O
hemolysis	O
on	O
serum/plasma	O
metabolite	O
profiling.	O

Myo	O
-inositol	O
ranked	O
first	O
among	O
lipid	O
metabolites	O
associated	O
with	O
retinol,	B
which	O
along	O
with	O
its	O
phosphorylated	O
derivatives	O
including	O
inositol	B
1-phosphate	I
(I1P),	O
may	O
be	O
related	O
to	O
mediation	O
of	O
retinoic	B
acid	I
signaling	O
and	O
cellular	O
functions	O
including	O
adhesion,	O
growth,	O
vesicular	O
trafficking,	O
and	O
cell	O
survival,	O
and	O
is	O
involved	O
in	O
regulation	O
of	O
enzyme	O
activity	O
and	O
hormone	O
secretion.	O

Individuals	O
with	O
any	O
allergies	O
other	O
than	O
possible	O
aspartame	B
sensitivity	O
were	O
excluded,	O
as	O
was	O
those	O
taking	O
any	O
over-the-counter	O
or	O
prescription	O
medications	O
during	O
the	O
previous	O
3	O
months.	O

DHT	O
is	O
an	O
intermediate	O
decomposition	O
product	O
of	O
thymine.	B

Using	O
reserpine	B
as	O
an	O
example,	O
10	O
μL	O
of	O
sample	O
mixture	O
were	O
delivered	O
from	O
the	O
well	O
on	O
the	O
plate	O
to	O
the	O
back	O
plane	O
of	O
the	O
nano-ESI	O
chip	O
with	O
the	O
optimized	O
positive	O
ionization	O
conditions	O
of	O
1.65	O
kV	B
in	O
positive	O
mode	O
and	O
0.5	O
psi	O
nitrogen	O
head	O
pressure,	O
so	O
that	O
the	O
solution	O
in	O
the	O
pipette	O
tip	O
had	O
a	O
constant	O
flow	O
to	O
the	O
chip	O
at	O
a	O
rate	O
of	O
200	O
nL/min.	O

However,	O
it	O
is	O
also	O
worth	O
noting	O
that	O
a	O
decrease	O
in	O
plasma	O
glucose	B
may	O
result	O
from	O
increased	O
insulin	O
secretion,	O
which	O
has	O
been	O
shown	O
previously	O
to	O
occur	O
upon	O
altitude	O
exposure.	O

(B)	O
Levels	O
of	O
glutamate	B
in	O
UM-SCC-14A	O
cells	O
cultured	O
in	O
the	O
presence	O
or	O
absence	O
of	O
the	O
glutaminase	O
inhibitor	O
(DON)	O
under	O
adherent	O
or	O
suspension	O
conditions	O
for	O
3	O
days,	O
based	O
on	O
isotope	O
dilution	O
GC-MS.	O

In	O
summary,	O
this	O
pilot	O
study	O
provides	O
preliminary	O
evidence	O
that	O
reductions	O
in	O
early	O
nighttime	O
melatonin	B
levels	O
may	O
be	O
important	O
in	O
the	O
pathophysiology	O
of	O
sleep	O
disturbances	O
in	O
individuals	O
with	O
IBS-D.	O
A	O
next	O
step	O
is	O
to	O
further	O
describe	O
the	O
pattern	O
of	O
metabolites	O
across	O
the	O
night	O
in	O
sync	O
with	O
cortisol	B
and	O
sleep	O
indices.	O

As	O
the	O
direct	O
method	O
provides	O
analysis	O
of	O
regioisomers	O
of	O
conjugates,	O
we	O
were	O
able	O
to	O
show	O
that	O
DA-3-O-S	B
predominates	O
over	O
DA-4-O-S	B
in	O
the	O
human	O
brain.	O

Given	O
the	O
inhibitory	O
effect	O
of	O
insulin	O
on	O
glycogen	B
breakdown,	O
the	O
higher	O
insulin	O
levels	O
observed	O
in	O
the	O
T1D	O
group	O
could	O
explain	O
in	O
part	O
the	O
attenuated	O
glycogenolytic	B
response.	O

Go	O
to:	O
To	O
characterize	O
daily	O
variation	O
of	O
amino	O
acids	O
(AAs)	O
and	O
acylcarnitines	B
(ACs)	O
in	O
response	O
to	O
feeding	O
and	O
activity,	O
we	O
measured	O
serum	O
metabolites	O
at	O
various	O
times	O
and	O
after	O
various	O
activities	O
during	O
the	O
day.	O

Thirdly,	O
we	O
do	O
not	O
believe	O
that	O
model	O
estimates	O
were	O
heavily	O
influenced	O
by	O
exposure	O
misclassification	O
given	O
that	O
our	O
analyses	O
relied	O
on	O
measured	O
paracetamol	B
in	O
urine,	O
rather	O
than	O
the	O
low	O
prevalence	O
of	O
the	O
self-reported	O
paracetamol	B
use	O
(2.6	O
and	O
1.2%	O
for	O
females	O
and	O
males	O
in	O
LIFE,	O
respectively).	O

The	O
notable	O
exception	O
is	O
that	O
AP	B
patients	O
had	O
more	O
instances	O
of	O
multiple	O
diagnoses	O
than	O
non-AP	O
patients.	O

DMSO	B
or	O
20	O
µM	O
Kyn	O
was	O
added	O
30	O
min	O
prior	O
to	O
harvesting	O
and	O
fractionation.	O

In	O
turn,	O
no	O
correlation	O
with	O
NOS2	O
,	O
ARG2	O
,	O
or	O
ODC1	O
,	O
controlling	O
alternative	O
routes	O
of	O
citrulline	B
synthesis,	O
could	O
be	O
found.	O

Acetylation	O
(10 min	O
at	O
40°C)	O
was	O
performed	O
after	O
adding	O
200 μ	O
L	O
of	O
1	O
methylimidazole	B
and	O
1 mL	O
of	O
acetic	B
anhydride.	I

While	O
the	O
primary	O
endpoint	O
of	O
the	O
completed	O
clinical	O
trial	O
was	O
disposition	O
of	O
limonene	B
to	O
the	O
breast	O
tissue	O
and	O
plasma,	O
here	O
we	O
used	O
metabolomic	O
profiling	O
to	O
generate	O
hypotheses	O
about	O
limonene’s	O
systemic	O
anti-cancer	O
effects.	O

Anastrozole	B
is	O
primarily	O
cleared	O
by	O
hepatic	O
metabolism	O
via	O
oxidative	O
and	O
conjugating	O
enzymes.	O

Formation	O
of	O
hydroxyanastrozole	B
from	O
anastrozole	B
was	O
markedly	O
inhibited	O
by	O
CYP3A	O
selective	O
chemical	O
inhibitors	O
(by	O
>90%)	O
and	O
significantly	O
correlated	O
with	O
CYP3A	O
activity	O
in	O
a	O
panel	O
of	O
HLMs	O
(r	O
=	O
0.96,	O
P	O
=	O
0.0005)	O
and	O
mainly	O
catalyzed	O
by	O
expressed	O
CYP3A4	O
and	O
CYP3A5.	O

We	O
firstly	O
reported	O
that	O
Fumaric	B
acid,	I
identified	O
from	O
metabolomic	O
profiling,	O
was	O
associated	O
with	O
PDR	O
and	O
it	O
might	O
be	O
a	O
new	O
biomarker	O
and	O
potential	O
therapeutic	O
target	O
for	O
DR.	O

Both	O
TMA	O
and	O
TMAO	B
are	O
found	O
to	O
be	O
directly	O
linked	O
to	O
the	O
composition	O
of	O
the	O
intestinal	O
microbiota	O
and	O
are	O
considered	O
biomarkers	O
for	O
inflammation	O
and	O
atherosclerosis	O
(,	O
).	O

N1,N12-diacetylspermine	B
is	O
an	O
acetylated	O
product	O
of	O
spermidine	B
and	O
spermine	B
controlled	O
by	O
spermidine-spermineN1-acetyltransferase	O
(SSAT)	O
using	O
acetyl-CoA	B
as	O
substrate.	O

Glucose	B
plasma	O
concentration	O
was	O
positively	O
correlated	O
with	O
propionylcarnitine	B
(r	O
=	O
0.48)	O
and	O
with	O
the	O
ratio	O
of	O
BCAA-derived	O
acylcarnitines	B
(r	O
=	O
0.51),	O
but	O
negatively	O
correlated	O
to	O
SM	O
C18:0	B
and	O
SM	B
C18:1	I
(r	O
=	O
−0.42	O
and	O
−0.46,	O
respectively).	O

Electron	O
ionization	O
mass	O
spectrometer;	O
EN:	O
Enniatin;	B
ERK:	O

p(x,y;Θ)	B
p(x,y;Θ)	I
p(x,y;Θ)	I
p(x,y;Θ)	I

These	O
results	O
show	O
therefore	O
that	O
urinary	O
3-HPMA,	O
formed	O
from	O
the	O
toxic	O
cigarette	O
smoke	O
constituent	O
acrolein,	B
is	O
a	O
smoking-related	O
biomarker.	O

Ahr,	O
activated	B
by	O
a	O
wide	O
variety	O
of	O
hydrophobic	O
ligands,	O
could	O
indirectly	O
regulate	O
the	O
ER	O
signaling.	O

This	O
mitochondrial	O
dysfunction	O
was	O
accompanied	O
by	O
altered	O
expression	O
of	O
19	O
mitochondrial-associated	O
genes	O
and	O
significantly	O
reduced	O
intracellular	O
ATP	B
levels.	O

Similarly,	O
knock-down	O
of	O
the	O
TMPRSS2-ERG	O
gene	O
fusion	O
in	O
VCaP	O
cells	O
resulted	O
in	O
>	O
3-fold	O
decrease	O
in	O
sarcosine	B
with	O
a	O
similar	O
decrease	O
in	O
the	O
invasive	O
phenotype.	O

Tissue	O
targets	O
were	O
defined	O
as	O
5-mm-diameter	B
spheres	O
on	O
surgical	O
navigation	O
software.	O

(,	O
)	O
Clusters	O
1	O
and	O
2	O
comprised	O
uremic	O
solutes	O
and	O
C-glycosyltryptophan.	B

Glycine	B
is	O
generated	O
from	O
the	O
glycolytic	B
intermediate	O
3-phosphoglycerate,	B
which	O
supplies	O
carbon	O
both	O
to	O
serine	B
and	O
glycine.	B

In	O
addition,	O
the	O
mothers'	O
nocturnal	O
urinary	O
levels	O
of	O
8-oxodG,	B
as	O
a	O
function	O
of	O
aMT6s/Cr,	O
clearly	O
appear	O
to	O
have	O
a	O
linear	O
component	O
with	O
a	O
negative	O
slope	O
(Figure	O
).	O

A	O
typical	O
_1	O
H	O
NMR	O
spectrum	O
of	O
human	O
serum	O
is	O
characterized	O
by	O
broad	O
resonances	O
from	O
the	O
lipid	O
molecules	O
of	O
lipoprotein	O
particles,	O
such	O
as	O
the	O
−CH_3	O
group	O
of	O
triglycerides,	B
cholesterol	B
compounds	O
and	O
phospholipids.	B

MS-MS	O
was	O
performed	O
in	O
the	O
MRM	O
mode	O
(see	O
above),	O
and	O
resulting	O
data	O
were	O
processed	O
by	O
using	O
QuanLynx	O
software	O
(Waters)	O
to	O
quantify	O
the	O
estrogen	B
metabolites.	O

Next,	O
NGA	O
and	O
GA	O
were	O
separated	O
on	O
boronate	B
affinity	O
column.	O

Associations	O
of	O
circulating	O
vitamin	B
D	I
metabolites	O
measured	O
at	O
the	O
end	O
of	O
the	O
DCCT	O
with	O
the	O
mean	O
eGFR	O
and	O
change	O
in	O
eGFR	O
over	O
time	O
during	O
the	O
EDIC	O
study	O
All	O
models	O
are	O
adjusted	O
for	O
age,	O
duration	B
of	O
diabetes,	O
season,	O
body	O
mass	O
index,	O
and	O
AER	O
at	O
the	O
time	O
of	O
biomarker	O
measurement	O
as	O
well	O
as	O
sex,	O
race,	O
DCCT	O
treatment	O
assignment,	O
and	O
solar	O
irradiation	O
of	O
DCCT	O
clinic	O
site.	O

Meanwhile,	O
aMCI	O
patients	O
had	O
significant	O
reduced	O
urinary	O
global	O
arginine	B
bioavailability	O
ratio	O
(GABR),	O
and	O
GABR	O
in	O
urine	O
displayed	O
a	O
positive	O
correlation	O
with	O
the	O
score	O
of	O
CMMSE.	O

This	O
process	O
involves	O
the	O
anaerobic	O
fermentation	O
of	O
glucose	B
and	O
butanediol	B
is	O
one	O
of	O
the	O
end	O
products.	O

However,	O
at	O
18	O
months	O
post-eradication,	O
the	O
bile	O
acids	O
in	O
plasma	O
were	O
down-regulated	O
instead,	O
and	O
strange	O
enough,	O
majority	O
of	O
the	O
plasma	O
TG	B
were	O
still	O
down-regulated	O
as	O
compared	O
to	O
Baseline.	O

Bradykinin	B
metabolites,	O
biliverdin,	B
gamma-glutamylmethionine,	B
the	O
sphingomyelin	B
C24:1,	I
the	O
amino	O
acids	O
glutamine,	O
glycine	B
and	O
serine,	B
and	O
some	O
compounds	O
with	O
unknown	O
chemical	O
identity	O
were	O
shared	O
by	O
at	O
least	O
two	O
of	O
the	O
assessed	O
traits.	O

(d_5	O
-LXA_4	O
)	O
and	O
d_4	B
-prostaglandin	I
E_2	O
(d_4	O
-PGE_2	O
)	O
to	O
facilitate	O
quantification	O
of	O
mediator	O
recovery.	O

Sphingolipids,	B
key	O
components	O
of	O
biologic	O
membranes,	O
are	O
involved	O
in	O
numerous	O
processes	O
related	O
to	O
tumor	O
progression	O
and	O
have	O
been	O
found	O
to	O
inhibit	O
the	O
growth	O
of	O
cancer	O
cells	O
and	O
induce	O
their	O
apoptosis.	O

Kynurenic	B
acid	I
is	O
a	O
NMDA	O
(N-Methyl-D-aspartate)	O
receptor	O
antagonist	O
[,	O
,	O
],	O
unlike	O
quinolinic	B
acid,	I
a	O
NMDA	O
receptor	O
agonist	O
which	O
causes	O
excitotoxic	O
neurodegenerative	O
changes	O
[,	O
].	O

The	O
limits	O
of	O
detection	O
(LOD)	O
were	O
IL-1β	B
(0.36 pg/mL),	I
IL-2	O
(0.35 pg/mL),	O
IL-6	O
(0.27 pg/mL),	O
IL-8	O
(0.09 pg/mL),	O
IL-10	O
(0.21 pg/mL),	O
IL-12p70	O
(1.4 pg/mL),	O
TNF-α,	O
(0.5 pg/mL),	O
IFN-γ	O
(0.74 pg/mL),	O
and	O
GM-CSF	O
(0.20 pg/mL).	O

This	O
study	O
demonstrates	O
that	O
intake	O
of	O
TFA	O
affects	O
phospholipid	B
metabolism.	O

Moreover,	O
in	O
our	O
study	O
we	O
observed	O
that	O
eight	O
lysophosphatidylcholines	B
(LysoPCs)	O
were	O
significantly	O
lower	O
in	O
NDMM	O
patients.	O

To	O
determine	O
the	O
effect	O
of	O
alpha-linolenic	B
acid	I
on	O
proliferation	O
of	O
PCa	O
cell	O
lines,	O
LNCaP	O
and	O
PC3	O
cells	O
were	O
seeded	O
in	O
12	O
well	O
plates	O
(1.0	O
X	O
10_6	O
cells	O
per	O
well)	O
in	O
complete	O
medium.	O

bOHBut	O
=	O
3-hydroxybutyrate.	B

Indeed,	O
it	O
was	O
shown	O
that	O
the	O
enzymatic	O
activity	O
of	O
the	O
enzyme	O
responsible	O
for	O
the	O
endogenous	O
production	O
of	O
taurine	B
(cysteine	O
sulfinic	O
acid	O
decarboxylase;	O
EC	O
4.1.1.29)	O
is	O
the	O
rate-limiting	O
factor	O
for	O
taurine	B
biosynthesis.	O

For	O
example,	O
polyamines	B
are	O
correlated	O
with	O
cell	O
growth	O
and	O
proliferation	O
(Casero	O
and	O
Marton	O
;	O
Gerner	O
and	O
Meyskens	O
;	O
Tabor	O
and	O
Tabor	O
),	O
and	O
with	O
tumor	O
growth	O
in	O
oral	O
cancer	O
(Dimery	O
et	O
al.	O
),	O
while	O
putrescine	B
is	O
used	O
to	O
monitor	O
the	O
effect	O
of	O
chemotherapy	O
on	O
oral	O
cancer	O
cells	O
(Okamura	O
et	O
al.	O
).	O

In	O
case	O
of	O
ET,	O
we	O
observed	O
higher	O
baseline	O
serum	O
concentrations	O
of	O
glycerol	B
and	O
skeletal	O
muscle	O
alanine,	B
proline,	B
threonine	B
and	O
pyruvate	B
in	O
HRE	O
compared	O
to	O
LRE.	O

Finally,	O
ammonium	B
phosphate	I
buffer	O
is	O
a	O
silanol	O
masking	O
agent	O
and	O
is	O
a	O
potent	O
buffer	O
at	O
high	O
pH	O
especially	O
when	O
a	O
high	O
volume	O
of	O
samples	O
are	O
injected	O
and	O
when	O
the	O
pK	O
_a	O
of	O
the	O
compound	O
is	O
≥8,	O
which	O
is	O
often	O
the	O
case	O
for	O
nucleotides,	O
producing	O
a	O
better	O
peak	O
shape	O
and	O
making	O
it	O
the	O
optimal	O
buffer	O
for	O
nucleotide	O
analysis.	O

Thus,	O
unaltered	O
peripheral	O
levels	O
of	O
tryptophan	B
have	O
been	O
reported	O
in	O
depressed	O
patients	O
after	O
single	O
or	O
repeated	O
ECT	O
administrations	O
[,	O
,	O
],	O
whereas	O
two	O
other	O
studies	O
showed	O
increased	O
plasma	O
tryptophan	B
levels	O
after	O
ECT	O
[,	O
].	O

In	O
case	O
of	O
Levetiracetam,	B
this	O
possibility	O
could	O
be	O
ruled	O
out	O
by	O
the	O
validation	O
set,	O
in	O
which	O
only	O
one	O
CLN2	O
case	O
received	O
this	O
drug.	O

The	O
CDC	O
LC-MS/MS	O
method	O
also	O
did	O
not	O
account	O
for	O
the	O
presence	O
of	O
3-epi-25(OH)D_3	B
in	O
any	O
of	O
the	O
four	O
levels	O
of	O
SRM	O
972.	O

For	O
all	O
the	O
above	O
reasons,	O
the	O
method	O
of	O
Xu	O
et	O
al.	O
is	O
clearly	O
unsuitable	O
for	O
the	O
measurement	O
of	O
the	O
3	O
most	O
frequently	O
requested	O
estrogens,	O
estradiol,	B
estrone	B
and	O
estriol	B
in	O
the	O
routine	O
clinical	O
chemistry	O
laboratory.	O

oxysterols,	B
breast	O
cancer,	O
estrogen,	B
plasma,	O
therapy	O

For	O
instance,	O
creatine	B
levels	O
were	O
found	O
to	O
be	O
higher	O
in	O
HFrEF	O
patients	O
than	O
controls.	O

Pyruvate	B
fluctuation	O
in	O
plasma	O
moderately	O
corresponded	O
to	O
the	O
level	O
of	O
glucose,	B
which	O
was	O
higher	O
in	O
T2	O
than	O
in	O
the	O
subsequent	O
periods	O
of	O
pregnancy.	O

As	O
noted	O
in	O
,	O
major	O
metabolites	O
identified	O
in	O
serum	O
included	O
amino	O
acids	O
(valine,	O
alanine,	B
glutamine,	B
methionine,	B
glycine),	B
organic	O
acid	O
(3-hydroxybutyrate,	O
lactate,	B
acetone,	B
succinate,	B
creatine),	B
low-density	O
lipoprotein	O
(LDL)	O
and	O
VLDL,	O
glucose,	B
choline	B
and	O
phosphocholine,	B
N-Acetyl	B
glycoprotein,	I
and	O
trimethylamine-N-oxide.	B

To	O
take	O
advantage	O
of	O
the	O
correlation	O
between	O
the	O
measures	O
of	O
AAs	O
and	O
ACs	O
and	O
to	O
reduce	O
the	O
Type-I	O
error	O
risks	O
inherent	O
in	O
tests	O
of	O
so	O
many	O
measures,	O
principal	O
components	O
analysis	O
(PCA)	O
was	O
used	O
to	O
reduce	O
the	O
sets	O
of	O
15	O
amino	O
acids	O
and	O
45	O
acylcarnitines	B
each	O
to	O
a	O
single	O
AA	O
or	O
AC	O
factor.	O

Multivariable	O
linear	O
regression	O
models	O
were	O
used	O
to	O
test	O
associations	O
of	O
clinical	O
characteristics	O
(including	O
eGFR)	O
with	O
24,25(OH)_2	B
D_3	O
concentration	O
(the	O
dependent	O
variable),	O
adjusting	O
for	O
potential	O
confounding	O
variables	O
and	O
cohort.	O

Compared	O
with	O
the	O
control	O
group,	O
BMI	O
and	O
serum	O
levels	O
of	O
ALT,	O
AST,	O
ALP,	O
γ-GT,	B
and	O
TAG	O
in	O
the	O
NAFLD	O
group	O
were	O
significantly	O
increased.	O

Stability	O
of	O
thiopurine	B
nucleotides	O
in	O
different	O
anticoagulant	O
syringes	O
used	O
for	O
collection	O
of	O
blood	O
samples	O
and	O
different	O
holding	O
times	O
of	O
such	O
samples.	O

Thus,	O
separate	O
measurement	O
of	O
the	O
D_2	O
and	O
D_3	O
forms	O
of	O
vitamin	B
D	I
is	O
especially	O
valuable	O
for	O
studying	O
the	O
photosynthesis	O
of	O
this	O
vitamin.	O

Significant	O
differences	O
between	O
study	O
groups	O
in	O
the	O
pattern	O
of	O
intra-subject	O
medication	O
change	O
from	O
time	O
of	O
enrollment	O
(T0)	O
to	O
quiescent	O
state	O
follow-up	O
were	O
limited	O
to	O
heparin.	B

μ	O
mol/L;	O
range:	O
71.6	O
to	O
163.5	O
μ	O
mol/L;	O
EH:	O
80.8	O
μ	O
mol/L;	O
range:	O
52.1	O
to	O
95.4	O
μ	O
mol/L;	O
control	O
subjects:	O
67.6	O
μ	O
mol/L;	O
range:	O
60.0	O
to	O
102.5	O
μ	O
mol/L;	O
P	O
<0.05,	O
RVD	O
versus	O
control	O
subjects)	O
and	O
a	O
lower	O
creatinine	B
clearance	O
(RVD:	O
50.1	O
mL/min;	O
range:	O
29.3	O
to	O
168.7	O
mL/min;	O
EH:	O
79.9	O
mL/min;	O
range:	O
51.5	O
to	O
134.5	O
mL/min;	O
control	O
subjects:	O
84.8	O
mL/min;	O
range:	O
42.0	O
to	O
170.3	O
mL/min;	O
P	O
<0.05,	O
RVD	O
versus	O
control	O
subjects;	O
).	O

Following	O
NMR	O
analysis,	O
an	O
aliquot	O
(50–100	O
μl)	O
of	O
the	O
NMR	O
sample	O
was	O
re-equilibrated	O
with	O
H_2	O
O	O
and	O
lyophilized	O
to	O
remove	O
any	O
deuteration,	O
then	O
silylated	O
with	O
25–50	O
μl	O
1:1	O
(v/v)	O
acetonitrile:MTBSTFA	O
(N-methyl-N-[tert-butyldimethylsilyl]trifluoroacetamide,	O
(Regis	O
Chemical,	O
Morton	O
Grove,	O
IL)	O
by	O
3	O
h	O
of	O
sonication	O
followed	O
by	O
standing	O
overnight	O
[,].	O

Patients	O
treated	O
with	O
tamoxifen	B
had	O
significantly	O
higher	O
plasma	O
levels	O
of	O
7-ketocholesterol	B
in	O
the	O
second	O
sampling	O
compared	O
to	O
the	O
corresponding	O
first	O
sampling	O
(n=15/16,	O
first/second	O
sampling	O
without	O
outliers,	O
p	O
=0.034	O
by	O
the	O
Mann-Whitney	O
test).	O

With	O
the	O
combinatory	O
help	O
of	O
MassWorks_TM	O
and	O
online	O
databases	O
such	O
as	O
HMD,	O
the	O
component	O
was	O
putatively	O
identified	O
as	O
phosphotidylcholine	B
PC34:2.	I

Malate	B
was	O
also	O
significantly	O
increased	O
by	O
asphyxia.	O

Formic	B
acid	I
(HCOOH)	O
and	O
ammonium	B
hydrogen	I
carbonate	I
(NH_4	O
HCO_3	O
)	O
were	O
purchased	O
from	O
Fluka	O
(St.	O
Louis,	O
MO).	O

Under	O
such	O
circumstances,	O
increased	O
fatty	O
acid	O
mobilization	O
may	O
occur	O
as	O
a	O
potential	O
energy	O
source,	O
explaining	O
the	O
rise	O
in	O
plasma	O
oleic	B
acid.	I

However,	O
if	O
differentiating	O
metabolites	O
between	O
the	O
obese	O
and	O
nonobese	O
controls	O
were	O
also	O
represented	O
as	O
a	O
differentiating	O
metabolite	O
in	O
the	O
schizophrenia	O
analysis,	O
but	O
their	O
concentrations	O
trended	O
in	O
the	O
opposite	O
direction	O
as	O
weight	O
(e.g.,	O
glycine),	B
they	O
were	O
not	O
removed	O
from	O
the	O
Metscape	O
analysis.	O

(C)	O
fatty	O
acid	O
oxidation,	O
(D)	O
branched	O
chain	O
amino	O
acid	O
pools,	O
(E)	O
lipid	O
biosynthesis,	O
(F)	O
essential	O
fatty	O
acids,	O
(G)	O
urea	B
cycle	O
and	O
(H)	O
purine	B
metabolisms.	O

Associations	O
Between	O
Nonlipid	O
Metabolites	O
and	O
VAT	O
Model	O
adjusted	O
for	O
age,	O
sex,	O
race/ethnicity,	O
socioeconomic	O
status,	O
smoking,	O
physical	O
activity,	O
glucose	B
and	O
lipid‐lowering	O
medication	O
use,	O
and	O
body	O
mass	O
index.	O

The	O
urinary	O
changes	O
in	O
DMA,	B
hippurate,	B
and	O
TMAO	B
implicate	O
alterations	O
in	O
the	O
gut	O
microbiome.	O

Elevated	O
H_2	O
S	O
concentration	O
has	O
been	O
shown	O
to	O
reduce	O
the	O
extent	O
of	O
β-cell	O
apoptosis	O
during	O
glucose	B
elevation.	O

Finally,	O
no	O
significant	O
variation	O
was	O
observed	O
in	O
our	O
LC/MS	O
conditions	O
for	O
hippuric	B
acid,	I
whereas	O
concentrations	O
increased	O
by	O
a	O
factor	O
of	O
1.5	O
were	O
measured	O
by	O
NMR	O
in	O
those	O
samples	O
of	O
Exp.	O

A	O
key	O
feature	O
of	O
this	O
method	O
for	O
analysis	O
of	O
cotinine	B
was	O
monitoring	O
of	O
the	O
m	O
/z	O
178.08	O
peak	O
of	O
cotinine,	B
which	O
is	O
the	O
[M	O
+	O
H]_+	O
ion	O
of	O
naturally	O
occurring	O
[_13	O
C]cotinine,	O
comprising	O
11%	O
of	O
the	O
[_12	O
C]cotinine	O
[M	O
+	O
H]_+	O
ion.	O

The	O
sperm	O
chromatin	B
structural	O
assay	O
(SCSA)	O
was	O
performed	O
as	O
described	O
with	O
slight	O
modifications.	O

Seven	O
of	O
17	O
metabolites-—	O
phytosphingosine,	B
ARA,	O
DPA,	O
S1P,	O
UA,	O
adrenic	B
acid	I
and	O
DHA	O
—	O
were	O
identified	O
using	O
reference	O
compounds;	O
chemical	O
structures	O
and	O
mass	O
fragment	O
information	O
on	O
principal	O
metabolites	O
are	O
shown	O
in	O
Appendix	O
1,	O
Figure	O
S2.	O

The	O
concentration	O
of	O
tyrosine	B
was	O
shown	O
to	O
increase	O
during	O
cheese	O
ripening	O
in	O
a	O
model	O
cheese	O
as	O
well	O
as	O
in	O
Gruyère.	O

On	O
average	O
triglycerides	B
more	O
than	O
doubled	O
in	O
these	O
subjects	O
after	O
the	O
meal.	O

The	O
difference	O
in	O
α	B
-hydroxybutyrate	I
AUC	O
among	O
WBISI	O
tertiles	O
remained	O
statistically	O
significant	O
after	O
correction	O
for	O
age,	O
sex,	O
ethnicity,	O
Tanner	O
stage,	O
and	O
BMI	O
z-score	O
(P	O
=	O
0.034).	O

A	O
possible	O
explanation	O
would	O
be	O
that	O
HBV,	O
alcohol	O
consumption,	O
smoking	O
and	O
presence	O
of	O
Mets	O
induced	O
changes	O
in	O
gut	O
flora	O
composition	O
and	O
normal	O
function	O
[–],	O
which	O
consequently	O
affected	O
the	O
generation	O
of	O
TMAO.	B

Identity	O
of	O
specific	O
D-series	O
resolvins,	O
glutamate	B
and	O
Mycobacterium	O
tuberculosis	O
(Mtb)	O
-derived	O
trehalose-6-mycolate	B
was	O
confirmed	O
using	O
LC-MS/MS	O
analysis.	O

metabolomics,	O
cytokines,	O
breast	O
cancer,	O
estrogen	B
receptors,	O
HER2-positive	O

Metabolites	O
were	O
eluted	O
using	O
a	O
gradient	O
composed	O
of	O
A,	O
water	O
with	O
0.1%	O
(v	O
/v	O
)	O
formic	B
acid,	I
and	O
B,	O
acetonitrile/isopropanol	O
(75/25,	O
v	O
/v	O
)	O
with	O
0.1%	O
(v	O
/v	O
)	O
formic	B
acid.	I

In	O
addition	O
to	O
inflammation,	O
GlycA	B
has	O
also	O
been	O
reported	O
to	O
strongly	O
predict	O
the	O
short-term	O
risk	O
of	O
all-cause	O
mortality.	O

In	O
brief,	O
serum	O
samples,	O
which	O
had	O
been	O
stored	O
at	O
−70°C	O
and	O
not	O
previously	O
thawed,	O
were	O
subjected	O
to	O
an	O
untargeted	O
single	O
methanol	B
extraction	O
followed	O
by	O
protein	O
precipitation.	O

As	O
far	O
as	O
we	O
are	O
aware,	O
all	O
studies	O
reported	O
to	O
date,	O
regardless	O
of	O
methodology,	O
have	O
measured	O
urinary	O
cotinine	B
and	O
NNAL	O
separately.	O

Acetonitrile	B
(ACN),	O
methanol,	B
isopropanol,	B
and	O
chloroform	B
were	O
from	O
Fisher	O
Scientific	O
(Pittsburg,	O
PA).	O

Prior	O
to	O
extraction,	O
the	O
phase	O
was	O
activated	B
with	O
2	O
×	O
300 μL	O
of	O
methanol	B
and	O
then	O
further	O
conditioned	O
with	O
2	O
×	O
300 μL	O
of	O
water.	O

For	O
plasma	O
metabolite	O
concentrations,	O
enzymatic	O
kits	O
were	O
used	O
for	O
plasma-TG	O
in	O
TRL	O
(WAKO,	O
#461-09092,	O
#461-08992,	O
Richmond,	O
VA),	O
glucose	B
(WAKO,	O
#439-90901),	O
and	O
FFA	O
(WAKO,	O
#999-34691,	O
#991-34891).	O

Irreversible	O
binding	O
of	O
tolmetin	B
glucuronic	I
acid	I
esters	I
to	O
albumin	O
in	O
vitro.	O

The	O
derivatization	O
mixture	O
from	O
above	O
(∼3	O
ml	O
of	O
70%	O
methanol,	B
5%	O
acetic	B
acid,	I
3%	O
propanol-2-ol,	B
containing	O
150	O
mg	O
of	O
GP	B
reagent	O
and	O
6	O
μg	O
of	O
cholesterol	B
oxidase)	O
was	O
applied	O
to	O
the	O
column	O
followed	O
by	O
1	O
ml	O
of	O
70%	O
methanol	B
and	O
1	O
ml	O
of	O
35%	O
methanol.	B

Shown	O
are	O
the	O
results	O
of	O
assays	O
for	O
TMAO	B
(Panel	O
A)	O
and	O
d9-TMAO	O
(Panel	O
B)	O
after	O
the	O
phosphatidylcholine	B
challenge,	O
before	O
and	O
after	O
the	O
administration	O
of	O
antibiotics,	O
with	O
the	O
intensity	O
of	O
stable-isotope-dilution	O
assays	O
measured	O
by	O
means	O
of	O
high-performance	O
liquid	O
chromatography	O
with	O
online	O
electro-spray	O
ionization	O
tandem	O
mass	O
spectrometry.	O

L-tryptophan,	B
on	O
the	O
other	O
hand,	O
was	O
lower	O
in	O
plasma	O
of	O
patients	O
relative	O
to	O
controls.	O

The	O
first	O
obstacle	O
is	O
the	O
high	O
polarity	O
induced	O
by	O
the	O
phosphate	B
moieties	O
of	O
nucleotides	O
rendering	O
their	O
retention	O
by	O
reverse-phase	O
chromatography	O
a	O
challenge.	O

Treatment	O
with	O
10	O
nm	O
β-carotene,	B
β-apo-13-carotenone,	B
or	O
other	O
β-apocarotenoids	B
expectedly	O
did	O
not	O
markedly	O
induce	O
expression	O
of	O
either	O
gene	O
(data	O
not	O
shown).	O

Blood	O
was	O
obtained	O
prior	O
to	O
infusion	O
of	O
[U-_13	B
C]glucose	I
and	O
approximately	O
every	O
30	O
minutes	O
during	O
the	O
infusion	O
until	O
the	O
end	O
of	O
tumor	O
sampling.	O

